PMID,Title,Authors,Citation,First Author,Journal/Book,Publication Year,Create Date,PMCID,NIHMS ID,DOI
"30181359","Genetics and biology of prostate cancer","Wang G, Zhao D, Spring DJ, DePinho RA.","Genes Dev. 2018 Sep 1;32(17-18):1105-1140. doi: 10.1101/gad.315739.118.","Wang G","Genes Dev","2018","2018/09/06","PMC6120714","","10.1101/gad.315739.118"
"27275890","Prostate cancer","","Nurs Stand. 2016 Jun 1;30(40):17. doi: 10.7748/ns.30.40.17.s20.","","Nurs Stand","2016","2016/06/09","","","10.7748/ns.30.40.17.s20"
"28895566","WNT signalling in prostate cancer","Murillo-Garzón V, Kypta R.","Nat Rev Urol. 2017 Nov;14(11):683-696. doi: 10.1038/nrurol.2017.144. Epub 2017 Sep 12.","Murillo-Garzón V","Nat Rev Urol","2017","2017/09/13","","","10.1038/nrurol.2017.144"
"27986209","Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography","Rebbeck TR.","Semin Radiat Oncol. 2017 Jan;27(1):3-10. doi: 10.1016/j.semradonc.2016.08.002. Epub 2016 Aug 26.","Rebbeck TR","Semin Radiat Oncol","2017","2016/12/18","PMC5175208","NIHMS824865","10.1016/j.semradonc.2016.08.002"
"28255369","Prostate cancer between prognosis and adequate/proper therapy","Grozescu T, Popa F.","J Med Life. 2017 Jan-Mar;10(1):5-12.","Grozescu T","J Med Life","2017","2017/03/04","PMC5304372","",""
"30345007","Recent trends in the management of advanced prostate cancer","Ritch C, Cookson M.","F1000Res. 2018 Sep 21;7:F1000 Faculty Rev-1513. doi: 10.12688/f1000research.15382.1. eCollection 2018.","Ritch C","F1000Res","2018","2018/10/23","PMC6173112","","10.12688/f1000research.15382.1"
"24840073","High-risk prostate cancer-classification and therapy","Chang AJ, Autio KA, Roach M 3rd, Scher HI.","Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. doi: 10.1038/nrclinonc.2014.68. Epub 2014 May 20.","Chang AJ","Nat Rev Clin Oncol","2014","2014/05/21","PMC4508854","NIHMS700557","10.1038/nrclinonc.2014.68"
"24384911","Androgen receptor signaling in prostate cancer","Culig Z, Santer FR.","Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27. doi: 10.1007/s10555-013-9474-0.","Culig Z","Cancer Metastasis Rev","2014","2014/01/04","","","10.1007/s10555-013-9474-0"
"29580436","The Surgical Management of Prostate Cancer","Sebesta EM, Anderson CB.","Semin Oncol. 2017 Oct;44(5):347-357. doi: 10.1053/j.seminoncol.2018.01.003. Epub 2018 Feb 13.","Sebesta EM","Semin Oncol","2017","2018/03/28","","","10.1053/j.seminoncol.2018.01.003"
"29266472","Current treatment strategies for advanced prostate cancer","Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW.","Int J Urol. 2018 Mar;25(3):220-231. doi: 10.1111/iju.13512. Epub 2017 Dec 20.","Komura K","Int J Urol","2018","2017/12/22","PMC6053280","NIHMS966878","10.1111/iju.13512"
"30521067","Oligometastatic prostate cancer: Reality or figment of imagination?","Foster CC, Weichselbaum RR, Pitroda SP.","Cancer. 2019 Feb 1;125(3):340-352. doi: 10.1002/cncr.31860. Epub 2018 Dec 6.","Foster CC","Cancer","2019","2018/12/07","PMC6587458","","10.1002/cncr.31860"
"30229546","Brief Overview of Prostate Cancer Statistics, Grading, Diagnosis and Treatment Strategies","Schatten H.","Adv Exp Med Biol. 2018;1095:1-14. doi: 10.1007/978-3-319-95693-0_1.","Schatten H","Adv Exp Med Biol","2018","2018/09/20","","","10.1007/978-3-319-95693-0_1"
"27825428","Diagnostic and Therapeutic Strategies for Prostate Cancer","Nguyen-Nielsen M, Borre M.","Semin Nucl Med. 2016 Nov;46(6):484-490. doi: 10.1053/j.semnuclmed.2016.07.002. Epub 2016 Sep 3.","Nguyen-Nielsen M","Semin Nucl Med","2016","2016/11/10","","","10.1053/j.semnuclmed.2016.07.002"
"30374010","[Endocrine therapy for prostate cancer.]","Nagaya N, Horie S.","Clin Calcium. 2018;28(11):1527-1533.","Nagaya N","Clin Calcium","2018","2018/10/31","","",""
"29198331","Biomarkers in prostate cancer - Current clinical utility and future perspectives","Kretschmer A, Tilki D.","Crit Rev Oncol Hematol. 2017 Dec;120:180-193. doi: 10.1016/j.critrevonc.2017.11.007. Epub 2017 Nov 13.","Kretschmer A","Crit Rev Oncol Hematol","2017","2017/12/05","","","10.1016/j.critrevonc.2017.11.007"
"30324354","Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer","Schatten H.","Adv Exp Med Biol. 2018;1096:185-194. doi: 10.1007/978-3-319-99286-0_10.","Schatten H","Adv Exp Med Biol","2018","2018/10/17","","","10.1007/978-3-319-99286-0_10"
"28597635","Modern treatment of metastatic prostate cancer","Holm HV, Dahl AA, Klepp OH, Fosså SD.","Tidsskr Nor Laegeforen. 2017 Jun 6;137(11):803-805. doi: 10.4045/tidsskr.16.0265. eCollection 2017 Jun.","Holm HV","Tidsskr Nor Laegeforen","2017","2017/06/10","","","10.4045/tidsskr.16.0265"
"26984216","Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations","Serrano NA, Anscher MS.","Oncology (Williston Park). 2016 Mar;30(3):229-36.","Serrano NA","Oncology (Williston Park)","2016","2016/03/18","","",""
"30684842","Oligometastatic prostate cancer: The game is afoot","Lancia A, Zilli T, Achard V, Dirix P, Everaerts W, Gomez-Iturriaga A, Ingrosso G, Liefhooghe N, Miralbell R, Siva S, Van der Eecken K, Ost P.","Cancer Treat Rev. 2019 Feb;73:84-90. doi: 10.1016/j.ctrv.2019.01.005. Epub 2019 Jan 17.","Lancia A","Cancer Treat Rev","2019","2019/01/27","","","10.1016/j.ctrv.2019.01.005"
"29393241","The Heterogeneity of Prostate Cancer: A Practical Approach","Tolkach Y, Kristiansen G.","Pathobiology. 2018;85(1-2):108-116. doi: 10.1159/000477852. Epub 2018 Jan 31.","Tolkach Y","Pathobiology","2018","2018/02/03","","","10.1159/000477852"
"30279577","Updates in advanced prostate cancer 2018","Armstrong AJ.","Prostate Cancer Prostatic Dis. 2018 Nov;21(4):449-450. doi: 10.1038/s41391-018-0100-7. Epub 2018 Oct 2.","Armstrong AJ","Prostate Cancer Prostatic Dis","2018","2018/10/04","","","10.1038/s41391-018-0100-7"
"30893147","The evolving role of diet in prostate cancer risk and progression","Kaiser A, Haskins C, Siddiqui MM, Hussain A, D'Adamo C.","Curr Opin Oncol. 2019 May;31(3):222-229. doi: 10.1097/CCO.0000000000000519.","Kaiser A","Curr Opin Oncol","2019","2019/03/21","PMC7379157","NIHMS1607305","10.1097/CCO.0000000000000519"
"29961247","The Role of Testosterone Therapy in the Setting of Prostate Cancer","Rodriguez KM, Pastuszak AW, Khera M.","Curr Urol Rep. 2018 Jun 30;19(8):67. doi: 10.1007/s11934-018-0812-1.","Rodriguez KM","Curr Urol Rep","2018","2018/07/02","","","10.1007/s11934-018-0812-1"
"31825540","Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting","Miyahira AK, Sharp A, Ellis L, Jones J, Kaochar S, Larman HB, Quigley DA, Ye H, Simons JW, Pienta KJ, Soule HR.","Prostate. 2020 Feb;80(2):113-132. doi: 10.1002/pros.23934. Epub 2019 Dec 11.","Miyahira AK","Prostate","2020","2019/12/12","PMC7301761","NIHMS1589745","10.1002/pros.23934"
"29633943","[Locally advanced prostate cancer. Definition, diagnosis and treatment.]","Mayor de Castro J, Caño Velasco J, Aragón Chamizo J, Andrés Boville G, Herranz Amo F, Hernández Fernández C.","Arch Esp Urol. 2018 Mar;71(3):231-238.","Mayor de Castro J","Arch Esp Urol","2018","2018/04/11","","",""
"28882782","Prostate Cancer in Transgender Women: Incidence, Etiopathogenesis, and Management Challenges","Deebel NA, Morin JP, Autorino R, Vince R, Grob B, Hampton LJ.","Urology. 2017 Dec;110:166-171. doi: 10.1016/j.urology.2017.08.032. Epub 2017 Sep 4.","Deebel NA","Urology","2017","2017/09/09","","","10.1016/j.urology.2017.08.032"
"28095710","The evolving role of chemotherapy in prostate cancer","Boulos S, Mazhar D.","Future Oncol. 2017 May;13(12):1091-1095. doi: 10.2217/fon-2016-0464. Epub 2017 Jan 18.","Boulos S","Future Oncol","2017","2017/01/19","","","10.2217/fon-2016-0464"
"26728408","New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy","Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M.","Clin Cancer Res. 2016 Jan 1;22(1):9-15. doi: 10.1158/1078-0432.CCR-15-0820.","Haberkorn U","Clin Cancer Res","2016","2016/01/06","","","10.1158/1078-0432.CCR-15-0820"
"30374609","PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics","Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N.","World J Urol. 2019 Jul;37(7):1255-1261. doi: 10.1007/s00345-018-2524-z. Epub 2018 Oct 29.","Eapen RS","World J Urol","2019","2018/10/31","","","10.1007/s00345-018-2524-z"
"31466098","[Personalised medicine in prostate cancer]","Pfister D, Haidl F, Paffenholz P, Nestler T, Heidenreich A.","Aktuelle Urol. 2019 Sep;50(5):509-512. doi: 10.1055/a-0972-0824. Epub 2019 Aug 29.","Pfister D","Aktuelle Urol","2019","2019/08/30","","","10.1055/a-0972-0824"
"31117038","NCCN Guidelines Updates: Management of Prostate Cancer","Mohler JL, Antonarakis ES.","J Natl Compr Canc Netw. 2019 May 1;17(5.5):583-586. doi: 10.6004/jnccn.2019.5011.","Mohler JL","J Natl Compr Canc Netw","2019","2019/05/23","","","10.6004/jnccn.2019.5011"
"28945566","[Androgen receptor variants in prostate cancer]","Schreyer E, Barthélémy P, Cottard F, Ould Madi-Berthélémy P, Schaff-Wendling F, Kurtz JE, Céraline J.","Med Sci (Paris). 2017 Aug-Sep;33(8-9):758-764. doi: 10.1051/medsci/20173308021. Epub 2017 Sep 18.","Schreyer E","Med Sci (Paris)","2017","2017/09/26","","","10.1051/medsci/20173308021"
"30310278","Targeted nonviral gene therapy in prostate cancer","Altwaijry N, Somani S, Dufès C.","Int J Nanomedicine. 2018 Sep 25;13:5753-5767. doi: 10.2147/IJN.S139080. eCollection 2018.","Altwaijry N","Int J Nanomedicine","2018","2018/10/13","PMC6165780","","10.2147/IJN.S139080"
"30889622","[The role of exercise in prostate cancer prevention and treatment]","Biró K, Géczi L.","Magy Onkol. 2019 Mar 19;63(1):60-64. Epub 2019 Jan 15.","Biró K","Magy Onkol","2019","2019/03/20","","",""
"28241429","Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer","Smolle MA, Bauernhofer T, Pummer K, Calin GA, Pichler M.","Int J Mol Sci. 2017 Feb 22;18(2):473. doi: 10.3390/ijms18020473.","Smolle MA","Int J Mol Sci","2017","2017/03/01","PMC5344005","","10.3390/ijms18020473"
"21479346","Prostate cancer","Scott E.","ScientificWorldJournal. 2011 Apr 5;11:749-50. doi: 10.1100/tsw.2011.79.","Scott E","ScientificWorldJournal","2011","2011/04/12","PMC5719996","","10.1100/tsw.2011.79"
"29860848","Immunotherapy: a glimmer of hope for metastatic prostate cancer","Jindal V.","Chin Clin Oncol. 2018 Dec;7(6):61. doi: 10.21037/cco.2018.02.01. Epub 2018 Mar 12.","Jindal V","Chin Clin Oncol","2018","2018/06/05","","","10.21037/cco.2018.02.01"
"28170061","[Prostate cancer units – hubs in the future care of men with prostate cancer]","Bratt O, Ahlgren G, Börjedahl AC, Franck-Lissbrant I, Waller C.","Lakartidningen. 2017 Jan 31;114:D77U.","Bratt O","Lakartidningen","2017","2017/02/08","","",""
"28503903","The 23rd Annual Prostate Cancer Foundation Scientific Retreat report","Miyahira AK, Soule HR.","Prostate. 2017 Jul;77(10):1093-1106. doi: 10.1002/pros.23366. Epub 2017 May 14.","Miyahira AK","Prostate","2017","2017/05/16","","","10.1002/pros.23366"
"28986509","Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer","Donin NM, Reiter RE.","J Nucl Med. 2018 Feb;59(2):177-182. doi: 10.2967/jnumed.117.191874. Epub 2017 Oct 6.","Donin NM","J Nucl Med","2018","2017/10/08","PMC6910619","","10.2967/jnumed.117.191874"
"30925537","Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future","Gourdin T.","Curr Opin Oncol. 2019 May;31(3):188-193. doi: 10.1097/CCO.0000000000000521.","Gourdin T","Curr Opin Oncol","2019","2019/03/30","","","10.1097/CCO.0000000000000521"
"28385455","Prostate Cancer and the John West Effect","EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel.","Eur Urol. 2017 Jul;72(1):7-9. doi: 10.1016/j.eururo.2017.02.006. Epub 2017 Apr 25.","EAU-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel","Eur Urol","2017","2017/04/08","","","10.1016/j.eururo.2017.02.006"
"24775717","Current management of advanced and castration resistant prostate cancer","Gomella LG, Petrylak DP, Shayegan B.","Can J Urol. 2014 Apr;21(2 Supp 1):1-6.","Gomella LG","Can J Urol","2014","2014/04/30","","",""
"24568399","Prostate cancer","","Nurs Stand. 2014 Feb 26-Mar 4;28(26):18. doi: 10.7748/ns2014.02.28.26.18.s25.","","Nurs Stand","2014","2014/02/27","","","10.7748/ns2014.02.28.26.18.s25"
"27879495","Fish consumption and prostate cancer risk and mortality in a Danish cohort study","Outzen M, Tjønneland A, Christensen J, Olsen A.","Eur J Cancer Prev. 2018 Jul;27(4):355-360. doi: 10.1097/CEJ.0000000000000330.","Outzen M","Eur J Cancer Prev","2018","2016/11/24","","","10.1097/CEJ.0000000000000330"
"28078896","[The incidence, mortality and risk factors of prostate cancer]","Nesvadba M, Cmorej P, Mamova A, Slowik O.","Epidemiol Mikrobiol Imunol. 2016 Fall;65(4):211-214.","Nesvadba M","Epidemiol Mikrobiol Imunol","2016","2017/01/13","","",""
"31134920","Role of tumor-associated immune cells in prostate cancer: angel or devil?","Wu SQ, Su H, Wang YH, Zhao XK.","Asian J Androl. 2019 Sep-Oct;21(5):433-437. doi: 10.4103/aja.aja_47_19.","Wu SQ","Asian J Androl","2019","2019/05/29","PMC6732889","","10.4103/aja.aja_47_19"
"26977847","The evolving role of immunotherapy in prostate cancer","Cordes LM, Gulley JL, Madan RA.","Curr Opin Oncol. 2016 May;28(3):232-40. doi: 10.1097/CCO.0000000000000281.","Cordes LM","Curr Opin Oncol","2016","2016/03/16","","","10.1097/CCO.0000000000000281"
"16368524","Prostate cancer epidemiology","Hsing AW, Chokkalingam AP.","Front Biosci. 2006 May 1;11:1388-413. doi: 10.2741/1891.","Hsing AW","Front Biosci","2006","2005/12/22","","","10.2741/1891"
"26593898","Prostate Cancer Stem Cells: Research Advances","Jaworska D, Król W, Szliszka E.","Int J Mol Sci. 2015 Nov 17;16(11):27433-49. doi: 10.3390/ijms161126036.","Jaworska D","Int J Mol Sci","2015","2015/11/24","PMC4661894","","10.3390/ijms161126036"
"23773409","GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update","Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, Kovacs G.","Radiother Oncol. 2013 Jun;107(3):325-32. doi: 10.1016/j.radonc.2013.05.002. Epub 2013 Jun 14.","Hoskin PJ","Radiother Oncol","2013","2013/06/19","","","10.1016/j.radonc.2013.05.002"
"28925066","Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting","Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR.","Prostate. 2017 Nov;77(15):1478-1488. doi: 10.1002/pros.23424. Epub 2017 Sep 18.","Miyahira AK","Prostate","2017","2017/09/20","","","10.1002/pros.23424"
"27272144","The 22nd annual prostate cancer foundation scientific retreat report","Miyahira AK, Simons JW, Soule HR.","Prostate. 2016 Sep;76(12):1037-52. doi: 10.1002/pros.23193. Epub 2016 Jun 8.","Miyahira AK","Prostate","2016","2016/06/09","","","10.1002/pros.23193"
"26415820","MicroRNA in prostate cancer","Khanmi K, Ignacimuthu S, Paulraj MG.","Clin Chim Acta. 2015 Dec 7;451(Pt B):154-60. doi: 10.1016/j.cca.2015.09.022. Epub 2015 Sep 28.","Khanmi K","Clin Chim Acta","2015","2015/09/30","","","10.1016/j.cca.2015.09.022"
"28631917","[Contemporary concept of the diagnosis of prostate cancer]","Vinnik YY, Andreichikov AV, Klimov NY.","Urologiia. 2017 Jun;(2):110-115. doi: 10.18565/urol.2017.2.110-115.","Vinnik YY","Urologiia","2017","2017/06/21","","","10.18565/urol.2017.2.110-115"
"28265958","[Prostate Cancer - Update 2017]","Herlemann A, Kretschmer A, Apfelbeck M, Tritschler S, Fendler W, Bartenstein P, Reiser M, Stief CG, Gratzke C.","MMW Fortschr Med. 2017 Mar;159(4):58-65. doi: 10.1007/s15006-017-9037-3.","Herlemann A","MMW Fortschr Med","2017","2017/03/08","","","10.1007/s15006-017-9037-3"
"27091662","The role of glycans in the development and progression of prostate cancer","Munkley J, Mills IG, Elliott DJ.","Nat Rev Urol. 2016 Jun;13(6):324-33. doi: 10.1038/nrurol.2016.65. Epub 2016 Apr 19.","Munkley J","Nat Rev Urol","2016","2016/04/20","","","10.1038/nrurol.2016.65"
"28910812","What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective","Zapała P, Dybowski B, Poletajew S, Radziszewski P.","Urol Int. 2018;100(1):1-12. doi: 10.1159/000479982. Epub 2017 Sep 15.","Zapała P","Urol Int","2018","2017/09/15","","","10.1159/000479982"
"29553949","Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions","Gourdin T.","Curr Opin Oncol. 2018 May;30(3):159-164. doi: 10.1097/CCO.0000000000000443.","Gourdin T","Curr Opin Oncol","2018","2018/03/20","","","10.1097/CCO.0000000000000443"
"9115452","Prostate cancer","Balducci L, Pow-Sang J, Friedland J, Diaz JI.","Clin Geriatr Med. 1997 May;13(2):283-306.","Balducci L","Clin Geriatr Med","1997","1997/05/01","","",""
"28056257","[Review of hot topics in the diagnosis and treatment of prostate cancer in 2016]","Li HZ, Zhang YS.","Zhonghua Wai Ke Za Zhi. 2017 Jan 1;55(1):59-62. doi: 10.3760/cma.j.issn.0529-5815.2017.01.015.","Li HZ","Zhonghua Wai Ke Za Zhi","2017","2017/01/06","","","10.3760/cma.j.issn.0529-5815.2017.01.015"
"32209821","Recent progress in treating advanced prostate cancer","Gourdin T.","Curr Opin Oncol. 2020 May;32(3):210-215. doi: 10.1097/CCO.0000000000000624.","Gourdin T","Curr Opin Oncol","2020","2020/03/27","","","10.1097/CCO.0000000000000624"
"25219826","Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization","Alberti C.","Eur Rev Med Pharmacol Sci. 2014 Aug;18(16):2275-82.","Alberti C","Eur Rev Med Pharmacol Sci","2014","2014/09/16","","",""
"12139156","Prostate cancer","Rao RK.","Trop Doct. 2002 Jul;32(3):155-7. doi: 10.1177/004947550203200312.","Rao RK","Trop Doct","2002","2002/07/26","","","10.1177/004947550203200312"
"29549504","A standardized analysis of the current surgical and non-surgical treatment selection process for men with localized prostate cancer","Zhong W, Haghighi K, Rathore P, Wong E, Mancuso P.","J Robot Surg. 2018 Jun;12(2):215-221. doi: 10.1007/s11701-018-0796-3. Epub 2018 Mar 16.","Zhong W","J Robot Surg","2018","2018/03/18","","","10.1007/s11701-018-0796-3"
"30278883","[DNA damage repair: An emerging strategy in metastatic prostate cancer]","Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A.","Bull Cancer. 2018 Oct;105(10):944-954. doi: 10.1016/j.bulcan.2018.05.017. Epub 2018 Sep 29.","Loriot Y","Bull Cancer","2018","2018/10/04","","","10.1016/j.bulcan.2018.05.017"
"27728977","Prognostic outlier genes for enhanced prostate cancer treatment","Kim H, Skowronski J, Den RB.","Future Oncol. 2017 Feb;13(3):249-261. doi: 10.2217/fon-2016-0223. Epub 2016 Oct 12.","Kim H","Future Oncol","2017","2016/10/13","","","10.2217/fon-2016-0223"
"30381857","Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting","Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR.","Prostate. 2019 Feb;79(3):244-258. doi: 10.1002/pros.23729. Epub 2018 Oct 31.","Miyahira AK","Prostate","2019","2018/11/02","","","10.1002/pros.23729"
"19202959","[Prostate cancer]","Matousková M.","Klin Onkol. 2008;21(5):280-7.","Matousková M","Klin Onkol","2008","2009/02/11","","",""
"30369229","[A Case of Rectum-Infiltrating Prostate Cancer Mimicking Prostate-Infiltrating Rectal Cancer]","Hishiki K, Takada H, Nakashima Y, Kohei N, Nishio Y, Muro H, Ohata K, Yoshimura K.","Hinyokika Kiyo. 2018 Sep;64(9):373-377. doi: 10.14989/ActaUrolJap_64_9_373.","Hishiki K","Hinyokika Kiyo","2018","2018/10/30","","","10.14989/ActaUrolJap_64_9_373"
"16334137","Prostate cancer in the elderly","Syrigos KN, Karapanagiotou E, Harrington KJ.","Anticancer Res. 2005 Nov-Dec;25(6C):4527-33.","Syrigos KN","Anticancer Res","2005","2005/12/13","","",""
"17432554","Prostate cancer screening","Tenke P, Horti J, Balint P, Kovacs B.","Recent Results Cancer Res. 2007;175:65-81. doi: 10.1007/978-3-540-40901-4_5.","Tenke P","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_5"
"30334240","When to Order an MRI in the Initial Evaluation and Management of Prostate Cancer","Walton-Diaz A, Rais-Bahrami S.","Oncology (Williston Park). 2018 Oct 15;32(10):501-4.","Walton-Diaz A","Oncology (Williston Park)","2018","2018/10/19","","",""
"28980045","[The role of PSMA PET-CT in patients with metastatic prostate cancer]","von Hardenberg J, Büsing KA, Nuhn P, Ritter M.","Urologe A. 2017 Nov;56(11):1410-1416. doi: 10.1007/s00120-017-0513-2.","von Hardenberg J","Urologe A","2017","2017/10/06","","","10.1007/s00120-017-0513-2"
"24625881","Glucocorticoids and prostate cancer treatment: friend or foe?","Montgomery B, Cheng HH, Drechsler J, Mostaghel EA.","Asian J Androl. 2014 May-Jun;16(3):354-8. doi: 10.4103/1008-682X.125392.","Montgomery B","Asian J Androl","2014","2014/03/15","PMC4023359","","10.4103/1008-682X.125392"
"24235880","Prostate cancer: all aspects","Tefekli A, Tunc M, Tugcu V, Esen T.","ScientificWorldJournal. 2013 Oct 1;2013:265234. doi: 10.1155/2013/265234. eCollection 2013.","Tefekli A","ScientificWorldJournal","2013","2013/11/16","PMC3818643","","10.1155/2013/265234"
"18786842","Prostate cancer in dogs: comparative and clinical aspects","Leroy BE, Northrup N.","Vet J. 2009 May;180(2):149-62. doi: 10.1016/j.tvjl.2008.07.012. Epub 2008 Sep 10.","Leroy BE","Vet J","2009","2008/09/13","","","10.1016/j.tvjl.2008.07.012"
"28635333","Molecular biomarkers to guide precision medicine in localized prostate cancer","Smits M, Mehra N, Sedelaar M, Gerritsen W, Schalken JA.","Expert Rev Mol Diagn. 2017 Aug;17(8):791-804. doi: 10.1080/14737159.2017.1345627.","Smits M","Expert Rev Mol Diagn","2017","2017/06/22","","","10.1080/14737159.2017.1345627"
"8290819","Cancer of the prostate","Maxwell MB.","Semin Oncol Nurs. 1993 Nov;9(4):237-51. doi: 10.1016/s0749-2081(05)80052-x.","Maxwell MB","Semin Oncol Nurs","1993","1993/11/01","","","10.1016/s0749-2081(05)80052-x"
"27846402","Focal therapy in prostate cancer: A review of seven common controversies","Bass EJ, Ahmed HU.","Cancer Treat Rev. 2016 Dec;51:27-34. doi: 10.1016/j.ctrv.2016.07.004. Epub 2016 Jul 18.","Bass EJ","Cancer Treat Rev","2016","2016/11/16","","","10.1016/j.ctrv.2016.07.004"
"24914837","[Overdiagnosis in prostate cancer]","Villeda C, Gomez MO, Sotomayor M.","Arch Esp Urol. 2014 Jun;67(5):388-92.","Villeda C","Arch Esp Urol","2014","2014/06/11","","",""
"17321194","Prostate cancer: Re-focusing on androgen receptor signaling","Nieto M, Finn S, Loda M, Hahn WC.","Int J Biochem Cell Biol. 2007;39(9):1562-8. doi: 10.1016/j.biocel.2007.01.005. Epub 2007 Jan 20.","Nieto M","Int J Biochem Cell Biol","2007","2007/02/27","PMC2000831","NIHMS28507","10.1016/j.biocel.2007.01.005"
"31206997","NICE Guidance - Prostate cancer: diagnosis and management: © NICE (2019) Prostate cancer: diagnosis and management","","BJU Int. 2019 Jul;124(1):9-26. doi: 10.1111/bju.14809.","","BJU Int","2019","2019/06/18","","","10.1111/bju.14809"
"18568350","What is low-risk prostate cancer and what is its natural history?","O'Donnell H, Parker C.","World J Urol. 2008 Oct;26(5):415-22. doi: 10.1007/s00345-008-0277-9. Epub 2008 Jun 21.","O'Donnell H","World J Urol","2008","2008/06/24","","","10.1007/s00345-008-0277-9"
"31629425","Germline testing in those at risk of prostate cancer","Carroll PR, Witte JS, Parsons JK.","Can J Urol. 2019 Oct;26(5 Suppl 2):31-33.","Carroll PR","Can J Urol","2019","2019/10/21","","",""
"25708578","Radiotherapy for high-risk prostate cancer","Mohiuddin JJ, Baker BR, Chen RC.","Nat Rev Urol. 2015 Mar;12(3):145-54. doi: 10.1038/nrurol.2015.25. Epub 2015 Feb 24.","Mohiuddin JJ","Nat Rev Urol","2015","2015/02/25","","","10.1038/nrurol.2015.25"
"20414018","[Prostate cancer]","Hinotsu S.","Gan To Kagaku Ryoho. 2010 Apr;37(4):620-3.","Hinotsu S","Gan To Kagaku Ryoho","2010","2010/04/24","","",""
"25796694","[Prostate cancer stem cells: advances in current research]","Wu G, Wu DL.","Zhonghua Nan Ke Xue. 2015 Feb;21(2):170-4.","Wu G","Zhonghua Nan Ke Xue","2015","2015/03/24","","",""
"21319990","Prostate cancer proteomics","Masters JR.","OMICS. 2011 Mar;15(3):169-71. doi: 10.1089/omi.2010.0083. Epub 2011 Feb 14.","Masters JR","OMICS","2011","2011/02/16","","","10.1089/omi.2010.0083"
"22369972","Targeting prostate cancer stem cells for cancer therapy","Wang G, Wang Z, Sarkar FH, Wei W.","Discov Med. 2012 Feb;13(69):135-42.","Wang G","Discov Med","2012","2012/02/29","PMC3367460","NIHMS380534",""
"22470904","Advanced prostate cancer: treatment and patient-centred care","Peate I.","Br J Nurs. 2012 Feb 23-Mar 7;21(4):S24-30. doi: 10.12968/bjon.2012.21.Sup4.S24.","Peate I","Br J Nurs","2012","2012/04/04","","","10.12968/bjon.2012.21.Sup4.S24"
"18427568","Prostate cancer stem cell therapy: hype or hope?","Masters JR, Kane C, Yamamoto H, Ahmed A.","Prostate Cancer Prostatic Dis. 2008;11(4):316-9. doi: 10.1038/pcan.2008.22. Epub 2008 Apr 22.","Masters JR","Prostate Cancer Prostatic Dis","2008","2008/04/23","","","10.1038/pcan.2008.22"
"31609776","Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer","Hamid AA, Choudhury AD.","Curr Opin Urol. 2020 Jan;30(1):30-35. doi: 10.1097/MOU.0000000000000682.","Hamid AA","Curr Opin Urol","2020","2019/10/15","","","10.1097/MOU.0000000000000682"
"24452740","Real-time elastography for the detection of prostate cancer","Salomon G, Schiffmann J.","Curr Urol Rep. 2014 Mar;15(3):392. doi: 10.1007/s11934-013-0392-z.","Salomon G","Curr Urol Rep","2014","2014/01/24","","","10.1007/s11934-013-0392-z"
"23761200","Mapping of prostate cancer by 1H MRSI","Kobus T, Wright AJ, Scheenen TW, Heerschap A.","NMR Biomed. 2014 Jan;27(1):39-52. doi: 10.1002/nbm.2973. Epub 2013 Jun 13.","Kobus T","NMR Biomed","2014","2013/06/14","","","10.1002/nbm.2973"
"29848245","Low risk prostate cancer and an opportunity lost: more activity required in active surveillance","Smith DP, Wittert GA.","Med J Aust. 2018 Jun 4;208(10):430-431.","Smith DP","Med J Aust","2018","2018/06/01","","",""
"18765133","Prostate cancer and chronic prostatitis","Sandhu JS.","Curr Urol Rep. 2008 Jul;9(4):328-32. doi: 10.1007/s11934-008-0056-6.","Sandhu JS","Curr Urol Rep","2008","2008/09/04","","","10.1007/s11934-008-0056-6"
"26436556","Emerging treatments for recurrent prostate cancer","Hanna C, Jones RJ.","Future Oncol. 2015;11(21):2873-80. doi: 10.2217/fon.15.228. Epub 2015 Oct 5.","Hanna C","Future Oncol","2015","2015/10/06","","","10.2217/fon.15.228"
"28395050","Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death","Vollmer RT.","Am J Clin Pathol. 2017 Mar 1;147(3):273-277. doi: 10.1093/ajcp/aqw212.","Vollmer RT","Am J Clin Pathol","2017","2017/04/11","","","10.1093/ajcp/aqw212"
"21912423","The endocannabinoid system in prostate cancer","Díaz-Laviada I.","Nat Rev Urol. 2011 Sep 13;8(10):553-61. doi: 10.1038/nrurol.2011.130.","Díaz-Laviada I","Nat Rev Urol","2011","2011/09/14","","","10.1038/nrurol.2011.130"
"30549869","[Current multidisciplinary approaches for metastatic prostate cancer]","Satoh T, Ishiyama H.","Nihon Rinsho. 2017 Apr;75(4):620-625.","Satoh T","Nihon Rinsho","2017","2018/12/15","","",""
"24188255","Surgical management of prostate cancer","Wright JL, Izard JP, Lin DW.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1111-35, vii. doi: 10.1016/j.hoc.2013.08.010.","Wright JL","Hematol Oncol Clin North Am","2013","2013/11/06","","","10.1016/j.hoc.2013.08.010"
"31629419","Polygenic risk scores for prostate cancer: testing considerations","Toland AE.","Can J Urol. 2019 Oct;26(5 Suppl 2):17-18.","Toland AE","Can J Urol","2019","2019/10/21","","",""
"26859444","The genetic classification of prostate cancer: what's on the horizon?","Ross-Adams H, Lamb AD.","Future Oncol. 2016 Mar;12(6):729-33. doi: 10.2217/fon.15.352. Epub 2016 Feb 9.","Ross-Adams H","Future Oncol","2016","2016/02/10","","","10.2217/fon.15.352"
"19198622","Risk factors for prostate cancer","Patel AR, Klein EA.","Nat Clin Pract Urol. 2009 Feb;6(2):87-95. doi: 10.1038/ncpuro1290.","Patel AR","Nat Clin Pract Urol","2009","2009/02/10","","","10.1038/ncpuro1290"
"15694830","Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways","Uzgare AR, Isaacs JT.","Int J Biochem Cell Biol. 2005 Apr;37(4):707-14. doi: 10.1016/j.biocel.2004.11.018.","Uzgare AR","Int J Biochem Cell Biol","2005","2005/02/08","","","10.1016/j.biocel.2004.11.018"
"19863346","Management of anaemia in prostate cancer","Colloca G, Venturino A, Vitucci P, Gianni W.","Cancer Invest. 2010 Mar;28(3):280-8. doi: 10.3109/07357900903124480.","Colloca G","Cancer Invest","2010","2009/10/30","","","10.3109/07357900903124480"
"27273830","PBX3 is a putative biomarker of aggressive prostate cancer","Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA.","Int J Cancer. 2016 Oct 15;139(8):1810-20. doi: 10.1002/ijc.30220. Epub 2016 Jun 25.","Ramberg H","Int J Cancer","2016","2016/06/09","","","10.1002/ijc.30220"
"24274615","Emerging drugs for prostate cancer","Chung PH, Gayed BA, Thoreson GR, Raj GV.","Expert Opin Emerg Drugs. 2013 Dec;18(4):533-50. doi: 10.1517/14728214.2013.864635.","Chung PH","Expert Opin Emerg Drugs","2013","2013/11/27","","","10.1517/14728214.2013.864635"
"19562492","Smoking and aggressive prostate cancer: a review of the epidemiologic evidence","Zu K, Giovannucci E.","Cancer Causes Control. 2009 Dec;20(10):1799-810. doi: 10.1007/s10552-009-9387-y.","Zu K","Cancer Causes Control","2009","2009/06/30","","","10.1007/s10552-009-9387-y"
"16046052","EAU guidelines on prostate cancer","Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J, Zattoni F; European Association of Urology.","Eur Urol. 2005 Oct;48(4):546-51. doi: 10.1016/j.eururo.2005.06.001.","Aus G","Eur Urol","2005","2005/07/28","","","10.1016/j.eururo.2005.06.001"
"23495081","Role of MRI in prostate cancer detection","Shukla-Dave A, Hricak H.","NMR Biomed. 2014 Jan;27(1):16-24. doi: 10.1002/nbm.2934. Epub 2013 Mar 13.","Shukla-Dave A","NMR Biomed","2014","2013/03/16","","","10.1002/nbm.2934"
"21116296","Tumor focality in prostate cancer: implications for focal therapy","Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH.","Nat Rev Clin Oncol. 2011 Jan;8(1):48-55. doi: 10.1038/nrclinonc.2010.190. Epub 2010 Nov 23.","Karavitakis M","Nat Rev Clin Oncol","2011","2010/12/01","","","10.1038/nrclinonc.2010.190"
"20538204","[Hypermethylation and prostate cancer]","Colombel M, Ricci E, Picard A, Bourrelly E; Groupe Urezus.","Prog Urol. 2010 Jun;20(6):408-15. doi: 10.1016/j.purol.2009.10.015. Epub 2010 Jan 29.","Colombel M","Prog Urol","2010","2010/06/12","","","10.1016/j.purol.2009.10.015"
"16130015","Impact of diet on prostate cancer: a review","Sonn GA, Aronson W, Litwin MS.","Prostate Cancer Prostatic Dis. 2005;8(4):304-10. doi: 10.1038/sj.pcan.4500825.","Sonn GA","Prostate Cancer Prostatic Dis","2005","2005/09/01","","","10.1038/sj.pcan.4500825"
"6387660","Review: prostate cancer epidemiology","Flanders WD.","Prostate. 1984;5(6):621-9. doi: 10.1002/pros.2990050608.","Flanders WD","Prostate","1984","1984/01/01","","","10.1002/pros.2990050608"
"24754104","Diagnosis and treatment of prostate cancer","Bagnall P.","Nurs Times. 2014 Feb 26-Mar 4;110(9):12-5.","Bagnall P","Nurs Times","2014","2014/04/24","","",""
"26997311","Characteristics of Anteriorly Located Prostate Cancer and the Usefulness of Multiparametric Magnetic Resonance Imaging for Diagnosis","Kim M, Choi SK, Park M, Shim M, Song C, Jeong IG, Hong JH, Kim CS, Ahn H.","J Urol. 2016 Aug;196(2):367-73. doi: 10.1016/j.juro.2016.03.075. Epub 2016 Mar 17.","Kim M","J Urol","2016","2016/03/22","","","10.1016/j.juro.2016.03.075"
"17024870","Treatment of prostate cancer in obese patients","Mitsuyama H, Wallner KE, Merrick GS.","Oncology (Williston Park). 2006 Sep;20(10):1191-7; discussion 1198, 1206, 1208.","Mitsuyama H","Oncology (Williston Park)","2006","2006/10/10","","",""
"23924475","Novel role of microRNAs in prostate cancer","Yu JJ, Xia SJ.","Chin Med J (Engl). 2013;126(15):2960-4.","Yu JJ","Chin Med J (Engl)","2013","2013/08/09","","",""
"10636566","Hereditary prostate cancer","Damber JE.","Scand J Urol Nephrol Suppl. 1999;203:25-8. doi: 10.1080/00365599950510012-1.","Damber JE","Scand J Urol Nephrol Suppl","1999","2000/01/15","","","10.1080/00365599950510012-1"
"17939301","Prostate cancer stem cells: a target for new therapies","Maitland NJ, Bryce SD, Stower MJ, Collins AT.","Ernst Schering Found Symp Proc. 2006;(5):155-79. doi: 10.1007/2789_2007_050.","Maitland NJ","Ernst Schering Found Symp Proc","2006","2007/10/18","","","10.1007/2789_2007_050"
"21955852","Focal therapy for prostate cancer: opportunities and uncertainties","Karavitakis M, Winkler MH, Abel PD, Hazell S, Ahmed HU.","Discov Med. 2011 Sep;12(64):245-55.","Karavitakis M","Discov Med","2011","2011/09/30","","",""
"12168382","Prostate cancer update","Lewey J.","Nurs Times. 2002 Jul 9-15;98(28):56-7.","Lewey J","Nurs Times","2002","2002/08/10","","",""
"22840598","Functional imaging for prostate cancer: therapeutic implications","Mari Aparici C, Seo Y.","Semin Nucl Med. 2012 Sep;42(5):328-42. doi: 10.1053/j.semnuclmed.2012.04.004.","Mari Aparici C","Semin Nucl Med","2012","2012/07/31","PMC3408625","NIHMS385488","10.1053/j.semnuclmed.2012.04.004"
"23811619","Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH.","Cancer Discov. 2013 Aug;3(8):849-61. doi: 10.1158/2159-8290.CD-12-0460. Epub 2013 Jun 28.","Logothetis CJ","Cancer Discov","2013","2013/07/02","PMC3926428","NIHMS548495","10.1158/2159-8290.CD-12-0460"
"11879332","The treatment of prostate cancer: an overview of current options","Pirtskhalaishvili G, Hrebinko RL, Nelson JB.","Cancer Pract. 2001 Nov-Dec;9(6):295-306. doi: 10.1046/j.1523-5394.2001.96009.x.","Pirtskhalaishvili G","Cancer Pract","2001","2002/03/07","","","10.1046/j.1523-5394.2001.96009.x"
"8673658","Prostate cancer: current and evolving strategies","Cersosimo RJ, Carr D.","Am J Health Syst Pharm. 1996 Feb 15;53(4):381-96; quiz 446-8. doi: 10.1093/ajhp/53.4.381.","Cersosimo RJ","Am J Health Syst Pharm","1996","1996/02/15","","","10.1093/ajhp/53.4.381"
"11819979","[Prostate cancer]","Fernandez del Moral P, Witjes WP.","Ned Tijdschr Tandheelkd. 1992 Apr;99(4):131-3.","Fernandez del Moral P","Ned Tijdschr Tandheelkd","1992","1992/04/01","","",""
"11928454","[Prostate cancer]","Bol P.","Ned Tijdschr Tandheelkd. 1998 Oct;105(10):371-2.","Bol P","Ned Tijdschr Tandheelkd","1998","2002/04/04","","",""
"25893521","The 21st Annual Prostate Cancer Foundation Scientific Retreat report","Miyahira AK, Simons JW, Soule HR.","Prostate. 2015 Aug 1;75(11):1119-28. doi: 10.1002/pros.22993. Epub 2015 Apr 20.","Miyahira AK","Prostate","2015","2015/04/21","","","10.1002/pros.22993"
"26560323","An Overview of Current Screening and Management Approaches for Prostate Cancer","Akram ON, Mushtaq G, Kamal MA.","Curr Drug Metab. 2015;16(8):713-8. doi: 10.2174/1389200216666150812122430.","Akram ON","Curr Drug Metab","2015","2015/11/13","","","10.2174/1389200216666150812122430"
"31575477","Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer","Kodama H, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Narita T, Sato H, Mitsuzuka K, Tochigi T, Tsuchiya N, Arai Y, Habuchi T, Ohyama C.","Clin Genitourin Cancer. 2019 Dec;17(6):e1091-e1098. doi: 10.1016/j.clgc.2019.05.029. Epub 2019 Sep 10.","Kodama H","Clin Genitourin Cancer","2019","2019/10/03","","","10.1016/j.clgc.2019.05.029"
"32462838","[Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy]","Mechahougui H, Achard V, Friedlaender A.","Rev Med Suisse. 2020 May 27;16(695):1098-1101.","Mechahougui H","Rev Med Suisse","2020","2020/05/29","","",""
"30273137","How AI Is Optimizing the Detection and Management of Prostate Cancer","Yadav KK.","IEEE Pulse. 2018 Sep-Oct;9(5):19. doi: 10.1109/MPUL.2018.2866354.","Yadav KK","IEEE Pulse","2018","2018/10/02","","","10.1109/MPUL.2018.2866354"
"18095882","Diet and prostate cancer risk reduction","Cheung E, Wadhera P, Dorff T, Pinski J.","Expert Rev Anticancer Ther. 2008 Jan;8(1):43-50. doi: 10.1586/14737140.8.1.43.","Cheung E","Expert Rev Anticancer Ther","2008","2007/12/22","","","10.1586/14737140.8.1.43"
"23504524","PCA3 in the detection and management of early prostate cancer","Filella X, Foj L, Milà M, Augé JM, Molina R, Jiménez W.","Tumour Biol. 2013 Jun;34(3):1337-47. doi: 10.1007/s13277-013-0739-6. Epub 2013 Mar 16.","Filella X","Tumour Biol","2013","2013/03/19","","","10.1007/s13277-013-0739-6"
"9858329","Prostate cancer in the African American: is this a different disease?","Powell IJ.","Semin Urol Oncol. 1998 Nov;16(4):221-6.","Powell IJ","Semin Urol Oncol","1998","1998/12/19","","",""
"29786789","Protocols for Tissue Microarrays in Prostate Cancer Studies","Vlajnic T, Eppenberger-Castori S, Bubendorf L.","Methods Mol Biol. 2018;1786:103-116. doi: 10.1007/978-1-4939-7845-8_6.","Vlajnic T","Methods Mol Biol","2018","2018/05/23","","","10.1007/978-1-4939-7845-8_6"
"16278465","The changing face of prostate cancer","Cooperberg MR, Moul JW, Carroll PR.","J Clin Oncol. 2005 Nov 10;23(32):8146-51. doi: 10.1200/JCO.2005.02.9751.","Cooperberg MR","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.02.9751"
"12087789","A prostate cancer primer","Gray M.","Urol Nurs. 2002 Jun;22(3):151-67; quiz 172.","Gray M","Urol Nurs","2002","2002/06/29","","",""
"22118354","[High-risk prostate cancer. Review by the Oncology Committee of the French Urology Association]","Rozet F, Hennequin C, Fromont G, Mongiat-Artus P, Bastide C, Beuzeboc P, Cormier L, Eiss D, Peyromaure M, Richaud P, Salomon L, Soulié M.","Prog Urol. 2011 Dec;21(13):901-8. doi: 10.1016/j.purol.2011.09.006. Epub 2011 Oct 19.","Rozet F","Prog Urol","2011","2011/11/29","","","10.1016/j.purol.2011.09.006"
"16885911","The role of prevalence in the diagnosis of prostate cancer","Delongchamps NB, Singh A, Haas GP.","Cancer Control. 2006 Jul;13(3):158-68. doi: 10.1177/107327480601300302.","Delongchamps NB","Cancer Control","2006","2006/08/04","","","10.1177/107327480601300302"
"24495446","Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor","Lou DY, Fong L.","Urol Oncol. 2016 Apr;34(4):182-92. doi: 10.1016/j.urolonc.2013.12.001. Epub 2014 Feb 2.","Lou DY","Urol Oncol","2016","2014/02/06","PMC4499005","NIHMS549889","10.1016/j.urolonc.2013.12.001"
"12735506","The physical burden of prostate cancer","Penson DF, Litwin MS.","Urol Clin North Am. 2003 May;30(2):305-13. doi: 10.1016/s0094-0143(02)00187-8.","Penson DF","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00187-8"
"17956216","Molecular mechanisms of apoptosis in prostate cancer","Lorenzo PI, Arnoldussen YJ, Saatcioglu F.","Crit Rev Oncog. 2007 Aug;13(1):1-38. doi: 10.1615/critrevoncog.v13.i1.10.","Lorenzo PI","Crit Rev Oncog","2007","2007/10/25","","","10.1615/critrevoncog.v13.i1.10"
"25366417","Drug design strategies for the treatment of prostate cancer","Lauer RC, Friend SC, Rietz C, Pasqualini R, Arap W.","Expert Opin Drug Discov. 2015 Jan;10(1):81-90. doi: 10.1517/17460441.2015.978855. Epub 2014 Nov 4.","Lauer RC","Expert Opin Drug Discov","2015","2014/11/05","","","10.1517/17460441.2015.978855"
"30514554","Personalising Prostate Radiotherapy in the Era of Precision Medicine: A Review","Spence W.","J Med Imaging Radiat Sci. 2018 Dec;49(4):376-382. doi: 10.1016/j.jmir.2018.01.002. Epub 2018 Mar 12.","Spence W","J Med Imaging Radiat Sci","2018","2018/12/06","","","10.1016/j.jmir.2018.01.002"
"22391123","Epigenetic biomarkers in prostate cancer: Current and future uses","Chiam K, Ricciardelli C, Bianco-Miotto T.","Cancer Lett. 2014 Jan 28;342(2):248-56. doi: 10.1016/j.canlet.2012.02.011. Epub 2012 Mar 3.","Chiam K","Cancer Lett","2014","2012/03/07","","","10.1016/j.canlet.2012.02.011"
"23856029","Long noncoding RNAs: new players in prostate cancer","Cheng W, Zhang Z, Wang J.","Cancer Lett. 2013 Oct 1;339(1):8-14. doi: 10.1016/j.canlet.2013.07.008. Epub 2013 Jul 12.","Cheng W","Cancer Lett","2013","2013/07/17","","","10.1016/j.canlet.2013.07.008"
"19169957","Cancer vaccines: current directions and perspectives in prostate cancer","Mohebtash M, Gulley JL, Madan RA, Ferrara T, Arlen PM.","Curr Opin Mol Ther. 2009 Feb;11(1):31-6.","Mohebtash M","Curr Opin Mol Ther","2009","2009/01/27","PMC3488286","NIHMS415899",""
"29071871","[Expression of SRD5A1 and its prognostic role in prostate cancer: Analysis based on the data-mining of ONCOMINE]","Xu B, Liu N, Chen SQ, Jiang H, Zhang LJ, Zhang XW, Yang Y, Sha GZ, Liu J, Zhu WD, Chen M.","Zhonghua Nan Ke Xue. 2016 Sep;22(9):771-776.","Xu B","Zhonghua Nan Ke Xue","2016","2017/10/27","","",""
"12787711","Radical radiotherapy for prostate cancer","Parker CC, Dearnaley DP.","Cancer Treat Rev. 2003 Jun;29(3):161-9. doi: 10.1016/s0305-7372(03)00070-7.","Parker CC","Cancer Treat Rev","2003","2003/06/06","","","10.1016/s0305-7372(03)00070-7"
"17666980","Quality of life for men with prostate cancer","Katz A.","Cancer Nurs. 2007 Jul-Aug;30(4):302-8. doi: 10.1097/01.NCC.0000281726.87490.f2.","Katz A","Cancer Nurs","2007","2007/08/02","","","10.1097/01.NCC.0000281726.87490.f2"
"23075237","Biomarkers for the diagnosis of new and recurrent prostate cancer","Sardana G, Diamandis EP.","Biomark Med. 2012 Oct;6(5):587-96. doi: 10.2217/bmm.12.72.","Sardana G","Biomark Med","2012","2012/10/19","","","10.2217/bmm.12.72"
"7816678","Cancer of the prostate: treatment and nursing implications","Held JL, Osborne DM, Volpe H, Waldman AR.","Oncol Nurs Forum. 1994 Oct;21(9):1517-29.","Held JL","Oncol Nurs Forum","1994","1994/10/01","","",""
"19095126","Prostate cancer: epidemiology and health-related quality of life","Penson DF, Rossignol M, Sartor AO, Scardino PT, Abenhaim LL.","Urology. 2008 Dec;72(6 Suppl):S3-11. doi: 10.1016/j.urology.2008.10.006.","Penson DF","Urology","2008","2008/12/20","","","10.1016/j.urology.2008.10.006"
"12856638","Early prostate cancer: is there a need for new treatment options?","Klimberg I, Locke DR, Madore RA, Smith WW.","Urol Oncol. 2003 Mar-Apr;21(2):105-16. doi: 10.1016/s1078-1439(02)00211-9.","Klimberg I","Urol Oncol","2003","2003/07/15","","","10.1016/s1078-1439(02)00211-9"
"24188258","Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer","Lam ET, Glodé LM.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. doi: 10.1016/j.hoc.2013.08.004. Epub 2013 Sep 21.","Lam ET","Hematol Oncol Clin North Am","2013","2013/11/06","","","10.1016/j.hoc.2013.08.004"
"23614617","Functional role of microRNAs in prostate cancer and therapeutic opportunities","Maugeri-Sacca M, Coppola V, De Maria R, Bonci D.","Crit Rev Oncog. 2013;18(4):303-15. doi: 10.1615/critrevoncog.2013007206.","Maugeri-Sacca M","Crit Rev Oncog","2013","2013/04/26","","","10.1615/critrevoncog.2013007206"
"27453303","Targeted PET imaging for prostate-specific membrane antigen in prostate cancer","Hope TA, Aggarwal RR, Westphalen AC, Cooperberg MR, Greene KL.","Future Oncol. 2016 Nov;12(21):2393-2396. doi: 10.2217/fon-2016-0312. Epub 2016 Jul 25.","Hope TA","Future Oncol","2016","2016/07/26","","","10.2217/fon-2016-0312"
"25123041","Implementation of PSA-based active surveillance in prostate cancer","Jalloh M, Cooperberg MR.","Biomark Med. 2014;8(5):747-53. doi: 10.2217/bmm.14.5.","Jalloh M","Biomark Med","2014","2014/08/16","","","10.2217/bmm.14.5"
"10380061","Treatment of prostate cancer","Henry RY, O'Mahony D.","J Clin Pharm Ther. 1999 Apr;24(2):93-102. doi: 10.1046/j.1365-2710.1999.00207.x.","Henry RY","J Clin Pharm Ther","1999","1999/06/24","","","10.1046/j.1365-2710.1999.00207.x"
"17553361","[Prostate cancer--incidence and risk factors]","Brasso K.","Ugeskr Laeger. 2007 May 14;169(20):1883-6.","Brasso K","Ugeskr Laeger","2007","2007/06/08","","",""
"19002169","Concepts of epigenetics in prostate cancer development","Cooper CS, Foster CS.","Br J Cancer. 2009 Jan 27;100(2):240-5. doi: 10.1038/sj.bjc.6604771. Epub 2008 Nov 11.","Cooper CS","Br J Cancer","2009","2008/11/13","PMC2634711","","10.1038/sj.bjc.6604771"
"31629435","Genetically-informed treatment for advanced and metastatic prostate cancer","Morgans AK, Szymaniak BM.","Can J Urol. 2019 Oct;26(5 Suppl 2):54-56.","Morgans AK","Can J Urol","2019","2019/10/21","","",""
"23123814","Prostate cancer overview. Part 2: metastatic prostate cancer","Drudge-Coates L, Turner B.","Br J Nurs. 2012 Oct 11-24;21(18):S23-4, S26-8.","Drudge-Coates L","Br J Nurs","2012","2012/11/06","","",""
"23660300","The future of systemic therapies for localised prostate cancer","Eigl BJ, Gleave ME, Chi KN.","Clin Oncol (R Coll Radiol). 2013 Aug;25(8):506-13. doi: 10.1016/j.clon.2013.04.002. Epub 2013 May 7.","Eigl BJ","Clin Oncol (R Coll Radiol)","2013","2013/05/11","","","10.1016/j.clon.2013.04.002"
"9923204","Prostate cancer: clinical perspectives","Vetrosky D, White GL Jr.","AAOHN J. 1998 Sep;46(9):434-40; quiz 441-2.","Vetrosky D","AAOHN J","1998","1999/01/29","","",""
"23632485","Circulating microRNAs as potential new biomarkers for prostate cancer","Sita-Lumsden A, Dart DA, Waxman J, Bevan CL.","Br J Cancer. 2013 May 28;108(10):1925-30. doi: 10.1038/bjc.2013.192. Epub 2013 Apr 30.","Sita-Lumsden A","Br J Cancer","2013","2013/05/02","PMC3670496","","10.1038/bjc.2013.192"
"12469925","Psychological complications of prostate cancer","Pirl WF, Mello J.","Oncology (Williston Park). 2002 Nov;16(11):1448-53; discussion 1453-4, 1457-8, 1467.","Pirl WF","Oncology (Williston Park)","2002","2002/12/10","","",""
"23759249","Focal therapy for prostate cancer: rationale and treatment opportunities","Kasivisvanathan V, Emberton M, Ahmed HU.","Clin Oncol (R Coll Radiol). 2013 Aug;25(8):461-73. doi: 10.1016/j.clon.2013.05.002. Epub 2013 Jun 4.","Kasivisvanathan V","Clin Oncol (R Coll Radiol)","2013","2013/06/14","PMC4042323","","10.1016/j.clon.2013.05.002"
"11702151","Ultrasonography of prostate cancer","Clements R.","Eur Radiol. 2001;11(11):2119-25. doi: 10.1007/s003300101028.","Clements R","Eur Radiol","2001","2001/11/10","","","10.1007/s003300101028"
"31576551","Resolution of Cellular Heterogeneity in Human Prostate Cancers: Implications for Diagnosis and Treatment","Maitland NJ, Frame FM, Rane JK, Erb HH, Packer JR, Archer LK, Pellacani D.","Adv Exp Med Biol. 2019;1164:207-224. doi: 10.1007/978-3-030-22254-3_16.","Maitland NJ","Adv Exp Med Biol","2019","2019/10/03","","","10.1007/978-3-030-22254-3_16"
"21088497","Prostate cancer genomic signature offers prognostic value","Troutman SM, Price DK, Figg WD.","Cancer Biol Ther. 2010 Dec 1;10(11):1079-80. doi: 10.4161/cbt.10.11.14086. Epub 2010 Dec 1.","Troutman SM","Cancer Biol Ther","2010","2010/11/20","PMC3230291","","10.4161/cbt.10.11.14086"
"11242644","[The epidemiology of prostate cancer--recent trends in prostate cancer incidence and mortality]","Sata F, Umemura T, Kishi R.","Gan To Kagaku Ryoho. 2001 Feb;28(2):184-8.","Sata F","Gan To Kagaku Ryoho","2001","2001/03/13","","",""
"9858323","Prostate cancer and black men","Brawley OW.","Semin Urol Oncol. 1998 Nov;16(4):184-6.","Brawley OW","Semin Urol Oncol","1998","1998/12/19","","",""
"15271371","MR imaging and MR spectroscopic imaging of prostate cancer","Rajesh A, Coakley FV.","Magn Reson Imaging Clin N Am. 2004 Aug;12(3):557-79, vii. doi: 10.1016/j.mric.2004.03.011.","Rajesh A","Magn Reson Imaging Clin N Am","2004","2004/07/24","","","10.1016/j.mric.2004.03.011"
"2662337","Early detection of prostate cancer","Huben RP.","Semin Surg Oncol. 1989;5(3):201-4. doi: 10.1002/ssu.2980050310.","Huben RP","Semin Surg Oncol","1989","1989/01/01","","","10.1002/ssu.2980050310"
"28982870","Both High and Low Serum Total Testosterone Levels Indicate Poor Prognosis in Patients with Prostate Cancer","Izumi K, Shigehara K, Nohara T, Narimoto K, Kadono Y, Mizokami A.","Anticancer Res. 2017 Oct;37(10):5559-5564. doi: 10.21873/anticanres.11988.","Izumi K","Anticancer Res","2017","2017/10/07","","","10.21873/anticanres.11988"
"16130016","Expectant management: an option for localized prostate cancer","Khan MA, Partin AW.","Prostate Cancer Prostatic Dis. 2005;8(4):311-5. doi: 10.1038/sj.pcan.4500824.","Khan MA","Prostate Cancer Prostatic Dis","2005","2005/09/01","","","10.1038/sj.pcan.4500824"
"23337753","The changing natural history of metastatic prostate cancer","Alva A, Hussain M.","Cancer J. 2013 Jan-Feb;19(1):19-24. doi: 10.1097/PPO.0b013e318281197e.","Alva A","Cancer J","2013","2013/01/23","","","10.1097/PPO.0b013e318281197e"
"20350487","Emerging role of microRNAs in prostate cancer: implications for personalized medicine","Gandellini P, Folini M, Zaffaroni N.","Discov Med. 2010 Mar;9(46):212-8.","Gandellini P","Discov Med","2010","2010/03/31","","",""
"12910365","Molecular and genetic prognostic factors of prostate cancer","Chakravarti A, Zhai GG.","World J Urol. 2003 Sep;21(4):265-74. doi: 10.1007/s00345-003-0362-z. Epub 2003 Aug 9.","Chakravarti A","World J Urol","2003","2003/08/12","","","10.1007/s00345-003-0362-z"
"27424848","Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine","Aoun F, Rassy EE, Assi T, Kattan J.","Future Oncol. 2016 Oct;12(20):2359-61. doi: 10.2217/fon-2016-0292. Epub 2016 Jul 18.","Aoun F","Future Oncol","2016","2016/07/19","","","10.2217/fon-2016-0292"
"26493449","Prevalence and management of prostate cancer among East Asian men: Current trends and future perspectives","Monn MF, Tatem AJ, Cheng L.","Urol Oncol. 2016 Feb;34(2):58.e1-9. doi: 10.1016/j.urolonc.2015.09.003. Epub 2015 Oct 20.","Monn MF","Urol Oncol","2016","2015/10/24","","","10.1016/j.urolonc.2015.09.003"
"19363343","Emerging therapies in castrate-resistant prostate cancer","Lassi K, Dawson NA.","Curr Opin Oncol. 2009 May;21(3):260-5. doi: 10.1097/CCO.0b013e32832a1868.","Lassi K","Curr Opin Oncol","2009","2009/04/14","","","10.1097/CCO.0b013e32832a1868"
"15120667","Environmental, genetic, and molecular features of prostate cancer","Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B.","Lancet Oncol. 2004 May;5(5):303-13. doi: 10.1016/S1470-2045(04)01468-8.","Deutsch E","Lancet Oncol","2004","2004/05/04","","","10.1016/S1470-2045(04)01468-8"
"25234189","Role of radical prostatectomy in clinically non-organ-confined prostate cancer","Gratzke C, Engel J, Stief CG.","Curr Urol Rep. 2014 Nov;15(11):455. doi: 10.1007/s11934-014-0455-9.","Gratzke C","Curr Urol Rep","2014","2014/09/20","","","10.1007/s11934-014-0455-9"
"24846991","[DNA methylation of prostate cancer and clinical application]","Fan Z, Ze Y.","Yi Chuan. 2014 May;36(5):420-30.","Fan Z","Yi Chuan","2014","2014/05/22","","",""
"28457880","The Notch-1 receptor in prostate tumorigenesis","O'Brien R, Marignol L.","Cancer Treat Rev. 2017 May;56:36-46. doi: 10.1016/j.ctrv.2017.04.003. Epub 2017 Apr 17.","O'Brien R","Cancer Treat Rev","2017","2017/05/02","","","10.1016/j.ctrv.2017.04.003"
"18217529","An overview of prostate cancer: diagnosis and treatment","Strief DM.","Urol Nurs. 2007 Dec;27(6):475-9; quiz 480.","Strief DM","Urol Nurs","2007","2008/01/26","","",""
"8439808","Prostate cancer","Handler S.","CA Cancer J Clin. 1993 Mar-Apr;43(2):125-7.","Handler S","CA Cancer J Clin","1993","1993/03/01","","",""
"25052225","Prostate cancer: review in 2014","Barry Delongchamps N.","Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):739-42. doi: 10.1016/j.diii.2014.06.005. Epub 2014 Jul 16.","Barry Delongchamps N","Diagn Interv Imaging","2014","2014/07/24","","","10.1016/j.diii.2014.06.005"
"28255378","Immunotherapy and gene therapy in prostate cancer treatment","Grozescu T, Popa F.","J Med Life. 2017 Jan-Mar;10(1):54-55.","Grozescu T","J Med Life","2017","2017/03/04","PMC5304374","",""
"17402521","Prostate cancer in Maiduguri","Yawe KT, Tahir MB, Nggada HA.","West Afr J Med. 2006 Oct-Dec;25(4):298-300.","Yawe KT","West Afr J Med","2006","2007/04/04","","",""
"12085960","Molecular profiling in prostate cancer","Feroze-Merzoug F, Schober MS, Chen YQ.","Cancer Metastasis Rev. 2001;20(3-4):165-71. doi: 10.1023/a:1015523124871.","Feroze-Merzoug F","Cancer Metastasis Rev","2001","2002/06/28","","","10.1023/a:1015523124871"
"25211935","[Diagnosis and treatment of incidental prostate cancer]","Marisov LV, Vinarov AZ.","Urologiia. 2014 May-Jun;(3):82-5.","Marisov LV","Urologiia","2014","2014/09/13","","",""
"16329268","Prostate cancer","","Nurs Times. 2005 Nov 22-28;101(47):21.","","Nurs Times","2005","2005/12/07","","",""
"1525971","Prostate cancer: current concepts in diagnosis and treatment","Klein EA.","Cleve Clin J Med. 1992 Jul-Aug;59(4):383-9. doi: 10.3949/ccjm.59.4.383.","Klein EA","Cleve Clin J Med","1992","1992/07/01","","","10.3949/ccjm.59.4.383"
"25418898","A concise update on prostate pathology","Xu W, Zhou M.","Cesk Patol. 2014;50(4):120-8.","Xu W","Cesk Patol","2014","2014/11/25","","",""
"15218688","Molecular mechanisms in prostate cancer. A review","Mazzucchelli R, Barbisan F, Tarquini LM, Galosi AB, Stramazzotti D.","Anal Quant Cytol Histol. 2004 Jun;26(3):127-33.","Mazzucchelli R","Anal Quant Cytol Histol","2004","2004/06/29","","",""
"12888934","Role of coagulation and fibrinolytic system in prostate cancer","Kohli M, Kaushal V, Mehta P.","Semin Thromb Hemost. 2003 Jun;29(3):301-8. doi: 10.1055/s-2003-40968.","Kohli M","Semin Thromb Hemost","2003","2003/07/31","","","10.1055/s-2003-40968"
"25066306","Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies","Cai H, Xu Z, Xu T, Yu B, Zou Q.","Diabetes Metab Res Rev. 2015 May;31(4):336-43. doi: 10.1002/dmrr.2582. Epub 2014 Sep 14.","Cai H","Diabetes Metab Res Rev","2015","2014/07/29","","","10.1002/dmrr.2582"
"24506126","Hard decisions about prostate cancer","Nichols C, Zamudio A.","Am Fam Physician. 2014 Feb 1;89(3):219.","Nichols C","Am Fam Physician","2014","2014/02/11","","",""
"1958294","The efficacy of transrectal ultrasound and prostate cancer","Mandell MJ, Hopper KD, Jarowenko MV, Rohner TJ, Belis JA, Stryker JA, Meilstrup JW, Thieme GA.","Crit Rev Diagn Imaging. 1991;32(4):273-300.","Mandell MJ","Crit Rev Diagn Imaging","1991","1991/01/01","","",""
"32147685","Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer","Tateishi U.","Jpn J Clin Oncol. 2020 Apr 7;50(4):349-356. doi: 10.1093/jjco/hyaa004.","Tateishi U","Jpn J Clin Oncol","2020","2020/03/10","PMC7160915","","10.1093/jjco/hyaa004"
"17092289","The association between local atherosclerosis and prostate cancer","Hager M, Mikuz G, Bartsch G, Kolbitsch C, Moser PL.","BJU Int. 2007 Jan;99(1):46-8. doi: 10.1111/j.1464-410X.2006.06549.x.","Hager M","BJU Int","2007","2006/11/10","","","10.1111/j.1464-410X.2006.06549.x"
"25518348","[Novel treatment for prostate cancer targeting prostaglandins]","Terada N, Inoue T, Kamba T, Ogawa O.","Nihon Rinsho. 2014 Dec;72(12):2141-6.","Terada N","Nihon Rinsho","2014","2014/12/19","","",""
"29251471","SUPPORTIVE CARE NEEDS OF PROSTATE CANCER SURVIVORS","O'Shaughnessy K.","Aust Nurs Midwifery J. 2016 Nov;24(5):34.","O'Shaughnessy K","Aust Nurs Midwifery J","2016","2017/12/19","","",""
"17485372","Abnormal DNA methylation, epigenetics, and prostate cancer","Nelson WG, Yegnasubramanian S, Agoston AT, Bastian PJ, Lee BH, Nakayama M, De Marzo AM.","Front Biosci. 2007 May 1;12:4254-66. doi: 10.2741/2385.","Nelson WG","Front Biosci","2007","2007/05/09","","","10.2741/2385"
"17614829","Towards rational and evidence-based use of melatonin in prostate cancer prevention and treatment","Shiu SY.","J Pineal Res. 2007 Aug;43(1):1-9. doi: 10.1111/j.1600-079X.2007.00451.x.","Shiu SY","J Pineal Res","2007","2007/07/07","","","10.1111/j.1600-079X.2007.00451.x"
"26410927","[The Role of MiRNAs in the Development of Prostate Cancer]","Kunsbaeva GB, Gilyazova IR, Pavlov VN, Khusnutdinova EK.","Genetika. 2015 Jul;51(7):737-53.","Kunsbaeva GB","Genetika","2015","2015/09/29","","",""
"27019626","Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer","Wadosky KM, Koochekpour S.","Int J Biol Sci. 2016 Feb 6;12(4):409-26. doi: 10.7150/ijbs.14090. eCollection 2016.","Wadosky KM","Int J Biol Sci","2016","2016/03/29","PMC4807161","","10.7150/ijbs.14090"
"21604942","Role of histopathology and molecular markers in the active surveillance of prostate cancer","Montironi R, Egevad L, Bjartell A, Berney DM.","Acta Oncol. 2011 Jun;50 Suppl 1:56-60. doi: 10.3109/0284186X.2010.522199.","Montironi R","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.522199"
"15498784","Prostate carcinogenesis and inflammation: emerging insights","Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG.","Carcinogenesis. 2005 Jul;26(7):1170-81. doi: 10.1093/carcin/bgh317. Epub 2004 Oct 21.","Palapattu GS","Carcinogenesis","2005","2004/10/23","","","10.1093/carcin/bgh317"
"10550165","Treatment of locally advanced prostate cancer: is chemotherapy the next step?","Oh WK, Kantoff PW.","J Clin Oncol. 1999 Nov;17(11):3664-75. doi: 10.1200/JCO.1999.17.11.3664.","Oh WK","J Clin Oncol","1999","1999/11/05","","","10.1200/JCO.1999.17.11.3664"
"2035996","The diagnosis and treatment of prostate cancer","Andriole GL, Catalona WJ.","Annu Rev Med. 1991;42:9-15. doi: 10.1146/annurev.me.42.020191.000301.","Andriole GL","Annu Rev Med","1991","1991/01/01","","","10.1146/annurev.me.42.020191.000301"
"12640809","The management of prostate cancer","Templeton H.","Nurs Stand. 2003 Feb 5-11;17(21):45-53; quiz 54-5. doi: 10.7748/ns2003.02.17.21.45.c3340.","Templeton H","Nurs Stand","2003","2003/03/19","","","10.7748/ns2003.02.17.21.45.c3340"
"1372877","Early detection of prostate cancer","Scardino PT, Weaver R, Hudson MA.","Hum Pathol. 1992 Mar;23(3):211-22. doi: 10.1016/0046-8177(92)90102-9.","Scardino PT","Hum Pathol","1992","1992/03/01","","","10.1016/0046-8177(92)90102-9"
"24610744","Active surveillance for clinically localized prostate cancer--a systematic review","Thomsen FB, Brasso K, Klotz LH, Røder MA, Berg KD, Iversen P.","J Surg Oncol. 2014 Jun;109(8):830-5. doi: 10.1002/jso.23584. Epub 2014 Mar 7.","Thomsen FB","J Surg Oncol","2014","2014/03/11","","","10.1002/jso.23584"
"24448395","GATA2 as a potential metastasis-driving gene in prostate cancer","Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y.","Oncotarget. 2014 Jan 30;5(2):451-61. doi: 10.18632/oncotarget.1296.","Chiang YT","Oncotarget","2014","2014/01/23","PMC3964220","","10.18632/oncotarget.1296"
"18154201","An update on the treatment of advanced prostate cancer","Ngugi PM.","East Afr Med J. 2007 Sep;84(9 Suppl):S36-9. doi: 10.4314/eamj.v84i9.9560.","Ngugi PM","East Afr Med J","2007","2007/12/25","","","10.4314/eamj.v84i9.9560"
"12381239","The economic costs of early stage prostate cancer","Saigal CS, Litwin MS.","Pharmacoeconomics. 2002;20(13):869-78. doi: 10.2165/00019053-200220130-00001.","Saigal CS","Pharmacoeconomics","2002","2002/10/17","","","10.2165/00019053-200220130-00001"
"7522122","Prostate cancer screening. Appropriate choices? Investigators of the American Cancer Society National Prostate Cancer Detection Project","Littrup PJ.","Cancer. 1994 Oct 1;74(7 Suppl):2016-22. doi: 10.1002/1097-0142(19941001)74:7+<2016::aid-cncr2820741705>3.0.co;2-j.","Littrup PJ","Cancer","1994","1994/10/01","","","10.1002/1097-0142(19941001)74:7+<2016::aid-cncr2820741705>3.0.co;2-j"
"24249419","Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting","Pienta KJ, Walia G, Simons JW, Soule HR.","Prostate. 2014 Feb;74(3):314-20. doi: 10.1002/pros.22753.","Pienta KJ","Prostate","2014","2013/11/20","PMC4253084","","10.1002/pros.22753"
"17996804","The needs of men with prostate cancer: results of a focus group study","Wallace M, Storms S.","Appl Nurs Res. 2007 Nov;20(4):181-7. doi: 10.1016/j.apnr.2006.08.008.","Wallace M","Appl Nurs Res","2007","2007/11/13","","","10.1016/j.apnr.2006.08.008"
"15583704","Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy","Ahmed S, Lindsey B, Davies J.","Prostate Cancer Prostatic Dis. 2005;8(1):31-5. doi: 10.1038/sj.pcan.4500774.","Ahmed S","Prostate Cancer Prostatic Dis","2005","2004/12/08","","","10.1038/sj.pcan.4500774"
"15013685","The androgen receptor: a potential target for therapy of prostate cancer","Santos AF, Huang H, Tindall DJ.","Steroids. 2004 Feb;69(2):79-85. doi: 10.1016/j.steroids.2003.10.005.","Santos AF","Steroids","2004","2004/03/12","","","10.1016/j.steroids.2003.10.005"
"9365551","Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial","Thompson IM, Coltman CA Jr, Crowley J.","Prostate. 1997 Nov 1;33(3):217-21. doi: 10.1002/(sici)1097-0045(19971101)33:3<217::aid-pros11>3.0.co;2-n.","Thompson IM","Prostate","1997","1997/11/20","","","10.1002/(sici)1097-0045(19971101)33:3<217::aid-pros11>3.0.co;2-n"
"25944677","Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer","Renard-Penna R, Cancel-Tassin G, Comperat E, Roupret M, Mozer P, Cussenot O.","World J Urol. 2015 Jul;33(7):929-36. doi: 10.1007/s00345-015-1570-z. Epub 2015 May 6.","Renard-Penna R","World J Urol","2015","2015/05/07","","","10.1007/s00345-015-1570-z"
"31742661","Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics","Eggener SE.","Cancer. 2020 Feb 1;126(3):470-472. doi: 10.1002/cncr.32574. Epub 2019 Nov 19.","Eggener SE","Cancer","2020","2019/11/20","","","10.1002/cncr.32574"
"18762948","A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies","Gonzalez JR, Laudano MA, McCann TR, McKiernan JM, Benson MC.","World J Urol. 2008 Oct;26(5):475-80. doi: 10.1007/s00345-008-0314-8. Epub 2008 Sep 2.","Gonzalez JR","World J Urol","2008","2008/09/03","","","10.1007/s00345-008-0314-8"
"2663330","Treatment of prostate cancer","Korman LB.","Clin Pharm. 1989 Jun;8(6):412-24.","Korman LB","Clin Pharm","1989","1989/06/01","","",""
"31629414","Natural history and imaging in men with high genetic risk for developing prostate cancer","Dahut WL, Couvillon A, Pinto PA, Turkbey B, Karzai F.","Can J Urol. 2019 Oct;26(5 Suppl 2):7-8.","Dahut WL","Can J Urol","2019","2019/10/21","","",""
"20944154","Active surveillance for low-risk prostate cancer","Mazzucchelli R, Nesseris I, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M.","Anticancer Res. 2010 Sep;30(9):3683-92.","Mazzucchelli R","Anticancer Res","2010","2010/10/15","","",""
"21274650","Racial differences in well-being and cancer concerns in prostate cancer patients","Chhatre S, Wein AJ, Malkowicz SB, Jayadevappa R.","J Cancer Surviv. 2011 Jun;5(2):182-90. doi: 10.1007/s11764-011-0170-1. Epub 2011 Jan 28.","Chhatre S","J Cancer Surviv","2011","2011/01/29","","","10.1007/s11764-011-0170-1"
"9186314","The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues","Häggman MJ, Macoska JA, Wojno KJ, Oesterling JE.","J Urol. 1997 Jul;158(1):12-22. doi: 10.1097/00005392-199707000-00004.","Häggman MJ","J Urol","1997","1997/07/01","","","10.1097/00005392-199707000-00004"
"20385354","Prostate cancer: beta control your hormones","Loda M, Kaelin WG Jr.","Cancer Cell. 2010 Apr 13;17(4):311-2. doi: 10.1016/j.ccr.2010.03.013.","Loda M","Cancer Cell","2010","2010/04/14","","","10.1016/j.ccr.2010.03.013"
"24948871","Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer","Kahn B, Collazo J, Kyprianou N.","Int J Biol Sci. 2014 Jun 1;10(6):588-95. doi: 10.7150/ijbs.8671. eCollection 2014.","Kahn B","Int J Biol Sci","2014","2014/06/21","PMC4062951","","10.7150/ijbs.8671"
"9987501","[Prostate cancer]","Uchida K, Akaza H.","Gan To Kagaku Ryoho. 1999 Jan;26(1):76-82.","Uchida K","Gan To Kagaku Ryoho","1999","1999/02/13","","",""
"23811702","Sequencing systemic therapies in metastatic castration-resistant prostate cancer","Liu JJ, Zhang J.","Cancer Control. 2013 Jul;20(3):181-7. doi: 10.1177/107327481302000306.","Liu JJ","Cancer Control","2013","2013/07/02","","","10.1177/107327481302000306"
"15698538","Major impact of hormonal therapy in localized prostate cancer--death can already be an exception","Labrie F, Cusan L, Gomez J, Luu-The V, Candas B, Bélanger A, Labrie C.","J Steroid Biochem Mol Biol. 2004 Dec;92(5):327-44. doi: 10.1016/j.jsbmb.2004.10.011. Epub 2004 Dec 21.","Labrie F","J Steroid Biochem Mol Biol","2004","2005/02/09","","","10.1016/j.jsbmb.2004.10.011"
"28418285","A new predictive tool for postoperative radiotherapy in prostate cancer","Lee DK, Figg WD.","Cancer Biol Ther. 2017 May 4;18(5):277-278. doi: 10.1080/15384047.2017.1310347. Epub 2017 Apr 18.","Lee DK","Cancer Biol Ther","2017","2017/04/19","PMC5499754","","10.1080/15384047.2017.1310347"
"23959476","Clinical characteristics and prognostic factors of prostate cancer with liver metastases","Wang H, Li B, Zhang P, Yao Y, Chang J.","Tumour Biol. 2014 Jan;35(1):595-601. doi: 10.1007/s13277-013-1083-6.","Wang H","Tumour Biol","2014","2013/08/21","","","10.1007/s13277-013-1083-6"
"15714965","[Prostate cancer. Introduction]","Kakizoe T.","Nihon Rinsho. 2005 Feb;63(2):199-200.","Kakizoe T","Nihon Rinsho","2005","2005/02/18","","",""
"20361321","[The significance of chronic prostatitis for the etiopathology of prostate cancer]","Wittschieber D, Schenkenberg S, Dietel M, Erbersdobler A.","Urologe A. 2010 Aug;49(8):947-51. doi: 10.1007/s00120-010-2284-x.","Wittschieber D","Urologe A","2010","2010/04/03","","","10.1007/s00120-010-2284-x"
"24289901","Metastatic castration resistant prostate cancer: current strategies of management in the Middle East","Bazarbashi S, Bachour M, Bulbul M, Alotaibi M, Jaloudi M, Jaafar H, Mukherji D, Farah N, Alrubai T, Shamseddine A.","Crit Rev Oncol Hematol. 2014 Apr;90(1):36-48. doi: 10.1016/j.critrevonc.2013.11.001. Epub 2013 Nov 8.","Bazarbashi S","Crit Rev Oncol Hematol","2014","2013/12/03","","","10.1016/j.critrevonc.2013.11.001"
"7933229","Detection and treatment of prostate cancer: perspective of the urologist","Olsson CA, Goluboff ET.","J Urol. 1994 Nov;152(5 Pt 2):1695-9. doi: 10.1016/s0022-5347(17)32364-9.","Olsson CA","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32364-9"
"9589364","Development of human prostate cancer models for chemoprevention and experimental therapeutics studies","Chung LW, Zhau HE, Wu TT.","J Cell Biochem Suppl. 1997;28-29:174-81.","Chung LW","J Cell Biochem Suppl","1997","1997/01/01","","",""
"23957008","Translational bioinformatics for diagnostic and prognostic prediction of prostate cancer in the next-generation sequencing era","Chen J, Zhang D, Yan W, Yang D, Shen B.","Biomed Res Int. 2013;2013:901578. doi: 10.1155/2013/901578. Epub 2013 Jul 15.","Chen J","Biomed Res Int","2013","2013/08/20","PMC3727129","","10.1155/2013/901578"
"22565373","Prostate cancer: the benefits of multidisciplinary prostate cancer care","Gomella LG.","Nat Rev Urol. 2012 May 8;9(7):360-2. doi: 10.1038/nrurol.2012.105.","Gomella LG","Nat Rev Urol","2012","2012/05/09","","","10.1038/nrurol.2012.105"
"19899373","[Prostate cancer treatments in Belgium]","Kaitouni MI, Roumeguère T.","Rev Med Brux. 2009 Sep;30(4):270-8.","Kaitouni MI","Rev Med Brux","2009","2009/11/11","","",""
"24775718","The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions","Tilki D, Evans CP.","Can J Urol. 2014 Apr;21(2 Supp 1):7-13.","Tilki D","Can J Urol","2014","2014/04/30","","",""
"24976163","From skid row to Main Street: the Bowery series and the transformation of prostate cancer, 1951-1966","Aronowitz R.","Bull Hist Med. 2014 Summer;88(2):287-318. doi: 10.1353/bhm.2014.0037.","Aronowitz R","Bull Hist Med","2014","2014/07/01","","","10.1353/bhm.2014.0037"
"21606287","Prostate cancer imaging: what surgeons, radiation oncologists, and medical oncologists want to know","Tabatabaei S, Saylor PJ, Coen J, Dahl DM.","AJR Am J Roentgenol. 2011 Jun;196(6):1263-6. doi: 10.2214/AJR.10.6263.","Tabatabaei S","AJR Am J Roentgenol","2011","2011/05/25","","","10.2214/AJR.10.6263"
"11992050","Hereditary prostate cancer: clinical characteristics and survival","Bratt O, Damber JE, Emanuelsson M, Grönberg H.","J Urol. 2002 Jun;167(6):2423-6.","Bratt O","J Urol","2002","2002/05/07","","",""
"32150635","Update of Guidelines for Management of Prostate Cancer in West Africa 2019: Consensus Working Document","Osaghae SO.","West Afr J Med. 2020 Apr-Jun;37(2):159-172.","Osaghae SO","West Afr J Med","2020","2020/03/10","","",""
"22764588","Communication: the key to improving the prostate cancer patient experience","Waldie M, Smylie J.","Can Oncol Nurs J. 2012 Spring;22(2):129-39. doi: 10.5737/1181912x222129133.","Waldie M","Can Oncol Nurs J","2012","2012/07/07","","","10.5737/1181912x222129133"
"26467501","Contemporary approaches to prostate cancer management","Schalken JA, Westcott G.","Future Oncol. 2015;11(20):2735-6. doi: 10.2217/fon.15.238.","Schalken JA","Future Oncol","2015","2015/10/16","","","10.2217/fon.15.238"
"7586489","An update on prostate cancer","Klein EA.","Cleve Clin J Med. 1995 Sep-Oct;62(5):325-38. doi: 10.3949/ccjm.62.5.325.","Klein EA","Cleve Clin J Med","1995","1995/09/01","","","10.3949/ccjm.62.5.325"
"15535438","Expression of genes and proteins specific for prostate cancer","Gelmann EP, Semmes OJ.","J Urol. 2004 Nov;172(5 Pt 2):S23-6; discussion S26-7. doi: 10.1097/01.ju.0000141781.70474.48.","Gelmann EP","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000141781.70474.48"
"7689740","Treatment of stage A1 prostate cancer: the case for observation","Austenfeld MS.","Semin Urol. 1993 May;11(2):58-63.","Austenfeld MS","Semin Urol","1993","1993/05/01","","",""
"8062197","The National Cancer Data Base report on prostate cancer","Mettlin CJ, Murphy G.","Cancer. 1994 Sep 1;74(5):1640-8. doi: 10.1002/1097-0142(19940901)74:5<1640::aid-cncr2820740525>3.0.co;2-3.","Mettlin CJ","Cancer","1994","1994/09/01","","","10.1002/1097-0142(19940901)74:5<1640::aid-cncr2820740525>3.0.co;2-3"
"11307066","An update on prostate cancer","Rini BI, Small EJ.","Curr Opin Oncol. 2001 May;13(3):204-11. doi: 10.1097/00001622-200105000-00013.","Rini BI","Curr Opin Oncol","2001","2001/04/18","","","10.1097/00001622-200105000-00013"
"17491274","[Hypoxia-inducible factor 1 and prostate cancer]","Pan ZH, Chen ZD.","Zhonghua Nan Ke Xue. 2007 Apr;13(4):356-9.","Pan ZH","Zhonghua Nan Ke Xue","2007","2007/05/12","","",""
"19300409","Amplification and co-regulators of androgen receptor gene in prostate cancer","Golias Ch, Iliadis I, Peschos D, Charalabopoulos K.","Exp Oncol. 2009 Mar;31(1):3-8.","Golias Ch","Exp Oncol","2009","2009/03/21","","",""
"26576913","Effect of erectile dysfunction following prostate cancer treatment","McConkey R.","Nurs Stand. 2015 Nov 18;30(12):38-44. doi: 10.7748/ns.30.12.38.s46.","McConkey R","Nurs Stand","2015","2015/11/19","","","10.7748/ns.30.12.38.s46"
"10411025","Prostate specific antigen: a decade of discovery--what we have learned and where we are going","Polascik TJ, Oesterling JE, Partin AW.","J Urol. 1999 Aug;162(2):293-306. doi: 10.1016/s0022-5347(05)68543-6.","Polascik TJ","J Urol","1999","1999/07/20","","","10.1016/s0022-5347(05)68543-6"
"1384077","Prostate cancer screening","Roetzheim RG, Herold AH.","Prim Care. 1992 Sep;19(3):637-49.","Roetzheim RG","Prim Care","1992","1992/09/01","","",""
"26080836","Precision medicine path for prostate cancer","","Cancer Discov. 2015 Aug;5(8):786. doi: 10.1158/2159-8290.CD-NB2015-089. Epub 2015 Jun 16.","","Cancer Discov","2015","2015/06/18","","","10.1158/2159-8290.CD-NB2015-089"
"20369138","Early management of prostate cancer","Izard M.","Aust Fam Physician. 2010 Jan-Feb;39(1-2):61-2.","Izard M","Aust Fam Physician","2010","2010/04/07","","",""
"8880970","Epidemiology, diagnosis and treatment of prostate cancer","Newman J.","Radiol Technol. 1996 Sep-Oct;68(1):39-64; quiz 65-8.","Newman J","Radiol Technol","1996","1996/09/01","","",""
"19287960","Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe","Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M.","Int J Oncol. 2009 Apr;34(4):1037-44. doi: 10.3892/ijo_00000229.","Belpomme D","Int J Oncol","2009","2009/03/17","","","10.3892/ijo_00000229"
"17414641","Prostate cancer update: 2006","Lin AM, Small EJ.","Curr Opin Oncol. 2007 May;19(3):229-33. doi: 10.1097/CCO.0b013e3280ad43bd.","Lin AM","Curr Opin Oncol","2007","2007/04/07","","","10.1097/CCO.0b013e3280ad43bd"
"22824289","Current concepts and significance of estrogen receptor β in prostate cancer","Hartman J, Ström A, Gustafsson JÅ.","Steroids. 2012 Oct;77(12):1262-6. doi: 10.1016/j.steroids.2012.07.002. Epub 2012 Jul 20.","Hartman J","Steroids","2012","2012/07/25","","","10.1016/j.steroids.2012.07.002"
"12375010","Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review)","Hill B, Kyprianou N.","Oncol Rep. 2002 Nov-Dec;9(6):1151-6.","Hill B","Oncol Rep","2002","2002/10/11","","",""
"21658978","Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?","Aggarwal RR, Ryan CJ, Chan JM.","Urol Oncol. 2013 Jul;31(5):522-30. doi: 10.1016/j.urolonc.2011.05.001. Epub 2011 Jun 12.","Aggarwal RR","Urol Oncol","2013","2011/06/11","","","10.1016/j.urolonc.2011.05.001"
"1828689","Current status of transrectal ultrasonography in the detection of prostate cancer","Wilson TM, Guthman DA.","Oncology (Williston Park). 1991 Jan;5(1):73-8; discussion 83.","Wilson TM","Oncology (Williston Park)","1991","1991/01/01","","",""
"19795607","Prostate cancer. NCCN clinical practice guidelines in oncology","National Comprehensive Cancer Network.","J Natl Compr Canc Netw. 2004 May;2(3):224-48. doi: 10.6004/jnccn.2004.0021.","National Comprehensive Cancer Network","J Natl Compr Canc Netw","2004","2009/10/03","","","10.6004/jnccn.2004.0021"
"10325488","Molecular biology of progression of prostate cancer","Nupponen N, Visakorpi T.","Eur Urol. 1999;35(5-6):351-4. doi: 10.1159/000019907.","Nupponen N","Eur Urol","1999","1999/05/15","","","10.1159/000019907"
"21656153","Treating prostate cancer in elderly men: how does aging affect the outcome?","Shelke AR, Mohile SG.","Curr Treat Options Oncol. 2011 Sep;12(3):263-75. doi: 10.1007/s11864-011-0160-6.","Shelke AR","Curr Treat Options Oncol","2011","2011/06/10","","","10.1007/s11864-011-0160-6"
"7705321","Prostate cancer","Ellis WJ, Lange PH.","Endocrinol Metab Clin North Am. 1994 Dec;23(4):809-24.","Ellis WJ","Endocrinol Metab Clin North Am","1994","1994/12/01","","",""
"23722008","Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer","Turkbey B, Mena E, Aras O, Garvey B, Grant K, Choyke PL.","Clin Oncol (R Coll Radiol). 2013 Aug;25(8):451-60. doi: 10.1016/j.clon.2013.05.001. Epub 2013 May 27.","Turkbey B","Clin Oncol (R Coll Radiol)","2013","2013/06/01","PMC6330112","NIHMS1005087","10.1016/j.clon.2013.05.001"
"9854188","Molecular diagnostics and therapy of prostate cancer: new avenues","Schalken J.","Eur Urol. 1998;34 Suppl 3:3-6. doi: 10.1159/000052289.","Schalken J","Eur Urol","1998","1998/12/17","","","10.1159/000052289"
"15126789","Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation","Albertsen PC, Hanley JA, Penson DF, Fine J.","J Urol. 2004 Jun;171(6 Pt 1):2221-5. doi: 10.1097/01.ju.0000124381.93689.b4.","Albertsen PC","J Urol","2004","2004/05/06","","","10.1097/01.ju.0000124381.93689.b4"
"7541864","Long-term survival and mortality in prostate cancer treated with noncurative intent","Aus G, Hugosson J, Norlén L.","J Urol. 1995 Aug;154(2 Pt 1):460-5. doi: 10.1097/00005392-199508000-00033.","Aus G","J Urol","1995","1995/08/01","","","10.1097/00005392-199508000-00033"
"26995992","[Evaluation of survival of prostate cancer patients after transurethral resection of the prostate]","Sidorova SA, Shkolnik MI, Bogomolov OA, Zharinov GM.","Vopr Onkol. 2015;61(6):982-5.","Sidorova SA","Vopr Onkol","2015","2016/03/22","","",""
"24264315","D-glucuronyl C5-epimerase cell type specifically affects angiogenesis pathway in different prostate cancer cells","Rosenberg EE, Prudnikova TY, Zabarovsky ER, Kashuba VI, Grigorieva EV.","Tumour Biol. 2014 Apr;35(4):3237-45. doi: 10.1007/s13277-013-1423-6. Epub 2013 Nov 22.","Rosenberg EE","Tumour Biol","2014","2013/11/23","","","10.1007/s13277-013-1423-6"
"10772664","When is a death from prostate cancer not a death from prostate cancer?","Albertsen P.","J Natl Cancer Inst. 2000 Apr 19;92(8):590-1. doi: 10.1093/jnci/92.8.590.","Albertsen P","J Natl Cancer Inst","2000","2000/04/20","","","10.1093/jnci/92.8.590"
"17080009","The function of poliamine metabolism in prostate cancer","Palavan-Unsal N, Aloglu-Senturk SM, Arsan D.","Exp Oncol. 2006 Sep;28(3):178-86.","Palavan-Unsal N","Exp Oncol","2006","2006/11/03","","",""
"17084163","The case for adjuvant therapy for prostate cancer","Glodé LM.","J Urol. 2006 Dec;176(6 Pt 2):S30-3. doi: 10.1016/j.juro.2006.06.074.","Glodé LM","J Urol","2006","2006/11/07","","","10.1016/j.juro.2006.06.074"
"10664669","The prostate: MR imaging and spectroscopy. Present and future","Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H.","Radiol Clin North Am. 2000 Jan;38(1):115-38, viii-ix. doi: 10.1016/s0033-8389(05)70152-4.","Kurhanewicz J","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70152-4"
"23536559","The 19th annual Prostate Cancer Foundation scientific retreat","Walia G, Pienta KJ, Simons JW, Soule HR.","Cancer Res. 2013 Aug 15;73(16):4988-91. doi: 10.1158/0008-5472.CAN-12-4576. Epub 2013 Mar 27.","Walia G","Cancer Res","2013","2013/03/29","","","10.1158/0008-5472.CAN-12-4576"
"24188259","Management of patients with biochemical recurrence after local therapy for prostate cancer","Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18.","Paller CJ","Hematol Oncol Clin North Am","2013","2013/11/06","PMC3818691","NIHMS515194","10.1016/j.hoc.2013.08.005"
"8428342","Prostate cancer. An overview of an increasing dilemma","Coffey DS.","Cancer. 1993 Feb 1;71(3 Suppl):880-6. doi: 10.1002/1097-0142(19930201)71:3+<880::aid-cncr2820711403>3.0.co;2-6.","Coffey DS","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<880::aid-cncr2820711403>3.0.co;2-6"
"9179186","Gene therapy of prostate cancer: p53, suicidal genes, and other targets","Boulikas T.","Anticancer Res. 1997 May-Jun;17(3A):1471-505.","Boulikas T","Anticancer Res","1997","1997/05/01","","",""
"9193343","Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome","Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA.","J Clin Oncol. 1997 Apr;15(4):1478-80. doi: 10.1200/JCO.1997.15.4.1478.","Kupelian PA","J Clin Oncol","1997","1997/04/01","","","10.1200/JCO.1997.15.4.1478"
"8625214","The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society","Mettlin CJ, Murphy GP, McGinnis LS, Menck HR.","Cancer. 1995 Sep 15;76(6):1104-12. doi: 10.1002/1097-0142(19950915)76:6<1104::aid-cncr2820760627>3.0.co;2-d.","Mettlin CJ","Cancer","1995","1995/09/15","","","10.1002/1097-0142(19950915)76:6<1104::aid-cncr2820760627>3.0.co;2-d"
"10332920","Vitamin D in the prevention and treatment of prostate cancer","Konety BR, Johnson CS, Trump DL, Getzenberg RH.","Semin Urol Oncol. 1999 May;17(2):77-84.","Konety BR","Semin Urol Oncol","1999","1999/05/20","","",""
"10776164","Prostate cancer elder alert. Epidemiology, screening, and early detection","Bruner DW, Pickett M, Joseph A, Burggraf V.","J Gerontol Nurs. 2000 Jan;26(1):6-15; quiz 54-5. doi: 10.3928/0098-9134-20000101-06.","Bruner DW","J Gerontol Nurs","2000","2000/04/25","","","10.3928/0098-9134-20000101-06"
"17711162","[Current treatment in high risk and locally advanced prostate cancer]","Esquena Fernández S, Maroto Rey P, Sancho Pardo G, Palou Redorta J, Villavicencio Mavrich H.","Actas Urol Esp. 2007 May;31(5):445-51. doi: 10.1016/s0210-4806(07)73667-7.","Esquena Fernández S","Actas Urol Esp","2007","2007/08/23","","","10.1016/s0210-4806(07)73667-7"
"20585343","The function of microRNAs, small but potent molecules, in human prostate cancer","Sevli S, Uzumcu A, Solak M, Ittmann M, Ozen M.","Prostate Cancer Prostatic Dis. 2010 Sep;13(3):208-17. doi: 10.1038/pcan.2010.21. Epub 2010 Jun 29.","Sevli S","Prostate Cancer Prostatic Dis","2010","2010/06/30","","","10.1038/pcan.2010.21"
"17543727","Hormonal implications in the development and treatment of prostate cancer","Ip C, Hall SJ.","Endocrinol Metab Clin North Am. 2007 Jun;36(2):421-34. doi: 10.1016/j.ecl.2007.03.009.","Ip C","Endocrinol Metab Clin North Am","2007","2007/06/05","","","10.1016/j.ecl.2007.03.009"
"18260605","[Prostate MRI spectroscopy]","Younès P, Chemla N, Hamzé B, Mani J, Naouri JF.","Ann Urol (Paris). 2007 Aug;41(4):145-57. doi: 10.1016/j.anuro.2007.05.001.","Younès P","Ann Urol (Paris)","2007","2008/02/12","","","10.1016/j.anuro.2007.05.001"
"28475407","Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects","Rodgers L, Peer CJ, Figg WD.","Cancer Biol Ther. 2017 Jul 3;18(7):470-472. doi: 10.1080/15384047.2017.1323600. Epub 2017 May 5.","Rodgers L","Cancer Biol Ther","2017","2017/05/06","PMC5639830","","10.1080/15384047.2017.1323600"
"2479160","Early detection of prostate cancer","Scardino PT.","Urol Clin North Am. 1989 Nov;16(4):635-55.","Scardino PT","Urol Clin North Am","1989","1989/11/01","","",""
"23404051","Hormone therapy in prostate cancer","Currie GM, Haase M, Hashmi R, Kiat H.","J Nucl Med Technol. 2013 Mar;41(1):49-51. doi: 10.2967/jnmt.112.118034. Epub 2013 Feb 12.","Currie GM","J Nucl Med Technol","2013","2013/02/14","","","10.2967/jnmt.112.118034"
"25201623","Prostate cancer: REDUCE-ing the link between smoking and prostate cancer","Fenner A.","Nat Rev Urol. 2014 Nov;11(11):601. doi: 10.1038/nrurol.2014.250. Epub 2014 Sep 9.","Fenner A","Nat Rev Urol","2014","2014/09/10","","","10.1038/nrurol.2014.250"
"17692175","Point: the value of predicting life expectancy in men with clinically localized prostate cancer","Clayton DB, Urban DA.","J Natl Compr Canc Netw. 2007 Aug;5(7):703-8. doi: 10.6004/jnccn.2007.0062.","Clayton DB","J Natl Compr Canc Netw","2007","2007/08/19","","","10.6004/jnccn.2007.0062"
"9973103","Defeating prostate cancer: crucial directions for research--excerpt from the report of the Prostate Cancer Progress Review Group","Tindall DJ, Scardino PT.","Prostate. 1999 Feb 1;38(2):166-71. doi: 10.1002/(sici)1097-0045(19990201)38:2<166::aid-pros11>3.0.co;2-a.","Tindall DJ","Prostate","1999","1999/02/11","","","10.1002/(sici)1097-0045(19990201)38:2<166::aid-pros11>3.0.co;2-a"
"2206583","Prostatic cancer. An overview","Denis L, Mahler C.","Acta Oncol. 1990;29(5):665-77. doi: 10.3109/02841869009090072.","Denis L","Acta Oncol","1990","1990/01/01","","","10.3109/02841869009090072"
"8717474","Quality of life in prostate cancer: what are the issues and how are they measured?","Fosså SD.","Eur Urol. 1996;29 Suppl 2:121-3. doi: 10.1159/000473852.","Fosså SD","Eur Urol","1996","1996/01/01","","","10.1159/000473852"
"9155514","Recent developments in the epidemiology of prostate cancer","Mettlin C.","Eur J Cancer. 1997 Mar;33(3):340-7. doi: 10.1016/s0959-8049(97)89003-x.","Mettlin C","Eur J Cancer","1997","1997/03/01","","","10.1016/s0959-8049(97)89003-x"
"20871510","Prostate cancer: how assessment of QoL can improve delivery of care","Brown M.","Br J Nurs. 2010 Sep 23-Oct 13;19(17):1080-4. doi: 10.12968/bjon.2010.19.17.78564.","Brown M","Br J Nurs","2010","2010/09/28","","","10.12968/bjon.2010.19.17.78564"
"20690063","From gene to clinic: TMA-based clinical validation of molecular markers in prostate cancer","Schlomm T, Chun FKh, Erbersdobler A.","Methods Mol Biol. 2010;664:177-89. doi: 10.1007/978-1-60761-806-5_17.","Schlomm T","Methods Mol Biol","2010","2010/08/07","","","10.1007/978-1-60761-806-5_17"
"8717452","Incidence of prostate cancer will double by the year 2030: the argument for","Boyle P, Maisonneuve P, Napalkov P.","Eur Urol. 1996;29 Suppl 2:3-9. doi: 10.1159/000473828.","Boyle P","Eur Urol","1996","1996/01/01","","","10.1159/000473828"
"25777346","The Prostate Cancer DREAM Challenge: A Community-Wide Effort to Use Open Clinical Trial Data for the Quantitative Prediction of Outcomes in Metastatic Prostate Cancer","Abdallah K, Hugh-Jones C, Norman T, Friend S, Stolovitzky G.","Oncologist. 2015 May;20(5):459-60. doi: 10.1634/theoncologist.2015-0054. Epub 2015 Mar 16.","Abdallah K","Oncologist","2015","2015/03/18","PMC4425397","","10.1634/theoncologist.2015-0054"
"18427572","Measuring the individual quality of life of patients with prostate cancer","Stone PC, Murphy RF, Matar HE, Almerie MQ.","Prostate Cancer Prostatic Dis. 2008;11(4):390-6. doi: 10.1038/pcan.2008.16. Epub 2008 Apr 22.","Stone PC","Prostate Cancer Prostatic Dis","2008","2008/04/23","","","10.1038/pcan.2008.16"
"16680835","Markers of bone metabolism in prostate cancer","Smith MR.","Cancer Treat Rev. 2006;32 Suppl 1:23-6. doi: 10.1016/s0305-7372(06)80006-x.","Smith MR","Cancer Treat Rev","2006","2006/05/09","","","10.1016/s0305-7372(06)80006-x"
"18020004","[New aspects in prostate cancer therapy]","Dvorácek J.","Cas Lek Cesk. 2007;146(10):736-45.","Dvorácek J","Cas Lek Cesk","2007","2007/11/21","","",""
"18773736","Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation","Egevad L.","Anal Quant Cytol Histol. 2008 Aug;30(4):190-8.","Egevad L","Anal Quant Cytol Histol","2008","2008/09/09","","",""
"9706231","Diet, nutrition, and prostate cancer","Clinton SK, Giovannucci E.","Annu Rev Nutr. 1998;18:413-40. doi: 10.1146/annurev.nutr.18.1.413.","Clinton SK","Annu Rev Nutr","1998","1998/08/26","","","10.1146/annurev.nutr.18.1.413"
"8529748","Current controversies in the management of localized prostate cancer","Dillioglugil O, Miles BJ, Scardino PT.","Eur Urol. 1995;28(2):85-101. doi: 10.1159/000475029.","Dillioglugil O","Eur Urol","1995","1995/01/01","","","10.1159/000475029"
"12044035","Prostate cancer: status of current treatments and emerging antisense-based therapies","Devi GR.","Curr Opin Mol Ther. 2002 Apr;4(2):138-48.","Devi GR","Curr Opin Mol Ther","2002","2002/06/05","","",""
"16679850","What's new in prostate cancer disease assessment in 2006?","Epstein JI.","Curr Opin Urol. 2006 May;16(3):146-51. doi: 10.1097/01.mou.0000193389.31727.9b.","Epstein JI","Curr Opin Urol","2006","2006/05/09","","","10.1097/01.mou.0000193389.31727.9b"
"7974899","The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy","Mayer FJ, Crawford ED.","Urol Clin North Am. 1994 Nov;21(4):707-15.","Mayer FJ","Urol Clin North Am","1994","1994/11/01","","",""
"20353535","Prostate-cancer screening in an Afro-Caribbean population: the Tobago Prostate Cancer Screening Study","Patrick A.","BJU Int. 2010 Mar;105(6):745-6. doi: 10.1111/j.1464-410X.2010.09222.x.","Patrick A","BJU Int","2010","2010/04/01","","","10.1111/j.1464-410X.2010.09222.x"
"18018527","Prostate cancer: screening, diagnosis and management in 2007","Grubb RL 3rd, Kibel AS.","Mo Med. 2007 Sep-Oct;104(5):408-13; quiz 413-4.","Grubb RL 3rd","Mo Med","2007","2007/11/21","","",""
"7621463","The geography of prostate cancer and its treatment in Japan","Oishi K, Yoshida O, Schroeder FH.","Cancer Surv. 1995;23:267-80.","Oishi K","Cancer Surv","1995","1995/01/01","","",""
"11383453","[Hormonal and molecular biological factors in pathogenesis of prostate cancer]","Zezerov EG.","Vopr Onkol. 2001;47(2):174-81.","Zezerov EG","Vopr Onkol","2001","2001/06/01","","",""
"9301698","Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing","Bratt O, Kristoffersson U, Lundgren R, Olsson H.","Urology. 1997 Sep;50(3):360-5. doi: 10.1016/S0090-4295(97)00250-1.","Bratt O","Urology","1997","1997/09/25","","","10.1016/S0090-4295(97)00250-1"
"17310835","Adjuvant and neoadjuvant therapies in high risk localized prostate cancer","Giannakopoulos X, Stagikas D, Charalabopoulos A, Sofikitis N, Charalabopoulos K.","J Exp Clin Cancer Res. 2006 Dec;25(4):469-73.","Giannakopoulos X","J Exp Clin Cancer Res","2006","2007/02/22","","",""
"9713397","Prostate cancer screening: more harm than good?","Lefevre ML.","Am Fam Physician. 1998 Aug;58(2):432-8.","Lefevre ML","Am Fam Physician","1998","1998/08/26","","",""
"20708869","Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy--correlation with prostate biopsy and prostatectomy histopathological data","Chabanova E, Balslev I, Logager V, Hansen A, Jakobsen H, Kromann-Andersen B, Norgaard N, Horn T, Thomsen HS.","Eur J Radiol. 2011 Nov;80(2):292-6. doi: 10.1016/j.ejrad.2010.07.004. Epub 2010 Aug 13.","Chabanova E","Eur J Radiol","2011","2010/08/17","","","10.1016/j.ejrad.2010.07.004"
"10328599","Advances in prostate cancer","Small EJ.","Curr Opin Oncol. 1999 May;11(3):226-35. doi: 10.1097/00001622-199905000-00016.","Small EJ","Curr Opin Oncol","1999","1999/05/18","","","10.1097/00001622-199905000-00016"
"17405349","Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance","Alberti C.","Eur Rev Med Pharmacol Sci. 2007 Jan-Feb;11(1):59-64.","Alberti C","Eur Rev Med Pharmacol Sci","2007","2007/04/05","","",""
"17765456","3D MR spectroscopic imaging in the evaluation of prostate cancer","Rajesh A, Coakley FV, Kurhanewicz J.","Clin Radiol. 2007 Oct;62(10):921-9. doi: 10.1016/j.crad.2007.04.014. Epub 2007 Jul 10.","Rajesh A","Clin Radiol","2007","2007/09/04","","","10.1016/j.crad.2007.04.014"
"19056697","Changed men: the embodied impact of prostate cancer","Kelly D.","Qual Health Res. 2009 Feb;19(2):151-63. doi: 10.1177/1049732308328067. Epub 2008 Dec 3.","Kelly D","Qual Health Res","2009","2008/12/06","","","10.1177/1049732308328067"
"19572250","[Frequent gene fusion in prostate cancer: clinical applications in diagnosis, prognosis and therapy]","Schmidt F, Scheble V, Mertz K, Perner S, Rubin MA.","Dtsch Med Wochenschr. 2009 Jul;134(28-29):1483-6. doi: 10.1055/s-0029-1225305. Epub 2009 Jul 1.","Schmidt F","Dtsch Med Wochenschr","2009","2009/07/03","","","10.1055/s-0029-1225305"
"9554328","An analysis of watchful waiting for clinically localized prostate cancer","Steinberg GD, Bales GT, Brendler CB.","J Urol. 1998 May;159(5):1431-6. doi: 10.1097/00005392-199805000-00003.","Steinberg GD","J Urol","1998","1998/04/29","","","10.1097/00005392-199805000-00003"
"12756083","Radiotherapy for t3 prostate cancer","Bayley A, Gospodarowicz MK.","Curr Urol Rep. 2003 Jun;4(3):205-10. doi: 10.1007/s11934-003-0070-7.","Bayley A","Curr Urol Rep","2003","2003/05/21","","","10.1007/s11934-003-0070-7"
"9508080","The significance of changing trends in prostate cancer incidence and mortality","Krongrad A, Lai S, Vidal EM.","Semin Urol Oncol. 1998 Feb;16(1):30-4.","Krongrad A","Semin Urol Oncol","1998","1998/03/21","","",""
"25963421","Determination of synthetic lethal interactions to provide therapeutic direction to end aggressive prostate cancer","Ellis L.","Future Oncol. 2015;11(10):1451-4. doi: 10.2217/fon.15.61.","Ellis L","Future Oncol","2015","2015/05/13","","","10.2217/fon.15.61"
"22003477","Localised prostate cancer - current treatment options","Duchesne G.","Aust Fam Physician. 2011 Oct;40(10):768-71.","Duchesne G","Aust Fam Physician","2011","2011/10/18","","",""
"11219024","Prostate cancer Tx. Therapeutic options based on tumor grade, life expectancy, and patient preferences","Cohen SP, Jaskulsky SR.","Geriatrics. 2001 Feb;56(2):39, 42, 47-8 passim.","Cohen SP","Geriatrics","2001","2001/02/24","","",""
"10612956","Fatty acids and prostate cancer: current status and future challenges","Pandian SS, Eremin OE, McClinton S, Wahle KW, Heys SD.","J R Coll Surg Edinb. 1999 Dec;44(6):352-61.","Pandian SS","J R Coll Surg Edinb","1999","1999/12/29","","",""
"10841200","An update on prostate cancer research","Small EJ, Reese DM.","Curr Opin Oncol. 2000 May;12(3):265-72. doi: 10.1097/00001622-200005000-00014.","Small EJ","Curr Opin Oncol","2000","2000/06/07","","","10.1097/00001622-200005000-00014"
"24445913","Prostate cancer: How to manage prostate cancer with lymph node metastases?","Janetschek G, Hruby S.","Nat Rev Urol. 2014 Mar;11(3):137-8. doi: 10.1038/nrurol.2013.321. Epub 2014 Jan 21.","Janetschek G","Nat Rev Urol","2014","2014/01/22","","","10.1038/nrurol.2013.321"
"6678468","Prostate cancer grading: the NPCP system","Gaeta JF, Asirwatham JE.","Semin Urol. 1983 Aug;1(3):193-203.","Gaeta JF","Semin Urol","1983","1983/08/01","","",""
"8203988","Increasing incidence of cancer of the prostate. The experience of black and white men in the Detroit metropolitan area","Demers RY, Swanson GM, Weiss LK, Kau TY.","Arch Intern Med. 1994 Jun 13;154(11):1211-6.","Demers RY","Arch Intern Med","1994","1994/06/13","","",""
"1574462","The natural history of locally confined prostate cancer: a review","Fair WR.","Prostate Suppl. 1992;4:79-84. doi: 10.1002/pros.2990210512.","Fair WR","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210512"
"8632573","Prostate cancer--staging and prognosis","Miles BJ.","J Urol. 1996 Apr;155(4):1355-6. doi: 10.1016/s0022-5347(01)66265-7.","Miles BJ","J Urol","1996","1996/04/01","","","10.1016/s0022-5347(01)66265-7"
"24416882","[Prostate cancer center: a multidisciplinary approach to accurately manage patients with prostate cancer]","Tawadros T, Burruni R, Herrera F, Codeluppi C, Zurkinden C, Meuwly JY, Lhermitte B, Berthold D.","Rev Med Suisse. 2013 Dec 4;9(409):2270-2, 2274.","Tawadros T","Rev Med Suisse","2013","2014/01/15","","",""
"9550730","Monograph series on aging-related diseases: X. Prostate cancer","Ellison LF, Stokes J, Gibbons L, Lindsay J, Levy I, Morrison H.","Chronic Dis Can. 1998;19(1):1-18.","Ellison LF","Chronic Dis Can","1998","1998/05/23","","",""
"27062395","Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer","Wood GJ, Hayden RP, Tanrikut C.","Andrologia. 2017 Feb;49(1). doi: 10.1111/and.12578. Epub 2016 Apr 6.","Wood GJ","Andrologia","2017","2016/04/11","","","10.1111/and.12578"
"11104881","The role of active treatment in early prostate cancer","Denis LJ.","Radiother Oncol. 2000 Dec;57(3):251-8. doi: 10.1016/s0167-8140(00)00284-x.","Denis LJ","Radiother Oncol","2000","2000/12/06","","","10.1016/s0167-8140(00)00284-x"
"27524169","Das Prostatakarzinom: aktuelle Diagnostik und Therapiestandard","Brachlow J, Kälin M, Randazzo M, Förster B, John H.","Praxis (Bern 1994). 2016 Aug;105(16):971-7. doi: 10.1024/1661-8157/a002437.","Brachlow J","Praxis (Bern 1994)","2016","2016/08/16","","","10.1024/1661-8157/a002437"
"7823591","Target populations and strategies for chemoprevention trials of prostate cancer","Bostwick DG.","J Cell Biochem Suppl. 1994;19:191-6.","Bostwick DG","J Cell Biochem Suppl","1994","1994/01/01","","",""
"11586202","Efficacy of digital rectal examination after radiotherapy for prostate cancer","Johnstone PA, McFarland JT, Riffenburgh RH, Amling CL.","J Urol. 2001 Nov;166(5):1684-7.","Johnstone PA","J Urol","2001","2001/10/05","","",""
"16144676","How could getting screened for prostate cancer hurt you?","Talcott JA.","Urol Oncol. 2005 Sep-Oct;23(5):374-5. doi: 10.1016/j.urolonc.2005.05.011.","Talcott JA","Urol Oncol","2005","2005/09/08","","","10.1016/j.urolonc.2005.05.011"
"11901478","New discoveries in prostate cancer biology and treatment. 5-9 December 2001, Naples, Florida, USA","Cooper CR, Chay CH, Pienta KJ.","Expert Opin Ther Targets. 2002 Feb;6(1):123-7. doi: 10.1517/14728222.6.1.123.","Cooper CR","Expert Opin Ther Targets","2002","2002/03/21","","","10.1517/14728222.6.1.123"
"8776810","Issues on early diagnosis and treatment of localized prostate cancer","Pontes JE.","Urol Int. 1996;56 Suppl 1:1-5. doi: 10.1159/000282860.","Pontes JE","Urol Int","1996","1996/01/01","","","10.1159/000282860"
"7540938","Prostate cancer screening. Why the controversy?","Walther PJ.","Surg Oncol Clin N Am. 1995 Apr;4(2):315-34.","Walther PJ","Surg Oncol Clin N Am","1995","1995/04/01","","",""
"16613546","Management of prostate cancer. Part 2: localized and locally advanced disease","Sooriakumaran P, Khaksar SJ, Shah J.","Expert Rev Anticancer Ther. 2006 Apr;6(4):595-603. doi: 10.1586/14737140.6.4.595.","Sooriakumaran P","Expert Rev Anticancer Ther","2006","2006/04/15","","","10.1586/14737140.6.4.595"
"12827257","[Urological diagnosis of prostate carcinoma]","Müller-Lisse UL, Hofstetter A.","Radiologe. 2003 Jun;43(6):432-40. doi: 10.1007/s00117-003-0913-8.","Müller-Lisse UL","Radiologe","2003","2003/06/27","","","10.1007/s00117-003-0913-8"
"7803733","Early detection issues of prostate cancer in African American men","Powell IJ.","In Vivo. 1994 May-Jun;8(3):451-2.","Powell IJ","In Vivo","1994","1994/05/01","","",""
"9644311","[Treatment of prostate cancer in patients aged 75 or older]","Kanamaru H, Akino H, Arai Y, Yoshida H, Okada K.","Gan To Kagaku Ryoho. 1998 Jun;25(7):985-9.","Kanamaru H","Gan To Kagaku Ryoho","1998","1998/06/30","","",""
"24914841","[Selection criteria and nomograms for active surveillance in prostate cáncer]","Borque A, Esteban LM, Sanz G, Rubio-Briones J, Gil MJ.","Arch Esp Urol. 2014 Jun;67(5):419-30.","Borque A","Arch Esp Urol","2014","2014/06/11","","",""
"17593619","Clinical applications of expression profiling and proteomics in prostate cancer","Masters JR.","Anticancer Res. 2007 May-Jun;27(3A):1273-6.","Masters JR","Anticancer Res","2007","2007/06/28","","",""
"25308065","Targeted local therapy in oligometastatic prostate cancer: a promising potential opportunity after failed primary treatment","Reeves F, Murphy D, Evans C, Bowden P, Costello A.","BJU Int. 2015 Aug;116(2):170-2. doi: 10.1111/bju.12957. Epub 2014 Dec 30.","Reeves F","BJU Int","2015","2014/10/14","","","10.1111/bju.12957"
"11383245","Quality of life in patients with prostate cancer","McPherson CP, Swenson KK, Kjellberg J.","Semin Oncol Nurs. 2001 May;17(2):138-46. doi: 10.1016/s0749-2081(01)80021-8.","McPherson CP","Semin Oncol Nurs","2001","2001/06/01","","","10.1016/s0749-2081(01)80021-8"
"7933226","The early detection and treatment of prostate cancer: the perspective of the Canadian Task Force on the Periodic Health Examination","Feightner JW.","J Urol. 1994 Nov;152(5 Pt 2):1682-4. doi: 10.1016/s0022-5347(17)32360-1.","Feightner JW","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32360-1"
"25518347","[Elucidating the molecular mechanism of prostate cancer progression under chronic hypoxia and development of the novel therapeutic approach]","Nomura T, Yamasaki M, Mimata H.","Nihon Rinsho. 2014 Dec;72(12):2136-40.","Nomura T","Nihon Rinsho","2014","2014/12/19","","",""
"9857369","Prospects for gene therapy in human prostate cancer","Ficazzola MA, Taneja SS.","Mol Med Today. 1998 Nov;4(11):494-504. doi: 10.1016/s1357-4310(98)01334-3.","Ficazzola MA","Mol Med Today","1998","1998/12/19","","","10.1016/s1357-4310(98)01334-3"
"23955683","Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis","Mohsenzadegan M, Madjd Z, Asgari M, Abolhasani M, Shekarabi M, Taeb J, Shariftabrizi A.","Cancer Immunol Immunother. 2013 Oct;62(10):1609-18. doi: 10.1007/s00262-013-1463-1. Epub 2013 Aug 17.","Mohsenzadegan M","Cancer Immunol Immunother","2013","2013/08/20","","","10.1007/s00262-013-1463-1"
"18154196","Prostate cancer","Magoha GA.","East Afr Med J. 2007 Sep;84(9 Suppl):S1-2.","Magoha GA","East Afr Med J","2007","2007/12/25","","",""
"10814947","Urinary incontinence as a factor in prostate cancer treatment selection","O'Rourke ME.","J Wound Ostomy Continence Nurs. 2000 May;27(3):146-54. doi: 10.1016/s1071-5754(00)90052-4.","O'Rourke ME","J Wound Ostomy Continence Nurs","2000","2000/05/18","","","10.1016/s1071-5754(00)90052-4"
"23478499","Predicting high-risk disease using tissue biomarkers","Donovan MJ, Cordon-Cardo C.","Curr Opin Urol. 2013 May;23(3):245-51. doi: 10.1097/MOU.0b013e32835f89cc.","Donovan MJ","Curr Opin Urol","2013","2013/03/13","","","10.1097/MOU.0b013e32835f89cc"
"23089345","PSA implications and medical management of prostate cancer for the primary care physician","Rehsia S, Shayegan B.","Can J Urol. 2012 Oct;19 Suppl 1:28-35.","Rehsia S","Can J Urol","2012","2012/10/24","","",""
"18444164","The interaction of genetic polymorphisms with lifestyle factors: implications for the dietary prevention of prostate cancer","Nelson EC, Rodriguez RL, Dawson K, Galvez AF, Evans CP.","Nutr Cancer. 2008;60(3):301-12. doi: 10.1080/01635580701745319.","Nelson EC","Nutr Cancer","2008","2008/04/30","","","10.1080/01635580701745319"
"18227857","Sweet's syndrome in prostate cancer","Glendenning J, Khoo V.","Prostate Cancer Prostatic Dis. 2008;11(4):397-8. doi: 10.1038/sj.pcan.4501029. Epub 2008 Jan 29.","Glendenning J","Prostate Cancer Prostatic Dis","2008","2008/01/30","","","10.1038/sj.pcan.4501029"
"10769794","[Clinical profiles of prostate cancer in our hospital: association between primary symptoms and clinical stage]","Kimura T, Ikemoto I, Ohishi Y.","Hinyokika Kiyo. 2000 Feb;46(2):83-6.","Kimura T","Hinyokika Kiyo","2000","2000/04/19","","",""
"12955891","Role of screening in detection of clinically localized prostate cancer","Galić J, Karner I, Cenan L, Tucak A, Vranjes Z, Bilandzija-Peranović M, Hegedus I.","Coll Antropol. 2003;27 Suppl 1:49-54.","Galić J","Coll Antropol","2003","2003/09/06","","",""
"8645589","Waning sexual function--the most important disease-specific distress for patients with prostate cancer","Helgason AR, Adolfsson J, Dickman P, Fredrikson M, Arver S, Steineck G.","Br J Cancer. 1996 Jun;73(11):1417-21. doi: 10.1038/bjc.1996.268.","Helgason AR","Br J Cancer","1996","1996/06/01","PMC2074472","","10.1038/bjc.1996.268"
"22249373","Intraprostatic targeting","Ukimura O, Faber K, Gill IS.","Curr Opin Urol. 2012 Mar;22(2):97-103. doi: 10.1097/MOU.0b013e32835017fa.","Ukimura O","Curr Opin Urol","2012","2012/01/18","","","10.1097/MOU.0b013e32835017fa"
"8685580","Role of laparoscopy in the diagnosis and treatment of prostate cancer","Moore RG, Partin AW, Kavoussi LR.","Semin Surg Oncol. 1996 Mar-Apr;12(2):139-44. doi: 10.1002/(SICI)1098-2388(199603/04)12:2<139::AID-SSU9>3.0.CO;2-A.","Moore RG","Semin Surg Oncol","1996","1996/03/01","","","10.1002/(SICI)1098-2388(199603/04)12:2<139::AID-SSU9>3.0.CO;2-A"
"9111616","How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium","Altwein J, Ekman P, Barry M, Biermann C, Carlsson P, Fosså S, Kiebert G, Küchler T, McLeod D, Porter A, Steineck G.","Urology. 1997 Apr;49(4A Suppl):66-76. doi: 10.1016/s0090-4295(99)80325-2.","Altwein J","Urology","1997","1997/04/01","","","10.1016/s0090-4295(99)80325-2"
"4138838","Prostate cancer","Murphy GP.","CA Cancer J Clin. 1974 Sep-Oct;24(5):282-8. doi: 10.3322/canjclin.24.5.282.","Murphy GP","CA Cancer J Clin","1974","1974/09/01","","","10.3322/canjclin.24.5.282"
"16170999","[How to treat a localized prostate cancer: irradiation, surgery or watchful waiting?]","Zellweger T, Gasser T.","Praxis (Bern 1994). 2005 Aug 24;94(34):1307-8. doi: 10.1024/0369-8394.94.34.1307.","Zellweger T","Praxis (Bern 1994)","2005","2005/09/21","","","10.1024/0369-8394.94.34.1307"
"6202247","[Prostate cancer]","Kawai T, Washizuka M, Takahashi T, Kusuyama H.","Gan To Kagaku Ryoho. 1984 May;11(5):999-1004.","Kawai T","Gan To Kagaku Ryoho","1984","1984/05/01","","",""
"1380941","Prostate specific antigen: clinical use in the diagnosis and management of prostate cancer","Kabalin JN.","Geriatrics. 1992 Sep;47(9):26-32.","Kabalin JN","Geriatrics","1992","1992/09/01","","",""
"9617317","[Mass screening for prostate cancer--how to eliminate clinically insignificant cancer]","Imai K, Kubota H.","Gan To Kagaku Ryoho. 1998 May;25(6):809-12.","Imai K","Gan To Kagaku Ryoho","1998","1998/06/09","","",""
"7687519","Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology","Hsieh WS, Simons JW.","Cancer Treat Rev. 1993 Jul;19(3):229-60. doi: 10.1016/0305-7372(93)90037-r.","Hsieh WS","Cancer Treat Rev","1993","1993/07/01","","","10.1016/0305-7372(93)90037-r"
"17037681","[Prostate cancer]","Romics I.","Orv Hetil. 2006 Aug 20;147(33):1578-9.","Romics I","Orv Hetil","2006","2006/10/14","","",""
"9076479","Prostate cancer: to screen or not to screen?","Bouffioux C.","Eur Urol. 1997;31 Suppl 1:2-4. doi: 10.1159/000474524.","Bouffioux C","Eur Urol","1997","1997/01/01","","","10.1159/000474524"
"17431368","Treatment options in locally advanced prostate cancer","Swanson GP.","Minerva Urol Nefrol. 2007 Mar;59(1):27-42.","Swanson GP","Minerva Urol Nefrol","2007","2007/04/14","","",""
"10563177","[Epidemiology of prostatic cancer]","Harvei S.","Tidsskr Nor Laegeforen. 1999 Oct 10;119(24):3589-94.","Harvei S","Tidsskr Nor Laegeforen","1999","1999/11/24","","",""
"8428347","Salvage surgery for radiation failure in prostate cancer","Pontes JE, Montie J, Klein E, Huben R.","Cancer. 1993 Feb 1;71(3 Suppl):976-80. doi: 10.1002/1097-0142(19930201)71:3+<976::aid-cncr2820711413>3.0.co;2-m.","Pontes JE","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<976::aid-cncr2820711413>3.0.co;2-m"
"16938574","Polysomy 13 in a canine prostate carcinoma underlining its significance in the development of prostate cancer","Winkler S, Reimann-Berg N, Murua Escobar H, Loeschke S, Eberle N, Höinghaus R, Nolte I, Bullerdiek J.","Cancer Genet Cytogenet. 2006 Sep;169(2):154-8. doi: 10.1016/j.cancergencyto.2006.03.015.","Winkler S","Cancer Genet Cytogenet","2006","2006/08/30","","","10.1016/j.cancergencyto.2006.03.015"
"12731435","[Localized prostate cancer]","Rodríguez Duarte C.","Arch Esp Urol. 2003 Mar;56(2):103-10.","Rodríguez Duarte C","Arch Esp Urol","2003","2003/05/07","","",""
"29251887","TAKING ACTION TO IMPROVE OUTCOMES FOR MEN LIVING WITH AND BEYOND PROSTATE CANCER","Yates P, Liu WH, Dixon C.","Aust Nurs Midwifery J. 2016 Dec;24(6):35.","Yates P","Aust Nurs Midwifery J","2016","2017/12/19","","",""
"19424171","Prostate cancer: local control and radiotherapy matter in prostate cancer","Rosenthal SA.","Nat Rev Urol. 2009 May;6(5):250-1. doi: 10.1038/nrurol.2009.56.","Rosenthal SA","Nat Rev Urol","2009","2009/05/09","","","10.1038/nrurol.2009.56"
"15373195","[Endocrine therapy for localized or locally advanced prostate cancer]","Fontaine E, Ruffion A, Staerman F.","Prog Urol. 2004 Jun;14(3):433-6.","Fontaine E","Prog Urol","2004","2004/09/18","","",""
"18307684","Optimizing the management of prostate diseases: prostate cancer. Introduction","Fitzpatrick JM.","BJU Int. 2008 Mar;101 Suppl 2:1. doi: 10.1111/j.1464-410X.2007.07484.x.","Fitzpatrick JM","BJU Int","2008","2008/03/01","","","10.1111/j.1464-410X.2007.07484.x"
"2681836","Sonographic and pathological staging of patients with clinically localized prostate cancer","Andriole GL, Coplen DE, Mikkelsen DJ, Catalona WJ.","J Urol. 1989 Nov;142(5):1259-61. doi: 10.1016/s0022-5347(17)39050-x.","Andriole GL","J Urol","1989","1989/11/01","","","10.1016/s0022-5347(17)39050-x"
"18236453","""Limited"" prostate cancer on biopsy: a note of caution","Schlegel PN.","Cancer. 2008 Mar 1;112(5):966-7. doi: 10.1002/cncr.23274.","Schlegel PN","Cancer","2008","2008/02/01","","","10.1002/cncr.23274"
"9314821","The American Cancer Society National Prostate Cancer Detection Project and National patterns of prostate cancer detection and treatment","Mettlin C.","CA Cancer J Clin. 1997 Sep-Oct;47(5):265-72. doi: 10.3322/canjclin.47.5.265.","Mettlin C","CA Cancer J Clin","1997","1997/10/07","","","10.3322/canjclin.47.5.265"
"7541865","Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent","Aus G, Hugosson J, Norlén L.","J Urol. 1995 Aug;154(2 Pt 1):466-9. doi: 10.1097/00005392-199508000-00034.","Aus G","J Urol","1995","1995/08/01","","","10.1097/00005392-199508000-00034"
"17639714","[Modern methods of prostate cancer diagnostics]","Bryzgunova OE, Vlasov VV, Laktiononv PP.","Biomed Khim. 2007 Mar-Apr;53(2):128-39.","Bryzgunova OE","Biomed Khim","2007","2007/07/21","","",""
"8948411","Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer","Hugosson J, Aus G, Norlén L.","Urol Clin North Am. 1996 Nov;23(4):557-73. doi: 10.1016/s0094-0143(05)70336-0.","Hugosson J","Urol Clin North Am","1996","1996/11/01","","","10.1016/s0094-0143(05)70336-0"
"9750492","[Clinical staging and management of prostate cancer]","Maeda O, Usami M, Kotake T.","Nihon Rinsho. 1998 Aug;56(8):1984-8.","Maeda O","Nihon Rinsho","1998","1998/09/29","","",""
"10370367","Decision to operate, radiate, or watch and wait: the prostate cancer dilemma","Nanus DM.","Cancer Invest. 1999;17(5):374-5. doi: 10.3109/07357909909032881.","Nanus DM","Cancer Invest","1999","1999/06/17","","","10.3109/07357909909032881"
"21287542","Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer","Madlung A, Simcock M, Ghadjar P.","Cancer. 2011 Aug 1;117(15):3532; author reply 3532-3. doi: 10.1002/cncr.25949. Epub 2011 Feb 1.","Madlung A","Cancer","2011","2011/02/03","","","10.1002/cncr.25949"
"10636567","Prostate cancer in Denmark. Incidence, morbidity and mortality","Brasso K, Iverson P.","Scand J Urol Nephrol Suppl. 1999;203:29-33.","Brasso K","Scand J Urol Nephrol Suppl","1999","2000/01/15","","",""
"1371557","Prostate cancer in nonurological patients with normal prostates on digital rectal examination","Hammerer P, Loy V, Dieringer J, Huland H.","J Urol. 1992 Mar;147(3 Pt 2):833-6. doi: 10.1016/s0022-5347(17)37399-8.","Hammerer P","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37399-8"
"7503660","College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group","Grignon DJ, Hammond EH.","Arch Pathol Lab Med. 1995 Dec;119(12):1122-6.","Grignon DJ","Arch Pathol Lab Med","1995","1995/12/01","","",""
"2405975","Prostatic oncology","Narayan P, Jajodia P.","Clin Geriatr Med. 1990 Feb;6(1):131-61.","Narayan P","Clin Geriatr Med","1990","1990/02/01","","",""
"7781804","Update on urology--prostate cancer. 1--The molecular basis for prostatic cancer: how it may influence treatment choice","Newling DW.","Eur J Surg Oncol. 1995 Jun;21(3):310-5. doi: 10.1016/s0748-7983(95)91723-3.","Newling DW","Eur J Surg Oncol","1995","1995/06/01","","","10.1016/s0748-7983(95)91723-3"
"22522499","Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer","Getzenberg RH, Carter HB.","Asian J Androl. 2012 May;14(3):347-8. doi: 10.1038/aja.2012.34. Epub 2012 Apr 23.","Getzenberg RH","Asian J Androl","2012","2012/04/24","PMC3720160","","10.1038/aja.2012.34"
"7022594","Prostate cancer. Perspectives and prospects","Chisholm GD.","Recent Results Cancer Res. 1981;78:173-84.","Chisholm GD","Recent Results Cancer Res","1981","1981/01/01","","",""
"23689252","Prostate cancer: to EBRT or not to EBRT: surgery or radiotherapy for localized prostate cancer? That is the question","Fenner A.","Nat Rev Urol. 2013 Jun;10(6):305. doi: 10.1038/nrurol.2013.109. Epub 2013 May 21.","Fenner A","Nat Rev Urol","2013","2013/05/22","","","10.1038/nrurol.2013.109"
"7005544","The immune response to prostate cancer: an evaluation and a review","Guinan P, Bhatti R, Sharifi R, Sundar B, Nagubadi S, Baumgartner G.","J Surg Oncol. 1980;15(4):309-18. doi: 10.1002/jso.2930150402.","Guinan P","J Surg Oncol","1980","1980/01/01","","","10.1002/jso.2930150402"
"11037590","[Diet probably plays an important role in the development of prostatic cancer]","Damber JE.","Lakartidningen. 2000 Aug 9;97(32-33):3475-80.","Damber JE","Lakartidningen","2000","2000/10/19","","",""
"1509035","Questions regarding the treatment of localized prostate cancer","Steinfeld AD.","Radiology. 1992 Sep;184(3):593-8. doi: 10.1148/radiology.184.3.1509035.","Steinfeld AD","Radiology","1992","1992/09/01","","","10.1148/radiology.184.3.1509035"
"15998940","Employment after therapy for localized prostate cancer: widening the perspective","Talcott JA.","J Natl Cancer Inst. 2005 Jul 6;97(13):948-9. doi: 10.1093/jnci/dji182.","Talcott JA","J Natl Cancer Inst","2005","2005/07/07","","","10.1093/jnci/dji182"
"7487134","[Prognostic factors of prostatic cancer]","Okada Y, Shichiri Y, Ogawa O, Yoshida O.","Gan To Kagaku Ryoho. 1995 Nov;22(13):1999-2005.","Okada Y","Gan To Kagaku Ryoho","1995","1995/11/01","","",""
"21394742","The 17th Annual Prostate Cancer Foundation scientific retreat: meeting report","Ericson KR, Simons JW, Soule HR.","Prostate. 2011 Nov;71(15):1616-20. doi: 10.1002/pros.21378. Epub 2011 Mar 10.","Ericson KR","Prostate","2011","2011/03/12","","","10.1002/pros.21378"
"18391938","Brachytherapy for advanced prostate cancer bleeding","Thurairaja R, Pocock R, Crundwell M, Stott M, Rowlands C, Srinivasan R, Sheehan D.","Prostate Cancer Prostatic Dis. 2008;11(4):367-70. doi: 10.1038/pcan.2008.12. Epub 2008 Mar 4.","Thurairaja R","Prostate Cancer Prostatic Dis","2008","2008/04/09","","","10.1038/pcan.2008.12"
"7933228","Prostate cancer, screening and the generalist physician","Roberts RG.","J Urol. 1994 Nov;152(5 Pt 2):1693-4. doi: 10.1016/s0022-5347(17)32363-7.","Roberts RG","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32363-7"
"8066394","[Diagnosis and evaluation of spread of prostate cancer]","Joubert P, Fendler JP, Devonec M, Perrin P.","Rev Prat. 1994 Mar 1;44(5):586-90.","Joubert P","Rev Prat","1994","1994/03/01","","",""
"8526386","Changes in early detection of prostate cancer in the United States","Mettlin C.","Ann N Y Acad Sci. 1995 Sep 30;768:68-72. doi: 10.1111/j.1749-6632.1995.tb12110.x.","Mettlin C","Ann N Y Acad Sci","1995","1995/09/30","","","10.1111/j.1749-6632.1995.tb12110.x"
"2092769","Predicting biologic potential in prostate cancer","Scher HI.","Curr Opin Oncol. 1990 Jun;2(3):520-8.","Scher HI","Curr Opin Oncol","1990","1990/06/01","","",""
"10529559","The natural history of early prostate cancer and the impact of endocrine treatment","Adolfsson J.","Eur Urol. 1999;36 Suppl 2:3-8. doi: 10.1159/000052336.","Adolfsson J","Eur Urol","1999","1999/10/26","","","10.1159/000052336"
"8262120","Radical prostatectomy or wait-and-watch?","Studer UE, Thalmann G, Zingg EJ.","Eur Urol. 1993;24 Suppl 2:24-8. doi: 10.1159/000474384.","Studer UE","Eur Urol","1993","1993/01/01","","","10.1159/000474384"
"9250500","[Treatment of prostate cancer by radiotherapy]","Akino H, Ohyama N, Mori H, Kanamaru H, Okada K, Yoshida M, Ishii Y, Arai Y.","Hinyokika Kiyo. 1997 Jun;43(6):461-4.","Akino H","Hinyokika Kiyo","1997","1997/06/01","","",""
"17379396","Finding a balanced strategy in prostate cancer diagnosis for case detection by prostate needle biopsy at first presentation: ""all for more cores and more cores for all"" or individualised sampling regimens? Which way forward?","Patel A.","Eur Urol. 2007 Aug;52(2):313-5. doi: 10.1016/j.eururo.2007.03.031. Epub 2007 Mar 16.","Patel A","Eur Urol","2007","2007/03/24","","","10.1016/j.eururo.2007.03.031"
"8433754","Prostate cancer","Cooper MR.","N C Med J. 1993 Feb;54(2):87-90.","Cooper MR","N C Med J","1993","1993/02/01","","",""
"2927135","Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies","Natarajan N, Murphy GP, Mettlin C.","J Surg Oncol. 1989 Apr;40(4):232-6. doi: 10.1002/jso.2930400406.","Natarajan N","J Surg Oncol","1989","1989/04/01","","","10.1002/jso.2930400406"
"3335387","A uniform histopathologic grading system for prostate cancer. Subcommittee on Diagnostic Nomenclature, Prostate Cancer Working Group, Organ Systems Program","Gardner WA Jr, Coffey D, Karr JP, Chiarodo A, Epstein J, McNeal JE, Miller G.","Hum Pathol. 1988 Jan;19(1):119-20. doi: 10.1016/s0046-8177(88)80330-7.","Gardner WA Jr","Hum Pathol","1988","1988/01/01","","","10.1016/s0046-8177(88)80330-7"
"7850720","Report of the consensus workshop on screening and global strategy for prostate cancer","Denis LJ, Murphy GP, Schröder FH.","Cancer. 1995 Mar 1;75(5):1187-207. doi: 10.1002/1097-0142(19950301)75:5<1187::aid-cncr2820750521>3.0.co;2-g.","Denis LJ","Cancer","1995","1995/03/01","","","10.1002/1097-0142(19950301)75:5<1187::aid-cncr2820750521>3.0.co;2-g"
"15503318","A misleading paper on prostate cancer screening","Elwood M.","Prostate. 2004 Dec 1;61(4):372; author reply 373-4. doi: 10.1002/pros.20160.","Elwood M","Prostate","2004","2004/10/27","","","10.1002/pros.20160"
"23712267","[Prostate cancer: increase information exchange!]","","Aktuelle Urol. 2013 May;44(3):172. doi: 10.1055/s-0033-1348106. Epub 2013 May 27.","","Aktuelle Urol","2013","2013/05/29","","","10.1055/s-0033-1348106"
"18271097","On call. I had radiation for prostate cancer when I was 63, and I've been fine for the past eight years, with a low PSA. My dear friend just went in for prostate cancer and was diagnosed with a sarcoma. His doctors seem very gloomy. What's the difference?","Simon HB.","Harv Mens Health Watch. 2005 Mar;9(8):8.","Simon HB","Harv Mens Health Watch","2005","2008/02/15","","",""
"7597758","Prostate cancer: detection and treatment options","Pobursky J.","Todays OR Nurse. 1995 May-Jun;17(3):5-9.","Pobursky J","Todays OR Nurse","1995","1995/05/01","","",""
"8583546","Cost conscious evaluation and treatment of prostate cancer","Presti J Jr.","J Urol. 1996 Mar;155(3):1004. doi: 10.1016/s0022-5347(01)66368-7.","Presti J Jr","J Urol","1996","1996/03/01","","","10.1016/s0022-5347(01)66368-7"
"7679036","The challenge of treating node-positive prostate cancer. An approach to resolving the questions","Hanks GE.","Cancer. 1993 Feb 1;71(3 Suppl):1014-8. doi: 10.1002/1097-0142(19930201)71:3+<1014::aid-cncr2820711419>3.0.co;2-h.","Hanks GE","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1014::aid-cncr2820711419>3.0.co;2-h"
"14971848","Information from your family doctor. Prostate cancer","","Am Fam Physician. 2004 Feb 1;69(3):619-20.","","Am Fam Physician","2004","2004/02/20","","",""
"16116730","Prostate cancer's difficult choices","Springen K, Adler J.","Newsweek. 2003 Jun 16;141(24):54, 56-8, 63.","Springen K","Newsweek","2003","2005/08/25","","",""
"19826019","Prostate cancer screening and surveillance","Rogers CS.","JAMA. 2009 Oct 14;302(14):1529; author reply 1529-30. doi: 10.1001/jama.2009.1438.","Rogers CS","JAMA","2009","2009/10/15","","","10.1001/jama.2009.1438"
"18198610","[Role of density of prostate-specific antigen transitory zone in early diagnosis of prostate cancer]","Topuzov ME.","Vopr Onkol. 2007;53(3):295-7.","Topuzov ME","Vopr Onkol","2007","2008/01/18","","",""
"7939744","Introduction: prostate cancer","Scher HI.","Semin Oncol. 1994 Oct;21(5):511-3.","Scher HI","Semin Oncol","1994","1994/10/01","","",""
"402200","Radiation oncology: cancer of the prostate","Taylor WJ.","Cancer. 1977 Feb;39(2 Suppl):856-61. doi: 10.1002/1097-0142(197702)39:2+<856::aid-cncr2820390722>3.0.co;2-#.","Taylor WJ","Cancer","1977","1977/02/01","","","10.1002/1097-0142(197702)39:2+<856::aid-cncr2820390722>3.0.co;2-#"
"19711574","[Treatment of localized prostate cancer having a good prognosis may cause more harm than benefit]","Ruutu M, Rannikko A, Malmi H, Vasarainen H, Mikkola A.","Duodecim. 2009;125(14):1516-23.","Ruutu M","Duodecim","2009","2009/08/29","","",""
"20145629","Report from Durham","Moul JW.","Prostate Cancer Prostatic Dis. 2010 Mar;13(1):1. doi: 10.1038/pcan.2009.65.","Moul JW","Prostate Cancer Prostatic Dis","2010","2010/02/11","","","10.1038/pcan.2009.65"
"15952248","Advances in prostate cancer research. Part II","Languino LR.","J Cell Biochem. 2004 Feb 15;91(3):431-2. doi: 10.1002/jcb.20020.","Languino LR","J Cell Biochem","2004","2005/06/14","","","10.1002/jcb.20020"
"17419579","[Prostate cancer and care. Bibliography]","Régent L.","Soins. 2007 Mar;(713):55.","Régent L","Soins","2007","2007/04/11","","",""
"7692463","Prostate-specific antigen and screening for prostate cancer: much ado about something?","Pollack HM, Resnick MI.","Radiology. 1993 Nov;189(2):353-6. doi: 10.1148/radiology.189.2.7692463.","Pollack HM","Radiology","1993","1993/11/01","","","10.1148/radiology.189.2.7692463"
"17553367","[Treatment of localised prostate cancer]","Jakobsen H, Iversen P, Mikines KJ, Nørgaard N, Høyer M.","Ugeskr Laeger. 2007 May 14;169(20):1902-4.","Jakobsen H","Ugeskr Laeger","2007","2007/06/08","","",""
"6498745","Multiple primary tumors in association with prostatic cancer","Liskow AS, Romas N, Ozzello L, Suarez R, Veenema R, Chang CH.","Cancer. 1984 Dec 1;54(11):2549-55. doi: 10.1002/1097-0142(19841201)54:11<2549::aid-cncr2820541141>3.0.co;2-2.","Liskow AS","Cancer","1984","1984/12/01","","","10.1002/1097-0142(19841201)54:11<2549::aid-cncr2820541141>3.0.co;2-2"
"9144886","Prostate cancer: are we under the lee?","Kurth KH.","Urol Res. 1997;25 Suppl 2:S51-2. doi: 10.1007/BF00941987.","Kurth KH","Urol Res","1997","1997/01/01","","","10.1007/BF00941987"
"11314181","Your health. Prostate cancer","","J Okla Dent Assoc. 2001 Winter;91(3):7-8.","","J Okla Dent Assoc","2001","2001/04/21","","",""
"2318417","Current management modalities for prostate cancer","Gross JS.","Geriatrics. 1990 Apr;45(4):60-2, 67-8.","Gross JS","Geriatrics","1990","1990/04/01","","",""
"8053718","[Prostate cancer in 1994]","Gil-Vernet JM, Gil-Vernet Sedó JM.","Arch Esp Urol. 1994 May;47(4):315-35.","Gil-Vernet JM","Arch Esp Urol","1994","1994/05/01","","",""
"2029411","Deferred therapy in well and moderately differentiated prostate cancer","Adolfsson J.","Acta Oncol. 1991;30(2):225-6. doi: 10.3109/02841869109092357.","Adolfsson J","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092357"
"12087709","The implications of improvements in screening for prostate cancer","Kelly D.","Prof Nurse. 2002 Jun;17(10):605-8.","Kelly D","Prof Nurse","2002","2002/06/29","","",""
"1957721","[Management of prostate cancer--current status and hazards]","Kotake T, Okada K.","Hinyokika Kiyo. 1991 Aug;37(8):781-3.","Kotake T","Hinyokika Kiyo","1991","1991/08/01","","",""
"10434314","[Theoretical conditions for cancer screening. Example of prostate cancer]","Irani J.","Prog Urol. 1999 Jun;9(3):435-9.","Irani J","Prog Urol","1999","1999/08/06","","",""
"7695746","How far should we investigate and treat prostate cancer?","Sladden MJ, Dickinson JA, Thomson A.","Med J Aust. 1994 Dec 5-19;161(11-12):722.","Sladden MJ","Med J Aust","1994","1994/12/05","","",""
"17414520","Bibliography. Current world literature. Prostate cancer","","Curr Opin Urol. 2007 May;17(3):208-19. doi: 10.1097/MOU.0b013e328125ffa6.","","Curr Opin Urol","2007","2007/04/07","","","10.1097/MOU.0b013e328125ffa6"
"1533146","External beam radiation treatment for prostate cancer: still the gold standard","Hanks GE.","Oncology (Williston Park). 1992 Mar;6(3):79-86, 89; discussion 90-4.","Hanks GE","Oncology (Williston Park)","1992","1992/03/01","","",""
"15069311","Bibliography. Current world literature. Prostate cancer","","Curr Opin Urol. 2004 May;14(3):195-206.","","Curr Opin Urol","2004","2004/04/08","","",""
"24119316","A positive surgical margin following radical prostatectomy should not routinely be the indication for adjuvant radiation therapy","Graefen M, Huland H.","Eur Urol. 2014 Apr;65(4):681-2. doi: 10.1016/j.eururo.2013.09.020. Epub 2013 Sep 20.","Graefen M","Eur Urol","2014","2013/10/15","","","10.1016/j.eururo.2013.09.020"
"16379249","[Prostate cancer: between early diagnosis and total care]","Kaulen H.","Dtsch Med Wochenschr. 2005 Oct 28;Suppl 1:74.","Kaulen H","Dtsch Med Wochenschr","2005","2005/12/29","","",""
"20166134","The Prostate Cancer Foundation 16th Annual Scientific Retreat: meeting report","Rhodes KE, Simons JW, Soule HR.","Prostate. 2010 Jun 1;70(8):916-20. doi: 10.1002/pros.21127.","Rhodes KE","Prostate","2010","2010/02/19","","","10.1002/pros.21127"
"12079805","Prostate cancer: three research advances","","Harv Mens Health Watch. 2002 Jun;6(11):7.","","Harv Mens Health Watch","2002","2002/06/25","","",""
"1870141","Early detection for prostate cancer?","Lange PH.","J Natl Cancer Inst. 1991 Sep 4;83(17):1199-201. doi: 10.1093/jnci/83.17.1199.","Lange PH","J Natl Cancer Inst","1991","1991/09/04","","","10.1093/jnci/83.17.1199"
"18651999","I've been diagnosed with prostate cancer. Can you tell me how high intensity focused ultrasound works, and where I can find it?","","Duke Med Health News. 2008 May;14(5):12.","","Duke Med Health News","2008","2008/07/25","","",""
"26194410","Identification of Candidates for Active Surveillance: Should We Change the Current Paradigm?","Alcover J, Filella X.","Clin Genitourin Cancer. 2015 Dec;13(6):499-504. doi: 10.1016/j.clgc.2015.06.001. Epub 2015 Jun 16.","Alcover J","Clin Genitourin Cancer","2015","2015/07/22","","","10.1016/j.clgc.2015.06.001"
"7686440","Prostate cancer. Technology versus biology","Coleman CN, Kaplan ID.","Cancer. 1993 Jul 15;72(2):305-9. doi: 10.1002/1097-0142(19930715)72:2<305::aid-cncr2820720202>3.0.co;2-i.","Coleman CN","Cancer","1993","1993/07/15","","","10.1002/1097-0142(19930715)72:2<305::aid-cncr2820720202>3.0.co;2-i"
"15545979","Prostate Cancer Charitable Trust 2004 Forum: a personal overview","Bodmer W.","Prostate Cancer Prostatic Dis. 2004;7(4):277-81. doi: 10.1038/sj.pcan.4500766.","Bodmer W","Prostate Cancer Prostatic Dis","2004","2004/11/17","","","10.1038/sj.pcan.4500766"
"9065085","[Prostate cancer screening: an unsolved problem]","Berenguer Sánchez A.","Actas Urol Esp. 1996 Oct;20(9):768-71.","Berenguer Sánchez A","Actas Urol Esp","1996","1996/10/01","","",""
"9155513","Prostate cancer, populations, politicians and power","Raghavan D.","Eur J Cancer. 1997 Mar;33(3):329-30. doi: 10.1016/s0959-8049(97)89001-6.","Raghavan D","Eur J Cancer","1997","1997/03/01","","","10.1016/s0959-8049(97)89001-6"
"5394369","Cancer of the urogenital tract: prostate cancer","Rubin P.","JAMA. 1969 Oct 13;210(2):322-3.","Rubin P","JAMA","1969","1969/10/13","","",""
"10555476","Update on prostate cancer","Waples MJ.","WMJ. 1999 Jul-Aug;98(4):40-2.","Waples MJ","WMJ","1999","1999/11/11","","",""
"2613216","Treatment of early prostate cancer","Soloway M.","Horm Res. 1989;32 Suppl 1:59-60; discussion 60-1. doi: 10.1159/000181312.","Soloway M","Horm Res","1989","1989/01/01","","","10.1159/000181312"
"12966678","Clinical trials referral resource. Current NCI-sponsored clinical trials in prostate cancer: prevention, treatment, supportive care, and imaging","Martin A, Lieberman R, Parnes H, Schoenfeldt M.","Oncology (Williston Park). 2003 Aug;17(8):1097-8, 1103-5, 1110-6.","Martin A","Oncology (Williston Park)","2003","2003/09/12","","",""
"8780622","Defining clinically significant prostate cancer: pathologic criteria versus outcomes data","Albertsen PC.","J Natl Cancer Inst. 1996 Sep 4;88(17):1177-8. doi: 10.1093/jnci/88.17.1177.","Albertsen PC","J Natl Cancer Inst","1996","1996/09/04","","","10.1093/jnci/88.17.1177"
"9377496","Review of current data impacting early detection guidelines for prostate cancer. Proceedings of an American Cancer Society workshop. Phoenix, Arizona, March 10-11, 1997","","Cancer. 1997 Nov 1;80(9):1808-81.","","Cancer","1997","1998/02/12","","",""
"8262123","Perspectives on the role of radiotherapy in organ-confined and locally advanced prostate cancer","Porter AT, Kaczor JG, Forman JD.","Eur Urol. 1993;24 Suppl 2:39-43. doi: 10.1159/000474387.","Porter AT","Eur Urol","1993","1993/01/01","","","10.1159/000474387"
"2234633","[What do you know about prostate cancer?]","","Nurs Que. 1990 Nov-Dec;10(6):27.","","Nurs Que","1990","1990/11/01","","",""
"3684909","Prostate cancer: the depressing facts","Doble A, Williams G.","Practitioner. 1987 Feb;231(1424):239-43.","Doble A","Practitioner","1987","1987/02/01","","",""
"3177205","Prostate cancer: detection, prevention, and therapeutics","Balmer CM.","Am Pharm. 1988 Aug;NS28(8):34-40. doi: 10.1016/s0160-3450(15)31918-8.","Balmer CM","Am Pharm","1988","1988/08/01","","","10.1016/s0160-3450(15)31918-8"
"6168782","More aggressive treatment urged for patients with prostate cancer","Bolsen B.","JAMA. 1981 Oct 16;246(16):1757-8.","Bolsen B","JAMA","1981","1981/10/16","","",""
"7511829","Benign and malignant prostatic neoplasms: human studies","Partin AW, Coffey DS.","Recent Prog Horm Res. 1994;49:293-331. doi: 10.1016/b978-0-12-571149-4.50020-9.","Partin AW","Recent Prog Horm Res","1994","1994/01/01","","","10.1016/b978-0-12-571149-4.50020-9"
"2641310","Clinical trials referral resource. Prostate cancer","Cheson BD.","Oncology (Williston Park). 1989 Nov;3(11):65-6, 71, 74-8.","Cheson BD","Oncology (Williston Park)","1989","1989/11/01","","",""
"3275334","Surgery vs radiation for localized prostate cancer","Lieber MM.","Oncology (Williston Park). 1987 Mar;1(1):61-71.","Lieber MM","Oncology (Williston Park)","1987","1987/03/01","","",""
"8105170","Prostate cancer. Report of a meeting of physicians and scientists, Institute of Cancer Research and the Royal Marsden Hospital","","Lancet. 1993 Oct 9;342(8876):901-5.","","Lancet","1993","1993/10/09","","",""
"2606559","[Elderly men should undergo an annual screening for prostate cancer]","Capiello A.","Infirm Aux. 1989 Winter;62(3):15.","Capiello A","Infirm Aux","1989","1989/01/01","","",""
"12497009","Innovators in Urology, 4th International Meeting. 9-11 March 2002, Miami, Florida, USA. Abstracts","","Prostate Cancer Prostatic Dis. 2002;5 Suppl 1:S1-39. doi: 10.1038/sj.pcan.4500591.","","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500591"
"24686773","Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis","Brungs D, Chen J, Masson P, Epstein RJ.","Prostate Cancer Prostatic Dis. 2014 Jun;17(2):105-11. doi: 10.1038/pcan.2014.10. Epub 2014 Apr 1.","Brungs D","Prostate Cancer Prostatic Dis","2014","2014/04/02","","","10.1038/pcan.2014.10"
"17302038","[Advances in researches on hormonal refractory prostate cancer]","Song HZ, Chen LB.","Zhonghua Nan Ke Xue. 2007 Jan;13(1):57-60.","Song HZ","Zhonghua Nan Ke Xue","2007","2007/02/17","","",""
"22349655","The role of connexins in prostate cancer promotion and progression","Czyż J, Szpak K, Madeja Z.","Nat Rev Urol. 2012 Feb 21;9(5):274-82. doi: 10.1038/nrurol.2012.14.","Czyż J","Nat Rev Urol","2012","2012/02/22","","","10.1038/nrurol.2012.14"
"15018081","[Therapeutic options and controversies in the management of prostate cancer]","Peyromaure M, Thiounn N.","Rev Prat. 2003 Dec 31;53(20):2263-7.","Peyromaure M","Rev Prat","2003","2004/03/17","","",""
"15575077","Proceedings of the 4th International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. November 7-8, 2003, Cambridge, Massachusetts, USA","","J Urol. 2004 Nov;172(5 Pt 2):S1-62; quiz S63-7.","","J Urol","2004","2004/12/04","","",""
"3564173","[When should treatment of prostate cancer begin?]","Cukier J.","Union Med Can. 1987 Jan;116(1):suppl 6-9.","Cukier J","Union Med Can","1987","1987/01/01","","",""
"19891595","Prostate cancer gene expression marker 1 (PCGEM1): a patented prostate- specific non-coding gene and regulator of prostate cancer progression","Ifere GO, Ananaba GA.","Recent Pat DNA Gene Seq. 2009;3(3):151-63. doi: 10.2174/187221509789318360.","Ifere GO","Recent Pat DNA Gene Seq","2009","2009/11/07","","","10.2174/187221509789318360"
"17382719","Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect","Walsh RM, Thompson IM.","J Urol. 2007 Apr;177(4):1303-6. doi: 10.1016/j.juro.2006.11.064.","Walsh RM","J Urol","2007","2007/03/27","","","10.1016/j.juro.2006.11.064"
"8428348","Screening and early detection of prostate cancer","Chodak GW.","Cancer. 1993 Feb 1;71(3 Suppl):981-3. doi: 10.1002/1097-0142(19930201)71:3+<981::aid-cncr2820711414>3.0.co;2-x.","Chodak GW","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<981::aid-cncr2820711414>3.0.co;2-x"
"12398045","Prostate cancer. Unlocking its DNA secrets","Zyla G.","InTouch. 2002 May;4(3):35-7, 42.","Zyla G","InTouch","2002","2002/10/26","","",""
"23792785","Novel therapeutic approaches for the treatment of castration-resistant prostate cancer","Heidegger I, Massoner P, Eder IE, Pircher A, Pichler R, Aigner F, Bektic J, Horninger W, Klocker H.","J Steroid Biochem Mol Biol. 2013 Nov;138:248-56. doi: 10.1016/j.jsbmb.2013.06.002. Epub 2013 Jun 20.","Heidegger I","J Steroid Biochem Mol Biol","2013","2013/06/25","PMC3834152","","10.1016/j.jsbmb.2013.06.002"
"22362073","Highlights in prostate cancer from the 2011 American Urological Association Annual Meeting and the 2011 American Society of Clinical Oncology Annual Meeting","Yu EY.","Clin Adv Hematol Oncol. 2011 Aug;9(8 Suppl 21):1-24.","Yu EY","Clin Adv Hematol Oncol","2011","2012/02/25","","",""
"27777131","Incorporating imaging into personalized medicine for the detection of prostate cancer: Pharmacological research-Urogenital pharmacology","Mertan F, Turkbey B.","Pharmacol Res. 2016 Dec;114:163-165. doi: 10.1016/j.phrs.2016.10.020. Epub 2016 Oct 21.","Mertan F","Pharmacol Res","2016","2016/11/07","","","10.1016/j.phrs.2016.10.020"
"32580211","Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer","Taguchi S, Shiraishi K, Fukuhara H.","Jpn J Clin Oncol. 2020 Sep 5;50(9):963-969. doi: 10.1093/jjco/hyaa105.","Taguchi S","Jpn J Clin Oncol","2020","2020/06/25","","","10.1093/jjco/hyaa105"
"25816107","Cognitive factors influencing treatment decision-making in patients with localised prostate cancer: development of a standardised questionnaire","Devos J, Van Praet C, Decaestecker K, Claeys T, Fonteyne V, Decalf V, De Meerleer G, Ost P, Lumen N.","Acta Clin Belg. 2015 Aug;70(4):272-9. doi: 10.1179/2295333715Y.0000000015. Epub 2015 Mar 27.","Devos J","Acta Clin Belg","2015","2015/03/28","","","10.1179/2295333715Y.0000000015"
"1690883","Prostate cancer. Promising advances that may alter survival rates","Badalament RA, Drago JR.","Postgrad Med. 1990 Apr;87(5):65-7, 70-2. doi: 10.1080/00325481.1990.11704627.","Badalament RA","Postgrad Med","1990","1990/04/01","","","10.1080/00325481.1990.11704627"
"32460527","Gene Expression-Based Immune Cell Infiltration Analyses of Prostate Cancer and Their Associations with Survival Outcome","Hu P, Gao Y, Huang Y, Zhao Y, Yan H, Zhang J, Zhao L.","DNA Cell Biol. 2020 Jul;39(7):1194-1204. doi: 10.1089/dna.2020.5371. Epub 2020 May 27.","Hu P","DNA Cell Biol","2020","2020/05/29","","","10.1089/dna.2020.5371"
"1771714","[Localized prostate cancer]","Huland H.","Urologe A. 1991 Nov;30(6):345-7.","Huland H","Urologe A","1991","1991/11/01","","",""
"25871263","Men's strategies for preserving emotional well-being in advanced prostate cancer: An interpretative phenomenological analysis","Levy A, Cartwright T.","Psychol Health. 2015;30(10):1164-82. doi: 10.1080/08870446.2015.1040016. Epub 2015 May 15.","Levy A","Psychol Health","2015","2015/04/15","","","10.1080/08870446.2015.1040016"
"26947089","[Novelties in diagnostics and treatment of prostate cancer]","Riesz P, Nyírádi P.","Orv Hetil. 2016 Mar 13;157(11):410-4. doi: 10.1556/650.2016.30363.","Riesz P","Orv Hetil","2016","2016/03/08","","","10.1556/650.2016.30363"
"12415080","Prostate cancer","Mazhar D, Waxman J.","Postgrad Med J. 2002 Oct;78(924):590-5. doi: 10.1136/pmj.78.924.590.","Mazhar D","Postgrad Med J","2002","2002/11/05","PMC1742511","","10.1136/pmj.78.924.590"
"27187167","Clinical Perspective of Prostate Cancer","Patil N, Gaitonde K.","Top Magn Reson Imaging. 2016 Jun;25(3):103-8. doi: 10.1097/RMR.0000000000000091.","Patil N","Top Magn Reson Imaging","2016","2016/05/18","","","10.1097/RMR.0000000000000091"
"15365576","Future opportunities for the diagnosis and treatment of prostate cancer","Watson RW, Schalken JA.","Prostate Cancer Prostatic Dis. 2004 Sep;7 Suppl 1:S8-S13. doi: 10.1038/sj.pcan.4500742.","Watson RW","Prostate Cancer Prostatic Dis","2004","2004/09/15","","","10.1038/sj.pcan.4500742"
"25597493","Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments","Gavin AT, Drummond FJ, Donnelly C, O'Leary E, Sharp L, Kinnear HR.","BJU Int. 2015 Sep;116(3):397-406. doi: 10.1111/bju.13036. Epub 2015 Jun 22.","Gavin AT","BJU Int","2015","2015/01/20","PMC5008189","","10.1111/bju.13036"
"24726082","A review of the current epidemiology and treatment options for prostate cancer","Saman DM, Lemieux AM, Nawal Lutfiyya M, Lipsky MS.","Dis Mon. 2014 Apr;60(4):150-4. doi: 10.1016/j.disamonth.2014.02.003.","Saman DM","Dis Mon","2014","2014/04/15","","","10.1016/j.disamonth.2014.02.003"
"28808871","African-American Prostate Cancer Disparities","Smith ZL, Eggener SE, Murphy AB.","Curr Urol Rep. 2017 Aug 14;18(10):81. doi: 10.1007/s11934-017-0724-5.","Smith ZL","Curr Urol Rep","2017","2017/08/16","","","10.1007/s11934-017-0724-5"
"20832032","[Nutrition, dietary supplements and prostate cancer]","Desgrandchamps F, Bastien L.","Prog Urol. 2010 Sep;20(8):560-5. doi: 10.1016/j.purol.2010.03.010. Epub 2010 Jun 2.","Desgrandchamps F","Prog Urol","2010","2010/09/14","","","10.1016/j.purol.2010.03.010"
"18290282","Multi-level advances in prostate cancer treatment. Biopsy location is key; surgery offers best long-term survival","","Duke Med Health News. 2008 Jan;14(1):8.","","Duke Med Health News","2008","2008/02/23","","",""
"25367320","Biography: Dr Iain Frame, director of research, prostate cancer UK","Frame I, Maprayil S.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1261-4. doi: 10.1586/14737140.2014.974898.","Frame I","Expert Rev Anticancer Ther","2014","2014/11/05","","","10.1586/14737140.2014.974898"
"28661898","Genomic testing for localized prostate cancer: where do we go from here?","Loeb S, Ross AE.","Curr Opin Urol. 2017 Sep;27(5):495-499. doi: 10.1097/MOU.0000000000000419.","Loeb S","Curr Opin Urol","2017","2017/06/30","PMC5674810","NIHMS910265","10.1097/MOU.0000000000000419"
"25471035","Advances in systemic therapies for metastatic castration-resistant prostate cancer","Pant MK, Abughaban A, Aragon-Ching JB.","Future Oncol. 2014 Nov;10(14):2213-26. doi: 10.2217/fon.14.128.","Pant MK","Future Oncol","2014","2014/12/05","","","10.2217/fon.14.128"
"11577426","[Radiation therapy for prostate cancer]","Nakamura K.","Nihon Igaku Hoshasen Gakkai Zasshi. 2001 Aug;61(9):455-60.","Nakamura K","Nihon Igaku Hoshasen Gakkai Zasshi","2001","2001/10/02","","",""
"17892357","Progensa PCA3 test for prostate cancer detection","de la Taille A.","Expert Rev Mol Diagn. 2007 Sep;7(5):491-7. doi: 10.1586/14737159.7.5.491.","de la Taille A","Expert Rev Mol Diagn","2007","2007/09/26","","","10.1586/14737159.7.5.491"
"18078352","Genomic signatures associated with the development, progression, and outcome of prostate cancer","Mendiratta P, Febbo PG.","Mol Diagn Ther. 2007;11(6):345-54. doi: 10.1007/BF03256258.","Mendiratta P","Mol Diagn Ther","2007","2007/12/15","","","10.1007/BF03256258"
"8795649","Treatment of localized prostate cancer. Choosing the best alternative","Williams TR, Love N.","Postgrad Med. 1996 Sep;100(3):105-7, 111-2, 118-20. doi: 10.3810/pgm.1996.09.72.","Williams TR","Postgrad Med","1996","1996/09/01","","","10.3810/pgm.1996.09.72"
"11848422","Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer","Lissbrant IF, Lissbrant E, Damber JE, Bergh A.","Scand J Urol Nephrol. 2001 Dec;35(6):437-52. doi: 10.1080/003655901753367532.","Lissbrant IF","Scand J Urol Nephrol","2001","2002/02/19","","","10.1080/003655901753367532"
"29179252","Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy","Moul JW.","Oncology (Williston Park). 2017 Nov 15;31(11):830, 833-5.","Moul JW","Oncology (Williston Park)","2017","2017/11/28","","",""
"25587592","Words of wisdom. Re: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","van Rij S, Murphy DG.","Eur Urol. 2014 Dec;66(6):1187-8. doi: 10.1016/j.eururo.2014.08.044.","van Rij S","Eur Urol","2014","2015/01/15","","","10.1016/j.eururo.2014.08.044"
"12735498","The epidemiology of prostate cancer","Boyle P, Severi G, Giles GG.","Urol Clin North Am. 2003 May;30(2):209-17. doi: 10.1016/s0094-0143(02)00181-7.","Boyle P","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00181-7"
"27105511","Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer","Xu P, Xu N, Guo K, Xu A, Takenaka F, Matsuura E, Liu C, Kumon H, Huang P.","Oncotarget. 2016 May 31;7(22):33025-34. doi: 10.18632/oncotarget.8846.","Xu P","Oncotarget","2016","2016/04/23","PMC5078072","","10.18632/oncotarget.8846"
"7754275","Natural history of clinically localized prostate cancer","Barry MJ.","Semin Surg Oncol. 1995 Jan-Feb;11(1):3-8. doi: 10.1002/ssu.2980110103.","Barry MJ","Semin Surg Oncol","1995","1995/01/01","","","10.1002/ssu.2980110103"
"9179181","Natural course of localized prostate cancer. a personal view with a review of published papers","Hugosson J, Aus G.","Anticancer Res. 1997 May-Jun;17(3A):1441-8.","Hugosson J","Anticancer Res","1997","1997/05/01","","",""
"9299581","Family studies and the evidence for genetic susceptibility to prostate cancer","Bishop DT, Kiemeney LA.","Semin Cancer Biol. 1997 Feb;8(1):45-51. doi: 10.1006/scbi.1997.0053.","Bishop DT","Semin Cancer Biol","1997","1997/02/01","","","10.1006/scbi.1997.0053"
"26075438","Advanced prostate cancer: Every Voice Matters","Payne H, Westcott G.","Future Oncol. 2015;11(12):1711-3. doi: 10.2217/fon.15.88.","Payne H","Future Oncol","2015","2015/06/16","","","10.2217/fon.15.88"
"24423668","Prevalence of prostate cancer among the population of Sumy region","Romaniuk A, Shkroba A.","Georgian Med News. 2013 Dec;(225):12-6.","Romaniuk A","Georgian Med News","2013","2014/01/16","","",""
"9167480","Prostate cancer","Chodak GW.","Lancet. 1997 May 24;349(9064):1551; author reply 1551-2. doi: 10.1016/S0140-6736(05)62128-9.","Chodak GW","Lancet","1997","1997/05/24","","","10.1016/S0140-6736(05)62128-9"
"23290885","New treatment developments applied to elderly patients with advanced prostate cancer","Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS.","Cancer Treat Rev. 2013 Oct;39(6):578-83. doi: 10.1016/j.ctrv.2012.12.004. Epub 2013 Jan 3.","Mukherji D","Cancer Treat Rev","2013","2013/01/08","","","10.1016/j.ctrv.2012.12.004"
"22859773","Treating prostate cancer","Parker C.","BMJ. 2012 Aug 1;345:e5122. doi: 10.1136/bmj.e5122.","Parker C","BMJ","2012","2012/08/04","","","10.1136/bmj.e5122"
"7653020","Geographical and temporal patterns of incidence and mortality from prostate cancer","Boyle P, Maisonneuve P, Napalkov P.","Urology. 1995 Sep;46(3 Suppl A):47-55. doi: 10.1016/s0090-4295(99)80250-7.","Boyle P","Urology","1995","1995/09/01","","","10.1016/s0090-4295(99)80250-7"
"12371270","[Is it possible to prevent prostate cancer?]","Schulman C.","Bull Mem Acad R Med Belg. 2001;156(10-12):499-509; discussion 509-10.","Schulman C","Bull Mem Acad R Med Belg","2001","2002/10/10","","",""
"28971747","Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy","Faramarzi S, Ghafouri-Fard S.","Immunotherapy. 2017 Sep;9(12):1019-1034. doi: 10.2217/imt-2017-0083.","Faramarzi S","Immunotherapy","2017","2017/10/04","","","10.2217/imt-2017-0083"
"26917215","Clinical, pathological and molecular prognostic factors in prostate cancer decision-making process","Pugliese D, Palermo G, Totaro A, Bassi PF, Pinto F.","Urologia. 2016 Jan-Mar;83(1):14-20. doi: 10.5301/uro.5000166. Epub 2016 Feb 24.","Pugliese D","Urologia","2016","2016/02/27","","","10.5301/uro.5000166"
"11695843","Epidemiology of prostatic cancer in East Asia","Sasagawa I, Nakada T.","Arch Androl. 2001 Nov-Dec;47(3):195-201. doi: 10.1080/014850101753145906.","Sasagawa I","Arch Androl","2001","2001/11/07","","","10.1080/014850101753145906"
"15017185","Alpha-linolenic acid and the risk of prostate cancer. What is the evidence?","Attar-Bashi NM, Frauman AG, Sinclair AJ.","J Urol. 2004 Apr;171(4):1402-7. doi: 10.1097/01.ju.0000116544.09581.55.","Attar-Bashi NM","J Urol","2004","2004/03/17","","","10.1097/01.ju.0000116544.09581.55"
"28555500","Updates on the diagnosis and treatment of prostate cancer","Gasnier A, Parvizi N.","Br J Radiol. 2017 Jul;90(1075):20170180. doi: 10.1259/bjr.20170180. Epub 2017 May 30.","Gasnier A","Br J Radiol","2017","2017/05/31","PMC5594995","","10.1259/bjr.20170180"
"9327227","Decisions about prostate cancer screening in managed care","Kaplan RM.","Curr Opin Oncol. 1997 Sep;9(5):480-6. doi: 10.1097/00001622-199709050-00014.","Kaplan RM","Curr Opin Oncol","1997","1997/11/05","","","10.1097/00001622-199709050-00014"
"10797496","Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support","Labrie F.","Prostate. 2000 May 15;43(3):215-22. doi: 10.1002/(sici)1097-0045(20000515)43:3<215::aid-pros7>3.0.co;2-g.","Labrie F","Prostate","2000","2000/05/08","","","10.1002/(sici)1097-0045(20000515)43:3<215::aid-pros7>3.0.co;2-g"
"24840076","Evolution of androgen receptor targeted therapy for advanced prostate cancer","Wong YN, Ferraldeschi R, Attard G, de Bono J.","Nat Rev Clin Oncol. 2014 Jun;11(6):365-76. doi: 10.1038/nrclinonc.2014.72. Epub 2014 May 20.","Wong YN","Nat Rev Clin Oncol","2014","2014/05/21","","","10.1038/nrclinonc.2014.72"
"1700529","Prostatic specific antigen in diagnosis and management of prostate cancer","Lange PH.","Urology. 1990 Nov;36(5 Suppl):25-9. doi: 10.1016/0090-4295(90)80179-q.","Lange PH","Urology","1990","1990/11/01","","","10.1016/0090-4295(90)80179-q"
"25432497","Appraising the European randomized study of screening for prostate cancer: what do the results mean?","Ilic D.","Asian J Androl. 2015 Mar-Apr;17(2):221-2. doi: 10.4103/1008-682X.142131.","Ilic D","Asian J Androl","2015","2014/11/30","PMC4650457","","10.4103/1008-682X.142131"
"7897920","[Diagnosis and treatment of locally invasive prostate cancer (stage C)]","Okada K.","Nihon Hinyokika Gakkai Zasshi. 1995 Jan;86(1):48-50.","Okada K","Nihon Hinyokika Gakkai Zasshi","1995","1995/01/01","","",""
"11417964","Prognostic and predictive factors in prostate cancer","Hamdy FC.","Cancer Treat Rev. 2001 Jun;27(3):143-51. doi: 10.1053/ctrv.2000.0208.","Hamdy FC","Cancer Treat Rev","2001","2001/06/22","","","10.1053/ctrv.2000.0208"
"21979906","[Diagnosis prostate cancer: who makes the treatment decision and which treatment is selected? Opinion survey in a prostate cancer patient support group]","Schnell D, Fiebrandt H, Weissbach L.","Urologe A. 2012 Feb;51(2):238-41. doi: 10.1007/s00120-011-2725-1.","Schnell D","Urologe A","2012","2011/10/08","","","10.1007/s00120-011-2725-1"
"7022592","Prostate cancer. Surgery","Hendry WF.","Recent Results Cancer Res. 1981;78:119-31.","Hendry WF","Recent Results Cancer Res","1981","1981/01/01","","",""
"31900912","Canonical and Noncanonical Androgen Metabolism and Activity","Storbeck KH, Mostaghel EA.","Adv Exp Med Biol. 2019;1210:239-277. doi: 10.1007/978-3-030-32656-2_11.","Storbeck KH","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_11"
"22482176","Management of patients with metastatic prostate cancer","Turner B, Drudge-Coates L.","Nurs Stand. 2012 Mar 7-13;26(27):49-57; quiz 58. doi: 10.7748/ns2012.03.26.27.49.c8984.","Turner B","Nurs Stand","2012","2012/04/10","","","10.7748/ns2012.03.26.27.49.c8984"
"7672943","Update on prostate cancer","Fitzpatrick JM.","Ir Med J. 1995 Jul-Aug;88(4):117-8.","Fitzpatrick JM","Ir Med J","1995","1995/07/01","","",""
"8182820","Staging for prostate cancer","Brawer MK.","JAMA. 1994 May 25;271(20):1628-9. doi: 10.1001/jama.271.20.1628a.","Brawer MK","JAMA","1994","1994/05/25","","","10.1001/jama.271.20.1628a"
"26537520","Younger British men's understandings of prostate cancer: A qualitative study","Grogan S, Parlane VL, Buckley E.","J Health Psychol. 2017 May;22(6):743-753. doi: 10.1177/1359105315613776. Epub 2015 Nov 4.","Grogan S","J Health Psychol","2017","2015/11/06","","","10.1177/1359105315613776"
"30426794","Apalutamide and its use in the treatment of prostate cancer","Borno HT, Small EJ.","Future Oncol. 2019 Feb;15(6):591-599. doi: 10.2217/fon-2018-0546. Epub 2018 Nov 14.","Borno HT","Future Oncol","2019","2018/11/15","PMC6391625","","10.2217/fon-2018-0546"
"29483500","Current epidemiological knowledge about the role of flavonoids in prostate carcinogenesis","Sak K.","Exp Oncol. 2017 Jul;39(2):98-105.","Sak K","Exp Oncol","2017","2018/02/28","","",""
"26659491","Non-coding RNAs in Prostate Cancer: From Discovery to Clinical Applications","Ceder Y.","Adv Exp Med Biol. 2016;886:155-170. doi: 10.1007/978-94-017-7417-8_8.","Ceder Y","Adv Exp Med Biol","2016","2015/12/15","","","10.1007/978-94-017-7417-8_8"
"18709901","From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer","Polascik TJ, Mayes JM, Mouraviev V.","Oncology (Williston Park). 2008 Jul;22(8):900-6; discussion 906-7, 914.","Polascik TJ","Oncology (Williston Park)","2008","2008/08/20","","",""
"25757684","Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction","Musunuru HB, Loblaw A.","Future Oncol. 2015;11(5):819-31. doi: 10.2217/fon.15.14.","Musunuru HB","Future Oncol","2015","2015/03/12","","","10.2217/fon.15.14"
"21786733","Prostate cancer among different racial groups in the Western Cape: presenting features and management","Heyns CF, Fisher M, Lecuona A, van der Merwe A.","S Afr Med J. 2011 Apr;101(4):267-70. doi: 10.7196/samj.4420.","Heyns CF","S Afr Med J","2011","2011/07/27","","","10.7196/samj.4420"
"7523717","Prognostic factors and clinical significance of cancers detected by screening: growth rate and progression of prostate cancer","Lange PH.","J Urol. 1994 Nov;152(5 Pt 2):1707-8. doi: 10.1016/s0022-5347(17)32367-4.","Lange PH","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32367-4"
"20809016","Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious","Tomuleasa C, Kacsó G, Soriţău O, Suşman S, Irimie A, Virág P.","Rom J Morphol Embryol. 2010;51(3):427-35.","Tomuleasa C","Rom J Morphol Embryol","2010","2010/09/03","","",""
"26839021","The evolving role of enzalutamide on the treatment of prostate cancer","Nadal R, Bellmunt J.","Future Oncol. 2016 Mar;12(5):607-16. doi: 10.2217/fon.15.351. Epub 2016 Feb 3.","Nadal R","Future Oncol","2016","2016/02/04","PMC5551941","","10.2217/fon.15.351"
"16848360","[Treatment for locally advanced prostate cancer: value of surgery]","Azuma H, Katsuoka Y.","Hinyokika Kiyo. 2006 Jun;52(6):459-67.","Azuma H","Hinyokika Kiyo","2006","2006/07/20","","",""
"29421982","Immune-based therapies for metastatic prostate cancer: an update","Hossain MK, Nahar K, Donkor O, Apostolopoulos V.","Immunotherapy. 2018 Feb 1;10(4):283-298. doi: 10.2217/imt-2017-0123.","Hossain MK","Immunotherapy","2018","2018/02/10","","","10.2217/imt-2017-0123"
"17911506","JAMA patient page. Grading of prostate cancer","Zeller JL, Lynm C, Glass RM.","JAMA. 2007 Oct 3;298(13):1596. doi: 10.1001/jama.298.13.1596.","Zeller JL","JAMA","2007","2007/10/04","","","10.1001/jama.298.13.1596"
"12642191","Psychosocial and educational aspects in prostate cancer patients","Visser A, van Andel G.","Patient Educ Couns. 2003 Mar;49(3):203-6. doi: 10.1016/s0738-3991(03)00024-7.","Visser A","Patient Educ Couns","2003","2003/03/19","","","10.1016/s0738-3991(03)00024-7"
"29939814","Tissue proteomics studies in the investigation of prostate cancer","Mantsiou A, Vlahou A, Zoidakis J.","Expert Rev Proteomics. 2018 Jul;15(7):593-611. doi: 10.1080/14789450.2018.1491796. Epub 2018 Jul 16.","Mantsiou A","Expert Rev Proteomics","2018","2018/06/26","","","10.1080/14789450.2018.1491796"
"11074610","Impact of screening on prostate cancer rates and trends","Mettlin C.","Microsc Res Tech. 2000 Dec 1;51(5):415-8. doi: 10.1002/1097-0029(20001201)51:5<415::AID-JEMT2>3.0.CO;2-B.","Mettlin C","Microsc Res Tech","2000","2000/11/14","","","10.1002/1097-0029(20001201)51:5<415::AID-JEMT2>3.0.CO;2-B"
"9542019","Prostate cancer: the diagnostic dilemma and the place of imaging in detection and staging","Rifkin MD.","World J Urol. 1998;16(1):76-80. doi: 10.1007/s003450050029.","Rifkin MD","World J Urol","1998","1998/05/16","","","10.1007/s003450050029"
"27349215","Value in prostate cancer treatment","Bahnson RR.","J Surg Oncol. 2016 Sep;114(3):288-90. doi: 10.1002/jso.24285. Epub 2016 Jun 28.","Bahnson RR","J Surg Oncol","2016","2016/06/29","","","10.1002/jso.24285"
"23462616","Prostate cancer and physical activity: adaptive response to oxidative stress","Rebillard A, Lefeuvre-Orfila L, Gueritat J, Cillard J.","Free Radic Biol Med. 2013 Jul;60:115-24. doi: 10.1016/j.freeradbiomed.2013.02.009. Epub 2013 Feb 24.","Rebillard A","Free Radic Biol Med","2013","2013/03/07","","","10.1016/j.freeradbiomed.2013.02.009"
"22341739","Nanoparticle therapeutics for prostate cancer treatment","Sanna V, Sechi M.","Maturitas. 2012 Sep;73(1):27-32. doi: 10.1016/j.maturitas.2012.01.016. Epub 2012 Feb 17.","Sanna V","Maturitas","2012","2012/02/21","","","10.1016/j.maturitas.2012.01.016"
"21258758","Using large institutional or national databases to evaluate prostate cancer outcomes and patterns of care: possibilities and limitations","Su D, Jang TL.","ScientificWorldJournal. 2011 Jan 18;11:147-60. doi: 10.1100/tsw.2010.248.","Su D","ScientificWorldJournal","2011","2011/01/25","PMC5720068","","10.1100/tsw.2010.248"
"24725488","Decision making and prostate cancer screening","Knight SJ.","Urol Clin North Am. 2014 May;41(2):257-66. doi: 10.1016/j.ucl.2014.01.008. Epub 2014 Feb 28.","Knight SJ","Urol Clin North Am","2014","2014/04/15","","","10.1016/j.ucl.2014.01.008"
"21604935","The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in context","Berg CD.","Acta Oncol. 2011 Jun;50 Suppl 1:12-7. doi: 10.3109/0284186X.2010.531283.","Berg CD","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.531283"
"7089009","What do men know about prostate cancer and methods for detecting prostate cancer?","Urich VC, Cummings KM, Murphy GP.","Prog Clin Biol Res. 1982;83:499-509.","Urich VC","Prog Clin Biol Res","1982","1982/01/01","","",""
"9159788","Prostate cancer and African-American men","Powell IJ.","Oncology (Williston Park). 1997 May;11(5):599-605; discussion 606-15 passim.","Powell IJ","Oncology (Williston Park)","1997","1997/05/01","","",""
"9186395","Prostate cancer diagnosis and management","Frydenberg M, Stricker PD, Kaye KW.","Lancet. 1997 Jun 7;349(9066):1681-7. doi: 10.1016/S0140-6736(96)07393-X.","Frydenberg M","Lancet","1997","1997/06/07","","","10.1016/S0140-6736(96)07393-X"
"28577627","Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection","Barry MJ, Simmons LH.","Med Clin North Am. 2017 Jul;101(4):787-806. doi: 10.1016/j.mcna.2017.03.009.","Barry MJ","Med Clin North Am","2017","2017/06/05","","","10.1016/j.mcna.2017.03.009"
"20844012","Molecular genetics of prostate cancer: new prospects for old challenges","Shen MM, Abate-Shen C.","Genes Dev. 2010 Sep 15;24(18):1967-2000. doi: 10.1101/gad.1965810.","Shen MM","Genes Dev","2010","2010/09/17","PMC2939361","","10.1101/gad.1965810"
"16708706","Hormone-refractory prostate cancer: a shifting paradigm in treatment","Gallagher E, Gapstur R.","Clin J Oncol Nurs. 2006 Apr;10(2):233-40. doi: 10.1188/06.CJON.233-240.","Gallagher E","Clin J Oncol Nurs","2006","2006/05/20","","","10.1188/06.CJON.233-240"
"17022571","[Prostate cancer]","Ueda T, Maruoka M, Komiya A, Suzuki H, Ichikawa T.","Nihon Rinsho. 2006 Sep 28;Suppl 3:388-92.","Ueda T","Nihon Rinsho","2006","2006/10/07","","",""
"30031466","Prostate MR Imaging for Posttreatment Evaluation and Recurrence","Gaur S, Turkbey B.","Urol Clin North Am. 2018 Aug;45(3):467-479. doi: 10.1016/j.ucl.2018.03.011.","Gaur S","Urol Clin North Am","2018","2018/07/23","","","10.1016/j.ucl.2018.03.011"
"26067250","Androgen pathway resistance in prostate cancer and therapeutic implications","Maughan BL, Antonarakis ES.","Expert Opin Pharmacother. 2015;16(10):1521-37. doi: 10.1517/14656566.2015.1055249. Epub 2015 Jun 12.","Maughan BL","Expert Opin Pharmacother","2015","2015/06/13","PMC4696015","NIHMS737471","10.1517/14656566.2015.1055249"
"9571960","[Hormone tolerance mechanism of prostate cancer]","Tozawa K, Kohri K.","Gan To Kagaku Ryoho. 1998 Apr;25(5):639-44.","Tozawa K","Gan To Kagaku Ryoho","1998","1998/05/08","","",""
"16484852","[Advancement of treatment for prostate cancer]","Hara I.","Gan To Kagaku Ryoho. 2006 Feb;33(2):178-82.","Hara I","Gan To Kagaku Ryoho","2006","2006/02/18","","",""
"18236727","Prostate cancer: too much dogma, not enough data","Raghavan D.","Cleve Clin J Med. 2008 Jan;75(1):33-4. doi: 10.3949/ccjm.75.1.33.","Raghavan D","Cleve Clin J Med","2008","2008/02/02","","","10.3949/ccjm.75.1.33"
"27882638","Anxiety symptoms prior to a prostate cancer diagnosis: Associations with knowledge and openness to treatment","Dillard AJ, Scherer LD, Ubel PA, Alexander S, Fagerlin A.","Br J Health Psychol. 2017 Feb;22(1):151-168. doi: 10.1111/bjhp.12222. Epub 2016 Nov 24.","Dillard AJ","Br J Health Psychol","2017","2016/11/25","","","10.1111/bjhp.12222"
"24469850","Promising areas of prostate cancer research","Heath EI.","Cancer Metastasis Rev. 2014 Sep;33(2-3):375-6. doi: 10.1007/s10555-013-9491-z.","Heath EI","Cancer Metastasis Rev","2014","2014/01/29","","","10.1007/s10555-013-9491-z"
"1877107","Digital rectal examination and carcinoma of the prostate","Phillips TH, Thompson IM.","Urol Clin North Am. 1991 Aug;18(3):459-65.","Phillips TH","Urol Clin North Am","1991","1991/08/01","","",""
"31692911","The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population","Park JS, Koo KC, Chung BH, Lee KS.","Investig Clin Urol. 2019 Nov;60(6):442-446. doi: 10.4111/icu.2019.60.6.442. Epub 2019 Sep 5.","Park JS","Investig Clin Urol","2019","2019/11/07","PMC6821985","","10.4111/icu.2019.60.6.442"
"18310272","The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer","Murphy TM, Perry AS, Lawler M.","Endocr Relat Cancer. 2008 Mar;15(1):11-25. doi: 10.1677/ERC-07-0208.","Murphy TM","Endocr Relat Cancer","2008","2008/03/04","","","10.1677/ERC-07-0208"
"16775986","[Prostate cancer]","Villers A, Berthon N.","Rev Prat. 2006 May 15;56(9):1021-5.","Villers A","Rev Prat","2006","2006/06/17","","",""
"9599352","Quality of life of patients with prostate cancer treated with surgery or radiation therapy","Yarbro CH, Ferrans CE.","Oncol Nurs Forum. 1998 May;25(4):685-93.","Yarbro CH","Oncol Nurs Forum","1998","1998/05/26","","",""
"11146903","External beam radiation therapy for prostate cancer","Horwitz EM, Hanks GE.","CA Cancer J Clin. 2000 Nov-Dec;50(6):349-75; quiz 376-9. doi: 10.3322/canjclin.50.6.349.","Horwitz EM","CA Cancer J Clin","2000","2001/01/09","","","10.3322/canjclin.50.6.349"
"25595909","Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression","Rybak AP, Bristow RG, Kapoor A.","Oncotarget. 2015 Feb 10;6(4):1900-19. doi: 10.18632/oncotarget.2953.","Rybak AP","Oncotarget","2015","2015/01/18","PMC4385825","","10.18632/oncotarget.2953"
"8094029","American Cancer Society National Conference on Prostate Cancer. Proceedings. San Francisco, California, February 13-15, 1992","","Cancer. 1993 Feb 1;71(3 Suppl):879-1186.","","Cancer","1993","1993/02/01","","",""
"30178777","The regulatory pathways leading to stem-like cells underlie prostate cancer progression","Lin CJ, Lo UG, Hsieh JT.","Asian J Androl. 2019 May-Jun;21(3):233-240. doi: 10.4103/aja.aja_72_18.","Lin CJ","Asian J Androl","2019","2018/09/05","PMC6498735","","10.4103/aja.aja_72_18"
"21068743","Prostate Cancer and Prostatic Diseases. Editor's comments","Freedland SJ.","Prostate Cancer Prostatic Dis. 2010 Dec;13(4):295. doi: 10.1038/pcan.2010.45.","Freedland SJ","Prostate Cancer Prostatic Dis","2010","2010/11/12","","","10.1038/pcan.2010.45"
"26195362","Re: Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up","Taneja SS.","J Urol. 2015 Aug;194(2):392. doi: 10.1016/j.juro.2015.05.064. Epub 2015 May 18.","Taneja SS","J Urol","2015","2015/07/22","","","10.1016/j.juro.2015.05.064"
"9474215","Re: Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy","Lawrence G.","J Urol. 1998 Mar;159(3):996. doi: 10.1016/s0022-5347(01)63818-7.","Lawrence G","J Urol","1998","1998/02/25","","","10.1016/s0022-5347(01)63818-7"
"16859573","The emotional burden of low-risk prostate cancer: proposal for a change in nomenclature","Sartor O, Loriaux DL.","Clin Genitourin Cancer. 2006 Jun;5(1):16-7. doi: 10.3816/CGC.2006.n.013.","Sartor O","Clin Genitourin Cancer","2006","2006/07/25","","","10.3816/CGC.2006.n.013"
"29374691","Exploratory Radiomics in Computed Tomography Perfusion of Prostate Cancer","Tanadini-Lang S, Bogowicz M, Veit-Haibach P, Huellner M, Pauli C, Shukla V, Guckenberger M, Riesterer O.","Anticancer Res. 2018 Feb;38(2):685-690. doi: 10.21873/anticanres.12273.","Tanadini-Lang S","Anticancer Res","2018","2018/01/29","","","10.21873/anticanres.12273"
"26884576","Query About the Frequency of Biopsy Complications","Scholz MC, Lam RY, Turner JS.","J Clin Oncol. 2016 Apr 10;34(11):1284. doi: 10.1200/JCO.2015.65.6827. Epub 2016 Feb 16.","Scholz MC","J Clin Oncol","2016","2016/02/18","","","10.1200/JCO.2015.65.6827"
"16734208","[Apoptosis and treatment of prostate cancer: from concepts to applications, from hypothesis to reason]","Colombel M.","Prog Urol. 2005 Dec;15(6 Suppl 1):1225-6.","Colombel M","Prog Urol","2005","2006/06/01","","",""
"31101896","Prostate cancer in sexual minorities and the influence of HIV status","Amarasekera C, Wong V, Yura E, Manjunath A, Schaeffer E, Kundu S.","Nat Rev Urol. 2019 Jul;16(7):404-421. doi: 10.1038/s41585-019-0194-2.","Amarasekera C","Nat Rev Urol","2019","2019/05/19","","","10.1038/s41585-019-0194-2"
"11879321","Altered sexual patterns after treatment for prostate cancer","Berterö C.","Cancer Pract. 2001 Sep-Oct;9(5):245-51. doi: 10.1046/j.1523-5394.2001.009005245.x.","Berterö C","Cancer Pract","2001","2002/03/07","","","10.1046/j.1523-5394.2001.009005245.x"
"22018406","Access to health care and quality of life for underserved men with prostate cancer","Maliski SL, Connor SE, Oduro C, Litwin MS.","Semin Oncol Nurs. 2011 Nov;27(4):267-77. doi: 10.1016/j.soncn.2011.07.005.","Maliski SL","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.005"
"17239271","Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer","Reddy GK, Balk SP.","Clin Genitourin Cancer. 2006 Dec;5(3):187-9. doi: 10.3816/CGC.2006.n.035.","Reddy GK","Clin Genitourin Cancer","2006","2007/01/24","","","10.3816/CGC.2006.n.035"
"23527518","The influence of family history on cognitive heuristics, risk perceptions, and prostate cancer screening behavior","McDowell ME, Occhipinti S, Chambers SK.","Health Psychol. 2013 Nov;32(11):1158-69. doi: 10.1037/a0031622. Epub 2013 Mar 25.","McDowell ME","Health Psychol","2013","2013/03/27","","","10.1037/a0031622"
"24128601","[Treating 'healthy' men who have localised cancer of the prostate]","de Jong IJ.","Ned Tijdschr Geneeskd. 2013;157(42):A6703.","de Jong IJ","Ned Tijdschr Geneeskd","2013","2013/10/17","","",""
"23986043","[Treatable and untreatable forms of recurrent prostate cancer]","Ueda T, Kobayashi M, Komaru A, Fukazawa K, Akakura K.","Gan To Kagaku Ryoho. 2013 Aug;40(8):998-1002.","Ueda T","Gan To Kagaku Ryoho","2013","2013/08/30","","",""
"15776028","[Biology and treatment options during the development of prostate cancer]","Lilleby W, Sudbø J, Fosså SD.","Tidsskr Nor Laegeforen. 2005 Mar 3;125(5):571-4.","Lilleby W","Tidsskr Nor Laegeforen","2005","2005/03/19","","",""
"15586023","Obesity and prostate cancer","Presti JC Jr.","Curr Opin Urol. 2005 Jan;15(1):13-6. doi: 10.1097/00042307-200501000-00004.","Presti JC Jr","Curr Opin Urol","2005","2004/12/09","","","10.1097/00042307-200501000-00004"
"29434372","A stage-dependent link between metabolic syndrome components and incident prostate cancer","Hammarsten J, Damber JE, Haghsheno MA, Mellström D, Peeker R.","Nat Rev Urol. 2018 May;15(5):321-333. doi: 10.1038/nrurol.2018.8. Epub 2018 Feb 13.","Hammarsten J","Nat Rev Urol","2018","2018/02/14","","","10.1038/nrurol.2018.8"
"24870260","Highlights in advanced prostate cancer from the 2014 American Society of Clinical Oncology genitourinary cancers symposium: commentary","George DJ.","Clin Adv Hematol Oncol. 2014 Apr;12(4 Suppl 11):12-6.","George DJ","Clin Adv Hematol Oncol","2014","2014/05/30","","",""
"29633944","[Oligometastatic prostate cancer. concept and implications.]","Carrasco Valiente J, Ruiz García JM, Requena Tapia MJ.","Arch Esp Urol. 2018 Mar;71(3):239-246.","Carrasco Valiente J","Arch Esp Urol","2018","2018/04/11","","",""
"17342489","Treatment of localized prostate cancer","Burchardt M, Huland H.","World J Urol. 2007 Mar;25(1):1-2. doi: 10.1007/s00345-007-0161-z.","Burchardt M","World J Urol","2007","2007/03/08","","","10.1007/s00345-007-0161-z"
"19839425","Radical radiotherapy for prostate cancer is the 'only way to go'","Sandler HM, Mirhadi AJ.","Oncology (Williston Park). 2009 Sep;23(10):840-3.","Sandler HM","Oncology (Williston Park)","2009","2009/10/21","","",""
"16604995","Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA","Khauli RB.","J Med Liban. 2005 Apr-Jun;53(2):95-102.","Khauli RB","J Med Liban","2005","2006/04/12","","",""
"30173435","[Long non-coding RNAs in prostate cancer: An update]","Wu PG, Zhang YX.","Zhonghua Nan Ke Xue. 2018 Aug;24(8):735-739.","Wu PG","Zhonghua Nan Ke Xue","2018","2018/09/03","","",""
"9713390","Prostate cancer screening","Witte MN, Morton RA Jr.","Am Fam Physician. 1998 Aug;58(2):342, 345-6, 348.","Witte MN","Am Fam Physician","1998","1998/08/26","","",""
"10510707","[Diagnosis and treatment of prostate cancer]","Auvert J.","Ann Urol (Paris). 1999;33(4):259-62.","Auvert J","Ann Urol (Paris)","1999","1999/10/08","","",""
"26299608","Therapy escape mechanisms in the malignant prostate","Santer FR, Erb HH, McNeill RV.","Semin Cancer Biol. 2015 Dec;35:133-44. doi: 10.1016/j.semcancer.2015.08.005. Epub 2015 Aug 21.","Santer FR","Semin Cancer Biol","2015","2015/08/25","","","10.1016/j.semcancer.2015.08.005"
"28430624","Photosensitizers in prostate cancer therapy","Gheewala T, Skwor T, Munirathinam G.","Oncotarget. 2017 May 2;8(18):30524-30538. doi: 10.18632/oncotarget.15496.","Gheewala T","Oncotarget","2017","2017/04/22","PMC5444762","","10.18632/oncotarget.15496"
"2189359","The assessment of disease aggressivity in stage D2 prostate cancer patients (review)","Koutsilieris M, Laroche B, Thabet M, Fradet Y.","Anticancer Res. 1990 Mar-Apr;10(2A):333-6.","Koutsilieris M","Anticancer Res","1990","1990/03/01","","",""
"7933230","Prostate cancer: a patient's perspective","Howe RJ.","J Urol. 1994 Nov;152(5 Pt 2):1700-3. doi: 10.1016/s0022-5347(17)32365-0.","Howe RJ","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32365-0"
"23737026","Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research","Chornokur G, Kumar NB.","Cancer Causes Control. 2013 Aug;24(8):1465-80. doi: 10.1007/s10552-013-0241-x. Epub 2013 Jun 5.","Chornokur G","Cancer Causes Control","2013","2013/06/06","PMC4184029","NIHMS489035","10.1007/s10552-013-0241-x"
"23731990","[Magnetic resonance imaging facilitate appropriate treatment selection of prostate cancer patients]","Boesen L, Thomsen HS.","Ugeskr Laeger. 2013 Jun 3;175(23):1634-7.","Boesen L","Ugeskr Laeger","2013","2013/06/05","","",""
"9858332","Prostate cancer research and the National Cancer Institute","Brawley OW, Figueroa-Valles N.","Semin Urol Oncol. 1998 Nov;16(4):235-40.","Brawley OW","Semin Urol Oncol","1998","1998/12/19","","",""
"16362603","Prostate cancer in the elderly","Konstantinos H.","Int Urol Nephrol. 2005;37(4):797-806. doi: 10.1007/s11255-005-0402-2.","Konstantinos H","Int Urol Nephrol","2005","2005/12/20","","","10.1007/s11255-005-0402-2"
"8319164","Recent results of management of palpable clinically localized prostate cancer","Adolfsson J, Steineck G, Whitmore WF Jr.","Cancer. 1993 Jul 15;72(2):310-22. doi: 10.1002/1097-0142(19930715)72:2<310::aid-cncr2820720203>3.0.co;2-t.","Adolfsson J","Cancer","1993","1993/07/15","","","10.1002/1097-0142(19930715)72:2<310::aid-cncr2820720203>3.0.co;2-t"
"20590366","Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer","Ishkanian AS, Zafarana G, Thoms J, Bristow RG.","Acta Oncol. 2010 Oct;49(7):888-94. doi: 10.3109/0284186X.2010.499371.","Ishkanian AS","Acta Oncol","2010","2010/07/02","","","10.3109/0284186X.2010.499371"
"9317177","The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment","Mettlin CJ, Murphy GP, Cunningham MP, Menck HR.","Cancer. 1997 Oct 1;80(7):1261-6.","Mettlin CJ","Cancer","1997","1997/10/08","","",""
"16319942","Abstracts from the British Prostate Group Spring Meeting. March 11, 2004. London, United Kingdom","","Prostate Cancer Prostatic Dis. 2005;8(4):381-96. doi: 10.1038/sj.pcan.4500832.","","Prostate Cancer Prostatic Dis","2005","2005/12/02","","","10.1038/sj.pcan.4500832"
"22033113","Defining and predicting indolent and low risk prostate cancer","Bangma CH, Roobol MJ.","Crit Rev Oncol Hematol. 2012 Aug;83(2):235-41. doi: 10.1016/j.critrevonc.2011.10.003. Epub 2011 Oct 26.","Bangma CH","Crit Rev Oncol Hematol","2012","2011/10/29","","","10.1016/j.critrevonc.2011.10.003"
"8439813","Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer","Mettlin C, Jones GW, Murphy GP.","CA Cancer J Clin. 1993 Mar-Apr;43(2):83-91. doi: 10.3322/canjclin.43.2.83.","Mettlin C","CA Cancer J Clin","1993","1993/03/01","","","10.3322/canjclin.43.2.83"
"8012376","The prognosis for prostate cancer","","Nat Genet. 1994 Mar;6(3):215-6. doi: 10.1038/ng0394-215.","","Nat Genet","1994","1994/03/01","","","10.1038/ng0394-215"
"27575537","[Role of radiotherapy in the management of node-positive prostate cancer]","Supiot S, Doré M, Rio E, Cellier P, Mesguez-Nebout N, Goineau A.","Cancer Radiother. 2016 Oct;20(6-7):442-4. doi: 10.1016/j.canrad.2016.06.002. Epub 2016 Aug 27.","Supiot S","Cancer Radiother","2016","2016/08/31","","","10.1016/j.canrad.2016.06.002"
"8853494","Screening for prostate cancer: conceptual considerations","Meyer F.","Can J Oncol. 1994 Nov;4 Suppl 1:72-3.","Meyer F","Can J Oncol","1994","1994/11/01","","",""
"18997810","Report from London","Kirby R.","Prostate Cancer Prostatic Dis. 2008;11(4):311. doi: 10.1038/pcan.2008.55.","Kirby R","Prostate Cancer Prostatic Dis","2008","2008/11/11","","","10.1038/pcan.2008.55"
"19567307","Proposed update on substaging metastatic prostate cancer","Crawford ED, Connor T.","Urology. 2009 Jul;74(1):237. doi: 10.1016/j.urology.2009.03.005.","Crawford ED","Urology","2009","2009/07/02","","","10.1016/j.urology.2009.03.005"
"17432558","Guidelines and counselling for treatment options in the management of prostate cancer","Heidenreich A.","Recent Results Cancer Res. 2007;175:131-62. doi: 10.1007/978-3-540-40901-4_9.","Heidenreich A","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_9"
"22083265","Cause-specific mortality following radical prostatectomy","Shikanov S, Kocherginsky M, Shalhav AL, Eggener SE.","Prostate Cancer Prostatic Dis. 2012 Mar;15(1):106-10. doi: 10.1038/pcan.2011.55. Epub 2011 Nov 15.","Shikanov S","Prostate Cancer Prostatic Dis","2012","2011/11/16","","","10.1038/pcan.2011.55"
"29319382","CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer","Bastos DA, Antonarakis ES.","Expert Rev Mol Diagn. 2018 Feb;18(2):155-163. doi: 10.1080/14737159.2018.1427068. Epub 2018 Jan 16.","Bastos DA","Expert Rev Mol Diagn","2018","2018/01/11","PMC6088794","NIHMS1500829","10.1080/14737159.2018.1427068"
"27038059","Patients' perceptions of mortality risk for localized prostate cancer vary markedly depending on their treatment strategy","Kendel F, Helbig L, Neumann K, Herden J, Stephan C, Schrader M, Gaissmaier W.","Int J Cancer. 2016 Aug 15;139(4):749-53. doi: 10.1002/ijc.30123. Epub 2016 Apr 19.","Kendel F","Int J Cancer","2016","2016/04/03","","","10.1002/ijc.30123"
"18922121","Inflammation and prostate cancer","Vasto S, Carruba G, Candore G, Italiano E, Di Bona D, Caruso C.","Future Oncol. 2008 Oct;4(5):637-45. doi: 10.2217/14796694.4.5.637.","Vasto S","Future Oncol","2008","2008/10/17","","","10.2217/14796694.4.5.637"
"1381969","Changes in PSA and early diagnosis of cancer of the prostate","Drago JR.","In Vivo. 1992 Mar-Apr;6(2):211-3.","Drago JR","In Vivo","1992","1992/03/01","","",""
"9225161","Hyperactive androgen receptor in prostate cancer: what does it mean for new therapy concepts?","Culig Z, Hobisch A, Hittmair A, Peterziel H, Radmayr C, Bartsch G, Cato AC, Klocker H.","Histol Histopathol. 1997 Jul;12(3):781-6.","Culig Z","Histol Histopathol","1997","1997/07/01","","",""
"22617061","Value of contrast-enhanced ultrasonography in prostate cancer","Kundavaram CR, Halpern EJ, Trabulsi EJ.","Curr Opin Urol. 2012 Jul;22(4):303-9. doi: 10.1097/MOU.0b013e328354831f.","Kundavaram CR","Curr Opin Urol","2012","2012/05/24","","","10.1097/MOU.0b013e328354831f"
"9612596","Early-stage prostate cancer: controversies, confusion, and difficult choices","Zelefsky MJ.","Cancer J Sci Am. 1998 May-Jun;4(3):159-61.","Zelefsky MJ","Cancer J Sci Am","1998","1998/06/05","","",""
"1374176","Rectal examination and ultrasonography in the diagnosis of prostate cancer","Cooner WH.","Prostate Suppl. 1992;4:3-10. doi: 10.1002/pros.2990210503.","Cooner WH","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210503"
"27344702","[Hereditary and familial prostate cancer]","Fukabori Y, Ohtake N, Matsui H, Suzuki K.","Nihon Rinsho. 2016 May 20;74 Suppl 3:47-51.","Fukabori Y","Nihon Rinsho","2016","2016/06/28","","",""
"12572219","Psychological and psychosocial effects of prostate cancer","Fan A.","Nurs Stand. 2002 Dec 11-17;17(13):33-7. doi: 10.7748/ns2002.12.17.13.33.c3314.","Fan A","Nurs Stand","2002","2003/02/08","","","10.7748/ns2002.12.17.13.33.c3314"
"18471787","Current status and prospects of androgen depletion therapy for prostate cancer","Akaza H.","Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):293-302. doi: 10.1016/j.beem.2008.01.010.","Akaza H","Best Pract Res Clin Endocrinol Metab","2008","2008/05/13","","","10.1016/j.beem.2008.01.010"
"7541531","Pathology review in an early prostate cancer detection program: results from the American Cancer Society-National Prostate Cancer Detection Project","Mostofi FK, Murphy GP, Mettlin C, Sesterhenn IA, Batsakis JG, Khaliq SU, Nadimpalli V, Tahan S, Siders DB, Kollin J, et al.","Prostate. 1995 Jul;27(1):7-12. doi: 10.1002/pros.2990270103.","Mostofi FK","Prostate","1995","1995/07/01","","","10.1002/pros.2990270103"
"21252057","Novel approaches and future directions in castration-resistant prostate cancer","Nabhan C, Parsons B, Touloukian EZ, Stadler WM.","Ann Oncol. 2011 Sep;22(9):1948-1957. doi: 10.1093/annonc/mdq639. Epub 2011 Jan 20.","Nabhan C","Ann Oncol","2011","2011/01/22","","","10.1093/annonc/mdq639"
"9571318","Prostate cancer","Repetto L, Granetto C, Hall RR.","Crit Rev Oncol Hematol. 1998 Feb;27(2):145-6. doi: 10.1016/s1040-8428(97)10024-5.","Repetto L","Crit Rev Oncol Hematol","1998","1998/05/08","","","10.1016/s1040-8428(97)10024-5"
"23765584","Treatment of early-stage prostate cancer among rural and urban patients","Baldwin LM, Andrilla CH, Porter MP, Rosenblatt RA, Patel S, Doescher MP.","Cancer. 2013 Aug 15;119(16):3067-75. doi: 10.1002/cncr.28037. Epub 2013 Jun 13.","Baldwin LM","Cancer","2013","2013/06/15","","","10.1002/cncr.28037"
"18090496","The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery","Pucar D, Sella T, Schöder H.","Curr Opin Urol. 2008 Jan;18(1):87-97. doi: 10.1097/MOU.0b013e3282f13ac3.","Pucar D","Curr Opin Urol","2008","2007/12/20","","","10.1097/MOU.0b013e3282f13ac3"
"25080928","Prostate cancer in East Asia: evolving trend over the last decade","Zhu Y, Wang HK, Qu YY, Ye DW.","Asian J Androl. 2015 Jan-Feb;17(1):48-57. doi: 10.4103/1008-682X.132780.","Zhu Y","Asian J Androl","2015","2014/08/02","PMC4291877","","10.4103/1008-682X.132780"
"23806490","Introduction: the changing landscape of prostate cancer","Dicker AP, Gomella LG, Kevin Kelly W.","Semin Oncol. 2013 Jun;40(3):241-3. doi: 10.1053/j.seminoncol.2013.04.017.","Dicker AP","Semin Oncol","2013","2013/06/29","","","10.1053/j.seminoncol.2013.04.017"
"24414193","The role of epithelial plasticity in prostate cancer dissemination and treatment resistance","Bitting RL, Schaeffer D, Somarelli JA, Garcia-Blanco MA, Armstrong AJ.","Cancer Metastasis Rev. 2014 Sep;33(2-3):441-68. doi: 10.1007/s10555-013-9483-z.","Bitting RL","Cancer Metastasis Rev","2014","2014/01/14","PMC4230790","NIHMS640016","10.1007/s10555-013-9483-z"
"18391629","Prostate cancer update: 2007","Lin AM, Small EJ.","Curr Opin Oncol. 2008 May;20(3):294-9. doi: 10.1097/CCO.0b013e3282f8b075.","Lin AM","Curr Opin Oncol","2008","2008/04/09","","","10.1097/CCO.0b013e3282f8b075"
"1563735","Flow cytometry as a predictive modality in prostate cancer","Deitch AD, deVere White RW.","Hum Pathol. 1992 Apr;23(4):352-9. doi: 10.1016/0046-8177(92)90081-d.","Deitch AD","Hum Pathol","1992","1992/04/01","","","10.1016/0046-8177(92)90081-d"
"15161563","Genetic alterations in prostate cancer","Chin JL, Reiter RE.","Curr Urol Rep. 2004 Jun;5(3):157-65. doi: 10.1007/s11934-004-0032-8.","Chin JL","Curr Urol Rep","2004","2004/05/27","","","10.1007/s11934-004-0032-8"
"18203520","[The clinical status of prostate cancer in elderly patients 75 years of age or older in the Kitamurayama District of Yamagata Prefecture, Japan]","Nemoto K, Tomita Y, Kimata R.","Hinyokika Kiyo. 2007 Dec;53(12):843-9.","Nemoto K","Hinyokika Kiyo","2007","2008/01/22","","",""
"26631038","Prognostic significance of GPC5 expression in patients with prostate cancer","Zhang C, Liu Z, Wang L, Qiao B, Du E, Li L, Xu Y, Zhang Z.","Tumour Biol. 2016 May;37(5):6413-8. doi: 10.1007/s13277-015-4499-3. Epub 2015 Dec 2.","Zhang C","Tumour Biol","2016","2015/12/04","","","10.1007/s13277-015-4499-3"
"31430233","Under Treatment of Prostate Cancer in Rural Locations","Maganty A, Sabik LM, Sun Z, Eom KY, Li J, Davies BJ, Jacobs BL.","J Urol. 2020 Jan;203(1):108-114. doi: 10.1097/JU.0000000000000500. Epub 2019 Aug 20.","Maganty A","J Urol","2020","2019/08/21","PMC7098431","NIHMS1063226","10.1097/JU.0000000000000500"
"11022760","[Is cure of T1c prostate cancer necessary in those for whom it is possible?]","Ohori M.","Nihon Rinsho. 2000 Jul;58 Suppl:416-9.","Ohori M","Nihon Rinsho","2000","2000/10/07","","",""
"23449497","Predicting high risk disease using serum and DNA biomarkers","Vesprini D, Liu S, Nam R.","Curr Opin Urol. 2013 May;23(3):252-60. doi: 10.1097/MOU.0b013e32835f89b8.","Vesprini D","Curr Opin Urol","2013","2013/03/02","","","10.1097/MOU.0b013e32835f89b8"
"25961317","Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer","Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D.","Oncotarget. 2015 Jun 10;6(16):14360-73. doi: 10.18632/oncotarget.3965.","Pasero C","Oncotarget","2015","2015/05/12","PMC4546472","","10.18632/oncotarget.3965"
"18061030","Inflammation and prostate cancer: a future target for prevention and therapy?","Stock D, Groome PA, Siemens DR.","Urol Clin North Am. 2008 Feb;35(1):117-30; vii. doi: 10.1016/j.ucl.2007.09.006.","Stock D","Urol Clin North Am","2008","2007/12/07","","","10.1016/j.ucl.2007.09.006"
"19088721","Incidence and mortality of incidental prostate cancer: a Swedish register-based study","Andrèn O, Garmo H, Mucci L, Andersson SO, Johansson JE, Fall K.","Br J Cancer. 2009 Jan 13;100(1):170-3. doi: 10.1038/sj.bjc.6604834. Epub 2008 Dec 16.","Andrèn O","Br J Cancer","2009","2008/12/18","PMC2634678","","10.1038/sj.bjc.6604834"
"25277175","Molecular pathways and targets in prostate cancer","Shtivelman E, Beer TM, Evans CP.","Oncotarget. 2014 Sep 15;5(17):7217-59. doi: 10.18632/oncotarget.2406.","Shtivelman E","Oncotarget","2014","2014/10/04","PMC4202120","","10.18632/oncotarget.2406"
"10146228","Ultrasound, MR back up prostate cancer diagnosis","Rifkin MD.","Diagn Imaging (San Franc). 1993 Jul;15(7):70-3, 85.","Rifkin MD","Diagn Imaging (San Franc)","1993","1993/06/07","","",""
"17896552","[The treatment of prostatic cancer: present and future, realities and possibilities]","Vera Donoso CD.","Actas Urol Esp. 2007 Jun;31(6):575-9. doi: 10.1016/s0210-4806(07)73692-6.","Vera Donoso CD","Actas Urol Esp","2007","2007/09/28","","","10.1016/s0210-4806(07)73692-6"
"15061743","Preferences of husbands and wives for outcomes of prostate cancer screening and treatment","Volk RJ, Cantor SB, Cass AR, Spann SJ, Weller SC, Krahn MD.","J Gen Intern Med. 2004 Apr;19(4):339-48. doi: 10.1111/j.1525-1497.2004.30046.x.","Volk RJ","J Gen Intern Med","2004","2004/04/06","PMC1492196","","10.1111/j.1525-1497.2004.30046.x"
"28486411","Exploiting Epigenetic Alterations in Prostate Cancer","Baumgart SJ, Haendler B.","Int J Mol Sci. 2017 May 9;18(5):1017. doi: 10.3390/ijms18051017.","Baumgart SJ","Int J Mol Sci","2017","2017/05/10","PMC5454930","","10.3390/ijms18051017"
"3286957","Diagnosis and staging of prostate cancer","Brendler CB.","Keio J Med. 1988 Mar;37(1):10-23. doi: 10.2302/kjm.37.10.","Brendler CB","Keio J Med","1988","1988/03/01","","","10.2302/kjm.37.10"
"28236452","Multiparametric magnetic resonance imaging and prostate cancer: what's new?","Catalá V, Vilanova JC, Gaya JM, Algaba F, Martí T.","Radiologia. 2017 May-Jun;59(3):196-208. doi: 10.1016/j.rx.2016.12.003. Epub 2017 Feb 21.","Catalá V","Radiologia","2017","2017/02/26","","","10.1016/j.rx.2016.12.003"
"22235075","Expert panel advocates surveillance for men with low-risk prostate cancer","Slomski A.","JAMA. 2012 Jan 11;307(2):133. doi: 10.1001/jama.2011.1965.","Slomski A","JAMA","2012","2012/01/12","","","10.1001/jama.2011.1965"
"20858068","Heat shock proteins in prostate cancer: from tumorigenesis to the clinic","Ciocca DR, Fanelli MA, Cuello-Carrion FD, Castro GN.","Int J Hyperthermia. 2010;26(8):737-47. doi: 10.3109/02656731003776968. Epub 2010 Sep 21.","Ciocca DR","Int J Hyperthermia","2010","2010/09/23","","","10.3109/02656731003776968"
"16890705","Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy","Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.","J Urol. 2006 Sep;176(3):1118-21. doi: 10.1016/j.juro.2006.04.077.","Siddiqui SA","J Urol","2006","2006/08/08","","","10.1016/j.juro.2006.04.077"
"29730018","Palliative Radical Prostatectomy in Men with Metastatic Castration-resistant Prostate Cancer: Only When Your Back Is Against the Wall!","Knipper S, Graefen M.","Eur Urol. 2018 Aug;74(2):144-145. doi: 10.1016/j.eururo.2018.04.028. Epub 2018 May 3.","Knipper S","Eur Urol","2018","2018/05/07","","","10.1016/j.eururo.2018.04.028"
"24821211","Challenges of managing elderly men with prostate cancer","Jha GG, Anand V, Soubra A, Konety BR.","Nat Rev Clin Oncol. 2014 Jun;11(6):354-64. doi: 10.1038/nrclinonc.2014.71. Epub 2014 May 13.","Jha GG","Nat Rev Clin Oncol","2014","2014/05/14","PMC5788018","NIHMS888270","10.1038/nrclinonc.2014.71"
"15161570","Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer","Hollenbeck BK, Dunn RL, Wei JT, Sandler HM, Sanda MG.","Curr Urol Rep. 2004 Jun;5(3):212-9. doi: 10.1007/s11934-004-0039-1.","Hollenbeck BK","Curr Urol Rep","2004","2004/05/27","","","10.1007/s11934-004-0039-1"
"7084087","[Prognosis of prostate cancer]","Rannikko S.","Duodecim. 1982;98(4):258-66.","Rannikko S","Duodecim","1982","1982/01/01","","",""
"23712946","Prevalence and predictors of cancer specific distress in men with a family history of prostate cancer","McDowell ME, Occhipinti S, Gardiner RA, Chambers SK.","Psychooncology. 2013 Nov;22(11):2496-504. doi: 10.1002/pon.3312. Epub 2013 May 27.","McDowell ME","Psychooncology","2013","2013/05/29","","","10.1002/pon.3312"
"23985455","[Editorial comment of: cryosurgery for prostate cancer: a comprehensive review]","Banus Gassol JM.","Arch Esp Urol. 2013 Jul-Aug;66(6):557.","Banus Gassol JM","Arch Esp Urol","2013","2013/08/30","","",""
"23545099","Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer","Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N.","J Urol. 2013 Aug;190(2):389-98. doi: 10.1016/j.juro.2013.02.005. Epub 2013 Mar 29.","Bradley LA","J Urol","2013","2013/04/03","","","10.1016/j.juro.2013.02.005"
"8717476","The future management of prostate cancer?","Kirby RS.","Eur Urol. 1996;29 Suppl 2:132-3. doi: 10.1159/000473854.","Kirby RS","Eur Urol","1996","1996/01/01","","","10.1159/000473854"
"26639290","Psychosexual care is important after prostate cancer treatment","Rooke A.","Nurs Stand. 2015 Dec 2;30(14):31. doi: 10.7748/ns.30.14.31.s39.","Rooke A","Nurs Stand","2015","2015/12/08","","","10.7748/ns.30.14.31.s39"
"20719368","Enhanced transrectal ultrasound modalities in the diagnosis of prostate cancer","Trabulsi EJ, Sackett D, Gomella LG, Halpern EJ.","Urology. 2010 Nov;76(5):1025-33. doi: 10.1016/j.urology.2010.05.022. Epub 2010 Aug 16.","Trabulsi EJ","Urology","2010","2010/08/20","","","10.1016/j.urology.2010.05.022"
"15847713","Angiogenesis and prostate cancer: important laboratory and clinical findings","Cox MC, Permenter M, Figg WD.","Curr Oncol Rep. 2005 May;7(3):215-9. doi: 10.1007/s11912-005-0076-z.","Cox MC","Curr Oncol Rep","2005","2005/04/26","","","10.1007/s11912-005-0076-z"
"19098969","PSA testing and DRE, TRUS scanning with sector biopsy, improved histology, curative treatments, and active surveillance for prostate cancer: a success story for men's health","Smart R.","N Z Med J. 2008 Dec 12;121(1287):57-68.","Smart R","N Z Med J","2008","2008/12/23","","",""
"31493090","The Microbiome and Prostate Cancer Risk","Wheeler KM, Liss MA.","Curr Urol Rep. 2019 Sep 7;20(10):66. doi: 10.1007/s11934-019-0922-4.","Wheeler KM","Curr Urol Rep","2019","2019/09/08","","","10.1007/s11934-019-0922-4"
"15067311","Predicting the clinical course of prostate cancer","McKiernan J, Benson MC.","J Clin Invest. 2004 Mar;113(6):806-8. doi: 10.1172/JCI21310.","McKiernan J","J Clin Invest","2004","2004/04/07","PMC362125","","10.1172/JCI21310"
"24818851","Prostate cancer: surgery versus observation for localized prostate cancer","van den Bergh RC, Giannarini G.","Nat Rev Urol. 2014 Jun;11(6):312-3. doi: 10.1038/nrurol.2014.109. Epub 2014 May 13.","van den Bergh RC","Nat Rev Urol","2014","2014/05/14","","","10.1038/nrurol.2014.109"
"7939751","Current status of monoclonal antibodies for imaging and therapy of prostate cancer","Bander NH.","Semin Oncol. 1994 Oct;21(5):607-12.","Bander NH","Semin Oncol","1994","1994/10/01","","",""
"8648770","Preoperative diagnosis and staging of prostate cancer","Lowe FC.","J Urol. 1996 Jul;156(1):114. doi: 10.1016/s0022-5347(01)65957-3.","Lowe FC","J Urol","1996","1996/07/01","","","10.1016/s0022-5347(01)65957-3"
"19947347","Brachytherapy or surgery? A composite view","Ciezki JP, Klein EA.","Oncology (Williston Park). 2009 Oct;23(11):960-4.","Ciezki JP","Oncology (Williston Park)","2009","2009/12/02","","",""
"17364211","Overdiagnosis and overtreatment of early detected prostate cancer","Bangma CH, Roemeling S, Schröder FH.","World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.","Bangma CH","World J Urol","2007","2007/03/17","PMC1913182","","10.1007/s00345-007-0145-z"
"24477410","Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel","Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albini A, Pfeffer U.","Cancer Metastasis Rev. 2014 Sep;33(2-3):657-71. doi: 10.1007/s10555-013-9470-4.","Amaro A","Cancer Metastasis Rev","2014","2014/01/31","PMC4113682","","10.1007/s10555-013-9470-4"
"9159797","Role for androgen withdrawal prior to radiation and surgery for prostate cancer?","","Oncology (Williston Park). 1997 May;11(5):738.","","Oncology (Williston Park)","1997","1997/05/01","","",""
"3312666","Consensus conference. The management of clinically localized prostate cancer","","JAMA. 1987 Nov 20;258(19):2727-30.","","JAMA","1987","1987/11/20","","",""
"7689738","The case for prostate cancer screening","Andriole GL.","Semin Urol. 1993 May;11(2):50-3.","Andriole GL","Semin Urol","1993","1993/05/01","","",""
"30788590","The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer","van der Poel H, Grivas N, van Leeuwen P, Heijmink S, Schoots I.","World J Urol. 2019 Aug;37(8):1485-1490. doi: 10.1007/s00345-019-02677-y. Epub 2019 Feb 20.","van der Poel H","World J Urol","2019","2019/02/22","","","10.1007/s00345-019-02677-y"
"21842194","[Prostate cancer. Current and practice-relevant news from urology in 2011]","Wirth M, Zastrow S.","Urologe A. 2011 Sep;50 Suppl 1:173-5. doi: 10.1007/s00120-011-2680-x.","Wirth M","Urologe A","2011","2011/08/16","","","10.1007/s00120-011-2680-x"
"30585345","Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study","Tsumura H, Ishiyama H, Tabata KI, Sekiguchi A, Kawakami S, Satoh T, Kitano M, Iwamura M.","Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.","Tsumura H","Prostate","2019","2018/12/27","","","10.1002/pros.23757"
"19398944","The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer","Fuchsjäger M, Akin O, Shukla-Dave A, Pucar D, Hricak H.","Clin Adv Hematol Oncol. 2009 Mar;7(3):193-202.","Fuchsjäger M","Clin Adv Hematol Oncol","2009","2009/04/29","","",""
"12584476","Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies","Litwin MS.","Curr Opin Urol. 2003 Mar;13(2):153-6. doi: 10.1097/00042307-200303000-00011.","Litwin MS","Curr Opin Urol","2003","2003/02/14","","","10.1097/00042307-200303000-00011"
"30527643","The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer","Kucharczyk MJ, Gravis G, Niazi T.","Eur Urol Focus. 2019 Mar;5(2):117-118. doi: 10.1016/j.euf.2018.11.011. Epub 2018 Dec 4.","Kucharczyk MJ","Eur Urol Focus","2019","2018/12/12","","","10.1016/j.euf.2018.11.011"
"22446342","Role of 5α-reductase inhibitors in prostate cancer prevention and treatment","Azzouni F, Mohler J.","Urology. 2012 Jun;79(6):1197-205. doi: 10.1016/j.urology.2012.01.024. Epub 2012 Mar 23.","Azzouni F","Urology","2012","2012/03/27","","","10.1016/j.urology.2012.01.024"
"22343605","Prostate-specific antigen screening for prostate cancer in older men in the United States of America","Black A, Berg CD.","Gerontology. 2012;58(4):331-6. doi: 10.1159/000334242. Epub 2012 Feb 16.","Black A","Gerontology","2012","2012/02/21","","","10.1159/000334242"
"18712956","Dietary agents in prevention of prostate cancer","Süral YS, Sari D, Turgay AS, Turan D.","Asian Pac J Cancer Prev. 2008 Apr-Jun;9(2):183-6.","Süral YS","Asian Pac J Cancer Prev","2008","2008/08/21","","",""
"32015294","Magnetic Resonance Imaging Assessment After Therapy in Prostate Cancer","Koopman AGMM, Jenniskens SFM, Fütterer JJ.","Top Magn Reson Imaging. 2020 Feb;29(1):47-58. doi: 10.1097/RMR.0000000000000231.","Koopman AGMM","Top Magn Reson Imaging","2020","2020/02/05","","","10.1097/RMR.0000000000000231"
"1545435","NCI strengthens commitment to prostate cancer","Volkers N.","J Natl Cancer Inst. 1992 Apr 1;84(7):478-9. doi: 10.1093/jnci/84.7.478.","Volkers N","J Natl Cancer Inst","1992","1992/04/01","","","10.1093/jnci/84.7.478"
"22827935","Implementation and scientific evaluation of rehabilitative sports groups for prostate cancer patients: study protocol of the ProRehab Study","Zopf EM, Braun M, Machtens S, Zumbé J, Bloch W, Baumann FT.","BMC Cancer. 2012 Jul 24;12:312. doi: 10.1186/1471-2407-12-312.","Zopf EM","BMC Cancer","2012","2012/07/26","PMC3414755","","10.1186/1471-2407-12-312"
"30855009","New paradigms in prostate cancer","Álvarez-Maestro M, Gómez Rivas J.","Arch Esp Urol. 2019 Mar;72(2):95-97.","Álvarez-Maestro M","Arch Esp Urol","2019","2019/03/12","","",""
"31227052","Contribution of Radiology to Staging of Prostate Cancer","Woo S, Ghafoor S, Vargas HA.","Semin Nucl Med. 2019 Jul;49(4):294-301. doi: 10.1053/j.semnuclmed.2019.02.007. Epub 2019 Mar 9.","Woo S","Semin Nucl Med","2019","2019/06/23","PMC7425779","NIHMS1612543","10.1053/j.semnuclmed.2019.02.007"
"15247720","Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation","Swanson GP, Riggs M, Earle J.","J Urol. 2004 Aug;172(2):525-8. doi: 10.1097/01.ju.0000132412.74468.57.","Swanson GP","J Urol","2004","2004/07/13","","","10.1097/01.ju.0000132412.74468.57"
"19293807","Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study","Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J.","Br J Cancer. 2009 Mar 24;100(6):888-93. doi: 10.1038/sj.bjc.6604951.","Berney DM","Br J Cancer","2009","2009/03/19","PMC2661778","","10.1038/sj.bjc.6604951"
"28825923","Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?","Laccetti AL, Subudhi SK.","Curr Opin Urol. 2017 Nov;27(6):566-571. doi: 10.1097/MOU.0000000000000433.","Laccetti AL","Curr Opin Urol","2017","2017/08/22","PMC6351068","NIHMS1005652","10.1097/MOU.0000000000000433"
"24710055","Management of low risk prostate cancer: active surveillance and focal therapy","Klotz L, Emberton M.","Curr Opin Urol. 2014 May;24(3):270-9. doi: 10.1097/MOU.0000000000000055.","Klotz L","Curr Opin Urol","2014","2014/04/09","","","10.1097/MOU.0000000000000055"
"7910919","Screening for prostate cancer","Feneley M, Kirby R, Parkinson C.","Lancet. 1994 Jun 4;343(8910):1436-7.","Feneley M","Lancet","1994","1994/06/04","","",""
"6834500","Prostate cancer","Gittes RF.","J Urol. 1983 Feb;129(2):330. doi: 10.1016/s0022-5347(17)52082-0.","Gittes RF","J Urol","1983","1983/02/01","","","10.1016/s0022-5347(17)52082-0"
"501818","Prostate cancer","Murphy GP.","J Urol. 1979 Nov;122(5):644. doi: 10.1016/s0022-5347(17)56540-4.","Murphy GP","J Urol","1979","1979/11/01","","","10.1016/s0022-5347(17)56540-4"
"1878824","Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Canadian Task Force on the Periodic Health Examination","","CMAJ. 1991 Sep 1;145(5):413-28.","","CMAJ","1991","1991/09/01","PMC1335825","",""
"15643450","Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade","Woodward WA, Wachsberger P, Burd R, Dicker AP.","Prostate Cancer Prostatic Dis. 2005;8(2):127-32. doi: 10.1038/sj.pcan.4500779.","Woodward WA","Prostate Cancer Prostatic Dis","2005","2005/01/12","","","10.1038/sj.pcan.4500779"
"23410127","Androgen receptor gene rearrangements: new perspectives on prostate cancer progression","Brand LJ, Dehm SM.","Curr Drug Targets. 2013 Apr;14(4):441-9. doi: 10.2174/1389450111314040005.","Brand LJ","Curr Drug Targets","2013","2013/02/16","PMC3957184","NIHMS561516","10.2174/1389450111314040005"
"1778180","Endocrine therapy for prostate cancer","Labrie F.","Endocrinol Metab Clin North Am. 1991 Dec;20(4):845-72.","Labrie F","Endocrinol Metab Clin North Am","1991","1991/12/01","","",""
"21568683","Imaging in prostate cancer","Abdellaoui A, Iyengar S, Freeman S.","Future Oncol. 2011 May;7(5):679-91. doi: 10.2217/fon.11.43.","Abdellaoui A","Future Oncol","2011","2011/05/17","","","10.2217/fon.11.43"
"10198454","I am a 54-year-old man. My father is a healthy 84-year-old, but my two brothers (59 and 61 years old) have been diagnosed with prostate cancer within the past year. I am worried not only about myself but about my two sons. Is there any hope of a vaccine for prostate cancer?","Simon HB.","Harv Mens Health Watch. 1999 May;3(10):8.","Simon HB","Harv Mens Health Watch","1999","1999/04/13","","",""
"25396016","[Scrotal elephantiasis revealing prostate cancer]","Taghy A, Hassam B.","Pan Afr Med J. 2014 Mar 12;17:190. doi: 10.11604/pamj.2014.17.190.3601. eCollection 2014.","Taghy A","Pan Afr Med J","2014","2014/11/15","PMC4228993","","10.11604/pamj.2014.17.190.3601"
"23316506","Prostate cancer diagnosis: surgery or not?","","Aust Nurs J. 2012 Nov;20(5):49.","","Aust Nurs J","2012","2013/01/15","","",""
"7966740","Prostate cancer","Brawer MK.","J Urol. 1995 Jan;153(1):115-6. doi: 10.1097/00005392-199501000-00039.","Brawer MK","J Urol","1995","1995/01/01","","","10.1097/00005392-199501000-00039"
"9666644","Prostate cancer: out of the closet","Lesesne JB.","J Med Assoc Ga. 1998 Jan;87(1):23-6.","Lesesne JB","J Med Assoc Ga","1998","1998/07/17","","",""
"7524232","Prostate cancer kills: strategy to reduce deaths","Walsh PC.","Urology. 1994 Oct;44(4):463-6. doi: 10.1016/s0090-4295(94)80039-1.","Walsh PC","Urology","1994","1994/10/01","","","10.1016/s0090-4295(94)80039-1"
"26267226","What is the Need for Prostatic Biomarkers in Prostate Cancer Management?","Spahn M, Boxler S, Joniau S, Moschini M, Tombal B, Karnes RJ.","Curr Urol Rep. 2015 Oct;16(10):70. doi: 10.1007/s11934-015-0545-3.","Spahn M","Curr Urol Rep","2015","2015/08/13","PMC4534510","","10.1007/s11934-015-0545-3"
"18807624","Treating prostate cancer, Part II: determining its severity","","Harv Mens Health Watch. 2008 Jun;12(11):1-4.","","Harv Mens Health Watch","2008","2008/09/24","","",""
"18268527","Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America","Colli JL, Amling CL.","Prostate Cancer Prostatic Dis. 2008;11(3):247-51. doi: 10.1038/pcan.2008.7. Epub 2008 Feb 12.","Colli JL","Prostate Cancer Prostatic Dis","2008","2008/02/13","","","10.1038/pcan.2008.7"
"17432552","Prognostic factors in prostate cancer","Braeckman J, Michielsen D.","Recent Results Cancer Res. 2007;175:25-32. doi: 10.1007/978-3-540-40901-4_3.","Braeckman J","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_3"
"23603920","Global advances in prostate cancer diagnosis and therapy","Walia G, Sun Y, Soule HR.","Asian J Androl. 2013 May;15(3):299-300. doi: 10.1038/aja.2013.50. Epub 2013 Apr 22.","Walia G","Asian J Androl","2013","2013/04/23","PMC3739652","","10.1038/aja.2013.50"
"30453292","[Clinical value of transperineal saturation biopsy in patients with suspicious for prostate cancer]","Novikov RV, Novikov SN, Kanaev SV, Iliin ND, Klimashevsky VF, Artemieva AS, Ivantsov AO, Reva SA.","Vopr Onkol. 2016;62(2):290-5.","Novikov RV","Vopr Onkol","2016","2018/11/20","","",""
"30565298","Defining clinically significant prostate cancer on the basis of pathological findings","Matoso A, Epstein JI.","Histopathology. 2019 Jan;74(1):135-145. doi: 10.1111/his.13712.","Matoso A","Histopathology","2019","2018/12/20","","","10.1111/his.13712"
"24881167","Optimising the management of early prostate cancer","Kirby R.","Practitioner. 2014 Apr;258(1770):15-8, 2.","Kirby R","Practitioner","2014","2014/06/03","","",""
"26817355","[Dural metastatic infiltration in prostate cancer--case report]","Mocarska A, Starosławska E, Czarnocki K, Kubiatowska H, Żelazowska-Cieślińska I, Kubiatowski T, Burdan F.","Przegl Lek. 2015;72(7):391-3.","Mocarska A","Przegl Lek","2015","2016/01/29","","",""
"16979705","Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy","Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Gleave M, Fujisawa M.","Urology. 2006 Sep;68(3):609-14. doi: 10.1016/j.urology.2006.03.017. Epub 2006 Sep 18.","Miyake H","Urology","2006","2006/09/19","","","10.1016/j.urology.2006.03.017"
"21842788","Treatment options for localized prostate cancer","Mohan R, Schellhammer PF.","Am Fam Physician. 2011 Aug 15;84(4):413-20.","Mohan R","Am Fam Physician","2011","2011/08/17","","",""
"11114595","Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out","Van Poppel H.","Eur Urol. 2001;39 Suppl 1:10-4. doi: 10.1159/000052544.","Van Poppel H","Eur Urol","2001","2000/12/15","","","10.1159/000052544"
"25675126","Economic evaluation of prostate cancer screening: a systematic review","Lao C, Brown C, Rouse P, Edlin R, Lawrenson R.","Future Oncol. 2015;11(3):467-77. doi: 10.2217/fon.14.273.","Lao C","Future Oncol","2015","2015/02/13","","","10.2217/fon.14.273"
"27919140","[Undifferentiated Prostate Cancer Treated with Radiation Therapy]","Osakabe H, Tamura K, Yamasaki I, Fukata S, Ashida S, Hiroi M, Tanimura M, Inoue K, Shuin T.","Hinyokika Kiyo. 2016 Nov;62(11):599-604. doi: 10.14989/ActaUrolJap_62_11_599.","Osakabe H","Hinyokika Kiyo","2016","2016/12/06","","","10.14989/ActaUrolJap_62_11_599"
"22207941","[Mechanisms of carcinogenesis and proliferation in prostate cancer]","Inoue T, Tsuchiya N, Habuchi T.","Nihon Rinsho. 2011 Jun;69 Suppl 5:50-5.","Inoue T","Nihon Rinsho","2011","2012/01/03","","",""
"24146262","Noncoding RNAs in prostate cancer: the long and the short of it","Bolton EM, Tuzova AV, Walsh AL, Lynch T, Perry AS.","Clin Cancer Res. 2014 Jan 1;20(1):35-43. doi: 10.1158/1078-0432.CCR-13-1989. Epub 2013 Oct 21.","Bolton EM","Clin Cancer Res","2014","2013/10/23","","","10.1158/1078-0432.CCR-13-1989"
"29064739","Estimation of the Most Influential Factors for Survival Probability Prediction of Prostate Cancer Patients","Stanković J, Stanković M.","Cancer Invest. 2017 Oct 21;35(9):594-600. doi: 10.1080/07357907.2017.1385791. Epub 2017 Oct 24.","Stanković J","Cancer Invest","2017","2017/10/25","","","10.1080/07357907.2017.1385791"
"18596900","Prostate cancer screening: why it's not for every man","LeFevre M.","Medscape J Med. 2008 May 23;10(5):124.","LeFevre M","Medscape J Med","2008","2008/07/04","PMC2438499","",""
"16739309","External beam radiotherapy for prostate cancer: current position and trends","Koukourakis MI, Touloupidis S.","Anticancer Res. 2006 Jan-Feb;26(1B):485-94.","Koukourakis MI","Anticancer Res","2006","2006/06/03","","",""
"15495440","Prostate cancer: a review of common underwriting problems, Part 1","Richie RC, Swanson JO.","J Insur Med. 2004;36(3):242-54.","Richie RC","J Insur Med","2004","2004/10/22","","",""
"15233488","A focus group study of factors influencing African-American men's prostate cancer screening behavior","Odedina FT, Scrivens J, Emanuel A, LaRose-Pierre M, Brown J, Nash R.","J Natl Med Assoc. 2004 Jun;96(6):780-8.","Odedina FT","J Natl Med Assoc","2004","2004/07/06","PMC2568374","",""
"22333688","MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics","Gordanpour A, Nam RK, Sugar L, Seth A.","Prostate Cancer Prostatic Dis. 2012 Dec;15(4):314-9. doi: 10.1038/pcan.2012.3. Epub 2012 Feb 14.","Gordanpour A","Prostate Cancer Prostatic Dis","2012","2012/02/16","","","10.1038/pcan.2012.3"
"8673696","The management of clinically localized prostate cancer: guidelines from the American Urological Association","Middleton RG.","CA Cancer J Clin. 1996 Jul-Aug;46(4):249-53. doi: 10.3322/canjclin.46.4.249.","Middleton RG","CA Cancer J Clin","1996","1996/07/01","","","10.3322/canjclin.46.4.249"
"25454485","Radiotherapy before and after radical prostatectomy for high-risk and locally advanced prostate cancer","Perez BA, Koontz BF.","Urol Oncol. 2015 May;33(5):226-34. doi: 10.1016/j.urolonc.2014.09.018. Epub 2014 Oct 30.","Perez BA","Urol Oncol","2015","2014/12/03","","","10.1016/j.urolonc.2014.09.018"
"24646125","Prostate cancer and its mimics at multiparametric prostate MRI","Yu J, Fulcher AS, Turner MA, Cockrell CH, Cote EP, Wallace TJ.","Br J Radiol. 2014 May;87(1037):20130659. doi: 10.1259/bjr.20130659. Epub 2014 Mar 20.","Yu J","Br J Radiol","2014","2014/03/21","PMC4075530","","10.1259/bjr.20130659"
"22697604","Tea consumption and the risk of overall and grade specific prostate cancer: a large prospective cohort study of Scottish men","Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.","Nutr Cancer. 2012 Aug;64(6):790-7. doi: 10.1080/01635581.2012.690063. Epub 2012 Jun 14.","Shafique K","Nutr Cancer","2012","2012/06/16","","","10.1080/01635581.2012.690063"
"27557386","Prostate cancer","Castillejos-Molina RA, Gabilondo-Navarro FB.","Salud Publica Mex. 2016 Apr;58(2):279-84. doi: 10.21149/spm.v58i2.7797.","Castillejos-Molina RA","Salud Publica Mex","2016","2016/08/25","","","10.21149/spm.v58i2.7797"
"9801750","Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens","Bostwick DG.","Anal Quant Cytol Histol. 1998 Oct;20(5):323-42.","Bostwick DG","Anal Quant Cytol Histol","1998","1998/11/05","","",""
"24768356","Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer","Fraser M, Berlin A, Bristow RG, van der Kwast T.","Urol Oncol. 2015 Feb;33(2):85-94. doi: 10.1016/j.urolonc.2013.10.020. Epub 2014 Apr 24.","Fraser M","Urol Oncol","2015","2014/04/29","","","10.1016/j.urolonc.2013.10.020"
"25857774","Spotlight on prostate cancer: the latest evidence and current controversies","Carlsson S, Vickers A.","BMC Med. 2015 Mar 24;13:60. doi: 10.1186/s12916-015-0311-x.","Carlsson S","BMC Med","2015","2015/04/11","PMC4372269","","10.1186/s12916-015-0311-x"
"8863569","Immunohistochemical localization of metallothionein in human prostate cancer","Zhang XH, Jin L, Sakamoto H, Takenaka I.","J Urol. 1996 Nov;156(5):1679-81.","Zhang XH","J Urol","1996","1996/11/01","","",""
"21331939","Prostate cancer","Jadvar H.","Methods Mol Biol. 2011;727:265-90. doi: 10.1007/978-1-61779-062-1_15.","Jadvar H","Methods Mol Biol","2011","2011/02/19","","","10.1007/978-1-61779-062-1_15"
"27306275","Imaging of local recurrence in prostate cancer","McCammack KC, Raman SS, Margolis DJ.","Future Oncol. 2016 Nov;12(21):2401-2415. doi: 10.2217/fon-2016-0122. Epub 2016 Jun 16.","McCammack KC","Future Oncol","2016","2016/06/17","","","10.2217/fon-2016-0122"
"12669711","Bibliography. Current world literature. Prostate cancer","","Curr Opin Urol. 2003 Mar;13(2):161-75.","","Curr Opin Urol","2003","2003/04/03","","",""
"16306632","MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer","Hricak H.","Br J Radiol. 2005;78 Spec No 2:S103-11. doi: 10.1259/bjr/11253478.","Hricak H","Br J Radiol","2005","2005/11/25","","","10.1259/bjr/11253478"
"11074609","Current topics in prostate cancer research","Hoedemaeker RF.","Microsc Res Tech. 2000 Dec 1;51(5):413-4. doi: 10.1002/1097-0029(20001201)51:5<413::AID-JEMT1>3.0.CO;2-G.","Hoedemaeker RF","Microsc Res Tech","2000","2000/11/14","","","10.1002/1097-0029(20001201)51:5<413::AID-JEMT1>3.0.CO;2-G"
"20384583","Molecular pathways in the progression of hormone-independent and metastatic prostate cancer","Wegiel B, Evans S, Hellsten R, Otterbein LE, Bjartell A, Persson JL.","Curr Cancer Drug Targets. 2010 Jun;10(4):392-401. doi: 10.2174/156800910791208562.","Wegiel B","Curr Cancer Drug Targets","2010","2010/04/14","","","10.2174/156800910791208562"
"15738648","Molecular and phenotypic heterogeneity of metastatic prostate cancer","Chau CH, Figg WD.","Cancer Biol Ther. 2005 Feb;4(2):166-7. doi: 10.4161/cbt.4.2.1571. Epub 2005 Feb 28.","Chau CH","Cancer Biol Ther","2005","2005/03/02","","","10.4161/cbt.4.2.1571"
"15157121","Exercise and prostate cancer","Torti DC, Matheson GO.","Sports Med. 2004;34(6):363-9. doi: 10.2165/00007256-200434060-00003.","Torti DC","Sports Med","2004","2004/05/26","","","10.2165/00007256-200434060-00003"
"16123581","Cyclooxygenase-2 and angiogenesis in prostate cancer","Tkacz VL, Tohnya TM, Figg WD.","Cancer Biol Ther. 2005 Aug;4(8):813-4. doi: 10.4161/cbt.4.8.2089.","Tkacz VL","Cancer Biol Ther","2005","2005/08/27","","","10.4161/cbt.4.8.2089"
"31629412","Introduction to the 2019 Philadelphia Prostate Cancer Consensus Program: 'Implementation of Genetic Testing for Inherited Prostate Cancer'","Gomella LG, Knudsen KE, Giri VN.","Can J Urol. 2019 Oct;26(5 Suppl 2):1-4.","Gomella LG","Can J Urol","2019","2019/10/21","","",""
"15049578","Diagnosis and treatment of prostate cancer","Hernandez J, Thompson IM.","Med Clin North Am. 2004 Mar;88(2):267-79, ix. doi: 10.1016/S0025-7125(03)00144-5.","Hernandez J","Med Clin North Am","2004","2004/03/31","","","10.1016/S0025-7125(03)00144-5"
"19805750","What now on screening for prostate cancer?","Law M.","J Med Screen. 2009;16(3):109-11. doi: 10.1258/jms.2009.009067.","Law M","J Med Screen","2009","2009/10/07","","","10.1258/jms.2009.009067"
"7714979","Prostate cancer","Schroeder FH.","J Urol. 1995 May;153(5):1592-3. doi: 10.1016/s0022-5347(01)67468-8.","Schroeder FH","J Urol","1995","1995/05/01","","","10.1016/s0022-5347(01)67468-8"
"27344727","[Development of promising biomarkers for prostate cancer]","Yoneyama T, Ohyama C.","Nihon Rinsho. 2016 May 20;74 Suppl 3:191-5.","Yoneyama T","Nihon Rinsho","2016","2016/06/28","","",""
"29087141","[COCHRANE SYSTEMATIC REVIEWS ON PROSTATE CANCER]","Vrdoljak D.","Acta Med Croatica. 2016 Dec;70(4-5):257-62.","Vrdoljak D","Acta Med Croatica","2016","2017/11/01","","",""
"23879900","Are we ready for the new wave of focal therapy interventions for men with early prostate cancer?","Emberton M.","BJU Int. 2013 Aug;112(4):423-4. doi: 10.1111/bju.12300.","Emberton M","BJU Int","2013","2013/07/25","","","10.1111/bju.12300"
"9815728","Prognostic criteria in patients with prostate cancer: Gleason score versus volume-weighted mean nuclear volume","Fujikawa K, Sasaki M, Arai Y, Yamabe H, Ogawa O, Yoshida O.","Clin Cancer Res. 1997 Apr;3(4):613-8.","Fujikawa K","Clin Cancer Res","1997","1997/04/01","","",""
"16979720","Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?","Reeve BB, Potosky AL, Willis GB.","Urology. 2006 Sep;68(3):599-603. doi: 10.1016/j.urology.2006.03.037. Epub 2006 Sep 18.","Reeve BB","Urology","2006","2006/09/19","","","10.1016/j.urology.2006.03.037"
"26496025","Transient receptor potential melastatin 4 channel contributes to migration of androgen-insensitive prostate cancer cells","Holzmann C, Kappel S, Kilch T, Jochum MM, Urban SK, Jung V, Stöckle M, Rother K, Greiner M, Peinelt C.","Oncotarget. 2015 Dec 8;6(39):41783-93. doi: 10.18632/oncotarget.6157.","Holzmann C","Oncotarget","2015","2015/10/27","PMC4747188","","10.18632/oncotarget.6157"
"23743823","Autophagy in prostate cancer and androgen suppression therapy","Ziparo E, Petrungaro S, Marini ES, Starace D, Conti S, Facchiano A, Filippini A, Giampietri C.","Int J Mol Sci. 2013 Jun 6;14(6):12090-106. doi: 10.3390/ijms140612090.","Ziparo E","Int J Mol Sci","2013","2013/06/08","PMC3709775","","10.3390/ijms140612090"
"22550073","Disparities in prostate cancer in African American men: what primary care physicians can do","Wu I, Modlin CS.","Cleve Clin J Med. 2012 May;79(5):313-20. doi: 10.3949/ccjm.79a.11001.","Wu I","Cleve Clin J Med","2012","2012/05/03","","","10.3949/ccjm.79a.11001"
"22342674","Breaking through a roadblock in prostate cancer research: an update on human model systems","Toivanen R, Taylor RA, Pook DW, Ellem SJ, Risbridger GP.","J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):122-31. doi: 10.1016/j.jsbmb.2012.01.005. Epub 2012 Feb 8.","Toivanen R","J Steroid Biochem Mol Biol","2012","2012/02/21","","","10.1016/j.jsbmb.2012.01.005"
"7679336","Prostate-specific antigen: biochemistry, analytical methods, and clinical application","Armbruster DA.","Clin Chem. 1993 Feb;39(2):181-95.","Armbruster DA","Clin Chem","1993","1993/02/01","","",""
"17902462","[Gene therapy: is possible a vaccine for prostate cancer?]","Gómez Pérez L, Oliva Delgado FJ, Vera Donoso CD, Jimenez Cruz JF, Herádndez Andreu JM.","Actas Urol Esp. 2007 Jul-Aug;31(7):705-13. doi: 10.1016/s0210-4806(07)73710-5.","Gómez Pérez L","Actas Urol Esp","2007","2007/10/02","","","10.1016/s0210-4806(07)73710-5"
"10854529","Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review)","Szostak MJ, Kyprianou N.","Oncol Rep. 2000 Jul-Aug;7(4):699-706. doi: 10.3892/or.7.4.699.","Szostak MJ","Oncol Rep","2000","2000/06/16","","","10.3892/or.7.4.699"
"20870924","Prostate Cancer Working Group report","Namiki M, Akaza H, Lee SE, Song JM, Umbas R, Zhou L, Lee BC, Cheng C, Chung MK, Fukagai T, Hinotsu S, Horie S.","Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i70-75. doi: 10.1093/jjco/hyq130.","Namiki M","Jpn J Clin Oncol","2010","2010/09/28","","","10.1093/jjco/hyq130"
"23481182","Proton beam therapy and localised prostate cancer: current status and controversies","Efstathiou JA, Gray PJ, Zietman AL.","Br J Cancer. 2013 Apr 2;108(6):1225-30. doi: 10.1038/bjc.2013.100. Epub 2013 Mar 12.","Efstathiou JA","Br J Cancer","2013","2013/03/14","PMC3619274","","10.1038/bjc.2013.100"
"22504874","ETS rearrangements in prostate cancer","Rubin MA.","Asian J Androl. 2012 May;14(3):393-9. doi: 10.1038/aja.2011.145. Epub 2012 Apr 16.","Rubin MA","Asian J Androl","2012","2012/04/17","PMC3724201","","10.1038/aja.2011.145"
"1838264","Iodine 125 brachytherapy for early stage prostate cancer: new techniques may achieve better results","Wallner K.","Oncology (Williston Park). 1991 Oct;5(10):115-22; discussion 122, 125-6.","Wallner K","Oncology (Williston Park)","1991","1991/10/01","","",""
"11407949","Autochthonous mouse models for prostate cancer: past, present and future","Huss WJ, Maddison LA, Greenberg NM.","Semin Cancer Biol. 2001 Jun;11(3):245-60. doi: 10.1006/scbi.2001.0373.","Huss WJ","Semin Cancer Biol","2001","2001/06/16","","","10.1006/scbi.2001.0373"
"10386474","Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction","Boer R, Schröder FH.","Prostate. 1999 Jul 1;40(2):130-4. doi: 10.1002/(sici)1097-0045(19990701)40:2<130::aid-pros9>3.0.co;2-x.","Boer R","Prostate","1999","1999/07/01","","","10.1002/(sici)1097-0045(19990701)40:2<130::aid-pros9>3.0.co;2-x"
"28796922","Long non-coding RNAs and prostate cancer","Misawa A, Takayama KI, Inoue S.","Cancer Sci. 2017 Nov;108(11):2107-2114. doi: 10.1111/cas.13352. Epub 2017 Sep 5.","Misawa A","Cancer Sci","2017","2017/08/11","PMC5665759","","10.1111/cas.13352"
"19375621","Prostate cancer risk: overview of the disease, predictive factors, and potential targets for risk reduction. Introduction","Andriole GL.","Urology. 2009 May;73(5 Suppl):S1-3. doi: 10.1016/j.urology.2009.02.021.","Andriole GL","Urology","2009","2009/04/21","","","10.1016/j.urology.2009.02.021"
"24097331","Locally advanced prostate cancer: optimal therapy in older patients","Froehner M, Wirth MP.","Drugs Aging. 2013 Dec;30(12):959-67. doi: 10.1007/s40266-013-0123-7.","Froehner M","Drugs Aging","2013","2013/10/08","","","10.1007/s40266-013-0123-7"
"17430695","Immunotherapy for prostate cancer","Fong L, Small EJ.","Curr Oncol Rep. 2007 May;9(3):226-33. doi: 10.1007/s11912-007-0026-z.","Fong L","Curr Oncol Rep","2007","2007/04/14","","","10.1007/s11912-007-0026-z"
"21798397","Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies","Dusing RW, Drisko JA, Grado GG, Levine M, Holzbeierlein JM, Van Veldhuizen P.","Urol Clin North Am. 2011 Aug;38(3):343-57. doi: 10.1016/j.ucl.2011.04.003.","Dusing RW","Urol Clin North Am","2011","2011/07/30","","","10.1016/j.ucl.2011.04.003"
"11204373","Management of advanced/metastatic prostate cancer: 2000 update","Hussain A, Dawson N.","Oncology (Williston Park). 2000 Dec;14(12):1677-88; discussion 1688, 1691-4.","Hussain A","Oncology (Williston Park)","2000","2001/02/24","","",""
"16220832","Prostate cancer outcome: epidemiology and biostatistics","Burke HB, Bostwick DG, Meiers I, Montironi R.","Anal Quant Cytol Histol. 2005 Aug;27(4):211-7.","Burke HB","Anal Quant Cytol Histol","2005","2005/10/14","","",""
"31227048","Molecular Imaging and Theranostics-A Multidisciplinary Approach","Farolfi A, Lima GM, Oyen W, Fanti S.","Semin Nucl Med. 2019 Jul;49(4):247-254. doi: 10.1053/j.semnuclmed.2019.02.002. Epub 2019 Mar 2.","Farolfi A","Semin Nucl Med","2019","2019/06/23","","","10.1053/j.semnuclmed.2019.02.002"
"2194291","Transrectal ultrasonography in prostatic carcinoma","Wozniak-Petrofsky J.","Urol Nurs. 1990 Jun;10(2):12-6.","Wozniak-Petrofsky J","Urol Nurs","1990","1990/06/01","","",""
"28707844","Castration-resistance prostate cancer: what is in the pipeline?","DE Nunzio C, Presicce F, Giacinti S, Bassanelli M, Tubaro A.","Minerva Urol Nefrol. 2018 Feb;70(1):22-41. doi: 10.23736/S0393-2249.17.02976-9. Epub 2017 Jul 12.","DE Nunzio C","Minerva Urol Nefrol","2018","2017/07/15","","","10.23736/S0393-2249.17.02976-9"
"9675408","Prostate cancer treatment with radioactive seed implantation","Davis DL.","AORN J. 1998 Jul;68(1):18, 21-3, 26-30 passim; quiz 42, 45. doi: 10.1016/s0001-2092(06)62711-7.","Davis DL","AORN J","1998","1998/07/24","","","10.1016/s0001-2092(06)62711-7"
"18304457","Are we ready for prostate cancer?","Na YQ.","Chin Med J (Engl). 2008 Feb 20;121(4):291.","Na YQ","Chin Med J (Engl)","2008","2008/02/29","","",""
"22308973","Genetic variants associated with predisposition to prostate cancer and potential clinical implications","Goh CL, Schumacher FR, Easton D, Muir K, Henderson B, Kote-Jarai Z, Eeles RA.","J Intern Med. 2012 Apr;271(4):353-65. doi: 10.1111/j.1365-2796.2012.02511.x.","Goh CL","J Intern Med","2012","2012/02/08","","","10.1111/j.1365-2796.2012.02511.x"
"28086232","Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression","Tonry C, Armstrong J, Pennington SR.","Oncotarget. 2017 Feb 28;8(9):14374-14394. doi: 10.18632/oncotarget.14605.","Tonry C","Oncotarget","2017","2017/01/14","PMC5362412","","10.18632/oncotarget.14605"
"30762223","Multiparametric MRI and radiomics in prostate cancer: a review","Sun Y, Reynolds HM, Parameswaran B, Wraith D, Finnegan ME, Williams S, Haworth A.","Australas Phys Eng Sci Med. 2019 Mar;42(1):3-25. doi: 10.1007/s13246-019-00730-z. Epub 2019 Feb 14.","Sun Y","Australas Phys Eng Sci Med","2019","2019/02/15","","","10.1007/s13246-019-00730-z"
"31162907","[Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression]","Toropovsky AN, Nikitin AG, Pavlova ON, Viktorov DA.","Urologiia. 2019 Jun;(2):82-86.","Toropovsky AN","Urologiia","2019","2019/06/05","","",""
"22818151","[Localised prostate cancer: the PREFERE trial]","Stöckle M, Bussar-Maatz R.","Z Evid Fortbild Qual Gesundhwes. 2012;106(5):333-5; discussion 335. doi: 10.1016/j.zefq.2012.05.004. Epub 2012 Jun 18.","Stöckle M","Z Evid Fortbild Qual Gesundhwes","2012","2012/07/24","","","10.1016/j.zefq.2012.05.004"
"20088233","A case study: ductal adenocarcinoma of the prostate","Dziuba K.","Urol Nurs. 2009 Nov-Dec;29(6):422-4.","Dziuba K","Urol Nurs","2009","2010/01/22","","",""
"18665451","Insulin: a novel agent in the pathogenesis of prostate cancer","Nandeesha H.","Int Urol Nephrol. 2009;41(2):267-72. doi: 10.1007/s11255-008-9440-x. Epub 2008 Jul 30.","Nandeesha H","Int Urol Nephrol","2009","2008/07/31","","","10.1007/s11255-008-9440-x"
"27785926","Imaging on nodal staging of prostate cancer","Kilcoyne A, Price MC, McDermott S, Harisinghani MG.","Future Oncol. 2017 Mar;13(6):551-565. doi: 10.2217/fon-2016-0216. Epub 2016 Oct 27.","Kilcoyne A","Future Oncol","2017","2016/10/28","","","10.2217/fon-2016-0216"
"28952705","[Prostate cancer of high oncological risk. urrent trends in diagnosis and surgical treatment]","Bezrukov EA, Rapoport LM, Shpot EV, Enikeev ME, Morozov AO.","Urologiia. 2017 Sep;(4):129-134.","Bezrukov EA","Urologiia","2017","2017/09/28","","",""
"6866849","Epidemiologic observations from the American College of Surgeons' survey on prostate cancer","Mettlin C, Natarajan N.","Prostate. 1983;4(4):323-31. doi: 10.1002/pros.2990040402.","Mettlin C","Prostate","1983","1983/01/01","","","10.1002/pros.2990040402"
"15732168","A combination treatment for localized prostate cancer","","Mayo Clin Health Lett. 2005 Feb;23(2):4.","","Mayo Clin Health Lett","2005","2005/03/01","","",""
"16648113","Molecular biology in prostate cancer","Cansino Alcaide JR, Martínez-Piñeiro L.","Clin Transl Oncol. 2006 Mar;8(3):148-52. doi: 10.1007/s12094-006-0004-1.","Cansino Alcaide JR","Clin Transl Oncol","2006","2006/05/02","","","10.1007/s12094-006-0004-1"
"26203773","Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer","Kalmuk J, Folaron M, Buchinger J, Pili R, Seshadri M.","Oncotarget. 2015 Sep 15;6(27):24376-92. doi: 10.18632/oncotarget.4463.","Kalmuk J","Oncotarget","2015","2015/07/24","PMC4695192","","10.18632/oncotarget.4463"
"7678121","Natural history of prostate cancer","Carr TW.","Lancet. 1993 Jan 9;341(8837):91-2. doi: 10.1016/0140-6736(93)92565-b.","Carr TW","Lancet","1993","1993/01/09","","","10.1016/0140-6736(93)92565-b"
"9607395","Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines","Ohtake N, Nakata S, Sato J, Koya A, Saruki K, Kurihara J, Tsuji H, Imai K, Yamanaka H, Suzuki K, Tari K.","Tohoku J Exp Med. 1998 Jan;184(1):21-8. doi: 10.1620/tjem.184.21.","Ohtake N","Tohoku J Exp Med","1998","1998/06/02","","","10.1620/tjem.184.21"
"9089063","Prostate cancer: a clinical and basic science review","Long RJ, Roberts KP, Wilson MJ, Ercole CJ, Pryor JL.","J Androl. 1997 Jan-Feb;18(1):15-20.","Long RJ","J Androl","1997","1997/01/01","","",""
"21567081","Molecular targets of selenium in prostate cancer prevention (Review)","Abdulah R, Kobayashi K, Yamazaki C, Koyama H.","Int J Oncol. 2011 Aug;39(2):301-9. doi: 10.3892/ijo.2011.1035. Epub 2011 May 10.","Abdulah R","Int J Oncol","2011","2011/05/14","","","10.3892/ijo.2011.1035"
"9167659","Prostate cancer screening and management","Freid RM, Davis NS, Weiss GH.","Med Clin North Am. 1997 May;81(3):801-22. doi: 10.1016/s0025-7125(05)70547-2.","Freid RM","Med Clin North Am","1997","1997/05/01","","","10.1016/s0025-7125(05)70547-2"
"2217454","The diagnosis and management of localized prostate cancer","Chodak GW.","Prog Clin Biol Res. 1990;357:1-6.","Chodak GW","Prog Clin Biol Res","1990","1990/01/01","","",""
"9564139","[Gene for hereditary prostatic cancer has been located. New possibilities for early identification of men at risk]","Grönberg H, Bergh A, Damber JE.","Lakartidningen. 1998 Apr 1;95(14):1522-5.","Grönberg H","Lakartidningen","1998","1998/05/02","","",""
"29714425","[Laboratory techniques for the diagnosis of prostate cancer: An update]","Mou RY, Li XJ.","Zhonghua Nan Ke Xue. 2017 Apr;23(4):372-375.","Mou RY","Zhonghua Nan Ke Xue","2017","2018/05/02","","",""
"22500680","The role of abiraterone in the management of metastatic castration-resistant prostate cancer","Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M.","Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37. doi: 10.1586/era.12.12.","Rawlinson A","Expert Rev Anticancer Ther","2012","2012/04/17","","","10.1586/era.12.12"
"11021614","Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates","Tarone RE, Chu KC, Brawley OW.","Epidemiology. 2000 Mar;11(2):167-70. doi: 10.1097/00001648-200003000-00014.","Tarone RE","Epidemiology","2000","2000/10/06","","","10.1097/00001648-200003000-00014"
"28922958","Post-prostatectomy radiation therapy for locally recurrent prostate cancer","Isharwal S, Stephenson AJ.","Expert Rev Anticancer Ther. 2017 Nov;17(11):1003-1012. doi: 10.1080/14737140.2017.1378575. Epub 2017 Sep 18.","Isharwal S","Expert Rev Anticancer Ther","2017","2017/09/20","","","10.1080/14737140.2017.1378575"
"25845380","Quercetin in prostate cancer: Chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential (Review)","Yang F, Song L, Wang H, Wang J, Xu Z, Xing N.","Oncol Rep. 2015 Jun;33(6):2659-68. doi: 10.3892/or.2015.3886. Epub 2015 Mar 31.","Yang F","Oncol Rep","2015","2015/04/08","","","10.3892/or.2015.3886"
"8178117","The dilemmas of prostate cancer","Garnick MB.","Sci Am. 1994 Apr;270(4):72-81. doi: 10.1038/scientificamerican0494-72.","Garnick MB","Sci Am","1994","1994/04/01","","","10.1038/scientificamerican0494-72"
"1623432","Prostate cancer: evaluation and radiotherapeutic management","Epstein BE, Hanks GE.","CA Cancer J Clin. 1992 Jul-Aug;42(4):223-40. doi: 10.3322/canjclin.42.4.223.","Epstein BE","CA Cancer J Clin","1992","1992/07/01","","","10.3322/canjclin.42.4.223"
"26672789","Prostate cancer: 4 big questions","Hodson R.","Nature. 2015 Dec 17;528(7582):S137. doi: 10.1038/528S137a.","Hodson R","Nature","2015","2015/12/18","","","10.1038/528S137a"
"8977935","[Genetic aspects in cancers of the prostate]","Cussenot O, Valeri A, Meria P, Berthon P, Fournier G, Teillac P, Mangin, Le Duc A.","Pathol Biol (Paris). 1996 Oct;44(8):737-43.","Cussenot O","Pathol Biol (Paris)","1996","1996/10/01","","",""
"10849493","Clinical-pathological comparison of clinical prostate cancer between Japanese Americans in Hawaii and Japanese living in Japan","Fukagai T, Shimada M, Yoshida H, Namiki T, Carlile RG.","Int J Androl. 2000;23 Suppl 2:43-4. doi: 10.1046/j.1365-2605.2000.00009.x.","Fukagai T","Int J Androl","2000","2000/06/13","","","10.1046/j.1365-2605.2000.00009.x"
"12529701","Linkage of aggressive prostate cancer to chromosome 7q31-33 in German prostate cancer families","Paiss T, Wörner S, Kurtz F, Haeussler J, Hautmann RE, Gschwend JE, Herkommer K, Vogel W.","Eur J Hum Genet. 2003 Jan;11(1):17-22. doi: 10.1038/sj.ejhg.5200898.","Paiss T","Eur J Hum Genet","2003","2003/01/17","","","10.1038/sj.ejhg.5200898"
"8907872","Diagnosis and treatment of urological malignancy: the prostate","Doherty AP, Christmas TJ.","Br J Hosp Med. 1996 Feb 7-20;55(3):104-6, 123-4.","Doherty AP","Br J Hosp Med","1996","1996/02/07","","",""
"30184146","NCCN Asia Consensus Statement prostate cancer","Hinotsu S, Namiki M, Ozono S, Akaza H.","Jpn J Clin Oncol. 2018 Nov 1;48(11):964-965. doi: 10.1093/jjco/hyy116.","Hinotsu S","Jpn J Clin Oncol","2018","2018/09/06","","","10.1093/jjco/hyy116"
"23342259","Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer","Khaja AS, Egevad L, Helczynski L, Wiklund P, Andersson T, Bjartell A.","Cancer Med. 2012 Aug;1(1):96-104. doi: 10.1002/cam4.5. Epub 2012 Jun 4.","Khaja AS","Cancer Med","2012","2013/01/24","PMC3544436","","10.1002/cam4.5"
"8984601","[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma]","Recker F.","Schweiz Med Wochenschr. 1996 Nov 2;126(44):1881-90.","Recker F","Schweiz Med Wochenschr","1996","1996/11/02","","",""
"8087787","The role of conservative management in localized prostate cancer","Chodak GW.","Cancer. 1994 Oct 1;74(7 Suppl):2178-81. doi: 10.1002/1097-0142(19941001)74:7+<2178::aid-cncr2820741730>3.0.co;2-g.","Chodak GW","Cancer","1994","1994/10/01","","","10.1002/1097-0142(19941001)74:7+<2178::aid-cncr2820741730>3.0.co;2-g"
"9445178","Why is the prostate cancer death rate declining in the United States?","Mettlin CJ, Murphy GP.","Cancer. 1998 Jan 15;82(2):249-51. doi: 10.1002/(sici)1097-0142(19980115)82:2<249::aid-cncr1>3.0.co;2-m.","Mettlin CJ","Cancer","1998","1998/01/28","","","10.1002/(sici)1097-0142(19980115)82:2<249::aid-cncr1>3.0.co;2-m"
"23649489","Imaging-guided biopsy detects prostate cancer","Printz C.","Cancer. 2013 May 15;119(10):1767. doi: 10.1002/cncr.28140.","Printz C","Cancer","2013","2013/05/08","","","10.1002/cncr.28140"
"31067847","[A Case of Prostate Cancer with High Levels of Prostate-Specific Antigen Undetected by Prostate Biopsy]","Shimizu K, Nakano S, Okada Y, Nagahama K, Okubo K, Yasuhara Y.","Hinyokika Kiyo. 2019 Mar;65(3):75-80. doi: 10.14989/ActaUrolJap_65_3_75.","Shimizu K","Hinyokika Kiyo","2019","2019/05/10","","","10.14989/ActaUrolJap_65_3_75"
"27874061","Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer","Roubaud G, Liaw BC, Oh WK, Mulholland DJ.","Nat Rev Clin Oncol. 2017 May;14(5):269-283. doi: 10.1038/nrclinonc.2016.181. Epub 2016 Nov 22.","Roubaud G","Nat Rev Clin Oncol","2017","2016/11/23","PMC5567685","NIHMS892512","10.1038/nrclinonc.2016.181"
"16143027","Molecular pathology of prostate cancer","Konishi N, Shimada K, Ishida E, Nakamura M.","Pathol Int. 2005 Sep;55(9):531-9. doi: 10.1111/j.1440-1827.2005.01865.x.","Konishi N","Pathol Int","2005","2005/09/07","","","10.1111/j.1440-1827.2005.01865.x"
"28783264","High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsies","Dekalo S, Matzkin H, Mabjeesh NJ.","Int Braz J Urol. 2017 Jul-Aug;43(4):600-606. doi: 10.1590/S1677-5538.IBJU.2016.0511.","Dekalo S","Int Braz J Urol","2017","2017/08/08","PMC5557434","","10.1590/S1677-5538.IBJU.2016.0511"
"29950285","Prostate cancer: Basics on clinical appearance, diagnostics and treatment","Groeben C, Wirth MP.","Med Monatsschr Pharm. 2017 May;40(5):192-201.","Groeben C","Med Monatsschr Pharm","2017","2018/06/29","","",""
"22957321","The utility of transrectal sonoelastography in preoperative prostate cancer assessment","Rausch S, Alt W, Arps H, Alt B, Kälble T.","Med Ultrason. 2012 Sep;14(3):182-6. doi: 10.11152/mu.2013.2066.143.sr182.","Rausch S","Med Ultrason","2012","2012/09/08","","","10.11152/mu.2013.2066.143.sr182"
"11221436","Current concepts in the treatment of prostate cancer","Hirsch PJ.","N J Med. 2001 Feb;98(2):11.","Hirsch PJ","N J Med","2001","2001/02/28","","",""
"32692871","Increased nuclear factor I/B expression in prostate cancer correlates with AR expression","Nanda JS, Awadallah WN, Kohrt SE, Popovics P, Cates JMM, Mirosevich J, Clark PE, Giannico GA, Grabowska MM.","Prostate. 2020 Sep;80(13):1058-1070. doi: 10.1002/pros.24019. Epub 2020 Jul 21.","Nanda JS","Prostate","2020","2020/07/22","PMC7434711","NIHMS1606916","10.1002/pros.24019"
"15907723","Quality of life in patients with localized prostate cancer","Quek ML, Penson DF.","Urol Oncol. 2005 May-Jun;23(3):208-15. doi: 10.1016/j.urolonc.2005.03.003.","Quek ML","Urol Oncol","2005","2005/05/24","","","10.1016/j.urolonc.2005.03.003"
"17927521","Obesity and prostate cancer mortality","Kristal AR, Gong Z.","Future Oncol. 2007 Oct;3(5):557-67. doi: 10.2217/14796694.3.5.557.","Kristal AR","Future Oncol","2007","2007/10/12","","","10.2217/14796694.3.5.557"
"16406993","Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival","Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML.","J Urol. 2006 Feb;175(2):547-51. doi: 10.1016/S0022-5347(05)00152-7.","Tollefson MK","J Urol","2006","2006/01/13","","","10.1016/S0022-5347(05)00152-7"
"10370945","[Place of surveillance in the treatment of localized prostate cancer]","Ravery V, Boccon-Gibod L.","Prog Urol. 1999 Apr;9(2):225-30; discussion 229-30.","Ravery V","Prog Urol","1999","1999/06/17","","",""
"15861399","Regulation of androgen receptor levels: implications for prostate cancer progression and therapy","Burnstein KL.","J Cell Biochem. 2005 Jul 1;95(4):657-69. doi: 10.1002/jcb.20460.","Burnstein KL","J Cell Biochem","2005","2005/04/30","","","10.1002/jcb.20460"
"26959614","NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics","Kumar D, Gupta A, Nath K.","Expert Rev Mol Diagn. 2016 Jun;16(6):651-61. doi: 10.1586/14737159.2016.1164037. Epub 2016 Mar 25.","Kumar D","Expert Rev Mol Diagn","2016","2016/03/10","","","10.1586/14737159.2016.1164037"
"30413805","Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test","González-Billalabeitia E, Conteduca V, Wetterskog D, Jayaram A, Attard G.","Prostate Cancer Prostatic Dis. 2019 May;22(2):195-205. doi: 10.1038/s41391-018-0098-x. Epub 2018 Nov 9.","González-Billalabeitia E","Prostate Cancer Prostatic Dis","2019","2018/11/11","PMC6398580","EMS79467","10.1038/s41391-018-0098-x"
"8627852","Prostate cancer--adjusting the tiller","Pisters LL.","J Urol. 1996 May;155(5):1678-80. doi: 10.1016/s0022-5347(01)66163-9.","Pisters LL","J Urol","1996","1996/05/01","","","10.1016/s0022-5347(01)66163-9"
"23163774","Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective","Ahmed M, Li LC.","Int J Urol. 2013 Apr;20(4):362-71. doi: 10.1111/iju.12005. Epub 2012 Nov 19.","Ahmed M","Int J Urol","2013","2012/11/21","","","10.1111/iju.12005"
"18382235","Current controversies in the treatment of high-risk prostate cancer","Mitchell RE, Chang SS.","Curr Opin Urol. 2008 May;18(3):263-8. doi: 10.1097/MOU.0b013e3282f9b37f.","Mitchell RE","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282f9b37f"
"15217922","Retinoic acid receptor beta2 hypermethylation: implications for prostate cancer detection, prevention, and therapy","Lotan R, Lotan Y.","Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6. doi: 10.1158/1078-0432.CCR-04-0536.","Lotan R","Clin Cancer Res","2004","2004/06/26","","","10.1158/1078-0432.CCR-04-0536"
"1986469","Transurethral resection versus needle biopsy prior to radical prostatectomy for stage C prostate cancer. Influence on progression and survival","Nativ O, Bergstralh EJ, Boyle ET Jr, Zincke H.","Urology. 1991 Jan;37(1):22-7. doi: 10.1016/0090-4295(91)80071-e.","Nativ O","Urology","1991","1991/01/11","","","10.1016/0090-4295(91)80071-e"
"12204531","Focus on prostate cancer","Isaacs W, De Marzo A, Nelson WG.","Cancer Cell. 2002 Aug;2(2):113-6. doi: 10.1016/s1535-6108(02)00103-4.","Isaacs W","Cancer Cell","2002","2002/09/03","","","10.1016/s1535-6108(02)00103-4"
"20981510","Prostate cancer screening","Cook ED, Nelson AC.","Curr Oncol Rep. 2011 Feb;13(1):57-62. doi: 10.1007/s11912-010-0136-x.","Cook ED","Curr Oncol Rep","2011","2010/10/29","","","10.1007/s11912-010-0136-x"
"22048979","Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy","Gerritsen WR, Sharma P.","J Clin Immunol. 2012 Feb;32(1):25-35. doi: 10.1007/s10875-011-9595-6. Epub 2011 Nov 4.","Gerritsen WR","J Clin Immunol","2012","2011/11/04","PMC3276755","","10.1007/s10875-011-9595-6"
"21463143","Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives","Lassi K, Dawson NA.","Future Oncol. 2011 Apr;7(4):551-8. doi: 10.2217/fon.11.14.","Lassi K","Future Oncol","2011","2011/04/06","","","10.2217/fon.11.14"
"20304943","Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation","Schatz P, Dietrich D, Koenig T, Burger M, Lukas A, Fuhrmann I, Kristiansen G, Stoehr R, Schuster M, Lesche R, Weiss G, Corman J, Hartmann A.","J Mol Diagn. 2010 May;12(3):345-53. doi: 10.2353/jmoldx.2010.090088. Epub 2010 Mar 19.","Schatz P","J Mol Diagn","2010","2010/03/23","PMC2860471","","10.2353/jmoldx.2010.090088"
"10617895","Treatment of prostate cancer: watchful waiting, radical prostatectomy, and cryoablation","Drachenberg DE.","Semin Surg Oncol. 2000 Jan-Feb;18(1):37-44. doi: 10.1002/(sici)1098-2388(200001/02)18:1<37::aid-ssu6>3.0.co;2-#.","Drachenberg DE","Semin Surg Oncol","2000","2000/01/05","","","10.1002/(sici)1098-2388(200001/02)18:1<37::aid-ssu6>3.0.co;2-#"
"31416754","Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018","Marandino L, De Luca E, Zichi C, Lombardi P, Reale ML, Pignataro D, Di Stefano RF, Ghisoni E, Mariniello A, Trevisi E, Leone G, Muratori L, La Salvia A, Sonetto C, Buttigliero C, Tucci M, Aglietta M, Novello S, Scagliotti GV, Perrone F, Di Maio M.","Clin Genitourin Cancer. 2019 Oct;17(5):332-347.e2. doi: 10.1016/j.clgc.2019.07.007. Epub 2019 Jul 20.","Marandino L","Clin Genitourin Cancer","2019","2019/08/17","","","10.1016/j.clgc.2019.07.007"
"19073981","Clinical decisions. Management of prostate cancer","Schröder FH, Roach M 3rd, Scardino P.","N Engl J Med. 2008 Dec 11;359(24):2605-9. doi: 10.1056/NEJMclde0805491.","Schröder FH","N Engl J Med","2008","2008/12/17","","","10.1056/NEJMclde0805491"
"24272360","Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer","Taiakina D, Dal Pra A, Bristow RG.","Adv Exp Med Biol. 2014;772:189-204. doi: 10.1007/978-1-4614-5915-6_9.","Taiakina D","Adv Exp Med Biol","2014","2013/11/26","","","10.1007/978-1-4614-5915-6_9"
"29926761","Quality of Life Among Black Prostate Cancer Survivors: An Integrative Review","Dickey SL, Ogunsanya ME.","Am J Mens Health. 2018 Sep;12(5):1648-1664. doi: 10.1177/1557988318780857. Epub 2018 Jun 21.","Dickey SL","Am J Mens Health","2018","2018/06/22","PMC6142144","","10.1177/1557988318780857"
"9750531","[Radiation therapy with neoadjuvant hormonal therapy for prostate cancer confined to pelvis]","Furuya Y, Akakura K, Ito H.","Nihon Rinsho. 1998 Aug;56(8):2181-4.","Furuya Y","Nihon Rinsho","1998","1998/09/29","","",""
"25728968","Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database","Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ.","Int J Urol. 2015 Apr;22(4):362-6. doi: 10.1111/iju.12704. Epub 2015 Feb 24.","Mithal P","Int J Urol","2015","2015/03/03","","","10.1111/iju.12704"
"3316713","The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference, June 15-17, 1987","","J Urol. 1987 Dec;138(6):1369-75.","","J Urol","1987","1987/12/01","","",""
"22721754","Implications of the Golgi apparatus in prostate cancer","Migita T, Inoue S.","Int J Biochem Cell Biol. 2012 Nov;44(11):1872-6. doi: 10.1016/j.biocel.2012.06.004. Epub 2012 Jun 19.","Migita T","Int J Biochem Cell Biol","2012","2012/06/23","","","10.1016/j.biocel.2012.06.004"
"30570843","Screening for prostate cancer: moving forward in the molecular era","Vlachaki A, Baltogiannis D, Batistatou A, Tsambalas S, V Simos Y, E Palatianou M, Vezyraki P, Ragos V, Tsiambas E, Giannakopoulos X, Peschos D.","J BUON. 2018 Sep-Oct;23(5):1242-1248.","Vlachaki A","J BUON","2018","2018/12/21","","",""
"3301734","Prostate cancer","Fitzpatrick JM.","Ir J Med Sci. 1987 May;156(5):iii.","Fitzpatrick JM","Ir J Med Sci","1987","1987/05/01","","",""
"24446298","Biochip analysis of prostate cancer","Fan MQ, Wang PX, Feng JY, Xiao Y, Huang CB.","Genet Mol Res. 2014 Jan 10;13(1):152-9. doi: 10.4238/2014.January.10.6.","Fan MQ","Genet Mol Res","2014","2014/01/22","","","10.4238/2014.January.10.6"
"20218320","[An update of biomarkers in prostate cancer tissue]","Wang YC, Xia SJ.","Zhonghua Nan Ke Xue. 2009 Nov;15(11):1039-43.","Wang YC","Zhonghua Nan Ke Xue","2009","2010/03/12","","",""
"12084272","Immunotherapy of prostate cancer","Freedland SJ, Pantuck AJ, Weider J, Zisman A, Belldegrun AS.","Curr Urol Rep. 2001 Jun;2(3):242-7. doi: 10.1007/s11934-001-0086-9.","Freedland SJ","Curr Urol Rep","2001","2002/06/27","","","10.1007/s11934-001-0086-9"
"21326934","Bioengineered viral vectors for targeting and killing prostate cancer cells","Zhang KX, Jia W, Rennie PS.","Bioeng Bugs. 2010 Mar-Apr;1(2):92-6. doi: 10.4161/bbug.1.2.11102. Epub 2010 Jan 4.","Zhang KX","Bioeng Bugs","2010","2011/02/18","PMC3026449","","10.4161/bbug.1.2.11102"
"26054412","Active surveillance in prostate cancer: a critical review","Zargar H, Giannarini G, Loeb S, Dasgupta P, Murphy DG, Ficarra V.","Minerva Urol Nefrol. 2015 Sep;67(3):247-61. Epub 2015 Jun 9.","Zargar H","Minerva Urol Nefrol","2015","2015/06/10","","",""
"8977584","[Treatment of cancer of the prostate]","Flam T.","Presse Med. 1996 Nov 16;25(35):1710-5.","Flam T","Presse Med","1996","1996/11/16","","",""
"7939748","Methodological issues in studies of the treatment, diagnosis, and etiology of prostate cancer","Begg CB.","Semin Oncol. 1994 Oct;21(5):569-79.","Begg CB","Semin Oncol","1994","1994/10/01","","",""
"16484947","[MR spectroscopic imaging for evaluation of prostate cancer]","Taouli B.","J Radiol. 2006 Feb;87(2 Pt 2):222-7. doi: 10.1016/s0221-0363(06)73996-8.","Taouli B","J Radiol","2006","2006/02/18","","","10.1016/s0221-0363(06)73996-8"
"23811467","Making personalized prostate cancer medicine a reality: challenges and opportunities in the re-establishment of gold standards","Farooqi AA, Butt G, Yousaf G, Qadir MI, Shaukat U, Mansoor Q, Awan M, Bhatti S, Begum A.","Pak J Pharm Sci. 2013 Jul;26(4):831-40.","Farooqi AA","Pak J Pharm Sci","2013","2013/07/02","","",""
"7506850","[PSA volume quotient: an additional parameter in diagnosis of locally confined prostate cancer]","Gottfried HW, Kleinschmidt K, Flohr P, Miller K, Hautmann R.","Urologe A. 1993 Nov;32(6):455-9.","Gottfried HW","Urologe A","1993","1993/11/01","","",""
"12697941","Clinical approaches to osseous metastases in prostate cancer","Morris MJ, Scher HI.","Oncologist. 2003;8(2):161-73. doi: 10.1634/theoncologist.8-2-161.","Morris MJ","Oncologist","2003","2003/04/17","","","10.1634/theoncologist.8-2-161"
"8707772","The prostate specific antigen. Its use as a tumor marker for prostate cancer","Kantoff PW, Talcott JA.","Hematol Oncol Clin North Am. 1994 Jun;8(3):555-72.","Kantoff PW","Hematol Oncol Clin North Am","1994","1994/06/01","","",""
"12549642","Immunopathological prognostic and predictive factors in prostate cancer","Sivridis E, Touloupidis S, Giatromanolaki A.","Int Urol Nephrol. 2002;34(1):63-71. doi: 10.1023/a:1021306928664.","Sivridis E","Int Urol Nephrol","2002","2003/01/29","","","10.1023/a:1021306928664"
"30913537","BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer","Lee II, Kuznik NC, Rottenberg JT, Brown M, Cato ACB.","J Mol Endocrinol. 2019 May;62(4):R289-R299. doi: 10.1530/JME-19-0034.","Lee II","J Mol Endocrinol","2019","2019/03/27","","","10.1530/JME-19-0034"
"24706660","Radiation plus hormone therapy reduces prostate cancer mortality","","Cancer Discov. 2014 Apr;4(4):OF1. doi: 10.1158/2159-8290.CD-NB2014-026. Epub 2014 Feb 20.","","Cancer Discov","2014","2014/04/08","","","10.1158/2159-8290.CD-NB2014-026"
"17927517","Examining the co-occurrence of bladder and prostate cancer: a worthwhile investigation?","Kellen E, Zeegers MP, Joniau S, Buntinx F.","Future Oncol. 2007 Oct;3(5):515-9. doi: 10.2217/14796694.3.5.515.","Kellen E","Future Oncol","2007","2007/10/12","","","10.2217/14796694.3.5.515"
"27986207","Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy","Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY.","Semin Radiat Oncol. 2017 Jan;27(1):11-20. doi: 10.1016/j.semradonc.2016.09.001. Epub 2016 Sep 16.","Hall WA","Semin Radiat Oncol","2017","2016/12/18","","","10.1016/j.semradonc.2016.09.001"
"16474622","Prostate-specific antigen doubling time as a prognostic marker in prostate cancer","Eastham JA.","Nat Clin Pract Urol. 2005 Oct;2(10):482-91. doi: 10.1038/ncpuro0321.","Eastham JA","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0321"
"8886054","Recommendations of the first Michigan conference on prostate cancer","Porter AT, Zimmerman J, Ruffin M, Chernew M, Callaghan C, Davis R, Lee F, Montie J, Swanson GM, Oesterling JE.","Urology. 1996 Oct;48(4):519-33; discussion 533-4. doi: 10.1016/s0090-4295(96)00241-5.","Porter AT","Urology","1996","1996/10/01","","","10.1016/s0090-4295(96)00241-5"
"12886521","Foundation for the integration of biologically based therapy in the management of prostate cancer","Logothetis CJ.","Prostate. 2003 Sep 15;57(1):32-8. doi: 10.1002/pros.10270.","Logothetis CJ","Prostate","2003","2003/07/30","","","10.1002/pros.10270"
"26519965","[Oncological outcomes of prostate cancer surgery]","Soulié M, Salomon L.","Prog Urol. 2015 Nov;25(15):1010-27. doi: 10.1016/j.purol.2015.07.015.","Soulié M","Prog Urol","2015","2015/11/02","","","10.1016/j.purol.2015.07.015"
"15018082","[Prostate cancer and quality of life]","Ellis S, Sebag F, Karsenty G, Bladou F.","Rev Prat. 2003 Dec 31;53(20):2268-71.","Ellis S","Rev Prat","2003","2004/03/17","","",""
"16474814","Artificial neural networks: has the time come for their use in prostate cancer patients?","Stephan C, Cammann H, Jung K.","Nat Clin Pract Urol. 2005 Jun;2(6):262-3. doi: 10.1038/ncpuro0207.","Stephan C","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0207"
"28292895","Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids","Banerjee S, Zare RN, Tibshirani RJ, Kunder CA, Nolley R, Fan R, Brooks JD, Sonn GA.","Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3334-3339. doi: 10.1073/pnas.1700677114. Epub 2017 Mar 14.","Banerjee S","Proc Natl Acad Sci U S A","2017","2017/03/16","PMC5380053","","10.1073/pnas.1700677114"
"28442163","The Search for the Missing Heritability of Prostate Cancer","Walsh PC.","Eur Urol. 2017 Nov;72(5):657-659. doi: 10.1016/j.eururo.2017.04.003. Epub 2017 Apr 22.","Walsh PC","Eur Urol","2017","2017/04/27","","","10.1016/j.eururo.2017.04.003"
"29070780","No change in the prevalence of latent prostate cancer over the last 10 years: a forensic autopsy study in Japan","Hitosugi M, Mukaisho K, Kido M, Kamimura S, Furukawa S, Sugihara H.","Biomed Res. 2017;38(5):307-312. doi: 10.2220/biomedres.38.307.","Hitosugi M","Biomed Res","2017","2017/10/27","","","10.2220/biomedres.38.307"
"23410173","MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets","Fenderico N, Casamichele A, Profumo V, Zaffaroni N, Gandellini P.","Curr Med Chem. 2013;20(12):1566-84. doi: 10.2174/0929867311320120007.","Fenderico N","Curr Med Chem","2013","2013/02/16","","","10.2174/0929867311320120007"
"15679079","[Congress of the American Urological Association (AUA): update on prostate cancer]","Patard JJ.","Ann Urol (Paris). 2004 Dec;38 Suppl 3:S69-82.","Patard JJ","Ann Urol (Paris)","2004","2005/02/01","","",""
"18484590","Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance","Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S.","Cancer. 2008 Jul 15;113(2):286-92. doi: 10.1002/cncr.23575.","Al Otaibi M","Cancer","2008","2008/05/20","","","10.1002/cncr.23575"
"18574095","""Short- and long-term mortality with localized prostate cancer"": errors and omissions?","Roach M 3rd.","Arch Intern Med. 2008 Jun 23;168(12):1351; author reply 1353. doi: 10.1001/archinte.168.12.1351.","Roach M 3rd","Arch Intern Med","2008","2008/06/25","","","10.1001/archinte.168.12.1351"
"18795354","MR imaging of the prostate in clinical practice","Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H.","MAGMA. 2008 Nov;21(6):379-92. doi: 10.1007/s10334-008-0138-y. Epub 2008 Sep 16.","Mazaheri Y","MAGMA","2008","2008/09/17","","","10.1007/s10334-008-0138-y"
"28283344","""Gotta Catch 'em All"", or Do We? Pokemet Approach to Metastatic Prostate Cancer","Murphy DG, Sweeney CJ, Tombal B.","Eur Urol. 2017 Jul;72(1):1-3. doi: 10.1016/j.eururo.2017.02.036. Epub 2017 Mar 7.","Murphy DG","Eur Urol","2017","2017/03/12","","","10.1016/j.eururo.2017.02.036"
"17762754","Surgery versus implant for early prostate cancer: what is equivalence?","Crook J.","Cancer J. 2007 Jul-Aug;13(4):223-5. doi: 10.1097/PPO.0b013e31813c124d.","Crook J","Cancer J","2007","2007/09/01","","","10.1097/PPO.0b013e31813c124d"
"19107448","Racial differences in clinical outcome after prostate cancer treatment","Fukagai T, Namiki T, Carlile RG, Namiki M.","Methods Mol Biol. 2009;472:455-66. doi: 10.1007/978-1-60327-492-0_22.","Fukagai T","Methods Mol Biol","2009","2008/12/25","","","10.1007/978-1-60327-492-0_22"
"22059257","Smoking and prostate cancer. Research suggests that smoking makes prostate cancer worse","","Johns Hopkins Med Lett Health After 50. 2011 Oct;23(8):6.","","Johns Hopkins Med Lett Health After 50","2011","2011/11/09","","",""
"19663730","Bladder neck involvement as pT4 disease in prostate cancer: implications for prognosis and patient surveillance","Ploussard G, Rotondo S, Salomon L.","Future Oncol. 2009 Aug;5(6):803-10. doi: 10.2217/fon.09.59.","Ploussard G","Future Oncol","2009","2009/08/12","","","10.2217/fon.09.59"
"21884356","The economic burden of prostate cancer","Roehrborn CG, Black LK.","BJU Int. 2011 Sep;108(6):806-13. doi: 10.1111/j.1464-410X.2011.10365.x.","Roehrborn CG","BJU Int","2011","2011/09/03","","","10.1111/j.1464-410X.2011.10365.x"
"23271777","Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening?","Roach M 3rd, Thomas K.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):221-9. doi: 10.1093/jncimonographs/lgs039.","Roach M 3rd","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540886","","10.1093/jncimonographs/lgs039"
"7512282","Screening for prostate cancer","Mitchell TS.","Urol Nurs. 1994 Mar;14(1):9-11.","Mitchell TS","Urol Nurs","1994","1994/03/01","","",""
"29040258","Prognostic and therapeutic implications of DNA repair gene mutations in advanced prostate cancer","Schweizer MT, Antonarakis ES.","Clin Adv Hematol Oncol. 2017 Oct;15(10):785-795.","Schweizer MT","Clin Adv Hematol Oncol","2017","2017/10/18","","",""
"23102446","Out-of-pocket expenses and treatment choice for men with prostate cancer","Jung OS, Guzzo T, Lee D, Mehler M, Christodouleas J, Deville C, Hollis G, Shah A, Vapiwala N, Wein A, Pauly M, Bekelman JE.","Urology. 2012 Dec;80(6):1252-7. doi: 10.1016/j.urology.2012.08.027. Epub 2012 Oct 23.","Jung OS","Urology","2012","2012/10/30","PMC3535177","NIHMS404035","10.1016/j.urology.2012.08.027"
"26793892","[Hormonal therapy for advanced prostate cancer: current status and issues]","Akakura K.","Nihon Rinsho. 2016 Jan;74(1):124-8.","Akakura K","Nihon Rinsho","2016","2016/01/23","","",""
"27659696","Newly Proposed Prognostic Grade Group System for Prostate Cancer: Genesis, Utility and its Implications in Clinical Practice","Khochikar M.","Curr Urol Rep. 2016 Nov;17(11):80. doi: 10.1007/s11934-016-0635-x.","Khochikar M","Curr Urol Rep","2016","2016/09/24","","","10.1007/s11934-016-0635-x"
"19657379","Alternative splicing and biological heterogeneity in prostate cancer","Rajan P, Elliott DJ, Robson CN, Leung HY.","Nat Rev Urol. 2009 Aug;6(8):454-60. doi: 10.1038/nrurol.2009.125.","Rajan P","Nat Rev Urol","2009","2009/08/07","","","10.1038/nrurol.2009.125"
"28475401","Cellular identity crisis: Antiandrogen resistance by lineage plasticity","Tuerff D, Sissung T, Figg WD.","Cancer Biol Ther. 2017 Nov 2;18(11):841-842. doi: 10.1080/15384047.2017.1323599. Epub 2017 May 5.","Tuerff D","Cancer Biol Ther","2017","2017/05/06","PMC5710664","","10.1080/15384047.2017.1323599"
"20440270","Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails","Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C.","Oncogene. 2010 Jun 24;29(25):3593-604. doi: 10.1038/onc.2010.121. Epub 2010 May 3.","Niu Y","Oncogene","2010","2010/05/05","","","10.1038/onc.2010.121"
"6739373","International overview on the treatment of prostate cancer--Scandinavian experience","Könyves I, Andersson L.","Prostate. 1984;5(4):383-6. doi: 10.1002/pros.2990050403.","Könyves I","Prostate","1984","1984/01/01","","","10.1002/pros.2990050403"
"3365648","Radical prostatectomy or radiation therapy for early prostate cancer. Two roads to the same end","Hanks GE.","Cancer. 1988 Jun 1;61(11):2153-60. doi: 10.1002/1097-0142(19880601)61:11<2153::aid-cncr2820611104>3.0.co;2-0.","Hanks GE","Cancer","1988","1988/06/01","","","10.1002/1097-0142(19880601)61:11<2153::aid-cncr2820611104>3.0.co;2-0"
"17111897","Information from your family doctor: Prostate cancer: what you should know","","Am Fam Physician. 2006 Nov 1;74(9):1569-70.","","Am Fam Physician","2006","2006/11/23","","",""
"22402350","Chemotherapy and immunotherapy combination in advanced prostate cancer","Slovin S.","Clin Adv Hematol Oncol. 2012 Feb;10(2):90-100.","Slovin S","Clin Adv Hematol Oncol","2012","2012/03/10","","",""
"18261152","The future of prostate cancer","Sternberg CN.","BJU Int. 2008 Apr;101(8):934-6. doi: 10.1111/j.1464-410X.2008.07483.x. Epub 2008 Feb 5.","Sternberg CN","BJU Int","2008","2008/02/12","","","10.1111/j.1464-410X.2008.07483.x"
"9787503","[Adenocarcinoma of the prostate]","Dvorácek J.","Cas Lek Cesk. 1998 Aug 31;137(17):515-21.","Dvorácek J","Cas Lek Cesk","1998","1998/10/27","","",""
"30173426","[Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer]","Huang FM, Li XH, Liang Y.","Zhonghua Nan Ke Xue. 2018 Aug;24(8):690-694.","Huang FM","Zhonghua Nan Ke Xue","2018","2018/09/03","","",""
"18323568","Does postoperative radiation therapy benefit patients with prostate cancer?","Vikram B.","J Clin Oncol. 2008 Mar 10;26(8):1392; author reply 1392-3. doi: 10.1200/JCO.2007.15.4302.","Vikram B","J Clin Oncol","2008","2008/03/08","","","10.1200/JCO.2007.15.4302"
"29359862","Obesity does not influence prostate intrafractional motion","Brown A, Tan A, Cooper S, Fielding A.","J Med Radiat Sci. 2018 Mar;65(1):31-38. doi: 10.1002/jmrs.255. Epub 2018 Jan 23.","Brown A","J Med Radiat Sci","2018","2018/01/24","PMC5846017","","10.1002/jmrs.255"
"15563047","Management of localised prostate cancer","","Drug Ther Bull. 2004 Nov;42(11):81-5. doi: 10.1136/dtb.2004.421181.","","Drug Ther Bull","2004","2004/11/26","","","10.1136/dtb.2004.421181"
"18630478","Clinical efficacy of proton magnetic resonance spectroscopy (1H-MRS) in the diagnosis of localized prostate cancer","Saito K, Kaminaga T, Muto S, Ide H, Nishio K, Kamiyama Y, Okada H, Terado Y, Furui S, Horie S.","Anticancer Res. 2008 May-Jun;28(3B):1899-904.","Saito K","Anticancer Res","2008","2008/07/18","","",""
"19192646","Prostate cancer--are ethnic minorities disadvantaged?","Lamb DS, Bupha-Intr O, Bethwaite P, Murray J, Nacey J, Russell G, Delahunt B.","Anticancer Res. 2008 Nov-Dec;28(6B):3891-5.","Lamb DS","Anticancer Res","2008","2009/02/06","","",""
"18284062","[DNA methylation and prostate cancer]","Zhou SG, Sun YH, Gao JP.","Zhonghua Nan Ke Xue. 2007 Dec;13(12):1108-12.","Zhou SG","Zhonghua Nan Ke Xue","2007","2008/02/21","","",""
"20472365","Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer","Dillman RO, Hafer R, Cox C, McClure SE.","Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):719-23. doi: 10.1016/j.ijrobp.2009.11.041. Epub 2010 May 14.","Dillman RO","Int J Radiat Oncol Biol Phys","2011","2010/05/18","","","10.1016/j.ijrobp.2009.11.041"
"15592439","What's hot in the prostate?","Gleave M, Evans CP.","Prostate Cancer Prostatic Dis. 2004;7(4):273-6. doi: 10.1038/sj.pcan.4500773.","Gleave M","Prostate Cancer Prostatic Dis","2004","2004/12/14","","","10.1038/sj.pcan.4500773"
"10528021","Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study","Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff JM, Deapen D, Stephenson RA, Legler J, Ferrans CE, Talcott JA, Litwin MS.","J Natl Cancer Inst. 1999 Oct 20;91(20):1719-24. doi: 10.1093/jnci/91.20.1719.","Potosky AL","J Natl Cancer Inst","1999","1999/10/21","","","10.1093/jnci/91.20.1719"
"8426412","Deferred treatment of low grade stage T3 prostate cancer without distant metastases","Adolfsson J.","J Urol. 1993 Feb;149(2):326-8; discussion 328-9. doi: 10.1016/s0022-5347(17)36071-8.","Adolfsson J","J Urol","1993","1993/02/01","","","10.1016/s0022-5347(17)36071-8"
"16613161","[Clinical analysis of 1,000 patients with prostate cancer]","Saito T, Kasahara T, Kitamura Y, Komatsubara S.","Nihon Hinyokika Gakkai Zasshi. 2006 Mar;97(3):591-7. doi: 10.5980/jpnjurol1989.97.591.","Saito T","Nihon Hinyokika Gakkai Zasshi","2006","2006/04/15","","","10.5980/jpnjurol1989.97.591"
"27344818","[Treatment strategy for high-risk localized prostate cancer]","Narita S, Inoue T, Habuchi T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:693-700.","Narita S","Nihon Rinsho","2016","2016/06/28","","",""
"7605484","Localised prostate cancer: which way forward?","Graham P.","Med J Aust. 1995 May 1;162(9):503.","Graham P","Med J Aust","1995","1995/05/01","","",""
"14661397","[Mediterranean diet, micronutrients and prostate carcinoma: a rationale approach to primary prevention of prostate cancer]","Miano L.","Arch Ital Urol Androl. 2003 Sep;75(3):166-78.","Miano L","Arch Ital Urol Androl","2003","2003/12/10","","",""
"18000802","Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice?","Albertsen P.","Cancer. 2008 Jan 1;112(1):1-3. doi: 10.1002/cncr.23107.","Albertsen P","Cancer","2008","2007/11/15","","","10.1002/cncr.23107"
"23117005","Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","Ahmed HU, Arya M, Freeman A, Emberton M.","Lancet Oncol. 2012 Nov;13(11):e509-17. doi: 10.1016/S1470-2045(12)70388-1.","Ahmed HU","Lancet Oncol","2012","2012/11/03","","","10.1016/S1470-2045(12)70388-1"
"6431576","External radiotherapy for localized prostate cancer","Liskow A.","Semin Urol. 1983 Aug;1(3):217-21.","Liskow A","Semin Urol","1983","1983/08/01","","",""
"27773847","Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer","Vella V, Malaguarnera R, Lappano R, Maggiolini M, Belfiore A.","Mol Cell Endocrinol. 2017 Dec 5;457:57-72. doi: 10.1016/j.mce.2016.10.020. Epub 2016 Oct 20.","Vella V","Mol Cell Endocrinol","2017","2016/10/25","","","10.1016/j.mce.2016.10.020"
"19379083","DNA methylation changes in prostate cancer: current developments and future clinical implementation","Hoque MO.","Expert Rev Mol Diagn. 2009 Apr;9(3):243-57. doi: 10.1586/erm.09.10.","Hoque MO","Expert Rev Mol Diagn","2009","2009/04/22","PMC4441323","NIHMS520121","10.1586/erm.09.10"
"8539638","Adjuvant systemic therapy of prostate cancer","Raghavan D.","Semin Oncol. 1995 Dec;22(6):633-40.","Raghavan D","Semin Oncol","1995","1995/12/01","","",""
"7933224","Detection and Treatment of Early Stage Prostate Cancer. Proceedings of a conference. Crystal City, Virginia, December 3-5, 1993","","J Urol. 1994 Nov;152(5 Pt 2):1677-940.","","J Urol","1994","1994/11/01","","",""
"20859283","Drug resistance in metastatic castration-resistant prostate cancer","Seruga B, Ocana A, Tannock IF.","Nat Rev Clin Oncol. 2011 Jan;8(1):12-23. doi: 10.1038/nrclinonc.2010.136. Epub 2010 Sep 21.","Seruga B","Nat Rev Clin Oncol","2011","2010/09/23","","","10.1038/nrclinonc.2010.136"
"23084522","Biology of castration-recurrent prostate cancer","Azzouni F, Mohler J.","Urol Clin North Am. 2012 Nov;39(4):435-52. doi: 10.1016/j.ucl.2012.07.002. Epub 2012 Aug 27.","Azzouni F","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.07.002"
"29727322","Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management","Nguyen JK, Magi-Galluzzi C.","Adv Anat Pathol. 2018 Sep;25(5):293-303. doi: 10.1097/PAP.0000000000000192.","Nguyen JK","Adv Anat Pathol","2018","2018/05/05","","","10.1097/PAP.0000000000000192"
"10797497","Screening and early treatment of prostate cancer are accumulating strong evidence and support","Mettlin C.","Prostate. 2000 May 15;43(3):223-4. doi: 10.1002/(sici)1097-0045(20000515)43:3<223::aid-pros8>3.0.co;2-c.","Mettlin C","Prostate","2000","2000/05/08","","","10.1002/(sici)1097-0045(20000515)43:3<223::aid-pros8>3.0.co;2-c"
"19720970","Prostate cancer screening; is this a teachable moment?","Brawley OW.","J Natl Cancer Inst. 2009 Oct 7;101(19):1295-7. doi: 10.1093/jnci/djp310. Epub 2009 Aug 31.","Brawley OW","J Natl Cancer Inst","2009","2009/09/02","","","10.1093/jnci/djp310"
"26527749","Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling","Wang T, Song W, Chen Y, Chen R, Liu Z, Wu L, Li M, Yang J, Wang L, Liu J, Ye Z, Wang C, Chen K.","Clin Cancer Res. 2016 Mar 15;22(6):1531-44. doi: 10.1158/1078-0432.CCR-15-1632. Epub 2015 Nov 2.","Wang T","Clin Cancer Res","2016","2015/11/04","","","10.1158/1078-0432.CCR-15-1632"
"10920760","Prostate cancer in Victoria in 1993: patterns of reported management","Hughes PD.","Med J Aust. 2000 Jun 5;172(11):565-6.","Hughes PD","Med J Aust","2000","2000/08/02","","",""
"25368970","Epigenetic test could eliminate repeat biopsies for prostate cancer","Printz C.","Cancer. 2014 Nov 15;120(22):3428-9. doi: 10.1002/cncr.29109.","Printz C","Cancer","2014","2014/11/05","","","10.1002/cncr.29109"
"20051566","Age and prostate cancer survival","Froehner M.","JAMA. 2010 Jan 6;303(1):33-4; author reply 34. doi: 10.1001/jama.2009.1933.","Froehner M","JAMA","2010","2010/01/07","","","10.1001/jama.2009.1933"
"8808877","Prostate cancer--in search of certain knowledge","Rukstalis DB.","J Urol. 1996 Oct;156(4):1386-7. doi: 10.1016/s0022-5347(01)65594-0.","Rukstalis DB","J Urol","1996","1996/10/01","","","10.1016/s0022-5347(01)65594-0"
"16187544","[Treatment of prostate cancer]","Imre R.","Orv Hetil. 2005 Aug 28;146(35):1839-42.","Imre R","Orv Hetil","2005","2005/09/29","","",""
"18765119","Extended lymph node dissection for prostate cancer","Jeschke S, Burkhard FC, Thurairaja R, Dhar N, Studer UE.","Curr Urol Rep. 2008 May;9(3):237-42. doi: 10.1007/s11934-008-0041-0.","Jeschke S","Curr Urol Rep","2008","2008/09/04","","","10.1007/s11934-008-0041-0"
"8085844","[The role of radical prostatectomy for early stage prostate cancer]","Arai Y.","Gan To Kagaku Ryoho. 1994 Sep;21(12):1934-9.","Arai Y","Gan To Kagaku Ryoho","1994","1994/09/01","","",""
"16299861","I'm 72, have early prostate cancer, and my doctor recommended ""watchful waiting"". What does that mean and why would I do this instead of removing the cancer?","","Health News. 2005 Nov;11(11):16.","","Health News","2005","2005/11/22","","",""
"7689192","Prostate-specific antigen: the new early detection test for prostate cancer","Greco KE, Blank B.","Nurse Pract. 1993 May;18(5):30-8. doi: 10.1097/00006205-199305000-00013.","Greco KE","Nurse Pract","1993","1993/05/01","","","10.1097/00006205-199305000-00013"
"27314183","Acute Aortic Dissection Following Treatment for Castration-Resistant  Prostate Cancer","Horrill T.","Oncol Nurs Forum. 2016 Jul 1;43(4):413-6. doi: 10.1188/16.ONF.413-416.","Horrill T","Oncol Nurs Forum","2016","2016/06/18","","","10.1188/16.ONF.413-416"
"18822261","[Prostate cancer: news in 2008]","Salomon L, Descazeaud A.","Prog Urol. 2008 Sep;18 Suppl 6:S116-24. doi: 10.1016/S1166-7087(08)73936-8.","Salomon L","Prog Urol","2008","2008/11/26","","","10.1016/S1166-7087(08)73936-8"
"30228708","Prostate Cancer Pathology: Recent Updates and Controversies","Sehn JK.","Mo Med. 2018 Mar-Apr;115(2):151-155.","Sehn JK","Mo Med","2018","2018/09/20","PMC6139855","",""
"19670743","[Diagnosis and treatment of early prostate cancer]","Kaprin AD, Khalil Farzat M, Gafanov RA, Kostin AA.","Vopr Onkol. 2009;55(3):382-5.","Kaprin AD","Vopr Onkol","2009","2009/08/13","","",""
"25608413","['Men are not dying with, but from prostate cancer']","Stief C.","MMW Fortschr Med. 2014 Dec 15;156(21-22):66.","Stief C","MMW Fortschr Med","2014","2015/01/23","","",""
"11409059","Correlates of actual and perceived knowledge of prostate cancer among African Americans","Agho AO, Lewis MA.","Cancer Nurs. 2001 Jun;24(3):165-71. doi: 10.1097/00002820-200106000-00001.","Agho AO","Cancer Nurs","2001","2001/06/21","","","10.1097/00002820-200106000-00001"
"17622077","[Specific features of the early diagnosis of prostate cancer in the presence of neurogenic bladder]","Gignoux A, Chartier-Kastler E, Ruffion A.","Prog Urol. 2007 May;17(3):457-61. doi: 10.1016/s1166-7087(07)92348-9.","Gignoux A","Prog Urol","2007","2007/07/12","","","10.1016/s1166-7087(07)92348-9"
"9854194","Therapeutic dilemmas in prostate cancer: justification for watchful waiting","George N.","Eur Urol. 1998;34 Suppl 3:33-6. doi: 10.1159/000052296.","George N","Eur Urol","1998","1998/12/17","","","10.1159/000052296"
"31629431","Considerations of germline testing in prostate cancer screening","Polascik TJ, Orabi H.","Can J Urol. 2019 Oct;26(5 Suppl 2):46-47.","Polascik TJ","Can J Urol","2019","2019/10/21","","",""
"28562375","Exercise medicine for advanced prostate cancer","Hart NH, Galvão DA, Newton RU.","Curr Opin Support Palliat Care. 2017 Sep;11(3):247-257. doi: 10.1097/SPC.0000000000000276.","Hart NH","Curr Opin Support Palliat Care","2017","2017/06/01","","","10.1097/SPC.0000000000000276"
"24262722","'Race' and prostate cancer mortality in equal-access healthcare systems","Graham-Steed T, Uchio E, Wells CK, Aslan M, Ko J, Concato J.","Am J Med. 2013 Dec;126(12):1084-8. doi: 10.1016/j.amjmed.2013.08.012.","Graham-Steed T","Am J Med","2013","2013/11/23","PMC4100601","NIHMS554063","10.1016/j.amjmed.2013.08.012"
"25399333","Malignant acanthosis nigricans associated with prostate cancer: a case report","Kubicka-Wołkowska J, Dębska-Szmich S, Lisik-Habib M, Noweta M, Potemski P.","BMC Urol. 2014 Nov 15;14:88. doi: 10.1186/1471-2490-14-88.","Kubicka-Wołkowska J","BMC Urol","2014","2014/11/17","PMC4239373","","10.1186/1471-2490-14-88"
"10623685","Experimental models of prostate cancer research","Cohen MB, Padarathsingh M, Hendrix MJ.","Am J Pathol. 2000 Jan;156(1):355-8. doi: 10.1016/S0002-9440(10)64737-2.","Cohen MB","Am J Pathol","2000","2000/01/07","PMC1868621","","10.1016/S0002-9440(10)64737-2"
"10743734","The value of examining blood supply in prostate cancer using Doppler frequency analysis","Zát'ura F, Student V.","Acta Univ Palacki Olomuc Fac Med. 1999;142:93-5.","Zát'ura F","Acta Univ Palacki Olomuc Fac Med","1999","2000/04/01","","",""
"30489036","Advanced prostate cancer update 2018","Sartor O.","Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:9-12. doi: 10.1111/ajco.13057.","Sartor O","Asia Pac J Clin Oncol","2018","2018/11/30","","","10.1111/ajco.13057"
"28868501","The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer","Kim J, Park JS, Ham WS.","Investig Clin Urol. 2017 Sep;58(5):307-316. doi: 10.4111/icu.2017.58.5.307. Epub 2017 Aug 8.","Kim J","Investig Clin Urol","2017","2017/09/05","PMC5577326","","10.4111/icu.2017.58.5.307"
"11696752","Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor","Lubeck DP, Kim H, Grossfeld G, Ray P, Penson DF, Flanders SC, Carroll PR.","J Urol. 2001 Dec;166(6):2281-5.","Lubeck DP","J Urol","2001","2001/11/07","","",""
"24979663","Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer","ChunJiao S, Huan C, ChaoYang X, GuoMei R.","IUBMB Life. 2014 Jun;66(6):379-86. doi: 10.1002/iub.1281. Epub 2014 Jun 30.","ChunJiao S","IUBMB Life","2014","2014/07/01","PMC4140600","","10.1002/iub.1281"
"1349433","Prostate Cancer: imaging, management, and screening. Proceedings of the Prostate Sessions at the First International Congress of the Dutch Urological Association. Rotterdam, the Netherlands, October 9-13, 1991","","Prostate Suppl. 1992;4:1-169.","","Prostate Suppl","1992","1992/01/01","","",""
"14552074","Prostate cancer: perspectives on quality of life and impact of treatment on patients and their partners","Crowe H, Costello AJ.","Urol Nurs. 2003 Aug;23(4):279-85.","Crowe H","Urol Nurs","2003","2003/10/14","","",""
"25146443","Italianity is associated with lower risk of prostate cancer mortality in Switzerland","Richard A, Faeh D, Rohrmann S, Braun J, Tarnutzer S, Bopp M.","Cancer Causes Control. 2014 Nov;25(11):1523-9. doi: 10.1007/s10552-014-0456-5. Epub 2014 Aug 22.","Richard A","Cancer Causes Control","2014","2014/08/23","","","10.1007/s10552-014-0456-5"
"22974436","Prostate cancer: germline prediction for a commonly variable malignancy","Bambury RM, Gallagher DJ.","BJU Int. 2012 Dec;110(11 Pt C):E809-18. doi: 10.1111/j.1464-410X.2012.11450.x. Epub 2012 Sep 14.","Bambury RM","BJU Int","2012","2012/09/15","","","10.1111/j.1464-410X.2012.11450.x"
"19144933","Clinical decisions. Management of prostate cancer--polling results","Schwartz RS.","N Engl J Med. 2009 Jan 15;360(3):e4. doi: 10.1056/NEJMclde0810802.","Schwartz RS","N Engl J Med","2009","2009/01/16","","","10.1056/NEJMclde0810802"
"10386470","Advanced prostate cancer: course, care, and cost implications","Beemsterboer PM, de Koning HJ, Birnie E, van der Maas PJ, Schröder FH.","Prostate. 1999 Jul 1;40(2):97-104. doi: 10.1002/(sici)1097-0045(19990701)40:2<97::aid-pros5>3.0.co;2-a.","Beemsterboer PM","Prostate","1999","1999/07/01","","","10.1002/(sici)1097-0045(19990701)40:2<97::aid-pros5>3.0.co;2-a"
"9179182","Clinical strategies for improving the radiotherapeutic management of prostate cancer","Chuba PJ, Forman JD, Ben-Josef E, Hart KH, Porter AT.","Anticancer Res. 1997 May-Jun;17(3A):1449-54.","Chuba PJ","Anticancer Res","1997","1997/05/01","","",""
"26685282","The emerging role of noncoding RNA in prostate cancer progression and its implication on diagnosis and treatment","Takayama K, Inoue S.","Brief Funct Genomics. 2016 May;15(3):257-65. doi: 10.1093/bfgp/elv057. Epub 2015 Dec 17.","Takayama K","Brief Funct Genomics","2016","2015/12/20","","","10.1093/bfgp/elv057"
"17392714","Drug insight: role of the androgen receptor in the development and progression of prostate cancer","Taplin ME.","Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. doi: 10.1038/ncponc0765.","Taplin ME","Nat Clin Pract Oncol","2007","2007/03/30","","","10.1038/ncponc0765"
"12853798","More information on prostate specific antigen and prostate cancer","Stamey TA.","J Urol. 2003 Aug;170(2 Pt 1):457-8. doi: 10.1097/01.ju.0000077443.49060.83.","Stamey TA","J Urol","2003","2003/07/11","","","10.1097/01.ju.0000077443.49060.83"
"2219572","Natural history of low-stage prostatic cancer and the impact of early detection","Whitmore WF Jr.","Urol Clin North Am. 1990 Nov;17(4):689-97.","Whitmore WF Jr","Urol Clin North Am","1990","1990/11/01","","",""
"9600471","Detection of early prostate cancer: serendipitous or systematic?","Pitts WR Jr.","JAMA. 1998 May 13;279(18):1440-1.","Pitts WR Jr","JAMA","1998","1998/05/26","","",""
"18154200","Descriptive case series of patients presenting with cancer of the prostate and their management at Kenyatta National Hospital, Nairobi","Wasike RW, Magoha GA.","East Afr Med J. 2007 Sep;84(9 Suppl):S31-5. doi: 10.4314/eamj.v84i9.9559.","Wasike RW","East Afr Med J","2007","2007/12/25","","","10.4314/eamj.v84i9.9559"
"9315393","The aetiology and pathogenesis of prostate cancer","Rowley KH, Mason MD.","Clin Oncol (R Coll Radiol). 1997;9(4):213-8. doi: 10.1016/s0936-6555(97)80003-9.","Rowley KH","Clin Oncol (R Coll Radiol)","1997","1997/01/01","","","10.1016/s0936-6555(97)80003-9"
"23271769","What is the risk posed by prostate cancer?","Albertsen PC.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):169-74. doi: 10.1093/jncimonographs/lgs028.","Albertsen PC","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540873","","10.1093/jncimonographs/lgs028"
"26700655","Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis","Wallis CJD, Saskin R, Choo R, Herschorn S, Kodama RT, Satkunasivam R, Shah PS, Danjoux C, Nam RK.","Eur Urol. 2016 Jul;70(1):21-30. doi: 10.1016/j.eururo.2015.11.010. Epub 2015 Dec 15.","Wallis CJD","Eur Urol","2016","2015/12/25","","","10.1016/j.eururo.2015.11.010"
"19925392","Prostate cancer therapy","Sharifi N, Aragon-Ching JB.","Anticancer Agents Med Chem. 2009 Dec;9(10):1039. doi: 10.2174/187152009789735026.","Sharifi N","Anticancer Agents Med Chem","2009","2009/11/21","","","10.2174/187152009789735026"
"10361558","Gene therapy for prostate cancer. New perspectives on an old problem","Palapattu GS, Naitoh J, Belldegrun AS.","Urol Clin North Am. 1999 May;26(2):353-63, ix. doi: 10.1016/s0094-0143(05)70075-6.","Palapattu GS","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70075-6"
"16018945","An update on randomized clinical trials in localized and locoregional prostate cancer","Penson DF.","Urol Oncol. 2005 Jul-Aug;23(4):280-8. doi: 10.1016/j.urolonc.2005.05.006.","Penson DF","Urol Oncol","2005","2005/07/16","","","10.1016/j.urolonc.2005.05.006"
"17432553","The prevention of prostate cancer","Griffiths K, Prezioso D, Turkes A, Denis LJ.","Recent Results Cancer Res. 2007;175:33-63. doi: 10.1007/978-3-540-40901-4_4.","Griffiths K","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_4"
"26515982","Molecular Profiles of Prostate Cancer: To Treat or Not to Treat","Sternberg IA, Vela I, Scardino PT.","Annu Rev Med. 2016;67:119-35. doi: 10.1146/annurev-med-060413-112226. Epub 2015 Oct 29.","Sternberg IA","Annu Rev Med","2016","2015/10/31","","","10.1146/annurev-med-060413-112226"
"8717453","Incidence of prostate cancer will double by the year 2030: the argument against","George NJ.","Eur Urol. 1996;29 Suppl 2:10-2. doi: 10.1159/000473829.","George NJ","Eur Urol","1996","1996/01/01","","","10.1159/000473829"
"26536720","[Magnetic resonance imaging of prostate cancer]","Kenttämies A, Rannikko A.","Duodecim. 2015;131(13-14):1233-44.","Kenttämies A","Duodecim","2015","2015/11/06","","",""
"7702316","Radical prostatectomy and prostate cancer screening: the need for national audit and research","Hall RR.","Ann R Coll Surg Engl. 1994 Nov;76(6):367-72.","Hall RR","Ann R Coll Surg Engl","1994","1994/11/01","PMC2502271","",""
"12765053","[Prostate cancer screening]","Villers A, Rébillard X, Soulié M, Davin JL, Coloby P, Moreau JL, Mejean A, Irani J, Coulange C, Mangin P; French Association of Urology.","Prog Urol. 2003 Apr;13(2):209-14.","Villers A","Prog Urol","2003","2003/05/27","","",""
"21999480","Should men drink more coffee to delay progression of prostate cancer?","Arab L.","Nutr Cancer. 2011 Nov;63(8):1161-2. doi: 10.1080/01635581.2011.627295. Epub 2011 Oct 14.","Arab L","Nutr Cancer","2011","2011/10/18","","","10.1080/01635581.2011.627295"
"10975493","Deciding on radical prostatectomy: the physician's perspective","El-Gabry EA, Strup SE, Gomella LG.","Semin Urol Oncol. 2000 Aug;18(3):205-13.","El-Gabry EA","Semin Urol Oncol","2000","2000/09/07","","",""
"29107277","Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?","Damodaran S, Kyriakopoulos CE, Jarrard DF.","Urol Clin North Am. 2017 Nov;44(4):611-621. doi: 10.1016/j.ucl.2017.07.008.","Damodaran S","Urol Clin North Am","2017","2017/11/07","PMC6402766","NIHMS892695","10.1016/j.ucl.2017.07.008"
"14521652","Prostate cancer and race: variation in diagnosis and treatment","Bernstein SJ.","J Gen Intern Med. 2003 Oct;18(10):873-4. doi: 10.1046/j.1525-1497.2003.30801.x.","Bernstein SJ","J Gen Intern Med","2003","2003/10/03","PMC1494936","","10.1046/j.1525-1497.2003.30801.x"
"10763395","The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model","Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.","CMAJ. 2000 Apr 4;162(7):977-83.","Grover SA","CMAJ","2000","2000/04/14","PMC1232349","",""
"15018080","[Metastatic prostate cancer]","Droz JP, Flechon A, Terret C.","Rev Prat. 2003 Dec 31;53(20):2258-62.","Droz JP","Rev Prat","2003","2004/03/17","","",""
"22940524","The lived experience of men diagnosed with prostate cancer","Krumwiede KA, Krumwiede N.","Oncol Nurs Forum. 2012 Sep;39(5):E443-50. doi: 10.1188/12.ONF.E443-E450.","Krumwiede KA","Oncol Nurs Forum","2012","2012/09/04","","","10.1188/12.ONF.E443-E450"
"15852051","Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer","Kaisary AV.","Prostate Cancer Prostatic Dis. 2005;8(2):140-51. doi: 10.1038/sj.pcan.4500800.","Kaisary AV","Prostate Cancer Prostatic Dis","2005","2005/04/27","","","10.1038/sj.pcan.4500800"
"23427682","Exposed and vulnerable","Wright S.","Nurs Stand. 2013 Jan 23-29;27(21):20-1. doi: 10.7748/ns2013.01.27.21.20.s13.","Wright S","Nurs Stand","2013","2013/02/23","","","10.7748/ns2013.01.27.21.20.s13"
"17997027","Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer","Litwin MS.","Eur Urol. 2008 Jul;54(1):106. doi: 10.1016/j.eururo.2007.10.072. Epub 2007 Nov 6.","Litwin MS","Eur Urol","2008","2007/11/13","","","10.1016/j.eururo.2007.10.072"
"8638366","Deoxyribonucleic acid ploidy status as no basis for pathologic stage prediction in clinically resectable prostate cancer","Egawa S, Satoh T, Iwamura M, Aihara M, Kuwao S, Uchida T, Koshiba K.","Urology. 1996 Apr;47(4):548-52. doi: 10.1016/S0090-4295(99)80493-2.","Egawa S","Urology","1996","1996/04/01","","","10.1016/S0090-4295(99)80493-2"
"23921797","Reactive oxygen species mediate isoalantolactone-induced apoptosis in human prostate cancer cells","Rasul A, Di J, Millimouno FM, Malhi M, Tsuji I, Ali M, Li J, Li X.","Molecules. 2013 Aug 5;18(8):9382-96. doi: 10.3390/molecules18089382.","Rasul A","Molecules","2013","2013/08/08","PMC6270412","","10.3390/molecules18089382"
"19151558","[Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis]","Ohori M.","Gan To Kagaku Ryoho. 2009 Jan;36(1):6-10.","Ohori M","Gan To Kagaku Ryoho","2009","2009/01/20","","",""
"12949426","Adjuvant hormonal treatment for prostate cancer: the bicalutamide early prostate cancer program","Wirth MP, Froehner M.","Oncology. 2003;65 Suppl 1:1-4. doi: 10.1159/000072484.","Wirth MP","Oncology","2003","2003/09/02","","","10.1159/000072484"
"27363064","High Incidence of Incidental Prostate Cancer in Transurethral Resection of Prostate Specimens in China. The Value of Pathologic Review","Lin J, Yu X, Yang X, Jin J, Zhou L, Liu L, Su J, Li Y, Shang M.","Anal Quant Cytopathol Histpathol. 2016 Feb;38(1):31-7.","Lin J","Anal Quant Cytopathol Histpathol","2016","2016/07/02","","",""
"28267452","Clinical Applications of Molecular Imaging in the Management of Prostate Cancer","Gorin MA, Rowe SP, Denmeade SR.","PET Clin. 2017 Apr;12(2):185-192. doi: 10.1016/j.cpet.2016.11.001. Epub 2017 Jan 16.","Gorin MA","PET Clin","2017","2017/03/08","","","10.1016/j.cpet.2016.11.001"
"24034727","ICP: A novel approach to predict prognosis of prostate cancer with inner-class clustering of gene expression data","Kim H, Ahn J, Park C, Yoon Y, Park S.","Comput Biol Med. 2013 Oct;43(10):1363-73. doi: 10.1016/j.compbiomed.2013.06.014. Epub 2013 Jul 4.","Kim H","Comput Biol Med","2013","2013/09/17","","","10.1016/j.compbiomed.2013.06.014"
"12099578","Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer","Figg WD, Kruger EA, Price DK, Kim S, Dahut WD.","Invest New Drugs. 2002 May;20(2):183-94. doi: 10.1023/a:1015626410273.","Figg WD","Invest New Drugs","2002","2002/07/09","","","10.1023/a:1015626410273"
"9064881","[Non-curative treatment of prostate carcinoma. Outcome in Göteborg]","Aus G, Hugosson J.","Urologe A. 1996 Nov;35(6):449-53. doi: 10.1007/s001200050050.","Aus G","Urologe A","1996","1996/11/01","","","10.1007/s001200050050"
"28338305","Prostate cancer in renal transplant recipients","Sherer BA, Warrior K, Godlewski K, Hertl M, Olaitan O, Nehra A, Deane LA.","Int Braz J Urol. 2017 Nov-Dec;43(6):1021-1032. doi: 10.1590/S1677-5538.IBJU.2016.0510.","Sherer BA","Int Braz J Urol","2017","2017/03/25","PMC5734064","","10.1590/S1677-5538.IBJU.2016.0510"
"25988689","Proton therapy for prostate cancer: why and what orthopaedic surgeons need to know about it","Edmunds JO, Lee AK.","J Surg Orthop Adv. 2015 Summer;24(2):91-8.","Edmunds JO","J Surg Orthop Adv","2015","2015/05/20","","",""
"15336979","Ca2+ homeostasis in apoptotic resistance of prostate cancer cells","Prevarskaya N, Skryma R, Shuba Y.","Biochem Biophys Res Commun. 2004 Oct 1;322(4):1326-35. doi: 10.1016/j.bbrc.2004.08.037.","Prevarskaya N","Biochem Biophys Res Commun","2004","2004/09/01","","","10.1016/j.bbrc.2004.08.037"
"19068391","[Histological modifications observed in prostate after preserving treatments for prostate cancer and their impact on Gleason score interpretation]","Molinié V, Mahjoub WK, Balaton A.","Ann Pathol. 2008 Oct;28(5):363-73. doi: 10.1016/j.annpat.2008.07.008. Epub 2008 Oct 16.","Molinié V","Ann Pathol","2008","2008/12/11","","","10.1016/j.annpat.2008.07.008"
"29016076","Active monitoring vs treatment for localised prostate cancer","Rees J.","Practitioner. 2016 Oct;260(1797):5.","Rees J","Practitioner","2016","2017/10/11","","",""
"20065953","Urine biomarkers in prostate cancer","Ploussard G, de la Taille A.","Nat Rev Urol. 2010 Feb;7(2):101-9. doi: 10.1038/nrurol.2009.261. Epub 2010 Jan 12.","Ploussard G","Nat Rev Urol","2010","2010/01/13","","","10.1038/nrurol.2009.261"
"17997012","Editorial comment on: high provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer","Roach M 3rd.","Eur Urol. 2008 Jul;54(1):105-6. doi: 10.1016/j.eururo.2007.10.071. Epub 2007 Nov 6.","Roach M 3rd","Eur Urol","2008","2007/11/13","","","10.1016/j.eururo.2007.10.071"
"20976601","Prostate cancer: novel aspects of diagnostics and surgical technology","Herrmann TR, Merseburger AS, Burchardt M.","World J Urol. 2010 Dec;28(6):665. doi: 10.1007/s00345-010-0607-6. Epub 2010 Oct 26.","Herrmann TR","World J Urol","2010","2010/10/27","","","10.1007/s00345-010-0607-6"
"27221830","Multimodality Treatment for Patients with Node-Positive Prostate Cancer: the Role of Radiation Therapy","Ochiai S, Nomoto Y, Kobayashi S, Yamashita Y, Watanabe Y, Toyomasu Y, Kawamura T, Takada A, Ii N, Sakuma H.","Asian Pac J Cancer Prev. 2016;17(4):1625-30. doi: 10.7314/apjcp.2016.17.4.1625.","Ochiai S","Asian Pac J Cancer Prev","2016","2016/05/26","","","10.7314/apjcp.2016.17.4.1625"
"27344699","[Epidemiology of prostate cancer: International variation]","Hinotsu S.","Nihon Rinsho. 2016 May 20;74 Suppl 3:34-8.","Hinotsu S","Nihon Rinsho","2016","2016/06/28","","",""
"12518662","[Prostate cancer: diagnosis and survival]","Ruiz de Burgos Moreno JE.","An R Acad Nac Med (Madr). 2002;119(2):413-8; discussion 419-22.","Ruiz de Burgos Moreno JE","An R Acad Nac Med (Madr)","2002","2003/01/10","","",""
"16935414","Prostate cancer nomograms: an update","Chun FK, Karakiewicz PI, Briganti A, Gallina A, Kattan MW, Montorsi F, Huland H, Graefen M.","Eur Urol. 2006 Nov;50(5):914-26; discussion 926. doi: 10.1016/j.eururo.2006.07.042. Epub 2006 Aug 11.","Chun FK","Eur Urol","2006","2006/08/29","","","10.1016/j.eururo.2006.07.042"
"6399612","Radiation and chemotherapy for stage D1 prostate cancer","deVere White R.","Semin Urol. 1983 Nov;1(4):261-8.","deVere White R","Semin Urol","1983","1983/11/01","","",""
"21604944","Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers","Bjartell A, Montironi R, Berney DM, Egevad L.","Acta Oncol. 2011 Jun;50 Suppl 1:76-84. doi: 10.3109/0284186X.2010.531284.","Bjartell A","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.531284"
"19482780","Critical review: is watchful waiting a viable management option for older men with prostate cancer?","Bailey DE Jr, Wallace M.","Am J Mens Health. 2007 Mar;1(1):18-28. doi: 10.1177/1557988306294161.","Bailey DE Jr","Am J Mens Health","2007","2009/06/02","","","10.1177/1557988306294161"
"28655021","The Diagnosis and Treatment of Prostate Cancer: A Review","Litwin MS, Tan HJ.","JAMA. 2017 Jun 27;317(24):2532-2542. doi: 10.1001/jama.2017.7248.","Litwin MS","JAMA","2017","2017/06/28","","","10.1001/jama.2017.7248"
"25053197","Upper limit of cancer extent on biopsy defining very low-risk prostate cancer","Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P.","BJU Int. 2015 Aug;116(2):213-9. doi: 10.1111/bju.12874. Epub 2015 Mar 7.","Bratt O","BJU Int","2015","2014/07/24","","","10.1111/bju.12874"
"30178248","MicroRNAs Role in Prostate Cancer","Balacescu O, Dumitrescu RG, Marian C.","Methods Mol Biol. 2018;1856:103-117. doi: 10.1007/978-1-4939-8751-1_6.","Balacescu O","Methods Mol Biol","2018","2018/09/05","","","10.1007/978-1-4939-8751-1_6"
"8865478","Staging of incidentally detected prostate cancer: role of repeat resection, prostate-specific antigen, needle biopsy, and imaging","Griebling TL, Williams RD.","Semin Urol Oncol. 1996 Aug;14(3):156-64.","Griebling TL","Semin Urol Oncol","1996","1996/08/01","","",""
"12783666","[Expression and significance of clusterin in normal prostate, benign prostate hyperplasia and prostate cancer]","Zhou LQ, Yang XZ, Zeng L, Liang LL, Yang XY, Ren L, Chung L, Zhang ZW, Na YQ, Gu FL, Guo YL.","Zhonghua Wai Ke Za Zhi. 2003 Feb;41(2):93-5.","Zhou LQ","Zhonghua Wai Ke Za Zhi","2003","2003/06/05","","",""
"23316855","""The only way I know how to live is to work"": a qualitative study of work following treatment for prostate cancer","Grunfeld EA, Drudge-Coates L, Rixon L, Eaton E, Cooper AF.","Health Psychol. 2013 Jan;32(1):75-82. doi: 10.1037/a0030387.","Grunfeld EA","Health Psychol","2013","2013/01/16","","","10.1037/a0030387"
"7528556","Methods of early detection of prostate cancer: the role of prostatic specific antigen, transrectal ultrasound and digital rectal examination","Pontes JE.","In Vivo. 1994 May-Jun;8(3):413-4.","Pontes JE","In Vivo","1994","1994/05/01","","",""
"11490251","Predictors of utilities for health states in early stage prostate cancer","Saigal CS, Gornbein J, Nease R, Litwin MS.","J Urol. 2001 Sep;166(3):942-6.","Saigal CS","J Urol","2001","2001/08/08","","",""
"27344723","[Prognostic factors in hormone-sensitive advanced prostate cancer]","Fujimoto N.","Nihon Rinsho. 2016 May 20;74 Suppl 3:166-70.","Fujimoto N","Nihon Rinsho","2016","2016/06/28","","",""
"22472508","Overcoming castration resistance in prostate cancer","Tsao CK, Small AC, Galsky MD, Oh WK.","Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b.","Tsao CK","Curr Opin Urol","2012","2012/04/05","","","10.1097/MOU.0b013e3283523b8b"
"22929553","Detecting microRNAs of high influence on protein functional interaction networks: a prostate cancer case study","Alshalalfa M, Bader GD, Goldenberg A, Morris Q, Alhajj R.","BMC Syst Biol. 2012 Aug 28;6:112. doi: 10.1186/1752-0509-6-112.","Alshalalfa M","BMC Syst Biol","2012","2012/08/30","PMC3490713","","10.1186/1752-0509-6-112"
"12767361","Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy","Paiss T, Herkommer K, Bock B, Heinz H, Vogel W, Kron M, Kuefer R, Hautmann RE, Gschwend JE.","Eur Urol. 2003 Jun;43(6):615-21. doi: 10.1016/s0302-2838(03)00146-5.","Paiss T","Eur Urol","2003","2003/05/28","","","10.1016/s0302-2838(03)00146-5"
"10710901","Surgical management of localized prostate cancer","Bissada NK, Gunhan M, Hull JW.","J S C Med Assoc. 2000 Feb;96(2):60-4.","Bissada NK","J S C Med Assoc","2000","2000/03/11","","",""
"17026796","Assessing progress against prostate cancer","Sartor O, Alchalabi T, Figg WD.","Clin Genitourin Cancer. 2006 Sep;5(2):102-3. doi: 10.3816/CGC.2006.n.025.","Sartor O","Clin Genitourin Cancer","2006","2006/10/10","","","10.3816/CGC.2006.n.025"
"9474214","Re: The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues","Murphy WM.","J Urol. 1998 Mar;159(3):995-6. doi: 10.1016/s0022-5347(01)63816-3.","Murphy WM","J Urol","1998","1998/02/25","","","10.1016/s0022-5347(01)63816-3"
"17996360","Editorial comment on: poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men","Barry MJ.","Eur Urol. 2008 Jul;54(1):116-7. doi: 10.1016/j.eururo.2007.10.039. Epub 2007 Oct 30.","Barry MJ","Eur Urol","2008","2007/11/13","","","10.1016/j.eururo.2007.10.039"
"2484149","[Early diagnosis of cancer of the prostate. Value of systemic screening and of diagnosis in incidental cancer (stage A)]","Solé Balcells FJ.","Arch Esp Urol. 1989;42 Suppl 2:131-8.","Solé Balcells FJ","Arch Esp Urol","1989","1989/01/01","","",""
"26718455","Prostate cancer in men of African origin","McGinley KF, Tay KJ, Moul JW.","Nat Rev Urol. 2016 Feb;13(2):99-107. doi: 10.1038/nrurol.2015.298. Epub 2015 Dec 31.","McGinley KF","Nat Rev Urol","2016","2016/01/01","","","10.1038/nrurol.2015.298"
"9858324","The epidemiology of prostate cancer part I: descriptive epidemiology","Brawley OW, Knopf K, Merrill R.","Semin Urol Oncol. 1998 Nov;16(4):187-92.","Brawley OW","Semin Urol Oncol","1998","1998/12/19","","",""
"22336886","Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer","Campbell TJ, Tindall DJ, Figg WD.","Cancer Biol Ther. 2012 Mar;13(5):237-8. doi: 10.4161/cbt.19608. Epub 2012 Mar 1.","Campbell TJ","Cancer Biol Ther","2012","2012/02/17","PMC3367713","","10.4161/cbt.19608"
"24817261","Management of advanced prostate cancer - role of the urologist","Shore N.","Curr Urol Rep. 2014 Jul;15(7):419. doi: 10.1007/s11934-014-0419-0.","Shore N","Curr Urol Rep","2014","2014/05/13","","","10.1007/s11934-014-0419-0"
"30905075","Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer","Xia H, Hu C, Bai S, Lyu J, Zhang BY, Yu X, Zhan Y, Zhao L, Dong Y.","J Cell Mol Med. 2019 May;23(5):3656-3664. doi: 10.1111/jcmm.14267. Epub 2019 Mar 23.","Xia H","J Cell Mol Med","2019","2019/03/25","PMC6484324","","10.1111/jcmm.14267"
"23443136","Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression","Saraon P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, van der Kwast T, Mizokami A, Morrissey C, Jarvi K, Diamandis EP.","Mol Cell Proteomics. 2013 Jun;12(6):1589-601. doi: 10.1074/mcp.M112.023887. Epub 2013 Feb 26.","Saraon P","Mol Cell Proteomics","2013","2013/02/28","PMC3675816","","10.1074/mcp.M112.023887"
"3050542","External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States","Hanks GE.","NCI Monogr. 1988;(7):75-84.","Hanks GE","NCI Monogr","1988","1988/01/01","","",""
"16630525","Radiation therapy in the management of locally advanced prostate cancer","Michalski JM.","Curr Urol Rep. 2006 May;7(3):217-24. doi: 10.1007/s11934-006-0024-y.","Michalski JM","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0024-y"
"24914850","[Economic features of active surveillance]","Huguet J, Musquera M, Ribal MJ, Alcaraz A.","Arch Esp Urol. 2014 Jun;67(5):509-13.","Huguet J","Arch Esp Urol","2014","2014/06/11","","",""
"26858164","Magnetic resonance imaging for prostate cancer radiotherapy","Dinh CV, Steenbergen P, Ghobadi G, Heijmink SW, Pos FJ, Haustermans K, van der Heide UA.","Phys Med. 2016 Mar;32(3):446-51. doi: 10.1016/j.ejmp.2016.01.484. Epub 2016 Feb 5.","Dinh CV","Phys Med","2016","2016/02/10","","","10.1016/j.ejmp.2016.01.484"
"27619665","Prostate cancer screening in Brazil: should it be done or not?","Busato WF Jr, Almeida GL.","Int Braz J Urol. 2016 Nov-Dec;42(6):1069-1080. doi: 10.1590/S1677-5538.IBJU.2015.0709.","Busato WF Jr","Int Braz J Urol","2016","2016/09/14","PMC5117962","","10.1590/S1677-5538.IBJU.2015.0709"
"21170486","Active surveillance for localized prostate cancer--current practices and recommendations","Wu JN, Dall'Era MA.","ScientificWorldJournal. 2010 Dec 14;10:2352-61. doi: 10.1100/tsw.2010.227.","Wu JN","ScientificWorldJournal","2010","2010/12/21","PMC5763778","","10.1100/tsw.2010.227"
"15493781","Understanding prostate cancer","Siddiqui E, Mumtaz FH, Gelister J.","J R Soc Promot Health. 2004 Sep;124(5):219-21. doi: 10.1177/146642400412400518.","Siddiqui E","J R Soc Promot Health","2004","2004/10/21","","","10.1177/146642400412400518"
"27322161","Integration of multiparametric MRI into active surveillance of prostate cancer","Holtz JN, Tay KJ, Polascik TJ, Gupta RT.","Future Oncol. 2016 Nov;12(21):2513-2529. doi: 10.2217/fon-2016-0142. Epub 2016 Jun 20.","Holtz JN","Future Oncol","2016","2016/06/21","","","10.2217/fon-2016-0142"
"7816676","Prostate cancer: controversies surrounding risk, screening, and management","Loescher LJ.","Oncol Nurs Forum. 1994 Oct;21(9):1503-4.","Loescher LJ","Oncol Nurs Forum","1994","1994/10/01","","",""
"29317479","Sex steroids in the tumor microenvironment and prostate cancer progression","Boibessot C, Toren P.","Endocr Relat Cancer. 2018 Mar;25(3):R179-R196. doi: 10.1530/ERC-17-0493. Epub 2018 Jan 9.","Boibessot C","Endocr Relat Cancer","2018","2018/01/11","","","10.1530/ERC-17-0493"
"8678366","Prostate cancer: emerging concepts. Part I","Garnick MB, Fair WR.","Ann Intern Med. 1996 Jul 15;125(2):118-25. doi: 10.7326/0003-4819-125-2-199607150-00008.","Garnick MB","Ann Intern Med","1996","1996/07/15","","","10.7326/0003-4819-125-2-199607150-00008"
"16622122","Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr.","J Natl Cancer Inst. 2006 Apr 19;98(8):529-34. doi: 10.1093/jnci/djj131.","Thompson IM","J Natl Cancer Inst","2006","2006/04/20","","","10.1093/jnci/djj131"
"24985060","microRNA and non-canonical TGF-β signalling: implications for prostate cancer therapy","Ottley E, Gold E.","Crit Rev Oncol Hematol. 2014 Oct;92(1):49-60. doi: 10.1016/j.critrevonc.2014.05.011. Epub 2014 Jun 9.","Ottley E","Crit Rev Oncol Hematol","2014","2014/07/03","","","10.1016/j.critrevonc.2014.05.011"
"18063544","Prostate cancer: a chronic illness","Doyle-Lindrud S.","Clin J Oncol Nurs. 2007 Dec;11(6):857-61. doi: 10.1188/07.CJON.857-861.","Doyle-Lindrud S","Clin J Oncol Nurs","2007","2007/12/08","","","10.1188/07.CJON.857-861"
"28756597","Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence","Norum J, Nieder C.","Pharmacoeconomics. 2017 Dec;35(12):1223-1236. doi: 10.1007/s40273-017-0555-8.","Norum J","Pharmacoeconomics","2017","2017/07/31","","","10.1007/s40273-017-0555-8"
"9436183","Screening for prostate cancer--the European view","","Oncology (Williston Park). 1997 Dec;11(12):1775.","","Oncology (Williston Park)","1997","1998/01/22","","",""
"8201677","Results of conservative management of clinically localized prostate cancer","Walsh PC.","J Urol. 1994 Jul;152(1):255-6.","Walsh PC","J Urol","1994","1994/07/01","","",""
"8367919","Questioning the value of screening for prostate cancer in asymptomatic men","Chodak GW.","Urology. 1993 Aug;42(2):116-8. doi: 10.1016/0090-4295(93)90633-l.","Chodak GW","Urology","1993","1993/08/01","","","10.1016/0090-4295(93)90633-l"
"23763880","Prostate cancer: where we have been, where we are, and where we are going","D'Amico AV.","Semin Radiat Oncol. 2013 Jul;23(3):155-6. doi: 10.1016/j.semradonc.2013.03.001.","D'Amico AV","Semin Radiat Oncol","2013","2013/06/15","","","10.1016/j.semradonc.2013.03.001"
"19544538","Nomograms for staging, prognosis, and predicting treatment outcomes","Touijer K, Scardino PT.","Cancer. 2009 Jul 1;115(13 Suppl):3107-11. doi: 10.1002/cncr.24352.","Touijer K","Cancer","2009","2009/06/23","","","10.1002/cncr.24352"
"16855379","Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy","Sharifi N, Kawasaki BT, Hurt EM, Farrar WL.","Cancer Biol Ther. 2006 Aug;5(8):901-6. doi: 10.4161/cbt.5.8.2949. Epub 2006 Aug 28.","Sharifi N","Cancer Biol Ther","2006","2006/07/21","","","10.4161/cbt.5.8.2949"
"22207968","[An international comparison of epidemiologic factors of prostate cancer]","Hinotsu S.","Nihon Rinsho. 2011 Jun;69 Suppl 5:187-92.","Hinotsu S","Nihon Rinsho","2011","2012/01/03","","",""
"12600219","Health-related quality-of-life assessments in patients with advanced cancer of the prostate","Adolfsson J.","Pharmacoeconomics. 2003;21(4):241-7. doi: 10.2165/00019053-200321040-00002.","Adolfsson J","Pharmacoeconomics","2003","2003/02/26","","","10.2165/00019053-200321040-00002"
"21740733","Biochemical recurrence of prostate cancer: the controversial recognition and management","Xia SJ, Jing YF.","Chin Med J (Engl). 2011 May;124(9):1283-5.","Xia SJ","Chin Med J (Engl)","2011","2011/07/12","","",""
"20685032","The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening","Ficarra V, Novara G, Zattoni F.","Eur Urol. 2010 Oct;58(4):482-4; discussion 484-5. doi: 10.1016/j.eururo.2010.07.025. Epub 2010 Jul 30.","Ficarra V","Eur Urol","2010","2010/08/06","","","10.1016/j.eururo.2010.07.025"
"9616546","Cancer of the prostate. 3: Men's healthcare needs","Peate I.","Br J Nurs. 1998 Mar 12-25;7(5):262-4, 277-9. doi: 10.12968/bjon.1998.7.5.262.","Peate I","Br J Nurs","1998","1998/06/09","","","10.12968/bjon.1998.7.5.262"
"29246732","Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis","Vasavada SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, Moreira DM.","J Urol. 2018 May;199(5):1174-1181. doi: 10.1016/j.juro.2017.11.120. Epub 2017 Dec 12.","Vasavada SR","J Urol","2018","2017/12/17","","","10.1016/j.juro.2017.11.120"
"9750530","[Intraoperative radiotherapy combined with external beam radiation for prostate cancer without metastasis]","Higashi Y, Hyochi N, Tari K.","Nihon Rinsho. 1998 Aug;56(8):2177-80.","Higashi Y","Nihon Rinsho","1998","1998/09/29","","",""
"19487081","Treatment of prostate cancer in unfit senior adult patients","Falci C, Morello E, Droz JP.","Cancer Treat Rev. 2009 Oct;35(6):522-7. doi: 10.1016/j.ctrv.2009.04.014. Epub 2009 May 31.","Falci C","Cancer Treat Rev","2009","2009/06/03","","","10.1016/j.ctrv.2009.04.014"
"25159199","Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer","Iacovelli R, Santoni M, de Braud F, Cascinu S, Procopio G.","Expert Rev Anticancer Ther. 2014 Dec;14(12):1407-9. doi: 10.1586/14737140.2014.953937. Epub 2014 Aug 27.","Iacovelli R","Expert Rev Anticancer Ther","2014","2014/08/28","","","10.1586/14737140.2014.953937"
"12111991","Nuclear matrix proteins as biomarkers in prostate cancer","Leman ES, Getzenberg RH.","J Cell Biochem. 2002;86(2):213-23. doi: 10.1002/jcb.10218.","Leman ES","J Cell Biochem","2002","2002/07/12","","","10.1002/jcb.10218"
"27377159","Prostate cancer: Novel subtyping could aid stratification and therapy","Fenner A.","Nat Rev Urol. 2016 Aug;13(8):434-5. doi: 10.1038/nrurol.2016.130. Epub 2016 Jul 5.","Fenner A","Nat Rev Urol","2016","2016/07/06","","","10.1038/nrurol.2016.130"
"18700283","Treating prostate cancer, Part I: The big picture","","Harv Mens Health Watch. 2008 May;12(10):1-4.","","Harv Mens Health Watch","2008","2008/08/15","","",""
"28724869","[4. Pathology of Prostate Cancer]","Ohnuma H.","Nihon Hoshasen Gijutsu Gakkai Zasshi. 2017;73(7):571-577. doi: 10.6009/jjrt.2017_JSRT_73.7.571.","Ohnuma H","Nihon Hoshasen Gijutsu Gakkai Zasshi","2017","2017/07/21","","","10.6009/jjrt.2017_JSRT_73.7.571"
"10625243","Localised prostate cancer: can we do better? There have been some advances in local control, but little impact on survival","Prior T, Waxman J.","BMJ. 2000 Jan 8;320(7227):69-70. doi: 10.1136/bmj.320.7227.69.","Prior T","BMJ","2000","2000/01/22","PMC1117385","","10.1136/bmj.320.7227.69"
"9187695","Detection of intact prostate cancer cells in the blood of men with prostate cancer","Ts'o PO, Pannek J, Wang ZP, Lesko SA, Bova GS, Partin AW.","Urology. 1997 Jun;49(6):881-5. doi: 10.1016/s0090-4295(97)00157-x.","Ts'o PO","Urology","1997","1997/06/01","","","10.1016/s0090-4295(97)00157-x"
"30919167","Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer","Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.","Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6.","Athie A","Curr Oncol Rep","2019","2019/03/29","","","10.1007/s11912-019-0790-6"
"18020010","[Controversial opinions in the prostate cancer treatment]","Pacík D.","Cas Lek Cesk. 2007;146(10):771-5.","Pacík D","Cas Lek Cesk","2007","2007/11/21","","",""
"31082943","Treating the primary in metastatic prostate cancer: where do we stand?","Nason GJ, Hamilton RJ.","Curr Opin Support Palliat Care. 2019 Sep;13(3):243-248. doi: 10.1097/SPC.0000000000000432.","Nason GJ","Curr Opin Support Palliat Care","2019","2019/05/15","","","10.1097/SPC.0000000000000432"
"11188764","[Malignant prostatic neoplasms in the Czech Republic. Hospital case-control study]","Celko AM, Dánová J, Urban M.","Epidemiol Mikrobiol Imunol. 2000 Nov;49(4):162-4.","Celko AM","Epidemiol Mikrobiol Imunol","2000","2001/02/24","","",""
"18774462","What is the best approach for screen-detected low volume cancers?--The case for observation","Klotz L.","Urol Oncol. 2008 Sep-Oct;26(5):495-9. doi: 10.1016/j.urolonc.2008.03.003.","Klotz L","Urol Oncol","2008","2008/09/09","","","10.1016/j.urolonc.2008.03.003"
"29738188","[Assessment of the physical status of elderly patients with prostate cancer]","Liu BT, Wu B.","Zhonghua Nan Ke Xue. 2017 Dec;23(12):1132-1137.","Liu BT","Zhonghua Nan Ke Xue","2017","2018/05/09","","",""
"12493418","Renal transplantation and prostate cancer: guidelines for screening and treatment","Whang M, Geffner S, Khachikian Z, Kumar A, Bonomini L, Mulgaonkar S.","Transplant Proc. 2002 Dec;34(8):3196-9. doi: 10.1016/s0041-1345(02)03628-x.","Whang M","Transplant Proc","2002","2002/12/21","","","10.1016/s0041-1345(02)03628-x"
"1710531","The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men","Mettlin C, Lee F, Drago J, Murphy GP.","Cancer. 1991 Jun 15;67(12):2949-58. doi: 10.1002/1097-0142(19910615)67:12<2949::aid-cncr2820671202>3.0.co;2-x.","Mettlin C","Cancer","1991","1991/06/15","","","10.1002/1097-0142(19910615)67:12<2949::aid-cncr2820671202>3.0.co;2-x"
"12496976","What's hot in the prostate?","Gleave M, Evans C.","Prostate Cancer Prostatic Dis. 2002;5(3):168-71. doi: 10.1038/sj.pcan.4500618.","Gleave M","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500618"
"15815197","Bibliography. Current world literature. Prostate cancer","","Curr Opin Urol. 2005 May;15(3):197-210.","","Curr Opin Urol","2005","2005/04/09","","",""
"26839141","The role of radical prostatectomy in high-risk localized, node-positive and metastatic prostate cancer","Ristau BT, Cahn D, Uzzo RG, Chapin BF, Smaldone MC.","Future Oncol. 2016 Mar;12(5):687-99. doi: 10.2217/fon.15.355. Epub 2016 Feb 3.","Ristau BT","Future Oncol","2016","2016/02/04","","","10.2217/fon.15.355"
"22504873","Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes","Kakehi Y.","Asian J Androl. 2012 May;14(3):361-4. doi: 10.1038/aja.2011.151. Epub 2012 Apr 16.","Kakehi Y","Asian J Androl","2012","2012/04/17","PMC3720161","","10.1038/aja.2011.151"
"29572798","Clinical Usefulness of the Histoculture Drug Response Assay for Prostate Cancer and Benign Prostate Hypertrophy (BPH)","Hoffman RM.","Methods Mol Biol. 2018;1760:101-107. doi: 10.1007/978-1-4939-7745-1_11.","Hoffman RM","Methods Mol Biol","2018","2018/03/25","","","10.1007/978-1-4939-7745-1_11"
"28188049","Gene Polymorphism-related Individual and Interracial Differences in the Outcomes of Androgen Deprivation Therapy for Prostate Cancer","Fujimoto N, Shiota M, Tomisaki I, Minato A.","Clin Genitourin Cancer. 2017 Jun;15(3):337-342. doi: 10.1016/j.clgc.2017.01.006. Epub 2017 Jan 18.","Fujimoto N","Clin Genitourin Cancer","2017","2017/02/12","","","10.1016/j.clgc.2017.01.006"
"30782686","Prostate care and prostate cancer from the perspectives of undiagnosed men: a systematic review of qualitative research","Kannan A, Kirkman M, Ruseckaite R, Evans SM.","BMJ Open. 2019 Jan 28;9(1):e022842. doi: 10.1136/bmjopen-2018-022842.","Kannan A","BMJ Open","2019","2019/02/21","PMC6352751","","10.1136/bmjopen-2018-022842"
"10633722","How to care for men with prostate cancer","Held-Warmkessel J.","Nursing. 1999 Nov;29(11):51-3. doi: 10.1097/00152193-199911000-00020.","Held-Warmkessel J","Nursing","1999","2000/01/14","","","10.1097/00152193-199911000-00020"
"8262128","Is the outcome of conservative management for localized prostate cancer acceptable? An overview","Chisholm GD, Rana A.","Eur Urol. 1993;24 Suppl 2:64-6. doi: 10.1159/000474393.","Chisholm GD","Eur Urol","1993","1993/01/01","","","10.1159/000474393"
"8863577","Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy","Fowler JE Jr, Terrell FL, Renfroe DL.","J Urol. 1996 Nov;156(5):1714-8.","Fowler JE Jr","J Urol","1996","1996/11/01","","",""
"18185510","Localized prostate cancer is rarely a fatal disease","Scardino PT.","Nat Clin Pract Urol. 2008 Jan;5(1):1. doi: 10.1038/ncpuro1013.","Scardino PT","Nat Clin Pract Urol","2008","2008/01/11","","","10.1038/ncpuro1013"
"24435055","Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications","Singh BH, Gulley JL.","Asian J Androl. 2014 May-Jun;16(3):364-71. doi: 10.4103/1008-682X.122585.","Singh BH","Asian J Androl","2014","2014/01/18","PMC4023361","","10.4103/1008-682X.122585"
"2790688","Prognosis in stage D-1 prostate cancer relative to anatomic sites of nodal metastases. National Prostatic Cancer Treatment Group","Schmidt JD, Gibbons RP, Bartolucci A, Murphy GP.","Cancer. 1989 Oct 15;64(8):1743-6. doi: 10.1002/1097-0142(19891015)64:8<1743::aid-cncr2820640831>3.0.co;2-u.","Schmidt JD","Cancer","1989","1989/10/15","","","10.1002/1097-0142(19891015)64:8<1743::aid-cncr2820640831>3.0.co;2-u"
"2219576","Management of stage A prostate cancer","Smith JA Jr, Cho YH.","Urol Clin North Am. 1990 Nov;17(4):769-77.","Smith JA Jr","Urol Clin North Am","1990","1990/11/01","","",""
"26495726","[New Radiopharmaceuticals Based on Prostate-Specific Inhibitors of Membrane Antigen for Diagnostics and Therapy of Metastatic Prostate Cancer]","Vlasova OP, German KE, Krilov VV, Petriev VM, Epstein NB.","Vestn Ross Akad Med Nauk. 2015;(3):360-5. doi: 10.15690/vramn.v70i3.1334.","Vlasova OP","Vestn Ross Akad Med Nauk","2015","2015/10/27","","","10.15690/vramn.v70i3.1334"
"9170573","Correlation of transrectal ultrasonography and core biopsies with pathology results in radical prostatectomy specimens","Türkeri L, Tarcan T, Biren T, Küllü S, Akdaş A.","Int J Urol. 1996 Nov;3(6):459-61. doi: 10.1111/j.1442-2042.1996.tb00576.x.","Türkeri L","Int J Urol","1996","1996/11/01","","","10.1111/j.1442-2042.1996.tb00576.x"
"26814501","The expanding landscape of diffusion-weighted MRI in prostate cancer","Wibmer AG, Sala E, Hricak H, Vargas HA.","Abdom Radiol (NY). 2016 May;41(5):854-61. doi: 10.1007/s00261-016-0646-6.","Wibmer AG","Abdom Radiol (NY)","2016","2016/01/28","PMC5458420","NIHMS866167","10.1007/s00261-016-0646-6"
"18759700","Androgen receptor: role and novel therapeutic prospects in prostate cancer","Taplin ME.","Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495.","Taplin ME","Expert Rev Anticancer Ther","2008","2008/09/02","","","10.1586/14737140.8.9.1495"
"32481386","Role of long non-coding RNA NEAT1 in the prognosis of prostate cancer patients","Bai J, Huang G.","Medicine (Baltimore). 2020 May 29;99(22):e20204. doi: 10.1097/MD.0000000000020204.","Bai J","Medicine (Baltimore)","2020","2020/06/03","","","10.1097/MD.0000000000020204"
"8982371","Cryoablation for carcinoma of the prostate","Patel BG, Parsons CL, Bidair M, Schmidt JD.","J Surg Oncol. 1996 Dec;63(4):256-64. doi: 10.1002/(SICI)1096-9098(199612)63:4<256::AID-JSO8>3.0.CO;2-B.","Patel BG","J Surg Oncol","1996","1996/12/01","","","10.1002/(SICI)1096-9098(199612)63:4<256::AID-JSO8>3.0.CO;2-B"
"7977655","Prostate cancer progression. Implications of histopathology","Ware JL.","Am J Pathol. 1994 Nov;145(5):983-93.","Ware JL","Am J Pathol","1994","1994/11/01","PMC1887423","",""
"30910515","New prognostic model for prostate cancer","Gourd E.","Lancet Oncol. 2019 Apr;20(4):e198. doi: 10.1016/S1470-2045(19)30185-8. Epub 2019 Mar 22.","Gourd E","Lancet Oncol","2019","2019/03/27","","","10.1016/S1470-2045(19)30185-8"
"15700381","Proceedings from the Prostate Cancer Global Opinion Leaders' Workshop. 28-29 January 2004, Paris, France","","BJU Int. 2004 Dec;94 Suppl 3:1-19.","","BJU Int","2004","2005/02/11","","",""
"8667530","Defining clinically insignificant prostate cancer","Woolf SH.","JAMA. 1996 Jul 3;276(1):28-9.","Woolf SH","JAMA","1996","1996/07/03","","",""
"22425079","Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer","Mullins JK, Han M, Pierorazio PM, Partin AW, Carter HB.","J Urol. 2012 May;187(5):1620-5. doi: 10.1016/j.juro.2011.12.072. Epub 2012 Mar 14.","Mullins JK","J Urol","2012","2012/03/20","","","10.1016/j.juro.2011.12.072"
"31307631","[Optimizing local control of high-risk prostate cancers through multimodal treatments]","Latorzeff I.","Prog Urol. 2019 Jun;29 Suppl 1:S8-S19. doi: 10.1016/S1166-7087(19)30166-6.","Latorzeff I","Prog Urol","2019","2019/07/17","","","10.1016/S1166-7087(19)30166-6"
"15072599","Current status of prostate cancer management in the prostate-specific antigen era","Sartor O.","Clin Prostate Cancer. 2004 Mar;2(4):200-1. doi: 10.3816/cgc.2004.n.001.","Sartor O","Clin Prostate Cancer","2004","2004/04/10","","","10.3816/cgc.2004.n.001"
"8795648","Screening for prostate cancer. Is it a service or a disservice?","Luttge S, Love N.","Postgrad Med. 1996 Sep;100(3):90-2, 95-6, 101-2. doi: 10.3810/pgm.1996.09.71.","Luttge S","Postgrad Med","1996","1996/09/01","","","10.3810/pgm.1996.09.71"
"20874046","The evolving role of familial history for prostate cancer","Colloca G, Venturino A.","Acta Oncol. 2011 Jan;50(1):14-24. doi: 10.3109/0284186X.2010.521191. Epub 2010 Sep 27.","Colloca G","Acta Oncol","2011","2010/09/30","","","10.3109/0284186X.2010.521191"
"8535365","Prostate cancer in Czech Republic 1959-1992. Descriptive survey","Celko AM.","Cent Eur J Public Health. 1995 Aug;3(3):119-23.","Celko AM","Cent Eur J Public Health","1995","1995/08/01","","",""
"22018408","Implications of treatment on body image and quality of life","Harrington JM.","Semin Oncol Nurs. 2011 Nov;27(4):290-9. doi: 10.1016/j.soncn.2011.07.007.","Harrington JM","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.007"
"26666105","LOW RISK PROSTATE CANCER: ACTIVE TREATMENT OR ACTIVE SURVEILLANCE?","Tomašković I.","Acta Clin Croat. 2015 Sep;54(3):337-44.","Tomašković I","Acta Clin Croat","2015","2015/12/16","","",""
"11727520","In situ gene therapy for prostate cancer: immunomodulatory approaches","Thompson TC, Timme TL, Ebara S, Satoh T, Yang G, Wang J, Miles BJ, Ayala G, Wheeler TM, Kadmon D.","Expert Opin Biol Ther. 2001 May;1(3):481-95. doi: 10.1517/14712598.1.3.481.","Thompson TC","Expert Opin Biol Ther","2001","2001/12/01","","","10.1517/14712598.1.3.481"
"9154097","Prostate cancer","Frödin JE.","Acta Oncol. 1996;35 Suppl 7:70-4. doi: 10.3109/02841869609101665.","Frödin JE","Acta Oncol","1996","1996/01/01","","","10.3109/02841869609101665"
"8630231","A glimpse at the future of some endocrine aspects of prostate cancer","Montie JE.","Prostate Suppl. 1996;6:57-61.","Montie JE","Prostate Suppl","1996","1996/01/01","","",""
"12815979","[Is it beneficial to operate a localized prostate cancer?]","Ruutu M, Salo J.","Duodecim. 2003;119(9):821-3.","Ruutu M","Duodecim","2003","2003/06/21","","",""
"3510459","Prostate cancer--some aspects of epidemiology, risk factors, treatment and survival","Walker AR.","S Afr Med J. 1986 Jan 4;69(1):44-7.","Walker AR","S Afr Med J","1986","1986/01/04","","",""
"24914836","Natural history of prostate cancer","Estebanez J, Teyrouz A, Gutierrez MA, Linazasoro I, Belloso J, Cano C, Peralta JM, Sanz JP.","Arch Esp Urol. 2014 Jun;67(5):383-7.","Estebanez J","Arch Esp Urol","2014","2014/06/11","","",""
"28460430","Metabolic heterogeneity signature of primary treatment-naïve prostate cancer","Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y.","Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237.","Lin D","Oncotarget","2017","2017/05/03","PMC5432227","","10.18632/oncotarget.15237"
"16007895","Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease","Routh JC, Leibovich BC.","Mayo Clin Proc. 2005 Jul;80(7):899-907. doi: 10.4065/80.7.899.","Routh JC","Mayo Clin Proc","2005","2005/07/13","","","10.4065/80.7.899"
"21290863","[The urologist at the center of the expected progress on the management of localized prostate cancer!]","Jichlinski P, Iselin C.","Rev Med Suisse. 2010 Dec 8;6(274):2331-2.","Jichlinski P","Rev Med Suisse","2010","2011/02/05","","",""
"21368483","[Radical prostatectomy for high-risk prostate cancer]","Arai Y, Kawamorita N, Kaiho Y, Ishidoya S.","Gan To Kagaku Ryoho. 2011 Feb;38(2):193-6.","Arai Y","Gan To Kagaku Ryoho","2011","2011/03/04","","",""
"31900906","Prostate Cancer Genomic Subtypes","Fraser M, Rouette A.","Adv Exp Med Biol. 2019;1210:87-110. doi: 10.1007/978-3-030-32656-2_5.","Fraser M","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_5"
"3449581","[Clinical and pathological study of prostate cancer using Gleason's classification]","Nemoto R, Uchida K, Kiriyama I, Koiso K, Harada M.","Nihon Gan Chiryo Gakkai Shi. 1987 Dec 20;22(10):2325-30.","Nemoto R","Nihon Gan Chiryo Gakkai Shi","1987","1987/12/20","","",""
"26399721","The role for surgery in high-risk prostate cancer","Lanchon C, F Shariat S, Rouprêt M.","Wien Med Wochenschr. 2015 Oct;165(19-20):395-400. doi: 10.1007/s10354-015-0389-y. Epub 2015 Sep 23.","Lanchon C","Wien Med Wochenschr","2015","2015/09/25","","","10.1007/s10354-015-0389-y"
"7960647","The medical treatment of advanced prostate cancer","O'Reilly E, Crown J.","Ir Med J. 1994 Sep-Oct;87(5):130, 132.","O'Reilly E","Ir Med J","1994","1994/09/01","","",""
"10439165","Measuring quality of life after prostate cancer treatment","Litwin MS.","Cancer J Sci Am. 1999 Jul-Aug;5(4):211-3.","Litwin MS","Cancer J Sci Am","1999","1999/08/10","","",""
"23335024","A novel canine model for prostate cancer","Keller JM, Schade GR, Ives K, Cheng X, Rosol TJ, Piert M, Siddiqui J, Roberts WW, Keller ET.","Prostate. 2013 Jun;73(9):952-9. doi: 10.1002/pros.22642. Epub 2013 Jan 17.","Keller JM","Prostate","2013","2013/01/22","","","10.1002/pros.22642"
"26793881","[The mechanism of progression without androgen receptor interaction in prostate cancer]","Matsuyama H, Matsumoto H.","Nihon Rinsho. 2016 Jan;74(1):60-5.","Matsuyama H","Nihon Rinsho","2016","2016/01/23","","",""
"16474547","Angiogenesis imaging in the management of prostate cancer","Padhani AR, Harvey CJ, Cosgrove DO.","Nat Clin Pract Urol. 2005 Dec;2(12):596-607. doi: 10.1038/ncpuro0356.","Padhani AR","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0356"
"23411385","The role of active surveillance in the management of prostate cancer","Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M.","J Natl Compr Canc Netw. 2013 Feb 1;11(2):183-7. doi: 10.6004/jnccn.2013.0026.","Fung-Kee-Fung SD","J Natl Compr Canc Netw","2013","2013/02/16","","","10.6004/jnccn.2013.0026"
"16417962","Diffusion and economic consequences of health technologies in prostate cancer care in Sweden, 1991-2002","Sennfält K, Carlsson P, Varenhorst E.","Eur Urol. 2006 Jun;49(6):1028-34. doi: 10.1016/j.eururo.2005.12.018. Epub 2006 Jan 6.","Sennfält K","Eur Urol","2006","2006/01/19","","","10.1016/j.eururo.2005.12.018"
"17111715","[Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance]","Leibovici D, Lindner A, Stay K, Zisman A.","Harefuah. 2006 Oct;145(10):763-7, 781, 780.","Leibovici D","Harefuah","2006","2006/11/23","","",""
"24176571","Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013","Williams S, Chiong E, Lojanapiwat B, Umbas R, Akaza H; Asian Oncology Summit 2013.","Lancet Oncol. 2013 Nov;14(12):e524-34. doi: 10.1016/S1470-2045(13)70451-0.","Williams S","Lancet Oncol","2013","2013/11/02","","","10.1016/S1470-2045(13)70451-0"
"1841757","Familial risk factors for prostate cancer","Carter BS, Steinberg GD, Beaty TH, Childs B, Walsh PC.","Cancer Surv. 1991;11:5-13.","Carter BS","Cancer Surv","1991","1991/01/01","","",""
"15369449","Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease","Foley R, Hollywood D, Lawler M.","Endocr Relat Cancer. 2004 Sep;11(3):477-88. doi: 10.1677/erc.1.00699.","Foley R","Endocr Relat Cancer","2004","2004/09/17","","","10.1677/erc.1.00699"
"8066395","[Practical management of localized prostate cancer: surveillance, surgery or radiotherapy]","Le Duc A.","Rev Prat. 1994 Mar 1;44(5):591-3.","Le Duc A","Rev Prat","1994","1994/03/01","","",""
"19623304","Active surveillance or active treatment in localized prostate cancer?","Weissbach L, Altwein J.","Dtsch Arztebl Int. 2009 May;106(22):371-6. doi: 10.3238/arztebl.2009.0371. Epub 2009 May 29.","Weissbach L","Dtsch Arztebl Int","2009","2009/07/23","PMC2704359","","10.3238/arztebl.2009.0371"
"19326658","Early detection the key to prostate cancer","Kirby R.","Practitioner. 2009 Feb;253(1715):17-8, 21-2.","Kirby R","Practitioner","2009","2009/03/31","","",""
"1771720","[The role of radiotherapy in locally limited prostate cancer]","Herr HW.","Urologe A. 1991 Nov;30(6):413-6.","Herr HW","Urologe A","1991","1991/11/01","","",""
"21394176","Biomarker research in prostate cancer--towards utility, not futility","Oon SF, Pennington SR, Fitzpatrick JM, Watson RW.","Nat Rev Urol. 2011 Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11.","Oon SF","Nat Rev Urol","2011","2011/03/12","","","10.1038/nrurol.2011.11"
"29781343","Issues and promises of bevacizumab in prostate cancer treatment","Cereda V, Formica V, Roselli M.","Expert Opin Biol Ther. 2018 Jun;18(6):707-717. doi: 10.1080/14712598.2018.1479737. Epub 2018 May 30.","Cereda V","Expert Opin Biol Ther","2018","2018/05/22","","","10.1080/14712598.2018.1479737"
"24686446","Isolation of cancer stem cells from human prostate cancer samples","Vidal SJ, Quinn SA, de la Iglesia-Vicente J, Bonal DM, Rodriguez-Bravo V, Firpo-Betancourt A, Cordon-Cardo C, Domingo-Domenech J.","J Vis Exp. 2014 Mar 14;(85):51332. doi: 10.3791/51332.","Vidal SJ","J Vis Exp","2014","2014/04/02","PMC4151380","","10.3791/51332"
"16171569","Different approaches of gene therapy used in prostate cancer","Ghosh A.","Cell Mol Biol (Noisy-le-grand). 2005 Sep 2;51(1):103-11.","Ghosh A","Cell Mol Biol (Noisy-le-grand)","2005","2005/09/21","","",""
"12495889","[Surgery or surveillance for limited prostate cancer?]","Vallancien G.","Bull Cancer. 2002 Nov;89(11):992.","Vallancien G","Bull Cancer","2002","2002/12/24","","",""
"16672129","Treatment of radiation failure in prostate cancer","Chin JL, Izawa JI.","Can J Urol. 2006 Apr;13 Suppl 2:48-51.","Chin JL","Can J Urol","2006","2006/05/05","","",""
"22565105","In the middle and on the sideline: the experience of spouses of men with prostate cancer","Ervik B, Nordøy T, Asplund K.","Cancer Nurs. 2013 May-Jun;36(3):E7-E14. doi: 10.1097/NCC.0b013e31824fe1ef.","Ervik B","Cancer Nurs","2013","2012/05/09","","","10.1097/NCC.0b013e31824fe1ef"
"7553490","Hereditary aspects of prostate cancer","McLellan DL, Norman RW.","CMAJ. 1995 Oct 1;153(7):895-900.","McLellan DL","CMAJ","1995","1995/10/01","PMC1487359","",""
"19836968","Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults","Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN.","Crit Rev Oncol Hematol. 2010 Jan;73(1):68-91. doi: 10.1016/j.critrevonc.2009.09.005.","Droz JP","Crit Rev Oncol Hematol","2010","2009/10/20","","","10.1016/j.critrevonc.2009.09.005"
"3334948","Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan","Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M.","Cancer. 1988 Jan 1;61(1):195-202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y.","Soloway MS","Cancer","1988","1988/01/01","","","10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y"
"28303657","What does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?","Mervin MC, Lowe A, Gardiner RA, Smith DP, Aitken J, Chambers SK, Gordon LG.","Asia Pac J Clin Oncol. 2017 Jun;13(3):152-159. doi: 10.1111/ajco.12663. Epub 2017 Mar 16.","Mervin MC","Asia Pac J Clin Oncol","2017","2017/03/18","","","10.1111/ajco.12663"
"9474176","Hospitalization, inpatient physical therapy and institutionalization after hospital discharge of prostate cancer patients in south Florida","Krongrad A, Lai H, Lai S.","J Urol. 1998 Mar;159(3):888-92.","Krongrad A","J Urol","1998","1998/02/25","","",""
"30193761","The Whitmore aphorism","Loughlin KR.","Urol Oncol. 2018 Nov;36(11):473-474. doi: 10.1016/j.urolonc.2018.07.015. Epub 2018 Sep 5.","Loughlin KR","Urol Oncol","2018","2018/09/09","","","10.1016/j.urolonc.2018.07.015"
"19465334","[Epidemiology, diagnosis and prognosis of localized prostate cancer: what's new?]","Drouin SJ, Rouprêt M.","Prog Urol. 2009 Apr;19 Suppl 1:S3-7. doi: 10.1016/S1166-7087(09)73898-9.","Drouin SJ","Prog Urol","2009","2009/05/26","","","10.1016/S1166-7087(09)73898-9"
"22308512","Ten years of progress in prostate cancer","Mohler JL.","J Natl Compr Canc Netw. 2012 Feb;10(2):136-40. doi: 10.6004/jnccn.2012.0016.","Mohler JL","J Natl Compr Canc Netw","2012","2012/02/07","","","10.6004/jnccn.2012.0016"
"30691365","Treatment of Advanced Prostate Cancer","Teo MY, Rathkopf DE, Kantoff P.","Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947.","Teo MY","Annu Rev Med","2019","2019/01/30","PMC6441973","NIHMS1019728","10.1146/annurev-med-051517-011947"
"17179485","Re: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States","Vikram B.","J Natl Cancer Inst. 2006 Dec 20;98(24):1826; author reply 1826. doi: 10.1093/jnci/djj490.","Vikram B","J Natl Cancer Inst","2006","2006/12/21","","","10.1093/jnci/djj490"
"14612999","[From the gene to the clinic: prostate cancer death can now be an exception?]","Labrie F, Cusan L, Gomez JL, Candas B, Bélanger A, Luu-The V, Labrie C, Simard J.","Med Sci (Paris). 2003 Oct;19(10):910-9. doi: 10.1051/medsci/20031910910.","Labrie F","Med Sci (Paris)","2003","2003/11/13","","","10.1051/medsci/20031910910"
"25958817","Expectant management for men with early stage prostate cancer","Filson CP, Marks LS, Litwin MS.","CA Cancer J Clin. 2015 Jul-Aug;65(4):265-82. doi: 10.3322/caac.21278. Epub 2015 May 8.","Filson CP","CA Cancer J Clin","2015","2015/05/12","","","10.3322/caac.21278"
"9411165","[Decreasing number of orchiectomies in prostatic cancer. Results of 9-year registration of the disease are reviewed]","Sandblom G, Dufmats M, Astrand M, Nordenskjöld K, Varenhorst E.","Lakartidningen. 1997 Oct 29;94(44):3966-8, 3971-2, 3975-6.","Sandblom G","Lakartidningen","1997","1997/12/31","","",""
"9414542","The diagnosis, management, treatment and costs of prostate cancer in England and Wales","Chamberlain J, Melia J, Moss S, Brown J.","Health Technol Assess. 1997;1(3):i-vi, 1-53.","Chamberlain J","Health Technol Assess","1997","1997/01/01","","",""
"22901586","Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c-T3b)","Chin JL, Al-Zahrani AA, Autran-Gomez AM, Williams AK, Bauman G.","J Urol. 2012 Oct;188(4):1170-5. doi: 10.1016/j.juro.2012.06.014. Epub 2012 Aug 15.","Chin JL","J Urol","2012","2012/08/21","","","10.1016/j.juro.2012.06.014"
"6841066","Prostate cancer: the paradox of early diagnosis","Mariani AJ, Tom C, Hariharan A, Stams UK.","Hawaii Med J. 1983 Feb;42(2):34-8.","Mariani AJ","Hawaii Med J","1983","1983/02/01","","",""
"19574101","Anti-inflammatory drugs, antioxidants, and prostate cancer prevention","Bardia A, Platz EA, Yegnasubramanian S, De Marzo AM, Nelson WG.","Curr Opin Pharmacol. 2009 Aug;9(4):419-26. doi: 10.1016/j.coph.2009.06.002. Epub 2009 Jul 1.","Bardia A","Curr Opin Pharmacol","2009","2009/07/04","PMC4479123","NIHMS700749","10.1016/j.coph.2009.06.002"
"9743695","Impact of transition zone biopsies in detection and evaluation of prostate cancer","Onder AU, Yalcin V, Arar O, Yaycioglu O, Citci A, Solok V.","Eur Urol. 1998;33(6):542-8. doi: 10.1159/000019653.","Onder AU","Eur Urol","1998","1998/09/23","","","10.1159/000019653"
"9805030","Prostate cancer: 3. Individual risk factors","Gallagher RP, Fleshner N.","CMAJ. 1998 Oct 6;159(7):807-13.","Gallagher RP","CMAJ","1998","1998/11/07","PMC1232741","",""
"24827595","Computer-assisted three-dimensional analysis of multifocal/multicentric prostate cancer","Fujii T, Ishida E, Shimada K, Hirao K, Tanaka N, Fujimoto K, Konishi N.","Cancer Invest. 2014 Aug;32(7):303-10. doi: 10.3109/07357907.2014.911878. Epub 2014 May 14.","Fujii T","Cancer Invest","2014","2014/05/16","","","10.3109/07357907.2014.911878"
"25066872","Impact of family history on prostate cancer mortality in white men undergoing prostate specific antigen based screening","Liss MA, Chen H, Hemal S, Krane S, Kane CJ, Xu J, Kader AK.","J Urol. 2015 Jan;193(1):75-9. doi: 10.1016/j.juro.2014.07.085. Epub 2014 Jul 24.","Liss MA","J Urol","2015","2014/07/29","","","10.1016/j.juro.2014.07.085"
"12932926","Awareness of prostate cancer among the general public: findings of an independent international survey","Schulman CC, Kirby R, Fitzpatrick JM.","Eur Urol. 2003 Sep;44(3):294-302. doi: 10.1016/s0302-2838(03)00200-8.","Schulman CC","Eur Urol","2003","2003/08/23","","","10.1016/s0302-2838(03)00200-8"
"8717215","[Prognostic factor in patients with prostate cancer]","Fujikawa K, Aoyama T, Sasaki M.","Nihon Hinyokika Gakkai Zasshi. 1995 Dec;86(12):1745-50. doi: 10.5980/jpnjurol1989.86.1745.","Fujikawa K","Nihon Hinyokika Gakkai Zasshi","1995","1995/12/01","","","10.5980/jpnjurol1989.86.1745"
"18283297","Prostate cancer: genes, environment, immunity and the use of immunotherapy","Karan D, Thrasher JB, Lubaroff D.","Prostate Cancer Prostatic Dis. 2008;11(3):230-6. doi: 10.1038/pcan.2008.3. Epub 2008 Feb 19.","Karan D","Prostate Cancer Prostatic Dis","2008","2008/02/20","","","10.1038/pcan.2008.3"
"14663465","What's hot in the prostate?","Gleave M, Evans CP.","Prostate Cancer Prostatic Dis. 2003;6(4):268-71. doi: 10.1038/sj.pcan.4500699.","Gleave M","Prostate Cancer Prostatic Dis","2003","2003/12/10","","","10.1038/sj.pcan.4500699"
"26960257","[Early detection or screening in the prevention of prostate cancer?]","Brenes Bermúdez FJ, Alcántara Montero A.","Semergen. 2017 Mar;43(2):100-108. doi: 10.1016/j.semerg.2016.01.014. Epub 2016 Mar 6.","Brenes Bermúdez FJ","Semergen","2017","2016/03/11","","","10.1016/j.semerg.2016.01.014"
"23598987","Recent advances in the management of castration-resistant prostate cancer","George DJ.","Clin Adv Hematol Oncol. 2013 Mar;11(3):181-3.","George DJ","Clin Adv Hematol Oncol","2013","2013/04/20","","",""
"28614092","Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo","Demirci S, Doğan A, Başak Türkmen N, Telci D, Çağlayan AB, Beker MÇ, Kiliç E, Özkan F, Dede B, Şahin F.","Anticancer Drugs. 2017 Sep;28(8):869-879. doi: 10.1097/CAD.0000000000000528.","Demirci S","Anticancer Drugs","2017","2017/06/15","","","10.1097/CAD.0000000000000528"
"7571240","Prostate needle biopsy following radiotherapy for prostate cancer","Kabalin JN.","Urology. 1995 Oct;46(4):603-5. doi: 10.1016/S0090-4295(99)80284-2.","Kabalin JN","Urology","1995","1995/10/01","","","10.1016/S0090-4295(99)80284-2"
"15672937","Changing trends of prostate cancer in Asia","Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J.","Aging Male. 2004 Jun;7(2):120-32. doi: 10.1080/13685530412331284687.","Pu YS","Aging Male","2004","2005/01/28","","","10.1080/13685530412331284687"
"7933232","Expectant management and the natural history of localized prostate cancer","Catalona WJ.","J Urol. 1994 Nov;152(5 Pt 2):1751-2. doi: 10.1016/s0022-5347(17)32377-7.","Catalona WJ","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32377-7"
"20535988","[Clinical value of diffusion-weighted magnetic resonance imaging for localization of prostate cancer--comparison with the step sections of radical prostatectomy]","Hatano K, Tsuda K, Kawamura N, Kakuta Y, Takada T, Adachi S, Hara T, Yamaguchi S.","Nihon Hinyokika Gakkai Zasshi. 2010 May;101(4):603-8. doi: 10.5980/jpnjurol.101.603.","Hatano K","Nihon Hinyokika Gakkai Zasshi","2010","2010/06/12","","","10.5980/jpnjurol.101.603"
"31910165","What chance do we have to decrease prostate cancer overdiagnosis and overtreatment? A narrative review","Ziglioli F, Granelli G, Cavalieri D, Bocchialini T, Maestroni U.","Acta Biomed. 2019 Dec 23;90(4):423-426. doi: 10.23750/abm.v90i4.9070.","Ziglioli F","Acta Biomed","2019","2020/01/08","PMC7233784","","10.23750/abm.v90i4.9070"
"15903036","[The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation]","Bonneux L.","Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):966-71.","Bonneux L","Ned Tijdschr Geneeskd","2005","2005/05/21","","",""
"17786228","The evolving biology and treatment of prostate cancer","Taichman RS, Loberg RD, Mehra R, Pienta KJ.","J Clin Invest. 2007 Sep;117(9):2351-61. doi: 10.1172/JCI31791.","Taichman RS","J Clin Invest","2007","2007/09/06","PMC1952634","","10.1172/JCI31791"
"21475327","Radical prostatectomy--too soon to abandon the perineal approach?","Nargund VH, Zaman F.","Nat Rev Urol. 2011 Apr;8(4):179-80. doi: 10.1038/nrurol.2011.25.","Nargund VH","Nat Rev Urol","2011","2011/04/09","","","10.1038/nrurol.2011.25"
"15976835","[Cryotherapy for prostate cancer]","Johansen TE.","Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1661-3.","Johansen TE","Tidsskr Nor Laegeforen","2005","2005/06/25","","",""
"26965999","Long non-coding RNA: A newly deciphered ""code"" in prostate cancer","Zhang A, Zhang J, Kaipainen A, Lucas JM, Yang H.","Cancer Lett. 2016 Jun 1;375(2):323-330. doi: 10.1016/j.canlet.2016.03.003. Epub 2016 Mar 7.","Zhang A","Cancer Lett","2016","2016/03/12","","","10.1016/j.canlet.2016.03.003"
"22684834","Salvage radiotherapy after high intensity focused ultrasound for prostate cancer","Dickinson P, Sundar S.","BMJ Case Rep. 2012 Jun 8;2012:bcr0320126127. doi: 10.1136/bcr.03.2012.6127.","Dickinson P","BMJ Case Rep","2012","2012/06/12","PMC4542959","","10.1136/bcr.03.2012.6127"
"16018829","Low-risk prostate cancer patient: active treatment","Moul JW, Saad F.","Can J Urol. 2005 Jun;12 Suppl 2:25-7.","Moul JW","Can J Urol","2005","2005/07/16","","",""
"18284065","[Anti-apoptotic effect of the androgen receptor in human prostate cancer]","Shen FY, Li BY.","Zhonghua Nan Ke Xue. 2007 Dec;13(12):1121-4.","Shen FY","Zhonghua Nan Ke Xue","2007","2008/02/21","","",""
"7853551","Prostate cancer: some issues of treatment and tumor behavior","deKernion JB.","J Urol. 1995 Mar;153(3 Pt 2):1032-3. doi: 10.1016/s0022-5347(01)67628-6.","deKernion JB","J Urol","1995","1995/03/01","","","10.1016/s0022-5347(01)67628-6"
"5380261","[Modern therapy of prostate cancer]","Schneider HJ, Hienzsch E, Albert L.","Z Alternsforsch. 1969;22(2):149-54.","Schneider HJ","Z Alternsforsch","1969","1969/01/01","","",""
"21663671","Detection of antibodies directed at M. hyorhinis p37 in the serum of men with newly diagnosed prostate cancer","Urbanek C, Goodison S, Chang M, Porvasnik S, Sakamoto N, Li CZ, Boehlein SK, Rosser CJ.","BMC Cancer. 2011 Jun 10;11:233. doi: 10.1186/1471-2407-11-233.","Urbanek C","BMC Cancer","2011","2011/06/14","PMC3129326","","10.1186/1471-2407-11-233"
"9037283","Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs","Matchar DB, McCrory DC, Bennett CL.","Urology. 1997 Feb;49(2):218-24. doi: 10.1016/S0090-4295(96)00434-7.","Matchar DB","Urology","1997","1997/02/01","","","10.1016/S0090-4295(96)00434-7"
"18456765","Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","Horwich A, Parker C, Kataja V; ESMO Guidelines Working Group.","Ann Oncol. 2008 May;19 Suppl 2:ii45-6. doi: 10.1093/annonc/mdn084.","Horwich A","Ann Oncol","2008","2008/05/09","","","10.1093/annonc/mdn084"
"21378572","The role of PET/computed tomography scan in the management of prostate cancer","Picchio M, Giovannini E, Messa C.","Curr Opin Urol. 2011 May;21(3):230-6. doi: 10.1097/MOU.0b013e328344e556.","Picchio M","Curr Opin Urol","2011","2011/03/08","","","10.1097/MOU.0b013e328344e556"
"9299576","Gene therapy for prostate cancer","Bower M, Waxman J.","Semin Cancer Biol. 1997 Feb;8(1):3-9. doi: 10.1006/scbi.1997.0055.","Bower M","Semin Cancer Biol","1997","1997/02/01","","","10.1006/scbi.1997.0055"
"12932925","Early prostate cancer: prevention, treatment modalities, and quality of life issues","Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulman CC.","Eur Urol. 2003 Sep;44(3):283-93. doi: 10.1016/s0302-2838(03)00296-3.","Moul JW","Eur Urol","2003","2003/08/23","","","10.1016/s0302-2838(03)00296-3"
"17482420","[We must screen prostate cancer in the general population]","Coulange C.","Presse Med. 2007 Jul-Aug;36(7-8):1043-4. doi: 10.1016/j.lpm.2007.03.015. Epub 2007 May 4.","Coulange C","Presse Med","2007","2007/05/08","","","10.1016/j.lpm.2007.03.015"
"7543768","Prostate cancer: a continuum of controversy","Denis LJ.","Eur J Cancer. 1995;31A(5):839-40. doi: 10.1016/0959-8049(95)00112-v.","Denis LJ","Eur J Cancer","1995","1995/01/01","","","10.1016/0959-8049(95)00112-v"
"12109343","Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database","Stephenson RA.","Urol Clin North Am. 2002 Feb;29(1):173-81. doi: 10.1016/s0094-0143(02)00002-2.","Stephenson RA","Urol Clin North Am","2002","2002/07/12","","","10.1016/s0094-0143(02)00002-2"
"29325503","Immunogenetics of prostate cancer: a still unexplored field of study","Dreussi E, Ecca F, Scarabel L, Gagno S, Toffoli G.","Pharmacogenomics. 2018 Feb;19(3):263-283. doi: 10.2217/pgs-2017-0163. Epub 2018 Jan 12.","Dreussi E","Pharmacogenomics","2018","2018/01/13","","","10.2217/pgs-2017-0163"
"20620965","[Update about advanced prostate cancer: diagnosis, treatment and ongoing perspectives]","Drouin SJ, Rouprêt M.","Prog Urol. 2010 Jun;20 Suppl 3:S198-202. doi: 10.1016/S1166-7087(10)70039-7. Epub 2010 Jun 29.","Drouin SJ","Prog Urol","2010","2010/07/13","","","10.1016/S1166-7087(10)70039-7"
"9425324","Prostate cancer facts and fiction","Smart CR.","J Surg Oncol. 1997 Dec;66(4):223-9. doi: 10.1002/(sici)1096-9098(199712)66:4<223::aid-jso1>3.0.co;2-d.","Smart CR","J Surg Oncol","1997","1998/01/13","","","10.1002/(sici)1096-9098(199712)66:4<223::aid-jso1>3.0.co;2-d"
"10176369","Adenocarcinoma of the prostate","Swanson JO.","J Insur Med. 1997;29(3):195-203.","Swanson JO","J Insur Med","1997","1996/12/08","","",""
"18067635","Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention","Shirai T.","Pathol Int. 2008 Jan;58(1):1-16. doi: 10.1111/j.1440-1827.2007.02182.x.","Shirai T","Pathol Int","2008","2007/12/11","","","10.1111/j.1440-1827.2007.02182.x"
"29605444","Performance Characteristics of Transrectal Shear Wave Elastography Imaging in the Evaluation of Clinically Localized Prostate Cancer: A Prospective Study","Wei C, Li C, Szewczyk-Bieda M, Upreti D, Lang S, Huang Z, Nabi G.","J Urol. 2018 Sep;200(3):549-558. doi: 10.1016/j.juro.2018.03.116. Epub 2018 Mar 30.","Wei C","J Urol","2018","2018/04/02","","","10.1016/j.juro.2018.03.116"
"15535443","Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer","Klotz L.","J Urol. 2004 Nov;172(5 Pt 2):S48-50; discussion S50-1. doi: 10.1097/01.ju.0000141712.79986.77.","Klotz L","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000141712.79986.77"
"25609482","[Update on genetic predisposition to prostate cancer]","Cussenot O, Cancel-Tassin G.","Bull Cancer. 2015 Jan;102(1):53-6. doi: 10.1016/j.bulcan.2014.12.007. Epub 2014 Dec 29.","Cussenot O","Bull Cancer","2015","2015/01/23","","","10.1016/j.bulcan.2014.12.007"
"15923436","Hormonotherapy of advanced prostate cancer","Pronzato P, Rondini M.","Ann Oncol. 2005 May;16 Suppl 4:iv80-84. doi: 10.1093/annonc/mdi913.","Pronzato P","Ann Oncol","2005","2005/06/01","","","10.1093/annonc/mdi913"
"9730455","Prostate cancer in the post-transplant population. Urologic Society for Transplantation and Vascular Surgery","Konety BR, Tewari A, Howard RJ, Barry JM, Hodge EE, Taylor R, Jordan ML.","Urology. 1998 Sep;52(3):428-32. doi: 10.1016/s0090-4295(98)00211-8.","Konety BR","Urology","1998","1998/09/08","","","10.1016/s0090-4295(98)00211-8"
"9436284","Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy","Beduschi MC, Beduschi R, Oesterling JE.","World J Urol. 1997;15(6):346-58. doi: 10.1007/BF01300182.","Beduschi MC","World J Urol","1997","1997/01/01","","","10.1007/BF01300182"
"17553368","[Treatment of hormonal refractory metastatic prostate cancer]","Sengeløv L, Klarskov OP, Karlsson S.","Ugeskr Laeger. 2007 May 14;169(20):1905-7.","Sengeløv L","Ugeskr Laeger","2007","2007/06/08","","",""
"11958879","MR imaging for prostate cancer staging: beauty or beast?","Wallner K.","Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):886-7. doi: 10.1016/s0360-3016(01)02737-7.","Wallner K","Int J Radiat Oncol Biol Phys","2002","2002/04/18","","","10.1016/s0360-3016(01)02737-7"
"7823593","Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer","Wheeler TM, Rogers E, Aihara M, Scardino PT, Thompson TC.","J Cell Biochem Suppl. 1994;19:202-7.","Wheeler TM","J Cell Biochem Suppl","1994","1994/01/01","","",""
"9460777","Prostate cancer treatment decisions: a focus group exploration","O'Rourke ME, Germino BB.","Oncol Nurs Forum. 1998 Jan-Feb;25(1):97-104.","O'Rourke ME","Oncol Nurs Forum","1998","1998/02/14","","",""
"20042563","New developments in the medical management of prostate cancer","Kohli M, Tindall DJ.","Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.","Kohli M","Mayo Clin Proc","2010","2010/01/01","PMC2800284","","10.4065/mcp.2009.0442"
"21604933","Screening for prostate cancer: defining critical issues","Holmberg L, Akre O.","Acta Oncol. 2011 Jun;50 Suppl 1:2-3. doi: 10.3109/0284186X.2010.529459.","Holmberg L","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.529459"
"28033149","Partial gland ablation in the management of prostate cancer: a review","McClure TD, Margolis DJ, Hu JC.","Curr Opin Urol. 2017 Mar;27(2):156-160. doi: 10.1097/MOU.0000000000000376.","McClure TD","Curr Opin Urol","2017","2016/12/30","","","10.1097/MOU.0000000000000376"
"26013953","Focal therapy for prostate cancer: current status and future perspectives","Miano R, Asimakopoulos AD, Da Silva RD, Bove P, Jones SJ, De La Rosette JJ, Kim FJ.","Minerva Urol Nefrol. 2015 Sep;67(3):263-80. Epub 2015 May 27.","Miano R","Minerva Urol Nefrol","2015","2015/05/28","","",""
"26072633","Histologic classification of prostate cancer","Mikuz G.","Anal Quant Cytopathol Histpathol. 2015 Feb;37(1):39-47.","Mikuz G","Anal Quant Cytopathol Histpathol","2015","2015/06/16","","",""
"23609043","Prostate cancer overdiagnosis and overtreatment","Klotz L.","Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a.","Klotz L","Curr Opin Endocrinol Diabetes Obes","2013","2013/04/24","","","10.1097/MED.0b013e328360332a"
"11760560","NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer","Carducci MA; NCCN Prostate Cancer practice Guidelines Panel.","Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):62-5.","Carducci MA","Cancer Control","2001","2002/01/05","","",""
"23072827","Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting","Shore ND.","Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 12):1-24.","Shore ND","Clin Adv Hematol Oncol","2012","2012/10/18","","",""
"19997071","Nutraceuticals and prostate cancer prevention: a current review","Trottier G, Boström PJ, Lawrentschuk N, Fleshner NE.","Nat Rev Urol. 2010 Jan;7(1):21-30. doi: 10.1038/nrurol.2009.234. Epub 2009 Dec 8.","Trottier G","Nat Rev Urol","2010","2009/12/10","","","10.1038/nrurol.2009.234"
"20645696","Contemporary treatment of high-risk localized prostate cancer","Tareen B, Kimmel J, Huang WC.","Expert Rev Anticancer Ther. 2010 Jul;10(7):1069-76. doi: 10.1586/era.10.36.","Tareen B","Expert Rev Anticancer Ther","2010","2010/07/22","","","10.1586/era.10.36"
"27680190","[Primary Tumour Treatment in Patients with Metastatic Prostate Cancer]","Steuber T, Beyer B.","Aktuelle Urol. 2016 Sep;47(5):388-94. doi: 10.1055/s-0042-113547. Epub 2016 Sep 28.","Steuber T","Aktuelle Urol","2016","2016/09/30","","","10.1055/s-0042-113547"
"7803726","Epidemiology of early prostate cancer (introduction)","Haas GP.","In Vivo. 1994 May-Jun;8(3):403-5.","Haas GP","In Vivo","1994","1994/05/01","","",""
"29235808","Prostate Cancer","","Aust Nurs Midwifery J. 2014 Nov;22(5):26-8.","","Aust Nurs Midwifery J","2014","2017/12/14","","",""
"18803533","Knowledge and attitudes of men about prostate cancer","Arnold-Reed DE, Hince DA, Bulsara MK, Ngo H, Eaton M, Wright AR, Jones FR, Kaczmarczyk W, Marangou AG, Brett TD.","Med J Aust. 2008 Sep 15;189(6):312-4.","Arnold-Reed DE","Med J Aust","2008","2008/09/23","","",""
"10402318","Treating prostate cancer: An overview","","Harv Mens Health Watch. 1999 Aug;4(1):1-4.","","Harv Mens Health Watch","1999","1999/07/13","","",""
"20421876","Management of prostate cancer in HIV-positive patients","Wosnitzer MS, Lowe FC.","Nat Rev Urol. 2010 Jun;7(6):348-57. doi: 10.1038/nrurol.2010.61. Epub 2010 Apr 27.","Wosnitzer MS","Nat Rev Urol","2010","2010/04/28","","","10.1038/nrurol.2010.61"
"31702061","Disparities in prostate cancer incidence and mortality rates: Solvable or not?","Badal S, Aiken W, Morrison B, Valentine H, Bryan S, Gachii A, Ragin C.","Prostate. 2020 Jan;80(1):3-16. doi: 10.1002/pros.23923. Epub 2019 Nov 8.","Badal S","Prostate","2020","2019/11/09","","","10.1002/pros.23923"
"7533688","Staging prostate cancer","Levy DA, Resnick MI.","Compr Ther. 1994;20(12):665-8.","Levy DA","Compr Ther","1994","1994/01/01","","",""
"27892790","LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality","Fiano V, Zugna D, Grasso C, Trevisan M, Delsedime L, Molinaro L, Gillio-Tos A, Merletti F, Richiardi L.","Epigenetics. 2017 Jan 2;12(1):11-18. doi: 10.1080/15592294.2016.1261786. Epub 2016 Nov 28.","Fiano V","Epigenetics","2017","2016/11/29","PMC5270633","","10.1080/15592294.2016.1261786"
"17030223","MR imaging and MR spectroscopy in prostate cancer management","Katz S, Rosen M.","Radiol Clin North Am. 2006 Sep;44(5):723-34, viii. doi: 10.1016/j.rcl.2006.07.008.","Katz S","Radiol Clin North Am","2006","2006/10/13","","","10.1016/j.rcl.2006.07.008"
"15475939","Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!","Raghavan D.","Br J Cancer. 2004 Sep 13;91(6):1003-4. doi: 10.1038/sj.bjc.6602157.","Raghavan D","Br J Cancer","2004","2004/10/12","PMC2747692","","10.1038/sj.bjc.6602157"
"18406047","The management of category T1a-T1b (incidental) prostate cancer: can we predict who needs treatment?","Adolfsson J.","Eur Urol. 2008 Jul;54(1):16-8. doi: 10.1016/j.eururo.2008.03.099. Epub 2008 Mar 28.","Adolfsson J","Eur Urol","2008","2008/04/15","","","10.1016/j.eururo.2008.03.099"
"24120778","Re: Prostate HistoScanning: a screening tool for prostate cancer?","Taneja SS.","J Urol. 2013 Nov;190(5):1763. doi: 10.1016/j.juro.2013.07.081. Epub 2013 Aug 2.","Taneja SS","J Urol","2013","2013/10/15","","","10.1016/j.juro.2013.07.081"
"19514372","[Poorly differentiated prostate cancer may be associated with cytomegalovirus infection in prostatic tissue]","Andabekov TT, Klochkova TG, Urbanskiĭ AI, Samsonov RB, Shkol'nik MI, Evtushenko VI, Karelin MI.","Vopr Onkol. 2009;55(2):183-6.","Andabekov TT","Vopr Onkol","2009","2009/06/12","","",""
"26094387","[VALUE OF THE -2PROPSA INDEX AND THE PROSTATE HEALTH INDEX IN PATIENTS WITH PROSTATE CANCER: REVIEW OF LITERATURE AND DATA OF RUSSIAN PROSPECTIVE STUDY]","Kolontarev KB, Govorov AV, Osipova TA, Sidorenkov AV, Pushkar DY.","Urologiia. 2015 Jan-Feb;(1):49-53.","Kolontarev KB","Urologiia","2015","2015/06/23","","",""
"21498781","Cigarette smoking and prostate cancer recurrence after prostatectomy","Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, Platz EA.","J Natl Cancer Inst. 2011 May 18;103(10):835-8. doi: 10.1093/jnci/djr124. Epub 2011 Apr 15.","Joshu CE","J Natl Cancer Inst","2011","2011/04/19","PMC3096800","","10.1093/jnci/djr124"
"8967703","Prostate cancer: emerging concepts","Wilt TJ.","Ann Intern Med. 1996 Dec 15;125(12):1014-5. doi: 10.7326/0003-4819-125-12-199612150-00033.","Wilt TJ","Ann Intern Med","1996","1996/12/15","","","10.7326/0003-4819-125-12-199612150-00033"
"8753724","Reflections of a prostate cancer patient","DeHart E.","Urology. 1996 Aug;48(2):171-6; discussion 176-7. doi: 10.1016/S0090-4295(96)00150-1.","DeHart E","Urology","1996","1996/08/01","","","10.1016/S0090-4295(96)00150-1"
"17476554","Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging","Vilanova JC, Barceló J.","Abdom Imaging. 2007 Mar-Apr;32(2):253-61. doi: 10.1007/s00261-007-9191-7.","Vilanova JC","Abdom Imaging","2007","2007/05/04","","","10.1007/s00261-007-9191-7"
"19914774","Re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56:594-605","Friedman AE.","Eur Urol. 2010 Feb;57(2):e16; author reply e17. doi: 10.1016/j.eururo.2009.11.006. Epub 2009 Nov 10.","Friedman AE","Eur Urol","2010","2009/11/17","","","10.1016/j.eururo.2009.11.006"
"7905093","Changes in prostate cancer incidence and treatment in USA","Lu-Yao GL, Greenberg ER.","Lancet. 1994 Jan 29;343(8892):251-4. doi: 10.1016/s0140-6736(94)91109-6.","Lu-Yao GL","Lancet","1994","1994/01/29","","","10.1016/s0140-6736(94)91109-6"
"9687994","What is the prognostic significance of seminal vesicle invasion by prostate cancer?","Guillonneau B, Vallancien G.","Prostate. 1998 Aug 1;36(3):207-8. doi: 10.1002/(sici)1097-0045(19980801)36:3<207::aid-pros10>3.0.co;2-g.","Guillonneau B","Prostate","1998","1998/08/04","","","10.1002/(sici)1097-0045(19980801)36:3<207::aid-pros10>3.0.co;2-g"
"26559104","Meeting the unmet support needs of BME men with prostate cancer","Cremin M.","Br J Nurs. 2015 Nov 12-25;24(20):1010-4. doi: 10.12968/bjon.2015.24.20.1010.","Cremin M","Br J Nurs","2015","2015/11/13","","","10.12968/bjon.2015.24.20.1010"
"17373245","[Active treatment or surveillance in prostate cancer]","Irani J.","Prog Urol. 2007 Feb;17(1):98. doi: 10.1016/s1166-7087(07)92233-2.","Irani J","Prog Urol","2007","2007/03/22","","","10.1016/s1166-7087(07)92233-2"
"30644608","Non-coding and coding genomic variants distinguish prostate cancer, castration-resistant prostate cancer, familial prostate cancer, and metastatic castration-resistant prostate cancer from each other","Alanazi IO, Al Shehri ZS, Ebrahimie E, Giahi H, Mohammadi-Dehcheshmeh M.","Mol Carcinog. 2019 Jun;58(6):862-874. doi: 10.1002/mc.22975. Epub 2019 Jan 31.","Alanazi IO","Mol Carcinog","2019","2019/01/16","","","10.1002/mc.22975"
"25686826","Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer","Böttcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G.","Oncotarget. 2015 Feb 28;6(6):4036-50. doi: 10.18632/oncotarget.2879.","Böttcher R","Oncotarget","2015","2015/02/18","PMC4414171","","10.18632/oncotarget.2879"
"30591352","Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?","Di Lorenzo G, Buonerba C.","Eur Urol. 2019 May;75(5):705-706. doi: 10.1016/j.eururo.2018.12.010. Epub 2018 Dec 24.","Di Lorenzo G","Eur Urol","2019","2018/12/29","","","10.1016/j.eururo.2018.12.010"
"17692174","Counterpoint: the case for immediate active treatment","Loeb S, Catalona WJ.","J Natl Compr Canc Netw. 2007 Aug;5(7):699-702. doi: 10.6004/jnccn.2007.0061.","Loeb S","J Natl Compr Canc Netw","2007","2007/08/19","","","10.6004/jnccn.2007.0061"
"9334617","Prostate cancer 1997--practicing what we preach","Moul JW.","J Urol. 1997 Nov;158(5):1859-60. doi: 10.1016/s0022-5347(01)64146-6.","Moul JW","J Urol","1997","1997/10/23","","","10.1016/s0022-5347(01)64146-6"
"19121370","Oxidative stress-related aging: A role for prostate cancer?","Minelli A, Bellezza I, Conte C, Culig Z.","Biochim Biophys Acta. 2009 Apr;1795(2):83-91. doi: 10.1016/j.bbcan.2008.11.001. Epub 2008 Dec 11.","Minelli A","Biochim Biophys Acta","2009","2009/01/06","","","10.1016/j.bbcan.2008.11.001"
"21986538","Disseminated intravascular coagulation with excessive fibrinolysis in prostate cancer: a case series and review of the literature","Hyman DM, Soff GA, Kampel LJ.","Oncology. 2011;81(2):119-25. doi: 10.1159/000331705. Epub 2011 Oct 6.","Hyman DM","Oncology","2011","2011/10/12","","","10.1159/000331705"
"29335526","Prostate cancer: Race and prostate cancer personalized medicine: the future","Freedland S.","Nat Rev Urol. 2018 Apr;15(4):207-208. doi: 10.1038/nrurol.2017.215. Epub 2018 Jan 16.","Freedland S","Nat Rev Urol","2018","2018/01/17","","","10.1038/nrurol.2017.215"
"19857185","Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design","Madan RA, Mohebtash M, Schlom J, Gulley JL.","Expert Opin Biol Ther. 2010 Jan;10(1):19-28. doi: 10.1517/14712590903321421.","Madan RA","Expert Opin Biol Ther","2010","2009/10/28","PMC6628898","NIHMS1037337","10.1517/14712590903321421"
"17704399","Predicting outcomes in prostate cancer: how many more nomograms do we need?","Ross RW, Kantoff PW.","J Clin Oncol. 2007 Aug 20;25(24):3563-4. doi: 10.1200/JCO.2007.12.2721.","Ross RW","J Clin Oncol","2007","2007/08/21","","","10.1200/JCO.2007.12.2721"
"19141784","Re: Prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian Prostate Cancer Group-4 randomized trial","Schulz RJ, Kagan AR.","J Natl Cancer Inst. 2009 Jan 21;101(2):124. doi: 10.1093/jnci/djn443. Epub 2009 Jan 13.","Schulz RJ","J Natl Cancer Inst","2009","2009/01/15","","","10.1093/jnci/djn443"
"9051145","Race and the histologic grade of prostate cancer","Freeman VL, Leszczak J, Cooper RS.","Prostate. 1997 Feb 1;30(2):79-84. doi: 10.1002/(sici)1097-0045(19970201)30:2<79::aid-pros2>3.0.co;2-f.","Freeman VL","Prostate","1997","1997/02/01","","","10.1002/(sici)1097-0045(19970201)30:2<79::aid-pros2>3.0.co;2-f"
"22765394","Radiotherapy and surgery for high-risk localized prostate cancer: a UK questionnaire survey of urologists and clinical oncologists","Gnanapragasam VJ, Persad R, Payne HA.","BJU Int. 2012 Sep;110(5):608-12. doi: 10.1111/j.1464-410X.2012.11328.x. Epub 2012 Jul 5.","Gnanapragasam VJ","BJU Int","2012","2012/07/07","","","10.1111/j.1464-410X.2012.11328.x"
"16414939","Mortality following prostate cancer recurrence after radical prostectomy","Trainer TD.","JAMA. 2005 Dec 21;294(23):2969; author reply 2969-70. doi: 10.1001/jama.294.23.2969-a.","Trainer TD","JAMA","2005","2006/01/18","","","10.1001/jama.294.23.2969-a"
"9421450","Radiation-based approaches to the management of T3 prostate cancer","Zietman AL, Westgeest JC, Shipley WU.","Semin Urol Oncol. 1997 Nov;15(4):230-8.","Zietman AL","Semin Urol Oncol","1997","1998/01/08","","",""
"25039087","[Active surveillance in prostate cancer. Introduction]","Briones JR.","Arch Esp Urol. 2014 Jun;67(5):367-8.","Briones JR","Arch Esp Urol","2014","2014/07/22","","",""
"10503062","Prostate cancer","Hahnfeld LE, Moon TD.","Med Clin North Am. 1999 Sep;83(5):1231-45, vi. doi: 10.1016/s0025-7125(05)70160-7.","Hahnfeld LE","Med Clin North Am","1999","1999/09/30","","","10.1016/s0025-7125(05)70160-7"
"31629422","Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness","Pritchard CC.","Can J Urol. 2019 Oct;26(5 Suppl 2):24-26.","Pritchard CC","Can J Urol","2019","2019/10/21","","",""
"21604953","Chemoprevention of prostate cancer","Rittmaster RS.","Acta Oncol. 2011 Jun;50 Suppl 1:127-36. doi: 10.3109/0284186X.2010.527367.","Rittmaster RS","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.527367"
"16521506","[Nutrition and physical activity in prevention of prostate cancer]","Kwaśniewska M, Kaleta D, Drygas WK.","Przegl Lek. 2005;62(8):821-4.","Kwaśniewska M","Przegl Lek","2005","2006/03/09","","",""
"7500057","Prostate cancer screening","Lawrence G.","J Fam Pract. 1995 Dec;41(6):536-7.","Lawrence G","J Fam Pract","1995","1995/12/01","","",""
"16521807","[Treatment for cancer specifically diagnosed in high-aged population, prostate cancer]","Miki T.","Nihon Ronen Igakkai Zasshi. 2006 Jan;43(1):71-3. doi: 10.3143/geriatrics.43.71.","Miki T","Nihon Ronen Igakkai Zasshi","2006","2006/03/09","","","10.3143/geriatrics.43.71"
"22189217","[Pros and cons of active surveillance for low-risk prostate cancer]","Chiba K, Akakura K.","Gan To Kagaku Ryoho. 2011 Dec;38(13):2538-41.","Chiba K","Gan To Kagaku Ryoho","2011","2011/12/23","","",""
"19363350","Current Opinion in Urology. Prostate cancer. Current world literature","","Curr Opin Urol. 2009 May;19(3):327-34. doi: 10.1097/MOU.0b013e32832b2192.","","Curr Opin Urol","2009","2009/04/14","","","10.1097/MOU.0b013e32832b2192"
"3050539","Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel","","NCI Monogr. 1988;(7):3-6.","","NCI Monogr","1988","1988/01/01","","",""
"7684455","Prostate cancer rates climbed sharply in 1990","Reynolds T.","J Natl Cancer Inst. 1993 Jun 16;85(12):947-8. doi: 10.1093/jnci/85.12.947.","Reynolds T","J Natl Cancer Inst","1993","1993/06/16","","","10.1093/jnci/85.12.947"
"16101195","Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression","Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I.","Anticancer Res. 2005 Sep-Oct;25(5):3645-9.","Miyake H","Anticancer Res","2005","2005/08/17","","",""
"22018402","Current issues in prostate cancer. Introduction","Kazer MW, Bailey DE Jr.","Semin Oncol Nurs. 2011 Nov;27(4):239-40. doi: 10.1016/j.soncn.2011.07.001.","Kazer MW","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.001"
"17402804","Pharmacoeconomics of available treatment options for metastatic prostate cancer","Zeliadt SB, Penson DF.","Pharmacoeconomics. 2007;25(4):309-27. doi: 10.2165/00019053-200725040-00004.","Zeliadt SB","Pharmacoeconomics","2007","2007/04/04","","","10.2165/00019053-200725040-00004"
"30103901","Molecular correlates of intermediate- and high-risk localized prostate cancer","Ye H, Sowalsky AG.","Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.","Ye H","Urol Oncol","2018","2018/08/15","PMC6093287","NIHMS931865","10.1016/j.urolonc.2017.12.022"
"8886440","Prostate cancer screening: current issues","Prorok PC, Potosky AL, Gohagan JK, Kramer BS.","Cancer Treat Res. 1996;86:93-112. doi: 10.1007/978-1-4613-1265-9_7.","Prorok PC","Cancer Treat Res","1996","1996/01/01","","","10.1007/978-1-4613-1265-9_7"
"17649740","[Frequency of latent prostate cancer in patients with minute adenocarcinoma in a multi-focal biopsy]","Urbanskiĭ AI.","Vopr Onkol. 2007;53(1):84-6.","Urbanskiĭ AI","Vopr Onkol","2007","2007/07/26","","",""
"18262723","Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms","Schröder FH.","Eur Urol. 2008 Jun;53(6):1129-37. doi: 10.1016/j.eururo.2008.01.049. Epub 2008 Jan 28.","Schröder FH","Eur Urol","2008","2008/02/12","","","10.1016/j.eururo.2008.01.049"
"11593906","[Natural disease course in untreated early prostatic carcinoma--the Orebro Study]","Johansson JE.","Praxis (Bern 1994). 2001 Sep 6;90(36):1507-14.","Johansson JE","Praxis (Bern 1994)","2001","2001/10/12","","",""
"1784995","'Local recurrence' and 'disease-free survival'. Doubtful parameters when comparing non-randomized studies of prostate cancer","Steineck G, Adolfsson J, Whitmore WF Jr.","Scand J Urol Nephrol Suppl. 1991;138:121-6.","Steineck G","Scand J Urol Nephrol Suppl","1991","1991/01/11","","",""
"23248095","New strategies in prostate cancer: translating genomics into the clinic","Beltran H, Rubin MA.","Clin Cancer Res. 2013 Feb 1;19(3):517-23. doi: 10.1158/1078-0432.CCR-12-1452. Epub 2012 Dec 17.","Beltran H","Clin Cancer Res","2013","2012/12/19","PMC4123124","NIHMS428484","10.1158/1078-0432.CCR-12-1452"
"21796651","PDEF in prostate cancer","Sood AK, Kim H, Geradts J.","Prostate. 2012 May 1;72(6):592-6. doi: 10.1002/pros.21461. Epub 2011 Jul 27.","Sood AK","Prostate","2012","2011/07/29","","","10.1002/pros.21461"
"19091656","[Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer]","Bolla M, Fourneret P, Descotes JL.","Bull Cancer. 2008 Dec;95(12):1213-8. doi: 10.1684/bdc.2008.0755.","Bolla M","Bull Cancer","2008","2008/12/19","","","10.1684/bdc.2008.0755"
"23758475","Gene panel model predictive of outcome in patients with prostate cancer","Rabiau N, Dantal Y, Guy L, Ngollo M, Dagdemir A, Kemeny JL, Terris B, Vieillefond A, Boiteux JP, Bignon YJ, Bernard-Gallon D.","OMICS. 2013 Aug;17(8):407-13. doi: 10.1089/omi.2012.0124. Epub 2013 Jun 11.","Rabiau N","OMICS","2013","2013/06/14","PMC3727569","","10.1089/omi.2012.0124"
"22367181","Formalized prediction of clinically significant prostate cancer: is it possible?","Nguyen CT, Kattan MW.","Asian J Androl. 2012 May;14(3):349-54. doi: 10.1038/aja.2011.140. Epub 2012 Feb 27.","Nguyen CT","Asian J Androl","2012","2012/02/28","PMC3720158","","10.1038/aja.2011.140"
"14978964","[Future prospects for primary hormone therapy in localized and locally advanced prostate cancer]","Akaza H, Hirao Y, Labrie F, Soloway MS.","Hinyokika Kiyo. 2003 Dec;49(12):771-7.","Akaza H","Hinyokika Kiyo","2003","2004/02/26","","",""
"23448469","Targeted radiosensitization in prostate cancer","Ghotra VP, Geldof AA, Danen EH.","Curr Pharm Des. 2013;19(15):2819-28. doi: 10.2174/1381612811319150017.","Ghotra VP","Curr Pharm Des","2013","2013/03/02","","","10.2174/1381612811319150017"
"22775507","Bevacizumab treatment of prostate cancer","Small AC, Oh WK.","Expert Opin Biol Ther. 2012 Sep;12(9):1241-9. doi: 10.1517/14712598.2012.704015. Epub 2012 Jul 9.","Small AC","Expert Opin Biol Ther","2012","2012/07/11","","","10.1517/14712598.2012.704015"
"15926408","Information from your family doctor. Early prostate cancer: what you should know","American Academy of Family Physicians.","Am Fam Physician. 2005 May 15;71(10):1929-30.","American Academy of Family Physicians","Am Fam Physician","2005","2005/06/02","","",""
"1574456","The management of incidental T1aG1 (TNM 1987) prostate cancer","Soloway MS, Altwein JE.","Prostate Suppl. 1992;4:149-51. doi: 10.1002/pros.2990210524.","Soloway MS","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210524"
"19889065","The relevance of a hypoxic tumour microenvironment in prostate cancer","Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC.","BJU Int. 2010 Jan;105(1):8-13. doi: 10.1111/j.1464-410X.2009.08921.x. Epub 2009 Nov 4.","Stewart GD","BJU Int","2010","2009/11/06","","","10.1111/j.1464-410X.2009.08921.x"
"2029407","Modal DNA-values in prostate cancer patients with deferred therapy or endocrine therapy","Adolfsson J, Tribukait B.","Acta Oncol. 1991;30(2):209-10. doi: 10.3109/02841869109092352.","Adolfsson J","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092352"
"21105126","Genetics of prostate cancer risk","Pomerantz MM, Freedman ML.","Mt Sinai J Med. 2010 Nov-Dec;77(6):643-54. doi: 10.1002/msj.20222.","Pomerantz MM","Mt Sinai J Med","2010","2010/11/25","","","10.1002/msj.20222"
"7526522","Racial differences in adenocarcinoma of the prostate in North American men","Morton RA Jr.","Urology. 1994 Nov;44(5):637-45. doi: 10.1016/s0090-4295(94)80196-7.","Morton RA Jr","Urology","1994","1994/11/01","","","10.1016/s0090-4295(94)80196-7"
"21616444","[News and perspective in management of high-risk prostate cancer]","Audenet F, Rouprêt M.","Prog Urol. 2011 May;21 Suppl 3:S80-3. doi: 10.1016/S1166-7087(11)70018-5.","Audenet F","Prog Urol","2011","2011/05/28","","","10.1016/S1166-7087(11)70018-5"
"30031465","Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making","Duvnjak P, Schulman AA, Holtz JN, Huang J, Polascik TJ, Gupta RT.","Urol Clin North Am. 2018 Aug;45(3):455-466. doi: 10.1016/j.ucl.2018.03.010.","Duvnjak P","Urol Clin North Am","2018","2018/07/23","","","10.1016/j.ucl.2018.03.010"
"26027105","[Progress in the studies of prostate cancer related molecules]","Shi W, Dong L, Bao JS.","Zhonghua Nan Ke Xue. 2015 Apr;21(4):357-62.","Shi W","Zhonghua Nan Ke Xue","2015","2015/06/02","","",""
"24980613","Prognostic value of RASSF1 promoter methylation in prostate cancer","Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F.","J Urol. 2014 Dec;192(6):1849-55. doi: 10.1016/j.juro.2014.06.075. Epub 2014 Jun 26.","Daniunaite K","J Urol","2014","2014/07/02","","","10.1016/j.juro.2014.06.075"
"25903072","Patient comorbidity is associated with conservative treatment of localized prostate cancer","Jespersen CG, Nørgaard M, Jacobsen JB, Borre M.","Scand J Urol. 2015;49(5):366-70. doi: 10.3109/21681805.2015.1026936. Epub 2015 Apr 22.","Jespersen CG","Scand J Urol","2015","2015/04/24","","","10.3109/21681805.2015.1026936"
"12118499","The prevalence of prostate cancer screening in Thai elderly","Tantiwong A, Soontrapa S, Sujijantrarat P, Vanprapar N, Sawangsak L.","J Med Assoc Thai. 2002 Apr;85(4):502-8.","Tantiwong A","J Med Assoc Thai","2002","2002/07/18","","",""
"8709331","Re: Editorial: what to expect from prostate cancer","Hugosson J, Aus G.","J Urol. 1996 Sep;156(3):1138; author reply 1139. doi: 10.1016/s0022-5347(01)65733-1.","Hugosson J","J Urol","1996","1996/09/01","","","10.1016/s0022-5347(01)65733-1"
"8284876","The natural history of early untreated prostate cancer","Lingardh G.","Urology. 1994 Jan;43(1):130. doi: 10.1016/s0090-4295(94)80286-6.","Lingardh G","Urology","1994","1994/01/01","","","10.1016/s0090-4295(94)80286-6"
"30203935","Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies","Jiang Z, Zhao Y, Tian Y.","Minerva Urol Nefrol. 2019 Aug;71(4):373-380. doi: 10.23736/S0393-2249.18.03093-X. Epub 2018 Sep 10.","Jiang Z","Minerva Urol Nefrol","2019","2018/09/12","","","10.23736/S0393-2249.18.03093-X"
"7933246","A critique of the decision analysis for clinically localized prostate cancer","Beck JR, Kattan MW, Miles BJ.","J Urol. 1994 Nov;152(5 Pt 2):1894-9. doi: 10.1016/s0022-5347(17)32409-6.","Beck JR","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32409-6"
"8402485","Radiation therapy for prostate cancer. Long-term results and implications for future advances","Ennis RD, Peschel RE.","Cancer. 1993 Nov 1;72(9):2644-50. doi: 10.1002/1097-0142(19931101)72:9<2644::aid-cncr2820720920>3.0.co;2-n.","Ennis RD","Cancer","1993","1993/11/01","","","10.1002/1097-0142(19931101)72:9<2644::aid-cncr2820720920>3.0.co;2-n"
"16278482","Prostate cancer immunology: biology, therapeutics, and challenges","Webster WS, Small EJ, Rini BI, Kwon ED.","J Clin Oncol. 2005 Nov 10;23(32):8262-9. doi: 10.1200/JCO.2005.03.4595.","Webster WS","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.03.4595"
"9101211","Influence of urological complications on the prognosis of prostate cancer","Colombel M, Mallame W, Abbou CC.","Eur Urol. 1997;31 Suppl 3:21-4. doi: 10.1159/000474556.","Colombel M","Eur Urol","1997","1997/01/01","","","10.1159/000474556"
"7504647","[Prostatic specific antigen--tumor markers in prostate cancer]","Cohen A, Cohen Y.","Harefuah. 1993 Nov 1;125(9):312-5.","Cohen A","Harefuah","1993","1993/11/01","","",""
"19544553","Predictive modeling in prostate cancer. Proceedings of the 2008 European School of Oncology Inside Track Conference","","Cancer. 2009 Jul 1;115(13 Suppl):3035-162. doi: 10.1002/cncr.24455.","","Cancer","2009","2009/06/23","","","10.1002/cncr.24455"
"23636742","Ultrasonography in prostate cancer: current roles and potential applications in radiorecurrent disease","Rosoff JS, Prasad SM, Savage SJ.","World J Urol. 2013 Dec;31(6):1353-9. doi: 10.1007/s00345-013-1080-9. Epub 2013 May 1.","Rosoff JS","World J Urol","2013","2013/05/03","","","10.1007/s00345-013-1080-9"
"10639196","Calcium, lycopene, vitamin D and prostate cancer","Grant WB.","Prostate. 2000 Feb 15;42(3):243. doi: 10.1002/(sici)1097-0045(20000215)42:3<243::aid-pros11>3.0.co;2-u.","Grant WB","Prostate","2000","2000/01/19","","","10.1002/(sici)1097-0045(20000215)42:3<243::aid-pros11>3.0.co;2-u"
"26672779","Prostate cancer","Brody H.","Nature. 2015 Dec 17;528(7582):S117. doi: 10.1038/528S117a.","Brody H","Nature","2015","2015/12/18","","","10.1038/528S117a"
"9541677","Prostate cancer: screening or watchful waiting?","Weyler J.","Ann Oncol. 1998 Jan;9(1):9-11. doi: 10.1023/a:1008267904448.","Weyler J","Ann Oncol","1998","1998/05/30","","","10.1023/a:1008267904448"
"9711412","Racial variation in cancer care: a case study of prostate cancer","Horner RD.","Cancer Treat Res. 1998;97:99-114. doi: 10.1007/978-0-585-30498-4_8.","Horner RD","Cancer Treat Res","1998","1998/08/26","","","10.1007/978-0-585-30498-4_8"
"1622801","Malignant disease of the prostate gland","Marsh M.","Nurs Stand. 1992 May 27-Jun 2;6(36):28-31.","Marsh M","Nurs Stand","1992","1992/05/02","","",""
"23649462","Functional and molecular imaging of localized and recurrent prostate cancer","Grant K, Lindenberg ML, Shebel H, Pang Y, Agarwal HK, Bernardo M, Kurdziel KA, Turkbey B, Choyke PL.","Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1(Suppl 1):S48-59. doi: 10.1007/s00259-013-2419-6. Epub 2013 May 7.","Grant K","Eur J Nucl Med Mol Imaging","2013","2013/05/08","PMC6330105","NIHMS1005088","10.1007/s00259-013-2419-6"
"22429378","Prognostic value of a mitochondrial functional score in prostate cancer","Sun X, Liao NK, Yu JJ.","J Int Med Res. 2012;40(1):371-6. doi: 10.1177/147323001204000139.","Sun X","J Int Med Res","2012","2012/03/21","","","10.1177/147323001204000139"
"18349265","Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases","Schwartz GG.","Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):478-83. doi: 10.1158/1055-9965.EPI-07-2747.","Schwartz GG","Cancer Epidemiol Biomarkers Prev","2008","2008/03/20","","","10.1158/1055-9965.EPI-07-2747"
"27109021","Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals","Bosutti A, Zanconati F, Grassi G, Dapas B, Passamonti S, Scaggiante B.","Anticancer Agents Med Chem. 2016;16(11):1385-1402. doi: 10.2174/1871520616666160425105257.","Bosutti A","Anticancer Agents Med Chem","2016","2016/04/26","PMC5068501","","10.2174/1871520616666160425105257"
"8526199","Patient counseling regarding treatment of T1/2 (A/B) prostate cancer. A personal view","Schellhammer PF.","Am J Clin Oncol. 1995 Dec;18(6):532-7. doi: 10.1097/00000421-199512000-00015.","Schellhammer PF","Am J Clin Oncol","1995","1995/12/01","","","10.1097/00000421-199512000-00015"
"16815663","Salvage radical prostatectomy for radiorecurrent prostate cancer: indications and results","Darras J, Joniau S, Van Poppel H.","Eur J Surg Oncol. 2006 Nov;32(9):964-9. doi: 10.1016/j.ejso.2006.05.015. Epub 2006 Jul 11.","Darras J","Eur J Surg Oncol","2006","2006/07/04","","","10.1016/j.ejso.2006.05.015"
"18536878","Algorithms, nomograms and the detection of indolent prostate cancer","Roobol MJ.","World J Urol. 2008 Oct;26(5):423-9. doi: 10.1007/s00345-008-0278-8. Epub 2008 Jun 7.","Roobol MJ","World J Urol","2008","2008/06/10","","","10.1007/s00345-008-0278-8"
"21698998","Prostate cancer: overview of screening, diagnosis and treatment","Porche D.","Adv NPs PAs. 2011 Jun;2(6):18-21; quiz 22.","Porche D","Adv NPs PAs","2011","2011/06/25","","",""
"16821338","[Management of positive margins after total prostatectomy for localized prostate cancer]","Staerman F, Soulié M, Tostain J, de Fromont M, Davin JL, Coulange C; Sous-Comité Prostate du CCAFU.","Prog Urol. 2006 Jun;16(3):286-91.","Staerman F","Prog Urol","2006","2006/07/11","","",""
"7681843","Managing prostate cancer. Part I: Localized disease","Edelstein RA, Babayan RK.","Hosp Pract (Off Ed). 1993 Apr 15;28(4):61-4, 68-70, 75-8. doi: 10.1080/21548331.1993.11442778.","Edelstein RA","Hosp Pract (Off Ed)","1993","1993/04/15","","","10.1080/21548331.1993.11442778"
"10858902","Salvage radical prostatectomy for radio-recurrent prostate cancer: is this a viable option?","Steinberg GD.","Curr Opin Urol. 2000 May;10(3):229-32. doi: 10.1097/00042307-200005000-00008.","Steinberg GD","Curr Opin Urol","2000","2000/06/20","","","10.1097/00042307-200005000-00008"
"8866197","The management of prostate cancer in blacks: the physician's dilemma intensified","Haynes MA.","Compr Ther. 1996 Jul;22(7):449-53.","Haynes MA","Compr Ther","1996","1996/07/01","","",""
"24485295","[CCAFU Recommendations 2013: Prostate cancer]","Salomon L, Bastide C, Beuzeboc P, Cormier L, Fromont G, Hennequin C, Mongiat-Artus P, Peyromaure M, Ploussard G, Renard-Penna R, Rozet F, Azria D, Coloby P, Molinié V, Ravery V, Rebillard X, Richaud P, Villers A, Soulié M; Les membres du CCAFU.","Prog Urol. 2013 Nov;23 Suppl 2:S69-101. doi: 10.1016/S1166-7087(13)70048-4.","Salomon L","Prog Urol","2013","2014/02/04","","","10.1016/S1166-7087(13)70048-4"
"23806492","Molecular diagnosis of prostate cancer: are we up to age?","Bhavsar T, McCue P, Birbe R.","Semin Oncol. 2013 Jun;40(3):259-75. doi: 10.1053/j.seminoncol.2013.04.002.","Bhavsar T","Semin Oncol","2013","2013/06/29","","","10.1053/j.seminoncol.2013.04.002"
"9302146","Treatment of prostate cancer--a controversial issue","Carter HB.","J Urol. 1997 Oct;158(4):1476. doi: 10.1016/s0022-5347(01)64246-0.","Carter HB","J Urol","1997","1997/09/25","","","10.1016/s0022-5347(01)64246-0"
"9915436","Deferred treatment of locally advanced nonmetastatic prostate cancer: a long-term followup","Adolfsson J, Steineck G, Hedlund PO.","J Urol. 1999 Feb;161(2):505-8.","Adolfsson J","J Urol","1999","1999/01/23","","",""
"10146433","Prostate cancer and prostate-specific antigen: facts, figures and commentary","Chambers DC.","J Insur Med. 1993 Fall;25(3):336-40.","Chambers DC","J Insur Med","1993","1994/03/04","","",""
"19899258","[Palliative surgery for locally advanced prostate cancer]","Raz O, Pisters LL, Spiess PE, Lindner A, Leibovici D.","Harefuah. 2009 Aug;148(8):535-8, 571.","Raz O","Harefuah","2009","2009/11/11","","",""
"30462461","[Relationship between benign prostatic hyperplasia and prostate cancer: new opportunities for prostate cancer chemoprevention]","Bespalov VG, Kuzhanov AA, Vasilieva IN, Semenov AL, Alexandrov VA.","Vopr Onkol. 2016;62(2):360-71.","Bespalov VG","Vopr Onkol","2016","2018/11/22","","",""
"20310055","Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer","Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV.","Cancer. 2010 Jun 1;116(11):2590-5. doi: 10.1002/cncr.24974.","Hoffman KE","Cancer","2010","2010/03/24","","","10.1002/cncr.24974"
"23790256","A computational bioinformatics analysis of gene expression identifies candidate agents for prostate cancer","Wen DY, Geng J, Li W, Guo CC, Zheng JH.","Andrologia. 2014 Aug;46(6):625-32. doi: 10.1111/and.12127. Epub 2013 Jun 24.","Wen DY","Andrologia","2014","2013/06/25","","","10.1111/and.12127"
"17346186","The IGF axis in prostate cancer","Monti S, Proietti-Pannunzi L, Sciarra A, Lolli F, Falasca P, Poggi M, Celi FS, Toscano V.","Curr Pharm Des. 2007;13(7):719-27. doi: 10.2174/138161207780249128.","Monti S","Curr Pharm Des","2007","2007/03/10","","","10.2174/138161207780249128"
"19914392","Transcription factor Stat5a/b as a therapeutic target protein for prostate cancer","Liao Z, Lutz J, Nevalainen MT.","Int J Biochem Cell Biol. 2010 Feb;42(2):186-92. doi: 10.1016/j.biocel.2009.11.001. Epub 2009 Nov 13.","Liao Z","Int J Biochem Cell Biol","2010","2009/11/17","PMC2818495","NIHMS159192","10.1016/j.biocel.2009.11.001"
"7515136","Screening for prostate cancer","Catalona WJ.","Lancet. 1994 Jun 4;343(8910):1437.","Catalona WJ","Lancet","1994","1994/06/04","","",""
"25956920","The need for a personalized approach for prostate cancer management","Sedelaar JP, Schalken JA.","BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.","Sedelaar JP","BMC Med","2015","2015/05/10","PMC4425856","","10.1186/s12916-015-0344-1"
"12027414","Prostate cancer gene therapy and the role of radiation","Kaminski JM, Nguyen K, Buyyounouski M, Pollack A.","Cancer Treat Rev. 2002 Feb;28(1):49-64. doi: 10.1053/ctrv.2002.0250.","Kaminski JM","Cancer Treat Rev","2002","2002/05/25","","","10.1053/ctrv.2002.0250"
"23084534","Urologic Clinics of North America. Castrate-resistant prostate cancer. Foreword","Taneja SS.","Urol Clin North Am. 2012 Nov;39(4):xiii. doi: 10.1016/j.ucl.2012.09.003.","Taneja SS","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.09.003"
"28552708","Recent Changes in Prostate Cancer Screening Practices and Epidemiology","Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ, Barocas DA.","J Urol. 2017 Dec;198(6):1230-1240. doi: 10.1016/j.juro.2017.05.074. Epub 2017 May 25.","Lee DJ","J Urol","2017","2017/05/30","","","10.1016/j.juro.2017.05.074"
"21703040","New findings in localized and advanced prostate cancer: AUA 2011 review","Kazzazi A, Momtahen S, Bruhn A, Hemani M, Ramaswamy K, Djavan B.","Can J Urol. 2011 Jun;18(3):5683-8.","Kazzazi A","Can J Urol","2011","2011/06/28","","",""
"12735501","Screening for prostate cancer","Schröder FH.","Urol Clin North Am. 2003 May;30(2):239-51, viii. doi: 10.1016/s0094-0143(02)00180-5.","Schröder FH","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00180-5"
"27468562","Association of XPC Gene Polymorphisms with Prostate Cancer Risk","Kahnamouei SA, Narouie B, Sotoudeh M, Mollakouchekian MJ, Simforoosh N, Ziaee SA, Samzadeh M, Afshari M, Jamaldini SH, Imeni M, Hasanzad M.","Clin Lab. 2016;62(6):1009-15. doi: 10.7754/clin.lab.2015.150914.","Kahnamouei SA","Clin Lab","2016","2016/07/30","","","10.7754/clin.lab.2015.150914"
"16763406","Peroxisome proliferator-activated receptor-gamma polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction","Zmuda JM, Modugno F, Weissfeld JL, Cauley JA, Trump DL, Moffett SP, Ferrell RE.","Oncology. 2006;70(3):185-9. doi: 10.1159/000093805. Epub 2006 Jun 7.","Zmuda JM","Oncology","2006","2006/06/10","","","10.1159/000093805"
"16006890","Prognostic features in men who died of prostate cancer","Thompson KE, Hernández J, Canby-Hagino ED, Troyer D, Thompson IM.","J Urol. 2005 Aug;174(2):553-6; discussion 556. doi: 10.1097/01.ju.0000165184.72337.9d.","Thompson KE","J Urol","2005","2005/07/12","","","10.1097/01.ju.0000165184.72337.9d"
"20211019","Female partners of patients after surgical prostate cancer treatment: interactions with physicians and support needs","Evertsen JM, Wolkenstein AS.","BMC Fam Pract. 2010 Mar 8;11:19. doi: 10.1186/1471-2296-11-19.","Evertsen JM","BMC Fam Pract","2010","2010/03/10","PMC2843600","","10.1186/1471-2296-11-19"
"31629432","Germline testing for prostate cancer prognosis: implications for active surveillance","Helfand BT, Xu J.","Can J Urol. 2019 Oct;26(5 Suppl 2):48-49.","Helfand BT","Can J Urol","2019","2019/10/21","","",""
"22077660","Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer","Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR.","BJU Int. 2012 Jul;110(1):50-5. doi: 10.1111/j.1464-410X.2011.10704.x. Epub 2011 Nov 11.","Washington SL","BJU Int","2012","2011/11/15","","","10.1111/j.1464-410X.2011.10704.x"
"20818327","Therapeutic targeting of the prostate cancer microenvironment","Karlou M, Tzelepi V, Efstathiou E.","Nat Rev Urol. 2010 Sep;7(9):494-509. doi: 10.1038/nrurol.2010.134.","Karlou M","Nat Rev Urol","2010","2010/09/07","","","10.1038/nrurol.2010.134"
"7692577","Prostate cancer: screening and early detection update","Berger NS.","Semin Oncol Nurs. 1993 Aug;9(3):180-3. doi: 10.1016/s0749-2081(05)80033-6.","Berger NS","Semin Oncol Nurs","1993","1993/08/01","","","10.1016/s0749-2081(05)80033-6"
"12642065","Prostate cancer epidemiology","Grönberg H.","Lancet. 2003 Mar 8;361(9360):859-64. doi: 10.1016/S0140-6736(03)12713-4.","Grönberg H","Lancet","2003","2003/03/19","","","10.1016/S0140-6736(03)12713-4"
"16008113","[Congress of the Association Française d'Urologie (AFU) 2004: prostate cancer management]","Bruyère F, Traxer O.","Ann Urol (Paris). 2005 Apr;39 Suppl 1:S1-15. doi: 10.1016/s0003-4401(05)80001-4.","Bruyère F","Ann Urol (Paris)","2005","2005/07/13","","","10.1016/s0003-4401(05)80001-4"
"15541107","Prostate cancer screening","Catalona WJ.","BJU Int. 2004 Nov;94(7):964-6. doi: 10.1111/j.1464-410X.2004.05187.x.","Catalona WJ","BJU Int","2004","2004/11/16","","","10.1111/j.1464-410X.2004.05187.x"
"9800964","Prostate cancer in the elderly","Kirk D.","Eur J Surg Oncol. 1998 Oct;24(5):379-83. doi: 10.1016/s0748-7983(98)92031-5.","Kirk D","Eur J Surg Oncol","1998","1998/11/04","","","10.1016/s0748-7983(98)92031-5"
"22046617","Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival","Peskin SR.","Manag Care. 2011 Sep;20(9 Suppl 5):3-4, 6-11.","Peskin SR","Manag Care","2011","2011/11/03","","",""
"21871709","Contemporary role of prostate cancer antigen 3 in the management of prostate cancer","Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.","Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25.","Auprich M","Eur Urol","2011","2011/08/30","","","10.1016/j.eururo.2011.08.003"
"21553276","Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU)","Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, Maccagnano C, Liguori G, Valentino M, Battaglia M, Barozzi L.","World J Urol. 2011 Oct;29(5):595-605. doi: 10.1007/s00345-011-0687-y. Epub 2011 May 8.","Martino P","World J Urol","2011","2011/05/10","","","10.1007/s00345-011-0687-y"
"28589400","Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary","Matulay JT, DeCastro GJ.","Curr Urol Rep. 2017 Jul;18(7):53. doi: 10.1007/s11934-017-0703-x.","Matulay JT","Curr Urol Rep","2017","2017/06/08","","","10.1007/s11934-017-0703-x"
"1483259","Early manifestations of induced prostate tumors in Lobund-Wistar rats","Pollard M, Luckert PH.","Cancer Lett. 1992 Dec 24;67(2-3):113-6. doi: 10.1016/0304-3835(92)90133-g.","Pollard M","Cancer Lett","1992","1992/12/24","","","10.1016/0304-3835(92)90133-g"
"15535441","Optimizing hormone therapy in localized prostate cancer: focus on external beam radiotherapy","Sandler HM.","J Urol. 2004 Nov;172(5 Pt 2):S38-41; discussion S41. doi: 10.1097/01.ju.0000141682.27320.c6.","Sandler HM","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000141682.27320.c6"
"16118104","Characteristics of patients with stage T1b incidental prostate cancer","Argyropoulos A, Doumas K, Farmakis A, Aristas O, Kontogeorgos G, Lykourinas M.","Scand J Urol Nephrol. 2005;39(4):289-93. doi: 10.1080/00365590510031200.","Argyropoulos A","Scand J Urol Nephrol","2005","2005/08/25","","","10.1080/00365590510031200"
"9126230","Prostate-specific antigen density","Beduschi MC, Oesterling JE.","Urol Clin North Am. 1997 May;24(2):323-32. doi: 10.1016/s0094-0143(05)70379-7.","Beduschi MC","Urol Clin North Am","1997","1997/05/01","","","10.1016/s0094-0143(05)70379-7"
"17085123","Characteristics of patients with familial versus sporadic prostate cancer","Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ.","J Urol. 2006 Dec;176(6 Pt 1):2438-42; discussion 2442. doi: 10.1016/j.juro.2006.07.159.","Roehl KA","J Urol","2006","2006/11/07","","","10.1016/j.juro.2006.07.159"
"19695936","[Prostate cancer: what role for curative radiotherapy in elderly?]","Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC.","Cancer Radiother. 2009 Oct;13(6-7):623-7. doi: 10.1016/j.canrad.2009.06.013. Epub 2009 Aug 19.","Nguyen TD","Cancer Radiother","2009","2009/08/22","","","10.1016/j.canrad.2009.06.013"
"28952699","[Local recurrence of prostate cancer after radical prostatectomy]","Petrovskii NV, Glybochko PV, Alyaev YG, Amosov AV, Krupinov GE.","Urologiia. 2017 Sep;(4):85-90.","Petrovskii NV","Urologiia","2017","2017/09/28","","",""
"9182381","[Prostatic cancer: an expensive dilemma]","Borre M, Nerstrøm B, Overgaard J.","Ugeskr Laeger. 1997 Apr 21;159(17):2534-7.","Borre M","Ugeskr Laeger","1997","1997/04/21","","",""
"15384004","[Tools for download on prostate cancer]","Schostak M.","Aktuelle Urol. 2004 Sep;35(5):379-80. doi: 10.1055/s-2004-834364.","Schostak M","Aktuelle Urol","2004","2004/09/24","","","10.1055/s-2004-834364"
"8428331","Expanding the definition of quality of life for prostate cancer","Sharp JW.","Cancer. 1993 Feb 1;71(3 Suppl):1078-82. doi: 10.1002/1097-0142(19930201)71:3+<1078::aid-cncr2820711429>3.0.co;2-z.","Sharp JW","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1078::aid-cncr2820711429>3.0.co;2-z"
"28667698","Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition)","Kakehi Y, Sugimoto M, Taoka R; committee for establishment of the evidenced-based clinical practice guideline for prostate cancer of the Japanese Urological Association.","Int J Urol. 2017 Sep;24(9):648-666. doi: 10.1111/iju.13380. Epub 2017 Jul 1.","Kakehi Y","Int J Urol","2017","2017/07/02","","","10.1111/iju.13380"
"10754530","Role of antioxidant systems in human androgen-independent prostate cancer cells","Suzuki Y, Kondo Y, Himeno S, Nemoto K, Akimoto M, Imura N.","Prostate. 2000 May 1;43(2):144-9. doi: 10.1002/(sici)1097-0045(20000501)43:2<144::aid-pros9>3.0.co;2-h.","Suzuki Y","Prostate","2000","2001/02/07","","","10.1002/(sici)1097-0045(20000501)43:2<144::aid-pros9>3.0.co;2-h"
"8547727","Update: prostate cancer screening","Fulton JP, Lindenmayer JM.","R I Med. 1995 Nov;78(11):330-1.","Fulton JP","R I Med","1995","1995/11/01","","",""
"8853482","Facing the challenge of prostate cancer: the family physician's perspective. Patient perspective #1","Poitras JM.","Can J Oncol. 1994 Nov;4 Suppl 1:14-5; discussion 17.","Poitras JM","Can J Oncol","1994","1994/11/01","","",""
"3098758","Management of localized prostate cancer","Bagshaw MA.","Hosp Pract (Off Ed). 1986 Dec 15;21(12):73-88.","Bagshaw MA","Hosp Pract (Off Ed)","1986","1986/12/15","","",""
"15499671","Prostate cancer with low PSA levels","Rocco B, Matei DV, de Cobelli O.","N Engl J Med. 2004 Oct 21;351(17):1802-3.","Rocco B","N Engl J Med","2004","2004/10/23","","",""
"17268397","Role of radiation therapy in the treatment of unfavorable risk prostate cancer","Chan LW, Roach M 3rd.","Minerva Urol Nefrol. 2006 Dec;58(4):321-7.","Chan LW","Minerva Urol Nefrol","2006","2007/02/03","","",""
"21931344","Robotic prostate biopsy and its relevance to focal therapy of prostate cancer","Ho H, Yuen JS, Cheng CW.","Nat Rev Urol. 2011 Sep 20;8(10):579-85. doi: 10.1038/nrurol.2011.131.","Ho H","Nat Rev Urol","2011","2011/09/21","","","10.1038/nrurol.2011.131"
"10422478","[Treatment of advanced prostate cancer]","Leisinger HJ, Jichlinski P.","Rev Med Suisse Romande. 1999 Jun;119(6):507-11.","Leisinger HJ","Rev Med Suisse Romande","1999","1999/07/28","","",""
"8364818","Prostate cancer trends in Canada: rising incidence or increased detection?","Levy IG, Gibbons L, Collins JP, Perkins DG, Mao Y.","CMAJ. 1993 Sep 1;149(5):617-24.","Levy IG","CMAJ","1993","1993/09/01","PMC1486022","",""
"11295591","State of research for prostate cancer: Excerpt from the report of the Prostate Cancer Progress Review Group","Tindall DJ, Scardino PJ.","Urology. 2001 Apr;57(4 Suppl 1):28-30. doi: 10.1016/s0090-4295(00)00932-8.","Tindall DJ","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00932-8"
"14651077","Proceedings of the 3rd International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. November 15-16, 2002, Cambridge, Massachusetts, USA","","J Urol. 2003 Dec;170(6 Pt 2):S1-89; quiz 90-4.","","J Urol","2003","2003/12/04","","",""
"7483149","[Advances in the diagnosis and therapy of prostate cancer. International symposium, 13 March 1993, Vienna]","","Urologe A. 1993 Jul;32(4 Suppl):1-8.","","Urologe A","1993","1993/07/01","","",""
"30262339","Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?","Shinde A, Li R, Glaser S, Amini A.","Eur Urol. 2019 Mar;75(3):355-357. doi: 10.1016/j.eururo.2018.09.017. Epub 2018 Sep 24.","Shinde A","Eur Urol","2019","2018/09/29","","","10.1016/j.eururo.2018.09.017"
"20367409","Salvage cryotherapy: is there a role for focal therapy?","Gowardhan B, Greene D.","J Endourol. 2010 May;24(5):861-4. doi: 10.1089/end.2009.0451.","Gowardhan B","J Endourol","2010","2010/04/07","","","10.1089/end.2009.0451"
"31227054","Radionuclide Therapy of Metastatic Prostate Cancer","Kratochwil C, Haberkorn U, Giesel FL.","Semin Nucl Med. 2019 Jul;49(4):313-325. doi: 10.1053/j.semnuclmed.2019.02.003. Epub 2019 Mar 2.","Kratochwil C","Semin Nucl Med","2019","2019/06/23","","","10.1053/j.semnuclmed.2019.02.003"
"28585762","Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients","Zhao R, Sun F, Bei X, Wang X, Zhu Y, Jiang C, Zhao F, Han B, Xia S.","Prostate. 2017 Jul;77(10):1107-1117. doi: 10.1002/pros.23367. Epub 2017 Jun 6.","Zhao R","Prostate","2017","2017/06/07","","","10.1002/pros.23367"
"9750503","[Efficacy of transrectal ultrasonography in staging prostate cancer]","Soh S, Egawa S.","Nihon Rinsho. 1998 Aug;56(8):2036-41.","Soh S","Nihon Rinsho","1998","1998/09/29","","",""
"11905682","Prostate cancer: to screen or not to screen?","Neal DE, Donovan JL.","Lancet Oncol. 2000 Sep;1(1):17-24. doi: 10.1016/S1470-2045(00)00005-X.","Neal DE","Lancet Oncol","2000","2002/03/22","","","10.1016/S1470-2045(00)00005-X"
"7682002","1992 staging system for prostate cancer","Montie JE.","Semin Urol. 1993 Feb;11(1):10-3.","Montie JE","Semin Urol","1993","1993/02/01","","",""
"25375001","Information for patients. Advanced prostate cancer","","Oncology (Williston Park). 2011 Jul;25(7 Suppl Nurse Ed):2 p. preceding 33.","","Oncology (Williston Park)","2011","2014/11/07","","",""
"7792507","Prostate cancer: the pros and cons of treatment","Greifzu S, Tiedemann D.","RN. 1995 Jun;58(6):22-6; quiz 27.","Greifzu S","RN","1995","1995/06/01","","",""
"22736235","The prostate cancer conundrum revisited: further insights","Albertsen P.","Cancer. 2012 Dec 1;118(23):5724-7. doi: 10.1002/cncr.27718. Epub 2012 Jun 26.","Albertsen P","Cancer","2012","2012/06/28","","","10.1002/cncr.27718"
"26411411","EN2 in Prostate Cancer","McGrath SE, Michael A, Morgan R, Pandha H.","Adv Clin Chem. 2015;71:47-76. doi: 10.1016/bs.acc.2015.06.002. Epub 2015 Jul 21.","McGrath SE","Adv Clin Chem","2015","2015/09/29","","","10.1016/bs.acc.2015.06.002"
"28557396","[Age peculiarities in prostate cancer detection based on the prostate-specific antigen and its alterations control]","Ponkratov SV, Kheyfets VK, Kagan OF.","Adv Gerontol. 2017;30(1):92-97.","Ponkratov SV","Adv Gerontol","2017","2017/05/31","","",""
"27771734","Clinicopathological and Prognostic Factors in 106 Prostate Cancer Patients Aged ≤55 Years: A Single-Center Study in China","Xu Y, Yang X, Si T, Yu H, Zhang W, Li Y, Guo Z.","Med Sci Monit. 2016 Oct 23;22:3935-3942. doi: 10.12659/msm.901040.","Xu Y","Med Sci Monit","2016","2016/10/25","PMC5081234","","10.12659/msm.901040"
"525072","[Recommendations for the diagnosis and therapy of prostate cancer]","Rockstroh H.","Z Urol Nephrol. 1979 Jul;72(12):515-6.","Rockstroh H","Z Urol Nephrol","1979","1979/07/01","","",""
"29786787","Protocols for Migration and Invasion Studies in Prostate Cancer","van de Merbel AF, van der Horst G, Buijs JT, van der Pluijm G.","Methods Mol Biol. 2018;1786:67-79. doi: 10.1007/978-1-4939-7845-8_4.","van de Merbel AF","Methods Mol Biol","2018","2018/05/23","","","10.1007/978-1-4939-7845-8_4"
"29742084","First-line use of novel hormonal agents in prostate cancer: a critical appraisal","Raghavan D.","Clin Adv Hematol Oncol. 2018 Apr;16(4):289-295.","Raghavan D","Clin Adv Hematol Oncol","2018","2018/05/10","","",""
"18374472","Editorial comment on: evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy","Cagiannos I.","Eur Urol. 2008 Dec;54(6):1361-2. doi: 10.1016/j.eururo.2008.02.036. Epub 2008 Mar 10.","Cagiannos I","Eur Urol","2008","2008/04/01","","","10.1016/j.eururo.2008.02.036"
"1699956","Therapeutic progress--review XXXVIII. Are we making progress in the treatment of prostate cancer?","Carr TW.","J Clin Pharm Ther. 1990 Aug;15(4):247-55. doi: 10.1111/j.1365-2710.1990.tb00382.x.","Carr TW","J Clin Pharm Ther","1990","1990/08/01","","","10.1111/j.1365-2710.1990.tb00382.x"
"12722880","Chemoprevention of prostate cancer","Ward JF, Blute ML.","Expert Rev Anticancer Ther. 2003 Apr;3(2):203-14. doi: 10.1586/14737140.3.2.203.","Ward JF","Expert Rev Anticancer Ther","2003","2003/05/02","","","10.1586/14737140.3.2.203"
"23680106","Locally advanced prostate cancer: current controversies and optimisation opportunities","Sridharan S, Dal Pra A, Catton C, Bristow RG, Warde P.","Clin Oncol (R Coll Radiol). 2013 Aug;25(8):499-505. doi: 10.1016/j.clon.2013.04.004. Epub 2013 May 13.","Sridharan S","Clin Oncol (R Coll Radiol)","2013","2013/05/18","","","10.1016/j.clon.2013.04.004"
"23351141","Radiosensitization in prostate cancer: mechanisms and targets","Palacios DA, Miyake M, Rosser CJ.","BMC Urol. 2013 Jan 26;13:4. doi: 10.1186/1471-2490-13-4.","Palacios DA","BMC Urol","2013","2013/01/29","PMC3583813","","10.1186/1471-2490-13-4"
"11588831","New insights and methodologies are needed to solve the many epidemiologic enigmas of prostate cancer","Coffey DS.","Epidemiol Rev. 2001;23(1):1. doi: 10.1093/oxfordjournals.epirev.a000772.","Coffey DS","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000772"
"15124488","[Prostate cancer: view of the horizon]","Dauriac P.","Rev Infirm. 2004 Mar;(99):18-9.","Dauriac P","Rev Infirm","2004","2004/05/06","","",""
"19661347","New molecular biomarkers for the prognosis and management of prostate cancer--the post PSA era","Bickers B, Aukim-Hastie C.","Anticancer Res. 2009 Aug;29(8):3289-98.","Bickers B","Anticancer Res","2009","2009/08/08","","",""
"22710832","Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram","Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA.","Prostate Cancer Prostatic Dis. 2012 Dec;15(4):374-9. doi: 10.1038/pcan.2012.21. Epub 2012 Jun 19.","Kutikov A","Prostate Cancer Prostatic Dis","2012","2012/06/20","PMC3815610","NIHMS520183","10.1038/pcan.2012.21"
"27534689","Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective","Monn MF, Cheng L.","Expert Rev Anticancer Ther. 2016 Oct;16(10):1029-37. doi: 10.1080/14737140.2016.1226137. Epub 2016 Aug 26.","Monn MF","Expert Rev Anticancer Ther","2016","2016/08/19","","","10.1080/14737140.2016.1226137"
"12816012","Prostate cancer--testing, incidence, surgery and mortality","Gibbons L, Waters C.","Health Rep. 2003 May;14(3):9-20.","Gibbons L","Health Rep","2003","2003/06/21","","",""
"10504670","The surgery of prostate cancer: An update of contemporary radical prostatectomy and brachytherapy series","Krumholtz JS, Andriole GL.","Semin Surg Oncol. 1999 Oct-Nov;17(3):213-8. doi: 10.1002/(sici)1098-2388(199910/11)17:3<213::aid-ssu11>3.0.co;2-p.","Krumholtz JS","Semin Surg Oncol","1999","1999/10/03","","","10.1002/(sici)1098-2388(199910/11)17:3<213::aid-ssu11>3.0.co;2-p"
"22889793","A case of multimodality multiparametric 11C-choline PET/MR for biopsy targeting in prior biopsy-negative primary prostate cancer","Takei T, Souvatzoglou M, Beer AJ, Drzezga A, Ziegler S, Rummeny EJ, Schwaiger M, Eiber M.","Clin Nucl Med. 2012 Sep;37(9):918-9. doi: 10.1097/RLU.0b013e31825b23a6.","Takei T","Clin Nucl Med","2012","2012/08/15","","","10.1097/RLU.0b013e31825b23a6"
"31047869","Piperine blocks voltage gated K(+) current and inhibits proliferation in androgen sensitive and insensitive human prostate cancer cell lines","George K, Thomas NS, Malathi R.","Arch Biochem Biophys. 2019 May 30;667:36-48. doi: 10.1016/j.abb.2019.04.007. Epub 2019 Apr 29.","George K","Arch Biochem Biophys","2019","2019/05/04","","","10.1016/j.abb.2019.04.007"
"23757912","[Immunotherapy: a therapeutic revolution against prostate cancer?]","Pracht M, Herrera F, Tawadros T, Berthold D.","Rev Med Suisse. 2013 May 22;9(387):1070-5.","Pracht M","Rev Med Suisse","2013","2013/06/14","","",""
"26370606","Prostate cancer: AS-contemplation, not intervention","Fenner A.","Nat Rev Clin Oncol. 2015 Nov;12(11):623. doi: 10.1038/nrclinonc.2015.160. Epub 2015 Sep 15.","Fenner A","Nat Rev Clin Oncol","2015","2015/09/16","","","10.1038/nrclinonc.2015.160"
"24750975","Histopathological characteristics of microfocal prostate cancer detected during systematic prostate biopsy","Guttilla A, Zazzara M, Zattoni F, Novara G, Zanin M, Gardiman M, Ficarra V, Zattoni F.","BJU Int. 2015 Aug;116(2):202-6. doi: 10.1111/bju.12786. Epub 2015 Mar 12.","Guttilla A","BJU Int","2015","2014/04/23","","","10.1111/bju.12786"
"18226472","Multidimensional approaches in dealing with prostate cancer","Ali S, Ali S.","Gene. 2008 Feb 29;410(1):1-8. doi: 10.1016/j.gene.2007.11.020. Epub 2007 Dec 14.","Ali S","Gene","2008","2008/01/30","","","10.1016/j.gene.2007.11.020"
"25831274","Cyberknife treatment for low and intermediate risk prostate cancer","Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Cataldo V, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L.","Cancer Invest. 2015 May;33(5):188-92. doi: 10.3109/07357907.2015.1019679. Epub 2015 Apr 1.","Detti B","Cancer Invest","2015","2015/04/02","","","10.3109/07357907.2015.1019679"
"20299055","Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity","Powell IJ, Bock CH, Ruterbusch JJ, Sakr W.","J Urol. 2010 May;183(5):1792-6. doi: 10.1016/j.juro.2010.01.015. Epub 2010 Mar 17.","Powell IJ","J Urol","2010","2010/03/20","PMC3840791","NIHMS511893","10.1016/j.juro.2010.01.015"
"15069310","Update on hormone-refractory prostate cancer","Kasamon KM, Dawson NA.","Curr Opin Urol. 2004 May;14(3):185-93. doi: 10.1097/00042307-200405000-00008.","Kasamon KM","Curr Opin Urol","2004","2004/04/08","","","10.1097/00042307-200405000-00008"
"27527923","PET imaging of recurrent and metastatic prostate cancer with novel tracers","Mertan FV, Lindenberg L, Choyke PL, Turkbey B.","Future Oncol. 2016 Nov;12(21):2463-2477. doi: 10.2217/fon-2016-0270. Epub 2016 Aug 16.","Mertan FV","Future Oncol","2016","2016/08/17","PMC5066117","","10.2217/fon-2016-0270"
"15739207","Estimated impact of the Prostate Cancer Prevention Trial on population mortality","Unger JM, Thompson IM Jr, LeBlanc M, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr.","Cancer. 2005 Apr 1;103(7):1375-80. doi: 10.1002/cncr.20919.","Unger JM","Cancer","2005","2005/03/02","","","10.1002/cncr.20919"
"17628024","Prostate cancer: palliative care and pain relief","Thompson JC, Wood J, Feuer D.","Br Med Bull. 2007;83:341-54. doi: 10.1093/bmb/ldm018. Epub 2007 Jul 12.","Thompson JC","Br Med Bull","2007","2007/07/14","","","10.1093/bmb/ldm018"
"7529409","Screening for prostate cancer","Waldman AR, Osborne DM.","Oncol Nurs Forum. 1994 Oct;21(9):1513-7.","Waldman AR","Oncol Nurs Forum","1994","1994/10/01","","",""
"17492410","[Radiotherapy for prostate cancer]","Stanek C.","Wien Med Wochenschr. 2007;157(7-8):149-52. doi: 10.1007/s10354-007-0404-z.","Stanek C","Wien Med Wochenschr","2007","2007/05/12","","","10.1007/s10354-007-0404-z"
"9919111","Epidemiology of prostate cancer in two European countries: Scotland and Norway","Galletly C, Whyte F.","Eur J Cancer Care (Engl). 1998 Dec;7(4):240-6. doi: 10.1046/j.1365-2354.1998.00104.x.","Galletly C","Eur J Cancer Care (Engl)","1998","1999/01/27","","","10.1046/j.1365-2354.1998.00104.x"
"22246942","Explaining racial differences in prostate cancer mortality","Taksler GB, Keating NL, Cutler DM.","Cancer. 2012 Sep 1;118(17):4280-9. doi: 10.1002/cncr.27379. Epub 2012 Jan 13.","Taksler GB","Cancer","2012","2012/01/17","","","10.1002/cncr.27379"
"27344760","[Pathology of the prostate cancer: present conditions and future prospects]","Miyagi Y.","Nihon Rinsho. 2016 May 20;74 Suppl 3:374-8.","Miyagi Y","Nihon Rinsho","2016","2016/06/28","","",""
"20428221","Radiotherapy: Secondary malignancies after prostate cancer treatment","Moul JW.","Nat Rev Clin Oncol. 2010 May;7(5):249-50. doi: 10.1038/nrclinonc.2010.59.","Moul JW","Nat Rev Clin Oncol","2010","2010/04/30","","","10.1038/nrclinonc.2010.59"
"31158106","Clinical implications of genetic aberrations in metastatic prostate cancer","Reichert ZR, McKay RR.","Curr Opin Urol. 2019 Jul;29(4):319-325. doi: 10.1097/MOU.0000000000000647.","Reichert ZR","Curr Opin Urol","2019","2019/06/04","","","10.1097/MOU.0000000000000647"
"20222795","Effect of the number of biopsy cores on prostate cancer detection and staging","Lughezzani G, Sun M, Budäus L, Thuret R, Shariat SF, Perrotte P, Karakiewicz PI.","Future Oncol. 2010 Mar;6(3):381-90. doi: 10.2217/fon.10.4.","Lughezzani G","Future Oncol","2010","2010/03/13","","","10.2217/fon.10.4"
"24053777","The transcriptional programme of the androgen receptor (AR) in prostate cancer","Lamb AD, Massie CE, Neal DE.","BJU Int. 2014 Mar;113(3):358-66. doi: 10.1111/bju.12415.","Lamb AD","BJU Int","2014","2013/09/24","","","10.1111/bju.12415"
"31822000","miR-1231 Is Downregulated in Prostate Cancer with Prognostic and Functional Implications","Wang Y, Zhang Q, Guo B, Feng J, Zhao D.","Oncol Res Treat. 2020;43(3):78-86. doi: 10.1159/000504606. Epub 2019 Dec 10.","Wang Y","Oncol Res Treat","2020","2019/12/11","","","10.1159/000504606"
"10210420","Re: Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy","Kupelian PA, Klein EA, Witte JS.","J Urol. 1999 May;161(5):1585-6. doi: 10.1016/s0022-5347(05)68984-7.","Kupelian PA","J Urol","1999","1999/04/21","","","10.1016/s0022-5347(05)68984-7"
"28247663","[Radical prostatectomy in patients with incident prostate cancer]","Alyaev YG, Rapoport LM, Enikeev ME, Bezrukov ES, Shpot EV, Korolev DO, Fokin IV, Marisov LV.","Urologiia. 2016 Apr;(2):63-66.","Alyaev YG","Urologiia","2016","2017/03/02","","",""
"21720833","[Information needs of patients with prostate cancer. Pronounced differences between individuals after diagnosis of localised prostate carcinoma]","Schaffert R, Rüesch P, Gügler R, Fischer S, Schmid HP, Spörri P, Zurkirchen M, Ruszat R.","Urologe A. 2011 Sep;50(9):1089-94. doi: 10.1007/s00120-011-2626-3.","Schaffert R","Urologe A","2011","2011/07/02","","","10.1007/s00120-011-2626-3"
"1992572","Future developments of nonhormonal systemic therapy for prostatic carcinoma","Warner JA, Heston WD.","Urol Clin North Am. 1991 Feb;18(1):25-33.","Warner JA","Urol Clin North Am","1991","1991/02/01","","",""
"15062187","Ultrasonic spectrum-analysis and neural-network classification as a basis for ultrasonic imaging to target brachytherapy of prostate cancer","Feleppa EJ, Ennis RD, Schiff PB, Wuu CS, Kalisz A, Ketterling J, Urban S, Liu T, Fair WR, Porter CR, Gillespie JR.","Brachytherapy. 2002;1(1):48-53. doi: 10.1016/s1538-4721(02)00002-8.","Feleppa EJ","Brachytherapy","2002","2004/04/06","","","10.1016/s1538-4721(02)00002-8"
"23490232","Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy","Meeks JJ, Walker M, Bernstein M, Kent M, Eastham JA.","BJU Int. 2013 Aug;112(3):308-12. doi: 10.1111/bju.12015. Epub 2013 Mar 13.","Meeks JJ","BJU Int","2013","2013/03/16","","","10.1111/bju.12015"
"22052762","Focal therapy for clinically localized prostate cancer","Marchetti P, Eggener S.","Arch Esp Urol. 2011 Oct;64(8):815-22.","Marchetti P","Arch Esp Urol","2011","2011/11/05","","",""
"20206022","Response to ""Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy"" (Int J Radiat Oncol Biol Phys 2009, in press)","Froehner M, Koch R, Litz RJ, Wirth MP.","Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1274. doi: 10.1016/j.ijrobp.2009.11.052.","Froehner M","Int J Radiat Oncol Biol Phys","2010","2010/03/09","","","10.1016/j.ijrobp.2009.11.052"
"2029418","Adjuvant cytotoxic chemotherapy in association with radical surgery or radical radiation treatment in presumably localized prostatic cancer","Chatelain C.","Acta Oncol. 1991;30(2):259-62. doi: 10.3109/02841869109092365.","Chatelain C","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092365"
"7515137","Screening for prostate cancer","Karnauchow PN.","Lancet. 1994 Jun 4;343(8910):1437-8.","Karnauchow PN","Lancet","1994","1994/06/04","","",""
"20493449","[What's new in 2009 in prostate cancer: highlights from ASTRO, EAU, ASCO and AUA meetings]","Salomon L, Peyromaure M, Mongiat-Artus P, Roset F, Gachignard N, Bastide C, Richaud P, Beuzeboc P, Cornud F, Molinié V, Soulié M, Benchikh El Fegoun A; les membres du CC-AFU.","Prog Urol. 2010 Mar;20 Suppl 1:S61-7. doi: 10.1016/S1166-7087(10)70030-0.","Salomon L","Prog Urol","2010","2010/05/25","","","10.1016/S1166-7087(10)70030-0"
"21789810","Prostate cancer progression and obesity are linked. Men who are overweight or obese who have prostate cancer have an elevated risk of cancer progression compared to normal-weight men","","Duke Med Health News. 2011 Jul;17(7):4-5.","","Duke Med Health News","2011","2011/07/28","","",""
"12756084","Salvage radical prostatectomy for recurrence of prostate cancer after radiation therapy","Eastham JA, DiBlasio CJ, Scardino PT.","Curr Urol Rep. 2003 Jun;4(3):211-5. doi: 10.1007/s11934-003-0071-6.","Eastham JA","Curr Urol Rep","2003","2003/05/21","","","10.1007/s11934-003-0071-6"
"12534312","Value of endocrine therapy for early and locally advanced prostate cancer","Wirth MP, Froehner M.","Drugs Aging. 2003;20(2):115-24. doi: 10.2165/00002512-200320020-00003.","Wirth MP","Drugs Aging","2003","2003/01/22","","","10.2165/00002512-200320020-00003"
"10078642","Defining the implant treatment volume for patients with low risk prostate cancer: does the anterior base need to be treated?","D'Amico AV, Davis A, Vargas SO, Renshaw AA, Jiroutek M, Richie JP.","Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):587-90. doi: 10.1016/s0360-3016(98)00434-9.","D'Amico AV","Int J Radiat Oncol Biol Phys","1999","1999/03/17","","","10.1016/s0360-3016(98)00434-9"
"20088118","[Active surveillance for early-stage prostate cancer]","Jichlinski P, Berthold DR, Zouhair A, Griesser AC, Meuwly JY, Prior JO, Lhermitte B, Doerfler A, Treuthardt C, Praz V, Tawadros T, Vaucher L, Aymon D, Marazzi A, Levi F, Beckmann J, Leyvraz S, Bauer J.","Rev Med Suisse. 2009 Dec 2;5(228):2442-4, 2446-7.","Jichlinski P","Rev Med Suisse","2009","2010/01/22","","",""
"27825430","Is There Use for FDG-PET in Prostate Cancer?","Jadvar H.","Semin Nucl Med. 2016 Nov;46(6):502-506. doi: 10.1053/j.semnuclmed.2016.07.004. Epub 2016 Sep 3.","Jadvar H","Semin Nucl Med","2016","2016/11/10","PMC5119923","NIHMS803237","10.1053/j.semnuclmed.2016.07.004"
"11186506","Prostate cancer patients blindsided by side effects","","J Oncol Manag. 2000 Jul-Aug;9(4):10-2.","","J Oncol Manag","2000","2001/02/24","","",""
"3916055","Transrectal ultrasonography of the prostate and prostate cancer--an update","Huben RP, Murphy GP.","Appl Pathol. 1985;3(4):198-205.","Huben RP","Appl Pathol","1985","1985/01/01","","",""
"27825427","Guest Editorial-Prostate Cancer","Bouchelouche K.","Semin Nucl Med. 2016 Nov;46(6):482-483. doi: 10.1053/j.semnuclmed.2016.07.010. Epub 2016 Sep 3.","Bouchelouche K","Semin Nucl Med","2016","2016/11/10","","","10.1053/j.semnuclmed.2016.07.010"
"15714970","[Clinical and pathological staging of prostate cancer]","Tobisu K.","Nihon Rinsho. 2005 Feb;63(2):225-30.","Tobisu K","Nihon Rinsho","2005","2005/02/18","","",""
"18559088","ProCOC: the prostate cancer outcomes cohort study","Umbehr M, Kessler TM, Sulser T, Kristiansen G, Probst N, Steurer J, Bachmann LM.","BMC Urol. 2008 Jun 17;8:9. doi: 10.1186/1471-2490-8-9.","Umbehr M","BMC Urol","2008","2008/06/19","PMC2441625","","10.1186/1471-2490-8-9"
"12226156","Surgery and the reduction of mortality from prostate cancer","Walsh PC.","N Engl J Med. 2002 Sep 12;347(11):839-40. doi: 10.1056/NEJMe020089.","Walsh PC","N Engl J Med","2002","2002/09/13","","","10.1056/NEJMe020089"
"23998859","Prostate cancer: is it all just hype?","Kumar R.","Natl Med J India. 2012 Nov-Dec;25(6):319-22.","Kumar R","Natl Med J India","2012","2013/09/04","","",""
"3826545","Early diagnosis of prostate cancer","Bueschen AJ.","Ala J Med Sci. 1987 Jan;24(1):58-60.","Bueschen AJ","Ala J Med Sci","1987","1987/01/01","","",""
"10877865","Prostate cancer treatment","","Harv Health Lett. 2000 Jul;25(9):6-7.","","Harv Health Lett","2000","2000/07/06","","",""
"7528555","Controversies in the early detection of prostate cancer","Montie JE.","In Vivo. 1994 May-Jun;8(3):407-11.","Montie JE","In Vivo","1994","1994/05/01","","",""
"26614025","New Genetic Markers for Prostate Cancer","Leapman MS, Carroll PR.","Urol Clin North Am. 2016 Feb;43(1):7-15. doi: 10.1016/j.ucl.2015.08.002. Epub 2015 Oct 31.","Leapman MS","Urol Clin North Am","2016","2015/11/29","","","10.1016/j.ucl.2015.08.002"
"24439724","Active surveillance for early-stage prostate cancer","","Lancet. 2014 Jan 18;383(9913):188. doi: 10.1016/S0140-6736(14)60058-1.","","Lancet","2014","2014/01/21","","","10.1016/S0140-6736(14)60058-1"
"27641839","The role of MRI in prostate cancer diagnosis and management","Mendhiratta N, Taneja SS, Rosenkrantz AB.","Future Oncol. 2016 Nov;12(21):2431-2443. doi: 10.2217/fon-2016-0169. Epub 2016 Sep 19.","Mendhiratta N","Future Oncol","2016","2016/09/20","","","10.2217/fon-2016-0169"
"8618269","Clinical and pathological features of hereditary prostate cancer","Keetch DW, Humphrey PA, Smith DS, Stahl D, Catalona WJ.","J Urol. 1996 Jun;155(6):1841-3.","Keetch DW","J Urol","1996","1996/06/01","","",""
"20065529","[Urodynamic evaluation in prostate cancer patients with urinary incontinence]","Méndez Rubio S, Salinas Casado J, Virseda Chamorro M, Chiarelli L, Silmi Moyano A.","Arch Esp Urol. 2009 Dec;62(10):793-808. doi: 10.4321/s0004-06142009001000004.","Méndez Rubio S","Arch Esp Urol","2009","2010/01/13","","","10.4321/s0004-06142009001000004"
"8640686","The National Cancer Data Base report on longitudinal observations on prostate cancer","Mettlin CJ, Murphy GP, Ho R, Menck HR.","Cancer. 1996 May 15;77(10):2162-6. doi: 10.1002/(SICI)1097-0142(19960515)77:10<2162::AID-CNCR30>3.0.CO;2-R.","Mettlin CJ","Cancer","1996","1996/05/15","","","10.1002/(SICI)1097-0142(19960515)77:10<2162::AID-CNCR30>3.0.CO;2-R"
"8732735","Should we and can we cure prostate cancer?","Weldon VE.","West J Med. 1996 Apr;164(4):341-2.","Weldon VE","West J Med","1996","1996/04/01","PMC1303511","",""
"11665471","[Morbidity among patients with clinically localized prostatic cancer. A registry-based case-control study]","Brasso K, Friis S, Juel K, Jørgensen T, Iversen P.","Ugeskr Laeger. 2001 Oct 8;163(41):5673-6.","Brasso K","Ugeskr Laeger","2001","2001/10/23","","",""
"12710689","Progression model of prostate cancer","Almeida TA, Papadopoulos N.","Methods Mol Biol. 2003;222:211-22. doi: 10.1385/1-59259-328-3:211.","Almeida TA","Methods Mol Biol","2003","2003/04/25","","","10.1385/1-59259-328-3:211"
"19035151","[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease]","Ma CG, Ye DW, Li CL, Zhou FJ, Yao XD, Zhang SL, Dai B, Zhang HL, Zhu Y, Shen YJ.","Zhonghua Wai Ke Za Zhi. 2008 Jun 15;46(12):921-5.","Ma CG","Zhonghua Wai Ke Za Zhi","2008","2008/11/28","","",""
"22018405","Active surveillance as a treatment option for prostate cancer","Hegarty J, Bailey DE Jr.","Semin Oncol Nurs. 2011 Nov;27(4):260-6. doi: 10.1016/j.soncn.2011.07.004.","Hegarty J","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.004"
"17709223","Proton MR spectroscopy of the prostate","Mueller-Lisse UG, Scherr MK.","Eur J Radiol. 2007 Sep;63(3):351-60. doi: 10.1016/j.ejrad.2007.06.024. Epub 2007 Aug 20.","Mueller-Lisse UG","Eur J Radiol","2007","2007/08/22","","","10.1016/j.ejrad.2007.06.024"
"23026884","[Advances in the treatment of prostate cancer - dawn of a new era]","Merki R, Cathomas R.","Ther Umsch. 2012 Oct;69(10):585-90. doi: 10.1024/0040-5930/a000334.","Merki R","Ther Umsch","2012","2012/10/03","","","10.1024/0040-5930/a000334"
"27425814","High frequency of gene mutations in metastatic prostate cancer","Wilkinson E.","Lancet Oncol. 2016 Aug;17(8):e326. doi: 10.1016/S1470-2045(16)30316-3. Epub 2016 Jul 14.","Wilkinson E","Lancet Oncol","2016","2016/07/19","","","10.1016/S1470-2045(16)30316-3"
"11383246","The epidemiology of prostate cancer in the United States","Brawley OW, Barnes S.","Semin Oncol Nurs. 2001 May;17(2):72-7. doi: 10.1053/sonu.2001.23056.","Brawley OW","Semin Oncol Nurs","2001","2001/06/01","","","10.1053/sonu.2001.23056"
"2284528","Pathological stage C (pT3) prostate cancer treated by radical prostatectomy: clinical implications of DNA ploidy analysis","Lieber MM.","Semin Urol. 1990 Nov;8(4):219-24.","Lieber MM","Semin Urol","1990","1990/11/01","","",""
"27344697","[Current status and future perspectives of clinical research for prostate cancer]","Kakehi Y.","Nihon Rinsho. 2016 May 20;74 Suppl 3:17-24.","Kakehi Y","Nihon Rinsho","2016","2016/06/28","","",""
"16752716","Confronting prostate cancer: a personal reflection","Hoyle DW.","N C Med J. 2006 Mar-Apr;67(2):128-9.","Hoyle DW","N C Med J","2006","2006/06/07","","",""
"8958305","Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia","Asadi F, Farraj M, Sharifi R, Malakouti S, Antar S, Kukreja S.","Hum Pathol. 1996 Dec;27(12):1319-23. doi: 10.1016/s0046-8177(96)90344-5.","Asadi F","Hum Pathol","1996","1996/12/01","","","10.1016/s0046-8177(96)90344-5"
"28893523","[Therapeutic innovations in urology for localized prostate cancer]","Cormier L, Créhange G.","Cancer Radiother. 2017 Oct;21(6-7):442-446. doi: 10.1016/j.canrad.2017.08.107.","Cormier L","Cancer Radiother","2017","2017/09/13","","","10.1016/j.canrad.2017.08.107"
"7538042","Screening for prostate cancer: an analysis of the early experience","Slawin KM, Ohori M, Dillioglugil O, Scardino PT.","CA Cancer J Clin. 1995 May-Jun;45(3):134-47. doi: 10.3322/canjclin.45.3.134.","Slawin KM","CA Cancer J Clin","1995","1995/05/01","","","10.3322/canjclin.45.3.134"
"21239002","Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden","Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M.","J Urol. 2011 Mar;185(3):833-9. doi: 10.1016/j.juro.2010.10.061. Epub 2011 Jan 15.","Berglund A","J Urol","2011","2011/01/18","","","10.1016/j.juro.2010.10.061"
"16408326","Cryoablation proves effective, safe, durable treatment for prostate cancer","","Oncology (Williston Park). 2005 Aug;19(9):1142.","","Oncology (Williston Park)","2005","2006/01/13","","",""
"16462155","Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists","Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL.","Adv Anat Pathol. 2006 Jan;13(1):57-9. doi: 10.1097/01.pap.0000202017.78917.18.","Epstein JI","Adv Anat Pathol","2006","2006/02/08","","","10.1097/01.pap.0000202017.78917.18"
"29391368","Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data","Merriel SWD, May MT, Martin RM.","BMJ Open. 2018 Jan 31;8(1):e019409. doi: 10.1136/bmjopen-2017-019409.","Merriel SWD","BMJ Open","2018","2018/02/03","PMC5829815","","10.1136/bmjopen-2017-019409"
"9195828","Prostate cancer in the UK","","J R Soc Health. 1997 Jun;117(3):156. doi: 10.1177/146642409711700305.","","J R Soc Health","1997","1997/06/01","","","10.1177/146642409711700305"
"7791655","Localised prostate cancer: which way forward?","Gunter D.","Med J Aust. 1995 Jun 5;162(11):613-4.","Gunter D","Med J Aust","1995","1995/06/05","","",""
"24914835","Prostate cancer epidemiology","Plata Bello A, Concepcion Masip T.","Arch Esp Urol. 2014 Jun;67(5):373-82.","Plata Bello A","Arch Esp Urol","2014","2014/06/11","","",""
"11062376","Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense?","Garzotto M.","Mol Urol. 2000 Fall;4(3):209-13;discussion 215.","Garzotto M","Mol Urol","2000","2000/11/04","","",""
"19939895","Age at diagnosis and age at death in familial prostate cancer","Brandt A, Bermejo JL, Sundquist J, Hemminki K.","Oncologist. 2009 Dec;14(12):1209-17. doi: 10.1634/theoncologist.2009-0132. Epub 2009 Nov 25.","Brandt A","Oncologist","2009","2009/11/27","","","10.1634/theoncologist.2009-0132"
"27506103","[THE EVOLUTION OF MARKERS OF PROSTATE CANCER]","Peshkov MN, Generozov EV, Kostryukova ES.","Klin Lab Diagn. 2016 Mar;61(3):132-40.","Peshkov MN","Klin Lab Diagn","2016","2016/08/11","","",""
"1992601","Anandron: a new step in the treatment of advanced prostate cancer","Debruyne FM.","Urology. 1991;37(2 Suppl):3-4. doi: 10.1016/0090-4295(91)80094-n.","Debruyne FM","Urology","1991","1991/01/01","","","10.1016/0090-4295(91)80094-n"
"25309903","MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples","Cannistraci A, Di Pace AL, De Maria R, Bonci D.","Biomed Res Int. 2014;2014:146170. doi: 10.1155/2014/146170. Epub 2014 Sep 16.","Cannistraci A","Biomed Res Int","2014","2014/10/14","PMC4182080","","10.1155/2014/146170"
"30420441","Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer","Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.","Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.","Gerke T","Cancer Epidemiol Biomarkers Prev","2019","2018/11/14","PMC6494092","NIHMS1512380","10.1158/1055-9965.EPI-18-0667"
"25416653","High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy","Mortensen MM, Høyer S, Orntoft TF, Sørensen KD, Dyrskjøt L, Borre M.","BMC Cancer. 2014 Nov 21;14:859. doi: 10.1186/1471-2407-14-859.","Mortensen MM","BMC Cancer","2014","2014/11/23","PMC4247690","","10.1186/1471-2407-14-859"
"10822923","Screening for early prostate cancer: what is the problem?","Moffat L.","J R Coll Surg Edinb. 2000 Apr;45(2):127-31.","Moffat L","J R Coll Surg Edinb","2000","2000/05/24","","",""
"15003149","A systematic review of randomized trials in localized prostate cancer","Alibhai SM, Klotz LH.","Can J Urol. 2004 Feb;11(1):2110-7.","Alibhai SM","Can J Urol","2004","2004/03/09","","",""
"30889005","Detection of Local Relapse of Prostate Cancer With 18F-PSMA-1007","Seifert R, Schafigh D, Bögemann M, Weckesser M, Rahbar K.","Clin Nucl Med. 2019 Jun;44(6):e394-e395. doi: 10.1097/RLU.0000000000002543.","Seifert R","Clin Nucl Med","2019","2019/03/20","","","10.1097/RLU.0000000000002543"
"21720991","What is the best way to treat high-risk prostate cancer?","Klein EA.","Cancer. 2012 Jan 1;118(1):12-4. doi: 10.1002/cncr.26281. Epub 2011 Jun 30.","Klein EA","Cancer","2012","2011/07/02","","","10.1002/cncr.26281"
"25800589","Physical activity and its mechanistic effects on prostate cancer","Wekesa A, Harrison M, Watson RW.","Prostate Cancer Prostatic Dis. 2015 Sep;18(3):197-207. doi: 10.1038/pcan.2015.9. Epub 2015 Mar 24.","Wekesa A","Prostate Cancer Prostatic Dis","2015","2015/03/25","","","10.1038/pcan.2015.9"
"7600464","Prostate cancer: detection and patient involvement in treatment","Marshall K.","CMAJ. 1995 Jul 15;153(2):140-1; author reply 141-2.","Marshall K","CMAJ","1995","1995/07/15","PMC1338047","",""
"24818853","Prostate cancer in young men: an important clinical entity","Salinas CA, Tsodikov A, Ishak-Howard M, Cooney KA.","Nat Rev Urol. 2014 Jun;11(6):317-23. doi: 10.1038/nrurol.2014.91. Epub 2014 May 13.","Salinas CA","Nat Rev Urol","2014","2014/05/14","PMC4191828","NIHMS632105","10.1038/nrurol.2014.91"
"23305529","Radical prostatectomy in high-risk prostate cancer","Ischia J, Gleave M.","Int J Urol. 2013 Mar;20(3):290-300. doi: 10.1111/iju.12069. Epub 2013 Jan 10.","Ischia J","Int J Urol","2013","2013/01/12","","","10.1111/iju.12069"
"1382893","Prostate-specific antigen comes of age in diagnosis and management of prostate cancer","Graves HC.","Clin Chem. 1992 Oct;38(10):1930-2.","Graves HC","Clin Chem","1992","1992/10/01","","",""
"25314297","Lactate transporters in the context of prostate cancer metabolism: what do we know?","Pértega-Gomes N, Baltazar F.","Int J Mol Sci. 2014 Oct 13;15(10):18333-48. doi: 10.3390/ijms151018333.","Pértega-Gomes N","Int J Mol Sci","2014","2014/10/15","PMC4227218","","10.3390/ijms151018333"
"19188770","Focal therapy for prostate cancer: pathologic basis","Mouraviev V, Madden JF.","Curr Opin Urol. 2009 Mar;19(2):161-7. doi: 10.1097/MOU.0b013e328323f62b.","Mouraviev V","Curr Opin Urol","2009","2009/02/04","","","10.1097/MOU.0b013e328323f62b"
"16683010","Histopathological findings after radiofrequency (RITA) treatment for prostate cancer","Patriarca C, Bergamaschi F, Gazzano G, Corrada P, Ordesi G, Zanitzer L, Di Pasquale M, Giunta P, Campo B.","Prostate Cancer Prostatic Dis. 2006;9(3):266-9. doi: 10.1038/sj.pcan.4500877. Epub 2006 May 9.","Patriarca C","Prostate Cancer Prostatic Dis","2006","2006/05/10","","","10.1038/sj.pcan.4500877"
"20701068","Comparison between incidentally and clinically detected prostate cancer: implications for prostate cancer screening programs and focal therapy","Mazzucchelli R, Montironi R, Morichetti D, Scarpelli M, Lopez-Beltran A, Cheng L.","Anal Quant Cytol Histol. 2010 Jun;32(3):151-4.","Mazzucchelli R","Anal Quant Cytol Histol","2010","2010/08/13","","",""
"27344719","[Molecular and anatomical mechanism of bone metastasis in prostate cancer]","Yokomizo A, Shiota M.","Nihon Rinsho. 2016 May 20;74 Suppl 3:145-8.","Yokomizo A","Nihon Rinsho","2016","2016/06/28","","",""
"27814581","Mitochondrial dysfunction and prostate cancer racial disparities among American men","Chaudhary AK, O'Malley J, Kumar S, Inigo JR, Kumar R, Yadav N, Chandra D.","Front Biosci (Schol Ed). 2017 Jan 1;9:154-164. doi: 10.2741/s479.","Chaudhary AK","Front Biosci (Schol Ed)","2017","2016/11/05","","","10.2741/s479"
"30446451","Local failure is a dominant mode of recurrence in locally advanced and clinical node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy","Hayman J, Hole KH, Seierstad T, Perin J, DeWeese TL, Tran PT, Lilleby W.","Urol Oncol. 2019 Apr;37(4):289.e19-289.e26. doi: 10.1016/j.urolonc.2018.09.016. Epub 2018 Nov 13.","Hayman J","Urol Oncol","2019","2018/11/18","","","10.1016/j.urolonc.2018.09.016"
"25160575","Adjustment and discussion of cancer: a comparison of breast and prostate cancer survivors","Ullrich PM, Rothrock NE, Lutgendorf SK, Jochimsen PR, Williams RD.","Psychol Health. 2008;23(4):391-406. doi: 10.1080/14768320701227980.","Ullrich PM","Psychol Health","2008","2014/08/28","","","10.1080/14768320701227980"
"29383928","The future of choline PET in the era of prostate specific membrane antigen","Evangelista L, Cuppari L, Zattoni F, Mansi L, Bombardieri E.","Q J Nucl Med Mol Imaging. 2019 Mar;63(1):19-28. doi: 10.23736/S1824-4785.18.03062-5. Epub 2018 Jan 30.","Evangelista L","Q J Nucl Med Mol Imaging","2019","2018/02/01","","","10.23736/S1824-4785.18.03062-5"
"19424173","The use of PCA3 in the diagnosis of prostate cancer","Hessels D, Schalken JA.","Nat Rev Urol. 2009 May;6(5):255-61. doi: 10.1038/nrurol.2009.40.","Hessels D","Nat Rev Urol","2009","2009/05/09","","","10.1038/nrurol.2009.40"
"24687032","Prostate cancer: muddying the waters by overlooking treatment modality","Ennis RD, Quinn SA.","Nat Rev Clin Oncol. 2014 Jun;11(6):305-7. doi: 10.1038/nrclinonc.2014.52. Epub 2014 Apr 1.","Ennis RD","Nat Rev Clin Oncol","2014","2014/04/02","","","10.1038/nrclinonc.2014.52"
"7653022","Screening, early detection, and treatment of prostate cancer: a European view","Schröder FH.","Urology. 1995 Sep;46(3 Suppl A):62-70. doi: 10.1016/s0090-4295(99)80252-0.","Schröder FH","Urology","1995","1995/09/01","","","10.1016/s0090-4295(99)80252-0"
"21297655","PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making","Venderbos LD, Roobol MJ.","Asian J Androl. 2011 Mar;13(2):219-24. doi: 10.1038/aja.2010.180. Epub 2011 Feb 7.","Venderbos LD","Asian J Androl","2011","2011/02/08","PMC3739214","","10.1038/aja.2010.180"
"7492831","[Chemoprevention of cancer of the prostate]","Droz JP.","Bull Cancer. 1995 Jul;82 Suppl 3:178s-180s.","Droz JP","Bull Cancer","1995","1995/07/01","","",""
"21095422","Use and assessment of PSA in prostate cancer","Gjertson CK, Albertsen PC.","Med Clin North Am. 2011 Jan;95(1):191-200. doi: 10.1016/j.mcna.2010.08.024.","Gjertson CK","Med Clin North Am","2011","2010/11/25","","","10.1016/j.mcna.2010.08.024"
"31017389","Ultrasensitive and Reversible Nanoplatform of Urinary Exosomes for Prostate Cancer Diagnosis","Li P, Yu X, Han W, Kong Y, Bao W, Zhang J, Zhang W, Gu Y.","ACS Sens. 2019 May 24;4(5):1433-1441. doi: 10.1021/acssensors.9b00621. Epub 2019 May 6.","Li P","ACS Sens","2019","2019/04/25","","","10.1021/acssensors.9b00621"
"12509652","How are we looking after prostate cancer?","Waxman J, Mazhar D.","QJM. 2003 Jan;96(1):75-9. doi: 10.1093/qjmed/hcg009.","Waxman J","QJM","2003","2003/01/02","","","10.1093/qjmed/hcg009"
"26402245","Vasectomy: potential links to an increased risk of aggressive prostate cancer?","Gaines AR, Vidal AC, Freedland SJ.","Expert Rev Anticancer Ther. 2015;15(10):1123-5. doi: 10.1586/14737140.2015.1086648. Epub 2015 Sep 7.","Gaines AR","Expert Rev Anticancer Ther","2015","2015/09/25","PMC4844546","NIHMS775934","10.1586/14737140.2015.1086648"
"18268131","How statins may increase prostate cancer","Goldstein MR, Mascitelli L, Pezzetta F.","Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):459. doi: 10.1158/1055-9965.EPI-07-2776.","Goldstein MR","Cancer Epidemiol Biomarkers Prev","2008","2008/02/13","","","10.1158/1055-9965.EPI-07-2776"
"17996358","Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men","Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI.","Eur Urol. 2008 Jul;54(1):107-16. doi: 10.1016/j.eururo.2007.10.038. Epub 2007 Oct 30.","Jeldres C","Eur Urol","2008","2007/11/13","","","10.1016/j.eururo.2007.10.038"
"26177645","A New Era of Immunotherapy in Prostate Cancer","Pizzola C, Rizvi SM, Joshi M.","Curr Mol Pharmacol. 2016;9(3):217-225. doi: 10.2174/1874467208666150716120551.","Pizzola C","Curr Mol Pharmacol","2016","2015/07/17","","","10.2174/1874467208666150716120551"
"21481534","Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients","Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D.","Cancer Treat Rev. 2011 Dec;37(8):643-54. doi: 10.1016/j.ctrv.2011.03.003. Epub 2011 Apr 9.","Vajda A","Cancer Treat Rev","2011","2011/04/13","","","10.1016/j.ctrv.2011.03.003"
"18367120","High cholesterol levels are associated with reduced prostate cancer mortality rates during periods of high but not low statin use in the United States","Colli JL, Amling CL.","Urol Oncol. 2009 Mar-Apr;27(2):170-3. doi: 10.1016/j.urolonc.2007.11.029. Epub 2008 Feb 4.","Colli JL","Urol Oncol","2009","2008/03/28","","","10.1016/j.urolonc.2007.11.029"
"17992025","Presence of symptom distress and prostate cancer-related anxiety in patients at the beginning of cancer rehabilitation","Mehnert A, Lehmann C, Schulte T, Koch U.","Onkologie. 2007 Nov;30(11):551-6. doi: 10.1159/000108578. Epub 2007 Oct 16.","Mehnert A","Onkologie","2007","2007/11/10","","","10.1159/000108578"
"81107","Dihydrotestosterone concentration in prostate cancer tissue as a predictor of tumor differentiation and hormonal dependency","Geller J, Albert J, de la Vega D, Loza D, Stoeltzing W.","Cancer Res. 1978 Nov;38(11 Pt 2):4349-52.","Geller J","Cancer Res","1978","1978/11/01","","",""
"22313600","Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria","Popert R.","BJU Int. 2012 Sep;110(6 Pt B):E182. doi: 10.1111/j.1464-410X.2012.10956.x. Epub 2012 Feb 7.","Popert R","BJU Int","2012","2012/02/09","","","10.1111/j.1464-410X.2012.10956.x"
"29685789","Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer","Panja S, Hayati S, Epsi NJ, Parrott JS, Mitrofanova A.","EBioMedicine. 2018 May;31:110-121. doi: 10.1016/j.ebiom.2018.04.007. Epub 2018 Apr 12.","Panja S","EBioMedicine","2018","2018/04/25","PMC6013754","","10.1016/j.ebiom.2018.04.007"
"20697128","Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region","Hassen WA, Karsan FA, Abbas F, Beduk Y, El-Khodary A, Ghosn M, Khader J, Khauli R, Rabah DM, Shamseddine A, Srinivas S; MENA Prostate Cancer Regional Guidelines Committee.","J Natl Compr Canc Netw. 2010 Jul;8 Suppl 3:S26-8. doi: 10.6004/jnccn.2010.0121.","Hassen WA","J Natl Compr Canc Netw","2010","2010/08/11","","","10.6004/jnccn.2010.0121"
"9516588","Radiation therapy or prostatectomy: an old conflict revisited in the PSA era. A radiation oncologist's viewpoint","Zietman AL.","Semin Radiat Oncol. 1998 Apr;8(2):81-6. doi: 10.1016/s1053-4296(98)80003-9.","Zietman AL","Semin Radiat Oncol","1998","1998/04/29","","","10.1016/s1053-4296(98)80003-9"
"8087788","Pretreatment of metastatic disease. Prostate cancer in the older male","DeAntoni EP, Crawford ED.","Cancer. 1994 Oct 1;74(7 Suppl):2182-7. doi: 10.1002/1097-0142(19941001)74:7+<2182::aid-cncr2820741731>3.0.co;2-u.","DeAntoni EP","Cancer","1994","1994/10/01","","","10.1002/1097-0142(19941001)74:7+<2182::aid-cncr2820741731>3.0.co;2-u"
"25367931","Prostate cancer organoids make debut","","Cancer Discov. 2014 Nov;4(11):1248. doi: 10.1158/2159-8290.CD-NB2014-143. Epub 2014 Sep 25.","","Cancer Discov","2014","2014/11/05","","","10.1158/2159-8290.CD-NB2014-143"
"16630526","Primary hormone therapy for locally advanced prostate cancer","Swanson GP.","Curr Urol Rep. 2006 May;7(3):225-32. doi: 10.1007/s11934-006-0025-x.","Swanson GP","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0025-x"
"11326166","Clinically localized prostate cancer: the paradox of paradoxes","Pow-Sang JM.","Cancer Control. 2001 Mar-Apr;8(2):126. doi: 10.1177/107327480100800202.","Pow-Sang JM","Cancer Control","2001","2001/04/28","","","10.1177/107327480100800202"
"10393715","PSA as a treatment marker for prostate cancer?","Miller M.","J Natl Cancer Inst. 1999 Jul 7;91(13):1108-10. doi: 10.1093/jnci/91.13.1108.","Miller M","J Natl Cancer Inst","1999","1999/07/07","","","10.1093/jnci/91.13.1108"
"22642277","Prostate cancer","Klemm J, Mehr SR.","Am J Manag Care. 2012 May;18(3 Spec No.):SP119-21.","Klemm J","Am J Manag Care","2012","2012/05/31","","",""
"23481613","Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis","Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E, Lenzi A, Giugliano D.","J Endocrinol Invest. 2013 Feb;36(2):132-9. doi: 10.1007/BF03346748.","Esposito K","J Endocrinol Invest","2013","2013/03/14","","","10.1007/BF03346748"
"11887984","Prostate cancer: natural history and surgical treatment of localised disease","Schröder FH.","Eur J Cancer. 2001 Oct;37 Suppl 7:S127-36. doi: 10.1016/s0959-8049(01)80014-9.","Schröder FH","Eur J Cancer","2001","2002/03/13","","","10.1016/s0959-8049(01)80014-9"
"27344701","[Natural history of prostate cancer--The evolutionary history of lethal clone]","Kamoi K.","Nihon Rinsho. 2016 May 20;74 Suppl 3:43-6.","Kamoi K","Nihon Rinsho","2016","2016/06/28","","",""
"25520069","Epidemiology, etiology, diagnosis and treatment of prostate cancer","Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A.","Asian Pac J Cancer Prev. 2014;15(22):9575-8. doi: 10.7314/apjcp.2014.15.22.9575.","Daniyal M","Asian Pac J Cancer Prev","2014","2014/12/19","","","10.7314/apjcp.2014.15.22.9575"
"695051","[Curative radiotherapy of prostate cancer]","Gadeberg CC, Sell A.","Ugeskr Laeger. 1978 Aug 7;140(32):1946-9.","Gadeberg CC","Ugeskr Laeger","1978","1978/08/07","","",""
"14680306","Populations at high risk for prostate cancer","Hsieh K, Albertsen PC.","Urol Clin North Am. 2003 Nov;30(4):669-76. doi: 10.1016/s0094-0143(03)00058-2.","Hsieh K","Urol Clin North Am","2003","2003/12/19","","","10.1016/s0094-0143(03)00058-2"
"3594390","Selecting initial therapy for prostate cancer. Radiation therapy perspective","Bagshaw MA, Ray GR, Cox RS.","Cancer. 1987 Aug 1;60(3 Suppl):521-5. doi: 10.1002/1097-0142(19870801)60:3+<521::aid-cncr2820601514>3.0.co;2-r.","Bagshaw MA","Cancer","1987","1987/08/01","","","10.1002/1097-0142(19870801)60:3+<521::aid-cncr2820601514>3.0.co;2-r"
"21616443","[Ongoing debates on localized prostate cancer: epidemiology, screening and stratification]","Audenet F, Rouprêt M.","Prog Urol. 2011 May;21 Suppl 3:S75-9. doi: 10.1016/S1166-7087(11)70017-3.","Audenet F","Prog Urol","2011","2011/05/28","","","10.1016/S1166-7087(11)70017-3"
"7682426","Screening for prostate cancer--necessity or nonsense?","Schröder FH, Boyle P.","Eur J Cancer. 1993;29A(5):656-61. doi: 10.1016/s0959-8049(05)80339-9.","Schröder FH","Eur J Cancer","1993","1993/01/01","","","10.1016/s0959-8049(05)80339-9"
"9436286","Expectant management as an option for men with stage T1c prostate cancer: a preliminary study","Mohler JL, Williams BT, Freeman JA.","World J Urol. 1997;15(6):364-8. doi: 10.1007/BF01300184.","Mohler JL","World J Urol","1997","1997/01/01","","","10.1007/BF01300184"
"11859652","[Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer]","Soulié M, Villers A, Richaud P, Prapotnich D, Ruffion A, Grosclaude P.","Prog Urol. 2001 Dec;11(6):1195-204.","Soulié M","Prog Urol","2001","2002/02/28","","",""
"8097008","Natural history of prostate cancer","Chisholm GD, Habib FK.","Lancet. 1993 Apr 24;341(8852):1103. doi: 10.1016/0140-6736(93)92471-5.","Chisholm GD","Lancet","1993","1993/04/24","","","10.1016/0140-6736(93)92471-5"
"25367978","Prostate cancer immunotherapy: beyond immunity to curability","Simons JW.","Cancer Immunol Res. 2014 Nov;2(11):1034-43. doi: 10.1158/2326-6066.CIR-14-0174.","Simons JW","Cancer Immunol Res","2014","2014/11/05","","","10.1158/2326-6066.CIR-14-0174"
"25039088","[Editorial. Monographic: Active surveillance in prostate cancer]","Rubio-Briones J, Narbón ES.","Arch Esp Urol. 2014 Jun;67(5):369-71.","Rubio-Briones J","Arch Esp Urol","2014","2014/07/22","","",""
"16402090","Watchful waiting for prostate cancer: a review article","Chodak GW, Warren KS.","Prostate Cancer Prostatic Dis. 2006;9(1):25-9. doi: 10.1038/sj.pcan.4500857.","Chodak GW","Prostate Cancer Prostatic Dis","2006","2006/01/13","","","10.1038/sj.pcan.4500857"
"30129068","Urinary biomarkers of prostate cancer","Fujita K, Nonomura N.","Int J Urol. 2018 Sep;25(9):770-779. doi: 10.1111/iju.13734. Epub 2018 Aug 21.","Fujita K","Int J Urol","2018","2018/08/22","","","10.1111/iju.13734"
"20132102","Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK","Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R.","BJU Int. 2010 Jan;105(1):49-56. doi: 10.1111/j.1464-410X.2009.08716.x.","Fourcade RO","BJU Int","2010","2010/02/06","","","10.1111/j.1464-410X.2009.08716.x"
"16370939","Gene delivery and gene therapy of prostate cancer","Kaliberov SA, Buchsbaum DJ.","Expert Opin Drug Deliv. 2006 Jan;3(1):37-51. doi: 10.1517/17425247.3.1.37.","Kaliberov SA","Expert Opin Drug Deliv","2006","2005/12/24","","","10.1517/17425247.3.1.37"
"25061087","Prostate cancer support groups: Canada-based specialists' perspectives","Oliffe JL, Chambers S, Garrett B, Bottorff JL, McKenzie M, Han CS, Ogrodniczuk JS.","Am J Mens Health. 2015 Mar;9(2):163-72. doi: 10.1177/1557988314543510. Epub 2014 Jul 24.","Oliffe JL","Am J Mens Health","2015","2014/07/26","PMC4361490","","10.1177/1557988314543510"
"23720582","A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors","Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.","Sci Transl Med. 2013 May 29;5(187):187ra71. doi: 10.1126/scitranslmed.3005688.","Toivanen R","Sci Transl Med","2013","2013/05/31","","","10.1126/scitranslmed.3005688"
"30971530","Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression","Feng N, Huang J.","Asian J Androl. 2019 May-Jun;21(3):213-214. doi: 10.4103/aja.aja_31_19.","Feng N","Asian J Androl","2019","2019/04/12","PMC6498730","","10.4103/aja.aja_31_19"
"26301650","No evidence for increased prostate cancer risk among calcium channel blockers user","Fan Y, Zhou Y, Gong D, Zou C.","Int J Cardiol. 2015 Dec 15;201:255-7. doi: 10.1016/j.ijcard.2015.08.046. Epub 2015 Aug 5.","Fan Y","Int J Cardiol","2015","2015/08/25","","","10.1016/j.ijcard.2015.08.046"
"16450723","[The treatment options for localized prostate cancer]","Livne PM.","Harefuah. 2006 Jan;145(1):36-7, 77.","Livne PM","Harefuah","2006","2006/02/03","","",""
"26782572","Association between MTHFR gene polymorphisms (C677T, A1298C) and genetic susceptibility to prostate cancer: a meta-analysis","Chen PL, Li WT, Wang J, Jiang YD, Wu P, Chen T, Zheng SB.","Genet Mol Res. 2015 Dec 29;14(4):19191-202. doi: 10.4238/2015.December.29.29.","Chen PL","Genet Mol Res","2015","2016/01/20","","","10.4238/2015.December.29.29"
"11406537","Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling","Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, Trent JM, Isaacs WB.","Cancer Res. 2001 Jun 15;61(12):4683-8.","Luo J","Cancer Res","2001","2001/06/19","","",""
"31503032","The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy","Faisal FA, Lotan TL.","Adv Anat Pathol. 2020 Jan;27(1):11-19. doi: 10.1097/PAP.0000000000000245.","Faisal FA","Adv Anat Pathol","2020","2019/09/11","","","10.1097/PAP.0000000000000245"
"18781895","Prostatic tumor stroma: a key player in cancer progression","Taylor RA, Risbridger GP.","Curr Cancer Drug Targets. 2008 Sep;8(6):490-7. doi: 10.2174/156800908785699351.","Taylor RA","Curr Cancer Drug Targets","2008","2008/09/11","","","10.2174/156800908785699351"
"17172813","Exploiting the complex biology of prostate cancer","Thompson TC.","Cancer Biol Ther. 2006 Nov;5(11):1573-6. doi: 10.4161/cbt.5.11.3609. Epub 2006 Nov 21.","Thompson TC","Cancer Biol Ther","2006","2006/12/19","","","10.4161/cbt.5.11.3609"
"11758871","Spectroscopy in prostate cancer: hope or hype?","Roach M 3rd, Kurhanewicz J, Carroll P.","Oncology (Williston Park). 2001 Nov;15(11):1399-410; discussion 1415-6, 1418.","Roach M 3rd","Oncology (Williston Park)","2001","2002/01/05","","",""
"23870479","How will focal therapy fit in with existing treatments?","Emberton M, Gómez-Veiga F, Ahmed H, Dickinson L.","Actas Urol Esp. 2013 Nov-Dec;37(10):597-602. doi: 10.1016/j.acuro.2013.02.008. Epub 2013 Jul 17.","Emberton M","Actas Urol Esp","2013","2013/07/23","","","10.1016/j.acuro.2013.02.008"
"9915484","Glyoxalase I activity in human prostate cancer: a potential marker and importance in chemotherapy","Davidson SD, Cherry JP, Choudhury MS, Tazaki H, Mallouh C, Konno S.","J Urol. 1999 Feb;161(2):690-1.","Davidson SD","J Urol","1999","1999/01/23","","",""
"8696636","Compliance with hormonal treatment for prostate cancer","Kaisary AV.","Br J Hosp Med. 1996 Mar 20-Apr 2;55(6):359-66.","Kaisary AV","Br J Hosp Med","1996","1996/03/02","","",""
"1284590","Prostate-specific antigen levels and subsequent prostate cancer: potential for screening","Helzlsouer KJ, Newby J, Comstock GW.","Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):537-40.","Helzlsouer KJ","Cancer Epidemiol Biomarkers Prev","1992","1992/11/01","","",""
"21229632","Nutrition and prostate cancer","Vlajinac H, Ilic M, Marinkovic J, Sipetic S.","J BUON. 2010 Oct-Dec;15(4):698-703.","Vlajinac H","J BUON","2010","2011/01/14","","",""
"18665756","Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression","Housa D, Vernerova Z, Heracek J, Cechak P, Rosova B, Kuncova J, Haluzik M.","Neoplasma. 2008;55(5):442-6.","Housa D","Neoplasma","2008","2008/07/31","","",""
"26369724","Prostate cancer: Analysing prostate cancer biomarkers in voided urine","Kelsey R.","Nat Rev Urol. 2015 Oct;12(10):538. doi: 10.1038/nrurol.2015.233. Epub 2015 Sep 15.","Kelsey R","Nat Rev Urol","2015","2015/09/16","","","10.1038/nrurol.2015.233"
"16813885","Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone","Granfors T, Modig H, Damber JE, Tomic R.","J Urol. 2006 Aug;176(2):544-7. doi: 10.1016/j.juro.2006.03.092.","Granfors T","J Urol","2006","2006/07/04","","","10.1016/j.juro.2006.03.092"
"1600491","Management of localized prostate cancer","Smith JA Jr.","Cancer. 1992 Jul 1;70(1 Suppl):302-6. doi: 10.1002/1097-0142(19920701)70:1+<302::aid-cncr2820701318>3.0.co;2-4.","Smith JA Jr","Cancer","1992","1992/07/11","","","10.1002/1097-0142(19920701)70:1+<302::aid-cncr2820701318>3.0.co;2-4"
"31629434","Genetic counseling perspective of engagement with urology and primary care","Hyatt C, Russo J, McDougall C.","Can J Urol. 2019 Oct;26(5 Suppl 2):52-53.","Hyatt C","Can J Urol","2019","2019/10/21","","",""
"17923593","Short- and long-term mortality with localized prostate cancer","Merglen A, Schmidlin F, Fioretta G, Verkooijen HM, Rapiti E, Zanetti R, Miralbell R, Bouchardy C.","Arch Intern Med. 2007 Oct 8;167(18):1944-50. doi: 10.1001/archinte.167.18.1944.","Merglen A","Arch Intern Med","2007","2007/10/10","","","10.1001/archinte.167.18.1944"
"21844912","Targeted therapies: An important piece of the localized prostate cancer puzzle?","Denham JW.","Nat Rev Clin Oncol. 2011 Aug 16;8(10):573-4. doi: 10.1038/nrclinonc.2011.128.","Denham JW","Nat Rev Clin Oncol","2011","2011/08/17","","","10.1038/nrclinonc.2011.128"
"15467048","Natural history of early localized prostate cancer","Oláno JP.","JAMA. 2004 Oct 6;292(13):1549; author reply 1549-50. doi: 10.1001/jama.292.13.1549-b.","Oláno JP","JAMA","2004","2004/10/07","","","10.1001/jama.292.13.1549-b"
"10921334","[Hereditary prostate cancer]","Nakata S, Ohtake N, Takei T, Yamanaka H.","Nihon Rinsho. 2000 Jul;58(7):1515-8.","Nakata S","Nihon Rinsho","2000","2000/08/02","","",""
"17685384","Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option","Allen GW, Howard AR, Jarrard DF, Ritter MA.","Cancer. 2007 Oct 1;110(7):1405-16. doi: 10.1002/cncr.22940.","Allen GW","Cancer","2007","2007/08/10","","","10.1002/cncr.22940"
"7653021","Prostate cancer screening and prevention: ""realities and hope""","Denis LJ.","Urology. 1995 Sep;46(3 Suppl A):56-61. doi: 10.1016/s0090-4295(99)80251-9.","Denis LJ","Urology","1995","1995/09/01","","","10.1016/s0090-4295(99)80251-9"
"19304374","Editorial comment on: Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram","Briganti A.","Eur Urol. 2009 Oct;56(4):667-8. doi: 10.1016/j.eururo.2009.03.030. Epub 2009 Mar 13.","Briganti A","Eur Urol","2009","2009/03/24","","","10.1016/j.eururo.2009.03.030"
"15833837","Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease","Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L.","Cancer Res. 2005 Apr 15;65(8):3081-91. doi: 10.1158/0008-5472.CAN-04-3218.","Lin B","Cancer Res","2005","2005/04/19","","","10.1158/0008-5472.CAN-04-3218"
"25597184","[Updated treatment of castration-resistant prostate cancer]","Xu S, Zhang ZY.","Zhonghua Nan Ke Xue. 2014 Dec;20(12):1136-40.","Xu S","Zhonghua Nan Ke Xue","2014","2015/01/20","","",""
"22207970","[Characteristics of hereditary and familial prostate cancer in Japan 2011]","Fukabori Y, Ohtake N, Nakata S, Suzuki K.","Nihon Rinsho. 2011 Jun;69 Suppl 5:197-202.","Fukabori Y","Nihon Rinsho","2011","2012/01/03","","",""
"18612121","JAMA patient page. Prostate cancer","Zeller JL, Lynm C, Glass RM.","JAMA. 2008 Jul 9;300(2):236. doi: 10.1001/jama.300.2.236.","Zeller JL","JAMA","2008","2008/07/10","","","10.1001/jama.300.2.236"
"9414541","Diagnosis, management and screening of early localised prostate cancer","Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.","Health Technol Assess. 1997;1(2):i, 1-96.","Selley S","Health Technol Assess","1997","1997/01/01","","",""
"2029398","Fine-needle aspiration biopsy with a new automatic fine-needle gun versus histological core in ultrasonically-guided transrectal biopsy for detection of prostate cancer","Norming U, Gustafsson O, Nyman CR, Raaschou-Nielsen T, Näslund I.","Acta Oncol. 1991;30(2):155-7. doi: 10.3109/02841869109092340.","Norming U","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092340"
"31629416","DNA repair genes: contributions to prostate cancer predisposition and aggressiveness","Boyle J, Cooney KA.","Can J Urol. 2019 Oct;26(5 Suppl 2):10-11.","Boyle J","Can J Urol","2019","2019/10/21","","",""
"12549773","Pathology of prostate cancer","Che M, Grignon D.","Cancer Metastasis Rev. 2002;21(3-4):381-95. doi: 10.1023/a:1021242813374.","Che M","Cancer Metastasis Rev","2002","2003/01/29","","","10.1023/a:1021242813374"
"12477140","Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992-1998","Polednak AP.","Ethn Dis. 2002 Fall;12(4):536-40.","Polednak AP","Ethn Dis","2002","2002/12/13","","",""
"21062647","Prostate cancer around the world. An overview","Schröder FH.","Urol Oncol. 2010 Nov-Dec;28(6):663-7. doi: 10.1016/j.urolonc.2009.12.013.","Schröder FH","Urol Oncol","2010","2010/11/11","","","10.1016/j.urolonc.2009.12.013"
"7538041","Prostate cancer: here and now","Murphy GP.","CA Cancer J Clin. 1995 May-Jun;45(3):133. doi: 10.3322/canjclin.45.3.133.","Murphy GP","CA Cancer J Clin","1995","1995/05/01","","","10.3322/canjclin.45.3.133"
"25182883","Specialist help for BME community","","Nurs Stand. 2014 Sep 9;29(1):11. doi: 10.7748/ns.29.1.11.s12.","","Nurs Stand","2014","2014/09/04","","","10.7748/ns.29.1.11.s12"
"10561969","Is prostate-specific antigen still the best tumor marker for prostate cancer?","Leewansangtong S, Soontrapa S, Tantiwong A.","J Med Assoc Thai. 1999 Oct;82(10):1034-40.","Leewansangtong S","J Med Assoc Thai","1999","1999/11/24","","",""
"16752719","The role of the pathologist in diagnosing prostate cancer and guiding therapy","Weinstein MH.","N C Med J. 2006 Mar-Apr;67(2):140-5.","Weinstein MH","N C Med J","2006","2006/06/07","","",""
"24399415","Coffee consumption linked to a reduction in prostate cancer recurrence","Printz C.","Cancer. 2014 Jan 15;120(2):157. doi: 10.1002/cncr.28542.","Printz C","Cancer","2014","2014/01/09","","","10.1002/cncr.28542"
"12837920","Molecular biology of prostate cancer","Schulz WA, Burchardt M, Cronauer MV.","Mol Hum Reprod. 2003 Aug;9(8):437-48. doi: 10.1093/molehr/gag064.","Schulz WA","Mol Hum Reprod","2003","2003/07/03","","","10.1093/molehr/gag064"
"24053309","Inflammation and prostate cancer: the role of interleukin 6 (IL-6)","Nguyen DP, Li J, Tewari AK.","BJU Int. 2014 Jun;113(6):986-92. doi: 10.1111/bju.12452.","Nguyen DP","BJU Int","2014","2013/09/24","","","10.1111/bju.12452"
"20707801","Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy","Merrick GS, Butler WM, Galbreath RW, Lief J, Bittner N, Wallner KE, Adamovich E.","BJU Int. 2011 Jan;107(2):226-32. doi: 10.1111/j.1464-410X.2010.09486.x. Epub 2010 Aug 12.","Merrick GS","BJU Int","2011","2010/08/17","","","10.1111/j.1464-410X.2010.09486.x"
"9264768","[Survival of metastatic prostate cancer: 71 patients followed for seven to eleven years]","","Prog Urol. 1997 Apr;7(2):254-8.","","Prog Urol","1997","1997/04/01","","",""
"7688658","Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project","Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK.","Cancer. 1993 Sep 1;72(5):1701-8. doi: 10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e.","Mettlin C","Cancer","1993","1993/09/01","","","10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e"
"26369726","Prostate cancer: AS--contemplation, not intervention","Fenner A.","Nat Rev Urol. 2015 Nov;12(11):595. doi: 10.1038/nrurol.2015.224. Epub 2015 Sep 15.","Fenner A","Nat Rev Urol","2015","2015/09/16","","","10.1038/nrurol.2015.224"
"26235177","How can we decrease suicide risk in cases of genitourinary cancer?","Klaassen Z, Yaguchi G, Terris MK.","Future Oncol. 2015;11(15):2113-5. doi: 10.2217/fon.15.131.","Klaassen Z","Future Oncol","2015","2015/08/04","","","10.2217/fon.15.131"
"11489681","Perspectives on prostate cancer diagnosis and treatment: a roundtable","Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR.","Urology. 2001 Aug;58(2):135-40. doi: 10.1016/s0090-4295(01)01178-5.","Brawer MK","Urology","2001","2001/08/08","","","10.1016/s0090-4295(01)01178-5"
"2689788","Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer","Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.","J Steroid Biochem. 1989 Oct;33(4B):817-21. doi: 10.1016/0022-4731(89)90499-8.","Labrie F","J Steroid Biochem","1989","1989/10/01","","","10.1016/0022-4731(89)90499-8"
"23456439","Follistatin as potential therapeutic target in prostate cancer","Sepporta MV, Tumminello FM, Flandina C, Crescimanno M, Giammanco M, La Guardia M, di Majo D, Leto G.","Target Oncol. 2013 Dec;8(4):215-23. doi: 10.1007/s11523-013-0268-7. Epub 2013 Mar 1.","Sepporta MV","Target Oncol","2013","2013/03/05","","","10.1007/s11523-013-0268-7"
"15952250","Under-investigated area in prostate cancer: cross talk between the bone microenvironment and prostate cancer bone metastasis","Mohla S.","J Cell Biochem. 2004 Mar 1;91(4):684-5. doi: 10.1002/jcb.20055.","Mohla S","J Cell Biochem","2004","2005/06/14","","","10.1002/jcb.20055"
"8262132","Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer","Labrie F, Dupont A, Simard J, Luu-The V, Bélanger A.","Eur Urol. 1993;24 Suppl 2:94-105. doi: 10.1159/000474399.","Labrie F","Eur Urol","1993","1993/01/01","","","10.1159/000474399"
"25302607","Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer","Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK.","Cancer. 2014 Mar 15;120(6):833-9. doi: 10.1002/cncr.28494. Epub 2013 Dec 30.","Doctor SM","Cancer","2014","2014/10/11","","","10.1002/cncr.28494"
"7508524","Prostate cancer","Middleton RG.","J Urol. 1994 Mar;151(3):655. doi: 10.1016/s0022-5347(17)35039-5.","Middleton RG","J Urol","1994","1994/03/01","","","10.1016/s0022-5347(17)35039-5"
"15925066","Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment","Paule B.","Eur Urol. 2005 Jun;47(6):729-35. doi: 10.1016/j.eururo.2005.03.012. Epub 2005 Mar 28.","Paule B","Eur Urol","2005","2005/06/01","","","10.1016/j.eururo.2005.03.012"
"9700305","[Use of prostate specific antigen. A review]","Brasso K, Skaarup P, Roosen JU, Iverson P.","Ugeskr Laeger. 1998 Jul 27;160(31):4510-6.","Brasso K","Ugeskr Laeger","1998","1998/08/13","","",""
"27899188","Familial prostate cancer","Giri VN, Beebe-Dimmer JL.","Semin Oncol. 2016 Oct;43(5):560-565. doi: 10.1053/j.seminoncol.2016.08.001. Epub 2016 Aug 18.","Giri VN","Semin Oncol","2016","2016/12/01","PMC6986340","NIHMS1058131","10.1053/j.seminoncol.2016.08.001"
"9207959","Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk","Shibata A, Whittemore AS.","Prostate. 1997 Jun 15;32(1):65-72. doi: 10.1002/(sici)1097-0045(19970615)32:1<65::aid-pros9>3.0.co;2-b.","Shibata A","Prostate","1997","1997/06/15","","","10.1002/(sici)1097-0045(19970615)32:1<65::aid-pros9>3.0.co;2-b"
"28867136","Prostascore: A Simplified Tool for Predicting Outcomes among Patients with Treatment-naive Advanced Prostate Cancer","Abdel-Rahman O.","Clin Oncol (R Coll Radiol). 2017 Nov;29(11):732-738. doi: 10.1016/j.clon.2017.08.003. Epub 2017 Sep 1.","Abdel-Rahman O","Clin Oncol (R Coll Radiol)","2017","2017/09/05","","","10.1016/j.clon.2017.08.003"
"22144090","CrkI and p130(Cas) complex regulates the migration and invasion of prostate cancer cells","Dai Y, Qi L, Zhang X, Li Y, Chen M, Zu X.","Cell Biochem Funct. 2011 Dec;29(8):625-9. doi: 10.1002/cbf.1797.","Dai Y","Cell Biochem Funct","2011","2011/12/07","","","10.1002/cbf.1797"
"30706785","Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals","Diao W, Cai H, Chen L, Jin X, Liao X, Jia Z.","Curr Top Med Chem. 2019;19(1):33-56. doi: 10.2174/1568026619666190201100739.","Diao W","Curr Top Med Chem","2019","2019/02/02","","","10.2174/1568026619666190201100739"
"1451068","Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation","Hanchette CL, Schwartz GG.","Cancer. 1992 Dec 15;70(12):2861-9. doi: 10.1002/1097-0142(19921215)70:12<2861::aid-cncr2820701224>3.0.co;2-g.","Hanchette CL","Cancer","1992","1992/12/15","","","10.1002/1097-0142(19921215)70:12<2861::aid-cncr2820701224>3.0.co;2-g"
"9301726","Surgery or radiotherapy for prostate cancer: level the playing field","Williams WH, Critz FA.","Urology. 1997 Sep;50(3):481-2.","Williams WH","Urology","1997","1997/09/25","","",""
"8648828","The definition and preoperative prediction of clinically insignificant prostate cancer","Walsh PC.","J Urol. 1996 Jul;156(1):300-1.","Walsh PC","J Urol","1996","1996/07/01","","",""
"8953609","NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network","Baker LH, Hanks G, Gershenson D, Kantoff P, Lange P, Logothetis C, Sandler H, Walsh P.","Oncology (Williston Park). 1996 Nov;10(11 Suppl):265-88.","Baker LH","Oncology (Williston Park)","1996","1996/11/01","","",""
"31629430","Genetic education and practice considerations of non-genetic providers","Giri VN.","Can J Urol. 2019 Oct;26(5 Suppl 2):44-45.","Giri VN","Can J Urol","2019","2019/10/21","","",""
"8717457","Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against","Hall RR.","Eur Urol. 1996;29 Suppl 2:24-6. doi: 10.1159/000473833.","Hall RR","Eur Urol","1996","1996/01/01","","","10.1159/000473833"
"15685445","Chemotherapy for androgen-independent prostate cancer","Petrylak DP.","World J Urol. 2005 Feb;23(1):10-3. doi: 10.1007/s00345-004-0482-0. Epub 2005 Feb 1.","Petrylak DP","World J Urol","2005","2005/02/03","","","10.1007/s00345-004-0482-0"
"15161567","Early versus late hormonal therapy for prostate cancer","Miyamoto H, Messing EM.","Curr Urol Rep. 2004 Jun;5(3):188-96. doi: 10.1007/s11934-004-0036-4.","Miyamoto H","Curr Urol Rep","2004","2004/05/27","","","10.1007/s11934-004-0036-4"
"31100231","Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer","Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T.","Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15.","Aggarwal R","Eur Urol Oncol","2018","2019/05/18","","","10.1016/j.euo.2018.03.010"
"7794337","Prostate cancer kills","Ansong KS.","Urology. 1995 Mar;45(3):550-1. doi: 10.1016/s0090-4295(99)80035-1.","Ansong KS","Urology","1995","1995/03/01","","","10.1016/s0090-4295(99)80035-1"
"20696967","Impact of biochemical recurrence in prostate cancer among US veterans","Uchio EM, Aslan M, Wells CK, Calderone J, Concato J.","Arch Intern Med. 2010 Aug 9;170(15):1390-5. doi: 10.1001/archinternmed.2010.262.","Uchio EM","Arch Intern Med","2010","2010/08/11","","","10.1001/archinternmed.2010.262"
"31142061","[Using the theory of precision medicine to optimize the multidisciplinary comprehensive treatment of prostate cancer]","Ye DW, Zhu Y.","Zhonghua Wai Ke Za Zhi. 2019 Jun 1;57(6):401-403. doi: 10.3760/cma.j.issn.0529-5815.2019.06.001.","Ye DW","Zhonghua Wai Ke Za Zhi","2019","2019/05/31","","","10.3760/cma.j.issn.0529-5815.2019.06.001"
"24042377","Prostate cancer treatment choices","Wolf AM.","Ann Intern Med. 2013 Sep 17;159(6):435-6. doi: 10.7326/0003-4819-159-6-201309170-00018.","Wolf AM","Ann Intern Med","2013","2013/09/18","","","10.7326/0003-4819-159-6-201309170-00018"
"22070222","The multi-cancer marker, rs6983267, located at region 3 of chromosome 8q24, is associated with prostate cancer in Greek patients but does not contribute to the aggressiveness of the disease","Papanikolopoulou A, Landt O, Ntoumas K, Bolomitis S, Tyritzis SI, Constantinides C, Drakoulis N.","Clin Chem Lab Med. 2011 Nov 14;50(2):379-85. doi: 10.1515/CCLM.2011.778.","Papanikolopoulou A","Clin Chem Lab Med","2011","2011/11/11","","","10.1515/CCLM.2011.778"
"7538694","Radical prostatectomy or deferred treatment?","Studer UE.","Semin Surg Oncol. 1995 Jan-Feb;11(1):46-9. doi: 10.1002/ssu.2980110107.","Studer UE","Semin Surg Oncol","1995","1995/01/01","","","10.1002/ssu.2980110107"
"30358212","Interobserver agreement in prostate cancer detection using multiparametric MRI","Popita C, Popita AR, Andrei A, Rusu A, Fetica B, Petrut B, Eliade Ciuleanu T, Coman I.","J BUON. 2018 Jul-Aug;23(4):1061-1069.","Popita C","J BUON","2018","2018/10/26","","",""
"16556007","Hedgehog signaling in prostate cancer","Xie J.","Future Oncol. 2005 Jun;1(3):331-8. doi: 10.1517/14796694.1.3.331.","Xie J","Future Oncol","2005","2006/03/25","","","10.1517/14796694.1.3.331"
"16165910","Second Acta Oncologia symposium on prostate cancer controversies","Levitt S.","Acta Oncol. 2005;44(6):526-8. doi: 10.1080/02841860500251919.","Levitt S","Acta Oncol","2005","2005/09/17","","","10.1080/02841860500251919"
"16281513","[Long term survival results in advanced prostate cancer treated with combined androgen blockade]","Zhang SG, Wang YH, Ding Y, Wu Y.","Zhonghua Nan Ke Xue. 2005 Oct;11(10):770-1, 774.","Zhang SG","Zhonghua Nan Ke Xue","2005","2005/11/12","","",""
"15495199","Human prostate cancer risk factors","Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B.","Cancer. 2004 Nov 15;101(10 Suppl):2371-490. doi: 10.1002/cncr.20408.","Bostwick DG","Cancer","2004","2004/10/21","","","10.1002/cncr.20408"
"20180059","[A paradigm shift. Defensive strategies for the treatment of localized prostate cancer in the new S3 guideline]","Weissbach L, Schaefer C, Heidenreich A.","Urologe A. 2010 Feb;49(2):199-205. doi: 10.1007/s00120-010-2236-5.","Weissbach L","Urologe A","2010","2010/02/25","","","10.1007/s00120-010-2236-5"
"23271770","Active surveillance for prostate cancer: an underutilized opportunity for reducing harm","Carter HB.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):175-83. doi: 10.1093/jncimonographs/lgs036.","Carter HB","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540867","","10.1093/jncimonographs/lgs036"
"9921573","Quality-of-life evaluation in patients receiving treatment for advanced prostate cancer","Esper P, Hampton JN, Smith DC, Pienta KJ.","Oncol Nurs Forum. 1999 Jan-Feb;26(1):107-12.","Esper P","Oncol Nurs Forum","1999","1999/01/28","","",""
"7682387","Prostate cancer: screening, diagnosis, and management","Garnick MB.","Ann Intern Med. 1993 May 15;118(10):804-18. doi: 10.7326/0003-4819-118-10-199305150-00008.","Garnick MB","Ann Intern Med","1993","1993/05/15","","","10.7326/0003-4819-118-10-199305150-00008"
"9168273","Prostate cancer's complexities of causation, detection, and treatment challenge researchers","Gunby P.","JAMA. 1997 May 28;277(20):1580, 1582. doi: 10.1001/jama.277.20.1580.","Gunby P","JAMA","1997","1997/05/28","","","10.1001/jama.277.20.1580"
"27344696","[Perspective of basic research on prostate cancer]","Suzuki K, Matsui H.","Nihon Rinsho. 2016 May 20;74 Suppl 3:12-6.","Suzuki K","Nihon Rinsho","2016","2016/06/28","","",""
"21604937","Introduction. Dilemmas in the field of prostate cancer detection and treatment","Joniau S.","Acta Oncol. 2011 Jun;50 Suppl 1:24. doi: 10.3109/0284186X.2010.578378.","Joniau S","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.578378"
"10645501","Rehabilitation of prostate cancer","Georges CR, McVary KT.","Cancer Treat Res. 1999;100:135-60. doi: 10.1007/978-1-4615-5003-7_8.","Georges CR","Cancer Treat Res","1999","2000/01/25","","","10.1007/978-1-4615-5003-7_8"
"8428335","Pain management in the patient with prostate cancer","Payne R.","Cancer. 1993 Feb 1;71(3 Suppl):1131-7. doi: 10.1002/1097-0142(19930201)71:3+<1131::aid-cncr2820711435>3.0.co;2-v.","Payne R","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1131::aid-cncr2820711435>3.0.co;2-v"
"27344731","[Recent trend in the development of novel treatments based on the mechanisms of prostate cancer progression]","Inoue T, Narita S, Habuchi T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:211-20.","Inoue T","Nihon Rinsho","2016","2016/06/28","","",""
"9496291","Localized prostate cancer: early intervention or expectant therapy?","Griffiths TR, Neal DE.","J R Soc Med. 1997 Dec;90(12):665-9. doi: 10.1177/014107689709001208.","Griffiths TR","J R Soc Med","1997","1998/03/13","PMC1296735","","10.1177/014107689709001208"
"21118060","Adjuvant medical therapy for prostate cancer","Sumey C, Flaig TW.","Expert Opin Pharmacother. 2011 Jan;12(1):73-84. doi: 10.1517/14656566.2010.516252. Epub 2010 Dec 1.","Sumey C","Expert Opin Pharmacother","2011","2010/12/02","","","10.1517/14656566.2010.516252"
"30231379","The Winds of Change: Emerging Therapeutics in Prostate Cancer","Pezaro CJ, Marciscano AE, Madan RA.","Am Soc Clin Oncol Educ Book. 2018 May 23;38:382-390. doi: 10.1200/EDBK_201295.","Pezaro CJ","Am Soc Clin Oncol Educ Book","2018","2018/09/21","","","10.1200/EDBK_201295"
"14620936","Inherited predisposition to prostate cancer","Verhage BA, Kiemeney LA.","Eur J Epidemiol. 2003;18(11):1027-36. doi: 10.1023/a:1026101914592.","Verhage BA","Eur J Epidemiol","2003","2003/11/19","","","10.1023/a:1026101914592"
"17364212","Role of lymphadenectomy in clinically organ-confined prostate cancer","Dhar NB, Burkhard FC, Studer UE.","World J Urol. 2007 Mar;25(1):39-44. doi: 10.1007/s00345-007-0149-8. Epub 2007 Feb 14.","Dhar NB","World J Urol","2007","2007/03/17","","","10.1007/s00345-007-0149-8"
"8087789","The role of the support group, ""Us Too""","Kaps EC.","Cancer. 1994 Oct 1;74(7 Suppl):2188-9. doi: 10.1002/1097-0142(19941001)74:7+<2188::aid-cncr2820741732>3.0.co;2-9.","Kaps EC","Cancer","1994","1994/10/01","","","10.1002/1097-0142(19941001)74:7+<2188::aid-cncr2820741732>3.0.co;2-9"
"11967956","CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy","Suzuki H, Akakura K, Komiya A, Ueda T, Imamoto T, Furuya Y, Ichikawa T, Watanabe M, Shiraishi T, Ito H.","Prostate. 2002 May 15;51(3):219-24. doi: 10.1002/pros.10080.","Suzuki H","Prostate","2002","2002/04/23","","","10.1002/pros.10080"
"24759584","Androgen receptor functions in prostate cancer development and progression","Balk SP.","Asian J Androl. 2014 Jul-Aug;16(4):561-4. doi: 10.4103/1008-682X.126396.","Balk SP","Asian J Androl","2014","2014/04/25","PMC4104081","","10.4103/1008-682X.126396"
"24567085","Prostate cancer: The role of local therapy for metastatic prostate cancer","Tosco L, Van Poppel H.","Nat Rev Urol. 2014 Mar;11(3):134-5. doi: 10.1038/nrurol.2014.33. Epub 2014 Feb 25.","Tosco L","Nat Rev Urol","2014","2014/02/26","","","10.1038/nrurol.2014.33"
"24560205","[Stage IV prostate cancer in Guadeloupe, a French Caribbean archipelago]","Casenave J, Sénéchal C, Nevoux P, Gourtaud G, Tressières B, Blanchet P.","Prog Urol. 2014 Mar;24(3):167-72. doi: 10.1016/j.purol.2013.08.311. Epub 2013 Sep 27.","Casenave J","Prog Urol","2014","2014/02/25","","","10.1016/j.purol.2013.08.311"
"17483024","Genetic variability in inflammation pathways and prostate cancer risk","Sun J, Turner A, Xu J, Grönberg H, Isaacs W.","Urol Oncol. 2007 May-Jun;25(3):250-9. doi: 10.1016/j.urolonc.2006.10.001.","Sun J","Urol Oncol","2007","2007/05/08","","","10.1016/j.urolonc.2006.10.001"
"8996582","Cancer and Leukemia Group B trials for advanced prostate cancer","Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ.","Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31.","Small EJ","Semin Oncol","1996","1996/12/01","","",""
"18494353","Treating prostate cancer: costs and benefits","Vikram B.","Oncology (Williston Park). 2008 Mar;22(3):254, 256; author reply 256.","Vikram B","Oncology (Williston Park)","2008","2008/05/23","","",""
"28259691","HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population","Taheri M, Habibi M, Noroozi R, Rakhshan A, Sarrafzadeh S, Sayad A, Omrani MD, Ghafouri-Fard S.","Gene. 2017 May 20;613:20-24. doi: 10.1016/j.gene.2017.02.031. Epub 2017 Mar 1.","Taheri M","Gene","2017","2017/03/06","","","10.1016/j.gene.2017.02.031"
"22375496","[Utilization of screening and treatment of prostate cancer in 2011]","Tombal B.","Bull Mem Acad R Med Belg. 2011;166(3-4):170-6; discussion 177.","Tombal B","Bull Mem Acad R Med Belg","2011","2012/03/02","","",""
"23455492","The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature","Langston B, Armes J, Levy A, Tidey E, Ream E.","Support Care Cancer. 2013 Jun;21(6):1761-71. doi: 10.1007/s00520-013-1751-5. Epub 2013 Mar 3.","Langston B","Support Care Cancer","2013","2013/03/05","","","10.1007/s00520-013-1751-5"
"9229151","Prostate cancer","Small EJ.","Curr Opin Oncol. 1997 May;9(3):277-86. doi: 10.1097/00001622-199709030-00011.","Small EJ","Curr Opin Oncol","1997","1997/05/01","","","10.1097/00001622-199709030-00011"
"27530265","Does true Gleason pattern 3 merit its cancer descriptor?","Miah S, Ahmed HU, Freeman A, Emberton M.","Nat Rev Urol. 2016 Sep;13(9):541-8. doi: 10.1038/nrurol.2016.141. Epub 2016 Aug 17.","Miah S","Nat Rev Urol","2016","2016/08/18","","","10.1038/nrurol.2016.141"
"3317421","The use of transrectal ultrasound in the diagnosis and management of prostate cancer. Proceedings of a meeting. Detroit, Michigan, September 11-12, 1986","","Prog Clin Biol Res. 1987;237:1-228.","","Prog Clin Biol Res","1987","1987/01/01","","",""
"30538124","Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management","Wu A, Attard G.","Clin Chem. 2019 Jan;65(1):100-107. doi: 10.1373/clinchem.2018.287250. Epub 2018 Dec 11.","Wu A","Clin Chem","2019","2018/12/13","","","10.1373/clinchem.2018.287250"
"25465187","Evaluation of data quality in the National Prostate Cancer Register of Sweden","Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P.","Eur J Cancer. 2015 Jan;51(1):101-11. doi: 10.1016/j.ejca.2014.10.025. Epub 2014 Nov 20.","Tomic K","Eur J Cancer","2015","2014/12/04","","","10.1016/j.ejca.2014.10.025"
"27008982","Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases","Saluja R, Cheung P, Zukotynski K, Emmenegger U.","Urol Oncol. 2016 May;34(5):225-32. doi: 10.1016/j.urolonc.2016.02.016. Epub 2016 Mar 19.","Saluja R","Urol Oncol","2016","2016/03/25","","","10.1016/j.urolonc.2016.02.016"
"8608045","An overview cost-utility analysis of prostate cancer screening","Thompson IM, Optenberg SA.","Oncology (Williston Park). 1995 Nov;9(11 Suppl):141-5.","Thompson IM","Oncology (Williston Park)","1995","1995/11/01","","",""
"18497033","Hormone refractory prostate cancer: Lessons learned from the PTEN prostate cancer model","Mulholland DJ, Jiao J, Wu H.","Adv Exp Med Biol. 2008;617:87-95. doi: 10.1007/978-0-387-69080-3_8.","Mulholland DJ","Adv Exp Med Biol","2008","2008/05/24","","","10.1007/978-0-387-69080-3_8"
"12496990","The management of locally advanced prostate cancer","Valicenti RK.","Prostate Cancer Prostatic Dis. 2002;5 Suppl 2:S8-11. doi: 10.1038/sj.pcan.4500620.","Valicenti RK","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500620"
"1892925","Prostatic cancer: where do we go from here?","Scher H.","Curr Opin Oncol. 1991 Jun;3(3):568-74.","Scher H","Curr Opin Oncol","1991","1991/06/01","","",""
"17982117","Epidemiologic musing on statin drugs in the prevention of advanced prostate cancer","Platz EA.","Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2175-80. doi: 10.1158/1055-9965.EPI-07-0777. Epub 2007 Nov 2.","Platz EA","Cancer Epidemiol Biomarkers Prev","2007","2007/11/06","","","10.1158/1055-9965.EPI-07-0777"
"10909860","Current challenges in cancer screening. Part II. Prostate cancer screening","Clarke P.","Dis Mon. 2000 Jun;46(6):381-404. doi: 10.1016/s0011-5029(00)90003-8.","Clarke P","Dis Mon","2000","2000/07/26","","","10.1016/s0011-5029(00)90003-8"
"8158780","Survival of men with clinically localized prostate cancer detected in the eighth decade of life","Corral DA, Bahnson RR.","J Urol. 1994 May;151(5):1326-9. doi: 10.1016/s0022-5347(17)35242-4.","Corral DA","J Urol","1994","1994/05/01","","","10.1016/s0022-5347(17)35242-4"
"28385253","Prostate cancer: state of the art imaging and focal treatment","Woodrum DA, Kawashima A, Gorny KR, Mynderse LA.","Clin Radiol. 2017 Aug;72(8):665-679. doi: 10.1016/j.crad.2017.02.010. Epub 2017 Apr 3.","Woodrum DA","Clin Radiol","2017","2017/04/08","","","10.1016/j.crad.2017.02.010"
"19573774","Quality of care indicators for prostate cancer: progress toward consensus","Miller DC, Saigal CS.","Urol Oncol. 2009 Jul-Aug;27(4):427-34. doi: 10.1016/j.urolonc.2009.01.011.","Miller DC","Urol Oncol","2009","2009/07/04","","","10.1016/j.urolonc.2009.01.011"
"21208849","Advanced prostate cancer 2010: what a year!","Sartor O, Vogelzang N.","Clin Genitourin Cancer. 2010 Dec 1;8(1):8-9. doi: 10.3816/CGC.2010.n.001.","Sartor O","Clin Genitourin Cancer","2010","2011/01/07","","","10.3816/CGC.2010.n.001"
"15288235","Gene-based therapy in prostate cancer","Foley R, Lawler M, Hollywood D.","Lancet Oncol. 2004 Aug;5(8):469-79. doi: 10.1016/S1470-2045(04)01525-6.","Foley R","Lancet Oncol","2004","2004/08/04","","","10.1016/S1470-2045(04)01525-6"
"19228753","Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study","Glinsky GV.","Clin Cancer Res. 2009 Feb 15;15(4):1504; 1504-5. doi: 10.1158/1078-0432.CCR-08-2580.","Glinsky GV","Clin Cancer Res","2009","2009/02/21","","","10.1158/1078-0432.CCR-08-2580"
"18203556","Prostate cancer initiatives","","J Med Assoc Ga. 2007;96(3):32-3.","","J Med Assoc Ga","2007","2008/01/22","","",""
"2981007","Optimal treatment of prostate cancer","","Oncology (Williston Park). 1987 Sep;1(7):17.","","Oncology (Williston Park)","1987","1987/09/01","","",""
"31230029","Models predicting survival to guide treatment decision-making in newly diagnosed primary non-metastatic prostate cancer: a systematic review","Thurtle D, Rossi SH, Berry B, Pharoah P, Gnanapragasam VJ.","BMJ Open. 2019 Jun 22;9(6):e029149. doi: 10.1136/bmjopen-2019-029149.","Thurtle D","BMJ Open","2019","2019/06/24","PMC6596988","","10.1136/bmjopen-2019-029149"
"20590682","Vaccines as monotherapy and in combination therapy for prostate cancer","Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW.","Clin Transl Sci. 2010 Jun;3(3):116-22. doi: 10.1111/j.1752-8062.2010.00186.x.","Rotow J","Clin Transl Sci","2010","2010/07/02","PMC2914613","NIHMS190632","10.1111/j.1752-8062.2010.00186.x"
"27344748","[Transrectal ultrasound in the diagnosis of prostate cancer]","Kimura G.","Nihon Rinsho. 2016 May 20;74 Suppl 3:310-7.","Kimura G","Nihon Rinsho","2016","2016/06/28","","",""
"19035011","Treating prostate cancer, Part VI: androgen deprivation and beyond","","Harv Mens Health Watch. 2008 Oct;13(3):1-5.","","Harv Mens Health Watch","2008","2008/11/28","","",""
"9650915","Conference summary: First International Workshop on Animal models of Prostate Cancer","Waters DJ, Bostwick DG, Murphy GP.","Prostate. 1998 Jun 15;36(1):47-8. doi: 10.1002/(sici)1097-0045(19980615)36:1<47::aid-pros8>3.0.co;2-8.","Waters DJ","Prostate","1998","1998/07/03","","","10.1002/(sici)1097-0045(19980615)36:1<47::aid-pros8>3.0.co;2-8"
"11584249","Early diagnosis and treatment of prostate cancer","Eastham JA, Scardino PT.","Dis Mon. 2001 Sep;47(9):421-59. doi: 10.1067/mda.2001.119016.","Eastham JA","Dis Mon","2001","2001/10/05","","","10.1067/mda.2001.119016"
"23012811","[Renin-angiotensin system (RAS) as new molecular therapeutic targets in prostate cancer]","Kubota Y, Uemura H.","Nihon Rinsho. 2012 Sep;70(9):1604-12.","Kubota Y","Nihon Rinsho","2012","2012/09/28","","",""
"1574453","The TNM classification of prostate cancer","Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M.","Prostate Suppl. 1992;4:129-38. doi: 10.1002/pros.2990210521.","Schröder FH","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210521"
"12643472","Par-4 for molecular therapy of prostate cancer","Butler J, Rangnekar VM.","Curr Drug Targets. 2003 Apr;4(3):223-30. doi: 10.2174/1389450033491163.","Butler J","Curr Drug Targets","2003","2003/03/20","","","10.2174/1389450033491163"
"12085966","Metastasis suppression in prostate cancer","Jaeger EB, Samant RS, Rinker-Schaeffer CW.","Cancer Metastasis Rev. 2001;20(3-4):279-86. doi: 10.1023/a:1015587411668.","Jaeger EB","Cancer Metastasis Rev","2001","2002/06/28","","","10.1023/a:1015587411668"
"20711438","Is there an optimal management for localized prostate cancer?","Singh J, Trabulsi EJ, Gomella LG.","Clin Interv Aging. 2010 Aug 9;5:187-97. doi: 10.2147/cia.s6555.","Singh J","Clin Interv Aging","2010","2010/08/17","PMC2920199","","10.2147/cia.s6555"
"31753020","Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer","Zhang X.","Cancer Commun (Lond). 2019 Nov 21;39(1):76. doi: 10.1186/s40880-019-0425-1.","Zhang X","Cancer Commun (Lond)","2019","2019/11/23","PMC6873445","","10.1186/s40880-019-0425-1"
"31307628","[Oligometastatic prostate cancer management]","Kleinclauss F, Thiery-Vuillemin A.","Prog Urol. 2019 Jun;29 Suppl 1:S20-S34. doi: 10.1016/S1166-7087(19)30167-8.","Kleinclauss F","Prog Urol","2019","2019/07/17","","","10.1016/S1166-7087(19)30167-8"
"10335135","Using the health belief model in understanding prostate cancer in African American men","Plowden KO.","ABNF J. 1999 Jan-Feb;10(1):4-8.","Plowden KO","ABNF J","1999","1999/05/21","","",""
"10361562","Nutrition and prostate cancer","Yip I, Heber D, Aronson W.","Urol Clin North Am. 1999 May;26(2):403-11, x. doi: 10.1016/s0094-0143(05)70079-3.","Yip I","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70079-3"
"19945666","[Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives]","Beuzeboc P, Soulié M, Richaud P, Salomon L, Staerman F, Peyromaure M, Mongiat-Artus P, Cornud F, Paparel P, Davin JL, Molinié V.","Prog Urol. 2009 Dec;19(11):819-24. doi: 10.1016/j.purol.2009.06.002. Epub 2009 Jul 16.","Beuzeboc P","Prog Urol","2009","2009/12/01","","","10.1016/j.purol.2009.06.002"
"17846740","[DiaPat test for prostate cancer diagnosis]","Semjonow A.","Urologe A. 2007 Oct;46(10):1428. doi: 10.1007/s00120-007-1532-1.","Semjonow A","Urologe A","2007","2007/09/12","","","10.1007/s00120-007-1532-1"
"29179251","Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery","Yu JB, Hamstra D.","Oncology (Williston Park). 2017 Nov 15;31(11):830-2, 835.","Yu JB","Oncology (Williston Park)","2017","2017/11/28","","",""
"26366271","Genetic classifiers for prostate cancer: A new era on the horizon?","Hong SK.","Korean J Urol. 2015 Sep;56(9):605-6. doi: 10.4111/kju.2015.56.9.605.","Hong SK","Korean J Urol","2015","2015/09/15","PMC4565893","","10.4111/kju.2015.56.9.605"
"24571894","Treatment strategies for locally advanced prostate cancer","Zhang K, Zhang X.","Chin Med J (Engl). 2014;127(5):957-60.","Zhang K","Chin Med J (Engl)","2014","2014/02/28","","",""
"8928465","[Current hormone therapy of prostate cancer]","Perevodchikova NI, Bukharkin BV.","Vopr Onkol. 1996;42(4):7-11.","Perevodchikova NI","Vopr Onkol","1996","1996/01/01","","",""
"22157287","Prognostic determinants in prostate cancer","Martin NE, Mucci LA, Loda M, Depinho RA.","Cancer J. 2011 Nov-Dec;17(6):429-37. doi: 10.1097/PPO.0b013e31823b042c.","Martin NE","Cancer J","2011","2011/12/14","PMC3240856","NIHMS336713","10.1097/PPO.0b013e31823b042c"
"8124608","Report on the American Urologic Association/American Cancer Society scientific seminar on the detection and treatment of early-stage prostate cancer","Murphy GP.","CA Cancer J Clin. 1994 Mar-Apr;44(2):91-5. doi: 10.3322/canjclin.44.2.91.","Murphy GP","CA Cancer J Clin","1994","1994/03/01","","","10.3322/canjclin.44.2.91"
"26123038","Prostate cancer: Transdifferentiate to prevail","Thoma C.","Nat Rev Urol. 2015 Aug;12(8):416. doi: 10.1038/nrurol.2015.156. Epub 2015 Jun 30.","Thoma C","Nat Rev Urol","2015","2015/07/01","","","10.1038/nrurol.2015.156"
"17436421","EBRT less effective for early-stage prostate cancer","Nelson R.","Lancet Oncol. 2007 Apr;8(4):286. doi: 10.1016/s1470-2045(07)70089-x.","Nelson R","Lancet Oncol","2007","2007/04/17","","","10.1016/s1470-2045(07)70089-x"
"30111069","High prostate cancer mortality in Poland. A spatial, temporal and structural analysis","Czaderny K.","Przegl Epidemiol. 2018;72(2):235-246.","Czaderny K","Przegl Epidemiol","2018","2018/08/17","","",""
"16114130","Genetics, disparities, and prostate cancer","Rebbeck TR.","LDI Issue Brief. 2005 May-Jun;10(7):1-4.","Rebbeck TR","LDI Issue Brief","2005","2005/08/24","","",""
"26415357","[CLINICAL SURVEILLANCE OF PROSTATE CANCER--COMPARISON WITH CLINICAL MASS STUDY IN JAPAN]","Takada T, Minato N, Koga M, Sugao H.","Nihon Hinyokika Gakkai Zasshi. 2015 Apr;106(2):79-88. doi: 10.5980/jpnjurol.106.79.","Takada T","Nihon Hinyokika Gakkai Zasshi","2015","2015/09/30","","","10.5980/jpnjurol.106.79"
"15354531","[Prospects for early diagnosis of prostate cancer by detection of plasma DNA]","Yu Z, Chen L.","Zhonghua Nan Ke Xue. 2004 Jul;10(7):543-6.","Yu Z","Zhonghua Nan Ke Xue","2004","2004/09/10","","",""
"31512792","Informing informed decision-making in primary prostate cancer treatment selection","Gnanapragasam VJ.","BJU Int. 2020 Feb;125(2):194-196. doi: 10.1111/bju.14910. Epub 2019 Oct 3.","Gnanapragasam VJ","BJU Int","2020","2019/09/13","","","10.1111/bju.14910"
"9752828","Treatment options clearer for prostate cancer","Senior K.","Lancet. 1998 Sep 19;352(9132):963. doi: 10.1016/S0140-6736(98)00016-6.","Senior K","Lancet","1998","1998/09/30","","","10.1016/S0140-6736(98)00016-6"
"10749454","Early prostate cancer","Morton GC.","Curr Probl Cancer. 2000 Jan-Feb;24(1):5-51. doi: 10.1016/s0147-0272(00)90007-2.","Morton GC","Curr Probl Cancer","2000","2000/04/05","","","10.1016/s0147-0272(00)90007-2"
"26754259","Comparison of digit ratio (2D:4D) between Brazilian men with and without prostate cancer","Mendes PH, Martelli DR, de Melo Costa S, Gonçalves E, Macedo CP, Silveira MF, Martelli Júnior H.","Prostate Cancer Prostatic Dis. 2016 Mar;19(1):107-10. doi: 10.1038/pcan.2015.62. Epub 2016 Jan 12.","Mendes PH","Prostate Cancer Prostatic Dis","2016","2016/01/13","","","10.1038/pcan.2015.62"
"8638380","Should we treat localized prostate cancer? An opinion","Hanks GE.","Urology. 1996 Apr;47(4):615-6. doi: 10.1016/S0090-4295(99)80507-X.","Hanks GE","Urology","1996","1996/04/01","","","10.1016/S0090-4295(99)80507-X"
"16892547","[Molecular pathology of prostate carcinoma. Academic playground or guide for diagnosis and therapy planning?]","Bubendorf L.","Verh Dtsch Ges Pathol. 2004;88:158-64.","Bubendorf L","Verh Dtsch Ges Pathol","2004","2006/08/09","","",""
"19931892","The unintended burden of increased prostate cancer detection associated with prostate cancer screening and diagnosis","Albertsen PC.","Urology. 2010 Feb;75(2):399-405. doi: 10.1016/j.urology.2009.08.078. Epub 2009 Nov 22.","Albertsen PC","Urology","2010","2009/11/26","","","10.1016/j.urology.2009.08.078"
"19371478","Update on cryotherapy for localized prostate cancer","Ritch CR, Katz AE.","Curr Urol Rep. 2009 May;10(3):206-11. doi: 10.1007/s11934-009-0035-6.","Ritch CR","Curr Urol Rep","2009","2009/04/18","","","10.1007/s11934-009-0035-6"
"17485362","SNPs associated with prostate cancer risk and prognosis","Naylor SL.","Front Biosci. 2007 May 1;12:4111-31. doi: 10.2741/2375.","Naylor SL","Front Biosci","2007","2007/05/09","","","10.2741/2375"
"8865477","Prostatic intraepithelial neoplasia: significance and management","Lipski BA, Garcia RL, Brawer MK.","Semin Urol Oncol. 1996 Aug;14(3):149-55.","Lipski BA","Semin Urol Oncol","1996","1996/08/01","","",""
"24042378","Prostate cancer treatment choices","Repetto LM, Abbatecola AM, Paolisso G.","Ann Intern Med. 2013 Sep 17;159(6):436. doi: 10.7326/0003-4819-159-6-201309170-00019.","Repetto LM","Ann Intern Med","2013","2013/09/18","","","10.7326/0003-4819-159-6-201309170-00019"
"17105804","JAMA patient page. Prostate cancer","Zeller JL, Lynm C, Glass RM.","JAMA. 2006 Nov 15;296(19):2402. doi: 10.1001/jama.296.19.2402.","Zeller JL","JAMA","2006","2006/11/16","","","10.1001/jama.296.19.2402"
"9329560","Pathological aspects of prostate cancer and benign nodular hyperplasia","Wernert N, Bieroff E, Hügel A.","Anticancer Res. 1997 Jul-Aug;17(4B):2907-10.","Wernert N","Anticancer Res","1997","1997/07/01","","",""
"21140180","Response to commentary ""Zinc is decreased in prostate cancer: an established relationship of prostate cancer!""","Banas AM, Banas K.","J Biol Inorg Chem. 2011 Jan;16(1):9-13. doi: 10.1007/s00775-010-0737-8. Epub 2010 Dec 8.","Banas AM","J Biol Inorg Chem","2011","2010/12/09","PMC3019356","","10.1007/s00775-010-0737-8"
"20852828","Radiotherapeutic strategies in the management of low-risk prostate cancer","Choe KS, Liauw SL.","ScientificWorldJournal. 2010 Sep 14;10:1854-69. doi: 10.1100/tsw.2010.179.","Choe KS","ScientificWorldJournal","2010","2010/09/21","PMC5763745","","10.1100/tsw.2010.179"
"10572993","Prostate cancer registration in four Swedish regions 1996-- differences in incidence, age structure and management","Sandblom G, Mattsson E, Nilsson J, Damber JE, Johansson JE, Lundgren R, Varenhorst E.","Scand J Urol Nephrol. 1999 Oct;33(5):306-11. doi: 10.1080/003655999750017374.","Sandblom G","Scand J Urol Nephrol","1999","1999/11/26","","","10.1080/003655999750017374"
"17124481","The best local therapy for unfavorable risk prostate cancer: the role of surgery","Studd RC, Sowery RD, Gleave ME.","Minerva Urol Nefrol. 2006 Sep;58(3):99-118.","Studd RC","Minerva Urol Nefrol","2006","2006/11/25","","",""
"7531782","A potpourri of new observations about prostate cancer","Lange PH.","J Urol. 1995 Mar;153(3 Pt 2):1009-10. doi: 10.1016/s0022-5347(01)67623-7.","Lange PH","J Urol","1995","1995/03/01","","","10.1016/s0022-5347(01)67623-7"
"29700008","Smoking and Prostate Cancer-Specific Mortality after Diagnosis in a Large Prospective Cohort","Gansler T, Shah R, Wang Y, Stevens VL, Yang B, Newton CC, Gapstur SM, Jacobs EJ.","Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):665-672. doi: 10.1158/1055-9965.EPI-17-0890. Epub 2018 Apr 26.","Gansler T","Cancer Epidemiol Biomarkers Prev","2018","2018/04/28","","","10.1158/1055-9965.EPI-17-0890"
"25518363","[Cancer stem cells in prostate cancer]","Nishida S, Masumori N.","Nihon Rinsho. 2014 Dec;72(12):2229-33.","Nishida S","Nihon Rinsho","2014","2014/12/19","","",""
"28817399","Chemotherapy for oligometastatic prostate cancer","Dorff TB, Sweeney CJ.","Curr Opin Urol. 2017 Nov;27(6):553-558. doi: 10.1097/MOU.0000000000000446.","Dorff TB","Curr Opin Urol","2017","2017/08/18","","","10.1097/MOU.0000000000000446"
"9812508","[Study on the quality of life in patients with prostate cancer]","Du SF, Shi LY, Zhang HJ.","Zhonghua Liu Xing Bing Xue Za Zhi. 1997 Apr;18(2):95-7.","Du SF","Zhonghua Liu Xing Bing Xue Za Zhi","1997","1997/04/01","","",""
"9801541","Ultrasonically guided interstitial brachytherapy for prostate cancer: care of the patient in ambulatory surgery","Redmond MC.","J Perianesth Nurs. 1998 Jun;13(3):156-64; quiz 164-7. doi: 10.1016/s1089-9472(98)80045-2.","Redmond MC","J Perianesth Nurs","1998","1998/11/05","","","10.1016/s1089-9472(98)80045-2"
"11325210","Incidence rate and management of prostate carcinoma","Sandblom G, Varenhorst E.","Biomed Pharmacother. 2001 Apr;55(3):135-43. doi: 10.1016/s0753-3322(01)00038-5.","Sandblom G","Biomed Pharmacother","2001","2001/04/28","","","10.1016/s0753-3322(01)00038-5"
"23925926","The effect of a Rapid Access Prostate Cancer Clinic on prostate cancer patient and disease characteristics, primary treatment and surgical workload","Oon SF, Cullen IM, Moran D, Bolton EM, McDermott T, Grainger R, Lynch TH.","Ir J Med Sci. 2014 Jun;183(2):241-7. doi: 10.1007/s11845-013-0997-8. Epub 2013 Aug 8.","Oon SF","Ir J Med Sci","2014","2013/08/09","","","10.1007/s11845-013-0997-8"
"11293992","[Adenocarcinoma of prostate in men younger than 50--rectal palpation mandatory with micturition problems]","Wymenga LF, Mensink HJ.","Ned Tijdschr Geneeskd. 2001 Mar 24;145(12):553-7.","Wymenga LF","Ned Tijdschr Geneeskd","2001","2001/04/11","","",""
"18190394","Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis","Ide H, Hatake K, Terado Y, Tsukino H, Okegawa T, Nutahara K, Higashihara E, Horie S.","Hum Cell. 2008 Feb;21(1):1-6. doi: 10.1111/j.1749-0774.2007.00042.x.","Ide H","Hum Cell","2008","2008/01/15","","","10.1111/j.1749-0774.2007.00042.x"
"27482892","On Risk Estimation versus Risk Stratification in Early Prostate Cancer","Carlsson SV, Kattan MW.","PLoS Med. 2016 Aug 2;13(8):e1002100. doi: 10.1371/journal.pmed.1002100. eCollection 2016 Aug.","Carlsson SV","PLoS Med","2016","2016/08/03","PMC4970733","","10.1371/journal.pmed.1002100"
"27882770","Focal therapy as primary treatment for localized prostate cancer: definition, needs and future","Ouzzane A, Betrouni N, Valerio M, Rastinehad A, Colin P, Ploussard G.","Future Oncol. 2017 Apr;13(8):727-741. doi: 10.2217/fon-2016-0229. Epub 2016 Nov 24.","Ouzzane A","Future Oncol","2017","2016/11/25","","","10.2217/fon-2016-0229"
"18593620","Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient","Beekman KW, Hussain M.","Urol Oncol. 2008 Jul-Aug;26(4):415-9. doi: 10.1016/j.urolonc.2007.11.003.","Beekman KW","Urol Oncol","2008","2008/07/03","","","10.1016/j.urolonc.2007.11.003"
"6369279","Immunotherapy of prostate cancer: a review","Guinan P, Ray P, Shaw M.","Prostate. 1984;5(2):221-30. doi: 10.1002/pros.2990050212.","Guinan P","Prostate","1984","1984/01/01","","","10.1002/pros.2990050212"
"17340546","[The participation experiences of localized prostate cancer patients in the treatment decision-making process]","Chien CH, Chuang CK, Liu KL, Liu HE.","Hu Li Za Zhi. 2007 Feb;54(1):35-42.","Chien CH","Hu Li Za Zhi","2007","2007/03/07","","",""
"1623384","Natural history and prognosis of prostate carcinoma in adolescents and men under 35 years of age","Sandhu DP, Munson KW, Benghiat A, Hopper IP.","Br J Urol. 1992 May;69(5):525-9. doi: 10.1111/j.1464-410x.1992.tb15602.x.","Sandhu DP","Br J Urol","1992","1992/05/01","","","10.1111/j.1464-410x.1992.tb15602.x"
"17549396","Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review)","Ye L, Kynaston HG, Jiang WG.","Int J Mol Med. 2007 Jul;20(1):103-11.","Ye L","Int J Mol Med","2007","2007/06/06","","",""
"23303340","Prostate cancer: ESMO Consensus Conference Guidelines 2012","Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members; European Society for Medical Oncology.","Ann Oncol. 2013 May;24(5):1141-62. doi: 10.1093/annonc/mds624. Epub 2013 Jan 9.","Horwich A","Ann Oncol","2013","2013/01/11","","","10.1093/annonc/mds624"
"7685704","Clinical observations on the doubling time of prostate cancer","Schmid HP, McNeal JE, Stamey TA.","Eur Urol. 1993;23 Suppl 2:60-3. doi: 10.1159/000474708.","Schmid HP","Eur Urol","1993","1993/01/01","","","10.1159/000474708"
"2769878","Re: Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy","Lange PH.","J Urol. 1989 Sep;142(3):832-3. doi: 10.1016/s0022-5347(17)38919-x.","Lange PH","J Urol","1989","1989/09/01","","","10.1016/s0022-5347(17)38919-x"
"19051034","Prostate cancer cognitive-behavioral factors in a West African population","Odedina FT, Yu D, Akinremi TO, Reams RR, Freedman ML, Kumar N.","J Immigr Minor Health. 2009 Aug;11(4):258-67. doi: 10.1007/s10903-008-9212-9. Epub 2008 Dec 4.","Odedina FT","J Immigr Minor Health","2009","2008/12/04","","","10.1007/s10903-008-9212-9"
"12469638","[Modern approaches to treating locally-advanced and disseminated prostate cancer]","Veliev EI.","Ter Arkh. 2002;74(10):67-70.","Veliev EI","Ter Arkh","2002","2002/12/10","","",""
"12539246","Correlation between prostate cancer grade and vascularity on color doppler imaging: preliminary findings","Tang J, Li S, Li J, Luo Y, Xu J, Zhang Y, Li X, Shi H, Zhang G.","J Clin Ultrasound. 2003 Feb;31(2):61-8. doi: 10.1002/jcu.10139.","Tang J","J Clin Ultrasound","2003","2003/01/23","","","10.1002/jcu.10139"
"1724347","[PSA in the staging and monitoring of cancer of the prostate]","Gil Sanz MJ, Sanz Velez JI, Liedana Torres JM, Roncales Badal AL, Allepuz Losa C, Rioja Sanz LA.","Actas Urol Esp. 1991 Nov-Dec;15(6):527-31.","Gil Sanz MJ","Actas Urol Esp","1991","1991/11/01","","",""
"8473090","Bilateral orchiectomy in the management of stage D-2 prostate cancer","Guinan P, Firfer R, Targonski P, Rubenstein M.","Int Surg. 1993 Jan-Mar;78(1):73-5.","Guinan P","Int Surg","1993","1993/01/01","","",""
"14689882","[Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer]","Zhao XJ, Kong XB, Wang WH.","Zhonghua Nan Ke Xue. 2003 Nov;9(8):563-5, 568.","Zhao XJ","Zhonghua Nan Ke Xue","2003","2003/12/24","","",""
"8196078","Concern grows over prostate cancer treatment options","Parkins T.","J Natl Cancer Inst. 1994 Jun 15;86(12):897-8. doi: 10.1093/jnci/86.12.897.","Parkins T","J Natl Cancer Inst","1994","1994/06/15","","","10.1093/jnci/86.12.897"
"26991008","Recent advances in prostate cancer pathology: Gleason grading and beyond","Shah RB, Zhou M.","Pathol Int. 2016 May;66(5):260-72. doi: 10.1111/pin.12398. Epub 2016 Mar 18.","Shah RB","Pathol Int","2016","2016/03/19","","","10.1111/pin.12398"
"10664668","Prostate cancer: the role of transrectal ultrasound and its impact on cancer detection and management","Littrup PJ, Bailey SE.","Radiol Clin North Am. 2000 Jan;38(1):87-113. doi: 10.1016/s0033-8389(05)70151-2.","Littrup PJ","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70151-2"
"27039434","Prostate cancer rates decreasing as screening declines. Some experts question the wisdom of reduced screening","","Duke Med Health News. 2016 Feb;22(2):6.","","Duke Med Health News","2016","2016/04/05","","",""
"18842992","Androgen and prostate cancer: is the hypothesis dead?","Hsing AW, Chu LW, Stanczyk FZ.","Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2525-30. doi: 10.1158/1055-9965.EPI-08-0448.","Hsing AW","Cancer Epidemiol Biomarkers Prev","2008","2008/10/10","","","10.1158/1055-9965.EPI-08-0448"
"15892724","Men, culture and hegemonic masculinity: understanding the experience of prostate cancer","Wall D, Kristjanson L.","Nurs Inq. 2005 Jun;12(2):87-97. doi: 10.1111/j.1440-1800.2005.00258.x.","Wall D","Nurs Inq","2005","2005/05/17","","","10.1111/j.1440-1800.2005.00258.x"
"21220228","[High-risk clinically localised prostate cancer]","Rozet F, Cornu JN, Cussenot O, Fromont G, Hennequin C.","Bull Cancer. 2010 Dec;97(12):1517-36. doi: 10.1684/bdc.2010.1228.","Rozet F","Bull Cancer","2010","2011/01/12","","","10.1684/bdc.2010.1228"
"10352075","Presurgery experiences of prostate cancer patients and their spouses","Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L.","Cancer Pract. 1999 May-Jun;7(3):130-5. doi: 10.1046/j.1523-5394.1999.07308.x.","Gray RE","Cancer Pract","1999","1999/06/03","","","10.1046/j.1523-5394.1999.07308.x"
"23410126","Genome-wide integrated analyses of androgen receptor signaling in prostate cancer based on high-throughput technology","Horie-Inoue K, Inoue S.","Curr Drug Targets. 2013 Apr;14(4):472-80. doi: 10.2174/1389450111314040008.","Horie-Inoue K","Curr Drug Targets","2013","2013/02/16","","","10.2174/1389450111314040008"
"27776423","MRI-guided focal therapy of prostate cancer","Mathew MS, Oto A.","Future Oncol. 2017 Mar;13(6):537-549. doi: 10.2217/fon-2016-0201. Epub 2016 Oct 25.","Mathew MS","Future Oncol","2017","2016/10/26","","","10.2217/fon-2016-0201"
"8717456","Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for","Brawer MK.","Eur Urol. 1996;29 Suppl 2:19-23. doi: 10.1159/000473832.","Brawer MK","Eur Urol","1996","1996/01/01","","","10.1159/000473832"
"29806760","Oligometastatic prostate cancer and salvage lymph node dissection: systematic review","Brassetti A, Proietti F, Pansadoro V.","Minerva Chir. 2019 Feb;74(1):97-106. doi: 10.23736/S0026-4733.18.07796-9. Epub 2018 May 25.","Brassetti A","Minerva Chir","2019","2018/05/29","","","10.23736/S0026-4733.18.07796-9"
"23413606","Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO?","Burgess EF, Raghavan D.","Oncology (Williston Park). 2012 Dec;26(12):1216-21.","Burgess EF","Oncology (Williston Park)","2012","2013/02/19","","",""
"20140279","Targeted therapy for advanced prostate cancer: Looking through new lenses","Vogiatzi P, Cassone M, Claudio L, Claudio PP.","Drug News Perspect. 2009 Dec;22(10):593-601. doi: 10.1358/dnp.2009.10.1428872.","Vogiatzi P","Drug News Perspect","2009","2010/02/09","","","10.1358/dnp.2009.10.1428872"
"22038225","Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators","Makarewicz R, Zyromska A, Andrusewicz H.","Folia Histochem Cytobiol. 2011;49(3):452-7. doi: 10.5603/fhc.2011.0064.","Makarewicz R","Folia Histochem Cytobiol","2011","2011/11/01","","","10.5603/fhc.2011.0064"
"7707440","Recent trends in incidence and treatment of prostate cancer among elderly men","Severson RK, Montie JE, Porter AT, Demers RY.","J Natl Cancer Inst. 1995 Apr 5;87(7):532-4. doi: 10.1093/jnci/87.7.532.","Severson RK","J Natl Cancer Inst","1995","1995/04/05","","","10.1093/jnci/87.7.532"
"28189566","Revisiting the role of Wnt/β-catenin signaling in prostate cancer","Schneider JA, Logan SK.","Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):3-8. doi: 10.1016/j.mce.2017.02.008. Epub 2017 Feb 9.","Schneider JA","Mol Cell Endocrinol","2018","2017/02/13","PMC5550366","NIHMS854581","10.1016/j.mce.2017.02.008"
"27709828","Understanding the role of new systemic agents in the treatment of prostate cancer","Corfield J, Crozier J, Joshua AM, Bolton D, Lawrentschuk N.","BJU Int. 2016 Oct;118 Suppl 3:8-13. doi: 10.1111/bju.13633. Epub 2016 Oct 6.","Corfield J","BJU Int","2016","2016/10/07","","","10.1111/bju.13633"
"11170136","Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment","Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH.","Prostate. 2001 Feb 1;46(2):87-97. doi: 10.1002/1097-0045(20010201)46:2<87::aid-pros1012>3.0.co;2-r.","Madalinska JB","Prostate","2001","2001/02/15","","","10.1002/1097-0045(20010201)46:2<87::aid-pros1012>3.0.co;2-r"
"30060812","Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer","Voelkel-Johnson C, Norris JS, White-Gilbertson S.","Adv Cancer Res. 2018;140:265-293. doi: 10.1016/bs.acr.2018.04.014. Epub 2018 Jun 20.","Voelkel-Johnson C","Adv Cancer Res","2018","2018/08/01","PMC6460930","NIHMS1016666","10.1016/bs.acr.2018.04.014"
"27779202","The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients","Moschini M, Soria F, Briganti A, Shariat SF.","Prostate Cancer Prostatic Dis. 2017 Mar;20(1):7-11. doi: 10.1038/pcan.2016.52. Epub 2016 Oct 25.","Moschini M","Prostate Cancer Prostatic Dis","2017","2016/10/26","","","10.1038/pcan.2016.52"
"17459270","Managing the local complications of locally advanced prostate cancer","Anast JW, Andriole GL, Grubb RL 2nd.","Curr Urol Rep. 2007 May;8(3):211-6. doi: 10.1007/s11934-007-0008-6.","Anast JW","Curr Urol Rep","2007","2007/04/27","","","10.1007/s11934-007-0008-6"
"21714161","Patients and solipsism: the psychology of decision making for prostate cancer treatment","Chamie K, Saigal CS, Litwin MS.","Urol Oncol. 2011 May-Jun;29(3):233-4. doi: 10.1016/j.urolonc.2010.11.015.","Chamie K","Urol Oncol","2011","2011/06/30","","","10.1016/j.urolonc.2010.11.015"
"18723368","Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach","Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, Dogliotti L, Conti G, Turesson I, James N, Heidenreich A, Solsona E, Guillem V, Herchenhorn D, Moul J, van Moorselaar J, Coetzee LJ, Wilson A, Bamias A, De Wit R, Chrisofos M.","Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S9-S22. doi: 10.1016/j.critrevonc.2008.07.019. Epub 2008 Aug 23.","Fitzpatrick JM","Crit Rev Oncol Hematol","2008","2008/08/30","","","10.1016/j.critrevonc.2008.07.019"
"25023239","[Low-risk prostate cancer]","Stief CG, Roosen A.","Urologe A. 2014 Jul;53(7):1030. doi: 10.1007/s00120-014-3522-4.","Stief CG","Urologe A","2014","2014/07/16","","","10.1007/s00120-014-3522-4"
"17399888","Re: Chao-Yu Hsu, Steven Joniau, Raymond Oyen et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur urol 2007;51:121-9","Nickers P, Lartigau E.","Eur Urol. 2007 Aug;52(2):612. doi: 10.1016/j.eururo.2007.03.048. Epub 2007 Mar 26.","Nickers P","Eur Urol","2007","2007/04/03","","","10.1016/j.eururo.2007.03.048"
"18711369","Report from Durham","Moul JW.","Prostate Cancer Prostatic Dis. 2008;11(3):211. doi: 10.1038/pcan.2008.43.","Moul JW","Prostate Cancer Prostatic Dis","2008","2008/08/20","","","10.1038/pcan.2008.43"
"29439879","Can Focal Therapy Replace Radical Therapy for Prostate Cancer? Against Focal Therapy","Reichard C, Chapin BF.","Eur Urol Focus. 2017 Dec;3(6):524-525. doi: 10.1016/j.euf.2018.01.011. Epub 2018 Feb 10.","Reichard C","Eur Urol Focus","2017","2018/02/15","","","10.1016/j.euf.2018.01.011"
"9038119","Has ultrasonography a role in screening for prostatic cancer?","Clements R.","Eur Radiol. 1997;7(2):217-23. doi: 10.1007/s003300050139.","Clements R","Eur Radiol","1997","1997/01/01","","","10.1007/s003300050139"
"24249383","The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases","O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW.","Prostate. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752.","O'Hurley G","Prostate","2014","2013/11/20","","","10.1002/pros.22752"
"8717458","The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument for","Abrahamsson PA.","Eur Urol. 1996;29 Suppl 2:27-30. doi: 10.1159/000473834.","Abrahamsson PA","Eur Urol","1996","1996/01/01","","","10.1159/000473834"
"19901934","Cryoablation of the prostate: technical recommendations","Cytron S, Greene D, Witzsch U, Nylund P, Bjerklund Johansen TE.","Prostate Cancer Prostatic Dis. 2009;12(4):339-46. doi: 10.1038/pcan.2009.26. Epub 2009 Sep 1.","Cytron S","Prostate Cancer Prostatic Dis","2009","2009/11/11","","","10.1038/pcan.2009.26"
"10548316","Vasectomy and risk of prostate cancer","Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK.","Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):881-6.","Stanford JL","Cancer Epidemiol Biomarkers Prev","1999","1999/11/05","","",""
"18327816","Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy","Palma D, Pickles T.","Cancer. 2008 May 15;112(10):2322-3; author reply 2323. doi: 10.1002/cncr.23423.","Palma D","Cancer","2008","2008/03/11","","","10.1002/cncr.23423"
"8686979","Prostate cancer: emerging concepts. Part II","Garnick MB, Fair WR.","Ann Intern Med. 1996 Aug 1;125(3):205-12. doi: 10.7326/0003-4819-125-3-199608010-00009.","Garnick MB","Ann Intern Med","1996","1996/08/01","","","10.7326/0003-4819-125-3-199608010-00009"
"18924634","Prostate cancer screening: why it's not for every man","Lakhan SE.","Medscape J Med. 2008;10(8):182; author reply 182. Epub 2008 Aug 4.","Lakhan SE","Medscape J Med","2008","2008/10/18","PMC2562049","",""
"8813905","Prostate cancer: anatomical and surgical considerations","Gil-Vernet JM.","Br J Urol. 1996 Aug;78(2):161-8. doi: 10.1046/j.1464-410x.1996.00841.x.","Gil-Vernet JM","Br J Urol","1996","1996/08/01","","","10.1046/j.1464-410x.1996.00841.x"
"7910920","Screening for prostate cancer","Schröder FH.","Lancet. 1994 Jun 4;343(8910):1438-9.","Schröder FH","Lancet","1994","1994/06/04","","",""
"21139643","Paraneoplastic syndromes in prostate cancer","Hong MK, Kong J, Namdarian B, Longano A, Grummet J, Hovens CM, Costello AJ, Corcoran NM.","Nat Rev Urol. 2010 Dec;7(12):681-92. doi: 10.1038/nrurol.2010.186.","Hong MK","Nat Rev Urol","2010","2010/12/09","","","10.1038/nrurol.2010.186"
"16010283","An elevated PSA, which normalizes, does not exclude the presence of prostate cancer","Boddy JL, Pike DJ, Al-Hayek S, Shaida N, Malone PR.","Prostate Cancer Prostatic Dis. 2005;8(4):349-52. doi: 10.1038/sj.pcan.4500819.","Boddy JL","Prostate Cancer Prostatic Dis","2005","2005/07/13","","","10.1038/sj.pcan.4500819"
"10420155","Future prospects in prostate cancer","Hegarty NJ, Fitzpatrick JM, Richie JP, Scardino PT, deVere White RW, Schröder FH, Coffey DS.","Prostate. 1999 Sep 1;40(4):261-8. doi: 10.1002/(sici)1097-0045(19990901)40:4<261::aid-pros8>3.0.co;2-h.","Hegarty NJ","Prostate","1999","1999/07/27","","","10.1002/(sici)1097-0045(19990901)40:4<261::aid-pros8>3.0.co;2-h"
"11114596","Advanced prostate cancer: immediate or deferred hormone therapy?","Newling D.","Eur Urol. 2001;39 Suppl 1:15-21. doi: 10.1159/000052545.","Newling D","Eur Urol","2001","2000/12/15","","","10.1159/000052545"
"15714978","[Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer]","Fujimoto H.","Nihon Rinsho. 2005 Feb;63(2):271-8.","Fujimoto H","Nihon Rinsho","2005","2005/02/18","","",""
"16598883","Localised prostate cancer: treatment versus surveillance?","Burton A.","Lancet Oncol. 2006 Apr;7(4):289. doi: 10.1016/s1470-2045(06)70642-8.","Burton A","Lancet Oncol","2006","2006/04/08","","","10.1016/s1470-2045(06)70642-8"
"9112524","Localized prostate cancer-mortality and morbidity","Walsh PC.","J Urol. 1997 May;157(5):1773. doi: 10.1016/s0022-5347(01)64860-2.","Walsh PC","J Urol","1997","1997/05/01","","","10.1016/s0022-5347(01)64860-2"
"17925542","American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer","Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI; American Society of Clinical Oncology.","J Clin Oncol. 2007 Nov 20;25(33):5313-8. doi: 10.1200/JCO.2007.13.4536. Epub 2007 Oct 9.","Basch EM","J Clin Oncol","2007","2007/10/11","","","10.1200/JCO.2007.13.4536"
"8411497","Treatment strategies for prostate cancer","Cohen MH.","JAMA. 1993 Oct 13;270(14):1693.","Cohen MH","JAMA","1993","1993/10/13","","",""
"19424170","Prostate cancer: thalidomide for prostate cancer: is there progress?","Efstathiou E, Logothetis CJ.","Nat Rev Urol. 2009 May;6(5):248-50. doi: 10.1038/nrurol.2009.68.","Efstathiou E","Nat Rev Urol","2009","2009/05/09","","","10.1038/nrurol.2009.68"
"9334615","Trends in diagnosis of stage T1a-b prostate cancer","Fowler JE Jr, Pandey P, Bigler SA, Yee DT, Kolski JM.","J Urol. 1997 Nov;158(5):1849-52. doi: 10.1016/s0022-5347(01)64144-2.","Fowler JE Jr","J Urol","1997","1997/10/23","","","10.1016/s0022-5347(01)64144-2"
"27272004","[Uncommon manifestation of prostate cancer : Sister Mary Joseph's nodule]","Hansen T, Weckesser M, Schäfers M, Gunnemann A.","Urologe A. 2017 Jan;56(1):50-53. doi: 10.1007/s00120-016-0130-5.","Hansen T","Urologe A","2017","2016/06/09","","","10.1007/s00120-016-0130-5"
"27649586","New insights on prostate cancer progression","Valcarcel-Jimenez L, Torrano V, Carracedo A.","Cell Cycle. 2017 Jan 2;16(1):13-14. doi: 10.1080/15384101.2016.1235845. Epub 2016 Sep 20.","Valcarcel-Jimenez L","Cell Cycle","2017","2016/09/22","PMC5270526","","10.1080/15384101.2016.1235845"
"20729153","Precedence for prostate brachytherapy","Aronowitz JN, Grimard L, Robison R.","Brachytherapy. 2011 May-Jun;10(3):201-7. doi: 10.1016/j.brachy.2010.07.001. Epub 2010 Aug 21.","Aronowitz JN","Brachytherapy","2011","2010/08/24","","","10.1016/j.brachy.2010.07.001"
"9397611","Application of cryoablation in the management of prostate cancer","Chuang CK, Chu SH, Chen HW, Chiang YJ, Chou CC.","Changgeng Yi Xue Za Zhi. 1997 Sep;20(3):201-6.","Chuang CK","Changgeng Yi Xue Za Zhi","1997","1997/12/16","","",""
"22795499","Defining prostate cancer risk before prostate biopsy","Pal RP, Maitra NU, Mellon JK, Khan MA.","Urol Oncol. 2013 Nov;31(8):1408-18. doi: 10.1016/j.urolonc.2012.05.012. Epub 2012 Jul 12.","Pal RP","Urol Oncol","2013","2012/07/17","","","10.1016/j.urolonc.2012.05.012"
"15808958","Quality of life in prostate cancer","Talcott JA, Clark JA.","Eur J Cancer. 2005 Apr;41(6):922-31. doi: 10.1016/j.ejca.2004.12.030.","Talcott JA","Eur J Cancer","2005","2005/04/06","","","10.1016/j.ejca.2004.12.030"
"28885207","Effect of irreversible electroporation of prostate cancer on microcirculation: Imaging findings in contrast-enhanced T1-weighted 3D MRI","Beyer LP, Pregler B, Verloh N, Brünn K, Haimerl M, Stroszczynski C, Jung EM, Wiggermann P.","Clin Hemorheol Microcirc. 2017;67(3-4):399-405. doi: 10.3233/CH-179220.","Beyer LP","Clin Hemorheol Microcirc","2017","2017/09/09","","","10.3233/CH-179220"
"1538485","Why make an early diagnosis of prostate cancer","Walsh PC.","J Urol. 1992 Mar;147(3 Pt 2):853-4. doi: 10.1016/s0022-5347(17)37404-9.","Walsh PC","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37404-9"
"7638470","Early intervention or expectant management for prostate cancer. The Prostate Cancer Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with expectant management for the treatment of clinically localized prostate cancer","Wilt TJ, Brawer MK.","Semin Urol. 1995 May;13(2):130-6.","Wilt TJ","Semin Urol","1995","1995/05/01","","",""
"15663802","Which patients with prostate cancer are actually candidates for hormone therapy?","Sciarra A, Cardi A, Salvatori G, D'Eramo G, Mariotti G, Di Silverio F.","Int Braz J Urol. 2004 Nov-Dec;30(6):455-65. doi: 10.1590/s1677-55382004000600002.","Sciarra A","Int Braz J Urol","2004","2005/01/25","","","10.1590/s1677-55382004000600002"
"16229075","Surgery effective for advanced form of prostate cancer","","Mayo Clin Health Lett. 2005 Aug;23(8):4.","","Mayo Clin Health Lett","2005","2005/10/19","","",""
"7933191","Prostate cancer","Lange PH.","J Urol. 1994 Nov;152(5 Pt 1):1496-7. doi: 10.1016/s0022-5347(17)32454-0.","Lange PH","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32454-0"
"9363972","Early detection of prostate cancer. Serendipity strikes again","McNaughton Collins M, Ransohoff DF, Barry MJ.","JAMA. 1997 Nov 12;278(18):1516-9. doi: 10.1001/jama.278.18.1516.","McNaughton Collins M","JAMA","1997","1997/11/18","","","10.1001/jama.278.18.1516"
"9989206","Genetic epidemiology of prostate cancer","Narod S.","Biochim Biophys Acta. 1999 Jan 29;1423(1):F1-13. doi: 10.1016/s0304-419x(98)00030-4.","Narod S","Biochim Biophys Acta","1999","1999/02/16","","","10.1016/s0304-419x(98)00030-4"
"8326561","Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer","Chelsky MJ, Schnall MD, Seidmon EJ, Pollack HM.","J Urol. 1993 Aug;150(2 Pt 1):391-5. doi: 10.1016/s0022-5347(17)35490-3.","Chelsky MJ","J Urol","1993","1993/08/01","","","10.1016/s0022-5347(17)35490-3"
"10664670","The prostate: diagnostic evaluation of metastatic disease","Yu KK, Hawkins RA.","Radiol Clin North Am. 2000 Jan;38(1):139-57, ix. doi: 10.1016/s0033-8389(05)70153-6.","Yu KK","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70153-6"
"19953931","[Expression and significance of CD147 protein in prostate cancer]","He HC, Han ZD, Dai QS, Zou J, Zhang Y, Zhang Z, Liang YX, Ye YK, Chen ZN, Zhong WD.","Zhonghua Yi Xue Za Zhi. 2009 Jul 14;89(26):1844-6.","He HC","Zhonghua Yi Xue Za Zhi","2009","2009/12/04","","",""
"12028298","Clinical features of prostate cancer patients younger than 50 years: report of seven cases","Kanto S, Ohyama C, Okada Y, MitSukawa S, Takemoto J, Hoshi S, Orikasa S.","Int J Urol. 2002 Feb;9(2):91-4. doi: 10.1046/j.1442-2042.2002.00427.x.","Kanto S","Int J Urol","2002","2002/05/25","","","10.1046/j.1442-2042.2002.00427.x"
"9749489","JAMA patient page: prostate cancer","","JAMA. 1998 Sep 16;280(11):1030.","","JAMA","1998","1998/09/28","","",""
"11249473","Prostate-specific antigen","Ornstein DK, Pruthi RS.","Expert Opin Pharmacother. 2000 Dec;1(7):1399-411. doi: 10.1517/14656566.1.7.1399.","Ornstein DK","Expert Opin Pharmacother","2000","2001/03/16","","","10.1517/14656566.1.7.1399"
"15074729","Controversies in the radiotherapeutic management of poor prognosis locally advanced prostate cancer","Henry AM, Price P, Logue JP, Cowan RA, Shanks JH, Dearnaley DP, Khoo VS.","Clin Oncol (R Coll Radiol). 2004 Apr;16(2):87-94. doi: 10.1016/j.clon.2003.10.012.","Henry AM","Clin Oncol (R Coll Radiol)","2004","2004/04/13","","","10.1016/j.clon.2003.10.012"
"9563122","[Adjuvant therapy in lymph node positive prostate carcinoma?]","Schmeller N.","Urologe A. 1998 Mar;37(2):141-4. doi: 10.1007/s001200050161.","Schmeller N","Urologe A","1998","1998/05/01","","","10.1007/s001200050161"
"10992405","Re: radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer","Walsh PC.","J Urol. 2000 Oct;164(4):1322-3.","Walsh PC","J Urol","2000","2000/09/19","","",""
"7268980","[Treatment of prostate cancer]","Kan DV, Dunaevskiĭ IaL.","Urol Nefrol (Mosk). 1981 Jul-Aug;(4):29-34.","Kan DV","Urol Nefrol (Mosk)","1981","1981/07/01","","",""
"22640911","Nanoparticle therapeutics for prostate cancer treatment","Sanna V, Sechi M.","Nanomedicine. 2012 Sep;8 Suppl 1:S31-6. doi: 10.1016/j.nano.2012.05.009. Epub 2012 May 26.","Sanna V","Nanomedicine","2012","2012/05/30","","","10.1016/j.nano.2012.05.009"
"22840862","Diagnostic significance of overexpression of Golgi membrane protein 1 in prostate cancer","Li W, Wang X, Li B, Lu J, Chen G.","Urology. 2012 Oct;80(4):952.e1-7. doi: 10.1016/j.urology.2012.06.017. Epub 2012 Jul 25.","Li W","Urology","2012","2012/07/31","","","10.1016/j.urology.2012.06.017"
"14719450","[Clinical study of endocrine therapy in stage B and C prostate cancer]","Uei T, Okazaki H, Nakamura T, Katou N, Suzuki K, Yamanaka H.","Hinyokika Kiyo. 2003 Nov;49(11):639-43.","Uei T","Hinyokika Kiyo","2003","2004/01/15","","",""
"9451392","Expanding the evidence base for localised prostate cancer","Hamilton CS.","Med J Aust. 1998 Jan 5;168(1):28-30.","Hamilton CS","Med J Aust","1998","1998/02/06","","",""
"27447616","Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer","Zhang K, Zhou S, Wang L, Wang J, Zou Q, Zhao W, Fu Q, Fang X.","Int J Mol Sci. 2016 Jul 19;17(7):1163. doi: 10.3390/ijms17071163.","Zhang K","Int J Mol Sci","2016","2016/07/23","PMC4964535","","10.3390/ijms17071163"
"23797237","Methylation markers for prostate cancer prognosis: a systematic review","Chao C, Chi M, Preciado M, Black MH.","Cancer Causes Control. 2013 Sep;24(9):1615-41. doi: 10.1007/s10552-013-0249-2.","Chao C","Cancer Causes Control","2013","2013/06/26","","","10.1007/s10552-013-0249-2"
"28477422","Prostate cancer molecular profiling: the Achilles heel for the implementation of precision medicine","Oliveira-Barros EG, Nicolau-Neto P, Da Costa NM, Pinto LFR, Palumbo A Jr, Nasciutti LE.","Cell Biol Int. 2017 Nov;41(11):1239-1245. doi: 10.1002/cbin.10785. Epub 2017 May 18.","Oliveira-Barros EG","Cell Biol Int","2017","2017/05/07","","","10.1002/cbin.10785"
"29050519","LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer","Yang J, Li C, Mudd A, Gu X.","Biosci Biotechnol Biochem. 2017 Dec;81(12):2301-2306. doi: 10.1080/09168451.2017.1387048. Epub 2017 Oct 20.","Yang J","Biosci Biotechnol Biochem","2017","2017/10/21","","","10.1080/09168451.2017.1387048"
"20646638","[Clinical considerations in the diagnosis and treatment of prostate cancer]","Zhang YF, Jiang HW.","Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):937-9.","Zhang YF","Zhonghua Yi Xue Za Zhi","2010","2010/07/22","","",""
"15604294","Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program","Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.","Cancer Res. 2004 Dec 15;64(24):9209-16. doi: 10.1158/0008-5472.CAN-04-2442.","Shah RB","Cancer Res","2004","2004/12/18","","","10.1158/0008-5472.CAN-04-2442"
"8518866","Treatment preferences of urologists in Great Britain and Ireland in the management of prostate cancer","Waymont B, Lynch TH, Dunn J, Bathers S, Wallace DM.","Br J Urol. 1993 May;71(5):577-82. doi: 10.1111/j.1464-410x.1993.tb16028.x.","Waymont B","Br J Urol","1993","1993/05/01","","","10.1111/j.1464-410x.1993.tb16028.x"
"15947879","Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden","Chang ET, Hedelin M, Adami HO, Grönberg H, Bälter KA.","Cancer Causes Control. 2005 Apr;16(3):275-84. doi: 10.1007/s10552-004-3364-2.","Chang ET","Cancer Causes Control","2005","2005/06/11","","","10.1007/s10552-004-3364-2"
"17078328","Cultural disparities in the diagnosis and treatment of prostate cancer","Ward-Smith P.","Urol Nurs. 2006 Oct;26(5):397-9, 405.","Ward-Smith P","Urol Nurs","2006","2006/11/03","","",""
"31271305","HOXC6 in the prognosis of prostate cancer","Zhou J, Yang X, Song P, Wang H, Wang X.","Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2715-2720. doi: 10.1080/21691401.2019.1635136.","Zhou J","Artif Cells Nanomed Biotechnol","2019","2019/07/05","","","10.1080/21691401.2019.1635136"
"24776974","Prostate cancer: alcohol, cancer and 5α-reductase inhibitors-is there a link?","Gomella LG.","Nat Rev Urol. 2014 May;11(5):253-4. doi: 10.1038/nrurol.2014.90. Epub 2014 Apr 29.","Gomella LG","Nat Rev Urol","2014","2014/04/30","","","10.1038/nrurol.2014.90"
"9174811","Prostate cancer","Garzotto M, Fair WR.","Curr Ther Endocrinol Metab. 1997;6:582-6.","Garzotto M","Curr Ther Endocrinol Metab","1997","1997/01/01","","",""
"12712405","Nuclear matrix proteins changes in cancerous prostate tissues and their prognostic value in clinically localized prostate cancer","Boccardo F, Rubagotti A, Carmignani G, Romagnoli A, Nicolò G, Barboro P, Parodi S, Patrone E, Balbi C.","Prostate. 2003 Jun 1;55(4):259-64. doi: 10.1002/pros.10248.","Boccardo F","Prostate","2003","2003/04/25","","","10.1002/pros.10248"
"21129661","[Postoperative radiotherapy for prostate cancer]","Vieillot S, Fenoglietto P, Ailleres N, Hay MH, Dubois JB, Azria D.","Cancer Radiother. 2010 Nov;14 Suppl 1:S174-81. doi: 10.1016/S1278-3218(10)70021-4.","Vieillot S","Cancer Radiother","2010","2010/12/07","","","10.1016/S1278-3218(10)70021-4"
"23419742","Margin status is a very important prognostic factor for patients with pT3b prostate cancer","Ramírez-Backhaus M, Rubio-Briones J, Calatrava-Fons A, Gómez-Ferrer Á, Collado A, Iborra I, Monrós JA, Ricós J, Solsona Narbón E.","Actas Urol Esp. 2013 Oct;37(9):538-43. doi: 10.1016/j.acuro.2012.11.007. Epub 2013 Feb 16.","Ramírez-Backhaus M","Actas Urol Esp","2013","2013/02/20","","","10.1016/j.acuro.2012.11.007"
"24652998","Androgen deprivation therapy is ineffective for early prostate cancer, US study shows","Mayor S.","BMJ. 2014 Mar 19;348:g2230. doi: 10.1136/bmj.g2230.","Mayor S","BMJ","2014","2014/03/22","","","10.1136/bmj.g2230"
"8497651","Staging prostate cancer with MR imaging","Sumers EH.","Radiology. 1993 Jun;187(3):875. doi: 10.1148/radiology.187.3.8497651.","Sumers EH","Radiology","1993","1993/06/01","","","10.1148/radiology.187.3.8497651"
"22248515","Focal therapy will become standard treatment for localized prostate cancer: con","Nelson JB.","J Urol. 2012 Mar;187(3):791-2. doi: 10.1016/j.juro.2011.12.022. Epub 2012 Jan 15.","Nelson JB","J Urol","2012","2012/01/18","","","10.1016/j.juro.2011.12.022"
"20710098","An overview of the diagnosis and management of prostate cancer in Nigeria: experience from a north-central state of Nigeria","Bowa K.","Ann Afr Med. 2010 Jul-Sep;9(3):111-2. doi: 10.4103/1596-3519.68350.","Bowa K","Ann Afr Med","2010","2010/08/17","","","10.4103/1596-3519.68350"
"15095309","Food groups and risk of prostate cancer in Italy","Bosetti C, Micelotta S, Dal Maso L, Talamini R, Montella M, Negri E, Conti E, Franceschi S, La Vecchia C.","Int J Cancer. 2004 Jun 20;110(3):424-8. doi: 10.1002/ijc.20142.","Bosetti C","Int J Cancer","2004","2004/04/20","","","10.1002/ijc.20142"
"17848666","High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?","Andriole GL, Humphrey PA, Serfling RJ, Grubb RL.","J Natl Cancer Inst. 2007 Sep 19;99(18):1355-6. doi: 10.1093/jnci/djm151. Epub 2007 Sep 11.","Andriole GL","J Natl Cancer Inst","2007","2007/09/13","","","10.1093/jnci/djm151"
"15460038","[Calcium-dependent programmed cell death in prostate cancer]","Shuba IaM, Prevars'ka N, Skryma R.","Fiziol Zh. 2004;50(4):128-41.","Shuba IaM","Fiziol Zh","2004","2004/10/06","","",""
"23775445","Function of mutant and wild-type plexinb1 in prostate cancer cells","Damola A, Legendre A, Ball S, Masters JR, Williamson M.","Prostate. 2013 Sep;73(12):1326-35. doi: 10.1002/pros.22678. Epub 2013 Jun 15.","Damola A","Prostate","2013","2013/06/19","PMC4282548","","10.1002/pros.22678"
"9750514","[The definition and frequency of clinically unimportant prostate cancer in the patients treated with radical prostatectomy]","Ohori M.","Nihon Rinsho. 1998 Aug;56(8):2092-7.","Ohori M","Nihon Rinsho","1998","1998/09/29","","",""
"27344715","[Neuroendocrine differentiation of prostate cancer]","Nishikawa K, Sugimura Y.","Nihon Rinsho. 2016 May 20;74 Suppl 3:122-6.","Nishikawa K","Nihon Rinsho","2016","2016/06/28","","",""
"24934371","Caveolin-1 as a biomarker to predict therapeutic effect of low-frequency ultrasound combined with SonoVue on prostate cancer in nude mice model","Xu W, Nan S, Bai W, Shen E, Hu B.","Cancer Biomark. 2014;14(4):279-86. doi: 10.3233/CBM-140405.","Xu W","Cancer Biomark","2014","2014/06/18","","","10.3233/CBM-140405"
"8512779","Treatment of progressive metastatic prostate cancer","Dawson NA.","Oncology (Williston Park). 1993 May;7(5):17-24, 27; discussion 27-9.","Dawson NA","Oncology (Williston Park)","1993","1993/05/01","","",""
"30045668","First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer","Dong S, Wang H, Zhao Y, Sun Y, Yao C.","Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789692. doi: 10.1177/1533033818789692.","Dong S","Technol Cancer Res Treat","2018","2018/07/27","PMC6071159","","10.1177/1533033818789692"
"18427434","Management of lymph nodes in early prostate cancer","Liatsikos E, Kallidonis P, Stolzenburg JU.","Minerva Urol Nefrol. 2008 Mar;60(1):41-9.","Liatsikos E","Minerva Urol Nefrol","2008","2008/04/23","","",""
"21536828","A practical guide to prostate cancer diagnosis and management","Simmons MN, Berglund RK, Jones JS.","Cleve Clin J Med. 2011 May;78(5):321-31. doi: 10.3949/ccjm.78a.10104.","Simmons MN","Cleve Clin J Med","2011","2011/05/04","","","10.3949/ccjm.78a.10104"
"11592091","The androgen receptor gene and its influence on the development and progression of prostate cancer","Montgomery JS, Price DK, Figg WD.","J Pathol. 2001 Sep;195(2):138-46. doi: 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y.","Montgomery JS","J Pathol","2001","2001/10/10","","","10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y"
"27344787","[Management of recurrence after external beam radiotherapy for prostate cancer]","Inoue T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:525-9.","Inoue T","Nihon Rinsho","2016","2016/06/28","","",""
"8863574","Prostate cancer--bench to bedside","Fowler JE Jr.","J Urol. 1996 Nov;156(5):1701-2. doi: 10.1016/s0022-5347(01)65486-7.","Fowler JE Jr","J Urol","1996","1996/11/01","","","10.1016/s0022-5347(01)65486-7"
"1376205","Detection and screening for prostate cancer","Lee F, Torp-Pedersen S, Cooner W, Drago J, Holtgrewe L, Littrup P, Resnick M.","Cancer. 1992 Jul 1;70(1 Suppl):355-6. doi: 10.1002/1097-0142(19920701)70:1+<355::aid-cncr2820701327>3.0.co;2-t.","Lee F","Cancer","1992","1992/07/01","","","10.1002/1097-0142(19920701)70:1+<355::aid-cncr2820701327>3.0.co;2-t"
"11037555","Locally advanced (high-risk) prostate cancer. American College of Radiology. ACR Appropriateness Criteria","Pollack A, Paryani SB, Hussey D, Perez CA, Beyer DC, Blasko JC, Forman JD, Lee WR, Potters L, Roach M 3rd, Scardino P, Schellhammer P, Leibel S.","Radiology. 2000 Jun;215 Suppl:1401-12.","Pollack A","Radiology","2000","2000/10/19","","",""
"15535440","An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer","Oh WK.","J Urol. 2004 Nov;172(5 Pt 2):S34-7; discussion S37. doi: 10.1097/01.ju.0000141674.92253.fe.","Oh WK","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000141674.92253.fe"
"24401467","Prostate cancer: summary of updated NICE guidance","Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M.","BMJ. 2014 Jan 8;348:f7524. doi: 10.1136/bmj.f7524.","Graham J","BMJ","2014","2014/01/10","","","10.1136/bmj.f7524"
"22469149","What's new--what's changing in prostate cancer? Abstracts of an interactive one-day educational meeting of the Royal Society of Medicine Sections of Oncology. February 17, 2012. London, United Kingdom","","Int J Clin Pract Suppl. 2012 Apr;(176):1-4. doi: 10.1111/j.1742-1241.2012.02915.x.","","Int J Clin Pract Suppl","2012","2012/04/04","","","10.1111/j.1742-1241.2012.02915.x"
"18082582","Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?","Klotz L.","Semin Radiat Oncol. 2008 Jan;18(1):2-6. doi: 10.1016/j.semradonc.2007.09.001.","Klotz L","Semin Radiat Oncol","2008","2007/12/18","","","10.1016/j.semradonc.2007.09.001"
"30420958","Predicting Advanced Prostate Cancer from Modeling Early Indications in Biopsy and Prostatectomy Samples via Transductive Semi-Supervised Survival Analysis","Khan FM.","Biomed Res Int. 2018 Oct 21;2018:2178645. doi: 10.1155/2018/2178645. eCollection 2018.","Khan FM","Biomed Res Int","2018","2018/11/14","PMC6215592","","10.1155/2018/2178645"
"23806495","Pushing the limits of radiation therapy for prostate cancer: where do we go next?","Mishra MV, Showalter TN.","Semin Oncol. 2013 Jun;40(3):297-307. doi: 10.1053/j.seminoncol.2013.04.005.","Mishra MV","Semin Oncol","2013","2013/06/29","","","10.1053/j.seminoncol.2013.04.005"
"1702894","Determination of prostate volume with transrectal US for cancer screening. Part I. Comparison with prostate-specific antigen assays","Littrup PJ, Kane RA, Williams CR, Egglin TK, Lee F, Torp-Pedersen S, Church PA.","Radiology. 1991 Feb;178(2):537-42. doi: 10.1148/radiology.178.2.1702894.","Littrup PJ","Radiology","1991","1991/02/01","","","10.1148/radiology.178.2.1702894"
"8900764","Patient resources for prostate cancer","Sharp JW, Aviv L.","Cancer Pract. 1996 Jul-Aug;4(4):216-8.","Sharp JW","Cancer Pract","1996","1996/07/01","","",""
"25849602","Gleason 6 Prostate Cancer: Translating Biology into Population Health","Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT.","J Urol. 2015 Sep;194(3):626-34. doi: 10.1016/j.juro.2015.01.126. Epub 2015 Apr 4.","Eggener SE","J Urol","2015","2015/04/08","PMC4551510","NIHMS702588","10.1016/j.juro.2015.01.126"
"18367118","Sexual intimacy in heterosexual couples after prostate cancer treatment: What we know and what we still need to learn","Beck AM, Robinson JW, Carlson LE.","Urol Oncol. 2009 Mar-Apr;27(2):137-43. doi: 10.1016/j.urolonc.2007.11.032. Epub 2008 Mar 4.","Beck AM","Urol Oncol","2009","2008/03/28","","","10.1016/j.urolonc.2007.11.032"
"19286303","Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications","Aus G.","Eur Urol. 2009 Jun;55(6):1331. doi: 10.1016/j.eururo.2009.02.030. Epub 2009 Mar 6.","Aus G","Eur Urol","2009","2009/03/17","","","10.1016/j.eururo.2009.02.030"
"17550409","'Time, gentlemen, please' for watchful waiting in prostate cancer?","Kenny LM, Ngan S, Waxman J.","BJU Int. 2007 Aug;100(2):244-6. doi: 10.1111/j.1464-410X.2007.07063.x. Epub 2007 Jun 5.","Kenny LM","BJU Int","2007","2007/06/07","","","10.1111/j.1464-410X.2007.07063.x"
"22292443","Tissue biomarkers for prostate cancer radiation therapy","Tran PT, Hales RK, Zeng J, Aziz K, Salih T, Gajula RP, Chettiar S, Gandhi N, Wild AT, Kumar R, Herman JM, Song DY, DeWeese TL.","Curr Mol Med. 2012 Jul 1;12(6):772-87. doi: 10.2174/156652412800792589.","Tran PT","Curr Mol Med","2012","2012/02/02","PMC3412203","","10.2174/156652412800792589"
"1877106","Accuracy of imaging modalities in staging the local extent of prostate cancer","Ebert T, Schmitz-Dräger BJ, Bürrig KF, Miller S, Pauli N, Kahn T, Ackermann R.","Urol Clin North Am. 1991 Aug;18(3):453-7.","Ebert T","Urol Clin North Am","1991","1991/08/01","","",""
"9727630","Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review","Westin P, Bergh A.","Cancer Detect Prev. 1998;22(5):476-84.","Westin P","Cancer Detect Prev","1998","1998/09/04","","",""
"7095868","Recent patterns of care of prostate cancer patients in the United States: results from the surveys of the American college of Surgeons Commission on Cancer","Mettlin C, Natarajan N, Murphy GP.","Int Adv Surg Oncol. 1982;5:277-321.","Mettlin C","Int Adv Surg Oncol","1982","1982/01/01","","",""
"25311673","Prostate cancer: sniffing out prostate cancer","Stone L.","Nat Rev Urol. 2014 Dec;11(12):662. doi: 10.1038/nrurol.2014.289. Epub 2014 Oct 14.","Stone L","Nat Rev Urol","2014","2014/10/15","","","10.1038/nrurol.2014.289"
"23406686","The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence","Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB.","J Exp Clin Cancer Res. 2013 Feb 13;32(1):9. doi: 10.1186/1756-9966-32-9.","Xiang YZ","J Exp Clin Cancer Res","2013","2013/02/15","PMC3598969","","10.1186/1756-9966-32-9"
"9299578","Basic science aspects of prostate cancer","Dorkin TJ, Neal DE.","Semin Cancer Biol. 1997 Feb;8(1):21-7. doi: 10.1006/scbi.1997.0049.","Dorkin TJ","Semin Cancer Biol","1997","1997/02/01","","","10.1006/scbi.1997.0049"
"12728441","Treatment of prostate cancer with regional lymph node (N1) metastasis","Pollack A, Horwitz EM, Movsas B.","Semin Radiat Oncol. 2003 Apr;13(2):121-9. doi: 10.1053/srao.2003.50011.","Pollack A","Semin Radiat Oncol","2003","2003/05/03","","","10.1053/srao.2003.50011"
"27327120","Hypoxia-Responsive Mir-301a and Mir-301b Promote Radioresistance of Prostate Cancer Cells via Downregulating NDRG2","Wang W, Liu M, Guan Y, Wu Q.","Med Sci Monit. 2016 Jun 21;22:2126-32. doi: 10.12659/msm.896832.","Wang W","Med Sci Monit","2016","2016/06/22","PMC4920099","","10.12659/msm.896832"
"27716456","Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: Yes","Costa WH, Guimarães GC.","Int Braz J Urol. 2016 Sep-Oct;42(5):876-879. doi: 10.1590/S1677-5538.IBJU.2016.05.04.","Costa WH","Int Braz J Urol","2016","2016/10/08","PMC5066882","","10.1590/S1677-5538.IBJU.2016.05.04"
"23047508","Pathway crosstalk analysis based on protein-protein network analysis in prostate cancer","Wang JM, Wu JT, Sun DK, Zhang P, Wang L.","Eur Rev Med Pharmacol Sci. 2012 Sep;16(9):1235-42.","Wang JM","Eur Rev Med Pharmacol Sci","2012","2012/10/11","","",""
"25595907","Androgen receptors beyond prostate cancer: an old marker as a new target","Munoz J, Wheler JJ, Kurzrock R.","Oncotarget. 2015 Jan 20;6(2):592-603. doi: 10.18632/oncotarget.2831.","Munoz J","Oncotarget","2015","2015/01/18","PMC4359241","","10.18632/oncotarget.2831"
"28980139","Evidence of depression-associated circadian rhythm disruption and regret in prostate cancer patients after surgery","Christie J, Sharpley CF, Bitsika V, Christie D.","Support Care Cancer. 2017 Dec;25(12):3603-3605. doi: 10.1007/s00520-017-3913-3. Epub 2017 Oct 4.","Christie J","Support Care Cancer","2017","2017/10/06","","","10.1007/s00520-017-3913-3"
"19716766","Towards the definition of prostate cancer-related microRNAs: where are we now?","Gandellini P, Folini M, Zaffaroni N.","Trends Mol Med. 2009 Sep;15(9):381-90. doi: 10.1016/j.molmed.2009.07.004. Epub 2009 Aug 27.","Gandellini P","Trends Mol Med","2009","2009/09/01","","","10.1016/j.molmed.2009.07.004"
"8211248","Prostate cancer screening: getting your patients to follow-up","Greco KE.","Urol Nurs. 1993 Sep;13(3):76-9.","Greco KE","Urol Nurs","1993","1993/09/01","","",""
"24079112","The role of biomarkers in the detection and treatment of prostate cancer","Ward-Smith P.","Urol Nurs. 2013 Jul-Aug;33(4):161-2.","Ward-Smith P","Urol Nurs","2013","2013/10/02","","",""
"10492191","Race as an independent predictor of outcome after treatment for localized prostate cancer","Sohayda CJ, Kupelian PA, Altsman KA, Klein EA.","J Urol. 1999 Oct;162(4):1331-6.","Sohayda CJ","J Urol","1999","1999/09/24","","",""
"19756633","Considerations on prostate cancer: diagnosis and treatment decisions","Herrmann TR, Merseburger AS, Burchardt M.","World J Urol. 2009 Oct;27(5):579-80. doi: 10.1007/s00345-009-0475-0.","Herrmann TR","World J Urol","2009","2009/09/17","","","10.1007/s00345-009-0475-0"
"22734010","Novel therapies for advanced prostate cancer: have we have widened the goal posts too far?","Raghavan D.","Ann Oncol. 2012 Oct;23(10):2473-2475. doi: 10.1093/annonc/mds185. Epub 2012 Jun 24.","Raghavan D","Ann Oncol","2012","2012/06/27","","","10.1093/annonc/mds185"
"10563174","[Timely screening routines for prostatic cancer by Norwegian physicians]","Fosså SD, Eri LM.","Tidsskr Nor Laegeforen. 1999 Oct 10;119(24):3572-6.","Fosså SD","Tidsskr Nor Laegeforen","1999","1999/11/24","","",""
"12184407","High-risk prostate cancer: how high is high?","Sandler HM.","Cancer J. 2002 Jul-Aug;8(4):301-2. doi: 10.1097/00130404-200207000-00005.","Sandler HM","Cancer J","2002","2002/08/20","","","10.1097/00130404-200207000-00005"
"19465331","[News aspects on surgical management of localized prostate cancer]","Drouin SJ, Rouprêt M.","Prog Urol. 2009 Apr;19 Suppl 1:S12-4. doi: 10.1016/S1166-7087(09)73900-4.","Drouin SJ","Prog Urol","2009","2009/05/26","","","10.1016/S1166-7087(09)73900-4"
"23872953","Dietary factors and risk for advanced prostate cancer","Gathirua-Mwangi WG, Zhang J.","Eur J Cancer Prev. 2014 Mar;23(2):96-109. doi: 10.1097/CEJ.0b013e3283647394.","Gathirua-Mwangi WG","Eur J Cancer Prev","2014","2013/07/23","PMC4091618","NIHMS595579","10.1097/CEJ.0b013e3283647394"
"18709810","[Antioxidant power and cellular damage in prostate cancer]","López Laur JD, Abud M, López Fontana C, Silva J, Cisella Y, Pérez Elizalde R, Ortiz A.","Arch Esp Urol. 2008 Jun;61(5):563-9. doi: 10.4321/s0004-06142008000500001.","López Laur JD","Arch Esp Urol","2008","2008/08/20","","","10.4321/s0004-06142008000500001"
"25497220","Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options","Conde Moreno AJ, Ferrer Albiach C, Muelas Soria R, González Vidal V, García Gómez R, Albert Antequera M.","Radiat Oncol. 2014 Dec 11;9:258. doi: 10.1186/s13014-014-0258-7.","Conde Moreno AJ","Radiat Oncol","2014","2014/12/16","PMC4272793","","10.1186/s13014-014-0258-7"
"8558212","Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out","D'Amico AV, Coleman CN.","J Clin Oncol. 1996 Jan;14(1):304-15. doi: 10.1200/JCO.1996.14.1.304.","D'Amico AV","J Clin Oncol","1996","1996/01/01","","","10.1200/JCO.1996.14.1.304"
"15714987","[Sentinel lymph node concept in prostate cancer]","Egawa M, Fukuda M, Imao T, Namiki M.","Nihon Rinsho. 2005 Feb;63(2):327-32.","Egawa M","Nihon Rinsho","2005","2005/02/18","","",""
"21791716","Transrectal high-intensity focused ultrasound for local treatment of prostate cancer: current role","Chaussy CG, Thüroff S.","Arch Esp Urol. 2011 Jul;64(6):493-506.","Chaussy CG","Arch Esp Urol","2011","2011/07/28","","",""
"16310371","Cancer of the prostate","Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, de Braud F, Bartsch G.","Crit Rev Oncol Hematol. 2005 Dec;56(3):379-96. doi: 10.1016/j.critrevonc.2005.03.010.","Bracarda S","Crit Rev Oncol Hematol","2005","2005/11/29","","","10.1016/j.critrevonc.2005.03.010"
"19947349","Active surveillance for low-risk localized prostate cancer","Large MC, Eggener SE.","Oncology (Williston Park). 2009 Oct;23(11):974-9.","Large MC","Oncology (Williston Park)","2009","2009/12/02","","",""
"10584346","[Early diagnosis of prostate cancer in patients with prostate symptoms by DRE, PSA, TRU and DPSA]","Mínguez Martínez R, Fernández Borrell A, Gómez Sancha F, Ruiz Zarate C, Teba del Pino F, Romero Tejada JC, Arellano Gañan R, Pereira Sanz I.","Actas Urol Esp. 1999 Sep;23(8):688-93.","Mínguez Martínez R","Actas Urol Esp","1999","1999/12/10","","",""
"30889618","[Surgical treatment of prostate cancer]","Nyirády P.","Magy Onkol. 2019 Mar 19;63(1):26-31. Epub 2019 Feb 27.","Nyirády P","Magy Onkol","2019","2019/03/20","","",""
"25948794","[What has changed in the epidemiology and screening of prostate cancer?]","Portela-Pereira P, Gómez-Veiga F.","Arch Esp Urol. 2015 Apr;68(3):202-9.","Portela-Pereira P","Arch Esp Urol","2015","2015/05/08","","",""
"10207628","Smoking and risk of total and fatal prostate cancer in United States health professionals","Giovannucci E, Rimm EB, Ascherio A, Colditz GA, Spiegelman D, Stampfer MJ, Willett WC.","Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82.","Giovannucci E","Cancer Epidemiol Biomarkers Prev","1999","1999/04/20","","",""
"21111858","PET/CT Imaging and Radioimmunotherapy of Prostate Cancer","Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P.","Semin Nucl Med. 2011 Jan;41(1):29-44. doi: 10.1053/j.semnuclmed.2010.08.005.","Bouchelouche K","Semin Nucl Med","2011","2010/11/30","PMC3392994","NIHMS389899","10.1053/j.semnuclmed.2010.08.005"
"20046498","Contrast-enhanced harmonic ultrasonography for the assessment of prostate cancer aggressiveness: a preliminary study","Zhu Y, Chen Y, Jiang J, Wang R, Zhou Y, Zhang H.","Korean J Radiol. 2010 Jan-Feb;11(1):75-83. doi: 10.3348/kjr.2010.11.1.75. Epub 2009 Dec 28.","Zhu Y","Korean J Radiol","2010","2010/01/05","PMC2799654","","10.3348/kjr.2010.11.1.75"
"12084265","Gene therapy for prostate cancer","Gingrich JR, Chauhan RD, Steiner MS.","Curr Urol Rep. 2001 Jun;2(3):199-208. doi: 10.1007/s11934-001-0079-8.","Gingrich JR","Curr Urol Rep","2001","2002/06/27","","","10.1007/s11934-001-0079-8"
"20082648","Investigations of prostate epithelial stem cells and prostate cancer stem cells","Miki J.","Int J Urol. 2010 Feb;17(2):139-47. doi: 10.1111/j.1442-2042.2009.02438.x. Epub 2010 Jan 15.","Miki J","Int J Urol","2010","2010/01/20","","","10.1111/j.1442-2042.2009.02438.x"
"27742691","Exposure to polychlorinated biphenyls and prostate cancer: population-based prospective cohort and experimental studies","Ali I, Julin B, Glynn A, Högberg J, Berglund M, Johansson JE, Andersson SO, Andrén O, Giovannucci E, Wolk A, Stenius U, Åkesson A.","Carcinogenesis. 2016 Dec;37(12):1144-1151. doi: 10.1093/carcin/bgw105. Epub 2016 Oct 7.","Ali I","Carcinogenesis","2016","2016/10/16","","","10.1093/carcin/bgw105"
"3253740","Clinical and morphometric observations on prostate cancer","Stamey TA.","Med Sect Proc. 1988:29-42.","Stamey TA","Med Sect Proc","1988","1988/01/01","","",""
"2482118","The pathology of early prostate cancer","Bostwick DG.","CA Cancer J Clin. 1989 Nov-Dec;39(6):376-93. doi: 10.3322/canjclin.39.6.376.","Bostwick DG","CA Cancer J Clin","1989","1989/11/01","","","10.3322/canjclin.39.6.376"
"14666653","Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice","Ng SS, Figg WD.","Anticancer Res. 2003 Sep-Oct;23(5A):3585-90.","Ng SS","Anticancer Res","2003","2003/12/12","","",""
"15897972","Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen","Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, Zhang L, Tateno H, Sato I, Kuwahara M, Zhao XJ.","Asian J Androl. 2005 Jun;7(2):159-63. doi: 10.1111/j.1745-7262.2005.00029.x.","Gao HW","Asian J Androl","2005","2005/05/18","","","10.1111/j.1745-7262.2005.00029.x"
"9314823","Prostate Cancer Awareness Week: September 22 to 28, 1997","Crawford ED.","CA Cancer J Clin. 1997 Sep-Oct;47(5):288-96. doi: 10.3322/canjclin.47.5.288.","Crawford ED","CA Cancer J Clin","1997","1997/10/07","","","10.3322/canjclin.47.5.288"
"24080341","Spirituality in men with advanced prostate cancer: ""it's a holistic thing . . . it's a package""","Lepherd L.","J Holist Nurs. 2014 Jun;32(2):89-101; quiz 102-3. doi: 10.1177/0898010113504492. Epub 2013 Sep 30.","Lepherd L","J Holist Nurs","2014","2013/10/02","","","10.1177/0898010113504492"
"20702155","A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer","Hammarsten J, Damber JE, Peeker R, Mellström D, Högstedt B.","Cancer Epidemiol. 2010 Oct;34(5):574-9. doi: 10.1016/j.canep.2010.06.014. Epub 2010 Aug 10.","Hammarsten J","Cancer Epidemiol","2010","2010/08/13","","","10.1016/j.canep.2010.06.014"
"15592250","Prostate cancer and sexuality: implications for nursing","Johnson BK.","Geriatr Nurs. 2004 Nov-Dec;25(6):341-7. doi: 10.1016/j.gerinurse.2004.09.014.","Johnson BK","Geriatr Nurs","2004","2004/12/14","","","10.1016/j.gerinurse.2004.09.014"
"11519121","[Prostate tumor and its diagnosis]","Yamanaka H.","Rinsho Byori. 2001 Jul;49(7):633-7.","Yamanaka H","Rinsho Byori","2001","2001/08/25","","",""
"23556487","The role of magnetic resonance imaging in prostate cancer","Lawrentschuk N.","ANZ J Surg. 2013 Apr;83(4):197. doi: 10.1111/ans.12082.","Lawrentschuk N","ANZ J Surg","2013","2013/04/06","","","10.1111/ans.12082"
"24597940","Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts (""ICE"")","Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward JF.","Aging Male. 2014 Jun;17(2):66-71. doi: 10.3109/13685538.2014.895319. Epub 2014 Mar 6.","Reis LO","Aging Male","2014","2014/03/07","","","10.3109/13685538.2014.895319"
"24946744","Use of oral anticoagulants and risk of prostate cancer: a population-based case-control study in Montreal, Canada","Blanc-Lapierre A, Weiss D, Parent MÉ.","Cancer Causes Control. 2014 Sep;25(9):1159-66. doi: 10.1007/s10552-014-0417-z. Epub 2014 Jun 20.","Blanc-Lapierre A","Cancer Causes Control","2014","2014/06/21","","","10.1007/s10552-014-0417-z"
"15551464","Watchful waiting in prostate cancer","","Health News. 2004 Aug;10(8):13.","","Health News","2004","2004/11/24","","",""
"19477777","Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland","Hegarty JM, Wallace M, Comber H.","Am J Mens Health. 2008 Jun;2(2):133-42. doi: 10.1177/1557988307300467. Epub 2007 May 23.","Hegarty JM","Am J Mens Health","2008","2009/05/30","","","10.1177/1557988307300467"
"21987211","[Epidemiology of prostate cancer]","Becker N.","Radiologe. 2011 Nov;51(11):922-9. doi: 10.1007/s00117-011-2183-1.","Becker N","Radiologe","2011","2011/10/12","","","10.1007/s00117-011-2183-1"
"28500118","Isolated prostate cancer soft tissue recurrence 10 years after radical prostatectomy","Khan M, Davidson AJ, McKinley M, Ischia J.","BMJ Case Rep. 2017 May 12;2017:bcr2017220140. doi: 10.1136/bcr-2017-220140.","Khan M","BMJ Case Rep","2017","2017/05/14","PMC5613988","","10.1136/bcr-2017-220140"
"21693354","[Active surveillance for localized prostate cancer]","Staerman F, Peyromaure M, Irani J, Gaschignard N, Mottet N, Soulié M, Salomon L; CCAFU.","Prog Urol. 2011 Jul;21(7):448-54. doi: 10.1016/j.purol.2011.02.015. Epub 2011 May 14.","Staerman F","Prog Urol","2011","2011/06/23","","","10.1016/j.purol.2011.02.015"
"21196398","Obesity and prostate cancer: collateral damage in the battle of the bulge","Thomas JA 2nd, Freedland SJ.","Front Biosci (Schol Ed). 2011 Jan 1;3:594-605. doi: 10.2741/s173.","Thomas JA 2nd","Front Biosci (Schol Ed)","2011","2011/01/04","","","10.2741/s173"
"15630842","Management of patients with hormone refractory prostate cancer","Muthuramalingam SR, Patel K, Protheroe A.","Clin Oncol (R Coll Radiol). 2004 Dec;16(8):505-16. doi: 10.1016/j.clon.2004.07.009.","Muthuramalingam SR","Clin Oncol (R Coll Radiol)","2004","2005/01/06","","","10.1016/j.clon.2004.07.009"
"16520275","Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype","Koeneman KS.","Urol Oncol. 2006 Mar-Apr;24(2):119-21. doi: 10.1016/j.urolonc.2005.11.031.","Koeneman KS","Urol Oncol","2006","2006/03/08","","","10.1016/j.urolonc.2005.11.031"
"16826441","A validation study of the Dutch version of the Quality of Life-Cancer Survivor (QOL-CS) questionnaire in a group of prostate cancer survivors","van Dis FW, Mols F, Vingerhoets AJ, Ferrell B, van de Poll-Franse LV.","Qual Life Res. 2006 Dec;15(10):1607-12. doi: 10.1007/s11136-006-0015-y. Epub 2006 Jul 7.","van Dis FW","Qual Life Res","2006","2006/07/11","","","10.1007/s11136-006-0015-y"
"1994421","Prostate cancer: local staging with endorectal surface coil MR imaging","Schnall MD, Imai Y, Tomaszewski J, Pollack HM, Lenkinski RE, Kressel HY.","Radiology. 1991 Mar;178(3):797-802. doi: 10.1148/radiology.178.3.1994421.","Schnall MD","Radiology","1991","1991/03/01","","","10.1148/radiology.178.3.1994421"
"18163940","Radiotherapy for localized prostate cancer","Eichler TJ.","Can J Urol. 2007 Dec;14 Suppl 1:19-23.","Eichler TJ","Can J Urol","2007","2008/02/07","","",""
"21739727","Active surveillance monitoring more stringent in updated NCCN Guidelines for prostate cancer","","J Natl Compr Canc Netw. 2011 May;9(5):xxxvii-xlii.","","J Natl Compr Canc Netw","2011","2011/07/12","","",""
"25528396","Words of wisdom. Re: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","Bill-Axelson A, Bratt O.","Eur Urol. 2015 Jan;67(1):175. doi: 10.1016/j.eururo.2014.09.048. Epub 2014 Nov 25.","Bill-Axelson A","Eur Urol","2015","2014/12/22","","","10.1016/j.eururo.2014.09.048"
"18382237","Current decision-making in prostate cancer therapy","Cox J, Amling CL.","Curr Opin Urol. 2008 May;18(3):275-8. doi: 10.1097/MOU.0b013e3282fba5f2.","Cox J","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282fba5f2"
"11817252","[Diseases of the prostate in elderly patients. Benign prostate hyperplasia and prostate carcinoma]","Madersbacher S.","Wien Med Wochenschr. 2001;151(18-20):430-8.","Madersbacher S","Wien Med Wochenschr","2001","2002/01/31","","",""
"32162682","Protein may be linked to racial disparities in prostate cancer","Printz C.","Cancer. 2019 Jul 1;125(13):2147. doi: 10.1002/cncr.32300.","Printz C","Cancer","2019","2020/03/13","","","10.1002/cncr.32300"
"20818326","Prostate cancer screening: current status and future perspectives","Strope SA, Andriole GL.","Nat Rev Urol. 2010 Sep;7(9):487-93. doi: 10.1038/nrurol.2010.120.","Strope SA","Nat Rev Urol","2010","2010/09/07","","","10.1038/nrurol.2010.120"
"10647252","Expectant management of prostate cancer--the author replies","Griffin AS.","N C Med J. 2000 Jan-Feb;61(1):377.","Griffin AS","N C Med J","2000","2000/01/27","","",""
"24188263","Preface. Prostate cancer","Sweeney CJ.","Hematol Oncol Clin North Am. 2013 Dec;27(6):xi-xii. doi: 10.1016/j.hoc.2013.10.006.","Sweeney CJ","Hematol Oncol Clin North Am","2013","2013/11/06","","","10.1016/j.hoc.2013.10.006"
"17310261","Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy","Kibel AS, Nelson JB.","Prostate Cancer Prostatic Dis. 2007;10(2):119-26. doi: 10.1038/sj.pcan.4500947. Epub 2007 Feb 20.","Kibel AS","Prostate Cancer Prostatic Dis","2007","2007/02/21","","","10.1038/sj.pcan.4500947"
"15693427","A novel spectral ultrasonic differentiation method for marking regions of interest in biological tissue: in vitro results for prostate","Ponchietti R, Martorana G, Di Loro F, Bertaccini A, Nesi G, Grigioni WF, Granchi S, Breschi L, Biagi E, Masotti L.","Arch Ital Urol Androl. 2004 Dec;76(4):147-53.","Ponchietti R","Arch Ital Urol Androl","2004","2005/02/08","","",""
"22522266","Detecting and treating prostate cancer: a surgeon's perspective","Buchan NC.","N Z Med J. 2012 Apr 20;125(1353):6-8.","Buchan NC","N Z Med J","2012","2012/04/24","","",""
"9471876","[Advanced cancer of the prostate. Study of 60 cases treated in our milieu]","Bigas i Farreres J, Sarasa Claver P, Morales Murillo S, Balil Gilart A, Bordalba JR, Mitjavila i López J.","Actas Urol Esp. 1997 Oct;21(9):922-5.","Bigas i Farreres J","Actas Urol Esp","1997","1998/02/21","","",""
"17483023","Inflammation in the etiology of prostate cancer: an epidemiologic perspective","Sutcliffe S, Platz EA.","Urol Oncol. 2007 May-Jun;25(3):242-9. doi: 10.1016/j.urolonc.2006.09.014.","Sutcliffe S","Urol Oncol","2007","2007/05/08","","","10.1016/j.urolonc.2006.09.014"
"11912637","[Treatment of prostate cancer. Practice recommendations from the Finnish Urological Association]","","Duodecim. 1999;115(14):1508-16.","","Duodecim","1999","2002/03/27","","",""
"2078069","[Early diagnosis of cancer of the prostate. Is is useful?]","Benítez Navío J, Arrizabalaga Moreno M, Delgado I, Casanueva Luis T, Gallardo Galán C.","Arch Esp Urol. 1990;43 Suppl 1:81-95.","Benítez Navío J","Arch Esp Urol","1990","1990/01/01","","",""
"12085964","Regulation of apoptosis in prostate cancer","Gurumurthy S, Vasudevan KM, Rangnekar VM.","Cancer Metastasis Rev. 2001;20(3-4):225-43. doi: 10.1023/a:1015583310759.","Gurumurthy S","Cancer Metastasis Rev","2001","2002/06/28","","","10.1023/a:1015583310759"
"25596644","Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer","Cha EK, Eastham JA.","Urol Oncol. 2015 May;33(5):217-25. doi: 10.1016/j.urolonc.2014.11.020. Epub 2015 Jan 14.","Cha EK","Urol Oncol","2015","2015/01/19","","","10.1016/j.urolonc.2014.11.020"
"11022708","[Management of prostate cancer-by-stage]","Takahashi A, Tsukamoto T.","Nihon Rinsho. 2000 Jul;58 Suppl:169-75.","Takahashi A","Nihon Rinsho","2000","2000/10/07","","",""
"31436568","Serum and urinary biomarkers for detection and active surveillance of prostate cancer","Becerra MF, Bhat A, Mouzannar A, Atluri VS, Punnen S.","Curr Opin Urol. 2019 Nov;29(6):593-597. doi: 10.1097/MOU.0000000000000670.","Becerra MF","Curr Opin Urol","2019","2019/08/23","","","10.1097/MOU.0000000000000670"
"9130269","Prostate cancer: to screen or not to screen?","","Oncology (Williston Park). 1997 Apr;11(4):447-8, 451-2.","","Oncology (Williston Park)","1997","1997/04/01","","",""
"30524166","A Contribution into Developing a Model for Prostate Cancer Self-Care Mobile Application","Zargarzadeh P, Ehteshami A, Mohammadi-Sichani M.","Med Arch. 2018 Nov;72(5):344-347. doi: 10.5455/medarh.2018.72.344-347.","Zargarzadeh P","Med Arch","2018","2018/12/08","PMC6282921","","10.5455/medarh.2018.72.344-347"
"22116601","Familial risk and familial survival in prostate cancer","Hemminki K.","World J Urol. 2012 Apr;30(2):143-8. doi: 10.1007/s00345-011-0801-1. Epub 2011 Nov 25.","Hemminki K","World J Urol","2012","2011/11/26","","","10.1007/s00345-011-0801-1"
"9695693","Management of localised prostate cancer: state of the art","Frydenberg M, Duchesne G, Stricker PD.","Med J Aust. 1998 Jul 6;169(1):11-2.","Frydenberg M","Med J Aust","1998","1998/08/08","","",""
"22805007","Clinical usefulness of bone markers in prostate cancer with bone metastasis","Kamiya N, Suzuki H, Endo T, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T.","Int J Urol. 2012 Nov;19(11):968-79. doi: 10.1111/j.1442-2042.2012.03098.x. Epub 2012 Jul 17.","Kamiya N","Int J Urol","2012","2012/07/19","","","10.1111/j.1442-2042.2012.03098.x"
"1467876","Challenges in the management of prostate cancer","Crawford ED.","Br J Urol. 1992 Nov;70 Suppl 1:33-8. doi: 10.1111/j.1464-410x.1992.tb15865.x.","Crawford ED","Br J Urol","1992","1992/11/01","","","10.1111/j.1464-410x.1992.tb15865.x"
"8337772","Prostate cancer","Kantoff PW.","Trans Am Acad Insur Med. 1993;76:64-72.","Kantoff PW","Trans Am Acad Insur Med","1993","1993/01/01","","",""
"26793893","[Current diagnosis and the multidisciplinary approach to the treatment of bone metastases in patients with prostate cancer]","Satoh T, Ishiyama H.","Nihon Rinsho. 2016 Jan;74(1):129-36.","Satoh T","Nihon Rinsho","2016","2016/01/23","","",""
"8262131","Nonsteroidal antiandrogen monotherapy of metastatic cancer of the prostate","Boccon-Gibod L.","Eur Urol. 1993;24 Suppl 2:77-80. doi: 10.1159/000474396.","Boccon-Gibod L","Eur Urol","1993","1993/01/01","","","10.1159/000474396"
"19219374","Association between HIV status and positive prostate biopsy in a study of US veterans","Hsiao W, Anastasia K, Hall J, Goodman M, Rimland D, Ritenour CW, Issa MM.","ScientificWorldJournal. 2009 Feb 15;9:102-8. doi: 10.1100/tsw.2009.20.","Hsiao W","ScientificWorldJournal","2009","2009/02/17","PMC5823076","","10.1100/tsw.2009.20"
"16623066","Roots of prostate cancer in African-American men","Odedina FT, Ogunbiyi JO, Ukoli FA.","J Natl Med Assoc. 2006 Apr;98(4):539-43.","Odedina FT","J Natl Med Assoc","2006","2006/04/21","PMC2569237","",""
"26754596","Favorable outcome of intraoperative radiotherapy to the primary site in patients with metastatic prostate cancer","Kanda T, Fukuda S, Fukui N, Ohkubo Y, Kazumoto T, Saito Y, Ishikawa A, Kurosumi M, Kageyama Y, Fujii Y, Kihara K.","Int J Clin Oncol. 2016 Aug;21(4):764-772. doi: 10.1007/s10147-016-0947-3. Epub 2016 Jan 11.","Kanda T","Int J Clin Oncol","2016","2016/01/13","","","10.1007/s10147-016-0947-3"
"24781338","Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population","Matsumoto K, Hagiwara M, Tanaka N, Hayakawa N, Ishida M, Ninomiya A, Nakajima Y, Nakamura S.","Med Oncol. 2014 Jun;31(6):979. doi: 10.1007/s12032-014-0979-3. Epub 2014 Apr 30.","Matsumoto K","Med Oncol","2014","2014/05/01","","","10.1007/s12032-014-0979-3"
"17018726","Systemic treatment for prostate cancer","Horwich A.","Ann Oncol. 2006 Sep;17 Suppl 10:x211-3. doi: 10.1093/annonc/mdl262.","Horwich A","Ann Oncol","2006","2006/10/05","","","10.1093/annonc/mdl262"
"17491038","Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","ESMO Guidelines Working Group, Horwich A, Parker C.","Ann Oncol. 2007 Apr;18 Suppl 2:ii36-7. doi: 10.1093/annonc/mdm028.","ESMO Guidelines Working Group","Ann Oncol","2007","2007/05/11","","","10.1093/annonc/mdm028"
"16289577","Radical prostatectomy for early prostate cancer improves long term survival","Alibhai SM, Gogov S.","Cancer Treat Rev. 2005 Dec;31(8):640-3. doi: 10.1016/j.ctrv.2005.09.008. Epub 2005 Nov 11.","Alibhai SM","Cancer Treat Rev","2005","2005/11/18","","","10.1016/j.ctrv.2005.09.008"
"22286304","Imaging in prostate cancer staging: present role and future perspectives","Pinto F, Totaro A, Palermo G, Calarco A, Sacco E, D'Addessi A, Racioppi M, Valentini A, Gui B, Bassi P.","Urol Int. 2012;88(2):125-36. doi: 10.1159/000335205. Epub 2012 Jan 27.","Pinto F","Urol Int","2012","2012/01/31","","","10.1159/000335205"
"22285952","Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre's experience","Philippou P, Yap T, Chinegwundoh F.","Urol Int. 2012;88(2):137-44. doi: 10.1159/000332220. Epub 2012 Jan 24.","Philippou P","Urol Int","2012","2012/01/31","","","10.1159/000332220"
"25518343","[Lipid metabolism and castration resistant prostate cancer]","Suzuki K, Sekine Y, Matsui H.","Nihon Rinsho. 2014 Dec;72(12):2116-20.","Suzuki K","Nihon Rinsho","2014","2014/12/19","","",""
"7600465","Prostate cancer detection and patient involvement in treatment","Robins RE.","CMAJ. 1995 Jul 15;153(2):141; author reply 141-2.","Robins RE","CMAJ","1995","1995/07/15","PMC1338048","",""
"24337765","Patterns and predictors of symptom incongruence in older couples coping with prostate cancer","Winters-Stone KM, Lyons KS, Bennett JA, Beer TM.","Support Care Cancer. 2014 May;22(5):1341-8. doi: 10.1007/s00520-013-2092-0. Epub 2013 Dec 17.","Winters-Stone KM","Support Care Cancer","2014","2013/12/17","PMC3969757","NIHMS549444","10.1007/s00520-013-2092-0"
"24195246","[Focus on the screening for prostate cancer by PSA]","Roumeguère T, Van Velthoven R.","Rev Med Brux. 2013 Sep;34(4):311-9.","Roumeguère T","Rev Med Brux","2013","2013/11/08","","",""
"22450149","Active surveillance for prostate cancer: past, present and future","Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL.","Curr Opin Oncol. 2012 May;24(3):243-50. doi: 10.1097/CCO.0b013e3283527f99.","Singer EA","Curr Opin Oncol","2012","2012/03/28","PMC7473449","NIHMS1620935","10.1097/CCO.0b013e3283527f99"
"12642199","What information patients with localised prostate cancer hear and understand","McGregor S.","Patient Educ Couns. 2003 Mar;49(3):273-8. doi: 10.1016/s0738-3991(02)00182-9.","McGregor S","Patient Educ Couns","2003","2003/03/19","","","10.1016/s0738-3991(02)00182-9"
"29179248","Radical Prostatectomy for Patients With Oligometastatic Prostate Cancer","Ahmad AE, Leão R, Hamilton RJ.","Oncology (Williston Park). 2017 Nov 15;31(11):794-802.","Ahmad AE","Oncology (Williston Park)","2017","2017/11/28","","",""
"12177094","Comparing contemporary surgery to external-beam radiotherapy for clinically localized prostate cancer","Zelefsky MJ, Leibel SA.","J Clin Oncol. 2002 Aug 15;20(16):3363-4. doi: 10.1200/JCO.2002.20.16.3363.","Zelefsky MJ","J Clin Oncol","2002","2002/08/15","","","10.1200/JCO.2002.20.16.3363"
"15336984","TRPV6 and prostate cancer: cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression","Wissenbach U, Niemeyer B, Himmerkus N, Fixemer T, Bonkhoff H, Flockerzi V.","Biochem Biophys Res Commun. 2004 Oct 1;322(4):1359-63. doi: 10.1016/j.bbrc.2004.08.042.","Wissenbach U","Biochem Biophys Res Commun","2004","2004/09/01","","","10.1016/j.bbrc.2004.08.042"
"25962187","Gene expression analysis for prostate cancer management","Ratko TA; Blue Cross Blue Shield Asssociation.","Technol Eval Cent Assess Program Exec Summ. 2015 Jan;29(9):1-9.","Ratko TA","Technol Eval Cent Assess Program Exec Summ","2015","2015/05/13","","",""
"21304540","Prostate cancer in 2010: GSU: misclassification or biological progression?","Capitanio U, Suardi N.","Nat Rev Urol. 2011 Feb;8(2):65-6. doi: 10.1038/nrurol.2010.247.","Capitanio U","Nat Rev Urol","2011","2011/02/10","","","10.1038/nrurol.2010.247"
"19544551","Predictive models in diagnosing indolent cancer","Bangma CH, Roobol MJ, Steyerberg EW.","Cancer. 2009 Jul 1;115(13 Suppl):3100-6. doi: 10.1002/cncr.24347.","Bangma CH","Cancer","2009","2009/06/23","","","10.1002/cncr.24347"
"18707724","Predicting prostate cancer risk through incorporation of prostate cancer gene 3","Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, Tangen C, Parekh D, Leach RJ, Thompson I.","J Urol. 2008 Oct;180(4):1303-8; discussion 1308. doi: 10.1016/j.juro.2008.06.038. Epub 2008 Aug 15.","Ankerst DP","J Urol","2008","2008/08/19","","","10.1016/j.juro.2008.06.038"
"29412547","PCA3 rs544190G>A and prostate cancer risk in an eastern Chinese population","Cao D, Gu C, Ye D, Dai B, Zhu Y.","Int Braz J Urol. 2018 May-Jun;44(3):500-505. doi: 10.1590/S1677-5538.IBJU.2017.0146.","Cao D","Int Braz J Urol","2018","2018/02/08","PMC5996780","","10.1590/S1677-5538.IBJU.2017.0146"
"11684844","Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer","Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JA, Debruyne FM, Wijkstra H, de la Rosette JJ.","Eur Urol. 2001 Sep;40(3):285-93. doi: 10.1159/000049788.","Sedelaar JP","Eur Urol","2001","2001/10/31","","","10.1159/000049788"
"28620691","Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet","Petrylak DP, Crawford ED.","Target Oncol. 2017 Aug;12(4):401-412. doi: 10.1007/s11523-017-0500-y.","Petrylak DP","Target Oncol","2017","2017/06/17","","","10.1007/s11523-017-0500-y"
"19359330","Real-time elastography for the diagnosis of prostate cancer: evaluation of elastographic moving images","Miyagawa T, Tsutsumi M, Matsumura T, Kawazoe N, Ishikawa S, Shimokama T, Miyanaga N, Akaza H.","Jpn J Clin Oncol. 2009 Jun;39(6):394-8. doi: 10.1093/jjco/hyp026. Epub 2009 Apr 9.","Miyagawa T","Jpn J Clin Oncol","2009","2009/04/11","","","10.1093/jjco/hyp026"
"19650748","Emerging drugs for prostate cancer","Siddiqui K, Klotz LH.","Expert Opin Emerg Drugs. 2009 Sep;14(3):455-70. doi: 10.1517/14728210903142147.","Siddiqui K","Expert Opin Emerg Drugs","2009","2009/08/05","","","10.1517/14728210903142147"
"29229664","Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities","Zadra G, Loda M.","Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a030569. doi: 10.1101/cshperspect.a030569.","Zadra G","Cold Spring Harb Perspect Med","2018","2017/12/13","PMC6169980","","10.1101/cshperspect.a030569"
"9698661","Prostate cancer: how aware is the public?","Fitzpatrick P, Corcoran N, Fitzpatrick JM.","Br J Urol. 1998 Jul;82(1):43-8. doi: 10.1046/j.1464-410x.1998.00685.x.","Fitzpatrick P","Br J Urol","1998","1998/08/12","","","10.1046/j.1464-410x.1998.00685.x"
"7912173","Advances in Diagnosis and Treatment of Early Stage Prostate Cancer. Symposium proceedings. Quebec City, Quebec, May 29-30, 1993","","Clin Invest Med. 1993 Dec;16(6):407-538.","","Clin Invest Med","1993","1993/12/01","","",""
"1746073","[Value of imaging systems in prostate cancer]","Eickenberg HU.","Urologe A. 1991 May;30(3 Suppl):5.","Eickenberg HU","Urologe A","1991","1991/05/01","","",""
"27633860","Risk of dying from early prostate cancer is low regardless of treatment, study finds","White C.","BMJ. 2016 Sep 14;354:i4984. doi: 10.1136/bmj.i4984.","White C","BMJ","2016","2016/09/17","","","10.1136/bmj.i4984"
"15247359","Progress toward identifying aggressive prostate cancer","Eisenberger M, Partin A.","N Engl J Med. 2004 Jul 8;351(2):180-1. doi: 10.1056/NEJMe048119.","Eisenberger M","N Engl J Med","2004","2004/07/13","","","10.1056/NEJMe048119"
"18401585","The face of high risk prostate cancer","Albertsen PC.","World J Urol. 2008 Jun;26(3):205-10. doi: 10.1007/s00345-008-0254-3. Epub 2008 Apr 10.","Albertsen PC","World J Urol","2008","2008/04/11","","","10.1007/s00345-008-0254-3"
"27801900","Active surveillance for intermediate-risk prostate cancer","Dall'Era MA, Klotz L.","Prostate Cancer Prostatic Dis. 2017 Mar;20(1):1-6. doi: 10.1038/pcan.2016.51. Epub 2016 Nov 1.","Dall'Era MA","Prostate Cancer Prostatic Dis","2017","2016/11/02","PMC5303136","NIHMS802413","10.1038/pcan.2016.51"
"16676354","The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression","Knudsen BS, Miranti CK.","J Cell Biochem. 2006 Oct 1;99(2):345-61. doi: 10.1002/jcb.20934.","Knudsen BS","J Cell Biochem","2006","2006/05/06","","","10.1002/jcb.20934"
"25692722","Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer","Carter HB.","Curr Opin Urol. 2015 May;25(3):277-82. doi: 10.1097/MOU.0000000000000153.","Carter HB","Curr Opin Urol","2015","2015/02/19","","","10.1097/MOU.0000000000000153"
"9436281","Population-based prostate cancer trends in the United States: patterns of change in the era of prostate-specific antigen","Stephenson RA, Stanford JL.","World J Urol. 1997;15(6):331-5. doi: 10.1007/BF01300179.","Stephenson RA","World J Urol","1997","1997/01/01","","","10.1007/BF01300179"
"7543603","Prostate cancer","Flanigan RC.","J Urol. 1995 Sep;154(3):1084. doi: 10.1016/s0022-5347(01)66982-9.","Flanigan RC","J Urol","1995","1995/09/01","","","10.1016/s0022-5347(01)66982-9"
"27533500","Immunotherapy for prostate cancer: is prostate an immune responsive tumor?","Slovin SF.","Curr Opin Urol. 2016 Nov;26(6):529-34. doi: 10.1097/MOU.0000000000000334.","Slovin SF","Curr Opin Urol","2016","2016/08/18","","","10.1097/MOU.0000000000000334"
"20608362","[Advances in prostate-specific membrane antigen targeted therapies for prostate cancer]","Wang W, Mo ZN.","Zhonghua Nan Ke Xue. 2010 Jun;16(6):547-51.","Wang W","Zhonghua Nan Ke Xue","2010","2010/07/09","","",""
"11371867","Prostate cancer: a brief history and the discovery of hormonal ablation treatment","Lytton B.","J Urol. 2001 Jun;165(6 Pt 1):1859-62.","Lytton B","J Urol","2001","2001/05/24","","",""
"8711594","[What is the role of neoadjuvant therapy in prostate cancer?]","Witjes WP, Horenblas S, Oosterhof GO, Schaafsma HE, Debruyne FM.","Minerva Urol Nefrol. 1995 Dec;47(4):209-14.","Witjes WP","Minerva Urol Nefrol","1995","1995/12/01","","",""
"15018079","[External beam radiotherapy and brachytherapy in prostate cancer]","Laporte C, Larrouy A, Housset M.","Rev Prat. 2003 Dec 31;53(20):2253-7.","Laporte C","Rev Prat","2003","2004/03/17","","",""
"16458793","What can geography tell us about prostate cancer?","Klassen AC, Platz EA.","Am J Prev Med. 2006 Feb;30(2 Suppl):S7-15. doi: 10.1016/j.amepre.2005.09.004.","Klassen AC","Am J Prev Med","2006","2006/02/07","","","10.1016/j.amepre.2005.09.004"
"15912909","Prostate cancer and life insurance","Milano AE.","J Insur Med. 2000;32(2):96-108.","Milano AE","J Insur Med","2000","2005/05/26","","",""
"21520160","Prostate cancer risk variants are not associated with disease progression","Szulkin R, Holmberg E, Stattin P, Xu J, Zheng S, Palmgren J, Grönberg H, Wiklund F.","Prostate. 2012 Jan;72(1):30-9. doi: 10.1002/pros.21403. Epub 2011 Apr 25.","Szulkin R","Prostate","2012","2011/04/27","","","10.1002/pros.21403"
"17253080","A genetics perspective on prostate cancer","Lessick M, Katz A.","Urol Nurs. 2006 Dec;26(6):454-60.","Lessick M","Urol Nurs","2006","2007/01/27","","",""
"28882555","Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer","Prekovic S, Van den Broeck T, Moris L, Smeets E, Claessens F, Joniau S, Helsen C, Attard G.","Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):56-63. doi: 10.1016/j.mce.2017.08.020. Epub 2017 Sep 4.","Prekovic S","Mol Cell Endocrinol","2018","2017/09/09","","","10.1016/j.mce.2017.08.020"
"7553496","The dilemma of hereditary prostate cancer","Nickel JC.","CMAJ. 1995 Oct 1;153(7):935-8.","Nickel JC","CMAJ","1995","1995/10/01","PMC1487375","",""
"10455574","Primary care screening for prostate cancer","O'Sullivan J.","Clin Excell Nurse Pract. 1998 Sep;2(5):270-2.","O'Sullivan J","Clin Excell Nurse Pract","1998","1999/08/24","","",""
"19886716","Current perspectives on the Gleason grading of prostate cancer","Shah RB.","Arch Pathol Lab Med. 2009 Nov;133(11):1810-6. doi: 10.1043/1543-2165-133.11.1810.","Shah RB","Arch Pathol Lab Med","2009","2009/11/06","","","10.1043/1543-2165-133.11.1810"
"15776917","[Diet and prostate cancer: from prevention to treatment]","Amsellem-Ouazana D, Conquy S.","Prog Urol. 2004 Sep;14(4):573-6.","Amsellem-Ouazana D","Prog Urol","2004","2005/03/22","","",""
"17458572","Case report: Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer","Hicks J.","J Gen Intern Med. 2007 Jul;22(7):1062. doi: 10.1007/s11606-007-0216-2.","Hicks J","J Gen Intern Med","2007","2007/04/27","PMC2219720","","10.1007/s11606-007-0216-2"
"2363055","Prostate cancer: screening through treatment and nursing implications","Mahon SM, Casperson D, Wozniak-Petrofsky J.","Urol Nurs. 1990 Jun;10(2):5-11.","Mahon SM","Urol Nurs","1990","1990/06/01","","",""
"23888737","[Vitamin D and prostate cancer]","Marusić G, Jeremić D, Vojinov S, Filipović N, Popov M.","Med Pregl. 2013 May-Jun;66(5-6):259-62. doi: 10.2298/mpns1306259m.","Marusić G","Med Pregl","2013","2013/07/30","","","10.2298/mpns1306259m"
"1698754","A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate","Meek AG, Park TL, Oberman E, Wielopolski L.","Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):733-41. doi: 10.1016/0360-3016(90)90504-d.","Meek AG","Int J Radiat Oncol Biol Phys","1990","1990/09/01","","","10.1016/0360-3016(90)90504-d"
"29717499","Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group","Miyahira AK, Pienta KJ, Morris MJ, Bander NH, Baum RP, Fendler WP, Goeckeler W, Gorin MA, Hennekes H, Pomper MG, Sartor O, Tagawa ST, Williams S, Soule HR.","Prostate. 2018 Aug;78(11):775-789. doi: 10.1002/pros.23642. Epub 2018 May 1.","Miyahira AK","Prostate","2018","2018/05/03","","","10.1002/pros.23642"
"17921730","The current use and future trends of focal surgical therapy in the management of localized prostate cancer","Barqawi AB, Crawford ED.","Cancer J. 2007 Sep-Oct;13(5):313-7. doi: 10.1097/PPO.0b013e318156eb99.","Barqawi AB","Cancer J","2007","2007/10/09","","","10.1097/PPO.0b013e318156eb99"
"27085833","How I Do It: Genetic counseling and genetic testing for inherited prostate cancer","Giri VN, Gross L, Gomella LG, Hyatt C.","Can J Urol. 2016 Apr;23(2):8247-53.","Giri VN","Can J Urol","2016","2016/04/18","","",""
"29699054","Prevalence, Cognitive and Socio-Demographic Determinants of Prostate Cancer Screening","Mirzaei-Alavijeh M, Ahmadi-Jouybari T, Vaezi M, Jalilian F.","Asian Pac J Cancer Prev. 2018 Apr 27;19(4):1041-1046. doi: 10.22034/APJCP.2018.19.4.1041.","Mirzaei-Alavijeh M","Asian Pac J Cancer Prev","2018","2018/04/27","PMC6031777","","10.22034/APJCP.2018.19.4.1041"
"18996314","Dendritic cell vaccines for the treatment of prostate cancer","Lehrfeld TJ, Lee DI.","Urol Oncol. 2008 Nov-Dec;26(6):576-80. doi: 10.1016/j.urolonc.2007.12.002.","Lehrfeld TJ","Urol Oncol","2008","2008/11/11","","","10.1016/j.urolonc.2007.12.002"
"14630385","Development of a reliable and valid questionnaire to test the prostate cancer knowledge of men with the disease","Rees C, Abed R, Sheard C.","Patient Educ Couns. 2003 Nov;51(3):285-92. doi: 10.1016/s0738-3991(02)00243-4.","Rees C","Patient Educ Couns","2003","2003/11/25","","","10.1016/s0738-3991(02)00243-4"
"17020451","Sipuleucel-T (APC8015) for prostate cancer","So-Rosillo R, Small EJ.","Expert Rev Anticancer Ther. 2006 Sep;6(9):1163-7. doi: 10.1586/14737140.6.9.1163.","So-Rosillo R","Expert Rev Anticancer Ther","2006","2006/10/06","","","10.1586/14737140.6.9.1163"
"1722920","[Endosonography of the prostate]","Hammerer P.","Urologe A. 1991 Nov;30(6):370-7.","Hammerer P","Urologe A","1991","1991/11/01","","",""
"537622","Epidemiology of prostate cancer with special reference to the role of diet","Hirayama T.","Natl Cancer Inst Monogr. 1979 Nov;(53):149-55.","Hirayama T","Natl Cancer Inst Monogr","1979","1979/11/01","","",""
"11603136","Spectrum of prostate cancer in the Singapore General Hospital (1980 to 1985)","Koh JS, Cheng CW, Foo KT.","Ann Acad Med Singap. 2001 Sep;30(5):513-5.","Koh JS","Ann Acad Med Singap","2001","2001/10/18","","",""
"30995848","Oligometastatic Prostate Cancer","Navrátil J, Poprach A, Lakomý R, Kocák I, Vašina J, Krupa P, Vyzula R.","Klin Onkol. 2019 Spring;32(2):97-100. doi: 10.14735/amko201997.","Navrátil J","Klin Onkol","2019","2019/04/19","","","10.14735/amko201997"
"9430189","Update of the NCCN guidelines for treatment of prostate cancer","Millikan R, Logothetis C.","Oncology (Williston Park). 1997 Nov;11(11A):180-93.","Millikan R","Oncology (Williston Park)","1997","1998/01/16","","",""
"18176054","[Biological behavior of prostate cancer cells in 3D culture systems]","Watanabe M, Takagi A.","Yakugaku Zasshi. 2008 Jan;128(1):37-44. doi: 10.1248/yakushi.128.37.","Watanabe M","Yakugaku Zasshi","2008","2008/01/08","","","10.1248/yakushi.128.37"
"18536785","Sipuleucel-T for the treatment of prostate cancer","Harzstark AL, Small EJ.","Drugs Today (Barc). 2008 Apr;44(4):271-8. doi: 10.1358/dot.2008.44.4.1212301.","Harzstark AL","Drugs Today (Barc)","2008","2008/06/10","","","10.1358/dot.2008.44.4.1212301"
"26186079","MicroRNA in prostate cancer: Practical aspects","Patil PA, Magi-Galluzzi C.","Histol Histopathol. 2015 Dec;30(12):1379-96. doi: 10.14670/HH-11-647. Epub 2015 Jul 17.","Patil PA","Histol Histopathol","2015","2015/07/18","","","10.14670/HH-11-647"
"17921727","Active surveillance with selective radical treatment for localized prostate cancer","van As NJ, Parker CC.","Cancer J. 2007 Sep-Oct;13(5):289-94. doi: 10.1097/PPO.0b013e318156ff65.","van As NJ","Cancer J","2007","2007/10/09","","","10.1097/PPO.0b013e318156ff65"
"28409220","PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies","Giovacchini G, Giovannini E, Leoncini R, Riondato M, Ciarmiello A.","Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1751-1776. doi: 10.1007/s00259-017-3700-x. Epub 2017 Apr 14.","Giovacchini G","Eur J Nucl Med Mol Imaging","2017","2017/04/15","","","10.1007/s00259-017-3700-x"
"24934448","Prostate cancer: extended pelvic lymph node removal--extended survival","Thoma C.","Nat Rev Urol. 2014 Jul;11(7):363. doi: 10.1038/nrurol.2014.137. Epub 2014 Jun 17.","Thoma C","Nat Rev Urol","2014","2014/06/18","","","10.1038/nrurol.2014.137"
"24194978","Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank","Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S.","Biopreserv Biobank. 2013 Oct;11(5):285-90. doi: 10.1089/bio.2013.0025.","Brimo F","Biopreserv Biobank","2013","2013/11/07","PMC3809609","","10.1089/bio.2013.0025"
"20425619","The quality-of-life impact of prostate cancer treatments","Singh J, Trabulsi EJ, Gomella LG.","Curr Urol Rep. 2010 May;11(3):139-46. doi: 10.1007/s11934-010-0103-y.","Singh J","Curr Urol Rep","2010","2010/04/29","","","10.1007/s11934-010-0103-y"
"23236637","[Prostate cancer screening: genetic testing]","Mantha MM.","Perspect Infirm. 2012 Nov-Dec;9(6):57-8.","Mantha MM","Perspect Infirm","2012","2012/12/14","","",""
"20956725","Mortality reductions produced by sustained prostate cancer screening have been underestimated","Hanley JA.","J Med Screen. 2010;17(3):147-51. doi: 10.1258/jms.2010.010005.","Hanley JA","J Med Screen","2010","2010/10/20","","","10.1258/jms.2010.010005"
"23855286","It is time to start active treatment in senior adults with prostate cancer","Van den Broeck T, Tosco L, Joniau S.","Future Oncol. 2014 Jan;10(1):5-8. doi: 10.2217/fon.13.131. Epub 2013 Jul 15.","Van den Broeck T","Future Oncol","2014","2013/07/17","","","10.2217/fon.13.131"
"29417257","Oncological effect of palliative transurethral resection of the prostate in patients with advanced prostate cancer: a propensity score matching study","Choi SY, Ryu J, You D, Jeong IG, Hong JH, Ahn H, Kim CS.","J Cancer Res Clin Oncol. 2018 Apr;144(4):751-758. doi: 10.1007/s00432-018-2597-5. Epub 2018 Feb 7.","Choi SY","J Cancer Res Clin Oncol","2018","2018/02/09","","","10.1007/s00432-018-2597-5"
"19107447","Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities","Williams H, Powell IJ.","Methods Mol Biol. 2009;472:439-53. doi: 10.1007/978-1-60327-492-0_21.","Williams H","Methods Mol Biol","2009","2008/12/25","","","10.1007/978-1-60327-492-0_21"
"25363844","Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer","Alberti C.","Br J Radiol. 2015 Jan;88(1045):20140630. doi: 10.1259/bjr.20140630.","Alberti C","Br J Radiol","2015","2014/11/04","PMC4277386","","10.1259/bjr.20140630"
"27273955","MicroRNA-146b acts as a potential tumor suppressor in human prostate cancer","Ding HY, Qian WQ, Xu J.","J BUON. 2016 Mar-Apr;21(2):434-43.","Ding HY","J BUON","2016","2016/06/09","","",""
"28899970","Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition","Ketola K, Munuganti RSN, Davies A, Nip KM, Bishop JL, Zoubeidi A.","Clin Cancer Res. 2017 Nov 15;23(22):6923-6933. doi: 10.1158/1078-0432.CCR-17-0901. Epub 2017 Sep 12.","Ketola K","Clin Cancer Res","2017","2017/09/14","","","10.1158/1078-0432.CCR-17-0901"
"15069320","Advances in prostate cancer","Ryan CJ, Small EJ.","Curr Opin Oncol. 2004 May;16(3):242-6. doi: 10.1097/00001622-200405000-00009.","Ryan CJ","Curr Opin Oncol","2004","2004/04/08","","","10.1097/00001622-200405000-00009"
"16952615","Metastatic prostate cancer-does treatment of the primary tumor matter?","Swanson G, Thompson I, Basler J, Crawford ED.","J Urol. 2006 Oct;176(4 Pt 1):1292-8. doi: 10.1016/j.juro.2006.06.069.","Swanson G","J Urol","2006","2006/09/06","","","10.1016/j.juro.2006.06.069"
"9757174","Prostate cancer: progress and perplexity","Hoey J.","CMAJ. 1998 Sep 8;159(5):491-2.","Hoey J","CMAJ","1998","1998/10/03","PMC1229645","",""
"31713121","Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer","Kim J, Feagins LA.","Dig Dis Sci. 2020 Jan;65(1):22-30. doi: 10.1007/s10620-019-05934-7. Epub 2019 Nov 11.","Kim J","Dig Dis Sci","2020","2019/11/13","","","10.1007/s10620-019-05934-7"
"9048830","Surgery's role in prostate cancer spurs ongoing debate","Holzman D.","J Natl Cancer Inst. 1997 Feb 19;89(4):282-3. doi: 10.1093/jnci/89.4.282.","Holzman D","J Natl Cancer Inst","1997","1997/02/19","","","10.1093/jnci/89.4.282"
"18416071","[Current methods of radical treatment for localized prostate cancer]","Kaprin AD, Khmelevskiĭ EV, Fadeev AV.","Vopr Onkol. 2008;54(1):108-12.","Kaprin AD","Vopr Onkol","2008","2008/04/18","","",""
"10485446","On the prevention and therapy of prostate cancer by androgen administration","Prehn RT.","Cancer Res. 1999 Sep 1;59(17):4161-4.","Prehn RT","Cancer Res","1999","1999/09/15","","",""
"2263512","Interstitially implanted I125 for prostate cancer using transrectal ultrasound","Greenburg S, Petersen J, Hansen-Peters I, Baylinson W.","Oncol Nurs Forum. 1990 Nov-Dec;17(6):849-54.","Greenburg S","Oncol Nurs Forum","1990","1990/11/01","","",""
"8853483","Facing the challenge of prostate cancer: the family physician's perspective. Patient perspective #2","Duval J.","Can J Oncol. 1994 Nov;4 Suppl 1:15-6; discussion 17.","Duval J","Can J Oncol","1994","1994/11/01","","",""
"26905104","Advanced prostate cancer presenting as bilateral testicular hydrocele","Gupta S, Mehta A, Kaur J.","Indian J Cancer. 2015 Jul-Sep;52(3):264-5. doi: 10.4103/0019-509X.176754.","Gupta S","Indian J Cancer","2015","2016/02/25","","","10.4103/0019-509X.176754"
"23031761","Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum","Nash GF, Turner KJ, Hickish T, Smith J, Chand M, Moran BJ.","Ann R Coll Surg Engl. 2012 Oct;94(7):456-62. doi: 10.1308/003588412X13373405384611.","Nash GF","Ann R Coll Surg Engl","2012","2012/10/04","PMC3954237","","10.1308/003588412X13373405384611"
"10798510","Clinical and biopsy specimen features in black and white men with clinically localized prostate cancer","Bozeman C, Williams BJ, Whatley T, Crow A, Eastham J.","South Med J. 2000 Apr;93(4):400-2.","Bozeman C","South Med J","2000","2000/05/08","","",""
"26656522","NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015","Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D.","J Natl Compr Canc Netw. 2015 Dec;13(12):1534-61. doi: 10.6004/jnccn.2015.0181.","Carroll PR","J Natl Compr Canc Netw","2015","2015/12/15","","","10.6004/jnccn.2015.0181"
"1428986","The epidemiology of prostate cancer in black men","Burks DA, Littleton RH.","Henry Ford Hosp Med J. 1992;40(1-2):89-92.","Burks DA","Henry Ford Hosp Med J","1992","1992/01/01","","",""
"17067773","Transrectal ultrasound in the staging of clinical T3a prostate cancer","Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H.","Eur J Surg Oncol. 2007 Feb;33(1):79-82. doi: 10.1016/j.ejso.2006.09.007. Epub 2006 Oct 24.","Hsu CY","Eur J Surg Oncol","2007","2006/10/28","","","10.1016/j.ejso.2006.09.007"
"12901296","Predicting outcome in localized prostate cancer: how far have we come?","Oh WK.","Cancer Invest. 2003 Jun;21(3):487-8. doi: 10.1081/cnv-120018656.","Oh WK","Cancer Invest","2003","2003/08/07","","","10.1081/cnv-120018656"
"17633990","[Bulletin of synthesis 2005. Recommendations for clinical practice. Management of non metastatic prostate cancer]","Soulie M, Beuzeboc P, Richaud P, Villers A, Kassab-Chahmi D, Bataillard A; Association Francaise d'Urologie; Fédération Nationale des Centres de Lutte contre le Cancer.","Prog Urol. 2007 Jun;17(4):801-9. doi: 10.1016/s1166-7087(07)92296-4.","Soulie M","Prog Urol","2007","2007/07/20","","","10.1016/s1166-7087(07)92296-4"
"15992907","Immunohistochemical study of chromogranin A in Stage D2 prostate cancer","Kokubo H, Yamada Y, Nishio Y, Fukatsu H, Honda N, Nakagawa A, Saga S, Tsuzuki T, Hara K.","Urology. 2005 Jul;66(1):135-40. doi: 10.1016/j.urology.2005.01.026.","Kokubo H","Urology","2005","2005/07/05","","","10.1016/j.urology.2005.01.026"
"18828469","Symposium issue: prostate cancer 2008","Bissada NK.","J Ark Med Soc. 2008 Sep;105(3):54.","Bissada NK","J Ark Med Soc","2008","2008/10/03","","",""
"10070940","Dietary fat and prostate cancer: current status","Kolonel LN, Nomura AM, Cooney RV.","J Natl Cancer Inst. 1999 Mar 3;91(5):414-28. doi: 10.1093/jnci/91.5.414.","Kolonel LN","J Natl Cancer Inst","1999","1999/03/10","","","10.1093/jnci/91.5.414"
"8996357","Prostate cancer","Oyasu R.","J Urol. 1997 Feb;157(2):563-4. doi: 10.1016/s0022-5347(01)65202-9.","Oyasu R","J Urol","1997","1997/02/01","","","10.1016/s0022-5347(01)65202-9"
"24861331","Prostate cancer: European urologists prefer surgery for high-risk prostate cancer","Payton S.","Nat Rev Urol. 2014 Jun;11(6):307. doi: 10.1038/nrurol.2014.122. Epub 2014 May 27.","Payton S","Nat Rev Urol","2014","2014/05/28","","","10.1038/nrurol.2014.122"
"8535677","The burden of prostate cancer from diagnosis until death","Otnes B, Harvei S, Fosså SD.","Br J Urol. 1995 Nov;76(5):587-94. doi: 10.1111/j.1464-410x.1995.tb07783.x.","Otnes B","Br J Urol","1995","1995/11/01","","","10.1111/j.1464-410x.1995.tb07783.x"
"24816306","Prostate cancer: measuring PSA","Pezaro C, Woo HH, Davis ID.","Intern Med J. 2014 May;44(5):433-40. doi: 10.1111/imj.12407.","Pezaro C","Intern Med J","2014","2014/05/13","","","10.1111/imj.12407"
"2660761","Prostate cancer: a model of cancer in the elderly","Balducci L, Khansur T, Smith T, Hardy C.","Arch Gerontol Geriatr. 1989 Mar;8(2):165-87. doi: 10.1016/0167-4943(89)90060-5.","Balducci L","Arch Gerontol Geriatr","1989","1989/03/01","","","10.1016/0167-4943(89)90060-5"
"22318178","[Molecular markers as predictive factors biochemical failure after radical treatment of prostate cancer]","Zapatero A, Martín de Vidales C, Conde AC, Leaman O.","Arch Esp Urol. 2012 Jan-Feb;65(1):61-78.","Zapatero A","Arch Esp Urol","2012","2012/02/10","","",""
"14689575","Advances in prostate cancer research","Languino LR.","J Cell Biochem. 2004 Jan 1;91(1):1-2. doi: 10.1002/jcb.10792.","Languino LR","J Cell Biochem","2004","2003/12/23","","","10.1002/jcb.10792"
"22307530","[Prostate cancer unit for an optimal management of prostate cancer unit]","Sciarra A, Salciccia S, Gentilucci A, Innocenzi M, Alfarone A, Cattarino S, Ravaziol M, Panebianco V.","Urologia. 2012;79(1):1-4. doi: 10.5301/RU.2012.8993.","Sciarra A","Urologia","2012","2012/02/07","","","10.5301/RU.2012.8993"
"26826413","Expression of store-operated channel components in prostate cancer: the prognostic paradox","Perrouin Verbe MA, Bruyere F, Rozet F, Vandier C, Fromont G.","Hum Pathol. 2016 Mar;49:77-82. doi: 10.1016/j.humpath.2015.09.042. Epub 2015 Nov 2.","Perrouin Verbe MA","Hum Pathol","2016","2016/01/31","","","10.1016/j.humpath.2015.09.042"
"24029235","SnapShot: Prostate cancer","Barlow LJ, Shen MM.","Cancer Cell. 2013 Sep 9;24(3):400.e1. doi: 10.1016/j.ccr.2013.08.033.","Barlow LJ","Cancer Cell","2013","2013/09/14","","","10.1016/j.ccr.2013.08.033"
"15865593","Communicating prostate cancer risk: what should we be telling our patients?","Baade PD, Steginga SK, Pinnock CB, Aitken JF.","Med J Aust. 2005 May 2;182(9):472-5.","Baade PD","Med J Aust","2005","2005/05/04","","",""
"16623064","Managing the low-socioeconomic-status prostate cancer patient","Rayford W.","J Natl Med Assoc. 2006 Apr;98(4):521-30.","Rayford W","J Natl Med Assoc","2006","2006/04/21","PMC2569254","",""
"29742075","The timing of molecular imaging in prostate cancer","Morris MJ.","Clin Adv Hematol Oncol. 2018 Mar;16(3):195-197.","Morris MJ","Clin Adv Hematol Oncol","2018","2018/05/10","","",""
"12735507","Localized prostate cancer: radiation or surgery?","Klein EA, Kupelian PA.","Urol Clin North Am. 2003 May;30(2):315-30, ix. doi: 10.1016/s0094-0143(02)00179-9.","Klein EA","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00179-9"
"7541858","Prostate cancer","Paulson DF.","J Urol. 1995 Aug;154(2 Pt 1):422-3.","Paulson DF","J Urol","1995","1995/08/01","","",""
"17637535","[Surgical and medical treatment for localized prostate cancer]","Kawai K.","Gan To Kagaku Ryoho. 2007 Jul;34(7):1002-5.","Kawai K","Gan To Kagaku Ryoho","2007","2007/07/20","","",""
"24861329","Prostate cancer: primary ADT monotherapy not suitable for localized disease","Sartor O, Silberstein J.","Nat Rev Urol. 2014 Jun;11(6):309-10. doi: 10.1038/nrurol.2014.119. Epub 2014 May 27.","Sartor O","Nat Rev Urol","2014","2014/05/28","","","10.1038/nrurol.2014.119"
"28248064","[Contemporary markers and histological features of prostate cancer]","Vasilyev AO, Prilepskaya EA, Kovylina MV, Govorov AV, Sadchenko AV, Sidorenkov AV, Pushkar DY.","Urologiia. 2016 Dec;(6):164-166.","Vasilyev AO","Urologiia","2016","2017/03/02","","",""
"26091565","Management of low- and intermediate-risk prostate cancer","van der Poel H, Klotz L, Stief CG.","World J Urol. 2015 Jul;33(7):905-6. doi: 10.1007/s00345-015-1618-0.","van der Poel H","World J Urol","2015","2015/06/21","","","10.1007/s00345-015-1618-0"
"29990335","Predictors of participation in risk-based prostate cancer screening","Koitsalu M, Eklund M, Adolfsson J, Sprangers MAG, Grönberg H, Brandberg Y.","PLoS One. 2018 Jul 10;13(7):e0200409. doi: 10.1371/journal.pone.0200409. eCollection 2018.","Koitsalu M","PLoS One","2018","2018/07/11","PMC6039032","","10.1371/journal.pone.0200409"
"16277184","[Treatment alternatives of the locally advanced prostate cancer]","Pacík D.","Cas Lek Cesk. 2005;144 Suppl 2:39-44.","Pacík D","Cas Lek Cesk","2005","2005/11/10","","",""
"7776553","[Usefulness of fine needle aspiration cytology in the diagnosis of prostate cancer]","Nakamura T, Akimoto S, Shimazaki J.","Nihon Hinyokika Gakkai Zasshi. 1995 Apr;86(4):853-9. doi: 10.5980/jpnjurol1989.86.853.","Nakamura T","Nihon Hinyokika Gakkai Zasshi","1995","1995/04/01","","","10.5980/jpnjurol1989.86.853"
"17229492","[Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia]","Albiges L, Cottu PH, Cojean-Zelek I, Raymond F, Zerkak D, Aerts J, Ziza JM.","Rev Med Interne. 2007 Mar;28(3):176-8. doi: 10.1016/j.revmed.2006.12.007. Epub 2007 Jan 3.","Albiges L","Rev Med Interne","2007","2007/01/19","","","10.1016/j.revmed.2006.12.007"
"8911100","Do we know what's best for prostate cancer?","Waxman J, Pandha H.","Eur J Cancer. 1996 Aug;32A(9):1455-6. doi: 10.1016/0959-8049(96)00084-6.","Waxman J","Eur J Cancer","1996","1996/08/01","","","10.1016/0959-8049(96)00084-6"
"22824183","Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population","Forma E, Krzeslak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Brys M.","Cancer Genet. 2012 Sep;205(9):432-5. doi: 10.1016/j.cancergen.2012.05.005. Epub 2012 Jul 21.","Forma E","Cancer Genet","2012","2012/07/25","","","10.1016/j.cancergen.2012.05.005"
"8411496","Treatment strategies for prostate cancer","Cockett AT.","JAMA. 1993 Oct 13;270(14):1692-3; author reply 1693-4. doi: 10.1001/jama.1993.03510140051023.","Cockett AT","JAMA","1993","1993/10/13","","","10.1001/jama.1993.03510140051023"
"16861118","Prognostic markers under watchful waiting and radical prostatectomy","Holmberg L, Bill-Axelson A, Garmo H, Palmgren J, Norlén BJ, Adami HO, Johansson JE; SPCG-4 Study Group.","Hematol Oncol Clin North Am. 2006 Aug;20(4):845-55. doi: 10.1016/j.hoc.2006.03.007.","Holmberg L","Hematol Oncol Clin North Am","2006","2006/07/25","","","10.1016/j.hoc.2006.03.007"
"28918871","[Indications and limits of ablative therapies in prostate cancer]","Sanchez-Salas R, Barret E, Renard-Penna R, Cosset JM, Dell'Oglio P, Battista J, Gangi A, Lang H, Cathelineau X.","Prog Urol. 2017 Nov;27(15):865-886. doi: 10.1016/j.purol.2017.08.004. Epub 2017 Sep 15.","Sanchez-Salas R","Prog Urol","2017","2017/09/19","","","10.1016/j.purol.2017.08.004"
"11790276","Use of artificial neural networks in prostate cancer","Errejon A, Crawford ED, Dayhoff J, O'Donnell C, Tewari A, Finkelstein J, Gamito EJ.","Mol Urol. 2001 Winter;5(4):153-8. doi: 10.1089/10915360152745821.","Errejon A","Mol Urol","2001","2002/01/16","","","10.1089/10915360152745821"
"6857881","Evaluation of gleason classification system in prostate cancer","Guinan P, Talluri K, Nagubadi S, Sharifi R, Ray V, Shaw M.","Urology. 1983 May;21(5):458-60. doi: 10.1016/0090-4295(83)90039-0.","Guinan P","Urology","1983","1983/05/01","","","10.1016/0090-4295(83)90039-0"
"17003775","Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy","Hayashi N, Urashima M, Ikemoto I, Kuruma H, Arai Y, Kuwao S, Baba S, Egawa S.","Prostate Cancer Prostatic Dis. 2007;10(1):60-5. doi: 10.1038/sj.pcan.4500902. Epub 2006 Oct 3.","Hayashi N","Prostate Cancer Prostatic Dis","2007","2006/09/28","","","10.1038/sj.pcan.4500902"
"16515497","Immunotherapy for prostate cancer","Karnes RJ, Whelan CM, Kwon ED.","Curr Pharm Des. 2006;12(7):807-17. doi: 10.2174/138161206776056001.","Karnes RJ","Curr Pharm Des","2006","2006/03/07","","","10.2174/138161206776056001"
"11296649","[Consumption coagulopathy disclosing prostatic cancer]","Vantaux P, Schneider P, Le Coz S, Villers A.","Prog Urol. 2001 Feb;11(1):68-9.","Vantaux P","Prog Urol","2001","2001/04/12","","",""
"25625726","[Prostate cancer--new guidelines and the first care program]","Bratt O, Damber JE, Aldehag A, Brändström H.","Lakartidningen. 2015 Jan 27;112:C6XC.","Bratt O","Lakartidningen","2015","2015/01/28","","",""
"23118100","Current management of prostate cancer: dilemmas and trials","O'Hanlon Brown C, Waxman J.","Br J Radiol. 2012 Nov;85 Spec No 1(Spec Iss 1):S28-40. doi: 10.1259/bjr/13017671.","O'Hanlon Brown C","Br J Radiol","2012","2012/11/03","PMC3746401","","10.1259/bjr/13017671"
"21377001","Editorial comment. Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer","Jones JS.","Urology. 2011 Mar;77(3):552. doi: 10.1016/j.urology.2010.09.044.","Jones JS","Urology","2011","2011/03/08","","","10.1016/j.urology.2010.09.044"
"27613410","Overview of Dietary Supplements in Prostate Cancer","Yacoubian A, Dargham RA, Khauli RB, Bachir BG.","Curr Urol Rep. 2016 Nov;17(11):78. doi: 10.1007/s11934-016-0637-8.","Yacoubian A","Curr Urol Rep","2016","2016/09/11","","","10.1007/s11934-016-0637-8"
"19760632","From pathogenesis to prevention of castration resistant prostate cancer","Bonkhoff H, Berges R.","Prostate. 2010 Jan 1;70(1):100-12. doi: 10.1002/pros.21042.","Bonkhoff H","Prostate","2010","2009/09/18","","","10.1002/pros.21042"
"10764132","Ethnic and racial differences in prostate cancer incidence and mortality","Farkas A, Marcella S, Rhoads GG.","Ethn Dis. 2000 Winter;10(1):69-75.","Farkas A","Ethn Dis","2000","2000/04/14","","",""
"23793762","[Non-invasive diagnosis of prostate cancer: serum and urine markers]","Rubio-Briones J, Casanova-Casas I, Fernández-Serra A, Casanova Ramón-Borja J, Ramírez Backhaus M, Collado Sierra A, Domínguez-Escrig J, Gómez-Ferrer A, López-Guerrero JA.","Arch Esp Urol. 2013 Jun;66(5):440-52.","Rubio-Briones J","Arch Esp Urol","2013","2013/06/25","","",""
"21391212","Toward predictors of survival in castration-resistant prostate cancer","Graff JN, Beer TM.","Cancer. 2011 Sep 1;117(17):3882-4. doi: 10.1002/cncr.25986. Epub 2011 Mar 9.","Graff JN","Cancer","2011","2011/03/11","","","10.1002/cncr.25986"
"2689740","[Prostate cancer]","Shimazaki J.","Nihon Hinyokika Gakkai Zasshi. 1989 Oct;80(10):1407-16. doi: 10.5980/jpnjurol1989.80.1407.","Shimazaki J","Nihon Hinyokika Gakkai Zasshi","1989","1989/10/01","","","10.5980/jpnjurol1989.80.1407"
"10423880","[Prostate cancer]","Ruah J.","Acta Med Port. 1999 Jan-Mar;12(1-3):91-4.","Ruah J","Acta Med Port","1999","1999/07/29","","",""
"21680543","Targeting continued androgen receptor signaling in prostate cancer","Massard C, Fizazi K.","Clin Cancer Res. 2011 Jun 15;17(12):3876-83. doi: 10.1158/1078-0432.CCR-10-2815.","Massard C","Clin Cancer Res","2011","2011/06/18","","","10.1158/1078-0432.CCR-10-2815"
"9751324","Progress in management of advanced prostate cancer--don't throw the baby out with the bath water","Raghavan D.","J Urol. 1998 Oct;160(4):1230-1. doi: 10.1016/s0022-5347(01)62502-3.","Raghavan D","J Urol","1998","1998/09/29","","","10.1016/s0022-5347(01)62502-3"
"19492521","[Prostate cancer screening: new data]","Nau JY.","Rev Med Suisse. 2009 Apr 1;5(197):744.","Nau JY","Rev Med Suisse","2009","2009/06/05","","",""
"7621465","The geography of prostate cancer and its treatment in Israel","Brenner HJ, Rath P, Tichler T, Nussbaum B.","Cancer Surv. 1995;23:287-8.","Brenner HJ","Cancer Surv","1995","1995/01/01","","",""
"21737169","Tobacco smoking and long-lasting symptoms from the bowel and the anal-sphincter region after radiotherapy for prostate cancer","Alsadius D, Hedelin M, Johansson KA, Pettersson N, Wilderäng U, Lundstedt D, Steineck G.","Radiother Oncol. 2011 Dec;101(3):495-501. doi: 10.1016/j.radonc.2011.06.010. Epub 2011 Jul 5.","Alsadius D","Radiother Oncol","2011","2011/07/09","","","10.1016/j.radonc.2011.06.010"
"8815548","Is there always a role for radical prostatectomy in the treatment of localized prostate cancer?","Di Silverio F, D'Eramo G, Buscarini M, Casale P, Di Nicola S, Colella D, Sciarra A.","Minerva Urol Nefrol. 1995 Sep;47(3):117-24.","Di Silverio F","Minerva Urol Nefrol","1995","1995/09/01","","",""
"30898552","Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer","Sweeney CJ.","Eur Urol Focus. 2019 Mar;5(2):111-113. doi: 10.1016/j.euf.2019.03.008. Epub 2019 Mar 18.","Sweeney CJ","Eur Urol Focus","2019","2019/03/23","","","10.1016/j.euf.2019.03.008"
"26123120","Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer","Ross AE, D'Amico AV, Freedland SJ.","Prostate Cancer Prostatic Dis. 2016 Mar;19(1):1-6. doi: 10.1038/pcan.2015.31. Epub 2015 Jun 30.","Ross AE","Prostate Cancer Prostatic Dis","2016","2015/07/01","","","10.1038/pcan.2015.31"
"8465018","Sizes and sources of field placement error in routine irradiation for prostate cancer","Dunscombe P, Loose S, Leszczynski K.","Radiother Oncol. 1993 Feb;26(2):174-6. doi: 10.1016/0167-8140(93)90100-m.","Dunscombe P","Radiother Oncol","1993","1993/02/01","","","10.1016/0167-8140(93)90100-m"
"30065357","Landmarks in prostate cancer","Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk N.","Nat Rev Urol. 2018 Oct;15(10):627-642. doi: 10.1038/s41585-018-0060-7.","Sathianathen NJ","Nat Rev Urol","2018","2018/08/02","","","10.1038/s41585-018-0060-7"
"25794094","Prostate cancer: top places where tumors hide on multiparametric MRI","Rosenkrantz AB, Verma S, Turkbey B.","AJR Am J Roentgenol. 2015 Apr;204(4):W449-56. doi: 10.2214/AJR.14.13280.","Rosenkrantz AB","AJR Am J Roentgenol","2015","2015/03/21","","","10.2214/AJR.14.13280"
"8531276","Survival and conservative treatment for localized prostate cancer","Swanson G.","JAMA. 1996 Jan 3;275(1):31; author reply 32. doi: 10.1001/jama.275.1.31b.","Swanson G","JAMA","1996","1996/01/03","","","10.1001/jama.275.1.31b"
"16873140","Redistribution of androgen receptors in acquired hormone-refractory prostate cancer cells","Yu DS, Hsieh DS, Chang SY.","Arch Androl. 2006 Sep-Oct;52(5):389-95. doi: 10.1080/01485010600666854.","Yu DS","Arch Androl","2006","2006/07/29","","","10.1080/01485010600666854"
"19101947","International epidemiology of prostate cancer: geographical distribution and secular trends","Baade PD, Youlden DR, Krnjacki LJ.","Mol Nutr Food Res. 2009 Feb;53(2):171-84. doi: 10.1002/mnfr.200700511.","Baade PD","Mol Nutr Food Res","2009","2008/12/23","","","10.1002/mnfr.200700511"
"9166527","Practice guidelines for prostate cancer","Ahlering T, Parker R, Kumar S, Taylor C, Gilden R, Figlin RA.","Cancer J Sci Am. 1996 May-Jun;2(3A Suppl):S77-86.","Ahlering T","Cancer J Sci Am","1996","1996/05/01","","",""
"14654575","Prostate cancer management: 2. An update on locally advanced and metastatic disease","Bott SR, Birtle AJ, Taylor CJ, Kirby RS.","Postgrad Med J. 2003 Nov;79(937):643-5. doi: 10.1136/pmj.79.937.643.","Bott SR","Postgrad Med J","2003","2003/12/05","PMC1742876","","10.1136/pmj.79.937.643"
"17290852","PCA3 improves diagnosis of prostate cancer","Kirby R.","Practitioner. 2007 Jan;251(1690):18, 21, 23.","Kirby R","Practitioner","2007","2007/02/13","","",""
"12573817","Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease","Labrie F.","Mol Cell Endocrinol. 2002 Dec 30;198(1-2):77-87. doi: 10.1016/s0303-7207(02)00371-4.","Labrie F","Mol Cell Endocrinol","2002","2003/02/08","","","10.1016/s0303-7207(02)00371-4"
"12796672","Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer","Diefenbach MA, Hamrick N, Uzzo R, Pollack A, Horwitz E, Greenberg R, Engstrom PF.","J Urol. 2003 Jul;170(1):166-9. doi: 10.1097/01.ju.0000070963.12496.cc.","Diefenbach MA","J Urol","2003","2003/06/11","","","10.1097/01.ju.0000070963.12496.cc"
"17335593","Epigenetic targets in the diagnosis and treatment of prostate cancer","Manoharan M, Ramachandran K, Soloway MS, Singal R.","Int Braz J Urol. 2007 Jan-Feb;33(1):11-8. doi: 10.1590/s1677-55382007000100003.","Manoharan M","Int Braz J Urol","2007","2007/03/06","","","10.1590/s1677-55382007000100003"
"28220449","Current Management Strategy for Active Surveillance in Prostate Cancer","Syed JS, Javier-Desloges J, Tatzel S, Bhagat A, Nguyen KA, Hwang K, Kim S, Sprenkle PC.","Curr Oncol Rep. 2017 Feb;19(2):11. doi: 10.1007/s11912-017-0569-6.","Syed JS","Curr Oncol Rep","2017","2017/02/22","","","10.1007/s11912-017-0569-6"
"11280887","[Diagnosis and treatment of prostate cancer--it's diversity and future prospects]","Ogawa O.","Hinyokika Kiyo. 2001 Feb;47(2):131-8.","Ogawa O","Hinyokika Kiyo","2001","2001/04/03","","",""
"22078408","Surgical therapy for intermediate risk prostate cancer","Schade GR, Wood DP Jr.","Urol Oncol. 2011 Nov-Dec;29(6):833-6. doi: 10.1016/j.urolonc.2011.03.010.","Schade GR","Urol Oncol","2011","2011/11/15","","","10.1016/j.urolonc.2011.03.010"
"12820781","Cryotherapy for prostate cancer","Bermejo CE, Pisters LL.","Expert Rev Anticancer Ther. 2003 Jun;3(3):393-401. doi: 10.1586/14737140.3.3.393.","Bermejo CE","Expert Rev Anticancer Ther","2003","2003/06/25","","","10.1586/14737140.3.3.393"
"18089886","MRI or bone scan or both for staging of prostate cancer?","Venkitaraman R, Sohaib A, Cook G.","J Clin Oncol. 2007 Dec 20;25(36):5837-8; author reply 5838-9. doi: 10.1200/JCO.2007.14.3875.","Venkitaraman R","J Clin Oncol","2007","2007/12/20","","","10.1200/JCO.2007.14.3875"
"22986617","Gene expression signature predicting high-grade prostate cancer responses to oxaliplatin","Puyo S, Houédé N, Kauffmann A, Richaud P, Robert J, Pourquier P.","Mol Pharmacol. 2012 Dec;82(6):1205-16. doi: 10.1124/mol.112.080333. Epub 2012 Sep 17.","Puyo S","Mol Pharmacol","2012","2012/09/19","","","10.1124/mol.112.080333"
"15305791","Radical prostatectomy versus watchful waiting in early prostate cancer","Kirkpatrick J.","J Insur Med. 2002;34(2):131-2.","Kirkpatrick J","J Insur Med","2002","2004/08/13","","",""
"7531812","Localised prostate cancer: which way forward?","Stuart-Harris R, Berry MP.","Med J Aust. 1995 Feb 6;162(3):116-7.","Stuart-Harris R","Med J Aust","1995","1995/02/06","","",""
"1371556","Diagnosis of prostate cancer: a personal view","Stamey TA.","J Urol. 1992 Mar;147(3 Pt 2):830-2. doi: 10.1016/s0022-5347(17)37398-6.","Stamey TA","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37398-6"
"8631420","Update on urology--prostate cancer. 4--Treatment of local disease","Bowsher WG.","Eur J Surg Oncol. 1995 Dec;21(6):679-82. doi: 10.1016/s0748-7983(95)96036-8.","Bowsher WG","Eur J Surg Oncol","1995","1995/12/01","","","10.1016/s0748-7983(95)96036-8"
"2741566","[Recommendations for the diagnosis and therapy of prostate cancer]","Langkopf B.","Z Urol Nephrol. 1989 Apr;82(4):221-5.","Langkopf B","Z Urol Nephrol","1989","1989/04/01","","",""
"1423327","The importance of steroid hormones in prostate cancer","Wilding G.","Cancer Surv. 1992;14:113-30.","Wilding G","Cancer Surv","1992","1992/01/01","","",""
"10926084","Management of locally advanced prostate cancer. 1. Staging, natural history, and results of radical surgery","van den Ouden D, Schröder FH.","World J Urol. 2000 Jun;18(3):194-203. doi: 10.1007/s003459900102.","van den Ouden D","World J Urol","2000","2000/08/05","","","10.1007/s003459900102"
"11074611","Prostate cancer screening","Alexander FE.","Microsc Res Tech. 2000 Dec 1;51(5):419-22. doi: 10.1002/1097-0029(20001201)51:5<419::AID-JEMT3>3.0.CO;2-4.","Alexander FE","Microsc Res Tech","2000","2000/11/14","","","10.1002/1097-0029(20001201)51:5<419::AID-JEMT3>3.0.CO;2-4"
"30964115","Evaluation of 24-core coaxial needle saturation biopsy of the prostate by the transperineal approach in detecting prostate cancer in patients without previous biopsy history: A single-center report","Zhang F, Shao Q, Du Y, Tian Y.","J Cancer Res Ther. 2019;15(2):380-385. doi: 10.4103/jcrt.JCRT_384_18.","Zhang F","J Cancer Res Ther","2019","2019/04/10","","","10.4103/jcrt.JCRT_384_18"
"7621458","Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer","Oliver RT, Gallagher CJ.","Cancer Surv. 1995;23:191-207.","Oliver RT","Cancer Surv","1995","1995/01/01","","",""
"18800346","PrLZ expression is associated with the progression of prostate cancer LNCaP cells","Li L, Zhang D, Zhang L, Zhu G, Sun Y, Wu K, Wang X, He D.","Mol Carcinog. 2009 May;48(5):432-40. doi: 10.1002/mc.20481.","Li L","Mol Carcinog","2009","2008/09/19","","","10.1002/mc.20481"
"25922237","[Difficult balance between over- and undertreatment of localized prostate cancer]","Borre M.","Ugeskr Laeger. 2015 Apr 27;177(18):835.","Borre M","Ugeskr Laeger","2015","2015/04/30","","",""
"10235146","Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer","Sharkey J.","JAMA. 1999 May 5;281(17):1584-6.","Sharkey J","JAMA","1999","1999/05/11","","",""
"8411495","Treatment strategies for prostate cancer","Switzer RW.","JAMA. 1993 Oct 13;270(14):1692; author reply 1693. doi: 10.1001/jama.270.14.1692b.","Switzer RW","JAMA","1993","1993/10/13","","","10.1001/jama.270.14.1692b"
"8411494","Treatment strategies for prostate cancer","Catalona WJ.","JAMA. 1993 Oct 13;270(14):1691; author reply 1693. doi: 10.1001/jama.270.14.1691.","Catalona WJ","JAMA","1993","1993/10/13","","","10.1001/jama.270.14.1691"
"7370939","Current status of classification and staging of prostate cancer","Murphy GP, Gaeta JF, Pickren J, Wajsman Z.","Cancer. 1980 Apr 15;45(7 Suppl):1889-95.","Murphy GP","Cancer","1980","1980/04/15","","",""
"11410195","Detection of prostate cancer with a microbubble ultrasound contrast agent","Frauscher F, Klauser A, Halpern EJ, Horninger W, Bartsch G.","Lancet. 2001 Jun 9;357(9271):1849-50. doi: 10.1016/s0140-6736(00)04970-9.","Frauscher F","Lancet","2001","2001/06/19","","","10.1016/s0140-6736(00)04970-9"
"21788044","Coronary artery revascularization and the risk of death in men with prostate cancer","D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S, Ross R, Goldhaber SZ.","J Urol. 2011 Sep;186(3):898-902. doi: 10.1016/j.juro.2011.04.076. Epub 2011 Jul 23.","D'Amico AV","J Urol","2011","2011/07/27","","","10.1016/j.juro.2011.04.076"
"29333925","Androgen receptor-independent prostate cancer: an emerging clinical entity","Sahin I, Mega AE, Carneiro BA.","Cancer Biol Ther. 2018 May 4;19(5):347-348. doi: 10.1080/15384047.2018.1423926. Epub 2018 Feb 2.","Sahin I","Cancer Biol Ther","2018","2018/01/16","PMC5915038","","10.1080/15384047.2018.1423926"
"15723221","Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer","Chi KN.","World J Urol. 2005 Feb;23(1):33-7. doi: 10.1007/s00345-004-0477-x. Epub 2005 Feb 19.","Chi KN","World J Urol","2005","2005/02/22","","","10.1007/s00345-004-0477-x"
"21837490","[Prostate cancer]","Noldus J.","Urologe A. 2011 Sep;50 Suppl 1:171-2. doi: 10.1007/s00120-011-2674-8.","Noldus J","Urologe A","2011","2011/08/13","","","10.1007/s00120-011-2674-8"
"23290320","Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies","Limonta P, Manea M.","Cancer Treat Rev. 2013 Oct;39(6):647-63. doi: 10.1016/j.ctrv.2012.12.003. Epub 2013 Jan 3.","Limonta P","Cancer Treat Rev","2013","2013/01/08","","","10.1016/j.ctrv.2012.12.003"
"7685000","Early diagnosis of prostate cancer","Gerber GS, Chodak GW.","Important Adv Oncol. 1993:93-101.","Gerber GS","Important Adv Oncol","1993","1993/01/01","","",""
"10710900","Management of localized prostate cancer","Bissada NK.","J S C Med Assoc. 2000 Feb;96(2):57-9.","Bissada NK","J S C Med Assoc","2000","2000/03/11","","",""
"31573840","The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer","Hryniewicz-Jankowska A, Augoff K, Sikorski AF.","Exp Biol Med (Maywood). 2019 Oct;244(13):1053-1061. doi: 10.1177/1535370219870771.","Hryniewicz-Jankowska A","Exp Biol Med (Maywood)","2019","2019/10/02","PMC6775568","","10.1177/1535370219870771"
"26186090","Immature Colon Carcinoma Transcript 1 Is Essential for Prostate Cancer Cell Viability and Proliferation","Wang Z, Xu D, Gao Y, Liu Y, Ren J, Yao Y, Yin L, Chen J, Gan S, Cui X.","Cancer Biother Radiopharm. 2015 Sep;30(7):278-84. doi: 10.1089/cbr.2014.1728. Epub 2015 Jul 17.","Wang Z","Cancer Biother Radiopharm","2015","2015/07/18","","","10.1089/cbr.2014.1728"
"25537662","Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer","LeBeau AM, Denmeade SR.","Mol Cancer Ther. 2015 Mar;14(3):659-68. doi: 10.1158/1535-7163.MCT-14-0744. Epub 2014 Dec 23.","LeBeau AM","Mol Cancer Ther","2015","2014/12/25","PMC4659352","NIHMS737466","10.1158/1535-7163.MCT-14-0744"
"25734965","Management of early-stage prostate cancer","Shore N.","Am J Manag Care. 2014 Dec;20(12 Suppl):S260-72.","Shore N","Am J Manag Care","2014","2015/03/04","","",""
"16474712","How close are we to preventing prostate cancer?","Scardino PT.","Nat Clin Pract Urol. 2005 Aug;2(8):355. doi: 10.1038/ncpuro0256.","Scardino PT","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0256"
"8846853","5--Surgical pathology of prostate cancer","Algaba F.","Eur J Surg Oncol. 1996 Feb;22(1):102-7. doi: 10.1016/s0748-7983(96)91847-8.","Algaba F","Eur J Surg Oncol","1996","1996/02/01","","","10.1016/s0748-7983(96)91847-8"
"18971121","Androgens and prostate cancer risk","Wirén S, Stattin P.","Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):601-13. doi: 10.1016/j.beem.2008.06.002.","Wirén S","Best Pract Res Clin Endocrinol Metab","2008","2008/10/31","","","10.1016/j.beem.2008.06.002"
"23868789","Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation","Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.","Prostate. 2013 Nov;73(15):1699-709. doi: 10.1002/pros.22711. Epub 2013 Jul 19.","Thelen P","Prostate","2013","2013/07/23","","","10.1002/pros.22711"
"18374470","Evaluation of prostate cancer detection with ultrasound real-time elastography: a comparison with step section pathological analysis after radical prostatectomy","Salomon G, Köllerman J, Thederan I, Chun FK, Budäus L, Schlomm T, Isbarn H, Heinzer H, Huland H, Graefen M.","Eur Urol. 2008 Dec;54(6):1354-62. doi: 10.1016/j.eururo.2008.02.035. Epub 2008 Mar 10.","Salomon G","Eur Urol","2008","2008/04/01","","","10.1016/j.eururo.2008.02.035"
"8019365","Screening for prostate cancer: are we ready?","Adami HO, Baron J.","Cancer Epidemiol Biomarkers Prev. 1994 Apr-May;3(3):193-5.","Adami HO","Cancer Epidemiol Biomarkers Prev","1994","1994/04/01","","",""
"19925754","[Vanishing prostate cancer. Clinical presentation and histological review]","Ebel Sepúlveda L, Corti D, Foneron A, Troncoso L, Gil G, Carpio D, Cañoles R, Hornig A, Valdevenito G.","Actas Urol Esp. 2009 Oct;33(9):956-9. doi: 10.1016/s0210-4806(09)72893-1.","Ebel Sepúlveda L","Actas Urol Esp","2009","2009/11/21","","","10.1016/s0210-4806(09)72893-1"
"16673590","Clinically significant and non significant prostate cancer an ongoing question","Becopoulos T.","Acta Chir Iugosl. 2005;52(4):27-9. doi: 10.2298/aci0504027b.","Becopoulos T","Acta Chir Iugosl","2005","2006/05/06","","","10.2298/aci0504027b"
"11916650","Clinical trials for prostate cancer","","Harv Mens Health Watch. 2002 Mar;6(8):5-8.","","Harv Mens Health Watch","2002","2002/03/28","","",""
"11295627","Dietary trial in prostate cancer: Early experience and implications for clinical trial design","Ornish DM, Lee KL, Fair WR, Pettengill EB, Carroll PR.","Urology. 2001 Apr;57(4 Suppl 1):200-1. doi: 10.1016/s0090-4295(00)00974-2.","Ornish DM","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00974-2"
"19333894","Advances in Prostate Cancer Research--AACR Special Conference In Cancer Research","Kuslak SL, Van Dyke T.","IDrugs. 2009 Mar;12(3):159-62.","Kuslak SL","IDrugs","2009","2009/04/01","","",""
"12421104","Bicalutamide: in early-stage prostate cancer","Carswell CI, Figgitt DP.","Drugs. 2002;62(17):2471-79; discussion 2480-1. doi: 10.2165/00003495-200262170-00006.","Carswell CI","Drugs","2002","2002/11/08","","","10.2165/00003495-200262170-00006"
"30456709","Treatment of the primary tumor in metastatic prostate cancer","Yuan Y, Kishan AU, Nickols NG.","World J Urol. 2019 Dec;37(12):2597-2606. doi: 10.1007/s00345-018-2552-8. Epub 2018 Nov 19.","Yuan Y","World J Urol","2019","2018/11/21","","","10.1007/s00345-018-2552-8"
"8190170","Conservative management of prostate cancer","Catalona WJ.","N Engl J Med. 1994 Jun 23;330(25):1830-1; author reply 1831-2.","Catalona WJ","N Engl J Med","1994","1994/06/23","","",""
"7690167","Screening for prostate cancer: enthusiasm","Catalona WJ.","Urology. 1993 Aug;42(2):113-5. doi: 10.1016/0090-4295(93)90632-k.","Catalona WJ","Urology","1993","1993/08/01","","","10.1016/0090-4295(93)90632-k"
"22019035","Diabetes mellitus, race and the odds of high grade prostate cancer in men treated with radiation therapy","Mitin T, Chen MH, Zhang Y, Moran BJ, Dosoretz DE, Katin MJ, Braccioforte MH, Salenius SA, D'Amico AV.","J Urol. 2011 Dec;186(6):2233-7. doi: 10.1016/j.juro.2011.07.072. Epub 2011 Oct 22.","Mitin T","J Urol","2011","2011/10/25","","","10.1016/j.juro.2011.07.072"
"8082080","Prostate adenocarcinoma in men younger than 50 years. A retrospective review of 151 patients","Aprikian AG, Zhang ZF, Fair WR.","Cancer. 1994 Sep 15;74(6):1768-77. doi: 10.1002/1097-0142(19940915)74:6<1768::aid-cncr2820740620>3.0.co;2-9.","Aprikian AG","Cancer","1994","1994/09/15","","","10.1002/1097-0142(19940915)74:6<1768::aid-cncr2820740620>3.0.co;2-9"
"19809978","[Prostate cancer: a review of therapeutic strategies]","Winterhalder RC.","Praxis (Bern 1994). 2009 Oct 7;98(20):1149-53. doi: 10.1024/1661-8157.98.20.1149.","Winterhalder RC","Praxis (Bern 1994)","2009","2009/10/08","","","10.1024/1661-8157.98.20.1149"
"3043671","Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs","Raghavan D.","Semin Oncol. 1988 Aug;15(4):371-89.","Raghavan D","Semin Oncol","1988","1988/08/01","","",""
"8428325","Sexual rehabilitation after treatment for prostate cancer","Schover LR.","Cancer. 1993 Feb 1;71(3 Suppl):1024-30. doi: 10.1002/1097-0142(19930201)71:3+<1024::aid-cncr2820711421>3.0.co;2-2.","Schover LR","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1024::aid-cncr2820711421>3.0.co;2-2"
"22591675","The Development of an eHealth tool suite for prostate cancer patients and their partners","Van Bogaert D, Hawkins R, Pingree S, Jarrard D.","J Support Oncol. 2012 Sep-Oct;10(5):202-8. doi: 10.1016/j.suponc.2012.02.003. Epub 2012 May 15.","Van Bogaert D","J Support Oncol","2012","2012/05/18","PMC4139151","NIHMS450653","10.1016/j.suponc.2012.02.003"
"21936828","Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins","Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith RA.","Biochem Soc Trans. 2011 Oct;39(5):1433-6. doi: 10.1042/BST0391433.","Galustian C","Biochem Soc Trans","2011","2011/09/23","","","10.1042/BST0391433"
"8194021","Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care","Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC.","Cancer. 1994 Jun 1;73(11):2791-802. doi: 10.1002/1097-0142(19940601)73:11<2791::aid-cncr2820731123>3.0.co;2-9.","Kornblith AB","Cancer","1994","1994/06/01","","","10.1002/1097-0142(19940601)73:11<2791::aid-cncr2820731123>3.0.co;2-9"
"26292858","Re: Complications following Surgery with or without Radiotherapy or Radiotherapy Alone for Prostate Cancer","Taneja SS.","J Urol. 2015 Sep;194(3):703. doi: 10.1016/j.juro.2015.06.048. Epub 2015 Jun 15.","Taneja SS","J Urol","2015","2015/08/22","","","10.1016/j.juro.2015.06.048"
"19293771","PET-CT for treatment planning in prostate cancer","Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C.","Q J Nucl Med Mol Imaging. 2009 Apr;53(2):245-68.","Picchio M","Q J Nucl Med Mol Imaging","2009","2009/03/19","","",""
"23399726","Prostate cancer: Interpreting cost-utility analysis of prostate cancer treatment","Yu JB.","Nat Rev Urol. 2013 Mar;10(3):129-31. doi: 10.1038/nrurol.2013.17. Epub 2013 Feb 12.","Yu JB","Nat Rev Urol","2013","2013/02/13","","","10.1038/nrurol.2013.17"
"27842331","Chemoprevention in African American Men With Prostate Cancer","Kumar NB, Pow-Sang JM, Spiess PE, Park JY, Chornokur G, Leone AR, Phelan CM.","Cancer Control. 2016 Oct;23(4):415-423. doi: 10.1177/107327481602300413.","Kumar NB","Cancer Control","2016","2016/11/15","","","10.1177/107327481602300413"
"31277188","Mediterranean dietary pattern and the risk of prostate cancer: A meta-analysis","Cheng S, Zheng Q, Ding G, Li G.","Medicine (Baltimore). 2019 Jul;98(27):e16341. doi: 10.1097/MD.0000000000016341.","Cheng S","Medicine (Baltimore)","2019","2019/07/07","PMC6635247","","10.1097/MD.0000000000016341"
"16729907","Clinical utility of radiolabeled monoclonal antibodies in prostate cancer","David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.","Clin Genitourin Cancer. 2006 Mar;4(4):249-56. doi: 10.3816/CGC.2006.n.003.","David KA","Clin Genitourin Cancer","2006","2006/05/30","","","10.3816/CGC.2006.n.003"
"19536865","Promising tumor-associated antigens for future prostate cancer therapy","Li Y, Cozzi PJ, Russell PJ.","Med Res Rev. 2010 Jan;30(1):67-101. doi: 10.1002/med.20165.","Li Y","Med Res Rev","2010","2009/06/19","","","10.1002/med.20165"
"18996822","Testosterone and prostate cancer: challenging dogma with data","Spark RF.","Endocr Pract. 2008 Oct;14(7):902-3. doi: 10.4158/EP.14.7.902.","Spark RF","Endocr Pract","2008","2008/11/11","","","10.4158/EP.14.7.902"
"9490083","The dilemma of prostate cancer--a growing human and economic burden irrespective of treatment strategies","Borre M, Nerstrøm B, Overgaard J.","Acta Oncol. 1997;36(7):681-7. doi: 10.3109/02841869709001337.","Borre M","Acta Oncol","1997","1997/01/01","","","10.3109/02841869709001337"
"9338753","Predicting probability of prostate cancer","Callas PW, Stanley DE.","Urology. 1997 Oct;50(4):655-6. doi: 10.1016/S0090-4295(97)00416-0.","Callas PW","Urology","1997","1997/10/24","","","10.1016/S0090-4295(97)00416-0"
"22545317","New way to predict prostate cancer severity: size of prostate","","Oncology (Williston Park). 2012 Mar;26(3):309.","","Oncology (Williston Park)","2012","2012/05/02","","",""
"17868738","Novel targeted pro-apoptotic agents for the treatment of prostate cancer","Huang X, Zhang X, Farahvash B, Olumi AF.","J Urol. 2007 Nov;178(5):1846-54. doi: 10.1016/j.juro.2007.06.039. Epub 2007 Sep 17.","Huang X","J Urol","2007","2007/09/18","","","10.1016/j.juro.2007.06.039"
"6506392","Pelvic lymph node dissection in prostate cancer","Guinan P, Habibi H, Sharifi R, Ray P, Shaw M, Mouli K.","Urology. 1984 Dec;24(6):540-3. doi: 10.1016/0090-4295(84)90097-9.","Guinan P","Urology","1984","1984/12/01","","","10.1016/0090-4295(84)90097-9"
"19318950","The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer","Reed AB, Parekh DJ.","Curr Opin Urol. 2009 May;19(3):238-42. doi: 10.1097/MOU.0b013e328329eb29.","Reed AB","Curr Opin Urol","2009","2009/03/26","","","10.1097/MOU.0b013e328329eb29"
"23492838","Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer","Rove KO, Crawford ED.","Curr Opin Urol. 2013 May;23(3):208-13. doi: 10.1097/MOU.0b013e32835fa889.","Rove KO","Curr Opin Urol","2013","2013/03/16","","","10.1097/MOU.0b013e32835fa889"
"16806432","Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer","Joslyn SA, Konety BR.","Urology. 2006 Jul;68(1):121-5. doi: 10.1016/j.urology.2006.01.055. Epub 2006 Jun 27.","Joslyn SA","Urology","2006","2006/06/30","","","10.1016/j.urology.2006.01.055"
"26548550","Prognostic and predictive biomarkers in prostate cancer","Kontos CK, Adamopoulos PG, Scorilas A.","Expert Rev Mol Diagn. 2015;15(12):1567-76. doi: 10.1586/14737159.2015.1110022. Epub 2015 Nov 7.","Kontos CK","Expert Rev Mol Diagn","2015","2015/11/10","","","10.1586/14737159.2015.1110022"
"10225443","Trends in survival of prostate cancer in southeastern Netherlands, 1971-1989","Post PN, Kil PJ, Coebergh JW.","Int J Cancer. 1999 May 17;81(4):551-4. doi: 10.1002/(sici)1097-0215(19990517)81:4<551::aid-ijc8>3.0.co;2-5.","Post PN","Int J Cancer","1999","1999/05/04","","","10.1002/(sici)1097-0215(19990517)81:4<551::aid-ijc8>3.0.co;2-5"
"1538496","Radical surgery for advanced prostate cancer and for radiation failures","Catalona WJ.","J Urol. 1992 Mar;147(3 Pt 2):916. doi: 10.1016/s0022-5347(17)37421-9.","Catalona WJ","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37421-9"
"1490020","Screening for prostate cancer in Rhode Island during National Prostate Cancer Awareness Week","Cohen SI, Kingston T.","R I Med. 1992 Nov;75(11):523-5.","Cohen SI","R I Med","1992","1992/11/01","","",""
"21109712","[Molecular biology in prostate cancer. Editorial comment]","Fernández Gómez JM.","Arch Esp Urol. 2010 Jan-Feb;63(1):10-1.","Fernández Gómez JM","Arch Esp Urol","2010","2010/11/27","","",""
"24127391","Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database","Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ.","Cancer. 2014 Jan 15;120(2):197-204. doi: 10.1002/cncr.28423. Epub 2013 Oct 11.","Moreira DM","Cancer","2014","2013/10/16","PMC4149056","NIHMS529600","10.1002/cncr.28423"
"2070330","Bone scan as a stratification variable in advanced prostate cancer","Knudson G, Grinis G, Lopez-Majano V, Sansi P, Targonski P, Rubenstein M, Sharifi R, Guinan P.","Cancer. 1991 Jul 15;68(2):316-20. doi: 10.1002/1097-0142(19910715)68:2<316::aid-cncr2820680218>3.0.co;2-0.","Knudson G","Cancer","1991","1991/07/15","","","10.1002/1097-0142(19910715)68:2<316::aid-cncr2820680218>3.0.co;2-0"
"10692784","[General features and strategy in the diagnosis of prostatic carcinoma]","Stoffel F, Gasser TC.","Ann Ital Chir. 1999 Sep-Oct;70(5):657-63.","Stoffel F","Ann Ital Chir","1999","2000/02/29","","",""
"10492190","Imaging prostate cancer","Hricak H.","J Urol. 1999 Oct;162(4):1329-30. doi: 10.1016/s0022-5347(05)68278-x.","Hricak H","J Urol","1999","1999/09/24","","","10.1016/s0022-5347(05)68278-x"
"21847658","The clinical impact of pathological review on selection the treatment modality for localized prostate cancer in candidates for brachytherapy monotherapy","Kishimoto R, Saika T, Bekku K, Nose H, Abarzua F, Kobayashi Y, Araki M, Yanai H, Nasu Y, Kumon H.","World J Urol. 2012 Jun;30(3):375-8. doi: 10.1007/s00345-011-0738-4. Epub 2011 Aug 17.","Kishimoto R","World J Urol","2012","2011/08/18","","","10.1007/s00345-011-0738-4"
"22770662","Active surveillance for prostate cancer: barriers to widespread adoption","Sandhu GS, Andriole GL.","Eur Urol. 2012 Dec;62(6):984-5. doi: 10.1016/j.eururo.2012.06.047. Epub 2012 Jun 30.","Sandhu GS","Eur Urol","2012","2012/07/10","","","10.1016/j.eururo.2012.06.047"
"18186496","The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis","Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD.","Cancer. 2008 Mar 1;112(5):971-81. doi: 10.1002/cncr.23277.","Harnden P","Cancer","2008","2008/01/12","","","10.1002/cncr.23277"
"19652037","The new data on prostate cancer screening: what should we do now?","Gilligan T.","Cleve Clin J Med. 2009 Aug;76(8):446-8. doi: 10.3949/ccjm.76a.09079.","Gilligan T","Cleve Clin J Med","2009","2009/08/05","","","10.3949/ccjm.76a.09079"
"20534149","Periostin is up-regulated in high grade and high stage prostate cancer","Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, Hermanns T, Mortezavi A, Gerhardt J, Schraml P, Jung K, Moch H, Soltermann A, Kristiansen G.","BMC Cancer. 2010 Jun 9;10:273. doi: 10.1186/1471-2407-10-273.","Tischler V","BMC Cancer","2010","2010/06/11","PMC2903527","","10.1186/1471-2407-10-273"
"24142545","Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis","Yao Y, Wang H, Li B, Tang Y.","Tumour Biol. 2014 Mar;35(3):2157-66. doi: 10.1007/s13277-013-1286-x. Epub 2013 Oct 20.","Yao Y","Tumour Biol","2014","2013/10/22","","","10.1007/s13277-013-1286-x"
"18369636","The role of lymphadenectomy in high risk prostate cancer","Burkhard FC, Studer UE.","World J Urol. 2008 Jun;26(3):231-6. doi: 10.1007/s00345-008-0251-6. Epub 2008 Mar 28.","Burkhard FC","World J Urol","2008","2008/03/29","","","10.1007/s00345-008-0251-6"
"21383304","Prostate cancer-specific survival in elderly patients","Froehner M.","J Clin Oncol. 2011 Apr 1;29(10):e281; author reply e282. doi: 10.1200/JCO.2010.34.2378. Epub 2011 Mar 7.","Froehner M","J Clin Oncol","2011","2011/03/09","","","10.1200/JCO.2010.34.2378"
"10914766","Prostate cancer epidemic: early detection mandatory","Scobie B.","Aust N Z J Med. 2000 Jun;30(3):406. doi: 10.1111/j.1445-5994.2000.tb00850.x.","Scobie B","Aust N Z J Med","2000","2000/07/29","","","10.1111/j.1445-5994.2000.tb00850.x"
"7210366","Prostate cancer today","Murphy GP.","Urology. 1981 Mar;17(Suppl 3):1-3.","Murphy GP","Urology","1981","1981/03/01","","",""
"19365892","Optimal biopsy strategies for the diagnosis and staging of prostate cancer","Patel AR, Jones JS.","Curr Opin Urol. 2009 May;19(3):232-7. doi: 10.1097/mou.0b013e328329a33e.","Patel AR","Curr Opin Urol","2009","2009/04/16","","","10.1097/mou.0b013e328329a33e"
"20212181","The prostate cancer treatment bazaar: comment on ""Physician visits prior to treatment for clinically localized prostate cancer""","Barry MJ.","Arch Intern Med. 2010 Mar 8;170(5):450-2. doi: 10.1001/archinternmed.2010.2.","Barry MJ","Arch Intern Med","2010","2010/03/10","","","10.1001/archinternmed.2010.2"
"25306159","Robot-assisted radical prostatectomy: inching toward gold standard","Sood A, Jeong W, Peabody JO, Hemal AK, Menon M.","Urol Clin North Am. 2014 Nov;41(4):473-84. doi: 10.1016/j.ucl.2014.07.002. Epub 2014 Aug 22.","Sood A","Urol Clin North Am","2014","2014/10/13","","","10.1016/j.ucl.2014.07.002"
"24836411","Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?","Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS.","Trends Mol Med. 2014 Aug;20(8):428-36. doi: 10.1016/j.molmed.2014.03.005. Epub 2014 May 13.","Walsh AL","Trends Mol Med","2014","2014/05/20","","","10.1016/j.molmed.2014.03.005"
"29870466","MR-Guided Prostate Interventions","Woodrum DA, Gorny KR, Mynderse LA.","Top Magn Reson Imaging. 2018 Jun;27(3):141-151. doi: 10.1097/RMR.0000000000000155.","Woodrum DA","Top Magn Reson Imaging","2018","2018/06/06","","","10.1097/RMR.0000000000000155"
"10235145","Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer","Potters L, Freeman K.","JAMA. 1999 May 5;281(17):1584; author reply 1585-6.","Potters L","JAMA","1999","1999/05/11","","",""
"2057785","Helping patients with prostate cancer","Bates P.","Urol Nurs. 1991 Jun;11(2):4.","Bates P","Urol Nurs","1991","1991/06/01","","",""
"7541800","Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality","Labrie F, Cusan L, Gomez JL, Diamond P, Candas B.","J Clin Endocrinol Metab. 1995 Jul;80(7):2002-13. doi: 10.1210/jcem.80.7.7541800.","Labrie F","J Clin Endocrinol Metab","1995","1995/07/01","","","10.1210/jcem.80.7.7541800"
"20152525","Immunotherapy for prostate cancer: an emerging treatment modality","Drake CG.","Urol Clin North Am. 2010 Feb;37(1):121-9, Table of Contents. doi: 10.1016/j.ucl.2009.11.001.","Drake CG","Urol Clin North Am","2010","2010/02/16","PMC4886226","NIHMS787038","10.1016/j.ucl.2009.11.001"
"23726114","Population-based validation of a policy change to use long-term androgen deprivation therapy for cT3-4 prostate cancer: impact of the EORTC22863 and RTOG 85-31 and 92-02 trials","Tran E, Paquette M, Pickles T, Jay J, Hamm J, Liu M, Lim J, Keyes M, Kwan W, Tyldesley S.","Radiother Oncol. 2013 Jun;107(3):366-71. doi: 10.1016/j.radonc.2013.05.003. Epub 2013 May 29.","Tran E","Radiother Oncol","2013","2013/06/04","","","10.1016/j.radonc.2013.05.003"
"22805323","Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis","Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC.","Br J Cancer. 2012 Aug 7;107(4):646-51. doi: 10.1038/bjc.2012.315. Epub 2012 Jul 17.","Tu SM","Br J Cancer","2012","2012/07/19","PMC3419961","","10.1038/bjc.2012.315"
"19502188","A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse","Madsen LT, Craig C, Kuban D.","Clin J Oncol Nurs. 2009 Jun;13(3):305-9. doi: 10.1188/09.CJON.305-309.","Madsen LT","Clin J Oncol Nurs","2009","2009/06/09","","","10.1188/09.CJON.305-309"
"17921731","Quality of life after therapy for localized prostate cancer","Penson DF.","Cancer J. 2007 Sep-Oct;13(5):318-26. doi: 10.1097/PPO.0b013e3181570121.","Penson DF","Cancer J","2007","2007/10/09","","","10.1097/PPO.0b013e3181570121"
"7520346","Comparison of different serum prostate specific antigen measures for early prostate cancer detection","Catalona WJ, Smith DS.","Cancer. 1994 Sep 1;74(5):1516-8. doi: 10.1002/1097-0142(19940901)74:5<1516::aid-cncr2820740503>3.0.co;2-#.","Catalona WJ","Cancer","1994","1994/09/01","","","10.1002/1097-0142(19940901)74:5<1516::aid-cncr2820740503>3.0.co;2-#"
"27986091","From early detection to rehabilitation in the community: reading beyond the blog testimonies of survivors' quality of life and prostate cancer representation","Zanchetta MS, Cognet M, Lam-Kin-Teng MR, Dumitriu ME, Renaud L, Rhéaume J.","Health Qual Life Outcomes. 2016 Dec 16;14(1):171. doi: 10.1186/s12955-016-0568-6.","Zanchetta MS","Health Qual Life Outcomes","2016","2016/12/18","PMC5162078","","10.1186/s12955-016-0568-6"
"29054792","[Management of prostate cancer in patients older than 75 years]","Mongiat-Artus P, Avenin D.","Presse Med. 2017 Oct;46(10):948-953. doi: 10.1016/j.lpm.2017.09.009. Epub 2017 Oct 18.","Mongiat-Artus P","Presse Med","2017","2017/10/22","","","10.1016/j.lpm.2017.09.009"
"19879477","Prostate cancer in the elderly","Heinzer H, Steuber T.","Urol Oncol. 2009 Nov-Dec;27(6):668-72. doi: 10.1016/j.urolonc.2009.07.015.","Heinzer H","Urol Oncol","2009","2009/11/03","","","10.1016/j.urolonc.2009.07.015"
"9858325","The epidemiology of prostate cancer part II: the risk factors","Brawley OW, Knopf K, Thompson I.","Semin Urol Oncol. 1998 Nov;16(4):193-201.","Brawley OW","Semin Urol Oncol","1998","1998/12/19","","",""
"8797584","Identification and characterization of proximal 6q deletions in prostate cancer","Cooney KA, Wetzel JC, Consolino CM, Wojno KJ.","Cancer Res. 1996 Sep 15;56(18):4150-3.","Cooney KA","Cancer Res","1996","1996/09/15","","",""
"25046532","Personalizing prostate cancer therapy: the way forward","Cetnar JP, Beer TM.","Drug Discov Today. 2014 Sep;19(9):1483-7. doi: 10.1016/j.drudis.2014.07.006. Epub 2014 Jul 18.","Cetnar JP","Drug Discov Today","2014","2014/07/22","","","10.1016/j.drudis.2014.07.006"
"28277880","Genomic tests to guide prostate cancer management following diagnosis","Colicchia M, Morlacco A, Cheville JC, Karnes RJ.","Expert Rev Mol Diagn. 2017 Apr;17(4):367-377. doi: 10.1080/14737159.2017.1302332. Epub 2017 Mar 13.","Colicchia M","Expert Rev Mol Diagn","2017","2017/03/10","","","10.1080/14737159.2017.1302332"
"9229202","Prostate cancer incidence and mortality rates among white and black men","Merrill RM, Brawley OW.","Epidemiology. 1997 Mar;8(2):126-31. doi: 10.1097/00001648-199703000-00001.","Merrill RM","Epidemiology","1997","1997/03/01","","","10.1097/00001648-199703000-00001"
"10230844","Is diabetes mellitus associated with prostate cancer incidence and survival?","Will JC, Vinicor F, Calle EE.","Epidemiology. 1999 May;10(3):313-8.","Will JC","Epidemiology","1999","1999/05/07","","",""
"27249693","Approach to Oligometastatic Prostate Cancer","Bernard B, Gershman B, Karnes RJ, Sweeney CJ, Vapiwala N.","Am Soc Clin Oncol Educ Book. 2016;35:119-29. doi: 10.1200/EDBK_159241.","Bernard B","Am Soc Clin Oncol Educ Book","2016","2016/06/02","","","10.1200/EDBK_159241"
"19154477","Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome","Borre M.","BJU Int. 2009 Jul;104(2):205-8. doi: 10.1111/j.1464-410X.2008.08306.x. Epub 2009 Jan 12.","Borre M","BJU Int","2009","2009/01/22","","","10.1111/j.1464-410X.2008.08306.x"
"2946658","Prostate cancer","Barnett TF, Chisholm DP, Harris DR, Haynes WD, Padilla F, Scott DI.","J Ark Med Soc. 1986 Oct;83(5):224-5.","Barnett TF","J Ark Med Soc","1986","1986/10/01","","",""
"8697393","Factors associated with intention to undergo annual prostate cancer screening among African American men in Philadelphia","Myers RE, Wolf TA, McKee L, McGrory G, Burgh DY, Nelson G, Nelson GA.","Cancer. 1996 Aug 1;78(3):471-9. doi: 10.1002/(SICI)1097-0142(19960801)78:3<471::AID-CNCR14>3.0.CO;2-W.","Myers RE","Cancer","1996","1996/08/01","","","10.1002/(SICI)1097-0142(19960801)78:3<471::AID-CNCR14>3.0.CO;2-W"
"9577260","Vitamins, minerals, diet, and prostate cancer","","Harv Mens Health Watch. 1998 May;2(10):1-4.","","Harv Mens Health Watch","1998","1998/05/13","","",""
"17569378","Diagnosis and treatment of patients with prostate cancer: the nurse's role","Turner B.","Nurs Stand. 2007 Jun 6-12;21(39):48-56; quiz 58. doi: 10.7748/ns2007.06.21.39.48.c4568.","Turner B","Nurs Stand","2007","2007/06/16","","","10.7748/ns2007.06.21.39.48.c4568"
"27941540","New and Emerging Diagnostic and Prognostic Immunohistochemical Biomarkers in Prostate Pathology","Giannico GA, Arnold SA, Gellert LL, Hameed O.","Adv Anat Pathol. 2017 Jan;24(1):35-44. doi: 10.1097/PAP.0000000000000136.","Giannico GA","Adv Anat Pathol","2017","2016/12/13","","","10.1097/PAP.0000000000000136"
"21070913","Mechanisms of prostate cancer initiation and progression","Knudsen BS, Vasioukhin V.","Adv Cancer Res. 2010;109:1-50. doi: 10.1016/B978-0-12-380890-5.00001-6.","Knudsen BS","Adv Cancer Res","2010","2010/11/13","","","10.1016/B978-0-12-380890-5.00001-6"
"29702096","Noninvasive Detection of High Grade Prostate Cancer by DNA Methylation Analysis of Urine Cells Captured by Microfiltration","Larsen LK, Jakobsen JS, Abdul-Al A, Guldberg P.","J Urol. 2018 Oct;200(4):749-757. doi: 10.1016/j.juro.2018.04.067. Epub 2018 Apr 24.","Larsen LK","J Urol","2018","2018/04/28","","","10.1016/j.juro.2018.04.067"
"25048254","Androgen receptor splice variants in the era of enzalutamide and abiraterone","Nakazawa M, Antonarakis ES, Luo J.","Horm Cancer. 2014 Oct;5(5):265-73. doi: 10.1007/s12672-014-0190-1. Epub 2014 Jul 22.","Nakazawa M","Horm Cancer","2014","2014/07/23","PMC4167475","NIHMS615317","10.1007/s12672-014-0190-1"
"10344724","Correlation between preoperative predictors and pathologic features in radical prostatectomy specimens in PSA-based screening","Horninger W, Rogatsch H, Reissigl A, Volgger H, Klocker H, Hobisch A, Bartsch G.","Prostate. 1999 Jun 15;40(1):56-61. doi: 10.1002/(sici)1097-0045(19990615)40:1<56::aid-pros7>3.0.co;2-e.","Horninger W","Prostate","1999","1999/05/27","","","10.1002/(sici)1097-0045(19990615)40:1<56::aid-pros7>3.0.co;2-e"
"17113217","Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer","Maffezzini M, Bossi A, Collette L.","Eur Urol. 2007 Mar;51(3):605-13; discussion 613. doi: 10.1016/j.eururo.2006.10.062. Epub 2006 Nov 13.","Maffezzini M","Eur Urol","2007","2006/11/23","","","10.1016/j.eururo.2006.10.062"
"1563738","Markers of the metastatic phenotype in prostate cancer","Foster CS, McLoughlin J, Bashir I, Abel PD.","Hum Pathol. 1992 Apr;23(4):381-94. doi: 10.1016/0046-8177(92)90084-g.","Foster CS","Hum Pathol","1992","1992/04/01","","","10.1016/0046-8177(92)90084-g"
"24373801","The prevalence of persistent prostate cancer after radiotherapy detected at radical cystoprostatectomy for bladder cancer","Meeks JJ, Kern SQ, Dalbagni G, Eastham JA, Sandhu JS.","J Urol. 2014 Jun;191(6):1760-3. doi: 10.1016/j.juro.2013.12.037. Epub 2013 Dec 25.","Meeks JJ","J Urol","2014","2013/12/31","","","10.1016/j.juro.2013.12.037"
"25043063","Targeting the relaxin hormonal pathway in prostate cancer","Neschadim A, Summerlee AJ, Silvertown JD.","Int J Cancer. 2015 Nov 15;137(10):2287-95. doi: 10.1002/ijc.29079. Epub 2014 Jul 22.","Neschadim A","Int J Cancer","2015","2014/07/22","","","10.1002/ijc.29079"
"15175660","'Urology: Today's Advances, Tomorrow's Clinical Practice', Cannes, November 2003. Current thinking in prostatic diseases: insights into dual 5alpha-reductase inhibitor therapy in BPH and prostate cancer","Fitzpatrick JM.","Prostate Cancer Prostatic Dis. 2004;7(2):91-2. doi: 10.1038/sj.pcan.4500724.","Fitzpatrick JM","Prostate Cancer Prostatic Dis","2004","2004/06/04","","","10.1038/sj.pcan.4500724"
"30324350","Applications of Nanoparticles Probes for Prostate Cancer Imaging and Therapy","Gao T, Bi A, Yang S, Liu Y, Kong X, Zeng W.","Adv Exp Med Biol. 2018;1096:99-115. doi: 10.1007/978-3-319-99286-0_6.","Gao T","Adv Exp Med Biol","2018","2018/10/17","","","10.1007/978-3-319-99286-0_6"
"1590086","[Is the early diagnosis of prostatic cancer possible using transrectal echography?]","Espuela Orgaz R, Abad Menor F, Nogueras Gimeno MA, Martínez Perez E, Pérez Arbej JA, Arnaiz Esteban F, Fernández Rosaenz J, Guinda Sevillano C.","Actas Urol Esp. 1992 Feb;16(2):120-6.","Espuela Orgaz R","Actas Urol Esp","1992","1992/02/01","","",""
"9109125","Prostate cancer: to screen or not to screen?","","Oncology (Williston Park). 1997 Mar;11(3):325-6, 329-30.","","Oncology (Williston Park)","1997","1997/03/01","","",""
"27630286","The Utility of Serum CA9 for Prognostication in Prostate Cancer","Smith AD, Truong M, Bristow R, Yip P, Milosevic MF, Joshua AM.","Anticancer Res. 2016 Sep;36(9):4489-92. doi: 10.21873/anticanres.10994.","Smith AD","Anticancer Res","2016","2016/09/16","","","10.21873/anticanres.10994"
"22958524","Angiogenesis in prostate cancer: onset, progression and imaging","Russo G, Mischi M, Scheepens W, De la Rosette JJ, Wijkstra H.","BJU Int. 2012 Dec;110(11 Pt C):E794-808. doi: 10.1111/j.1464-410X.2012.11444.x. Epub 2012 Sep 7.","Russo G","BJU Int","2012","2012/09/11","","","10.1111/j.1464-410X.2012.11444.x"
"15897931","Depression in men with prostate cancer","Bennett G, Badger TA.","Oncol Nurs Forum. 2005 May 10;32(3):545-56. doi: 10.1188/05.ONF.545-556.","Bennett G","Oncol Nurs Forum","2005","2005/05/18","","","10.1188/05.ONF.545-556"
"28301652","To ProtecT Our Patients With Prostate Cancer","Spratt DE.","JAMA Oncol. 2017 Nov 1;3(11):1461-1462. doi: 10.1001/jamaoncol.2017.0274.","Spratt DE","JAMA Oncol","2017","2017/03/17","","","10.1001/jamaoncol.2017.0274"
"18807047","Management of low-risk prostate cancer","Gardiner RA, Hamdy FC.","World J Urol. 2008 Oct;26(5):411-4. doi: 10.1007/s00345-008-0329-1. Epub 2008 Sep 19.","Gardiner RA","World J Urol","2008","2008/09/23","","","10.1007/s00345-008-0329-1"
"25354871","Precision medicine for prostate cancer","Galazi M, Rodriguez-Vida A, Ng T, Mason M, Chowdhury S.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1305-15. doi: 10.1586/14737140.2014.972948. Epub 2014 Oct 30.","Galazi M","Expert Rev Anticancer Ther","2014","2014/10/31","","","10.1586/14737140.2014.972948"
"16405831","[Attach importance to the research of criterion of treatment in prostate cancer]","Na YQ, Li M.","Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3169.","Na YQ","Zhonghua Yi Xue Za Zhi","2005","2006/01/13","","",""
"1557859","Curability of patients with prostate cancer","Lawrence G.","Urology. 1992 Apr;39(4):395-6. doi: 10.1016/0090-4295(92)90225-l.","Lawrence G","Urology","1992","1992/04/01","","","10.1016/0090-4295(92)90225-l"
"3275347","""Stow biases"" in treating localized prostate cancer","","Oncology (Williston Park). 1987 Oct;1(8):16.","","Oncology (Williston Park)","1987","1987/10/01","","",""
"25373266","[Benign prostatic hypertrophy and prostate cancer]","Mourey L, Doumerc N, Gaudin C, Gérard S, Balardy L.","Soins Gerontol. 2014 Sep-Oct;(109):28-32.","Mourey L","Soins Gerontol","2014","2014/11/07","","",""
"12831292","Treatments for improving survival of patients with prostate cancer","David AK, Khwaja R, Hudes GR.","Drugs Aging. 2003;20(9):683-99. doi: 10.2165/00002512-200320090-00005.","David AK","Drugs Aging","2003","2003/07/02","","","10.2165/00002512-200320090-00005"
"7721637","Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life","Helgason AR, Fredrikson M, Adolfsson J, Steineck G.","Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):33-9. doi: 10.1016/0360-3016(95)00542-7.","Helgason AR","Int J Radiat Oncol Biol Phys","1995","1995/04/30","","","10.1016/0360-3016(95)00542-7"
"17283713","[Current role of MRI for the local staging of prostate cancer]","Busquets JC, Batlle JC, Obregón JB, Ortega MV, Morell NR.","Arch Esp Urol. 2006 Dec;59(10):1001-10.","Busquets JC","Arch Esp Urol","2006","2007/02/08","","",""
"12530031","Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer","Ohta S, Wada H, Nakazaki T, Maeda Y, Nobori T, Shiku H, Nakamura S, Nagakawa O, Furuya Y, Fuse H.","Anticancer Res. 2002 Sep-Oct;22(5):2991-6.","Ohta S","Anticancer Res","2002","2003/01/18","","",""
"23768149","The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients","Shafique K, Proctor MJ, McMillan DC, Leung H, Smith K, Sloan B, Morrison DS.","BMC Cancer. 2013 Jun 17;13:292. doi: 10.1186/1471-2407-13-292.","Shafique K","BMC Cancer","2013","2013/06/18","PMC3686580","","10.1186/1471-2407-13-292"
"14765015","The evolving role of androgen deprivation therapy in the management of prostate cancer","Cooperberg MR, Small EJ, D'Amico A, Carroll PR.","Minerva Urol Nefrol. 2003 Dec;55(4):219-38.","Cooperberg MR","Minerva Urol Nefrol","2003","2004/02/07","","",""
"15931270","Report from London","Kirby RS.","Prostate Cancer Prostatic Dis. 2005;8(2):103. doi: 10.1038/sj.pcan.4500807.","Kirby RS","Prostate Cancer Prostatic Dis","2005","2005/06/03","","","10.1038/sj.pcan.4500807"
"23249102","Anatomic, morphologic and genetic heterogeneity of prostate cancer: implications for clinical practice","Cheng L, MacLennan GT, Lopez-Beltran A, Montironi R.","Expert Rev Anticancer Ther. 2012 Nov;12(11):1371-4. doi: 10.1586/era.12.127.","Cheng L","Expert Rev Anticancer Ther","2012","2012/12/20","","","10.1586/era.12.127"
"31120400","Management of patients with metastatic prostate cancer (mPC) in a rural part of North Norway with a scattered population: does living near the department of oncology translate into a different pattern of care and survival?","Nieder C, Dalhaug A, Haukland E, Norum J.","Int J Circumpolar Health. 2019 Dec;78(1):1620086. doi: 10.1080/22423982.2019.1620086.","Nieder C","Int J Circumpolar Health","2019","2019/05/24","PMC6534221","","10.1080/22423982.2019.1620086"
"28045610","Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer","Clement JM, Sweeney CJ.","J Oncol Pract. 2017 Jan;13(1):9-18. doi: 10.1200/JOP.2016.018523. Epub 2017 Jan 3.","Clement JM","J Oncol Pract","2017","2017/01/04","","","10.1200/JOP.2016.018523"
"18158026","Prevalence of high-grade prostatic intraepithelial neoplasia in prostate gland of Korean men: comparisons between radical prostatectomy and cystoprostatectomy","Han KS, Jeong IG, Joung JY, Yang SO, Chung J, Seo HK, Park WS, Lee KH.","Urology. 2007 Dec;70(6):1100-3. doi: 10.1016/j.urology.2007.07.015.","Han KS","Urology","2007","2007/12/26","","","10.1016/j.urology.2007.07.015"
"19633362","Large scale genomic instability as an additive prognostic marker in early prostate cancer","Pretorius ME, Waehre H, Abeler VM, Davidson B, Vlatkovic L, Lothe RA, Giercksky KE, Danielsen HE.","Cell Oncol. 2009;31(4):251-9. doi: 10.3233/CLO-2009-0463.","Pretorius ME","Cell Oncol","2009","2009/07/28","PMC4618993","","10.3233/CLO-2009-0463"
"8080862","Prostate cancer: how can a common disease be so controversial?","Kelly WK, Scher HI.","Curr Opin Oncol. 1994 May;6(3):318-31.","Kelly WK","Curr Opin Oncol","1994","1994/05/01","","",""
"26174258","Prostate cancer","","Nurs Stand. 2015 Jul 15;29(46):17. doi: 10.7748/ns.29.46.17.s20.","","Nurs Stand","2015","2015/07/16","","","10.7748/ns.29.46.17.s20"
"14627670","A Y chromosomal influence on prostate cancer risk: the multi-ethnic cohort study","Paracchini S, Pearce CL, Kolonel LN, Altshuler D, Henderson BE, Tyler-Smith C.","J Med Genet. 2003 Nov;40(11):815-9. doi: 10.1136/jmg.40.11.815.","Paracchini S","J Med Genet","2003","2003/11/25","PMC1735314","","10.1136/jmg.40.11.815"
"2357190","Doing the best for patients with prostate cancer","Kearsley JH.","Australas Radiol. 1990 Feb;34(1):4. doi: 10.1111/j.1440-1673.1990.tb02798.x.","Kearsley JH","Australas Radiol","1990","1990/02/01","","","10.1111/j.1440-1673.1990.tb02798.x"
"28212371","Circulating tumor cells in prostate cancer: beyond enumeration","Chen JF, Lu YT, Cheng S, Tseng HR, Figlin RA, Posadas EM.","Clin Adv Hematol Oncol. 2017 Jan;15(1):63-73.","Chen JF","Clin Adv Hematol Oncol","2017","2017/02/18","","",""
"28758908","Targeting Apoptotic Activity Against Prostate Cancer Stem Cells","Jaworska D, Szliszka E.","Int J Mol Sci. 2017 Jul 29;18(8):1648. doi: 10.3390/ijms18081648.","Jaworska D","Int J Mol Sci","2017","2017/08/01","PMC5578038","","10.3390/ijms18081648"
"23271766","Trends in prostate cancer in the United States","Brawley OW.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):152-6. doi: 10.1093/jncimonographs/lgs035.","Brawley OW","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540881","","10.1093/jncimonographs/lgs035"
"29793403","Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria","Evans MA, Millar JL, Earnest A, Frydenberg M, Davis ID, Murphy DG, Kearns PA, Evans SM.","Med J Aust. 2018 Jun 4;208(10):439-443. Epub 2018 May 28.","Evans MA","Med J Aust","2018","2018/05/26","","",""
"2683303","Ultrasonographic changes in the normal and malignant prostate after definitive radiotherapy","Egawa S, Carter SS, Wheeler TM, Scardino PT.","Urol Clin North Am. 1989 Nov;16(4):741-9.","Egawa S","Urol Clin North Am","1989","1989/11/01","","",""
"28145675","Active Surveillance for Localized Prostate Cancer: No Increased Mortality, but Higher Rates of Clinical Progression","Ebell MH.","Am Fam Physician. 2017 Feb 1;95(3):196.","Ebell MH","Am Fam Physician","2017","2017/02/02","","",""
"17252712","[Forty years' use of Gleason grading in the diagnostics and treatment of prostate cancer]","Cerović S, Brajusković G.","Vojnosanit Pregl. 2006 Dec;63(12):1049-53.","Cerović S","Vojnosanit Pregl","2006","2007/01/27","","",""
"9742897","Status report on prostate cancer in African Americans: a national blueprint for action","Eyre HJ, Feldman GE.","CA Cancer J Clin. 1998 Sep-Oct;48(5):315-9. doi: 10.3322/canjclin.48.5.315.","Eyre HJ","CA Cancer J Clin","1998","1998/09/22","","","10.3322/canjclin.48.5.315"
"19465332","[Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update]","Drouin SJ, Rouprêt M, Davin JL, Soulié M.","Prog Urol. 2009 Apr;19 Suppl 1:S15-9. doi: 10.1016/S1166-7087(09)73901-6.","Drouin SJ","Prog Urol","2009","2009/05/26","","","10.1016/S1166-7087(09)73901-6"
"31277346","Clinical Impact of Circulating Tumor Cells in Patients with Localized Prostate Cancer","Broncy L, Paterlini-Bréchot P.","Cells. 2019 Jul 3;8(7):676. doi: 10.3390/cells8070676.","Broncy L","Cells","2019","2019/07/07","PMC6678597","","10.3390/cells8070676"
"8773496","Can screening for early-stage prostate cancer be rationalized?","Jacobson JO.","Hematol Oncol Clin North Am. 1996 Jun;10(3):549-64. doi: 10.1016/s0889-8588(05)70352-x.","Jacobson JO","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70352-x"
"22398510","Selective lymph node dissection for castration-resistant prostate cancer","Busch J, Hinz S, Kempkensteffen C, Erber B, Klopf C, Weikert S, Miller K, Magheli A.","Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7.","Busch J","Urol Int","2012","2012/03/09","","","10.1159/000335206"
"31013716","A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges","Kohaar I, Petrovics G, Srivastava S.","Int J Mol Sci. 2019 Apr 12;20(8):1813. doi: 10.3390/ijms20081813.","Kohaar I","Int J Mol Sci","2019","2019/04/25","PMC6515282","","10.3390/ijms20081813"
"24818848","The status of surgery in the management of high-risk prostate cancer","Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, Persad R, Koupparis A.","Nat Rev Urol. 2014 Jun;11(6):342-51. doi: 10.1038/nrurol.2014.100. Epub 2014 May 13.","Bach C","Nat Rev Urol","2014","2014/05/14","","","10.1038/nrurol.2014.100"
"8773507","Treatment of metastatic prostate cancer. Lessons from the androgen receptor","Bubley GJ, Balk SP.","Hematol Oncol Clin North Am. 1996 Jun;10(3):713-25. doi: 10.1016/s0889-8588(05)70363-4.","Bubley GJ","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70363-4"
"8717459","The risks outweigh the benefits of radical prostatectomy in localised prostate cancer: the argument against","Huland H.","Eur Urol. 1996;29 Suppl 2:31-3. doi: 10.1159/000473835.","Huland H","Eur Urol","1996","1996/01/01","","","10.1159/000473835"
"20147902","Breast and prostate cancer: more similar than different","Risbridger GP, Davis ID, Birrell SN, Tilley WD.","Nat Rev Cancer. 2010 Mar;10(3):205-12. doi: 10.1038/nrc2795. Epub 2010 Feb 11.","Risbridger GP","Nat Rev Cancer","2010","2010/02/12","","","10.1038/nrc2795"
"15992908","Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings","Jani AB, Gratzle J.","Urology. 2005 Jul;66(1):124-9. doi: 10.1016/j.urology.2005.01.057.","Jani AB","Urology","2005","2005/07/05","","","10.1016/j.urology.2005.01.057"
"30240689","Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study","Thomsen FB, Jakobsen H, Langkilde NC, Borre M, Jakobsen EB, Frey A, Lund L, Lunden D, Dahl C, Helgstrand JT, Brasso K.","J Urol. 2019 Mar;201(3):520-527. doi: 10.1016/j.juro.2018.09.045.","Thomsen FB","J Urol","2019","2018/09/22","","","10.1016/j.juro.2018.09.045"
"22749734","Will biomarkers save prostate cancer screening?","Cooperberg MR.","Eur Urol. 2012 Dec;62(6):962-3; discussion 964-5. doi: 10.1016/j.eururo.2012.06.034. Epub 2012 Jun 27.","Cooperberg MR","Eur Urol","2012","2012/07/04","","","10.1016/j.eururo.2012.06.034"
"12787714","Immunotherapy and prostate cancer","Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B.","Cancer Treat Rev. 2003 Jun;29(3):199-209. doi: 10.1016/s0305-7372(03)00005-7.","Kaminski JM","Cancer Treat Rev","2003","2003/06/06","","","10.1016/s0305-7372(03)00005-7"
"16777198","Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists","Penson D, Moul J, Gandhi S, Newling D.","Urology. 2006 Jul;68(1):80-4. doi: 10.1016/j.urology.2006.01.028. Epub 2006 Jun 13.","Penson D","Urology","2006","2006/06/17","","","10.1016/j.urology.2006.01.028"
"26601517","[SIGNIFICANCE OF DOPPLER-GRAPHIC RESEARCHES FOR DIAGNOSTICS OF PROSTATE CANCER]","Kurnakov AM, Borovets SY, Al'-Shukri SKh, Al'-Shukri AS.","Vestn Khir Im I I Grek. 2015;174(4):45-9.","Kurnakov AM","Vestn Khir Im I I Grek","2015","2015/11/26","","",""
"9108889","Public health impact of prostate cancer early detection","Mettlin C.","Prostate. 1997 Apr 1;31(1):71-3. doi: 10.1002/(sici)1097-0045(19970401)31:1<71::aid-pros11>3.0.co;2-l.","Mettlin C","Prostate","1997","1997/04/01","","","10.1002/(sici)1097-0045(19970401)31:1<71::aid-pros11>3.0.co;2-l"
"9020276","The Swedish prostate cancer paradox","Walsh PC, Brooks JD.","JAMA. 1997 Feb 12;277(6):497-8.","Walsh PC","JAMA","1997","1997/02/12","","",""
"11022679","[International comparisons of prostate cancer incidence and mortality]","Kuroishi T.","Nihon Rinsho. 2000 Jul;58 Suppl:12-21.","Kuroishi T","Nihon Rinsho","2000","2000/10/07","","",""
"28238758","Pathological Findings in Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion-guided Biopsy: Relation to Prostate Cancer Focal Therapy","Gordetsky J, Rais-Bahrami S, Epstein JI.","Urology. 2017 Jul;105:18-23. doi: 10.1016/j.urology.2017.02.027. Epub 2017 Feb 24.","Gordetsky J","Urology","2017","2017/02/28","","","10.1016/j.urology.2017.02.027"
"16518832","Molecular regulation of androgen action in prostate cancer","Dehm SM, Tindall DJ.","J Cell Biochem. 2006 Oct 1;99(2):333-44. doi: 10.1002/jcb.20794.","Dehm SM","J Cell Biochem","2006","2006/03/07","","","10.1002/jcb.20794"
"20150635","A multicountry ecological study of risk-modifying factors for prostate cancer: apolipoprotein E epsilon4 as a risk factor and cereals as a risk reduction factor","Grant WB.","Anticancer Res. 2010 Jan;30(1):189-99.","Grant WB","Anticancer Res","2010","2010/02/13","","",""
"15791914","[Prostate cancer]","Gabilondo-Navarro F, Arroyo C.","Rev Invest Clin. 2004 Nov-Dec;56(6):773-82.","Gabilondo-Navarro F","Rev Invest Clin","2004","2005/03/29","","",""
"30868798","Incidentally Found Metastatic Prostatic Carcinoma In A Therapeutic Orchiectomy Specimen","Bilal M, Uddin Z, Khan MA.","J Ayub Med Coll Abbottabad. 2019 Jan-Mar;31(1):129-130.","Bilal M","J Ayub Med Coll Abbottabad","2019","2019/03/15","","",""
"10204154","Prostate cancer risk assessment program. A model for the early detection of prostate cancer","Bruner DW, Baffoe-Bonnie A, Miller S, Diefenbach M, Tricoli JV, Daly M, Pinover W, Grumet SC, Stofey J, Ross E, Raysor S, Balshem A, Malick J, Engstrom P, Hanks GE, Mirchandani I.","Oncology (Williston Park). 1999 Mar;13(3):325-34; discussion 337-9, 343-4 pas.","Bruner DW","Oncology (Williston Park)","1999","1999/04/16","","",""
"10663191","[Prognostic markers for prostate cancer]","Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H.","Urologe A. 2000 Jan;39(1):14-21. doi: 10.1007/s001200050004.","Graefen M","Urologe A","2000","2000/02/09","","","10.1007/s001200050004"
"16630520","New imaging techniques in prostate cancer","Trabulsi EJ, Merriam WG, Gomella LG.","Curr Urol Rep. 2006 May;7(3):175-80. doi: 10.1007/s11934-006-0018-9.","Trabulsi EJ","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0018-9"
"1895422","Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease","Larsen MP, Carter HB, Epstein JI.","J Urol. 1991 Oct;146(4):1059-63. doi: 10.1016/s0022-5347(17)38000-x.","Larsen MP","J Urol","1991","1991/10/01","","","10.1016/s0022-5347(17)38000-x"
"17375307","Urologic imaging for localized prostate cancer in 2007","Loch T.","World J Urol. 2007 Apr;25(2):121-9. doi: 10.1007/s00345-007-0155-x. Epub 2007 Mar 21.","Loch T","World J Urol","2007","2007/03/22","","","10.1007/s00345-007-0155-x"
"18774466","Local-regional prostate cancer","Jones MJ, Koeneman KS.","Urol Oncol. 2008 Sep-Oct;26(5):516-21. doi: 10.1016/j.urolonc.2008.03.007.","Jones MJ","Urol Oncol","2008","2008/09/09","","","10.1016/j.urolonc.2008.03.007"
"30905848","Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning","Turanli B, Zhang C, Kim W, Benfeitas R, Uhlen M, Arga KY, Mardinoglu A.","EBioMedicine. 2019 Apr;42:386-396. doi: 10.1016/j.ebiom.2019.03.009. Epub 2019 Mar 21.","Turanli B","EBioMedicine","2019","2019/03/26","PMC6491384","","10.1016/j.ebiom.2019.03.009"
"18497043","Strategy for the application of therapy in prostate cancer","Logothetis CJ.","Adv Exp Med Biol. 2008;617:193-9. doi: 10.1007/978-0-387-69080-3_18.","Logothetis CJ","Adv Exp Med Biol","2008","2008/05/24","","","10.1007/978-0-387-69080-3_18"
"7565273","Prostate cancer: enthusiasm for screening","Sladden MJ, Thomson AN.","Med J Aust. 1995 Oct 2;163(7):389-90.","Sladden MJ","Med J Aust","1995","1995/10/02","","",""
"30384811","Combination of singularly perturbed vector field method and method of directly defining the inverse mapping applied to complex ODE system prostate cancer model","Nave O, Elbaz M.","J Biol Dyn. 2018 Dec;12(1):983-1008. doi: 10.1080/17513758.2018.1541104.","Nave O","J Biol Dyn","2018","2018/11/03","","","10.1080/17513758.2018.1541104"
"24584698","Rsf-1 overexpression in human prostate cancer, implication as a prognostic marker","Li H, Zhang Y, Zhang Y, Bai X, Peng Y, He P.","Tumour Biol. 2014 Jun;35(6):5771-6. doi: 10.1007/s13277-014-1766-7. Epub 2014 Mar 1.","Li H","Tumour Biol","2014","2014/03/04","","","10.1007/s13277-014-1766-7"
"30231388","Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment","Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N.","Am Soc Clin Oncol Educ Book. 2018 May 23;38:363-371. doi: 10.1200/EDBK_200967.","Hahn AW","Am Soc Clin Oncol Educ Book","2018","2018/09/21","","","10.1200/EDBK_200967"
"14667512","pT0 after radical prostatectomy: overtreatment for insignificant prostate cancer?","Hammerer P.","Eur Urol. 2004 Jan;45(1):35. doi: 10.1016/j.eururo.2003.08.002.","Hammerer P","Eur Urol","2004","2003/12/12","","","10.1016/j.eururo.2003.08.002"
"23129387","Surgery no better than observation for localized prostate cancer","Printz C.","Cancer. 2012 Nov 15;118(22):5452-3. doi: 10.1002/cncr.27885.","Printz C","Cancer","2012","2012/11/07","","","10.1002/cncr.27885"
"2319613","Iodine 125 interstitial irradiation for localized prostate cancer","Kumar PP, Good RR, Bartone FF.","J Natl Med Assoc. 1990 Mar;82(3):181-93.","Kumar PP","J Natl Med Assoc","1990","1990/03/01","PMC2626027","",""
"29137489","Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics","Polotti CF, Kim CJ, Chuchvara N, Polotti AB, Singer EA, Elsamra S.","Expert Opin Drug Metab Toxicol. 2017 Dec;13(12):1265-1273. doi: 10.1080/17425255.2017.1405934. Epub 2017 Nov 20.","Polotti CF","Expert Opin Drug Metab Toxicol","2017","2017/11/16","","","10.1080/17425255.2017.1405934"
"10632123","Predictive factors in prostate cancer: current concepts from the 1999 College of American Pathologists Conference on Solid Tumor Prognostic Factors and the 1999 World Health Organization Second International Consultation on Prostate Cancer","Bostwick DG, Foster CS.","Semin Urol Oncol. 1999 Nov;17(4):222-72.","Bostwick DG","Semin Urol Oncol","1999","2000/01/13","","",""
"23656263","New circulating tumor cell technology could advance personalized medicine in prostate cancer","Miller S.","Nanomedicine (Lond). 2013 May;8(5):683-4. doi: 10.2217/nnm.13.78.","Miller S","Nanomedicine (Lond)","2013","2013/05/10","","","10.2217/nnm.13.78"
"17119042","Family history, perceived risk, and prostate cancer screening among African American men","Bloom JR, Stewart SL, Oakley Girvan I, Banks PJ, Chang S.","Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2167-73. doi: 10.1158/1055-9965.EPI-05-0738.","Bloom JR","Cancer Epidemiol Biomarkers Prev","2006","2006/11/23","","","10.1158/1055-9965.EPI-05-0738"
"29521482","Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer","Ceci F, Castellucci P, Fanti S.","Q J Nucl Med Mol Imaging. 2019 Mar;63(1):7-18. doi: 10.23736/S1824-4785.18.03059-5. Epub 2018 Mar 8.","Ceci F","Q J Nucl Med Mol Imaging","2019","2018/03/10","","","10.23736/S1824-4785.18.03059-5"
"31844170","Progress in therapy across the spectrum of advanced prostate cancer","Schmid S, Omlin A.","Nat Rev Urol. 2020 Feb;17(2):71-72. doi: 10.1038/s41585-019-0270-7.","Schmid S","Nat Rev Urol","2020","2019/12/18","","","10.1038/s41585-019-0270-7"
"19089402","[Role of lymph node dissection in prostate cancer]","Schlomm T, Börgermann C, Heinzer H, Rübben H, Huland H, Graefen M.","Urologe A. 2009 Jan;48(1):37-45. doi: 10.1007/s00120-008-1758-6.","Schlomm T","Urologe A","2009","2008/12/18","","","10.1007/s00120-008-1758-6"
"12117178","Can cancer centres in New Zealand help the cancer registry generate survival data? A pilot study in prostate cancer","Evans TK, Lamb DS, Cornes DA, Fraser J, Johnson CA, Hamilton DA.","N Z Med J. 2002 May 24;115(1154):246-7.","Evans TK","N Z Med J","2002","2002/07/16","","",""
"15952249","Advances in prostate cancer research. Part III","Languino LR.","J Cell Biochem. 2004 Mar 1;91(4):647-8. doi: 10.1002/jcb.20054.","Languino LR","J Cell Biochem","2004","2005/06/14","","","10.1002/jcb.20054"
"15837977","Gay men and prostate cancer: invisible diversity","Blank TO.","J Clin Oncol. 2005 Apr 20;23(12):2593-6. doi: 10.1200/JCO.2005.00.968.","Blank TO","J Clin Oncol","2005","2005/04/20","","","10.1200/JCO.2005.00.968"
"22473441","Screening for prostate cancer","Carlsson S, Vickers A, Lilja H, Hugosson J.","Ann Intern Med. 2012 Apr 3;156(7):539; author reply 540. doi: 10.7326/0003-4819-156-7-201204030-00014.","Carlsson S","Ann Intern Med","2012","2012/04/05","","","10.7326/0003-4819-156-7-201204030-00014"
"18309995","NICE clarifies diagnosis and management of prostate cancer and advises on smoking cessation","Mayor S.","BMJ. 2008 Mar 1;336(7642):471. doi: 10.1136/bmj.39504.480752.DB.","Mayor S","BMJ","2008","2008/03/04","PMC2258380","","10.1136/bmj.39504.480752.DB"
"25264293","Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark","Møller H, Roswall N, Van Hemelrijck M, Larsen SB, Cuzick J, Holmberg L, Overvad K, Tjønneland A.","Int J Cancer. 2015 Apr 15;136(8):1940-7. doi: 10.1002/ijc.29238. Epub 2014 Oct 9.","Møller H","Int J Cancer","2015","2014/09/30","","","10.1002/ijc.29238"
"12100956","Interstitial thermal therapy in patients with localized prostate cancer: histologic analysis","Tucker RD, Platz CE, Huidobro C, Larson T.","Urology. 2002 Jul;60(1):166-9. doi: 10.1016/s0090-4295(02)01653-9.","Tucker RD","Urology","2002","2002/07/09","","","10.1016/s0090-4295(02)01653-9"
"17058896","[Nutrition and prostate cancer--what is the scientific evidence?]","Theobald S.","Med Monatsschr Pharm. 2006 Oct;29(10):371-7.","Theobald S","Med Monatsschr Pharm","2006","2006/10/25","","",""
"8984072","Patient treatment preference in metastatic prostate cancer","Creagh T.","Ir Med J. 1996 Jan-Feb;89(1):12.","Creagh T","Ir Med J","1996","1996/01/01","","",""
"18076938","The role of pelvic lymphadenectomy for prostate cancer--therapeutic?","Wagner M, Sokoloff M, Daneshmand S.","J Urol. 2008 Feb;179(2):408-13. doi: 10.1016/j.juro.2007.09.027.","Wagner M","J Urol","2008","2007/12/14","","","10.1016/j.juro.2007.09.027"
"20367408","Impact of prostate cancer multifocality on its biology and treatment","Algaba F, Montironi R.","J Endourol. 2010 May;24(5):799-804. doi: 10.1089/end.2009.0462.","Algaba F","J Endourol","2010","2010/04/07","","","10.1089/end.2009.0462"
"31067347","Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","Pinsky PF, Black A, Daugherty SE, Hoover R, Parnes H, Smith ZL, Eggener S, Andriole GL, Berndt SI.","Cancer. 2019 Sep 1;125(17):2965-2974. doi: 10.1002/cncr.32176. Epub 2019 May 8.","Pinsky PF","Cancer","2019","2019/05/09","PMC6690759","NIHMS1025074","10.1002/cncr.32176"
"28561697","Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum","Morgans AK, Dale W, Briganti A.","Am Soc Clin Oncol Educ Book. 2017;37:370-381. doi: 10.1200/EDBK_175491.","Morgans AK","Am Soc Clin Oncol Educ Book","2017","2017/06/01","","","10.1200/EDBK_175491"
"23907786","Localized prostate cancer treatment decision-making information online: improving its effectiveness and dissemination for nonprofit and government-supported organizations","Silk KJ, Perrault EK, Nazione S, Pace K, Hager P, Springer S.","J Cancer Educ. 2013 Dec;28(4):709-16. doi: 10.1007/s13187-013-0515-8.","Silk KJ","J Cancer Educ","2013","2013/08/03","","","10.1007/s13187-013-0515-8"
"18506142","Supportive care needs of men living with prostate cancer in England: a survey","Ream E, Quennell A, Fincham L, Faithfull S, Khoo V, Wilson-Barnett J, Richardson A.","Br J Cancer. 2008 Jun 17;98(12):1903-9. doi: 10.1038/sj.bjc.6604406. Epub 2008 May 27.","Ream E","Br J Cancer","2008","2008/05/29","PMC2441950","","10.1038/sj.bjc.6604406"
"12214469","[Second cancer after starting treatment for prostate cancer]","Mikata N, Imao S, Fukasawa R.","Gan To Kagaku Ryoho. 2002 Aug;29(8):1411-5.","Mikata N","Gan To Kagaku Ryoho","2002","2002/09/07","","",""
"15028447","Prostate cancer diagnosed in spinal cord-injured patients is more commonly advanced stage than in able-bodied patients","Scott PA Sr, Perkash I, Mode D, Wolfe VA, Terris MK.","Urology. 2004 Mar;63(3):509-12. doi: 10.1016/j.urology.2003.10.022.","Scott PA Sr","Urology","2004","2004/03/19","","","10.1016/j.urology.2003.10.022"
"26354611","Local relapse of prostate cancer after primary definitive treatment: the management","Palermo G, Foschi N, D'Agostino D, Sacco E, Bassi P, Pinto F.","Minerva Urol Nefrol. 2016 Jun;68(3):282-92. Epub 2015 Sep 9.","Palermo G","Minerva Urol Nefrol","2016","2015/09/11","","",""
"25325826","Prostate changes related to therapy: with special reference to hormone therapy","Mazzucchelli R, Lopez-Beltran A, Galosi AB, Zizzi A, Scarpelli M, Bracarda S, Cheng L, Montironi R.","Future Oncol. 2014 Aug;10(11):1873-86. doi: 10.2217/fon.14.37.","Mazzucchelli R","Future Oncol","2014","2014/10/18","","","10.2217/fon.14.37"
"27344703","[Molecular biology and genetics of prostate cancer]","Goto Y, Sakamoto S, Ichikawa T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:55-9.","Goto Y","Nihon Rinsho","2016","2016/06/28","","",""
"28589398","The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer","Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ.","Curr Urol Rep. 2017 Jul;18(7):52. doi: 10.1007/s11934-017-0699-2.","Schulman AA","Curr Urol Rep","2017","2017/06/08","","","10.1007/s11934-017-0699-2"
"7621476","Geographical epidemiology of prostate cancer: is there an association with infection?","Sitas F.","Cancer Surv. 1995;23:79-89.","Sitas F","Cancer Surv","1995","1995/01/01","","",""
"23977760","Lymph node-positive prostate cancer: the benefit of local therapy","Hoffman KE, Kuban DA.","Oncology (Williston Park). 2013 Jul;27(7):655, 660-1.","Hoffman KE","Oncology (Williston Park)","2013","2013/08/28","","",""
"9145972","Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to volume of high-grade prostatic intraepithelial neoplasia","Wiley EL, Davidson P, McIntire DD, Sagalowsky AI.","Urology. 1997 May;49(5):692-6. doi: 10.1016/S0090-4295(96)00627-9.","Wiley EL","Urology","1997","1997/05/01","","","10.1016/S0090-4295(96)00627-9"
"30031469","Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging","Hofman MS, Iravani A, Nzenza T, Murphy DG.","Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15.","Hofman MS","Urol Clin North Am","2018","2018/07/23","","","10.1016/j.ucl.2018.03.016"
"2143400","Management of breast and prostate cancer: how does quality of life enter the equation?","Tannock IF.","Oncology (Williston Park). 1990 May;4(5):149-56; discussion 171.","Tannock IF","Oncology (Williston Park)","1990","1990/05/01","","",""
"18695131","SPCG-4: a needed START to PIVOTal data to promote and protect evidence-based prostate cancer care","Wilt TJ.","J Natl Cancer Inst. 2008 Aug 20;100(16):1123-5. doi: 10.1093/jnci/djn259. Epub 2008 Aug 11.","Wilt TJ","J Natl Cancer Inst","2008","2008/08/13","","","10.1093/jnci/djn259"
"7520600","Prostate cancer screening","Sweet MD.","Sci Am. 1994 Aug;271(2):9.","Sweet MD","Sci Am","1994","1994/08/01","","",""
"7520598","Prostate cancer screening","Hahn DL.","Sci Am. 1994 Aug;271(2):9.","Hahn DL","Sci Am","1994","1994/08/01","","",""
"15759059","Prostate cancer survivors' and partners' self-reports of health-related quality of life, treatment symptoms, and marital satisfaction 2.5-5.5 years after treatment","Galbraith ME, Arechiga A, Ramirez J, Pedro LW.","Oncol Nurs Forum. 2005 Mar 5;32(2):E30-41. doi: 10.1188/05.ONF.E30-E41.","Galbraith ME","Oncol Nurs Forum","2005","2005/03/11","","","10.1188/05.ONF.E30-E41"
"25796092","Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion","Hollmann BG, van Triest B, Ghobadi G, Groenendaal G, de Jong J, van der Poel HG, van der Heide UA.","Radiother Oncol. 2015 Apr;115(1):96-100. doi: 10.1016/j.radonc.2015.01.021. Epub 2015 Mar 18.","Hollmann BG","Radiother Oncol","2015","2015/03/23","","","10.1016/j.radonc.2015.01.021"
"12352440","Re: Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection","Peyromaure M.","J Urol. 2002 Oct;168(4 Pt 1):1505-6; author reply 1506. doi: 10.1097/01.ju.0000027811.48712.88.","Peyromaure M","J Urol","2002","2002/09/28","","","10.1097/01.ju.0000027811.48712.88"
"7683042","Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer","Andriole GL.","J Clin Oncol. 1993 Apr;11(4):596-7. doi: 10.1200/JCO.1993.11.4.596.","Andriole GL","J Clin Oncol","1993","1993/04/01","","","10.1200/JCO.1993.11.4.596"
"28502900","Nuclear morphometry in histological specimens of canine prostate cancer: Correlation with histological subtypes, Gleason score, methods of collection and survival time","Di Donato G, Laufer-Amorim R, Palmieri C.","Res Vet Sci. 2017 Oct;114:212-217. doi: 10.1016/j.rvsc.2017.05.007. Epub 2017 May 6.","Di Donato G","Res Vet Sci","2017","2017/05/16","","","10.1016/j.rvsc.2017.05.007"
"25363875","Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer: author reply","Berlin A, Dal Pra A, Bristow RG.","Br J Radiol. 2015 Jan;88(1045):20140701. doi: 10.1259/bjr.20140701.","Berlin A","Br J Radiol","2015","2014/11/04","PMC4277390","","10.1259/bjr.20140701"
"27986214","Management of Node-Positive and Oligometastatic Prostate Cancer","Broughman JR, Chen RC.","Semin Radiat Oncol. 2017 Jan;27(1):79-86. doi: 10.1016/j.semradonc.2016.08.006. Epub 2016 Aug 31.","Broughman JR","Semin Radiat Oncol","2017","2016/12/18","","","10.1016/j.semradonc.2016.08.006"
"30382379","Developments in oligometastatic hormone-sensitive prostate cancer","Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM.","World J Urol. 2019 Dec;37(12):2549-2555. doi: 10.1007/s00345-018-2542-x. Epub 2018 Oct 31.","Chow K","World J Urol","2019","2018/11/02","","","10.1007/s00345-018-2542-x"
"22249340","Diet and prostate cancer prevention","Marshall JR.","World J Urol. 2012 Apr;30(2):157-65. doi: 10.1007/s00345-011-0810-0. Epub 2012 Jan 17.","Marshall JR","World J Urol","2012","2012/01/18","PMC4303588","NIHMS464700","10.1007/s00345-011-0810-0"
"7920531","[Metastatic prostate cancer. High-dose diethylstilbestrol and hormonal escape]","Chaouat D, Court B.","Rev Rhum Ed Fr. 1994 Apr;61(4):290.","Chaouat D","Rev Rhum Ed Fr","1994","1994/04/01","","",""
"9218023","Approaches to prostate cancer by managed care organizations","Bennett CL, Buchner DA, Ullman M.","Urology. 1997 Jul;50(1):79-86. doi: 10.1016/S0090-4295(97)00239-2.","Bennett CL","Urology","1997","1997/07/01","","","10.1016/S0090-4295(97)00239-2"
"2693331","Prostatic cancer: aetiology and endocrinology","Griffiths K, Eaton CL, Davies P.","Horm Res. 1989;32 Suppl 1:38-43. doi: 10.1159/000181307.","Griffiths K","Horm Res","1989","1989/01/01","","","10.1159/000181307"
"30602361","Incidence, Management, and Clinical Outcomes of Prostate Cancer in Kidney Transplant Recipients","Haroon UH, Davis NF, Mohan P, Little DM, Smyth G, Forde JC, Power RE.","Exp Clin Transplant. 2019 Jun;17(3):298-303. doi: 10.6002/ect.2018.0048. Epub 2018 Dec 31.","Haroon UH","Exp Clin Transplant","2019","2019/01/04","","","10.6002/ect.2018.0048"
"26149066","Applying precision medicine to the active surveillance of prostate cancer","Reichard CA, Stephenson AJ, Klein EA.","Cancer. 2015 Oct 1;121(19):3403-11. doi: 10.1002/cncr.29496. Epub 2015 Jul 6.","Reichard CA","Cancer","2015","2015/07/08","PMC4758404","","10.1002/cncr.29496"
"16618388","The use of herbal and over-the-counter dietary supplements for the prevention of prostate cancer","Bemis DL, Capodice JL, Costello JE, Vorys GC, Katz AE, Buttyan R.","Curr Oncol Rep. 2006 May;8(3):228-36. doi: 10.1007/s11912-006-0024-6.","Bemis DL","Curr Oncol Rep","2006","2006/04/19","","","10.1007/s11912-006-0024-6"
"24560758","Does family history of prostate cancer affect outcomes following radiotherapy?","Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK.","Radiother Oncol. 2014 Feb;110(2):229-34. doi: 10.1016/j.radonc.2013.11.014. Epub 2014 Feb 20.","Bagshaw H","Radiother Oncol","2014","2014/02/25","PMC3991234","NIHMS569961","10.1016/j.radonc.2013.11.014"
"10810410","Changes in cell proliferation and apoptosis during local progression of prostate cancer","Kaibuchi T, Furuya Y, Akakura K, Masai M, Ito H.","Anticancer Res. 2000 Mar-Apr;20(2B):1135-9.","Kaibuchi T","Anticancer Res","2000","2000/05/16","","",""
"22305509","Biopsy and implantation of the seminal vesicles","Stone NN, Skouteris VM, Stock RG.","Brachytherapy. 2012 Sep-Oct;11(5):334-40. doi: 10.1016/j.brachy.2011.12.008. Epub 2012 Feb 2.","Stone NN","Brachytherapy","2012","2012/02/07","","","10.1016/j.brachy.2011.12.008"
"10795622","High-intensive focused ultrasound in localized prostate cancer","Chaussy CG, Thüroff S.","J Endourol. 2000 Apr;14(3):293-9. doi: 10.1089/end.2000.14.293.","Chaussy CG","J Endourol","2000","2000/05/05","","","10.1089/end.2000.14.293"
"17414513","Prostate cancer prevention","Nelson WG.","Curr Opin Urol. 2007 May;17(3):157-67. doi: 10.1097/MOU.0b013e3280eb110f.","Nelson WG","Curr Opin Urol","2007","2007/04/07","","","10.1097/MOU.0b013e3280eb110f"
"8473366","Managing prostate cancer. Part II: Disseminated disease","Edelstein RA, Babayan RK.","Hosp Pract (Off Ed). 1993 Apr 30;28(4A):25-31, 35-6. doi: 10.1080/21548331.1993.11442905.","Edelstein RA","Hosp Pract (Off Ed)","1993","1993/04/30","","","10.1080/21548331.1993.11442905"
"17442481","What do we really know about prostate cancer?","Albertsen P.","Eur Urol. 2007 Oct;52(4):948-50. doi: 10.1016/j.eururo.2007.04.021. Epub 2007 Apr 11.","Albertsen P","Eur Urol","2007","2007/04/20","","","10.1016/j.eururo.2007.04.021"
"18947077","Prostate cancer hope","Wallis L.","Nurs Stand. 2008 Oct 8-14;23(5):21. doi: 10.7748/ns.23.5.21.s25.","Wallis L","Nurs Stand","2008","2008/10/25","","","10.7748/ns.23.5.21.s25"
"20633982","Re: Jutta Engel, Patrick J. Bastian, Helmut Baur, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754-61","Qin X, Ye D.","Eur Urol. 2010 Oct;58(4):e43; author reply e44. doi: 10.1016/j.eururo.2010.06.030. Epub 2010 Jul 12.","Qin X","Eur Urol","2010","2010/07/17","","","10.1016/j.eururo.2010.06.030"
"23725181","Prostate cancer: a hospital-based survival study from Mumbai, India","Balasubramaniam G, Talole S, Mahantshetty U, Saoba S, Shrivastava S.","Asian Pac J Cancer Prev. 2013;14(4):2595-8. doi: 10.7314/apjcp.2013.14.4.2595.","Balasubramaniam G","Asian Pac J Cancer Prev","2013","2013/06/04","","","10.7314/apjcp.2013.14.4.2595"
"20062072","Treatment strategies for high-risk locally advanced prostate cancer","Rosenthal SA, Sandler HM.","Nat Rev Urol. 2010 Jan;7(1):31-8. doi: 10.1038/nrurol.2009.237.","Rosenthal SA","Nat Rev Urol","2010","2010/01/12","","","10.1038/nrurol.2009.237"
"12967402","Prostate cancer (non-metastatic)","Wilt T.","Clin Evid. 2003 Jun;(9):973-85.","Wilt T","Clin Evid","2003","2003/09/12","","",""
"9831218","Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation","Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy FC.","Prostate. 1998 Dec 1;37(4):223-9. doi: 10.1002/(sici)1097-0045(19981201)37:4<223::aid-pros3>3.0.co;2-o.","Johnson MI","Prostate","1998","1998/11/27","","","10.1002/(sici)1097-0045(19981201)37:4<223::aid-pros3>3.0.co;2-o"
"18367111","Exploring causes for declining prostate cancer mortality rates in the United States","Colli JL, Amling CL.","Urol Oncol. 2008 Nov-Dec;26(6):627-33. doi: 10.1016/j.urolonc.2007.05.016. Epub 2008 Jan 14.","Colli JL","Urol Oncol","2008","2008/03/28","","","10.1016/j.urolonc.2007.05.016"
"10453286","Mechanistic concepts in androgen-dependence of prostate cancer","Craft N, Sawyers CL.","Cancer Metastasis Rev. 1998-1999;17(4):421-7. doi: 10.1023/a:1006141806801.","Craft N","Cancer Metastasis Rev","1998","1999/08/24","","","10.1023/a:1006141806801"
"14755679","Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence","Taplin ME, Balk SP.","J Cell Biochem. 2004 Feb 15;91(3):483-90. doi: 10.1002/jcb.10653.","Taplin ME","J Cell Biochem","2004","2004/02/03","","","10.1002/jcb.10653"
"10679753","Analysis of recent trends in prostate cancer incidence and mortality","Dennis LK, Resnick MI.","Prostate. 2000 Mar 1;42(4):247-52. doi: 10.1002/(sici)1097-0045(20000301)42:4<247::aid-pros1>3.0.co;2-5.","Dennis LK","Prostate","2000","2000/02/19","","","10.1002/(sici)1097-0045(20000301)42:4<247::aid-pros1>3.0.co;2-5"
"19574196","Spanish researchers at the forefront of clinical investigation: the case of quality of life in prostate cancer","Guedea F, Ferrer M.","Clin Transl Oncol. 2009 Jul;11(7):403-4. doi: 10.1007/s12094-009-0377-z.","Guedea F","Clin Transl Oncol","2009","2009/07/04","","","10.1007/s12094-009-0377-z"
"26404775","Trichosporon asahii Infection in a Patient with Metastatic Prostate Cancer as an Example of an Emerging Fungal Pathogen","Magee K, Hata DJ, Meza D.","Lab Med. 2015 Summer;46(3):e74-8. doi: 10.1309/LMDDUCADJ31LE0ML.","Magee K","Lab Med","2015","2015/09/26","","","10.1309/LMDDUCADJ31LE0ML"
"11998140","High-fat diet and prostate cancer: the controversial connection","Fisher LM.","Urol Nurs. 2000 Jun;20(3):205-6, 209-10.","Fisher LM","Urol Nurs","2000","2002/05/10","","",""
"12359844","Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?","Canil CM, Tannock IF.","J Natl Cancer Inst. 2002 Oct 2;94(19):1422-3. doi: 10.1093/jnci/94.19.1422.","Canil CM","J Natl Cancer Inst","2002","2002/10/03","","","10.1093/jnci/94.19.1422"
"25262981","Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide","Conteduca V, Burgio SL, Menna C, Carretta E, Rossi L, Bianchi E, Masini C, Amadori D, De Giorgi U.","Prostate. 2014 Dec;74(16):1691-6. doi: 10.1002/pros.22890. Epub 2014 Sep 27.","Conteduca V","Prostate","2014","2014/09/30","","","10.1002/pros.22890"
"20690342","New Zealand should introduce population screening for prostate cancer using PSA testing: yes","Smart R.","J Prim Health Care. 2009 Dec;1(4):319-20.","Smart R","J Prim Health Care","2009","2010/08/10","","",""
"16670611","Facing up to prostate cancer","Ficorelli CT, Weeks B.","Nursing. 2006 May;36(5):66-8. doi: 10.1097/01.nurse.0000393394.10445.07.","Ficorelli CT","Nursing","2006","2006/05/04","","","10.1097/01.nurse.0000393394.10445.07"
"7515138","Screening for prostate cancer","Neal DE, Hamdy FC.","Lancet. 1994 Jun 4;343(8910):1438.","Neal DE","Lancet","1994","1994/06/04","","",""
"27421074","Development of an explanatory model of sexual intimacy following treatment for localised prostate cancer: A systematic review and meta-synthesis of qualitative evidence","Tucker SR, Speer SA, Peters S.","Soc Sci Med. 2016 Aug;163:80-8. doi: 10.1016/j.socscimed.2016.07.001. Epub 2016 Jul 4.","Tucker SR","Soc Sci Med","2016","2016/07/16","","","10.1016/j.socscimed.2016.07.001"
"26423576","Financial toxicity: a potential side effect of prostate cancer treatment among Australian men","Gordon LG, Walker SM, Mervin MC, Lowe A, Smith DP, Gardiner RA, Chambers SK.","Eur J Cancer Care (Engl). 2017 Jan;26(1):e12392. doi: 10.1111/ecc.12392. Epub 2015 Oct 1.","Gordon LG","Eur J Cancer Care (Engl)","2017","2015/10/02","PMC5297983","","10.1111/ecc.12392"
"17432556","Does localized prostate cancer exist?","Lobel B.","Recent Results Cancer Res. 2007;175:101-7. doi: 10.1007/978-3-540-40901-4_7.","Lobel B","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_7"
"17667758","Prostate cancer screening: an individual decision","Holcomb SS.","Nurse Pract. 2007 Aug;32(8):6-8. doi: 10.1097/01.NPR.0000282793.51324.6b.","Holcomb SS","Nurse Pract","2007","2007/08/02","","","10.1097/01.NPR.0000282793.51324.6b"
"12622042","Prostate cancer treatment offers growth opportunities","Worrell B.","Health Care Strateg Manage. 2003 Feb;21(2):1, 18-9.","Worrell B","Health Care Strateg Manage","2003","2003/03/08","","",""
"11980026","[CAT Scan in hormone-independent prostate cancer]","Staerman F, Villers A.","Prog Urol. 2002 Feb;12(1 Suppl 2):37-43.","Staerman F","Prog Urol","2002","2002/05/01","","",""
"29712494","Chromogranin A as a biomarker for prostate cancer: is it actually relevant for clinical practice?","Appetecchia M, Lauretta R, Sperduti I, Gallucci M.","Future Oncol. 2018 Jun;14(13):1233-1235. doi: 10.2217/fon-2018-0025. Epub 2018 May 1.","Appetecchia M","Future Oncol","2018","2018/05/02","","","10.2217/fon-2018-0025"
"9336358","Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer","Eastham JA, Kattan MW, Groshen S, Scardino PT, Rogers E, Carlton CE Jr, Lerner SP.","J Clin Oncol. 1997 Oct;15(10):3214-22. doi: 10.1200/JCO.1997.15.10.3214.","Eastham JA","J Clin Oncol","1997","1997/10/23","","","10.1200/JCO.1997.15.10.3214"
"19371474","New and novel markers for prostate cancer detection","Risk MC, Lin DW.","Curr Urol Rep. 2009 May;10(3):179-86. doi: 10.1007/s11934-009-0031-x.","Risk MC","Curr Urol Rep","2009","2009/04/18","","","10.1007/s11934-009-0031-x"
"18272636","Approach to primary care follow-up of patients with prostate cancer","Wilkinson AN, Brundage MD, Siemens R.","Can Fam Physician. 2008 Feb;54(2):204-10.","Wilkinson AN","Can Fam Physician","2008","2008/02/15","PMC2278312","",""
"19393533","[Radiotherapy in prostate cancer: data from ASTRO 2008]","Coquard R.","Prog Urol. 2009 May;19(5):297-300. doi: 10.1016/j.purol.2009.01.001. Epub 2009 Mar 4.","Coquard R","Prog Urol","2009","2009/04/28","","","10.1016/j.purol.2009.01.001"
"22018407","Erectile dysfunction and urinary incontinence after prostate cancer treatment","Mirza M, Griebling TL, Kazer MW.","Semin Oncol Nurs. 2011 Nov;27(4):278-89. doi: 10.1016/j.soncn.2011.07.006.","Mirza M","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.006"
"12084188","The role of transrectal ultrasound in diagnosing prostate cancer","Clements R.","Curr Urol Rep. 2002 Jun;3(3):194-200. doi: 10.1007/s11934-002-0064-x.","Clements R","Curr Urol Rep","2002","2002/06/27","","","10.1007/s11934-002-0064-x"
"21875782","American College of Radiology Appropriateness Criteria(®)--locally advanced (high-risk) prostate cancer","Ciezki JP, Hsu IC, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G; American College of Radiology Appropriateness Criteria.","Clin Oncol (R Coll Radiol). 2012 Feb;24(1):43-51. doi: 10.1016/j.clon.2011.08.003. Epub 2011 Aug 27.","Ciezki JP","Clin Oncol (R Coll Radiol)","2012","2011/08/31","","","10.1016/j.clon.2011.08.003"
"12725111","Epidemiological investigation of prostate cancer","Giles GG.","Methods Mol Med. 2003;81:1-19. doi: 10.1385/1-59259-372-0:1.","Giles GG","Methods Mol Med","2003","2003/05/03","","","10.1385/1-59259-372-0:1"
"8153734","Treatment options for prostate cancer","Lassen PM, Thompson IM.","Urol Nurs. 1994 Mar;14(1):12-5.","Lassen PM","Urol Nurs","1994","1994/03/01","","",""
"16916765","Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987","Jonsson E, Sigbjarnarson HP, Tomasson J, Benediktsdottir KR, Tryggvadottir L, Hrafnkelsson J, Olafsdottir EJ, Tulinius H, Jonasson JG.","Scand J Urol Nephrol. 2006;40(4):265-71. doi: 10.1080/00365590600750110.","Jonsson E","Scand J Urol Nephrol","2006","2006/08/19","","","10.1080/00365590600750110"
"10901778","Prostate cancer testing","","Med J Aust. 2000 May 15;172(10):516.","","Med J Aust","2000","2000/07/21","","",""
"18001643","[Survival of patients diagnosed with prostate cancer and monitored in primary care]","Díaz Grávalos GJ, Palmeiro Fernández G, Casado Górriz I, Arandia García M, Alvarez Araújo S, González Dacosta M.","Aten Primaria. 2007 Nov;39(11):603-8. doi: 10.1157/13112197.","Díaz Grávalos GJ","Aten Primaria","2007","2007/11/16","","","10.1157/13112197"
"30855013","New markers in prostate cancer: Inmunohistochemical","Compérat E.","Arch Esp Urol. 2019 Mar;72(2):126-134.","Compérat E","Arch Esp Urol","2019","2019/03/12","","",""
"12599573","[Significance of surgical treatment of prostate cancer: problems and measures]","Katsuoka Y, Azuma H.","Nihon Rinsho. 2002 Dec;60 Suppl 11:211-7.","Katsuoka Y","Nihon Rinsho","2002","2003/02/26","","",""
"1377980","Canadian MDs begin major push to promote early detection of prostate cancer","Spurgeon D.","CMAJ. 1992 Jul 15;147(2):220-2.","Spurgeon D","CMAJ","1992","1992/07/15","PMC1336169","",""
"25933277","Prostate cancer screening in Europe","Caicoya M.","Lancet. 2015 Apr 18;385(9977):1507. doi: 10.1016/S0140-6736(15)60748-6.","Caicoya M","Lancet","2015","2015/05/02","","","10.1016/S0140-6736(15)60748-6"
"23265390","Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain","Graefen M, Schlomm T.","Eur Urol. 2013 Apr;63(4):604-5. doi: 10.1016/j.eururo.2012.12.003. Epub 2012 Dec 13.","Graefen M","Eur Urol","2013","2012/12/26","","","10.1016/j.eururo.2012.12.003"
"14765018","External beam radiotherapy as definitive treatment for prostate cancer","Sosa M, Sanguineti G.","Minerva Urol Nefrol. 2003 Dec;55(4):263-75.","Sosa M","Minerva Urol Nefrol","2003","2004/02/07","","",""
"16314892","PSA testing: an evolving relationship with prostate cancer screening","Constantinou J, Feneley MR.","Prostate Cancer Prostatic Dis. 2006;9(1):6-13. doi: 10.1038/sj.pcan.4500838.","Constantinou J","Prostate Cancer Prostatic Dis","2006","2005/11/30","","","10.1038/sj.pcan.4500838"
"31095719","The Role of Primary Tumor Treatment and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer","Gupta A, Pugh TJ, Lam E, Sheridan AD, Nath S.","Oncology (Williston Park). 2019 May 14;33(5):187-91.","Gupta A","Oncology (Williston Park)","2019","2019/05/17","","",""
"15636685","Role of magnetic resonance spectroscopic imaging in the prediction of treatment outcome in prostate cancer","Bezabeh T.","Clin Prostate Cancer. 2004 Dec;3(3):182-3. doi: 10.1016/s1540-0352(11)70082-8.","Bezabeh T","Clin Prostate Cancer","2004","2005/01/08","","","10.1016/s1540-0352(11)70082-8"
"8278282","Sexual dysfunction following treatment for prostate cancer: nursing assessment and interventions","Waxman ES.","Oncol Nurs Forum. 1993 Nov-Dec;20(10):1567-71.","Waxman ES","Oncol Nurs Forum","1993","1993/11/01","","",""
"12901292","Predictive factors in prostate cancer: implications for decision making","Yossepowitch O, Trabulsi EJ, Kattan MW, Scardino PT.","Cancer Invest. 2003 Jun;21(3):465-80. doi: 10.1081/cnv-120018239.","Yossepowitch O","Cancer Invest","2003","2003/08/07","","","10.1081/cnv-120018239"
"23576101","Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer","Schwarzenböck SM, Kurth J, Gocke Ch, Kuhnt T, Hildebrandt G, Krause BJ.","Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S28-35. doi: 10.1007/s00259-013-2404-0. Epub 2013 Apr 11.","Schwarzenböck SM","Eur J Nucl Med Mol Imaging","2013","2013/04/12","","","10.1007/s00259-013-2404-0"
"19395877","The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications","Shah RB, Chinnaiyan AM.","Adv Anat Pathol. 2009 May;16(3):145-53. doi: 10.1097/PAP.0b013e3181a12da7.","Shah RB","Adv Anat Pathol","2009","2009/04/28","","","10.1097/PAP.0b013e3181a12da7"
"27489183","The evolving role of chemotherapy in prostate cancer","Saad F.","Curr Opin Support Palliat Care. 2016 Sep;10(3):262-5. doi: 10.1097/SPC.0000000000000216.","Saad F","Curr Opin Support Palliat Care","2016","2016/08/05","","","10.1097/SPC.0000000000000216"
"1884145","The sonographic appearance of irradiated prostate cancer","Egawa S, Wheeler TM, Scardino PT.","Br J Urol. 1991 Aug;68(2):172-7. doi: 10.1111/j.1464-410x.1991.tb15289.x.","Egawa S","Br J Urol","1991","1991/08/01","","","10.1111/j.1464-410x.1991.tb15289.x"
"15666516","[Prostate cancer recurrence after radical prostatectomy and salvage radiotherapy]","Ojea Calvo A, Pérez Rodríguez A, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, González Piñeiro A, Otero García M, Muñoz Garzón V.","Actas Urol Esp. 2004 Nov-Dec;28(10):743-8. doi: 10.1016/s0210-4806(04)73175-7.","Ojea Calvo A","Actas Urol Esp","2004","2005/01/26","","","10.1016/s0210-4806(04)73175-7"
"27680192","[Significance and Importance of Pelvic Lymphadenectomy in Low-Risk Prostate Cancer Patients]","Janßen I, Naumann CM, Hamann M, Knüpfer S, Jünemann KP, Osmonov DK.","Aktuelle Urol. 2016 Sep;47(5):402-7. doi: 10.1055/s-0042-104788. Epub 2016 Sep 28.","Janßen I","Aktuelle Urol","2016","2016/09/30","","","10.1055/s-0042-104788"
"12643475","Therapeutic targets for metastatic prostate cancer","Timme TL, Satoh T, Tahir SA, Wang H, Teh BS, Butler EB, Miles BJ, Amato RJ, Kadmon D, Thompson TC.","Curr Drug Targets. 2003 Apr;4(3):251-61. doi: 10.2174/1389450033491127.","Timme TL","Curr Drug Targets","2003","2003/03/20","","","10.2174/1389450033491127"
"16095722","Prostate cancer-induced immunodysfunction: a lesson from organ cultures","Kasic T, Viola A.","Immunol Lett. 2005 Aug 15;100(1):98-102. doi: 10.1016/j.imlet.2005.06.021.","Kasic T","Immunol Lett","2005","2005/08/13","","","10.1016/j.imlet.2005.06.021"
"25711672","Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria","Mandel P, Steuber T, Ahyai S, Kriegmair M, Schiffmann J, Boehm K, Heinzer H, Michl U, Schlomm T, Haese A, Huland H, Graefen M, Tilki D.","BJU Int. 2016 Jan;117(1):55-61. doi: 10.1111/bju.13103. Epub 2015 May 11.","Mandel P","BJU Int","2016","2015/02/26","","","10.1111/bju.13103"
"20562372","Diagnosis of localized, screen-detected, prostate cancer--crisis or opportunity?","Yao SL, Lu-Yao GL.","J Natl Cancer Inst. 2010 Jul 7;102(13):919-20. doi: 10.1093/jnci/djq219. Epub 2010 Jun 18.","Yao SL","J Natl Cancer Inst","2010","2010/06/22","PMC2897880","","10.1093/jnci/djq219"
"7589606","Update on urology--prostate cancer. 3--Systemic and palliative treatment of prostate cancer","Ekman P.","Eur J Surg Oncol. 1995 Oct;21(5):555-7; quiz 557, 567. doi: 10.1016/s0748-7983(95)97379-6.","Ekman P","Eur J Surg Oncol","1995","1995/10/01","","","10.1016/s0748-7983(95)97379-6"
"28142149","Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy","Leão R, Domingos C, Figueiredo A, Hamilton R, Tabori U, Castelo-Branco P.","Urol Int. 2017;99(2):125-136. doi: 10.1159/000455160. Epub 2017 Feb 1.","Leão R","Urol Int","2017","2017/02/01","","","10.1159/000455160"
"9403043","Exploring new technologies and treatment strategies for locally advanced prostate cancer","Zelefsky MJ.","Cancer J Sci Am. 1997 Nov-Dec;3(6):331-2.","Zelefsky MJ","Cancer J Sci Am","1997","1997/12/24","","",""
"23984455","Can you tell me the pros and cons of brachytherapy versus external-beam therapy versus surgery for prostate cancer?","","Duke Med Health News. 2013 Aug;19(8):8.","","Duke Med Health News","2013","2013/08/30","","",""
"10403903","Prostate cancer screening: promise and peril--a review","Godley PA.","Cancer Detect Prev. 1999;23(4):316-24. doi: 10.1046/j.1525-1500.1999.99033.x.","Godley PA","Cancer Detect Prev","1999","1999/07/15","","","10.1046/j.1525-1500.1999.99033.x"
"26970978","Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches","Doldi V, Pennati M, Forte B, Gandellini P, Zaffaroni N.","Cell Mol Life Sci. 2016 Jul;73(13):2531-42. doi: 10.1007/s00018-016-2176-3. Epub 2016 Mar 12.","Doldi V","Cell Mol Life Sci","2016","2016/03/14","","","10.1007/s00018-016-2176-3"
"21540577","Getting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle","Farooqi AA, Bhatti S.","Urol Int. 2011;87(2):127-33. doi: 10.1159/000327723. Epub 2011 Apr 30.","Farooqi AA","Urol Int","2011","2011/05/05","","","10.1159/000327723"
"29046984","Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning","Sidelsky S, Setia S, Vourganti S.","Curr Urol Rep. 2017 Oct 18;18(12):93. doi: 10.1007/s11934-017-0741-4.","Sidelsky S","Curr Urol Rep","2017","2017/10/20","","","10.1007/s11934-017-0741-4"
"11696737","Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer","Zincke H, Lau W, Bergstralh E, Blute ML.","J Urol. 2001 Dec;166(6):2208-15.","Zincke H","J Urol","2001","2001/11/07","","",""
"16425536","The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy","Begic A, Kucukalic-Selimovic E, Obralic N, Duric O, Lacevic N, Begovic-Hadzimuratovic S, Skopljak A, Dzubur-Aganovic M.","Med Arh. 2006;60(1):54-5.","Begic A","Med Arh","2006","2006/01/24","","",""
"85478","Radiation therapy for localized prostate cancer","Taylor WJ, Richardson RG, Hafermann MD.","Cancer. 1979 Mar;43(3):1123-7. doi: 10.1002/1097-0142(197903)43:3<1123::aid-cncr2820430351>3.0.co;2-f.","Taylor WJ","Cancer","1979","1979/03/01","","","10.1002/1097-0142(197903)43:3<1123::aid-cncr2820430351>3.0.co;2-f"
"7526517","Management of patients with positive surgical margins following radical prostatectomy","Richie JP.","Urol Clin North Am. 1994 Nov;21(4):717-23.","Richie JP","Urol Clin North Am","1994","1994/11/01","","",""
"27112389","Prostate cancer: Towards effective combination of ADT and immunotherapy","Thoma C.","Nat Rev Urol. 2016 Jun;13(6):300. doi: 10.1038/nrurol.2016.80. Epub 2016 Apr 26.","Thoma C","Nat Rev Urol","2016","2016/04/27","","","10.1038/nrurol.2016.80"
"28183253","Optimal Management of Prostate Cancer Based on its Natural Clinical History","Facchini G, Perri F, Misso G, D'Aniello C, Scarpati GDV, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C.","Curr Cancer Drug Targets. 2018;18(5):457-467. doi: 10.2174/1568009617666170209093101.","Facchini G","Curr Cancer Drug Targets","2018","2017/02/11","","","10.2174/1568009617666170209093101"
"15168357","Neuropeptides, apoptosis and ion changes in prostate cancer. Methods of study and recent developments","Vilches J, Salido M, Fernández-Segura E, Roomans GM.","Histol Histopathol. 2004 Jul;19(3):951-61. doi: 10.14670/HH-19.951.","Vilches J","Histol Histopathol","2004","2004/05/29","","","10.14670/HH-19.951"
"29496646","Viral etiology of prostate cancer: Genetic alterations and immune response. A literature review","Abidi SH, Bilwani F, Ghias K, Abbas F.","Int J Surg. 2018 Apr;52:136-140. doi: 10.1016/j.ijsu.2018.02.050. Epub 2018 Feb 26.","Abidi SH","Int J Surg","2018","2018/03/03","","","10.1016/j.ijsu.2018.02.050"
"8717467","The management of hormone refractory prostate cancer","Newling DW.","Eur Urol. 1996;29 Suppl 2:69-74. doi: 10.1159/000473843.","Newling DW","Eur Urol","1996","1996/01/01","","","10.1159/000473843"
"19609297","Counseling patients about sexual health when considering post-prostatectomy radiation treatment","Wittmann D, Montie JE, Hamstra DA, Sandler H, Wood DP Jr.","Int J Impot Res. 2009 Sep-Oct;21(5):275-84. doi: 10.1038/ijir.2009.32. Epub 2009 Jul 16.","Wittmann D","Int J Impot Res","2009","2009/07/18","PMC2834328","","10.1038/ijir.2009.32"
"23716470","Racial differences in time from prostate cancer diagnosis to treatment initiation: a population-based study","Stokes WA, Hendrix LH, Royce TJ, Allen IM, Godley PA, Wang AZ, Chen RC.","Cancer. 2013 Jul 1;119(13):2486-93. doi: 10.1002/cncr.27975. Epub 2013 May 28.","Stokes WA","Cancer","2013","2013/05/30","","","10.1002/cncr.27975"
"17550130","Molecular genetics of prostate cancer: clinical translational opportunities","Vecchione A, Gottardo F, Gomella LG, Wildemore B, Fassan Ms, Bragantini E, Pagano F, Baffa R.","J Exp Clin Cancer Res. 2007 Mar;26(1):25-37.","Vecchione A","J Exp Clin Cancer Res","2007","2007/06/07","","",""
"9676409","Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor","Bratt O, Kristoffersson U, Olsson H, Lundgren R.","Eur Urol. 1998;34(1):19-24. doi: 10.1159/000019672.","Bratt O","Eur Urol","1998","1998/07/24","","","10.1159/000019672"
"15087415","Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62:6015-20","Andela VB.","Cancer Res. 2004 Apr 15;64(8):2934-5; author reply 2935-6.","Andela VB","Cancer Res","2004","2004/04/17","","",""
"30238132","[Shared decision-making in prostate cancer patients]","Gröger S, Mäder-Porombka C, Stang C, Wallacher S.","Urologe A. 2019 Nov;58(11):1324-1330. doi: 10.1007/s00120-018-0774-4.","Gröger S","Urologe A","2019","2018/09/22","","","10.1007/s00120-018-0774-4"
"32274541","[Treatment concepts for primary oligometastatic prostate cancer]","Knipper S, Graefen M, Hadaschik B, Wiegel T.","Urologe A. 2020 Jun;59(6):659-664. doi: 10.1007/s00120-020-01186-w.","Knipper S","Urologe A","2020","2020/04/11","","","10.1007/s00120-020-01186-w"
"20141675","A method for using life tables to estimate lifetime risk for prostate cancer death","Kim HL, Puymon MR, Qin M, Guru K, Mohler JL.","J Natl Compr Canc Netw. 2010 Feb;8(2):148-54. doi: 10.6004/jnccn.2010.0011.","Kim HL","J Natl Compr Canc Netw","2010","2010/02/10","","","10.6004/jnccn.2010.0011"
"21504645","Current status of pelvic lymph node dissection in prostate cancer: the New York PLND nomogram","Kazzazi A, Djavan B.","Can J Urol. 2011 Apr;18(2):5585-91.","Kazzazi A","Can J Urol","2011","2011/04/21","","",""
"9622052","Human prostate carcinogenesis","Rhim JS, Kung HF.","Crit Rev Oncog. 1997;8(4):305-28. doi: 10.1615/critrevoncog.v8.i4.20.","Rhim JS","Crit Rev Oncog","1997","1997/01/01","","","10.1615/critrevoncog.v8.i4.20"
"25723513","High progesterone receptor expression in prostate cancer is associated with clinical failure","Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.","PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.","Grindstad T","PLoS One","2015","2015/02/28","PMC4344236","","10.1371/journal.pone.0116691"
"7547515","Radiotherapy for prostate cancer: the changing scene","Dearnaley DP.","Clin Oncol (R Coll Radiol). 1995;7(3):147-50. doi: 10.1016/s0936-6555(05)80505-9.","Dearnaley DP","Clin Oncol (R Coll Radiol)","1995","1995/01/01","","","10.1016/s0936-6555(05)80505-9"
"24108540","Molecular pathology and prostate cancer therapeutics: from biology to bedside","Rodrigues DN, Butler LM, Estelles DL, de Bono JS.","J Pathol. 2014 Jan;232(2):178-84. doi: 10.1002/path.4272.","Rodrigues DN","J Pathol","2014","2013/10/11","","","10.1002/path.4272"
"12735505","Emotional and cognitive burden of prostate cancer","Burke MA, Lowrance W, Perczek R.","Urol Clin North Am. 2003 May;30(2):295-304. doi: 10.1016/s0094-0143(02)00190-8.","Burke MA","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00190-8"
"17283721","[PSA doubling time as a new diagnostic and prognostic method for prostate cancer]","Llorente C, de la Morena JM, Ardura MA.","Arch Esp Urol. 2006 Dec;59(10):1083-7. doi: 10.4321/s0004-06142006001000015.","Llorente C","Arch Esp Urol","2006","2007/02/08","","","10.4321/s0004-06142006001000015"
"28816713","Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology?","Blanchard P, Bossi A, Fizazi K.","Curr Opin Urol. 2017 Nov;27(6):580-586. doi: 10.1097/MOU.0000000000000444.","Blanchard P","Curr Opin Urol","2017","2017/08/18","","","10.1097/MOU.0000000000000444"
"16770340","The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting","Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S.","Prostate Cancer Prostatic Dis. 2006;9(3):270-4. doi: 10.1038/sj.pcan.4500889. Epub 2006 Jun 13.","Kastner C","Prostate Cancer Prostatic Dis","2006","2006/06/14","","","10.1038/sj.pcan.4500889"
"23596225","What happens to older men after a screening test for prostate cancer?","","BMJ. 2013 Apr 17;346:f2421. doi: 10.1136/bmj.f2421.","","BMJ","2013","2013/04/19","","","10.1136/bmj.f2421"
"21446100","[Treatment of locally advanced prostatic cancer]","Marusić G, Vojinov S, Levakov I.","Med Pregl. 2010 Sep-Oct;63(9-10):689-95. doi: 10.2298/mpns1010689m.","Marusić G","Med Pregl","2010","2011/03/31","","","10.2298/mpns1010689m"
"26045016","Localized Prostate Cancer Is Spatially and Genomically Heterogeneous","","Cancer Discov. 2015 Jul;5(7):691. doi: 10.1158/2159-8290.CD-RW2015-106. Epub 2015 Jun 4.","","Cancer Discov","2015","2015/06/06","","","10.1158/2159-8290.CD-RW2015-106"
"32275845","Use of multiparametric magnetic resonance imaging (mpMRI) in localized prostate cancer","O'Connor L, Wang A, Walker SM, Yerram N, Pinto PA, Turkbey B.","Expert Rev Med Devices. 2020 May;17(5):435-442. doi: 10.1080/17434440.2020.1755257. Epub 2020 Apr 26.","O'Connor L","Expert Rev Med Devices","2020","2020/04/11","","","10.1080/17434440.2020.1755257"
"18774464","Transperineal 3D mapping biopsy of the prostate: an essential tool in selecting patients for focal prostate cancer therapy","Onik G, Barzell W.","Urol Oncol. 2008 Sep-Oct;26(5):506-10. doi: 10.1016/j.urolonc.2008.03.005.","Onik G","Urol Oncol","2008","2008/09/09","","","10.1016/j.urolonc.2008.03.005"
"17222627","The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials","Halabi S, Vogelzang NJ, Ou SS, Small EJ.","J Urol. 2007 Feb;177(2):531-4. doi: 10.1016/j.juro.2006.09.050.","Halabi S","J Urol","2007","2007/01/16","","","10.1016/j.juro.2006.09.050"
"24687033","Prostate cancer: a new look at prostate cancer treatment complications","Cooperberg MR.","Nat Rev Clin Oncol. 2014 Jun;11(6):304-5. doi: 10.1038/nrclinonc.2014.58. Epub 2014 Apr 1.","Cooperberg MR","Nat Rev Clin Oncol","2014","2014/04/02","","","10.1038/nrclinonc.2014.58"
"16474786","The role of lymphadenectomy in prostate cancer","Burkhard FC, Schumacher M, Studer UE.","Nat Clin Pract Urol. 2005 Jul;2(7):336-42. doi: 10.1038/ncpuro0245.","Burkhard FC","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0245"
"11442672","Androgen deprivation in combination with radical prostatectomy for localized prostate cancer","Naito S.","Int J Urol. 2001 Jul;8(7):S19-21. doi: 10.1046/j.1442-2042.2001.00329.x.","Naito S","Int J Urol","2001","2001/07/10","","","10.1046/j.1442-2042.2001.00329.x"
"19093873","2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer","Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW.","J Proteome Res. 2009 Feb;8(2):942-57. doi: 10.1021/pr800570s.","Byrne JC","J Proteome Res","2009","2008/12/20","","","10.1021/pr800570s"
"10527256","Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen","Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M.","Tech Urol. 1999 Sep;5(3):139-42.","Djavan B","Tech Urol","1999","1999/10/20","","",""
"20653654","'Insignificant' prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme 'low-volume/low-grade' prostate cancer?","Trpkov K, Yilmaz A, Bismar TA, Montironi R.","BJU Int. 2010 Aug;106(3):304-15. doi: 10.1111/j.1464-410X.2010.09499.x.","Trpkov K","BJU Int","2010","2010/07/27","","","10.1111/j.1464-410X.2010.09499.x"
"22527736","[Possible correlation between prostate cancer and temporary increase in eye pressure]","Rademacher P.","Ophthalmologe. 2012 Apr;109(4):377-8. doi: 10.1007/s00347-011-2518-3.","Rademacher P","Ophthalmologe","2012","2012/04/25","","","10.1007/s00347-011-2518-3"
"28107324","Symptom Burden: Experiences of Puerto Rican Men With Prostate Cancer Prior to External Beam Radiation Therapy","Gonzalez VJ, McMillan SC, Groer M, Imbert S, Pedro E, Tome J.","Clin J Oncol Nurs. 2017 Feb 1;21(1):104-112. doi: 10.1188/17.CJON.104-112.","Gonzalez VJ","Clin J Oncol Nurs","2017","2017/01/21","","","10.1188/17.CJON.104-112"
"2282250","Growth factors and oncogenes in prostate cancer","Thompson TC.","Cancer Cells. 1990 Nov;2(11):345-54.","Thompson TC","Cancer Cells","1990","1990/11/01","","",""
"10093628","Quebec prostate cancer mortality dropped in 1996","Meyer F, Moore L, Bairati I, Fradet Y.","Cancer Prev Control. 1998 Aug;2(4):163-6.","Meyer F","Cancer Prev Control","1998","1999/03/27","","",""
"17958041","Prostate cancer's prognosis","Volland A.","US News World Rep. 2007 Sep 17;143(9):71-3.","Volland A","US News World Rep","2007","2007/10/26","","",""
"15711635","Prostate cancer screening--finding the middle road forward","Lamb DS, Delahunt B.","N Z Med J. 2005 Feb 11;118(1209):U1306.","Lamb DS","N Z Med J","2005","2005/02/16","","",""
"27379946","Update on the biology and management of neuroendocrine prostate cancer","Beltran H.","Clin Adv Hematol Oncol. 2016 Jul;14(7):513-5.","Beltran H","Clin Adv Hematol Oncol","2016","2016/07/06","","",""
"27770995","[Localized prostate cancer: Changes are still expected]","Vignot S, Bay JO, Massard C, Thariat J; Comité de rédaction.","Bull Cancer. 2016 Oct;103(10):809-810. doi: 10.1016/j.bulcan.2016.09.015.","Vignot S","Bull Cancer","2016","2016/10/25","","","10.1016/j.bulcan.2016.09.015"
"15002372","More precise prostate cancer prediction","","Health News. 2004 Jan;10(1):2.","","Health News","2004","2004/03/09","","",""
"21270749","Prostate cancer which affects an elderly man is a feature of senescence (cellular) - a biology phenomenon","Drewa T, Jasinski M, Marszalek A, Chlosta P.","Exp Oncol. 2010 Dec;32(4):228-32.","Drewa T","Exp Oncol","2010","2011/01/29","","",""
"11274011","Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure","Stamey TA.","Clin Chem. 2001 Apr;47(4):631-4.","Stamey TA","Clin Chem","2001","2001/03/29","","",""
"10495654","Not every prostate cancer needs to be treated. The place for expectant management","Griffin AS, O'Rourke ME.","N C Med J. 1999 Sep-Oct;60(5):261-7.","Griffin AS","N C Med J","1999","1999/09/25","","",""
"8545342","[Early diagnosis and screening of cancer of the prostate]","Fendler JP, Perrin P.","Presse Med. 1995 Oct 28;24(32):1461-3.","Fendler JP","Presse Med","1995","1995/10/28","","",""
"14969807","PSA relapse prostate cancer: the importance of tailored therapy","Aranha O, Vaishampayan U.","Urol Oncol. 2004 Jan-Feb;22(1):62-9. doi: 10.1016/j.urolonc.2003.12.002.","Aranha O","Urol Oncol","2004","2004/02/19","","","10.1016/j.urolonc.2003.12.002"
"19620493","Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function","Chen RC, Clark JA, Talcott JA.","J Clin Oncol. 2009 Aug 20;27(24):3916-22. doi: 10.1200/JCO.2008.18.6486. Epub 2009 Jul 20.","Chen RC","J Clin Oncol","2009","2009/07/22","","","10.1200/JCO.2008.18.6486"
"26117946","[MicroRNAs and prostate cancer]","Xu WT, Jia YJ, Li XJ, Chen J.","Zhonghua Nan Ke Xue. 2015 May;21(5):458-62.","Xu WT","Zhonghua Nan Ke Xue","2015","2015/06/30","","",""
"11122010","Mean time to cancer-specific death of apparently clinically localised prostate cancer: policy implications for threshold ages in prostate-specific antigen and ablative therapy","Kooiman GG, Muir G.","BJU Int. 2001 Jan;87(1):128-9. doi: 10.1046/j.1464-410x.2001.00025-4.x.","Kooiman GG","BJU Int","2001","2000/12/21","","","10.1046/j.1464-410x.2001.00025-4.x"
"25743972","[Is prostate cancer screening only an illusion?]","Zeidler U, Stief CG.","MMW Fortschr Med. 2015 Mar 5;157(4):32. doi: 10.1007/s15006-015-2762-6.","Zeidler U","MMW Fortschr Med","2015","2015/03/07","","","10.1007/s15006-015-2762-6"
"22208036","[A history and current state of chemotherapy against prostate cancer]","Yasumoto H, Igawa M.","Nihon Rinsho. 2011 Jun;69 Suppl 5:516-21.","Yasumoto H","Nihon Rinsho","2011","2012/01/03","","",""
"20478959","Diagnosis and treatment of prostate cancer are on cusp of major change, conference hears","Tanne JH.","BMJ. 2010 May 17;340:c2652. doi: 10.1136/bmj.c2652.","Tanne JH","BMJ","2010","2010/05/19","","","10.1136/bmj.c2652"
"7538745","[Role of radiotherapy in the treatment of localized prostatic carcinoma]","Casas Durán F, Ferrer González F, Casals Farrán J, Farrus Lucaya B, Rovirosa Casino A, Biete Sola A.","Arch Esp Urol. 1995 Mar;48(2):137-50.","Casas Durán F","Arch Esp Urol","1995","1995/03/01","","",""
"14571415","Endothelin receptor antagonists in the treatment of prostate cancer","Lassiter LK, Carducci MA.","Semin Oncol. 2003 Oct;30(5):678-88. doi: 10.1016/s0093-7754(03)00353-1.","Lassiter LK","Semin Oncol","2003","2003/10/23","","","10.1016/s0093-7754(03)00353-1"
"30180883","Minimal residual disease in prostate cancer patients after primary treatment: theoretical considerations, evidence and possible use in clinical management","Murray NP.","Biol Res. 2018 Sep 4;51(1):32. doi: 10.1186/s40659-018-0180-9.","Murray NP","Biol Res","2018","2018/09/06","PMC6122199","","10.1186/s40659-018-0180-9"
"17069507","Application of genomic technologies to human prostate cancer","Li S, Bhamre S, Lapointe J, Pollack JR, Brooks JD.","OMICS. 2006 Fall;10(3):261-75. doi: 10.1089/omi.2006.10.261.","Li S","OMICS","2006","2006/10/31","","","10.1089/omi.2006.10.261"
"31584887","Prostate radiotherapy in newly diagnosed metastatic prostate cancer","Ali A, Parker CC, Clarke NW.","Curr Opin Urol. 2019 Nov;29(6):620-628. doi: 10.1097/MOU.0000000000000675.","Ali A","Curr Opin Urol","2019","2019/10/05","","","10.1097/MOU.0000000000000675"
"31588674","Assessment and predictors of fatigue in men with prostate cancer receiving radiotherapy and androgen deprivation therapy","Bandara V, Capp A, Ahmed G, Arm J, Martin J.","J Med Imaging Radiat Oncol. 2019 Oct;63(5):683-690. doi: 10.1111/1754-9485.12922. Epub 2019 Jul 10.","Bandara V","J Med Imaging Radiat Oncol","2019","2019/10/08","","","10.1111/1754-9485.12922"
"25799731","[Treatment of prostate cancer using cryoablation: a prospective study]","Govorov AV, Vasil'ev AO, Ivanov VIu, Kovylina MV, Prilepskaia EA, Pushkar' DIu.","Urologiia. 2014 Nov-Dec;(6):69-72, 74.","Govorov AV","Urologiia","2014","2015/03/25","","",""
"8865473","Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia?","Hall MC, Roehrborn CG, McConnell JD.","Semin Urol Oncol. 1996 Aug;14(3):122-33.","Hall MC","Semin Urol Oncol","1996","1996/08/01","","",""
"25099562","Multiparametric magnetic resonance imaging of the prostate: technical aspects and role in clinical management","Costa DN, Pedrosa I, Roehrborn C, Rofsky NM.","Top Magn Reson Imaging. 2014 Aug;23(4):243-57. doi: 10.1097/RMR.0000000000000027.","Costa DN","Top Magn Reson Imaging","2014","2014/08/08","","","10.1097/RMR.0000000000000027"
"17611544","Treating prostate cancer: a rationale for targeting local oestrogens","Ellem SJ, Risbridger GP.","Nat Rev Cancer. 2007 Aug;7(8):621-7. doi: 10.1038/nrc2174. Epub 2007 Jul 5.","Ellem SJ","Nat Rev Cancer","2007","2007/07/06","","","10.1038/nrc2174"
"23329234","Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort","Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group.","Br J Cancer. 2013 Feb 5;108(2):271-7. doi: 10.1038/bjc.2012.598. Epub 2013 Jan 17.","Fisher G","Br J Cancer","2013","2013/01/19","PMC3566811","","10.1038/bjc.2012.598"
"30623865","Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations","Dellis A, Zagouri F, Liontos M, Mitropoulos D, Bamias A, Papatsoris AG; Hellenic Genito-Urinary Cancer Group (HCUCG).","Cancer Treat Rev. 2019 Feb;73:54-61. doi: 10.1016/j.ctrv.2018.11.005. Epub 2018 Dec 1.","Dellis A","Cancer Treat Rev","2019","2019/01/10","","","10.1016/j.ctrv.2018.11.005"
"20693964","Alcohol consumption and prostate cancer: a mini review","Rizos Ch, Papassava M, Golias Ch, Charalabopoulos K.","Exp Oncol. 2010 Jul;32(2):66-70.","Rizos Ch","Exp Oncol","2010","2010/08/10","","",""
"10926081","Neoadjuvant and adjuvant hormone therapy for prostate cancer","Zlotta AR, Schulman CC.","World J Urol. 2000 Jun;18(3):179-82. doi: 10.1007/s003450000119.","Zlotta AR","World J Urol","2000","2000/08/05","","","10.1007/s003450000119"
"10871814","Prostate cancer: a comprehensive review","Pentyala SN, Lee J, Hsieh K, Waltzer WC, Trocchia A, Musacchia L, Rebecchi MJ, Khan SA.","Med Oncol. 2000 May;17(2):85-105. doi: 10.1007/BF02796203.","Pentyala SN","Med Oncol","2000","2000/06/29","","","10.1007/BF02796203"
"26310786","Tectonic‑1 contributes to the growth and migration of prostate cancer cells in vitro","Wang Z, Gao Y, Liu Y, Chen J, Wang J, Gan S, Xu D, Cui X.","Int J Mol Med. 2015 Oct;36(4):931-8. doi: 10.3892/ijmm.2015.2313. Epub 2015 Aug 14.","Wang Z","Int J Mol Med","2015","2015/08/28","PMC4564073","","10.3892/ijmm.2015.2313"
"22473443","Screening for prostate cancer","Feldstein MS.","Ann Intern Med. 2012 Apr 3;156(7):540; author reply 540. doi: 10.7326/0003-4819-156-7-201204030-00016.","Feldstein MS","Ann Intern Med","2012","2012/04/05","","","10.7326/0003-4819-156-7-201204030-00016"
"8517003","Radiotherapy versus surgery for stage C prostate cancer","Zagars GK, von Eschenbach AC, Johnson DE.","Urology. 1993 Jun;41(6):605. doi: 10.1016/0090-4295(93)90117-s.","Zagars GK","Urology","1993","1993/06/01","","","10.1016/0090-4295(93)90117-s"
"25773349","Organ-confined prostate cancer: are we moving towards more or less radical surgical intervention?","Stevens DJ, Sharma NL, Tewari AK, Kirby R, Sooriakumaran P.","Curr Urol Rep. 2015 May;16(5):27. doi: 10.1007/s11934-015-0504-z.","Stevens DJ","Curr Urol Rep","2015","2015/03/17","","","10.1007/s11934-015-0504-z"
"27193788","Prostate cancer post-treatment follow-up and recurrence evaluation","May EJ, Viers LD, Viers BR, Kawashima A, Kwon ED, Karnes RJ, Froemming AT.","Abdom Radiol (NY). 2016 May;41(5):862-76. doi: 10.1007/s00261-015-0562-1.","May EJ","Abdom Radiol (NY)","2016","2016/05/20","","","10.1007/s00261-015-0562-1"
"28687599","PSMA Ligands for PET Imaging of Prostate Cancer","Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Afshar-Oromieh A, Herrmann K, Eiber M.","J Nucl Med. 2017 Oct;58(10):1545-1552. doi: 10.2967/jnumed.117.191031. Epub 2017 Jul 7.","Schwarzenboeck SM","J Nucl Med","2017","2017/07/09","","","10.2967/jnumed.117.191031"
"23732014","Exploring the relationship between coping, social support and health-related quality of life for prostate cancer survivors: a review of the literature","Paterson C, Jones M, Rattray J, Lauder W.","Eur J Oncol Nurs. 2013 Dec;17(6):750-9. doi: 10.1016/j.ejon.2013.04.002. Epub 2013 May 31.","Paterson C","Eur J Oncol Nurs","2013","2013/06/05","","","10.1016/j.ejon.2013.04.002"
"11268141","Married couples' perspectives on prostate cancer diagnosis and treatment decision-making","Boehmer U, Clark JA.","Psychooncology. 2001 Mar-Apr;10(2):147-55. doi: 10.1002/pon.504.","Boehmer U","Psychooncology","2001","2001/03/27","","","10.1002/pon.504"
"30704655","Prostate Cancer Screening: Shared Decision-Making for Screening and Treatment","Blackwelder R, Chessman A.","Prim Care. 2019 Mar;46(1):149-155. doi: 10.1016/j.pop.2018.10.012. Epub 2018 Dec 24.","Blackwelder R","Prim Care","2019","2019/02/02","","","10.1016/j.pop.2018.10.012"
"26519969","[Economic evaluation of the treatments of non-metastatic prostate cancer]","Perlbarg J, Rabetrano H, Soulié M, Salomon L, Durand-Zaleski I.","Prog Urol. 2015 Nov;25(15):1108-15. doi: 10.1016/j.purol.2015.07.012.","Perlbarg J","Prog Urol","2015","2015/11/02","","","10.1016/j.purol.2015.07.012"
"16630524","Surgery for locally advanced disease","Spiess PE, Leibovici D, Pisters LL.","Curr Urol Rep. 2006 May;7(3):209-16. doi: 10.1007/s11934-006-0023-z.","Spiess PE","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0023-z"
"8814851","Impalpable prostate cancer: clinicopathological features","Rogers E, Eastham JA, Ohori M, Sariyuce O, Aihara M, Wheeler TM, Scardino PT.","Br J Urol. 1996 Mar;77(3):429-32. doi: 10.1046/j.1464-410x.1996.88819.x.","Rogers E","Br J Urol","1996","1996/03/01","","","10.1046/j.1464-410x.1996.88819.x"
"16372514","Early diagnosis of prostatic cancer: disease-related survival improvement or extension of observation time?","Ruoppolo M.","Arch Ital Urol Androl. 2005 Jun;77(3):169-72.","Ruoppolo M","Arch Ital Urol Androl","2005","2005/12/24","","",""
"28362652","The association between plasma C-peptide concentration and the risk of prostate cancer: a nested case-control study within a Japanese population-based prospective study","Kiyabu GY, Sawada N, Iwasaki M, Yamaji T, Shimazu T, Sasazuki S, Inoue M, Tsugane S; JPHC Study Group.","Eur J Cancer Prev. 2018 Sep;27(5):461-467. doi: 10.1097/CEJ.0000000000000363.","Kiyabu GY","Eur J Cancer Prev","2018","2017/04/01","","","10.1097/CEJ.0000000000000363"
"8630882","Prognostic criteria in patients with stage D2 prostate cancer. Correlation with mean nuclear volume","Fujikawa K, Sasaki M, Aoyama T, Itoh T.","Cancer. 1995 Jul 1;76(1):91-5. doi: 10.1002/1097-0142(19950701)76:1<91::aid-cncr2820760113>3.0.co;2-w.","Fujikawa K","Cancer","1995","1995/07/01","","","10.1002/1097-0142(19950701)76:1<91::aid-cncr2820760113>3.0.co;2-w"
"24797777","[Circulating tumor cells and prostate cancer prognosis]","Capoun O, Soukup V, Mikulová V, Jančíková M, Honová H, Kološtová K, Zima T, Hanuš T.","Cas Lek Cesk. 2014;153(2):72-7.","Capoun O","Cas Lek Cesk","2014","2014/05/07","","",""
"9182383","[Prostatic cancer men under age 65. Occurrence and need for study]","Brasso K, Friis S, Kjaer SK, Iversen P.","Ugeskr Laeger. 1997 Apr 21;159(17):2543-5.","Brasso K","Ugeskr Laeger","1997","1997/04/21","","",""
"28572868","Prostate Cancer Patient Perspectives on the Use of Information in Treatment Decision-Making: A Systematic Review and Qualitative Meta-synthesis","Kandasamy S, Khalid AF, Majid U, Vanstone M.","Ont Health Technol Assess Ser. 2017 May 1;17(7):1-32. eCollection 2017.","Kandasamy S","Ont Health Technol Assess Ser","2017","2017/06/03","PMC5451209","",""
"22792655","Possible prevention and treatment of prostate cancer by exercise","Zaslau S, Jansen R, Riggs DR, Jackson BJ, Bryner RW.","W V Med J. 2012 May-Jun;108(3):42-7.","Zaslau S","W V Med J","2012","2012/07/17","","",""
"20039976","Health-related quality of life in men with localized prostate cancer","Namiki S, Arai Y.","Int J Urol. 2010 Feb;17(2):125-38. doi: 10.1111/j.1442-2042.2009.02437.x. Epub 2009 Dec 16.","Namiki S","Int J Urol","2010","2009/12/31","","","10.1111/j.1442-2042.2009.02437.x"
"11025425","Neoadjuvant hormonal therapy in radical prostatectomy and radiation-treated patients","Schmid HP, Semjonow A, Aus G, Hertle L.","Urol Int. 2000;65(2):63-7. doi: 10.1159/000064841.","Schmid HP","Urol Int","2000","2000/10/12","","","10.1159/000064841"
"1373015","Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy","Egawa S, Wheeler TM, Greene DR, Scardino PT.","Urology. 1992 Apr;39(4):358-63. doi: 10.1016/0090-4295(92)90213-g.","Egawa S","Urology","1992","1992/04/01","","","10.1016/0090-4295(92)90213-g"
"27524489","Communication networks of men facing a diagnosis of prostate cancer","Brown D, Oetzel J, Henderson A.","J Clin Nurs. 2016 Nov;25(21-22):3266-3278. doi: 10.1111/jocn.13369. Epub 2016 Aug 15.","Brown D","J Clin Nurs","2016","2016/08/16","","","10.1111/jocn.13369"
"17437834","Prostate cancer knowledge among low income minority men","Deibert CM, Maliski S, Kwan L, Fink A, Connor SE, Litwin MS.","J Urol. 2007 May;177(5):1851-5. doi: 10.1016/j.juro.2007.01.062.","Deibert CM","J Urol","2007","2007/04/18","","","10.1016/j.juro.2007.01.062"
"7933225","Perspectives on the problem of prostate cancer","Litwin MS, deKernion JB.","J Urol. 1994 Nov;152(5 Pt 2):1680-1. doi: 10.1016/s0022-5347(17)32359-5.","Litwin MS","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32359-5"
"17348371","Sexual dysfunction in men with prostate cancer: psychosocial issues","","J Support Oncol. 2007 Feb;5(2):91-2.","","J Support Oncol","2007","2007/03/14","","",""
"9302164","Re: Editorial comment: taking on prostate cancer","Evans RA.","J Urol. 1997 Oct;158(4):1528-9. doi: 10.1016/s0022-5347(01)64269-1.","Evans RA","J Urol","1997","1997/09/25","","","10.1016/s0022-5347(01)64269-1"
"17450441","History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study","Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, Hollenbeck A, Schatzkin A, Leitzmann MF.","Cancer Causes Control. 2007 Jun;18(5):493-503. doi: 10.1007/s10552-007-0126-y. Epub 2007 Apr 21.","Calton BA","Cancer Causes Control","2007","2007/04/24","","","10.1007/s10552-007-0126-y"
"8072027","Early-stage prostate cancer study compares therapy to watchful waiting","Randal J.","J Natl Cancer Inst. 1994 Sep 21;86(18):1376-7. doi: 10.1093/jnci/86.18.1376.","Randal J","J Natl Cancer Inst","1994","1994/09/21","","","10.1093/jnci/86.18.1376"
"24780936","Defining young in the context of prostate cancer","Chambers SK, Lowe A, Hyde MK, Zajdlewicz L, Gardiner RA, Sandoe D, Dunn J.","Am J Mens Health. 2015 Mar;9(2):103-14. doi: 10.1177/1557988314529991. Epub 2014 Apr 29.","Chambers SK","Am J Mens Health","2015","2014/05/01","PMC4361457","","10.1177/1557988314529991"
"18754308","[Practice guideline 'Prostate cancer: diagnosis and treatment']","de Reijke TM, Battermann JJ, van Moorselaar RJ, de Jong IJ, Visser AP, Burgers JS.","Ned Tijdschr Geneeskd. 2008 Aug 9;152(32):1771-5.","de Reijke TM","Ned Tijdschr Geneeskd","2008","2008/08/30","","",""
"27067717","Techniques for adaptive prostate radiotherapy","McVicar N, Popescu IA, Heath E.","Phys Med. 2016 Mar;32(3):492-8. doi: 10.1016/j.ejmp.2016.03.010. Epub 2016 Apr 7.","McVicar N","Phys Med","2016","2016/04/13","","","10.1016/j.ejmp.2016.03.010"
"16459666","[Follow-up of prostate cancer. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie]","Richaud P, Moreau JL, Beuzeboc P, Rébillard X, Villers A, Peyromaure M, Cornud F, Soulié M, Davin JL; Comité de Cancérologie de l'Association Française d'Urologie.","Prog Urol. 2005 Sep;15(4):586-92.","Richaud P","Prog Urol","2005","2006/02/08","","",""
"1548873","Localized prostate cancer: prostatectomy versus interstitial implantation","Schmidt JD.","J Surg Oncol. 1992 Jan;49(1):1-2. doi: 10.1002/jso.2930490102.","Schmidt JD","J Surg Oncol","1992","1992/01/01","","","10.1002/jso.2930490102"
"1723013","Two year experience with transrectal prostate ultrasound","Badalament RA, York JP, Drago JR.","In Vivo. 1990 Sep-Oct;4(5):325-6.","Badalament RA","In Vivo","1990","1990/09/01","","",""
"11832720","A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition","Critz FA.","J Urol. 2002 Mar;167(3):1310-3. doi: 10.1016/s0022-5347(05)65288-3.","Critz FA","J Urol","2002","2002/02/08","","","10.1016/s0022-5347(05)65288-3"
"20617433","Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer","Vermeeren L, Meinhardt W, van der Poel HG, Valdés Olmos RA.","Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2021-6. doi: 10.1007/s00259-010-1527-9. Epub 2010 Jul 9.","Vermeeren L","Eur J Nucl Med Mol Imaging","2010","2010/07/10","","","10.1007/s00259-010-1527-9"
"16720845","Therapeutic vaccines for prostate cancer","Tarassoff CP, Arlen PM, Gulley JL.","Oncologist. 2006 May;11(5):451-62. doi: 10.1634/theoncologist.11-5-451.","Tarassoff CP","Oncologist","2006","2006/05/25","","","10.1634/theoncologist.11-5-451"
"17918170","Is garlic a promising food for benign prostatic hyperplasia and prostate cancer?","Devrim E, Durak I.","Mol Nutr Food Res. 2007 Nov;51(11):1319-23. doi: 10.1002/mnfr.200600302.","Devrim E","Mol Nutr Food Res","2007","2007/10/06","","","10.1002/mnfr.200600302"
"23879909","Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer","Won AC, Gurney H, Marx G, De Souza P, Patel MI.","BJU Int. 2013 Aug;112(4):E250-5. doi: 10.1111/bju.12169.","Won AC","BJU Int","2013","2013/07/25","","","10.1111/bju.12169"
"16158079","Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy","Cavanaugh SX, Fuller CD, Kupelian PA, Reddy C, Bradshaw P, Pollock BH, Fuss M.","Prostate Cancer Prostatic Dis. 2005;8(4):353-8. doi: 10.1038/sj.pcan.4500831.","Cavanaugh SX","Prostate Cancer Prostatic Dis","2005","2005/09/15","","","10.1038/sj.pcan.4500831"
"12756082","Radical prostatectomy for the patient with locally advanced prostate cancer","Ward JF, Zincke H.","Curr Urol Rep. 2003 Jun;4(3):196-204. doi: 10.1007/s11934-003-0069-0.","Ward JF","Curr Urol Rep","2003","2003/05/21","","","10.1007/s11934-003-0069-0"
"20397765","The prostate cancer pseudo-epidemic","Adami HO.","Acta Oncol. 2010 Apr;49(3):298-304. doi: 10.3109/02841860903584945.","Adami HO","Acta Oncol","2010","2010/04/20","","","10.3109/02841860903584945"
"17544570","Editorial comment on: local progression among men with conservatively treated localized prostate cancer: results from the transatlantic prostate group","Hakenberg OW.","Eur Urol. 2008 Feb;53(2):354. doi: 10.1016/j.eururo.2007.05.016.","Hakenberg OW","Eur Urol","2008","2007/06/05","","","10.1016/j.eururo.2007.05.016"
"24464504","MSMB variation and prostate cancer risk: clues towards a possible fungal etiology","Sutcliffe S, De Marzo AM, Sfanos KS, Laurence M.","Prostate. 2014 May;74(6):569-78. doi: 10.1002/pros.22778. Epub 2014 Jan 24.","Sutcliffe S","Prostate","2014","2014/01/28","PMC4037912","NIHMS572633","10.1002/pros.22778"
"28561699","Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies","Friedlander TW, Pritchard CC, Beltran H.","Am Soc Clin Oncol Educ Book. 2017;37:358-369. doi: 10.1200/EDBK_175510.","Friedlander TW","Am Soc Clin Oncol Educ Book","2017","2017/06/01","","","10.1200/EDBK_175510"
"21504653","High intensity focused ultrasound (HIFU)","Barkin J.","Can J Urol. 2011 Apr;18(2):5634-43.","Barkin J","Can J Urol","2011","2011/04/21","","",""
"7504646","Prostate cancer: who to screen, and what the results mean","Small EJ.","Geriatrics. 1993 Dec;48(12):28-30, 35-8.","Small EJ","Geriatrics","1993","1993/12/01","","",""
"10606282","Chemotherapy for advanced hormone refractory prostate cancer","Petrylak DP.","Urology. 1999 Dec;54(6A Suppl):30-5. doi: 10.1016/s0090-4295(99)00452-5.","Petrylak DP","Urology","1999","1999/12/22","","","10.1016/s0090-4295(99)00452-5"
"20126849","IGF-I, insulin and prostate cancer","Lima GA, Corrêa LL, Gabrich R, Miranda LC, Gadelha MR.","Arq Bras Endocrinol Metabol. 2009 Nov;53(8):969-75. doi: 10.1590/s0004-27302009000800010.","Lima GA","Arq Bras Endocrinol Metabol","2009","2010/02/04","","","10.1590/s0004-27302009000800010"
"30358932","Multiparametric MRI: an important tool to improve risk stratification for active surveillance in prostate cancer","Chandrasekar T, Dall'Era MA, Tilki D.","BJU Int. 2018 Nov;122(5):721-722. doi: 10.1111/bju.14494.","Chandrasekar T","BJU Int","2018","2018/10/26","","","10.1111/bju.14494"
"16208809","New test detects early prostate cancer","","Health News. 2005 Sep;11(9):9.","","Health News","2005","2005/10/08","","",""
"26174441","Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer","Lucarelli G, Rutigliano M, Galleggiante V, Giglio A, Palazzo S, Ferro M, Simone C, Bettocchi C, Battaglia M, Ditonno P.","Expert Rev Mol Diagn. 2015;15(9):1211-24. doi: 10.1586/14737159.2015.1069711. Epub 2015 Jul 15.","Lucarelli G","Expert Rev Mol Diagn","2015","2015/07/16","","","10.1586/14737159.2015.1069711"
"9085540","Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review","Soderdahl DW, Wettlaufer JN, Corn B, Gomella LG.","Tech Urol. 1996 Winter;2(4):194-206.","Soderdahl DW","Tech Urol","1996","1996/01/01","","",""
"25756134","Avoiding obsolescence in advanced prostate cancer management: a guide for urologists","Shore ND, Karsh L, Gomella LG, Keane TE, Concepcion RS, Crawford ED.","BJU Int. 2015 Feb;115(2):188-97. doi: 10.1111/bju.12665.","Shore ND","BJU Int","2015","2015/03/11","","","10.1111/bju.12665"
"23202482","Barriers to prostate cancer care: affordable care is not enough","Oduro C, Connor SE, Litwin MS, Maliski SL.","Qual Health Res. 2013 Mar;23(3):375-84. doi: 10.1177/1049732312467852. Epub 2012 Nov 30.","Oduro C","Qual Health Res","2013","2012/12/04","","","10.1177/1049732312467852"
"26659397","Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy","Tannock IF, Sternberg CN.","Ann Oncol. 2016 Mar;27(3):545-6. doi: 10.1093/annonc/mdv600. Epub 2015 Dec 12.","Tannock IF","Ann Oncol","2016","2015/12/15","","","10.1093/annonc/mdv600"
"21345070","Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling","Hao Y, Zhao Y, Zhao X, He C, Pang X, Wu TC, Califano JA, Gu X.","Cancer Invest. 2011 May;29(4):318-24. doi: 10.3109/07357907.2011.554477. Epub 2011 Feb 23.","Hao Y","Cancer Invest","2011","2011/02/25","PMC3305797","NIHMS359772","10.3109/07357907.2011.554477"
"11232479","The latest strategies for treating prostate cancer","","Johns Hopkins Med Lett Health After 50. 2001 Mar;13(1):4-5.","","Johns Hopkins Med Lett Health After 50","2001","2001/03/10","","",""
"11170300","Role of transforming growth factor-beta1 in prostate cancer","Wikström P, Damber J, Bergh A.","Microsc Res Tech. 2001 Feb 15;52(4):411-9. doi: 10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8.","Wikström P","Microsc Res Tech","2001","2001/02/15","","","10.1002/1097-0029(20010215)52:4<411::AID-JEMT1026>3.0.CO;2-8"
"10524892","Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial","de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA, Sylvester RJ.","J Urol. 1999 Nov;162(5):1658-64; discussion 1664-5. doi: 10.1097/00005392-199911000-00023.","de Reijke TM","J Urol","1999","1999/10/19","","","10.1097/00005392-199911000-00023"
"9268978","Prostate cancer clinical trials of the Southwest Oncology Group","Crawford ED, DeAntoni EP, Hussain M, Thompson IM, Coltman CA Jr.","Oncology (Williston Park). 1997 Aug;11(8):1154-63; discussion 1163-70.","Crawford ED","Oncology (Williston Park)","1997","1997/08/01","","",""
"24754780","How good is post-biopsy multiparametric magnetic resonance imaging in detecting and characterising the index lesion of localised prostate cancer?","Engelhard K, Labanaris AP, Bogner K, Lübke L, Dworak O, Kühn R.","Scand J Urol. 2014 Dec;48(6):499-505. doi: 10.3109/21681805.2014.907338. Epub 2014 Apr 22.","Engelhard K","Scand J Urol","2014","2014/04/24","","","10.3109/21681805.2014.907338"
"8270455","Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports","Coleman CN, Beard CJ, Kantoff PW, Gelman R.","Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):303-13. doi: 10.1016/0360-3016(94)90171-6.","Coleman CN","Int J Radiat Oncol Biol Phys","1994","1994/01/01","","","10.1016/0360-3016(94)90171-6"
"21129660","[Prostate cancer]","Vieillot S, Fenoglietto P, Aillères N, Hay MH, Dubois JB, Azria D.","Cancer Radiother. 2010 Nov;14 Suppl 1:S161-73. doi: 10.1016/S1278-3218(10)70020-2.","Vieillot S","Cancer Radiother","2010","2010/12/07","","","10.1016/S1278-3218(10)70020-2"
"11702664","[Histopathological changes of prostate cancer after castration therapy and correlative factors]","Yin T, Shen M, Ji X.","Zhonghua Yi Xue Za Zhi. 2001 Aug 10;81(15):910-3.","Yin T","Zhonghua Yi Xue Za Zhi","2001","2001/11/13","","",""
"20814400","New treatments for metastic prostate cancer","","Med Lett Drugs Ther. 2010 Sep 6;52(1346):69-70.","","Med Lett Drugs Ther","2010","2010/09/04","","",""
"27716457","Difference of opinion - Radical prostatectomy in metastatic prostate cancer: is there enough evidence? | Opinion: No","Ristau BT, Smaldone MC.","Int Braz J Urol. 2016 Sep-Oct;42(5):880-882. doi: 10.1590/S1677-5538.IBJU.2016.05.05.","Ristau BT","Int Braz J Urol","2016","2016/10/08","PMC5066883","","10.1590/S1677-5538.IBJU.2016.05.05"
"23147919","Prostate cancer: epidemiologic studies and changing clinical practice","Novara G, Ficarra V.","Nat Rev Urol. 2012 Dec;9(12):676-7. doi: 10.1038/nrurol.2012.203. Epub 2012 Nov 13.","Novara G","Nat Rev Urol","2012","2012/11/14","","","10.1038/nrurol.2012.203"
"24888965","Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers","Hart TL, Coon DW, Kowalkowski MA, Zhang K, Hersom JI, Goltz HH, Wittmann DA, Latini DM.","J Sex Med. 2014 Sep;11(9):2308-17. doi: 10.1111/jsm.12598. Epub 2014 May 30.","Hart TL","J Sex Med","2014","2014/06/04","PMC4415517","NIHMS683429","10.1111/jsm.12598"
"15050018","Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment","Basu S.","BJU Int. 2004 Apr;93(6):889. doi: 10.1111/j.1464-410X.2004.4737e.x.","Basu S","BJU Int","2004","2004/03/31","","","10.1111/j.1464-410X.2004.4737e.x"
"21616448","[Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer]","Audenet F, Rouprêt M, Tombal B.","Prog Urol. 2011 May;21 Suppl 3:S96-101. doi: 10.1016/S1166-7087(11)70022-7.","Audenet F","Prog Urol","2011","2011/05/28","","","10.1016/S1166-7087(11)70022-7"
"25268733","5-Alpha-reductase inhibitors in diseases of the prostate","Carrasquillo RJ, Nealy SW, Wang DS.","Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):488-92. doi: 10.1097/MED.0000000000000110.","Carrasquillo RJ","Curr Opin Endocrinol Diabetes Obes","2014","2014/10/01","","","10.1097/MED.0000000000000110"
"19873936","Radiation therapy of prostate cancer: rationale, pitfalls and the continuing prospect of success forged by medical physics","Williams SG.","Australas Phys Eng Sci Med. 2009 Sep;32(3):119-28. doi: 10.1007/BF03178639.","Williams SG","Australas Phys Eng Sci Med","2009","2009/10/31","","","10.1007/BF03178639"
"25797015","Body concentrations of persistent organic pollutants and prostate cancer: a meta-analysis","Lim JE, Park SH, Jee SH, Park H.","Environ Sci Pollut Res Int. 2015 Aug;22(15):11275-84. doi: 10.1007/s11356-015-4315-z. Epub 2015 Mar 24.","Lim JE","Environ Sci Pollut Res Int","2015","2015/03/24","","","10.1007/s11356-015-4315-z"
"11383241","Expectant management of prostate cancer","Griffin AS, O'Rourke ME.","Semin Oncol Nurs. 2001 May;17(2):101-7. doi: 10.1053/sonu.2001.23074.","Griffin AS","Semin Oncol Nurs","2001","2001/06/01","","","10.1053/sonu.2001.23074"
"29795250","Yes or no to local therapy for oligometastatic prostate cancer?","Moul JW.","Nat Rev Urol. 2018 Jul;15(7):399-400. doi: 10.1038/s41585-018-0028-7.","Moul JW","Nat Rev Urol","2018","2018/05/26","","","10.1038/s41585-018-0028-7"
"22212082","Diagnostic and prognostic molecular biomarkers for prostate cancer","Kristiansen G.","Histopathology. 2012 Jan;60(1):125-41. doi: 10.1111/j.1365-2559.2011.04083.x.","Kristiansen G","Histopathology","2012","2012/01/04","","","10.1111/j.1365-2559.2011.04083.x"
"8948364","Prostate cancer: endpoints for treatment benefits-re: Schild et al. IJROBP 34:535-541; 1996","Lawrence G, Collins B.","Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):757-8. doi: 10.1016/s0360-3016(97)85091-2.","Lawrence G","Int J Radiat Oncol Biol Phys","1996","1996/10/01","","","10.1016/s0360-3016(97)85091-2"
"27291866","Types of chronic conditions combinations and initial cancer treatment among elderly Medicare beneficiaries with localised prostate cancer","Raval AD, Madhavan S, Mattes MD, Sambamoorthi U.","Int J Clin Pract. 2016 Jul;70(7):606-18. doi: 10.1111/ijcp.12838. Epub 2016 Jun 13.","Raval AD","Int J Clin Pract","2016","2016/06/14","PMC4927389","NIHMS795923","10.1111/ijcp.12838"
"10725864","Magnetic resonance imaging of prostatic cancer: does detection vary between high and low gleason score tumors?","Ikonen S, Kärkkäinen P, Kivisaari L, Salo JO, Taari K, Vehmas T, Tervahartiala P, Rannikko S.","Prostate. 2000 Apr 1;43(1):43-8. doi: 10.1002/(sici)1097-0045(20000401)43:1<43::aid-pros6>3.0.co;2-s.","Ikonen S","Prostate","2000","2000/03/22","","","10.1002/(sici)1097-0045(20000401)43:1<43::aid-pros6>3.0.co;2-s"
"22516516","[Prostate cancer and chemotherapy: standards care and perspectives]","Hadjarab Y, Oudard S.","Bull Cancer. 2012 Jul;99 Suppl 1:S46-56. doi: 10.1684/bdc.2012.1563.","Hadjarab Y","Bull Cancer","2012","2012/04/21","","","10.1684/bdc.2012.1563"
"25571871","Evaluation of the current prostate cancer staging system based on cancer-specific mortality in the surveillance, epidemiology, and end results database","Shukla ME, Yu C, Reddy CA, Stephans KL, Klein EA, Abdel-Wahab M, Ciezki J, Tendulkar RD.","Clin Genitourin Cancer. 2015 Feb;13(1):17-21. doi: 10.1016/j.clgc.2014.07.003. Epub 2014 Jul 14.","Shukla ME","Clin Genitourin Cancer","2015","2015/01/10","","","10.1016/j.clgc.2014.07.003"
"27694176","What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer","Ballas LK, de Castro Abreu AL, Quinn DI.","J Nucl Med. 2016 Oct;57(Suppl 3):6S-12S. doi: 10.2967/jnumed.115.170142.","Ballas LK","J Nucl Med","2016","2016/10/04","","","10.2967/jnumed.115.170142"
"15796183","In vitro antiproliferation in prostate cancer cell lines with cytostatics and combinations with resistance modifiers","Pintér O, Mucsi I, Molnár J.","In Vivo. 2005 Jan-Feb;19(1):253-9.","Pintér O","In Vivo","2005","2005/03/31","","",""
"25189017","Early prostate cancer care questioned","Rice S.","Mod Healthc. 2014 Jul 21;44(29):21.","Rice S","Mod Healthc","2014","2014/09/06","","",""
"22128564","How do nurse navigators guide patients through prostate cancer treatment?","Jackowski G.","ONS Connect. 2011 Oct;26(10):13.","Jackowski G","ONS Connect","2011","2011/12/02","","",""
"8211253","A prostate cancer support group: does it work?","Mason M.","Urol Nurs. 1993 Sep;13(3):95-6.","Mason M","Urol Nurs","1993","1993/09/01","","",""
"29107278","The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?","Nair R, Lamb BW, Geurts N, Alghazo O, Lam W, Lawrentschuk N, Murphy DG.","Urol Clin North Am. 2017 Nov;44(4):623-633. doi: 10.1016/j.ucl.2017.07.013.","Nair R","Urol Clin North Am","2017","2017/11/07","","","10.1016/j.ucl.2017.07.013"
"8935621","Early detection of prostate cancer in African-American men with an increased familial risk of disease","Sartor O.","J La State Med Soc. 1996 Apr;148(4):179-85.","Sartor O","J La State Med Soc","1996","1996/04/01","","",""
"29297175","Sipuleucel-T: When and for Whom to Recommend It","Slovin SF.","Oncology (Williston Park). 2017 Dec 15;31(12):900-1, 910-2.","Slovin SF","Oncology (Williston Park)","2017","2018/01/04","","",""
"8853480","Screening for prostate cancer: a urological perspective","Fradet Y.","Can J Oncol. 1994 Nov;4 Suppl 1:8-12.","Fradet Y","Can J Oncol","1994","1994/11/01","","",""
"28263123","Prostate Cancer Statistics: Anything You Want Them To Be","Gomella LG.","Can J Urol. 2017 Feb;24(1):8603-8604.","Gomella LG","Can J Urol","2017","2017/03/07","","",""
"23529667","Multidisciplinary care in patients with prostate cancer: room for improvement","Strebel RT, Sulser T, Schmid HP, Gillessen S, Fehr M, Huber U, Pless M, Morant R, Winterhalder R, Cathomas R.","Support Care Cancer. 2013 Aug;21(8):2327-33. doi: 10.1007/s00520-013-1791-x. Epub 2013 Mar 26.","Strebel RT","Support Care Cancer","2013","2013/03/27","","","10.1007/s00520-013-1791-x"
"22052754","The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis","Powell IJ.","Arch Esp Urol. 2011 Oct;64(8):711-9.","Powell IJ","Arch Esp Urol","2011","2011/11/05","PMC3859428","NIHMS511895",""
"31629421","The AR-DNA repair axis: insights into prostate cancer aggressiveness","Knudsen KE.","Can J Urol. 2019 Oct;26(5 Suppl 2):22-23.","Knudsen KE","Can J Urol","2019","2019/10/21","","",""
"16713069","Interview with Jack Schalken. PCA3 and its use as a diagnostic test in prostate cancer. Interview by Christine McKillop","Schalken J.","Eur Urol. 2006 Jul;50(1):153-4. doi: 10.1016/j.eururo.2006.04.021. Epub 2006 May 8.","Schalken J","Eur Urol","2006","2006/05/23","","","10.1016/j.eururo.2006.04.021"
"26782711","Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","Raval AD, Thakker D, Negi H, Vyas A, Kaur H, Salkini MW.","Prostate Cancer Prostatic Dis. 2016 Jun;19(2):151-62. doi: 10.1038/pcan.2015.58. Epub 2016 Jan 19.","Raval AD","Prostate Cancer Prostatic Dis","2016","2016/01/20","","","10.1038/pcan.2015.58"
"32721477","Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer","Ghafouri-Fard S, Shoorei H, Taheri M.","Gene. 2020 Oct 30;759:144995. doi: 10.1016/j.gene.2020.144995. Epub 2020 Jul 25.","Ghafouri-Fard S","Gene","2020","2020/07/30","","","10.1016/j.gene.2020.144995"
"18378540","What to do with an abnormal PSA test","Loeb S, Catalona WJ.","Oncologist. 2008 Mar;13(3):299-305. doi: 10.1634/theoncologist.2007-0139.","Loeb S","Oncologist","2008","2008/04/02","","","10.1634/theoncologist.2007-0139"
"10482179","Introduction: a therapeutically relevant framework for the classification of human prostate cancer","Logothetis CJ.","Semin Oncol. 1999 Aug;26(4):369-74.","Logothetis CJ","Semin Oncol","1999","1999/09/11","","",""
"31730580","Prostate cancer in military veterans","Montgomery B.","Clin Adv Hematol Oncol. 2019 Oct;17(10):552-554.","Montgomery B","Clin Adv Hematol Oncol","2019","2019/11/16","","",""
"7693317","Rising incidence rate of prostate cancer","Meyer F.","CMAJ. 1993 Nov 15;149(10):1375-6.","Meyer F","CMAJ","1993","1993/11/15","PMC1485902","",""
"32481356","Increased expression of microRNA-93 correlates with progression and prognosis of prostate cancer","Wang C, Tian S, Zhang D, Deng J, Cai H, Shi C, Yang W.","Medicine (Baltimore). 2020 May 29;99(22):e18432. doi: 10.1097/MD.0000000000018432.","Wang C","Medicine (Baltimore)","2020","2020/06/03","","","10.1097/MD.0000000000018432"
"9126065","The concept of evolution in the pathogenesis and treatment of prostate cancer","Garcia-Schurmann M, Coffey DS.","Br J Urol. 1997 Apr;79 Suppl 2:9-17. doi: 10.1111/j.1464-410x.1997.tb16916.x.","Garcia-Schurmann M","Br J Urol","1997","1997/04/01","","","10.1111/j.1464-410x.1997.tb16916.x"
"2802498","Faltin lecture 1988. Prostate cancer: current concepts on therapy","Andersson L.","Ann Chir Gynaecol. 1989;78(2):88-93.","Andersson L","Ann Chir Gynaecol","1989","1989/01/01","","",""
"20587838","How many early detected prostate cancers are needed to prevent one death?","Valle Gerhold J.","Arch Esp Urol. 2010 Jun;63(5):335-41.","Valle Gerhold J","Arch Esp Urol","2010","2010/07/01","","",""
"24840072","Multiparametric MRI in prostate cancer management","Johnson LM, Turkbey B, Figg WD, Choyke PL.","Nat Rev Clin Oncol. 2014 Jun;11(6):346-53. doi: 10.1038/nrclinonc.2014.69. Epub 2014 May 20.","Johnson LM","Nat Rev Clin Oncol","2014","2014/05/21","PMC6330110","NIHMS1005086","10.1038/nrclinonc.2014.69"
"27344797","[Combined androgen blockade for prostate cancer]","Shimazui T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:578-83.","Shimazui T","Nihon Rinsho","2016","2016/06/28","","",""
"21207840","Length of survival and causes of death in men with prostate cancer","","Harv Mens Health Watch. 2010 Dec;15(5):7.","","Harv Mens Health Watch","2010","2011/01/07","","",""
"18618945","Quality of life and satisfaction with outcome among prostate-cancer survivors","Vordermark D.","N Engl J Med. 2008 Jul 10;359(2):201; author reply 201-2.","Vordermark D","N Engl J Med","2008","2008/07/12","","",""
"21604932","Introduction from the chairmen of the WHO International Consultation on Prostate Cancer","Nilsson S, Andersson L.","Acta Oncol. 2011 Jun;50 Suppl 1:1. doi: 10.3109/0284186X.2010.542176.","Nilsson S","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.542176"
"31116139","Germline genetics in localized prostate cancer","Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK.","Curr Opin Urol. 2019 Jul;29(4):326-333. doi: 10.1097/MOU.0000000000000648.","Ryan ST","Curr Opin Urol","2019","2019/05/23","","","10.1097/MOU.0000000000000648"
"19352391","Prostate cancer: regeneration of interest in the prostate","Collins AT, Maitland NJ.","Nat Rev Urol. 2009 Apr;6(4):184-6. doi: 10.1038/nrurol.2009.48.","Collins AT","Nat Rev Urol","2009","2009/04/09","","","10.1038/nrurol.2009.48"
"18090495","Imaging low-risk prostate cancer","Shukla-Dave A, Hricak H, Scardino PT.","Curr Opin Urol. 2008 Jan;18(1):78-86. doi: 10.1097/MOU.0b013e3282f13adc.","Shukla-Dave A","Curr Opin Urol","2008","2007/12/20","","","10.1097/MOU.0b013e3282f13adc"
"1691839","Epidemiologic evidence regarding predisposing factors to prostate cancer","Carter BS, Carter HB, Isaacs JT.","Prostate. 1990;16(3):187-97. doi: 10.1002/pros.2990160302.","Carter BS","Prostate","1990","1990/01/01","","","10.1002/pros.2990160302"
"29019420","What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?","Phillips R, Ost P, Tran PT.","Future Oncol. 2017 Oct;13(24):2121-2124. doi: 10.2217/fon-2017-0337. Epub 2017 Oct 11.","Phillips R","Future Oncol","2017","2017/10/12","","","10.2217/fon-2017-0337"
"12853339","ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer","Kataja VV; ESMO Guidelines Task Force.","Ann Oncol. 2003 Jul;14(7):1010-1. doi: 10.1093/annonc/mdg293.","Kataja VV","Ann Oncol","2003","2003/07/11","","","10.1093/annonc/mdg293"
"15815196","Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer","Ward JF, Moul JW.","Curr Opin Urol. 2005 May;15(3):187-95. doi: 10.1097/01.mou.0000165553.17534.e3.","Ward JF","Curr Opin Urol","2005","2005/04/09","","","10.1097/01.mou.0000165553.17534.e3"
"26333232","[Radical prostatectomy and radiation therapy for high-risk prostate cancer: An update]","Lei JH, Chen YJ, Liu LR, Wei Q.","Zhonghua Nan Ke Xue. 2015 Jul;21(7):663-6.","Lei JH","Zhonghua Nan Ke Xue","2015","2015/09/04","","",""
"15503321","Results of a randomized controlled trail of prostate cancer screening","Pinsky PF.","Prostate. 2004 Dec 1;61(4):371. doi: 10.1002/pros.20165.","Pinsky PF","Prostate","2004","2004/10/27","","","10.1002/pros.20165"
"17235222","The impact of inadequate knowledge on patient and spouse experience of prostate cancer","Docherty A, Brothwell CP, Symons M.","Cancer Nurs. 2007 Jan-Feb;30(1):58-63. doi: 10.1097/00002820-200701000-00011.","Docherty A","Cancer Nurs","2007","2007/01/20","","","10.1097/00002820-200701000-00011"
"3275344","More on surgery vs radiation for localized prostate cancer","","Oncology (Williston Park). 1987 Aug;1(6):24.","","Oncology (Williston Park)","1987","1987/08/01","","",""
"27622278","Prostate cancer in Brazil and Latin America: epidemiology and screening","Tourinho-Barbosa RR, Pompeo AC, Glina S.","Int Braz J Urol. 2016 Nov-Dec;42(6):1081-1090. doi: 10.1590/S1677-5538.IBJU.2015.0690.","Tourinho-Barbosa RR","Int Braz J Urol","2016","2016/09/14","PMC5117963","","10.1590/S1677-5538.IBJU.2015.0690"
"19912202","Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men","Lee SE, Kim DS, Lee WK, Park HZ, Lee CJ, Doo SH, Jeong SJ, Yoon CY, Byun SS, Choe G, Hwang SI, Lee HJ, Hong SK.","BJU Int. 2010 Jun;105(11):1526-30. doi: 10.1111/j.1464-410X.2009.09070.x. Epub 2009 Nov 13.","Lee SE","BJU Int","2010","2009/11/17","","","10.1111/j.1464-410X.2009.09070.x"
"26001612","Molecular subtyping of prostate cancer: a partnership model","Mills IG.","Eur Urol. 2015 Oct;68(4):568-9. doi: 10.1016/j.eururo.2015.05.012. Epub 2015 May 20.","Mills IG","Eur Urol","2015","2015/05/24","","","10.1016/j.eururo.2015.05.012"
"19670739","[Urodynamics in the course of distant and interstitial radiotherapy for locally-advanced prostate cancer]","Kaprin AD, Khalil Farzat M, Ivanov SA, Gafanov RA.","Vopr Onkol. 2009;55(3):361-4.","Kaprin AD","Vopr Onkol","2009","2009/08/13","","",""
"20724726","Effects of prostate-specific antigen testing on familial prostate cancer risk estimates","Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P.","J Natl Cancer Inst. 2010 Sep 8;102(17):1336-43. doi: 10.1093/jnci/djq265. Epub 2010 Aug 19.","Bratt O","J Natl Cancer Inst","2010","2010/08/21","","","10.1093/jnci/djq265"
"19646631","Editorial comment. Variations in International Prostate Symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer","Macaluso JN Jr.","Urology. 2009 Aug;74(2):412; author reply 412-3. doi: 10.1016/j.urology.2009.01.032.","Macaluso JN Jr","Urology","2009","2009/08/04","","","10.1016/j.urology.2009.01.032"
"22118357","[Real time elastography in the diagnosis of prostate cancer: comparison of preoperative imaging and histology after radical prostatectomy]","Walz J, Marcy M, Maubon T, Brunelle S, Laroche J, Gravis G, Salem N, Bladou F.","Prog Urol. 2011 Dec;21(13):925-31. doi: 10.1016/j.purol.2011.04.006. Epub 2011 Jun 2.","Walz J","Prog Urol","2011","2011/11/29","","","10.1016/j.purol.2011.04.006"
"8545281","Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project","Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A.","Prostate. 1996 Jan;28(1):51-7. doi: 10.1002/(SICI)1097-0045(199601)28:1<51::AID-PROS7>3.0.CO;2-R.","Schmidt JD","Prostate","1996","1996/01/01","","","10.1002/(SICI)1097-0045(199601)28:1<51::AID-PROS7>3.0.CO;2-R"
"22937730","Prostate cancer treatment: the times they are a' changin'","Kirby R, Challacombe B, Dasgupta P, Fitzpatrick JM.","BJU Int. 2012 Nov;110(10):1408-11. doi: 10.1111/j.1464-410X.2012.11441.x. Epub 2012 Sep 3.","Kirby R","BJU Int","2012","2012/09/04","","","10.1111/j.1464-410X.2012.11441.x"
"9274436","Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer","Raghavan D, Koczwara B, Javle M.","Eur J Cancer. 1997 Apr;33(4):566-74. doi: 10.1016/s0959-8049(96)00510-2.","Raghavan D","Eur J Cancer","1997","1997/04/01","","","10.1016/s0959-8049(96)00510-2"
"7541860","Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group","Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L.","J Urol. 1995 Aug;154(2 Pt 1):429-34. doi: 10.1097/00005392-199508000-00027.","Van Poppel H","J Urol","1995","1995/08/01","","","10.1097/00005392-199508000-00027"
"23628095","[Treatment of bladder outlet obstruction in locally advanced prostate cancer]","Martin L, Thiery-Vuillemin A, Kleinclauss F.","Prog Urol. 2013 May;23(6):386-8. doi: 10.1016/j.purol.2013.02.005. Epub 2013 Mar 26.","Martin L","Prog Urol","2013","2013/05/01","","","10.1016/j.purol.2013.02.005"
"23951320","Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1","Haflidadóttir BS, Larne O, Martin M, Persson M, Edsjö A, Bjartell A, Ceder Y.","PLoS One. 2013 Aug 12;8(8):e72400. doi: 10.1371/journal.pone.0072400. eCollection 2013.","Haflidadóttir BS","PLoS One","2013","2013/08/17","PMC3741168","","10.1371/journal.pone.0072400"
"12875804","Effects of misattribution in assigning cause of death on prostate cancer mortality rates","Hoffman RM, Stone SN, Hunt WC, Key CR, Gilliland FD.","Ann Epidemiol. 2003 Jul;13(6):450-4. doi: 10.1016/s1047-2797(02)00439-8.","Hoffman RM","Ann Epidemiol","2003","2003/07/24","","","10.1016/s1047-2797(02)00439-8"
"9989421","Expectant management of stage A-1 (T1a) prostate cancer utilizing serum PSA levels: a preliminary report","Loughlin KR, Renshaw AA, Kumar S.","J Surg Oncol. 1999 Jan;70(1):49-53. doi: 10.1002/(sici)1096-9098(199901)70:1<49::aid-jso9>3.0.co;2-x.","Loughlin KR","J Surg Oncol","1999","1999/02/16","","","10.1002/(sici)1096-9098(199901)70:1<49::aid-jso9>3.0.co;2-x"
"22959351","Locally recurrent prostate cancer following radiation therapy: to cut or to freeze?","Heidenreich A.","Eur Urol. 2013 Jul;64(1):8-10. doi: 10.1016/j.eururo.2012.08.045. Epub 2012 Aug 28.","Heidenreich A","Eur Urol","2013","2012/09/11","","","10.1016/j.eururo.2012.08.045"
"17250951","Prostate cancer chemotherapy. Interview by Christine McKillop","Sternberg CN.","Eur Urol. 2007 Apr;51(4):1136-8. doi: 10.1016/j.eururo.2007.01.037. Epub 2007 Jan 16.","Sternberg CN","Eur Urol","2007","2007/01/26","","","10.1016/j.eururo.2007.01.037"
"26447381","Immunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate Cancer","Quián YP, Crombet T, Batista JF, Prats A, Perera A.","Clin Nucl Med. 2016 Mar;41(3):244-6. doi: 10.1097/RLU.0000000000001011.","Quián YP","Clin Nucl Med","2016","2015/10/09","","","10.1097/RLU.0000000000001011"
"31919691","Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan","Narita S, Hatakeyama S, Takahashi M, Sakurai T, Kawamura S, Hoshi S, Ishida M, Kawaguchi T, Ishidoya S, Shimoda J, Sato H, Koizumi A, Mitsuzuka K, Tochigi T, Tsuchiya N, Ohyama C, Arai Y, Nomura K, Habuchi T.","Int J Clin Oncol. 2020 May;25(5):912-920. doi: 10.1007/s10147-019-01614-8. Epub 2020 Jan 9.","Narita S","Int J Clin Oncol","2020","2020/01/11","","","10.1007/s10147-019-01614-8"
"17933704","Impact of low prostate specific antigen on prostate cancer--a rare case report","Schneider HB.","Eur J Med Res. 2007 Jul 26;12(7):311-3.","Schneider HB","Eur J Med Res","2007","2007/10/16","","",""
"31629427","Current prostate cancer genetic testing capabilities and considerations","Pilarski R.","Can J Urol. 2019 Oct;26(5 Suppl 2):38-39.","Pilarski R","Can J Urol","2019","2019/10/21","","",""
"15344560","[Clinics in prostate cancer]","Sugimura Y.","Rinsho Byori. 2004 Jul;52(7):604-10.","Sugimura Y","Rinsho Byori","2004","2004/09/04","","",""
"26726168","Prostate Cancer Virtual Special Issue","Jena R.","Clin Oncol (R Coll Radiol). 2016 Mar;28(3):163-4. doi: 10.1016/j.clon.2015.12.005. Epub 2015 Dec 22.","Jena R","Clin Oncol (R Coll Radiol)","2016","2016/01/05","","","10.1016/j.clon.2015.12.005"
"22207995","[History and present status of the treatment of prostate cancer]","Ogawa O.","Nihon Rinsho. 2011 Jun;69 Suppl 5:326-9.","Ogawa O","Nihon Rinsho","2011","2012/01/03","","",""
"27749324","Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer: A Review","Kyriakopoulos CE, Liu G.","Cancer J. 2016 Sep/Oct;22(5):322-325. doi: 10.1097/PPO.0000000000000215.","Kyriakopoulos CE","Cancer J","2016","2016/10/18","","","10.1097/PPO.0000000000000215"
"10235143","Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer","Fuller DB.","JAMA. 1999 May 5;281(17):1583; author reply 1585-6.","Fuller DB","JAMA","1999","1999/05/11","","",""
"20142048","[Prostate cancer: medicoeconomic aspects]","Kanso C, Etner J, Debré B, Zerbib M.","Prog Urol. 2010 Feb;20(2):85-90. doi: 10.1016/j.purol.2009.06.007. Epub 2009 Aug 7.","Kanso C","Prog Urol","2010","2010/02/10","","","10.1016/j.purol.2009.06.007"
"9314824","Evaluating prostate needle biopsy: therapeutic and prognostic importance","Bostwick DG.","CA Cancer J Clin. 1997 Sep-Oct;47(5):297-319. doi: 10.3322/canjclin.47.5.297.","Bostwick DG","CA Cancer J Clin","1997","1997/10/07","","","10.3322/canjclin.47.5.297"
"20583127","Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia","Peehl DM, Chen Z, Nolley R.","Prostate. 2011 Jan 1;71(1):26-31. doi: 10.1002/pros.21218.","Peehl DM","Prostate","2011","2010/06/29","","","10.1002/pros.21218"
"11981273","Prostate cancer update","Rini BI, Small EJ.","Curr Opin Oncol. 2002 May;14(3):286-91. doi: 10.1097/00001622-200205000-00006.","Rini BI","Curr Opin Oncol","2002","2002/05/01","","","10.1097/00001622-200205000-00006"
"12735502","When to biopsy and when to stop biopsying","Djavan B, Remzi M, Marberger M.","Urol Clin North Am. 2003 May;30(2):253-62, viii. doi: 10.1016/s0094-0143(02)00188-x.","Djavan B","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00188-x"
"21830973","Early prostate cancer--treat or watch?","Shigeta K, Naito Y, Takano T.","N Engl J Med. 2011 Aug 11;365(6):568-9. doi: 10.1056/NEJMc1106325.","Shigeta K","N Engl J Med","2011","2011/08/12","","","10.1056/NEJMc1106325"
"12544552","Patient and community preferences for outcomes in prostate cancer: implications for clinical policy","Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, Trachtenberg J, Naglie G.","Med Care. 2003 Jan;41(1):153-64. doi: 10.1097/00005650-200301000-00017.","Krahn M","Med Care","2003","2003/01/25","","","10.1097/00005650-200301000-00017"
"19626653","Partnership and outcomes in men with prostate cancer","Bergman J, Gore JL, Saigal CS, Kwan L, Litwin MS.","Cancer. 2009 Oct 15;115(20):4688-94. doi: 10.1002/cncr.24544.","Bergman J","Cancer","2009","2009/07/24","","","10.1002/cncr.24544"
"24402967","Growth factor and signaling pathways and their relevance to prostate cancer therapeutics","Wozney JL, Antonarakis ES.","Cancer Metastasis Rev. 2014 Sep;33(2-3):581-94. doi: 10.1007/s10555-013-9475-z.","Wozney JL","Cancer Metastasis Rev","2014","2014/01/10","PMC4090293","NIHMS571657","10.1007/s10555-013-9475-z"
"1284591","Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer","Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM.","Cancer Epidemiol Biomarkers Prev. 1992 Nov-Dec;1(7):541-5.","Vijayakumar S","Cancer Epidemiol Biomarkers Prev","1992","1992/11/01","","",""
"29169847","Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis","Gordon LG, Tuffaha HW, James R, Keller AT, Lowe A, Scuffham PA, Gardiner RA.","Urol Oncol. 2018 Mar;36(3):91.e7-91.e15. doi: 10.1016/j.urolonc.2017.10.024. Epub 2017 Nov 21.","Gordon LG","Urol Oncol","2018","2017/11/25","","","10.1016/j.urolonc.2017.10.024"
"19535293","Men's experience of their life situation when diagnosed with advanced prostate cancer","Jonsson A, Aus G, Berterö C.","Eur J Oncol Nurs. 2009 Sep;13(4):268-73. doi: 10.1016/j.ejon.2009.02.006. Epub 2009 Jun 16.","Jonsson A","Eur J Oncol Nurs","2009","2009/06/19","","","10.1016/j.ejon.2009.02.006"
"15195122","What's hot in the prostate?","Belldegrun A.","Prostate Cancer Prostatic Dis. 2002;5(1):2-5. doi: 10.1038/sj.pcan.4500576.","Belldegrun A","Prostate Cancer Prostatic Dis","2002","2004/06/15","","","10.1038/sj.pcan.4500576"
"28901630","Role of robot-assisted radical prostatectomy in locally advanced prostate cancer","Saika T, Miura N, Fukumoto T, Yanagihara Y, Miyauchi Y, Kikugawa T.","Int J Urol. 2018 Jan;25(1):30-35. doi: 10.1111/iju.13441. Epub 2017 Sep 13.","Saika T","Int J Urol","2018","2017/09/14","","","10.1111/iju.13441"
"16211683","Men in relationships fare better after prostate cancer treatment","","Health News. 2005 Sep;11(9):9.","","Health News","2005","2005/10/08","","",""
"31260412","N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, Hwang I, Bagadion AM, Sboner A, Elemento O, Paik J, Yu J, Barbieri CE, Dephoure N, Beltran H, Rickman DS.","J Clin Invest. 2019 Jul 1;129(9):3924-3940. doi: 10.1172/JCI127961.","Berger A","J Clin Invest","2019","2019/07/02","PMC6715370","","10.1172/JCI127961"
"26699831","Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base","Amini A, Rusthoven CG, Jones BL, Armstrong H, Raben D, Kavanagh BD.","Urol Oncol. 2016 Apr;34(4):165.e1-9. doi: 10.1016/j.urolonc.2015.11.004. Epub 2015 Dec 11.","Amini A","Urol Oncol","2016","2015/12/25","","","10.1016/j.urolonc.2015.11.004"
"24024652","Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer","Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M.","Expert Opin Investig Drugs. 2013 Nov;22(11):1385-400. doi: 10.1517/13543784.2013.824422. Epub 2013 Sep 12.","Msaouel P","Expert Opin Investig Drugs","2013","2013/09/13","","","10.1517/13543784.2013.824422"
"8853481","Facing the challenge of prostate cancer: the family physician's perspective","Owen G.","Can J Oncol. 1994 Nov;4 Suppl 1:13.","Owen G","Can J Oncol","1994","1994/11/01","","",""
"18214059","Omission of lymphadenectomy in low risk prostate cancer","Naselli A, Andreatta R, Introini C, Fontana V, Puppo P.","Anticancer Res. 2007 Nov-Dec;27(6C):4451-6.","Naselli A","Anticancer Res","2007","2008/01/25","","",""
"19286304","Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications","Albertson PC.","Eur Urol. 2009 Jun;55(6):1331-2. doi: 10.1016/j.eururo.2009.02.029. Epub 2009 Mar 6.","Albertson PC","Eur Urol","2009","2009/03/17","","","10.1016/j.eururo.2009.02.029"
"7678866","International group aims for guidelines for BPH and prostate cancer","Vanchieri C.","J Natl Cancer Inst. 1993 Feb 17;85(4):267-8. doi: 10.1093/jnci/85.4.267.","Vanchieri C","J Natl Cancer Inst","1993","1993/02/17","","","10.1093/jnci/85.4.267"
"21943975","Novel treatments for castration-resistant prostate cancer","Sternberg CN.","Eur J Cancer. 2011 Sep;47 Suppl 3:S195-9. doi: 10.1016/S0959-8049(11)70165-4.","Sternberg CN","Eur J Cancer","2011","2011/09/28","","","10.1016/S0959-8049(11)70165-4"
"11121224","Molecular and genetic mechanisms of prostate cancer","Rhim JS.","Radiat Res. 2001 Jan;155(1 Pt 2):128-132. doi: 10.1667/0033-7587(2001)155[0128:magmop]2.0.co;2.","Rhim JS","Radiat Res","2001","2000/12/20","","","10.1667/0033-7587(2001)155[0128:magmop]2.0.co;2"
"17084164","Management of locally advanced prostate cancer: past, present, future","Swanson GP.","J Urol. 2006 Dec;176(6 Pt 2):S34-41. doi: 10.1016/j.juro.2006.06.079.","Swanson GP","J Urol","2006","2006/11/07","","","10.1016/j.juro.2006.06.079"
"21601982","The contemporary concept of significant versus insignificant prostate cancer","Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH.","Eur Urol. 2011 Aug;60(2):291-303. doi: 10.1016/j.eururo.2011.05.006. Epub 2011 May 17.","Ploussard G","Eur Urol","2011","2011/05/24","","","10.1016/j.eururo.2011.05.006"
"23733712","Association between exercise and primary incidence of prostate cancer: does race matter?","Kaufman JS.","Cancer. 2013 Sep 1;119(17):3251. doi: 10.1002/cncr.28179. Epub 2013 Jun 3.","Kaufman JS","Cancer","2013","2013/06/05","","","10.1002/cncr.28179"
"19838047","A genomic strategy for predicting androgen receptor activity in prostate tumors","Jonsson JG, Sissung TM, Figg WD.","Cancer Biol Ther. 2009 Nov;8(21):2002-3. doi: 10.4161/cbt.8.21.10180. Epub 2009 Nov 25.","Jonsson JG","Cancer Biol Ther","2009","2009/10/20","","","10.4161/cbt.8.21.10180"
"9269268","Phytoestrogens and prostate cancer: possible preventive role","Stephens FO.","Med J Aust. 1997 Aug 4;167(3):138-40.","Stephens FO","Med J Aust","1997","1997/08/04","","",""
"9738581","Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer","Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O.","J Clin Oncol. 1998 Sep;16(9):3101-4. doi: 10.1200/JCO.1998.16.9.3101.","Bennett CL","J Clin Oncol","1998","1998/09/17","","","10.1200/JCO.1998.16.9.3101"
"7935999","Prostate cancer. From the general practitioner's point of view","Månsson J, Bengtsson C.","Neoplasma. 1994;41(4):237-40.","Månsson J","Neoplasma","1994","1994/01/01","","",""
"23604966","Imaging treated prostate cancer","De Visschere PJ, Vargas HA, Ost P, De Meerleer GO, Villeirs GM.","Abdom Imaging. 2013 Dec;38(6):1431-46. doi: 10.1007/s00261-013-9998-3.","De Visschere PJ","Abdom Imaging","2013","2013/04/23","","","10.1007/s00261-013-9998-3"
"25363179","Survey of clinical and pathological characteristics and outcomes of patients with prostate cancer","Alizadeh M, Alizadeh S.","Glob J Health Sci. 2014 Sep 18;6(7 Spec No):49-57. doi: 10.5539/gjhs.v6n7p49.","Alizadeh M","Glob J Health Sci","2014","2014/11/04","PMC4796357","","10.5539/gjhs.v6n7p49"
"18842531","Uncertainty after treatment for prostate cancer: definition, assessment, and management","Yu Ko WF, Degner LF.","Clin J Oncol Nurs. 2008 Oct;12(5):749-55. doi: 10.1188/08.CJON.749-755.","Yu Ko WF","Clin J Oncol Nurs","2008","2008/10/10","","","10.1188/08.CJON.749-755"
"26782713","Variation in prostate cancer treatment associated with population density of the county of residence","Cary C, Odisho AY, Cooperberg MR.","Prostate Cancer Prostatic Dis. 2016 Jun;19(2):174-9. doi: 10.1038/pcan.2015.65. Epub 2016 Jan 19.","Cary C","Prostate Cancer Prostatic Dis","2016","2016/01/20","","","10.1038/pcan.2015.65"
"24022845","Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer","Bae H, Yoshida S, Matsuoka Y, Nakajima H, Ito E, Tanaka H, Oya M, Nakayama T, Takeshita H, Kijima T, Ishioka J, Numao N, Koga F, Saito K, Akashi T, Fujii Y, Kihara K.","Int Urol Nephrol. 2014 Mar;46(3):555-61. doi: 10.1007/s11255-013-0557-1.","Bae H","Int Urol Nephrol","2014","2013/09/12","","","10.1007/s11255-013-0557-1"
"19454471","Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up","Horwich A, Parker C, Kataja V; ESMO Guidelines Working Group.","Ann Oncol. 2009 May;20 Suppl 4:76-8. doi: 10.1093/annonc/mdp135.","Horwich A","Ann Oncol","2009","2009/05/21","","","10.1093/annonc/mdp135"
"18184333","Comments on: Saturation biopsy for detecting and characterizing prostate cancer; and A review of targeted screening for prostate cancer: introducing the IMPACT study","Pitt WR.","BJU Int. 2008 Feb;101(3):392. doi: 10.1111/j.1464-410X.2007.07417_1.x.","Pitt WR","BJU Int","2008","2008/01/11","","","10.1111/j.1464-410X.2007.07417_1.x"
"16859581","Development of an integrated prostate cancer research information system","Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.","Clin Genitourin Cancer. 2006 Jun;5(1):61-6. doi: 10.3816/CGC.2006.n.019.","Oh WK","Clin Genitourin Cancer","2006","2006/07/25","","","10.3816/CGC.2006.n.019"
"8824546","A prospective study of smoking and risk of prostate cancer","Adami HO, Bergström R, Engholm G, Nyrén O, Wolk A, Ekbom A, Englund A, Baron J.","Int J Cancer. 1996 Sep 17;67(6):764-8. doi: 10.1002/(SICI)1097-0215(19960917)67:6<764::AID-IJC3>3.0.CO;2-P.","Adami HO","Int J Cancer","1996","1996/09/17","","","10.1002/(SICI)1097-0215(19960917)67:6<764::AID-IJC3>3.0.CO;2-P"
"15726312","[Is the prostate cancer screening behaviour of men with familial predisposition predictable?]","Paiss T, Kahn D, Küfer R, Maier C, Vogel W, Gschwend JE, Hautmann RE, Herkommer K.","Urologe A. 2005 Apr;44(4):387-92. doi: 10.1007/s00120-005-0780-1.","Paiss T","Urologe A","2005","2005/02/24","","","10.1007/s00120-005-0780-1"
"8853490","PSA and early prostate cancer detection: the importance of age-specific reference ranges","Oesterling JE.","Can J Oncol. 1994 Nov;4 Suppl 1:52-6.","Oesterling JE","Can J Oncol","1994","1994/11/01","","",""
"29369565","[Mutational landscape of prostate tumors revealed by whole-exome sequencing]","Gilyazova IR, Yankina MA, Kunsbaeva GB, Klimentova EA, Izmaylov AA, Pavlov VN, Khusnutdinova EK.","Genetika. 2016 Sep;52(9):1103-8.","Gilyazova IR","Genetika","2016","2018/01/26","","",""
"16425987","Prostate cancer therapy with high-intensity focused ultrasound","Gardner TA, Koch MO.","Clin Genitourin Cancer. 2005 Dec;4(3):187-92. doi: 10.3816/CGC.2005.n.031.","Gardner TA","Clin Genitourin Cancer","2005","2006/01/24","","","10.3816/CGC.2005.n.031"
"22273756","Focal therapy for the treatment of localized prostate cancer: a potential therapeutic paradigm shift awaiting better imaging","Ward JF 3rd, Rewcastle JC, Ukimura O, Gill IS.","Curr Opin Urol. 2012 Mar;22(2):104-8. doi: 10.1097/MOU.0b013e3283501813.","Ward JF 3rd","Curr Opin Urol","2012","2012/01/26","","","10.1097/MOU.0b013e3283501813"
"11769471","[Prostate cancer]","Tanikawa T.","Rinsho Byori. 2001 Oct;49(10):955-62.","Tanikawa T","Rinsho Byori","2001","2002/01/05","","",""
"21690487","Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data","Vickers AJ.","J Natl Cancer Inst. 2011 Jul 20;103(14):1134; author reply 1134-5. doi: 10.1093/jnci/djr208. Epub 2011 Jun 20.","Vickers AJ","J Natl Cancer Inst","2011","2011/06/22","","","10.1093/jnci/djr208"
"24589461","Perspectives on the clinical management of localized prostate cancer","Nelson JB.","Asian J Androl. 2014 Jul-Aug;16(4):511-4. doi: 10.4103/1008-682X.123672.","Nelson JB","Asian J Androl","2014","2014/03/05","PMC4104072","","10.4103/1008-682X.123672"
"9333266","Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus","Grönberg H, Isaacs SD, Smith JR, Carpten JD, Bova GS, Freije D, Xu J, Meyers DA, Collins FS, Trent JM, Walsh PC, Isaacs WB.","JAMA. 1997 Oct 15;278(15):1251-5. doi: 10.1001/jama.1997.03550150055035.","Grönberg H","JAMA","1997","1997/10/23","","","10.1001/jama.1997.03550150055035"
"20964854","CIP2A expression is increased in prostate cancer","Vaarala MH, Väisänen MR, Ristimäki A.","J Exp Clin Cancer Res. 2010 Oct 21;29(1):136. doi: 10.1186/1756-9966-29-136.","Vaarala MH","J Exp Clin Cancer Res","2010","2010/10/23","PMC2984408","","10.1186/1756-9966-29-136"
"26394786","Is scintigraphy necessary to detect migration of 125I seeds after brachytherapy for early prostate cancer?","Odagaki Y, Ohori M, Yoshimura M, Nakshima J, Ohno Y, Mikami R, Nakayama H, Tokuuye K, Tachibana M.","Int J Clin Oncol. 2016 Apr;21(2):397-401. doi: 10.1007/s10147-015-0901-9. Epub 2015 Sep 22.","Odagaki Y","Int J Clin Oncol","2016","2015/09/24","","","10.1007/s10147-015-0901-9"
"7528825","[Tumor marker in prostate cancer]","Arai Y.","Nihon Hinyokika Gakkai Zasshi. 1994 Nov;85(11):1575-92. doi: 10.5980/jpnjurol1989.85.1575.","Arai Y","Nihon Hinyokika Gakkai Zasshi","1994","1994/11/01","","","10.5980/jpnjurol1989.85.1575"
"27171855","Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012","Baker BR, Basak R, Mohiuddin JJ, Chen RC.","Cancer. 2016 Jul 15;122(14):2234-41. doi: 10.1002/cncr.30034. Epub 2016 May 12.","Baker BR","Cancer","2016","2016/05/13","","","10.1002/cncr.30034"
"23052374","Potentially clinically relevant prostate cancer is found more frequently after complete than after partial histopathological processing of radical cystoprostatectomy specimens","Fritsche HM, Aziz A, Eder F, Otto W, Denzinger S, Wieland WF, May M, Hofstädter F, Hartmann A, Burger M.","Virchows Arch. 2012 Dec;461(6):655-61. doi: 10.1007/s00428-012-1328-6. Epub 2012 Oct 9.","Fritsche HM","Virchows Arch","2012","2012/10/12","","","10.1007/s00428-012-1328-6"
"16679853","Evidence-based medicine in prostate cancer: where do we stand in 2006?","Dahm P.","Curr Opin Urol. 2006 May;16(3):162-7. doi: 10.1097/01.mou.0000193395.00340.3e.","Dahm P","Curr Opin Urol","2006","2006/05/09","","","10.1097/01.mou.0000193395.00340.3e"
"25154914","Serum tri- and tetra-antennary N-glycan is a potential predictive biomarker for castration-resistant prostate cancer","Ishibashi Y, Tobisawa Y, Hatakeyama S, Ohashi T, Tanaka M, Narita S, Koie T, Habuchi T, Nishimura S, Ohyama C, Yoneyama T.","Prostate. 2014 Nov;74(15):1521-9. doi: 10.1002/pros.22869. Epub 2014 Aug 23.","Ishibashi Y","Prostate","2014","2014/08/27","","","10.1002/pros.22869"
"20117879","Molecular and traditional chemotherapy: a united front against prostate cancer","Singh P, Yam M, Russell PJ, Khatri A.","Cancer Lett. 2010 Jul 1;293(1):1-14. doi: 10.1016/j.canlet.2009.11.019. Epub 2010 Feb 1.","Singh P","Cancer Lett","2010","2010/02/02","","","10.1016/j.canlet.2009.11.019"
"15279683","Stem cells and prostate cancer","Sartor O, Koochekpour S.","Clin Prostate Cancer. 2004 Jun;3(1):11-2. doi: 10.3816/cgc.2004.n.007.","Sartor O","Clin Prostate Cancer","2004","2004/07/29","","","10.3816/cgc.2004.n.007"
"20406916","Active surveillance for prostate cancer: has the time finally come?","Aragon-Ching JB.","J Clin Oncol. 2010 Jun 1;28(16):e265-6; author reply e267. doi: 10.1200/JCO.2010.28.1584. Epub 2010 Apr 20.","Aragon-Ching JB","J Clin Oncol","2010","2010/04/22","","","10.1200/JCO.2010.28.1584"
"24094418","Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years","Kavasmaa OT, Tyomkin DB, Mehik A, Parpala TM, Tonttila P, Paananen I, Kunelius P, Vaarala MH, Ohtonen P, Hellström PA.","World J Surg Oncol. 2013 Oct 5;11:258. doi: 10.1186/1477-7819-11-258.","Kavasmaa OT","World J Surg Oncol","2013","2013/10/08","PMC3851745","","10.1186/1477-7819-11-258"
"27769959","More men with low risk prostate cancer are opting for active surveillance, study finds","","BMJ. 2016 Oct 20;355:i5688. doi: 10.1136/bmj.i5688.","","BMJ","2016","2016/10/23","","","10.1136/bmj.i5688"
"19195118","[Topics of prostate cancer]","Tomida K.","Gan To Kagaku Ryoho. 2009 Jan;36(1):43-6.","Tomida K","Gan To Kagaku Ryoho","2009","2009/02/07","","",""
"25280282","Re: cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database","Taneja SS.","J Urol. 2014 Jun;191(6):1784. doi: 10.1016/j.juro.2014.03.065. Epub 2014 Mar 20.","Taneja SS","J Urol","2014","2014/10/04","","","10.1016/j.juro.2014.03.065"
"23977761","N+, M0 prostate cancer: local therapy for systemic disease","Messing EM.","Oncology (Williston Park). 2013 Jul;27(7):661-2, 668.","Messing EM","Oncology (Williston Park)","2013","2013/08/28","","",""
"26116413","Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy","Vlaeminck-Guillem V.","Urol Oncol. 2015 Nov;33(11):498. doi: 10.1016/j.urolonc.2015.05.027. Epub 2015 Jun 23.","Vlaeminck-Guillem V","Urol Oncol","2015","2015/06/28","","","10.1016/j.urolonc.2015.05.027"
"10749945","Biopsychosocial aspects of prostate cancer","Kunkel EJ, Bakker JR, Myers RE, Oyesanmi O, Gomella LG.","Psychosomatics. 2000 Mar-Apr;41(2):85-94. doi: 10.1176/appi.psy.41.2.85.","Kunkel EJ","Psychosomatics","2000","2000/04/06","","","10.1176/appi.psy.41.2.85"
"17286752","Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention","Tam CW, Mo CW, Yao KM, Shiu SY.","J Pineal Res. 2007 Mar;42(2):191-202. doi: 10.1111/j.1600-079X.2006.00406.x.","Tam CW","J Pineal Res","2007","2007/02/09","","","10.1111/j.1600-079X.2006.00406.x"
"748795","Cryosurgery in prostate carcinoma: clinical evidence of immunostimulation of host versus tumor","Gonder MJ.","Natl Cancer Inst Monogr. 1978 Dec;(49):369.","Gonder MJ","Natl Cancer Inst Monogr","1978","1978/12/01","","",""
"15808952","Screening for prostate cancer","Postma R, Schröder FH.","Eur J Cancer. 2005 Apr;41(6):825-33. doi: 10.1016/j.ejca.2004.12.029.","Postma R","Eur J Cancer","2005","2005/04/06","","","10.1016/j.ejca.2004.12.029"
"9563121","[What is the value of radical prostatectomy in lymph node positive prostate carcinoma?]","Huland H.","Urologe A. 1998 Mar;37(2):138-40. doi: 10.1007/s001200050160.","Huland H","Urologe A","1998","1998/05/01","","","10.1007/s001200050160"
"9661908","The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer","Naitoh J, Witte O, Belldegrun A.","Cancer Res. 1998 Jul 1;58(13):2895-900.","Naitoh J","Cancer Res","1998","1998/07/14","","",""
"14594683","Prostate cancer--prevalence-based healthcare costs","Norlund A, Alvegård T, Lithman T, Merlo J, Noreen D.","Scand J Urol Nephrol. 2003;37(5):371-5. doi: 10.1080/00365590310006228.","Norlund A","Scand J Urol Nephrol","2003","2003/11/05","","","10.1080/00365590310006228"
"27807103","Radiation Therapy Advances for Prostate Cancer","","Cancer Discov. 2016 Nov;6(11):OF1. doi: 10.1158/2159-8290.CD-NB2016-123. Epub 2016 Oct 7.","","Cancer Discov","2016","2016/11/04","","","10.1158/2159-8290.CD-NB2016-123"
"23295236","Prostate cancer in 2012: Paradigm shifts in prostate cancer diagnosis and treatment","Hoag NA, Goldenberg SL.","Nat Rev Urol. 2013 Feb;10(2):69-70. doi: 10.1038/nrurol.2012.251. Epub 2013 Jan 8.","Hoag NA","Nat Rev Urol","2013","2013/01/09","","","10.1038/nrurol.2012.251"
"27892740","How can plasma RNA be used to diagnose prostate cancer?","Shi X, Ren S, Sun Y.","Expert Rev Anticancer Ther. 2017 Jan;17(1):5-7. doi: 10.1080/14737140.2017.1266262. Epub 2016 Dec 10.","Shi X","Expert Rev Anticancer Ther","2017","2016/11/29","","","10.1080/14737140.2017.1266262"
"20812046","[Prostate cancer: an update]","Hohenfellner M.","Urologe A. 2010 Sep;49 Suppl 1:169-71. doi: 10.1007/s00120-010-2376-7.","Hohenfellner M","Urologe A","2010","2010/09/03","","","10.1007/s00120-010-2376-7"
"16218532","[Tissue microarray--an infrastructure for prostate cancer outcome research]","Zisman A, Rozin LS, Stav K, Merded H, Lindner A, Sandbank J.","Harefuah. 2005 Sep;144(9):622-5; 677.","Zisman A","Harefuah","2005","2005/10/13","","",""
"11828355","Web resources for patients with prostate cancer: a starting point","Lipp ER.","Semin Urol Oncol. 2002 Feb;20(1):32-8. doi: 10.1053/suro.2002.30396.","Lipp ER","Semin Urol Oncol","2002","2002/02/06","","","10.1053/suro.2002.30396"
"21720836","[Benefit assessment by the Federal Joint Committee: assessment of treatment strategies for low risk prostate cancer]","Schmedders M, Janatzek S, Zimmer B.","Urologe A. 2011 Aug;50(8):938-43. doi: 10.1007/s00120-011-2545-3.","Schmedders M","Urologe A","2011","2011/07/02","","","10.1007/s00120-011-2545-3"
"11461173","A bridge between neuroscience and oncology: prostate cancer genesis. A 'negative' consequence of learning?","Zermann DH, Ishigooka M, Schmidt RA.","Med Hypotheses. 2001 Aug;57(2):201-6. doi: 10.1054/mehy.2000.1294.","Zermann DH","Med Hypotheses","2001","2001/07/20","","","10.1054/mehy.2000.1294"
"9474178","Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen","Lodding P, Aus G, Bergdahl S, Frösing R, Lilja H, Pihl CG, Hugosson J.","J Urol. 1998 Mar;159(3):899-903.","Lodding P","J Urol","1998","1998/02/25","","",""
"15187059","Waiting time in prostate cancer","Neugut AI, Grann VR.","JAMA. 2004 Jun 9;291(22):2757-8. doi: 10.1001/jama.291.22.2757.","Neugut AI","JAMA","2004","2004/06/10","","","10.1001/jama.291.22.2757"
"15296564","Symptomatic diagnosis of prostate cancer in primary care: a structured review","Hamilton W, Sharp D.","Br J Gen Pract. 2004 Aug;54(505):617-21.","Hamilton W","Br J Gen Pract","2004","2004/08/07","PMC1324845","",""
"9750508","[Diagnosis of organ-confined prostate cancer by systematic biopsy under guidance of TRUS]","Gohji K, Fujii A.","Nihon Rinsho. 1998 Aug;56(8):2062-6.","Gohji K","Nihon Rinsho","1998","1998/09/29","","",""
"10022701","Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer","Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H.","J Urol. 1999 Mar;161(3):857-62; discussion 862-3.","Amling CL","J Urol","1999","1999/02/18","","",""
"23311087","Men's decision-making for prostate cancer treatment","Budden L.","Aust Nurs J. 2012 Nov;20(5):50-1.","Budden L","Aust Nurs J","2012","2013/01/15","","",""
"11828351","Prostate cancer and the educated consumer","Uzzo RG, Wei JT.","Semin Urol Oncol. 2002 Feb;20(1):1-2. doi: 10.1053/suro.2002.30386.","Uzzo RG","Semin Urol Oncol","2002","2002/02/06","","","10.1053/suro.2002.30386"
"3309988","Management of stage A-2 prostate cancer","Gibbons RP.","Prog Clin Biol Res. 1987;243B:333-8.","Gibbons RP","Prog Clin Biol Res","1987","1987/01/01","","",""
"24563422","Genetic tests could detect high risk of aggressive prostate cancer","Hawkes N.","BMJ. 2014 Feb 20;348:g1700. doi: 10.1136/bmj.g1700.","Hawkes N","BMJ","2014","2014/02/25","","","10.1136/bmj.g1700"
"23747895","The role of BRCA1 and BRCA2 in prostate cancer","Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA.","Front Biosci (Landmark Ed). 2013 Jun 1;18:1445-59. doi: 10.2741/4191.","Li D","Front Biosci (Landmark Ed)","2013","2013/06/11","","","10.2741/4191"
"14999233","Molecular biology of prostate cancer","Karayi MK, Markham AF.","Prostate Cancer Prostatic Dis. 2004;7(1):6-20. doi: 10.1038/sj.pcan.4500697.","Karayi MK","Prostate Cancer Prostatic Dis","2004","2004/03/05","","","10.1038/sj.pcan.4500697"
"30105573","Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation","Xu L, Pachynski RK.","Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7.","Xu L","Curr Urol Rep","2018","2018/08/15","","","10.1007/s11934-018-0835-7"
"10225698","Long-term treatment results of elderly patients with prostate cancer in Japan: an analysis of prognostic factors","Kanamaru H, Arai Y, Akino H, Suzuki Y, Oyama N, Yoshida H, Okada K.","Jpn J Clin Oncol. 1999 Mar;29(3):151-5. doi: 10.1093/jjco/29.3.151.","Kanamaru H","Jpn J Clin Oncol","1999","1999/05/04","","","10.1093/jjco/29.3.151"
"11002455","Primary care perspective of prostate cancer screening after national guidance: a questionnaire survey","Kalsi GS, Rajaratnam G, Bridgman SA.","J Med Screen. 2000;7(2):116-7. doi: 10.1136/jms.7.2.116.","Kalsi GS","J Med Screen","2000","2000/09/26","","","10.1136/jms.7.2.116"
"23689767","""The older, the wiser"" in prostate cancer treatment choices?","Repetto L, Abbatecola AM, Paolisso G.","Ann Intern Med. 2013 May 21;158(10):772-3. doi: 10.7326/0003-4819-158-10-201305210-00013.","Repetto L","Ann Intern Med","2013","2013/05/22","","","10.7326/0003-4819-158-10-201305210-00013"
"30039761","Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions","Tran LNK, Kichenadasse G, Sykes PJ.","Curr Cancer Drug Targets. 2019;19(5):368-381. doi: 10.2174/1568009618666180724111604.","Tran LNK","Curr Cancer Drug Targets","2019","2018/07/25","","","10.2174/1568009618666180724111604"
"20823333","Prediction of a gene regulatory network linked to prostate cancer from gene expression, microRNA and clinical data","Bonnet E, Michoel T, Van de Peer Y.","Bioinformatics. 2010 Sep 15;26(18):i638-44. doi: 10.1093/bioinformatics/btq395.","Bonnet E","Bioinformatics","2010","2010/09/09","PMC2935430","","10.1093/bioinformatics/btq395"
"24188260","Management of hormone-sensitive metastatic prostate cancer","Agarwal N, Hussain M.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1221-41, viii. doi: 10.1016/j.hoc.2013.08.007. Epub 2013 Sep 21.","Agarwal N","Hematol Oncol Clin North Am","2013","2013/11/06","","","10.1016/j.hoc.2013.08.007"
"9397195","Heredity and prostate cancer: a study of World War II veteran twins","Page WF, Braun MM, Partin AW, Caporaso N, Walsh P.","Prostate. 1997 Dec 1;33(4):240-5. doi: 10.1002/(sici)1097-0045(19971201)33:4<240::aid-pros3>3.0.co;2-l.","Page WF","Prostate","1997","1997/12/16","","","10.1002/(sici)1097-0045(19971201)33:4<240::aid-pros3>3.0.co;2-l"
"10812902","Prostate cancer: correlation between local and systemic disease","Marzi M, Rosi P, Mearini E, Bracarda S, Cesaroni S, Porena M.","Minerva Urol Nefrol. 1999 Dec;51(4):187-90.","Marzi M","Minerva Urol Nefrol","1999","2000/05/17","","",""
"29730201","Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens","Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.","J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3.","Crawford ED","J Urol","2018","2018/05/07","","","10.1016/j.juro.2018.04.083"
"23880604","Highlights in advanced prostate cancer from the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium","","Clin Adv Hematol Oncol. 2013 Apr;11(4 Suppl 7):1-22.","","Clin Adv Hematol Oncol","2013","2013/07/25","","",""
"10664673","New treatment strategies in advanced prostate cancer","Small EJ, Reese DM.","Radiol Clin North Am. 2000 Jan;38(1):203-11, ix-x. doi: 10.1016/s0033-8389(05)70156-1.","Small EJ","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70156-1"
"15000300","[Management of bladder cancer associated with prostate cancer]","Bonnal JL, Irani J, Maidenberg M, Théodore C, Mauroy B.","Prog Urol. 2003 Dec;13(6):1286-9.","Bonnal JL","Prog Urol","2003","2004/03/06","","",""
"11388028","[Can we prevent prostatic cancer: role of nutrition?]","Zlotta AR, Ekane S, Schulman CC.","Rev Med Brux. 2001 Apr;22(2):87-92.","Zlotta AR","Rev Med Brux","2001","2001/06/05","","",""
"29633942","[New conceptual framework in advanced prostate cancer.]","Miñana López B.","Arch Esp Urol. 2018 Mar;71(3):227-230.","Miñana López B","Arch Esp Urol","2018","2018/04/11","","",""
"22464995","Imaging techniques for local recurrence of prostate cancer: for whom, why and how?","Rouvière O.","Diagn Interv Imaging. 2012 Apr;93(4):279-90. doi: 10.1016/j.diii.2012.01.012. Epub 2012 Mar 30.","Rouvière O","Diagn Interv Imaging","2012","2012/04/03","","","10.1016/j.diii.2012.01.012"
"16705215","Prostate cancer detection rate in patients with obstructive voiding symptoms by sextant biopsy: preliminary results","Kiknavelidze K, Tsintsadze O, Goguadze M, Pertia A, Managadze L.","Georgian Med News. 2006 Apr;(133):9-14.","Kiknavelidze K","Georgian Med News","2006","2006/05/18","","",""
"24595118","Prostate cancer in Asian men","Ito K.","Nat Rev Urol. 2014 Apr;11(4):197-212. doi: 10.1038/nrurol.2014.42. Epub 2014 Mar 4.","Ito K","Nat Rev Urol","2014","2014/03/06","","","10.1038/nrurol.2014.42"
"28831710","Intervention for patient reported urinary symptoms in prostate cancer survivors: Systematic review","Kim K, Kim JS.","J Cancer Surviv. 2017 Oct;11(5):643-654. doi: 10.1007/s11764-017-0637-9. Epub 2017 Aug 22.","Kim K","J Cancer Surviv","2017","2017/08/24","","","10.1007/s11764-017-0637-9"
"20977596","Can lifestyle modification lower the risk of prostate cancer?","Chukwura Mgbakor A, Ogbonna AO.","BJU Int. 2010 Nov;106(10):1555-6. doi: 10.1111/j.1464-410X.2010.09915_2.x.","Chukwura Mgbakor A","BJU Int","2010","2010/10/28","","","10.1111/j.1464-410X.2010.09915_2.x"
"18801276","NICE prostate cancer clinical guideline: implications for primary care","Neal RD.","Br J Gen Pract. 2008 Sep;58(554):607-8. doi: 10.3399/bjgp08X330708.","Neal RD","Br J Gen Pract","2008","2008/09/20","PMC2529196","","10.3399/bjgp08X330708"
"25242417","Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer","Kuo KF, Hunter-Merrill R, Gulati R, Hall SP, Gambol TE, Higano CS, Yu EY.","Clin Genitourin Cancer. 2015 Feb;13(1):10-6. doi: 10.1016/j.clgc.2014.08.003. Epub 2014 Aug 10.","Kuo KF","Clin Genitourin Cancer","2015","2014/09/23","PMC4289425","NIHMS629851","10.1016/j.clgc.2014.08.003"
"20846264","Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors","Ali A, Furusato B, Ts'o PO, Lum ZP, Elsamanoudi S, Mohamed A, Srivastava S, Moul JW, Brassell SA, Sesterhenn IA, McLeod DG.","Pathol Int. 2010 Oct;60(10):667-72. doi: 10.1111/j.1440-1827.2010.02584.x.","Ali A","Pathol Int","2010","2010/09/18","","","10.1111/j.1440-1827.2010.02584.x"
"29146441","Combining immunotherapies for the treatment of prostate cancer","Redman JM, Gulley JL, Madan RA.","Urol Oncol. 2017 Dec;35(12):694-700. doi: 10.1016/j.urolonc.2017.09.024.","Redman JM","Urol Oncol","2017","2017/11/18","PMC6599516","NIHMS1037827","10.1016/j.urolonc.2017.09.024"
"1705732","Early detection program for prostate cancer: results and identification of high-risk patient population","Babaian RJ, Miyashita H, Evans RB, von Eschenbach AC, Ramirez EI.","Urology. 1991 Mar;37(3):193-7. doi: 10.1016/0090-4295(91)80283-d.","Babaian RJ","Urology","1991","1991/03/01","","","10.1016/0090-4295(91)80283-d"
"10363084","Minimal requirements in prostate cancer irradiation: a consensus document by the AIRO Lombardia Cooperative Group","Valdagni R, Bertoni F, Bossi A, Caraffini B, Corbella F, Italia C, Källi M, Leoni M, Nava S, Sarti E, Vavassori V, Villa S.","Tumori. 1999 Mar-Apr;85(2):143-8.","Valdagni R","Tumori","1999","1999/06/11","","",""
"30130546","Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is Not Informative","Loughlin KR.","J Urol. 2019 Jan;201(1):40-41. doi: 10.1016/j.juro.2018.08.042.","Loughlin KR","J Urol","2019","2018/08/22","","","10.1016/j.juro.2018.08.042"
"23609846","Prostate cancer: plasma whole-genome sequencing put to the test","Razzak M.","Nat Rev Urol. 2013 Jun;10(6):309. doi: 10.1038/nrurol.2013.94. Epub 2013 Apr 23.","Razzak M","Nat Rev Urol","2013","2013/04/24","","","10.1038/nrurol.2013.94"
"19787636","Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis","Rapiti E, Fioretta G, Schaffar R, Neyroud-Caspar I, Verkooijen HM, Schmidlin F, Miralbell R, Zanetti R, Bouchardy C.","Cancer. 2009 Dec 1;115(23):5556-65. doi: 10.1002/cncr.24607.","Rapiti E","Cancer","2009","2009/09/30","","","10.1002/cncr.24607"
"17088928","Technology insight: radioguided sentinel lymph node dissection in the staging of prostate cancer","Beri A, Janetschek G.","Nat Clin Pract Urol. 2006 Nov;3(11):602-10. doi: 10.1038/ncpuro0625.","Beri A","Nat Clin Pract Urol","2006","2006/11/08","","","10.1038/ncpuro0625"
"9207958","Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens","Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, Sesterhenn IA.","Prostate. 1997 Jun 15;32(1):59-64. doi: 10.1002/(sici)1097-0045(19970615)32:1<59::aid-pros8>3.0.co;2-7.","Douglas TH","Prostate","1997","1997/06/15","","","10.1002/(sici)1097-0045(19970615)32:1<59::aid-pros8>3.0.co;2-7"
"15882708","Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients","Stranne J, Hugosson J, Iversen P, Morris T, Lodding P.","Urology. 2005 May;65(5):847-51. doi: 10.1016/j.urology.2004.11.014.","Stranne J","Urology","2005","2005/05/11","","","10.1016/j.urology.2004.11.014"
"27872477","The role of GATA2 in lethal prostate cancer aggressiveness","Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J.","Nat Rev Urol. 2017 Jan;14(1):38-48. doi: 10.1038/nrurol.2016.225. Epub 2016 Nov 22.","Rodriguez-Bravo V","Nat Rev Urol","2017","2016/11/23","PMC5489122","NIHMS868937","10.1038/nrurol.2016.225"
"12230617","Clinical oncologists favour radical radiotherapy for localized prostate cancer: a questionnaire survey","Hanna CL, Mason MD, Donovan JL, Barber JP.","BJU Int. 2002 Oct;90(6):558-60. doi: 10.1046/j.1464-410x.2002.02970.x.","Hanna CL","BJU Int","2002","2002/09/17","","","10.1046/j.1464-410x.2002.02970.x"
"8865481","Management of stage T1a prostate cancer","Lowe BA.","Semin Urol Oncol. 1996 Aug;14(3):178-82.","Lowe BA","Semin Urol Oncol","1996","1996/08/01","","",""
"17823988","Prostate cancer update: advances in disease management over the past 20 years. Proceedings of a meeting. September 2006. Budapest, Hungary","","BJU Int. 2007 Jul;100 Suppl 2:1-62.","","BJU Int","2007","2007/09/08","","",""
"10710898","Prostate cancer: an overview","Bissada NK.","J S C Med Assoc. 2000 Feb;96(2):52.","Bissada NK","J S C Med Assoc","2000","2000/03/11","","",""
"9120956","Re: Letters to the editor on long-term survival and mortality in prostate cancer treated with noncurative intent","Lawrence G.","J Urol. 1997 Apr;157(4):1372-3. doi: 10.1016/s0022-5347(01)64991-7.","Lawrence G","J Urol","1997","1997/04/01","","","10.1016/s0022-5347(01)64991-7"
"12236836","An evaluation of the Man to Man self-help group in Colorado and Utah","Smith RL, Crane LA, Byers T, Nelson-Marten P.","Cancer Pract. 2002 Sep-Oct;10(5):234-9. doi: 10.1046/j.1523-5394.2002.105002.x.","Smith RL","Cancer Pract","2002","2002/09/19","","","10.1046/j.1523-5394.2002.105002.x"
"27191936","Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer","Falchook AD, Basak R, Mohiuddin JJ, Chen RC.","Cancer. 2016 Aug 1;122(15):2341-9. doi: 10.1002/cncr.30049. Epub 2016 May 18.","Falchook AD","Cancer","2016","2016/05/19","","","10.1002/cncr.30049"
"12750799","[Molecular diagnostics of prostate cancer]","Kamradt J, Stöckle M, Wullich B.","Urologe A. 2003 May;42(5):641-9. doi: 10.1007/s00120-003-0346-z. Epub 2003 Apr 3.","Kamradt J","Urologe A","2003","2003/05/17","","","10.1007/s00120-003-0346-z"
"22018403","Prostate cancer overview","Dunn MW, Kazer MW.","Semin Oncol Nurs. 2011 Nov;27(4):241-50. doi: 10.1016/j.soncn.2011.07.002.","Dunn MW","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.002"
"15103922","[Mass screening for prostate cancer in Tokushima City: the results of 2001]","Kanayama HO, Kagawa S, Utsunomiya M, Kawashima S, Takehisa I, Sumitani H, Yokozeki H.","Nihon Hinyokika Gakkai Zasshi. 2004 Mar;95(3):596-603. doi: 10.5980/jpnjurol1989.95.596.","Kanayama HO","Nihon Hinyokika Gakkai Zasshi","2004","2004/04/24","","","10.5980/jpnjurol1989.95.596"
"20724727","Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma","Thompson IM, Ankerst DP, Tangen CM.","J Natl Cancer Inst. 2010 Sep 8;102(17):1299-301. doi: 10.1093/jnci/djq313. Epub 2010 Aug 19.","Thompson IM","J Natl Cancer Inst","2010","2010/08/21","PMC2935478","","10.1093/jnci/djq313"
"21717899","Benefits and pitfalls of prostate cancer screening: ""no proof of benefit"" does not equal ""proof of no benefit""","Chen CP, Staggers FE, Roach M 3rd.","Oncology (Williston Park). 2011 May;25(6):466, 468.","Chen CP","Oncology (Williston Park)","2011","2011/07/02","","",""
"23592290","[Prostate cancer: large PREFERE Study evaluates therapies]","","Aktuelle Urol. 2013 Mar;44(2):105. doi: 10.1055/s-0033-1343926. Epub 2013 Apr 16.","","Aktuelle Urol","2013","2013/04/18","","","10.1055/s-0033-1343926"
"19451000","Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer?","Mayes JM, Mouraviev V, Sun L, Tsivian M, Madden JF, Polascik TJ.","Urol Oncol. 2011 Mar-Apr;29(2):166-70. doi: 10.1016/j.urolonc.2009.03.011. Epub 2009 May 17.","Mayes JM","Urol Oncol","2011","2009/05/20","","","10.1016/j.urolonc.2009.03.011"
"25689354","Understanding heterogeneity of treatment effect in prostate cancer","Aly A, Mullins CD, Hussain A.","Curr Opin Oncol. 2015 May;27(3):209-16. doi: 10.1097/CCO.0000000000000172.","Aly A","Curr Opin Oncol","2015","2015/02/18","","","10.1097/CCO.0000000000000172"
"23288211","Minimally invasive treatment for localized prostate cancer","Porres D, Pfister D, Heidenreich A.","Minerva Urol Nefrol. 2012 Dec;64(4):245-53.","Porres D","Minerva Urol Nefrol","2012","2013/01/05","","",""
"18933396","[Current treatment of prostate cancer]","PERRIER C.","Rev Med Suisse Romande. 1948 Sep 25;68(9):619.","PERRIER C","Rev Med Suisse Romande","1948","1948/09/25","","",""
"14965270","Novel targeting of apoptosis pathways for prostate cancer therapy","Garrison JB, Kyprianou N.","Curr Cancer Drug Targets. 2004 Feb;4(1):85-95. doi: 10.2174/1568009043481623.","Garrison JB","Curr Cancer Drug Targets","2004","2004/02/18","","","10.2174/1568009043481623"
"30160020","Increased levels of serum miR-148a-3p are associated with prostate cancer","Dybos SA, Flatberg A, Halgunset J, Viset T, Rolfseng T, Kvam S, Skogseth H.","APMIS. 2018 Sep;126(9):722-731. doi: 10.1111/apm.12880.","Dybos SA","APMIS","2018","2018/08/31","","","10.1111/apm.12880"
"17687794","Lifestyle therapy for prostate cancer: does it work?","","Harv Mens Health Watch. 2007 Jul;11(12):1-3.","","Harv Mens Health Watch","2007","2007/08/11","","",""
"25552062","[Dynamics of prostate-specific antigen concentration--growth kinetics of prostate cancer?]","Bogomolov, Zharinov GM, Shkol'nik MI.","Vopr Onkol. 2014;60(4):437-48.","Bogomolov","Vopr Onkol","2014","2015/01/02","","",""
"1769904","Overview of enzyme inhibitors and anti-androgens in prostatic cancer","Geller J.","J Androl. 1991 Nov-Dec;12(6):364-71.","Geller J","J Androl","1991","1991/11/01","","",""
"25137936","Nurses support prostate cancer drug appeal","","Nurs Times. 2014 Jul 16-22;110(29):4.","","Nurs Times","2014","2014/08/21","","",""
"23712781","Diffusion-weighted MRI and its role in prostate cancer","Tamada T, Sone T, Jo Y, Yamamoto A, Ito K.","NMR Biomed. 2014 Jan;27(1):25-38. doi: 10.1002/nbm.2956. Epub 2013 May 27.","Tamada T","NMR Biomed","2014","2013/05/29","","","10.1002/nbm.2956"
"8206492","Treatment of early stage prostate cancer: conservative management--delayed therapy","Chodak GW.","Important Adv Oncol. 1994:241-4.","Chodak GW","Important Adv Oncol","1994","1994/01/01","","",""
"19138953","Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach","Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM.","Cancer Prev Res (Phila). 2008 Aug;1(3):174-81. doi: 10.1158/1940-6207.CAPR-08-0092. Epub 2008 May 18.","Redman MW","Cancer Prev Res (Phila)","2008","2009/01/14","PMC2844801","NIHMS182806","10.1158/1940-6207.CAPR-08-0092"
"8815666","[Radical surgery of locally advanced prostatic cancer]","Pesqueira D, Pereiro M, Rivas C, Comesaña E, Zungri E.","Actas Urol Esp. 1995 Jul-Aug;19(7):549-54.","Pesqueira D","Actas Urol Esp","1995","1995/07/01","","",""
"26831055","[Active surveillance for low-risk prostate cancer]","Herlemann A, Stief CG.","Urologe A. 2016 Feb;55(2):269-81. doi: 10.1007/s00120-015-0025-x.","Herlemann A","Urologe A","2016","2016/02/03","","","10.1007/s00120-015-0025-x"
"23893779","Delivering high-quality care to prostate cancer survivors","Anderson CB, Barocas DA.","Cancer. 2013 Oct 1;119(19):3426-8. doi: 10.1002/cncr.28236. Epub 2013 Jul 24.","Anderson CB","Cancer","2013","2013/07/30","","","10.1002/cncr.28236"
"23670256","Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics","Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH.","Prostate Cancer Prostatic Dis. 2013 Sep;16(3):217-25. doi: 10.1038/pcan.2013.13. Epub 2013 May 14.","Paschos A","Prostate Cancer Prostatic Dis","2013","2013/05/15","","","10.1038/pcan.2013.13"
"11329793","[Metastatic liver tumor arising from prostate cancer following transurethral resection of the prostate--a report of two cases]","Yamamoto N, Zhang X, Soramoto S, Kuroda I, Ueda N, Yamashita M, Takenaka I.","Gan To Kagaku Ryoho. 2001 Apr;28(4):545-8.","Yamamoto N","Gan To Kagaku Ryoho","2001","2001/05/02","","",""
"19325494","Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance","Villers A, Lemaitre L, Haffner J, Puech P.","Curr Opin Urol. 2009 May;19(3):274-82. doi: 10.1097/MOU.0b013e328329a2ed.","Villers A","Curr Opin Urol","2009","2009/03/28","","","10.1097/MOU.0b013e328329a2ed"
"27605446","WOMEN IN CANCER THEMATIC REVIEW: Diverse functions of DNA methylation: implications for prostate cancer and beyond","Sweet TJ, Ting AH.","Endocr Relat Cancer. 2016 Nov;23(11):T169-T178. doi: 10.1530/ERC-16-0306. Epub 2016 Sep 7.","Sweet TJ","Endocr Relat Cancer","2016","2016/09/09","","","10.1530/ERC-16-0306"
"8531277","Survival and conservative treatment for localized prostate cancer","Cowen ME, Kattan MW, Miles BJ.","JAMA. 1996 Jan 3;275(1):31-2. doi: 10.1001/jama.1996.03530250035013.","Cowen ME","JAMA","1996","1996/01/03","","","10.1001/jama.1996.03530250035013"
"7303128","[Lymphadenectomy and surgical procedures in interstitial therapy of prostate cancer]","Sommerkamp H.","Strahlentherapie Sonderb. 1981;76:70-3.","Sommerkamp H","Strahlentherapie Sonderb","1981","1981/01/01","","",""
"31099688","The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families","Pilarski R.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:79-86. doi: 10.1200/EDBK_238977. Epub 2019 May 17.","Pilarski R","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_238977"
"7854702","Cold comfort: treating prostate cancer with cryosurgery","Razanauzskas M, Hoebler L.","Nursing. 1994 Nov;24(11):66, 68. doi: 10.1097/00152193-199411000-00024.","Razanauzskas M","Nursing","1994","1994/11/01","","","10.1097/00152193-199411000-00024"
"18323175","[Prostate cancer in a relatively young adult: a case report]","Suzuki T, Togo Y, Yasuda K, Yamamoto H, Kokura K.","Hinyokika Kiyo. 2008 Feb;54(2):139-42.","Suzuki T","Hinyokika Kiyo","2008","2008/03/08","","",""
"7816677","Prostate cancer prevention: risk reduction through life-style, diet, and chemoprevention","Greco KE, Kulawiak L.","Oncol Nurs Forum. 1994 Oct;21(9):1504-11.","Greco KE","Oncol Nurs Forum","1994","1994/10/01","","",""
"28130102","Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy","Prendeville S, Nesbitt ME, Evans AJ, Fleshner NE, van der Kwast TH.","J Urol. 2017 Jul;198(1):79-85. doi: 10.1016/j.juro.2017.01.061. Epub 2017 Jan 24.","Prendeville S","J Urol","2017","2017/01/29","","","10.1016/j.juro.2017.01.061"
"9684103","Gene therapy for prostate cancer","Malkowicz SB, Johnson JO.","Hematol Oncol Clin North Am. 1998 Jun;12(3):649-64. doi: 10.1016/s0889-8588(05)70013-7.","Malkowicz SB","Hematol Oncol Clin North Am","1998","1998/07/31","","","10.1016/s0889-8588(05)70013-7"
"10680732","Prostate cancer in Saskatchewan Canada, before and during the PSA era","Skarsgard D, Tonita J.","Cancer Causes Control. 2000 Jan;11(1):79-88. doi: 10.1023/a:1008965617078.","Skarsgard D","Cancer Causes Control","2000","2000/02/19","","","10.1023/a:1008965617078"
"29652556","Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer","Jansson F, Drevin L, Frisell T, Stattin P, Bratt O, Akre O.","J Clin Oncol. 2018 Jun 20;36(18):1847-1852. doi: 10.1200/JCO.2017.76.6907. Epub 2018 Apr 13.","Jansson F","J Clin Oncol","2018","2018/04/14","","","10.1200/JCO.2017.76.6907"
"1704923","Routine screening for cancer of the prostate","Gerber GS, Chodak GW.","J Natl Cancer Inst. 1991 Mar 6;83(5):329-35. doi: 10.1093/jnci/83.5.329.","Gerber GS","J Natl Cancer Inst","1991","1991/03/06","","","10.1093/jnci/83.5.329"
"20668368","Two new cases of polysomy 13 in canine prostate cancer","Reimann-Berg N, Willenbrock S, Murua Escobar H, Eberle N, Gerhauser I, Mischke R, Bullerdiek J, Nolte I.","Cytogenet Genome Res. 2011;132(1-2):16-21. doi: 10.1159/000317077. Epub 2010 Jul 29.","Reimann-Berg N","Cytogenet Genome Res","2011","2010/07/30","","","10.1159/000317077"
"28065536","A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT","Polverari G, Ceci F, Graziani T, Cozzarini C, Castellucci P, Fanti S.","Clin Genitourin Cancer. 2017 Jun;15(3):e525-e527. doi: 10.1016/j.clgc.2016.12.011. Epub 2016 Dec 22.","Polverari G","Clin Genitourin Cancer","2017","2017/01/10","","","10.1016/j.clgc.2016.12.011"
"24145474","Prostate cancer: does genetic score justify early prostate biopsy?","Sugihara T, Kattan MW.","Nat Rev Urol. 2013 Nov;10(11):628-9. doi: 10.1038/nrurol.2013.238. Epub 2013 Oct 22.","Sugihara T","Nat Rev Urol","2013","2013/10/23","","","10.1038/nrurol.2013.238"
"16631267","The role of whole pelvic radiotherapy in locally advanced prostate cancer","Dirix P, Haustermans K, Junius S, Withers R, Oyen R, Van Poppel H.","Radiother Oncol. 2006 Apr;79(1):1-14. doi: 10.1016/j.radonc.2006.03.011.","Dirix P","Radiother Oncol","2006","2006/04/25","","","10.1016/j.radonc.2006.03.011"
"21855205","Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83","Fanti S, Krause B, Weber W, Castellucci P, Grosu AL, de Jong IJ, Messa C, Picchio M, Pruim J, Langsteger W, Chiti A; European Association of Nuclear Medicine (EANM).","Eur Urol. 2011 Nov;60(5):e37-8; author reply e39-41. doi: 10.1016/j.eururo.2011.08.009. Epub 2011 Aug 16.","Fanti S","Eur Urol","2011","2011/08/23","","","10.1016/j.eururo.2011.08.009"
"20180426","[Skip metastasis of prostate cancer: diagnosis and treatment]","Wang JQ, Li W, Wang Q, Liu K, Mao LJ, Chen JC, Zheng JN, Sun XQ.","Zhonghua Nan Ke Xue. 2009 Dec;15(12):1120-3.","Wang JQ","Zhonghua Nan Ke Xue","2009","2010/02/26","","",""
"18342930","Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer","Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR.","Urology. 2008 Dec;72(6):1269-73. doi: 10.1016/j.urology.2007.12.084. Epub 2008 Mar 17.","Bellizzi KM","Urology","2008","2008/03/18","","","10.1016/j.urology.2007.12.084"
"20838944","Androgen replacement therapy after prostate cancer treatment","Khera M.","Curr Urol Rep. 2010 Nov;11(6):393-9. doi: 10.1007/s11934-010-0143-3.","Khera M","Curr Urol Rep","2010","2010/09/15","","","10.1007/s11934-010-0143-3"
"9656817","[Diagnostic molecular biology in prostatic cancer]","Andersen TI.","Tidsskr Nor Laegeforen. 1998 May 30;118(14):2196-8.","Andersen TI","Tidsskr Nor Laegeforen","1998","1998/07/10","","",""
"22052749","[Localized prostate cancer. Quo vadis?]","Carballido Rodríguez J.","Arch Esp Urol. 2011 Oct;64(8):651-8.","Carballido Rodríguez J","Arch Esp Urol","2011","2011/11/05","","",""
"15698354","Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia","Coory MD, Baade PD.","Med J Aust. 2005 Feb 7;182(3):112-5.","Coory MD","Med J Aust","2005","2005/02/09","","",""
"7529431","Imaging in the diagnosis and assessment of prognosis in localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993","Høisaeter PA, Norlén BJ, Norming U, Ebert T, Mattrey R, Nilsson S, Norberg M, Pollack H, Salo J, Torp-Pedersen S.","Scand J Urol Nephrol Suppl. 1994;162:89-106; discussion 115-27.","Høisaeter PA","Scand J Urol Nephrol Suppl","1994","1994/01/01","","",""
"9268976","The Prostate Cancer Intervention Versus Observation Trial (PIVOT)","Wilt TJ, Brawer MK.","Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143.","Wilt TJ","Oncology (Williston Park)","1997","1997/08/01","","",""
"12775282","Technological changes in the management of prostate cancer result in increased healthcare costs--a retrospective study in a defined Swedish population","Sennfält K, Carlsson P, Thorfinn J, Frisk J, Henriksson M, Varenhorst E.","Scand J Urol Nephrol. 2003;37(3):226-31. doi: 10.1080/00365590310008109.","Sennfält K","Scand J Urol Nephrol","2003","2003/05/31","","","10.1080/00365590310008109"
"28589399","Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies","Wang JH, Downs TM, Jason Abel E, Richards KA, Jarrard DF.","Curr Urol Rep. 2017 Jul;18(7):48. doi: 10.1007/s11934-017-0702-y.","Wang JH","Curr Urol Rep","2017","2017/06/08","","","10.1007/s11934-017-0702-y"
"12376729","Localized prostate cancer","Ohori M, Scardino PT.","Curr Probl Surg. 2002 Sep;39(9):833-957. doi: 10.1067/msg.2002.126335.","Ohori M","Curr Probl Surg","2002","2002/10/12","","","10.1067/msg.2002.126335"
"19258223","[Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features]","Brureau L, Multigner L, Wallois A, Verhoest G, Ndong JR, Fofana M, Blanchet P.","Bull Cancer. 2009 Feb;96(2):165-70. doi: 10.1684/bdc.2008.0811.","Brureau L","Bull Cancer","2009","2009/03/05","","","10.1684/bdc.2008.0811"
"9836536","Treatment options for early prostate cancer","Kirby R.","Urology. 1998 Dec;52(6):948-62. doi: 10.1016/s0090-4295(98)00428-2.","Kirby R","Urology","1998","1998/12/04","","","10.1016/s0090-4295(98)00428-2"
"19256581","What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer","Carlucci JR, Nabizada-Pace F, Samadi DB.","Geriatrics. 2009 Feb;64(2):8-14.","Carlucci JR","Geriatrics","2009","2009/03/05","","",""
"24260896","[Features of high-dose brachytherapy in patients with localized prostate cancer]","Kanaev SV, Novikov SN.","Vopr Onkol. 2013;59(5):645-50.","Kanaev SV","Vopr Onkol","2013","2013/11/23","","",""
"26007708","Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings","Fraga A, Ribeiro R, Príncipe P, Lopes C, Medeiros R.","Clin Genitourin Cancer. 2015 Aug;13(4):295-301. doi: 10.1016/j.clgc.2015.03.006. Epub 2015 Mar 28.","Fraga A","Clin Genitourin Cancer","2015","2015/05/27","","","10.1016/j.clgc.2015.03.006"
"31356111","Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study","Sun Y, Williams S, Byrne D, Keam S, Reynolds HM, Mitchell C, Wraith D, Murphy D, Haworth A.","Br J Radiol. 2019 Dec;92(1104):20190373. doi: 10.1259/bjr.20190373. Epub 2019 Jul 30.","Sun Y","Br J Radiol","2019","2019/07/30","PMC6913351","","10.1259/bjr.20190373"
"16778194","EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action","Seethammagari MR, Xie X, Greenberg NM, Spencer DM.","Cancer Res. 2006 Jun 15;66(12):6199-209. doi: 10.1158/0008-5472.CAN-05-3954.","Seethammagari MR","Cancer Res","2006","2006/06/17","","","10.1158/0008-5472.CAN-05-3954"
"20157302","Clinical implications of changing definitions within the Gleason grading system","Lotan TL, Epstein JI.","Nat Rev Urol. 2010 Mar;7(3):136-42. doi: 10.1038/nrurol.2010.9. Epub 2010 Feb 16.","Lotan TL","Nat Rev Urol","2010","2010/02/17","","","10.1038/nrurol.2010.9"
"21445969","Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy","Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Chen LM, Ting WC, Hsieh CJ, Huang SP.","Int J Cancer. 2012 Feb 15;130(4):876-84. doi: 10.1002/ijc.26091. Epub 2011 May 25.","Bao BY","Int J Cancer","2012","2011/03/30","","","10.1002/ijc.26091"
"9842220","New aspects on prostate cancer: hereditary form, developmental estrogenization and differentiation therapy","Sciarra A, Casale P, Di Chirio C, Di Nicola S, Di Silverio F.","Minerva Urol Nefrol. 1998 Sep;50(3):185-90.","Sciarra A","Minerva Urol Nefrol","1998","1998/12/08","","",""
"27794184","LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a","Liu HT, Fang L, Cheng YX, Sun Q.","Cancer Med. 2016 Dec;5(12):3512-3519. doi: 10.1002/cam4.900. Epub 2016 Oct 28.","Liu HT","Cancer Med","2016","2016/10/30","PMC5224852","","10.1002/cam4.900"
"9263633","Comparison of prostate cancer treatments","Klein EA.","Cancer J Sci Am. 1997 Jul-Aug;3(4):255.","Klein EA","Cancer J Sci Am","1997","1997/07/01","","",""
"17440029","Commentary: on the incidence of histological prostate cancer and the probable diagnosis of cases with tumours too small to produce symptoms or to attract attention on physical examination--the findings of Dr Arnold Rice Rich","Adolfsson J.","Int J Epidemiol. 2007 Apr;36(2):285-7. doi: 10.1093/ije/dym053. Epub 2007 Apr 17.","Adolfsson J","Int J Epidemiol","2007","2007/04/19","","","10.1093/ije/dym053"
"29301928","The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer","Calais J, Cao M, Nickols NG.","J Nucl Med. 2018 Apr;59(4):557-567. doi: 10.2967/jnumed.117.196444. Epub 2018 Jan 4.","Calais J","J Nucl Med","2018","2018/01/06","PMC6910632","","10.2967/jnumed.117.196444"
"8522299","Hypothesis: the prenatal origins of prostate cancer","Gardner WA.","Hum Pathol. 1995 Dec;26(12):1291-2. doi: 10.1016/0046-8177(95)90291-0.","Gardner WA","Hum Pathol","1995","1995/12/01","","","10.1016/0046-8177(95)90291-0"
"16457943","The difficult case in prostate cancer diagnosis--when is a ""diagnostic TURP"" indicated?","Bratt O.","Eur Urol. 2006 May;49(5):769-71. doi: 10.1016/j.eururo.2006.01.010. Epub 2006 Jan 20.","Bratt O","Eur Urol","2006","2006/02/07","","","10.1016/j.eururo.2006.01.010"
"17313155","Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer","Crawford ED, Barqawi A.","Oncology (Williston Park). 2007 Jan;21(1):27-32; discussion 33-4, 39.","Crawford ED","Oncology (Williston Park)","2007","2007/02/23","","",""
"19239456","p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer","Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, Møller H, Kattan MW, Cooper CS, Scardino P, Cuzick J, Berney DM.","BJU Int. 2009 Jul;104(1):20-4. doi: 10.1111/j.1464-410X.2009.08407.x. Epub 2009 Feb 23.","Kudahetti S","BJU Int","2009","2009/02/26","","","10.1111/j.1464-410X.2009.08407.x"
"29182656","Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?","Abdel-Rahman O.","PLoS One. 2017 Nov 28;12(11):e0188450. doi: 10.1371/journal.pone.0188450. eCollection 2017.","Abdel-Rahman O","PLoS One","2017","2017/11/29","PMC5705121","","10.1371/journal.pone.0188450"
"18096460","Molecular imaging of reporter gene expression in prostate cancer: an overview","Singh A, Massoud TF, Deroose C, Gambhir SS.","Semin Nucl Med. 2008 Jan;38(1):9-19. doi: 10.1053/j.semnuclmed.2007.09.002.","Singh A","Semin Nucl Med","2008","2007/12/22","","","10.1053/j.semnuclmed.2007.09.002"
"9751362","Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy","van den Ouden D, Hop WC, Schröder FH.","J Urol. 1998 Oct;160(4):1392-7. doi: 10.1097/00005392-199810000-00048.","van den Ouden D","J Urol","1998","1998/09/29","","","10.1097/00005392-199810000-00048"
"8635077","Detection of residual prostate cancer after external radiotherapy","Anand A, Anand A.","Cancer. 1995 Nov 1;76(9):1682. doi: 10.1002/1097-0142(19951101)76:9<1682::aid-cncr2820760929>3.0.co;2-e.","Anand A","Cancer","1995","1995/11/01","","","10.1002/1097-0142(19951101)76:9<1682::aid-cncr2820760929>3.0.co;2-e"
"12487552","An estimate of prostate cancer prevalence in Italy","La Vecchia C, Bruzzi P, Decarli A, Gaboardi F, Boyle P.","Tumori. 2002 Sep-Oct;88(5):367-9.","La Vecchia C","Tumori","2002","2002/12/19","","",""
"10189432","Prostate cancer: 13. Whose prostate is it anyway? The view from the other side of the examining table","Gray RE, Philbrook A.","CMAJ. 1999 Mar 23;160(6):833-6.","Gray RE","CMAJ","1999","1999/04/06","PMC1230168","",""
"19107943","Risk of prostate cancer among Swedish-born and foreign-born men in Sweden, 1961-2004","Beiki O, Ekbom A, Allebeck P, Moradi T.","Int J Cancer. 2009 Apr 15;124(8):1941-53. doi: 10.1002/ijc.24138.","Beiki O","Int J Cancer","2009","2008/12/25","","","10.1002/ijc.24138"
"27709739","Perineural invasion on biopsy is associated with upstaging at radical prostatectomy in Gleason score 3 + 4 = 7 prostate cancer","Flood TA, Schieda N, Keefe DT, Morash C, Bateman J, Mai KT, Belanger EC, Robertson SJ, Breau RH.","Pathol Int. 2016 Nov;66(11):629-632. doi: 10.1111/pin.12467. Epub 2016 Oct 5.","Flood TA","Pathol Int","2016","2016/10/07","","","10.1111/pin.12467"
"15018076","[Prostate specific antigen and diagnosis of prostate cancer]","Rigaud J, Bouchot O.","Rev Prat. 2003 Dec 31;53(20):2229-36.","Rigaud J","Rev Prat","2003","2004/03/17","","",""
"24092918","Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection","Haines IE, Gabor Miklos GL.","J Natl Cancer Inst. 2013 Oct 16;105(20):1534-9. doi: 10.1093/jnci/djt248. Epub 2013 Oct 3.","Haines IE","J Natl Cancer Inst","2013","2013/10/05","","","10.1093/jnci/djt248"
"26315521","Prostate Cancer Screening and the Associated Controversy","Tabayoyong W, Abouassaly R.","Surg Clin North Am. 2015 Oct;95(5):1023-39. doi: 10.1016/j.suc.2015.05.001. Epub 2015 Jun 23.","Tabayoyong W","Surg Clin North Am","2015","2015/08/29","","","10.1016/j.suc.2015.05.001"
"9466617","ACS sets blueprint for action against prostate cancer in African Americans. American Cancer Society","Marwick C.","JAMA. 1998 Feb 11;279(6):418, 419. doi: 10.1001/jama.279.6.418.","Marwick C","JAMA","1998","1998/02/18","","","10.1001/jama.279.6.418"
"27427556","Intrinsically disordered proteins and prostate cancer: pouring new wine in an old bottle","Kulkarni P.","Asian J Androl. 2016 Sep-Oct;18(5):659-61. doi: 10.4103/1008-682X.184272.","Kulkarni P","Asian J Androl","2016","2016/07/19","PMC5000785","","10.4103/1008-682X.184272"
"19947382","[Results of adjuvant radiotherapy after radical prostatectomy in patients with locally-advanced prostate cancer]","Ivanov SA, Kaprin AD, Pan'shin GA, Garmash SV, Gamidov MI, Shestakov AV, Nesterov PV.","Vopr Onkol. 2009;55(4):512-4.","Ivanov SA","Vopr Onkol","2009","2009/12/02","","",""
"30614347","Testosterone, testosterone therapy and prostate cancer","Yassin A, AlRumaihi K, Alzubaidi R, Alkadhi S, Al Ansari A.","Aging Male. 2019 Dec;22(4):219-227. doi: 10.1080/13685538.2018.1524456. Epub 2019 Jan 7.","Yassin A","Aging Male","2019","2019/01/08","","","10.1080/13685538.2018.1524456"
"14965338","Targeting gene therapy for prostate cancer","Maitland NJ, Stanbridge LJ, Dussupt V.","Curr Pharm Des. 2004;10(5):531-55. doi: 10.2174/1381612043453252.","Maitland NJ","Curr Pharm Des","2004","2004/02/18","","","10.2174/1381612043453252"
"16450727","[Nutrition and pharmacological treatment for prevention of prostate cancer]","Segev Y, Nativ O.","Harefuah. 2006 Jan;145(1):47-51, 76-7.","Segev Y","Harefuah","2006","2006/02/03","","",""
"9011943","Hormone-refractory prostate cancer: an emerging epidemic. Proceedings from a roundtable workshop. Philadelphia, Pennsylvania, May 22, 1996","","Semin Oncol. 1996 Dec;23(6 Suppl 14):1-62.","","Semin Oncol","1996","1996/12/01","","",""
"14673059","Quality of life after treatment for prostate cancer: no difference between surgery and radiotherapy?","Vordermark D, Koelbl O.","J Clin Oncol. 2003 Dec 15;21(24):4655; author reply 4655-6. doi: 10.1200/JCO.2003.99.116.","Vordermark D","J Clin Oncol","2003","2003/12/16","","","10.1200/JCO.2003.99.116"
"25840558","Trends in initial management of prostate cancer in New Hampshire","Ingimarsson JP, Celaya MO, Laviolette M, Rees JR, Hyams ES.","Cancer Causes Control. 2015 Jun;26(6):923-9. doi: 10.1007/s10552-015-0574-8. Epub 2015 Apr 4.","Ingimarsson JP","Cancer Causes Control","2015","2015/04/05","","","10.1007/s10552-015-0574-8"
"27720870","Achieving resistance specificity in prostate cancer","Wadhwa B, Dumbre R.","Chem Biol Interact. 2016 Dec 25;260:243-247. doi: 10.1016/j.cbi.2016.10.002. Epub 2016 Oct 6.","Wadhwa B","Chem Biol Interact","2016","2016/10/11","","","10.1016/j.cbi.2016.10.002"
"7664893","Radical prostatectomy in the management of localized prostate cancer","Frohmüller HG, Theiss M.","Eur J Surg Oncol. 1995 Aug;21(4):336-40. doi: 10.1016/s0748-7983(95)92120-6.","Frohmüller HG","Eur J Surg Oncol","1995","1995/08/01","","","10.1016/s0748-7983(95)92120-6"
"9741415","Microvessel density in prostate cancer: prognostic and therapeutic utility","Bostwick DG, Iczkowski KA.","Semin Urol Oncol. 1998 Aug;16(3):118-23.","Bostwick DG","Semin Urol Oncol","1998","1998/09/19","","",""
"8363943","Expanding horizons in breast and prostate cancer prevention and early detection. The 1992 Samuel C. Harvey Lecture","Greenwald P, Kramer B, Weed D.","J Cancer Educ. 1993 Summer;8(2):91-107. doi: 10.1080/08858199309528215.","Greenwald P","J Cancer Educ","1993","1993/01/01","","","10.1080/08858199309528215"
"23050531","Radical prostatectomy versus observation for prostate cancer","Sartor O.","N Engl J Med. 2012 Oct 11;367(15):1467; author reply 1468-9. doi: 10.1056/NEJMc1209800.","Sartor O","N Engl J Med","2012","2012/10/12","","","10.1056/NEJMc1209800"
"14971095","Problems in staging prostate cancer","Swanson J.","J Insur Med. 2003;35(3-4):201-4.","Swanson J","J Insur Med","2003","2004/02/20","","",""
"20162716","Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy","Wilke DR, Krahn M, Tomlinson G, Bezjak A, Rutledge R, Warde P.","Cancer. 2010 Apr 15;116(8):1909-17. doi: 10.1002/cncr.24905.","Wilke DR","Cancer","2010","2010/02/18","","","10.1002/cncr.24905"
"17459275","The spectrum of prostate cancer care: from curative intent to palliation","Ali AS, Hamdy FC.","Curr Urol Rep. 2007 May;8(3):245-52. doi: 10.1007/s11934-007-0013-9.","Ali AS","Curr Urol Rep","2007","2007/04/27","","","10.1007/s11934-007-0013-9"
"18723370","Prostate cancer. Multidisciplinary approach: a key to success","Montagut C, Albanell J, Bellmunt J.","Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S32-6. doi: 10.1016/j.critrevonc.2008.07.009. Epub 2008 Aug 23.","Montagut C","Crit Rev Oncol Hematol","2008","2008/08/30","","","10.1016/j.critrevonc.2008.07.009"
"19997836","[How to use PSA in 2009]","Ponholzer A, Stoiber F, Loidl W, Rauchenwald M, Schramek P, Madersbacher S.","Wien Med Wochenschr. 2009;159(21-22):515-20. doi: 10.1007/s10354-009-0718-0.","Ponholzer A","Wien Med Wochenschr","2009","2009/12/10","","","10.1007/s10354-009-0718-0"
"23076049","The role of Snail in prostate cancer","Smith BN, Odero-Marah VA.","Cell Adh Migr. 2012 Sep-Oct;6(5):433-41. doi: 10.4161/cam.21687. Epub 2012 Sep 1.","Smith BN","Cell Adh Migr","2012","2012/10/19","PMC3496681","","10.4161/cam.21687"
"29740894","Epidemiology of prostate cancer in Asian countries","Kimura T, Egawa S.","Int J Urol. 2018 Jun;25(6):524-531. doi: 10.1111/iju.13593. Epub 2018 May 8.","Kimura T","Int J Urol","2018","2018/05/10","","","10.1111/iju.13593"
"11962333","Prognostic markers in prostate cancer","Ross JS, Sheehan CE, Fisher HA, Kauffman RA, Dolen EM, Kallakury BV.","Expert Rev Mol Diagn. 2002 Mar;2(2):129-42. doi: 10.1586/14737159.2.2.129.","Ross JS","Expert Rev Mol Diagn","2002","2002/04/19","","","10.1586/14737159.2.2.129"
"28753804","Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review","Kane CJ, Eggener SE, Shindel AW, Andriole GL.","Eur Urol Focus. 2017 Oct;3(4-5):487-497. doi: 10.1016/j.euf.2016.10.010. Epub 2017 Mar 11.","Kane CJ","Eur Urol Focus","2017","2017/07/30","","","10.1016/j.euf.2016.10.010"
"2313798","Clinical evidence for and implications of the multistep development of prostate cancer","Carter HB, Piantadosi S, Isaacs JT.","J Urol. 1990 Apr;143(4):742-6. doi: 10.1016/s0022-5347(17)40078-4.","Carter HB","J Urol","1990","1990/04/01","","","10.1016/s0022-5347(17)40078-4"
"26786562","African American Participation in Oncology Clinical Trials--Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions","Ahaghotu C, Tyler R, Sartor O.","Clin Genitourin Cancer. 2016 Apr;14(2):105-16. doi: 10.1016/j.clgc.2015.12.003. Epub 2015 Dec 17.","Ahaghotu C","Clin Genitourin Cancer","2016","2016/01/21","","","10.1016/j.clgc.2015.12.003"
"10472324","Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial","Boel K, Van Poppel H, Goethuys H, Derluyn J, Vandenbroucke F, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L.","Anticancer Res. 1999 May-Jun;19(3B):2157-61.","Boel K","Anticancer Res","1999","1999/09/03","","",""
"22690411","Prostate cancer overview. Part 1: non-metastatic disease","Drudge-Coates L, Turner B.","Br J Nurs. 2012 May 10-23;21(9):S23-8.","Drudge-Coates L","Br J Nurs","2012","2012/06/14","","",""
"22824828","The impact of county-level radiation oncologist density on prostate cancer mortality in the United States","Aneja S, Yu JB.","Prostate Cancer Prostatic Dis. 2012 Dec;15(4):391-6. doi: 10.1038/pcan.2012.28. Epub 2012 Jul 24.","Aneja S","Prostate Cancer Prostatic Dis","2012","2012/07/25","","","10.1038/pcan.2012.28"
"12108886","Cure in prostate cancer patients","Lawrence G.","Oncology (Williston Park). 2002 May;16(5):556.","Lawrence G","Oncology (Williston Park)","2002","2002/07/11","","",""
"29206372","Focal therapy will be the next step on prostate cancer management? | Opinion: Yes","Zequi SC.","Int Braz J Urol. 2017 Nov-Dec;43(6):1013-1016. doi: 10.1590/S1677-5538.IBJU.2017.06.02.","Zequi SC","Int Braz J Urol","2017","2017/12/06","PMC5734062","","10.1590/S1677-5538.IBJU.2017.06.02"
"15723353","Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival","Hasumi H, Ishiguro H, Nakamura M, Sugiura S, Osada Y, Miyoshi Y, Fujinami K, Yao M, Hamada K, Yamada-Okabe H, Kubota Y, Uemura H.","Int J Cancer. 2005 Jul 20;115(6):911-6. doi: 10.1002/ijc.20967.","Hasumi H","Int J Cancer","2005","2005/02/22","","","10.1002/ijc.20967"
"19537233","Men's knowledge and beliefs about prostate cancer: education, race, and screening status","Winterich JA, Grzywacz JG, Quandt SA, Clark PE, Miller DP, Acuña J, Dignan MB, Arcury TA.","Ethn Dis. 2009 Spring;19(2):199-203.","Winterich JA","Ethn Dis","2009","2009/06/20","PMC2699598","NIHMS89549",""
"18593619","Paradigms in androgen/castrate resistant states of prostate cancer in a biomarker era","Bianco FJ Jr.","Urol Oncol. 2008 Jul-Aug;26(4):408-14. doi: 10.1016/j.urolonc.2007.11.002.","Bianco FJ Jr","Urol Oncol","2008","2008/07/03","","","10.1016/j.urolonc.2007.11.002"
"21060342","The epigenome as a therapeutic target in prostate cancer","Perry AS, Watson RW, Lawler M, Hollywood D.","Nat Rev Urol. 2010 Dec;7(12):668-80. doi: 10.1038/nrurol.2010.185. Epub 2010 Nov 9.","Perry AS","Nat Rev Urol","2010","2010/11/10","","","10.1038/nrurol.2010.185"
"25616709","Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer","Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL.","Eur Urol. 2015 Jun;67(6):993-1005. doi: 10.1016/j.eururo.2015.01.004. Epub 2015 Jan 21.","Simpkin AJ","Eur Urol","2015","2015/01/25","","","10.1016/j.eururo.2015.01.004"
"20608876","Prostate cancer gene therapy: attempts to innovate","Kochanek S, Gansbacher B.","Hum Gene Ther. 2010 Jul;21(7):791. doi: 10.1089/hum.2010.1216.","Kochanek S","Hum Gene Ther","2010","2010/07/09","","","10.1089/hum.2010.1216"
"2142406","[Transrectal echography and cancer of the prostate. III. Monitoring of the treatment response]","Abad Menor F, Espuela Orgaz R, Pérez Arbej JA, Nogueras Gimeno MA, Martínez Pérez E, Arnaiz Esteban F.","Arch Esp Urol. 1990 Apr;43(3):265-7.","Abad Menor F","Arch Esp Urol","1990","1990/04/01","","",""
"24126652","Observation versus initial treatment for prostate cancer","Pinsky P.","Ann Intern Med. 2013 Oct 15;159(8):574. doi: 10.7326/0003-4819-159-8-201310150-00015.","Pinsky P","Ann Intern Med","2013","2013/10/16","","","10.7326/0003-4819-159-8-201310150-00015"
"20935269","PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?","Schmidt C.","J Natl Cancer Inst. 2010 Oct 20;102(20):1533-5. doi: 10.1093/jnci/djq424. Epub 2010 Oct 8.","Schmidt C","J Natl Cancer Inst","2010","2010/10/12","","","10.1093/jnci/djq424"
"7542562","Tumour markers in patients on deferred treatment: prostate specific antigen doubling times","Schmid HP.","Cancer Surv. 1995;23:157-67.","Schmid HP","Cancer Surv","1995","1995/01/01","","",""
"30855011","Biomarkers in prostate cancer management. Is there something new?","Carrion DM, Gómez Rivas J, Álvarez-Maestro M, Martínez-Piñeiro L.","Arch Esp Urol. 2019 Mar;72(2):105-115.","Carrion DM","Arch Esp Urol","2019","2019/03/12","","",""
"9284201","Tumour size measured by transrectal ultrasonography in the staging of prostate cancer before radical prostatectomy","Rørvik J, Albrektsen G, Halvorsen OJ, Haukaas S.","Br J Urol. 1997 Aug;80(2):269-73. doi: 10.1046/j.1464-410x.1997.00226.x.","Rørvik J","Br J Urol","1997","1997/08/01","","","10.1046/j.1464-410x.1997.00226.x"
"29191358","[Stereotactic body radiation therapy for oligometastatic prostate cancer]","Bibault JE.","Bull Cancer. 2018 Jan;105(1):120-125. doi: 10.1016/j.bulcan.2017.09.017. Epub 2017 Nov 27.","Bibault JE","Bull Cancer","2018","2017/12/02","","","10.1016/j.bulcan.2017.09.017"
"30790052","Lifestyles, health habits, and prostate cancer","Kawada T.","J Cancer Res Clin Oncol. 2020 Jun;146(6):1623-1624. doi: 10.1007/s00432-019-02871-w. Epub 2019 Feb 21.","Kawada T","J Cancer Res Clin Oncol","2020","2019/02/22","","","10.1007/s00432-019-02871-w"
"11475093","[Prostate cancer: prevention and patient education--wishes and demands from the viewpoint of patients]","Büchler EF.","Wien Med Wochenschr. 2001;151(9-10):206-7.","Büchler EF","Wien Med Wochenschr","2001","2001/07/28","","",""
"27793529","[Intraprostatic fiducials in stereotactic radiotherapy for prostate cancer]","Cordoba A, Pasquier D, Nickers P, Lacornerie T, Lartigau É.","Cancer Radiother. 2016 Dec;20(8):815-819. doi: 10.1016/j.canrad.2016.07.097. Epub 2016 Oct 25.","Cordoba A","Cancer Radiother","2016","2016/10/30","","","10.1016/j.canrad.2016.07.097"
"9749132","[Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]","Chauvet B.","Cancer Radiother. 1998 May-Jun;2(3):312. doi: 10.1016/s1278-3218(98)80023-1.","Chauvet B","Cancer Radiother","1998","1998/09/28","","","10.1016/s1278-3218(98)80023-1"
"30941976","Comparison of radical prostatectomy versus conservative treatment in localized prostate cancer: systematic review and meta-analysis","Tian Z, Wang X, Wu P, Shi T, Liu M.","J BUON. 2019 Jan-Feb;24(1):239-248.","Tian Z","J BUON","2019","2019/04/04","","",""
"24425228","AR function in promoting metastatic prostate cancer","Augello MA, Den RB, Knudsen KE.","Cancer Metastasis Rev. 2014 Sep;33(2-3):399-411. doi: 10.1007/s10555-013-9471-3.","Augello MA","Cancer Metastasis Rev","2014","2014/01/16","PMC4452946","NIHMS691295","10.1007/s10555-013-9471-3"
"18353530","Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)","Terris MK.","Eur Urol. 2009 Feb;55(2):392; discussion 393. doi: 10.1016/j.eururo.2008.02.047. Epub 2008 Mar 11.","Terris MK","Eur Urol","2009","2008/03/21","","","10.1016/j.eururo.2008.02.047"
"26246066","[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge]","Westdorp H, Benoist GE, Schers HJ, van Erp PH, Gerritsen WR, Mulders PF, Kramers C.","Ned Tijdschr Geneeskd. 2015;159:A9250.","Westdorp H","Ned Tijdschr Geneeskd","2015","2015/08/07","","",""
"12523307","Prostatectomy or watchful waiting in prostate cancer","Gambacorti-Passerini CB, Sala EA.","N Engl J Med. 2003 Jan 9;348(2):170-1; author reply 170-1.","Gambacorti-Passerini CB","N Engl J Med","2003","2003/01/14","","",""
"12795445","Emerging evidence on the role of soy in reducing prostate cancer risk","Messina MJ.","Nutr Rev. 2003 Apr;61(4):117-31. doi: 10.1301/nr.2003.apr.117-131.","Messina MJ","Nutr Rev","2003","2003/06/11","","","10.1301/nr.2003.apr.117-131"
"8182870","Urology","Chodak GW.","JAMA. 1994 Jun 1;271(21):1717-8.","Chodak GW","JAMA","1994","1994/06/01","","",""
"19414121","Beyond PSA: utility of novel tumor markers in the setting of elevated PSA","Lin DW.","Urol Oncol. 2009 May-Jun;27(3):315-21. doi: 10.1016/j.urolonc.2009.01.026.","Lin DW","Urol Oncol","2009","2009/05/06","","","10.1016/j.urolonc.2009.01.026"
"18274783","A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants","Thorsen L, Courneya KS, Stevinson C, Fosså SD.","Support Care Cancer. 2008 Sep;16(9):987-97. doi: 10.1007/s00520-008-0411-7. Epub 2008 Feb 15.","Thorsen L","Support Care Cancer","2008","2008/02/16","","","10.1007/s00520-008-0411-7"
"9340901","[Radical prostatectomy as primary monotherapy in capsule penetrating prostatic carcinoma. 15 years outcome]","Theiss M, Langer W, Hofmockel G, Frohmüller H.","Urologe A. 1997 Jul;36(4):343-7. doi: 10.1007/s001200050109.","Theiss M","Urologe A","1997","1997/07/01","","","10.1007/s001200050109"
"17141844","Prostate cancer and schizophrenia","Torrey EF.","Urology. 2006 Dec;68(6):1280-3. doi: 10.1016/j.urology.2006.08.1061. Epub 2006 Dec 4.","Torrey EF","Urology","2006","2006/12/05","","","10.1016/j.urology.2006.08.1061"
"10991699","Improving prostate cancer detection","Bahnson RR.","J Urol. 2000 Aug;164(2):405. doi: 10.1097/00005392-200008000-00032.","Bahnson RR","J Urol","2000","2000/09/19","","","10.1097/00005392-200008000-00032"
"29154675","Preprocessing Tools Applied to Improve the Assessment of Aldrin Effects on Prostate Cancer Cells Using Raman Spectroscopy","Olmos V, Bedia C, Tauler R, Juan A.","Appl Spectrosc. 2018 Mar;72(3):489-500. doi: 10.1177/0003702817746947. Epub 2017 Dec 28.","Olmos V","Appl Spectrosc","2018","2017/11/21","","","10.1177/0003702817746947"
"11588854","Hormones and prostate cancer: what's next?","Hsing AW.","Epidemiol Rev. 2001;23(1):42-58. doi: 10.1093/oxfordjournals.epirev.a000795.","Hsing AW","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000795"
"23399519","Biological determinants of health disparities in prostate cancer","Martin DN, Starks AM, Ambs S.","Curr Opin Oncol. 2013 May;25(3):235-41. doi: 10.1097/CCO.0b013e32835eb5d1.","Martin DN","Curr Opin Oncol","2013","2013/02/13","PMC6278601","NIHMS997818","10.1097/CCO.0b013e32835eb5d1"
"10235144","Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer","Vicini FA, Kestin LL, Martinez AA.","JAMA. 1999 May 5;281(17):1583-4; author reply 1585-6.","Vicini FA","JAMA","1999","1999/05/11","","",""
"2284294","The role of cytoreduction prior to definitive radiotherapy in locally advanced prostate cancer--the Canadian perspective","Porter AT, Venner PM.","Prog Clin Biol Res. 1990;359:231-7; discussion 249-50.","Porter AT","Prog Clin Biol Res","1990","1990/01/01","","",""
"19352394","Imaging techniques for prostate cancer: implications for focal therapy","Turkbey B, Pinto PA, Choyke PL.","Nat Rev Urol. 2009 Apr;6(4):191-203. doi: 10.1038/nrurol.2009.27.","Turkbey B","Nat Rev Urol","2009","2009/04/09","PMC3520096","NIHMS423214","10.1038/nrurol.2009.27"
"16310621","Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery","Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L.","J Pain Symptom Manage. 2005 Nov;30(5):474-84. doi: 10.1016/j.jpainsymman.2005.05.011.","Hervouet S","J Pain Symptom Manage","2005","2005/11/29","","","10.1016/j.jpainsymman.2005.05.011"
"9412190","[Yield of transrectal ultrasonography in the diagnosis of prostatic cancer in symptomatic patients with normal rectal digital test]","Herranz Amo F, Verdu Tartajo F, Diez Cordero JM, Sánchez Carreras F, Lledo García E, Bueno Chomon G, Leal Hernández F.","Actas Urol Esp. 1997 Jun;21(6):565-71.","Herranz Amo F","Actas Urol Esp","1997","1997/06/01","","",""
"19197774","Coping with prostate cancer in Asian-American, Native Hawaiian, and Caucasian families","Mitschke DB.","Soc Work Health Care. 2009;48(2):192-206. doi: 10.1080/00981380802580513.","Mitschke DB","Soc Work Health Care","2009","2009/02/07","","","10.1080/00981380802580513"
"10408856","Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer","Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Kosma VM.","Br J Cancer. 1999 May;80(3-4):477-82. doi: 10.1038/sj.bjc.6690381.","Aaltomaa S","Br J Cancer","1999","1999/07/17","PMC2362305","","10.1038/sj.bjc.6690381"
"27189160","Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review","Endzeliņš E, Melne V, Kalniņa Z, Lietuvietis V, Riekstiņa U, Llorente A, Linē A.","Mol Cancer. 2016 May 18;15(1):41. doi: 10.1186/s12943-016-0523-5.","Endzeliņš E","Mol Cancer","2016","2016/05/19","PMC4870749","","10.1186/s12943-016-0523-5"
"18201145","Androgen deprivation therapy for prostate cancer","Singer EA, Golijanin DJ, Miyamoto H, Messing EM.","Expert Opin Pharmacother. 2008 Feb;9(2):211-28. doi: 10.1517/14656566.9.2.211.","Singer EA","Expert Opin Pharmacother","2008","2008/01/19","","","10.1517/14656566.9.2.211"
"15365578","Laparoscopic radical prostatectomy a review of the literature and comparison with open techniques","Omar AM, Townell N.","Prostate Cancer Prostatic Dis. 2004;7(4):295-301. doi: 10.1038/sj.pcan.4500755.","Omar AM","Prostate Cancer Prostatic Dis","2004","2004/09/15","","","10.1038/sj.pcan.4500755"
"17086220","[Treatment of hormone-resistant prostate cancer]","Lilleby W, Hernes E, Waehre H, Raabe N, Fosså SD.","Tidsskr Nor Laegeforen. 2006 Nov 2;126(21):2798-801.","Lilleby W","Tidsskr Nor Laegeforen","2006","2006/11/07","","",""
"12873669","A chronological database to support outcomes research in prostate cancer","Potters L, Kattan MW, Fearn P.","Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1252-8. doi: 10.1016/s0360-3016(03)00255-4.","Potters L","Int J Radiat Oncol Biol Phys","2003","2003/07/23","","","10.1016/s0360-3016(03)00255-4"
"24085599","Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology","Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM.","Clin Exp Metastasis. 2014 Feb;31(2):159-67. doi: 10.1007/s10585-013-9617-2. Epub 2013 Oct 2.","Hong MK","Clin Exp Metastasis","2014","2013/10/03","","","10.1007/s10585-013-9617-2"
"17615529","Modern brachytherapy for treatment of prostate cancer","Heysek RV.","Cancer Control. 2007 Jul;14(3):238-43. doi: 10.1177/107327480701400306.","Heysek RV","Cancer Control","2007","2007/07/07","","","10.1177/107327480701400306"
"17928375","Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy","Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH.","Cancer Res. 2007 Oct 15;67(20):9613-5. doi: 10.1158/0008-5472.CAN-07-1529. Epub 2007 Oct 10.","Keller ET","Cancer Res","2007","2007/10/12","","","10.1158/0008-5472.CAN-07-1529"
"19375624","Current prostate cancer treatments: effect on quality of life","Gomella LG, Johannes J, Trabulsi EJ.","Urology. 2009 May;73(5 Suppl):S28-35. doi: 10.1016/j.urology.2009.03.003.","Gomella LG","Urology","2009","2009/04/21","","","10.1016/j.urology.2009.03.003"
"30729683","Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers","Fang D, Zhou L.","Asia Pac J Clin Oncol. 2019 Jun;15(3):108-120. doi: 10.1111/ajco.13108. Epub 2019 Feb 6.","Fang D","Asia Pac J Clin Oncol","2019","2019/02/08","PMC6850478","","10.1111/ajco.13108"
"11528184","EAU guidelines on prostate cancer","Aus G, Abbou CC, Pacik D, Schmid HP, van Poppel H, Wolff JM, Zattoni F; EAU Working Group on Oncological Urology.","Eur Urol. 2001 Aug;40(2):97-101. doi: 10.1159/000049758.","Aus G","Eur Urol","2001","2001/08/31","","","10.1159/000049758"
"17425511","Diagnostic and prognostic value of molecular cytogenetic analyses of sextant biopsies from prostate cancer suspects","da Silva Ribeiro FR.","Crit Rev Oncog. 2006 Dec;12(3-4):303-4; discussion 304. doi: 10.1615/critrevoncog.v12.i3-4.100.","da Silva Ribeiro FR","Crit Rev Oncog","2006","2007/04/12","","","10.1615/critrevoncog.v12.i3-4.100"
"12386926","Value of contrast ultrasonography in the detection of significant prostate cancer: correlation with radical prostatectomy specimens","Sedelaar JP, van Leenders GJ, Goossen TE, Hulsbergen-van der Kaa CA, van Adrichem NP, Wijkstra H, de la Rosette JJ.","Prostate. 2002 Nov 1;53(3):246-53. doi: 10.1002/pros.10145.","Sedelaar JP","Prostate","2002","2002/10/19","","","10.1002/pros.10145"
"25794813","Advances in the treatment of prostate cancer with radiotherapy","Gómez-Millán J, Lara MF, Correa Generoso R, Perez-Rozos A, Lupiáñez-Pérez Y, Medina Carmona JA.","Crit Rev Oncol Hematol. 2015 Aug;95(2):144-53. doi: 10.1016/j.critrevonc.2015.02.008. Epub 2015 Feb 25.","Gómez-Millán J","Crit Rev Oncol Hematol","2015","2015/03/22","","","10.1016/j.critrevonc.2015.02.008"
"11340280","Familial aggregation of prostate cancer management while waiting for the identification of hereditary prostate cancer genes","Damber JE.","Eur Urol. 2001 Apr;39 Suppl 4:19-21. doi: 10.1159/000052576.","Damber JE","Eur Urol","2001","2001/05/08","","","10.1159/000052576"
"11516850","Treatment planning aids in prostate cancer: friend or foe?","Malone S, Donker R, Dahrouge S, Eapen L, Aref I, Perry G, Szanto J.","Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):49-55. doi: 10.1016/s0360-3016(01)01563-2.","Malone S","Int J Radiat Oncol Biol Phys","2001","2001/08/23","","","10.1016/s0360-3016(01)01563-2"
"30059685","Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years","Huang H, Muscatelli S, Naslund M, Badiyan SN, Kaiser A, Siddiqui MM.","J Urol. 2019 Jan;201(1):120-128. doi: 10.1016/j.juro.2018.07.049.","Huang H","J Urol","2019","2018/07/31","","","10.1016/j.juro.2018.07.049"
"10478661","Histopathologic effects of three-dimensional conformal external beam radiation therapy on benign and malignant prostate tissues","Gaudin PB, Zelefsky MJ, Leibel SA, Fuks Z, Reuter VE.","Am J Surg Pathol. 1999 Sep;23(9):1021-31. doi: 10.1097/00000478-199909000-00004.","Gaudin PB","Am J Surg Pathol","1999","1999/09/09","","","10.1097/00000478-199909000-00004"
"15386638","Differences in health-related quality of life of prostate cancer patients based on stage of cancer","Rosenfeld B, Roth AJ, Gandhi S, Penson D.","Psychooncology. 2004 Nov;13(11):800-7. doi: 10.1002/pon.797.","Rosenfeld B","Psychooncology","2004","2004/09/24","","","10.1002/pon.797"
"22703831","Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm","Créhange G, Chen CP, Hsu CC, Kased N, Coakley FV, Kurhanewicz J, Roach M 3rd.","Cancer Treat Rev. 2012 Dec;38(8):956-67. doi: 10.1016/j.ctrv.2012.05.005. Epub 2012 Jun 15.","Créhange G","Cancer Treat Rev","2012","2012/06/19","PMC3739983","NIHMS489801","10.1016/j.ctrv.2012.05.005"
"15040865","Clinical prostate cancer in year two: new and promising therapies for treatment and possible prevention of prostate cancer","Sartor O.","Clin Prostate Cancer. 2003 Sep;2(2):71. doi: 10.3816/cgc.2003.n.014.","Sartor O","Clin Prostate Cancer","2003","2004/03/26","","","10.3816/cgc.2003.n.014"
"29692262","Active Surveillance for Low-risk Prostate Cancer: Are All Criteria Similar?","Cimino S, Privitera S, Favilla V, Cantiello F, Manno S, Cicione A, Damiano R, Russo GI, Morgia G.","Anticancer Agents Med Chem. 2018;18(7):958-963. doi: 10.2174/1871520618666180425121617.","Cimino S","Anticancer Agents Med Chem","2018","2018/04/26","","","10.2174/1871520618666180425121617"
"8252080","[Andrologic problems in prostatic carcinoma]","Austoni E, Colombo F, Mantovani F, Fenice O, Vecchio D.","Arch Ital Urol Androl. 1993 Oct;65(5):517-22.","Austoni E","Arch Ital Urol Androl","1993","1993/10/01","","",""
"16998812","Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway","Lindström S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, Bälter KA, Brookes AJ, Sun J, Chang BL, Liu W, Li G, Isaacs WB, Adolfsson J, Grönberg H, Xu J.","Prostate. 2006 Dec 1;66(16):1729-43. doi: 10.1002/pros.20489.","Lindström S","Prostate","2006","2006/09/26","","","10.1002/pros.20489"
"28818014","Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review","Becker JA, Berg KD, Røder MA, Brasso K, Iversen P.","Scand J Urol. 2018 Feb;52(1):1-7. doi: 10.1080/21681805.2017.1363816. Epub 2017 Aug 18.","Becker JA","Scand J Urol","2018","2017/08/19","","","10.1080/21681805.2017.1363816"
"2677409","Evaluation of transrectal ultrasound in the early detection of prostate cancer","Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC.","J Urol. 1989 Oct;142(4):1008-10. doi: 10.1016/s0022-5347(17)38971-1.","Carter HB","J Urol","1989","1989/10/01","","","10.1016/s0022-5347(17)38971-1"
"27164513","Surgery Provides Better Oncologic Outcomes than Radiation for the Treatment of Prostate Cancer","Klotz L, Evans CP.","J Urol. 2016 Aug;196(2):309-11. doi: 10.1016/j.juro.2016.05.008. Epub 2016 May 7.","Klotz L","J Urol","2016","2016/05/11","","","10.1016/j.juro.2016.05.008"
"19222885","A comparative study of prostate cancer detection and management in China and in France","Peyromaure EM, Mao K, Sun Y, Xia S, Jiang N, Zhang S, Wang G, Liu Z, Debré B.","Can J Urol. 2009 Feb;16(1):4472-7.","Peyromaure EM","Can J Urol","2009","2009/02/19","","",""
"6379805","Interstitial irradiation for localized prostate cancer","Herr HW.","Semin Urol. 1983 Aug;1(3):222-8.","Herr HW","Semin Urol","1983","1983/08/01","","",""
"20870082","Focal therapy meets prostate cancer","Lazzeri M, Guazzoni G.","Lancet. 2010 Sep 25;376(9746):1036-7. doi: 10.1016/S0140-6736(10)60594-6.","Lazzeri M","Lancet","2010","2010/09/28","","","10.1016/S0140-6736(10)60594-6"
"22994753","MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer","Liu DF, Wu JT, Wang JM, Liu QZ, Gao ZL, Liu YX.","Asian Pac J Cancer Prev. 2012;13(7):3313-7. doi: 10.7314/apjcp.2012.13.7.3313.","Liu DF","Asian Pac J Cancer Prev","2012","2012/09/22","","","10.7314/apjcp.2012.13.7.3313"
"27314568","Management of men with previous negative prostate biopsy","Perera M, Manning T, Finelli A, Lawrentschuk N.","Curr Opin Urol. 2016 Sep;26(5):481-7. doi: 10.1097/MOU.0000000000000315.","Perera M","Curr Opin Urol","2016","2016/06/18","","","10.1097/MOU.0000000000000315"
"8977989","Quality of life in prostate cancer patients","Rossetti SR, Terrone C.","Eur Urol. 1996;30 Suppl 1:44-8; discussion 49. doi: 10.1159/000474246.","Rossetti SR","Eur Urol","1996","1996/01/01","","","10.1159/000474246"
"10087729","Hormonal ablation therapy for metastatic prostatic carcinoma: a review","Leewansangtong S, Soontrapa S.","J Med Assoc Thai. 1999 Feb;82(2):192-205.","Leewansangtong S","J Med Assoc Thai","1999","1999/03/24","","",""
"29040256","The role of genomics in patients with advanced prostate cancer","Hussain MH.","Clin Adv Hematol Oncol. 2017 Oct;15(10):770-772.","Hussain MH","Clin Adv Hematol Oncol","2017","2017/10/18","","",""
"25623706","Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African American, human immunodeficiency virus-infected patients","Riedel DJ, Cox ER, Stafford KA, Gilliam BL.","Urology. 2015 Feb;85(2):415-21. doi: 10.1016/j.urology.2014.09.054. Epub 2014 Nov 4.","Riedel DJ","Urology","2015","2015/01/28","PMC4308815","NIHMS640355","10.1016/j.urology.2014.09.054"
"22733135","Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression","Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM.","Oncogene. 2013 May 2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25.","Longoni N","Oncogene","2013","2012/06/27","","","10.1038/onc.2012.245"
"11901827","Microscopic cantilever aids assay for prostate cancer","","Expert Rev Mol Diagn. 2001 Sep;1(3):247.","","Expert Rev Mol Diagn","2001","2002/03/21","","",""
"9091653","Rapid research response emphasized in unique prostate cancer program","Gunby P.","JAMA. 1997 Mar 26;277(12):945-8.","Gunby P","JAMA","1997","1997/03/26","","",""
"18338760","Re: Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer","Koontz BF, Moul J.","Cancer. 2008 Jun;112(11):2518-9; author reply 2519. doi: 10.1002/cncr.23464.","Koontz BF","Cancer","2008","2008/03/15","","","10.1002/cncr.23464"
"27100731","Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome","Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P, Cuzick J.","Br J Cancer. 2016 May 10;114(10):1078-83. doi: 10.1038/bjc.2016.86. Epub 2016 Apr 21.","Berney DM","Br J Cancer","2016","2016/04/22","PMC4865975","","10.1038/bjc.2016.86"
"25979544","Is radical prostatectomy appropriate for very-high-risk prostate cancer patients? No","Boyle JM, Lee WR.","Oncology (Williston Park). 2015 May;29(5):349, 389.","Boyle JM","Oncology (Williston Park)","2015","2015/05/17","","",""
"12806370","Gene delivery into prostate cancer cells by holmium laser application","Sagi S, Knoll T, Trojan L, Schaaf A, Alken P, Michel MS.","Prostate Cancer Prostatic Dis. 2003;6(2):127-30. doi: 10.1038/sj.pcan.4500653.","Sagi S","Prostate Cancer Prostatic Dis","2003","2003/06/14","","","10.1038/sj.pcan.4500653"
"30587496","The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs","Weidle UH, Epp A, Birzele F, Brinkmann U.","Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):1-19. doi: 10.21873/cgp.20108.","Weidle UH","Cancer Genomics Proteomics","2019","2018/12/28","PMC6348398","","10.21873/cgp.20108"
"17929562","[Role of RASSF1A hypermethylation in prostate cancer]","Wang YC, Yu ZH, Chen LB.","Zhonghua Nan Ke Xue. 2007 Sep;13(9):822-5.","Wang YC","Zhonghua Nan Ke Xue","2007","2007/10/13","","",""
"9855122","Long-term results of definitive treatment in elderly patients with localized prostate cancer","Kanamaru H, Arai Y, Moroi S, Yoshida H, Yoshimura K, Okada K.","Int J Urol. 1998 Nov;5(6):546-9. doi: 10.1111/j.1442-2042.1998.tb00410.x.","Kanamaru H","Int J Urol","1998","1998/12/17","","","10.1111/j.1442-2042.1998.tb00410.x"
"26390559","[QUALITY OF LIFE IN PATIENTS UNDERGOING PROSTATE CRYOABLATION]","Govorov AV, Vasil'ev AO, Pushkar DJ.","Urologiia. 2015 May-Jun;(3):43-8.","Govorov AV","Urologiia","2015","2015/09/23","","",""
"25353342","'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer","Voskoboynik M, Staffurth J, Malik Z, Sweeney C, Chowdhury S.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1253-6. doi: 10.1586/14737140.2014.971112. Epub 2014 Oct 29.","Voskoboynik M","Expert Rev Anticancer Ther","2014","2014/10/30","","","10.1586/14737140.2014.971112"
"3050538","Application of flow cytometry and automated image analysis to the study of prostate cancer","Benson MC.","NCI Monogr. 1988;(7):25-9.","Benson MC","NCI Monogr","1988","1988/01/01","","",""
"7515219","Prostate carcinoma","Andriole GL, Catalona WJ.","Annu Rev Med. 1994;45:351-9. doi: 10.1146/annurev.med.45.1.351.","Andriole GL","Annu Rev Med","1994","1994/01/01","","","10.1146/annurev.med.45.1.351"
"10695201","Use of a medical decision support system to improve the preoperative diagnosis of prostate cancer with pelvic lymph node metastases","Chang PL, Wang TM, Huang ST, Hsieh ML, Tsui KH, Lai RH.","Changgeng Yi Xue Za Zhi. 1999 Dec;22(4):556-64.","Chang PL","Changgeng Yi Xue Za Zhi","1999","2000/03/01","","",""
"31206999","NICE guidelines on prostate cancer 2019","Dasgupta P, Davis J, Hughes S.","BJU Int. 2019 Jul;124(1):1. doi: 10.1111/bju.14815.","Dasgupta P","BJU Int","2019","2019/06/18","","","10.1111/bju.14815"
"2674986","Is radiotherapy of use in stage C prostate cancer?","Porter AT.","Prog Clin Biol Res. 1989;303:211-8.","Porter AT","Prog Clin Biol Res","1989","1989/01/01","","",""
"10539394","A review of quality-of-life evaluations in prostate cancer","Sommers SD, Ramsey SD.","Pharmacoeconomics. 1999 Aug;16(2):127-40. doi: 10.2165/00019053-199916020-00002.","Sommers SD","Pharmacoeconomics","1999","1999/10/28","","","10.2165/00019053-199916020-00002"
"10521913","Treating prostate cancer. Part IV: radiotherapy","","Harv Mens Health Watch. 1999 Nov;4(4):2-6.","","Harv Mens Health Watch","1999","1999/10/16","","",""
"8158781","Prostate cancer therapy","Lowe BA.","J Urol. 1994 May;151(5):1334-5. doi: 10.1016/s0022-5347(17)35245-x.","Lowe BA","J Urol","1994","1994/05/01","","","10.1016/s0022-5347(17)35245-x"
"7500468","Familial aspects of prostate cancer: a case control study","Keetch DW, Rice JP, Suarez BK, Catalona WJ.","J Urol. 1995 Dec;154(6):2100-2.","Keetch DW","J Urol","1995","1995/12/01","","",""
"26618297","In the Clinic. Prostate Cancer","Talcott JA.","Ann Intern Med. 2015 Dec 1;163(11):ITC1-12. doi: 10.7326/AITC201512010.","Talcott JA","Ann Intern Med","2015","2015/12/01","","","10.7326/AITC201512010"
"9307343","Predicting pathological stage of localized prostate cancer","Petros JA.","JAMA. 1997 Sep 24;278(12):981; author reply 981-2. doi: 10.1001/jama.278.12.981.","Petros JA","JAMA","1997","1997/11/05","","","10.1001/jama.278.12.981"
"7753713","In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines","Cornel EB, Smits GA, de Ruijter JE, Oosterhof GO, Heerschap A, Debruyne FM, Schalken JA.","Prostate. 1995 May;26(5):275-80. doi: 10.1002/pros.2990260508.","Cornel EB","Prostate","1995","1995/05/01","","","10.1002/pros.2990260508"
"16353767","[High risk disseminated prostate cancer (consensus paper and recommendations)]","Grupo de Expertos en Cáncer de Próstata.","Actas Urol Esp. 2005 Oct;29(9):826-7. doi: 10.1016/s0210-4806(05)73352-0.","Grupo de Expertos en Cáncer de Próstata","Actas Urol Esp","2005","2005/12/16","","","10.1016/s0210-4806(05)73352-0"
"9156279","Molecular and cellular biology of prostate cancer","Lalani el-N, Laniado ME, Abel PD.","Cancer Metastasis Rev. 1997 Jun;16(1-2):29-66. doi: 10.1023/a:1005792206377.","Lalani el-N","Cancer Metastasis Rev","1997","1997/06/01","","","10.1023/a:1005792206377"
"10147438","Clinical and economic considerations in the treatment of prostate cancer","Varenhorst E, Carlsson P, Pedersen K.","Pharmacoeconomics. 1994 Aug;6(2):127-41. doi: 10.2165/00019053-199406020-00005.","Varenhorst E","Pharmacoeconomics","1994","1994/07/07","","","10.2165/00019053-199406020-00005"
"24909936","A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease","Severi G, FitzGerald LM, Muller DC, Pedersen J, Longano A, Southey MC, Hopper JL, English DR, Giles GG, Mills J.","Cancer Med. 2014 Oct;3(5):1266-74. doi: 10.1002/cam4.281. Epub 2014 Jun 7.","Severi G","Cancer Med","2014","2014/06/10","PMC4302676","","10.1002/cam4.281"
"25412869","(68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer","Eiber M, Nekolla SG, Maurer T, Weirich G, Wester HJ, Schwaiger M.","Abdom Imaging. 2015 Aug;40(6):1769-71. doi: 10.1007/s00261-014-0301-z.","Eiber M","Abdom Imaging","2015","2014/11/22","","","10.1007/s00261-014-0301-z"
"16310934","Prostate cancer: fine tuning our ability to accurately grade and stage the disease prior to therapy","Zlotta AR.","Eur Urol. 2006 Jan;49(1):8-10. doi: 10.1016/j.eururo.2005.10.018. Epub 2005 Nov 15.","Zlotta AR","Eur Urol","2006","2005/11/29","","","10.1016/j.eururo.2005.10.018"
"22824430","Cholesterol and prostate cancer","Pelton K, Freeman MR, Solomon KR.","Curr Opin Pharmacol. 2012 Dec;12(6):751-9. doi: 10.1016/j.coph.2012.07.006. Epub 2012 Jul 21.","Pelton K","Curr Opin Pharmacol","2012","2012/07/25","PMC3515742","NIHMS398951","10.1016/j.coph.2012.07.006"
"10492193","Predicting extracapsular extension of prostate cancer in men treated with radical prostatectomy: results from the population based prostate cancer outcomes study","Gilliland FD, Hoffman RM, Hamilton A, Albertsen P, Eley JW, Harlan L, Stanford JL, Hunt WC, Potosky A, Stephenson RA.","J Urol. 1999 Oct;162(4):1341-5.","Gilliland FD","J Urol","1999","1999/09/24","","",""
"15695425","Mass spectrometry-based expression profiling of clinical prostate cancer","Wright ME, Han DK, Aebersold R.","Mol Cell Proteomics. 2005 Apr;4(4):545-54. doi: 10.1074/mcp.R500008-MCP200. Epub 2005 Feb 2.","Wright ME","Mol Cell Proteomics","2005","2005/02/08","","","10.1074/mcp.R500008-MCP200"
"15026796","A population-based study of pain and quality of life during the year before death in men with prostate cancer","Sandblom G, Carlsson P, Sennfält K, Varenhorst E.","Br J Cancer. 2004 Mar 22;90(6):1163-8. doi: 10.1038/sj.bjc.6601654.","Sandblom G","Br J Cancer","2004","2004/03/18","PMC2409660","","10.1038/sj.bjc.6601654"
"15888746","ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer","Kataja VV, Bergh J.","Ann Oncol. 2005;16 Suppl 1:i34-6. doi: 10.1093/annonc/mdi826.","Kataja VV","Ann Oncol","2005","2005/05/13","","","10.1093/annonc/mdi826"
"26793884","[Optimization of prostate biopsy strategy in diagnosis of prostate cancer]","Kimura G.","Nihon Rinsho. 2016 Jan;74(1):79-84.","Kimura G","Nihon Rinsho","2016","2016/01/23","","",""
"15262429","DNA sequence copy number aberrations in prostate cancers: a comparison of comparative genomic hybridization data between Japan and European countries","Matsuda K, Matsuyama H, Hara T, Yoshihiro S, Oga A, Kawauchi S, Furuya T, Izumi H, Naito K, Sasaki K.","Cancer Genet Cytogenet. 2004 Jul 15;152(2):119-23. doi: 10.1016/j.cancergencyto.2003.11.017.","Matsuda K","Cancer Genet Cytogenet","2004","2004/07/21","","","10.1016/j.cancergencyto.2003.11.017"
"24686169","NF-κB gene signature predicts prostate cancer progression","Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA Jr, Matusik RJ.","Cancer Res. 2014 May 15;74(10):2763-72. doi: 10.1158/0008-5472.CAN-13-2543. Epub 2014 Mar 31.","Jin R","Cancer Res","2014","2014/04/02","PMC4024337","NIHMS578228","10.1158/0008-5472.CAN-13-2543"
"25824767","Case-control study of diet and prostate cancer in a rural population of Faisalabad, Pakistan","Bashir MN, Malik MA.","Asian Pac J Cancer Prev. 2015;16(6):2375-8. doi: 10.7314/apjcp.2015.16.6.2375.","Bashir MN","Asian Pac J Cancer Prev","2015","2015/04/01","","","10.7314/apjcp.2015.16.6.2375"
"25525592","The role of MRI in prostate cancer active surveillance","Johnson LM, Choyke PL, Figg WD, Turkbey B.","Biomed Res Int. 2014;2014:203906. doi: 10.1155/2014/203906. Epub 2014 Nov 30.","Johnson LM","Biomed Res Int","2014","2014/12/20","PMC4266760","","10.1155/2014/203906"
"18307688","Management of localized prostate cancer in senior adults: the crucial role of comorbidity","Fitzpatrick JM.","BJU Int. 2008 Mar;101 Suppl 2:16-22. doi: 10.1111/j.1464-410X.2007.07487.x.","Fitzpatrick JM","BJU Int","2008","2008/03/01","","","10.1111/j.1464-410X.2007.07487.x"
"31102571","Multiparametric MRI prior to radical prostatectomy identifies intraductal and cribriform growth patterns in prostate cancer","Tonttila PP, Ahtikoski A, Kuisma M, Pääkkö E, Hirvikoski P, Vaarala MH.","BJU Int. 2019 Dec;124(6):992-998. doi: 10.1111/bju.14812. Epub 2019 Jun 19.","Tonttila PP","BJU Int","2019","2019/05/19","","","10.1111/bju.14812"
"18522141","Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer","Wesley D, Cox HF.","J Insur Med. 2007;39(4):242-50.","Wesley D","J Insur Med","2007","2008/06/05","","",""
"8262850","Concurrent treatment planning for outpatient high dose rate prostate template implants","Edmundson GK, Rizzo NR, Teahan M, Brabbins D, Vicini FA, Martinez A.","Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1215-23. doi: 10.1016/0360-3016(93)90546-8.","Edmundson GK","Int J Radiat Oncol Biol Phys","1993","1993/12/01","","","10.1016/0360-3016(93)90546-8"
"9615377","[The treatment of locally advanced (T3) prostatic carcinoma using radical prostatectomy or radiotherapy. A review]","van den Ouden D, Schröder FH.","Tijdschr Gerontol Geriatr. 1998 Apr;29(2):74-9.","van den Ouden D","Tijdschr Gerontol Geriatr","1998","1998/06/06","","",""
"26575059","The Pendulum of Prostate Cancer Screening","Penson DF.","JAMA. 2015 Nov 17;314(19):2031-3. doi: 10.1001/jama.2015.13775.","Penson DF","JAMA","2015","2015/11/18","","","10.1001/jama.2015.13775"
"18074436","Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy","de Reijke TM.","Eur Urol. 2007 Dec;52(6):1650-1.","de Reijke TM","Eur Urol","2007","2007/12/13","","",""
"27374083","The activation of OR51E1 causes growth suppression of human prostate cancer cells","Maßberg D, Jovancevic N, Offermann A, Simon A, Baniahmad A, Perner S, Pungsrinont T, Luko K, Philippou S, Ubrig B, Heiland M, Weber L, Altmüller J, Becker C, Gisselmann G, Gelis L, Hatt H.","Oncotarget. 2016 Jul 26;7(30):48231-48249. doi: 10.18632/oncotarget.10197.","Maßberg D","Oncotarget","2016","2016/07/05","PMC5217014","","10.18632/oncotarget.10197"
"24672972","Speaking out on prostate cancer awareness","Rowan L.","Aust Nurs Midwifery J. 2013 Nov;21(5):38-9.","Rowan L","Aust Nurs Midwifery J","2013","2014/03/29","","",""
"16800134","[Prostate cancer and transrectal ultrasound]","Herranz Amo F, Verdú Tartajo F, Martínez Salamanca JI.","Arch Esp Urol. 2006 May;59(4):361-75.","Herranz Amo F","Arch Esp Urol","2006","2006/06/28","","",""
"30587560","Metastatic Prostate Cancer in a RAD51C Mutation Carrier","Potugari BR, Engel JM, Onitilo AA.","Clin Med Res. 2018 Dec;16(3-4):69-72. doi: 10.3121/cmr.2018.1411.","Potugari BR","Clin Med Res","2018","2018/12/28","PMC6306144","","10.3121/cmr.2018.1411"
"21930089","Application of metabolomics to prostate cancer","Trock BJ.","Urol Oncol. 2011 Sep-Oct;29(5):572-81. doi: 10.1016/j.urolonc.2011.08.002.","Trock BJ","Urol Oncol","2011","2011/09/21","PMC3180907","NIHMS322443","10.1016/j.urolonc.2011.08.002"
"23288649","Impact of genetic targets on prostate cancer therapy","Sheikh H, Abdulghani J, Ali S, Sinha R, Lipton A.","Adv Exp Med Biol. 2013;779:359-83. doi: 10.1007/978-1-4614-6176-0_17.","Sheikh H","Adv Exp Med Biol","2013","2013/01/05","","","10.1007/978-1-4614-6176-0_17"
"10328112","Re: Race, prostate cancer survival, and membership in a large health maintenance organization","Roach M 3rd, Forte D, Alexander M.","J Natl Cancer Inst. 1999 May 5;91(9):801-3. doi: 10.1093/jnci/91.9.801.","Roach M 3rd","J Natl Cancer Inst","1999","1999/05/18","","","10.1093/jnci/91.9.801"
"24344002","Current role of immunotherapy for the treatment of prostate cancer","Porfyris O, Kalomoiris P.","J BUON. 2013 Oct-Dec;18(4):809-17.","Porfyris O","J BUON","2013","2013/12/18","","",""
"22052755","Diet and prostate cancer - a holistic approach to management","Cheetham PJ, Katz AE.","Arch Esp Urol. 2011 Oct;64(8):720-34.","Cheetham PJ","Arch Esp Urol","2011","2011/11/05","","",""
"7690704","Value of prostate cancer screening","Gerber GS, Chodak GW.","Eur Urol. 1993;24(2):161-5. doi: 10.1159/000474287.","Gerber GS","Eur Urol","1993","1993/01/01","","","10.1159/000474287"
"28783263","Most of patients with localized prostate cancer will be treated in the future? | Opinion: No","Schulman AA, Polascik TJ.","Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03.","Schulman AA","Int Braz J Urol","2017","2017/08/08","PMC5557432","","10.1590/S1677-5538.IBJU.2017.04.03"
"20927021","PET/CT and radiotherapy in prostate cancer","De Jong IJ, De Haan TD, Wiegman EM, Van Den Bergh AC, Pruim J, Breeuwsma AJ.","Q J Nucl Med Mol Imaging. 2010 Oct;54(5):543-52.","De Jong IJ","Q J Nucl Med Mol Imaging","2010","2010/10/08","","",""
"24576172","Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry","Crawford ED, Scholz MC, Kar AJ, Fegan JE, Haregewoin A, Kaldate RR, Brawer MK.","Curr Med Res Opin. 2014 Jun;30(6):1025-31. doi: 10.1185/03007995.2014.899208. Epub 2014 Mar 13.","Crawford ED","Curr Med Res Opin","2014","2014/03/01","","","10.1185/03007995.2014.899208"
"16286120","Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages","Ross KS, Guess HA, Carter HB.","Urology. 2005 Nov;66(5):1038-42. doi: 10.1016/j.urology.2005.05.030.","Ross KS","Urology","2005","2005/11/16","","","10.1016/j.urology.2005.05.030"
"7684543","Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer","Morgan WR, Bergstralh EJ, Zincke H.","Urology. 1993 Feb;41(2):113-20. doi: 10.1016/0090-4295(93)90159-8.","Morgan WR","Urology","1993","1993/02/01","","","10.1016/0090-4295(93)90159-8"
"17073766","Mechanisms of androgen receptor repression in prostate cancer","Powell SM, Brooke GN, Whitaker HC, Reebye V, Gamble SC, Chotai D, Dart DA, Belandia B, Bevan CL.","Biochem Soc Trans. 2006 Dec;34(Pt 6):1124-7. doi: 10.1042/BST0341124.","Powell SM","Biochem Soc Trans","2006","2006/11/01","","","10.1042/BST0341124"
"21808286","Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy","Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ.","Prostate Cancer Prostatic Dis. 2012 Mar;15(1):56-62. doi: 10.1038/pcan.2011.36. Epub 2011 Aug 2.","Boorjian SA","Prostate Cancer Prostatic Dis","2012","2011/08/03","","","10.1038/pcan.2011.36"
"26583636","Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives","dela Rama F, Pratz C.","Clin J Oncol Nurs. 2015 Dec;19(6):723-32. doi: 10.1188/15.CJON.723-732.","dela Rama F","Clin J Oncol Nurs","2015","2015/11/20","","","10.1188/15.CJON.723-732"
"18581689","Biomagnetic activity in prostate cancer and BPH","Anninos P, Papadopoulos I, Kotini A.","Arch Esp Urol. 2008 Apr;61(3):459-63. doi: 10.4321/s0004-06142008000300018.","Anninos P","Arch Esp Urol","2008","2008/06/28","","","10.4321/s0004-06142008000300018"
"1428988","An update on the role of ploidy in prostate carcinoma","Peters-Gee JM.","Henry Ford Hosp Med J. 1992;40(1-2):99-102.","Peters-Gee JM","Henry Ford Hosp Med J","1992","1992/01/01","","",""
"16904050","Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?","Amling CL.","Curr Treat Options Oncol. 2006 Sep;7(5):337-45. doi: 10.1007/s11864-006-0001-1.","Amling CL","Curr Treat Options Oncol","2006","2006/08/15","","","10.1007/s11864-006-0001-1"
"18834662","Predictive modeling in prostate cancer: a conference summary","Valdagni R, Scardino PT, Denis L, Kattan MW.","Eur Urol. 2009 Feb;55(2):300-2. doi: 10.1016/j.eururo.2008.09.004. Epub 2008 Sep 17.","Valdagni R","Eur Urol","2009","2008/10/07","","","10.1016/j.eururo.2008.09.004"
"22193242","Should we really consider Gleason 6 prostate cancer?","Nickel JC, Speakman M.","BJU Int. 2012 Mar;109(5):645-6. doi: 10.1111/j.1464-410X.2011.10854.x. Epub 2011 Dec 22.","Nickel JC","BJU Int","2012","2011/12/24","","","10.1111/j.1464-410X.2011.10854.x"
"27813382","MRI should be routine for all patients with localized prostate cancer? | Opinion: No","Nelson JB.","Int Braz J Urol. 2016 Nov-Dec;42(6):1065-1068. doi: 10.1590/S1677-5538.IBJU.2016.06.04.","Nelson JB","Int Braz J Urol","2016","2016/11/05","PMC5117961","","10.1590/S1677-5538.IBJU.2016.06.04"
"12660074","Early prostate cancer: clinical decision-making","Jani AB, Hellman S.","Lancet. 2003 Mar 22;361(9362):1045-53. doi: 10.1016/S0140-6736(03)12833-4.","Jani AB","Lancet","2003","2003/03/28","","","10.1016/S0140-6736(03)12833-4"
"28281040","The effect of Rapid Access Prostate Clinics on the outcomes of Gleason 7 prostate cancer: does earlier diagnosis lead to better outcomes?","Broe MP, Forde JC, Inder MS, Galvin DJ, Mulvin DW, Quinlan DM.","Ir J Med Sci. 2017 Aug;186(3):583-588. doi: 10.1007/s11845-017-1583-2. Epub 2017 Mar 9.","Broe MP","Ir J Med Sci","2017","2017/03/11","","","10.1007/s11845-017-1583-2"
"1722921","[Diagnosis of localized prostate cancer: screening and preoperative staging]","Hammerer P, Huland H.","Urologe A. 1991 Nov;30(6):378-86.","Hammerer P","Urologe A","1991","1991/11/01","","",""
"8545344","[Prostate-specific antigen or PSA. Facts and probabilities]","Boccon-Gibod L.","Presse Med. 1995 Oct 28;24(32):1471-2.","Boccon-Gibod L","Presse Med","1995","1995/10/28","","",""
"16484944","[Prostatic neoplasms: clinical and biological aspects, histopathologic patterns]","Puech P, Villers A, Mouton D, Leroy X, Lemaître L.","J Radiol. 2006 Feb;87(2 Pt 2):189-200. doi: 10.1016/s0221-0363(06)73993-2.","Puech P","J Radiol","2006","2006/02/18","","","10.1016/s0221-0363(06)73993-2"
"7804970","The National Cancer Data Base report on prostate cancer","Aldrich T, Demark-Wahnefried W, Schildkraut JM, Lengerich E, Conlísk E.","Cancer. 1995 Jan 1;75(1):136-8. doi: 10.1002/1097-0142(19950101)75:1<136::aid-cncr2820750126>3.0.co;2-3.","Aldrich T","Cancer","1995","1995/01/01","","","10.1002/1097-0142(19950101)75:1<136::aid-cncr2820750126>3.0.co;2-3"
"31597067","The Scottish prostate cryotherapy service-the role of the clinical nurse specialist","Birrell F, Leung HY.","Br J Nurs. 2019 Oct 10;28(18):S12-S16. doi: 10.12968/bjon.2019.28.18.S12.","Birrell F","Br J Nurs","2019","2019/10/10","","","10.12968/bjon.2019.28.18.S12"
"21606971","Immunotherapy for the treatment of prostate cancer","Di Lorenzo G, Buonerba C, Kantoff PW.","Nat Rev Clin Oncol. 2011 May 24;8(9):551-61. doi: 10.1038/nrclinonc.2011.72.","Di Lorenzo G","Nat Rev Clin Oncol","2011","2011/05/25","","","10.1038/nrclinonc.2011.72"
"8521129","Preoperative estimate of extent of disease in T1c: how well can we predict?","Austenfeld MS.","Semin Urol Oncol. 1995 Aug;13(3):176-80.","Austenfeld MS","Semin Urol Oncol","1995","1995/08/01","","",""
"2674995","Management of hormone-resistant prostate cancer","Gibbons RP.","Prog Clin Biol Res. 1989;303:337-45.","Gibbons RP","Prog Clin Biol Res","1989","1989/01/01","","",""
"24169342","The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients","Dieperink KB, Johansen C, Hansen S, Wagner L, Andersen KK, Minet LR, Hansen O.","Br J Cancer. 2013 Dec 10;109(12):3005-13. doi: 10.1038/bjc.2013.679. Epub 2013 Oct 29.","Dieperink KB","Br J Cancer","2013","2013/10/31","PMC3859951","","10.1038/bjc.2013.679"
"15751404","[Therapeutic implications of the revised concept of hormone-refractory metastatic prostate cancer]","Paule B.","Prog Urol. 2004 Dec;14(6):1119-24.","Paule B","Prog Urol","2004","2005/03/09","","",""
"10617819","[Recommendations for reforming prostatic specimens. Les Membres du Sous-Comité Prostate du Comité de Cancerologie de l'Association Française d'Urologie]","Molinié V, Vieillefond A, Cochand-Priollet B, Dauge-Geffroy MC, Lefrère-Belda MA, de Fromont M, Lesourd A, Toublanc M, Berger N, Bouvier R, Villers A.","Ann Pathol. 1999 Dec;19(6):549-56.","Molinié V","Ann Pathol","1999","2000/01/05","","",""
"10325493","Dietary fat and prostate cancer progression and survival","Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L.","Eur Urol. 1999;35(5-6):388-91. doi: 10.1159/000019913.","Fradet Y","Eur Urol","1999","1999/05/15","","","10.1159/000019913"
"31478113","The Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in the Detection, Evaluation, and Surveillance of Clinically Significant Prostate Cancer (csPCa)","Patel P, Wang S, Siddiqui MM.","Curr Urol Rep. 2019 Sep 2;20(10):60. doi: 10.1007/s11934-019-0926-0.","Patel P","Curr Urol Rep","2019","2019/09/04","","","10.1007/s11934-019-0926-0"
"31614208","Intracrinology-revisited and prostate cancer","Penning TM, Detlefsen AJ.","J Steroid Biochem Mol Biol. 2020 Feb;196:105499. doi: 10.1016/j.jsbmb.2019.105499. Epub 2019 Oct 12.","Penning TM","J Steroid Biochem Mol Biol","2020","2019/10/16","PMC6954292","NIHMS1543269","10.1016/j.jsbmb.2019.105499"
"8717472","Appraisal of current therapies for prostate cancer","Trachtenberg J.","Eur Urol. 1996;29 Suppl 2:110-3. doi: 10.1159/000473849.","Trachtenberg J","Eur Urol","1996","1996/01/01","","","10.1159/000473849"
"9020270","Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden","Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO.","JAMA. 1997 Feb 12;277(6):467-71.","Johansson JE","JAMA","1997","1997/02/12","","",""
"23084531","Advanced clinical states in prostate cancer","Cheng HH, Lin DW, Yu EY.","Urol Clin North Am. 2012 Nov;39(4):561-71. doi: 10.1016/j.ucl.2012.07.011. Epub 2012 Sep 12.","Cheng HH","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.07.011"
"10520680","Evaluation of a decision-support system for preoperative staging of prostate cancer","Chang PL, Li YC, Wang TM, Huang ST, Hsieh ML, Tsui KH.","Med Decis Making. 1999 Oct-Dec;19(4):419-27. doi: 10.1177/0272989X9901900410.","Chang PL","Med Decis Making","1999","1999/10/16","","","10.1177/0272989X9901900410"
"30171228","The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort","Möller A, Olsson H, Grönberg H, Eklund M, Aly M, Nordström T.","Prostate Cancer Prostatic Dis. 2019 Mar;22(1):137-142. doi: 10.1038/s41391-018-0082-5. Epub 2018 Aug 31.","Möller A","Prostate Cancer Prostatic Dis","2019","2018/09/02","","","10.1038/s41391-018-0082-5"
"25605146","Evaluation of environmental risk factors for prostate cancer in a population of Iranian patients","Pouresmaeili F, Hosseini SJ, Farzaneh F, Karimpour A, Azargashb E, Yaghoobi M, Kamarehei M.","Asian Pac J Cancer Prev. 2014;15(24):10603-5. doi: 10.7314/apjcp.2014.15.24.10603.","Pouresmaeili F","Asian Pac J Cancer Prev","2014","2015/01/22","","","10.7314/apjcp.2014.15.24.10603"
"21717898","Screening for prostate cancer with PSA testing: current status and future directions","Croswell JM, Kramer BS, Crawford ED.","Oncology (Williston Park). 2011 May;25(6):452-60, 463.","Croswell JM","Oncology (Williston Park)","2011","2011/07/02","","",""
"9474190","Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup","Garzotto M, Wajsman Z.","J Urol. 1998 Mar;159(3):950-4; discussion 954-5.","Garzotto M","J Urol","1998","1998/02/25","","",""
"26857022","The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism","Shiota M, Fujimoto N, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M.","Prostate Cancer Prostatic Dis. 2016 Jun;19(2):191-6. doi: 10.1038/pcan.2016.2. Epub 2016 Feb 9.","Shiota M","Prostate Cancer Prostatic Dis","2016","2016/02/10","","","10.1038/pcan.2016.2"
"12400994","Prostate cancer diagnosis, staging and survival","Narain V, Cher ML, Wood DP Jr.","Cancer Metastasis Rev. 2002;21(1):17-27. doi: 10.1023/a:1020104004588.","Narain V","Cancer Metastasis Rev","2002","2002/10/29","","","10.1023/a:1020104004588"
"15882474","Is there a role for less invasive therapeutic approaches for low- and intermediate-grade organ-confined prostate cancer?","Sartor O.","Clin Prostate Cancer. 2005 Mar;3(4):205. doi: 10.3816/cgc.2005.n.001.","Sartor O","Clin Prostate Cancer","2005","2005/05/11","","","10.3816/cgc.2005.n.001"
"16418509","Advertising campaign puts face on prostate cancer","Vastag B.","J Natl Cancer Inst. 2006 Jan 18;98(2):89. doi: 10.1093/jnci/djj046.","Vastag B","J Natl Cancer Inst","2006","2006/01/19","","","10.1093/jnci/djj046"
"29508849","Prostate cancer: Mouse model for testing treatments","Kelsey R.","Nat Rev Urol. 2018 Apr;15(4):205. doi: 10.1038/nrurol.2018.35. Epub 2018 Mar 6.","Kelsey R","Nat Rev Urol","2018","2018/03/07","","","10.1038/nrurol.2018.35"
"19601514","You're the flight surgeon. Prostate cancer, erectile dysfunction, and seizure","York RR Jr.","Aviat Space Environ Med. 2009 Jul;80(7):670-1. doi: 10.3357/asem.23003.2009.","York RR Jr","Aviat Space Environ Med","2009","2009/07/16","","","10.3357/asem.23003.2009"
"27161545","Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis","Cui Y, Cao W, Li Q, Shen H, Liu C, Deng J, Xu J, Shao Q.","Sci Rep. 2016 May 10;6:25776. doi: 10.1038/srep25776.","Cui Y","Sci Rep","2016","2016/05/11","PMC4861967","","10.1038/srep25776"
"15341673","Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer","Nakabayashi M, Oh WK.","Curr Treat Options Oncol. 2004 Oct;5(5):349-55. doi: 10.1007/s11864-004-0025-3.","Nakabayashi M","Curr Treat Options Oncol","2004","2004/09/03","","","10.1007/s11864-004-0025-3"
"2683304","Ultrasound-guided implantation techniques in treatment of prostate cancer","Carter SS, Torp-Pedersen ST, Holm HH.","Urol Clin North Am. 1989 Nov;16(4):751-62.","Carter SS","Urol Clin North Am","1989","1989/11/01","","",""
"24683725","Active surveillance for African-American men with prostate cancer: proceed with caution. Con","Sundi D, Schaeffer EM.","Oncology (Williston Park). 2014 Jan;28(1):83, 85.","Sundi D","Oncology (Williston Park)","2014","2014/04/02","","",""
"9286819","PSA thresholds for prostate cancer detection","Moul JW.","JAMA. 1997 Sep 3;278(9):699; author reply 700-1. doi: 10.1001/jama.278.9.699b.","Moul JW","JAMA","1997","1997/09/03","","","10.1001/jama.278.9.699b"
"9120933","Predictors of prostate cancer","McDougal WS.","J Urol. 1997 Apr;157(4):1335-6. doi: 10.1016/s0022-5347(01)64964-4.","McDougal WS","J Urol","1997","1997/04/01","","","10.1016/s0022-5347(01)64964-4"
"11872289","Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer","DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexander RB, Yu C.","Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):429-38. doi: 10.1016/s0360-3016(01)02609-8.","DiBiase SJ","Int J Radiat Oncol Biol Phys","2002","2002/03/02","","","10.1016/s0360-3016(01)02609-8"
"23084526","Palliative care in castrate-resistant prostate cancer","Rabow MW, Lee MX.","Urol Clin North Am. 2012 Nov;39(4):491-503. doi: 10.1016/j.ucl.2012.07.006. Epub 2012 Aug 27.","Rabow MW","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.07.006"
"8494915","Incorporating tumor biology into therapy for prostate cancer","Bromberg J, Scher HI.","Curr Opin Oncol. 1993 May;5(3):546-58. doi: 10.1097/00001622-199305000-00017.","Bromberg J","Curr Opin Oncol","1993","1993/05/01","","","10.1097/00001622-199305000-00017"
"11588832","Role of phytochemicals in prevention and treatment of prostate cancer","Barnes S.","Epidemiol Rev. 2001;23(1):102-5. doi: 10.1093/oxfordjournals.epirev.a000773.","Barnes S","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000773"
"22906765","Coming up for air: follow-up and risk stratification after negative prostate cancer screening","Clarke NW.","Eur Urol. 2013 Apr;63(4):634-5; discussion 635-6. doi: 10.1016/j.eururo.2012.08.007. Epub 2012 Aug 13.","Clarke NW","Eur Urol","2013","2012/08/22","","","10.1016/j.eururo.2012.08.007"
"24503785","Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting","De Bari B, Fiorentino A, Greto D, Ciammella P, Arcangeli S, Avuzzi B, D'Angelillo RM, Desideri I, Kirienko M, Marchiori D, Massari F, Fundoni C, Franco P, Filippi AR, Alongi F.","Tumori. 2013 Nov-Dec;99(6):637-49. doi: 10.1700/1390.15450.","De Bari B","Tumori","2013","2014/02/08","","","10.1700/1390.15450"
"7531901","Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection","Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L, Butzin CA.","Urology. 1995 Feb;45(2):270-4. doi: 10.1016/0090-4295(95)80017-4.","Bishoff JT","Urology","1995","1995/02/01","","","10.1016/0090-4295(95)80017-4"
"28090626","Active Surveillance of Prostate Cancer","Choyke PL, Loeb S.","Oncology (Williston Park). 2017 Jan 15;31(1):67-70.","Choyke PL","Oncology (Williston Park)","2017","2017/01/17","PMC5555170","NIHMS888275",""
"29393702","Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA","Psimadas D, Valotassiou V, Alexiou S, Tsougos I, Georgoulias P.","Cancer Invest. 2018 Feb 7;36(2):118-128. doi: 10.1080/07357907.2018.1430816. Epub 2018 Feb 2.","Psimadas D","Cancer Invest","2018","2018/02/03","","","10.1080/07357907.2018.1430816"
"1670553","[Transrectal ultrasonography in prostate cancer]","Salo J.","Duodecim. 1990;106(18):1250-5.","Salo J","Duodecim","1990","1990/01/01","","",""
"22473442","Screening for prostate cancer","Hudson MA.","Ann Intern Med. 2012 Apr 3;156(7):539-40; author reply 540. doi: 10.7326/0003-4819-156-7-201204030-00015.","Hudson MA","Ann Intern Med","2012","2012/04/05","","","10.7326/0003-4819-156-7-201204030-00015"
"27344706","[Prostate cancer and oxidative stress]","Shiota M, Yokomizo A.","Nihon Rinsho. 2016 May 20;74 Suppl 3:71-4.","Shiota M","Nihon Rinsho","2016","2016/06/28","","",""
"2000853","Tobacco use and prostate cancer: 26-year follow-up of US veterans","Hsing AW, McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr.","Am J Epidemiol. 1991 Mar 1;133(5):437-41. doi: 10.1093/oxfordjournals.aje.a115910.","Hsing AW","Am J Epidemiol","1991","1991/03/01","","","10.1093/oxfordjournals.aje.a115910"
"22616627","Prostate cancer incidence and mortality in rural men--a systematic review of the literature","Obertova Z, Brown C, Holmes M, Lawrenson R.","Rural Remote Health. 2012;12(2):2039. Epub 2012 May 21.","Obertova Z","Rural Remote Health","2012","2012/05/24","","",""
"2019219","Prostate cancer","Badalament RA, Drago JR.","Dis Mon. 1991 Apr;37(4):199-268. doi: 10.1016/0011-5029(91)90004-u.","Badalament RA","Dis Mon","1991","1991/04/01","","","10.1016/0011-5029(91)90004-u"
"8560675","Hormone therapy for prostate cancer: a topical perspective","Klein EA.","Urology. 1996 Jan;47(1A Suppl):3-12; discussion 29-32. doi: 10.1016/s0090-4295(96)80002-1.","Klein EA","Urology","1996","1996/01/01","","","10.1016/s0090-4295(96)80002-1"
"19465330","[AFU 2008 congress: Summary of the main communications about prostate cancer]","Boccon-Gibod L.","Prog Urol. 2009 Apr;19 Suppl 1:S1-2. doi: 10.1016/S1166-7087(09)73897-7.","Boccon-Gibod L","Prog Urol","2009","2009/05/26","","","10.1016/S1166-7087(09)73897-7"
"27874051","Stable Upconversion Nanohybrid Particles for Specific Prostate Cancer Cell Immunodetection","Shi Y, Shi B, Dass AV, Lu Y, Sayyadi N, Kautto L, Willows RD, Chung R, Piper J, Nevalainen H, Walsh B, Jin D, Packer NH.","Sci Rep. 2016 Nov 22;6:37533. doi: 10.1038/srep37533.","Shi Y","Sci Rep","2016","2016/11/23","PMC5118722","","10.1038/srep37533"
"31526166","Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study","Westerberg M, Franck Lissbrant I, Damber JE, Robinson D, Garmo H, Stattin P.","Acta Oncol. 2020 Jan;59(1):106-111. doi: 10.1080/0284186X.2019.1662084. Epub 2019 Sep 17.","Westerberg M","Acta Oncol","2020","2019/09/19","","","10.1080/0284186X.2019.1662084"
"12002354","Treatment of patients with clinical T3 prostate cancer","Aus G, Adolfsson J, Selli C, Widmark A.","Scand J Urol Nephrol. 2002 Feb;36(1):28-33. doi: 10.1080/003655902317259337.","Aus G","Scand J Urol Nephrol","2002","2002/05/11","","","10.1080/003655902317259337"
"22072161","Revised status of PSA testing in the early detection and treatment of prostate cancer","Lamb DS, Delahunt B, Nacey JN.","N Z Med J. 2011 Nov 4;124(1345):13-5.","Lamb DS","N Z Med J","2011","2011/11/11","","",""
"22052753","[Epidemiological fundamentals of clinically localized prostate cancer]","Martínez-Salamanca JI, Ballesteros CM, Carballido Rodríguez J.","Arch Esp Urol. 2011 Oct;64(8):703-10.","Martínez-Salamanca JI","Arch Esp Urol","2011","2011/11/05","","",""
"26036626","Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells","Levina E, Ji H, Chen M, Baig M, Oliver D, Ohouo P, Lim CU, Schools G, Carmack S, Ding Y, Broude EV, Roninson IB, Buttyan R, Shtutman M.","Oncotarget. 2015 May 30;6(15):13088-104. doi: 10.18632/oncotarget.3743.","Levina E","Oncotarget","2015","2015/06/04","PMC4537001","","10.18632/oncotarget.3743"
"28438583","Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer","Lam WWT, Tse MA, Ng CNL, Chung EKM, Fielding R.","J Pain Symptom Manage. 2017 Jun;53(6):1085-1090. doi: 10.1016/j.jpainsymman.2017.02.010. Epub 2017 Apr 22.","Lam WWT","J Pain Symptom Manage","2017","2017/04/26","","","10.1016/j.jpainsymman.2017.02.010"
"17907065","[Image-guided radiotherapy for prostate cancer]","Lohr F, Boda-Heggemann J, Wenz F, Wiegel T.","Aktuelle Urol. 2007 Sep;38(5):386-91; discussion 385. doi: 10.1055/s-2007-980118.","Lohr F","Aktuelle Urol","2007","2007/10/02","","","10.1055/s-2007-980118"
"24344024","Genetic polymorphisms of vitamin D receptor and the risk of prostate cancer: a meta-analysis","Zhang Q, Shan Y.","J BUON. 2013 Oct-Dec;18(4):961-9.","Zhang Q","J BUON","2013","2013/12/18","","",""
"15750857","Social disparities and prostate cancer: mapping the gaps in our knowledge","Gilligan T.","Cancer Causes Control. 2005 Feb;16(1):45-53. doi: 10.1007/s10552-004-1291-x.","Gilligan T","Cancer Causes Control","2005","2005/03/08","","","10.1007/s10552-004-1291-x"
"21857523","The role of oxidative stress in prostate cancer","Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL.","Eur J Cancer Prev. 2012 Mar;21(2):155-62. doi: 10.1097/CEJ.0b013e32834a8002.","Gupta-Elera G","Eur J Cancer Prev","2012","2011/08/23","","","10.1097/CEJ.0b013e32834a8002"
"16622114","Assessing risk: does this patient have prostate cancer?","Carter HB.","J Natl Cancer Inst. 2006 Apr 19;98(8):506-7. doi: 10.1093/jnci/djj155.","Carter HB","J Natl Cancer Inst","2006","2006/04/20","","","10.1093/jnci/djj155"
"25837493","Young-age prostate cancer","Hussein S, Satturwar S, Van der Kwast T.","J Clin Pathol. 2015 Jul;68(7):511-5. doi: 10.1136/jclinpath-2015-202993. Epub 2015 Apr 2.","Hussein S","J Clin Pathol","2015","2015/04/04","","","10.1136/jclinpath-2015-202993"
"7544400","Prostate-specific antigen testing to screen for prostate cancer","Budenholzer BR.","J Fam Pract. 1995 Sep;41(3):270-8.","Budenholzer BR","J Fam Pract","1995","1995/09/01","","",""
"11572415","Psychosocial stress and prostate cancer: a theoretical model","Ellison GL, Coker AL, Hebert JR, Sanderson SM, Royal CD, Weinrich SP.","Ethn Dis. 2001 Autumn;11(3):484-95.","Ellison GL","Ethn Dis","2001","2001/09/27","","",""
"9535601","Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study","Kuriyama M, Ueno K, Uno H, Kawada Y, Akimoto S, Noda M, Nasu Y, Tsushima T, Ohmori H, Sakai H, Saito Y, Meguro N, Usami M, Kotake T, Suzuki Y, Arai Y, Shimazaki J.","Int J Urol. 1998 Jan;5(1):48-54. doi: 10.1111/j.1442-2042.1998.tb00234.x.","Kuriyama M","Int J Urol","1998","1998/04/16","","","10.1111/j.1442-2042.1998.tb00234.x"
"30612936","Patient-reported Outcomes in Metastatic Castration-sensitive Prostate Cancer in the Adjuvant Setting","Morgans AK, Stockler MR.","Eur Urol Focus. 2019 Mar;5(2):144-146. doi: 10.1016/j.euf.2018.12.007. Epub 2019 Jan 3.","Morgans AK","Eur Urol Focus","2019","2019/01/08","PMC6658671","NIHMS1033354","10.1016/j.euf.2018.12.007"
"21453400","Editorial comment to transrectal high-intensity focused ultrasound for treatment of localized prostate cancer","Berge V.","Int J Urol. 2011 May;18(5):363-4. doi: 10.1111/j.1442-2042.2011.02752.x. Epub 2011 Mar 31.","Berge V","Int J Urol","2011","2011/04/02","","","10.1111/j.1442-2042.2011.02752.x"
"11070990","[Prostate-specific antigen]","Eide IA, Angelsen A.","Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2528-31.","Eide IA","Tidsskr Nor Laegeforen","2000","2000/11/09","","",""
"19197166","What will the emperor say? Screening for prostate cancer as of 2008","Concato J.","Cancer J. 2009 Jan-Feb;15(1):7-12. doi: 10.1097/PPO.0b013e31819765da.","Concato J","Cancer J","2009","2009/02/07","","","10.1097/PPO.0b013e31819765da"
"17447437","Emerging role of immunotherapy in the management of prostate cancer","Slovin SF.","Oncology (Williston Park). 2007 Mar;21(3):326-33; discussion 334, 338, 346-8.","Slovin SF","Oncology (Williston Park)","2007","2007/04/24","","",""
"16523528","Psychosocial and sociodemographic correlates of benefit-finding in men treated for localized prostate cancer","Kinsinger DP, Penedo FJ, Antoni MH, Dahn JR, Lechner S, Schneiderman N.","Psychooncology. 2006 Nov;15(11):954-61. doi: 10.1002/pon.1028.","Kinsinger DP","Psychooncology","2006","2006/03/09","","","10.1002/pon.1028"
"23929168","[Status quo in radical prostate surgery]","Baumunk D, Schostak M.","Anasthesiol Intensivmed Notfallmed Schmerzther. 2013 Jul;48(7-8):480-6; quiz 487. doi: 10.1055/s-0033-1352495. Epub 2013 Aug 8.","Baumunk D","Anasthesiol Intensivmed Notfallmed Schmerzther","2013","2013/08/10","","","10.1055/s-0033-1352495"
"10444793","[Lymph node positive prostate carcinoma. A case for radiotherapy]","Steiner U, Wiegel T, Miller K.","Urologe A. 1999 Jul;38(4):349-52. doi: 10.1007/s001200050296.","Steiner U","Urologe A","1999","1999/08/13","","","10.1007/s001200050296"
"20456339","Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry","McVey GP, McPhail S, Fowler S, McIntosh G, Gillatt D, Parker CC.","BJU Int. 2010 Oct;106(8):1161-4. doi: 10.1111/j.1464-410X.2010.09288.x.","McVey GP","BJU Int","2010","2010/05/12","","","10.1111/j.1464-410X.2010.09288.x"
"9123733","The role of color Doppler and staging biopsies in prostate cancer detection","Bree RL.","Urology. 1997 Mar;49(3A Suppl):31-4. doi: 10.1016/s0090-4295(97)00166-0.","Bree RL","Urology","1997","1997/03/01","","","10.1016/s0090-4295(97)00166-0"
"15999487","[Omission factors in detecting early stage prostate cancer by TRUS needle biopsy]","Zhang SW, Guo HQ, Gan WD, Gong ZH, Sun ZY.","Zhonghua Nan Ke Xue. 2005 Jun;11(6):431-2, 437.","Zhang SW","Zhonghua Nan Ke Xue","2005","2005/07/08","","",""
"21454449","Randomised prostate cancer screening trial: 20 year follow-up","Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P.","BMJ. 2011 Mar 31;342:d1539. doi: 10.1136/bmj.d1539.","Sandblom G","BMJ","2011","2011/04/02","PMC3069219","","10.1136/bmj.d1539"
"12971313","Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea","Beer TM.","Health News. 2003 Aug;9(8):1-2.","Beer TM","Health News","2003","2003/09/16","","",""
"15040880","Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer","Kattan MW, Eastham J.","Clin Prostate Cancer. 2003 Mar;1(4):221-6. doi: 10.3816/cgc.2003.n.003.","Kattan MW","Clin Prostate Cancer","2003","2004/03/26","","","10.3816/cgc.2003.n.003"
"20661840","[Active surveillance for screen-detected prostate cancer - a strategy for the future?]","Weissbach L, Schaefer C.","Aktuelle Urol. 2010 Jul;41(4):239-44. doi: 10.1055/s-0030-1247461. Epub 2010 Jul 26.","Weissbach L","Aktuelle Urol","2010","2010/07/28","","","10.1055/s-0030-1247461"
"25545701","Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies","Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X, He X.","PLoS One. 2014 Dec 29;9(12):e116327. doi: 10.1371/journal.pone.0116327. eCollection 2014.","Yu H","PLoS One","2014","2014/12/30","PMC4278883","","10.1371/journal.pone.0116327"
"30109809","The upregulation of hypoxia-related miRNA 210 in primary tumor of lymphogenic metastatic prostate cancer","Eminaga O, Fries J, Neiß S, Heitmann M, Wötzel F, Heidenreich A, Bruns C, Alakus H, Warnecke-Eberz U.","Epigenomics. 2018 Oct;10(10):1347-1359. doi: 10.2217/epi-2017-0114. Epub 2018 Aug 15.","Eminaga O","Epigenomics","2018","2018/08/16","","","10.2217/epi-2017-0114"
"17991538","Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability","Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ.","Urology. 2007 Oct;70(4):685-90. doi: 10.1016/j.urology.2007.05.010.","Carter HB","Urology","2007","2007/11/10","PMC2645699","NIHMS45557","10.1016/j.urology.2007.05.010"
"29282518","Current status of theranostics in prostate cancer","Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C.","Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28.","Virgolini I","Eur J Nucl Med Mol Imaging","2018","2017/12/29","PMC5787224","","10.1007/s00259-017-3882-2"
"20613534","Is there a role for chemotherapy in nonmetastatic prostate cancer?","Keizman D, Eisenberger M.","Curr Opin Support Palliat Care. 2010 Sep;4(3):141-6. doi: 10.1097/SPC.0b013e32833c6cfe.","Keizman D","Curr Opin Support Palliat Care","2010","2010/07/09","","","10.1097/SPC.0b013e32833c6cfe"
"26182169","The Oncologist's Perspective: A Patient With Prostate Cancer","Afshar M.","JAMA Oncol. 2015 Aug;1(5):691. doi: 10.1001/jamaoncol.2015.1844.","Afshar M","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2015.1844"
"11238180","Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells","Xing N, Chen Y, Mitchell SH, Young CY.","Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.","Xing N","Carcinogenesis","2001","2001/03/10","","","10.1093/carcin/22.3.409"
"18570713","Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml","Wiebe E, Rodrigues G, Lock M, D'Souza D, Stitt L.","Can J Urol. 2008 Jun;15(3):4078-83.","Wiebe E","Can J Urol","2008","2008/06/24","","",""
"2644656","Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma","Lee F, Torp-Pedersen ST, Siders DB, Littrup PJ, McLeary RD.","Radiology. 1989 Mar;170(3 Pt 1):609-15. doi: 10.1148/radiology.170.3.2644656.","Lee F","Radiology","1989","1989/03/01","","","10.1148/radiology.170.3.2644656"
"15773790","Current status of salvage cryoablation for prostate cancer following radiation failure","Chin JL, Touma N.","Technol Cancer Res Treat. 2005 Apr;4(2):211-6. doi: 10.1177/153303460500400210.","Chin JL","Technol Cancer Res Treat","2005","2005/03/19","","","10.1177/153303460500400210"
"1844458","[The diagnosis, biopsy and treatment follow-up via ultrasound in patients with prostatic carcinoma]","Mladenov D, Tsvetkov M, Kumanov Kh.","Khirurgiia (Sofiia). 1991;44(5):18-20.","Mladenov D","Khirurgiia (Sofiia)","1991","1991/01/01","","",""
"30239415","Focal therapy of prostate cancer","Hübner N, Shariat SF, Remzi M.","Curr Opin Urol. 2018 Nov;28(6):550-554. doi: 10.1097/MOU.0000000000000547.","Hübner N","Curr Opin Urol","2018","2018/09/22","","","10.1097/MOU.0000000000000547"
"12512146","[Mechanisms of prostate cancer recurrence]","Mizokami A, Namiki M.","Hinyokika Kiyo. 2002 Nov;48(11):709-11.","Mizokami A","Hinyokika Kiyo","2002","2003/01/07","","",""
"11350402","Does age influence the behaviour of localized prostate cancer?","Parker CC, Gospodarowicz M, Warde P.","BJU Int. 2001 May;87(7):629-37. doi: 10.1046/j.1464-410x.2001.02141.x.","Parker CC","BJU Int","2001","2001/05/15","","","10.1046/j.1464-410x.2001.02141.x"
"30655600","Approaches to urinary detection of prostate cancer","Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J.","Prostate Cancer Prostatic Dis. 2019 Sep;22(3):362-381. doi: 10.1038/s41391-019-0127-4. Epub 2019 Jan 17.","Eskra JN","Prostate Cancer Prostatic Dis","2019","2019/01/19","PMC6640078","NIHMS1517509","10.1038/s41391-019-0127-4"
"12474540","Outcome research: prostate cancer databases","Moul JW.","Urol Oncol. 2002 Jan-Feb;7(1):39-42. doi: 10.1016/s1078-1439(01)00134-x.","Moul JW","Urol Oncol","2002","2002/12/12","","","10.1016/s1078-1439(01)00134-x"
"9226023","Adjuvant hormone therapy after radical prostatectomy: indications and results","Ditonno P, Battaglia M, Selvaggi FP.","Tumori. 1997 Mar-Apr;83(2):567-75.","Ditonno P","Tumori","1997","1997/03/01","","",""
"26042442","[Comparative analysis of two main prognostic classifications for predicting the locally advanced prostate cancer after radical prostatectomy]","Guliyev F, Kazimov A, Aliyev A.","Georgian Med News. 2015 May;(242):13-7.","Guliyev F","Georgian Med News","2015","2015/06/05","","",""
"17571482","Significance of prostate specific antigen in prostate cancer patients and in non cancerous prostatic disease patients","Hanif M, Zaidi P, Kamal S, Idrees S, Rasool SA.","J Pak Med Assoc. 2007 May;57(5):248-51.","Hanif M","J Pak Med Assoc","2007","2007/06/19","","",""
"16308948","Prostate cancer: screening approaches","Donovan JL, Martin RM, Neal DE, Hamdy FC.","Br J Hosp Med (Lond). 2005 Nov;66(11):623-6. doi: 10.12968/hmed.2005.66.11.20023.","Donovan JL","Br J Hosp Med (Lond)","2005","2005/11/29","","","10.12968/hmed.2005.66.11.20023"
"19421114","[Is power Doppler US a good predictor of prostate cancer aggressiveness]","Boukadoum N, Touati R, Demuynck F, Morvan J, Kadi A, Draouat S.","J Radiol. 2009 Mar;90(3 Pt 1):299-303. doi: 10.1016/s0221-0363(09)72508-9.","Boukadoum N","J Radiol","2009","2009/05/08","","","10.1016/s0221-0363(09)72508-9"
"25496525","The role of transperineal template biopsies of the prostate in the diagnosis of prostate cancer: a review","Abdulmajed MI, Hughes D, Shergill IS.","Expert Rev Med Devices. 2015 Mar;12(2):175-82. doi: 10.1586/17434440.2015.990376. Epub 2014 Dec 11.","Abdulmajed MI","Expert Rev Med Devices","2015","2014/12/16","","","10.1586/17434440.2015.990376"
"12154061","Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease","LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL.","Cancer Res. 2002 Aug 1;62(15):4499-506.","LaTulippe E","Cancer Res","2002","2002/08/03","","",""
"25060593","Disease-specific death and metastasis do not occur in patients with Gleason score ≤6 at radical prostatectomy","Kweldam CF, Wildhagen MF, Bangma CH, van Leenders GJ.","BJU Int. 2015 Aug;116(2):230-5. doi: 10.1111/bju.12879. Epub 2015 Mar 7.","Kweldam CF","BJU Int","2015","2014/07/26","","","10.1111/bju.12879"
"31771767","[Geriatric specificities of prostate cancer]","Mongiat-Artus P, Paillaud E, Caillet P, Albrand G, Neuzillet Y.","Prog Urol. 2019 Nov;29(14):828-839. doi: 10.1016/j.purol.2019.09.002.","Mongiat-Artus P","Prog Urol","2019","2019/11/28","","","10.1016/j.purol.2019.09.002"
"15870412","20-year outcomes following conservative management of clinically localized prostate cancer","Albertsen PC, Hanley JA, Fine J.","JAMA. 2005 May 4;293(17):2095-101. doi: 10.1001/jama.293.17.2095.","Albertsen PC","JAMA","2005","2005/05/05","","","10.1001/jama.293.17.2095"
"29420981","Prostate MR Imaging for Posttreatment Evaluation and Recurrence","Gaur S, Turkbey B.","Radiol Clin North Am. 2018 Mar;56(2):263-275. doi: 10.1016/j.rcl.2017.10.008. Epub 2017 Nov 27.","Gaur S","Radiol Clin North Am","2018","2018/02/09","PMC5844499","NIHMS917742","10.1016/j.rcl.2017.10.008"
"18923998","Does arsenic exposure increase the risk for prostate cancer?","Yang CY, Chang CC, Chiu HF.","J Toxicol Environ Health A. 2008;71(23):1559-63. doi: 10.1080/15287390802392065.","Yang CY","J Toxicol Environ Health A","2008","2008/10/17","","","10.1080/15287390802392065"
"9229198","Interpreting recent trends in prostate cancer incidence and mortality","Gann PH.","Epidemiology. 1997 Mar;8(2):117-20.","Gann PH","Epidemiology","1997","1997/03/01","","",""
"29465428","Recent advances in radiation oncology: multimodal targeting of high risk and recurrent prostate cancer","Kwok Y, Kaiser A, Rice SR, Cohen R, Mishra M.","Curr Opin Oncol. 2018 May;30(3):165-171. doi: 10.1097/CCO.0000000000000440.","Kwok Y","Curr Opin Oncol","2018","2018/02/22","","","10.1097/CCO.0000000000000440"
"27694164","Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art","Chen FK, de Castro Abreu AL, Palmer SL.","J Nucl Med. 2016 Oct;57(Suppl 3):13S-18S. doi: 10.2967/jnumed.116.177196.","Chen FK","J Nucl Med","2016","2016/10/04","","","10.2967/jnumed.116.177196"
"23417241","Emerging evidence for Gleason grade migration and distance impact in prostate cancer? An analysis of the rapid access prostate clinic in a tertiary referral center: St. Vincent's University Hospital, Dublin (2009-2011)","O'Kelly F, Thomas AZ, Murray D, Lee P, O'Carroll RF, Nicholson P, Forristal H, Swan N, Galvin D, Mulvin D, Quinlan DM.","Ir J Med Sci. 2013 Sep;182(3):487-91. doi: 10.1007/s11845-013-0920-3. Epub 2013 Feb 17.","O'Kelly F","Ir J Med Sci","2013","2013/02/19","","","10.1007/s11845-013-0920-3"
"24628119","Pre-screening age African-American males: what do they know about prostate cancer screening, knowledge, and risk perceptions?","Miller DB.","Soc Work Health Care. 2014;53(3):268-88. doi: 10.1080/00981389.2013.875503.","Miller DB","Soc Work Health Care","2014","2014/03/18","","","10.1080/00981389.2013.875503"
"12031377","Knowledge and beliefs among brothers and sons of men with prostate cancer","Cormier L, Kwan L, Reid K, Litwin MS.","Urology. 2002 Jun;59(6):895-900. doi: 10.1016/s0090-4295(01)01657-0.","Cormier L","Urology","2002","2002/05/29","","","10.1016/s0090-4295(01)01657-0"
"18245458","Meeting report: innovations in prostate cancer research","Arap W, Trepel M, Zetter BR, Pasqualini R.","Cancer Res. 2008 Feb 1;68(3):635-8. doi: 10.1158/0008-5472.CAN-07-3232. Epub 2008 Feb 1.","Arap W","Cancer Res","2008","2008/02/05","","","10.1158/0008-5472.CAN-07-3232"
"17356323","Relative contribution of digital rectal examination and transrectal ultrasonography in interpreting serum prostate-specific antigen values for screening prostate cancer in Arab men","Sheikh M, Sinan T, Kehinde EO, Hussein AY, Anim JT, Al-Hunayan AA.","Ann Saudi Med. 2007 Mar-Apr;27(2):73-8. doi: 10.5144/0256-4947.2007.73.","Sheikh M","Ann Saudi Med","2007","2007/03/16","PMC6077036","","10.5144/0256-4947.2007.73"
"21910023","Survival after incidental prostate cancer diagnosis at transurethral resection of prostate: 10-year outcomes","Ahmad S, O'Kelly F, Manecksha RP, Cullen IM, Flynn RJ, McDermott TE, Grainger R, Thornhill JA.","Ir J Med Sci. 2012 Mar;181(1):27-31. doi: 10.1007/s11845-011-0753-x. Epub 2011 Sep 11.","Ahmad S","Ir J Med Sci","2012","2011/09/13","","","10.1007/s11845-011-0753-x"
"26503110","Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer","Mouraviev V, Lee B, Patel V, Albala D, Johansen TE, Partin A, Ross A, Perera RJ.","Prostate Cancer Prostatic Dis. 2016 Mar;19(1):14-20. doi: 10.1038/pcan.2015.48. Epub 2015 Oct 27.","Mouraviev V","Prostate Cancer Prostatic Dis","2016","2015/10/28","","","10.1038/pcan.2015.48"
"20078420","Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality","Arnold PC.","Med J Aust. 2010 Jan 18;192(2):110; author reply 110.","Arnold PC","Med J Aust","2010","2010/01/19","","",""
"9471863","[New review of radical prostatectomy]","Matos-Ferreira A.","Actas Urol Esp. 1997 Oct;21(9):817-21.","Matos-Ferreira A","Actas Urol Esp","1997","1998/02/21","","",""
"1563737","Chromosomal abnormalities and related events in prostate cancer","Sandberg AA.","Hum Pathol. 1992 Apr;23(4):368-80. doi: 10.1016/0046-8177(92)90083-f.","Sandberg AA","Hum Pathol","1992","1992/04/01","","","10.1016/0046-8177(92)90083-f"
"11018617","Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy","Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schröder FH, van der Kwast TH.","Urology. 2000 Oct 1;56(4):617-21. doi: 10.1016/s0090-4295(00)00681-6.","Vis AN","Urology","2000","2000/10/06","","","10.1016/s0090-4295(00)00681-6"
"12523308","Prostatectomy or watchful waiting in prostate cancer","Sonpavde G.","N Engl J Med. 2003 Jan 9;348(2):170-1; author reply 170-1.","Sonpavde G","N Engl J Med","2003","2003/01/14","","",""
"31629418","Considerations of multigene test findings among men with prostate cancer - knowns and unknowns","AlDubayan SH.","Can J Urol. 2019 Oct;26(5 Suppl 2):14-16.","AlDubayan SH","Can J Urol","2019","2019/10/21","","",""
"22813937","Competing mortality contributes to excess mortality in patients with poor-risk lymph node-positive prostate cancer treated with radical prostatectomy","Froehner M, Scholz A, Koch R, Hakenberg OW, Baretton GB, Wirth MP.","Urol Int. 2012;89(2):148-54. doi: 10.1159/000339279. Epub 2012 Jul 19.","Froehner M","Urol Int","2012","2012/07/21","","","10.1159/000339279"
"9254902","Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993","Mettlin C.","Prostate. 1997 Aug 1;32(3):221-6. doi: 10.1002/(sici)1097-0045(19970801)32:3<221::aid-pros9>3.0.co;2-n.","Mettlin C","Prostate","1997","1997/08/01","","","10.1002/(sici)1097-0045(19970801)32:3<221::aid-pros9>3.0.co;2-n"
"30665733","Genomics of Prostate Cancer: What Nurses Need to Know","McReynolds KM, Connors LM.","Semin Oncol Nurs. 2019 Feb;35(1):79-92. doi: 10.1016/j.soncn.2018.12.003. Epub 2019 Jan 18.","McReynolds KM","Semin Oncol Nurs","2019","2019/01/23","","","10.1016/j.soncn.2018.12.003"
"24701701","New biomarkers in prostate cancer","Crawford ED, Ventii K, Shore ND.","Oncology (Williston Park). 2014 Feb;28(2):135-42.","Crawford ED","Oncology (Williston Park)","2014","2014/04/08","","",""
"10483076","Audit of prostate cancer: lessons learnt for current clinical practice, surrogates for quality of care and standardisation and quality assurance","Silcocks P, Needham P, Hemsley F.","Public Health. 1999 Jul;113(4):161-4. doi: 10.1038/sj.ph.1900567.","Silcocks P","Public Health","1999","1999/09/14","","","10.1038/sj.ph.1900567"
"21550304","Dealing with a troublesome body: a qualitative interview study of men's experiences living with prostate cancer treated with endocrine therapy","Ervik B, Asplund K.","Eur J Oncol Nurs. 2012 Apr;16(2):103-8. doi: 10.1016/j.ejon.2011.04.005. Epub 2011 May 7.","Ervik B","Eur J Oncol Nurs","2012","2011/05/10","","","10.1016/j.ejon.2011.04.005"
"24269217","Optimizing the management of pathologic, possible, and putative N1 prostate cancer","Chin JL.","Eur Urol. 2014 Mar;65(3):563-4. doi: 10.1016/j.eururo.2013.10.010. Epub 2013 Oct 18.","Chin JL","Eur Urol","2014","2013/11/26","","","10.1016/j.eururo.2013.10.010"
"23107383","Progress in emerging therapies for advanced prostate cancer","Oudard S.","Cancer Treat Rev. 2013 May;39(3):275-89. doi: 10.1016/j.ctrv.2012.09.005. Epub 2012 Oct 26.","Oudard S","Cancer Treat Rev","2013","2012/10/31","","","10.1016/j.ctrv.2012.09.005"
"26395365","Androgen deprivation therapy should be used with caution in some prostate cancer cases, study warns","Wise J.","BMJ. 2015 Sep 22;351:h5043. doi: 10.1136/bmj.h5043.","Wise J","BMJ","2015","2015/09/24","","","10.1136/bmj.h5043"
"22407145","The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer","Armstrong AJ, Ferrari AC, Quinn DI.","Clin Adv Hematol Oncol. 2011 Dec;9(12 Suppl 28):1-14; quiz 15-6.","Armstrong AJ","Clin Adv Hematol Oncol","2011","2012/03/13","","",""
"28941925","Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study","Xu X, Zhang X, Zhong Y, Saad F, Perez-Patron MJ, Haider K, Haider A.","J Urol. 2018 Feb;199(2):465-473. doi: 10.1016/j.juro.2017.08.117. Epub 2017 Sep 20.","Xu X","J Urol","2018","2017/09/25","","","10.1016/j.juro.2017.08.117"
"25862450","Prostate cancer incidence in Podkarpackie province in 2002-2011","Karczmarek-Borowska B, Radziszewska A.","Przegl Epidemiol. 2015;69(1):65-72, 163-7.","Karczmarek-Borowska B","Przegl Epidemiol","2015","2015/04/12","","",""
"10453275","Diet, androgens, oxidative stress and prostate cancer susceptibility","Fleshner NE, Klotz LH.","Cancer Metastasis Rev. 1998-1999;17(4):325-30. doi: 10.1023/a:1006118628183.","Fleshner NE","Cancer Metastasis Rev","1998","1999/08/24","","","10.1023/a:1006118628183"
"14679018","Significance of MMP-2 expression in prostate cancer: an immunohistochemical study","Trudel D, Fradet Y, Meyer F, Harel F, Têtu B.","Cancer Res. 2003 Dec 1;63(23):8511-5.","Trudel D","Cancer Res","2003","2003/12/18","","",""
"20505284","MR imaging of prostate cancer at 3T with an external phased-array coil: evaluation of T2-weighted images","Sakoda J, Uchida M, Nagata S, Matsuoka K, Abe T, Hayabuchi N.","Kurume Med J. 2009;56(3-4):71-7. doi: 10.2739/kurumemedj.56.71.","Sakoda J","Kurume Med J","2009","2010/05/28","","","10.2739/kurumemedj.56.71"
"1574452","DNA content/ploidy as prognostic factors in prostate cancer","Lieber MM.","Prostate Suppl. 1992;4:119-24. doi: 10.1002/pros.2990210519.","Lieber MM","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210519"
"14558209","[Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary]","Damber JE.","Lakartidningen. 2003 Sep 18;100(38):2916-8, 2921.","Damber JE","Lakartidningen","2003","2003/10/16","","",""
"24206066","The Melbourne Consensus Statement on the early detection of prostate cancer","Murphy DG, Ahlering T, Catalona WJ, Crowe H, Crowe J, Clarke N, Cooperberg M, Gillatt D, Gleave M, Loeb S, Roobol M, Sartor O, Pickles T, Wootten A, Walsh PC, Costello AJ.","BJU Int. 2014 Feb;113(2):186-8. doi: 10.1111/bju.12556.","Murphy DG","BJU Int","2014","2013/11/12","","","10.1111/bju.12556"
"15592032","Analysis of prostate cancer by proteomics using tissue specimens","Liu AY, Zhang H, Sorensen CM, Diamond DL.","J Urol. 2005 Jan;173(1):73-8. doi: 10.1097/01.ju.0000146543.33543.a3.","Liu AY","J Urol","2005","2004/12/14","","","10.1097/01.ju.0000146543.33543.a3"
"25232174","The fringe benefits of cloning cancer","Kyprianou N.","Sci Transl Med. 2014 Sep 17;6(254):254fs36. doi: 10.1126/scitranslmed.3010174.","Kyprianou N","Sci Transl Med","2014","2014/09/19","","","10.1126/scitranslmed.3010174"
"22329190","Are we trumping bone disease in prostate cancer?","Slovin SF.","Oncology (Williston Park). 2011 Dec;25(14):1390, 1393.","Slovin SF","Oncology (Williston Park)","2011","2012/02/15","","",""
"2219573","Epidemiology of prostate cancer","Meikle AW, Smith JA Jr.","Urol Clin North Am. 1990 Nov;17(4):709-18.","Meikle AW","Urol Clin North Am","1990","1990/11/01","","",""
"25892137","Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer","Marks LS.","J Urol. 2015 Jul;194(1):8-9. doi: 10.1016/j.juro.2015.04.069. Epub 2015 Apr 16.","Marks LS","J Urol","2015","2015/04/21","","","10.1016/j.juro.2015.04.069"
"21750502","Prostate cancer: PSA velocity in prostate cancer screening--the debate continues","Borofsky MS, Makarov DV.","Nat Rev Urol. 2011 Jul 12;8(8):413-4. doi: 10.1038/nrurol.2011.87.","Borofsky MS","Nat Rev Urol","2011","2011/07/14","","","10.1038/nrurol.2011.87"
"10569613","The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer","Rittmaster RS, Thomas LN, Wright AS, Murray SK, Carlson K, Douglas RC, Yung J, Messieh M, Bell D, Lazier CB.","J Urol. 1999 Dec;162(6):2165-9. doi: 10.1016/s0022-5347(05)68153-0.","Rittmaster RS","J Urol","1999","1999/11/24","","","10.1016/s0022-5347(05)68153-0"
"24857068","Progress in the treatment of advanced prostate cancer","Sternberg CN, Petrylak DP, Madan RA, Parker C.","Am Soc Clin Oncol Educ Book. 2014:117-31. doi: 10.14694/EdBook_AM.2014.34.117.","Sternberg CN","Am Soc Clin Oncol Educ Book","2014","2014/05/27","","","10.14694/EdBook_AM.2014.34.117"
"22388665","MRI and surveillance","Ouzzane A, Puech P, Villers A.","Curr Opin Urol. 2012 May;22(3):231-6. doi: 10.1097/MOU.0b013e328351dcf7.","Ouzzane A","Curr Opin Urol","2012","2012/03/06","","","10.1097/MOU.0b013e328351dcf7"
"22451179","Primary hormonal treatment in localized and locally advanced prostate cancer: effectiveness and survival predictive factors","Utomo NB, Mochtar CA, Umbas R.","Acta Med Indones. 2012 Jan;44(1):10-5.","Utomo NB","Acta Med Indones","2012","2012/03/28","","",""
"7933223","Problem of prostate cancer","Scardino PT.","J Urol. 1994 Nov;152(5 Pt 2):1677-8. doi: 10.1016/s0022-5347(17)32357-1.","Scardino PT","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32357-1"
"3658995","Issues on mortality from prostate cancer: role of clinical trials","Horton J.","Prog Clin Biol Res. 1987;239:797-800.","Horton J","Prog Clin Biol Res","1987","1987/01/01","","",""
"23851444","Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance","Li S, Hu MG, Sun Y, Yoshioka N, Ibaragi S, Sheng J, Sun G, Kishimoto K, Hu GF.","Mol Cancer Res. 2013 Oct;11(10):1203-14. doi: 10.1158/1541-7786.MCR-13-0072. Epub 2013 Jul 12.","Li S","Mol Cancer Res","2013","2013/07/16","PMC3800479","NIHMS505786","10.1158/1541-7786.MCR-13-0072"
"9692364","Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells","Li WX, Franklin WA.","Radiat Res. 1998 Aug;150(2):190-4.","Li WX","Radiat Res","1998","1998/08/06","","",""
"17440142","Outcomes of treatment vs observation of localized prostate cancer in elderly men","Mark GA.","JAMA. 2007 Apr 18;297(15):1652; author reply 1652-3. doi: 10.1001/jama.297.15.1652-a.","Mark GA","JAMA","2007","2007/04/19","","","10.1001/jama.297.15.1652-a"
"29170243","Trajectories of prostate-specific antigen after treatment for prostate cancer","Wu Z, Aslan M, Lin H, Ko J, Radhakrishnan K, Wells CK, Uchio E, Concato J.","J Investig Med. 2018 Apr;66(4):768-772. doi: 10.1136/jim-2017-000627. Epub 2017 Nov 22.","Wu Z","J Investig Med","2018","2017/11/25","","","10.1136/jim-2017-000627"
"10158023","Prostate cancer: to screen or not to screen?","Bonney R.","Am Clin Lab. 1995 Sep;14(9):4.","Bonney R","Am Clin Lab","1995","1995/08/06","","",""
"15072607","Geriatric assessment in elderly patients with prostate cancer","Terret C, Albrand G, Droz JP.","Clin Prostate Cancer. 2004 Mar;2(4):236-40. doi: 10.3816/cgc.2004.n.005.","Terret C","Clin Prostate Cancer","2004","2004/04/10","","","10.3816/cgc.2004.n.005"
"30200076","Comparisons between magnetic resonance/ultrasound fusion-guided biopsy and standard biopsy in the diagnosis of prostate cancer: A prospective cohort study","Zhu G, Wang Q.","Medicine (Baltimore). 2018 Sep;97(36):e11962. doi: 10.1097/MD.0000000000011962.","Zhu G","Medicine (Baltimore)","2018","2018/09/12","PMC6133427","","10.1097/MD.0000000000011962"
"9288188","Target to apoptosis: a hopeful weapon for prostate cancer","Tang DG, Porter AT.","Prostate. 1997 Sep 1;32(4):284-93. doi: 10.1002/(sici)1097-0045(19970901)32:4<284::aid-pros9>3.0.co;2-j.","Tang DG","Prostate","1997","1997/09/01","","","10.1002/(sici)1097-0045(19970901)32:4<284::aid-pros9>3.0.co;2-j"
"8625081","Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level","Leibman BD, Dillioglugil O, Wheeler TM, Scardino PT.","Cancer. 1995 Dec 15;76(12):2530-4. doi: 10.1002/1097-0142(19951215)76:12<2530::aid-cncr2820761219>3.0.co;2-f.","Leibman BD","Cancer","1995","1995/12/15","","","10.1002/1097-0142(19951215)76:12<2530::aid-cncr2820761219>3.0.co;2-f"
"28600375","Night work and prostate cancer in men: a Swedish prospective cohort study","Åkerstedt T, Narusyte J, Svedberg P, Kecklund G, Alexanderson K.","BMJ Open. 2017 Jun 8;7(6):e015751. doi: 10.1136/bmjopen-2016-015751.","Åkerstedt T","BMJ Open","2017","2017/06/11","PMC5541514","","10.1136/bmjopen-2016-015751"
"8873013","Surgical perspective on prostate cancer. Detection, staging, and treatment","Loughlin KR.","Magn Reson Imaging Clin N Am. 1996 Aug;4(3):449-69.","Loughlin KR","Magn Reson Imaging Clin N Am","1996","1996/08/01","","",""
"26658661","Impact of a family history of prostate cancer on clinicopathologic outcomes and survival following radical prostatectomy","Westerman ME, Gershman B, Karnes RJ, Thompson RH, Rangel L, Boorjian SA.","World J Urol. 2016 Aug;34(8):1115-22. doi: 10.1007/s00345-015-1738-6. Epub 2015 Dec 9.","Westerman ME","World J Urol","2016","2015/12/15","","","10.1007/s00345-015-1738-6"
"19684076","Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature","Armstrong AJ, Febbo PG.","Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14.","Armstrong AJ","Oncologist","2009","2009/08/18","","","10.1634/theoncologist.2009-0043"
"19197172","Sexual side effects and prostate cancer treatment decisions: patient information needs and preferences","Knight SJ, Latini DM.","Cancer J. 2009 Jan-Feb;15(1):41-4. doi: 10.1097/PPO.0b013e31819764cc.","Knight SJ","Cancer J","2009","2009/02/07","","","10.1097/PPO.0b013e31819764cc"
"9465941","Prostate cancer in pesticide applicators in Swedish agriculture","Dich J, Wiklund K.","Prostate. 1998 Feb 1;34(2):100-12. doi: 10.1002/(sici)1097-0045(19980201)34:2<100::aid-pros4>3.0.co;2-o.","Dich J","Prostate","1998","1998/02/18","","","10.1002/(sici)1097-0045(19980201)34:2<100::aid-pros4>3.0.co;2-o"
"26793896","[Prostate cancer and metabolic syndrome]","Nagamatsu H, Teishima J, Inoue S, Hayashi T, Matsubara A.","Nihon Rinsho. 2016 Jan;74(1):149-54.","Nagamatsu H","Nihon Rinsho","2016","2016/01/23","","",""
"20206029","Response to ""Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects"" (Int J Radiat Oncol Biol Phys 2009; in press)","Thoms J, Bristow R, Warde P, Supiot S.","Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1277; author reply 1277. doi: 10.1016/j.ijrobp.2009.11.050.","Thoms J","Int J Radiat Oncol Biol Phys","2010","2010/03/09","","","10.1016/j.ijrobp.2009.11.050"
"22006057","Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network Prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial","Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG.","Cancer. 2012 May 15;118(10):2651-8. doi: 10.1002/cncr.26396. Epub 2011 Oct 17.","Williams SB","Cancer","2012","2011/10/19","PMC3505607","NIHMS308127","10.1002/cncr.26396"
"14579823","[Today and tomorrow on the study of prostate cancer]","Xia TL.","Zhonghua Yi Xue Za Zhi. 2003 Aug 10;83(15):1289-91.","Xia TL","Zhonghua Yi Xue Za Zhi","2003","2003/10/29","","",""
"22331081","Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy","Rigamonti N, Bellone M.","Cancer Immunol Immunother. 2012 Apr;61(4):453-68. doi: 10.1007/s00262-012-1216-6. Epub 2012 Feb 14.","Rigamonti N","Cancer Immunol Immunother","2012","2012/02/15","","","10.1007/s00262-012-1216-6"
"15636680","Early use of chemotherapy in conjunction with radical prostatectomy","Alumkal JJ, Carducci MA.","Clin Prostate Cancer. 2004 Dec;3(3):144-9. doi: 10.3816/cgc.2004.n.024.","Alumkal JJ","Clin Prostate Cancer","2004","2005/01/08","","","10.3816/cgc.2004.n.024"
"12206841","Introduction. Recent scientific and technological advances have challenged the traditional treatment options for patients with localized prostate cancer","Katz AE, Rukstalis DB.","Urology. 2002 Aug;60(2 Suppl 1):1-2. doi: 10.1016/s0090-4295(02)01851-4.","Katz AE","Urology","2002","2002/09/07","","","10.1016/s0090-4295(02)01851-4"
"26529826","New developments in metastatic prostate cancer therapy","Manickavasagar T, Gilson C, Chowdhury S, Kirby R.","Practitioner. 2015 Apr;259(1781):21-4, 2-3.","Manickavasagar T","Practitioner","2015","2015/11/05","","",""
"25363609","Editorial comment on ""Simplified intraoperative sentinel-node detection performed by the urologist accurately determines lymph-node stage in prostate cancer""","Janetschek G, Hruby S.","Scand J Urol. 2015 Feb;49(1):77-8. doi: 10.3109/21681805.2014.975838. Epub 2014 Nov 3.","Janetschek G","Scand J Urol","2015","2014/11/04","","","10.3109/21681805.2014.975838"
"27352026","Pilot Study of the Use of Hybrid Multidimensional T2-Weighted Imaging-DWI for the Diagnosis of Prostate Cancer and Evaluation of Gleason Score","Sadinski M, Karczmar G, Peng Y, Wang S, Jiang Y, Medved M, Yousuf A, Antic T, Oto A.","AJR Am J Roentgenol. 2016 Sep;207(3):592-8. doi: 10.2214/AJR.15.15626. Epub 2016 Jun 28.","Sadinski M","AJR Am J Roentgenol","2016","2016/06/29","PMC5074540","NIHMS811006","10.2214/AJR.15.15626"
"23919321","A longitudinal study of coping strategies in men receiving radiotherapy and neo-adjuvant androgen deprivation for prostate cancer: a quantitative and qualitative study","McSorley O, McCaughan E, Prue G, Parahoo K, Bunting B, O'Sullivan J.","J Adv Nurs. 2014 Mar;70(3):625-38. doi: 10.1111/jan.12224. Epub 2013 Aug 6.","McSorley O","J Adv Nurs","2014","2013/08/08","","","10.1111/jan.12224"
"23905869","Elasticity as a biomarker for prostate cancer: a systematic review","Good DW, Stewart GD, Hammer S, Scanlan P, Shu W, Phipps S, Reuben R, McNeill AS.","BJU Int. 2014 Apr;113(4):523-34. doi: 10.1111/bju.12236. Epub 2013 Jul 26.","Good DW","BJU Int","2014","2013/08/03","","","10.1111/bju.12236"
"21129644","[Recommendations Onco-Urology 2010: Prostate cancer]","Salomon L, Azria D, Bastide C, Beuzeboc P, Cormier L, Cornud F, Eiss D, Eschwège P, Gaschignard N, Hennequin C, Molinié V, Mongiat Artus P, Moreau JL, Péneau M, Peyromaure M, Ravery V, Rebillard X, Richaud P, Rischmann P, Rozet F, Staerman F, Villers A, Soulié M; Oncology Committee of the French Association of Urology (CCAFU).","Prog Urol. 2010 Nov;20 Suppl 4:S217-51. doi: 10.1016/S1166-7087(10)70042-7.","Salomon L","Prog Urol","2010","2010/12/07","","","10.1016/S1166-7087(10)70042-7"
"8709309","Significant versus insignificant prostate cancer--can we identify the tigers from the pussy cats?","Boccon-Gibod L.","J Urol. 1996 Sep;156(3):1069-70. doi: 10.1016/s0022-5347(01)65704-5.","Boccon-Gibod L","J Urol","1996","1996/09/01","","","10.1016/s0022-5347(01)65704-5"
"9809017","Prostate cancer screening","","Mayo Clin Health Lett. 1998 Nov;16(11):1-3.","","Mayo Clin Health Lett","1998","1998/11/11","","",""
"10412301","[Angiogenesis: prognostic marker in prostatic cancer]","Borre M, Offersen IB, Nerstrøm B, Overgaard J.","Ugeskr Laeger. 1999 Jun 21;161(25):3832-6.","Borre M","Ugeskr Laeger","1999","1999/07/21","","",""
"18351318","[Cryoablation of prostate cancer]","Witzsch UK, Skriapas K, Becht E.","Urologe A. 2008 Apr;47(4):449-54. doi: 10.1007/s00120-008-1660-2.","Witzsch UK","Urologe A","2008","2008/03/21","","","10.1007/s00120-008-1660-2"
"22621691","Management of metastatic castration-resistant prostate cancer: recent advances","Mukherji D, Eichholz A, De Bono JS.","Drugs. 2012 May 28;72(8):1011-28. doi: 10.2165/11633360-000000000-00000.","Mukherji D","Drugs","2012","2012/05/25","","","10.2165/11633360-000000000-00000"
"14734000","Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio","Aus G, Becker C, Franzén S, Lilja H, Lodding P, Hugosson J.","Eur Urol. 2004 Feb;45(2):160-5. doi: 10.1016/j.eururo.2003.09.008.","Aus G","Eur Urol","2004","2004/01/22","","","10.1016/j.eururo.2003.09.008"
"31337649","Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk","Wu L, Shu X, Bao J, Guo X, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W; PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia.","Cancer Res. 2019 Sep 15;79(18):4592-4598. doi: 10.1158/0008-5472.CAN-18-3997. Epub 2019 Jul 23.","Wu L","Cancer Res","2019","2019/07/25","PMC6744971","NIHMS1535686","10.1158/0008-5472.CAN-18-3997"
"31072791","Role of novel imaging in the management of prostate cancer","Xu KM, Chen RC, Schuster DM, Jani AB.","Urol Oncol. 2019 Sep;37(9):611-618. doi: 10.1016/j.urolonc.2019.04.008. Epub 2019 May 6.","Xu KM","Urol Oncol","2019","2019/05/11","","","10.1016/j.urolonc.2019.04.008"
"10741283","Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer","Bratt O, Damber JE, Emanuelsson M, Kristoffersson U, Lundgren R, Olsson H, Grönberg H.","Eur J Cancer. 2000 Jan;36(2):235-41. doi: 10.1016/s0959-8049(99)00272-5.","Bratt O","Eur J Cancer","2000","2000/03/31","","","10.1016/s0959-8049(99)00272-5"
"23770146","Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men","Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM.","J Urol. 2014 Jan;191(1):60-7. doi: 10.1016/j.juro.2013.06.021. Epub 2013 Jun 14.","Sundi D","J Urol","2014","2013/06/18","PMC4042393","NIHMS563197","10.1016/j.juro.2013.06.021"
"16598769","Androgen axis in prostate cancer","Culig Z, Bartsch G.","J Cell Biochem. 2006 Oct 1;99(2):373-81. doi: 10.1002/jcb.20898.","Culig Z","J Cell Biochem","2006","2006/04/07","","","10.1002/jcb.20898"
"17134367","Evolving treatment paradigms for locally advanced and metastatic prostate cancer","Dorff TB, Quek ML, Daneshmand S, Pinski J.","Expert Rev Anticancer Ther. 2006 Nov;6(11):1639-51. doi: 10.1586/14737140.6.11.1639.","Dorff TB","Expert Rev Anticancer Ther","2006","2006/12/01","","","10.1586/14737140.6.11.1639"
"25547276","Commentary on ""The clinical significance of persistent prostate cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer""","Crook J.","Brachytherapy. 2015 May-Jun;14(3):315. doi: 10.1016/j.brachy.2014.11.010. Epub 2014 Dec 23.","Crook J","Brachytherapy","2015","2014/12/31","","","10.1016/j.brachy.2014.11.010"
"18281649","Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer","D'Amico AV.","J Clin Oncol. 2008 Feb 20;26(6):823-4. doi: 10.1200/JCO.2007.15.1902.","D'Amico AV","J Clin Oncol","2008","2008/02/19","","","10.1200/JCO.2007.15.1902"
"10164138","Prostate cancer: sometimes it pays to do nothing","Smith MD, McGhan WF.","Bus Health. 1997 Jan;15(1):42-3.","Smith MD","Bus Health","1997","1996/12/08","","",""
"8283552","Re: Deferred treatment of low grade stage T3 prostate cancer without distant metastases","Blackard CE.","J Urol. 1994 Feb;151(2):436. doi: 10.1016/s0022-5347(17)34980-7.","Blackard CE","J Urol","1994","1994/02/01","","","10.1016/s0022-5347(17)34980-7"
"20065526","[Voiding dysfunction in prostate cancer]","Prieto Chaparro L.","Arch Esp Urol. 2009 Dec;62(10):770-2.","Prieto Chaparro L","Arch Esp Urol","2009","2010/01/13","","",""
"17070648","Is surgery good for advanced localised prostate cancer? It's time to find out!","Lange PH.","Eur Urol. 2007 Apr;51(4):873-5. doi: 10.1016/j.eururo.2006.09.044. Epub 2006 Oct 17.","Lange PH","Eur Urol","2007","2006/10/31","","","10.1016/j.eururo.2006.09.044"
"25124231","Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand","Obertová Z, Scott N, Brown C, Stewart A, Lawrenson R.","BJU Int. 2015 Apr;115 Suppl 5:24-30. doi: 10.1111/bju.12900.","Obertová Z","BJU Int","2015","2014/08/16","","","10.1111/bju.12900"
"23046035","Landmarks in prostate cancer diagnosis: the biomarkers","Artibani W.","BJU Int. 2012 Oct;110 Suppl 1:8-13. doi: 10.1111/j.1464-410X.2012.011429.x.","Artibani W","BJU Int","2012","2012/10/11","","","10.1111/j.1464-410X.2012.011429.x"
"8865479","Can insignificant prostate cancer be predicted preoperatively in men with stage T1 disease?","Epstein JI.","Semin Urol Oncol. 1996 Aug;14(3):165-73.","Epstein JI","Semin Urol Oncol","1996","1996/08/01","","",""
"1390011","New treatments for prostate cancer: do they improve survival?","Lawrence GA.","Oncology (Williston Park). 1992 Oct;6(10):17-20.","Lawrence GA","Oncology (Williston Park)","1992","1992/10/01","","",""
"25104234","[Organ and function preservation in prostate cancer]","Fröhner M, Wirth M.","Urologe A. 2014 Sep;53(9):1295-301. doi: 10.1007/s00120-014-3526-0.","Fröhner M","Urologe A","2014","2014/08/09","","","10.1007/s00120-014-3526-0"
"20167690","Early prostate cancer antigen-2: a controversial prostate cancer biomarker?","Diamandis EP.","Clin Chem. 2010 Apr;56(4):542-4. doi: 10.1373/clinchem.2009.140061. Epub 2010 Feb 18.","Diamandis EP","Clin Chem","2010","2010/02/20","","","10.1373/clinchem.2009.140061"
"20620963","[Combined hormonotherapy with external beam radiotherapy in locally advanced prostate cancer: do side effects overlap the advantages?]","Drouin SJ, Rouprêt M, Bossi A, Bolla M.","Prog Urol. 2010 Jun;20 Suppl 3:S186-91. doi: 10.1016/S1166-7087(10)70037-3. Epub 2010 Jun 29.","Drouin SJ","Prog Urol","2010","2010/07/13","","","10.1016/S1166-7087(10)70037-3"
"25358693","Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting","Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR.","Prostate. 2015 Mar 1;75(4):337-47. doi: 10.1002/pros.22920. Epub 2014 Oct 30.","Miyahira AK","Prostate","2015","2014/11/01","","","10.1002/pros.22920"
"8635950","Radiotherapy vs. surgery for prostate cancer: an age old question","Pollack A, Zagars GK.","Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):407-9. doi: 10.1016/0360-3016(96)00142-3.","Pollack A","Int J Radiat Oncol Biol Phys","1996","1996/05/01","","","10.1016/0360-3016(96)00142-3"
"2024008","The role of imaging in prostate cancer","Friedland GW, Chang P.","Radiol Clin North Am. 1991 May;29(3):581-9.","Friedland GW","Radiol Clin North Am","1991","1991/05/01","","",""
"20150759","Sarcosine as a potential prostate cancer biomarker and therapeutic target","Baum CE, Price DK, Figg WD.","Cancer Biol Ther. 2010 Mar 1;9(5):341-2. doi: 10.4161/cbt.9.5.11310. Epub 2010 Mar 26.","Baum CE","Cancer Biol Ther","2010","2010/02/13","PMC2874119","NIHMS177085","10.4161/cbt.9.5.11310"
"14610407","The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer","Oh WK.","J Urol. 2003 Dec;170(6 Pt 2):S28-32; discussion S33-4. doi: 10.1097/01.ju.0000095356.02647.64.","Oh WK","J Urol","2003","2003/11/12","","","10.1097/01.ju.0000095356.02647.64"
"17118027","Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report","Miyanaga N, Akaza H, Yamakawa M, Oikawa T, Sekido N, Hinotsu S, Kawai K, Shimazui T, Shiina T.","Int J Urol. 2006 Dec;13(12):1514-8. doi: 10.1111/j.1442-2042.2006.01612.x.","Miyanaga N","Int J Urol","2006","2006/11/23","","","10.1111/j.1442-2042.2006.01612.x"
"27249729","Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools","Tosoian JJ, Loeb S, Epstein JI, Turkbey B, Choyke PL, Schaeffer EM.","Am Soc Clin Oncol Educ Book. 2016;35:e235-45. doi: 10.1200/EDBK_159244.","Tosoian JJ","Am Soc Clin Oncol Educ Book","2016","2016/06/02","PMC4917301","NIHMS794925","10.1200/EDBK_159244"
"23648323","Management of high-risk prostate cancer: radiation therapy and hormonal therapy","Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, Kamada T.","Cancer Treat Rev. 2013 Dec;39(8):872-8. doi: 10.1016/j.ctrv.2013.04.003. Epub 2013 May 3.","Nomiya T","Cancer Treat Rev","2013","2013/05/08","","","10.1016/j.ctrv.2013.04.003"
"7804923","I am 60 and I have cancer","Evason R.","CMAJ. 1995 Jan 1;152(1):84-6.","Evason R","CMAJ","1995","1995/01/01","PMC1337497","",""
"19646629","Editorial comment. Variations in International Prostate Symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer","Sandhu JS.","Urology. 2009 Aug;74(2):411; author reply 411-2. doi: 10.1016/j.urology.2009.01.027.","Sandhu JS","Urology","2009","2009/08/04","","","10.1016/j.urology.2009.01.027"
"19295434","Outcomes and follow-up strategies for patients on active surveillance","Dall'Era MA, Carroll PR.","Curr Opin Urol. 2009 May;19(3):258-62. doi: 10.1097/MOU.0b013e328329eba3.","Dall'Era MA","Curr Opin Urol","2009","2009/03/20","","","10.1097/MOU.0b013e328329eba3"
"27349499","Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer","Jang WS, Cho KS, Kim KH, Yoon CY, Kang YJ, Lee JY, Ham WS, Rha KH, Hong SJ, Choi YD.","Prostate Cancer Prostatic Dis. 2016 Sep;19(3):298-304. doi: 10.1038/pcan.2016.20. Epub 2016 Jun 28.","Jang WS","Prostate Cancer Prostatic Dis","2016","2016/06/29","","","10.1038/pcan.2016.20"
"26008968","Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy","Shah K, Bradbury NA.","Oncotarget. 2015 Jun 10;6(16):14233-46. doi: 10.18632/oncotarget.3899.","Shah K","Oncotarget","2015","2015/05/27","PMC4546463","","10.18632/oncotarget.3899"
"15775990","Report from Durham","Moul J.","Prostate Cancer Prostatic Dis. 2005;8(1):1. doi: 10.1038/sj.pcan.4500795.","Moul J","Prostate Cancer Prostatic Dis","2005","2005/03/19","","","10.1038/sj.pcan.4500795"
"27535659","Cholesterol and prostate cancer risk: a long-term prospective cohort study","Heir T, Falk RS, Robsahm TE, Sandvik L, Erikssen J, Tretli S.","BMC Cancer. 2016 Aug 17;16:643. doi: 10.1186/s12885-016-2691-5.","Heir T","BMC Cancer","2016","2016/08/19","PMC4989293","","10.1186/s12885-016-2691-5"
"27824348","Androgen synthesis in prostate cancer: do all roads lead to Rome?","Stuchbery R, McCoy PJ, Hovens CM, Corcoran NM.","Nat Rev Urol. 2017 Jan;14(1):49-58. doi: 10.1038/nrurol.2016.221. Epub 2016 Nov 8.","Stuchbery R","Nat Rev Urol","2017","2016/11/09","","","10.1038/nrurol.2016.221"
"3314438","Prostate cancer","Guthrie TH Jr, Watson P.","Am Fam Physician. 1987 Oct;36(4):217-24.","Guthrie TH Jr","Am Fam Physician","1987","1987/10/01","","",""
"20332445","Prophylactic noscapine therapy inhibits human prostate cancer progression and metastasis in a mouse model","Barken I, Geller J, Rogosnitzky M.","Anticancer Res. 2010 Feb;30(2):399-401.","Barken I","Anticancer Res","2010","2010/03/25","","",""
"9704173","Can randomized treatment trials in early stage prostate cancer be completed?","Wilt TJ.","Clin Oncol (R Coll Radiol). 1998;10(3):141-3. doi: 10.1016/s0936-6555(98)80052-6.","Wilt TJ","Clin Oncol (R Coll Radiol)","1998","1998/08/15","","","10.1016/s0936-6555(98)80052-6"
"17949893","An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer","Van Poppel H, Joniau S.","Eur Urol. 2008 Feb;53(2):253-9. doi: 10.1016/j.eururo.2007.10.009. Epub 2007 Oct 12.","Van Poppel H","Eur Urol","2008","2007/10/24","","","10.1016/j.eururo.2007.10.009"
"8948407","Screening for prostate cancer is neither appropriate nor cost-effective","Albertsen PC.","Urol Clin North Am. 1996 Nov;23(4):521-30. doi: 10.1016/s0094-0143(05)70332-3.","Albertsen PC","Urol Clin North Am","1996","1996/11/01","","","10.1016/s0094-0143(05)70332-3"
"1600492","Prospective, conservative management of localized prostate cancer","Jones GW.","Cancer. 1992 Jul 1;70(1 Suppl):307-10. doi: 10.1002/1097-0142(19920701)70:1+<307::aid-cncr2820701319>3.0.co;2-n.","Jones GW","Cancer","1992","1992/07/01","","","10.1002/1097-0142(19920701)70:1+<307::aid-cncr2820701319>3.0.co;2-n"
"18548254","The decision-related psychosocial concerns of men with localised prostate cancer: targets for intervention and research","Steginga SK, Turner E, Donovan J.","World J Urol. 2008 Oct;26(5):469-74. doi: 10.1007/s00345-008-0279-7. Epub 2008 Jun 12.","Steginga SK","World J Urol","2008","2008/06/13","","","10.1007/s00345-008-0279-7"
"11588855","Insulin-like growth factors and prostate cancer","Pollak M.","Epidemiol Rev. 2001;23(1):59-66. doi: 10.1093/oxfordjournals.epirev.a000796.","Pollak M","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000796"
"17971518","Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort","Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE.","Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2213-7. doi: 10.1158/1055-9965.EPI-07-0448. Epub 2007 Oct 30.","Jacobs EJ","Cancer Epidemiol Biomarkers Prev","2007","2007/11/01","","","10.1158/1055-9965.EPI-07-0448"
"20196067","Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)","Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW.","Int J Cancer. 2010 Dec 1;127(11):2639-44. doi: 10.1002/ijc.25278.","Kerkhof M","Int J Cancer","2010","2010/03/03","","","10.1002/ijc.25278"
"14584292","The 2nd conference on Asian trends in prostate cancer hormone therapy","Akaza H, Chang SJ, Chen KK, Esuvaranathan K, Fujioka T, Hirao Y, Hong SJ, Hinotsu S, Kim WJ, Lau W, Lee SE, Murai M, Naito S, Ogawa O, Rim JS, Soebadi DM, Song JM, Tsukamoto T, Umbas R, Usami M, Yang CR, Yoon JH, Zhou L.","Gan To Kagaku Ryoho. 2003 Oct;30(10):1533-42.","Akaza H","Gan To Kagaku Ryoho","2003","2003/10/31","","",""
"18565231","FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate","Liu Y.","World J Surg Oncol. 2008 Jun 19;6:64. doi: 10.1186/1477-7819-6-64.","Liu Y","World J Surg Oncol","2008","2008/06/21","PMC2440384","","10.1186/1477-7819-6-64"
"25544761","Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer","Lin D, Dong X, Wang K, Wyatt AW, Crea F, Xue H, Wang Y, Wu R, Bell RH, Haegert A, Brahmbhatt S, Hurtado-Coll A, Gout PW, Fazli L, Gleave ME, Collins CC, Wang Y.","Oncotarget. 2015 Jan 30;6(3):1806-20. doi: 10.18632/oncotarget.2809.","Lin D","Oncotarget","2015","2014/12/30","PMC4359333","","10.18632/oncotarget.2809"
"30875166","The Management of Incidental Prostate Cancer Following TURP","Matanhelia DM, Croghan S, Nason GJ, O’Connell C, Galvin DJ.","Ir Med J. 2019 Feb 14;112(2):866.","Matanhelia DM","Ir Med J","2019","2019/03/16","","",""
"27966447","A four gene signature predictive of recurrent prostate cancer","Komisarof J, McCall M, Newman L, Bshara W, Mohler JL, Morrison C, Land H.","Oncotarget. 2017 Jan 10;8(2):3430-3440. doi: 10.18632/oncotarget.13837.","Komisarof J","Oncotarget","2017","2016/12/15","PMC5356893","","10.18632/oncotarget.13837"
"25565065","Design of the North Carolina Prostate Cancer Comparative Effectiveness and Survivorship Study (NC ProCESS)","Chen RC, Carpenter WR, Kim M, Hendrix LH, Agans RP, Meyer AM, Hoffmeyer A, Reeve BB, Nielsen ME, Usinger DS, Strigo TS, Jackman AM, Anderson M, Godley PA.","J Comp Eff Res. 2015 Jan;4(1):3-9. doi: 10.2217/cer.14.67.","Chen RC","J Comp Eff Res","2015","2015/01/08","","","10.2217/cer.14.67"
"29570262","Polygamy, sexual behavior in a population under risk for prostate cancer diagnostic: an observational study from the Black Sea Region in Turkey","Cirakoglu A, Benli E, Yuce A.","Int Braz J Urol. 2018 Jul-Aug;44(4):704-708. doi: 10.1590/S1677-5538.IBJU.2017.0525.","Cirakoglu A","Int Braz J Urol","2018","2018/03/24","PMC6092644","","10.1590/S1677-5538.IBJU.2017.0525"
"24670871","Biopsy strategies for selecting patients for focal therapy for prostate cancer","Kanthabalan A, Emberton M, Ahmed HU.","Curr Opin Urol. 2014 May;24(3):209-17. doi: 10.1097/MOU.0000000000000046.","Kanthabalan A","Curr Opin Urol","2014","2014/03/28","","","10.1097/MOU.0000000000000046"
"26627905","Prostate Cancer Ambassadors: Enhancing a Theory-Informed Training Program for Informed Decision-Making","Vines AI, Hunter JC, Carlisle VA, Richmond AN.","J Cancer Educ. 2017 Sep;32(3):454-459. doi: 10.1007/s13187-015-0955-4.","Vines AI","J Cancer Educ","2017","2015/12/03","PMC4889563","NIHMS742286","10.1007/s13187-015-0955-4"
"20424133","Is prostate cancer prevention with selenium all in the genes?","Platz EA.","Cancer Prev Res (Phila). 2010 May;3(5):576-8. doi: 10.1158/1940-6207.CAPR-10-0072. Epub 2010 Apr 27.","Platz EA","Cancer Prev Res (Phila)","2010","2010/04/29","","","10.1158/1940-6207.CAPR-10-0072"
"7853550","Experience with radical prostatectomy and radiation therapy for localized prostate cancer at a Veterans Affairs Medical Center","Fowler JE Jr, Braswell NT, Pandey P, Seaver L.","J Urol. 1995 Mar;153(3 Pt 2):1026-31.","Fowler JE Jr","J Urol","1995","1995/03/01","","",""
"11603888","Uroradiology: imaging in prostate cancer","Cochlin DL, Evans C.","Clin Radiol. 2001 Nov;56(11):871-2. doi: 10.1053/crad.2001.0835.","Cochlin DL","Clin Radiol","2001","2001/10/18","","","10.1053/crad.2001.0835"
"16195861","[Significance of the PSA-concentration for the detection of prostate cancer]","Stachon A.","Pathologe. 2005 Nov;26(6):469-72. doi: 10.1007/s00292-005-0788-8.","Stachon A","Pathologe","2005","2005/10/01","","","10.1007/s00292-005-0788-8"
"17146932","[Current opinions on the treatment of androgen-independent prostate cancer]","Guan XX, Chen LB.","Zhonghua Nan Ke Xue. 2006 Nov;12(11):1021-5.","Guan XX","Zhonghua Nan Ke Xue","2006","2006/12/07","","",""
"20963422","Image guidance for focal therapy of prostate cancer","Lindner U, Lawrentschuk N, Trachtenberg J.","World J Urol. 2010 Dec;28(6):727-34. doi: 10.1007/s00345-010-0604-9. Epub 2010 Oct 21.","Lindner U","World J Urol","2010","2010/10/22","","","10.1007/s00345-010-0604-9"
"10098761","European randomized study of prostate cancer screening: first-year results of the Finnish trial","Määttänen L, Auvinen A, Stenman UH, Rannikko S, Tammela T, Aro J, Juusela H, Hakama M.","Br J Cancer. 1999 Mar;79(7-8):1210-4. doi: 10.1038/sj.bjc.6690194.","Määttänen L","Br J Cancer","1999","1999/03/31","PMC2362232","","10.1038/sj.bjc.6690194"
"7561994","Prostate cancer in African American men: increasing knowledge and self-efficacy","Boehm S, Coleman-Burns P, Schlenk EA, Funnell MM, Parzuchowski J, Powell IJ.","J Community Health Nurs. 1995;12(3):161-9. doi: 10.1207/s15327655jchn1203_4.","Boehm S","J Community Health Nurs","1995","1995/01/01","","","10.1207/s15327655jchn1203_4"
"24188256","Contemporary issues in radiotherapy for clinically localized prostate cancer","Khor R, Williams S.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1137-62, vii. doi: 10.1016/j.hoc.2013.08.006. Epub 2013 Sep 21.","Khor R","Hematol Oncol Clin North Am","2013","2013/11/06","","","10.1016/j.hoc.2013.08.006"
"31359187","Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?","Roy S, Morgan SC.","Curr Urol Rep. 2019 Jul 29;20(9):53. doi: 10.1007/s11934-019-0918-0.","Roy S","Curr Urol Rep","2019","2019/07/31","","","10.1007/s11934-019-0918-0"
"18593624","Immunotherapy for metastatic prostate cancer","Drake CG.","Urol Oncol. 2008 Jul-Aug;26(4):438-44. doi: 10.1016/j.urolonc.2007.03.029. Epub 2007 Dec 21.","Drake CG","Urol Oncol","2008","2008/07/03","PMC4886229","NIHMS787032","10.1016/j.urolonc.2007.03.029"
"18544984","Adjuvant hormonal treatment - the bicalutamide early prostate cancer program","Wirth MP, Hakenberg OW, Froehner M.","Front Radiat Ther Oncol. 2008;41:39-48. doi: 10.1159/000139877.","Wirth MP","Front Radiat Ther Oncol","2008","2008/06/12","","","10.1159/000139877"
"21979905","[Which components should living guidelines contain?]","Weissbach L.","Urologe A. 2012 Jan;51(1):57-9. doi: 10.1007/s00120-011-2714-4.","Weissbach L","Urologe A","2012","2011/10/08","","","10.1007/s00120-011-2714-4"
"25850455","[Early detection of prostate cancer--recommendations after 13 years of follow-up in the European randomised study]","Schröder FH, Roobol MJ, Bangma CH.","Ned Tijdschr Geneeskd. 2015;159:A8677.","Schröder FH","Ned Tijdschr Geneeskd","2015","2015/04/09","","",""
"23358818","The PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among Italian radiation oncologists on postoperative radiotherapy in prostate cancer","Alongi F, De Bari B, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; AIRO Young and AIRO Prostate cancer Working Group.","Radiol Med. 2013 Jun;118(4):660-78. doi: 10.1007/s11547-012-0913-8. Epub 2013 Jan 28.","Alongi F","Radiol Med","2013","2013/01/30","","","10.1007/s11547-012-0913-8"
"16382716","[Biochemical failure after curative treatment for localized prostate cancer]","Zouhair A, Jichlinski P, Mirimanoff RO.","Rev Med Suisse. 2005 Dec 7;1(44):2844-6, 2848.","Zouhair A","Rev Med Suisse","2005","2005/12/31","","",""
"9064880","[The natural course of untreated, localized primary prostate carcinoma]","Johansson JE.","Urologe A. 1996 Nov;35(6):446-8. doi: 10.1007/s001200050049.","Johansson JE","Urologe A","1996","1996/11/01","","","10.1007/s001200050049"
"17225300","Gleason grading of prostate cancer in needle biopsies vs. radical prostatectomy specimens","Vidal-Jimenez A.","Anal Quant Cytol Histol. 2006 Dec;28(6):340-1.","Vidal-Jimenez A","Anal Quant Cytol Histol","2006","2007/01/17","","",""
"11192822","Screening for prostate cancer by PSA determination: a time for caution","Ciatto S.","Int J Biol Markers. 2000 Oct-Dec;15(4):285-7.","Ciatto S","Int J Biol Markers","2000","2001/02/24","","",""
"18286512","Is there an optimal comorbidity index for prostate cancer?","Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G.","Cancer. 2008 Mar 1;112(5):1043-50. doi: 10.1002/cncr.23269.","Alibhai SM","Cancer","2008","2008/02/21","","","10.1002/cncr.23269"
"8441185","Prostate cancer: results of external irradiation","Reddy EK, Krishnan L, Giri S, Evans RG, Mebust WK, Weigel JW.","J Natl Med Assoc. 1993 Feb;85(2):109-12.","Reddy EK","J Natl Med Assoc","1993","1993/02/01","PMC2571856","",""
"8773500","Early-stage prostate cancer. When is observation appropriate?","Albertsen PC.","Hematol Oncol Clin North Am. 1996 Jun;10(3):611-25. doi: 10.1016/s0889-8588(05)70356-7.","Albertsen PC","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70356-7"
"30817318","Interplay between the androgen receptor signaling axis and microRNAs in prostate cancer","Fernandes RC, Hickey TE, Tilley WD, Selth LA.","Endocr Relat Cancer. 2019 May;26(5):R237-R257. doi: 10.1530/ERC-18-0571.","Fernandes RC","Endocr Relat Cancer","2019","2019/03/01","","","10.1530/ERC-18-0571"
"22077546","Management of low (favourable)-risk prostate cancer","Carter HB.","BJU Int. 2011 Dec;108(11):1684-95. doi: 10.1111/j.1464-410X.2010.10489.x.","Carter HB","BJU Int","2011","2011/11/15","PMC4086468","NIHMS407190","10.1111/j.1464-410X.2010.10489.x"
"23600310","[Clinical and prognostic significance of the doubling time of initial prostate-specific antigen in patients with prostate cancer]","Zharinov GM, Neklasova NIu, Zimin AA.","Vopr Onkol. 2012;58(6):817-20.","Zharinov GM","Vopr Onkol","2012","2013/04/23","","",""
"7692113","Stage A prostate cancer today","Kabalin JN.","J Urol. 1993 Nov;150(5 Pt 2):1749-50. doi: 10.1016/s0022-5347(17)35885-8.","Kabalin JN","J Urol","1993","1993/11/01","","","10.1016/s0022-5347(17)35885-8"
"9828586","Keynote address: prostate cancer among African-American men--from the bench to the community","Powell I.","J Natl Med Assoc. 1998 Nov;90(11 Suppl):S705-9.","Powell I","J Natl Med Assoc","1998","1998/11/26","PMC2652608","",""
"8853496","The need to measure quality of life in a prostate cancer screening trial","Iverson D.","Can J Oncol. 1994 Nov;4 Suppl 1:76-7.","Iverson D","Can J Oncol","1994","1994/11/01","","",""
"19439915","When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example","Li-Wan-Po A, Farndon P, Cooley C, Lithgow J.","Public Health Genomics. 2010;13(1):55-62. doi: 10.1159/000218710. Epub 2009 May 13.","Li-Wan-Po A","Public Health Genomics","2010","2009/05/15","","","10.1159/000218710"
"17644125","Contemporary trends in low risk prostate cancer: risk assessment and treatment","Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.","J Urol. 2007 Sep;178(3 Pt 2):S14-9. doi: 10.1016/j.juro.2007.03.135. Epub 2007 Jul 20.","Cooperberg MR","J Urol","2007","2007/07/24","PMC2987559","NIHMS233416","10.1016/j.juro.2007.03.135"
"24683724","Active surveillance for African-American men with prostate cancer: of course! Pro","Moul JW.","Oncology (Williston Park). 2014 Jan;28(1):82, 84-5.","Moul JW","Oncology (Williston Park)","2014","2014/04/02","","",""
"21830972","Early prostate cancer--treat or watch?","Klotz L, Thompson I.","N Engl J Med. 2011 Aug 11;365(6):569. doi: 10.1056/NEJMc1106325.","Klotz L","N Engl J Med","2011","2011/08/12","","","10.1056/NEJMc1106325"
"11338762","Quality of life, health outcomes, and identity for patients with prostate cancer in five different treatment groups","Galbraith ME, Ramirez JM, Pedro LW.","Oncol Nurs Forum. 2001 Apr;28(3):551-60.","Galbraith ME","Oncol Nurs Forum","2001","2001/05/08","","",""
"7707618","Screening for prostate cancer","Catalona WJ.","JAMA. 1995 Apr 19;273(15):1174; author reply 1175-6. doi: 10.1001/jama.273.15.1174.","Catalona WJ","JAMA","1995","1995/04/19","","","10.1001/jama.273.15.1174"
"7708515","Being sensitive to the psychological needs of patients with prostate cancer","Berger NS, Crawford ED.","Oncol Nurs Forum. 1995 Jan-Feb;22(1):14.","Berger NS","Oncol Nurs Forum","1995","1995/01/01","","",""
"25499294","Prostate cancer services vary in England and Wales","Mayor S.","Lancet Oncol. 2014 Dec;15(13):e593. doi: 10.1016/S1470-2045(14)71119-2. Epub 2014 Nov 14.","Mayor S","Lancet Oncol","2014","2014/12/16","","","10.1016/S1470-2045(14)71119-2"
"19022492","Why external beam radiotherapy is treatment of choice for most men with early-stage nonmetastatic prostate cancer","Horwitz EM.","Urology. 2009 Mar;73(3):470-2. doi: 10.1016/j.urology.2008.09.029. Epub 2008 Nov 20.","Horwitz EM","Urology","2009","2008/11/22","","","10.1016/j.urology.2008.09.029"
"17164461","Treating older men with prostate cancer: survival (or selection) of the fittest?","Litwin MS, Miller DC.","JAMA. 2006 Dec 13;296(22):2733-4. doi: 10.1001/jama.296.22.2733.","Litwin MS","JAMA","2006","2006/12/14","","","10.1001/jama.296.22.2733"
"20664922","Prostate cancer chemopreventive activity of phenethyl isothiocyanate through epigenetic regulation (review)","Wang LG, Chiao JW.","Int J Oncol. 2010 Sep;37(3):533-9. doi: 10.3892/ijo_00000702.","Wang LG","Int J Oncol","2010","2010/07/29","","","10.3892/ijo_00000702"
"16327854","[Markers for diagnosis, prediction and prognosis of prostate cancer]","Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S.","Tidsskr Nor Laegeforen. 2005 Dec 1;125(23):3279-82.","Taskén KA","Tidsskr Nor Laegeforen","2005","2005/12/06","","",""
"24016674","Postoperative high-dose pelvic radiotherapy for N+ prostate cancer: toxicity and matched case comparison with postoperative prostate bed-only radiotherapy","Van Praet C, Ost P, Lumen N, De Meerleer G, Vandecasteele K, Villeirs G, Decaestecker K, Fonteyne V.","Radiother Oncol. 2013 Nov;109(2):222-8. doi: 10.1016/j.radonc.2013.08.021. Epub 2013 Sep 7.","Van Praet C","Radiother Oncol","2013","2013/09/11","","","10.1016/j.radonc.2013.08.021"
"19514384","[Prostate cancer: evolution of approach]","Vorob'ëv AV.","Vopr Onkol. 2009;55(2):241-9.","Vorob'ëv AV","Vopr Onkol","2009","2009/06/12","","",""
"19070814","[Management of metastatic androgeno-independent prostate cancer]","Lebret T, Méjean A.","Prog Urol. 2008 Nov;18 Suppl 7:S343-8. doi: 10.1016/S1166-7087(08)74565-2.","Lebret T","Prog Urol","2008","2008/12/17","","","10.1016/S1166-7087(08)74565-2"
"26210103","Molecular landscape of prostate cancer: implications for current clinical trials","Khemlina G, Ikeda S, Kurzrock R.","Cancer Treat Rev. 2015 Nov;41(9):761-6. doi: 10.1016/j.ctrv.2015.07.001. Epub 2015 Jul 9.","Khemlina G","Cancer Treat Rev","2015","2015/07/27","","","10.1016/j.ctrv.2015.07.001"
"19204997","Central quadrant procurement of radical prostatectomy specimens","Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL.","Prostate. 2009 May 15;69(7):770-3. doi: 10.1002/pros.20925.","Morrison C","Prostate","2009","2009/02/11","PMC2851159","NIHMS188618","10.1002/pros.20925"
"7488401","Prostate cancer--what should be studied?","James ND, Glaholm J.","Eur J Cancer. 1995 Sep;31A(10):1565-6. doi: 10.1016/0959-8049(95)00390-5.","James ND","Eur J Cancer","1995","1995/09/01","","","10.1016/0959-8049(95)00390-5"
"17361914","[Localized prostate cancer. What to say to the patient?]","Coloby P.","Ann Urol (Paris). 2006 Dec;40 Suppl 2:S18-23. doi: 10.1016/s0003-4401(06)80014-8.","Coloby P","Ann Urol (Paris)","2006","2007/03/17","","","10.1016/s0003-4401(06)80014-8"
"9695702","Management of metastatic prostate cancer","Rosenthal MA.","Med J Aust. 1998 Jul 6;169(1):46-50.","Rosenthal MA","Med J Aust","1998","1998/08/08","","",""
"16372513","The natural history: how has prostate cancer trend modified?","Schiaffino E.","Arch Ital Urol Androl. 2005 Jun;77(3):167-8.","Schiaffino E","Arch Ital Urol Androl","2005","2005/12/24","","",""
"8594281","Evaluation of serum prostate-specific antigen levels after postoperative radiation therapy for pathologic stage T3, N0 prostate cancer","Buskirk SJ, Schild SE, Durr ED, Robinow JS, Bock FF, Wolfe JT, Tomera KM, Ferrigni RG.","Mayo Clin Proc. 1996 Mar;71(3):242-8. doi: 10.4065/71.3.242.","Buskirk SJ","Mayo Clin Proc","1996","1996/03/01","","","10.4065/71.3.242"
"24877145","Novel tools for prostate cancer prognosis, diagnosis, and follow-up","Dimakakos A, Armakolas A, Koutsilieris M.","Biomed Res Int. 2014;2014:890697. doi: 10.1155/2014/890697. Epub 2014 May 4.","Dimakakos A","Biomed Res Int","2014","2014/05/31","PMC4024423","","10.1155/2014/890697"
"8252510","Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies","Hucher M, de Gery A, Bertagna C.","Cancer. 1993 Dec 15;72(12 Suppl):3886-7. doi: 10.1002/1097-0142(19931215)72:12+<3886::aid-cncr2820721725>3.0.co;2-k.","Hucher M","Cancer","1993","1993/12/15","","","10.1002/1097-0142(19931215)72:12+<3886::aid-cncr2820721725>3.0.co;2-k"
"12113579","Clinical significance of pepsinogen C tumor expression in patients with stage D2 prostate carcinoma","Díaz M, Rodríguez JC, Sánchez J, Sánchez MT, Martín A, Merino AM, Vizoso F.","Int J Biol Markers. 2002 Apr-Jun;17(2):125-9. doi: 10.5301/jbm.2008.4026.","Díaz M","Int J Biol Markers","2002","2002/07/13","","","10.5301/jbm.2008.4026"
"10325497","Changes in gene expression and targets for therapy","Bussemakers MJ.","Eur Urol. 1999;35(5-6):408-12. doi: 10.1159/000019917.","Bussemakers MJ","Eur Urol","1999","1999/05/15","","","10.1159/000019917"
"10495525","Prostate cancer and PSA screening","Mameghan H.","Aust Fam Physician. 1999 Aug;28(8):777-81.","Mameghan H","Aust Fam Physician","1999","1999/09/25","","",""
"21128282","LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer","Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman H.","Int J Cancer. 2011 Jun 15;128(12):2843-52. doi: 10.1002/ijc.25820. Epub 2011 Apr 8.","Thomasson M","Int J Cancer","2011","2010/12/04","","","10.1002/ijc.25820"
"25034993","Re: The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease","Taneja SS.","J Urol. 2014 Aug;192(2):422. doi: 10.1016/j.juro.2014.05.078. Epub 2014 May 14.","Taneja SS","J Urol","2014","2014/07/19","","","10.1016/j.juro.2014.05.078"
"22959353","It's time to change the treatment paradigm for prostate cancer!","Studer UE, Albertsen PC.","Eur Urol. 2013 Jan;63(1):97-9; discussion 99-100. doi: 10.1016/j.eururo.2012.08.046. Epub 2012 Aug 30.","Studer UE","Eur Urol","2013","2012/09/11","","","10.1016/j.eururo.2012.08.046"
"2269011","Update: prostate cancer","Fukuda CS, Brawer MK.","Compr Ther. 1990 Nov;16(11):15-25.","Fukuda CS","Compr Ther","1990","1990/11/01","","",""
"10699601","Clinical states in prostate cancer: toward a dynamic model of disease progression","Scher HI, Heller G.","Urology. 2000 Mar;55(3):323-7. doi: 10.1016/s0090-4295(99)00471-9.","Scher HI","Urology","2000","2000/03/04","","","10.1016/s0090-4295(99)00471-9"
"14702629","Androgen receptor outwits prostate cancer drugs","Isaacs JT, Isaacs WB.","Nat Med. 2004 Jan;10(1):26-7. doi: 10.1038/nm0104-26.","Isaacs JT","Nat Med","2004","2004/01/02","","","10.1038/nm0104-26"
"15018077","[Imaging of cancer prostate]","Ghouadni M, Sandoz C, Eiss D, Cornud F, Thiounn N, Hélénon O.","Rev Prat. 2003 Dec 31;53(20):2237-43.","Ghouadni M","Rev Prat","2003","2004/03/17","","",""
"20813451","Kindlin-2 controls sensitivity of prostate cancer cells to cisplatin-induced cell death","Gong X, An Z, Wang Y, Guan L, Fang W, Strömblad S, Jiang Y, Zhang H.","Cancer Lett. 2010 Dec 18;299(1):54-62. doi: 10.1016/j.canlet.2010.08.003. Epub 2010 Sep 1.","Gong X","Cancer Lett","2010","2010/09/04","","","10.1016/j.canlet.2010.08.003"
"19371477","Salvage therapy for prostate cancer recurrence after radiation therapy","Cox JM, Busby JE.","Curr Urol Rep. 2009 May;10(3):199-205. doi: 10.1007/s11934-009-0034-7.","Cox JM","Curr Urol Rep","2009","2009/04/18","","","10.1007/s11934-009-0034-7"
"8066864","[Risk factors of prostatic cancer]","Friis S, Kjaer SK, Storm HH.","Ugeskr Laeger. 1994 Jun 6;156(23):3485-90.","Friis S","Ugeskr Laeger","1994","1994/06/06","","",""
"28984478","PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy","Bonfiglio R, Nardozi D, Scimeca M, Cerroni C, Mauriello A, Bonanno E.","Future Oncol. 2017 Oct;13(24):2129-2131. doi: 10.2217/fon-2017-0278. Epub 2017 Oct 6.","Bonfiglio R","Future Oncol","2017","2017/10/07","","","10.2217/fon-2017-0278"
"19773114","Re: Alberto Briganti, Michael L. Blute, James H. Eastham, et al. Pelvic lymph node dissection in prostate cancer. Eur urol 2009;55:1251-65","Alcover J, Filella X.","Eur Urol. 2009 Dec;56(6):e53. doi: 10.1016/j.eururo.2009.09.003. Epub 2009 Sep 9.","Alcover J","Eur Urol","2009","2009/09/24","","","10.1016/j.eururo.2009.09.003"
"3552544","Current concepts in the treatment of prostate cancer","Melamed AJ.","Drug Intell Clin Pharm. 1987 Mar;21(3):247-54. doi: 10.1177/106002808702100302.","Melamed AJ","Drug Intell Clin Pharm","1987","1987/03/01","","","10.1177/106002808702100302"
"16861116","New clinical imaging modalities in prostate cancer","Ross R, Harisinghani M.","Hematol Oncol Clin North Am. 2006 Aug;20(4):811-30. doi: 10.1016/j.hoc.2006.03.009.","Ross R","Hematol Oncol Clin North Am","2006","2006/07/25","","","10.1016/j.hoc.2006.03.009"
"16608420","PSA-based vaccines for the treatment of prostate cancer","Madan RA, Gulley JL, Arlen PM.","Expert Rev Vaccines. 2006 Apr;5(2):199-209. doi: 10.1586/14760584.5.2.199.","Madan RA","Expert Rev Vaccines","2006","2006/04/13","","","10.1586/14760584.5.2.199"
"22123334","Abiraterone acetate in castration-resistant prostate cancer","Iacovelli R, Palazzo A, Procopio G, Gazzaniga P, Cortesi E.","Anticancer Drugs. 2012 Mar;23(3):247-54. doi: 10.1097/CAD.0b013e32834e696c.","Iacovelli R","Anticancer Drugs","2012","2011/11/30","","","10.1097/CAD.0b013e32834e696c"
"27630337","Multiparametric-Magnetic Resonance/Ultrasound Fusion Targeted Prostate Biopsy Improves Agreement Between Biopsy and Radical Prostatectomy Gleason Score","Porpiglia F, DE Luca S, Passera R, Manfredi M, Mele F, Bollito E, DE Pascale A, Cossu M, Aimar R, Veltri A.","Anticancer Res. 2016 Sep;36(9):4833-9. doi: 10.21873/anticanres.11045.","Porpiglia F","Anticancer Res","2016","2016/09/16","","","10.21873/anticanres.11045"
"29417258","Impact of comorbidities at diagnosis on prostate cancer treatment and survival","Matthes KL, Limam M, Pestoni G, Held L, Korol D, Rohrmann S.","J Cancer Res Clin Oncol. 2018 Apr;144(4):707-715. doi: 10.1007/s00432-018-2596-6. Epub 2018 Feb 7.","Matthes KL","J Cancer Res Clin Oncol","2018","2018/02/09","","","10.1007/s00432-018-2596-6"
"2665288","Transrectal ultrasound in early detection of clinical stage A prostate cancer","Gluck R, Cohen M, Warner R.","Urology. 1989 Jul;34(1):58-61. doi: 10.1016/0090-4295(89)90161-1.","Gluck R","Urology","1989","1989/07/01","","","10.1016/0090-4295(89)90161-1"
"22544633","Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: a population-based study","Reeve BB, Stover AM, Jensen RE, Chen RC, Taylor KL, Clauser SB, Collins SP, Potosky AL.","Cancer. 2012 Nov 15;118(22):5679-87. doi: 10.1002/cncr.27578. Epub 2012 Apr 27.","Reeve BB","Cancer","2012","2012/05/01","PMC3410051","NIHMS366085","10.1002/cncr.27578"
"21320276","Epstein criteria for insignificant prostate cancer","Oon SF, Watson RW, O'Leary JJ, Fitzpatrick JM.","BJU Int. 2011 Aug;108(4):518-25. doi: 10.1111/j.1464-410X.2011.09979.x. Epub 2011 Feb 14.","Oon SF","BJU Int","2011","2011/02/16","","","10.1111/j.1464-410X.2011.09979.x"
"29386061","Dihydroisotanshinone I combined with radiation inhibits the migration ability of prostate cancer cells through DNA damage and CCL2 pathway","Lee IY, Lin YY, Yang YH, Lin YS, Lin CL, Lin WY, Cheng YC, Shu LH, Wu CY.","BMC Pharmacol Toxicol. 2018 Jan 31;19(1):5. doi: 10.1186/s40360-018-0195-4.","Lee IY","BMC Pharmacol Toxicol","2018","2018/02/02","PMC5793371","","10.1186/s40360-018-0195-4"
"23320634","Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer","Preston MA, Harisinghani MG, Mucci L, Witiuk K, Breau RH.","BJU Int. 2013 Mar;111(3):514-7. doi: 10.1111/j.1464-410X.2012.11447.x. Epub 2013 Jan 15.","Preston MA","BJU Int","2013","2013/01/17","","","10.1111/j.1464-410X.2012.11447.x"
"7511323","Current status of PSA in the management of prostate cancer","Carter HB.","Adv Surg. 1994;27:81-95.","Carter HB","Adv Surg","1994","1994/01/01","","",""
"11880074","Rise and fall of radical prostatectomy rates from 1989 to 1996","Sheikh K, Bullock C.","Urology. 2002 Mar;59(3):378-82. doi: 10.1016/s0090-4295(01)01588-6.","Sheikh K","Urology","2002","2002/03/07","","","10.1016/s0090-4295(01)01588-6"
"28599761","Racial Disparity in Localized Prostate Cancer Mortality","Xin H.","J Natl Med Assoc. 2017 Summer;109(2):86-92. doi: 10.1016/j.jnma.2017.01.007. Epub 2017 Feb 14.","Xin H","J Natl Med Assoc","2017","2017/06/11","","","10.1016/j.jnma.2017.01.007"
"12677774","[Prostate-specific antigen: appropriate and inappropriate use]","Ciatto S.","Recenti Prog Med. 2003 Mar;94(3):95-8.","Ciatto S","Recenti Prog Med","2003","2003/04/08","","",""
"7742699","Detection of prostate cancer. Methods are changing rapidly","Hamdy FC, Neal DE.","BMJ. 1995 Apr 29;310(6987):1140. doi: 10.1136/bmj.310.6987.1140.","Hamdy FC","BMJ","1995","1995/04/29","PMC2549526","","10.1136/bmj.310.6987.1140"
"8487908","[Vasectomy and prostate cancer; education and practical advice]","Thomas S.","Ned Tijdschr Geneeskd. 1993 Apr 24;137(17):879-80.","Thomas S","Ned Tijdschr Geneeskd","1993","1993/04/24","","",""
"8595992","Management dilemmas in prostate cancer","Bruskewitz R, Carbone PP.","Hosp Pract (1995). 1996 Jan 15;31(1):79-86.","Bruskewitz R","Hosp Pract (1995)","1996","1996/01/15","","",""
"15539935","Therapeutic targeting of prostate cancer","Cress AE, Mohla S.","Cancer Biol Ther. 2004 Oct;3(10):1028-30. doi: 10.4161/cbt.3.10.1266. Epub 2004 Oct 15.","Cress AE","Cancer Biol Ther","2004","2004/11/13","","","10.4161/cbt.3.10.1266"
"26298924","Current and Future Applications Of Genetic Prostate Cancer Screening in the Urologic Clinic","Feng F, Schaich M, Hughes L.","Urol Nurs. 2014 Nov-Dec;34(6):281-9, 311.","Feng F","Urol Nurs","2014","2015/08/25","","",""
"25557291","Surgery for high-risk prostate cancer and metastatic prostate cancer","Safir IJ, Lian F, Alemozaffar M, Master VA.","Curr Probl Cancer. 2015 Jan-Feb;39(1):33-40. doi: 10.1016/j.currproblcancer.2014.11.006. Epub 2014 Nov 25.","Safir IJ","Curr Probl Cancer","2015","2015/01/06","","","10.1016/j.currproblcancer.2014.11.006"
"27362886","Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer","Habibian DJ, Katz AE.","Int J Hyperthermia. 2016 Nov;32(7):795-800. doi: 10.1080/02656736.2016.1195925. Epub 2016 Jun 30.","Habibian DJ","Int J Hyperthermia","2016","2016/07/01","","","10.1080/02656736.2016.1195925"
"22236417","[Nondetectable prostate cancer in radical prostatectomy specimens]","Murányi M, Morshed AS, Benyó M, Tóth C, Flaskó T.","Orv Hetil. 2012 Jan 22;153(3):113-7. doi: 10.1556/OH.2012.29285.","Murányi M","Orv Hetil","2012","2012/01/13","","","10.1556/OH.2012.29285"
"8045065","Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings","Spencer JA, Golding SJ.","Clin Radiol. 1994 Jun;49(6):404-7. doi: 10.1016/s0009-9260(05)81826-4.","Spencer JA","Clin Radiol","1994","1994/06/01","","","10.1016/s0009-9260(05)81826-4"
"21547350","Within-group differences between native-born and foreign-born Black men on prostate cancer risk reduction and early detection practices","Odedina FT, Dagne G, LaRose-Pierre M, Scrivens J, Emanuel F, Adams A, Pressey S, Odedina O.","J Immigr Minor Health. 2011 Dec;13(6):996-1004. doi: 10.1007/s10903-011-9471-8.","Odedina FT","J Immigr Minor Health","2011","2011/05/07","","","10.1007/s10903-011-9471-8"
"31990107","Bacterial signatures and their inflammatory potentials associated with prostate cancer","Brüggemann H, Al-Zeer MA.","APMIS. 2020 Feb;128(2):80-91. doi: 10.1111/apm.13021. Epub 2020 Jan 28.","Brüggemann H","APMIS","2020","2020/01/29","","","10.1111/apm.13021"
"8728357","Attitude of African-Americans regarding prostate cancer clinical trials","Robinson SB, Ashley M, Haynes MA.","J Community Health. 1996 Apr;21(2):77-87. doi: 10.1007/BF01682300.","Robinson SB","J Community Health","1996","1996/04/01","","","10.1007/BF01682300"
"16413692","Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features","Aslan G, Irer B, Tuna B, Yorukoglu K, Saatcioglu F, Celebi I.","Pathol Res Pract. 2006;202(2):93-8. doi: 10.1016/j.prp.2005.11.007. Epub 2006 Jan 18.","Aslan G","Pathol Res Pract","2006","2006/01/18","","","10.1016/j.prp.2005.11.007"
"25260832","The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy","Klap J, Schmid M, Loughlin KR.","J Urol. 2015 Feb;193(2):403-13. doi: 10.1016/j.juro.2014.07.123. Epub 2014 Sep 28.","Klap J","J Urol","2015","2014/09/28","","","10.1016/j.juro.2014.07.123"
"29189229","Study Finds Overall Prostate Cancer Mortality Decreases with PSA Screening","Zolot J.","Am J Nurs. 2017 Dec;117(12):16. doi: 10.1097/01.NAJ.0000527472.38965.1f.","Zolot J","Am J Nurs","2017","2017/12/01","","","10.1097/01.NAJ.0000527472.38965.1f"
"20356946","Prostate cancer incidence rates have started to decrease in central Italy","Crocetti E, Ciatto S, Buzzoni C, Zappa M.","J Med Screen. 2010;17(1):50-1. doi: 10.1258/jms.2009.009123.","Crocetti E","J Med Screen","2010","2010/04/02","","","10.1258/jms.2009.009123"
"9137077","Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer","Isaacs JT.","Am J Pathol. 1997 May;150(5):1511-21.","Isaacs JT","Am J Pathol","1997","1997/05/01","PMC1858207","",""
"27340776","SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells","Gwak J, Shin JY, Lee K, Hong SK, Oh S, Goh SH, Kim WS, Ju BG.","Oncotarget. 2016 Jul 26;7(30):48250-48264. doi: 10.18632/oncotarget.10198.","Gwak J","Oncotarget","2016","2016/06/25","PMC5217015","","10.18632/oncotarget.10198"
"23194122","Informed prostate cancer risk-adjusted testing: a new paradigm","Stricker PD, Frydenberg M, Kneebone A, Chopra S.","BJU Int. 2012 Dec;110 Suppl 4:30-4. doi: 10.1111/j.1464-410X.2012.11621.x.","Stricker PD","BJU Int","2012","2012/12/01","","","10.1111/j.1464-410X.2012.11621.x"
"8479895","[Prostate cancer in Scandinavia. Variations in practice and attitude to radical treatment]","Heggestad T, Jonsson PM, Danneskiold-Samsøe B, Leisti S.","Nord Med. 1993;108(4):104-6.","Heggestad T","Nord Med","1993","1993/01/01","","",""
"17325424","Epigenetic markers for molecular detection of prostate cancer","Costa VL, Henrique R, Jerónimo C.","Dis Markers. 2007;23(1-2):31-41. doi: 10.1155/2007/356742.","Costa VL","Dis Markers","2007","2007/02/28","PMC3850633","","10.1155/2007/356742"
"10818452","Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications","Nie D, Tang K, Szekeres K, Li L, Honn KV.","Ann N Y Acad Sci. 2000 Apr;905:165-76. doi: 10.1111/j.1749-6632.2000.tb06548.x.","Nie D","Ann N Y Acad Sci","2000","2000/05/20","","","10.1111/j.1749-6632.2000.tb06548.x"
"10361552","Prostate-specific antigen and other markers of therapeutic response","Carducci MA, DeWeese TL, Nelson JB.","Urol Clin North Am. 1999 May;26(2):291-302, viii. doi: 10.1016/s0094-0143(05)70069-0.","Carducci MA","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70069-0"
"23459024","The influence of family ties on men's prostate cancer screening, biopsy, and treatment decisions","Shaw EK, Scott JG, Ferrante JM.","Am J Mens Health. 2013 Nov;7(6):461-71. doi: 10.1177/1557988313480226. Epub 2013 Mar 3.","Shaw EK","Am J Mens Health","2013","2013/03/06","","","10.1177/1557988313480226"
"9118393","Use of transrectal ultrasound and biopsy in the detection of prostate cancer","Selzman AA, Resnick MI.","Tech Urol. 1995 Winter;1(4):209-16.","Selzman AA","Tech Urol","1995","1995/01/01","","",""
"23050534","Radical prostatectomy versus observation for prostate cancer","Rosenthal M.","N Engl J Med. 2012 Oct 11;367(15):1468; author reply 1468-9. doi: 10.1056/NEJMc1209800.","Rosenthal M","N Engl J Med","2012","2012/10/12","","","10.1056/NEJMc1209800"
"18240807","Prostate cancer","Smith I.","Nurs Stand. 2008 Jan 9-15;22(18):59.","Smith I","Nurs Stand","2008","2008/02/05","","",""
"30677815","A novel case of NKX3.1-positive metastatic cutaneous prostate cancer","Wong JK, Minni JP, Nowak MA.","Dermatol Online J. 2018 Oct 15;24(10):13030/qt3x81m0jw.","Wong JK","Dermatol Online J","2018","2019/01/25","","",""
"20307219","Castrate-resistant prostate cancer: therapeutic strategies","Harzstark AL, Small EJ.","Expert Opin Pharmacother. 2010 Apr;11(6):937-45. doi: 10.1517/14656561003677382.","Harzstark AL","Expert Opin Pharmacother","2010","2010/03/24","","","10.1517/14656561003677382"
"1887532","Transurethral resection of prostate prior to definitive irradiation for prostate cancer. Lack of correlation with treatment outcome","Anscher MS, Prosnitz LR.","Urology. 1991 Sep;38(3):206-11. doi: 10.1016/s0090-4295(91)80345-8.","Anscher MS","Urology","1991","1991/09/01","","","10.1016/s0090-4295(91)80345-8"
"17905512","Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells","Killilea AN, Downing KH, Killilea DW.","Cancer Lett. 2007 Dec 8;258(1):70-9. doi: 10.1016/j.canlet.2007.08.010. Epub 2007 Oct 1.","Killilea AN","Cancer Lett","2007","2007/10/02","","","10.1016/j.canlet.2007.08.010"
"9589365","Interracial comparative study of prostate cancer in the United States, China, and Japan","Zhau HE, Zhao LS, Chen BQ, Kojima M.","J Cell Biochem Suppl. 1997;28-29:182-5.","Zhau HE","J Cell Biochem Suppl","1997","1997/01/01","","",""
"16223112","[Early detection in prostate cancer and shared decision making]","Junod AF.","Praxis (Bern 1994). 2005 Sep 28;94(39):1525-9. doi: 10.1024/0369-8394.94.39.1525.","Junod AF","Praxis (Bern 1994)","2005","2005/10/15","","","10.1024/0369-8394.94.39.1525"
"7242091","Prostate cancer mortality among Catholic priests","Michalek AM, Mettlin C, Priore RL.","J Surg Oncol. 1981;17(2):129-33. doi: 10.1002/jso.2930170205.","Michalek AM","J Surg Oncol","1981","1981/01/01","","","10.1002/jso.2930170205"
"22975940","First results of endocavity evaluation of the microvascularization of malignant prostate tumors using contrast enhanced ultrasound (CEUS) including perfusion analysis: first results","Jung EM, Wiggermann P, Greis C, Eder F, Ehrich J, Jung W, Schreyer AG, Stroszczynski C, Ganzer R.","Clin Hemorheol Microcirc. 2012;52(2-4):167-77. doi: 10.3233/CH-2012-1594.","Jung EM","Clin Hemorheol Microcirc","2012","2012/09/15","","","10.3233/CH-2012-1594"
"26647892","[Role of the Immune System and Possibilities of Immunotherapy in Prostate Cancer]","Kubáčková K.","Klin Onkol. 2015;28 Suppl 4:4S69-72. doi: 10.14735/amko20154s69.","Kubáčková K","Klin Onkol","2015","2015/12/10","","","10.14735/amko20154s69"
"15781230","Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells","Stanley G, Harvey K, Slivova V, Jiang J, Sliva D.","Biochem Biophys Res Commun. 2005 Apr 29;330(1):46-52. doi: 10.1016/j.bbrc.2005.02.116.","Stanley G","Biochem Biophys Res Commun","2005","2005/03/23","","","10.1016/j.bbrc.2005.02.116"
"19775613","Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer","Bottke D, de Reijke TM, Bartkowiak D, Wiegel T.","Eur J Cancer. 2009 Sep;45 Suppl 1:148-57. doi: 10.1016/S0959-8049(09)70027-9.","Bottke D","Eur J Cancer","2009","2009/09/25","","","10.1016/S0959-8049(09)70027-9"
"11342919","Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer","Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T.","J Urol. 2001 May;165(5):1569-74.","Isola J","J Urol","2001","2001/05/09","","",""
"12086878","Gene expression correlates of clinical prostate cancer behavior","Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.","Cancer Cell. 2002 Mar;1(2):203-9. doi: 10.1016/s1535-6108(02)00030-2.","Singh D","Cancer Cell","2002","2002/06/28","","","10.1016/s1535-6108(02)00030-2"
"24896544","Clinical phenotypes of castration-resistant prostate cancer","Zhang T, Armstrong AJ.","Clin Adv Hematol Oncol. 2013 Nov;11(11):707-18.","Zhang T","Clin Adv Hematol Oncol","2013","2014/06/05","","",""
"15495948","[Congress of the European Urology Association 2004: state and perspective of prostate cancer management]","Rouprêt M, Beley S.","Ann Urol (Paris). 2004 Aug;38 Suppl(1):S1-15.","Rouprêt M","Ann Urol (Paris)","2004","2004/10/22","","",""
"2254873","[Endorectal Doppler echography of prostate cancer. Potential role in therapeutic evaluation. A case report]","Fornage BD.","J Radiol. 1990 Jun-Jul;71(6-7):433-8.","Fornage BD","J Radiol","1990","1990/06/01","","",""
"22453333","The Prostate cancer Research International: Active Surveillance study","Bangma CH, Bul M, Roobol M.","Curr Opin Urol. 2012 May;22(3):216-21. doi: 10.1097/MOU.0b013e328351dcc7.","Bangma CH","Curr Opin Urol","2012","2012/03/29","","","10.1097/MOU.0b013e328351dcc7"
"19394132","Prostate cancer screening: the need for problem-solving that puts men's interests first","Holmberg L.","Eur Urol. 2009 Jul;56(1):34-7. doi: 10.1016/j.eururo.2009.04.026. Epub 2009 Apr 21.","Holmberg L","Eur Urol","2009","2009/04/28","","","10.1016/j.eururo.2009.04.026"
"21668040","Pharmacotherapeutic management of locally advanced prostate cancer: current status","Martin JM, Supiot S, Berthold DR.","Drugs. 2011 May 28;71(8):1019-41. doi: 10.2165/11591500-000000000-00000.","Martin JM","Drugs","2011","2011/06/15","","","10.2165/11591500-000000000-00000"
"31283598","18F-Fluciclovine Uptake in Celiac Ganglia: A Pitfall in Prostate Cancer PET Imaging","Wo S, Matesan MC.","Clin Nucl Med. 2019 Sep;44(9):743-745. doi: 10.1097/RLU.0000000000002693.","Wo S","Clin Nucl Med","2019","2019/07/09","","","10.1097/RLU.0000000000002693"
"22144497","Assessing the clinical role of genetic markers of early-onset prostate cancer among high-risk men enrolled in prostate cancer early detection","Hughes L, Zhu F, Ross E, Gross L, Uzzo RG, Chen DY, Viterbo R, Rebbeck TR, Giri VN.","Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):53-60. doi: 10.1158/1055-9965.EPI-11-0727. Epub 2011 Dec 5.","Hughes L","Cancer Epidemiol Biomarkers Prev","2012","2011/12/07","PMC3253936","NIHMS340281","10.1158/1055-9965.EPI-11-0727"
"25971432","Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project","Fleisher L, Davis SN, Gross L, Bagden L, Zakrzewski D, González E, Kandadai V, Rusten C, Baskett J, Obeid E, Giri VN.","J Cancer Educ. 2016 Mar;31(1):191-7. doi: 10.1007/s13187-015-0854-8.","Fleisher L","J Cancer Educ","2016","2015/05/15","","","10.1007/s13187-015-0854-8"
"18957710","Potential benefits of intra-prostatic cancer-specific imaging to guide therapy and monitor outcome in patients treated with radiation-based treatments for localized prostate cancer","Ennis RD.","Cancer Biomark. 2008;4(4-5):197-9. doi: 10.3233/cbm-2008-44-503.","Ennis RD","Cancer Biomark","2008","2008/10/30","","","10.3233/cbm-2008-44-503"
"8646242","Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer?","Thon WF, Gadban F, Truss MC, Kuczyk M, Hartmann U, Jonas U.","World J Urol. 1996;14(1):53-8. doi: 10.1007/BF01836345.","Thon WF","World J Urol","1996","1996/01/01","","","10.1007/BF01836345"
"19268572","Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer","Ahmed HU, Moore C, Emberton M.","Surg Oncol. 2009 Sep;18(3):219-32. doi: 10.1016/j.suronc.2009.02.002. Epub 2009 Mar 5.","Ahmed HU","Surg Oncol","2009","2009/03/10","","","10.1016/j.suronc.2009.02.002"
"26793880","[The mechanisms of prostate cancer progression through androgen receptor]","Goto Y, Sakamoto S, Ichikawa T.","Nihon Rinsho. 2016 Jan;74(1):55-9.","Goto Y","Nihon Rinsho","2016","2016/01/23","","",""
"8773499","Prostate cancer. Who is best benefited by external beam radiation therapy?","Hartford AC, Zietman AL.","Hematol Oncol Clin North Am. 1996 Jun;10(3):595-610. doi: 10.1016/s0889-8588(05)70355-5.","Hartford AC","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70355-5"
"11125403","Re: Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate","Sharkey J, Chovnick S, Behar R, Otheguy J, Rabinowitz R.","J Urol. 2001 Jan;165(1):192-3. doi: 10.1097/00005392-200101000-00054.","Sharkey J","J Urol","2001","2000/01/11","","","10.1097/00005392-200101000-00054"
"7529450","Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies","Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA.","Urology. 1995 Jan;45(1):75-80. doi: 10.1016/s0090-4295(95)96858-x.","Terris MK","Urology","1995","1995/01/01","","","10.1016/s0090-4295(95)96858-x"
"28124398","Regret and fear in prostate cancer: The relationship between treatment appraisals and fear of recurrence in prostate cancer survivors","Maguire R, Hanly P, Drummond FJ, Gavin A, Sharp L.","Psychooncology. 2017 Nov;26(11):1825-1831. doi: 10.1002/pon.4384. Epub 2017 Feb 20.","Maguire R","Psychooncology","2017","2017/01/27","","","10.1002/pon.4384"
"18405744","Commentary on prostate brachytherapy for localized prostate cancer","Crook J.","J Urol. 2008 May;179(5 Suppl):S25-6. doi: 10.1016/j.juro.2008.03.004.","Crook J","J Urol","2008","2008/04/25","","","10.1016/j.juro.2008.03.004"
"17531217","Neuro-fuzzy classification of prostate cancer using NEFCLASS-J","Keles A, Hasiloglu AS, Keles A, Aksoy Y.","Comput Biol Med. 2007 Nov;37(11):1617-28. doi: 10.1016/j.compbiomed.2007.03.006. Epub 2007 May 25.","Keles A","Comput Biol Med","2007","2007/05/29","","","10.1016/j.compbiomed.2007.03.006"
"12109357","Prostate cancer and selenium","Nelson MA, Reid M, Duffield-Lillico AJ, Marshall JR.","Urol Clin North Am. 2002 Feb;29(1):67-70. doi: 10.1016/s0094-0143(02)00018-6.","Nelson MA","Urol Clin North Am","2002","2002/07/12","","","10.1016/s0094-0143(02)00018-6"
"9839511","Lest we abandon digital rectal examination as a screening test for prostate cancer","Basler JW, Thompson IM.","J Natl Cancer Inst. 1998 Dec 2;90(23):1761-3. doi: 10.1093/jnci/90.23.1761.","Basler JW","J Natl Cancer Inst","1998","1998/12/05","","","10.1093/jnci/90.23.1761"
"8871506","Prostate cancer: essays on decision making","Kissil D, Lippman AJ.","N J Med. 1996 May;93(5):57-60.","Kissil D","N J Med","1996","1996/05/01","","",""
"8628178","Prostate cancer: don't be too casual","Stricker PD.","Med J Aust. 1996 Mar 4;164(5):319-20.","Stricker PD","Med J Aust","1996","1996/03/04","","",""
"27943512","Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer","Chambers SK, Ng SK, Baade P, Aitken JF, Hyde MK, Wittert G, Frydenberg M, Dunn J.","Psychooncology. 2017 Oct;26(10):1576-1585. doi: 10.1002/pon.4342. Epub 2017 Jan 11.","Chambers SK","Psychooncology","2017","2016/12/13","PMC5655930","","10.1002/pon.4342"
"10482184","Metastasis-related genes in prostate cancer","Bangma CH, Nasu Y, Ren C, Thompson TC.","Semin Oncol. 1999 Aug;26(4):422-7.","Bangma CH","Semin Oncol","1999","1999/09/11","","",""
"9720516","Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy","Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, Walsh PC.","J Urol. 1998 Sep;160(3 Pt 1):660-3.","Bova GS","J Urol","1998","1998/08/28","","",""
"17913653","Cyclooxygenase-2 inhibitors and prostate cancer","James N.","Lancet Oncol. 2007 Oct;8(10):859-60. doi: 10.1016/S1470-2045(07)70291-7.","James N","Lancet Oncol","2007","2007/10/05","","","10.1016/S1470-2045(07)70291-7"
"10613299","The cost-benefit of 3D conformal radiation therapy compared with conventional techniques for patients with clinically localized prostate cancer","Perez CA.","Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1103-4. doi: 10.1016/s0360-3016(99)00322-3.","Perez CA","Int J Radiat Oncol Biol Phys","1999","1999/12/29","","","10.1016/s0360-3016(99)00322-3"
"26793897","[Recent advances in prostate pathology]","Tsuzuki T, Maeda N, Murase Y.","Nihon Rinsho. 2016 Jan;74(1):155-62.","Tsuzuki T","Nihon Rinsho","2016","2016/01/23","","",""
"12753724","[Recent advances on molecular pathology of prostate carcinoma]","Niu HL, Tao Y.","Ai Zheng. 2003 May;22(5):552-6.","Niu HL","Ai Zheng","2003","2003/05/20","","",""
"25121103","Stem cell based gene therapy in prostate cancer","Kim JH, Lee HJ, Song YS.","Biomed Res Int. 2014;2014:549136. doi: 10.1155/2014/549136. Epub 2014 Jul 10.","Kim JH","Biomed Res Int","2014","2014/08/15","PMC4120795","","10.1155/2014/549136"
"19046491","Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?","Singer EA, Golijanin DJ, Messing EM.","Can J Urol. 2008 Dec;15(6):4381-7.","Singer EA","Can J Urol","2008","2008/12/03","","",""
"15650255","Molecular biology and the staging of prostate cancer","Marandola P, Bonghi A, Jallous H, Bombardelli E, Morazzoni P, Gerardini M, Tiscione D, Albergati F.","Ann N Y Acad Sci. 2004 Dec;1028:294-312. doi: 10.1196/annals.1322.034.","Marandola P","Ann N Y Acad Sci","2004","2005/01/15","","","10.1196/annals.1322.034"
"30587443","Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe","Herlemann A, Washington SL 3rd, Cooperberg MR.","Eur Urol Focus. 2019 Mar;5(2):155-158. doi: 10.1016/j.euf.2018.12.003. Epub 2018 Dec 23.","Herlemann A","Eur Urol Focus","2019","2018/12/28","","","10.1016/j.euf.2018.12.003"
"11220659","Intermediate biomarkers for chemoprevention of prostate cancer","van der Kwast TH.","IARC Sci Publ. 2001;154:199-205.","van der Kwast TH","IARC Sci Publ","2001","2001/02/28","","",""
"17302190","Prevention of prostate cancer: more questions than data","Schmid HP, Engeler DS, Pummer K, Schmitz-Dräger BJ.","Recent Results Cancer Res. 2007;174:101-7. doi: 10.1007/978-3-540-37696-5_10.","Schmid HP","Recent Results Cancer Res","2007","2007/02/17","","","10.1007/978-3-540-37696-5_10"
"9144887","Screening for prostate cancer","Kirkels WJ, Rietbergen JB.","Urol Res. 1997;25 Suppl 2:S53-6. doi: 10.1007/BF00941988.","Kirkels WJ","Urol Res","1997","1997/01/01","","","10.1007/BF00941988"
"24027196","Androgen receptor signaling regulates DNA repair in prostate cancers","Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, Goglia AG, Gopalan A, Hieronymus H, Wongvipat J, Scardino PT, Zelefsky MJ, Jasin M, Chaudhuri J, Powell SN, Sawyers CL.","Cancer Discov. 2013 Nov;3(11):1245-53. doi: 10.1158/2159-8290.CD-13-0172. Epub 2013 Sep 11.","Polkinghorn WR","Cancer Discov","2013","2013/09/13","PMC3888815","NIHMS525526","10.1158/2159-8290.CD-13-0172"
"11313206","[Genetics of prostate cancer]","Thomas F, Jaïs P, Cohen-Akenine A.","Bull Cancer. 2001 Mar;88(3):287-94.","Thomas F","Bull Cancer","2001","2001/04/21","","",""
"6683897","[Cytological monitoring of the therapy of conservatively treated prostate cancer. Classification and clinical significance]","Leistenschneider W, Nagel R.","Urologe A. 1983 May;22(3):144-50.","Leistenschneider W","Urologe A","1983","1983/05/01","","",""
"26339361","Expression and mechanism of action of the SARI tumor suppressor in prostate cancer","Chen Q, Gu Y, Liu B.","Int J Clin Exp Pathol. 2015 Jul 1;8(7):7953-60. eCollection 2015.","Chen Q","Int J Clin Exp Pathol","2015","2015/09/05","PMC4555689","",""
"18006910","Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study","Murtola TJ, Tammela TL, Lahtela J, Auvinen A.","Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32. doi: 10.1158/1055-9965.EPI-07-0599.","Murtola TJ","Cancer Epidemiol Biomarkers Prev","2007","2007/11/17","","","10.1158/1055-9965.EPI-07-0599"
"2658355","Progress and problems in screening for carcinoma of the prostate","Chodak GW, Schoenberg HW.","World J Surg. 1989 Jan-Feb;13(1):60-4. doi: 10.1007/BF01671155.","Chodak GW","World J Surg","1989","1989/01/01","","","10.1007/BF01671155"
"8326560","The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients","Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD.","J Urol. 1993 Aug;150(2 Pt 1):379-85. doi: 10.1016/s0022-5347(17)35487-3.","Sakr WA","J Urol","1993","1993/08/01","","","10.1016/s0022-5347(17)35487-3"
"11295606","New concepts in the pathology of prostatic epithelial carcinogenesis","De Marzo AM, Putzi MJ, Nelson WG.","Urology. 2001 Apr;57(4 Suppl 1):103-14. doi: 10.1016/s0090-4295(00)00952-3.","De Marzo AM","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00952-3"
"15073124","Evidence for prostate cancer-associated diagnostic marker-1: immunohistochemistry and in situ hybridization studies","Ohkia A, Hu Y, Wang M, Garcia FU, Stearns ME.","Clin Cancer Res. 2004 Apr 1;10(7):2452-8. doi: 10.1158/1078-0432.ccr-03-0170.","Ohkia A","Clin Cancer Res","2004","2004/04/10","","","10.1158/1078-0432.ccr-03-0170"
"22124843","Beyond castration-defining future directions in the hormonal treatment of prostate cancer","Niraula S, Chi K, Joshua AM.","Horm Cancer. 2012 Apr;3(1-2):3-13. doi: 10.1007/s12672-011-0096-0.","Niraula S","Horm Cancer","2012","2011/11/30","","","10.1007/s12672-011-0096-0"
"1942345","The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer","Holzman M, Carlton CE Jr, Scardino PT.","J Urol. 1991 Dec;146(6):1578-82. doi: 10.1016/s0022-5347(17)38171-5.","Holzman M","J Urol","1991","1991/12/11","","","10.1016/s0022-5347(17)38171-5"
"9749485","Comparing treatments for localized prostate cancer--persisting uncertainty","Chodak GW.","JAMA. 1998 Sep 16;280(11):1008-10. doi: 10.1001/jama.280.11.1008.","Chodak GW","JAMA","1998","1998/09/28","","","10.1001/jama.280.11.1008"
"22453335","Active surveillance: the Canadian experience","Klotz L.","Curr Opin Urol. 2012 May;22(3):222-30. doi: 10.1097/MOU.0b013e328352598c.","Klotz L","Curr Opin Urol","2012","2012/03/29","","","10.1097/MOU.0b013e328352598c"
"15066233","Artificial neural networks for predictive modeling in prostate cancer","Gamito EJ, Crawford ED.","Curr Oncol Rep. 2004 May;6(3):216-21. doi: 10.1007/s11912-004-0052-z.","Gamito EJ","Curr Oncol Rep","2004","2004/04/07","","","10.1007/s11912-004-0052-z"
"11545461","A review of physical activity and prostate cancer risk","Friedenreich CM, Thune I.","Cancer Causes Control. 2001 Jun;12(5):461-75. doi: 10.1023/a:1011210121901.","Friedenreich CM","Cancer Causes Control","2001","2001/09/08","","","10.1023/a:1011210121901"
"20044631","Pathology of prostate cancer and focal therapy ('male lumpectomy')","Mazzucchelli R, Scarpelli M, Cheng L, Lopez-Beltran A, Galosi AB, Kirkali Z, Montironi R.","Anticancer Res. 2009 Dec;29(12):5155-61.","Mazzucchelli R","Anticancer Res","2009","2010/01/02","","",""
"15247353","Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","D'Amico AV, Chen MH, Roehl KA, Catalona WJ.","N Engl J Med. 2004 Jul 8;351(2):125-35. doi: 10.1056/NEJMoa032975.","D'Amico AV","N Engl J Med","2004","2004/07/13","","","10.1056/NEJMoa032975"
"7614403","The value of neoadjuvant therapy in localized prostate cancer","Witjes WP, Oosterhof GO, Schaafsma HE, Debruyne FM.","Int J Urol. 1995 Mar;2(1):1-5. doi: 10.1111/j.1442-2042.1995.tb00611.x.","Witjes WP","Int J Urol","1995","1995/03/01","","","10.1111/j.1442-2042.1995.tb00611.x"
"1434533","Prostate cancer: therapeutic, diagnostic, and basic studies","Stearns ME, McGarvey T.","Lab Invest. 1992 Nov;67(5):540-52.","Stearns ME","Lab Invest","1992","1992/11/01","","",""
"24568512","Survival of patients with prostate cancer in Yazd, Iran","Zahir ST, Nazemian MR, Zand S, Zare S.","Asian Pac J Cancer Prev. 2014;15(2):883-6. doi: 10.7314/apjcp.2014.15.2.883.","Zahir ST","Asian Pac J Cancer Prev","2014","2014/02/27","","","10.7314/apjcp.2014.15.2.883"
"29562686","Profiling Prostate Cancer Therapeutic Resistance","Wade CA, Kyprianou N.","Int J Mol Sci. 2018 Mar 19;19(3):904. doi: 10.3390/ijms19030904.","Wade CA","Int J Mol Sci","2018","2018/03/23","PMC5877765","","10.3390/ijms19030904"
"15046712","Molecular markers in prostate cancer: the role in preoperative staging","Moul JW, Merseburger AS, Srivastava S.","Clin Prostate Cancer. 2002 Jun;1(1):42-50. doi: 10.3816/cgc.2002.n.006.","Moul JW","Clin Prostate Cancer","2002","2004/03/30","","","10.3816/cgc.2002.n.006"
"18382242","Inflammation, infection, and prostate cancer","Klein EA, Silverman R.","Curr Opin Urol. 2008 May;18(3):315-9. doi: 10.1097/MOU.0b013e3282f9b3b7.","Klein EA","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282f9b3b7"
"22212074","Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis","Berney D, Cheng L.","Histopathology. 2012 Jan;60(1):1-3. doi: 10.1111/j.1365-2559.2011.04080.x.","Berney D","Histopathology","2012","2012/01/04","","","10.1111/j.1365-2559.2011.04080.x"
"22018409","Couples surviving prostate cancer: challenges in their lives and relationships","Galbraith ME, Fink R, Wilkins GG.","Semin Oncol Nurs. 2011 Nov;27(4):300-8. doi: 10.1016/j.soncn.2011.07.008.","Galbraith ME","Semin Oncol Nurs","2011","2011/10/25","","","10.1016/j.soncn.2011.07.008"
"22208017","[Treatment option for locally and/or biochemically radiorecurrent prostate cancer]","Okihara K.","Nihon Rinsho. 2011 Jun;69 Suppl 5:431-4.","Okihara K","Nihon Rinsho","2011","2012/01/03","","",""
"7543154","Localized prostate cancer. Diagnosis and treatment","Bulbul MA.","J Med Liban. 1993;41(4):218-22.","Bulbul MA","J Med Liban","1993","1993/01/01","","",""
"19836060","Prognostic relevance of cyclooxygenase-2 (COX-2) expression in Chinese patients with prostate cancer","Bin W, He W, Feng Z, Xiangdong L, Yong C, Lele K, Hongbin Z, Honglin G.","Acta Histochem. 2011 Feb;113(2):131-6. doi: 10.1016/j.acthis.2009.09.004.","Bin W","Acta Histochem","2011","2009/10/20","","","10.1016/j.acthis.2009.09.004"
"26489139","Modelling and structural characteristics analysis of gene networks for prostate cancer","Zhang Y, Wang S, Meng D.","Int J Data Min Bioinform. 2015;12(1):14-23. doi: 10.1504/ijdmb.2015.068950.","Zhang Y","Int J Data Min Bioinform","2015","2015/10/23","","","10.1504/ijdmb.2015.068950"
"14634448","Molecular pathways to prostate cancer","Gonzalgo ML, Isaacs WB.","J Urol. 2003 Dec;170(6 Pt 1):2444-52. doi: 10.1097/01.ju.0000085381.20139.b6.","Gonzalgo ML","J Urol","2003","2003/11/25","","","10.1097/01.ju.0000085381.20139.b6"
"11675915","[The role of radical prostatectomy in cT3 prostate carcinoma]","Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L.","Praxis (Bern 1994). 2001 Sep 20;90(38):1623-31.","Van Poppel H","Praxis (Bern 1994)","2001","2001/10/26","","",""
"2419598","Incidental carcinoma of the prostate: histopathology and natural history","Nemoto R, Harada M, Uchida K, Koiso K, Abe R, Kato T.","Jpn J Clin Oncol. 1985 Dec;15(4):619-23.","Nemoto R","Jpn J Clin Oncol","1985","1985/12/01","","",""
"6256993","[Course of prostate cancer]","Heinrichs HJ, Hasselbacher K.","Z Urol Nephrol. 1980 Oct;73(10):737-9.","Heinrichs HJ","Z Urol Nephrol","1980","1980/10/01","","",""
"12870141","An evidence-based approach to prostate cancer follow-up","Yao SL, Dipaola RS.","Semin Oncol. 2003 Jun;30(3):390-400. doi: 10.1016/s0093-7754(03)00099-x.","Yao SL","Semin Oncol","2003","2003/07/19","","","10.1016/s0093-7754(03)00099-x"
"31983186","The Effect of Prostate Cancer Educational Program on the level of Knowledge and Intention to Screen among Jordanian Men in Amman","Saleh AM, Ebrahim EE, Aldossary EH, Almutairi MAM.","Asian Pac J Cancer Prev. 2020 Jan 1;21(1):211-215. doi: 10.31557/APJCP.2020.21.1.211.","Saleh AM","Asian Pac J Cancer Prev","2020","2020/01/28","PMC7294022","","10.31557/APJCP.2020.21.1.211"
"22100582","Targeting advanced prostate cancer","Fillon M.","J Natl Cancer Inst. 2011 Dec 7;103(23):1733. doi: 10.1093/jnci/djr506. Epub 2011 Nov 18.","Fillon M","J Natl Cancer Inst","2011","2011/11/22","","","10.1093/jnci/djr506"
"11683314","Cues to participation in prostate cancer screening: a theory for practice","Nivens AS, Herman J, Pweinrich S, Weinrich MC.","Oncol Nurs Forum. 2001 Oct;28(9):1449-56.","Nivens AS","Oncol Nurs Forum","2001","2001/10/31","","",""
"14503938","Alterations of p53 are common in early stage prostate cancer","Downing SR, Russell PJ, Jackson P.","Can J Urol. 2003 Aug;10(4):1924-33.","Downing SR","Can J Urol","2003","2003/09/25","","",""
"25692724","Patient and disease factors affecting the choice and adherence to active surveillance","Dall'Era MA.","Curr Opin Urol. 2015 May;25(3):272-6. doi: 10.1097/MOU.0000000000000154.","Dall'Era MA","Curr Opin Urol","2015","2015/02/19","","","10.1097/MOU.0000000000000154"
"24960604","Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?","Oudard S, Angelergues A.","Nat Rev Urol. 2014 Jul;11(7):370-2. doi: 10.1038/nrurol.2014.144. Epub 2014 Jun 24.","Oudard S","Nat Rev Urol","2014","2014/06/25","","","10.1038/nrurol.2014.144"
"17115417","IL-2 gene C/T polymorphism is associated with prostate cancer","Wu HC, Chang CH, Wan L, Wu CI, Tsai FJ, Chen WC.","J Clin Lab Anal. 2006;20(6):245-9. doi: 10.1002/jcla.20149.","Wu HC","J Clin Lab Anal","2006","2006/11/23","PMC6807315","","10.1002/jcla.20149"
"12084341","Recent advances in chemotherapy for advanced prostate cancer","Olson KB, Pienta KJ.","Curr Urol Rep. 2000 May;1(1):48-56. doi: 10.1007/s11934-000-0035-z.","Olson KB","Curr Urol Rep","2000","2002/06/27","","","10.1007/s11934-000-0035-z"
"29196529","No Association of Waist Circumference and Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort","Stevens VL, Jacobs EJ, Maliniak ML, Patel AV, Gapstur SM.","Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1812-1814. doi: 10.1158/1055-9965.EPI-17-0802.","Stevens VL","Cancer Epidemiol Biomarkers Prev","2017","2017/12/03","","","10.1158/1055-9965.EPI-17-0802"
"31433509","Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?","Wu T, Zhao J, Liu Z, Shen P, Zhang M, Sun G, Liu J, Liao B, Chen J, Zhu S, Dai J, Wang Z, Zhang H, Zhao P, Zhang X, Zhu X, Ni Y, Chen N, Zeng H.","Prostate. 2019 Oct;79(14):1673-1682. doi: 10.1002/pros.23892. Epub 2019 Aug 21.","Wu T","Prostate","2019","2019/08/22","","","10.1002/pros.23892"
"27919668","Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10","Kim EH, Weaver JK, Shetty AS, Vetter JM, Andriole GL, Strope SA.","Urology. 2017 Apr;102:183-189. doi: 10.1016/j.urology.2016.08.074. Epub 2016 Dec 2.","Kim EH","Urology","2017","2016/12/07","","","10.1016/j.urology.2016.08.074"
"27749016","Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry","Jia X, Chen J, Sun S, Yang W, Yang S, Shah P, Hoti N, Veltri B, Zhang H.","Proteomics. 2016 Dec;16(23):2989-2996. doi: 10.1002/pmic.201500506.","Jia X","Proteomics","2016","2016/10/18","PMC5407186","NIHMS855876","10.1002/pmic.201500506"
"16911853","Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction","Schröder FH, Habbema DF, Roobol MJ, Bangma CH.","Eur Urol. 2007 Mar;51(3):588-90. doi: 10.1016/j.eururo.2006.07.013. Epub 2006 Jul 28.","Schröder FH","Eur Urol","2007","2006/08/17","","","10.1016/j.eururo.2006.07.013"
"3660521","Importance of acid phosphatase in response criteria for prostate cancer","Sieber PR, Rohner TJ Jr.","Urology. 1987 Oct;30(4):316-7. doi: 10.1016/0090-4295(87)90291-3.","Sieber PR","Urology","1987","1987/10/01","","","10.1016/0090-4295(87)90291-3"
"14501770","Androgen receptors in prostate cancer","Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A.","J Urol. 2003 Oct;170(4 Pt 1):1363-9. doi: 10.1097/01.ju.0000075099.20662.7f.","Culig Z","J Urol","2003","2003/09/23","","","10.1097/01.ju.0000075099.20662.7f"
"29107275","Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-Based Approach","Vollstedt A, Hyams E.","Urol Clin North Am. 2017 Nov;44(4):587-595. doi: 10.1016/j.ucl.2017.07.007.","Vollstedt A","Urol Clin North Am","2017","2017/11/07","","","10.1016/j.ucl.2017.07.007"
"15566312","Agents in development for prostate cancer prevention","Nelson WG.","Expert Opin Investig Drugs. 2004 Dec;13(12):1541-54. doi: 10.1517/13543784.13.12.1541.","Nelson WG","Expert Opin Investig Drugs","2004","2004/11/30","","","10.1517/13543784.13.12.1541"
"25709045","Family history of prostate cancer in men being followed by active surveillance does not increase risk of being diagnosed with high-grade disease","Selkirk CG, Wang CH, Lapin B, Helfand BT.","Urology. 2015 Apr;85(4):742-7. doi: 10.1016/j.urology.2014.10.060. Epub 2015 Feb 21.","Selkirk CG","Urology","2015","2015/02/25","","","10.1016/j.urology.2014.10.060"
"17470867","Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality","Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.","J Clin Oncol. 2007 May 1;25(13):1765-71. doi: 10.1200/JCO.2006.08.0572.","Freedland SJ","J Clin Oncol","2007","2007/05/02","","","10.1200/JCO.2006.08.0572"
"17763836","Diet and lifestyle interventions in active surveillance patients with favorable-risk prostate cancer","Kenfield SA, Chang ST, Chan JM.","Curr Treat Options Oncol. 2007 Jun;8(3):173-96. doi: 10.1007/s11864-007-0034-0.","Kenfield SA","Curr Treat Options Oncol","2007","2007/09/04","","","10.1007/s11864-007-0034-0"
"8046800","Use of transrectal ultrasound to stage prostate cancer","Kaplan EJ, Hanks GE.","JAMA. 1994 Aug 17;272(7):516-7. doi: 10.1001/jama.1994.03520070034024.","Kaplan EJ","JAMA","1994","1994/08/17","","","10.1001/jama.1994.03520070034024"
"4059571","Re: CT staging of prostate cancer","Styles RA, Seltzer SE.","Radiology. 1985 Dec;157(3):838. doi: 10.1148/radiology.157.3.838-b.","Styles RA","Radiology","1985","1985/12/01","","","10.1148/radiology.157.3.838-b"
"3407629","Transperineal 125iodine endocurietherapy of prostate cancer","Kumar PP, Good RR, Bartone FF, Jones EO, Lynch G.","Am J Clin Oncol. 1988 Aug;11(4):479-89. doi: 10.1097/00000421-198808000-00014.","Kumar PP","Am J Clin Oncol","1988","1988/08/01","","","10.1097/00000421-198808000-00014"
"30919390","[Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)]","Miller K.","Aktuelle Urol. 2019 Dec;50(6):625-628. doi: 10.1055/a-0852-3405. Epub 2019 Mar 27.","Miller K","Aktuelle Urol","2019","2019/03/29","","","10.1055/a-0852-3405"
"18642765","[Quality of life among patients with advanced prostate cancer: a survey using functional assessment of cancer therapy-prostate in China]","Zhang K, Gong K, Zhou LQ, Na YQ.","Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):665-8.","Zhang K","Zhonghua Yi Xue Za Zhi","2008","2008/07/23","","",""
"27416634","High intensity focused ultrasound for Focal Therapy of prostate cancer","Sivaraman A.","Arch Esp Urol. 2016 Jul;69(6):311-6.","Sivaraman A","Arch Esp Urol","2016","2016/07/15","","",""
"9302187","Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group","Walsh PC.","J Urol. 1997 Oct;158(4):1623-4.","Walsh PC","J Urol","1997","1997/09/25","","",""
"23733662","Reply to association between exercise and primary incidence of prostate cancer: does race matter?","Bañez LL, Singh AA.","Cancer. 2013 Sep 1;119(17):3251-2. doi: 10.1002/cncr.28178. Epub 2013 Jun 3.","Bañez LL","Cancer","2013","2013/06/05","","","10.1002/cncr.28178"
"30990896","Some black men may have more aggressive prostate cancer than scoring indicates","Printz C.","Cancer. 2019 May 1;125(9):1398-1399. doi: 10.1002/cncr.32133.","Printz C","Cancer","2019","2019/04/17","","","10.1002/cncr.32133"
"24931061","Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study","Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, Vidal AC.","BJU Int. 2015 May;115(5):736-43. doi: 10.1111/bju.12843. Epub 2014 Oct 20.","Sourbeer KN","BJU Int","2015","2014/06/17","PMC4564864","NIHMS719821","10.1111/bju.12843"
"22207973","[Mass screening program for prostate cancer in urban area of Kyoto]","Kitamura K.","Nihon Rinsho. 2011 Jun;69 Suppl 5:212-6.","Kitamura K","Nihon Rinsho","2011","2012/01/03","","",""
"8008271","Caring for patients with prostate cancer","Cali-Ascani MA.","Nursing. 1994 Jun;24(6):32C-32D.","Cali-Ascani MA","Nursing","1994","1994/06/01","","",""
"11838718","Information needs and information-seeking behaviors of men with prostate cancer and their partners: a review of the literature","Echlin KN, Rees CE.","Cancer Nurs. 2002 Feb;25(1):35-41. doi: 10.1097/00002820-200202000-00008.","Echlin KN","Cancer Nurs","2002","2002/02/13","","","10.1097/00002820-200202000-00008"
"24637994","Observation for clinically localized prostate cancer","Nelson JB.","J Clin Oncol. 2014 May 1;32(13):1295-8. doi: 10.1200/JCO.2013.54.2043. Epub 2014 Mar 17.","Nelson JB","J Clin Oncol","2014","2014/03/19","","","10.1200/JCO.2013.54.2043"
"3309992","The management of stage C prostate cancer","deKernion JB, Mukamel E.","Prog Clin Biol Res. 1987;243B:403-9.","deKernion JB","Prog Clin Biol Res","1987","1987/01/01","","",""
"8343887","Endocrine therapy for prostate cancer: recent developments and current status","Schröder FH.","Br J Urol. 1993 Jun;71(6):633-40. doi: 10.1111/j.1464-410x.1993.tb16056.x.","Schröder FH","Br J Urol","1993","1993/06/01","","","10.1111/j.1464-410x.1993.tb16056.x"
"19246151","CyberKnife in the treatment of prostate cancer: a revolutionary system","Morgia G, De Renzis C.","Eur Urol. 2009 Jul;56(1):40-2. doi: 10.1016/j.eururo.2009.02.020. Epub 2009 Feb 23.","Morgia G","Eur Urol","2009","2009/02/28","","","10.1016/j.eururo.2009.02.020"
"24335867","African and Afro-Caribbean men's experiences of prostate cancer","Anderson B, Marshall-Lucette S.","Br J Nurs. 2013 Dec 12-2014 Jan 8;22(22):1296-8, 1300-2, 1304-7. doi: 10.12968/bjon.2013.22.22.1296.","Anderson B","Br J Nurs","2013","2013/12/17","","","10.12968/bjon.2013.22.22.1296"
"18084140","[Importance of repeat laterally directed sextant prostate biopsy for detection of prostate cancer in high-risk patients]","Vaiciūnas K, Auskalnis S, Matjosaitis A, Mickevicius A, Mickevicius R, Trumbeckas D, Jievaltas M.","Medicina (Kaunas). 2007;43(11):843-9.","Vaiciūnas K","Medicina (Kaunas)","2007","2007/12/18","","",""
"4012943","[Classification, histologic and cytologic grading and regression grading of prostate cancer]","Helpap B, Böcking A, Dhom G, Faul P, Kastendieck H, Leistenschneider W, Müller HA.","Urologe A. 1985 May;24(3):156-9.","Helpap B","Urologe A","1985","1985/05/01","","",""
"19344379","A systematic review of the effect of diet in prostate cancer prevention and treatment","Ma RW, Chapman K.","J Hum Nutr Diet. 2009 Jun;22(3):187-99; quiz 200-2. doi: 10.1111/j.1365-277X.2009.00946.x. Epub 2009 Apr 1.","Ma RW","J Hum Nutr Diet","2009","2009/04/07","","","10.1111/j.1365-277X.2009.00946.x"
"13678383","Angiogenesis of prostate cancer and antiangiogenic therapy","Uehara H.","J Med Invest. 2003 Aug;50(3-4):146-53.","Uehara H","J Med Invest","2003","2003/09/19","","",""
"17109445","Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis","Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH.","Cancer. 2006 Dec 15;107(12):2779-85. doi: 10.1002/cncr.22374.","Roemeling S","Cancer","2006","2006/11/17","","","10.1002/cncr.22374"
"6189576","Diagnosis and management of prostate cancer","Jones GW.","Cancer. 1983 Jun 15;51(12 Suppl):2456-9. doi: 10.1002/1097-0142(19830615)51:12+<2456::aid-cncr2820511313>3.0.co;2-k.","Jones GW","Cancer","1983","1983/06/15","","","10.1002/1097-0142(19830615)51:12+<2456::aid-cncr2820511313>3.0.co;2-k"
"23973458","[Choice of optimal margins in prostate conformal radiotherapy]","Khalifa J, Commandeur F, Bachaud JM, de Crevoisier R.","Cancer Radiother. 2013 Oct;17(5-6):461-9. doi: 10.1016/j.canrad.2013.06.031. Epub 2013 Aug 20.","Khalifa J","Cancer Radiother","2013","2013/08/27","","","10.1016/j.canrad.2013.06.031"
"28012728","Magnetic resonance imaging in the new paradigm for the diagnosis of prostate cancer","Vilanova JC, Catalá V.","Radiologia. 2017 Mar-Apr;59(2):94-99. doi: 10.1016/j.rx.2016.10.009. Epub 2016 Dec 21.","Vilanova JC","Radiologia","2017","2016/12/26","","","10.1016/j.rx.2016.10.009"
"12696188","[Two cases of prostate cancer associated with acute myeloid leukemia presenting as thrombocytopenia during endocrine therapy]","Matsuura H, Sakurai M, Arima K.","Hinyokika Kiyo. 2003 Feb;49(2):87-90.","Matsuura H","Hinyokika Kiyo","2003","2003/04/17","","",""
"7691051","Effectiveness of screening for prostate cancer","Sladden M, Dickinson J.","Aust Fam Physician. 1993 Aug;22(8):1385-6, 1390-2.","Sladden M","Aust Fam Physician","1993","1993/08/01","","",""
"21688178","Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?","Dunning NL, Laversin SA, Miles AK, Rees RC.","Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19.","Dunning NL","Cancer Immunol Immunother","2011","2011/06/21","","","10.1007/s00262-011-1065-8"
"12484163","Prostate cancer: rates in Europe, dietary hypotheses, and plans for EPIC","Key TJ; EPIC Working Group on Prostate Cancer.","IARC Sci Publ. 2002;156:197-200.","Key TJ","IARC Sci Publ","2002","2002/12/18","","",""
"16554883","[Curative treatment of prostatic cancer in Norway in 1998 and 2001]","Kvåle R, Skarre E, Tønne A, Kyrdalen AE, Norstein J, Angelsen A, Wahlqvist R, Fosså SD.","Tidsskr Nor Laegeforen. 2006 Mar 23;126(7):912-6.","Kvåle R","Tidsskr Nor Laegeforen","2006","2006/03/24","","",""
"26341082","Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis","Bender RJ, Mac Gabhann F.","BMC Syst Biol. 2015 Sep 4;9:55. doi: 10.1186/s12918-015-0201-z.","Bender RJ","BMC Syst Biol","2015","2015/09/06","PMC4559909","","10.1186/s12918-015-0201-z"
"12085968","Angiogenesis in prostate cancer: biology and therapeutic opportunities","Nicholson B, Schaefer G, Theodorescu D.","Cancer Metastasis Rev. 2001;20(3-4):297-319. doi: 10.1023/a:1015543713485.","Nicholson B","Cancer Metastasis Rev","2001","2002/06/28","","","10.1023/a:1015543713485"
"28784100","A case report of prostate cancer metastasis to the stomach resembling undifferentiated-type early gastric cancer","Inagaki C, Suzuki T, Kitagawa Y, Hara T, Yamaguchi T.","BMC Gastroenterol. 2017 Aug 7;17(1):93. doi: 10.1186/s12876-017-0655-0.","Inagaki C","BMC Gastroenterol","2017","2017/08/09","PMC5547505","","10.1186/s12876-017-0655-0"
"1555838","Histologic grading of prostate cancer: a perspective","Gleason DF.","Hum Pathol. 1992 Mar;23(3):273-9. doi: 10.1016/0046-8177(92)90108-f.","Gleason DF","Hum Pathol","1992","1992/03/01","","","10.1016/0046-8177(92)90108-f"
"8544268","The definition and preoperative prediction of clinically insignificant prostate cancer","Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE.","JAMA. 1996 Jan 24-31;275(4):288-94.","Dugan JA","JAMA","1996","1996/01/24","","",""
"22036643","The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature","Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND.","Eur Urol. 2012 Apr;61(4):639-47. doi: 10.1016/j.eururo.2011.10.027. Epub 2011 Oct 24.","Sonpavde G","Eur Urol","2012","2011/11/01","","","10.1016/j.eururo.2011.10.027"
"29227252","[MORTALITY AND MORBIDITY FROM PROSTATE CANCER IN THE REPUBLIC OF KAZAKHSTAN FROM 2007 TO 2016]","Ospanov Е, Adylkhanov Т, Tokanova S, Semenova Y, Dauletyarova М, Bolsynbekova S, Zhumykbaeva N.","Georgian Med News. 2017 Nov;(272):17-22.","Ospanov Е","Georgian Med News","2017","2017/12/12","","",""
"24442790","In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation","Neal RE 2nd, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A, Smith R, Davalos RV, Thomson KR.","Prostate. 2014 May;74(5):458-68. doi: 10.1002/pros.22760. Epub 2014 Jan 17.","Neal RE 2nd","Prostate","2014","2014/01/21","","","10.1002/pros.22760"
"24261361","The expanding role of MRI in prostate cancer","Murphy G, Haider M, Ghai S, Sreeharsha B.","AJR Am J Roentgenol. 2013 Dec;201(6):1229-38. doi: 10.2214/AJR.12.10178.","Murphy G","AJR Am J Roentgenol","2013","2013/11/23","","","10.2214/AJR.12.10178"
"23108139","A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease","Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA.","Cancer Res. 2013 Jan 1;73(1):86-96. doi: 10.1158/0008-5472.CAN-12-1260. Epub 2012 Oct 29.","Laderach DJ","Cancer Res","2013","2012/10/31","","","10.1158/0008-5472.CAN-12-1260"
"2284296","Parameters of response and progression in prostate cancer","Newling DW.","Prog Clin Biol Res. 1990;359:25-48; discussion 73-4.","Newling DW","Prog Clin Biol Res","1990","1990/01/01","","",""
"7714069","Is there a best endocrine treatment of prostate cancer?","Schröder FH.","J Clin Endocrinol Metab. 1995 Apr;80(4):1071-4. doi: 10.1210/jcem.80.4.7714069.","Schröder FH","J Clin Endocrinol Metab","1995","1995/04/01","","","10.1210/jcem.80.4.7714069"
"30864701","Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells","Yang C, Zhang W, Wang J, Chen P, Jin J.","Mol Med Rep. 2019 May;19(5):3864-3870. doi: 10.3892/mmr.2019.9998. Epub 2019 Mar 1.","Yang C","Mol Med Rep","2019","2019/03/14","","","10.3892/mmr.2019.9998"
"17431371","Mediterranean diet, monounsaturated: saturated fat ratio and low prostate cancer risk. A myth or a reality?","Stamatiou K, Delakas D, Sofras F.","Minerva Urol Nefrol. 2007 Mar;59(1):59-66.","Stamatiou K","Minerva Urol Nefrol","2007","2007/04/14","","",""
"27344718","[Patterns of metastasis and recurrence of prostate cancer]","Kitamura H.","Nihon Rinsho. 2016 May 20;74 Suppl 3:140-4.","Kitamura H","Nihon Rinsho","2016","2016/06/28","","",""
"16978293","The economics of drug development in prostate cancer","","BJU Int. 2006 Oct;98(4):913-4. doi: 10.1111/j.1464-410X.2006.06472.x.","","BJU Int","2006","2006/09/19","","","10.1111/j.1464-410X.2006.06472.x"
"26744870","Should prostate cancer be considered as a differential diagnosis in patients with osteolytic bone lesions?","Bakhsh MU, Lee S, Ahmad S, Takher J, Pareek A, Syed U, Seashore J, Szemraj E.","Eur Rev Med Pharmacol Sci. 2015 Dec;19(24):4791-4.","Bakhsh MU","Eur Rev Med Pharmacol Sci","2015","2016/01/09","","",""
"8996577","Highlights of abstracts on hormone-refractory prostate cancer presented at the 1996 annual meeting of the American Society of Clinical Oncology","Roth BJ.","Semin Oncol. 1996 Dec;23(6 Suppl 14):6-7.","Roth BJ","Semin Oncol","1996","1996/12/01","","",""
"17296351","The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia","Dobosy JR, Roberts JL, Fu VX, Jarrard DF.","J Urol. 2007 Mar;177(3):822-31. doi: 10.1016/j.juro.2006.10.063.","Dobosy JR","J Urol","2007","2007/02/14","","","10.1016/j.juro.2006.10.063"
"25034349","Capture rate and representativity of The National Prostate Cancer Register of Sweden","Tomic K, Berglund A, Robinson D, Hjälm-Eriksson M, Carlsson S, Lambe M, Stattin P.","Acta Oncol. 2015 Feb;54(2):158-63. doi: 10.3109/0284186X.2014.939299. Epub 2014 Jul 18.","Tomic K","Acta Oncol","2015","2014/07/19","","","10.3109/0284186X.2014.939299"
"15995623","Combined use of antisense oligonucleotides and chemotherapeutics in the treatment of refractory prostate cancer","Baltogiannis D, Charalabopoulos K, Giannakopoulos X, Karakosta A, Sofikitis N.","Exp Oncol. 2005 Jun;27(2):91-3.","Baltogiannis D","Exp Oncol","2005","2005/07/05","","",""
"18506331","Management of advanced prostate cancer","Kaliks RA, Del Giglio A.","Rev Assoc Med Bras (1992). 2008 Mar-Apr;54(2):178-82. doi: 10.1590/s0104-42302008000200025.","Kaliks RA","Rev Assoc Med Bras (1992)","2008","2008/05/29","","","10.1590/s0104-42302008000200025"
"25605246","NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect","Etani T, Suzuki T, Naiki T, Naiki-Ito A, Ando R, Iida K, Kawai N, Tozawa K, Miyata N, Kohri K, Takahashi S.","Oncotarget. 2015 Feb 20;6(5):2865-78. doi: 10.18632/oncotarget.3067.","Etani T","Oncotarget","2015","2015/01/22","PMC4413623","","10.18632/oncotarget.3067"
"9307342","Predicting pathological stage of localized prostate cancer","Naitoh J, Dorey F, deKernion JB.","JAMA. 1997 Sep 24;278(12):980-1; author reply 981-2.","Naitoh J","JAMA","1997","1997/11/05","","",""
"8116106","Watchful waiting for early stage prostate cancer","Johansson JE.","Urology. 1994 Feb;43(2):138-42. doi: 10.1016/0090-4295(94)90032-9.","Johansson JE","Urology","1994","1994/02/01","","","10.1016/0090-4295(94)90032-9"
"29710684","The utility and limitations of contrast-enhanced transrectal ultrasound scanning for the detection of prostate cancer in different area of prostate","Xie SW, Dong BJ, Xia JG, Li HL, Zhang SJ, Du J, Yang WQ, Li FH, Xue W.","Clin Hemorheol Microcirc. 2018;70(3):281-290. doi: 10.3233/CH-170346.","Xie SW","Clin Hemorheol Microcirc","2018","2018/05/02","","","10.3233/CH-170346"
"11037588","[Treatment of advanced prostatic cancer]","Hedlund PO.","Lakartidningen. 2000 Aug 9;97(32-33):3466-9.","Hedlund PO","Lakartidningen","2000","2000/10/19","","",""
"10736812","Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA)","","Oncology (Williston Park). 2000 Feb;14(2):267-72, 277-8, 280 passim.","","Oncology (Williston Park)","2000","2000/03/29","","",""
"25775366","Focal therapy of prostate cancer: making steady progress toward a first-line image-guided treatment modality","Polascik TJ.","Curr Opin Urol. 2015 May;25(3):183-4. doi: 10.1097/MOU.0000000000000171.","Polascik TJ","Curr Opin Urol","2015","2015/03/17","","","10.1097/MOU.0000000000000171"
"16758251","Radical versus postoperative radiotherapy for localized prostate cancer: a 10-year experience of an academic hospital","Pakos EE, Tsekeris PG, Pitouli EJ, Gritzeli SP, Briasoulis E.","World J Urol. 2006 Jun;24(2):214-9. doi: 10.1007/s00345-006-0074-2. Epub 2006 May 10.","Pakos EE","World J Urol","2006","2006/06/08","","","10.1007/s00345-006-0074-2"
"16294431","Sunlight = prostate cancer protection","","Health News. 2005 Nov;11(11):10.","","Health News","2005","2005/11/22","","",""
"8940319","Prostatectomy and survival among men with clinically localized prostate cancer","Lawrence G.","JAMA. 1996 Dec 4;276(21):1724; author reply 1724. doi: 10.1001/jama.276.21.1724.","Lawrence G","JAMA","1996","1996/12/04","","","10.1001/jama.276.21.1724"
"22472510","Cancer overdiagnosis and overtreatment","Klotz L.","Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa.","Klotz L","Curr Opin Urol","2012","2012/04/05","","","10.1097/MOU.0b013e32835259aa"
"25715887","Guideline of Guidelines: Imaging of Localized Prostate Cancer","Wollin DA, Makarov DV.","BJU Int. 2015 Oct;116(4):526-30. doi: 10.1111/bju.13104. Epub 2015 Jun 6.","Wollin DA","BJU Int","2015","2015/02/27","PMC4768736","NIHMS747677","10.1111/bju.13104"
"23828638","High-resolution NMR spectroscopy of human body fluids and tissues in relation to prostate cancer","Kumar V, Dwivedi DK, Jagannathan NR.","NMR Biomed. 2014 Jan;27(1):80-9. doi: 10.1002/nbm.2979. Epub 2013 Jul 4.","Kumar V","NMR Biomed","2014","2013/07/06","","","10.1002/nbm.2979"
"3976112","Gleason grading of prostate cancer: a predictor of survival","Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF Jr.","Urology. 1985 Mar;25(3):223-7. doi: 10.1016/0090-4295(85)90316-4.","Sogani PC","Urology","1985","1985/03/01","","","10.1016/0090-4295(85)90316-4"
"22068007","The use of MRI scanning to triage patients","Kpandemoi Abu V.","Br J Nurs. 2011 Nov 10-23;20(20):1310-4. doi: 10.12968/bjon.2011.20.20.1310.","Kpandemoi Abu V","Br J Nurs","2011","2011/11/10","","","10.12968/bjon.2011.20.20.1310"
"12667423","The role of bisphosphonates in the management of metastatic prostate cancer","Michaelson MD, Smith MR.","Curr Oncol Rep. 2003 May;5(3):245-9. doi: 10.1007/s11912-003-0117-4.","Michaelson MD","Curr Oncol Rep","2003","2003/04/02","","","10.1007/s11912-003-0117-4"
"23286766","[Radical prostatectomy in patients with advanced prostate cancer]","Røder MA, Iversen P.","Ugeskr Laeger. 2012 Dec 10;174(50):3160-1.","Røder MA","Ugeskr Laeger","2012","2013/01/05","","",""
"23704236","New developments in the management of prostate cancer","Kantoff PW, Mohler JL.","J Natl Compr Canc Netw. 2013 May;11(5 Suppl):653-7. doi: 10.6004/jnccn.2013.0194.","Kantoff PW","J Natl Compr Canc Netw","2013","2013/05/25","","","10.6004/jnccn.2013.0194"
"11037558","Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria","Roach M 3rd, Blasko JC, Perez CA, Beyer DC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Potters L, Scardino P, Schellhammer P, Leibel S.","Radiology. 2000 Jun;215 Suppl:1441-8.","Roach M 3rd","Radiology","2000","2000/10/19","","",""
"10185808","Claims based on exposure to ionizing radiation (prostate cancer and any other cancer)--VA. Final rule","","Fed Regist. 1998 Sep 24;63(185):50993-5.","","Fed Regist","1998","1998/08/28","","",""
"18047962","Low risk prostate cancer in men under age 65: the case for definitive treatment","Jang TL, Yossepowitch O, Bianco FJ Jr, Scardino PT.","Urol Oncol. 2007 Nov-Dec;25(6):510-4. doi: 10.1016/j.urolonc.2007.05.025.","Jang TL","Urol Oncol","2007","2007/12/01","PMC2748722","NIHMS87315","10.1016/j.urolonc.2007.05.025"
"12116838","[Prostate cancer: has local radiation treatment had an impact on survival?]","Chauvet B, Alfonsi M, de Rauglaudre G, Reboul F.","Cancer Radiother. 2002 May;6(3):141-6. doi: 10.1016/s1278-3218(02)00164-6.","Chauvet B","Cancer Radiother","2002","2002/07/16","","","10.1016/s1278-3218(02)00164-6"
"15477873","Proteome analysis of prostate cancer","Kuruma H, Egawa S, Oh-Ishi M, Kodera Y, Maeda T.","Prostate Cancer Prostatic Dis. 2005;8(1):14-21. doi: 10.1038/sj.pcan.4500764.","Kuruma H","Prostate Cancer Prostatic Dis","2005","2004/10/13","","","10.1038/sj.pcan.4500764"
"18752970","Adapting treatment for prostate cancer according to risk of disease progression","Anderson J, Sternberg CN.","Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S23-31. doi: 10.1016/j.critrevonc.2008.07.011. Epub 2008 Aug 26.","Anderson J","Crit Rev Oncol Hematol","2008","2008/08/30","","","10.1016/j.critrevonc.2008.07.011"
"7645428","Vitamin D and prostate cancer","Feldman D, Skowronski RJ, Peehl DM.","Adv Exp Med Biol. 1995;375:53-63. doi: 10.1007/978-1-4899-0949-7_5.","Feldman D","Adv Exp Med Biol","1995","1995/01/01","","","10.1007/978-1-4899-0949-7_5"
"22048000","Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting","Sartor O, Michels RM, Massard C, de Bono JS.","Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2.","Sartor O","Oncologist","2011","2011/11/04","PMC3233282","","10.1634/theoncologist.2010-0412"
"8483892","Methods of radical prostatectomy specimen processing: a novel technique for harvesting fresh prostate cancer tissue and review of processing techniques","Bova GS, Fox WM, Epstein JI.","Mod Pathol. 1993 Mar;6(2):201-7.","Bova GS","Mod Pathol","1993","1993/03/01","","",""
"16286958","Long-term clinical outcomes of 420 consecutive prostate cancer patients in a single institute","Edamura K, Saika T, Senoh T, Koizumi F, Manabe D, Ebara S, Kaku H, Yokoyama T, Abarzua F, Nagai A, Nasu Y, Tsushima T, Kumon H.","Acta Med Okayama. 2005 Oct;59(5):195-9. doi: 10.18926/AMO/31973.","Edamura K","Acta Med Okayama","2005","2005/11/16","","","10.18926/AMO/31973"
"12773748","Management of high-risk populations with locally advanced prostate cancer","Khan MA, Partin AW.","Oncologist. 2003;8(3):259-69. doi: 10.1634/theoncologist.8-3-259.","Khan MA","Oncologist","2003","2003/05/30","","","10.1634/theoncologist.8-3-259"
"25367323","Nutrition and prostate cancer: an overview","Patel VH.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1295-304. doi: 10.1586/14737140.2014.972946.","Patel VH","Expert Rev Anticancer Ther","2014","2014/11/05","","","10.1586/14737140.2014.972946"
"15916986","Phytoestrogens and prostate cancer risk","Ganry O.","Prev Med. 2005 Jul;41(1):1-6. doi: 10.1016/j.ypmed.2004.10.022. Epub 2004 Dec 9.","Ganry O","Prev Med","2005","2005/05/27","","","10.1016/j.ypmed.2004.10.022"
"30423193","Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers","Sundi D, Tosoian JJ, Nyame YA, Alam R, Achim M, Reichard CA, Li J, Wilkins L, Schwen Z, Han M, Davis JW, Klein EA, Schaeffer EM, Stephenson AJ, Ross AE, Chapin BF.","Cancer. 2019 Feb 1;125(3):391-397. doi: 10.1002/cncr.31833. Epub 2018 Nov 13.","Sundi D","Cancer","2019","2018/11/14","","","10.1002/cncr.31833"
"27813381","MRI should be routine for all patients with localized prostate cancer? | Opinion: Yes","Baroni RH.","Int Braz J Urol. 2016 Nov-Dec;42(6):1062-1064. doi: 10.1590/S1677-5538.IBJU.2016.06.03.","Baroni RH","Int Braz J Urol","2016","2016/11/05","PMC5117960","","10.1590/S1677-5538.IBJU.2016.06.03"
"17785564","Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer","Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA.","Clin Cancer Res. 2007 Sep 1;13(17):5103-8. doi: 10.1158/1078-0432.CCR-07-0700.","Hessels D","Clin Cancer Res","2007","2007/09/06","","","10.1158/1078-0432.CCR-07-0700"
"19062155","Re: E. David Crawford, Per-Anders Abrahamsson. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 2008;54:262-73","Kvåle R, Hernes E, Bray F.","Eur Urol. 2009 May;55(5):e88-9; author reply e90-1. doi: 10.1016/j.eururo.2008.11.036. Epub 2008 Nov 29.","Kvåle R","Eur Urol","2009","2008/12/09","","","10.1016/j.eururo.2008.11.036"
"18414448","Prostate cancer and metastasis initiating stem cells","Kelly K, Yin JJ.","Cell Res. 2008 May;18(5):528-37. doi: 10.1038/cr.2008.50.","Kelly K","Cell Res","2008","2008/04/17","","","10.1038/cr.2008.50"
"18655341","[Do older men with localized prostate cancer Gleason 8-10 benefit from curative therapy?]","Ojea Calvo A, López García S, Rey Rey J, Alonso Rodrigo A, Rodríguez Iglesias B, Barros Rodríguez JM.","Actas Urol Esp. 2008 Jun;32(6):589-93. doi: 10.1016/s0210-4806(08)73892-0.","Ojea Calvo A","Actas Urol Esp","2008","2008/07/29","","","10.1016/s0210-4806(08)73892-0"
"23500637","[Prostate cancer: how do patients choose their treatment?]","Enel C, Matte A, Berchi C, Binquet C, Cormier L, Lejeune C.","Bull Cancer. 2013 Mar;100(3):191-9. doi: 10.1684/bdc.2013.1707.","Enel C","Bull Cancer","2013","2013/03/19","","","10.1684/bdc.2013.1707"
"15887028","70 Gy or more: which dose for which prostate cancer?","Ganswindt U, Paulsen F, Anastasiadis AG, Stenzl A, Bamberg M, Belka C.","J Cancer Res Clin Oncol. 2005 Jul;131(7):407-19. doi: 10.1007/s00432-005-0681-0. Epub 2005 May 11.","Ganswindt U","J Cancer Res Clin Oncol","2005","2005/05/12","","","10.1007/s00432-005-0681-0"
"16247351","Immune response in prostate cancer","Cracco CM, Terrone C, Porpiglia F, Scarpa RM.","Minerva Urol Nefrol. 2005 Dec;57(4):301-11.","Cracco CM","Minerva Urol Nefrol","2005","2005/10/26","","",""
"8023498","Future trends in the incidence and management of prostate cancer","Mayer FJ.","West J Med. 1994 Apr;160(4):380-1.","Mayer FJ","West J Med","1994","1994/04/01","PMC1022443","",""
"24217611","Angiogenesis inhibitors in the treatment of prostate cancer","Adesunloye BA, Karzai FH, Dahut WL.","Chem Immunol Allergy. 2014;99:197-215. doi: 10.1159/000353255. Epub 2013 Oct 17.","Adesunloye BA","Chem Immunol Allergy","2014","2013/11/13","","","10.1159/000353255"
"22648711","Selenium and prostate cancer: systematic review and meta-analysis","Hurst R, Hooper L, Norat T, Lau R, Aune D, Greenwood DC, Vieira R, Collings R, Harvey LJ, Sterne JA, Beynon R, Savović J, Fairweather-Tait SJ.","Am J Clin Nutr. 2012 Jul;96(1):111-22. doi: 10.3945/ajcn.111.033373. Epub 2012 May 30.","Hurst R","Am J Clin Nutr","2012","2012/06/01","","","10.3945/ajcn.111.033373"
"30131605","BRCAness and prostate cancer: diagnostic and therapeutic considerations","Dhawan M, Ryan CJ.","Prostate Cancer Prostatic Dis. 2018 Nov;21(4):488-498. doi: 10.1038/s41391-018-0069-2. Epub 2018 Aug 21.","Dhawan M","Prostate Cancer Prostatic Dis","2018","2018/08/23","","","10.1038/s41391-018-0069-2"
"8165527","[Simultaneous radiotherapy and hormontherapy in Stages II and III prostate cancer]","Strnad V.","Strahlenther Onkol. 1994 Apr;170(4):248-9.","Strnad V","Strahlenther Onkol","1994","1994/04/01","","",""
"1988839","MRI and ultrasonography in staging prostate cancer","Gasser TC, Streule K, Nidecker A, Rist M.","N Engl J Med. 1991 Feb 14;324(7):494-5. doi: 10.1056/nejm199102143240717.","Gasser TC","N Engl J Med","1991","1991/02/14","","","10.1056/nejm199102143240717"
"1784991","An institutional experience in handling intracapsularly located prostate cancer","Høisaeter PA.","Scand J Urol Nephrol Suppl. 1991;138:105-7.","Høisaeter PA","Scand J Urol Nephrol Suppl","1991","1991/01/01","","",""
"11958585","Spectrum-analysis and neural networks for imaging to detect and treat prostate cancer","Feleppa EJ, Ennis RD, Schiff PB, Wuu CS, Kalisz A, Ketterling J, Urban S, Liu T, Fair WR, Porter CR, Gillespie JR.","Ultrason Imaging. 2001 Jul;23(3):135-46. doi: 10.1177/016173460102300301.","Feleppa EJ","Ultrason Imaging","2001","2002/04/18","","","10.1177/016173460102300301"
"19451064","Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study","Bonet M, Merglen A, Fioretta G, Rapiti E, Neyroud-Caspar I, Zanetti R, Miralbell R, Bouchardy C.","Clin Transl Oncol. 2009 May;11(5):312-7. doi: 10.1007/s12094-009-0359-1.","Bonet M","Clin Transl Oncol","2009","2009/05/20","","","10.1007/s12094-009-0359-1"
"23977752","Remembering old lessons in prostate cancer: avoiding errors 'in PARPituity'","Raghavan D.","Oncology (Williston Park). 2013 Jul;27(7):595.","Raghavan D","Oncology (Williston Park)","2013","2013/08/28","","",""
"19654575","Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial","Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A.","Br J Cancer. 2009 Sep 1;101(5):843-8. doi: 10.1038/sj.bjc.6605188. Epub 2009 Aug 4.","Murtola TJ","Br J Cancer","2009","2009/08/06","PMC2736846","","10.1038/sj.bjc.6605188"
"22343492","Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer","Shiraishi T, Getzenberg RH, Kulkarni P.","Asian J Androl. 2012 May;14(3):400-4. doi: 10.1038/aja.2011.144. Epub 2012 Feb 20.","Shiraishi T","Asian J Androl","2012","2012/02/21","PMC3720165","","10.1038/aja.2011.144"
"10483075","Audit of prostate cancer: validity and feasibility of registry-based staging","Silcocks P, Needham P, Hemsley F.","Public Health. 1999 Jul;113(4):157-60. doi: 10.1038/sj.ph.1900566.","Silcocks P","Public Health","1999","1999/09/14","","","10.1038/sj.ph.1900566"
"21130396","[Urinary biomarkers in prostate cancer: an update]","Durand X, Xylinas E, Ploussard G, De la Taille A.","Prog Urol. 2010 Dec;20(13):1184-91. doi: 10.1016/j.purol.2010.07.017.","Durand X","Prog Urol","2010","2010/12/07","","","10.1016/j.purol.2010.07.017"
"10453278","Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma","Gjertsen BT, Logothetis CJ, McDonnell TJ.","Cancer Metastasis Rev. 1998-1999;17(4):345-51. doi: 10.1023/a:1006170332301.","Gjertsen BT","Cancer Metastasis Rev","1998","1999/08/24","","","10.1023/a:1006170332301"
"12735509","Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment","Pollack A, Horwitz EM, Movsas B, Hanlon AL.","Urol Clin North Am. 2003 May;30(2):337-49, x. doi: 10.1016/s0094-0143(02)00177-5.","Pollack A","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00177-5"
"19720969","Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005","Welch HG, Albertsen PC.","J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.","Welch HG","J Natl Cancer Inst","2009","2009/09/02","PMC2758309","","10.1093/jnci/djp278"
"25667110","Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project","Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR; NIDDK Urologic Diseases in America Project.","Prostate Cancer Prostatic Dis. 2015 Jun;18(2):149-54. doi: 10.1038/pcan.2015.3. Epub 2015 Feb 10.","Cary KC","Prostate Cancer Prostatic Dis","2015","2015/02/11","PMC4430397","NIHMS648617","10.1038/pcan.2015.3"
"29970667","Urine PCA3 mRNA level in diagnostic of prostate cancer","Li M, Zhou D, Zhang W, Gao S, Zhou X.","J Cancer Res Ther. 2018;14(4):864-866. doi: 10.4103/jcrt.JCRT_734_17.","Li M","J Cancer Res Ther","2018","2018/07/05","","","10.4103/jcrt.JCRT_734_17"
"28345187","Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice","Narayan VM, Konety BR, Warlick C.","Int J Urol. 2017 May;24(5):352-360. doi: 10.1111/iju.13326. Epub 2017 Mar 27.","Narayan VM","Int J Urol","2017","2017/03/28","","","10.1111/iju.13326"
"24057691","Knowledge and awareness of prostate cancer among the general public in Burkina Faso","Kabore FA, Kambou T, Zango B, Ouédraogo A.","J Cancer Educ. 2014 Mar;29(1):69-73. doi: 10.1007/s13187-013-0545-2.","Kabore FA","J Cancer Educ","2014","2013/09/24","","","10.1007/s13187-013-0545-2"
"24586868","Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer","Ajibade AA, Kirk JS, Karasik E, Gillard B, Moser MT, Johnson CS, Trump DL, Foster BA.","PLoS One. 2014 Feb 26;9(2):e89555. doi: 10.1371/journal.pone.0089555. eCollection 2014.","Ajibade AA","PLoS One","2014","2014/03/04","PMC3935875","","10.1371/journal.pone.0089555"
"27620702","Dynamic thiol/disulphide homeostasis before and after radical prostatectomy in patients with prostate cancer","Hanikoglu F, Hanikoglu A, Kucuksayan E, Alisik M, Gocener AA, Erel O, Baykara M, Cuoghi A, Tomasi A, Ozben T.","Free Radic Res. 2016 Nov;50(sup1):S79-S84. doi: 10.1080/10715762.2016.1235787. Epub 2016 Oct 25.","Hanikoglu F","Free Radic Res","2016","2016/09/14","","","10.1080/10715762.2016.1235787"
"8066397","[Radiotherapy of prostate cancer]","Eschwège F, Wibault P.","Rev Prat. 1994 Mar 1;44(5):604-8.","Eschwège F","Rev Prat","1994","1994/03/01","","",""
"22316505","Editorial: Renaming low risk prostate cancer: proceed cautiously","Gomella LG.","Can J Urol. 2012 Feb;19(1):6069.","Gomella LG","Can J Urol","2012","2012/02/10","","",""
"10789616","Prostate cancer screening in high-risk patients","Feingold RM.","Arch Intern Med. 2000 Apr 24;160(8):1204. doi: 10.1001/archinte.160.8.1204.","Feingold RM","Arch Intern Med","2000","2000/05/02","","","10.1001/archinte.160.8.1204"
"10636568","Treatment of clinically organ confined prostate cancer","McLeod DG.","Scand J Urol Nephrol Suppl. 1999;203:35-9.","McLeod DG","Scand J Urol Nephrol Suppl","1999","2000/01/15","","",""
"15818171","Progress in detection and treatment of prostate cancer","Ryan CJ, Small EJ.","Curr Opin Oncol. 2005 May;17(3):257-60. doi: 10.1097/01.cco.0000155008.37524.8e.","Ryan CJ","Curr Opin Oncol","2005","2005/04/09","","","10.1097/01.cco.0000155008.37524.8e"
"21268949","Magnetic resonance imaging in diagnosis, staging and radiotherapy planning for prostate cancer","Villeirs GM, De Visschere PJ, Fonteyne VH, Lumen N, De Meerleer GO.","Acta Clin Belg. 2010 Nov-Dec;65(6):371-6. doi: 10.1179/acb.2010.65.6.001.","Villeirs GM","Acta Clin Belg","2010","2011/01/29","","","10.1179/acb.2010.65.6.001"
"17499308","Under diagnosis and over diagnosis of prostate cancer","Graif T, Loeb S, Roehl KA, Gashti SN, Griffin C, Yu X, Catalona WJ.","J Urol. 2007 Jul;178(1):88-92. doi: 10.1016/j.juro.2007.03.017. Epub 2007 May 11.","Graif T","J Urol","2007","2007/05/15","","","10.1016/j.juro.2007.03.017"
"25828171","Survival after the diagnosis of prostate cancer for Australian Aboriginal and Māori men","Carson PJ.","BJU Int. 2015 Apr;115 Suppl 5:14-5. doi: 10.1111/bju.13077.","Carson PJ","BJU Int","2015","2015/04/02","","","10.1111/bju.13077"
"22151749","Focal therapy for localised prostate cancer: are we asking the correct research questions?","Murphy DG, Walton TJ, Connolly S, Costello AJ.","BJU Int. 2012 Jan;109(1):1-3. doi: 10.1111/j.1464-410X.2011.10804.x.","Murphy DG","BJU Int","2012","2011/12/14","","","10.1111/j.1464-410X.2011.10804.x"
"28524006","Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?","Ciccarese C, Montironi R, Fiorentino M, Martignoni G, Brunelli M, Iacovelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Moch H, Tortora G, Massari F.","Curr Drug Metab. 2017;18(8):692-699. doi: 10.2174/1389200218666170518163549.","Ciccarese C","Curr Drug Metab","2017","2017/05/20","","","10.2174/1389200218666170518163549"
"10606280","Review of phase II hormone refractory prostate cancer trials","Murphy GP.","Urology. 1999 Dec;54(6A Suppl):19-21. doi: 10.1016/s0090-4295(99)00450-1.","Murphy GP","Urology","1999","1999/12/22","","","10.1016/s0090-4295(99)00450-1"
"17923854","Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates","Polascik TJ.","Prostate Cancer Prostatic Dis. 2008;11(1):13-9. doi: 10.1038/sj.pcan.4501019. Epub 2007 Oct 9.","Polascik TJ","Prostate Cancer Prostatic Dis","2008","2007/10/10","","","10.1038/sj.pcan.4501019"
"20378241","Focal therapy for prostate cancer: possibilities and limitations","Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S.","Eur Urol. 2010 Jul;58(1):57-64. doi: 10.1016/j.eururo.2010.03.034. Epub 2010 Mar 26.","Eggener S","Eur Urol","2010","2010/04/10","","","10.1016/j.eururo.2010.03.034"
"16921833","[Prognostic factor and prediction tables for clinically localized prostate cancer]","Segarra Tomás J, Millán Rodríguez F, Palou Redorta J, Villavicencio Mavrich H.","Actas Urol Esp. 2006 Jun;30(6):567-73. doi: 10.1016/s0210-4806(06)73496-9.","Segarra Tomás J","Actas Urol Esp","2006","2006/08/23","","","10.1016/s0210-4806(06)73496-9"
"19642730","Molecular biology underlying the clinical heterogeneity of prostate cancer: an update","Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA.","Arch Pathol Lab Med. 2009 Jul;133(7):1033-40. doi: 10.1043/1543-2165-133.7.1033.","Mackinnon AC","Arch Pathol Lab Med","2009","2009/08/01","","","10.1043/1543-2165-133.7.1033"
"26416059","Association of p16 gene methylation with prostate cancer risk: a meta-analysis","Feng W, Han Z, Zhu R, Liu P, Liu S.","J BUON. 2015 Jul-Aug;20(4):1074-80.","Feng W","J BUON","2015","2015/09/30","","",""
"29339663","Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy","Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton GB, Froehner M, Zastrow S, Wirth MP.","Urol Int. 2018;100(2):155-163. doi: 10.1159/000486041. Epub 2018 Jan 16.","Borkowetz A","Urol Int","2018","2018/01/18","","","10.1159/000486041"
"24882718","Alternative approaches to prevent androgen action in prostate cancer: are we there yet?","Elbanna M, Heemers HV.","Discov Med. 2014 May;17(95):267-74.","Elbanna M","Discov Med","2014","2014/06/03","","",""
"22343493","Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics","Carter HB.","Asian J Androl. 2012 May;14(3):355-60. doi: 10.1038/aja.2011.141. Epub 2012 Feb 20.","Carter HB","Asian J Androl","2012","2012/02/21","PMC3720162","","10.1038/aja.2011.141"
"15586021","Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part I","Moyad MA.","Curr Opin Urol. 2005 Jan;15(1):1-6. doi: 10.1097/00042307-200501000-00002.","Moyad MA","Curr Opin Urol","2005","2004/12/09","","","10.1097/00042307-200501000-00002"
"24029312","Re: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer","Taneja SS.","J Urol. 2013 Oct;190(4):1247. doi: 10.1016/j.juro.2013.06.104. Epub 2013 Jul 4.","Taneja SS","J Urol","2013","2013/09/14","","","10.1016/j.juro.2013.06.104"
"15714985","[Quality of life after radical prostatectomy]","Kuwata Y, Kakehi Y.","Nihon Rinsho. 2005 Feb;63(2):315-20.","Kuwata Y","Nihon Rinsho","2005","2005/02/18","","",""
"29331546","Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options","Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.","J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.","Sanda MG","J Urol","2018","2018/01/15","","","10.1016/j.juro.2018.01.002"
"12874026","Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse","Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL.","Cancer Res. 2003 Jul 15;63(14):4196-203.","Henshall SM","Cancer Res","2003","2003/07/23","","",""
"16226044","[Indications of the association of radiotherapy and hormonal treatment in prostate cancer]","Bolla M, Maingon P, Fourneret P, Artignan X, Descotes JL.","Cancer Radiother. 2005 Nov;9(6-7):394-8. doi: 10.1016/j.canrad.2005.07.006. Epub 2005 Oct 11.","Bolla M","Cancer Radiother","2005","2005/10/18","","","10.1016/j.canrad.2005.07.006"
"23268329","High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study","Chornokur G, Han G, Tanner R, Lin HY, Green BL, Pow-Sang J, Phelan CM.","Cancer Lett. 2013 May 1;331(2):154-7. doi: 10.1016/j.canlet.2012.12.014. Epub 2012 Dec 23.","Chornokur G","Cancer Lett","2013","2012/12/27","PMC3603576","NIHMS443003","10.1016/j.canlet.2012.12.014"
"8618304","Some aspects of prostate cancer","McLeod DG.","J Urol. 1996 Jun;155(6):1987-8. doi: 10.1016/s0022-5347(01)66070-1.","McLeod DG","J Urol","1996","1996/06/01","","","10.1016/s0022-5347(01)66070-1"
"10750886","Change in the ratio of free-to-total prostate-specific antigen during progression of advanced prostate cancer","Tanaka M, Murakami S, Suzuki N, Shimazaki J.","Int J Urol. 2000 Mar;7(3):83-7. doi: 10.1046/j.1442-2042.2000.00144.x.","Tanaka M","Int J Urol","2000","2000/04/06","","","10.1046/j.1442-2042.2000.00144.x"
"31937919","Tumour innervation and neurosignalling in prostate cancer","March B, Faulkner S, Jobling P, Steigler A, Blatt A, Denham J, Hondermarck H.","Nat Rev Urol. 2020 Feb;17(2):119-130. doi: 10.1038/s41585-019-0274-3. Epub 2020 Jan 14.","March B","Nat Rev Urol","2020","2020/01/16","","","10.1038/s41585-019-0274-3"
"25827049","Comprehensive assessment for novel prostate cancer markers in the prostate-specific antigen era: focusing on Asians and Asian countries","Okihara K, Ochiai A, Kamoi K, Fujizuka Y, Miki T, Ito K.","Int J Urol. 2015 Apr;22(4):334-41. doi: 10.1111/iju.12701.","Okihara K","Int J Urol","2015","2015/04/02","","","10.1111/iju.12701"
"8998177","NPCC unifies prostate cancer advocates","Steimle S.","J Natl Cancer Inst. 1997 Jan 15;89(2):117-8. doi: 10.1093/jnci/89.2.117.","Steimle S","J Natl Cancer Inst","1997","1997/01/15","","","10.1093/jnci/89.2.117"
"15847715","Secondary hormonal manipulations in prostate cancer","Ryan CJ, Small EJ.","Curr Oncol Rep. 2005 May;7(3):228-33. doi: 10.1007/s11912-005-0078-x.","Ryan CJ","Curr Oncol Rep","2005","2005/04/26","","","10.1007/s11912-005-0078-x"
"29776882","Possible prostate cancer in northern Peru: Differential diagnosis, vascular anatomy, and molecular signaling in the paleopathology of metastatic bone disease","Klaus HD.","Int J Paleopathol. 2018 Jun;21:147-157. doi: 10.1016/j.ijpp.2016.11.004. Epub 2017 Feb 6.","Klaus HD","Int J Paleopathol","2018","2018/05/20","","","10.1016/j.ijpp.2016.11.004"
"15331908","Dramatic remission of hormone refractory prostate cancer achieved with extract of the mushroom, Phellinus linteus","Shibata Y, Kurita S, Okugi H, Yamanaka H.","Urol Int. 2004;73(2):188-90. doi: 10.1159/000079704.","Shibata Y","Urol Int","2004","2004/08/28","","","10.1159/000079704"
"15833828","Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy","Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL.","Cancer Res. 2005 Apr 15;65(8):3030-4. doi: 10.1158/0008-5472.CAN-04-4106.","Cheng LL","Cancer Res","2005","2005/04/19","","","10.1158/0008-5472.CAN-04-4106"
"7985307","An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing","Thompson IM, Paradelo JC, Crawford ED, Coltman CA, Blumenstein B.","Urology. 1994 Dec;44(6):804-11. doi: 10.1016/s0090-4295(94)80161-4.","Thompson IM","Urology","1994","1994/12/01","","","10.1016/s0090-4295(94)80161-4"
"29135121","Hepcidin and iron metabolism in the pathogenesis of prostate cancer","Wang F, Liu A, Bai R, Zhang B, Jin Y, Guo W, Li Y, Gao J, Liu L.","J BUON. 2017 Sep-Oct;22(5):1328-1332.","Wang F","J BUON","2017","2017/11/15","","",""
"9095173","Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice","Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL.","Nat Med. 1997 Apr;3(4):402-8. doi: 10.1038/nm0497-402.","Klein KA","Nat Med","1997","1997/04/01","","","10.1038/nm0497-402"
"9521161","Vitamin E reduces prostate cancer rates in Finnish trial: U.S. considers follow-up","Smigel K.","J Natl Cancer Inst. 1998 Mar 18;90(6):416-7. doi: 10.1093/jnci/90.6.416.","Smigel K","J Natl Cancer Inst","1998","1998/04/01","","","10.1093/jnci/90.6.416"
"23962515","Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality","Etzioni R, Durand-Zaleski I, Lansdorp-Vogelaar I.","J Natl Cancer Inst Monogr. 2013;2013(46):117-23. doi: 10.1093/jncimonographs/lgt010.","Etzioni R","J Natl Cancer Inst Monogr","2013","2013/08/22","PMC3748002","","10.1093/jncimonographs/lgt010"
"18190826","Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer?","Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, Pisters LL.","Urol Oncol. 2008 Jan-Feb;26(1):25-30. doi: 10.1016/j.urolonc.2006.12.019. Epub 2007 Oct 18.","Spiess PE","Urol Oncol","2008","2008/01/15","","","10.1016/j.urolonc.2006.12.019"
"23793765","Stem cells in prostate cancer","Mateo F, Fernandez PL, Thomson TM.","Arch Esp Urol. 2013 Jun;66(5):475-86.","Mateo F","Arch Esp Urol","2013","2013/06/25","","",""
"31900919","Oncogenic ETS Factors in Prostate Cancer","Nicholas TR, Strittmatter BG, Hollenhorst PC.","Adv Exp Med Biol. 2019;1210:409-436. doi: 10.1007/978-3-030-32656-2_18.","Nicholas TR","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_18"
"8853479","Prostate cancer: the epidemiologic perspective","Levy I.","Can J Oncol. 1994 Nov;4 Suppl 1:4-7.","Levy I","Can J Oncol","1994","1994/11/01","","",""
"7539884","Prostate cancer: enthusiasm for screening","Kaye KW.","Med J Aust. 1995 May 15;162(10):540-1.","Kaye KW","Med J Aust","1995","1995/05/15","","",""
"11326167","Prostate cancer: screening and early detection","Cookson MM.","Cancer Control. 2001 Mar-Apr;8(2):133-40. doi: 10.1177/107327480100800203.","Cookson MM","Cancer Control","2001","2001/04/28","","","10.1177/107327480100800203"
"30213689","New developments in mechanisms of prostate cancer progression","Howard N, Clementino M, Kim D, Wang L, Verma A, Shi X, Zhang Z, DiPaola RS.","Semin Cancer Biol. 2019 Aug;57:111-116. doi: 10.1016/j.semcancer.2018.09.003. Epub 2018 Sep 10.","Howard N","Semin Cancer Biol","2019","2018/09/15","","","10.1016/j.semcancer.2018.09.003"
"10197878","Digital rectal examination and mortality from prostate cancer","Weiss NS, Friedman GD, van den Eeden S.","Urology. 1999 Apr;53(4):863-4.","Weiss NS","Urology","1999","1999/04/10","","",""
"20440282","Treatment of localized prostate cancer: when is active surveillance appropriate?","Albertsen PC.","Nat Rev Clin Oncol. 2010 Jul;7(7):394-400. doi: 10.1038/nrclinonc.2010.63. Epub 2010 May 4.","Albertsen PC","Nat Rev Clin Oncol","2010","2010/05/05","","","10.1038/nrclinonc.2010.63"
"17997025","Prostate cancer in men with serum PSA of <4 ng/ml: under-diagnosed or over-treated?","Yossepowitch O.","Eur Urol. 2008 Apr;53(4):686-8. doi: 10.1016/j.eururo.2007.10.067. Epub 2007 Nov 6.","Yossepowitch O","Eur Urol","2008","2007/11/13","","","10.1016/j.eururo.2007.10.067"
"8606819","Prostate cancer screening is experimental","Cox B.","N Z Med J. 1996 Mar 8;109(1017):63-4.","Cox B","N Z Med J","1996","1996/03/08","","",""
"25659982","[Cryoablation of prostate cancer]","Witzsch UK, Becht E.","Urologe A. 2015 Feb;54(2):191-201. doi: 10.1007/s00120-014-3667-1.","Witzsch UK","Urologe A","2015","2015/02/10","","","10.1007/s00120-014-3667-1"
"21705812","Prostate cancer: to screen or not to screen","Bailey SJ, Brewster SF.","Arch Esp Urol. 2011 Jun;64(5):406-18.","Bailey SJ","Arch Esp Urol","2011","2011/06/28","","",""
"2693332","Treatment of advanced prostate cancer","Rasmussen F.","Horm Res. 1989;32 Suppl 1:47-9. doi: 10.1159/000181309.","Rasmussen F","Horm Res","1989","1989/01/01","","","10.1159/000181309"
"17342490","Biopsy standards for detection of prostate cancer","Djavan B, Margreiter M.","World J Urol. 2007 Mar;25(1):11-7. doi: 10.1007/s00345-007-0151-1. Epub 2007 Mar 7.","Djavan B","World J Urol","2007","2007/03/08","","","10.1007/s00345-007-0151-1"
"18752151","Laparoscopic pelvic lymph-node dissection in prostate cancer before external beam radiotherapy: Risk factors of nodal involvement and relapse following intended curative treatment","Bjerggaard Jensen J, Johansen JK, Graversen PH.","Scand J Urol Nephrol. 2009;43(1):19-24. doi: 10.1080/00365590802273234.","Bjerggaard Jensen J","Scand J Urol Nephrol","2009","2008/08/30","","","10.1080/00365590802273234"
"26884865","Anacardic acid sensitizes prostate cancer cells to radiation therapy by regulating H2AX expression","Yao K, Jiang X, He L, Tang Y, Yin G, Zeng Q, Jiang Z, Tan J.","Int J Clin Exp Pathol. 2015 Dec 1;8(12):15926-32. eCollection 2015.","Yao K","Int J Clin Exp Pathol","2015","2016/02/18","PMC4730078","",""
"20399459","Positive surgical margins at radical prostatectomy predict prostate cancer specific mortality","Wright JL, Dalkin BL, True LD, Ellis WJ, Stanford JL, Lange PH, Lin DW.","J Urol. 2010 Jun;183(6):2213-8. doi: 10.1016/j.juro.2010.02.017.","Wright JL","J Urol","2010","2010/04/20","PMC2903223","NIHMS176535","10.1016/j.juro.2010.02.017"
"9146620","Unraveling the epidemiology of prostate cancer","Albertsen P.","J Urol. 1997 Jun;157(6):2223-4. doi: 10.1016/s0022-5347(01)64723-2.","Albertsen P","J Urol","1997","1997/06/01","","","10.1016/s0022-5347(01)64723-2"
"7754278","European trials and the management of prostate cancer","Newling DW.","Semin Surg Oncol. 1995 Jan-Feb;11(1):65-71. doi: 10.1002/ssu.2980110110.","Newling DW","Semin Surg Oncol","1995","1995/01/01","","","10.1002/ssu.2980110110"
"28890087","[Therapeutic innovations in radiation oncology for localized prostate cancer]","Créhange G, Cormier L.","Cancer Radiother. 2017 Oct;21(6-7):454-461. doi: 10.1016/j.canrad.2017.07.037. Epub 2017 Sep 8.","Créhange G","Cancer Radiother","2017","2017/09/12","","","10.1016/j.canrad.2017.07.037"
"24182969","Transrectal prostate biopsy","Ismail MT, Gomella LG.","Urol Clin North Am. 2013 Nov;40(4):457-72. doi: 10.1016/j.ucl.2013.07.012. Epub 2013 Sep 11.","Ismail MT","Urol Clin North Am","2013","2013/11/05","","","10.1016/j.ucl.2013.07.012"
"17222606","Epidemiology and pathophysiology of prostate cancer in African-American men","Powell IJ.","J Urol. 2007 Feb;177(2):444-9. doi: 10.1016/j.juro.2006.09.024.","Powell IJ","J Urol","2007","2007/01/16","","","10.1016/j.juro.2006.09.024"
"16831072","New molecular targets in advanced prostate cancer","Dawson NA.","Expert Rev Anticancer Ther. 2006 Jul;6(7):993-1002. doi: 10.1586/14737140.6.7.993.","Dawson NA","Expert Rev Anticancer Ther","2006","2006/07/13","","","10.1586/14737140.6.7.993"
"24802231","Real-time transrectal ultrasonography-guided hands-free technique for focal cryoablation of the prostate","de Castro Abreu AL, Bahn D, Chopra S, Leslie S, Matsugasumi T, Gill IS, Ukimura O.","BJU Int. 2014 Nov;114(5):784-9. doi: 10.1111/bju.12795. Epub 2014 Aug 11.","de Castro Abreu AL","BJU Int","2014","2014/05/08","","","10.1111/bju.12795"
"11828352","Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001","Sarma AV, Schottenfeld D.","Semin Urol Oncol. 2002 Feb;20(1):3-9. doi: 10.1053/suro.2002.30390.","Sarma AV","Semin Urol Oncol","2002","2002/02/06","","","10.1053/suro.2002.30390"
"10187640","Prostate cancer. It couldn't happen here","Bryan J.","Health Serv J. 1998 Nov 26;108(5632):suppl 4-6.","Bryan J","Health Serv J","1998","1998/10/29","","",""
"24103424","Characteristics of cases with unknown stage prostate cancer in a population-based cancer registry","Luo Q, Yu XQ, Cooke-Yarborough C, Smith DP, O'Connell DL.","Cancer Epidemiol. 2013 Dec;37(6):813-9. doi: 10.1016/j.canep.2013.09.008. Epub 2013 Oct 6.","Luo Q","Cancer Epidemiol","2013","2013/10/10","","","10.1016/j.canep.2013.09.008"
"20397489","Prostate cancer screening: what's a fellow to do?","Thanel FH, Huntington MK.","S D Med. 2010;Spec No:41-5.","Thanel FH","S D Med","2010","2010/04/20","","",""
"20164013","Focus on breast and prostate cancer prevention, early detection and new trends in management highlights of the 1st National Conference on Cancer Control in Kuwait","Ragheb AM.","Gulf J Oncolog. 2010 Jan;(7):64-74.","Ragheb AM","Gulf J Oncolog","2010","2010/02/19","","",""
"23615688","Is it time to reevaluate definitive therapy in prostate cancer?","Madan RA, Shah AA, Dahut WL.","J Natl Cancer Inst. 2013 May 15;105(10):683-5. doi: 10.1093/jnci/djt094. Epub 2013 Apr 24.","Madan RA","J Natl Cancer Inst","2013","2013/04/26","PMC3691939","","10.1093/jnci/djt094"
"7551833","The TNM classification of prostate cancer: a discussion of the 1992 classification. The British Association of Urological Surgeons TNM Subcommittee","","Br J Urol. 1995 Sep;76(3):279-85. doi: 10.1111/j.1464-410x.1995.tb07701.x.","","Br J Urol","1995","1995/09/01","","","10.1111/j.1464-410x.1995.tb07701.x"
"16630521","Prostate cancer detection strategies","Brand TC, Hernandez J, Canby-Hagino ED, Basler JW, Thompson IM.","Curr Urol Rep. 2006 May;7(3):181-5. doi: 10.1007/s11934-006-0019-8.","Brand TC","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0019-8"
"9334621","Pretreatment prostate specific antigen doubling times: use in patients before radical prostatectomy","Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA.","J Urol. 1997 Nov;158(5):1876-8; discussion 1878-9. doi: 10.1016/s0022-5347(01)64154-5.","Goluboff ET","J Urol","1997","1997/10/23","","","10.1016/s0022-5347(01)64154-5"
"22374419","Castration-resistant metastatic prostate cancer: current status and treatment possibilities","Carles J, Castellano D, Climent MÁ, Maroto P, Medina R, Alcaraz A.","Clin Transl Oncol. 2012 Mar;14(3):169-76. doi: 10.1007/s12094-012-0780-8.","Carles J","Clin Transl Oncol","2012","2012/03/01","","","10.1007/s12094-012-0780-8"
"26416035","Role of of Nuclear Medicine in the multidisciplinary management of prostate cancer","Ceresoli GL, Bombardieri E.","Q J Nucl Med Mol Imaging. 2015 Dec;59(4):357-8.","Ceresoli GL","Q J Nucl Med Mol Imaging","2015","2015/09/30","","",""
"7666473","Europeans collaborate on screening trials for prostate cancer","Reynolds T.","J Natl Cancer Inst. 1995 Jun 21;87(12):868-71. doi: 10.1093/jnci/87.12.868.","Reynolds T","J Natl Cancer Inst","1995","1995/06/21","","","10.1093/jnci/87.12.868"
"27344792","[Proton therapy for localized prostate cancer]","Takagi M, Demizu Y, Okimoto T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:552-6.","Takagi M","Nihon Rinsho","2016","2016/06/28","","",""
"21925305","Prostate cancer as a model system for genetic diversity in tumors","Squire JA, Park PC, Yoshimoto M, Alami J, Williams JL, Evans A, Joshua AM.","Adv Cancer Res. 2011;112:183-216. doi: 10.1016/B978-0-12-387688-1.00007-7.","Squire JA","Adv Cancer Res","2011","2011/09/20","","","10.1016/B978-0-12-387688-1.00007-7"
"30045654","Choosing Channels, Sources, and Content for Communicating Prostate Cancer Information to Black Men: A Systematic Review of the Literature","Walsh-Childers K, Odedina F, Poitier A, Kaninjing E, Taylor G 3rd.","Am J Mens Health. 2018 Sep;12(5):1728-1745. doi: 10.1177/1557988318786669. Epub 2018 Jul 25.","Walsh-Childers K","Am J Mens Health","2018","2018/07/27","PMC6142158","","10.1177/1557988318786669"
"6713343","Transphenoidal hypophysectomy in the management of carcinoma of the prostate","Smith JA Jr, Eyre HJ, Roberts TS, Middleton RG.","Cancer. 1984 Jun 1;53(11):2385-7. doi: 10.1002/1097-0142(19840601)53:11<2385::aid-cncr2820531102>3.0.co;2-m.","Smith JA Jr","Cancer","1984","1984/06/01","","","10.1002/1097-0142(19840601)53:11<2385::aid-cncr2820531102>3.0.co;2-m"
"15264274","Unravelling the genetics of prostate cancer","Edwards SM, Eeles RA.","Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):65-73. doi: 10.1002/ajmg.c.30027.","Edwards SM","Am J Med Genet C Semin Med Genet","2004","2004/07/21","","","10.1002/ajmg.c.30027"
"26974844","New developments in prostate cancer biomarkers","Martin NE.","Curr Opin Oncol. 2016 May;28(3):248-52. doi: 10.1097/CCO.0000000000000279.","Martin NE","Curr Opin Oncol","2016","2016/03/15","","","10.1097/CCO.0000000000000279"
"22213054","A stochastic model for survival of early prostate cancer with adjustments for leadtime, length bias, and over-detection","Wu GH, Auvinen A, Yen AM, Hakama M, Walter SD, Chen HH.","Biom J. 2012 Jan;54(1):20-44. doi: 10.1002/bimj.201000107. Epub 2011 Dec 23.","Wu GH","Biom J","2012","2012/01/04","","","10.1002/bimj.201000107"
"22322981","Novel strategies in the treatment of castration-resistant prostate cancer (Review)","Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.","Int J Oncol. 2012 May;40(5):1313-20. doi: 10.3892/ijo.2012.1364. Epub 2012 Feb 9.","Marech I","Int J Oncol","2012","2012/02/11","","","10.3892/ijo.2012.1364"
"19790236","The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target","Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.","Prostate. 2010 Feb 15;70(3):333-40. doi: 10.1002/pros.21059.","Whitaker HC","Prostate","2010","2009/10/01","","","10.1002/pros.21059"
"18186497","Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis","Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.","Cancer. 2008 Mar 1;112(5):1058-65. doi: 10.1002/cncr.23276.","Svatek RS","Cancer","2008","2008/01/12","","","10.1002/cncr.23276"
"17681420","Prostate cancer following BPH treatments: what the patient should know","Gilling PJ.","Eur Urol. 2008 Jun;53(6):1109-10. doi: 10.1016/j.eururo.2007.07.036. Epub 2007 Aug 3.","Gilling PJ","Eur Urol","2008","2007/08/08","","","10.1016/j.eururo.2007.07.036"
"23820638","Urological cancer: Poorer prostate cancer outcomes in African American men","Marchesi V.","Nat Rev Clin Oncol. 2013 Aug;10(8):427. doi: 10.1038/nrclinonc.2013.114. Epub 2013 Jul 2.","Marchesi V","Nat Rev Clin Oncol","2013","2013/07/04","","","10.1038/nrclinonc.2013.114"
"8752742","[Prostate cancer screening in the primary care consultation]","Subías Loren PJ, Salvador Milian MA.","Aten Primaria. 1996 May 31;17(9):545-6.","Subías Loren PJ","Aten Primaria","1996","1996/05/31","","",""
"10960925","To tell or not to tell: patterns of disclosure among men with prostate cancer","Gray RE, Fitch M, Phillips C, Labrecque M, Fergus K.","Psychooncology. 2000 Jul-Aug;9(4):273-82. doi: 10.1002/1099-1611(200007/08)9:4<273::aid-pon463>3.0.co;2-f.","Gray RE","Psychooncology","2000","2000/08/29","","","10.1002/1099-1611(200007/08)9:4<273::aid-pon463>3.0.co;2-f"
"24725760","Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer","Gondo T, Poon BY, Matsumoto K, Bernstein M, Sjoberg DD, Eastham JA.","BJU Int. 2015 Jan;115(1):81-6. doi: 10.1111/bju.12769. Epub 2014 Aug 13.","Gondo T","BJU Int","2015","2014/04/15","PMC4194186","NIHMS586276","10.1111/bju.12769"
"9516346","Side effects of prostate cancer treatment","","Health News. 1998 Mar 10;4(3):7.","","Health News","1998","1998/03/27","","",""
"3054907","Management of metastatic prostatic cancer","Murphy GP.","Prog Clin Biol Res. 1988;277:127-34.","Murphy GP","Prog Clin Biol Res","1988","1988/01/01","","",""
"28056390","Disparities in hospitalization outcomes among African-American and White prostate cancer patients","Naik G, Akinyemiju T.","Cancer Epidemiol. 2017 Feb;46:73-79. doi: 10.1016/j.canep.2016.12.001. Epub 2017 Jan 3.","Naik G","Cancer Epidemiol","2017","2017/01/06","","","10.1016/j.canep.2016.12.001"
"11295609","Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials","Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB.","Urology. 2001 Apr;57(4 Suppl 1):124-8. doi: 10.1016/s0090-4295(00)00955-9.","Kurhanewicz J","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00955-9"
"20864250","Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer","Warmuth M, Johansson T, Mad P.","Eur Urol. 2010 Dec;58(6):803-15. doi: 10.1016/j.eururo.2010.09.009. Epub 2010 Sep 17.","Warmuth M","Eur Urol","2010","2010/09/25","","","10.1016/j.eururo.2010.09.009"
"21920156","Should baseline PSA testing be performed in men aged 40 to detect those aged 50 or less who are at risk of aggressive prostate cancer?","Heyns CF, Fisher M, Lecuona A, Van der Merwe A.","S Afr Med J. 2011 Sep 5;101(9):642-4.","Heyns CF","S Afr Med J","2011","2011/09/17","","",""
"25356578","The effect of diet and supplements on prostate cancer","Freedland SJ.","Clin Adv Hematol Oncol. 2014 Aug;12(8):538-40.","Freedland SJ","Clin Adv Hematol Oncol","2014","2014/10/31","","",""
"3317429","The European experience: use of transrectal ultrasound in the diagnosis and management of prostate cancer","Bertermann H.","Prog Clin Biol Res. 1987;237:177-94.","Bertermann H","Prog Clin Biol Res","1987","1987/01/01","","",""
"31629426","Current recommendations for prostate cancer genetic testing: NCCN prostate guideline","Mohler JL, Higano CS, Schaeffer EM, Cheng HH.","Can J Urol. 2019 Oct;26(5 Suppl 2):34-37.","Mohler JL","Can J Urol","2019","2019/10/21","","",""
"9051147","Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer","Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG.","Prostate. 1997 Feb 1;30(2):92-7. doi: 10.1002/(sici)1097-0045(19970201)30:2<92::aid-pros4>3.0.co;2-m.","Waters DJ","Prostate","1997","1997/02/01","","","10.1002/(sici)1097-0045(19970201)30:2<92::aid-pros4>3.0.co;2-m"
"22032753","Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates","Gulati R, Mariotto AB, Chen S, Gore JL, Etzioni R.","J Clin Epidemiol. 2011 Dec;64(12):1412-7. doi: 10.1016/j.jclinepi.2011.06.011.","Gulati R","J Clin Epidemiol","2011","2011/10/29","PMC3517213","NIHMS331310","10.1016/j.jclinepi.2011.06.011"
"21430379","Castration-resistant prostate cancer: targeted therapies","Leo S, Accettura C, Lorusso V.","Chemotherapy. 2011;57(2):115-27. doi: 10.1159/000323581. Epub 2011 Mar 24.","Leo S","Chemotherapy","2011","2011/03/25","","","10.1159/000323581"
"27589333","Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer","Pillai MRA, Nanabala R, Joy A, Sasikumar A, Russ Knapp FF.","Nucl Med Biol. 2016 Nov;43(11):692-720. doi: 10.1016/j.nucmedbio.2016.08.006. Epub 2016 Aug 11.","Pillai MRA","Nucl Med Biol","2016","2016/09/03","","","10.1016/j.nucmedbio.2016.08.006"
"27238617","SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort","Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G, Partin AW, Trock BJ, Davicioni E, Schaeffer EM.","J Urol. 2016 Nov;196(5):1436-1444. doi: 10.1016/j.juro.2016.05.092. Epub 2016 May 27.","Johnson MH","J Urol","2016","2016/05/31","PMC6615051","NIHMS1026211","10.1016/j.juro.2016.05.092"
"23977759","Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy","Mitin T, Blute M, Lee R, Efstathiou J.","Oncology (Williston Park). 2013 Jul;27(7):647-55.","Mitin T","Oncology (Williston Park)","2013","2013/08/28","","",""
"8142838","Cancer of the prostate","Dearnaley DP.","BMJ. 1994 Mar 19;308(6931):780-4. doi: 10.1136/bmj.308.6931.780.","Dearnaley DP","BMJ","1994","1994/03/19","PMC2539670","","10.1136/bmj.308.6931.780"
"11588852","Risk of prostate cancer in relation to polymorphisms of metabolic genes","Chen C.","Epidemiol Rev. 2001;23(1):30-5. doi: 10.1093/oxfordjournals.epirev.a000793.","Chen C","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000793"
"31629420","Germline contributions to metastatic prostate cancer","Cheng HH.","Can J Urol. 2019 Oct;26(5 Suppl 2):19-21.","Cheng HH","Can J Urol","2019","2019/10/21","","",""
"27541955","Prostate Cancer Incidence Rates 2 Years After the US Preventive Services Task Force Recommendations Against Screening","Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM.","JAMA Oncol. 2016 Dec 1;2(12):1657-1660. doi: 10.1001/jamaoncol.2016.2667.","Jemal A","JAMA Oncol","2016","2016/08/20","","","10.1001/jamaoncol.2016.2667"
"21514531","[Physiopathology and new therapeutic strategies in the management of bone metastases of prostate cancer]","Lebret T, Méjean A, Houédé N.","Prog Urol. 2011 May;21(5):301-7. doi: 10.1016/j.purol.2010.12.001. Epub 2011 Jan 28.","Lebret T","Prog Urol","2011","2011/04/26","","","10.1016/j.purol.2010.12.001"
"7523720","The nature of prostate cancer detected through prostate specific antigen based screening","Smith DS, Catalona WJ.","J Urol. 1994 Nov;152(5 Pt 2):1732-6. doi: 10.1016/s0022-5347(17)32372-8.","Smith DS","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32372-8"
"30396917","Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC","Giacinti S, Poti G, Roberto M, Macrini S, Bassanelli M, DI Pietro F, Aschelter AM, Ceribelli A, Ruggeri EM, Marchetti P.","Anticancer Res. 2018 Nov;38(11):6029-6039. doi: 10.21873/anticanres.12953.","Giacinti S","Anticancer Res","2018","2018/11/07","","","10.21873/anticanres.12953"
"11692605","[A case of prostate cancer with cyst formation]","Kim SC, Fujimoto K, Matsumoto Y, Cho M, Natsume O, Uemura H, Ozono S, Hirao Y.","Hinyokika Kiyo. 2001 Sep;47(9):653-6.","Kim SC","Hinyokika Kiyo","2001","2001/11/06","","",""
"22318176","[Predictive models for biochemical recurrence of prostate cancer after local treatment. Nomograms]","Fernando AB, Escaño LM, Saiz GS, Sanz LA.","Arch Esp Urol. 2012 Jan-Feb;65(1):39-50.","Fernando AB","Arch Esp Urol","2012","2012/02/10","","",""
"15199892","Urinary symptoms and prostate cancer treatment","","Health News. 2004 Jun;10(6):2.","","Health News","2004","2004/06/18","","",""
"12745735","Psychological aspects of screening in families with hereditary prostate cancer","Bratt O, Emanuelsson M, Grönberg H.","Scand J Urol Nephrol. 2003;37(1):5-9. doi: 10.1080/00365590310008604.","Bratt O","Scand J Urol Nephrol","2003","2003/05/15","","","10.1080/00365590310008604"
"23084525","Moving toward personalized medicine in castration-resistant prostate cancer","Van Allen EM, Pomerantz M.","Urol Clin North Am. 2012 Nov;39(4):483-90. doi: 10.1016/j.ucl.2012.07.005. Epub 2012 Aug 27.","Van Allen EM","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.07.005"
"21434292","[Update of treatment for prostate cancer]","Ito K.","Gan To Kagaku Ryoho. 2011 Jan;38(1):48-53.","Ito K","Gan To Kagaku Ryoho","2011","2011/03/26","","",""
"25832517","Coping with losses, grief, and mourning in prostate cancer","Wittmann D.","Adv Psychosom Med. 2015;34:109-22. doi: 10.1159/000369089. Epub 2015 Mar 30.","Wittmann D","Adv Psychosom Med","2015","2015/04/03","","","10.1159/000369089"
"15714966","[Summary of 'General Rule for Clinical and Pathological Studies on Prostate Cancer (the 3rd Edition)']","Maeda O, Usami M.","Nihon Rinsho. 2005 Feb;63(2):201-6.","Maeda O","Nihon Rinsho","2005","2005/02/18","","",""
"24931803","Current clinical presentation and treatment of localized prostate cancer in the United States","Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE.","J Urol. 2014 Dec;192(6):1650-6. doi: 10.1016/j.juro.2014.06.017. Epub 2014 Jun 12.","Mahmood U","J Urol","2014","2014/06/17","","","10.1016/j.juro.2014.06.017"
"26676900","Upfront Chemotherapy for Metastatic Prostate Cancer","Lam ET, Flaig TW.","Oncology (Williston Park). 2015 Dec;29(12):956-62.","Lam ET","Oncology (Williston Park)","2015","2015/12/18","","",""
"9490084","Erythrocyte sedimentation rate--a predictor of malignant potential in early prostate cancer","Borre M, Nerstrøm B, Overgaard J.","Acta Oncol. 1997;36(7):689-94. doi: 10.3109/02841869709001338.","Borre M","Acta Oncol","1997","1997/01/01","","","10.3109/02841869709001338"
"18342199","Screening and management of prostate cancer in elderly men: the Iowa Prostate Cancer Consensus","Konety BR, Sharp VJ, Raut H, Williams RD.","Urology. 2008 Mar;71(3):511-4. doi: 10.1016/j.urology.2007.09.019.","Konety BR","Urology","2008","2008/03/18","","","10.1016/j.urology.2007.09.019"
"23196780","[Osteosarcoma of the prostate after radiotherapy]","Stangelberger A, Riedl CR, Susani M.","Aktuelle Urol. 2012 Dec;43(6):409-11. doi: 10.1055/s-0032-1323744. Epub 2012 Nov 29.","Stangelberger A","Aktuelle Urol","2012","2012/12/01","","","10.1055/s-0032-1323744"
"11593907","[Surgical therapy of prostatic carcinoma]","Vögeli TA.","Praxis (Bern 1994). 2001 Sep 6;90(36):1516-22.","Vögeli TA","Praxis (Bern 1994)","2001","2001/10/12","","",""
"27932742","Differences in cancer characteristics of Chinese patients with prostate cancer who present with different symptoms","Chan SY, Ng CF, Lee KW, Yee CH, Chiu PK, Teoh JY, Hou SS.","Hong Kong Med J. 2017 Feb;23(1):6-12. doi: 10.12809/hkmj164875. Epub 2016 Dec 9.","Chan SY","Hong Kong Med J","2017","2016/12/10","","","10.12809/hkmj164875"
"12861739","Brachytherapy for prostate cancer: the patient's perspective","Ward-Smith P.","Urol Nurs. 2003 Jun;23(3):213-7.","Ward-Smith P","Urol Nurs","2003","2003/07/17","","",""
"16006858","Measuring the quality of care for localized prostate cancer","Miller DC, Montie JE, Wei JT.","J Urol. 2005 Aug;174(2):425-31. doi: 10.1097/01.ju.0000165387.20989.91.","Miller DC","J Urol","2005","2005/07/12","","","10.1097/01.ju.0000165387.20989.91"
"22208007","[Recurrence diagnosis of prostate cancer after radical prostatectomy]","Goto T, Kamoto T.","Nihon Rinsho. 2011 Jun;69 Suppl 5:385-9.","Goto T","Nihon Rinsho","2011","2012/01/03","","",""
"3079494","NIH Consensus Development Conference. Management of clinically localized prostate cancer","","Oncology (Williston Park). 1987 Nov;1(9):46-9, 54.","","Oncology (Williston Park)","1987","1987/11/01","","",""
"17199135","Global analysis of differentially expressed genes in androgen-independent prostate cancer","Wei Q, Li M, Fu X, Tang R, Na Y, Jiang M, Li Y.","Prostate Cancer Prostatic Dis. 2007;10(2):167-74. doi: 10.1038/sj.pcan.4500933. Epub 2007 Jan 2.","Wei Q","Prostate Cancer Prostatic Dis","2007","2007/01/03","","","10.1038/sj.pcan.4500933"
"16809161","Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique","Jani AB.","Cancer Invest. 2006 Apr-May;24(3):318-27. doi: 10.1080/07357900600633775.","Jani AB","Cancer Invest","2006","2006/07/01","","","10.1080/07357900600633775"
"18379587","Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era","Jones JS, Follis HW, Johnson JR.","Prostate Cancer Prostatic Dis. 2009;12(1):57-60. doi: 10.1038/pcan.2008.14. Epub 2008 Apr 1.","Jones JS","Prostate Cancer Prostatic Dis","2009","2008/04/02","","","10.1038/pcan.2008.14"
"18025909","Symptoms and symptom distress in localized prostate cancer","Hsiao CP, Loescher LJ, Moore IM.","Cancer Nurs. 2007 Nov-Dec;30(6):E19-32. doi: 10.1097/01.NCC.0000300163.13639.bc.","Hsiao CP","Cancer Nurs","2007","2007/11/21","","","10.1097/01.NCC.0000300163.13639.bc"
"16308711","[Diagnostics and treatment of prostate cancer after kidney transplantation]","Wicht A, Hamza A, Loertzer H, Dietl M, Heynemann H, Fornara P.","Urologe A. 2006 Jan;45(1):32-7. doi: 10.1007/s00120-005-0961-y.","Wicht A","Urologe A","2006","2005/11/26","","","10.1007/s00120-005-0961-y"
"19544546","Genomic approaches to outcome prediction in prostate cancer","Febbo PG.","Cancer. 2009 Jul 1;115(13 Suppl):3046-57. doi: 10.1002/cncr.24350.","Febbo PG","Cancer","2009","2009/06/23","","","10.1002/cncr.24350"
"23536478","Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication","Qin X, Zhang H, Ye D, Yao X, Zhang S, Dai B.","Andrology. 2013 May;1(3):512-6. doi: 10.1111/j.2047-2927.2013.00078.x. Epub 2013 Mar 28.","Qin X","Andrology","2013","2013/03/29","","","10.1111/j.2047-2927.2013.00078.x"
"24324078","Evaluation of stem cell marker gene expression in canine prostate carcinoma- and prostate cyst-derived cell lines","Moulay M, Liu W, Willenbrock S, Sterenczak KA, Carlson R, Ngezahayo A, Murua Escobar H, Nolte I.","Anticancer Res. 2013 Dec;33(12):5421-31.","Moulay M","Anticancer Res","2013","2013/12/11","","",""
"8020082","Is pre-treatment testosterone a prognostic factor in prostate cancer?","Akumabor PN.","Cent Afr J Med. 1993 Aug;39(8):170-2.","Akumabor PN","Cent Afr J Med","1993","1993/08/01","","",""
"29461871","Continuous, comprehensive and crucial care: The role of the CNS in the metastatic castration-resistant prostate cancer patient pathway","Basketter V, Benney M, Causer L, Fleure L, Hames D, Jones S, Patel K, White L.","Br J Nurs. 2018 Feb 1;27(Sup4b):S1-S8. doi: 10.12968/bjon.2018.27.Sup4b.S1.","Basketter V","Br J Nurs","2018","2018/02/21","","","10.12968/bjon.2018.27.Sup4b.S1"
"30350016","The importance of targeting intracrinology in prostate cancer management","Hamid ARAH, Tendi W, Sesari SS, Mochtar CA, Umbas R, Verhaegh G, Schalken JA.","World J Urol. 2019 May;37(5):751-757. doi: 10.1007/s00345-018-2529-7. Epub 2018 Oct 22.","Hamid ARAH","World J Urol","2019","2018/10/24","","","10.1007/s00345-018-2529-7"
"12735512","Complementary and alternative therapies","Cassileth BR, Vickers AJ.","Urol Clin North Am. 2003 May;30(2):369-76. doi: 10.1016/s0094-0143(02)00191-x.","Cassileth BR","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00191-x"
"23590811","Re: Markus Graefen, Thorsten Schlomm. Active surveillance for low-risk prostate cancer: some questions are answered, but many questions remain. Eur Urol 2013;63:604-5","Somford DM.","Eur Urol. 2013 Sep;64(3):e65-6. doi: 10.1016/j.eururo.2013.03.060. Epub 2013 Apr 11.","Somford DM","Eur Urol","2013","2013/04/18","","","10.1016/j.eururo.2013.03.060"
"29311125","Molecular Biomarkers in the Clinical Management of Prostate Cancer","Udager AM, Tomlins SA.","Cold Spring Harb Perspect Med. 2018 Nov 1;8(11):a030601. doi: 10.1101/cshperspect.a030601.","Udager AM","Cold Spring Harb Perspect Med","2018","2018/01/10","PMC6211380","","10.1101/cshperspect.a030601"
"27431620","Dickkopf 2 promotes proliferation and invasion via Wnt signaling in prostate cancer","Xu W, Pang K, Zhou ZG, Chen YF, Mo T, Li M, Liu CB.","Mol Med Rep. 2016 Sep;14(3):2283-8. doi: 10.3892/mmr.2016.5502. Epub 2016 Jul 11.","Xu W","Mol Med Rep","2016","2016/07/20","","","10.3892/mmr.2016.5502"
"23187933","The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review","Kachroo N, Gnanapragasam VJ.","J Cancer Res Clin Oncol. 2013 Jan;139(1):1-24. doi: 10.1007/s00432-012-1351-7. Epub 2012 Nov 28.","Kachroo N","J Cancer Res Clin Oncol","2013","2012/11/29","","","10.1007/s00432-012-1351-7"
"7545340","Prostate cancer screening--is the controversy resolved?","Norcross WA, Ganiats TG.","West J Med. 1995 Jul;163(1):65-6.","Norcross WA","West J Med","1995","1995/07/01","PMC1302920","",""
"28869990","Different Effects of Screening on Prostate Cancer Death in Two Trials","","Ann Intern Med. 2017 Oct 3;167(7). doi: 10.7326/P17-9043. Epub 2017 Sep 5.","","Ann Intern Med","2017","2017/09/05","","","10.7326/P17-9043"
"14678395","Sexual factors and prostate cancer","Brody S.","BJU Int. 2004 Jan;93(1):180. doi: 10.1111/j.1464-410x.2004.04581.x.","Brody S","BJU Int","2004","2003/12/18","","","10.1111/j.1464-410x.2004.04581.x"
"547163","Prostate cancer mimicking malignant lymphoma","Oster MW, Wolff M, Starrett S.","Med Pediatr Oncol. 1979;7(4):387-92. doi: 10.1002/mpo.2950070414.","Oster MW","Med Pediatr Oncol","1979","1979/01/01","","","10.1002/mpo.2950070414"
"7513895","[Sonographic diagnosis of prostatic cancer]","Hammerer PG.","Radiologe. 1994 Mar;34(3):116-21.","Hammerer PG","Radiologe","1994","1994/03/01","","",""
"16140113","Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer","Horinaga M, Okita H, Nakashima J, Kanao K, Sakamoto M, Murai M.","Urology. 2005 Sep;66(3):671-5. doi: 10.1016/j.urology.2005.03.066.","Horinaga M","Urology","2005","2005/09/06","","","10.1016/j.urology.2005.03.066"
"25199875","Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen?","Hu B, Goldkorn A.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1257-60. doi: 10.1586/14737140.2014.957190. Epub 2014 Sep 9.","Hu B","Expert Rev Anticancer Ther","2014","2014/09/10","","","10.1586/14737140.2014.957190"
"20159817","Castration-resistant prostate cancer--hormone therapy redux","Tolcher AW, Cooper J.","J Clin Oncol. 2010 Mar 20;28(9):1447-9. doi: 10.1200/JCO.2009.25.3781. Epub 2010 Feb 16.","Tolcher AW","J Clin Oncol","2010","2010/02/18","","","10.1200/JCO.2009.25.3781"
"20860834","Prognostic value of radical cystoprostatectomy in men with bladder cancer infiltrating prostate versus co-existing prostate cancer: a research study","Bryniarski P, Fryczkowski M, Pawlaczek P, Pliszek K, Prokopowicz G, Kaletka Z, Paradysz A.","BMC Urol. 2010 Sep 22;10:16. doi: 10.1186/1471-2490-10-16.","Bryniarski P","BMC Urol","2010","2010/09/24","PMC2954913","","10.1186/1471-2490-10-16"
"17465223","Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis","Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T.","Anticancer Res. 2007 Mar-Apr;27(2):933-6.","Yigit B","Anticancer Res","2007","2007/05/01","","",""
"29572963","Local treatment for metastatic prostate cancer: A systematic review","Tilki D, Pompe RS, Bandini M, Marchioni M, Kretschmer A, Tian Z, Karakiewicz PI, Evans CP.","Int J Urol. 2018 May;25(5):390-403. doi: 10.1111/iju.13535. Epub 2018 Mar 23.","Tilki D","Int J Urol","2018","2018/03/25","","","10.1111/iju.13535"
"26049369","Gene interference strategies as a new tool for the treatment of prostate cancer","Boccellino M, Alaia C, Misso G, Cossu AM, Facchini G, Piscitelli R, Quagliuolo L, Caraglia M.","Endocrine. 2015 Aug;49(3):588-605. doi: 10.1007/s12020-015-0629-3. Epub 2015 Jun 7.","Boccellino M","Endocrine","2015","2015/06/08","","","10.1007/s12020-015-0629-3"
"17760747","Initial evaluation of prostate cancer with real-time elastography based on step-section pathologic analysis after radical prostatectomy: a preliminary study","Sumura M, Shigeno K, Hyuga T, Yoneda T, Shiina H, Igawa M.","Int J Urol. 2007 Sep;14(9):811-6. doi: 10.1111/j.1442-2042.2007.01829.x.","Sumura M","Int J Urol","2007","2007/09/01","","","10.1111/j.1442-2042.2007.01829.x"
"15993579","Molecular changes in prostatic cancer","Bott SR, Arya M, Shergill IS, Williamson M.","Surg Oncol. 2005 Aug;14(2):91-104. doi: 10.1016/j.suronc.2005.05.003.","Bott SR","Surg Oncol","2005","2005/07/05","","","10.1016/j.suronc.2005.05.003"
"9412796","Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer","Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE.","Eur Urol. 1997;32(4):404-9.","Stattin P","Eur Urol","1997","1997/01/01","","",""
"25626247","[Management of prostate cancer in the elderly man]","Fenner V, Iselin CE.","Rev Med Suisse. 2014 Dec 3;10(453):2311-5.","Fenner V","Rev Med Suisse","2014","2015/01/29","","",""
"15311487","Shared decision making in patients with newly diagnosed prostate cancer: a model for treatment education and support","Colella KM, DeLuca G.","Urol Nurs. 2004 Jun;24(3):187-91, 195-6.","Colella KM","Urol Nurs","2004","2004/08/18","","",""
"8499136","Is vasectomy a risk factor for prostate cancer?","Guess HA.","Eur J Cancer. 1993;29A(7):1055-60. doi: 10.1016/s0959-8049(05)80223-0.","Guess HA","Eur J Cancer","1993","1993/01/01","","","10.1016/s0959-8049(05)80223-0"
"19027221","Editorial comment on: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review","Novara G.","Eur Urol. 2009 Apr;55(4):873-4. doi: 10.1016/j.eururo.2008.11.012. Epub 2008 Nov 21.","Novara G","Eur Urol","2009","2008/11/26","","","10.1016/j.eururo.2008.11.012"
"14767319","Re: histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications","Kumar H.","J Urol. 2004 Mar;171(3):1244. doi: 10.1097/01.ju.0000110461.09373.4f.","Kumar H","J Urol","2004","2004/02/10","","","10.1097/01.ju.0000110461.09373.4f"
"16333032","Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis","Gao X, LaValley MP, Tucker KL.","J Natl Cancer Inst. 2005 Dec 7;97(23):1768-77. doi: 10.1093/jnci/dji402.","Gao X","J Natl Cancer Inst","2005","2005/12/08","","","10.1093/jnci/dji402"
"30238772","Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?","Mather RL, Wang Y, Crea F.","Epigenomics. 2018 Oct;10(10):1259-1261. doi: 10.2217/epi-2018-0107. Epub 2018 Sep 21.","Mather RL","Epigenomics","2018","2018/09/22","","","10.2217/epi-2018-0107"
"11696701","Plasma selenium level before diagnosis and the risk of prostate cancer development","Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, Muller D, Andres R, Carter HB.","J Urol. 2001 Dec;166(6):2034-8.","Brooks JD","J Urol","2001","2001/11/07","","",""
"30929179","Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study","Abdel-Rahman O.","Clin Transl Oncol. 2019 Dec;21(12):1673-1679. doi: 10.1007/s12094-019-02098-8. Epub 2019 Mar 30.","Abdel-Rahman O","Clin Transl Oncol","2019","2019/04/01","","","10.1007/s12094-019-02098-8"
"23271772","Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring","Donovan JL.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):191-6. doi: 10.1093/jncimonographs/lgs030.","Donovan JL","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540874","","10.1093/jncimonographs/lgs030"
"10445987","Treating prostate cancer. Part II: watchful waiting","","Harv Mens Health Watch. 1999 Sep;4(2):3-6.","","Harv Mens Health Watch","1999","1999/08/13","","",""
"27188668","Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise","Palmbos PL, Hussain MH.","Oncology (Williston Park). 2016 May;30(5):377-85.","Palmbos PL","Oncology (Williston Park)","2016","2016/05/19","","",""
"1717134","The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy","Babaian RJ, Camps JL.","Cancer. 1991 Nov 1;68(9):2060-3. doi: 10.1002/1097-0142(19911101)68:9<2060::aid-cncr2820680936>3.0.co;2-i.","Babaian RJ","Cancer","1991","1991/11/01","","","10.1002/1097-0142(19911101)68:9<2060::aid-cncr2820680936>3.0.co;2-i"
"1512834","A screening study of prostate cancer in high risk families","McWhorter WP, Hernandez AD, Meikle AW, Terreros DA, Smith JA Jr, Skolnick MH, Cannon-Albright LA, Eyre HJ.","J Urol. 1992 Sep;148(3):826-8. doi: 10.1016/s0022-5347(17)36733-2.","McWhorter WP","J Urol","1992","1992/09/11","","","10.1016/s0022-5347(17)36733-2"
"12431251","HIP1 as a marker of aggressive prostate cancer","Chan EY.","Clin Genet. 2002 Nov;62(5):372-5. doi: 10.1034/j.1399-0004.2002.620503_4.x.","Chan EY","Clin Genet","2002","2002/11/15","","","10.1034/j.1399-0004.2002.620503_4.x"
"15889497","Radiotherapy versus surgery for prostate cancer","Bosch X.","Lancet Oncol. 2005 May;6(5):263. doi: 10.1016/s1470-2045(05)70150-9.","Bosch X","Lancet Oncol","2005","2005/05/14","","","10.1016/s1470-2045(05)70150-9"
"18166884","[Rectal cancer after radiation treatment for prostate cancer: radioinduced or chance association?]","Girodet J, Cosset JM, Asselain B, Salmon R.","Gastroenterol Clin Biol. 2007 Nov;31(11):957-8. doi: 10.1016/s0399-8320(07)78304-5.","Girodet J","Gastroenterol Clin Biol","2007","2008/01/02","","","10.1016/s0399-8320(07)78304-5"
"11370498","Improved outcomes with radiation for prostate cancer","Wallner K.","Hematol Oncol Clin North Am. 2001 Apr;15(2):359-75. doi: 10.1016/s0889-8588(05)70217-3.","Wallner K","Hematol Oncol Clin North Am","2001","2001/05/24","","","10.1016/s0889-8588(05)70217-3"
"12243659","Preperitoneal mesh-plug herniorraphy during radical retropubic prostatectomy","Drachenberg DE, Bell DG.","Can J Urol. 2002 Aug;9(4):1602-6.","Drachenberg DE","Can J Urol","2002","2002/09/24","","",""
"24914846","[New biomarkers to optimize the selection and follow up of patients with prostate cancer on active surveillance]","López-Guerrero JA, Casanova-Salas I, Fernández-Serra A, Rubio L, Calatrava A, García-Flores M, García-Casado Z, Rubio-Briones J.","Arch Esp Urol. 2014 Jun;67(5):462-72.","López-Guerrero JA","Arch Esp Urol","2014","2014/06/11","","",""
"8978401","Algorithms vie for diagnostic role in prostate cancer","Holzman D.","J Natl Cancer Inst. 1997 Jan 1;89(1):13-5. doi: 10.1093/jnci/89.1.13.","Holzman D","J Natl Cancer Inst","1997","1997/01/01","","","10.1093/jnci/89.1.13"
"25485280","A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer","Aoun F, Peltier A, van Velthoven R.","Biomed Res Int. 2014;2014:501213. doi: 10.1155/2014/501213. Epub 2014 Nov 17.","Aoun F","Biomed Res Int","2014","2014/12/09","PMC4251412","","10.1155/2014/501213"
"9529752","Screening and early detection for prostate cancer","Magoha GA.","East Afr Med J. 1997 Oct;74(10):664-7.","Magoha GA","East Afr Med J","1997","1998/04/08","","",""
"11832703","Expectant management of nonpalpable prostate cancer with curative intent: preliminary results","Carter HB, Walsh PC, Landis P, Epstein JI.","J Urol. 2002 Mar;167(3):1231-4.","Carter HB","J Urol","2002","2002/02/08","","",""
"17431367","Systemic strategies for prostate cancer","Armstrong AJ, Febbo PG, George DJ, Moul J.","Minerva Urol Nefrol. 2007 Mar;59(1):11-25.","Armstrong AJ","Minerva Urol Nefrol","2007","2007/04/14","","",""
"417774","Prostate cancer: progress and change","Murphy GP.","CA Cancer J Clin. 1978 Mar-Apr;28(2):104-15. doi: 10.3322/canjclin.28.2.104.","Murphy GP","CA Cancer J Clin","1978","1978/03/01","","","10.3322/canjclin.28.2.104"
"20716547","Whether Black men have a poorer prognosis compared with White men following a diagnosis of prostate cancer. Letter to the editor","Metcalfe C, Evans S, Ben-Shlomo Y.","Am J Mens Health. 2010 Sep;4(3):186-8. doi: 10.1177/1557988310379391.","Metcalfe C","Am J Mens Health","2010","2010/08/19","","","10.1177/1557988310379391"
"18093722","The search for better prognostic factors for men treated for localized prostate cancer continues","Karakiewicz PI, Suardi N, Shariat SF.","Eur Urol. 2008 Apr;53(4):689-90. doi: 10.1016/j.eururo.2007.12.009. Epub 2007 Dec 17.","Karakiewicz PI","Eur Urol","2008","2007/12/21","","","10.1016/j.eururo.2007.12.009"
"15371898","Re: racial/ethnic disparities in the treatment of localized/regional prostate cancer","Denberg TD.","J Urol. 2004 Oct;172(4 Pt 1):1547-8; author reply 1548. doi: 10.1016/s0022-5347(05)61227-x.","Denberg TD","J Urol","2004","2004/09/17","","","10.1016/s0022-5347(05)61227-x"
"11528106","Prostate cancer and the problem of genotype phenotype correlation","Vogel W, Maier C, Paiss T.","Cytogenet Cell Genet. 2001;93(3-4):162-7. doi: 10.1159/000056978.","Vogel W","Cytogenet Cell Genet","2001","2001/08/31","","","10.1159/000056978"
"18176088","The roles of PET and PET/CT in the diagnosis and management of prostate cancer","Takahashi N, Inoue T, Lee J, Yamaguchi T, Shizukuishi K.","Oncology. 2007;72(3-4):226-33. doi: 10.1159/000112946. Epub 2008 Jan 7.","Takahashi N","Oncology","2007","2008/01/08","","","10.1159/000112946"
"30100124","[Image guided radiation therapy for prostate cancer; how, when and why?]","Escande A, Supiot S.","Cancer Radiother. 2018 Oct;22(6-7):586-592. doi: 10.1016/j.canrad.2018.06.010. Epub 2018 Aug 9.","Escande A","Cancer Radiother","2018","2018/08/14","","","10.1016/j.canrad.2018.06.010"
"18281654","Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population","Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H.","J Clin Oncol. 2008 Feb 20;26(6):835-41. doi: 10.1200/JCO.2007.13.1490.","Ulmert D","J Clin Oncol","2008","2008/02/19","","","10.1200/JCO.2007.13.1490"
"3828960","Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy","Benson RC Jr, Gorman PA, O'Brien PC, Holicky EL, Veneziale CM.","Cancer. 1987 May 1;59(9):1599-606. doi: 10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v.","Benson RC Jr","Cancer","1987","1987/05/01","","","10.1002/1097-0142(19870501)59:9<1599::aid-cncr2820590913>3.0.co;2-v"
"7524306","Grading prostate cancer","Bostwick DG.","Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S38-56.","Bostwick DG","Am J Clin Pathol","1994","1994/10/01","","",""
"17563779","Early versus delayed intervention for prostate cancer: the case for early intervention","Loeb S, Catalona WJ.","Nat Clin Pract Urol. 2007 Jul;4(7):348-9. doi: 10.1038/ncpuro0838. Epub 2007 Jun 12.","Loeb S","Nat Clin Pract Urol","2007","2007/06/15","","","10.1038/ncpuro0838"
"19091392","Radiotherapy in locally advanced prostate cancer","Tan A, Parker C.","Lancet. 2009 Jan 24;373(9660):274-6. doi: 10.1016/S0140-6736(08)61816-4. Epub 2008 Dec 16.","Tan A","Lancet","2009","2008/12/19","","","10.1016/S0140-6736(08)61816-4"
"18271419","[Prostate cancer: comparative study of stage T1a and stage T1b]","Lefi M, Hellara W, Touffahi M, Fredj N, Adnene M, Saidi R, Saad H.","Prog Urol. 2007 Nov;17(7):1343-6. doi: 10.1016/s1166-7087(07)78574-3.","Lefi M","Prog Urol","2007","2008/02/15","","","10.1016/s1166-7087(07)78574-3"
"29488095","The impact of time to metastasis on overall survival in patients with prostate cancer","Frees S, Akamatsu S, Bidnur S, Khalaf D, Chavez-Munoz C, Struss W, Eigl BJ, Gleave M, Chi KN, So A.","World J Urol. 2018 Jul;36(7):1039-1046. doi: 10.1007/s00345-018-2236-4. Epub 2018 Feb 27.","Frees S","World J Urol","2018","2018/03/01","","","10.1007/s00345-018-2236-4"
"25934687","Regulation of tumor cell plasticity by the androgen receptor in prostate cancer","Bishop JL, Davies A, Ketola K, Zoubeidi A.","Endocr Relat Cancer. 2015 Jun;22(3):R165-82. doi: 10.1530/ERC-15-0137. Epub 2015 May 1.","Bishop JL","Endocr Relat Cancer","2015","2015/05/03","","","10.1530/ERC-15-0137"
"28847189","Does HERV-K represent a potential therapeutic target for prostate cancer?","Schulz WA.","Expert Opin Ther Targets. 2017 Oct;21(10):921-924. doi: 10.1080/14728222.2017.1373095. Epub 2017 Aug 30.","Schulz WA","Expert Opin Ther Targets","2017","2017/08/30","","","10.1080/14728222.2017.1373095"
"18459113","Stem cells: The root of prostate cancer?","Kasper S.","J Cell Physiol. 2008 Aug;216(2):332-6. doi: 10.1002/jcp.21489.","Kasper S","J Cell Physiol","2008","2008/05/07","","","10.1002/jcp.21489"
"19013009","Positive lymph nodes at lymphadenectomy for prostate cancer: where do we set the tiller?","Thalmann GN.","Eur Urol. 2009 Feb;55(2):271-2; discussion 273-4. doi: 10.1016/j.eururo.2008.10.039. Epub 2008 Nov 11.","Thalmann GN","Eur Urol","2009","2008/11/18","","","10.1016/j.eururo.2008.10.039"
"15610133","Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort","Okamoto H, Terai C, Kamatani N.","BJU Int. 2004 Dec;94(9):1401-2. doi: 10.1111/j.1464-410X.2004.05224_5.x.","Okamoto H","BJU Int","2004","2004/12/22","","","10.1111/j.1464-410X.2004.05224_5.x"
"10458358","Influence of sextant prostate needle biopsy or surgery on the detection and harvest of intact circulating prostate cancer cells","Polascik TJ, Wang ZP, Shue M, Di S, Gurganus RT, Hortopan SC, Ts'o PO, Partin AW.","J Urol. 1999 Sep;162(3 Pt 1):749-52. doi: 10.1097/00005392-199909010-00034.","Polascik TJ","J Urol","1999","1999/08/24","","","10.1097/00005392-199909010-00034"
"27431496","Increasing incidence of metastatic prostate cancer in the United States (2004-2013)","Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM.","Prostate Cancer Prostatic Dis. 2016 Dec;19(4):395-397. doi: 10.1038/pcan.2016.30. Epub 2016 Jul 19.","Weiner AB","Prostate Cancer Prostatic Dis","2016","2016/07/20","","","10.1038/pcan.2016.30"
"22487487","Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?","Liu Y, Vlatkovic L, Sæter T, Servoll E, Waaler G, Nesland JM, Giercksky KE, Axcrona K.","Int J Urol. 2012 Aug;19(8):749-56. doi: 10.1111/j.1442-2042.2012.03017.x. Epub 2012 Apr 4.","Liu Y","Int J Urol","2012","2012/04/11","","","10.1111/j.1442-2042.2012.03017.x"
"17341707","Advanced prostate cancer and postoperative radiotherapy","Sherr DL.","JAMA. 2007 Mar 7;297(9):950; author reply 951. doi: 10.1001/jama.297.9.950-a.","Sherr DL","JAMA","2007","2007/03/08","","","10.1001/jama.297.9.950-a"
"14767317","Re: diagnostic potential of serum proteomic patterns in prostate cancer","Diamandis EP.","J Urol. 2004 Mar;171(3):1244-5; author reply 124-5-64. doi: 10.1097/01.ju.0000112784.51142.bd.","Diamandis EP","J Urol","2004","2004/02/10","","","10.1097/01.ju.0000112784.51142.bd"
"8191763","Hormonal therapy for metastatic prostate cancer","Small EJ.","West J Med. 1994 Mar;160(3):253-4.","Small EJ","West J Med","1994","1994/03/01","PMC1022396","",""
"7010757","Roles of lymphangiography and pelvic lymphadenectomy in staging prostate cancer","Johnson DE, von Eschenbach AC.","Urology. 1981 Mar;17(Suppl 3):66-71.","Johnson DE","Urology","1981","1981/03/01","","",""
"5682546","Twenty single nodules of prostate cancer not treated by total prostatectomy","Cook GB, Watson FR.","J Urol. 1968 Nov;100(5):672-4. doi: 10.1016/s0022-5347(17)62595-3.","Cook GB","J Urol","1968","1968/11/01","","","10.1016/s0022-5347(17)62595-3"
"24123298","Assessment of relational intimacy: factor analysis of the personal assessment of intimacy in relationships questionnaire","Walker LM, Hampton A, Robinson JW.","Psychooncology. 2014 Mar;23(3):346-9. doi: 10.1002/pon.3416. Epub 2013 Oct 14.","Walker LM","Psychooncology","2014","2013/10/15","","","10.1002/pon.3416"
"18272022","Survival analyses overview in hormone-refractory prostate cancer clinical trials in the prostate-specific antigen era","Sartor O.","Clin Genitourin Cancer. 2007 Dec;5(7):420-1. doi: 10.3816/CGC.2007.n.028.","Sartor O","Clin Genitourin Cancer","2007","2008/02/15","","","10.3816/CGC.2007.n.028"
"9715372","Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features","López-Otín C, Diamandis EP.","Endocr Rev. 1998 Aug;19(4):365-96. doi: 10.1210/edrv.19.4.0337.","López-Otín C","Endocr Rev","1998","1998/08/26","","","10.1210/edrv.19.4.0337"
"15496636","Prostate cancer with low PSA levels","Beatty PA.","N Engl J Med. 2004 Oct 21;351(17):1802-3. doi: 10.1056/NEJM200410213511724.","Beatty PA","N Engl J Med","2004","2004/10/22","","","10.1056/NEJM200410213511724"
"12738338","Evaluating radiation therapy in prostate cancer","Lawrence G, Crawford J.","Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):599. doi: 10.1016/s0360-3016(03)00064-6.","Lawrence G","Int J Radiat Oncol Biol Phys","2003","2003/05/10","","","10.1016/s0360-3016(03)00064-6"
"22290249","Improvement in prostate cancer survival over time: a 20-year analysis","Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA.","Cancer J. 2012 Jan-Feb;18(1):1-8. doi: 10.1097/PPO.0b013e3182467419.","Kim MM","Cancer J","2012","2012/02/01","","","10.1097/PPO.0b013e3182467419"
"28370948","Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model","Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L, Grutters JPC, Sedelaar JPM, van Oort IM.","BJU Int. 2017 Nov;120(5):659-665. doi: 10.1111/bju.13861. Epub 2017 Apr 29.","Dijkstra S","BJU Int","2017","2017/04/04","","","10.1111/bju.13861"
"10574254","CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk","Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, Olsson H.","Br J Cancer. 1999 Oct;81(4):672-6. doi: 10.1038/sj.bjc.6690746.","Bratt O","Br J Cancer","1999","1999/11/26","PMC2362888","","10.1038/sj.bjc.6690746"
"16474813","Locally advanced prostate cancer treated with radiotherapy and androgen deprivation","Kirby R.","Nat Clin Pract Urol. 2005 Jun;2(6):304-8. doi: 10.1038/ncpuro0212.","Kirby R","Nat Clin Pract Urol","2005","2006/02/14","","","10.1038/ncpuro0212"
"7520030","Prostate cancer therapy: a recipe for confusion","See W.","Iowa Med. 1994 Jun;84(6):255-8.","See W","Iowa Med","1994","1994/06/01","","",""
"19482806","Understanding how masculine gender scripts may contribute to men's adjustment following treatment for prostate cancer","Burns SM, Mahalik JR.","Am J Mens Health. 2007 Dec;1(4):250-61. doi: 10.1177/1557988306293380. Epub 2007 May 23.","Burns SM","Am J Mens Health","2007","2009/06/02","","","10.1177/1557988306293380"
"12751912","Quality of life and economic considerations in the management of prostate cancer","Turini M, Redaelli A, Gramegna P, Radice D.","Pharmacoeconomics. 2003;21(8):527-41. doi: 10.2165/00019053-200321080-00001.","Turini M","Pharmacoeconomics","2003","2003/05/20","","","10.2165/00019053-200321080-00001"
"28186973","Upregulation of FAM84B during prostate cancer progression","Wong N, Gu Y, Kapoor A, Lin X, Ojo D, Wei F, Yan J, de Melo J, Major P, Wood G, Aziz T, Cutz JC, Bonert M, Patterson AJ, Tang D.","Oncotarget. 2017 Mar 21;8(12):19218-19235. doi: 10.18632/oncotarget.15168.","Wong N","Oncotarget","2017","2017/02/11","PMC5386679","","10.18632/oncotarget.15168"
"26613709","Predicting prostate cancer treatment choices: The role of numeracy, time discounting, and risk attitudes","López-Pérez B, Barnes A, Frosch DL, Hanoch Y.","J Health Psychol. 2017 May;22(6):788-797. doi: 10.1177/1359105315615931. Epub 2015 Nov 26.","López-Pérez B","J Health Psychol","2017","2015/11/29","","","10.1177/1359105315615931"
"27193789","Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer","Jadvar H.","Abdom Radiol (NY). 2016 May;41(5):889-98. doi: 10.1007/s00261-015-0563-0.","Jadvar H","Abdom Radiol (NY)","2016","2016/05/20","PMC5412588","NIHMS855662","10.1007/s00261-015-0563-0"
"1382317","Prostatic specific antigen in prostate cancer","Wozniak-Petrofsky J.","Urol Nurs. 1992 Sep;12(3):104-5.","Wozniak-Petrofsky J","Urol Nurs","1992","1992/09/01","","",""
"25421124","Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain","López-Abente G, Mispireta S, Pollán M.","BMC Cancer. 2014 Nov 24;14:874. doi: 10.1186/1471-2407-14-874.","López-Abente G","BMC Cancer","2014","2014/11/26","PMC4251688","","10.1186/1471-2407-14-874"
"9152164","Differences in patterns of care of prostate cancer, New South Wales, 1991","Carson P.","Aust N Z J Surg. 1997 May;67(5):296-7. doi: 10.1111/j.1445-2197.1997.tb01969.x.","Carson P","Aust N Z J Surg","1997","1997/05/01","","","10.1111/j.1445-2197.1997.tb01969.x"
"10686282","Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy","Scorilas A, Yu H, Soosaipillai AR, Gregorakis AK, Diamandis EP.","Clin Chim Acta. 2000 Feb 25;292(1-2):127-38. doi: 10.1016/s0009-8981(99)00211-9.","Scorilas A","Clin Chim Acta","2000","2000/02/25","","","10.1016/s0009-8981(99)00211-9"
"21359471","[Factors associated with prostate cancer screening: a population-based study]","Amorim VM, Barros MB, César CL, Goldbaum M, Carandina L, Alves MC.","Cad Saude Publica. 2011 Feb;27(2):347-56. doi: 10.1590/s0102-311x2011000200016.","Amorim VM","Cad Saude Publica","2011","2011/03/02","","","10.1590/s0102-311x2011000200016"
"19300265","Dietary intervention strategies to modulate prostate cancer risk and prognosis","Freedland SJ, Aronson WJ.","Curr Opin Urol. 2009 May;19(3):263-7. doi: 10.1097/MOU.0b013e328329ea6c.","Freedland SJ","Curr Opin Urol","2009","2009/03/21","","","10.1097/MOU.0b013e328329ea6c"
"19711743","[Impact of prostate cancer screening on mortality]","Robles JM.","Actas Urol Esp. 2009 Jun;33(6):619-20. doi: 10.1016/s0210-4806(09)74198-1.","Robles JM","Actas Urol Esp","2009","2009/08/29","","","10.1016/s0210-4806(09)74198-1"
"11807417","Prostate cancer at the beginning of the 21st century: more options and better outcomes","Pow-Sang JM.","Cancer Control. 2001 Nov-Dec;8(6):480-1. doi: 10.1177/107327480100800602.","Pow-Sang JM","Cancer Control","2001","2002/01/25","","","10.1177/107327480100800602"
"28423352","Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor","Huang J, Mondul AM, Weinstein SJ, Karoly ED, Sampson JN, Albanes D.","Oncotarget. 2017 Jul 11;8(28):45190-45199. doi: 10.18632/oncotarget.16775.","Huang J","Oncotarget","2017","2017/04/20","PMC5542177","","10.18632/oncotarget.16775"
"29494958","Abiraterone acetate in the treatment of prostate cancer","Thakur A, Roy A, Ghosh A, Chhabra M, Banerjee S.","Biomed Pharmacother. 2018 May;101:211-218. doi: 10.1016/j.biopha.2018.02.067. Epub 2018 Feb 26.","Thakur A","Biomed Pharmacother","2018","2018/03/02","","","10.1016/j.biopha.2018.02.067"
"21499278","Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer","Sartor O.","Asian J Androl. 2011 May;13(3):366-8. doi: 10.1038/aja.2011.23. Epub 2011 Apr 18.","Sartor O","Asian J Androl","2011","2011/04/19","PMC3739349","","10.1038/aja.2011.23"
"2683301","Staging of prostate cancer. Value of ultrasonography","Scardino PT, Shinohara K, Wheeler TM, Carter SS.","Urol Clin North Am. 1989 Nov;16(4):713-34.","Scardino PT","Urol Clin North Am","1989","1989/11/01","","",""
"16515496","Controversies of androgen ablation therapy for metastatic prostate cancer","Wilson SS, Crawford ED.","Curr Pharm Des. 2006;12(7):799-805. doi: 10.2174/138161206776056056.","Wilson SS","Curr Pharm Des","2006","2006/03/07","","","10.2174/138161206776056056"
"22213318","The roles of cytochrome P450 enzymes in prostate cancer development and treatment","Chen TC, Sakaki T, Yamamoto K, Kittaka A.","Anticancer Res. 2012 Jan;32(1):291-8.","Chen TC","Anticancer Res","2012","2012/01/04","","",""
"10664674","Imaging for recurrent prostate cancer","Nudell DM, Wefer AE, Hricak H, Carroll PR.","Radiol Clin North Am. 2000 Jan;38(1):213-29. doi: 10.1016/s0033-8389(05)70157-3.","Nudell DM","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70157-3"
"7796290","Controversies in the treatment of prostate cancer with maximal androgen deprivation","McLeod DG, Moul JW.","Surg Oncol Clin N Am. 1995 Apr;4(2):345-59.","McLeod DG","Surg Oncol Clin N Am","1995","1995/04/01","","",""
"11036336","[Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy]","Adolfsson J.","Lakartidningen. 2000 Sep 6;97(36):3870-4.","Adolfsson J","Lakartidningen","2000","2000/10/19","","",""
"12557701","[Treatment strategy of localized prostate cancer]","Maeda O.","Gan To Kagaku Ryoho. 2003 Jan;30(1):26-31.","Maeda O","Gan To Kagaku Ryoho","2003","2003/02/01","","",""
"8470854","Risk factors for prostate cancer","Pienta KJ, Esper PS.","Ann Intern Med. 1993 May 15;118(10):793-803. doi: 10.7326/0003-4819-118-10-199305150-00007.","Pienta KJ","Ann Intern Med","1993","1993/05/15","","","10.7326/0003-4819-118-10-199305150-00007"
"25343547","Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy","Chen J, Yan WG, Li HZ, Ji ZG, Zhou Y, Zhou ZE, Mai ZP.","Tumori. 2014 Sep-Oct;100(5):524-8. doi: 10.1700/1660.18170.","Chen J","Tumori","2014","2014/10/25","","","10.1700/1660.18170"
"7863051","[Screening of prostate cancer]","Caicoya M.","Rev Clin Esp. 1994 Dec;194(12):1034-42.","Caicoya M","Rev Clin Esp","1994","1994/12/01","","",""
"21657837","The need for personalized therapy and companion diagnostics in prostate cancer","Ablin RJ.","Biomark Med. 2011 Jun;5(3):281-3. doi: 10.2217/bmm.11.42.","Ablin RJ","Biomark Med","2011","2011/06/11","","","10.2217/bmm.11.42"
"10052879","Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy","Bylund A, Stattin P, Widmark A, Bergh A.","Radiother Oncol. 1998 Nov;49(2):143-8. doi: 10.1016/s0167-8140(98)00111-x.","Bylund A","Radiother Oncol","1998","1999/03/03","","","10.1016/s0167-8140(98)00111-x"
"9388518","[Prostate cancer]","Shimazaki J, Isaka S, Akakura K, Akimoto S, Morita S.","Gan To Kagaku Ryoho. 1997 Nov;24(14):2092-7.","Shimazaki J","Gan To Kagaku Ryoho","1997","1997/12/06","","",""
"31515026","Automatic gas detection in prostate cancer patients during image-guided radiation therapy using a deep convolutional neural network","Miura H, Ozawa S, Doi Y, Nakao M, Ohnishi K, Kenjo M, Nagata Y.","Phys Med. 2019 Aug;64:24-28. doi: 10.1016/j.ejmp.2019.06.009. Epub 2019 Jun 21.","Miura H","Phys Med","2019","2019/09/14","","","10.1016/j.ejmp.2019.06.009"
"32483877","High-throughput screen identifies 5-HT receptor as a modulator of AR and a therapeutic target for prostate cancer","Itsumi M, Shiota M, Sekino Y, Ushijima M, Kashiwagi E, Takeuchi A, Inokuchi J, Kajioka S, Uchiumi T, Eto M.","Prostate. 2020 Aug;80(11):885-894. doi: 10.1002/pros.24022. Epub 2020 Jun 1.","Itsumi M","Prostate","2020","2020/06/03","","","10.1002/pros.24022"
"15270587","The male lumpectomy: rationale for a cancer targeted approach for prostate cryoablation. A review","Onik G.","Technol Cancer Res Treat. 2004 Aug;3(4):365-70. doi: 10.1177/153303460400300406.","Onik G","Technol Cancer Res Treat","2004","2004/07/24","","","10.1177/153303460400300406"
"27188476","External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC","Poyet C, Wettstein MS, Lundon DJ, Bhindi B, Kulkarni GS, Saba K, Sulser T, Vickers AJ, Hermanns T.","J Urol. 2016 Nov;196(5):1402-1407. doi: 10.1016/j.juro.2016.05.081. Epub 2016 May 14.","Poyet C","J Urol","2016","2016/05/19","PMC5576554","NIHMS895841","10.1016/j.juro.2016.05.081"
"19223910","Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study","Eschwège P, Moutereau S, Droupy S, Douard R, Gala JL, Benoit G, Conti M, Manivet P, Loric S.","Br J Cancer. 2009 Feb 24;100(4):608-10. doi: 10.1038/sj.bjc.6604912.","Eschwège P","Br J Cancer","2009","2009/02/19","PMC2653745","","10.1038/sj.bjc.6604912"
"14713750","Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale","Lucia MS, Torkko KC.","J Urol. 2004 Feb;171(2 Pt 2):S30-4; discussion S35. doi: 10.1097/01.ju.0000108142.53241.47.","Lucia MS","J Urol","2004","2004/01/10","","","10.1097/01.ju.0000108142.53241.47"
"29368429","Accuracy of standardized 12-core template biopsies versus non-standardized biopsies for detection of Epstein Grade 5 prostate cancer regarding the histology of the prostatectomy specimen","Würnschimmel C, Grande P, Moschini M, Ferrari M, Mordasini L, Mattei A.","Prostate. 2018 Apr;78(5):365-369. doi: 10.1002/pros.23480. Epub 2018 Jan 25.","Würnschimmel C","Prostate","2018","2018/01/26","","","10.1002/pros.23480"
"24304020","Clinical innovations in urologic oncology","Williams RD.","Int J Urol. 1996 Jan;3(1 Suppl):S40. doi: 10.1111/j.1442-2042.1996.tb00082.x.","Williams RD","Int J Urol","1996","2013/12/06","","","10.1111/j.1442-2042.1996.tb00082.x"
"10093626","The long-awaited drop in prostate cancer mortality: what does it mean?","Levy IG.","Cancer Prev Control. 1998 Aug;2(4):159.","Levy IG","Cancer Prev Control","1998","1999/03/27","","",""
"11037556","Node-positive prostate cancer. American College of Radiology. ACR Appropriateness Criteria","Lee WR, Pollack A, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Paryani SB, Potters L, Roach M 3rd, Scardino P, Schellhammer P, Leibel S.","Radiology. 2000 Jun;215 Suppl:1413-8.","Lee WR","Radiology","2000","2000/10/19","","",""
"18837906","Radical prostatectomy","Hammad FT.","Ann N Y Acad Sci. 2008 Sep;1138:267-77. doi: 10.1196/annals.1414.032.","Hammad FT","Ann N Y Acad Sci","2008","2008/10/08","","","10.1196/annals.1414.032"
"12868707","Multiple primary neoplasms developing in a case of prostate cancer","Kulkarni D, Miller GA.","Ulster Med J. 2003 May;72(1):55-7.","Kulkarni D","Ulster Med J","2003","2003/07/19","PMC2475399","",""
"8190171","Conservative management of prostate cancer","Scardino PT, Beck JR, Miles BJ.","N Engl J Med. 1994 Jun 23;330(25):1831; author reply 1831-2.","Scardino PT","N Engl J Med","1994","1994/06/23","","",""
"22652234","Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?","Zumsteg ZS, Zelefsky MJ.","Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0.","Zumsteg ZS","Lancet Oncol","2012","2012/06/02","","","10.1016/S1470-2045(12)70084-0"
"22759881","The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study","Shafique K, Oliphant R, Morrison DS.","Br J Cancer. 2012 Jul 24;107(3):575-82. doi: 10.1038/bjc.2012.289. Epub 2012 Jul 3.","Shafique K","Br J Cancer","2012","2012/07/05","PMC3405226","","10.1038/bjc.2012.289"
"25459359","Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective","Stewart SB, Boorjian SA.","Urol Oncol. 2015 May;33(5):235-44. doi: 10.1016/j.urolonc.2014.10.003. Epub 2014 Nov 4.","Stewart SB","Urol Oncol","2015","2014/12/03","","","10.1016/j.urolonc.2014.10.003"
"27344710","[Alteration of androgen receptor cofactor in prostate cancer]","Tozawa K, Hashimoto Y, Yasui T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:93-8.","Tozawa K","Nihon Rinsho","2016","2016/06/28","","",""
"16548466","When prostate cancer strikes","Roberts G.","J Christ Nurs. 2006 Spring;23(2):6-11; quiz 12. doi: 10.1097/00005217-200605000-00003.","Roberts G","J Christ Nurs","2006","2006/03/22","","","10.1097/00005217-200605000-00003"
"30228706","Surgical Management for Prostate Cancer","Kim EH, Bullock AD.","Mo Med. 2018 Mar-Apr;115(2):142-145.","Kim EH","Mo Med","2018","2018/09/20","PMC6139865","",""
"16698363","Outcome after radical prostatectomy in young men with or without a family history of prostate cancer","Rouprêt M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O.","Urology. 2006 May;67(5):1028-32. doi: 10.1016/j.urology.2005.11.035.","Rouprêt M","Urology","2006","2006/05/16","","","10.1016/j.urology.2005.11.035"
"16238143","Imaging for prostate cancer","Carey BM.","Clin Oncol (R Coll Radiol). 2005 Oct;17(7):553-9. doi: 10.1016/j.clon.2005.07.003.","Carey BM","Clin Oncol (R Coll Radiol)","2005","2005/10/22","","","10.1016/j.clon.2005.07.003"
"15663358","Neuroendocrine cells in prostate cancer","Amorino GP, Parsons SJ.","Crit Rev Eukaryot Gene Expr. 2004;14(4):287-300. doi: 10.1615/critreveukaryotgeneexpr.v14.i4.40.","Amorino GP","Crit Rev Eukaryot Gene Expr","2004","2005/01/25","","","10.1615/critreveukaryotgeneexpr.v14.i4.40"
"31099786","Prostate Cancer: How Nurse Practitioners Can Aid in Disease Diagnosis and Management","Cadet M, Allen D, Patterson-Johnson J.","Clin J Oncol Nurs. 2019 Jun 1;23(3):247-250. doi: 10.1188/19.CJON.247-250.","Cadet M","Clin J Oncol Nurs","2019","2019/05/18","","","10.1188/19.CJON.247-250"
"15837975","Radioimmunotherapy of prostate cancer: does tumor size matter?","Scott AM.","J Clin Oncol. 2005 Jul 20;23(21):4567-9. doi: 10.1200/JCO.2005.01.903. Epub 2005 Apr 18.","Scott AM","J Clin Oncol","2005","2005/04/20","","","10.1200/JCO.2005.01.903"
"8853489","Quality of life and prostate cancer treatment: decision-making and rehabilitative support","Ritvo PG.","Can J Oncol. 1994 Nov;4 Suppl 1:43-5; discussion 46.","Ritvo PG","Can J Oncol","1994","1994/11/01","","",""
"22208015","[Radiation therapy for locally advanced prostate cancer]","Niwakawa M.","Nihon Rinsho. 2011 Jun;69 Suppl 5:424-6.","Niwakawa M","Nihon Rinsho","2011","2012/01/03","","",""
"20382633","Outcome of patients with localized prostate cancer treated by radiotherapy after confirming the absence of lymph node invasion","Suzuki N, Shimbo M, Amiya Y, Tomioka S, Shima T, Murakami S, Nakatsu H, Oota S, Shimazaki J.","Jpn J Clin Oncol. 2010 Jul;40(7):652-7. doi: 10.1093/jjco/hyq032. Epub 2010 Apr 8.","Suzuki N","Jpn J Clin Oncol","2010","2010/04/13","PMC2893779","","10.1093/jjco/hyq032"
"7167179","Proposal for a collaborative epidemiology study of prostate cancer in the Pacific Basin","Thomas DB, Kolonel LN, Ross RK, Thompson DJ.","Natl Cancer Inst Monogr. 1982;62:151-5.","Thomas DB","Natl Cancer Inst Monogr","1982","1982/01/01","","",""
"15555135","Prostate cancer (metastatic)","Michaelson MD, Smith MR, Talcott JA.","Clin Evid. 2003 Dec;(10):1012-22.","Michaelson MD","Clin Evid","2003","2004/11/24","","",""
"18478274","Forecasting changes in preference over the life span: a qualitative study of African-American men's prostate cancer decision making","Goldberg JH, Schwartz A.","Support Care Cancer. 2009 Jan;17(1):69-74. doi: 10.1007/s00520-008-0463-8. Epub 2008 May 14.","Goldberg JH","Support Care Cancer","2009","2008/05/15","","","10.1007/s00520-008-0463-8"
"26551285","Epithelial-mesenchymal transition in prostatic disease","Broster SA, Kyprianou N.","Future Oncol. 2015;11(23):3197-206. doi: 10.2217/fon.15.253. Epub 2015 Nov 9.","Broster SA","Future Oncol","2015","2015/11/10","","","10.2217/fon.15.253"
"27860454","Geographical miss of the prostate during image-guided radiotherapy with a 6-mm posterior expansion margin","Oates R, Jones D, Foroudi F, Gill S, Ramachandran P, Schneider M, Lim Joon M, Kron T.","J Med Radiat Sci. 2017 Jun;64(2):97-105. doi: 10.1002/jmrs.186. Epub 2016 Nov 8.","Oates R","J Med Radiat Sci","2017","2016/11/19","PMC5454331","","10.1002/jmrs.186"
"23496665","Prostate cancer vaccines","Michael A, Relph K, Annels N, Pandha H.","Expert Rev Vaccines. 2013 Mar;12(3):253-62. doi: 10.1586/erv.13.27.","Michael A","Expert Rev Vaccines","2013","2013/03/19","","","10.1586/erv.13.27"
"17937333","[Preliminary data of the Spanish contribution to the European Randomized Study on Screening of Prostate Cancer (ERSPC)]","Torres Zambrano G, Lujan Galán M, Pascual Mateo C, García Tello A, Rodríguez N, Berenguer Sánchez A.","Arch Esp Urol. 2007 Sep;60(7):737-43. doi: 10.4321/s0004-06142007000700003.","Torres Zambrano G","Arch Esp Urol","2007","2007/10/17","","","10.4321/s0004-06142007000700003"
"12496999","Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml","Egawa S, Suyama K, Takashima R, Kuwao S, Baba S.","Prostate Cancer Prostatic Dis. 2002;5(2):115-8. doi: 10.1038/sj.pcan.4500562.","Egawa S","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500562"
"18367315","Re: Axel Heidenreich, Gunnar Aus, Michel Bolla, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80","Kirollos M.","Eur Urol. 2008 Sep;54(3):693-5; author reply 695-7. doi: 10.1016/j.eururo.2008.03.002. Epub 2008 Mar 18.","Kirollos M","Eur Urol","2008","2008/03/28","","","10.1016/j.eururo.2008.03.002"
"10588970","Early androgen deprivation for prostate cancer?","Eisenberger MA, Walsh PC.","N Engl J Med. 1999 Dec 9;341(24):1837-8. doi: 10.1056/NEJM199912093412409.","Eisenberger MA","N Engl J Med","1999","1999/12/10","","","10.1056/NEJM199912093412409"
"21680808","Modeling prostate cancer in mice: limitations and opportunities","Hensley PJ, Kyprianou N.","J Androl. 2012 Mar-Apr;33(2):133-44. doi: 10.2164/jandrol.111.013987. Epub 2011 Jun 16.","Hensley PJ","J Androl","2012","2011/06/18","PMC3726197","NIHMS489384","10.2164/jandrol.111.013987"
"19261258","Trials of prostate-cancer screening are not worthwhile","Dubben HH.","Lancet Oncol. 2009 Mar;10(3):294-8. doi: 10.1016/S1470-2045(09)70066-X.","Dubben HH","Lancet Oncol","2009","2009/03/06","","","10.1016/S1470-2045(09)70066-X"
"19497171","Dietary intervention after definitive therapy for localized prostate cancer: results from a pilot study","Parsons JK, Newman VA, Mohler JL, Pierce JP, Flatt S, Messer K, Marshall J.","Can J Urol. 2009 Jun;16(3):4648-54.","Parsons JK","Can J Urol","2009","2009/06/06","","",""
"24737481","The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base","Martin JM, Handorf EA, Kutikov A, Uzzo RG, Bekelman JE, Horwitz EM, Smaldone MC.","Cancer. 2014 Jul 15;120(14):2114-21. doi: 10.1002/cncr.28697. Epub 2014 Apr 15.","Martin JM","Cancer","2014","2014/04/17","PMC4429530","NIHMS602747","10.1002/cncr.28697"
"11478141","[Neoadjuvant hormonal therapy for prostate cancer]","Miki T, Kamoi K.","Gan To Kagaku Ryoho. 2001 Jul;28(7):927-33.","Miki T","Gan To Kagaku Ryoho","2001","2001/08/02","","",""
"31161846","The evolving landscape of immunotherapy in advanced prostate cancer","Patel VG, Oh WK.","Immunotherapy. 2019 Jul;11(10):903-912. doi: 10.2217/imt-2019-0019. Epub 2019 Jun 4.","Patel VG","Immunotherapy","2019","2019/06/05","","","10.2217/imt-2019-0019"
"9883780","Increasing prostate cancer screening in African American men with peer-educator and client-navigator interventions","Weinrich SP, Boyd MD, Weinrich M, Greene F, Reynolds WA Jr, Metlin C.","J Cancer Educ. 1998 Winter;13(4):213-9. doi: 10.1080/08858199809528549.","Weinrich SP","J Cancer Educ","1998","1999/01/12","","","10.1080/08858199809528549"
"28743224","Isolated testicular prostate cancer metastasis","Maibom SL, Jacobsen A, Hansen RB, Brasso K.","Scand J Urol. 2017 Oct;51(5):426-427. doi: 10.1080/21681805.2017.1347818. Epub 2017 Jul 26.","Maibom SL","Scand J Urol","2017","2017/07/27","","","10.1080/21681805.2017.1347818"
"25358908","Surgical treatment of high-risk prostate cancer","Soares R, Eden CG.","Minerva Urol Nefrol. 2015 Mar;67(1):33-46. Epub 2014 Oct 31.","Soares R","Minerva Urol Nefrol","2015","2014/11/01","","",""
"11403817","Fatty fish consumption and risk of prostate cancer","Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A.","Lancet. 2001 Jun 2;357(9270):1764-6. doi: 10.1016/S0140-6736(00)04889-3.","Terry P","Lancet","2001","2001/06/14","","","10.1016/S0140-6736(00)04889-3"
"8336985","Comparison of prostate cancer patients with and without pain","Heim HM, Oei TP.","Pain. 1993 May;53(2):159-62. doi: 10.1016/0304-3959(93)90075-z.","Heim HM","Pain","1993","1993/05/01","","","10.1016/0304-3959(93)90075-z"
"29107281","Prostate Cancer","Bjurlin MA, Taneja SS.","Urol Clin North Am. 2017 Nov;44(4):xv-xvi. doi: 10.1016/j.ucl.2017.08.001.","Bjurlin MA","Urol Clin North Am","2017","2017/11/07","","","10.1016/j.ucl.2017.08.001"
"28970333","Will GRPR Compete with PSMA as a Target in Prostate Cancer?","Iagaru A.","J Nucl Med. 2017 Dec;58(12):1883-1884. doi: 10.2967/jnumed.117.198192. Epub 2017 Sep 28.","Iagaru A","J Nucl Med","2017","2017/10/04","","","10.2967/jnumed.117.198192"
"3230343","[Clinical significance of nuclear DNA contents in prostate cancer]","Fujimoto Y.","Nihon Gan Chiryo Gakkai Shi. 1988 Jun 20;23(6):1265-76.","Fujimoto Y","Nihon Gan Chiryo Gakkai Shi","1988","1988/06/20","","",""
"9099454","A comparison of prostate cancer treatments: are therapeutic implications justified?","Scardino PT, Hanks GE.","Cancer J Sci Am. 1997 Mar-Apr;3(2):70-2.","Scardino PT","Cancer J Sci Am","1997","1997/03/01","","",""
"17704029","Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies","Qin LQ, Xu JY, Wang PY, Tong J, Hoshi K.","Asia Pac J Clin Nutr. 2007;16(3):467-76.","Qin LQ","Asia Pac J Clin Nutr","2007","2007/08/21","","",""
"26032541","Prostate cancer: Treatment with ADT impairs cognitive performance","Sidaway P.","Nat Rev Urol. 2015 Jul;12(7):361. doi: 10.1038/nrurol.2015.126. Epub 2015 May 26.","Sidaway P","Nat Rev Urol","2015","2015/06/03","","","10.1038/nrurol.2015.126"
"23775347","Prostate cancer imaging","Picchio M, Piert M.","Eur J Nucl Med Mol Imaging. 2013 Jul;40 Suppl 1:S1-4. doi: 10.1007/s00259-013-2444-5.","Picchio M","Eur J Nucl Med Mol Imaging","2013","2013/06/19","","","10.1007/s00259-013-2444-5"
"12697667","Androgen receptor: good guy or bad guy in prostate cancer invasion?","Baldi E, Bonaccorsi L, Forti G.","Endocrinology. 2003 May;144(5):1653-5. doi: 10.1210/en.2003-0234.","Baldi E","Endocrinology","2003","2003/04/17","","","10.1210/en.2003-0234"
"9751360","Complications of treatment for localized prostate cancer","Fowler JE Jr.","J Urol. 1998 Oct;160(4):1386. doi: 10.1016/s0022-5347(01)62544-8.","Fowler JE Jr","J Urol","1998","1998/09/29","","","10.1016/s0022-5347(01)62544-8"
"12212509","[Prostate cancer, generalized screening soon?]","Girault V.","Presse Med. 2002 Aug 10;31(26):1205.","Girault V","Presse Med","2002","2002/09/06","","",""
"15821599","Re: impact of surgical delay on long-term cancer control for clinically localized prostate cancer","Rao AR, Karim OM.","J Urol. 2005 May;173(5):1827-8. doi: 10.1097/00005392-200505000-00148.","Rao AR","J Urol","2005","2005/04/12","","","10.1097/00005392-200505000-00148"
"12270375","Relevance and meaning of prostate cancer in kidney transplantation","Schönberger B, Giessing M, Vogler H, Budde K, Loening S.","Transplant Proc. 2002 Sep;34(6):2225-6. doi: 10.1016/s0041-1345(02)03213-x.","Schönberger B","Transplant Proc","2002","2002/09/25","","","10.1016/s0041-1345(02)03213-x"
"8126745","Prostate cancer: perceptions of African-American males","Price JH, Colvin TL, Smith D.","J Natl Med Assoc. 1993 Dec;85(12):941-7.","Price JH","J Natl Med Assoc","1993","1993/12/01","PMC2568199","",""
"9836554","Urinary symptoms, potency, and quality of life in patients with localized prostate cancer followed up with deferred treatment","Jønler M, Nielsen OS, Wolf H.","Urology. 1998 Dec;52(6):1055-62; discussion 1063. doi: 10.1016/s0090-4295(98)00449-x.","Jønler M","Urology","1998","1998/12/04","","","10.1016/s0090-4295(98)00449-x"
"30842174","Prostate Cancer Diagnosis and Management Across Twenty Years of Clinical Practice: A Single-center Experience on 2,500 Cases","Pepe P, Pennisi M.","Anticancer Res. 2019 Mar;39(3):1397-1401. doi: 10.21873/anticanres.13254.","Pepe P","Anticancer Res","2019","2019/03/08","","","10.21873/anticanres.13254"
"31566779","Impact of positive surgical margins on secondary treatment, palliative radiotherapy and prostate cancer-specific mortality. A population-based study of 13 198 patients","Kvåle R, Myklebust TÅ, Fosså SD, Aas K, Ekanger C, Helle SI, Honoré A, Møller B.","Prostate. 2019 Dec;79(16):1852-1860. doi: 10.1002/pros.23911. Epub 2019 Sep 30.","Kvåle R","Prostate","2019","2019/10/01","","","10.1002/pros.23911"
"31434999","Genomics and risk stratification in high-risk prostate cancer","Al Hussein Al Awamlh B, Shoag JE.","Nat Rev Urol. 2019 Nov;16(11):641-642. doi: 10.1038/s41585-019-0227-x.","Al Hussein Al Awamlh B","Nat Rev Urol","2019","2019/08/23","","","10.1038/s41585-019-0227-x"
"26072634","Morphology of treatment-related changes in the prostate and prostatic cancer","Volavšek M.","Anal Quant Cytopathol Histpathol. 2015 Feb;37(1):48-56.","Volavšek M","Anal Quant Cytopathol Histpathol","2015","2015/06/16","","",""
"9674725","Prostate cancer screening: practice what the evidence preaches","Wilt TJ.","Am J Med. 1998 Jun;104(6):602-4. doi: 10.1016/s0002-9343(98)00127-2.","Wilt TJ","Am J Med","1998","1998/07/23","","","10.1016/s0002-9343(98)00127-2"
"20677622","[Pathohistological diagnosis of prostatic carcinoma in needle core biopsies]","Kruslin B, Tomas D, Spajić B.","Lijec Vjesn. 2010 May-Jun;132(5-6):155-61.","Kruslin B","Lijec Vjesn","2010","2010/08/04","","",""
"19855155","Further analysis of the survival benefit of clodronate","Aragon-Ching JB.","Cancer Biol Ther. 2009 Dec;8(23):2221-2. doi: 10.4161/cbt.8.23.10203. Epub 2009 Dec 30.","Aragon-Ching JB","Cancer Biol Ther","2009","2009/10/27","","","10.4161/cbt.8.23.10203"
"19199907","Targeted therapies for prostate cancer against the prostate specific membrane antigen","Elsässer-Beile U, Bühler P, Wolf P.","Curr Drug Targets. 2009 Feb;10(2):118-25. doi: 10.2174/138945009787354601.","Elsässer-Beile U","Curr Drug Targets","2009","2009/02/10","","","10.2174/138945009787354601"
"16520652","Managing locally advanced prostate cancer: a urologist's and a patient's perspective","Kirby R, Offen N.","Anticancer Drugs. 2006 Mar;17(3):245-50. doi: 10.1097/00001813-200603000-00002.","Kirby R","Anticancer Drugs","2006","2006/03/08","","","10.1097/00001813-200603000-00002"
"11748582","Molecular markers and determinants of prostate cancer metastasis","Gopalkrishnan RV, Kang DC, Fisher PB.","J Cell Physiol. 2001 Dec;189(3):245-56. doi: 10.1002/jcp.10023.","Gopalkrishnan RV","J Cell Physiol","2001","2001/12/19","","","10.1002/jcp.10023"
"26689247","Gene expression profiling of prostate cancer-associated genes identifies fibromodulin as potential novel biomarker for prostate cancer","Bettin A, Reyes I, Reyes N.","Int J Biol Markers. 2016 May 28;31(2):e153-62. doi: 10.5301/jbm.5000184.","Bettin A","Int J Biol Markers","2016","2015/12/23","","","10.5301/jbm.5000184"
"19713548","Contemporary risk profile of prostate cancer in the United States","Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, Dipaola RS, Lu-Yao GL.","J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3. doi: 10.1093/jnci/djp262. Epub 2009 Aug 27.","Shao YH","J Natl Cancer Inst","2009","2009/08/29","PMC2744729","","10.1093/jnci/djp262"
"25793920","Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM)","Pinto Á, Pérez Segura P.","Eur J Cancer Prev. 2016 Mar;25(2):137-41. doi: 10.1097/CEJ.0000000000000149.","Pinto Á","Eur J Cancer Prev","2016","2015/03/21","","","10.1097/CEJ.0000000000000149"
"10325517","Practical aspects of clinical trials on chemoprevention of prostate cancer","van der Meijden AP.","Eur Urol. 1999;35(5-6):515-8. doi: 10.1159/000019891.","van der Meijden AP","Eur Urol","1999","1999/05/15","","","10.1159/000019891"
"21951841","The role of surgery in high-risk localised prostate cancer","Gnanapragasam VJ, Mason MD, Shaw GL, Neal DE.","BJU Int. 2012 Mar;109(5):648-58. doi: 10.1111/j.1464-410X.2011.10596.x. Epub 2011 Sep 27.","Gnanapragasam VJ","BJU Int","2012","2011/09/29","","","10.1111/j.1464-410X.2011.10596.x"
"4216125","Radiotherapy combined with hormone therapy for prostate cancer","Tsuya A, Kawai T, Fukushima S, Shida K, Shimazaki J.","Strahlentherapie. 1974 Jul;148(1):24-34.","Tsuya A","Strahlentherapie","1974","1974/07/01","","",""
"30624125","The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis","Jønck S, Helgstrand JT, Røder MA, Klemann N, Grønkaer Toft B, Brasso K.","Scand J Urol. 2018 Oct-Dec;52(5-6):358-363. doi: 10.1080/21681805.2018.1534885. Epub 2019 Jan 9.","Jønck S","Scand J Urol","2018","2019/01/10","","","10.1080/21681805.2018.1534885"
"19465335","[Surgical's innovations and perspectives in management of localized prostate cancer]","Drouin SJ, Rouprêt M.","Prog Urol. 2009 Apr;19 Suppl 1:S8-S11. doi: 10.1016/S1166-7087(09)73899-0.","Drouin SJ","Prog Urol","2009","2009/05/26","","","10.1016/S1166-7087(09)73899-0"
"28376608","Decision-making tools in prostate cancer: from risk grouping to nomograms","Fontanella P, Benecchi L, Grasso A, Patel V, Albala D, Abbou C, Porpiglia F, Sandri M, Rocco B, Bianchi G.","Minerva Urol Nefrol. 2017 Dec;69(6):556-566. doi: 10.23736/S0393-2249.17.02832-6. Epub 2017 Mar 30.","Fontanella P","Minerva Urol Nefrol","2017","2017/04/06","","","10.23736/S0393-2249.17.02832-6"
"7384080","Models for prostate cancer","","Prog Clin Biol Res. 1980;37:1-397.","","Prog Clin Biol Res","1980","1980/01/01","","",""
"29620061","Prostate cancer: Quality of life during chemohormonal therapy","Thoma C.","Nat Rev Urol. 2018 May;15(5):263. doi: 10.1038/nrurol.2018.44. Epub 2018 Apr 5.","Thoma C","Nat Rev Urol","2018","2018/04/06","","","10.1038/nrurol.2018.44"
"17018724","Biomarkers and screening for prostate cancer","Schröder FH.","Ann Oncol. 2006 Sep;17 Suppl 10:x201-6. doi: 10.1093/annonc/mdl260.","Schröder FH","Ann Oncol","2006","2006/10/05","","","10.1093/annonc/mdl260"
"7772144","Screening for prostate cancer","Miles BJ, Kattan MW, Giesler RB, Cowen M.","JAMA. 1995 Apr 19;273(15):1173-4; author reply 1175-6. doi: 10.1001/jama.1995.03520390031018.","Miles BJ","JAMA","1995","1995/04/19","","","10.1001/jama.1995.03520390031018"
"22258371","[How should hormone therapy for castration-resistant prostate cancer be continued?]","Spahn M, Krebs M.","Urologe A. 2012 Jan;51(1):15-9. doi: 10.1007/s00120-011-2738-9.","Spahn M","Urologe A","2012","2012/01/20","","","10.1007/s00120-011-2738-9"
"23959841","Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer","Alva A, Hussain M.","Drugs. 2013 Sep;73(14):1517-24. doi: 10.1007/s40265-013-0106-3.","Alva A","Drugs","2013","2013/08/21","","","10.1007/s40265-013-0106-3"
"18061372","Associations between timing of exposure to ultraviolet radiation, T-stage and survival in prostate cancer","Rukin N, Blagojevic M, Luscombe CJ, Liu S, Saxby MF, Ramachandran S, Fryer AA, Jones PW, Strange RC.","Cancer Detect Prev. 2007;31(6):443-9. doi: 10.1016/j.cdp.2007.10.017.","Rukin N","Cancer Detect Prev","2007","2007/12/07","","","10.1016/j.cdp.2007.10.017"
"15471196","Intermediate- to high-risk prostate cancer patient treated with radiation therapy","Crawford ED, Barqawi A.","Oncology (Williston Park). 2004 Aug;18(9):1105-10.","Crawford ED","Oncology (Williston Park)","2004","2004/10/09","","",""
"27344708","[Mechanism of development and progression in prostate cancer: Overview]","Teishima J, Matsubara A.","Nihon Rinsho. 2016 May 20;74 Suppl 3:80-6.","Teishima J","Nihon Rinsho","2016","2016/06/28","","",""
"25618151","Studies see value of prostate cancer diagnostic test, but will CMS pay for it?","Caffrey MK.","Am J Manag Care. 2014 Aug;20(11 Spec No.):E9.","Caffrey MK","Am J Manag Care","2014","2015/01/26","","",""
"20152524","Novel targeted therapies for prostate cancer","Macfarlane RJ, Chi KN.","Urol Clin North Am. 2010 Feb;37(1):105-19, Table of Contents. doi: 10.1016/j.ucl.2009.11.011.","Macfarlane RJ","Urol Clin North Am","2010","2010/02/16","","","10.1016/j.ucl.2009.11.011"
"32487653","Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series","Suzuki K, Terakawa T, Jimbo N, Inaba R, Nakano Y, Fujisawa M.","Anticancer Res. 2020 Jun;40(6):3519-3526. doi: 10.21873/anticanres.14340.","Suzuki K","Anticancer Res","2020","2020/06/04","","","10.21873/anticanres.14340"
"8116131","Counseling the patient with localized prostate cancer","Montie JE.","Urology. 1994 Feb;43(2 Suppl):36-40. doi: 10.1016/0090-4295(94)90216-x.","Montie JE","Urology","1994","1994/02/01","","","10.1016/0090-4295(94)90216-x"
"26605852","Pelvis Plus Prostate Radiation Therapy and the Risk of Death in Men With Newly Diagnosed Node-Positive Prostate Cancer","D'Amico AV.","JAMA Oncol. 2016 Mar;2(3):357-8. doi: 10.1001/jamaoncol.2015.4342.","D'Amico AV","JAMA Oncol","2016","2015/11/26","","","10.1001/jamaoncol.2015.4342"
"25666893","Are androgen receptor variants a substitute for the full-length receptor?","Lu J, Van der Steen T, Tindall DJ.","Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10.","Lu J","Nat Rev Urol","2015","2015/02/11","","","10.1038/nrurol.2015.13"
"21784232","Baculoviruses as gene therapy vectors for human prostate cancer","Rivera-Gonzalez GC, Swift SL, Dussupt V, Georgopoulos LJ, Maitland NJ.","J Invertebr Pathol. 2011 Jul;107 Suppl:S59-70. doi: 10.1016/j.jip.2011.05.006.","Rivera-Gonzalez GC","J Invertebr Pathol","2011","2011/07/26","","","10.1016/j.jip.2011.05.006"
"7713123","Conservative approach to the management of prostate cancer. A critical review","Gerber GS.","Eur Urol. 1994;26(4):271-5. doi: 10.1159/000475398.","Gerber GS","Eur Urol","1994","1994/01/01","","","10.1159/000475398"
"28688745","[2017 ASCO: Complete androgen blockade strikes back]","Penel N.","Bull Cancer. 2017 Jul-Aug;104(7-8):599-601. doi: 10.1016/j.bulcan.2017.06.001. Epub 2017 Jul 5.","Penel N","Bull Cancer","2017","2017/07/10","","","10.1016/j.bulcan.2017.06.001"
"22278167","[Temporal changes in quality of life after prostate carcinoma]","Perl M, Waldmann A, Pritzkuleit R, Katalinic A.","Urologe A. 2012 May;51(5):706-12. doi: 10.1007/s00120-011-2788-z.","Perl M","Urologe A","2012","2012/01/27","","","10.1007/s00120-011-2788-z"
"25816659","[The observed and relative survival of prostate cancer patients]","Merabishvili VM, Atroshchenko AV, Kharitonov MV.","Vopr Onkol. 2014;60(5):563-70.","Merabishvili VM","Vopr Onkol","2014","2015/03/31","","",""
"9155166","[Mechanism on androgen-independent progression of prostate cancer]","Shimazaki J, Akakura K, Furuya Y, Ito H.","Nihon Rinsho. 1997 May;55(5):1143-8.","Shimazaki J","Nihon Rinsho","1997","1997/05/01","","",""
"29368341","Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","Isaacsson Velho P, Silberstein JL, Markowski MC, Luo J, Lotan TL, Isaacs WB, Antonarakis ES.","Prostate. 2018 Apr;78(5):401-407. doi: 10.1002/pros.23484. Epub 2018 Jan 25.","Isaacsson Velho P","Prostate","2018","2018/01/26","PMC6524639","NIHMS1025805","10.1002/pros.23484"
"1989452","Transrectal ultrasound: a new screening tool for prostate cancer","Martin JP.","Am J Nurs. 1991 Feb;91(2):69. doi: 10.1097/00000446-199102000-00026.","Martin JP","Am J Nurs","1991","1991/02/01","","","10.1097/00000446-199102000-00026"
"10701369","Radiation therapy options in the treatment of prostate cancer","Pollack JM.","Cancer Invest. 2000;18(1):66-77. doi: 10.3109/07357900009023064.","Pollack JM","Cancer Invest","2000","2000/03/04","","","10.3109/07357900009023064"
"17874231","[Is there an indication for adjuvant or neoadjuvant systemic therapy in prostate cancer?]","Börgermann C, Miller K, vom Dorp F, Jäger T, Rübben H.","Urologe A. 2007 Oct;46(10):1385-6, 1388. doi: 10.1007/s00120-007-1544-x.","Börgermann C","Urologe A","2007","2007/09/18","","","10.1007/s00120-007-1544-x"
"20870581","[Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer]","Yousra S, Rafik E, Manel M, Kacem M.","Ann Biol Clin (Paris). 2010 Sep-Oct;68(5):585-93. doi: 10.1684/abc.2010.0481.","Yousra S","Ann Biol Clin (Paris)","2010","2010/09/28","","","10.1684/abc.2010.0481"
"28212369","Prognostic biomarkers in early-stage prostate cancer","Klein E.","Clin Adv Hematol Oncol. 2017 Jan;15(1):43-45.","Klein E","Clin Adv Hematol Oncol","2017","2017/02/18","","",""
"17987815","Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer","Mazzucchelli R, Barbisan F, Galosi AB.","Anal Quant Cytol Histol. 2007 Oct;29(5):339-40.","Mazzucchelli R","Anal Quant Cytol Histol","2007","2007/11/09","","",""
"26174117","The Effects of Social Support on Health-Related Quality of Life of Patients with Metastatic Prostate Cancer","Colloca G, Colloca P.","J Cancer Educ. 2016 Jun;31(2):244-52. doi: 10.1007/s13187-015-0884-2.","Colloca G","J Cancer Educ","2016","2015/07/16","","","10.1007/s13187-015-0884-2"
"1719940","[Prostate cancer--treatment of hormone independent cancer]","Yamanaka H, Imai K, Suzuki T, Masimo T.","Gan To Kagaku Ryoho. 1991 Nov;18(14):2390-5.","Yamanaka H","Gan To Kagaku Ryoho","1991","1991/11/01","","",""
"16945120","Detection of clinical unilateral T3a prostate cancer - by digital rectal examination or transrectal ultrasonography?","Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H.","BJU Int. 2006 Nov;98(5):982-5. doi: 10.1111/j.1464-410X.2006.06452.x. Epub 2006 Aug 31.","Hsu CY","BJU Int","2006","2006/09/02","","","10.1111/j.1464-410X.2006.06452.x"
"18550127","Cryotherapy for prostate cancer: what we know, what we need to know","Theodorescu D.","J Urol. 2008 Aug;180(2):437-8. doi: 10.1016/j.juro.2008.05.081. Epub 2008 Jun 11.","Theodorescu D","J Urol","2008","2008/06/14","","","10.1016/j.juro.2008.05.081"
"15509525","Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile","Liu AY, Roudier MP, True LD.","Am J Pathol. 2004 Nov;165(5):1543-56. doi: 10.1016/S0002-9440(10)63412-8.","Liu AY","Am J Pathol","2004","2004/10/29","PMC1618667","","10.1016/S0002-9440(10)63412-8"
"12500849","The conundrum of prostate cancer","Albertsen PC.","Cancer J. 2002 Nov-Dec;8(6):432-4. doi: 10.1097/00130404-200211000-00004.","Albertsen PC","Cancer J","2002","2002/12/26","","","10.1097/00130404-200211000-00004"
"16197614","Molecular effects of the isoflavonoid genistein in prostate cancer","Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G, Klocker H.","Clin Prostate Cancer. 2005 Sep;4(2):124-9. doi: 10.3816/cgc.2005.n.021.","Bektic J","Clin Prostate Cancer","2005","2005/10/04","","","10.3816/cgc.2005.n.021"
"12017659","Researchers study quality of life after prostate cancer","","ONS News. 2000 Aug;15(8):13.","","ONS News","2000","2002/05/23","","",""
"6399611","Radical surgery for stage D1 prostate cancer","Zincke H, Utz DC.","Semin Urol. 1983 Nov;1(4):253-60.","Zincke H","Semin Urol","1983","1983/11/01","","",""
"27853089","Disseminated Mycobacterium tuberculosis Infection Masquerading as Metastasis after Heavy Ion Radiotherapy for Prostate Cancer","Ando M, Mukai Y, Ushijima RI, Shioyama Y, Umeki K, Okada F, Nureki SI, Mimata H, Kadota JI.","Intern Med. 2016;55(22):3387-3392. doi: 10.2169/internalmedicine.55.7039. Epub 2016 Nov 15.","Ando M","Intern Med","2016","2016/11/18","PMC5173514","","10.2169/internalmedicine.55.7039"
"9581595","Prostate cancer in the serum prostate-specific antigen era","Humphrey PA.","Mayo Clin Proc. 1998 May;73(5):489-90. doi: 10.1016/S0025-6196(11)63737-3.","Humphrey PA","Mayo Clin Proc","1998","1998/05/15","","","10.1016/S0025-6196(11)63737-3"
"21773817","The association between height and prostate cancer grade in the Early Stage Prostate Cancer Cohort Study","Farwell WR, Lourenco C, Holmberg E, Hall RB, D'Avolio L, Lawler EV, Michael Gaziano J.","Cancer Causes Control. 2011 Oct;22(10):1453-9. doi: 10.1007/s10552-011-9820-x. Epub 2011 Jul 20.","Farwell WR","Cancer Causes Control","2011","2011/07/21","PMC4428304","NIHMS618795","10.1007/s10552-011-9820-x"
"20647991","Diet and prostate cancer: mechanisms of action and implications for chemoprevention","Venkateswaran V, Klotz LH.","Nat Rev Urol. 2010 Aug;7(8):442-53. doi: 10.1038/nrurol.2010.102. Epub 2010 Jul 20.","Venkateswaran V","Nat Rev Urol","2010","2010/07/22","","","10.1038/nrurol.2010.102"
"21846212","Early detection of prostate cancer: is screening in general practice justifiable?","Sigurdsson EL.","Scand J Prim Health Care. 2011 Sep;29(3):133-4. doi: 10.3109/02813432.2011.602555. Epub 2011 Aug 16.","Sigurdsson EL","Scand J Prim Health Care","2011","2011/08/18","PMC3347959","","10.3109/02813432.2011.602555"
"27059769","A monte carlo study of restricted diffusion: Implications for diffusion MRI of prostate cancer","Gilani N, Malcolm P, Johnson G.","Magn Reson Med. 2017 Apr;77(4):1671-1677. doi: 10.1002/mrm.26230. Epub 2016 Apr 5.","Gilani N","Magn Reson Med","2017","2016/04/10","","","10.1002/mrm.26230"
"2184331","Update in the management of prostate cancer","Raghavan D, Rogers J.","Med J Aust. 1990 Apr 16;152(8):419-26.","Raghavan D","Med J Aust","1990","1990/04/16","","",""
"24775723","Imaging approaches with advanced prostate cancer: techniques and timing","Leung D, Krishnamoorthy S, Schwartz L, Divgi C.","Can J Urol. 2014 Apr;21(2 Supp 1):42-7.","Leung D","Can J Urol","2014","2014/04/30","","",""
"17969793","[Prognostic significance of ""sawtooth"" PSA and ""stepwise"" PSA]","Celhay O, De La Taille A, Salomon L, Doré B, Abbou CC, Irani J.","Prog Urol. 2007 Sep;17(5):943-6. doi: 10.1016/s1166-7087(07)92393-3.","Celhay O","Prog Urol","2007","2007/11/01","","","10.1016/s1166-7087(07)92393-3"
"8229130","Importance of continued testicular suppression in hormone-refractory prostate cancer","Taylor CD, Elson P, Trump DL.","J Clin Oncol. 1993 Nov;11(11):2167-72. doi: 10.1200/JCO.1993.11.11.2167.","Taylor CD","J Clin Oncol","1993","1993/11/01","","","10.1200/JCO.1993.11.11.2167"
"29633950","[Surgical treatment of local disease in metastatic prostate cancer.]","Gaya JM, Huguet J, Breda A, Palou J.","Arch Esp Urol. 2018 Mar;71(3):288-297.","Gaya JM","Arch Esp Urol","2018","2018/04/11","","",""
"18304399","Teaching radical prostatectomy in sub-Saharan Africa","Ruenes A Jr, Gueye SM.","Can J Urol. 2008 Feb;15(1):3886-9.","Ruenes A Jr","Can J Urol","2008","2008/02/29","","",""
"28247736","[Cancer and genitourinary tuberculosis (literature review and clinical observations)]","Kholtobin DP, Kulchavenya DP, Khomyakov BT.","Urologiia. 2016 Aug;(4):106-109.","Kholtobin DP","Urologiia","2016","2017/03/02","","",""
"31900908","Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy","Prokhnevska N, Emerson DA, Kissick HT, Redmond WL.","Adv Exp Med Biol. 2019;1210:121-147. doi: 10.1007/978-3-030-32656-2_7.","Prokhnevska N","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_7"
"25518338","[Mechanism of prostate cancer invasion and metastasis]","Sakamoto S, Ichikawa T.","Nihon Rinsho. 2014 Dec;72(12):2086-9.","Sakamoto S","Nihon Rinsho","2014","2014/12/19","","",""
"15111981","A 3-y prospective study of health-related and disease-specific quality of life in patients with nonmetastatic prostate cancer treated with radical prostatectomy or external beam radiotherapy","Yoshimura K, Arai Y, Ichioka K, Matsui Y, Ogura K, Terai A.","Prostate Cancer Prostatic Dis. 2004;7(2):144-51. doi: 10.1038/sj.pcan.4500714.","Yoshimura K","Prostate Cancer Prostatic Dis","2004","2004/04/28","","","10.1038/sj.pcan.4500714"
"20942621","Chemoprevention of prostate cancer: breakthroughs and controversies","Kim J.","Expert Rev Anticancer Ther. 2010 Oct;10(10):1517-22. doi: 10.1586/era.10.122.","Kim J","Expert Rev Anticancer Ther","2010","2010/10/15","","","10.1586/era.10.122"
"27273062","A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer","Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M.","Prostate. 2016 Oct;76(14):1285-92. doi: 10.1002/pros.23215. Epub 2016 Jun 8.","Murphy C","Prostate","2016","2016/06/09","PMC4988926","NIHMS796552","10.1002/pros.23215"
"17031373","Individualized assessment of prostate cancer risk","Adolfsson J.","Nat Clin Pract Urol. 2006 Oct;3(10):522-3. doi: 10.1038/ncpuro0586.","Adolfsson J","Nat Clin Pract Urol","2006","2006/10/13","","","10.1038/ncpuro0586"
"25881865","Expression Profile of Autophagy-related Markers in Localized Prostate Cancer: Correlation With Biochemical Recurrence After Radical Prostatectomy","Liu B, Miyake H, Nishikawa M, Tei H, Fujisawa M.","Urology. 2015 Jun;85(6):1424-30. doi: 10.1016/j.urology.2015.03.006. Epub 2015 Apr 14.","Liu B","Urology","2015","2015/04/18","","","10.1016/j.urology.2015.03.006"
"15535439","Predicting prostate cancer behavior using transcript profiles","Nelson PS.","J Urol. 2004 Nov;172(5 Pt 2):S28-32; discussion S33. doi: 10.1097/01.ju.0000142067.17181.68.","Nelson PS","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000142067.17181.68"
"25048862","Prostate cancer: Unravelling bias in vasectomy associations","Thoma C.","Nat Rev Urol. 2014 Aug;11(8):425. doi: 10.1038/nrurol.2014.182. Epub 2014 Jul 22.","Thoma C","Nat Rev Urol","2014","2014/07/23","","","10.1038/nrurol.2014.182"
"23571745","Patients with prostate cancer and BRCA2 mutations need urgent treatment","Torjesen I.","BMJ. 2013 Apr 9;346:f2223. doi: 10.1136/bmj.f2223.","Torjesen I","BMJ","2013","2013/04/11","","","10.1136/bmj.f2223"
"8332290","Vasectomy and prostate cancer: is there a link?","Skegg D.","N Z Med J. 1993 Jun 23;106(958):242-3.","Skegg D","N Z Med J","1993","1993/06/23","","",""
"31451487","Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics","Rahbar K, Bodei L, Morris MJ.","J Nucl Med. 2019 Nov;60(11):1504-1506. doi: 10.2967/jnumed.119.234054. Epub 2019 Aug 26.","Rahbar K","J Nucl Med","2019","2019/08/28","","","10.2967/jnumed.119.234054"
"18154199","The management of early prostate cancer: a review","Ngugi PM, Magoha GA.","East Afr Med J. 2007 Sep;84(9 Suppl):S24-30. doi: 10.4314/eamj.v84i9.9558.","Ngugi PM","East Afr Med J","2007","2007/12/25","","","10.4314/eamj.v84i9.9558"
"29873824","Combined therapies improve survival in aggressive prostate cancer","Printz C.","Cancer. 2018 Jun 15;124(12):2470. doi: 10.1002/cncr.31562.","Printz C","Cancer","2018","2018/06/07","","","10.1002/cncr.31562"
"3121651","Current approaches to prostate cancer","O'Brien WM, Lynch JH.","Hosp Pract (Off Ed). 1988 Jan 15;23(1):143-5, 149-50, 155 passim. doi: 10.1080/21548331.1988.11703407.","O'Brien WM","Hosp Pract (Off Ed)","1988","1988/01/15","","","10.1080/21548331.1988.11703407"
"16280755","Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer","Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, Scardino PT.","J Urol. 2005 Dec;174(6):2158-63. doi: 10.1097/01.ju.0000181224.95276.82.","Mullerad M","J Urol","2005","2005/11/11","","","10.1097/01.ju.0000181224.95276.82"
"31283606","Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer","Ries M, Khreish F, Berchem G, Ezziddin S.","Clin Nucl Med. 2019 Sep;44(9):730-731. doi: 10.1097/RLU.0000000000002704.","Ries M","Clin Nucl Med","2019","2019/07/09","","","10.1097/RLU.0000000000002704"
"23682472","[New markers of prostate cancer]","Benchikh A, Ravery V.","Rev Prat. 2013 Apr;63(4):478.","Benchikh A","Rev Prat","2013","2013/05/21","","",""
"15902626","[MRI for troubleshooting detection of prostate cancer]","Beyersdorff D, Hamm B.","Rofo. 2005 Jun;177(6):788-95. doi: 10.1055/s-2005-858151.","Beyersdorff D","Rofo","2005","2005/05/20","","","10.1055/s-2005-858151"
"9051151","Frequency and clinical significance of transition zone cancer in prostate cancer screening","Reissigl A, Pointner J, Strasser H, Ennemoser O, Klocker H, Bartsch G.","Prostate. 1997 Feb 1;30(2):130-5. doi: 10.1002/(sici)1097-0045(19970201)30:2<130::aid-pros8>3.0.co;2-s.","Reissigl A","Prostate","1997","1997/02/01","","","10.1002/(sici)1097-0045(19970201)30:2<130::aid-pros8>3.0.co;2-s"
"27645052","WOMEN IN CANCER THEMATIC REVIEW: New roles for nuclear receptors in prostate cancer","Leach DA, Powell SM, Bevan CL.","Endocr Relat Cancer. 2016 Nov;23(11):T85-T108. doi: 10.1530/ERC-16-0319. Epub 2016 Sep 19.","Leach DA","Endocr Relat Cancer","2016","2016/09/21","","","10.1530/ERC-16-0319"
"24914843","[Optimization of follow up in prostate cancer active surveillance]","Celma Domènech A, Planas Morin J, Morote Robles J.","Arch Esp Urol. 2014 Jun;67(5):442-51.","Celma Domènech A","Arch Esp Urol","2014","2014/06/11","","",""
"27338150","Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study","Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR.","Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.","Schweizer MT","Prostate","2016","2016/06/25","","","10.1002/pros.23209"
"10332922","Selenium and prostate cancer prevention","Nelson MA, Porterfield BW, Jacobs ET, Clark LC.","Semin Urol Oncol. 1999 May;17(2):91-6.","Nelson MA","Semin Urol Oncol","1999","1999/05/20","","",""
"7682265","Evaluation of the current incidence of nodal metastasis from prostate cancer","Bundrick WS, Culkin DJ, Mata JA, Zitman RI, Venable DD.","J Surg Oncol. 1993 Apr;52(4):269-71. doi: 10.1002/jso.2930520416.","Bundrick WS","J Surg Oncol","1993","1993/04/01","","","10.1002/jso.2930520416"
"23482776","Functional polymorphism in the CAV1 T29107A gene and its association with prostate cancer risk among Japanese men","Sugie S, Tsukino H, Yamauchi T, Mukai S, Fujii M, Shibata N, Kuroda Y, Kamoto T.","Anticancer Res. 2013 Mar;33(3):1023-7.","Sugie S","Anticancer Res","2013","2013/03/14","","",""
"29671889","Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer","Bayat H, Narouie B, Ziaee SM, Mowla SJ.","Prostate. 2018 Aug;78(11):812-818. doi: 10.1002/pros.23538. Epub 2018 Apr 19.","Bayat H","Prostate","2018","2018/04/20","","","10.1002/pros.23538"
"16981834","Novel targets in prostate cancer","Berthold DR, Moore MJ.","Expert Opin Ther Targets. 2006 Oct;10(5):777-80. doi: 10.1517/14728222.10.5.777.","Berthold DR","Expert Opin Ther Targets","2006","2006/09/20","","","10.1517/14728222.10.5.777"
"3597144","Postoperative radiation therapy for pathologic stage C prostate cancer","Jacobson GM, Smith JA Jr, Stewart JR.","Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1021-4. doi: 10.1016/0360-3016(87)90040-x.","Jacobson GM","Int J Radiat Oncol Biol Phys","1987","1987/07/01","","","10.1016/0360-3016(87)90040-x"
"11848530","Surgical pathology examination of radical prostatectomy specimens. Updated protocol based on the Italian TAP study","Mazzucchelli R, Montironi R, Prezioso D, Bono AV, Ferrari P, Manganelli A, Morelli P, De Vito ML, Santinelli A, Diamanti L, Lotti T, Polito M; Takeda Italian TAP Study Group.","Anticancer Res. 2001 Sep-Oct;21(5):3599-607.","Mazzucchelli R","Anticancer Res","2001","2002/02/19","","",""
"26482553","Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer","Roth JA, Ramsey SD, Carlson JJ.","Oncologist. 2015 Dec;20(12):1355-64. doi: 10.1634/theoncologist.2015-0214. Epub 2015 Oct 19.","Roth JA","Oncologist","2015","2015/10/21","PMC4679086","","10.1634/theoncologist.2015-0214"
"31176447","New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer-through the looking glass darkly","Khoo V.","Clin Radiol. 2019 Nov;74(11):865-875. doi: 10.1016/j.crad.2019.05.003. Epub 2019 Jun 5.","Khoo V","Clin Radiol","2019","2019/06/10","","","10.1016/j.crad.2019.05.003"
"31900909","The Tumor Microenvironments of Lethal Prostate Cancer","Harryman WL, Warfel NA, Nagle RB, Cress AE.","Adv Exp Med Biol. 2019;1210:149-170. doi: 10.1007/978-3-030-32656-2_8.","Harryman WL","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_8"
"21546364","What are the consequences if i postpone treatment of my PSA-detected prostate cancer?","Sampson JN.","Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):727-8. doi: 10.1158/1055-9965.EPI-11-0057.","Sampson JN","Cancer Epidemiol Biomarkers Prev","2011","2011/05/07","","","10.1158/1055-9965.EPI-11-0057"
"10367415","Screening for prostate cancer: the current position","Moss SM, Melia J.","Br Med Bull. 1998;54(4):791-805. doi: 10.1093/oxfordjournals.bmb.a011730.","Moss SM","Br Med Bull","1998","1999/06/15","","","10.1093/oxfordjournals.bmb.a011730"
"24994559","Molecular markers to guide primary radical treatment selection in localized prostate cancer","Gnanapragasam VJ.","Expert Rev Mol Diagn. 2014 Sep;14(7):871-81. doi: 10.1586/14737159.2014.936851. Epub 2014 Jul 4.","Gnanapragasam VJ","Expert Rev Mol Diagn","2014","2014/07/05","","","10.1586/14737159.2014.936851"
"17206534","Screening for prostate cancer: a Cochrane systematic review","Ilic D, O'Connor D, Green S, Wilt T.","Cancer Causes Control. 2007 Apr;18(3):279-85. doi: 10.1007/s10552-006-0087-6. Epub 2007 Jan 6.","Ilic D","Cancer Causes Control","2007","2007/01/09","","","10.1007/s10552-006-0087-6"
"10961481","Subcutaneous bleeding: first sign of prostate cancer","Jensen JB, Langkilde NC.","Scand J Urol Nephrol. 2000 Jun;34(3):215-6.","Jensen JB","Scand J Urol Nephrol","2000","2000/08/29","","",""
"15247718","Bowel function and bother after treatment for early stage prostate cancer: a longitudinal quality of life analysis from CaPSURE","Litwin MS, Sadetsky N, Pasta DJ, Lubeck DP.","J Urol. 2004 Aug;172(2):515-9. doi: 10.1097/01.ju.0000129236.56712.e7.","Litwin MS","J Urol","2004","2004/07/13","","","10.1097/01.ju.0000129236.56712.e7"
"8918377","Differences in patterns of care of prostate cancer, New South Wales, 1991","McCredie M, Bell J, Lee A, Rogers J.","Aust N Z J Surg. 1996 Nov;66(11):727-30. doi: 10.1111/j.1445-2197.1996.tb00730.x.","McCredie M","Aust N Z J Surg","1996","1996/11/01","","","10.1111/j.1445-2197.1996.tb00730.x"
"10522656","Role of transurethral resection of the prostate in population-based prostate cancer incidence rates","Merrill RM, Feuer EJ, Warren JL, Schussler N, Stephenson RA.","Am J Epidemiol. 1999 Oct 15;150(8):848-60. doi: 10.1093/oxfordjournals.aje.a010090.","Merrill RM","Am J Epidemiol","1999","1999/10/16","","","10.1093/oxfordjournals.aje.a010090"
"26078203","Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial","Norris MK, Bell GJ, North S, Courneya KS.","Prostate Cancer Prostatic Dis. 2015 Sep;18(3):281-7. doi: 10.1038/pcan.2015.28. Epub 2015 Jun 16.","Norris MK","Prostate Cancer Prostatic Dis","2015","2015/06/17","","","10.1038/pcan.2015.28"
"27344705","[Stem cell biology in prostate cancer]","Kosaka T, Oya M.","Nihon Rinsho. 2016 May 20;74 Suppl 3:65-70.","Kosaka T","Nihon Rinsho","2016","2016/06/28","","",""
"17440141","Outcomes of treatment vs observation of localized prostate cancer in elderly men","Porter MP.","JAMA. 2007 Apr 18;297(15):1652; author reply 1652-3. doi: 10.1001/jama.297.15.1652-b.","Porter MP","JAMA","2007","2007/04/19","","","10.1001/jama.297.15.1652-b"
"16905042","Low risks at high latitudes: Does the arctic hold clues to prostate cancer?","Erren TC.","Am J Prev Med. 2006 Sep;31(3):273. doi: 10.1016/j.amepre.2006.05.004. Epub 2006 Jul 13.","Erren TC","Am J Prev Med","2006","2006/08/15","","","10.1016/j.amepre.2006.05.004"
"10456032","Review of AACR meeting: new research approaches in the prevention and cure of prostate cancer, 2-6 December 1998, Indian Wells, CA","Ornstein DK, Dahut WL, Liotta LA, Emmert-Buck MR.","Biochim Biophys Acta. 1999 Jul 29;1424(1):R11-9. doi: 10.1016/s0304-419x(99)00017-7.","Ornstein DK","Biochim Biophys Acta","1999","1999/08/24","","","10.1016/s0304-419x(99)00017-7"
"20225764","Role of the adiponectin leptin ratio in prostate cancer","Grossmann ME, Mizuno NK, Bonorden MJ, Ray A, Sokolchik I, Narasimhan ML, Cleary MP.","Oncol Res. 2009;18(5-6):269-77. doi: 10.3727/096504009x12596189659367.","Grossmann ME","Oncol Res","2009","2010/03/16","","","10.3727/096504009x12596189659367"
"26402179","[PSA screening]","Spek A, Szabados B, Roosen A, Stief C.","Dtsch Med Wochenschr. 2015 Sep;140(19):1435-7. doi: 10.1055/s-0041-102939. Epub 2015 Sep 24.","Spek A","Dtsch Med Wochenschr","2015","2015/09/25","","","10.1055/s-0041-102939"
"19261249","Predicting the future in castration-resistant prostate cancer","Verhagen P.","Lancet Oncol. 2009 Mar;10(3):201-2. doi: 10.1016/S1470-2045(09)70049-X.","Verhagen P","Lancet Oncol","2009","2009/03/06","","","10.1016/S1470-2045(09)70049-X"
"19769655","Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer","Boscolo-Berto R.","Int J Urol. 2009 Sep;16(9):711. doi: 10.1111/j.1442-2042.2009.02359.x.","Boscolo-Berto R","Int J Urol","2009","2009/09/23","","","10.1111/j.1442-2042.2009.02359.x"
"12648986","Pathological and molecular aspects of prostate cancer","DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI.","Lancet. 2003 Mar 15;361(9361):955-64. doi: 10.1016/S0140-6736(03)12779-1.","DeMarzo AM","Lancet","2003","2003/03/22","","","10.1016/S0140-6736(03)12779-1"
"7686076","Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread?","Adamson AS, Francis JL, Witherow RO, Snell ME.","Br J Urol. 1993 May;71(5):587-92. doi: 10.1111/j.1464-410x.1993.tb16030.x.","Adamson AS","Br J Urol","1993","1993/05/01","","","10.1111/j.1464-410x.1993.tb16030.x"
"30885200","Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada","Smith-Palmer J, Takizawa C, Valentine W.","BMC Urol. 2019 Mar 18;19(1):19. doi: 10.1186/s12894-019-0448-6.","Smith-Palmer J","BMC Urol","2019","2019/03/20","PMC6421711","","10.1186/s12894-019-0448-6"
"21754986","MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer","von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth AA, Old LJ, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild PJ.","PLoS One. 2011;6(7):e21366. doi: 10.1371/journal.pone.0021366. Epub 2011 Jul 6.","von Boehmer L","PLoS One","2011","2011/07/15","PMC3130772","","10.1371/journal.pone.0021366"
"10189038","Diet and prostate cancer risk: the embarrassment of riches","Gann PH.","Cancer Causes Control. 1998 Dec;9(6):541-3. doi: 10.1023/a:1008898918799.","Gann PH","Cancer Causes Control","1998","1999/04/03","","","10.1023/a:1008898918799"
"11998041","Sowing seeds: transperineal implantation","Amerine E, Nagle GM, Bollinger JR.","Urol Nurs. 2000 Feb;20(1):47-53.","Amerine E","Urol Nurs","2000","2002/05/10","","",""
"20493642","Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?","Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A.","Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1310-7. doi: 10.1016/j.ijrobp.2010.01.006. Epub 2010 May 20.","Kuban DA","Int J Radiat Oncol Biol Phys","2011","2010/05/25","","","10.1016/j.ijrobp.2010.01.006"
"31044594","Suicide Risk Associated with a Prostate Cancer Diagnosis","Nason GJ, O’Connell C, Galvin DJ.","Ir Med J. 2019 Mar 14;112(3):892.","Nason GJ","Ir Med J","2019","2019/05/03","","",""
"7279364","A highly successful approach to operable prostate cancer in a community hospital","Spagnola NR, Paul WT, Smith JP, Saylor M.","Ohio State Med J. 1981 Aug;77(8):503-6.","Spagnola NR","Ohio State Med J","1981","1981/08/01","","",""
"10918970","Diagnosis of localized prostate cancer: 10 years of progress","Feneley MR, Partin AW.","Curr Opin Urol. 2000 Jul;10(4):319-27. doi: 10.1097/00042307-200007000-00006.","Feneley MR","Curr Opin Urol","2000","2000/08/05","","","10.1097/00042307-200007000-00006"
"22642004","[Management of prostate cancer]","Zilinberg K, Roosen A, Belka C, Ganswindt U, Stief CG.","MMW Fortschr Med. 2012 Jan 19;154(1):47-50. doi: 10.1007/s15006-012-0036-0.","Zilinberg K","MMW Fortschr Med","2012","2012/05/31","","","10.1007/s15006-012-0036-0"
"29385878","Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden","Franck Lissbrant I, Ventimiglia E, Robinson D, Törnblom M, Hjälm-Eriksson M, Lambe M, Folkvaljon Y, Stattin P.","Scand J Urol. 2018 Apr;52(2):143-150. doi: 10.1080/21681805.2018.1426039. Epub 2018 Feb 1.","Franck Lissbrant I","Scand J Urol","2018","2018/02/02","","","10.1080/21681805.2018.1426039"
"18382243","The critical use of population-based medical databases for prostate cancer research","Scales CD Jr, Dahm P.","Curr Opin Urol. 2008 May;18(3):320-5. doi: 10.1097/MOU.0b013e3282fb781b.","Scales CD Jr","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282fb781b"
"15066293","Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation","Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA.","Radiother Oncol. 2004 Apr;71(1):29-33. doi: 10.1016/j.radonc.2003.12.011.","Potters L","Radiother Oncol","2004","2004/04/07","","","10.1016/j.radonc.2003.12.011"
"5040189","Long lasting results of the hormonal treatment for prostate cancer","Ljunggren E.","Acta Urol Belg. 1972 Jan;40(1):108-12.","Ljunggren E","Acta Urol Belg","1972","1972/01/01","","",""
"23953795","Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review","Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM, Scorsetti M, Orecchia R, Jereczek-Fossa BA.","Crit Rev Oncol Hematol. 2013 Dec;88(3):550-63. doi: 10.1016/j.critrevonc.2013.07.009. Epub 2013 Aug 15.","Alongi F","Crit Rev Oncol Hematol","2013","2013/08/20","","","10.1016/j.critrevonc.2013.07.009"
"25630451","Active Surveillance for Prostate Cancer: Debate over the Application, Not the Concept","Klotz L.","Eur Urol. 2015 Jun;67(6):1006-1008. doi: 10.1016/j.eururo.2015.01.007. Epub 2015 Jan 24.","Klotz L","Eur Urol","2015","2015/01/30","","","10.1016/j.eururo.2015.01.007"
"6654955","Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate","Dhom G.","J Cancer Res Clin Oncol. 1983;106(3):210-8. doi: 10.1007/BF00402610.","Dhom G","J Cancer Res Clin Oncol","1983","1983/01/01","","","10.1007/BF00402610"
"6683898","[Single cell photometry analysis of nuclear DNA in treated undifferentiated prostate cancer and its clinical significance]","Leistenschneider W, Nagel R.","Urologe A. 1983 May;22(3):157-61.","Leistenschneider W","Urologe A","1983","1983/05/01","","",""
"11147976","Biochemical outcomes of treatment for prostate cancer","Vicini FA, Kestin L, Martinez A.","JAMA. 2000 Dec 13;284(22):2869. doi: 10.1001/jama.284.22.2869.","Vicini FA","JAMA","2000","2001/01/09","","","10.1001/jama.284.22.2869"
"8411807","[Reassessment of the sonographic criterion of prostate cancer--nonspecificity of a hypoechoic lesion]","Egawa S, Kuwao S, Uchida T, Yokoyama E, Mashimo S, Koshiba K.","Nihon Hinyokika Gakkai Zasshi. 1993 Aug;84(8):1456-64. doi: 10.5980/jpnjurol1989.84.1456.","Egawa S","Nihon Hinyokika Gakkai Zasshi","1993","1993/08/01","","","10.5980/jpnjurol1989.84.1456"
"18105382","[Papanicolaou's cytological cancer diagnosis and its use in prostate cancer]","HRYNTSCHAK T.","Wien Klin Wochenschr. 1948 Nov 25;60(47):772.","HRYNTSCHAK T","Wien Klin Wochenschr","1948","1948/11/25","","",""
"15538296","Re: inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale","Pitts WR Jr.","J Urol. 2004 Dec;172(6 Pt 1):2483-4. doi: 10.1097/01.ju.0000144062.31241.c3.","Pitts WR Jr","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000144062.31241.c3"
"9047249","Risk of incontinence with transurethral resection of the prostate after radiation therapy for prostate cancer","Patel H, Peddada AV, Zimmern PE, Hernandez R, Kagan R.","J Surg Oncol. 1997 Feb;64(2):127-9. doi: 10.1002/(sici)1096-9098(199702)64:2<127::aid-jso7>3.0.co;2-d.","Patel H","J Surg Oncol","1997","1997/02/01","","","10.1002/(sici)1096-9098(199702)64:2<127::aid-jso7>3.0.co;2-d"
"29674422","A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies","O'Keefe DS, Bacich DJ, Huang SS, Heston WDW.","J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19.","O'Keefe DS","J Nucl Med","2018","2018/04/21","PMC6910646","","10.2967/jnumed.117.203877"
"16496412","GREB1 is a novel androgen-regulated gene required for prostate cancer growth","Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME.","Prostate. 2006 Jun 1;66(8):886-94. doi: 10.1002/pros.20403.","Rae JM","Prostate","2006","2006/02/24","","","10.1002/pros.20403"
"24053308","Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance","Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.","BJU Int. 2014 Jun;113(6):864-70. doi: 10.1111/bju.12423. Epub 2013 Dec 2.","Park BH","BJU Int","2014","2013/09/24","","","10.1111/bju.12423"
"18095881","ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer","Turner DP, Watson DK.","Expert Rev Anticancer Ther. 2008 Jan;8(1):33-42. doi: 10.1586/14737140.8.1.33.","Turner DP","Expert Rev Anticancer Ther","2008","2007/12/22","","","10.1586/14737140.8.1.33"
"22516590","[Association of radiotherapy and hormonotherapy in locally advanced prostate cancer]","Quero L, Wong-Hee-Kam S, Rivera S, Hennequin C.","Bull Cancer. 2012 Jul;99 Suppl 1:S30-6. doi: 10.1684/bdc.2012.1567.","Quero L","Bull Cancer","2012","2012/04/21","","","10.1684/bdc.2012.1567"
"21956922","Molecular alterations during progression of prostate cancer to androgen independence","Saraon P, Jarvi K, Diamandis EP.","Clin Chem. 2011 Oct;57(10):1366-75. doi: 10.1373/clinchem.2011.165977.","Saraon P","Clin Chem","2011","2011/09/30","","","10.1373/clinchem.2011.165977"
"30730411","Bringing Prostate Cancer Germline Genetics into Clinical Practice","Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.","J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.","Das S","J Urol","2019","2019/02/08","","","10.1097/JU.0000000000000137"
"22198724","Potential for prostate cancer prevention through physical activity","Young-McCaughan S.","World J Urol. 2012 Apr;30(2):167-79. doi: 10.1007/s00345-011-0812-y. Epub 2011 Dec 24.","Young-McCaughan S","World J Urol","2012","2011/12/27","","","10.1007/s00345-011-0812-y"
"25245246","Prostate cancer: care beyond prostate cancer-improving patient outcomes","Frydenberg M.","Nat Rev Urol. 2014 Dec;11(12):669-71. doi: 10.1038/nrurol.2014.261. Epub 2014 Sep 23.","Frydenberg M","Nat Rev Urol","2014","2014/09/24","","","10.1038/nrurol.2014.261"
"31553489","Prostate cancer in young men: An emerging young adult and older adolescent challenge","Bleyer A, Spreafico F, Barr R.","Cancer. 2020 Jan 1;126(1):46-57. doi: 10.1002/cncr.32498. Epub 2019 Sep 25.","Bleyer A","Cancer","2020","2019/09/26","","","10.1002/cncr.32498"
"29723463","[Gene regulation of prostaglandin synthase and prostate diseases]","Wu SS, Wu JH, Sun ZY.","Zhonghua Nan Ke Xue. 2017 Jul;23(7):663-667.","Wu SS","Zhonghua Nan Ke Xue","2017","2018/05/04","","",""
"25040091","Editorial Comment to Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life","Sio TT.","Int J Urol. 2014 Sep;21(9):904. doi: 10.1111/iju.12579. Epub 2014 Jul 14.","Sio TT","Int J Urol","2014","2014/07/22","","","10.1111/iju.12579"
"8693592","Recent advances in prostate cancer metastasis","Waltregny D, Castronovo V.","Tumori. 1996 May-Jun;82(3):193-204.","Waltregny D","Tumori","1996","1996/05/01","","",""
"29036003","68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI","Ahuja A, Taneja S, Thorat K, Jena A.","Clin Nucl Med. 2017 Dec;42(12):e509-e510. doi: 10.1097/RLU.0000000000001874.","Ahuja A","Clin Nucl Med","2017","2017/10/17","","","10.1097/RLU.0000000000001874"
"28437031","Patient-reported outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments","Protopapa E, van der Meulen J, Moore CM, Smith SC.","BJU Int. 2017 Oct;120(4):468-481. doi: 10.1111/bju.13896. Epub 2017 May 30.","Protopapa E","BJU Int","2017","2017/04/25","","","10.1111/bju.13896"
"18048709","'A matter of faith, not science': analysis of media coverage of prostate cancer screening in Australian news media 2003-2006","MacKenzie R, Chapman S, Holding S, McGeechan K.","J R Soc Med. 2007 Nov;100(11):513-21. doi: 10.1177/014107680710001114.","MacKenzie R","J R Soc Med","2007","2007/12/01","PMC2099410","","10.1177/014107680710001114"
"2290110","Cancer of the prostate--an overview","Roy JB.","J Okla State Med Assoc. 1990 Dec;83(12):591-3.","Roy JB","J Okla State Med Assoc","1990","1990/12/01","","",""
"27785560","Multiparametric magnetic resonance imaging for prostate cancer-a comparative study including radical prostatectomy specimens","Toner L, Papa N, Perera M, Katelaris N, Weerakoon M, Chin K, Harewood L, Bolton DM, Lawrentschuk N.","World J Urol. 2017 Jun;35(6):935-941. doi: 10.1007/s00345-016-1960-x. Epub 2016 Oct 26.","Toner L","World J Urol","2017","2016/10/28","","","10.1007/s00345-016-1960-x"
"1992569","Advanced prostatic carcinoma. Early versus late endocrine therapy","Kozlowski JM, Ellis WJ, Grayhack JT.","Urol Clin North Am. 1991 Feb;18(1):15-24.","Kozlowski JM","Urol Clin North Am","1991","1991/02/01","","",""
"18338814","Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy","Palma D, Tyldesley S, Pickles T; Prostate Cohort Outcomes Initiative.","Cancer. 2008 May 1;112(9):1941-8. doi: 10.1002/cncr.23388.","Palma D","Cancer","2008","2008/03/15","","","10.1002/cncr.23388"
"26631052","Cadmium Levels in Tissue and Plasma as a Risk Factor for Prostate Carcinoma: a Meta-Analysis","Zhang L, Zhu Y, Hao R, Shao M, Luo Y.","Biol Trace Elem Res. 2016 Jul;172(1):86-92. doi: 10.1007/s12011-015-0576-0. Epub 2015 Dec 3.","Zhang L","Biol Trace Elem Res","2016","2015/12/04","","","10.1007/s12011-015-0576-0"
"11328422","Endocrine therapy for recurrence after definitive radiotherapy in patients with prostate cancer","Furuya Y, Akakura K, Tanaka M, Ichikawa T, Igarashi T, Murakami S, Ito H.","Int J Urol. 2001 May;8(5):222-6. doi: 10.1046/j.1442-2042.2001.00288.x.","Furuya Y","Int J Urol","2001","2001/05/01","","","10.1046/j.1442-2042.2001.00288.x"
"7536529","[The value of PSA density for the diagnosis of prostatic cancer and for the indication of radical prostatectomy]","Doublet JD, Ciofu C, Fouret P, Gattegno B, Thibault P.","Prog Urol. 1995 Apr;5(2):211-9, 220; discussion 219-20.","Doublet JD","Prog Urol","1995","1995/04/01","","",""
"22270169","Postoperative radiotherapy in prostate cancer: the case of the missing target","Croke J, Malone S, Roustan Delatour N, Belanger E, Avruch L, Morash C, Kayser C, Underhill K, Spaans J.","Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1160-8. doi: 10.1016/j.ijrobp.2011.09.039. Epub 2012 Jan 21.","Croke J","Int J Radiat Oncol Biol Phys","2012","2012/01/25","","","10.1016/j.ijrobp.2011.09.039"
"10492600","Prostate cancer and prostate specific antigen. A Jamaican perspective","Douglas LL.","West Indian Med J. 1999 Jun;48(2):47-9.","Douglas LL","West Indian Med J","1999","1999/09/24","","",""
"1709357","Digital rectal examination versus transrectal ultrasound in detection of prostate cancer. Preliminary results from a study of a randomly selected population","Norming U, Gustafsson O, Nyman CR, Almgård LE, Fredriksson A, Gustafsson G, Harvig B.","Acta Oncol. 1991;30(2):277-9. doi: 10.3109/02841869109092370.","Norming U","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092370"
"8940318","Prostatectomy and survival among men with clinically localized prostate cancer","Fryback DG, Albertsen PC, Storer BE.","JAMA. 1996 Dec 4;276(21):1723-4; author reply 1724.","Fryback DG","JAMA","1996","1996/12/04","","",""
"23944298","Long-term survival of participants in the prostate cancer prevention trial","Thompson IM Jr, Goodman PJ, Tangen CM, Parnes HL, Minasian LM, Godley PA, Lucia MS, Ford LG.","N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.","Thompson IM Jr","N Engl J Med","2013","2013/08/16","PMC4141537","NIHMS526412","10.1056/NEJMoa1215932"
"10892734","Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines","Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF 3rd, Emmert-Buck MR.","Electrophoresis. 2000 Jun;21(11):2235-42. doi: 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A.","Ornstein DK","Electrophoresis","2000","2000/07/13","","","10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.0.CO;2-A"
"29229666","Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood","Rebbeck TR.","Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a030387. doi: 10.1101/cshperspect.a030387.","Rebbeck TR","Cold Spring Harb Perspect Med","2018","2017/12/13","PMC6120694","","10.1101/cshperspect.a030387"
"9757178","Prostate cancer: 1. The descriptive epidemiology in Canada","Levy IG, Iscoe NA, Klotz LH.","CMAJ. 1998 Sep 8;159(5):509-13.","Levy IG","CMAJ","1998","1998/10/03","PMC1229652","",""
"27111695","Men's help-seeking in the first year after diagnosis of localised prostate cancer","Hyde MK, Newton RU, Galvão DA, Gardiner RA, Occhipinti S, Lowe A, Wittert GA, Chambers SK.","Eur J Cancer Care (Engl). 2017 Mar;26(2):e12497. doi: 10.1111/ecc.12497. Epub 2016 Apr 25.","Hyde MK","Eur J Cancer Care (Engl)","2017","2016/04/26","PMC5347946","","10.1111/ecc.12497"
"10135481","Prostate cancer: new hope, new controversy","Phillips L.","Hosp Technol Ser. 1994 Aug;13(10):1-4.","Phillips L","Hosp Technol Ser","1994","1994/07/07","","",""
"11901845","Potential screening test for prostate cancer","","Expert Rev Mol Diagn. 2001 Nov;1(4):367-8.","","Expert Rev Mol Diagn","2001","2002/03/21","","",""
"24737393","Notch signaling in prostate cancer: a moving target","Carvalho FL, Simons BW, Eberhart CG, Berman DM.","Prostate. 2014 Jun;74(9):933-45. doi: 10.1002/pros.22811. Epub 2014 Apr 16.","Carvalho FL","Prostate","2014","2014/04/17","PMC4323172","NIHMS659337","10.1002/pros.22811"
"23159265","The impact of clinical stage on prostate cancer survival following radical prostatectomy","Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA.","J Urol. 2013 May;189(5):1707-12. doi: 10.1016/j.juro.2012.11.065. Epub 2012 Nov 15.","Tollefson MK","J Urol","2013","2012/11/20","","","10.1016/j.juro.2012.11.065"
"9239480","The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial","Brawley OW, Thompson IM.","Cancer Treat Res. 1996;88:189-200. doi: 10.1007/978-1-4615-6343-3_11.","Brawley OW","Cancer Treat Res","1996","1996/01/01","","","10.1007/978-1-4615-6343-3_11"
"8583625","Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose","Effert PJ, Bares R, Handt S, Wolff JM, Büll U, Jakse G.","J Urol. 1996 Mar;155(3):994-8.","Effert PJ","J Urol","1996","1996/03/01","","",""
"9348559","Management of progressive metastatic prostate cancer","Waselenko JK, Dawson NA.","Oncology (Williston Park). 1997 Oct;11(10):1551-60; discussion 1560-3, 1567-8.","Waselenko JK","Oncology (Williston Park)","1997","1998/02/12","","",""
"12465395","Asian trends in prostate cancer hormone therapy","Akaza H, Naito S, Cheng C, Kaisary A, Soebadi DM, Umbas R, Esuvaranathan K, Gu FL, Zhou L, Hong SJ, Kim WJ, Lee SE, Rim JS, Song JM, Yoon JH, Chang SJ, Huang CH, Yang CR, Hirao Y, Murai M, Tsukamoto T, Usami M.","Gan To Kagaku Ryoho. 2002 Nov;29(11):1951-61.","Akaza H","Gan To Kagaku Ryoho","2002","2002/12/06","","",""
"10772597","Prostate cancer testing","Gunter D.","Med J Aust. 2000 Feb 21;172(4):190.","Gunter D","Med J Aust","2000","2000/04/20","","",""
"16999665","Chemoprevention in prostate cancer","Parnes HL, Figg WD.","Pharmacotherapy. 2006 Oct;26(10):1533; author reply 1533. doi: 10.1592/phco.26.10.1533.","Parnes HL","Pharmacotherapy","2006","2006/09/27","","","10.1592/phco.26.10.1533"
"10692785","[Staging and therapeutic options in local prostatic carcinoma]","Stoffel F, Forster T, Gasser TC.","Ann Ital Chir. 1999 Sep-Oct;70(5):665-70.","Stoffel F","Ann Ital Chir","1999","2000/02/29","","",""
"30324351","Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment","Mansinho A, Macedo D, Fernandes I, Costa L.","Adv Exp Med Biol. 2018;1096:117-133. doi: 10.1007/978-3-319-99286-0_7.","Mansinho A","Adv Exp Med Biol","2018","2018/10/17","","","10.1007/978-3-319-99286-0_7"
"7523721","Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project","Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK.","J Urol. 1994 Nov;152(5 Pt 2):1737-40. doi: 10.1016/s0022-5347(17)32373-x.","Mettlin C","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32373-x"
"29031684","[Management of prostate cancer: The new challenges]","Cussenot O.","Presse Med. 2017 Oct;46(10):923-927. doi: 10.1016/j.lpm.2017.09.011. Epub 2017 Oct 12.","Cussenot O","Presse Med","2017","2017/10/17","","","10.1016/j.lpm.2017.09.011"
"24464532","Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","Eder M, Schäfer M, Bauder-Wüst U, Haberkorn U, Eisenhut M, Kopka K.","Prostate. 2014 May;74(6):659-68. doi: 10.1002/pros.22784. Epub 2014 Jan 25.","Eder M","Prostate","2014","2014/01/28","","","10.1002/pros.22784"
"23098793","[Sexuality and prostate cancer]","Colson MH, Lechevallier E, Rambeaud JJ, Alimi JC, Faix A, Gravis G, Hannoun-Levi JM, Quintens H, Rébillard X, Droupy S.","Prog Urol. 2012 Sep;22 Suppl 2:S72-92. doi: 10.1016/S1166-7087(12)70039-8.","Colson MH","Prog Urol","2012","2012/10/27","","","10.1016/S1166-7087(12)70039-8"
"24948873","Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation","Mostaghel EA.","Int J Biol Sci. 2014 Jun 3;10(6):602-13. doi: 10.7150/ijbs.8844. eCollection 2014.","Mostaghel EA","Int J Biol Sci","2014","2014/06/21","PMC4062953","","10.7150/ijbs.8844"
"18709589","Prostate cancer knowledge and screening attitudes of inner-city men","Pendleton J, Hopkins C, Anai S, Nakamura K, Chang M, Grissett A, Rosser CJ.","J Cancer Educ. 2008;23(3):172-9. doi: 10.1080/08858190802235429.","Pendleton J","J Cancer Educ","2008","2008/08/19","","","10.1080/08858190802235429"
"26450816","Prostate cancer survivorship: a nurse-led service model","Ferguson J, Aning J.","Br J Nurs. 2015 Oct 8-21;24(18):S14-21. doi: 10.12968/bjon.2015.24.Sup18.S14.","Ferguson J","Br J Nurs","2015","2015/10/10","","","10.12968/bjon.2015.24.Sup18.S14"
"28634789","Detection and grading of prostate cancer using temporal enhanced ultrasound: combining deep neural networks and tissue mimicking simulations","Azizi S, Bayat S, Yan P, Tahmasebi A, Nir G, Kwak JT, Xu S, Wilson S, Iczkowski KA, Lucia MS, Goldenberg L, Salcudean SE, Pinto PA, Wood B, Abolmaesumi P, Mousavi P.","Int J Comput Assist Radiol Surg. 2017 Aug;12(8):1293-1305. doi: 10.1007/s11548-017-1627-0. Epub 2017 Jun 20.","Azizi S","Int J Comput Assist Radiol Surg","2017","2017/06/22","","","10.1007/s11548-017-1627-0"
"26989049","The clinical phenotype of hereditary versus sporadic prostate cancer: HPC definition revisited","Cremers RG, Aben KK, van Oort IM, Sedelaar JP, Vasen HF, Vermeulen SH, Kiemeney LA.","Prostate. 2016 Jul;76(10):897-904. doi: 10.1002/pros.23179. Epub 2016 Mar 14.","Cremers RG","Prostate","2016","2016/03/19","PMC5069637","","10.1002/pros.23179"
"18540566","Prostate cancer at the 2007 ASCO meeting: an urologist's perspective","Mottet N.","Ann Urol (Paris). 2007 Nov;41 Suppl 5:S105-18.","Mottet N","Ann Urol (Paris)","2007","2008/06/11","","",""
"8865480","Does transurethral resection of the prostate compromise the radical treatment of prostate cancer?","Mansfield JT, Stephenson RA.","Semin Urol Oncol. 1996 Aug;14(3):174-7.","Mansfield JT","Semin Urol Oncol","1996","1996/08/01","","",""
"11114597","Treatment of locally advanced prostate cancer--a new role for antiandrogen monotherapy?","Abrahamsson PA.","Eur Urol. 2001;39 Suppl 1:22-8. doi: 10.1159/000052546.","Abrahamsson PA","Eur Urol","2001","2000/12/15","","","10.1159/000052546"
"10081868","The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study","Rietbergen JB, Hoedemaeker RF, Kruger AE, Kirkels WJ, Schröder FH.","J Urol. 1999 Apr;161(4):1192-8.","Rietbergen JB","J Urol","1999","1999/03/19","","",""
"11238694","African-Americans and prostate cancer: why the discrepancies?","Jones J.","J Natl Cancer Inst. 2001 Mar 7;93(5):342-4. doi: 10.1093/jnci/93.5.342.","Jones J","J Natl Cancer Inst","2001","2001/03/10","","","10.1093/jnci/93.5.342"
"22375530","Factors affecting health-related quality of life in prostate cancer patients","Mickevičienė A, Vanagas G, Ulys A, Jievaltas M, Smailytė G, Padaiga Ž.","Scand J Urol Nephrol. 2012 Jun;46(3):180-7. doi: 10.3109/00365599.2012.661765. Epub 2012 Mar 1.","Mickevičienė A","Scand J Urol Nephrol","2012","2012/03/02","","","10.3109/00365599.2012.661765"
"7679753","Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml","Colberg JW, Smith DS, Catalona WJ.","J Urol. 1993 Mar;149(3):507-9. doi: 10.1016/s0022-5347(17)36130-x.","Colberg JW","J Urol","1993","1993/03/01","","","10.1016/s0022-5347(17)36130-x"
"24637419","Prostate cancer: substratification of intermediate-risk disease using the current NCCN criteria","Killock D.","Nat Rev Urol. 2014 Apr;11(4):188. doi: 10.1038/nrurol.2014.66. Epub 2014 Mar 18.","Killock D","Nat Rev Urol","2014","2014/03/19","","","10.1038/nrurol.2014.66"
"22641163","Prostate cancer: PSA testing in older men--are we following the guidelines?","Dale W.","Nat Rev Urol. 2012 May 29;9(7):357-8. doi: 10.1038/nrurol.2012.115.","Dale W","Nat Rev Urol","2012","2012/05/30","","","10.1038/nrurol.2012.115"
"3275341","Controversy over surgery vs radiation for localized prostate cancer","","Oncology (Williston Park). 1987 Jul;1(5):13-4, 18-9.","","Oncology (Williston Park)","1987","1987/07/01","","",""
"18160689","Clinical practice. Localized prostate cancer","Walsh PC, DeWeese TL, Eisenberger MA.","N Engl J Med. 2007 Dec 27;357(26):2696-705. doi: 10.1056/NEJMcp0706784.","Walsh PC","N Engl J Med","2007","2007/12/28","","","10.1056/NEJMcp0706784"
"15066932","Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer","García Rodríguez LA, González-Pérez A.","Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):649-53.","García Rodríguez LA","Cancer Epidemiol Biomarkers Prev","2004","2004/04/07","","",""
"19027219","Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review","Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R.","Eur Urol. 2009 Apr;55(4):864-73. doi: 10.1016/j.eururo.2008.11.011. Epub 2008 Nov 21.","Alcaraz A","Eur Urol","2009","2008/11/26","","","10.1016/j.eururo.2008.11.011"
"19019564","Usefulness of diffusion-weighted imaging in the localization of prostate cancer","Kajihara H, Hayashida Y, Murakami R, Katahira K, Nishimura R, Hamada Y, Kitani K, Kitaoka M, Suzuki Y, Kitajima M, Hirai T, Morishita S, Awai K, Yamashita Y.","Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):399-403. doi: 10.1016/j.ijrobp.2008.08.017. Epub 2008 Nov 18.","Kajihara H","Int J Radiat Oncol Biol Phys","2009","2008/11/21","","","10.1016/j.ijrobp.2008.08.017"
"25459667","Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era","D'Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F.","Crit Rev Oncol Hematol. 2015 Feb;93(2):136-48. doi: 10.1016/j.critrevonc.2014.10.003. Epub 2014 Oct 17.","D'Angelillo RM","Crit Rev Oncol Hematol","2015","2014/12/03","","","10.1016/j.critrevonc.2014.10.003"
"18325062","Active surveillance: a safe, low-cost prognostic test for prostate cancer","Zietman A.","BJU Int. 2008 May;101(9):1059-60. doi: 10.1111/j.1464-410X.2008.07553.x. Epub 2008 Mar 5.","Zietman A","BJU Int","2008","2008/03/08","","","10.1111/j.1464-410X.2008.07553.x"
"20730590","Exploring cancer support needs for older African-American men with prostate cancer","Jones RA, Wenzel J, Hinton I, Cary M, Jones NR, Krumm S, Ford JG.","Support Care Cancer. 2011 Sep;19(9):1411-9. doi: 10.1007/s00520-010-0967-x. Epub 2010 Aug 22.","Jones RA","Support Care Cancer","2011","2010/08/24","","","10.1007/s00520-010-0967-x"
"23549812","Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?","Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SH, Chung BH.","Yonsei Med J. 2013 May 1;54(3):665-71. doi: 10.3349/ymj.2013.54.3.665.","Lee DH","Yonsei Med J","2013","2013/04/04","PMC3635620","","10.3349/ymj.2013.54.3.665"
"17692178","Update on PSA testing","Gonzalgo ML, Carter HB.","J Natl Compr Canc Netw. 2007 Aug;5(7):737-42. doi: 10.6004/jnccn.2007.0065.","Gonzalgo ML","J Natl Compr Canc Netw","2007","2007/08/19","","","10.6004/jnccn.2007.0065"
"19739124","The effect of study arm on prostate cancer treatment in the large screening trial ERSPC","Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Luján M, Nelen V, Tammela TL, Schröder FH.","Int J Cancer. 2010 May 15;126(10):2387-93. doi: 10.1002/ijc.24870.","Wolters T","Int J Cancer","2010","2009/09/10","","","10.1002/ijc.24870"
"17622507","[Adjuvant hormone therapy for prostate cancer after local treatment in the context of evidence based medicine]","Heine K, Wolff JM.","Urologe A. 2007 Nov;46(11):1534-41. doi: 10.1007/s00120-007-1368-8.","Heine K","Urologe A","2007","2007/07/12","","","10.1007/s00120-007-1368-8"
"24700068","Multiparametric magnetic resonance imaging in the detection of prostate cancer","Durmus T, Baur A, Hamm B.","Aktuelle Urol. 2014 Mar;45(2):119-26. doi: 10.1055/s-0034-1371875. Epub 2014 Apr 3.","Durmus T","Aktuelle Urol","2014","2014/04/05","","","10.1055/s-0034-1371875"
"18430151","The role of testosterone in the pathogenesis of prostate cancer","Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, Komiya A, Nihei N, Naya Y, Ichikawa T.","Int J Urol. 2008 Jun;15(6):472-80. doi: 10.1111/j.1442-2042.2008.02074.x. Epub 2008 Apr 22.","Imamoto T","Int J Urol","2008","2008/04/24","","","10.1111/j.1442-2042.2008.02074.x"
"1950727","Association for Voluntary Surgical Contraception (AVSC) statements about vasectomy and prostate cancer","","Adv Contracept. 1991 Jun-Sep;7(2-3):313-5.","","Adv Contracept","1991","1991/06/01","","",""
"18297820","[Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer]","Tang QL, Yao MY.","Zhonghua Nan Ke Xue. 2008 Jan;14(1):79-82.","Tang QL","Zhonghua Nan Ke Xue","2008","2008/02/27","","",""
"19050683","Management of locally advanced prostate cancer","Payne H.","Asian J Androl. 2009 Jan;11(1):81-7. doi: 10.1038/aja.2008.9. Epub 2008 Dec 1.","Payne H","Asian J Androl","2009","2008/12/04","PMC3735210","","10.1038/aja.2008.9"
"21381010","Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression","Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK.","Cancer. 2011 Mar 15;117(6):1172-82. doi: 10.1002/cncr.25504. Epub 2010 Nov 8.","Anees M","Cancer","2011","2011/03/08","","","10.1002/cncr.25504"
"27356204","Current Status of Prostate Cancer Diagnosis and Management in the United States","Maurice MJ, Kim SP, Abouassaly R.","JAMA Oncol. 2016 Nov 1;2(11):1505-1507. doi: 10.1001/jamaoncol.2016.1785.","Maurice MJ","JAMA Oncol","2016","2016/06/30","","","10.1001/jamaoncol.2016.1785"
"8965375","[Diagnosis and treatment of bladder and prostate cancer in early stages]","Watanabe H, Nakagawa S, Kojima M.","Nihon Rinsho. 1996 May;54(5):1405-9.","Watanabe H","Nihon Rinsho","1996","1996/05/01","","",""
"1616866","Analogues of LHRH versus orchidectomy: comparison of economic costs for castration in advanced prostate cancer","Rutqvist LE, Wilking N.","Br J Cancer. 1992 Jun;65(6):927-9. doi: 10.1038/bjc.1992.194.","Rutqvist LE","Br J Cancer","1992","1992/06/01","PMC1977763","","10.1038/bjc.1992.194"
"8609674","PSA screening and prostate cancer incidence","Berman JJ, Moore GW, Alonsozana EL, Brown LA.","JAMA. 1996 Apr 17;275(15):1155-6.","Berman JJ","JAMA","1996","1996/04/17","","",""
"7690013","New prostate cancer screening guidelines","Wartinger DD.","J Am Osteopath Assoc. 1993 Jul;93(7):736.","Wartinger DD","J Am Osteopath Assoc","1993","1993/07/01","","",""
"29558314","Prostate Cancer: Improving the Flow of Research","Lawton CAF.","Radiology. 2018 Apr;287(1):5-9. doi: 10.1148/radiol.2018171046.","Lawton CAF","Radiology","2018","2018/03/21","","","10.1148/radiol.2018171046"
"25765848","Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches","Matei DV, Ferro M, Jereczek-Fossa BA, Renne G, Crisan N, Bottero D, Mazzarella C, Terracciano D, Autorino R, De Cobelli O.","Urol Int. 2015;94(4):373-82. doi: 10.1159/000371893. Epub 2015 Mar 4.","Matei DV","Urol Int","2015","2015/03/14","","","10.1159/000371893"
"16402596","RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin","","Oncology (Williston Park). 2005 Aug;19(9):1142.","","Oncology (Williston Park)","2005","2006/01/13","","",""
"2059016","Transrectal ultrasound. An aid to diagnosing prostate cancer","Stevens JK, Miller JI.","AORN J. 1991 May;53(5):1166-70, 1172-8. doi: 10.1016/s0001-2092(07)69253-9.","Stevens JK","AORN J","1991","1991/05/01","","","10.1016/s0001-2092(07)69253-9"
"2220525","Screening for prostate cancer. The U.S. Preventive Services Task Force","","Am Fam Physician. 1990 Oct;42(4):991-4.","","Am Fam Physician","1990","1990/10/01","","",""
"24339711","Diagnostic role of prostate resection in the elderly patients who experience significant co-morbidity with a high clinical suspicion of prostate cancer","Kang HW, Yang JB, Kwon WA, Lee YS, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim IY, Kim WJ.","J Korean Med Sci. 2013 Dec;28(12):1796-800. doi: 10.3346/jkms.2013.28.12.1796. Epub 2013 Nov 26.","Kang HW","J Korean Med Sci","2013","2013/12/17","PMC3857377","","10.3346/jkms.2013.28.12.1796"
"24662729","Prostate cancer: radiotherapy-treating patients in a fast-moving field","Payton S.","Nat Rev Urol. 2014 Apr;11(4):183. doi: 10.1038/nrurol.2014.72. Epub 2014 Mar 25.","Payton S","Nat Rev Urol","2014","2014/03/26","","","10.1038/nrurol.2014.72"
"24369138","Tools to identify the men with prostate cancer most appropriate for active surveillance?","Getzenberg RH.","Asian J Androl. 2014 Jan-Feb;16(1):97-8. doi: 10.4103/1008-682X.122369.","Getzenberg RH","Asian J Androl","2014","2013/12/27","PMC3901887","","10.4103/1008-682X.122369"
"8797969","Primary staging of prostate cancer","Jager GJ, Barentz JO, Ruijter ET, de la Rosette JJ, Oosterhof GO.","Eur Radiol. 1996;6(2):134-9. doi: 10.1007/BF00181127.","Jager GJ","Eur Radiol","1996","1996/01/01","","","10.1007/BF00181127"
"23508824","Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis","Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R, Mucci LA.","Ann Oncol. 2013 Jun;24(6):1427-34. doi: 10.1093/annonc/mdt077. Epub 2013 Mar 18.","Park HS","Ann Oncol","2013","2013/03/20","PMC3660083","","10.1093/annonc/mdt077"
"17984999","Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells","Miki J, Rhim JS.","Prostate Cancer Prostatic Dis. 2008;11(1):32-9. doi: 10.1038/sj.pcan.4501018. Epub 2007 Nov 6.","Miki J","Prostate Cancer Prostatic Dis","2008","2007/11/07","","","10.1038/sj.pcan.4501018"
"17656031","The androgen receptor and prostate cancer: a role for sexual selection and sexual conflict?","Summers K, Crespi B.","Med Hypotheses. 2008;70(2):435-43. doi: 10.1016/j.mehy.2007.04.044. Epub 2007 Jul 25.","Summers K","Med Hypotheses","2008","2007/07/28","","","10.1016/j.mehy.2007.04.044"
"15046679","Androgen-deprivation therapy for prostate cancer","Higano C.","Clin Prostate Cancer. 2003 Jun;2(1):22-3. doi: 10.1016/s1540-0352(11)70015-4.","Higano C","Clin Prostate Cancer","2003","2004/03/30","","","10.1016/s1540-0352(11)70015-4"
"19512934","PSA testing in Austria: induced morbidity and saved mortality","Vutuc C, Waldhoer T, Lunglmayr G, Hoeltl W, Haidinger G.","Eur J Cancer Prev. 2009 Sep;18(5):377-80. doi: 10.1097/CEJ.0b013e32832e092f.","Vutuc C","Eur J Cancer Prev","2009","2009/06/11","","","10.1097/CEJ.0b013e32832e092f"
"22127918","Prospects in radionuclide imaging of prostate cancer","Lütje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, Mulders PF.","Prostate. 2012 Aug 1;72(11):1262-72. doi: 10.1002/pros.22462. Epub 2011 Nov 29.","Lütje S","Prostate","2012","2011/12/01","","","10.1002/pros.22462"
"25345838","Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity","Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ.","BJU Int. 2015 Oct;116(4):596-603. doi: 10.1111/bju.12969. Epub 2015 Jan 27.","Steinberger E","BJU Int","2015","2014/10/28","","","10.1111/bju.12969"
"10470211","Prostate-specific antigen (PSA) and radiotherapy in locally confined prostate cancer","Schaefer U, Micke O, Willich N.","Anticancer Res. 1999 Jul-Aug;19(4A):2645-8.","Schaefer U","Anticancer Res","1999","1999/09/02","","",""
"23097534","Mixed results after 10 years for men given postoperative radiotherapy for prostate cancer","","BMJ. 2012 Oct 24;345:e7067. doi: 10.1136/bmj.e7067.","","BMJ","2012","2012/10/26","","","10.1136/bmj.e7067"
"12212417","Prostate cancer: management and controversies","Lee F, Patel HR.","Hosp Med. 2002 Aug;63(8):465-70. doi: 10.12968/hosp.2002.63.8.1966.","Lee F","Hosp Med","2002","2002/09/06","","","10.12968/hosp.2002.63.8.1966"
"9052476","Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group","","Br J Urol. 1997 Feb;79(2):235-46. doi: 10.1046/j.1464-410x.1997.d01-6840.x.","","Br J Urol","1997","1997/02/01","","","10.1046/j.1464-410x.1997.d01-6840.x"
"15040868","Clinical trials of atrasentan in hormone-refractory prostate cancer","Lee D.","Clin Prostate Cancer. 2003 Sep;2(2):84-6. doi: 10.1016/s1540-0352(11)70025-7.","Lee D","Clin Prostate Cancer","2003","2004/03/26","","","10.1016/s1540-0352(11)70025-7"
"10591825","Superior vena cava obstruction in prostate cancer","Old SE.","Clin Oncol (R Coll Radiol). 1999;11(5):352-4. doi: 10.1053/clon.1999.9079.","Old SE","Clin Oncol (R Coll Radiol)","1999","1999/12/11","","","10.1053/clon.1999.9079"
"24325407","Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)--a comparison between 2004-2006 and 2007-2009","Tanaka N, Hirayama A, Yoneda T, Yoshida K, Shimada K, Konishi N, Fujimoto K.","BMC Cancer. 2013 Dec 10;13:588. doi: 10.1186/1471-2407-13-588.","Tanaka N","BMC Cancer","2013","2013/12/12","PMC4028809","","10.1186/1471-2407-13-588"
"26329497","Lymph-node relapsed prostate cancer management and PET-driven external beam radiotherapy: salvage or palliative treatment?","Vavassori V, Alongi F, D'agostino GA, Della Bosca E, Scorsetti M.","Q J Nucl Med Mol Imaging. 2015 Dec;59(4):411-9. Epub 2015 Sep 1.","Vavassori V","Q J Nucl Med Mol Imaging","2015","2015/09/03","","",""
"11547065","Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer","Belldegrun A, Bander NH, Lerner SP, Wood DP, Pantuck AJ.","J Urol. 2001 Oct;166(4):1316-21. doi: 10.1016/s0022-5347(05)65760-6.","Belldegrun A","J Urol","2001","2001/09/08","","","10.1016/s0022-5347(05)65760-6"
"19027220","Editorial comment on: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review","Ahyai SA, Schlomm T.","Eur Urol. 2009 Apr;55(4):874-5. doi: 10.1016/j.eururo.2008.11.013. Epub 2008 Nov 21.","Ahyai SA","Eur Urol","2009","2008/11/26","","","10.1016/j.eururo.2008.11.013"
"11783074","[Evaluation of methods of detection for prostate neoplasm]","Zhong C, Chen M, Wan B.","Zhonghua Zhong Liu Za Zhi. 2001 Jan;23(1):64-6.","Zhong C","Zhonghua Zhong Liu Za Zhi","2001","2002/01/11","","",""
"30831666","[Prostate Cancer Diagnosed during Androgen Replacement Therapy for Late-Onset Hypogonadism Treatment: A Case Report]","Sunada T, Hama Y, Ikeuchi R, Funada S, Masuda N, Yoshikawa T, Yoshida T, Hataya Y, Komatsu Y, Segawa T.","Hinyokika Kiyo. 2018 Dec;64(12):501-504. doi: 10.14989/ActaUrolJap_64_12_501.","Sunada T","Hinyokika Kiyo","2018","2019/03/05","","","10.14989/ActaUrolJap_64_12_501"
"11888345","Strategies for management of prostate cancer-related bone pain","Pelger RC, Soerdjbalie-Maikoe V, Hamdy NA.","Drugs Aging. 2001;18(12):899-911. doi: 10.2165/00002512-200118120-00002.","Pelger RC","Drugs Aging","2001","2002/03/13","","","10.2165/00002512-200118120-00002"
"19434101","Proton radiation for localized prostate cancer","Coen JJ, Zietman AL.","Nat Rev Urol. 2009 Jun;6(6):324-30. doi: 10.1038/nrurol.2009.83. Epub 2009 May 12.","Coen JJ","Nat Rev Urol","2009","2009/05/13","","","10.1038/nrurol.2009.83"
"27863486","Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis","Brandes A, Koerber F, Schwarzkopf L, Hunger M, Rogowski WH, Waidelich R.","BMC Health Serv Res. 2016 Nov 18;16(1):664. doi: 10.1186/s12913-016-1886-4.","Brandes A","BMC Health Serv Res","2016","2016/11/20","PMC5116165","","10.1186/s12913-016-1886-4"
"2464090","[Histopathological studies of origin of benign prostatic hypertrophy and prostate cancer. Consideration of incidental carcinoma]","Suzuki T, Jinbo S, Inaba S, Shimizu T, Imai K, Yamanaka H, Suzuki K.","Nihon Hinyokika Gakkai Zasshi. 1988 Nov;79(11):1806-10. doi: 10.5980/jpnjurol1928.79.11_1806.","Suzuki T","Nihon Hinyokika Gakkai Zasshi","1988","1988/11/01","","","10.5980/jpnjurol1928.79.11_1806"
"8690660","Prostate cancer--evaluating cancer-free survival: regarding Hahn et al. IJROBP 34(1):41-47; 1996","Lawrence G, Collins B.","Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):855-6. doi: 10.1016/0360-3016(96)84115-0.","Lawrence G","Int J Radiat Oncol Biol Phys","1996","1996/07/01","","","10.1016/0360-3016(96)84115-0"
"21463142","High-risk prostate cancer: the role of radical prostatectomy for local therapy","Ghavamian R, Williams SK, Hakimi AA.","Future Oncol. 2011 Apr;7(4):543-50. doi: 10.2217/fon.11.22.","Ghavamian R","Future Oncol","2011","2011/04/06","","","10.2217/fon.11.22"
"26656523","PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice","Wilt TJ, Dahm P.","J Natl Compr Canc Netw. 2015 Dec;13(12):1566-74. doi: 10.6004/jnccn.2015.0182.","Wilt TJ","J Natl Compr Canc Netw","2015","2015/12/15","","","10.6004/jnccn.2015.0182"
"19210674","Prostate-specific antigen kinetics in localized and advanced prostate cancer","Fitzpatrick JM, Banu E, Oudard S.","BJU Int. 2009 Mar;103(5):578-87. doi: 10.1111/j.1464-410X.2009.08345.x. Epub 2009 Feb 6.","Fitzpatrick JM","BJU Int","2009","2009/02/13","","","10.1111/j.1464-410X.2009.08345.x"
"21134822","[Actualities in prostate cancer in ASCO annual meeting 2010]","Pouessel D, Culine S.","Bull Cancer. 2010 Dec;97(12):1563-72. doi: 10.1684/bdc.2010.1222.","Pouessel D","Bull Cancer","2010","2010/12/08","","","10.1684/bdc.2010.1222"
"27260350","Influence of demographic and tumour variables on prostate cancer treatment with curative intent in Spain. Results of the 2010 national prostate cancer registry","Martínez-Jabaloyas JM, Castelló-Porcar A, González-Baena AC, Cózar-Olmo JM, Miñana-López B, Gómez-Veiga F, Rodriguez-Antolín A; Grupo Español de Cáncer de Próstata.","Actas Urol Esp. 2016 Oct;40(8):485-91. doi: 10.1016/j.acuro.2016.04.011. Epub 2016 May 31.","Martínez-Jabaloyas JM","Actas Urol Esp","2016","2016/06/05","","","10.1016/j.acuro.2016.04.011"
"9064879","[Mortality due to prostatic carcinoma in northern Sweden]","Damber JE, Grönberg H.","Urologe A. 1996 Nov;35(6):443-5. doi: 10.1007/s001200050048.","Damber JE","Urologe A","1996","1996/11/01","","","10.1007/s001200050048"
"8073925","[Current status of prostatic cancer screening]","Morote Robles J.","Actas Urol Esp. 1994 May;18 Suppl:400-3.","Morote Robles J","Actas Urol Esp","1994","1994/05/01","","",""
"15901941","Prostate cancer screening","Wilson SS.","Compr Ther. 2005 Summer;31(2):119-23. doi: 10.1007/s12019-005-0007-9.","Wilson SS","Compr Ther","2005","2005/05/20","","","10.1007/s12019-005-0007-9"
"16372494","Gleason scoring varies among pathologists and this affects clinical risk in patients with prostate cancer","Sooriakumaran P, Lovell DP, Henderson A, Denham P, Langley SE, Laing RW.","Clin Oncol (R Coll Radiol). 2005 Dec;17(8):655-8. doi: 10.1016/j.clon.2005.06.011.","Sooriakumaran P","Clin Oncol (R Coll Radiol)","2005","2005/12/24","","","10.1016/j.clon.2005.06.011"
"29497858","Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results","Yoo S, Park J, Cho SY, Cho MC, Ku JH, Son H, Kwak C, Kim HH, Jeong H.","World J Urol. 2018 Jul;36(7):1047-1053. doi: 10.1007/s00345-018-2239-1. Epub 2018 Mar 1.","Yoo S","World J Urol","2018","2018/03/03","","","10.1007/s00345-018-2239-1"
"31483694","Minimum Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective, Lesion Based Analyses of Patients Treated with Radical Prostatectomy","Leyh-Bannurah SR, Kachanov M, Beyersdorff D, Tian Z, Karakiewicz PI, Tilki D, Fisch M, Maurer T, Graefen M, Budäus L.","J Urol. 2020 Feb;203(2):299-303. doi: 10.1097/JU.0000000000000527. Epub 2019 Sep 4.","Leyh-Bannurah SR","J Urol","2020","2019/09/05","","","10.1097/JU.0000000000000527"
"31909690","Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center","Carlsson S, Benfante N, Alvim R, Sjoberg DD, Vickers A, Reuter VE, Fine SW, Vargas HA, Wiseman M, Mamoor M, Ehdaie B, Laudone V, Scardino P, Eastham J, Touijer K.","J Urol. 2020 Jun;203(6):1117-1121. doi: 10.1097/JU.0000000000000742. Epub 2020 Jan 7.","Carlsson S","J Urol","2020","2020/01/08","","","10.1097/JU.0000000000000742"
"26320516","Single Cell Analysis and Circulating Tumor Cells in Prostate Cancer: Experience of an Observership at Cold Spring Harbor Laboratory, CSH and New York Presbyterian Hospital (Cornell Campus), New York","Pandey S, Khanna A.","Asian Pac J Cancer Prev. 2015;16(14):6173-4. doi: 10.7314/apjcp.2015.16.14.6173.","Pandey S","Asian Pac J Cancer Prev","2015","2015/09/01","","","10.7314/apjcp.2015.16.14.6173"
"7658555","Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity","Lerner SE, Blute ML, Zincke H.","J Urol. 1995 Oct;154(4):1447-52.","Lerner SE","J Urol","1995","1995/10/01","","",""
"19495832","A review of repeat prostate biopsies and the influence of technique on cancer detection: our experience","Quinlan MR, Casey RG, Flynn R, Grainger R, McDermott TE, Thornhill JA.","Ir J Med Sci. 2009 Sep;178(3):287-90. doi: 10.1007/s11845-009-0362-0. Epub 2009 Jun 4.","Quinlan MR","Ir J Med Sci","2009","2009/06/05","","","10.1007/s11845-009-0362-0"
"25675127","Genitourinary small cell malignancies: prostate and bladder","Shatagopam K, Kaimakliotis HZ, Cheng L, Koch MO.","Future Oncol. 2015;11(3):479-88. doi: 10.2217/fon.14.277.","Shatagopam K","Future Oncol","2015","2015/02/13","","","10.2217/fon.14.277"
"2337747","De-differentiation with time in prostate cancer and the influence of treatment on the course of the disease","Cumming JA, Ritchie AW, Goodman CM, McIntyre MA, Chisholm GD.","Br J Urol. 1990 Mar;65(3):271-4. doi: 10.1111/j.1464-410x.1990.tb14725.x.","Cumming JA","Br J Urol","1990","1990/03/01","","","10.1111/j.1464-410x.1990.tb14725.x"
"21806327","PET and PET/CT in radiation treatment planning for prostate cancer","Pinkawa M, Eble MJ, Mottaghy FM.","Expert Rev Anticancer Ther. 2011 Jul;11(7):1033-9. doi: 10.1586/era.11.51.","Pinkawa M","Expert Rev Anticancer Ther","2011","2011/08/03","","","10.1586/era.11.51"
"17430694","The role of high-intensity focused ultrasound in prostate cancer","Lynch JH, Loeb S.","Curr Oncol Rep. 2007 May;9(3):222-5. doi: 10.1007/s11912-007-0025-0.","Lynch JH","Curr Oncol Rep","2007","2007/04/14","","","10.1007/s11912-007-0025-0"
"18708369","The role of the BRCA2 gene in susceptibility to prostate cancer revisited","Ostrander EA, Udler MS.","Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1843-8. doi: 10.1158/1055-9965.EPI-08-0556.","Ostrander EA","Cancer Epidemiol Biomarkers Prev","2008","2008/08/19","PMC2562346","NIHMS62326","10.1158/1055-9965.EPI-08-0556"
"22458267","Quality of life in men receiving radiotherapy and neo-adjuvant androgen deprivation for prostate cancer: results from a prospective longitudinal study","Mc Caughan E, Mc Sorley O, Prue G, Parahoo K, Bunting B, Sullivan JO, McKenna H.","J Adv Nurs. 2013 Jan;69(1):53-65. doi: 10.1111/j.1365-2648.2012.05987.x. Epub 2012 Mar 27.","Mc Caughan E","J Adv Nurs","2013","2012/03/31","","","10.1111/j.1365-2648.2012.05987.x"
"17026724","Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer","Duran I, Tannock IF.","J Gen Intern Med. 2006 Nov;21(11):C6-8. doi: 10.1111/j.1525-1497.2006.00506.x.","Duran I","J Gen Intern Med","2006","2006/10/10","PMC1831660","","10.1111/j.1525-1497.2006.00506.x"
"12060438","Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens","Cam K, Yucel S, Turkeri L, Akdas A.","Int J Urol. 2002 May;9(5):257-60. doi: 10.1046/j.1442-2042.2002.00456.x.","Cam K","Int J Urol","2002","2002/06/13","","","10.1046/j.1442-2042.2002.00456.x"
"24518785","Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy","Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M, Armiñán A, Domínguez-Escrig J, Martínez F, García-Casado Z, Scotlandi K, Vicent MJ, López-Guerrero JA.","J Urol. 2014 Jul;192(1):252-9. doi: 10.1016/j.juro.2014.01.107. Epub 2014 Feb 8.","Casanova-Salas I","J Urol","2014","2014/02/13","","","10.1016/j.juro.2014.01.107"
"24224716","Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study","Bellardita L, Rancati T, Valdagni R.","Int J Urol. 2014 Apr;21(4):375-6. doi: 10.1111/iju.12342. Epub 2013 Nov 13.","Bellardita L","Int J Urol","2014","2013/11/15","","","10.1111/iju.12342"
"23849997","Is it time to change the treatment paradigm for lymph node-positive prostate cancer?","Spahn M.","Eur Urol. 2014 Aug;66(2):200-1. doi: 10.1016/j.eururo.2013.06.040. Epub 2013 Jul 2.","Spahn M","Eur Urol","2014","2013/07/16","","","10.1016/j.eururo.2013.06.040"
"10232167","Nursing management of patients receiving brachytherapy for early stage prostate cancer","Abel LJ, Blatt HJ, Stipetich RL, Fuscardo JA, Zeroski D, Miller SE, Dorsey AT, Butler WM, Merrick GS.","Clin J Oncol Nurs. 1999 Jan;3(1):7-15.","Abel LJ","Clin J Oncol Nurs","1999","1999/05/08","","",""
"8723282","Fox Chase/Stanford study: radiation therapy effective in treating younger men with early-stage prostate cancer","","Oncology (Williston Park). 1996 Apr;10(4):522, 525.","","Oncology (Williston Park)","1996","1996/04/01","","",""
"25583770","Cost implications and complications of overtreatment of low-risk prostate cancer in the United States","Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL.","J Natl Compr Canc Netw. 2015 Jan;13(1):61-8. doi: 10.6004/jnccn.2015.0009.","Aizer AA","J Natl Compr Canc Netw","2015","2015/01/14","","","10.6004/jnccn.2015.0009"
"10814950","Quality of life in men with urinary incontinence after prostate cancer surgery","Powel LL.","J Wound Ostomy Continence Nurs. 2000 May;27(3):174-8. doi: 10.1016/s1071-5754(00)90055-x.","Powel LL","J Wound Ostomy Continence Nurs","2000","2000/05/18","","","10.1016/s1071-5754(00)90055-x"
"17639295","[Gene expression profile in hormone refractory prostate cancer]","Stoss O, Jost N, Czeloth K, Rüschoff J, Henkel T, Albers P.","Urologe A. 2007 Sep;46(9):1117-9. doi: 10.1007/s00120-007-1447-x.","Stoss O","Urologe A","2007","2007/07/20","","","10.1007/s00120-007-1447-x"
"12031863","Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom","Penson DF, Albertsen PC.","Surg Oncol. 2002 Jun;11(1-2):3-11. doi: 10.1016/s0960-7404(02)00009-9.","Penson DF","Surg Oncol","2002","2002/05/29","","","10.1016/s0960-7404(02)00009-9"
"10325489","Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility","Ross RK, Coetzee GA, Pearce CL, Reichardt JK, Bretsky P, Kolonel LN, Henderson BE, Lander E, Altshuler D, Daley G.","Eur Urol. 1999;35(5-6):355-61. doi: 10.1159/000019909.","Ross RK","Eur Urol","1999","1999/05/15","","","10.1159/000019909"
"31858836","Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles","Liu N, Ji J, Qiu H, Shao Z, Wen X, Chen A, Yao S, Zhang X, Yao H, Zhang L.","Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):305-314. doi: 10.1080/21691401.2019.1703726.","Liu N","Artif Cells Nanomed Biotechnol","2020","2019/12/21","","","10.1080/21691401.2019.1703726"
"19070211","Color Doppler quantitative measures to predict outcome of biopsies in prostate cancer","Strigari L, Marsella A, Canitano S, Gomellini S, Arcangeli S, Genovese E, Saracino B, Petrongari MG, Sentinelli S, Crecco M, Benassi M, Arcangeli G.","Med Phys. 2008 Nov;35(11):4793-9. doi: 10.1118/1.2990778.","Strigari L","Med Phys","2008","2008/12/17","","","10.1118/1.2990778"
"17211440","Lack of survival benefit of post-operative radiation therapy in prostate cancer patients with positive lymph nodes","Johnstone PA, Assikis V, Goodman M, Ward KC, Riffenburgh RH, Master V.","Prostate Cancer Prostatic Dis. 2007;10(2):185-8. doi: 10.1038/sj.pcan.4500940. Epub 2007 Jan 9.","Johnstone PA","Prostate Cancer Prostatic Dis","2007","2007/01/11","","","10.1038/sj.pcan.4500940"
"9387599","[A case-control study of prostate cancer]","Du SF, Shi LY, He SP.","Zhonghua Liu Xing Bing Xue Za Zhi. 1996 Dec;17(6):343-5.","Du SF","Zhonghua Liu Xing Bing Xue Za Zhi","1996","1996/12/01","","",""
"20645977","Can lifestyle modification lower the risk of prostate cancer?","Kirby R, Kirby M, Fitzpatrick JM.","BJU Int. 2010 Jul;106(2):157-9. doi: 10.1111/j.1464-410X.2010.09420.x.","Kirby R","BJU Int","2010","2010/07/22","","","10.1111/j.1464-410X.2010.09420.x"
"28736186","Surgery no better than observation for localised prostate cancer","Das M.","Lancet Oncol. 2017 Sep;18(9):e512. doi: 10.1016/S1470-2045(17)30565-X. Epub 2017 Jul 20.","Das M","Lancet Oncol","2017","2017/07/25","","","10.1016/S1470-2045(17)30565-X"
"18801502","Cryosurgery for prostate cancer","Aus G.","J Urol. 2008 Nov;180(5):1882-3. doi: 10.1016/j.juro.2008.08.085. Epub 2008 Sep 17.","Aus G","J Urol","2008","2008/09/20","","","10.1016/j.juro.2008.08.085"
"9780970","Prostate cancer: 2. Natural history","Nam RK, Jewett MA, Krahn MD.","CMAJ. 1998 Sep 22;159(6):685-91.","Nam RK","CMAJ","1998","1998/10/22","PMC1229700","",""
"8853503","What studies should be undertaken in Canada to determine the value of screening for prostate cancer?","","Can J Oncol. 1994 Nov;4 Suppl 1:119-24.","","Can J Oncol","1994","1994/11/01","","",""
"18407727","Linking fatherhood to prostate cancer risk","Jørgensen KT, Frisch M.","Future Oncol. 2008 Apr;4(2):137-40. doi: 10.2217/14796694.4.2.137.","Jørgensen KT","Future Oncol","2008","2008/04/15","","","10.2217/14796694.4.2.137"
"17554943","Optimizing decisions about treatment in locally advanced prostate cancer","Payne H, Lim F.","Br J Hosp Med (Lond). 2007 May;68(5):252-6. doi: 10.12968/hmed.2007.68.5.23331.","Payne H","Br J Hosp Med (Lond)","2007","2007/06/09","","","10.12968/hmed.2007.68.5.23331"
"17172224","[Detection of prostate cancer: yes or no?]","Van Cangh PJ.","Bull Mem Acad R Med Belg. 2006;161(3-4):159-69.","Van Cangh PJ","Bull Mem Acad R Med Belg","2006","2006/12/19","","",""
"10379964","Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates","Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS.","J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24. doi: 10.1093/jnci/91.12.1017.","Hankey BF","J Natl Cancer Inst","1999","1999/06/24","","","10.1093/jnci/91.12.1017"
"8621301","Adjuvant therapy for pathologic stage C prostate cancer: a casualty of the PSA revolution?","Anscher MS.","Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):745-7. doi: 10.1016/0360-3016(95)02294-5.","Anscher MS","Int J Radiat Oncol Biol Phys","1996","1996/02/01","","","10.1016/0360-3016(95)02294-5"
"27364545","Steroid hormone receptors and prostate cancer: role of structural dynamics in therapeutic targeting","Kumar R.","Asian J Androl. 2016 Sep-Oct;18(5):682-6. doi: 10.4103/1008-682X.183380.","Kumar R","Asian J Androl","2016","2016/07/02","PMC5000788","","10.4103/1008-682X.183380"
"12576794","The patient's dilemma: prostate cancer treatment choices","Patel HR, Mirsadraee S, Emberton M.","J Urol. 2003 Mar;169(3):828-33. doi: 10.1097/01.ju.0000052056.27609.8a.","Patel HR","J Urol","2003","2003/02/11","","","10.1097/01.ju.0000052056.27609.8a"
"17157749","Paraneoplastic liver dysfunction in prostate cancer","Shah SH.","J Pain Symptom Manage. 2006 Dec;32(6):511-3. doi: 10.1016/j.jpainsymman.2006.03.015.","Shah SH","J Pain Symptom Manage","2006","2006/12/13","","","10.1016/j.jpainsymman.2006.03.015"
"8701816","Adjuvant radiation therapy for pT3 prostate cancer","Boccon-Gibod L.","Acta Urol Belg. 1996 May;64(2):65-6.","Boccon-Gibod L","Acta Urol Belg","1996","1996/05/01","","",""
"2217459","Biopsy techniques and cytology in prostate cancer","Spaander PJ, Mostofi K, Blom J.","Prog Clin Biol Res. 1990;357:157-8.","Spaander PJ","Prog Clin Biol Res","1990","1990/01/01","","",""
"17374841","Re: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability","Etzioni RD, Ankerst DP, Thompson IM.","J Natl Cancer Inst. 2007 Mar 21;99(6):489-90; author reply 490. doi: 10.1093/jnci/djk100.","Etzioni RD","J Natl Cancer Inst","2007","2007/03/22","","","10.1093/jnci/djk100"
"17387320","'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy","Johnstone PA, Rossi PJ, Jani AB, Master V.","Prostate Cancer Prostatic Dis. 2007;10(3):237-41. doi: 10.1038/sj.pcan.4500963. Epub 2007 Mar 27.","Johnstone PA","Prostate Cancer Prostatic Dis","2007","2007/03/28","","","10.1038/sj.pcan.4500963"
"29548065","Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines","Patel A, Fong L.","Oncology (Williston Park). 2018 Mar 15;32(3):112-20.","Patel A","Oncology (Williston Park)","2018","2018/03/17","","",""
"26793891","[Radiation therapy for prostate cancer in modern era]","Nishimura T.","Nihon Rinsho. 2016 Jan;74(1):120-3.","Nishimura T","Nihon Rinsho","2016","2016/01/23","","",""
"7933235","The role of watchful waiting in the management of localized prostate cancer","Chodak GW.","J Urol. 1994 Nov;152(5 Pt 2):1766-8. doi: 10.1016/s0022-5347(17)32381-9.","Chodak GW","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32381-9"
"19419885","Curative external beam radiotherapy in patients over 80 years of age with localized prostate cancer: a retrospective rare cancer network study","Nguyen TD, Azria D, Brochon D, Poortmans P, Miller RC, Scandolaro L, Majewski W, Krengli M, Abacioglu U, Moretti L, Villa S, Akyol F, Jovenin N.","Crit Rev Oncol Hematol. 2010 Apr;74(1):66-71. doi: 10.1016/j.critrevonc.2009.04.004. Epub 2009 May 5.","Nguyen TD","Crit Rev Oncol Hematol","2010","2009/05/08","","","10.1016/j.critrevonc.2009.04.004"
"26790588","The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy","Rai BP, Baum RP, Patel A, Hughes R, Alonzi R, Lane T, Adshead J, Vasdev N.","Urology. 2016 Sep;95:11-5. doi: 10.1016/j.urology.2015.12.048. Epub 2016 Jan 11.","Rai BP","Urology","2016","2016/01/22","","","10.1016/j.urology.2015.12.048"
"14529309","Range, range modulation, and field radius requirements for proton therapy of prostate cancer","Moyers MF, Miller DW.","Technol Cancer Res Treat. 2003 Oct;2(5):445-7. doi: 10.1177/153303460300200509.","Moyers MF","Technol Cancer Res Treat","2003","2003/10/08","","","10.1177/153303460300200509"
"16614517","The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales in men with prostate cancer: reliability and validity of the Korean version","Hong JH, Jeon SS, Lee HM, Choi YH, Kim S, Choi HY.","J Korean Med Sci. 2006 Apr;21(2):295-9. doi: 10.3346/jkms.2006.21.2.295.","Hong JH","J Korean Med Sci","2006","2006/04/15","PMC2734007","","10.3346/jkms.2006.21.2.295"
"18769375","Early chemotherapy in prostate cancer","Mazhar D, Waxman J.","Nat Clin Pract Urol. 2008 Sep;5(9):486-93. doi: 10.1038/ncpuro1204.","Mazhar D","Nat Clin Pract Urol","2008","2008/09/05","","","10.1038/ncpuro1204"
"10438218","Breast and prostate cancer: genes, hormones and the environment. International symposium. Castle Elmau, Germany, 22-24 April 1999. Abstracts","","J Mol Med (Berl). 1999 Apr;77(4):B1-15.","","J Mol Med (Berl)","1999","1999/08/07","","",""
"10636571","Good quality of life in prostate cancer patients: how can it be obtained?","Fosså SD.","Scand J Urol Nephrol Suppl. 1999;203:51-2. doi: 10.1080/003655999750169385-1.","Fosså SD","Scand J Urol Nephrol Suppl","1999","2000/01/15","","","10.1080/003655999750169385-1"
"7679046","Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications","Zietman AL, Shipley WU, Willett CG.","Cancer. 1993 Feb 1;71(3 Suppl):959-69. doi: 10.1002/1097-0142(19930201)71:3+<959::aid-cncr2820711411>3.0.co;2-l.","Zietman AL","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<959::aid-cncr2820711411>3.0.co;2-l"
"25531194","The role of stem/progenitor cells and Wnt/β-catenin signaling pathway in the patients with prostate cancer","Vatansever HS, Gumus B, Aydogdu O, Sivrikoz ON, Türköz-Uluer E, Kivanç M, Ateşçi YZ, Bugdayci H.","Minerva Urol Nefrol. 2014 Dec;66(4):249-55.","Vatansever HS","Minerva Urol Nefrol","2014","2014/12/23","","",""
"18006217","Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer","Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ.","Eur Urol. 2008 Feb;53(2):244-52. doi: 10.1016/j.eururo.2007.10.052. Epub 2007 Nov 5.","Thomas LN","Eur Urol","2008","2007/11/17","","","10.1016/j.eururo.2007.10.052"
"8305340","Prostate cancer: pelvic nodes revisited--sites, incidence and prospects for treatment with radiotherapy","Neal AJ, Dearnaley DP.","Clin Oncol (R Coll Radiol). 1993;5(5):309-12. doi: 10.1016/s0936-6555(05)80907-0.","Neal AJ","Clin Oncol (R Coll Radiol)","1993","1993/01/01","","","10.1016/s0936-6555(05)80907-0"
"15815193","Relationship between obesity and prostate cancer","Amling CL.","Curr Opin Urol. 2005 May;15(3):167-71. doi: 10.1097/01.mou.0000165550.94663.fb.","Amling CL","Curr Opin Urol","2005","2005/04/09","","","10.1097/01.mou.0000165550.94663.fb"
"12765061","[UCLA/RAND Cancer Prostate Index quality of life questionnaire after external beam radiotherapy for localized prostate cancer: repercussions of complications and quality of life in general]","Almeras C, Zerbib M, Eschwege F, Debré B.","Prog Urol. 2003 Apr;13(2):256-65.","Almeras C","Prog Urol","2003","2003/05/27","","",""
"18162152","[Incidence and pathological features of incidental prostate cancer and clinical significance thereof]","Yang XY, Xia TL, He Q, Li W, Wang JH, Su JW, Li J, Na YQ.","Zhonghua Yi Xue Za Zhi. 2007 Oct 9;87(37):2632-4.","Yang XY","Zhonghua Yi Xue Za Zhi","2007","2007/12/29","","",""
"26957566","What Is a ""Good"" Treatment Decision? Decisional Control, Knowledge, Treatment Decision Making, and Quality of Life in Men with Clinically Localized Prostate Cancer","Orom H, Biddle C, Underwood W 3rd, Nelson CJ, Homish DL.","Med Decis Making. 2016 Aug;36(6):714-25. doi: 10.1177/0272989X16635633. Epub 2016 Mar 8.","Orom H","Med Decis Making","2016","2016/03/10","PMC4930707","NIHMS758209","10.1177/0272989X16635633"
"26439507","Prostate cancer: How to differenti-8 Gleason scores?","Fenner A.","Nat Rev Urol. 2015 Nov;12(11):597. doi: 10.1038/nrurol.2015.245. Epub 2015 Oct 6.","Fenner A","Nat Rev Urol","2015","2015/10/07","","","10.1038/nrurol.2015.245"
"22812050","Nurses play direct role in the care of prostate cancer patients","Pascoe W.","Aust Nurs J. 2012 Jun;19(11):47.","Pascoe W","Aust Nurs J","2012","2012/07/21","","",""
"22454983","[Prostate cancer]","Sakamoto S, Ichikawa T.","Gan To Kagaku Ryoho. 2012 Jan;39(1):43-7.","Sakamoto S","Gan To Kagaku Ryoho","2012","2012/03/30","","",""
"22073900","The lonely female partner: a central aspect of prostate cancer","Bruun P, Pedersen BD, Osther PJ, Wagner L.","Urol Nurs. 2011 Sep-Oct;31(5):294-9.","Bruun P","Urol Nurs","2011","2011/11/12","","",""
"28657393","Contemporary and past challenges of prostate cancer diagnostics","Kaipia A, Riikonen J.","Scand J Urol. 2017 Jun;51(3):193-201. doi: 10.1080/21681805.2017.1329902.","Kaipia A","Scand J Urol","2017","2017/06/29","","","10.1080/21681805.2017.1329902"
"10325518","Statistical considerations of chemoprevention clinical trials in prostate cancer","Sylvester R, Collette L.","Eur Urol. 1999;35(5-6):519-22. doi: 10.1159/000019892.","Sylvester R","Eur Urol","1999","1999/05/15","","","10.1159/000019892"
"29926137","Radiomics and radiogenomics of prostate cancer","Smith CP, Czarniecki M, Mehralivand S, Stoyanova R, Choyke PL, Harmon S, Turkbey B.","Abdom Radiol (NY). 2019 Jun;44(6):2021-2029. doi: 10.1007/s00261-018-1660-7.","Smith CP","Abdom Radiol (NY)","2019","2018/06/22","","","10.1007/s00261-018-1660-7"
"16270077","What is the value of screening for prostate cancer in the US?","Albertsen PC.","Nat Clin Pract Oncol. 2005 Nov;2(11):536-7. doi: 10.1038/ncponc0348.","Albertsen PC","Nat Clin Pract Oncol","2005","2005/11/05","","","10.1038/ncponc0348"
"1984305","Biologic aggressiveness of palpable and nonpalpable prostate cancer: assessment with endosonography","Baran GW, Golin AL, Bergsma CJ, Stone TE, Wilson PR, Reichardt BA, Lobert PF, Locke CS.","Radiology. 1991 Jan;178(1):201-6. doi: 10.1148/radiology.178.1.1984305.","Baran GW","Radiology","1991","1991/01/01","","","10.1148/radiology.178.1.1984305"
"11061892","Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database","Smith CV, Bauer JJ, Connelly RR, Seay T, Kane C, Foley J, Thrasher JB, Kusuda L, Moul JW.","J Urol. 2000 Dec;164(6):1964-7. doi: 10.1016/s0022-5347(05)66929-7.","Smith CV","J Urol","2000","2000/11/04","","","10.1016/s0022-5347(05)66929-7"
"12496994","What's hot in the prostate?","Belldegrun A.","Prostate Cancer Prostatic Dis. 2002;5(2):84-7. doi: 10.1038/sj.pcan.4500589.","Belldegrun A","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500589"
"28427519","A comprehensive review of immunotherapies in prostate cancer","Maia MC, Hansen AR.","Crit Rev Oncol Hematol. 2017 May;113:292-303. doi: 10.1016/j.critrevonc.2017.02.026. Epub 2017 Mar 2.","Maia MC","Crit Rev Oncol Hematol","2017","2017/04/22","","","10.1016/j.critrevonc.2017.02.026"
"19863420","Prostate cancer detection: the value of performing an MRI before a biopsy","Shimizu T, Nishie A, Ro T, Tajima T, Yamaguchi A, Kono S, Honda H.","Acta Radiol. 2009 Nov;50(9):1080-8. doi: 10.3109/02841850903216718.","Shimizu T","Acta Radiol","2009","2009/10/30","","","10.3109/02841850903216718"
"23932157","Quality of life among prostate cancer patients: a prospective longitudinal population-based study","Schaake W, de Groot M, Krijnen WP, Langendijk JA, van den Bergh AC.","Radiother Oncol. 2013 Aug;108(2):299-305. doi: 10.1016/j.radonc.2013.06.039. Epub 2013 Aug 8.","Schaake W","Radiother Oncol","2013","2013/08/13","","","10.1016/j.radonc.2013.06.039"
"20860984","Prostate cancer awareness, knowledge, and screening practices among older men in Oyo State, Nigeria","Oladimeji O, Bidemi YO, Olufisayo JA, Sola AO.","Int Q Community Health Educ. 2009-2010;30(3):271-86. doi: 10.2190/IQ.30.3.g.","Oladimeji O","Int Q Community Health Educ","2009","2010/09/24","","","10.2190/IQ.30.3.g"
"17454947","Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors","Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E.","Scand J Urol Nephrol. 2007;41(2):103-9. doi: 10.1080/00365590600991268.","Robinson D","Scand J Urol Nephrol","2007","2007/04/25","","","10.1080/00365590600991268"
"20008768","Relevance of molecular markers in prostate cancer","Concato J, Uchio E, Wells CK.","Ann Intern Med. 2009 Dec 15;151(12):894; author reply 894-5. doi: 10.7326/0003-4819-151-12-200912150-00016.","Concato J","Ann Intern Med","2009","2009/12/17","","","10.7326/0003-4819-151-12-200912150-00016"
"3624035","Cost comparison of various treatment methods for early prostate cancer","Mittal BB.","Int J Radiat Oncol Biol Phys. 1987 Oct;13(10):1603. doi: 10.1016/0360-3016(87)90332-4.","Mittal BB","Int J Radiat Oncol Biol Phys","1987","1987/10/01","","","10.1016/0360-3016(87)90332-4"
"1836654","[Comparison of rectal examination, transrectal echography, CAT and MRI in the local staging of prostatic carcinoma]","Montorsi F, Guazzoni G, Consonni P, Colombo R, Nava L, Bergamaschi F, Scattoni V, Rigatti P.","Arch Ital Urol Nefrol Androl. 1991 Jun;63 Suppl 2:143-5.","Montorsi F","Arch Ital Urol Nefrol Androl","1991","1991/06/01","","",""
"8018366","Prostate cancer in northern Sweden. Incidence, survival and mortality in relation to tumour grade","Grönberg H, Bergh A, Damber JE, Jonsson H, Lenner P, Angström T.","Acta Oncol. 1994;33(4):359-63. doi: 10.3109/02841869409098429.","Grönberg H","Acta Oncol","1994","1994/01/01","","","10.3109/02841869409098429"
"21296483","Re: Firas Abdollah, Maxine Sun, Rodolphe Thuret, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011;59:88-95","Simone CB 2nd, Simone CB.","Eur Urol. 2011 May;59(5):e29-30; author reply e31-2. doi: 10.1016/j.eururo.2011.01.042. Epub 2011 Feb 1.","Simone CB 2nd","Eur Urol","2011","2011/02/08","","","10.1016/j.eururo.2011.01.042"
"17459273","Bone metabolism and new targets for intervention","Akduman B, Crawford ED.","Curr Urol Rep. 2007 May;8(3):233-8. doi: 10.1007/s11934-007-0011-y.","Akduman B","Curr Urol Rep","2007","2007/04/27","","","10.1007/s11934-007-0011-y"
"11390538","Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy","Crocetti E, Ciatto S, Zappa M.","J Natl Cancer Inst. 2001 Jun 6;93(11):876-7. doi: 10.1093/jnci/93.11.876-a.","Crocetti E","J Natl Cancer Inst","2001","2001/06/08","","","10.1093/jnci/93.11.876-a"
"9224330","A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer","Barry MJ, Fowler FJ Jr, Bin L, Oesterling JE.","J Urol. 1997 Aug;158(2):488-91; discussion 492. doi: 10.1016/s0022-5347(01)64510-5.","Barry MJ","J Urol","1997","1997/08/01","","","10.1016/s0022-5347(01)64510-5"
"22773765","Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development","Etzioni RD.","Evid Based Med. 2013 Apr;18(2):75-6. doi: 10.1136/eb-2012-100803. Epub 2012 Jul 7.","Etzioni RD","Evid Based Med","2013","2012/07/10","","","10.1136/eb-2012-100803"
"29511674","Advances in Localized Prostate Cancer Management","Samadi DB, Feuerstein MA, Jazayeri SB, Kaplan SA, Farahat Y.","Biomed Res Int. 2018 Feb 4;2018:2807813. doi: 10.1155/2018/2807813. eCollection 2018.","Samadi DB","Biomed Res Int","2018","2018/03/08","PMC5817362","","10.1155/2018/2807813"
"25306287","Income inequality and treatment of African American men with high-risk prostate cancer","Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.","Urol Oncol. 2015 Jan;33(1):18.e7-18.e13. doi: 10.1016/j.urolonc.2014.09.005. Epub 2014 Oct 11.","Ziehr DR","Urol Oncol","2015","2014/10/13","","","10.1016/j.urolonc.2014.09.005"
"4410606","[Prostate cancer in Orebro county from 1958-1967]","Dolk T, Fritjofsson A.","Lakartidningen. 1974 Sep 18;71(38):3517-9.","Dolk T","Lakartidningen","1974","1974/09/18","","",""
"9046415","[Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels]","Kihara T, Ito F, Kobayashi C, Ryoji O, Tokumoto T, Iguchi Y, Maeda Y, Onizuka S, Goya N, Nakazawa H, Toma H.","Hinyokika Kiyo. 1997 Jan;43(1):13-8.","Kihara T","Hinyokika Kiyo","1997","1997/01/01","","",""
"10492601","Is it worth diagnosing early prostate cancer?","Naraynsingh V.","West Indian Med J. 1999 Jun;48(2):50-1.","Naraynsingh V","West Indian Med J","1999","1999/09/24","","",""
"8609675","PSA screening and prostate cancer incidence","Rhoads GG, Mills OF.","JAMA. 1996 Apr 17;275(15):1155-6. doi: 10.1001/jama.1996.03530390021014.","Rhoads GG","JAMA","1996","1996/04/17","","","10.1001/jama.1996.03530390021014"
"31335671","Upregulation of microRNA-191 can serve as an independent prognostic marker for poor survival in prostate cancer","Liu JB, Yan YJ, Shi J, Wu YB, Li YF, Dai LF, Ma XT.","Medicine (Baltimore). 2019 Jul;98(29):e16193. doi: 10.1097/MD.0000000000016193.","Liu JB","Medicine (Baltimore)","2019","2019/07/24","PMC6709308","","10.1097/MD.0000000000016193"
"28669765","Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification","Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson RH, Boorjian SA.","J Urol. 2017 Dec;198(6):1286-1294. doi: 10.1016/j.juro.2017.06.085. Epub 2017 Jun 29.","Bhindi B","J Urol","2017","2017/07/04","","","10.1016/j.juro.2017.06.085"
"18059157","Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway","Lehmann BD, McCubrey JA, Terrian DM.","Cancer Biol Ther. 2007 Aug;6(8):1165-70. doi: 10.4161/cbt.6.8.4544. Epub 2007 Aug 5.","Lehmann BD","Cancer Biol Ther","2007","2007/12/07","PMC2889025","NIHMS79775","10.4161/cbt.6.8.4544"
"16765530","Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer","Beard C, Schultz D, Loffredo M, Cote K, Renshaw AA, Hurwitz MD, D'Amico AV.","Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):403-7. doi: 10.1016/j.ijrobp.2006.03.033. Epub 2006 Jun 9.","Beard C","Int J Radiat Oncol Biol Phys","2006","2006/06/13","","","10.1016/j.ijrobp.2006.03.033"
"28714919","Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer","Bryant G, Wang L, Mulholland DJ.","Int J Mol Sci. 2017 Jul 17;18(7):1542. doi: 10.3390/ijms18071542.","Bryant G","Int J Mol Sci","2017","2017/07/18","PMC5536030","","10.3390/ijms18071542"
"9507506","Review of epidemiologic studies of alcohol and prostate cancer: 1971-1996","Breslow RA, Weed DL.","Nutr Cancer. 1998;30(1):1-13. doi: 10.1080/01635589809514633.","Breslow RA","Nutr Cancer","1998","1998/03/21","","","10.1080/01635589809514633"
"26498748","Piloting prostate cancer patient-reported outcomesin clinical practice","Korzeniowski M, Kalyvas M, Mahmud A, Shenfield C, Tong C, Zaza K, Howell D, Brundage M.","Support Care Cancer. 2016 May;24(5):1983-1990. doi: 10.1007/s00520-015-2949-5. Epub 2015 Oct 24.","Korzeniowski M","Support Care Cancer","2016","2015/10/27","","","10.1007/s00520-015-2949-5"
"7540482","Increase of serum prostatic specific antigen and clinical progression in pN + MO prostate cancer","Josefsen D, Waehre H, Paus E, Fosså SD.","Br J Urol. 1995 Apr;75(4):502-6. doi: 10.1111/j.1464-410x.1995.tb07273.x.","Josefsen D","Br J Urol","1995","1995/04/01","","","10.1111/j.1464-410x.1995.tb07273.x"
"12087071","The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white?","Lentsch AB.","FASEB J. 2002 Jul;16(9):1093-5. doi: 10.1096/fj.02-0066hyp.","Lentsch AB","FASEB J","2002","2002/06/28","","","10.1096/fj.02-0066hyp"
"31629413","Urology perspective on the expanding world of germline testing for prostate cancer","Cookson MS.","Can J Urol. 2019 Oct;26(5 Suppl 2):5-6.","Cookson MS","Can J Urol","2019","2019/10/21","","",""
"9719024","DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure","Borre M, Høyer M, Nerstrøm B, Overgaard J.","Prostate. 1998 Sep 1;36(4):244-9. doi: 10.1002/(sici)1097-0045(19980901)36:4<244::aid-pros5>3.0.co;2-f.","Borre M","Prostate","1998","1998/08/27","","","10.1002/(sici)1097-0045(19980901)36:4<244::aid-pros5>3.0.co;2-f"
"18778344","Seminal vesicle amyloidosis does not provide any protection from invasion by prostate cancer","Erbersdobler A, Kollermann J, Graefen M, Röcken C, Schlomm T.","BJU Int. 2009 Feb;103(3):324-6. doi: 10.1111/j.1464-410X.2008.08024.x. Epub 2008 Sep 3.","Erbersdobler A","BJU Int","2009","2008/09/10","","","10.1111/j.1464-410X.2008.08024.x"
"2453076","Incipient prostate cancer: definition, histology, and clinical consequences","Dhom G.","Recent Results Cancer Res. 1988;106:85-93. doi: 10.1007/978-3-642-83245-1_11.","Dhom G","Recent Results Cancer Res","1988","1988/01/01","","","10.1007/978-3-642-83245-1_11"
"18030007","[Prostate cancer]","Fujii Y, Fukui I.","Gan To Kagaku Ryoho. 2007 Nov;34(11):1740-4.","Fujii Y","Gan To Kagaku Ryoho","2007","2007/11/22","","",""
"8950366","Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review","Catalona WJ.","Prostate Suppl. 1996;7:64-9. doi: 10.1002/(sici)1097-0045(1996)7+<64::aid-pros9>3.0.co;2-j.","Catalona WJ","Prostate Suppl","1996","1996/01/01","","","10.1002/(sici)1097-0045(1996)7+<64::aid-pros9>3.0.co;2-j"
"18810381","[Treatment strategies for local advanced prostate cancer]","Kälble T.","Urologe A. 2008 Nov;47(11):1403-4. doi: 10.1007/s00120-008-1871-6.","Kälble T","Urologe A","2008","2008/09/24","","","10.1007/s00120-008-1871-6"
"11291087","Plasma prolactin and prostate cancer risk: A prospective study","Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R.","Int J Cancer. 2001 May 1;92(3):463-5. doi: 10.1002/ijc.1191.","Stattin P","Int J Cancer","2001","2001/04/06","","","10.1002/ijc.1191"
"26792003","[Prostate cancer. Part 1: Review of cell kinetics over the years 1966-2015 and future perspectives of the new grading of the International Society of Urological Pathology (ISUP)]","Helpap B, Bubendorf L.","Pathologe. 2016 Feb;37(1):3-10. doi: 10.1007/s00292-015-0123-y.","Helpap B","Pathologe","2016","2016/01/22","","","10.1007/s00292-015-0123-y"
"24597872","Steroid receptors aplenty in prostate cancer","Sharifi N.","N Engl J Med. 2014 Mar 6;370(10):970-1. doi: 10.1056/NEJMcibr1315706.","Sharifi N","N Engl J Med","2014","2014/03/07","","","10.1056/NEJMcibr1315706"
"18602743","Editorial comment on: adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?","Cozzarini C.","Eur Urol. 2008 Sep;54(3):540-1. doi: 10.1016/j.eururo.2008.06.060. Epub 2008 Jun 23.","Cozzarini C","Eur Urol","2008","2008/07/08","","","10.1016/j.eururo.2008.06.060"
"25578739","Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer","Lei JH, Liu LR, Wei Q, Yan SB, Song TR, Lin FS, Yang L, Cao DH, Yuan HC, Xue WB, Lv X, Cai YC, Zeng H, Han P.","Sci Rep. 2015 Jan 12;5:7713. doi: 10.1038/srep07713.","Lei JH","Sci Rep","2015","2015/01/13","PMC5378991","","10.1038/srep07713"
"15941961","Physical activity and the risk of prostate cancer in the Netherlands cohort study, results after 9.3 years of follow-up","Zeegers MP, Dirx MJ, van den Brandt PA.","Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1490-5. doi: 10.1158/1055-9965.EPI-04-0771.","Zeegers MP","Cancer Epidemiol Biomarkers Prev","2005","2005/06/09","","","10.1158/1055-9965.EPI-04-0771"
"11417970","Markers of bone turnover in prostate cancer","Garnero P.","Cancer Treat Rev. 2001 Jun;27(3):187-92; discussion 193-6. doi: 10.1053/ctrv.2000.0213.","Garnero P","Cancer Treat Rev","2001","2001/06/22","","","10.1053/ctrv.2000.0213"
"24332638","Defining the level of evidence for technology adoption in the localized prostate cancer pathway","Valerio M, El-Shater Bosaily A, Emberton M, Ahmed HU.","Urol Oncol. 2014 Aug;32(6):924-30. doi: 10.1016/j.urolonc.2013.10.008. Epub 2013 Dec 12.","Valerio M","Urol Oncol","2014","2013/12/17","PMC4136740","","10.1016/j.urolonc.2013.10.008"
"17633993","[Cell ploidy: predictive factor of locally advanced prostate cancer]","Milcent S, Lorenzato M, Enaschescu D, Enaschescu C, Birembaut P, Staerman F.","Prog Urol. 2007 Jun;17(4):819-23. doi: 10.1016/s1166-7087(07)92299-x.","Milcent S","Prog Urol","2007","2007/07/20","","","10.1016/s1166-7087(07)92299-x"
"29792198","Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches","Awang ZH, Essler M, Ahmadzadehfar H.","Radiat Oncol. 2018 May 23;13(1):98. doi: 10.1186/s13014-018-1037-7.","Awang ZH","Radiat Oncol","2018","2018/05/25","PMC5966863","","10.1186/s13014-018-1037-7"
"29057511","Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate","Yano A, Kagawa M, Takeshita H, Okada Y, Morozumi M, Kawakami S.","Int J Urol. 2017 Dec;24(12):863-865. doi: 10.1111/iju.13479. Epub 2017 Oct 23.","Yano A","Int J Urol","2017","2017/10/24","","","10.1111/iju.13479"
"30135717","Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects","Frank S, Nelson P, Vasioukhin V.","F1000Res. 2018 Aug 2;7:F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018.","Frank S","F1000Res","2018","2018/08/24","PMC6073096","","10.12688/f1000research.14499.1"
"14624913","Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies","Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, Pummer K, Hubmer G.","Urology. 2003 Nov;62(5):883-7. doi: 10.1016/s0090-4295(03)00663-0.","Zigeuner R","Urology","2003","2003/11/20","","","10.1016/s0090-4295(03)00663-0"
"12622716","Prostate cancer in patients with Hansen's disease","Kiriyama I, Ohgaki K, Ohba S, Egawa K, Nishimura T.","Int J Urol. 2003 Mar;10(3):177-9. doi: 10.1046/j.1442-2042.2003.00584.x.","Kiriyama I","Int J Urol","2003","2003/03/08","","","10.1046/j.1442-2042.2003.00584.x"
"27129857","Photovoice: a Link between Research and Practice for Prostate Cancer Advocacy in Black Communities","Gilbert LR.","J Racial Ethn Health Disparities. 2017 Jun;4(3):364-375. doi: 10.1007/s40615-016-0237-9. Epub 2016 Apr 29.","Gilbert LR","J Racial Ethn Health Disparities","2017","2016/05/01","","","10.1007/s40615-016-0237-9"
"7754364","New clue to prostate cancer spread","Marx J.","Science. 1995 May 12;268(5212):799-800. doi: 10.1126/science.7754364.","Marx J","Science","1995","1995/05/12","","","10.1126/science.7754364"
"23562839","The fat side of prostate cancer","Zadra G, Photopoulos C, Loda M.","Biochim Biophys Acta. 2013 Oct;1831(10):1518-32. doi: 10.1016/j.bbalip.2013.03.010. Epub 2013 Apr 2.","Zadra G","Biochim Biophys Acta","2013","2013/04/09","PMC3766375","NIHMS473496","10.1016/j.bbalip.2013.03.010"
"21854304","Provenge: combating prostate cancer with a vengeance?","Schwaab T, Pili R.","Expert Rev Vaccines. 2011 Aug;10(8):1113-4. doi: 10.1586/erv.11.85.","Schwaab T","Expert Rev Vaccines","2011","2011/08/23","","","10.1586/erv.11.85"
"30502104","Dissemination of Misinformative and Biased Information about Prostate Cancer on YouTube","Loeb S, Sengupta S, Butaney M, Macaluso JN Jr, Czarniecki SW, Robbins R, Braithwaite RS, Gao L, Byrne N, Walter D, Langford A.","Eur Urol. 2019 Apr;75(4):564-567. doi: 10.1016/j.eururo.2018.10.056. Epub 2018 Nov 28.","Loeb S","Eur Urol","2019","2018/12/04","","","10.1016/j.eururo.2018.10.056"
"30713089","Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer","Tierney JF, Vale CL, Parelukar WR, Rydzewska L, Halabi S.","Eur Urol Focus. 2019 Mar;5(2):137-143. doi: 10.1016/j.euf.2019.01.005. Epub 2019 Feb 1.","Tierney JF","Eur Urol Focus","2019","2019/02/05","","","10.1016/j.euf.2019.01.005"
"12837821","The prostate cancer conundrum","Albertsen PC.","J Natl Cancer Inst. 2003 Jul 2;95(13):930-1. doi: 10.1093/jnci/95.13.930.","Albertsen PC","J Natl Cancer Inst","2003","2003/07/03","","","10.1093/jnci/95.13.930"
"10081469","Prostate cancer: 11. Alternative approaches and the future of treatment","Trachtenberg J, Crook J, Tannock IF.","CMAJ. 1999 Feb 23;160(4):528-34.","Trachtenberg J","CMAJ","1999","1999/03/19","PMC1230078","",""
"25761682","Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1","Xuan H, Xue W, Pan J, Sha J, Dong B, Huang Y.","Biochemistry (Mosc). 2015 Mar;80(3):276-83. doi: 10.1134/S0006297915030037.","Xuan H","Biochemistry (Mosc)","2015","2015/03/13","","","10.1134/S0006297915030037"
"20432116","Theorizing about social support and health communication in a prostate cancer support group","Arrington MI.","J Psychosoc Oncol. 2010;28(3):260-8. doi: 10.1080/07347331003678337.","Arrington MI","J Psychosoc Oncol","2010","2010/05/01","","","10.1080/07347331003678337"
"22385713","Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to ""Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI"": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727)","Dal Pra A, Milosevic M, Hill R, Wouters B, Warde P, Bristow RG.","Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1319. doi: 10.1016/j.ijrobp.2011.11.017.","Dal Pra A","Int J Radiat Oncol Biol Phys","2012","2012/03/06","","","10.1016/j.ijrobp.2011.11.017"
"29231062","Promising immunotherapy for prostate cancer","Henegan JC, Sonpavde G.","Expert Opin Biol Ther. 2018 Feb;18(2):109-120. doi: 10.1080/14712598.2018.1406916. Epub 2017 Dec 12.","Henegan JC","Expert Opin Biol Ther","2018","2017/12/13","","","10.1080/14712598.2018.1406916"
"19647427","History of prostate cancer treatment","Sriprasad S, Feneley MR, Thompson PM.","Surg Oncol. 2009 Sep;18(3):185-91. doi: 10.1016/j.suronc.2009.07.001. Epub 2009 Jul 31.","Sriprasad S","Surg Oncol","2009","2009/08/04","","","10.1016/j.suronc.2009.07.001"
"23164392","Clinically significant prostate cancer is rarely missed by ablative procedures of the prostate in men with prostate specific antigen less than 4 ng/ml","Meeks JJ, Maschino AC, McVary KT, Sandhu JS.","J Urol. 2013 Jan;189(1):111-5. doi: 10.1016/j.juro.2012.08.093. Epub 2012 Nov 16.","Meeks JJ","J Urol","2013","2012/11/21","","","10.1016/j.juro.2012.08.093"
"16353826","Sexual consequences of prostate cancer treatment","Hoehn JB.","Can Fam Physician. 2005 Nov;51(11):1472.","Hoehn JB","Can Fam Physician","2005","2005/12/16","PMC1479481","",""
"15926404","The liability of giving patients a choice: shared decision making and prostate cancer","Woolf SH, Krist A.","Am Fam Physician. 2005 May 15;71(10):1871-2.","Woolf SH","Am Fam Physician","2005","2005/06/02","","",""
"27708246","A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors","Ahmad AS, Vasiljević N, Carter P, Berney DM, Møller H, Foster CS, Cuzick J, Lorincz AT.","Oncotarget. 2016 Nov 1;7(44):71833-71840. doi: 10.18632/oncotarget.12377.","Ahmad AS","Oncotarget","2016","2016/10/07","PMC5342126","","10.18632/oncotarget.12377"
"8853498","Early detection of prostate cancer. Recommendations from the Canadian Urological Association","Ramsey EW.","Can J Oncol. 1994 Nov;4 Suppl 1:82-5.","Ramsey EW","Can J Oncol","1994","1994/11/01","","",""
"12556955","Effectiveness and cost-effectiveness of prognostic markers in prostate cancer","Calvert NW, Morgan AB, Catto JW, Hamdy FC, Akehurst RL, Mouncey P, Paisley S.","Br J Cancer. 2003 Jan 13;88(1):31-5. doi: 10.1038/sj.bjc.6600630.","Calvert NW","Br J Cancer","2003","2003/01/31","PMC2376796","","10.1038/sj.bjc.6600630"
"25155557","Advances in local and ablative treatment of oligometastasis in prostate cancer","Yao HH, Hong MKh, Corcoran NM, Siva S, Foroudi F.","Asia Pac J Clin Oncol. 2014 Dec;10(4):308-21. doi: 10.1111/ajco.12256. Epub 2014 Aug 25.","Yao HH","Asia Pac J Clin Oncol","2014","2014/08/27","","","10.1111/ajco.12256"
"22571442","Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-Related Quality of Life (HrQoL) over time among men treated for localized prostate cancer","Cruess DG, Benedict C, Lattie EG, Molton I, Kinsinger D, Kava B, Manoharan M, Soloway M, Penedo FJ.","J Pers Assess. 2013;95(1):54-61. doi: 10.1080/00223891.2012.681819. Epub 2012 May 9.","Cruess DG","J Pers Assess","2013","2012/05/11","PMC4347933","NIHMS402249","10.1080/00223891.2012.681819"
"20718249","Who, when, where, and how: salvage prostate cancer with radiotherapy","Chien CP, Roach M 3rd.","Oncology (Williston Park). 2010 Jul;24(8):702, 704.","Chien CP","Oncology (Williston Park)","2010","2010/08/20","","",""
"16254712","Comment by E. Weiss and C. F. Hess on G. M. Villeirs et al. ""Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer"" in: Strahlenther Onkol 2005;181:424-30 (No. 7)","Weiss E, Hess CF.","Strahlenther Onkol. 2005 Nov;181(11):743-4; author reply 745-6. doi: 10.1007/s00066-005-9383-4.","Weiss E","Strahlenther Onkol","2005","2005/10/29","","","10.1007/s00066-005-9383-4"
"15878111","Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation","McAleese J, O'Sullivan JM.","Radiother Oncol. 2005 Apr;75(1):121. doi: 10.1016/j.radonc.2005.02.005. Epub 2005 Mar 16.","McAleese J","Radiother Oncol","2005","2005/05/10","","","10.1016/j.radonc.2005.02.005"
"18813901","[Radiotherapy for locally advanced prostate cancer]","Herfarth K, Sterzing F.","Urologe A. 2008 Nov;47(11):1424-30. doi: 10.1007/s00120-008-1872-5.","Herfarth K","Urologe A","2008","2008/09/25","","","10.1007/s00120-008-1872-5"
"3631892","Pretreatment transurethral resection of prostate cancer and disease-free survival","Natarajan N, Mettlin C, Murphy GP, Schmidt J.","Anticancer Res. 1987 May-Jun;7(3 Pt B):395-9.","Natarajan N","Anticancer Res","1987","1987/05/01","","",""
"11519764","A prospective study on intake of animal products and risk of prostate cancer","Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willet WC, Giovannucci E.","Cancer Causes Control. 2001 Aug;12(6):557-67. doi: 10.1023/a:1011256201044.","Michaud DS","Cancer Causes Control","2001","2001/08/25","","","10.1023/a:1011256201044"
"2471347","Histopathology of prostate cancer: prediction of malignant behavior and correlation with ultrasonography","Miller GJ.","Urology. 1989 Jun;33(6 Suppl):18-26. doi: 10.1016/s0090-4295(89)80004-4.","Miller GJ","Urology","1989","1989/06/01","","","10.1016/s0090-4295(89)80004-4"
"8172710","Role of maximal androgen blockade in advanced prostate cancer","Denis L.","Prostate Suppl. 1994;5:17-22. doi: 10.1002/pros.2990250707.","Denis L","Prostate Suppl","1994","1994/01/01","","","10.1002/pros.2990250707"
"23819189","Prostate biopsy: what to expect. Here are the benefits, risks, and uncertainties of the only diagnostic procedure that can tell you whether you have prostate cancer","","Harv Mens Health Watch. 2013 Jan;17(6):4-5.","","Harv Mens Health Watch","2013","2013/07/04","","",""
"10768873","Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system","Uchida K, Takeshima H, Akaza H, Ono Y.","Jpn J Clin Oncol. 2000 Feb;30(2):95-100. doi: 10.1093/jjco/hyd021.","Uchida K","Jpn J Clin Oncol","2000","2000/04/18","","","10.1093/jjco/hyd021"
"28609648","When no treatment is the best treatment: Active surveillance strategies for low risk prostate cancers","Stavrinides V, Parker CC, Moore CM.","Cancer Treat Rev. 2017 Jul;58:14-21. doi: 10.1016/j.ctrv.2017.05.004. Epub 2017 May 23.","Stavrinides V","Cancer Treat Rev","2017","2017/06/14","","","10.1016/j.ctrv.2017.05.004"
"7853548","Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer","Lui PD, Terris MK, McNeal JE, Stamey TA.","J Urol. 1995 Mar;153(3 Pt 2):1000-3.","Lui PD","J Urol","1995","1995/03/01","","",""
"17419566","[Prostate cancer epidemiology]","Beuzeboc P; Membres du CCAFU.","Soins. 2007 Mar;(713):32-3.","Beuzeboc P","Soins","2007","2007/04/11","","",""
"26384005","Human endogenous retrovirus HERV-K(HML-2) activity in prostate cancer is dominated by a few loci","Goering W, Schmitt K, Dostert M, Schaal H, Deenen R, Mayer J, Schulz WA.","Prostate. 2015 Dec;75(16):1958-71. doi: 10.1002/pros.23095. Epub 2015 Sep 18.","Goering W","Prostate","2015","2015/09/19","","","10.1002/pros.23095"
"26572085","Prostate cancer: Galeterone ARMORs up against CRPC","Fenner A.","Nat Rev Urol. 2016 Jan;13(1):2. doi: 10.1038/nrurol.2015.279. Epub 2015 Nov 17.","Fenner A","Nat Rev Urol","2016","2015/11/18","","","10.1038/nrurol.2015.279"
"16406963","Sentinel lymph node mapping in prostate cancer: opportunities remain to identify truly positive nodes","Petros JA.","J Urol. 2006 Feb;175(2):421-2. doi: 10.1016/S0022-5347(05)00397-6.","Petros JA","J Urol","2006","2006/01/13","","","10.1016/S0022-5347(05)00397-6"
"7505981","PSA after definitive radiotherapy for clinically localized prostate cancer","Goad JR, Chang SJ, Ohori M, Scardino PT.","Urol Clin North Am. 1993 Nov;20(4):727-36.","Goad JR","Urol Clin North Am","1993","1993/11/01","","",""
"12913104","The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes","Taplin ME, Kantoff PW.","J Clin Oncol. 2003 Oct 1;21(19):3552-3. doi: 10.1200/JCO.2003.07.083. Epub 2003 Aug 11.","Taplin ME","J Clin Oncol","2003","2003/08/13","","","10.1200/JCO.2003.07.083"
"25454610","Prostate cancer outcomes: the three questions","Glaser AW, Corner JL.","Eur Urol. 2015 Mar;67(3):357-8. doi: 10.1016/j.eururo.2014.10.023. Epub 2014 Nov 10.","Glaser AW","Eur Urol","2015","2014/12/03","","","10.1016/j.eururo.2014.10.023"
"14710249","[Expressions of MAD2 and p55CDC in prostate cancer and their correlations with the prostate cancer grading]","Xu K, Wang X, Xue W, Wang X, Hou S.","Beijing Da Xue Xue Bao Yi Xue Ban. 2003 Dec 18;35(6):586-90.","Xu K","Beijing Da Xue Xue Bao Yi Xue Ban","2003","2004/01/08","","",""
"11280130","Progress in the control of prostate cancer, Rhode Island, 1987-1998","Fulton JP.","Med Health R I. 2001 Mar;84(3):100-1.","Fulton JP","Med Health R I","2001","2001/03/31","","",""
"7803727","The epidemiology of prostate cancer: clues for chemoprevention","Pienta KJ.","In Vivo. 1994 May-Jun;8(3):419-22.","Pienta KJ","In Vivo","1994","1994/05/01","","",""
"7529429","Clinical utility of cellular DNA measurements in prostate carcinoma. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993","Schröder F, Tribukait B, Böcking A, DeVere White R, Koss L, Lieber M, Stenkvist B, Zetterberg A.","Scand J Urol Nephrol Suppl. 1994;162:51-63; discussion 15-27.","Schröder F","Scand J Urol Nephrol Suppl","1994","1994/01/01","","",""
"1574450","Local staging of prostate cancer with transrectal ultrasound: a literature review","Lorentzen T, Nerstrom H, Iversen P, Torp-Pedersen ST.","Prostate Suppl. 1992;4:11-6. doi: 10.1002/pros.2990210504.","Lorentzen T","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210504"
"32049793","Long non-coding RNA small nucleolar RNA host gene 7 expression level in prostate cancer tissues predicts the prognosis of patients with prostate cancer","Xia Q, Li J, Yang Z, Zhang D, Tian J, Gu B.","Medicine (Baltimore). 2020 Feb;99(7):e18993. doi: 10.1097/MD.0000000000018993.","Xia Q","Medicine (Baltimore)","2020","2020/02/13","PMC7035107","","10.1097/MD.0000000000018993"
"19402048","Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy","Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, Guo CC, Kuban DA, Johnson MM, Pisters LL.","Cancer. 2009 Jul 1;115(13):2872-80. doi: 10.1002/cncr.24326.","Tu SM","Cancer","2009","2009/04/30","","","10.1002/cncr.24326"
"17635949","Prostate cancer quality of life: beyond initial treatment and the patient","Talcott JA.","J Clin Oncol. 2007 Sep 20;25(27):4155-6. doi: 10.1200/JCO.2007.12.1996. Epub 2007 Jul 16.","Talcott JA","J Clin Oncol","2007","2007/07/20","","","10.1200/JCO.2007.12.1996"
"7935297","The use of radical prostatectomy to treat localized prostate cancer: an emerging consensus on treatment","Fortune GJ, Chehval MJ, Hardy DA, Ross G, Laiben GR.","Mo Med. 1994 Sep;91(9):585-8.","Fortune GJ","Mo Med","1994","1994/09/01","","",""
"16775868","On call. My 77-year-old father is healthy, but his older brother has just been diagnosed with prostate cancer. Dad says he read that carrot juice will prevent prostate cancer, and he's now drinking it every day. Is he just kidding himself?","Simon HB.","Harv Mens Health Watch. 2006 Jun;10(11):8.","Simon HB","Harv Mens Health Watch","2006","2006/06/17","","",""
"25519703","Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer","Rajan P, Stockley J, Sudbery IM, Fleming JT, Hedley A, Kalna G, Sims D, Ponting CP, Heger A, Robson CN, McMenemin RM, Pedley ID, Leung HY.","BMC Cancer. 2014 Dec 18;14:977. doi: 10.1186/1471-2407-14-977.","Rajan P","BMC Cancer","2014","2014/12/19","PMC4301544","","10.1186/1471-2407-14-977"
"18951581","Optimal parameters for the destruction of prostate cancer using irreversible electroporation","Rubinsky J, Onik G, Mikus P, Rubinsky B.","J Urol. 2008 Dec;180(6):2668-74. doi: 10.1016/j.juro.2008.08.003. Epub 2008 Oct 31.","Rubinsky J","J Urol","2008","2008/10/28","","","10.1016/j.juro.2008.08.003"
"17158750","Androgen receptor corepressors and prostate cancer","Burd CJ, Morey LM, Knudsen KE.","Endocr Relat Cancer. 2006 Dec;13(4):979-94. doi: 10.1677/erc.1.01115.","Burd CJ","Endocr Relat Cancer","2006","2006/12/13","","","10.1677/erc.1.01115"
"20299498","Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data","Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y.","Jpn J Clin Oncol. 2010 Jun;40(6):588-92. doi: 10.1093/jjco/hyq008. Epub 2010 Mar 18.","Tanaka N","Jpn J Clin Oncol","2010","2010/03/20","","","10.1093/jjco/hyq008"
"16021571","Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens","Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL, Bostwick DG.","Hum Pathol. 2005 Jun;36(6):646-54. doi: 10.1016/j.humpath.2005.03.018.","Montironi R","Hum Pathol","2005","2005/07/16","","","10.1016/j.humpath.2005.03.018"
"15854351","[Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer]","Niu YN, Xin DQ, He ZS, Zhou LQ, Pan BN, Na YQ, Guo YL.","Zhonghua Wai Ke Za Zhi. 2005 Mar 15;43(6):394-7.","Niu YN","Zhonghua Wai Ke Za Zhi","2005","2005/04/28","","",""
"25791432","Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?","Augustin H, Mayerhofer K, Seles M, Pummer K.","Urol Int. 2015;95(2):125-31. doi: 10.1159/000371895. Epub 2015 Mar 17.","Augustin H","Urol Int","2015","2015/03/21","","","10.1159/000371895"
"2029395","The epidemiology of prostatic cancer. Geographical distribution and time-trends","Muir CS, Nectoux J, Staszewski J.","Acta Oncol. 1991;30(2):133-40. doi: 10.3109/02841869109092336.","Muir CS","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092336"
"11144903","Clinical management of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical Significance of Premalignant Alterations in the Genitourinary Tract","Häggman MJ, Adolfsson J, Khoury S, Montie JE, Norlén J.","Scand J Urol Nephrol Suppl. 2000;(205):44-9.","Häggman MJ","Scand J Urol Nephrol Suppl","2000","2001/01/06","","",""
"12131302","Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age","Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H.","J Urol. 2002 Aug;168(2):525-9.","Sweat SD","J Urol","2002","2002/07/20","","",""
"10449998","Trend and variation in treatment of localized prostate cancer in the southern part of The Netherlands, 1988-1996. Regional Study Group for Urological Oncology IKZ, Eindhoven","Post PN, Kil PJ, Hendrikx AJ, Poortmans PM, Crommelin MA, Coebergh JW.","Eur Urol. 1999 Sep;36(3):175-80. doi: 10.1159/000067993.","Post PN","Eur Urol","1999","1999/08/18","","","10.1159/000067993"
"15815178","Developmental life stage and couples' experiences with prostate cancer: a review of the literature","Harden J.","Cancer Nurs. 2005 Mar-Apr;28(2):85-98. doi: 10.1097/00002820-200503000-00002.","Harden J","Cancer Nurs","2005","2005/04/09","","","10.1097/00002820-200503000-00002"
"30324353","Targeted Prostate Biopsy and MR-Guided Therapy for Prostate Cancer","Woodrum DA, Kawashima A, Gorny KR, Mynderse LA.","Adv Exp Med Biol. 2018;1096:159-184. doi: 10.1007/978-3-319-99286-0_9.","Woodrum DA","Adv Exp Med Biol","2018","2018/10/17","","","10.1007/978-3-319-99286-0_9"
"26332786","Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer","Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Utsunomiya N, Makino Y, Sumiyoshi S, Yamasaki T, Kamba T, Ogawa O.","Prostate. 2015 Dec;75(16):1821-30. doi: 10.1002/pros.23088. Epub 2015 Sep 1.","Goto T","Prostate","2015","2015/09/03","","","10.1002/pros.23088"
"24048805","Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer","Froehner M.","Cancer. 2011 Jun 1;117(11):2577; author reply 2577-8. doi: 10.1002/cncr.25819. Epub 2010 Dec 14.","Froehner M","Cancer","2011","2013/09/20","","","10.1002/cncr.25819"
"10798539","Infrequent involvement of the anterior base in low-risk patients with clinically localized prostate cancer and its possible significance in definitive radiation therapy","Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S.","Jpn J Clin Oncol. 2000 Mar;30(3):126-30. doi: 10.1093/jjco/hyd029.","Egawa S","Jpn J Clin Oncol","2000","2000/05/08","","","10.1093/jjco/hyd029"
"15196231","The experience of radiotherapy for localized prostate cancer: the men's perspective","Kelsey SG, Owens J, White A.","Eur J Cancer Care (Engl). 2004 Jul;13(3):272-8. doi: 10.1111/j.1365-2354.2004.00487.x.","Kelsey SG","Eur J Cancer Care (Engl)","2004","2004/06/16","","","10.1111/j.1365-2354.2004.00487.x"
"28663235","Immunotherapy of Prostate Cancer: Facts and Hopes","Bilusic M, Madan RA, Gulley JL.","Clin Cancer Res. 2017 Nov 15;23(22):6764-6770. doi: 10.1158/1078-0432.CCR-17-0019. Epub 2017 Jun 29.","Bilusic M","Clin Cancer Res","2017","2017/07/01","PMC5690854","NIHMS887907","10.1158/1078-0432.CCR-17-0019"
"29350549","Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review","Caffo O, Veccia A, Kinspergher S, Maines F.","Future Oncol. 2018 Feb;14(5):431-442. doi: 10.2217/fon-2017-0430. Epub 2018 Jan 19.","Caffo O","Future Oncol","2018","2018/01/20","","","10.2217/fon-2017-0430"
"9614828","Protect-your-prostate message delivered on Parliament Hill","Gray C.","CMAJ. 1998 May 19;158(10):1339-40.","Gray C","CMAJ","1998","1998/06/06","PMC1229330","",""
"11022762","[Evaluation of prostate cancer with FDG PET study after therapy]","Koyama K, Inoue T, Shimizu N.","Nihon Rinsho. 2000 Jul;58 Suppl:423-6.","Koyama K","Nihon Rinsho","2000","2000/10/07","","",""
"23259431","Screening for prostate cancer: an updated review","Marta GN, Hanna SA, Fernandes da Silva JL, Carvalho Hde A.","Expert Rev Anticancer Ther. 2013 Jan;13(1):101-8. doi: 10.1586/era.12.154.","Marta GN","Expert Rev Anticancer Ther","2013","2012/12/25","","","10.1586/era.12.154"
"30064301","Stereotactic Body Radiotherapy for Primary Prostate Cancer","Kothari G, Loblaw A, Tree AC, van As NJ, Moghanaki D, Lo SS, Ost P, Siva S.","Technol Cancer Res Treat. 2018 Jan 1;17:1533033818789633. doi: 10.1177/1533033818789633.","Kothari G","Technol Cancer Res Treat","2018","2018/08/02","PMC6069023","","10.1177/1533033818789633"
"24574496","Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","Sooriakumaran P, Nyberg T, Akre O, Haendler L, Heus I, Olsson M, Carlsson S, Roobol MJ, Steineck G, Wiklund P.","BMJ. 2014 Feb 26;348:g1502. doi: 10.1136/bmj.g1502.","Sooriakumaran P","BMJ","2014","2014/02/28","PMC3936107","","10.1136/bmj.g1502"
"29032014","High-intermediate prostate cancer treated with low-dose-rate brachytherapy with or without androgen deprivation therapy","Pickles T, Morris WJ, Keyes M.","Brachytherapy. 2017 Nov-Dec;16(6):1101-1105. doi: 10.1016/j.brachy.2017.08.003. Epub 2017 Oct 12.","Pickles T","Brachytherapy","2017","2017/10/17","","","10.1016/j.brachy.2017.08.003"
"17381410","New concepts regarding the relationship of testosterone and prostate cancer","Morgentaler A.","Future Oncol. 2007 Apr;3(2):123-6. doi: 10.2217/14796694.3.2.123.","Morgentaler A","Future Oncol","2007","2007/03/27","","","10.2217/14796694.3.2.123"
"10788256","Prostate cancer: kinder cuts mean sharper dilemmas","Brink S.","US News World Rep. 2000 Apr 3;128(13):58-60.","Brink S","US News World Rep","2000","2000/05/02","","",""
"1723583","Screening for carcinoma of the prostate with prostate specific antigen","Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN.","Ann Clin Lab Sci. 1991 Nov-Dec;21(6):371-80.","Muschenheim F","Ann Clin Lab Sci","1991","1991/11/01","","",""
"9155516","Is screening for prostate cancer the current gold standard?--""yes""","Lange PH.","Eur J Cancer. 1997 Mar;33(3):354-6.","Lange PH","Eur J Cancer","1997","1997/03/01","","",""
"14556929","Medical and non-medical determinants of prostate cancer management: a population-based study","Bauvin E, Soulié M, Ménégoz F, Macé-Lesec'h J, Buémi A, Velten M, Villers A, Grosclaude P.","Eur J Cancer. 2003 Nov;39(16):2364-71. doi: 10.1016/s0959-8049(03)00551-3.","Bauvin E","Eur J Cancer","2003","2003/10/15","","","10.1016/s0959-8049(03)00551-3"
"24903838","[Cross-sectional analysis of routine treatment for prostate cancer patients: CAPRIS - a healthcare research project of the IQUO]","Schulze M, Stiegler H, Thielecke C, Colling C, Merseburger AS.","Urologe A. 2014 Jun;53(6):865-70. doi: 10.1007/s00120-014-3530-4.","Schulze M","Urologe A","2014","2014/06/07","","","10.1007/s00120-014-3530-4"
"23196061","Sequencing the transcriptional network of androgen receptor in prostate cancer","Chng KR, Cheung E.","Cancer Lett. 2013 Nov 1;340(2):254-60. doi: 10.1016/j.canlet.2012.11.009. Epub 2012 Nov 27.","Chng KR","Cancer Lett","2013","2012/12/01","","","10.1016/j.canlet.2012.11.009"
"30855019","Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy?","Marenco J, Sooriakumaran P.","Arch Esp Urol. 2019 Mar;72(2):174-181.","Marenco J","Arch Esp Urol","2019","2019/03/12","","",""
"15661054","Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association","Cancer Registration Committee of the Japanese Urological Association.","Int J Urol. 2005 Jan;12(1):46-61. doi: 10.1111/j.1442-2042.2004.00984.x.","Cancer Registration Committee of the Japanese Urological Association","Int J Urol","2005","2005/01/22","","","10.1111/j.1442-2042.2004.00984.x"
"1523746","Sonographic monitoring of prostate cancer after definitive radiotherapy","Egawa S, Carter SS, Wheeler TM, Scardino PT.","Urology. 1992 Sep;40(3):230-6. doi: 10.1016/0090-4295(92)90480-k.","Egawa S","Urology","1992","1992/09/01","","","10.1016/0090-4295(92)90480-k"
"9430782","Molecular heterogeneity in prostate cancer: can TP53 mutation unravel tumorigenesis?","Roy-Burman P, Zheng J, Miller GJ.","Mol Med Today. 1997 Nov;3(11):476-82. doi: 10.1016/S1357-4310(97)01126-X.","Roy-Burman P","Mol Med Today","1997","1998/02/07","","","10.1016/S1357-4310(97)01126-X"
"24816472","Decisional conflict in economically disadvantaged men with newly diagnosed prostate cancer: baseline results from a shared decision-making trial","Kaplan AL, Crespi CM, Saucedo JD, Connor SE, Litwin MS, Saigal CS.","Cancer. 2014 Sep 1;120(17):2721-7. doi: 10.1002/cncr.28755. Epub 2014 May 9.","Kaplan AL","Cancer","2014","2014/05/13","PMC4552329","NIHMS716864","10.1002/cncr.28755"
"15322319","Promise and challenge: Markers of prostate cancer detection, diagnosis and prognosis","Troyer DA, Mubiru J, Leach RJ, Naylor SL.","Dis Markers. 2004;20(2):117-28. doi: 10.1155/2004/509276.","Troyer DA","Dis Markers","2004","2004/08/24","PMC3839267","","10.1155/2004/509276"
"30843898","Adjuvant therapy in high-risk prostate cancer","Shevach J, Chaudhuri P, Morgans AK.","Clin Adv Hematol Oncol. 2019 Jan;17(1):45-53.","Shevach J","Clin Adv Hematol Oncol","2019","2019/03/08","","",""
"11895202","An evidence-based analysis of the management of localized prostate cancer","Abdalla I, Basu A, Hellman S.","Cancer J. 2002 Jan-Feb;8(1):40-6. doi: 10.1097/00130404-200201000-00008.","Abdalla I","Cancer J","2002","2002/03/16","","","10.1097/00130404-200201000-00008"
"19276451","Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?","Barry MJ, Mulley AJ Jr.","J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.","Barry MJ","J Natl Cancer Inst","2009","2009/03/12","","","10.1093/jnci/djp028"
"12400995","Surgery for prostate cancer: rationale, technique and outcomes","Downs TM, Kane CJ, Grossfeld GD, Meng MV, Carroll PR.","Cancer Metastasis Rev. 2002;21(1):29-44. doi: 10.1023/a:1020164206406.","Downs TM","Cancer Metastasis Rev","2002","2002/10/29","","","10.1023/a:1020164206406"
"22674509","[Salvage prostatectomy. Principles of diagnostics and operative therapy]","Franz T, Pfeiffer H, Holze S, Do M, Dietel A, Nicolaus M, Truss M, Stolzenburg JU.","Urologe A. 2012 Jun;51(6):869-78; quiz 879-80. doi: 10.1007/s00120-012-2894-6.","Franz T","Urologe A","2012","2012/06/08","","","10.1007/s00120-012-2894-6"
"9051152","Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications","Webber MM, Bello D, Quader S.","Prostate. 1997 Feb 1;30(2):136-42. doi: 10.1002/(sici)1097-0045(19970201)30:2<136::aid-pros9>3.0.co;2-m.","Webber MM","Prostate","1997","1997/02/01","","","10.1002/(sici)1097-0045(19970201)30:2<136::aid-pros9>3.0.co;2-m"
"10737492","More data on locally extensive prostate cancer--betting on the margin","Jarrard DF.","J Urol. 2000 Apr;163(4):1189-90. doi: 10.1016/s0022-5347(05)67719-1.","Jarrard DF","J Urol","2000","2000/03/29","","","10.1016/s0022-5347(05)67719-1"
"30642810","What Is Oligometastatic Prostate Cancer?","Fraser M, Koontz B, Emmenegger U, De Meerleer G, Khoo V, Feng F, Corcoran NM, Hovens CM, Tran PT, Ost P, Boutros PC; GAP6 Consortium.","Eur Urol Focus. 2019 Mar;5(2):159-161. doi: 10.1016/j.euf.2018.12.009. Epub 2019 Jan 12.","Fraser M","Eur Urol Focus","2019","2019/01/16","","","10.1016/j.euf.2018.12.009"
"9313534","Update on prostate cancer screening","Lazzaro M, Thompson M.","Lippincotts Prim Care Pract. 1997 Sep-Oct;1(4):408-18; quiz 419-20.","Lazzaro M","Lippincotts Prim Care Pract","1997","1997/10/06","","",""
"16388505","Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer","Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B.","Prostate. 2006 May 1;66(6):613-24. doi: 10.1002/pros.20353.","Wang J","Prostate","2006","2006/01/03","","","10.1002/pros.20353"
"9120958","Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation","Ignatoff JM.","J Urol. 1997 Apr;157(4):1373; author reply 1373-4. doi: 10.1016/s0022-5347(01)64992-9.","Ignatoff JM","J Urol","1997","1997/04/01","","","10.1016/s0022-5347(01)64992-9"
"9120957","Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation","Horan AH.","J Urol. 1997 Apr;157(4):1373; author reply 1373-4. doi: 10.1016/s0022-5347(01)64993-0.","Horan AH","J Urol","1997","1997/04/01","","","10.1016/s0022-5347(01)64993-0"
"24020088","New method created to easily and safely detect prostate cancer","Potticary J.","Bioanalysis. 2013 Jul;5(14):1712.","Potticary J","Bioanalysis","2013","2013/09/12","","",""
"1538486","Estimation of prostate cancer volume by transrectal ultrasound imaging","Terris MK, McNeal JE, Stamey TA.","J Urol. 1992 Mar;147(3 Pt 2):855-7. doi: 10.1016/s0022-5347(17)37405-0.","Terris MK","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37405-0"
"7601183","Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone","Frohmüller HG, Theiss M, Manseck A, Wirth MP.","Eur Urol. 1995;27(3):202-6. doi: 10.1159/000475161.","Frohmüller HG","Eur Urol","1995","1995/01/01","","","10.1159/000475161"
"25126949","Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer","Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR.","PLoS One. 2014 Aug 15;9(8):e94048. doi: 10.1371/journal.pone.0094048. eCollection 2014.","Chaturvedi S","PLoS One","2014","2014/08/16","PMC4134135","","10.1371/journal.pone.0094048"
"15078173","The effects of dietary factors on the androgen receptor and related cellular factors in prostate cancer","Young CY, Jatoi A, Ward JF, Blute ML.","Curr Med Chem. 2004 Apr;11(7):909-23. doi: 10.2174/0929867043455657.","Young CY","Curr Med Chem","2004","2004/04/14","","","10.2174/0929867043455657"
"24952997","Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies","Conteduca V, Aieta M, Amadori D, De Giorgi U.","Crit Rev Oncol Hematol. 2014 Oct;92(1):11-24. doi: 10.1016/j.critrevonc.2014.05.008. Epub 2014 May 27.","Conteduca V","Crit Rev Oncol Hematol","2014","2014/06/24","","","10.1016/j.critrevonc.2014.05.008"
"18574097","Prostate cancer--which treatment to choose?","Adkison JB, Ritter MA.","Arch Intern Med. 2008 Jun 23;168(12):1352; author reply 1353. doi: 10.1001/archinte.168.12.1352-a.","Adkison JB","Arch Intern Med","2008","2008/06/25","","","10.1001/archinte.168.12.1352-a"
"14756539","Prostate cancer screening policy in Italy. A statement endorsed by twenty scientific societies: towards unanimous consent","Gion M.","Int J Biol Markers. 2003 Oct-Dec;18(4):237. doi: 10.1177/172460080301800401.","Gion M","Int J Biol Markers","2003","2004/02/06","","","10.1177/172460080301800401"
"12504845","Primary radiation therapy for localized prostate cancer","Eng TY, Thomas CR, Herman TS.","Urol Oncol. 2002 Nov-Dec;7(6):239-57. doi: 10.1016/s1078-1439(02)00198-9.","Eng TY","Urol Oncol","2002","2002/12/31","","","10.1016/s1078-1439(02)00198-9"
"7543756","PSA screening: a public health dilemma","Mandelson MT, Wagner EH, Thompson RS.","Annu Rev Public Health. 1995;16:283-306. doi: 10.1146/annurev.pu.16.050195.001435.","Mandelson MT","Annu Rev Public Health","1995","1995/01/01","","","10.1146/annurev.pu.16.050195.001435"
"15479490","Double primary cancers of the prostate and bladder: a literature review","Kinoshita Y, Singh A, Rovito PM Jr, Wang CY, Haas GP.","Clin Prostate Cancer. 2004 Sep;3(2):83-6. doi: 10.3816/cgc.2004.n.016.","Kinoshita Y","Clin Prostate Cancer","2004","2004/10/14","","","10.3816/cgc.2004.n.016"
"18335221","Radical prostatectomy for high-risk prostate cancer","Yossepowitch O, Eastham JA.","World J Urol. 2008 Jun;26(3):219-24. doi: 10.1007/s00345-008-0247-2. Epub 2008 Mar 12.","Yossepowitch O","World J Urol","2008","2008/03/13","","","10.1007/s00345-008-0247-2"
"12117612","Real time MRI-ultrasound image guided stereotactic prostate biopsy","Kaplan I, Oldenburg NE, Meskell P, Blake M, Church P, Holupka EJ.","Magn Reson Imaging. 2002 Apr;20(3):295-9. doi: 10.1016/s0730-725x(02)00490-3.","Kaplan I","Magn Reson Imaging","2002","2002/07/16","","","10.1016/s0730-725x(02)00490-3"
"8252502","Long-term results of Danish Prostatic Cancer Group trial 86. Goserelin acetate plus flutamide versus orchiectomy in advanced prostate cancer","Iversen P, Rasmussen F, Klarskov P, Christensen IJ.","Cancer. 1993 Dec 15;72(12 Suppl):3851-4. doi: 10.1002/1097-0142(19931215)72:12+<3851::aid-cncr2820721717>3.0.co;2-x.","Iversen P","Cancer","1993","1993/12/15","","","10.1002/1097-0142(19931215)72:12+<3851::aid-cncr2820721717>3.0.co;2-x"
"10394276","[Normal tissue radiation toxicity in radiotherapy of localized prostatic cancer]","Bakken AM, Ogreid P, Iversen J, Langberg CW.","Tidsskr Nor Laegeforen. 1999 May 30;119(14):2017-21.","Bakken AM","Tidsskr Nor Laegeforen","1999","1999/07/08","","",""
"15452447","Leptin and prostate: implications for cancer prevention--overview of genetics and molecular interactions","Ribeiro R, Lopes C, Medeiros R.","Eur J Cancer Prev. 2004 Oct;13(5):359-68. doi: 10.1097/00008469-200410000-00002.","Ribeiro R","Eur J Cancer Prev","2004","2004/09/29","","","10.1097/00008469-200410000-00002"
"14767285","Lymph node positive prostate cancer: long-term survival data after radical prostatectomy","Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stoeckle M.","J Urol. 2004 Mar;171(3):1128-31. doi: 10.1097/01.ju.0000113202.37783.1f.","Zwergel U","J Urol","2004","2004/02/10","","","10.1097/01.ju.0000113202.37783.1f"
"10026767","Elevated prostate-specific antigen, abnormal prostate evaluation on digital rectal examination, and transrectal ultrasound and prostate biopsy","Partin AW, Stutzman RE.","Urol Clin North Am. 1998 Nov;25(4):581-9, viii. doi: 10.1016/s0094-0143(05)70049-5.","Partin AW","Urol Clin North Am","1998","1999/02/23","","","10.1016/s0094-0143(05)70049-5"
"8580742","Imaging of prostate cancer","Choyke PL.","Abdom Imaging. 1995 Nov-Dec;20(6):505-15. doi: 10.1007/BF01256700.","Choyke PL","Abdom Imaging","1995","1995/11/01","","","10.1007/BF01256700"
"30933998","Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway","Sekhar KR, Wang J, Freeman ML, Kirschner AN.","PLoS One. 2019 Apr 1;14(4):e0214670. doi: 10.1371/journal.pone.0214670. eCollection 2019.","Sekhar KR","PLoS One","2019","2019/04/02","PMC6443157","","10.1371/journal.pone.0214670"
"25444956","HIF1α expression under normoxia in prostate cancer--which pathways to target?","Ranasinghe WK, Baldwin GS, Bolton D, Shulkes A, Ischia J, Patel O.","J Urol. 2015 Mar;193(3):763-70. doi: 10.1016/j.juro.2014.10.085. Epub 2014 Oct 19.","Ranasinghe WK","J Urol","2015","2014/12/03","","","10.1016/j.juro.2014.10.085"
"28436356","Association between natural killer cell activity and prostate cancer: a pilot study","Barkin J, Rodriguez-Suarez R, Betito K.","Can J Urol. 2017 Apr;24(2):8708-8713.","Barkin J","Can J Urol","2017","2017/04/25","","",""
"8178748","A case of extremely advanced prostate cancer presenting hemolytic jaundice","Wakisaka M, Takagishi H.","Hinyokika Kiyo. 1994 Mar;40(3):261-3.","Wakisaka M","Hinyokika Kiyo","1994","1994/03/01","","",""
"20190186","Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005","Belpomme D, Irigaray P.","J Natl Cancer Inst. 2010 Apr 7;102(7):506-7. doi: 10.1093/jnci/djq045. Epub 2010 Feb 26.","Belpomme D","J Natl Cancer Inst","2010","2010/03/02","","","10.1093/jnci/djq045"
"17486914","[Techniques, indications and results of permanent prostate brachytherapy for localized prostate cancer]","Bladou F, Thuret R, Gravis G, Karsenty G, Serment G, Salem N.","Ann Urol (Paris). 2007 Apr;41(2):68-79. doi: 10.1016/j.anuro.2007.02.001.","Bladou F","Ann Urol (Paris)","2007","2007/05/10","","","10.1016/j.anuro.2007.02.001"
"1299464","Quality of life and psychosocial status in stage D prostate cancer. Zoladex Prostate Cancer Study Group","Cassileth BR, Soloway MS, Vogelzang NJ, Chou JM, Schellhammer PD, Seidmon EJ, Kennealey GT.","Qual Life Res. 1992 Oct;1(5):323-9. doi: 10.1007/BF00434946.","Cassileth BR","Qual Life Res","1992","1992/10/01","","","10.1007/BF00434946"
"31713906","Prostate cancer survivorship priorities for men and their partners: Delphi consensus from a nurse specialist cohort","Ralph N, Green A, Sara S, McDonald S, Norris P, Terry V, Dunn JC, Chambers SK.","J Clin Nurs. 2020 Jan;29(1-2):265-273. doi: 10.1111/jocn.15096. Epub 2019 Nov 27.","Ralph N","J Clin Nurs","2020","2019/11/13","","","10.1111/jocn.15096"
"22149835","A self-adaptive case-based reasoning system for dose planning in prostate cancer radiotherapy","Mishra N, Petrovic S, Sundar S.","Med Phys. 2011 Dec;38(12):6528-38. doi: 10.1118/1.3660517.","Mishra N","Med Phys","2011","2011/12/14","","","10.1118/1.3660517"
"28189165","The Big 3: An Updated Overview of Colorectal, Breast, and Prostate Cancers","Gordon J, Fischer-Cartlidge E, Barton-Burke M.","Nurs Clin North Am. 2017 Mar;52(1):27-52. doi: 10.1016/j.cnur.2016.11.004.","Gordon J","Nurs Clin North Am","2017","2017/02/13","","","10.1016/j.cnur.2016.11.004"
"9811313","Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study","Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS.","J Natl Cancer Inst. 1998 Nov 4;90(21):1637-47. doi: 10.1093/jnci/90.21.1637.","Hebert JR","J Natl Cancer Inst","1998","1998/11/12","","","10.1093/jnci/90.21.1637"
"22208031","[Criteria and issues of PSA only relapse in hormonal therapy for prostate cancer]","Sakai H.","Nihon Rinsho. 2011 Jun;69 Suppl 5:492-5.","Sakai H","Nihon Rinsho","2011","2012/01/03","","",""
"25108887","Prostate cancer screening comes of age","Thompson IM, Tangen CM.","Lancet. 2014 Dec 6;384(9959):2004-6. doi: 10.1016/S0140-6736(14)61008-4. Epub 2014 Aug 6.","Thompson IM","Lancet","2014","2014/08/11","","","10.1016/S0140-6736(14)61008-4"
"21264843","Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer","Holzbeierlein JM.","Cancer. 2011 Jul 1;117(13):2830-2. doi: 10.1002/cncr.25899. Epub 2011 Jan 24.","Holzbeierlein JM","Cancer","2011","2011/01/26","","","10.1002/cncr.25899"
"10781186","Facts and future lines of research in prostate cancer: concluding remarks","Abrams P.","BJU Int. 2000 Apr;85 Suppl 2:49-51. doi: 10.1046/j.1464-410x.2000.00065.x.","Abrams P","BJU Int","2000","2000/04/26","","","10.1046/j.1464-410x.2000.00065.x"
"23321869","How surgical innovation reduced death and suffering from prostate cancer","Walsh PC.","J Craniofac Surg. 2013 Jan;24(1):49-50. doi: 10.1097/SCS.0b013e318270fbe0.","Walsh PC","J Craniofac Surg","2013","2013/01/17","","","10.1097/SCS.0b013e318270fbe0"
"17979615","""The news is [not] all good"": misrepresentations and inaccuracies in Australian news media reports on prostate cancer screening","MacKenzie R, Chapman S, Barratt A, Holding S.","Med J Aust. 2007 Nov 5;187(9):507-10.","MacKenzie R","Med J Aust","2007","2007/11/06","","",""
"12108336","[Epidemiology of prostate cancer in the Limousin area]","Druet-Cabanac M, Colombeau P, Preux PM, Paulhac P, Vergnenegre A, Dumas JP.","Prog Urol. 2002 Apr;12(2):226-31.","Druet-Cabanac M","Prog Urol","2002","2002/07/11","","",""
"19095124","Evaluating localized prostate cancer and identifying candidates for focal therapy","Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT.","Urology. 2008 Dec;72(6 Suppl):S12-24. doi: 10.1016/j.urology.2008.10.004.","Sartor AO","Urology","2008","2008/12/20","","","10.1016/j.urology.2008.10.004"
"29633949","[The role of corticoids in the management of advanced prostate cancer.]","González-Del-Alba Baamonde A, Sevillano Fernández E.","Arch Esp Urol. 2018 Mar;71(3):281-287.","González-Del-Alba Baamonde A","Arch Esp Urol","2018","2018/04/11","","",""
"25550581","Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy","Nishida S, Hirohashi Y, Torigoe T, Nojima M, Inoue R, Kitamura H, Tanaka T, Asanuma H, Sato N, Masumori N.","Anticancer Res. 2015 Jan;35(1):413-8.","Nishida S","Anticancer Res","2015","2015/01/01","","",""
"23157640","Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs","Pekarik V, Gumulec J, Masarik M, Kizek R, Adam V.","Curr Med Chem. 2013;20(4):534-44. doi: 10.2174/0929867311320040005.","Pekarik V","Curr Med Chem","2013","2012/11/20","","","10.2174/0929867311320040005"
"26707507","National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions","Weiner AB, Conti RM, Eggener SE.","J Urol. 2016 May;195(5):1383-1389. doi: 10.1016/j.juro.2015.12.071. Epub 2015 Dec 18.","Weiner AB","J Urol","2016","2015/12/29","","","10.1016/j.juro.2015.12.071"
"19675860","Prostate cancer incidence, mortality, total and free prostate specific antigen","Bantis A, Vasiliou O.","Hell J Nucl Med. 2009 May-Aug;12(2):106-9.","Bantis A","Hell J Nucl Med","2009","2009/08/14","","",""
"27273379","Prostate cancer: Urology journals recommend new prostate cancer grade groups","Epstein JI.","Nat Rev Urol. 2016 Jul;13(7):374-5. doi: 10.1038/nrurol.2016.96. Epub 2016 Jun 7.","Epstein JI","Nat Rev Urol","2016","2016/06/09","","","10.1038/nrurol.2016.96"
"7853410","Inhibition of prostate cancer metastasis: a critical challenge ahead","Linehan WM.","J Natl Cancer Inst. 1995 Mar 1;87(5):331-2. doi: 10.1093/jnci/87.5.331.","Linehan WM","J Natl Cancer Inst","1995","1995/03/01","","","10.1093/jnci/87.5.331"
"3969370","DHT in prostate cancer tissue--a guide to management and therapy","Geller J, Albert JD.","Prostate. 1985;6(1):19-25. doi: 10.1002/pros.2990060104.","Geller J","Prostate","1985","1985/01/01","","","10.1002/pros.2990060104"
"15272941","Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy","Trask PC.","Health Qual Life Outcomes. 2004 Jul 23;2:37. doi: 10.1186/1477-7525-2-37.","Trask PC","Health Qual Life Outcomes","2004","2004/07/27","PMC497052","","10.1186/1477-7525-2-37"
"23712205","Defining the threshold for significant versus insignificant prostate cancer","Van der Kwast TH, Roobol MJ.","Nat Rev Urol. 2013 Aug;10(8):473-82. doi: 10.1038/nrurol.2013.112. Epub 2013 May 28.","Van der Kwast TH","Nat Rev Urol","2013","2013/05/29","","","10.1038/nrurol.2013.112"
"9766566","Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer","Plas E, Carroll VA, Jilch R, Mihaly J, Vesely M, Ulrich W, Pflüger H, Binder BR.","Int J Cancer. 1998 Oct 29;78(3):320-5. doi: 10.1002/(SICI)1097-0215(19981029)78:3<320::AID-IJC11>3.0.CO;2-A.","Plas E","Int J Cancer","1998","1998/10/10","","","10.1002/(SICI)1097-0215(19981029)78:3<320::AID-IJC11>3.0.CO;2-A"
"10553603","Prostate cancer: detection, staging, and treatment of localized disease","Potter SR, Partin AW.","Semin Roentgenol. 1999 Oct;34(4):269-83. doi: 10.1016/s0037-198x(99)80005-4.","Potter SR","Semin Roentgenol","1999","1999/12/20","","","10.1016/s0037-198x(99)80005-4"
"24220693","HDAC inhibitor confers radiosensitivity to prostate stem-like cells","Frame FM, Pellacani D, Collins AT, Simms MS, Mann VM, Jones GD, Meuth M, Bristow RG, Maitland NJ.","Br J Cancer. 2013 Dec 10;109(12):3023-33. doi: 10.1038/bjc.2013.691. Epub 2013 Nov 12.","Frame FM","Br J Cancer","2013","2013/11/14","PMC3859953","","10.1038/bjc.2013.691"
"27979746","Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study","Shao X, Pan J, Wang Y, Zhu Y, Xu F, Shangguan X, Dong B, Sha J, Chen N, Chen Z, Wang T, Liu S, Xue W.","Nanomedicine. 2017 Apr;13(3):1051-1059. doi: 10.1016/j.nano.2016.12.001. Epub 2016 Dec 13.","Shao X","Nanomedicine","2017","2016/12/17","","","10.1016/j.nano.2016.12.001"
"28420419","Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial","Skolarus TA, Metreger T, Hwang S, Kim HM, Grubb RL 3rd, Gingrich JR, Hawley ST.","Trials. 2017 Apr 18;18(1):181. doi: 10.1186/s13063-017-1925-4.","Skolarus TA","Trials","2017","2017/04/20","PMC5395886","","10.1186/s13063-017-1925-4"
"9145717","Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements","Catalona WJ, Smith DS, Ornstein DK.","JAMA. 1997 May 14;277(18):1452-5.","Catalona WJ","JAMA","1997","1997/05/14","","",""
"24499138","Targeting HOX transcription factors in prostate cancer","Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A, Pandha HS.","BMC Urol. 2014 Feb 5;14:17. doi: 10.1186/1471-2490-14-17.","Morgan R","BMC Urol","2014","2014/02/07","PMC3942264","","10.1186/1471-2490-14-17"
"22503713","Steroid biosynthesis and prostate cancer","Sharifi N, Auchus RJ.","Steroids. 2012 Jun;77(7):719-26. doi: 10.1016/j.steroids.2012.03.015. Epub 2012 Apr 5.","Sharifi N","Steroids","2012","2012/04/17","","","10.1016/j.steroids.2012.03.015"
"12621851","[Prostatic carcinoma: current status of diagnostic imaging]","Bloch BN, Helbich T, Heinz-Peer G.","Wien Med Wochenschr Suppl. 2002;(113):89-91.","Bloch BN","Wien Med Wochenschr Suppl","2002","2003/03/08","","",""
"7933247","Proving early detection and treatment of prostate cancer does more good than harm: the need to support randomized trials actively","Barry MJ.","J Urol. 1994 Nov;152(5 Pt 2):1903-4. doi: 10.1016/s0022-5347(17)32411-4.","Barry MJ","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32411-4"
"12736021","Clinical characteristics of prostate cancer in African Americans, American whites, and Senegalese men","Gueye SM, Zeigler-Johnson CM, Friebel T, Spangler E, Jalloh M, MacBride S, Malkowicz SB, Rebbeck TR.","Urology. 2003 May;61(5):987-92. doi: 10.1016/s0090-4295(02)02588-8.","Gueye SM","Urology","2003","2003/05/09","","","10.1016/s0090-4295(02)02588-8"
"16598738","The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening","Porter MP, Stanford JL, Lange PH.","Prostate. 2006 Jul 1;66(10):1044-51. doi: 10.1002/pros.20417.","Porter MP","Prostate","2006","2006/04/07","","","10.1002/pros.20417"
"25648635","DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer","Zhang L, Zhang Q, Li L, Wang Z, Ying J, Fan Y, He Q, Lv T, Han W, Li J, Yang Y, Xu B, Wang L, Liu Q, Sun Y, Guo Y, Tao Q, Jin J.","J Mol Med (Berl). 2015 Jun;93(6):691-701. doi: 10.1007/s00109-015-1255-5. Epub 2015 Feb 5.","Zhang L","J Mol Med (Berl)","2015","2015/02/05","","","10.1007/s00109-015-1255-5"
"18295394","Clinical stage T3 prostate cancer: the added value of three-dimensional conformal/intensity-modulated external-beam radiotherapy","Bolla M.","Eur Urol. 2008 Jun;53(6):1104-6; discussion 1106-8. doi: 10.1016/j.eururo.2008.02.004. Epub 2008 Feb 20.","Bolla M","Eur Urol","2008","2008/02/26","","","10.1016/j.eururo.2008.02.004"
"18663611","Association of TGIFLX/Y mRNA expression with prostate cancer","Ousati Ashtiani Z, Ayati M, Modarresi MH, Raoofian R, Sabah Goulian B, Greene WK, Heidari M.","Med Oncol. 2009;26(1):73-7. doi: 10.1007/s12032-008-9086-7. Epub 2008 Jul 29.","Ousati Ashtiani Z","Med Oncol","2009","2008/07/30","","","10.1007/s12032-008-9086-7"
"28941449","Diet and lifestyle can influence prostate cancer outcomes","Leapman MS, Clark CJ, Meng MV, Boughey JC.","Bull Am Coll Surg. 2016 Jul;101(7):50-2.","Leapman MS","Bull Am Coll Surg","2016","2017/09/25","","",""
"26981530","Cancer Related Fatigue and Quality of Life in Patients with Advanced Prostate Cancer Undergoing Chemotherapy","Charalambous A, Kouta C.","Biomed Res Int. 2016;2016:3989286. doi: 10.1155/2016/3989286. Epub 2016 Feb 14.","Charalambous A","Biomed Res Int","2016","2016/03/17","PMC4769736","","10.1155/2016/3989286"
"12149287","Challenge of locally persistent prostate cancer: an unresolved clinical dilemma","Logothetis CJ.","J Clin Oncol. 2002 Aug 1;20(15):3187. doi: 10.1200/JCO.2002.20.15.3187.","Logothetis CJ","J Clin Oncol","2002","2002/08/01","","","10.1200/JCO.2002.20.15.3187"
"10121730","Chilling prostate cancer","Newman RJ.","US News World Rep. 1992 Oct 12;113(14):84-5.","Newman RJ","US News World Rep","1992","1992/09/16","","",""
"30064932","Introduction to ""Molecular drivers of prostate cancer development, progression, and resistance to therapy""","Barbieri CE.","Urol Oncol. 2018 Aug;36(8):367. doi: 10.1016/j.urolonc.2018.06.003. Epub 2018 Jul 29.","Barbieri CE","Urol Oncol","2018","2018/08/02","","","10.1016/j.urolonc.2018.06.003"
"28918872","[Management of ablative therapies in prostate cancer]","Barret E, Sanchez-Salas R, Galiano M, Cathala N, Mombet A, Prapotnich D, Rozet F, Gangi A, Lang H, Cathelineau X.","Prog Urol. 2017 Nov;27(15):909-925. doi: 10.1016/j.purol.2017.07.243. Epub 2017 Sep 15.","Barret E","Prog Urol","2017","2017/09/19","","","10.1016/j.purol.2017.07.243"
"20940693","Personalized approach to prostate cancer prognosis","Donovan MJ, Costa J, Cordon-Cardo C.","Minerva Urol Nefrol. 2010 Sep;62(3):231-9.","Donovan MJ","Minerva Urol Nefrol","2010","2010/10/14","","",""
"9348558","The economics of prostate cancer screening","Benoit RM, Naslund MJ.","Oncology (Williston Park). 1997 Oct;11(10):1533-43; discussion 1543, 1547-8.","Benoit RM","Oncology (Williston Park)","1997","1998/02/12","","",""
"8375788","[Limits of surgical therapy of prostate cancer in the aged?]","Schultze-Seemann W.","Fortschr Med. 1993 Jul 20;111(20-21):343-6.","Schultze-Seemann W","Fortschr Med","1993","1993/07/20","","",""
"31319388","Digital Rectal Examination Remains a Key Prognostic Tool for Prostate Cancer: A National Cancer Database Review","Borkenhagen JF, Eastwood D, Kilari D, See WA, Van Wickle JD, Lawton CA, Hall WA.","J Natl Compr Canc Netw. 2019 Jul 1;17(7):829-837. doi: 10.6004/jnccn.2018.7278.","Borkenhagen JF","J Natl Compr Canc Netw","2019","2019/07/19","","","10.6004/jnccn.2018.7278"
"20581002","Contrast-enhanced ultrasonography of the prostate with Sonazoid","Matsumoto K, Nakagawa K, Hashiguchi A, Kono H, Kikuchi E, Nagata H, Miyajima A, Oya M.","Jpn J Clin Oncol. 2010 Nov;40(11):1099-104. doi: 10.1093/jjco/hyq102. Epub 2010 Jun 24.","Matsumoto K","Jpn J Clin Oncol","2010","2010/06/29","","","10.1093/jjco/hyq102"
"17414646","Imaging of prostate cancer","Oehr P, Bouchelouche K.","Curr Opin Oncol. 2007 May;19(3):259-64. doi: 10.1097/CCO.0b013e3280ad439b.","Oehr P","Curr Opin Oncol","2007","2007/04/07","","","10.1097/CCO.0b013e3280ad439b"
"21310657","Show us a sign: the search for ""game changing"" prostate cancer biomarkers","Quinn D, Gross M.","Lancet Oncol. 2011 Mar;12(3):204-6. doi: 10.1016/S1470-2045(11)70003-1.","Quinn D","Lancet Oncol","2011","2011/02/12","","","10.1016/S1470-2045(11)70003-1"
"17299418","A network biology approach to prostate cancer","Ergün A, Lawrence CA, Kohanski MA, Brennan TA, Collins JJ.","Mol Syst Biol. 2007;3:82. doi: 10.1038/msb4100125. Epub 2007 Feb 13.","Ergün A","Mol Syst Biol","2007","2007/02/15","PMC1828752","","10.1038/msb4100125"
"18704441","Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way?","Ahmed HU, Emberton M.","World J Urol. 2008 Oct;26(5):457-67. doi: 10.1007/s00345-008-0317-5. Epub 2008 Aug 14.","Ahmed HU","World J Urol","2008","2008/08/16","","","10.1007/s00345-008-0317-5"
"9495713","Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy","D'Amico AV, Chang E, Garnick M, Kantoff P, Jiroutek M, Tempany CM.","Urology. 1998 Feb;51(2):287-92. doi: 10.1016/s0090-4295(97)00610-9.","D'Amico AV","Urology","1998","1998/03/12","","","10.1016/s0090-4295(97)00610-9"
"26786713","Active surveillance in prostate cancer: a concept analysis","Horrill T.","J Clin Nurs. 2016 Apr;25(7-8):1166-72. doi: 10.1111/jocn.13111. Epub 2016 Jan 20.","Horrill T","J Clin Nurs","2016","2016/01/21","","","10.1111/jocn.13111"
"18711699","Validation of quality indicators for radical prostatectomy","Chan EO, Groome PA, Siemens DR.","Int J Cancer. 2008 Dec 1;123(11):2651-7. doi: 10.1002/ijc.23782.","Chan EO","Int J Cancer","2008","2008/08/20","","","10.1002/ijc.23782"
"8976217","Coincidence of bladder and prostate cancer","Chun TY.","J Urol. 1997 Jan;157(1):65-7.","Chun TY","J Urol","1997","1997/01/01","","",""
"29303080","Latest Evidence on the Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Insignificant Prostate Cancer: A Systematic Review","Cantiello F, Manno S, Russo GI, Cimino S, Privitera S, Morgia G, Cicione A, Damiano R.","Anticancer Agents Med Chem. 2018;18(7):925-930. doi: 10.2174/1871520618666180105105413.","Cantiello F","Anticancer Agents Med Chem","2018","2018/01/06","","","10.2174/1871520618666180105105413"
"12756089","Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer","Lagerveld BW, Laguna MP, de la Rosette JJ.","Curr Urol Rep. 2003 Jun;4(3):240-7. doi: 10.1007/s11934-003-0076-1.","Lagerveld BW","Curr Urol Rep","2003","2003/05/21","","","10.1007/s11934-003-0076-1"
"8237066","[Rational diagnosis of prostate cancer]","Althaus P, Hahn M, Kössler R.","Z Arztl Fortbild (Jena). 1993 Sep 13;87(9):711-3.","Althaus P","Z Arztl Fortbild (Jena)","1993","1993/09/13","","",""
"18985656","Tea, coffee and prostate cancer","Lee AH, Fraser ML, Binns CW.","Mol Nutr Food Res. 2009 Feb;53(2):256-65. doi: 10.1002/mnfr.200800218.","Lee AH","Mol Nutr Food Res","2009","2008/11/06","","","10.1002/mnfr.200800218"
"28941920","Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance","Nyame YA, Grimberg DC, Greene DJ, Gupta K, Kartha GK, Berglund R, Gong M, Stephenson AJ, Magi-Galluzzi C, Klein EA.","J Urol. 2018 Feb;199(2):438-444. doi: 10.1016/j.juro.2017.09.077. Epub 2017 Sep 20.","Nyame YA","J Urol","2018","2017/09/25","","","10.1016/j.juro.2017.09.077"
"21717905","Advanced prostate cancer: new agents, new questions","Dorff TB, Pinski J.","Oncology (Williston Park). 2011 May;25(6):509, 512.","Dorff TB","Oncology (Williston Park)","2011","2011/07/02","","",""
"11998659","Prostate cancer patients blindsided by side effects","","Urol Nurs. 2001 Jun;21(3):225-6.","","Urol Nurs","2001","2002/05/10","","",""
"19228146","Treatment of prostate cancer with hormonal therapy in Europe","Miller K, Anderson J, Abrahamsson PA.","BJU Int. 2009 Mar;103 Suppl 2:2-6. doi: 10.1111/j.1464-410X.2009.08382.x.","Miller K","BJU Int","2009","2009/02/21","","","10.1111/j.1464-410X.2009.08382.x"
"17021907","The changing face of prostate cancer: can gains in epigenetic knowledge translate into improvements in clinical care?","Catto JW.","J Mol Med (Berl). 2006 Nov;84(11):883-5. doi: 10.1007/s00109-006-0110-0. Epub 2006 Oct 5.","Catto JW","J Mol Med (Berl)","2006","2006/10/06","","","10.1007/s00109-006-0110-0"
"26222275","Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer","Ceresoli GL, De Vincenzo F, Sauta MG, Bonomi M, Zucali PA.","Q J Nucl Med Mol Imaging. 2015 Dec;59(4):374-80. Epub 2015 Jul 29.","Ceresoli GL","Q J Nucl Med Mol Imaging","2015","2015/07/30","","",""
"17355370","Economic conditions and marriage quality of men with prostate cancer","Sunny L, Hopfgarten T, Adolfsson J, Steineck G.","BJU Int. 2007 Jun;99(6):1391-7. doi: 10.1111/j.1464-410X.2007.06807.x. Epub 2007 Mar 12.","Sunny L","BJU Int","2007","2007/03/16","","","10.1111/j.1464-410X.2007.06807.x"
"28222672","Long leukocyte telomere length in prostate cancer patients at diagnosis is associated with poor metastasis-free and cancer-specific survival","Svenson U, Roos G, Wikström P.","Tumour Biol. 2017 Feb;39(2):1010428317692236. doi: 10.1177/1010428317692236.","Svenson U","Tumour Biol","2017","2017/02/23","","","10.1177/1010428317692236"
"9162350","[Role of expectant therapy in prostatic carcinoma of low grade and staging]","Lorusso A, Curatolo C, Giocoli Nacci G, Ludovico GM, Cirillo Limitone DA, Marucco EC, Pagliarulo A.","Arch Ital Urol Androl. 1996 Dec;68(5 Suppl):155-7.","Lorusso A","Arch Ital Urol Androl","1996","1996/12/01","","",""
"21528655","Postoperative radiotherapy in prostate cancer: acquired certainties and still open issues. A review of recent literature","Alongi F, Cozzarini C, Di Muzio N, Scorsetti M.","Tumori. 2011 Jan-Feb;97(1):1-8.","Alongi F","Tumori","2011","2011/05/03","","",""
"19150091","Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer","Okegawa T, Nutahara K, Higashihara E.","J Urol. 2009 Mar;181(3):1091-7. doi: 10.1016/j.juro.2008.11.015. Epub 2009 Jan 16.","Okegawa T","J Urol","2009","2009/01/20","","","10.1016/j.juro.2008.11.015"
"15714974","[MR imaging and MR spectroscopy in prostate cancer]","Sugimura K.","Nihon Rinsho. 2005 Feb;63(2):247-52.","Sugimura K","Nihon Rinsho","2005","2005/02/18","","",""
"24905402","Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study","Hjertholm P, Fenger-Grøn M, Vestergaard M, Christensen MB, Borre M, Møller H, Vedsted P.","Int J Cancer. 2015 Jan 15;136(2):435-42. doi: 10.1002/ijc.29008. Epub 2014 Jun 12.","Hjertholm P","Int J Cancer","2015","2014/06/07","","","10.1002/ijc.29008"
"3759540","A comparison of the cost of various treatment methods for early cancer of the prostate","Hanks GE, Dunlap K.","Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1879-81. doi: 10.1016/0360-3016(86)90334-2.","Hanks GE","Int J Radiat Oncol Biol Phys","1986","1986/10/01","","","10.1016/0360-3016(86)90334-2"
"27384993","Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer","Lefort K, Ostano P, Mello-Grand M, Calpini V, Scatolini M, Farsetti A, Dotto GP, Chiorino G.","Oncotarget. 2016 Jul 26;7(30):48011-48026. doi: 10.18632/oncotarget.10333.","Lefort K","Oncotarget","2016","2016/07/08","PMC5216996","","10.18632/oncotarget.10333"
"21467126","Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer","Brandt A, Sundquist J, Hemminki K.","Ann Oncol. 2012 Jan;23(1):251-256. doi: 10.1093/annonc/mdr056. Epub 2011 Apr 5.","Brandt A","Ann Oncol","2012","2011/04/07","","","10.1093/annonc/mdr056"
"11870805","Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities","Kubota Y, Ito K, Imai K, Yamanaka H.","Prostate. 2002 Mar 1;50(4):262-9. doi: 10.1002/pros.10057.","Kubota Y","Prostate","2002","2002/03/01","","","10.1002/pros.10057"
"9695692","Prostate-specific antigen testing for prostate cancer: the case for informed consent","McCredie M, Cox B.","Med J Aust. 1998 Jul 6;169(1):9-10.","McCredie M","Med J Aust","1998","1998/08/08","","",""
"17893870","Prostate cancer prevention: past, present, and future","Fleshner N, Zlotta AR.","Cancer. 2007 Nov 1;110(9):1889-99. doi: 10.1002/cncr.23009.","Fleshner N","Cancer","2007","2007/09/26","","","10.1002/cncr.23009"
"10801170","Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group","","Lancet. 2000 Apr 29;355(9214):1491-8.","","Lancet","2000","2000/05/09","","",""
"26951714","Pretreatment plasma fibrinogen as an independent prognostic indicator of prostate cancer patients treated with androgen deprivation therapy","Wang Y, Yin W, Wang Z, Huang J, Pan J, Zhu Y, Xu F, Shao X, Sha J, Cai Y, Liu Q, Dong B, Xue W, Huang Y.","Prostate Cancer Prostatic Dis. 2016 Jun;19(2):209-15. doi: 10.1038/pcan.2016.6. Epub 2016 Mar 8.","Wang Y","Prostate Cancer Prostatic Dis","2016","2016/03/09","","","10.1038/pcan.2016.6"
"11008903","Prostate cancer risk in relation to anthropometry and physical activity: the National Health and Nutrition Examination Survey I Epidemiological Follow-Up Study","Clarke G, Whittemore AS.","Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):875-81.","Clarke G","Cancer Epidemiol Biomarkers Prev","2000","2000/09/29","","",""
"8602401","Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer","Denmeade SR, Lin XS, Isaacs JT.","Prostate. 1996 Apr;28(4):251-65. doi: 10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G.","Denmeade SR","Prostate","1996","1996/04/01","","","10.1002/(SICI)1097-0045(199604)28:4<251::AID-PROS6>3.0.CO;2-G"
"7516834","Prostate-specific antigen and transrectal ultrasound of the prostate in detection of prostate cancer","Cooner WH.","Clin Invest Med. 1993 Dec;16(6):471-4.","Cooner WH","Clin Invest Med","1993","1993/12/01","","",""
"28814451","Androgen deprivation and immunotherapy for the treatment of prostate cancer","Gamat M, McNeel DG.","Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16.","Gamat M","Endocr Relat Cancer","2017","2017/08/18","PMC5669826","NIHMS904610","10.1530/ERC-17-0145"
"32396170","PET-CT Improved High-risk Prostate Cancer Staging in Trial","Abbasi J.","JAMA. 2020 May 12;323(18):1764. doi: 10.1001/jama.2020.6994.","Abbasi J","JAMA","2020","2020/05/13","","","10.1001/jama.2020.6994"
"27637114","Current Prostate Cancer Screening Guidelines May Lead to More Deaths from the Disease","Stevens R.","Am Fam Physician. 2016 Sep 15;94(6):414-8.","Stevens R","Am Fam Physician","2016","2016/09/17","","",""
"15519896","Does vasectomy reversal protect against prostate cancer?","Borgmeier I, Holman CD.","Ann Epidemiol. 2004 Nov;14(10):748-9. doi: 10.1016/j.annepidem.2003.12.003.","Borgmeier I","Ann Epidemiol","2004","2004/11/03","","","10.1016/j.annepidem.2003.12.003"
"8618327","Re: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer","Walsh PC.","J Urol. 1996 Jun;155(6):2038-9. doi: 10.1016/s0022-5347(01)66096-8.","Walsh PC","J Urol","1996","1996/06/01","","","10.1016/s0022-5347(01)66096-8"
"29786790","Functional Studies on Steroid Receptors","Schlanger S, Heemers HV.","Methods Mol Biol. 2018;1786:117-130. doi: 10.1007/978-1-4939-7845-8_7.","Schlanger S","Methods Mol Biol","2018","2018/05/23","","","10.1007/978-1-4939-7845-8_7"
"23636138","Mitochondria, prostate cancer, and biopsy sampling error","Parr RL, Mills J, Harbottle A, Creed JM, Crewdson G, Reguly B, Guimont FS.","Discov Med. 2013 Apr;15(83):213-20.","Parr RL","Discov Med","2013","2013/05/03","","",""
"11056489","Immediate vs. delayed androgen deprivation for prostate cancer","Van Cangh PJ, Gala JL, Tombal B.","Prostate Suppl. 2000;10:19-25. doi: 10.1002/1097-0045(2000)45:10+<19::aid-pros5>3.0.co;2-#.","Van Cangh PJ","Prostate Suppl","2000","2000/11/01","","","10.1002/1097-0045(2000)45:10+<19::aid-pros5>3.0.co;2-#"
"10378220","QOL and outcomes research in prostate cancer patients with low socioeconomic status","Kim SP, Bennett CL, Chan C, Chmiel J, Falcone D, Knight SJ, Kuzel T, Davis TC, Elstein AS, Moran E, Robertson CN, Smith JS.","Oncology (Williston Park). 1999 Jun;13(6):823-32; discussion 835-8.","Kim SP","Oncology (Williston Park)","1999","1999/06/23","","",""
"28522125","[Prostate cancer histoseminar: Update of the 2016 WHO classification - case n(o)4: Mucinous prostatic adenocarcinoma]","Leroy X.","Ann Pathol. 2017 Jun;37(3):241-244. doi: 10.1016/j.annpat.2017.02.009. Epub 2017 May 15.","Leroy X","Ann Pathol","2017","2017/05/20","","","10.1016/j.annpat.2017.02.009"
"18347151","Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation","Frigo DE, McDonnell DP.","Mol Cancer Ther. 2008 Mar;7(3):659-69. doi: 10.1158/1535-7163.MCT-07-0480.","Frigo DE","Mol Cancer Ther","2008","2008/03/19","","","10.1158/1535-7163.MCT-07-0480"
"24586101","RE: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer","Ghadjar P, Budach V, Zwahlen DR.","J Natl Cancer Inst. 2014 Mar;106(3):djt464. doi: 10.1093/jnci/djt464. Epub 2014 Mar 1.","Ghadjar P","J Natl Cancer Inst","2014","2014/03/04","","","10.1093/jnci/djt464"
"22801674","Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","Moyer VA; U.S. Preventive Services Task Force.","Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459.","Moyer VA","Ann Intern Med","2012","2012/07/18","","","10.7326/0003-4819-157-2-201207170-00459"
"19242073","Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study","Chavan PR, Chavan SV, Chavan NR, Trivedi VD.","J Postgrad Med. 2009 Jan-Mar;55(1):17-21. doi: 10.4103/0022-3859.43548.","Chavan PR","J Postgrad Med","2009","2009/02/27","","","10.4103/0022-3859.43548"
"16457946","The choice between a therapy-induced long-term symptom and shortened survival due to prostate cancer","Hopfgarten T, Adolfsson J, Henningsohn L, Onelöv E, Steineck G.","Eur Urol. 2006 Aug;50(2):280-9. doi: 10.1016/j.eururo.2005.12.038. Epub 2006 Jan 18.","Hopfgarten T","Eur Urol","2006","2006/02/07","","","10.1016/j.eururo.2005.12.038"
"16025261","Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer","Duke JM, Treloar CJ, Byles JE.","Support Care Cancer. 2005 Nov;13(11):895-903. doi: 10.1007/s00520-005-0808-5. Epub 2005 Jul 16.","Duke JM","Support Care Cancer","2005","2005/07/19","","","10.1007/s00520-005-0808-5"
"18073376","Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries","Kvåle R, Auvinen A, Adami HO, Klint A, Hernes E, Møller B, Pukkala E, Storm HH, Tryggvadottir L, Tretli S, Wahlqvist R, Weiderpass E, Bray F.","J Natl Cancer Inst. 2007 Dec 19;99(24):1881-7. doi: 10.1093/jnci/djm249. Epub 2007 Dec 11.","Kvåle R","J Natl Cancer Inst","2007","2007/12/13","","","10.1093/jnci/djm249"
"31243337","Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy","Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot S.","Prostate Cancer Prostatic Dis. 2020 Mar;23(1):102-107. doi: 10.1038/s41391-019-0159-9. Epub 2019 Jun 27.","Canter DJ","Prostate Cancer Prostatic Dis","2020","2019/06/28","PMC7027968","","10.1038/s41391-019-0159-9"
"18251000","[Prostate cancer -- quo vadis? Surgery, radiation therapy, or active monitoring?]","Hautmann S.","Urologe A. 2008 Mar;47(3):259-60. doi: 10.1007/s00120-008-1635-3.","Hautmann S","Urologe A","2008","2008/02/06","","","10.1007/s00120-008-1635-3"
"26269155","[Epidemiology of prostate cancer in China: an overview and clinical implication]","Ye D, Zhu Y.","Zhonghua Wai Ke Za Zhi. 2015 Apr;53(4):249-52.","Ye D","Zhonghua Wai Ke Za Zhi","2015","2015/08/14","","",""
"9886607","Recall and attitudes in patients with prostate cancer","Miles BJ, Giesler B, Kattan MW.","Urology. 1999 Jan;53(1):169-74. doi: 10.1016/s0090-4295(98)00456-7.","Miles BJ","Urology","1999","1999/01/14","","","10.1016/s0090-4295(98)00456-7"
"9699477","Marital status and survival in prostate cancer","","Harv Mens Health Watch. 1998 Aug;3(1):7-8.","","Harv Mens Health Watch","1998","1998/08/12","","",""
"9291424","Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer","Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA.","Int J Cancer. 1997 Aug 22;74(4):374-7. doi: 10.1002/(sici)1097-0215(19970822)74:4<374::aid-ijc2>3.0.co;2-s.","Umbas R","Int J Cancer","1997","1997/08/22","","","10.1002/(sici)1097-0215(19970822)74:4<374::aid-ijc2>3.0.co;2-s"
"23570436","Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer","Hatoum HT, Crawford ED, Nielsen SK, Lin SJ, Marshall DC.","Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):251-9. doi: 10.1586/erp.13.12.","Hatoum HT","Expert Rev Pharmacoecon Outcomes Res","2013","2013/04/11","","","10.1586/erp.13.12"
"23360718","Prostate cancer screening and the management of clinically localized disease","Wilt TJ, Ahmed HU.","BMJ. 2013 Jan 29;346:f325. doi: 10.1136/bmj.f325.","Wilt TJ","BMJ","2013","2013/01/31","PMC3938276","","10.1136/bmj.f325"
"24084704","Molecular imaging of prostate cancer with PET","Jadvar H.","J Nucl Med. 2013 Oct;54(10):1685-8. doi: 10.2967/jnumed.113.126094.","Jadvar H","J Nucl Med","2013","2013/10/03","","","10.2967/jnumed.113.126094"
"23752992","Prostate cancer: lymph node metastases: not always the same prognosis","Schiavina R, Brunocilla E.","Nat Rev Urol. 2013 Aug;10(8):435-6. doi: 10.1038/nrurol.2013.127. Epub 2013 Jun 11.","Schiavina R","Nat Rev Urol","2013","2013/06/12","","","10.1038/nrurol.2013.127"
"7836101","Local treatment for prostate cancer: 90 years later--response to M. V. Pilepich","Pollack A, Zagars GK, Sands ME.","Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):436. doi: 10.1016/0360-3016(95)93159-5.","Pollack A","Int J Radiat Oncol Biol Phys","1995","1995/01/15","","","10.1016/0360-3016(95)93159-5"
"16981300","Sipuleucel-T shows partial advantage in prostate cancer","Gould P.","Lancet Oncol. 2006 Sep;7(9):710. doi: 10.1016/s1470-2045(06)70846-4.","Gould P","Lancet Oncol","2006","2006/09/19","","","10.1016/s1470-2045(06)70846-4"
"16841800","Novel combined therapy for prostate cancer proves significantly more effective","","Oncology (Williston Park). 2006 Jun;20(7):785.","","Oncology (Williston Park)","2006","2006/07/18","","",""
"31112886","Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions","Iacovelli R, Ciccarese C, Schinzari G, Maiorano BA, Rossi E, Pierconti F, Bassi PF, Bria E, Tortora G.","Crit Rev Oncol Hematol. 2019 Jul;139:83-86. doi: 10.1016/j.critrevonc.2019.05.005. Epub 2019 May 11.","Iacovelli R","Crit Rev Oncol Hematol","2019","2019/05/22","","","10.1016/j.critrevonc.2019.05.005"
"12454114","Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer","D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D.","J Clin Oncol. 2002 Dec 1;20(23):4567-73. doi: 10.1200/JCO.2002.03.061.","D'Amico AV","J Clin Oncol","2002","2002/11/28","","","10.1200/JCO.2002.03.061"
"23567497","Prostate cancer: in favour of active surveillance--functional outcomes matter","Pfister D.","Nat Rev Urol. 2013 May;10(5):263-5. doi: 10.1038/nrurol.2013.70. Epub 2013 Apr 9.","Pfister D","Nat Rev Urol","2013","2013/04/10","","","10.1038/nrurol.2013.70"
"8212426","[Value of transrectal ultrasound in determining the T-stage of prostate cancer]","Hofmockel G, Wirth MP, Manseck A, Frohmüller HG.","Urologe A. 1993 Sep;32(5):407-10.","Hofmockel G","Urologe A","1993","1993/09/01","","",""
"22260743","Focal therapy will become standard treatment for localized prostate cancer: pro","Ahmed HU.","J Urol. 2012 Mar;187(3):792-4. doi: 10.1016/j.juro.2011.12.023. Epub 2012 Jan 18.","Ahmed HU","J Urol","2012","2012/01/21","","","10.1016/j.juro.2011.12.023"
"12011916","Couples' experiences with prostate cancer: focus group research","Harden J, Schafenacker A, Northouse L, Mood D, Smith D, Pienta K, Hussain M, Baranowski K.","Oncol Nurs Forum. 2002 May;29(4):701-9. doi: 10.1188/02.ONF.701-709.","Harden J","Oncol Nurs Forum","2002","2002/05/16","","","10.1188/02.ONF.701-709"
"12532481","[Detection of localized prostate cancer during multifocal biopsy]","Veliev EI, Petrov SB, Eloev RA.","Voen Med Zh. 2002 Nov;323(11):40-3.","Veliev EI","Voen Med Zh","2002","2003/01/21","","",""
"8371411","Re: Deferred treatment of low grade stage T3 prostate cancer without distant metastases","Zincke H, Oesterling JE.","J Urol. 1993 Oct;150(4):1256-8. doi: 10.1016/s0022-5347(17)35755-5.","Zincke H","J Urol","1993","1993/10/01","","","10.1016/s0022-5347(17)35755-5"
"31172421","Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies","Boukovala M, Spetsieris N, Efstathiou E.","Drugs Aging. 2019 Aug;36(8):701-717. doi: 10.1007/s40266-019-00677-6.","Boukovala M","Drugs Aging","2019","2019/06/08","","","10.1007/s40266-019-00677-6"
"11586228","The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer","Bacon CG, Giovannucci E, Testa M, Kawachi I.","J Urol. 2001 Nov;166(5):1804-10.","Bacon CG","J Urol","2001","2001/10/05","","",""
"29081414","Arylsulfatase B is reduced in prostate cancer recurrences","Feferman L, Deaton R, Bhattacharyya S, Xie H, Gann PH, Melamed J, Tobacman JK.","Cancer Biomark. 2017 Dec 12;21(1):229-234. doi: 10.3233/CBM-170680.","Feferman L","Cancer Biomark","2017","2017/10/31","","","10.3233/CBM-170680"
"15592675","Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer","Figg WD, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM, Van Bingham W, Eastham JA, Reed E, Sartor O.","World J Urol. 2004 Dec;22(6):425-30. doi: 10.1007/s00345-004-0443-7. Epub 2004 Dec 8.","Figg WD","World J Urol","2004","2004/12/14","","","10.1007/s00345-004-0443-7"
"25456974","Psychometric properties and performance of the 17-item Benefit Finding Scale (BFS) in an outpatient population of men with prostate cancer","Pascoe L, Edvardsson D.","Eur J Oncol Nurs. 2015 Apr;19(2):169-73. doi: 10.1016/j.ejon.2014.09.004. Epub 2014 Oct 22.","Pascoe L","Eur J Oncol Nurs","2015","2014/12/03","","","10.1016/j.ejon.2014.09.004"
"28797714","Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer","Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW, Sfanos KS.","J Urol. 2018 Jan;199(1):161-171. doi: 10.1016/j.juro.2017.08.001. Epub 2017 Aug 7.","Shrestha E","J Urol","2018","2017/08/12","PMC5937117","NIHMS962908","10.1016/j.juro.2017.08.001"
"29251468","MEN'S HEALTH -- THE MAN WITH PROSTATE CANCER","Middleton R.","Aust Nurs Midwifery J. 2016 Nov;24(5):33.","Middleton R","Aust Nurs Midwifery J","2016","2017/12/19","","",""
"12582456","Gene expression alterations in human prostate cancer","Luo JH.","Drugs Today (Barc). 2002 Oct;38(10):713-9. doi: 10.1358/dot.2002.38.10.704653.","Luo JH","Drugs Today (Barc)","2002","2003/02/13","","","10.1358/dot.2002.38.10.704653"
"16673603","New generation urethral stents in treatment bladder outlet obstruction caused by prostate cancer","Markovic B, Markovic Z, Filimonovic J, Hadzi Djokic J.","Acta Chir Iugosl. 2005;52(4):89-92. doi: 10.2298/aci0504089m.","Markovic B","Acta Chir Iugosl","2005","2006/05/06","","","10.2298/aci0504089m"
"15266325","The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer","McArdle PA, Canna K, McMillan DC, McNicol AM, Campbell R, Underwood MA.","Br J Cancer. 2004 Aug 2;91(3):541-3. doi: 10.1038/sj.bjc.6601943.","McArdle PA","Br J Cancer","2004","2004/07/22","PMC2409839","","10.1038/sj.bjc.6601943"
"30348512","Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer","Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.","Clin Genitourin Cancer. 2019 Feb;17(1):32-37. doi: 10.1016/j.clgc.2018.09.022. Epub 2018 Oct 4.","Vicier C","Clin Genitourin Cancer","2019","2018/10/24","","","10.1016/j.clgc.2018.09.022"
"28039542","The Relationships Between Spiritual Well-Being, Quality of Life, and Psychological Factors Before Radiotherapy for Prostate Cancer","Walker SJ, Chen Y, Paik K, Mirly B, Thomas CR Jr, Hung AY.","J Relig Health. 2017 Oct;56(5):1846-1855. doi: 10.1007/s10943-016-0352-2.","Walker SJ","J Relig Health","2017","2017/01/01","","","10.1007/s10943-016-0352-2"
"10426191","The androgen receptor: genetic considerations in the development and treatment of prostate cancer","Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD.","J Mol Med (Berl). 1999 May;77(5):419-26. doi: 10.1007/s001090050372.","Cude KJ","J Mol Med (Berl)","1999","1999/07/30","","","10.1007/s001090050372"
"15054907","Including partners into the diagnosis of prostate cancer: a review of the literature to provide a model of care","Riechers EA.","Urol Nurs. 2004 Feb;24(1):22-9, 38.","Riechers EA","Urol Nurs","2004","2004/04/02","","",""
"22082921","Re: comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer","Walsh PC.","J Urol. 2011 Jan;185(1):141. doi: 10.1016/S0022-5347(11)60115-8.","Walsh PC","J Urol","2011","2011/11/16","","","10.1016/S0022-5347(11)60115-8"
"9836551","Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose","Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Strup S, Petersen RO, Corn BW, Lu JD.","Urology. 1998 Dec;52(6):1034-40. doi: 10.1016/s0090-4295(98)00405-1.","Valicenti RK","Urology","1998","1998/12/04","","","10.1016/s0090-4295(98)00405-1"
"17387277","Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation","Vander Griend DJ, Litvinov IV, Isaacs JT.","Cell Cycle. 2007 Mar 15;6(6):647-51. doi: 10.4161/cc.6.6.4028. Epub 2007 Mar 21.","Vander Griend DJ","Cell Cycle","2007","2007/03/28","","","10.4161/cc.6.6.4028"
"24180518","Metabolic atrophy and 3-T 1H-magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer","Panebianco V, Barchetti F, Musio D, Forte V, Pace A, De Felice F, Barchetti G, Tombolini V, Catalano C.","BJU Int. 2014 Dec;114(6):852-9. doi: 10.1111/bju.12553. Epub 2014 Feb 20.","Panebianco V","BJU Int","2014","2013/11/05","","","10.1111/bju.12553"
"20549536","Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data","Molinier L, Castelli C, Bauvin E, Rebillard X, Soulié M, Daurès JP, Grosclaude P.","Eur J Health Econ. 2011 Aug;12(4):363-71. doi: 10.1007/s10198-010-0250-6. Epub 2010 Jun 13.","Molinier L","Eur J Health Econ","2011","2010/06/16","","","10.1007/s10198-010-0250-6"
"16686708","Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective","Newton FJ, Burney S, Millar JL, Frydenberg M, Ng KT.","BJU Int. 2006 Jun;97(6):1179-83. doi: 10.1111/j.1464-410X.2006.06152.x.","Newton FJ","BJU Int","2006","2006/05/12","","","10.1111/j.1464-410X.2006.06152.x"
"15812351","Quality of life survey in patients with advanced prostate cancer","Giannakopoulos X, Charalabopoulos K, Charalabopoulos A, Golias C, Peschos D, Sofikitis N.","Exp Oncol. 2005 Mar;27(1):13-7.","Giannakopoulos X","Exp Oncol","2005","2005/04/07","","",""
"9504297","Prostate cancer, birthweight, and diet","Lawson JS.","Epidemiology. 1998 Mar;9(2):217. doi: 10.1097/00001648-199803000-00024.","Lawson JS","Epidemiology","1998","1998/03/21","","","10.1097/00001648-199803000-00024"
"30245085","Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men","Tonon L, Fromont G, Boyault S, Thomas E, Ferrari A, Sertier AS, Kielbassa J, Le Texier V, Kamoun A, Elarouci N, Irani J, Multigner L, Gut IG, Gut M, Blanchet P, De Reynies A, Cancel-Tassin G, Viari A, Cussenot O.","Eur Urol. 2019 Jan;75(1):11-15. doi: 10.1016/j.eururo.2018.08.026. Epub 2018 Sep 21.","Tonon L","Eur Urol","2019","2018/09/25","","","10.1016/j.eururo.2018.08.026"
"8635929","Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation","Freedman GM, Hanlon AL, Lee WR, Hanks GE.","Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):243-50. doi: 10.1016/0360-3016(96)00017-x.","Freedman GM","Int J Radiat Oncol Biol Phys","1996","1996/05/01","","","10.1016/0360-3016(96)00017-x"
"11295608","Imaging and prostate cancer chemoprevention: Current diagnosis and future directions","Littrup PJ.","Urology. 2001 Apr;57(4 Suppl 1):121-3. doi: 10.1016/s0090-4295(00)00954-7.","Littrup PJ","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00954-7"
"10848698","Benign prostatic hyperplasia and prostate carcinoma in native Africans","Dawam D, Rafindadi AH, Kalayi GD.","BJU Int. 2000 Jun;85(9):1074-7. doi: 10.1046/j.1464-410x.2000.00677.x.","Dawam D","BJU Int","2000","2000/06/10","","","10.1046/j.1464-410x.2000.00677.x"
"16480669","Tissue print micropeel: a new technique for mapping tumor invasion in prostate cancer","Gaston SM, Upton MP.","Curr Urol Rep. 2006 Jan;7(1):50-6. doi: 10.1007/s11934-006-0038-5.","Gaston SM","Curr Urol Rep","2006","2006/02/17","","","10.1007/s11934-006-0038-5"
"27024839","New tests promise smarter prostate cancer screening and treatment. Clues from genes and other cancer markers can help men make decisions, but come with important limitations","","Harv Mens Health Watch. 2013 Dec;18(5):6-7.","","Harv Mens Health Watch","2013","2016/03/31","","",""
"23896625","Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation","Fujimoto N, Kubo T, Inatomi H, Bui HT, Shiota M, Sho T, Matsumoto T.","Prostate Cancer Prostatic Dis. 2013 Dec;16(4):336-40. doi: 10.1038/pcan.2013.23. Epub 2013 Jul 30.","Fujimoto N","Prostate Cancer Prostatic Dis","2013","2013/07/31","","","10.1038/pcan.2013.23"
"27922627","Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions","Hendriks RJ, van Oort IM, Schalken JA.","Prostate Cancer Prostatic Dis. 2017 Mar;20(1):12-19. doi: 10.1038/pcan.2016.59. Epub 2016 Dec 6.","Hendriks RJ","Prostate Cancer Prostatic Dis","2017","2016/12/07","","","10.1038/pcan.2016.59"
"8633409","Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer","Zhang XZ, Donovan MP, Williams BT, Mohler JL.","Urology. 1996 Mar;47(3):402-4. doi: 10.1016/S0090-4295(99)80460-9.","Zhang XZ","Urology","1996","1996/03/01","","","10.1016/S0090-4295(99)80460-9"
"12887469","Sexual factors and prostate cancer","Giles GG, Severi G, English DR, McCredie MR, Borland R, Boyle P, Hopper JL.","BJU Int. 2003 Aug;92(3):211-6. doi: 10.1046/j.1464-410x.2003.04319.x.","Giles GG","BJU Int","2003","2003/07/31","","","10.1046/j.1464-410x.2003.04319.x"
"17979611","The media and prostate cancer screening","Steginga SK, Gardiner RF.","Med J Aust. 2007 Nov 5;187(9):501-2.","Steginga SK","Med J Aust","2007","2007/11/06","","",""
"12599590","[Problems of prostate cancer in elderly patients]","Kato H, Nishizawa O.","Nihon Rinsho. 2002 Dec;60 Suppl 11:304-8.","Kato H","Nihon Rinsho","2002","2003/02/26","","",""
"7526513","Follow-up after radical prostatectomy or radiation therapy for prostate cancer","Montie JE.","Urol Clin North Am. 1994 Nov;21(4):673-6.","Montie JE","Urol Clin North Am","1994","1994/11/01","","",""
"29936077","Liquid biopsy approach in the management of prostate cancer","Riaz IB, Wang L, Kohli M.","Transl Res. 2018 Nov;201:60-70. doi: 10.1016/j.trsl.2018.05.004. Epub 2018 May 31.","Riaz IB","Transl Res","2018","2018/06/25","PMC6631037","NIHMS1033187","10.1016/j.trsl.2018.05.004"
"26334121","Re: effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer","Du K, Luzny P, Lowrance WT.","Eur Urol. 2015 Oct;68(4):738-9. doi: 10.1016/j.eururo.2015.06.034.","Du K","Eur Urol","2015","2015/09/04","","","10.1016/j.eururo.2015.06.034"
"29667615","Vitamin D in prostate cancer","Trump DL, Aragon-Ching JB.","Asian J Androl. 2018 May-Jun;20(3):244-252. doi: 10.4103/aja.aja_14_18.","Trump DL","Asian J Androl","2018","2018/04/19","PMC5952478","","10.4103/aja.aja_14_18"
"25785490","Prostate cancer incidence and agriculture practices in Georgia, 2000-2010","Welton M, Robb SW, Shen Y, Guillebeau P, Vena J.","Int J Occup Environ Health. 2015 Jul-Sep;21(3):251-7. doi: 10.1179/2049396714Y.0000000106. Epub 2015 Mar 18.","Welton M","Int J Occup Environ Health","2015","2015/03/19","PMC4597014","","10.1179/2049396714Y.0000000106"
"11198886","Dendritic cell-based immunotherapy for prostate cancer","Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP.","CA Cancer J Clin. 1999 Mar-Apr;49(2):117-28, 65. doi: 10.3322/canjclin.49.2.117.","Tjoa BA","CA Cancer J Clin","1999","2001/02/24","","","10.3322/canjclin.49.2.117"
"17492408","[Therapy of locoregional prostate cancer]","Lamche M, Bauer WA, Schramek P.","Wien Med Wochenschr. 2007;157(7-8):140-4. doi: 10.1007/s10354-007-0398-6.","Lamche M","Wien Med Wochenschr","2007","2007/05/12","","","10.1007/s10354-007-0398-6"
"31294141","A structured framework for optimizing high-intensity focused ultrasound ablative treatment in localized prostate cancer","Castellani D, Branchi A, Claudini R, Gasparri L, Pierangeli T, Ravasi E, Dellabella M.","Investig Clin Urol. 2019 Jul;60(4):312-318. doi: 10.4111/icu.2019.60.4.312. Epub 2019 Jun 20.","Castellani D","Investig Clin Urol","2019","2019/07/12","PMC6607080","","10.4111/icu.2019.60.4.312"
"11600812","[Ldr brachytherapy, a minimally invasive alternative in the treatment of organ-confined prostate cancer]","Siegsmund M, Musial A, Weiss J, Alken P.","Onkologie. 2001 Sep;24 Suppl 5:46-50. doi: 10.1159/000055186.","Siegsmund M","Onkologie","2001","2001/10/16","","","10.1159/000055186"
"22748289","Permanent seed brachytherapy for locally recurrent prostate cancer after radical prostatectomy: a case report and review of the literature","Gaztañaga M, Crook JM.","Brachytherapy. 2013 Jul-Aug;12(4):338-42. doi: 10.1016/j.brachy.2012.04.006. Epub 2012 Jun 28.","Gaztañaga M","Brachytherapy","2013","2012/07/04","","","10.1016/j.brachy.2012.04.006"
"11510516","Prostate cancer","Frank RE.","J Insur Med. 2001;33(2):189-91.","Frank RE","J Insur Med","2001","2001/08/21","","",""
"20698170","Polymorphisms in Toll-like receptor genes--implications for prostate cancer development","Vidas Z.","Coll Antropol. 2010 Jun;34(2):779-83.","Vidas Z","Coll Antropol","2010","2010/08/12","","",""
"7679047","Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy","Cheng CW, Bergstralh EJ, Zincke H.","Cancer. 1993 Feb 1;71(3 Suppl):996-1004. doi: 10.1002/1097-0142(19930201)71:3+<996::aid-cncr2820711417>3.0.co;2-8.","Cheng CW","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<996::aid-cncr2820711417>3.0.co;2-8"
"29580712","Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients","Mordasini L, Hechelhammer L, Diener PA, Diebold J, Mattei A, Engeler D, Müllhaupt G, Kim SK, Schmid HP, Abt D.","J Vasc Interv Radiol. 2018 May;29(5):589-597. doi: 10.1016/j.jvir.2018.01.766. Epub 2018 Mar 23.","Mordasini L","J Vasc Interv Radiol","2018","2018/03/28","","","10.1016/j.jvir.2018.01.766"
"25986841","Re: Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer","Atala A.","J Urol. 2015 Jun;193(6):2146-7. doi: 10.1016/j.juro.2015.03.005. Epub 2015 Mar 13.","Atala A","J Urol","2015","2015/05/20","","","10.1016/j.juro.2015.03.005"
"23845333","Re: quality of life in men undergoing active surveillance for localized prostate cancer","Taneja SS.","J Urol. 2013 Aug;190(2):536-7. doi: 10.1016/j.juro.2013.04.118. Epub 2013 May 2.","Taneja SS","J Urol","2013","2013/07/13","","","10.1016/j.juro.2013.04.118"
"17440139","Outcomes of treatment vs observation of localized prostate cancer in elderly men","Scholz MC, Lam RY, Klotz L.","JAMA. 2007 Apr 18;297(15):1651-2; author reply 1652-3. doi: 10.1001/jama.297.15.1651-b.","Scholz MC","JAMA","2007","2007/04/19","","","10.1001/jama.297.15.1651-b"
"15199027","Use and timing of radiotherapy in high-risk prostate cancer","Ward JF, Blute ML.","JAMA. 2004 Jun 16;291(23):2817; author reply 2817-8. doi: 10.1001/jama.291.23.2817-a.","Ward JF","JAMA","2004","2004/06/17","","","10.1001/jama.291.23.2817-a"
"15072603","Improved survival benefit of autologous dendritic cell-based vaccine for hormone refractory prostate cancer: a retrospective subset analysis of the d9901 trial","Price N.","Clin Prostate Cancer. 2004 Mar;2(4):212. doi: 10.1016/s1540-0352(11)70047-6.","Price N","Clin Prostate Cancer","2004","2004/04/10","","","10.1016/s1540-0352(11)70047-6"
"15770516","Mechanisms of the development of androgen independence in prostate cancer","So A, Gleave M, Hurtado-Col A, Nelson C.","World J Urol. 2005 Feb;23(1):1-9. doi: 10.1007/s00345-004-0473-1. Epub 2005 Jan 27.","So A","World J Urol","2005","2005/03/17","","","10.1007/s00345-004-0473-1"
"23582878","Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease","Cardwell CR, Suissa S, Murray LJ.","Eur Urol. 2013 Jul;64(1):e10. doi: 10.1016/j.eururo.2013.03.046. Epub 2013 Apr 4.","Cardwell CR","Eur Urol","2013","2013/04/16","","","10.1016/j.eururo.2013.03.046"
"24819057","PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?","Miralbell R, Buchegger F.","Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1267-9. doi: 10.1007/s00259-014-2793-8.","Miralbell R","Eur J Nucl Med Mol Imaging","2014","2014/05/14","","","10.1007/s00259-014-2793-8"
"8854070","p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer","Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE.","Eur Urol. 1996;30(1):65-72. doi: 10.1159/000474147.","Stattin P","Eur Urol","1996","1996/01/01","","","10.1159/000474147"
"15815195","Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer","Ward JF, Moul JW.","Curr Opin Urol. 2005 May;15(3):181-6. doi: 10.1097/01.mou.0000165552.79416.11.","Ward JF","Curr Opin Urol","2005","2005/04/09","","","10.1097/01.mou.0000165552.79416.11"
"10492188","Staging of prostate cancer using 3-dimensional transrectal ultrasound images: a pilot study","Garg S, Fortling B, Chadwick D, Robinson MC, Hamdy FC.","J Urol. 1999 Oct;162(4):1318-21.","Garg S","J Urol","1999","1999/09/24","","",""
"24980193","Prostate cancer: intriguing data on inflammation and prostate cancer","Vignozzi L, Maggi M.","Nat Rev Urol. 2014 Jul;11(7):369-70. doi: 10.1038/nrurol.2014.143. Epub 2014 Jul 1.","Vignozzi L","Nat Rev Urol","2014","2014/07/02","","","10.1038/nrurol.2014.143"
"15447980","Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers","Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, Gruber SB, Ostrander EA, Cooney KA.","Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5975-80. doi: 10.1158/1078-0432.CCR-04-0554.","Zuhlke KA","Clin Cancer Res","2004","2004/09/28","","","10.1158/1078-0432.CCR-04-0554"
"25596362","Novel biomarkers and advanced imaging modalities in the early detection of prostate cancer","Parsons JK.","J Urol. 2015 Apr;193(4):1084-5. doi: 10.1016/j.juro.2015.01.040. Epub 2015 Jan 14.","Parsons JK","J Urol","2015","2015/01/18","","","10.1016/j.juro.2015.01.040"
"18947507","A 43-year-old African American man with low-risk prostate cancer","Soloway M.","Curr Urol Rep. 2008 Nov;9(6):437; discussion 437-40. doi: 10.1007/s11934-008-0075-3.","Soloway M","Curr Urol Rep","2008","2008/10/25","","","10.1007/s11934-008-0075-3"
"10981465","Re: ""differences in socioeconomic status and survival among white and black men with prostate cancer""","Kaufman JS, Millikan R, Poole C, Godley P, Cooper RS, Freeman V.","Am J Epidemiol. 2000 Sep 1;152(5):493-4. doi: 10.1093/aje/152.5.493.","Kaufman JS","Am J Epidemiol","2000","2000/09/12","","","10.1093/aje/152.5.493"
"9828588","Is race an independent prognostic factor for survival from prostate cancer?","Roach M 3rd.","J Natl Med Assoc. 1998 Nov;90(11 Suppl):S713-9.","Roach M 3rd","J Natl Med Assoc","1998","1998/11/26","PMC2653096","",""
"8943763","Androgen receptors in prostate cancer","Bentel JM, Tilley WD.","J Endocrinol. 1996 Oct;151(1):1-11. doi: 10.1677/joe.0.1510001.","Bentel JM","J Endocrinol","1996","1996/10/01","","","10.1677/joe.0.1510001"
"17465703","Adiponectin as a potential marker of prostate cancer progression: studies in organ-confined and locally advanced prostate cancer","Housa D, Vernerová Z, Herácek J, Procházka B, Cechák P, Kuncová J, Haluzík M.","Physiol Res. 2008;57(3):451-8. Epub 2007 Apr 25.","Housa D","Physiol Res","2008","2007/05/01","","",""
"17671638","Stem cells in prostate cancer initiation and progression","Lawson DA, Witte ON.","J Clin Invest. 2007 Aug;117(8):2044-50. doi: 10.1172/JCI32810.","Lawson DA","J Clin Invest","2007","2007/08/03","PMC1934594","","10.1172/JCI32810"
"21343530","A clinically relevant approach to imaging prostate cancer: self-assessment module","Verma S, Rajesh A.","AJR Am J Roentgenol. 2011 Mar;196(3 Suppl):S11-4. doi: 10.2214/AJR.10.7295.","Verma S","AJR Am J Roentgenol","2011","2011/02/24","","","10.2214/AJR.10.7295"
"11962189","Computed tomogram prior to prostatectomy. Advantage in defining planning target volumes for postoperative adjuvant radiotherapy in patients with stage C prostate cancer?","Höcht S, Wiegel T, Bottke D, Jentsch H, Sternemann M, Rosenthal P, Hinkelbein W.","Strahlenther Onkol. 2002 Mar;178(3):134-8. doi: 10.1007/s00066-002-0896-9.","Höcht S","Strahlenther Onkol","2002","2002/04/19","","","10.1007/s00066-002-0896-9"
"24367875","Are 5-ARIs suitable for prevention of prostate cancer?","Rees J.","Practitioner. 2013 Oct;257(1765):5.","Rees J","Practitioner","2013","2013/12/26","","",""
"14634433","Re: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy","Tiguert R, Inman BA.","J Urol. 2003 Dec;170(6 Pt 1):2392; author reply 2392. doi: 10.1097/01.ju.0000095148.84868.ba.","Tiguert R","J Urol","2003","2003/11/25","","","10.1097/01.ju.0000095148.84868.ba"
"10494233","Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men","Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE.","Med J Aust. 1999 Aug 16;171(4):185-8.","Slevin TJ","Med J Aust","1999","1999/09/24","","",""
"9697787","Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men","Egawa S, Suyama K, Soh S, Kuwao S, Uchida T, Koshiba K.","Urology. 1998 Aug;52(2):230-6. doi: 10.1016/s0090-4295(98)00179-4.","Egawa S","Urology","1998","1998/08/11","","","10.1016/s0090-4295(98)00179-4"
"25882061","Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer","Stuchbery R, Kurganovs NJ, McCoy PJ, Nelson CC, Hayes VM, Corcoran NM, Hovens CM.","Curr Cancer Drug Targets. 2015;15(5):394-405. doi: 10.2174/1568009615666150416113453.","Stuchbery R","Curr Cancer Drug Targets","2015","2015/04/18","","","10.2174/1568009615666150416113453"
"23549870","Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer","Kron K, Trudel D, Pethe V, Briollais L, Fleshner N, van der Kwast T, Bapat B.","Clin Cancer Res. 2013 Jul 1;19(13):3450-61. doi: 10.1158/1078-0432.CCR-12-3139. Epub 2013 Apr 2.","Kron K","Clin Cancer Res","2013","2013/04/04","","","10.1158/1078-0432.CCR-12-3139"
"10488608","[Early versus late hormonal treatment in advanced prostate cancer]","Allepuz Losa C, Gil Martínez P, Gil Sanz MJ, Rioja Sanz LA.","Actas Urol Esp. 1999 Jul-Aug;23(7):557-64.","Allepuz Losa C","Actas Urol Esp","1999","1999/09/17","","",""
"31868959","Overall, specific, and metastasis-free survival of Afro-Caribbean men with pathological Gleason 6 prostate cancer","Mollard P, Perrot E, Blanchet P, Brureau L.","Prostate. 2020 Mar;80(4):329-335. doi: 10.1002/pros.23947. Epub 2019 Dec 23.","Mollard P","Prostate","2020","2019/12/24","","","10.1002/pros.23947"
"10962312","Long-term survival in a Swedish population-based cohort of men with prostate cancer","Sandblom G, Dufmats M, Varenhorst E.","Urology. 2000 Sep 1;56(3):442-7. doi: 10.1016/s0090-4295(00)00696-8.","Sandblom G","Urology","2000","2000/08/30","","","10.1016/s0090-4295(00)00696-8"
"25405934","Diagnostic associations of gene expression signatures in prostate cancer tissue","Nguyen HG, Welty CJ, Cooperberg MR.","Curr Opin Urol. 2015 Jan;25(1):65-70. doi: 10.1097/MOU.0000000000000131.","Nguyen HG","Curr Opin Urol","2015","2014/11/19","","","10.1097/MOU.0000000000000131"
"8165761","Chemoprevention of prostate cancer","Brawley OW, Thompson IM.","Urology. 1994 May;43(5):594-9. doi: 10.1016/0090-4295(94)90169-4.","Brawley OW","Urology","1994","1994/05/01","","","10.1016/0090-4295(94)90169-4"
"21602036","A population-based study of prostate cancer chemotherapy","Harris V, Lloyd K, Forsey S, Rogers P, Roche M, Parker C.","Clin Oncol (R Coll Radiol). 2011 Dec;23(10):706-8. doi: 10.1016/j.clon.2011.04.014. Epub 2011 May 23.","Harris V","Clin Oncol (R Coll Radiol)","2011","2011/05/24","","","10.1016/j.clon.2011.04.014"
"10433626","Re: Lest we abandon digital rectal examination as a screening test for prostate cancer","Schröder FH.","J Natl Cancer Inst. 1999 Aug 4;91(15):1331-2. doi: 10.1093/jnci/91.15.1331b.","Schröder FH","J Natl Cancer Inst","1999","1999/08/05","","","10.1093/jnci/91.15.1331b"
"29856649","Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer","Dellis AE, Papatsoris AG.","Expert Opin Investig Drugs. 2018 Jun;27(6):553-559. doi: 10.1080/13543784.2018.1484107. Epub 2018 Jun 18.","Dellis AE","Expert Opin Investig Drugs","2018","2018/06/02","","","10.1080/13543784.2018.1484107"
"28130104","Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration","Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ.","J Urol. 2017 Jul;198(1):86-91. doi: 10.1016/j.juro.2017.01.063. Epub 2017 Jan 24.","Bhindi B","J Urol","2017","2017/01/29","","","10.1016/j.juro.2017.01.063"
"23184647","miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer","Larne O, Martens-Uzunova E, Hagman Z, Edsjö A, Lippolis G, den Berg MS, Bjartell A, Jenster G, Ceder Y.","Int J Cancer. 2013 Jun 15;132(12):2867-75. doi: 10.1002/ijc.27973. Epub 2012 Dec 21.","Larne O","Int J Cancer","2013","2012/11/28","","","10.1002/ijc.27973"
"19237624","Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority","Nanda A, Chen MH, D'Amico AV.","J Clin Oncol. 2009 Apr 1;27(10):1728-9; author reply 1729. doi: 10.1200/JCO.2008.21.5392. Epub 2009 Feb 23.","Nanda A","J Clin Oncol","2009","2009/02/25","","","10.1200/JCO.2008.21.5392"
"17432557","Staging of prostate cancer","Dotan ZA, Ramon J.","Recent Results Cancer Res. 2007;175:109-30. doi: 10.1007/978-3-540-40901-4_8.","Dotan ZA","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_8"
"18405741","Commentary on watchful waiting and health related quality of life for patients with localized prostate cancer","Strope SA, Hollenbeck BK.","J Urol. 2008 May;179(5 Suppl):S19. doi: 10.1016/j.juro.2008.03.005.","Strope SA","J Urol","2008","2008/04/25","","","10.1016/j.juro.2008.03.005"
"8628164","Screening for prostate cancer: the case against","Hirst GH, Ward JE, Del Mar CB.","Med J Aust. 1996 Mar 4;164(5):285-8.","Hirst GH","Med J Aust","1996","1996/03/04","","",""
"12954499","Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)","Cho D, Di Blasio CJ, Rhee AC, Kattan MW.","Urol Oncol. 2003 Jul-Aug;21(4):282-91. doi: 10.1016/s1078-1439(03)00057-7.","Cho D","Urol Oncol","2003","2003/09/05","","","10.1016/s1078-1439(03)00057-7"
"19549125","Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer","Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, Donovan JL, Hamdy FC, Martin RM, Neal DE.","BJU Int. 2009 Dec;104(11):1592-8. doi: 10.1111/j.1464-410X.2009.08652.x. Epub 2009 Jun 19.","Moore AL","BJU Int","2009","2009/06/25","","","10.1111/j.1464-410X.2009.08652.x"
"25895769","Re: Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology","Griebling TL.","J Urol. 2015 May;193(5):1543-4. doi: 10.1016/j.juro.2015.02.049. Epub 2015 Feb 18.","Griebling TL","J Urol","2015","2015/04/22","","","10.1016/j.juro.2015.02.049"
"25617273","Re: Diffusion-weighted MR imaging in early assessment of tumor response to radiotherapy in high-risk prostate cancer","Taneja SS.","J Urol. 2015 Feb;193(2):539-40. doi: 10.1016/j.juro.2014.11.068. Epub 2014 Nov 15.","Taneja SS","J Urol","2015","2015/01/25","","","10.1016/j.juro.2014.11.068"
"25152091","Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy","Mitsuzuka K, Arai Y.","Int J Clin Oncol. 2014 Oct;19(5):793-9. doi: 10.1007/s10147-014-0738-7. Epub 2014 Aug 26.","Mitsuzuka K","Int J Clin Oncol","2014","2014/08/26","","","10.1007/s10147-014-0738-7"
"21365621","Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates","Alibhai SM.","Cancer. 2011 Sep 1;117(17):3872-4. doi: 10.1002/cncr.25976. Epub 2011 Mar 1.","Alibhai SM","Cancer","2011","2011/03/03","","","10.1002/cncr.25976"
"27094969","PSA testing and early management of test-detected prostate cancer--consensus at last","Lawrentschuk N.","BJU Int. 2016 Apr;117 Suppl 4:5-6. doi: 10.1111/bju.13481.","Lawrentschuk N","BJU Int","2016","2016/04/21","","","10.1111/bju.13481"
"23273666","How to select the optimal therapy for early-stage prostate cancer","Kollmeier MA, Zelefsky MJ.","Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e6-e15. doi: 10.1016/j.critrevonc.2012.12.002.","Kollmeier MA","Crit Rev Oncol Hematol","2012","2013/01/01","","","10.1016/j.critrevonc.2012.12.002"
"14501720","No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination","Bill-Axelson A, Holmberg L, Norlén B, Busch C, Norberg M.","J Urol. 2003 Oct;170(4 Pt 1):1180-3. doi: 10.1097/01.ju.0000087325.57314.5c.","Bill-Axelson A","J Urol","2003","2003/09/23","","","10.1097/01.ju.0000087325.57314.5c"
"18319508","Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach","Etzioni R, Gulati R, Falcon S, Penson DF.","Med Decis Making. 2008 May-Jun;28(3):323-31. doi: 10.1177/0272989X07312719. Epub 2008 Mar 4.","Etzioni R","Med Decis Making","2008","2008/03/06","","","10.1177/0272989X07312719"
"23855042","Four new studies show advances against prostate cancer. Men facing prostate cancer can now make more informed decisions regarding diagnosis, treatment, and quality of life","","Duke Med Health News. 2013 Apr;19(4):3-4.","","Duke Med Health News","2013","2013/07/17","","",""
"16521081","Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature","Couper J, Bloch S, Love A, Macvean M, Duchesne GM, Kissane D.","Psychooncology. 2006 Nov;15(11):937-53. doi: 10.1002/pon.1031.","Couper J","Psychooncology","2006","2006/03/08","","","10.1002/pon.1031"
"18027850","Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer","Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M.","Int J Cancer. 2008 Mar 15;122(6):1400-10. doi: 10.1002/ijc.23243.","Qian X","Int J Cancer","2008","2007/11/22","","","10.1002/ijc.23243"
"30777011","Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer","Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, Ren S, Collins CC.","BMC Genomics. 2019 Feb 18;20(1):146. doi: 10.1186/s12864-019-5457-z.","Feng Y","BMC Genomics","2019","2019/02/20","PMC6379980","","10.1186/s12864-019-5457-z"
"9112521","Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy","Powell CR, Huisman TK, Riffenburgh RH, Saunders EL, Bethel KJ, Johnstone PA.","J Urol. 1997 May;157(5):1754-9.","Powell CR","J Urol","1997","1997/05/01","","",""
"28847462","[Radiotherapy of oligometastatic pelvic node relapses in patients with prostate cancer]","Supiot S, Doré M, Rio E.","Cancer Radiother. 2017 Oct;21(6-7):495-497. doi: 10.1016/j.canrad.2017.07.017. Epub 2017 Aug 25.","Supiot S","Cancer Radiother","2017","2017/08/30","","","10.1016/j.canrad.2017.07.017"
"7543669","[Results of studies of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hypertrophy and prostatic cancer]","Romics I, Bodrogi I, Frang D.","Orv Hetil. 1995 Jul 23;136(30):1599-602.","Romics I","Orv Hetil","1995","1995/07/23","","",""
"21397049","Infection, inflammation and prostate carcinogenesis","Omabe M, Ezeani M.","Infect Genet Evol. 2011 Aug;11(6):1195-8. doi: 10.1016/j.meegid.2011.03.002. Epub 2011 Mar 21.","Omabe M","Infect Genet Evol","2011","2011/03/15","","","10.1016/j.meegid.2011.03.002"
"21054791","Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy","Pahlajani G, Raina R, Jones S, Ali M, Zippe C.","J Sex Med. 2012 Apr;9(4):1182-9. doi: 10.1111/j.1743-6109.2010.01881.x. Epub 2010 Nov 3.","Pahlajani G","J Sex Med","2012","2010/11/09","","","10.1111/j.1743-6109.2010.01881.x"
"24314095","Obesity is associated with higher risk of prostate cancer detection in a biopsy population in Korea","Park J, Cho SY, Lee SB, Son H, Jeong H.","BJU Int. 2014 Dec;114(6):891-5. doi: 10.1111/bju.12600. Epub 2014 Oct 20.","Park J","BJU Int","2014","2013/12/10","","","10.1111/bju.12600"
"28653241","Anti-Prostate Cancer Activity of 8-Hydroxyquinoline-2-Carboxaldehyde-Thiosemicarbazide Copper Complexes by Fluorescent Microscopic Imaging","Xie F, Peng F.","J Fluoresc. 2017 Nov;27(6):1937-1941. doi: 10.1007/s10895-017-2133-z. Epub 2017 Jun 26.","Xie F","J Fluoresc","2017","2017/06/28","","","10.1007/s10895-017-2133-z"
"9064882","[Delayed therapy of clinically localized prostatic carcinoma. Experiences of the Karolinska Hospital]","Adolfsson J.","Urologe A. 1996 Nov;35(6):454-5. doi: 10.1007/s001200050051.","Adolfsson J","Urologe A","1996","1996/11/01","","","10.1007/s001200050051"
"26709895","Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence","Hao J, Chiang YT, Gout PW, Wang Y.","Front Biosci (Schol Ed). 2016 Jan 1;8:44-55. doi: 10.2741/s445.","Hao J","Front Biosci (Schol Ed)","2016","2015/12/29","","","10.2741/s445"
"29063497","Coping and adjustment in men with prostate cancer: a systematic review of qualitative studies","Spendelow JS, Eli Joubert H, Lee H, Fairhurst BR.","J Cancer Surviv. 2018 Apr;12(2):155-168. doi: 10.1007/s11764-017-0654-8. Epub 2017 Oct 23.","Spendelow JS","J Cancer Surviv","2018","2017/10/25","PMC5884891","","10.1007/s11764-017-0654-8"
"25981647","[Prostate cancer prevention]","Miyanaga N, Akaza H.","Gan To Kagaku Ryoho. 2015 May;42(5):538-43.","Miyanaga N","Gan To Kagaku Ryoho","2015","2015/05/19","","",""
"11182368","Immunohistochemical localization of platelet-derived endothelial cell growth factor expression and its relation to angiogenesis in prostate","Okada K, Yokoyama K, Okihara K, Ukimura O, Kojima M, Miki T, Takamatsu T.","Urology. 2001 Feb;57(2):376-81. doi: 10.1016/s0090-4295(00)00907-9.","Okada K","Urology","2001","2001/02/22","","","10.1016/s0090-4295(00)00907-9"
"19027464","Management of prostate cancer in the older man","Mohile SG, Lachs M, Dale W.","Semin Oncol. 2008 Dec;35(6):597-617. doi: 10.1053/j.seminoncol.2008.08.003.","Mohile SG","Semin Oncol","2008","2008/11/26","","","10.1053/j.seminoncol.2008.08.003"
"10878541","Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines","Jenster G.","J Pathol. 2000 Jul;191(3):227-8. doi: 10.1002/1096-9896(200007)191:3<227::AID-PATH636>3.0.CO;2-3.","Jenster G","J Pathol","2000","2000/07/06","","","10.1002/1096-9896(200007)191:3<227::AID-PATH636>3.0.CO;2-3"
"19514557","[Diagnostic value of lesion-directed prostate biopsy under TRUS in early detection of prostate cancer]","Zhu J, Liu XM, Du CJ, Zhang ZW, Qiu YQ, Gong Y, Liu JR, Hong YR, Luo ZY, Zhang Y.","Zhonghua Nan Ke Xue. 2009 May;15(5):437-40.","Zhu J","Zhonghua Nan Ke Xue","2009","2009/06/12","","",""
"1698232","[The histological expression of prostate-specific antigen and its clinical significance in patients with prostate cancer]","Okano M.","Nihon Hinyokika Gakkai Zasshi. 1990 Jun;81(6):847-54. doi: 10.5980/jpnjurol1989.81.847.","Okano M","Nihon Hinyokika Gakkai Zasshi","1990","1990/06/01","","","10.5980/jpnjurol1989.81.847"
"25182503","High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients","Rachner TD, Thiele S, Göbel A, Browne A, Fuessel S, Erdmann K, Wirth MP, Fröhner M, Todenhöfer T, Muders MH, Kieslinger M, Rauner M, Hofbauer LC.","BMC Cancer. 2014 Sep 2;14:649. doi: 10.1186/1471-2407-14-649.","Rachner TD","BMC Cancer","2014","2014/09/04","PMC4167148","","10.1186/1471-2407-14-649"
"26094386","[EVALUATION OF DIAGNOSTIC SIGNIFICANCE OF PELVIC MRI IN PROSTATE CANCER PATIENTS]","Rasner PI, Kotenko DV, Kolontarev KB, Brodeckij BM, Pushkar DY.","Urologiia. 2015 Jan-Feb;(1):44-8.","Rasner PI","Urologiia","2015","2015/06/23","","",""
"19368139","Review. Current role and future perspectives of hyperthermia for prostate cancer treatment","Baronzio G, Gramaglia A, Fiorentini G.","In Vivo. 2009 Jan-Feb;23(1):143-6.","Baronzio G","In Vivo","2009","2009/04/17","","",""
"12243658","Post-renal acute renal failure during pelvis irradiation for prostate cancer","David M, Souhami L, Aprikian A.","Can J Urol. 2002 Aug;9(4):1599-601.","David M","Can J Urol","2002","2002/09/24","","",""
"28916284","Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis","Helou J, Torres S, Musunuru HB, Raphael J, Cheung P, Vesprini D, Chung HT, D'Alimonte L, Krahn M, Morton G, Loblaw A.","Clin Oncol (R Coll Radiol). 2017 Nov;29(11):718-731. doi: 10.1016/j.clon.2017.08.002. Epub 2017 Sep 12.","Helou J","Clin Oncol (R Coll Radiol)","2017","2017/09/17","","","10.1016/j.clon.2017.08.002"
"28388542","Emerging proteomics biomarkers and prostate cancer burden in Africa","Adeola HA, Blackburn JM, Rebbeck TR, Zerbini LF.","Oncotarget. 2017 Jun 6;8(23):37991-38007. doi: 10.18632/oncotarget.16568.","Adeola HA","Oncotarget","2017","2017/04/08","PMC5514967","","10.18632/oncotarget.16568"
"16010507","Palliative radiofrequency ablation for recurrent prostate cancer","Jindal G, Friedman M, Locklin J, Wood BJ.","Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):482-5. doi: 10.1007/s00270-004-0200-8.","Jindal G","Cardiovasc Intervent Radiol","2006","2005/07/13","PMC2386884","NIHMS36439","10.1007/s00270-004-0200-8"
"12523309","Prostatectomy or watchful waiting in prostate cancer","Stern SD.","N Engl J Med. 2003 Jan 9;348(2):170-1; author reply 170-1.","Stern SD","N Engl J Med","2003","2003/01/14","","",""
"10492196","New methods for predicting extracapsular extension before surgery for prostate cancer","Fitzpatrick JM.","J Urol. 1999 Oct;162(4):1359-60.","Fitzpatrick JM","J Urol","1999","1999/09/24","","",""
"10081894","Re: Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions","Weldon VE.","J Urol. 1999 Apr;161(4):1287.","Weldon VE","J Urol","1999","1999/03/19","","",""
"9248453","Prostate cancer","Dean M, Downey P.","Prof Nurse. 1997 Jul;12(10):722-4.","Dean M","Prof Nurse","1997","1997/07/01","","",""
"1371563","Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer","Kennedy TJ, Sonneland AM, Marlett MM, Troup RH.","J Urol. 1992 Mar;147(3 Pt 2):891-3. doi: 10.1016/s0022-5347(17)37414-1.","Kennedy TJ","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37414-1"
"25660097","Genetic Variants of DICE1/INTS6 in German Prostate Cancer Families with Linkage to 13q14","Böhm M, Maier C, Küfer R, Röpke A, Vogel W, Wieland I.","Urol Int. 2015;95(4):386-9. doi: 10.1159/000366229. Epub 2015 Jan 31.","Böhm M","Urol Int","2015","2015/02/10","","","10.1159/000366229"
"20649829","Editorial comment to Feasibility of antegrade radical prostatectomy for clinically locally advanced prostate cancer: a comparative study with clinically localized disease","Ishidoya S.","Int J Urol. 2010 Aug;17(8):725-6. doi: 10.1111/j.1442-2042.2010.02577.x.","Ishidoya S","Int J Urol","2010","2010/07/24","","","10.1111/j.1442-2042.2010.02577.x"
"12599557","[Clinical usefulness of transrectal ultrasonography in screening and staging for prostate cancer]","Ushijima S, Ukimura O, Miki T.","Nihon Rinsho. 2002 Dec;60 Suppl 11:123-7.","Ushijima S","Nihon Rinsho","2002","2003/02/26","","",""
"10710908","Special issue--prostate cancer","Brown JM.","J S C Med Assoc. 2000 Feb;96(2):88-9.","Brown JM","J S C Med Assoc","2000","2000/03/11","","",""
"15815190","Proteomics in prostate cancer","Bañez LL, Srivastava S, Moul JW.","Curr Opin Urol. 2005 May;15(3):151-6. doi: 10.1097/01.mou.0000165547.48922.12.","Bañez LL","Curr Opin Urol","2005","2005/04/09","","","10.1097/01.mou.0000165547.48922.12"
"28753787","In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database","Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.","Eur Urol Focus. 2017 Oct;3(4-5):480-486. doi: 10.1016/j.euf.2016.08.007. Epub 2016 Aug 29.","Whitney CA","Eur Urol Focus","2017","2017/07/30","","","10.1016/j.euf.2016.08.007"
"17478439","Obesity and prostate cancer: making sense out of apparently conflicting data","Freedland SJ, Platz EA.","Epidemiol Rev. 2007;29:88-97. doi: 10.1093/epirev/mxm006. Epub 2007 May 3.","Freedland SJ","Epidemiol Rev","2007","2007/05/05","","","10.1093/epirev/mxm006"
"21477723","Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment","Miocinovic R, Berglund RK, Stephenson AJ, Jones JS, Fergany A, Kaouk J, Klein EA.","Urology. 2011 Apr;77(4):946-50. doi: 10.1016/j.urology.2010.11.057.","Miocinovic R","Urology","2011","2011/04/12","","","10.1016/j.urology.2010.11.057"
"19904264","Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000-2006","Fairley L, Baker M, Whiteway J, Cross W, Forman D.","Br J Cancer. 2009 Dec 1;101(11):1839-45. doi: 10.1038/sj.bjc.6605424. Epub 2009 Nov 10.","Fairley L","Br J Cancer","2009","2009/11/12","PMC2788251","","10.1038/sj.bjc.6605424"
"23339130","Racial disparities in survival after diagnosis of prostate cancer in Kentucky, 2001-2010","Antwi S, Tucker TC, Coker AL, Fleming ST.","Am J Mens Health. 2013 Jul;7(4):306-16. doi: 10.1177/1557988312473774. Epub 2013 Jan 20.","Antwi S","Am J Mens Health","2013","2013/01/23","","","10.1177/1557988312473774"
"15542264","Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men","Escobedo LG, Rivas SD, Holmes MD.","Cancer Detect Prev. 2004;28(5):375-80. doi: 10.1016/j.cdp.2004.06.003.","Escobedo LG","Cancer Detect Prev","2004","2004/11/16","","","10.1016/j.cdp.2004.06.003"
"26242441","[Transference in the Nurse-Patient Relationship: A Case Report on a Prostate Cancer Patient]","Wang MC, Huang WT, Chang SC.","Hu Li Za Zhi. 2015 Aug;62(4):95-102. doi: 10.6224/JN62.4.95.","Wang MC","Hu Li Za Zhi","2015","2015/08/06","","","10.6224/JN62.4.95"
"18813934","Active surveillance for prostate cancer: trials and tribulations","Klotz L.","World J Urol. 2008 Oct;26(5):437-42. doi: 10.1007/s00345-008-0330-8. Epub 2008 Sep 24.","Klotz L","World J Urol","2008","2008/09/25","","","10.1007/s00345-008-0330-8"
"27787754","Oligometastatic Prostate Cancer","Stevens DJ, Sooriakumaran P.","Curr Treat Options Oncol. 2016 Dec;17(12):62. doi: 10.1007/s11864-016-0439-8.","Stevens DJ","Curr Treat Options Oncol","2016","2016/10/28","PMC5083765","","10.1007/s11864-016-0439-8"
"1716022","Prostate cancer screening in younger men: prostate-specific antigen and public awareness","Moon TD, Clejan S.","Urology. 1991 Sep;38(3):216-9. doi: 10.1016/s0090-4295(91)80347-a.","Moon TD","Urology","1991","1991/09/01","","","10.1016/s0090-4295(91)80347-a"
"21092117","Solitary pulmonary metastasis from prostate sarcomatoid cancer","Goto T, Maeshima A, Oyamada Y, Kato R.","World J Surg Oncol. 2010 Nov 19;8:101. doi: 10.1186/1477-7819-8-101.","Goto T","World J Surg Oncol","2010","2010/11/25","PMC2995788","","10.1186/1477-7819-8-101"
"11280789","Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression","Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ.","Cancer Res. 2001 Mar 1;61(5):2212-9.","Pihan GA","Cancer Res","2001","2001/03/31","","",""
"22487909","Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry","Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF.","Prostate Cancer Prostatic Dis. 2012 Sep;15(3):256-9. doi: 10.1038/pcan.2012.10.","Blana A","Prostate Cancer Prostatic Dis","2012","2012/04/11","","","10.1038/pcan.2012.10"
"25948802","[Advances in ultrasound techniques for the diagnosis and staging of prostate cancer. Elastography, Doppler ultrasound, ultrasound contrast media, ultrasound quantification media and MRI fusion]","Westendarp M, Postema A, de la Rosette JJ, Wijkstra H, Laguna MP.","Arch Esp Urol. 2015 Apr;68(3):307-15.","Westendarp M","Arch Esp Urol","2015","2015/05/08","","",""
"16832417","Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia","Pashayan N, Powles J, Brown C, Duffy SW.","Br J Cancer. 2006 Aug 7;95(3):401-5. doi: 10.1038/sj.bjc.6603246. Epub 2006 Jul 11.","Pashayan N","Br J Cancer","2006","2006/07/13","PMC2360645","","10.1038/sj.bjc.6603246"
"12599542","[Summary and characteristics of 'General rule for clinical and pathological studies on prostate cancer (the 3rd edition)']","Murai M.","Nihon Rinsho. 2002 Dec;60 Suppl 11:39-43.","Murai M","Nihon Rinsho","2002","2003/02/26","","",""
"476583","Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate","Berry WR, Laszlo J, Cox E, Walker A, Paulson D.","Cancer. 1979 Aug;44(2):763-75. doi: 10.1002/1097-0142(197908)44:2<763::aid-cncr2820440251>3.0.co;2-5.","Berry WR","Cancer","1979","1979/08/01","","","10.1002/1097-0142(197908)44:2<763::aid-cncr2820440251>3.0.co;2-5"
"26225679","Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer","Murray NP, Reyes E, Fuentealba C, Orellana N, Morales F, Jacob O.","Asian Pac J Cancer Prev. 2015;16(13):5365-70. doi: 10.7314/apjcp.2015.16.13.5365.","Murray NP","Asian Pac J Cancer Prev","2015","2015/07/31","","","10.7314/apjcp.2015.16.13.5365"
"28004265","Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU)","Eredics K, Dorfinger K, Kramer G, Ponholzer A, Madersbacher S.","Wien Klin Wochenschr. 2017 Jun;129(11-12):375-379. doi: 10.1007/s00508-016-1149-8. Epub 2016 Dec 21.","Eredics K","Wien Klin Wochenschr","2017","2016/12/23","","","10.1007/s00508-016-1149-8"
"20032410","Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months","Ogawa K, Nakamura K, Sasaki T, Onishi H, Koizumi M, Araya M, Mukumoto N, Mitsumori M, Teshima T; Japanese Patterns of Care Study Working Subgroup of Prostate Cancer.","Anticancer Res. 2009 Nov;29(11):4605-13.","Ogawa K","Anticancer Res","2009","2009/12/25","","",""
"22328018","Current status of immunological approaches for the treatment of prostate cancer","Drake CG, Antonarakis ES.","Curr Opin Urol. 2012 May;22(3):197-202. doi: 10.1097/MOU.0b013e3283519ad5.","Drake CG","Curr Opin Urol","2012","2012/02/14","PMC3444809","NIHMS401486","10.1097/MOU.0b013e3283519ad5"
"2219583","New concepts in the treatment of stage D1 adenocarcinoma of the prostate","Austenfeld MS, Davis BE.","Urol Clin North Am. 1990 Nov;17(4):867-84.","Austenfeld MS","Urol Clin North Am","1990","1990/11/01","","",""
"28971750","The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer","Sathianathen NJ, Krishna S, Konety BR, Griffith TS.","Immunotherapy. 2017 Sep;9(12):1005-1018. doi: 10.2217/imt-2017-0051.","Sathianathen NJ","Immunotherapy","2017","2017/10/04","","","10.2217/imt-2017-0051"
"32216230","[Comprehensive nursing intervention helps improve medication compliance of prostate cancer patients undergoing endocrine therapy]","Ding Y, Lu YW.","Zhonghua Nan Ke Xue. 2019 May;25(5):434-436.","Ding Y","Zhonghua Nan Ke Xue","2019","2020/03/28","","",""
"17138129","Improved prostate cancer detection with anterior apical prostate biopsies","Wright JL, Ellis WJ.","Urol Oncol. 2006 Nov-Dec;24(6):492-5. doi: 10.1016/j.urolonc.2006.03.003.","Wright JL","Urol Oncol","2006","2006/12/02","","","10.1016/j.urolonc.2006.03.003"
"26768791","Biomarkers in localized prostate cancer","Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, Deliu VM, Ditonno P, Perdonà S, Autorino R, Coman I, De Placido S, Di Lorenzo G, De Cobelli O.","Future Oncol. 2016 Feb;12(3):399-411. doi: 10.2217/fon.15.318. Epub 2016 Jan 15.","Ferro M","Future Oncol","2016","2016/01/16","PMC5549774","","10.2217/fon.15.318"
"26793873","[Epidemiology and prevention]","Akaza H.","Nihon Rinsho. 2016 Jan;74(1):13-9.","Akaza H","Nihon Rinsho","2016","2016/01/23","","",""
"10926085","Management of locally advanced prostate cancer. 2. Radiotherapy, neoadjuvant endocrine treatment, update 1997-1999","Schröder FH, van den Ouden D.","World J Urol. 2000 Jun;18(3):204-15. doi: 10.1007/s003459900103.","Schröder FH","World J Urol","2000","2000/08/05","","","10.1007/s003459900103"
"28737470","Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review","Parimi S, Ko JJ.","Expert Rev Anticancer Ther. 2017 Oct;17(10):939-949. doi: 10.1080/14737140.2017.1359544. Epub 2017 Jul 31.","Parimi S","Expert Rev Anticancer Ther","2017","2017/07/25","","","10.1080/14737140.2017.1359544"
"21045777","Prostate cancer multifocality: impact on cancer biology and treatment recommendations","Delacroix SE, Ward JF.","Panminerva Med. 2010 Sep;52(3):209-16.","Delacroix SE","Panminerva Med","2010","2010/11/04","","",""
"24128823","Prostate cancer: a high value target for cost containment","Gomella LG.","Can J Urol. 2013 Oct;20(5):6888.","Gomella LG","Can J Urol","2013","2013/10/17","","",""
"16190576","Link between exercise and lower risk for prostate cancer found","AVMA Group Health and Life Insurance Trust.","J Am Vet Med Assoc. 2005 Sep 15;227(6):858-9.","AVMA Group Health and Life Insurance Trust","J Am Vet Med Assoc","2005","2005/09/30","","",""
"29488426","MRI-only based radiation therapy of prostate cancer: workflow and early clinical experience","Tenhunen M, Korhonen J, Kapanen M, Seppälä T, Koivula L, Collan J, Saarilahti K, Visapää H.","Acta Oncol. 2018 Jul;57(7):902-907. doi: 10.1080/0284186X.2018.1445284. Epub 2018 Feb 28.","Tenhunen M","Acta Oncol","2018","2018/03/01","","","10.1080/0284186X.2018.1445284"
"16094096","Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?","Lynch MJ.","J Urol. 2005 Sep;174(3):1155; author reply 1155-6. doi: 10.1016/s0022-5347(01)68555-0.","Lynch MJ","J Urol","2005","2005/08/12","","","10.1016/s0022-5347(01)68555-0"
"29251768","Evolving detection and treatment methods change approaches to prostate cancer: US Preventive Services Task Force draft recommendations now align more closely with others","Printz C.","Cancer. 2018 Jan 1;124(1):11-12. doi: 10.1002/cncr.31180.","Printz C","Cancer","2018","2017/12/19","","","10.1002/cncr.31180"
"17565157","Prostate cancer progression and survival in BRCA2 mutation carriers","Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H.","J Natl Cancer Inst. 2007 Jun 20;99(12):929-35. doi: 10.1093/jnci/djm005. Epub 2007 Jun 12.","Tryggvadóttir L","J Natl Cancer Inst","2007","2007/06/15","","","10.1093/jnci/djm005"
"15619920","Animal models for prostate cancer","Pollard M.","Prostate. 1980;1(2):207-13. doi: 10.1002/pros.2990010206.","Pollard M","Prostate","1980","1980/01/01","","","10.1002/pros.2990010206"
"7681241","Diagnosis, prognosis and management of incidentally found prostate cancer","Davidson PJ.","Urol Res. 1993 Jan;21(1):1-8. doi: 10.1007/BF00295184.","Davidson PJ","Urol Res","1993","1993/01/01","","","10.1007/BF00295184"
"1574457","The management of bladder outlet obstruction due to prostate cancer, untreated and after endocrine treatment","Montie JE.","Prostate Suppl. 1992;4:153-7. doi: 10.1002/pros.2990210525.","Montie JE","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210525"
"23370446","New insights into prostate cancer stem cells","Chen X, Rycaj K, Liu X, Tang DG.","Cell Cycle. 2013 Feb 15;12(4):579-86. doi: 10.4161/cc.23721. Epub 2013 Jan 31.","Chen X","Cell Cycle","2013","2013/02/02","PMC3594258","","10.4161/cc.23721"
"19298603","Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer","Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.","Cancer Sci. 2009 May;100(5):914-9. doi: 10.1111/j.1349-7006.2009.01117.x. Epub 2009 Feb 26.","Tamura K","Cancer Sci","2009","2009/03/21","","","10.1111/j.1349-7006.2009.01117.x"
"19414846","Clinically relevant prognostic markers for prostate cancer: the search goes on","Gelmann EP, Henshall SM.","Ann Intern Med. 2009 May 5;150(9):647-9. doi: 10.7326/0003-4819-150-9-200905050-00014.","Gelmann EP","Ann Intern Med","2009","2009/05/06","","","10.7326/0003-4819-150-9-200905050-00014"
"28222630","Association of VDR polymorphisms ( Taq I and Bsm I) with prostate cancer: a new meta-analysis","Liu S, Cai H, Cheng W, Zhang H, Pan Z, Wang D.","J Int Med Res. 2017 Feb;45(1):3-10. doi: 10.1177/0300060516668939. Epub 2017 Jan 17.","Liu S","J Int Med Res","2017","2017/02/23","PMC5536582","","10.1177/0300060516668939"
"25099119","PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer","Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, Stone S, Freedland SJ.","Int J Urol. 2014 Dec;21(12):1209-14. doi: 10.1111/iju.12571. Epub 2014 Aug 5.","Mithal P","Int J Urol","2014","2014/08/08","","","10.1111/iju.12571"
"29385039","Glyoxalases in Urological Malignancies","Antognelli C, Talesa VN.","Int J Mol Sci. 2018 Jan 31;19(2):415. doi: 10.3390/ijms19020415.","Antognelli C","Int J Mol Sci","2018","2018/02/01","PMC5855637","","10.3390/ijms19020415"
"31063245","Using prognosis to guide inclusion criteria, define standardised endpoints and stratify follow-up in active surveillance for prostate cancer","Gnanapragasam VJ, Barrett T, Thankapannair V, Thurtle D, Rubio-Briones J, Domínguez-Escrig J, Bratt O, Statin P, Muir K, Lophatananon A.","BJU Int. 2019 Nov;124(5):758-767. doi: 10.1111/bju.14800. Epub 2019 Jun 2.","Gnanapragasam VJ","BJU Int","2019","2019/05/08","","","10.1111/bju.14800"
"23587509","Perineural invasion and TRUS findings are complementary in predicting prostate cancer biology","Martinez CH, Williams AK, Chin JL, Stitt L, Izawa JI.","Can J Urol. 2013 Apr;20(2):6696-701.","Martinez CH","Can J Urol","2013","2013/04/17","","",""
"17701951","Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004","Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK.","Cancer. 2007 Sep 15;110(6):1255-63. doi: 10.1002/cncr.22872.","Robbins AS","Cancer","2007","2007/08/19","","","10.1002/cncr.22872"
"24873168","[Updated roles of adrenergic receptors in prostate cancer]","Luo HQ, Kuang XX, Li BY.","Zhonghua Nan Ke Xue. 2014 Apr;20(4):372-6.","Luo HQ","Zhonghua Nan Ke Xue","2014","2014/05/31","","",""
"2480442","Prostate cancer: radiation seed implantation without open surgery","Gregory B, Van Valkenburgh J.","J Post Anesth Nurs. 1989 Dec;4(6):373-6.","Gregory B","J Post Anesth Nurs","1989","1989/12/01","","",""
"1438940","Prostate cancer treated by radiotherapy: a multivariate study","Albuisson E, Allain YM, Rozan R, Giraud B, Bolla M, Brune D, Carteaux A, Castelain B, Cuillere JC, Douchez J, et al.","Radiother Oncol. 1992 Oct;25(2):89-96. doi: 10.1016/0167-8140(92)90014-l.","Albuisson E","Radiother Oncol","1992","1992/10/01","","","10.1016/0167-8140(92)90014-l"
"15526829","Prostate cancer 2004: insights from national disease registries","Cooperberg MR, Park S, Carroll PR.","Oncology (Williston Park). 2004 Sep;18(10):1239-47; discussion 1248-50, 1256-8.","Cooperberg MR","Oncology (Williston Park)","2004","2004/11/06","","",""
"26183750","Idiopathic cholestatic jaundice may be a paraneoplastic manifestation of underlying malignancy: a case of prostate cancer","Okano A, Ohana M, Kusumi F.","Clin J Gastroenterol. 2014 Jun;7(3):278-82. doi: 10.1007/s12328-014-0484-4. Epub 2014 Apr 12.","Okano A","Clin J Gastroenterol","2014","2015/07/18","","","10.1007/s12328-014-0484-4"
"25134834","Prostate cancer: PSA update--no change yet","Phillips R.","Nat Rev Urol. 2014 Sep;11(9):483. doi: 10.1038/nrurol.2014.210. Epub 2014 Aug 19.","Phillips R","Nat Rev Urol","2014","2014/08/20","","","10.1038/nrurol.2014.210"
"17467883","The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity","Adolfsson J, Tribukait B, Levitt S.","Eur Urol. 2007 Oct;52(4):1028-35. doi: 10.1016/j.eururo.2007.04.002. Epub 2007 Apr 9.","Adolfsson J","Eur Urol","2007","2007/05/01","","","10.1016/j.eururo.2007.04.002"
"26382778","Re: Relationship between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","Penson DF.","J Urol. 2015 Oct;194(4):990-1. doi: 10.1016/j.juro.2015.07.029. Epub 2015 Jul 14.","Penson DF","J Urol","2015","2015/09/19","","","10.1016/j.juro.2015.07.029"
"17077347","Prostate-specific antigen and prostate cancer prognosis","Church TR.","J Natl Cancer Inst. 2006 Nov 1;98(21):1509-10. doi: 10.1093/jnci/djj455.","Church TR","J Natl Cancer Inst","2006","2006/11/02","","","10.1093/jnci/djj455"
"16888416","Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer","McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC.","Urol Int. 2006;77(2):127-9. doi: 10.1159/000093905.","McArdle PA","Urol Int","2006","2006/08/05","","","10.1159/000093905"
"25185085","Stereotactic body radiation therapy for prostate cancer: the need to assess patient-reported outcomes","Vordermark D.","J Clin Oncol. 2014 Oct 20;32(30):3456. doi: 10.1200/JCO.2014.56.2215. Epub 2014 Sep 2.","Vordermark D","J Clin Oncol","2014","2014/09/04","","","10.1200/JCO.2014.56.2215"
"25185083","Regarding relative toxicities of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer","Fuller DB.","J Clin Oncol. 2014 Oct 20;32(30):3455-6. doi: 10.1200/JCO.2014.56.5572. Epub 2014 Sep 2.","Fuller DB","J Clin Oncol","2014","2014/09/04","","","10.1200/JCO.2014.56.5572"
"15123414","Prevention and management of prostate cancer chemotherapy complications","Beer TM, Bubalo JS.","Urol Clin North Am. 2004 May;31(2):367-78. doi: 10.1016/j.ucl.2004.01.003.","Beer TM","Urol Clin North Am","2004","2004/05/05","","","10.1016/j.ucl.2004.01.003"
"31659799","The role of masculinities in psychological and emotional help seeking by men with prostate cancer","Goodwin BC, Ralph N, Ireland MJ, Hyde MK, Oliffe JL, Dunn J, Chambers S.","Psychooncology. 2020 Feb;29(2):356-363. doi: 10.1002/pon.5264. Epub 2019 Nov 19.","Goodwin BC","Psychooncology","2020","2019/10/30","","","10.1002/pon.5264"
"10803834","Screening and hormonal therapy of localized prostate cancer shows major benefits on survival","Labrie F.","Cancer J. 2000 Apr;6 Suppl 2:S182-7.","Labrie F","Cancer J","2000","2000/05/10","","",""
"28646014","The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study","Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.","J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23.","Roach PJ","J Nucl Med","2018","2017/06/25","","","10.2967/jnumed.117.197160"
"9741422","Systematic biopsy-based staging of prostate cancer: scientific background, individual variables, combination of parameters, and current integrative models","Narayan P, Tewari A.","Semin Urol Oncol. 1998 Aug;16(3):172-81.","Narayan P","Semin Urol Oncol","1998","1998/09/19","","",""
"20102687","Prostate specific membrane antigen- a target for imaging and therapy with radionuclides","Bouchelouche K, Choyke PL, Capala J.","Discov Med. 2010 Jan;9(44):55-61.","Bouchelouche K","Discov Med","2010","2010/01/28","PMC3410553","NIHMS395316",""
"24825727","Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study","Pignot G, Salomon L, Lebacle C, Neuzillet Y, Lunardi P, Rischmann P, Zerbib M, Champy C, Roupret M, Peyronnet B, Verhoest G, Murez T, Quintens H, Larré S, Houédé N, Compérat E, Soulié M, Pfister C.","BJU Int. 2015 Jan;115(1):87-93. doi: 10.1111/bju.12803. Epub 2014 Aug 11.","Pignot G","BJU Int","2015","2014/05/15","","","10.1111/bju.12803"
"28800317","Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach","Fang E, Zhang X, Wang Q, Wang D.","Cancer Biomark. 2017 Dec 6;20(4):553-561. doi: 10.3233/CBM-170362.","Fang E","Cancer Biomark","2017","2017/08/12","","","10.3233/CBM-170362"
"23582283","Inflammation and prostate cancer","Dal Moro F, Zattoni F.","Urol Oncol. 2013 Jul;31(5):712. doi: 10.1016/j.urolonc.2013.03.002. Epub 2013 Apr 10.","Dal Moro F","Urol Oncol","2013","2013/04/16","","","10.1016/j.urolonc.2013.03.002"
"22910034","Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database","Hirst CJ, Cabrera C, Kirby M.","Cancer Epidemiol. 2012 Dec;36(6):e349-53. doi: 10.1016/j.canep.2012.07.012. Epub 2012 Aug 19.","Hirst CJ","Cancer Epidemiol","2012","2012/08/23","","","10.1016/j.canep.2012.07.012"
"8843963","Dietary factors and risk of prostate cancer in Poland. Results of case-control study","Pawlega J, Rachtan J, Dyba T.","Neoplasma. 1996;43(1):61-3.","Pawlega J","Neoplasma","1996","1996/01/01","","",""
"8648776","Prostate cancer--the added factors","Lynch JH.","J Urol. 1996 Jul;156(1):144-5. doi: 10.1016/s0022-5347(01)65968-8.","Lynch JH","J Urol","1996","1996/07/01","","","10.1016/s0022-5347(01)65968-8"
"7529937","Prostate cancer: US-guided percutaneous cryoablation. Work in progress","Bahn DK, Lee F, Solomon MH, Gontina H, Klionsky DL, Lee FT Jr.","Radiology. 1995 Feb;194(2):551-6. doi: 10.1148/radiology.194.2.7529937.","Bahn DK","Radiology","1995","1995/02/01","","","10.1148/radiology.194.2.7529937"
"12949932","Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens","Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W.","Prostate. 2003 Oct 1;57(2):93-8. doi: 10.1002/pros.10278.","Berger AP","Prostate","2003","2003/09/02","","","10.1002/pros.10278"
"12230707","Prostate cancer: non-metastatic","Wilt T.","Clin Evid. 2002 Jun;(7):812-23.","Wilt T","Clin Evid","2002","2002/09/17","","",""
"19102508","[Cyclooxygenase-2 and cyclooxygenase-2 inhibitors in prostate cancer]","Xu S, Gao JP, Zhou WQ.","Zhonghua Nan Ke Xue. 2008 Nov;14(11):1031-4.","Xu S","Zhonghua Nan Ke Xue","2008","2008/12/24","","",""
"31661149","Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?","Phillips RM, Deek MP, Deweese TL, Tran PT.","Oncology (Williston Park). 2019 Oct 28;33(10):686509.","Phillips RM","Oncology (Williston Park)","2019","2019/10/30","","",""
"20677093","Adenovirus-based therapy for prostate cancer","Ekblad M, Halldén G.","Curr Opin Mol Ther. 2010 Aug;12(4):421-31.","Ekblad M","Curr Opin Mol Ther","2010","2010/08/03","","",""
"27431337","Prostate cancer: Biomarkers from liquid biopsy","Stone L.","Nat Rev Urol. 2016 Aug;13(8):434. doi: 10.1038/nrurol.2016.133. Epub 2016 Jul 19.","Stone L","Nat Rev Urol","2016","2016/07/20","","","10.1038/nrurol.2016.133"
"24492436","Prostate cancer: Post-treatment complications of radiotherapy and prostatectomy","Phillips R.","Nat Rev Urol. 2014 Mar;11(3):129. doi: 10.1038/nrurol.2014.18. Epub 2014 Feb 4.","Phillips R","Nat Rev Urol","2014","2014/02/05","","","10.1038/nrurol.2014.18"
"27344745","[Clinical implication of PSA in the diagnosis of prostate cancer]","Nakashima J, Hirasawa Y, Kashima T, Shimodaira K, Sugihara T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:295-9.","Nakashima J","Nihon Rinsho","2016","2016/06/28","","",""
"16613539","Protective effects of green tea against prostate cancer","Lee AH, Fraser ML, Meng X, Binns CW.","Expert Rev Anticancer Ther. 2006 Apr;6(4):507-13. doi: 10.1586/14737140.6.4.507.","Lee AH","Expert Rev Anticancer Ther","2006","2006/04/15","","","10.1586/14737140.6.4.507"
"10786086","[Therapy of prostate carcinoma. Age, general health status and stage determine choice of therapy]","Otto T, Seegenschmiedt MH, Rübben H.","MMW Fortschr Med. 2000 Mar 16;142(11):32-4.","Otto T","MMW Fortschr Med","2000","2000/04/29","","",""
"24422979","Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer","Zhang H, Qi C, Wang A, Yao B, Li L, Wang Y, Xu Y.","J Exp Clin Cancer Res. 2013 Oct 16;32(1):77. doi: 10.1186/1756-9966-32-77.","Zhang H","J Exp Clin Cancer Res","2013","2014/01/16","PMC3852884","","10.1186/1756-9966-32-77"
"16637072","Germline ATBF1 mutations and prostate cancer risk","Xu J, Sauvageot J, Ewing CM, Sun J, Liu W, Isaacs SD, Wiley KE, Diaz L, Zheng SL, Walsh PC, Isaacs WB.","Prostate. 2006 Jul 1;66(10):1082-5. doi: 10.1002/pros.20430.","Xu J","Prostate","2006","2006/04/26","","","10.1002/pros.20430"
"20180404","[Diagnosis and treatment of coincident vesical transitional cell carcinoma and prostate cancer: a report of 5 cases]","Song YS, Song Y, Luo JY, Wu B.","Zhonghua Nan Ke Xue. 2010 Jan;16(1):44-7.","Song YS","Zhonghua Nan Ke Xue","2010","2010/02/26","","",""
"15555136","Prostate cancer (non-metastatic)","Wilt T.","Clin Evid. 2003 Dec;(10):1023-38.","Wilt T","Clin Evid","2003","2004/11/24","","",""
"18813903","[Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent]","Wolff I, Grimm MO, Wirth M.","Urologe A. 2008 Nov;47(11):1436-40. doi: 10.1007/s00120-008-1723-4.","Wolff I","Urologe A","2008","2008/09/25","","","10.1007/s00120-008-1723-4"
"8013153","Science behind total androgen blockade: from gene to combination therapy","Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, Labrie C.","Clin Invest Med. 1993 Dec;16(6):475-92.","Labrie F","Clin Invest Med","1993","1993/12/01","","",""
"18957713","Sonohistology - ultrasonic tissue characterization for prostate cancer diagnostics","Scheipers U, König K, Sommerfeld HJ, Garcia-Schürmann M, Senge T, Ermert H.","Cancer Biomark. 2008;4(4-5):227-50. doi: 10.3233/cbm-2008-44-506.","Scheipers U","Cancer Biomark","2008","2008/10/30","","","10.3233/cbm-2008-44-506"
"8777511","Comment: dilemmas of diagnosis and treatment of prostate cancer","Sandu DP.","Br J Hosp Med. 1996 Mar 6-19;55(5):233-4.","Sandu DP","Br J Hosp Med","1996","1996/03/06","","",""
"11270899","Men's attitudes toward prostate cancer and seeking prostate-specific antigen testing","Steginga SK, Occhipinti S, McCaffrey J, Dunn J.","J Cancer Educ. 2001 Spring;16(1):42-5. doi: 10.1080/08858190109528723.","Steginga SK","J Cancer Educ","2001","2001/03/29","","","10.1080/08858190109528723"
"9421449","Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer","Amling CL, Blute ML, Bergstralh EJ, Slezak JM, Martin SK, Zincke H.","Semin Urol Oncol. 1997 Nov;15(4):222-9.","Amling CL","Semin Urol Oncol","1997","1998/01/08","","",""
"29858674","Molecular Subtypes of Prostate Cancer","Arora K, Barbieri CE.","Curr Oncol Rep. 2018 Jun 1;20(8):58. doi: 10.1007/s11912-018-0707-9.","Arora K","Curr Oncol Rep","2018","2018/06/03","","","10.1007/s11912-018-0707-9"
"24095905","Impact of folate intake on prostate cancer recurrence following definitive therapy: data from CaPSURE™","Tomaszewski JJ, Richman EL, Sadetsky N, O'Keefe DS, Carroll PR, Davies BJ, Chan JM.","J Urol. 2014 Apr;191(4):971-6. doi: 10.1016/j.juro.2013.09.065. Epub 2013 Oct 3.","Tomaszewski JJ","J Urol","2014","2013/10/08","PMC5480381","NIHMS857265","10.1016/j.juro.2013.09.065"
"19652929","Postoperative radiotherapy for advanced prostate cancer: improved local control translates into increased survival","Sautter-Bihl ML, Sedlmayer F, Wiegel T.","Strahlenther Onkol. 2009 Aug;185(8):485-7. doi: 10.1007/s00066-009-8001-2.","Sautter-Bihl ML","Strahlenther Onkol","2009","2009/08/05","","","10.1007/s00066-009-8001-2"
"11139301","By the way, doctor... I can't understand why there are reservations about the prostate-specific antigen (PSA) test. The ""score"" goes up when you have prostate cancer. So isn't getting a PSA test a good way of catching prostate cancer early? But my doctor seems reluctant to order it. What's the problem?","Lee TH.","Harv Health Lett. 2001 Jan;26(3):8.","Lee TH","Harv Health Lett","2001","2001/01/04","","",""
"28392429","[Management of a progressing prostate cancer: results of a national study]","Rozet F, Roupret M, Hennequin C, Massard C, Blanchard P, Le Moulec S.","Prog Urol. 2017 May;27(6):381-388. doi: 10.1016/j.purol.2017.02.001. Epub 2017 Apr 6.","Rozet F","Prog Urol","2017","2017/04/11","","","10.1016/j.purol.2017.02.001"
"15642124","Is DRE essential for the follow up of prostate cancer patients? A prospective audit of 194 patients","Ragavan N, Sangar VK, Gupta S, Herdman J, Matanhelia SS, Watson ME, Blades RA.","BMC Urol. 2005 Jan 10;5:1. doi: 10.1186/1471-2490-5-1.","Ragavan N","BMC Urol","2005","2005/01/12","PMC544886","","10.1186/1471-2490-5-1"
"30201551","Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review","Aoun F, Slaoui A, Walid AHO, Albisinni S, Assenmacher G, de Plaen E, Azzo JM, Peltier A, Roumeguère T.","Prog Urol. 2018 Oct;28(12):560-566. doi: 10.1016/j.purol.2018.07.004. Epub 2018 Sep 7.","Aoun F","Prog Urol","2018","2018/09/12","","","10.1016/j.purol.2018.07.004"
"10918763","Changes in radical prostatectomy and radiation therapy rates for African Americans and whites","Shaw M, Elterman L, Rubenstein M, McKiel CF, Guinan P.","J Natl Med Assoc. 2000 Jun;92(6):281-4.","Shaw M","J Natl Med Assoc","2000","2000/08/05","PMC2640525","",""
"26069250","Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach","Cerasuolo M, Paris D, Iannotti FA, Melck D, Verde R, Mazzarella E, Motta A, Ligresti A.","Cancer Res. 2015 Aug 1;75(15):2975-86. doi: 10.1158/0008-5472.CAN-14-3830. Epub 2015 Jun 11.","Cerasuolo M","Cancer Res","2015","2015/06/13","","","10.1158/0008-5472.CAN-14-3830"
"9894261","[Does PSA of less than 20 ng/ml exclude the diagnosis of metastatic prostate cancer?]","Amsellem D, Ogiez N, Salomon L, Chopin D, Abbou CC, Colombel M.","Prog Urol. 1998 Dec;8(6):1018-21.","Amsellem D","Prog Urol","1998","1999/01/23","","",""
"11444729","Analysis of three-dimensional Doppler ultrasonographic quantitative measures for the discrimination of prostate cancer","Moskalik AP, Rubin MA, Wojno KJ, Bree R, Rubin JM, Fowlkes JB, Montie JE, Manley S, Carson PL.","J Ultrasound Med. 2001 Jul;20(7):713-22. doi: 10.7863/jum.2001.20.7.713.","Moskalik AP","J Ultrasound Med","2001","2001/07/11","","","10.7863/jum.2001.20.7.713"
"21906460","[Metabolic disorder after androgen deprivation therapy in patients with prostate cancer]","Yuan JQ, Zhang XW, Xu T, Wang XF.","Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Aug;33(4):468-72. doi: 10.3881/j.issn.1000-503X.2011.04.024.","Yuan JQ","Zhongguo Yi Xue Ke Xue Yuan Xue Bao","2011","2011/09/13","","","10.3881/j.issn.1000-503X.2011.04.024"
"15679774","Focal therapy in prostate cancer: future trends","Barqawi A, Crawford ED.","BJU Int. 2005 Feb;95(3):273-4. doi: 10.1111/j.1464-410X.2005.05278.x.","Barqawi A","BJU Int","2005","2005/02/01","","","10.1111/j.1464-410X.2005.05278.x"
"28675891","The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","Fahmy O, Khairul-Asri MG, Hadi SHSM, Gakis G, Stenzl A.","Urol Int. 2017;99(3):249-256. doi: 10.1159/000478789. Epub 2017 Jul 4.","Fahmy O","Urol Int","2017","2017/07/05","","","10.1159/000478789"
"20640899","Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation","Katahira K, Takahara T, Kwee TC, Oda S, Suzuki Y, Morishita S, Kitani K, Hamada Y, Kitaoka M, Yamashita Y.","Eur Radiol. 2011 Jan;21(1):188-96. doi: 10.1007/s00330-010-1883-7. Epub 2010 Jul 18.","Katahira K","Eur Radiol","2011","2010/07/20","","","10.1007/s00330-010-1883-7"
"23878300","Re-examining racial disparities in prostate cancer outcomes","Cooperberg MR.","J Clin Oncol. 2013 Aug 20;31(24):2979-80. doi: 10.1200/JCO.2013.50.7723. Epub 2013 Jul 22.","Cooperberg MR","J Clin Oncol","2013","2013/07/24","","","10.1200/JCO.2013.50.7723"
"15279688","Ethnic variation in localized prostate cancer: a pilot study of preferences, optimism, and quality of life among black and white veterans","Knight SJ, Siston AK, Chmiel JS, Slimack N, Elstein AS, Chapman GB, Nadler RB, Bennett CL.","Clin Prostate Cancer. 2004 Jun;3(1):31-7. doi: 10.3816/cgc.2004.n.010.","Knight SJ","Clin Prostate Cancer","2004","2004/07/29","","","10.3816/cgc.2004.n.010"
"17628187","The roles of alpha-vitamin E and its analogues in prostate cancer","Ni J, Yeh S.","Vitam Horm. 2007;76:493-518. doi: 10.1016/S0083-6729(07)76019-3.","Ni J","Vitam Horm","2007","2007/07/14","","","10.1016/S0083-6729(07)76019-3"
"20635444","Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?","Lee HW, Seo SI, Jeon SS, Lee HM, Choi HY.","Yonsei Med J. 2010 Sep;51(5):700-7. doi: 10.3349/ymj.2010.51.5.700.","Lee HW","Yonsei Med J","2010","2010/07/17","PMC2908868","","10.3349/ymj.2010.51.5.700"
"22737953","[Prostate, cancer and lost patients]","Nau JY.","Rev Med Suisse. 2012 May 30;8(343):1186-7.","Nau JY","Rev Med Suisse","2012","2012/06/29","","",""
"16980238","[Keyrole of endocrinology in the victory against prostate cancer]","Labrie F.","Bull Cancer. 2006 Sep;93(9):949-58.","Labrie F","Bull Cancer","2006","2006/09/19","","",""
"14612600","Prostate cancer management: (1) an update on localised disease","Bott SR, Birtle AJ, Taylor CJ, Kirby RS.","Postgrad Med J. 2003 Oct;79(936):575-80. doi: 10.1136/pmj.79.936.575.","Bott SR","Postgrad Med J","2003","2003/11/13","PMC1742848","","10.1136/pmj.79.936.575"
"21720830","[Acting in concert: comments on the article by M. Schmedders et al on different therapy approaches for prostate cancer with low risks]","Stöckle M.","Urologe A. 2011 Aug;50(8):944-5. doi: 10.1007/s00120-011-2641-4.","Stöckle M","Urologe A","2011","2011/07/02","","","10.1007/s00120-011-2641-4"
"18304472","Metabolism of adrenal androgen and its impacts on prostate cancer after castration","Hu MQ, Na YQ.","Chin Med J (Engl). 2008 Feb 20;121(4):369-74.","Hu MQ","Chin Med J (Engl)","2008","2008/02/29","","",""
"32557725","Can ultrasound irradiation be a therapeutic option for prostate cancer?","Maeshige N, Kitagawa K, Yamasaki S, Ishii A, Shirakawa T, Yang YM, Sung SY, Chen KC, Yuan ZM, Shigemura K, Fujisawa M.","Prostate. 2020 Sep;80(12):986-992. doi: 10.1002/pros.24030. Epub 2020 Jun 18.","Maeshige N","Prostate","2020","2020/06/20","","","10.1002/pros.24030"
"31809622","mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer","Park HK, Lim SD, Kwon GY.","Scand J Urol. 2019 Dec;53(6):365-371. doi: 10.1080/21681805.2019.1697359. Epub 2019 Dec 6.","Park HK","Scand J Urol","2019","2019/12/07","","","10.1080/21681805.2019.1697359"
"27104784","Androgen Control in Prostate Cancer","Pelekanou V, Castanas E.","J Cell Biochem. 2016 Oct;117(10):2224-34. doi: 10.1002/jcb.25572. Epub 2016 May 11.","Pelekanou V","J Cell Biochem","2016","2016/04/23","","","10.1002/jcb.25572"
"17672951","[Individualization of transrectal ultrasonography-guided prostate biopsy for prostate cancer detection]","Liang H, Qiu SP, Zheng KL, Wu RP.","Ai Zheng. 2007 May;26(5):552-4.","Liang H","Ai Zheng","2007","2007/08/04","","",""
"10048971","Diet and cancer of the prostate: a case-control study in Greece","Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, Trichopoulou A.","Int J Cancer. 1999 Mar 1;80(5):704-8. doi: 10.1002/(sici)1097-0215(19990301)80:5<704::aid-ijc13>3.0.co;2-z.","Tzonou A","Int J Cancer","1999","1999/02/27","","","10.1002/(sici)1097-0215(19990301)80:5<704::aid-ijc13>3.0.co;2-z"
"1422690","Prostate cancer--the impact of irradiation on urinary outlet obstruction","Green N, Treible D, Wallack H, Frey HS.","Br J Urol. 1992 Sep;70(3):310-3. doi: 10.1111/j.1464-410x.1992.tb15737.x.","Green N","Br J Urol","1992","1992/09/01","","","10.1111/j.1464-410x.1992.tb15737.x"
"16076349","Vitamin D and the epidemiology of prostate cancer","Schwartz GG.","Semin Dial. 2005 Jul-Aug;18(4):276-89. doi: 10.1111/j.1525-139X.2005.18403.x.","Schwartz GG","Semin Dial","2005","2005/08/04","","","10.1111/j.1525-139X.2005.18403.x"
"17641982","Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men","Agalliu I, Weiss NS, Lin DW, Stanford JL.","Cancer Causes Control. 2007 Nov;18(9):931-7. doi: 10.1007/s10552-007-9031-7. Epub 2007 Jul 20.","Agalliu I","Cancer Causes Control","2007","2007/07/21","","","10.1007/s10552-007-9031-7"
"9865423","Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland","Dorgan JF, Albanes D, Virtamo J, Heinonen OP, Chandler DW, Galmarini M, McShane LM, Barrett MJ, Tangrea J, Taylor PR.","Cancer Epidemiol Biomarkers Prev. 1998 Dec;7(12):1069-74.","Dorgan JF","Cancer Epidemiol Biomarkers Prev","1998","1998/12/29","","",""
"25243131","Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review","Hoogland AM, Kweldam CF, van Leenders GJ.","Biomed Res Int. 2014;2014:341324. doi: 10.1155/2014/341324. Epub 2014 Aug 27.","Hoogland AM","Biomed Res Int","2014","2014/09/23","PMC4163394","","10.1155/2014/341324"
"10367371","The need for microdissectional tumor cell preparation during the molecular genetic analysis of prostate cancer","Kuczyk M, Serth J, Bokemeyer C, Machtens S, Schwede J, Herrmann R, Paeslack U, Truss MC, Knüchel R, Jonas U.","World J Urol. 1999 Apr;17(2):115-22. doi: 10.1007/s003450050116.","Kuczyk M","World J Urol","1999","1999/06/15","","","10.1007/s003450050116"
"11013784","Prostate cancer. What men want from their family physicians","Gray R.","Can Fam Physician. 2000 Sep;46:1713-5, 1722-4.","Gray R","Can Fam Physician","2000","2000/10/03","PMC2145043","",""
"2022104","The role of nuclear DNA ploidy in the prognosis and management of patients with prostate cancer","Lieber MM, Cheng WS.","Compr Ther. 1991 Feb;17(2):26-32.","Lieber MM","Compr Ther","1991","1991/02/01","","",""
"30165195","Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer","Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, Cherkasov A.","Cancer Lett. 2018 Nov 28;437:35-43. doi: 10.1016/j.canlet.2018.08.016. Epub 2018 Aug 27.","Dalal K","Cancer Lett","2018","2018/08/31","","","10.1016/j.canlet.2018.08.016"
"16964181","The case against extended lymph-node dissection for prostate cancer","Huland H.","Nat Clin Pract Urol. 2006 Sep;3(9):456-7. doi: 10.1038/ncpuro0561.","Huland H","Nat Clin Pract Urol","2006","2006/09/12","","","10.1038/ncpuro0561"
"11340290","Consideration of low PSA cut-off levels to optimize the detection of curable prostate cancer","Horninger W, Volgger H, Rogatsch H, Gschwendtner A, Bartsch G.","Eur Urol. 2001 Apr;39 Suppl 4:43-6. doi: 10.1159/000052586.","Horninger W","Eur Urol","2001","2001/05/08","","","10.1159/000052586"
"28314971","[When is surgical treatment indicated in metastatic prostate cancer and what is the scientific rationale?]","Kretschmer A, Herlemann A, Stief CG, Gratzke C.","Urologe A. 2017 May;56(5):599-603. doi: 10.1007/s00120-017-0361-0.","Kretschmer A","Urologe A","2017","2017/03/19","","","10.1007/s00120-017-0361-0"
"21825257","Active surveillance for prostate cancer: progress and promise","Cooperberg MR, Carroll PR, Klotz L.","J Clin Oncol. 2011 Sep 20;29(27):3669-76. doi: 10.1200/JCO.2011.34.9738. Epub 2011 Aug 8.","Cooperberg MR","J Clin Oncol","2011","2011/08/10","","","10.1200/JCO.2011.34.9738"
"28762288","The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory","Sathianathen NJ, Geurts N, Nair R, Lawrentschuk N, Murphy DG, Lamb AD.","Future Oncol. 2017 Aug;13(20):1801-1807. doi: 10.2217/fon-2017-0074. Epub 2017 Aug 1.","Sathianathen NJ","Future Oncol","2017","2017/08/02","","","10.2217/fon-2017-0074"
"22042252","Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer","Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K.","Prostate Cancer Prostatic Dis. 2012 Mar;15(1):100-5. doi: 10.1038/pcan.2011.52. Epub 2011 Nov 1.","Wu AK","Prostate Cancer Prostatic Dis","2012","2011/11/02","","","10.1038/pcan.2011.52"
"2006120","Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma","Ekman P, Brolin J.","Prostate. 1991;18(2):147-53. doi: 10.1002/pros.2990180207.","Ekman P","Prostate","1991","1991/01/01","","","10.1002/pros.2990180207"
"10849491","Prostate cancer in Honolulu, Hawaii: pathological and clinical characteristics","Namiki TS, Carlile R.","Int J Androl. 2000;23 Suppl 2:37-9. doi: 10.1046/j.1365-2605.2000.00011.x.","Namiki TS","Int J Androl","2000","2000/06/13","","","10.1046/j.1365-2605.2000.00011.x"
"18783873","Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial","Gattellari M, Ward JE.","Eur Urol. 2009 Feb;55(2):431. doi: 10.1016/j.eururo.2008.08.055. Epub 2008 Sep 2.","Gattellari M","Eur Urol","2009","2008/09/12","","","10.1016/j.eururo.2008.08.055"
"12642193","Reacting to the diagnosis of prostate cancer: patient learning in a community of practice","Roos IA.","Patient Educ Couns. 2003 Mar;49(3):219-24. doi: 10.1016/s0738-3991(02)00184-2.","Roos IA","Patient Educ Couns","2003","2003/03/19","","","10.1016/s0738-3991(02)00184-2"
"29542178","National trends in management of localized prostate cancer: A population based analysis 2004-2013","Chen J, Oromendia C, Halpern JA, Ballman KV.","Prostate. 2018 May;78(7):512-520. doi: 10.1002/pros.23496. Epub 2018 Mar 14.","Chen J","Prostate","2018","2018/03/16","","","10.1002/pros.23496"
"20066456","Malignant pericardial tamponade in a patient with hormone-refractory prostate cancer","Minagawa T, Murata Y, Uchikawa S, Uehara T.","Int J Clin Oncol. 2010 Feb;15(1):101-3. doi: 10.1007/s10147-009-0002-8.","Minagawa T","Int J Clin Oncol","2010","2010/01/13","","","10.1007/s10147-009-0002-8"
"25727153","Altered glycosylation in prostate cancer","Drake RR, Jones EE, Powers TW, Nyalwidhe JO.","Adv Cancer Res. 2015;126:345-82. doi: 10.1016/bs.acr.2014.12.001. Epub 2015 Feb 7.","Drake RR","Adv Cancer Res","2015","2015/03/03","","","10.1016/bs.acr.2014.12.001"
"16256292","Exploring beliefs about prostate cancer and early detection in men and women of three ethnic groups","McFall SL, Hamm RM, Volk RJ.","Patient Educ Couns. 2006 Apr;61(1):109-16. doi: 10.1016/j.pec.2005.02.016. Epub 2005 Oct 26.","McFall SL","Patient Educ Couns","2006","2005/11/01","","","10.1016/j.pec.2005.02.016"
"14733837","Molecular profiling of prostate cancer","Huppi K, Chandramouli GV.","Curr Urol Rep. 2004 Feb;5(1):45-51. doi: 10.1007/s11934-004-0011-0.","Huppi K","Curr Urol Rep","2004","2004/01/22","","","10.1007/s11934-004-0011-0"
"31099652","Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?","Rao A, Vapiwala N, Schaeffer EM, Ryan CJ.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:309-320. doi: 10.1200/EDBK_239041. Epub 2019 May 17.","Rao A","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_239041"
"29079965","ISUP Group 4 - a Homogenous Group of Prostate Cancers?","Lu TC, Moretti K, Beckmann K, Cohen P, O'Callaghan M.","Pathol Oncol Res. 2018 Oct;24(4):921-925. doi: 10.1007/s12253-017-0331-2. Epub 2017 Oct 27.","Lu TC","Pathol Oncol Res","2018","2017/10/29","","","10.1007/s12253-017-0331-2"
"31674233","The many challenges of living with prostate cancer","Nyatanga B.","Br J Community Nurs. 2019 Nov 2;24(11):558. doi: 10.12968/bjcn.2019.24.11.558.","Nyatanga B","Br J Community Nurs","2019","2019/11/02","","","10.12968/bjcn.2019.24.11.558"
"26676901","Chemotherapy in Prostate Cancer Beyond Metastatic CRPC","Park JC, Eisenberger M.","Oncology (Williston Park). 2015 Dec;29(12):964-5.","Park JC","Oncology (Williston Park)","2015","2015/12/18","","",""
"23050533","Radical prostatectomy versus observation for prostate cancer","Tyldesley S, McKenzie MR, So AI.","N Engl J Med. 2012 Oct 11;367(15):1468; author reply 1468-9. doi: 10.1056/NEJMc1209800.","Tyldesley S","N Engl J Med","2012","2012/10/12","","","10.1056/NEJMc1209800"
"22808963","Prostate cancer--uncertainty and a way forward","Thompson IM Jr, Tangen CM.","N Engl J Med. 2012 Jul 19;367(3):270-1. doi: 10.1056/NEJMe1205012.","Thompson IM Jr","N Engl J Med","2012","2012/07/20","","","10.1056/NEJMe1205012"
"21056273","Editorial comment. Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic","Dalkin BL.","Urology. 2010 Nov;76(5):1238; author reply 1238-9. doi: 10.1016/j.urology.2010.03.088.","Dalkin BL","Urology","2010","2010/11/09","","","10.1016/j.urology.2010.03.088"
"15271316","The role of lymphadenectomy in prostate cancer","Burkhard FC, Studer UE.","Urol Oncol. 2004 May-Jun;22(3):198-202; discussion 202-4. doi: 10.1016/j.urolonc.2004.04.032.","Burkhard FC","Urol Oncol","2004","2004/07/24","","","10.1016/j.urolonc.2004.04.032"
"7591913","Some concerns about prostate cancer location, Gleason grade, and postradiation doubling times","Stamey TA.","Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):967-8; discussion 972. doi: 10.1016/0360-3016(95)02145-6.","Stamey TA","Int J Radiat Oncol Biol Phys","1995","1995/11/01","","","10.1016/0360-3016(95)02145-6"
"24588670","An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy","Bristow RG, Berlin A, Dal Pra A.","Br J Radiol. 2014 Mar;87(1035):20130753. doi: 10.1259/bjr.20130753. Epub 2014 Feb 3.","Bristow RG","Br J Radiol","2014","2014/03/05","PMC4064607","","10.1259/bjr.20130753"
"19195129","Prostate cancer: the new landscape","Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ.","Curr Opin Urol. 2009 Mar;19(2):154-60. doi: 10.1097/mou.0b013e328323f5d6.","Moul JW","Curr Opin Urol","2009","2009/02/07","","","10.1097/mou.0b013e328323f5d6"
"10087392","Diagnostic value of ten systematic TRUS-guided prostate biopsies","Ravery V, Billebaud T, Toublanc M, Boccon-Gibod L, Hermieu JF, Moulinier F, Blanc E, Delmas V, Boccon-Gibod L.","Eur Urol. 1999 Apr;35(4):298-303. doi: 10.1159/000019866.","Ravery V","Eur Urol","1999","1999/03/24","","","10.1159/000019866"
"31265213","Targeted Gold Nanocluster-Enhanced Radiotherapy of Prostate Cancer","Luo D, Wang X, Zeng S, Ramamurthy G, Burda C, Basilion JP.","Small. 2019 Aug;15(34):e1900968. doi: 10.1002/smll.201900968. Epub 2019 Jul 2.","Luo D","Small","2019","2019/07/03","PMC6707872","NIHMS1040175","10.1002/smll.201900968"
"16145036","Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor","Thompson IM, Canby-Hagino E, Lucia MS.","J Natl Cancer Inst. 2005 Sep 7;97(17):1236-7. doi: 10.1093/jnci/dji286.","Thompson IM","J Natl Cancer Inst","2005","2005/09/08","","","10.1093/jnci/dji286"
"26384806","Should Men Diagnosed With Prostate Cancer Hit the Gym?","Feng TS, Vidal AC, Freedland SJ.","Oncology (Williston Park). 2015 Sep;29(9):689-90, 694.","Feng TS","Oncology (Williston Park)","2015","2015/09/20","","",""
"23608675","Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study","Morgan RM, Steele RJ, Nabi G, McCowan C.","J Urol. 2013 Oct;190(4):1207-12. doi: 10.1016/j.juro.2013.04.044. Epub 2013 Apr 19.","Morgan RM","J Urol","2013","2013/04/24","","","10.1016/j.juro.2013.04.044"
"1593688","Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer","Petros JA, Catalona WJ.","J Urol. 1992 Jun;147(6):1574-5. doi: 10.1016/s0022-5347(17)37630-9.","Petros JA","J Urol","1992","1992/06/01","","","10.1016/s0022-5347(17)37630-9"
"9451865","[Radiotherapy of localized prostatic carcinoma]","Gez E, Netzer-Horowitz Y, Waiman E, Rubinov R, Cohen Y, Kuten A.","Harefuah. 1997 Dec 15;133(12):593-6, 664.","Gez E","Harefuah","1997","1998/02/06","","",""
"19864076","Why does diabetes offer protective effects against prostate cancer? The possible role of its microvascular complications","Zhang W, Hu R.","Med Hypotheses. 2010 Feb;74(2):242-3. doi: 10.1016/j.mehy.2009.09.042. Epub 2009 Oct 27.","Zhang W","Med Hypotheses","2010","2009/10/30","","","10.1016/j.mehy.2009.09.042"
"8597766","Measurement of prostate specific antigen as screening test for prostate cancer. Trials of treatment are needed before trials of screening","Sandhu S, Morris R, Matveev V, Kaisary AV.","BMJ. 1996 Mar 16;312(7032):709; author reply 709-10. doi: 10.1136/bmj.312.7032.709a.","Sandhu S","BMJ","1996","1996/03/16","PMC2350510","","10.1136/bmj.312.7032.709a"
"7571223","Detection of latent prostate cancer from routine screening: comparison with breast cancer screening","Benoit RM, Naslund MJ.","Urology. 1995 Oct;46(4):533-6; discussion 536-7. doi: 10.1016/s0090-4295(99)80267-2.","Benoit RM","Urology","1995","1995/10/01","","","10.1016/s0090-4295(99)80267-2"
"11785860","Interviewing men on sensitive issues","Yong VT.","Contemp Nurse. 2001 Sep;11(1):18-27. doi: 10.5172/conu.11.1.18.","Yong VT","Contemp Nurse","2001","2002/01/12","","","10.5172/conu.11.1.18"
"11951790","Prostate cancer in Arkansas","Nash C, Hall C.","J Ark Med Soc. 2002 Apr;98(10):331-8.","Nash C","J Ark Med Soc","2002","2002/04/16","","",""
"28366421","(18)F-Choline PET/CT scan in staging and biochemical recurrence in prostate cancer patients: Changes in classification and radiotherapy planning","Cardona Arboniés J, Rodríguez Alfonso B, Mucientes Rasilla J, Martínez Ballesteros C, Zapata Paz I, Prieto Soriano A, Carballido Rodriguez J, Mitjavila Casanovas M.","Rev Esp Med Nucl Imagen Mol. 2017 Sep-Oct;36(5):292-297. doi: 10.1016/j.remn.2017.02.007. Epub 2017 Mar 31.","Cardona Arboniés J","Rev Esp Med Nucl Imagen Mol","2017","2017/04/04","","","10.1016/j.remn.2017.02.007"
"10361560","Supportive care, pain management, and quality of life in advanced prostate cancer","Esper P, Redman BG.","Urol Clin North Am. 1999 May;26(2):375-89. doi: 10.1016/s0094-0143(05)70077-x.","Esper P","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70077-x"
"19342957","Patient selection for focal therapy of localized prostate cancer","Jayram G, Eggener SE.","Curr Opin Urol. 2009 May;19(3):268-73. doi: 10.1097/MOU.0b013e328329eb3c.","Jayram G","Curr Opin Urol","2009","2009/04/04","","","10.1097/MOU.0b013e328329eb3c"
"16886649","Role of surgery in treatment of locally advanced prostate cancer","Prezioso D, Galasso R, Di Martino M, Iapicca G, Iacono F.","Anticancer Res. 2006 Jul-Aug;26(4B):3151-8.","Prezioso D","Anticancer Res","2006","2006/08/05","","",""
"28216328","Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use","Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A.","J Urol. 2017 Aug;198(2):305-309. doi: 10.1016/j.juro.2017.02.069. Epub 2017 Feb 16.","Murtola TJ","J Urol","2017","2017/02/21","","","10.1016/j.juro.2017.02.069"
"9331068","Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2","Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T.","Cancer Res. 1997 Oct 1;57(19):4167-70.","Kawakami M","Cancer Res","1997","1997/10/23","","",""
"16552242","Prostate cancer update: 2005","Ryan CJ, Small EJ.","Curr Opin Oncol. 2006 May;18(3):284-8. doi: 10.1097/01.cco.0000219259.83585.f3.","Ryan CJ","Curr Opin Oncol","2006","2006/03/23","","","10.1097/01.cco.0000219259.83585.f3"
"24796290","Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review","Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houédé N, Merino C, Roubaud G, Dallaudiére B, Richaud P, Fléchon A.","Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6. doi: 10.1038/pcan.2014.17. Epub 2014 May 6.","Sargos P","Prostate Cancer Prostatic Dis","2014","2014/05/07","","","10.1038/pcan.2014.17"
"15989093","[Subcapsular orchiectomy in the treatment of prostate cancer: results]","Pascual Mateo C, Luján Galán M, Santos Arrontes D, Berenguer Sánchez A.","Arch Esp Urol. 2005 May;58(4):305-8. doi: 10.4321/s0004-06142005000400004.","Pascual Mateo C","Arch Esp Urol","2005","2005/07/02","","","10.4321/s0004-06142005000400004"
"29658595","Huaier suppresses proliferative and metastatic potential of prostate cancer PC3 cells via downregulation of Lamin B1 and induction of autophagy","Yang A, Zhao Y, Wang Y, Zha X, Zhao Y, Tu P, Hu Z.","Oncol Rep. 2018 Jun;39(6):3055-3063. doi: 10.3892/or.2018.6358. Epub 2018 Apr 5.","Yang A","Oncol Rep","2018","2018/04/17","","","10.3892/or.2018.6358"
"9474189","Second primary malignancies in T1-3N0 prostate cancer patients treated with radiation therapy with 10-year followup","Johnstone PA, Powell CR, Riffenburgh R, Rohde DC, Kane CJ.","J Urol. 1998 Mar;159(3):946-9.","Johnstone PA","J Urol","1998","1998/02/25","","",""
"9519179","Localised carcinoma of the prostate: a paradigm of uncertainty","Sandhu SS, Kaisary AV.","Postgrad Med J. 1997 Nov;73(865):691-6. doi: 10.1136/pgmj.73.865.691.","Sandhu SS","Postgrad Med J","1997","1998/03/31","PMC2431575","","10.1136/pgmj.73.865.691"
"22318181","[Rescue cryotherapy for prostate cancer after radiotherapy]","García EL, Amo FH, San Segundo CG, Fagundo EP, Escudero RM, Alonso AH, Piniés GO, Rascón JJ, Fernández CH.","Arch Esp Urol. 2012 Jan-Feb;65(1):93-100.","García EL","Arch Esp Urol","2012","2012/02/10","","",""
"31468212","Quality of Life-Focused Decision-Making for Prostate Cancer","Shevach J, Weiner A, Morgans AK.","Curr Urol Rep. 2019 Aug 29;20(10):57. doi: 10.1007/s11934-019-0924-2.","Shevach J","Curr Urol Rep","2019","2019/08/31","","","10.1007/s11934-019-0924-2"
"19428062","XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis","Geng J, Zhang Q, Zhu C, Wang J, Chen L.","Urology. 2009 Sep;74(3):648-53. doi: 10.1016/j.urology.2009.02.046. Epub 2009 May 9.","Geng J","Urology","2009","2009/05/12","","","10.1016/j.urology.2009.02.046"
"21518227","The success of focal therapy hinges on the success of imaging platforms","Sooriakumaran P, Grover S, Tewari A.","BJU Int. 2011 May;107(9):1344-6. doi: 10.1111/j.1464-410X.2011.10226.x.","Sooriakumaran P","BJU Int","2011","2011/04/27","","","10.1111/j.1464-410X.2011.10226.x"
"23913676","Quality of prostate cancer care among rural men in the Veterans Health Administration","Skolarus TA, Chan S, Shelton JB, Antonio AL, Sales AE, Malin JL, Saigal CS.","Cancer. 2013 Oct 15;119(20):3629-35. doi: 10.1002/cncr.28275. Epub 2013 Jul 30.","Skolarus TA","Cancer","2013","2013/08/06","","","10.1002/cncr.28275"
"7966437","Cadmium and prostate cancer","Waalkes MP, Rehm S.","J Toxicol Environ Health. 1994 Nov;43(3):251-69. doi: 10.1080/15287399409531920.","Waalkes MP","J Toxicol Environ Health","1994","1994/11/01","","","10.1080/15287399409531920"
"23813660","Integrative analysis of prostate cancer aggressiveness","Feik E, Schweifer N, Baierl A, Sommergruber W, Haslinger C, Hofer P, Maj-Hes A, Madersbacher S, Gsur A.","Prostate. 2013 Sep;73(13):1413-26. doi: 10.1002/pros.22688. Epub 2013 Jun 27.","Feik E","Prostate","2013","2013/07/02","","","10.1002/pros.22688"
"28417980","Is active surveillance a suitable option for African American men with prostate cancer? A systemic literature review","Gökce MI, Sundi D, Schaeffer E, Pettaway C.","Prostate Cancer Prostatic Dis. 2017 Jun;20(2):127-136. doi: 10.1038/pcan.2016.56. Epub 2017 Apr 18.","Gökce MI","Prostate Cancer Prostatic Dis","2017","2017/04/19","","","10.1038/pcan.2016.56"
"18497046","Castration-recurrent prostate cancer is not androgen-independent","Mohler JL.","Adv Exp Med Biol. 2008;617:223-34. doi: 10.1007/978-0-387-69080-3_21.","Mohler JL","Adv Exp Med Biol","2008","2008/05/24","","","10.1007/978-0-387-69080-3_21"
"9349916","Blood pressure and heart rate: no evidence for a positive association with prostate cancer","Friedman GD.","Ann Epidemiol. 1997 Oct;7(7):486-9. doi: 10.1016/s1047-2797(97)00083-5.","Friedman GD","Ann Epidemiol","1997","1997/11/14","","","10.1016/s1047-2797(97)00083-5"
"17969415","[Preliminary results of radical surgery and radiotherapy of locally advanced prostate cancer (basal PSA >50 ng/ml)]","Kaprin AD, Khmelevskiĭ EV, Fadeev AV.","Vopr Onkol. 2007;53(4):479-81.","Kaprin AD","Vopr Onkol","2007","2007/11/01","","",""
"29625757","Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?","Giannarini G, Fossati N, Gandaglia G, Cucchiara V, Ficarra V, Mirone V, Montorsi F, Briganti A.","Eur Urol. 2018 Aug;74(2):131-133. doi: 10.1016/j.eururo.2018.03.021. Epub 2018 Apr 4.","Giannarini G","Eur Urol","2018","2018/04/08","","","10.1016/j.eururo.2018.03.021"
"10510932","Limitations of transperineal ultrasound-guided prostate biopsies","Shinghal R, Terris MK.","Urology. 1999 Oct;54(4):706-8. doi: 10.1016/s0090-4295(99)00193-4.","Shinghal R","Urology","1999","1999/10/08","","","10.1016/s0090-4295(99)00193-4"
"8961978","Re: Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors","Burke HB.","J Natl Cancer Inst. 1996 Dec 18;88(24):1864. doi: 10.1093/jnci/88.24.1864.","Burke HB","J Natl Cancer Inst","1996","1996/12/18","","","10.1093/jnci/88.24.1864"
"29250550","Prostate Cancer: From Genomics to the Whole Body and Beyond","Grizzi F, Taverna G, Cote RJ, Guazzoni G.","Biomed Res Int. 2017;2017:8707690. doi: 10.1155/2017/8707690. Epub 2017 Nov 9.","Grizzi F","Biomed Res Int","2017","2017/12/19","PMC5700474","","10.1155/2017/8707690"
"8795650","Follow-up after therapy for prostate cancer. Treating the problems and caring for the man","Freedman A, Hahn G, Love N.","Postgrad Med. 1996 Sep;100(3):125-9, 133-4, 136. doi: 10.3810/pgm.1996.09.73.","Freedman A","Postgrad Med","1996","1996/09/01","","","10.3810/pgm.1996.09.73"
"12946745","Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients","Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, Pummer K, Hubmer G.","Urology. 2003 Sep;62(3):451-5. doi: 10.1016/s0090-4295(03)00459-x.","Zigeuner RE","Urology","2003","2003/08/30","","","10.1016/s0090-4295(03)00459-x"
"12865455","Re: Insulin resistance and prostate cancer risk","Stattin P, Kaaks R.","J Natl Cancer Inst. 2003 Jul 16;95(14):1086-7; author reply 1087. doi: 10.1093/jnci/95.14.1086.","Stattin P","J Natl Cancer Inst","2003","2003/07/17","","","10.1093/jnci/95.14.1086"
"23979665","Prostate cancer: PSA enzymatic activity to assess disease aggressiveness","Fenner A.","Nat Rev Urol. 2013 Oct;10(10):557. doi: 10.1038/nrurol.2013.187. Epub 2013 Aug 27.","Fenner A","Nat Rev Urol","2013","2013/08/28","","","10.1038/nrurol.2013.187"
"9743697","A comparative study of a double-line versus a fan-shaped technique for obtaining transrectal ultrasound-guided biopsies of the prostate","Brössner C, Madersbacher S, Klingler HC, Pycha A, Kuber W, Marberger M.","Eur Urol. 1998;33(6):556-61. doi: 10.1159/000019655.","Brössner C","Eur Urol","1998","1998/09/23","","","10.1159/000019655"
"8448822","Rodent models for targeted oncogenesis of the prostate gland","Buttyan R, Slawin K.","Cancer Metastasis Rev. 1993 Mar;12(1):11-9. doi: 10.1007/BF00689786.","Buttyan R","Cancer Metastasis Rev","1993","1993/03/01","","","10.1007/BF00689786"
"15883238","A prospective study of physical activity and incident and fatal prostate cancer","Giovannucci EL, Liu Y, Leitzmann MF, Stampfer MJ, Willett WC.","Arch Intern Med. 2005 May 9;165(9):1005-10. doi: 10.1001/archinte.165.9.1005.","Giovannucci EL","Arch Intern Med","2005","2005/05/11","","","10.1001/archinte.165.9.1005"
"31430244","Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml","Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E, Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, Suzuki K; Members of PROPHET.","J Urol. 2020 Jan;203(1):83-91. doi: 10.1097/JU.0000000000000495. Epub 2019 Aug 20.","Ito K","J Urol","2020","2019/08/21","","","10.1097/JU.0000000000000495"
"26053031","Identification of Pathogen Signatures in Prostate Cancer Using RNA-seq","Chen Y, Wei J.","PLoS One. 2015 Jun 8;10(6):e0128955. doi: 10.1371/journal.pone.0128955. eCollection 2015.","Chen Y","PLoS One","2015","2015/06/09","PMC4460021","","10.1371/journal.pone.0128955"
"30607114","The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy","Matthew A, Lutzky-Cohen N, Jamnicky L, Currie K, Gentile A, Mina DS, Fleshner N, Finelli A, Hamilton R, Kulkarni G, Jewett M, Zlotta A, Trachtenberg J, Yang Z, Elterman D.","Curr Oncol. 2018 Dec;25(6):393-402. doi: 10.3747/co.25.4111. Epub 2018 Dec 1.","Matthew A","Curr Oncol","2018","2019/01/05","PMC6291273","","10.3747/co.25.4111"
"12441977","Re: Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993","Schellhammer PF.","J Urol. 2002 Dec;168(6):2555-6.","Schellhammer PF","J Urol","2002","2002/11/21","","",""
"11022678","[Epidemiological trends of prostate cancer in Japan]","Nakata S, Ohtake N, Yamanaka H.","Nihon Rinsho. 2000 Jul;58 Suppl:5-11.","Nakata S","Nihon Rinsho","2000","2000/10/07","","",""
"28561752","Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy","Liu VWS, Yau WL, Tam CW, Yao KM, Shiu SYW.","Int J Mol Sci. 2017 May 31;18(6):1130. doi: 10.3390/ijms18061130.","Liu VWS","Int J Mol Sci","2017","2017/06/01","PMC5485954","","10.3390/ijms18061130"
"21592649","New therapies for castration-resistant prostate cancer: efficacy and safety","Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.","Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4.","Beltran H","Eur Urol","2011","2011/05/20","","","10.1016/j.eururo.2011.04.038"
"16685076","Cancer as part of the journey: the role of spirituality in the decision to decline conventional prostate cancer treatment and to use complementary and alternative medicine","White M, Verhoef M.","Integr Cancer Ther. 2006 Jun;5(2):117-22. doi: 10.1177/1534735406288084.","White M","Integr Cancer Ther","2006","2006/05/11","","","10.1177/1534735406288084"
"22893105","Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials","Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, Thompson I, Parnes H.","Cancer. 2013 Feb 1;119(3):593-601. doi: 10.1002/cncr.27774. Epub 2012 Aug 14.","Pinsky PF","Cancer","2013","2012/08/16","PMC3502695","NIHMS395172","10.1002/cncr.27774"
"19935788","Clinical presentation and initial management of black men and white men with prostate cancer in the United Kingdom: the PROCESS cohort study","Evans S, Metcalfe C, Patel B, Ibrahim F, Anson K, Chinegwundoh F, Corbishley C, Gillatt D, Kirby R, Muir G, Nargund V, Popert R, Wilson P, Persad R, Ben-Shlomo Y.","Br J Cancer. 2010 Jan 19;102(2):249-54. doi: 10.1038/sj.bjc.6605461. Epub 2009 Nov 24.","Evans S","Br J Cancer","2010","2009/11/26","PMC2816646","","10.1038/sj.bjc.6605461"
"9268974","Will current clinical trials answer the most important questions about prostate adenocarcinoma?","Thompson IM, Seay TM.","Oncology (Williston Park). 1997 Aug;11(8):1109-17; discussion 1117-8, 1121.","Thompson IM","Oncology (Williston Park)","1997","1997/08/01","","",""
"7528519","""Screening for prostate cancer""","Gohagan JK, Kramer BS, Greenwald P.","Am J Prev Med. 1994 Jul-Aug;10(4):245-6.","Gohagan JK","Am J Prev Med","1994","1994/07/01","","",""
"27779230","The current evidence on statin use and prostate cancer prevention: are we there yet?","Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ.","Nat Rev Urol. 2017 Feb;14(2):107-119. doi: 10.1038/nrurol.2016.199. Epub 2016 Oct 25.","Alfaqih MA","Nat Rev Urol","2017","2016/11/03","PMC5830185","NIHMS943122","10.1038/nrurol.2016.199"
"16328356","Current practice of Gleason grading of prostate carcinoma","Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R.","Virchows Arch. 2006 Feb;448(2):111-8. doi: 10.1007/s00428-005-0102-4. Epub 2005 Nov 23.","Lopez-Beltran A","Virchows Arch","2006","2005/12/06","","","10.1007/s00428-005-0102-4"
"20152513","Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface","Oh WK, Hu JC.","Urol Clin North Am. 2010 Feb;37(1):xiii. doi: 10.1016/j.ucl.2009.12.001.","Oh WK","Urol Clin North Am","2010","2010/02/16","","","10.1016/j.ucl.2009.12.001"
"16257109","Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer","Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M.","Eur Urol. 2005 Dec;48(6):900-5. doi: 10.1016/j.eururo.2005.09.005. Epub 2005 Oct 11.","Abrahamsson PA","Eur Urol","2005","2005/11/01","","","10.1016/j.eururo.2005.09.005"
"28410213","BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer","Cui M, Gao XS, Gu X, Guo W, Li X, Ma M, Qin S, Qi X, Xie M, Peng C, Bai Y.","Oncotarget. 2017 Jun 20;8(25):40222-40232. doi: 10.18632/oncotarget.16712.","Cui M","Oncotarget","2017","2017/04/15","PMC5522317","","10.18632/oncotarget.16712"
"15638707","Gene therapy strategies in prostate cancer","Eder IE, Haag P, Bartsch G, Klocker H.","Curr Gene Ther. 2005 Feb;5(1):1-10. doi: 10.2174/1566523052997424.","Eder IE","Curr Gene Ther","2005","2005/01/11","","","10.2174/1566523052997424"
"22595047","Sipuleucel-T for the treatment of advanced prostate cancer","Frohlich MW.","Semin Oncol. 2012 Jun;39(3):245-52. doi: 10.1053/j.seminoncol.2012.02.004.","Frohlich MW","Semin Oncol","2012","2012/05/19","","","10.1053/j.seminoncol.2012.02.004"
"16197611","Quantitative computed tomography perfusion of prostate cancer: correlation with whole-mount pathology","Ives EP, Burke MA, Edmonds PR, Gomella LG, Halpern EJ.","Clin Prostate Cancer. 2005 Sep;4(2):109-12. doi: 10.3816/cgc.2005.n.018.","Ives EP","Clin Prostate Cancer","2005","2005/10/04","","","10.3816/cgc.2005.n.018"
"7093902","Prostate cancer with an unusual presentation: polymyositis and mediastinal adenopathy","Kopelson G.","Cancer. 1982 Aug 1;50(3):606.","Kopelson G","Cancer","1982","1982/08/01","","",""
"17166237","Bone and prostate cancer cell interactions in metastatic prostate cancer","Vela I, Gregory L, Gardiner EM, Clements JA, Nicol DL.","BJU Int. 2007 Apr;99(4):735-42. doi: 10.1111/j.1464-410X.2006.06670.x. Epub 2006 Dec 13.","Vela I","BJU Int","2007","2006/12/15","","","10.1111/j.1464-410X.2006.06670.x"
"7528558","Prostate cancer trends in southeast Michigan 1973-1992","Demers RY.","In Vivo. 1994 May-Jun;8(3):429-31.","Demers RY","In Vivo","1994","1994/05/01","","",""
"9915440","Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study","Brasso K, Friis S, Juel K, Jørgensen T, Iversen P.","J Urol. 1999 Feb;161(2):524-8.","Brasso K","J Urol","1999","1999/01/23","","",""
"25046691","Coexisting prostate cancer found at the time of holmium laser enucleation of the prostate for benign prostatic hyperplasia: predicting its presence and grade in analyzed tissue","Bhojani N, Boris RS, Monn MF, Mandeville JA, Lingeman JE.","J Endourol. 2015 Jan;29(1):41-6. doi: 10.1089/end.2014.0359.","Bhojani N","J Endourol","2015","2014/07/22","","","10.1089/end.2014.0359"
"1570957","Factors influencing early detection of prostate cancer","Millon-Underwood S.","Appl Nurs Res. 1992 Feb;5(1):30-1. doi: 10.1016/s0897-1897(05)80082-5.","Millon-Underwood S","Appl Nurs Res","1992","1992/02/01","","","10.1016/s0897-1897(05)80082-5"
"1574460","Preliminary results of three-dimensional reconstruction of previously imaged prostates","Sesterhenn IA, Mostofi FK, Mattrey RR, Sands JP, Davis CJ Jr, McCarthy WF.","Prostate Suppl. 1992;4:33-41. doi: 10.1002/pros.2990210506.","Sesterhenn IA","Prostate Suppl","1992","1992/01/11","","","10.1002/pros.2990210506"
"23316854","Cancer-related masculine threat, emotional approach coping, and physical functioning following treatment for prostate cancer","Hoyt MA, Stanton AL, Irwin MR, Thomas KS.","Health Psychol. 2013 Jan;32(1):66-74. doi: 10.1037/a0030020.","Hoyt MA","Health Psychol","2013","2013/01/16","","","10.1037/a0030020"
"17492409","[The hormone refractory prostate cancer - a challenge for the internal specialist]","Kudlacek S, Meran JG, Beke D.","Wien Med Wochenschr. 2007;157(7-8):145-8. doi: 10.1007/s10354-007-0397-7.","Kudlacek S","Wien Med Wochenschr","2007","2007/05/12","","","10.1007/s10354-007-0397-7"
"17631347","Pathological features after radical prostatectomy in potential candidates for active monitoring","Griffin CR, Yu X, Loeb S, Desireddi VN, Han M, Graif T, Catalona WJ.","J Urol. 2007 Sep;178(3 Pt 1):860-3; discussion 863. doi: 10.1016/j.juro.2007.05.016. Epub 2007 Jul 16.","Griffin CR","J Urol","2007","2007/07/17","","","10.1016/j.juro.2007.05.016"
"28187509","Dairy intake in relation to prostate cancer survival","Downer MK, Batista JL, Mucci LA, Stampfer MJ, Epstein MM, Håkansson N, Wolk A, Johansson JE, Andrén O, Fall K, Andersson SO.","Int J Cancer. 2017 May 1;140(9):2060-2069. doi: 10.1002/ijc.30642. Epub 2017 Feb 22.","Downer MK","Int J Cancer","2017","2017/02/11","","","10.1002/ijc.30642"
"25228112","TGF-β1 mediates the radiation response of prostate cancer","Wu CT, Hsieh CC, Yen TC, Chen WC, Chen MF.","J Mol Med (Berl). 2015 Jan;93(1):73-82. doi: 10.1007/s00109-014-1206-6. Epub 2014 Sep 18.","Wu CT","J Mol Med (Berl)","2015","2014/09/18","","","10.1007/s00109-014-1206-6"
"20960523","Screening, risk assessment, and the approach to therapy in patients with prostate cancer","Freedland SJ.","Cancer. 2011 Mar 15;117(6):1123-35. doi: 10.1002/cncr.25477. Epub 2010 Oct 19.","Freedland SJ","Cancer","2011","2010/10/21","","","10.1002/cncr.25477"
"25667109","Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U.","Prostate Cancer Prostatic Dis. 2015 Jun;18(2):110-21. doi: 10.1038/pcan.2014.52. Epub 2015 Feb 10.","Raval AD","Prostate Cancer Prostatic Dis","2015","2015/02/11","PMC4904224","NIHMS792191","10.1038/pcan.2014.52"
"16885915","Novel agents and targets in managing patients with metastatic prostate cancer","Tan WW.","Cancer Control. 2006 Jul;13(3):194-8. doi: 10.1177/107327480601300306.","Tan WW","Cancer Control","2006","2006/08/04","","","10.1177/107327480601300306"
"7902778","3rd International Workshop on Randomized Trials on Maximal Androgen Blockade in M1 Prostate Cancer Patients. Proceedings. Paris, France, June 19, 1992","","Cancer. 1993 Dec 15;72(12 Suppl):3781-895.","","Cancer","1993","1993/12/15","","",""
"23565753","Androgen receptor: past, present and future","Schmidt LJ, Tindall DJ.","Curr Drug Targets. 2013 Apr;14(4):401-7. doi: 10.2174/1389450111314040002.","Schmidt LJ","Curr Drug Targets","2013","2013/04/10","","","10.2174/1389450111314040002"
"27212125","Prostate cancer epigenetics and its clinical implications","Yegnasubramanian S.","Asian J Androl. 2016 Jul-Aug;18(4):549-58. doi: 10.4103/1008-682X.179859.","Yegnasubramanian S","Asian J Androl","2016","2016/05/24","PMC4955178","","10.4103/1008-682X.179859"
"19586654","Urinary prostate cancer 3 test: toward the age of reason?","Vlaeminck-Guillem V, Ruffion A, André J, Devonec M, Paparel P.","Urology. 2010 Feb;75(2):447-53. doi: 10.1016/j.urology.2009.03.046. Epub 2009 Jul 8.","Vlaeminck-Guillem V","Urology","2010","2009/07/10","","","10.1016/j.urology.2009.03.046"
"26519961","[Prostate cancer imaging: MRI and nuclear imaging]","Renard Penna R, Brenot-Rossi I, Salomon L, Soulié M.","Prog Urol. 2015 Nov;25(15):933-46. doi: 10.1016/j.purol.2015.07.016.","Renard Penna R","Prog Urol","2015","2015/11/02","","","10.1016/j.purol.2015.07.016"
"21356660","Barriers and facilitators of prostate cancer screening among Filipino men in Hawaii","Conde FA, Landier W, Ishida D, Bell R, Cuaresma CF, Misola J.","Oncol Nurs Forum. 2011 Mar;38(2):227-33. doi: 10.1188/11.ONF.227-233.","Conde FA","Oncol Nurs Forum","2011","2011/03/02","PMC3662804","NIHMS457529","10.1188/11.ONF.227-233"
"9744310","Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer","Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, Mihatsch MJ, Sauter G.","Hum Pathol. 1998 Sep;29(9):949-54. doi: 10.1016/s0046-8177(98)90199-x.","Bubendorf L","Hum Pathol","1998","1998/09/23","","","10.1016/s0046-8177(98)90199-x"
"1413294","[Periodical medical examination update 1991: 3. Secondary prevention of prostate cancer. Canadian study group on the periodical medical examination]","","Union Med Can. 1992 Jul-Aug;121(4):243-5, 248-57.","","Union Med Can","1992","1992/07/01","","",""
"22258369","[Advanced prostate cancer: where are we going?]","Thalmann G.","Urologe A. 2012 Jan;51(1):7. doi: 10.1007/s00120-011-2736-y.","Thalmann G","Urologe A","2012","2012/01/20","","","10.1007/s00120-011-2736-y"
"27686644","[New progress of castration-resistant prostate cancer immunotherapy]","Liu JP, Wang H.","Zhonghua Wai Ke Za Zhi. 2016 Oct 1;54(10):787-791. doi: 10.3760/cma.j.issn.0529-5815.2016.10.015.","Liu JP","Zhonghua Wai Ke Za Zhi","2016","2016/10/01","","","10.3760/cma.j.issn.0529-5815.2016.10.015"
"21392882","Eppin expression in prostate cancer","Izumi K, Zheng Y, Miyamoto H.","Eur Urol. 2011 Jun;59(6):1071-2. doi: 10.1016/j.eururo.2011.02.027.","Izumi K","Eur Urol","2011","2011/03/12","","","10.1016/j.eururo.2011.02.027"
"20363552","Defining and treating high-risk prostate cancer: can we do better?","Gerber L, Bañez LL, Freedland SJ.","Eur Urol. 2010 Jul;58(1):8-9. doi: 10.1016/j.eururo.2010.03.030. Epub 2010 Mar 26.","Gerber L","Eur Urol","2010","2010/04/06","","","10.1016/j.eururo.2010.03.030"
"16440300","Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer","Wang G, Sadar MD.","J Cell Biochem. 2006 May 1;98(1):36-53. doi: 10.1002/jcb.20802.","Wang G","J Cell Biochem","2006","2006/01/28","","","10.1002/jcb.20802"
"12480869","Watchfulness may not be as good as surgery for prostate cancer","Silcocks PB.","BMJ. 2002 Dec 14;325(7377):1423. doi: 10.1136/bmj.325.7377.1423.","Silcocks PB","BMJ","2002","2002/12/14","PMC1124872","","10.1136/bmj.325.7377.1423"
"23953359","Prostate-specific antigen and prostate cancer mortality: a systematic review","Wallner LP, Jacobsen SJ.","Am J Prev Med. 2013 Sep;45(3):318-26. doi: 10.1016/j.amepre.2013.04.015.","Wallner LP","Am J Prev Med","2013","2013/08/20","","","10.1016/j.amepre.2013.04.015"
"19149228","Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia","Galić J, Simunović D.","Coll Antropol. 2008 Dec;32(4):1195-202.","Galić J","Coll Antropol","2008","2009/01/20","","",""
"11684846","Patient selection for magnetic resonance imaging of prostate cancer","Engelbrecht MR, Jager GJ, Severens JL.","Eur Urol. 2001 Sep;40(3):300-7. doi: 10.1159/000049790.","Engelbrecht MR","Eur Urol","2001","2001/10/31","","","10.1159/000049790"
"10482180","African American men, prostate cancer early detection examination use, and informed decision-making","Myers RE.","Semin Oncol. 1999 Aug;26(4):375-81.","Myers RE","Semin Oncol","1999","1999/09/11","","",""
"26519962","[Preoperative assessment of patient candidate to prostate cancer surgery]","Beauval JB, Mazerolles M, Salomon L, Soulié M.","Prog Urol. 2015 Nov;25(15):947-65. doi: 10.1016/j.purol.2015.08.001.","Beauval JB","Prog Urol","2015","2015/11/02","","","10.1016/j.purol.2015.08.001"
"26066011","Designing Normative Messages About Active Surveillance for Men With Localized Prostate Cancer","Volk RJ, Kinsman GT, Le YC, Swank P, Blumenthal-Barby J, McFall SL, Byrd TL, Mullen PD, Cantor SB.","J Health Commun. 2015;20(9):1014-20. doi: 10.1080/10810730.2015.1018618. Epub 2015 Jun 11.","Volk RJ","J Health Commun","2015","2015/06/13","PMC4784693","NIHMS747075","10.1080/10810730.2015.1018618"
"27638094","Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer","Dalela D, Karabon P, Sammon J, Sood A, Löppenberg B, Trinh QD, Menon M, Abdollah F.","Eur Urol. 2017 Apr;71(4):511-514. doi: 10.1016/j.eururo.2016.08.048. Epub 2016 Sep 13.","Dalela D","Eur Urol","2017","2016/09/18","","","10.1016/j.eururo.2016.08.048"
"7638468","Endorectal coil magnetic resonance imaging of prostate cancer","Milestone BN, Seidman EJ.","Semin Urol. 1995 May;13(2):113-21.","Milestone BN","Semin Urol","1995","1995/05/01","","",""
"26175867","Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists","Yoo S, Kim JK, Jeong IG.","Korean J Urol. 2015 Jul;56(7):487-97. doi: 10.4111/kju.2015.56.7.487. Epub 2015 Jun 30.","Yoo S","Korean J Urol","2015","2015/07/16","PMC4500805","","10.4111/kju.2015.56.7.487"
"16132789","History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States)","Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR.","Cancer Causes Control. 2005 Sep;16(7):789-97. doi: 10.1007/s10552-005-3301-z.","Chan JM","Cancer Causes Control","2005","2005/09/01","","","10.1007/s10552-005-3301-z"
"28823964","MicroRNAs in prostate cancer: Functional role as biomarkers","Kanwal R, Plaga AR, Liu X, Shukla GC, Gupta S.","Cancer Lett. 2017 Oct 28;407:9-20. doi: 10.1016/j.canlet.2017.08.011. Epub 2017 Aug 18.","Kanwal R","Cancer Lett","2017","2017/08/22","","","10.1016/j.canlet.2017.08.011"
"21144766","Combined hormone therapy and radiation therapy for locally advanced prostate cancer","Bolla M, Laramas M; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).","Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e30-4. doi: 10.1016/j.critrevonc.2010.11.003. Epub 2010 Dec 8.","Bolla M","Crit Rev Oncol Hematol","2012","2010/12/15","","","10.1016/j.critrevonc.2010.11.003"
"27647999","Prognostic Value of Prostaglandin-endoperoxide Synthase 2 Polymorphisms in Prostate Cancer Recurrence after Radical Prostatectomy","Lee CH, Pao JB, Lu TL, Lee HZ, Lee YC, Liu CC, Huang CY, Lin VC, Yu CC, Yin HL, Huang SP, Bao BY.","Int J Med Sci. 2016 Aug 11;13(9):696-700. doi: 10.7150/ijms.16259. eCollection 2016.","Lee CH","Int J Med Sci","2016","2016/09/21","PMC5027188","","10.7150/ijms.16259"
"22402316","Androgen action in the prostate gland","Yadav N, Heemers HV.","Minerva Urol Nefrol. 2012 Mar;64(1):35-49.","Yadav N","Minerva Urol Nefrol","2012","2012/03/10","","",""
"15595340","Tissue ablation technologies for localized prostate cancer","Gillett MD, Gettman MT, Zincke H, Blute ML.","Mayo Clin Proc. 2004 Dec;79(12):1547-55. doi: 10.4065/79.12.1547.","Gillett MD","Mayo Clin Proc","2004","2004/12/15","","","10.4065/79.12.1547"
"24592520","Survivorship health information counseling for patients with prostate cancer","Colella J, Gejerman G.","Urol Nurs. 2013 Nov-Dec;33(6):273-80, 311.","Colella J","Urol Nurs","2013","2014/03/06","","",""
"26333222","[Transrectal shear wave elastography combined with transition zone biopsy for detecting prostate cancer]","Zhang M, Wang P, Yin B, Fei X, Xu XW, Song YS.","Zhonghua Nan Ke Xue. 2015 Jul;21(7):610-4.","Zhang M","Zhonghua Nan Ke Xue","2015","2015/09/04","","",""
"16619532","Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer","Zhu X, Mao Z, Na Y, Guo Y, Wang X, Xin D.","Anticancer Res. 2006 Mar-Apr;26(2A):1253-9.","Zhu X","Anticancer Res","2006","2006/04/20","","",""
"23272139","Association of the innate immunity and inflammation pathway with advanced prostate cancer risk","Kazma R, Mefford JA, Cheng I, Plummer SJ, Levin AM, Rybicki BA, Casey G, Witte JS.","PLoS One. 2012;7(12):e51680. doi: 10.1371/journal.pone.0051680. Epub 2012 Dec 14.","Kazma R","PLoS One","2012","2012/12/29","PMC3522730","","10.1371/journal.pone.0051680"
"19578350","Risk factors: improved risk stratification for prostate cancer","Isbarn H, Karakiewicz PI.","Nat Rev Urol. 2009 Jul;6(7):355-6. doi: 10.1038/nrurol.2009.106.","Isbarn H","Nat Rev Urol","2009","2009/07/07","","","10.1038/nrurol.2009.106"
"1667150","Impact of radiation on prostate cancer","Lilley LL.","Geriatr Nurs. 1991 Jul-Aug;12(4):174-7. doi: 10.1016/s0197-4572(05)80194-6.","Lilley LL","Geriatr Nurs","1991","1991/07/01","","","10.1016/s0197-4572(05)80194-6"
"22690466","Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer","Gaines KK.","Urol Nurs. 2012 Mar-Apr;32(2):95-8.","Gaines KK","Urol Nurs","2012","2012/06/14","","",""
"10975490","The multidisciplinary clinic approach to prostate cancer counseling and treatment","Valicenti RK, Gomella LG, El-Gabry EA, Myers R, Nathan F, Strup S, Dicker A, McGinnis DE, Cardi G, Baltish M, Simirgliano M, Vizzard A, Mulholland SG.","Semin Urol Oncol. 2000 Aug;18(3):188-91.","Valicenti RK","Semin Urol Oncol","2000","2000/09/07","","",""
"11025373","Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer","Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L.","Eur Urol. 2000 Oct;38(4):372-9. doi: 10.1159/000020311.","Van Poppel H","Eur Urol","2000","2000/10/12","","","10.1159/000020311"
"21061679","[Detection of DNA hypermethylation as a potential biomarker for prostate cancer]","Tilandyová P, Kajo K, Kliment J, Plank L, Lasabová Z.","Klin Onkol. 2010;23(5):293-9.","Tilandyová P","Klin Onkol","2010","2010/11/11","","",""
"15958559","Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target","Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X.","Cancer Res. 2005 Jun 15;65(12):5153-62. doi: 10.1158/0008-5472.CAN-04-3785.","Kwok WK","Cancer Res","2005","2005/06/17","","","10.1158/0008-5472.CAN-04-3785"
"18602740","Editorial comment on: adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?","Da Pozzo L.","Eur Urol. 2008 Sep;54(3):541-2. doi: 10.1016/j.eururo.2008.06.061. Epub 2008 Jun 23.","Da Pozzo L","Eur Urol","2008","2008/07/08","","","10.1016/j.eururo.2008.06.061"
"23247694","Adaptation or selection--mechanisms of castration-resistant prostate cancer","Zong Y, Goldstein AS.","Nat Rev Urol. 2013 Feb;10(2):90-8. doi: 10.1038/nrurol.2012.237. Epub 2012 Dec 18.","Zong Y","Nat Rev Urol","2013","2012/12/19","","","10.1038/nrurol.2012.237"
"23990529","Conservative management for low-risk prostate cancer improves quality-adjusted life expectancy at lower cost compared with initial treatment","Klotz L.","Evid Based Med. 2014 Feb;19(1):40. doi: 10.1136/eb-2013-101481. Epub 2013 Aug 29.","Klotz L","Evid Based Med","2014","2013/08/31","","","10.1136/eb-2013-101481"
"8895677","Significance of preoperative parameters for predicting tumor volume in nonpalpable prostate cancer","Egawa S, Satoh T, Suyama K, Kuwao S, Uchida T, Koshiba K.","Jpn J Clin Oncol. 1996 Oct;26(5):356-61. doi: 10.1093/oxfordjournals.jjco.a023245.","Egawa S","Jpn J Clin Oncol","1996","1996/10/01","","","10.1093/oxfordjournals.jjco.a023245"
"2926986","[Fast neutron radiotherapy of prostate cancer]","Morita S, Tsunemoto H, Akimoto S, Fuse H, Shimazaki J, Fukushima G, Kitagawa R.","Gan No Rinsho. 1989 Feb;35(3):378-84.","Morita S","Gan No Rinsho","1989","1989/02/01","","",""
"9072934","Prostate cancer: are we screening and treating too much?","Middleton RG.","Ann Intern Med. 1997 Mar 15;126(6):465-7. doi: 10.7326/0003-4819-126-6-199703150-00009.","Middleton RG","Ann Intern Med","1997","1997/03/15","","","10.7326/0003-4819-126-6-199703150-00009"
"18726672","[Chemotherapy for prostate cancer]","Rauchenwald M, De Santis M, Fink E, Höltl W, Kramer G, Marei IC, Neumann HJ, Reissigl A, Schmeller N, Stackl W, Hobisch A, Krainer M.","Wien Klin Wochenschr. 2008;120(13-14):440-9. doi: 10.1007/s00508-008-1008-3.","Rauchenwald M","Wien Klin Wochenschr","2008","2008/08/30","","","10.1007/s00508-008-1008-3"
"26804670","5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial","Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A.","Int J Cancer. 2016 Jun 15;138(12):2820-8. doi: 10.1002/ijc.30017. Epub 2016 Feb 11.","Murtola TJ","Int J Cancer","2016","2016/01/26","","","10.1002/ijc.30017"
"9751363","Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database","Grossfeld GD, Stier DM, Flanders SC, Henning JM, Schonfeld W, Warolin K, Carroll PR.","J Urol. 1998 Oct;160(4):1398-404.","Grossfeld GD","J Urol","1998","1998/09/29","","",""
"29877127","Understanding Medical Decision-making in Prostate Cancer Care","Thera R, Carr DT, Groot DG, Baba N, Jana DK.","Am J Mens Health. 2018 Sep;12(5):1635-1647. doi: 10.1177/1557988318780851. Epub 2018 Jun 7.","Thera R","Am J Mens Health","2018","2018/06/08","PMC6142146","","10.1177/1557988318780851"
"28420543","Serum persistent organic pollutants (POPs) and prostate cancer risk: A case-cohort study","Lim JE, Nam C, Yang J, Rha KH, Lim KM, Jee SH.","Int J Hyg Environ Health. 2017 Jul;220(5):849-856. doi: 10.1016/j.ijheh.2017.03.014. Epub 2017 Apr 10.","Lim JE","Int J Hyg Environ Health","2017","2017/04/20","","","10.1016/j.ijheh.2017.03.014"
"9541943","[What does the urologist expect and hope for from the pathologist in diagnosis of prostate carcinoma]","Breul J, Hartung R.","Pathologe. 1998 Jan;19(1):59-62. doi: 10.1007/s002920050255.","Breul J","Pathologe","1998","1998/06/06","","","10.1007/s002920050255"
"11904307","Androgen deprivation as primary treatment for early prostate cancer: should we ""just do something""?","Talcott JA.","J Natl Cancer Inst. 2002 Mar 20;94(6):407-9. doi: 10.1093/jnci/94.6.407.","Talcott JA","J Natl Cancer Inst","2002","2002/03/21","","","10.1093/jnci/94.6.407"
"19284377","Promising novel immunotherapies and combinations for prostate cancer","Arlen PM, Mohebtash M, Madan RA, Gulley JL.","Future Oncol. 2009 Mar;5(2):187-96. doi: 10.2217/14796694.5.2.187.","Arlen PM","Future Oncol","2009","2009/03/17","PMC2705770","NIHMS114788","10.2217/14796694.5.2.187"
"7754276","Radiotherapy of prostate cancer: established results and new developments","Dearnaley DP.","Semin Surg Oncol. 1995 Jan-Feb;11(1):50-9. doi: 10.1002/ssu.2980110108.","Dearnaley DP","Semin Surg Oncol","1995","1995/01/01","","","10.1002/ssu.2980110108"
"7523702","The clinical usefulness of prostate specific antigen: update 1994","Partin AW, Oesterling JE.","J Urol. 1994 Nov;152(5 Pt 1):1358-68. doi: 10.1016/s0022-5347(17)32422-9.","Partin AW","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32422-9"
"19076134","Outcome of radical prostatectomy for incidental carcinoma of the prostate","Melchior S, Hadaschik B, Thüroff S, Thomas C, Gillitzer R, Thüroff J.","BJU Int. 2009 Jun;103(11):1478-81. doi: 10.1111/j.1464-410X.2008.08279.x. Epub 2008 Dec 8.","Melchior S","BJU Int","2009","2008/12/17","","","10.1111/j.1464-410X.2008.08279.x"
"12890079","Metastatic prostate cancer: complications and treatment","McMurtry CT, McMurtry JM.","J Am Geriatr Soc. 2003 Aug;51(8):1136-42. doi: 10.1046/j.1532-5415.2003.51367.x.","McMurtry CT","J Am Geriatr Soc","2003","2003/08/02","","","10.1046/j.1532-5415.2003.51367.x"
"22154187","How to select the optimal therapy for early-stage prostate cancer","Kollmeier MA, Zelefsky MJ.","Crit Rev Oncol Hematol. 2012 Aug;83(2):225-34. doi: 10.1016/j.critrevonc.2011.11.001. Epub 2011 Dec 6.","Kollmeier MA","Crit Rev Oncol Hematol","2012","2011/12/14","","","10.1016/j.critrevonc.2011.11.001"
"25547457","Patient experiences at diagnosis and psychological well-being in prostate cancer: A Finnish national survey","Lehto US, Helander S, Taari K, Aromaa A.","Eur J Oncol Nurs. 2015 Jun;19(3):220-9. doi: 10.1016/j.ejon.2014.10.018. Epub 2014 Dec 24.","Lehto US","Eur J Oncol Nurs","2015","2014/12/31","","","10.1016/j.ejon.2014.10.018"
"23826842","SABRE 1 (Surgery Against Brachytherapy - a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer","Eccles BK, Cross W, Rosario DJ, Doble A, Parker C, Logue J, Little L, Stanton L, Bottomley D.","BJU Int. 2013 Aug;112(3):330-7. doi: 10.1111/bju.12127.","Eccles BK","BJU Int","2013","2013/07/06","","","10.1111/bju.12127"
"18700060","Update on the diagnosis and management of prostate cancer","LaSpina M, Haas GP.","Can J Urol. 2008 Aug;15 Suppl 1:3-13; discussion 13.","LaSpina M","Can J Urol","2008","2008/09/04","","",""
"23287462","Targeted prostate cancer ablation: energy options","Coleman JA, Scardino PT.","Curr Opin Urol. 2013 Mar;23(2):123-8. doi: 10.1097/MOU.0b013e32835d9e94.","Coleman JA","Curr Opin Urol","2013","2013/01/05","","","10.1097/MOU.0b013e32835d9e94"
"27613161","Trichomonas vaginalis: a possible foe to prostate cancer","Zhu Z, Davidson KT, Brittingham A, Wakefield MR, Bai Q, Xiao H, Fang Y.","Med Oncol. 2016 Oct;33(10):115. doi: 10.1007/s12032-016-0832-y. Epub 2016 Sep 8.","Zhu Z","Med Oncol","2016","2016/09/11","","","10.1007/s12032-016-0832-y"
"19854473","Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy","Jans J, van Dijk JH, van Schelven S, van der Groep P, Willems SH, Jonges TN, van Diest PJ, Bosch JL.","Urology. 2010 Apr;75(4):786-92. doi: 10.1016/j.urology.2009.08.024. Epub 2009 Oct 24.","Jans J","Urology","2010","2009/10/27","","","10.1016/j.urology.2009.08.024"
"22208041","[Gene therapy for prostate cancer: current status and future prospects]","Kumon H.","Nihon Rinsho. 2011 Jun;69 Suppl 5:544-9.","Kumon H","Nihon Rinsho","2011","2012/01/03","","",""
"27694174","Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs","Schuster DM, Nanni C, Fanti S.","J Nucl Med. 2016 Oct;57(Suppl 3):61S-66S. doi: 10.2967/jnumed.115.170209.","Schuster DM","J Nucl Med","2016","2016/10/04","","","10.2967/jnumed.115.170209"
"9831223","ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients","Elgamal AA, Troychak MJ, Murphy GP.","Prostate. 1998 Dec 1;37(4):261-9. doi: 10.1002/(sici)1097-0045(19981201)37:4<261::aid-pros8>3.0.co;2-#.","Elgamal AA","Prostate","1998","1998/11/27","","","10.1002/(sici)1097-0045(19981201)37:4<261::aid-pros8>3.0.co;2-#"
"7747716","Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer","Vandenbroucke F, Van Poppel H, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L.","Am J Clin Oncol. 1995 Jun;18(3):263-6. doi: 10.1097/00000421-199506000-00015.","Vandenbroucke F","Am J Clin Oncol","1995","1995/06/01","","","10.1097/00000421-199506000-00015"
"31403335","Clinicopathologic Diagnostic Approach to Aggressive Variant Prostate Cancer","Manucha V, Henegan J.","Arch Pathol Lab Med. 2020 Jan;144(1):18-23. doi: 10.5858/arpa.2019-0124-RA. Epub 2019 Aug 12.","Manucha V","Arch Pathol Lab Med","2020","2019/08/13","","","10.5858/arpa.2019-0124-RA"
"11818479","Early management of prostate cancer: how to respond to an elevated PSA?","Canto EI, Slawin KM.","Annu Rev Med. 2002;53:355-68. doi: 10.1146/annurev.med.53.082901.104000.","Canto EI","Annu Rev Med","2002","2002/01/31","","","10.1146/annurev.med.53.082901.104000"
"10975495","Counseling patients about cryotherapy for prostate cancer in the information age","Benoit RM, Cohen JK, Miller RJ Jr.","Semin Urol Oncol. 2000 Aug;18(3):226-32.","Benoit RM","Semin Urol Oncol","2000","2000/09/07","","",""
"21601425","Occult prostate cancer detected by hyoid bone metastasis after resection of thyroglossal duct cyst","Wang SH, Lee JC, Liu TC.","Int J Oral Maxillofac Surg. 2011 Nov;40(11):1326-8. doi: 10.1016/j.ijom.2011.04.010. Epub 2011 May 20.","Wang SH","Int J Oral Maxillofac Surg","2011","2011/05/24","","","10.1016/j.ijom.2011.04.010"
"29496983","Effects of Fasting on (18)F-DCFPyL Uptake in Prostate Cancer Lesions and Tissues with Known High Physiologic Uptake","Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ.","J Nucl Med. 2018 Jul;59(7):1081-1084. doi: 10.2967/jnumed.117.207316. Epub 2018 Mar 1.","Wondergem M","J Nucl Med","2018","2018/03/03","","","10.2967/jnumed.117.207316"
"16013148","Prostate cancer: is the PSA test the answer?","Berlin B.","N J Med. 1998 Mar;95(3):53-5.","Berlin B","N J Med","1998","2005/07/15","","",""
"9454344","Study suggests new way to gauge prostate cancer risk","Barinaga M.","Science. 1998 Jan 23;279(5350):475. doi: 10.1126/science.279.5350.475.","Barinaga M","Science","1998","1998/02/07","","","10.1126/science.279.5350.475"
"19375907","Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?","Macefield RC, Lane JA, Metcalfe C, Down L, Neal DE, Hamdy FC, Donovan JL.","Eur J Cancer. 2009 Sep;45(14):2569-73. doi: 10.1016/j.ejca.2009.03.016. Epub 2009 Apr 16.","Macefield RC","Eur J Cancer","2009","2009/04/21","","","10.1016/j.ejca.2009.03.016"
"25306503","A review of prostate cancer incidence and mortality studies of farmers and non-farmers, 2002-2013","Depczynski J, Lower T.","Cancer Epidemiol. 2014 Dec;38(6):654-62. doi: 10.1016/j.canep.2014.09.001. Epub 2014 Oct 8.","Depczynski J","Cancer Epidemiol","2014","2014/10/13","","","10.1016/j.canep.2014.09.001"
"8630226","Neuroendocrine differentiation and hormone-refractory prostate cancer","Abrahamsson PA.","Prostate Suppl. 1996;6:3-8. doi: 10.1002/(sici)1097-0045(1996)6+<3::aid-pros2>3.0.co;2-t.","Abrahamsson PA","Prostate Suppl","1996","1996/01/01","","","10.1002/(sici)1097-0045(1996)6+<3::aid-pros2>3.0.co;2-t"
"19758620","Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy","Antonelli JA, Jones LW, Bañez LL, Thomas JA, Anderson K, Taylor LA, Gerber L, Anderson T, Hoyo C, Grant D, Freedland SJ.","J Urol. 2009 Nov;182(5):2226-31. doi: 10.1016/j.juro.2009.07.028. Epub 2009 Sep 16.","Antonelli JA","J Urol","2009","2009/09/18","","","10.1016/j.juro.2009.07.028"
"11442674","Autocrine expression of neurotrophins and their receptors in prostate cancer","Satoh F, Mimata H, Nomura T, Fujita Y, Shin T, Sakamoto S, Hamada Y, Nomura Y.","Int J Urol. 2001 Jul;8(7):S28-34. doi: 10.1046/j.1442-2042.2001.00331.x.","Satoh F","Int J Urol","2001","2001/07/10","","","10.1046/j.1442-2042.2001.00331.x"
"2029399","Franzén transrectal fine-needle biopsy versus ultrasound-guided transrectal core biopsy of the prostate gland","Adolfsson J, Skoog L, Löwhagen T, Waisman J.","Acta Oncol. 1991;30(2):159-60. doi: 10.3109/02841869109092341.","Adolfsson J","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092341"
"14713850","A diagnostic test for prostate cancer from gene expression profiling data","Bueno R, Loughlin KR, Powell MH, Gordon GJ.","J Urol. 2004 Feb;171(2 Pt 1):903-6. doi: 10.1097/01.ju.0000095446.10443.52.","Bueno R","J Urol","2004","2004/01/10","","","10.1097/01.ju.0000095446.10443.52"
"9769407","E-cadherin and associated molecules in the invasion and progression of prostate cancer","Davies G, Jiang WG, Mason MD.","Oncol Rep. 1998 Nov-Dec;5(6):1567-76. doi: 10.3892/or.5.6.1567.","Davies G","Oncol Rep","1998","1998/10/14","","","10.3892/or.5.6.1567"
"23260764","The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man","Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, Neal DE.","Cancer Cell. 2013 Jan 14;23(1):35-47. doi: 10.1016/j.ccr.2012.11.010. Epub 2012 Dec 20.","Sharma NL","Cancer Cell","2013","2012/12/25","","","10.1016/j.ccr.2012.11.010"
"8853497","Recommendations on secondary prevention of prostate cancer from the Canadian Task Force on the Periodic Health Examination","Feightner JW.","Can J Oncol. 1994 Nov;4 Suppl 1:80-1.","Feightner JW","Can J Oncol","1994","1994/11/01","","",""
"9721062","Lobund-Wistar rat model of prostate cancer in man","Pollard M.","Prostate. 1998 Sep 15;37(1):1-4. doi: 10.1002/(sici)1097-0045(19980915)37:1<1::aid-pros1>3.0.co;2-l.","Pollard M","Prostate","1998","1998/08/28","","","10.1002/(sici)1097-0045(19980915)37:1<1::aid-pros1>3.0.co;2-l"
"3191340","Deferred treatment for prostate cancer","Handley R, Carr TW, Travis D, Powell PH, Hall RR.","Br J Urol. 1988 Sep;62(3):249-53. doi: 10.1111/j.1464-410x.1988.tb04328.x.","Handley R","Br J Urol","1988","1988/09/01","","","10.1111/j.1464-410x.1988.tb04328.x"
"24238563","Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience","Fosså SD, Nilssen Y, Kvåle R, Hernes E, Axcrona K, Møller B.","Urology. 2014 Jan;83(1):146-52. doi: 10.1016/j.urology.2013.08.081. Epub 2013 Nov 12.","Fosså SD","Urology","2014","2013/11/19","","","10.1016/j.urology.2013.08.081"
"22036166","Response to ""Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size"" (Int J Radiat Oncol Biol Phys 2011;79:1318-1322)","Tunio M, Hashmi A.","Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1195-6; author reply 1196. doi: 10.1016/j.ijrobp.2011.05.072.","Tunio M","Int J Radiat Oncol Biol Phys","2011","2011/11/01","","","10.1016/j.ijrobp.2011.05.072"
"25543290","Role of brachytherapy for advanced prostate cancer","Rossi PJ.","Curr Probl Cancer. 2015 Jan-Feb;39(1):48-51. doi: 10.1016/j.currproblcancer.2014.11.008. Epub 2014 Nov 25.","Rossi PJ","Curr Probl Cancer","2015","2014/12/29","","","10.1016/j.currproblcancer.2014.11.008"
"16871101","Reclaiming wellness--living with bodily problems, as narrated by men with advanced prostate cancer","Lindqvist O, Widmark A, Rasmussen BH.","Cancer Nurs. 2006 Jul-Aug;29(4):327-37. doi: 10.1097/00002820-200607000-00012.","Lindqvist O","Cancer Nurs","2006","2006/07/28","","","10.1097/00002820-200607000-00012"
"22870534","Hypofractionated radiotherapy for prostate cancer: has the time come?","Abramowitz MC, Pollack A.","Oncology (Williston Park). 2012 Jun;26(6):519, 522.","Abramowitz MC","Oncology (Williston Park)","2012","2012/08/09","","",""
"21502968","The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer","Chan SM, Garcia FJ, Chin JL, Moussa M, Gabril MY.","Prostate Cancer Prostatic Dis. 2011 Dec;14(4):307-12. doi: 10.1038/pcan.2011.15. Epub 2011 Apr 19.","Chan SM","Prostate Cancer Prostatic Dis","2011","2011/04/20","","","10.1038/pcan.2011.15"
"25065737","Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer","Osmulski P, Mahalingam D, Gaczynska ME, Liu J, Huang S, Horning AM, Wang CM, Thompson IM, Huang TH, Chen CL.","Prostate. 2014 Sep;74(13):1297-307. doi: 10.1002/pros.22846. Epub 2014 Jul 25.","Osmulski P","Prostate","2014","2014/07/29","PMC4142568","NIHMS604646","10.1002/pros.22846"
"10938208","A message from preventive medicine and your physician. Prostate cancer","","Prev Med. 2000 Aug;31(2 Pt 1):101-2. doi: 10.1006/pmed.2000.0719.","","Prev Med","2000","2000/08/12","","","10.1006/pmed.2000.0719"
"16264955","Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer?","Miyamoto H, Messing EM, Chang C.","Nat Clin Pract Oncol. 2005 May;2(5):236-7. doi: 10.1038/ncponc0168.","Miyamoto H","Nat Clin Pract Oncol","2005","2005/11/03","","","10.1038/ncponc0168"
"14965337","Molecular therapy intervention prospects in prostate cancer","Rege YD, Rangnekar VM.","Curr Pharm Des. 2004;10(5):523-30. doi: 10.2174/1381612043453234.","Rege YD","Curr Pharm Des","2004","2004/02/18","","","10.2174/1381612043453234"
"30231311","Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer","Cheng H, Powers J, Schaffer K, Sartor O.","Am Soc Clin Oncol Educ Book. 2018 May 23;38:372-381. doi: 10.1200/EDBK_205441.","Cheng H","Am Soc Clin Oncol Educ Book","2018","2018/09/21","","","10.1200/EDBK_205441"
"16094093","Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?","Rosser CJ, Parker A.","J Urol. 2005 Sep;174(3):1154-5; author reply 1155-6. doi: 10.1097/01.ju.0000169211.49050.8f.","Rosser CJ","J Urol","2005","2005/08/12","","","10.1097/01.ju.0000169211.49050.8f"
"28493535","The mongolian gerbil (Meriones unguiculatus) as a model for inflammation-promoted prostate carcinogenesis","Quintar AA, Gonçalves BF, Taboga SR, Maldonado CA.","Cell Biol Int. 2017 Nov;41(11):1234-1238. doi: 10.1002/cbin.10789. Epub 2017 May 25.","Quintar AA","Cell Biol Int","2017","2017/05/12","","","10.1002/cbin.10789"
"11198953","The challenge of prostate cancer","von Eschenbach AC.","CA Cancer J Clin. 1999 Sep-Oct;49(5):262-3. doi: 10.3322/canjclin.49.5.262.","von Eschenbach AC","CA Cancer J Clin","1999","2001/02/24","","","10.3322/canjclin.49.5.262"
"26881518","Clinicopathological characteristics and primary treatment of prostate cancer in a urology unit of Sri Lanka","Abeygunasekera AM, Wijayarathna SN, de Silva K, Gobi U, Swarna S, Sujeeva W.","J Cancer Res Ther. 2015 Oct-Dec;11(4):780-5. doi: 10.4103/0973-1482.140839.","Abeygunasekera AM","J Cancer Res Ther","2015","2016/02/17","","","10.4103/0973-1482.140839"
"8673000","Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993","Gilliland FD, Welsh DJ, Hoffman RM, Key CR.","Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):797-800.","Gilliland FD","Cancer Epidemiol Biomarkers Prev","1995","1995/10/01","","",""
"26484677","Integrated Analysis Reveals together miR-182, miR-200c and miR-221 Can Help in the Diagnosis of Prostate Cancer","Gu Y, Lei D, Qin X, Chen P, Zou YM, Hu Y.","PLoS One. 2015 Oct 20;10(10):e0140862. doi: 10.1371/journal.pone.0140862. eCollection 2015.","Gu Y","PLoS One","2015","2015/10/21","PMC4618846","","10.1371/journal.pone.0140862"
"19564245","Screening for prostate cancer","Brawley OW, Ankerst DP, Thompson IM.","CA Cancer J Clin. 2009 Jul-Aug;59(4):264-73. doi: 10.3322/caac.20026. Epub 2009 Jun 29.","Brawley OW","CA Cancer J Clin","2009","2009/07/01","","","10.3322/caac.20026"
"20483872","Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis","Sridhar G, Masho SW, Adera T, Ramakrishnan V, Roberts JD.","Am J Mens Health. 2010 Sep;4(3):189-206. doi: 10.1177/1557988309353934. Epub 2010 May 18.","Sridhar G","Am J Mens Health","2010","2010/05/21","","","10.1177/1557988309353934"
"19827050","Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells","Nadiminty N, Dutt S, Tepper C, Gao AC.","Prostate. 2010 Feb 15;70(3):276-87. doi: 10.1002/pros.21062.","Nadiminty N","Prostate","2010","2009/10/15","","","10.1002/pros.21062"
"25749042","Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer","Keller XE, Kardas P, Acevedo C, Sais G, Poyet C, Banzola I, Mortezavi A, Seifert B, Sulser T, Hirsch HH, Provenzano M.","Oncotarget. 2015 Mar 20;6(8):6459-69. doi: 10.18632/oncotarget.3363.","Keller XE","Oncotarget","2015","2015/03/10","PMC4467449","","10.18632/oncotarget.3363"
"7621464","The geography of prostate cancer and its treatment in Africa","Kehinde EO.","Cancer Surv. 1995;23:281-6.","Kehinde EO","Cancer Surv","1995","1995/01/01","","",""
"17186528","Cumulative cost pattern comparison of prostate cancer treatments","Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR.","Cancer. 2007 Feb 1;109(3):518-27. doi: 10.1002/cncr.22433.","Wilson LS","Cancer","2007","2006/12/23","","","10.1002/cncr.22433"
"12671538","Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants","Quaglia A, Vercelli M, Puppo A, Casella C, Artioli E, Crocetti E, Falcini F, Ramazzotti V, Tagliabue G; Prostate Working Group.","Eur J Cancer Prev. 2003 Apr;12(2):145-52. doi: 10.1097/00008469-200304000-00008.","Quaglia A","Eur J Cancer Prev","2003","2003/04/03","","","10.1097/00008469-200304000-00008"
"24511112","Repurposing to fight cancer: the metformin-prostate cancer connection","Azvolinsky A.","J Natl Cancer Inst. 2014 Feb;106(2):dju030. doi: 10.1093/jnci/dju030.","Azvolinsky A","J Natl Cancer Inst","2014","2014/02/11","","","10.1093/jnci/dju030"
"31262399","Membranous nephropathy and thrombotic microangiopathy secondary to metastatic prostate cancer after Iodine-125 prostate brachytherapy: A case report ","Yang L, Liang D, Cheng S, Ge Y.","Clin Nephrol. 2019 Sep;92(3):155-158. doi: 10.5414/CN109582.","Yang L","Clin Nephrol","2019","2019/07/03","","","10.5414/CN109582"
"28502474","[Role of prostate MRI, TRUS fusion biopsies and new markers in the diagnostic strategy of prostate cancer]","Renard-Penna R, Mozer P, Lunelli L, Cussenot O.","Presse Med. 2017 Oct;46(10):928-934. doi: 10.1016/j.lpm.2017.03.017. Epub 2017 May 11.","Renard-Penna R","Presse Med","2017","2017/05/16","","","10.1016/j.lpm.2017.03.017"
"21149617","Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy","Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Chen LM, Hsieh CJ, Huang SP.","Clin Cancer Res. 2011 Feb 15;17(4):928-36. doi: 10.1158/1078-0432.CCR-10-2648. Epub 2010 Dec 13.","Bao BY","Clin Cancer Res","2011","2010/12/15","","","10.1158/1078-0432.CCR-10-2648"
"30889615","[Molecular pathology of prostate cancer]","Tímár J.","Magy Onkol. 2019 Mar 19;63(1):5-9. Epub 2019 Jan 2.","Tímár J","Magy Onkol","2019","2019/03/20","","",""
"23929133","Alcohol and smoking and subsequent risk of prostate cancer in Japanese men: the Japan Public Health Center-based prospective study","Sawada N, Inoue M, Iwasaki M, Sasazuki S, Yamaji T, Shimazu T, Tsugane S.","Int J Cancer. 2014 Feb 15;134(4):971-8. doi: 10.1002/ijc.28423. Epub 2013 Sep 4.","Sawada N","Int J Cancer","2014","2013/08/10","","","10.1002/ijc.28423"
"22509301","Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening","Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL.","PLoS One. 2012;7(4):e34414. doi: 10.1371/journal.pone.0034414. Epub 2012 Apr 11.","Dahlman KB","PLoS One","2012","2012/04/18","PMC3324507","","10.1371/journal.pone.0034414"
"12669394","[Prostate cancer]","Karasawa K.","Gan To Kagaku Ryoho. 2003 Mar;30(3):358-64.","Karasawa K","Gan To Kagaku Ryoho","2003","2003/04/03","","",""
"26316313","Consolidation of proteomics data in the Cancer Proteomics database","Arntzen MØ, Boddie P, Frick R, Koehler CJ, Thiede B.","Proteomics. 2015 Nov;15(22):3765-71. doi: 10.1002/pmic.201500144. Epub 2015 Oct 26.","Arntzen MØ","Proteomics","2015","2015/08/29","","","10.1002/pmic.201500144"
"21675840","Evolution from active surveillance to focal therapy in the management of prostate cancer","Lindner U, Lawrentschuk N, Schatloff O, Trachtenberg J, Lindner A.","Future Oncol. 2011 Jun;7(6):775-87. doi: 10.2217/fon.11.51.","Lindner U","Future Oncol","2011","2011/06/17","","","10.2217/fon.11.51"
"10854562","Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients","McCabe NP, Angwafo FF 3rd, Zaher A, Selman SH, Kouinche A, Jankun J.","Oncol Rep. 2000 Jul-Aug;7(4):879-82. doi: 10.3892/or.7.4.879.","McCabe NP","Oncol Rep","2000","2000/06/16","","","10.3892/or.7.4.879"
"19660791","Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients","Polascik TJ, Mouraviev V.","Urology. 2009 Oct;74(4):726-30. doi: 10.1016/j.urology.2009.02.084. Epub 2009 Aug 5.","Polascik TJ","Urology","2009","2009/08/08","","","10.1016/j.urology.2009.02.084"
"26491818","Recent progress in urinary proteome analysis for prostate cancer diagnosis and management","Frantzi M, Latosinska A, Merseburger AS, Mischak H.","Expert Rev Mol Diagn. 2015;15(12):1539-54. doi: 10.1586/14737159.2015.1104248. Epub 2015 Oct 22.","Frantzi M","Expert Rev Mol Diagn","2015","2015/10/23","","","10.1586/14737159.2015.1104248"
"25158234","Pomegranate and its components as alternative treatment for prostate cancer","Wang L, Martins-Green M.","Int J Mol Sci. 2014 Aug 25;15(9):14949-66. doi: 10.3390/ijms150914949.","Wang L","Int J Mol Sci","2014","2014/08/27","PMC4200766","","10.3390/ijms150914949"
"30558081","Cystic metastasis of prostate cancer: A case report","Zhang B, Bian B, Bi L, Wang Z, Zhao Y, Wang J.","Medicine (Baltimore). 2018 Dec;97(50):e13697. doi: 10.1097/MD.0000000000013697.","Zhang B","Medicine (Baltimore)","2018","2018/12/19","PMC6320181","","10.1097/MD.0000000000013697"
"18079521","Prostate cancer screening: Unacceptable in the under 50s","Braillon A, Dubois G.","BMJ. 2007 Dec 15;335(7632):1225. doi: 10.1136/bmj.39422.598125.3A.","Braillon A","BMJ","2007","2007/12/15","PMC2137092","","10.1136/bmj.39422.598125.3A"
"29740116","Revisiting 5α-reductase inhibitors and the risk of prostate cancer","Chau CH, Figg WD.","Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.","Chau CH","Nat Rev Urol","2018","2018/05/10","PMC6358277","NIHMS1008534","10.1038/s41585-018-0018-9"
"30913454","Emerging therapeutic targets for patients with advanced prostate cancer","Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA.","Cancer Treat Rev. 2019 Jun;76:1-9. doi: 10.1016/j.ctrv.2019.03.002. Epub 2019 Mar 19.","Saad F","Cancer Treat Rev","2019","2019/03/27","","","10.1016/j.ctrv.2019.03.002"
"22997399","An intravoxel incoherent motion diffusion-weighted imaging study of prostate cancer","Shinmoto H, Tamura C, Soga S, Shiomi E, Yoshihara N, Kaji T, Mulkern RV.","AJR Am J Roentgenol. 2012 Oct;199(4):W496-500. doi: 10.2214/AJR.11.8347.","Shinmoto H","AJR Am J Roentgenol","2012","2012/09/22","","","10.2214/AJR.11.8347"
"22665854","Adhering to the standard of care for prostate cancer","Kapoor DA, Penson D.","Health Aff (Millwood). 2012 Jun;31(6):1367; author reply 1367. doi: 10.1377/hlthaff.2012.0478.","Kapoor DA","Health Aff (Millwood)","2012","2012/06/06","","","10.1377/hlthaff.2012.0478"
"12515782","Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity","Coldman AJ, Phillips N, Pickles TA.","CMAJ. 2003 Jan 7;168(1):31-5.","Coldman AJ","CMAJ","2003","2003/01/08","PMC139315","",""
"11125381","Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer","Van Brussel JP, Jan Van Steenbrugge G, Van Krimpen C, Bogdanowicz JF, Van Der Kwast TH, Schröder FH, Mickisch GH.","J Urol. 2001 Jan;165(1):130-5. doi: 10.1097/00005392-200101000-00032.","Van Brussel JP","J Urol","2001","2000/12/23","","","10.1097/00005392-200101000-00032"
"23670181","An introduction to acinar pressures in BPH and prostate cancer","Wadhera P.","Nat Rev Urol. 2013 Jun;10(6):358-66. doi: 10.1038/nrurol.2013.86. Epub 2013 May 14.","Wadhera P","Nat Rev Urol","2013","2013/05/15","","","10.1038/nrurol.2013.86"
"23485998","Are somatic symptoms a legitimate part of the depression profile in prostate cancer patients?","Sharpley CF, Bitsika V, Christie DH.","Onkologie. 2013;36(3):110-4. doi: 10.1159/000348531. Epub 2013 Feb 21.","Sharpley CF","Onkologie","2013","2013/03/15","","","10.1159/000348531"
"14661990","High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy","Eastham JA.","Expert Opin Emerg Drugs. 2003 Nov;8(2):291-5. doi: 10.1517/14728214.8.2.291.","Eastham JA","Expert Opin Emerg Drugs","2003","2003/12/10","","","10.1517/14728214.8.2.291"
"11038139","Comments on an in vitro model of hormonally refractory prostate cancer","Joyal JL, Israel DI, Garnick MB.","Cancer J. 2000 Jul-Aug;6(4):213-4.","Joyal JL","Cancer J","2000","2000/10/19","","",""
"22047394","Automated intraoperative calibration for prostate cancer brachytherapy","Kuiran Chen T, Heffter T, Lasso A, Pinter C, Abolmaesumi P, Burdette EC, Fichtinger G.","Med Phys. 2011 Nov;38(11):6285-99. doi: 10.1118/1.3651690.","Kuiran Chen T","Med Phys","2011","2011/11/04","","","10.1118/1.3651690"
"26806748","[Restriction landmark genomic scanning for screening aberrant CpG methylations in prostate cancer]","Li D, Xu Z, Liu J, Pu X, Luo Y, Zheng X.","Nan Fang Yi Ke Da Xue Xue Bao. 2016 Jan;36(1):103-8.","Li D","Nan Fang Yi Ke Da Xue Xue Bao","2016","2016/01/26","","",""
"28644303","Prostate cancer immunotherapy: the path forward","Madan RA, Gulley JL.","Curr Opin Support Palliat Care. 2017 Sep;11(3):225-230. doi: 10.1097/SPC.0000000000000278.","Madan RA","Curr Opin Support Palliat Care","2017","2017/06/24","","","10.1097/SPC.0000000000000278"
"28825924","Radical prostatectomy in oligometastatic prostate cancer","Mandel P, Steuber T, Graefen M.","Curr Opin Urol. 2017 Nov;27(6):572-579. doi: 10.1097/MOU.0000000000000445.","Mandel P","Curr Opin Urol","2017","2017/08/22","","","10.1097/MOU.0000000000000445"
"8564894","Hereditary prostate cancer","Levy I, Coombs A.","CMAJ. 1996 Feb 1;154(3):300-1.","Levy I","CMAJ","1996","1996/02/01","PMC1487516","",""
"16093719","Radiosensitivity detected by the micronucleus test is not generally increased in sporadic prostate cancer patients","Varga D, Michel I, Patino-Garcia B, Paiss T, Vogel W, Maier C.","Cytogenet Genome Res. 2005;111(1):41-5. doi: 10.1159/000085668.","Varga D","Cytogenet Genome Res","2005","2005/08/12","","","10.1159/000085668"
"11790281","Advancing perspectives on prostate cancer: multihormonal influences in pathogenesis","Porter A, Ben-Josef E, Crawford ED, Garde S, Huhtaniemi I, Pontes JE.","Mol Urol. 2001 Winter;5(4):181-8. doi: 10.1089/10915360152745876.","Porter A","Mol Urol","2001","2002/01/16","","","10.1089/10915360152745876"
"9516589","Radiation therapy versus radical prostatectomy in the PSA era: a urologist's view","Klein EA.","Semin Radiat Oncol. 1998 Apr;8(2):87-94. doi: 10.1016/s1053-4296(98)80004-0.","Klein EA","Semin Radiat Oncol","1998","1998/04/29","","","10.1016/s1053-4296(98)80004-0"
"16622914","Patient Information Page from the Hormone Foundation. Prostate cancer and bone loss","","J Clin Endocrinol Metab. 2006 Apr;91(4):following 1620.","","J Clin Endocrinol Metab","2006","2006/04/20","","",""
"22149034","Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions","Shen X, Zaorsky NG, Mishra MV, Foley KA, Hyslop T, Hegarty S, Pizzi LT, Dicker AP, Showalter TN.","Future Oncol. 2012 Jan;8(1):37-54. doi: 10.2217/fon.11.131.","Shen X","Future Oncol","2012","2011/12/14","","","10.2217/fon.11.131"
"24917001","[Future perspectives on screening for prostate cancer - an experienced Urologist's viewpoint]","Ito K.","Gan To Kagaku Ryoho. 2014 May;41(5):545-52.","Ito K","Gan To Kagaku Ryoho","2014","2014/06/12","","",""
"27987128","The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside","Hu J, Chen Q.","Int Urol Nephrol. 2017 Mar;49(3):369-380. doi: 10.1007/s11255-016-1476-8. Epub 2016 Dec 16.","Hu J","Int Urol Nephrol","2017","2016/12/18","","","10.1007/s11255-016-1476-8"
"2091533","[Cancer of the prostate with rectal invasion]","Fariña LA, Iglesias JM, Hocsman H, Vicente R.","Arch Esp Urol. 1990 Nov-Dec;43(9):1010-2.","Fariña LA","Arch Esp Urol","1990","1990/11/01","","",""
"4194186","[Treatment of cancer of the prostate]","Vernet SG.","Ann Urol (Paris). 1970 Feb;4(1):9-16.","Vernet SG","Ann Urol (Paris)","1970","1970/02/01","","",""
"19878505","Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England","Jack RH, Davies EA, Møller H.","BJU Int. 2010 May;105(9):1226-30. doi: 10.1111/j.1464-410X.2009.08940.x. Epub 2009 Oct 30.","Jack RH","BJU Int","2010","2009/11/03","","","10.1111/j.1464-410X.2009.08940.x"
"28813037","Concomitant bladder cancer and prostate cancer: challenges and controversies","Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M, Raspollini MR, Montironi R.","Nat Rev Urol. 2017 Oct;14(10):620-629. doi: 10.1038/nrurol.2017.124. Epub 2017 Aug 16.","Lopez-Beltran A","Nat Rev Urol","2017","2017/08/17","","","10.1038/nrurol.2017.124"
"22149091","Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer","Ellinger J, Kahl P, von der Gathen J, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Bastian PJ, von Ruecker A, Müller SC, Rogenhofer S.","Cancer Invest. 2012 Feb;30(2):92-7. doi: 10.3109/07357907.2011.636117. Epub 2011 Dec 7.","Ellinger J","Cancer Invest","2012","2011/12/14","","","10.3109/07357907.2011.636117"
"28626107","[Molecular basis for prostate carcinogenesis]","Chen F, Zhao X.","Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 May 28;42(5):581-587. doi: 10.11817/j.issn.1672-7347.2017.05.017.","Chen F","Zhong Nan Da Xue Xue Bao Yi Xue Ban","2017","2017/06/20","","","10.11817/j.issn.1672-7347.2017.05.017"
"17189956","Visual estimation of the tumor volume in prostate cancer: a useful means for predicting biochemical-free survival after radical prostatectomy?","May M, Siegsmund M, Hammermann F, Loy V, Gunia S.","Prostate Cancer Prostatic Dis. 2007;10(1):66-71. doi: 10.1038/sj.pcan.4500928. Epub 2006 Dec 26.","May M","Prostate Cancer Prostatic Dis","2007","2006/12/27","","","10.1038/sj.pcan.4500928"
"25692723","Observational studies and the natural history of screen-detected prostate cancer","Albertsen PC.","Curr Opin Urol. 2015 May;25(3):232-7. doi: 10.1097/MOU.0000000000000157.","Albertsen PC","Curr Opin Urol","2015","2015/02/19","","","10.1097/MOU.0000000000000157"
"18625567","Association of chromosomal locus 8q24 and risk of prostate cancer: a hospital-based study of German patients treated with brachytherapy","Meyer A, Schürmann P, Ghahremani M, Kocak E, Brinkhaus MJ, Bremer M, Karstens JH, Hagemann J, Machtens S, Dörk T.","Urol Oncol. 2009 Jul-Aug;27(4):373-6. doi: 10.1016/j.urolonc.2008.04.010. Epub 2008 Jul 14.","Meyer A","Urol Oncol","2009","2008/07/16","","","10.1016/j.urolonc.2008.04.010"
"19443295","Unsuspected prostate cancer after cystoprostatectomy: a comparison between two periods in taiwan","Li JR, Yang CR, Wang J, Ou YC, Ho HC, Cheng CL.","J Formos Med Assoc. 2009 May;108(5):409-13. doi: 10.1016/S0929-6646(09)60085-1.","Li JR","J Formos Med Assoc","2009","2009/05/16","","","10.1016/S0929-6646(09)60085-1"
"18342929","Delayed diagnosis of prostate cancer with neuroendocrine differentiation after laser TURP","Meeks JJ, Habermacher GM, Le B, Smith ND.","Urology. 2008 Oct;72(4):948.e11-2. doi: 10.1016/j.urology.2008.01.007. Epub 2008 Mar 17.","Meeks JJ","Urology","2008","2008/03/18","","","10.1016/j.urology.2008.01.007"
"26967329","Age Bias in Time From Diagnosis Comparisons of Prostate Cancer Treatment","Kendal WS.","Am J Clin Oncol. 2018 Apr;41(4):402-408. doi: 10.1097/COC.0000000000000284.","Kendal WS","Am J Clin Oncol","2018","2016/03/12","","","10.1097/COC.0000000000000284"
"24989419","Multiparametric 3D in vivo ultrasound vibroelastography imaging of prostate cancer: Preliminary results","Moradi M, Mahdavi SS, Nir G, Mohareri O, Koupparis A, Gagnon LO, Fazli L, Casey RG, Ischia J, Jones EC, Goldenberg SL, Salcudean SE.","Med Phys. 2014 Jul;41(7):073505. doi: 10.1118/1.4884226.","Moradi M","Med Phys","2014","2014/07/04","","","10.1118/1.4884226"
"18807706","Advances in prostate cancer treatment","Saca-Hazboun H.","ONS Connect. 2008 Sep;23(9):8-12.","Saca-Hazboun H","ONS Connect","2008","2008/09/24","","",""
"17593640","[Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?]","Kranjcević K, Marković BB.","Acta Med Croatica. 2007 Feb;61(1):45-8.","Kranjcević K","Acta Med Croatica","2007","2007/06/28","","",""
"25700132","Opportunities for targeted focal treatment in Japan","Kimura M, Muto S, Horie S.","Curr Opin Urol. 2015 May;25(3):225-9. doi: 10.1097/MOU.0000000000000163.","Kimura M","Curr Opin Urol","2015","2015/02/21","","","10.1097/MOU.0000000000000163"
"20060331","Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer","Payne H, Cornford P.","Urol Oncol. 2011 Nov-Dec;29(6):593-601. doi: 10.1016/j.urolonc.2009.11.003. Epub 2010 Jan 8.","Payne H","Urol Oncol","2011","2010/01/12","","","10.1016/j.urolonc.2009.11.003"
"8066393","[Natural history and prognostic factors of prostate cancer]","Cussenot O.","Rev Prat. 1994 Mar 1;44(5):580-5.","Cussenot O","Rev Prat","1994","1994/03/01","","",""
"30552940","Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies","Martin DT, Ghabili K, Levi A, Humphrey PA, Sprenkle PC.","Urology. 2019 Mar;125:64-72. doi: 10.1016/j.urology.2018.12.001. Epub 2018 Dec 12.","Martin DT","Urology","2019","2018/12/16","","","10.1016/j.urology.2018.12.001"
"12600424","Costs of prostate cancer, metastatic to the bone, in the Netherlands","Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA.","Eur Urol. 2003 Mar;43(3):226-32. doi: 10.1016/s0302-2838(03)00007-1.","Groot MT","Eur Urol","2003","2003/02/26","","","10.1016/s0302-2838(03)00007-1"
"17684809","The role of diet in breast and prostate cancer survival","Ferdowsian HR, Barnard ND.","Ethn Dis. 2007 Spring;17(2 Suppl 2):S2-18-22.","Ferdowsian HR","Ethn Dis","2007","2007/08/09","","",""
"23895794","Re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007.: beta-blockers and prostate cancer survival--interpretation of competing risks models","Bhaskaran K, Rachet B, Evans S, Smeeth L.","Eur Urol. 2013 Oct;64(4):e86-7. doi: 10.1016/j.eururo.2013.07.004. Epub 2013 Jul 12.","Bhaskaran K","Eur Urol","2013","2013/07/31","","","10.1016/j.eururo.2013.07.004"
"18307686","Localized prostate cancer: can we better define who is at risk of unfavourable outcome?","Joniau S, Van Poppel H.","BJU Int. 2008 Mar;101 Suppl 2:5-10. doi: 10.1111/j.1464-410X.2007.07488.x.","Joniau S","BJU Int","2008","2008/03/01","","","10.1111/j.1464-410X.2007.07488.x"
"16945521","Are men with low selenium levels at increased risk of prostate cancer?","Brinkman M, Reulen RC, Kellen E, Buntinx F, Zeegers MP.","Eur J Cancer. 2006 Oct;42(15):2463-71. doi: 10.1016/j.ejca.2006.02.027. Epub 2006 Sep 1.","Brinkman M","Eur J Cancer","2006","2006/09/02","","","10.1016/j.ejca.2006.02.027"
"17823907","Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy","Cheng L, Davidson DD, Lin H, Koch MO.","Cancer. 2007 Nov 1;110(9):1967-72. doi: 10.1002/cncr.23004.","Cheng L","Cancer","2007","2007/09/08","","","10.1002/cncr.23004"
"10917069","Prospects for vaccination in prostate cancer","Perry MJ, Hroulda D, Dalgleish AG.","Drugs Aging. 2000 May;16(5):321-7. doi: 10.2165/00002512-200016050-00001.","Perry MJ","Drugs Aging","2000","2000/08/05","","","10.2165/00002512-200016050-00001"
"16275675","The 18th International Symposium: Controversies in Prostate Cancer Diagnosis and Treatment","Pu YS, Fujimoto H, Kakizoe T, Myers R.","Jpn J Clin Oncol. 2005 Nov;35(11):680-9. doi: 10.1093/jjco/hyi180. Epub 2005 Nov 7.","Pu YS","Jpn J Clin Oncol","2005","2005/11/09","","","10.1093/jjco/hyi180"
"20696519","Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8","Hewavitharana AK.","Eur Urol. 2010 Oct;58(4):e39-40; author reply e41-2. doi: 10.1016/j.eururo.2010.07.031. Epub 2010 Aug 4.","Hewavitharana AK","Eur Urol","2010","2010/08/11","","","10.1016/j.eururo.2010.07.031"
"12599540","[Molecular diagnosis and gene therapy for prostate cancer]","Nasu Y, Kumon H.","Nihon Rinsho. 2002 Dec;60 Suppl 11:28-32.","Nasu Y","Nihon Rinsho","2002","2003/02/26","","",""
"19544535","Predictive modeling in prostate cancer. Conclusions and reflections","Denis LJ, Gospodarowicz MK.","Cancer. 2009 Jul 1;115(13 Suppl):3160-2. doi: 10.1002/cncr.24343.","Denis LJ","Cancer","2009","2009/06/23","","","10.1002/cncr.24343"
"17061756","Stress, coping, social support, and prostate cancer risk among older African American and Caucasian men","Coker AL, Sanderson M, Ellison GL, Fadden MK.","Ethn Dis. 2006 Autumn;16(4):978-87.","Coker AL","Ethn Dis","2006","2006/10/26","","",""
"23682480","[Castration in the treatment of locally advanced or metastatic prostate cancer]","Mongiat-Artus P.","Rev Prat. 2013 Apr;63(4):509-10.","Mongiat-Artus P","Rev Prat","2013","2013/05/21","","",""
"17311030","Gene therapy prolongs PSA doubling time in prostate cancer patients","Thompson TC, Rodriguez R.","Mol Ther. 2007 Mar;15(3):442-3. doi: 10.1038/sj.mt.6300085.","Thompson TC","Mol Ther","2007","2007/02/22","","","10.1038/sj.mt.6300085"
"19518000","Donald Gleason and the grading of prostate cancer","MacKenzie R.","J Insur Med. 2009;41(1):4-5.","MacKenzie R","J Insur Med","2009","2009/06/13","","",""
"23575802","Racial disparities in prostate cancer care: is adherence to National Comprehensive Cancer Network guidelines good enough for our patients?","Master VA, Moses KA.","Cancer. 2013 Jun 15;119(12):2209-11. doi: 10.1002/cncr.28006. Epub 2013 Apr 10.","Master VA","Cancer","2013","2013/04/12","","","10.1002/cncr.28006"
"7609353","[The quality of life of prostatic cancer patients]","Nishiyama T, Terunuma M.","Nihon Hinyokika Gakkai Zasshi. 1995 Jun;86(6):1117-22. doi: 10.5980/jpnjurol1989.86.1117.","Nishiyama T","Nihon Hinyokika Gakkai Zasshi","1995","1995/06/01","","","10.5980/jpnjurol1989.86.1117"
"9422451","Immediate radical prostatectomy for incidentally found prostate cancer after open prostatectomy for benign prostatic hyperplasia","Bauer JJ, Heidenberg HB.","Tech Urol. 1997 Fall;3(3):172-5.","Bauer JJ","Tech Urol","1997","1998/01/09","","",""
"21603625","Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population","Luk SU, Lee TK, Liu J, Lee DT, Chiu YT, Ma S, Ng IO, Wong YC, Chan FL, Ling MT.","PLoS One. 2011;6(5):e19804. doi: 10.1371/journal.pone.0019804. Epub 2011 May 16.","Luk SU","PLoS One","2011","2011/05/24","PMC3095629","","10.1371/journal.pone.0019804"
"21145797","Oxidative balance score and risk of prostate cancer: results from a case-cohort study","Agalliu I, Kirsh VA, Kreiger N, Soskolne CL, Rohan TE.","Cancer Epidemiol. 2011 Aug;35(4):353-61. doi: 10.1016/j.canep.2010.11.002. Epub 2010 Dec 9.","Agalliu I","Cancer Epidemiol","2011","2010/12/15","","","10.1016/j.canep.2010.11.002"
"10373672","The rising incidence of breast cancer in women and prostate cancer in men. Dietary influences: a possible preventive role for nature's sex hormone modifiers - the phytoestrogens (review)","Stephens FO.","Oncol Rep. 1999 Jul-Aug;6(4):865-70. doi: 10.3892/or.6.4.865.","Stephens FO","Oncol Rep","1999","1999/06/22","","","10.3892/or.6.4.865"
"30396958","Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer","Heath EI, Heilbrun LK, Smith D, Schopperle WM, Ju Y, Bolton S, Ahmed Q, Sakr WA.","Anticancer Res. 2018 Nov;38(11):6361-6366. doi: 10.21873/anticanres.12994.","Heath EI","Anticancer Res","2018","2018/11/07","PMC6844084","NIHMS1057845","10.21873/anticanres.12994"
"12778015","Prostate cancer update","Rosenberg J, Small EJ.","Curr Opin Oncol. 2003 May;15(3):217-21. doi: 10.1097/00001622-200305000-00007.","Rosenberg J","Curr Opin Oncol","2003","2003/06/05","","","10.1097/00001622-200305000-00007"
"27344767","[Advancement of surgical treatment in prostate cancer]","Harabayashi T, Takada N, Minami K, Nagamori S.","Nihon Rinsho. 2016 May 20;74 Suppl 3:416-20.","Harabayashi T","Nihon Rinsho","2016","2016/06/28","","",""
"26718456","Prostate cancer: SLCO2B1 variants correlate with castration resistance","Sidaway P.","Nat Rev Urol. 2016 Feb;13(2):65. doi: 10.1038/nrurol.2015.306. Epub 2015 Dec 31.","Sidaway P","Nat Rev Urol","2016","2016/01/01","","","10.1038/nrurol.2015.306"
"15040877","Prostate-specific antigen doubling time predicts disease progression and survival","Lee D.","Clin Prostate Cancer. 2003 Mar;1(4):208-11. doi: 10.1016/s1540-0352(11)70003-8.","Lee D","Clin Prostate Cancer","2003","2004/03/26","","","10.1016/s1540-0352(11)70003-8"
"24120782","Re: Effect of age, tumor risk, and comorbidity on competing risks for survival in a u.s. Population-based cohort of men with prostate cancer","Penson DF.","J Urol. 2013 Nov;190(5):1766-7. doi: 10.1016/j.juro.2013.07.079. Epub 2013 Aug 2.","Penson DF","J Urol","2013","2013/10/15","","","10.1016/j.juro.2013.07.079"
"15148767","[Chronological changes of incidence rates, clinical stages and pathological differentiation of prostate cancer in Gunma Prefecture, Japan]","Nakata S, Ohtake N, Kubota Y, Ito K, Suzuki K, Yamanaka H; Gunma University Urological Oncology Study Group.","Hinyokika Kiyo. 2004 Mar;50(3):165-70.","Nakata S","Hinyokika Kiyo","2004","2004/05/20","","",""
"22229025","Prostate cancer in Germany among migrants from the Former Soviet Union","Winkler V, Holleczek B, Stegmaier C, Becher H.","Glob Health Action. 2012;5:9135. doi: 10.3402/gha.v5i0.9135. Epub 2012 Jan 2.","Winkler V","Glob Health Action","2012","2012/01/10","PMC3252511","","10.3402/gha.v5i0.9135"
"8608840","Update on urology--prostate cancer. Screening for prostate cancer: an European view","de Silva FC.","Eur J Surg Oncol. 1996 Apr;22(2):189-91, 196. doi: 10.1016/s0748-7983(96)90879-3.","de Silva FC","Eur J Surg Oncol","1996","1996/04/01","","","10.1016/s0748-7983(96)90879-3"
"9831217","Urinary symptoms as a predictor for participation in prostate cancer screening among African American men","Weinrich SP, Weinrich M, Mettlin C, Reynolds WA Jr, Wofford JE.","Prostate. 1998 Dec 1;37(4):215-22. doi: 10.1002/(sici)1097-0045(19981201)37:4<215::aid-pros2>3.0.co;2-s.","Weinrich SP","Prostate","1998","1998/11/27","","","10.1002/(sici)1097-0045(19981201)37:4<215::aid-pros2>3.0.co;2-s"
"19417179","A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment","Sanda MG, Kaplan ID.","JAMA. 2009 May 27;301(20):2141-51. doi: 10.1001/jama.2009.674. Epub 2009 May 5.","Sanda MG","JAMA","2009","2009/05/07","","","10.1001/jama.2009.674"
"17013914","Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study","Mols F, van de Poll-Franse LV, Vingerhoets AJ, Hendrikx A, Aaronson NK, Houterman S, Coebergh JW, Essink-Bot ML.","Cancer. 2006 Nov 1;107(9):2186-96. doi: 10.1002/cncr.22231.","Mols F","Cancer","2006","2006/10/03","","","10.1002/cncr.22231"
"20142051","[First line indications for hormonal therapy in prostate cancer]","Boccon-Gibod L, Richaud P, Coloby P, Coulange C, Culine S, Davin JL, Soulié M, Zerbib M.","Prog Urol. 2010 Feb;20(2):109-15. doi: 10.1016/j.purol.2009.11.001. Epub 2009 Dec 22.","Boccon-Gibod L","Prog Urol","2010","2010/02/10","","","10.1016/j.purol.2009.11.001"
"31721301","Crosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer: MDSCs and immune system in Prostate cancer","Sanaei MJ, Salimzadeh L, Bagheri N.","J Leukoc Biol. 2020 Jan;107(1):43-56. doi: 10.1002/JLB.4RU0819-150RR. Epub 2019 Nov 13.","Sanaei MJ","J Leukoc Biol","2020","2019/11/14","","","10.1002/JLB.4RU0819-150RR"
"30281887","DNA repair defects in prostate cancer: impact for screening, prognostication and treatment","Warner EW, Yip SM, Chi KN, Wyatt AW.","BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26.","Warner EW","BJU Int","2019","2018/10/04","","","10.1111/bju.14576"
"12496988","Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer","Rothermund CA, Kondrikov D, Lin MF, Vishwanatha JK.","Prostate Cancer Prostatic Dis. 2002;5(3):236-45. doi: 10.1038/sj.pcan.4500582.","Rothermund CA","Prostate Cancer Prostatic Dis","2002","2002/12/24","","","10.1038/sj.pcan.4500582"
"11405125","[Brachytherapy of local prostatic carcinoma]","Deger S, Böhmer D, Roigas J, Türk I, Budach V, Loening SA.","Urologe A. 2001 May;40(3):181-4. doi: 10.1007/s001200050459.","Deger S","Urologe A","2001","2001/06/19","","","10.1007/s001200050459"
"11692794","[Radical prostatectomy or radiotherapy? A qualitative structured review]","Campoy Martínez P, Díaz Alfaro M, Barrero Candau R, Morales López A, Grau Fibla G, Pascual del Pobil JL.","Actas Urol Esp. 2001 Sep;25(8):535-43. doi: 10.1016/s0210-4806(01)72668-x.","Campoy Martínez P","Actas Urol Esp","2001","2001/11/06","","","10.1016/s0210-4806(01)72668-x"
"1711588","The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia","Coplen DE, Andriole GL, Yuan JJ, Catalona WJ.","J Urol. 1991 Jul;146(1):75-7. doi: 10.1016/s0022-5347(17)37717-0.","Coplen DE","J Urol","1991","1991/07/01","","","10.1016/s0022-5347(17)37717-0"
"23154199","Educating men about prostate cancer in the workplace","Ilic D.","Am J Mens Health. 2013 Jul;7(4):285-94. doi: 10.1177/1557988312467050. Epub 2012 Nov 14.","Ilic D","Am J Mens Health","2013","2012/11/17","","","10.1177/1557988312467050"
"31342822","Long non-coding RNA NORAD induces cell proliferation and migration in prostate cancer","Zhang H, Guo H.","J Int Med Res. 2019 Aug;47(8):3898-3904. doi: 10.1177/0300060519862076. Epub 2019 Jul 25.","Zhang H","J Int Med Res","2019","2019/07/26","PMC6726771","","10.1177/0300060519862076"
"26070344","Optimal sequence of bone target drugs in metastatic prostatic cancer","Gernone A, Bordonaro S, Tralongo P.","Expert Rev Anticancer Ther. 2015;15(8):923-9. doi: 10.1586/14737140.2015.1054813. Epub 2015 Jun 12.","Gernone A","Expert Rev Anticancer Ther","2015","2015/06/14","","","10.1586/14737140.2015.1054813"
"23449496","The economics of active surveillance for prostate cancer","Dall'Era MA.","Curr Opin Urol. 2013 May;23(3):278-82. doi: 10.1097/MOU.0b013e32835f4b6b.","Dall'Era MA","Curr Opin Urol","2013","2013/03/02","","","10.1097/MOU.0b013e32835f4b6b"
"30031463","Technique of Multiparametric MR Imaging of the Prostate","Purysko AS, Rosenkrantz AB.","Urol Clin North Am. 2018 Aug;45(3):427-438. doi: 10.1016/j.ucl.2018.03.008.","Purysko AS","Urol Clin North Am","2018","2018/07/23","","","10.1016/j.ucl.2018.03.008"
"17991546","The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens","Spajic B, Eupic H, Tomas D, Stimac G, Kruslin B, Kraus O.","Urology. 2007 Oct;70(4):734-7. doi: 10.1016/j.urology.2007.06.1092.","Spajic B","Urology","2007","2007/11/10","","","10.1016/j.urology.2007.06.1092"
"9718529","Screening digital rectal examination and prostate cancer mortality: a case-control study","Richert-Boe KE, Humphrey LL, Glass AG, Weiss NS.","J Med Screen. 1998;5(2):99-103. doi: 10.1136/jms.5.2.99.","Richert-Boe KE","J Med Screen","1998","1998/08/27","","","10.1136/jms.5.2.99"
"18957714","The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach","Bloch BN, Lenkinski RE, Rofsky NM.","Cancer Biomark. 2008;4(4-5):251-62. doi: 10.3233/cbm-2008-44-507.","Bloch BN","Cancer Biomark","2008","2008/10/30","PMC2739836","NIHMS124629","10.3233/cbm-2008-44-507"
"9308936","Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV","D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN.","Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):335-40. doi: 10.1016/s0360-3016(97)00320-9.","D'Amico AV","Int J Radiat Oncol Biol Phys","1997","1997/10/06","","","10.1016/s0360-3016(97)00320-9"
"16673587","Clinical correlation, ecographic and levels of prostate specific antigen in patients with prostate cancer","Salirrosas SV, Armborgo J, Mostacero M.","Acta Chir Iugosl. 2005;52(4):13-7. doi: 10.2298/aci0504013s.","Salirrosas SV","Acta Chir Iugosl","2005","2006/05/06","","","10.2298/aci0504013s"
"24526735","Aberrant presentation of HPA-reactive carbohydrates implies Selectin-independent metastasis formation in human prostate cancer","Lange T, Kupfernagel M, Wicklein D, Gebauer F, Maar H, Brügge K, Müller I, Simon R, Schlomm T, Sauter G, Schumacher U.","Clin Cancer Res. 2014 Apr 1;20(7):1791-802. doi: 10.1158/1078-0432.CCR-13-2308. Epub 2014 Feb 13.","Lange T","Clin Cancer Res","2014","2014/02/15","","","10.1158/1078-0432.CCR-13-2308"
"28233228","MR/US Fusion Technology: What Makes It Tick?","Vourganti S, Starkweather N, Wojtowycz A.","Curr Urol Rep. 2017 Mar;18(3):20. doi: 10.1007/s11934-017-0671-1.","Vourganti S","Curr Urol Rep","2017","2017/02/25","","","10.1007/s11934-017-0671-1"
"26801762","Development of South Australian-Victorian Prostate Cancer Health Outcomes Research Dataset","Ruseckaite R, Beckmann K, O'Callaghan M, Roder D, Moretti K, Zalcberg J, Millar J, Evans S.","BMC Res Notes. 2016 Jan 22;9:37. doi: 10.1186/s13104-016-1855-3.","Ruseckaite R","BMC Res Notes","2016","2016/01/24","PMC4724115","","10.1186/s13104-016-1855-3"
"21852113","Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer","Berglund A, Garmo H, Robinson D, Tishelman C, Holmberg L, Bratt O, Adolfsson J, Stattin P, Lambe M.","Eur J Cancer. 2012 Jan;48(1):75-84. doi: 10.1016/j.ejca.2011.07.009. Epub 2011 Aug 16.","Berglund A","Eur J Cancer","2012","2011/08/20","","","10.1016/j.ejca.2011.07.009"
"9380916","[Long-term survival in patients with localized prostate cancer]","Asselain B.","Rev Epidemiol Sante Publique. 1997 Sep;45(4):347-8.","Asselain B","Rev Epidemiol Sante Publique","1997","1998/02/12","","",""
"1856933","Transrectal ultrasonography in stage A prostate cancer: detection of residual tumor after transurethral resection of prostate","Egawa S, Greene DR, Flanagan WF, Wheeler TM, Scardino PT.","J Urol. 1991 Aug;146(2):366-71. doi: 10.1016/s0022-5347(17)37796-0.","Egawa S","J Urol","1991","1991/08/01","","","10.1016/s0022-5347(17)37796-0"
"17971600","Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review","Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA.","J Clin Oncol. 2007 Nov 1;25(31):4998-5008. doi: 10.1200/JCO.2007.11.1559.","Antonarakis ES","J Clin Oncol","2007","2007/11/01","PMC4133788","NIHMS401588","10.1200/JCO.2007.11.1559"
"21823352","[Androgen receptor mutation and progression of prostate cancer]","Ma JG, Li WP, Jiang YQ.","Zhonghua Nan Ke Xue. 2011 Jul;17(7):649-54.","Ma JG","Zhonghua Nan Ke Xue","2011","2011/08/10","","",""
"20451979","Burden of prostate cancer in southwestern Nigeria","Badmus TA, Adesunkanmi AR, Yusuf BM, Oseni GO, Eziyi AK, Bakare TI, Adetiloye JA, Badmus SA.","Urology. 2010 Aug;76(2):412-6. doi: 10.1016/j.urology.2010.03.020. Epub 2010 May 7.","Badmus TA","Urology","2010","2010/05/11","","","10.1016/j.urology.2010.03.020"
"19888980","The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer","Eisenberg ML, Cowan JE, Carroll PR, Shinohara K.","BJU Int. 2010 May;105(9):1237-41. doi: 10.1111/j.1464-410X.2009.08958.x. Epub 2009 Nov 3.","Eisenberg ML","BJU Int","2010","2009/11/06","","","10.1111/j.1464-410X.2009.08958.x"
"27706949","Age-related racial disparities in prostate cancer patients: A systematic review","He T, Mullins CD.","Ethn Health. 2017 Apr;22(2):184-195. doi: 10.1080/13557858.2016.1235682. Epub 2016 Oct 5.","He T","Ethn Health","2017","2016/10/07","PMC5573592","NIHMS882619","10.1080/13557858.2016.1235682"
"20037200","Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers","Talesa VN, Antognelli C, Del Buono C, Stracci F, Serva MR, Cottini E, Mearini E.","Cancer Biomark. 2009;5(6):241-51. doi: 10.3233/CBM-2009-0109.","Talesa VN","Cancer Biomark","2009","2009/12/29","","","10.3233/CBM-2009-0109"
"23775699","Searching for prostate cancer stem cells: markers and methods","Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD.","Stem Cell Rev Rep. 2013 Oct;9(5):721-30. doi: 10.1007/s12015-013-9453-4.","Sharpe B","Stem Cell Rev Rep","2013","2013/06/19","","","10.1007/s12015-013-9453-4"
"22189219","[Controversy over treatment options in clinical T3 prostate cancer]","Nishimura K, Yamamoto Y, Nakayama M, Kakimoto K.","Gan To Kagaku Ryoho. 2011 Dec;38(13):2548-52.","Nishimura K","Gan To Kagaku Ryoho","2011","2011/12/23","","",""
"7474244","Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system","Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B.","JAMA. 1995 Nov 22-29;274(20):1599-605.","Optenberg SA","JAMA","1995","1995/11/22","","",""
"16009085","Screening for prostate cancer: who and how often?","Schwartz K, Deschere B, Xu J.","J Fam Pract. 2005 Jul;54(7):586-96.","Schwartz K","J Fam Pract","2005","2005/07/13","","",""
"12131340","Re: Plasma selenium level before diagnosis and the risk of prostate cancer development","Schwartz DT.","J Urol. 2002 Aug;168(2):662; author reply 662.","Schwartz DT","J Urol","2002","2002/07/20","","",""
"11250986","Prostate cancer: the price of early detection","Ganz PA, Litwin MS.","J Clin Oncol. 2001 Mar 15;19(6):1587-8. doi: 10.1200/JCO.2001.19.6.1587.","Ganz PA","J Clin Oncol","2001","2001/03/17","","","10.1200/JCO.2001.19.6.1587"
"11464109","Comparison of Gleason scores from sextant prostate biopsies and radical prostatectomy specimens","Altay B, Kefi A, Nazli O, Killi R, Semerci B, Akar I.","Urol Int. 2001;67(1):14-8. doi: 10.1159/000050937.","Altay B","Urol Int","2001","2001/07/21","","","10.1159/000050937"
"23759328","Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis","Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL.","Eur Urol. 2014 Apr;65(4):693-700. doi: 10.1016/j.eururo.2013.05.023. Epub 2013 May 21.","Shao YH","Eur Urol","2014","2013/06/14","PMC3825778","NIHMS490707","10.1016/j.eururo.2013.05.023"
"12141790","An investigation into the use of palliative care services by patients with prostate cancer","Green JS.","Am J Hosp Palliat Care. 2002 Jul-Aug;19(4):259-62. doi: 10.1177/104990910201900410.","Green JS","Am J Hosp Palliat Care","2002","2002/07/27","","","10.1177/104990910201900410"
"17189645","Prostate cancer chemoprevention: current status and future prospects","Gupta S.","Toxicol Appl Pharmacol. 2007 Nov 1;224(3):369-76. doi: 10.1016/j.taap.2006.11.008. Epub 2006 Nov 15.","Gupta S","Toxicol Appl Pharmacol","2007","2006/12/27","","","10.1016/j.taap.2006.11.008"
"23703839","Role of high-field MR in studies of localized prostate cancer","Lagemaat MW, Scheenen TW.","NMR Biomed. 2014 Jan;27(1):67-79. doi: 10.1002/nbm.2967. Epub 2013 May 24.","Lagemaat MW","NMR Biomed","2014","2013/05/25","","","10.1002/nbm.2967"
"7538187","PSA-detected prostate cancer: contrasts with palpable disease","Matthews GJ, Fracchia JA.","J Surg Oncol. 1995 May;59(1):28-30. doi: 10.1002/jso.2930590108.","Matthews GJ","J Surg Oncol","1995","1995/05/01","","","10.1002/jso.2930590108"
"21540324","Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial","Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.","Am J Epidemiol. 2011 Jun 15;173(12):1419-28. doi: 10.1093/aje/kwq493. Epub 2011 May 3.","Schenk JM","Am J Epidemiol","2011","2011/05/05","PMC3276227","","10.1093/aje/kwq493"
"21405964","Progensa™ PCA3 test for prostate cancer","Durand X, Moutereau S, Xylinas E, de la Taille A.","Expert Rev Mol Diagn. 2011 Mar;11(2):137-44. doi: 10.1586/erm.10.122.","Durand X","Expert Rev Mol Diagn","2011","2011/03/17","","","10.1586/erm.10.122"
"1743911","Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial","Rifkin M.","Invest Radiol. 1991 Nov;26(11):1024-5.","Rifkin M","Invest Radiol","1991","1991/11/01","","",""
"24321301","Prostate cancer in deceased organ donors: a review","Doerfler A, Tillou X, Le Gal S, Desmonts A, Orczyk C, Bensadoun H.","Transplant Rev (Orlando). 2014 Jan;28(1):1-5. doi: 10.1016/j.trre.2013.10.003. Epub 2013 Oct 24.","Doerfler A","Transplant Rev (Orlando)","2014","2013/12/11","","","10.1016/j.trre.2013.10.003"
"20941869","Immunotherapy: a new option for advanced prostate cancer","","Harv Mens Health Watch. 2010 Sep;15(2):1-2.","","Harv Mens Health Watch","2010","2010/10/15","","",""
"16831137","Radiommunotherapy and prostate cancer: a promising new therapy in the management of metastatic disease","Khan A, Shergill I, Arya M, Barua JM, Kaisary AV.","BJU Int. 2006 Jul;98(1):8-9. doi: 10.1111/j.1464-410X.2006.06245.x.","Khan A","BJU Int","2006","2006/07/13","","","10.1111/j.1464-410X.2006.06245.x"
"12163131","Transition to androgen-independence in prostate cancer","Navarro D, Luzardo OP, Fernández L, Chesa N, Díaz-Chico BN.","J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201. doi: 10.1016/s0960-0760(02)00064-x.","Navarro D","J Steroid Biochem Mol Biol","2002","2002/08/07","","","10.1016/s0960-0760(02)00064-x"
"23066423","Analysis of Gleason grade and scores in 90 Nigerian Africans with prostate cancer during the period 1994 to 2004","Ugare UG, Bassey IE, Jibrin PG, Ekanem IA.","Afr Health Sci. 2012 Mar;12(1):69-73.","Ugare UG","Afr Health Sci","2012","2012/10/16","PMC3462511","",""
"23167323","Association between trace element and heavy metal levels in hair and nail with prostate cancer","Karimi G, Shahar S, Homayouni N, Rajikan R, Abu Bakar NF, Othman MS.","Asian Pac J Cancer Prev. 2012;13(9):4249-53. doi: 10.7314/apjcp.2012.13.9.4249.","Karimi G","Asian Pac J Cancer Prev","2012","2012/11/22","","","10.7314/apjcp.2012.13.9.4249"
"7519944","Public awareness of prostate cancer and the prostate-specific antigen test","Mainous AG 3rd, Hagen MD.","Cancer Pract. 1994 May-Jun;2(3):217-21.","Mainous AG 3rd","Cancer Pract","1994","1994/05/01","","",""
"21278045","To screen or not to screen: ongoing debate in the early detection of prostate cancer","Marroquin JM.","Clin J Oncol Nurs. 2011 Feb;15(1):97-8. doi: 10.1188/11.CJON.97-98.","Marroquin JM","Clin J Oncol Nurs","2011","2011/02/01","","","10.1188/11.CJON.97-98"
"26350955","In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance","Porpiglia F, Cantiello F, De Luca S, Manfredi M, Veltri A, Russo F, Sottile A, Damiano R.","BJU Int. 2016 Oct;118(4):527-34. doi: 10.1111/bju.13318. Epub 2015 Oct 12.","Porpiglia F","BJU Int","2016","2015/09/10","","","10.1111/bju.13318"
"25480118","Immunotherapy in prostate cancer: review of the current evidence","Fernández-García EM, Vera-Badillo FE, Perez-Valderrama B, Matos-Pita AS, Duran I.","Clin Transl Oncol. 2015 May;17(5):339-57. doi: 10.1007/s12094-014-1259-6. Epub 2014 Dec 6.","Fernández-García EM","Clin Transl Oncol","2015","2014/12/07","","","10.1007/s12094-014-1259-6"
"22459536","Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer","Delacruz A.","Clin J Oncol Nurs. 2012 Apr;16(2):E44-7. doi: 10.1188/12.CJON.E44-E47.","Delacruz A","Clin J Oncol Nurs","2012","2012/03/31","","","10.1188/12.CJON.E44-E47"
"25367321","Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers?","Su MZ, Kneebone AB, Woo HH.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1265-70. doi: 10.1586/14737140.2014.972381.","Su MZ","Expert Rev Anticancer Ther","2014","2014/11/05","","","10.1586/14737140.2014.972381"
"1565904","Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer","Abdel-Nabi H, Wright GL, Gulfo JV, Petrylak DP, Neal CE, Texter JE, Begun FP, Tyson I, Heal A, Mitchell E, et al.","Semin Urol. 1992 Feb;10(1):45-54.","Abdel-Nabi H","Semin Urol","1992","1992/02/01","","",""
"24477411","Immunotherapy for prostate cancer: recent developments and future challenges","Schweizer MT, Drake CG.","Cancer Metastasis Rev. 2014 Sep;33(2-3):641-55. doi: 10.1007/s10555-013-9479-8.","Schweizer MT","Cancer Metastasis Rev","2014","2014/01/31","PMC4116461","NIHMS561499","10.1007/s10555-013-9479-8"
"16275680","Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer","Hashine K, Numata K, Azuma K, Sumiyoshi Y, Kataoka M.","Jpn J Clin Oncol. 2005 Nov;35(11):655-9. doi: 10.1093/jjco/hyi174. Epub 2005 Nov 7.","Hashine K","Jpn J Clin Oncol","2005","2005/11/09","","","10.1093/jjco/hyi174"
"19341365","Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives","Ito K.","Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1.","Ito K","Int J Urol","2009","2009/04/04","","","10.1111/j.1442-2042.2009.02293.x"
"23050532","Radical prostatectomy versus observation for prostate cancer","Vickers AJ, Eastham JA, Scardino PT.","N Engl J Med. 2012 Oct 11;367(15):1467-8; author reply 1468-9. doi: 10.1056/NEJMc1209800.","Vickers AJ","N Engl J Med","2012","2012/10/12","","","10.1056/NEJMc1209800"
"18835203","Prostate cancer in dogs and men: a unique opportunity to study the disease","Argyle DJ.","Vet J. 2009 May;180(2):137-8. doi: 10.1016/j.tvjl.2008.08.012. Epub 2008 Oct 2.","Argyle DJ","Vet J","2009","2008/10/07","","","10.1016/j.tvjl.2008.08.012"
"21178872","[Prostate cancer: the importance of tumor mapping]","Rouvière O.","J Radiol. 2010 Nov;91(11 Pt 1):1101-2. doi: 10.1016/s0221-0363(10)70154-2.","Rouvière O","J Radiol","2010","2010/12/24","","","10.1016/s0221-0363(10)70154-2"
"21357663","New options for the management of castration-resistant prostate cancer: a case perspective","Goetz D.","J Natl Compr Canc Netw. 2011 Feb;9 Suppl 3:S13-23; quiz S24. doi: 10.6004/jnccn.2011.0128.","Goetz D","J Natl Compr Canc Netw","2011","2011/03/02","","","10.6004/jnccn.2011.0128"
"24211598","Prostate cancer biomarker profiles in urinary sediments and exosomes","Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA.","J Urol. 2014 Apr;191(4):1132-8. doi: 10.1016/j.juro.2013.11.001. Epub 2013 Nov 7.","Dijkstra S","J Urol","2014","2013/11/12","","","10.1016/j.juro.2013.11.001"
"28094199","Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study","Klemann N, Røder MA, Helgstrand JT, Brasso K, Toft BG, Vainer B, Iversen P.","Lancet Oncol. 2017 Feb;18(2):221-229. doi: 10.1016/S1470-2045(17)30025-6. Epub 2017 Jan 14.","Klemann N","Lancet Oncol","2017","2017/01/18","","","10.1016/S1470-2045(17)30025-6"
"27898099","Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease","Reichard CA, Klein EA.","Nat Rev Urol. 2017 Jan;14(1):59-64. doi: 10.1038/nrurol.2016.240. Epub 2016 Nov 29.","Reichard CA","Nat Rev Urol","2017","2016/11/30","","","10.1038/nrurol.2016.240"
"20497843","Prostate cancer in the older man: conflict between tumor biology and medical advancement","Cummings JM.","Clin Geriatr Med. 2010 May;26(2):241-7. doi: 10.1016/j.cger.2010.02.004.","Cummings JM","Clin Geriatr Med","2010","2010/05/26","","","10.1016/j.cger.2010.02.004"
"28747520","Impact of (68)Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management","Afaq A, Alahmed S, Chen SH, Lengana T, Haroon A, Payne H, Ahmed H, Punwani S, Sathekge M, Bomanji J.","J Nucl Med. 2018 Jan;59(1):89-92. doi: 10.2967/jnumed.117.192625. Epub 2017 Jul 26.","Afaq A","J Nucl Med","2018","2017/07/28","","","10.2967/jnumed.117.192625"
"21721191","Aggressive prostate cancer: high blood levels of omega-3s doubled the risk, but high levels of trans-fatty acids cut risk in half","","Oncology (Williston Park). 2011 May;25(6):544, 546.","","Oncology (Williston Park)","2011","2011/07/02","","",""
"10584601","Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness","Burack RC, Wood DP Jr.","Med Clin North Am. 1999 Nov;83(6):1423-42, vi. doi: 10.1016/s0025-7125(05)70173-5.","Burack RC","Med Clin North Am","1999","1999/12/10","","","10.1016/s0025-7125(05)70173-5"
"24612460","Stratification of patients with intermediate-risk prostate cancer","Jung JW, Lee JK, Hong SK, Byun SS, Lee SE.","BJU Int. 2015 Jun;115(6):907-12. doi: 10.1111/bju.12703. Epub 2015 Mar 27.","Jung JW","BJU Int","2015","2014/03/12","","","10.1111/bju.12703"
"18455088","[Economic and political aspects of prostate cancer prevention]","Durand-Zaleski I.","Prog Urol. 2008 Apr;18 Suppl 3:S66-8. doi: 10.1016/S1166-7087(08)70518-9.","Durand-Zaleski I","Prog Urol","2008","2008/09/26","","","10.1016/S1166-7087(08)70518-9"
"17120384","Perceived risk and worry about prostate cancer: a proposed conceptual model","Schnur JB, DiLorenzo TA, Montgomery GH, Erblich J, Winkel G, Hall SJ, Bovbjerg DH.","Behav Med. 2006 Fall;32(3):89-96. doi: 10.3200/BMED.32.3.89-96.","Schnur JB","Behav Med","2006","2006/11/24","PMC2258456","NIHMS39110","10.3200/BMED.32.3.89-96"
"16904052","Active surveillance versus radical treatment for favorable-risk localized prostate cancer","Klotz L.","Curr Treat Options Oncol. 2006 Sep;7(5):355-62. doi: 10.1007/s11864-006-0003-z.","Klotz L","Curr Treat Options Oncol","2006","2006/08/15","","","10.1007/s11864-006-0003-z"
"27454454","The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia","Zargar H, van den Bergh R, Moon D, Lawrentschuk N, Costello A, Murphy D.","BJU Int. 2017 Jan;119(1):110-115. doi: 10.1111/bju.13602. Epub 2016 Aug 22.","Zargar H","BJU Int","2017","2016/07/26","","","10.1111/bju.13602"
"16429675","[Re: ""Current role of chemotherapy in the treatment of hormone-resistant metastatic prostate cancer"" by Xavier Breton, Eric Lechevallier, Christian Coulange, Prog. Urol., 2005, 15, 398-404]","Berdah JF.","Prog Urol. 2005 Dec;15(6):1160.","Berdah JF","Prog Urol","2005","2006/01/25","","",""
"25108922","When is it time to stop being checked for prostate cancer? The answer depends on your current health and your level of concern about cancer","","Harv Mens Health Watch. 2014 Apr;18(9):6.","","Harv Mens Health Watch","2014","2014/08/12","","",""
"8853495","Does early detection of prostate cancer offer more good than harm?","Feightner JW.","Can J Oncol. 1994 Nov;4 Suppl 1:74-5.","Feightner JW","Can J Oncol","1994","1994/11/01","","",""
"10221268","Role of radical prostatectomy in patients with prostate cancer of high Gleason score","Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon D, Wood DP Jr, Pontes JE.","Prostate. 1999 Apr 1;39(1):60-6. doi: 10.1002/(sici)1097-0045(19990401)39:1<60::aid-pros10>3.0.co;2-u.","Tefilli MV","Prostate","1999","1999/04/30","","","10.1002/(sici)1097-0045(19990401)39:1<60::aid-pros10>3.0.co;2-u"
"15459209","Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group","Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, de Reijke TM, Fossà SD.","J Clin Oncol. 2004 Oct 1;22(19):3877-85. doi: 10.1200/JCO.2004.07.089.","Collette L","J Clin Oncol","2004","2004/10/02","","","10.1200/JCO.2004.07.089"
"20616796","Risk factors: increased risk of suicide after prostate cancer diagnosis","van Leeuwen PJ, Schröder FH.","Nat Rev Urol. 2010 Jul;7(7):369-70. doi: 10.1038/nrurol.2010.83.","van Leeuwen PJ","Nat Rev Urol","2010","2010/07/10","","","10.1038/nrurol.2010.83"
"23337760","Bone-targeting radiopharmaceuticals including radium-223","Brady D, Parker CC, O'Sullivan JM.","Cancer J. 2013 Jan-Feb;19(1):71-8. doi: 10.1097/PPO.0b013e318282479b.","Brady D","Cancer J","2013","2013/01/23","","","10.1097/PPO.0b013e318282479b"
"20836318","Knowledge of prostate cancer screening among native African urban population in Nigeria","Ajape AA, Babata A, Abiola OO.","Nig Q J Hosp Med. 2009 Jul-Sep;19(3):145-7. doi: 10.4314/nqjhm.v19i3.54494.","Ajape AA","Nig Q J Hosp Med","2009","2010/09/15","","","10.4314/nqjhm.v19i3.54494"
"14607375","When to diagnose and how to treat prostate cancer in the ""not too fit"" elderly","Dahm P, Silverstein AD, Weizer AZ, Crisci A, Vieweg J, Paulson DF.","Crit Rev Oncol Hematol. 2003 Nov;48(2):123-31. doi: 10.1016/j.critrevonc.2003.04.003.","Dahm P","Crit Rev Oncol Hematol","2003","2003/11/11","","","10.1016/j.critrevonc.2003.04.003"
"9719936","[Clinical study on prostate cancer initially presenting with disseminated intravascular coagulation syndrome]","Ohtake N, Kurita S, Fukabori Y, Imai K, Yamanaka H, Nakata S, Sato J, Kurihara J, Mashimo M, Sekihara T, Saruki K, Kawashima K, Takahashi H, Tsuchiya K, Okabe K, Jimbo S, Kurita M.","Hinyokika Kiyo. 1998 Jun;44(6):387-90.","Ohtake N","Hinyokika Kiyo","1998","1998/08/28","","",""
"11007245","Solitary pelvic nodule: diagnosis of metastatic prostate cancer by endoscopic ultrasound-guided, fine-needle aspiration","Woodward TA, Menke DM, Buskirk SJ.","Am J Gastroenterol. 2000 Sep;95(9):2372-3. doi: 10.1111/j.1572-0241.2000.02335.x.","Woodward TA","Am J Gastroenterol","2000","2000/09/28","","","10.1111/j.1572-0241.2000.02335.x"
"24821214","Management of low risk prostate cancer-active surveillance and focal therapy","Klotz L, Emberton M.","Nat Rev Clin Oncol. 2014 Jun;11(6):324-34. doi: 10.1038/nrclinonc.2014.73. Epub 2014 May 13.","Klotz L","Nat Rev Clin Oncol","2014","2014/05/14","","","10.1038/nrclinonc.2014.73"
"14688472","In vivo visualization of metastatic prostate cancer","Hensley H, Pollack A.","Cancer Biol Ther. 2003 Nov-Dec;2(6):661-2.","Hensley H","Cancer Biol Ther","2003","2003/12/23","","",""
"28552709","Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation","Feldman AS, Meyer CP, Sanchez A, Krasnova A, Reznor G, Menon M, Kibel AS, Choueiri TK, Lipsitz SR, Sun M, Trinh QD.","J Urol. 2017 Nov;198(5):1061-1068. doi: 10.1016/j.juro.2017.05.073. Epub 2017 May 26.","Feldman AS","J Urol","2017","2017/05/30","","","10.1016/j.juro.2017.05.073"
"30646676","Prostate cancer surgery: a voyage through time","Pansadoro V, Brassetti A.","Minerva Chir. 2019 Feb;74(1):26-27. doi: 10.23736/S0026-4733.18.07927-0.","Pansadoro V","Minerva Chir","2019","2019/01/17","","","10.23736/S0026-4733.18.07927-0"
"10903068","Transforming growth factor-beta1 and prostate cancer","Wikström P, Bergh A, Damber JE.","Scand J Urol Nephrol. 2000 Apr;34(2):85-94. doi: 10.1080/003655900750016689.","Wikström P","Scand J Urol Nephrol","2000","2000/07/21","","","10.1080/003655900750016689"
"25367322","Hypofractioned radiotherapy in prostate cancer: is it the next step?","Moraes FY, Siqueira GM, Abreu CE, da Silva JL, Gadia R.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1271-6. doi: 10.1586/14737140.2014.972380.","Moraes FY","Expert Rev Anticancer Ther","2014","2014/11/05","","","10.1586/14737140.2014.972380"
"9101208","Influence of urological morbidity on quality of life in patients with prostate cancer","Fosså SD, Woehre H, Kurth KH, Hetherington J, Bakke H, Rustad DA, Skånvik R.","Eur Urol. 1997;31 Suppl 3:3-8. doi: 10.1159/000474553.","Fosså SD","Eur Urol","1997","1997/01/01","","","10.1159/000474553"
"25933275","Prostate cancer screening in Europe","Haines I, Ablin RJ, Miklos GL.","Lancet. 2015 Apr 18;385(9977):1506. doi: 10.1016/S0140-6736(15)60747-4.","Haines I","Lancet","2015","2015/05/02","","","10.1016/S0140-6736(15)60747-4"
"25933274","Prostate cancer screening in Europe","Ilic D, Dahm P.","Lancet. 2015 Apr 18;385(9977):1506. doi: 10.1016/S0140-6736(15)60746-2.","Ilic D","Lancet","2015","2015/05/02","","","10.1016/S0140-6736(15)60746-2"
"24905655","Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions","Mullins JK, Carter HB.","BJU Int. 2014 Jun;113(6):844-5. doi: 10.1111/bju.12473.","Mullins JK","BJU Int","2014","2014/06/07","","","10.1111/bju.12473"
"12493315","Androgen suppression and irradiation for locally advanced prostate cancer","Lane T, Ansell W, Oliver T.","Lancet. 2002 Dec 14;360(9349):1987; author reply 1987-8. doi: 10.1016/S0140-6736(02)11897-6.","Lane T","Lancet","2002","2002/12/21","","","10.1016/S0140-6736(02)11897-6"
"28667392","[Multiparametric MRI of the prostate : Important radiological findings for urologists]","Schlemmer HP.","Radiologe. 2017 Aug;57(8):621-630. doi: 10.1007/s00117-017-0277-0.","Schlemmer HP","Radiologe","2017","2017/07/02","","","10.1007/s00117-017-0277-0"
"8428345","Prostate brachytherapy. An overview","Porter AT, Forman JD.","Cancer. 1993 Feb 1;71(3 Suppl):953-8. doi: 10.1002/1097-0142(19930201)71:3+<953::aid-cncr2820711410>3.0.co;2-5.","Porter AT","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<953::aid-cncr2820711410>3.0.co;2-5"
"8968017","Occult prostate cancer in men with low serum testosterone levels","Morgentaler A, Bruning CO 3rd, DeWolf WC.","JAMA. 1996 Dec 18;276(23):1904-6.","Morgentaler A","JAMA","1996","1996/12/18","","",""
"25762203","Dual-modality probe intended for prostate cancer detection combining Raman spectroscopy and tactile resonance technology--discrimination of normal human prostate tissues ex vivo","Nyberg M, Jalkanen V, Ramser K, Ljungberg B, Bergh A, Lindahl OA.","J Med Eng Technol. 2015 Apr;39(3):198-207. doi: 10.3109/03091902.2015.1021430. Epub 2015 Mar 12.","Nyberg M","J Med Eng Technol","2015","2015/03/13","","","10.3109/03091902.2015.1021430"
"28785912","Consensus statement on definition, diagnosis, and management of high-risk prostate cancer patients on behalf of the Spanish Groups of Uro-Oncology Societies URONCOR, GUO, and SOGUG","Henríquez I, Rodríguez-Antolín A, Cassinello J, Gonzalez San Segundo C, Unda M, Gallardo E, López-Torrecilla J, Juarez A, Arranz J.","Clin Transl Oncol. 2018 Mar;20(3):392-401. doi: 10.1007/s12094-017-1726-y. Epub 2017 Aug 7.","Henríquez I","Clin Transl Oncol","2018","2017/08/09","","","10.1007/s12094-017-1726-y"
"27967297","Active surveillance as a therapeutic option for patients with low-risk prostate cancer according to the 2014 International Society of Urological Pathology grading system: a review","Helpap B, Gevensleben H.","Scand J Urol. 2017 Feb;51(1):1-4. doi: 10.1080/21681805.2016.1264996. Epub 2016 Dec 14.","Helpap B","Scand J Urol","2017","2016/12/15","","","10.1080/21681805.2016.1264996"
"23592289","[Prostate cancer: radiotherapy or operation?]","","Aktuelle Urol. 2013 Mar;44(2):103-4. doi: 10.1055/s-0033-1343922. Epub 2013 Apr 16.","","Aktuelle Urol","2013","2013/04/18","","","10.1055/s-0033-1343922"
"11025429","Pathologic 'fused gland' as a prognostic factor for prostate cancer","Noguchi S, Kubota Y, Kondoh I, Harada M, Masuda M, Uemura H, Hosaka M.","Urol Int. 2000;65(2):84-8. doi: 10.1159/000064845.","Noguchi S","Urol Int","2000","2000/10/12","","","10.1159/000064845"
"28398272","Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer","Armstrong AJ.","Clin Adv Hematol Oncol. 2017 Mar;15(3):184-188.","Armstrong AJ","Clin Adv Hematol Oncol","2017","2017/04/12","","",""
"27036219","Do calcium channel blockers appear to have a protective effect on the development of prostate cancer clinically?","Zhang P, Hu WL, Wang XH.","Urol Oncol. 2016 May;34(5):242-3. doi: 10.1016/j.urolonc.2016.02.022. Epub 2016 Mar 29.","Zhang P","Urol Oncol","2016","2016/04/03","","","10.1016/j.urolonc.2016.02.022"
"19087276","Incidence, mortality and survival patterns of prostate cancer among residents in Singapore from 1968 to 2002","Chia SE, Tan CS, Lim GH, Sim X, Pawitan Y, Reilly M, Mohamed Ali S, Lau W, Chia KS.","BMC Cancer. 2008 Dec 16;8:368. doi: 10.1186/1471-2407-8-368.","Chia SE","BMC Cancer","2008","2008/12/18","PMC2642843","","10.1186/1471-2407-8-368"
"7707619","Screening for prostate cancer","Leichtling D.","JAMA. 1995 Apr 19;273(15):1175.","Leichtling D","JAMA","1995","1995/04/19","","",""
"22018148","Screening for prostate cancer: the current evidence and guidelines controversy","Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R.","Can J Urol. 2011 Oct;18(5):5875-83.","Gomella LG","Can J Urol","2011","2011/10/25","","",""
"14665352","Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002","Lowe FC, Gilbert SM, Kahane H.","Urology. 2003 Dec;62(6):1045-9. doi: 10.1016/s0090-4295(03)00782-9.","Lowe FC","Urology","2003","2003/12/11","","","10.1016/s0090-4295(03)00782-9"
"15145156","Long-term follow-up of radiotherapy for prostate cancer","Swanson GP, Riggs MW, Earle JD.","Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):406-11. doi: 10.1016/j.ijrobp.2003.10.026.","Swanson GP","Int J Radiat Oncol Biol Phys","2004","2004/05/18","","","10.1016/j.ijrobp.2003.10.026"
"29318656","Circadian genes and risk of prostate cancer in the prostate cancer prevention trial","Chu LW, Till C, Yang B, Tangen CM, Goodman PJ, Yu K, Zhu Y, Han S, Hoque AM, Ambrosone C, Thompson I, Leach R, Hsing AW.","Mol Carcinog. 2018 Mar;57(3):462-466. doi: 10.1002/mc.22770. Epub 2018 Jan 12.","Chu LW","Mol Carcinog","2018","2018/01/11","PMC5940353","NIHMS932816","10.1002/mc.22770"
"16962494","Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer","Simons JW, Sacks N.","Urol Oncol. 2006 Sep-Oct;24(5):419-24. doi: 10.1016/j.urolonc.2005.08.021.","Simons JW","Urol Oncol","2006","2006/09/12","","","10.1016/j.urolonc.2005.08.021"
"23712199","Prostate cancer: intermittent ADT--tales from a 27-year odyssey","Klotz L.","Nat Rev Urol. 2013 Jul;10(7):372-4. doi: 10.1038/nrurol.2013.118. Epub 2013 May 28.","Klotz L","Nat Rev Urol","2013","2013/05/29","","","10.1038/nrurol.2013.118"
"17035651","External-beam radiotherapy for localized prostate cancer","Pisansky TM.","N Engl J Med. 2006 Oct 12;355(15):1583-91. doi: 10.1056/NEJMct055263.","Pisansky TM","N Engl J Med","2006","2006/10/13","","","10.1056/NEJMct055263"
"11558210","Prostate cancer in general practice. Results of a five year prospective clinical study in one practice","Brett T.","Aust Fam Physician. 2001 Jul;30(7):717-23.","Brett T","Aust Fam Physician","2001","2001/09/18","","",""
"10344214","Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment","Koeneman KS, Yeung F, Chung LW.","Prostate. 1999 Jun 1;39(4):246-61. doi: 10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u.","Koeneman KS","Prostate","1999","1999/05/27","","","10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u"
"9351433","ACP issues guidelines on the early detection of prostate cancer and screening for prostate cancer","Rose VL.","Am Fam Physician. 1997 Oct 15;56(6):1674-5.","Rose VL","Am Fam Physician","1997","1997/11/14","","",""
"1351334","Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients","Mortensen PB.","Acta Psychiatr Scand. 1992 May;85(5):390-3. doi: 10.1111/j.1600-0447.1992.tb10325.x.","Mortensen PB","Acta Psychiatr Scand","1992","1992/05/01","","","10.1111/j.1600-0447.1992.tb10325.x"
"7519789","Voluntary screening program for prostate cancer: detection rate and cost","Abramson N, Cotton S, Eckels R, Baldock J.","South Med J. 1994 Aug;87(8):785-8. doi: 10.1097/00007611-199408000-00003.","Abramson N","South Med J","1994","1994/08/01","","","10.1097/00007611-199408000-00003"
"22186123","Epidemiologic, clinical, and molecular characteristics of hereditary prostate cancer in Latvia","Abele A, Vjaters E, Irmejs A, Trofimovičs G, Miklaševičs E, Gardovskis J.","Medicina (Kaunas). 2011;47(10):579-85.","Abele A","Medicina (Kaunas)","2011","2011/12/22","","",""
"2683298","Pathologic basis of the sonographic appearance of the normal and malignant prostate","Shinohara K, Scardino PT, Carter SS, Wheeler TM.","Urol Clin North Am. 1989 Nov;16(4):675-91.","Shinohara K","Urol Clin North Am","1989","1989/11/01","","",""
"17569623","Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer","Aragon-Ching JB, Williams KM, Gulley JL.","Front Biosci. 2007 Sep 1;12:4957-71. doi: 10.2741/2441.","Aragon-Ching JB","Front Biosci","2007","2007/06/16","","","10.2741/2441"
"16752723","The economic impact of prostate cancer screening and treatment","DiSantostefano RL, Lavelle JP.","N C Med J. 2006 Mar-Apr;67(2):158-60.","DiSantostefano RL","N C Med J","2006","2006/06/07","","",""
"406421","[Tele-irradiation of 25 cases of prostate cancer. Preliminary results]","Auvert J, Lachand AT, Tsvetkov M, Pierquin B, Pieter E, Salle M.","J Urol Nephrol (Paris). 1977 Jan-Feb;83(1-2):106-13.","Auvert J","J Urol Nephrol (Paris)","1977","1977/01/01","","",""
"24317972","The effect of meeting physical activity guidelines for cancer survivors on quality of life following radical prostatectomy for prostate cancer","Santa Mina D, Guglietti CL, Alibhai SM, Matthew AG, Kalnin R, Ahmad N, Lindner U, Trachtenberg J.","J Cancer Surviv. 2014 Jun;8(2):190-8. doi: 10.1007/s11764-013-0329-z. Epub 2013 Dec 7.","Santa Mina D","J Cancer Surviv","2014","2013/12/10","","","10.1007/s11764-013-0329-z"
"18280514","The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer","Tindall DJ, Rittmaster RS.","J Urol. 2008 Apr;179(4):1235-42. doi: 10.1016/j.juro.2007.11.033. Epub 2008 Feb 20.","Tindall DJ","J Urol","2008","2008/02/19","PMC2667246","NIHMS99183","10.1016/j.juro.2007.11.033"
"22158594","Prostate cancer: ideal candidates for focal therapy","Tsivian M, Polascik TJ.","Nat Rev Urol. 2011 Dec 13;9(1):12-3. doi: 10.1038/nrurol.2011.206.","Tsivian M","Nat Rev Urol","2011","2011/12/14","","","10.1038/nrurol.2011.206"
"16006982","Re: Association of hemospermia with prostate cancer","Mahmud SM.","J Urol. 2005 Aug;174(2):789; author reply 789.","Mahmud SM","J Urol","2005","2005/07/12","","",""
"9109123","Guidelines for radiographic studies in prostate cancer questioned","Huncharek M, Muscat J.","Oncology (Williston Park). 1997 Mar;11(3):284.","Huncharek M","Oncology (Williston Park)","1997","1997/03/01","","",""
"7903736","Treatment of advanced prostate cancer","Bishop MC.","Lancet. 1994 Jan 8;343(8889):110-1. doi: 10.1016/s0140-6736(94)90837-0.","Bishop MC","Lancet","1994","1994/01/08","","","10.1016/s0140-6736(94)90837-0"
"25443269","Using imaging biomarkers to improve the planning of radical prostatectomies","Faure Walker NA, Nir D, Simmons L, Agrawal S, Chung C, Leminski A, Rashid T, Shamsuddin A, Winkler M.","Urol Oncol. 2015 Jan;33(1):17.e19-17.e25. doi: 10.1016/j.urolonc.2014.09.009. Epub 2014 Oct 23.","Faure Walker NA","Urol Oncol","2015","2014/12/03","","","10.1016/j.urolonc.2014.09.009"
"19393705","Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer","Lu Y.","Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):572-88. doi: 10.1016/j.addr.2009.03.014. Epub 2009 Apr 23.","Lu Y","Adv Drug Deliv Rev","2009","2009/04/28","","","10.1016/j.addr.2009.03.014"
"12084344","Quality of life following prostate cancer treatments","Penson DF.","Curr Urol Rep. 2000 May;1(1):71-7. doi: 10.1007/s11934-000-0038-9.","Penson DF","Curr Urol Rep","2000","2002/06/27","","","10.1007/s11934-000-0038-9"
"27842506","Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis","Zhao J, Stockwell T, Roemer A, Chikritzhs T.","BMC Cancer. 2016 Nov 15;16(1):845. doi: 10.1186/s12885-016-2891-z.","Zhao J","BMC Cancer","2016","2016/11/16","PMC5109713","","10.1186/s12885-016-2891-z"
"7518346","Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer","Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA.","Cancer Res. 1994 Jul 15;54(14):3929-33.","Umbas R","Cancer Res","1994","1994/07/15","","",""
"22536725","Testing care pathways for prostate cancer survivors","Frew G, Dashfield E.","Nurs Times. 2012 Mar 27-Apr 2;108(13):30-1.","Frew G","Nurs Times","2012","2012/04/28","","",""
"30242397","Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men","Trogdon JG, Falchook AD, Basak R, Carpenter WR, Chen RC.","JAMA Oncol. 2019 Jan 1;5(1):60-66. doi: 10.1001/jamaoncol.2018.3701.","Trogdon JG","JAMA Oncol","2019","2018/09/23","PMC6439776","","10.1001/jamaoncol.2018.3701"
"22795075","Life after failure of traditional androgen deprivation therapy","Schellhammer P.","Urol Oncol. 2012 Jul-Aug;30(4 Suppl):S10-4. doi: 10.1016/j.urolonc.2012.01.009.","Schellhammer P","Urol Oncol","2012","2012/07/17","","","10.1016/j.urolonc.2012.01.009"
"10434321","[What is the role of the correspondence of free PSA/total PSA in the staging of local prostate cancer? Series of 50 radical prostatectomy cases]","Anfossi E, Rossi D, Grisoni V, Sauvan R, Bladou F, Serment G.","Prog Urol. 1999 Jun;9(3):479-82.","Anfossi E","Prog Urol","1999","1999/08/06","","",""
"25754033","Methylselenocysteine preventing castration-resistant progression of prostate cancer","Liu Y, Liu X, Guo Y, Liang Z, Tian Y, Lu L, Zhao X, Sun Y, Zhao X, Zhang H, Dong Y.","Prostate. 2015 Jun 15;75(9):1001-8. doi: 10.1002/pros.22987. Epub 2015 Mar 8.","Liu Y","Prostate","2015","2015/03/11","PMC4424181","NIHMS660756","10.1002/pros.22987"
"19727147","Prostate cancer: quality of life after radiation and androgen deprivation","Makarov DV, Penson DF.","Nat Rev Urol. 2009 Sep;6(9):477-8. doi: 10.1038/nrurol.2009.168.","Makarov DV","Nat Rev Urol","2009","2009/09/04","","","10.1038/nrurol.2009.168"
"18439748","Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: a modern approach in prostate cancer imaging","Sciarra A, Salciccia S, Panebianco V.","Eur Urol. 2008 Sep;54(3):485-8. doi: 10.1016/j.eururo.2008.04.032. Epub 2008 Apr 18.","Sciarra A","Eur Urol","2008","2008/04/29","","","10.1016/j.eururo.2008.04.032"
"3962039","[Radiotherapy of prostate cancer]","Knüfermann H, Wannenmacher M.","Urologe A. 1986 Jan;25(1):18-22.","Knüfermann H","Urologe A","1986","1986/01/01","","",""
"1441036","Objective treatment response to endocrine therapy in metastatic prostate cancer","Zaragoza MR, Grossman HB.","Urology. 1992 Nov;40(5):405-8. doi: 10.1016/0090-4295(92)90452-3.","Zaragoza MR","Urology","1992","1992/11/01","","","10.1016/0090-4295(92)90452-3"
"24935732","The role of microRNA in castration-resistant prostate cancer","Thieu W, Tilki D, de Vere White R, Evans CP.","Urol Oncol. 2014 Jul;32(5):517-523. doi: 10.1016/j.urolonc.2013.11.004.","Thieu W","Urol Oncol","2014","2014/06/18","PMC4570565","NIHMS721848","10.1016/j.urolonc.2013.11.004"
"20803609","Effects of complementary therapies on clinical outcomes in patients being treated with radiation therapy for prostate cancer","Beard C, Stason WB, Wang Q, Manola J, Dean-Clower E, Dusek JA, Decristofaro S, Webster A, Doherty-Gilman AM, Rosenthal DS, Benson H.","Cancer. 2011 Jan 1;117(1):96-102. doi: 10.1002/cncr.25291. Epub 2010 Aug 27.","Beard C","Cancer","2011","2010/08/31","","","10.1002/cncr.25291"
"11106674","Prostate cancer: numbers may not tell the whole story","Reynolds T.","J Natl Cancer Inst. 2000 Dec 6;92(23):1873-6. doi: 10.1093/jnci/92.23.1873.","Reynolds T","J Natl Cancer Inst","2000","2000/12/07","","","10.1093/jnci/92.23.1873"
"17906295","Green tea consumption and prostate cancer risk in Japanese men: a prospective study","Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S; JPHC Study Group.","Am J Epidemiol. 2008 Jan 1;167(1):71-7. doi: 10.1093/aje/kwm249. Epub 2007 Sep 29.","Kurahashi N","Am J Epidemiol","2008","2007/10/02","","","10.1093/aje/kwm249"
"11807423","Urinary incontinence following treatment of localized prostate cancer","Grise P, Thurman S.","Cancer Control. 2001 Nov-Dec;8(6):532-9. doi: 10.1177/107327480100800608.","Grise P","Cancer Control","2001","2002/01/25","","","10.1177/107327480100800608"
"9285567","Keratinocyte growth factor expression in hormone insensitive prostate cancer","Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE.","Oncogene. 1997 Aug 28;15(9):1115-20. doi: 10.1038/sj.onc.1201256.","Leung HY","Oncogene","1997","1997/08/28","","","10.1038/sj.onc.1201256"
"24035631","Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality","Stephenson AJ, Eggener SE, Hernandez AV, Klein EA, Kattan MW, Wood DP Jr, Rabah DM, Eastham JA, Scardino PT.","Eur Urol. 2014 Apr;65(4):675-80. doi: 10.1016/j.eururo.2013.08.036. Epub 2013 Aug 27.","Stephenson AJ","Eur Urol","2014","2013/09/17","","","10.1016/j.eururo.2013.08.036"
"30855016","The future of molecular and functional imaging in prostate cancer","Renard-Penna R, Gauthé M.","Arch Esp Urol. 2019 Mar;72(2):150-156.","Renard-Penna R","Arch Esp Urol","2019","2019/03/12","","",""
"19860934","Gleason score and laterality concordance between prostate biopsy and prostatectomy specimens","Nepple KG, Wahls TL, Hillis SL, Joudi FN.","Int Braz J Urol. 2009 Sep-Oct;35(5):559-64. doi: 10.1590/s1677-55382009000500007.","Nepple KG","Int Braz J Urol","2009","2009/10/29","","","10.1590/s1677-55382009000500007"
"11998038","The identification and screening of men at high risk for developing prostate cancer","Grumet SC, Bruner DW.","Urol Nurs. 2000 Feb;20(1):15-8, 23-4, 46.","Grumet SC","Urol Nurs","2000","2002/05/10","","",""
"28925566","Raman spectroscopy for accurately characterizing biomolecular changes in androgen-independent prostate cancer cells","Corsetti S, Rabl T, McGloin D, Nabi G.","J Biophotonics. 2018 Mar;11(3):e201700166. doi: 10.1002/jbio.201700166. Epub 2017 Nov 23.","Corsetti S","J Biophotonics","2018","2017/09/20","PMC6538931","","10.1002/jbio.201700166"
"17619718","Comorbidities and the risk of late-stage prostate cancer","Fleming ST, McDavid K, Pearce K, Pavlov D.","ScientificWorldJournal. 2006 Jul 28;6:2460-70. doi: 10.1100/tsw.2006.383.","Fleming ST","ScientificWorldJournal","2006","2007/07/11","PMC5917144","","10.1100/tsw.2006.383"
"12085963","Contribution of the androgen receptor to prostate cancer predisposition and progression","Buchanan G, Irvine RA, Coetzee GA, Tilley WD.","Cancer Metastasis Rev. 2001;20(3-4):207-23. doi: 10.1023/a:1015531326689.","Buchanan G","Cancer Metastasis Rev","2001","2002/06/28","","","10.1023/a:1015531326689"
"12678401","Toward an understanding of the molecular genetics of prostate cancer progression","Lijovic M, Frauman AG.","J Environ Pathol Toxicol Oncol. 2003;22(1):1-15. doi: 10.1615/jenvpathtoxoncol.v22.i1.10.","Lijovic M","J Environ Pathol Toxicol Oncol","2003","2003/04/08","","","10.1615/jenvpathtoxoncol.v22.i1.10"
"26202726","Perceived influences on post-diagnostic dietary change among a group of men with prostate cancer","Kassianos AP, Coyle A, Raats MM.","Eur J Cancer Care (Engl). 2015 Nov;24(6):818-26. doi: 10.1111/ecc.12357. Epub 2015 Jul 22.","Kassianos AP","Eur J Cancer Care (Engl)","2015","2015/07/24","","","10.1111/ecc.12357"
"27765854","Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells","Mukhtar E, Adhami VM, Siddiqui IA, Verma AK, Mukhtar H.","Mol Cancer Ther. 2016 Dec;15(12):2863-2874. doi: 10.1158/1535-7163.MCT-16-0515. Epub 2016 Oct 7.","Mukhtar E","Mol Cancer Ther","2016","2016/10/22","PMC5136329","NIHMS827064","10.1158/1535-7163.MCT-16-0515"
"10801162","Choice of hormonal therapy for prostate cancer","Reese DM.","Lancet. 2000 Apr 29;355(9214):1474-5. doi: 10.1016/S0140-6736(00)02155-3.","Reese DM","Lancet","2000","2000/05/09","","","10.1016/S0140-6736(00)02155-3"
"14661391","Prostate cancer: preliminary results of a case finding campaign","Bono AV, Spasciani R, Lovisolo JA, Damiano G, Buzzi M.","Arch Ital Urol Androl. 2003 Sep;75(3):135-7.","Bono AV","Arch Ital Urol Androl","2003","2003/12/10","","",""
"26471467","Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy","Jacobs C, Tumati V, Kapur P, Yan J, Xie XJ, Hannan R, Hsieh JT, Kim DW, Saha D.","Cancer Med. 2015 Dec;4(12):1844-52. doi: 10.1002/cam4.554. Epub 2015 Oct 16.","Jacobs C","Cancer Med","2015","2015/10/17","PMC4940806","","10.1002/cam4.554"
"10604391","Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE","Walsh PC.","J Urol. 2000 Jan;163(1):370. doi: 10.1016/s0022-5347(05)68052-4.","Walsh PC","J Urol","2000","1999/12/22","","","10.1016/s0022-5347(05)68052-4"
"29599304","Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe?","Mascan B, Marignol L.","Anticancer Res. 2018 Apr;38(4):1897-1902. doi: 10.21873/anticanres.12426.","Mascan B","Anticancer Res","2018","2018/03/31","","","10.21873/anticanres.12426"
"1394045","Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut","Polednak AP, Flannery JT.","Cancer. 1992 Oct 15;70(8):2152-8. doi: 10.1002/1097-0142(19921015)70:8<2152::aid-cncr2820700824>3.0.co;2-#.","Polednak AP","Cancer","1992","1992/10/15","","","10.1002/1097-0142(19921015)70:8<2152::aid-cncr2820700824>3.0.co;2-#"
"31149790","Radical prostatectomy for high-risk prostate cancer | Opinion: NO","Ghodoussipour S, Cacciamani GE, Abreu ALC.","Int Braz J Urol. 2019 May-Jun;45(3):428-434. doi: 10.1590/S1677-5538.IBJU.2019.03.03.","Ghodoussipour S","Int Braz J Urol","2019","2019/06/01","PMC6786100","","10.1590/S1677-5538.IBJU.2019.03.03"
"12654574","All in the family: heredity and prostate cancer","","Harv Mens Health Watch. 2003 Mar;7(8):6-8.","","Harv Mens Health Watch","2003","2003/03/26","","",""
"15788672","Reg IV: a promising marker of hormone refractory metastatic prostate cancer","Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE.","Clin Cancer Res. 2005 Mar 15;11(6):2237-43. doi: 10.1158/1078-0432.CCR-04-0356.","Gu Z","Clin Cancer Res","2005","2005/03/25","","","10.1158/1078-0432.CCR-04-0356"
"15269132","The cooperative prostate cancer tissue resource: a specimen and data resource for cancer researchers","Melamed J, Datta MW, Becich MJ, Orenstein JM, Dhir R, Silver S, Fidélia-Lambert M, Kadjacsy-Balla A, Macias V, Patel A, Walden PD, Bosland MC, Berman JJ.","Clin Cancer Res. 2004 Jul 15;10(14):4614-21. doi: 10.1158/1078-0432.CCR-04-0240.","Melamed J","Clin Cancer Res","2004","2004/07/23","","","10.1158/1078-0432.CCR-04-0240"
"16417961","Substaging pathologically organ confined (pT2) prostate cancer: an exercise in futility?","van der Kwast TH.","Eur Urol. 2006 Feb;49(2):209-11. doi: 10.1016/j.eururo.2005.12.027. Epub 2006 Jan 4.","van der Kwast TH","Eur Urol","2006","2006/01/19","","","10.1016/j.eururo.2005.12.027"
"23221459","Therapeutic implications of autophagy modulation in prostate cancer","Giampietri C, Petrungaro S, Facchiano A, Filippini A, Ziparo E.","J Endocrinol Invest. 2012 Nov;35(10):945. doi: 10.1007/BF03346738.","Giampietri C","J Endocrinol Invest","2012","2012/12/11","","","10.1007/BF03346738"
"22154194","Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymphadenectomy: optimizing a risk-adapted surgical approach","Heidenreich A.","Eur Urol. 2012 Mar;61(3):488-90. doi: 10.1016/j.eururo.2011.11.032. Epub 2011 Nov 24.","Heidenreich A","Eur Urol","2012","2011/12/14","","","10.1016/j.eururo.2011.11.032"
"7791261","A 72-year-old man with localized prostate cancer","Albertsen P.","JAMA. 1995 Jul 5;274(1):69-74.","Albertsen P","JAMA","1995","1995/07/05","","",""
"19806595","Many unknowns in low-risk prostate cancer treatment. Ongoing studies and biomarker research may shed light on best approach","Printz C.","Cancer. 2009 Oct 15;115(20):4645-6. doi: 10.1002/cncr.24672.","Printz C","Cancer","2009","2009/10/07","","","10.1002/cncr.24672"
"17938936","Ultrasound of prostate cancer: recent advances","Pallwein L, Mitterberger M, Pelzer A, Bartsch G, Strasser H, Pinggera GM, Aigner F, Gradl J, Zur Nedden D, Frauscher F.","Eur Radiol. 2008 Apr;18(4):707-15. doi: 10.1007/s00330-007-0779-7. Epub 2007 Oct 16.","Pallwein L","Eur Radiol","2008","2007/10/17","","","10.1007/s00330-007-0779-7"
"21631697","Discussing the sexual consequences of treatment in radiotherapy and urology consultations with couples affected by prostate cancer","Forbat L, White I, Marshall-Lucette S, Kelly D.","BJU Int. 2012 Jan;109(1):98-103. doi: 10.1111/j.1464-410X.2011.10257.x. Epub 2011 Jun 1.","Forbat L","BJU Int","2012","2011/06/03","","","10.1111/j.1464-410X.2011.10257.x"
"12667713","Recent trends in prostate cancer incidence and mortality in southeast England","Evans HS, Møller H.","Eur Urol. 2003 Apr;43(4):337-41. doi: 10.1016/s0302-2838(03)00085-x.","Evans HS","Eur Urol","2003","2003/04/02","","","10.1016/s0302-2838(03)00085-x"
"9864495","[The relationship between serum prostate-specific antigen and the skeletal- and CT-scan in staging of primary prostate cancer]","Jager GJ.","Ned Tijdschr Geneeskd. 1998 Oct 3;142(40):2218.","Jager GJ","Ned Tijdschr Geneeskd","1998","1998/12/29","","",""
"24448834","Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients","Lin VC, Huang CY, Lee YC, Yu CC, Chang TY, Lu TL, Huang SP, Bao BY.","Arch Toxicol. 2014 Apr;88(4):901-11. doi: 10.1007/s00204-014-1196-8. Epub 2014 Jan 22.","Lin VC","Arch Toxicol","2014","2014/01/23","","","10.1007/s00204-014-1196-8"
"10849492","Clinical characteristics of prostate cancer in Gunma prefecture","Kurokawa K, Fukabori Y, Ito K, Suzuki K, Nakata S, Suzuki T, Imai K, Namiki TS, Yamanaka H.","Int J Androl. 2000;23 Suppl 2:40-2. doi: 10.1046/j.1365-2605.2000.00010.x.","Kurokawa K","Int J Androl","2000","2000/06/13","","","10.1046/j.1365-2605.2000.00010.x"
"21683411","Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178","Zhang M.","J Urol. 2011 Aug;186(2):756. doi: 10.1016/j.juro.2011.03.160. Epub 2011 Jun 17.","Zhang M","J Urol","2011","2011/06/21","","","10.1016/j.juro.2011.03.160"
"17516554","Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells","Sgambato A, De Paola B, Migaldi M, Di Salvatore M, Rettino A, Rossi G, Faraglia B, Boninsegna A, Maiorana A, Cittadini A.","J Cell Physiol. 2007 Nov;213(2):528-39. doi: 10.1002/jcp.21130.","Sgambato A","J Cell Physiol","2007","2007/05/23","","","10.1002/jcp.21130"
"15897914","Metastatic prostate cancer presenting as an asymptomatic neck mass","Carleton J, van der Riet P, Dahm P.","Prostate Cancer Prostatic Dis. 2005;8(3):293-5; discussion 295. doi: 10.1038/sj.pcan.4500805.","Carleton J","Prostate Cancer Prostatic Dis","2005","2005/05/18","","","10.1038/sj.pcan.4500805"
"15162829","Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men","Sakai I, Harada K, Hara I, Eto H, Miyake H.","Int J Clin Oncol. 2004 Feb;9(1):64-7. doi: 10.1007/s10147-003-0365-1.","Sakai I","Int J Clin Oncol","2004","2004/05/28","","","10.1007/s10147-003-0365-1"
"24931269","High-risk prostate cancer: a disease of genomic instability","Tapia-Laliena MA, Korzeniewski N, Hohenfellner M, Duensing S.","Urol Oncol. 2014 Nov;32(8):1101-7. doi: 10.1016/j.urolonc.2014.02.005. Epub 2014 Jun 13.","Tapia-Laliena MA","Urol Oncol","2014","2014/06/17","","","10.1016/j.urolonc.2014.02.005"
"23793963","Opinions from the experts: exploring what prostate cancer patients should know about post-operative radiotherapy","D'Alimonte L, Koo K, Chen E, Feldman-Stewart D, Court A, Fitch M, Di Prospero L, Maamoun J, Kiss A, Szumacher E.","J Cancer Educ. 2013 Sep;28(3):509-15. doi: 10.1007/s13187-013-0494-9.","D'Alimonte L","J Cancer Educ","2013","2013/06/25","","","10.1007/s13187-013-0494-9"
"15992461","Active surveillance for prostate cancer with selective delayed definitive therapy","Eastham JA.","Clin Prostate Cancer. 2005 Jun;4(1):45-9. doi: 10.3816/cgc.2005.n.011.","Eastham JA","Clin Prostate Cancer","2005","2005/07/05","","","10.3816/cgc.2005.n.011"
"22116599","Randomized controlled screening trials for prostate cancer using prostate-specific antigen: a tale of contrasts","Rove KO, Crawford ED.","World J Urol. 2012 Apr;30(2):137-42. doi: 10.1007/s00345-011-0799-4. Epub 2011 Nov 25.","Rove KO","World J Urol","2012","2011/11/26","","","10.1007/s00345-011-0799-4"
"12084336","The role of prostate-specific antigen velocity in prostate cancer early detection","Potter SR, Carter HB.","Curr Urol Rep. 2000 May;1(1):15-9. doi: 10.1007/s11934-000-0030-4.","Potter SR","Curr Urol Rep","2000","2002/06/27","","","10.1007/s11934-000-0030-4"
"23712204","Hypoxia, notch signalling, and prostate cancer","Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D.","Nat Rev Urol. 2013 Jul;10(7):405-13. doi: 10.1038/nrurol.2013.110. Epub 2013 May 28.","Marignol L","Nat Rev Urol","2013","2013/05/29","PMC5240418","NIHMS836007","10.1038/nrurol.2013.110"
"24398858","Histone H2A.Z deregulation in prostate cancer. Cause or effect?","Dryhurst D, Ausió J.","Cancer Metastasis Rev. 2014 Sep;33(2-3):429-39. doi: 10.1007/s10555-013-9486-9.","Dryhurst D","Cancer Metastasis Rev","2014","2014/01/09","PMC4113680","","10.1007/s10555-013-9486-9"
"27846936","[CCAFU french national guidelines 2016-2018 on prostate cancer]","Rozet F, Hennequin C, Beauval JB, Beuzeboc P, Cormier L, Fromont G, Mongiat-Artus P, Ouzzane A, Ploussard G, Azria D, Brenot-Rossi I, Cancel-Tassin G, Cussenot O, Lebret T, Rebillard X, Soulié M, Renard-Penna R, Méjean A.","Prog Urol. 2016 Nov;27 Suppl 1:S95-S143. doi: 10.1016/S1166-7087(16)30705-9.","Rozet F","Prog Urol","2016","2016/11/17","","","10.1016/S1166-7087(16)30705-9"
"29020718","MP-MRI could improve the diagnosis of prostate cancer","Rees J.","Practitioner. 2017 Feb;261(1801):5.","Rees J","Practitioner","2017","2017/10/12","","",""
"23422588","Psychosocial aspects of active surveillance","Kazer MW, Psutka SP, Latini DM, Bailey DE Jr.","Curr Opin Urol. 2013 May;23(3):273-7. doi: 10.1097/MOU.0b013e32835eff24.","Kazer MW","Curr Opin Urol","2013","2013/02/21","","","10.1097/MOU.0b013e32835eff24"
"22902440","[Management for bone metastasis of prostate cancer]","Kamoto T.","Gan To Kagaku Ryoho. 2012 Aug;39(8):1178-82.","Kamoto T","Gan To Kagaku Ryoho","2012","2012/08/21","","",""
"9474213","Re: The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population","Elgamal AA, Baert L.","J Urol. 1998 Mar;159(3):994-5. doi: 10.1016/s0022-5347(01)63814-x.","Elgamal AA","J Urol","1998","1998/02/25","","","10.1016/s0022-5347(01)63814-x"
"12168926","MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer","Hasumi M, Suzuki K, Oya N, Ito K, Kurokawa K, Fukabori Y, Yamanaka H.","Anticancer Res. 2002 Mar-Apr;22(2B):1205-8.","Hasumi M","Anticancer Res","2002","2002/08/10","","",""
"27030083","Genomic predictors for treatment of late stage prostate cancer","Shevrin DH.","Asian J Androl. 2016 Jul-Aug;18(4):586-91. doi: 10.4103/1008-682X.177121.","Shevrin DH","Asian J Androl","2016","2016/04/01","PMC4955183","","10.4103/1008-682X.177121"
"31066129","Information in radiotherapy for men with localised prostate cancer: An integrative review","Gordon L, Dickinson A, Offredy M.","Eur J Cancer Care (Engl). 2019 May;28(3):e13085. doi: 10.1111/ecc.13085. Epub 2019 May 8.","Gordon L","Eur J Cancer Care (Engl)","2019","2019/05/09","","","10.1111/ecc.13085"
"20087895","Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men","Calistro Alvarado L.","Am J Hum Biol. 2010 Jul-Aug;22(4):449-55. doi: 10.1002/ajhb.21016.","Calistro Alvarado L","Am J Hum Biol","2010","2010/01/21","","","10.1002/ajhb.21016"
"28678408","Longitudinal regret after treatment for low- and intermediate-risk prostate cancer","Hurwitz LM, Cullen J, Kim DJ, Elsamanoudi S, Hudak J, Colston M, Travis J, Kuo HC, Rice KR, Porter CR, Rosner IL.","Cancer. 2017 Nov 1;123(21):4252-4258. doi: 10.1002/cncr.30841. Epub 2017 Jul 5.","Hurwitz LM","Cancer","2017","2017/07/06","","","10.1002/cncr.30841"
"25625153","Re: prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging","Siegel C.","J Urol. 2014 Jul;192(1):128-9. doi: 10.1016/j.juro.2014.04.037.","Siegel C","J Urol","2014","2015/01/28","","","10.1016/j.juro.2014.04.037"
"24687824","Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer?","Giannarini G, Gandaglia G, Montorsi F, Briganti A.","J Clin Oncol. 2014 May 1;32(13):1299-301. doi: 10.1200/JCO.2013.54.8214. Epub 2014 Mar 31.","Giannarini G","J Clin Oncol","2014","2014/04/02","","","10.1200/JCO.2013.54.8214"
"23930445","Adding to the evidence base: effects of an online support group for prostate cancer survivors: a randomized trial","Sublett CM.","Urol Nurs. 2013 May-Jun;33(3):134-5.","Sublett CM","Urol Nurs","2013","2013/08/13","","",""
"21604952","When is active surveillance the appropriate treatment for prostate cancer?","Albertsen PC.","Acta Oncol. 2011 Jun;50 Suppl 1:120-6. doi: 10.3109/0284186X.2010.526634.","Albertsen PC","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.526634"
"18432529","Body mass index and prognostic markers at radical prostatectomy","Paaskesen CE, Borre M.","Scand J Urol Nephrol. 2008;42(3):230-6. doi: 10.1080/00365590701777798.","Paaskesen CE","Scand J Urol Nephrol","2008","2008/04/25","","","10.1080/00365590701777798"
"20620413","The economic burden of prostate cancer survivorship care","Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK.","J Urol. 2010 Aug;184(2):532-8. doi: 10.1016/j.juro.2010.03.136. Epub 2010 Jun 17.","Skolarus TA","J Urol","2010","2010/07/13","","","10.1016/j.juro.2010.03.136"
"31442444","Hypoxia induced microRNA-301b-3p overexpression promotes proliferation, migration and invasion of prostate cancer cells by targeting LRP1B","Zheng H, Bai L.","Exp Mol Pathol. 2019 Dec;111:104301. doi: 10.1016/j.yexmp.2019.104301. Epub 2019 Aug 21.","Zheng H","Exp Mol Pathol","2019","2019/08/24","","","10.1016/j.yexmp.2019.104301"
"11058606","Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer","Hillner BE, Roberts JD.","J Natl Cancer Inst. 2000 Nov 1;92(21):1704-6. doi: 10.1093/jnci/92.21.1704.","Hillner BE","J Natl Cancer Inst","2000","2000/11/04","","","10.1093/jnci/92.21.1704"
"20227209","Tumorsize dependent detection rate of endorectal MRI of prostate cancer--a histopathologic correlation with whole-mount sections in 70 patients with prostate cancer","Roethke MC, Lichy MP, Jurgschat L, Hennenlotter J, Vogel U, Schilling D, Stenzl A, Claussen CD, Schlemmer HP.","Eur J Radiol. 2011 Aug;79(2):189-95. doi: 10.1016/j.ejrad.2010.01.014. Epub 2010 Mar 12.","Roethke MC","Eur J Radiol","2011","2010/03/16","","","10.1016/j.ejrad.2010.01.014"
"25597200","GPs could play key role in prostate cancer survivorship programmes","MacKenzie KR, Aning JJ.","Practitioner. 2014 Nov;258(1776):27-31, 3.","MacKenzie KR","Practitioner","2014","2015/01/20","","",""
"19671305","[Ultrasound guided transrectal prostate biopsy: 11-year experience]","Zhu G, Lu ZH, Ma H, Yan W, Wan B, Wang JY.","Zhonghua Yi Xue Za Zhi. 2009 Apr 14;89(14):955-7.","Zhu G","Zhonghua Yi Xue Za Zhi","2009","2009/08/13","","",""
"7744581","Radical retropubic prostatectomy in the treatment of localized prostate cancer: experience with 100 consecutive cases","Mor Y, Shenfeld O, Leibovich I, Raviv G, Nativ O, Goldwasser B.","Isr J Med Sci. 1995 Feb-Mar;31(2-3):129-32.","Mor Y","Isr J Med Sci","1995","1995/02/01","","",""
"1594011","Trends in prostate cancer--United States, 1980-1988","Centers for Disease Control (CDC).","MMWR Morb Mortal Wkly Rep. 1992 Jun 12;41(23):401-4.","Centers for Disease Control (CDC)","MMWR Morb Mortal Wkly Rep","1992","1992/06/12","","",""
"26026127","PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer","Heidegger I, Klocker H, Pichler R, Horninger W, Bektic J.","Anticancer Res. 2015 Jun;35(6):3567-70.","Heidegger I","Anticancer Res","2015","2015/05/31","","",""
"18299212","Piezoelectricity and prostate cancer: proposed interaction between electromagnetic field and prostatic crystalloids","Ghabili K, Shoja MM, Agutter PS.","Cell Biol Int. 2008 Jun;32(6):688-91. doi: 10.1016/j.cellbi.2008.01.009. Epub 2008 Jan 25.","Ghabili K","Cell Biol Int","2008","2008/02/27","","","10.1016/j.cellbi.2008.01.009"
"7516781","[Screening for the early diagnosis of prostatic carcinoma in Ossola: results after 1 year of effort]","Pagani G, Iannicelli P, Rosa A, Aimè G, Ceratti G, Cobianchi PG.","Arch Ital Urol Androl. 1994 Feb;66(1):47-50.","Pagani G","Arch Ital Urol Androl","1994","1994/02/01","","",""
"9140128","Prostate cancer in African-American men","Littrup PJ.","Prostate. 1997 May 1;31(2):139-41; discussion 142. doi: 10.1002/(sici)1097-0045(19970501)31:2<139::aid-pros10>3.0.co;2-h.","Littrup PJ","Prostate","1997","1997/05/01","","","10.1002/(sici)1097-0045(19970501)31:2<139::aid-pros10>3.0.co;2-h"
"10186224","Economic evaluation of screening for prostate cancer: a randomized population based programme during a 10-year period in Sweden","Holmberg H, Carlsson P, Löfman O, Varenhorst E.","Health Policy. 1998 Aug;45(2):133-47. doi: 10.1016/s0168-8510(98)00037-2.","Holmberg H","Health Policy","1998","1998/07/06","","","10.1016/s0168-8510(98)00037-2"
"24919965","Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies","van Hove A, Savoie PH, Maurin C, Brunelle S, Gravis G, Salem N, Walz J.","World J Urol. 2014 Aug;32(4):847-58. doi: 10.1007/s00345-014-1332-3. Epub 2014 Jun 12.","van Hove A","World J Urol","2014","2014/06/13","","","10.1007/s00345-014-1332-3"
"20605366","Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size","Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV.","Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1318-22. doi: 10.1016/j.ijrobp.2010.01.023. Epub 2010 Jun 3.","Nguyen PL","Int J Radiat Oncol Biol Phys","2011","2010/07/08","","","10.1016/j.ijrobp.2010.01.023"
"27077643","Preoperative Evaluation of Prostate Cancer Aggressiveness: Using ADC and ADC Ratio in Determining Gleason Score","Woo S, Kim SY, Cho JY, Kim SH.","AJR Am J Roentgenol. 2016 Jul;207(1):114-20. doi: 10.2214/AJR.15.15894. Epub 2016 Apr 14.","Woo S","AJR Am J Roentgenol","2016","2016/04/15","","","10.2214/AJR.15.15894"
"28342640","Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories","Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA.","Eur Urol. 2017 Oct;72(4):492-495. doi: 10.1016/j.eururo.2017.03.013. Epub 2017 Mar 22.","Porter LH","Eur Urol","2017","2017/03/27","","","10.1016/j.eururo.2017.03.013"
"7532323","New agents in the therapy of hormone-refractory patients with prostate cancer","Kantoff PW.","Semin Oncol. 1995 Feb;22(1 Suppl 1):32-4.","Kantoff PW","Semin Oncol","1995","1995/02/01","","",""
"24375392","Recent progress on nutraceutical research in prostate cancer","Li Y, Ahmad A, Kong D, Bao B, Sarkar FH.","Cancer Metastasis Rev. 2014 Sep;33(2-3):629-40. doi: 10.1007/s10555-013-9478-9.","Li Y","Cancer Metastasis Rev","2014","2013/12/31","PMC4074449","NIHMS552356","10.1007/s10555-013-9478-9"
"3297287","Prostate cancer. Chemotherapy","Gibbons RP.","Cancer. 1987 Aug 1;60(3 Suppl):586-8. doi: 10.1002/1097-0142(19870801)60:3+<586::aid-cncr2820601525>3.0.co;2-2.","Gibbons RP","Cancer","1987","1987/08/01","","","10.1002/1097-0142(19870801)60:3+<586::aid-cncr2820601525>3.0.co;2-2"
"18924633","To screen or not to screen? Prostate cancer screening: why it's not for every man","Lefevre M.","Medscape J Med. 2008;10(8):181. Epub 2008 Aug 3.","Lefevre M","Medscape J Med","2008","2008/10/18","PMC2562143","",""
"25262538","Epithelial plasticity in prostate cancer: principles and clinical perspectives","Das R, Gregory PA, Hollier BG, Tilley WD, Selth LA.","Trends Mol Med. 2014 Nov;20(11):643-51. doi: 10.1016/j.molmed.2014.09.004. Epub 2014 Sep 25.","Das R","Trends Mol Med","2014","2014/09/29","","","10.1016/j.molmed.2014.09.004"
"23234625","Prostate specific antigen best practice statement: 2009 update","Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association.","J Urol. 2013 Jan;189(1 Suppl):S2-S11. doi: 10.1016/j.juro.2012.11.014.","Greene KL","J Urol","2013","2012/12/14","","","10.1016/j.juro.2012.11.014"
"1988579","Sex or survival: trade-offs between quality and quantity of life","Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R.","J Clin Oncol. 1991 Feb;9(2):328-34. doi: 10.1200/JCO.1991.9.2.328.","Singer PA","J Clin Oncol","1991","1991/02/01","","","10.1200/JCO.1991.9.2.328"
"28946846","Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis","Abhyankar N, Hoskins KF, Abern MR, Calip GS.","BMC Cancer. 2017 Sep 25;17(1):659. doi: 10.1186/s12885-017-3640-7.","Abhyankar N","BMC Cancer","2017","2017/09/27","PMC5613320","","10.1186/s12885-017-3640-7"
"10848693","Transrectal power Doppler imaging in the detection of prostate cancer","Okihara K, Kojima M, Nakanouchi T, Okada K, Miki T.","BJU Int. 2000 Jun;85(9):1053-7. doi: 10.1046/j.1464-410x.2000.00663.x.","Okihara K","BJU Int","2000","2000/06/10","","","10.1046/j.1464-410x.2000.00663.x"
"31153637","Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53","Cao Z, Xu L, Zhao S.","Biochem Biophys Res Commun. 2019 Jul 23;515(2):345-351. doi: 10.1016/j.bbrc.2019.05.120. Epub 2019 May 29.","Cao Z","Biochem Biophys Res Commun","2019","2019/06/03","","","10.1016/j.bbrc.2019.05.120"
"12115378","The economic burden of prostate cancer, California, 1998","Max W, Rice DP, Sung HY, Michel M, Breuer W, Zhang X.","Cancer. 2002 Jun 1;94(11):2906-13. doi: 10.1002/cncr.10532.","Max W","Cancer","2002","2002/07/13","","","10.1002/cncr.10532"
"22439942","Prostate radiation in non-metastatic castrate refractory prostate cancer provides an interesting insight into biology of prostate cancer","Pascoe AC, Sundar S.","Radiat Oncol. 2012 Mar 22;7:43. doi: 10.1186/1748-717X-7-43.","Pascoe AC","Radiat Oncol","2012","2012/03/24","PMC3348090","","10.1186/1748-717X-7-43"
"31213414","Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial","Abdel-Rahman O.","Clin Genitourin Cancer. 2019 Aug;17(4):e837-e844. doi: 10.1016/j.clgc.2019.05.015. Epub 2019 May 25.","Abdel-Rahman O","Clin Genitourin Cancer","2019","2019/06/20","","","10.1016/j.clgc.2019.05.015"
"9495708","External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up?","Pollack A, Zagars GK.","Urology. 1998 Feb;51(2):258-64. doi: 10.1016/s0090-4295(97)00621-3.","Pollack A","Urology","1998","1998/03/12","","","10.1016/s0090-4295(97)00621-3"
"11272670","Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer","Rosenthal SA, Haseman MK, Polascik TJ.","Tech Urol. 2001 Mar;7(1):27-37.","Rosenthal SA","Tech Urol","2001","2001/03/29","","",""
"26087476","CRISPR/Cas9-mediated gene knockout of NANOG and NANOGP8 decreases the malignant potential of prostate cancer cells","Kawamura N, Nimura K, Nagano H, Yamaguchi S, Nonomura N, Kaneda Y.","Oncotarget. 2015 Sep 8;6(26):22361-74. doi: 10.18632/oncotarget.4293.","Kawamura N","Oncotarget","2015","2015/06/19","PMC4673169","","10.18632/oncotarget.4293"
"19670727","[Quality of life of patients with locally-advanced prostate cancer as a criterium of therapeutic effectiveness]","Kaprin AD, Kostin AA, Tsybul'skiĭ AD.","Vopr Onkol. 2009;55(3):285-90.","Kaprin AD","Vopr Onkol","2009","2009/08/13","","",""
"28209917","Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184","Zhou Y, Wang X, Zhang J, He A, Wang YL, Han K, Su Y, Yin J, Lv X, Hu H.","Oncotarget. 2017 Mar 14;8(11):18260-18270. doi: 10.18632/oncotarget.15353.","Zhou Y","Oncotarget","2017","2017/02/18","PMC5392325","","10.18632/oncotarget.15353"
"17594350","Current prostate cancer: 20 years later","Marberger M.","BJU Int. 2007 Jul;100 Suppl 2:11-4. doi: 10.1111/j.1464-410X.2007.06945.x.","Marberger M","BJU Int","2007","2007/06/28","","","10.1111/j.1464-410X.2007.06945.x"
"22433633","Risk of subsequent primary cancer among prostate cancer patients in Bavaria, Germany","Braisch U, Meyer M, Radespiel-Tröger M.","Eur J Cancer Prev. 2012 Nov;21(6):552-9. doi: 10.1097/CEJ.0b013e328351c748.","Braisch U","Eur J Cancer Prev","2012","2012/03/22","","","10.1097/CEJ.0b013e328351c748"
"11588845","Prostate cancer early detection: a clinical perspective","Grossfeld GD, Carroll PR.","Epidemiol Rev. 2001;23(1):173-80. doi: 10.1093/oxfordjournals.epirev.a000786.","Grossfeld GD","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000786"
"20180061","[Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]","Böhmer D, Wenz F, Martin T, Sedlmayr F, Hinkelbein W, Wiegel T.","Urologe A. 2010 Feb;49(2):211-5. doi: 10.1007/s00120-010-2241-8.","Böhmer D","Urologe A","2010","2010/02/25","","","10.1007/s00120-010-2241-8"
"24110260","Prostate cancer localization by novel magnetic resonance dispersion imaging","Mischi M, Saidov T, Kompatsiari K, Engelbrecht MR, Breeuwer M, Wijkstra H.","Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:2603-6. doi: 10.1109/EMBC.2013.6610073.","Mischi M","Annu Int Conf IEEE Eng Med Biol Soc","2013","2013/10/11","","","10.1109/EMBC.2013.6610073"
"12787710","Early diagnosis and surgical management of prostate cancer","Linton KD, Hamdy FC.","Cancer Treat Rev. 2003 Jun;29(3):151-60. doi: 10.1016/s0305-7372(03)00096-3.","Linton KD","Cancer Treat Rev","2003","2003/06/06","","","10.1016/s0305-7372(03)00096-3"
"26996776","Hair dye use, regular exercise, and the risk and prognosis of prostate cancer: multicenter case-control and case-only studies","Tai SY, Hsieh HM, Huang SP, Wu MT.","BMC Cancer. 2016 Mar 21;16:242. doi: 10.1186/s12885-016-2280-7.","Tai SY","BMC Cancer","2016","2016/03/22","PMC4800765","","10.1186/s12885-016-2280-7"
"15934465","[Role of dietary factors in prostate cancer development]","Zhu G, Zhang YQ, Wan B.","Zhonghua Nan Ke Xue. 2005 May;11(5):375-8.","Zhu G","Zhonghua Nan Ke Xue","2005","2005/06/07","","",""
"24859835","The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk","Fu C, Dong WQ, Wang A, Qiu G.","Tumour Biol. 2014 Aug;35(8):8319-28. doi: 10.1007/s13277-014-2086-7. Epub 2014 May 24.","Fu C","Tumour Biol","2014","2014/05/27","","","10.1007/s13277-014-2086-7"
"8693464","[Increased incidence of prostatic cancer. The significance of prostate-specific antigen]","Otnes B, Harvei S, Fosså SD.","Tidsskr Nor Laegeforen. 1996 Jun 10;116(15):1795-9.","Otnes B","Tidsskr Nor Laegeforen","1996","1996/06/10","","",""
"15471071","[A case of papillary cystadenocarcinoma of the prostate]","Fukuhara S, Hara T, Koichi T, Mori N, Yamaguchi S, Adachi S, Fujisue T.","Hinyokika Kiyo. 2004 Aug;50(8):531-4.","Fukuhara S","Hinyokika Kiyo","2004","2004/10/09","","",""
"11194946","[Multidisciplinary approach in the treatment of localized forms of cancer of the prostate]","Bolla M.","Cancer Radiother. 2000 Nov;4 Suppl 1:105s-108s.","Bolla M","Cancer Radiother","2000","2001/02/24","","",""
"27344716","[Mechanism of invasion and metastasis of prostate cancer: over view]","Kanayama H.","Nihon Rinsho. 2016 May 20;74 Suppl 3:129-34.","Kanayama H","Nihon Rinsho","2016","2016/06/28","","",""
"24709969","Prostate cancer: radiotherapy after surgery","Payton S.","Nat Rev Urol. 2014 May;11(5):248. doi: 10.1038/nrurol.2014.82. Epub 2014 Apr 8.","Payton S","Nat Rev Urol","2014","2014/04/09","","","10.1038/nrurol.2014.82"
"22704316","Re: Active surveillance failure for prostate cancer: does the delay in treatment increase the risk of urinary incontinence?","Eggener S.","Can J Urol. 2012 Jun;19(3):6292.","Eggener S","Can J Urol","2012","2012/06/19","","",""
"7901701","Apoptosis in prostate cancer after hormonal treatment","Szende B, Romics I, Vass L.","Lancet. 1993 Dec 4;342(8884):1422. doi: 10.1016/0140-6736(93)92779-s.","Szende B","Lancet","1993","1993/12/04","","","10.1016/0140-6736(93)92779-s"
"10656060","Management of carcinoma of the prostate","Kirby RS.","Hosp Med. 1999 Oct;60(10):700-3. doi: 10.12968/hosp.1999.60.10.1211.","Kirby RS","Hosp Med","1999","2000/02/03","","","10.12968/hosp.1999.60.10.1211"
"26101187","Primary radiotherapy vs conservative management for localized prostate cancer--a population-based study","Lu-Yao GL, Kim S, Moore DF, Shih W, Lin Y, DiPaola RS, Shen S, Zietman A, Yao SL.","Prostate Cancer Prostatic Dis. 2015 Dec;18(4):317-24. doi: 10.1038/pcan.2015.30. Epub 2015 Jun 23.","Lu-Yao GL","Prostate Cancer Prostatic Dis","2015","2015/06/24","PMC5518310","NIHMS877821","10.1038/pcan.2015.30"
"22290250","Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns","Lee WR.","Cancer J. 2012 Jan-Feb;18(1):9-10. doi: 10.1097/PPO.0b013e31824672e1.","Lee WR","Cancer J","2012","2012/02/01","","","10.1097/PPO.0b013e31824672e1"
"9162382","[Preoperative staging of prostatic carcinoma: evaluation of the role of transrectal echography]","Lorusso A, Curatolo C, Cirillo Marucco E, Ludovico GM, Limitone DA, Pagliarulo A.","Arch Ital Urol Androl. 1996 Dec;68(5 Suppl):83-5.","Lorusso A","Arch Ital Urol Androl","1996","1996/12/01","","",""
"24659630","Engineered repressors are potent inhibitors of androgen receptor activity","Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, Bevan CL.","Oncotarget. 2014 Feb 28;5(4):959-69. doi: 10.18632/oncotarget.1360.","Brooke GN","Oncotarget","2014","2014/03/25","PMC4011597","","10.18632/oncotarget.1360"
"7543607","Prostate cancer","Andriole GL.","J Urol. 1995 Sep;154(3):1102. doi: 10.1016/s0022-5347(01)66987-8.","Andriole GL","J Urol","1995","1995/09/01","","","10.1016/s0022-5347(01)66987-8"
"20332076","[Treatment of prostate cancer]","Romics I.","Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810.","Romics I","Orv Hetil","2010","2010/03/25","","","10.1556/OH.2010.28810"
"17965641","Will focal therapy become a standard of care for men with localized prostate cancer?","Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M.","Nat Clin Pract Oncol. 2007 Nov;4(11):632-42. doi: 10.1038/ncponc0959.","Ahmed HU","Nat Clin Pract Oncol","2007","2007/10/30","","","10.1038/ncponc0959"
"29569731","Exercise and prostate cancer: From basic science to clinical applications","Campos C, Sotomayor P, Jerez D, González J, Schmidt CB, Schmidt K, Banzer W, Godoy AS.","Prostate. 2018 Jun;78(9):639-645. doi: 10.1002/pros.23502. Epub 2018 Mar 23.","Campos C","Prostate","2018","2018/03/24","","","10.1002/pros.23502"
"7992712","[Treatment of advanced prostate cancer]","Okada K, Akino H, Suzuki Y, Miwa Y, Saikawa S, Fujita T, Aoki Y, Iwaoka K.","Hinyokika Kiyo. 1994 Oct;40(10):945-50.","Okada K","Hinyokika Kiyo","1994","1994/10/01","","",""
"9123701","Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age","Grönberg H, Damber L, Jonson H, Damber JE.","Urology. 1997 Mar;49(3):374-8. doi: 10.1016/S0090-4295(96)00508-0.","Grönberg H","Urology","1997","1997/03/01","","","10.1016/S0090-4295(96)00508-0"
"7714070","Prolonging survival in metastatic prostate cancer: the case for adrenal androgens--overview and summary of therapeutic controversies in prostatic cancer","Geller J.","J Clin Endocrinol Metab. 1995 Apr;80(4):1074-8. doi: 10.1210/jcem.80.4.7714070.","Geller J","J Clin Endocrinol Metab","1995","1995/04/01","","","10.1210/jcem.80.4.7714070"
"22759214","From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer","Hori S, Blanchet JS, McLoughlin J.","BJU Int. 2013 Oct;112(6):717-28. doi: 10.1111/j.1464-410X.2012.11329.x. Epub 2012 Jul 3.","Hori S","BJU Int","2013","2012/07/05","","","10.1111/j.1464-410X.2012.11329.x"
"12394261","The prospects of retinoids in the treatment of prostate cancer","Hammond LA, Brown G, Keedwell RG, Durham J, Chandraratna RA.","Anticancer Drugs. 2002 Sep;13(8):781-90. doi: 10.1097/00001813-200209000-00001.","Hammond LA","Anticancer Drugs","2002","2002/10/24","","","10.1097/00001813-200209000-00001"
"28077788","Androgen receptor splice variants and prostate cancer: From bench to bedside","Wadosky KM, Koochekpour S.","Oncotarget. 2017 Mar 14;8(11):18550-18576. doi: 10.18632/oncotarget.14537.","Wadosky KM","Oncotarget","2017","2017/01/13","PMC5392349","","10.18632/oncotarget.14537"
"26449841","The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer","Gandaglia G, Cozzarini C, Mottrie A, Bossi A, Fossati N, Montorsi F, Briganti A.","Curr Oncol Rep. 2015 Dec;17(12):53. doi: 10.1007/s11912-015-0478-5.","Gandaglia G","Curr Oncol Rep","2015","2015/10/10","","","10.1007/s11912-015-0478-5"
"9000208","Transforming growth factor beta as a clinical biomarker for prostate cancer","Perry KT, Anthony CT, Case T, Steiner MS.","Urology. 1997 Jan;49(1):151-5. doi: 10.1016/S0090-4295(96)00426-8.","Perry KT","Urology","1997","1997/01/01","","","10.1016/S0090-4295(96)00426-8"
"27344698","[Epidemiological trend of prostate cancer in Japan]","Yamaguchi K, Takahashi S.","Nihon Rinsho. 2016 May 20;74 Suppl 3:27-33.","Yamaguchi K","Nihon Rinsho","2016","2016/06/28","","",""
"14532778","Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors","Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat S, Slawin KM, Ohori M.","J Urol. 2003 Nov;170(5):1792-7. doi: 10.1097/01.ju.0000091806.70171.41.","Kattan MW","J Urol","2003","2003/10/09","","","10.1097/01.ju.0000091806.70171.41"
"27386626","Automated Region-based Prostate Cancer Cell Nuclei Localization. Part of a Prognostic Modality Tool for Prostate Cancer Patients","Zarei N, Bakhtiari A, Korbelik J, Carraro A, Keyes M, Guillaud M, MacAulay C.","Anal Quant Cytopathol Histpathol. 2016 Apr;38(2):59-69.","Zarei N","Anal Quant Cytopathol Histpathol","2016","2016/07/09","","",""
"8758236","PSA and prostate cancer diagnosis","Savage P, Waxman J.","Eur J Cancer. 1996 Jun;32A(7):1097-9. doi: 10.1016/0959-8049(96)00098-6.","Savage P","Eur J Cancer","1996","1996/06/01","","","10.1016/0959-8049(96)00098-6"
"20118519","[Bone and Men's Health. Bisphosphonate therapy for prostate cancer]","Suzuki H, Kamiya N, Yano M, Endo T, Takano M, Kawamura K, Imamoto T, Ichikawa T.","Clin Calcium. 2010 Feb;20(2):258-66.","Suzuki H","Clin Calcium","2010","2010/02/02","","",""
"11446133","Screening and clinical management of prostate cancer. A cross-national comparison","Peters SM, Jovell AJ, García-Altes A, Serra-Prat M.","Int J Technol Assess Health Care. 2001 Spring;17(2):215-21. doi: 10.1017/s0266462300105070.","Peters SM","Int J Technol Assess Health Care","2001","2001/07/12","","","10.1017/s0266462300105070"
"15046677","Radical prostatectomy improves cancer-specific survival but not overall survival in early-stage prostate cancer","Lee D.","Clin Prostate Cancer. 2003 Jun;2(1):15-7. doi: 10.1016/s1540-0352(11)70013-0.","Lee D","Clin Prostate Cancer","2003","2004/03/30","","","10.1016/s1540-0352(11)70013-0"
"18648944","Cancer-related identity and positive affect in survivors of prostate cancer","Bellizzi KM, Blank TO.","J Cancer Surviv. 2007 Mar;1(1):44-8. doi: 10.1007/s11764-007-0005-2.","Bellizzi KM","J Cancer Surviv","2007","2008/07/24","","","10.1007/s11764-007-0005-2"
"25056284","Development of clinical models for predicting erectile function after localized prostate cancer treatment","Haskins AE, Han PK, Lucas FL, Bristol I, Hansen M.","Int J Urol. 2014 Dec;21(12):1227-33. doi: 10.1111/iju.12566. Epub 2014 Jul 23.","Haskins AE","Int J Urol","2014","2014/07/25","","","10.1111/iju.12566"
"11383249","Radiation therapy for prostate cancer","Iwamoto RR, Maher KE.","Semin Oncol Nurs. 2001 May;17(2):90-100. doi: 10.1053/sonu.2000.23071.","Iwamoto RR","Semin Oncol Nurs","2001","2001/06/01","","","10.1053/sonu.2000.23071"
"9521168","Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial","Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Mäenpää H, Teerenhovi L, Koss L, Virolainen M, Edwards BK.","J Natl Cancer Inst. 1998 Mar 18;90(6):440-6. doi: 10.1093/jnci/90.6.440.","Heinonen OP","J Natl Cancer Inst","1998","1998/04/01","","","10.1093/jnci/90.6.440"
"21791109","Living with prostate cancer: randomised controlled trial of a multimodal supportive care intervention for men with prostate cancer","Chambers SK, Newton RU, Girgis A, Nielsen L, Lepore S, Mihalopoulos C, Gardiner R, Galvão DA, Occhipinti S.","BMC Cancer. 2011 Jul 27;11:317. doi: 10.1186/1471-2407-11-317.","Chambers SK","BMC Cancer","2011","2011/07/28","PMC3161036","","10.1186/1471-2407-11-317"
"28788048","Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors","Genitsch V, Zlobec I, Seiler R, Thalmann GN, Fleischmann A.","Int J Mol Sci. 2017 Jul 28;18(8):1640. doi: 10.3390/ijms18081640.","Genitsch V","Int J Mol Sci","2017","2017/08/10","PMC5578030","","10.3390/ijms18081640"
"8379481","[A case of müellerian duct cyst with prostate cancer]","Iwamura H, Matsuda T, Arai Y, Hida S, Takeuchi H, Yoshida O.","Hinyokika Kiyo. 1993 Aug;39(8):765-7.","Iwamura H","Hinyokika Kiyo","1993","1993/08/01","","",""
"3069334","Carcinoma of the prostate: pathology, staging, and treatment","Freiha FS, Bagshaw MA, Torti FM.","Curr Probl Cancer. 1988 Nov-Dec;12(6):329-411. doi: 10.1016/s0147-0272(88)80003-5.","Freiha FS","Curr Probl Cancer","1988","1988/11/01","","","10.1016/s0147-0272(88)80003-5"
"7979207","[Indications for radical prostatectomy in localized cancer of the prostate]","Jichlinski P.","Ann Urol (Paris). 1994;28(4):184-9.","Jichlinski P","Ann Urol (Paris)","1994","1994/01/01","","",""
"18807707","What advancements have you seen in prostate cancer treatment?","Matlin S.","ONS Connect. 2008 Sep;23(9):13.","Matlin S","ONS Connect","2008","2008/09/24","","",""
"9700306","[Localized prostatic cancer. Survival and loss of life expectancy]","Brasso K, Friis S, Juel K, Jørgensen T, Iversen P.","Ugeskr Laeger. 1998 Jul 27;160(31):4517-20.","Brasso K","Ugeskr Laeger","1998","1998/08/13","","",""
"7502411","Impact of prostate-specific antigen screening on the natural history of prostate cancer","Rosen MA.","Urology. 1995 Dec;46(6):757-68. doi: 10.1016/S0090-4295(99)80339-2.","Rosen MA","Urology","1995","1995/12/01","","","10.1016/S0090-4295(99)80339-2"
"17333203","Role of nomograms for prostate cancer in 2007","Chun FK, Karakiewicz PI, Huland H, Graefen M.","World J Urol. 2007 Apr;25(2):131-42. doi: 10.1007/s00345-007-0146-y. Epub 2007 Feb 27.","Chun FK","World J Urol","2007","2007/03/03","","","10.1007/s00345-007-0146-y"
"29578115","Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer","Gourdin T, Sonpavde G.","Asian J Androl. 2018 May-Jun;20(3):230-237. doi: 10.4103/aja.aja_1_18.","Gourdin T","Asian J Androl","2018","2018/03/27","PMC5952476","","10.4103/aja.aja_1_18"
"12231041","Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer","Pollack A, Kuban DA, Zagars GK.","Urology. 2002 Sep;60(3 Suppl 1):22-30; discussion 30-1. doi: 10.1016/s0090-4295(02)01564-9.","Pollack A","Urology","2002","2002/09/17","","","10.1016/s0090-4295(02)01564-9"
"17686830","B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy","Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, Krambeck AE, McKenney ME, Karnes RJ, Blute ML, Cheville JC, Sebo TJ, Kwon ED.","Cancer Res. 2007 Aug 15;67(16):7893-900. doi: 10.1158/0008-5472.CAN-07-1068. Epub 2007 Aug 8.","Roth TJ","Cancer Res","2007","2007/08/10","","","10.1158/0008-5472.CAN-07-1068"
"25569713","Technological aspects of delivering cryotherapy for prostate cancer","Lau B, Shah TT, Valerio M, Hamid S, Ahmed HU, Arya M.","Expert Rev Med Devices. 2015 Mar;12(2):183-90. doi: 10.1586/17434440.2015.990377. Epub 2015 Jan 8.","Lau B","Expert Rev Med Devices","2015","2015/01/09","","","10.1586/17434440.2015.990377"
"21461841","[Ten years national research project ""familial prostate cancer"": problems in identifying risk families]","Herkommer K, Schmidt C, Gschwend JE.","Urologe A. 2011 Jul;50(7):813-20. doi: 10.1007/s00120-011-2552-4.","Herkommer K","Urologe A","2011","2011/04/05","","","10.1007/s00120-011-2552-4"
"10963487","Role of transurethral biopsy sampling of the prostate to diagnose prostate cancer in men undergoing surgical intervention for benign prostatic hyperplasia","Bales GT, Flynn TJ, Kynaston HG, Golash A, Hart A, Kim HL, Gerber GS.","Tech Urol. 2000 Sep;6(3):201-4.","Bales GT","Tech Urol","2000","2000/08/30","","",""
"25626246","[Focal therapy in prostate cancer: rationale, results and perspectives]","Valerio M, Benamran D, Tawadros T, Cerantola Y, Meuwly JY, Lutchmaya-Flick C, Lhermitte B, Wirth G, Iselin C, Jichlinski P.","Rev Med Suisse. 2014 Dec 3;10(453):2306-10.","Valerio M","Rev Med Suisse","2014","2015/01/29","","",""
"27036046","Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines","Daoud G, Monzer A, Bahmad H, Chamaa F, Hamdar L, Mouhieddine TH, Shayya S, Eid A, Kobeissy F, Liu YN, Abou-Kheir W.","Oncotarget. 2016 May 17;7(20):28961-75. doi: 10.18632/oncotarget.8436.","Daoud G","Oncotarget","2016","2016/04/02","PMC5045370","","10.18632/oncotarget.8436"
"29049045","Nutrition, physical activity, and lifestyle factors in prostate cancer prevention","Ballon-Landa E, Parsons JK.","Curr Opin Urol. 2018 Jan;28(1):55-61. doi: 10.1097/MOU.0000000000000460.","Ballon-Landa E","Curr Opin Urol","2018","2017/10/20","","","10.1097/MOU.0000000000000460"
"13129636","High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions","Hoskin PJ, Bownes PJ, Ostler P, Walker K, Bryant L.","Radiother Oncol. 2003 Sep;68(3):285-8. doi: 10.1016/s0167-8140(03)00203-2.","Hoskin PJ","Radiother Oncol","2003","2003/09/18","","","10.1016/s0167-8140(03)00203-2"
"26341575","African-American Men with Gleason Score 3+3=6 Prostate Cancer Produce Less Prostate Specific Antigen than Caucasian Men: A Potential Impact on Active Surveillance","Kryvenko ON, Balise R, Soodana Prakash N, Epstein JI.","J Urol. 2016 Feb;195(2):301-6. doi: 10.1016/j.juro.2015.08.089. Epub 2015 Sep 2.","Kryvenko ON","J Urol","2016","2015/09/06","","","10.1016/j.juro.2015.08.089"
"21113818","The experiences of unpartnered men with prostate cancer: a qualitative analysis","Kazer MW, Harden J, Burke M, Sanda MG, Hardy J, Bailey DE; PROSTQA Study Group.","J Cancer Surviv. 2011 Jun;5(2):132-41. doi: 10.1007/s11764-010-0157-3. Epub 2010 Nov 28.","Kazer MW","J Cancer Surviv","2011","2010/11/30","PMC3897226","NIHMS520943","10.1007/s11764-010-0157-3"
"30115960","MRI in active surveillance: a critical review","Stavrinides V, Giganti F, Emberton M, Moore CM.","Prostate Cancer Prostatic Dis. 2019 Mar;22(1):5-15. doi: 10.1038/s41391-018-0077-2. Epub 2018 Aug 16.","Stavrinides V","Prostate Cancer Prostatic Dis","2019","2018/08/18","","","10.1038/s41391-018-0077-2"
"24043589","A new RNA-seq method to detect the transcription and non-coding RNA in prostate cancer","Zhang XM, Ma ZW, Wang Q, Wang JN, Yang JW, Li XD, Li H, Men TY.","Pathol Oncol Res. 2014 Jan;20(1):43-50. doi: 10.1007/s12253-013-9618-0. Epub 2013 Sep 17.","Zhang XM","Pathol Oncol Res","2014","2013/09/18","","","10.1007/s12253-013-9618-0"
"19758625","A framework for the identification of men at increased risk for prostate cancer","Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL.","J Urol. 2009 Nov;182(5):2112-20. doi: 10.1016/j.juro.2009.07.018. Epub 2009 Sep 16.","Roobol MJ","J Urol","2009","2009/09/18","","","10.1016/j.juro.2009.07.018"
"21301341","Contemporary role of prostate cancer gene 3 in the management of prostate cancer","Roobol MJ.","Curr Opin Urol. 2011 May;21(3):225-9. doi: 10.1097/MOU.0b013e328344939c.","Roobol MJ","Curr Opin Urol","2011","2011/02/09","","","10.1097/MOU.0b013e328344939c"
"25948412","Using CBPR to Extend Prostate Cancer Education, Counseling, and Screening Opportunities to Urban-Dwelling African-Americans","Ross L, Johnson J, Smallwood SW, Luque JS, Tedders SH, Airhihenbuwa CO, Alford T; MAN UP Prostate Cancer Advocates, Underwood W 3rd.","J Cancer Educ. 2016 Dec;31(4):702-708. doi: 10.1007/s13187-015-0849-5.","Ross L","J Cancer Educ","2016","2015/05/08","PMC5393453","NIHMS688520","10.1007/s13187-015-0849-5"
"15245824","Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16","Jung M, Xu C, Spethmann J, Johannsen M, Deger S, Stephan C, Loening SA, Jung K.","Eur Urol. 2004 Aug;46(2):271-2. doi: 10.1016/j.eururo.2004.03.003.","Jung M","Eur Urol","2004","2004/07/13","","","10.1016/j.eururo.2004.03.003"
"18438175","Androgens and the molecular epidemiology of prostate cancer","Chu LW, Reichardt JK, Hsing AW.","Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):261-70. doi: 10.1097/MED.0b013e3282febcf6.","Chu LW","Curr Opin Endocrinol Diabetes Obes","2008","2008/04/29","","","10.1097/MED.0b013e3282febcf6"
"25911361","The truth is in the water: metastatic prostate cancer presenting as an intermittent facial nerve palsy","Wooles N, Gupta S, Wilkin-Crowe H, Juratli A.","BMJ Case Rep. 2015 Apr 24;2015:bcr2014209168. doi: 10.1136/bcr-2014-209168.","Wooles N","BMJ Case Rep","2015","2015/04/26","PMC4420822","","10.1136/bcr-2014-209168"
"31639607","Variations in prostate biopsy recommendation and acceptance confound evaluation of risk factors for prostate cancer: Examining race and BMI","Tangen CM, Schenk J, Till C, Goodman PJ, Barrington W, Lucia MS, Thompson IM.","Cancer Epidemiol. 2019 Dec;63:101619. doi: 10.1016/j.canep.2019.101619. Epub 2019 Oct 19.","Tangen CM","Cancer Epidemiol","2019","2019/10/23","PMC6938232","NIHMS1543440","10.1016/j.canep.2019.101619"
"20380491","Candidate selection for prostate cancer focal therapy","Taneja SS, Mason M.","J Endourol. 2010 May;24(5):835-41. doi: 10.1089/end.2010.0006.","Taneja SS","J Endourol","2010","2010/04/13","","","10.1089/end.2010.0006"
"15065089","Vitamin D receptor gene polymorphisms and prostate cancer risk","Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA.","Prostate. 2004 Jun 1;59(4):409-18. doi: 10.1002/pros.20001.","Cheteri MB","Prostate","2004","2004/04/06","","","10.1002/pros.20001"
"16583213","Contemporary issues in the diagnosis of prostate cancer for the radiologist","Clements R.","Eur Radiol. 2006 Jul;16(7):1580-90. doi: 10.1007/s00330-006-0221-6. Epub 2006 Apr 1.","Clements R","Eur Radiol","2006","2006/04/04","","","10.1007/s00330-006-0221-6"
"30390642","Performance of prostate cancer recurrence nomograms by obesity status: a retrospective analysis of a radical prostatectomy cohort","Zeigler-Johnson C, Hudson A, Glanz K, Spangler E, Morales KH.","BMC Cancer. 2018 Nov 3;18(1):1061. doi: 10.1186/s12885-018-4942-0.","Zeigler-Johnson C","BMC Cancer","2018","2018/11/05","PMC6215603","","10.1186/s12885-018-4942-0"
"8911366","Significance of serum free prostate specific antigen in the screening of prostate cancer","Higashihara E, Nutahara K, Kojima M, Okegawa T, Miura I, Miyata A, Kato M, Sugisaki H, Tomaru T.","J Urol. 1996 Dec;156(6):1964-8.","Higashihara E","J Urol","1996","1996/12/01","","",""
"10129683","One man's tough choices on prostate cancer","Alexander T.","Fortune. 1993 Sep 20;128(6):86-8, 90, 92 passim.","Alexander T","Fortune","1993","1993/09/20","","",""
"21914109","Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy","Powell IJ.","BJU Int. 2011 Oct;108(7):1092. doi: 10.1111/j.1464-410X.2011.10541.x.","Powell IJ","BJU Int","2011","2011/09/15","","","10.1111/j.1464-410X.2011.10541.x"
"15879794","Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution?","Cohen RJ, Shannon BA, McNeal JE, Shannon T, Garrett KL.","J Urol. 2005 Jun;173(6):1969-74. doi: 10.1097/01.ju.0000158161.15277.78.","Cohen RJ","J Urol","2005","2005/05/10","","","10.1097/01.ju.0000158161.15277.78"
"25964833","Current role of multiparametric magnetic resonance imaging in the management of prostate cancer","Katelaris NC, Bolton DM, Weerakoon M, Toner L, Katelaris PM, Lawrentschuk N.","Korean J Urol. 2015 May;56(5):337-45. doi: 10.4111/kju.2015.56.5.337. Epub 2015 Apr 6.","Katelaris NC","Korean J Urol","2015","2015/05/13","PMC4426504","","10.4111/kju.2015.56.5.337"
"31280214","Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study","Kubo N, Kawamura H, Oike T, Sato H, Iwanaga M, Mizukami T, Adachi A, Matsui H, Ito K, Suzuki K, Nakano T.","In Vivo. 2019 Jul-Aug;33(4):1235-1241. doi: 10.21873/invivo.11595.","Kubo N","In Vivo","2019","2019/07/08","PMC6689351","","10.21873/invivo.11595"
"31399302","Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer","Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM.","Urol Oncol. 2019 Oct;37(10):688-695. doi: 10.1016/j.urolonc.2019.05.017. Epub 2019 Aug 6.","Ramamurthy C","Urol Oncol","2019","2019/08/11","","","10.1016/j.urolonc.2019.05.017"
"20731875","Diagnostic and treatment pathways for men with prostate cancer in Queensland: investigating spatial and demographic inequalities","Baade PD, Aitken JF, Ferguson M, Gardiner RA, Chambers SK.","BMC Cancer. 2010 Aug 23;10:452. doi: 10.1186/1471-2407-10-452.","Baade PD","BMC Cancer","2010","2010/08/25","PMC2936907","","10.1186/1471-2407-10-452"
"2443924","The role of surgery in the treatment of hormone resistant prostatic cancer","Benson MC.","Prog Clin Biol Res. 1987;243B:457-60.","Benson MC","Prog Clin Biol Res","1987","1987/01/01","","",""
"22767265","Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer","Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Møller H, Cooper CS, Cuzick J, Berney DM; Trans-Atlantic Prostate Group.","Virchows Arch. 2012 Aug;461(2):103-7. doi: 10.1007/s00428-012-1259-2. Epub 2012 Jul 6.","Jeetle SS","Virchows Arch","2012","2012/07/07","","","10.1007/s00428-012-1259-2"
"30893145","Targeting the androgen receptor and overcoming resistance in prostate cancer","Einstein DJ, Arai S, Balk SP.","Curr Opin Oncol. 2019 May;31(3):175-182. doi: 10.1097/CCO.0000000000000520.","Einstein DJ","Curr Opin Oncol","2019","2019/03/21","PMC6465077","NIHMS1521445","10.1097/CCO.0000000000000520"
"27087414","Symptomatic and quality-of-life outcomes after treatment for clinically localised prostate cancer: a systematic review","Whiting PF, Moore TH, Jameson CM, Davies P, Rowlands MA, Burke M, Beynon R, Savovic J, Donovan JL.","BJU Int. 2016 Aug;118(2):193-204. doi: 10.1111/bju.13499. Epub 2016 May 13.","Whiting PF","BJU Int","2016","2016/04/19","","","10.1111/bju.13499"
"10528023","Prostate-specific antigen testing of older men","Carter HB, Landis PK, Metter EJ, Fleisher LA, Pearson JD.","J Natl Cancer Inst. 1999 Oct 20;91(20):1733-7. doi: 10.1093/jnci/91.20.1733.","Carter HB","J Natl Cancer Inst","1999","1999/10/21","PMC3474977","NIHMS407180","10.1093/jnci/91.20.1733"
"15452554","Principles and results of high-intensity focused ultrasound for localized prostate cancer","Colombel M, Gelet A.","Prostate Cancer Prostatic Dis. 2004;7(4):289-94. doi: 10.1038/sj.pcan.4500721.","Colombel M","Prostate Cancer Prostatic Dis","2004","2004/09/29","","","10.1038/sj.pcan.4500721"
"16257838","Geographical variation in incidence of prostate cancer in Sweden","Stattin P, Johansson R, Lodnert R, Andrén O, Bill-Axelsson A, Bratt O, Damber JE, Hellström M, Hugosson J, Lundgren R, Törnblom M, Varenhorst E, Johansson JE.","Scand J Urol Nephrol. 2005;39(5):372-9. doi: 10.1080/00365590500375463.","Stattin P","Scand J Urol Nephrol","2005","2005/11/01","","","10.1080/00365590500375463"
"3317427","The U.S.A. experience: diagnosis and follow-up of prostate malignancy by transrectal ultrasound","Huben RP.","Prog Clin Biol Res. 1987;237:153-9.","Huben RP","Prog Clin Biol Res","1987","1987/01/01","","",""
"30978156","Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management","Giri VN, Hyatt C, Gomella LG.","J Clin Oncol. 2019 Jun 10;37(17):1455-1459. doi: 10.1200/JCO.18.02181. Epub 2019 Apr 12.","Giri VN","J Clin Oncol","2019","2019/04/13","","","10.1200/JCO.18.02181"
"12814673","Brachytherapy for prostate cancer: a systematic review of clinical and cost effectiveness","Norderhaug I, Dahl O, Høisaeter PA, Heikkilä R, Klepp O, Olsen DR, Kristiansen IS, Waehre H, Bjerklund Johansen TE.","Eur Urol. 2003 Jul;44(1):40-6. doi: 10.1016/s0302-2838(03)00187-8.","Norderhaug I","Eur Urol","2003","2003/06/20","","","10.1016/s0302-2838(03)00187-8"
"22038761","Castration-resistant prostate cancer: many treatments, many options, many challenges ahead","Garcia JA, Rini BI.","Cancer. 2012 May 15;118(10):2583-93. doi: 10.1002/cncr.26582. Epub 2011 Oct 28.","Garcia JA","Cancer","2012","2011/11/01","","","10.1002/cncr.26582"
"22771268","Genetic markers in prostate cancer: progress and limitations","Culig Z.","Eur Urol. 2012 Oct;62(4):588-9. doi: 10.1016/j.eururo.2012.06.040. Epub 2012 Jun 27.","Culig Z","Eur Urol","2012","2012/07/10","","","10.1016/j.eururo.2012.06.040"
"9806507","Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer","Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW.","Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):501-6. doi: 10.1016/s0360-3016(98)00270-3.","Valicenti RK","Int J Radiat Oncol Biol Phys","1998","1998/11/07","","","10.1016/s0360-3016(98)00270-3"
"21680196","Circulating tumor cells in prostate cancer: a potential surrogate marker of survival","Doyen J, Alix-Panabières C, Hofman P, Parks SK, Chamorey E, Naman H, Hannoun-Lévi JM.","Crit Rev Oncol Hematol. 2012 Mar;81(3):241-56. doi: 10.1016/j.critrevonc.2011.05.004. Epub 2011 Jun 15.","Doyen J","Crit Rev Oncol Hematol","2012","2011/06/18","","","10.1016/j.critrevonc.2011.05.004"
"20925112","Nanoparticle PSA test helps predict likelihood of prostate cancer recurrence","","Cancer. 2010 Oct 15;116(20):4669. doi: 10.1002/cncr.25663.","","Cancer","2010","2010/10/07","","","10.1002/cncr.25663"
"20584576","Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer","Krauss D, Kestin L, Ye H, Brabbins D, Ghilezan M, Gustafson G, Vicini F, Martinez A.","Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1064-71. doi: 10.1016/j.ijrobp.2010.04.004. Epub 2010 Jun 26.","Krauss D","Int J Radiat Oncol Biol Phys","2011","2010/06/30","","","10.1016/j.ijrobp.2010.04.004"
"21577233","Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer","Antonarakis ES, Armstrong AJ.","Prostate Cancer Prostatic Dis. 2011 Sep;14(3):206-18. doi: 10.1038/pcan.2011.24. Epub 2011 May 17.","Antonarakis ES","Prostate Cancer Prostatic Dis","2011","2011/05/18","PMC4124621","NIHMS599361","10.1038/pcan.2011.24"
"20715498","[Mass screening for prostate cancer at Ikeda City in Osaka Prefecture--results of screening with PSA alone between 2003 and 2007]","Inoue H, Kinouchi T, Kinoshita T, Kobayashi M, Ued T, Takada T, Hara T, Yamaguchi S, Kajimoto M, Kitamura K.","Nihon Hinyokika Gakkai Zasshi. 2010 Jul;101(5):671-5. doi: 10.5980/jpnjurol.101.671.","Inoue H","Nihon Hinyokika Gakkai Zasshi","2010","2010/08/19","","","10.5980/jpnjurol.101.671"
"22653787","Role of glyoxalase I in the proliferation and apoptosis control of human LNCaP and PC3 prostate cancer cells","Antognelli C, Mezzasoma L, Fettucciari K, Mearini E, Talesa VN.","Prostate. 2013 Jan;73(2):121-32. doi: 10.1002/pros.22547. Epub 2012 Jun 1.","Antognelli C","Prostate","2013","2012/06/02","","","10.1002/pros.22547"
"30908670","Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer","Kristiansen A, Bergström R, Delahunt B, Samaratunga H, Guðjónsdóttir J, Grönberg H, Egevad L, Lindberg J.","Prostate. 2019 Jun;79(8):920-928. doi: 10.1002/pros.23797. Epub 2019 Mar 25.","Kristiansen A","Prostate","2019","2019/03/26","","","10.1002/pros.23797"
"16795064","Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome","Swanson GP, Thompson IM, Basler J.","Cancer. 2006 Aug 1;107(3):439-50. doi: 10.1002/cncr.22034.","Swanson GP","Cancer","2006","2006/06/24","","","10.1002/cncr.22034"
"25966983","MicroRNAs targeting prostate cancer stem cells","Fang YX, Chang YL, Gao WQ.","Exp Biol Med (Maywood). 2015 Aug;240(8):1071-8. doi: 10.1177/1535370215584935. Epub 2015 May 12.","Fang YX","Exp Biol Med (Maywood)","2015","2015/05/14","PMC4935282","","10.1177/1535370215584935"
"12727674","Use of agricultural pesticides and prostate cancer risk in the Agricultural Health Study cohort","Alavanja MC, Samanic C, Dosemeci M, Lubin J, Tarone R, Lynch CF, Knott C, Thomas K, Hoppin JA, Barker J, Coble J, Sandler DP, Blair A.","Am J Epidemiol. 2003 May 1;157(9):800-14. doi: 10.1093/aje/kwg040.","Alavanja MC","Am J Epidemiol","2003","2003/05/03","","","10.1093/aje/kwg040"
"32404713","Focal 18F-NaF PET Prostate Activity in the Setting of Prostate Adenocarcinoma","Chiang J, Gershenson JP, Lewis MS, Vahidi K, Berenji GR.","Clin Nucl Med. 2020 Jul;45(7):e334-e335. doi: 10.1097/RLU.0000000000003094.","Chiang J","Clin Nucl Med","2020","2020/05/15","","","10.1097/RLU.0000000000003094"
"24265090","Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?","Butoescu V, Ambroise J, Stainier A, Dekairelle AF, Gala JL, Tombal B.","Prostate. 2014 Apr;74(4):365-71. doi: 10.1002/pros.22757. Epub 2013 Nov 22.","Butoescu V","Prostate","2014","2013/11/23","","","10.1002/pros.22757"
"19468284","First-year costs of treating prostate cancer: estimates from SEER-Medicare data","Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A.","Prostate Cancer Prostatic Dis. 2009;12(4):355-60. doi: 10.1038/pcan.2009.21. Epub 2009 May 26.","Roehrborn CG","Prostate Cancer Prostatic Dis","2009","2009/05/27","","","10.1038/pcan.2009.21"
"12131299","Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection","Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P.","J Urol. 2002 Aug;168(2):509-13.","Egevad L","J Urol","2002","2002/07/20","","",""
"9598512","Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study","Granfors T, Modig H, Damber JE, Tomic R.","J Urol. 1998 Jun;159(6):2030-4.","Granfors T","J Urol","1998","1998/05/23","","",""
"16142454","[Treatment errors involving diagnosis using prostate specific antigen. Decisions of the commission of experts for medical mistakes of treatment of the state medical board of North Rhine]","Lent V, Baumbusch F, Weber G.","Urologe A. 2005 Dec;44(12):1458-62. doi: 10.1007/s00120-005-0894-5.","Lent V","Urologe A","2005","2005/09/06","","","10.1007/s00120-005-0894-5"
"875130","[Value of several unusual examinations (deferentography, cavernography, arteriography) in prostate cancer and the possibility of therapeutic embolization]","Le Guillou M, Mugnier C, Jonchères P, Lange J.","J Urol Nephrol (Paris). 1977 Jan-Feb;83(1-2):89-91.","Le Guillou M","J Urol Nephrol (Paris)","1977","1977/01/01","","",""
"12382511","Minimally invasive procedure and robotic technology combined to treat prostate cancer","","Expert Rev Anticancer Ther. 2002 Oct;2(5):482.","","Expert Rev Anticancer Ther","2002","2002/10/18","","",""
"10389909","Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families","Matikainen MP, Schleutker J, Mörsky P, Kallioniemi OP, Tammela TL.","Clin Cancer Res. 1999 Jun;5(6):1275-9.","Matikainen MP","Clin Cancer Res","1999","1999/07/02","","",""
"24029318","Re: Prostate cancer screening in men ages 75 and older fell by 8 percentage points after Task Force recommendation","Penson DF.","J Urol. 2013 Oct;190(4):1250. doi: 10.1016/j.juro.2013.06.066. Epub 2013 Jun 26.","Penson DF","J Urol","2013","2013/09/14","","","10.1016/j.juro.2013.06.066"
"30482167","Differences in prostate tumor characteristics and survival among religious groups in Songkhla, Thailand","Alvarez CS, Villamor E, Meza R, Rozek LS, Sriplung H, Mondul AM.","BMC Cancer. 2018 Nov 27;18(1):1175. doi: 10.1186/s12885-018-5102-2.","Alvarez CS","BMC Cancer","2018","2018/11/29","PMC6260711","","10.1186/s12885-018-5102-2"
"28228136","Circulating tumor cells capture disease evolution in advanced prostate cancer","Lack J, Gillard M, Cam M, Paner GP, VanderWeele DJ.","J Transl Med. 2017 Feb 23;15(1):44. doi: 10.1186/s12967-017-1138-3.","Lack J","J Transl Med","2017","2017/02/24","PMC5322599","","10.1186/s12967-017-1138-3"
"17414645","Bone metastases in prostate cancer: a targeted approach","Storey JA, Torti FM.","Curr Opin Oncol. 2007 May;19(3):254-8. doi: 10.1097/CCO.0b013e32805e8787.","Storey JA","Curr Opin Oncol","2007","2007/04/07","","","10.1097/CCO.0b013e32805e8787"
"14628595","[Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer]","Xiang ST, Zhou SW, Guan W, Wang QZ, Zhang B, Liu JH, Ye ZQ.","Zhonghua Nan Ke Xue. 2003 Oct;9(7):497-500.","Xiang ST","Zhonghua Nan Ke Xue","2003","2003/11/25","","",""
"24614347","Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer","Welty CJ, Cooperberg MR, Carroll PR.","Curr Opin Urol. 2014 May;24(3):288-92. doi: 10.1097/MOU.0000000000000039.","Welty CJ","Curr Opin Urol","2014","2014/03/12","PMC6586410","NIHMS589206","10.1097/MOU.0000000000000039"
"20204704","Association between utility and treatment among patients with prostate cancer","Jayadevappa R, Schwartz JS, Chhatre S, Wein AJ, Malkowicz SB.","Qual Life Res. 2010 Jun;19(5):711-20. doi: 10.1007/s11136-010-9622-8. Epub 2010 Mar 5.","Jayadevappa R","Qual Life Res","2010","2010/03/06","","","10.1007/s11136-010-9622-8"
"20088117","[Prostate cancer screening: an update]","Tawadros T, Doerfler A, Treuthardt C, Praz V, Levi F, Zouhair A, Berthold D, Bauer J, Iselin C, Jichlinski P.","Rev Med Suisse. 2009 Dec 2;5(228):2438-41.","Tawadros T","Rev Med Suisse","2009","2010/01/22","","",""
"9559840","Public awareness and knowledge of prostate cancer in Japan: results of a survey at short-stay examination facilities","Egawa S, Suyama K, Shitara T, Uchida T, Koshiba K.","Int J Urol. 1998 Mar;5(2):146-51. doi: 10.1111/j.1442-2042.1998.tb00265.x.","Egawa S","Int J Urol","1998","1998/04/29","","","10.1111/j.1442-2042.1998.tb00265.x"
"30503851","Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy","Olson B, Patnaik A.","Urol Oncol. 2019 Aug;37(8):535-542. doi: 10.1016/j.urolonc.2018.11.009. Epub 2018 Nov 29.","Olson B","Urol Oncol","2019","2018/12/04","","","10.1016/j.urolonc.2018.11.009"
"10751858","Differences between urologists in the United States and Canada in the approach to prostate cancer","Fleshner N, Rakovitch E, Klotz L.","J Urol. 2000 May;163(5):1461-6.","Fleshner N","J Urol","2000","2001/02/07","","",""
"7694555","An evaluation of prostate-specific antigen as a screening test for prostate cancer","Dorr VJ, Williamson SK, Stephens RL.","Arch Intern Med. 1993 Nov 22;153(22):2529-37.","Dorr VJ","Arch Intern Med","1993","1993/11/22","","",""
"19752612","Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease","Bright EA, Manuel C, Goddard JC, Khan MA.","Urol Int. 2009;83(2):171-4. doi: 10.1159/000230019. Epub 2009 Sep 10.","Bright EA","Urol Int","2009","2009/09/16","","","10.1159/000230019"
"2029413","Radiotherapy or surgery for prostate cancer? Ten and fifteen-year results of external beam therapy","Hanks GE.","Acta Oncol. 1991;30(2):231-7. doi: 10.3109/02841869109092359.","Hanks GE","Acta Oncol","1991","1991/01/01","","","10.3109/02841869109092359"
"8208961","Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms?","Lawton CA, Cantrell JE, Derus SW, Murray KJ, Byhardt RW, Wilson JF.","Radiology. 1994 Jul;192(1):37-40. doi: 10.1148/radiology.192.1.8208961.","Lawton CA","Radiology","1994","1994/07/01","","","10.1148/radiology.192.1.8208961"
"1371562","Transrectal ultrasound imaging and ultrasound guided prostate biopsies in the detection of residual carcinoma in clinical stage A carcinoma of the prostate","Terris MK, McNeal JE, Stamey TA.","J Urol. 1992 Mar;147(3 Pt 2):864-9. doi: 10.1016/s0022-5347(17)37407-4.","Terris MK","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37407-4"
"16172240","Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy","Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ.","Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2257-60. doi: 10.1158/1055-9965.EPI-04-0715.","Parsons JK","Cancer Epidemiol Biomarkers Prev","2005","2005/09/21","","","10.1158/1055-9965.EPI-04-0715"
"25537214","Precision therapy to target apoptosis in prostate cancer","Kulik G.","Exp Oncol. 2014 Dec;36(4):226-30.","Kulik G","Exp Oncol","2014","2014/12/25","","",""
"12459730","Bloodborne biomolecular markers in prostate cancer development and progression","Bok RA, Small EJ.","Nat Rev Cancer. 2002 Dec;2(12):918-26. doi: 10.1038/nrc951.","Bok RA","Nat Rev Cancer","2002","2002/12/03","","","10.1038/nrc951"
"22841322","Prostate cancer: send away the PSA?","","Lancet. 2012 Jul 28;380(9839):307. doi: 10.1016/S0140-6736(12)61232-X.","","Lancet","2012","2012/07/31","","","10.1016/S0140-6736(12)61232-X"
"28371016","Prostate cancer family history and eligibility for active surveillance: a systematic review of the literature","Telang JM, Lane BR, Cher ML, Miller DC, Dupree JM.","BJU Int. 2017 Oct;120(4):464-467. doi: 10.1111/bju.13862. Epub 2017 May 3.","Telang JM","BJU Int","2017","2017/04/04","","","10.1111/bju.13862"
"17189080","In regards to Thames et al.: increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. (Int J Radiat Oncol Biol Phys 2006;65:975-981)","Pickles T, Williams SG.","Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):318-9; author reply 319. doi: 10.1016/j.ijrobp.2006.09.016.","Pickles T","Int J Radiat Oncol Biol Phys","2007","2006/12/26","","","10.1016/j.ijrobp.2006.09.016"
"11238710","Re: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study","Dalkin BL.","J Natl Cancer Inst. 2001 Mar 7;93(5):401-2. doi: 10.1093/jnci/93.5.401.","Dalkin BL","J Natl Cancer Inst","2001","2001/03/10","","","10.1093/jnci/93.5.401"
"31421692","Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer","Liu J, Li Y, Yang D, Yang C, Mao L.","Discov Med. 2019 Jun;27(150):235-243.","Liu J","Discov Med","2019","2019/08/19","","",""
"27618134","Is negative multiparametric magnetic resonance imaging really able to exclude significant prostate cancer? The real-life experience","Branger N, Maubon T, Traumann M, Thomassin-Piana J, Brandone N, Taix S, Touzlian J, Brunelle S, Pignot G, Salem N, Gravis G, Walz J.","BJU Int. 2017 Mar;119(3):449-455. doi: 10.1111/bju.13657. Epub 2016 Oct 4.","Branger N","BJU Int","2017","2016/09/13","","","10.1111/bju.13657"
"17240039","Editorial comment on: Improved accuracy in predicting the presence of gleason pattern 4/5 prostate cancer by three-dimensional 26-core systematic biopsy","Remzi M.","Eur Urol. 2007 Dec;52(6):1668-9. doi: 10.1016/j.eururo.2007.01.026.","Remzi M","Eur Urol","2007","2007/01/24","","","10.1016/j.eururo.2007.01.026"
"28797228","Oncological outcomes in an Australian cohort according to the new prostate cancer grading groupings","Beckmann KR, Vincent AD, O'Callaghan ME, Cohen P, Chang S, Borg M, Evans SM, Roder DM, Moretti KL; South Australia Prostate Cancer Clinical Outcomes Collaborative.","BMC Cancer. 2017 Aug 10;17(1):537. doi: 10.1186/s12885-017-3533-9.","Beckmann KR","BMC Cancer","2017","2017/08/12","PMC5553659","","10.1186/s12885-017-3533-9"
"23969936","Characterization and clinical relevance of ALDHbright populations in prostate cancer","Le Magnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, Rieken M, Thalmann GN, Cecchini MG, Germann M, Bachmann A, Wyler S, Heberer M, Spagnoli GC.","Clin Cancer Res. 2013 Oct 1;19(19):5361-71. doi: 10.1158/1078-0432.CCR-12-2857. Epub 2013 Aug 22.","Le Magnen C","Clin Cancer Res","2013","2013/08/24","","","10.1158/1078-0432.CCR-12-2857"
"25854335","Biomarkers for evaluation of prostate cancer prognosis","Esfahani M, Ataei N, Panjehpour M.","Asian Pac J Cancer Prev. 2015;16(7):2601-11. doi: 10.7314/apjcp.2015.16.7.2601.","Esfahani M","Asian Pac J Cancer Prev","2015","2015/04/10","","","10.7314/apjcp.2015.16.7.2601"
"8539714","[Prostate-specific membrane antigen. A new sensitive molecular indicator in metastasizing prostatic cancer]","Kippersund JT, Haukeland B, Lilleeng BF, Daehlin L, Haukaas S, Høisaeter PA, Ogreid D.","Tidsskr Nor Laegeforen. 1995 Nov 30;115(29):3612-5.","Kippersund JT","Tidsskr Nor Laegeforen","1995","1995/11/30","","",""
"15958594","The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype","Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini PG, Katzenellenbogen BS, Martini L, Motta M, Poletti A.","Cancer Res. 2005 Jun 15;65(12):5445-53. doi: 10.1158/0008-5472.CAN-04-1941.","Guerini V","Cancer Res","2005","2005/06/17","","","10.1158/0008-5472.CAN-04-1941"
"23581418","Trends and estimates in prostate cancer incidence, mortality and prevalence in the Slovak Republic, 1968-2012","Ondrusova M, Mrozova L, Ondrus D, Mrinakova B.","Neoplasma. 2013;60(4):446-51. doi: 10.4149/neo_2013_058.","Ondrusova M","Neoplasma","2013","2013/04/16","","","10.4149/neo_2013_058"
"27804860","Highly Disordered Proteins in Prostate Cancer","Uversky VN, Na I, Landau KS, Schenck RO.","Curr Protein Pept Sci. 2017;18(5):453-481. doi: 10.2174/1389203717666161028145848.","Uversky VN","Curr Protein Pept Sci","2017","2016/11/03","","","10.2174/1389203717666161028145848"
"8547540","The accuracy of prostate cancer staging in a population-based tumor registry and its impact on the black-white stage difference (Connecticut, United States)","Liu WL, Kasl S, Flannery JT, Lindo A, Dubrow R.","Cancer Causes Control. 1995 Sep;6(5):425-30. doi: 10.1007/BF00052182.","Liu WL","Cancer Causes Control","1995","1995/09/01","","","10.1007/BF00052182"
"20868409","Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?","Lynn R, Krunic A.","Dermatol Ther. 2010 Sep-Oct;23(5):544-6. doi: 10.1111/j.1529-8019.2010.01358.x.","Lynn R","Dermatol Ther","2010","2010/09/28","","","10.1111/j.1529-8019.2010.01358.x"
"28637962","[3. Diagnostic Imaging for Prostate Cancer]","Yoshida R, Yoshizako T, Kitagaki H.","Nihon Hoshasen Gijutsu Gakkai Zasshi. 2017;73(6):477-485. doi: 10.6009/jjrt.2017_JSRT_73.6.477.","Yoshida R","Nihon Hoshasen Gijutsu Gakkai Zasshi","2017","2017/06/23","","","10.6009/jjrt.2017_JSRT_73.6.477"
"19501457","Editorial comment on: Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients","Yossepowitch O.","Eur Urol. 2009 Oct;56(4):676-7. doi: 10.1016/j.eururo.2009.05.043. Epub 2009 May 29.","Yossepowitch O","Eur Urol","2009","2009/06/09","","","10.1016/j.eururo.2009.05.043"
"10408950","Strategies for the Chemoprevention of Prostate Cancer. Symposium proceedings. Brussels, Belgium. October 29-31, 1998","","Eur Urol. 1999;35(5-6):341-547.","","Eur Urol","1999","1999/07/17","","",""
"19388987","Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience","DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.","BJU Int. 2009 Nov;104(9):1208-14. doi: 10.1111/j.1464-410X.2009.08593.x. Epub 2009 Apr 17.","DiBlasio CJ","BJU Int","2009","2009/04/25","","","10.1111/j.1464-410X.2009.08593.x"
"9266239","Relationship between DNA ploidy and functional estrogen receptors in operable prostate cancer","Nativ O, Umehara T, Colvard DS, Therneau TM, Farrow GM, Spelsberg TC, Lieber MM.","Eur Urol. 1997;32(1):96-9.","Nativ O","Eur Urol","1997","1997/01/01","","",""
"19319183","New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression","Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, Samaratunga H, Lavin MF, Gardiner RA.","PLoS One. 2009;4(3):e4995. doi: 10.1371/journal.pone.0004995. Epub 2009 Mar 25.","Clarke RA","PLoS One","2009","2009/03/26","PMC2655648","","10.1371/journal.pone.0004995"
"15749642","[Preclinical models of prostate cancer]","Fizazi K, Navone NM.","Bull Cancer. 2005 Feb;92(2):129-41.","Fizazi K","Bull Cancer","2005","2005/03/08","","",""
"24236006","Quantitative network measures as biomarkers for classifying prostate cancer disease states: a systems approach to diagnostic biomarkers","Dehmer M, Mueller LA, Emmert-Streib F.","PLoS One. 2013 Nov 13;8(11):e77602. doi: 10.1371/journal.pone.0077602. eCollection 2013.","Dehmer M","PLoS One","2013","2013/11/16","PMC3827206","","10.1371/journal.pone.0077602"
"23293883","Sugar-borate esters--potential chemical agents in prostate cancer chemoprevention","Scorei RI, Popa R.","Anticancer Agents Med Chem. 2013 Jul 1;13(6):901-9. doi: 10.2174/18715206113139990124.","Scorei RI","Anticancer Agents Med Chem","2013","2013/01/09","","","10.2174/18715206113139990124"
"11149684","MR imaging of prostate cancer","Wong-You-Cheong JJ, Krebs TL.","Magn Reson Imaging Clin N Am. 2000 Nov;8(4):869-86.","Wong-You-Cheong JJ","Magn Reson Imaging Clin N Am","2000","2001/01/10","","",""
"22336908","Significant addition to treatment options for bone metastasis in prostate cancer","Richardson ED, Price DK, Figg WD.","Cancer Biol Ther. 2012 Jan 15;13(2):69-70. doi: 10.4161/cbt.13.2.18441.","Richardson ED","Cancer Biol Ther","2012","2012/02/17","PMC3342941","","10.4161/cbt.13.2.18441"
"15982318","Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature","Varma M, Jasani B.","Histopathology. 2005 Jul;47(1):1-16. doi: 10.1111/j.1365-2559.2005.02188.x.","Varma M","Histopathology","2005","2005/06/29","","","10.1111/j.1365-2559.2005.02188.x"
"32195681","Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer","Hadavand MA, Mayer D, Chen W, Wnorowski A, Siddiqui MM.","Curr Opin Oncol. 2020 May;32(3):223-231. doi: 10.1097/CCO.0000000000000625.","Hadavand MA","Curr Opin Oncol","2020","2020/03/21","PMC7328528","NIHMS1593021","10.1097/CCO.0000000000000625"
"1374178","Volume of normal prostate, of prostate cancer, and of benign prostatic hyperplasia: are correlations with prostate specific antigen clinically useful?","Clements R, Penney MD, Etherington RJ, Griffiths GJ, Hughes H, Peeling WB.","Prostate Suppl. 1992;4:51-7. doi: 10.1002/pros.2990210508.","Clements R","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210508"
"20014922","Discovery of prostate cancer biomarkers by microarray gene expression profiling","Sørensen KD, Ørntoft TF.","Expert Rev Mol Diagn. 2010 Jan;10(1):49-64. doi: 10.1586/erm.09.74.","Sørensen KD","Expert Rev Mol Diagn","2010","2009/12/18","","","10.1586/erm.09.74"
"18246671","Differentiation between benign prostatic hyperplasia and prostate cancer in the transitional zone evaluated by 1H magnetic resonance spectroscopic imaging","Li SY, Chen M, Wang R, Zhou C.","Chin Med Sci J. 2007 Dec;22(4):238-42.","Li SY","Chin Med Sci J","2007","2008/02/06","","",""
"29243485","Molecular imaging of prostate cancer","Boustani AM, Pucar D, Saperstein L.","Br J Radiol. 2018 Apr;91(1084):20170736. doi: 10.1259/bjr.20170736. Epub 2018 Feb 1.","Boustani AM","Br J Radiol","2018","2017/12/16","PMC5966010","","10.1259/bjr.20170736"
"12883728","FDG PET in suspected recurrent and metastatic prostate cancer","Jadvar H, Pinski JK, Conti PS.","Oncol Rep. 2003 Sep-Oct;10(5):1485-8.","Jadvar H","Oncol Rep","2003","2003/07/29","","",""
"9700304","[Radical prostatectomy for localized prostatic cancer]","Brasso K, Iversen P.","Ugeskr Laeger. 1998 Jul 27;160(31):4505-9.","Brasso K","Ugeskr Laeger","1998","1998/08/13","","",""
"8158675","Do diet and androgens alter prostate cancer risk via a common etiologic pathway?","Ross RK, Henderson BE.","J Natl Cancer Inst. 1994 Feb 16;86(4):252-4. doi: 10.1093/jnci/86.4.252.","Ross RK","J Natl Cancer Inst","1994","1994/02/16","","","10.1093/jnci/86.4.252"
"22870533","Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system","Aneja S, Pratiwadi RR, Yu JB.","Oncology (Williston Park). 2012 Jun;26(6):512-8.","Aneja S","Oncology (Williston Park)","2012","2012/08/09","","",""
"25570710","Multiparametric MRI prostate cancer analysis via a hybrid morphological-textural model","Cameron A, Modhafar A, Khalvati F, Lui D, Shafiee MJ, Wong A, Haider M.","Annu Int Conf IEEE Eng Med Biol Soc. 2014;2014:3357-60. doi: 10.1109/EMBC.2014.6944342.","Cameron A","Annu Int Conf IEEE Eng Med Biol Soc","2014","2015/01/09","","","10.1109/EMBC.2014.6944342"
"25042396","Substance use disorder and its effects on outcomes in men with advanced-stage prostate cancer","Chhatre S, Metzger DS, Malkowicz SB, Woody G, Jayadevappa R.","Cancer. 2014 Nov 1;120(21):3338-45. doi: 10.1002/cncr.28861. Epub 2014 Jul 9.","Chhatre S","Cancer","2014","2014/07/22","PMC4205195","NIHMS618741","10.1002/cncr.28861"
"26814711","Gene-expression profiling of localized prostate cancer: still miles to go before we sleep","Garzotto M, Kopp RP.","Future Oncol. 2016 Feb;12(3):273-6. doi: 10.2217/fon.15.316. Epub 2016 Jan 19.","Garzotto M","Future Oncol","2016","2016/01/28","","","10.2217/fon.15.316"
"23442556","A randomised controlled trial of a mindfulness intervention for men with advanced prostate cancer","Chambers SK, Smith DP, Berry M, Lepore SJ, Foley E, Clutton S, McDowall R, Occhipinti S, Frydenberg M, Gardiner RA.","BMC Cancer. 2013 Feb 26;13:89. doi: 10.1186/1471-2407-13-89.","Chambers SK","BMC Cancer","2013","2013/02/28","PMC3598536","","10.1186/1471-2407-13-89"
"21675925","Recent advances in immunotherapy for the treatment of prostate cancer","Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW.","Expert Opin Biol Ther. 2011 Aug;11(8):997-1009. doi: 10.1517/14712598.2011.575357. Epub 2011 Jun 15.","Sonpavde G","Expert Opin Biol Ther","2011","2011/06/17","","","10.1517/14712598.2011.575357"
"26519964","[Analysis and prognostic factors of the specimen of radical prostatectomy in prostate cancer]","Fromont G, Molinié V, Soulié M, Salomon L.","Prog Urol. 2015 Nov;25(15):999-1009. doi: 10.1016/j.purol.2015.08.002.","Fromont G","Prog Urol","2015","2015/11/02","","","10.1016/j.purol.2015.08.002"
"11856106","Making decisions about treatment for localized prostate cancer","Steginga SK, Occhipinti S, Gardiner RA, Yaxley J, Heathcote P.","BJU Int. 2002 Feb;89(3):255-60. doi: 10.1046/j.1464-4096.2001.01741.x.","Steginga SK","BJU Int","2002","2002/02/22","","","10.1046/j.1464-4096.2001.01741.x"
"23393351","Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer","Yasuda K, Komiya A, Watanabe A, Morii A, Oya T, Nagakawa O, Fujiuchi Y, Fuse H.","Anticancer Res. 2013 Feb;33(2):575-81.","Yasuda K","Anticancer Res","2013","2013/02/09","","",""
"24719035","The 20th Annual Prostate Cancer Foundation Scientific Retreat report","Miyahira AK, Simons JW, Soule HR.","Prostate. 2014 Jun;74(8):811-9. doi: 10.1002/pros.22808. Epub 2014 Apr 9.","Miyahira AK","Prostate","2014","2014/04/11","","","10.1002/pros.22808"
"21720862","Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion","Tombal B, Ameye F, de la Taille A, de Reijke T, Gontero P, Haese A, Kil P, Perrin P, Remzi M, Schröder J, Speakman M, Volpe A, Meesen B, Stoevelaar H.","World J Urol. 2012 Apr;30(2):251-6. doi: 10.1007/s00345-011-0721-0. Epub 2011 Jul 1.","Tombal B","World J Urol","2012","2011/07/02","","","10.1007/s00345-011-0721-0"
"18039115","Integrative biology of prostate cancer progression","Tomlins SA, Rubin MA, Chinnaiyan AM.","Annu Rev Pathol. 2006;1:243-71. doi: 10.1146/annurev.pathol.1.110304.100047.","Tomlins SA","Annu Rev Pathol","2006","2007/11/28","","","10.1146/annurev.pathol.1.110304.100047"
"12845682","Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer","Perron L, Bairati I, Moore L, Meyer F.","Int J Cancer. 2003 Sep 1;106(3):409-15. doi: 10.1002/ijc.11250.","Perron L","Int J Cancer","2003","2003/07/08","","","10.1002/ijc.11250"
"1283897","The role of digital rectal examination, transrectal ultrasound, and prostate specific antigen for the detection of confined and clinically relevant prostate cancer","Lee F, Littrup PJ.","J Cell Biochem Suppl. 1992;16H:69-73. doi: 10.1002/jcb.240501216.","Lee F","J Cell Biochem Suppl","1992","1992/01/01","","","10.1002/jcb.240501216"
"24996773","Genetic predisposition to prostate cancer: Update and future perspectives","Demichelis F, Stanford JL.","Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 2.","Demichelis F","Urol Oncol","2015","2014/07/06","","","10.1016/j.urolonc.2014.04.021"
"31219610","Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?","Madueke I, Abern MR.","Oncology (Williston Park). 2019 Jun 19;33(6):235, 237-8, 242.","Madueke I","Oncology (Williston Park)","2019","2019/06/21","","",""
"12231037","Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer","Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR.","Urology. 2002 Sep;60(3 Suppl 1):7-11; discussion 11-2. doi: 10.1016/s0090-4295(02)01560-1.","Meng MV","Urology","2002","2002/09/17","","","10.1016/s0090-4295(02)01560-1"
"25593038","Chronic inflammatory mediators enhance prostate cancer development and progression","Thapa D, Ghosh R.","Biochem Pharmacol. 2015 Mar 15;94(2):53-62. doi: 10.1016/j.bcp.2014.12.023. Epub 2015 Jan 12.","Thapa D","Biochem Pharmacol","2015","2015/01/17","","","10.1016/j.bcp.2014.12.023"
"14620298","The role of prostate specific antigen in screening and management of clinically localized prostate cancer","Guru K, Tewari A, Hemal AK, Wei J, Javidan J, Peabody J, Menon M.","Int Urol Nephrol. 2003;35(1):107-13. doi: 10.1023/a:1025978512921.","Guru K","Int Urol Nephrol","2003","2003/11/19","","","10.1023/a:1025978512921"
"28597850","The role of peroxisome proliferator-activated receptor gamma in prostate cancer","Elix C, Pal SK, Jones JO.","Asian J Androl. 2018 May-Jun;20(3):238-243. doi: 10.4103/aja.aja_15_17.","Elix C","Asian J Androl","2018","2017/06/10","PMC5952477","","10.4103/aja.aja_15_17"
"17453919","Precursor lesions of prostate cancer","Chrisofos M, Papatsoris AG, Lazaris A, Deliveliotis C.","Crit Rev Clin Lab Sci. 2007;44(3):243-70. doi: 10.1080/10408360601177236.","Chrisofos M","Crit Rev Clin Lab Sci","2007","2007/04/25","","","10.1080/10408360601177236"
"25523210","Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate cancer","Borkowetz A, Platzek I, Toma M, Laniado M, Baretton G, Froehner M, Koch R, Wirth M, Zastrow S.","BJU Int. 2015 Dec;116(6):873-9. doi: 10.1111/bju.13023. Epub 2015 Apr 27.","Borkowetz A","BJU Int","2015","2014/12/20","","","10.1111/bju.13023"
"17611016","Re: Felix K.-H. Chun, Thomas Steuber, Andreas Erbersdobler, et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006;49:820-26","Beckley I, Khan MA.","Eur Urol. 2007 Oct;52(4):1270; author reply 1271. doi: 10.1016/j.eururo.2007.06.024. Epub 2007 Jun 26.","Beckley I","Eur Urol","2007","2007/07/06","","","10.1016/j.eururo.2007.06.024"
"9612676","Etiology and diagnosis of prostate cancer: what's new? A review","Zlotta AR, Schulman CC.","Eur Urol. 1998;33(4):351-8. doi: 10.1159/000019615.","Zlotta AR","Eur Urol","1998","1998/06/05","","","10.1159/000019615"
"25617303","Re: Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study","Penson DF.","J Urol. 2015 Feb;193(2):628-9. doi: 10.1016/j.juro.2014.11.054. Epub 2014 Nov 18.","Penson DF","J Urol","2015","2015/01/25","","","10.1016/j.juro.2014.11.054"
"25523658","Re: Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study","Taneja SS.","J Urol. 2015 Jan;193(1):127-8. doi: 10.1016/j.juro.2014.10.075. Epub 2014 Oct 22.","Taneja SS","J Urol","2015","2014/12/20","","","10.1016/j.juro.2014.10.075"
"18574096","Radiotherapy dose in the treatment of localized prostate cancer","Kälkner KM.","Arch Intern Med. 2008 Jun 23;168(12):1352-3; author reply 1353. doi: 10.1001/archinte.168.12.1352-b.","Kälkner KM","Arch Intern Med","2008","2008/06/25","","","10.1001/archinte.168.12.1352-b"
"8230618","Disease-specific survival following routine prostate cancer screening by digital rectal examination: corrected patient classification","Gerber GS, Thisted R, Chodak GW, Thompson IM.","JAMA. 1993 Nov 24;270(20):2437.","Gerber GS","JAMA","1993","1993/11/24","","",""
"15822870","[GnRH analogues in the treatment of prostate cancer]","Zerbib M.","Rev Prat. 2005;Spec. No:35-41.","Zerbib M","Rev Prat","2005","2005/04/13","","",""
"19692759","[Role of renin-angiotensin system in prostate cancer]","Uemura H, Kubota Y.","Gan To Kagaku Ryoho. 2009 Aug;36(8):1228-33.","Uemura H","Gan To Kagaku Ryoho","2009","2009/08/21","","",""
"11042744","Do increased 5-year survival rates in prostate cancer indicate better outcomes?","Kind P.","JAMA. 2000 Oct 25;284(16):2054-5.","Kind P","JAMA","2000","2000/10/24","","",""
"21548469","Prostate cancer immunotherapy: the role for sipuleucel-T and other immunologic approaches","Arlen PM.","Oncology (Williston Park). 2011 Mar;25(3):261-2.","Arlen PM","Oncology (Williston Park)","2011","2011/05/10","","",""
"19903116","Living with a prostate cancer diagnosis: a qualitative 2-year follow-up","Jonsson A, Aus G, Berterö C.","Aging Male. 2010 Mar;13(1):25-31. doi: 10.3109/13685530903424170.","Jonsson A","Aging Male","2010","2009/11/12","","","10.3109/13685530903424170"
"15093933","CTV margins in prostate cancer irradiation. In regard to Teh et al.: IMRT for prostate cancer: defining target volume based on correlated pathologic volume of disease (Int J Radiat Oncol Biol Phys 2003;56:184-191)","Macias V.","Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):320-1; author reply 321-2. doi: 10.1016/j.ijrobp.2004.01.008.","Macias V","Int J Radiat Oncol Biol Phys","2004","2004/04/20","","","10.1016/j.ijrobp.2004.01.008"
"18289590","Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer","Meeks JJ, Thaxton CS, Loeb S, Roehl KA, Helfand BT, Catalona WJ.","J Urol. 2008 Apr;179(4):1340-3. doi: 10.1016/j.juro.2007.11.068. Epub 2008 Mar 4.","Meeks JJ","J Urol","2008","2008/02/22","","","10.1016/j.juro.2007.11.068"
"24167930","[Lycopene and tomatoes--their effect on prevention of prostatic cancer]","Silberstein T, Silberstein E, Saphier O.","Harefuah. 2013 Aug;152(8):461-3, 499.","Silberstein T","Harefuah","2013","2013/10/31","","",""
"30242839","Association between Trichomonas vaginalis and prostate cancer mortality","Tsang SH, Peisch SF, Rowan B, Markt SC, Gonzalez-Feliciano AG, Sutcliffe S, Platz EA, Mucci LA, Ebot EM.","Int J Cancer. 2019 May 15;144(10):2377-2380. doi: 10.1002/ijc.31885. Epub 2018 Dec 4.","Tsang SH","Int J Cancer","2019","2018/09/23","PMC6430694","NIHMS993084","10.1002/ijc.31885"
"20627284","Prediction of mortality after radical prostatectomy by Charlson comorbidity index","Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M.","Urology. 2010 Sep;76(3):553-7. doi: 10.1016/j.urology.2010.02.069.","Guzzo TJ","Urology","2010","2010/07/15","PMC3643003","NIHMS371839","10.1016/j.urology.2010.02.069"
"9249887","Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group","Iversen P.","Scand J Urol Nephrol. 1997 Jun;31(3):249-54. doi: 10.3109/00365599709070342.","Iversen P","Scand J Urol Nephrol","1997","1997/06/01","","","10.3109/00365599709070342"
"8616355","ABC of urology. Urological malignancy--1: Prostate cancer","Dawson C, Whitfield H.","BMJ. 1996 Apr 20;312(7037):1032-4. doi: 10.1136/bmj.312.7037.1032.","Dawson C","BMJ","1996","1996/04/20","PMC2350852","","10.1136/bmj.312.7037.1032"
"17263128","Targeting metastatic prostate cancer: the search for innovative systemic therapies","Berthold DR, Moore MJ.","Oncology (Williston Park). 2006 Dec;20(14):1787-91; discussion 1791-6.","Berthold DR","Oncology (Williston Park)","2006","2007/02/01","","",""
"19453762","Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy","Leonardo C, Simone G, Papalia R, Franco G, Guaglianone S, Gallucci M.","Int J Urol. 2009 Jun;16(6):584-6. doi: 10.1111/j.1442-2042.2008.02209.x. Epub 2009 Apr 22.","Leonardo C","Int J Urol","2009","2009/05/21","","","10.1111/j.1442-2042.2008.02209.x"
"22208014","[Clinical significance and indication of androgen ablation therapy in radiation therapy for localized prostate cancer]","Akimoto T.","Nihon Rinsho. 2011 Jun;69 Suppl 5:418-23.","Akimoto T","Nihon Rinsho","2011","2012/01/03","","",""
"23793738","Surveillance biopsy and active treatment during active surveillance for low-risk prostate cancer","Hashine K, Iio H, Ueno Y, Tsukimori S, Ninomiya I.","Int J Clin Oncol. 2014;19(3):531-5. doi: 10.1007/s10147-013-0584-z. Epub 2013 Jun 22.","Hashine K","Int J Clin Oncol","2014","2013/06/25","","","10.1007/s10147-013-0584-z"
"9488071","Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer","Zlotta AR, Djavan B, Matos C, Noel JC, Peny MO, Silverman DE, Marberger M, Schulman CC.","Br J Urol. 1998 Feb;81(2):265-75. doi: 10.1046/j.1464-410x.1998.00504.x.","Zlotta AR","Br J Urol","1998","1998/03/06","","","10.1046/j.1464-410x.1998.00504.x"
"12787712","Current strategies in the management of hormone refractory prostate cancer","Martel CL, Gumerlock PH, Meyers FJ, Lara PN.","Cancer Treat Rev. 2003 Jun;29(3):171-87. doi: 10.1016/s0305-7372(02)00090-7.","Martel CL","Cancer Treat Rev","2003","2003/06/06","","","10.1016/s0305-7372(02)00090-7"
"18823041","An updated catalog of prostate cancer predictive tools","Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW.","Cancer. 2008 Dec 1;113(11):3075-99. doi: 10.1002/cncr.23908.","Shariat SF","Cancer","2008","2008/10/01","","","10.1002/cncr.23908"
"27705925","Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer","Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.","Aging (Albany NY). 2016 Oct 5;8(11):2702-2712. doi: 10.18632/aging.101044.","Kalsbeek AM","Aging (Albany NY)","2016","2016/10/06","PMC5191864","","10.18632/aging.101044"
"16634712","Chemoprevention of prostate cancer with finasteride","Canby-Hagino ED, Brand TC, Hernandez J, Thompson IM.","Expert Opin Pharmacother. 2006 May;7(7):899-905. doi: 10.1517/14656566.7.7.899.","Canby-Hagino ED","Expert Opin Pharmacother","2006","2006/04/26","","","10.1517/14656566.7.7.899"
"16227960","Treatment options for androgen-independent prostate cancer","Gulley J, Figg WD, Dahut WL.","Clin Adv Hematol Oncol. 2003 Jan;1(1):49-57.","Gulley J","Clin Adv Hematol Oncol","2003","2005/10/18","","",""
"2024104","Ultrasound of the prostate--applications and indications","Rifkin MD.","Schweiz Med Wochenschr. 1991 Mar 2;121(9):282-91.","Rifkin MD","Schweiz Med Wochenschr","1991","1991/03/02","","",""
"8137232","Recent results of management of palpable clinically localized prostate cancer","Levitt SH, Aeppli DM.","Cancer. 1994 Apr 1;73(7):2006-8. doi: 10.1002/1097-0142(19940401)73:7<2006::aid-cncr2820730739>3.0.co;2-4.","Levitt SH","Cancer","1994","1994/04/01","","","10.1002/1097-0142(19940401)73:7<2006::aid-cncr2820730739>3.0.co;2-4"
"10354754","[Monotherapy with antiandrogens for prostatic cancer]","Sander S.","Tidsskr Nor Laegeforen. 1999 Apr 20;119(10):1451-3.","Sander S","Tidsskr Nor Laegeforen","1999","1999/06/04","","",""
"24266814","Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?","Citrin D, Camphausen KA.","Biomark Med. 2013 Dec;7(6):823-5. doi: 10.2217/bmm.13.127.","Citrin D","Biomark Med","2013","2013/11/26","PMC6368180","NIHMS1002170","10.2217/bmm.13.127"
"17594346","Editorial. Prostate cancer update","Djavan B.","BJU Int. 2007 Jul;100 Suppl 2:1. doi: 10.1111/j.1464-410X.2007.06941.x.","Djavan B","BJU Int","2007","2007/06/28","","","10.1111/j.1464-410X.2007.06941.x"
"16139417","The PSA era is not over for prostate cancer","Catalona WJ, Loeb S.","Eur Urol. 2005 Oct;48(4):541-5. doi: 10.1016/j.eururo.2005.07.014.","Catalona WJ","Eur Urol","2005","2005/09/06","","","10.1016/j.eururo.2005.07.014"
"27146482","Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study","Karasneh RA, Murray LJ, Hughes CM, Cardwell CR.","Pharmacoepidemiol Drug Saf. 2016 Sep;25(9):1099-103. doi: 10.1002/pds.4018. Epub 2016 May 4.","Karasneh RA","Pharmacoepidemiol Drug Saf","2016","2016/05/06","","","10.1002/pds.4018"
"25920098","[II. Radiotherapy for prostate cancer-the role of multi-disciplinary team]","Suzuki K, Matsui H, Kawamura H, Hirado J, Shibuya K, Taniyama N, Hashimoto T, Kanai T, NAkano T, Ohno T.","Gan To Kagaku Ryoho. 2015 Jan;42(1):32-5.","Suzuki K","Gan To Kagaku Ryoho","2015","2015/04/30","","",""
"12735497","Contemporary pathology of prostate cancer","Bostwick DG, Qian J, Schlesinger C.","Urol Clin North Am. 2003 May;30(2):181-207. doi: 10.1016/s0094-0143(02)00189-1.","Bostwick DG","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00189-1"
"17476688","Feasibility of constructing tissue microarrays from diagnostic prostate biopsies","Singh SS, Mehedint DC, Ford OH 3rd, Maygarden SJ, Ruiz B, Mohler JL.","Prostate. 2007 Jul 1;67(10):1011-8. doi: 10.1002/pros.20603.","Singh SS","Prostate","2007","2007/05/04","","","10.1002/pros.20603"
"22544661","Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method","Zaorsky NG, Li T, Devarajan K, Horwitz EM, Buyyounouski MK.","Cancer. 2012 Nov 15;118(22):5535-43. doi: 10.1002/cncr.27597. Epub 2012 Apr 27.","Zaorsky NG","Cancer","2012","2012/05/01","PMC3410044","NIHMS367635","10.1002/cncr.27597"
"24803095","Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection","Foj L, Milà M, Mengual L, Luque P, Alcaraz A, Jiménez W, Filella X.","Clin Chim Acta. 2014 Aug 5;435:53-8. doi: 10.1016/j.cca.2014.04.025. Epub 2014 May 5.","Foj L","Clin Chim Acta","2014","2014/05/08","","","10.1016/j.cca.2014.04.025"
"10861502","Epidemiologic determinants of clinically relevant prostate cancer","Spitz MR, Strom SS, Yamamura Y, Troncoso P, Babaian RJ, Scardino PT, Wheeler T, Amos CI, von Eschenbach A, Kagan J.","Int J Cancer. 2000 May 20;89(3):259-64. doi: 10.1002/1097-0215(20000520)89:3<259::aid-ijc8>3.0.co;2-f.","Spitz MR","Int J Cancer","2000","2000/06/22","","","10.1002/1097-0215(20000520)89:3<259::aid-ijc8>3.0.co;2-f"
"8066398","[Medical treatment of prostate cancer]","Lobel B, Cipolla B, Labrador J.","Rev Prat. 1994 Mar 1;44(5):611-5.","Lobel B","Rev Prat","1994","1994/03/01","","",""
"25847604","Prostate-specific antigen-based prostate cancer screening: Past and future","Alberts AR, Schoots IG, Roobol MJ.","Int J Urol. 2015 Jun;22(6):524-32. doi: 10.1111/iju.12750. Epub 2015 Apr 6.","Alberts AR","Int J Urol","2015","2015/04/08","","","10.1111/iju.12750"
"18065746","Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer","Van der Kwast TH, Collette L, Bolla M.","J Clin Oncol. 2007 Dec 10;25(35):5671-2. doi: 10.1200/JCO.2007.14.2018.","Van der Kwast TH","J Clin Oncol","2007","2007/12/11","","","10.1200/JCO.2007.14.2018"
"22053700","Six-year experience of permanent prostate brachytherapy for clinically localized prostate cancer","Teishima J, Kenjo M, Kobatake K, Iwamoto H, Goriki A, Oki M, Shoji K, Miyamoto K, Masumoto H, Inoue S, Kobayashi K, Ohara S, Kajiwara M, Kimura T, Murakami Y, Kaneyasu Y, Nishibuchi I, Nagata Y, Matsubara A.","Hiroshima J Med Sci. 2011 Sep;60(3):51-6.","Teishima J","Hiroshima J Med Sci","2011","2011/11/08","","",""
"25736982","Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology","Deng G, Ma L, Meng Q, Ju X, Jiang K, Jiang P, Yu Z.","J Cancer Res Clin Oncol. 2016 Mar;142(3):531-47. doi: 10.1007/s00432-015-1946-x. Epub 2015 Mar 4.","Deng G","J Cancer Res Clin Oncol","2016","2015/03/05","","","10.1007/s00432-015-1946-x"
"8537974","Prostate cancer--look to Denmark?","Tretli S, Engeland A, Haldorsen T, Hakulinen T, Hörte LG, Luostarinen T, Schou G, Sigvaldason H, Storm HH, Tulinius H, Vaittinen P.","J Natl Cancer Inst. 1996 Jan 17;88(2):128. doi: 10.1093/jnci/88.2.128.","Tretli S","J Natl Cancer Inst","1996","1996/01/17","","","10.1093/jnci/88.2.128"
"22257098","Novel approaches to improve prostate cancer diagnosis and management in early-stage disease","Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SF, Vickers A.","BJU Int. 2012 Mar;109 Suppl 2:1-7. doi: 10.1111/j.1464-410X.2011.10870.x.","Marberger M","BJU Int","2012","2012/01/20","","","10.1111/j.1464-410X.2011.10870.x"
"25124107","Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia","Rodger JC, Supramaniam R, Gibberd AJ, Smith DP, Armstrong BK, Dillon A, O'Connell DL.","BJU Int. 2015 Apr;115 Suppl 5(Suppl Suppl 5):16-23. doi: 10.1111/bju.12899.","Rodger JC","BJU Int","2015","2014/08/16","PMC4409091","","10.1111/bju.12899"
"19222884","Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms","Sayre EC, Bunting PS, Kopec JA.","Can J Urol. 2009 Feb;16(1):4463-71.","Sayre EC","Can J Urol","2009","2009/02/19","","",""
"8521131","Counseling patients about therapy for localized prostate cancer","Middleton RG.","Semin Urol Oncol. 1995 Aug;13(3):187-90.","Middleton RG","Semin Urol Oncol","1995","1995/08/01","","",""
"16225505","The Scandinavian Prostate Cancer Group Study: the case for conservative management","Parker C.","BJU Int. 2005 Nov;96(7):952-3. doi: 10.1111/j.1464-410X.2005.05794.x.","Parker C","BJU Int","2005","2005/10/18","","","10.1111/j.1464-410X.2005.05794.x"
"11013795","Short report: what do men with prostate cancer want to know?","Gulavita S, Sinnott C, Setliff AE, Sellick SM.","Can Fam Physician. 2000 Sep;46:1769-71.","Gulavita S","Can Fam Physician","2000","2000/10/03","PMC2145024","",""
"7544627","Prostate cancer in the era of prostate-specific antigen","Scher HI, Fossa S.","Curr Opin Oncol. 1995 May;7(3):281-91. doi: 10.1097/00001622-199505000-00014.","Scher HI","Curr Opin Oncol","1995","1995/05/01","","","10.1097/00001622-199505000-00014"
"26372037","The role of MRI in active surveillance for men with localized prostate cancer","Recabal P, Ehdaie B.","Curr Opin Urol. 2015 Nov;25(6):504-9. doi: 10.1097/MOU.0000000000000221.","Recabal P","Curr Opin Urol","2015","2015/09/16","","","10.1097/MOU.0000000000000221"
"16924894","Preliminary treatment results of intensity-modulated radiotherapy for prostate cancer","Fan KH, Chen YC, Chuang CK, Hsieh ML, Hong JH.","Chang Gung Med J. 2006 May-Jun;29(3):313-24.","Fan KH","Chang Gung Med J","2006","2006/08/24","","",""
"25168453","Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms","Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, Mirone V, Vickers AJ, Montorsi F, Briganti A.","BJU Int. 2015 Sep;116(3):366-72. doi: 10.1111/bju.12912. Epub 2015 Jan 21.","Fossati N","BJU Int","2015","2014/08/30","","","10.1111/bju.12912"
"8521132","Radiotherapy of T1c prostate cancer","Ben-Josef E, Porter AT.","Semin Urol Oncol. 1995 Aug;13(3):191-6.","Ben-Josef E","Semin Urol Oncol","1995","1995/08/01","","",""
"406423","[Preliminary results of radiotherapy of prostate cancer by 25 Mev photons]","Douchez J, Pontonnier F, Combes PF.","J Urol Nephrol (Paris). 1977 Jan-Feb;83(1-2):77-82.","Douchez J","J Urol Nephrol (Paris)","1977","1977/01/01","","",""
"22284594","[pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence]","Barry Delongchamps N, Peyromaure M, Kpatcha F, Beuvon F, Legrand G, Zerbib M.","Prog Urol. 2012 Feb;22(2):100-5. doi: 10.1016/j.purol.2011.08.041. Epub 2011 Oct 14.","Barry Delongchamps N","Prog Urol","2012","2012/01/31","","","10.1016/j.purol.2011.08.041"
"25255713","Long-term oncologic outcomes of radical prostatectomy compared with brachytherapy-based approaches for intermediate- and high-risk prostate cancer","Crook J.","Brachytherapy. 2015 Mar-Apr;14(2):142-7. doi: 10.1016/j.brachy.2014.08.047. Epub 2014 Sep 23.","Crook J","Brachytherapy","2015","2014/09/27","","","10.1016/j.brachy.2014.08.047"
"17212095","[Acquired tumor ""robustness"" in the case of prostate cancer]","Homma S, Noguchi M, Sato Y, Maeda Y, Shomura H, Komohara Y, Mine T, Harada M, Yamada A, Todo S, Itoh K.","Gan To Kagaku Ryoho. 2006 Nov;33(12):1748-50.","Homma S","Gan To Kagaku Ryoho","2006","2007/01/11","","",""
"22212088","Targeted therapy in prostate cancer","Corcoran NM, Gleave ME.","Histopathology. 2012 Jan;60(1):216-31. doi: 10.1111/j.1365-2559.2011.04030.x.","Corcoran NM","Histopathology","2012","2012/01/04","","","10.1111/j.1365-2559.2011.04030.x"
"21109711","[Effectiveness of two ultrasound-guided transrectal biopsy schemes in the diagnosis of prostate cancer. A randomized study. Editorial comment]","Gómez Rodríguez A.","Arch Esp Urol. 2010 Mar;63(2):117. doi: 10.4321/s0004-06142010000200006.","Gómez Rodríguez A","Arch Esp Urol","2010","2010/11/27","","","10.4321/s0004-06142010000200006"
"2284529","Radiation therapy of stage C prostate cancer: significance of Gleason grade to survival","Babaian RJ, Zagars GK, Ayala AG.","Semin Urol. 1990 Nov;8(4):225-31.","Babaian RJ","Semin Urol","1990","1990/11/01","","",""
"26631616","The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer","Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, Feng FY.","Clin Cancer Res. 2016 Apr 1;22(7):1777-86. doi: 10.1158/1078-0432.CCR-15-1250. Epub 2015 Dec 2.","Zhao SG","Clin Cancer Res","2016","2015/12/04","","","10.1158/1078-0432.CCR-15-1250"
"28647394","Whole-genome gene expression analysis in urine samples of patients with prostate cancer and benign prostate hyperplasia","Özdemir TR, Şimşir A, Onay H, Cüreklibatır İ, Özkınay F, Akın H.","Urol Oncol. 2017 Oct;35(10):607.e15-607.e24. doi: 10.1016/j.urolonc.2017.05.020. Epub 2017 Jun 21.","Özdemir TR","Urol Oncol","2017","2017/06/26","","","10.1016/j.urolonc.2017.05.020"
"26055824","Systematic Review of Decision Aids for Newly Diagnosed Patients with Prostate Cancer Making Treatment Decisions","Adsul P, Wray R, Spradling K, Darwish O, Weaver N, Siddiqui S.","J Urol. 2015 Nov;194(5):1247-52. doi: 10.1016/j.juro.2015.05.093. Epub 2015 Jun 6.","Adsul P","J Urol","2015","2015/06/10","","","10.1016/j.juro.2015.05.093"
"16474470","Prostate cancer: risks and benefits of screening","Roemeling S, Schröder FH.","Nat Clin Pract Urol. 2006 Jan;3(1):4-5. doi: 10.1038/ncpuro0374.","Roemeling S","Nat Clin Pract Urol","2006","2006/02/14","","","10.1038/ncpuro0374"
"24998045","Patient demographic characteristics and disease stage as drivers of disparities in mortality in prostate cancer patients who receive care at a safety net academic medical center","Rand AE, Agarwal A, Ahuja D, Ngo T, Qureshi MM, Gupta A, Hirsch AE.","Clin Genitourin Cancer. 2014 Dec;12(6):455-60. doi: 10.1016/j.clgc.2014.04.005. Epub 2014 Jun 11.","Rand AE","Clin Genitourin Cancer","2014","2014/07/07","","","10.1016/j.clgc.2014.04.005"
"19639194","Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer","Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T, Satoh S, Ogawa O, Habuchi T.","Oncol Rep. 2009 Sep;22(3):493-9. doi: 10.3892/or_00000462.","Tsuchiya N","Oncol Rep","2009","2009/07/30","","","10.3892/or_00000462"
"14702130","Research into molecular and genetic mechanisms underlying prostate carcinogenesis would be greatly advanced by in vitro prostate cell models","Rhim JS.","Drugs Today (Barc). 2003 Nov;39(11):837-47. doi: 10.1358/dot.2003.39.11.799462.","Rhim JS","Drugs Today (Barc)","2003","2004/01/01","","","10.1358/dot.2003.39.11.799462"
"25639219","Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer","Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y.","Cancer. 2015 May 1;121(9):1422-30. doi: 10.1002/cncr.29233. Epub 2015 Jan 13.","Terry S","Cancer","2015","2015/02/03","","","10.1002/cncr.29233"
"15738547","What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?","Carducci MA.","J Clin Oncol. 2005 May 20;23(15):3304-7. doi: 10.1200/JCO.2005.11.934. Epub 2005 Feb 28.","Carducci MA","J Clin Oncol","2005","2005/03/02","","","10.1200/JCO.2005.11.934"
"30545222","Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion","Burdova A, Rulisek P, Bouchal J, Král M, Student V, Kolar Z.","Klin Onkol. 2018 Fall;31(6):421-428. doi: 10.14735/amko2018421.","Burdova A","Klin Onkol","2018","2018/12/15","","","10.14735/amko2018421"
"11751389","Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer","Chang CY, Walther PJ, McDonnell DP.","Cancer Res. 2001 Dec 15;61(24):8712-7.","Chang CY","Cancer Res","2001","2001/12/26","","",""
"16752374","The use of nomograms in the detection of prostate cancer","Roobol MJ.","Prostate. 2006 Sep 1;66(12):1266-7. doi: 10.1002/pros.20454.","Roobol MJ","Prostate","2006","2006/06/06","","","10.1002/pros.20454"
"9780560","The current status of adjuvant hormonal therapy combined with radiation therapy for localised prostate cancer","Armstrong J.","Ir J Med Sci. 1998 Jul-Sep;167(3):138-44. doi: 10.1007/BF02937924.","Armstrong J","Ir J Med Sci","1998","1998/10/22","","","10.1007/BF02937924"
"12106580","[Updating in prevention and treatment of prostate cancer]","Marzo Castillejo M, Peña López F, Alonso Coello P, Mascort Roca JJ.","Aten Primaria. 2002 Jun 15;30(1):57-63. doi: 10.1016/s0212-6567(02)78963-4.","Marzo Castillejo M","Aten Primaria","2002","2002/07/11","","","10.1016/s0212-6567(02)78963-4"
"15780168","Surgery or radiation: what is the optimal management for locally advanced prostate cancer?","Fletcher SG, Theodorescu D.","Can J Urol. 2005 Feb;12 Suppl 1:58-61; discussion 101-2.","Fletcher SG","Can J Urol","2005","2005/03/23","","",""
"7528795","Prostate-specific antigen in screening of prostate cancer","Chu TM.","J Clin Lab Anal. 1994;8(5):323-6. doi: 10.1002/jcla.1860080511.","Chu TM","J Clin Lab Anal","1994","1994/01/01","","","10.1002/jcla.1860080511"
"12512148","[Clinicopathological significance of neoadjuvant hormonal therapy prior to radical prostatectomy: whole section analysis]","Uemura H, Cho M, Hirao Y, Konishi N.","Hinyokika Kiyo. 2002 Nov;48(11):719-23.","Uemura H","Hinyokika Kiyo","2002","2003/01/07","","",""
"19597531","Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer","Mulders PF, Schalken JA.","Prostate Cancer Prostatic Dis. 2009;12(3):241-6. doi: 10.1038/pcan.2009.25. Epub 2009 Jul 14.","Mulders PF","Prostate Cancer Prostatic Dis","2009","2009/07/15","","","10.1038/pcan.2009.25"
"15253159","[PSA-screening for prostate cancer--yes or no?]","Recker F, Kwiatkowski M.","Ther Umsch. 2004 Jun;61(6):353-8. doi: 10.1024/0040-5930.61.6.353.","Recker F","Ther Umsch","2004","2004/07/16","","","10.1024/0040-5930.61.6.353"
"16278466","Role of diet in prostate cancer development and progression","Chan JM, Gann PH, Giovannucci EL.","J Clin Oncol. 2005 Nov 10;23(32):8152-60. doi: 10.1200/JCO.2005.03.1492.","Chan JM","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.03.1492"
"19307063","Apocrine sweat gland obstruction by antiperspirants allowing transdermal absorption of cutaneous generated hormones and pheromones as a link to the observed incidence rates of breast and prostate cancer in the 20th century","McGrath KG.","Med Hypotheses. 2009 Jun;72(6):665-74. doi: 10.1016/j.mehy.2009.01.025.","McGrath KG","Med Hypotheses","2009","2009/03/25","","","10.1016/j.mehy.2009.01.025"
"29784665","SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer","Audet-Walsh É, Vernier M, Yee T, Laflamme C, Li S, Chen Y, Giguère V.","Mol Cancer Res. 2018 Sep;16(9):1396-1405. doi: 10.1158/1541-7786.MCR-17-0410. Epub 2018 May 21.","Audet-Walsh É","Mol Cancer Res","2018","2018/05/23","","","10.1158/1541-7786.MCR-17-0410"
"19714336","Prognostic value of microvessel density in prostate cancer: a tissue microarray study","Erbersdobler A, Isbarn H, Dix K, Steiner I, Schlomm T, Mirlacher M, Sauter G, Haese A.","World J Urol. 2010 Dec;28(6):687-92. doi: 10.1007/s00345-009-0471-4. Epub 2009 Aug 28.","Erbersdobler A","World J Urol","2010","2009/08/29","","","10.1007/s00345-009-0471-4"
"12044015","A history of prostate cancer treatment","Denmeade SR, Isaacs JT.","Nat Rev Cancer. 2002 May;2(5):389-96. doi: 10.1038/nrc801.","Denmeade SR","Nat Rev Cancer","2002","2002/06/05","PMC4124639","NIHMS401585","10.1038/nrc801"
"24112742","Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer?","Tombal B, Alcaraz A, James N, Valdagni R, Irani J.","BJU Int. 2014 Feb;113(2):189-99. doi: 10.1111/bju.12469.","Tombal B","BJU Int","2014","2013/10/12","","","10.1111/bju.12469"
"9858330","The influence of race on the efficacy of curative radiation therapy for carcinoma of the prostate","Hart KB, Porter AT, Shamsa F, Chuba PJ, Pontes JE, Forman JD.","Semin Urol Oncol. 1998 Nov;16(4):227-31.","Hart KB","Semin Urol Oncol","1998","1998/12/19","","",""
"29795140","The microbiome in prostate inflammation and prostate cancer","Porter CM, Shrestha E, Peiffer LB, Sfanos KS.","Prostate Cancer Prostatic Dis. 2018 Sep;21(3):345-354. doi: 10.1038/s41391-018-0041-1. Epub 2018 May 23.","Porter CM","Prostate Cancer Prostatic Dis","2018","2018/05/26","","","10.1038/s41391-018-0041-1"
"26041315","Vasectomy and risk of prostate cancer: a systematic review and meta-analysis of cohort studies","Liu LH, Kang R, He J, Zhao SK, Li FT, Wan SP, Zhao ZG.","Andrology. 2015 Jul;3(4):643-9. doi: 10.1111/andr.12040. Epub 2015 Jun 3.","Liu LH","Andrology","2015","2015/06/05","","","10.1111/andr.12040"
"21604936","Early detection of prostate cancer with emphasis on genetic markers","Aly M, Wiklund F, Grönberg H.","Acta Oncol. 2011 Jun;50 Suppl 1:18-23. doi: 10.3109/0284186X.2010.529824.","Aly M","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.529824"
"23623362","Prostate cancer: treat or not treat?","Gomez-Veiga F, Pertega Diaz S, Martinez Breijo S.","Actas Urol Esp. 2013 Jul-Aug;37(7):451-2. doi: 10.1016/j.acuro.2013.02.001. Epub 2013 Apr 25.","Gomez-Veiga F","Actas Urol Esp","2013","2013/04/30","","","10.1016/j.acuro.2013.02.001"
"28635336","New advances in focal therapy for early stage prostate cancer","Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ.","Expert Rev Anticancer Ther. 2017 Aug;17(8):737-743. doi: 10.1080/14737140.2017.1345630. Epub 2017 Jun 28.","Tay KJ","Expert Rev Anticancer Ther","2017","2017/06/22","","","10.1080/14737140.2017.1345630"
"8931616","Comparing the age at prostate cancer diagnosis in humans and dogs","Waters DJ, Patronek GJ, Bostwick DG, Glickman LT.","J Natl Cancer Inst. 1996 Nov 20;88(22):1686-7. doi: 10.1093/jnci/88.22.1686-b.","Waters DJ","J Natl Cancer Inst","1996","1996/11/20","","","10.1093/jnci/88.22.1686-b"
"18342917","Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study","Lund L, Borre M, Jacobsen J, Sørensen HT, Nørgaard M.","Urology. 2008 Dec;72(6):1258-62. doi: 10.1016/j.urology.2007.12.018. Epub 2008 Mar 17.","Lund L","Urology","2008","2008/03/18","","","10.1016/j.urology.2007.12.018"
"7635445","Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation","Bonkhoff H, Stein U, Welter C, Remberger K.","Hum Pathol. 1995 Aug;26(8):824-8. doi: 10.1016/0046-8177(95)90002-0.","Bonkhoff H","Hum Pathol","1995","1995/08/01","","","10.1016/0046-8177(95)90002-0"
"23302902","Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer","Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN.","Cancer Control. 2013 Jan;20(1):7-16. doi: 10.1177/107327481302000103.","Shore ND","Cancer Control","2013","2013/01/11","","","10.1177/107327481302000103"
"18475263","Report from London","Kirby R.","Prostate Cancer Prostatic Dis. 2008;11(2):107. doi: 10.1038/pcan.2008.25.","Kirby R","Prostate Cancer Prostatic Dis","2008","2008/05/14","","","10.1038/pcan.2008.25"
"7740235","[Disseminated intravascular coagulation associated with prostatic cancer]","Cabane J, Etarian C, Louvet C, Robert A, Blum L, Wattiaux MJ, Imbert JC.","Rev Med Interne. 1995;16(3):219-24. doi: 10.1016/0248-8663(96)80696-5.","Cabane J","Rev Med Interne","1995","1995/01/01","","","10.1016/0248-8663(96)80696-5"
"28235549","Clinical Outcome Following Low Suspicion Multiparametric Prostate Magnetic Resonance Imaging or Benign Magnetic Resonance Imaging Guided Biopsy to Detect Prostate Cancer","Boesen L, Nørgaard N, Løgager V, Thomsen HS.","J Urol. 2017 Aug;198(2):310-315. doi: 10.1016/j.juro.2017.02.073. Epub 2017 Feb 21.","Boesen L","J Urol","2017","2017/02/26","","","10.1016/j.juro.2017.02.073"
"22258374","[Immunotherapy for metastatic prostate cancer: do we really need this?]","Heidenreich A.","Urologe A. 2012 Jan;51(1):32-8. doi: 10.1007/s00120-011-2740-2.","Heidenreich A","Urologe A","2012","2012/01/20","","","10.1007/s00120-011-2740-2"
"26993766","Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer","Destouches D, Sader M, Terry S, Marchand C, Maillé P, Soyeux P, Carpentier G, Semprez F, Céraline J, Allory Y, Courty J, De La Taille A, Vacherot F.","Oncotarget. 2016 Oct 25;7(43):69397-69411. doi: 10.18632/oncotarget.8043.","Destouches D","Oncotarget","2016","2016/03/20","PMC5342486","","10.18632/oncotarget.8043"
"10325491","Epidemiology of prostate cancer chemoprevention","Boyle P, Severi G.","Eur Urol. 1999;35(5-6):370-6. doi: 10.1159/000019911.","Boyle P","Eur Urol","1999","1999/05/15","","","10.1159/000019911"
"9250926","A case of prostate cancer in 34 year old man presenting with generalized lymphadenopathy mimicking malignant lymphoma","Ahn MJ, Oh SJ, Lee YY, Jung TJ, Kim IS, Choi IY, Jang SJ, Park YW, Shin KY, Kim YS.","J Korean Med Sci. 1997 Jun;12(3):262-5. doi: 10.3346/jkms.1997.12.3.262.","Ahn MJ","J Korean Med Sci","1997","1997/06/01","PMC3054289","","10.3346/jkms.1997.12.3.262"
"25195370","[Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis]","Liu Y, Xu Y, Zhang ZH, Yang K.","Zhonghua Nan Ke Xue. 2014 Aug;20(8):723-9.","Liu Y","Zhonghua Nan Ke Xue","2014","2014/09/09","","",""
"20535970","[Management of locally advanced prostate cancer]","Ichikawa T, Suzuki H, Imamoto T.","Nihon Rinsho. 2010 Jun;68(6):1151-5.","Ichikawa T","Nihon Rinsho","2010","2010/06/12","","",""
"17845994","[Locally advanced prostate cancer: definition, prognosis and treatment]","Plantade A, Massard C, de Crevoisier R, Fizazi K.","Bull Cancer. 2007 Jul;94(7 Suppl):F50-61.","Plantade A","Bull Cancer","2007","2007/09/13","","",""
"10881343","The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer","Scardino PT.","Trans Am Clin Climatol Assoc. 2000;111:201-41.","Scardino PT","Trans Am Clin Climatol Assoc","2000","2000/07/06","PMC2194384","",""
"27362790","8-Farnesyloxycoumarin induces apoptosis in PC-3 prostate cancer cells by inhibition of 15-lipoxygenase-1 enzymatic activity","Hosseinymehr M, Matin MM, Sadeghian H, Bahrami AR, Kaseb-Mojaver N.","Anticancer Drugs. 2016 Oct;27(9):854-62. doi: 10.1097/CAD.0000000000000399.","Hosseinymehr M","Anticancer Drugs","2016","2016/07/01","","","10.1097/CAD.0000000000000399"
"19652675","PSA testing in asymptomatic men to diagnose prostate cancer remains experimental","Cox B, Sneyd MJ.","N Z Med J. 2009 Jun 5;122(1296):10-4.","Cox B","N Z Med J","2009","2009/08/05","","",""
"17467881","Editorial comment on: Prostate cancer characteristics in a multiracial community","Chun FK.","Eur Urol. 2008 Mar;53(3):538-9. doi: 10.1016/j.eururo.2007.04.049.","Chun FK","Eur Urol","2008","2007/05/01","","","10.1016/j.eururo.2007.04.049"
"18359149","Editorial comment on: The feasibility of prostate cancer detection by triple spectroscopy","Da Pozzo LF.","Eur Urol. 2009 Feb;55(2):383-4. doi: 10.1016/j.eururo.2008.02.023. Epub 2008 Mar 7.","Da Pozzo LF","Eur Urol","2009","2008/03/25","","","10.1016/j.eururo.2008.02.023"
"26956509","Grading of prostatic adenocarcinoma: current state and prognostic implications","Gordetsky J, Epstein J.","Diagn Pathol. 2016 Mar 9;11:25. doi: 10.1186/s13000-016-0478-2.","Gordetsky J","Diagn Pathol","2016","2016/03/10","PMC4784293","","10.1186/s13000-016-0478-2"
"12954495","CYP17 gene promoter allelic variant is not associated with prostate cancer","Lin CC, Wu HC, Chen WC, Chen HY, Tsai FJ.","Urol Oncol. 2003 Jul-Aug;21(4):262-5. doi: 10.1016/s1078-1439(02)00276-4.","Lin CC","Urol Oncol","2003","2003/09/05","","","10.1016/s1078-1439(02)00276-4"
"11340277","Morphogenesis of prostate cancer","Bonkhoff H.","Eur Urol. 2001 Apr;39 Suppl 4:5-7. doi: 10.1159/000052573.","Bonkhoff H","Eur Urol","2001","2001/05/08","","","10.1159/000052573"
"23723314","Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes","Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P.","Jpn J Clin Oncol. 2013 Jul;43(7):756-66. doi: 10.1093/jjco/hyt071. Epub 2013 May 29.","Akaza H","Jpn J Clin Oncol","2013","2013/06/01","","","10.1093/jjco/hyt071"
"21764210","Re: Daher C. Chade, Shahrokh F. Shariat, Angel M. Cronin, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur urol 2011;60:205-10","Qin X, Ye D.","Eur Urol. 2011 Oct;60(4):e34. doi: 10.1016/j.eururo.2011.06.055. Epub 2011 Jul 13.","Qin X","Eur Urol","2011","2011/07/19","","","10.1016/j.eururo.2011.06.055"
"25251387","Targeting extra-gonadal androgens in castration-resistant prostate cancer","Grist E, de Bono JS, Attard G.","J Steroid Biochem Mol Biol. 2015 Jan;145:157-63. doi: 10.1016/j.jsbmb.2014.09.006. Epub 2014 Sep 22.","Grist E","J Steroid Biochem Mol Biol","2015","2014/09/25","","","10.1016/j.jsbmb.2014.09.006"
"27207889","Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy","Kobayashi T, Kimura T, Lee C, Inoue T, Terada N, Kono Y, Kamba T, Kim CS, Egawa S, Ogawa O.","Jpn J Clin Oncol. 2016 Aug;46(8):762-7. doi: 10.1093/jjco/hyw061. Epub 2016 May 20.","Kobayashi T","Jpn J Clin Oncol","2016","2016/05/22","","","10.1093/jjco/hyw061"
"17485955","[Importance of prostate volume for detection of prostate cancer by first sextant biopsy in high-risk patients]","Vaiciūnas K, Auskalnis S, Matjosaitis A, Trumbeckas D, Jievaltas M.","Medicina (Kaunas). 2007;43(4):285-90.","Vaiciūnas K","Medicina (Kaunas)","2007","2007/05/09","","",""
"31133370","A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer","Steele EM, Holmes JA.","Urol Oncol. 2019 Sep;37(9):582-598. doi: 10.1016/j.urolonc.2019.04.030. Epub 2019 May 24.","Steele EM","Urol Oncol","2019","2019/05/29","","","10.1016/j.urolonc.2019.04.030"
"28783262","Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes","Dell'Oglio P, Sanchez-Salas R.","Int Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi: 10.1590/S1677-5538.IBJU.2017.04.02.","Dell'Oglio P","Int Braz J Urol","2017","2017/08/08","PMC5557431","","10.1590/S1677-5538.IBJU.2017.04.02"
"2524048","[Early screening of prostate cancer. The rectal touch remains a current entity]","Vallancien G.","Presse Med. 1989 Apr 15;18(15):750-2.","Vallancien G","Presse Med","1989","1989/04/15","","",""
"16904427","Role of vascular endothelial growth factor in prostate cancer","Delongchamps NB, Peyromaure M, Dinh-Xuan AT.","Urology. 2006 Aug;68(2):244-8. doi: 10.1016/j.urology.2006.03.010.","Delongchamps NB","Urology","2006","2006/08/15","","","10.1016/j.urology.2006.03.010"
"15250328","[Bladder cancer and prostate cancer in hemodialysis patients]","Hatori M, Suzuki K, Yamanaka H.","Nihon Rinsho. 2004 Jun;62 Suppl 6:374-7.","Hatori M","Nihon Rinsho","2004","2004/07/15","","",""
"8189656","[Laparoscopic pelvic lymphadenectomy for localized prostate cancer]","Igarashi T, Yuki T, Tobe T, Mikami K, Murakami S, Matsuzaki O, Shimazaki J.","Nihon Hinyokika Gakkai Zasshi. 1994 Apr;85(4):579-83. doi: 10.5980/jpnjurol1989.85.579.","Igarashi T","Nihon Hinyokika Gakkai Zasshi","1994","1994/04/01","","","10.5980/jpnjurol1989.85.579"
"23337755","Agents that target androgen synthesis in castration-resistant prostate cancer","Ferraldeschi R, de Bono J.","Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f.","Ferraldeschi R","Cancer J","2013","2013/01/23","","","10.1097/PPO.0b013e31827e0b6f"
"16406978","Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy","Nam RK, Toi A, Trachtenberg J, Klotz LH, Jewett MA, Emami M, Sugar L, Sweet J, Pond GR, Narod SA.","J Urol. 2006 Feb;175(2):489-94. doi: 10.1016/S0022-5347(05)00159-X.","Nam RK","J Urol","2006","2006/01/13","","","10.1016/S0022-5347(05)00159-X"
"24583160","Revised Gleason grading system is a better predictor of indolent prostate cancer at the time of diagnosis: retrospective clinical-pathological study on matched biopsy and radical prostatectomy specimens","Giunchi F, Brunocilla E, Borghesi M, Rizzi S, Ricci MS, Romagnoli D, Martorana G, Schiavina R, Fiorentino M.","Clin Genitourin Cancer. 2014 Oct;12(5):325-9. doi: 10.1016/j.clgc.2014.01.009. Epub 2014 Feb 4.","Giunchi F","Clin Genitourin Cancer","2014","2014/03/04","","","10.1016/j.clgc.2014.01.009"
"18154197","Overview of prostate cancer in indigenous black Africans and blacks of African ancestry in diaspora 1935-2007","Magoha GA.","East Afr Med J. 2007 Sep;84(9 Suppl):S3-11. doi: 10.4314/eamj.v84i9.9556.","Magoha GA","East Afr Med J","2007","2007/12/25","","","10.4314/eamj.v84i9.9556"
"18687149","ProsCan for Couples: randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer who receive radical prostatectomy","Chambers SK, Schover L, Halford K, Clutton S, Ferguson M, Gordon L, Gardiner RA, Occhipinti S, Dunn J.","BMC Cancer. 2008 Aug 8;8:226. doi: 10.1186/1471-2407-8-226.","Chambers SK","BMC Cancer","2008","2008/08/09","PMC2529334","","10.1186/1471-2407-8-226"
"17432563","Androgen-independent prostate cancer","Schrijvers D.","Recent Results Cancer Res. 2007;175:239-49. doi: 10.1007/978-3-540-40901-4_14.","Schrijvers D","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_14"
"24725487","The politics of prostate cancer screening","Kaffenberger SD, Penson DF.","Urol Clin North Am. 2014 May;41(2):249-55. doi: 10.1016/j.ucl.2014.01.004. Epub 2014 Feb 19.","Kaffenberger SD","Urol Clin North Am","2014","2014/04/15","","","10.1016/j.ucl.2014.01.004"
"18783875","Editorial comment on: Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial","Korfage IJ.","Eur Urol. 2009 Feb;55(2):432. doi: 10.1016/j.eururo.2008.08.056. Epub 2008 Sep 2.","Korfage IJ","Eur Urol","2009","2008/09/12","","","10.1016/j.eururo.2008.08.056"
"19847141","Do alpha-reductase inhibitors prevent prostate cancer? 2008 practice guideline from the American society of clinical oncology and American urological association","Thüer D, Pfister D, Epplen R, Brehmer B, Heidenreich A.","Pol Arch Med Wewn. 2009 Oct;119(10):648-53.","Thüer D","Pol Arch Med Wewn","2009","2009/10/23","","",""
"9111707","Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy","Culig Z, Hobisch A, Hittmair A, Cronauer MV, Radmayr C, Bartsch G, Klocker H.","Drugs Aging. 1997 Jan;10(1):50-8. doi: 10.2165/00002512-199710010-00005.","Culig Z","Drugs Aging","1997","1997/01/01","","","10.2165/00002512-199710010-00005"
"25711194","Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis","Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS.","J Urol. 2015 Aug;194(2):378-85. doi: 10.1016/j.juro.2015.02.084. Epub 2015 Feb 21.","Satkunasivam R","J Urol","2015","2015/02/26","PMC4834920","NIHMS775422","10.1016/j.juro.2015.02.084"
"23862238","[Molecular mechanisms of leupaxin involved in prostate carcinoma metastasis]","Zhu GH, Dai HP, Shen Q.","Zhonghua Nan Ke Xue. 2013 Jun;19(6):555-8.","Zhu GH","Zhonghua Nan Ke Xue","2013","2013/07/19","","",""
"28753865","Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review","Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.","Eur Urol Focus. 2018 Dec;4(6):790-803. doi: 10.1016/j.euf.2017.02.017. Epub 2017 Mar 7.","Lamy PJ","Eur Urol Focus","2018","2017/07/30","","","10.1016/j.euf.2017.02.017"
"7543466","Incidental prostate cancer detected by transurethral resection","Rogers E, Thornhill J.","Ir Med J. 1995 May-Jun;88(3):86, 88.","Rogers E","Ir Med J","1995","1995/05/01","","",""
"22052751","Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis","Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, Samadi DB, Akhavan A.","Arch Esp Urol. 2011 Oct;64(8):681-94.","Shariat SF","Arch Esp Urol","2011","2011/11/05","","",""
"12063679","Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response","Small EJ, Roach M 3rd.","Semin Oncol. 2002 Jun;29(3):264-73. doi: 10.1053/sonc.2002.32902.","Small EJ","Semin Oncol","2002","2002/06/14","","","10.1053/sonc.2002.32902"
"22583908","Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer","Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R.","BJU Int. 2012 Sep;110(6 Pt B):E287-92. doi: 10.1111/j.1464-410X.2012.11208.x. Epub 2012 May 15.","Pandha H","BJU Int","2012","2012/05/16","","","10.1111/j.1464-410X.2012.11208.x"
"16225504","Radical prostatectomy vs watchful waiting in early prostate cancer","Richie JP.","BJU Int. 2005 Nov;96(7):951-2. doi: 10.1111/j.1464-410X.2005.05793.x.","Richie JP","BJU Int","2005","2005/10/18","","","10.1111/j.1464-410X.2005.05793.x"
"22848758","XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model?","Stieler K, Schumacher U, Horst AK, Fischer N.","PLoS One. 2012;7(7):e42321. doi: 10.1371/journal.pone.0042321. Epub 2012 Jul 27.","Stieler K","PLoS One","2012","2012/08/01","PMC3407105","","10.1371/journal.pone.0042321"
"24362494","Impact of Psychological Distress on Prostate Cancer Screening in U.S. Military Veterans","Silberbogen AK, Busby AK, Ulloa EW.","Am J Mens Health. 2014 Sep;8(5):399-408. doi: 10.1177/1557988313516357. Epub 2013 Dec 20.","Silberbogen AK","Am J Mens Health","2014","2013/12/24","","","10.1177/1557988313516357"
"19781717","Prostate specific antigen best practice statement: 2009 update","Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P.","J Urol. 2009 Nov;182(5):2232-41. doi: 10.1016/j.juro.2009.07.093. Epub 2009 Sep 24.","Greene KL","J Urol","2009","2009/09/29","","","10.1016/j.juro.2009.07.093"
"11780928","Vitamin D and prostate cancer","Polek TC, Weigel NL.","J Androl. 2002 Jan-Feb;23(1):9-17. doi: 10.1002/j.1939-4640.2002.tb02596.x.","Polek TC","J Androl","2002","2002/01/10","","","10.1002/j.1939-4640.2002.tb02596.x"
"8379027","Characteristics of men reporting for prostate cancer screening","Demark-Wahnefried W, Catoe KE, Paskett E, Robertson CN, Rimer BK.","Urology. 1993 Sep;42(3):269-74; discussion 274-5. doi: 10.1016/0090-4295(93)90615-h.","Demark-Wahnefried W","Urology","1993","1993/09/01","","","10.1016/0090-4295(93)90615-h"
"16273367","Hormone treatment for prostate cancer: current issues and future directions","Ichikawa T, Suzuki H, Ueda T, Komiya A, Imamoto T, Kojima S.","Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:58-63. doi: 10.1007/s00280-005-0100-x.","Ichikawa T","Cancer Chemother Pharmacol","2005","2005/11/08","","","10.1007/s00280-005-0100-x"
"16014286","Association between body mass index and prostate cancer detection rates in Japanese urologic patients","Kobayashi T, Mitsumori K, Nishizawa K, Kawahara T, Ogura K, Ide Y.","Urology. 2005 Jul;66(1):130-4. doi: 10.1016/j.urology.2005.01.041.","Kobayashi T","Urology","2005","2005/07/15","","","10.1016/j.urology.2005.01.041"
"18538269","[Value of urinary PCA3 test for prostate cancer diagnosis]","Vlaeminck-Guillem V, Ruffion A, Andre J.","Prog Urol. 2008 May;18(5):259-65. doi: 10.1016/j.purol.2008.03.029. Epub 2008 May 16.","Vlaeminck-Guillem V","Prog Urol","2008","2008/06/10","","","10.1016/j.purol.2008.03.029"
"1942283","Failure of open radioactive 125iodine implantation to control localized prostate cancer: a study of 41 patients","Gottesman JE, Tesh DG, Weissman WD.","J Urol. 1991 Nov;146(5):1317-9; discussion 1319-20. doi: 10.1016/s0022-5347(17)38078-3.","Gottesman JE","J Urol","1991","1991/11/01","","","10.1016/s0022-5347(17)38078-3"
"19220249","Gene expression of forkhead transcription factors in the normal and diseased human prostate","van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G.","BJU Int. 2009 Jun;103(11):1574-80. doi: 10.1111/j.1464-410X.2009.08351.x. Epub 2009 Feb 11.","van der Heul-Nieuwenhuijsen L","BJU Int","2009","2009/02/18","","","10.1111/j.1464-410X.2009.08351.x"
"30229550","MicroRNAs as Regulators of Prostate Cancer Metastasis","Bhagirath D, Yang TL, Dahiya R, Saini S.","Adv Exp Med Biol. 2018;1095:83-100. doi: 10.1007/978-3-319-95693-0_5.","Bhagirath D","Adv Exp Med Biol","2018","2018/09/20","","","10.1007/978-3-319-95693-0_5"
"18431897","Expectant management as a treatment for early-stage prostate cancer","O'Rourke ME.","Oncology (Williston Park). 2008 Feb;22(2 Suppl Nurse Ed):36-8.","O'Rourke ME","Oncology (Williston Park)","2008","2008/04/25","","",""
"22130293","Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer","Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV.","Clin Genitourin Cancer. 2012 Mar;10(1):21-5. doi: 10.1016/j.clgc.2011.10.003. Epub 2011 Nov 29.","Rosenberg JE","Clin Genitourin Cancer","2012","2011/12/02","","","10.1016/j.clgc.2011.10.003"
"15270669","Dose-escalated 3D conformal radiotherapy in prostate cancer","Malone S.","Expert Rev Anticancer Ther. 2004 Aug;4(4):663-8. doi: 10.1586/14737140.4.4.663.","Malone S","Expert Rev Anticancer Ther","2004","2004/07/24","","","10.1586/14737140.4.4.663"
"17484271","Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer","Prayer-Galetti T, Gardiman M, Sacco E, Fracalanza S, Betto G, Pinto F.","Anal Quant Cytol Histol. 2007 Apr;29(2):79-86.","Prayer-Galetti T","Anal Quant Cytol Histol","2007","2007/05/09","","",""
"9751384","Re: Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation","Zaviacic M, Ablin RJ.","J Urol. 1998 Oct;160(4):1441. doi: 10.1016/s0022-5347(01)62575-8.","Zaviacic M","J Urol","1998","1998/09/29","","","10.1016/s0022-5347(01)62575-8"
"22018147","Immunotherapy in the treatment of advanced prostate cancer","Djavan B, Nelson K, Kazzazi A, Bruhn A, Sadri H, Gomez-Pinillos A, Ferrari AC.","Can J Urol. 2011 Oct;18(5):5865-74.","Djavan B","Can J Urol","2011","2011/10/25","","",""
"28560739","Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL","Fujizuka Y, Ito K, Oki R, Suzuki R, Sekine Y, Koike H, Matsui H, Shibata Y, Suzuki K.","Int J Urol. 2017 Aug;24(8):602-609. doi: 10.1111/iju.13381. Epub 2017 May 31.","Fujizuka Y","Int J Urol","2017","2017/06/01","","","10.1111/iju.13381"
"7526529","Cryosurgery for stage T3 prostate cancer","Bales GT, Chodak GW.","Urology. 1994 Nov;44(5):789-90. doi: 10.1016/s0090-4295(94)80232-7.","Bales GT","Urology","1994","1994/11/01","","","10.1016/s0090-4295(94)80232-7"
"14724589","Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients","Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S.","Oncogene. 2004 Jan 15;23(2):605-11. doi: 10.1038/sj.onc.1207069.","Petrovics G","Oncogene","2004","2004/01/16","","","10.1038/sj.onc.1207069"
"23463896","[Update of treatment for prostate cancer]","Namiki M, Mizokami A, Kitagawa I.","Gan To Kagaku Ryoho. 2013 Jan;40(1):47-51.","Namiki M","Gan To Kagaku Ryoho","2013","2013/03/08","","",""
"18499849","Three-dimensional sonography with needle tracking: role in diagnosis and treatment of prostate cancer","Shen F, Shinohara K, Kumar D, Khemka A, Simoneau AR, Werahera PN, Li L, Guo Y, Narayanan R, Wei L, Barqawi A, Crawford ED, Davatzikos C, Suri JS.","J Ultrasound Med. 2008 Jun;27(6):895-905. doi: 10.7863/jum.2008.27.6.895.","Shen F","J Ultrasound Med","2008","2008/05/24","PMC3402711","NIHMS165519","10.7863/jum.2008.27.6.895"
"28522126","[Prostate cancer histoseminar: Update of the 2016 WHO classification: Introduction]","Ferlicot S.","Ann Pathol. 2017 Jun;37(3):223. doi: 10.1016/j.annpat.2017.02.002. Epub 2017 May 15.","Ferlicot S","Ann Pathol","2017","2017/05/20","","","10.1016/j.annpat.2017.02.002"
"24094573","Surgical management of node-positive prostate cancer: perspectives from breast oncology","Kennecke HF, Keyes M.","Eur Urol. 2014 Aug;66(2):202-3. doi: 10.1016/j.eururo.2013.09.007. Epub 2013 Sep 13.","Kennecke HF","Eur Urol","2014","2013/10/08","","","10.1016/j.eururo.2013.09.007"
"1924461","Iridium-192 implants in patients with large stage C prostate cancer","Brosman SA.","Prog Clin Biol Res. 1991;370:281-90.","Brosman SA","Prog Clin Biol Res","1991","1991/01/01","","",""
"18761838","[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients]","Røder MA, Reinhardt S, Brasso K, Iversen P.","Ugeskr Laeger. 2008 Aug 18;170(34):2554-8.","Røder MA","Ugeskr Laeger","2008","2008/09/03","","",""
"8948414","Long-term control of prostate cancer with radiation. Past, present, and future","Hanks GE.","Urol Clin North Am. 1996 Nov;23(4):605-16. doi: 10.1016/s0094-0143(05)70339-6.","Hanks GE","Urol Clin North Am","1996","1996/11/01","","","10.1016/s0094-0143(05)70339-6"
"22391014","Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care","Collins L, Mohammed N, Ahmad T, Basaria S.","J Endocrinol Invest. 2012 Mar;35(3):332-9. doi: 10.3275/8284. Epub 2012 Feb 28.","Collins L","J Endocrinol Invest","2012","2012/03/07","","","10.3275/8284"
"14747039","Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer","Kumar-Sinha C, Chinnaiyan AM.","Urology. 2003 Dec 29;62 Suppl 1:19-35. doi: 10.1016/j.urology.2003.10.007.","Kumar-Sinha C","Urology","2003","2004/01/30","","","10.1016/j.urology.2003.10.007"
"26802159","Reply to the letter to the editor 'Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy' by Tannock et al","Parker C, Gillessen S, Heidenreich A, Horwich A.","Ann Oncol. 2016 Apr;27(4):750-1. doi: 10.1093/annonc/mdw023. Epub 2016 Jan 22.","Parker C","Ann Oncol","2016","2016/01/24","","","10.1093/annonc/mdw023"
"25068472","Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance","Merrick GS, Delatore A, Butler WM, Bennett A, Fiano R, Anderson R, Adamovich E.","Am J Clin Oncol. 2017 Feb;40(1):53-59. doi: 10.1097/COC.0000000000000105.","Merrick GS","Am J Clin Oncol","2017","2014/07/29","","","10.1097/COC.0000000000000105"
"15142130","Genes differentially expressed in prostate cancer","Eder IE, Bektic J, Haag P, Bartsch G, Klocker H.","BJU Int. 2004 May;93(8):1151-5. doi: 10.1111/j.1464-410X.2004.04869.x.","Eder IE","BJU Int","2004","2004/05/15","","","10.1111/j.1464-410X.2004.04869.x"
"17908481","Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer","Yang GS, Wang Y, Wang P, Chen ZD.","Chin Med J (Engl). 2007 Sep 20;120(18):1611-5.","Yang GS","Chin Med J (Engl)","2007","2007/10/03","","",""
"8667425","Search for prostate cancer gene sites may succeed in 1996","Eastman P.","J Natl Cancer Inst. 1996 Jul 17;88(14):952-3. doi: 10.1093/jnci/88.14.952.","Eastman P","J Natl Cancer Inst","1996","1996/07/17","","","10.1093/jnci/88.14.952"
"20962505","Could prostate biopsies be avoided in men older than 75 years with raised PSA?","Nomikos M, Mariappan P, Zachou A, McNeill A, Bollina PR.","Urol Int. 2010;85(4):410-4. doi: 10.1159/000320378. Epub 2010 Oct 20.","Nomikos M","Urol Int","2010","2010/10/22","","","10.1159/000320378"
"28143868","Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients","Wang R, Wang J, Gao G, Hu J, Jiang Y, Zhao Z, Zhang X, Zhang YD, Wang X.","Clin Cancer Res. 2017 Jul 15;23(14):3692-3699. doi: 10.1158/1078-0432.CCR-16-2884. Epub 2017 Jan 31.","Wang R","Clin Cancer Res","2017","2017/02/02","","","10.1158/1078-0432.CCR-16-2884"
"1512835","Deoxyribonucleic acid cytometry and histological findings before and after 125iodine implantation of primary prostate cancer","Waehre H, Amellem O, Stenwig AE, Tverå K, Juul M, Pettersen EO, Fosså SD.","J Urol. 1992 Sep;148(3):838-41; discussion 841-2. doi: 10.1016/s0022-5347(17)36737-x.","Waehre H","J Urol","1992","1992/09/01","","","10.1016/s0022-5347(17)36737-x"
"29282359","The molecular biology of prostate cancer: current understanding and clinical implications","Gandhi J, Afridi A, Vatsia S, Joshi G, Joshi G, Kaplan SA, Smith NL, Khan SA.","Prostate Cancer Prostatic Dis. 2018 Apr;21(1):22-36. doi: 10.1038/s41391-017-0023-8. Epub 2017 Dec 27.","Gandhi J","Prostate Cancer Prostatic Dis","2018","2017/12/29","","","10.1038/s41391-017-0023-8"
"24810654","Body mass index and weight change in men with prostate cancer: progression and mortality","Bonn SE, Wiklund F, Sjölander A, Szulkin R, Stattin P, Holmberg E, Grönberg H, Bälter K.","Cancer Causes Control. 2014 Aug;25(8):933-43. doi: 10.1007/s10552-014-0393-3. Epub 2014 May 9.","Bonn SE","Cancer Causes Control","2014","2014/05/10","","","10.1007/s10552-014-0393-3"
"22241351","[Screening for prostate cancer: an up date]","Ito K.","Gan To Kagaku Ryoho. 2012 Jan;39(1):33-7.","Ito K","Gan To Kagaku Ryoho","2012","2012/01/14","","",""
"15195025","The treatment of non-metastatic prostate cancer with external beam radiation therapy","Horwitz EM, Feigenberg SJ, Uzzo RG.","Minerva Urol Nefrol. 2004 Jun;56(2):173-88.","Horwitz EM","Minerva Urol Nefrol","2004","2004/06/15","","",""
"22852773","Inflammation and prostate carcinogenesis","Nakai Y, Nonomura N.","Int J Urol. 2013 Feb;20(2):150-60. doi: 10.1111/j.1442-2042.2012.03101.x. Epub 2012 Jul 31.","Nakai Y","Int J Urol","2013","2012/08/03","","","10.1111/j.1442-2042.2012.03101.x"
"25618382","Sorting out what makes sense in diagnosing, treating prostate cancer","Beagin N.","Am J Manag Care. 2014 Feb;20(2 Spec No.):E5.","Beagin N","Am J Manag Care","2014","2015/01/26","","",""
"17500101","Implication of protocadherin-PC in the progression of the advanced prostate cancer","Giannakopoulos X, Stagikas D, Peschos D, Batistatou A, Charalabopoulos K.","Exp Oncol. 2007 Mar;29(1):74-5.","Giannakopoulos X","Exp Oncol","2007","2007/05/16","","",""
"9507871","Re: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients","Lehrer S.","J Urol. 1998 Apr;159(4):1311. doi: 10.1016/s0022-5347(01)63600-0.","Lehrer S","J Urol","1998","1998/03/21","","","10.1016/s0022-5347(01)63600-0"
"1616886","Hormone refractory metastatic prostate cancer","Sternberg CN.","Ann Oncol. 1992 May;3(5):331-5. doi: 10.1093/oxfordjournals.annonc.a058201.","Sternberg CN","Ann Oncol","1992","1992/05/01","","","10.1093/oxfordjournals.annonc.a058201"
"4446173","[Results of the treatment of prostate cancer]","Roman LI.","Urol Nefrol (Mosk). 1974 May-Jun;(3):57-8.","Roman LI","Urol Nefrol (Mosk)","1974","1974/05/01","","",""
"26938268","Early-stage prostate cancer, PSA screening rates decline","Printz C.","Cancer. 2016 Mar 15;122(6):825. doi: 10.1002/cncr.29930.","Printz C","Cancer","2016","2016/03/04","","","10.1002/cncr.29930"
"23670185","Prostate cancer: improvements in risk stratification of prostate cancer","Sandhu GS, Andriole GL.","Nat Rev Urol. 2013 Jun;10(6):314-5. doi: 10.1038/nrurol.2013.107. Epub 2013 May 14.","Sandhu GS","Nat Rev Urol","2013","2013/05/15","","","10.1038/nrurol.2013.107"
"32988880","Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer","Yuno T, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Mistunari K, Ohba K, Suda T, Saito S, Sakai H.","Anticancer Res. 2020 Oct;40(10):5567-5575. doi: 10.21873/anticanres.14569.","Yuno T","Anticancer Res","2020","2020/09/29","","","10.21873/anticanres.14569"
"28547593","Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review","Sita TL, Petras KG, Wafford QE, Berendsen MA, Kruser TJ.","J Neurooncol. 2017 Jul;133(3):531-538. doi: 10.1007/s11060-017-2460-6. Epub 2017 May 25.","Sita TL","J Neurooncol","2017","2017/05/27","","","10.1007/s11060-017-2460-6"
"2014593","Comparison of transrectal prostate digital aspiration and ultrasound-guided core biopsies in 99 men","Waisman J, Adolfsson J, Löwhagen T, Skoog L.","Urology. 1991 Apr;37(4):301-7. doi: 10.1016/0090-4295(91)80253-4.","Waisman J","Urology","1991","1991/04/01","","","10.1016/0090-4295(91)80253-4"
"25405931","A genetic-based approach to personalized prostate cancer screening and treatment","Helfand BT, Catalona WJ, Xu J.","Curr Opin Urol. 2015 Jan;25(1):53-8. doi: 10.1097/MOU.0000000000000130.","Helfand BT","Curr Opin Urol","2015","2014/11/19","PMC4281884","NIHMS647956","10.1097/MOU.0000000000000130"
"17169648","Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy)","Tewari A, Raman JD, Chang P, Rao S, Divine G, Menon M.","Urology. 2006 Dec;68(6):1268-74. doi: 10.1016/j.urology.2006.08.1059.","Tewari A","Urology","2006","2006/12/16","","","10.1016/j.urology.2006.08.1059"
"7523722","Natural history of changes in prostate specific antigen in early stage prostate cancer","Pearson JD, Carter HB.","J Urol. 1994 Nov;152(5 Pt 2):1743-8. doi: 10.1016/s0022-5347(17)32375-3.","Pearson JD","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32375-3"
"9539253","Re: Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line","Grothey A, McCrea PD.","J Natl Cancer Inst. 1998 Apr 1;90(7):547. doi: 10.1093/jnci/90.7.547.","Grothey A","J Natl Cancer Inst","1998","1998/04/16","","","10.1093/jnci/90.7.547"
"19031923","Interferon gamma, a possible therapeutic approach for late-stage prostate cancer?","Hastie C.","Anticancer Res. 2008 Sep-Oct;28(5B):2843-9.","Hastie C","Anticancer Res","2008","2008/11/27","","",""
"10866876","Uncertainty in prostate cancer care: the physician's role in clearing the confusion","Wilt TJ.","JAMA. 2000 Jun 28;283(24):3258-60. doi: 10.1001/jama.283.24.3258.","Wilt TJ","JAMA","2000","2000/06/24","","","10.1001/jama.283.24.3258"
"8703675","AUA's response to the OTA study on prostate cancer screening for elderly men","","Oncology (Williston Park). 1995 Nov;9(11):1123.","","Oncology (Williston Park)","1995","1995/11/01","","",""
"9563153","Brain metastasis as a sole recurrence of prostate cancer after total prostatectomy","Hayashi T, Igarashi K, Tanizawa A, Terada Y, Sekine H.","Urol Int. 1998;60(2):121-3. doi: 10.1159/000030225.","Hayashi T","Urol Int","1998","1998/05/01","","","10.1159/000030225"
"23411592","Effects of screening on radical prostatectomy efficacy: the prostate cancer intervention versus observation trial","Xia J, Gulati R, Au M, Gore JL, Lin DW, Etzioni R.","J Natl Cancer Inst. 2013 Apr 17;105(8):546-50. doi: 10.1093/jnci/djt017. Epub 2013 Feb 14.","Xia J","J Natl Cancer Inst","2013","2013/02/16","PMC3691943","","10.1093/jnci/djt017"
"20607766","Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer","Denmeade SR, Isaacs JT.","Prostate. 2010 Oct 1;70(14):1600-7. doi: 10.1002/pros.21196.","Denmeade SR","Prostate","2010","2010/07/08","PMC4124628","NIHMS402964","10.1002/pros.21196"
"30538099","Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride","Dai JY, LeBlanc M, Goodman PJ, Lucia MS, Thompson IM, Tangen CM.","Cancer Prev Res (Phila). 2019 Feb;12(2):113-120. doi: 10.1158/1940-6207.CAPR-18-0284. Epub 2018 Dec 11.","Dai JY","Cancer Prev Res (Phila)","2019","2018/12/13","PMC6365187","NIHMS1516480","10.1158/1940-6207.CAPR-18-0284"
"24821212","Managing bone metastases and reducing skeletal related events in prostate cancer","Gartrell BA, Saad F.","Nat Rev Clin Oncol. 2014 Jun;11(6):335-45. doi: 10.1038/nrclinonc.2014.70. Epub 2014 May 13.","Gartrell BA","Nat Rev Clin Oncol","2014","2014/05/14","","","10.1038/nrclinonc.2014.70"
"26150029","What is the correct staging and treatment strategy for locally advanced prostate cancer extending to the bladder?","Yüksel ÖH, Verit A, Ürkmez A.","Arch Ital Urol Androl. 2015 Jul 7;87(2):130-5. doi: 10.4081/aiua.2015.2.130.","Yüksel ÖH","Arch Ital Urol Androl","2015","2015/07/08","","","10.4081/aiua.2015.2.130"
"28670154","Multiparametric MRI in the Detection of Clinically Significant Prostate Cancer","Fütterer JJ.","Korean J Radiol. 2017 Jul-Aug;18(4):597-606. doi: 10.3348/kjr.2017.18.4.597. Epub 2017 May 19.","Fütterer JJ","Korean J Radiol","2017","2017/07/04","PMC5447635","","10.3348/kjr.2017.18.4.597"
"9436288","Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer","Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW.","World J Urol. 1997;15(6):373-7. doi: 10.1007/BF01300186.","Pound CR","World J Urol","1997","1997/01/01","","","10.1007/BF01300186"
"15828261","[Usefulness of extension of disease as a prognostic factor in relapsed prostate cancer patients of stage D]","Kawai M, Uemura H, Hasumi H, Osada Y, Ohta J, Miyoshi Y, Mikata K, Oh-uchi H, Sugiura S, Fujinami K, Kubota Y.","Nihon Hinyokika Gakkai Zasshi. 2005 Mar;96(3):442-7. doi: 10.5980/jpnjurol1989.96.442.","Kawai M","Nihon Hinyokika Gakkai Zasshi","2005","2005/04/15","","","10.5980/jpnjurol1989.96.442"
"18937615","Management of the side effects of androgen deprivation therapy in men with prostate cancer","Flaig TW, Glodé LM.","Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829.","Flaig TW","Expert Opin Pharmacother","2008","2008/10/22","","","10.1517/14656566.9.16.2829"
"2219580","The case for no initial treatment of localized prostate cancer","Smith PH.","Urol Clin North Am. 1990 Nov;17(4):827-34.","Smith PH","Urol Clin North Am","1990","1990/11/01","","",""
"22656421","Re: Ito et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel (Urology 2011;78:1131-1135)","Kathpalia R, Mandal S, Sankhwar S.","Urology. 2012 Jun;79(6):1414; author reply 1414-5. doi: 10.1016/j.urology.2011.12.051.","Kathpalia R","Urology","2012","2012/06/05","","","10.1016/j.urology.2011.12.051"
"9189945","Prostate cancer surgical practice guidelines. Society of Surgical Oncology practice guidelines","Richie JP, Murphy GP, Walther P.","Oncology (Williston Park). 1997 Jun;11(6):907-12.","Richie JP","Oncology (Williston Park)","1997","1997/06/01","","",""
"8853484","Conservative management of clinically-localized prostate cancer","Chodak G.","Can J Oncol. 1994 Nov;4 Suppl 1:20-1; discussion 22-3.","Chodak G","Can J Oncol","1994","1994/11/01","","",""
"25520098","Epidemiology and prevention of prostate cancer in Vietnam","Van Dong H, Lee AH, Nga NH, Quang N, Le Chuyen V, Binns CW.","Asian Pac J Cancer Prev. 2014;15(22):9747-51. doi: 10.7314/apjcp.2014.15.22.9747.","Van Dong H","Asian Pac J Cancer Prev","2014","2014/12/19","","","10.7314/apjcp.2014.15.22.9747"
"9730458","National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening","Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS.","Urology. 1998 Sep;52(3):444-8; discussion 448-9. doi: 10.1016/s0090-4295(98)00242-8.","Farkas A","Urology","1998","1998/09/08","","","10.1016/s0090-4295(98)00242-8"
"20583890","Evolution of precise and multimodal MRI and TRUS in detection and management of early prostate cancer","Ukimura O.","Expert Rev Med Devices. 2010 Jul;7(4):541-54. doi: 10.1586/erd.10.24.","Ukimura O","Expert Rev Med Devices","2010","2010/06/30","","","10.1586/erd.10.24"
"18187718","Hormone treatment plus radiation delays growth of prostate cancer","Tanne JH.","BMJ. 2008 Jan 12;336(7635):66. doi: 10.1136/bmj.39451.609514.DB.","Tanne JH","BMJ","2008","2008/01/12","PMC2190269","","10.1136/bmj.39451.609514.DB"
"26313417","The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target","Muhammad LA, Saad F.","Expert Rev Anticancer Ther. 2015;15(9):1049-61. doi: 10.1586/14737140.2015.1064769.","Muhammad LA","Expert Rev Anticancer Ther","2015","2015/08/28","","","10.1586/14737140.2015.1064769"
"30939845","Splicing Factors Have an Essential Role in Prostate Cancer Progression and Androgen Receptor Signaling","Takayama KI.","Biomolecules. 2019 Apr 1;9(4):131. doi: 10.3390/biom9040131.","Takayama KI","Biomolecules","2019","2019/04/04","PMC6523118","","10.3390/biom9040131"
"26854432","Emerging therapies targeting castration-resistant prostate cancer","Gkialas IK, Fragkoulis C.","J BUON. 2015 Nov-Dec;20(6):1389-96.","Gkialas IK","J BUON","2015","2016/02/09","","",""
"12146852","Segregation analysis of prostate cancer in 1,719 white, African-American and Asian-American families in the United States and Canada","Gong G, Oakley-Girvan I, Wu AH, Kolonel LN, John EM, West DW, Felberg A, Gallagher RP, Whittemore AS.","Cancer Causes Control. 2002 Jun;13(5):471-82. doi: 10.1023/a:1015755219674.","Gong G","Cancer Causes Control","2002","2002/07/31","","","10.1023/a:1015755219674"
"25146527","Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact","Davis JW.","BJU Int. 2014 Sep;114(3):320-2. doi: 10.1111/bju.12695. Epub 2014 Jul 14.","Davis JW","BJU Int","2014","2014/08/23","","","10.1111/bju.12695"
"11912383","Early onset prostate cancer: predictors of clinical grade","Kotsis SV, Spencer SL, Peyser PA, Montie JE, Cooney KA.","J Urol. 2002 Apr;167(4):1659-63.","Kotsis SV","J Urol","2002","2002/03/26","","",""
"10760426","Follow-up costs after external radiation for low risk prostate cancer","Tralins K, Wallner K.","Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):323-6. doi: 10.1016/s0360-3016(99)00017-6.","Tralins K","Int J Radiat Oncol Biol Phys","1999","2000/04/13","","","10.1016/s0360-3016(99)00017-6"
"25465299","Toward a prostate cancer precision medicine","Rubin MA.","Urol Oncol. 2015 Feb;33(2):73-4. doi: 10.1016/j.urolonc.2014.10.011. Epub 2014 Nov 20.","Rubin MA","Urol Oncol","2015","2014/12/04","","","10.1016/j.urolonc.2014.10.011"
"17419861","Patient information preferences among breast and prostate cancer patients","Sharpley CF, Christie DR.","Australas Radiol. 2007 Apr;51(2):154-8. doi: 10.1111/j.1440-1673.2007.01687.x.","Sharpley CF","Australas Radiol","2007","2007/04/11","","","10.1111/j.1440-1673.2007.01687.x"
"1629908","Metastatic models and molecular genetics of prostate cancer","Linehan WM, Long JP, Steeg PS, Gnarra JR.","J Natl Cancer Inst. 1992 Jun 17;84(12):914-5. doi: 10.1093/jnci/84.12.914.","Linehan WM","J Natl Cancer Inst","1992","1992/06/17","","","10.1093/jnci/84.12.914"
"14661390","Target populations, pathological biomarkers and chemopreventive agents in prostate cancer prevention","Montironi R, Barbisan F, Mazzucchelli R.","Arch Ital Urol Androl. 2003 Sep;75(3):127-34.","Montironi R","Arch Ital Urol Androl","2003","2003/12/10","","",""
"20979690","Using CT imaging to delineate the prostatic apex for radiation treatment planning","Li XM, Gao XS, Guo XM, Li YG, Wang XY.","Chin J Cancer. 2010 Nov;29(11):914-22. doi: 10.5732/cjc.010.10193.","Li XM","Chin J Cancer","2010","2010/10/29","","","10.5732/cjc.010.10193"
"26782033","[Intraductal carcinoma of the prostate]","Kristiansen G, Varma M, Seitz G.","Pathologe. 2016 Feb;37(1):27-32. doi: 10.1007/s00292-015-0138-4.","Kristiansen G","Pathologe","2016","2016/01/20","","","10.1007/s00292-015-0138-4"
"25398277","Stratification of Contemporary Patients Undergoing Radical Prostatectomy for High-risk Prostate Cancer","Jo JK, Kook HR, Byun SS, Lee SE, Hong SK.","Ann Surg Oncol. 2015;22(6):2088-93. doi: 10.1245/s10434-014-4183-7. Epub 2014 Nov 15.","Jo JK","Ann Surg Oncol","2015","2014/11/16","","","10.1245/s10434-014-4183-7"
"19593851","Prostate-cancer screening","Ojha RP, Thertulien R, Fischbach LA.","N Engl J Med. 2009 Jul 9;361(2):203; author reply 204-5.","Ojha RP","N Engl J Med","2009","2009/07/14","","",""
"19138409","Can urinary exosomes act as treatment response markers in prostate cancer?","Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A.","J Transl Med. 2009 Jan 12;7:4. doi: 10.1186/1479-5876-7-4.","Mitchell PJ","J Transl Med","2009","2009/01/14","PMC2631476","","10.1186/1479-5876-7-4"
"23806501","Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?","Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI.","Semin Oncol. 2013 Jun;40(3):375-92. doi: 10.1053/j.seminoncol.2013.04.008.","Morris MJ","Semin Oncol","2013","2013/06/29","","","10.1053/j.seminoncol.2013.04.008"
"30573917","Burned-out Prostate Cancer ? Primary Metastatic Cancer Not Detected on Repeat Biopsy","Mitsui Y, Sadahira T, Maruyama Y, Wada K, Tanimoto R, Sugimoto M, Araki M, Watanabe M, Yanai H, Watanabe T, Nasu Y.","Acta Med Okayama. 2018 Dec;72(6):605-609. doi: 10.18926/AMO/56380.","Mitsui Y","Acta Med Okayama","2018","2018/12/22","","","10.18926/AMO/56380"
"11042743","Do increased 5-year survival rates in prostate cancer indicate better outcomes?","Donnelly B.","JAMA. 2000 Oct 25;284(16):2053-4; author reply 2054-5. doi: 10.1001/jama.284.16.2053-a.","Donnelly B","JAMA","2000","2000/10/24","","","10.1001/jama.284.16.2053-a"
"3874496","[Epidemiology and etiology of prostate cancer]","Hoffmann L, Gase P, Simonn C, Russbült R, Erdmann T.","Z Gesamte Hyg. 1985 Apr;31(4):221-3.","Hoffmann L","Z Gesamte Hyg","1985","1985/04/01","","",""
"9187694","Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program","Rietbergen JB, Kruger AE, Kranse R, Schröder FH.","Urology. 1997 Jun;49(6):875-80. doi: 10.1016/s0090-4295(97)00100-3.","Rietbergen JB","Urology","1997","1997/06/01","","","10.1016/s0090-4295(97)00100-3"
"8521137","Stage T1c prostate cancer: perspectives on clinical management","Smith JA Jr.","Semin Urol Oncol. 1995 Aug;13(3):238-44.","Smith JA Jr","Semin Urol Oncol","1995","1995/08/01","","",""
"9801760","Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Relationship to pathologic parameters, volume and spatial distribution of carcinoma of the prostate","Sakr WA, Grignon DJ.","Anal Quant Cytol Histol. 1998 Oct;20(5):417-23.","Sakr WA","Anal Quant Cytol Histol","1998","1998/11/05","","",""
"22521091","The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer","Van der Kwast TH.","Eur Urol. 2012 Sep;62(3):469-71. doi: 10.1016/j.eururo.2012.04.017. Epub 2012 Apr 14.","Van der Kwast TH","Eur Urol","2012","2012/04/24","","","10.1016/j.eururo.2012.04.017"
"22112793","Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials","D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW.","Lancet Oncol. 2012 Feb;13(2):189-95. doi: 10.1016/S1470-2045(11)70295-9. Epub 2011 Nov 21.","D'Amico AV","Lancet Oncol","2012","2011/11/25","","","10.1016/S1470-2045(11)70295-9"
"12868328","[Can the development of prostate cancer be prevented?]","Bouffioux L, Willems E, Waltregny D.","Rev Med Liege. 2003 Apr;58(4):240-6.","Bouffioux L","Rev Med Liege","2003","2003/07/19","","",""
"29306855","Ureteral intramural metastatic deposit of prostate cancer with ureteric obstruction","Pascoe C, Manning TG, Wetherell D, Lawrentschuk N.","BMJ Case Rep. 2018 Jan 6;2018:bcr2017222480. doi: 10.1136/bcr-2017-222480.","Pascoe C","BMJ Case Rep","2018","2018/01/08","PMC5775798","","10.1136/bcr-2017-222480"
"29465489","Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer","Chaussé G, Abikhzer G, Probst S.","Clin Nucl Med. 2018 Apr;43(4):250-251. doi: 10.1097/RLU.0000000000002009.","Chaussé G","Clin Nucl Med","2018","2018/02/22","","","10.1097/RLU.0000000000002009"
"19896265","DNA mismatch repair and the transition to hormone independence in breast and prostate cancer","Martin L, Coffey M, Lawler M, Hollywood D, Marignol L.","Cancer Lett. 2010 May 28;291(2):142-9. doi: 10.1016/j.canlet.2009.10.007. Epub 2009 Nov 5.","Martin L","Cancer Lett","2010","2009/11/10","","","10.1016/j.canlet.2009.10.007"
"23888964","Histone modifications, stem cells and prostate cancer","Crea F, Clermont PL, Mai A, Helgason CD.","Curr Pharm Des. 2014;20(11):1687-97. doi: 10.2174/13816128113199990522.","Crea F","Curr Pharm Des","2014","2013/07/30","","","10.2174/13816128113199990522"
"30522164","[Genetic profiling in the diagnosis of hereditary prostate cancer: Where do we stand?]","Boehm K, Thomas C, Tsaur I.","Aktuelle Urol. 2018 Dec;49(6):525-529. doi: 10.1055/a-0755-7360. Epub 2018 Dec 6.","Boehm K","Aktuelle Urol","2018","2018/12/07","","","10.1055/a-0755-7360"
"15049974","Decreasing mortality rates for prostate cancer: possible role of hormonal therapy?","Damber JE.","BJU Int. 2004 Apr;93(6):695-701. doi: 10.1111/j.1464-410X.2003.04713.x.","Damber JE","BJU Int","2004","2004/03/31","","","10.1111/j.1464-410X.2003.04713.x"
"27882400","[Questionnaire study for patients with low-risk prostate cancer : Therapy decision and coping strategies after a diagnosis of low-risk prostate cancer (COPCa) - study AP 91/15 from the AUO]","Rexer H, Wülfing C.","Urologe A. 2017 Jan;56(1):75-76. doi: 10.1007/s00120-016-0280-5.","Rexer H","Urologe A","2017","2016/11/25","","","10.1007/s00120-016-0280-5"
"23762859","Mechanisms of omega-3 polyunsaturated fatty acids in prostate cancer prevention","Gu Z, Suburu J, Chen H, Chen YQ.","Biomed Res Int. 2013;2013:824563. doi: 10.1155/2013/824563. Epub 2013 May 23.","Gu Z","Biomed Res Int","2013","2013/06/14","PMC3676993","","10.1155/2013/824563"
"22149434","Focal therapy for prostate cancer: patient selection and evaluation","Gravas S, Tzortzis V, de la Riva SI, Laguna P, de la Rosette J.","Expert Rev Anticancer Ther. 2012 Jan;12(1):77-86. doi: 10.1586/era.11.144.","Gravas S","Expert Rev Anticancer Ther","2012","2011/12/14","","","10.1586/era.11.144"
"11939250","Active consideration: conceptualizing patient-provided support for spouse caregivers in the context of prostate cancer","Fergus KD, Gray RE, Fitch MI, Labrecque M, Phillips C.","Qual Health Res. 2002 Apr;12(4):492-514. doi: 10.1177/104973202129120034.","Fergus KD","Qual Health Res","2002","2002/04/10","","","10.1177/104973202129120034"
"23441448","[Methylation and protein expression of RASSF2 in prostate cancer]","Liu G, Yin B, Song YS.","Zhonghua Nan Ke Xue. 2013 Feb;19(2):107-10.","Liu G","Zhonghua Nan Ke Xue","2013","2013/02/28","","",""
"30447836","Large-Gland Proliferations of the Prostate","Iczkowski KA.","Surg Pathol Clin. 2018 Dec;11(4):687-712. doi: 10.1016/j.path.2018.07.001. Epub 2018 Oct 17.","Iczkowski KA","Surg Pathol Clin","2018","2018/11/19","","","10.1016/j.path.2018.07.001"
"9750507","[The advance of ultrasound guided prostate biopsy--comparison between 4 quadrant and 6 sextant biopsy]","Ishitoya S, Maeda H, Arai Y.","Nihon Rinsho. 1998 Aug;56(8):2056-61.","Ishitoya S","Nihon Rinsho","1998","1998/09/29","","",""
"31635895","[Patients with prostate cancer treated by androgen deprivation therapy: Impact of adapted physical activity]","Veni T, Leroy V, Pradère B, Rébillard A, Mathieu R.","Prog Urol. 2019 Nov;29(15):912-916. doi: 10.1016/j.purol.2019.09.005. Epub 2019 Oct 18.","Veni T","Prog Urol","2019","2019/10/23","","","10.1016/j.purol.2019.09.005"
"26390560","[THE ROLE OF KALLIKREIN-KININ AND RENIN- ANGIOTENSIN SYSTEM IN THE PATHOGENESIS OF PROSTATE CANCER]","Kogan MI, Chernogubova EA, Chibichjan MB, Macionis AJ, Povilajtite PJ, Matishov DG.","Urologiia. 2015 May-Jun;(3):50-4.","Kogan MI","Urologiia","2015","2015/09/23","","",""
"17923856","PSA recurrence after brachytherapy for seed misplacement: a double-blind radiologic and pathologic work-up after salvage prostatectomy","Gacci M, Serni S, Lapini A, Vittori G, Vignolini G, Nesi G, Carini M.","Prostate Cancer Prostatic Dis. 2008;11(1):99-101. doi: 10.1038/sj.pcan.4501011. Epub 2007 Oct 9.","Gacci M","Prostate Cancer Prostatic Dis","2008","2007/10/10","","","10.1038/sj.pcan.4501011"
"21989588","[Prostate carcinoma: vaccination as a new option for treatment]","Bedke J, Gouttefangeas C, Stenzl A.","Urologe A. 2012 Jan;51(1):44-9. doi: 10.1007/s00120-011-2712-6.","Bedke J","Urologe A","2012","2011/10/13","","","10.1007/s00120-011-2712-6"
"27091858","New Therapeutic Target for Prostate Cancer","","Cancer Discov. 2016 Jun;6(6):OF6. doi: 10.1158/2159-8290.CD-NB2016-043. Epub 2016 Apr 18.","","Cancer Discov","2016","2016/04/20","","","10.1158/2159-8290.CD-NB2016-043"
"20690197","Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer","Cooperberg MR, Vickers AJ, Broering JM, Carroll PR.","Cancer. 2010 Nov 15;116(22):5226-34. doi: 10.1002/cncr.25456.","Cooperberg MR","Cancer","2010","2010/08/07","PMC2975879","NIHMS209200","10.1002/cncr.25456"
"17432564","Prostate cancer treatment and quality of life","Prezioso D, Galasso R, Di Martino M, Iapicca G.","Recent Results Cancer Res. 2007;175:251-65. doi: 10.1007/978-3-540-40901-4_15.","Prezioso D","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_15"
"9093244","Early prostate cancer--to treat or not to treat?","Dearnaley DP, Melia J.","Lancet. 1997 Mar 29;349(9056):892-3. doi: 10.1016/S0140-6736(97)22013-1.","Dearnaley DP","Lancet","1997","1997/03/29","","","10.1016/S0140-6736(97)22013-1"
"24585931","Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy","Akakura K, Tsuji H, Suzuki H, Ichikawa T, Ishikawa H, Okada T, Kamada T, Harada M, Tsujii H, Shimazaki J.","Jpn J Clin Oncol. 2014 Apr;44(4):360-5. doi: 10.1093/jjco/hyu006. Epub 2014 Feb 28.","Akakura K","Jpn J Clin Oncol","2014","2014/03/04","","","10.1093/jjco/hyu006"
"17569270","[Trends in the management of prostate cancer over the last 20 years]","Mangin P, Cornu JN, Rouprêt M.","Prog Urol. 2007 Apr;17(2 Suppl 1):282-4.","Mangin P","Prog Urol","2007","2007/06/16","","",""
"19333896","Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials","Priolo C, Oh WK, Loda M.","IDrugs. 2009 Mar;12(3):165-8.","Priolo C","IDrugs","2009","2009/04/01","","",""
"21623387","TRP channels in prostate cancer: the good, the bad and the ugly?","Gkika D, Prevarskaya N.","Asian J Androl. 2011 Sep;13(5):673-6. doi: 10.1038/aja.2011.18. Epub 2011 May 30.","Gkika D","Asian J Androl","2011","2011/05/31","PMC3739589","","10.1038/aja.2011.18"
"30457244","Epidemiology of Prostate Cancer in Croatia - Situation and Perspectives","Reljić A, Čukelj P, Tomašković I, Ružić B, Šekerija M.","Acta Clin Croat. 2018 Oct;57(Suppl 1):27-34. doi: 10.20471/acc.2018.57.s1.03.","Reljić A","Acta Clin Croat","2018","2018/11/21","","","10.20471/acc.2018.57.s1.03"
"28813713","Primary Treatment Choice Over Time and Relative Survival of Prostate Cancer Patients: Influence of Age, Grade, and Stage","Matthes KL, Limam M, Dehler S, Korol D, Rohrmann S.","Oncol Res Treat. 2017;40(9):484-489. doi: 10.1159/000477096. Epub 2017 Aug 17.","Matthes KL","Oncol Res Treat","2017","2017/08/17","","","10.1159/000477096"
"31160688","Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies","Morse N, Jamaspishvili T, Simon D, Patel PG, Ren KYM, Wang J, Oleschuk R, Kaufmann M, Gooding RJ, Berman DM.","Lab Invest. 2019 Oct;99(10):1561-1571. doi: 10.1038/s41374-019-0265-2. Epub 2019 Jun 3.","Morse N","Lab Invest","2019","2019/06/05","","","10.1038/s41374-019-0265-2"
"15183962","Accuracy and completeness in reporting family history of prostate cancer by unaffected men","Gaff CL, Aragona C, MacInnis RJ, Cowan R, Payne C, Giles GG, Lindeman GJ.","Urology. 2004 Jun;63(6):1111-6. doi: 10.1016/j.urology.2003.12.032.","Gaff CL","Urology","2004","2004/06/09","","","10.1016/j.urology.2003.12.032"
"21964003","The epothilones: new therapeutic agents for castration-resistant prostate cancer","Dorff TB, Gross ME.","Oncologist. 2011;16(10):1349-58. doi: 10.1634/theoncologist.2010-0014. Epub 2011 Sep 30.","Dorff TB","Oncologist","2011","2011/10/04","PMC3228074","","10.1634/theoncologist.2010-0014"
"30249870","Asthma and the risk of prostate cancer","Li W, Mao S, Tu M, Ge X, Li K, Xie F, Song Y, Miao Y.","J Cancer Res Ther. 2018 Sep;14(Supplement):S571-S575. doi: 10.4103/0973-1482.176422.","Li W","J Cancer Res Ther","2018","2018/09/26","","","10.4103/0973-1482.176422"
"32014912","Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer","Xoxakos I, Petraki C, Msaouel P, Armakolas A, Grigorakis A, Stefanakis S, Koutsilieris M.","Anticancer Res. 2020 Feb;40(2):709-718. doi: 10.21873/anticanres.14001.","Xoxakos I","Anticancer Res","2020","2020/02/05","","","10.21873/anticanres.14001"
"18423739","Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles","Helfand BT, Loeb S, Cashy J, Meeks JJ, Thaxton CS, Han M, Catalona WJ.","J Urol. 2008 Jun;179(6):2197-201; discussion 2202. doi: 10.1016/j.juro.2008.01.110. Epub 2008 Apr 18.","Helfand BT","J Urol","2008","2008/04/22","","","10.1016/j.juro.2008.01.110"
"29741162","The Urinary Sarcosine/Creatinine Ratio is a Potential Diagnostic and Prognostic Marker in Prostate Cancer","Wang M, Zou L, Liang J, Wang X, Zhang D, Fang Y, Zhang J, Xiao F, Liu M.","Med Sci Monit. 2018 May 9;24:3034-3041. doi: 10.12659/MSM.909949.","Wang M","Med Sci Monit","2018","2018/05/10","PMC5967288","","10.12659/MSM.909949"
"32014960","Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer","Miyake H, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Ito T, Sugiyama T, Otsuka A.","Anticancer Res. 2020 Feb;40(2):1101-1106. doi: 10.21873/anticanres.14049.","Miyake H","Anticancer Res","2020","2020/02/05","","","10.21873/anticanres.14049"
"17452387","Commentary: the ubiquity of prostate cancer: echoes of the past, implications for the present: ""what has been will be again, what has been done will be done again; there is nothing new under the sun."" ECCLESIASTES 1:9","Thompson IM, Lucia MS, Tangen CM.","Int J Epidemiol. 2007 Apr;36(2):287-9. doi: 10.1093/ije/dym056. Epub 2007 Apr 23.","Thompson IM","Int J Epidemiol","2007","2007/04/25","","","10.1093/ije/dym056"
"7508631","[Prostate-specific antigen: the most useful marker for prostate cancer]","Janssen T, Schulman C.","Rev Med Brux. 1993 Nov-Dec;14(9-10):279-83.","Janssen T","Rev Med Brux","1993","1993/11/01","","",""
"19902377","Validation of Epstein criteria of insignificant prostate cancer in Middle East patients","Hekal IA, El-Tabey NA, Nabeeh MA, El-Assmy A, Abd El-Hameed M, Nabeeh A, Ibrahiem EI.","Int Urol Nephrol. 2010 Sep;42(3):667-71. doi: 10.1007/s11255-009-9670-6. Epub 2009 Nov 10.","Hekal IA","Int Urol Nephrol","2010","2009/11/11","","","10.1007/s11255-009-9670-6"
"14519748","Stat bite: Distant-stage prostate cancer diagnoses by ethnicity and socioeconomic status","","J Natl Cancer Inst. 2003 Oct 1;95(19):1432.","","J Natl Cancer Inst","2003","2003/10/02","","",""
"28373135","The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction","Distler FA, Radtke JP, Bonekamp D, Kesch C, Schlemmer HP, Wieczorek K, Kirchner M, Pahernik S, Hohenfellner M, Hadaschik BA.","J Urol. 2017 Sep;198(3):575-582. doi: 10.1016/j.juro.2017.03.130. Epub 2017 Mar 31.","Distler FA","J Urol","2017","2017/04/05","","","10.1016/j.juro.2017.03.130"
"19883806","Choosing health, choosing treatment: patient choice after diagnosis of localized prostate cancer","Branney P, White A, Jain S, Hiley C, Flowers P.","Urology. 2009 Nov;74(5):968-71. doi: 10.1016/j.urology.2009.03.015.","Branney P","Urology","2009","2009/11/04","","","10.1016/j.urology.2009.03.015"
"90455","[Cancer of the prostate]","Bouffioux C.","Acta Urol Belg. 1979 Apr;47(2):189-470.","Bouffioux C","Acta Urol Belg","1979","1979/04/01","","",""
"22335870","Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era","Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, Deasy JO, Michalski JM, Kallogjeri D, Piccirillo JF, Rabah DM, Yu C, Kattan MW, Stephenson AJ.","J Urol. 2012 Apr;187(4):1259-65. doi: 10.1016/j.juro.2011.11.084. Epub 2012 Feb 14.","Kibel AS","J Urol","2012","2012/02/17","","","10.1016/j.juro.2011.11.084"
"16432533","Gynecomastia in patients with prostate cancer: update on treatment options","Autorino R, Perdonà S, D'Armiento M, De Sio M, Damiano R, Cosentino L, Di Lorenzo G.","Prostate Cancer Prostatic Dis. 2006;9(2):109-14. doi: 10.1038/sj.pcan.4500859. Epub 2006 Jan 24.","Autorino R","Prostate Cancer Prostatic Dis","2006","2006/01/25","","","10.1038/sj.pcan.4500859"
"18455086","[Practical follow-up of a patient treated with finasteride in screening for prostate cancer]","Villers A.","Prog Urol. 2008 Apr;18 Suppl 3:S58-62. doi: 10.1016/S1166-7087(08)70516-5.","Villers A","Prog Urol","2008","2008/09/26","","","10.1016/S1166-7087(08)70516-5"
"24652869","Clarifying the positive association between education and prostate cancer: a Monte Carlo simulation approach","Pudrovska T, Anishkin A.","J Appl Gerontol. 2015 Apr;34(3):293-316. doi: 10.1177/0733464812473798. Epub 2013 Mar 21.","Pudrovska T","J Appl Gerontol","2015","2014/03/22","PMC4198504","NIHMS584715","10.1177/0733464812473798"
"29132550","Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis","Sheng MX, Wan LL, Liu CM, Liu CX, Chen SS.","Kaohsiung J Med Sci. 2017 Dec;33(12):609-615. doi: 10.1016/j.kjms.2017.07.002. Epub 2017 Aug 18.","Sheng MX","Kaohsiung J Med Sci","2017","2017/11/15","","","10.1016/j.kjms.2017.07.002"
"26083679","Quality assessment of prostate cancer reports to the Danish Cancer Registry","Ingimarsdóttir IJ, Rusch E, Engholm G, Storm HH, Brasso K.","Acta Oncol. 2016;55(1):24-9. doi: 10.3109/0284186X.2015.1054948. Epub 2015 Jun 17.","Ingimarsdóttir IJ","Acta Oncol","2016","2015/06/18","","","10.3109/0284186X.2015.1054948"
"32377764","[PSMA-based theranostics for prostate cancer : From imaging to treatment]","Ilhan H, la Fougère C, Krause BJ.","Urologe A. 2020 May;59(5):617-625. doi: 10.1007/s00120-020-01193-x.","Ilhan H","Urologe A","2020","2020/05/08","","","10.1007/s00120-020-01193-x"
"15246125","Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors","Courneya KS, Segal RJ, Reid RD, Jones LW, Malone SC, Venner PM, Parliament MB, Scott CG, Quinney HA, Wells GA.","J Clin Epidemiol. 2004 Jun;57(6):571-9. doi: 10.1016/j.jclinepi.2003.11.010.","Courneya KS","J Clin Epidemiol","2004","2004/07/13","","","10.1016/j.jclinepi.2003.11.010"
"28888752","Incidence of Clinically Significant Prostate Cancer After a Diagnosis of Atypical Small Acinar Proliferation, High-grade Prostatic Intraepithelial Neoplasia, or Benign Tissue","Wiener S, Haddock P, Cusano J, Staff I, McLaughlin T, Wagner J.","Urology. 2017 Dec;110:161-165. doi: 10.1016/j.urology.2017.08.040. Epub 2017 Sep 6.","Wiener S","Urology","2017","2017/09/11","","","10.1016/j.urology.2017.08.040"
"1720275","[Clinical evaluation on serum osteocalcin in advanced prostate cancer patients]","Abe H, Nakagami YJ, Ito H, Ikeda K, Oka F, Niwa N.","Hinyokika Kiyo. 1991 Aug;37(8):877-80.","Abe H","Hinyokika Kiyo","1991","1991/08/01","","",""
"19839427","Radical prostatectomy reigns supreme","Rayala HJ, Richie JP.","Oncology (Williston Park). 2009 Sep;23(10):863-7.","Rayala HJ","Oncology (Williston Park)","2009","2009/10/21","","",""
"22569300","[Circulating tumor cells and advanced prostate cancer]","Murez T, Droupy S, Rebillard X, Alix-Panabieres C.","Bull Cancer. 2012 Jul;99 Suppl 1:S4-15. doi: 10.1684/bdc.2012.1565.","Murez T","Bull Cancer","2012","2012/05/10","","","10.1684/bdc.2012.1565"
"1348721","The Pathology of Prostate Cancer--Part 2: Novel Aspects of Human Prostate Cancer Pathology. Symposium","","Hum Pathol. 1992 Apr;23(4):335-406.","","Hum Pathol","1992","1992/04/01","","",""
"30097885","Prostate Cancer in Primary Care","Merriel SWD, Funston G, Hamilton W.","Adv Ther. 2018 Sep;35(9):1285-1294. doi: 10.1007/s12325-018-0766-1. Epub 2018 Aug 10.","Merriel SWD","Adv Ther","2018","2018/08/12","PMC6133140","","10.1007/s12325-018-0766-1"
"7086995","The national survey of prostate cancer in the United States by the American College of Surgeons","Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C.","J Urol. 1982 May;127(5):928-34. doi: 10.1016/s0022-5347(17)54135-x.","Murphy GP","J Urol","1982","1982/05/01","","","10.1016/s0022-5347(17)54135-x"
"18649736","Evaluation of resistance index in patients with prostate cancer","Huang ST, Hsieh ML.","Anticancer Res. 2008 Jul-Aug;28(4A):1985-8.","Huang ST","Anticancer Res","2008","2008/07/25","","",""
"30644306","Prostate-specific membrane antigen radioligand therapy of prostate cancer","Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM.","Q J Nucl Med Mol Imaging. 2019 Mar;63(1):29-36. doi: 10.23736/S1824-4785.19.03155-8. Epub 2019 Jan 15.","Beheshti M","Q J Nucl Med Mol Imaging","2019","2019/01/16","","","10.23736/S1824-4785.19.03155-8"
"12695812","Characterization of time-enhancement curves of benign and malignant prostate tissue at dynamic MR imaging","Rouvière O, Raudrant A, Ecochard R, Colin-Pangaud C, Pasquiou C, Bouvier R, Maréchal JM, Lyonnet D.","Eur Radiol. 2003 May;13(5):931-42. doi: 10.1007/s00330-002-1617-6. Epub 2002 Aug 16.","Rouvière O","Eur Radiol","2003","2003/04/16","","","10.1007/s00330-002-1617-6"
"22347453","Androgen-regulated transcriptional control of sialyltransferases in prostate cancer cells","Hatano K, Miyamoto Y, Mori M, Nimura K, Nakai Y, Nonomura N, Kaneda Y.","PLoS One. 2012;7(2):e31234. doi: 10.1371/journal.pone.0031234. Epub 2012 Feb 8.","Hatano K","PLoS One","2012","2012/02/21","PMC3275626","","10.1371/journal.pone.0031234"
"25807434","Epidemiology of prostate cancer: current status","Tao ZQ, Shi AM, Wang KX, Zhang WD.","Eur Rev Med Pharmacol Sci. 2015;19(5):805-12.","Tao ZQ","Eur Rev Med Pharmacol Sci","2015","2015/03/26","","",""
"19773626","[Review on the effectiveness of prostate cancer brachytherapy]","Inciūra A, Jarusevicus L, Vaiciūnas K, Juozaityte E.","Medicina (Kaunas). 2009;45(8):660-71.","Inciūra A","Medicina (Kaunas)","2009","2009/09/24","","",""
"9868829","[Prostatic cancer in the Grand Duchy of Luxembourg. Role of PSA]","Lamy S, Hein T, Wilmart JF, Capesius C, Scheiden R, Gilson G, Humbel RL.","Bull Soc Sci Med Grand Duche Luxemb. 1998;135(1):11-23.","Lamy S","Bull Soc Sci Med Grand Duche Luxemb","1998","1998/12/30","","",""
"2251225","Family history and the risk of prostate cancer","Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC.","Prostate. 1990;17(4):337-47. doi: 10.1002/pros.2990170409.","Steinberg GD","Prostate","1990","1990/01/01","","","10.1002/pros.2990170409"
"10638996","Height-related risk factors for prostate cancer","Norrish AE, McRae CU, Holdaway IM, Jackson RT.","Br J Cancer. 2000 Jan;82(1):241-5. doi: 10.1054/bjoc.1999.0906.","Norrish AE","Br J Cancer","2000","2000/01/19","PMC2363202","","10.1054/bjoc.1999.0906"
"31701789","Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer","Häggman M.","Scand J Urol. 2019 Oct;53(5):303. doi: 10.1080/21681805.2019.1685795. Epub 2019 Nov 8.","Häggman M","Scand J Urol","2019","2019/11/09","","","10.1080/21681805.2019.1685795"
"17227487","Young men with prostate cancer: are they different and how should they be managed?","Hotston MR, Burden H, Thurairaja R, McFarlane J, Persad RA.","BJU Int. 2007 Jan;99(1):5-7. doi: 10.1111/j.1464-410X.2007.06534.x.","Hotston MR","BJU Int","2007","2007/01/18","","","10.1111/j.1464-410X.2007.06534.x"
"21886062","Socioeconomic disparities in prostate cancer mortality and the impact of geographic scale","Wan N, Zhan FB, Cai Z.","South Med J. 2011 Aug;104(8):553-9. doi: 10.1097/SMJ.0b013e31821f99ff.","Wan N","South Med J","2011","2011/09/03","","","10.1097/SMJ.0b013e31821f99ff"
"25402412","Management and characteristics of patients with metastatic prostate cancer in a cohort of New Zealand men","Lawrenson R, Lao C, Obertová Z, Brown C, Holmes M, Tyrie L, Scott N, Fong P, Laking G.","Oncology. 2015;88(3):157-63. doi: 10.1159/000368319. Epub 2014 Nov 15.","Lawrenson R","Oncology","2015","2014/11/18","","","10.1159/000368319"
"28029646","The role of prostate tumor overexpressed 1 in cancer progression","Cánovas V, Lleonart M, Morote J, Paciucci R.","Oncotarget. 2017 Feb 14;8(7):12451-12471. doi: 10.18632/oncotarget.14104.","Cánovas V","Oncotarget","2017","2016/12/29","PMC5355357","","10.18632/oncotarget.14104"
"11796229","Cell adhesion molecules and adhesion abnormalities in prostate cancer","Mason MD, Davies G, Jiang WG.","Crit Rev Oncol Hematol. 2002 Jan;41(1):11-28. doi: 10.1016/s1040-8428(01)00171-8.","Mason MD","Crit Rev Oncol Hematol","2002","2002/02/14","","","10.1016/s1040-8428(01)00171-8"
"9204338","Amyloidosis of the seminal vesicles simulating tumor invasion of prostatic carcinoma on endorectal MR images","Jager GJ, Ruijter ET, de la Rosette JJ, van de Kaa CA.","Eur Radiol. 1997;7(4):552-4. doi: 10.1007/s003300050202.","Jager GJ","Eur Radiol","1997","1997/01/01","","","10.1007/s003300050202"
"27683042","Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening","Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE.","Oncotarget. 2016 Nov 8;7(45):72593-72607. doi: 10.18632/oncotarget.12241.","Kumar B","Oncotarget","2016","2016/09/30","PMC5341930","","10.18632/oncotarget.12241"
"8625082","Survival after radical retropubic prostatectomy of men with clinically localized high grade carcinoma of the prostate","Oefelein MG, Grayhack JT, McVary KT.","Cancer. 1995 Dec 15;76(12):2535-42. doi: 10.1002/1097-0142(19951215)76:12<2535::aid-cncr2820761220>3.0.co;2-q.","Oefelein MG","Cancer","1995","1995/12/15","","","10.1002/1097-0142(19951215)76:12<2535::aid-cncr2820761220>3.0.co;2-q"
"29260950","Dose painting of prostate cancer based on Gleason score correlations with apparent diffusion coefficients","Grönlund E, Johansson S, Nyholm T, Thellenberg C, Ahnesjö A.","Acta Oncol. 2018 May;57(5):574-581. doi: 10.1080/0284186X.2017.1415457. Epub 2017 Dec 20.","Grönlund E","Acta Oncol","2018","2017/12/21","","","10.1080/0284186X.2017.1415457"
"23749003","A 32-gene risk index: a new prognostic approach for prostate cancer progression","Cai C, Zhong WD, McDougal WS, Wu CL.","Asian J Androl. 2013 Sep;15(5):590-1. doi: 10.1038/aja.2013.85. Epub 2013 Jun 10.","Cai C","Asian J Androl","2013","2013/06/11","PMC3881634","","10.1038/aja.2013.85"
"12970722","Models of metastatic prostate cancer: a transgenic perspective","Winter SF, Cooper AB, Greenberg NM.","Prostate Cancer Prostatic Dis. 2003;6(3):204-11. doi: 10.1038/sj.pcan.4500655.","Winter SF","Prostate Cancer Prostatic Dis","2003","2003/09/13","","","10.1038/sj.pcan.4500655"
"21448904","Identifying and characterizing ""escapes""-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)","Zhu X, van Leeuwen PJ, Bul M, Bangma CH, Roobol MJ, Schröder FH.","Int J Cancer. 2011 Dec 15;129(12):2847-54. doi: 10.1002/ijc.25947. Epub 2011 Mar 29.","Zhu X","Int J Cancer","2011","2011/03/31","","","10.1002/ijc.25947"
"30306355","Mendelian randomization does not support serum calcium in prostate cancer risk","Yarmolinsky J, Berryman K, Langdon R, Bonilla C; PRACTICAL consortium, Davey Smith G, Martin RM, Lewis SJ.","Cancer Causes Control. 2018 Nov;29(11):1073-1080. doi: 10.1007/s10552-018-1081-5. Epub 2018 Oct 10.","Yarmolinsky J","Cancer Causes Control","2018","2018/10/12","PMC6245088","","10.1007/s10552-018-1081-5"
"19189299","Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer","Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY, Choe G, Lee SE.","Prostate. 2009 Jun 1;69(8):820-6. doi: 10.1002/pros.20932.","Hong SK","Prostate","2009","2009/02/04","","","10.1002/pros.20932"
"18294307","Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis","Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F.","BJU Int. 2008 May;101(10):1302-9. doi: 10.1111/j.1464-410X.2008.07514.x. Epub 2008 Feb 21.","Diallo JS","BJU Int","2008","2008/02/26","","","10.1111/j.1464-410X.2008.07514.x"
"30958743","Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness","Hectors SJ, Cherny M, Yadav KK, Beksaç AT, Thulasidass H, Lewis S, Davicioni E, Wang P, Tewari AK, Taouli B.","J Urol. 2019 Sep;202(3):498-505. doi: 10.1097/JU.0000000000000272. Epub 2019 Aug 8.","Hectors SJ","J Urol","2019","2019/04/09","","","10.1097/JU.0000000000000272"
"21481860","EUS-guided fiducial placement after radical prostatectomy before targeted radiation therapy for prostate cancer recurrence","Yang J, Abdel-Wahab M, Ribeiro A.","Gastrointest Endosc. 2011 Jun;73(6):1302-5. doi: 10.1016/j.gie.2011.01.045. Epub 2011 Apr 8.","Yang J","Gastrointest Endosc","2011","2011/04/13","","","10.1016/j.gie.2011.01.045"
"9346464","Is there an easier way to determine whether early detection of prostate cancer reduces mortality?","Barry MJ.","J Gen Intern Med. 1997 Oct;12(10):657-8. doi: 10.1046/j.1525-1497.1997.07129.x.","Barry MJ","J Gen Intern Med","1997","1997/11/05","PMC1497180","","10.1046/j.1525-1497.1997.07129.x"
"8354122","Consensus review of the clinical utility of DNA content cytometry in prostate cancer","Shankey TV, Kallioniemi OP, Koslowski JM, Lieber ML, Mayall BH, Miller G, Smith GJ.","Cytometry. 1993;14(5):497-500. doi: 10.1002/cyto.990140508.","Shankey TV","Cytometry","1993","1993/01/01","","","10.1002/cyto.990140508"
"22212706","Psychological aspects of prostate cancer: a clinical review","De Sousa A, Sonavane S, Mehta J.","Prostate Cancer Prostatic Dis. 2012 Jun;15(2):120-7. doi: 10.1038/pcan.2011.66. Epub 2012 Jan 3.","De Sousa A","Prostate Cancer Prostatic Dis","2012","2012/01/04","","","10.1038/pcan.2011.66"
"26776222","Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer","Kaur P, Khatik GL.","Mini Rev Med Chem. 2016;16(7):531-46. doi: 10.2174/1389557516666160118112448.","Kaur P","Mini Rev Med Chem","2016","2016/01/19","","","10.2174/1389557516666160118112448"
"29223415","[Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy]","de la Taille A, Mardoyan S, Lafaye A.","Prog Urol. 2018 Jan;28(1):32-38. doi: 10.1016/j.purol.2017.10.004. Epub 2017 Dec 7.","de la Taille A","Prog Urol","2018","2017/12/11","","","10.1016/j.purol.2017.10.004"
"25060664","Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?","Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.","BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.","Chen DJ","BJU Int","2015","2014/07/26","","","10.1111/bju.12880"
"29203269","Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options","Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR.","J Urol. 2018 Mar;199(3):683-690. doi: 10.1016/j.juro.2017.11.095. Epub 2017 Dec 15.","Sanda MG","J Urol","2018","2017/12/06","","","10.1016/j.juro.2017.11.095"
"25578935","Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia","Kitagawa Y, Namiki M.","Asian J Androl. 2015 May-Jun;17(3):475-80. doi: 10.4103/1008-682X.143756.","Kitagawa Y","Asian J Androl","2015","2015/01/13","PMC4430954","","10.4103/1008-682X.143756"
"21290864","[Prostate cancer screening: utility, goals and perspectives in 2010]","Iselin C, Jichlinski P.","Rev Med Suisse. 2010 Dec 8;6(274):2336-9.","Iselin C","Rev Med Suisse","2010","2011/02/05","","",""
"21830974","Early prostate cancer--treat or watch?","Froehner M, Wirth MP.","N Engl J Med. 2011 Aug 11;365(6):568. doi: 10.1056/NEJMc1106325.","Froehner M","N Engl J Med","2011","2011/08/12","","","10.1056/NEJMc1106325"
"21420228","Genetic markers and the risk of developing prostate cancer","Bjartell A.","Eur Urol. 2011 Jul;60(1):29-31. doi: 10.1016/j.eururo.2011.03.005. Epub 2011 Mar 21.","Bjartell A","Eur Urol","2011","2011/03/23","","","10.1016/j.eururo.2011.03.005"
"20101733","Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers","Parsons JK, Kwan L, Connor SE, Miller DC, Litwin MS.","Cancer. 2010 Mar 1;116(5):1378-84. doi: 10.1002/cncr.24856.","Parsons JK","Cancer","2010","2010/01/27","","","10.1002/cncr.24856"
"29720348","Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection","Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, Briganti A, Montorsi F, Peabody JO, Menon M.","Eur Urol. 2018 Sep;74(3):253-256. doi: 10.1016/j.eururo.2018.04.017. Epub 2018 Apr 30.","Abdollah F","Eur Urol","2018","2018/05/04","","","10.1016/j.eururo.2018.04.017"
"21823116","Vegetable and fruit intake after diagnosis and risk of prostate cancer progression","Richman EL, Carroll PR, Chan JM.","Int J Cancer. 2012 Jul 1;131(1):201-10. doi: 10.1002/ijc.26348. Epub 2011 Aug 30.","Richman EL","Int J Cancer","2012","2011/08/09","PMC3310254","NIHMS342044","10.1002/ijc.26348"
"26204306","Anterior Prostate Cancer: Diagnostic Performance of T2-Weighted MRI and an Apparent Diffusion Coefficient Map","Shinmoto H, Tamura C, Soga S, Okamura T, Horiguchi A, Asano T, Kaji T.","AJR Am J Roentgenol. 2015 Aug;205(2):W185-92. doi: 10.2214/AJR.14.13392.","Shinmoto H","AJR Am J Roentgenol","2015","2015/07/24","","","10.2214/AJR.14.13392"
"29534584","Tumor suppressor RKIP inhibits prostate cancer cell metastasis and sensitizes prostate cancer cells to docetaxel treatment","Zhu CX, Li WZ, Guo YL, Chen L, Li GH, Yu JJ, Shu B, Peng S.","Neoplasma. 2018;65(2):228-233. doi: 10.4149/neo_2018_170203N72.","Zhu CX","Neoplasma","2018","2018/03/15","","","10.4149/neo_2018_170203N72"
"9488009","Precursor lesions for prostate cancer","Feneley MR, Busch C.","J R Soc Med. 1997 Oct;90(10):533-9. doi: 10.1177/014107689709001003.","Feneley MR","J R Soc Med","1997","1998/03/06","PMC1296593","","10.1177/014107689709001003"
"12464759","From ""death sentence"" to ""good cancer"": couples' transformation of a prostate cancer diagnosis","Maliski SL, Heilemann MV, McCorkle R.","Nurs Res. 2002 Nov-Dec;51(6):391-7. doi: 10.1097/00006199-200211000-00007.","Maliski SL","Nurs Res","2002","2002/12/05","","","10.1097/00006199-200211000-00007"
"15169984","Intermittent androgen deprivation therapy for prostate cancer","Rashid MH, Chaudhary UB.","Oncologist. 2004;9(3):295-301. doi: 10.1634/theoncologist.9-3-295.","Rashid MH","Oncologist","2004","2004/06/01","","","10.1634/theoncologist.9-3-295"
"31281063","Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy","Huang H, Chen S, Li W, Bai P, Wu X, Xing J.","Clin Genitourin Cancer. 2019 Oct;17(5):e1036-e1047. doi: 10.1016/j.clgc.2019.06.001. Epub 2019 Jun 13.","Huang H","Clin Genitourin Cancer","2019","2019/07/09","","","10.1016/j.clgc.2019.06.001"
"29965785","Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies","Zhao Y, Deng FM, Huang H, Lee P, Lepor H, Rosenkrantz AB, Taneja S, Melamed J, Zhou M.","Arch Pathol Lab Med. 2019 Jan;143(1):86-91. doi: 10.5858/arpa.2017-0410-OA. Epub 2018 Jul 2.","Zhao Y","Arch Pathol Lab Med","2019","2018/07/03","","","10.5858/arpa.2017-0410-OA"
"9933059","Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer","Ozen M, Hopwood VL, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S.","Urology. 1999 Feb;53(2):381-5. doi: 10.1016/s0090-4295(98)00487-7.","Ozen M","Urology","1999","1999/02/05","","","10.1016/s0090-4295(98)00487-7"
"1722159","Is there a relationship between benign prostatic hyperplasia and prostatic cancer?","Pagano F, Zattoni F, Vianello F, Piazza R, Capitanio G.","Eur Urol. 1991;20 Suppl 1:31-5. doi: 10.1159/000471743.","Pagano F","Eur Urol","1991","1991/01/01","","","10.1159/000471743"
"26628287","Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score","Herget KA, Patel DP, Hanson HA, Sweeney C, Lowrance WT.","Cancer Med. 2016 Jan;5(1):136-41. doi: 10.1002/cam4.549. Epub 2015 Dec 2.","Herget KA","Cancer Med","2016","2015/12/03","PMC4708896","","10.1002/cam4.549"
"18682720","Circulating endothelial cells as biomarkers of prostate cancer","Georgiou HD, Namdarian B, Corcoran NM, Costello AJ, Hovens CM.","Nat Clin Pract Urol. 2008 Aug;5(8):445-54. doi: 10.1038/ncpuro1188.","Georgiou HD","Nat Clin Pract Urol","2008","2008/08/07","","","10.1038/ncpuro1188"
"8951471","[Diagnosis and treatment of localized prostate cancer]","Usami M, Arai Y.","Hinyokika Kiyo. 1996 Oct;42(10):759-61.","Usami M","Hinyokika Kiyo","1996","1996/10/01","","",""
"19945663","[Characteristics of prostate cancer in men less than 50-year-old]","Peyromaure M, Valéri A, Rebillard X, Beuzeboc P, Richaud P, Soulié M, Salomon L; CCAFU.","Prog Urol. 2009 Dec;19(11):803-9. doi: 10.1016/j.purol.2009.04.010. Epub 2009 Jun 4.","Peyromaure M","Prog Urol","2009","2009/12/01","","","10.1016/j.purol.2009.04.010"
"17007995","Antiandrogens in the treatment of prostate cancer","Wirth MP, Hakenberg OW, Froehner M.","Eur Urol. 2007 Feb;51(2):306-13; discussion 314. doi: 10.1016/j.eururo.2006.08.043. Epub 2006 Sep 11.","Wirth MP","Eur Urol","2007","2006/09/30","","","10.1016/j.eururo.2006.08.043"
"11912386","Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone","Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johnston D, Reyes AO, Babaian RJ.","J Urol. 2002 Apr;167(4):1675-80.","Mian BM","J Urol","2002","2002/03/26","","",""
"17440140","Outcomes of treatment vs observation of localized prostate cancer in elderly men","Lu-Yao GL, Barry MJ, Albertsen PC, Yao SL.","JAMA. 2007 Apr 18;297(15):1651; author reply 1652-3. doi: 10.1001/jama.297.15.1651-a.","Lu-Yao GL","JAMA","2007","2007/04/19","","","10.1001/jama.297.15.1651-a"
"7505232","Value of prostate-specific antigen as a tumor marker","Wirth M, Manseck A, Heimbach D.","Eur Urol. 1993;24 Suppl 2:6-12. doi: 10.1159/000474380.","Wirth M","Eur Urol","1993","1993/01/01","","","10.1159/000474380"
"29122446","Review of the comparative effectiveness of radical prostatectomy, radiation therapy, or expectant management of localized prostate cancer in registry data","Serrell EC, Pitts D, Hayn M, Beaule L, Hansen MH, Sammon JD.","Urol Oncol. 2018 Apr;36(4):183-192. doi: 10.1016/j.urolonc.2017.10.003. Epub 2017 Nov 6.","Serrell EC","Urol Oncol","2018","2017/11/11","","","10.1016/j.urolonc.2017.10.003"
"24586102","RE: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer","Hamstra DA, Chen RC.","J Natl Cancer Inst. 2014 Mar;106(3):djt463. doi: 10.1093/jnci/djt463. Epub 2014 Mar 1.","Hamstra DA","J Natl Cancer Inst","2014","2014/03/04","","","10.1093/jnci/djt463"
"11438447","Estrogen receptor beta in prostate cancer: brake pedal or accelerator?","Signoretti S, Loda M.","Am J Pathol. 2001 Jul;159(1):13-6. doi: 10.1016/s0002-9440(10)61666-5.","Signoretti S","Am J Pathol","2001","2001/07/05","PMC1850394","","10.1016/s0002-9440(10)61666-5"
"30824971","[Active surveillance of prostate cancer : An update]","Chaloupka M, Westhofen T, Kretschmer A, Grimm T, Stief C, Apfelbeck M.","Urologe A. 2019 Mar;58(3):329-340. doi: 10.1007/s00120-019-0894-5.","Chaloupka M","Urologe A","2019","2019/03/03","","","10.1007/s00120-019-0894-5"
"24625431","Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers","Donovan MJ, Cordon-Cardo C.","Curr Opin Urol. 2014 May;24(3):303-10. doi: 10.1097/MOU.0000000000000051.","Donovan MJ","Curr Opin Urol","2014","2014/03/15","","","10.1097/MOU.0000000000000051"
"12007976","The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century","Vaishampayan U, Hussain M.","Crit Rev Oncol Hematol. 2002 May;42(2):179-88. doi: 10.1016/s1040-8428(01)00187-1.","Vaishampayan U","Crit Rev Oncol Hematol","2002","2002/05/15","","","10.1016/s1040-8428(01)00187-1"
"28684411","The Path of Most Resistance: Transdifferentiation Underlies Exceptional Nonresponses to Androgen Receptor Pathway Inhibition in Prostate Cancer","Sinha S, Nelson PS.","Cancer Discov. 2017 Jul;7(7):673-674. doi: 10.1158/2159-8290.CD-17-0481.","Sinha S","Cancer Discov","2017","2017/07/08","","","10.1158/2159-8290.CD-17-0481"
"7691145","Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer","Uchida T, Wada C, Shitara T, Egawa S, Koshiba K.","Br J Cancer. 1993 Oct;68(4):751-5. doi: 10.1038/bjc.1993.423.","Uchida T","Br J Cancer","1993","1993/10/01","PMC1968625","","10.1038/bjc.1993.423"
"8648774","Survival in blacks and whites after treatment for localized prostate cancer","Fowler JE Jr, Terrell F.","J Urol. 1996 Jul;156(1):133-6.","Fowler JE Jr","J Urol","1996","1996/07/01","","",""
"20844859","[Node-positive prostate cancer. Value of radical prostatectomy]","Heidenreich A, Schrader AJ.","Urologe A. 2010 Oct;49(10):1266-73. doi: 10.1007/s00120-010-2399-0.","Heidenreich A","Urologe A","2010","2010/09/17","","","10.1007/s00120-010-2399-0"
"24486022","The rate of overdiagnosis inextricably linked to prostate-specific antigen-based screening for prostate cancer can be quantified in several ways, but what is the practicable message?","Roobol MJ, Schröder FH.","Eur Urol. 2014 Jun;65(6):1056-7. doi: 10.1016/j.eururo.2014.01.016. Epub 2014 Jan 24.","Roobol MJ","Eur Urol","2014","2014/02/04","","","10.1016/j.eururo.2014.01.016"
"25316814","Modernizing the diagnostic and decision-making pathway for prostate cancer","Polascik TJ, Passoni NM, Villers A, Choyke PL.","Clin Cancer Res. 2014 Dec 15;20(24):6254-7. doi: 10.1158/1078-0432.CCR-14-0247. Epub 2014 Oct 14.","Polascik TJ","Clin Cancer Res","2014","2014/10/16","PMC6330107","NIHMS1005094","10.1158/1078-0432.CCR-14-0247"
"18824426","Decision-making in clinically localized prostate cancer: evaluating and communicating risks","Sartor O.","Clin Genitourin Cancer. 2008 Sep;6(2):63-4. doi: 10.3816/CGC.2008.n.010.","Sartor O","Clin Genitourin Cancer","2008","2008/10/01","","","10.3816/CGC.2008.n.010"
"23171028","Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy","Mitra R, Chao O, Urasaki Y, Goodman OB, Le TT.","BMC Cancer. 2012 Nov 21;12:540. doi: 10.1186/1471-2407-12-540.","Mitra R","BMC Cancer","2012","2012/11/23","PMC3519750","","10.1186/1471-2407-12-540"
"11221051","[Ultrasound-guided biopsy: screening of prostate cancer with a single set of 14 systematic biopsies]","Perdonà S, De Sio M, Damiano R, Oliva A, D'Armiento M.","Arch Ital Urol Androl. 2000 Dec;72(4):258-63.","Perdonà S","Arch Ital Urol Androl","2000","2001/02/28","","",""
"31227050","Molecular Imaging for Primary Staging of Prostate Cancer","Pomykala KL, Farolfi A, Hadaschik B, Fendler WP, Herrmann K.","Semin Nucl Med. 2019 Jul;49(4):271-279. doi: 10.1053/j.semnuclmed.2019.02.004. Epub 2019 Mar 20.","Pomykala KL","Semin Nucl Med","2019","2019/06/23","","","10.1053/j.semnuclmed.2019.02.004"
"25773350","Lymph node staging in prostate cancer","Sankineni S, Brown AM, Fascelli M, Law YM, Pinto PA, Choyke PL, Turkbey B.","Curr Urol Rep. 2015 May;16(5):30. doi: 10.1007/s11934-015-0505-y.","Sankineni S","Curr Urol Rep","2015","2015/03/17","PMC6330104","NIHMS1005090","10.1007/s11934-015-0505-y"
"29775158","microRNA expression in tumour tissue and plasma in patients with newly diagnosed metastatic prostate cancer","Zedan AH, Hansen TF, Assenholt J, Pleckaitis M, Madsen JS, Osther PJS.","Tumour Biol. 2018 May;40(5):1010428318775864. doi: 10.1177/1010428318775864.","Zedan AH","Tumour Biol","2018","2018/05/19","","","10.1177/1010428318775864"
"27147512","Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage","Wendler JJ, Ganzer R, Hadaschik B, Blana A, Henkel T, Köhrmann KU, Machtens S, Roosen A, Salomon G, Sentker L, Witzsch U, Schlemmer HP, Baumunk D, Köllermann J, Schostak M, Liehr UB.","World J Urol. 2017 Jan;35(1):11-20. doi: 10.1007/s00345-016-1838-y. Epub 2016 May 4.","Wendler JJ","World J Urol","2017","2016/05/06","","","10.1007/s00345-016-1838-y"
"10915672","Helical CT of prostate cancer: early clinical experience","Prando A, Wallace S.","AJR Am J Roentgenol. 2000 Aug;175(2):343-6. doi: 10.2214/ajr.175.2.1750343.","Prando A","AJR Am J Roentgenol","2000","2000/08/01","","","10.2214/ajr.175.2.1750343"
"12642044","Prostate cancer: hopes and controversies","Sharp D.","Lancet. 2003 Mar 8;361(9360):798. doi: 10.1016/S0140-6736(03)12722-5.","Sharp D","Lancet","2003","2003/03/19","","","10.1016/S0140-6736(03)12722-5"
"10531767","Early detection of prostate cancer","Mehdi I.","J Pak Med Assoc. 1998 Dec;48(12):359-60.","Mehdi I","J Pak Med Assoc","1998","1999/10/26","","",""
"27430478","Liquid biopsy: ready to guide therapy in advanced prostate cancer?","Hegemann M, Stenzl A, Bedke J, Chi KN, Black PC, Todenhöfer T.","BJU Int. 2016 Dec;118(6):855-863. doi: 10.1111/bju.13586. Epub 2016 Aug 19.","Hegemann M","BJU Int","2016","2016/07/20","","","10.1111/bju.13586"
"17141840","Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy","Symon Z, Daignault S, Symon R, Dunn RL, Sanda MG, Sandler HM.","Urology. 2006 Dec;68(6):1224-9. doi: 10.1016/j.urology.2006.08.1092. Epub 2006 Dec 4.","Symon Z","Urology","2006","2006/12/05","","","10.1016/j.urology.2006.08.1092"
"15217152","[Anatomical basis of lymph node dissection in prostate cancer]","Delmas V, Durand X, Boccon-Gibod L.","Prog Urol. 2004 Apr;14(2):252-4.","Delmas V","Prog Urol","2004","2004/06/26","","",""
"23857672","Quantification of a proteotypic peptide from protein C inhibitor by liquid chromatography-free SISCAPA-MALDI mass spectrometry: application to identification of recurrence of prostate cancer","Razavi M, Johnson LD, Lum JJ, Kruppa G, Anderson NL, Pearson TW.","Clin Chem. 2013 Oct;59(10):1514-22. doi: 10.1373/clinchem.2012.199786. Epub 2013 Jul 15.","Razavi M","Clin Chem","2013","2013/07/17","","","10.1373/clinchem.2012.199786"
"25204357","The impact of prostate cancer on men's everyday life","Appleton L, Wyatt D, Perkins E, Parker C, Crane J, Jones A, Moorhead L, Brown V, Wall C, Pagett M.","Eur J Cancer Care (Engl). 2015;24(1):71-84. doi: 10.1111/ecc.12233. Epub 2014 Sep 10.","Appleton L","Eur J Cancer Care (Engl)","2015","2014/09/11","","","10.1111/ecc.12233"
"29730256","The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points","Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, Duan Y, Vyas U, Harisinghani M, Mahmood U, Samir AE.","Urology. 2018 Sep;119:23-31. doi: 10.1016/j.urology.2018.04.026. Epub 2018 May 3.","Li Q","Urology","2018","2018/05/07","","","10.1016/j.urology.2018.04.026"
"12109360","Vitamin D and prostate cancer","Konety BR, Getzenberg RH.","Urol Clin North Am. 2002 Feb;29(1):95-106, ix. doi: 10.1016/s0094-0143(02)00021-6.","Konety BR","Urol Clin North Am","2002","2002/07/12","","","10.1016/s0094-0143(02)00021-6"
"10763282","Barriers to prostate cancer screening","Weinrich SP, Reynolds WA Jr, Tingen MS, Starr CR.","Cancer Nurs. 2000 Apr;23(2):117-21. doi: 10.1097/00002820-200004000-00007.","Weinrich SP","Cancer Nurs","2000","2000/04/14","","","10.1097/00002820-200004000-00007"
"27430689","[Association between polymorphism in Vav3 genes and risk of primary prostatic cancer in Chinese Han population]","Liu M, Miao N, Zhu Y, Gu CY, Shi XL, Cui WL, Zhang W, Li QX.","Zhonghua Bing Li Xue Za Zhi. 2016 Jul 8;45(7):451-6. doi: 10.3760/cma.j.issn.0529-5807.2016.07.005.","Liu M","Zhonghua Bing Li Xue Za Zhi","2016","2016/07/20","","","10.3760/cma.j.issn.0529-5807.2016.07.005"
"25707146","[Imaging fusion in the diagnosis of prostate cancer]","Zhang YY, Hu B, Chen L.","Zhonghua Nan Ke Xue. 2015 Jan;21(1):78-81.","Zhang YY","Zhonghua Nan Ke Xue","2015","2015/02/25","","",""
"6168015","Prostate cancer. Diagnostic imaging","Mamtora H, Gowland MR, Isherwood I.","Recent Results Cancer Res. 1981;78:76-96.","Mamtora H","Recent Results Cancer Res","1981","1981/01/01","","",""
"27840359","The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review","Perdana NR, Mochtar CA, Umbas R, Hamid AR.","Acta Med Indones. 2016 Jul;48(3):228-238.","Perdana NR","Acta Med Indones","2016","2016/11/15","","",""
"11193312","[Staging and tissue characterization of prostate carcinoma: role of endorectal MR imaging and MR spectroscopy]","Sugimura K.","Hinyokika Kiyo. 2000 Nov;46(11):855-9.","Sugimura K","Hinyokika Kiyo","2000","2001/02/24","","",""
"30516662","Pleural Mesothelioma Detects by 18F-Choline PET/CT in a Patient With Biochemical Recurrence of Prostate Cancer","Rensi M, Ferretti G, Di Gregorio F, Evangelista L.","Clin Nucl Med. 2019 Feb;44(2):e116-e117. doi: 10.1097/RLU.0000000000002416.","Rensi M","Clin Nucl Med","2019","2018/12/06","","","10.1097/RLU.0000000000002416"
"28332895","Comorbidities as predictors of incidental prostate cancer after Holmium laser enucleation of the prostate: diabetes and high-risk cancer","Ohwaki K, Endo F, Shimbo M, Fujisaki A, Hattori K.","Aging Male. 2017 Dec;20(4):257-260. doi: 10.1080/13685538.2017.1301417. Epub 2017 Mar 23.","Ohwaki K","Aging Male","2017","2017/03/24","","","10.1080/13685538.2017.1301417"
"18556193","Significance of micrometastases in prostate cancer","Fujisawa M, Miyake H.","Surg Oncol. 2008 Sep;17(3):247-52. doi: 10.1016/j.suronc.2008.05.002. Epub 2008 Jun 16.","Fujisawa M","Surg Oncol","2008","2008/06/17","","","10.1016/j.suronc.2008.05.002"
"7933250","Future studies in localized prostate cancer. What should we think? What can we do?","Lange PH.","J Urol. 1994 Nov;152(5 Pt 2):1932-8. doi: 10.1016/s0022-5347(17)32418-7.","Lange PH","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32418-7"
"24416883","[3D ultrasound guidance for prostate biopsy with MRI-image fusion]","Klein J, De Gorski A, Iselin C.","Rev Med Suisse. 2013 Dec 4;9(409):2275-8.","Klein J","Rev Med Suisse","2013","2014/01/15","","",""
"7689739","Treatment of stage A1 prostate cancer: the case for treatment","Bahnson RR.","Semin Urol. 1993 May;11(2):54-7.","Bahnson RR","Semin Urol","1993","1993/05/01","","",""
"8853493","The American Cancer Society's National Prostate Cancer Detection Project","Littrup PJ.","Can J Oncol. 1994 Nov;4 Suppl 1:65-9.","Littrup PJ","Can J Oncol","1994","1994/11/01","","",""
"30447847","Urologic Pathology: Key Parameters from a Urologist's Perspective","Borchert A, Rogers CG.","Surg Pathol Clin. 2018 Dec;11(4):893-901. doi: 10.1016/j.path.2018.07.012. Epub 2018 Oct 17.","Borchert A","Surg Pathol Clin","2018","2018/11/19","","","10.1016/j.path.2018.07.012"
"28974120","The oncologic results of cryoablation in prostate cancer patients with bone metastases","Si T, Guo Z, Yang X, Zhang W, Xing W.","Int J Hyperthermia. 2018 Nov;34(7):1044-1048. doi: 10.1080/02656736.2017.1387940. Epub 2017 Oct 30.","Si T","Int J Hyperthermia","2018","2017/10/05","","","10.1080/02656736.2017.1387940"
"8535465","Epididymo-orchitis after cryoablation of prostate for prostate cancer","Fournier G, Indudhara R, Gajendran V, Huang E, Narayan P.","J Endourol. 1995 Aug;9(4):349-51. doi: 10.1089/end.1995.9.349.","Fournier G","J Endourol","1995","1995/08/01","","","10.1089/end.1995.9.349"
"8973937","[Combination therapy with hormonal, radiation and chemotherapy for stage C prostate cancer]","Iwasawa T, Matsumoto H.","Hinyokika Kiyo. 1996 Nov;42(11):869-74.","Iwasawa T","Hinyokika Kiyo","1996","1996/11/01","","",""
"29713007","Historical and contemporary perspectives on cribriform morphology in prostate cancer","Truong M, Frye T, Messing E, Miyamoto H.","Nat Rev Urol. 2018 Aug;15(8):475-482. doi: 10.1038/s41585-018-0013-1.","Truong M","Nat Rev Urol","2018","2018/05/02","","","10.1038/s41585-018-0013-1"
"23931190","Re: Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer","Taneja SS.","J Urol. 2013 Sep;190(3):878. doi: 10.1016/j.juro.2013.05.101. Epub 2013 Jun 7.","Taneja SS","J Urol","2013","2013/08/13","","","10.1016/j.juro.2013.05.101"
"23565752","Androgen receptor and prostate cancer: new insights in an old target translate into novel therapeutic strategies","Heemers HV.","Curr Drug Targets. 2013 Apr;14(4):399-400. doi: 10.2174/1389450111314040001.","Heemers HV","Curr Drug Targets","2013","2013/04/10","","","10.2174/1389450111314040001"
"21788037","Imaging for staging prostate cancer--too much or not enough?","Borin JF.","J Urol. 2011 Sep;186(3):779-80. doi: 10.1016/j.juro.2011.07.039. Epub 2011 Jul 23.","Borin JF","J Urol","2011","2011/07/27","","","10.1016/j.juro.2011.07.039"
"29356739","Prostate Cancer Lytic Bone Metastases Imaged With 18F-Fluorocholine PET/CT","Alabed YZ.","Clin Nucl Med. 2018 Mar;43(3):220-221. doi: 10.1097/RLU.0000000000001973.","Alabed YZ","Clin Nucl Med","2018","2018/01/23","","","10.1097/RLU.0000000000001973"
"18093474","Pharmacotherapy for prostate cancer: the role of hormonal treatment","Shahani R, Fleshner NE, Zlotta AR.","Discov Med. 2007 Aug;7(39):118-24.","Shahani R","Discov Med","2007","2007/12/21","","",""
"14963347","Antiandrogen monotherapy: recommendations for the treatment of prostate cancer","Sciarra A, Cardi A, Di Silverio F.","Urol Int. 2004;72(2):91-8. doi: 10.1159/000075960.","Sciarra A","Urol Int","2004","2004/02/14","","","10.1159/000075960"
"8501794","Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial","Van Poppel H, van den Broucke F, Derluyn J, Popelier G, Casselman J, Billiet I, van Uytsel L, Paridaens R, Baert L.","J Urol. 1993 Jun;149(6):1485-7. doi: 10.1016/s0022-5347(17)36423-6.","Van Poppel H","J Urol","1993","1993/06/01","","","10.1016/s0022-5347(17)36423-6"
"19156715","Alcohol use and prostate cancer: a meta-analysis","Middleton Fillmore K, Chikritzhs T, Stockwell T, Bostrom A, Pascal R.","Mol Nutr Food Res. 2009 Feb;53(2):240-55. doi: 10.1002/mnfr.200800122.","Middleton Fillmore K","Mol Nutr Food Res","2009","2009/01/22","","","10.1002/mnfr.200800122"
"18022549","Current immunotherapeutic strategies in prostate cancer","Grosso JF, Drake CG.","Surg Oncol Clin N Am. 2007 Oct;16(4):861-71, x. doi: 10.1016/j.soc.2007.07.009.","Grosso JF","Surg Oncol Clin N Am","2007","2007/11/21","","","10.1016/j.soc.2007.07.009"
"26898070","Validation of Epstein Biopsy Criteria for Insignificant Prostate Cancer in Contemporary Cohort of Croatian Patients","Tomasković I, Ulamec M, Tomić M, Pezelj I, Grubisić I, Kruslin B.","Coll Antropol. 2015 Sep;39(3):709-11.","Tomasković I","Coll Antropol","2015","2016/02/23","","",""
"23244085","Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China","Wang JJ, Liu YX, Wang W, Yan W, Zheng YP, Qiao LD, Liu D, Chen S.","Asian Pac J Cancer Prev. 2012;13(10):4935-8. doi: 10.7314/apjcp.2012.13.10.4935.","Wang JJ","Asian Pac J Cancer Prev","2012","2012/12/19","","","10.7314/apjcp.2012.13.10.4935"
"23557718","Effective management of localized prostate cancer: first, do no harm","Ehdaie B, Eastham JA.","Eur Urol. 2013 Sep;64(3):379-80. doi: 10.1016/j.eururo.2013.03.035. Epub 2013 Mar 26.","Ehdaie B","Eur Urol","2013","2013/04/06","","","10.1016/j.eururo.2013.03.035"
"7812389","Brachytherapy: a minimally invasive option for treating prostate cancer","Stahlinski CR, Friedman FP, Finklestein S.","Minim Invasive Surg Nurs. 1994 Fall;8(3):106-9.","Stahlinski CR","Minim Invasive Surg Nurs","1994","1994/01/01","","",""
"1829949","American Urological Association response to two articles on the relationship of vasectomy and prostate cancer","Howards SS.","Oncology (Williston Park). 1991 Mar;5(3):78, 80.","Howards SS","Oncology (Williston Park)","1991","1991/03/01","","",""
"19429481","Epigenetic mechanisms in the biology of prostate cancer","Schulz WA, Hoffmann MJ.","Semin Cancer Biol. 2009 Jun;19(3):172-80. doi: 10.1016/j.semcancer.2009.02.006. Epub 2009 Feb 20.","Schulz WA","Semin Cancer Biol","2009","2009/05/12","","","10.1016/j.semcancer.2009.02.006"
"24258693","No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period","Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA.","Cancer. 2014 Mar 15;120(6):818-23. doi: 10.1002/cncr.28485. Epub 2013 Nov 20.","Wu JN","Cancer","2014","2013/11/22","","","10.1002/cncr.28485"
"14704108","Prostate specific antigen: an updated review","So A, Goldenberg L, Gleave ME.","Can J Urol. 2003 Dec;10(6):2040-50.","So A","Can J Urol","2003","2004/01/06","","",""
"23399728","Artificial neural networks and prostate cancer--tools for diagnosis and management","Hu X, Cammann H, Meyer HA, Miller K, Jung K, Stephan C.","Nat Rev Urol. 2013 Mar;10(3):174-82. doi: 10.1038/nrurol.2013.9. Epub 2013 Feb 12.","Hu X","Nat Rev Urol","2013","2013/02/13","","","10.1038/nrurol.2013.9"
"21945513","Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110","Catalona WJ.","J Urol. 2011 Nov;186(5):2131-2; author reply 2132. doi: 10.1016/j.juro.2011.07.015. Epub 2011 Sep 25.","Catalona WJ","J Urol","2011","2011/09/28","","","10.1016/j.juro.2011.07.015"
"11104892","ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer","Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L; ESTRA/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group.","Radiother Oncol. 2000 Dec;57(3):315-21. doi: 10.1016/s0167-8140(00)00306-6.","Ash D","Radiother Oncol","2000","2000/12/06","","","10.1016/s0167-8140(00)00306-6"
"29420982","Multiparametric MR imaging of the Prostate: Pitfalls in Interpretation","Thomas S, Oto A.","Radiol Clin North Am. 2018 Mar;56(2):277-287. doi: 10.1016/j.rcl.2017.10.009. Epub 2017 Dec 16.","Thomas S","Radiol Clin North Am","2018","2018/02/09","","","10.1016/j.rcl.2017.10.009"
"11679950","Grade I prostate cancer","Epstein JI.","Hum Pathol. 2001 Oct;32(10):1141-2. doi: 10.1053/hupa.2001.28219.","Epstein JI","Hum Pathol","2001","2001/10/27","","","10.1053/hupa.2001.28219"
"8078147","Screening for prostate cancer. The debate continues","Chodak GW.","JAMA. 1994 Sep 14;272(10):813-4.","Chodak GW","JAMA","1994","1994/09/14","","",""
"29183925","Cohort profile: the TrueNTH Global Registry - an international registry to monitor and improve localised prostate cancer health outcomes","Evans SM, Millar JL, Moore CM, Lewis JD, Huland H, Sampurno F, Connor SE, Villanti P, Litwin MS.","BMJ Open. 2017 Nov 28;7(11):e017006. doi: 10.1136/bmjopen-2017-017006.","Evans SM","BMJ Open","2017","2017/11/30","PMC5719323","","10.1136/bmjopen-2017-017006"
"8751397","Pretreatment p53 immunoreactivity does not infer radioresistance in prostate cancer patients","Stattin P, Damber JE, Modig H, Bergh A.","Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):885-9. doi: 10.1016/0360-3016(96)00134-4.","Stattin P","Int J Radiat Oncol Biol Phys","1996","1996/07/15","","","10.1016/0360-3016(96)00134-4"
"21397831","[Bone prevention in prostate cancer]","Bessede T, Houede N, Lebret T.","Prog Urol. 2011 Mar;21 Suppl 2:S58-62. doi: 10.1016/S1166-7087(11)70013-6.","Bessede T","Prog Urol","2011","2011/03/15","","","10.1016/S1166-7087(11)70013-6"
"24134358","""Screening"" for prostate cancer in New York's skid row: history and implications","Aronowitz R.","Am J Public Health. 2014 Jan;104(1):70-6. doi: 10.2105/AJPH.2013.301446. Epub 2013 Oct 17.","Aronowitz R","Am J Public Health","2014","2013/10/19","PMC3910041","","10.2105/AJPH.2013.301446"
"9800488","[Prostate-specific antigen in the follow-up of conservatively treated prostatic cancer]","Otnes B, Hernes E, Fosså SD.","Tidsskr Nor Laegeforen. 1998 Sep 20;118(22):3401-5.","Otnes B","Tidsskr Nor Laegeforen","1998","1998/11/04","","",""
"12796636","Histological changes of minimally invasive procedures for the treatment of benign prostatic hyperplasia and prostate cancer: clinical implications","Larson BT, Bostwick DG, Corica AG, Larson TR.","J Urol. 2003 Jul;170(1):12-9. doi: 10.1097/01.ju.0000072200.22089.c3.","Larson BT","J Urol","2003","2003/06/11","","","10.1097/01.ju.0000072200.22089.c3"
"2577183","Prostatic ultrasound for the early detection of prostate cancer","Angell A, Resnick MI.","Cancer Treat Res. 1989;46:1-13. doi: 10.1007/978-1-4613-1595-7_1.","Angell A","Cancer Treat Res","1989","1989/01/01","","","10.1007/978-1-4613-1595-7_1"
"16459671","[Anaemia and prostatic cancer]","Boustany R, Zerbib M.","Prog Urol. 2005 Sep;15(4):604-10.","Boustany R","Prog Urol","2005","2006/02/08","","",""
"8977985","Maximum androgen blockade in 1996","Boccon-Gibod L.","Eur Urol. 1996;30 Suppl 1:15-8; discussion 19-21. doi: 10.1159/000474239.","Boccon-Gibod L","Eur Urol","1996","1996/01/01","","","10.1159/000474239"
"11792908","Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer","Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H.","J Urol. 2002 Feb;167(2 Pt 1):512-5. doi: 10.1097/00005392-200202000-00014.","Isshiki S","J Urol","2002","2002/01/17","","","10.1097/00005392-200202000-00014"
"21898167","No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patients","Akgül B, Pfister D, Knüchel R, Heidenreich A, Wieland U, Pfister H.","Med Microbiol Immunol. 2012 May;201(2):245-8. doi: 10.1007/s00430-011-0215-0. Epub 2011 Sep 6.","Akgül B","Med Microbiol Immunol","2012","2011/09/08","","","10.1007/s00430-011-0215-0"
"9179222","Rhenium-186-HEDP palliative treatment in disseminated bone metastases due to prostate cancer","Limouris G, Shukla SK, Manetou A, Kouvaris I, Plataniotis G, Triantafyllou N, Rigas AV, Vlahos L.","Anticancer Res. 1997 May-Jun;17(3B):1699-704.","Limouris G","Anticancer Res","1997","1997/05/01","","",""
"28885333","Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study","Ji G, Song G, Huang C, He S, Zhou L.","Medicine (Baltimore). 2017 Sep;96(36):e7823. doi: 10.1097/MD.0000000000007823.","Ji G","Medicine (Baltimore)","2017","2017/09/09","PMC6392679","","10.1097/MD.0000000000007823"
"31524299","Effective targeting of RNA polymerase I in treatment-resistant prostate cancer","Low JY, Sirajuddin P, Moubarek M, Agarwal S, Rege A, Guner G, Liu H, Yang Z, De Marzo AM, Bieberich C, Laiho M.","Prostate. 2019 Dec;79(16):1837-1851. doi: 10.1002/pros.23909. Epub 2019 Sep 16.","Low JY","Prostate","2019","2019/09/17","PMC7025478","NIHMS1068952","10.1002/pros.23909"
"26793872","[Recent advancements in prostate cancer basic research]","Inoue T, Ogawa O.","Nihon Rinsho. 2016 Jan;74(1):7-12.","Inoue T","Nihon Rinsho","2016","2016/01/23","","",""
"23602404","Reply to Chris R. Cardwell, Samy Suissa and Liam J. Murray's letter to the editor re: Helene Hartvedt Grytli, Morten Wang Fagerland, Sophie D. Fosså, Kristin Austlid Taskén. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.01.007","Grytli HH, Fagerland MW, Fosså SD, Taskén KA.","Eur Urol. 2013 Jul;64(1):e11-2. doi: 10.1016/j.eururo.2013.03.045. Epub 2013 Apr 11.","Grytli HH","Eur Urol","2013","2013/04/23","","","10.1016/j.eururo.2013.03.045"
"21349547","Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937","Calışkan S.","J Urol. 2011 Apr;185(4):1537-8; author reply 1538. doi: 10.1016/j.juro.2010.11.068. Epub 2011 Feb 23.","Calışkan S","J Urol","2011","2011/02/26","","","10.1016/j.juro.2010.11.068"
"2196004","[Transrectal echography and cancer of the prostate. I. Echographic characteristics]","Abad Menor F, Espuela Orgaz R, Martínez Pérez E, Pérez Arbej JA, Nogueras Gimeno MA, Arnaiz Esteban F.","Arch Esp Urol. 1990 Apr;43(3):253-7.","Abad Menor F","Arch Esp Urol","1990","1990/04/01","","",""
"23706252","Developments in external beam radiotherapy for prostate cancer","Lumen N, Ost P, Van Praet C, De Meerleer G, Villeirs G, Fonteyne V.","Urology. 2013 Jul;82(1):5-10. doi: 10.1016/j.urology.2013.03.043. Epub 2013 May 21.","Lumen N","Urology","2013","2013/05/28","","","10.1016/j.urology.2013.03.043"
"23888406","[Value of intermittent androgen deprivation in the context of the current data situation]","Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C, Rulf W, Suttmann H, Wolff JM.","Aktuelle Urol. 2013 Jul;44(4):271-6. doi: 10.1055/s-0033-1348245. Epub 2013 Jul 25.","Miller K","Aktuelle Urol","2013","2013/07/27","","","10.1055/s-0033-1348245"
"17010728","Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer","Semeniuk RC, Venner PM, North S.","Urology. 2006 Sep;68(3):565-9. doi: 10.1016/j.urology.2006.03.055.","Semeniuk RC","Urology","2006","2006/10/03","","","10.1016/j.urology.2006.03.055"
"30887820","Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting","Abdel-Rahman O.","Future Oncol. 2019 Apr;15(11):1269-1277. doi: 10.2217/fon-2018-0539. Epub 2019 Mar 19.","Abdel-Rahman O","Future Oncol","2019","2019/03/20","","","10.2217/fon-2018-0539"
"8618329","Re: Long-term survival and mortality in prostate cancer treated with noncurative intent","Chun TY.","J Urol. 1996 Jun;155(6):2039; author reply 2039-41. doi: 10.1016/s0022-5347(01)66098-1.","Chun TY","J Urol","1996","1996/06/01","","","10.1016/s0022-5347(01)66098-1"
"19419125","Values of prostate specific antigen in patients with operable prostate carcinoma","Obralic N, Kulovac B, Aganovic D, Junuzovic D.","Med Arh. 2009;63(1):34-7.","Obralic N","Med Arh","2009","2009/05/08","","",""
"17656215","Association of prostate size and tumor grade in Korean men with clinically localized prostate cancer","Hong SK, Yu JH, Han BK, Chang IH, Jeong SJ, Byun SS, Lee HJ, Choe G, Lee SE.","Urology. 2007 Jul;70(1):91-5. doi: 10.1016/j.urology.2007.03.006.","Hong SK","Urology","2007","2007/07/28","","","10.1016/j.urology.2007.03.006"
"21730975","Second to fourth digit ratio (2D:4D) and prostate cancer risk in the Melbourne Collaborative Cohort Study","Muller DC, Giles GG, Manning JT, Hopper JL, English DR, Severi G.","Br J Cancer. 2011 Jul 26;105(3):438-40. doi: 10.1038/bjc.2011.253. Epub 2011 Jul 5.","Muller DC","Br J Cancer","2011","2011/07/07","PMC3172910","","10.1038/bjc.2011.253"
"16821336","[Place of contrast imaging in prostate cancer detection]","Cornud F, Rebillard X, Villers A, Peyromaure M, Soulié M, Sous-Comité de Prostate du CCAFU.","Prog Urol. 2006 Jun;16(3):275-80.","Cornud F","Prog Urol","2006","2006/07/11","","",""
"18452171","Recent trends in prostate cancer mortality show a continuous decrease in several countries","Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R, Zanetti R.","Int J Cancer. 2008 Jul 15;123(2):421-429. doi: 10.1002/ijc.23520.","Bouchardy C","Int J Cancer","2008","2008/05/03","","","10.1002/ijc.23520"
"16061372","The finasteride prostate cancer prevention trial (PCPT)--what have we learned?","Mellon JK.","Eur J Cancer. 2005 Sep;41(13):2016-22. doi: 10.1016/j.ejca.2005.06.010.","Mellon JK","Eur J Cancer","2005","2005/08/03","","","10.1016/j.ejca.2005.06.010"
"15368470","Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy","Williams H, Powell IJ, Land SJ, Sakr WA, Hughes MR, Patel NP, Heilbrun LK, Everson RB.","Prostate. 2004 Nov 1;61(3):267-75. doi: 10.1002/pros.20103.","Williams H","Prostate","2004","2004/09/16","","","10.1002/pros.20103"
"1308688","Current trends in the management of localised prostate cancer","Sibley GN, Kabala J.","West Engl Med J. 1992 Dec;107(3):70-2.","Sibley GN","West Engl Med J","1992","1992/12/01","PMC5115008","",""
"15956982","Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo","Wannenes F, Ciafré SA, Niola F, Frajese G, Farace MG.","Cancer Gene Ther. 2005 Dec;12(12):926-34. doi: 10.1038/sj.cgt.7700862.","Wannenes F","Cancer Gene Ther","2005","2005/06/16","","","10.1038/sj.cgt.7700862"
"18286255","[Brachytherapy of the prostate cancer]","Stübinger SH, Wilhelm R, Kaufmann S, Döring M, Hautmann S, Jünemann KP, Galalae R.","Urologe A. 2008 Mar;47(3):284-90. doi: 10.1007/s00120-008-1634-4.","Stübinger SH","Urologe A","2008","2008/02/21","","","10.1007/s00120-008-1634-4"
"9626486","Prostate cancer switch may yield map of cancer machinery, targets for drugs","","Compr Ther. 1998 May;24(5):276-8.","","Compr Ther","1998","1998/06/17","","",""
"31177044","Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group","Lieng H, Kneebone A, Hayden AJ, Christie DRH, Davis BJ, Eade TN, Emmett L, Holt T, Hruby G, Pryor D, Sidhom M, Skala M, Yaxley J, Shakespeare TP.","Radiother Oncol. 2019 Nov;140:68-75. doi: 10.1016/j.radonc.2019.05.016. Epub 2019 Jun 6.","Lieng H","Radiother Oncol","2019","2019/06/10","","","10.1016/j.radonc.2019.05.016"
"22022994","Targeting Sp1 transcription factors in prostate cancer therapy","Sankpal UT, Goodison S, Abdelrahim M, Basha R.","Med Chem. 2011 Sep;7(5):518-25. doi: 10.2174/157340611796799203.","Sankpal UT","Med Chem","2011","2011/10/26","","","10.2174/157340611796799203"
"11493770","The prospect of gene therapy for prostate cancer: update on theory and status","Koeneman KS, Hsieh JT.","Curr Opin Urol. 2001 Sep;11(5):489-94. doi: 10.1097/00042307-200109000-00007.","Koeneman KS","Curr Opin Urol","2001","2001/08/09","","","10.1097/00042307-200109000-00007"
"15160993","Molecular pathogenesis and prevention of prostate cancer","Bounous G, Beer D.","Anticancer Res. 2004 Mar-Apr;24(2B):553-4.","Bounous G","Anticancer Res","2004","2004/05/27","","",""
"17269614","Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification","Ankerst DP, Thompson IM.","Arch Ital Urol Androl. 2006 Dec;78(4):125-9.","Ankerst DP","Arch Ital Urol Androl","2006","2007/02/03","","",""
"27400667","Prostate cancer: Why the prostate arm of the PLCO trial failed and what it has taught us","Cooperberg MR.","Nat Rev Urol. 2016 Aug;13(8):439-40. doi: 10.1038/nrurol.2016.116. Epub 2016 Jul 12.","Cooperberg MR","Nat Rev Urol","2016","2016/07/13","","","10.1038/nrurol.2016.116"
"16132164","Prostate cancer underlying acute, definitive dermatomyositis: successful treatment with radical perineal prostatectomy","Tállai B, Flaskó T, György T, Ponyi A, András C, Tóth C, Dankó K.","Clin Rheumatol. 2006 Feb;25(1):119-20. doi: 10.1007/s10067-005-1130-9. Epub 2005 Aug 13.","Tállai B","Clin Rheumatol","2006","2005/09/01","","","10.1007/s10067-005-1130-9"
"27426128","Targeted Nanosystems to Prostate Cancer","da Silva LC, Carmoa FA, Nasciutti LE, Zancan P, Sathler PC, Cabral LM.","Curr Pharm Des. 2016;22(39):5962-5975. doi: 10.2174/1381612822666160715131359.","da Silva LC","Curr Pharm Des","2016","2016/07/19","","","10.2174/1381612822666160715131359"
"16018833","Advanced prostate cancer: the future","Armstrong AJ, Carducci MA.","Can J Urol. 2005 Jun;12 Suppl 2:42-7.","Armstrong AJ","Can J Urol","2005","2005/07/16","","",""
"31661703","Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy","Froehner M, Koch R, Farahzadi S, Heberling U, Borkowetz A, Twelker L, Baretton GB, Wirth MP, Thomas C.","Urol Int. 2019;103(4):427-432. doi: 10.1159/000500961. Epub 2019 Oct 29.","Froehner M","Urol Int","2019","2019/10/30","","","10.1159/000500961"
"27179268","Influence of gross specimen sampling on the incidence of incidental prostatic carcinoma in cystoprostatectomy specimens of patients with bladder carcinoma","Mlakar J, Volavšek M.","Pol J Pathol. 2016 Mar;67(1):8-12. doi: 10.5114/pjp.2016.59226.","Mlakar J","Pol J Pathol","2016","2016/05/15","","","10.5114/pjp.2016.59226"
"17375971","Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy","Mouraviev V, Mayes JM, Madden JF, Sun L, Polascik TJ.","Technol Cancer Res Treat. 2007 Apr;6(2):91-5. doi: 10.1177/153303460700600205.","Mouraviev V","Technol Cancer Res Treat","2007","2007/03/23","","","10.1177/153303460700600205"
"24980190","Targeting notch in prostate cancer--combination is the key","Marignol L.","Nat Rev Urol. 2014 Jul;11(7):419. doi: 10.1038/nrurol.2013.110-c3. Epub 2014 Jul 1.","Marignol L","Nat Rev Urol","2014","2014/07/02","","","10.1038/nrurol.2013.110-c3"
"10910145","Historical perspective on prostate brachytherapy","Garzotto M, Fair WR.","J Endourol. 2000 May;14(4):315-8. doi: 10.1089/end.2000.14.315.","Garzotto M","J Endourol","2000","2000/07/26","","","10.1089/end.2000.14.315"
"1757281","Testicular metastasis from adenocarcinoma of the prostate","Bashein HJ, Ginsberg P, Zond JR, Finkelstein LH.","J Am Osteopath Assoc. 1991 Sep;91(9):895-7.","Bashein HJ","J Am Osteopath Assoc","1991","1991/09/01","","",""
"22462566","Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel","Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, Frauscher F, Kovacs G, Matin SF, Mischi M, Pinto P, Rastinehad A, Rouviere O, Salomon G, Polascik T, Walz J, Wijkstra H, Marberger M.","BJU Int. 2012 Oct;110(7):942-8. doi: 10.1111/j.1464-410X.2012.11072.x. Epub 2012 Mar 30.","Smeenge M","BJU Int","2012","2012/04/03","","","10.1111/j.1464-410X.2012.11072.x"
"23035756","Combination of real-time elastography and urine prostate cancer gene 3 (PCA3) detects more than 97% of significant prostate cancers","Nygård Y, Haukaas SA, Waage JE, Halvorsen OJ, Gravdal K, Frugård J, Akslen LA, Beisland C.","Scand J Urol. 2013 Jun;47(3):211-6. doi: 10.3109/00365599.2012.727859. Epub 2012 Oct 4.","Nygård Y","Scand J Urol","2013","2012/10/06","","","10.3109/00365599.2012.727859"
"23294147","Editorial comment to standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates","Lee M.","Int J Urol. 2013 Sep;20(9):864-5. doi: 10.1111/iju.12076. Epub 2013 Jan 8.","Lee M","Int J Urol","2013","2013/01/09","","","10.1111/iju.12076"
"18813902","[Adjuvant and neoadjuvant drug therapy for prostate cancer]","Miller K, Lein M, Schostak M, Schrader M.","Urologe A. 2008 Nov;47(11):1460-4. doi: 10.1007/s00120-008-1728-z.","Miller K","Urologe A","2008","2008/09/25","","","10.1007/s00120-008-1728-z"
"21256080","Development and validation of health beliefs model scale for prostate cancer screenings (HBM-PCS): evidence from exploratory and confirmatory factor analyses","Capık C, Gözüm S.","Eur J Oncol Nurs. 2011 Dec;15(5):478-85. doi: 10.1016/j.ejon.2010.12.003. Epub 2011 Jan 20.","Capık C","Eur J Oncol Nurs","2011","2011/01/25","","","10.1016/j.ejon.2010.12.003"
"7512660","Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia","Monda JM, Barry MJ, Oesterling JE.","J Urol. 1994 May;151(5):1291-5. doi: 10.1016/s0022-5347(17)35234-5.","Monda JM","J Urol","1994","1994/05/01","","","10.1016/s0022-5347(17)35234-5"
"7645458","[Complete remission of prostate cancer after LH-RH agonist neoadjuvant therapy: a case report]","Furuse H, Ishikawa A, Masuda H, Ushiyama T, Suzuki K, Fujita K.","Hinyokika Kiyo. 1995 Jun;41(6):485-8.","Furuse H","Hinyokika Kiyo","1995","1995/06/01","","",""
"15221282","[Therapy induced regressive changes of prostate cancer]","Helpap B, Köllermann J.","Pathologe. 2004 Nov;25(6):461-8. doi: 10.1007/s00292-004-0708-3.","Helpap B","Pathologe","2004","2004/06/29","","","10.1007/s00292-004-0708-3"
"19200641","Pharmacological approaches to reducing the risk of prostate cancer","Rittmaster RS, Fleshner NE, Thompson IM.","Eur Urol. 2009 May;55(5):1064-73. doi: 10.1016/j.eururo.2009.01.037. Epub 2009 Feb 5.","Rittmaster RS","Eur Urol","2009","2009/02/10","","","10.1016/j.eururo.2009.01.037"
"10232154","Life after cancer: breast and prostate cancer survivors","O'Rourke ME.","Clin J Oncol Nurs. 1998 Jul;2(3):110-1.","O'Rourke ME","Clin J Oncol Nurs","1998","1999/05/08","","",""
"24713338","[MRI/US-fusion for targeted prostate biopsy]","Schoots IG, Bangma CH.","Ned Tijdschr Geneeskd. 2014;158:A7205.","Schoots IG","Ned Tijdschr Geneeskd","2014","2014/04/10","","",""
"29266527","Assessment of the need for DCE MRI in the detection of dominant lesions in the whole gland: Correlation between histology and MRI of prostate cancer","Kozlowski P, Chang SD, Jones EC, Goldenberg SL.","NMR Biomed. 2018 Mar;31(3). doi: 10.1002/nbm.3882. Epub 2017 Dec 20.","Kozlowski P","NMR Biomed","2018","2017/12/22","","","10.1002/nbm.3882"
"23770138","Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population","Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.","J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.","Karnes RJ","J Urol","2013","2013/06/18","PMC4097302","NIHMS568672","10.1016/j.juro.2013.06.017"
"23628808","Prostate cancer: prostatic swelling and shift upon HIFU","Clyne M.","Nat Rev Urol. 2013 Jun;10(6):306. doi: 10.1038/nrurol.2013.98. Epub 2013 Apr 30.","Clyne M","Nat Rev Urol","2013","2013/05/01","","","10.1038/nrurol.2013.98"
"22511114","[Management of advanced prostate cancer in elderly patients]","Bompas E, Dedecker L.","Bull Cancer. 2012 Jul;99 Suppl 1:S21-9. doi: 10.1684/bdc.2012.1561.","Bompas E","Bull Cancer","2012","2012/04/19","","","10.1684/bdc.2012.1561"
"30695585","[Brachytherapy as monotherapy for prostate cancer with the use of temporary sources]","Solodky VA, Pavlov AY, Panshin GA, Tsybulsky AD, Kravtsov LB, Isaev TK.","Vopr Onkol. 2016;62(5):611-614.","Solodky VA","Vopr Onkol","2016","2019/01/30","","",""
"20104003","[Symptoms of prostate cancer that required treatment in the terminal stage for two years]","Nakamura T, Katou H, Makino T, Okugi H, Okazaki H.","Hinyokika Kiyo. 2010 Jan;56(1):11-5.","Nakamura T","Hinyokika Kiyo","2010","2010/01/28","","",""
"23364535","Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer","Huang HF, Shu P, Murphy TF, Aisner S, Fitzhugh VA, Jordan ML.","Mol Cancer Res. 2013 Apr;11(4):427-39. doi: 10.1158/1541-7786.MCR-12-0464. Epub 2013 Jan 30.","Huang HF","Mol Cancer Res","2013","2013/02/01","","","10.1158/1541-7786.MCR-12-0464"
"17647201","Pathological factors evaluating prostate cancer","Yu YP, Luo JH.","Histol Histopathol. 2007 Nov;22(11):1291-300. doi: 10.14670/HH-22.1291.","Yu YP","Histol Histopathol","2007","2007/07/25","","","10.14670/HH-22.1291"
"11752854","Active monitoring (deferred treatment or watchful waiting) in the treatment of prostate cancer. A review","Schmid HP, Adolfsson J, Aus G.","Eur Urol. 2001 Nov;40(5):488-94. doi: 10.1159/000049824.","Schmid HP","Eur Urol","2001","2001/12/26","","","10.1159/000049824"
"20564423","Phenoxodiol inhibits growth of metastatic prostate cancer cells","Aguero MF, Venero M, Brown DM, Smulson ME, Espinoza LA.","Prostate. 2010 Aug;70(11):1211-21. doi: 10.1002/pros.21156.","Aguero MF","Prostate","2010","2010/06/22","","","10.1002/pros.21156"
"20501756","Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001","Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN.","Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1460-7. doi: 10.1158/1055-9965.EPI-09-1310. Epub 2010 May 25.","Altekruse SF","Cancer Epidemiol Biomarkers Prev","2010","2010/05/27","PMC2883026","NIHMS191438","10.1158/1055-9965.EPI-09-1310"
"18717207","Black men are dying from prostate cancer","Toles CA.","ABNF J. 2008 Summer;19(3):92-5.","Toles CA","ABNF J","2008","2008/08/23","","",""
"21078539","Glucocorticoid receptor signaling and prostate cancer","Kassi E, Moutsatsou P.","Cancer Lett. 2011 Mar 1;302(1):1-10. doi: 10.1016/j.canlet.2010.10.020.","Kassi E","Cancer Lett","2011","2010/11/17","","","10.1016/j.canlet.2010.10.020"
"21664423","Interleukin-6: a multifunctional targetable cytokine in human prostate cancer","Culig Z, Puhr M.","Mol Cell Endocrinol. 2012 Sep 5;360(1-2):52-8. doi: 10.1016/j.mce.2011.05.033. Epub 2011 Jun 1.","Culig Z","Mol Cell Endocrinol","2012","2011/06/14","PMC3409376","","10.1016/j.mce.2011.05.033"
"16425989","Antiangiogenesis: a possible treatment option for prostate cancer?","Longoria RL, Cox MC, Figg WD.","Clin Genitourin Cancer. 2005 Dec;4(3):197-202. doi: 10.3816/CGC.2005.n.033.","Longoria RL","Clin Genitourin Cancer","2005","2006/01/24","","","10.3816/CGC.2005.n.033"
"7505973","PSA density (PSAD). Role in patient evaluation and management","Seaman E, Whang M, Olsson CA, Katz A, Cooner WH, Benson MC.","Urol Clin North Am. 1993 Nov;20(4):653-63.","Seaman E","Urol Clin North Am","1993","1993/11/01","","",""
"23465143","Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance","Ha YS, Salmasi A, Karellas M, Singer EA, Kim JH, Han M, Partin AW, Kim WJ, Lee DH, Kim IY.","Urology. 2013 Apr;81(4):831-5. doi: 10.1016/j.urology.2012.12.046. Epub 2013 Mar 7.","Ha YS","Urology","2013","2013/03/08","PMC3978180","NIHMS563148","10.1016/j.urology.2012.12.046"
"24641912","Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening","Vertosick EA, Poon BY, Vickers AJ.","J Urol. 2014 Sep;192(3):724-8. doi: 10.1016/j.juro.2014.03.032. Epub 2014 Mar 15.","Vertosick EA","J Urol","2014","2014/03/20","PMC4143426","NIHMS597951","10.1016/j.juro.2014.03.032"
"15184867","Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome","Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS.","Oncogene. 2004 Aug 5;23(35):5871-9. doi: 10.1038/sj.onc.1207800.","Foster CS","Oncogene","2004","2004/06/09","","","10.1038/sj.onc.1207800"
"29426695","Only <10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)","Froehner M, Koch R, Hübler M, Renner T, Borkowetz A, Zastrow S, Wirth MP.","Eur Urol Focus. 2019 May;5(3):361-364. doi: 10.1016/j.euf.2018.01.019. Epub 2018 Feb 6.","Froehner M","Eur Urol Focus","2019","2018/02/11","","","10.1016/j.euf.2018.01.019"
"9681532","Associations of demographic and health-related characteristics with prostate cancer screening in Washington State","Close DR, Kristal AR, Li S, Patterson RE, White E.","Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):627-30.","Close DR","Cancer Epidemiol Biomarkers Prev","1998","1998/07/29","","",""
"27165033","[Diagnosis, prognosis and treatment of low-risk prostate cancer - Expert panel from the 2015 BPS Annual Meeting]","Dietz J.","Urologe A. 2016 Jun;55(6):823-4. doi: 10.1007/s00120-016-0110-9.","Dietz J","Urologe A","2016","2016/05/12","","","10.1007/s00120-016-0110-9"
"21062649","Prostate cancer screening perspective, Malaysia","Sothilingam S, Sundram M, Malek R, Sahabuddin RM.","Urol Oncol. 2010 Nov-Dec;28(6):670-2. doi: 10.1016/j.urolonc.2009.12.014.","Sothilingam S","Urol Oncol","2010","2010/11/11","","","10.1016/j.urolonc.2009.12.014"
"17239317","Therapeutic options in advanced prostate cancer: present and future","Sowery RD, So AI, Gleave ME.","Curr Urol Rep. 2007 Jan;8(1):53-9. doi: 10.1007/s11934-007-0021-9.","Sowery RD","Curr Urol Rep","2007","2007/01/24","","","10.1007/s11934-007-0021-9"
"20141674","The 2010 NCCN clinical practice guidelines in oncology on prostate cancer","Mohler JL.","J Natl Compr Canc Netw. 2010 Feb;8(2):145. doi: 10.6004/jnccn.2010.0010.","Mohler JL","J Natl Compr Canc Netw","2010","2010/02/10","","","10.6004/jnccn.2010.0010"
"6150912","Prostate cancer in Illinois","Guinan PD, Wiggishoff CC, Rotkin ID, Chmiel JS, Sylvester J, Cunningham MP.","IMJ Ill Med J. 1984 Nov;166(5):341-5.","Guinan PD","IMJ Ill Med J","1984","1984/11/01","","",""
"6801722","[Methods of topometric radiotherapy planning in prostate cancer]","Merkle K, Balter SA, Gabunija RI, Tkachev SI.","Radiobiol Radiother (Berl). 1981;22(6):771-8.","Merkle K","Radiobiol Radiother (Berl)","1981","1981/01/01","","",""
"10808195","The role of prostate specific antigen measurement in the detection and management of prostate cancer","Nash AF, Melezinek I.","Endocr Relat Cancer. 2000 Mar;7(1):37-51. doi: 10.1677/erc.0.0070037.","Nash AF","Endocr Relat Cancer","2000","2000/05/16","","","10.1677/erc.0.0070037"
"7679045","Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer","Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP.","Cancer. 1993 Feb 1;71(3 Suppl):933-8. doi: 10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l.","Stamey TA","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l"
"22579070","Insensitivity to the growth inhibitory effects of activin A: an acquired capability in prostate cancer progression","Ottley E, Gold E.","Cytokine Growth Factor Rev. 2012 Jun;23(3):119-25. doi: 10.1016/j.cytogfr.2012.04.004. Epub 2012 May 10.","Ottley E","Cytokine Growth Factor Rev","2012","2012/05/15","","","10.1016/j.cytogfr.2012.04.004"
"10378644","The Royal College of Radiologists' Clinical Oncology Information Network. British Association of Urological Surgeons. Guidelines on the management of prostate cancer","","Clin Oncol (R Coll Radiol). 1999;11(2):S53-88.","","Clin Oncol (R Coll Radiol)","1999","1999/06/23","","",""
"23714643","Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer","Edwards A, Laing R, Langley S.","BJU Int. 2013 Jun;111(8):1181-2. doi: 10.1111/j.1464-410X.2012.11769.x.","Edwards A","BJU Int","2013","2013/05/30","","","10.1111/j.1464-410X.2012.11769.x"
"20648853","Controversies in prostate cancer screening and treatment","Gaines KK.","Urol Nurs. 2010 May-Jun;30(3):165-6.","Gaines KK","Urol Nurs","2010","2010/07/23","","",""
"24589207","Health behaviour models and patient preferences regarding nutrition and physical activity after breast or prostate cancer diagnosis","Green HJ, Steinnagel G, Morris C, Laakso EL.","Eur J Cancer Care (Engl). 2014 Sep;23(5):640-52. doi: 10.1111/ecc.12190. Epub 2014 Mar 3.","Green HJ","Eur J Cancer Care (Engl)","2014","2014/03/05","","","10.1111/ecc.12190"
"16939047","Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer","Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, Allen ZA, Adamovich E.","Urol Nurs. 2006 Aug;26(4):298-303.","Moyad MA","Urol Nurs","2006","2006/08/31","","",""
"24824511","Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis","Daskivich TJ, Lai J, Dick AW, Setodji CM, Hanley JM, Litwin MS, Saigal C; Urologic Diseases in America Project.","Cancer. 2014 Aug 15;120(16):2432-9. doi: 10.1002/cncr.28757. Epub 2014 May 13.","Daskivich TJ","Cancer","2014","2014/05/15","","","10.1002/cncr.28757"
"16708371","Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy","Huang SP, Huang CY, Wu WJ, Pu YS, Chen J, Chen YY, Yu CC, Wu TT, Wang JS, Lee YH, Huang JK, Huang CH, Wu MT.","Int J Cancer. 2006 Oct 15;119(8):1902-7. doi: 10.1002/ijc.22053.","Huang SP","Int J Cancer","2006","2006/05/19","","","10.1002/ijc.22053"
"25734964","Managing advanced prostate cancer: the rapidly changing treatment landscape","Dreicer R.","Am J Manag Care. 2014 Dec;20(12 Suppl):S282-9.","Dreicer R","Am J Manag Care","2014","2015/03/04","","",""
"7687922","Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate","Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J.","Cancer. 1993 Aug 15;72(4):1291-9. doi: 10.1002/1097-0142(19930815)72:4<1291::aid-cncr2820720423>3.0.co;2-i.","Onik GM","Cancer","1993","1993/08/15","","","10.1002/1097-0142(19930815)72:4<1291::aid-cncr2820720423>3.0.co;2-i"
"23724747","Advances in the treatment of metastatic prostate cancer","Chowdhury S, Kirby R.","Practitioner. 2013 Apr;257(1760):15-8, 2.","Chowdhury S","Practitioner","2013","2013/06/04","","",""
"25690791","Prostate cancer vaccines: the long road to clinical application","Baxevanis CN, Papamichail M, Perez SA.","Cancer Immunol Immunother. 2015 Apr;64(4):401-8. doi: 10.1007/s00262-015-1667-7. Epub 2015 Feb 19.","Baxevanis CN","Cancer Immunol Immunother","2015","2015/02/19","","","10.1007/s00262-015-1667-7"
"9088266","Prostate cancer: where are we and where are we going?","Denmeade SR, Isaacs JT.","Br J Urol. 1997 Mar;79 Suppl 1:2-7. doi: 10.1111/j.1464-410x.1997.tb00794.x.","Denmeade SR","Br J Urol","1997","1997/03/01","","","10.1111/j.1464-410x.1997.tb00794.x"
"21789784","Mycoplasmas and human prostate cancer: an exciting but cautionary note","Lo SC, Tsai S.","Oncotarget. 2011 May;2(5):352-5. doi: 10.18632/oncotarget.282.","Lo SC","Oncotarget","2011","2011/07/27","PMC3248186","","10.18632/oncotarget.282"
"9751359","Radical prostatectomy for prostate cancer: the perineal approach increases the risk of surgically induced positive margins and capsular incisions","Boccon-Gibod L, Ravery V, Vordos D, Toublanc M, Delmas V, Boccon-Gibod L.","J Urol. 1998 Oct;160(4):1383-5. doi: 10.1016/s0022-5347(01)62543-6.","Boccon-Gibod L","J Urol","1998","1998/09/29","","","10.1016/s0022-5347(01)62543-6"
"1374175","Prostate specific antigen in diagnosis, staging, and follow-up of prostate cancer","Cooper EH.","Prostate Suppl. 1992;4:125-8. doi: 10.1002/pros.2990210520.","Cooper EH","Prostate Suppl","1992","1992/01/01","","","10.1002/pros.2990210520"
"17095076","Practice patterns in screening and management of prostate cancer in elderly men","Konety BR, Sharp VJ, Verma M, Williams RD; Iowa Prostate Cancer Consensus Panel.","Urology. 2006 Nov;68(5):1051-6. doi: 10.1016/j.urology.2006.06.011. Epub 2006 Nov 7.","Konety BR","Urology","2006","2006/11/11","","","10.1016/j.urology.2006.06.011"
"8036179","Socioeconomic status, urbanization grade, and prostate cancer","van der Gulden JW, Kolk JJ, Verbeek AL.","Prostate. 1994 Aug;25(2):59-65. doi: 10.1002/pros.2990250202.","van der Gulden JW","Prostate","1994","1994/08/01","","","10.1002/pros.2990250202"
"10218515","Re: Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study","Mills PK.","J Natl Cancer Inst. 1999 Apr 21;91(8):725-6. doi: 10.1093/jnci/91.8.725.","Mills PK","J Natl Cancer Inst","1999","1999/04/28","","","10.1093/jnci/91.8.725"
"21278759","Androgen deprivation therapy for prostate cancer: not so simple","Tadros NN, Garzotto M.","Asian J Androl. 2011 Mar;13(2):187-8. doi: 10.1038/aja.2010.174. Epub 2011 Jan 31.","Tadros NN","Asian J Androl","2011","2011/02/01","PMC3739209","","10.1038/aja.2010.174"
"9258113","Re: Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease","Gardiner RA, Samaratunga ML, Rohde P, Clements JA, Hyland V, Lavin MF.","J Urol. 1997 Sep;158(3 Pt 1):889. doi: 10.1097/00005392-199709000-00066.","Gardiner RA","J Urol","1997","1997/09/01","","","10.1097/00005392-199709000-00066"
"8371423","A decision analysis of alternative treatment strategies for clinically localized prostate cancer","Walsh PC.","J Urol. 1993 Oct;150(4):1330-2.","Walsh PC","J Urol","1993","1993/10/01","","",""
"17082219","A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months","Akakura K, Suzuki H, Ichikawa T, Fujimoto H, Maeda O, Usami M, Hirano D, Takimoto Y, Kamoto T, Ogawa O, Sumiyoshi Y, Shimazaki J, Kakizoe T; Japanese Study Group for Locally Advanced Prostate Cancer.","Jpn J Clin Oncol. 2006 Dec;36(12):789-93. doi: 10.1093/jjco/hyl115. Epub 2006 Nov 2.","Akakura K","Jpn J Clin Oncol","2006","2006/11/04","","","10.1093/jjco/hyl115"
"21265982","The tumour-node-metastasis staging of prostate cancer in transurethral resection of the prostate chips requires revision","Berney DM.","BJU Int. 2011 Feb;107(3):351-2. doi: 10.1111/j.1464-410X.2010.09950.x.","Berney DM","BJU Int","2011","2011/01/27","","","10.1111/j.1464-410X.2010.09950.x"
"19615834","Prostate cancer and urinary incontinence","Parsons BA, Evans S, Wright MP.","Maturitas. 2009 Aug 20;63(4):323-8. doi: 10.1016/j.maturitas.2009.06.005. Epub 2009 Jul 16.","Parsons BA","Maturitas","2009","2009/07/21","","","10.1016/j.maturitas.2009.06.005"
"15453805","Serum interleukin-8 is elevated in men with prostate cancer and bone metastases","Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG.","Technol Cancer Res Treat. 2004 Oct;3(5):411. doi: 10.1177/153303460400300501.","Lehrer S","Technol Cancer Res Treat","2004","2004/09/30","","","10.1177/153303460400300501"
"15869721","What's new in the field of prostate cancer chemoprevention?","Mahal K, Hernandez J, Basler JW, Thompson IM.","Curr Urol Rep. 2005 May;6(3):177-82. doi: 10.1007/s11934-005-0005-6.","Mahal K","Curr Urol Rep","2005","2005/05/05","","","10.1007/s11934-005-0005-6"
"15066236","What's new in the field of prostate cancer chemoprevention?","Mahal K, Hernandez J, Basler JW, Thompson IM.","Curr Oncol Rep. 2004 May;6(3):237-42. doi: 10.1007/s11912-004-0055-9.","Mahal K","Curr Oncol Rep","2004","2004/04/07","","","10.1007/s11912-004-0055-9"
"26969245","[Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?]","Bellefqih S, Hadadi K, Mezouri I, Maghous A, Marnouche E, Andaloussi K, Elmarjany M, Sifat H, Mansouri H, Benjaafar N.","Cancer Radiother. 2016 Apr;20(2):141-50. doi: 10.1016/j.canrad.2015.12.002. Epub 2016 Mar 8.","Bellefqih S","Cancer Radiother","2016","2016/03/13","","","10.1016/j.canrad.2015.12.002"
"24559864","Underestimated role of MRI in EAU guidelines on prostate cancer","Scialpi M, Piscioli I, D'Andrea A.","Magn Reson Imaging. 2014 May;32(4):402-3. doi: 10.1016/j.mri.2014.01.002. Epub 2014 Jan 10.","Scialpi M","Magn Reson Imaging","2014","2014/02/25","","","10.1016/j.mri.2014.01.002"
"9870033","What causes prostate cancer? A brief summary of the epidemiology","Chan JM, Stampfer MJ, Giovannucci EL.","Semin Cancer Biol. 1998 Aug;8(4):263-73. doi: 10.1006/scbi.1998.0075.","Chan JM","Semin Cancer Biol","1998","1998/12/31","","","10.1006/scbi.1998.0075"
"9894256","[Clinical stage T3 prostate cancer: natural history, therapeutic choices and their results]","Peneau M, Piéchaud T, Cariou G, Ragni E, Fontaine E, Fournier G.","Prog Urol. 1998 Dec;8(6):977-93.","Peneau M","Prog Urol","1998","1999/01/23","","",""
"22269996","Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer","Nishiyama T.","J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):179-90. doi: 10.1016/j.jsbmb.2011.12.019. Epub 2012 Jan 17.","Nishiyama T","J Steroid Biochem Mol Biol","2012","2012/01/25","","","10.1016/j.jsbmb.2011.12.019"
"28283376","Navigating the evolving therapeutic landscape in advanced prostate cancer","Crawford ED, Petrylak D, Sartor O.","Urol Oncol. 2017 May;35S:S1-S13. doi: 10.1016/j.urolonc.2017.01.020. Epub 2017 Mar 7.","Crawford ED","Urol Oncol","2017","2017/03/12","","","10.1016/j.urolonc.2017.01.020"
"12673967","[Controversial guidelines in early diagnosis of prostate cancer]","Casal ER, Majdalani MP.","Medicina (B Aires). 2003;63(1):77-81.","Casal ER","Medicina (B Aires)","2003","2003/04/04","","",""
"9779009","Prostate cancer","Henkel J.","FDA Consum. 1998 Sep-Oct;32(5):22-7.","Henkel J","FDA Consum","1998","1998/10/21","","",""
"24283992","Time from diagnosis to surgery and prostate cancer survival: a retrospective cohort study","Redaniel MT, Martin RM, Gillatt D, Wade J, Jeffreys M.","BMC Cancer. 2013 Nov 27;13:559. doi: 10.1186/1471-2407-13-559.","Redaniel MT","BMC Cancer","2013","2013/11/29","PMC4219457","","10.1186/1471-2407-13-559"
"10768221","[Value of radiotherapy in urology]","Boehmer D, Buchali A, Deger S, Loening SA, Budach V.","Urologe A. 2000 Mar;39(2):120-5. doi: 10.1007/s001200050019.","Boehmer D","Urologe A","2000","2000/04/18","","","10.1007/s001200050019"
"27618148","Effects of Serum Triglycerides on Prostate Cancer and Breast Cancer Risk: A Meta-Analysis of Prospective Studies","Ma HQ, Cui LH, Li CC, Yu Z, Piao JM.","Nutr Cancer. 2016 Oct;68(7):1073-82. doi: 10.1080/01635581.2016.1206582. Epub 2016 Aug 11.","Ma HQ","Nutr Cancer","2016","2016/09/13","","","10.1080/01635581.2016.1206582"
"19579052","Cigarette smoking and risk of prostate cancer among Singapore Chinese","Butler LM, Wang R, Wong AS, Koh WP, Yu MC.","Cancer Causes Control. 2009 Dec;20(10):1967-74. doi: 10.1007/s10552-009-9391-2.","Butler LM","Cancer Causes Control","2009","2009/07/07","","","10.1007/s10552-009-9391-2"
"16618387","The role of bisphosphonates in the management of prostate cancer","Saad F.","Curr Oncol Rep. 2006 May;8(3):221-7. doi: 10.1007/s11912-006-0023-7.","Saad F","Curr Oncol Rep","2006","2006/04/19","","","10.1007/s11912-006-0023-7"
"21945719","Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden","Van Hemelrijck M, Garmo H, Holmberg L, Stattin P, Adolfsson J.","Eur Urol. 2012 Apr;61(4):690-700. doi: 10.1016/j.eururo.2011.09.010. Epub 2011 Sep 17.","Van Hemelrijck M","Eur Urol","2012","2011/09/28","","","10.1016/j.eururo.2011.09.010"
"15017214","Oxidative DNA damage in patients with prostate cancer and its response to treatment","Miyake H, Hara I, Kamidono S, Eto H.","J Urol. 2004 Apr;171(4):1533-6. doi: 10.1097/01.ju.0000116617.32728.ca.","Miyake H","J Urol","2004","2004/03/17","","","10.1097/01.ju.0000116617.32728.ca"
"21552284","Prostate cancer: an emerging threat to the health of aging men in Asia","Zhang L, Yang BX, Zhang HT, Wang JG, Wang HL, Zhao XJ.","Asian J Androl. 2011 Jul;13(4):574-8. doi: 10.1038/aja.2010.126. Epub 2011 May 9.","Zhang L","Asian J Androl","2011","2011/05/10","PMC3739604","","10.1038/aja.2010.126"
"11304906","Nutrition and prostate cancer: a proposal for dietary intervention","Wynder EL, Rose DP, Cohen LA.","Nutr Cancer. 1994;22(1):1-10. doi: 10.1080/01635589409514327.","Wynder EL","Nutr Cancer","1994","1994/01/01","","","10.1080/01635589409514327"
"27121323","Gene expression in normal-appearing tissue adjacent to prostate cancers are predictive of clinical outcome: evidence for a biologically meaningful field effect","Magi-Galluzzi C, Maddala T, Falzarano SM, Cherbavaz DB, Zhang N, Knezevic D, Febbo PG, Lee M, Lawrence HJ, Klein EA.","Oncotarget. 2016 Jun 7;7(23):33855-65. doi: 10.18632/oncotarget.8944.","Magi-Galluzzi C","Oncotarget","2016","2016/04/29","PMC5085124","","10.18632/oncotarget.8944"
"11597542","Possible use of transrectal power Doppler imaging as an indicator of microvascular density of prostate cancer","Nakanouchi T, Okihara K, Kojima M, Ukimura O, Yokoyama K, Takamatsu T, Miki T.","Urology. 2001 Oct;58(4):573-7. doi: 10.1016/s0090-4295(01)01263-8.","Nakanouchi T","Urology","2001","2001/10/13","","","10.1016/s0090-4295(01)01263-8"
"25189687","Effect of targeted biopsy guided by elastic image fusion of MRI with 3D-TRUS on diagnosis of anterior prostate cancer","Baco E, Rud E, Ukimura O, Vlatkovic L, Svindland A, Matsugasumi T, Bernhard JC, Rewcastle JC, Eggesbø HB.","Urol Oncol. 2014 Nov;32(8):1300-7. doi: 10.1016/j.urolonc.2014.07.014. Epub 2014 Sep 2.","Baco E","Urol Oncol","2014","2014/09/06","","","10.1016/j.urolonc.2014.07.014"
"11113727","Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer","Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG.","Urology. 2000 Dec 20;56(6):899-905. doi: 10.1016/s0090-4295(00)00858-x.","Wei JT","Urology","2000","2000/01/11","","","10.1016/s0090-4295(00)00858-x"
"25726356","Reprint of: The prostate cancer genome: Perspectives and potential","Barbieri CE, Tomlins SA.","Urol Oncol. 2015 Feb;33(2):95-102. doi: 10.1016/j.urolonc.2015.01.002.","Barbieri CE","Urol Oncol","2015","2015/03/02","","","10.1016/j.urolonc.2015.01.002"
"15217433","Information needs and prostate cancer: the development of a systematic means of identification","Dale J, Jatsch W, Hughes N, Pearce A, Meystre C.","BJU Int. 2004 Jul;94(1):63-9. doi: 10.1111/j.1464-410X.2004.04902.x.","Dale J","BJU Int","2004","2004/06/26","","","10.1111/j.1464-410X.2004.04902.x"
"10840430","Ability of the 1992 and 1997 American Joint Committee on Cancer staging systems for prostate cancer to predict progression-free survival after radical prostatectomy for stage T2 disease","Han M, Walsh PC, Partin AW, Rodriguez R.","J Urol. 2000 Jul;164(1):89-92.","Han M","J Urol","2000","2000/06/07","","",""
"26782712","Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study","Moreira DM, Nickel JC, Andriole GL, Castro-Santamaria R, Freedland SJ.","Prostate Cancer Prostatic Dis. 2016 Jun;19(2):180-4. doi: 10.1038/pcan.2015.66. Epub 2016 Jan 19.","Moreira DM","Prostate Cancer Prostatic Dis","2016","2016/01/20","","","10.1038/pcan.2015.66"
"12231043","Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer","D'Amico AV.","Urology. 2002 Sep;60(3 Suppl 1):32-7; discussion 37-8. doi: 10.1016/s0090-4295(02)01566-2.","D'Amico AV","Urology","2002","2002/09/17","","","10.1016/s0090-4295(02)01566-2"
"22640746","Editorial comment to comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis","Costantini E, Mearini L.","Int J Urol. 2012 Sep;19(9):844-5. doi: 10.1111/j.1442-2042.2012.03061.x. Epub 2012 May 28.","Costantini E","Int J Urol","2012","2012/05/30","","","10.1111/j.1442-2042.2012.03061.x"
"29665325","A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases","Ong CW, Maxwell P, Alvi MA, McQuaid S, Waugh D, Mills I, Salto-Tellez M.","J Pathol Clin Res. 2018 Apr;4(2):103-113. doi: 10.1002/cjp2.94. Epub 2018 Feb 28.","Ong CW","J Pathol Clin Res","2018","2018/04/18","PMC5903700","","10.1002/cjp2.94"
"21208852","Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer","Sartor O, Halstead M, Katz L.","Clin Genitourin Cancer. 2010 Dec 1;8(1):23-8. doi: 10.3816/CGC.2010.n.004.","Sartor O","Clin Genitourin Cancer","2010","2011/01/07","","","10.3816/CGC.2010.n.004"
"7069093","Improving survival in patients with prostate cancer regionally spread at the time of diagnosis","Holmes FF, Liu KJ.","J Am Geriatr Soc. 1982 Apr;30(4):248-50. doi: 10.1111/j.1532-5415.1982.tb07095.x.","Holmes FF","J Am Geriatr Soc","1982","1982/04/01","","","10.1111/j.1532-5415.1982.tb07095.x"
"29900883","Lineage plasticity-mediated therapy resistance in prostate cancer","Blee AM, Huang H.","Asian J Androl. 2019 May-Jun;21(3):241-248. doi: 10.4103/aja.aja_41_18.","Blee AM","Asian J Androl","2019","2018/06/15","PMC6498731","","10.4103/aja.aja_41_18"
"17253194","Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma","Babiker AA, Ekdahl KN, Nilsson B, Ronquist G.","Semin Thromb Hemost. 2007 Feb;33(1):80-6. doi: 10.1055/s-2006-958466.","Babiker AA","Semin Thromb Hemost","2007","2007/01/27","","","10.1055/s-2006-958466"
"25015764","Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer","Wang L, Lin YL, Li B, Wang YZ, Li WP, Ma JG.","J Int Med Res. 2014 Oct;42(5):1085-92. doi: 10.1177/0300060514540631. Epub 2014 Jul 11.","Wang L","J Int Med Res","2014","2014/07/13","","","10.1177/0300060514540631"
"25770150","Although the evidence is not clear, decreases in prostate cancer mortality in specific subgroups of men may be due to screening","Ilic D, Dahm P.","Evid Based Med. 2015 Jun;20(3):102. doi: 10.1136/ebmed-2015-110166. Epub 2015 Mar 13.","Ilic D","Evid Based Med","2015","2015/03/15","","","10.1136/ebmed-2015-110166"
"1813640","Prostate cancer: the stage disadvantage in the black male","Targonski PV, Guinan P, Phillips CW.","J Natl Med Assoc. 1991 Dec;83(12):1094-6.","Targonski PV","J Natl Med Assoc","1991","1991/12/01","PMC2571685","",""
"15477327","Prostate cancer management","Horwich A.","Ann Oncol. 2004;15 Suppl 4:iv307-12. doi: 10.1093/annonc/mdh944.","Horwich A","Ann Oncol","2004","2004/10/13","","","10.1093/annonc/mdh944"
"28389514","Histopathology of Prostate Cancer","Humphrey PA.","Cold Spring Harb Perspect Med. 2017 Oct 3;7(10):a030411. doi: 10.1101/cshperspect.a030411.","Humphrey PA","Cold Spring Harb Perspect Med","2017","2017/04/09","PMC5629988","","10.1101/cshperspect.a030411"
"12750247","Plasma leptin is not associated with prostate cancer risk","Stattin P, Kaaks R, Johansson R, Gislefoss R, Söderberg S, Alfthan H, Stenman UH, Jellum E, Olsson T.","Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):474-5.","Stattin P","Cancer Epidemiol Biomarkers Prev","2003","2003/05/17","","",""
"7693984","Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer","Roach M 3rd.","J Urol. 1993 Dec;150(6):1923-4. doi: 10.1016/s0022-5347(17)35937-2.","Roach M 3rd","J Urol","1993","1993/12/01","","","10.1016/s0022-5347(17)35937-2"
"9733417","Recruiting black men to a clinical trial to evaluate prostate cancer screening--Detroit, Michigan, 1998","Centers for Disease Control and Prevention (CDC).","MMWR Morb Mortal Wkly Rep. 1998 Aug 28;47(33):694-6.","Centers for Disease Control and Prevention (CDC)","MMWR Morb Mortal Wkly Rep","1998","1998/09/11","","",""
"29891440","Three-year interim results of overall and progression-free survival in a cohort of patients with prostate cancer (GESCAP group)","Cózar JM, Miñana B, Gómez-Veiga F, Rodríguez-Antolín A; Grupo Gescap.","Actas Urol Esp. 2019 Jan-Feb;43(1):4-11. doi: 10.1016/j.acuro.2018.03.004. Epub 2018 Jun 8.","Cózar JM","Actas Urol Esp","2019","2018/06/13","","","10.1016/j.acuro.2018.03.004"
"26503326","Love, faith and hope - a secondary analysis of prostate cancer survivors and their partners","O'Shaughnessy PK, Laws TA, Esterman AJ.","Contemp Nurse. 2015;50(2-3):149-68. doi: 10.1080/10376178.2015.1101352. Epub 2015 Oct 27.","O'Shaughnessy PK","Contemp Nurse","2015","2015/10/28","","","10.1080/10376178.2015.1101352"
"10754526","Efficient DNA-mediated gene transfer into prostate cancer cell line LNCaP","Frønsdal K, Engedal N, Saatcioglu F.","Prostate. 2000 May 1;43(2):111-7. doi: 10.1002/(sici)1097-0045(20000501)43:2<111::aid-pros5>3.0.co;2-4.","Frønsdal K","Prostate","2000","2001/02/07","","","10.1002/(sici)1097-0045(20000501)43:2<111::aid-pros5>3.0.co;2-4"
"7538601","Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome","Dawson NA, McLeod DG.","J Urol. 1995 Jun;153(6):1946-7.","Dawson NA","J Urol","1995","1995/06/01","","",""
"28322260","Prostate cancer: New model to test immunotherapy combinations","Thoma C.","Nat Rev Urol. 2017 Jun;14(6):323. doi: 10.1038/nrurol.2017.44. Epub 2017 Mar 21.","Thoma C","Nat Rev Urol","2017","2017/03/22","","","10.1038/nrurol.2017.44"
"22528629","The influence of distress on knowledge transfer for men newly diagnosed with prostate cancer","Hovey RB, Cuthbertson KE, Birnie KA, Robinson JW, Thomas BC, Massfeller HF, Ruether JD, Scott C.","J Cancer Educ. 2012 Jun;27(3):540-5. doi: 10.1007/s13187-012-0343-2.","Hovey RB","J Cancer Educ","2012","2012/04/25","","","10.1007/s13187-012-0343-2"
"28404898","NUSAP1 promotes invasion and metastasis of prostate cancer","Gordon CA, Gong X, Ganesh D, Brooks JD.","Oncotarget. 2017 May 2;8(18):29935-29950. doi: 10.18632/oncotarget.15604.","Gordon CA","Oncotarget","2017","2017/04/14","PMC5444715","","10.18632/oncotarget.15604"
"19594290","Rural residence and prostate cancer screening with prostate-specific antigen","Stamatiou K, Skolarikos A.","Rural Remote Health. 2009 Apr-Jun;9(2):1227. Epub 2009 Jun 18.","Stamatiou K","Rural Remote Health","2009","2009/07/15","","",""
"23739794","Prostate histopathology: learning tissue component histograms for cancer detection and classification","Gorelick L, Veksler O, Gaed M, Gomez JA, Moussa M, Bauman G, Fenster A, Ward AD.","IEEE Trans Med Imaging. 2013 Oct;32(10):1804-18. doi: 10.1109/TMI.2013.2265334. Epub 2013 May 31.","Gorelick L","IEEE Trans Med Imaging","2013","2013/06/07","","","10.1109/TMI.2013.2265334"
"16426731","Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report","Rocco B, de Cobelli O, Leon ME, Ferruti M, Mastropasqua MG, Matei DV, Gazzano G, Verweij F, Scardino E, Musi G, Djavan B, Rocco F.","Eur Urol. 2006 May;49(5):827-33. doi: 10.1016/j.eururo.2005.12.021. Epub 2006 Jan 6.","Rocco B","Eur Urol","2006","2006/01/24","","","10.1016/j.eururo.2005.12.021"
"9507888","Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer","Figueroa JA, De Raad S, Tadlock L, Speights VO, Rinehart JJ.","J Urol. 1998 Apr;159(4):1379-83.","Figueroa JA","J Urol","1998","1998/03/21","","",""
"7630245","Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group","","Lancet. 1995 Jul 29;346(8970):265-9.","","Lancet","1995","1995/07/29","","",""
"31099647","All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care","Borno H, George DJ, Schnipper LE, Cavalli F, Cerny T, Gillessen S.","Am Soc Clin Oncol Educ Book. 2019 Jan;39:302-308. doi: 10.1200/EDBK_238879. Epub 2019 May 17.","Borno H","Am Soc Clin Oncol Educ Book","2019","2019/05/18","","","10.1200/EDBK_238879"
"30529932","An immunohistochemical study of T and B lymphocyte density in prostatic hyperplasia and prostate carcinoma in dogs","Palmieri C, Hood G, Fonseca-Alves CE, Laufer-Amorim R, Allavena R.","Res Vet Sci. 2019 Feb;122:189-192. doi: 10.1016/j.rvsc.2018.11.022. Epub 2018 Nov 27.","Palmieri C","Res Vet Sci","2019","2018/12/12","","","10.1016/j.rvsc.2018.11.022"
"18890627","Stilboestrol and prostatic carcinoma","GAUDIN H.","N Z Med J. 1948 Aug;47(260):372.","GAUDIN H","N Z Med J","1948","1948/08/01","","",""
"26324374","Personalizing the Use of Active Surveillance As an Initial Approach for Men With Newly Diagnosed Prostate Cancer","D'Amico AV.","J Clin Oncol. 2015 Oct 20;33(30):3365-6. doi: 10.1200/JCO.2015.63.6118. Epub 2015 Aug 31.","D'Amico AV","J Clin Oncol","2015","2015/09/02","","","10.1200/JCO.2015.63.6118"
"8362120","Screening for prostate cancer in 1993: is it appropriate, or not?","Chodak GW.","Semin Urol. 1993 May;11(2):47-9.","Chodak GW","Semin Urol","1993","1993/05/01","","",""
"27344707","[Prostate cancer and epigenetics]","Yamashita S.","Nihon Rinsho. 2016 May 20;74 Suppl 3:75-9.","Yamashita S","Nihon Rinsho","2016","2016/06/28","","",""
"8214991","Cost-effectiveness of prostate cancer screening and treatment","Hahn DL.","Ann Intern Med. 1993 Nov 15;119(10):1054; author reply 1055. doi: 10.7326/0003-4819-119-10-199311150-00029.","Hahn DL","Ann Intern Med","1993","1993/11/15","","","10.7326/0003-4819-119-10-199311150-00029"
"27923674","Impact of a decision aid on newly diagnosed prostate cancer patients' understanding of the rationale for active surveillance","Formica MK, Wason S, Seigne JD, Stewart TM.","Patient Educ Couns. 2017 May;100(5):812-817. doi: 10.1016/j.pec.2016.11.019. Epub 2016 Nov 22.","Formica MK","Patient Educ Couns","2017","2016/12/08","","","10.1016/j.pec.2016.11.019"
"18074437","Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy","Parker C.","Eur Urol. 2007 Dec;52(6):1651-2.","Parker C","Eur Urol","2007","2007/12/13","","",""
"2810514","New staging systems for prostate cancer","Catalona WJ, Whitmore WF Jr.","J Urol. 1989 Nov;142(5):1302-4. doi: 10.1016/s0022-5347(17)39066-3.","Catalona WJ","J Urol","1989","1989/11/01","","","10.1016/s0022-5347(17)39066-3"
"8678489","[Etiology of prostate cancer and significance of screening for early prostate cancer]","Imai K, Fukabori Y, Yamanaka H.","Gan To Kagaku Ryoho. 1996 Mar;23(4):403-6.","Imai K","Gan To Kagaku Ryoho","1996","1996/03/01","","",""
"21428844","Secondary squamous cell prostate cancer after prostate brachytherapy treatment","Aaltomaa S, Kärjä V, Kainulainen S.","Scand J Urol Nephrol. 2011 Nov;45(5):356-8. doi: 10.3109/00365599.2011.562237. Epub 2011 Mar 24.","Aaltomaa S","Scand J Urol Nephrol","2011","2011/03/25","","","10.3109/00365599.2011.562237"
"17690889","Biomarkers for prostate cancer","Schiffer E.","World J Urol. 2007 Dec;25(6):557-62. doi: 10.1007/s00345-007-0203-6. Epub 2007 Aug 10.","Schiffer E","World J Urol","2007","2007/08/11","","","10.1007/s00345-007-0203-6"
"15046676","High androgen receptor levels are predictive of decreased survival in prostate cancer","Lee D.","Clin Prostate Cancer. 2003 Jun;2(1):13-4. doi: 10.1016/s1540-0352(11)70012-9.","Lee D","Clin Prostate Cancer","2003","2004/03/30","","","10.1016/s1540-0352(11)70012-9"
"25010865","Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial","Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.","Br J Cancer. 2014 Sep 23;111(7):1421-31. doi: 10.1038/bjc.2014.381. Epub 2014 Jul 10.","Veitonmäki T","Br J Cancer","2014","2014/07/11","PMC4183838","","10.1038/bjc.2014.381"
"8362544","[Value of prognostic factors in prostate cancer]","Schubert J, Kowalik S.","Z Arztl Fortbild (Jena). 1993 Jul 12;87(7):593-7.","Schubert J","Z Arztl Fortbild (Jena)","1993","1993/07/12","","",""
"9139872","Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector","Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, Srivastava S.","Int J Cancer. 1997 May 2;71(3):377-82. doi: 10.1002/(sici)1097-0215(19970502)71:3<377::aid-ijc13>3.0.co;2-d.","Asgari K","Int J Cancer","1997","1997/05/02","","","10.1002/(sici)1097-0215(19970502)71:3<377::aid-ijc13>3.0.co;2-d"
"19904497","Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population","Gupta L, Thakur H, Sobti RC, Seth A, Singh SK.","Mol Cell Biochem. 2010 Feb;335(1-2):255-61. doi: 10.1007/s11010-009-0275-2. Epub 2009 Nov 11.","Gupta L","Mol Cell Biochem","2010","2009/11/12","","","10.1007/s11010-009-0275-2"
"12095947","Methods to obtain more clinical and pathologic information from needle core biopsy of the prostate gland","Galosi AB, Muzzonigro G.","Ann N Y Acad Sci. 2002 Jun;963:218-20. doi: 10.1111/j.1749-6632.2002.tb04113.x.","Galosi AB","Ann N Y Acad Sci","2002","2002/07/04","","","10.1111/j.1749-6632.2002.tb04113.x"
"15947596","Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer","Krygiel JM, Smith DS, Homan SM, Sumner W 2nd, Nease RF Jr, Brownson RC, Catalona WJ.","J Urol. 2005 Jul;174(1):126-30. doi: 10.1097/01.ju.0000162051.15616.70.","Krygiel JM","J Urol","2005","2005/06/11","","","10.1097/01.ju.0000162051.15616.70"
"21927042","Smoking and prostate cancer survival and recurrence","Muller RL, Moreira DM.","Asian J Androl. 2011 Nov;13(6):787-8. doi: 10.1038/aja.2011.126. Epub 2011 Sep 19.","Muller RL","Asian J Androl","2011","2011/09/20","PMC3739564","","10.1038/aja.2011.126"
"23088984","Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265","Stenmark MH, Hamstra DA.","J Urol. 2012 Dec;188(6):2438-9; author reply 2439-40. doi: 10.1016/j.juro.2012.08.032. Epub 2012 Oct 22.","Stenmark MH","J Urol","2012","2012/10/24","","","10.1016/j.juro.2012.08.032"
"7497416","The impending Canadian prostate cancer epidemic","Morrison HI, MacNeill IB, Miller D, Levy I, Xie L, Mao Y.","Can J Public Health. 1995 Jul-Aug;86(4):274-8.","Morrison HI","Can J Public Health","1995","1995/07/01","","",""
"7683043","Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer","Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD.","J Clin Oncol. 1993 Apr;11(4):607-15. doi: 10.1200/JCO.1993.11.4.607.","Kelly WK","J Clin Oncol","1993","1993/04/01","","","10.1200/JCO.1993.11.4.607"
"16629532","Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls","Chaimuangraj S, Thammachoti R, Ongphiphadhanakul B, Thammavit W.","Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):136-9.","Chaimuangraj S","Asian Pac J Cancer Prev","2006","2006/04/25","","",""
"21113652","The prognostic role of cancer-specific beliefs among prostate cancer survivors","Soler-Vilá H, Dubrow R, Franco VI, Kasl SV, Jones BA.","Cancer Causes Control. 2011 Feb;22(2):251-60. doi: 10.1007/s10552-010-9693-4. Epub 2010 Nov 27.","Soler-Vilá H","Cancer Causes Control","2011","2010/11/30","","","10.1007/s10552-010-9693-4"
"10799171","Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology","Hautmann SH, Conrad S, Henke RP, Erbersdobler A, Simon J, Straub M, Graefen M, Hautmann RE, Huland H.","J Urol. 2000 Jun;163(6):1734-8.","Hautmann SH","J Urol","2000","2000/05/08","","",""
"25900404","Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer","Alshalalfa M, Schliekelman M, Shin H, Erho N, Davicioni E.","Biol Cell. 2015 Jul;107(7):232-44. doi: 10.1111/boc.201400097. Epub 2015 Jun 16.","Alshalalfa M","Biol Cell","2015","2015/04/23","PMC4744779","","10.1111/boc.201400097"
"31271825","Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer","Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL.","Int J Radiat Oncol Biol Phys. 2019 Nov 1;105(3):621-627. doi: 10.1016/j.ijrobp.2019.06.2510. Epub 2019 Jul 2.","Muralidhar V","Int J Radiat Oncol Biol Phys","2019","2019/07/05","","","10.1016/j.ijrobp.2019.06.2510"
"8976256","Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer","Stattin P, Damber JE, Karlberg L, Bergh A.","J Urol. 1997 Jan;157(1):219-22.","Stattin P","J Urol","1997","1997/01/01","","",""
"17121439","High intensity focused ultrasound for prostate cancer: a review of the scientific foundation, technology and clinical outcomes","Rewcastle JC.","Technol Cancer Res Treat. 2006 Dec;5(6):619-25. doi: 10.1177/153303460600500610.","Rewcastle JC","Technol Cancer Res Treat","2006","2006/11/24","","","10.1177/153303460600500610"
"24000667","[Development of a diagnostic test system for early non-invasive detection of prostate cancer based on PCA3 mRNA levels in urine sediment using quantitative reverse tanscription polymerase chain reaction (qRT-PCR)]","Pavlov KA, Shkoporov AN, Khokhlova EV, Korchagina AA, Sidorenkov AV, Grigor'ev MÉ, Pushkar' DIu, Chekhonin VP.","Vestn Ross Akad Med Nauk. 2013;(5):45-51. doi: 10.15690/vramn.v68i5.662.","Pavlov KA","Vestn Ross Akad Med Nauk","2013","2013/09/05","","","10.15690/vramn.v68i5.662"
"23925365","Early versus delayed hormonal treatment in locally advanced or asymptomatic metastatic prostatic cancer patient dilemma","Prezioso D, Iacono F, Romeo G, Ruffo A, Russo N, Illiano E.","World J Urol. 2014 Jun;32(3):661-7. doi: 10.1007/s00345-013-1144-x. Epub 2013 Aug 8.","Prezioso D","World J Urol","2014","2013/08/09","","","10.1007/s00345-013-1144-x"
"12841325","Neuroendocrine differentiation in prostatic carcinoma","Hansson J, Abrahamsson PA.","Scand J Urol Nephrol Suppl. 2003;(212):28-36. doi: 10.1080/03008880310006922.","Hansson J","Scand J Urol Nephrol Suppl","2003","2003/07/05","","","10.1080/03008880310006922"
"10482188","Gene therapy for prostate cancer","Hrouda D, Perry M, Dalgleish AG.","Semin Oncol. 1999 Aug;26(4):455-71.","Hrouda D","Semin Oncol","1999","1999/09/11","","",""
"9026742","[Incidence and treatment of prostatic carcinoma in the region of the Comprehensive Cancer Center Amsterdam, 1989-1994]","Visser O, Horenblas S.","Ned Tijdschr Geneeskd. 1996 Dec 28;140(52):2627-31.","Visser O","Ned Tijdschr Geneeskd","1996","1996/12/28","","",""
"25518342","[Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)]","Akaza H.","Nihon Rinsho. 2014 Dec;72(12):2108-15.","Akaza H","Nihon Rinsho","2014","2014/12/19","","",""
"7743474","Pulmonary metastases from prostate cancer","Fabozzi SJ, Schellhammer PF, el-Mahdi AM.","Cancer. 1995 Jun 1;75(11):2706-9. doi: 10.1002/1097-0142(19950601)75:11<2706::aid-cncr2820751111>3.0.co;2-y.","Fabozzi SJ","Cancer","1995","1995/06/01","","","10.1002/1097-0142(19950601)75:11<2706::aid-cncr2820751111>3.0.co;2-y"
"27694162","Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles","Kilcoyne A, Harisinghani MG, Mahmood U.","J Nucl Med. 2016 Oct;57(Suppl 3):105S-110S. doi: 10.2967/jnumed.115.170738.","Kilcoyne A","J Nucl Med","2016","2016/10/04","","","10.2967/jnumed.115.170738"
"25297489","[Importance of complementary medicine approaches for patients with prostate cancer]","Gschwendtner KM, Klein G, Güthlin C, Holmberg C, Horneber M, Weis J.","Urologe A. 2014 Nov;53(11):1600-9. doi: 10.1007/s00120-014-3613-2.","Gschwendtner KM","Urologe A","2014","2014/10/10","","","10.1007/s00120-014-3613-2"
"27600766","Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells","Rae C, Mairs RJ.","Int J Radiat Biol. 2017 Feb;93(2):194-203. doi: 10.1080/09553002.2017.1231946. Epub 2016 Oct 3.","Rae C","Int J Radiat Biol","2017","2016/09/08","","","10.1080/09553002.2017.1231946"
"29510844","Association Between Socioeconomic Status and Tumor Grade Among Black Men with Prostate Cancer","Percy-Laurry A, Altekruse SF, Hossain MB, O'Keefe AM, Johnson NJ, Kamangar F.","J Natl Med Assoc. 2018 Feb;110(1):53-57. doi: 10.1016/j.jnma.2017.06.019. Epub 2017 Jul 13.","Percy-Laurry A","J Natl Med Assoc","2018","2018/03/08","PMC5846117","NIHMS888797","10.1016/j.jnma.2017.06.019"
"9440754","Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy","Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J.","J Clin Oncol. 1998 Jan;16(1):284-9. doi: 10.1200/JCO.1998.16.1.284.","Kahn D","J Clin Oncol","1998","1998/01/24","","","10.1200/JCO.1998.16.1.284"
"8653318","Farmers at risk for prostate cancer","Van Der Gulden JW, Vogelzang PF.","Br J Urol. 1996 Jan;77(1):6-14. doi: 10.1046/j.1464-410x.1996.07751.x.","Van Der Gulden JW","Br J Urol","1996","1996/01/01","","","10.1046/j.1464-410x.1996.07751.x"
"19470282","Prostate cancer: issues in psychosomatic medicine","Chism K, Kunkel EJ.","Curr Psychiatry Rep. 2009 Jun;11(3):205-10. doi: 10.1007/s11920-009-0032-y.","Chism K","Curr Psychiatry Rep","2009","2009/05/28","","","10.1007/s11920-009-0032-y"
"7686805","Advanced prostate cancer: what's new in hormonal manipulation?","Brewster SF, Gillatt DA.","Br J Hosp Med. 1993 May 19-Jun 1;49(10):710-1, 714-5.","Brewster SF","Br J Hosp Med","1993","1993/05/01","","",""
"21604945","Tumour markers in prostate cancer III: biomarkers in urine","Roobol MJ, Haese A, Bjartell A.","Acta Oncol. 2011 Jun;50 Suppl 1:85-9. doi: 10.3109/0284186X.2010.524935.","Roobol MJ","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.524935"
"7475557","Anti-androgens in treatment of prostate cancer","Labrie F, Crawford D.","Lancet. 1995 Oct 14;346(8981):1030-1.","Labrie F","Lancet","1995","1995/10/14","","",""
"21063657","Association of physicians' knowledge and behavior with prostate cancer counseling and screening in Saudi Arabia","Arafa MA, Rabah DM, Abdel-Gawad E, Ibrahim FK.","Saudi Med J. 2010 Nov;31(11):1245-50.","Arafa MA","Saudi Med J","2010","2010/11/11","","",""
"29356020","Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B","Huang H, Wang Q, Du T, Lin C, Lai Y, Zhu D, Wu W, Ma X, Bai S, Li Z, Liu L, Li Q.","Prostate. 2018 Apr;78(5):327-335. doi: 10.1002/pros.23469. Epub 2018 Jan 21.","Huang H","Prostate","2018","2018/01/23","","","10.1002/pros.23469"
"12599553","[The use of prostate specific antigen in prostate cancer--prediction for treatment failure]","Egawa S.","Nihon Rinsho. 2002 Dec;60 Suppl 11:100-6.","Egawa S","Nihon Rinsho","2002","2003/02/26","","",""
"22001108","Nutrition, dietary supplements and adenocarcinoma of the prostate","Schultz C, Meier M, Schmid HP.","Maturitas. 2011 Dec;70(4):339-42. doi: 10.1016/j.maturitas.2011.08.007. Epub 2011 Oct 13.","Schultz C","Maturitas","2011","2011/10/18","","","10.1016/j.maturitas.2011.08.007"
"29633951","[Radiotherapy for local disease in metastatic prostate cancer.]","Cambeiro M, Calvo FA.","Arch Esp Urol. 2018 Mar;71(3):298-305.","Cambeiro M","Arch Esp Urol","2018","2018/04/11","","",""
"26499278","Magnetic Resonance-Guided Thermal Therapy for Localized and Recurrent Prostate Cancer","Woodrum DA, Kawashima A, Gorny KR, Mynderse LA.","Magn Reson Imaging Clin N Am. 2015 Nov;23(4):607-19. doi: 10.1016/j.mric.2015.05.014. Epub 2015 Aug 5.","Woodrum DA","Magn Reson Imaging Clin N Am","2015","2015/10/27","","","10.1016/j.mric.2015.05.014"
"22381571","Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme","Smailyte G, Aleknaviciene B.","Public Health. 2012 Dec;126(12):1075-7. doi: 10.1016/j.puhe.2012.01.016. Epub 2012 Feb 29.","Smailyte G","Public Health","2012","2012/03/03","","","10.1016/j.puhe.2012.01.016"
"20364154","Human prostate cancer heterotransplants: a review on this experimental model","Lopez-Barcons LA.","Asian J Androl. 2010 Jul;12(4):509-18. doi: 10.1038/aja.2010.17. Epub 2010 Apr 5.","Lopez-Barcons LA","Asian J Androl","2010","2010/04/06","PMC3739361","","10.1038/aja.2010.17"
"28561698","Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists","James N, Graham J, Maurer T, Eiber M, Gschwend JE.","Am Soc Clin Oncol Educ Book. 2017;37:344-357. doi: 10.1200/EDBK_175496.","James N","Am Soc Clin Oncol Educ Book","2017","2017/06/01","","","10.1200/EDBK_175496"
"22818140","Assessment of the quality of medical care among patients with early stage prostate cancer undergoing expectant management in the United States","Ritchey J, Gay EG, Spencer BA, Miller DC, Wallner LP, Stewart AK, Dunn RL, Litwin MS, Wei JT.","J Urol. 2012 Sep;188(3):769-74. doi: 10.1016/j.juro.2012.04.106. Epub 2012 Jul 19.","Ritchey J","J Urol","2012","2012/07/24","","","10.1016/j.juro.2012.04.106"
"19573778","Response to the article by J.E. Montie, Screen detected, low volume prostate cancer: the case for active treatment. Urol Oncol 2008;26:511-515","Klotz L.","Urol Oncol. 2009 Jul-Aug;27(4):454; author reply 454. doi: 10.1016/j.urolonc.2009.03.010.","Klotz L","Urol Oncol","2009","2009/07/04","","","10.1016/j.urolonc.2009.03.010"
"22375605","Involvement of estrogen receptors in prostatic diseases","Kawashima H, Nakatani T.","Int J Urol. 2012 Jun;19(6):512-22; author reply 522-3. doi: 10.1111/j.1442-2042.2012.02987.x. Epub 2012 Feb 29.","Kawashima H","Int J Urol","2012","2012/03/02","","","10.1111/j.1442-2042.2012.02987.x"
"24237792","Managing cancer-related fatigue in men with prostate cancer: a systematic review of non-pharmacological interventions","Larkin D, Lopez V, Aromataris E.","Int J Nurs Pract. 2014 Oct;20(5):549-60. doi: 10.1111/ijn.12211. Epub 2013 Nov 15.","Larkin D","Int J Nurs Pract","2014","2013/11/19","","","10.1111/ijn.12211"
"14997188","The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials","Gottschalk AR, Roach M 3rd.","Br J Cancer. 2004 Mar 8;90(5):950-4. doi: 10.1038/sj.bjc.6601625.","Gottschalk AR","Br J Cancer","2004","2004/03/05","PMC2409615","","10.1038/sj.bjc.6601625"
"7520352","Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Data from the American Cancer Society National Prostate Cancer Detection Project","Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK.","Cancer. 1994 Sep 1;74(5):1615-20. doi: 10.1002/1097-0142(19940901)74:5<1615::aid-cncr2820740520>3.0.co;2-6.","Mettlin C","Cancer","1994","1994/09/01","","","10.1002/1097-0142(19940901)74:5<1615::aid-cncr2820740520>3.0.co;2-6"
"22805324","To be screened or not to be screened? Modeling the consequences of PSA screening for the individual","Wever EM, Hugosson J, Heijnsdijk EA, Bangma CH, Draisma G, de Koning HJ.","Br J Cancer. 2012 Aug 21;107(5):778-84. doi: 10.1038/bjc.2012.317. Epub 2012 Jul 17.","Wever EM","Br J Cancer","2012","2012/07/19","PMC3425982","","10.1038/bjc.2012.317"
"15150583","Diabetes mellitus and prostate cancer risk among older men: population-based case-control study","Coker AL, Sanderson M, Zheng W, Fadden MK.","Br J Cancer. 2004 Jun 1;90(11):2171-5. doi: 10.1038/sj.bjc.6601857.","Coker AL","Br J Cancer","2004","2004/05/20","PMC2410287","","10.1038/sj.bjc.6601857"
"23033314","Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer","Shiota M, Yokomizo A, Naito S.","Endocr Relat Cancer. 2012 Nov 9;19(6):R243-53. doi: 10.1530/ERC-12-0232. Print 2012 Dec.","Shiota M","Endocr Relat Cancer","2012","2012/10/04","","","10.1530/ERC-12-0232"
"19836772","Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort","Wright JL, Salinas CA, Lin DW, Kolb S, Koopmeiners J, Feng Z, Stanford JL.","J Urol. 2009 Dec;182(6):2702-7. doi: 10.1016/j.juro.2009.08.026.","Wright JL","J Urol","2009","2009/10/20","PMC2828768","NIHMS166136","10.1016/j.juro.2009.08.026"
"26242049","[2014 Annual Meeting of the American Urological Association: early screening and molecular markers of prostate cancer]","Tao T, Guan H, Chen M.","Zhonghua Nan Ke Xue. 2015 Jun;21(6):555-60.","Tao T","Zhonghua Nan Ke Xue","2015","2015/08/06","","",""
"24526595","[Radiotherapy in men with prostate cancer: indications, evolutions and integrated approaches]","Mantini G, Alitto AR, Fionda B, Frascino V, Mattiucci GC, Balducci M, Morganti AG, Valentini V.","Urologia. 2013 Jul-Sep;80(3):188-201. doi: 10.5301/RU.2013.11499.","Mantini G","Urologia","2013","2014/02/15","","","10.5301/RU.2013.11499"
"18063545","Reducing prostate cancer morbidity and mortality in African American men: issues and challenges","Jones RA, Underwood SM, Rivers BM.","Clin J Oncol Nurs. 2007 Dec;11(6):865-72. doi: 10.1188/07.CJON.865-872.","Jones RA","Clin J Oncol Nurs","2007","2007/12/08","","","10.1188/07.CJON.865-872"
"8853502","A prostate cancer screening trial in Canada?","Miller A.","Can J Oncol. 1994 Nov;4 Suppl 1:110-2; discussion 113-8.","Miller A","Can J Oncol","1994","1994/11/01","","",""
"12771784","Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer","Yashi M, Tokue A.","J Urol. 2003 Jun;169(6):2305; author reply 2305. doi: 10.1097/01.ju.0000065590.46394.1d.","Yashi M","J Urol","2003","2003/05/29","","","10.1097/01.ju.0000065590.46394.1d"
"19827538","[Clinical study of radical prostatectomy for prostate cancer from a single institution]","Ishida R, Kobayashi H, Yoshida S, Ogawa M, Shiota T, Nishikimi T, Yamada H, Yokoi K.","Nihon Hinyokika Gakkai Zasshi. 2009 Sep;100(6):615-24. doi: 10.5980/jpnjurol.100.615.","Ishida R","Nihon Hinyokika Gakkai Zasshi","2009","2009/10/16","","","10.5980/jpnjurol.100.615"
"16278478","Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype","Loberg RD, Logothetis CJ, Keller ET, Pienta KJ.","J Clin Oncol. 2005 Nov 10;23(32):8232-41. doi: 10.1200/JCO.2005.03.0841.","Loberg RD","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.03.0841"
"9444853","Screening of prostate cancer in males with prostatism","Saxena S, Mohanty NK, Jain AK.","Indian J Pathol Microbiol. 1997 Oct;40(4):441-50.","Saxena S","Indian J Pathol Microbiol","1997","1998/01/28","","",""
"12771770","Regret in men treated for localized prostate cancer","Hu JC, Kwan L, Saigal CS, Litwin MS.","J Urol. 2003 Jun;169(6):2279-83. doi: 10.1097/01.ju.0000065662.52170.6f.","Hu JC","J Urol","2003","2003/05/29","","","10.1097/01.ju.0000065662.52170.6f"
"19544547","Biomolecular markers of outcome prediction in prostate cancer","Lopergolo A, Zaffaroni N.","Cancer. 2009 Jul 1;115(13 Suppl):3058-67. doi: 10.1002/cncr.24346.","Lopergolo A","Cancer","2009","2009/06/23","","","10.1002/cncr.24346"
"11490269","Undetectable prostate specific antigen in disseminated prostate cancer","Beardo P, Fernández PL, Corral JM, Filella X, Alcover J.","J Urol. 2001 Sep;166(3):993.","Beardo P","J Urol","2001","2001/08/08","","",""
"12949936","TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3","Mu X, Chang C.","Prostate. 2003 Oct 1;57(2):129-33. doi: 10.1002/pros.10282.","Mu X","Prostate","2003","2003/09/02","","","10.1002/pros.10282"
"17848953","Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells","Zvereff V, Wang JC, Shun K, Lacoste J, Chevrette M.","Br J Cancer. 2007 Oct 8;97(7):941-8. doi: 10.1038/sj.bjc.6603964. Epub 2007 Sep 11.","Zvereff V","Br J Cancer","2007","2007/09/13","PMC2360413","","10.1038/sj.bjc.6603964"
"21166516","Predictors in the outcome of 125I brachytherapy as monotherapy for prostate cancer","Hinnen KA, van Vulpen M.","Expert Rev Anticancer Ther. 2011 Jan;11(1):115-23. doi: 10.1586/era.10.211.","Hinnen KA","Expert Rev Anticancer Ther","2011","2010/12/21","","","10.1586/era.10.211"
"10757272","Follow-up of prostate cancer patients by on-demand contacts with a specialist nurse: a randomized study","Helgesen F, Andersson SO, Gustafsson O, Varenhorst E, Gobén B, Carnock S, Sehlstedt L, Carlsson P, Holmberg L, Johansson JE.","Scand J Urol Nephrol. 2000 Feb;34(1):55-61. doi: 10.1080/003655900750016904.","Helgesen F","Scand J Urol Nephrol","2000","2000/04/11","","","10.1080/003655900750016904"
"27609145","Oxidative stress in prostate hyperplasia and carcinogenesis","Udensi UK, Tchounwou PB.","J Exp Clin Cancer Res. 2016 Sep 8;35(1):139. doi: 10.1186/s13046-016-0418-8.","Udensi UK","J Exp Clin Cancer Res","2016","2016/09/10","PMC5017015","","10.1186/s13046-016-0418-8"
"2643148","Echogenicity of prostate cancer correlated with histologic grade and stromal fibrosis: endorectal US studies","Rifkin MD, McGlynn ET, Choi H.","Radiology. 1989 Feb;170(2):549-52. doi: 10.1148/radiology.170.2.2643148.","Rifkin MD","Radiology","1989","1989/02/01","","","10.1148/radiology.170.2.2643148"
"24904995","Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols","Kates M, Tosoian JJ, Trock BJ, Feng Z, Carter HB, Partin AW.","BJU Int. 2015 Feb;115(2):216-22. doi: 10.1111/bju.12828. Epub 2014 Aug 16.","Kates M","BJU Int","2015","2014/06/07","","","10.1111/bju.12828"
"17895474","Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence","Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H, de la Roza G.","J Natl Cancer Inst. 2007 Oct 3;99(19):1484-9. doi: 10.1093/jnci/djm153. Epub 2007 Sep 25.","Haas GP","J Natl Cancer Inst","2007","2007/09/27","","","10.1093/jnci/djm153"
"8650871","Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer","Noldus J, Ferrari M, Prestigiacomo A, Stamey TA.","Urology. 1996 May;47(5):713-8. doi: 10.1016/s0090-4295(96)00013-1.","Noldus J","Urology","1996","1996/05/01","","","10.1016/s0090-4295(96)00013-1"
"12107014","PSA vaccine for prostate cancer","Burton A.","Lancet Oncol. 2002 Jun;3(6):329. doi: 10.1016/s1470-2045(02)00767-2.","Burton A","Lancet Oncol","2002","2002/07/11","","","10.1016/s1470-2045(02)00767-2"
"23069258","Microvessel density is not increased in prostate cancer: digital imaging of routine sections and tissue microarrays","Tretiakova M, Antic T, Binder D, Kocherginsky M, Liao C, Taxy JB, Oto A.","Hum Pathol. 2013 Apr;44(4):495-502. doi: 10.1016/j.humpath.2012.06.009. Epub 2012 Oct 12.","Tretiakova M","Hum Pathol","2013","2012/10/17","","","10.1016/j.humpath.2012.06.009"
"11593908","[Low dose brachytherapy with seeds--an interdisciplinary therapy alternative to radical prostatectomy]","Kahmann F, Henkel T.","Praxis (Bern 1994). 2001 Sep 6;90(36):1523-31.","Kahmann F","Praxis (Bern 1994)","2001","2001/10/12","","",""
"12735508","Nonmedical factors in treatment selection","Brawley OW.","Urol Clin North Am. 2003 May;30(2):331-5. doi: 10.1016/s0094-0143(02)00186-6.","Brawley OW","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00186-6"
"15782124","Impaired homologous recombination DNA repair and enhanced sensitivity to DNA damage in prostate cancer cells exposed to anchorage-independence","Wang JY, Ho T, Trojanek J, Chintapalli J, Grabacka M, Stoklosa T, Garcia FU, Skorski T, Reiss K.","Oncogene. 2005 May 26;24(23):3748-58. doi: 10.1038/sj.onc.1208537.","Wang JY","Oncogene","2005","2005/03/23","","","10.1038/sj.onc.1208537"
"26751899","miRNAs as novel biomarkers in the management of prostate cancer","Filella X, Foj L.","Clin Chem Lab Med. 2017 May 1;55(5):715-736. doi: 10.1515/cclm-2015-1073.","Filella X","Clin Chem Lab Med","2017","2016/01/12","","","10.1515/cclm-2015-1073"
"10361553","Prognostic indicators in hormone refractory prostate cancer","George DJ, Kantoff PW.","Urol Clin North Am. 1999 May;26(2):303-10, viii. doi: 10.1016/s0094-0143(05)70070-7.","George DJ","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70070-7"
"17895878","Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer","Smith AD, Phillips JL.","Nat Clin Pract Urol. 2007 Nov;4(11):576-7. doi: 10.1038/ncpuro0936. Epub 2007 Sep 25.","Smith AD","Nat Clin Pract Urol","2007","2007/09/27","","","10.1038/ncpuro0936"
"24556387","Metabolomic evaluation of the response to endocrine therapy in patients with prostate cancer","Huang G, Liu X, Jiao L, Xu C, Zhang Z, Wang L, Li Y, Yang C, Zhang W, Sun Y.","Eur J Pharmacol. 2014 Apr 15;729:132-7. doi: 10.1016/j.ejphar.2014.01.048. Epub 2014 Feb 18.","Huang G","Eur J Pharmacol","2014","2014/02/22","","","10.1016/j.ejphar.2014.01.048"
"15562791","[Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer]","Deng J, Li W, Yang L, Wang L, Zou D.","Zhonghua Nan Ke Xue. 2004 Oct;10(10):761-3.","Deng J","Zhonghua Nan Ke Xue","2004","2004/11/26","","",""
"19440008","Impact of surgical and medical castration on serum testosterone level in prostate cancer patients","Novara G, Galfano A, Secco S, Ficarra V, Artibani W.","Urol Int. 2009;82(3):249-55. doi: 10.1159/000209352. Epub 2009 May 11.","Novara G","Urol Int","2009","2009/05/15","","","10.1159/000209352"
"28792144","Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL","Lee DH, Nam JK, Lee SS, Han JY, Lee JW, Chung MK, Park SW.","Yonsei Med J. 2017 Sep;58(5):994-999. doi: 10.3349/ymj.2017.58.5.994.","Lee DH","Yonsei Med J","2017","2017/08/10","PMC5552655","","10.3349/ymj.2017.58.5.994"
"18838210","Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth","Sciarra A.","Eur Urol. 2009 Feb;55(2):320-1. doi: 10.1016/j.eururo.2008.09.025. Epub 2008 Sep 24.","Sciarra A","Eur Urol","2009","2008/10/08","","","10.1016/j.eururo.2008.09.025"
"11221036","[Repeated ultrasound-guided transrectal prostate biopsy in patients with negative histologic test]","Raber M, Scattoni V, Salonia A, Consonni P, Rigatti P.","Arch Ital Urol Androl. 2000 Dec;72(4):197-9.","Raber M","Arch Ital Urol Androl","2000","2001/02/28","","",""
"25126559","Multiparametric MRI in biopsy guidance for prostate cancer: fusion-guided","Rothwax JT, George AK, Wood BJ, Pinto PA.","Biomed Res Int. 2014;2014:439171. doi: 10.1155/2014/439171. Epub 2014 Jul 13.","Rothwax JT","Biomed Res Int","2014","2014/08/16","PMC4122009","","10.1155/2014/439171"
"25557292","Epidemiology of advanced prostate cancer: overview of known and less explored disparities in prostate cancer prognosis","Holz LE, Goodman M.","Curr Probl Cancer. 2015 Jan-Feb;39(1):11-6. doi: 10.1016/j.currproblcancer.2014.11.003. Epub 2014 Nov 26.","Holz LE","Curr Probl Cancer","2015","2015/01/06","","","10.1016/j.currproblcancer.2014.11.003"
"19061194","Spirituality and quality of life in low-income men with metastatic prostate cancer","Zavala MW, Maliski SL, Kwan L, Fink A, Litwin MS.","Psychooncology. 2009 Jul;18(7):753-61. doi: 10.1002/pon.1460.","Zavala MW","Psychooncology","2009","2008/12/09","","","10.1002/pon.1460"
"8678493","[QOL assessment in the treatment of prostate cancer]","Isaka S.","Gan To Kagaku Ryoho. 1996 Mar;23(4):427-31.","Isaka S","Gan To Kagaku Ryoho","1996","1996/03/01","","",""
"20937024","Use of transgenic mice as models for prostate cancer chemoprevention","Nguewa PA, Calvo A.","Curr Mol Med. 2010 Nov;10(8):705-18. doi: 10.2174/156652410793384196.","Nguewa PA","Curr Mol Med","2010","2010/10/13","","","10.2174/156652410793384196"
"19925378","Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?","Morgan C, Wagstaff J.","Acta Oncol. 2009;48(6):882-9. doi: 10.1080/02841860902874748.","Morgan C","Acta Oncol","2009","2009/11/21","","","10.1080/02841860902874748"
"29406053","Prostate Cancer Screening","Catalona WJ.","Med Clin North Am. 2018 Mar;102(2):199-214. doi: 10.1016/j.mcna.2017.11.001.","Catalona WJ","Med Clin North Am","2018","2018/02/07","PMC5935113","NIHMS963347","10.1016/j.mcna.2017.11.001"
"26051659","Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy","Coulter JA, Butterworth KT, Jain S.","Br J Radiol. 2015 Oct;88(1054):20150256. doi: 10.1259/bjr.20150256. Epub 2015 Jun 8.","Coulter JA","Br J Radiol","2015","2015/06/09","PMC4738107","","10.1259/bjr.20150256"
"11238701","Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study","Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL.","J Natl Cancer Inst. 2001 Mar 7;93(5):388-95. doi: 10.1093/jnci/93.5.388.","Hoffman RM","J Natl Cancer Inst","2001","2001/03/10","","","10.1093/jnci/93.5.388"
"30116988","Awareness and Attitudes of Nigerian Men Living in Abuja on Prostate Cancer and Screening","Farazi PA, Siahpush M, Maloney S, Dinkel D, Michalek A, John R, Oluwole O.","J Cancer Educ. 2019 Dec;34(6):1107-1111. doi: 10.1007/s13187-018-1416-7.","Farazi PA","J Cancer Educ","2019","2018/08/18","","","10.1007/s13187-018-1416-7"
"11312117","Interleukin-6 and prostate cancer progression","Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET.","Cytokine Growth Factor Rev. 2001 Mar;12(1):33-40. doi: 10.1016/s1359-6101(00)00021-6.","Smith PC","Cytokine Growth Factor Rev","2001","2001/04/20","","","10.1016/s1359-6101(00)00021-6"
"20562373","Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study","Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.","J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.","Stattin P","J Natl Cancer Inst","2010","2010/06/22","PMC2897875","","10.1093/jnci/djq154"
"7614384","A comparison of prostate cancer patients in Japan and the USA","Imai K, Takahashi Y, Nakata S, Karr JP, Huben R.","Int J Urol. 1994 Sep;1(3):256-62. doi: 10.1111/j.1442-2042.1994.tb00046.x.","Imai K","Int J Urol","1994","1994/09/01","","","10.1111/j.1442-2042.1994.tb00046.x"
"30778860","Clinicopathological predictors of positive (68)Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy","Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.","Ann Nucl Med. 2019 May;33(5):326-332. doi: 10.1007/s12149-019-01340-1. Epub 2019 Feb 18.","Aydin AM","Ann Nucl Med","2019","2019/02/20","","","10.1007/s12149-019-01340-1"
"25773347","Guidance on patient consultation. Current evidence for prostate-specific antigen screening in healthy men and treatment options for men with proven localised prostate cancer","Pini G, Collins J, Ghadjar P, Wiklund P.","Curr Urol Rep. 2015 May;16(5):28. doi: 10.1007/s11934-015-0502-1.","Pini G","Curr Urol Rep","2015","2015/03/17","","","10.1007/s11934-015-0502-1"
"25881805","The Impact of Husbands' Prostate Cancer Diagnosis and Participation in a Behavioral Lifestyle Intervention on Spouses' Lives and Relationships With Their Partners","Rossen S, Hansen-Nord NS, Kayser L, Borre M, Borre M, Larsen RG, Trichopoulou A, Boffetta P, Tjønneland A, Hansen RD.","Cancer Nurs. 2016 Mar-Apr;39(2):E1-9. doi: 10.1097/NCC.0000000000000259.","Rossen S","Cancer Nurs","2016","2015/04/18","","","10.1097/NCC.0000000000000259"
"9074902","New avenues and perspectives in the management of advanced prostate cancer. Proceedings of a symposium. Paris, France, September 1, 1996","","Eur Urol. 1997;31 Suppl 2:1-39.","","Eur Urol","1997","1997/01/01","","",""
"10450001","PSA decline is an independent prognostic marker in hormonally treated prostate cancer","Palmberg C, Koivisto P, Visakorpi T, Tammela TL.","Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996.","Palmberg C","Eur Urol","1999","1999/08/18","","","10.1159/000067996"
"24000432","Prostate cancer: to treat or not to treat?","","Johns Hopkins Med Lett Health After 50. 2013 Jan;24(12):1-2.","","Johns Hopkins Med Lett Health After 50","2013","2013/09/05","","",""
"10810970","The correlation of stage and pathology of prostate cancer in Japan","Kubota Y, Imai K, Yamanaka H.","Int J Urol. 2000 Apr;7(4):139-44. doi: 10.1046/j.1442-2042.2000.00156.x.","Kubota Y","Int J Urol","2000","2000/05/16","","","10.1046/j.1442-2042.2000.00156.x"
"12944993","Prostate cancer detection using power Doppler imaging","Okihara K, Ukimura O, Mizutani Y, Kawauchi A, Nakao M, Miki T.","Drugs Today (Barc). 2003 Jun;39(6):389-98. doi: 10.1358/dot.2003.39.6.799446.","Okihara K","Drugs Today (Barc)","2003","2003/08/29","","","10.1358/dot.2003.39.6.799446"
"7077086","Radiation of prostate cancer","Kays HW.","J Indiana State Med Assoc. 1982 Mar;75(3):182-3.","Kays HW","J Indiana State Med Assoc","1982","1982/03/01","","",""
"21929319","Lymph node-positive prostate cancer: current issues, emerging technology and impact on clinical outcome","Adams J, Cheng L.","Expert Rev Anticancer Ther. 2011 Sep;11(9):1457-69. doi: 10.1586/era.11.104.","Adams J","Expert Rev Anticancer Ther","2011","2011/09/21","","","10.1586/era.11.104"
"18948763","Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets","Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM.","Adv Anat Pathol. 2008 Nov;15(6):319-31. doi: 10.1097/PAP.0b013e31818a5c19.","Gurel B","Adv Anat Pathol","2008","2008/10/25","PMC3214657","NIHMS118034","10.1097/PAP.0b013e31818a5c19"
"12915903","Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001)","Villers A, Pommier P, Bataillard A, Fervers B, Bachaud JM, Berger N, Bertrand AF, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O, Lagrange JL, Molinie V, Muratet JP, Pabot du Chatelard P, Peneau M, Prapotnich D, Ravery V, Richaud P, Rossi D, Soulie M; FNCLCC; AFU.","Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S50-8. doi: 10.1038/sj.bjc.6601084.","Villers A","Br J Cancer","2003","2003/08/14","PMC2753017","","10.1038/sj.bjc.6601084"
"25845958","Words of wisdom. Re: Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort","Damiano R, Cicione A, Cantiello F.","Eur Urol. 2015 May;67(5):972-3. doi: 10.1016/j.eururo.2014.12.062.","Damiano R","Eur Urol","2015","2015/04/08","","","10.1016/j.eururo.2014.12.062"
"8951622","Does prostate cancer start at puberty?","Diamandis EP, Yu H.","J Clin Lab Anal. 1996;10(6):468-9. doi: 10.1002/(SICI)1098-2825(1996)10:6<468::AID-JCLA27>3.0.CO;2-U.","Diamandis EP","J Clin Lab Anal","1996","1996/01/01","","","10.1002/(SICI)1098-2825(1996)10:6<468::AID-JCLA27>3.0.CO;2-U"
"17873302","Current perspectives in the treatment of advanced prostate cancer","Valdespino V, Tsagozis P, Pisa P.","Med Oncol. 2007;24(3):273-86. doi: 10.1007/s12032-007-0017-9.","Valdespino V","Med Oncol","2007","2007/09/18","","","10.1007/s12032-007-0017-9"
"14701899","Who decides about prostate cancer treatment? A qualitative study","Cohen H, Britten N.","Fam Pract. 2003 Dec;20(6):724-9. doi: 10.1093/fampra/cmg617.","Cohen H","Fam Pract","2003","2004/01/01","","","10.1093/fampra/cmg617"
"15003150","Comparison of histologic grade between initial and follow-up biopsy in untreated, low to intermediate grade, localized prostate cancer","Choo R, Do V, Sugar L, Klotz L, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G.","Can J Urol. 2004 Feb;11(1):2118-24.","Choo R","Can J Urol","2004","2004/03/09","","",""
"21718432","Prediction of outcomes after radical prostatectomy in patients diagnosed with prostate cancer of biopsy Gleason score ≥ 8 via contemporary multi(≥ 12)-core prostate biopsy","Loeb S.","BJU Int. 2011 Jul;108(2):222. doi: 10.1111/j.1464-410X.2011.10440.x.","Loeb S","BJU Int","2011","2011/07/02","","","10.1111/j.1464-410X.2011.10440.x"
"10196617","Biopsy-based diagnosis of prostate cancer in 1290 patients referred for prostate examination: results according to the PSA level, digital rectal examination and ultrasonography","Szabó J, Végh A, Gasman D, Hoznek A, Chopin DK, Abbou CC.","Acta Chir Hung. 1998;37(1-2):95-100.","Szabó J","Acta Chir Hung","1998","1999/04/10","","",""
"8110985","Endocrine treatment of prostate cancer: standard treatment and new perspectives","Boccardo F, Pace M.","In Vivo. 1993 Sep-Oct;7(5):423-4.","Boccardo F","In Vivo","1993","1993/09/01","","",""
"2102638","Neodymium-YAG laser in the treatment of localized prostate cancer","Beisland HO.","Ann Chir Gynaecol. 1990;79(4):200-2.","Beisland HO","Ann Chir Gynaecol","1990","1990/01/01","","",""
"31444696","Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy","Porcaro AB, Tafuri A, Sebben M, Processali T, Pirozzi M, Shakir A, Amigoni N, Rizzetto R, Brunelli M, Migliorini F, Siracusano S, Artibani W.","Int Urol Nephrol. 2019 Dec;51(12):2169-2180. doi: 10.1007/s11255-019-02263-6. Epub 2019 Aug 23.","Porcaro AB","Int Urol Nephrol","2019","2019/08/25","","","10.1007/s11255-019-02263-6"
"31085765","Germline and Somatic Mutations in Prostate Cancer for the Clinician","Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.","J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307.","Cheng HH","J Natl Compr Canc Netw","2019","2019/05/16","","","10.6004/jnccn.2019.7307"
"18337319","Variation of clinical target volume definition among Japanese radiation oncologists in external beam radiotherapy for prostate cancer","Nakamura K, Shioyama Y, Tokumaru S, Hayashi N, Oya N, Hiraki Y, Kusuhara K, Toita T, Suefuji H, Hayabuchi N, Terashima H, Makino M, Jingu K.","Jpn J Clin Oncol. 2008 Apr;38(4):275-80. doi: 10.1093/jjco/hyn014. Epub 2008 Mar 12.","Nakamura K","Jpn J Clin Oncol","2008","2008/03/14","","","10.1093/jjco/hyn014"
"9242169","Quality of life in prostate cancer patients","Herr HW.","CA Cancer J Clin. 1997 Jul-Aug;47(4):207-17. doi: 10.3322/canjclin.47.4.207.","Herr HW","CA Cancer J Clin","1997","1997/07/01","","","10.3322/canjclin.47.4.207"
"17576986","Prostate-specific antigen in the early detection of prostate cancer","Thompson IM, Ankerst DP.","CMAJ. 2007 Jun 19;176(13):1853-8. doi: 10.1503/cmaj.060955.","Thompson IM","CMAJ","2007","2007/06/20","PMC1891131","","10.1503/cmaj.060955"
"21614469","Identification of the prostate cancer index lesion by real-time elastography: considerations for focal therapy of prostate cancer","Walz J, Marcy M, Pianna JT, Brunelle S, Gravis G, Salem N, Bladou F.","World J Urol. 2011 Oct;29(5):589-94. doi: 10.1007/s00345-011-0688-x. Epub 2011 May 26.","Walz J","World J Urol","2011","2011/05/27","","","10.1007/s00345-011-0688-x"
"23475555","Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer","Alanee S, Shah S, Vijai J, Schrader K, Hamilton R, Rau-Murthy R, Sarrel K, Manschreck C, Eastham J, Offit K.","Fam Cancer. 2013 Dec;12(4):597-600. doi: 10.1007/s10689-013-9618-y.","Alanee S","Fam Cancer","2013","2013/03/12","PMC5073797","NIHMS454105","10.1007/s10689-013-9618-y"
"17402955","Watching, waiting and uncertainty in prostate cancer","Bailey DE Jr, Wallace M, Mishel MH.","J Clin Nurs. 2007 Apr;16(4):734-41. doi: 10.1111/j.1365-2702.2005.01545.x.","Bailey DE Jr","J Clin Nurs","2007","2007/04/04","","","10.1111/j.1365-2702.2005.01545.x"
"17217995","Androgen receptor amplification is associated with increased cell proliferation in prostate cancer","Haapala K, Kuukasjärvi T, Hyytinen E, Rantala I, Helin HJ, Koivisto PA.","Hum Pathol. 2007 Mar;38(3):474-8. doi: 10.1016/j.humpath.2006.09.008. Epub 2007 Jan 10.","Haapala K","Hum Pathol","2007","2007/01/16","","","10.1016/j.humpath.2006.09.008"
"24972966","MiR-26a inhibits prostate cancer progression by repression of Wnt5a","Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F, Li L.","Tumour Biol. 2014 Oct;35(10):9725-33. doi: 10.1007/s13277-014-2206-4. Epub 2014 Jun 28.","Zhao S","Tumour Biol","2014","2014/06/29","","","10.1007/s13277-014-2206-4"
"15303500","Trends in the use of androgen deprivation in prostate cancer","Salminen EK, Wickström JE, Vahlberg T, Duchesne GM.","Acta Oncol. 2004;43(4):382-7. doi: 10.1080/02841860410029500.","Salminen EK","Acta Oncol","2004","2004/08/12","","","10.1080/02841860410029500"
"10975492","Deciding on radiation therapy: a patient's perspective","Hilsman WJ.","Semin Urol Oncol. 2000 Aug;18(3):200-4.","Hilsman WJ","Semin Urol Oncol","2000","2000/09/07","","",""
"12743145","Quality-of-care indicators for early-stage prostate cancer","Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS.","J Clin Oncol. 2003 May 15;21(10):1928-36. doi: 10.1200/JCO.2003.05.157.","Spencer BA","J Clin Oncol","2003","2003/05/14","","","10.1200/JCO.2003.05.157"
"28905446","Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy","Tsumura H, Ishiyama H, Tabata KI, Katsumata H, Kobayashi M, Ikeda M, Kurosaka S, Fujita T, Kitano M, Satoh T, Yanagisawa N, Hayakawa K, Iwamura M.","Prostate. 2017 Nov;77(15):1520-1527. doi: 10.1002/pros.23430. Epub 2017 Sep 14.","Tsumura H","Prostate","2017","2017/09/15","","","10.1002/pros.23430"
"25367324","Focal cryotherapy of localized prostate cancer: a systematic review of the literature","Shah TT, Ahmed H, Kanthabalan A, Lau B, Ghei M, Maraj B, Arya M.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1337-47. doi: 10.1586/14737140.2014.965687.","Shah TT","Expert Rev Anticancer Ther","2014","2014/11/05","","","10.1586/14737140.2014.965687"
"30914803","The role of multiparametric MRI in biopsy-naive prostate cancer","Lebastchi AH, Pinto PA.","Nat Rev Urol. 2019 May;16(5):276-277. doi: 10.1038/s41585-019-0173-7.","Lebastchi AH","Nat Rev Urol","2019","2019/03/28","","","10.1038/s41585-019-0173-7"
"25270521","Safety of antiandrogen therapy for treating prostate cancer","Ricci F, Buzzatti G, Rubagotti A, Boccardo F.","Expert Opin Drug Saf. 2014 Nov;13(11):1483-99. doi: 10.1517/14740338.2014.966686. Epub 2014 Oct 1.","Ricci F","Expert Opin Drug Saf","2014","2014/10/02","","","10.1517/14740338.2014.966686"
"14563434","Myths and fallacies in permanent prostate brachytherapy","Butler WM, Merrick GS.","Med Dosim. 2003 Fall;28(3):155-65. doi: 10.1016/S0958-3947(03)00066-9.","Butler WM","Med Dosim","2003","2003/10/18","","","10.1016/S0958-3947(03)00066-9"
"7542033","Prostate cancer screening (United States)","Waterbor JW, Bueschen AJ.","Cancer Causes Control. 1995 May;6(3):267-74. doi: 10.1007/BF00051798.","Waterbor JW","Cancer Causes Control","1995","1995/05/01","","","10.1007/BF00051798"
"26699965","Re: Course and Predictors of Cognitive Function in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison","Penson DF.","J Urol. 2016 Jan;195(1):97. doi: 10.1016/j.juro.2015.10.038. Epub 2015 Nov 19.","Penson DF","J Urol","2016","2015/12/25","","","10.1016/j.juro.2015.10.038"
"26088730","Re: The Impact of Definitive Local Therapy for Lymph Node-positive Prostate Cancer: A Population-based Study","Bossi A.","Eur Urol. 2015 Jul;68(1):161. doi: 10.1016/j.eururo.2015.03.052.","Bossi A","Eur Urol","2015","2015/06/20","","","10.1016/j.eururo.2015.03.052"
"18669477","Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials","Roach M 3rd.","J Clin Oncol. 2008 Aug 1;26(22):3816-7; author reply 3817-8. doi: 10.1200/JCO.2008.17.9879.","Roach M 3rd","J Clin Oncol","2008","2008/08/02","","","10.1200/JCO.2008.17.9879"
"21137672","A case-control study of risk factors for prostate cancer in Iran","Hosseini M, SeyedAlinaghi S, Mahmoudi M, McFarland W.","Acta Med Iran. 2010 Jan-Feb;48(1):61-6.","Hosseini M","Acta Med Iran","2010","2010/12/09","","",""
"26923217","Impact of a brief exercise program on the physical and psychosocial health of prostate cancer survivors: A pilot study","Skinner TL, Peeters GG, Croci I, Bell KR, Burton NW, Chambers SK, Bolam KA.","Asia Pac J Clin Oncol. 2016 Sep;12(3):225-34. doi: 10.1111/ajco.12474. Epub 2016 Feb 28.","Skinner TL","Asia Pac J Clin Oncol","2016","2016/03/01","","","10.1111/ajco.12474"
"9610570","Granins and prostate cancer","Deftos LJ, Abrahamsson PA.","Urology. 1998 May;51(5A Suppl):141-5. doi: 10.1016/s0090-4295(98)00062-4.","Deftos LJ","Urology","1998","1998/06/04","","","10.1016/s0090-4295(98)00062-4"
"29420977","Technique of Multiparametric MR Imaging of the Prostate","Purysko AS, Rosenkrantz AB.","Radiol Clin North Am. 2018 Mar;56(2):211-222. doi: 10.1016/j.rcl.2017.10.004. Epub 2017 Dec 6.","Purysko AS","Radiol Clin North Am","2018","2018/02/09","","","10.1016/j.rcl.2017.10.004"
"10776173","Prostate cancer elder alert. Living with treatment choices and outcomes","Pickett M, Bruner DW, Joseph A, Burggraf V.","J Gerontol Nurs. 2000 Feb;26(2):22-34; quiz 54-5. doi: 10.3928/0098-9134-20000201-11.","Pickett M","J Gerontol Nurs","2000","2000/04/25","","","10.3928/0098-9134-20000201-11"
"24967466","[Population-based analysis of complications after local therapy for prostate cancer. Prostatectomy versus radiotherapy]","Eble MJ.","Strahlenther Onkol. 2014 Jun;190(6):594-6. doi: 10.1007/s00066-014-0665-6.","Eble MJ","Strahlenther Onkol","2014","2014/06/27","","","10.1007/s00066-014-0665-6"
"18768497","Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey","Skinner HG, Schwartz GG.","Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2302-5. doi: 10.1158/1055-9965.EPI-08-0365.","Skinner HG","Cancer Epidemiol Biomarkers Prev","2008","2008/09/05","PMC2760313","NIHMS143964","10.1158/1055-9965.EPI-08-0365"
"28898333","[Usefulness of imaging studies in prostate cancer: Analysis of 241 patients]","Martínez M N, Calvo C, Ibarra Á, Ramos C, Zambrano N.","Rev Med Chil. 2017 May;145(5):579-584. doi: 10.4067/S0034-98872017000500004.","Martínez M N","Rev Med Chil","2017","2017/09/13","","","10.4067/S0034-98872017000500004"
"9635693","Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer: will more prove better?","Schellhammer PF.","Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):489-90. doi: 10.1016/s0360-3016(98)00090-x.","Schellhammer PF","Int J Radiat Oncol Biol Phys","1998","1998/07/04","","","10.1016/s0360-3016(98)00090-x"
"30648824","Role of Adiponectin in prostate cancer","Hu X, Hu C, Zhang C, Zhang M, Long S, Cao Z.","Int Braz J Urol. 2019 Mar-Apr;45(2):220-228. doi: 10.1590/S1677-5538.IBJU.2018.0261.","Hu X","Int Braz J Urol","2019","2019/01/17","PMC6541146","","10.1590/S1677-5538.IBJU.2018.0261"
"14722588","Describing a nurse case manager intervention to empower low-income men with prostate cancer","Maliski SL, Clerkin B, Litwin MS.","Oncol Nurs Forum. 2004 Jan-Feb;31(1):57-64. doi: 10.1188/04.ONF.57-64.","Maliski SL","Oncol Nurs Forum","2004","2004/01/15","","","10.1188/04.ONF.57-64"
"8583584","Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis","Lerner SE, Seay TM, Blute ML, Bergstralh EJ, Barrett D, Zincke H.","J Urol. 1996 Mar;155(3):821-6.","Lerner SE","J Urol","1996","1996/03/01","","",""
"25764118","Active surveillance for low-risk prostate cancer","Klotz L.","Curr Urol Rep. 2015 Apr;16(4):24. doi: 10.1007/s11934-015-0492-z.","Klotz L","Curr Urol Rep","2015","2015/03/13","","","10.1007/s11934-015-0492-z"
"19423541","Established prostate cancer susceptibility variants are not associated with disease outcome","Wiklund FE, Adami HO, Zheng SL, Stattin P, Isaacs WB, Grönberg H, Xu J.","Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1659-62. doi: 10.1158/1055-9965.EPI-08-1148.","Wiklund FE","Cancer Epidemiol Biomarkers Prev","2009","2009/05/09","PMC3353269","NIHMS374262","10.1158/1055-9965.EPI-08-1148"
"23704282","Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification","Schoenborn JR, Nelson P, Fang M.","Clin Cancer Res. 2013 Aug 1;19(15):4058-66. doi: 10.1158/1078-0432.CCR-12-3606. Epub 2013 May 23.","Schoenborn JR","Clin Cancer Res","2013","2013/05/25","PMC3732571","NIHMS480397","10.1158/1078-0432.CCR-12-3606"
"8270375","Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer","Kubota Y, Nakada T, Suzuki Y, Iizima Y, Adachi Y, Hashimoto T.","Int Urol Nephrol. 1993;25(5):469-74.","Kubota Y","Int Urol Nephrol","1993","1993/01/01","","",""
"11325208","Impotence-free hormonal treatment of prostate cancer","Mathé G.","Biomed Pharmacother. 2001 Apr;55(3):127-9. doi: 10.1016/s0753-3322(01)00048-8.","Mathé G","Biomed Pharmacother","2001","2001/04/28","","","10.1016/s0753-3322(01)00048-8"
"11299802","Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer","Kanoh Y, Ohtani N, Mashiko T, Ohtani S, Nishikawa T, Egawa S, Baba S, Ohtani H.","Anticancer Res. 2001 Jan-Feb;21(1B):551-6.","Kanoh Y","Anticancer Res","2001","2001/04/13","","",""
"21819532","Comparison of real-time elastography with grey-scale ultrasonography for detection of organ-confined prostate cancer and extra capsular extension: a prospective analysis using whole mount sections after radical prostatectomy","Brock M, von Bodman C, Sommerer F, Löppenberg B, Klein T, Deix T, Palisaar JR, Noldus J, Eggert T.","BJU Int. 2011 Oct;108(8 Pt 2):E217-22. doi: 10.1111/j.1464-410X.2011.10209.x. Epub 2011 Aug 5.","Brock M","BJU Int","2011","2011/08/09","","","10.1111/j.1464-410X.2011.10209.x"
"20381846","Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer","Corcoran AT, Peele PB, Benoit RM.","Urology. 2010 Sep;76(3):703-7. doi: 10.1016/j.urology.2009.12.071. Epub 2010 Apr 9.","Corcoran AT","Urology","2010","2010/04/13","","","10.1016/j.urology.2009.12.071"
"15490814","Early onset of prostate cancer in a patient with common variable immunodeficiency","Mohammed I.","Clin Oncol (R Coll Radiol). 2004 Oct;16(7):502. doi: 10.1016/j.clon.2004.06.026.","Mohammed I","Clin Oncol (R Coll Radiol)","2004","2004/10/20","","","10.1016/j.clon.2004.06.026"
"21234867","[Real-time elastography in the diagnosis of prostate cancer: personal experience]","Romagnoli A, Autieri G, Centrella D, Gastaldi C, Pedaci G, Rivolta L, Pozzi E, Anghileri A, Cerabino M, Bianchi CM, Roggia A.","Urologia. 2010 Oct-Dec;77(4):248-53.","Romagnoli A","Urologia","2010","2011/01/15","","",""
"17269618","Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool","Ankerst DP, Thompson IM.","Arch Ital Urol Androl. 2006 Dec;78(4):143-6.","Ankerst DP","Arch Ital Urol Androl","2006","2007/02/03","","",""
"18544985","Hormone therapy for prostate cancer - immediate initiation","Schostak M, Miller K, Schrader M.","Front Radiat Ther Oncol. 2008;41:49-57. doi: 10.1159/000139878.","Schostak M","Front Radiat Ther Oncol","2008","2008/06/12","","","10.1159/000139878"
"31705198","Developments in oligometastatic hormone-sensitive prostate cancer","Tran PT, Ost P.","World J Urol. 2019 Dec;37(12):2545-2547. doi: 10.1007/s00345-019-03009-w.","Tran PT","World J Urol","2019","2019/11/10","","","10.1007/s00345-019-03009-w"
"24957523","[Active surveillance of low risk prostate cancer]","Lellig K, Beyer B, Graefen M, Zaak D, Stief C.","Urologe A. 2014 Jul;53(7):1031-9. doi: 10.1007/s00120-014-3535-z.","Lellig K","Urologe A","2014","2014/06/25","","","10.1007/s00120-014-3535-z"
"9973093","Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial","Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A.","Prostate. 1999 Feb 1;38(2):83-91. doi: 10.1002/(sici)1097-0045(19990201)38:2<83::aid-pros1>3.0.co;2-b.","Labrie F","Prostate","1999","1999/02/11","","","10.1002/(sici)1097-0045(19990201)38:2<83::aid-pros1>3.0.co;2-b"
"12963877","Biochemical recurrence of prostate cancer","Moul JW.","Curr Probl Cancer. 2003 Sep-Oct;27(5):243-72. doi: 10.1016/s0147-0272(03)00032-1.","Moul JW","Curr Probl Cancer","2003","2003/09/10","","","10.1016/s0147-0272(03)00032-1"
"25098707","Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan","Onozawa M, Hinotsu S, Tsukamoto T, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Akaza H.","Jpn J Clin Oncol. 2014 Oct;44(10):969-81. doi: 10.1093/jjco/hyu104. Epub 2014 Aug 6.","Onozawa M","Jpn J Clin Oncol","2014","2014/08/08","","","10.1093/jjco/hyu104"
"26906131","Functional Quality-of-Life Outcomes Reported by Men Treated for Localized Prostate Cancer: A Systematic Literature Review","Baker H, Wellman S, Lavender V.","Oncol Nurs Forum. 2016 Mar;43(2):199-218. doi: 10.1188/16.ONF.199-218.","Baker H","Oncol Nurs Forum","2016","2016/02/25","","","10.1188/16.ONF.199-218"
"28528448","Prostate cancer-related anxiety in long-term survivors after radical prostatectomy","Meissner VH, Herkommer K, Marten-Mittag B, Gschwend JE, Dinkel A.","J Cancer Surviv. 2017 Dec;11(6):800-807. doi: 10.1007/s11764-017-0619-y. Epub 2017 May 21.","Meissner VH","J Cancer Surviv","2017","2017/05/22","","","10.1007/s11764-017-0619-y"
"30990112","Triple treatment of high-risk prostate cancer. A matched cohort study with up to 19 years follow-up comparing survival outcomes after triple treatment and treatment with hormones and radiotherapy","Gunnarsson O, Schelin S, Brudin L, Carlsson S, Damber JE.","Scand J Urol. 2019 Apr-Jun;53(2-3):102-108. doi: 10.1080/21681805.2019.1600580. Epub 2019 Apr 16.","Gunnarsson O","Scand J Urol","2019","2019/04/17","","","10.1080/21681805.2019.1600580"
"25269372","[Update on current care guideline: prostate cancer]","","Duodecim. 2014;130(16):1666-7.","","Duodecim","2014","2014/10/02","","",""
"22335862","Detection of prostate cancer in an ethnically diverse, disadvantaged population with multiple prostate specific antigen measurements before biopsy","Hakimi AA, Agalliu I, Ho GY, Ghavamian R, Yu C, Kattan MW, Rabbani F.","J Urol. 2012 Apr;187(4):1234-40. doi: 10.1016/j.juro.2011.11.090. Epub 2012 Feb 14.","Hakimi AA","J Urol","2012","2012/02/17","","","10.1016/j.juro.2011.11.090"
"22698574","Active surveillance for prostate cancer: a systematic review of the literature","Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS.","Eur Urol. 2012 Dec;62(6):976-83. doi: 10.1016/j.eururo.2012.05.072. Epub 2012 Jun 7.","Dall'Era MA","Eur Urol","2012","2012/06/16","","","10.1016/j.eururo.2012.05.072"
"25518345","[ASC-J9 for castration-resistant prostate cancer]","Yamashita S, Arai Y.","Nihon Rinsho. 2014 Dec;72(12):2126-9.","Yamashita S","Nihon Rinsho","2014","2014/12/19","","",""
"11588841","Benign prostatic hyperplasia and prostate cancer","Guess HA.","Epidemiol Rev. 2001;23(1):152-8. doi: 10.1093/oxfordjournals.epirev.a000782.","Guess HA","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000782"
"23647296","Radiotherapy in the management of prostate cancer after radical prostatectomy","Bartkowiak D, Bottke D, Wiegel T.","Future Oncol. 2013 May;9(5):669-79. doi: 10.2217/fon.13.3.","Bartkowiak D","Future Oncol","2013","2013/05/08","","","10.2217/fon.13.3"
"28269525","Impact of prostate biopsy tumor amount on imaging based prognostics employing transductive semi-supervised regression","Khan FM, Kulikowski CA.","Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:5604-5607. doi: 10.1109/EMBC.2016.7591997.","Khan FM","Annu Int Conf IEEE Eng Med Biol Soc","2016","2017/03/09","","","10.1109/EMBC.2016.7591997"
"22207967","[Epidemiology of prostate cancer in Japan]","Nakata S, Ohtake N, Yamanaka H.","Nihon Rinsho. 2011 Jun;69 Suppl 5:181-6.","Nakata S","Nihon Rinsho","2011","2012/01/03","","",""
"17803183","Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects","Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, Arai Y, Sadilek M, Murayama K, Dell A, Nishimura S, Hakomori SI.","Int J Cancer. 2008 Jan 1;122(1):39-49. doi: 10.1002/ijc.22958.","Fujimura T","Int J Cancer","2008","2007/09/07","","","10.1002/ijc.22958"
"23551612","Contrast-enhanced transrectal ultrasonography: measurement of prostate cancer tumor size and correlation with radical prostatectomy specimens","Qi TY, Chen YQ, Jiang J, Zhu YK, Yao XH, Qi J.","Int J Urol. 2013 Nov;20(11):1085-91. doi: 10.1111/iju.12125. Epub 2013 Mar 31.","Qi TY","Int J Urol","2013","2013/04/05","","","10.1111/iju.12125"
"30641680","Serum insulin level, HOMA-IR and prostate cancer risk: A systematic review and meta-analysis","Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E.","Diabetes Metab Syndr. 2019 Jan-Feb;13(1):110-115. doi: 10.1016/j.dsx.2018.08.031. Epub 2018 Aug 29.","Saboori S","Diabetes Metab Syndr","2019","2019/01/16","","","10.1016/j.dsx.2018.08.031"
"24976538","Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control","Saracino B, Petrongari MG, Marzi S, Bruzzaniti V, Sara G, Arcangeli S, Arcangeli G, Pinnarò P, Giordano C, Ferraro AM, Strigari L.","Cancer Med. 2014 Oct;3(5):1313-21. doi: 10.1002/cam4.278. Epub 2014 Jun 28.","Saracino B","Cancer Med","2014","2014/07/01","PMC4302681","","10.1002/cam4.278"
"21861672","Prostate-specific antigen testing across the spectrum of prostate cancer","Haythorn MR, Ablin RJ.","Biomark Med. 2011 Aug;5(4):515-26. doi: 10.2217/bmm.11.53.","Haythorn MR","Biomark Med","2011","2011/08/25","","","10.2217/bmm.11.53"
"10848695","Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy","Horan AH, McGehee M.","BJU Int. 2000 Jun;85(9):1063-6. doi: 10.1046/j.1464-410x.2000.00658.x.","Horan AH","BJU Int","2000","2000/06/10","","","10.1046/j.1464-410x.2000.00658.x"
"14501724","Serial histopathology results of salvage cryoablation for prostate cancer after radiation failure","Chin JL, Touma N, Pautler SE, Guram KS, Bella AJ, Downey DB, Moussa M.","J Urol. 2003 Oct;170(4 Pt 1):1199-202. doi: 10.1097/01.ju.0000085620.28141.40.","Chin JL","J Urol","2003","2003/09/23","","","10.1097/01.ju.0000085620.28141.40"
"28554776","[Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 7: STUMP (stromal tumor of uncertain malignancy potential) and low grade stromal sarcoma]","Fromont G.","Ann Pathol. 2017 Jun;37(3):254-258. doi: 10.1016/j.annpat.2017.02.007. Epub 2017 May 26.","Fromont G","Ann Pathol","2017","2017/05/31","","","10.1016/j.annpat.2017.02.007"
"20886629","Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153","Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID.","Cancer. 2011 Feb 1;117(3):510-6. doi: 10.1002/cncr.25619. Epub 2010 Sep 30.","Hurwitz MD","Cancer","2011","2010/10/02","PMC3025043","NIHMS230582","10.1002/cncr.25619"
"18176128","Quality of life for members of Swedish Prostate Cancer Patient Associations","Fransson P.","Cancer Nurs. 2008 Jan-Feb;31(1):23-31. doi: 10.1097/01.NCC.0000305671.60469.c9.","Fransson P","Cancer Nurs","2008","2008/01/08","","","10.1097/01.NCC.0000305671.60469.c9"
"9381242","Dimensions of quality of life expressed by men treated for metastatic prostate cancer","Clark JA, Wray N, Brody B, Ashton C, Giesler B, Watkins H.","Soc Sci Med. 1997 Oct;45(8):1299-309. doi: 10.1016/s0277-9536(97)00058-0.","Clark JA","Soc Sci Med","1997","1997/09/25","","","10.1016/s0277-9536(97)00058-0"
"25454616","PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate","Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, Ravi P, Pezaro C, Omlin A, Lorente D, Zafeiriou Z, Mateo J, Altavilla A, Sideris S, Bianchini D, Grist E, Thway K, Perez Lopez R, Tunariu N, Parker C, Dearnaley D, Reid A, Attard G, de Bono J.","Eur Urol. 2015 Apr;67(4):795-802. doi: 10.1016/j.eururo.2014.10.027. Epub 2014 Nov 4.","Ferraldeschi R","Eur Urol","2015","2014/12/03","PMC4410287","","10.1016/j.eururo.2014.10.027"
"18592772","[Retroorbital metastasis in the initial diagnosis of prostate cancer]","Pastor Navarro H, Donate Moreno MJ, Carrión López P, Martínez Ruiz J, Lorenzo Romero JG, Jiménez Bachs JM, Polo Ruiz L, Salinas Sanchez AS, Virseda Rodríguez JA.","Arch Esp Urol. 2008 May;61(4):524-7. doi: 10.4321/s0004-06142008000400010.","Pastor Navarro H","Arch Esp Urol","2008","2008/07/03","","","10.4321/s0004-06142008000400010"
"9860309","Screening for prostate cancer--more questions than answers","Rietbergen JB, Schröder FH.","Acta Oncol. 1998;37(6):515-32. doi: 10.1080/028418698430214.","Rietbergen JB","Acta Oncol","1998","1998/12/22","","","10.1080/028418698430214"
"26012532","Heterogeneous copper concentrations in cancerous human prostate tissues","Denoyer D, Clatworthy SA, Masaldan S, Meggyesy PM, Cater MA.","Prostate. 2015 Oct;75(14):1510-7. doi: 10.1002/pros.23022. Epub 2015 May 27.","Denoyer D","Prostate","2015","2015/05/28","","","10.1002/pros.23022"
"31629433","Germline testing for prostate cancer: community urology perspective","Concepcion RS.","Can J Urol. 2019 Oct;26(5 Suppl 2):50-51.","Concepcion RS","Can J Urol","2019","2019/10/21","","",""
"22258373","[Castration-resistant prostate cancer: surgical and radio-oncological therapeutic options]","Preusser S, Putora PM, Plasswilm L, Schmid HP.","Urologe A. 2012 Jan;51(1):27-31. doi: 10.1007/s00120-011-2742-0.","Preusser S","Urologe A","2012","2012/01/20","","","10.1007/s00120-011-2742-0"
"10664671","Imaging and radiotherapy of the prostate","Speight JL, Roach M 3rd.","Radiol Clin North Am. 2000 Jan;38(1):159-77, ix. doi: 10.1016/s0033-8389(05)70154-8.","Speight JL","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70154-8"
"27636505","Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer","Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A.","Cancer Epidemiol. 2016 Dec;45:1-5. doi: 10.1016/j.canep.2016.08.022. Epub 2016 Sep 14.","Kilpeläinen TP","Cancer Epidemiol","2016","2016/09/17","","","10.1016/j.canep.2016.08.022"
"22349984","A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008","Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ.","Prostate Cancer Prostatic Dis. 2012 Sep;15(3):283-8. doi: 10.1038/pcan.2012.4. Epub 2012 Feb 21.","Marcus DM","Prostate Cancer Prostatic Dis","2012","2012/02/22","","","10.1038/pcan.2012.4"
"1378908","Transrectal microwave hyperthermia for advanced prostate cancer: long-term clinical results","Montorsi F, Guazzoni G, Colombo R, Galli L, Bergamaschi F, Rigatti P.","J Urol. 1992 Aug;148(2 Pt 1):342-5. doi: 10.1016/s0022-5347(17)36589-8.","Montorsi F","J Urol","1992","1992/08/01","","","10.1016/s0022-5347(17)36589-8"
"24061908","Modeling potential time to event data with competing risks","Li L, Hu B, Kattan MW.","Lifetime Data Anal. 2014 Apr;20(2):316-34. doi: 10.1007/s10985-013-9279-z. Epub 2013 Sep 24.","Li L","Lifetime Data Anal","2014","2013/09/25","PMC4197853","NIHMS633615","10.1007/s10985-013-9279-z"
"11249749","Technology evaluation: CN-706, Calydon Inc","Doehn C, Jocham D.","Curr Opin Mol Ther. 2000 Dec;2(6):703-8.","Doehn C","Curr Opin Mol Ther","2000","2001/03/16","","",""
"21360566","Gene expression pathways of high grade localized prostate cancer","Ross AE, Marchionni L, Vuica-Ross M, Cheadle C, Fan J, Berman DM, Schaeffer EM.","Prostate. 2011 Oct 1;71(14):1568-77. doi: 10.1002/pros.21373. Epub 2011 Feb 25.","Ross AE","Prostate","2011","2011/03/02","","","10.1002/pros.21373"
"27166670","Lethal Prostate Cancer in the PLCO Cancer Screening Trial","Shoag J, Mittal S, Halpern JA, Scherr D, Hu JC, Barbieri CE.","Eur Urol. 2016 Jul;70(1):2-5. doi: 10.1016/j.eururo.2016.01.009. Epub 2016 May 7.","Shoag J","Eur Urol","2016","2016/05/12","PMC4909529","NIHMS788780","10.1016/j.eururo.2016.01.009"
"10929996","Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study","Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL.","Med Care. 2000 Aug;38(8):847-57. doi: 10.1097/00005650-200008000-00008.","Legler J","Med Care","2000","2000/08/10","","","10.1097/00005650-200008000-00008"
"28423666","Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death","Mortezavi A, Salemi S, Rupp NJ, Rüschoff JH, Hermanns T, Poyet C, Randazzo M, Simon HU, Moch H, Sulser T, Wild P, Eberli D.","Oncotarget. 2017 May 9;8(19):31765-31774. doi: 10.18632/oncotarget.15986.","Mortezavi A","Oncotarget","2017","2017/04/21","PMC5458246","","10.18632/oncotarget.15986"
"19395188","Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer","Arcangeli G, Strigari L, Arcangeli S, Petrongari MG, Saracino B, Gomellini S, Papalia R, Simone G, De Carli P, Gallucci M.","Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):975-82. doi: 10.1016/j.ijrobp.2008.12.045. Epub 2009 Apr 22.","Arcangeli G","Int J Radiat Oncol Biol Phys","2009","2009/04/28","","","10.1016/j.ijrobp.2008.12.045"
"17594742","Prostate cancer detection: beware of the low PSA","Haas GP.","Can J Urol. 2007 Jun;14(3):3534.","Haas GP","Can J Urol","2007","2007/06/28","","",""
"28939587","Expression and Genetic Variation in Neuroendocrine Signaling Pathways in Lethal and Nonlethal Prostate Cancer among Men Diagnosed with Localized Disease","Lu D, Carlsson J, Penney KL, Davidsson S, Andersson SO, Mucci LA, Valdimarsdóttir U, Andrén O, Fang F, Fall K.","Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1781-1787. doi: 10.1158/1055-9965.EPI-17-0453. Epub 2017 Sep 22.","Lu D","Cancer Epidemiol Biomarkers Prev","2017","2017/09/24","","","10.1158/1055-9965.EPI-17-0453"
"23963533","[The importance of pathology in the German prostate cancer study PREFERE]","Kristiansen G, Stöckle M, Albers P, Schmidberger H, Martus P, Wellek S, Härter M, Bussar-Maatz R, Wiegel T.","Pathologe. 2013 Sep;34(5):449-62. doi: 10.1007/s00292-013-1788-8.","Kristiansen G","Pathologe","2013","2013/08/22","","","10.1007/s00292-013-1788-8"
"31849389","A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure","Muramatsu T, Funahashi Y, Yamamoto A, Sassa N, Matsukawa Y, Gotoh M.","Nagoya J Med Sci. 2019 Nov;81(4):707-710. doi: 10.18999/nagjms.81.4.707.","Muramatsu T","Nagoya J Med Sci","2019","2019/12/19","PMC6892669","","10.18999/nagjms.81.4.707"
"3173497","Long-term results of radical prostatectomy in clinically localized prostate cancer: experience at the Johns Hopkins Hospital","Lepor H, Walsh PC.","NCI Monogr. 1988;(7):117-22.","Lepor H","NCI Monogr","1988","1988/01/01","","",""
"30293231","Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology","Gómez-Caamaño A, González-San Segundo C, Henríquez I, Maldonado X, Zapatero A; Expert Panel for the Consensus on Management of Castration-Resistant Prostate Cancer 2017, Urological Tumours Working Group (URONCOR), Spanish Society of Radiation Oncology (SEOR).","Clin Transl Oncol. 2019 Apr;21(4):420-432. doi: 10.1007/s12094-018-1940-2. Epub 2018 Oct 6.","Gómez-Caamaño A","Clin Transl Oncol","2019","2018/10/08","","","10.1007/s12094-018-1940-2"
"24446691","Editorial comment from Dr Hsiao to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy","Hsiao W.","Int J Urol. 2014 Jun;21(6):584-5. doi: 10.1111/iju.12399. Epub 2014 Jan 21.","Hsiao W","Int J Urol","2014","2014/01/23","","","10.1111/iju.12399"
"24112612","Words of wisdom. Re: Active surveillance for prostate cancer compared with immediate treatment: an economic analysis","Klaassen Z, Wyatt B, Moses KA, Terris MK.","Eur Urol. 2013 Nov;64(5):855. doi: 10.1016/j.eururo.2013.08.039.","Klaassen Z","Eur Urol","2013","2013/10/12","","","10.1016/j.eururo.2013.08.039"
"18811763","Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy?","Lin C, Turner S, Gurney H, Peduto A.","J Med Imaging Radiat Oncol. 2008 Aug;52(4):376-81. doi: 10.1111/j.1440-1673.2008.01973.x.","Lin C","J Med Imaging Radiat Oncol","2008","2008/09/25","","","10.1111/j.1440-1673.2008.01973.x"
"17030406","Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention","Canby-Hagino E, Hernandez J, Brand TC, Thompson I.","Eur Urol. 2007 Jan;51(1):27-33. doi: 10.1016/j.eururo.2006.09.002. Epub 2006 Sep 15.","Canby-Hagino E","Eur Urol","2007","2006/10/13","","","10.1016/j.eururo.2006.09.002"
"19286302","Insignificant prostate cancer and active surveillance: from definition to clinical implications","Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, Stief CG, Schröder F.","Eur Urol. 2009 Jun;55(6):1321-30. doi: 10.1016/j.eururo.2009.02.028. Epub 2009 Mar 6.","Bastian PJ","Eur Urol","2009","2009/03/17","","","10.1016/j.eururo.2009.02.028"
"16857310","Control of prostate cancer by transrectal HIFU in 227 patients","Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard JM, Gelet A.","Eur Urol. 2007 Feb;51(2):381-7. doi: 10.1016/j.eururo.2006.04.012. Epub 2006 May 2.","Poissonnier L","Eur Urol","2007","2006/07/22","","","10.1016/j.eururo.2006.04.012"
"22424666","International variation in prostate cancer incidence and mortality rates","Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F.","Eur Urol. 2012 Jun;61(6):1079-92. doi: 10.1016/j.eururo.2012.02.054. Epub 2012 Mar 8.","Center MM","Eur Urol","2012","2012/03/20","","","10.1016/j.eururo.2012.02.054"
"12084287","Should laparoscopy be the standard approach used for pelvic lymph node dissection?","Kim JC, Gerber GS.","Curr Urol Rep. 2001 Apr;2(2):171-9. doi: 10.1007/s11934-001-0015-y.","Kim JC","Curr Urol Rep","2001","2002/06/27","","","10.1007/s11934-001-0015-y"
"24581188","[Prostate cancer: are we able to diagnose those in need? And are those that are diagnosed and treated those that are effectively in need?]","Palma dos Reis J.","Acta Med Port. 2014 Jan-Feb;27(1):12-4. Epub 2014 Feb 28.","Palma dos Reis J","Acta Med Port","2014","2014/03/04","","",""
"26827990","Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro","Makarević J, Tsaur I, Juengel E, Borgmann H, Nelson K, Thomas C, Bartsch G, Haferkamp A, Blaheta RA.","Life Sci. 2016 Feb 15;147:137-42. doi: 10.1016/j.lfs.2016.01.039. Epub 2016 Jan 29.","Makarević J","Life Sci","2016","2016/02/02","","","10.1016/j.lfs.2016.01.039"
"7516832","Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project","Mettlin C.","Clin Invest Med. 1993 Dec;16(6):440-7.","Mettlin C","Clin Invest Med","1993","1993/12/01","","",""
"25527761","Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study","Wilson KM, Shui IM, Mucci LA, Giovannucci E.","Am J Clin Nutr. 2015 Jan;101(1):173-83. doi: 10.3945/ajcn.114.088716. Epub 2014 Nov 19.","Wilson KM","Am J Clin Nutr","2015","2014/12/21","PMC4266887","","10.3945/ajcn.114.088716"
"25492737","[Prostate cancer screening benefit very low, even after 13 years]","Blanker MH, Noordzij MA.","Ned Tijdschr Geneeskd. 2014;158:A8349.","Blanker MH","Ned Tijdschr Geneeskd","2014","2014/12/11","","",""
"10803317","Capromab Pendetide immunoscintigraphy: connecting the dots for prostate cancer imaging","Manyak MJ.","Cancer Biother Radiopharm. 2000 Apr;15(2):127-30. doi: 10.1089/cbr.2000.15.127.","Manyak MJ","Cancer Biother Radiopharm","2000","2000/05/10","","","10.1089/cbr.2000.15.127"
"25103825","Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation","Mak G, Chin M, Nahar N, De Souza P.","BMC Res Notes. 2014 Aug 8;7:505. doi: 10.1186/1756-0500-7-505.","Mak G","BMC Res Notes","2014","2014/08/09","PMC4266901","","10.1186/1756-0500-7-505"
"22546838","Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer","Fukuma Y, Matsui H, Koike H, Sekine Y, Shechter I, Ohtake N, Nakata S, Ito K, Suzuki K.","Prostate Cancer Prostatic Dis. 2012 Dec;15(4):339-45. doi: 10.1038/pcan.2012.14. Epub 2012 May 1.","Fukuma Y","Prostate Cancer Prostatic Dis","2012","2012/05/02","","","10.1038/pcan.2012.14"
"21788593","Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data","Weiss NS, Hutter CM.","J Natl Cancer Inst. 2011 Aug 17;103(16):1277. doi: 10.1093/jnci/djr262. Epub 2011 Jul 25.","Weiss NS","J Natl Cancer Inst","2011","2011/07/27","","","10.1093/jnci/djr262"
"21091846","Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness","Akaza H.","Cancer Sci. 2011 Jan;102(1):51-6. doi: 10.1111/j.1349-7006.2010.01774.x. Epub 2010 Nov 22.","Akaza H","Cancer Sci","2011","2010/11/25","","","10.1111/j.1349-7006.2010.01774.x"
"29680190","[French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017]","Rozet F, Hennequin C, Mongiat-Artus P, Beuzeboc P, Beauval JB, Cormier L, Fromont-Hankard G, Ouzzane A, Ploussard G, Renard-Penna R, Méjean A.","Prog Urol. 2018 May;28(6):303-306. doi: 10.1016/j.purol.2018.03.006. Epub 2018 Apr 19.","Rozet F","Prog Urol","2018","2018/04/23","","","10.1016/j.purol.2018.03.006"
"1693541","Prostate-specific antigen: questions often asked","Killian CS, Chu TM.","Cancer Invest. 1990;8(1):27-37. doi: 10.3109/07357909009017544.","Killian CS","Cancer Invest","1990","1990/01/01","","","10.3109/07357909009017544"
"31870703","The conflicting role of E2F1 in prostate cancer: A matter of cell context or interpretational flexibility?","Chun JN, Cho M, Park S, So I, Jeon JH.","Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188336. doi: 10.1016/j.bbcan.2019.188336. Epub 2019 Dec 21.","Chun JN","Biochim Biophys Acta Rev Cancer","2020","2019/12/25","","","10.1016/j.bbcan.2019.188336"
"26427561","Evaluation of a supervised multi-modal physical exercise program for prostate cancer survivors in the rehabilitation phase: Rationale and study protocol of the ProCaLife study","Schega L, Törpel A, Hein N, Napiontek A, Wenzel C, Becker T.","Contemp Clin Trials. 2015 Nov;45(Pt B):311-319. doi: 10.1016/j.cct.2015.09.020. Epub 2015 Sep 30.","Schega L","Contemp Clin Trials","2015","2015/10/03","","","10.1016/j.cct.2015.09.020"
"20097584","Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials","Mian BM.","Urol Oncol. 2010 May-Jun;28(3):233-6. doi: 10.1016/j.urolonc.2009.11.011. Epub 2010 Jan 25.","Mian BM","Urol Oncol","2010","2010/01/26","","","10.1016/j.urolonc.2009.11.011"
"25451671","[Intraprostatic calcifications as natural fiducial markers in image-guided radiotherapy for prostate cancer]","Sbai A, Thariat J, Tachfouti N, Pan Q, Lagrange JL.","Cancer Radiother. 2014 Dec;18(8):740-4. doi: 10.1016/j.canrad.2014.07.161. Epub 2014 Oct 19.","Sbai A","Cancer Radiother","2014","2014/12/03","","","10.1016/j.canrad.2014.07.161"
"28856701","Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer","Soekmadji C, Corcoran NM, Oleinikova I, Jovanovic L; Australian Prostate Cancer Collaboration BioResource, Ramm GA, Nelson CC, Jenster G, Russell PJ.","Prostate. 2017 Oct;77(14):1416-1423. doi: 10.1002/pros.23403. Epub 2017 Aug 29.","Soekmadji C","Prostate","2017","2017/09/01","","","10.1002/pros.23403"
"11455213","Early versus deferred hormonal treatment for asymptomatic prostate cancer","Mickisch GH.","Onkologie. 2001 Jun;24(3):214-20. doi: 10.1159/000055083.","Mickisch GH","Onkologie","2001","2001/07/17","","","10.1159/000055083"
"23868288","Audit of rapid access introduction reveals high prevalence of prostate cancer in Western Region","Bolton EM, Kelly BD, Quinlan MR, D'Arcy FT, Azar M, Dowling CM, Power M, McCarthy P, Roche C, Walsh K, Rogers E, Durkan GC.","Ir J Med Sci. 2014 Jun;183(2):173-9. doi: 10.1007/s11845-013-0986-y. Epub 2013 Jul 19.","Bolton EM","Ir J Med Sci","2014","2013/07/23","","","10.1007/s11845-013-0986-y"
"20233818","Screening and detection of breast cancer and prostate cancer","Garnick MB.","JAMA. 2010 Mar 17;303(11):1033; author reply 1033-4. doi: 10.1001/jama.2010.275.","Garnick MB","JAMA","2010","2010/03/18","","","10.1001/jama.2010.275"
"9074905","Adjuvant treatment for failure of local radical therapy","Fourcade RO.","Eur Urol. 1997;31 Suppl 2:11-3; discussion 24-7. doi: 10.1159/000474542.","Fourcade RO","Eur Urol","1997","1997/01/01","","","10.1159/000474542"
"16263011","Should HIV patients be considered a high risk group for the development of prostate cancer?","Quatan N, Nair S, Harrowes F, Hay P.","Ann R Coll Surg Engl. 2005 Nov;87(6):437-8. doi: 10.1308/003588405X60696.","Quatan N","Ann R Coll Surg Engl","2005","2005/11/03","PMC1964137","","10.1308/003588405X60696"
"10052875","The management of PSA failure after radical radiotherapy for localized prostate cancer","Parker CC, Dearnaley DP.","Radiother Oncol. 1998 Nov;49(2):103-10. doi: 10.1016/s0167-8140(98)00107-8.","Parker CC","Radiother Oncol","1998","1999/03/03","","","10.1016/s0167-8140(98)00107-8"
"30869315","[Treatment of metastatic prostate cancer: what recent progress?]","Oudard S, Velev M, Belhadj Y, Vano Y, Thibault C.","Rev Prat. 2018 Sep;68(7):707-712.","Oudard S","Rev Prat","2018","2019/03/15","","",""
"17296374","Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach","Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M.","J Urol. 2007 Mar;177(3):911-5. doi: 10.1016/j.juro.2006.10.040.","Tewari A","J Urol","2007","2007/02/14","","","10.1016/j.juro.2006.10.040"
"32638959","High D-dimer levels are associated with prostate cancer","Kalkan S, Caliskan S.","Rev Assoc Med Bras (1992). 2020 May;66(5):649-653. doi: 10.1590/1806-9282.66.5.649. Epub 2020 Jul 3.","Kalkan S","Rev Assoc Med Bras (1992)","2020","2020/07/09","","","10.1590/1806-9282.66.5.649"
"16533428","Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo","Loberg RD, Day LL, Dunn R, Kalikin LM, Pienta KJ.","Neoplasia. 2006 Jan;8(1):69-78. doi: 10.1593/neo.05679.","Loberg RD","Neoplasia","2006","2006/03/15","PMC1584292","","10.1593/neo.05679"
"30337500","A single-nucleotide polymorphism (rs1805087) in the methionine synthase (METH) gene increases the risk of prostate cancer","Zhang X, Tang J, Shen N, Ren K.","Aging (Albany NY). 2018 Oct 18;10(10):2741-2754. doi: 10.18632/aging.101584.","Zhang X","Aging (Albany NY)","2018","2018/10/20","PMC6224252","","10.18632/aging.101584"
"17559131","Locally advanced prostate cancer: biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy","Rocco B, Scardino E, de Cobelli O.","Cancer. 2007 Jul 15;110(2):467-8; author reply 468. doi: 10.1002/cncr.22802.","Rocco B","Cancer","2007","2007/06/15","","","10.1002/cncr.22802"
"8262117","Staging and prognosis of prostate cancer","Denis LJ.","Eur Urol. 1993;24 Suppl 2:13-8. doi: 10.1159/000474381.","Denis LJ","Eur Urol","1993","1993/01/01","","","10.1159/000474381"
"19352395","Pathologic basis of focal therapy for early-stage prostate cancer","Mouraviev V, Mayes JM, Polascik TJ.","Nat Rev Urol. 2009 Apr;6(4):205-15. doi: 10.1038/nrurol.2009.29.","Mouraviev V","Nat Rev Urol","2009","2009/04/09","","","10.1038/nrurol.2009.29"
"19050692","Prostate cancer: diagnosis and staging","Borley N, Feneley MR.","Asian J Androl. 2009 Jan;11(1):74-80. doi: 10.1038/aja.2008.19. Epub 2008 Dec 1.","Borley N","Asian J Androl","2009","2008/12/04","PMC3735216","","10.1038/aja.2008.19"
"16788786","[Innovative approaches in prostate cancer ultrasound]","Loch T.","Urologe A. 2006 Jun;45(6):692, 694-8, 700-1. doi: 10.1007/s00120-006-1089-4.","Loch T","Urologe A","2006","2006/06/22","","","10.1007/s00120-006-1089-4"
"26119671","Age is Associated with Upgrading at Confirmatory Biopsy among Men with Prostate Cancer Treated with Active Surveillance","Anderson CB, Sternberg IA, Karen-Paz G, Kim PH, Sjoberg D, Vargas HA, Touijer K, Eastham JA, Ehdaie B.","J Urol. 2015 Dec;194(6):1607-11. doi: 10.1016/j.juro.2015.06.084. Epub 2015 Jun 26.","Anderson CB","J Urol","2015","2015/06/30","","","10.1016/j.juro.2015.06.084"
"21991967","Radiotherapy and androgen deprivation for prostate cancer","Créhange G, Bolla M, Maingon P.","N Engl J Med. 2011 Oct 6;365(14):1354; author reply 1354-5. doi: 10.1056/NEJMc1109225.","Créhange G","N Engl J Med","2011","2011/10/14","","","10.1056/NEJMc1109225"
"6669688","[Computer tomography in topometric irradiation planning in prostate cancer]","Merkle K, Tkachev SI, Molchanov GV.","Radiobiol Radiother (Berl). 1983;24(6):779-89.","Merkle K","Radiobiol Radiother (Berl)","1983","1983/01/01","","",""
"28222223","Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, Kattan MW, Lin DW.","CA Cancer J Clin. 2017 May 6;67(3):245-253. doi: 10.3322/caac.21391. Epub 2017 Feb 21.","Buyyounouski MK","CA Cancer J Clin","2017","2017/02/22","PMC6375094","NIHMS1005432","10.3322/caac.21391"
"16904843","Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer","Zeliadt SB, Potosky AL, Penson DF, Etzioni R.","Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):395-402. doi: 10.1016/j.ijrobp.2006.04.048. Epub 2006 Aug 14.","Zeliadt SB","Int J Radiat Oncol Biol Phys","2006","2006/08/15","","","10.1016/j.ijrobp.2006.04.048"
"19024375","[Localized prostatic cancer: treatment exclusive by radiotherapy guided by imagery, experiences in Luxembourg in 2005 and 2006]","Untereiner M, Renard-Oldrini S, Mecellem H, Burie D, Lassen Y, Phy RR, Phy SJ, Phy LH.","Bull Soc Sci Med Grand Duche Luxemb. 2008;(4):559-64.","Untereiner M","Bull Soc Sci Med Grand Duche Luxemb","2008","2008/11/26","","",""
"18777953","Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer","Bittner N, Merrick GS, Wallner KE, Butler WM.","Oncology (Williston Park). 2008 Aug;22(9):995-1004; discussion 1006, 1011-7.","Bittner N","Oncology (Williston Park)","2008","2008/09/10","","",""
"11344767","Relationship between prostate size and percent free prostate-specific antigen in patients with operable prostate cancer","Nativ O, Sabo E, Wald M, Halachmi S, Moskovitz B.","Isr Med Assoc J. 2000 Dec;2(12):889-91.","Nativ O","Isr Med Assoc J","2000","2001/05/10","","",""
"30580007","Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer","Chang EM, Punglia RS, Steinberg ML, Raldow AC.","Urology. 2019 Apr;126:89-95. doi: 10.1016/j.urology.2018.12.016. Epub 2018 Dec 21.","Chang EM","Urology","2019","2018/12/24","","","10.1016/j.urology.2018.12.016"
"2201039","Overview of hormonal therapy for prostate cancer","Carter HB, Isaacs JT.","Prog Clin Biol Res. 1990;350:129-40.","Carter HB","Prog Clin Biol Res","1990","1990/01/01","","",""
"21940734","Adjuvant radiotherapy for a prostate cancer after renal transplantation and review of the literature","Detti B, Scoccianti S, Franceschini D, Villari D, Greto D, Cipressi S, Sardaro A, Zanassi M, Cai T, Biti G.","Jpn J Clin Oncol. 2011 Nov;41(11):1282-6. doi: 10.1093/jjco/hyr133. Epub 2011 Sep 22.","Detti B","Jpn J Clin Oncol","2011","2011/09/24","","","10.1093/jjco/hyr133"
"31465841","Long non-coding RNAs in prostate cancer: Functional roles and clinical implications","Xu YH, Deng JL, Wang G, Zhu YS.","Cancer Lett. 2019 Nov 1;464:37-55. doi: 10.1016/j.canlet.2019.08.010. Epub 2019 Aug 26.","Xu YH","Cancer Lett","2019","2019/08/30","","","10.1016/j.canlet.2019.08.010"
"17714047","No less a man: reconstructing identity after prostate cancer","Bokhour BG, Powel LL, Clark JA.","Commun Med. 2007;4(1):99-109. doi: 10.1515/CAM.2007.010.","Bokhour BG","Commun Med","2007","2007/08/24","","","10.1515/CAM.2007.010"
"25264337","Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: implications for targeted biopsies and active surveillance protocols","Boehm K, Salomon G, Beyer B, Schiffmann J, Simonis K, Graefen M, Budaeus L.","J Urol. 2015 Mar;193(3):794-800. doi: 10.1016/j.juro.2014.09.100. Epub 2014 Sep 28.","Boehm K","J Urol","2015","2014/09/30","","","10.1016/j.juro.2014.09.100"
"23128896","Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer","Singer A, Deuse Y, Koch U, Hölscher T, Pfitzmann D, Jakob C, Hehlgans S, Baretton GB, Rentsch A, Baumann M, Muders MH, Krause M.","Strahlenther Onkol. 2012 Dec;188(12):1125-32. doi: 10.1007/s00066-012-0228-7. Epub 2012 Nov 7.","Singer A","Strahlenther Onkol","2012","2012/11/07","","","10.1007/s00066-012-0228-7"
"27830286","[TNM-Classification of localized prostate cancer : The clinical T-category does not correspond to the required demands]","Herden J, Heidenreich A, Weißbach L.","Urologe A. 2016 Dec;55(12):1564-1572. doi: 10.1007/s00120-016-0264-5.","Herden J","Urologe A","2016","2016/11/11","","","10.1007/s00120-016-0264-5"
"19885309","Multidisciplinary functional MR imaging for prostate cancer","Kim JK, Jang YJ, Cho G.","Korean J Radiol. 2009 Nov-Dec;10(6):535-51. doi: 10.3348/kjr.2009.10.6.535.","Kim JK","Korean J Radiol","2009","2009/11/04","PMC2770824","","10.3348/kjr.2009.10.6.535"
"16136515","Hepatocyte growth factor/scatter factor and prostate cancer: a review","Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG.","Histol Histopathol. 2005 Oct;20(4):1339-49. doi: 10.14670/HH-20.1339.","Hurle RA","Histol Histopathol","2005","2005/09/02","","","10.14670/HH-20.1339"
"24791889","Prostate cancer antigen 3 test for prostate biopsy decision: a systematic review and meta analysis","Luo Y, Gou X, Huang P, Mou C.","Chin Med J (Engl). 2014;127(9):1768-74.","Luo Y","Chin Med J (Engl)","2014","2014/05/06","","",""
"15072602","Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer","Reddy GK.","Clin Prostate Cancer. 2004 Mar;2(4):209-11. doi: 10.1016/s1540-0352(11)70046-4.","Reddy GK","Clin Prostate Cancer","2004","2004/04/10","","","10.1016/s1540-0352(11)70046-4"
"20303152","Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL","Kim HS, Jeon SS, Choi JD, Kim W, Han DH, Jeong BC, Seo SI, Lee KS, Lee SW, Lee HM, Choi HY.","Urology. 2010 Oct;76(4):919-22. doi: 10.1016/j.urology.2009.12.036. Epub 2010 Mar 29.","Kim HS","Urology","2010","2010/03/23","","","10.1016/j.urology.2009.12.036"
"15879895","Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?","Hoeltl W, Müller MM, Lunglmayr G.","J Urol. 2005 Jun;173(6):2205; author reply 2205-6. doi: 10.1016/s0022-5347(05)60291-1.","Hoeltl W","J Urol","2005","2005/05/10","","","10.1016/s0022-5347(05)60291-1"
"22190655","MR imaging of treated prostate cancer","Vargas HA, Wassberg C, Akin O, Hricak H.","Radiology. 2012 Jan;262(1):26-42. doi: 10.1148/radiol.11101996.","Vargas HA","Radiology","2012","2011/12/23","PMC6940010","","10.1148/radiol.11101996"
"26118565","Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective","Baum N, Levy J.","Postgrad Med. 2015 Aug;127(6):654-9. doi: 10.1080/00325481.2015.1059248. Epub 2015 Jun 29.","Baum N","Postgrad Med","2015","2015/06/30","","","10.1080/00325481.2015.1059248"
"21944097","A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance","O'Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J.","J Urol. 2011 Nov;186(5):1811-7. doi: 10.1016/j.juro.2011.06.060. Epub 2011 Sep 25.","O'Brien BA","J Urol","2011","2011/09/28","","","10.1016/j.juro.2011.06.060"
"1371233","The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project","Babaian RJ, Mettlin C, Kane R, Murphy GP, Lee F, Drago JR, Chesley A.","Cancer. 1992 Mar 1;69(5):1195-200. doi: 10.1002/cncr.2820690521.","Babaian RJ","Cancer","1992","1992/03/01","","","10.1002/cncr.2820690521"
"25381855","Men and the challenge of prostate cancer","Nyatanga B.","Br J Community Nurs. 2014 Nov;19(11):560, 562. doi: 10.12968/bjcn.2014.19.11.560.","Nyatanga B","Br J Community Nurs","2014","2014/11/11","","","10.12968/bjcn.2014.19.11.560"
"9236904","Steroid hormones and cancer: IV. Prostate cancer","Habib FK.","Eur J Surg Oncol. 1997 Jun;23(3):264-8. doi: 10.1016/s0748-7983(97)92604-4.","Habib FK","Eur J Surg Oncol","1997","1997/06/01","","","10.1016/s0748-7983(97)92604-4"
"15187052","Natural history of early, localized prostate cancer","Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO.","JAMA. 2004 Jun 9;291(22):2713-9. doi: 10.1001/jama.291.22.2713.","Johansson JE","JAMA","2004","2004/06/10","","","10.1001/jama.291.22.2713"
"17303324","Molecular markers for prostate cancer","Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H.","Cancer Lett. 2007 Apr 28;249(1):5-13. doi: 10.1016/j.canlet.2006.12.029. Epub 2007 Feb 15.","Reynolds MA","Cancer Lett","2007","2007/02/17","","","10.1016/j.canlet.2006.12.029"
"21365235","Use of testosterone replacement therapy in patients with prostate cancer","Dorff TB, Vogelzang NJ.","Curr Urol Rep. 2011 Jun;12(3):223-8. doi: 10.1007/s11934-011-0176-2.","Dorff TB","Curr Urol Rep","2011","2011/03/03","","","10.1007/s11934-011-0176-2"
"12677777","[Clinical surveillance after surgery for prostate cancer]","Guercio S, Terrone C, Scarpa RM.","Recenti Prog Med. 2003 Mar;94(3):110-3.","Guercio S","Recenti Prog Med","2003","2003/04/08","","",""
"24561678","Unexpected diagnosis of peripheral schwannoma on 18F-fluoroethylcholine PET/CT for localization of prostate cancer recurrence and biopsy under real-time PET/ultrasound fusion guidance","Freesmeyer M, Drescher R, Winkens T.","Clin Nucl Med. 2014 Apr;39(4):385-6. doi: 10.1097/RLU.0000000000000375.","Freesmeyer M","Clin Nucl Med","2014","2014/02/25","","","10.1097/RLU.0000000000000375"
"2441583","Prostate cancer: new hope for early diagnosis","Cooner WH, Eggers GW, Lichtenstein P.","Ala Med. 1987 Jun;56(12):13-6.","Cooner WH","Ala Med","1987","1987/06/01","","",""
"21477737","Re: Kim et al.: detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/ml (Urology 2010;76:919-922)","Shenoy SP, Marla PK, Adappa KK.","Urology. 2011 Apr;77(4):1013-4; author reply 1014. doi: 10.1016/j.urology.2010.11.051.","Shenoy SP","Urology","2011","2011/04/12","","","10.1016/j.urology.2010.11.051"
"22822591","Abiraterone. After prostate cancer treatment failure: 4-month survival advantage","","Prescrire Int. 2012 Jun;21(128):147-9.","","Prescrire Int","2012","2012/07/25","","",""
"23793763","Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets","Mellado B, Marin Aguilera M, Pereira MV.","Arch Esp Urol. 2013 Jun;66(5):453-62.","Mellado B","Arch Esp Urol","2013","2013/06/25","","",""
"11114594","Radical prostatectomy: options and issues","Huland H.","Eur Urol. 2001;39 Suppl 1:3-9. doi: 10.1159/000052543.","Huland H","Eur Urol","2001","2000/12/15","","","10.1159/000052543"
"19185981","Functional magnetic resonance imaging in prostate cancer","Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A.","Eur Urol. 2009 Apr;55(4):801-14. doi: 10.1016/j.eururo.2009.01.027. Epub 2009 Jan 21.","Seitz M","Eur Urol","2009","2009/02/03","","","10.1016/j.eururo.2009.01.027"
"9243460","Prostate simulation made easy","Duncan E, Reed WR.","Med Dosim. 1997 Summer;22(2):91-4. doi: 10.1016/s0958-3947(97)00006-x.","Duncan E","Med Dosim","1997","1997/07/01","","","10.1016/s0958-3947(97)00006-x"
"16563092","Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model","Habuchi T.","Future Oncol. 2006 Apr;2(2):233-45. doi: 10.2217/14796694.2.2.233.","Habuchi T","Future Oncol","2006","2006/03/28","","","10.2217/14796694.2.2.233"
"7504744","Prostate cancer","Cooner WH.","J Urol. 1994 Jan;151(1):103-4. doi: 10.1016/s0022-5347(17)34881-4.","Cooner WH","J Urol","1994","1994/01/01","","","10.1016/s0022-5347(17)34881-4"
"15762353","Treatment options in hormone-refractory metastatic prostate carcinoma","Fusi A, Procopio G, Della Torre S, Ricotta R, Bianchini G, Salvioni R, Ferrari L, Martinetti A, Savelli G, Villa S, Bajetta E.","Tumori. 2004 Nov-Dec;90(6):535-46.","Fusi A","Tumori","2004","2005/03/15","","",""
"18759701","Salvage laparoscopic surgery in advanced prostate cancer: is it possible or beneficial?","Patel HR, Amodeo A, Joseph JV.","Expert Rev Anticancer Ther. 2008 Sep;8(9):1509-13. doi: 10.1586/14737140.8.9.1509.","Patel HR","Expert Rev Anticancer Ther","2008","2008/09/02","","","10.1586/14737140.8.9.1509"
"19796750","Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target","Chen Y, Clegg NJ, Scher HI.","Lancet Oncol. 2009 Oct;10(10):981-91. doi: 10.1016/S1470-2045(09)70229-3.","Chen Y","Lancet Oncol","2009","2009/10/03","PMC2935850","NIHMS189415","10.1016/S1470-2045(09)70229-3"
"16678058","The use of thalidomide in androgen-independent prostate cancer","Cox MC, Dahut WL, Figg WD.","Urol Oncol. 2006 May-Jun;24(3):246-9. doi: 10.1016/j.urolonc.2005.11.020.","Cox MC","Urol Oncol","2006","2006/05/09","","","10.1016/j.urolonc.2005.11.020"
"12757602","Significance of capsular attachment and invasion of cancer tissues in prostate cancer","Tanaka M, Suzuki N, Nakatsu H, Murakami S, Matsuzaki O, Shimazaki J.","Int J Urol. 2003 Jun;10(6):309-14. doi: 10.1046/j.1442-2042.2003.00630.x.","Tanaka M","Int J Urol","2003","2003/05/22","","","10.1046/j.1442-2042.2003.00630.x"
"1984304","Nonpalpable cancer of the prostate: assessment with transrectal US","Lee F Jr, Bronson JP, Lee F, Torp-Pedersen ST, Siders DB, Thornbury JR, McHugh TA.","Radiology. 1991 Jan;178(1):197-9. doi: 10.1148/radiology.178.1.1984304.","Lee F Jr","Radiology","1991","1991/01/11","","","10.1148/radiology.178.1.1984304"
"18025613","Radiation therapy for prostate cancer: the role for dose escalation","Swartz MJ, Janson K, Deweese TL, Song DY.","Compr Ther. 2007 Winter;33(4):216-22. doi: 10.1007/s12019-007-8014-7.","Swartz MJ","Compr Ther","2007","2007/11/21","","","10.1007/s12019-007-8014-7"
"8197932","Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review","Oosterlinck W, Mast P.","Acta Urol Belg. 1994 Apr;62(1):67-71.","Oosterlinck W","Acta Urol Belg","1994","1994/04/01","","",""
"10763396","The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model","Grover SA, Coupal L, Zowall H, Rajan R, Trachtenberg J, Elhilali M, Chetner M, Goldenberg L.","CMAJ. 2000 Apr 4;162(7):987-92.","Grover SA","CMAJ","2000","2000/04/14","PMC1232350","",""
"23122038","Role of transrectal ultrasonography in prostate cancer","Ghai S, Toi A.","Radiol Clin North Am. 2012 Nov;50(6):1061-73. doi: 10.1016/j.rcl.2012.08.007.","Ghai S","Radiol Clin North Am","2012","2012/11/06","","","10.1016/j.rcl.2012.08.007"
"18603349","Re: Fritz H. Schröder. Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms. Eur Urol 2008;53:1129-37","Drewa T.","Eur Urol. 2009 Jan;55(1):e6-7; author reply e8-9. doi: 10.1016/j.eururo.2008.06.066. Epub 2008 Jun 26.","Drewa T","Eur Urol","2009","2008/07/08","","","10.1016/j.eururo.2008.06.066"
"26939174","[Localized prostate cancer: detection, check-up and treatment]","Iselin CE.","Rev Med Suisse. 2016 Jan 27;12(503):184-5.","Iselin CE","Rev Med Suisse","2016","2016/03/05","","",""
"10069259","A case-cohort study on prostate cancer risk in relation to family history of prostate cancer","Schuurman AG, Zeegers MP, Goldbohm RA, van den Brandt PA.","Epidemiology. 1999 Mar;10(2):192-5.","Schuurman AG","Epidemiology","1999","1999/03/09","","",""
"26111708","Prostate Cancer Metastases to Inguinal Lymph Nodes Detected by Attenuation-Corrected 11C-Acetate PET/CT","Shah VA, Rixey A, Dusing R.","J Nucl Med Technol. 2016 Mar;44(1):46-8. doi: 10.2967/jnmt.115.157594. Epub 2015 Jun 25.","Shah VA","J Nucl Med Technol","2016","2015/06/27","","","10.2967/jnmt.115.157594"
"22751444","Updated results from the European Randomized Study of Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: are Asian countries encouraged to promote PSA screening?","Sugimoto M, Kakehi Y.","Asian J Androl. 2012 Jul;14(4):522-4. doi: 10.1038/aja.2012.50. Epub 2012 Jun 18.","Sugimoto M","Asian J Androl","2012","2012/07/04","PMC3720072","","10.1038/aja.2012.50"
"18220234","Tumor-stroma interactions of metastatic prostate cancer cell lines: analyses using microarrays","Wernert N, Kaminski A, Haddouti el-M, Hahne JC.","Methods Mol Biol. 2007;382:223-37. doi: 10.1007/978-1-59745-304-2_14.","Wernert N","Methods Mol Biol","2007","2008/01/29","","","10.1007/978-1-59745-304-2_14"
"17578342","The clinical applications of high intensity focused ultrasound in the prostate","Illing R, Chapman A.","Int J Hyperthermia. 2007 Mar;23(2):183-91. doi: 10.1080/02656730601173037.","Illing R","Int J Hyperthermia","2007","2007/06/21","","","10.1080/02656730601173037"
"19050685","Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China","Zhang L, Wu S, Guo LR, Zhao XJ.","Asian J Androl. 2009 Jan;11(1):9-13. doi: 10.1038/aja.2008.21. Epub 2008 Dec 1.","Zhang L","Asian J Androl","2009","2008/12/04","PMC3735220","","10.1038/aja.2008.21"
"30993852","Effect of genetic variants in cell adhesion pathways on the biochemical recurrence in prostate cancer patients with radical prostatectomy","Yu CC, Chen LC, Lin VC, Huang CY, Cheng WC, Hsieh AR, Chang TY, Lu TL, Lee CH, Huang SP, Bao BY.","Cancer Med. 2019 Jun;8(6):2777-2783. doi: 10.1002/cam4.2163. Epub 2019 Apr 16.","Yu CC","Cancer Med","2019","2019/04/18","PMC6558504","","10.1002/cam4.2163"
"22522500","Experimental therapeutics in prostate cancer: where are we now and where do we need to go","Sartor O.","Asian J Androl. 2012 May;14(3):421-2. doi: 10.1038/aja.2012.36. Epub 2012 Apr 23.","Sartor O","Asian J Androl","2012","2012/04/24","PMC3720170","","10.1038/aja.2012.36"
"7754280","Anatomy of the prostate and distribution of early prostate cancer","Greene DR, Fitzpatrick JM, Scardino PT.","Semin Surg Oncol. 1995 Jan-Feb;11(1):9-22. doi: 10.1002/ssu.2980110104.","Greene DR","Semin Surg Oncol","1995","1995/01/01","","","10.1002/ssu.2980110104"
"31021584","Super active surveillance for low-risk prostate cancer | Opinion: Yes","Reis LO, Andrade DL, Bianco FJ Jr.","Int Braz J Urol. 2019 Mar-Apr;45(2):210-214. doi: 10.1590/S1677-5538.IBJU.2019.02.02.","Reis LO","Int Braz J Urol","2019","2019/04/26","PMC6541119","","10.1590/S1677-5538.IBJU.2019.02.02"
"9240638","Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?","Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA.","Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9. doi: 10.1016/s0360-3016(97)00123-5.","Keyser D","Int J Radiat Oncol Biol Phys","1997","1997/07/01","","","10.1016/s0360-3016(97)00123-5"
"18550100","A critical review of clinical practice guidelines for the management of clinically localized prostate cancer","Dahm P, Yeung LL, Chang SS, Cookson MS.","J Urol. 2008 Aug;180(2):451-9; discussion 460. doi: 10.1016/j.juro.2008.04.004. Epub 2008 Jun 11.","Dahm P","J Urol","2008","2008/06/14","","","10.1016/j.juro.2008.04.004"
"16735373","Monotherapy with carbon ion radiation for localized prostate cancer","Shimazaki J, Akakura K, Suzuki H, Ichikawa T, Tsuji H, Ishikawa H, Harada M, Tsujii H.","Jpn J Clin Oncol. 2006 May;36(5):290-4. doi: 10.1093/jjco/hyl030. Epub 2006 May 30.","Shimazaki J","Jpn J Clin Oncol","2006","2006/06/01","","","10.1093/jjco/hyl030"
"29348298","A Review of Prostate Cancer Genome-Wide Association Studies (GWAS)","Benafif S, Kote-Jarai Z, Eeles RA; PRACTICAL Consortium.","Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):845-857. doi: 10.1158/1055-9965.EPI-16-1046. Epub 2018 Jan 18.","Benafif S","Cancer Epidemiol Biomarkers Prev","2018","2018/01/20","PMC6051932","NIHMS918080","10.1158/1055-9965.EPI-16-1046"
"23603922","Prostate cancer research in China","Ren SC, Chen R, Sun YH.","Asian J Androl. 2013 May;15(3):350-3. doi: 10.1038/aja.2013.37. Epub 2013 Apr 22.","Ren SC","Asian J Androl","2013","2013/04/23","PMC3739645","","10.1038/aja.2013.37"
"8633390","Undergrading of prostate cancer biopsies: a paradox inherent in all biologic bivariate distributions","Gleason DF.","Urology. 1996 Mar;47(3):289-91. doi: 10.1016/S0090-4295(99)80441-5.","Gleason DF","Urology","1996","1996/03/01","","","10.1016/S0090-4295(99)80441-5"
"15634636","[Prostate cancer diagnosed before 55: a retrospective study from the Rare Cancer Network]","Nguyen TD, Poortmans PM, van der Hulst M, Studer G, Pigois E, Collen TD, Belkacemi Y, Beckendorf V, Miralbell R, Scandolaro L, Soete G, Villa S, Gez E, Thomas O, Krengli M, Saliou M; Rare Cancer Network.","Bull Cancer. 2004 Dec;91(12):959-64.","Nguyen TD","Bull Cancer","2004","2005/01/07","","",""
"21572298","Primary care perspectives on prostate cancer screening","Skolarus TA, Holmes-Rovner M, Northouse LL, Fagerlin A, Garlinghouse C, Demers RY, Rovner DR, Darwish-Yassine M, Wei JT.","Nurse Pract. 2011 Jun;36(6):39-44. doi: 10.1097/01.NPR.0000397913.82821.bc.","Skolarus TA","Nurse Pract","2011","2011/05/17","","","10.1097/01.NPR.0000397913.82821.bc"
"12012294","Artificial neural networks for diagnosis and prognosis in prostate cancer","Schwarzer G, Schumacher M.","Semin Urol Oncol. 2002 May;20(2):89-95. doi: 10.1053/suro.2002.32492.","Schwarzer G","Semin Urol Oncol","2002","2002/05/16","","","10.1053/suro.2002.32492"
"26027277","[Prostate cancer: papillomaviruses as a possible cause]","Volgareva GM.","Vestn Ross Akad Med Nauk. 2015;(1):95-100. doi: 10.15690/vramn.v70i1.1237.","Volgareva GM","Vestn Ross Akad Med Nauk","2015","2015/06/02","","","10.15690/vramn.v70i1.1237"
"23157136","[Epidemiology and risk factors of the prostate cancer]","Stasiewicz D, Starosławska E, Brzozowska A, Mocarska A, Losicki M, Szumiło J, Burdan F.","Pol Merkur Lekarski. 2012 Sep;33(195):163-7.","Stasiewicz D","Pol Merkur Lekarski","2012","2012/11/20","","",""
"7776912","Trends in prostate cancer incidence and mortality rates in South Australia, 1977-1993","McCaul KA, Luke CG, Roder DM.","Med J Aust. 1995 May 15;162(10):520-2.","McCaul KA","Med J Aust","1995","1995/05/15","","",""
"29894214","Preoperative Prostate MRI: A Road Map for Surgery","McEvoy SH, Raeside MC, Chaim J, Ehdaie B, Akin O.","AJR Am J Roentgenol. 2018 Aug;211(2):383-391. doi: 10.2214/AJR.17.18757. Epub 2018 Jun 12.","McEvoy SH","AJR Am J Roentgenol","2018","2018/06/13","","","10.2214/AJR.17.18757"
"22647362","MicroRNAs and prostate cancer: from preclinical research to translational oncology","Maugeri-Saccà M, Coppola V, Bonci D, De Maria R.","Cancer J. 2012 May-Jun;18(3):253-61. doi: 10.1097/PPO.0b013e318258b5b6.","Maugeri-Saccà M","Cancer J","2012","2012/06/01","","","10.1097/PPO.0b013e318258b5b6"
"10230675","Prostate cancer--the snowball is rolling","Ruutu M, Salo J, Nordling S, Rannikko S.","Ann Chir Gynaecol. 1999;88(1):5-8.","Ruutu M","Ann Chir Gynaecol","1999","1999/05/07","","",""
"28161349","Obesity as a Risk Factor for Unfavorable Disease in Men with Low Risk Prostate Cancer and its Relationship with Anatomical Location of Tumor","Jeong IG, Yoo S, Lee C, Kim M, You D, Song C, Park S, Hong JH, Ahn H, Kim CS.","J Urol. 2017 Jul;198(1):71-78. doi: 10.1016/j.juro.2017.01.073. Epub 2017 Feb 1.","Jeong IG","J Urol","2017","2017/02/06","","","10.1016/j.juro.2017.01.073"
"20934243","Do we have enough evidence to recommend the routine use of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer?","Ganzer R, Blana A.","Eur Urol. 2010 Dec;58(6):816-8. doi: 10.1016/j.eururo.2010.09.032. Epub 2010 Oct 8.","Ganzer R","Eur Urol","2010","2010/10/12","","","10.1016/j.eururo.2010.09.032"
"16998820","Relaxin becomes upregulated during prostate cancer progression to androgen independence and is negatively regulated by androgens","Thompson VC, Morris TG, Cochrane DR, Cavanagh J, Wafa LA, Hamilton T, Wang S, Fazli L, Gleave ME, Nelson CC.","Prostate. 2006 Dec 1;66(16):1698-709. doi: 10.1002/pros.20423.","Thompson VC","Prostate","2006","2006/09/26","","","10.1002/pros.20423"
"26215782","Metformin and prostate cancer stem cells: a novel therapeutic target","Mayer MJ, Klotz LH, Venkateswaran V.","Prostate Cancer Prostatic Dis. 2015 Dec;18(4):303-9. doi: 10.1038/pcan.2015.35. Epub 2015 Jul 28.","Mayer MJ","Prostate Cancer Prostatic Dis","2015","2015/07/29","","","10.1038/pcan.2015.35"
"28103656","[Investigation on Clinical Course of Patients after Cessation of Long-Term Successful Hormone Monotherapy for Prostate Cancer]","Uno M, Hattori S, Kato S, Masue N, Fujimoto Y.","Hinyokika Kiyo. 2016 Dec;62(12):629-632. doi: 10.14989/ActaUrolJap_62_12_629.","Uno M","Hinyokika Kiyo","2016","2017/01/21","","","10.14989/ActaUrolJap_62_12_629"
"15663985","Steroids and prostate cancer","Cunha GR, Tuohimaa P, Visakorpi T.","J Steroid Biochem Mol Biol. 2004 Nov;92(4):219-20. doi: 10.1016/j.jsbmb.2004.10.001. Epub 2005 Jan 12.","Cunha GR","J Steroid Biochem Mol Biol","2004","2005/01/25","","","10.1016/j.jsbmb.2004.10.001"
"19852006","Differential expression of PCA3 and BMCC1 in prostate cancer","Lavin MF, Clarke R, Gardiner RA.","Prostate. 2009 Dec 1;69(16):1713-4; author reply 1715. doi: 10.1002/pros.21068.","Lavin MF","Prostate","2009","2009/10/24","","","10.1002/pros.21068"
"10725633","Needle displacement during HDR brachytherapy in the treatment of prostate cancer","Damore SJ, Syed AM, Puthawala AA, Sharma A.","Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1205-11. doi: 10.1016/s0360-3016(99)00477-0.","Damore SJ","Int J Radiat Oncol Biol Phys","2000","2000/03/22","","","10.1016/s0360-3016(99)00477-0"
"21796538","Analysis of androgen-induced increase in lipid accumulation in prostate cancer cells","Sikkeland J, Lindstad T, Saatcioglu F.","Methods Mol Biol. 2011;776:371-82. doi: 10.1007/978-1-61779-243-4_22.","Sikkeland J","Methods Mol Biol","2011","2011/07/29","","","10.1007/978-1-61779-243-4_22"
"12121723","Gleason score predicts androgen independent progression after androgen deprivation therapy","Benaim EA, Pace CM, Roehrborn CG.","Eur Urol. 2002 Jul;42(1):12-7. doi: 10.1016/s0302-2838(02)00238-5.","Benaim EA","Eur Urol","2002","2002/07/18","","","10.1016/s0302-2838(02)00238-5"
"7515447","Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications","Shinohara K, Wolf JS Jr, Narayan P, Carroll PR.","J Urol. 1994 Jul;152(1):120-3. doi: 10.1016/s0022-5347(17)32832-x.","Shinohara K","J Urol","1994","1994/07/01","","","10.1016/s0022-5347(17)32832-x"
"11104891","Brachytherapy with transperineal (125)Iodine seeds for localized prostate cancer","Blank LE, Gonzalez Gonzalez D, de Reijke TM, Dabhoiwala NF, Koedooder K.","Radiother Oncol. 2000 Dec;57(3):307-13. doi: 10.1016/s0167-8140(00)00231-0.","Blank LE","Radiother Oncol","2000","2000/12/06","","","10.1016/s0167-8140(00)00231-0"
"26922817","Anger Proneness and Prognostic Pessimism in Men With Prostate Cancer","Gerhart J, Schmidt E, Lillis T, O'Mahony S, Duberstein P, Hoerger M.","Am J Hosp Palliat Care. 2017 Jul;34(6):497-504. doi: 10.1177/1049909116636358. Epub 2016 Feb 27.","Gerhart J","Am J Hosp Palliat Care","2017","2016/02/29","","","10.1177/1049909116636358"
"31430247","Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database","Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.","J Urol. 2020 Jan;203(1):120-127. doi: 10.1097/JU.0000000000000494. Epub 2019 Aug 20.","Dambal S","J Urol","2020","2019/08/21","","","10.1097/JU.0000000000000494"
"8773505","Quality of life in early prostate cancer. Do we know enough to treat?","Talcott JA.","Hematol Oncol Clin North Am. 1996 Jun;10(3):691-701. doi: 10.1016/s0889-8588(05)70361-0.","Talcott JA","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70361-0"
"27391229","A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy","Nygård Y, Haukaas SA, Halvorsen OJ, Gravdal K, Frugård J, Akslen LA, Beisland C.","BMC Urol. 2016 Jul 8;16(1):39. doi: 10.1186/s12894-016-0159-1.","Nygård Y","BMC Urol","2016","2016/07/09","PMC4938932","","10.1186/s12894-016-0159-1"
"16904476","Isolated recurrence of ductal prostate cancer to anterior urethra","Green JM, Tang WW, Jensen BW, Orihuela E.","Urology. 2006 Aug;68(2):428.e13-5. doi: 10.1016/j.urology.2006.03.024.","Green JM","Urology","2006","2006/08/15","","","10.1016/j.urology.2006.03.024"
"18219719","In which patients with prostate cancer should we perform a lymph-node dissection?","Graefen M.","Eur Urol. 2006 Aug;50(2):278-9; author reply 279.","Graefen M","Eur Urol","2006","2008/01/26","","",""
"10388474","Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables","Virtanen A, Gomari M, Kranse R, Stenman UH.","Clin Chem. 1999 Jul;45(7):987-94.","Virtanen A","Clin Chem","1999","1999/07/01","","",""
"24620782","Sipuleucel-T and immunotherapy in the treatment of prostate cancer","Dawson NA, Roesch EE.","Expert Opin Biol Ther. 2014 May;14(5):709-19. doi: 10.1517/14712598.2014.896897. Epub 2014 Mar 12.","Dawson NA","Expert Opin Biol Ther","2014","2014/03/14","","","10.1517/14712598.2014.896897"
"25566598","Prostate cancer recurrence risk linked to high lipid levels","McBride D.","ONS Connect. 2014 Dec;29(4):10.","McBride D","ONS Connect","2014","2015/01/09","","",""
"24247427","Prostate cancer: Statins reduce mortality risk","Phillips R.","Nat Rev Urol. 2013 Dec;10(12):681. doi: 10.1038/nrurol.2013.272. Epub 2013 Nov 19.","Phillips R","Nat Rev Urol","2013","2013/11/20","","","10.1038/nrurol.2013.272"
"17352040","Open versus laparoscopic radical prostatectomy. The case for laparoscopic surgery","Eden C.","Ann R Coll Surg Engl. 2007 Mar;89(2):110-12; discussion 108.","Eden C","Ann R Coll Surg Engl","2007","2007/03/14","","",""
"17634715","Prostate cancer with supraclavicular lymphadenopathy and bulky abdominal tumor","Kosugi S, Mizumachi S, Kitajima A, Igarashi T, Hamada T, Kaya H, Kurihara K, Ogasawara K, Sakata H, Yamamoto M, Nagamine M, Yamazaki H.","Intern Med. 2007;46(14):1135-8. doi: 10.2169/internalmedicine.46.0014. Epub 2007 Jul 17.","Kosugi S","Intern Med","2007","2007/07/20","","","10.2169/internalmedicine.46.0014"
"15850937","Androgen Deprivation (AD) among low-risk and intermediate-risk prostate cancer patients: in regard to Ciezki et al. (Int J Radiat Oncol Biol Phys 2004;60:1347-1350)","Oton CA.","Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):291-2; author reply 292. doi: 10.1016/j.ijrobp.2005.01.012.","Oton CA","Int J Radiat Oncol Biol Phys","2005","2005/04/27","","","10.1016/j.ijrobp.2005.01.012"
"8583585","Prostate specific antigen detected prostate cancer","Gibbons RP.","J Urol. 1996 Mar;155(3):827. doi: 10.1016/s0022-5347(01)66318-3.","Gibbons RP","J Urol","1996","1996/03/01","","","10.1016/s0022-5347(01)66318-3"
"24168232","Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols","Kim TH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM.","Int J Urol. 2014 Apr;21(4):377-81. doi: 10.1111/iju.12326. Epub 2013 Oct 29.","Kim TH","Int J Urol","2014","2013/10/31","","","10.1111/iju.12326"
"20215509","Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic","Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, Johnston RN, Forsyth PA, Magliocco AM, Lee P, Nishikawa S, Donnelly B, Coffey M, Trpkov K, Fonseca K, Spurrell J, Morris DG.","Cancer Res. 2010 Mar 15;70(6):2435-44. doi: 10.1158/0008-5472.CAN-09-2408. Epub 2010 Mar 9.","Thirukkumaran CM","Cancer Res","2010","2010/03/11","","","10.1158/0008-5472.CAN-09-2408"
"20180056","[Methodology and process of developing the S3 guideline for prostate cancer]","Nothacker M, Röllig C, Wöckel A, Kopp I, Ollenschläger G, Weinbrenner S.","Urologe A. 2010 Feb;49(2):173-80. doi: 10.1007/s00120-010-2233-8.","Nothacker M","Urologe A","2010","2010/02/25","","","10.1007/s00120-010-2233-8"
"19376571","Patterns, art, and context: Donald Floyd Gleason and the development of the Gleason grading system","Phillips JL, Sinha AA.","Urology. 2009 Sep;74(3):497-503. doi: 10.1016/j.urology.2009.01.012. Epub 2009 Apr 18.","Phillips JL","Urology","2009","2009/04/21","","","10.1016/j.urology.2009.01.012"
"15305334","Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells","Koochekpour S, Sartor O, Lee TJ, Zieske A, Patten DY, Hiraiwa M, Sandhoff K, Remmel N, Minokadeh A.","Prostate. 2004 Oct 1;61(2):114-23. doi: 10.1002/pros.20082.","Koochekpour S","Prostate","2004","2004/08/12","","","10.1002/pros.20082"
"23499124","[Detection of second tumors in 11C-choline PET/CT studies performed due to biochemical recurrence of prostate cancer]","García JR, Ponce A, Canales M, Ayuso J, Moragas M, Soler M.","Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):28-31. doi: 10.1016/j.remn.2013.01.007. Epub 2013 Mar 14.","García JR","Rev Esp Med Nucl Imagen Mol","2014","2013/03/19","","","10.1016/j.remn.2013.01.007"
"9650916","Workgroup I: rodent models of prostate cancer","Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA.","Prostate. 1998 Jun 15;36(1):49-55. doi: 10.1002/(sici)1097-0045(19980615)36:1<49::aid-pros9>3.0.co;2-6.","Lucia MS","Prostate","1998","1998/07/03","","","10.1002/(sici)1097-0045(19980615)36:1<49::aid-pros9>3.0.co;2-6"
"27423822","The testosterone conundrum: The putative relationship between testosterone levels and prostate cancer","Loughlin KR.","Urol Oncol. 2016 Nov;34(11):482.e1-482.e4. doi: 10.1016/j.urolonc.2016.05.023. Epub 2016 Jul 14.","Loughlin KR","Urol Oncol","2016","2016/07/18","","","10.1016/j.urolonc.2016.05.023"
"31009295","Poly(I:C)-Mediated Death of Human Prostate Cancer Cell Lines Is Induced by Interleukin-27 Treatment","Kourko O, Smyth R, Cino D, Seaver K, Petes C, Eo SY, Basta S, Gee K.","J Interferon Cytokine Res. 2019 Aug;39(8):483-494. doi: 10.1089/jir.2018.0166. Epub 2019 Apr 22.","Kourko O","J Interferon Cytokine Res","2019","2019/04/23","","","10.1089/jir.2018.0166"
"18619854","Vitamin D and intervention trials in prostate cancer: from theory to therapy","Schwartz GG.","Ann Epidemiol. 2009 Feb;19(2):96-102. doi: 10.1016/j.annepidem.2008.03.007. Epub 2008 Jul 10.","Schwartz GG","Ann Epidemiol","2009","2008/07/16","","","10.1016/j.annepidem.2008.03.007"
"22098273","New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer","Connors SK, Chornokur G, Kumar NB.","Nutr Cancer. 2012;64(1):4-22. doi: 10.1080/01635581.2012.630158. Epub 2011 Nov 18.","Connors SK","Nutr Cancer","2012","2011/11/22","PMC3665011","NIHMS451958","10.1080/01635581.2012.630158"
"26439747","Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading","Pichon A, Neuzillet Y, Botto H, Raynaud JP, Radulescu C, Molinié V, Herve JM, Lebret T.","Prostate Cancer Prostatic Dis. 2015 Dec;18(4):382-7. doi: 10.1038/pcan.2015.44. Epub 2015 Oct 6.","Pichon A","Prostate Cancer Prostatic Dis","2015","2015/10/07","","","10.1038/pcan.2015.44"
"22284032","Castration therapy of prostate cancer results in downregulation of HIF-1α levels","Al-Ubaidi FL, Schultz N, Egevad L, Granfors T, Helleday T.","Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1243-8. doi: 10.1016/j.ijrobp.2011.10.038.","Al-Ubaidi FL","Int J Radiat Oncol Biol Phys","2012","2012/01/31","","","10.1016/j.ijrobp.2011.10.038"
"15588310","Expression of pS2 in prostate cancer correlates with grade and Chromogranin A expression but not with stage","Ather MH, Abbas F, Faruqui N, Israr M, Pervez S.","BMC Urol. 2004 Dec 10;4(1):14. doi: 10.1186/1471-2490-4-14.","Ather MH","BMC Urol","2004","2004/12/14","PMC539282","","10.1186/1471-2490-4-14"
"9029890","Survival of carcinoma of the prostate patients less than 55 years old compared to older patient groups","Routh A, Hickman BT, Meydrech E, Bass JD, Moulder JT.","J Miss State Med Assoc. 1997 Jan;38(1):1-4.","Routh A","J Miss State Med Assoc","1997","1997/01/01","","",""
"22146293","Progress of molecular targeted therapies for prostate cancers","Fu W, Madan E, Yee M, Zhang H.","Biochim Biophys Acta. 2012 Apr;1825(2):140-52. doi: 10.1016/j.bbcan.2011.11.003. Epub 2011 Nov 29.","Fu W","Biochim Biophys Acta","2012","2011/12/08","PMC3307854","NIHMS341999","10.1016/j.bbcan.2011.11.003"
"24641910","Targeted focal therapy for the management of organ confined prostate cancer","Barqawi AB, Stoimenova D, Krughoff K, Eid K, O'Donnell C, Phillips JM, Crawford ED.","J Urol. 2014 Sep;192(3):749-53. doi: 10.1016/j.juro.2014.03.033. Epub 2014 Mar 15.","Barqawi AB","J Urol","2014","2014/03/20","","","10.1016/j.juro.2014.03.033"
"27040772","Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy","Guan Y, Wu Y, Liu Y, Ni J, Nong S.","Prostate. 2016 Aug;76(11):986-93. doi: 10.1002/pros.23187. Epub 2016 Apr 4.","Guan Y","Prostate","2016","2016/04/05","","","10.1002/pros.23187"
"31601512","Advancing Age and the Odds of Upgrading and Upstaging at Radical Prostatectomy in Men with Gleason Score 6 Prostate Cancer","Leeman JE, Chen MH, Huland H, Graefen M, D'Amico AV, Tilki D.","Clin Genitourin Cancer. 2019 Dec;17(6):e1116-e1121. doi: 10.1016/j.clgc.2019.07.018. Epub 2019 Aug 5.","Leeman JE","Clin Genitourin Cancer","2019","2019/10/12","","","10.1016/j.clgc.2019.07.018"
"15477876","Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention","Zeng L, Kyprianou N.","Prostate Cancer Prostatic Dis. 2005;8(1):7-13. doi: 10.1038/sj.pcan.4500757.","Zeng L","Prostate Cancer Prostatic Dis","2005","2004/10/13","","","10.1038/sj.pcan.4500757"
"15773010","Prostate cancer: new studies of combination therapy","","Harv Mens Health Watch. 2005 Jan;9(6):5-7.","","Harv Mens Health Watch","2005","2005/03/19","","",""
"27344786","[Clinical problems on the PSA failure assessment and management for prostate cancer]","Karasawa K.","Nihon Rinsho. 2016 May 20;74 Suppl 3:520-4.","Karasawa K","Nihon Rinsho","2016","2016/06/28","","",""
"1370852","PSA becoming important tool in prostate cancer","Volkers N.","J Natl Cancer Inst. 1992 Feb 19;84(4):221-2. doi: 10.1093/jnci/84.4.221.","Volkers N","J Natl Cancer Inst","1992","1992/02/19","","","10.1093/jnci/84.4.221"
"32385034","[Research Progress of the Roles of Ubiquitination/Deubiquitination in Androgen Receptor Abnormalities and Prostate Cancer]","Zhang WY, Zhou JH, Wang HR, Mu Q, Wang Q, Xu KX, Xu T, Hu H.","Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2020 Apr 28;42(2):251-256. doi: 10.3881/j.issn.1000-503X.11069.","Zhang WY","Zhongguo Yi Xue Ke Xue Yuan Xue Bao","2020","2020/05/10","","","10.3881/j.issn.1000-503X.11069"
"30692586","Total nut, tree nut, peanut, and peanut butter intake and the risk of prostate cancer in the Netherlands Cohort Study","Boudewijns EA, Nieuwenhuis L, Geybels MS, van den Brandt PA.","Prostate Cancer Prostatic Dis. 2019 Sep;22(3):467-474. doi: 10.1038/s41391-019-0131-8. Epub 2019 Jan 28.","Boudewijns EA","Prostate Cancer Prostatic Dis","2019","2019/01/30","","","10.1038/s41391-019-0131-8"
"25002728","Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer","Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC.","J Clin Oncol. 2014 Aug 10;32(23):2471-8. doi: 10.1200/JCO.2013.51.1048. Epub 2014 Jul 7.","Prasad SM","J Clin Oncol","2014","2014/07/09","PMC4121505","","10.1200/JCO.2013.51.1048"
"17023778","Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy","Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, Gustafson GS, Gonzalez J, Martinez AA.","Am J Clin Oncol. 2006 Oct;29(5):451-7. doi: 10.1097/01.coc.0000221304.74360.8c.","Vargas CE","Am J Clin Oncol","2006","2006/10/07","","","10.1097/01.coc.0000221304.74360.8c"
"19551858","Housekeeping genes in prostate tumorigenesis","Byun J, Logothetis CJ, Gorlov IP.","Int J Cancer. 2009 Dec 1;125(11):2603-8. doi: 10.1002/ijc.24680.","Byun J","Int J Cancer","2009","2009/06/25","PMC4531049","NIHMS143561","10.1002/ijc.24680"
"25456999","Effect of surgical margin status after radical prostatectomy on health-related quality of life and illness perception in patients with prostate cancer","Richters A, Derks J, Husson O, Van Onna IEW, Fossion LMCL, Kil PJM, Verhoeven RHA, Aarts MJ.","Urol Oncol. 2015 Jan;33(1):16.e9-16.e15. doi: 10.1016/j.urolonc.2014.10.006. Epub 2014 Nov 14.","Richters A","Urol Oncol","2015","2014/12/03","","","10.1016/j.urolonc.2014.10.006"
"15711604","Long-term outcome of detectable PSA levels after radical prostatectomy","Ahlering TE, Skarecky DW.","Prostate Cancer Prostatic Dis. 2005;8(2):163-6. doi: 10.1038/sj.pcan.4500788.","Ahlering TE","Prostate Cancer Prostatic Dis","2005","2005/02/16","","","10.1038/sj.pcan.4500788"
"31705377","Exploring health behaviors, quality of life, and support needs in African-American prostate cancer survivors: a pilot study to support future interventions","Stolley MR, Sheean P, Matthews L, Banerjee A, Visotcky A, Papanek P, Woodley L, Flynn KE.","Support Care Cancer. 2020 Jul;28(7):3135-3143. doi: 10.1007/s00520-019-05092-6. Epub 2019 Nov 8.","Stolley MR","Support Care Cancer","2020","2019/11/10","","","10.1007/s00520-019-05092-6"
"27919653","Transperineal biopsies of MRI-detected aggressive index lesions in low- and intermediate-risk prostate cancer patients: Implications for treatment decision","Gomez-Iturriaga A, Casquero F, Lopez JI, Urresola A, Ezquerro A, Buscher D, Bilbao P, Crook J.","Brachytherapy. 2017 Jan-Feb;16(1):201-206. doi: 10.1016/j.brachy.2016.11.004. Epub 2016 Dec 3.","Gomez-Iturriaga A","Brachytherapy","2017","2016/12/07","","","10.1016/j.brachy.2016.11.004"
"24100689","Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer","Pinto Á.","Cancer Biol Ther. 2014 Feb;15(2):149-55. doi: 10.4161/cbt.26724. Epub 2013 Nov 1.","Pinto Á","Cancer Biol Ther","2014","2013/10/09","PMC3928129","","10.4161/cbt.26724"
"31673232","Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics","Lin CY, Wang SS, Yang CK, Li JR, Chen CS, Hung SC, Chiu KY, Cheng CL, Ou YC, Yang SF.","Int J Med Sci. 2019 Sep 20;16(11):1424-1429. doi: 10.7150/ijms.38080. eCollection 2019.","Lin CY","Int J Med Sci","2019","2019/11/02","PMC6818208","","10.7150/ijms.38080"
"20052734","Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy","Dosoretz AM, Chen MH, Salenius SA, Ross RH, Dosoretz DE, Katin MJ, Mantz C, Nakfoor BM, D'Amico AV.","Cancer. 2010 Feb 15;116(4):837-42. doi: 10.1002/cncr.24750.","Dosoretz AM","Cancer","2010","2010/01/07","","","10.1002/cncr.24750"
"24745490","Re: predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and american urological association symptom score","Babayan RK.","J Urol. 2014 May;191(5):1289. doi: 10.1016/j.juro.2014.02.014. Epub 2014 Feb 20.","Babayan RK","J Urol","2014","2014/04/22","","","10.1016/j.juro.2014.02.014"
"19635642","Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer","Bellmunt J, Rosenberg JE, Choueiri TK.","Eur Urol. 2009 Oct;56(4):606-8. doi: 10.1016/j.eururo.2009.07.015. Epub 2009 Jul 22.","Bellmunt J","Eur Urol","2009","2009/07/29","","","10.1016/j.eururo.2009.07.015"
"19727818","Quality of life among elderly men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy","Namiki S, Ishidoya S, Kawamura S, Tochigi T, Arai Y.","J Cancer Res Clin Oncol. 2010 Mar;136(3):379-86. doi: 10.1007/s00432-009-0665-6. Epub 2009 Sep 2.","Namiki S","J Cancer Res Clin Oncol","2010","2009/09/04","","","10.1007/s00432-009-0665-6"
"11989560","Prognostic significance of changes in prostate-specific antigen in patients with metastasis prostate cancer after endocrine treatment","Furuya Y, Akakura K, Tobe T, Ichikawa T, Igarashi T, Ito H.","Int Urol Nephrol. 2001;32(4):659-63. doi: 10.1023/a:1014410026495.","Furuya Y","Int Urol Nephrol","2001","2002/05/07","","","10.1023/a:1014410026495"
"22024780","Effects of commercially available soy products on PSA in androgen-deprivation-naïve and castration-resistant prostate cancer","Joshi M, Agostino NM, Gingrich R, Drabick JJ.","South Med J. 2011 Nov;104(11):736-40. doi: 10.1097/SMJ.0b013e3182335151.","Joshi M","South Med J","2011","2011/10/26","","","10.1097/SMJ.0b013e3182335151"
"22361784","The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer","Small EJ, Penson DF, Sartor O.","Clin Adv Hematol Oncol. 2011 Jul;9(7 Suppl 13):1-15.","Small EJ","Clin Adv Hematol Oncol","2011","2012/02/25","","",""
"29501976","Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data","Booth N, Rissanen P, Tammela TLJ, Taari K, Talala K, Auvinen A.","Eur J Cancer. 2018 Apr;93:108-118. doi: 10.1016/j.ejca.2018.01.111. Epub 2018 Mar 20.","Booth N","Eur J Cancer","2018","2018/03/05","","","10.1016/j.ejca.2018.01.111"
"12584691","Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid","Saad F.","Semin Oncol. 2002 Dec;29(6 Suppl 21):19-27. doi: 10.1053/sonc.2002.37418.","Saad F","Semin Oncol","2002","2003/02/14","","","10.1053/sonc.2002.37418"
"27569436","Clinicopathological Features and Prognostic Value of Incidental Prostatic Adenocarcinoma in Radical Cystoprostatectomy Specimens: A Systematic Review and Meta-Analysis of 13,140 Patients","Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G.","J Urol. 2017 Feb;197(2):385-390. doi: 10.1016/j.juro.2016.08.088. Epub 2016 Aug 26.","Fahmy O","J Urol","2017","2016/08/30","","","10.1016/j.juro.2016.08.088"
"28135193","Risk and preventive factors for prostate cancer in Japan: The Japan Public Health Center-based prospective (JPHC) study","Sawada N.","J Epidemiol. 2017 Jan;27(1):2-7. doi: 10.1016/j.je.2016.09.001. Epub 2016 Nov 15.","Sawada N","J Epidemiol","2017","2017/01/31","PMC5328733","","10.1016/j.je.2016.09.001"
"31393902","Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer","Burnell SEA, Spencer-Harty S, Howarth S, Bodger O, Kynaston H, Morgan C, Doak SH.","PLoS One. 2019 Aug 8;14(8):e0220456. doi: 10.1371/journal.pone.0220456. eCollection 2019.","Burnell SEA","PLoS One","2019","2019/08/09","PMC6687176","","10.1371/journal.pone.0220456"
"3791273","Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial","Moore MR, Graham SD, Birch R, Irwin L.","Cancer Treat Rep. 1987 Jan;71(1):89-90.","Moore MR","Cancer Treat Rep","1987","1987/01/01","","",""
"15045191","[Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system]","Hammerer PG, Augustin H, Blonski J, Graefen M, Haese A, Erbersdobler A, Daghofer F, Huland H.","Urologe A. 2004 Mar;43(3):307-12. doi: 10.1007/s00120-004-0531-8.","Hammerer PG","Urologe A","2004","2004/03/27","","","10.1007/s00120-004-0531-8"
"28438871","Multiparametric MRI Apparent Diffusion Coefficient (ADC) Accuracy in Diagnosing Clinically Significant Prostate Cancer","Pepe P, D'Urso D, Garufi A, Priolo G, Pennisi M, Russo G, Sabini MG, Valastro LM, Galia A, Fraggetta F.","In Vivo. 2017 May-Jun;31(3):415-418. doi: 10.21873/invivo.11075.","Pepe P","In Vivo","2017","2017/04/26","PMC5461453","","10.21873/invivo.11075"
"15976331","Molecular pathology of prostate cancer","Hughes C, Murphy A, Martin C, Sheils O, O'Leary J.","J Clin Pathol. 2005 Jul;58(7):673-84. doi: 10.1136/jcp.2002.003954.","Hughes C","J Clin Pathol","2005","2005/06/25","PMC1770715","","10.1136/jcp.2002.003954"
"29368230","Multiparametric ultrasound-targeted biopsy compares favorably to multiparametric MRI-transrectal ultrasound fusion-targeted biopsy on initial biopsy of men at risk for prostate cancer","Fulgham PF.","World J Urol. 2018 May;36(5):713-718. doi: 10.1007/s00345-018-2187-9. Epub 2018 Jan 24.","Fulgham PF","World J Urol","2018","2018/01/26","","","10.1007/s00345-018-2187-9"
"6399618","Prostate cancer research: current concepts and controversies","Benson MC, Coffey DS.","Semin Urol. 1983 Nov;1(4):323-30.","Benson MC","Semin Urol","1983","1983/11/01","","",""
"28177897","Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis","Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, Wang J, Xu Z, Yu B, Xu T, Zou Q.","Oncotarget. 2017 Apr 4;8(14):23322-23336. doi: 10.18632/oncotarget.15056.","Xue J","Oncotarget","2017","2017/02/09","PMC5410307","","10.18632/oncotarget.15056"
"8804500","Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases","Meyer-Siegler K, Hudson PB.","Urology. 1996 Sep;48(3):448-52. doi: 10.1016/S0090-4295(96)00207-5.","Meyer-Siegler K","Urology","1996","1996/09/01","","","10.1016/S0090-4295(96)00207-5"
"22220977","Paraneoplastic neurological and hematological syndromes associated with prostate cancer","Gakiya M, Naka H, Saito S.","Int J Urol. 2012 May;19(5):471-4. doi: 10.1111/j.1442-2042.2011.02949.x. Epub 2012 Jan 6.","Gakiya M","Int J Urol","2012","2012/01/07","","","10.1111/j.1442-2042.2011.02949.x"
"29932371","MicroRNAs in prostate cancer: From function to biomarker discovery","Moustafa AA, Kim H, Albeltagy RS, El-Habit OH, Abdel-Mageed AB.","Exp Biol Med (Maywood). 2018 Jun;243(10):817-825. doi: 10.1177/1535370218775657.","Moustafa AA","Exp Biol Med (Maywood)","2018","2018/06/23","PMC6022910","","10.1177/1535370218775657"
"16215708","[Gleason grading: diagnostic criteria and clinical implications]","Bonkhoff H.","Pathologe. 2005 Nov;26(6):422-32. doi: 10.1007/s00292-005-0793-y.","Bonkhoff H","Pathologe","2005","2005/10/11","","","10.1007/s00292-005-0793-y"
"17499280","Clinical judgment analysis of the parameters used by consultant urologists in the management of prostate cancer","Clarke MG, Wilson JR, Kennedy KP, MacDonagh RP.","J Urol. 2007 Jul;178(1):98-102. doi: 10.1016/j.juro.2007.03.029. Epub 2007 May 11.","Clarke MG","J Urol","2007","2007/05/15","","","10.1016/j.juro.2007.03.029"
"22012569","[Magnetic resonance tomography-guided interventional procedure for diagnosis of prostate cancer]","Schernthaner M, Helbich TH, Fueger BJ, Margreiter M, Memarsadeghi M, Stiglbauer A, Linhart HG, Doan A, Pinker K, Brader P.","Radiologe. 2011 Nov;51(11):962-8. doi: 10.1007/s00117-011-2180-4.","Schernthaner M","Radiologe","2011","2011/10/21","","","10.1007/s00117-011-2180-4"
"12629934","Treatment outcomes and quality-of-life issues for patients treated with prostate brachytherapy","Abel L, Dafoe-Lambie J, Butler WM, Merrick GS.","Clin J Oncol Nurs. 2003 Jan-Feb;7(1):48-54. doi: 10.1188/03.CJON.48-54.","Abel L","Clin J Oncol Nurs","2003","2003/03/13","","","10.1188/03.CJON.48-54"
"22231760","Prostate cancer in 2011: Hitting old targets better and identifying new targets","Chen Y, Scher HI.","Nat Rev Clin Oncol. 2012 Jan 10;9(2):70-2. doi: 10.1038/nrclinonc.2011.213.","Chen Y","Nat Rev Clin Oncol","2012","2012/01/11","PMC5572096","NIHMS887477","10.1038/nrclinonc.2011.213"
"21067392","Sipuleucel-T immunotherapy for castration-resistant prostate cancer","Tanimoto T, Hori A, Kami M.","N Engl J Med. 2010 Nov 11;363(20):1966; author reply 1967-8. doi: 10.1056/NEJMc1009982.","Tanimoto T","N Engl J Med","2010","2010/11/12","","","10.1056/NEJMc1009982"
"12376492","Inherited genotype and prostate cancer outcomes","Rebbeck TR.","Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):945-52.","Rebbeck TR","Cancer Epidemiol Biomarkers Prev","2002","2002/10/12","","",""
"23381056","Summaries for patients. Screening smarter, not harder, for prostate cancer","","Ann Intern Med. 2013 Feb 5;158(3):I-30. doi: 10.7326/0003-4819-158-3-201302050-00001.","","Ann Intern Med","2013","2013/02/06","","","10.7326/0003-4819-158-3-201302050-00001"
"17361920","[Early prostate cancer 2005. New 2005 data]","Fourcade RO.","Ann Urol (Paris). 2006 Dec;40 Suppl 2:S44-8. doi: 10.1016/s0003-4401(06)80020-3.","Fourcade RO","Ann Urol (Paris)","2006","2007/03/17","","","10.1016/s0003-4401(06)80020-3"
"18651985","ProsCan for men: randomised controlled trial of a decision support intervention for men with localised prostate cancer","Chambers SK, Ferguson M, Gardiner RA, Nicol D, Gordon L, Occhipinti S, Aitken J.","BMC Cancer. 2008 Jul 24;8:207. doi: 10.1186/1471-2407-8-207.","Chambers SK","BMC Cancer","2008","2008/07/25","PMC2515322","","10.1186/1471-2407-8-207"
"31114994","Long non-coding RNA DUXAP10 promotes the proliferation, migration, and inhibits apoptosis of prostate cancer cells","Wang XF, Chen J, Gong YB, Qin YC, Wang L, Li NC.","Eur Rev Med Pharmacol Sci. 2019 May;23(9):3699-3708. doi: 10.26355/eurrev_201905_17793.","Wang XF","Eur Rev Med Pharmacol Sci","2019","2019/05/23","","","10.26355/eurrev_201905_17793"
"26178396","Optimal management of prostate cancer with lethal biology--state-of-the-art local therapy","Chapin BF.","Asian J Androl. 2015 Nov-Dec;17(6):888-91. doi: 10.4103/1008-682X.156855.","Chapin BF","Asian J Androl","2015","2015/07/17","PMC4814949","","10.4103/1008-682X.156855"
"12111700","Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC-3 prostate cancer cells","Dutta R, Sens DA, Somji S, Sens MA, Garrett SH.","Prostate. 2002 Jul 1;52(2):89-97. doi: 10.1002/pros.10097.","Dutta R","Prostate","2002","2002/07/12","","","10.1002/pros.10097"
"8888492","The role of motility proteins and metastasis-suppressor genes in prostate cancer progression","Rinker-Schaeffer CW, Chekmareva MA, Mohler JL.","Stem Cells. 1996 Sep;14(5):508-16. doi: 10.1002/stem.140508.","Rinker-Schaeffer CW","Stem Cells","1996","1996/09/01","","","10.1002/stem.140508"
"27741508","Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles","Hoang DT, Iczkowski KA, Kilari D, See W, Nevalainen MT.","Oncotarget. 2017 Jan 10;8(2):3724-3745. doi: 10.18632/oncotarget.12554.","Hoang DT","Oncotarget","2017","2016/10/15","PMC5356914","","10.18632/oncotarget.12554"
"27165976","MUC1 is upregulated in advanced prostate cancer and is an independent prognostic factor","Genitsch V, Zlobec I, Thalmann GN, Fleischmann A.","Prostate Cancer Prostatic Dis. 2016 Sep;19(3):242-7. doi: 10.1038/pcan.2016.11. Epub 2016 May 10.","Genitsch V","Prostate Cancer Prostatic Dis","2016","2016/05/12","","","10.1038/pcan.2016.11"
"27725309","Androgen receptor variation affects prostate cancer progression and drug resistance","McCrea E, Sissung TM, Price DK, Chau CH, Figg WD.","Pharmacol Res. 2016 Dec;114:152-162. doi: 10.1016/j.phrs.2016.10.001. Epub 2016 Oct 7.","McCrea E","Pharmacol Res","2016","2016/11/07","PMC5154811","NIHMS827315","10.1016/j.phrs.2016.10.001"
"31230019","Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database","Zhuo L, Cheng Y, Pan Y, Zong J, Sun W, Xu L, Soriano-Gabarró M, Song Y, Lu J, Zhan S.","BMJ Open. 2019 Jun 22;9(6):e028214. doi: 10.1136/bmjopen-2018-028214.","Zhuo L","BMJ Open","2019","2019/06/24","PMC6597097","","10.1136/bmjopen-2018-028214"
"25587599","Words of wisdom. Re: Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study","Scovell JM, Wilken N, Ramasamy R, Lipshultz LI.","Eur Urol. 2014 Dec;66(6):1186-7. doi: 10.1016/j.eururo.2014.08.042.","Scovell JM","Eur Urol","2014","2015/01/15","","","10.1016/j.eururo.2014.08.042"
"23312570","Re: Christian Bolenz, Stephen J. Freedland, Brent K. Hollenbeck, et al. costs of radical prostatectomy for prostate cancer: a systematic review. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.08.059","Rassweiler J.","Eur Urol. 2013 Apr;63(4):e53-6. doi: 10.1016/j.eururo.2012.12.024. Epub 2012 Dec 31.","Rassweiler J","Eur Urol","2013","2013/01/15","","","10.1016/j.eururo.2012.12.024"
"12614240","Hormonal therapy as an adjuvant to radical radiotherapy for locally advanced prostate cancer","Parker C, Dearnaley D.","BJU Int. 2003 Jan;91(1):6-8. doi: 10.1046/j.1464-410x.2003.04008.x.","Parker C","BJU Int","2003","2003/03/05","","","10.1046/j.1464-410x.2003.04008.x"
"10749017","The role of staging CT scans in the treatment of prostate cancer: a retrospective audit","Burcombe RJ, Ostler PJ, Ayoub AW, Hoskin PJ.","Clin Oncol (R Coll Radiol). 2000;12(1):32-5. doi: 10.1053/clon.2000.9107.","Burcombe RJ","Clin Oncol (R Coll Radiol)","2000","2000/04/05","","","10.1053/clon.2000.9107"
"18504751","ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy","Takayama Y, Kishimoto R, Hanaoka S, Nonaka H, Kandatsu S, Tsuji H, Tsujii H, Ikehira H, Obata T.","J Magn Reson Imaging. 2008 Jun;27(6):1331-5. doi: 10.1002/jmri.21388.","Takayama Y","J Magn Reson Imaging","2008","2008/05/28","","","10.1002/jmri.21388"
"18539965","Prostate cancer stem cells: a new target for therapy","Maitland NJ, Collins AT.","J Clin Oncol. 2008 Jun 10;26(17):2862-70. doi: 10.1200/JCO.2007.15.1472.","Maitland NJ","J Clin Oncol","2008","2008/06/10","","","10.1200/JCO.2007.15.1472"
"16673604","Radiotherapy in prostate cancer treatment","Radosevic-Jelic Lj, Stojanovic S, Popov I.","Acta Chir Iugosl. 2005;52(4):93-102. doi: 10.2298/aci0504093r.","Radosevic-Jelic Lj","Acta Chir Iugosl","2005","2006/05/06","","","10.2298/aci0504093r"
"23993883","[Pelvic irradiation in prostate cancer: what place for what volumes?]","Chapet O, Enachescu C, Lorchel F.","Cancer Radiother. 2013 Oct;17(5-6):562-5. doi: 10.1016/j.canrad.2013.07.133. Epub 2013 Aug 29.","Chapet O","Cancer Radiother","2013","2013/09/03","","","10.1016/j.canrad.2013.07.133"
"12603918","Prostate cancer: metastatic","Michaelson MD, Talcott JA, Smith MR.","Clin Evid. 2002 Dec;(8):881-90.","Michaelson MD","Clin Evid","2002","2003/02/27","","",""
"28506193","Experiences of partners of prostate cancer survivors: A qualitative study","Pinks D, Davis C, Pinks C.","J Psychosoc Oncol. 2018 Jan-Feb;36(1):49-63. doi: 10.1080/07347332.2017.1329769. Epub 2017 Jun 14.","Pinks D","J Psychosoc Oncol","2018","2017/05/17","","","10.1080/07347332.2017.1329769"
"20824045","Evolving role of bone biomarkers in castration-resistant prostate cancer","Brown JE, Sim S.","Neoplasia. 2010 Sep;12(9):685-96. doi: 10.1593/neo.10610.","Brown JE","Neoplasia","2010","2010/09/09","PMC2933689","","10.1593/neo.10610"
"20721252","[Changes in clinical features of inpatients with prostate cancer in the past 11 years]","Zhang CJ, He ZS, Zhou LQ.","Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Aug 18;42(4):404-8.","Zhang CJ","Beijing Da Xue Xue Bao Yi Xue Ban","2010","2010/08/20","","",""
"16526983","Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis","Klotz LH, Nam RK.","Can J Urol. 2006 Feb;13 Suppl 1:48-55.","Klotz LH","Can J Urol","2006","2006/03/11","","",""
"24567173","Dietary flavonoid and proanthocyanidin intakes and prostate cancer risk in a prospective cohort of US men","Wang Y, Stevens VL, Shah R, Peterson JJ, Dwyer JT, Gapstur SM, McCullough ML.","Am J Epidemiol. 2014 Apr 15;179(8):974-86. doi: 10.1093/aje/kwu006. Epub 2014 Feb 23.","Wang Y","Am J Epidemiol","2014","2014/02/26","","","10.1093/aje/kwu006"
"31703602","Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients","Ihle CL, Provera MD, Straign DM, Smith EE, Edgerton SM, Van Bokhoven A, Lucia MS, Owens P.","J Immunother Cancer. 2019 Nov 8;7(1):293. doi: 10.1186/s40425-019-0753-3.","Ihle CL","J Immunother Cancer","2019","2019/11/10","PMC6839115","","10.1186/s40425-019-0753-3"
"26968417","Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy","Pietzak EJ, Eastham JA.","Curr Urol Rep. 2016 May;17(5):37. doi: 10.1007/s11934-016-0592-4.","Pietzak EJ","Curr Urol Rep","2016","2016/03/13","","","10.1007/s11934-016-0592-4"
"14508926","Prostate cancer in black men of African-Caribbean descent","Kleier JA.","J Cult Divers. 2003 Summer;10(2):56-61.","Kleier JA","J Cult Divers","2003","2003/09/26","","",""
"17253082","To screen or not to screen: factors influencing the decision to participate in prostate cancer screening among urban African-American men","Plowden KO.","Urol Nurs. 2006 Dec;26(6):477-82: discussion 483-5, 489.","Plowden KO","Urol Nurs","2006","2007/01/27","","",""
"24078345","Exploring prostate cancer literacy and family cancer awareness in college students: getting ahead of the curve in cancer education","Campbell LC, McClain J.","J Cancer Educ. 2013 Dec;28(4):617-22. doi: 10.1007/s13187-013-0546-1.","Campbell LC","J Cancer Educ","2013","2013/10/01","","","10.1007/s13187-013-0546-1"
"21489116","Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy","Mouraviev V, Villers A, Bostwick DG, Wheeler TM, Montironi R, Polascik TJ.","BJU Int. 2011 Oct;108(7):1074-85. doi: 10.1111/j.1464-410X.2010.10039.x. Epub 2011 Apr 13.","Mouraviev V","BJU Int","2011","2011/04/15","","","10.1111/j.1464-410X.2010.10039.x"
"26375435","""Hit the primary"": A paradigm shift in the treatment of metastatic prostate cancer?","Arcangeli S, Zilli T, De Bari B, Alongi F.","Crit Rev Oncol Hematol. 2016 Jan;97:231-7. doi: 10.1016/j.critrevonc.2015.08.023. Epub 2015 Aug 29.","Arcangeli S","Crit Rev Oncol Hematol","2016","2015/09/17","","","10.1016/j.critrevonc.2015.08.023"
"18288312","Inorganic arsenic and human prostate cancer","Benbrahim-Tallaa L, Waalkes MP.","Environ Health Perspect. 2008 Feb;116(2):158-64. doi: 10.1289/ehp.10423.","Benbrahim-Tallaa L","Environ Health Perspect","2008","2008/02/22","PMC2235216","","10.1289/ehp.10423"
"22142466","Oncological outcomes of the prostate cancer patients registered in 2004: report from the Cancer Registration Committee of the JUA","Fujimoto H, Nakanishi H, Miki T, Kubota Y, Takahashi S, Suzuki K, Kanayama HO, Mikami K, Homma Y.","Int J Urol. 2011 Dec;18(12):876-81. doi: 10.1111/j.1442-2042.2011.02895.x.","Fujimoto H","Int J Urol","2011","2011/12/07","","","10.1111/j.1442-2042.2011.02895.x"
"21626265","Patterns of information behavior and prostate cancer knowledge among African-American men","Ross L, Dark T, Orom H, Underwood W 3rd, Anderson-Lewis C, Johnson J, Erwin DO.","J Cancer Educ. 2011 Dec;26(4):708-16. doi: 10.1007/s13187-011-0241-z.","Ross L","J Cancer Educ","2011","2011/06/01","PMC3683292","NIHMS480332","10.1007/s13187-011-0241-z"
"9400426","Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer","Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC.","J Urol. 1998 Jan;159(1):5-12. doi: 10.1016/s0022-5347(01)63996-x.","Woodrum DL","J Urol","1998","1997/12/24","","","10.1016/s0022-5347(01)63996-x"
"29845595","Primary cryotherapy for localised or locally advanced prostate cancer","Jung JH, Risk MC, Goldfarb R, Reddy B, Coles B, Dahm P.","Cochrane Database Syst Rev. 2018 May 30;5(5):CD005010. doi: 10.1002/14651858.CD005010.pub3.","Jung JH","Cochrane Database Syst Rev","2018","2018/05/31","PMC6494517","","10.1002/14651858.CD005010.pub3"
"9775486","Self-transcendence in older men attending a prostate cancer support group","Chin-A-Loy SS, Fernsler JI.","Cancer Nurs. 1998 Oct;21(5):358-63. doi: 10.1097/00002820-199810000-00007.","Chin-A-Loy SS","Cancer Nurs","1998","1998/10/17","","","10.1097/00002820-199810000-00007"
"8773508","How is androgen-dependent metastatic prostate cancer best treated?","Robson M, Dawson N.","Hematol Oncol Clin North Am. 1996 Jun;10(3):727-47. doi: 10.1016/s0889-8588(05)70364-6.","Robson M","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70364-6"
"26440292","Is the Post-Radical Prostatectomy Gleason Score a Valid Predictor of Mortality after Neoadjuvant Hormonal Treatment?","Froehner M, Propping S, Koch R, Borkowetz A, Liebeheim D, Toma M, Baretton GB, Wirth MP.","Urol Int. 2016;96(3):302-8. doi: 10.1159/000440729. Epub 2015 Oct 7.","Froehner M","Urol Int","2016","2015/10/07","","","10.1159/000440729"
"31523057","Understanding of prognosis in non-metastatic prostate cancer: a randomised comparative study of clinician estimates measured against the PREDICT prostate prognostic model","Thurtle DR, Jenkins V, Pharoah PD, Gnanapragasam VJ.","Br J Cancer. 2019 Oct;121(8):715-718. doi: 10.1038/s41416-019-0569-4. Epub 2019 Sep 16.","Thurtle DR","Br J Cancer","2019","2019/09/17","PMC6889281","","10.1038/s41416-019-0569-4"
"25540245","The diffusion of docetaxel in patients with metastatic prostate cancer","Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.","J Natl Cancer Inst. 2014 Dec 24;107(2):dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.","Unger JM","J Natl Cancer Inst","2014","2014/12/26","PMC4326312","","10.1093/jnci/dju412"
"27352188","Diagnostic Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Detecting Residual or Recurrent Prostate Cancer After Radical Prostatectomy: A Pooled Analysis of 12 Individual Studies","Yu T, Meng N, Chi D, Zhao Y, Wang Z, Luo Y.","Cell Biochem Biophys. 2015 Jul;72(3):687-94. doi: 10.1007/s12013-015-0519-6.","Yu T","Cell Biochem Biophys","2015","2016/06/29","","","10.1007/s12013-015-0519-6"
"12386917","Association between prostate cancer and serum testosterone levels","Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G.","Prostate. 2002 Nov 1;53(3):179-82. doi: 10.1002/pros.10140.","Zhang PL","Prostate","2002","2002/10/19","","","10.1002/pros.10140"
"26920095","Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know","Catalá V, Salas D, Esquena S, Mateu S, Algaba F, Palou J, de la Torre P.","Actas Urol Esp. 2016 Jul-Aug;40(6):339-52. doi: 10.1016/j.acuro.2015.12.003. Epub 2016 Feb 24.","Catalá V","Actas Urol Esp","2016","2016/02/28","","","10.1016/j.acuro.2015.12.003"
"15947594","Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database","Langenstroer P, Carroll P, Thrasher JB.","J Urol. 2005 Jul;174(1):118-20. doi: 10.1097/01.ju.0000162038.62740.9f.","Langenstroer P","J Urol","2005","2005/06/11","","","10.1097/01.ju.0000162038.62740.9f"
"16204005","Geographic and socioeconomic variation in the treatment of prostate cancer","Krupski TL, Kwan L, Afifi AA, Litwin MS.","J Clin Oncol. 2005 Nov 1;23(31):7881-8. doi: 10.1200/JCO.2005.08.755. Epub 2005 Oct 3.","Krupski TL","J Clin Oncol","2005","2005/10/06","","","10.1200/JCO.2005.08.755"
"29951892","The microRNA signatures: aberrantly expressed miRNAs in prostate cancer","Sharma N, Baruah MM.","Clin Transl Oncol. 2019 Feb;21(2):126-144. doi: 10.1007/s12094-018-1910-8. Epub 2018 Jun 27.","Sharma N","Clin Transl Oncol","2019","2018/06/29","","","10.1007/s12094-018-1910-8"
"20192575","Risk factors for prostate cancer in Universiti Kebangsaan Malaysia Medical Centre: a case-control study","Subahir MN, Shah SA, Zainuddin ZM.","Asian Pac J Cancer Prev. 2009;10(6):1015-20.","Subahir MN","Asian Pac J Cancer Prev","2009","2010/03/03","","",""
"20014923","Putative molecular signatures for the imaging of prostate cancer","Yang S Y, Adelstein J, Kassis AI.","Expert Rev Mol Diagn. 2010 Jan;10(1):65-74. doi: 10.1586/erm.09.73.","Yang S Y","Expert Rev Mol Diagn","2010","2009/12/18","","","10.1586/erm.09.73"
"25328952","PSA testing beneficial for prostate cancer","Bagcchi S.","Lancet Oncol. 2014 Sep;15(10):e424. doi: 10.1016/s1470-2045(14)70385-7.","Bagcchi S","Lancet Oncol","2014","2014/10/21","","","10.1016/s1470-2045(14)70385-7"
"17150354","The metastatic cascade in prostate cancer","Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M, Patel HR.","Surg Oncol. 2006 Nov;15(3):117-28. doi: 10.1016/j.suronc.2006.10.002. Epub 2006 Dec 5.","Arya M","Surg Oncol","2006","2006/12/08","","","10.1016/j.suronc.2006.10.002"
"3078908","Hormonal therapy of prostate cancer: current concepts and future prospects","Smith JA Jr.","Clin Ther. 1988;10(3):281-6.","Smith JA Jr","Clin Ther","1988","1988/01/01","","",""
"23457453","Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E","MacInnis RJ, Severi G, Baglietto L, Dowty JG, Jenkins MA, Southey MC, Hopper JL, Giles GG.","PLoS One. 2013;8(2):e54727. doi: 10.1371/journal.pone.0054727. Epub 2013 Feb 15.","MacInnis RJ","PLoS One","2013","2013/03/05","PMC3574137","","10.1371/journal.pone.0054727"
"2124375","Tumor response and treatment complications in radiotherapy of localized prostate cancer","Strnad V, Tacev T, Prokes B, Ott O, Krystof V, Svobodova M, Rasovska O, Konecny M.","Strahlenther Onkol. 1990 Nov;166(11):728-32.","Strnad V","Strahlenther Onkol","1990","1990/11/01","","",""
"32303774","[Targeted molecular therapy and immunotherapy for prostate cancer]","Grüllich C, Nößner E, Pfister D, Grünwald V.","Urologe A. 2020 Jun;59(6):687-694. doi: 10.1007/s00120-020-01198-6.","Grüllich C","Urologe A","2020","2020/04/19","","","10.1007/s00120-020-01198-6"
"18539498","[Prostate specific antigen: utilization modalities and interpretation]","Hannoun-Levi JM, Ginot A, Thariat J.","Cancer Radiother. 2008 Dec;12(8):848-55. doi: 10.1016/j.canrad.2008.04.007. Epub 2008 Jun 9.","Hannoun-Levi JM","Cancer Radiother","2008","2008/06/10","","","10.1016/j.canrad.2008.04.007"
"27730440","Recent progress and perspectives on prostate cancer biomarkers","Hatakeyama S, Yoneyama T, Tobisawa Y, Ohyama C.","Int J Clin Oncol. 2017 Apr;22(2):214-221. doi: 10.1007/s10147-016-1049-y. Epub 2016 Oct 11.","Hatakeyama S","Int J Clin Oncol","2017","2016/10/13","PMC5378754","","10.1007/s10147-016-1049-y"
"7505233","Chemohormonal and immunohormonal approaches in advanced prostatic carcinoma","Pummer K, Lehnert M, Seewann HL.","Eur Urol. 1993;24 Suppl 2:81-6. doi: 10.1159/000474397.","Pummer K","Eur Urol","1993","1993/01/01","","","10.1159/000474397"
"16643613","Is interval from an initial biopsy a significant predictor of prostate cancer at repeat biopsies?","Satoh A, Matsumoto K, Nakamura S.","Int J Urol. 2006 Mar;13(3):224-7. doi: 10.1111/j.1442-2042.2006.01267.x.","Satoh A","Int J Urol","2006","2006/04/29","","","10.1111/j.1442-2042.2006.01267.x"
"27023445","Clinical Utility of Biomarkers in Localized Prostate Cancer","Leapman MS, Nguyen HG, Cooperberg MR.","Curr Oncol Rep. 2016 May;18(5):30. doi: 10.1007/s11912-016-0513-1.","Leapman MS","Curr Oncol Rep","2016","2016/03/30","","","10.1007/s11912-016-0513-1"
"23947187","[The functional and pathological analysis of mitochondrial protein p32]","Uchiumi T, Kang D.","Rinsho Byori. 2013 Jun;61(6):493-500.","Uchiumi T","Rinsho Byori","2013","2013/08/17","","",""
"26794623","The role of radical prostatectomy as an initial approach for the treatment of high-risk prostate cancer","Jaunarena JH, Villamil W, Martínez PF, Gueglio G, Giudice CR.","Actas Urol Esp. 2016 Jul-Aug;40(6):353-60. doi: 10.1016/j.acuro.2015.12.004. Epub 2016 Jan 12.","Jaunarena JH","Actas Urol Esp","2016","2016/01/23","","","10.1016/j.acuro.2015.12.004"
"19752610","Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significance","Normand G, Celhay O, Briffaux R, Pirès C, Doré B, Fromont G, Irani J.","Urol Int. 2009;83(2):160-5. doi: 10.1159/000230017. Epub 2009 Sep 10.","Normand G","Urol Int","2009","2009/09/16","","","10.1159/000230017"
"10605307","Economic and organizational aspects in the management of prostate cancer","Cellini N, Luzi S, Morganti AG, Mattiucci GC, Smaniotto D, Racioppi M.","Rays. 1999 Jul-Sep;24(3):460-71.","Cellini N","Rays","1999","1999/12/22","","",""
"12887471","Putative protein markers in the sera of men with prostatic neoplasms","Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG.","BJU Int. 2003 Aug;92(3):223-5. doi: 10.1046/j.1464-410x.2003.04341.x.","Lehrer S","BJU Int","2003","2003/07/31","","","10.1046/j.1464-410x.2003.04341.x"
"12956448","PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases","Aksoy Y, Oral A, Aksoy H, Demirel A, Akcay F.","Ann Clin Lab Sci. 2003 Summer;33(3):320-3.","Aksoy Y","Ann Clin Lab Sci","2003","2003/09/06","","",""
"28925899","A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer","Mohamad NV, Soelaiman IN, Chin KY.","Endocr Metab Immune Disord Drug Targets. 2017 Nov 16;17(4):276-284. doi: 10.2174/1871530317666170919112757.","Mohamad NV","Endocr Metab Immune Disord Drug Targets","2017","2017/09/20","","","10.2174/1871530317666170919112757"
"19806852","Prostate cancer treatment patterns among racial/ethnic groups in Florida","Xiao H, Warrick C, Huang Y.","J Natl Med Assoc. 2009 Sep;101(9):936-43. doi: 10.1016/s0027-9684(15)31042-7.","Xiao H","J Natl Med Assoc","2009","2009/10/08","","","10.1016/s0027-9684(15)31042-7"
"7505673","Screening for prostate cancer. How can patients give informed consent?","Marshall KG.","Can Fam Physician. 1993 Nov;39:2385-90.","Marshall KG","Can Fam Physician","1993","1993/11/01","PMC2379946","",""
"10466453","External beam radiation monotherapy for prostate cancer","Akakura K, Furuya Y, Suzuki H, Komiya A, Ichikawa T, Igarashi T, Tanaka M, Murakami S, Ito H.","Int J Urol. 1999 Aug;6(8):408-13. doi: 10.1046/j.1442-2042.1999.00082.x.","Akakura K","Int J Urol","1999","1999/08/31","","","10.1046/j.1442-2042.1999.00082.x"
"19754693","Men's and carers' experiences of care for prostate cancer: a narrative literature review","Sinfield P, Baker R, Camosso-Stefinovic J, Colman AM, Tarrant C, Mellon JK, Steward W, Kockelbergh R, Agarwal S.","Health Expect. 2009 Sep;12(3):301-12. doi: 10.1111/j.1369-7625.2009.00546.x.","Sinfield P","Health Expect","2009","2009/09/17","PMC5060497","","10.1111/j.1369-7625.2009.00546.x"
"30551978","Health Technology Assessment and Health Care Utilisation in the Management of Early Prostate Cancer","De Abreu Lourenco R, Williams S.","Eur Urol Focus. 2019 Mar;5(2):134-136. doi: 10.1016/j.euf.2018.11.010. Epub 2018 Dec 11.","De Abreu Lourenco R","Eur Urol Focus","2019","2018/12/16","","","10.1016/j.euf.2018.11.010"
"6192580","[Importance of impulse cytophotometry in the diagnosis and prognosis of prostate cancer]","Zimmermann A, Truss F, Blech M, Schröter W, Barth M.","Urologe A. 1983 May;22(3):151-6.","Zimmermann A","Urologe A","1983","1983/05/01","","",""
"30547961","Nurse-Led Supportive Care Intervention for Men With Advanced Prostate Cancer","Ralph N, Chambers S, Pomery A, Oliffe J, Dunn J.","Oncol Nurs Forum. 2019 Jan 13;46(1):92-103. doi: 10.1188/19.ONF.92-103.","Ralph N","Oncol Nurs Forum","2019","2018/12/15","","","10.1188/19.ONF.92-103"
"2399191","Flow cytometric analysis of localized adenocarcinoma of the prostate: the use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy","Ring KS, Karp FS, Olsson CA, O'Toole K, Bixon R, Benson MC.","Prostate. 1990;17(2):155-64. doi: 10.1002/pros.2990170209.","Ring KS","Prostate","1990","1990/01/01","","","10.1002/pros.2990170209"
"25870249","Regulation of vascular endothelial growth factor in prostate cancer","de Brot S, Ntekim A, Cardenas R, James V, Allegrucci C, Heery DM, Bates DO, Ødum N, Persson JL, Mongan NP.","Endocr Relat Cancer. 2015 Jun;22(3):R107-23. doi: 10.1530/ERC-15-0123. Epub 2015 Apr 13.","de Brot S","Endocr Relat Cancer","2015","2015/04/15","","","10.1530/ERC-15-0123"
"28366275","Quality of life after treatments for prostate cancer","Venkatesan P.","Lancet Oncol. 2017 May;18(5):e249. doi: 10.1016/S1470-2045(17)30244-9. Epub 2017 Mar 31.","Venkatesan P","Lancet Oncol","2017","2017/04/04","","","10.1016/S1470-2045(17)30244-9"
"8805875","Prostate cancer in HIV infection","Schwartz JD, Prince D.","AIDS. 1996 Jun;10(7):797-8. doi: 10.1097/00002030-199606001-00018.","Schwartz JD","AIDS","1996","1996/06/01","","","10.1097/00002030-199606001-00018"
"1719250","Re: Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer","Blackard CE.","J Urol. 1991 Dec;146(6):1621-2. doi: 10.1016/s0022-5347(17)38198-3.","Blackard CE","J Urol","1991","1991/12/01","","","10.1016/s0022-5347(17)38198-3"
"18560799","[Status of care for prostate cancer in 2008]","Arndt B, Kwiatkowski M, Recker F.","Urologe A. 2008 Aug;47(8):969-74. doi: 10.1007/s00120-008-1777-3.","Arndt B","Urologe A","2008","2008/06/19","","","10.1007/s00120-008-1777-3"
"21704261","Identifying novel prostate cancer associated pathways based on integrative microarray data analysis","Wang Y, Chen J, Li Q, Wang H, Liu G, Jing Q, Shen B.","Comput Biol Chem. 2011 Jun;35(3):151-8. doi: 10.1016/j.compbiolchem.2011.04.003. Epub 2011 Apr 27.","Wang Y","Comput Biol Chem","2011","2011/06/28","","","10.1016/j.compbiolchem.2011.04.003"
"27836710","Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial","Lewicki P, Shoag J, Golombos DM, Oromendia C, Ballman KV, Halpern JA, Stone BV, O'Malley P, Barbieri CE, Scherr DS.","J Urol. 2017 Apr;197(4):1014-1019. doi: 10.1016/j.juro.2016.11.002. Epub 2016 Nov 8.","Lewicki P","J Urol","2017","2016/11/13","","","10.1016/j.juro.2016.11.002"
"10691827","Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry","Spapen SJ, Damhuis RA, Kirkels WJ.","BJU Int. 2000 Mar;85(4):474-80. doi: 10.1046/j.1464-410x.2000.00481.x.","Spapen SJ","BJU Int","2000","2000/02/26","","","10.1046/j.1464-410x.2000.00481.x"
"20651075","Prostate cancer susceptibility variants confer increased risk of disease progression","Cheng I, Plummer SJ, Neslund-Dudas C, Klein EA, Casey G, Rybicki BA, Witte JS.","Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2124-32. doi: 10.1158/1055-9965.EPI-10-0268. Epub 2010 Jul 22.","Cheng I","Cancer Epidemiol Biomarkers Prev","2010","2010/07/24","PMC2950095","NIHMS218930","10.1158/1055-9965.EPI-10-0268"
"18451224","PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy","Morote J, Fernández S, Alaña L, Iglesias C, Planas J, Reventós J, Ramón Y Cajal S, Paciucci R, de Torres IM.","Clin Cancer Res. 2008 May 1;14(9):2617-22. doi: 10.1158/1078-0432.CCR-07-4987.","Morote J","Clin Cancer Res","2008","2008/05/03","","","10.1158/1078-0432.CCR-07-4987"
"23853045","Flow cytometric characterization of tumor subpopulations in three sublines of the Dunning R3327 rat prostate tumor model","Glowa C, Peschke P, Karger CP, Hahn EW, Huber PE, Debus J, Ehemann V.","Prostate. 2013 Nov;73(15):1710-20. doi: 10.1002/pros.22710. Epub 2013 Jul 12.","Glowa C","Prostate","2013","2013/07/16","","","10.1002/pros.22710"
"9474117","Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy","Prins GS, Sklarew RJ, Pertschuk LP.","J Urol. 1998 Mar;159(3):641-9.","Prins GS","J Urol","1998","1998/02/25","","",""
"27035282","Anticancer effect of docetaxel induces apoptosis of prostate cancer via the cofilin-1 and paxillin signaling pathway","Xiao P, Ma T, Zhou C, Xu Y, Liu Y, Zhang H.","Mol Med Rep. 2016 May;13(5):4079-84. doi: 10.3892/mmr.2016.5000. Epub 2016 Mar 18.","Xiao P","Mol Med Rep","2016","2016/04/02","","","10.3892/mmr.2016.5000"
"26190749","Active surveillance preferred for low-risk prostate cancer","Bagcchi S.","Lancet Oncol. 2015 Aug;16(8):e384. doi: 10.1016/S1470-2045(15)00155-2. Epub 2015 Jul 16.","Bagcchi S","Lancet Oncol","2015","2015/07/21","","","10.1016/S1470-2045(15)00155-2"
"28361223","Emerging Variants of Castration-Resistant Prostate Cancer","Vlachostergios PJ, Puca L, Beltran H.","Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6.","Vlachostergios PJ","Curr Oncol Rep","2017","2017/04/01","PMC5479409","NIHMS865072","10.1007/s11912-017-0593-6"
"16314891","Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines","Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, Klotz LH.","Prostate Cancer Prostatic Dis. 2006;9(1):68-76. doi: 10.1038/sj.pcan.4500845.","Haddad AQ","Prostate Cancer Prostatic Dis","2006","2005/11/30","","","10.1038/sj.pcan.4500845"
"8769028","[Prostate cancer: palpation versus ultrasonography]","Nagy V, Valanský L, Sokol L, Petrovicová J.","Rozhl Chir. 1996 Jun;75(6):322-6.","Nagy V","Rozhl Chir","1996","1996/06/01","","",""
"18043601","Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention","Klotz L.","Nat Clin Pract Urol. 2008 Jan;5(1):2-3. doi: 10.1038/ncpuro0993. Epub 2007 Nov 27.","Klotz L","Nat Clin Pract Urol","2008","2007/11/29","","","10.1038/ncpuro0993"
"10386630","What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy","Duchesne GM, Peters LJ.","Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):747-8. doi: 10.1016/s0360-3016(99)00024-3.","Duchesne GM","Int J Radiat Oncol Biol Phys","1999","1999/07/01","","","10.1016/s0360-3016(99)00024-3"
"15150616","Confounding effect of socioeconomic position in the study of height in relation to prostate cancer risk","Batty GD.","Br J Cancer. 2004 May 4;90(9):1875; author reply 1876. doi: 10.1038/sj.bjc.6601799.","Batty GD","Br J Cancer","2004","2004/05/20","PMC2409736","","10.1038/sj.bjc.6601799"
"11459874","Re: Prostate cancer incidence and mortality in the United States and the United Kingdom","Shibata A, Whittemore AS.","J Natl Cancer Inst. 2001 Jul 18;93(14):1109-10. doi: 10.1093/jnci/93.14.1109.","Shibata A","J Natl Cancer Inst","2001","2001/07/19","","","10.1093/jnci/93.14.1109"
"28620751","Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy","Maggio A, Gabriele D, Garibaldi E, Bresciani S, Delmastro E, Di Dia A, Miranti A, Poli M, Varetto T, Stasi M, Gabriele P.","Strahlenther Onkol. 2017 Sep;193(9):722-732. doi: 10.1007/s00066-017-1163-4. Epub 2017 Jun 15.","Maggio A","Strahlenther Onkol","2017","2017/06/17","","","10.1007/s00066-017-1163-4"
"8428323","Adjuvant therapy for localized prostate cancer","Schmidt JD, Gibbons RP, Murphy GP, Bartolucci A.","Cancer. 1993 Feb 1;71(3 Suppl):1005-13. doi: 10.1002/1097-0142(19930201)71:3+<1005::aid-cncr2820711418>3.0.co;2-i.","Schmidt JD","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1005::aid-cncr2820711418>3.0.co;2-i"
"25964638","Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center","Martin JM, Li T, Johnson ME, Murphy CT, Howald AG, Smaldone MC, Kutikov A, Chen DY, Viterbo R, Greenberg RE, Uzzo RG, Horwitz EM.","J Natl Compr Canc Netw. 2015 May;13(5):525-30. doi: 10.6004/jnccn.2015.0072.","Martin JM","J Natl Compr Canc Netw","2015","2015/05/13","","","10.6004/jnccn.2015.0072"
"19832899","Maintaining control over illness: a model of partner activity in prostate cancer","Nanton V, Osborne D, Dale J.","Eur J Cancer Care (Engl). 2010 May;19(3):329-39. doi: 10.1111/j.1365-2354.2008.01047.x. Epub 2009 Oct 15.","Nanton V","Eur J Cancer Care (Engl)","2010","2009/10/17","","","10.1111/j.1365-2354.2008.01047.x"
"31521707","Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer","O'Reilly D, Johnson P, Buchanan PJ.","Steroids. 2019 Dec;152:108497. doi: 10.1016/j.steroids.2019.108497. Epub 2019 Sep 12.","O'Reilly D","Steroids","2019","2019/09/16","","","10.1016/j.steroids.2019.108497"
"25603587","Obesity, metformin and prostate cancer risk","Rees J.","Practitioner. 2014 Dec;258(1777):5.","Rees J","Practitioner","2014","2015/01/22","","",""
"28781111","Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion","Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.","Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.","Bhindi B","Urol Oncol","2017","2017/08/08","","","10.1016/j.urolonc.2017.06.044"
"25715578","[Evaluation of prostate cancer progression]","Mocarska A, Czarnocki K, Starosławska E, Janczarek M, Zelazowska-Cieslińska I, Losicki M, Burdan F.","Pol Merkur Lekarski. 2014 Dec;37(222):356-64.","Mocarska A","Pol Merkur Lekarski","2014","2015/02/27","","",""
"20217905","By the way, doctor. I have heard that doctors feel men over 60 shouldn't be treated for prostate cancer because they're old enough that they are going to die anyway. Is that so?","Komaroff AL.","Harv Health Lett. 2010 Jan;35(3):8.","Komaroff AL","Harv Health Lett","2010","2010/03/11","","",""
"9598549","Re: Immediate versus deferred treatment for advanced prostate cancer: initial results of the medical research council trial","Kirk D.","J Urol. 1998 Jun;159(6):2105-6. doi: 10.1016/s0022-5347(01)63284-1.","Kirk D","J Urol","1998","1998/05/23","","","10.1016/s0022-5347(01)63284-1"
"3835348","[Perineal total prostatectomy for localized prostate cancer: follow-up study]","Horie M, Shinoda I, Fujimoto Y, Hasegawa Y, Fujihiro S, Takeuchi T, Kanematsu M, Kuriyama M, Ban Y, Nishiura T.","Nihon Hinyokika Gakkai Zasshi. 1985 Oct;76(10):1542-9. doi: 10.5980/jpnjurol1928.76.10_1542.","Horie M","Nihon Hinyokika Gakkai Zasshi","1985","1985/10/01","","","10.5980/jpnjurol1928.76.10_1542"
"21849659","Re: Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study","Lee AH, Binns CW.","J Natl Cancer Inst. 2011 Oct 5;103(19):1481; author reply 1481-2. doi: 10.1093/jnci/djr305. Epub 2011 Aug 17.","Lee AH","J Natl Cancer Inst","2011","2011/08/19","","","10.1093/jnci/djr305"
"30671889","Whole mount histopathological correlation with prostate MRI in Grade I and II prostatectomy patients","Wang M, Janaki N, Buzzy C, Bukavina L, Mahran A, Mishra K, MacLennan G, Ponsky L.","Int Urol Nephrol. 2019 Mar;51(3):425-434. doi: 10.1007/s11255-019-02083-8. Epub 2019 Jan 22.","Wang M","Int Urol Nephrol","2019","2019/01/24","","","10.1007/s11255-019-02083-8"
"18707696","Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era","Ercole B, Marietti SR, Fine J, Albertsen PC.","J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1. doi: 10.1016/j.juro.2008.06.027. Epub 2008 Aug 15.","Ercole B","J Urol","2008","2008/08/19","","","10.1016/j.juro.2008.06.027"
"18427432","Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer","Nguyen MM, Wang Z.","Minerva Urol Nefrol. 2008 Mar;60(1):15-29.","Nguyen MM","Minerva Urol Nefrol","2008","2008/04/23","","",""
"12493316","Androgen suppression and irradiation for locally advanced prostate cancer","Hrushesky WJ.","Lancet. 2002 Dec 14;360(9349):1987; author reply 1987-8. doi: 10.1016/S0140-6736(02)11898-8.","Hrushesky WJ","Lancet","2002","2002/12/21","","","10.1016/S0140-6736(02)11898-8"
"10810059","On call. I am a 69-year-old man who had a radical prostatectomy three years ago. I feel fine and my PSA is undetectable. I've heard that a special scan can detect prostate cancer, but my hospital doesn't seem to know about it. Should I try to arrange one?","Simon HB.","Harv Mens Health Watch. 2000 Jun;4(11):8.","Simon HB","Harv Mens Health Watch","2000","2000/05/16","","",""
"26482003","Symptoms and self-care strategies during and six months after radiotherapy for prostate cancer - Scoping the perspectives of patients, professionals and literature","Blomberg K, Wengström Y, Sundberg K, Browall M, Isaksson AK, Nyman MH, Langius-Eklöf A.","Eur J Oncol Nurs. 2016 Apr;21:139-45. doi: 10.1016/j.ejon.2015.09.004. Epub 2015 Oct 21.","Blomberg K","Eur J Oncol Nurs","2016","2015/10/21","","","10.1016/j.ejon.2015.09.004"
"27610695","Psychosocial screening for patients with prostate cancer: The development and validation of the psychosocial distress questionnaire-prostate cancer","Castermans E, Coenders M, Beerlage HP, de Vries J.","J Psychosoc Oncol. 2016 Nov-Dec;34(6):512-529. doi: 10.1080/07347332.2016.1233925. Epub 2016 Sep 9.","Castermans E","J Psychosoc Oncol","2016","2016/09/10","","","10.1080/07347332.2016.1233925"
"7544844","The central role of prostate specific antigen in diagnosis and progression of prostate cancer","Stamey TA.","J Urol. 1995 Oct;154(4):1418-9. doi: 10.1016/s0022-5347(01)66880-0.","Stamey TA","J Urol","1995","1995/10/01","","","10.1016/s0022-5347(01)66880-0"
"11164134","Gene therapy for prostate cancer","Shalev M, Thompson TC, Kadmon D, Ayala G, Kernen K, Miles BJ.","Urology. 2001 Jan;57(1):8-16. doi: 10.1016/s0090-4295(00)00903-1.","Shalev M","Urology","2001","2001/02/13","","","10.1016/s0090-4295(00)00903-1"
"18813218","What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?","Kollmeier MA, Zelefsky MJ.","Nat Clin Pract Urol. 2008 Nov;5(11):584-5. doi: 10.1038/ncpuro1217. Epub 2008 Sep 23.","Kollmeier MA","Nat Clin Pract Urol","2008","2008/09/25","","","10.1038/ncpuro1217"
"15040876","Third annual meeting of the Society of Urologic Oncology: Bethesda, Maryland, December 13-14, 2002","Lee D.","Clin Prostate Cancer. 2003 Mar;1(4):203-6.","Lee D","Clin Prostate Cancer","2003","2004/03/26","","",""
"20127633","[Prostate cancer]","Hefermehl L, Elke B, Sulser T.","Praxis (Bern 1994). 2010 Feb 3;99(3):149-56, 158; quiz 157. doi: 10.1024/1661-8157/a000044.","Hefermehl L","Praxis (Bern 1994)","2010","2010/02/04","","","10.1024/1661-8157/a000044"
"17075603","Clinical implications of neuroendocrine differentiation in prostate cancer","Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr, Evans CP.","Prostate Cancer Prostatic Dis. 2007;10(1):6-14. doi: 10.1038/sj.pcan.4500922. Epub 2006 Oct 31.","Nelson EC","Prostate Cancer Prostatic Dis","2007","2006/11/01","","","10.1038/sj.pcan.4500922"
"29463374","Nano-Vesicles are a Potential Tool to Monitor Therapeutic Efficacy of Carbon Ion Radiotherapy in Prostate Cancer","Yu Q, Li P, Weng M, Wu S, Zhang Y, Chen X, Zhang Q, Shen G, Ding X, Fu S.","J Biomed Nanotechnol. 2018 Jan 1;14(1):168-178. doi: 10.1166/jbn.2018.2503.","Yu Q","J Biomed Nanotechnol","2018","2018/02/22","","","10.1166/jbn.2018.2503"
"21122899","Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy","Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ.","Urology. 2011 May;77(5):1161-5. doi: 10.1016/j.urology.2010.07.504. Epub 2010 Dec 3.","Tollefson MK","Urology","2011","2010/12/03","","","10.1016/j.urology.2010.07.504"
"28865421","Trends in risk classification and primary therapy of Japanese patients with prostate cancer in Nara urological research and treatment group (NURTG) - comparison between 2004-2006, 2007-2009, and 2010-2012","Tanaka N, Nakai Y, Miyake M, Anai S, Inoue T, Fujii T, Konishi N, Fujimoto K.","BMC Cancer. 2017 Sep 2;17(1):616. doi: 10.1186/s12885-017-3637-2.","Tanaka N","BMC Cancer","2017","2017/09/04","PMC5581463","","10.1186/s12885-017-3637-2"
"27863019","78Gy with Fiducial Marker Image-Guided Radiotherapy in Prostate Cancer: Single Center Analysis of 301 Patients","Choong ES, Hruby G, Yang J, Kwong C, Patanjali N.","Asia Pac J Clin Oncol. 2017 Oct;13(5):e356-e363. doi: 10.1111/ajco.12637. Epub 2016 Nov 10.","Choong ES","Asia Pac J Clin Oncol","2017","2016/11/19","","","10.1111/ajco.12637"
"14655599","[Stage A prostate cancer: comparison of subclassification between Japanese rule and TNM, and outcome]","Tanaka M, Suzuki N, Nakatsu H, Murakami S, Matsuzaki O, Shimazaki J.","Hinyokika Kiyo. 2003 Oct;49(10):579-82.","Tanaka M","Hinyokika Kiyo","2003","2003/12/06","","",""
"22183772","Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior","Gueron G, De Siervi A, Vazquez E.","Prostate Cancer Prostatic Dis. 2012 Sep;15(3):213-21. doi: 10.1038/pcan.2011.64. Epub 2011 Dec 20.","Gueron G","Prostate Cancer Prostatic Dis","2012","2011/12/21","","","10.1038/pcan.2011.64"
"17091359","Responsiveness of disease-specific and generic utility instruments in prostate cancer patients","Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G.","Qual Life Res. 2007 Apr;16(3):509-22. doi: 10.1007/s11136-006-9132-x. Epub 2006 Nov 8.","Krahn M","Qual Life Res","2007","2006/11/09","","","10.1007/s11136-006-9132-x"
"17701110","Focal or subtotal therapy for early stage prostate cancer","Jones JS.","Curr Treat Options Oncol. 2007 Jun;8(3):165-72. doi: 10.1007/s11864-007-0033-1.","Jones JS","Curr Treat Options Oncol","2007","2007/08/19","","","10.1007/s11864-007-0033-1"
"31030228","Recurrence in prostate cancer: salvage diagnostic and therapeutic strategies","Goonewardene S.","World J Urol. 2019 Aug;37(8):1467-1468. doi: 10.1007/s00345-019-02778-8.","Goonewardene S","World J Urol","2019","2019/04/29","","","10.1007/s00345-019-02778-8"
"19616286","Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients: oppose","Stone NN.","Urology. 2009 Oct;74(4):731-4. doi: 10.1016/j.urology.2009.05.023. Epub 2009 Jul 17.","Stone NN","Urology","2009","2009/07/21","","","10.1016/j.urology.2009.05.023"
"16904051","Should finasteride be used to prevent prostate cancer?","Fleshner N, Kulkarni G.","Curr Treat Options Oncol. 2006 Sep;7(5):346-54. doi: 10.1007/s11864-006-0002-0.","Fleshner N","Curr Treat Options Oncol","2006","2006/08/15","","","10.1007/s11864-006-0002-0"
"10853027","Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters","Ozen M, Hopwood VL, Balbay MD, Johnston DA, Babaian RJ, Logothetis CJ, von Eschenbach AC, Pathak S.","Int J Oncol. 2000 Jul;17(1):113-7. doi: 10.3892/ijo.17.1.113.","Ozen M","Int J Oncol","2000","2000/06/15","","","10.3892/ijo.17.1.113"
"15202585","New generation of bisphosphonates: broad clinical utility in breast and prostate cancer","Rosen LS.","Oncology (Williston Park). 2004 May;18(5 Suppl 3):26-32.","Rosen LS","Oncology (Williston Park)","2004","2004/06/19","","",""
"7513530","Role of prostate-specific antigen as a predictor of outcome in prostate cancer","Blackledge GR, Lowery K.","Prostate Suppl. 1994;5:34-8. doi: 10.1002/pros.2990250710.","Blackledge GR","Prostate Suppl","1994","1994/01/01","","","10.1002/pros.2990250710"
"19393531","[Oncologic and functional outcomes after radical prostatectomy in T3 prostate cancer]","Xylinas E, Misraï V, Comperat E, Renard-Penna R, Vaessen C, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O, Rouprêt M.","Prog Urol. 2009 May;19(5):285-90. doi: 10.1016/j.purol.2009.01.008. Epub 2009 Mar 9.","Xylinas E","Prog Urol","2009","2009/04/28","","","10.1016/j.purol.2009.01.008"
"29906406","The malignancy index in plasma samples as a prostate cancer biomarker","Serafin AM, Chinhengo A, Fernandez P, Akudugu JM.","Discov Med. 2018 May;25(139):235-242.","Serafin AM","Discov Med","2018","2018/06/16","","",""
"15534082","The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer","Nishiyama T, Hashimoto Y, Takahashi K.","Clin Cancer Res. 2004 Nov 1;10(21):7121-6. doi: 10.1158/1078-0432.CCR-04-0913.","Nishiyama T","Clin Cancer Res","2004","2004/11/10","","","10.1158/1078-0432.CCR-04-0913"
"24924835","Diffusion kurtosis imaging study of prostate cancer: preliminary findings","Tamura C, Shinmoto H, Soga S, Okamura T, Sato H, Okuaki T, Pang Y, Kosuda S, Kaji T.","J Magn Reson Imaging. 2014 Sep;40(3):723-9. doi: 10.1002/jmri.24379. Epub 2013 Oct 31.","Tamura C","J Magn Reson Imaging","2014","2014/06/14","","","10.1002/jmri.24379"
"11011430","[Survival in prostatic cancer, treated conservatively]","Mesa García A, Pérez García FJ.","Actas Urol Esp. 2000 Jun;24(6):475-80. doi: 10.1016/s0210-4806(00)72486-7.","Mesa García A","Actas Urol Esp","2000","2000/09/30","","","10.1016/s0210-4806(00)72486-7"
"17323487","Obesity and prostate cancer","","Harv Mens Health Watch. 2007 Jan;11(6):1-3.","","Harv Mens Health Watch","2007","2007/02/28","","",""
"25454576","Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment","Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM.","Brachytherapy. 2015 May-Jun;14(3):316-21. doi: 10.1016/j.brachy.2014.09.012. Epub 2014 Nov 7.","Shaikh T","Brachytherapy","2015","2014/12/03","PMC4424094","NIHMS642367","10.1016/j.brachy.2014.09.012"
"27894505","[Prostate cancer: To treat or not to treat?]","Mazeron JJ.","Bull Cancer. 2017 Jan;104(1):4-5. doi: 10.1016/j.bulcan.2016.10.021. Epub 2016 Nov 25.","Mazeron JJ","Bull Cancer","2017","2016/11/30","","","10.1016/j.bulcan.2016.10.021"
"1376191","Clinical diagnosis of prostate cancer","Schmidt JD.","Cancer. 1992 Jul 1;70(1 Suppl):221-4. doi: 10.1002/1097-0142(19920701)70:1+<221::aid-cncr2820701308>3.0.co;2-9.","Schmidt JD","Cancer","1992","1992/07/01","","","10.1002/1097-0142(19920701)70:1+<221::aid-cncr2820701308>3.0.co;2-9"
"15298146","Prognostic factors in prostate cancer","Ross JS, Jennings TA, Nazeer T, Sheehan CE, Fisher HA, Kauffman RA, Anwar S, Kallakury BV.","Am J Clin Pathol. 2003 Dec;120 Suppl:S85-100. doi: 10.1309/PW69K48RRFJLXKBD.","Ross JS","Am J Clin Pathol","2003","2004/08/10","","","10.1309/PW69K48RRFJLXKBD"
"30325986","Association of Androgen Deprivation Therapy With Dementia in Men With Prostate Cancer Who Receive Definitive Radiation Therapy","Deka R, Simpson DR, Bryant AK, Nalawade V, McKay R, Murphy JD, Rose BS.","JAMA Oncol. 2018 Nov 1;4(11):1616-1617. doi: 10.1001/jamaoncol.2018.4423.","Deka R","JAMA Oncol","2018","2018/10/17","PMC6248075","","10.1001/jamaoncol.2018.4423"
"18983007","[Could the transrectal prostate biopsy predict the rate of positive lymph nodes in prostate cancer patients?]","Ormanov D, Kirilov S, Simeonov P, Bonev K, Ianev K, Dimitrov P, Vasilev V, Georgiev M, Panchev P.","Khirurgiia (Sofiia). 2008;(1-2):37-9.","Ormanov D","Khirurgiia (Sofiia)","2008","2008/11/06","","",""
"9743699","Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate","Akakura K, Akimoto S, Furuya Y, Ito H.","Eur Urol. 1998;33(6):567-71. doi: 10.1159/000019657.","Akakura K","Eur Urol","1998","1998/09/23","","","10.1159/000019657"
"19174583","Finasteride and high-grade prostate cancer","Edwards JL.","Cancer Prev Res (Phila). 2009 Feb;2(2):185; author reply 185. doi: 10.1158/1940-6207.CAPR-08-0117. Epub 2009 Jan 27.","Edwards JL","Cancer Prev Res (Phila)","2009","2009/01/29","","","10.1158/1940-6207.CAPR-08-0117"
"21185115","Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer","Williams AK, Martínez CH, Lu C, Ng CK, Pautler SE, Chin JL.","Eur Urol. 2011 Sep;60(3):405-10. doi: 10.1016/j.eururo.2010.12.012. Epub 2010 Dec 21.","Williams AK","Eur Urol","2011","2010/12/28","","","10.1016/j.eururo.2010.12.012"
"17607048","The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients","Jani AB, Liauw SL, Blend MJ.","Clin Med Res. 2007 Jun;5(2):123-31. doi: 10.3121/cmr.2007.740.","Jani AB","Clin Med Res","2007","2007/07/04","PMC1905929","","10.3121/cmr.2007.740"
"10961282","Prostate cancer staging using imaging","Engelbrecht MR, Barentsz JO, Jager GJ, van der Graaf M, Heerschap A, Sedelaar JP, Aarnink RG, de la Rosette JJ.","BJU Int. 2000 Jul;86 Suppl 1:123-34. doi: 10.1046/j.1464-410x.2000.00592.x.","Engelbrecht MR","BJU Int","2000","2000/08/29","","","10.1046/j.1464-410x.2000.00592.x"
"19788872","Targeting alternative splicing in prostate oncology","Carling PJ, Elliott DJ, Robson CN, Leung HY, Rajan P.","Discov Med. 2009 Aug;8(41):74-80.","Carling PJ","Discov Med","2009","2009/10/01","","",""
"21233290","Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis","Cao Y, Ma J.","Cancer Prev Res (Phila). 2011 Apr;4(4):486-501. doi: 10.1158/1940-6207.CAPR-10-0229. Epub 2011 Jan 13.","Cao Y","Cancer Prev Res (Phila)","2011","2011/01/15","PMC3071449","NIHMS264532","10.1158/1940-6207.CAPR-10-0229"
"15707506","Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility","Labrie F.","Int Braz J Urol. 2004 Jan-Feb;30(1):3-11. doi: 10.1590/s1677-55382004000100002.","Labrie F","Int Braz J Urol","2004","2005/02/15","","","10.1590/s1677-55382004000100002"
"20976069","Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models","Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G.","PLoS One. 2010 Oct 19;5(10):e13500. doi: 10.1371/journal.pone.0013500.","Marques RB","PLoS One","2010","2010/10/27","PMC2957443","","10.1371/journal.pone.0013500"
"18098220","External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis","Hoffman KE, Hong TS, Zietman AL, Russell AH.","Cancer. 2008 Feb 15;112(4):943-9. doi: 10.1002/cncr.23241.","Hoffman KE","Cancer","2008","2007/12/22","","","10.1002/cncr.23241"
"30466907","MR Imaging-Guided Focal Therapies of Prostate Cancer","Mathew MS, Oto A.","Magn Reson Imaging Clin N Am. 2019 Feb;27(1):131-138. doi: 10.1016/j.mric.2018.08.004. Epub 2018 Oct 29.","Mathew MS","Magn Reson Imaging Clin N Am","2019","2018/11/24","","","10.1016/j.mric.2018.08.004"
"9293678","Four-week arc radiotherapy for B2-C prostate cancer: the need for prospective evaluation of short fractionation schemes","Graham PH, Morris WJ, Pickles TP.","Australas Radiol. 1997 Aug;41(3):266-9. doi: 10.1111/j.1440-1673.1997.tb00671.x.","Graham PH","Australas Radiol","1997","1997/08/01","","","10.1111/j.1440-1673.1997.tb00671.x"
"16890678","Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading","Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, Reuter VA, Eastham JA.","J Urol. 2006 Sep;176(3):991-5. doi: 10.1016/j.juro.2006.04.048.","Donohue JF","J Urol","2006","2006/08/08","PMC2239297","NIHMS38088","10.1016/j.juro.2006.04.048"
"26452032","Effects of interferons and double-stranded RNA on human prostate cancer cell apoptosis","Tan H, Zeng C, Xie J, Alghamdi NJ, Song Y, Zhang H, Zhou A, Jin D.","Oncotarget. 2015 Nov 17;6(36):39184-95. doi: 10.18632/oncotarget.5508.","Tan H","Oncotarget","2015","2015/10/10","PMC4770765","","10.18632/oncotarget.5508"
"9834724","Prostate cancer: 4. Screening","Meyer F, Fradet Y.","CMAJ. 1998 Oct 20;159(8):968-72.","Meyer F","CMAJ","1998","1998/12/03","PMC1229744","",""
"8456053","DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate","Crissman JD, Sakr WA, Hussein ME, Pontes JE.","Prostate. 1993;22(2):155-62. doi: 10.1002/pros.2990220208.","Crissman JD","Prostate","1993","1993/01/01","","","10.1002/pros.2990220208"
"21541975","Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer","Chornokur G, Dalton K, Borysova ME, Kumar NB.","Prostate. 2011 Jun 15;71(9):985-97. doi: 10.1002/pros.21314. Epub 2010 Dec 28.","Chornokur G","Prostate","2011","2011/05/05","PMC3083484","NIHMS262906","10.1002/pros.21314"
"27067830","Prostate cancer urine assay could spare biopsies","Carlson RH.","Lancet Oncol. 2016 May;17(5):e185. doi: 10.1016/S1470-2045(16)30046-8. Epub 2016 Apr 7.","Carlson RH","Lancet Oncol","2016","2016/04/13","","","10.1016/S1470-2045(16)30046-8"
"20369697","[Comparison of transcription factors repressing epithelial phenotype in two different prostate cancer EMT models and its significance]","Wu KJ, Zeng J, Zhu GD, Zhang D, Xue Y, Chen YL, Wang XY, He DL.","Zhonghua Nan Ke Xue. 2010 Feb;16(2):137-41.","Wu KJ","Zhonghua Nan Ke Xue","2010","2010/04/08","","",""
"10699614","Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters?","Zhang YH, Kanamaru H, Oyama N, Miwa Y, Suzuki Y, Akino H, Noriki S, Okada K.","Urology. 2000 Mar;55(3):377-81. doi: 10.1016/s0090-4295(99)00456-2.","Zhang YH","Urology","2000","2000/03/04","","","10.1016/s0090-4295(99)00456-2"
"15714972","[Recent advancement in diagnosis and treatment of prostate cancer--general concepts]","Akaza H.","Nihon Rinsho. 2005 Feb;63(2):237-40.","Akaza H","Nihon Rinsho","2005","2005/02/18","","",""
"7885688","[Follow up of patients with prostatic cancer after radical prostatectomy: results, late complication, survival rate]","Romics I, Bach D, Würtz U.","Orv Hetil. 1995 Feb 19;136(8):421-3.","Romics I","Orv Hetil","1995","1995/02/19","","",""
"26612463","Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer","Murphy SJ, Karnes RJ, Kosari F, Castellar BE, Kipp BR, Johnson SH, Terra S, Harris FR, Halling GC, Klein JL, Nasir A, Bergstrahl E, Rangel LJ, Sukov WR, Vasmatzis G, Cheville JC.","Mod Pathol. 2016 Feb;29(2):143-56. doi: 10.1038/modpathol.2015.136. Epub 2015 Nov 27.","Murphy SJ","Mod Pathol","2016","2015/11/28","","","10.1038/modpathol.2015.136"
"24432616","[Expressions of netrin-1 and UNC5B in prostate cancer and their clinical significance]","Liu J, Kong CZ.","Zhonghua Nan Ke Xue. 2013 Dec;19(12):1072-6.","Liu J","Zhonghua Nan Ke Xue","2013","2014/01/18","","",""
"28816169","Long-Term Results of a Randomized Trial Comparing Iridium Implant Plus External Beam Radiation Therapy With External Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate","Dayes IS, Parpia S, Gilbert J, Julian JA, Davis IR, Levine MN, Sathya J.","Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):90-93. doi: 10.1016/j.ijrobp.2017.05.013. Epub 2017 May 17.","Dayes IS","Int J Radiat Oncol Biol Phys","2017","2017/08/18","","","10.1016/j.ijrobp.2017.05.013"
"7526772","The diagnostic and therapeutic window for localized carcinoma of the prostate","Schmid HP.","Ann Urol (Paris). 1994;28(4):178-83.","Schmid HP","Ann Urol (Paris)","1994","1994/01/01","","",""
"16676364","The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes","Schroeder JC, Bensen JT, Su LJ, Mishel M, Ivanova A, Smith GJ, Godley PA, Fontham ET, Mohler JL.","Prostate. 2006 Aug 1;66(11):1162-76. doi: 10.1002/pros.20449.","Schroeder JC","Prostate","2006","2006/05/06","","","10.1002/pros.20449"
"10394406","Conformal proton beam therapy of prostate cancer--update on the Loma Linda University medical center experience","Rossi CJ.","Strahlenther Onkol. 1999 Jun;175 Suppl 2:82-4. doi: 10.1007/BF03038897.","Rossi CJ","Strahlenther Onkol","1999","1999/07/08","","","10.1007/BF03038897"
"30772671","Initial results of a randomized phase III trial of high dose image guided radiation with or without androgen deprivation therapy for intermediate-risk prostate cancer","Vargas CE, Alam NB, Terk M, Niska JR, Cesaretti J, Swartz D, Vashi A, Kasraeian A, West CS, Blasser M, Moore C.","Cancer Treat Res Commun. 2019;19:100119. doi: 10.1016/j.ctarc.2019.100119. Epub 2019 Feb 10.","Vargas CE","Cancer Treat Res Commun","2019","2019/02/18","","","10.1016/j.ctarc.2019.100119"
"28229393","Mechanisms of Therapeutic Resistance in Prostate Cancer","Nakazawa M, Paller C, Kyprianou N.","Curr Oncol Rep. 2017 Feb;19(2):13. doi: 10.1007/s11912-017-0568-7.","Nakazawa M","Curr Oncol Rep","2017","2017/02/24","PMC5812366","NIHMS934575","10.1007/s11912-017-0568-7"
"24962590","Racial disparities in urologist visits among elderly men with prostate cancer: a cohort analysis of patient-related and county of residence-related factors","Onukwugha E, Osteen P, Jayasekera J, Mullins CD, Mair CA, Hussain A.","Cancer. 2014 Nov 1;120(21):3385-92. doi: 10.1002/cncr.28894. Epub 2014 Jun 24.","Onukwugha E","Cancer","2014","2014/06/26","","","10.1002/cncr.28894"
"15947593","Initial experiences with real-time elastography guided biopsies of the prostate","König K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T.","J Urol. 2005 Jul;174(1):115-7. doi: 10.1097/01.ju.0000162043.72294.4a.","König K","J Urol","2005","2005/06/11","","","10.1097/01.ju.0000162043.72294.4a"
"15765234","In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer","Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ.","Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):668-73. doi: 10.1007/s00259-004-1741-4. Epub 2005 Mar 12.","Breeuwsma AJ","Eur J Nucl Med Mol Imaging","2005","2005/03/15","","","10.1007/s00259-004-1741-4"
"7737257","A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment","Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Oosterhof GO.","Eur Urol. 1994;26 Suppl 1:4. doi: 10.1159/000475423.","Debruyne FM","Eur Urol","1994","1994/01/01","","","10.1159/000475423"
"25569548","Adding radiotherapy to hormone treatment improves survival in older men with prostate cancer","Mayor S.","BMJ. 2015 Jan 7;350:h84. doi: 10.1136/bmj.h84.","Mayor S","BMJ","2015","2015/01/09","","","10.1136/bmj.h84"
"21604951","Natural history of prostate cancer, chemoprevention and active surveillance","Bratt O, Schumacher MC.","Acta Oncol. 2011 Jun;50 Suppl 1:116-9. doi: 10.3109/0284186X.2010.527369.","Bratt O","Acta Oncol","2011","2011/05/25","","","10.3109/0284186X.2010.527369"
"20425628","Update: immunological strategies for prostate cancer","Drake CG, Antonarakis ES.","Curr Urol Rep. 2010 May;11(3):202-7. doi: 10.1007/s11934-010-0106-8.","Drake CG","Curr Urol Rep","2010","2010/04/29","PMC4020436","NIHMS571694","10.1007/s11934-010-0106-8"
"7523734","Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project","Littrup PJ, Goodman AC, Mettlin CJ, Murphy GP.","J Urol. 1994 Nov;152(5 Pt 2):1873-7. doi: 10.1016/s0022-5347(17)32405-9.","Littrup PJ","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32405-9"
"23379241","[Detection of prostate cancer based on monitoring of prostate-specific antigen in outpatient clinic]","Kamalov AA, Maksimov VA, Takhirzade TB, Gevorkian AR, Okhobotov DA, Avakian AIu, Vasil'eva EG.","Urologiia. 2012 Sep-Oct;(6):58-60.","Kamalov AA","Urologiia","2012","2013/02/06","","",""
"11823687","Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival","Do LV, Do TM, Smith R, Parker RG.","Am J Clin Oncol. 2002 Feb;25(1):1-8. doi: 10.1097/00000421-200202000-00001.","Do LV","Am J Clin Oncol","2002","2002/02/02","","","10.1097/00000421-200202000-00001"
"26087969","State-of-the-art imaging of prostate cancer","Marko J, Gould CF, Bonavia GH, Wolfman DJ.","Urol Oncol. 2016 Mar;34(3):134-46. doi: 10.1016/j.urolonc.2015.05.015. Epub 2015 Jun 16.","Marko J","Urol Oncol","2016","2015/06/20","","","10.1016/j.urolonc.2015.05.015"
"29483498","Expression of cancer-associated genes in prostate tumors","Rosenberg EE, Gerashchenko GV, Hryshchenko NV, Mevs LV, Nekrasov KA, Lytvynenko RA, Vitruk YV, Gryzodub OP, Stakhovsky EA, Kashuba VI.","Exp Oncol. 2017 Jul;39(2):131-137.","Rosenberg EE","Exp Oncol","2017","2018/02/28","","",""
"11179143","Prognostic factors in prostate cancer","Montironi R.","BMJ. 2001 Feb 17;322(7283):378-9. doi: 10.1136/bmj.322.7283.378.","Montironi R","BMJ","2001","2001/02/17","PMC1119620","","10.1136/bmj.322.7283.378"
"30738364","Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era","Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G.","Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7.","Tucci M","Cancer Treat Rev","2019","2019/02/10","","","10.1016/j.ctrv.2019.01.002"
"8773633","Results of radical prostatectomy in men with clinically localized prostate cancer","Gerber GS, Thisted RA, Scardino PT, Frohmuller HG, Schroeder FH, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Schellhammer PF, Ohori M, Chodak GW.","JAMA. 1996 Aug 28;276(8):615-9.","Gerber GS","JAMA","1996","1996/08/28","","",""
"22103570","Urinary proteome analysis for prostate cancer diagnosis: cost-effective application in routine clinical practice in Germany","Schiffer E, Bick C, Grizelj B, Pietzker S, Schöfer W.","Int J Urol. 2012 Feb;19(2):118-25. doi: 10.1111/j.1442-2042.2011.02901.x. Epub 2011 Nov 22.","Schiffer E","Int J Urol","2012","2011/11/23","","","10.1111/j.1442-2042.2011.02901.x"
"16858675","Gleason score, age and screening: modeling dedifferentiation in prostate cancer","Draisma G, Postma R, Schröder FH, van der Kwast TH, de Koning HJ.","Int J Cancer. 2006 Nov 15;119(10):2366-71. doi: 10.1002/ijc.22158.","Draisma G","Int J Cancer","2006","2006/07/22","","","10.1002/ijc.22158"
"17393945","Analysis of prostate cancer incidence using geographic information system and multilevel modeling","Xiao H, Gwede CK, Kiros G, Milla K.","J Natl Med Assoc. 2007 Mar;99(3):218-25.","Xiao H","J Natl Med Assoc","2007","2007/03/31","PMC2569639","",""
"19536866","Angiogenesis as a strategic target for prostate cancer therapy","Li Y, Cozzi PJ.","Med Res Rev. 2010 Jan;30(1):23-66. doi: 10.1002/med.20161.","Li Y","Med Res Rev","2010","2009/06/19","","","10.1002/med.20161"
"23084535","Urologic Clinics of North America. Castrate-resistant prostate cancer. Preface","Kibel AS.","Urol Clin North Am. 2012 Nov;39(4):xv. doi: 10.1016/j.ucl.2012.08.001. Epub 2012 Aug 30.","Kibel AS","Urol Clin North Am","2012","2012/10/23","","","10.1016/j.ucl.2012.08.001"
"19813273","Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees","Bergdahl AG, Aus G, Lilja H, Hugosson J.","Cancer. 2009 Dec 15;115(24):5672-9. doi: 10.1002/cncr.24680.","Bergdahl AG","Cancer","2009","2009/10/09","","","10.1002/cncr.24680"
"1697693","[Hormone therapy in prostate cancer: clinical results]","Morote-Robles J.","Rev Esp Fisiol. 1990 Mar;46(1):59-62.","Morote-Robles J","Rev Esp Fisiol","1990","1990/03/01","","",""
"8855681","Patient preferences for management of localized prostate cancer","Mazur DJ, Hickam DH.","West J Med. 1996 Jul-Aug;165(1-2):26-30.","Mazur DJ","West J Med","1996","1996/07/01","PMC1307537","",""
"18711409","HIV and prostate cancer: a systematic review of the literature","Silberstein J, Downs T, Lakin C, Kane CJ.","Prostate Cancer Prostatic Dis. 2009;12(1):6-12. doi: 10.1038/pcan.2008.44. Epub 2008 Aug 19.","Silberstein J","Prostate Cancer Prostatic Dis","2009","2008/08/20","","","10.1038/pcan.2008.44"
"2417118","Expression of ras oncogene p21 in prostate cancer","Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J.","N Engl J Med. 1986 Jan 16;314(3):133-7. doi: 10.1056/NEJM198601163140301.","Viola MV","N Engl J Med","1986","1986/01/16","","","10.1056/NEJM198601163140301"
"25782174","Prostate cancer: Multifocal disease--independent clonal lineages in malignant nodules and even in normal tissue","Thoma C.","Nat Rev Urol. 2015 Apr;12(4):177. doi: 10.1038/nrurol.2015.52. Epub 2015 Mar 17.","Thoma C","Nat Rev Urol","2015","2015/03/18","","","10.1038/nrurol.2015.52"
"23709425","Robotic mechanical localization of prostate cancer correlates with magnetic resonance imaging scans","Shin TY, Kim YJ, Lim SK, Kim J, Rha KH.","Yonsei Med J. 2013 Jul;54(4):907-11. doi: 10.3349/ymj.2013.54.4.907.","Shin TY","Yonsei Med J","2013","2013/05/28","PMC3663222","","10.3349/ymj.2013.54.4.907"
"14755684","GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer","Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG.","J Cell Biochem. 2004 Feb 15;91(3):540-52. doi: 10.1002/jcb.10740.","Nakayama M","J Cell Biochem","2004","2004/02/03","","","10.1002/jcb.10740"
"19116872","Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum","Mahajna J, Dotan N, Zaidman BZ, Petrova RD, Wasser SP.","Nutr Cancer. 2009;61(1):16-26. doi: 10.1080/01635580802379323.","Mahajna J","Nutr Cancer","2009","2009/01/01","","","10.1080/01635580802379323"
"29690977","Clinicopathological Characteristics of Prostate Cancer in Patients Presenting to a Tertiary Care Private Sector Hospital","Masood A, Iqbal N, Shohab D, Hasan A, Aimon S, Mahmood U, Akhter S.","J Coll Physicians Surg Pak. 2018 May;28(5):409-411. doi: 10.29271/jcpsp.2018.05.409.","Masood A","J Coll Physicians Surg Pak","2018","2018/04/26","","","10.29271/jcpsp.2018.05.409"
"1712422","The present role of prostatic specific antigen (PSA) as a tumor marker in carcinoma of the prostate","Parra RO.","Mo Med. 1991 Jun;88(6):349-52.","Parra RO","Mo Med","1991","1991/06/01","","",""
"21621302","[Estimation of the projections of incidence rates, prevalence and mortality due to prostate cancer in Aragon (Spain)]","Bernal M, Romero FJ, Souza DL, Gómez-Bernal FJ, Gómez-Bernal GJ.","Actas Urol Esp. 2011 Sep;35(8):470-4. doi: 10.1016/j.acuro.2011.03.010. Epub 2011 May 28.","Bernal M","Actas Urol Esp","2011","2011/05/31","","","10.1016/j.acuro.2011.03.010"
"23661306","Lack of evidence for frequent MED12 p.L1224F mutation in prostate tumours from Caucasian patients","Stoehr R, Taubert H, Gaisa NT, Smeets D, Kneitz B, Giedl J, Ruemmele P, Wieland WF, Rau TT, Hartmann A.","J Pathol. 2013 Aug;230(4):453-6. doi: 10.1002/path.4208.","Stoehr R","J Pathol","2013","2013/05/11","","","10.1002/path.4208"
"21520274","Fracture risk in men with prostate cancer: a population-based study","Melton LJ 3rd, Lieber MM, Atkinson EJ, Achenbach SJ, Zincke H, Therneau TM, Khosla S.","J Bone Miner Res. 2011 Aug;26(8):1808-15. doi: 10.1002/jbmr.405.","Melton LJ 3rd","J Bone Miner Res","2011","2011/04/27","PMC3321611","NIHMS302213","10.1002/jbmr.405"
"29947352","Hidden Patients, Hidden Partners: Prostate Cancer Care for Gay and Bisexual Men","Arthur EK, Kamen CS.","Oncol Nurs Forum. 2018 Jul 2;45(4):435-438. doi: 10.1188/18.ONF.435-438.","Arthur EK","Oncol Nurs Forum","2018","2018/06/28","PMC6419741","NIHMS1012391","10.1188/18.ONF.435-438"
"17562051","Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications","Nelson EC, Evans CP, Pan CX, Lara PN Jr.","World J Urol. 2007 Aug;25(4):393-9. doi: 10.1007/s00345-007-0186-3. Epub 2007 Jun 12.","Nelson EC","World J Urol","2007","2007/06/15","","","10.1007/s00345-007-0186-3"
"20831865","Re: Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease","Zhu Y, Ye D.","Clin Chim Acta. 2010 Dec 14;411(23-24):2117. doi: 10.1016/j.cca.2010.08.044. Epub 2010 Sep 7.","Zhu Y","Clin Chim Acta","2010","2010/09/14","","","10.1016/j.cca.2010.08.044"
"20299035","Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer","Yee DS, Shariat SF, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS.","J Urol. 2010 May;183(5):1751-6. doi: 10.1016/j.juro.2010.01.014. Epub 2010 Mar 17.","Yee DS","J Urol","2010","2010/03/20","PMC4295901","NIHMS626696","10.1016/j.juro.2010.01.014"
"15072903","Prostate cancer metastatic to the stomach","Christoph F, Grünbaum M, Wolkers F, Müller M, Miller K.","Urology. 2004 Apr;63(4):778-9. doi: 10.1016/j.urology.2003.12.009.","Christoph F","Urology","2004","2004/04/10","","","10.1016/j.urology.2003.12.009"
"21166517","Treatment of men with rising prostate-specific antigen levels following radical prostatectomy","Tzou K, Tan WW, Buskirk S.","Expert Rev Anticancer Ther. 2011 Jan;11(1):125-36. doi: 10.1586/era.10.210.","Tzou K","Expert Rev Anticancer Ther","2011","2010/12/21","","","10.1586/era.10.210"
"30658679","PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway","Lv C, Fu S, Dong Q, Yu Z, Zhang G, Kong C, Fu C, Zeng Y.","J Exp Clin Cancer Res. 2019 Jan 18;38(1):24. doi: 10.1186/s13046-019-1032-3.","Lv C","J Exp Clin Cancer Res","2019","2019/01/20","PMC6339303","","10.1186/s13046-019-1032-3"
"22475772","Thwarting high-risk prostate cancer: the right treatments for the right patients","Cooperberg MR.","Eur Urol. 2012 Jun;61(6):1107-9. doi: 10.1016/j.eururo.2012.03.037. Epub 2012 Mar 24.","Cooperberg MR","Eur Urol","2012","2012/04/06","","","10.1016/j.eururo.2012.03.037"
"7145866","[Postoperative pathomorphologic classification of prostate cancer. Recommendations for the processing of total prostatectomies and relevance of the findings]","Kastendieck H, Hüsselmann H.","Pathologe. 1982 Sep;3(5):278-86.","Kastendieck H","Pathologe","1982","1982/09/01","","",""
"9341640","Prostate disease in older men: 2. Cancer","Albertsen PC.","Hosp Pract (1995). 1997 Oct 15;32(10):159-66, 171, 175-6 passim. doi: 10.1080/21548331.1997.11443584.","Albertsen PC","Hosp Pract (1995)","1997","1997/10/28","","","10.1080/21548331.1997.11443584"
"14765013","Prostate cancer update","Wilson SS, Crawford ED.","Minerva Urol Nefrol. 2003 Dec;55(4):199-204.","Wilson SS","Minerva Urol Nefrol","2003","2004/02/07","","",""
"29059776","Re: Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer","Taneja SS.","J Urol. 2017 Nov;198(5):982-983. doi: 10.1016/j.juro.2017.08.037. Epub 2017 Aug 9.","Taneja SS","J Urol","2017","2017/10/25","","","10.1016/j.juro.2017.08.037"
"21573862","Commentary: Serum lycopene and prostate cancer progression: a re-consideration of findings from the prostate cancer prevention trial","Giovannucci E.","Cancer Causes Control. 2011 Jul;22(7):1055-9. doi: 10.1007/s10552-011-9776-x. Epub 2011 May 15.","Giovannucci E","Cancer Causes Control","2011","2011/05/17","","","10.1007/s10552-011-9776-x"
"1706440","Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?","Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE.","J Urol. 1991 Apr;145(4):802-6. doi: 10.1016/s0022-5347(17)38456-2.","Leo ME","J Urol","1991","1991/04/01","","","10.1016/s0022-5347(17)38456-2"
"2070207","Comparison of transrectal ultrasound and magnetic resonance imaging in the staging of prostate cancer","Chadwick DJ, Cobby M, Goddard P, Gingell JC.","Br J Urol. 1991 Jun;67(6):616-21. doi: 10.1111/j.1464-410x.1991.tb15226.x.","Chadwick DJ","Br J Urol","1991","1991/06/01","","","10.1111/j.1464-410x.1991.tb15226.x"
"28420895","The Downregulation of the Expression of CD147 by Tumor Suppressor REIC/Dkk-3, and Its Implication in Human Prostate Cancer Cell Growth Inhibition","Mori A, Watanabe M, Sadahira T, Kobayashi Y, Ariyoshi Y, Ueki H, Wada K, Ochiai K, Li SA, Nasu Y.","Acta Med Okayama. 2017 Apr;71(2):135-142. doi: 10.18926/AMO/54982.","Mori A","Acta Med Okayama","2017","2017/04/20","","","10.18926/AMO/54982"
"24604289","The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease","Keane FK, Chen MH, Zhang D, Loffredo MJ, Kantoff PW, Renshaw AA, D'Amico AV.","Cancer. 2014 Jun 15;120(12):1787-93. doi: 10.1002/cncr.28609. Epub 2014 Mar 6.","Keane FK","Cancer","2014","2014/03/08","","","10.1002/cncr.28609"
"25846751","Re: Steven Joniau, Alberto Briganti, Paolo Gontero, et al. Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. Eur Urol 2015;67:157-64","Sundi D, Schaeffer EM, Ross AE.","Eur Urol. 2015 Jul;68(1):e11-2. doi: 10.1016/j.eururo.2015.03.038. Epub 2015 Apr 3.","Sundi D","Eur Urol","2015","2015/04/08","","","10.1016/j.eururo.2015.03.038"
"15180634","The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer","Vallbo C, Wang W, Damber JE.","BJU Int. 2004 Jun;93(9):1339-43. doi: 10.1111/j.1464-410x.2004.04818.x.","Vallbo C","BJU Int","2004","2004/06/08","","","10.1111/j.1464-410x.2004.04818.x"
"12970726","Expression of a model gene in prostate cancer cells lentivirally transduced in vitro and in vivo","Bastide C, Maroc N, Bladou F, Hassoun J, Maitland N, Mannoni P, Bagnis C.","Prostate Cancer Prostatic Dis. 2003;6(3):228-34. doi: 10.1038/sj.pcan.4500668.","Bastide C","Prostate Cancer Prostatic Dis","2003","2003/09/13","","","10.1038/sj.pcan.4500668"
"28849878","[Prediction of life expectancy for prostate cancer patients based on the kinetic theory of aging of living systems]","Viktorov AA, Zharinov GM, Neklasova NJ, Morozova EE.","Adv Gerontol. 2017;30(3):356-362.","Viktorov AA","Adv Gerontol","2017","2017/08/30","","",""
"10930937","Legal pitfalls in the diagnosis of prostate cancer","Dunn IB, Kirk D.","BJU Int. 2000 Aug;86(3):304-7. doi: 10.1046/j.1464-410x.2000.00298.x.","Dunn IB","BJU Int","2000","2000/08/10","","","10.1046/j.1464-410x.2000.00298.x"
"23681018","A response to Sher et al, ""Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer""","Collins SP, Suy S, Chen LN, Collins BT, Dritschilo A.","Am J Clin Oncol. 2013 Jun;36(3):316-7. doi: 10.1097/COC.0b013e318294101b.","Collins SP","Am J Clin Oncol","2013","2013/05/18","","","10.1097/COC.0b013e318294101b"
"16268225","[Treatment of locally spread prostate cancer]","Tammela T.","Duodecim. 2005;121(16):1779-82.","Tammela T","Duodecim","2005","2005/11/05","","",""
"28550116","Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies","Lopez-Bujanda Z, Drake CG.","J Leukoc Biol. 2017 Aug;102(2):393-406. doi: 10.1189/jlb.5VMR1116-491RR. Epub 2017 May 26.","Lopez-Bujanda Z","J Leukoc Biol","2017","2017/05/28","PMC6608078","","10.1189/jlb.5VMR1116-491RR"
"26390963","Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review","Colloca G, Venturino A, Governato I, Checcaglini F.","Clin Genitourin Cancer. 2016 Feb;14(1):5-11. doi: 10.1016/j.clgc.2015.07.023. Epub 2015 Aug 6.","Colloca G","Clin Genitourin Cancer","2016","2015/09/23","","","10.1016/j.clgc.2015.07.023"
"12128115","Freedom from castration: an alternative end point for men with localized prostate cancer treated by external beam radiation therapy","Zietman A, Thakral H, Skowronski U, Shipley W.","Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1152-9. doi: 10.1016/s0360-3016(02)02858-4.","Zietman A","Int J Radiat Oncol Biol Phys","2002","2002/07/20","","","10.1016/s0360-3016(02)02858-4"
"28797855","Exploring Genetic Attributions Underlying Radiotherapy-Induced Fatigue in Prostate Cancer Patients","Hashemi S, Fernandez Martinez JL, Saligan L, Sonis S.","J Pain Symptom Manage. 2017 Sep;54(3):326-339. doi: 10.1016/j.jpainsymman.2017.04.015. Epub 2017 Aug 8.","Hashemi S","J Pain Symptom Manage","2017","2017/08/12","","","10.1016/j.jpainsymman.2017.04.015"
"20171779","Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members","Brandt A, Bermejo JL, Sundquist J, Hemminki K.","Eur Urol. 2010 Aug;58(2):275-80. doi: 10.1016/j.eururo.2010.02.002. Epub 2010 Feb 13.","Brandt A","Eur Urol","2010","2010/02/23","","","10.1016/j.eururo.2010.02.002"
"9806189","No difference in survival between sporadic, familial and hereditary prostate cancer","Grönberg H, Damber L, Tavelin B, Damber JE.","Br J Urol. 1998 Oct;82(4):564-7. doi: 10.1046/j.1464-410x.1998.00801.x.","Grönberg H","Br J Urol","1998","1998/11/07","","","10.1046/j.1464-410x.1998.00801.x"
"18486743","Prostate cancer","Damber JE, Aus G.","Lancet. 2008 May 17;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1.","Damber JE","Lancet","2008","2008/05/20","","","10.1016/S0140-6736(08)60729-1"
"19615204","[Mass screening prostate cancer and clinical comparison]","Zhao R, Kong XB, Zhang MC.","Zhonghua Wai Ke Za Zhi. 2009 May 15;47(10):734-6.","Zhao R","Zhonghua Wai Ke Za Zhi","2009","2009/07/21","","",""
"17981696","Gene therapy in prostate cancer: past, present and future","Shirakawa T, Fujisawa M, Gotoh A.","Front Biosci. 2008 Jan 1;13:2115-9. doi: 10.2741/2828.","Shirakawa T","Front Biosci","2008","2007/11/06","","","10.2741/2828"
"23385973","The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer","Ischia J, Saad F, Gleave M.","Curr Opin Urol. 2013 May;23(3):194-200. doi: 10.1097/MOU.0b013e32835e9f1a.","Ischia J","Curr Opin Urol","2013","2013/02/07","","","10.1097/MOU.0b013e32835e9f1a"
"19593998","[Vasectomy not associated with prostate cancer: a meta-analysis]","Tang LF, Jiang H, Shang XJ, Zhao LM, Bai Q, Hong K, Liu DF, Liu JM, Yuan RP, Chen Q, Ma LL.","Zhonghua Nan Ke Xue. 2009 Jun;15(6):545-50.","Tang LF","Zhonghua Nan Ke Xue","2009","2009/07/15","","",""
"8032836","Symptomatology of metastatic prostate cancer: prognostic significance","Rana A, Chisholm GD, Rashwan HM, Salim A, Merrick MV, Elton RA.","Br J Urol. 1994 Jun;73(6):683-6. doi: 10.1111/j.1464-410x.1994.tb07556.x.","Rana A","Br J Urol","1994","1994/06/01","","","10.1111/j.1464-410x.1994.tb07556.x"
"8717466","The management of localised cancer of the prostate","Boccon-Gibod L.","Eur Urol. 1996;29 Suppl 2:62-8. doi: 10.1159/000473842.","Boccon-Gibod L","Eur Urol","1996","1996/01/01","","","10.1159/000473842"
"8165765","Radiotherapy for prostatic cancer: patient selection and the impact of local control","Kaplan ID, Cox RS, Bagshaw MA.","Urology. 1994 May;43(5):634-9. doi: 10.1016/0090-4295(94)90177-5.","Kaplan ID","Urology","1994","1994/05/01","","","10.1016/0090-4295(94)90177-5"
"1724346","[Cancer of the prostate: current diagnostic aspects]","Sanz Velez JI, Gil Sanz MJ, Allepuz Losa C, Rioja Sanz LA.","Actas Urol Esp. 1991 Nov-Dec;15(6):518-26.","Sanz Velez JI","Actas Urol Esp","1991","1991/11/01","","",""
"16298040","Endocrine disrupting compounds and prostate cancer","Hess-Wilson JK, Knudsen KE.","Cancer Lett. 2006 Sep 8;241(1):1-12. doi: 10.1016/j.canlet.2005.10.006. Epub 2005 Nov 17.","Hess-Wilson JK","Cancer Lett","2006","2005/11/22","","","10.1016/j.canlet.2005.10.006"
"22046015","Disinvesting from prostate cancer screening","Wilson N.","BMJ. 2011 Nov 1;343:d7029. doi: 10.1136/bmj.d7029.","Wilson N","BMJ","2011","2011/11/03","","","10.1136/bmj.d7029"
"8970583","Localized prostate cancer: are prostatectomy and radiation therapy equally effective options?","","Semin Oncol. 1996 Dec;23(6):xxxi-xxxv.","","Semin Oncol","1996","1996/12/01","","",""
"8683715","Re: Editorial: the central role of prostate specific antigen in diagnosis and progression of prostate cancer","Lawrence G.","J Urol. 1996 Aug;156(2 Pt 1):484.","Lawrence G","J Urol","1996","1996/08/01","","",""
"27803100","How the TRAMP Model Revolutionized the Study of Prostate Cancer Progression","Gelman IH.","Cancer Res. 2016 Nov 1;76(21):6137-6139. doi: 10.1158/0008-5472.CAN-16-2636.","Gelman IH","Cancer Res","2016","2016/11/03","","","10.1158/0008-5472.CAN-16-2636"
"17343804","Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer","Khatri A, Russell PJ.","Discov Med. 2007 Feb;7(37):39-45.","Khatri A","Discov Med","2007","2007/03/09","","",""
"24875018","Co-occurring gland angularity in localized subgraphs: predicting biochemical recurrence in intermediate-risk prostate cancer patients","Lee G, Sparks R, Ali S, Shih NN, Feldman MD, Spangler E, Rebbeck T, Tomaszewski JE, Madabhushi A.","PLoS One. 2014 May 29;9(5):e97954. doi: 10.1371/journal.pone.0097954. eCollection 2014.","Lee G","PLoS One","2014","2014/05/31","PMC4038543","","10.1371/journal.pone.0097954"
"11442673","Brachytherapy for prostate cancer in Japan","Saito S, Momma T, Dokiya T, Murai M.","Int J Urol. 2001 Jul;8(7):S22-7. doi: 10.1046/j.1442-2042.2001.00330.x.","Saito S","Int J Urol","2001","2001/07/10","","","10.1046/j.1442-2042.2001.00330.x"
"22173635","Profiling prostate cancer","Nelson WG.","Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):20861-2. doi: 10.1073/pnas.1118444109. Epub 2011 Dec 15.","Nelson WG","Proc Natl Acad Sci U S A","2011","2011/12/17","PMC3248531","","10.1073/pnas.1118444109"
"29031313","Routes to diagnosis for men with prostate cancer: men's cultural beliefs about how changes to their bodies and symptoms influence help-seeking actions. A narrative review of the literature","King-Okoye M, Arber A, Faithfull S.","Eur J Oncol Nurs. 2017 Oct;30:48-58. doi: 10.1016/j.ejon.2017.06.005. Epub 2017 Aug 31.","King-Okoye M","Eur J Oncol Nurs","2017","2017/10/17","","","10.1016/j.ejon.2017.06.005"
"9175283","Maximal androgen blockade versus total androgen suppression","Dumez H, Van Poppel H, Baert L, Paridaens R.","Acta Urol Belg. 1997 Mar;65(1):49-54.","Dumez H","Acta Urol Belg","1997","1997/03/01","","",""
"23185851","Treatment of localised prostate cancer: inform patients about adverse effects","","Prescrire Int. 2012 Oct;21(131):247.","","Prescrire Int","2012","2012/11/29","","",""
"24929077","Re: Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer","Klaassen Z, Ruch A, Li Q, Terris MK.","Eur Urol. 2014 Jul;66(1):173. doi: 10.1016/j.eururo.2014.03.035.","Klaassen Z","Eur Urol","2014","2014/06/15","","","10.1016/j.eururo.2014.03.035"
"16755881","[Roles of endothelin and its receptors in prostate cancer]","Wang QB, Qu WS, Qin DS, Wang ZP.","Zhonghua Nan Ke Xue. 2006 May;12(5):450-2.","Wang QB","Zhonghua Nan Ke Xue","2006","2006/06/08","","",""
"21944124","Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner","Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT.","J Urol. 2011 Nov;186(5):2107-14. doi: 10.1016/j.juro.2011.06.048. Epub 2011 Sep 23.","Shariat SF","J Urol","2011","2011/09/28","","","10.1016/j.juro.2011.06.048"
"27142385","Introduction to special focus section on prostate cancer imaging","Froemming AT, Silva AC.","Abdom Radiol (NY). 2016 May;41(5):797. doi: 10.1007/s00261-016-0759-y.","Froemming AT","Abdom Radiol (NY)","2016","2016/05/05","","","10.1007/s00261-016-0759-y"
"19947348","Further perspectives on treating localized prostate cancer","Aronovitz JA, Sanda MG.","Oncology (Williston Park). 2009 Oct;23(11):964, 966.","Aronovitz JA","Oncology (Williston Park)","2009","2009/12/02","","",""
"6781114","[The combined treatment of prostate cancer (stage C) with definitive megavoltage irradiation and fast neutrons (DT, 14 MeV) (author's transl)]","Franke HD, Hess A, Langendorff G, Borchers HD.","Urologe A. 1980 Nov;19(6):341-9.","Franke HD","Urologe A","1980","1980/11/01","","",""
"1289663","Introductory remarks: development of chemopreventive agents for prostate cancer","Kelloff GJ, Boone CW, Malone WF, Steele VE, Doody LA.","J Cell Biochem Suppl. 1992;16H:1-8. doi: 10.1002/jcb.240501203.","Kelloff GJ","J Cell Biochem Suppl","1992","1992/01/01","","","10.1002/jcb.240501203"
"17880293","Significance of lateral biopsy specimens during transrectal ultrasound-guided prostate biopsies in Japanese men","Shigemura K, Arakawa S, Yamanaka K, Kataoka N, Yuien K, Fujisawa M.","Int J Urol. 2007 Oct;14(10):935-8. doi: 10.1111/j.1442-2042.2007.01865.x.","Shigemura K","Int J Urol","2007","2007/09/21","","","10.1111/j.1442-2042.2007.01865.x"
"15538229","Association of hemospermia with prostate cancer","Han M, Brannigan RE, Antenor JA, Roehl KA, Catalona WJ.","J Urol. 2004 Dec;172(6 Pt 1):2189-92. doi: 10.1097/01.ju.0000144565.76243.b1.","Han M","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000144565.76243.b1"
"7207052","[Roentgenotopometry in the radiation therapy of prostate cancer]","Sviridova TV, Dunchik VN, Astapov BM, Mardynskiĭ IuS.","Med Radiol (Mosk). 1981 Feb;26(2):36-40.","Sviridova TV","Med Radiol (Mosk)","1981","1981/02/01","","",""
"22537761","Historical prostate cancer screening and treatment outcomes from a single institution","Cross DS, Ritter M, Reding DJ.","Clin Med Res. 2012 Aug;10(3):97-105. doi: 10.3121/cmr.2011.1042. Epub 2012 Apr 25.","Cross DS","Clin Med Res","2012","2012/04/28","PMC3421330","","10.3121/cmr.2011.1042"
"25337702","Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study","Wirén S, Drevin L, Akre O, Robinson D, Stattin P.","PLoS One. 2014 Oct 22;9(10):e110506. doi: 10.1371/journal.pone.0110506. eCollection 2014.","Wirén S","PLoS One","2014","2014/10/23","PMC4206421","","10.1371/journal.pone.0110506"
"22718300","Circulating fibroblast-like cells in men with metastatic prostate cancer","Jones ML, Siddiqui J, Pienta KJ, Getzenberg RH.","Prostate. 2013 Jan;73(2):176-81. doi: 10.1002/pros.22553. Epub 2012 Jun 21.","Jones ML","Prostate","2013","2012/06/22","PMC3482413","NIHMS391266","10.1002/pros.22553"
"2740776","[Cancer of the prostate. Epidemiology, diagnosis, course and prognosis, principles of treatment]","Le Bourgeois JP.","Rev Prat. 1989 Apr 20;39(12):1077-80.","Le Bourgeois JP","Rev Prat","1989","1989/04/20","","",""
"16190507","Predicting the risk of prostate cancer on biopsy","Ebell MH.","Am Fam Physician. 2005 Sep 15;72(6):1091-2.","Ebell MH","Am Fam Physician","2005","2005/09/30","","",""
"17255261","Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer","Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE.","Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):421-6. doi: 10.1158/1078-0432.CCR-06-1087.","Mehra N","Clin Cancer Res","2007","2007/01/27","","","10.1158/1078-0432.CCR-06-1087"
"24365124","Prostate mucinous carcinoma treated with definitive radiotherapy and hormonal therapy: case report and review of the literature","Guler OC, Onal C, Erbay G, Bal N.","Clin Genitourin Cancer. 2014 Apr;12(2):e43-6. doi: 10.1016/j.clgc.2013.11.018. Epub 2013 Nov 12.","Guler OC","Clin Genitourin Cancer","2014","2013/12/25","","","10.1016/j.clgc.2013.11.018"
"21205079","Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy","Amamoto R, Yagi M, Song Y, Oda Y, Tsuneyoshi M, Naito S, Yokomizo A, Kuroiwa K, Tokunaga S, Kato S, Hiura H, Samori T, Kang D, Uchiumi T.","Cancer Sci. 2011 Mar;102(3):639-47. doi: 10.1111/j.1349-7006.2010.01828.x. Epub 2011 Jan 23.","Amamoto R","Cancer Sci","2011","2011/01/06","","","10.1111/j.1349-7006.2010.01828.x"
"24914840","Optimization of prostate biopsy in patients considered for active surveillance. The role of the confirmatory biopsy and transperineal techniques","Fernandez Gomez JM, Garcia Rodriguez J.","Arch Esp Urol. 2014 Jun;67(5):409-18.","Fernandez Gomez JM","Arch Esp Urol","2014","2014/06/11","","",""
"23114055","Hypofractionated helical intensity-modulated radiotherapy of the prostate bed after prostatectomy with or without the pelvic lymph nodes - the PRIAMOS trial","Krause S, Sterzing F, Neuhof D, Edler L, Debus J, Herfarth K.","BMC Cancer. 2012 Oct 31;12:504. doi: 10.1186/1471-2407-12-504.","Krause S","BMC Cancer","2012","2012/11/02","PMC3495015","","10.1186/1471-2407-12-504"
"8790311","Screening for prostate cancer: a comparison of urologists and primary care physicians","McKnight JT, Tietze PH, Adcock BB, Maxwell AJ, Smith WO, Nagy MC.","South Med J. 1996 Sep;89(9):885-8.","McKnight JT","South Med J","1996","1996/09/01","","",""
"19357018","[Prognosis and predictive factors in prostate cancer]","Albiges-Sauvin L, Lévy A, Massard C, Fizazi K.","Bull Cancer. 2009 Apr;96(4):439-49. doi: 10.1684/bdc.2009.0846.","Albiges-Sauvin L","Bull Cancer","2009","2009/04/10","","","10.1684/bdc.2009.0846"
"9239470","Epidemiology of prostate cancer and bladder cancer: an overview","Ross RK.","Cancer Treat Res. 1996;88:1-11. doi: 10.1007/978-1-4615-6343-3_1.","Ross RK","Cancer Treat Res","1996","1996/01/01","","","10.1007/978-1-4615-6343-3_1"
"21156999","The application of the RT-PCR method for the staging of the prostate cancer progression","Zummerova A, Labas P, Bohmer D, Blasko M, Polak S, Danisovic L, Repiska V.","Gen Physiol Biophys. 2010 Dec;29(4):362-72. doi: 10.4149/gpb_2010_04_362.","Zummerova A","Gen Physiol Biophys","2010","2010/12/16","","","10.4149/gpb_2010_04_362"
"31227053","PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy","Wester HJ, Schottelius M.","Semin Nucl Med. 2019 Jul;49(4):302-312. doi: 10.1053/j.semnuclmed.2019.02.008. Epub 2019 Apr 30.","Wester HJ","Semin Nucl Med","2019","2019/06/23","","","10.1053/j.semnuclmed.2019.02.008"
"25991382","Changes in lower urinary tract symptoms and quality of life after salvage radiotherapy for biochemical recurrence of prostate cancer","Miyake M, Tanaka N, Asakawa I, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N, Fujimoto K.","Radiother Oncol. 2015 Jun;115(3):321-6. doi: 10.1016/j.radonc.2015.04.026. Epub 2015 May 16.","Miyake M","Radiother Oncol","2015","2015/05/21","","","10.1016/j.radonc.2015.04.026"
"30998834","Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence","Honda M, Kimura T, Kamata Y, Tashiro K, Kimura S, Koike Y, Sato S, Yorozu T, Furusato B, Takahashi H, Kiyota H, Egawa S.","Prostate. 2019 Jun;79(9):1043-1052. doi: 10.1002/pros.23816. Epub 2019 Apr 18.","Honda M","Prostate","2019","2019/04/19","","","10.1002/pros.23816"
"23662383","Prostate cancer: do patients understand what they choose?","Abadi-Korek I, Shemer J.","Isr Med Assoc J. 2013 Mar;15(3):176-7.","Abadi-Korek I","Isr Med Assoc J","2013","2013/05/14","","",""
"7523718","The pathological features and prognosis of prostate cancer detectable with current diagnostic tests","Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT.","J Urol. 1994 Nov;152(5 Pt 2):1714-20. doi: 10.1016/s0022-5347(17)32369-8.","Ohori M","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32369-8"
"25733258","Four flawed arguments against prostate-specific antigen screening (and 1 good one)","Vickers AJ.","Urology. 2015 Mar;85(3):491-4. doi: 10.1016/j.urology.2014.11.003.","Vickers AJ","Urology","2015","2015/03/04","","","10.1016/j.urology.2014.11.003"
"27379691","Current understanding of resistance to abiraterone  and enzalutamide in advanced prostate cancer","Antonarakis ES.","Clin Adv Hematol Oncol. 2016 May;14(5):316-9.","Antonarakis ES","Clin Adv Hematol Oncol","2016","2016/07/06","","",""
"15225836","Residential sunlight exposure is associated with a decreased risk of prostate cancer","John EM, Dreon DM, Koo J, Schwartz GG.","J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):549-52. doi: 10.1016/j.jsbmb.2004.03.067.","John EM","J Steroid Biochem Mol Biol","2004","2004/07/01","","","10.1016/j.jsbmb.2004.03.067"
"20850840","Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression","Celhay O, Yacoub M, Irani J, Dore B, Cussenot O, Fromont G.","J Urol. 2010 Nov;184(5):2172-8. doi: 10.1016/j.juro.2010.06.089. Epub 2010 Sep 17.","Celhay O","J Urol","2010","2010/09/21","","","10.1016/j.juro.2010.06.089"
"15234275","Dietary influences on endocrine-inflammatory interactions in prostate cancer development","Ho E, Boileau TW, Bray TM.","Arch Biochem Biophys. 2004 Aug 1;428(1):109-17. doi: 10.1016/j.abb.2004.01.009.","Ho E","Arch Biochem Biophys","2004","2004/07/06","","","10.1016/j.abb.2004.01.009"
"19493624","Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials","Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD.","Cancer Treat Rev. 2009 Nov;35(7):540-6. doi: 10.1016/j.ctrv.2009.05.001. Epub 2009 Jun 2.","Shelley MD","Cancer Treat Rev","2009","2009/06/05","","","10.1016/j.ctrv.2009.05.001"
"8428328","Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy","Labrie F, Belanger A, Simard J, Labrie C, Dupont A.","Cancer. 1993 Feb 1;71(3 Suppl):1059-67. doi: 10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6.","Labrie F","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6"
"11342918","A catalog of prostate cancer nomograms","Ross PL, Scardino PT, Kattan MW.","J Urol. 2001 May;165(5):1562-8.","Ross PL","J Urol","2001","2001/05/09","","",""
"27821488","Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer","Audet-Walsh É, Yee T, McGuirk S, Vernier M, Ouellet C, St-Pierre J, Giguère V.","Cancer Res. 2017 Jan 15;77(2):378-389. doi: 10.1158/0008-5472.CAN-16-1204. Epub 2016 Nov 7.","Audet-Walsh É","Cancer Res","2017","2016/11/09","","","10.1158/0008-5472.CAN-16-1204"
"16631463","Future innovations in treating advanced prostate cancer","Desai P, Jiménez JA, Kao C, Gardner TA.","Urol Clin North Am. 2006 May;33(2):247-72, viii. doi: 10.1016/j.ucl.2005.12.005.","Desai P","Urol Clin North Am","2006","2006/04/25","","","10.1016/j.ucl.2005.12.005"
"16904054","Cytotoxic chemotherapy for prostate cancer: Who and when?","Moss RA, Petrylak DP.","Curr Treat Options Oncol. 2006 Sep;7(5):370-7. doi: 10.1007/s11864-006-0005-x.","Moss RA","Curr Treat Options Oncol","2006","2006/08/15","","","10.1007/s11864-006-0005-x"
"24531773","Germline genetic variants associated with prostate cancer and potential relevance to clinical practice","Goh CL, Eeles RA.","Recent Results Cancer Res. 2014;202:9-26. doi: 10.1007/978-3-642-45195-9_2.","Goh CL","Recent Results Cancer Res","2014","2014/02/18","","","10.1007/978-3-642-45195-9_2"
"19509365","Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer","Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS.","J Natl Cancer Inst. 2009 Jun 16;101(12):888-92. doi: 10.1093/jnci/djp114. Epub 2009 Jun 9.","Gore JL","J Natl Cancer Inst","2009","2009/06/11","","","10.1093/jnci/djp114"
"25233619","Measuring the quality of life in men with prostate cancer","Hooper G, Gerber E.","Urol Nurs. 2014 Jul-Aug;34(4):177-84.","Hooper G","Urol Nurs","2014","2014/09/20","","",""
"8986037","Risk of progression and dying of clinically localized prostate cancer in Japan","Egawa S, Satoh T, Suyama K, Iwamura M, Uchida T, Koshiba K.","World J Urol. 1996;14(6):363-9. doi: 10.1007/BF00183116.","Egawa S","World J Urol","1996","1996/01/01","","","10.1007/BF00183116"
"28952690","[Efficacy of tamsulosin for treating lower urinary tract symptoms in patients with advanced prostate cancer]","Govorov AV, Vasilyev AO, Pushkar DY.","Urologiia. 2017 Sep;(4):37-41.","Govorov AV","Urologiia","2017","2017/09/28","","",""
"16046649","Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW.","JAMA. 2005 Jul 27;294(4):433-9. doi: 10.1001/jama.294.4.433.","Freedland SJ","JAMA","2005","2005/07/28","","","10.1001/jama.294.4.433"
"16927903","Couples surviving prostate cancer: Long-term intimacy needs and concerns following treatment","Sanders S, Pedro LW, Bantum EO, Galbraith ME.","Clin J Oncol Nurs. 2006 Aug;10(4):503-8. doi: 10.1188/06.CJON.503-508.","Sanders S","Clin J Oncol Nurs","2006","2006/08/25","","","10.1188/06.CJON.503-508"
"17088925","An argument to screen for distress in men diagnosed with early-stage prostate cancer","Nelson CJ.","Nat Clin Pract Urol. 2006 Nov;3(11):586-7. doi: 10.1038/ncpuro0609.","Nelson CJ","Nat Clin Pract Urol","2006","2006/11/08","","","10.1038/ncpuro0609"
"26384805","What Should We Tell Patients About Physical Activity After a Prostate Cancer Diagnosis?","Ramalingam S, Pollak KI, Zullig LL, Harrison MR.","Oncology (Williston Park). 2015 Sep;29(9):680-5, 687-8, 694.","Ramalingam S","Oncology (Williston Park)","2015","2015/09/20","","",""
"23938946","Caveola-forming proteins caveolin-1 and PTRF in prostate cancer","Nassar ZD, Hill MM, Parton RG, Parat MO.","Nat Rev Urol. 2013 Sep;10(9):529-36. doi: 10.1038/nrurol.2013.168. Epub 2013 Aug 13.","Nassar ZD","Nat Rev Urol","2013","2013/08/14","","","10.1038/nrurol.2013.168"
"16750652","Perlecan signaling: helping hedgehog stimulate prostate cancer growth","Datta S, Pierce M, Datta MW.","Int J Biochem Cell Biol. 2006;38(11):1855-61. doi: 10.1016/j.biocel.2006.03.022. Epub 2006 Apr 25.","Datta S","Int J Biochem Cell Biol","2006","2006/06/06","","","10.1016/j.biocel.2006.03.022"
"18595242","Pelvic lymphadenectomy for localized prostate cancer","Bogdanovic J, Djozic J.","Acta Chir Iugosl. 2007;54(4):113-7. doi: 10.2298/aci0704113b.","Bogdanovic J","Acta Chir Iugosl","2007","2008/07/04","","","10.2298/aci0704113b"
"16411047","Are findings from studies of obesity and prostate cancer really in conflict?","Freedland SJ, Giovannucci E, Platz EA.","Cancer Causes Control. 2006 Feb;17(1):5-9. doi: 10.1007/s10552-005-0378-3.","Freedland SJ","Cancer Causes Control","2006","2006/01/18","","","10.1007/s10552-005-0378-3"
"25791578","Prostate MRI can reduce overdiagnosis and overtreatment of prostate cancer","Rosenkrantz AB, Taneja SS.","Acad Radiol. 2015 Aug;22(8):1000-6. doi: 10.1016/j.acra.2015.02.006. Epub 2015 Mar 17.","Rosenkrantz AB","Acad Radiol","2015","2015/03/21","","","10.1016/j.acra.2015.02.006"
"9268984","PSA nadir levels after radiotherapy for prostate cancer: 'a powerful prognostic variable'","","Oncology (Williston Park). 1997 Aug;11(8):1236, 1239.","","Oncology (Williston Park)","1997","1997/08/01","","",""
"12941195","Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer","See WA.","Curr Treat Options Oncol. 2003 Oct;4(5):351-62. doi: 10.1007/s11864-003-0036-5.","See WA","Curr Treat Options Oncol","2003","2003/08/28","","","10.1007/s11864-003-0036-5"
"15951629","Prostate cancer cell survival pathways activated by bone metastasis microenvironment","Tenta R, Sotiriou E, Pitulis N, Thyphronitis G, Koutsilieris M.","J Musculoskelet Neuronal Interact. 2005 Jun;5(2):135-44.","Tenta R","J Musculoskelet Neuronal Interact","2005","2005/06/14","","",""
"20425624","Technological advances in radiation therapy for prostate cancer","Choi M, Hung AY.","Curr Urol Rep. 2010 May;11(3):172-9. doi: 10.1007/s11934-010-0102-z.","Choi M","Curr Urol Rep","2010","2010/04/29","","","10.1007/s11934-010-0102-z"
"14713783","Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer","Crain DS, Amling CL, Kane CJ.","J Urol. 2004 Feb;171(2 Pt 1):668-71. doi: 10.1097/01.ju.0000104845.24632.92.","Crain DS","J Urol","2004","2004/01/10","","","10.1097/01.ju.0000104845.24632.92"
"26239337","No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy","Brath JM, Grill S, Ankerst DP, Thompson IM Jr, Gschwend JE, Herkommer K.","J Urol. 2016 Feb;195(2):343-8. doi: 10.1016/j.juro.2015.07.097. Epub 2015 Jul 31.","Brath JM","J Urol","2016","2015/08/05","","","10.1016/j.juro.2015.07.097"
"16084415","MR-guided interventions for prostate cancer","Atalar E, Ménard C.","Magn Reson Imaging Clin N Am. 2005 Aug;13(3):491-504. doi: 10.1016/j.mric.2005.04.012.","Atalar E","Magn Reson Imaging Clin N Am","2005","2005/08/09","","","10.1016/j.mric.2005.04.012"
"31637636","MRI for clinically suspected prostate cancer-the disparity between private and public sectors","Yap LC, Lynch TH, Manecksha RP.","Ir J Med Sci. 2020 May;189(2):461-465. doi: 10.1007/s11845-019-02103-7. Epub 2019 Oct 22.","Yap LC","Ir J Med Sci","2020","2019/10/23","","","10.1007/s11845-019-02103-7"
"29738003","Prostate cancer in the Arab population. An overview","Al-Abdin OZ, Al-Beeshi IZ.","Saudi Med J. 2018 May;39(5):453-458. doi: 10.15537/smj.2018.5.21986.","Al-Abdin OZ","Saudi Med J","2018","2018/05/09","PMC6118189","","10.15537/smj.2018.5.21986"
"23441351","Evaluating a theory-based health education intervention to improve awareness of prostate cancer among men in Western Jamaica","McCree-Hale R, Hale TM, Rutley KR, Aung M, Jolly PE.","West Indian Med J. 2012 Sep;61(6):580-6.","McCree-Hale R","West Indian Med J","2012","2013/02/28","","",""
"23020893","Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches","Miyake H, Fujisawa M.","Int J Urol. 2013 Mar;20(3):301-11. doi: 10.1111/j.1442-2042.2012.03175.x. Epub 2012 Sep 30.","Miyake H","Int J Urol","2013","2012/10/02","","","10.1111/j.1442-2042.2012.03175.x"
"15570705","[Prostate cancer: Diagnosis and staging]","Fournier G, Valeri A, Mangin P, Cussenot O.","Ann Urol (Paris). 2004 Oct;38(5):207-24. doi: 10.1016/j.anuro.2004.06.003.","Fournier G","Ann Urol (Paris)","2004","2004/12/02","","","10.1016/j.anuro.2004.06.003"
"23702886","Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study","Wilson KM, Bälter K, Möller E, Adami HO, Andrén O, Andersson SO, Grönberg H, Mucci LA.","Cancer Causes Control. 2013 Aug;24(8):1575-81. doi: 10.1007/s10552-013-0234-9. Epub 2013 May 24.","Wilson KM","Cancer Causes Control","2013","2013/05/25","","","10.1007/s10552-013-0234-9"
"22504869","Lifestyle and dietary factors in the prevention of lethal prostate cancer","Wilson KM, Giovannucci EL, Mucci LA.","Asian J Androl. 2012 May;14(3):365-74. doi: 10.1038/aja.2011.142. Epub 2012 Apr 16.","Wilson KM","Asian J Androl","2012","2012/04/17","PMC3720164","","10.1038/aja.2011.142"
"28159676","Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment","Gilani S, Guo CC, Li-Ning EM, Pettaway C, Troncoso P.","Hum Pathol. 2017 Jun;64:186-190. doi: 10.1016/j.humpath.2017.01.006. Epub 2017 Jan 31.","Gilani S","Hum Pathol","2017","2017/02/05","","","10.1016/j.humpath.2017.01.006"
"24050893","Climacturia after definitive treatment of prostate cancer","O'Neil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO.","J Urol. 2014 Jan;191(1):159-63. doi: 10.1016/j.juro.2013.06.122. Epub 2013 Sep 16.","O'Neil BB","J Urol","2014","2013/09/21","","","10.1016/j.juro.2013.06.122"
"31421994","Circulating microRNAs in plasma before and after radical prostatectomy","McDonald AC, Raman JD, Shen J, Liao J, Pandya B, Vira MA.","Urol Oncol. 2019 Nov;37(11):814.e1-814.e7. doi: 10.1016/j.urolonc.2019.07.001. Epub 2019 Aug 14.","McDonald AC","Urol Oncol","2019","2019/08/19","PMC7088453","NIHMS1537514","10.1016/j.urolonc.2019.07.001"
"22736256","The new aspects of immunotherapy in prostate cancer","Ghanei M, Shohrati M, Saburi A.","Cancer Immunol Immunother. 2012 Dec;61(12):2375-6. doi: 10.1007/s00262-012-1309-2. Epub 2012 Jun 27.","Ghanei M","Cancer Immunol Immunother","2012","2012/06/28","","","10.1007/s00262-012-1309-2"
"8717464","Epidemiology, prevention and screening for prostate cancer","Pavone-Macaluso M.","Eur Urol. 1996;29 Suppl 2:49-53. doi: 10.1159/000473840.","Pavone-Macaluso M","Eur Urol","1996","1996/01/01","","","10.1159/000473840"
"9010979","Heel pain as the inaugural manifestation of metastatic prostate cancer","Gisserot O, Jaureguiberry JP, Carli P, Paris JF, Jaubert D, Chagnon A.","Rev Rhum Engl Ed. 1996 Dec;63(11):870-1.","Gisserot O","Rev Rhum Engl Ed","1996","1996/12/01","","",""
"26575822","Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression","Böttcher R, Henderson DJ, Dulla K, van Strijp D, Waanders LF, Tevz G, Lehman ML, Merkle D, van Leenders GJ, Baillie GS, Jenster G, Houslay MD, Hoffmann R.","Br J Cancer. 2015 Nov 17;113(10):1502-11. doi: 10.1038/bjc.2015.335.","Böttcher R","Br J Cancer","2015","2015/11/18","PMC4815894","","10.1038/bjc.2015.335"
"15774783","Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes","Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM.","J Clin Oncol. 2005 Mar 20;23(9):1911-20. doi: 10.1200/JCO.2005.03.137.","Lotan Y","J Clin Oncol","2005","2005/03/19","","","10.1200/JCO.2005.03.137"
"15732527","Novel immunotherapeutic approaches to prostate cancer","Dalgleish A, Whelan M.","Curr Opin Mol Ther. 2005 Feb;7(1):30-4.","Dalgleish A","Curr Opin Mol Ther","2005","2005/03/01","","",""
"21864277","Clinical trial update and novel therapeutic approaches for metastatic prostate cancer","Larsson R, Mongan NP, Johansson M, Shcherbina L, Abrahamsson PA, Gudas LJ, Sterner O, Persson JL.","Curr Med Chem. 2011;18(29):4440-53. doi: 10.2174/092986711797287539.","Larsson R","Curr Med Chem","2011","2011/08/26","","","10.2174/092986711797287539"
"16061923","An editorial update: should benefits of radical prostatectomy affect the decision to screen for early prostate cancer?","Sox HC, Mulrow C.","Ann Intern Med. 2005 Aug 2;143(3):232-3. doi: 10.7326/0003-4819-143-3-200508020-00011.","Sox HC","Ann Intern Med","2005","2005/08/03","","","10.7326/0003-4819-143-3-200508020-00011"
"9577263","Treating prostate cancer: another step forward","","Harv Mens Health Watch. 1998 May;2(10):7.","","Harv Mens Health Watch","1998","1998/05/13","","",""
"19147032","Accuray company advertising successful prostate cancer treatments with CyberKnife (CK)","Yaeger TE.","Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):638-9. doi: 10.1016/j.ijrobp.2008.10.004.","Yaeger TE","Int J Radiat Oncol Biol Phys","2009","2009/01/17","","","10.1016/j.ijrobp.2008.10.004"
"12644219","Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate","Merrill RM, Wiggins CL.","Urol Oncol. 2002 Sep-Oct;7(5):213-9. doi: 10.1016/s1078-1439(02)00193-x.","Merrill RM","Urol Oncol","2002","2003/03/20","","","10.1016/s1078-1439(02)00193-x"
"23530635","Dietary patterns as predictors of prostate cancer in Jamaican men","Jackson M, Tulloch-Reid M, Walker S, McFarlane-Anderson N, Bennett F, Francis D, Coard K.","Nutr Cancer. 2013;65(3):367-74. doi: 10.1080/01635581.2013.757631.","Jackson M","Nutr Cancer","2013","2013/03/28","","","10.1080/01635581.2013.757631"
"14973089","Inverse association between prostate cancer and the use of calcium channel blockers","Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, Jacobsen SJ.","Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):255-9. doi: 10.1158/1055-9965.epi-03-0093.","Debes JD","Cancer Epidemiol Biomarkers Prev","2004","2004/02/20","","","10.1158/1055-9965.epi-03-0093"
"18440862","Experiences of symptoms in men with hormone refractory prostate cancer and skeletal metastases","Lindqvist O, Rasmussen BH, Widmark A.","Eur J Oncol Nurs. 2008 Sep;12(4):283-90. doi: 10.1016/j.ejon.2008.03.003. Epub 2008 Apr 28.","Lindqvist O","Eur J Oncol Nurs","2008","2008/04/29","","","10.1016/j.ejon.2008.03.003"
"17311344","Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men","Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR.","Cancer. 2007 Mar 15;109(6):1192-202. doi: 10.1002/cncr.22534.","Gong Z","Cancer","2007","2007/02/22","","","10.1002/cncr.22534"
"30249890","The impact of perioperative blood transfusion on survival and recurrence after radical prostatectomy for prostate cancer: A systematic review and meta-analysis","Pushan Z, Manbiao C, Sulai L, Jun L, Ruidong Z, Hanshen Y.","J Cancer Res Ther. 2018 Sep;14(Supplement):S701-S707. doi: 10.4103/0973-1482.193115.","Pushan Z","J Cancer Res Ther","2018","2018/09/26","","","10.4103/0973-1482.193115"
"17765406","Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A.","Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74. doi: 10.1016/j.ijrobp.2007.06.054. Epub 2007 Aug 31.","Kuban DA","Int J Radiat Oncol Biol Phys","2008","2007/09/04","","","10.1016/j.ijrobp.2007.06.054"
"21840577","Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading","Ouzzane A, Puech P, Lemaitre L, Leroy X, Nevoux P, Betrouni N, Haber GP, Villers A.","Urology. 2011 Dec;78(6):1356-62. doi: 10.1016/j.urology.2011.06.022. Epub 2011 Aug 16.","Ouzzane A","Urology","2011","2011/08/16","","","10.1016/j.urology.2011.06.022"
"28247707","[Hypofractionated radiation therapy for localized prostate cancer (first experience)]","Vorob'eva TG, Bednyj IV, Drobjazgin EA, Polovnikov ES.","Urologiia. 2016 Feb;(1):70-74.","Vorob'eva TG","Urologiia","2016","2017/03/02","","",""
"17003784","A model of the natural history of screen-detected prostate cancer","Metcalfe C, Lane JA, Hamdy F, Neal D, Donovan JL.","Br J Cancer. 2006 Oct 23;95(8):1122-3. doi: 10.1038/sj.bjc.6603368. Epub 2006 Sep 26.","Metcalfe C","Br J Cancer","2006","2006/09/28","PMC2360718","","10.1038/sj.bjc.6603368"
"12681261","New era in prostate-cancer care: what we know and what we don't","Talcott JA.","Lancet Oncol. 2003 Apr;4(4):204-5. doi: 10.1016/s1470-2045(03)01030-1.","Talcott JA","Lancet Oncol","2003","2003/04/12","","","10.1016/s1470-2045(03)01030-1"
"29471004","Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications","Chhabra G, Singh CK, Ndiaye MA, Fedorowicz S, Molot A, Ahmad N.","Cancer Lett. 2018 May 28;422:9-18. doi: 10.1016/j.canlet.2018.02.025. Epub 2018 Feb 20.","Chhabra G","Cancer Lett","2018","2018/02/23","PMC5869161","NIHMS944582","10.1016/j.canlet.2018.02.025"
"27686597","PARP inhibitors and stratified treatment of prostate cancer","Lavery A, Gilson C, Chowdhury S.","Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. doi: 10.1080/14737140.2016.1243474. Epub 2016 Oct 17.","Lavery A","Expert Rev Anticancer Ther","2016","2016/10/01","","","10.1080/14737140.2016.1243474"
"22868485","Is PCA3 score useful in preoperative staging of a single microfocus of prostate cancer diagnosed at saturation biopsy?","Pepe P, Fraggetta F, Galia A, Aragona F.","Urol Int. 2012;89(2):143-7. doi: 10.1159/000340055. Epub 2012 Aug 3.","Pepe P","Urol Int","2012","2012/08/08","","","10.1159/000340055"
"23867219","Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy","Bi X, Sterling JA, Merkel AR, Perrien DS, Nyman JS, Mahadevan-Jansen A.","Bone. 2013 Oct;56(2):454-60. doi: 10.1016/j.bone.2013.07.006. Epub 2013 Jul 15.","Bi X","Bone","2013","2013/07/23","PMC3799839","NIHMS514213","10.1016/j.bone.2013.07.006"
"11005246","Cell proliferation and apoptosis in prostate cancer: significance in disease progression and therapy","Kyprianou N, Bruckheimer EM, Guo Y.","Histol Histopathol. 2000 Oct;15(4):1211-23. doi: 10.14670/HH-15.1211.","Kyprianou N","Histol Histopathol","2000","2000/09/27","","","10.14670/HH-15.1211"
"20553251","Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap","Barocas DA, Penson DF.","BJU Int. 2010 Aug;106(3):322-8. doi: 10.1111/j.1464-410X.2010.09467.x. Epub 2010 Jun 14.","Barocas DA","BJU Int","2010","2010/06/18","PMC2910169","NIHMS210243","10.1111/j.1464-410X.2010.09467.x"
"17968424","Analysis of consultant decision-making in the management of prostate cancer","Wilson J, Kennedy K, Ewings P, Macdonagh R.","Prostate Cancer Prostatic Dis. 2008;11(3):288-93. doi: 10.1038/sj.pcan.4501025. Epub 2007 Oct 30.","Wilson J","Prostate Cancer Prostatic Dis","2008","2007/10/31","","","10.1038/sj.pcan.4501025"
"11901534","Diabetes mellitus and the risk of prostate cancer","Rosenberg DJ, Neugut AI, Ahsan H, Shea S.","Cancer Invest. 2002;20(2):157-65. doi: 10.1081/cnv-120001141.","Rosenberg DJ","Cancer Invest","2002","2002/03/21","","","10.1081/cnv-120001141"
"18528888","Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge","Rapkiewicz A, Gorokhovsky R, Farcon E, Das K.","Diagn Cytopathol. 2008 Jul;36(7):499-502. doi: 10.1002/dc.20814.","Rapkiewicz A","Diagn Cytopathol","2008","2008/06/06","","","10.1002/dc.20814"
"29495626","Chinese Medicines in the Treatment of Prostate Cancer: From Formulas to Extracts and Compounds","Wang X, Fang G, Pang Y.","Nutrients. 2018 Feb 28;10(3):283. doi: 10.3390/nu10030283.","Wang X","Nutrients","2018","2018/03/03","PMC5872701","","10.3390/nu10030283"
"15076276","Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population","Li J, White N, Zhang Z, Rosenzweig J, Mangold LA, Partin AW, Chan DW.","J Urol. 2004 May;171(5):1782-7. doi: 10.1097/01.ju.0000119823.86393.49.","Li J","J Urol","2004","2004/04/13","","","10.1097/01.ju.0000119823.86393.49"
"18760741","[Study of prostate cancer screening in a population of employees of a Kinshasa company in the Democratic Republic of Congo. Detection rate and nutritional and geographical risk factors]","Punga-Maole AM, Moningo DM, Kayembe PK, Tshikuela ML, Kabongo JM.","Prog Urol. 2008 Sep;18(8):512-8. doi: 10.1016/j.purol.2008.04.009. Epub 2008 Jun 10.","Punga-Maole AM","Prog Urol","2008","2008/09/02","","","10.1016/j.purol.2008.04.009"
"12099577","Endothelin-1 as a target for therapeutic intervention in prostate cancer","Kopetz ES, Nelson JB, Carducci MA.","Invest New Drugs. 2002 May;20(2):173-82. doi: 10.1023/a:1015630513908.","Kopetz ES","Invest New Drugs","2002","2002/07/09","","","10.1023/a:1015630513908"
"19012915","Defining increased future risk for prostate cancer: evidence from a population based screening cohort","Schröder FH, Roobol MJ, Andriole GL, Fleshner N.","J Urol. 2009 Jan;181(1):69-74; discussion 74. doi: 10.1016/j.juro.2008.09.012. Epub 2008 Nov 13.","Schröder FH","J Urol","2009","2008/11/18","","","10.1016/j.juro.2008.09.012"
"29529534","Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes","Kobayashi PE, Fonseca-Alves CE, Rivera-Calderón LG, Carvalho M, Kuasne H, Rogatto SR, Laufer-Amorim R.","Res Vet Sci. 2018 Jun;118:254-261. doi: 10.1016/j.rvsc.2018.03.004. Epub 2018 Mar 5.","Kobayashi PE","Res Vet Sci","2018","2018/03/13","","","10.1016/j.rvsc.2018.03.004"
"21630551","The analysis of some factors that influence on serum PSA level in localized prostate cancer patients: mathematical model","Pejcić T, Hadzi-Djokić J, Topuzović C, Basić D, Marjanović A, Djurasic L.","Acta Chir Iugosl. 2011;58(1):81-7. doi: 10.2298/aci1101081p.","Pejcić T","Acta Chir Iugosl","2011","2011/06/03","","","10.2298/aci1101081p"
"17179486","Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort","Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE.","Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9. doi: 10.1158/1055-9965.EPI-06-0754. Epub 2006 Dec 19.","Rodriguez C","Cancer Epidemiol Biomarkers Prev","2007","2006/12/21","","","10.1158/1055-9965.EPI-06-0754"
"16672122","Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer","Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Loblaw A, Pond GR, Emami M, Sugar L, Sweet J, Narod SA.","Can J Urol. 2006 Apr;13 Suppl 2:2-10.","Nam RK","Can J Urol","2006","2006/05/05","","",""
"27027344","Prediction of mycoplasma hominis proteins targeting in mitochondria and cytoplasm of host cells and their implication in prostate cancer etiology","Khan S, Zakariah M, Rolfo C, Robrecht L, Palaniappan S.","Oncotarget. 2017 May 9;8(19):30830-30843. doi: 10.18632/oncotarget.8306.","Khan S","Oncotarget","2017","2016/03/31","PMC5458171","","10.18632/oncotarget.8306"
"11528188","Orchidectomy following failure of antiandrogen monotherapy in patients with metastatic prostate cancer","Tan A, Tuckey J, Rice M.","Eur Urol. 2001 Aug;40(2):130-3; discussion 134. doi: 10.1159/000049762.","Tan A","Eur Urol","2001","2001/08/31","","","10.1159/000049762"
"16018941","Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression","Heresi GA, Wang J, Taichman R, Chirinos JA, Regalado JJ, Lichtstein DM, Rosenblatt JD.","Urol Oncol. 2005 Jul-Aug;23(4):261-7. doi: 10.1016/j.urolonc.2005.02.004.","Heresi GA","Urol Oncol","2005","2005/07/16","","","10.1016/j.urolonc.2005.02.004"
"30734839","[Focal therapy for prostate cancer]","Schostak M.","Urologe A. 2019 May;58(5):518-523. doi: 10.1007/s00120-019-0862-0.","Schostak M","Urologe A","2019","2019/02/09","","","10.1007/s00120-019-0862-0"
"25024274","On manhood and Movember ...or why the moustache works","Wassersug R, Oliffe J, Han C.","Glob Health Promot. 2015 Jun;22(2):65-70. doi: 10.1177/1757975914536913. Epub 2014 Jul 14.","Wassersug R","Glob Health Promot","2015","2014/07/16","","","10.1177/1757975914536913"
"15842467","Portrayals of treatment decision-making on popular breast and prostate cancer web sites","Seale C.","Eur J Cancer Care (Engl). 2005 May;14(2):171-4. doi: 10.1111/j.1365-2354.2005.00544.x.","Seale C","Eur J Cancer Care (Engl)","2005","2005/04/22","","","10.1111/j.1365-2354.2005.00544.x"
"12790784","Androgen receptor involvement in the progression of prostate cancer","Suzuki H, Ueda T, Ichikawa T, Ito H.","Endocr Relat Cancer. 2003 Jun;10(2):209-16. doi: 10.1677/erc.0.0100209.","Suzuki H","Endocr Relat Cancer","2003","2003/06/07","","","10.1677/erc.0.0100209"
"22925240","Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance","Shapiro RH, Johnstone PA.","Urology. 2012 Sep;80(3):661-6. doi: 10.1016/j.urology.2012.06.022.","Shapiro RH","Urology","2012","2012/08/29","","","10.1016/j.urology.2012.06.022"
"11383247","The debate about prostate cancer screening: what nurses need to know","Weinrich S.","Semin Oncol Nurs. 2001 May;17(2):78-84. doi: 10.1053/sonu.2001.23064.","Weinrich S","Semin Oncol Nurs","2001","2001/06/01","","","10.1053/sonu.2001.23064"
"16110761","Prognostic value of DNA analysis of prostate adenocarcinoma: correlation to clinicopathologic predictors","Bantis A, Gonidi M, Athanassiades P, Tsolos Ch, Liossi A, Aggelonidou E, Athanassiadou AM, Petrakakou E, Athanassiadou P.","J Exp Clin Cancer Res. 2005 Jun;24(2):273-8.","Bantis A","J Exp Clin Cancer Res","2005","2005/08/23","","",""
"20581469","Genetic variant associated with aggressive not indolent prostate cancer","Kirkland CT, Price DK, Figg WD.","Cancer Biol Ther. 2010 Jun 15;9(12):957-8. doi: 10.4161/cbt.9.12.12137. Epub 2010 Jun 22.","Kirkland CT","Cancer Biol Ther","2010","2010/06/29","","","10.4161/cbt.9.12.12137"
"12441950","Attitudes and use of complementary medicine in men with prostate cancer","Wilkinson S, Gomella LG, Smith JA, Brawer MK, Dawson NA, Wajsman Z, Dai L, Chodak GW.","J Urol. 2002 Dec;168(6):2505-9. doi: 10.1097/01.ju.0000037733.62447.50.","Wilkinson S","J Urol","2002","2002/11/21","","","10.1097/01.ju.0000037733.62447.50"
"20149703","[Prostate cancer screening and mortality in a European Community trial]","Delgado-Rodríguez M.","Enferm Clin. 2010 Jan-Feb;20(1):64-5. doi: 10.1016/j.enfcli.2009.10.005. Epub 2010 Feb 9.","Delgado-Rodríguez M","Enferm Clin","2010","2010/02/13","","","10.1016/j.enfcli.2009.10.005"
"19143286","[Clinical features and histopathology of prostate cancer diagnosed from the third biopsy]","Bahílo Mateu MP, Ramírez Backhaus M, Trassierra Villa M, Di Capua Sacoto C, Arlandis Guzmán S, Cruz Jiménez JF.","Actas Urol Esp. 2008 Nov-Dec;32(10):961-7. doi: 10.1016/s0210-4806(08)73973-1.","Bahílo Mateu MP","Actas Urol Esp","2008","2009/01/16","","","10.1016/s0210-4806(08)73973-1"
"12557703","[Treatment strategy for locally advanced prostate cancer]","Kurokawa K, Suzuki K, Yamanaka H.","Gan To Kagaku Ryoho. 2003 Jan;30(1):38-42.","Kurokawa K","Gan To Kagaku Ryoho","2003","2003/02/01","","",""
"27260776","Increased choline uptake in macrophages and prostate cancer cells does not allow for differentiation between benign and malignant prostate pathologies","Schwarz T, Seidl C, Schiemann M, Senekowitsch-Schmidtke R, Krause BJ.","Nucl Med Biol. 2016 Jun;43(6):355-9. doi: 10.1016/j.nucmedbio.2016.02.004. Epub 2016 Feb 27.","Schwarz T","Nucl Med Biol","2016","2016/06/05","","","10.1016/j.nucmedbio.2016.02.004"
"21728122","Specific isoforms of plasminogen in patients with prostate cancer","Vodolazhsky DI, Shin EF, Golikov AY, Belova TN, Zimakov DV, Cherkasova EN, Boyko NV, Kogan MI, Chibichian MB, Moshkovsky SA, Matishov DG.","Dokl Biol Sci. 2011 May-Jun;438:141-4. doi: 10.1134/S0012496611030148. Epub 2011 Jul 5.","Vodolazhsky DI","Dokl Biol Sci","2011","2011/07/06","","","10.1134/S0012496611030148"
"27283984","High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells","Xie J, Mølck C, Paquet-Fifield S, Butler L; Australian Prostate Cancer Bioresource, Sloan E, Ventura S, Hollande F.","Oncotarget. 2016 Jul 12;7(28):44492-44504. doi: 10.18632/oncotarget.9876.","Xie J","Oncotarget","2016","2016/06/11","PMC5190113","","10.18632/oncotarget.9876"
"9669857","Screening for prostate cancer. Surgery lengthens survival","Hodgson WB.","BMJ. 1998 Jun 20;316(7148):1903-4.","Hodgson WB","BMJ","1998","1998/07/20","","",""
"16949769","Relationship between delay in radiotherapy and biochemical control in prostate cancer","Kwan W, Pickles T, Duncan G, Liu M, Paltiel C.","Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):663-8. doi: 10.1016/j.ijrobp.2006.05.043. Epub 2006 Sep 1.","Kwan W","Int J Radiat Oncol Biol Phys","2006","2006/09/05","","","10.1016/j.ijrobp.2006.05.043"
"15151133","Raf kinase inhibitor protein: a prostate cancer metastasis suppressor gene","Keller ET, Fu Z, Yeung K, Brennan M.","Cancer Lett. 2004 Apr 30;207(2):131-7. doi: 10.1016/j.canlet.2004.02.006.","Keller ET","Cancer Lett","2004","2004/05/21","","","10.1016/j.canlet.2004.02.006"
"26874727","Computational prediction of Mycoplasma hominis proteins targeting in nucleus of host cell and their implication in prostate cancer etiology","Khan S, Zakariah M, Palaniappan S.","Tumour Biol. 2016 Aug;37(8):10805-13. doi: 10.1007/s13277-016-4970-9. Epub 2016 Feb 13.","Khan S","Tumour Biol","2016","2016/02/15","","","10.1007/s13277-016-4970-9"
"22260413","Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up","Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS.","BMC Cancer. 2012 Jan 19;12:25. doi: 10.1186/1471-2407-12-25.","Shafique K","BMC Cancer","2012","2012/01/21","PMC3271031","","10.1186/1471-2407-12-25"
"12537668","BCL2 antisense reduces prostate cancer cell survival following irradiation","Scott SL, Higdon R, Beckett L, Shi XB, deVere White RW, Earle JD, Gumerlock PH.","Cancer Biother Radiopharm. 2002 Dec;17(6):647-56. doi: 10.1089/108497802320970253.","Scott SL","Cancer Biother Radiopharm","2002","2003/01/23","","","10.1089/108497802320970253"
"20923033","Androgen deprivation therapy in high-risk prostate cancer","Buyyounouski MK.","Oncology (Williston Park). 2010 Aug;24(9):806, 809.","Buyyounouski MK","Oncology (Williston Park)","2010","2010/10/07","","",""
"25274038","Family history in the Finnish Prostate Cancer Screening Trial","Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A.","Int J Cancer. 2015 May 1;136(9):2172-7. doi: 10.1002/ijc.29243. Epub 2014 Oct 10.","Saarimäki L","Int J Cancer","2015","2014/10/03","","","10.1002/ijc.29243"
"9676539","Prostate cryoablation: update 1998","Schmidt JD, Doyle J, Larison S.","CA Cancer J Clin. 1998 Jul-Aug;48(4):239-53. doi: 10.3322/canjclin.48.4.239.","Schmidt JD","CA Cancer J Clin","1998","1998/07/24","","","10.3322/canjclin.48.4.239"
"12599545","[Statistical analysis of prostate cancer in Japan]","Hirao Y, Cho M.","Nihon Rinsho. 2002 Dec;60 Suppl 11:53-8.","Hirao Y","Nihon Rinsho","2002","2003/02/26","","",""
"23852643","The molecular basis for ethnic variation and histological subtype differences in prostate cancer","Zong Y, Goldstein AS, Huang J.","Sci China Life Sci. 2013 Sep;56(9):780-7. doi: 10.1007/s11427-013-4522-0. Epub 2013 Jul 13.","Zong Y","Sci China Life Sci","2013","2013/07/16","PMC4078990","NIHMS594444","10.1007/s11427-013-4522-0"
"8911367","Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic","Weingärtner K, Ramaswamy A, Bittinger A, Gerharz EW, Vöge D, Riedmiller H.","J Urol. 1996 Dec;156(6):1969-71. doi: 10.1016/s0022-5347(01)65406-5.","Weingärtner K","J Urol","1996","1996/12/01","","","10.1016/s0022-5347(01)65406-5"
"12545622","[Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer]","Rigaud J, Tiguert R, Fradet Y, Bouchot O.","Prog Urol. 2002 Dec;12(6):1179-87.","Rigaud J","Prog Urol","2002","2003/01/28","","",""
"1799852","[Controversies in local therapy of early prostatic cancer]","Thiel HJ.","Bildgebung. 1991;58 Suppl 1:56-64.","Thiel HJ","Bildgebung","1991","1991/01/01","","",""
"14991758","Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy","Lee EC, Tenniswood MP.","J Cell Biochem. 2004 Mar 1;91(4):662-70. doi: 10.1002/jcb.20040.","Lee EC","J Cell Biochem","2004","2004/03/03","","","10.1002/jcb.20040"
"25511701","microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression","Han G, Fan M, Zhang X.","Biochem Biophys Res Commun. 2015 Jan 16;456(3):804-9. doi: 10.1016/j.bbrc.2014.12.026. Epub 2014 Dec 13.","Han G","Biochem Biophys Res Commun","2015","2014/12/17","","","10.1016/j.bbrc.2014.12.026"
"19191782","Derivatives of prostate-specific antigen as predictors of incidental prostate cancer","Froehner M, Buck LM, Koch R, Hakenberg OW, Wirth MP.","BJU Int. 2009 Jul;104(1):25-8. doi: 10.1111/j.1464-410X.2009.08349.x. Epub 2009 Feb 3.","Froehner M","BJU Int","2009","2009/02/05","","","10.1111/j.1464-410X.2009.08349.x"
"29902938","Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study","Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.","Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.","Fantony JJ","Biomark Med","2018","2018/06/16","PMC6219443","","10.2217/bmm-2017-0322"
"26473737","Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells","Guo J, Huang X, Wang H, Yang H.","PLoS One. 2015 Oct 16;10(10):e0140745. doi: 10.1371/journal.pone.0140745. eCollection 2015.","Guo J","PLoS One","2015","2015/10/17","PMC4608724","","10.1371/journal.pone.0140745"
"15032020","[A case of prostate cancer with invasion to the middle ureter]","Matsuo T, Hayashida Y, Takehara K, Tsuda S, Furukawa M, Iwasaki S.","Hinyokika Kiyo. 2004 Jan;50(1):61-3.","Matsuo T","Hinyokika Kiyo","2004","2004/03/23","","",""
"11252211","Communication about prostate cancer between men and their wives","Boehmer U, Clark JA.","J Fam Pract. 2001 Mar;50(3):226-31.","Boehmer U","J Fam Pract","2001","2001/03/17","","",""
"23043150","Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer","Evans MJ.","Cancer Discov. 2012 Nov;2(11):985-94. doi: 10.1158/2159-8290.CD-12-0178. Epub 2012 Oct 5.","Evans MJ","Cancer Discov","2012","2012/10/09","PMC3508522","HHMIMS396062","10.1158/2159-8290.CD-12-0178"
"29330107","Prostate cancer-associated lncRNAs","Mitobe Y, Takayama KI, Horie-Inoue K, Inoue S.","Cancer Lett. 2018 Apr 1;418:159-166. doi: 10.1016/j.canlet.2018.01.012. Epub 2018 Jan 9.","Mitobe Y","Cancer Lett","2018","2018/01/14","","","10.1016/j.canlet.2018.01.012"
"19646431","Enhancing prostate cancer cryotherapy using tumour necrosis factor related apoptosis-inducing ligand (TRAIL) sensitisation in an in vitro cryotherapy model","Ismail M, Morgan R, Harrington K, Davies J, Pandha H.","Cryobiology. 2009 Oct;59(2):207-13. doi: 10.1016/j.cryobiol.2009.07.008. Epub 2009 Jul 29.","Ismail M","Cryobiology","2009","2009/08/04","","","10.1016/j.cryobiol.2009.07.008"
"23746297","Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance","Abdollah F, Suardi N, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.","BJU Int. 2013 Aug;112(4):E234-42. doi: 10.1111/bju.12152. Epub 2013 Jun 7.","Abdollah F","BJU Int","2013","2013/06/11","","","10.1111/bju.12152"
"10613318","The impact of race on biochemical disease-free survival in early-stage prostate cancer patients treated with surgery or radiation therapy","Hart KB, Wood DP Jr, Tekyi-Mensah S, Porter AT, Pontes JE, Forman JD.","Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1235-8. doi: 10.1016/s0360-3016(99)00321-1.","Hart KB","Int J Radiat Oncol Biol Phys","1999","1999/12/29","","","10.1016/s0360-3016(99)00321-1"
"9456247","Rising incidence of prostate cancer in Shanghai, China","Hsing AW, Devesa SS, Jin F, Gao YT.","Cancer Epidemiol Biomarkers Prev. 1998 Jan;7(1):83-4.","Hsing AW","Cancer Epidemiol Biomarkers Prev","1998","1998/02/10","","",""
"28526417","Imaging of a Pelvic Textiloma Using (18)F-FDG PET/CT in a Patient With a History of Prostate Cancer: A Case Report and Review of the Literature","Schollhammer R, De Clermont-Gallerande H, Fernandez P, Meyer M.","Clin Genitourin Cancer. 2017 Oct;15(5):e859-e861. doi: 10.1016/j.clgc.2017.04.027. Epub 2017 Apr 26.","Schollhammer R","Clin Genitourin Cancer","2017","2017/05/21","","","10.1016/j.clgc.2017.04.027"
"12515785","Radical prostatectomy as treatment for prostate cancer","Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J.","CMAJ. 2003 Jan 7;168(1):44-5.","Jewett MA","CMAJ","2003","2003/01/08","PMC139318","",""
"7679042","American Cancer Society--National Prostate Cancer Detection Project. Results from multiple examinations using transrectal ultrasound, digital rectal examination, and prostate specific antigen","Mettlin C, Murphy GP, Ray P, Shanberg A, Toi A, Chesley A, Babaian R, Badalament R, Kane RA, Lee F.","Cancer. 1993 Feb 1;71(3 Suppl):891-8. doi: 10.1002/1097-0142(19930201)71:3+<891::aid-cncr2820711405>3.0.co;2-x.","Mettlin C","Cancer","1993","1993/02/01","","","10.1002/1097-0142(19930201)71:3+<891::aid-cncr2820711405>3.0.co;2-x"
"18774469","Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC)","Schröder FH.","Urol Oncol. 2008 Sep-Oct;26(5):533-41. doi: 10.1016/j.urolonc.2008.03.011.","Schröder FH","Urol Oncol","2008","2008/09/09","","","10.1016/j.urolonc.2008.03.011"
"19050679","Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer","Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H.","Asian J Androl. 2009 Jan;11(1):131-7. doi: 10.1038/aja.2008.35. Epub 2008 Dec 15.","Hsu CY","Asian J Androl","2009","2008/12/04","PMC3735214","","10.1038/aja.2008.35"
"16324498","[Update of the treatment of advanced prostate cancer and management of its complications]","Gil-Bazo I, Ignacio Martínez-Salamanca J, Bianco FJ Jr.","Med Clin (Barc). 2005 Nov 12;125(17):671-7. doi: 10.1016/s0025-7753(05)72149-7.","Gil-Bazo I","Med Clin (Barc)","2005","2005/12/06","","","10.1016/s0025-7753(05)72149-7"
"28427194","Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression","Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.","Oncotarget. 2017 Apr 25;8(17):27966-27975. doi: 10.18632/oncotarget.15854.","Lee AR","Oncotarget","2017","2017/04/22","PMC5438622","","10.18632/oncotarget.15854"
"22208008","[Prognostic factors predicting for postoperative recurrence in prostate cancer]","Matsuyama H.","Nihon Rinsho. 2011 Jun;69 Suppl 5:390-4.","Matsuyama H","Nihon Rinsho","2011","2012/01/03","","",""
"15040872","Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up","Bahn DK, Lee F, Silverman P, Bahn E, Badalament R, Kumar A, Greski J, Rewcastle JC.","Clin Prostate Cancer. 2003 Sep;2(2):111-4. doi: 10.3816/cgc.2003.n.018.","Bahn DK","Clin Prostate Cancer","2003","2004/03/26","","","10.3816/cgc.2003.n.018"
"11955765","10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy: in regard to Grimm et al., IJROBP 2001;51:31-40","Albrecht CH.","Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1429; author reply 1429. doi: 10.1016/s0360-3016(01)02816-4.","Albrecht CH","Int J Radiat Oncol Biol Phys","2002","2002/04/17","","","10.1016/s0360-3016(01)02816-4"
"25422238","Identification of prostate cancer LncRNAs by RNA-Seq","Hu CC, Gan P, Zhang RY, Xue JX, Ran LK.","Asian Pac J Cancer Prev. 2014;15(21):9439-44. doi: 10.7314/apjcp.2014.15.21.9439.","Hu CC","Asian Pac J Cancer Prev","2014","2014/11/26","","","10.7314/apjcp.2014.15.21.9439"
"32690870","Management of prostate cancer patients during COVID-19 pandemic","Obek C, Doganca T, Argun OB, Kural AR.","Prostate Cancer Prostatic Dis. 2020 Sep;23(3):398-406. doi: 10.1038/s41391-020-0258-7. Epub 2020 Jul 20.","Obek C","Prostate Cancer Prostatic Dis","2020","2020/07/22","PMC7371779","","10.1038/s41391-020-0258-7"
"29536157","Association between race and oncologic outcome following radical prostatectomy for clinically organ-confined prostate cancer: a long-term follow-up study","Amini E, Palmer TC, Cai J, Lieskovsky G, Daneshmand S, Djaladat H.","World J Urol. 2018 Aug;36(8):1233-1239. doi: 10.1007/s00345-018-2266-y. Epub 2018 Mar 13.","Amini E","World J Urol","2018","2018/03/15","","","10.1007/s00345-018-2266-y"
"25498570","External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort","Tilki D, Mandel P, Schlomm T, Chun FK, Tennstedt P, Pehrke D, Haese A, Huland H, Graefen M, Salomon G.","J Urol. 2015 Jun;193(6):1970-5. doi: 10.1016/j.juro.2014.12.020. Epub 2014 Dec 11.","Tilki D","J Urol","2015","2014/12/16","","","10.1016/j.juro.2014.12.020"
"8773498","Who is best benefited by radical prostatectomy?","Nadler RB, Andriole GL.","Hematol Oncol Clin North Am. 1996 Jun;10(3):581-93. doi: 10.1016/s0889-8588(05)70354-3.","Nadler RB","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70354-3"
"31718684","Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies","Baci D, Bruno A, Cascini C, Gallazzi M, Mortara L, Sessa F, Pelosi G, Albini A, Noonan DM.","J Exp Clin Cancer Res. 2019 Nov 12;38(1):464. doi: 10.1186/s13046-019-1461-z.","Baci D","J Exp Clin Cancer Res","2019","2019/11/14","PMC6852951","","10.1186/s13046-019-1461-z"
"28437038","Impact of preoperative risk on metastatic progression and cancer-specific mortality in patients with adverse pathology at radical prostatectomy","Boehm K, Leyh-Bannurah SR, Rosenbaum C, Brandi LS, Budäus L, Graefen M, Huland H, Haferkamp A, Tilki D.","BJU Int. 2017 Nov;120(5):666-672. doi: 10.1111/bju.13887. Epub 2017 May 29.","Boehm K","BJU Int","2017","2017/04/25","","","10.1111/bju.13887"
"20953202","The complexities of identifying a cell of origin for human prostate cancer","Risbridger GP, Taylor RA.","Asian J Androl. 2011 Jan;13(1):118-9. doi: 10.1038/aja.2010.114. Epub 2010 Oct 18.","Risbridger GP","Asian J Androl","2011","2010/10/19","PMC3739383","","10.1038/aja.2010.114"
"15026335","A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer","Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB, Xu J.","Cancer Res. 2004 Mar 15;64(6):1997-9. doi: 10.1158/0008-5472.can-03-2340.","Chang BL","Cancer Res","2004","2004/03/18","","","10.1158/0008-5472.can-03-2340"
"29979320","Local ablative stereotactic body radiotherapy for oligometastatic prostate cancer","Niazi T, Elakshar S, Stroian G.","Curr Opin Support Palliat Care. 2018 Sep;12(3):351-358. doi: 10.1097/SPC.0000000000000371.","Niazi T","Curr Opin Support Palliat Care","2018","2018/07/07","","","10.1097/SPC.0000000000000371"
"23902245","Recent advances revolutionize treatment of metastatic prostate cancer","Madan RA, Arlen PM.","Future Oncol. 2013 Aug;9(8):1133-44. doi: 10.2217/fon.13.65.","Madan RA","Future Oncol","2013","2013/08/02","","","10.2217/fon.13.65"
"27184548","Personalized prostate cancer care: from screening to treatment","Conran CA, Brendler CB, Xu J.","Asian J Androl. 2016 Jul-Aug;18(4):505-8. doi: 10.4103/1008-682X.179529.","Conran CA","Asian J Androl","2016","2016/05/18","PMC4955170","","10.4103/1008-682X.179529"
"27344704","[Oncogene and tumor suppressor gene for prostate cancer]","Ueda T, Komaru A, Rii JR, Kobayashi M, Fukasawa S.","Nihon Rinsho. 2016 May 20;74 Suppl 3:60-4.","Ueda T","Nihon Rinsho","2016","2016/06/28","","",""
"23094757","Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis","Moghanaki D, Freedland SJ, Anscher M.","Int J Urol. 2013 May;20(5):547-8. doi: 10.1111/j.1442-2042.2012.03212.x. Epub 2012 Oct 24.","Moghanaki D","Int J Urol","2013","2012/10/26","","","10.1111/j.1442-2042.2012.03212.x"
"1454729","Prostate cancer","Chisholm G, Rana A.","Practitioner. 1992 Jun;236(1515):610-7.","Chisholm G","Practitioner","1992","1992/06/01","","",""
"7743383","Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer","Kreis W.","Cancer Invest. 1995;13(3):296-312. doi: 10.3109/07357909509094465.","Kreis W","Cancer Invest","1995","1995/01/01","","","10.3109/07357909509094465"
"22320965","A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients--a meta-analysis","Wang FB, Yang XQ, Yang S, Wang BC, Feng MH, Tu JC.","Asian Pac J Cancer Prev. 2011;12(10):2629-35.","Wang FB","Asian Pac J Cancer Prev","2011","2012/02/11","","",""
"16287439","Factors contributing to the racial differences in prostate cancer mortality","Tewari A, Horninger W, Pelzer AE, Demers R, Crawford ED, Gamito EJ, Divine G, Johnson CC, Bartsch G, Menon M.","BJU Int. 2005 Dec;96(9):1247-52. doi: 10.1111/j.1464-410X.2005.05824.x.","Tewari A","BJU Int","2005","2005/11/17","","","10.1111/j.1464-410X.2005.05824.x"
"15036649","Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer","Jung K, Stephan C, Lewandowski M, Klotzek S, Jung M, Kristiansen G, Lein M, Loening SA, Schnorr D.","Cancer Lett. 2004 Mar 18;205(2):173-80. doi: 10.1016/j.canlet.2003.11.023.","Jung K","Cancer Lett","2004","2004/03/24","","","10.1016/j.canlet.2003.11.023"
"27423973","[Prostate cancer microenvironment: Its structure, functions and therapeutic applications]","Lorion R, Bladou F, Spatz A, van Kempen L, Irani J.","Prog Urol. 2016 Jun;26(8):464-76. doi: 10.1016/j.purol.2016.06.006. Epub 2016 Aug 8.","Lorion R","Prog Urol","2016","2016/07/18","","","10.1016/j.purol.2016.06.006"
"24102230","Editorial Comment to: SAMS: a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer","Rannikko A.","Scand J Urol. 2013 Oct;47(5):356. doi: 10.3109/21681805.2013.840335.","Rannikko A","Scand J Urol","2013","2013/10/10","","","10.3109/21681805.2013.840335"
"26762899","The canine prostate cancer cell line CHP-1 shows over-expression of the co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α","Azakami D, Nakahira R, Kato Y, Michishita M, Kobayashi M, Onozawa E, Bonkobara M, Kobayashi M, Takahashi K, Watanabe M, Ishioka K, Sako T, Ochiai K, Omi T.","Vet Comp Oncol. 2017 Jun;15(2):557-562. doi: 10.1111/vco.12199. Epub 2016 Jan 14.","Azakami D","Vet Comp Oncol","2017","2016/01/15","","","10.1111/vco.12199"
"27344741","[Current status and future perspective in Japanese prostate cancer screening]","Okihara K.","Nihon Rinsho. 2016 May 20;74 Suppl 3:275-9.","Okihara K","Nihon Rinsho","2016","2016/06/28","","",""
"25728717","Latent prostate cancer in Japanese men who die unnatural deaths: A forensic autopsy study","Kido M, Hitosugi M, Ishii K, Kamimura S, Joh K.","Prostate. 2015 Jun 15;75(9):917-22. doi: 10.1002/pros.22975. Epub 2015 Mar 1.","Kido M","Prostate","2015","2015/03/03","","","10.1002/pros.22975"
"16236539","[Immediate or delayed postoperative radiotherapy in prostate cancer]","Carrie C, Pommier P.","Cancer Radiother. 2005 Nov;9(6-7):379-81. doi: 10.1016/j.canrad.2005.09.006. Epub 2005 Oct 19.","Carrie C","Cancer Radiother","2005","2005/10/21","","","10.1016/j.canrad.2005.09.006"
"18273597","[Active surveillance for prostate cancer]","Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H, Budäus L, Heinzer H, Huland H.","Urologe A. 2008 Mar;47(3):261-9. doi: 10.1007/s00120-008-1638-0.","Graefen M","Urologe A","2008","2008/02/15","","","10.1007/s00120-008-1638-0"
"16563992","Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","Martens C, Pond G, Webster D, McLean M, Gillan C, Crook J.","Brachytherapy. 2006 Jan-Mar;5(1):9-13. doi: 10.1016/j.brachy.2005.12.002.","Martens C","Brachytherapy","2006","2006/03/28","","","10.1016/j.brachy.2005.12.002"
"17553363","[Diagnosis, evaluation and follow-up of patients with prostatic cancer]","Jønler M, Pedersen KV.","Ugeskr Laeger. 2007 May 14;169(20):1889-91.","Jønler M","Ugeskr Laeger","2007","2007/06/08","","",""
"25091389","The clinical value of dynamic contrast-enhanced magnetic resonance imaging at 3.0T to detect prostate cancer","Zhang X, Quan X, Lu S, Huang F, Yang J, Chan Q, Lin T.","J Int Med Res. 2014 Oct;42(5):1077-84. doi: 10.1177/0300060514541827. Epub 2014 Aug 4.","Zhang X","J Int Med Res","2014","2014/08/06","","","10.1177/0300060514541827"
"27166412","Prostate Cancer Care Before and After Medicare Eligibility","Huesch MD, Ong MK.","Inquiry. 2016 May 10;53:0046958016647298. doi: 10.1177/0046958016647298. Print 2016.","Huesch MD","Inquiry","2016","2016/05/12","PMC5798696","","10.1177/0046958016647298"
"16943535","Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial","Otto SJ, Schröder FH, de Koning HJ.","J Clin Oncol. 2006 Sep 1;24(25):4184-9. doi: 10.1200/JCO.2005.05.4288.","Otto SJ","J Clin Oncol","2006","2006/09/01","","","10.1200/JCO.2005.05.4288"
"14997414","[PSA related screening of prostate cancer. Panic or improvement?]","Fornara P, Jurczok A.","Aktuelle Urol. 2004 Feb;35(1):43-8. doi: 10.1055/s-2003-812473.","Fornara P","Aktuelle Urol","2004","2004/03/05","","","10.1055/s-2003-812473"
"23883427","The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer","Bratt O, Carlsson S, Holmberg E, Holmberg L, Johansson E, Josefsson A, Nilsson A, Nyberg M, Robinsson D, Sandberg J, Sandblom D, Stattin P.","Scand J Urol. 2013 Oct;47(5):347-55. doi: 10.3109/21681805.2013.813962. Epub 2013 Jul 24.","Bratt O","Scand J Urol","2013","2013/07/26","PMC3810035","","10.3109/21681805.2013.813962"
"10458409","Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer","Afonso A, Emmert-Buck MR, Duray PH, Bostwick DG, Linehan WM, Vocke CD.","J Urol. 1999 Sep;162(3 Pt 1):922-6. doi: 10.1097/00005392-199909010-00091.","Afonso A","J Urol","1999","1999/08/24","","","10.1097/00005392-199909010-00091"
"31021585","Super active surveillance for low-risk prostate cancer | Opinion: No","Ghodoussipour S, Lebastchi AH, Bloom JB, Pinto PA, Berger A.","Int Braz J Urol. 2019 Mar-Apr;45(2):215-219. doi: 10.1590/S1677-5538.IBJU.2019.02.03.","Ghodoussipour S","Int Braz J Urol","2019","2019/04/26","PMC6541137","","10.1590/S1677-5538.IBJU.2019.02.03"
"21239021","Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer","Shteynshlyuger A, Andriole GL.","J Urol. 2011 Mar;185(3):828-32. doi: 10.1016/j.juro.2010.10.079. Epub 2011 Jan 15.","Shteynshlyuger A","J Urol","2011","2011/01/18","","","10.1016/j.juro.2010.10.079"
"11586208","Radioisotope guided pelvic lymph node dissection for prostate cancer","Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R.","J Urol. 2001 Nov;166(5):1715-9.","Wawroschek F","J Urol","2001","2001/10/05","","",""
"29026057","Pathological outcome for Chinese patients with low-risk prostate cancer eligible for active surveillance and undergoing radical prostatectomy: comparison of six different active surveillance protocols","Tsang CF, Tsu JH, Lai TC, Wong KW, Ho BS, Ng AT, Ma WK, Yiu MK.","Hong Kong Med J. 2017 Dec;23(6):609-15. doi: 10.12809/hkmj166194. Epub 2017 Oct 13.","Tsang CF","Hong Kong Med J","2017","2017/10/14","","","10.12809/hkmj166194"
"16683011","Prostate cancer incidence varies among males from different Y-chromosome lineages","Ewis AA, Lee J, Naroda T, Sano T, Kagawa S, Iwamoto T, Shinka T, Shinohara Y, Ishikawa M, Baba Y, Nakahori Y.","Prostate Cancer Prostatic Dis. 2006;9(3):303-9. doi: 10.1038/sj.pcan.4500876. Epub 2006 May 9.","Ewis AA","Prostate Cancer Prostatic Dis","2006","2006/05/10","","","10.1038/sj.pcan.4500876"
"27717152","Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine","Koo KM, Wee EJ, Mainwaring PN, Wang Y, Trau M.","Small. 2016 Dec;12(45):6233-6242. doi: 10.1002/smll.201602161. Epub 2016 Sep 26.","Koo KM","Small","2016","2016/10/08","","","10.1002/smll.201602161"
"15354516","[Four regions 12-core systemic prostate biopsy for diagnosis of prostate cancer]","Wu R, Zheng K, Li X, Zhong W.","Zhonghua Nan Ke Xue. 2004 Jul;10(7):493-5.","Wu R","Zhonghua Nan Ke Xue","2004","2004/09/10","","",""
"7541856","Family history and the risk of prostatic carcinoma in a high risk group of urological patients","Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, Nachabe M, Péloquin F, Déssureault J, Narod S, et al.","J Urol. 1995 Aug;154(2 Pt 1):404-6. doi: 10.1097/00005392-199508000-00022.","Aprikian AG","J Urol","1995","1995/08/01","","","10.1097/00005392-199508000-00022"
"22767266","ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer","Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.","Virchows Arch. 2012 Aug;461(2):157-62. doi: 10.1007/s00428-012-1270-7. Epub 2012 Jul 6.","Scheble VJ","Virchows Arch","2012","2012/07/07","","","10.1007/s00428-012-1270-7"
"17917793","Response shift due to diagnosis and primary treatment of localized prostate cancer: a then-test and a vignette study","Korfage IJ, de Koning HJ, Essink-Bot ML.","Qual Life Res. 2007 Dec;16(10):1627-34. doi: 10.1007/s11136-007-9265-6. Epub 2007 Oct 5.","Korfage IJ","Qual Life Res","2007","2007/10/06","PMC2062490","","10.1007/s11136-007-9265-6"
"22945439","Proteomic exploration of the impacts of pomegranate fruit juice on the global gene expression of prostate cancer cell","Lee ST, Wu YL, Chien LH, Chen ST, Tzeng YK, Wu TF.","Proteomics. 2012 Nov;12(21):3251-62. doi: 10.1002/pmic.201200084. Epub 2012 Oct 4.","Lee ST","Proteomics","2012","2012/09/05","","","10.1002/pmic.201200084"
"11720484","The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population","Wessel N, Liestøl K, Maehlen J, Brorson SH.","Br J Cancer. 2001 Nov 2;85(9):1418. doi: 10.1054/bjoc.2001.2098.","Wessel N","Br J Cancer","2001","2001/11/27","PMC2375259","","10.1054/bjoc.2001.2098"
"10232144","Survivors' perspectives on the impact of prostate cancer: implications for oncology nurses","Fitch MI, Johnson B, Gray R, Franssen E.","Can Oncol Nurs J. 1999 Winter;9(1):23-34. doi: 10.5737/1181912x912328.","Fitch MI","Can Oncol Nurs J","1999","1999/05/08","","","10.5737/1181912x912328"
"29311132","The Epidemiology of Prostate Cancer","Pernar CH, Ebot EM, Wilson KM, Mucci LA.","Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a030361. doi: 10.1101/cshperspect.a030361.","Pernar CH","Cold Spring Harb Perspect Med","2018","2018/01/10","PMC6280714","","10.1101/cshperspect.a030361"
"10227701","Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies","O'Connor KC.","Pharm Res. 1999 Apr;16(4):486-93. doi: 10.1023/a:1011906709680.","O'Connor KC","Pharm Res","1999","1999/05/05","","","10.1023/a:1011906709680"
"11838717","Interest in genetic prostate cancer susceptibility testing among african American men","Weinrich S, Royal C, Pettaway CA, Dunston G, Faison-Smith L, Priest JH, Roberson-Smith P, Frost J, Jenkins J, Brooks KA, Powell I.","Cancer Nurs. 2002 Feb;25(1):28-34. doi: 10.1097/00002820-200202000-00007.","Weinrich S","Cancer Nurs","2002","2002/02/13","","","10.1097/00002820-200202000-00007"
"1509919","[Can we do without bone gammagraphy in the staging of prostatic cancer?]","Morote J, Olona M, Villa J, Reig C, López MA, de Torres JA, Soler A.","Actas Urol Esp. 1992 Jun;16(6):487-9; discussion 489-90.","Morote J","Actas Urol Esp","1992","1992/06/01","","",""
"29658587","Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy","Zhang K, Yan F, Lei X, Wei D, Lu H, Zhu Z, Xiang A, Ye Z, Wang L, Zheng W, Li X, Yuan J, Lu Z, Yuan J.","Mol Med Rep. 2018 Jun;17(6):8203-8211. doi: 10.3892/mmr.2018.8882. Epub 2018 Apr 13.","Zhang K","Mol Med Rep","2018","2018/04/17","PMC5984001","","10.3892/mmr.2018.8882"
"28661899","Genomes of early onset prostate cancer","Weischenfeldt J, Korbel JO.","Curr Opin Urol. 2017 Sep;27(5):481-487. doi: 10.1097/MOU.0000000000000422.","Weischenfeldt J","Curr Opin Urol","2017","2017/06/30","","","10.1097/MOU.0000000000000422"
"28012730","Magnetic resonance imaging of the prostate: interpretation using the PI-RADS V2","Torregrosa Andrés A, Otero García M, Sineiro Galiñanes M.","Radiologia. 2017 Mar-Apr;59(2):128-138. doi: 10.1016/j.rx.2016.10.005. Epub 2016 Dec 21.","Torregrosa Andrés A","Radiologia","2017","2016/12/26","","","10.1016/j.rx.2016.10.005"
"1730125","Correlation between side of palpable tumor and side of pelvic lymph node metastasis in clinically localized prostate cancer","Harrison SH, Seale-Hawkins C, Schum CW, Dunn JK, Scardino PT.","Cancer. 1992 Feb 1;69(3):750-4. doi: 10.1002/1097-0142(19920201)69:3<750::aid-cncr2820690323>3.0.co;2-f.","Harrison SH","Cancer","1992","1992/02/01","","","10.1002/1097-0142(19920201)69:3<750::aid-cncr2820690323>3.0.co;2-f"
"15201744","Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study","Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ.","J Urol. 2004 Jul;172(1):90-3. doi: 10.1097/01.ju.0000132133.10470.bb.","Antenor JA","J Urol","2004","2004/06/18","","","10.1097/01.ju.0000132133.10470.bb"
"25683831","The role of radiotherapy in node-positive prostate cancer","Baker BR, Mohiuddin JJ, Chen RC.","Oncology (Williston Park). 2015 Feb;29(2):108-14, 116.","Baker BR","Oncology (Williston Park)","2015","2015/02/17","","",""
"16480662","Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA","Pantuck AJ, Zomorodian N, Belldegrun AS.","Curr Urol Rep. 2006 Jan;7(1):7. doi: 10.1007/s11934-006-0047-4.","Pantuck AJ","Curr Urol Rep","2006","2006/02/17","","","10.1007/s11934-006-0047-4"
"12194807","Localized prostate cancer: brachytherapy","Zietman AL.","Curr Treat Options Oncol. 2002 Oct;3(5):429-36. doi: 10.1007/s11864-002-0007-2.","Zietman AL","Curr Treat Options Oncol","2002","2002/08/27","","","10.1007/s11864-002-0007-2"
"23681472","Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study","Bosire C, Stampfer MJ, Subar AF, Wilson KM, Park Y, Sinha R.","Cancer Causes Control. 2013 Aug;24(8):1527-34. doi: 10.1007/s10552-013-0229-6. Epub 2013 May 17.","Bosire C","Cancer Causes Control","2013","2013/05/18","PMC3717413","NIHMS481607","10.1007/s10552-013-0229-6"
"30262263","Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature","Delporte G, Henon F, Ploussard G, Briganti A, Rizk J, Rozet F, Touijer K, Ouzzane A.","Prog Urol. 2018 Dec;28(16):875-889. doi: 10.1016/j.purol.2018.08.007. Epub 2018 Sep 24.","Delporte G","Prog Urol","2018","2018/09/29","","","10.1016/j.purol.2018.08.007"
"7953230","Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment","Swanson GP, Cupps RE, Utz DC, Ilstrup DM, Zincke H, Myers RP.","Br J Radiol. 1994 Sep;67(801):877-89. doi: 10.1259/0007-1285-67-801-877.","Swanson GP","Br J Radiol","1994","1994/09/01","","","10.1259/0007-1285-67-801-877"
"14569806","Prostate-specific antigen and the early diagnosis of prostate cancer","Caplan A, Kratz A.","Am J Clin Pathol. 2002 Jun;117 Suppl:S104-8. doi: 10.1309/C4UN-12LK-43HP-JXY3.","Caplan A","Am J Clin Pathol","2002","2003/10/23","","","10.1309/C4UN-12LK-43HP-JXY3"
"27000662","Clonal origin and spread of metastatic prostate cancer","Van Etten JL, Dehm SM.","Endocr Relat Cancer. 2016 Apr;23(4):R207-17. doi: 10.1530/ERC-16-0049. Epub 2016 Mar 21.","Van Etten JL","Endocr Relat Cancer","2016","2016/03/23","PMC4895916","NIHMS788167","10.1530/ERC-16-0049"
"19735258","Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry","Hernes E, Kyrdalen A, Kvåle R, Hem E, Klepp O, Axcrona K, Fosså SD.","BJU Int. 2010 Mar;105(6):805-11; discussion 811. doi: 10.1111/j.1464-410X.2009.08834.x. Epub 2009 Sep 4.","Hernes E","BJU Int","2010","2009/09/09","","","10.1111/j.1464-410X.2009.08834.x"
"12841321","Radical treatment of organ-localized and locally advanced prostate cancer in Norway--an overview","Vaage S.","Scand J Urol Nephrol Suppl. 2003;(212):11-5. doi: 10.1080/03008880310006887.","Vaage S","Scand J Urol Nephrol Suppl","2003","2003/07/05","","","10.1080/03008880310006887"
"16984655","Consistency in electronic portal imaging registration in prostate cancer radiation treatment verification","Berthelet E, Truong PT, Zavgorodni S, Moravan V, Liu MC, Runkel J, Bendorffe B, Sayers D.","Radiat Oncol. 2006 Sep 19;1:37. doi: 10.1186/1748-717X-1-37.","Berthelet E","Radiat Oncol","2006","2006/09/21","PMC1592498","","10.1186/1748-717X-1-37"
"23052323","Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010","Zhang Y, Zang T.","Urol Int. 2013;90(3):259-62. doi: 10.1159/000341977. Epub 2012 Oct 9.","Zhang Y","Urol Int","2013","2012/10/12","","","10.1159/000341977"
"15247142","Cruciferous vegetables and prostate cancer risk: confounding by PSA screening","Kristal AR, Stanford JL.","Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1265.","Kristal AR","Cancer Epidemiol Biomarkers Prev","2004","2004/07/13","","",""
"29219277","Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center","Tang S, Hao H, Fang D, Zheng W, Ge P, Su X, He Q, Yang X, Shen Q, Li X, Yu W, Lin J, Zhou L.","Int Braz J Urol. 2018 Mar-Apr;44(2):258-266. doi: 10.1590/S1677-5538.IBJU.2017.0430.","Tang S","Int Braz J Urol","2018","2017/12/09","PMC6050570","","10.1590/S1677-5538.IBJU.2017.0430"
"10752662","Long-term survival of prostate cancer in southeastern Netherlands","Post PN, Hendrikx AJ, Hansen BE, van der Heijden LH, Coebergh JW.","Acta Oncol. 2000;39(1):101-4. doi: 10.1080/028418600431058.","Post PN","Acta Oncol","2000","2001/02/07","","","10.1080/028418600431058"
"7520950","Prostate cancer diagnosis","Carter HB.","J Urol. 1994 Oct;152(4):1168-9. doi: 10.1016/s0022-5347(17)32529-6.","Carter HB","J Urol","1994","1994/10/01","","","10.1016/s0022-5347(17)32529-6"
"31196962","Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer","Zhang J, Mao S, Guo Y, Wu Y, Yao X, Huang Y.","Biosci Rep. 2019 Jun 25;39(6):BSR20181826. doi: 10.1042/BSR20181826. Print 2019 Jun 28.","Zhang J","Biosci Rep","2019","2019/06/15","PMC6591571","","10.1042/BSR20181826"
"27416635","Focal Cryotherapy for Localized Prostate Cancer","Tay KJ, Polascik TJ.","Arch Esp Urol. 2016 Jul;69(6):317-26.","Tay KJ","Arch Esp Urol","2016","2016/07/15","","",""
"11410487","Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer","Papadopoulos I, Sivridis E, Giatromanolaki A, Koukourakis MI.","Clin Cancer Res. 2001 Jun;7(6):1533-8.","Papadopoulos I","Clin Cancer Res","2001","2001/06/19","","",""
"9186342","Outcome of African American men screened for prostate cancer: the Detroit Education and Early Detection Study","Powell IJ, Heilbrun L, Littrup PL, Franklin A, Parzuchowski J, Gelfand D, Sakr W.","J Urol. 1997 Jul;158(1):146-9. doi: 10.1097/00005392-199707000-00045.","Powell IJ","J Urol","1997","1997/07/01","","","10.1097/00005392-199707000-00045"
"32366788","FDG Hepatic Superscan Due to Metastatic Infiltration of Prostate Cancer","Yildirim N, Dede DS, Gumuskaya B.","Clin Nucl Med. 2020 Jun;45(6):474-476. doi: 10.1097/RLU.0000000000003044.","Yildirim N","Clin Nucl Med","2020","2020/05/06","","","10.1097/RLU.0000000000003044"
"19430782","Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients","Holl G, Dorn R, Wengenmair H, Weckermann D, Sciuk J.","Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1377-82. doi: 10.1007/s00259-009-1157-2. Epub 2009 May 9.","Holl G","Eur J Nucl Med Mol Imaging","2009","2009/05/12","","","10.1007/s00259-009-1157-2"
"7569697","[Cancer of the prostate. Diagnosis, clinical course, prognosis, treatment]","Gattegno B.","Rev Prat. 1995 Sep 1;45(13):1681-5.","Gattegno B","Rev Prat","1995","1995/09/01","","",""
"25085454","High-dose-rate brachytherapy as monotherapy for prostate cancer","Demanes DJ, Ghilezan MI.","Brachytherapy. 2014 Nov-Dec;13(6):529-41. doi: 10.1016/j.brachy.2014.03.002. Epub 2014 Jul 30.","Demanes DJ","Brachytherapy","2014","2014/08/03","","","10.1016/j.brachy.2014.03.002"
"26561618","Are strict vegetarians protected against prostate cancer?","Tantamango-Bartley Y, Knutsen SF, Knutsen R, Jacobsen BK, Fan J, Beeson WL, Sabate J, Hadley D, Jaceldo-Siegl K, Penniecook J, Herring P, Butler T, Bennett H, Fraser G.","Am J Clin Nutr. 2016 Jan;103(1):153-60. doi: 10.3945/ajcn.114.106450. Epub 2015 Nov 11.","Tantamango-Bartley Y","Am J Clin Nutr","2016","2015/11/13","PMC4691666","","10.3945/ajcn.114.106450"
"23682481","[Chemotherapy in castrate-resistant metastatic prostate cancer]","Pouessel D, Serrate C, Gauthier H, Hennequin C, Culine S.","Rev Prat. 2013 Apr;63(4):511-4.","Pouessel D","Rev Prat","2013","2013/05/21","","",""
"15046703","Uteroglobin: a potential novel tumor suppressor and molecular therapeutic for prostate cancer","Patierno SR, Manyak MJ, Fernandez PM, Baker A, Weeraratna AT, Chou DS, Szlyk G, Geib KS, Walsh C, Patteras J.","Clin Prostate Cancer. 2002 Sep;1(2):118-24. doi: 10.3816/cgc.2002.n.014.","Patierno SR","Clin Prostate Cancer","2002","2004/03/30","","","10.3816/cgc.2002.n.014"
"9792977","Prognosis of patients with prostate carcinoma presenting as nonregional lymph node metastases","Furuya Y, Akakura K, Akimoto S, Ito H.","Urol Int. 1998 Oct;61(1):17-21. doi: 10.1159/000030277.","Furuya Y","Urol Int","1998","1998/10/30","","","10.1159/000030277"
"21830654","ERG oncoprotein overexpression in prostate cancer. Multiplex IHC adds to diagnostic prowess and efficiency of laboratory","Cross M.","MLO Med Lab Obs. 2011 Jul;43(7):22, 42.","Cross M","MLO Med Lab Obs","2011","2011/08/12","","",""
"18248878","Immunotherapy of prostate cancer","Doehn C.","Eur Urol. 2008 Apr;53(4):681-3; discussion 684-5. doi: 10.1016/j.eururo.2007.12.038. Epub 2008 Jan 3.","Doehn C","Eur Urol","2008","2008/02/06","","","10.1016/j.eururo.2007.12.038"
"27357548","Which coping strategies can predict beneficial feelings associated with prostate cancer?","Pascoe EC, Edvardsson D.","J Clin Nurs. 2016 Sep;25(17-18):2569-78. doi: 10.1111/jocn.13300. Epub 2016 Jun 29.","Pascoe EC","J Clin Nurs","2016","2016/07/01","","","10.1111/jocn.13300"
"18700688","Genetic and microenvironmental implications in prostate cancer progression and metastasis","Alberti C.","Eur Rev Med Pharmacol Sci. 2008 May-Jun;12(3):167-75.","Alberti C","Eur Rev Med Pharmacol Sci","2008","2008/08/15","","",""
"19652036","What's new in prostate cancer screening and prevention?","Klein EA.","Cleve Clin J Med. 2009 Aug;76(8):439-45. doi: 10.3949/ccjm.76a.02009.","Klein EA","Cleve Clin J Med","2009","2009/08/05","","","10.3949/ccjm.76a.02009"
"25640648","Current Use of Imaging after Primary Treatment of Prostate Cancer","Hussein AA, Punnen S, Zhao S, Cowan JE, Leapman M, Tran TC, Washington SL, Truesdale MD, Carroll PR, Cooperberg MR.","J Urol. 2015 Jul;194(1):98-104. doi: 10.1016/j.juro.2015.01.097. Epub 2015 Jan 30.","Hussein AA","J Urol","2015","2015/02/03","","","10.1016/j.juro.2015.01.097"
"31786881","SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment","Rucinska M, Osowiecka K, Kieszkowska Grudny A, Nawrocki S.","J BUON. 2019 Sep-Oct;24(5):2099-2106.","Rucinska M","J BUON","2019","2019/12/02","","",""
"18424233","Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study","Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J.","Lancet Oncol. 2008 May;9(5):445-52. doi: 10.1016/S1470-2045(08)70104-9. Epub 2008 Apr 16.","Collin SM","Lancet Oncol","2008","2008/04/22","PMC2760747","UKMS27915","10.1016/S1470-2045(08)70104-9"
"24053431","Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue","Korkes F, de Castro MG, de Cassio Zequi S, Nardi L, Del Giglio A, de Lima Pompeo AC.","BJU Int. 2014 May;113(5):822-9. doi: 10.1111/bju.12339. Epub 2013 Oct 31.","Korkes F","BJU Int","2014","2013/09/24","","","10.1111/bju.12339"
"19483737","Radiotherapy: Effect of treatment interruptions in prostate cancer","Kupelian P.","Nat Rev Clin Oncol. 2009 Jun;6(6):312-3. doi: 10.1038/nrclinonc.2009.71.","Kupelian P","Nat Rev Clin Oncol","2009","2009/06/02","","","10.1038/nrclinonc.2009.71"
"31931827","Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report","Hongo H, Kosaka T, Aimono E, Nishihara H, Oya M.","Diagn Pathol. 2020 Jan 13;15(1):5. doi: 10.1186/s13000-019-0916-z.","Hongo H","Diagn Pathol","2020","2020/01/15","PMC6958728","","10.1186/s13000-019-0916-z"
"27569432","Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm","Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Shih YT, Nguyen PL, Hu JC.","J Urol. 2017 Feb;197(2):363-368. doi: 10.1016/j.juro.2016.08.092. Epub 2016 Aug 26.","Halpern JA","J Urol","2017","2016/08/30","","","10.1016/j.juro.2016.08.092"
"12109339","Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. A novel PSA reducer and preventive/treatment option for prostate cancer?","Moyad MA.","Urol Clin North Am. 2002 Feb;29(1):115-24, ix. doi: 10.1016/s0094-0143(02)00037-x.","Moyad MA","Urol Clin North Am","2002","2002/07/12","","","10.1016/s0094-0143(02)00037-x"
"16357190","Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer","Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ.","Cancer Res. 2005 Dec 15;65(24):11771-8. doi: 10.1158/0008-5472.CAN-05-2078.","Chen YC","Cancer Res","2005","2005/12/17","","","10.1158/0008-5472.CAN-05-2078"
"23462420","Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer","Feng FY, Blas K, Olson K, Stenmark M, Sandler H, Hamstra DA.","Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):64-71. doi: 10.1016/j.ijrobp.2012.11.024. Epub 2013 Feb 22.","Feng FY","Int J Radiat Oncol Biol Phys","2013","2013/03/07","","","10.1016/j.ijrobp.2012.11.024"
"8976252","Prostate cancer","Brawer MK.","J Urol. 1997 Jan;157(1):207-8. doi: 10.1016/s0022-5347(01)65326-6.","Brawer MK","J Urol","1997","1997/01/01","","","10.1016/s0022-5347(01)65326-6"
"30322480","Nuclear Medicine Imaging of Prostate Cancer in the Elderly","Castellucci P, Nanni C, Ambrosini V.","Semin Nucl Med. 2018 Nov;48(6):541-547. doi: 10.1053/j.semnuclmed.2018.07.004. Epub 2018 Aug 8.","Castellucci P","Semin Nucl Med","2018","2018/10/17","","","10.1053/j.semnuclmed.2018.07.004"
"29995499","MRI Findings After MRI-Guided Focal Laser Ablation of Prostate Cancer","Westin C, Chatterjee A, Ku E, Yousuf A, Wang S, Thomas S, Fan X, Eggener S, Karczmar G, Oto A.","AJR Am J Roentgenol. 2018 Sep;211(3):595-604. doi: 10.2214/AJR.17.19201. Epub 2018 Jul 11.","Westin C","AJR Am J Roentgenol","2018","2018/07/12","","","10.2214/AJR.17.19201"
"12868144","[The economics of managing patients with prostate cancer]","Scattoni V, Lazzaro C, Rigatti P.","Arch Ital Urol Androl. 2003 Jun;75(2):75-87.","Scattoni V","Arch Ital Urol Androl","2003","2003/07/19","","",""
"3317434","Transrectal ultrasound in the diagnosis, staging, guided needle biopsy, and screening for prostate cancer","Lee F.","Prog Clin Biol Res. 1987;237:73-109.","Lee F","Prog Clin Biol Res","1987","1987/01/01","","",""
"24725490","The epidemiology and clinical implications of genetic variation in prostate cancer","Helfand BT, Catalona WJ.","Urol Clin North Am. 2014 May;41(2):277-97. doi: 10.1016/j.ucl.2014.01.001. Epub 2014 Feb 28.","Helfand BT","Urol Clin North Am","2014","2014/04/15","","","10.1016/j.ucl.2014.01.001"
"17363525","Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage","Rouprêt M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M, Ricci S, Lacave R, Cancel-Tassin G, de la Taille A, Rozet F, Cathelineau X, Vallancien G, Hamdy FC, Cussenot O.","Clin Cancer Res. 2007 Mar 15;13(6):1720-5. doi: 10.1158/1078-0432.CCR-06-2467.","Rouprêt M","Clin Cancer Res","2007","2007/03/17","","","10.1158/1078-0432.CCR-06-2467"
"19301612","[Histopathologic changes due to combination of androgen deprivation and transurethral microwave thermotherapy in patients with localized prostate cancer]","Suzuki R, Jujo Y, Koshiba K, Hoshiai O, Endo T, Aihara M, Nakajo H, Ohori M.","Hinyokika Kiyo. 2009 Feb;55(2):79-85.","Suzuki R","Hinyokika Kiyo","2009","2009/03/24","","",""
"9302860","Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer","Bergan RC, Walls RG, Figg WD, Dawson NA, Headlee D, Tompkins A, Steinberg SM, Reed E.","J Natl Med Assoc. 1997 Sep;89(9):622-8.","Bergan RC","J Natl Med Assoc","1997","1997/09/26","PMC2608263","",""
"26311046","A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer","Seibert JK, Quagliata L, Quintavalle C, Hammond TG, Terracciano L, Odermatt A.","Cancer Med. 2015 Nov;4(11):1717-29. doi: 10.1002/cam4.517. Epub 2015 Aug 26.","Seibert JK","Cancer Med","2015","2015/08/28","PMC4673999","","10.1002/cam4.517"
"7513929","[After care of locally advanced and metastatic prostate cancer]","Zermann DH, Schubert J.","Z Arztl Fortbild (Jena). 1994 Mar;88(3):221-4.","Zermann DH","Z Arztl Fortbild (Jena)","1994","1994/03/01","","",""
"11818600","Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients","Halpern EJ, McCue PA, Aksnes AK, Hagen EK, Frauscher F, Gomella LG.","Radiology. 2002 Feb;222(2):361-6. doi: 10.1148/radiol.2222010582.","Halpern EJ","Radiology","2002","2002/01/31","","","10.1148/radiol.2222010582"
"21548467","Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm","Garcia JA, Dreicer R.","Oncology (Williston Park). 2011 Mar;25(3):242-9.","Garcia JA","Oncology (Williston Park)","2011","2011/05/10","","",""
"20977595","Effect of prostate size on pathological outcome and biochemical recurrence after radical prostatectomy for prostate cancer: is it correlated with serum testosterone level?","Verit A.","BJU Int. 2010 Nov;106(10):1555. doi: 10.1111/j.1464-410X.2010.09915_1.x.","Verit A","BJU Int","2010","2010/10/28","","","10.1111/j.1464-410X.2010.09915_1.x"
"8188104","[Complete androgen blockage in the treatment of metastatic prostate cancer]","Matzkin H, Braf Z.","Harefuah. 1994 Mar 1;126(5):260-3.","Matzkin H","Harefuah","1994","1994/03/01","","",""
"10710907","Prostate cancer and nutrition","Nixon DW.","J S C Med Assoc. 2000 Feb;96(2):85-6.","Nixon DW","J S C Med Assoc","2000","2000/03/11","","",""
"14625261","Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer","Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA.","J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10. doi: 10.1093/jnci/djg094.","Godley PA","J Natl Cancer Inst","2003","2003/11/20","","","10.1093/jnci/djg094"
"25276838","From bench to bedside: immunotherapy for prostate cancer","Tse BW, Jovanovic L, Nelson CC, de Souza P, Power CA, Russell PJ.","Biomed Res Int. 2014;2014:981434. doi: 10.1155/2014/981434. Epub 2014 Sep 4.","Tse BW","Biomed Res Int","2014","2014/10/03","PMC4168152","","10.1155/2014/981434"
"19333226","Is it time to consider a role for MRI before prostate biopsy?","Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, Emberton M.","Nat Rev Clin Oncol. 2009 Apr;6(4):197-206. doi: 10.1038/nrclinonc.2009.18.","Ahmed HU","Nat Rev Clin Oncol","2009","2009/04/01","","","10.1038/nrclinonc.2009.18"
"9707970","[The role of prostate specific antigen and its derivatives (age-specific PSA, PSA density, velocity, free/total PSA) in the diagnosis of prostate cancer]","Di Silverio F, D'Eramo G, Buscarini M, Sciarra A, Casale P, Di Nicola S, Loreto A.","Minerva Urol Nefrol. 1998 Jun;50(2):143-54.","Di Silverio F","Minerva Urol Nefrol","1998","1998/08/26","","",""
"8341236","Radical prostatectomies--Wisconsin, 1982-1992","Centers for Disease Control and Prevention (CDC).","MMWR Morb Mortal Wkly Rep. 1993 Aug 20;42(32):620-1, 627.","Centers for Disease Control and Prevention (CDC)","MMWR Morb Mortal Wkly Rep","1993","1993/08/20","","",""
"10325490","Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts","Ekman P.","Eur Urol. 1999;35(5-6):362-9. doi: 10.1159/000019910.","Ekman P","Eur Urol","1999","1999/05/15","","","10.1159/000019910"
"30763406","A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data","Karlsson A, Jauhiainen A, Gulati R, Eklund M, Grönberg H, Etzioni R, Clements M.","PLoS One. 2019 Feb 14;14(2):e0211918. doi: 10.1371/journal.pone.0211918. eCollection 2019.","Karlsson A","PLoS One","2019","2019/02/15","PMC6375591","","10.1371/journal.pone.0211918"
"18047674","Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring","Wang XD, Reeves K, Luo FR, Xu LA, Lee F, Clark E, Huang F.","Genome Biol. 2007;8(11):R255. doi: 10.1186/gb-2007-8-11-r255.","Wang XD","Genome Biol","2007","2007/12/01","PMC2258199","","10.1186/gb-2007-8-11-r255"
"30317236","Single-Fraction Stereotactic Body Radiotherapy for Oligometastatic Lymph Node Relapse in Prostate Cancer","Loi M, Di Cataldo V, Francolini G, Bonomo P, Masi L, Simontacchi G, Detti B, Greto D, Desideri I, Livi L.","Oncol Res Treat. 2018;41(11):703-705. doi: 10.1159/000491605. Epub 2018 Oct 13.","Loi M","Oncol Res Treat","2018","2018/10/15","","","10.1159/000491605"
"17672372","Function and molecular mechanisms of neuroendocrine cells in prostate cancer","Huang J, Wu C, di Sant'Agnese PA, Yao JL, Cheng L, Na Y.","Anal Quant Cytol Histol. 2007 Jun;29(3):128-38.","Huang J","Anal Quant Cytol Histol","2007","2007/08/04","","",""
"23895122","Home tests for prostate-specific membrane antigen being developed for prostate cancer diagnosis","","Expert Rev Mol Diagn. 2013 Jul;13(6):523-5. doi: 10.1586/14737159.2013.825130.","","Expert Rev Mol Diagn","2013","2013/07/31","","","10.1586/14737159.2013.825130"
"28263389","Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment","Radhakrishnan A, Grande D, Mitra N, Bekelman J, Stillson C, Pollack CE.","Cancer. 2017 May 15;123(6):1027-1034. doi: 10.1002/cncr.30412. Epub 2016 Nov 7.","Radhakrishnan A","Cancer","2017","2017/03/07","PMC5341133","NIHMS824574","10.1002/cncr.30412"
"29297492","Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer","Kristiansen G.","Mod Pathol. 2018 Jan;31(S1):S143-155. doi: 10.1038/modpathol.2017.168.","Kristiansen G","Mod Pathol","2018","2018/01/04","","","10.1038/modpathol.2017.168"
"23375349","Angiogenesis and anti-angiogenic therapy in prostate cancer","Mukherji D, Temraz S, Wehbe D, Shamseddine A.","Crit Rev Oncol Hematol. 2013 Aug;87(2):122-31. doi: 10.1016/j.critrevonc.2013.01.002. Epub 2013 Jan 29.","Mukherji D","Crit Rev Oncol Hematol","2013","2013/02/05","","","10.1016/j.critrevonc.2013.01.002"
"19885571","Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro","Zhang N, Sanders AJ, Ye L, Kynaston HG, Jiang WG.","Int J Oncol. 2009 Dec;35(6):1473-80. doi: 10.3892/ijo_00000466.","Zhang N","Int J Oncol","2009","2009/11/04","","","10.3892/ijo_00000466"
"18082590","Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer","Dandapani SV, Sanda MG.","Semin Radiat Oncol. 2008 Jan;18(1):67-72. doi: 10.1016/j.semradonc.2007.10.001.","Dandapani SV","Semin Radiat Oncol","2008","2007/12/18","PMC2825380","NIHMS36733","10.1016/j.semradonc.2007.10.001"
"24411278","Is treatment of the primary tumor in metastatic prostate cancer justified?","Chapin BF, McGuire SE, Aparicio A.","Eur Urol. 2014 Jun;65(6):1067-8. doi: 10.1016/j.eururo.2013.12.011. Epub 2013 Dec 17.","Chapin BF","Eur Urol","2014","2014/01/14","","","10.1016/j.eururo.2013.12.011"
"32275187","High-intensity focused ultrasound for prostate cancer","Napoli A, Alfieri G, Scipione R, Leonardi A, Fierro D, Panebianco V, De Nunzio C, Leonardo C, Catalano C.","Expert Rev Med Devices. 2020 May;17(5):427-433. doi: 10.1080/17434440.2020.1755258.","Napoli A","Expert Rev Med Devices","2020","2020/04/11","","","10.1080/17434440.2020.1755258"
"24784420","Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery","Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.","BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11.","Badani KK","BJU Int","2015","2014/05/03","PMC4371645","","10.1111/bju.12789"
"18617489","Prostate cancer patients with BRCA2 mutation face poor survival","Dobson R.","BMJ. 2008 Jul 10;337:a705. doi: 10.1136/bmj.a705.","Dobson R","BMJ","2008","2008/07/12","","","10.1136/bmj.a705"
"25935742","Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation","Steenbergen P, Haustermans K, Lerut E, Oyen R, De Wever L, Van den Bergh L, Kerkmeijer LG, Pameijer FA, Veldhuis WB, van der Voort van Zyp JR, Pos FJ, Heijmink SW, Kalisvaart R, Teertstra HJ, Dinh CV, Ghobadi G, van der Heide UA.","Radiother Oncol. 2015 May;115(2):186-90. doi: 10.1016/j.radonc.2015.04.012. Epub 2015 Apr 29.","Steenbergen P","Radiother Oncol","2015","2015/05/04","","","10.1016/j.radonc.2015.04.012"
"3326898","[Natural history of cancer of the prostate]","Guiter J.","J Urol (Paris). 1987;93(8):469-74.","Guiter J","J Urol (Paris)","1987","1987/01/01","","",""
"25948798","[Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer]","Mora MJ.","Arch Esp Urol. 2015 Apr;68(3):250-66.","Mora MJ","Arch Esp Urol","2015","2015/05/08","","",""
"8865476","Pathological definitions and characteristics of stage T1 prostate cancer","Bhargava V.","Semin Urol Oncol. 1996 Aug;14(3):145-8.","Bhargava V","Semin Urol Oncol","1996","1996/08/01","","",""
"20225998","Abiraterone acetate for castration resistant prostate cancer","Shah S, Ryan C.","Expert Opin Investig Drugs. 2010 Apr;19(4):563-70. doi: 10.1517/13543781003639427.","Shah S","Expert Opin Investig Drugs","2010","2010/03/16","","","10.1517/13543781003639427"
"28093012","Male coping through a long-term cancer trajectory. Secondary outcomes from a RTC examining the effect of a multidisciplinary rehabilitation program (RePCa) among radiated men with prostate cancer","Dieperink KB, Johansen C, Hansen S, Wagner L, K Andersen K, Minet LR, Hansen O.","Acta Oncol. 2017 Feb;56(2):254-261. doi: 10.1080/0284186X.2016.1267395. Epub 2017 Jan 17.","Dieperink KB","Acta Oncol","2017","2017/01/18","","","10.1080/0284186X.2016.1267395"
"8973702","Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening","Reissigl A, Klocker H, Pointner J, Fink K, Horninger W, Ennemoser O, Strasser H, Colleselli K, Höltl L, Bartsch G.","Urology. 1996 Dec;48(6A Suppl):62-6. doi: 10.1016/s0090-4295(96)00612-7.","Reissigl A","Urology","1996","1996/12/01","","","10.1016/s0090-4295(96)00612-7"
"8683702","Prostate cancer","Brendler CB.","J Urol. 1996 Aug;156(2 Pt 1):459.","Brendler CB","J Urol","1996","1996/08/01","","",""
"25385751","Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis","Shen MJ, Nelson CJ, Peters E, Slovin SF, Hall SJ, Hall M, Herrera PC, Leventhal EA, Leventhal H, Diefenbach MA.","Med Decis Making. 2015 May;35(4):477-86. doi: 10.1177/0272989X14558424. Epub 2014 Nov 10.","Shen MJ","Med Decis Making","2015","2014/11/12","PMC4424110","NIHMS635861","10.1177/0272989X14558424"
"25845957","Words of wisdom. Re: Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumour? A SEER-based study","Eden CG.","Eur Urol. 2015 May;67(5):972. doi: 10.1016/j.eururo.2014.12.061.","Eden CG","Eur Urol","2015","2015/04/08","","","10.1016/j.eururo.2014.12.061"
"21820592","Re: Geng et al.: XRCC1 genetic polymorphism Arg399Gln and prostate cancer risk: a meta-analysis (Urology 2009;74:648-653)","Wei B, Xu Z, Ruan J, Zhu M, Hu Q, Wang Q, Wang Z, Yan Z.","Urology. 2011 Aug;78(2):481-2. doi: 10.1016/j.urology.2011.03.050.","Wei B","Urology","2011","2011/08/09","","","10.1016/j.urology.2011.03.050"
"8345587","Hereditary prostate cancer: epidemiologic and clinical features","Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC.","J Urol. 1993 Sep;150(3):797-802. doi: 10.1016/s0022-5347(17)35617-3.","Carter BS","J Urol","1993","1993/09/01","","","10.1016/s0022-5347(17)35617-3"
"20123518","[Evaluation of sexual dysfunction in prostate cancer management]","Savareux L, Droupy S; les membres du comité d'andrologie de l'AFU.","Prog Urol. 2009 Dec;19 Suppl 4:S189-92. doi: 10.1016/S1166-7087(09)73372-X.","Savareux L","Prog Urol","2009","2010/02/04","","","10.1016/S1166-7087(09)73372-X"
"12856642","Prostate biopsy: how many cores are enough?","Presti JC Jr.","Urol Oncol. 2003 Mar-Apr;21(2):135-40. doi: 10.1016/s1078-1439(03)00006-1.","Presti JC Jr","Urol Oncol","2003","2003/07/15","","","10.1016/s1078-1439(03)00006-1"
"32542009","Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy","Shin D, Shim SR, Kim CH.","PLoS One. 2020 Jun 15;15(6):e0234264. doi: 10.1371/journal.pone.0234264. eCollection 2020.","Shin D","PLoS One","2020","2020/06/17","PMC7295190","","10.1371/journal.pone.0234264"
"9326432","Segregation analysis of prostate cancer in Sweden: support for dominant inheritance","Grönberg H, Damber L, Damber JE, Iselius L.","Am J Epidemiol. 1997 Oct 1;146(7):552-7. doi: 10.1093/oxfordjournals.aje.a009313.","Grönberg H","Am J Epidemiol","1997","1997/10/27","","","10.1093/oxfordjournals.aje.a009313"
"26054644","Evaluating immune responses after sipuleucel-T therapy","Strauss J, Madan RA, Figg WD.","Cancer Biol Ther. 2015;16(8):1119-21. doi: 10.1080/15384047.2015.1056417. Epub 2015 Jun 8.","Strauss J","Cancer Biol Ther","2015","2015/06/10","PMC4622939","","10.1080/15384047.2015.1056417"
"1699238","The biochemical monitoring of prostate cancer. Yorkshire Regional Urological Cancer Research Group","Cooper EH, Armitage TG.","Prog Clin Biol Res. 1990;357:23-7.","Cooper EH","Prog Clin Biol Res","1990","1990/01/01","","",""
"1428958","Therapeutic options for localized carcinoma of the prostate: the role of external beam radiation therapy","Khil MS, Kim JH.","Henry Ford Hosp Med J. 1992;40(1-2):103-7.","Khil MS","Henry Ford Hosp Med J","1992","1992/01/01","","",""
"19170044","Lymph node assessment and lymphadenectomy in prostate cancer","Ordon M, Nam RK.","J Surg Oncol. 2009 Mar 15;99(4):215-24. doi: 10.1002/jso.21225.","Ordon M","J Surg Oncol","2009","2009/01/27","","","10.1002/jso.21225"
"16679847","Molecular biology of prostate-cancer pathogenesis","Shand RL, Gelmann EP.","Curr Opin Urol. 2006 May;16(3):123-31. doi: 10.1097/01.mou.0000193384.39351.64.","Shand RL","Curr Opin Urol","2006","2006/05/09","","","10.1097/01.mou.0000193384.39351.64"
"7680271","The value of prostate-specific antigen levels in pelvic lymph nodes for diagnosing metastatic spread of prostate cancer","Shoskes DA, Trachtenberg J.","Can J Surg. 1993 Feb;36(1):33-6.","Shoskes DA","Can J Surg","1993","1993/02/01","","",""
"20839415","Expression of SPANX proteins in normal prostatic tissue and in prostate cancer","Salemi M, Calogero AE, Zaccarello G, Castiglione R, Cosentino A, Campagna C, Vicari E, Rappazzo G.","Eur J Histochem. 2010;54(3):e41. doi: 10.4081/ejh.2010.e41.","Salemi M","Eur J Histochem","2010","2010/09/16","PMC3167315","","10.4081/ejh.2010.e41"
"14983965","Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited?","Essink-Bot ML, Korfage IJ, De Koning HJ.","BJU Int. 2003 Dec;92 Suppl 2:101-5. doi: 10.1111/j.1464-410x.2003.04409.x.","Essink-Bot ML","BJU Int","2003","2004/02/27","","","10.1111/j.1464-410x.2003.04409.x"
"17399889","Obesity and prostate cancer: a role for adipokines","Mistry T, Digby JE, Desai KM, Randeva HS.","Eur Urol. 2007 Jul;52(1):46-53. doi: 10.1016/j.eururo.2007.03.054. Epub 2007 Mar 26.","Mistry T","Eur Urol","2007","2007/04/03","","","10.1016/j.eururo.2007.03.054"
"23790537","Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers","Mohammed A, Miller S, Douglas-Moore J, Miller M.","Urol Oncol. 2014 Jan;32(1):39.e19-27. doi: 10.1016/j.urolonc.2013.04.004. Epub 2013 Jun 18.","Mohammed A","Urol Oncol","2014","2013/06/25","","","10.1016/j.urolonc.2013.04.004"
"12869398","Cigarette smoking and risk of prostate cancer in middle-aged men","Plaskon LA, Penson DF, Vaughan TL, Stanford JL.","Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):604-9.","Plaskon LA","Cancer Epidemiol Biomarkers Prev","2003","2003/07/19","","",""
"24324287","Mast cells as a potential prognostic marker in prostate cancer","Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, Grizzi F.","Dis Markers. 2013;35(6):711-20. doi: 10.1155/2013/478303. Epub 2013 Nov 11.","Taverna G","Dis Markers","2013","2013/12/11","PMC3844173","","10.1155/2013/478303"
"28389515","Androgen Signaling in Prostate Cancer","Dai C, Heemers H, Sharifi N.","Cold Spring Harb Perspect Med. 2017 Sep 1;7(9):a030452. doi: 10.1101/cshperspect.a030452.","Dai C","Cold Spring Harb Perspect Med","2017","2017/04/09","PMC5580512","","10.1101/cshperspect.a030452"
"15018075","[The epidemiology of prostate cancer]","Rébillard X, Tretarre B, Villers A.","Rev Prat. 2003 Dec 31;53(20):2224-8.","Rébillard X","Rev Prat","2003","2004/03/17","","",""
"10957775","[Mass screening for detection of prostatic carcinoma]","Bangma CH.","Urologe A. 2000 Jul;39(4):334-40. doi: 10.1007/s001200050366.","Bangma CH","Urologe A","2000","2000/08/25","","","10.1007/s001200050366"
"28871558","Examining the accessibility of high-quality physical activity behaviour change support freely available online for men with prostate cancer","Short CE, Gelder C, Binnewerg L, McIntosh M, Turnbull D.","J Cancer Surviv. 2018 Feb;12(1):10-17. doi: 10.1007/s11764-017-0638-8. Epub 2017 Sep 4.","Short CE","J Cancer Surviv","2018","2017/09/06","","","10.1007/s11764-017-0638-8"
"12512150","[Gene therapy for prostate cancer]","Gotoh A, Shirakawa T, Wada Y, Hinata N, Matsubara S, Hara I, Fujisawa M, Okada H, Arakawa S, Kamidono S.","Hinyokika Kiyo. 2002 Nov;48(11):729-32.","Gotoh A","Hinyokika Kiyo","2002","2003/01/07","","",""
"21347810","The example of CaPSURE: lessons learned from a national disease registry","Porten SP, Cooperberg MR, Konety BR, Carroll PR.","World J Urol. 2011 Jun;29(3):265-71. doi: 10.1007/s00345-011-0658-3. Epub 2011 Feb 24.","Porten SP","World J Urol","2011","2011/02/25","PMC3099175","","10.1007/s00345-011-0658-3"
"15026405","Salvage radiotherapy for recurrent prostate cancer: the earlier the better","Anscher MS.","JAMA. 2004 Mar 17;291(11):1380-2. doi: 10.1001/jama.291.11.1380.","Anscher MS","JAMA","2004","2004/03/18","","","10.1001/jama.291.11.1380"
"16882056","Baseline health-related quality of life in the management of prostate cancer","Ishihara M, Suzuki H, Akakura K, Komiya A, Imamoto T, Tobe T, Ichikawa T.","Int J Urol. 2006 Jul;13(7):920-5. doi: 10.1111/j.1442-2042.2006.01441.x.","Ishihara M","Int J Urol","2006","2006/08/03","","","10.1111/j.1442-2042.2006.01441.x"
"23608039","Diagnosing prostate cancer: getting to the core question","Hernandez DJ.","J Urol. 2013 Jul;190(1):11-2. doi: 10.1016/j.juro.2013.04.047. Epub 2013 Apr 19.","Hernandez DJ","J Urol","2013","2013/04/24","","","10.1016/j.juro.2013.04.047"
"20216316","Adjuvant vs. salvage radiotherapy for pathologically advanced prostate cancer","McVey GP, Parker C.","Curr Opin Urol. 2010 May;20(3):229-33. doi: 10.1097/MOU.0b013e3283383b6e.","McVey GP","Curr Opin Urol","2010","2010/03/11","","","10.1097/MOU.0b013e3283383b6e"
"10364974","An audit of the investigation and treatment of localised prostatic cancer in the south west region","Lodge RN.","Ann R Coll Surg Engl. 1999 Mar;81(2):133-8.","Lodge RN","Ann R Coll Surg Engl","1999","1999/06/12","PMC2503217","",""
"8948412","The role of neoadjuvant androgen deprivation prior to radical prostatectomy","Fradet Y.","Urol Clin North Am. 1996 Nov;23(4):575-85. doi: 10.1016/s0094-0143(05)70337-2.","Fradet Y","Urol Clin North Am","1996","1996/11/01","","","10.1016/s0094-0143(05)70337-2"
"19858377","To treat pelvic nodes or not: could the greater testicular scatter dose from whole pelvic fields confound results of prostate cancer trials?","King CR, Kapp DS.","J Clin Oncol. 2009 Dec 20;27(36):6076-8. doi: 10.1200/JCO.2009.24.3808. Epub 2009 Oct 26.","King CR","J Clin Oncol","2009","2009/10/28","","","10.1200/JCO.2009.24.3808"
"18217533","PSA spike after brachytherapy For localized prostate cancer","Abel L, Zeroski D, Brammer S, Butler W, Wallner KE, Merrick GS.","Urol Nurs. 2007 Dec;27(6):507-10, 518; quiz 511.","Abel L","Urol Nurs","2007","2008/01/26","","",""
"17431953","Rectal-cancer radiation and prostate-cancer risk","Susman E.","Lancet Oncol. 2007 Apr;8(4):289. doi: 10.1016/s1470-2045(07)70094-3.","Susman E","Lancet Oncol","2007","2007/04/17","","","10.1016/s1470-2045(07)70094-3"
"24491309","Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review","van den Bergh RC, Ahmed HU, Bangma CH, Cooperberg MR, Villers A, Parker CC.","Eur Urol. 2014 Jun;65(6):1023-31. doi: 10.1016/j.eururo.2014.01.027. Epub 2014 Jan 28.","van den Bergh RC","Eur Urol","2014","2014/02/05","","","10.1016/j.eururo.2014.01.027"
"23237000","In regard to Turaka et al. Re: Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results","Cheung R.","Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):9-10. doi: 10.1016/j.ijrobp.2012.04.031.","Cheung R","Int J Radiat Oncol Biol Phys","2013","2012/12/15","","","10.1016/j.ijrobp.2012.04.031"
"17521214","Hormone-refractory prostate cancer: where are we going?","Di Lorenzo G, Autorino R, Figg WD, De Placido S.","Drugs. 2007;67(8):1109-24. doi: 10.2165/00003495-200767080-00002.","Di Lorenzo G","Drugs","2007","2007/05/25","","","10.2165/00003495-200767080-00002"
"23845456","Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer","Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F, Wei M, Shen J, Hou J, Gao X, Xu C, Huang J, Zhao Y, Sun Y.","J Urol. 2013 Dec;190(6):2278-87. doi: 10.1016/j.juro.2013.07.001. Epub 2013 Jul 8.","Ren S","J Urol","2013","2013/07/13","","","10.1016/j.juro.2013.07.001"
"27435344","Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer","Bordeau BM, Ciulla DA, Callahan BP.","ChemMedChem. 2016 Sep 20;11(18):1983-6. doi: 10.1002/cmdc.201600238. Epub 2016 Jul 20.","Bordeau BM","ChemMedChem","2016","2016/07/21","PMC5588864","NIHMS898802","10.1002/cmdc.201600238"
"27589955","Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia","Ruseckaite R, Sampurno F, Millar J, Frydenberg M, Evans S.","BMC Urol. 2016 Sep 2;16(1):54. doi: 10.1186/s12894-016-0172-4.","Ruseckaite R","BMC Urol","2016","2016/09/04","PMC5010681","","10.1186/s12894-016-0172-4"
"16841802","Prostate-specific membrane antigen expression predicts prostate cancer recurrence","","Oncology (Williston Park). 2006 Jun;20(7):790.","","Oncology (Williston Park)","2006","2006/07/18","","",""
"28888997","Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells","Bashari O, Redko B, Cohen A, Luboshits G, Gellerman G, Firer MA.","Cancer Lett. 2017 Nov 1;408:164-173. doi: 10.1016/j.canlet.2017.08.040. Epub 2017 Sep 6.","Bashari O","Cancer Lett","2017","2017/09/11","","","10.1016/j.canlet.2017.08.040"
"9155515","Is screening for prostate cancer the current gold standard?--""no""","Kramer BS, Gohagan JK, Prorok PC.","Eur J Cancer. 1997 Mar;33(3):348-53.","Kramer BS","Eur J Cancer","1997","1997/03/01","","",""
"25848940","EDB Fibronectin Specific Peptide for Prostate Cancer Targeting","Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, Chen Y, Zhu H, Magi-Galluzzi C, Lu ZR.","Bioconjug Chem. 2015 May 20;26(5):830-8. doi: 10.1021/acs.bioconjchem.5b00178. Epub 2015 Apr 15.","Han Z","Bioconjug Chem","2015","2015/04/08","","","10.1021/acs.bioconjchem.5b00178"
"19282170","Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era","Punnen S, Nam RK.","Surg Oncol. 2009 Sep;18(3):192-9. doi: 10.1016/j.suronc.2009.02.006. Epub 2009 Mar 12.","Punnen S","Surg Oncol","2009","2009/03/14","","","10.1016/j.suronc.2009.02.006"
"15278095","Timing and choice of androgen ablation","Kirk D.","Prostate Cancer Prostatic Dis. 2004;7(3):217-22. doi: 10.1038/sj.pcan.4500733.","Kirk D","Prostate Cancer Prostatic Dis","2004","2004/07/28","","","10.1038/sj.pcan.4500733"
"12187209","Skeletal fractures negatively correlate with overall survival in men with prostate cancer","Oefelein MG, Ricchiuti V, Conrad W, Resnick MI.","J Urol. 2002 Sep;168(3):1005-7. doi: 10.1097/01.ju.0000024395.86788.cc.","Oefelein MG","J Urol","2002","2002/08/21","","","10.1097/01.ju.0000024395.86788.cc"
"1587984","Prostate cancer","Moon TD.","J Am Geriatr Soc. 1992 Jun;40(6):622-7. doi: 10.1111/j.1532-5415.1992.tb02116.x.","Moon TD","J Am Geriatr Soc","1992","1992/06/01","","","10.1111/j.1532-5415.1992.tb02116.x"
"16584794","Adverse effect of a distended rectum in intensity-modulated radiotherapy (IMRT) treatment planning of prostate cancer","Guckenberger M, Pohl F, Baier K, Meyer J, Vordermark D, Flentje M.","Radiother Oncol. 2006 Apr;79(1):59-64. doi: 10.1016/j.radonc.2006.03.004. Epub 2006 Apr 3.","Guckenberger M","Radiother Oncol","2006","2006/04/06","","","10.1016/j.radonc.2006.03.004"
"18158031","Risk factors for prostate cancer in men aged less than 60 years: a case-control study from Italy","Gallus S, Foschi R, Talamini R, Altieri A, Negri E, Franceschi S, Montella M, Dal Maso L, Ramazzotti V, La Vecchia C.","Urology. 2007 Dec;70(6):1121-6. doi: 10.1016/j.urology.2007.07.020.","Gallus S","Urology","2007","2007/12/26","","","10.1016/j.urology.2007.07.020"
"15206226","[The difficult choice: when not to treat. Hormone-refractory metastatic prostate cancer]","Bracarda S, Caserta C, Tonato M.","Suppl Tumori. 2004 Jul-Aug;3(4):S93.","Bracarda S","Suppl Tumori","2004","2004/06/23","","",""
"19945309","GREB1 tissue expression is associated with organ-confined prostate cancer","Antunes AA, Leite KR, Reis ST, Sousa-Canavez JM, Camara-Lopes LH, Dall'oglio MF, Srougi M.","Urol Oncol. 2012 Jan-Feb;30(1):16-20. doi: 10.1016/j.urolonc.2009.09.014. Epub 2009 Nov 27.","Antunes AA","Urol Oncol","2012","2009/12/01","","","10.1016/j.urolonc.2009.09.014"
"26699628","Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?","Pepe P, Garufi A, Priolo G, Pennisi M.","World J Urol. 2016 Sep;34(9):1249-53. doi: 10.1007/s00345-015-1749-3. Epub 2015 Dec 23.","Pepe P","World J Urol","2016","2015/12/25","","","10.1007/s00345-015-1749-3"
"12018929","The current state of hormonal therapy for prostate cancer","Hellerstedt BA, Pienta KJ.","CA Cancer J Clin. 2002 May-Jun;52(3):154-79. doi: 10.3322/canjclin.52.3.154.","Hellerstedt BA","CA Cancer J Clin","2002","2002/05/23","","","10.3322/canjclin.52.3.154"
"31100249","Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature","Vartolomei L, Shariat SF, Vartolomei MD.","Eur Urol Oncol. 2018 Sep;1(4):283-291. doi: 10.1016/j.euo.2018.04.011. Epub 2018 May 15.","Vartolomei L","Eur Urol Oncol","2018","2019/05/18","","","10.1016/j.euo.2018.04.011"
"25065910","Expected population impacts of discontinued prostate-specific antigen screening","Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, Cooperberg MR.","Cancer. 2014 Nov 15;120(22):3519-26. doi: 10.1002/cncr.28932. Epub 2014 Jul 25.","Gulati R","Cancer","2014","2014/07/29","PMC4221407","NIHMS613713","10.1002/cncr.28932"
"27823639","Prostate cancer perspectives after chaarted: Optimizing treatment sequence","Estévez SV, Herranz UA, Calvo OF, Afonso Afonso FJ, Couto LS, Quintela ML, Mateos LL, Maciá Escalante S.","Crit Rev Oncol Hematol. 2016 Nov;107:119-127. doi: 10.1016/j.critrevonc.2016.08.007. Epub 2016 Aug 21.","Estévez SV","Crit Rev Oncol Hematol","2016","2016/11/09","","","10.1016/j.critrevonc.2016.08.007"
"21167560","Loss of DMBT1 expression in human prostate cancer and its correlation with clinical progressive features","Du J, Guan M, Fan J, Jiang H.","Urology. 2011 Feb;77(2):509.e9-13. doi: 10.1016/j.urology.2010.09.023. Epub 2010 Dec 16.","Du J","Urology","2011","2010/12/21","","","10.1016/j.urology.2010.09.023"
"31424285","Sequencing strategies in the new treatment landscape of prostate cancer","Caffo O, Maines F, Kinspergher S, Veccia A, Messina C.","Future Oncol. 2019 Sep;15(25):2967-2982. doi: 10.2217/fon-2019-0190. Epub 2019 Aug 19.","Caffo O","Future Oncol","2019","2019/08/20","","","10.2217/fon-2019-0190"
"31357527","PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development","Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.","Genes (Basel). 2019 Jul 26;10(8):565. doi: 10.3390/genes10080565.","Virtanen V","Genes (Basel)","2019","2019/07/31","PMC6723995","","10.3390/genes10080565"
"28636142","Clinical development of immunotherapy for prostate cancer","Noguchi M, Koga N, Igawa T, Itoh K.","Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21.","Noguchi M","Int J Urol","2017","2017/06/22","","","10.1111/iju.13397"
"8650868","Early detection of prostate cancer in men with prostatism and intermediate prostate-specific antigen levels","Schmid HP, Ravery V, Billebaud T, Toublanc M, Boccon-Gibod LA, Hermieu JF, Delmas V, Boccon-Gibod L.","Urology. 1996 May;47(5):699-703. doi: 10.1016/s0090-4295(96)00018-0.","Schmid HP","Urology","1996","1996/05/01","","","10.1016/s0090-4295(96)00018-0"
"20351758","Prostate biopsy in Western Australia 1998-2004","O'Brien BA, Brown AL, Shannon T, Cohen RJ.","Prostate Cancer Prostatic Dis. 2010 Sep;13(3):263-9. doi: 10.1038/pcan.2010.7. Epub 2010 Mar 30.","O'Brien BA","Prostate Cancer Prostatic Dis","2010","2010/03/31","","","10.1038/pcan.2010.7"
"11061919","Re: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer","Pruthi RS.","J Urol. 2000 Dec;164(6):2031. doi: 10.1016/s0022-5347(05)66958-3.","Pruthi RS","J Urol","2000","2000/11/04","","","10.1016/s0022-5347(05)66958-3"
"17169635","Genetic susceptibility and oxidative stress in prostate cancer: integrated model with implications for prevention","Klein EA, Casey G, Silverman R.","Urology. 2006 Dec;68(6):1145-51. doi: 10.1016/j.urology.2006.08.1074.","Klein EA","Urology","2006","2006/12/16","","","10.1016/j.urology.2006.08.1074"
"12743140","A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer","Pollack A.","J Clin Oncol. 2003 May 15;21(10):1899-901. doi: 10.1200/JCO.2003.01.129.","Pollack A","J Clin Oncol","2003","2003/05/14","","","10.1200/JCO.2003.01.129"
"14654526","Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior","Latil A, Bièche I, Chêne L, Laurendeau I, Berthon P, Cussenot O, Vidaud M.","Clin Cancer Res. 2003 Nov 15;9(15):5477-85.","Latil A","Clin Cancer Res","2003","2003/12/05","","",""
"23274390","Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies","Park B, Jeon SS, Ju SH, Jeong BC, Seo SI, Lee HM, Choi HY.","Asian J Androl. 2013 Mar;15(2):236-40. doi: 10.1038/aja.2012.123. Epub 2012 Dec 31.","Park B","Asian J Androl","2013","2013/01/01","PMC3739144","","10.1038/aja.2012.123"
"15067324","Gene expression profiling predicts clinical outcome of prostate cancer","Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL.","J Clin Invest. 2004 Mar;113(6):913-23. doi: 10.1172/JCI20032.","Glinsky GV","J Clin Invest","2004","2004/04/07","PMC362118","","10.1172/JCI20032"
"7691393","Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer","D'Amico AV, Hanks GE.","Cancer. 1993 Nov 1;72(9):2638-43. doi: 10.1002/1097-0142(19931101)72:9<2638::aid-cncr2820720919>3.0.co;2-n.","D'Amico AV","Cancer","1993","1993/11/01","","","10.1002/1097-0142(19931101)72:9<2638::aid-cncr2820720919>3.0.co;2-n"
"23086567","Radical prostatectomy does not improve survival compared to observation for localised prostate cancer in a prospective randomised trial","Griffin JG, Holzbeierlein JM.","Evid Based Med. 2013 Aug;18(4):139-40. doi: 10.1136/eb-2012-100994. Epub 2012 Oct 20.","Griffin JG","Evid Based Med","2013","2012/10/23","","","10.1136/eb-2012-100994"
"22207962","[Role of renin-angiotensin system and antitumor effect of ARB in prostate cancer]","Uemura H, Hoshino K, Kubota Y.","Nihon Rinsho. 2011 Jun;69 Suppl 5:155-9.","Uemura H","Nihon Rinsho","2011","2012/01/03","","",""
"32519789","Early intervention exercise training does not delay prostate cancer progression in Pten(-/-) mice","Taylor RA, Farrelly SG, Clark AK, Watt MJ.","Prostate. 2020 Aug;80(11):906-914. doi: 10.1002/pros.24024. Epub 2020 Jun 10.","Taylor RA","Prostate","2020","2020/06/11","","","10.1002/pros.24024"
"20332606","Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection","Colleselli D, Schilling D, Lichy MP, Hennenlotter J, Vogel UH, Krueger SA, Kuehs U, Schlemmer HP, Stenzl A, Schwentner C.","Urol Int. 2010;84(4):388-94. doi: 10.1159/000300572. Epub 2010 Mar 20.","Colleselli D","Urol Int","2010","2010/03/25","","","10.1159/000300572"
"29419475","Biochemical Recurrence of Prostate Cancer: Initial Results with [(18)F]PSMA-1007 PET/CT","Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, Neels OC, Cardinale J, Hadaschik B, Hohenfellner M, Kopka K, Haberkorn U, Kratochwil C.","J Nucl Med. 2018 Apr;59(4):632-635. doi: 10.2967/jnumed.117.196329. Epub 2018 Feb 1.","Giesel FL","J Nucl Med","2018","2018/02/09","","","10.2967/jnumed.117.196329"
"8918661","[Prognosis in stage a prostate cancer]","Murase T, Kuriyama M, Maeda S, Ando Y, Itoh H, Watanabe H.","Hinyokika Kiyo. 1996 Sep;42(9):639-43.","Murase T","Hinyokika Kiyo","1996","1996/09/01","","",""
"26442305","[Vasectomy does not increase the risk of prostate cancer in Chinese men: A meta-analysis]","Lian WQ, Luo F, Chen PL, Wang SF, Zhou BW, Zhao SC.","Zhonghua Nan Ke Xue. 2015 Aug;21(8):742-6.","Lian WQ","Zhonghua Nan Ke Xue","2015","2015/10/08","","",""
"10332921","Vitamin E, alpha- and gamma-tocopherol, and prostate cancer","Moyad MA, Brumfield SK, Pienta KJ.","Semin Urol Oncol. 1999 May;17(2):85-90.","Moyad MA","Semin Urol Oncol","1999","1999/05/20","","",""
"22035221","Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)","Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.","BJU Int. 2012 Apr;109(7):968-85. doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28.","Lee DJ","BJU Int","2012","2011/11/01","","","10.1111/j.1464-410X.2011.10643.x"
"29460922","Cellular plasticity and the neuroendocrine phenotype in prostate cancer","Davies AH, Beltran H, Zoubeidi A.","Nat Rev Urol. 2018 May;15(5):271-286. doi: 10.1038/nrurol.2018.22. Epub 2018 Feb 20.","Davies AH","Nat Rev Urol","2018","2018/02/21","","","10.1038/nrurol.2018.22"
"23861016","Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer","Daskivich TJ, Chamie K, Kwan L, Dash A, Greenfield S, Litwin MS.","Cancer. 2013 Oct 1;119(19):3446-53. doi: 10.1002/cncr.28226. Epub 2013 Jul 16.","Daskivich TJ","Cancer","2013","2013/07/18","","","10.1002/cncr.28226"
"11142417","Intention to be tested for prostate cancer risk among African-American men","Myers RE, Hyslop T, Jennings-Dozier K, Wolf TA, Burgh DY, Diehl JA, Lerman C, Chodak GW.","Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1323-8.","Myers RE","Cancer Epidemiol Biomarkers Prev","2000","2001/01/06","","",""
"18824067","Role of the renin-angiotensin system in prostate cancer","Chow L, Rezmann L, Catt KJ, Louis WJ, Frauman AG, Nahmias C, Louis SN.","Mol Cell Endocrinol. 2009 Apr 29;302(2):219-29. doi: 10.1016/j.mce.2008.08.032. Epub 2008 Sep 7.","Chow L","Mol Cell Endocrinol","2009","2008/10/01","","","10.1016/j.mce.2008.08.032"
"9184448","[Androgen receptor gene mutations in prostate cancer]","Wang C, Uchida T.","Nihon Hinyokika Gakkai Zasshi. 1997 May;88(5):550-6. doi: 10.5980/jpnjurol1989.88.550.","Wang C","Nihon Hinyokika Gakkai Zasshi","1997","1997/05/01","","","10.5980/jpnjurol1989.88.550"
"16053358","Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer","Rebillard X, Gelet A, Davin JL, Soulie M, Prapotnich D, Cathelineau X, Rozet F, Vallancien G.","J Endourol. 2005 Jul-Aug;19(6):693-701. doi: 10.1089/end.2005.19.693.","Rebillard X","J Endourol","2005","2005/08/02","","","10.1089/end.2005.19.693"
"23862239","[PSA-based screening for prostate cancer: a comparative analysis]","Cao WL, Sun FK.","Zhonghua Nan Ke Xue. 2013 Jun;19(6):559-62.","Cao WL","Zhonghua Nan Ke Xue","2013","2013/07/19","","",""
"27130917","Prostate Cancer: A New Twist on Active Surveillance","Delude C.","J Natl Cancer Inst. 2016 Apr 29;108(5):djw136. doi: 10.1093/jnci/djw136. Print 2016 May.","Delude C","J Natl Cancer Inst","2016","2016/05/01","","","10.1093/jnci/djw136"
"28581205","Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial","Sooriakumaran P.","BJU Int. 2017 Nov;120(5B):E8-E20. doi: 10.1111/bju.13925. Epub 2017 Jul 16.","Sooriakumaran P","BJU Int","2017","2017/06/06","","","10.1111/bju.13925"
"29513724","Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors","Egger S, Hughes S, Smith DP, Chambers S, Kahn C, Moxey A, O'Connell DL.","PLoS One. 2018 Mar 7;13(3):e0193686. doi: 10.1371/journal.pone.0193686. eCollection 2018.","Egger S","PLoS One","2018","2018/03/08","PMC5841769","","10.1371/journal.pone.0193686"
"20967792","31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia","Komoroski RA, Holder JC, Pappas AA, Finkbeiner AE.","Magn Reson Med. 2011 Apr;65(4):911-3. doi: 10.1002/mrm.22677. Epub 2010 Oct 21.","Komoroski RA","Magn Reson Med","2011","2010/10/23","","","10.1002/mrm.22677"
"10494285","Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy","Bostwick DG, Ramnani D, Cheng L.","Urol Clin North Am. 1999 Aug;26(3):465-79. doi: 10.1016/s0094-0143(05)70195-6.","Bostwick DG","Urol Clin North Am","1999","1999/09/24","","","10.1016/s0094-0143(05)70195-6"
"16804523","No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study","Kikuchi N, Ohmori K, Shimazu T, Nakaya N, Kuriyama S, Nishino Y, Tsubono Y, Tsuji I.","Br J Cancer. 2006 Aug 7;95(3):371-3. doi: 10.1038/sj.bjc.6603230. Epub 2006 Jun 27.","Kikuchi N","Br J Cancer","2006","2006/06/29","PMC2360636","","10.1038/sj.bjc.6603230"
"7522394","Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?","Vijayakumar V, Vijayakumar S, Quadri SF, Blend MJ.","Am J Clin Oncol. 1994 Oct;17(5):432-6. doi: 10.1097/00000421-199410000-00016.","Vijayakumar V","Am J Clin Oncol","1994","1994/10/01","","","10.1097/00000421-199410000-00016"
"30042207","The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications","Iglesias-Gato D, Thysell E, Tyanova S, Crnalic S, Santos A, Lima TS, Geiger T, Cox J, Widmark A, Bergh A, Mann M, Flores-Morales A, Wikström P.","Clin Cancer Res. 2018 Nov 1;24(21):5433-5444. doi: 10.1158/1078-0432.CCR-18-1229. Epub 2018 Jul 24.","Iglesias-Gato D","Clin Cancer Res","2018","2018/07/26","","","10.1158/1078-0432.CCR-18-1229"
"8339217","Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen","Matzkin H, Soloway MS, Schellhammer PF, Chodak G, Smith JA, Caplan R, Kennealey GT.","Cancer. 1993 Aug 15;72(4):1286-90. doi: 10.1002/1097-0142(19930815)72:4<1286::aid-cncr2820720422>3.0.co;2-7.","Matzkin H","Cancer","1993","1993/08/15","","","10.1002/1097-0142(19930815)72:4<1286::aid-cncr2820720422>3.0.co;2-7"
"11340572","Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population","Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T.","Int J Cancer. 2001 Jun 1;92(5):683-6. doi: 10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4.","Yamada Y","Int J Cancer","2001","2001/05/08","","","10.1002/1097-0215(20010601)92:5<683::aid-ijc1255>3.0.co;2-4"
"9697778","Screening digital rectal examination and prostate cancer mortality: a population-based case-control study","Jacobsen SJ, Bergstralh EJ, Katusic SK, Guess HA, Darby CH, Silverstein MD, Oesterling JE, Lieber MM.","Urology. 1998 Aug;52(2):173-9. doi: 10.1016/s0090-4295(98)00171-x.","Jacobsen SJ","Urology","1998","1998/08/11","","","10.1016/s0090-4295(98)00171-x"
"8270458","Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure","Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, Owen JB.","Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):39-45. doi: 10.1016/0360-3016(94)90139-2.","Hanks GE","Int J Radiat Oncol Biol Phys","1994","1994/01/01","","","10.1016/0360-3016(94)90139-2"
"15017210","Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities","Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, Menon M.","J Urol. 2004 Apr;171(4):1513-9. doi: 10.1097/01.ju.0000117975.40782.95.","Tewari A","J Urol","2004","2004/03/17","","","10.1097/01.ju.0000117975.40782.95"
"19020742","Analysis of hypoxia-associated gene expression in prostate cancer: lysyl oxidase and glucose transporter-1 expression correlate with Gleason score","Stewart GD, Gray K, Pennington CJ, Edwards DR, Riddick AC, Ross JA, Habib FK.","Oncol Rep. 2008 Dec;20(6):1561-7.","Stewart GD","Oncol Rep","2008","2008/11/21","","",""
"19447327","[What's new in 2008 in the field of basic and clinical research in prostate cancer?]","Phé V, Rouprêt M, Salomon L, Soulié M.","Prog Urol. 2009 May;19 Suppl 2:S29-42. doi: 10.1016/S1166-7087(09)73893-X.","Phé V","Prog Urol","2009","2009/05/19","","","10.1016/S1166-7087(09)73893-X"
"17404658","This prostate cancer death should not have happened","","S Afr Med J. 2007 Feb;97(2):81.","","S Afr Med J","2007","2007/04/04","","",""
"27487263","Association Between Depression and Hospital Admission in Older Men with Prostate Cancer","Laurence B, Woods D, Tillman N, Singh S.","J Am Geriatr Soc. 2016 Sep;64(9):1924-5. doi: 10.1111/jgs.14424. Epub 2016 Aug 3.","Laurence B","J Am Geriatr Soc","2016","2016/08/04","","","10.1111/jgs.14424"
"18074432","Editorial comment on: Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution","Hurwitz M.","Eur Urol. 2007 Dec;52(6):1661-2.","Hurwitz M","Eur Urol","2007","2007/12/13","","",""
"12181860","Screening for prostate cancer","Whisnant JD Jr.","N C Med J. 2002 May-Jun;63(3):178-9.","Whisnant JD Jr","N C Med J","2002","2002/08/17","","",""
"24853547","Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method","Morken JD, Packer A, Everett RA, Nagy JD, Kuang Y.","Cancer Res. 2014 Jul 15;74(14):3673-83. doi: 10.1158/0008-5472.CAN-13-3162. Epub 2014 May 22.","Morken JD","Cancer Res","2014","2014/05/24","","","10.1158/0008-5472.CAN-13-3162"
"15142137","Diet and prostate cancer","Mazhar D, Waxman J.","BJU Int. 2004 May;93(7):919-22. doi: 10.1111/j.1464-410X.2003.04755.x.","Mazhar D","BJU Int","2004","2004/05/15","","","10.1111/j.1464-410X.2003.04755.x"
"20696746","A Patient's Journey. At sixes and sevens: prostate cancer","Profumo D, Dinneen M.","BMJ. 2010 Aug 9;341:c3834. doi: 10.1136/bmj.c3834.","Profumo D","BMJ","2010","2010/08/11","","","10.1136/bmj.c3834"
"12861315","Prostate cancer screening stretches services and offers little benefit to patients","Corwin P.","N Z Med J. 2003 Jul 11;116(1177):U504; author reply U504.","Corwin P","N Z Med J","2003","2003/07/16","","",""
"10926080","Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy","Dahm P, Vieweg J, Newhall PM, Robertson JE, Paulson DF.","World J Urol. 2000 Jun;18(3):173-8. doi: 10.1007/s003459900100.","Dahm P","World J Urol","2000","2000/08/05","","","10.1007/s003459900100"
"27324988","A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling","Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.","Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21.","Cheng HH","Prostate","2016","2016/06/22","PMC5549853","NIHMS888786","10.1002/pros.23219"
"17717436","The androgen receptor in prostate cancer: therapy target in search of an integrated diagnostic test","Ross JS.","Adv Anat Pathol. 2007 Sep;14(5):353-7. doi: 10.1097/PAP.0b013e31814a52c4.","Ross JS","Adv Anat Pathol","2007","2007/08/25","","","10.1097/PAP.0b013e31814a52c4"
"21542749","Effective treatment for early-stage prostate cancer--possible, necessary, or both?","Smith MR.","N Engl J Med. 2011 May 5;364(18):1770-2. doi: 10.1056/NEJMe1100787.","Smith MR","N Engl J Med","2011","2011/05/06","","","10.1056/NEJMe1100787"
"17916461","Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective","Matharoo-Ball B, Ball G, Rees R.","Vaccine. 2007 Sep 27;25 Suppl 2:B110-21. doi: 10.1016/j.vaccine.2007.06.040.","Matharoo-Ball B","Vaccine","2007","2007/11/02","","","10.1016/j.vaccine.2007.06.040"
"19945664","[Recommendations for the treatment of prostate cancer in the elderly man: A study by the oncology committee of the French association of urology]","Mongiat-Artus P, Peyromaure M, Richaud P, Droz JP, Rainfray M, Jeandel C, Rebillard X, Moreau JL, Davin JL, Salomon L, Soulié M; Sous-Comité Prostate du CC-AFU.","Prog Urol. 2009 Dec;19(11):810-7. doi: 10.1016/j.purol.2009.02.008. Epub 2009 Apr 8.","Mongiat-Artus P","Prog Urol","2009","2009/12/01","","","10.1016/j.purol.2009.02.008"
"7692579","[Screening for prostate cancer in the Anticancer Center of Liège]","Chevalier P, Bologne MC, Guillaume D, Herman MG, Magis C, Mouawad F, Sart B, Thys B.","Rev Med Liege. 1993 Sep 1;48(9):512-8.","Chevalier P","Rev Med Liege","1993","1993/09/01","","",""
"15018074","[Prostate cancer. Progress and controversies]","Thiounn N.","Rev Prat. 2003 Dec 31;53(20):2223.","Thiounn N","Rev Prat","2003","2004/03/17","","",""
"21823112","Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States","Prasad SM, Gu X, Lipsitz SR, Nguyen PL, Hu JC.","Cancer. 2012 Mar 1;118(5):1260-7. doi: 10.1002/cncr.26416. Epub 2011 Aug 5.","Prasad SM","Cancer","2012","2011/08/09","","","10.1002/cncr.26416"
"17224383","Acquired hypertrichosis lanuginosa as a presenting sign of metastatic prostate cancer with rapid resolution after treatment","Wyatt JP, Anderson HF, Greer KE, Cordoro KM.","J Am Acad Dermatol. 2007 Feb;56(2 Suppl):S45-7. doi: 10.1016/j.jaad.2006.07.011.","Wyatt JP","J Am Acad Dermatol","2007","2007/01/17","","","10.1016/j.jaad.2006.07.011"
"7652489","Some aspects of the biology and endocrinology of prostate cancer","Griffiths K, Harper ME, Peeling WB.","Scand J Clin Lab Invest Suppl. 1995;221:23-31. doi: 10.3109/00365519509090560.","Griffiths K","Scand J Clin Lab Invest Suppl","1995","1995/01/01","","","10.3109/00365519509090560"
"16262089","Prostate cancer: appraisal, coping, and health status","Ahmad MM, Musil CM, Zauszniewski JA, Resnick MI.","J Gerontol Nurs. 2005 Oct;31(10):34-43. doi: 10.3928/0098-9134-20051001-08.","Ahmad MM","J Gerontol Nurs","2005","2005/11/03","","","10.3928/0098-9134-20051001-08"
"28422738","Peripheral zone volume ratio (PZ-ratio) is relevant with biopsy results and can increase the accuracy of current diagnostic modality","Chang Y, Chen R, Yang Q, Gao X, Xu C, Lu J, Sun Y.","Oncotarget. 2017 May 23;8(21):34836-34843. doi: 10.18632/oncotarget.16753.","Chang Y","Oncotarget","2017","2017/04/20","PMC5471015","","10.18632/oncotarget.16753"
"8961716","Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994","Bauer JJ, Mcleod DG, Moul JW.","Mil Med. 1996 Nov;161(11):646-53.","Bauer JJ","Mil Med","1996","1996/11/01","","",""
"7519363","Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer","Fowler JE Jr, Pandey P, Braswell NT, Seaver L.","Surgery. 1994 Aug;116(2):302-5; discussion 305-6.","Fowler JE Jr","Surgery","1994","1994/08/01","","",""
"22851092","New research reveals positive therapies and methods for treating prostate cancer","Mitka M.","JAMA. 2012 Aug 1;308(5):441-2. doi: 10.1001/jama.2012.7960.","Mitka M","JAMA","2012","2012/08/02","","","10.1001/jama.2012.7960"
"11405126","[Value of cryotherapy in localized prostatic carcinoma]","Sommer F, Derakhshani P, Zumbé J, Engelmann U.","Urologe A. 2001 May;40(3):185-90. doi: 10.1007/s001200050460.","Sommer F","Urologe A","2001","2001/06/19","","","10.1007/s001200050460"
"26633167","Gleason Score 6 - Prostate Cancer or Benign Variant?","Knüchel R.","Oncol Res Treat. 2015;38(12):629-32. doi: 10.1159/000441735. Epub 2015 Nov 12.","Knüchel R","Oncol Res Treat","2015","2015/12/04","","","10.1159/000441735"
"1826749","Transperitoneal endosurgical lymphadenectomy in patients with localized prostate cancer","Schuessler WW, Vancaillie TG, Reich H, Griffith DP.","J Urol. 1991 May;145(5):988-91. doi: 10.1016/s0022-5347(17)38509-9.","Schuessler WW","J Urol","1991","1991/05/01","","","10.1016/s0022-5347(17)38509-9"
"23109831","NAD(P)H:quinone oxidoreductase 1 (NQO1) P187S polymorphism and prostate cancer risk in Caucasians","Stoehr CG, Nolte E, Wach S, Wieland WF, Hofstaedter F, Hartmann A, Stoehr R.","Int J Mol Sci. 2012;13(9):10959-69. doi: 10.3390/ijms130910959. Epub 2012 Jul 26.","Stoehr CG","Int J Mol Sci","2012","2012/10/31","PMC3472723","","10.3390/ijms130910959"
"29297487","Prostate cancer grading: a decade after the 2005 modified system","Epstein JI.","Mod Pathol. 2018 Jan;31(S1):S47-63. doi: 10.1038/modpathol.2017.133.","Epstein JI","Mod Pathol","2018","2018/01/04","","","10.1038/modpathol.2017.133"
"7536722","The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?","Zagars GK, Kavadi VS, Pollack A, von Eschenbach AC, Sands ME.","Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):21-32. doi: 10.1016/0360-3016(95)00566-H.","Zagars GK","Int J Radiat Oncol Biol Phys","1995","1995/04/30","","","10.1016/0360-3016(95)00566-H"
"8536772","Attitudes of European urologists to early prostatic carcinoma, II. Attitude to therapy and to screening examinations","Hansen MV, Grönberg A.","Eur Urol. 1995;28(3):196-201. doi: 10.1159/000475051.","Hansen MV","Eur Urol","1995","1995/01/01","","","10.1159/000475051"
"17626387","[Mass screening guidelines for prostate cancer: Should they be utilized in France?]","Gignon M, Braillon A, Chaine FX, Dubois G.","Can J Public Health. 2007 May-Jun;98(3):212-6. doi: 10.1007/BF03403715.","Gignon M","Can J Public Health","2007","2007/07/14","PMC6975731","","10.1007/BF03403715"
"9790041","Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer","Petronis JD, Regan F, Lin K.","Clin Nucl Med. 1998 Oct;23(10):672-7. doi: 10.1097/00003072-199810000-00005.","Petronis JD","Clin Nucl Med","1998","1998/10/28","","","10.1097/00003072-199810000-00005"
"26564412","Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy","Mai ZP, Yan WG, Li HZ, Zhou Y, Zhou ZE.","Chin Med Sci J. 2015 Sep;30(3):143-9. doi: 10.1016/s1001-9294(15)30038-9.","Mai ZP","Chin Med Sci J","2015","2015/11/14","","","10.1016/s1001-9294(15)30038-9"
"11893639","Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy","Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley DP.","Br J Radiol. 2002 Feb;75(890):151-61. doi: 10.1259/bjr.75.890.750151.","Nutting CM","Br J Radiol","2002","2002/03/15","","","10.1259/bjr.75.890.750151"
"32380503","Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review","Assi T, Rassy E, Farhat F, Kattan C, Kattan J.","Oncol Res Treat. 2020;43(6):299-306. doi: 10.1159/000506693. Epub 2020 May 7.","Assi T","Oncol Res Treat","2020","2020/05/08","","","10.1159/000506693"
"12858917","Management and survival in advanced prostate cancer in Nairobi","Magoha GA.","East Afr Med J. 2000 May;77(5):260-3. doi: 10.4314/eamj.v77i5.46630.","Magoha GA","East Afr Med J","2000","2003/07/16","","","10.4314/eamj.v77i5.46630"
"15289810","Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions","Lujan M, Paez A, Santonja C, Pascual T, Fernandez I, Berenguer A.","Prostate Cancer Prostatic Dis. 2004;7(3):238-42. doi: 10.1038/sj.pcan.4500730.","Lujan M","Prostate Cancer Prostatic Dis","2004","2004/08/04","","","10.1038/sj.pcan.4500730"
"18382244","Shifting focus to cancer survivorship in prostate cancer: challenges and opportunities","Gilbert SM.","Curr Opin Urol. 2008 May;18(3):326-32. doi: 10.1097/MOU.0b013e3282f9b3ff.","Gilbert SM","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282f9b3ff"
"27482937","Health-related quality of life in rehabilitants with different cancer entities","Lamprecht J, Thyrolf A, Mau W.","Eur J Cancer Care (Engl). 2017 Sep;26(5). doi: 10.1111/ecc.12554. Epub 2016 Aug 2.","Lamprecht J","Eur J Cancer Care (Engl)","2017","2016/08/03","","","10.1111/ecc.12554"
"12835805","Prostate cancer screening: knowledge, experiences and attitudes of men aged 40-79 years","Arroll B, Pandit S, Buetow S.","N Z Med J. 2003 Jun 20;116(1176):U477.","Arroll B","N Z Med J","2003","2003/07/02","","",""
"28089303","Practical Polling for Prostate Cancer: AR-V7-based Treatment Selection","Lamb AD, Lawrence MG, Sandhu S.","Eur Urol. 2017 Jun;71(6):883-885. doi: 10.1016/j.eururo.2016.12.028. Epub 2017 Jan 11.","Lamb AD","Eur Urol","2017","2017/01/17","","","10.1016/j.eururo.2016.12.028"
"20140819","Therapeutic vaccines for prostate cancer","Cha E, Fong L.","Curr Opin Mol Ther. 2010 Feb;12(1):77-85.","Cha E","Curr Opin Mol Ther","2010","2010/02/09","","",""
"12351616","Prostate cancer risk groups and comparisons: fruitless or fruitful?","Gray JR.","J Clin Oncol. 2002 Oct 1;20(19):4129; author reply 4129-30. doi: 10.1200/JCO.2002.99.140.","Gray JR","J Clin Oncol","2002","2002/09/28","","","10.1200/JCO.2002.99.140"
"21616447","[Evolution of modern imaging and development of targeted prostatic biopsies for the diagnosis of prostate cancer]","Audenet F, Rouprêt M, Mozer P.","Prog Urol. 2011 May;21 Suppl 3:S93-5. doi: 10.1016/S1166-7087(11)70021-5.","Audenet F","Prog Urol","2011","2011/05/28","","","10.1016/S1166-7087(11)70021-5"
"26829214","The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance","Zarif JC, Miranti CK.","Cell Signal. 2016 May;28(5):348-356. doi: 10.1016/j.cellsig.2016.01.013. Epub 2016 Jan 29.","Zarif JC","Cell Signal","2016","2016/02/02","PMC4788534","NIHMS756485","10.1016/j.cellsig.2016.01.013"
"20425627","Prostate cancer screening: what we have learned from the PLCO and ERSPC trials","La Rochelle J, Amling CL.","Curr Urol Rep. 2010 May;11(3):198-201. doi: 10.1007/s11934-010-0109-5.","La Rochelle J","Curr Urol Rep","2010","2010/04/29","","","10.1007/s11934-010-0109-5"
"24215139","Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer","Nguyen DP, Li J, Yadav SS, Tewari AK.","BJU Int. 2014 Aug;114(2):168-76. doi: 10.1111/bju.12488. Epub 2014 Feb 20.","Nguyen DP","BJU Int","2014","2013/11/13","","","10.1111/bju.12488"
"19357513","Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer","Schröder FH, Roobol MJ.","Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0.","Schröder FH","Curr Opin Urol","2009","2009/04/10","","","10.1097/MOU.0b013e328329a2d0"
"17956709","Combined androgen blockade in advanced prostate cancer: looking back to move forward","Chodak G, Gomella L, Phung de H.","Clin Genitourin Cancer. 2007 Sep;5(6):371-8. doi: 10.3816/cgc.2007.n.019.","Chodak G","Clin Genitourin Cancer","2007","2007/10/25","","","10.3816/cgc.2007.n.019"
"18158035","Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy","Mouraviev V, Sun L, Madden JF, Mayes JM, Moul JW, Polascik TJ.","Urology. 2007 Dec;70(6):1141-5. doi: 10.1016/j.urology.2007.07.066.","Mouraviev V","Urology","2007","2007/12/26","","","10.1016/j.urology.2007.07.066"
"24726733","High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome","Tidehag V, Hammarsten P, Egevad L, Granfors T, Stattin P, Leanderson T, Wikström P, Josefsson A, Hägglöf C, Bergh A.","Eur J Cancer. 2014 Jul;50(10):1829-1835. doi: 10.1016/j.ejca.2014.03.278. Epub 2014 Apr 10.","Tidehag V","Eur J Cancer","2014","2014/04/15","","","10.1016/j.ejca.2014.03.278"
"18263996","Longitudinal quality of life in low-income men in a state-funded prostate cancer treatment program","Zavala MW, Maliski SL, Kwan L, Miller DC, Fink A, Litwin MS.","J Health Care Poor Underserved. 2008 Feb;19(1):200-14. doi: 10.1353/hpu.2008.0026.","Zavala MW","J Health Care Poor Underserved","2008","2008/02/12","","","10.1353/hpu.2008.0026"
"26797252","Upregulation of PAWR by small activating RNAs induces cell apoptosis in human prostate cancer cells","Yang K, Shen J, Chen SW, Qin J, Zheng XY, Xie LP.","Oncol Rep. 2016 Apr;35(4):2487-93. doi: 10.3892/or.2016.4582. Epub 2016 Jan 21.","Yang K","Oncol Rep","2016","2016/01/23","","","10.3892/or.2016.4582"
"19521126","Systemic therapies for non-metastatic prostate cancer: review of the literature","Jereczek-Fossa BA, Curigliano G, Orecchia R.","Onkologie. 2009 Jun;32(6):359-63. doi: 10.1159/000215713. Epub 2009 May 14.","Jereczek-Fossa BA","Onkologie","2009","2009/06/13","","","10.1159/000215713"
"8038240","Fat and prostate cancer","Franceschi S.","Epidemiology. 1994 May;5(3):271-3.","Franceschi S","Epidemiology","1994","1994/05/01","","",""
"10361559","Vaccine therapy for prostate cancer","Tjoa BA, Elgamal AA, Murphy GP.","Urol Clin North Am. 1999 May;26(2):365-74, ix. doi: 10.1016/s0094-0143(05)70076-8.","Tjoa BA","Urol Clin North Am","1999","1999/06/11","","","10.1016/s0094-0143(05)70076-8"
"28193130","Religious Coping and Types and Sources of Information Used in Making Prostate Cancer Treatment Decisions","Bowie JV, Bell CN, Ewing A, Kinlock B, Ezema A, Thorpe RJ Jr, LaVeist TA.","Am J Mens Health. 2017 Jul;11(4):1237-1246. doi: 10.1177/1557988317690977. Epub 2017 Feb 13.","Bowie JV","Am J Mens Health","2017","2017/02/15","PMC5675355","","10.1177/1557988317690977"
"12548131","Diagnosis and treatment of prostate cancers in renal-transplant recipients","Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K, Descottes JL, Doré B, Guy L, Malavaud B, Martin X, Patard JJ, Petit J, Salomon L.","Transplantation. 2003 Jan 27;75(2):237-9. doi: 10.1097/01.TP.0000041785.38998.6C.","Cormier L","Transplantation","2003","2003/01/28","","","10.1097/01.TP.0000041785.38998.6C"
"18045073","Recent approaches in chemoprevention of prostate cancer","Young CY.","Curr Cancer Drug Targets. 2007 Nov;7(7):681-8. doi: 10.2174/156800907782418284.","Young CY","Curr Cancer Drug Targets","2007","2007/11/30","","","10.2174/156800907782418284"
"17667966","The treatment of chyluria secondary to advanced carcinoma of the prostate","Cluskey SA, Myatt A, Ferro MA.","Prostate Cancer Prostatic Dis. 2008;11(1):102-5. doi: 10.1038/sj.pcan.4500994. Epub 2007 Jul 31.","Cluskey SA","Prostate Cancer Prostatic Dis","2008","2007/08/02","","","10.1038/sj.pcan.4500994"
"18883084","[Las Prostate cancer and its hormonal treatment]","WILDBOLZ E.","Dtsch Med Wochenschr. 1948 Aug 13;73(29-32):305-9. doi: 10.1055/s-0028-1118135.","WILDBOLZ E","Dtsch Med Wochenschr","1948","1948/08/13","","","10.1055/s-0028-1118135"
"17382696","Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes","Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM.","J Urol. 2007 Apr;177(4):1229-37. doi: 10.1016/j.juro.2006.11.032.","Flaig TW","J Urol","2007","2007/03/27","","","10.1016/j.juro.2006.11.032"
"19152157","Changing the conversation about prostate cancer among African Americans: results of formative research","Wray RJ, McClure S, Vijaykumar S, Smith C, Ivy A, Jupka K, Hess R.","Ethn Health. 2009 Feb;14(1):27-43. doi: 10.1080/13557850802056448.","Wray RJ","Ethn Health","2009","2009/01/20","","","10.1080/13557850802056448"
"7521783","Prostate specific antigen and prostate specific antigen density. Roles in patient evaluation and management","Benson MC, Olsson CA.","Cancer. 1994 Sep 15;74(6):1667-73. doi: 10.1002/1097-0142(19940915)74:6<1667::aid-cncr2820740605>3.0.co;2-2.","Benson MC","Cancer","1994","1994/09/15","","","10.1002/1097-0142(19940915)74:6<1667::aid-cncr2820740605>3.0.co;2-2"
"19352389","Focal therapy for prostate cancer","Scardino PT.","Nat Rev Urol. 2009 Apr;6(4):175. doi: 10.1038/nrurol.2009.52.","Scardino PT","Nat Rev Urol","2009","2009/04/09","","","10.1038/nrurol.2009.52"
"9698691","Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer","Hennenfent BR.","Br J Urol. 1998 Jul;82(1):166.","Hennenfent BR","Br J Urol","1998","1998/08/12","","",""
"15535435","The role of inflammation in the pathogenesis of prostate cancer","Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB.","J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2. doi: 10.1097/01.ju.0000142058.99614.ff.","Nelson WG","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000142058.99614.ff"
"24775719","Traditional androgen ablation approaches to advanced prostate cancer: new insights","Rove KO, Crawford ED.","Can J Urol. 2014 Apr;21(2 Supp 1):14-21.","Rove KO","Can J Urol","2014","2014/04/30","","",""
"24528078","Association between urinary cadmium and all cause, all cancer and prostate cancer specific mortalities for men: an analysis of national health and nutrition examination survey (NHANES III) data","Cheung MR, Kang J, Ouyang D, Yeung V.","Asian Pac J Cancer Prev. 2014;15(1):483-8. doi: 10.7314/apjcp.2014.15.1.483.","Cheung MR","Asian Pac J Cancer Prev","2014","2014/02/18","","","10.7314/apjcp.2014.15.1.483"
"28267429","Knockdown of FOXK1 Suppresses Proliferation, Migration, and Invasion in Prostate Cancer Cells","Chen F, Xiong W, Dou K, Ran Q.","Oncol Res. 2017 Sep 21;25(8):1261-1267. doi: 10.3727/096504017X14871164924588. Epub 2017 Mar 2.","Chen F","Oncol Res","2017","2017/03/08","","","10.3727/096504017X14871164924588"
"16604996","Role of dietary modification and vitamins in prostate cancer","Sommerkamp HW, Khauli RB.","J Med Liban. 2005 Apr-Jun;53(2):103-6.","Sommerkamp HW","J Med Liban","2005","2006/04/12","","",""
"20841388","Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development","Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.","Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. doi: 10.1158/1055-9965.EPI-10-0555. Epub 2010 Sep 14.","Bianco-Miotto T","Cancer Epidemiol Biomarkers Prev","2010","2010/09/16","","","10.1158/1055-9965.EPI-10-0555"
"31564554","MRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial","Alayed Y, D'Alimonte L, Helou J, Ravi A, Morton G, Chung HT, Haider M, McGuffin M, Zhang L, Loblaw A.","Radiother Oncol. 2019 Dec;141:144-148. doi: 10.1016/j.radonc.2019.09.011. Epub 2019 Sep 26.","Alayed Y","Radiother Oncol","2019","2019/10/01","","","10.1016/j.radonc.2019.09.011"
"16118101","Pathways to the diagnosis of prostate cancer in a British city. A population-based study","Barrett J, Hamilton W.","Scand J Urol Nephrol. 2005;39(4):267-70. doi: 10.1080/00365590510031282.","Barrett J","Scand J Urol Nephrol","2005","2005/08/25","","","10.1080/00365590510031282"
"16489902","Maintaining bone health in patients with prostate cancer","Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR.","Med J Aust. 2006 Feb 20;184(4):176-9.","Holmes-Walker DJ","Med J Aust","2006","2006/02/24","","",""
"31039571","Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer","Fujimoto N, Shiota M, Tomisaki I, Minato A, Yahara K.","Urol Int. 2019;103(2):125-136. doi: 10.1159/000497280. Epub 2019 Apr 30.","Fujimoto N","Urol Int","2019","2019/05/01","","","10.1159/000497280"
"27905327","Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer","Xu X, Huang YH, Li YJ, Cohen A, Li Z, Squires J, Zhang W, Chen XF, Zhang M, Huang JT.","Asian J Androl. 2017 Nov-Dec;19(6):686-693. doi: 10.4103/1008-682X.191518.","Xu X","Asian J Androl","2017","2016/12/02","PMC5676429","","10.4103/1008-682X.191518"
"17005316","The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening","Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, Naya Y, Ichikawa T.","Eur Urol. 2007 Feb;51(2):375-80. doi: 10.1016/j.eururo.2006.08.047. Epub 2006 Sep 12.","Yano M","Eur Urol","2007","2006/09/29","","","10.1016/j.eururo.2006.08.047"
"11458120","Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value","Weckermann D, Müller P, Wawroschek F, Harzmann R, Riethmüller G, Schlimok G.","J Urol. 2001 Aug;166(2):699-703.","Weckermann D","J Urol","2001","2001/07/18","","",""
"1765112","Prostate cancer: a current perspective","Nomura AM, Kolonel LN.","Epidemiol Rev. 1991;13:200-27. doi: 10.1093/oxfordjournals.epirev.a036069.","Nomura AM","Epidemiol Rev","1991","1991/01/01","","","10.1093/oxfordjournals.epirev.a036069"
"7671257","Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo","Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R.","Cancer Res. 1995 Oct 1;55(19):4438-45.","Raffo AJ","Cancer Res","1995","1995/10/01","","",""
"31319390","PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes","Magnani CJ, Li K, Seto T, McDonald KM, Blayney DW, Brooks JD, Hernandez-Boussard T.","J Natl Compr Canc Netw. 2019 Jul 1;17(7):795-803. doi: 10.6004/jnccn.2018.7274.","Magnani CJ","J Natl Compr Canc Netw","2019","2019/07/19","PMC7195904","NIHMS1556296","10.6004/jnccn.2018.7274"
"18646267","Manganese superoxide dismutase (MnSOD) genetic polymorphism is associated with risk of early-onset prostate cancer","Arsova-Sarafinovska Z, Matevska N, Petrovski D, Banev S, Dzikova S, Georgiev V, Sikole A, Sayal A, Aydin A, Suturkova L, Dimovski AJ.","Cell Biochem Funct. 2008 Oct;26(7):771-7. doi: 10.1002/cbf.1504.","Arsova-Sarafinovska Z","Cell Biochem Funct","2008","2008/07/23","","","10.1002/cbf.1504"
"15649095","Impact on late toxicity of using transabdominal ultrasound for prostate cancer patients treated with intensity modulated radiotherapy","Jani AB, Gratzle J, Muresan E, Martel MK.","Technol Cancer Res Treat. 2005 Feb;4(1):115-20. doi: 10.1177/153303460500400115.","Jani AB","Technol Cancer Res Treat","2005","2005/01/15","","","10.1177/153303460500400115"
"29580149","A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy","Liu Q, Tong D, Liu G, Yi Y, Xu J, Yang X, Wang L, Zhang J, Ye J, Zhang Y, Yuan G, Wang P, Chen R, Guan Y, Yi X, Zhang D, Jiang J.","Cancer Biol Ther. 2018 Aug 3;19(8):669-675. doi: 10.1080/15384047.2018.1451278. Epub 2018 Apr 19.","Liu Q","Cancer Biol Ther","2018","2018/03/28","PMC6067857","","10.1080/15384047.2018.1451278"
"17674435","This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT","Yossepowitch O.","Eur Urol. 2007 Aug;52(2):453.","Yossepowitch O","Eur Urol","2007","2007/08/04","","",""
"22093294","Re: Firas Abdollah, Maxine Sun, Jan Schmitges, et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 2011;60:920-30","Froehner M.","Eur Urol. 2012 Feb;61(2):e11; author reply e12. doi: 10.1016/j.eururo.2011.11.004. Epub 2011 Nov 10.","Froehner M","Eur Urol","2012","2011/11/19","","","10.1016/j.eururo.2011.11.004"
"23886795","Treatment of lymph node-positive prostate cancer: teaching old dogmas new tricks","Briganti A, Passoni NM, Abdollah F, Nini A, Montorsi F, Karnes RJ.","Eur Urol. 2014 Jan;65(1):26-7; discussion 28. doi: 10.1016/j.eururo.2013.07.003. Epub 2013 Jul 10.","Briganti A","Eur Urol","2014","2013/07/27","","","10.1016/j.eururo.2013.07.003"
"20557002","[Therapeutic options in localized prostate cancer]","Bastian PJ.","MMW Fortschr Med. 2010 May 13;152(19):43-4. doi: 10.1007/BF03366556.","Bastian PJ","MMW Fortschr Med","2010","2010/06/19","","","10.1007/BF03366556"
"28512731","Active Surveillance for Prostate Cancer: How to Do It Right","Garisto JD, Klotz L.","Oncology (Williston Park). 2017 May 15;31(5):333-40, 345.","Garisto JD","Oncology (Williston Park)","2017","2017/05/18","","",""
"7803728","Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project","Littrup PJ, Goodman AC.","In Vivo. 1994 May-Jun;8(3):423-7.","Littrup PJ","In Vivo","1994","1994/05/01","","",""
"17178188","Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting","Berge V, Thompson T, Blackman D.","Eur Urol. 2007 Oct;52(4):1036-43. doi: 10.1016/j.eururo.2006.12.012. Epub 2006 Dec 12.","Berge V","Eur Urol","2007","2006/12/21","","","10.1016/j.eururo.2006.12.012"
"12878745","Prostate cancer","Nelson WG, De Marzo AM, Isaacs WB.","N Engl J Med. 2003 Jul 24;349(4):366-81. doi: 10.1056/NEJMra021562.","Nelson WG","N Engl J Med","2003","2003/07/25","","","10.1056/NEJMra021562"
"15330213","Ethnic differences in diet and associations with clinical markers of prostate disease in New Zealand men","Harris A, Gray MA, Slaney DP, Turley ML, Fowles JR, Weinstein P.","Anticancer Res. 2004 Jul-Aug;24(4):2551-6.","Harris A","Anticancer Res","2004","2004/08/28","","",""
"19547971","Commentary on: Validation of sentinel lymph node dissection in prostate cancer: experience in more than 2,000 patients","Brenot-Rossi I, Bastide C.","Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1375-6. doi: 10.1007/s00259-009-1191-0.","Brenot-Rossi I","Eur J Nucl Med Mol Imaging","2009","2009/06/24","","","10.1007/s00259-009-1191-0"
"30457248","Histopathological Outcomes after Radical Prostatectomy for Prostate Cancer Based On a New Grading System","Spajić B, Nikles S, Grubišić I, Knežević M, Shoipi S, Ulamec M, Štimac G, Tomašković I, Ružić B.","Acta Clin Croat. 2018 Oct;57(Suppl 1):50-55. doi: 10.20471/acc.2018.57.s1.07.","Spajić B","Acta Clin Croat","2018","2018/11/21","","","10.20471/acc.2018.57.s1.07"
"22935678","A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells","Russo A, Espinoza CL, Caggia S, Garbarino JA, Peña-Cortés H, Carvajal TM, Cardile V.","Cancer Lett. 2012 Dec 30;326(2):199-205. doi: 10.1016/j.canlet.2012.08.025. Epub 2012 Aug 27.","Russo A","Cancer Lett","2012","2012/09/01","","","10.1016/j.canlet.2012.08.025"
"23588585","Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer","Ting H, Deep G, Agarwal R.","AAPS J. 2013 Jul;15(3):707-16. doi: 10.1208/s12248-013-9486-2. Epub 2013 Apr 16.","Ting H","AAPS J","2013","2013/04/17","PMC3691417","","10.1208/s12248-013-9486-2"
"31077419","Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy","Shiota M, Ushijima M, Imada K, Kashiwagi E, Takeuchi A, Inokuchi J, Tatsugami K, Kajioka S, Eto M.","Prostate. 2019 Jul;79(10):1147-1155. doi: 10.1002/pros.23828. Epub 2019 May 11.","Shiota M","Prostate","2019","2019/05/12","","","10.1002/pros.23828"
"18321314","Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality","Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, Schennach H, Schäfer G, Frauscher F, Boniol M, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group.","BJU Int. 2008 Apr;101(7):809-16. doi: 10.1111/j.1464-410X.2008.07502.x.","Bartsch G","BJU Int","2008","2008/03/07","","","10.1111/j.1464-410X.2008.07502.x"
"25461803","The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer","Ragnum HB, Vlatkovic L, Lie AK, Axcrona K, Julin CH, Frikstad KM, Hole KH, Seierstad T, Lyng H.","Br J Cancer. 2015 Jan 20;112(2):382-90. doi: 10.1038/bjc.2014.604. Epub 2014 Dec 2.","Ragnum HB","Br J Cancer","2015","2014/12/03","PMC4453458","","10.1038/bjc.2014.604"
"20678073","Tubulin-independent tau in Alzheimer's disease and cancer: implications for disease pathogenesis and treatment","Souter S, Lee G.","Curr Alzheimer Res. 2010 Dec;7(8):697-707. doi: 10.2174/156720510793611637.","Souter S","Curr Alzheimer Res","2010","2010/08/04","","","10.2174/156720510793611637"
"30945473","Impact of serious mental illness on the treatment and mortality of older patients with locoregional high-grade (nonmetastatic) prostate cancer: retrospective cohort analysis of 49 985 SEER-Medicare patients diagnosed between 2006 and 2013","Fried DA, Sadeghi-Nejad H, Gu D, Zhou S, He W, Giordano SH, Pentakota SR, Demissie K, Helmer D, Shen C.","Cancer Med. 2019 May;8(5):2612-2622. doi: 10.1002/cam4.2109. Epub 2019 Apr 3.","Fried DA","Cancer Med","2019","2019/04/05","PMC6536920","","10.1002/cam4.2109"
"12839927","Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study","Bettuzzi S, Scaltriti M, Caporali A, Brausi M, D'Arca D, Astancolle S, Davalli P, Corti A.","Cancer Res. 2003 Jul 1;63(13):3469-72.","Bettuzzi S","Cancer Res","2003","2003/07/04","","",""
"28100434","MNX1: a novel prostate cancer oncogene","Das M.","Lancet Oncol. 2016 Dec;17(12):e521. doi: 10.1016/S1470-2045(16)30553-8. Epub 2016 Oct 27.","Das M","Lancet Oncol","2016","2017/01/20","","","10.1016/S1470-2045(16)30553-8"
"22846379","Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy","Lee CE, Kilgour A, Lau YK.","BMC Cancer. 2012 Jul 30;12:324. doi: 10.1186/1471-2407-12-324.","Lee CE","BMC Cancer","2012","2012/08/01","PMC3517385","","10.1186/1471-2407-12-324"
"24050482","Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application","Wang Z, Fan J, Liu M, Yeung S, Chang A, Chow MS, Pon D, Huang Y.","Expert Opin Investig Drugs. 2013 Dec;22(12):1613-26. doi: 10.1517/13543784.2013.833183. Epub 2013 Sep 19.","Wang Z","Expert Opin Investig Drugs","2013","2013/09/21","","","10.1517/13543784.2013.833183"
"3672676","Experience with Gleason histopathologic grading of prostatic cancer in Japan","Nemoto R, Uchida K, Harada M, Koiso K, Abe R, Kato T.","Urology. 1987 Nov;30(5):436-40. doi: 10.1016/0090-4295(87)90374-8.","Nemoto R","Urology","1987","1987/11/01","","","10.1016/0090-4295(87)90374-8"
"25118646","Overexpression of oxidored-nitro domain containing protein 1 induces growth inhibition and apoptosis in human prostate cancer PC3 cells","Shan Z, Hou Q, Zhang N, Guo L, Zhang X, Ma Y, Zhou Y.","Oncol Rep. 2014 Nov;32(5):1939-46. doi: 10.3892/or.2014.3407. Epub 2014 Aug 14.","Shan Z","Oncol Rep","2014","2014/08/15","","","10.3892/or.2014.3407"
"26337241","Improvement in survival and quality of life with new therapeutic agents in metastatic castration-resistant prostate cancer: comparison among the results","Recine F, Ceresoli GL, Baciarello G, Cerbone L, Calabrò F.","Q J Nucl Med Mol Imaging. 2015 Dec;59(4):400-10. Epub 2015 Sep 3.","Recine F","Q J Nucl Med Mol Imaging","2015","2015/09/05","","",""
"16077071","Prostate-specific antigen levels in the United States: implications of various definitions for abnormal","Welch HG, Schwartz LM, Woloshin S.","J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7. doi: 10.1093/jnci/dji205.","Welch HG","J Natl Cancer Inst","2005","2005/08/04","","","10.1093/jnci/dji205"
"21663529","New therapies for castrate-resistant prostate cancer","Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK, Pal SK.","Expert Opin Pharmacother. 2011 Sep;12(13):2069-74. doi: 10.1517/14656566.2011.590133. Epub 2011 Jun 11.","Williams SB","Expert Opin Pharmacother","2011","2011/06/14","","","10.1517/14656566.2011.590133"
"17479239","[Optimized standards for prostate biopsy]","Wullich B, Füssel S, Grobholz R.","Urologe A. 2007 Jun;46(6):675-82; quiz 682-4. doi: 10.1007/s00120-007-1359-9.","Wullich B","Urologe A","2007","2007/05/05","","","10.1007/s00120-007-1359-9"
"11089719","Early detection and aggressive treatment of prostate cancer: groping in the dark","Barry MJ.","J Gen Intern Med. 2000 Oct;15(10):749-51. doi: 10.1046/j.1525-1497.2000.00816.x.","Barry MJ","J Gen Intern Med","2000","2000/11/23","PMC1495598","","10.1046/j.1525-1497.2000.00816.x"
"30848157","Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer","Sternberg CN.","Future Oncol. 2019 May;15(13):1437-1457. doi: 10.2217/fon-2018-0940. Epub 2019 Mar 8.","Sternberg CN","Future Oncol","2019","2019/03/09","","","10.2217/fon-2018-0940"
"28570099","Accuracy and Interobserver Agreement for Prostate Imaging Reporting and Data System, Version 2, for the Characterization of Lesions Identified on Multiparametric MRI of the Prostate","Purysko AS, Bittencourt LK, Bullen JA, Mostardeiro TR, Herts BR, Klein EA.","AJR Am J Roentgenol. 2017 Aug;209(2):339-349. doi: 10.2214/AJR.16.17289. Epub 2017 Jun 1.","Purysko AS","AJR Am J Roentgenol","2017","2017/06/02","","","10.2214/AJR.16.17289"
"23482794","Efficacy of androgen deprivation therapy for localized prostate cancer: analysis of pT0 evaluated by radical prostatectomy specimen","Kadono Y, Yaegashi H, Izumi K, Ueno S, Kitagawa Y, Mizokami A, Asahi H, Kobashi K, Koshida K, Namiki M.","Anticancer Res. 2013 Mar;33(3):1147-51.","Kadono Y","Anticancer Res","2013","2013/03/14","","",""
"28823634","Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway","Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD.","Urology. 2017 Dec;110:140-147. doi: 10.1016/j.urology.2017.07.048. Epub 2017 Aug 18.","Aas K","Urology","2017","2017/08/22","","","10.1016/j.urology.2017.07.048"
"7527294","Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays","Israeli RS, Miller WH Jr, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, et al.","Cancer Res. 1994 Dec 15;54(24):6306-10.","Israeli RS","Cancer Res","1994","1994/12/15","","",""
"15368469","Lesions predictive for prostate cancer in a screened population: first and second screening round findings","Postma R, Roobol M, Schröder FH, van der Kwast TH.","Prostate. 2004 Nov 1;61(3):260-6. doi: 10.1002/pros.20105.","Postma R","Prostate","2004","2004/09/16","","","10.1002/pros.20105"
"12599566","[Treatment strategy for prostate cancer]","Kakehi Y.","Nihon Rinsho. 2002 Dec;60 Suppl 11:170-6.","Kakehi Y","Nihon Rinsho","2002","2003/02/26","","",""
"22755703","What do we know about the α/β for prostate cancer?","Oliveira SM, Teixeira NJ, Fernandes L.","Med Phys. 2012 Jun;39(6):3189-201. doi: 10.1118/1.4712224.","Oliveira SM","Med Phys","2012","2012/07/05","","","10.1118/1.4712224"
"11326171","The evolving role of prostate brachytherapy","Beyer DC.","Cancer Control. 2001 Mar-Apr;8(2):163-70. doi: 10.1177/107327480100800207.","Beyer DC","Cancer Control","2001","2001/04/28","","","10.1177/107327480100800207"
"23208302","Prostate cancer: Diabetes and prostate cancer--an open debate","De Nunzio C, Tubaro A.","Nat Rev Urol. 2013 Jan;10(1):12-4. doi: 10.1038/nrurol.2012.239. Epub 2012 Dec 4.","De Nunzio C","Nat Rev Urol","2013","2012/12/05","","","10.1038/nrurol.2012.239"
"8717461","Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against","Fitzpatrick JM.","Eur Urol. 1996;29 Suppl 2:37-9. doi: 10.1159/000473837.","Fitzpatrick JM","Eur Urol","1996","1996/01/01","","","10.1159/000473837"
"15705868","Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness","Ghosh A, Wang X, Klein E, Heston WD.","Cancer Res. 2005 Feb 1;65(3):727-31.","Ghosh A","Cancer Res","2005","2005/02/12","","",""
"16158078","Hypertriglyceridemia as a possible risk factor for prostate cancer","Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, Thomas G, Krek W, Cerny T, Gillessen S.","Prostate Cancer Prostatic Dis. 2005;8(4):316-20. doi: 10.1038/sj.pcan.4500834.","Wuermli L","Prostate Cancer Prostatic Dis","2005","2005/09/15","","","10.1038/sj.pcan.4500834"
"28481440","Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance","Tosoian JJ, Chappidi MR, Bishoff JT, Freedland SJ, Reid J, Brawer M, Stone S, Schlomm T, Ross AE.","BJU Int. 2017 Dec;120(6):808-814. doi: 10.1111/bju.13911. Epub 2017 Jun 11.","Tosoian JJ","BJU Int","2017","2017/05/09","","","10.1111/bju.13911"
"23649288","Prostate cancer: active surveillance in African American men","Moul JW.","Nat Rev Urol. 2013 Jun;10(6):311-2. doi: 10.1038/nrurol.2013.97. Epub 2013 May 7.","Moul JW","Nat Rev Urol","2013","2013/05/08","","","10.1038/nrurol.2013.97"
"12644546","Re: Serum proteomic patterns for detection of prostate cancer","Diamandis EP.","J Natl Cancer Inst. 2003 Mar 19;95(6):489-90; author reply 490-1. doi: 10.1093/jnci/95.6.489.","Diamandis EP","J Natl Cancer Inst","2003","2003/03/20","","","10.1093/jnci/95.6.489"
"23943203","Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer","McKay RR, Choueiri TK, Taplin ME.","Drugs. 2013 Sep;73(13):1417-30. doi: 10.1007/s40265-013-0107-2.","McKay RR","Drugs","2013","2013/08/15","PMC4127573","NIHMS606881","10.1007/s40265-013-0107-2"
"23223644","Diagnosis and overdiagnosis of prostate cancer: a personal view","Tam PC.","Hong Kong Med J. 2012 Dec;18(6):456-8.","Tam PC","Hong Kong Med J","2012","2012/12/11","","",""
"21768329","Prioritizing candidate disease miRNAs by topological features in the miRNA target-dysregulated network: case study of prostate cancer","Xu J, Li CX, Lv JY, Li YS, Xiao Y, Shao TT, Huo X, Li X, Zou Y, Han QL, Li X, Wang LH, Ren H.","Mol Cancer Ther. 2011 Oct;10(10):1857-66. doi: 10.1158/1535-7163.MCT-11-0055. Epub 2011 Jul 18.","Xu J","Mol Cancer Ther","2011","2011/10/06","","","10.1158/1535-7163.MCT-11-0055"
"15815192","Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer","Brassell SA, Rosner IL, McLeod DG.","Curr Opin Urol. 2005 May;15(3):163-6. doi: 10.1097/01.mou.0000165549.94663.2d.","Brassell SA","Curr Opin Urol","2005","2005/04/09","","","10.1097/01.mou.0000165549.94663.2d"
"25693083","Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens","Korski K, Malicka-Durczak A, Bręborowicz J.","Pol J Pathol. 2014 Dec;65(4):291-5. doi: 10.5114/pjp.2014.48190.","Korski K","Pol J Pathol","2014","2015/02/19","","","10.5114/pjp.2014.48190"
"18544993","Hormone-refractory and metastatic prostate cancer - palliative radiotherapy","Moser L, Schubert T, Hinkelbein W.","Front Radiat Ther Oncol. 2008;41:117-125. doi: 10.1159/000139886.","Moser L","Front Radiat Ther Oncol","2008","2008/06/12","","","10.1159/000139886"
"16608523","Profiling alternatively spliced mRNA isoforms for prostate cancer classification","Zhang C, Li HR, Fan JB, Wang-Rodriguez J, Downs T, Fu XD, Zhang MQ.","BMC Bioinformatics. 2006 Apr 11;7:202. doi: 10.1186/1471-2105-7-202.","Zhang C","BMC Bioinformatics","2006","2006/04/13","PMC1458362","","10.1186/1471-2105-7-202"
"30174471","Computed Diffusion-Weighted Imaging in Prostate Cancer: Basics, Advantages, Cautions, and Future Prospects","Ueno YR, Tamada T, Takahashi S, Tanaka U, Sofue K, Kanda T, Nogami M, Ohno Y, Hinata N, Fujisawa M, Murakami T.","Korean J Radiol. 2018 Sep-Oct;19(5):832-837. doi: 10.3348/kjr.2018.19.5.832. Epub 2018 Aug 6.","Ueno YR","Korean J Radiol","2018","2018/09/04","PMC6082756","","10.3348/kjr.2018.19.5.832"
"24999475","Hypofractionation in prostate cancer: radiobiological basis and clinical appliance","Mangoni M, Desideri I, Detti B, Bonomo P, Greto D, Paiar F, Simontacchi G, Meattini I, Scoccianti S, Masoni T, Ciabatti C, Turkaj A, Serni S, Minervini A, Gacci M, Carini M, Livi L.","Biomed Res Int. 2014;2014:781340. doi: 10.1155/2014/781340. Epub 2014 Apr 30.","Mangoni M","Biomed Res Int","2014","2014/07/08","PMC4066864","","10.1155/2014/781340"
"17419567","[Prostate cancer physiopathology, diagnosis and therapy]","Geay JF.","Soins. 2007 Mar;(713):34-7.","Geay JF","Soins","2007","2007/04/11","","",""
"21587223","A decade in prostate cancer: from NMR to metabolomics","DeFeo EM, Wu CL, McDougal WS, Cheng LL.","Nat Rev Urol. 2011 May 17;8(6):301-11. doi: 10.1038/nrurol.2011.53.","DeFeo EM","Nat Rev Urol","2011","2011/05/19","","","10.1038/nrurol.2011.53"
"26420595","PREDICT: model for prediction of survival in localized prostate cancer","Kerkmeijer LG, Monninkhof EM, van Oort IM, van der Poel HG, de Meerleer G, van Vulpen M.","World J Urol. 2016 Jun;34(6):789-95. doi: 10.1007/s00345-015-1691-4. Epub 2015 Sep 29.","Kerkmeijer LG","World J Urol","2016","2015/10/01","PMC4879170","","10.1007/s00345-015-1691-4"
"21089675","[Radioiodide treatment mediated by adenovirus transfer of human sodium iodide symporter gene into androgen-independent prostate cancer]","Huang R, Ma X, Li S, Mu D, Gong R, Kuang A.","Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Oct;27(5):1080-4.","Huang R","Sheng Wu Yi Xue Gong Cheng Xue Za Zhi","2010","2010/11/25","","",""
"19716590","External validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology among Japanese patients","Imamoto T, Suzuki H, Utsumi T, Takano M, Suyama T, Kawamura K, Kamiya N, Naya Y, Ueda T, Ichikawa T.","Urology. 2010 Aug;76(2):404-10. doi: 10.1016/j.urology.2009.05.084. Epub 2009 Aug 29.","Imamoto T","Urology","2010","2009/09/01","","","10.1016/j.urology.2009.05.084"
"26045118","Doppler ultrasound measurement of resistance index in the diagnosis of prostate cancer","Huang W, Cen S, Kang XL, Wang WF, Wang Y, Chen X.","Tumori. 2015 Nov-Dec;101(6):644-9. doi: 10.5301/tj.5000309. Epub 2015 May 18.","Huang W","Tumori","2015","2015/06/06","","","10.5301/tj.5000309"
"18313115","Determinants of treatment regret in low-income, uninsured men with prostate cancer","Hu JC, Kwan L, Krupski TL, Anger JT, Maliski SL, Connor S, Litwin MS.","Urology. 2008 Dec;72(6):1274-9. doi: 10.1016/j.urology.2007.11.066. Epub 2008 Mar 3.","Hu JC","Urology","2008","2008/03/04","","","10.1016/j.urology.2007.11.066"
"19104507","Therapeutic effects of gelatin matrix-embedded IL-12 gene-modified macrophages in a mouse model of residual prostate cancer","Tabata K, Watanabe M, Naruishi K, Edamura K, Satoh T, Yang G, Abdel Fattah E, Wang J, Goltsov A, Floryk D, Soni SD, Kadmon D, Thompson TC.","Prostate Cancer Prostatic Dis. 2009;12(3):301-9. doi: 10.1038/pcan.2008.57. Epub 2008 Dec 23.","Tabata K","Prostate Cancer Prostatic Dis","2009","2008/12/24","","","10.1038/pcan.2008.57"
"12837837","Zinc supplement use and risk of prostate cancer","Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL.","J Natl Cancer Inst. 2003 Jul 2;95(13):1004-7. doi: 10.1093/jnci/95.13.1004.","Leitzmann MF","J Natl Cancer Inst","2003","2003/07/03","","","10.1093/jnci/95.13.1004"
"16783816","Patterns of care for men with prostate cancer after failure of primary treatment","Krupski TL, Saigal CS, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.","Cancer. 2006 Jul 15;107(2):258-65. doi: 10.1002/cncr.21981.","Krupski TL","Cancer","2006","2006/06/20","","","10.1002/cncr.21981"
"29644451","Emerging Therapies in Metastatic Prostate Cancer","Sonnenburg DW, Morgans AK.","Curr Oncol Rep. 2018 Apr 11;20(6):46. doi: 10.1007/s11912-018-0692-z.","Sonnenburg DW","Curr Oncol Rep","2018","2018/04/13","","","10.1007/s11912-018-0692-z"
"23403776","Variability over time-since- diagnosis in the protective effect of psychological resilience against depression in Australian prostate cancer patients: implications for patient treatment models","Sharpley CF, Wootten AC, Bitsika V, Christie DR.","Am J Mens Health. 2013 Sep;7(5):414-22. doi: 10.1177/1557988313477126. Epub 2013 Feb 11.","Sharpley CF","Am J Mens Health","2013","2013/02/14","","","10.1177/1557988313477126"
"31246685","68Ga-PSMA-617 Compared With 68Ga-RM2 and 18F-FCholine PET/CT for the Initial Staging of High-Risk Prostate Cancer","Schollhammer R, de Clermont Gallerande H, Robert G, Yacoub M, Vimont D, Hindié E, Fernandez P, Morgat C.","Clin Nucl Med. 2019 Sep;44(9):e535-e536. doi: 10.1097/RLU.0000000000002672.","Schollhammer R","Clin Nucl Med","2019","2019/06/28","","","10.1097/RLU.0000000000002672"
"27189718","Prostate cancer glands with cribriform architecture and with glomeruloid features should be considered as Gleason pattern 4 and not pattern 3","Minardi D, Mazzucchelli R, Scarpelli M, Massari F, Ciccarese C, Lopez-Beltran A, Cheng L, Montironi R.","Future Oncol. 2016 Jun;12(12):1431-3. doi: 10.2217/fon-2016-0113. Epub 2016 Mar 30.","Minardi D","Future Oncol","2016","2016/05/19","","","10.2217/fon-2016-0113"
"19498408","Prostate cancer: is PSA velocity useful?","Loeb S.","Nat Rev Urol. 2009 Jun;6(6):305-6. doi: 10.1038/nrurol.2009.93.","Loeb S","Nat Rev Urol","2009","2009/06/06","","","10.1038/nrurol.2009.93"
"24272204","The prognostic value of Smad4 mRNA in patients with prostate cancer","Zhang DT, Shi JG, Liu Y, Jiang HM.","Tumour Biol. 2014 Apr;35(4):3333-7. doi: 10.1007/s13277-013-1439-y. Epub 2013 Nov 24.","Zhang DT","Tumour Biol","2014","2013/11/26","","","10.1007/s13277-013-1439-y"
"23131672","Adding age and genetic risk to PSA test could improve screening for prostate cancer","Kmietowicz Z.","BMJ. 2012 Nov 6;345:e7467. doi: 10.1136/bmj.e7467.","Kmietowicz Z","BMJ","2012","2012/11/08","","","10.1136/bmj.e7467"
"9443646","Detection of circulating prostatic cells during radical prostatectomy","Planz B, Szyska P, Valdor M, Boeckmann W, Füzesi L, Jakse G.","Urol Res. 1997;25(6):385-9. doi: 10.1007/BF01268852.","Planz B","Urol Res","1997","1997/01/01","","","10.1007/BF01268852"
"19509351","Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis","Cooperberg MR, Broering JM, Carroll PR.","J Natl Cancer Inst. 2009 Jun 16;101(12):878-87. doi: 10.1093/jnci/djp122. Epub 2009 Jun 9.","Cooperberg MR","J Natl Cancer Inst","2009","2009/06/11","PMC2697208","","10.1093/jnci/djp122"
"30030344","Oligometastatic Prostate Cancer: Molecular Imaging and Clinical Management Implications in the Era of Precision Oncology","Jadvar H.","J Nucl Med. 2018 Sep;59(9):1338-1339. doi: 10.2967/jnumed.118.213470. Epub 2018 Jul 20.","Jadvar H","J Nucl Med","2018","2018/07/22","PMC6126444","","10.2967/jnumed.118.213470"
"30021484","The Ability of Prostate Health Index (PHI) to Predict Gleason Score in Patients With Prostate Cancer and Discriminate Patients Between Gleason Score 6 and Gleason Score Higher Than 6-A Study on 320 Patients After Radical Prostatectomy","Dolejsova O, Kucera R, Fuchsova R, Topolcan O, Svobodova H, Hes O, Eret V, Pecen L, Hora M.","Technol Cancer Res Treat. 2018 Jan 1;17:1533033818787377. doi: 10.1177/1533033818787377.","Dolejsova O","Technol Cancer Res Treat","2018","2018/07/20","PMC6052498","","10.1177/1533033818787377"
"12210490","Does amount or type of alcohol influence the risk of prostate cancer?","Albertsen K, Grønbaek M.","Prostate. 2002 Sep 1;52(4):297-304. doi: 10.1002/pros.10120.","Albertsen K","Prostate","2002","2002/09/05","","","10.1002/pros.10120"
"8685348","Quantitating regrowth delay of prostate cancers after failure of radiation therapy","Hood-Hanks S, Hanlon AL, Hanks GE.","Radiology. 1996 Aug;200(2):505-8. doi: 10.1148/radiology.200.2.8685348.","Hood-Hanks S","Radiology","1996","1996/08/01","","","10.1148/radiology.200.2.8685348"
"15389782","Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis","Gustavsson H, Welén K, Damber JE.","Prostate. 2005 Mar 1;62(4):364-73. doi: 10.1002/pros.20145.","Gustavsson H","Prostate","2005","2004/09/25","","","10.1002/pros.20145"
"18304396","The worldwide epidemiology of prostate cancer: perspectives from autopsy studies","Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G.","Can J Urol. 2008 Feb;15(1):3866-71.","Haas GP","Can J Urol","2008","2008/02/29","PMC2706483","NIHMS95269",""
"27226508","Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management","Mohler JL.","J Natl Compr Canc Netw. 2016 May;14(5 Suppl):663-5. doi: 10.6004/jnccn.2016.0186.","Mohler JL","J Natl Compr Canc Netw","2016","2016/05/27","","","10.6004/jnccn.2016.0186"
"19342958","Novel secondary hormonal therapy in advanced prostate cancer: an update","Van Allen EM, Ryan CJ.","Curr Opin Urol. 2009 May;19(3):315-21. doi: 10.1097/MOU.0b013e328329b73a.","Van Allen EM","Curr Opin Urol","2009","2009/04/04","","","10.1097/MOU.0b013e328329b73a"
"8801795","[Non-palpable prostatic cancer. Cure with adenomectomy?]","Cambronero Santos J, Carrero López V, Ortiz Vico FJ, Calahorra Fernández L, Rodríguez Antolín A, Passas Martínez J, Leiva Galvis O.","Actas Urol Esp. 1996 Apr;20(4):346-50.","Cambronero Santos J","Actas Urol Esp","1996","1996/04/01","","",""
"27007485","Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes","Storstein A, Raspotnig M, Vitaliani R, Giometto B, Graus F, Grisold W, Honnorat J, Vedeler CA.","J Neurol. 2016 May;263(5):1001-1007. doi: 10.1007/s00415-016-8090-7. Epub 2016 Mar 23.","Storstein A","J Neurol","2016","2016/03/24","","","10.1007/s00415-016-8090-7"
"14693731","Body size and composition and prostate cancer risk","MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG.","Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1417-21.","MacInnis RJ","Cancer Epidemiol Biomarkers Prev","2003","2003/12/25","","",""
"26549591","Personalising the treatment of prostate cancer","Gunjur A.","Lancet Oncol. 2015 Dec;16(16):e592. doi: 10.1016/S1470-2045(15)00474-X. Epub 2015 Nov 6.","Gunjur A","Lancet Oncol","2015","2015/11/10","","","10.1016/S1470-2045(15)00474-X"
"8508885","The state of prostate cancer screening in the United States","Haas GP, Montie JE, Pontes JE.","Eur Urol. 1993;23(3):337-47. doi: 10.1159/000474626.","Haas GP","Eur Urol","1993","1993/01/01","","","10.1159/000474626"
"7524157","Prostate cancer: improving the therapeutic index","Scher HI.","Semin Oncol. 1994 Oct;21(5):688-93.","Scher HI","Semin Oncol","1994","1994/10/01","","",""
"16792548","Histopathological approach to prostatic contour alterations with the concept of left-right asymmetry","Kiyoshima K, Oda Y, Tamiya S, Hori Y, Yamada T, Naito S, Tsuneyoshi M.","Pathol Int. 2006 Jul;56(7):390-6. doi: 10.1111/j.1440-1827.2006.01975.x.","Kiyoshima K","Pathol Int","2006","2006/06/24","","","10.1111/j.1440-1827.2006.01975.x"
"31468158","Semi-automatic classification of prostate cancer on multi-parametric MR imaging using a multi-channel 3D convolutional neural network","Aldoj N, Lukas S, Dewey M, Penzkofer T.","Eur Radiol. 2020 Feb;30(2):1243-1253. doi: 10.1007/s00330-019-06417-z. Epub 2019 Aug 29.","Aldoj N","Eur Radiol","2020","2019/08/31","","","10.1007/s00330-019-06417-z"
"26060265","ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer","Berg KD, Brasso K, Thomsen FB, Røder MA, Holten-Rossing H, Toft BG, Iversen P, Vainer B.","J Clin Pathol. 2015 Oct;68(10):788-94. doi: 10.1136/jclinpath-2015-202894. Epub 2015 Jun 9.","Berg KD","J Clin Pathol","2015","2015/06/11","","","10.1136/jclinpath-2015-202894"
"22103653","Population screening for prostate cancer: an overview of available studies and meta-analysis","Lumen N, Fonteyne V, De Meerleert G, Ost P, Villeirs G, Mottrie A, De Visschere P, De Troyer B, Oosterlinck W.","Int J Urol. 2012 Feb;19(2):100-8. doi: 10.1111/j.1442-2042.2011.02912.x. Epub 2011 Nov 22.","Lumen N","Int J Urol","2012","2011/11/23","","","10.1111/j.1442-2042.2011.02912.x"
"12605962","Biochemical failure after definitive therapy of prostate cancer: defining the chicken switch","Johnstone PA.","Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):859-60. doi: 10.1016/s0360-3016(02)04214-1.","Johnstone PA","Int J Radiat Oncol Biol Phys","2003","2003/02/28","","","10.1016/s0360-3016(02)04214-1"
"20923031","Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?","Fang LC, Merrick GS, Wallner KE.","Oncology (Williston Park). 2010 Aug;24(9):790-6, 798.","Fang LC","Oncology (Williston Park)","2010","2010/10/07","","",""
"12740495","Prognostic implication of microvascular invasion in biochemical failure in patients treated with radical prostatectomy","Ito K, Nakashima J, Mukai M, Asakura H, Ohigashi T, Saito S, Tachibana M, Hata J, Murai M.","Urol Int. 2003;70(4):297-302. doi: 10.1159/000070139.","Ito K","Urol Int","2003","2003/05/13","","","10.1159/000070139"
"25444987","Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer","Koo KC, Yoo H, Kim KH, Park SU, Han KS, Rha KH, Hong SJ, Yang SC, Chung BH.","J Urol. 2015 Apr;193(4):1239-44. doi: 10.1016/j.juro.2014.10.088. Epub 2014 Oct 23.","Koo KC","J Urol","2015","2014/12/03","","","10.1016/j.juro.2014.10.088"
"25059922","Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses","Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N.","Clin Oncol (R Coll Radiol). 2014 Oct;26(10):e21-46. doi: 10.1016/j.clon.2014.06.016. Epub 2014 Jul 21.","Schmidt-Hansen M","Clin Oncol (R Coll Radiol)","2014","2014/07/26","","","10.1016/j.clon.2014.06.016"
"31727298","Progress in Low Dose Rate Brachytherapy for Prostate Cancer","McLaughlin PW, Narayana V.","Semin Radiat Oncol. 2020 Jan;30(1):39-48. doi: 10.1016/j.semradonc.2019.08.002.","McLaughlin PW","Semin Radiat Oncol","2020","2019/11/16","","","10.1016/j.semradonc.2019.08.002"
"6512929","Early detection of prostate cancer by routine screening","Chodak GW, Schoenberg HW.","JAMA. 1984 Dec 21;252(23):3261-4.","Chodak GW","JAMA","1984","1984/12/21","","",""
"17921729","Brachytherapy for the treatment of prostate cancer","Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG.","Cancer J. 2007 Sep-Oct;13(5):302-12. doi: 10.1097/PPO.0b013e318156dcbe.","Cesaretti JA","Cancer J","2007","2007/10/09","","","10.1097/PPO.0b013e318156dcbe"
"24565566","Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models in vitro and in vivo","Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, Beheshti EH, Locke J, Guns ET.","J Steroid Biochem Mol Biol. 2014 Sep;143:19-28. doi: 10.1016/j.jsbmb.2014.02.006. Epub 2014 Feb 22.","Ming DS","J Steroid Biochem Mol Biol","2014","2014/02/26","","","10.1016/j.jsbmb.2014.02.006"
"23643730","Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells","Xu H, Yu X, Qu S, Sui D.","Bioorg Med Chem Lett. 2013 Jun 15;23(12):3631-4. doi: 10.1016/j.bmcl.2013.04.007. Epub 2013 Apr 11.","Xu H","Bioorg Med Chem Lett","2013","2013/05/07","","","10.1016/j.bmcl.2013.04.007"
"11828360","Shared decision-making strategies for early prostate cancer","Wei JT, Uzzo RG.","Semin Urol Oncol. 2002 Feb;20(1):74-8. doi: 10.1053/suro.2002.30401.","Wei JT","Semin Urol Oncol","2002","2002/02/06","","","10.1053/suro.2002.30401"
"15687369","Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","Grenader T, Shavit L, Uziely B, Peretz T.","J Natl Cancer Inst. 2005 Feb 2;97(3):235-6. doi: 10.1093/jnci/dji037.","Grenader T","J Natl Cancer Inst","2005","2005/02/03","","","10.1093/jnci/dji037"
"21154740","Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden","Jonsson H, Holmström B, Duffy SW, Stattin P.","Int J Cancer. 2011 Oct 15;129(8):1881-8. doi: 10.1002/ijc.25846. Epub 2011 Mar 25.","Jonsson H","Int J Cancer","2011","2010/12/15","","","10.1002/ijc.25846"
"11930866","Use of PSA measurement in practice","Goolsby MJ.","J Am Acad Nurse Pract. 2001 Jun;13(6):246-8. doi: 10.1111/j.1745-7599.2001.tb00029.x.","Goolsby MJ","J Am Acad Nurse Pract","2001","2002/04/05","","","10.1111/j.1745-7599.2001.tb00029.x"
"10394648","[Results of a screening program for prostatic cancer]","Martín Oses E, Luján Galán M, Sánchez Sánchez E, Herrero Payo A, Páez Borda A, Berenguer Sánchez A.","Actas Urol Esp. 1999 Apr;23(4):287-95.","Martín Oses E","Actas Urol Esp","1999","1999/07/08","","",""
"12664062","High-grade intra-epithelial neoplasia and prostate cancer in Dibombari, Cameroon","Angwafo FF 3rd, Zaher A, Befidi-Mengue R, Wonkam A, Takougang I, Powell I, Murphy G; National Health Survey Team for The National Epidemiology Board of Cameroon.","Prostate Cancer Prostatic Dis. 2003;6(1):34-8. doi: 10.1038/sj.pcan.4500587.","Angwafo FF 3rd","Prostate Cancer Prostatic Dis","2003","2003/03/29","","","10.1038/sj.pcan.4500587"
"16631459","Advancing prostate cancer: treatment options for the urologist","Lowrance WT, Chang SS.","Urol Clin North Am. 2006 May;33(2):211-7, vii. doi: 10.1016/j.ucl.2005.12.003.","Lowrance WT","Urol Clin North Am","2006","2006/04/25","","","10.1016/j.ucl.2005.12.003"
"25560926","Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience","Ong WL, Weerakoon M, Huang S, Paul E, Lawrentschuk N, Frydenberg M, Moon D, Murphy D, Grummet J.","BJU Int. 2015 Oct;116(4):568-76. doi: 10.1111/bju.13031. Epub 2015 Apr 6.","Ong WL","BJU Int","2015","2015/01/07","","","10.1111/bju.13031"
"8911508","Epidemiology of prostate cancer: molecular and environmental clues","Pienta KJ, Goodson JA, Esper PS.","Urology. 1996 Nov;48(5):676-83. doi: 10.1016/S0090-4295(96)00219-1.","Pienta KJ","Urology","1996","1996/11/01","","","10.1016/S0090-4295(96)00219-1"
"7475655","Is prostate cancer worth diagnosing?","Waxman J, Sheer D.","Lancet. 1995 Nov 4;346(8984):1177-8. doi: 10.1016/s0140-6736(95)92895-2.","Waxman J","Lancet","1995","1995/11/04","","","10.1016/s0140-6736(95)92895-2"
"27152744","Disorder, Promiscuous Interactions, and Stochasticity Regulate State Switching in the Unstable Prostate","Kulkarni P, Getzenberg RH.","J Cell Biochem. 2016 Oct;117(10):2235-40. doi: 10.1002/jcb.25578. Epub 2016 Jun 3.","Kulkarni P","J Cell Biochem","2016","2016/05/07","","","10.1002/jcb.25578"
"24297455","Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida","Xiao H, Tan F, Goovaerts P, Ali A, Adunlin G, Gwede CK, Huang Y.","Am J Mens Health. 2014 Jul;8(4):316-26. doi: 10.1177/1557988313512862. Epub 2013 Dec 1.","Xiao H","Am J Mens Health","2014","2013/12/04","PMC4040343","NIHMS548940","10.1177/1557988313512862"
"20464780","Recent advances in understanding hormonal therapy resistant prostate cancer","Donkena KV, Yuan H, Young CY.","Curr Cancer Drug Targets. 2010 Jun;10(4):402-10. doi: 10.2174/156800910791208544.","Donkena KV","Curr Cancer Drug Targets","2010","2010/05/14","","","10.2174/156800910791208544"
"15963238","Evidence-based patient choice: a prostate cancer decision aid in plain language","Holmes-Rovner M, Stableford S, Fagerlin A, Wei JT, Dunn RL, Ohene-Frempong J, Kelly-Blake K, Rovner DR.","BMC Med Inform Decis Mak. 2005 Jun 20;5:16. doi: 10.1186/1472-6947-5-16.","Holmes-Rovner M","BMC Med Inform Decis Mak","2005","2005/06/21","PMC1168900","","10.1186/1472-6947-5-16"
"29490658","The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","Gnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A.","BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5.","Gnanapragasam VJ","BMC Med","2018","2018/03/02","PMC5831573","","10.1186/s12916-018-1019-5"
"24005860","Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts","Zins K, Thomas A, Lucas T, Sioud M, Aharinejad S, Abraham D.","Int J Mol Sci. 2013 Sep 3;14(9):17958-71. doi: 10.3390/ijms140917958.","Zins K","Int J Mol Sci","2013","2013/09/06","PMC3794762","","10.3390/ijms140917958"
"24266821","EN2: a novel prostate cancer biomarker","McGrath SE, Michael A, Morgan R, Pandha H.","Biomark Med. 2013 Dec;7(6):893-901. doi: 10.2217/bmm.13.115.","McGrath SE","Biomark Med","2013","2013/11/26","","","10.2217/bmm.13.115"
"25427700","A synthesis of clinical recommendations and primary research for survivors of prostate or breast cancer","Sandoval M, Wenzel J, Jones R.","Clin J Oncol Nurs. 2014 Dec;18(6):667-73. doi: 10.1188/14.CJON.667-673.","Sandoval M","Clin J Oncol Nurs","2014","2014/11/28","PMC4332822","NIHMS660621","10.1188/14.CJON.667-673"
"24074916","High-risk prostate cancer in the modern era: does a single standard of care exist?","Ciezki JP.","Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):440-2. doi: 10.1016/j.ijrobp.2013.06.006.","Ciezki JP","Int J Radiat Oncol Biol Phys","2013","2013/10/01","","","10.1016/j.ijrobp.2013.06.006"
"23160610","[The results of the European randomized study of screening for prostate cancer (ERSPC) 2012: confirmation or disappointment?]","Schaefer C, Weissbach L.","Urologe A. 2012 Dec;51(12):1751-3; discussion 1753-8. doi: 10.1007/s00120-012-3058-4.","Schaefer C","Urologe A","2012","2012/11/20","","","10.1007/s00120-012-3058-4"
"30610806","Aspirin use improves the biochemical control of prostate cancer in Chinese men","Hao Q, Gong H, Zong H, Huang S, Wang T, Zhou Y, Zhang Y, Zhang Y.","J BUON. 2018 Nov-Dec;23(6):1803-1808.","Hao Q","J BUON","2018","2019/01/06","","",""
"11454671","Amplification of urokinase gene in prostate cancer","Helenius MA, Saramäki OR, Linja MJ, Tammela TL, Visakorpi T.","Cancer Res. 2001 Jul 15;61(14):5340-4.","Helenius MA","Cancer Res","2001","2001/07/17","","",""
"32453086","Metastatic Parathyroid Hormone-Secreting Prostate Adenocarcinoma Mimicking Ectopic Parathyroid Adenoma Demonstrated on 99mTc-MIBI Image","Chen YH, Hsu YH, Chen HT, Chang BS, Liu SH.","Clin Nucl Med. 2020 Jul;45(7):555-556. doi: 10.1097/RLU.0000000000003064.","Chen YH","Clin Nucl Med","2020","2020/05/27","","","10.1097/RLU.0000000000003064"
"26758517","Words of Wisdom. Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer","Gandaglia G, Briganti A, Montorsi F.","Eur Urol. 2016 Feb;69(2):370. doi: 10.1016/j.eururo.2015.10.059.","Gandaglia G","Eur Urol","2016","2016/01/14","","","10.1016/j.eururo.2015.10.059"
"20073578","Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer","Sciarra A, Panebianco V, Ciccariello M, Salciccia S, Lisi D, Osimani M, Alfarone A, Gentilucci A, Parente U, Passariello R, Gentile V.","Cancer Invest. 2010 May;28(4):424-32. doi: 10.3109/07357900903287048.","Sciarra A","Cancer Invest","2010","2010/01/16","","","10.3109/07357900903287048"
"15255168","Contemporary management of prostate cancer with lethal potential","Davis JW, Shaves ME, Schellhammer PF.","Oncology (Williston Park). 2004 Jun;18(7):811-20; discussion 820-4, 829-32.","Davis JW","Oncology (Williston Park)","2004","2004/07/17","","",""
"18304458","Comparisons of the incidence and pathological characteristics of prostate cancer between Chinese and Portuguese in Macau","Ian LH, Li H, Yang Y, Ho CF.","Chin Med J (Engl). 2008 Feb 20;121(4):292-4.","Ian LH","Chin Med J (Engl)","2008","2008/02/29","","",""
"2691973","[Cancer of the prostate]","Teillac P.","Pathol Biol (Paris). 1989 Nov;37(9):1071.","Teillac P","Pathol Biol (Paris)","1989","1989/11/01","","",""
"17363883","Prostate cancer telephone helpline: nursing from a different perspective","Ross T.","Br J Nurs. 2007 Feb 8-21;16(3):161-5. doi: 10.12968/bjon.2007.16.3.22970.","Ross T","Br J Nurs","2007","2007/03/17","","","10.12968/bjon.2007.16.3.22970"
"10737490","Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin","Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H.","J Urol. 2000 Apr;163(4):1178-82.","Leibovich BC","J Urol","2000","2000/03/29","","",""
"28674394","Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression","Chen Y, Zhang Q, Wang Q, Li J, Sipeky C, Xia J, Gao P, Hu Y, Zhang H, Yang X, Chen H, Jiang Y, Yang Y, Yao Z, Chen Y, Gao Y, Tan A, Liao M, Schleutker J, Xu J, Sun Y, Wei GH, Mo Z.","Sci Rep. 2017 Jul 3;7(1):4538. doi: 10.1038/s41598-017-04731-4.","Chen Y","Sci Rep","2017","2017/07/05","PMC5495790","","10.1038/s41598-017-04731-4"
"30366021","Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen","Li-Sheng Chen S, Ching-Yuan Fann J, Sipeky C, Yang TK, Yueh-Hsia Chiu S, Ming-Fang Yen A, Laitinen V, Tammela TLJ, Stenman UH, Auvinen A, Schleutker J, Chen HH.","J Urol. 2019 Mar;201(3):486-495. doi: 10.1016/j.juro.2018.10.015.","Li-Sheng Chen S","J Urol","2019","2018/10/27","","","10.1016/j.juro.2018.10.015"
"15354922","Prostate cancer recurrence fear: the prostate-specific antigen bounce","Balmer LL, Greco KE.","Clin J Oncol Nurs. 2004 Aug;8(4):361-6. doi: 10.1188/04.CJON.361-366.","Balmer LL","Clin J Oncol Nurs","2004","2004/09/10","","","10.1188/04.CJON.361-366"
"19211454","Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial","Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM.","J Natl Cancer Inst. 2009 Feb 18;101(4):228-36. doi: 10.1093/jnci/djn489. Epub 2009 Feb 10.","Ray ME","J Natl Cancer Inst","2009","2009/02/13","PMC2734115","","10.1093/jnci/djn489"
"24440475","Complications from treatment of localised prostate cancer","Eble MJ.","Lancet Oncol. 2014 Feb;15(2):134-5. doi: 10.1016/S1470-2045(14)70015-4. Epub 2014 Jan 17.","Eble MJ","Lancet Oncol","2014","2014/01/21","","","10.1016/S1470-2045(14)70015-4"
"10592495","Brachytherapy for prostate cancer","Wirth MP, Hakenberg OW.","Urol Int. 1999;63(2):87-91. doi: 10.1159/000030424.","Wirth MP","Urol Int","1999","1999/12/11","","","10.1159/000030424"
"28256901","Diagnosis of typical and atypical transition zone prostate cancer and its mimics at multiparametric prostate MRI","Yu J, Fulcher AS, Winks SG, Turner MA, Clayton RD, Brooks M, Li S.","Br J Radiol. 2017 May;90(1073):20160693. doi: 10.1259/bjr.20160693. Epub 2017 Mar 29.","Yu J","Br J Radiol","2017","2017/03/04","PMC5605102","","10.1259/bjr.20160693"
"7495109","Should we treat localized prostate cancer? An opinion","Menon M, Parulkar BG, Baker S.","Urology. 1995 Nov;46(5):607-16. doi: 10.1016/S0090-4295(99)80289-1.","Menon M","Urology","1995","1995/11/01","","","10.1016/S0090-4295(99)80289-1"
"26954419","Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer","Voog JC, Smith MR, Efstathiou JA.","JAMA. 2016 Mar 8;315(10):1054-5. doi: 10.1001/jama.2015.17567.","Voog JC","JAMA","2016","2016/03/09","","","10.1001/jama.2015.17567"
"15183545","Comorbidity assessment in localized prostate cancer: a review of currently available techniques","Singh R, O'Brien TS.","Eur Urol. 2004 Jul;46(1):28-41; discussion 41. doi: 10.1016/j.eururo.2004.01.010.","Singh R","Eur Urol","2004","2004/06/09","","","10.1016/j.eururo.2004.01.010"
"30007819","Metabolic Biosynthesis Pathways Identified from Fecal Microbiome Associated with Prostate Cancer","Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D, Shah DP.","Eur Urol. 2018 Nov;74(5):575-582. doi: 10.1016/j.eururo.2018.06.033. Epub 2018 Jul 12.","Liss MA","Eur Urol","2018","2018/07/16","PMC6716160","NIHMS1028304","10.1016/j.eururo.2018.06.033"
"18501497","Molecular cancer phenotype in normal prostate tissue","Schlomm T, Hellwinkel OJ, Buness A, Ruschhaupt M, Lübke AM, Chun FK, Simon R, Budäus L, Erbersdobler A, Graefen M, Huland H, Poustka A, Sültmann H.","Eur Urol. 2009 Apr;55(4):885-90. doi: 10.1016/j.eururo.2008.04.105. Epub 2008 May 16.","Schlomm T","Eur Urol","2009","2008/05/27","","","10.1016/j.eururo.2008.04.105"
"20495366","Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer","Gao R, Price DK, Dahut WL, Reed E, Figg WD.","Cancer Biol Ther. 2010 Jul 1;10(1):13-8. doi: 10.4161/cbt.10.1.12172.","Gao R","Cancer Biol Ther","2010","2010/05/25","PMC3040830","","10.4161/cbt.10.1.12172"
"25314954","Magnetic resonance imaging-directed transperineal limited-mapping prostatic biopsies to diagnose prostate cancer: a Scottish experience","Mukherjee A, Morton S, Fraser S, Salmond J, Baxter G, Leung HY.","Scott Med J. 2014 Nov;59(4):204-8. doi: 10.1177/0036933014556197. Epub 2014 Oct 14.","Mukherjee A","Scott Med J","2014","2014/10/16","","","10.1177/0036933014556197"
"8515632","[Sequential estrogen and radiation therapy for stage C prostate cancer]","Tachibana Y, Kawai T, Kobayashi T, Yamauchi T, Aizawa T.","Nihon Hinyokika Gakkai Zasshi. 1993 Mar;84(3):463-8. doi: 10.5980/jpnjurol1989.84.463.","Tachibana Y","Nihon Hinyokika Gakkai Zasshi","1993","1993/03/01","","","10.5980/jpnjurol1989.84.463"
"17125469","Prostate-specific antigen kinetics and the diagnosis and management of prostate cancer","Goldstraw MA, Fitzpatrick JM, Kirby RS.","BJU Int. 2006 Dec;98(6):1141-2. doi: 10.1111/j.1464-410X.2006.06572.x.","Goldstraw MA","BJU Int","2006","2006/11/28","","","10.1111/j.1464-410X.2006.06572.x"
"30719829","Prostate cancer screening: where are we now?","Light A, Elhage O, Marconi L, Dasgupta P.","BJU Int. 2019 Jun;123(6):916-917. doi: 10.1111/bju.14692. Epub 2019 Feb 19.","Light A","BJU Int","2019","2019/02/06","","","10.1111/bju.14692"
"16238439","Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia","Howe O, O'Malley K, Lavin M, Gardner RA, Seymour C, Lyng F, Mulvin D, Quinlan DM, Mothersill C.","Radiat Res. 2005 Nov;164(5):627-34. doi: 10.1667/rr3454.1.","Howe O","Radiat Res","2005","2005/10/22","","","10.1667/rr3454.1"
"16705742","Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy","Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, Norstedt G, Bergman T, Pousette A.","Prostate. 2006 Sep 1;66(12):1235-44. doi: 10.1002/pros.20453.","Johansson B","Prostate","2006","2006/05/18","PMC7168115","","10.1002/pros.20453"
"19559381","[Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial]","Richard F.","Prog Urol. 2009 Jul;19(7):499-500. doi: 10.1016/j.purol.2009.04.011. Epub 2009 Jun 3.","Richard F","Prog Urol","2009","2009/06/30","","","10.1016/j.purol.2009.04.011"
"24555436","Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer","Tang Y, Yan W, Chen J, Luo C, Kaipia A, Shen B.","BMC Syst Biol. 2013 Oct 16;7 Suppl 3(Suppl 3):S6. doi: 10.1186/1752-0509-7-S3-S6.","Tang Y","BMC Syst Biol","2013","2014/02/22","PMC3852103","","10.1186/1752-0509-7-S3-S6"
"26388503","Gleason Score 3 + 5 or 5 + 3 versus 4 + 4 Prostate Cancer: The Risk of Death","Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV.","Eur Urol. 2016 Jun;69(6):976-9. doi: 10.1016/j.eururo.2015.08.054. Epub 2015 Sep 19.","Huynh MA","Eur Urol","2016","2015/09/22","","","10.1016/j.eururo.2015.08.054"
"14562806","Prevention of prostate cancer with finasteride","Burke HB.","N Engl J Med. 2003 Oct 16;349(16):1569-72; author reply 1569-72.","Burke HB","N Engl J Med","2003","2003/10/18","","",""
"20035976","Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology","Furusato B, Tsunoda T, Shaheduzzaman S, Nau ME, Vahey M, Petrovics G, McLeod DG, Naito S, Shirasawa S, Srivastava S, Sesterhenn IA.","Urology. 2010 Apr;75(4):768-72. doi: 10.1016/j.urology.2009.10.026. Epub 2009 Dec 29.","Furusato B","Urology","2010","2009/12/29","","","10.1016/j.urology.2009.10.026"
"18323866","Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer","Ebara S, Katayama N, Tanimoto R, Edamura K, Nose H, Manabe D, Kobayashi T, Kobayashi Y, Kobuke M, Takemoto M, Saika T, Nasu Y, Kanazawa S, Kumon H.","Acta Med Okayama. 2008 Feb;62(1):9-13.","Ebara S","Acta Med Okayama","2008","2008/03/08","","",""
"19246230","[Conformal intensity modulated radiation therapy for localized prostate cancer: Toward a new standard]","Azria D, Aillères N, Llacer Moscardo C, Hay MH, Dubois JB, Fenoglietto P.","Cancer Radiother. 2009 Sep;13(5):409-15. doi: 10.1016/j.canrad.2008.12.004. Epub 2009 Feb 25.","Azria D","Cancer Radiother","2009","2009/02/28","","","10.1016/j.canrad.2008.12.004"
"27809594","Outcomes and toxicities in patients treated with definitive focal therapy for primary prostate cancer: systematic review","Baydoun A, Traughber B, Morris N, Abi Zeid Daou M, McGraw M, Podder TK, Muzic RF Jr, Lo SS, Ponsky LE, Machtay M, Ellis R.","Future Oncol. 2017 Mar;13(7):649-663. doi: 10.2217/fon-2016-0354. Epub 2016 Nov 4.","Baydoun A","Future Oncol","2017","2016/11/05","","","10.2217/fon-2016-0354"
"26767890","Velocity and doubling time of prostate-specific antigen: mathematics can matter","Uchio E, Aslan M, Ko J, Wells CK, Radhakrishnan K, Concato J.","J Investig Med. 2016 Feb;64(2):400-4. doi: 10.1136/jim-2015-000008. Epub 2016 Jan 14.","Uchio E","J Investig Med","2016","2016/01/16","","","10.1136/jim-2015-000008"
"20816616","What is the optimal management of high risk, clinically localized prostate cancer?","Eastham JA, Evans CP, Zietman A.","Urol Oncol. 2010 Sep-Oct;28(5):557-67. doi: 10.1016/j.urolonc.2009.12.012.","Eastham JA","Urol Oncol","2010","2010/09/07","","","10.1016/j.urolonc.2009.12.012"
"20142584","Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam","Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ.","J Natl Cancer Inst. 2010 Mar 3;102(5):352-5. doi: 10.1093/jnci/djp533. Epub 2010 Feb 8.","Wever EM","J Natl Cancer Inst","2010","2010/02/10","PMC2831048","","10.1093/jnci/djp533"
"32167713","Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment","Busato WFS Júnior.","Int Braz J Urol. 2020 May-Jun;46(3):456-458. doi: 10.1590/S1677-5538.IBJU.2020.03.02.","Busato WFS Júnior","Int Braz J Urol","2020","2020/03/14","PMC7088470","","10.1590/S1677-5538.IBJU.2020.03.02"
"16528286","Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?","Slovin SF.","Nat Clin Pract Urol. 2006 Mar;3(3):138-44. doi: 10.1038/ncpuro0435.","Slovin SF","Nat Clin Pract Urol","2006","2006/03/11","","","10.1038/ncpuro0435"
"21354784","Statins and prostate cancer: molecular and clinical aspects","Papadopoulos G, Delakas D, Nakopoulou L, Kassimatis T.","Eur J Cancer. 2011 Apr;47(6):819-30. doi: 10.1016/j.ejca.2011.01.005. Epub 2011 Feb 25.","Papadopoulos G","Eur J Cancer","2011","2011/03/01","","","10.1016/j.ejca.2011.01.005"
"19183230","Implications of insulin-like growth factor-I for prostate cancer therapies","Kojima S, Inahara M, Suzuki H, Ichikawa T, Furuya Y.","Int J Urol. 2009 Feb;16(2):161-7. doi: 10.1111/j.1442-2042.2008.02224.x. Epub 2008 Dec 5.","Kojima S","Int J Urol","2009","2009/02/03","","","10.1111/j.1442-2042.2008.02224.x"
"22905844","The current role of high-intensity focused ultrasound for the management of radiation-recurrent prostate cancer","Sountoulides P, Theodosiou A, Finazzi-Agró E.","Expert Rev Med Devices. 2012 Jul;9(4):401-8. doi: 10.1586/erd.12.26.","Sountoulides P","Expert Rev Med Devices","2012","2012/08/22","","","10.1586/erd.12.26"
"9801751","Proliferation, apoptosis and cell cycle regulation in prostatic carcinogenesis","Magi-Galluzzi C, Murphy M, Cangi MG, Loda M.","Anal Quant Cytol Histol. 1998 Oct;20(5):343-50.","Magi-Galluzzi C","Anal Quant Cytol Histol","1998","1998/11/05","","",""
"26918691","Differences in survival between Māori and New Zealand Europeans with prostate cancer","Lao C, Obertová Z, Brown C, Scott N, Edlin R, Gilling P, Holmes M, Tyrie L, Lawrenson R.","Eur J Cancer Care (Engl). 2016 Mar;25(2):262-8. doi: 10.1111/ecc.12468.","Lao C","Eur J Cancer Care (Engl)","2016","2016/02/27","","","10.1111/ecc.12468"
"25185086","Toxicity of stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: a potential comparison bias","Arcangeli S, De Bari B, Alongi F.","J Clin Oncol. 2014 Oct 20;32(30):3454. doi: 10.1200/JCO.2014.56.3213. Epub 2014 Sep 2.","Arcangeli S","J Clin Oncol","2014","2014/09/04","","","10.1200/JCO.2014.56.3213"
"12661032","KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer","Chen C, Bhalala HV, Vessella RL, Dong JT.","Prostate. 2003 May 1;55(2):81-8. doi: 10.1002/pros.10205.","Chen C","Prostate","2003","2003/03/28","","","10.1002/pros.10205"
"19477898","Health-related quality of life using SF-8 and EPIC questionnaires after treatment with radical retropubic prostatectomy and permanent prostate brachytherapy","Hashine K, Kusuhara Y, Miura N, Shirato A, Sumiyoshi Y, Kataoka M.","Jpn J Clin Oncol. 2009 Aug;39(8):502-8. doi: 10.1093/jjco/hyp053. Epub 2009 May 28.","Hashine K","Jpn J Clin Oncol","2009","2009/05/30","PMC2724881","","10.1093/jjco/hyp053"
"9120951","Prostatic cutaneous fistula after radiation therapy for localized prostate cancer","Feuer-Regan A, Rosen MA.","J Urol. 1997 Apr;157(4):1367-8. doi: 10.1097/00005392-199704000-00065.","Feuer-Regan A","J Urol","1997","1997/04/01","","","10.1097/00005392-199704000-00065"
"23551391","Fruit and vegetable intake and prostate cancer risk: a meta-analysis","Meng H, Hu W, Chen Z, Shen Y.","Asia Pac J Clin Oncol. 2014 Jun;10(2):133-40. doi: 10.1111/ajco.12067. Epub 2013 Apr 1.","Meng H","Asia Pac J Clin Oncol","2014","2013/04/05","","","10.1111/ajco.12067"
"12481255","Allelic imbalance in hereditary and sporadic prostate cancer","Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA.","Prostate. 2003 Jan 1;54(1):50-7. doi: 10.1002/pros.10148.","Verhage BA","Prostate","2003","2002/12/14","","","10.1002/pros.10148"
"10222753","Value of transrectal ultrasound in preoperative staging of prostate cancer","Colombo T, Schips L, Augustin H, Gruber H, Hebel P, Petritsch PH, Hubmer G.","Minerva Urol Nefrol. 1999 Mar;51(1):1-4.","Colombo T","Minerva Urol Nefrol","1999","1999/05/01","","",""
"28286059","Mining Human Prostate Cancer Datasets: The ""camcAPP"" Shiny App","Dunning MJ, Vowler SL, Lalonde E, Ross-Adams H, Boutros P, Mills IG, Lynch AG, Lamb AD.","EBioMedicine. 2017 Mar;17:5-6. doi: 10.1016/j.ebiom.2017.02.022. Epub 2017 Mar 2.","Dunning MJ","EBioMedicine","2017","2017/03/14","PMC5360593","","10.1016/j.ebiom.2017.02.022"
"16515993","How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden","Andrén O, Fall K, Franzén L, Andersson SO, Johansson JE, Rubin MA.","J Urol. 2006 Apr;175(4):1337-40. doi: 10.1016/S0022-5347(05)00734-2.","Andrén O","J Urol","2006","2006/03/07","","","10.1016/S0022-5347(05)00734-2"
"23682478","[Radiotherapy for localized prostate cancer (with and without hormonal treatment)]","Richaud P.","Rev Prat. 2013 Apr;63(4):503-8.","Richaud P","Rev Prat","2013","2013/05/21","","",""
"32003613","Risk of Postoperative Up Staging or Upgrading among Men with Low Risk Familial Prostate Cancer","Jansson F, Folkvaljon F, Stattin P, Bratt O, Akre O.","J Urol. 2020 Jul;204(1):79-81. doi: 10.1097/JU.0000000000000793. Epub 2020 Jan 31.","Jansson F","J Urol","2020","2020/02/01","","","10.1097/JU.0000000000000793"
"11442659","M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL","Yamamoto S, Ito T, Akiyama A, Aizawa T, Miki M, Tachibana M.","Int J Urol. 2001 Jul;8(7):374-9. doi: 10.1046/j.1442-2042.2001.00316.x.","Yamamoto S","Int J Urol","2001","2001/07/10","","","10.1046/j.1442-2042.2001.00316.x"
"31042325","Modulation of miR-34a in curcumin-induced antiproliferation of prostate cancer cells","Zhu M, Zheng Z, Huang J, Ma X, Huang C, Wu R, Li X, Liang Z, Deng F, Wu J, Geng S, Xie C, Zhong C.","J Cell Biochem. 2019 Sep;120(9):15616-15624. doi: 10.1002/jcb.28828. Epub 2019 May 1.","Zhu M","J Cell Biochem","2019","2019/05/02","","","10.1002/jcb.28828"
"24965268","Prostate cancer and occupational exposure to whole-body vibration in a national population-based cohort study","Jones MK, Harris MA, Peters PA, Tjepkema M, Demers PA.","Am J Ind Med. 2014 Aug;57(8):896-905. doi: 10.1002/ajim.22354. Epub 2014 Jun 25.","Jones MK","Am J Ind Med","2014","2014/06/27","","","10.1002/ajim.22354"
"28221194","Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer: Value of Early Dynamic and Delayed Imaging","Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, Sohns JM, Geworski L, Ross TL, Wester HJ, Christiansen H, Bengel FM, Derlin T.","Clin Nucl Med. 2017 Jun;42(6):e286-e293. doi: 10.1097/RLU.0000000000001589.","Schmuck S","Clin Nucl Med","2017","2017/02/22","","","10.1097/RLU.0000000000001589"
"31437121","Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience","Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, Bakavicius A, Carneiro A, Stabile A, Moschini M, Cathala N, Tobias-Machado M, Cathelineau X.","J Urol. 2020 Feb;203(2):320-330. doi: 10.1097/JU.0000000000000506. Epub 2019 Aug 22.","Tourinho-Barbosa RR","J Urol","2020","2019/08/23","","","10.1097/JU.0000000000000506"
"30734156","Prostate cancer and subsequent nutritional outcomes: the role of diagnosis and treatment","Slade AN.","J Cancer Surviv. 2019 Apr;13(2):171-179. doi: 10.1007/s11764-019-00739-z. Epub 2019 Feb 7.","Slade AN","J Cancer Surviv","2019","2019/02/09","","","10.1007/s11764-019-00739-z"
"17302534","3rd PacRim Breast and Prostate Cancer Meeting. 31 October-4 November 2006, Fraser Island, Queensland, Australia","Fuller PJ.","Expert Opin Investig Drugs. 2007 Mar;16(3):397-401. doi: 10.1517/13543784.16.3.397.","Fuller PJ","Expert Opin Investig Drugs","2007","2007/02/17","","","10.1517/13543784.16.3.397"
"10477006","The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis","Valicenti RK, Gomella LG, Ismail M, Strup SE, Mulholland SG, Dicker AP, Petersen RO, Newschaffer CJ.","Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):53-8. doi: 10.1016/s0360-3016(99)00169-8.","Valicenti RK","Int J Radiat Oncol Biol Phys","1999","1999/09/07","","","10.1016/s0360-3016(99)00169-8"
"24641777","Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies","Cormie P, Chambers SK, Newton RU, Gardiner RA, Spry N, Taaffe DR, Joseph D, Hamid MA, Chong P, Hughes D, Hamilton K, Galvão DA.","BMC Cancer. 2014 Mar 18;14:199. doi: 10.1186/1471-2407-14-199.","Cormie P","BMC Cancer","2014","2014/03/20","PMC3995188","","10.1186/1471-2407-14-199"
"4637393","[Diagnostic investigation of prostatic cancer: biochemical and immunologic study]","Bélanger L.","Vie Med Can Fr. 1972 Feb;1(2):156-70.","Bélanger L","Vie Med Can Fr","1972","1972/02/01","","",""
"25294866","Variability in Depressive Symptoms of Cognitive Deficit and Cognitive Bias During the First 2 Years After Diagnosis in Australian Men With Prostate Cancer","Sharpley CF, Bitsika V, Christie DR.","Am J Mens Health. 2016 Jan;10(1):6-13. doi: 10.1177/1557988314552669. Epub 2014 Oct 7.","Sharpley CF","Am J Mens Health","2016","2014/10/09","","","10.1177/1557988314552669"
"29072317","Implanted fiducial markers are no longer needed for prostate cancer radiotherapy","Njeh CF, Parker BC, Orton CG.","Med Phys. 2017 Dec;44(12):6113-6116. doi: 10.1002/mp.12633. Epub 2017 Nov 15.","Njeh CF","Med Phys","2017","2017/10/27","","","10.1002/mp.12633"
"8197928","Flow cytometry in prostate cancer: histological and clinical correlation","de Leval L, Waltregny D, Greimers R, Boniver J.","Acta Urol Belg. 1994 Apr;62(1):37-43.","de Leval L","Acta Urol Belg","1994","1994/04/01","","",""
"21365346","[Prostate-specific antigen for treatment monitoring]","Graefen M, Fröhner M, Wirth M.","Urologe A. 2011 Mar;50(3):309-12. doi: 10.1007/s00120-010-2413-6.","Graefen M","Urologe A","2011","2011/03/03","","","10.1007/s00120-010-2413-6"
"23746719","Improved survival with surgery in prostate cancer patients without medical comorbidity: a self-fulfilling prophecy?","Zumsteg ZS, Zelefsky MJ.","Eur Urol. 2013 Sep;64(3):381-3. doi: 10.1016/j.eururo.2013.05.037. Epub 2013 May 28.","Zumsteg ZS","Eur Urol","2013","2013/06/11","","","10.1016/j.eururo.2013.05.037"
"9115852","Prostate cancer: to screen or not to screen?","Crawford ED.","Oncology (Williston Park). 1997 Jan;11(1):50, 55-6, 59.","Crawford ED","Oncology (Williston Park)","1997","1997/01/01","","",""
"8773495","How is individual risk for prostate cancer assessed?","Giovannucci E.","Hematol Oncol Clin North Am. 1996 Jun;10(3):537-48. doi: 10.1016/s0889-8588(05)70351-8.","Giovannucci E","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70351-8"
"1830407","Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer","Migliari R, Scarpa RM, Campus G, De Lisa A, Zucca I, D'Atri M, Serra A, Usai E.","Arch Ital Urol Nefrol Androl. 1991 Mar;63(1):147-53.","Migliari R","Arch Ital Urol Nefrol Androl","1991","1991/03/01","","",""
"28103659","[A Case of Giant Prostate Carcinoma Effectively Treated with External-Beam Radiation Therapy]","Kanda S, Narita S, Komine N, Kitajima S, Yamauchi M, Sugita A, Saito Y, Habuchi T.","Hinyokika Kiyo. 2016 Dec;62(12):647-650. doi: 10.14989/ActaUrolJap_62_12_647.","Kanda S","Hinyokika Kiyo","2016","2017/01/21","","","10.14989/ActaUrolJap_62_12_647"
"18381603","Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer","Liu L, Coker AL, Du XL, Cormier JN, Ford CE, Fang S.","J Surg Oncol. 2008 Jun 1;97(7):583-91. doi: 10.1002/jso.21028.","Liu L","J Surg Oncol","2008","2008/04/03","","","10.1002/jso.21028"
"25773837","Significant association of alpha-methylacyl-CoA racemase gene polymorphisms with susceptibility to prostate cancer: a meta-analysis","Chen N, Wang JR, Huang L, Yang Y, Jiang YM, Guo XJ, He YZ, Zhou YH.","Asian Pac J Cancer Prev. 2015;16(5):1857-63. doi: 10.7314/apjcp.2015.16.5.1857.","Chen N","Asian Pac J Cancer Prev","2015","2015/03/17","","","10.7314/apjcp.2015.16.5.1857"
"18346372","[The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men]","Li M, Na YQ.","Zhonghua Yi Xue Za Zhi. 2008 Jan 1;88(1):16-8.","Li M","Zhonghua Yi Xue Za Zhi","2008","2008/03/19","","",""
"7906001","Prostate cancer","Labrie F.","Lancet. 1994 Feb 19;343(8895):491-2. doi: 10.1016/s0140-6736(94)92747-2.","Labrie F","Lancet","1994","1994/02/19","","","10.1016/s0140-6736(94)92747-2"
"27616702","Radioligand therapy with (177)Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use","Ahmadzadehfar H, Essler M, Schäfers M, Rahbar K.","Nucl Med Biol. 2016 Dec;43(12):835. doi: 10.1016/j.nucmedbio.2016.08.003. Epub 2016 Aug 13.","Ahmadzadehfar H","Nucl Med Biol","2016","2016/09/13","","","10.1016/j.nucmedbio.2016.08.003"
"17015840","Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells","Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM, Drake CG, Isaacs JT.","Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90. doi: 10.1073/pnas.0603057103. Epub 2006 Oct 2.","Litvinov IV","Proc Natl Acad Sci U S A","2006","2006/10/04","PMC1622781","","10.1073/pnas.0603057103"
"10444791","[Lymph node positive prostate carcinoma. A case for primary hormone therapy]","Altwein JE.","Urologe A. 1999 Jul;38(4):337-43. doi: 10.1007/s001200050294.","Altwein JE","Urologe A","1999","1999/08/13","","","10.1007/s001200050294"
"8815546","125I seeds implantation plus pelvic lymphadenectomy in the management of localized prostate cancer","D'Addessi A, Racioppi M, Giustacchini M, Alcini A, Alcini E.","Minerva Urol Nefrol. 1995 Sep;47(3):105-11.","D'Addessi A","Minerva Urol Nefrol","1995","1995/09/01","","",""
"22997360","MRI-guided interventions for the treatment of prostate cancer","Bomers JG, Sedelaar JP, Barentsz JO, Fütterer JJ.","AJR Am J Roentgenol. 2012 Oct;199(4):714-20. doi: 10.2214/AJR.12.8725.","Bomers JG","AJR Am J Roentgenol","2012","2012/09/22","","","10.2214/AJR.12.8725"
"25618796","¹⁸F-fluoromethylcholine or ¹⁸F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision","Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L.","Nucl Med Biol. 2015 Apr;42(4):340-8. doi: 10.1016/j.nucmedbio.2014.12.019. Epub 2015 Jan 7.","Evangelista L","Nucl Med Biol","2015","2015/01/26","","","10.1016/j.nucmedbio.2014.12.019"
"12686820","Transdermal estradiol therapy for advanced prostate cancer--forward to the past?","Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD.","J Urol. 2003 May;169(5):1735-7. doi: 10.1097/01.ju.0000061024.75334.40.","Ockrim JL","J Urol","2003","2003/04/11","","","10.1097/01.ju.0000061024.75334.40"
"17278153","Psychological adjustment of survivors of localised prostate cancer: investigating the role of dyadic adjustment, cognitive appraisal and coping style","Wootten AC, Burney S, Foroudi F, Frydenberg M, Coleman G, Ng KT.","Psychooncology. 2007 Nov;16(11):994-1002. doi: 10.1002/pon.1159.","Wootten AC","Psychooncology","2007","2007/02/06","","","10.1002/pon.1159"
"21387298","Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden","Robinson D, Garmo H, Lindahl B, Van Hemelrijck M, Adolfsson J, Bratt O, Holmberg L, Stattin P.","Int J Cancer. 2012 Jan 15;130(2):478-87. doi: 10.1002/ijc.26022. Epub 2011 May 2.","Robinson D","Int J Cancer","2012","2011/03/10","","","10.1002/ijc.26022"
"1407023","Prostate cancer in North Carolina","Robertson C, Demark-Wahnefried W, Aldrich T.","N C Med J. 1992 Sep;53(9):447-51.","Robertson C","N C Med J","1992","1992/09/01","","",""
"19375623","Risk of developing prostate cancer in the future: overview of prognostic biomarkers","Fleshner NE, Lawrentschuk N.","Urology. 2009 May;73(5 Suppl):S21-7. doi: 10.1016/j.urology.2009.02.022.","Fleshner NE","Urology","2009","2009/04/21","","","10.1016/j.urology.2009.02.022"
"23765687","Hyper-expression of PAX2 in human metastatic prostate tumors and its role as a cancer promoter in an in vitro invasion model","Ueda T, Ito S, Shiraishi T, Kulkarni P, Ueno A, Nakagawa H, Kimura Y, Hongo F, Kamoi K, Kawauchi A, Miki T.","Prostate. 2013 Sep;73(13):1403-12. doi: 10.1002/pros.22687. Epub 2013 Jun 14.","Ueda T","Prostate","2013","2013/06/15","","","10.1002/pros.22687"
"10228346","Diet, micronutrients, and the prostate gland","Thomas JA.","Nutr Rev. 1999 Apr;57(4):95-103. doi: 10.1111/j.1753-4887.1999.tb06932.x.","Thomas JA","Nutr Rev","1999","1999/05/06","","","10.1111/j.1753-4887.1999.tb06932.x"
"25195830","Benefits and risks of prostate cancer screening","Fornara P, Theil G, Schaefer C, Heß J, Rübben H.","Oncol Res Treat. 2014;37 Suppl 3:29-37. doi: 10.1159/000363756. Epub 2014 Aug 29.","Fornara P","Oncol Res Treat","2014","2014/09/09","","","10.1159/000363756"
"17319239","Prostate cancer disparities in South Carolina: two generations talking from a male community perspective","Moultrie LH 2nd, Smith JH.","J S C Med Assoc. 2006 Aug;102(7):250-2.","Moultrie LH 2nd","J S C Med Assoc","2006","2007/02/27","","",""
"28731947","Early Stage Cancer in Older Adults: Prostate-Avoiding Overtreatment and Undertreatment","Narayan V, Jiang S, Warlick CA.","Cancer J. 2017 Jul/Aug;23(4):238-241. doi: 10.1097/PPO.0000000000000273.","Narayan V","Cancer J","2017","2017/07/22","","","10.1097/PPO.0000000000000273"
"26048432","Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status","Faria EF, Chapin BF, Muller RL, Machado RD, Reis RB, Matin SF.","Urology. 2015 Jul;86(1):10-5. doi: 10.1016/j.urology.2015.03.012. Epub 2015 Jun 3.","Faria EF","Urology","2015","2015/06/07","","","10.1016/j.urology.2015.03.012"
"8740636","Usefulness of PSA density and PSA excess in the differential diagnosis between prostate cancer and benign prostatic hypertrophy","Diaz F, Morell M, Rojo G.","Int J Biol Markers. 1996 Jan-Mar;11(1):12-7.","Diaz F","Int J Biol Markers","1996","1996/01/01","","",""
"10679756","Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment","Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA.","Prostate. 2000 Mar 1;42(4):274-9. doi: 10.1002/(sici)1097-0045(20000301)42:4<274::aid-pros4>3.0.co;2-r.","Ahlgren G","Prostate","2000","2000/02/19","","","10.1002/(sici)1097-0045(20000301)42:4<274::aid-pros4>3.0.co;2-r"
"10581934","More about prostate cancer--expectant management versus treatment","Anscher MS.","N C Med J. 1999 Nov-Dec;60(6):313-4.","Anscher MS","N C Med J","1999","1999/12/03","","",""
"29398457","Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy","VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H.","Eur Urol Focus. 2019 May;5(3):416-424. doi: 10.1016/j.euf.2018.01.006. Epub 2018 Feb 15.","VanderWeele DJ","Eur Urol Focus","2019","2018/02/06","PMC6586528","NIHMS1530340","10.1016/j.euf.2018.01.006"
"29310978","Bowel and urinary quality of life after whole-pelvic versus prostate-only volumetric-modulated arc therapy for localized prostate cancer","Ishii K, Yamanaga T, Ogino R, Hosokawa Y, Kishimoto S, Nakahara R, Shimada C, Kawamorita R, Tada T, Hayashi Y, Nakajima T.","Pract Radiat Oncol. 2018 Mar-Apr;8(2):e49-e55. doi: 10.1016/j.prro.2017.10.005. Epub 2017 Nov 5.","Ishii K","Pract Radiat Oncol","2018","2018/01/10","","","10.1016/j.prro.2017.10.005"
"21553320","Preventive care in prostate cancer patients: following diagnosis and for five-year survivors","Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Carducci MA, Earle CC.","J Cancer Surviv. 2011 Sep;5(3):283-91. doi: 10.1007/s11764-011-0181-y. Epub 2011 May 8.","Snyder CF","J Cancer Surviv","2011","2011/05/10","PMC3700346","NIHMS374257","10.1007/s11764-011-0181-y"
"7541859","Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group","Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A.","J Urol. 1995 Aug;154(2 Pt 1):424-8.","Soloway MS","J Urol","1995","1995/08/01","","",""
"14745744","Psychoeducational group intervention for wives of men with prostate cancer","Manne S, Babb J, Pinover W, Horwitz E, Ebbert J.","Psychooncology. 2004 Jan;13(1):37-46. doi: 10.1002/pon.724.","Manne S","Psychooncology","2004","2004/01/28","","","10.1002/pon.724"
"18829446","Explaining the race difference in prostate cancer stage at diagnosis","Jones BA, Liu WL, Araujo AB, Kasl SV, Silvera SN, Soler-Vilá H, Curnen MG, Dubrow R.","Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2825-34. doi: 10.1158/1055-9965.EPI-08-0203. Epub 2008 Sep 30.","Jones BA","Cancer Epidemiol Biomarkers Prev","2008","2008/10/03","","","10.1158/1055-9965.EPI-08-0203"
"9632424","Screening for prostate cancer. Key studies have only just started","Hrouda D, Davies JH, Kirby RS.","BMJ. 1998 Jun 20;316(7148):1903.","Hrouda D","BMJ","1998","1998/06/19","PMC1113375","",""
"25327986","Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts","DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.","Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.","DiPippo VA","Prostate","2015","2014/10/21","","","10.1002/pros.22916"
"29530945","New Opportunities for Targeting the Androgen Receptor in Prostate Cancer","Centenera MM, Selth LA, Ebrahimie E, Butler LM, Tilley WD.","Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a030478. doi: 10.1101/cshperspect.a030478.","Centenera MM","Cold Spring Harb Perspect Med","2018","2018/03/14","PMC6280715","","10.1101/cshperspect.a030478"
"25444985","MUSIC: patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer","Ross I, Womble P, Ye J, Linsell S, Montie JE, Miller DC, Cher ML.","J Urol. 2015 Apr;193(4):1159-62. doi: 10.1016/j.juro.2014.10.102. Epub 2014 Oct 31.","Ross I","J Urol","2015","2014/12/03","","","10.1016/j.juro.2014.10.102"
"26583638","Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy","Feng L, Chen MK, Lukkahatai N, Hsiao CP, Kaushal A, Sechrest L, Saligan LN.","Clin J Oncol Nurs. 2015 Dec;19(6):744-50. doi: 10.1188/15.CJON.744-750.","Feng L","Clin J Oncol Nurs","2015","2015/11/20","","","10.1188/15.CJON.744-750"
"8049641","5-Alpha-reductase inhibition and prostate cancer prevention","Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS.","Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):177-82.","Brawley OW","Cancer Epidemiol Biomarkers Prev","1994","1994/03/01","","",""
"18514384","Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer","Vickers AJ.","Eur Urol. 2008 Oct;54(4):802-3. doi: 10.1016/j.eururo.2008.05.019. Epub 2008 May 21.","Vickers AJ","Eur Urol","2008","2008/06/03","","","10.1016/j.eururo.2008.05.019"
"7692112","The long-term risk of development of prostate cancer in patients with benign prostatic hyperplasia: correlation with stage A1 disease","Kearse WS Jr, Seay TM, Thompson IM.","J Urol. 1993 Nov;150(5 Pt 2):1746-8. doi: 10.1016/s0022-5347(17)35884-6.","Kearse WS Jr","J Urol","1993","1993/11/01","","","10.1016/s0022-5347(17)35884-6"
"29089606","The inflammatory microenvironment and microbiome in prostate cancer development","Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM.","Nat Rev Urol. 2018 Jan;15(1):11-24. doi: 10.1038/nrurol.2017.167. Epub 2017 Oct 31.","Sfanos KS","Nat Rev Urol","2018","2017/11/02","","","10.1038/nrurol.2017.167"
"15132224","Prostate cancer screening among military service members","Joseph HJ, Hickey JR.","Mil Med. 2004 Apr;169(4):257-60. doi: 10.7205/milmed.169.4.257.","Joseph HJ","Mil Med","2004","2004/05/11","","","10.7205/milmed.169.4.257"
"8853486","Long-term follow-up of patients treated by radiation therapy for clinically-localized prostate cancer","Eapen L.","Can J Oncol. 1994 Nov;4 Suppl 1:31-2.","Eapen L","Can J Oncol","1994","1994/11/01","","",""
"28057891","Prostate cancer, PI3K, PTEN and prognosis","Wise HM, Hermida MA, Leslie NR.","Clin Sci (Lond). 2017 Feb 1;131(3):197-210. doi: 10.1042/CS20160026.","Wise HM","Clin Sci (Lond)","2017","2017/01/07","","","10.1042/CS20160026"
"28780740","Knowledge, attitudes, and practices towards prostate cancer screening amongst men living in the southern Italian peninsula: the Prevention and Research in Oncology (PRO) non-profit Foundation experience","Mirone V, Imbimbo C, Arcaniolo D, Franco M, La Rocca R, Venturino L, Spirito L, Creta M, Verze P.","World J Urol. 2017 Dec;35(12):1857-1862. doi: 10.1007/s00345-017-2074-9. Epub 2017 Aug 5.","Mirone V","World J Urol","2017","2017/08/07","","","10.1007/s00345-017-2074-9"
"20963490","The effect of prostate cancer screening on stage IV disease in America","Colli JL.","Int Urol Nephrol. 2011 Jun;43(2):391-6. doi: 10.1007/s11255-010-9799-3. Epub 2010 Oct 21.","Colli JL","Int Urol Nephrol","2011","2010/10/22","","","10.1007/s11255-010-9799-3"
"10146746","Where is radiotherapy for stage C prostate cancer headed?","Hanks GE.","Contemp Urol. 1994 Mar;6(3):11-4.","Hanks GE","Contemp Urol","1994","1994/02/07","","",""
"29401152","Prostate-Specific Membrane Antigen PET/CT Incidental Finding of a Schwannoma","Dias AH, Bouchelouche K.","Clin Nucl Med. 2018 Apr;43(4):267-268. doi: 10.1097/RLU.0000000000001988.","Dias AH","Clin Nucl Med","2018","2018/02/06","","","10.1097/RLU.0000000000001988"
"20533778","Prostate cancer screening 2010: updated recommendations from the American Cancer Society","Brooks DD, Wolf A, Smith RA, Dash C, Guessous I.","J Natl Med Assoc. 2010 May;102(5):423-9. doi: 10.1016/s0027-9684(15)30578-2.","Brooks DD","J Natl Med Assoc","2010","2010/06/11","","","10.1016/s0027-9684(15)30578-2"
"16797831","Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience","Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H.","Eur Urol. 2007 Jan;51(1):121-8; discussion 128-9. doi: 10.1016/j.eururo.2006.05.024. Epub 2006 Jun 9.","Hsu CY","Eur Urol","2007","2006/06/27","","","10.1016/j.eururo.2006.05.024"
"9164477","Intratumoral heterogeneity in prostate cancer demonstrated by volume-weighted mean nuclear volume","Fujikawa K, Sasaki M, Aoyama T, Itoh T, Yoshida O.","APMIS. 1997 Apr;105(4):322-8. doi: 10.1111/j.1699-0463.1997.tb00577.x.","Fujikawa K","APMIS","1997","1997/04/01","","","10.1111/j.1699-0463.1997.tb00577.x"
"21243859","Knowledge of prostate cancer screening among native African urban population in Nigeria","Ajape AA, Babata A, Abiola OO.","Nig Q J Hosp Med. 2010 Apr-Jun;20(2):94-6. doi: 10.4314/nqjhm.v20i2.58044.","Ajape AA","Nig Q J Hosp Med","2010","2011/01/20","","","10.4314/nqjhm.v20i2.58044"
"9815882","DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications","Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner, Griffin C, Kallioniemi O, Visakorpi, McGill, Herath J, et al.","Clin Cancer Res. 1995 Jan;1(1):11-8.","Van Den Berg C","Clin Cancer Res","1995","1995/01/01","","",""
"22694290","Calcium channels and prostate cancer","Shapovalov G, Skryma R, Prevarskaya N.","Recent Pat Anticancer Drug Discov. 2013 Jan 1;8(1):18-26. doi: 10.2174/15748928130103.","Shapovalov G","Recent Pat Anticancer Drug Discov","2013","2012/06/15","","","10.2174/15748928130103"
"7521501","Why so many operations for localised prostate cancer?","Bilgrami S, Greenberg BR.","Lancet. 1994 Sep 10;344(8924):700-1. doi: 10.1016/s0140-6736(94)92202-0.","Bilgrami S","Lancet","1994","1994/09/10","","","10.1016/s0140-6736(94)92202-0"
"11803260","Perspectives in adjuvant treatment of prostate cancer","Wirth MP, Froehner M.","Urol Int. 2002;68(1):1-5. doi: 10.1159/000048409.","Wirth MP","Urol Int","2002","2002/01/23","","","10.1159/000048409"
"19189884","[PSA kinetics after total prostatectomy]","Riedinger JM, Eche N, Fulla Y, Thuillier F.","Ann Biol Clin (Paris). 2009 Jan-Feb;67(1):39-46. doi: 10.1684/abc.2009.0298.","Riedinger JM","Ann Biol Clin (Paris)","2009","2009/02/05","","","10.1684/abc.2009.0298"
"8773506","Should asymptomatic progression following definitive local treatment for prostate cancer be treated?","Lillis P, Thompson IM Jr.","Hematol Oncol Clin North Am. 1996 Jun;10(3):703-12. doi: 10.1016/s0889-8588(05)70362-2.","Lillis P","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70362-2"
"31008557","Editorial: Conversion to negative surgical margin after intraoperative frozen section - (un)necessary effort and relevance in 2019?","Herlemann A, Meng MV.","BJU Int. 2019 May;123(5):744-746. doi: 10.1111/bju.14610.","Herlemann A","BJU Int","2019","2019/04/23","","","10.1111/bju.14610"
"17587207","Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer","Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ.","Cancer. 2007 Aug 15;110(4):906-10. doi: 10.1002/cncr.22858.","Mouraviev V","Cancer","2007","2007/06/26","","","10.1002/cncr.22858"
"21376547","In pursuit of individualised margins for prostate cancer patients undergoing image-guided radiotherapy: the effect of body mass index on intrafraction prostate motion","Thompson AL, Gill S, Thomas J, Kron T, Fox C, Herschtal A, Tai KH, Foroudi F.","Clin Oncol (R Coll Radiol). 2011 Sep;23(7):449-53. doi: 10.1016/j.clon.2011.01.511. Epub 2011 Mar 3.","Thompson AL","Clin Oncol (R Coll Radiol)","2011","2011/03/08","","","10.1016/j.clon.2011.01.511"
"22361632","Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S; Transatlantic Prostate Group.","Br J Cancer. 2012 Mar 13;106(6):1095-9. doi: 10.1038/bjc.2012.39. Epub 2012 Feb 23.","Cuzick J","Br J Cancer","2012","2012/02/25","PMC3304411","","10.1038/bjc.2012.39"
"23395126","Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols","Müller G, Bonkat G, Rieken M, Wyler SF, Bubendorf L, Püschel H, Gasser TC, Bachmann A, Rentsch CA.","Urology. 2013 Apr;81(4):837-42. doi: 10.1016/j.urology.2012.10.068. Epub 2013 Feb 6.","Müller G","Urology","2013","2013/02/12","","","10.1016/j.urology.2012.10.068"
"11262340","[""Fortunately, there's nothing wrong with you."" PSA and prostate cancer]","de Lorenzo-Cáceres Ascanio A.","Aten Primaria. 2001 Mar 15;27(4):284-5. doi: 10.1016/s0212-6567(01)78810-5.","de Lorenzo-Cáceres Ascanio A","Aten Primaria","2001","2001/03/23","","","10.1016/s0212-6567(01)78810-5"
"26040853","Targetable mutations found in metastatic prostate cancer","Balakrishnan VS.","Lancet Oncol. 2015 Jul;16(7):e316. doi: 10.1016/S1470-2045(15)00010-8. Epub 2015 May 31.","Balakrishnan VS","Lancet Oncol","2015","2015/06/05","","","10.1016/S1470-2045(15)00010-8"
"21740993","Dose escalation in the radiation therapy of prostate cancer","Schulz RJ, Kagan AR.","Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1289-91. doi: 10.1016/j.ijrobp.2011.04.012.","Schulz RJ","Int J Radiat Oncol Biol Phys","2011","2011/07/12","","","10.1016/j.ijrobp.2011.04.012"
"19120335","Metastatic prostate cancer presenting as paraneoplastic pemphigus: a favourable clinical response to combined androgen blockade and conventional immunosuppressive therapy","Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E.","Br J Dermatol. 2009 Feb;160(2):468-70. doi: 10.1111/j.1365-2133.2008.08982.x. Epub 2008 Dec 11.","Mignogna MD","Br J Dermatol","2009","2009/01/06","","","10.1111/j.1365-2133.2008.08982.x"
"27779679","miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma","Xu S, Yi XM, Zhang ZY, Ge JP, Zhou WQ.","Mol Med Rep. 2016 Dec;14(6):5025-5032. doi: 10.3892/mmr.2016.5859. Epub 2016 Oct 19.","Xu S","Mol Med Rep","2016","2016/10/26","PMC5355665","","10.3892/mmr.2016.5859"
"22173177","Prostate cryoablation in patients with multiple-component inflatable penile prostheses","Garber BB, Tapscott AH.","Urology. 2012 Mar;79(3):722-4. doi: 10.1016/j.urology.2011.10.040. Epub 2011 Dec 14.","Garber BB","Urology","2012","2011/12/17","","","10.1016/j.urology.2011.10.040"
"12643469","Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy","Anastasiadis AG, Bemis DL, Stisser BC, Salomon L, Ghafar MA, Buttyan R.","Curr Drug Targets. 2003 Apr;4(3):191-6. doi: 10.2174/1389450033491136.","Anastasiadis AG","Curr Drug Targets","2003","2003/03/20","","","10.2174/1389450033491136"
"11588860","Selenium, zinc, and prostate cancer","Platz EA, Helzlsouer KJ.","Epidemiol Rev. 2001;23(1):93-101. doi: 10.1093/oxfordjournals.epirev.a000801.","Platz EA","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000801"
"15076656","A nested case-control study of prostate cancer and atrazine exposure","Hessel PA, Kalmes R, Smith TJ, Lau E, Mink PJ, Mandel J.","J Occup Environ Med. 2004 Apr;46(4):379-85. doi: 10.1097/01.jom.0000121128.73921.a1.","Hessel PA","J Occup Environ Med","2004","2004/04/13","","","10.1097/01.jom.0000121128.73921.a1"
"17077354","Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability","Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ.","J Natl Cancer Inst. 2006 Nov 1;98(21):1521-7. doi: 10.1093/jnci/djj410.","Carter HB","J Natl Cancer Inst","2006","2006/11/02","PMC2645644","NIHMS45619","10.1093/jnci/djj410"
"26282212","Prostate cancer: Novel xenografts in mice--a new wave of preclinical models","Risbridger GP.","Nat Rev Urol. 2015 Oct;12(10):540-1. doi: 10.1038/nrurol.2015.198. Epub 2015 Aug 18.","Risbridger GP","Nat Rev Urol","2015","2015/08/19","","","10.1038/nrurol.2015.198"
"19854485","Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension","Miyake H, Muramaki M, Furukawa J, Kurahashi T, Fujisawa M.","Urology. 2010 Feb;75(2):454-9. doi: 10.1016/j.urology.2009.08.029. Epub 2009 Oct 24.","Miyake H","Urology","2010","2009/10/27","","","10.1016/j.urology.2009.08.029"
"8156525","Contrasting trends of prostate cancer incidence and mortality in New Mexico's Hispanics, non-Hispanic whites, American Indians, and blacks","Gilliland FD, Becker TM, Key CR, Samet JM.","Cancer. 1994 Apr 15;73(8):2192-9. doi: 10.1002/1097-0142(19940415)73:8<2192::aid-cncr2820730826>3.0.co;2-y.","Gilliland FD","Cancer","1994","1994/04/15","","","10.1002/1097-0142(19940415)73:8<2192::aid-cncr2820730826>3.0.co;2-y"
"19352392","Prostate cancer: neither vitamin E nor selenium prevents prostate cancer","Allen NE, Key TJ.","Nat Rev Urol. 2009 Apr;6(4):187-8. doi: 10.1038/nrurol.2009.47.","Allen NE","Nat Rev Urol","2009","2009/04/09","","","10.1038/nrurol.2009.47"
"28113097","The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges","Solinas C, Chanzá NM, Awada A, Scartozzi M.","Cancer Treat Rev. 2017 Feb;53:138-145. doi: 10.1016/j.ctrv.2016.12.004. Epub 2016 Dec 30.","Solinas C","Cancer Treat Rev","2017","2017/01/24","","","10.1016/j.ctrv.2016.12.004"
"31348089","Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer: An Underexposed Issue","Yakar D, Noordzij W, Kwee TC.","Clin Nucl Med. 2020 Jan;45(1):e32-e35. doi: 10.1097/RLU.0000000000002750.","Yakar D","Clin Nucl Med","2020","2019/07/27","","","10.1097/RLU.0000000000002750"
"29940744","7-Farnesyloxycoumarin Exerts Anti-cancer Effects on a Prostate Cancer Cell Line by 15-LOX-1 Inhibition","Saboormaleki S, Sadeghian H, Bahrami AR, Orafaie A, Matin MM.","Arch Iran Med. 2018 Jun 1;21(6):251-259.","Saboormaleki S","Arch Iran Med","2018","2018/06/27","","",""
"24944315","Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?","Smith SC, Tomlins SA.","Clin Cancer Res. 2014 Sep 15;20(18):4733-6. doi: 10.1158/1078-0432.CCR-14-0818. Epub 2014 Jun 18.","Smith SC","Clin Cancer Res","2014","2014/06/20","PMC4167216","NIHMS605398","10.1158/1078-0432.CCR-14-0818"
"30171230","Practice patterns of primary EBRT with and without ADT in prostate cancer treatment","Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR.","Prostate Cancer Prostatic Dis. 2019 Mar;22(1):117-124. doi: 10.1038/s41391-018-0084-3. Epub 2018 Aug 31.","Schmidt B","Prostate Cancer Prostatic Dis","2019","2018/09/02","","","10.1038/s41391-018-0084-3"
"24552987","Immunologic biomarkers in prostate cancer: the AE37 paradigm","Baxevanis CN, Papamichail M, Perez SA.","Hum Vaccin Immunother. 2014;10(5):1244-7. doi: 10.4161/hv.28032. Epub 2014 Feb 19.","Baxevanis CN","Hum Vaccin Immunother","2014","2014/02/21","PMC4896604","","10.4161/hv.28032"
"20489646","Screening for prostate cancer: have we resolved the controversy?","Zhu X, Roobol MJ, Schröder FH.","Curr Opin Support Palliat Care. 2010 Sep;4(3):121-6. doi: 10.1097/SPC.0b013e32833abc21.","Zhu X","Curr Opin Support Palliat Care","2010","2010/05/22","","","10.1097/SPC.0b013e32833abc21"
"7287475","[Prognostic significance of clinical and morphological parameters in prostate cancer]","Rist M, Eichenberger T, Mihatsch MJ, Ohnacker H, Oberholzer M, Torhorst J, Spichtin HP.","Helv Chir Acta. 1981 Aug;48(3-4):387-90.","Rist M","Helv Chir Acta","1981","1981/08/01","","",""
"28267056","Active surveillance for low-risk prostate cancer","Klotz L.","Curr Opin Urol. 2017 May;27(3):225-230. doi: 10.1097/MOU.0000000000000393.","Klotz L","Curr Opin Urol","2017","2017/03/08","","","10.1097/MOU.0000000000000393"
"19278937","Promising marker found for deadly prostate cancer","Kuehn BM.","JAMA. 2009 Mar 11;301(10):1008. doi: 10.1001/jama.2009.299.","Kuehn BM","JAMA","2009","2009/03/13","","","10.1001/jama.2009.299"
"16461084","Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer","Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR.","Urology. 2006 Feb;67(2):349-53. doi: 10.1016/j.urology.2005.08.047.","Rossi PJ","Urology","2006","2006/02/08","","","10.1016/j.urology.2005.08.047"
"16583579","Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day)","Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.","J Med Assoc Thai. 2006 Jan;89(1):37-42.","Srinualnad S","J Med Assoc Thai","2006","2006/04/06","","",""
"17016769","Prostate cancer - 6th International Congress","Figg WD, Ockers S.","IDrugs. 2006 Oct;9(10):675-8.","Figg WD","IDrugs","2006","2006/10/04","","",""
"22748264","Focal HIFU for prostate cancer","Lazzeri M, Guazzoni G, Montorsi F.","Lancet Oncol. 2012 Jul;13(7):e281-2; author reply e284. doi: 10.1016/S1470-2045(12)70305-4. Epub 2012 Jun 28.","Lazzeri M","Lancet Oncol","2012","2012/07/04","","","10.1016/S1470-2045(12)70305-4"
"12515790","Radical prostatectomy or watchful waiting in early prostate cancer?","Siemens DR.","CMAJ. 2003 Jan 7;168(1):67.","Siemens DR","CMAJ","2003","2003/01/08","PMC139323","",""
"2217458","History and physical examination in prostate cancer. Which information is essential in diagnosis and follow-up?","Newling DW, Estrada Arras C, Bono A.","Prog Clin Biol Res. 1990;357:151-6.","Newling DW","Prog Clin Biol Res","1990","1990/01/01","","",""
"17341706","Advanced prostate cancer and postoperative radiotherapy","Pisansky TM, Pollack A, Sandler HM, Valicenti RK.","JAMA. 2007 Mar 7;297(9):950-1; author reply 951. doi: 10.1001/jama.297.9.950-b.","Pisansky TM","JAMA","2007","2007/03/08","","","10.1001/jama.297.9.950-b"
"23716281","The ""PROCAINA (PROstate CAncer INdication Attitudes) Project"" (Part II)--a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer","De Bari B, Alongi F, Franco P, Ciammella P, Chekrine T, Livi L, Jereczek-Fossa BA, Filippi AR; AIRO Young and AIRO Prostate cancer Working Group.","Radiol Med. 2013 Oct;118(7):1220-39. doi: 10.1007/s11547-013-0925-z. Epub 2013 May 27.","De Bari B","Radiol Med","2013","2013/05/30","","","10.1007/s11547-013-0925-z"
"10688070","Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time","Carducci MA.","Urology. 2000 Feb;55(2):157-60. doi: 10.1016/s0090-4295(99)00366-0.","Carducci MA","Urology","2000","2000/02/25","","","10.1016/s0090-4295(99)00366-0"
"9037307","Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen","Brown M, Feuer E.","Urology. 1997 Feb;49(2):306-7.","Brown M","Urology","1997","1997/02/01","","",""
"28482875","Qualitative insights into how men with low-risk prostate cancer choosing active surveillance negotiate stress and uncertainty","Mader EM, Li HH, Lyons KD, Morley CP, Formica MK, Perrapato SD, Irwin BH, Seigne JD, Hyams ES, Mosher T, Hegel MT, Stewart TM.","BMC Urol. 2017 May 8;17(1):35. doi: 10.1186/s12894-017-0225-3.","Mader EM","BMC Urol","2017","2017/05/10","PMC5422871","","10.1186/s12894-017-0225-3"
"24100515","Exercise therapy for sexual dysfunction after prostate cancer","Cormie P, Newton RU, Taaffe DR, Spry N, Galvão DA.","Nat Rev Urol. 2013 Dec;10(12):731-6. doi: 10.1038/nrurol.2013.206. Epub 2013 Oct 8.","Cormie P","Nat Rev Urol","2013","2013/10/09","","","10.1038/nrurol.2013.206"
"1722420","Study shows PSA better than DRE in screening for prostate cancer","","Oncology (Williston Park). 1991 Nov;5(11):36.","","Oncology (Williston Park)","1991","1991/11/01","","",""
"25112853","Prostate cancer: Probing progression in circulating tumour cells","Phillips R.","Nat Rev Urol. 2014 Sep;11(9):486. doi: 10.1038/nrurol.2014.208. Epub 2014 Aug 12.","Phillips R","Nat Rev Urol","2014","2014/08/13","","","10.1038/nrurol.2014.208"
"9182382","[Prostate-specific antigen, acid phosphatases and rectal exploration in the diagnosis of prostatic cancer]","Andersen BR, Knorr UB, Brasso K, Iversen P.","Ugeskr Laeger. 1997 Apr 21;159(17):2538-42.","Andersen BR","Ugeskr Laeger","1997","1997/04/21","","",""
"31900914","The Role of RB in Prostate Cancer Progression","Burkhart DL, Morel KL, Sheahan AV, Richards ZA, Ellis L.","Adv Exp Med Biol. 2019;1210:301-318. doi: 10.1007/978-3-030-32656-2_13.","Burkhart DL","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_13"
"22564869","Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies","Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, Mucci LA.","Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1002-11. doi: 10.1158/1055-9965.EPI-12-0116. Epub 2012 May 7.","Sigurdardottir LG","Cancer Epidemiol Biomarkers Prev","2012","2012/05/09","PMC3392423","NIHMS376887","10.1158/1055-9965.EPI-12-0116"
"8526188","Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy","Anscher MS.","Am J Clin Oncol. 1995 Dec;18(6):481-3. doi: 10.1097/00000421-199512000-00004.","Anscher MS","Am J Clin Oncol","1995","1995/12/01","","","10.1097/00000421-199512000-00004"
"19568707","Primary research on Chinese medicine treatment of androgen-independent prostate cancer","Zhang SW, Zhou SY, Shao JC, Qu XW.","Chin J Integr Med. 2009 Jun;15(3):168-9. doi: 10.1007/s11655-009-0168-y. Epub 2009 Jul 2.","Zhang SW","Chin J Integr Med","2009","2009/07/02","","","10.1007/s11655-009-0168-y"
"10367829","A unifying model to explain the increased incidence and higher mortality of prostate cancer in black men","Montie JE, Pienta KJ.","Urology. 1999 Jun;53(6):1073-6. doi: 10.1016/s0090-4295(99)00047-3.","Montie JE","Urology","1999","1999/06/15","","","10.1016/s0090-4295(99)00047-3"
"19556286","Emerging roles of chemokines in prostate cancer","Vindrieux D, Escobar P, Lazennec G.","Endocr Relat Cancer. 2009 Sep;16(3):663-73. doi: 10.1677/ERC-09-0109. Epub 2009 Jun 25.","Vindrieux D","Endocr Relat Cancer","2009","2009/06/27","","","10.1677/ERC-09-0109"
"25144280","Extended lymph node dissection in prostate cancer: a procedure with therapeutic utility","Gandaglia G, Di Trapani E, Briganti A.","Oncology (Williston Park). 2014 Jul;28(7):600, 602.","Gandaglia G","Oncology (Williston Park)","2014","2014/08/22","","",""
"19516038","Androgen deprivation in prostate cancer--step by step","Albertsen P.","N Engl J Med. 2009 Jun 11;360(24):2572-4. doi: 10.1056/NEJMe0901737.","Albertsen P","N Engl J Med","2009","2009/06/12","","","10.1056/NEJMe0901737"
"17318343","Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience","Kajdacsy-Balla A, Geynisman JM, Macias V, Setty S, Nanaji NM, Berman JJ, Dobbin K, Melamed J, Kong X, Bosland M, Orenstein J, Bayerl J, Becich MJ, Dhir R, Datta MW; Cooperative Prostate Cancer Tissue Resource.","J Mol Histol. 2007 May;38(2):113-21. doi: 10.1007/s10735-006-9054-5. Epub 2007 Feb 21.","Kajdacsy-Balla A","J Mol Histol","2007","2007/02/24","","","10.1007/s10735-006-9054-5"
"10078638","Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity","Storey MR, Landgren RC, Cottone JL, Stallings JW, Logan CW, Fraiser LP, Ross CS, Kock RJ, Berkley LW, Hauer-Jensen M.","Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):565-70. doi: 10.1016/s0360-3016(98)00451-9.","Storey MR","Int J Radiat Oncol Biol Phys","1999","1999/03/17","","","10.1016/s0360-3016(98)00451-9"
"20574451","Breast and prostate cancer: familial associations","Hemminki K, Försti A, Chen B.","Nat Rev Cancer. 2010 Jul;10(7):523. doi: 10.1038/nrc2795-c1.","Hemminki K","Nat Rev Cancer","2010","2010/06/25","","","10.1038/nrc2795-c1"
"20696969","Invited commentary: Prostate cancer: doing less might be more. Comment on ""Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer""","Ablin RJ, Sartor O, Bennett CL.","Arch Intern Med. 2010 Aug 9;170(15):1397-9. doi: 10.1001/archinternmed.2010.290.","Ablin RJ","Arch Intern Med","2010","2010/08/11","","","10.1001/archinternmed.2010.290"
"25877953","Psychometric properties of Functional Assessment of Cancer Therapy-Prostate (FACT-P) in Chinese patients with prostate cancer","Wong CK, Choi EP, Tsu JH, Ho BS, Ng AT, Chin WY, Yiu MK.","Qual Life Res. 2015 Oct;24(10):2397-402. doi: 10.1007/s11136-015-0993-8. Epub 2015 Apr 16.","Wong CK","Qual Life Res","2015","2015/04/17","","","10.1007/s11136-015-0993-8"
"22410678","Prostate cancer: modeling the outcomes of prostate cancer screening","Loeb S, Carlsson S, Braithwaite RS.","Nat Rev Urol. 2012 Mar 13;9(4):183-5. doi: 10.1038/nrurol.2012.34.","Loeb S","Nat Rev Urol","2012","2012/03/14","","","10.1038/nrurol.2012.34"
"26086732","Low testosterone level is an independent risk factor for high-grade prostate cancer detection at biopsy","Park J, Cho SY, Jeong SH, Lee SB, Son H, Jeong H.","BJU Int. 2016 Aug;118(2):230-5. doi: 10.1111/bju.13206. Epub 2015 Jul 21.","Park J","BJU Int","2016","2015/06/19","","","10.1111/bju.13206"
"21717900","Preventing prostate cancer overdiagnosis from becoming overtreatment","Hayes J, Barry MJ.","Oncology (Williston Park). 2011 May;25(6):468, 471, 478.","Hayes J","Oncology (Williston Park)","2011","2011/07/02","","",""
"17017872","Knowledge of epigenetic influence for prostate cancer therapy","Watanabe M, Takagi A, Matsuzaki T, Kami D, Toyota M, Hirokawa Y, Shiraishi T.","Curr Cancer Drug Targets. 2006 Sep;6(6):533-51. doi: 10.2174/156800906778194568.","Watanabe M","Curr Cancer Drug Targets","2006","2006/10/05","","","10.2174/156800906778194568"
"17405305","[Treatment of clinically localized prostate cancer. Part I--observation or treatment?]","Szelachowska J, Kornafel J, Gisterek I.","Pol Merkur Lekarski. 2006 Dec;21(126):594-7.","Szelachowska J","Pol Merkur Lekarski","2006","2007/04/05","","",""
"30037206","Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a high-volume center experience","Höffkes F, Arthanareeswaran VK, Stolzenburg JU, Ganzer R.","Minerva Urol Nefrol. 2018 Dec;70(6):588-593. doi: 10.23736/S0393-2249.18.03126-0. Epub 2018 Jul 23.","Höffkes F","Minerva Urol Nefrol","2018","2018/07/25","","","10.23736/S0393-2249.18.03126-0"
"9126243","The socioeconomic implications of prostate-specific antigen screening","Benoit RM, Naslund MJ.","Urol Clin North Am. 1997 May;24(2):451-8. doi: 10.1016/s0094-0143(05)70392-x.","Benoit RM","Urol Clin North Am","1997","1997/05/01","","","10.1016/s0094-0143(05)70392-x"
"18272029","A new case of signet ring cell carcinoma of the prostate","Derouiche A, Ouni A, Kourda N, Belhadj K, Ben Jilani S, Chebil M.","Clin Genitourin Cancer. 2007 Dec;5(7):455-6. doi: 10.3816/cgc.2007.n.035.","Derouiche A","Clin Genitourin Cancer","2007","2008/02/15","","","10.3816/cgc.2007.n.035"
"18804265","Point: effect of radiation-associated second malignancies on prostate cancer survival","Herr HW, Carver B.","Urology. 2008 Nov;72(5):968-70. doi: 10.1016/j.urology.2008.07.017. Epub 2008 Sep 19.","Herr HW","Urology","2008","2008/09/23","","","10.1016/j.urology.2008.07.017"
"24898352","The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy","Shiota M, Yokomizo A, Takeuchi A, Imada K, Kiyoshima K, Inokuchi J, Tatsugami K, Naito S.","J Surg Oncol. 2014 Sep;110(4):476-81. doi: 10.1002/jso.23677. Epub 2014 Jun 5.","Shiota M","J Surg Oncol","2014","2014/06/06","","","10.1002/jso.23677"
"17510388","DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells","Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S.","Cancer Res. 2007 May 15;67(10):4630-7. doi: 10.1158/0008-5472.CAN-06-4556.","Tillman JE","Cancer Res","2007","2007/05/19","","","10.1158/0008-5472.CAN-06-4556"
"1538495","Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup","Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM.","J Urol. 1992 Mar;147(3 Pt 2):910-5. doi: 10.1016/s0022-5347(17)37420-7.","Myers RP","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37420-7"
"30644307","Impact of functional imaging in prostate cancer: a clinical point of view","Nicolotti DG, Finessi M, Guarneri A, Pilati E, Giunta F, Deandreis D.","Q J Nucl Med Mol Imaging. 2019 Mar;63(1):1-6. doi: 10.23736/S1824-4785.19.03160-1. Epub 2019 Jan 15.","Nicolotti DG","Q J Nucl Med Mol Imaging","2019","2019/01/16","","","10.23736/S1824-4785.19.03160-1"
"23551614","Symptom self-management strategies in patients with non-metastatic prostate cancer","Hsiao CP, Moore IM, Insel KC, Merkle CJ.","J Clin Nurs. 2014 Feb;23(3-4):440-9. doi: 10.1111/jocn.12178. Epub 2013 Mar 29.","Hsiao CP","J Clin Nurs","2014","2013/04/05","","","10.1111/jocn.12178"
"26054410","Magnetic resonance imaging for prostate cancer: what the urologist needs to know","Kiechle J, Pahwa S, Gulani V, Kanaan G, Sedelaar J, Ponsky L.","Minerva Urol Nefrol. 2015 Sep;67(3):201-10. Epub 2015 Jun 9.","Kiechle J","Minerva Urol Nefrol","2015","2015/06/10","","",""
"10453288","Metastasis-related genes in prostate cancer: the role of caveolin-1","Thompson TC.","Cancer Metastasis Rev. 1998-1999;17(4):439-42. doi: 10.1023/a:1006110326366.","Thompson TC","Cancer Metastasis Rev","1998","1999/08/24","","","10.1023/a:1006110326366"
"27416638","[Localized prostate cancer Focal Therapy: ""A la carte"" Model]","Linares Espinós E, Barret E, Sivaraman A, Pérez-Reggeti JI, Sánchez-Salas R, Rozet F, Galiano M, Cathelineau X.","Arch Esp Urol. 2016 Jul;69(6):345-52.","Linares Espinós E","Arch Esp Urol","2016","2016/07/15","","",""
"16551847","Mechanisms underlying the development of androgen-independent prostate cancer","Pienta KJ, Bradley D.","Clin Cancer Res. 2006 Mar 15;12(6):1665-71. doi: 10.1158/1078-0432.CCR-06-0067.","Pienta KJ","Clin Cancer Res","2006","2006/03/23","","","10.1158/1078-0432.CCR-06-0067"
"27080479","Clinical variability and molecular heterogeneity in prostate cancer","Shoag J, Barbieri CE.","Asian J Androl. 2016 Jul-Aug;18(4):543-8. doi: 10.4103/1008-682X.178852.","Shoag J","Asian J Androl","2016","2016/04/16","PMC4955177","","10.4103/1008-682X.178852"
"9296766","[What can the clinician expect today from PSA determination?]","Teillac P.","Nucl Med Biol. 1994 Apr;21(3):455-69. doi: 10.1016/0969-8051(94)90069-8.","Teillac P","Nucl Med Biol","1994","1994/04/01","","","10.1016/0969-8051(94)90069-8"
"28212121","Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis","Ali A, Hoyle A, Baena E, Clarke NW.","Curr Opin Urol. 2017 May;27(3):217-224. doi: 10.1097/MOU.0000000000000385.","Ali A","Curr Opin Urol","2017","2017/02/18","","","10.1097/MOU.0000000000000385"
"17175925","[External beam radiotherapy on locally advanced prostate carcinoma following iliac staging lymphadenectomy]","Barbagelata López A, Ponce Díaz-Reixa JL, Romero Selas E, Gómez Veiga F, Fernández Rosado E, Gonzalez Martín M.","Actas Urol Esp. 2006 Oct;30(9):856-65. doi: 10.1016/s0210-4806(06)73551-3.","Barbagelata López A","Actas Urol Esp","2006","2006/12/21","","","10.1016/s0210-4806(06)73551-3"
"11035306","The controversy of prostate screening","McDougall GJ Jr, Weber BA, Dziuk TW, Heneghan R.","Geriatr Nurs. 2000 Sep-Oct;21(5):245-8; quiz 249. doi: 10.1067/mgn.2000.110829.","McDougall GJ Jr","Geriatr Nurs","2000","2000/10/18","PMC6466612","NIHMS1017283","10.1067/mgn.2000.110829"
"28027422","Care-related predictors for negative intrusive thoughts after prostate cancer diagnosis-data from the prospective LAPPRO trial","Thorsteinsdottir T, Valdimarsdottir H, Hauksdottir A, Stranne J, Wilderäng U, Haglind E, Steineck G.","Psychooncology. 2017 Nov;26(11):1749-1757. doi: 10.1002/pon.4359. Epub 2017 Feb 10.","Thorsteinsdottir T","Psychooncology","2017","2016/12/28","","","10.1002/pon.4359"
"31900913","Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer","Arce S, Athie A, Pritchard CC, Mateo J.","Adv Exp Med Biol. 2019;1210:279-300. doi: 10.1007/978-3-030-32656-2_12.","Arce S","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_12"
"24239470","The prostate cancer genome: perspectives and potential","Barbieri CE, Tomlins SA.","Urol Oncol. 2014 Jan;32(1):53.e15-22. doi: 10.1016/j.urolonc.2013.08.025. Epub 2013 Nov 13.","Barbieri CE","Urol Oncol","2014","2013/11/19","","","10.1016/j.urolonc.2013.08.025"
"18452170","Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis","Evans S, Metcalfe C, Ibrahim F, Persad R, Ben-Shlomo Y.","Int J Cancer. 2008 Jul 15;123(2):430-435. doi: 10.1002/ijc.23500.","Evans S","Int J Cancer","2008","2008/05/03","","","10.1002/ijc.23500"
"11992844","Percentage of core lengths involved with prostate cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific antigen outcome for men with intermediate-risk prostate cancer?","Linson PW, Lee AK, Doytchinova T, Chen MH, Weinstein MH, Richie JP, D'Amico AV.","Urology. 2002 May;59(5):704-8. doi: 10.1016/s0090-4295(01)01665-x.","Linson PW","Urology","2002","2002/05/07","","","10.1016/s0090-4295(01)01665-x"
"19634784","Endothelin-1 expression in prostate cancer and high grade prostatic intraepithelial neoplasia","Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, Egevad L.","Anal Quant Cytol Histol. 2009 Jun;31(3):137-42.","Rosenblatt R","Anal Quant Cytol Histol","2009","2009/07/29","","",""
"17483015","Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?","Phillips JJ, Hall MC, Lee WR, Clark PE.","Urol Oncol. 2007 May-Jun;25(3):196-200. doi: 10.1016/j.urolonc.2006.06.004.","Phillips JJ","Urol Oncol","2007","2007/05/08","","","10.1016/j.urolonc.2006.06.004"
"18020204","[A study of the progression of the incidental prostate cancer depending on the kind of treatment performed]","Napal Lecumberri S, Lameiro Couso FJ, Rubio Navarro C, Gómez Dorronsoro M, Larrínaga Liñero B, Ipiéns Aznar A.","Actas Urol Esp. 2007 Sep;31(8):810-8. doi: 10.1016/s0210-4806(07)73734-8.","Napal Lecumberri S","Actas Urol Esp","2007","2007/11/21","","","10.1016/s0210-4806(07)73734-8"
"12376504","Androgen receptor polymorphisms and the incidence of prostate cancer","Chen C, Lamharzi N, Weiss NS, Etzioni R, Dightman DA, Barnett M, DiTommaso D, Goodman G.","Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1033-40.","Chen C","Cancer Epidemiol Biomarkers Prev","2002","2002/10/12","","",""
"22465021","Novel endocrine aspects of prostate cancer","Visakorpi T.","Mol Cell Endocrinol. 2012 Sep 5;360(1-2):1-2. doi: 10.1016/j.mce.2012.03.015. Epub 2012 Mar 28.","Visakorpi T","Mol Cell Endocrinol","2012","2012/04/03","","","10.1016/j.mce.2012.03.015"
"19664112","Locally advanced prostate cancer: the role of surgical management","Stratton KL, Chang SS.","BJU Int. 2009 Aug;104(4):449-54. doi: 10.1111/j.1464-410X.2009.08741.x.","Stratton KL","BJU Int","2009","2009/08/12","","","10.1111/j.1464-410X.2009.08741.x"
"30855023","Inmunotherapy in prostate cancer","Anselmo da Costa I, Stenzl A, Bedke J.","Arch Esp Urol. 2019 Mar;72(2):211-222.","Anselmo da Costa I","Arch Esp Urol","2019","2019/03/12","","",""
"12006246","Tissue-specific promoters in gene therapy for the treatment of prostate cancer","Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW.","Mol Urol. 2000 Summer;4(2):73-82. doi: 10.1089/10915360050138620.","Shirakawa T","Mol Urol","2000","2002/05/15","","","10.1089/10915360050138620"
"18958922","Does Proscar prevent prostate cancer?","","Johns Hopkins Med Lett Health After 50. 2008 Oct;20(8):3.","","Johns Hopkins Med Lett Health After 50","2008","2008/10/31","","",""
"25603995","Prostate cancer organoids: a potential new tool for testing drug sensitivity","Vela I, Chen Y.","Expert Rev Anticancer Ther. 2015 Mar;15(3):261-3. doi: 10.1586/14737140.2015.1003046. Epub 2015 Jan 20.","Vela I","Expert Rev Anticancer Ther","2015","2015/01/22","PMC4691705","NIHMS741714","10.1586/14737140.2015.1003046"
"22526181","[Intermittent androgen deprivation as therapy for androgen-sensitive prostate cancer. Sense or nonsense?]","Thelen P, Ringert RH, Loertzer H, Strauß A.","Urologe A. 2012 Sep;51(9):1240-5. doi: 10.1007/s00120-012-2870-1.","Thelen P","Urologe A","2012","2012/04/25","","","10.1007/s00120-012-2870-1"
"16896037","The cost of prostate cancer chemoprevention: a decision analysis model","Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y.","Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1485-9. doi: 10.1158/1055-9965.EPI-06-0221.","Svatek RS","Cancer Epidemiol Biomarkers Prev","2006","2006/08/10","","","10.1158/1055-9965.EPI-06-0221"
"15780167","Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease","Klotz LH.","Can J Urol. 2005 Feb;12 Suppl 1:53-7; discussion 101-2.","Klotz LH","Can J Urol","2005","2005/03/23","","",""
"9179226","Advanced prostate cancer diagnosis and therapy with gallium-67 and yttrium-90, respectively","Shukla SK, Limouris GS, Cusumano R, Acconcia A, Cipriani C, Atzei G, Argirò G, Boemi S.","Anticancer Res. 1997 May-Jun;17(3B):1731-4.","Shukla SK","Anticancer Res","1997","1997/05/01","","",""
"11183927","Stats & facts. Prostate cancer in the gender-specific scheme of things","","Manag Care Interface. 2000 Jul;13(7):38-9.","","Manag Care Interface","2000","2001/02/24","","",""
"18780314","Targeted therapy in prostate cancer--are we our own worst enemy?","Dawson NA.","Cancer. 2008 Nov 1;113(9):2376-8. doi: 10.1002/cncr.23865.","Dawson NA","Cancer","2008","2008/09/10","","","10.1002/cncr.23865"
"26512743","Health-related quality of life in men with metastatic castration-resistant prostate cancer","Gee A, Challapalli A, Bahl A.","Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):941-9. doi: 10.1586/14737167.2015.1107479. Epub 2015 Oct 29.","Gee A","Expert Rev Pharmacoecon Outcomes Res","2015","2015/10/30","","","10.1586/14737167.2015.1107479"
"1538502","Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study","Sneller ZW, Hop WC, Carpentier PJ, Schröder FH.","J Urol. 1992 Mar;147(3 Pt 2):962-6. doi: 10.1016/s0022-5347(17)37434-7.","Sneller ZW","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37434-7"
"22740161","Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer","Bellone M, Rigamonti N.","Cancer Immunol Immunother. 2012 Dec;61(12):2377-8. doi: 10.1007/s00262-012-1310-9. Epub 2012 Jun 28.","Bellone M","Cancer Immunol Immunother","2012","2012/06/29","","","10.1007/s00262-012-1310-9"
"20727805","[Place of surgery in high-risk tumours of the prostate]","Soulié M, Rozet F, Hennequin C, Salomon L; Membres du Sous-Comité Prostate du CCAFU.","Cancer Radiother. 2010 Oct;14(6-7):493-9. doi: 10.1016/j.canrad.2010.06.006. Epub 2010 Aug 19.","Soulié M","Cancer Radiother","2010","2010/08/24","","","10.1016/j.canrad.2010.06.006"
"24947249","Testosterone serum levels and prostate cancer prognosis: the double face of Janus","Valcamonico F, Ferrari L, Consoli F, Amoroso V, Berruti A.","Future Oncol. 2014 May;10(7):1113-5. doi: 10.2217/fon.14.1.","Valcamonico F","Future Oncol","2014","2014/06/21","","","10.2217/fon.14.1"
"27825432","PSMA PET and Radionuclide Therapy in Prostate Cancer","Bouchelouche K, Turkbey B, Choyke PL.","Semin Nucl Med. 2016 Nov;46(6):522-535. doi: 10.1053/j.semnuclmed.2016.07.006. Epub 2016 Sep 3.","Bouchelouche K","Semin Nucl Med","2016","2016/11/10","PMC5123597","NIHMS814916","10.1053/j.semnuclmed.2016.07.006"
"31469662","Risk stratification and avoiding overtreatment in localized prostate cancer","Hanna B, Ranasinghe W, Lawrentschuk N.","Curr Opin Urol. 2019 Nov;29(6):612-619. doi: 10.1097/MOU.0000000000000672.","Hanna B","Curr Opin Urol","2019","2019/08/31","","","10.1097/MOU.0000000000000672"
"2433078","A preliminary study of urinary transferrin as a marker for prostatic cancer","Fernandez C, Rifai N, Wenger AS, Mickey DD, Silverman LM.","Clin Chim Acta. 1986 Dec 30;161(3):335-9. doi: 10.1016/0009-8981(86)90018-5.","Fernandez C","Clin Chim Acta","1986","1986/12/30","","","10.1016/0009-8981(86)90018-5"
"11441519","Sexual functioning in patients with localized prostate cancer awaiting treatment","Incrocci L, Madalinska JB, Essink-Bot ML, Van Putten WL, Koper PC, Schröder FH.","J Sex Marital Ther. 2001 Jul-Sep;27(4):353-63. doi: 10.1080/009262301317081106.","Incrocci L","J Sex Marital Ther","2001","2001/07/10","","","10.1080/009262301317081106"
"25139338","Smoking and risk of low- and high-grade prostate cancer: results from the REDUCE study","Ho T, Howard LE, Vidal AC, Gerber L, Moreira D, McKeever M, Andriole G, Castro-Santamaria R, Freedland SJ.","Clin Cancer Res. 2014 Oct 15;20(20):5331-8. doi: 10.1158/1078-0432.CCR-13-2394. Epub 2014 Aug 19.","Ho T","Clin Cancer Res","2014","2014/08/21","PMC4199866","NIHMS622400","10.1158/1078-0432.CCR-13-2394"
"1950983","Benign and malignant prostatic diseases","Crawford ED.","Am Fam Physician. 1991 Nov;44(5 Suppl):65S-70S.","Crawford ED","Am Fam Physician","1991","1991/11/01","","",""
"22191234","[Survival among patients with prostate cancer after distant radiotherapy and low-intensity near-infrared phototherapy]","Zharinov GM, Zimin AA, Samoĭlova KA, Neklasova NIu.","Vopr Onkol. 2011;57(4):457-61.","Zharinov GM","Vopr Onkol","2011","2011/12/24","","",""
"26161414","Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer","Silvestri I, Cattarino S, Aglianò AM, Collalti G, Sciarra A.","Biomed Res Int. 2015;2015:794968. doi: 10.1155/2015/794968. Epub 2015 Jun 16.","Silvestri I","Biomed Res Int","2015","2015/07/11","PMC4486485","","10.1155/2015/794968"
"8808876","Malignant cytological washings from radical prostatectomy specimens: a possible mechanism for local recurrence of prostate cancer following surgical treatment of organ confined disease","Ward JF, Nowacki M, Sands JP, Conner RJ, Huisman TK.","J Urol. 1996 Oct;156(4):1381-4; discussion 1384-5. doi: 10.1016/s0022-5347(01)65591-5.","Ward JF","J Urol","1996","1996/10/01","","","10.1016/s0022-5347(01)65591-5"
"31194822","Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study","Palsdottir T, Nordström T, Aly M, Lindberg J, Clements M, Egevad L, Grönberg H, Eklund M.","PLoS One. 2019 Jun 13;14(6):e0218280. doi: 10.1371/journal.pone.0218280. eCollection 2019.","Palsdottir T","PLoS One","2019","2019/06/14","PMC6564040","","10.1371/journal.pone.0218280"
"16409608","Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b","Masue N, Deguchi T, Nakano M, Ehara H, Uno H, Takahashi Y.","Int J Urol. 2005 Dec;12(12):1045-9. doi: 10.1111/j.1442-2042.2005.01205.x.","Masue N","Int J Urol","2005","2006/01/18","","","10.1111/j.1442-2042.2005.01205.x"
"24582538","Variation in prostate cancer detection rates in a statewide quality improvement collaborative","Riedinger CB, Womble PR, Linsell SM, Ye Z, Montie JE, Miller DC, Lane BR; Michigan Urological Surgery Improvement Collaborative.","J Urol. 2014 Aug;192(2):373-8. doi: 10.1016/j.juro.2014.02.088. Epub 2014 Feb 25.","Riedinger CB","J Urol","2014","2014/03/04","","","10.1016/j.juro.2014.02.088"
"24812137","Prostate cancer, version 2.2014","Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M; National Comprehensive Cancer Network.","J Natl Compr Canc Netw. 2014 May;12(5):686-718. doi: 10.6004/jnccn.2014.0072.","Mohler JL","J Natl Compr Canc Netw","2014","2014/05/10","","","10.6004/jnccn.2014.0072"
"1927770","[Clinical study of prostate cancer--statistical analysis in the last 10 years]","Yamamoto N, Shimabukuro T, Matsuyama H, Yoshihiro S, Mitsui H, Sakatoku J.","Hinyokika Kiyo. 1991 Jul;37(7):705-10.","Yamamoto N","Hinyokika Kiyo","1991","1991/07/01","","",""
"19343732","Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells","Dozmorov MG, Hurst RE, Culkin DJ, Kropp BP, Frank MB, Osban J, Penning TM, Lin HK.","Prostate. 2009 Jul 1;69(10):1077-90. doi: 10.1002/pros.20960.","Dozmorov MG","Prostate","2009","2009/04/04","PMC2755240","NIHMS129771","10.1002/pros.20960"
"27380910","Can vitamin D supplementation reduce prostate cancer disparities?","Batai K, Kittles RA.","Pharmacogenomics. 2016 Jul;17(10):1117-1120. doi: 10.2217/pgs-2016-0089. Epub 2016 Jul 6.","Batai K","Pharmacogenomics","2016","2016/07/07","PMC6562891","","10.2217/pgs-2016-0089"
"18398294","A multipronged approach to prostate cancer","Franklin RA, McCubrey JA.","Cancer Biol Ther. 2008 Apr;7(4):594-5. doi: 10.4161/cbt.7.4.5998. Epub 2008 Mar 28.","Franklin RA","Cancer Biol Ther","2008","2008/04/10","","","10.4161/cbt.7.4.5998"
"7515842","Treatment of early stage prostate cancer: radiotherapy","Hanks GE.","Important Adv Oncol. 1994:225-39.","Hanks GE","Important Adv Oncol","1994","1994/01/01","","",""
"19541477","Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study","Collin SM, Metcalfe C, Donovan JL, Athene Lane J, Davis M, Neal DE, Hamdy FC, Martin RM.","Eur J Cancer. 2009 Dec;45(18):3254-61. doi: 10.1016/j.ejca.2009.05.021. Epub 2009 Jun 21.","Collin SM","Eur J Cancer","2009","2009/06/23","","","10.1016/j.ejca.2009.05.021"
"29524974","African-American men with prostate cancer have larger tumor volume than Caucasian men despite no difference in serum prostate specific antigen","Fuletra JG, Kamenko A, Ramsey F, Eun DD, Reese AC.","Can J Urol. 2018 Feb;25(1):9193-9198.","Fuletra JG","Can J Urol","2018","2018/03/12","","",""
"22072504","Androgen deprivation for prostate cancer: the case for ""first, do no harm""","Shahinian VB.","Cancer. 2012 Jul 1;118(13):3232-5. doi: 10.1002/cncr.26624.","Shahinian VB","Cancer","2012","2011/11/11","","","10.1002/cncr.26624"
"3246826","[Comparison of grade of prostate cancer between pretreatment and autopsy]","Ando K, Fuse H, Shimazaki J, Murakami S, Matsuzaki O.","Nihon Hinyokika Gakkai Zasshi. 1988 Aug;79(8):1399-405. doi: 10.5980/jpnjurol1928.79.8_1399.","Ando K","Nihon Hinyokika Gakkai Zasshi","1988","1988/08/01","","","10.5980/jpnjurol1928.79.8_1399"
"1738190","Prostate cancer incidence in cimetidine users","Møller H, Mellemgaard A.","J Natl Cancer Inst. 1992 Mar 4;84(5):359-60. doi: 10.1093/jnci/84.5.359.","Møller H","J Natl Cancer Inst","1992","1992/03/04","","","10.1093/jnci/84.5.359"
"27367469","Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities","Leyh-Bannurah SR, Abou-Haidar H, Dell'Oglio P, Schiffmann J, Tian Z, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI.","BJU Int. 2017 May;119(5):692-699. doi: 10.1111/bju.13570. Epub 2016 Aug 5.","Leyh-Bannurah SR","BJU Int","2017","2016/07/02","","","10.1111/bju.13570"
"22537183","Fundamental role of microRNAs in androgen-dependent male reproductive biology and prostate cancerogenesis","Todorova K, Mincheff M, Hayrabedyan S, Mincheva J, Zasheva D, Kuzmanov A, Fernández N.","Am J Reprod Immunol. 2013 Feb;69(2):100-4. doi: 10.1111/j.1600-0897.2012.01139.x. Epub 2012 Apr 26.","Todorova K","Am J Reprod Immunol","2013","2012/04/28","","","10.1111/j.1600-0897.2012.01139.x"
"26269156","[The focus and prospect of prostate cancer research]","Li H, Dong D.","Zhonghua Wai Ke Za Zhi. 2015 Apr;53(4):253-6.","Li H","Zhonghua Wai Ke Za Zhi","2015","2015/08/14","","",""
"15048555","[Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype]","Bonkhoff H, Fixemer T.","Urologe A. 2004 Jul;43(7):836-42. doi: 10.1007/s00120-004-0559-9.","Bonkhoff H","Urologe A","2004","2004/03/30","","","10.1007/s00120-004-0559-9"
"18403093","Preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values","Spyropoulos E, Dellis AE.","Eur Urol. 2008 Sep;54(3):701-2. doi: 10.1016/j.eururo.2008.03.083. Epub 2008 Apr 3.","Spyropoulos E","Eur Urol","2008","2008/04/12","","","10.1016/j.eururo.2008.03.083"
"15656911","Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells","Li Y, Hussain M, Sarkar SH, Eliason J, Li R, Sarkar FH.","BMC Cancer. 2005 Jan 18;5:7. doi: 10.1186/1471-2407-5-7.","Li Y","BMC Cancer","2005","2005/01/20","PMC548501","","10.1186/1471-2407-5-7"
"22112545","Recent trends in prostate cancer testing and incidence among men under age of 50","Li J, German R, King J, Joseph D, Thompson T, Wu XC, Ajani U, Tai E.","Cancer Epidemiol. 2012 Apr;36(2):122-7. doi: 10.1016/j.canep.2011.10.014. Epub 2011 Nov 22.","Li J","Cancer Epidemiol","2012","2011/11/25","","","10.1016/j.canep.2011.10.014"
"23567761","Summaries for patients. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians","","Ann Intern Med. 2013 May 21;158(10):I-28. doi: 10.7326/0003-4819-158-10-201305210-00634.","","Ann Intern Med","2013","2013/04/10","","","10.7326/0003-4819-158-10-201305210-00634"
"12226148","A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer","Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, Andersson SO, Spångberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlén BJ; Scandinavian Prostatic Cancer Group Study Number 4.","N Engl J Med. 2002 Sep 12;347(11):781-9. doi: 10.1056/NEJMoa012794.","Holmberg L","N Engl J Med","2002","2002/09/13","","","10.1056/NEJMoa012794"
"29197360","Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations","Axcrona K, Nilsson R, Brennhovd B, Sørebø Ø, Fosså SD, Dahl AA.","BMC Urol. 2017 Dec 2;17(1):111. doi: 10.1186/s12894-017-0302-7.","Axcrona K","BMC Urol","2017","2017/12/04","PMC5712157","","10.1186/s12894-017-0302-7"
"8976247","Serum-to-urinary prostate specific antigen ratio: its impact in distinguishing prostate cancer when serum prostate specific antigen level is 4 to 10 ng./ml","Irani J, Millet C, Levillain P, Doré B, Begon F, Aubert J.","J Urol. 1997 Jan;157(1):185-8. doi: 10.1016/s0022-5347(01)65319-9.","Irani J","J Urol","1997","1997/01/01","","","10.1016/s0022-5347(01)65319-9"
"26332209","Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study","Herden J, Wille S, Weissbach L.","BJU Int. 2016 Aug;118(2):258-63. doi: 10.1111/bju.13308. Epub 2015 Sep 23.","Herden J","BJU Int","2016","2015/09/03","","","10.1111/bju.13308"
"27997745","Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer","Miller ET, Chamie K, Kwan L, Lewis MS, Knudsen BS, Garraway IP.","Cancer Med. 2017 Jan;6(1):163-172. doi: 10.1002/cam4.981. Epub 2016 Dec 20.","Miller ET","Cancer Med","2017","2016/12/21","PMC5269571","","10.1002/cam4.981"
"6823718","Understaging and undergrading of prostate cancer. Argument for postoperative radiation as adjuvant therapy","Lange PH, Narayan P.","Urology. 1983 Feb;21(2):113-8. doi: 10.1016/0090-4295(83)90002-x.","Lange PH","Urology","1983","1983/02/01","","","10.1016/0090-4295(83)90002-x"
"15538203","Adjunctive therapy for men with high risk localized and locally advanced prostate cancer: targeting disseminated tumor cells","Sokoloff MH, Rinker-Schaeffer CW, Chung LW, Brendler CB.","J Urol. 2004 Dec;172(6 Pt 2):2539-44. doi: 10.1097/01.ju.0000145044.97177.09.","Sokoloff MH","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000145044.97177.09"
"12833768","Patient education. Prostate cancer","Frydenberg M.","Aust Fam Physician. 2003 Jun;32(6):428.","Frydenberg M","Aust Fam Physician","2003","2003/07/02","","",""
"1633928","[Hormones and growth of cancer]","Matsumoto K.","Nihon Naibunpi Gakkai Zasshi. 1992 Jun 20;68(6):577-83. doi: 10.1507/endocrine1927.68.6_577.","Matsumoto K","Nihon Naibunpi Gakkai Zasshi","1992","1992/06/20","","","10.1507/endocrine1927.68.6_577"
"26771762","MicroRNA-103 suppresses tumor cell proliferation by targeting PDCD10 in prostate cancer","Fu X, Zhang W, Su Y, Lu L, Wang D, Wang H.","Prostate. 2016 May;76(6):543-51. doi: 10.1002/pros.23143. Epub 2016 Jan 15.","Fu X","Prostate","2016","2016/01/16","","","10.1002/pros.23143"
"11228528","Towards the optimal vector for prostate cancer gene therapy; a caPCURE meeting report","Rots MG, Curiel DT.","Cancer Gene Ther. 2000 Dec;7(12):1507-10. doi: 10.1038/sj.cgt.7700253.","Rots MG","Cancer Gene Ther","2000","2001/03/03","","","10.1038/sj.cgt.7700253"
"24036934","Seminal vesicle biopsies: an useful staging procedure-exposure of seminal vesicle biopsies protocol and review of the literature","Montoya-Chinchilla R, Rosino-Sánchez A, Fernandez-Aparicio T, Cano-García MC, Hidalgo-Agulló G, Reina-Alcaina L, Carrillo-George C, Izquierdo-Morejón E, Miñana-López B.","Int Urol Nephrol. 2014 Jan;46(1):297-302. doi: 10.1007/s11255-013-0473-4. Epub 2013 Sep 15.","Montoya-Chinchilla R","Int Urol Nephrol","2014","2013/09/17","","","10.1007/s11255-013-0473-4"
"22930822","Will identification of a prostate cancer stem cell lead to its cure?","Garraway IP.","Urol Oncol. 2012 Jul-Aug;30(4):351-2. doi: 10.1016/j.urolonc.2011.01.015.","Garraway IP","Urol Oncol","2012","2012/08/30","","","10.1016/j.urolonc.2011.01.015"
"26343525","The roles of stress and social support in prostate cancer mortality","Jan M, Bonn SE, Sjölander A, Wiklund F, Stattin P, Holmberg E, Grönberg H, Bälter K.","Scand J Urol. 2016;50(1):47-55. doi: 10.3109/21681805.2015.1079796. Epub 2015 Sep 7.","Jan M","Scand J Urol","2016","2015/09/08","","","10.3109/21681805.2015.1079796"
"27321179","Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization","Cai G, Wu D, Wang Z, Xu Z, Wong KB, Ng CF, Chan FL, Yu S.","Oncogene. 2017 Jan 26;36(4):546-558. doi: 10.1038/onc.2016.227. Epub 2016 Jun 20.","Cai G","Oncogene","2017","2016/06/21","PMC5290039","","10.1038/onc.2016.227"
"22373800","Clinical and pathological parameters predicting extracapsular disease in patients undergoing a radical prostatectomy for clinically localized prostate cancer","Sfoungaristos S, Perimenis P.","Prague Med Rep. 2012;113(1):5-15. doi: 10.14712/23362936.2015.32.","Sfoungaristos S","Prague Med Rep","2012","2012/03/01","","","10.14712/23362936.2015.32"
"27245501","Prostate cancer: Interfering with abiraterone metabolism to optimize therapy","Thoma C.","Nat Rev Urol. 2016 Jul;13(7):370. doi: 10.1038/nrurol.2016.101. Epub 2016 Jun 1.","Thoma C","Nat Rev Urol","2016","2016/06/02","","","10.1038/nrurol.2016.101"
"29101511","[Current treatment of advanced prostate cancer]","Gratzke C, Stief CG.","Urologe A. 2017 Nov;56(11):1381-1382. doi: 10.1007/s00120-017-0518-x.","Gratzke C","Urologe A","2017","2017/11/05","","","10.1007/s00120-017-0518-x"
"22343491","Cyr61 is a potential prognostic marker for prostate cancer","Terada N, Kulkarni P, Getzenberg RH.","Asian J Androl. 2012 May;14(3):405-8. doi: 10.1038/aja.2011.149. Epub 2012 Feb 20.","Terada N","Asian J Androl","2012","2012/02/21","PMC3472413","NIHMS405142","10.1038/aja.2011.149"
"12026768","The role of the prostate cancer nurse specialist","Higgins D.","Prof Nurse. 2000 May;15(8):539-42.","Higgins D","Prof Nurse","2000","2002/05/25","","",""
"25495908","Prostate cancer patients gradually advance goals for rehabilitation after radical prostatectomy: applying a lines-of-defense model to rehabilitation","Knoll N, Wiedemann AU, Schultze M, Schrader M, Heckhausen J.","Psychol Aging. 2014 Dec;29(4):787-92. doi: 10.1037/a0038311.","Knoll N","Psychol Aging","2014","2014/12/16","","","10.1037/a0038311"
"19031091","High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies","van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A.","MAGMA. 2008 Nov;21(6):435-42. doi: 10.1007/s10334-008-0156-9. Epub 2008 Nov 25.","van Asten JJ","MAGMA","2008","2008/11/26","","","10.1007/s10334-008-0156-9"
"29297495","Treatment effects in prostate cancer","Evans AJ.","Mod Pathol. 2018 Jan;31(S1):S110-121. doi: 10.1038/modpathol.2017.158.","Evans AJ","Mod Pathol","2018","2018/01/04","","","10.1038/modpathol.2017.158"
"8758241","Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study","Filella X, Molina R, Ballesta AM, Gil MJ, Allepuz C, Rioja LA.","Eur J Cancer. 1996 Jun;32A(7):1125-8. doi: 10.1016/0959-8049(96)00092-5.","Filella X","Eur J Cancer","1996","1996/06/01","","","10.1016/0959-8049(96)00092-5"
"8542338","Prostate cancer screening in a large corporation population","Kantrowitz W, Doyle J, Semeraro J, Krane RJ.","J Occup Environ Med. 1995 Oct;37(10):1193-8. doi: 10.1097/00043764-199510000-00009.","Kantrowitz W","J Occup Environ Med","1995","1995/10/01","","","10.1097/00043764-199510000-00009"
"12960963","Genetic deficiency in Pparg does not alter development of experimental prostate cancer","Saez E, Olson P, Evans RM.","Nat Med. 2003 Oct;9(10):1265-6. doi: 10.1038/nm928. Epub 2003 Sep 7.","Saez E","Nat Med","2003","2003/09/10","","","10.1038/nm928"
"8284886","Heterogeneity of prostate cancer in radical prostatectomy specimens","Aihara M, Wheeler TM, Ohori M, Scardino PT.","Urology. 1994 Jan;43(1):60-6; discussion 66-7. doi: 10.1016/s0090-4295(94)80264-5.","Aihara M","Urology","1994","1994/01/01","","","10.1016/s0090-4295(94)80264-5"
"27738867","Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials","Adamowicz K.","Qual Life Res. 2017 Apr;26(4):813-822. doi: 10.1007/s11136-016-1429-9. Epub 2016 Oct 13.","Adamowicz K","Qual Life Res","2017","2016/10/15","","","10.1007/s11136-016-1429-9"
"9123730","Clinical significance of repeat sextant biopsies in prostate cancer patients","Stroumbakis N, Cookson MS, Reuter VE, Fair WR.","Urology. 1997 Mar;49(3A Suppl):113-8. doi: 10.1016/s0090-4295(97)00178-7.","Stroumbakis N","Urology","1997","1997/03/01","","","10.1016/s0090-4295(97)00178-7"
"24018567","Evolution of advanced technologies in prostate cancer radiotherapy","Zaorsky NG, Harrison AS, Trabulsi EJ, Gomella LG, Showalter TN, Hurwitz MD, Dicker AP, Den RB.","Nat Rev Urol. 2013 Oct;10(10):565-79. doi: 10.1038/nrurol.2013.185. Epub 2013 Sep 10.","Zaorsky NG","Nat Rev Urol","2013","2013/09/11","","","10.1038/nrurol.2013.185"
"9093251","Population-based study of long-term survival in patients with clinically localised prostate cancer","Lu-Yao GL, Yao SL.","Lancet. 1997 Mar 29;349(9056):906-10. doi: 10.1016/S0140-6736(96)09380-4.","Lu-Yao GL","Lancet","1997","1997/03/29","","","10.1016/S0140-6736(96)09380-4"
"21047592","Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies","Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL.","Eur J Cancer. 2010 Nov;46(17):3095-101. doi: 10.1016/j.ejca.2010.09.016.","Lane JA","Eur J Cancer","2010","2010/11/05","","","10.1016/j.ejca.2010.09.016"
"12508727","[Imaging of the prostate: when should CT and MR be used?]","Barone D, Nocco AM, Golfieri R.","Arch Ital Urol Androl. 2002 Dec;74(4):186-7.","Barone D","Arch Ital Urol Androl","2002","2003/01/02","","",""
"1284556","[Early diagnosis of prostatic cancer with digital rectal examination, PSA determination, and endorectal echography. Correlations with the morphologic diagnosis in 200 consecutive cases]","Voisin E, Piaton E, Rivain T, Duco F.","Prog Urol. 1992 Dec;2(6):973-9.","Voisin E","Prog Urol","1992","1992/12/01","","",""
"3717904","[Place of prostatectomy and radiotherapy in the treatment of cancer of the prostate confined to the prostate gland (T0, T1, T2)]","Chopin DK, de Kernion JB.","Ann Urol (Paris). 1986;20(2):83-9.","Chopin DK","Ann Urol (Paris)","1986","1986/01/01","","",""
"23159990","Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?","Loeb S, Gupta A, Losonczy L, Tosoian J, Walsh PC.","Curr Opin Urol. 2013 Jan;23(1):2-4. doi: 10.1097/MOU.0b013e32835abcf2.","Loeb S","Curr Opin Urol","2013","2012/11/20","","","10.1097/MOU.0b013e32835abcf2"
"19477778","How prostate cancer support groups do and do not survive: British Columbian perspectives","Oliffe JL, Halpin M, Bottorff JL, Hislop TG, McKenzie M, Mroz L.","Am J Mens Health. 2008 Jun;2(2):143-55. doi: 10.1177/1557988307304147. Epub 2007 Jul 19.","Oliffe JL","Am J Mens Health","2008","2009/05/30","","","10.1177/1557988307304147"
"9507872","Re: Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: a clinicopathological molecular analysis of 121 patients","Westerhof AC, de Reijke TM, de Boer EC, Kurth KH, Schamhart DH.","J Urol. 1998 Apr;159(4):1311-3. doi: 10.1016/s0022-5347(01)63601-2.","Westerhof AC","J Urol","1998","1998/03/21","","","10.1016/s0022-5347(01)63601-2"
"31127901","Dietary Nutrient Patterns and Prostate Cancer Risk: A Case-Control Study from Iran","Bahrami A, Movahed M, Teymoori F, Mazandaranian MR, Rashidkhani B, Hekmatdoost A, Hejazi E.","Asian Pac J Cancer Prev. 2019 May 25;20(5):1415-1420. doi: 10.31557/APJCP.2019.20.5.1415.","Bahrami A","Asian Pac J Cancer Prev","2019","2019/05/26","PMC6857882","","10.31557/APJCP.2019.20.5.1415"
"30141351","Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer","Sundaresan L, Kumar P, Chatterjee S.","Future Oncol. 2018 Oct;14(23):2383-2401. doi: 10.2217/fon-2018-0090. Epub 2018 Aug 24.","Sundaresan L","Future Oncol","2018","2018/08/25","","","10.2217/fon-2018-0090"
"22270263","Editorial for special issue on epidemiology and prevention of prostate cancer","Thompson IM, Ankerst DP.","World J Urol. 2012 Apr;30(2):129-30. doi: 10.1007/s00345-012-0830-4. Epub 2012 Jan 22.","Thompson IM","World J Urol","2012","2012/01/25","","","10.1007/s00345-012-0830-4"
"14610414","Magnetic resonance imaging and spectroscopic imaging of prostate cancer","Coakley FV, Qayyum A, Kurhanewicz J.","J Urol. 2003 Dec;170(6 Pt 2):S69-75; discussion S75-6. doi: 10.1097/01.ju.0000094958.23276.c4.","Coakley FV","J Urol","2003","2003/11/12","","","10.1097/01.ju.0000094958.23276.c4"
"23271767","Temporal changes in the pathologic assessment of prostate cancer","Lucia MS, Bokhoven Av.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):157-61. doi: 10.1093/jncimonographs/lgs029.","Lucia MS","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540872","","10.1093/jncimonographs/lgs029"
"15269147","Her-2/neu expression in prostate cancer: a dynamic process?","Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, Nogue M, Domenech M, Fabregat X.","Clin Cancer Res. 2004 Jul 15;10(14):4742-5. doi: 10.1158/1078-0432.CCR-04-0115.","Carles J","Clin Cancer Res","2004","2004/07/23","","","10.1158/1078-0432.CCR-04-0115"
"22475908","Q Fever masquerading as prostate cancer metastases","Golden MJ, Fair JR.","Clin Nucl Med. 2012 May;37(5):511-3. doi: 10.1097/RLU.0b013e31823ea70a.","Golden MJ","Clin Nucl Med","2012","2012/04/06","","","10.1097/RLU.0b013e31823ea70a"
"1406742","The biology of prostate cancer: new and future directions in predicting tumor behavior","Partin AW, Carter HB, Epstein JI, Coffey DS.","Monogr Pathol. 1992;(34):198-218.","Partin AW","Monogr Pathol","1992","1992/01/01","","",""
"10759668","The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer","Endrizzi J, Seay T.","BJU Int. 2000 Apr;85(6):696-8. doi: 10.1046/j.1464-410x.2000.00518.x.","Endrizzi J","BJU Int","2000","2000/04/12","","","10.1046/j.1464-410x.2000.00518.x"
"16830128","[Prospective evaluation of prostate cancer screening in men with a family history of the disease]","Paiss T, Herkommer K, Kahn D, Gschwend JE, Küfer R, Maier C, Vogel W, Högel J, Hautmann RE.","Urologe A. 2006 Aug;45(8):1002-5. doi: 10.1007/s00120-006-1056-0.","Paiss T","Urologe A","2006","2006/07/11","","","10.1007/s00120-006-1056-0"
"28362316","Cancer/Testis Antigens: ""Smart"" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers","Kulkarni P, Uversky VN.","Int J Mol Sci. 2017 Mar 31;18(4):740. doi: 10.3390/ijms18040740.","Kulkarni P","Int J Mol Sci","2017","2017/04/01","PMC5412325","","10.3390/ijms18040740"
"16848361","[What is the best strategy of hormonal therapy in the treatment of locally advanced prostate cancer?]","Ehara H, Nakano M, Deguchi T.","Hinyokika Kiyo. 2006 Jun;52(6):473-7.","Ehara H","Hinyokika Kiyo","2006","2006/07/20","","",""
"9394717","Bridging animal and human studies: what are the missing segments in dietary fat and prostate cancer?","Zhou JR, Blackburn GL.","Am J Clin Nutr. 1997 Dec;66(6 Suppl):1572S-1580S. doi: 10.1093/ajcn/66.6.1572S.","Zhou JR","Am J Clin Nutr","1997","1997/12/12","","","10.1093/ajcn/66.6.1572S"
"29520850","Exploring the oncoproteomic response of human prostate cancer to therapeutic radiation using data-independent acquisition (DIA) mass spectrometry","Keam SP, Gulati T, Gamell C, Caramia F, Huang C, Schittenhelm RB, Kleifeld O, Neeson PJ, Haupt Y, Williams SG.","Prostate. 2018 Jun;78(8):563-575. doi: 10.1002/pros.23500. Epub 2018 Mar 9.","Keam SP","Prostate","2018","2018/03/10","","","10.1002/pros.23500"
"27226507","Multigene Testing in Localized Prostate Cancer","Ross AE.","J Natl Compr Canc Netw. 2016 May;14(5 Suppl):659-62. doi: 10.6004/jnccn.2016.0185.","Ross AE","J Natl Compr Canc Netw","2016","2016/05/27","","","10.6004/jnccn.2016.0185"
"30442538","Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes","Pompe RS, Leyh-Bannurah SR, Preisser F, Salomon G, Graefen M, Huland H, Karakiewicz PI, Tilki D.","Urol Oncol. 2018 Dec;36(12):527.e21-527.e28. doi: 10.1016/j.urolonc.2018.08.010. Epub 2018 Nov 12.","Pompe RS","Urol Oncol","2018","2018/11/17","","","10.1016/j.urolonc.2018.08.010"
"27377415","Treatment landscape of metastatic prostate cancer: the role of radium-223","Dermine A, Machiels JP.","Acta Clin Belg. 2017 Feb;72(1):19-23. doi: 10.1080/17843286.2016.1203545. Epub 2016 Jul 4.","Dermine A","Acta Clin Belg","2017","2016/07/06","","","10.1080/17843286.2016.1203545"
"23614596","Functional outcomes after treatment for prostate cancer","Rocco B, De Lorenzis E, Palumbo C.","N Engl J Med. 2013 Apr 25;368(17):1653. doi: 10.1056/NEJMc1302509.","Rocco B","N Engl J Med","2013","2013/04/26","","","10.1056/NEJMc1302509"
"18685362","Preservation of bone health in prostate cancer","Lattouf JB, Saad F.","Curr Opin Support Palliat Care. 2007 Oct;1(3):192-7. doi: 10.1097/SPC.0b013e3282f0c74f.","Lattouf JB","Curr Opin Support Palliat Care","2007","2008/08/08","","","10.1097/SPC.0b013e3282f0c74f"
"25951106","Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression","Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, Ekici ID, Caskurlu T, Solak M, Creighton CJ, Ittmann M.","Cancer Invest. 2015 Jul;33(6):251-8. doi: 10.3109/07357907.2015.1025407. Epub 2015 May 7.","Ozen M","Cancer Invest","2015","2015/05/08","","","10.3109/07357907.2015.1025407"
"9433056","The importance of screening African Americans for prostate cancer","Farkas A.","J Natl Med Assoc. 1997 Dec;89(12):779-82.","Farkas A","J Natl Med Assoc","1997","1998/01/20","PMC2608297","",""
"12913726","Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer","Man A, Pickles T, Chi KN; British Columbia Cancer Agency Prostate Cohort Outcomes Initiative.","J Urol. 2003 Sep;170(3):901-4. doi: 10.1097/01.ju.0000081423.37043.b4.","Man A","J Urol","2003","2003/08/13","","","10.1097/01.ju.0000081423.37043.b4"
"24091534","To target or not to target the enemy within localized prostate cancer","Risbridger G, Taylor R.","Cell Cycle. 2013 Nov 1;12(21):3349-50. doi: 10.4161/cc.26576. Epub 2013 Sep 23.","Risbridger G","Cell Cycle","2013","2013/10/05","PMC3895420","","10.4161/cc.26576"
"15323167","Increasing level of prostate-specific antigen and prostate cancer risk factors among 193 men examined in screening procedure","Opalińska E, Michalak A, Stoma F, Latalski M, Goniewicz M.","Ann Univ Mariae Curie Sklodowska Med. 2003;58(2):57-63.","Opalińska E","Ann Univ Mariae Curie Sklodowska Med","2003","2004/08/25","","",""
"17549691","Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer","Merrick GS, Galbreath RW, Butler WM, Waller KE, Allen ZA, Lief J, Adamovich E.","Cancer. 2007 Jul 15;110(2):289-96. doi: 10.1002/cncr.22793.","Merrick GS","Cancer","2007","2007/06/06","","","10.1002/cncr.22793"
"29079212","Gene Expression Correlates of Site-specific Metastasis Among Men With Lymph Node Positive Prostate Cancer Treated With Radical Prostatectomy: A Case Series","Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ.","Urology. 2018 Feb;112:29-32. doi: 10.1016/j.urology.2017.10.016. Epub 2017 Oct 25.","Sharma V","Urology","2018","2017/10/29","","","10.1016/j.urology.2017.10.016"
"23425994","Active surveillance: oncologic outcome","Venderbos LD, Bokhorst LP, Bangma CH, Roobol MJ.","Curr Opin Urol. 2013 May;23(3):268-72. doi: 10.1097/MOU.0b013e32835efe8f.","Venderbos LD","Curr Opin Urol","2013","2013/02/22","","","10.1097/MOU.0b013e32835efe8f"
"19848851","Technologies for localization and diagnosis of prostate cancer","Candefjord S, Ramser K, Lindahl OA.","J Med Eng Technol. 2009;33(8):585-603. doi: 10.3109/03091900903111966.","Candefjord S","J Med Eng Technol","2009","2009/10/24","","","10.3109/03091900903111966"
"10559607","Adjuvant and neoadjuvant hormonal therapy for prostate cancer","Tyrrell CJ.","Eur Urol. 1999 Dec;36(6):549-58. doi: 10.1159/000020047.","Tyrrell CJ","Eur Urol","1999","1999/11/24","","","10.1159/000020047"
"28745237","Anethole Inhibits the Proliferation of Human Prostate Cancer Cells via Induction of Cell Cycle Arrest and Apoptosis","Elkady AI.","Anticancer Agents Med Chem. 2018;18(2):216-236. doi: 10.2174/1871520617666170725165717.","Elkady AI","Anticancer Agents Med Chem","2018","2017/07/27","","","10.2174/1871520617666170725165717"
"19616835","Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy","Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ.","Urology. 2009 Nov;74(5):1090-3. doi: 10.1016/j.urology.2009.03.043. Epub 2009 Jul 18.","Tsivian M","Urology","2009","2009/07/21","","","10.1016/j.urology.2009.03.043"
"12541000","Predictive factors in prostate needle biopsy","Mazzucchelli R, Lopéz-Beltran A, Scarpelli M, Montironi R.","Pathologica. 2002 Dec;94(6):331-7. doi: 10.1007/s102420200060.","Mazzucchelli R","Pathologica","2002","2003/01/24","","","10.1007/s102420200060"
"27825431","PET Tracers Beyond FDG in Prostate Cancer","Schuster DM, Nanni C, Fanti S.","Semin Nucl Med. 2016 Nov;46(6):507-521. doi: 10.1053/j.semnuclmed.2016.07.005. Epub 2016 Sep 7.","Schuster DM","Semin Nucl Med","2016","2016/11/10","PMC5117950","NIHMS815457","10.1053/j.semnuclmed.2016.07.005"
"30112965","The Experiences of Gay and Bisexual Men Post-Prostate Cancer Treatment: A Meta-Synthesis of Qualitative Studies","Alexis O, Worsley AJ.","Am J Mens Health. 2018 Nov;12(6):2076-2088. doi: 10.1177/1557988318793785. Epub 2018 Aug 16.","Alexis O","Am J Mens Health","2018","2018/08/17","PMC6199434","","10.1177/1557988318793785"
"21986985","Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy","Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.","Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.","Miyamoto S","Prostate Cancer Prostatic Dis","2012","2011/10/12","","","10.1038/pcan.2011.47"
"19792961","Satraplatin for the therapy of castration-resistant prostate cancer","Sonpavde G, Sternberg CN.","Future Oncol. 2009 Sep;5(7):931-40. doi: 10.2217/fon.09.84.","Sonpavde G","Future Oncol","2009","2009/10/02","","","10.2217/fon.09.84"
"22052759","Personalized approach to prostate cancer prognosis","Donovan MJ, Costa J, Cordon-Cardo C.","Arch Esp Urol. 2011 Oct;64(8):783-91.","Donovan MJ","Arch Esp Urol","2011","2011/11/05","","",""
"19914133","Men's experiences of radical prostatectomy as treatment for prostate cancer","Walsh E, Hegarty J.","Eur J Oncol Nurs. 2010 Apr;14(2):125-33. doi: 10.1016/j.ejon.2009.10.003. Epub 2009 Nov 13.","Walsh E","Eur J Oncol Nurs","2010","2009/11/17","","","10.1016/j.ejon.2009.10.003"
"19892841","Adiponectin and prostate cancer mortality: to be or not to be skinny?","Freedland SJ, Williams CD, Masko EM.","Clin Chem. 2010 Jan;56(1):1-3. doi: 10.1373/clinchem.2009.137406. Epub 2009 Nov 5.","Freedland SJ","Clin Chem","2010","2009/11/07","","","10.1373/clinchem.2009.137406"
"6678469","Pelvic lymphadenectomy is not essential to staging accuracy in all patients with localized prostate cancer","Paulson DF.","Semin Urol. 1983 Aug;1(3):204-11.","Paulson DF","Semin Urol","1983","1983/08/01","","",""
"28914751","Magnetic Resonance Imaging-Based Prostate-Specific Antigen Density for Prediction of Gleason Score Upgrade in Patients With Low-Risk Prostate Cancer on Initial Biopsy","Sim KC, Sung DJ, Kang KW, Yang KS, Han NY, Park BJ, Kim MJ, Cho SB.","J Comput Assist Tomogr. 2017 Sep/Oct;41(5):731-736. doi: 10.1097/RCT.0000000000000579.","Sim KC","J Comput Assist Tomogr","2017","2017/09/16","","","10.1097/RCT.0000000000000579"
"12062600","Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer","D'Amico AV, Keshaviah A, Manola J, Cote K, Loffredo M, Iskrzytzky O, Renshaw AA.","Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):581-7. doi: 10.1016/s0360-3016(02)02797-9.","D'Amico AV","Int J Radiat Oncol Biol Phys","2002","2002/06/14","","","10.1016/s0360-3016(02)02797-9"
"26503286","Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer","Cifuentes FF, Valenzuela RH, Contreras HR, Castellón EA.","Oncol Rep. 2015 Dec;34(6):2837-44. doi: 10.3892/or.2015.4319.","Cifuentes FF","Oncol Rep","2015","2015/10/28","PMC4722890","","10.3892/or.2015.4319"
"25327466","Biologic differences between peripheral and transition zone prostate cancer","Lee JJ, Thomas IC, Nolley R, Ferrari M, Brooks JD, Leppert JT.","Prostate. 2015 Feb;75(2):183-90. doi: 10.1002/pros.22903. Epub 2014 Oct 18.","Lee JJ","Prostate","2015","2014/10/21","PMC4270836","NIHMS625034","10.1002/pros.22903"
"17034600","Predictive value of prostatic adenocarcinoma after a negative prostate biopsy","Park PC, Mai KT, Roustan Delatour NL, Morash C, Cagiannos I.","BJU Int. 2006 Nov;98(5):986-8. doi: 10.1111/j.1464-410X.2006.06453.x.","Park PC","BJU Int","2006","2006/10/13","","","10.1111/j.1464-410X.2006.06453.x"
"12191737","Overview of international collaborative group prostate cancer trials","Sternberg CN.","Crit Rev Oncol Hematol. 2002 Aug;43(2):153-8. doi: 10.1016/s1040-8428(02)00027-6.","Sternberg CN","Crit Rev Oncol Hematol","2002","2002/08/23","","","10.1016/s1040-8428(02)00027-6"
"30916290","Masculinities of prostate cancer survivors: a qualitative metasynthesis","Araújo JS, Zago MMF.","Rev Bras Enferm. 2019 Jan-Feb;72(1):231-240. doi: 10.1590/0034-7167-2017-0730.","Araújo JS","Rev Bras Enferm","2019","2019/03/28","","","10.1590/0034-7167-2017-0730"
"18848789","Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy","Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M.","Urol Oncol. 2010 Mar-Apr;28(2):145-51. doi: 10.1016/j.urolonc.2008.08.001. Epub 2008 Oct 10.","Miyake H","Urol Oncol","2010","2008/10/14","","","10.1016/j.urolonc.2008.08.001"
"10230693","The role of volume-weighted mean nuclear volume in predicting disease outcome in patients with stage M1 prostate cancer","Fujikawa K, Aoyama T, Itoh T, Nishio Y, Miyakawa M, Sasaki M.","APMIS. 1999 Apr;107(4):395-400. doi: 10.1111/j.1699-0463.1999.tb01571.x.","Fujikawa K","APMIS","1999","1999/05/07","","","10.1111/j.1699-0463.1999.tb01571.x"
"29994364","Using Dashboard Networks to Visualize Multiple Patient Histories: A Design Study on Post-Operative Prostate Cancer","Bernard J, Sessler D, Kohlhammer J, Ruddle RA.","IEEE Trans Vis Comput Graph. 2019 Mar;25(3):1615-1628. doi: 10.1109/TVCG.2018.2803829. Epub 2018 Feb 8.","Bernard J","IEEE Trans Vis Comput Graph","2019","2018/07/12","","","10.1109/TVCG.2018.2803829"
"11464107","Nutrition and prostate cancer","Schmitz-Dräger BJ, Eichholzer M, Beiche B, Ebert T.","Urol Int. 2001;67(1):1-11. doi: 10.1159/000050935.","Schmitz-Dräger BJ","Urol Int","2001","2001/07/21","","","10.1159/000050935"
"22613932","MicroRNAs as putative mediators of treatment response in prostate cancer","O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D.","Nat Rev Urol. 2012 May 22;9(7):397-407. doi: 10.1038/nrurol.2012.104.","O'Kelly F","Nat Rev Urol","2012","2012/05/23","","","10.1038/nrurol.2012.104"
"27926521","Moderate hypofractionated radiotherapy is more effective and safe for localized prostate cancer patients: a meta-analysis","Cao L, Yang YJ, Li ZW, Wu HF, Yang ZC, Liu SX, Wang P.","Oncotarget. 2017 Jan 10;8(2):2647-2658. doi: 10.18632/oncotarget.13735.","Cao L","Oncotarget","2017","2016/12/08","PMC5356830","","10.18632/oncotarget.13735"
"11059764","Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect","Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T.","Cancer Res. 2000 Oct 15;60(20):5710-3.","Habuchi T","Cancer Res","2000","2000/11/04","","",""
"28982880","Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer","Obata H, Shiota M, Akitake N, Takeuchi A, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Eto M.","Anticancer Res. 2017 Oct;37(10):5631-5637. doi: 10.21873/anticanres.11998.","Obata H","Anticancer Res","2017","2017/10/07","","","10.21873/anticanres.11998"
"25185084","Perils of comparing toxicities between stereotactic body radiation and intensity-modulated radiation therapy for prostate cancer on the basis of incomplete demographic registries","King CR, Steinberg MS, Kupelian P.","J Clin Oncol. 2014 Oct 20;32(30):3453. doi: 10.1200/JCO.2014.56.4229. Epub 2014 Sep 2.","King CR","J Clin Oncol","2014","2014/09/04","","","10.1200/JCO.2014.56.4229"
"11468562","[Prostatic intraepithelial neoplasia]","Molinié V.","Ann Pathol. 2001 Jun;21(3):245-54.","Molinié V","Ann Pathol","2001","2001/07/27","","",""
"11880864","Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients","Lissoni P, Malugani F, Casu M, Bukovec R, Egardi R, Bordin V, Fumagalli E, Mengo S, Gardani G.","Neuro Endocrinol Lett. 2002 Feb;23(1):61-3.","Lissoni P","Neuro Endocrinol Lett","2002","2002/03/07","","",""
"24447606","Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone","Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbø HB.","BJU Int. 2014 Dec;114(6b):E32-E42. doi: 10.1111/bju.12637.","Rud E","BJU Int","2014","2014/01/23","","","10.1111/bju.12637"
"24866157","Resveratrol-zinc combination for prostate cancer management","Singh CK, Pitschmann A, Ahmad N.","Cell Cycle. 2014;13(12):1867-74. doi: 10.4161/cc.29334. Epub 2014 May 27.","Singh CK","Cell Cycle","2014","2014/05/29","PMC4111750","","10.4161/cc.29334"
"9743691","Sexual dysfunction associated with the management of prostate cancer","Fitzpatrick JM, Kirby RS, Krane RJ, Adolfsson J, Newling DW, Goldstein I.","Eur Urol. 1998;33(6):513-22. doi: 10.1159/000019648.","Fitzpatrick JM","Eur Urol","1998","1998/09/23","","","10.1159/000019648"
"10705003","Quality of life in T1-3N0 prostate cancer patients treated with radiation therapy with minimum 10-year follow-up","Johnstone PA, Gray C, Powell CR.","Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):833-8. doi: 10.1016/s0360-3016(99)00496-4.","Johnstone PA","Int J Radiat Oncol Biol Phys","2000","2000/03/08","","","10.1016/s0360-3016(99)00496-4"
"11956261","Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?","Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW.","J Clin Oncol. 2002 Apr 15;20(8):2025-30. doi: 10.1200/JCO.2002.08.123.","Cagiannos I","J Clin Oncol","2002","2002/04/17","","","10.1200/JCO.2002.08.123"
"24556193","Focal therapy for prostate cancer. Rationale, indications and selection","Gómez-Veiga F, Portela-Pereira P, Cozar-Olmo JM, Ahmed H, Moore C, Dickinson L, Algaba F, Izquierdo L, Alcaraz Asensio A, Martinez-Breijo S, Emberton M.","Actas Urol Esp. 2014 Jul-Aug;38(6):405-12. doi: 10.1016/j.acuro.2013.12.005. Epub 2014 Feb 18.","Gómez-Veiga F","Actas Urol Esp","2014","2014/02/22","","","10.1016/j.acuro.2013.12.005"
"16006299","Hypocalcemia and parathyroid function in metastatic prostate cancer","Tandon PK, Rizvi AA.","Endocr Pract. 2005 Jul-Aug;11(4):254-8. doi: 10.4158/EP.11.4.254.","Tandon PK","Endocr Pract","2005","2005/07/12","","","10.4158/EP.11.4.254"
"32068492","Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men","Inaba H, Kimura T, Onuma H, Sato S, Kido M, Yamamoto T, Fukuda Y, Takahashi H, Egawa S.","J Urol. 2020 Aug;204(2):267-272. doi: 10.1097/JU.0000000000000804. Epub 2020 Feb 18.","Inaba H","J Urol","2020","2020/02/19","","","10.1097/JU.0000000000000804"
"20854067","The senescence pathway in prostatic carcinogenesis","Sharma S, Shin JS, Grimshaw M, Clarke RA, Lee CS.","Pathology. 2010;42(6):507-11. doi: 10.3109/00313025.2010.508791.","Sharma S","Pathology","2010","2010/09/22","","","10.3109/00313025.2010.508791"
"23568599","Optimal therapy sequencing in metastatic castration-resistant prostate cancer","Abouharb S, Corn PG.","Curr Oncol Rep. 2013 Jun;15(3):217-23. doi: 10.1007/s11912-013-0311-y.","Abouharb S","Curr Oncol Rep","2013","2013/04/10","","","10.1007/s11912-013-0311-y"
"12172428","Microsatellite instability and prostate cancer: clinical and pathological implications","Leach FS.","Curr Opin Urol. 2002 Sep;12(5):407-11. doi: 10.1097/00042307-200209000-00007.","Leach FS","Curr Opin Urol","2002","2002/08/13","","","10.1097/00042307-200209000-00007"
"31561351","Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging","Chaloupka M, Bischoff R, Pfitzinger P, Lellig E, Ledderose S, Buchner A, Schlenker B, Stief C, Clevert DA, Apfelbeck M.","Clin Hemorheol Microcirc. 2019;73(1):105-111. doi: 10.3233/CH-199223.","Chaloupka M","Clin Hemorheol Microcirc","2019","2019/09/29","","","10.3233/CH-199223"
"16202619","Androgen receptor in prostate cancer: cause or cure?","Bevan CL.","Trends Endocrinol Metab. 2005 Nov;16(9):395-7. doi: 10.1016/j.tem.2005.09.006. Epub 2005 Oct 3.","Bevan CL","Trends Endocrinol Metab","2005","2005/10/06","","","10.1016/j.tem.2005.09.006"
"30889621","[Stereotactic body radiation therapy with CyberKnife accelerator for low- and intermediate risk prostate cancer]","Jorgo K, Ágoston P, Jánváry L, Gesztesi L, Stelczer G, Kontra G, Major T, Polgár C.","Magy Onkol. 2019 Mar 19;63(1):52-59. Epub 2018 Oct 2.","Jorgo K","Magy Onkol","2019","2019/03/20","","",""
"24345439","Prostate cancer risk alleles are associated with prostate cancer volume and prostate size","Reinhardt D, Helfand BT, Cooper PR, Roehl KA, Catalona WJ, Loeb S.","J Urol. 2014 Jun;191(6):1733-6. doi: 10.1016/j.juro.2013.12.030. Epub 2013 Dec 15.","Reinhardt D","J Urol","2014","2013/12/19","PMC4107200","NIHMS601631","10.1016/j.juro.2013.12.030"
"30900644","Screening for prostate cancer starting at age 50-54 years","Joob B, Wiwanitkit V.","J Cancer Res Ther. 2019 Mar;15(Supplement):S177. doi: 10.4103/jcrt.JCRT_668_16.","Joob B","J Cancer Res Ther","2019","2019/03/23","","","10.4103/jcrt.JCRT_668_16"
"9650917","Workgroup 2: human xenograft models of prostate cancer","Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG 2nd, Thalmann GN.","Prostate. 1998 Jun 15;36(1):56-8. doi: 10.1002/(sici)1097-0045(19980615)36:1<56::aid-pros10>3.0.co;2-h.","Stearns ME","Prostate","1998","1998/07/03","","","10.1002/(sici)1097-0045(19980615)36:1<56::aid-pros10>3.0.co;2-h"
"12850926","A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia","Van Vulpen M, De Leeuw JR, Van Gellekom MP, Van Der Hoeven J, De Graeff A, Van Moorselaar RJ, Van Der Tweel I, Hofman P, Lagendijk JJ, Battermann JJ.","Int J Hyperthermia. 2003 Jul-Aug;19(4):402-13. doi: 10.1080/0265673031000063855.","Van Vulpen M","Int J Hyperthermia","2003","2003/07/10","","","10.1080/0265673031000063855"
"25176369","Prostate cancer: leading and misleading routes to TRAIL of death","Farooqi AA, Qureshi MZ, Rehman A, Nogueira DR, Awan II, Shahid A.","Pak J Pharm Sci. 2014 Sep;27(5):1371-7.","Farooqi AA","Pak J Pharm Sci","2014","2014/09/02","","",""
"26874537","Grading of Prostate Cancer: Past, Present, and Future","Matoso A, Epstein JI.","Curr Urol Rep. 2016 Mar;17(3):25. doi: 10.1007/s11934-016-0576-4.","Matoso A","Curr Urol Rep","2016","2016/02/15","","","10.1007/s11934-016-0576-4"
"18375959","Sequence variants of elaC homolog 2 (Escherichia coli) (ELAC2) gene and susceptibility to prostate cancer in the Health Professionals Follow-Up Study","Chen YC, Giovannucci E, Kraft P, J Hunter D.","Carcinogenesis. 2008 May;29(5):999-1004. doi: 10.1093/carcin/bgn081. Epub 2008 Mar 28.","Chen YC","Carcinogenesis","2008","2008/04/01","PMC2902389","","10.1093/carcin/bgn081"
"9563131","[Is gene therapy of advanced prostatic carcinoma on the verge of clinical application?]","Gschwend JE, Hautmann RE.","Urologe A. 1998 Mar;37(2):172-4. doi: 10.1007/s001200050170.","Gschwend JE","Urologe A","1998","1998/05/01","","","10.1007/s001200050170"
"30740876","Use of multiparametric magnetic resonance imaging in prostate cancer active surveillance","Glass AS, Dall'Era MA.","BJU Int. 2019 Nov;124(5):730-737. doi: 10.1111/bju.14705. Epub 2019 Mar 13.","Glass AS","BJU Int","2019","2019/02/12","","","10.1111/bju.14705"
"16257840","The significance of tumor heterogeneity for prediction of DNA ploidy of prostate cancer","Häggarth L, Auer G, Busch C, Norberg M, Häggman M, Egevad L.","Scand J Urol Nephrol. 2005;39(5):387-92. doi: 10.1080/00365590500239883.","Häggarth L","Scand J Urol Nephrol","2005","2005/11/01","","","10.1080/00365590500239883"
"8982323","Mass screening for prostate cancer. The Swedish Council on Technology Assessment in Health Care","","Int J Cancer Suppl. 1996;9:1-72.","","Int J Cancer Suppl","1996","1996/01/01","","",""
"15663993","Role of estrogens in development of prostate cancer","Härkönen PL, Mäkelä SI.","J Steroid Biochem Mol Biol. 2004 Nov;92(4):297-305. doi: 10.1016/j.jsbmb.2004.10.016. Epub 2004 Dec 19.","Härkönen PL","J Steroid Biochem Mol Biol","2004","2005/01/25","","","10.1016/j.jsbmb.2004.10.016"
"31710451","Overexpression of the Long Non-Coding RNA NeSt and FOXCUT in Early Stages of Prostate Cancer Samples as Promising Biomarkers","Rostami S, Nabi M, Naghavi P, Mohammadzadeh N, Khalili A.","Clin Lab. 2019 Nov 1;65(11). doi: 10.7754/Clin.Lab.2019.190332.","Rostami S","Clin Lab","2019","2019/11/12","","","10.7754/Clin.Lab.2019.190332"
"22708522","Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases","Glenn BA, Bastani R, Maxwell AE, Mojica CM, Herrmann AK, Gallardo NV, Swanson KA, Chang LC.","Health Psychol. 2012 Sep;31(5):562-70. doi: 10.1037/a0028626. Epub 2012 Jun 18.","Glenn BA","Health Psychol","2012","2012/06/20","","","10.1037/a0028626"
"19157109","[Association of mating type switching/sucrose non-fermenting complex with prostate cancer]","Yang J, Liu JH, Li BY.","Zhonghua Nan Ke Xue. 2008 Oct;14(10):935-8.","Yang J","Zhonghua Nan Ke Xue","2008","2009/01/23","","",""
"30157360","[Clinical value of contrast-enhanced ultrasonography in the diagnosis of prostate cancer in patients with different PSA concentrations]","Lu DY, Shen L, Cai JR, Chen YH, Xu L, Liu L.","Zhonghua Nan Ke Xue. 2018 Janurary;24(1):50-54.","Lu DY","Zhonghua Nan Ke Xue","2018","2018/08/30","","",""
"11588833","Tea and prostate cancer","Chhabra SK, Yang CS.","Epidemiol Rev. 2001;23(1):106-9. doi: 10.1093/oxfordjournals.epirev.a000774.","Chhabra SK","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000774"
"15035883","Decision-making control: why men decline treatment for prostate cancer","White MA, Verhoef MJ.","Integr Cancer Ther. 2003 Sep;2(3):217-24. doi: 10.1177/1534735403256411.","White MA","Integr Cancer Ther","2003","2004/03/24","","","10.1177/1534735403256411"
"30834999","Novel Imaging in Detection of Metastatic Prostate Cancer","Smith CP, Laucis A, Harmon S, Mena E, Lindenberg L, Choyke PL, Turkbey B.","Curr Oncol Rep. 2019 Mar 5;21(4):31. doi: 10.1007/s11912-019-0780-8.","Smith CP","Curr Oncol Rep","2019","2019/03/06","","","10.1007/s11912-019-0780-8"
"24912890","Mortality in prostate cancer and use of statins","Tural D, Yuce D, Kilickap S.","J Clin Oncol. 2014 Jul 20;32(21):2274. doi: 10.1200/JCO.2013.54.3264. Epub 2014 Jun 9.","Tural D","J Clin Oncol","2014","2014/06/11","","","10.1200/JCO.2013.54.3264"
"7525040","The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma","Bretton PR, Evans WP, Borden JD, Castellanos RD.","Cancer. 1994 Dec 1;74(11):2991-5. doi: 10.1002/1097-0142(19941201)74:11<2991::aid-cncr2820741116>3.0.co;2-r.","Bretton PR","Cancer","1994","1994/12/01","","","10.1002/1097-0142(19941201)74:11<2991::aid-cncr2820741116>3.0.co;2-r"
"11709272","Hypertension, heart rate, use of antihypertensives, and incident prostate cancer","Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL.","Ann Epidemiol. 2001 Nov;11(8):534-42. doi: 10.1016/s1047-2797(01)00246-0.","Fitzpatrick AL","Ann Epidemiol","2001","2001/11/16","","","10.1016/s1047-2797(01)00246-0"
"19001623","Adjuvant radiotherapy after surgery for prostate cancer","Parker C, Sydes M.","JAMA. 2008 Nov 12;300(18):2119; author reply 2119. doi: 10.1001/jama.2008.562.","Parker C","JAMA","2008","2008/11/13","","","10.1001/jama.2008.562"
"1488654","Etoposide in the treatment of hormone-refractory advanced carcinoma of the prostate","Crawford ED, Daneshgari F, Majeski SA.","Semin Oncol. 1992 Dec;19(6 Suppl 14):53-7.","Crawford ED","Semin Oncol","1992","1992/12/01","","",""
"25893276","Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells","Diaz R, Nguewa PA, Redrado M, Manrique I, Calvo A.","Prostate. 2015 Aug 1;75(11):1137-49. doi: 10.1002/pros.22980. Epub 2015 Apr 20.","Diaz R","Prostate","2015","2015/04/21","","","10.1002/pros.22980"
"28551819","MiR-1271 Inhibits Cell Growth in Prostate Cancer by Targeting ERG","Wang M, Gao W, Lu D, Teng L.","Pathol Oncol Res. 2018 Apr;24(2):385-391. doi: 10.1007/s12253-017-0254-y. Epub 2017 May 27.","Wang M","Pathol Oncol Res","2018","2017/05/29","","","10.1007/s12253-017-0254-y"
"24517089","Epigenetics of prostate cancer: distribution of histone H3K27me3 biomarkers in peri-tumoral tissue","Ngollo M, Dagdemir A, Judes G, Kemeny JL, Penault-Llorca F, Boiteux JP, Lebert A, Bignon YJ, Guy L, Bernard-Gallon D.","OMICS. 2014 Mar;18(3):207-9. doi: 10.1089/omi.2013.0117. Epub 2014 Feb 11.","Ngollo M","OMICS","2014","2014/02/13","","","10.1089/omi.2013.0117"
"20142058","[PSA and spironolactone]","Rybikowski S, Maurin C, Deturmeny J, Delaporte V, Lechevallier E, Coulange C.","Prog Urol. 2010 Feb;20(2):154-7. doi: 10.1016/j.purol.2009.04.002. Epub 2009 Jun 30.","Rybikowski S","Prog Urol","2010","2010/02/10","","","10.1016/j.purol.2009.04.002"
"19434062","Report from London","Kirby R.","Prostate Cancer Prostatic Dis. 2009;12(2):105. doi: 10.1038/pcan.2009.14.","Kirby R","Prostate Cancer Prostatic Dis","2009","2009/05/13","","","10.1038/pcan.2009.14"
"21220227","[Strategies for early diagnosis and prevention of prostate cancer]","Valeri A, Malavaud B, Desrichard O, Cornu JN, Blanchet P, Dervaux B, Puech P, Villers A, Cancel-Tassin G, Cussenot O.","Bull Cancer. 2010 Dec;97(12):1499-515. doi: 10.1684/bdc.2010.1227.","Valeri A","Bull Cancer","2010","2011/01/12","","","10.1684/bdc.2010.1227"
"26339615","Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer","Kim JH, Hong SK.","Biomed Res Int. 2015;2015:475920. doi: 10.1155/2015/475920. Epub 2015 Aug 3.","Kim JH","Biomed Res Int","2015","2015/09/05","PMC4538404","","10.1155/2015/475920"
"25518352","[New generation of androgen receptor antagonist in castration resistant prostate cancer]","Uemura H.","Nihon Rinsho. 2014 Dec;72(12):2164-9.","Uemura H","Nihon Rinsho","2014","2014/12/19","","",""
"26658665","Prostate Cancer Grading: A Contemporary Photomontage","Epstein JI.","Am J Surg Pathol. 2016 Jan;40(1):137. doi: 10.1097/PAS.0000000000000563.","Epstein JI","Am J Surg Pathol","2016","2015/12/15","","","10.1097/PAS.0000000000000563"
"24694637","Complications of prostate cancer treatment - Author's reply","Nam R.","Lancet Oncol. 2014 Apr;15(4):e152-3. doi: 10.1016/S1470-2045(14)70127-5.","Nam R","Lancet Oncol","2014","2014/04/04","","","10.1016/S1470-2045(14)70127-5"
"23278958","Response to Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis","Abdollah F, Briganti A, Montorsi F, Karakiewicz PI, Sun M.","Int J Urol. 2013 May;20(5):548-9. doi: 10.1111/iju.12063. Epub 2012 Dec 20.","Abdollah F","Int J Urol","2013","2013/01/03","","","10.1111/iju.12063"
"25557325","Treatment modalities for Māori and New Zealand European men with localised prostate cancer","Obertová Z, Lawrenson R, Scott N, Holmes M, Brown C, Lao C, Tyrie L, Gilling P.","Int J Clin Oncol. 2015 Aug;20(4):814-20. doi: 10.1007/s10147-014-0781-4. Epub 2015 Jan 6.","Obertová Z","Int J Clin Oncol","2015","2015/01/06","","","10.1007/s10147-014-0781-4"
"27105539","MET expression during prostate cancer progression","Verhoef EI, Kolijn K, De Herdt MJ, van der Steen B, Hoogland AM, Sleddens HF, Looijenga LH, van Leenders GJ.","Oncotarget. 2016 May 24;7(21):31029-36. doi: 10.18632/oncotarget.8829.","Verhoef EI","Oncotarget","2016","2016/04/23","PMC5058736","","10.18632/oncotarget.8829"
"30082901","Relative telomere length and prostate cancer mortality","Renner W, Krenn-Pilko S, Gruber HJ, Herrmann M, Langsenlehner T.","Prostate Cancer Prostatic Dis. 2018 Nov;21(4):579-583. doi: 10.1038/s41391-018-0068-3. Epub 2018 Aug 6.","Renner W","Prostate Cancer Prostatic Dis","2018","2018/08/08","","","10.1038/s41391-018-0068-3"
"15700051","The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer","Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S.","Prostate Cancer Prostatic Dis. 2005;8(1):22-30. doi: 10.1038/sj.pcan.4500772.","Hall WH","Prostate Cancer Prostatic Dis","2005","2005/02/09","","","10.1038/sj.pcan.4500772"
"28439616","[High intensity focused ultrasound (HIFU) : Importance in the treatment of prostate cancer]","Ganzer R.","Radiologe. 2017 Aug;57(8):659-664. doi: 10.1007/s00117-017-0245-8.","Ganzer R","Radiologe","2017","2017/04/26","","","10.1007/s00117-017-0245-8"
"14599155","Health technology assessment and implications for clinical practice: the case of prostate cancer screening","Norderhaug IN, Sandberg S, Fosså SD, Forland F, Malde K, Kvinnsland S, Traaholt I, Rossiné BK, Førde OH.","Scand J Clin Lab Invest. 2003;63(5):331-8. doi: 10.1080/00365510310002022.","Norderhaug IN","Scand J Clin Lab Invest","2003","2003/11/06","","","10.1080/00365510310002022"
"27193786","Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer","Gupta RT, Spilseth B, Patel N, Brown AF, Yu J.","Abdom Radiol (NY). 2016 May;41(5):831-43. doi: 10.1007/s00261-015-0579-5.","Gupta RT","Abdom Radiol (NY)","2016","2016/05/20","","","10.1007/s00261-015-0579-5"
"23219546","Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists","Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, Trinh QD, Sun M, Boorjian SA, Beebe TJ, Tilburt JC.","J Urol. 2013 Jun;189(6):2092-8. doi: 10.1016/j.juro.2012.11.174. Epub 2012 Dec 3.","Kim SP","J Urol","2013","2012/12/11","","","10.1016/j.juro.2012.11.174"
"1374729","[Prostatic specific antigen for detection and monitoring of prostatic cancer]","Gofrit O, Pode D, Gez E, Pfau A, Roizman I, Lifshitz Y, Barak V.","Harefuah. 1992 Mar 15;122(6):345-8, 408.","Gofrit O","Harefuah","1992","1992/03/15","","",""
"9491137","Zonal biopsy in the detection of prostate cancer in Japanese men","Egawa S, Matsumoto K, Shitara T, Uchida T, Kuwao S, Koshiba K.","Jpn J Clin Oncol. 1998 Jan;28(1):20-6. doi: 10.1093/jjco/28.1.20.","Egawa S","Jpn J Clin Oncol","1998","1998/03/10","","","10.1093/jjco/28.1.20"
"15538302","Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data","Pitts WR.","J Urol. 2004 Dec;172(6 Pt 1):2484. doi: 10.1097/01.ju.0000145135.83351.cb.","Pitts WR","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000145135.83351.cb"
"26982980","Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy","Kim SH, Park WS, Kim SH, Park B, Joo J, Lee GK, Joung JY, Seo HK, Chung J, Lee KH.","PLoS One. 2016 Mar 16;11(3):e0151646. doi: 10.1371/journal.pone.0151646. eCollection 2016.","Kim SH","PLoS One","2016","2016/03/17","PMC4794240","","10.1371/journal.pone.0151646"
"17124482","Androgen deprivation therapy in locally advanced and metastatic prostate cancer","Ryan CJ, Small EJ.","Minerva Urol Nefrol. 2006 Sep;58(3):119-26.","Ryan CJ","Minerva Urol Nefrol","2006","2006/11/25","","",""
"29514170","Association of Fatigue Intensification with Cognitive Impairment during Radiation Therapy for Prostate Cancer","Feng LR, Espina A, Saligan LN.","Oncology. 2018;94(6):363-372. doi: 10.1159/000487081. Epub 2018 Mar 7.","Feng LR","Oncology","2018","2018/03/08","PMC6067654","","10.1159/000487081"
"11306457","Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition","Hsu JY, Feldman D, McNeal JE, Peehl DM.","Cancer Res. 2001 Apr 1;61(7):2852-6.","Hsu JY","Cancer Res","2001","2001/04/18","","",""
"10440876","Defining an international research agenda for quality of life in men with prostate cancer","Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW.","Prostate. 1999 Sep 15;41(1):58-67. doi: 10.1002/(sici)1097-0045(19990915)41:1<58::aid-pros8>3.0.co;2-3.","Litwin MS","Prostate","1999","1999/08/10","","","10.1002/(sici)1097-0045(19990915)41:1<58::aid-pros8>3.0.co;2-3"
"20620410","Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease","Hsiao W, Moses KA, Goodman M, Jani AB, Rossi PJ, Master VA.","J Urol. 2010 Aug;184(2):512-8. doi: 10.1016/j.juro.2010.04.010. Epub 2010 Jun 17.","Hsiao W","J Urol","2010","2010/07/13","","","10.1016/j.juro.2010.04.010"
"26496548","Evaluation of Posttreatment Follow-Up of Patients With Prostate Cancer Relative to the American College of Radiology's Appropriateness Criteria","McDonald JS, Carter RE, Karnes RJ, Port JD, Kawashima A, Carlson SK, Bender CE.","AJR Am J Roentgenol. 2015 Nov;205(5):1008-15. doi: 10.2214/AJR.14.13766.","McDonald JS","AJR Am J Roentgenol","2015","2015/10/27","PMC4778397","NIHMS760517","10.2214/AJR.14.13766"
"30191954","Therapeutic potency of Wnt signaling antagonists in the pathogenesis of prostate cancer, current status and perspectives","Pashirzad M, Shafiee M, Khazaei M, Fiuji H, Ryzhikov M, Soleimanpour S, Hesari A, Avan A, Hassanian SM.","J Cell Physiol. 2019 Feb;234(2):1237-1247. doi: 10.1002/jcp.27137. Epub 2018 Sep 7.","Pashirzad M","J Cell Physiol","2019","2018/09/08","","","10.1002/jcp.27137"
"21243020","Prostate cancer: treatment triggers for patients on active surveillance","Hilton WM, Parekh DJ.","Nat Rev Urol. 2011 Mar;8(3):126-7. doi: 10.1038/nrurol.2010.235. Epub 2011 Jan 18.","Hilton WM","Nat Rev Urol","2011","2011/01/19","","","10.1038/nrurol.2010.235"
"23367681","Choice of treatment for locally advanced prostate cancer","","Prescrire Int. 2013 Jan;22(134):22.","","Prescrire Int","2013","2013/02/02","","",""
"22510170","Life insurance and genetic testing for prostate cancer: what advice for patients?","Meyer JP, Westera J.","ANZ J Surg. 2012 Apr;82(4):194-6. doi: 10.1111/j.1445-2197.2012.06003.x.","Meyer JP","ANZ J Surg","2012","2012/04/19","","","10.1111/j.1445-2197.2012.06003.x"
"22073901","Adding to the evidence base: The lonely female partner: a central aspect of prostate cancer","Sublett CM.","Urol Nurs. 2011 Sep-Oct;31(5):300-1.","Sublett CM","Urol Nurs","2011","2011/11/12","","",""
"20822934","Prostate cancer: evidence-based indications for postoperative radiotherapy","Azmi A, O'Neill B.","Urol Oncol. 2011 Mar-Apr;29(2):115-6; author reply 116-7. doi: 10.1016/j.urolonc.2010.05.010. Epub 2010 Sep 6.","Azmi A","Urol Oncol","2011","2010/09/09","","","10.1016/j.urolonc.2010.05.010"
"17304863","Screening for prostate cancer","Guirguis-Blake J.","Am Fam Physician. 2007 Feb 1;75(3):336-7.","Guirguis-Blake J","Am Fam Physician","2007","2007/02/20","","",""
"15049977","Cryosurgery for prostate cancer","Rees J, Patel B, MacDonagh R, Persad R.","BJU Int. 2004 Apr;93(6):710-4. doi: 10.1111/j.1464-410X.2003.04746.x.","Rees J","BJU Int","2004","2004/03/31","","","10.1111/j.1464-410X.2003.04746.x"
"10950646","A comment on proliferation rates in human prostate cancer","Hausterman K, Fowler JF.","Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):303. doi: 10.1016/s0360-3016(00)00562-9.","Hausterman K","Int J Radiat Oncol Biol Phys","2000","2000/08/19","","","10.1016/s0360-3016(00)00562-9"
"20643423","Smaller prostate size predicts high grade prostate cancer at final pathology","Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Baumgartner R, Chan R, Mishra V, Blume JD, Smith JA Jr, Barocas DA.","J Urol. 2010 Sep;184(3):930-7. doi: 10.1016/j.juro.2010.04.082.","Newton MR","J Urol","2010","2010/07/21","","","10.1016/j.juro.2010.04.082"
"24430170","Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential","Fortuin AS, Smeenk RJ, Meijer HJ, Witjes AJ, Barentsz JO.","Curr Urol Rep. 2014 Mar;15(3):389. doi: 10.1007/s11934-013-0389-7.","Fortuin AS","Curr Urol Rep","2014","2014/01/17","","","10.1007/s11934-013-0389-7"
"16842133","Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer","Uemura H, Ishiguro H, Kubota Y.","Mini Rev Med Chem. 2006 Jul;6(7):835-44. doi: 10.2174/138955706777698633.","Uemura H","Mini Rev Med Chem","2006","2006/07/18","","","10.2174/138955706777698633"
"17644842","Red wine and prostate cancer","","Harv Mens Health Watch. 2007 Jun;11(11):6-7.","","Harv Mens Health Watch","2007","2007/07/25","","",""
"8695216","Cancer of the prostate in Norway 1957-1991--a descriptive study","Harvei S, Tretli S, Langmark F.","Eur J Cancer. 1996 Jan;32A(1):111-7. doi: 10.1016/0959-8049(95)00505-6.","Harvei S","Eur J Cancer","1996","1996/01/01","","","10.1016/0959-8049(95)00505-6"
"30188333","Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer","Meyer AR, Joice GA, Allaf ME, Rowe SP, Gorin MA.","Curr Opin Urol. 2018 Nov;28(6):493-498. doi: 10.1097/MOU.0000000000000549.","Meyer AR","Curr Opin Urol","2018","2018/09/07","","","10.1097/MOU.0000000000000549"
"20838413","From bad to worse: comorbidity severity and quality of life after treatment for early-stage prostate cancer","Daskivich TJ, van de Poll-Franse LV, Kwan L, Sadetsky N, Stein DM, Litwin MS.","Prostate Cancer Prostatic Dis. 2010 Dec;13(4):320-7. doi: 10.1038/pcan.2010.33. Epub 2010 Sep 14.","Daskivich TJ","Prostate Cancer Prostatic Dis","2010","2010/09/15","","","10.1038/pcan.2010.33"
"23584381","Targeting psychoemotional stress to treat prostate cancer","Kulik G.","Asian J Androl. 2013 May;15(3):362-3. doi: 10.1038/aja.2013.30. Epub 2013 Apr 15.","Kulik G","Asian J Androl","2013","2013/04/16","PMC3739661","","10.1038/aja.2013.30"
"20001452","Clinical adenoviral gene therapy for prostate cancer","Schenk E, Essand M, Bangma CH; GIANT FP6 Consortium, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Danielsson A, Dautzenberg IJ, Dzojic H, Erbacher P, Fisher K, Frazier A, Georgopoulos LJ, Hoeben R, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Lindholm L, Magnusson M, Maitland N, Neuberg P, Nilsson B, Ogris M, Remy JS, Scaife M, Schooten E, Seymour L, Totterman T, Uil TG, Ulbrich K, Veldhoven-Zweistra JL, de Vrij J, van Weerden W, Wagner E, Willemsen R.","Hum Gene Ther. 2010 Jul;21(7):807-13. doi: 10.1089/hum.2009.206.","Schenk E","Hum Gene Ther","2010","2009/12/17","","","10.1089/hum.2009.206"
"9243458","The role of retrograde urethrography in the planning of prostate cancer radiotherapy","Schild SE, Wong W.","Med Dosim. 1997 Summer;22(2):83-6. doi: 10.1016/s0958-3947(97)00009-5.","Schild SE","Med Dosim","1997","1997/07/01","","","10.1016/s0958-3947(97)00009-5"
"23993415","Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death","Wen S, Niu Y, Lee SO, Chang C.","Cancer Treat Rev. 2014 Feb;40(1):31-40. doi: 10.1016/j.ctrv.2013.07.008. Epub 2013 Aug 7.","Wen S","Cancer Treat Rev","2014","2013/09/03","PMC3833078","NIHMS514253","10.1016/j.ctrv.2013.07.008"
"28280863","[Use of the S3 guidelines for early detection of prostate cancer in urological practices]","Tiedje D, Quer O, Breil B, Schrader AJ, Bothe C, Kruse K, Bögemann M, Donner-Banzhoff N, Semjonow A.","Urologe A. 2017 Jul;56(7):910-916. doi: 10.1007/s00120-017-0352-1.","Tiedje D","Urologe A","2017","2017/03/11","","","10.1007/s00120-017-0352-1"
"7510938","Tumor-associated angiogenesis in prostate cancer","Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA, Pienta KJ.","Anticancer Res. 1993 Nov-Dec;13(6B):2377-81.","Fregene TA","Anticancer Res","1993","1993/11/01","","",""
"18366293","Tribulations or triumphs in prostate cancer immunotherapy: on the road to victory?","Slovin SF.","Expert Rev Anticancer Ther. 2008 Mar;8(3):465-74. doi: 10.1586/14737140.8.3.465.","Slovin SF","Expert Rev Anticancer Ther","2008","2008/03/28","","","10.1586/14737140.8.3.465"
"10604719","Early castration reduces prostatic carcinogenesis in transgenic mice","Eng MH, Charles LG, Ross BD, Chrisp CE, Pienta KJ, Greenberg NM, Hsu CX, Sanda MG.","Urology. 1999 Dec;54(6):1112-9. doi: 10.1016/s0090-4295(99)00297-6.","Eng MH","Urology","1999","1999/12/22","","","10.1016/s0090-4295(99)00297-6"
"25818705","The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years","Boegemann M, Stephan C, Cammann H, Vincendeau S, Houlgatte A, Jung K, Blanchet JS, Semjonow A.","BJU Int. 2016 Jan;117(1):72-9. doi: 10.1111/bju.13139. Epub 2015 May 24.","Boegemann M","BJU Int","2016","2015/03/31","","","10.1111/bju.13139"
"20094956","Mass screening of prostate cancer and its impact on inhabitants in Akita Prefecture, Japan","Kato T, Habuchi T, Tsuchiya N, Sato K, Kitajima S, Kato S.","Aktuelle Urol. 2010 Jan;41 Suppl 1:S53-6. doi: 10.1055/s-0029-1224653. Epub 2010 Jan 21.","Kato T","Aktuelle Urol","2010","2010/01/23","","","10.1055/s-0029-1224653"
"12499134","On call. September 11 was an emotional day for all of us, but September 12 was a confusing day for me. I read two newspapers that reported on research in the New England Journal of Medicine. The New York Times headline said: ""Prostate cancer surgery found to cut death risk,"" but the Washington Post announced: ""Studies find no advantage to prostate cancer surgery."" Which was right?","Simon HB.","Harv Mens Health Watch. 2002 Dec;7(5):8.","Simon HB","Harv Mens Health Watch","2002","2002/12/25","","",""
"25979243","Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance","Koo KC, Park SU, Rha KH, Hong SJ, Yang SC, Hong CH, Chung BH.","Jpn J Clin Oncol. 2015 Aug;45(8):785-90. doi: 10.1093/jjco/hyv073. Epub 2015 May 15.","Koo KC","Jpn J Clin Oncol","2015","2015/05/17","","","10.1093/jjco/hyv073"
"10765092","Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893","Fosså SD, Curran D, Aaronson NK, Keuppens F, Kliment J, Robinson MR, DeReijke TM, Hetherington J, Kil PJ, Rea LA.","Eur Urol. 2000 May;37(5):541-51. doi: 10.1159/000020191.","Fosså SD","Eur Urol","2000","2000/04/15","","","10.1159/000020191"
"25683382","MiR200c targets IRS1 and suppresses prostate cancer cell growth","Su W, Xu M, Chen X, Nie L, Chen N, Gong J, Zhang M, Su Z, Huang L, Zhou Q.","Prostate. 2015 Jun;75(8):855-62. doi: 10.1002/pros.22968. Epub 2015 Feb 14.","Su W","Prostate","2015","2015/02/17","","","10.1002/pros.22968"
"9467040","The Will Rogers phenomenon in prostate cancer: a good thing","Gomella LG.","Cancer J Sci Am. 1998 Jan-Feb;4(1):19-21.","Gomella LG","Cancer J Sci Am","1998","1998/02/19","","",""
"20136572","Effect of mtDNA mutation on tumor malignant degree in patients with prostate cancer","Yu JJ, Yan T.","Aging Male. 2010 Sep;13(3):159-65. doi: 10.3109/13685530903536668.","Yu JJ","Aging Male","2010","2010/02/09","","","10.3109/13685530903536668"
"7524156","Assessment of quality of life in patients with prostate cancer","Fosså SD, Aass N, Opjordsmoen S.","Semin Oncol. 1994 Oct;21(5):657-61.","Fosså SD","Semin Oncol","1994","1994/10/01","","",""
"2000674","Simultaneous presentation of adenocarcinoma of prostate and transitional cell carcinoma of bladder","Konski A, Rubin P, DiSantangnese PA, Mayer E, Keys H, Cockett A, Frank I, Davis R, Lush C.","Urology. 1991 Mar;37(3):202-6. doi: 10.1016/0090-4295(91)80285-f.","Konski A","Urology","1991","1991/03/01","","","10.1016/0090-4295(91)80285-f"
"10197870","Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry, and literature review","Bassler TJ Jr, Orozco R, Bassler IC, Boyle LM, Bormes T.","Urology. 1999 Apr;53(4):832-4. doi: 10.1016/s0090-4295(98)00418-x.","Bassler TJ Jr","Urology","1999","1999/04/10","","","10.1016/s0090-4295(98)00418-x"
"21882048","ID4 is frequently downregulated and partially hypermethylated in prostate cancer","Vinarskaja A, Goering W, Ingenwerth M, Schulz WA.","World J Urol. 2012 Jun;30(3):319-25. doi: 10.1007/s00345-011-0750-8. Epub 2011 Sep 1.","Vinarskaja A","World J Urol","2012","2011/09/02","","","10.1007/s00345-011-0750-8"
"17875244","Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies","Ekwueme DU, Stroud LA, Chen Y.","Prev Chronic Dis. 2007 Oct;4(4):A100. Epub 2007 Sep 15.","Ekwueme DU","Prev Chronic Dis","2007","2007/09/19","PMC2099265","",""
"10664666","Prostate cancer: assessment of risk using digital rectal examination, tumor grade, prostate-specific antigen, and systematic biopsy","Presti JC Jr.","Radiol Clin North Am. 2000 Jan;38(1):49-58. doi: 10.1016/s0033-8389(05)70149-4.","Presti JC Jr","Radiol Clin North Am","2000","2000/02/09","","","10.1016/s0033-8389(05)70149-4"
"27643655","Can histological inflammation detected in a repeat prostate biopsy predict the risk of prostate cancer?","Dell'atti L.","Minerva Urol Nefrol. 2016 Oct;68(5):462-4.","Dell'atti L","Minerva Urol Nefrol","2016","2016/09/20","","",""
"27466544","The Value of Endorectal Magnetic Resonance Imaging of the Prostate in Improving the Detection of Anterior Prostate Cancer","Zugor V, Kühn R, Engelhard K, Poth S, Bernat MM, Porres D, Labanaris AP.","Anticancer Res. 2016 Aug;36(8):4279-83.","Zugor V","Anticancer Res","2016","2016/07/29","","",""
"11236795","MRI-guided diagnosis and treatment of prostate cancer","D'Amico AV, Cormack RA, Tempany CM.","N Engl J Med. 2001 Mar 8;344(10):776-7. doi: 10.1056/NEJM200103083441017.","D'Amico AV","N Engl J Med","2001","2001/03/10","","","10.1056/NEJM200103083441017"
"17698103","Higher frequency of familial clustering of prostate cancer in French-Canadian men","Filion E, Taussky D, Bahary JP, Maugard CM.","J Urol. 2007 Oct;178(4 Pt 1):1265-9; discussion 1270. doi: 10.1016/j.juro.2007.05.131. Epub 2007 Aug 14.","Filion E","J Urol","2007","2007/08/19","","","10.1016/j.juro.2007.05.131"
"14532784","Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE","Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll PR, Lubeck DP.","J Urol. 2003 Nov;170(5):1822-7. doi: 10.1097/01.ju.0000091426.55735.f0.","Downs TM","J Urol","2003","2003/10/09","","","10.1097/01.ju.0000091426.55735.f0"
"16294784","[Results of a series of transrectal ultrasound guided biopsy of the prostate in 6000 patients. Part II: PSA derived parameters]","Rodríguez-Patrón Rodríguez R, Mayayo Dehesa T, Burgos Revilla FJ, Alonso González M, Lennie Zucharino A, García González R.","Arch Esp Urol. 2005 Sep;58(7):623-34.","Rodríguez-Patrón Rodríguez R","Arch Esp Urol","2005","2005/11/22","","",""
"15254046","Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy","Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH.","J Clin Oncol. 2004 Jul 15;22(14):2790-9. doi: 10.1200/JCO.2004.05.158.","Yu YP","J Clin Oncol","2004","2004/07/16","","","10.1200/JCO.2004.05.158"
"31116024","Identification of critical pathways and hub genes in TP53 mutation prostate cancer by bioinformatics analysis","Sun J, Zhang K, Cai Z, Li K, Zhao C, Fan C, Wang J.","Biomark Med. 2019 Jul;13(10):831-840. doi: 10.2217/bmm-2019-0141. Epub 2019 May 22.","Sun J","Biomark Med","2019","2019/05/23","","","10.2217/bmm-2019-0141"
"27234764","Robot-Assisted Radical Prostatectomy for Localized Prostate Cancer in Asian Renal Transplant Recipients","Iizuka J, Hashimoto Y, Kondo T, Takagi T, Inui M, Nozaki T, Omoto K, Shimizu T, Ishida H, Tanabe K.","Transplant Proc. 2016 Apr;48(3):905-9. doi: 10.1016/j.transproceed.2016.01.036.","Iizuka J","Transplant Proc","2016","2016/05/29","","","10.1016/j.transproceed.2016.01.036"
"30340213","Association between bivariate expression of key oncogenes and metabolic phenotypes of patients with prostate cancer","Khodayari Moez E, Pyne S, Dinu I.","Comput Biol Med. 2018 Dec 1;103:55-63. doi: 10.1016/j.compbiomed.2018.09.017. Epub 2018 Oct 4.","Khodayari Moez E","Comput Biol Med","2018","2018/10/20","","","10.1016/j.compbiomed.2018.09.017"
"33025917","[Laser in prostate cancer. Applicability.]","Yebes A, Gómez Rivas J, Toribio C, Álvarez-Maestro M, Cansino R, Aguilera A, Martínez-Piñeiro L.","Arch Esp Urol. 2020 Oct;73(8):724-734.","Yebes A","Arch Esp Urol","2020","2020/10/07","","",""
"31094098","Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation","Beebe-Dimmer JL, Ruterbusch JJ, Cooney KA, Bolton A, Schwartz K, Schwartz AG, Heath E.","Cancer Med. 2019 Jun;8(6):3325-3335. doi: 10.1002/cam4.2092. Epub 2019 May 15.","Beebe-Dimmer JL","Cancer Med","2019","2019/05/17","PMC6558501","","10.1002/cam4.2092"
"15253325","Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer","Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL.","J Natl Med Assoc. 2004 Jul;96(7):939-44.","Rosser CJ","J Natl Med Assoc","2004","2004/07/16","PMC2568437","",""
"19908238","Common variants at 8q24 are associated with prostate cancer risk in Taiwanese men","Chen M, Huang YC, Yang S, Hsu JM, Chang YH, Huang WJ, Chen YM.","Prostate. 2010 Apr 1;70(5):502-7. doi: 10.1002/pros.21084.","Chen M","Prostate","2010","2009/11/13","","","10.1002/pros.21084"
"18514382","Editorial comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer","Shariat SF.","Eur Urol. 2008 Oct;54(4):803-4. doi: 10.1016/j.eururo.2008.05.020. Epub 2008 May 21.","Shariat SF","Eur Urol","2008","2008/06/03","","","10.1016/j.eururo.2008.05.020"
"11435835","20-year outcome of patients with T1-3N0 surgically staged prostate cancer treated with external beam radiation therapy","Gray CL, Powell CR, Riffenburgh RH, Johnstone PA.","J Urol. 2001 Jul;166(1):116-8.","Gray CL","J Urol","2001","2001/07/04","","",""
"11037554","Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria","Potters L, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Roach M 3rd, Scardino P, Schellhammer P, Leibel S.","Radiology. 2000 Jun;215 Suppl:1383-400.","Potters L","Radiology","2000","2000/10/19","","",""
"25243174","Anatomic imaging of the prostate","Bhavsar A, Verma S.","Biomed Res Int. 2014;2014:728539. doi: 10.1155/2014/728539. Epub 2014 Aug 27.","Bhavsar A","Biomed Res Int","2014","2014/09/23","PMC4160650","","10.1155/2014/728539"
"21334103","[Combined external radiotherapy and hormone therapy in patients with locally advanced prostate cancer: predictive factors of genitourinary toxicity]","Ferrandis C, March JA, Martínez JM, Hernández J, Diez N, Morillo V, García F, Chuan P.","Actas Urol Esp. 2011 Mar;35(3):146-51. doi: 10.1016/j.acuro.2010.08.006. Epub 2011 Feb 18.","Ferrandis C","Actas Urol Esp","2011","2011/02/22","","","10.1016/j.acuro.2010.08.006"
"18082589","Image-guided radiotherapy for localized prostate cancer: treating a moving target","Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL.","Semin Radiat Oncol. 2008 Jan;18(1):58-66. doi: 10.1016/j.semradonc.2007.09.008.","Kupelian PA","Semin Radiat Oncol","2008","2007/12/18","","","10.1016/j.semradonc.2007.09.008"
"7685308","The significance of prostatic specific antigen in men with prostate disease. An elevated PSA level may indicate prostate cancer--and it may not","Wozniak-Petrofsky J.","Geriatr Nurs. 1993 May-Jun;14(3):150-1. doi: 10.1016/s0197-4572(06)80133-3.","Wozniak-Petrofsky J","Geriatr Nurs","1993","1993/05/01","","","10.1016/s0197-4572(06)80133-3"
"18647299","Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option?","Brewster SF.","BJU Int. 2008 Sep;102(8):923-6. doi: 10.1111/j.1464-410X.2008.07848.x. Epub 2008 Jul 21.","Brewster SF","BJU Int","2008","2008/07/24","","","10.1111/j.1464-410X.2008.07848.x"
"9435821","[Conformational radiotherapy in cancers of the prostate: contribution of pelvic immobilization and new fiducial markers]","Garcia R, Oozeer R, Le Thanh H, Chauvet B, Toy BJ, Reboul F.","Cancer Radiother. 1997;1(4):307-13. doi: 10.1016/s1278-3218(97)81498-9.","Garcia R","Cancer Radiother","1997","1997/01/01","","","10.1016/s1278-3218(97)81498-9"
"9628612","High dose combination radiotherapy for the treatment of localized prostate cancer","Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P.","J Urol. 1998 Jul;160(1):91-5; discussion 95-6.","Zeitlin SI","J Urol","1998","1998/06/17","","",""
"30031464","Multiparametric MR imaging of the Prostate: Interpretation Including Prostate Imaging Reporting and Data System Version 2","Furlan A, Borhani AA, Westphalen AC.","Urol Clin North Am. 2018 Aug;45(3):439-454. doi: 10.1016/j.ucl.2018.03.009.","Furlan A","Urol Clin North Am","2018","2018/07/23","","","10.1016/j.ucl.2018.03.009"
"3779126","[Cancer of the prostate: therapeutic strategy in 1985]","Caty A, Cappelaere P, Demaille A.","Bull Cancer. 1986;73(1):81-4.","Caty A","Bull Cancer","1986","1986/01/01","","",""
"15679977","Baseline staging of newly diagnosed prostate cancer: a summary of the literature","Prando A.","Int Braz J Urol. 2004 Jul-Aug;30(4):341-2.","Prando A","Int Braz J Urol","2004","2005/02/01","","",""
"23831156","MALDI mass spectrometry in prostate cancer biomarker discovery","Flatley B, Malone P, Cramer R.","Biochim Biophys Acta. 2014 May;1844(5):940-9. doi: 10.1016/j.bbapap.2013.06.015. Epub 2013 Jul 2.","Flatley B","Biochim Biophys Acta","2014","2013/07/09","","","10.1016/j.bbapap.2013.06.015"
"30941975","The assessment of knowledge and attitudes of men in Serbia about prostate cancer and possibilities for its early detection and treatment in 2011: a cross-sectional study","Petrovic J, Acimovic M, Jovicevic A, Rafailovic D, Petrovic I, Dzamic Z, Pejcic T, Hadzi-Djokic J.","J BUON. 2019 Jan-Feb;24(1):233-238.","Petrovic J","J BUON","2019","2019/04/04","","",""
"18855919","Prostate cancer risk assessment: choosing the sharpest tool in the shed","Cooperberg MR.","Cancer. 2008 Dec 1;113(11):3062-6. doi: 10.1002/cncr.23920.","Cooperberg MR","Cancer","2008","2008/10/16","PMC2948568","NIHMS233414","10.1002/cncr.23920"
"21612943","Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care","Budäus L, Huland H, Graefen M; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).","Crit Rev Oncol Hematol. 2012 Dec;84 Suppl 1:e24-9. doi: 10.1016/j.critrevonc.2010.09.004. Epub 2011 May 25.","Budäus L","Crit Rev Oncol Hematol","2012","2011/05/27","","","10.1016/j.critrevonc.2010.09.004"
"19375622","Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later","Pienta KJ.","Urology. 2009 May;73(5 Suppl):S11-20. doi: 10.1016/j.urology.2009.02.016.","Pienta KJ","Urology","2009","2009/04/21","","","10.1016/j.urology.2009.02.016"
"21141246","PSA at 60 may predict risk of death from prostate cancer","Rees J.","Practitioner. 2010 Oct;254(1733):5.","Rees J","Practitioner","2010","2010/12/15","","",""
"24994787","Reappraisal of glucocorticoids in castrate-resistant prostate cancer","Sartor O, Parker CC, de Bono J.","Asian J Androl. 2014 Sep-Oct;16(5):666. doi: 10.4103/1008-682X.133314.","Sartor O","Asian J Androl","2014","2014/07/05","PMC4215665","","10.4103/1008-682X.133314"
"25099032","An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer","Schmid M, Ghani KR, Choueiri TK, Sood A, Kapoor V, Abdollah F, Chun FK, Leow JJ, Olugbade K Jr, Sammon JD, Menon M, Kibel AS, Fisch M, Nguyen PL, Trinh QD.","BJU Int. 2015 Dec;116(6):911-9. doi: 10.1111/bju.12891. Epub 2015 Jun 4.","Schmid M","BJU Int","2015","2014/08/08","","","10.1111/bju.12891"
"18217266","Multivitamins and prostate cancer: a new worry?","","Harv Mens Health Watch. 2007 Oct;12(3):5-8.","","Harv Mens Health Watch","2007","2008/01/26","","",""
"26219833","Counterpoint: Unfair comparisons lead to unwarranted conclusions-Can treatment modalities for localized prostate cancer truly be compared without bias?","Markovina S, Michalski J.","Brachytherapy. 2015 Nov-Dec;14(6):756-60. doi: 10.1016/j.brachy.2015.06.009. Epub 2015 Jul 26.","Markovina S","Brachytherapy","2015","2015/07/30","","","10.1016/j.brachy.2015.06.009"
"24561445","Maintaining and reprogramming genomic androgen receptor activity in prostate cancer","Mills IG.","Nat Rev Cancer. 2014 Mar;14(3):187-98. doi: 10.1038/nrc3678.","Mills IG","Nat Rev Cancer","2014","2014/02/25","","","10.1038/nrc3678"
"10135639","The use of clinical parameters in an interactive statistical package to predict pathological features associated with local failure after radical prostatectomy for prostate cancer","D'Amico A, Altschuler M, Whittington R, Kao G, Malkowicz SB, Wein A.","Clin Perform Qual Health Care. 1993 Oct-Dec;1(4):219-22.","D'Amico A","Clin Perform Qual Health Care","1993","1993/09/05","","",""
"20180065","[Risks and prevention of prostate cancer. Commentary on the new S3 guideline]","Schmitz-Dräger BJ, Bismarck E, Lümmen G; Mitglieder des Arbeitskreises Prävention, Umwelt und Komplementärmedizin (PUK).","Urologe A. 2010 Feb;49(2):233-7. doi: 10.1007/s00120-010-2240-9.","Schmitz-Dräger BJ","Urologe A","2010","2010/02/25","","","10.1007/s00120-010-2240-9"
"15201729","Genetically modified mice and their use in developing therapeutic strategies for prostate cancer","Kasper S, Smith JA Jr.","J Urol. 2004 Jul;172(1):12-9. doi: 10.1097/01.ju.0000132122.93436.aa.","Kasper S","J Urol","2004","2004/06/18","","","10.1097/01.ju.0000132122.93436.aa"
"12108141","What we thought we knew: African American males' perceptions of prostate cancer and screening methods","Clarke-Tasker VA, Wade R.","ABNF J. 2002 May-Jun;13(3):56-60.","Clarke-Tasker VA","ABNF J","2002","2002/07/11","","",""
"26171803","Addressing the need for repeat prostate biopsy: new technology and approaches","Blute ML Jr, Abel EJ, Downs TM, Kelcz F, Jarrard DF.","Nat Rev Urol. 2015 Aug;12(8):435-44. doi: 10.1038/nrurol.2015.159. Epub 2015 Jul 14.","Blute ML Jr","Nat Rev Urol","2015","2015/07/15","","","10.1038/nrurol.2015.159"
"12847583","Prostate cancer in Saudi Arabia in 2002","Mosli HA.","Saudi Med J. 2003 Jun;24(6):573-81.","Mosli HA","Saudi Med J","2003","2003/07/09","","",""
"14680308","Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy","Messing EM, Thompson I Jr.","Urol Clin North Am. 2003 Nov;30(4):687-702, viii. doi: 10.1016/s0094-0143(03)00050-8.","Messing EM","Urol Clin North Am","2003","2003/12/19","","","10.1016/s0094-0143(03)00050-8"
"21297383","Androgen regulation of prostate cancer: where are we now?","Corona G, Baldi E, Maggi M.","J Endocrinol Invest. 2011 Mar;34(3):232-43. doi: 10.1007/BF03347072. Epub 2011 Feb 4.","Corona G","J Endocrinol Invest","2011","2011/02/08","","","10.1007/BF03347072"
"9052375","Patient age and prostate cancer","Keetch DW, Humphrey PA.","Am J Clin Pathol. 1997 Mar;107(3):265-7. doi: 10.1093/ajcp/107.3.265.","Keetch DW","Am J Clin Pathol","1997","1997/03/01","","","10.1093/ajcp/107.3.265"
"1917610","Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06","Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, Sause W, Pilepich MV.","Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):1099-103. doi: 10.1016/0360-3016(91)90757-u.","Hanks GE","Int J Radiat Oncol Biol Phys","1991","1991/09/01","","","10.1016/0360-3016(91)90757-u"
"20409219","Editorial comment to Predicting the probability significant prostate cancer in Japanese men with serum prostate-specific antigen less than 10 ng/mL: development of a novel pre-biopsy nomogram","Yamamoto S.","Int J Urol. 2010 Mar;17(3):280. doi: 10.1111/j.1442-2042.2010.02477.x.","Yamamoto S","Int J Urol","2010","2010/04/23","","","10.1111/j.1442-2042.2010.02477.x"
"17619080","Editorial comment on: Erectile function in prostate cancer-free patients who underwent prostate saturation biopsy","Badalyan R.","Eur Urol. 2008 Mar;53(3):545-6. doi: 10.1016/j.eururo.2007.06.042. Epub 2007 Dec 27.","Badalyan R","Eur Urol","2008","2007/07/10","","","10.1016/j.eururo.2007.06.042"
"16447818","Proteomic analysis of protein expression in prostate cancer","Lexander H, Palmberg C, Auer G, Hellström M, Franzén B, Jörnvall H, Egevad L.","Anal Quant Cytol Histol. 2005 Oct;27(5):263-72.","Lexander H","Anal Quant Cytol Histol","2005","2006/02/02","","",""
"11511500","Re-irradiation and external hyperthermia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report","Kalapurakal JA, Mittal BB, Sathiaseelan V.","Br J Radiol. 2001 Aug;74(884):745-51. doi: 10.1259/bjr.74.884.740745.","Kalapurakal JA","Br J Radiol","2001","2001/08/21","","","10.1259/bjr.74.884.740745"
"11317943","Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen","Leinonen J, Wu P, Koivunen E, Närvänen A, Stenman UH.","Scand J Clin Lab Invest Suppl. 2000;233:59-64.","Leinonen J","Scand J Clin Lab Invest Suppl","2000","2001/04/25","","",""
"29133261","Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth in vitro and in vivo","Shen G, Jiang M, Pu J.","Biochem Biophys Res Commun. 2018 Jan 1;495(1):567-573. doi: 10.1016/j.bbrc.2017.11.062. Epub 2017 Nov 10.","Shen G","Biochem Biophys Res Commun","2018","2017/11/15","","","10.1016/j.bbrc.2017.11.062"
"16700035","Treatment options in lymph node-positive prostate cancer","Swanson GP, Thompson IM, Basler J.","Cancer. 2006 Jun 15;106(12):2531-9. doi: 10.1002/cncr.21947.","Swanson GP","Cancer","2006","2006/05/16","","","10.1002/cncr.21947"
"21565970","Pathways of chemotherapy resistance in castration-resistant prostate cancer","Mahon KL, Henshall SM, Sutherland RL, Horvath LG.","Endocr Relat Cancer. 2011 Jul 4;18(4):R103-23. doi: 10.1530/ERC-10-0343. Print 2011 Aug.","Mahon KL","Endocr Relat Cancer","2011","2011/05/14","","","10.1530/ERC-10-0343"
"21188385","Comparative effectiveness research in urology","Wang AT, Wang JK, Montori VM, Murad MH.","World J Urol. 2011 Jun;29(3):277-82. doi: 10.1007/s00345-010-0637-0. Epub 2010 Dec 28.","Wang AT","World J Urol","2011","2010/12/29","","","10.1007/s00345-010-0637-0"
"15733113","Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer","Miyake H, Sakai I, Harada K, Hara I, Eto H.","Int J Urol. 2005 Feb;12(2):182-6. doi: 10.1111/j.1442-2042.2005.01016.x.","Miyake H","Int J Urol","2005","2005/03/01","","","10.1111/j.1442-2042.2005.01016.x"
"27743493","Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy","Tilki D, Preisser F, Tennstedt P, Tober P, Mandel P, Schlomm T, Steuber T, Huland H, Schwarz R, Petersen C, Graefen M, Ahyai S.","BJU Int. 2017 May;119(5):717-723. doi: 10.1111/bju.13679. Epub 2016 Nov 21.","Tilki D","BJU Int","2017","2016/10/16","","","10.1111/bju.13679"
"30415878","Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis","Choi YH, Kang MY, Sung HH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Kim CK, Park BK, Lee HM.","Clin Genitourin Cancer. 2019 Feb;17(1):e19-e25. doi: 10.1016/j.clgc.2018.09.007. Epub 2018 Sep 13.","Choi YH","Clin Genitourin Cancer","2019","2018/11/13","","","10.1016/j.clgc.2018.09.007"
"16209214","[Diagnosis and treatment of early prostate cancer]","Zhu G, Liu M, Wan B.","Zhonghua Nan Ke Xue. 2005 Sep;11(9):693-6, 712.","Zhu G","Zhonghua Nan Ke Xue","2005","2005/10/08","","",""
"10617894","Screening for prostate cancer","Brawer MK.","Semin Surg Oncol. 2000 Jan-Feb;18(1):29-36. doi: 10.1002/(sici)1098-2388(200001/02)18:1<29::aid-ssu5>3.0.co;2-y.","Brawer MK","Semin Surg Oncol","2000","2000/01/05","","","10.1002/(sici)1098-2388(200001/02)18:1<29::aid-ssu5>3.0.co;2-y"
"8978396","Androgen-induced redox changes in prostate cancer cells: what are causes and effects?","Liehr JG.","J Natl Cancer Inst. 1997 Jan 1;89(1):3-4. doi: 10.1093/jnci/89.1.3.","Liehr JG","J Natl Cancer Inst","1997","1997/01/01","","","10.1093/jnci/89.1.3"
"31662544","A Population-based Statistical Model for Investigating Heterogeneous Intraprostatic Sensitivity to Radiation Toxicity After (125)I Seed Implantation","Kobayashi K, Murakami N, Takahashi K, Inaba K, Igaki H, Hamamoto R, Itami J.","In Vivo. 2019 Nov-Dec;33(6):2103-2111. doi: 10.21873/invivo.11710.","Kobayashi K","In Vivo","2019","2019/10/31","PMC6899147","","10.21873/invivo.11710"
"11911446","Is annexin 7 a tumor suppressor gene in prostate cancer?","Cardó-Vila M, Arden KC, Cavenee WK, Pasqualini R, Arap W.","Pharmacogenomics J. 2001;1(2):92-4. doi: 10.1038/sj.tpj.6500028.","Cardó-Vila M","Pharmacogenomics J","2001","2002/03/26","","","10.1038/sj.tpj.6500028"
"24496867","Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry","Cary KC, Paciorek A, Fuldeore MJ, Carroll PR, Cooperberg MR.","Cancer. 2014 Feb 15;120(4):507-12. doi: 10.1002/cncr.28446. Epub 2013 Oct 25.","Cary KC","Cancer","2014","2014/02/06","","","10.1002/cncr.28446"
"21520163","Treatment decision-making for localized prostate cancer: what younger men choose and why","Sidana A, Hernandez DJ, Feng Z, Partin AW, Trock BJ, Saha S, Epstein JI.","Prostate. 2012 Jan;72(1):58-64. doi: 10.1002/pros.21406. Epub 2011 Apr 25.","Sidana A","Prostate","2012","2011/04/27","PMC4612632","NIHMS728709","10.1002/pros.21406"
"11745507","Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era","Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW, Roach M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio L, Awan A, Weichselbaum RR, Vijayakumar S.","Int J Cancer. 2001 Dec 20;96(6):363-71. doi: 10.1002/ijc.1035.","Jani AB","Int J Cancer","2001","2001/12/18","","","10.1002/ijc.1035"
"15446376","Prostate cancer in older men","Calabrese DA.","Urol Nurs. 2004 Aug;24(4):258-64, 268; quiz 269.","Calabrese DA","Urol Nurs","2004","2004/09/28","","",""
"22674220","The quantitative Gleason score improves prostate cancer risk assessment","Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR.","Cancer. 2012 Dec 15;118(24):6046-54. doi: 10.1002/cncr.27670. Epub 2012 Jun 6.","Reese AC","Cancer","2012","2012/06/08","","","10.1002/cncr.27670"
"19493248","The association between leukocyte telomere length and cigarette smoking, dietary and physical variables, and risk of prostate cancer","Mirabello L, Huang WY, Wong JY, Chatterjee N, Reding D, Crawford ED, De Vivo I, Hayes RB, Savage SA.","Aging Cell. 2009 Aug;8(4):405-13. doi: 10.1111/j.1474-9726.2009.00485.x. Epub 2009 Jun 1.","Mirabello L","Aging Cell","2009","2009/06/05","PMC2742954","NIHMS134519","10.1111/j.1474-9726.2009.00485.x"
"20066006","Integrin involvement in freeze resistance of androgen-insensitive prostate cancer","Baust JG, Klossner DP, Vanbuskirk RG, Gage AA, Mouraviev V, Polascik TJ, Baust JM.","Prostate Cancer Prostatic Dis. 2010 Jun;13(2):151-61. doi: 10.1038/pcan.2009.59. Epub 2010 Jan 12.","Baust JG","Prostate Cancer Prostatic Dis","2010","2010/01/13","PMC2869388","NIHMS165741","10.1038/pcan.2009.59"
"8889563","[Clinical analysis of 169 patients with prostate cancer]","Okaneya T, Mizusawa H, Yoneyama T, Taguchi I, Komiyama I, Kawakami M, Hosaka K, Tsuruta T, Murata Y, Komatsu H, Misawa K, Kiyokawa H.","Hinyokika Kiyo. 1996 Aug;42(8):563-7.","Okaneya T","Hinyokika Kiyo","1996","1996/08/01","","",""
"17991547","Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake","Meiser B, Cowan R, Costello A, Giles GG, Lindeman GJ, Gaff CL.","Urology. 2007 Oct;70(4):738-42. doi: 10.1016/j.urology.2007.06.1093.","Meiser B","Urology","2007","2007/11/10","","","10.1016/j.urology.2007.06.1093"
"23887227","The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option?","Nanni C, Schiavina R, Rubello D, Ambrosini V, Brunocilla E, Martorana G, Fanti S.","Nucl Med Commun. 2013 Sep;34(9):831-3. doi: 10.1097/MNM.0b013e3283636eaf.","Nanni C","Nucl Med Commun","2013","2013/07/27","","","10.1097/MNM.0b013e3283636eaf"
"23298664","Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis","Xu H, Jiang HW, Ding GX, Zhang H, Zhang LM, Mao SH, Ding Q.","Diabetes Res Clin Pract. 2013 Mar;99(3):241-9. doi: 10.1016/j.diabres.2012.12.003. Epub 2013 Jan 5.","Xu H","Diabetes Res Clin Pract","2013","2013/01/10","","","10.1016/j.diabres.2012.12.003"
"15633772","[Interstitial brachytherapy--a minimal invasive urological option for treatment of prostate cancer of increasing importance]","Slany E, Senger V, Maurer U, Zumbè J.","Versicherungsmedizin. 2004 Dec 1;56(4):187-92.","Slany E","Versicherungsmedizin","2004","2005/01/07","","",""
"7853589","Pathological features of hereditary prostate cancer","Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI.","J Urol. 1995 Mar;153(3 Pt 2):987-92.","Bastacky SI","J Urol","1995","1995/03/01","","",""
"20890742","The German S3 guideline prostate cancer: aspects for the radiation oncologist","Wenz F, Martin T, Böhmer D, Martens S, Sedlmayer F, Wirth M, Miller K, Heidenreich A, Schrader M, Hinkelbein W, Wiegel T.","Strahlenther Onkol. 2010 Oct;186(10):531-4. doi: 10.1007/s00066-010-2193-3. Epub 2010 Sep 30.","Wenz F","Strahlenther Onkol","2010","2010/10/05","","","10.1007/s00066-010-2193-3"
"21498375","A feasibility study of MR elastography in the diagnosis of prostate cancer at 3.0T","Li S, Chen M, Wang W, Zhao W, Wang J, Zhao X, Zhou C.","Acta Radiol. 2011 Apr 1;52(3):354-8. doi: 10.1258/ar.2010.100276.","Li S","Acta Radiol","2011","2011/04/19","","","10.1258/ar.2010.100276"
"29492585","YRNA expression in prostate cancer patients: diagnostic and prognostic implications","Tolkach Y, Niehoff EM, Stahl AF, Zhao C, Kristiansen G, Müller SC, Ellinger J.","World J Urol. 2018 Jul;36(7):1073-1078. doi: 10.1007/s00345-018-2250-6. Epub 2018 Feb 28.","Tolkach Y","World J Urol","2018","2018/03/02","","","10.1007/s00345-018-2250-6"
"22629825","[Role of human cytomegalovirus in the pathogenesis, growth and aggressiveness of prostate cancer]","Klochkova TG, Evtushenko VI.","Vopr Onkol. 2012;58(1):33-40.","Klochkova TG","Vopr Onkol","2012","2012/05/29","","",""
"31791268","Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis","Sun J, Li S, Wang F, Fan C, Wang J.","BMC Med Genet. 2019 Dec 2;20(1):191. doi: 10.1186/s12881-019-0923-7.","Sun J","BMC Med Genet","2019","2019/12/04","PMC6889628","","10.1186/s12881-019-0923-7"
"10617898","Radiotherapy for the palliation of prostate cancer","Korb L.","Semin Surg Oncol. 2000 Jan-Feb;18(1):75-9. doi: 10.1002/(sici)1098-2388(200001/02)18:1<75::aid-ssu9>3.0.co;2-t.","Korb L","Semin Surg Oncol","2000","2000/01/05","","","10.1002/(sici)1098-2388(200001/02)18:1<75::aid-ssu9>3.0.co;2-t"
"15637399","Prevention of hormone-related cancers: prostate cancer","Parnes HL, Thompson IM, Ford LG.","J Clin Oncol. 2005 Jan 10;23(2):368-77. doi: 10.1200/JCO.2005.08.027.","Parnes HL","J Clin Oncol","2005","2005/01/08","","","10.1200/JCO.2005.08.027"
"26597612","Prostate cancer: STHLM3 model for prostate cancer screening","Kelsey R.","Nat Rev Urol. 2016 Jan;13(1):4. doi: 10.1038/nrurol.2015.286. Epub 2015 Nov 24.","Kelsey R","Nat Rev Urol","2016","2015/11/25","","","10.1038/nrurol.2015.286"
"12865443","Stat bite: Estimated effect of finasteride on prostate cancer development","","J Natl Cancer Inst. 2003 Jul 16;95(14):1031. doi: 10.1093/jnci/95.14.1031.","","J Natl Cancer Inst","2003","2003/07/17","","","10.1093/jnci/95.14.1031"
"24365126","Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66","Ost P, Briganti A, Giannarini G; Prostate Cancer Working Group of the Young Academic Urologist Working Party of the European Association of Urology.","Eur Urol. 2014 Jun;65(6):e97-8. doi: 10.1016/j.eururo.2013.12.009. Epub 2013 Dec 17.","Ost P","Eur Urol","2014","2013/12/25","","","10.1016/j.eururo.2013.12.009"
"21960078","Sensitivity and specificity of international prostate symptom score (IPSS) for the screening of Iranian patients with prostate cancer","Hosseini M, Ebrahimi SM, SeyedAlinaghi S, Mahmoodi M.","Acta Med Iran. 2011;49(7):451-5.","Hosseini M","Acta Med Iran","2011","2011/10/01","","",""
"15869722","Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?","Canby-Hagino ED, Swanson GP, Crawford ED, Basler JW, Hernandez J, Thompson IM.","Curr Urol Rep. 2005 May;6(3):183-9. doi: 10.1007/s11934-005-0006-5.","Canby-Hagino ED","Curr Urol Rep","2005","2005/05/05","","","10.1007/s11934-005-0006-5"
"22445138","Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols","Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS.","Eur Urol. 2012 Sep;62(3):462-8. doi: 10.1016/j.eururo.2012.03.011. Epub 2012 Mar 17.","Iremashvili V","Eur Urol","2012","2012/03/27","","","10.1016/j.eururo.2012.03.011"
"18706770","Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?","Drewa T, Styczynski J.","Med Hypotheses. 2008 Nov;71(5):694-9. doi: 10.1016/j.mehy.2008.06.021. Epub 2008 Aug 15.","Drewa T","Med Hypotheses","2008","2008/08/19","","","10.1016/j.mehy.2008.06.021"
"16821618","Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer","Sasaki T, Nakamura K, Shioyama Y, Ohga S, Toba T, Urashima Y, Yoshitake T, Terashima H, Koga H, Naito S, Noma H, Komatsu K, Yamaguchi A, Hiratsuka Y, Hirano T, Hanada K, Abe M, Fujisawa Y, Honda H.","Anticancer Res. 2006 May-Jun;26(3B):2367-74.","Sasaki T","Anticancer Res","2006","2006/07/11","","",""
"25786055","MR Imaging-Transrectal US Fusion for Targeted Prostate Biopsies: Implications for Diagnosis and Clinical Management","Costa DN, Pedrosa I, Donato F Jr, Roehrborn CG, Rofsky NM.","Radiographics. 2015 May-Jun;35(3):696-708. doi: 10.1148/rg.2015140058. Epub 2015 Mar 18.","Costa DN","Radiographics","2015","2015/03/19","","","10.1148/rg.2015140058"
"1744011","Incomplete rectal obstruction secondary to adenocarcinoma of the prostate","Desai PA, Fioerelli RL, Finkelstein LH.","J Am Osteopath Assoc. 1991 Aug;91(8):803-6.","Desai PA","J Am Osteopath Assoc","1991","1991/08/01","","",""
"12766610","Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis","Best CJ, Leiva IM, Chuaqui RF, Gillespie JW, Duray PH, Murgai M, Zhao Y, Simon R, Kang JJ, Green JE, Bostwick DG, Linehan WM, Emmert-Buck MR.","Diagn Mol Pathol. 2003 Jun;12(2):63-70. doi: 10.1097/00019606-200306000-00001.","Best CJ","Diagn Mol Pathol","2003","2003/05/27","","","10.1097/00019606-200306000-00001"
"27216195","Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects","Sheikh N, Cham J, Zhang L, DeVries T, Letarte S, Pufnock J, Hamm D, Trager J, Fong L.","Cancer Res. 2016 Jul 1;76(13):3711-8. doi: 10.1158/0008-5472.CAN-15-3173. Epub 2016 May 23.","Sheikh N","Cancer Res","2016","2016/05/25","","","10.1158/0008-5472.CAN-15-3173"
"31017091","Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments","Farolfi A, Fendler W, Iravani A, Haberkorn U, Hicks R, Herrmann K, Walz J, Fanti S.","Eur Urol Oncol. 2019 Mar;2(2):152-162. doi: 10.1016/j.euo.2019.01.001. Epub 2019 Jan 31.","Farolfi A","Eur Urol Oncol","2019","2019/04/25","","","10.1016/j.euo.2019.01.001"
"24166580","Proteomic signatures of angiogenesis in androgen-independent prostate cancer","Karagiannis GS, Saraon P, Jarvi KA, Diamandis EP.","Prostate. 2014 Feb;74(3):260-72. doi: 10.1002/pros.22747. Epub 2013 Oct 26.","Karagiannis GS","Prostate","2014","2013/10/30","","","10.1002/pros.22747"
"24616317","Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis","D'Amico AV.","J Clin Oncol. 2014 Apr 20;32(12):1183-5. doi: 10.1200/JCO.2014.55.2380. Epub 2014 Mar 10.","D'Amico AV","J Clin Oncol","2014","2014/03/12","","","10.1200/JCO.2014.55.2380"
"26552138","[The mechanisms of drug resistance in prostate cancer]","He Y, Liu YG, Cen S, Zhou JM.","Yao Xue Xue Bao. 2015 Jul;50(7):797-801.","He Y","Yao Xue Xue Bao","2015","2015/11/11","","",""
"27223260","BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion","Blee AM, Liu S, Wang L, Huang H.","Oncotarget. 2016 Jun 21;7(25):38319-38332. doi: 10.18632/oncotarget.9513.","Blee AM","Oncotarget","2016","2016/05/26","PMC5122392","","10.18632/oncotarget.9513"
"22212076","Diagnosis of limited adenocarcinoma of the prostate","Epstein JI.","Histopathology. 2012 Jan;60(1):28-40. doi: 10.1111/j.1365-2559.2011.03990.x.","Epstein JI","Histopathology","2012","2012/01/04","","","10.1111/j.1365-2559.2011.03990.x"
"22825933","Informed decision making about prostate cancer testing in predominantly immigrant black men: a randomized controlled trial","Lepore SJ, Wolf RL, Basch CE, Godfrey M, McGinty E, Shmukler C, Ullman R, Thomas N, Weinrich S.","Ann Behav Med. 2012 Dec;44(3):320-30. doi: 10.1007/s12160-012-9392-3.","Lepore SJ","Ann Behav Med","2012","2012/07/25","PMC3500675","NIHMS396026","10.1007/s12160-012-9392-3"
"12405261","The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis","Davis JN, Day ML.","Mol Biotechnol. 2002 Oct;22(2):129-38. doi: 10.1385/MB:22:2:129.","Davis JN","Mol Biotechnol","2002","2002/10/31","","","10.1385/MB:22:2:129"
"31748757","Expression of CDX2 in metastatic prostate cancer","Guerrieri C, Jobbagy Z, Hudacko R.","Pathologica. 2019 Sep;111(3):105-107. doi: 10.32074/1591-951X-19-19.","Guerrieri C","Pathologica","2019","2019/11/22","","","10.32074/1591-951X-19-19"
"1767273","Carcinoma of the prostate. Treatment philosophy in cancer of the prostate--primary treatment","Høisaeter PA.","Scand J Urol Nephrol Suppl. 1991;139:47-52.","Høisaeter PA","Scand J Urol Nephrol Suppl","1991","1991/01/01","","",""
"17904727","Radioisotope-guided lymph node dissection for prostate cancer: potential and limitations","Janetschek G.","Eur Urol. 2008 Jan;53(1):16-8; discussion 18-20. doi: 10.1016/j.eururo.2007.09.016. Epub 2007 Sep 17.","Janetschek G","Eur Urol","2008","2007/10/02","","","10.1016/j.eururo.2007.09.016"
"15767813","Vanishing prostate cancer syndrome: symptom of a larger clinical issue","Moskaluk CA.","Am J Surg Pathol. 2005 Apr;29(4):561-3. doi: 10.1097/01.pas.0000152567.85689.43.","Moskaluk CA","Am J Surg Pathol","2005","2005/03/16","","","10.1097/01.pas.0000152567.85689.43"
"14991761","Modulation of prostate cancer growth in bone microenvironments","Edlund M, Sung SY, Chung LW.","J Cell Biochem. 2004 Mar 1;91(4):686-705. doi: 10.1002/jcb.10702.","Edlund M","J Cell Biochem","2004","2004/03/03","","","10.1002/jcb.10702"
"30126988","Classification of prostate cancer using a protease activity nanosensor library","Dudani JS, Ibrahim M, Kirkpatrick J, Warren AD, Bhatia SN.","Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):8954-8959. doi: 10.1073/pnas.1805337115. Epub 2018 Aug 20.","Dudani JS","Proc Natl Acad Sci U S A","2018","2018/08/22","PMC6130343","","10.1073/pnas.1805337115"
"17219381","Gain of chromosome X in prostatic atrophy detected by CGH and FISH analyses","Yildiz-Sezer S, Verdorfer I, Schäfer G, Rogatsch H, Bartsch G, Mikuz G.","Prostate. 2007 Mar 1;67(4):433-8. doi: 10.1002/pros.20535.","Yildiz-Sezer S","Prostate","2007","2007/01/16","","","10.1002/pros.20535"
"27328367","Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study","Thorstenson A, Garmo H, Adolfsson J, Bratt O.","J Urol. 2017 Jan;197(1):61-66. doi: 10.1016/j.juro.2016.06.080. Epub 2016 Jun 17.","Thorstenson A","J Urol","2017","2016/06/22","","","10.1016/j.juro.2016.06.080"
"25767995","Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings","","Clin Adv Hematol Oncol. 2014 Sep;12(9 Suppl 17):1-21.","","Clin Adv Hematol Oncol","2014","2015/03/14","","",""
"10699613","Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial","Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH.","Urology. 2000 Mar;55(3):372-6. doi: 10.1016/s0090-4295(99)00547-6.","Catalona WJ","Urology","2000","2000/03/04","","","10.1016/s0090-4295(99)00547-6"
"7508786","Prostate-specific antigen coordinated with digital rectal examination and transrectal ultrasonography in the detection of prostate cancer","Cooner WH.","World J Urol. 1993;11(4):214-7. doi: 10.1007/BF00185071.","Cooner WH","World J Urol","1993","1993/01/01","","","10.1007/BF00185071"
"21727905","Blood lipid levels and prostate cancer risk; a cohort study","Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, Kampman E, Kiemeney LA.","Prostate Cancer Prostatic Dis. 2011 Dec;14(4):340-5. doi: 10.1038/pcan.2011.30. Epub 2011 Jul 5.","Kok DE","Prostate Cancer Prostatic Dis","2011","2011/07/06","","","10.1038/pcan.2011.30"
"27004601","The importance of surgical margins in prostate cancer","Sooriakumaran P, Dev HS, Skarecky D, Ahlering T.","J Surg Oncol. 2016 Mar;113(3):310-5. doi: 10.1002/jso.24109. Epub 2016 Mar 23.","Sooriakumaran P","J Surg Oncol","2016","2016/03/24","","","10.1002/jso.24109"
"25788425","Inflammation and prostate cancer: friends or foe?","Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F.","Inflamm Res. 2015 May;64(5):275-86. doi: 10.1007/s00011-015-0812-2. Epub 2015 Mar 19.","Taverna G","Inflamm Res","2015","2015/03/20","","","10.1007/s00011-015-0812-2"
"23942741","[Novel preclinical models and biomarkers for prostate cancer]","Korzeniewski N, Tapia-Laliena M, Tolstov Y, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.","Urologe A. 2013 Sep;52(9):1256-60. doi: 10.1007/s00120-013-3310-6.","Korzeniewski N","Urologe A","2013","2013/08/15","","","10.1007/s00120-013-3310-6"
"21745831","The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment","Barbiere JM, Greenberg DC, Wright KA, Brown CH, Palmer C, Neal DE, Lyratzopoulos G.","J Public Health (Oxf). 2012 Mar;34(1):108-14. doi: 10.1093/pubmed/fdr051. Epub 2011 Jul 10.","Barbiere JM","J Public Health (Oxf)","2012","2011/07/13","","","10.1093/pubmed/fdr051"
"17519924","Long-term outcome for lymph node-positive prostate cancer","Swanson GP, Riggs MW, Herman M.","Prostate Cancer Prostatic Dis. 2008;11(2):198-202. doi: 10.1038/sj.pcan.4500983. Epub 2007 May 22.","Swanson GP","Prostate Cancer Prostatic Dis","2008","2007/05/24","","","10.1038/sj.pcan.4500983"
"12923658","Radiation for prostate cancer: use of biochemical failure as an endpoint following radiotherapy","Kuban DA, Thames HD, Levy LB.","World J Urol. 2003 Sep;21(4):253-64. doi: 10.1007/s00345-003-0361-0. Epub 2003 Aug 16.","Kuban DA","World J Urol","2003","2003/08/19","","","10.1007/s00345-003-0361-0"
"25097944","A guide to a new prostate cancer tests","","Johns Hopkins Med Lett Health After 50. 2014 May;29(3):4-5.","","Johns Hopkins Med Lett Health After 50","2014","2014/08/08","","",""
"17418935","Editorial comment on: Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy","Gallina A.","Eur Urol. 2007 Oct;52(4):1065-6. doi: 10.1016/j.eururo.2007.03.057.","Gallina A","Eur Urol","2007","2007/04/10","","","10.1016/j.eururo.2007.03.057"
"17084166","The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE","Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Hirao Y, Murai M, Yamanaka H, Namiki M.","J Urol. 2006 Dec;176(6 Pt 2):S47-9. doi: 10.1016/j.juro.2006.06.070.","Akaza H","J Urol","2006","2006/11/07","","","10.1016/j.juro.2006.06.070"
"24685434","Metabolic syndrome as a marker for prostate cancer: still a work in progress","Gallina A, Nini A, Montorsi F, Briganti A.","Eur Urol. 2015 Jan;67(1):71-72. doi: 10.1016/j.eururo.2014.03.018. Epub 2014 Mar 25.","Gallina A","Eur Urol","2015","2014/04/02","","","10.1016/j.eururo.2014.03.018"
"24669383","Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death","","Prescrire Int. 2014 Feb;23(146):40-1.","","Prescrire Int","2014","2014/03/27","","",""
"9644508","Prostate cancer test becomes more accurate","","Health News. 1998 Jun 25;4(8):5.","","Health News","1998","1998/06/30","","",""
"20981458","Synergic effect of α-tocopherol and naringenin in transglutaminase-induced differentiation of human prostate cancer cells","Torricelli P, Ricci P, Provenzano B, Lentini A, Tabolacci C.","Amino Acids. 2011 Nov;41(5):1207-14. doi: 10.1007/s00726-010-0788-8. Epub 2010 Oct 28.","Torricelli P","Amino Acids","2011","2010/10/29","","","10.1007/s00726-010-0788-8"
"22257099","Advances in the management of high-risk localised and metastatic prostate cancer","Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W.","BJU Int. 2012 Mar;109 Suppl 2:8-13. doi: 10.1111/j.1464-410X.2011.10871.x.","Bellmunt J","BJU Int","2012","2012/01/20","","","10.1111/j.1464-410X.2011.10871.x"
"12429290","Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing","Paquette EL, Sun L, Paquette LR, Connelly R, Mcleod DG, Moul JW.","Urology. 2002 Nov;60(5):756-9. doi: 10.1016/s0090-4295(02)01960-x.","Paquette EL","Urology","2002","2002/11/14","","","10.1016/s0090-4295(02)01960-x"
"27535316","Transcultural Adaptation and Validation of Champion's Health Belief Model Scales for Prostate Cancer Screening","Abuadas MH, Petro-Nustas W, Albikawi ZF, Nabolsi M.","J Nurs Meas. 2016;24(2):296-313. doi: 10.1891/1061-3749.24.2.296.","Abuadas MH","J Nurs Meas","2016","2016/08/19","","","10.1891/1061-3749.24.2.296"
"24694633","Complications of prostate cancer treatment","Bece A, Hruby G.","Lancet Oncol. 2014 Apr;15(4):e149-50. doi: 10.1016/S1470-2045(14)70083-X.","Bece A","Lancet Oncol","2014","2014/04/04","","","10.1016/S1470-2045(14)70083-X"
"12787713","Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment","Eaton CL, Coleman RE.","Cancer Treat Rev. 2003 Jun;29(3):189-98. doi: 10.1016/s0305-7372(03)00071-9.","Eaton CL","Cancer Treat Rev","2003","2003/06/06","","","10.1016/s0305-7372(03)00071-9"
"28097317","Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial","Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV.","JAMA Oncol. 2017 May 1;3(5):652-658. doi: 10.1001/jamaoncol.2016.5983.","Royce TJ","JAMA Oncol","2017","2017/01/19","PMC5470391","","10.1001/jamaoncol.2016.5983"
"25735366","Geographic disparities in prostate cancer outcomes--review of international patterns","Baade PD, Yu XQ, Smith DP, Dunn J, Chambers SK.","Asian Pac J Cancer Prev. 2015;16(3):1259-75. doi: 10.7314/apjcp.2015.16.3.1259.","Baade PD","Asian Pac J Cancer Prev","2015","2015/03/05","","","10.7314/apjcp.2015.16.3.1259"
"21475372","Wnt signaling in prostate development and carcinogenesis","Kharaishvili G, Simkova D, Makharoblidze E, Trtkova K, Kolar Z, Bouchal J.","Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Mar;155(1):11-8. doi: 10.5507/bp.2011.016.","Kharaishvili G","Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub","2011","2011/04/09","","","10.5507/bp.2011.016"
"24123022","Survival in patients with metastatic spinal cord compression from prostate cancer is associated with the number of extra-spinal organs involved","Weber A, Bartscht T, Karstens JH, Schild SE, Rades D.","Anticancer Res. 2013 Oct;33(10):4505-7.","Weber A","Anticancer Res","2013","2013/10/15","","",""
"28928084","Follow-up Care for Survivors of Prostate Cancer - Clinical Management: a Program in Evidence-Based Care Systematic Review and Clinical Practice Guideline","Loblaw A, Souter LH, Canil C, Breau RH, Haider M, Jamnicky L, Morash R, Surchin M, Matthew A.","Clin Oncol (R Coll Radiol). 2017 Nov;29(11):711-717. doi: 10.1016/j.clon.2017.08.004. Epub 2017 Sep 18.","Loblaw A","Clin Oncol (R Coll Radiol)","2017","2017/09/21","","","10.1016/j.clon.2017.08.004"
"12230706","Prostate cancer: metastatic","Michaelson D, Talcott J, Smith M.","Clin Evid. 2002 Jun;(7):804-11.","Michaelson D","Clin Evid","2002","2002/09/17","","",""
"27296648","Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?","Arcangeli S, Greco C.","Nat Rev Urol. 2016 Jul;13(7):400-8. doi: 10.1038/nrurol.2016.106. Epub 2016 Jun 14.","Arcangeli S","Nat Rev Urol","2016","2016/06/15","","","10.1038/nrurol.2016.106"
"17406342","Prostate cancer gene therapy clinical trials","Freytag SO, Stricker H, Movsas B, Kim JH.","Mol Ther. 2007 Jun;15(6):1042-52. doi: 10.1038/sj.mt.6300162. Epub 2007 Apr 3.","Freytag SO","Mol Ther","2007","2007/04/05","","","10.1038/sj.mt.6300162"
"20557000","[Screening and prevention of prostate cancer]","Roosen A.","MMW Fortschr Med. 2010 May 13;152(19):37-9. doi: 10.1007/BF03366554.","Roosen A","MMW Fortschr Med","2010","2010/06/19","","","10.1007/BF03366554"
"30483947","Is time from diagnosis to radical prostatectomy associated with oncological outcomes?","Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V.","World J Urol. 2019 Aug;37(8):1571-1580. doi: 10.1007/s00345-018-2570-6. Epub 2018 Nov 27.","Aas K","World J Urol","2019","2018/11/29","","","10.1007/s00345-018-2570-6"
"10171985","Image-guided therapy tackles prostate cancer","Bieze J.","Diagn Imaging (San Franc). 1993 Sep;15(9):45-6, 50.","Bieze J","Diagn Imaging (San Franc)","1993","1993/08/06","","",""
"27098346","Fitness outcomes from a randomised controlled trial of exercise training for men with prostate cancer: the ENGAGE study","Gaskin CJ, Fraser SF, Owen PJ, Craike M, Orellana L, Livingston PM.","J Cancer Surviv. 2016 Dec;10(6):972-980. doi: 10.1007/s11764-016-0543-6. Epub 2016 Apr 20.","Gaskin CJ","J Cancer Surviv","2016","2016/04/22","PMC5093191","","10.1007/s11764-016-0543-6"
"19271033","Strategies to preserve prostate health","Neill MG, Appu S, Zlotta AR.","Drugs Today (Barc). 2009 Jan;45(1):63-80. doi: 10.1358/dot.2009.45.1.1315920.","Neill MG","Drugs Today (Barc)","2009","2009/03/10","","","10.1358/dot.2009.45.1.1315920"
"10221260","Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer","Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma VM.","Prostate. 1999 Apr 1;39(1):8-15. doi: 10.1002/(sici)1097-0045(19990401)39:1<8::aid-pros2>3.0.co;2-n.","Aaltomaa S","Prostate","1999","1999/04/30","","","10.1002/(sici)1097-0045(19990401)39:1<8::aid-pros2>3.0.co;2-n"
"22921309","The role of choline in prostate cancer","Awwad HM, Geisel J, Obeid R.","Clin Biochem. 2012 Dec;45(18):1548-53. doi: 10.1016/j.clinbiochem.2012.08.012. Epub 2012 Aug 19.","Awwad HM","Clin Biochem","2012","2012/08/28","","","10.1016/j.clinbiochem.2012.08.012"
"27586377","Treatment of Metastatic Prostate Cancer in Older Adults","Loh KP, Mohile SG, Kessler E, Fung C.","Curr Oncol Rep. 2016 Oct;18(10):63. doi: 10.1007/s11912-016-0548-3.","Loh KP","Curr Oncol Rep","2016","2016/09/03","","","10.1007/s11912-016-0548-3"
"14679709","Prostate cancer and psychosocial concerns in African American men: literature synthesis and recommendations","Pierce R, Chadiha LA, Vargas A, Mosley M.","Health Soc Work. 2003 Nov;28(4):302-11. doi: 10.1093/hsw/28.4.302.","Pierce R","Health Soc Work","2003","2003/12/19","","","10.1093/hsw/28.4.302"
"9074906","Antiandrogen monotherapy in the management of advanced prostate cancer","Kaisary AV.","Eur Urol. 1997;31 Suppl 2:14-9; discussion 24-7. doi: 10.1159/000474543.","Kaisary AV","Eur Urol","1997","1997/01/01","","","10.1159/000474543"
"25667108","Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer","Wong LM, Neal DE, Finelli A, Davis S, Bonner C, Kapoor J, Trachtenberg J, Thomas B, Hovens CM, Costello AJ, Corcoran NM.","Prostate Cancer Prostatic Dis. 2015 Jun;18(2):137-43. doi: 10.1038/pcan.2015.1. Epub 2015 Feb 10.","Wong LM","Prostate Cancer Prostatic Dis","2015","2015/02/11","","","10.1038/pcan.2015.1"
"31576545","Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans","Olender J, Lee NH.","Adv Exp Med Biol. 2019;1164:119-139. doi: 10.1007/978-3-030-22254-3_10.","Olender J","Adv Exp Med Biol","2019","2019/10/03","PMC6777849","NIHMS1010139","10.1007/978-3-030-22254-3_10"
"18931653","The prognostic significance of BMP-6 signaling in prostate cancer","Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW.","Mod Pathol. 2008 Dec;21(12):1436-43. doi: 10.1038/modpathol.2008.94. Epub 2008 Oct 17.","Yuen HF","Mod Pathol","2008","2008/10/22","","","10.1038/modpathol.2008.94"
"16630528","Immunotherapy for prostate cancer","Fong L, Small EJ.","Curr Urol Rep. 2006 May;7(3):239-46. doi: 10.1007/s11934-006-0027-8.","Fong L","Curr Urol Rep","2006","2006/04/25","","","10.1007/s11934-006-0027-8"
"23662500","[High-intensity focused ultrasound (HIFU) for the prostate cancer treatment: 5-year resuts]","Shaplysin LV, Solov VA, Vosdvizhenskiĭ MO, Khametov RZ.","Urologiia. 2013 Jan-Feb;(1):70-2.","Shaplysin LV","Urologiia","2013","2013/05/14","","",""
"15204421","The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment","Gjengstø P, Eide J, Frugård J, Bakke A, Høisaeter PA.","Scand J Urol Nephrol. 2004;38(1):15-8. doi: 10.1080/00365590310019990.","Gjengstø P","Scand J Urol Nephrol","2004","2004/06/19","","","10.1080/00365590310019990"
"16966001","Daily variations in the position of the prostate bed in patients with prostate cancer receiving postoperative external beam radiation therapy","Kupelian PA, Langen KM, Willoughby TR, Wagner TH, Zeidan OA, Meeks SL.","Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):593-6. doi: 10.1016/j.ijrobp.2006.05.071.","Kupelian PA","Int J Radiat Oncol Biol Phys","2006","2006/09/13","","","10.1016/j.ijrobp.2006.05.071"
"10408951","The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam","Schröder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W.","Eur Urol. 1999;35(5-6):539-43. doi: 10.1159/000019894.","Schröder FH","Eur Urol","1999","1999/07/17","","","10.1159/000019894"
"9750516","[Impact of life expectancy on the clinical significance and curability of prostate cancer]","Egawa S.","Nihon Rinsho. 1998 Aug;56(8):2103-7.","Egawa S","Nihon Rinsho","1998","1998/09/29","","",""
"15560269","[Prognostic factors of prostate cancer: usefulness of Ki-67 expression in preoperative biopsies]","Ojea Calvo A, Mosteiro Cerviño MJ, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, González Piñeiro A.","Arch Esp Urol. 2004 Oct;57(8):805-16.","Ojea Calvo A","Arch Esp Urol","2004","2004/11/25","","",""
"23271780","Quality of life in men undergoing active surveillance for localized prostate cancer","Bergman J, Litwin MS.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):242-9. doi: 10.1093/jncimonographs/lgs026.","Bergman J","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540887","","10.1093/jncimonographs/lgs026"
"26012482","Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study","Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, Mucci LA, Signorello LB.","Prostate. 2015 Sep;75(13):1384-93. doi: 10.1002/pros.23019. Epub 2015 May 27.","Kantor ED","Prostate","2015","2015/05/28","PMC4536142","NIHMS689471","10.1002/pros.23019"
"8526540","[Transurethral resection of prostate cancer: efficacy and morbidity]","Mora Durban M, Navarro Sebastián J, Arrizabalaga Moreno M, Mañas Pelillo A, Díez Rodríguez J, García González J, Paniagua Andrés P.","Arch Esp Urol. 1995 Oct;48(8):829-35.","Mora Durban M","Arch Esp Urol","1995","1995/10/01","","",""
"18041919","Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications","Hahn NM, Kelley MR, Klaunig JE, Koch MO, Li L, Sweeney CJ.","Future Oncol. 2007 Dec;3(6):665-82. doi: 10.2217/14796694.3.6.665.","Hahn NM","Future Oncol","2007","2007/11/29","","","10.2217/14796694.3.6.665"
"20723930","Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy","Talantov D, Jatkoe TA, Böhm M, Zhang Y, Ferguson AM, Stricker PD, Kattan MW, Sutherland RL, Kench JG, Wang Y, Henshall SM.","J Urol. 2010 Oct;184(4):1521-8. doi: 10.1016/j.juro.2010.05.084. Epub 2010 Aug 17.","Talantov D","J Urol","2010","2010/08/21","","","10.1016/j.juro.2010.05.084"
"19719454","Current perspectives in prostate cancer vaccines","Arlen PM, Gulley JL.","Anticancer Agents Med Chem. 2009 Dec;9(10):1052-7. doi: 10.2174/187152009789735062.","Arlen PM","Anticancer Agents Med Chem","2009","2009/09/02","PMC3471219","NIHMS407142","10.2174/187152009789735062"
"21728008","[From tumor tissue via primary cultures to xenograft models: a functional approach in prostate cancer research]","Saar M, Kamradt J, Jung V, Stöckle M, Unteregger G.","Urologe A. 2011 Aug;50(8):961-7. doi: 10.1007/s00120-011-2630-7.","Saar M","Urologe A","2011","2011/07/06","","","10.1007/s00120-011-2630-7"
"30120592","Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks","Comiskey MC, Dallos MC, Drake CG.","Curr Oncol Rep. 2018 Aug 18;20(9):75. doi: 10.1007/s11912-018-0712-z.","Comiskey MC","Curr Oncol Rep","2018","2018/08/19","","","10.1007/s11912-018-0712-z"
"22843370","Salvage radiotherapy after radical prostatectomy: outcomes and prognostic factors especially focusing on pathological findings","Hayashi S, Hayashi K, Yoshimura R, Masuda H, Kihara K, Shibuya H.","J Radiat Res. 2012 Sep;53(5):727-34. doi: 10.1093/jrr/rrs034. Epub 2012 Jul 10.","Hayashi S","J Radiat Res","2012","2012/07/31","PMC3430423","","10.1093/jrr/rrs034"
"19345321","Unraveling the complexities of androgen receptor signaling in prostate cancer cells","Heemers HV, Tindall DJ.","Cancer Cell. 2009 Apr 7;15(4):245-7. doi: 10.1016/j.ccr.2009.03.009.","Heemers HV","Cancer Cell","2009","2009/04/07","PMC2718563","NIHMS124844","10.1016/j.ccr.2009.03.009"
"24247426","Prostate cancer: Cardiovascular morbidity risk lower for ADT with GnRH antagonists than GnRH agonists","Clyne M.","Nat Rev Urol. 2013 Dec;10(12):679. doi: 10.1038/nrurol.2013.268. Epub 2013 Nov 19.","Clyne M","Nat Rev Urol","2013","2013/11/20","","","10.1038/nrurol.2013.268"
"8023729","Review: should we screen for prostate cancer?","Harwood RH.","Age Ageing. 1994 Mar;23(2):164-8. doi: 10.1093/ageing/23.2.164.","Harwood RH","Age Ageing","1994","1994/03/01","","","10.1093/ageing/23.2.164"
"23290851","[Estimates and prediction of prostate cancer incidence, mortality and prevalence in China, 2008]","Peng P, Gong YM, Bao PP, Ke JZ, Xiang YM, Zhang ML, Zheng Y.","Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Oct;33(10):1056-9.","Peng P","Zhonghua Liu Xing Bing Xue Za Zhi","2012","2013/01/08","","",""
"17620043","ProstaScint and its role in the diagnosis of prostate cancer","Mohammed AA, Shergill IS, Vandal MT, Gujral SS.","Expert Rev Mol Diagn. 2007 Jul;7(4):345-9. doi: 10.1586/14737159.7.4.345.","Mohammed AA","Expert Rev Mol Diagn","2007","2007/07/11","","","10.1586/14737159.7.4.345"
"31802704","Economic burden of illness associated with localized prostate cancer in the United States","Gustavsen G, Gullet L, Cole D, Lewine N, Bishoff JT.","Future Oncol. 2020 Jan;16(1):4265-4277. doi: 10.2217/fon-2019-0639. Epub 2019 Dec 5.","Gustavsen G","Future Oncol","2020","2019/12/06","","","10.2217/fon-2019-0639"
"19233435","15-year followup of a population based prostate cancer screening study","Kjellman A, Akre O, Norming U, Törnblom M, Gustafsson O.","J Urol. 2009 Apr;181(4):1615-21; discussion 1621. doi: 10.1016/j.juro.2008.11.115. Epub 2009 Feb 23.","Kjellman A","J Urol","2009","2009/02/24","","","10.1016/j.juro.2008.11.115"
"9815935","Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer","Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R.","Clin Cancer Res. 1995 Nov;1(11):1385-9.","Latil A","Clin Cancer Res","1995","1995/11/01","","",""
"18446367","The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4-10 ng/mL","Zheng XY, Xie LP, Wang YY, Ding W, Yang K, Shen HF, Qin J, Bai Y, Chen ZD.","J Cancer Res Clin Oncol. 2008 Nov;134(11):1207-10. doi: 10.1007/s00432-008-0400-8. Epub 2008 Apr 30.","Zheng XY","J Cancer Res Clin Oncol","2008","2008/05/01","","","10.1007/s00432-008-0400-8"
"24724611","Transurethral resection of the prostate after radiotherapy for prostate cancer: impact on quality of life","Pinkawa M, Klotz J, Djukic V, Petz D, Holy R, Eble MJ.","Int J Urol. 2014 Sep;21(9):899-903. doi: 10.1111/iju.12460. Epub 2014 Apr 13.","Pinkawa M","Int J Urol","2014","2014/04/15","","","10.1111/iju.12460"
"11733359","Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer","Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T.","Am J Pathol. 2001 Dec;159(6):2089-94. doi: 10.1016/S0002-9440(10)63060-X.","Saramäki O","Am J Pathol","2001","2001/12/26","PMC1850612","","10.1016/S0002-9440(10)63060-X"
"9087462","Is prostate cancer screening analogous to lung cancer screening?","Petty TL.","JAMA. 1997 Apr 9;277(14):1120-1; author reply 1121-2. doi: 10.1001/jama.1997.03540380034016.","Petty TL","JAMA","1997","1997/04/09","","","10.1001/jama.1997.03540380034016"
"19728195","Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer","Chopra S, Foltz WD, Milosevic MF, Toi A, Bristow RG, Ménard C, Haider MA.","Int J Radiat Biol. 2009 Sep;85(9):805-13. doi: 10.1080/09553000903043059.","Chopra S","Int J Radiat Biol","2009","2009/09/04","","","10.1080/09553000903043059"
"30073682","Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI-characterized prostates","Olivier J, Stavrinides V, Kay J, Freeman A, Pye H, Ahmed Z, Carmona Echeverria L, Heavey S, Simmons LAM, Kanthabalan A, Arya M, Briggs T, Barratt D, Charman SC, Gelister J, Hawkes D, Hu Y, Jameson C, McCartan N, Punwani S, van der Muelen J, Moore C, Emberton M, Ahmed HU, Whitaker HC.","Prostate. 2018 Dec;78(16):1229-1237. doi: 10.1002/pros.23698. Epub 2018 Aug 2.","Olivier J","Prostate","2018","2018/08/04","","","10.1002/pros.23698"
"19792968","Is EGR1 a potential target for prostate cancer therapy?","Gitenay D, Baron VT.","Future Oncol. 2009 Sep;5(7):993-1003. doi: 10.2217/fon.09.67.","Gitenay D","Future Oncol","2009","2009/10/02","PMC2776080","NIHMS155263","10.2217/fon.09.67"
"24078105","Innovations in diagnostic imaging of localized prostate cancer","Pummer K, Rieken M, Augustin H, Gutschi T, Shariat SF.","World J Urol. 2014 Aug;32(4):881-90. doi: 10.1007/s00345-013-1172-6.","Pummer K","World J Urol","2014","2013/10/01","","","10.1007/s00345-013-1172-6"
"12663708","Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein","Shariat SF, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM.","J Clin Oncol. 2003 Apr 1;21(7):1223-31. doi: 10.1200/JCO.2003.08.142.","Shariat SF","J Clin Oncol","2003","2003/03/29","","","10.1200/JCO.2003.08.142"
"15976834","[Radical therapy for prostate cancer in Norway]","Johansen TE.","Tidsskr Nor Laegeforen. 2005 Jun 16;125(12):1658-60.","Johansen TE","Tidsskr Nor Laegeforen","2005","2005/06/25","","",""
"26954420","Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply","D'Amico AV, Chen MH, Kantoff PW.","JAMA. 2016 Mar 8;315(10):1055-6. doi: 10.1001/jama.2015.17570.","D'Amico AV","JAMA","2016","2016/03/09","","","10.1001/jama.2015.17570"
"15485154","[Early diagnosis and surgical management of prostate cancer]","Linton DK, Hamdy FC.","Ann Urol (Paris). 2004 Aug;38(4):137-47. doi: 10.1016/j.anuro.2004.06.001.","Linton DK","Ann Urol (Paris)","2004","2004/10/16","","","10.1016/j.anuro.2004.06.001"
"20818868","New therapies for castration-resistant prostate cancer","Longo DL.","N Engl J Med. 2010 Jul 29;363(5):479-81. doi: 10.1056/NEJMe1006300.","Longo DL","N Engl J Med","2010","2010/09/08","","","10.1056/NEJMe1006300"
"10860088","Prostate cancer: what should be the sequel to diagnosis?","Gardiner RA.","Med J Aust. 2000 Mar 20;172(6):256-7.","Gardiner RA","Med J Aust","2000","2000/06/22","","",""
"8719101","PSA-based diagnoses are leading to improved prostate cancer outcomes","","Oncology (Williston Park). 1995 Jun;9(6):561.","","Oncology (Williston Park)","1995","1995/06/01","","",""
"30828899","Sexual minority men and the experience of undergoing treatment for prostate cancer: An integrative review","Moore MA, Batten J, Lazenby M.","Eur J Cancer Care (Engl). 2019 Jul;28(4):e13031. doi: 10.1111/ecc.13031. Epub 2019 Mar 3.","Moore MA","Eur J Cancer Care (Engl)","2019","2019/03/05","","","10.1111/ecc.13031"
"12094135","Prostatic intraepithelial neoplasia and prostate cancer","Montironi R, Santinelli A, Mazzucchelli R.","Panminerva Med. 2002 Sep;44(3):213-20.","Montironi R","Panminerva Med","2002","2002/07/03","","",""
"11188755","Three-dimensional conformal external beam radiotherapy or brachytherapy: which is the ""best alternative"" to radical prostatectomy?","Roach M 3rd.","CA Cancer J Clin. 2000 Nov-Dec;50(6):344-7. doi: 10.3322/canjclin.50.6.344.","Roach M 3rd","CA Cancer J Clin","2000","2001/02/24","","","10.3322/canjclin.50.6.344"
"23934862","PSA enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness","Ahrens MJ, Bertin PA, Vonesh EF, Meade TJ, Catalona WJ, Georganopoulou D.","Prostate. 2013 Dec;73(16):1731-7. doi: 10.1002/pros.22714. Epub 2013 Aug 9.","Ahrens MJ","Prostate","2013","2013/08/13","","","10.1002/pros.22714"
"15860261","Calcidiol and prostate cancer","Tuohimaa P, Golovko O, Kalueff A, Nazarova N, Qiao S, Syvälä H, Talonpoika R, Lou YR.","J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):183-90. doi: 10.1016/j.jsbmb.2004.12.009. Epub 2005 Jan 22.","Tuohimaa P","J Steroid Biochem Mol Biol","2005","2005/04/30","","","10.1016/j.jsbmb.2004.12.009"
"28220805","Meta-analysis of metabolic syndrome and prostate cancer","Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, Tubaro A, Morgia G, Serni S.","Prostate Cancer Prostatic Dis. 2017 Jun;20(2):146-155. doi: 10.1038/pcan.2017.1. Epub 2017 Feb 21.","Gacci M","Prostate Cancer Prostatic Dis","2017","2017/02/22","","","10.1038/pcan.2017.1"
"18440838","Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study","Hinz A, Krauss O, Stolzenburg JU, Schwalenberg T, Michalski D, Schwarz R.","Urol Oncol. 2009 Jul-Aug;27(4):367-72. doi: 10.1016/j.urolonc.2008.02.003. Epub 2008 Apr 28.","Hinz A","Urol Oncol","2009","2008/04/29","","","10.1016/j.urolonc.2008.02.003"
"15847714","Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies","Armstrong AJ, Carducci MA.","Curr Oncol Rep. 2005 May;7(3):220-7. doi: 10.1007/s11912-005-0077-y.","Armstrong AJ","Curr Oncol Rep","2005","2005/04/26","","","10.1007/s11912-005-0077-y"
"17826497","Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response","Alexander BM, Chen MH, Carroll P, D'Amico AV.","Urology. 2007 Aug;70(2):320-3. doi: 10.1016/j.urology.2007.03.074.","Alexander BM","Urology","2007","2007/09/11","","","10.1016/j.urology.2007.03.074"
"9145968","Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer","Critz FA, Levinson K, Williams WH, Holladay D, Holladay C, Griffin V.","Urology. 1997 May;49(5):668-72. doi: 10.1016/s0090-4295(97)00084-8.","Critz FA","Urology","1997","1997/05/01","","","10.1016/s0090-4295(97)00084-8"
"12121833","Vitamin A and apoptosis in prostate cancer","Zhang XK.","Endocr Relat Cancer. 2002 Jun;9(2):87-102. doi: 10.1677/erc.0.0090087.","Zhang XK","Endocr Relat Cancer","2002","2002/07/18","","","10.1677/erc.0.0090087"
"27935553","Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up","Beyer LP, Pregler B, Nießen C, Michalik K, Haimerl M, Stroszczynski C, Jung EM, Wiggermann P.","Clin Hemorheol Microcirc. 2016;64(3):501-506. doi: 10.3233/CH-168125.","Beyer LP","Clin Hemorheol Microcirc","2016","2016/12/10","","","10.3233/CH-168125"
"22349653","Proteoglycans in prostate cancer","Edwards IJ.","Nat Rev Urol. 2012 Feb 21;9(4):196-206. doi: 10.1038/nrurol.2012.19.","Edwards IJ","Nat Rev Urol","2012","2012/02/22","","","10.1038/nrurol.2012.19"
"23412126","[A case of prostate cancer presenting as extensive abdominal metastasis]","Shirono Y, Hanyu S, Ikarashi T.","Hinyokika Kiyo. 2013 Jan;59(1):51-5.","Shirono Y","Hinyokika Kiyo","2013","2013/02/16","","",""
"16601277","TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function?","Zhang L, Barritt GJ.","Endocr Relat Cancer. 2006 Mar;13(1):27-38. doi: 10.1677/erc.1.01093.","Zhang L","Endocr Relat Cancer","2006","2006/04/08","","","10.1677/erc.1.01093"
"26314254","Cardiolipin composition correlates with prostate cancer cell proliferation","Sapandowski A, Stope M, Evert K, Evert M, Zimmermann U, Peter D, Päge I, Burchardt M, Schild L.","Mol Cell Biochem. 2015 Dec;410(1-2):175-85. doi: 10.1007/s11010-015-2549-1. Epub 2015 Aug 28.","Sapandowski A","Mol Cell Biochem","2015","2015/08/29","","","10.1007/s11010-015-2549-1"
"10833941","[Digital image analysis in pathology--exemplified in prostatic cancer]","Danielsen HE, Kildal W, Sudbø J.","Tidsskr Nor Laegeforen. 2000 Feb 10;120(4):479-88.","Danielsen HE","Tidsskr Nor Laegeforen","2000","2000/06/02","","",""
"7474638","[An analysis of familial prostate cancer]","Nakata S, Masuda H, Sato J, Shimizu N, Suzuki K, Imai K, Yamanaka H, Saito K, Nakamura T, Kato N, et al.","Nihon Hinyokika Gakkai Zasshi. 1995 Sep;86(9):1483-7. doi: 10.5980/jpnjurol1989.86.1483.","Nakata S","Nihon Hinyokika Gakkai Zasshi","1995","1995/09/01","","","10.5980/jpnjurol1989.86.1483"
"25591817","Establishing implantation uncertainties for focal brachytherapy with I-125 seeds for the treatment of localized prostate cancer","Polders DL, Steggerda M, van Herk M, Nichol K, Witteveen T, Moonen L, Nijkamp J, van der Heide UA.","Acta Oncol. 2015 Jun;54(6):839-46. doi: 10.3109/0284186X.2014.995312. Epub 2015 Jan 16.","Polders DL","Acta Oncol","2015","2015/01/17","","","10.3109/0284186X.2014.995312"
"23665740","Defining high-risk prostate cancer","Goldberg H, Baniel J, Yossepowitch O.","Curr Opin Urol. 2013 Jul;23(4):337-41. doi: 10.1097/MOU.0b013e328361dba6.","Goldberg H","Curr Opin Urol","2013","2013/05/14","","","10.1097/MOU.0b013e328361dba6"
"29861328","[Active surveillance in prostate cancer: Assessment of MRI in the selection and follow-up of patients]","Raichi A, Marcq G, Fantoni JC, Puech P, Villers A, Ouzzane A.","Prog Urol. 2018 Jun;28(8-9):416-424. doi: 10.1016/j.purol.2018.03.011. Epub 2018 May 31.","Raichi A","Prog Urol","2018","2018/06/05","","","10.1016/j.purol.2018.03.011"
"24510997","Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study","Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.","Anticancer Res. 2014 Feb;34(2):665-9.","Westermann AM","Anticancer Res","2014","2014/02/11","","",""
"21927560","Pre-operative prediction of advanced prostatic cancer using clinical decision support systems: accuracy comparison between support vector machine and artificial neural network","Kim SY, Moon SK, Jung DC, Hwang SI, Sung CK, Cho JY, Kim SH, Lee J, Lee HJ.","Korean J Radiol. 2011 Sep-Oct;12(5):588-94. doi: 10.3348/kjr.2011.12.5.588. Epub 2011 Aug 24.","Kim SY","Korean J Radiol","2011","2011/09/20","PMC3168800","","10.3348/kjr.2011.12.5.588"
"17068650","Bilateral orchidectomy in three metastatic prostate cancer patients with failed LHRH-agonist therapy","Olapade-Olaopa EO, Oluwasola AO, Shonibare A, Falebita OA, Akang EE, Shokunbi MT.","S Afr Med J. 2006 Sep;96(9):810-1.","Olapade-Olaopa EO","S Afr Med J","2006","2006/10/28","","",""
"23102837","PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era","McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA.","Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e39-46. doi: 10.1016/j.ijrobp.2012.08.036. Epub 2012 Oct 23.","McGuire SE","Int J Radiat Oncol Biol Phys","2013","2012/10/30","PMC3840533","NIHMS522141","10.1016/j.ijrobp.2012.08.036"
"24005707","PSA measurement and prostate cancer--overdiagnosis and overtreatment?","Breidablik HJ, Meland E, Aakre KM, Førde OH.","Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1711-6. doi: 10.4045/tidsskr.13.0023.","Breidablik HJ","Tidsskr Nor Laegeforen","2013","2013/09/06","","","10.4045/tidsskr.13.0023"
"8221551","Localized prostate carcinoma. Surgical management","Gibbons RP.","Cancer. 1993 Nov 15;72(10):2865-12. doi: 10.1002/1097-0142(19931115)72:10<2865::aid-cncr2820721002>3.0.co;2-8.","Gibbons RP","Cancer","1993","1993/11/15","","","10.1002/1097-0142(19931115)72:10<2865::aid-cncr2820721002>3.0.co;2-8"
"31135180","Targeted Regulation of miR-26a on PTEN to Affect Proliferation and Apoptosis of Prostate Cancer Cells","Li W, Jiang Y, Wu X, Yang F.","Cancer Biother Radiopharm. 2019 Sep;34(7):480-485. doi: 10.1089/cbr.2018.2664. Epub 2019 May 24.","Li W","Cancer Biother Radiopharm","2019","2019/05/29","","","10.1089/cbr.2018.2664"
"15046709","Antisense therapy: recent advances and relevance to prostate cancer","Benimetskaya L, Stein CA.","Clin Prostate Cancer. 2002 Jun;1(1):20-30. doi: 10.3816/cgc.2002.n.003.","Benimetskaya L","Clin Prostate Cancer","2002","2004/03/30","","","10.3816/cgc.2002.n.003"
"30322875","The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC)","Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P, Stenman UH, Tammela TLJ, Auvinen A.","Clin Cancer Res. 2019 Jan 15;25(2):839-843. doi: 10.1158/1078-0432.CCR-18-1807. Epub 2018 Oct 15.","Pakarainen T","Clin Cancer Res","2019","2018/10/17","","","10.1158/1078-0432.CCR-18-1807"
"12642195","Assessing the unmet information, support and care delivery needs of men with prostate cancer","Boberg EW, Gustafson DH, Hawkins RP, Offord KP, Koch C, Wen KY, Kreutz K, Salner A.","Patient Educ Couns. 2003 Mar;49(3):233-42. doi: 10.1016/s0738-3991(02)00183-0.","Boberg EW","Patient Educ Couns","2003","2003/03/19","","","10.1016/s0738-3991(02)00183-0"
"25933276","Prostate cancer screening in Europe - Authors' reply","Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A.","Lancet. 2015 Apr 18;385(9977):1507-8. doi: 10.1016/S0140-6736(15)60749-8.","Schröder F","Lancet","2015","2015/05/02","","","10.1016/S0140-6736(15)60749-8"
"16161243","I know a bad diet can increase prostate cancer risk, but what about testicular cancer?","","Harv Mens Health Watch. 2005 Jul;9(12):8.","","Harv Mens Health Watch","2005","2005/09/16","","",""
"16110748","Prostate cancer: the role of hormonal therapy","Salesi N, Carlini P, Ruggeri EM, Ferretti G, Bria E, Cognetti F.","J Exp Clin Cancer Res. 2005 Jun;24(2):175-80.","Salesi N","J Exp Clin Cancer Res","2005","2005/08/23","","",""
"23357889","The prostate cancer journey: results of an online survey of men and their partners","O'Shaughnessy PK, Laws TA, Esterman AJ.","Cancer Nurs. 2015 Jan-Feb;38(1):E1-E12. doi: 10.1097/NCC.0b013e31827df2a9.","O'Shaughnessy PK","Cancer Nurs","2015","2013/01/30","","","10.1097/NCC.0b013e31827df2a9"
"28919575","An integrative model of prostate cancer interaction with the bone microenvironment","Farhat A, Jiang D, Cui D, Keller ET, Jackson TL.","Math Biosci. 2017 Dec;294:1-14. doi: 10.1016/j.mbs.2017.09.005. Epub 2017 Sep 14.","Farhat A","Math Biosci","2017","2017/09/19","PMC5714661","NIHMS905988","10.1016/j.mbs.2017.09.005"
"7933236","Radical treatment with radiation of ""early stage"" prostate cancer: impressive results with long-term followup","Shipley WU.","J Urol. 1994 Nov;152(5 Pt 2):1773-4. doi: 10.1016/s0022-5347(17)32383-2.","Shipley WU","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32383-2"
"22093966","Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™)","Simmons LA, Autier P, Zát'ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M.","BJU Int. 2012 Jul;110(1):28-35. doi: 10.1111/j.1464-410X.2011.10734.x. Epub 2011 Nov 17.","Simmons LA","BJU Int","2012","2011/11/19","","","10.1111/j.1464-410X.2011.10734.x"
"22119358","Re: Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease: N. D. Arvold, M. H. Chen, J. W. Moul, B. J. Moran, D. E. Dosoretz, L. L. Bañez, M. J. Katin, M. H. Braccioforte and A. V. D'Amico J Urol 2011; 186: 91-96","Trock BJ.","J Urol. 2012 Jan;187(1):356; author reply 356-7. doi: 10.1016/j.juro.2011.09.014. Epub 2011 Nov 25.","Trock BJ","J Urol","2012","2011/11/29","","","10.1016/j.juro.2011.09.014"
"12752629","Male patients with diagnoses of both breast cancer and prostate cancer","Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK.","Breast J. 2003 May-Jun;9(3):208-12. doi: 10.1046/j.1524-4741.2003.09312.x.","Leibowitz SB","Breast J","2003","2003/05/20","","","10.1046/j.1524-4741.2003.09312.x"
"21377006","The effect of race and rural residence on prostate cancer treatment choice among men in Georgia","Steenland K, Goodman M, Liff J, Diiorio C, Butler S, Roberts P, Smith JL, Ekwueme D, Hall IJ.","Urology. 2011 Mar;77(3):581-7. doi: 10.1016/j.urology.2010.10.020.","Steenland K","Urology","2011","2011/03/08","","","10.1016/j.urology.2010.10.020"
"1375772","[Prostate carcinoma--a current review]","Schmid HP.","Schweiz Rundsch Med Prax. 1992 May 12;81(20):647-53.","Schmid HP","Schweiz Rundsch Med Prax","1992","1992/05/12","","",""
"28662290","Resveratrol and pterostilbene as a microRNA-mediated chemopreventive and therapeutic strategy in prostate cancer","Kumar A, Rimando AM, Levenson AS.","Ann N Y Acad Sci. 2017 Sep;1403(1):15-26. doi: 10.1111/nyas.13372. Epub 2017 Jun 29.","Kumar A","Ann N Y Acad Sci","2017","2017/06/30","","","10.1111/nyas.13372"
"24922676","Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy","Yoshida K, Yamazaki H, Nakamura S, Masui K, Kotsuma T, Akiyama H, Tanaka E, Yoshioka Y.","Anticancer Res. 2014 Jun;34(6):3077-81.","Yoshida K","Anticancer Res","2014","2014/06/13","","",""
"30467373","Immunotherapy for lethal prostate cancer","Rescigno P, de Bono JS.","Nat Rev Urol. 2019 Feb;16(2):69-70. doi: 10.1038/s41585-018-0121-y.","Rescigno P","Nat Rev Urol","2019","2018/11/24","","","10.1038/s41585-018-0121-y"
"29473182","The androgen receptor malignancy shift in prostate cancer","Copeland BT, Pal SK, Bolton EC, Jones JO.","Prostate. 2018 May;78(7):521-531. doi: 10.1002/pros.23497. Epub 2018 Feb 23.","Copeland BT","Prostate","2018","2018/02/24","","","10.1002/pros.23497"
"17216324","Prostatic fatty acids and cancer recurrence after radical prostatectomy for early-stage prostate cancer","Freeman VL, Flanigan RC, Meydani M.","Cancer Causes Control. 2007 Mar;18(2):211-8. doi: 10.1007/s10552-006-0095-6. Epub 2007 Jan 9.","Freeman VL","Cancer Causes Control","2007","2007/01/12","","","10.1007/s10552-006-0095-6"
"31227055","New Targets for PET Molecular Imaging of Prostate Cancer","Mena E, Lindenberg LM, Choyke PL.","Semin Nucl Med. 2019 Jul;49(4):326-336. doi: 10.1053/j.semnuclmed.2019.02.001. Epub 2019 Mar 9.","Mena E","Semin Nucl Med","2019","2019/06/23","","","10.1053/j.semnuclmed.2019.02.001"
"7520577","Detection of prostate cancer in males with prostatism","Lepor H, Owens RS, Rogenes V, Kuhn E.","Prostate. 1994 Sep;25(3):132-40. doi: 10.1002/pros.2990250304.","Lepor H","Prostate","1994","1994/09/01","","","10.1002/pros.2990250304"
"17264863","Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy","Saad F, Sternberg CN.","Nat Clin Pract Urol. 2007 Feb;4 Suppl 1:S3-13. doi: 10.1038/ncpuro0727.","Saad F","Nat Clin Pract Urol","2007","2007/02/01","","","10.1038/ncpuro0727"
"29727540","[Laparoscopic radical prostatectomy for prostate cancer found in transurethral resection of the prostate: Report of 14 cases]","Li S, Yu GH.","Zhonghua Nan Ke Xue. 2017 Oct;23(10):903-907.","Li S","Zhonghua Nan Ke Xue","2017","2018/05/05","","",""
"10896514","Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","Walsh PC.","J Urol. 2000 Jul;164(1):246-7.","Walsh PC","J Urol","2000","2000/07/15","","",""
"10766527","Serum insulin-like growth factor is not a useful marker of prostate cancer","Serel TA, Kecelioglu M.","BJU Int. 2000 Mar;85(4):559-60.","Serel TA","BJU Int","2000","2000/04/15","","",""
"10203918","Increased incidence of prostate cancer in Nigerians","Ogunbiyi JO, Shittu OB.","J Natl Med Assoc. 1999 Mar;91(3):159-64.","Ogunbiyi JO","J Natl Med Assoc","1999","1999/04/16","PMC2608450","",""
"1283498","Nucleolar organizer regions in prostate cancer","Kobayashi S, Kuriyama M, Yamamoto N, Takahashi Y, Shinoda I, Takeuchi T, Deguchi T, Kawada Y.","Adv Exp Med Biol. 1992;324:183-8. doi: 10.1007/978-1-4615-3398-6_19.","Kobayashi S","Adv Exp Med Biol","1992","1992/01/01","","","10.1007/978-1-4615-3398-6_19"
"19501455","Editorial comment on: Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients","Da Pozzo LF.","Eur Urol. 2009 Oct;56(4):675-6. doi: 10.1016/j.eururo.2009.05.042. Epub 2009 May 29.","Da Pozzo LF","Eur Urol","2009","2009/06/09","","","10.1016/j.eururo.2009.05.042"
"27822685","Sequencing Treatment for Castration-Resistant Prostate Cancer","Handy CE, Antonarakis ES.","Curr Treat Options Oncol. 2016 Dec;17(12):64. doi: 10.1007/s11864-016-0438-9.","Handy CE","Curr Treat Options Oncol","2016","2016/11/09","","","10.1007/s11864-016-0438-9"
"19095248","Access to prostate cancer care and implications for survival among minorities","Oliver MN.","J Urol. 2009 Feb;181(2):447-8. doi: 10.1016/j.juro.2008.11.003. Epub 2008 Dec 17.","Oliver MN","J Urol","2009","2008/12/20","","","10.1016/j.juro.2008.11.003"
"22691890","Role of the IGF axis in prostate cancer","Biernacka KM, Perks CM, Holly JM.","Minerva Endocrinol. 2012 Jun;37(2):173-85.","Biernacka KM","Minerva Endocrinol","2012","2012/06/14","","",""
"23826876","The utility of prostate-specific antigen in the management of advanced prostate cancer","Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP.","BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061. Epub 2013 Jul 4.","Crawford ED","BJU Int","2013","2013/07/06","","","10.1111/bju.12061"
"27416639","Focalyx Dx, Bx, Tx et Apps: A novel contemporary fusion paradigm for the management of prostate cancer","Bianco FJ, Martínez-Salamanca JI.","Arch Esp Urol. 2016 Jul;69(6):353-63.","Bianco FJ","Arch Esp Urol","2016","2016/07/15","","",""
"11490252","Quality of life after treatment for localized prostate cancer: differences based on treatment modality","Davis JW, Kuban DA, Lynch DF, Schellhammer PF.","J Urol. 2001 Sep;166(3):947-52.","Davis JW","J Urol","2001","2001/08/08","","",""
"11408712","Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation","Munter G, Hershko C.","Acta Haematol. 2001;105(2):97-9. doi: 10.1159/000046542.","Munter G","Acta Haematol","2001","2001/06/16","","","10.1159/000046542"
"9787506","[Treatment of localized carcinoma of the prostate]","Jarolím J, Vachalovský V, Novák J, Hanus T, Babjuk M, Safarík L, Dvorácek J, Matras B, Simon V, Votocek E, Novák K.","Cas Lek Cesk. 1998 Aug 31;137(17):528-31.","Jarolím J","Cas Lek Cesk","1998","1998/10/27","","",""
"2471346","Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer","Lange PH, Brawer MK.","Urology. 1989 Jun;33(6 Suppl):13-7.","Lange PH","Urology","1989","1989/06/01","","",""
"23193568","Prostate cancer chemoprevention with 5α-reductase inhibitors","Nepple KG, Andriole GL.","Urol Oncol. 2012 Sep;30(5):553-4. doi: 10.1016/j.urolonc.2011.02.006.","Nepple KG","Urol Oncol","2012","2012/11/30","","","10.1016/j.urolonc.2011.02.006"
"19349110","Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example","Moul JW.","Eur Urol. 2009 Jun;55(6):1266-8. doi: 10.1016/j.eururo.2009.03.062. Epub 2009 Apr 1.","Moul JW","Eur Urol","2009","2009/04/08","","","10.1016/j.eururo.2009.03.062"
"22792684","Is there a link between BPH and prostate cancer?","Chang RT, Kirby R, Challacombe BJ.","Practitioner. 2012 Apr;256(1750):13-6, 2.","Chang RT","Practitioner","2012","2012/07/17","","",""
"19213672","Solitary adrenal metastatic lesion in a patient with a history of prostate cancer","Barrisford GW, Sartor O, Richie JP.","Clin Genitourin Cancer. 2009 Jan;7(1):64-6. doi: 10.3816/CGC.2009.n.012.","Barrisford GW","Clin Genitourin Cancer","2009","2009/02/14","","","10.3816/CGC.2009.n.012"
"31727300","HDR Prostate Brachytherapy","Crook J, Marbán M, Batchelar D.","Semin Radiat Oncol. 2020 Jan;30(1):49-60. doi: 10.1016/j.semradonc.2019.08.003.","Crook J","Semin Radiat Oncol","2020","2019/11/16","","","10.1016/j.semradonc.2019.08.003"
"11194947","[Methods and results of radical prostatectomy for localized cancer of the prostate]","Zerbib M.","Cancer Radiother. 2000 Nov;4 Suppl 1:109s-112s.","Zerbib M","Cancer Radiother","2000","2001/02/24","","",""
"27823973","Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer","Hayashi T, Fujita K, Tanigawa G, Kawashima A, Nagahara A, Ujike T, Uemura M, Takao T, Yamaguchi S, Nonomura N.","Oncotarget. 2017 May 23;8(21):35255-35261. doi: 10.18632/oncotarget.13052.","Hayashi T","Oncotarget","2017","2016/11/09","PMC5471051","","10.18632/oncotarget.13052"
"31535940","Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review","Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG.","Future Oncol. 2019 Oct;15(28):3283-3303. doi: 10.2217/fon-2019-0298. Epub 2019 Sep 19.","Swift SL","Future Oncol","2019","2019/09/20","","","10.2217/fon-2019-0298"
"29061480","The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer","Kenigsberg AP, Llukani E, Deng FM, Melamed J, Zhou M, Lepor H.","Urology. 2018 Feb;112:121-125. doi: 10.1016/j.urology.2017.10.014. Epub 2017 Oct 20.","Kenigsberg AP","Urology","2018","2017/10/25","","","10.1016/j.urology.2017.10.014"
"23809693","Analysis of high-dose rate brachytherapy dose distribution resemblance in CyberKnife hypofractionated treatment plans of localized prostate cancer","Sudahar H, Kurup PG, Murali V, Mahadev P, Velmurugan J.","Med Dosim. 2013 Winter;38(4):385-9. doi: 10.1016/j.meddos.2013.04.006. Epub 2013 Jun 25.","Sudahar H","Med Dosim","2013","2013/07/02","","","10.1016/j.meddos.2013.04.006"
"9831224","Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis","Kay PA, Robb RA, Bostwick DG.","Prostate. 1998 Dec 1;37(4):270-7. doi: 10.1002/(sici)1097-0045(19981201)37:4<270::aid-pros9>3.0.co;2-v.","Kay PA","Prostate","1998","1998/11/27","","","10.1002/(sici)1097-0045(19981201)37:4<270::aid-pros9>3.0.co;2-v"
"30900620","The effect of metabolic syndrome on prostate cancer final pathology","Caliskan S, Kaba S, Özsoy E, Keleş MO, Koca O, Akyüz M, Karaman MI.","J Cancer Res Ther. 2019 Mar;15(Supplement):S47-S50. doi: 10.4103/0973-1482.187290.","Caliskan S","J Cancer Res Ther","2019","2019/03/23","","","10.4103/0973-1482.187290"
"23419493","Prostate cancer: Are urologists ready to manage castration-resistant disease?","Woo HH.","Nat Rev Urol. 2013 Mar;10(3):133-4. doi: 10.1038/nrurol.2013.25. Epub 2013 Feb 19.","Woo HH","Nat Rev Urol","2013","2013/02/20","","","10.1038/nrurol.2013.25"
"32474391","Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis","Buonerba C, Ferro M, Dolce P, Crocetto F, Verde A, Lucarelli G, Scafuri L, Facchini S, Vaia A, Marinelli A, Terracciano D, Montella L, Longo N, Imbimbo C, Mirone V, Di Lorenzo G, De Placido S, Sonpavde G.","Crit Rev Oncol Hematol. 2020 Jul;151:102992. doi: 10.1016/j.critrevonc.2020.102992. Epub 2020 May 23.","Buonerba C","Crit Rev Oncol Hematol","2020","2020/06/01","","","10.1016/j.critrevonc.2020.102992"
"15017212","Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era","Oefelein MG, Agarwal PK, Resnick MI.","J Urol. 2004 Apr;171(4):1525-8. doi: 10.1097/01.ju.0000118294.88852.cd.","Oefelein MG","J Urol","2004","2004/03/17","","","10.1097/01.ju.0000118294.88852.cd"
"22561907","External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort","Zhu Y, Wang JY, Shen YJ, Dai B, Ma CG, Xiao WJ, Lin GW, Yao XD, Zhang SL, Ye DW.","Asian J Androl. 2012 Sep;14(5):738-44. doi: 10.1038/aja.2012.28. Epub 2012 May 7.","Zhu Y","Asian J Androl","2012","2012/05/08","PMC3734979","","10.1038/aja.2012.28"
"26990456","Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer","Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.","Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.","Roudier MP","Prostate","2016","2016/03/19","PMC5589183","NIHMS900993","10.1002/pros.23171"
"12084196","The use of bisphosphonates in the management of bone metastatic prostate cancer","Mercadante S.","Curr Urol Rep. 2002 Jun;3(3):244-9. doi: 10.1007/BF03200420.","Mercadante S","Curr Urol Rep","2002","2002/06/27","","","10.1007/BF03200420"
"25532573","Prostate cancer screening: and yet it moves!","Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F.","Asian J Androl. 2015 May-Jun;17(3):437-8. doi: 10.4103/1008-682X.143310.","Kwiatkowski M","Asian J Androl","2015","2014/12/24","PMC4430944","","10.4103/1008-682X.143310"
"12231064","Novel trial designs: which agents and how do we test them?","Kelly WK.","Urology. 2002 Sep;60(3 Suppl 1):109-13; discussion 113-4. doi: 10.1016/s0090-4295(02)01587-x.","Kelly WK","Urology","2002","2002/09/17","","","10.1016/s0090-4295(02)01587-x"
"24794998","Advanced prostate cancer is distinguished by cholesteryl ester accumulation","","Cancer Discov. 2014 May;4(5):505. doi: 10.1158/2159-8290.CD-RW2014-063. Epub 2014 Mar 20.","","Cancer Discov","2014","2014/05/06","","","10.1158/2159-8290.CD-RW2014-063"
"12191733","Highlights of contemporary issues in the medical management of prostate cancer","Sternberg CN.","Crit Rev Oncol Hematol. 2002 Aug;43(2):105-21. doi: 10.1016/s1040-8428(02)00023-9.","Sternberg CN","Crit Rev Oncol Hematol","2002","2002/08/23","","","10.1016/s1040-8428(02)00023-9"
"28139757","Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy","Hegde JV, Margolis DJ, Wang PC, Reiter RE, Huang J, Steinberg ML, Kamrava M.","Prostate Cancer Prostatic Dis. 2017 Jun;20(2):241-248. doi: 10.1038/pcan.2016.75. Epub 2017 Jan 31.","Hegde JV","Prostate Cancer Prostatic Dis","2017","2017/02/01","PMC6946385","NIHMS1063764","10.1038/pcan.2016.75"
"6085712","[An immunohistochemical study of prostate antigen using an enzyme-labeled antibody technique]","Okano M, Deguchi T, Takeuchi T, Kuriyama M, Nishiura T.","Hinyokika Kiyo. 1983 Oct;29(10):1369-71.","Okano M","Hinyokika Kiyo","1983","1983/10/01","","",""
"7966418","Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States","Lubke WL, Optenberg SA, Thompson IM.","J Natl Cancer Inst. 1994 Dec 7;86(23):1790-2. doi: 10.1093/jnci/86.23.1790.","Lubke WL","J Natl Cancer Inst","1994","1994/12/07","","","10.1093/jnci/86.23.1790"
"7692780","Prostate cancer screening: what we know and what we need to know","Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK.","Ann Intern Med. 1993 Nov 1;119(9):914-23. doi: 10.7326/0003-4819-119-9-199311010-00009.","Kramer BS","Ann Intern Med","1993","1993/11/01","","","10.7326/0003-4819-119-9-199311010-00009"
"19260381","High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results","Maestroni U, Ziveri M, Azzolini N, Dinale F, Ziglioli F, Campaniello G, Frattini A, Ferretti S.","Acta Biomed. 2008 Dec;79(3):211-6.","Maestroni U","Acta Biomed","2008","2009/03/06","","",""
"22056501","Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)","Lindström S, Schumacher FR, Campa D, Albanes D, Andriole G, Berndt SI, Bueno-de-Mesquita HB, Chanock SJ, Diver WR, Ganziano JM, Gapstur SM, Giovannucci E, Haiman CA, Henderson B, Hunter DJ, Johansson M, Kolonel LN, Le Marchand L, Ma J, Stampfer M, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Yeager M, Hsing AW, Kraft P.","Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):212-6. doi: 10.1158/1055-9965.EPI-11-0870-T. Epub 2011 Nov 4.","Lindström S","Cancer Epidemiol Biomarkers Prev","2012","2011/11/08","PMC3253912","NIHMS336884","10.1158/1055-9965.EPI-11-0870-T"
"30082473","Family History of Breast or Prostate Cancer and Prostate Cancer Risk","Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, Giovannucci E, Parmigiani G, Mucci LA.","Clin Cancer Res. 2018 Dec 1;24(23):5910-5917. doi: 10.1158/1078-0432.CCR-18-0370. Epub 2018 Aug 6.","Barber L","Clin Cancer Res","2018","2018/08/08","PMC6279573","NIHMS1503181","10.1158/1078-0432.CCR-18-0370"
"20514514","Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: comparative study between the Republic of Ireland and Northern Ireland","Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A.","Cancer Causes Control. 2010 Sep;21(9):1523-31. doi: 10.1007/s10552-010-9581-y. Epub 2010 Jun 1.","Carsin AE","Cancer Causes Control","2010","2010/06/02","","","10.1007/s10552-010-9581-y"
"22460432","[Screening for prostate cancer[editorial]]","Sigurdsson EL.","Laeknabladid. 2012 Apr;98(4):201. doi: 10.17992/lbl.2012.04.424.","Sigurdsson EL","Laeknabladid","2012","2012/03/31","","","10.17992/lbl.2012.04.424"
"10146749","Screening for prostate cancer: is it worthwhile?","Hudson MA.","Contemp Urol. 1994 Mar;6(3):37, 41-9.","Hudson MA","Contemp Urol","1994","1994/02/07","","",""
"10523894","[Cancer of the prostate: what treatment for what stage?]","Vanden Bossche M.","Rev Med Brux. 1999 Sep;20(4):A206-11.","Vanden Bossche M","Rev Med Brux","1999","1999/10/19","","",""
"16215709","[The role of PSA in diagnosis of prostate cancer and its recurrence]","Vergho DC, Heine K, Wolff JM.","Pathologe. 2005 Nov;26(6):473-8. doi: 10.1007/s00292-005-0789-7.","Vergho DC","Pathologe","2005","2005/10/11","","","10.1007/s00292-005-0789-7"
"30473408","Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study","Jenkins V, Solis-Trapala I, Payne H, Mason M, Fallowfield L, May S, Matthews L, Catt S.","Clin Oncol (R Coll Radiol). 2019 Feb;31(2):99-107. doi: 10.1016/j.clon.2018.11.001. Epub 2018 Nov 23.","Jenkins V","Clin Oncol (R Coll Radiol)","2019","2018/11/27","","","10.1016/j.clon.2018.11.001"
"1306104","A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience","Stemmermann GN, Nomura AM, Chyou PH, Yatani R.","Cancer Epidemiol Biomarkers Prev. 1992 Mar-Apr;1(3):189-93.","Stemmermann GN","Cancer Epidemiol Biomarkers Prev","1992","1992/03/01","","",""
"28646463","Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after (68)Ga-PSMA-PET imaging","Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl G.","Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1656-1662. doi: 10.1007/s00259-017-3746-9. Epub 2017 Jun 23.","Schiller K","Eur J Nucl Med Mol Imaging","2017","2017/06/25","","","10.1007/s00259-017-3746-9"
"11799927","Larry Clark's legacy: randomized controlled, selenium-based prostate cancer chemoprevention trials","Marshall JR.","Nutr Cancer. 2001;40(1):74-7. doi: 10.1207/S15327914NC401_13.","Marshall JR","Nutr Cancer","2001","2002/01/22","","","10.1207/S15327914NC401_13"
"31387966","Statin Use and Prostate Cancer Incidence in Manitoba, Canada: A Population-Based Nested Case-Control Study","Righolt CH, Bisewski R, Mahmud SM.","Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1765-1768. doi: 10.1158/1055-9965.EPI-19-0464. Epub 2019 Aug 6.","Righolt CH","Cancer Epidemiol Biomarkers Prev","2019","2019/08/08","","","10.1158/1055-9965.EPI-19-0464"
"30412304","New drug option for men with aggressive prostate cancer","Printz C.","Cancer. 2018 Oct 1;124(19):3797. doi: 10.1002/cncr.31753.","Printz C","Cancer","2018","2018/11/10","","","10.1002/cncr.31753"
"27927252","Dietary inflammatory index and prostate cancer risk in a case-control study in Mexico","Vázquez-Salas RA, Shivappa N, Galván-Portillo M, López-Carrillo L, Hébert JR, Torres-Sánchez L.","Br J Nutr. 2016 Dec;116(11):1945-1953. doi: 10.1017/S0007114516003986. Epub 2016 Dec 8.","Vázquez-Salas RA","Br J Nutr","2016","2016/12/09","","","10.1017/S0007114516003986"
"31184450","Re: The role of 68Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer","Cihan YB.","Int Braz J Urol. 2019 Jul-Aug;45(4):863-865. doi: 10.1590/S1677-5538.IBJU.2019.0130.","Cihan YB","Int Braz J Urol","2019","2019/06/12","PMC6837605","","10.1590/S1677-5538.IBJU.2019.0130"
"23385974","Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy","Huang J, Wang JK, Sun Y.","Curr Opin Urol. 2013 May;23(3):189-93. doi: 10.1097/MOU.0b013e32835e9ef4.","Huang J","Curr Opin Urol","2013","2013/02/07","PMC4086526","NIHMS594451","10.1097/MOU.0b013e32835e9ef4"
"24037407","TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology","Farooqi AA, De Rosa G.","Appl Microbiol Biotechnol. 2013 Oct;97(20):8849-57. doi: 10.1007/s00253-013-5227-9. Epub 2013 Sep 15.","Farooqi AA","Appl Microbiol Biotechnol","2013","2013/09/17","","","10.1007/s00253-013-5227-9"
"24286597","Editorial comment to high percent tumor volume predicts biochemical recurrence after radical prostatectomy in pathological stage T3a prostate cancer with a negative surgical margin","Yamamoto S.","Int J Urol. 2014 May;21(5):489-90. doi: 10.1111/iju.12365. Epub 2013 Nov 28.","Yamamoto S","Int J Urol","2014","2013/11/30","","","10.1111/iju.12365"
"17567642","Commentary: prostate cancer is omnipresent, but should we screen for it?","Martin RM.","Int J Epidemiol. 2007 Apr;36(2):278-81. doi: 10.1093/ije/dym049.","Martin RM","Int J Epidemiol","2007","2007/06/15","PMC2764984","UKMS27930","10.1093/ije/dym049"
"24240194","Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer","von Eyben FE, Kairemo K.","Nucl Med Commun. 2014 Mar;35(3):221-30. doi: 10.1097/MNM.0000000000000040.","von Eyben FE","Nucl Med Commun","2014","2013/11/19","","","10.1097/MNM.0000000000000040"
"11760286","Prostate screening health beliefs and practices of African American men","Fearing A, Bell D, Newton M, Lambert S.","ABNF J. 2000 Nov-Dec;11(6):141-4.","Fearing A","ABNF J","2000","2002/01/05","","",""
"21458094","Development of indicators of the quality of radiotherapy for localized prostate cancer","Danielson B, Brundage M, Pearcey R, Bass B, Pickles T, Bahary JP, Foley K, Mackillop W.","Radiother Oncol. 2011 Apr;99(1):29-36. doi: 10.1016/j.radonc.2011.02.013. Epub 2011 Mar 30.","Danielson B","Radiother Oncol","2011","2011/04/05","","","10.1016/j.radonc.2011.02.013"
"16018826","Bone health in men with prostate cancer: diagnostic and therapeutic considerations","Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.","Can J Urol. 2005 Jun;12 Suppl 2:9-15.","Saad F","Can J Urol","2005","2005/07/16","","",""
"18618944","Quality of life and satisfaction with outcome among prostate-cancer survivors","Arap W.","N Engl J Med. 2008 Jul 10;359(2):200-1; author reply 201-2.","Arap W","N Engl J Med","2008","2008/07/12","","",""
"6440997","External beam irradiation for prostate cancer: the MBMC experience and a literature review","Reagan MT, Smith RA, Steadham RE.","J Miss State Med Assoc. 1984 Dec;25(12):324-7.","Reagan MT","J Miss State Med Assoc","1984","1984/12/01","","",""
"27344717","[Molecules associated with invasion and metastasis in prostate cancer]","Ashida S, Inoue K, Shuin T.","Nihon Rinsho. 2016 May 20;74 Suppl 3:135-9.","Ashida S","Nihon Rinsho","2016","2016/06/28","","",""
"11963672","Laparoscopic radical prostatectomy","Bickert D, Frickel D.","AORN J. 2002 Apr;75(4):762-6, 768-74, 777-80 passim; quiz 785-90. doi: 10.1016/s0001-2092(06)61633-5.","Bickert D","AORN J","2002","2002/04/20","","","10.1016/s0001-2092(06)61633-5"
"18957947","Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?","Antonarakis ES, Eisenberger MA.","Nat Clin Pract Oncol. 2009 Jan;6(1):12-3. doi: 10.1038/ncponc1262. Epub 2008 Oct 28.","Antonarakis ES","Nat Clin Pract Oncol","2009","2008/10/30","PMC4014058","NIHMS571697","10.1038/ncponc1262"
"21152924","PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols","Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK.","World J Urol. 2011 Oct;29(5):683-8. doi: 10.1007/s00345-010-0623-6. Epub 2010 Dec 9.","Liss MA","World J Urol","2011","2010/12/15","PMC3189407","","10.1007/s00345-010-0623-6"
"2219577","Radiation therapy for localized prostate cancer. Justification by long-term follow-up","Bagshaw MA, Cox RS, Ramback JE.","Urol Clin North Am. 1990 Nov;17(4):787-802.","Bagshaw MA","Urol Clin North Am","1990","1990/11/01","","",""
"20152515","Chemoprevention of prostate cancer","Stephenson AJ, Abouassaly R, Klein EA.","Urol Clin North Am. 2010 Feb;37(1):11-21, Table of Contents. doi: 10.1016/j.ucl.2009.11.003.","Stephenson AJ","Urol Clin North Am","2010","2010/02/16","","","10.1016/j.ucl.2009.11.003"
"30859234","[Chemohormonal therapy for metastatic prostate cancer : Taxane-based approaches]","Spek A.","Urologe A. 2019 Apr;58(4):428-431. doi: 10.1007/s00120-019-0899-0.","Spek A","Urologe A","2019","2019/03/13","","","10.1007/s00120-019-0899-0"
"24645212","Drug may slow progression and increase prostate cancer survival. A Duke study is one of three recently published investigations that reflect progress against the disease that affects millions of men","","Duke Med Health News. 2014 Feb;20(2):7.","","Duke Med Health News","2014","2014/03/21","","",""
"22748265","Focal HIFU for prostate cancer","Créhange G, Azria D, Lartigau E, Peiffert D, Maingon P.","Lancet Oncol. 2012 Jul;13(7):e282-3; author reply e284. doi: 10.1016/S1470-2045(12)70244-9. Epub 2012 Jun 28.","Créhange G","Lancet Oncol","2012","2012/07/04","","","10.1016/S1470-2045(12)70244-9"
"12133061","A preliminary report on a patient-preference study to compare treatment options in early prostate cancer","North West Uro-Oncology Group.","BJU Int. 2002 Aug;90(3):253-6. doi: 10.1046/j.1464-410x.2002.02842.x.","North West Uro-Oncology Group","BJU Int","2002","2002/07/23","","","10.1046/j.1464-410x.2002.02842.x"
"7687077","Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate","Schellhammer PF, el-Mahdi AM, Wright GL Jr, Kolm P, Ragle R.","Urology. 1993 Jul;42(1):13-20. doi: 10.1016/0090-4295(93)90325-5.","Schellhammer PF","Urology","1993","1993/07/01","","","10.1016/0090-4295(93)90325-5"
"29397569","Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy","Kikkawa K, Iba A, Kohjimoto Y, Noda Y, Sonomura T, Hara I.","Int J Urol. 2018 Apr;25(4):366-371. doi: 10.1111/iju.13530. Epub 2018 Feb 4.","Kikkawa K","Int J Urol","2018","2018/02/05","","","10.1111/iju.13530"
"15040864","Ion channels as molecular targets in prostate cancer","Trepel JB.","Clin Prostate Cancer. 2003 Dec;2(3):188-9. doi: 10.1016/s1540-0352(11)70042-7.","Trepel JB","Clin Prostate Cancer","2003","2004/03/26","","","10.1016/s1540-0352(11)70042-7"
"26146750","What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer","Becze E.","ONS Connect. 2015 Jun;30(2):40-1.","Becze E","ONS Connect","2015","2015/07/07","","",""
"17941930","New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer","Shariat SF, Karam JA, Margulis V, Karakiewicz PI.","BJU Int. 2008 Mar;101(6):675-83. doi: 10.1111/j.1464-410X.2007.07283.x. Epub 2007 Oct 17.","Shariat SF","BJU Int","2008","2007/10/19","","","10.1111/j.1464-410X.2007.07283.x"
"9973099","Determination of optimal freezing parameters of human prostate cancer in a nude mouse model","Turk TM, Rees MA, Pietrow P, Myers CE, Mills SE, Gillenwater JY.","Prostate. 1999 Feb 1;38(2):137-43. doi: 10.1002/(sici)1097-0045(19990201)38:2<137::aid-pros7>3.0.co;2-5.","Turk TM","Prostate","1999","1999/02/11","","","10.1002/(sici)1097-0045(19990201)38:2<137::aid-pros7>3.0.co;2-5"
"18303476","New drugs in the management of advanced prostate cancer","Kelly WK.","Cancer J. 2008 Jan-Feb;14(1):10. doi: 10.1097/PPO.0b013e318164060a.","Kelly WK","Cancer J","2008","2008/02/28","","","10.1097/PPO.0b013e318164060a"
"24053368","Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk","Kim HJ, Kim KH, Lee J, Oh JJ, Cheong HS, Wong EL, Yang BS, Byun SS, Myung SC.","BJU Int. 2014 Aug;114(2):303-10. doi: 10.1111/bju.12396. Epub 2013 Dec 2.","Kim HJ","BJU Int","2014","2013/09/24","","","10.1111/bju.12396"
"26505861","Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer","Soydal C, Ozkan E, Akyurek S, Kucuk NO.","Clin Nucl Med. 2016 Feb;41(2):159-60. doi: 10.1097/RLU.0000000000001058.","Soydal C","Clin Nucl Med","2016","2015/10/28","","","10.1097/RLU.0000000000001058"
"16045559","Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing","Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T.","Int J Urol. 2005 Jul;12(7):662-7. doi: 10.1111/j.1442-2042.2005.01113.x.","Okihara K","Int J Urol","2005","2005/07/28","","","10.1111/j.1442-2042.2005.01113.x"
"26087186","Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer","Luo Y, Jiang QW, Wu JY, Qiu JG, Zhang WJ, Mei XL, Shi Z, Di JM.","Oncotarget. 2015 Sep 8;6(26):22564-74. doi: 10.18632/oncotarget.4197.","Luo Y","Oncotarget","2015","2015/06/19","PMC4673182","","10.18632/oncotarget.4197"
"16469006","Current role of prostate-specific antigen kinetics in managing patients with prostate cancer","Teahan SJ, Klotz LH.","BJU Int. 2006 Mar;97(3):451-5. doi: 10.1111/j.1464-410X.2006.05958.x.","Teahan SJ","BJU Int","2006","2006/02/14","","","10.1111/j.1464-410X.2006.05958.x"
"19167919","[Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?]","Chapet O, Quero L, Azria D, Bossi A, Hennequin C, Paparel P.","Cancer Radiother. 2009 Sep;13(5):416-22. doi: 10.1016/j.canrad.2008.11.006. Epub 2009 Jan 23.","Chapet O","Cancer Radiother","2009","2009/01/27","","","10.1016/j.canrad.2008.11.006"
"30177837","Reduced Arginyltransferase 1 is a driver and a potential prognostic indicator of prostate cancer metastasis","Birnbaum MD, Zhao N, Moorthy BT, Patel DM, Kryvenko ON, Heidman L, Kumar A, Morgan WM, Ban Y, Reis IM, Chen X, Gonzalgo ML, Jorda M, Burnstein KL, Zhang F.","Oncogene. 2019 Feb;38(6):838-851. doi: 10.1038/s41388-018-0462-2. Epub 2018 Sep 3.","Birnbaum MD","Oncogene","2019","2018/09/05","PMC6368462","NIHMS1501647","10.1038/s41388-018-0462-2"
"10588962","Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer","Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D.","N Engl J Med. 1999 Dec 9;341(24):1781-8. doi: 10.1056/NEJM199912093412401.","Messing EM","N Engl J Med","1999","1999/12/10","","","10.1056/NEJM199912093412401"
"26081820","[Adjuvant radiotherapy in lymph-node-positive prostate cancer with low tumor burden after radical prostatectomy : Multicenter randomized phase III trial on the effect of adjuvant radio therapy in patients with prostate cancer with or without positive margins after radical prostatectomy (RP) and lymph node metastasis with low tumor burden (micrometastases, ≤ 2 lymph node macrometastases). ART-2 trial AP 61/11 of the AUO]","Rexer H, Bartkowiak D.","Urologe A. 2015 Jun;54(6):871-4. doi: 10.1007/s00120-015-3824-1.","Rexer H","Urologe A","2015","2015/06/18","","","10.1007/s00120-015-3824-1"
"11917165","Morphologic and molecular prognostic markers in prostate cancer","Ross JS, Sheehan CE, Dolen EM, Kallakury BV.","Adv Anat Pathol. 2002 Mar;9(2):115-28. doi: 10.1097/00125480-200203000-00003.","Ross JS","Adv Anat Pathol","2002","2002/03/28","","","10.1097/00125480-200203000-00003"
"15046687","New treatment modalities for hormone-resistant prostate cancer","Lee D.","Clin Prostate Cancer. 2002 Dec;1(3):139-41. doi: 10.1016/s1540-0352(11)70136-6.","Lee D","Clin Prostate Cancer","2002","2004/03/30","","","10.1016/s1540-0352(11)70136-6"
"20498680","Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy","Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU.","Prostate Cancer Prostatic Dis. 2011 Mar;14(1):46-52. doi: 10.1038/pcan.2010.16. Epub 2010 May 25.","Karavitakis M","Prostate Cancer Prostatic Dis","2011","2010/05/26","","","10.1038/pcan.2010.16"
"16929891","Collet-sicard syndrome: an uncommon manifestation of metastatic prostate cancer","Chacon G, Alexandraki I, Palacio C.","South Med J. 2006 Aug;99(8):898-9. doi: 10.1097/01.smj.0000224747.50060.26.","Chacon G","South Med J","2006","2006/08/26","","","10.1097/01.smj.0000224747.50060.26"
"29417827","Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET","Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF.","Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8.","Flanders SC","Future Oncol","2018","2018/02/09","PMC5941708","","10.2217/fon-2017-0438"
"15369445","Telomerase as a new target for the treatment of hormone-refractory prostate cancer","Biroccio A, Leonetti C.","Endocr Relat Cancer. 2004 Sep;11(3):407-21. doi: 10.1677/erc.1.00764.","Biroccio A","Endocr Relat Cancer","2004","2004/09/17","","","10.1677/erc.1.00764"
"9186346","Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2","Jørgensen T, Kanagasingam Y, Kaalhus O, Tveter KJ, Bryne M, Skjørten F, Berner A, Danielsen HE.","J Urol. 1997 Jul;158(1):164-70. doi: 10.1097/00005392-199707000-00052.","Jørgensen T","J Urol","1997","1997/07/01","","","10.1097/00005392-199707000-00052"
"27470260","No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer","Jenkins VA, Fallowfield LJ.","Support Care Cancer. 2016 Nov;24(11):4471-3. doi: 10.1007/s00520-016-3358-0. Epub 2016 Jul 28.","Jenkins VA","Support Care Cancer","2016","2016/07/30","","","10.1007/s00520-016-3358-0"
"12752284","Men with colorectal cancer are predisposed to prostate cancer","Moot AR, Polglase A, Giles GG, Garson OM, Thursfield V, Gunter D.","ANZ J Surg. 2003 May;73(5):289-93. doi: 10.1046/j.1445-2197.2003.t01-1-02621.x.","Moot AR","ANZ J Surg","2003","2003/05/20","","","10.1046/j.1445-2197.2003.t01-1-02621.x"
"11744475","Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less","Yamamoto T, Ito K, Ohi M, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.","Urology. 2001 Dec;58(6):994-8. doi: 10.1016/s0090-4295(01)01409-1.","Yamamoto T","Urology","2001","2001/12/18","","","10.1016/s0090-4295(01)01409-1"
"14616435","Watchful waiting in prostate cancer: review and policy proposals","Schröder FH, de Vries SH, Bangma CH.","BJU Int. 2003 Nov;92(8):851-9. doi: 10.1046/j.1464-410x.2003.04493.x.","Schröder FH","BJU Int","2003","2003/11/18","","","10.1046/j.1464-410x.2003.04493.x"
"12599543","[Epidemiological trends of prostate cancer in Japan and international comparisons]","Nakata S, Ohtake N, Yamanaka H.","Nihon Rinsho. 2002 Dec;60 Suppl 11:44-8.","Nakata S","Nihon Rinsho","2002","2003/02/26","","",""
"15983628","Prostate cancer and consistency of reporting sexual histories in men over age 50","Dennis LK, Ritchie JM, Resnick MI.","Prostate Cancer Prostatic Dis. 2005;8(3):243-7. doi: 10.1038/sj.pcan.4500810.","Dennis LK","Prostate Cancer Prostatic Dis","2005","2005/06/29","","","10.1038/sj.pcan.4500810"
"24838947","Association between NQO1 C609T polymorphism and prostate cancer risk","Sun Z, Cui Y, Pei J, Fan Z.","Tumour Biol. 2014 Aug;35(8):7993-8. doi: 10.1007/s13277-014-2051-5. Epub 2014 May 17.","Sun Z","Tumour Biol","2014","2014/05/20","","","10.1007/s13277-014-2051-5"
"16926855","Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis","Wang Y, Sun G, Pan JG, Guo ZJ, Li T.","Prostate Cancer Prostatic Dis. 2006;9(4):374-8. doi: 10.1038/sj.pcan.4500906. Epub 2006 Aug 22.","Wang Y","Prostate Cancer Prostatic Dis","2006","2006/08/24","","","10.1038/sj.pcan.4500906"
"3433541","[The prognostic significance of prolactin in prostate cancer]","Røhl HF, Andersen OP.","Ugeskr Laeger. 1987 Dec 7;149(50):3402-3.","Røhl HF","Ugeskr Laeger","1987","1987/12/07","","",""
"29187477","Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical Failure","Lamb DS, Sondhauss S, Dunne JC, Woods L, Delahunt B, Ferguson P, Murray J, Nacey JN, Denham JW, Jordan TW.","Anticancer Res. 2017 Dec;37(12):6943-6946. doi: 10.21873/anticanres.12159.","Lamb DS","Anticancer Res","2017","2017/12/01","","","10.21873/anticanres.12159"
"26269169","[New progress in prostate cancer biomarker research]","Qu M, Ren S, Sun Y.","Zhonghua Wai Ke Za Zhi. 2015 Apr;53(4):317-20.","Qu M","Zhonghua Wai Ke Za Zhi","2015","2015/08/14","","",""
"26757076","The use of matrix coating assisted by an electric field (MCAEF) to enhance mass spectrometric imaging of human prostate cancer biomarkers","Wang X, Han J, Hardie DB, Yang J, Borchers CH.","J Mass Spectrom. 2016 Jan;51(1):86-95. doi: 10.1002/jms.3728.","Wang X","J Mass Spectrom","2016","2016/01/13","","","10.1002/jms.3728"
"25808443","Study of NGEP expression pattern in cancerous tissues provides novel insights into prognostic marker in prostate cancer","Mohsenzadegan M, Shekarabi M, Madjd Z, Asgari M, Abolhasani M, Tajik N, Farajollahi MM.","Biomark Med. 2015;9(4):391-401. doi: 10.2217/bmm.14.106.","Mohsenzadegan M","Biomark Med","2015","2015/03/27","","","10.2217/bmm.14.106"
"7323553","[Cancer of the prostate]","Graber P.","Rev Med Suisse Romande. 1981 Oct;101(10):767-70.","Graber P","Rev Med Suisse Romande","1981","1981/10/01","","",""
"25636465","Genetically engineered mouse models to study prostate cancer","Brzezinska EA, Nixon C, Patel R, Leung HY.","Methods Mol Biol. 2015;1267:73-91. doi: 10.1007/978-1-4939-2297-0_4.","Brzezinska EA","Methods Mol Biol","2015","2015/02/01","","","10.1007/978-1-4939-2297-0_4"
"12928350","Body mass index and risk of prostate cancer in U.S. health professionals","Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC.","J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4. doi: 10.1093/jnci/djg009.","Giovannucci E","J Natl Cancer Inst","2003","2003/08/21","","","10.1093/jnci/djg009"
"18593618","Evolving new treatments for patients with prostate cancer: the advanced disease paradigm of the PSA era","Eisenberger MA.","Urol Oncol. 2008 Jul-Aug;26(4):406-7. doi: 10.1016/j.urolonc.2007.11.001.","Eisenberger MA","Urol Oncol","2008","2008/07/03","","","10.1016/j.urolonc.2007.11.001"
"25964141","Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer","Brett SI, Kim Y, Biggs CN, Chin JL, Leong HS.","Prostate Cancer Prostatic Dis. 2015 Sep;18(3):213-20. doi: 10.1038/pcan.2015.17. Epub 2015 May 12.","Brett SI","Prostate Cancer Prostatic Dis","2015","2015/05/13","","","10.1038/pcan.2015.17"
"24853214","New developments in the treatment of castration-resistant prostate cancer","Higano CS.","J Natl Compr Canc Netw. 2014 May;12(5 Suppl):773-6. doi: 10.6004/jnccn.2014.0187.","Higano CS","J Natl Compr Canc Netw","2014","2014/05/24","","","10.6004/jnccn.2014.0187"
"2434937","Medical, life-style, and occupational risk factors for prostate cancer","Checkoway H, DiFerdinando G, Hulka BS, Mickey DD.","Prostate. 1987;10(1):79-88. doi: 10.1002/pros.2990100111.","Checkoway H","Prostate","1987","1987/01/01","","","10.1002/pros.2990100111"
"27277398","Multiparametric magnetic resonance imaging and active surveillance: How to better select insignificant prostate cancer?","Porpiglia F, Cantiello F, De Luca S, De Pascale A, Manfredi M, Mele F, Bollito E, Cirillo S, Damiano R, Russo F.","Int J Urol. 2016 Sep;23(9):752-7. doi: 10.1111/iju.13138. Epub 2016 Jun 9.","Porpiglia F","Int J Urol","2016","2016/06/10","","","10.1111/iju.13138"
"20399963","Androgen regulation of gene expression","Lamont KR, Tindall DJ.","Adv Cancer Res. 2010;107:137-62. doi: 10.1016/S0065-230X(10)07005-3.","Lamont KR","Adv Cancer Res","2010","2010/04/20","","","10.1016/S0065-230X(10)07005-3"
"28576185","Brachytherapy in the Management of Prostate Cancer","Stish BJ, Davis BJ, Mynderse LA, Deufel CL, Choo R.","Surg Oncol Clin N Am. 2017 Jul;26(3):491-513. doi: 10.1016/j.soc.2017.01.008. Epub 2017 May 11.","Stish BJ","Surg Oncol Clin N Am","2017","2017/06/04","","","10.1016/j.soc.2017.01.008"
"20383185","Prostate cancer: Defining biochemical failure in patients treated with HIFU","Abdel-Wahab M, Pollack A.","Nat Rev Urol. 2010 Apr;7(4):186-7. doi: 10.1038/nrurol.2010.12.","Abdel-Wahab M","Nat Rev Urol","2010","2010/04/13","","","10.1038/nrurol.2010.12"
"31478109","Irreversible Electroporation for the Ablation of Prostate Cancer","Karagiannis A, Varkarakis J.","Curr Urol Rep. 2019 Sep 2;20(10):63. doi: 10.1007/s11934-019-0929-x.","Karagiannis A","Curr Urol Rep","2019","2019/09/04","","","10.1007/s11934-019-0929-x"
"12376516","Aspirin use in relation to risk of prostate cancer","Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E.","Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1108-11.","Leitzmann MF","Cancer Epidemiol Biomarkers Prev","2002","2002/10/12","","",""
"17437768","Prostate cancer--more information and more questions","Dall'Era M, Carroll PR.","J Urol. 2007 May;177(5):1607-8. doi: 10.1016/j.juro.2007.02.008.","Dall'Era M","J Urol","2007","2007/04/18","","","10.1016/j.juro.2007.02.008"
"23392076","NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer","Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, Hammond ME, Kogan BA, Lynch CF, Newcomer L, Seifter EJ, Tooze JA, Viswanath KV, Wessells H.","NIH Consens State Sci Statements. 2011 Dec 5-7;28(1):1-27.","Ganz PA","NIH Consens State Sci Statements","2011","2013/02/09","","",""
"7621466","The geography of prostate cancer and its treatment in Europe","Newling DW.","Cancer Surv. 1995;23:289-96.","Newling DW","Cancer Surv","1995","1995/01/01","","",""
"31591549","Towards precision oncology in advanced prostate cancer","Ku SY, Gleave ME, Beltran H.","Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7.","Ku SY","Nat Rev Urol","2019","2019/10/09","PMC6858516","NIHMS1054030","10.1038/s41585-019-0237-8"
"1509913","[Complete hormonal blockade vs. monotherapy in the management of metastasizing prostatic cancer]","Morote Robles J, Vila Barja J, López Pacios MA, de Torres Mateos JA, Soler Roselló A.","Actas Urol Esp. 1992 Jun;16(6):451-4.","Morote Robles J","Actas Urol Esp","1992","1992/06/01","","",""
"30307525","Developing prognostic models for advanced prostate cancer when the goal line keeps changing","Fu SYF, Chi KN.","Ann Oncol. 2018 Nov 1;29(11):2155-2157. doi: 10.1093/annonc/mdy419.","Fu SYF","Ann Oncol","2018","2018/10/12","","","10.1093/annonc/mdy419"
"15535442","Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy","D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH.","J Urol. 2004 Nov;172(5 Pt 2):S42-6; discussion S46-7. doi: 10.1097/01.ju.0000141845.99899.12.","D'Amico AV","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000141845.99899.12"
"17309847","COX-2 inhibition: a possible role in the management of prostate cancer?","Sooriakumaran P, Langley SE, Laing RW, Coley HM.","J Chemother. 2007 Feb;19(1):21-32. doi: 10.1179/joc.2007.19.1.21.","Sooriakumaran P","J Chemother","2007","2007/02/21","","","10.1179/joc.2007.19.1.21"
"18822517","Treating prostate cancer, Part V: radiation therapy","","Harv Mens Health Watch. 2008 Sep;13(2):1-4.","","Harv Mens Health Watch","2008","2008/10/01","","",""
"7571224","Prostate cancer staging after radiation utilizing laparoscopic pelvic lymphadenectomy","Jarrard DF, Chodak GW.","Urology. 1995 Oct;46(4):538-41. doi: 10.1016/S0090-4295(99)80268-4.","Jarrard DF","Urology","1995","1995/10/01","","","10.1016/S0090-4295(99)80268-4"
"18267336","Effect of BMI on primary treatment of prostate cancer","Davies BJ, Walsh TJ, Ross PL, Knight SJ, Sadetsky N, Carroll PR, Kane CJ.","Urology. 2008 Aug;72(2):406-11. doi: 10.1016/j.urology.2007.11.032. Epub 2008 Feb 11.","Davies BJ","Urology","2008","2008/02/13","","","10.1016/j.urology.2007.11.032"
"10798801","Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy","Gamito EJ, Stone NN, Batuello JT, Crawford ED.","Tech Urol. 2000 Jun;6(2):60-3.","Gamito EJ","Tech Urol","2000","2000/05/08","","",""
"21645976","Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease","Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA.","Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7.","Stenmark MH","Int J Radiat Oncol Biol Phys","2011","2011/06/08","","","10.1016/j.ijrobp.2011.04.037"
"32484704","Metastasis-free survival as a new endpoint in castration- -resistant prostate cancer","Kuzma M, Kliment J.","Bratisl Lek Listy. 2020;121(6):411-414. doi: 10.4149/BLL_2020_066.","Kuzma M","Bratisl Lek Listy","2020","2020/06/03","","","10.4149/BLL_2020_066"
"25527754","Dairy products, calcium, and prostate cancer risk: a systematic review and meta-analysis of cohort studies","Aune D, Navarro Rosenblatt DA, Chan DS, Vieira AR, Vieira R, Greenwood DC, Vatten LJ, Norat T.","Am J Clin Nutr. 2015 Jan;101(1):87-117. doi: 10.3945/ajcn.113.067157. Epub 2014 Nov 19.","Aune D","Am J Clin Nutr","2015","2014/12/21","","","10.3945/ajcn.113.067157"
"24324056","Reliable housekeeping gene combination for quantitative PCR of lymph nodes in patients with prostate cancer","Tsaur I, Renninger M, Hennenlotter J, Oppermann E, Munz M, Kuehs U, Stenzl A, Schilling D.","Anticancer Res. 2013 Dec;33(12):5243-8.","Tsaur I","Anticancer Res","2013","2013/12/11","","",""
"23434102","Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy?","Elshafei A, Moussa AS, Hatem A, Ethan V, Panumatrassamee K, Hernandez AV, Jones JS.","Urology. 2013 Apr;81(4):826-30. doi: 10.1016/j.urology.2012.10.074. Epub 2013 Feb 20.","Elshafei A","Urology","2013","2013/02/26","","","10.1016/j.urology.2012.10.074"
"23039671","Methodology for registration of distended rectums in pelvic CT studies","Rodriguez-Vila B, Garcia-Vicente F, Gomez EJ.","Med Phys. 2012 Oct;39(10):6351-9. doi: 10.1118/1.4754798.","Rodriguez-Vila B","Med Phys","2012","2012/10/09","","","10.1118/1.4754798"
"16458417","Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?","Cella D, Petrylak DP, Fishman M, Teigland C, Young J, Mulani P.","Eur Urol. 2006 May;49(5):781-9. doi: 10.1016/j.eururo.2005.12.058. Epub 2006 Jan 19.","Cella D","Eur Urol","2006","2006/02/07","","","10.1016/j.eururo.2005.12.058"
"1434292","[Radiotherapy for stage B prostate cancer]","Kobayashi T, Kawai T, Tachibana Y, Yamauchi T, Aizawa T.","Nihon Hinyokika Gakkai Zasshi. 1992 Sep;83(9):1499-505. doi: 10.5980/jpnjurol1989.83.1499.","Kobayashi T","Nihon Hinyokika Gakkai Zasshi","1992","1992/09/01","","","10.5980/jpnjurol1989.83.1499"
"18586020","Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer","Avgeris M, Koutalellis G, Fragoulis EG, Scorilas A.","Clin Biochem. 2008 Oct;41(14-15):1140-9. doi: 10.1016/j.clinbiochem.2008.04.026. Epub 2008 Jun 10.","Avgeris M","Clin Biochem","2008","2008/07/01","","","10.1016/j.clinbiochem.2008.04.026"
"23991210","Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice","Poutahidis T, Cappelle K, Levkovich T, Lee CW, Doulberis M, Ge Z, Fox JG, Horwitz BH, Erdman SE.","PLoS One. 2013 Aug 26;8(8):e73933. doi: 10.1371/journal.pone.0073933. eCollection 2013.","Poutahidis T","PLoS One","2013","2013/08/31","PMC3753256","","10.1371/journal.pone.0073933"
"20532174","""Topological significance"" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response","Vellaichamy A, Dezso Z, JeBailey L, Chinnaiyan AM, Sreekumar A, Nesvizhskii AI, Omenn GS, Bugrim A.","PLoS One. 2010 Jun 3;5(6):e10936. doi: 10.1371/journal.pone.0010936.","Vellaichamy A","PLoS One","2010","2010/06/10","PMC2880599","","10.1371/journal.pone.0010936"
"1947115","Prostate cancer: retrograde urethrography to improve treatment planning for radiation therapy","Schild SE, Buskirk SJ, Robinow JS.","Radiology. 1991 Dec;181(3):885-7. doi: 10.1148/radiology.181.3.1947115.","Schild SE","Radiology","1991","1991/12/01","","","10.1148/radiology.181.3.1947115"
"31361646","18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer","Meijer D, Wondergem M, Knol RJJ, Broos WAM, van der Zant FM.","Clin Nucl Med. 2020 Feb;45(2):e96-e97. doi: 10.1097/RLU.0000000000002738.","Meijer D","Clin Nucl Med","2020","2019/07/31","","","10.1097/RLU.0000000000002738"
"10645813","Prostate cancer and dietary carotenoids","Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM.","Am J Epidemiol. 2000 Jan 15;151(2):119-23. doi: 10.1093/oxfordjournals.aje.a010176.","Norrish AE","Am J Epidemiol","2000","2000/01/25","","","10.1093/oxfordjournals.aje.a010176"
"19339216","Insights into Ca2+ homeostasis of advanced prostate cancer cells","Flourakis M, Prevarskaya N.","Biochim Biophys Acta. 2009 Jun;1793(6):1105-9. doi: 10.1016/j.bbamcr.2009.01.009. Epub 2009 Jan 24.","Flourakis M","Biochim Biophys Acta","2009","2009/04/03","","","10.1016/j.bbamcr.2009.01.009"
"10228465","[Non-localized cancer of the prostate. National Agency of Accreditation and Health Evaluation]","Cuzin B.","Presse Med. 1999 Mar 27;28(12):637-8.","Cuzin B","Presse Med","1999","1999/05/06","","",""
"32232449","Geographic Distribution of Racial Differences in Prostate Cancer Mortality","Fletcher SA, Marchese M, Cole AP, Mahal BA, Friedlander DF, Krimphove M, Kilbridge KL, Lipsitz SR, Nguyen PL, Choueiri TK, Kibel AS, Trinh QD.","JAMA Netw Open. 2020 Mar 2;3(3):e201839. doi: 10.1001/jamanetworkopen.2020.1839.","Fletcher SA","JAMA Netw Open","2020","2020/04/02","PMC7109596","","10.1001/jamanetworkopen.2020.1839"
"22318188","[Biochemical recurrence in patients with prostate cancer after radical treatment. Comparative study of prostatectomy vs. radiotherapy]","Amo FH, San Segundo CG, Facundo EV, González AA, Espi MG, García EL, García JT, Tartajo FV, Hernández CF.","Arch Esp Urol. 2012 Jan-Feb;65(1):176-84.","Amo FH","Arch Esp Urol","2012","2012/02/10","","",""
"16050199","[The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy]","Ojea Calvo A, Mosteiro Cerviño MJ, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, González Piñeiro A.","Actas Urol Esp. 2004 Oct;28(9):650-60. doi: 10.1016/s0210-4806(04)73156-3.","Ojea Calvo A","Actas Urol Esp","2004","2005/07/30","","","10.1016/s0210-4806(04)73156-3"
"8693652","Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate","Deftos LJ, Nakada S, Burton DW, di Sant'Agnese PA, Cockett AT, Abrahamsson PA.","Urology. 1996 Jul;48(1):58-62. doi: 10.1016/s0090-4295(96)00089-1.","Deftos LJ","Urology","1996","1996/07/01","","","10.1016/s0090-4295(96)00089-1"
"15759079","Routine PSA testing: an analysis of the controversy concerning its use","Hussain NS.","ScientificWorldJournal. 2005 Feb 16;5:147-50. doi: 10.1100/tsw.2005.21.","Hussain NS","ScientificWorldJournal","2005","2005/03/11","PMC5936566","","10.1100/tsw.2005.21"
"1873780","The role of radical surgery in the management of radiation recurrent and large volume prostate cancer","Moul JW, Paulson DF.","Cancer. 1991 Sep 15;68(6):1265-71. doi: 10.1002/1097-0142(19910915)68:6<1265::aid-cncr2820680615>3.0.co;2-g.","Moul JW","Cancer","1991","1991/09/15","","","10.1002/1097-0142(19910915)68:6<1265::aid-cncr2820680615>3.0.co;2-g"
"17977420","[Prostatic specific antigen: role and significance in urologic practice]","Manolović D, Pejcić T, Milović N.","Srp Arh Celok Lek. 1994 May-Jun;122(5-6):171-3.","Manolović D","Srp Arh Celok Lek","1994","1994/05/01","","",""
"15042290","[Chemoprevention of prostate cancer]","Djavan B, Thompson I, Michel MS, Waldert M, Seitz C.","Urologe A. 2004 May;43(5):557-61. doi: 10.1007/s00120-004-0537-2.","Djavan B","Urologe A","2004","2004/03/26","","","10.1007/s00120-004-0537-2"
"16813882","Use of hormonal therapy in men with metastatic prostate cancer","Lu-Yao G, Moore DF, Oleynick J, Dipaola RS, Yao SL.","J Urol. 2006 Aug;176(2):526-31. doi: 10.1016/j.juro.2006.03.098.","Lu-Yao G","J Urol","2006","2006/07/04","","","10.1016/j.juro.2006.03.098"
"23880826","Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up","Creak A, Hall E, Horwich A, Eeles R, Khoo V, Huddart R, Parker C, Griffin C, Bidmead M, Warrington J, Dearnaley D.","Br J Cancer. 2013 Aug 6;109(3):651-7. doi: 10.1038/bjc.2013.394. Epub 2013 Jul 23.","Creak A","Br J Cancer","2013","2013/07/25","PMC3738135","","10.1038/bjc.2013.394"
"21317957","Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy","Keogh JW, Shepherd D, Krägeloh CU, Ryan C, Masters J, Shepherd G, MacLeod R.","N Z Med J. 2010 Nov 5;123(1325):20-9.","Keogh JW","N Z Med J","2010","2011/02/15","","",""
"10728680","Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells","Ni Z, Lou W, Leman ES, Gao AC.","Cancer Res. 2000 Mar 1;60(5):1225-8.","Ni Z","Cancer Res","2000","2000/03/23","","",""
"25323615","In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet","Armstrong AJ.","Oncology (Williston Park). 2014 Oct;28(10):881, 883.","Armstrong AJ","Oncology (Williston Park)","2014","2014/10/18","","",""
"14529212","Functional CT imaging of prostate cancer","Henderson E, Milosevic MF, Haider MA, Yeung IW.","Phys Med Biol. 2003 Sep 21;48(18):3085-100. doi: 10.1088/0031-9155/48/18/309.","Henderson E","Phys Med Biol","2003","2003/10/08","","","10.1088/0031-9155/48/18/309"
"16672130","Therapeutic approach to hormone-refractory prostate cancer","Saad F, Al Dejmah A, Perrotte P, McCormack M, Bénard F, Valiquette L, Karakiewicz PI.","Can J Urol. 2006 Apr;13 Suppl 2:52-6.","Saad F","Can J Urol","2006","2006/05/05","","",""
"26628213","Clinical evaluation of prostate cancer gene 3 score in diagnosis among Chinese men with prostate cancer and benign prostatic hyperplasia","Huang J, Reilly KH, Zhang HZ, Wang HB.","BMC Urol. 2015 Dec 1;15:118. doi: 10.1186/s12894-015-0110-x.","Huang J","BMC Urol","2015","2015/12/03","PMC4666051","","10.1186/s12894-015-0110-x"
"23016259","PSA-based screening for prostate cancer. Too many adverse effects","","Prescrire Int. 2012 Sep;21(130):215-7.","","Prescrire Int","2012","2012/09/29","","",""
"24432401","[Prostate cancer staging: ¹ ¹ C-Acetat-PET/CT as a sensitive marker for nodal metastases]","Bischoff M.","Rofo. 2013 Dec;185(12):1134-5.","Bischoff M","Rofo","2013","2014/01/17","","",""
"23736690","Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?","Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.","Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.","Ibeawuchi C","Int J Mol Sci","2013","2013/06/06","PMC3709757","","10.3390/ijms140611816"
"11221034","[Validity of PSA density of the transition zone in the diagnosis of prostate cancer]","Anastasi G, Magno C, Carmignani A, Inferrera A, Petrelli A, Broccio G.","Arch Ital Urol Androl. 2000 Dec;72(4):190-3.","Anastasi G","Arch Ital Urol Androl","2000","2001/02/28","","",""
"1289672","DNA ploidy: early malignant lesions","Lieber MM.","J Cell Biochem Suppl. 1992;16H:44-6. doi: 10.1002/jcb.240501210.","Lieber MM","J Cell Biochem Suppl","1992","1992/01/01","","","10.1002/jcb.240501210"
"19616259","Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland","Mouraviev V, Madden JF, Broadwater G, Mayes JM, Burchette JL, Schneider F, Smith J, Tsivian M, Wong T, Polascik TJ.","J Urol. 2009 Sep;182(3):938-47. doi: 10.1016/j.juro.2009.05.047. Epub 2009 Jul 17.","Mouraviev V","J Urol","2009","2009/07/21","","","10.1016/j.juro.2009.05.047"
"25257405","Inhibition of soluble adenylyl cyclase increases the radiosensitivity of prostate cancer cells","Appukuttan A, Flacke JP, Flacke H, Posadowsky A, Reusch HP, Ladilov Y.","Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2656-63. doi: 10.1016/j.bbadis.2014.09.008. Epub 2014 Sep 23.","Appukuttan A","Biochim Biophys Acta","2014","2014/09/27","","","10.1016/j.bbadis.2014.09.008"
"7513531","Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer","Voges GE, Mottrie AM, Stöckle M, Müller SC.","Prostate Suppl. 1994;5:4-8. doi: 10.1002/pros.2990250704.","Voges GE","Prostate Suppl","1994","1994/01/01","","","10.1002/pros.2990250704"
"17396482","Hormone-refractory prostate cancer: choosing the appropriate treatment option","Ross RW, Kantoff PW.","Oncology (Williston Park). 2007 Feb;21(2):185-93; discussion 194, 199-200.","Ross RW","Oncology (Williston Park)","2007","2007/04/03","","",""
"23263824","Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance","Fu Q, Moul JW, Bañez L, Sun L, Mouraviev V, Xie D, Polascik TJ.","Med Oncol. 2013 Mar;30(1):326. doi: 10.1007/s12032-012-0326-5. Epub 2012 Dec 22.","Fu Q","Med Oncol","2013","2012/12/25","","","10.1007/s12032-012-0326-5"
"19882268","Cancer gene profiling in prostate cancer","Foye A, Febbo PG.","Methods Mol Biol. 2010;576:293-326. doi: 10.1007/978-1-59745-545-9_15.","Foye A","Methods Mol Biol","2010","2009/11/03","","","10.1007/978-1-59745-545-9_15"
"21382149","Maximizing outcomes in genitourinary cancers across the treatment continuum","Fitzpatrick JM, Bellmunt J, Dreicer R, Fleshner NE, Logothetis CJ, Moul JW, Tombal B, Zlotta A.","BJU Int. 2011 Apr;107 Suppl 2:1-12. doi: 10.1111/j.1464-410X.2010.10035.x.","Fitzpatrick JM","BJU Int","2011","2011/03/09","","","10.1111/j.1464-410X.2010.10035.x"
"12883743","Establishment and characterization of sublines of LNCaP human prostate cancer cells","Wan XS, Zhou Z, Steele V, Kopelovich L, Kennedy AR.","Oncol Rep. 2003 Sep-Oct;10(5):1569-75.","Wan XS","Oncol Rep","2003","2003/07/29","","",""
"7610506","Castration-induced lymphocytosis in prostate cancer: possible evidence for gonad/thymus endocrine interaction in man","Oliver RT, Joseph JV, Gallagher CJ.","Urol Int. 1995;54(4):226-9. doi: 10.1159/000282729.","Oliver RT","Urol Int","1995","1995/01/01","","","10.1159/000282729"
"9879324","[Treatment of metastatic prostate cancer: certainty and doubts]","Fournier G, Valéri A.","Presse Med. 1998 Dec 5;27(38):1996-2002.","Fournier G","Presse Med","1998","1999/01/08","","",""
"27215085","Expression Levels of MMP9 and PIWIL2 in Prostate Cancer: a Case-Control Study","Pouyanfar N, Monabbati A, Sharifi AA, Dianatpour M.","Clin Lab. 2016;62(4):651-7. doi: 10.7754/clin.lab.2015.150817.","Pouyanfar N","Clin Lab","2016","2016/05/25","","","10.7754/clin.lab.2015.150817"
"27540032","MicroRNA Theranostics in Prostate Cancer Precision Medicine","Matin F, Jeet V, Clements JA, Yousef GM, Batra J.","Clin Chem. 2016 Oct;62(10):1318-33. doi: 10.1373/clinchem.2015.242800. Epub 2016 Aug 18.","Matin F","Clin Chem","2016","2016/08/20","","","10.1373/clinchem.2015.242800"
"12729357","Vinorelbine and prednisone in older cancer patients with hormone-refractory metastatic prostate cancer. A phase II study","Tralongo P, Bollina R, Aiello R, Di Mari A, Moruzzi G, Beretta G, Mauceri G, Conti G.","Tumori. 2003 Jan-Feb;89(1):26-30.","Tralongo P","Tumori","2003","2003/05/06","","",""
"18685361","Management of hormone refractory prostate cancer","Lin AM, Small EJ.","Curr Opin Support Palliat Care. 2007 Oct;1(3):187-91. doi: 10.1097/SPC.0b013e3282efd689.","Lin AM","Curr Opin Support Palliat Care","2007","2008/08/08","","","10.1097/SPC.0b013e3282efd689"
"21956681","Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age","Stahl PR, Kilgué A, Tennstedt P, Minner S, Krohn A, Simon R, Krause GV, Izbicki J, Graefen M, Sauter G, Schlomm T, Wilczak W.","Prostate. 2012 Jun 1;72(8):898-903. doi: 10.1002/pros.21492. Epub 2011 Sep 28.","Stahl PR","Prostate","2012","2011/09/30","","","10.1002/pros.21492"
"7711914","Prostate cancer screening","Thompson IM.","Arch Fam Med. 1995 Apr;4(4):307-8. doi: 10.1001/archfami.4.4.307.","Thompson IM","Arch Fam Med","1995","1995/04/01","","","10.1001/archfami.4.4.307"
"18817338","[DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines]","Wang CY, Sun SK, Fu WJ, Song T, Cai W, Gao JP, Hong BF, Wang XX, Wang H.","Zhonghua Nan Ke Xue. 2008 Aug;14(8):685-9.","Wang CY","Zhonghua Nan Ke Xue","2008","2008/09/27","","",""
"26857160","Trajectories of total depression and depressive symptoms in prostate cancer patients receiving six months of hormone therapy","Sharpley CF, Christie DR, Bitsika V, Miller BJ.","Psychooncology. 2017 Jan;26(1):60-66. doi: 10.1002/pon.4100. Epub 2016 Feb 9.","Sharpley CF","Psychooncology","2017","2016/02/10","","","10.1002/pon.4100"
"16247872","Preliminary evaluation of prostate cancer metastatic risk biomarkers","Paris PL, Weinberg V, Simko J, Andaya A, Albo G, Rubin MA, Carroll PR, Collins C.","Int J Biol Markers. 2005 Jul-Sep;20(3):141-5. doi: 10.1177/172460080502000301.","Paris PL","Int J Biol Markers","2005","2005/10/27","","","10.1177/172460080502000301"
"23126653","An evidence review of active surveillance in men with localized prostate cancer","Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.","Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341.","Ip S","Evid Rep Technol Assess (Full Rep)","2011","2012/11/07","PMC4781622","",""
"30362684","Association between large prostate calculi and prostate cancer","Yucel C, Budak S.","Arch Ital Urol Androl. 2018 Sep 30;90(3):181-183. doi: 10.4081/aiua.2018.3.181.","Yucel C","Arch Ital Urol Androl","2018","2018/10/27","","","10.4081/aiua.2018.3.181"
"27131465","Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes","Ory J, Flannigan R, Lundeen C, Huang JG, Pommerville P, Goldenberg SL.","J Urol. 2016 Oct;196(4):1082-9. doi: 10.1016/j.juro.2016.04.069. Epub 2016 Apr 27.","Ory J","J Urol","2016","2016/05/02","PMC5025358","NIHMS789612","10.1016/j.juro.2016.04.069"
"20615892","Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy","Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML.","Cancer Epidemiol Biomarkers Prev. 2010 Jul;19(7):1871-8. doi: 10.1158/1055-9965.EPI-10-0216.","Sun T","Cancer Epidemiol Biomarkers Prev","2010","2010/07/10","PMC3755451","NIHMS512062","10.1158/1055-9965.EPI-10-0216"
"14572747","Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer","See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T.","Eur Urol. 2003 Nov;44(5):512-7; discussion 517-8. doi: 10.1016/s0302-2838(03)00366-x.","See W","Eur Urol","2003","2003/10/24","","","10.1016/s0302-2838(03)00366-x"
"10950120","Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region","Verkaik NS, van Steenbrugge GJ, van Weerden WM, Bussemakers MJ, van der Kwast TH.","Lab Invest. 2000 Aug;80(8):1291-8. doi: 10.1038/labinvest.3780137.","Verkaik NS","Lab Invest","2000","2000/08/19","","","10.1038/labinvest.3780137"
"24637318","Living with untreated prostate cancer: predictors of quality of life","Bellardita L, Villa S, Valdagni R.","Curr Opin Urol. 2014 May;24(3):311-7. doi: 10.1097/MOU.0000000000000038.","Bellardita L","Curr Opin Urol","2014","2014/03/19","","","10.1097/MOU.0000000000000038"
"16683009","Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer","Liu Y.","Prostate Cancer Prostatic Dis. 2006;9(3):230-4. doi: 10.1038/sj.pcan.4500879. Epub 2006 May 9.","Liu Y","Prostate Cancer Prostatic Dis","2006","2006/05/10","","","10.1038/sj.pcan.4500879"
"29278842","Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study","Leal J, Welton NJ, Martin RM, Donovan J, Hamdy F, Neal D, Noble S, Lane A, Wolstenholme J.","Cancer Epidemiol. 2018 Feb;52:99-105. doi: 10.1016/j.canep.2017.12.002. Epub 2018 Jan 4.","Leal J","Cancer Epidemiol","2018","2017/12/27","","","10.1016/j.canep.2017.12.002"
"28931292","[Salvage lymph node dissection in radical prostatectomy failure - a case study]","Marečková N, Staník M, Macík D, Doležel J.","Rozhl Chir. 2017 Summer;96(6):260-262.","Marečková N","Rozhl Chir","2017","2017/09/22","","",""
"24314069","Gas in the rectum tends to reduce during radical external beam radiotherapy for localised prostate cancer","Nakamura N, Hatanaka S, Takahashi O, Mizuno N, Endo H, Tamaki S, Shikama N, Ogita M, Kawamori J, Sekiguchi K.","J Med Imaging Radiat Oncol. 2014 Apr;58(2):253-6. doi: 10.1111/1754-9485.12141. Epub 2013 Dec 9.","Nakamura N","J Med Imaging Radiat Oncol","2014","2013/12/10","","","10.1111/1754-9485.12141"
"17979924","Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading","Berney DM, Fisher G, Kattan MW, Oliver RT, Møller H, Fearn P, Eastham J, Scardino P, Cuzick J, Reuter VE, Foster CS; Trans-Atlantic Prostate Group.","BJU Int. 2007 Dec;100(6):1240-4. doi: 10.1111/j.1464-410X.2007.07199.x.","Berney DM","BJU Int","2007","2007/11/06","","","10.1111/j.1464-410X.2007.07199.x"
"31246546","Multiparametric Ultrasound for Prostate Cancer Detection and Localization: Correlation of B-mode, Shear Wave Elastography and Contrast Enhanced Ultrasound with Radical Prostatectomy Specimens","Mannaerts CK, Wildeboer RR, Remmers S, van Kollenburg RAA, Kajtazovic A, Hagemann J, Postema AW, van Sloun RJG, J Roobol M, Tilki D, Mischi M, Wijkstra H, Salomon G.","J Urol. 2019 Dec;202(6):1166-1173. doi: 10.1097/JU.0000000000000415. Epub 2019 Jun 27.","Mannaerts CK","J Urol","2019","2019/06/28","","","10.1097/JU.0000000000000415"
"29949801","The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer","Darr C, Krafft U, Hadaschik B, Tschirdewahn S, Sevcenco S, Csizmarik A, Nyirady P, Küronya Z, Reis H, Maj-Hes A, Shariat SF, Kramer G, Szarvas T.","Urol Int. 2018;101(1):65-73. doi: 10.1159/000489891. Epub 2018 Jun 27.","Darr C","Urol Int","2018","2018/06/28","","","10.1159/000489891"
"25027490","Study links vasectomy to small raised risk of aggressive prostate cancer","Wise J.","BMJ. 2014 Jul 14;349:g4617. doi: 10.1136/bmj.g4617.","Wise J","BMJ","2014","2014/07/17","","","10.1136/bmj.g4617"
"28179298","Purinergic Receptor Expression and Cellular Responses to Purinergic Agonists in Human Prostate Cancer Cells","Lertsuwan K, Peters W, Johnson L, Lertsuwan J, Marwa I, Sikes RA.","Anticancer Res. 2017 Feb;37(2):529-537. doi: 10.21873/anticanres.11345.","Lertsuwan K","Anticancer Res","2017","2017/02/10","","","10.21873/anticanres.11345"
"19719456","Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function","Sharifi N.","Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. doi: 10.2174/187152009789735044.","Sharifi N","Anticancer Agents Med Chem","2009","2009/09/02","","","10.2174/187152009789735044"
"26776104","Addressing overtreatment following the diagnosis of localized prostate cancer","Tawadros T, Valerio M.","Expert Rev Anticancer Ther. 2016;16(4):373-4. doi: 10.1586/14737140.2016.1143779. Epub 2016 Feb 12.","Tawadros T","Expert Rev Anticancer Ther","2016","2016/01/19","","","10.1586/14737140.2016.1143779"
"24308679","Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications","Yang X, Guo Z, Liu Y, Si T, Yu H, Li B, Tian W.","Expert Rev Anticancer Ther. 2014 Jan;14(1):31-7. doi: 10.1586/14737140.2014.845372. Epub 2013 Nov 26.","Yang X","Expert Rev Anticancer Ther","2014","2013/12/07","","","10.1586/14737140.2014.845372"
"16729908","The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel","Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD, Tubaro A, Schulman C.","Clin Genitourin Cancer. 2006 Mar;4(4):257-62. doi: 10.3816/CGC.2006.n.004.","Saad F","Clin Genitourin Cancer","2006","2006/05/30","","","10.3816/CGC.2006.n.004"
"17022460","[Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies]","Kovalev LI, Shishkin SS, Khasigov PZ, Dzeranov NK, Kazachenko AV, Toropygin IIu, Mamykina SV.","Prikl Biokhim Mikrobiol. 2006 Jul-Aug;42(4):480-4.","Kovalev LI","Prikl Biokhim Mikrobiol","2006","2006/10/07","","",""
"1311029","Hypercalcemia and neuroendocrine carcinoma of the prostate: a report of three cases and a review of the literature","Smith DC, Tucker JA, Trump DL.","J Clin Oncol. 1992 Mar;10(3):499-505. doi: 10.1200/JCO.1992.10.3.499.","Smith DC","J Clin Oncol","1992","1992/03/01","","","10.1200/JCO.1992.10.3.499"
"28385586","[The role of a single PCA3 test before a first negative prostate biopsy: 5-year follow-up]","Bernardeau S, Charles T, Fromont-Hankard G, Irani J.","Prog Urol. 2017 Apr;27(5):325-330. doi: 10.1016/j.purol.2017.02.006. Epub 2017 Apr 3.","Bernardeau S","Prog Urol","2017","2017/04/08","","","10.1016/j.purol.2017.02.006"
"25973556","The evolution of radiotherapy techniques in the management of prostate cancer","Høyer M, Muren LP, Glimelius B.","Acta Oncol. 2015 Jun;54(6):821-4. doi: 10.3109/0284186X.2015.1048555.","Høyer M","Acta Oncol","2015","2015/05/15","","","10.3109/0284186X.2015.1048555"
"15380613","Some comments and data on the overtreatment of prostate cancer","Schulz RJ, Kagan AR.","Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):690-1. doi: 10.1016/j.ijrobp.2004.05.041.","Schulz RJ","Int J Radiat Oncol Biol Phys","2004","2004/09/24","","","10.1016/j.ijrobp.2004.05.041"
"30577091","Early-age drinkers more likely to have high-grade prostate cancer later","Printz C.","Cancer. 2019 Jan 1;125(1):11. doi: 10.1002/cncr.31899.","Printz C","Cancer","2019","2018/12/22","","","10.1002/cncr.31899"
"24358122","The role of adhesion molecules as biomarkers for the aggressive prostate cancer phenotype","Morgan C, Jenkins SA, Kynaston HG, Doak SH.","PLoS One. 2013 Dec 16;8(12):e81666. doi: 10.1371/journal.pone.0081666. eCollection 2013.","Morgan C","PLoS One","2013","2013/12/21","PMC3864842","","10.1371/journal.pone.0081666"
"26313523","Clinical significance of D4A in prostate cancer therapy with abiraterone","Emamekhoo H, Li Z, Sharifi N.","Cell Cycle. 2015;14(20):3213-4. doi: 10.1080/15384101.2015.1086201.","Emamekhoo H","Cell Cycle","2015","2015/08/28","PMC4825540","","10.1080/15384101.2015.1086201"
"18630840","Changes in prostate cancer at radical prostatectomy during the prostate specific antigen era: an Italian experience","Bollito E, Terrone C, Volpe A, Porpiglia F, Cracco C, Poggio M, Grande S, Righi L, Bellina M, Papotti M, Scarpa RM.","Anal Quant Cytol Histol. 2008 Jun;30(3):152-9.","Bollito E","Anal Quant Cytol Histol","2008","2008/07/18","","",""
"28461179","Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer","Baas W, Gershburg S, Dynda D, Delfino K, Robinson K, Nie D, Yearley JH, Alanee S.","Clin Genitourin Cancer. 2017 Oct;15(5):577-581. doi: 10.1016/j.clgc.2017.04.002. Epub 2017 Apr 10.","Baas W","Clin Genitourin Cancer","2017","2017/05/03","","","10.1016/j.clgc.2017.04.002"
"16167865","Revisiting the role of radical surgery in early stage prostate cancer","Costello AJ, Corcoran NM, Van Appledorn S.","Med J Aust. 2005 Sep 19;183(6):286-7.","Costello AJ","Med J Aust","2005","2005/09/20","","",""
"31900920","Neural Transcription Factors in Disease Progression","Thaper D, Vahid S, Zoubeidi A.","Adv Exp Med Biol. 2019;1210:437-462. doi: 10.1007/978-3-030-32656-2_19.","Thaper D","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_19"
"7535978","Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer","Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE.","Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4.","Figg WD","Am J Med","1995","1995/04/01","","","10.1016/S0002-9343(99)80323-4"
"17086572","An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer","Sharpley CF, Christie DR.","Psychooncology. 2007 Jul;16(7):660-7. doi: 10.1002/pon.1118.","Sharpley CF","Psychooncology","2007","2006/11/07","","","10.1002/pon.1118"
"31568648","Self-Identified African Americans and prostate cancer risk: West African genetic ancestry is associated with prostate cancer diagnosis and with higher Gleason sum on biopsy","Grizzle WE, Kittles RA, Rais-Bahrami S, Shah E, Adams GW, DeGuenther MS, Kolettis PN, Nix JW, Bryant JE, Chinsky R, Kearns JE, Dehimer K, Terrin N, Chang H, Gaston SM.","Cancer Med. 2019 Nov;8(16):6915-6922. doi: 10.1002/cam4.2434. Epub 2019 Sep 30.","Grizzle WE","Cancer Med","2019","2019/10/01","PMC6853835","","10.1002/cam4.2434"
"29599322","Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells","Takezawa Y, Izumi K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Natsagdorj A, Kadono Y, Keller ET, Zhang J, Mizokami A.","Anticancer Res. 2018 Apr;38(4):2045-2055. doi: 10.21873/anticanres.12444.","Takezawa Y","Anticancer Res","2018","2018/03/31","","","10.21873/anticanres.12444"
"24717057","Cryosurgery for clinical T3 prostate cancer","Ukimura O, de Castro Abreu AL, Hung AJ, Gill IS.","BJU Int. 2014 May;113(5):684-5. doi: 10.1111/bju.12512.","Ukimura O","BJU Int","2014","2014/04/11","","","10.1111/bju.12512"
"18024094","Salvage radiotherapy after high-intensity focused ultrasound for localised prostate cancer--a case report","Mitchell DM, Alam N, Rajpal S, Brown S, Taylor MB, Logue JP.","Clin Oncol (R Coll Radiol). 2008 Mar;20(2):200. doi: 10.1016/j.clon.2007.10.010. Epub 2007 Nov 19.","Mitchell DM","Clin Oncol (R Coll Radiol)","2008","2007/11/21","","","10.1016/j.clon.2007.10.010"
"12696224","Ketoconazole in the treatment of prostate cancer","O'Rourke ME.","Clin J Oncol Nurs. 2003 Mar-Apr;7(2):235-6. doi: 10.1188/03.CJON.234-237.","O'Rourke ME","Clin J Oncol Nurs","2003","2003/04/17","","","10.1188/03.CJON.234-237"
"9446173","[Do results of surgical treatment of cancer clinically localized to the prostate justify early screening?]","Rohner S, Graber P.","Praxis (Bern 1994). 1997 Oct 29;86(44):1730-3.","Rohner S","Praxis (Bern 1994)","1997","1998/01/31","","",""
"27356095","EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor","De Mol E, Fenwick RB, Phang CT, Buzón V, Szulc E, de la Fuente A, Escobedo A, García J, Bertoncini CW, Estébanez-Perpiñá E, McEwan IJ, Riera A, Salvatella X.","ACS Chem Biol. 2016 Sep 16;11(9):2499-505. doi: 10.1021/acschembio.6b00182. Epub 2016 Jul 14.","De Mol E","ACS Chem Biol","2016","2016/06/30","PMC5027137","EMS69357","10.1021/acschembio.6b00182"
"23591596","Cigarette smoke induces nuclear translocation of heme oxygenase 1 (HO-1) in prostate cancer cells: nuclear HO-1 promotes vascular endothelial growth factor secretion","Birrane G, Li H, Yang S, Tachado SD, Seng S.","Int J Oncol. 2013 Jun;42(6):1919-28. doi: 10.3892/ijo.2013.1910. Epub 2013 Apr 17.","Birrane G","Int J Oncol","2013","2013/04/18","PMC3699615","","10.3892/ijo.2013.1910"
"30067448","Antidiabetic drugs influence molecular mechanisms in prostate cancer","Pircher A, Zieher M, Eigentler A, Pichler R, Schäfer G, Fritz J, Puhr M, Steiner E, Horninger W, Klocker H, Heidegger I.","Cancer Biol Ther. 2018;19(12):1153-1161. doi: 10.1080/15384047.2018.1491490. Epub 2018 Aug 1.","Pircher A","Cancer Biol Ther","2018","2018/08/02","PMC6301819","","10.1080/15384047.2018.1491490"
"18996872","Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition","Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, Johnsen NF, Tjønneland A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Zavitsanou A, Trichopoulos D, Sacerdote C, Palli D, Tumino R, Agnoli C, Kiemeney LA, Bueno-de-Mesquita HB, Chirlaque MD, Ardanaz E, Larrañaga N, Quirós JR, Sánchez MJ, González CA, Stattin P, Hallmans G, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ.","Am J Clin Nutr. 2008 Nov;88(5):1353-63. doi: 10.3945/ajcn.2008.26369.","Crowe FL","Am J Clin Nutr","2008","2008/11/11","","","10.3945/ajcn.2008.26369"
"19209648","Diagnosis and treatment of prostate cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate","Loeb S, Catalona WJ.","Med Econ. 2008 Dec 19;85(24):36-41.","Loeb S","Med Econ","2008","2009/02/13","","",""
"21519351","Active surveillance for low-risk prostate cancer: an update","Lawrentschuk N, Klotz L.","Nat Rev Urol. 2011 Apr 26;8(6):312-20. doi: 10.1038/nrurol.2011.50.","Lawrentschuk N","Nat Rev Urol","2011","2011/04/27","","","10.1038/nrurol.2011.50"
"30414956","Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals","Krimphove MJ, Fletcher SA, Cole AP, Berg S, Sun M, Lipsitz SR, Mahal BA, Nguyen PL, Choueiri TK, Kibel AS, Kluth LA, Weissman JS, Trinh QD.","J Urol. 2019 Apr;201(4):735-741. doi: 10.1016/j.juro.2018.10.024.","Krimphove MJ","J Urol","2019","2018/11/12","","","10.1016/j.juro.2018.10.024"
"9267792","A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians","Bennett CL, Chapman G, Elstein AS, Knight SJ, Nadler RB, Sharifi R, Kuzel T.","Eur Urol. 1997;32 Suppl 3:86-8.","Bennett CL","Eur Urol","1997","1997/01/01","","",""
"23614595","Functional outcomes after treatment for prostate cancer","Resnick MJ, Penson DF.","N Engl J Med. 2013 Apr 25;368(17):1654. doi: 10.1056/NEJMc1302509.","Resnick MJ","N Engl J Med","2013","2013/04/26","","","10.1056/NEJMc1302509"
"17583470","Prostate cancer and liver dysfunction: a case of cytokine dysregulation","Prommer E.","J Pain Symptom Manage. 2007 Sep;34(3):225-6. doi: 10.1016/j.jpainsymman.2007.05.003. Epub 2007 Jun 21.","Prommer E","J Pain Symptom Manage","2007","2007/06/23","","","10.1016/j.jpainsymman.2007.05.003"
"9251561","Screening for prostate cancer. Early screening is important despite lack of data from trials","Catalona WJ.","BMJ. 1997 Jul 19;315(7101):187.","Catalona WJ","BMJ","1997","1997/07/19","PMC2127104","",""
"18382238","Inventory of prostate cancer predictive tools","Shariat SF, Karakiewicz PI, Margulis V, Kattan MW.","Curr Opin Urol. 2008 May;18(3):279-96. doi: 10.1097/MOU.0b013e3282f9b3e5.","Shariat SF","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282f9b3e5"
"22962694","Re: coffee consumption and prostate cancer risk and progression in the health professional follow-up study","Polesel J, Zucchetto A, Talamini R, Dal Maso L, Serraino D, La Vecchia C, Franceschi S.","J Natl Cancer Inst. 2012 Nov 7;104(21):1684-6; author reply 1686. doi: 10.1093/jnci/djs383. Epub 2012 Sep 6.","Polesel J","J Natl Cancer Inst","2012","2012/09/11","","","10.1093/jnci/djs383"
"19506151","Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer","D'Amico AV, Chen MH.","J Clin Oncol. 2009 Aug 1;27(22):3575-6. doi: 10.1200/JCO.2009.22.6068. Epub 2009 Jun 8.","D'Amico AV","J Clin Oncol","2009","2009/06/10","","","10.1200/JCO.2009.22.6068"
"24439788","Overdiagnosis and overtreatment of prostate cancer","Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R.","Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9.","Loeb S","Eur Urol","2014","2014/01/21","PMC4113338","NIHMS560518","10.1016/j.eururo.2013.12.062"
"21859993","Common gene rearrangements in prostate cancer","Rubin MA, Maher CA, Chinnaiyan AM.","J Clin Oncol. 2011 Sep 20;29(27):3659-68. doi: 10.1200/JCO.2011.35.1916. Epub 2011 Aug 22.","Rubin MA","J Clin Oncol","2011","2011/08/24","PMC4874145","","10.1200/JCO.2011.35.1916"
"19246059","Prostate specific antigen testing among the elderly--when to stop?","Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ.","J Urol. 2009 Apr;181(4):1606-14; discussion 1613-4. doi: 10.1016/j.juro.2008.11.117. Epub 2009 Feb 25.","Schaeffer EM","J Urol","2009","2009/02/28","PMC2668165","NIHMS100062","10.1016/j.juro.2008.11.117"
"9750505","[Assessment of local staging of prostate cancer by endorectal surface coil]","Miki K.","Nihon Rinsho. 1998 Aug;56(8):2046-51.","Miki K","Nihon Rinsho","1998","1998/09/29","","",""
"18959172","[Disease relapses after radical radiotherapy of prostate cancer--analysis of prognostic factors]","Josifovski T, Radosević-Jelić L, Tulić C, Milosević A.","Srp Arh Celok Lek. 2008 Jul-Aug;136(7-8):373-8. doi: 10.2298/sarh0808373j.","Josifovski T","Srp Arh Celok Lek","2008","2008/10/31","","","10.2298/sarh0808373j"
"17438709","""Between Men"": a psychosocial rehabilitation programme for men with prostate cancer","Berglund G, Petersson LM, Eriksson KC, Wallenius I, Roshanai A, Nordin KM, Sjödén PO, Häggman M.","Acta Oncol. 2007;46(1):83-9. doi: 10.1080/02841860600857326.","Berglund G","Acta Oncol","2007","2007/04/19","","","10.1080/02841860600857326"
"21880074","Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy","Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Wu PP, Huang CY, Hsieh CJ, Bao BY.","J Intern Med. 2012 May;271(5):499-509. doi: 10.1111/j.1365-2796.2011.02449.x. Epub 2011 Sep 29.","Huang CN","J Intern Med","2012","2011/09/02","","","10.1111/j.1365-2796.2011.02449.x"
"23938945","Prostate cancer: Prostate Health Index--improving screening in men with family history","Loeb S.","Nat Rev Urol. 2013 Sep;10(9):497-8. doi: 10.1038/nrurol.2013.169. Epub 2013 Aug 13.","Loeb S","Nat Rev Urol","2013","2013/08/14","","","10.1038/nrurol.2013.169"
"15666359","Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development","Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H.","Prostate. 2005 Jun 15;64(1):92-100. doi: 10.1002/pros.20219.","Ishiguro H","Prostate","2005","2005/01/25","","","10.1002/pros.20219"
"30977019","Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies","Haj-Hamed M, Karivedu V, Sidana A.","Int Urol Nephrol. 2019 Jul;51(7):1101-1106. doi: 10.1007/s11255-019-02114-4. Epub 2019 Apr 12.","Haj-Hamed M","Int Urol Nephrol","2019","2019/04/13","","","10.1007/s11255-019-02114-4"
"16634689","The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer","Miyake H, Hara I, Fujisawa M, Gleave ME.","Expert Opin Investig Drugs. 2006 May;15(5):507-17. doi: 10.1517/13543784.15.5.507.","Miyake H","Expert Opin Investig Drugs","2006","2006/04/26","","","10.1517/13543784.15.5.507"
"12111697","Hormones and prostate cancer: current perspectives and future directions","Hsing AW, Reichardt JK, Stanczyk FZ.","Prostate. 2002 Aug 1;52(3):213-35. doi: 10.1002/pros.10108.","Hsing AW","Prostate","2002","2002/07/12","","","10.1002/pros.10108"
"10830579","Fraction of prostate cancer incidence attributed to diet in Athens, Greece","Bosetti C, Tzonou A, Lagiou P, Negri E, Trichopoulos D, Hsieh CC.","Eur J Cancer Prev. 2000 Apr;9(2):119-23. doi: 10.1097/00008469-200004000-00008.","Bosetti C","Eur J Cancer Prev","2000","2000/06/01","","","10.1097/00008469-200004000-00008"
"26626273","The effects of attachment and outness on illness adjustment among gay men with prostate cancer","Crangle CJ, Latini DM, Hart TL.","Psychooncology. 2017 Apr;26(4):500-507. doi: 10.1002/pon.4043. Epub 2015 Dec 2.","Crangle CJ","Psychooncology","2017","2015/12/03","PMC6461036","NIHMS1021111","10.1002/pon.4043"
"15172117","Hypericum perforatum methanolic extract inhibits growth of human prostatic carcinoma cell line orthotopically implanted in nude mice","Martarelli D, Martarelli B, Pediconi D, Nabissi MI, Perfumi M, Pompei P.","Cancer Lett. 2004 Jul 8;210(1):27-33. doi: 10.1016/j.canlet.2004.01.031.","Martarelli D","Cancer Lett","2004","2004/06/03","","","10.1016/j.canlet.2004.01.031"
"11329956","[Clinical outcome and analysis of radical prostatectomy in clinical stage B and C prostate cancer]","Miyoshi Y, Uemura H, Mikata K, Ohuchi H, Jinza S, Yao M, Takeda M, Masuda M, Noguchi S, Noguchi K, Kubota Y, Hosaka M.","Hinyokika Kiyo. 2001 Mar;47(3):163-8.","Miyoshi Y","Hinyokika Kiyo","2001","2001/05/02","","",""
"22258370","[Inhibitors of androgen and estrogen biosynthesis in castration-resistant prostate cancer]","Omlin A, Gillessen S.","Urologe A. 2012 Jan;51(1):8-14. doi: 10.1007/s00120-011-2737-x.","Omlin A","Urologe A","2012","2012/01/20","","","10.1007/s00120-011-2737-x"
"8490755","Benefit and cost of prostate cancer early detection","Murphy GP.","CA Cancer J Clin. 1993 May-Jun;43(3):133. doi: 10.3322/canjclin.43.3.133.","Murphy GP","CA Cancer J Clin","1993","1993/05/01","","","10.3322/canjclin.43.3.133"
"8485032","Trends in prostate cancer: United States, 1980 to 1988","","Oncology (Williston Park). 1993 Apr;7(4):18-20, 23.","","Oncology (Williston Park)","1993","1993/04/01","","",""
"16861115","The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs","Chan JM, Feraco A, Shuman M, Hernández-Díaz S.","Hematol Oncol Clin North Am. 2006 Aug;20(4):797-809. doi: 10.1016/j.hoc.2006.03.002.","Chan JM","Hematol Oncol Clin North Am","2006","2006/07/25","","","10.1016/j.hoc.2006.03.002"
"10529561","A review of studies of hormonal adjuvant therapy in prostate cancer","Wirth M, Froehner M.","Eur Urol. 1999;36 Suppl 2:14-9. doi: 10.1159/000052338.","Wirth M","Eur Urol","1999","1999/10/26","","","10.1159/000052338"
"28324908","[Magnetic Sentinel Lymph Node Detection in Prostate Cancer after intraprostatic Injection of Superparamagnetic Iron Oxide Nanoparticles]","Winter A, Engels S, Kowald T, Paulo TS, Gerullis H, Chavan A, Wawroschek F.","Aktuelle Urol. 2017 Apr;48(2):132-139. doi: 10.1055/s-0042-121338. Epub 2017 Mar 21.","Winter A","Aktuelle Urol","2017","2017/03/22","","","10.1055/s-0042-121338"
"2258952","Current status of prostate cancer in North American black males","Mebane C, Gibbs T, Horm J.","J Natl Med Assoc. 1990 Nov;82(11):782-8.","Mebane C","J Natl Med Assoc","1990","1990/11/01","PMC2626941","",""
"15163300","Genetically defined mouse models that mimic natural aspects of human prostate cancer development","Roy-Burman P, Wu H, Powell WC, Hagenkord J, Cohen MB.","Endocr Relat Cancer. 2004 Jun;11(2):225-54. doi: 10.1677/erc.0.0110225.","Roy-Burman P","Endocr Relat Cancer","2004","2004/05/28","","","10.1677/erc.0.0110225"
"11121450","Gamma-tocopherol: a new player in prostate cancer prevention?","Giovannucci E.","J Natl Cancer Inst. 2000 Dec 20;92(24):1966-7. doi: 10.1093/jnci/92.24.1966.","Giovannucci E","J Natl Cancer Inst","2000","2000/12/21","","","10.1093/jnci/92.24.1966"
"25323607","Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer","Aparicio A, Tzelepi V.","Oncology (Williston Park). 2014 Oct 15;28(10):831-8.","Aparicio A","Oncology (Williston Park)","2014","2014/10/18","","",""
"10667080","[Prostatic carcinoma. Screening--when and what?]","Recker F, Lümmen G.","Ther Umsch. 2000 Jan;57(1):33-7. doi: 10.1024/0040-5930.57.1.33.","Recker F","Ther Umsch","2000","2000/02/10","","","10.1024/0040-5930.57.1.33"
"9563123","[Treatment of progressive, locally advanced prostate carcinoma]","Niesel T, Breul J, Hartung R.","Urologe A. 1998 Mar;37(2):145-8. doi: 10.1007/s001200050162.","Niesel T","Urologe A","1998","1998/05/01","","","10.1007/s001200050162"
"27400668","Prostate cancer: Tumour genomes are highly plastic","Stone L.","Nat Rev Urol. 2016 Aug;13(8):438. doi: 10.1038/nrurol.2016.132. Epub 2016 Jul 12.","Stone L","Nat Rev Urol","2016","2016/07/13","","","10.1038/nrurol.2016.132"
"19506150","""Staging the aging"" when considering androgen deprivation therapy for older men with prostate cancer","Dale W.","J Clin Oncol. 2009 Jul 20;27(21):3420-2. doi: 10.1200/JCO.2009.22.9104. Epub 2009 Jun 8.","Dale W","J Clin Oncol","2009","2009/06/10","","","10.1200/JCO.2009.22.9104"
"23883692","Lycopene/tomato consumption and the risk of prostate cancer: a systematic review and meta-analysis of prospective studies","Chen J, Song Y, Zhang L.","J Nutr Sci Vitaminol (Tokyo). 2013;59(3):213-23. doi: 10.3177/jnsv.59.213.","Chen J","J Nutr Sci Vitaminol (Tokyo)","2013","2013/07/26","","","10.3177/jnsv.59.213"
"15380796","Medical history, sexual, and maturational factors and prostate cancer risk","Lightfoot N, Conlon M, Kreiger N, Sass-Kortsak A, Purdham J, Darlington G.","Ann Epidemiol. 2004 Oct;14(9):655-62. doi: 10.1016/j.annepidem.2003.11.006.","Lightfoot N","Ann Epidemiol","2004","2004/09/24","","","10.1016/j.annepidem.2003.11.006"
"27623212","Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer","Xu N, Chen HJ, Chen SH, Xue XY, Chen H, Zheng QS, Wei Y, Li XD, Huang JB, Cai H, Sun XL.","Oncotarget. 2016 Oct 11;7(41):67476-67484. doi: 10.18632/oncotarget.11231.","Xu N","Oncotarget","2016","2016/09/14","PMC5341890","","10.18632/oncotarget.11231"
"14740973","Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery","Teh BS, Bastasch MD, Mai WY, Butler EB, Wheeler TM.","Cancer J. 2003 Nov-Dec;9(6):454-60. doi: 10.1097/00130404-200311000-00004.","Teh BS","Cancer J","2003","2004/01/27","","","10.1097/00130404-200311000-00004"
"25896606","Targeting the adaptive molecular landscape of castration-resistant prostate cancer","Wyatt AW, Gleave ME.","EMBO Mol Med. 2015 Jul;7(7):878-94. doi: 10.15252/emmm.201303701.","Wyatt AW","EMBO Mol Med","2015","2015/04/22","PMC4520654","","10.15252/emmm.201303701"
"12559291","Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study","Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL; Veterans Affairs Cancer of the Prostate Outcomes Study.","Urology. 2003 Jan;61(1):172-8. doi: 10.1016/s0090-4295(02)02141-6.","Siston AK","Urology","2003","2003/02/01","","","10.1016/s0090-4295(02)02141-6"
"9858331","Prostate cancer treatment outcome in blacks and whites: a summary of the literature","Alexander GA, Brawley OW.","Semin Urol Oncol. 1998 Nov;16(4):232-4.","Alexander GA","Semin Urol Oncol","1998","1998/12/19","","",""
"29257308","CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells","Wei C, Wang F, Liu W, Zhao W, Yang Y, Li K, Xiao L, Shen J.","Mol Med Rep. 2018 Feb;17(2):2901-2906. doi: 10.3892/mmr.2017.8257. Epub 2017 Dec 12.","Wei C","Mol Med Rep","2018","2017/12/20","PMC5783506","","10.3892/mmr.2017.8257"
"12085104","Suppression of metastasis of rat prostate cancer by introduction of human chromosome 13","Hosoki S, Ota S, Ichikawa Y, Suzuki H, Ueda T, Naya Y, Akakura K, Igarashi T, Oshimura M, Nihei N, Barrett JC, Ichikawa T, Ito H.","Asian J Androl. 2002 Jun;4(2):131-6.","Hosoki S","Asian J Androl","2002","2002/06/27","","",""
"24775574","A comparative analysis of prostate cancer pre-treatment characteristics stratified by age","Shah N, Ioffe V, Kapur A.","Can J Urol. 2014 Apr;21(2):7213-6.","Shah N","Can J Urol","2014","2014/04/30","","",""
"23781689","The state of prostate MRI in 2013","Gupta RT, Kauffman CR, Polascik TJ, Taneja SS, Rosenkrantz AB.","Oncology (Williston Park). 2013 Apr;27(4):262-70.","Gupta RT","Oncology (Williston Park)","2013","2013/06/21","","",""
"32481368","The diagnostic value of miRNA-141 in prostate cancer: A systematic review and PRISMA-compliant meta-analysis","Ye Y, Yuan XH, Wang JJ, Wang YC, Li SL.","Medicine (Baltimore). 2020 May 29;99(22):e19993. doi: 10.1097/MD.0000000000019993.","Ye Y","Medicine (Baltimore)","2020","2020/06/03","","","10.1097/MD.0000000000019993"
"30337059","Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations","Antonarakis ES, Shaukat F, Isaacsson Velho P, Kaur H, Shenderov E, Pardoll DM, Lotan TL.","Eur Urol. 2019 Mar;75(3):378-382. doi: 10.1016/j.eururo.2018.10.009. Epub 2018 Oct 15.","Antonarakis ES","Eur Urol","2019","2018/10/20","PMC6377812","NIHMS1508978","10.1016/j.eururo.2018.10.009"
"14649965","The pattern of prostate-specific antigen responses following hormonal therapy in Thai men with bone metastatic prostate cancer","Leewansangtong S, Soontrapa S.","J Med Assoc Thai. 2003 Sep;86(9):809-15.","Leewansangtong S","J Med Assoc Thai","2003","2003/12/03","","",""
"9815652","Establishment of two human prostate cancer cell lines derived from a single bone metastasis","Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ.","Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500.","Navone NM","Clin Cancer Res","1997","1998/11/17","","",""
"27829196","Computed diffusion-weighted imaging using 1.5-T magnetic resonance imaging for prostate cancer diagnosis","Yoshida R, Yoshizako T, Katsube T, Tamaki Y, Ishikawa N, Kitagaki H.","Clin Imaging. 2017 Jan-Feb;41:78-82. doi: 10.1016/j.clinimag.2016.10.005. Epub 2016 Oct 17.","Yoshida R","Clin Imaging","2017","2016/11/10","","","10.1016/j.clinimag.2016.10.005"
"19328712","Innovative biomarkers for prostate cancer early diagnosis and progression","You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P, Li Y.","Crit Rev Oncol Hematol. 2010 Jan;73(1):10-22. doi: 10.1016/j.critrevonc.2009.02.007.","You J","Crit Rev Oncol Hematol","2010","2009/03/31","","","10.1016/j.critrevonc.2009.02.007"
"16780570","An update on localised prostate cancer","Hodgson D, Acher P, Cahill D.","Int J Clin Pract. 2007 Feb;61(2):315-9. doi: 10.1111/j.1742-1241.2006.01013.x.","Hodgson D","Int J Clin Pract","2007","2006/06/20","","","10.1111/j.1742-1241.2006.01013.x"
"22824871","Time to stop screening for prostate cancer: comment on ""Declines in prostate cancer incidence after changes in screening recommendations""","Katz MH.","Arch Intern Med. 2012 Sep 10;172(16):1268. doi: 10.1001/archinternmed.2012.3000.","Katz MH","Arch Intern Med","2012","2012/07/25","","","10.1001/archinternmed.2012.3000"
"18585119","Incidence and risk factors for low trauma fractures in men with prostate cancer","Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV.","Bone. 2008 Sep;43(3):556-60. doi: 10.1016/j.bone.2008.05.003. Epub 2008 May 11.","Ahlborg HG","Bone","2008","2008/07/01","","","10.1016/j.bone.2008.05.003"
"27287889","Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score","Osses DF, van Asten JJ, Kieft GJ, Tijsterman JD.","World J Urol. 2017 Feb;35(2):207-212. doi: 10.1007/s00345-016-1874-7. Epub 2016 Jun 10.","Osses DF","World J Urol","2017","2016/06/12","","","10.1007/s00345-016-1874-7"
"16006944","Results of compliance with prostate cancer screening guidelines","Grubb RL, Roehl KA, Antenor JA, Catalona WJ.","J Urol. 2005 Aug;174(2):668-72; discussion 672. doi: 10.1097/01.ju.0000165149.66186.23.","Grubb RL","J Urol","2005","2005/07/12","","","10.1097/01.ju.0000165149.66186.23"
"19701842","Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?","Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, Kloetzer KH, Marx C.","Int J Radiat Biol. 2009 Sep;85(9):814-24. doi: 10.1080/09553000903090027.","Schmuecking M","Int J Radiat Biol","2009","2009/08/25","","","10.1080/09553000903090027"
"19138954","Estimating rates of true high-grade disease in the prostate cancer prevention trial","Pinsky P, Parnes H, Ford L.","Cancer Prev Res (Phila). 2008 Aug;1(3):182-6. doi: 10.1158/1940-6207.CAPR-07-0007. Epub 2008 May 18.","Pinsky P","Cancer Prev Res (Phila)","2008","2009/01/14","","","10.1158/1940-6207.CAPR-07-0007"
"28303694","Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J.","J Med Radiat Sci. 2017 Mar;64(1):52-60. doi: 10.1002/jmrs.227.","Emmett L","J Med Radiat Sci","2017","2017/03/18","PMC5355374","","10.1002/jmrs.227"
"17608823","Outcomes for radiation therapy after radical prostatectomy for prostate cancer: what really matters?","Montie JE, Hussain M.","BJU Int. 2007 Sep;100(3):485-6. doi: 10.1111/j.1464-410X.2007.07057.x. Epub 2007 Jul 3.","Montie JE","BJU Int","2007","2007/07/05","","","10.1111/j.1464-410X.2007.07057.x"
"17001787","Comments on ""Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer""","Daşu A, Fowler JF.","Phys Med Biol. 2005 Mar 21;50(6):L1-4; author reply L5-8. doi: 10.1088/0031-9155/50/6/l01.","Daşu A","Phys Med Biol","2005","2006/09/28","","","10.1088/0031-9155/50/6/l01"
"27344793","[History and current status of endocrine therapy (hormonal therapy) for prostate cancer: General consideration]","Namiki M, Mizokami A, Kitagawa Y.","Nihon Rinsho. 2016 May 20;74 Suppl 3:557-62.","Namiki M","Nihon Rinsho","2016","2016/06/28","","",""
"17431361","[A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]","Akaza H, Labrie F, Namiki M.","Gan To Kagaku Ryoho. 2007 Apr;34(4):657-69.","Akaza H","Gan To Kagaku Ryoho","2007","2007/04/14","","",""
"25195031","[Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11]","Lebdai S, Martin F, Bigot P, Azzouzi AR.","Prog Urol. 2014 Nov;24(14):911-4. doi: 10.1016/j.purol.2014.08.002. Epub 2014 Sep 5.","Lebdai S","Prog Urol","2014","2014/09/08","","","10.1016/j.purol.2014.08.002"
"21762076","Androgen receptor cofactors in prostate cancer: potential therapeutic targets of castration-resistant prostate cancer","Shiota M, Yokomizo A, Fujimoto N, Naito S.","Curr Cancer Drug Targets. 2011 Sep;11(7):870-81. doi: 10.2174/156800911796798904.","Shiota M","Curr Cancer Drug Targets","2011","2011/07/19","","","10.2174/156800911796798904"
"18380820","The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer","Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O.","Int J Urol. 2008 Apr;15(4):322-6; discussion 327. doi: 10.1111/j.1442-2042.2008.01991.x.","Kubota Y","Int J Urol","2008","2008/04/03","","","10.1111/j.1442-2042.2008.01991.x"
"22075945","Identification of markers of prostate cancer progression using candidate gene expression","Larkin SE, Holmes S, Cree IA, Walker T, Basketter V, Bickers B, Harris S, Garbis SD, Townsend PA, Aukim-Hastie C.","Br J Cancer. 2012 Jan 3;106(1):157-65. doi: 10.1038/bjc.2011.490. Epub 2011 Nov 10.","Larkin SE","Br J Cancer","2012","2011/11/15","PMC3251845","","10.1038/bjc.2011.490"
"30772034","Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes","Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D.","Eur Urol. 2019 Jul;76(1):106-114. doi: 10.1016/j.eururo.2019.01.048. Epub 2019 Feb 14.","Preisser F","Eur Urol","2019","2019/02/18","","","10.1016/j.eururo.2019.01.048"
"11987156","Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing","Cormier L, Valéri A, Azzouzi R, Fournier G, Cussenot O, Berthon P, Guillemin F, Mangin P.","Prostate. 2002 Jun 1;51(4):276-85. doi: 10.1002/pros.10092.","Cormier L","Prostate","2002","2002/05/03","","","10.1002/pros.10092"
"17635953","Living with prostate cancer: patients' and spouses' psychosocial status and quality of life","Northouse LL, Mood DW, Montie JE, Sandler HM, Forman JD, Hussain M, Pienta KJ, Smith DC, Sanda MG, Kershaw T.","J Clin Oncol. 2007 Sep 20;25(27):4171-7. doi: 10.1200/JCO.2006.09.6503. Epub 2007 Jul 16.","Northouse LL","J Clin Oncol","2007","2007/07/20","","","10.1200/JCO.2006.09.6503"
"11002395","Erectile function and quality of life after interstitial radiation therapy for prostate cancer","Sánchez-Ortiz RF, Broderick GA, Rovner ES, Wein AJ, Whittington R, Malkowicz SB.","Int J Impot Res. 2000 Sep;12 Suppl 3:S18-24. doi: 10.1038/sj.ijir.3900557.","Sánchez-Ortiz RF","Int J Impot Res","2000","2000/09/26","","","10.1038/sj.ijir.3900557"
"18272635","The top 13: what family physicians should know about prostate cancer","Katz A, Katz A.","Can Fam Physician. 2008 Feb;54(2):198-203.","Katz A","Can Fam Physician","2008","2008/02/15","PMC2278311","",""
"25733303","Nanowire analysis of cancer-testis antigens as biomarkers of aggressive prostate cancer","Takahashi S, Shiraishi T, Miles N, Trock BJ, Kulkarni P, Getzenberg RH.","Urology. 2015 Mar;85(3):704.e1-7. doi: 10.1016/j.urology.2014.12.004.","Takahashi S","Urology","2015","2015/03/04","PMC4695987","NIHMS737795","10.1016/j.urology.2014.12.004"
"17962060","[Brachytherapy for localised prostate cancer]","Peiffert D.","Cancer Radiother. 2007 Nov;11(6-7):373-8. doi: 10.1016/j.canrad.2007.09.007. Epub 2007 Oct 24.","Peiffert D","Cancer Radiother","2007","2007/10/27","","","10.1016/j.canrad.2007.09.007"
"20071710","A seminal finding for prostate cancer?","Huang J, Witte ON.","N Engl J Med. 2010 Jan 14;362(2):175-6. doi: 10.1056/NEJMcibr0909965.","Huang J","N Engl J Med","2010","2010/01/15","","","10.1056/NEJMcibr0909965"
"8618302","Prostate specimen reevaluation in patients with organ confined prostate cancer and postoperative biological recurrence","Ravery V, De la Taille A, Toublanc M, Boccon-Gibod L, Hermieu JF, Delmas V, Boccon-Gibod L.","J Urol. 1996 Jun;155(6):1981-2.","Ravery V","J Urol","1996","1996/06/01","","",""
"23399727","Proposed mechanisms of action for prostate cancer vaccines","Geary SM, Lemke CD, Lubaroff DM, Salem AK.","Nat Rev Urol. 2013 Mar;10(3):149-60. doi: 10.1038/nrurol.2013.8. Epub 2013 Feb 12.","Geary SM","Nat Rev Urol","2013","2013/02/13","PMC4358823","NIHMS667314","10.1038/nrurol.2013.8"
"31792635","Detectability of prostate cancer in different parts of the gland with 3-Tesla multiparametric magnetic resonance imaging: correlation with whole-mount histopathology","Ito K, Furuta A, Kido A, Teramoto Y, Akamatsu S, Terada N, Yamasaki T, Inoue T, Ogawa O, Kobayashi T.","Int J Clin Oncol. 2020 Apr;25(4):732-740. doi: 10.1007/s10147-019-01587-8. Epub 2019 Dec 2.","Ito K","Int J Clin Oncol","2020","2019/12/04","","","10.1007/s10147-019-01587-8"
"27460352","Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer","White NM, Zhao SG, Zhang J, Rozycki EB, Dang HX, McFadden SD, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N, Arbeit JM, Karnes RJ, Den RB, Davicioni E, Maher CA.","Eur Urol. 2017 Feb;71(2):257-266. doi: 10.1016/j.eururo.2016.07.012. Epub 2016 Jul 22.","White NM","Eur Urol","2017","2016/07/28","","","10.1016/j.eururo.2016.07.012"
"11016624","The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy","Okegawa T, Li Y, Pong RC, Bergelson JM, Zhou J, Hsieh JT.","Cancer Res. 2000 Sep 15;60(18):5031-6.","Okegawa T","Cancer Res","2000","2000/10/04","","",""
"15540729","Controversies in prostate cancer screening","Murphy AM, McKiernan JM, Olsson CA.","J Urol. 2004 Nov;172(5 Pt 1):1822-4. doi: 10.1097/01.ju.0000140500.65341.9a.","Murphy AM","J Urol","2004","2004/11/16","","","10.1097/01.ju.0000140500.65341.9a"
"12430000","Differential expression of genes during TPA-induced differentiation of human prostatic cancer TSU-Pr1 cells","Suzuki T, Shimizu T, Satoh K, Sugibayashi R, Takeda K.","Int J Mol Med. 2002 Dec;10(6):735-9.","Suzuki T","Int J Mol Med","2002","2002/11/14","","",""
"28480341","Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up","Ha JY, Shin TJ, Jung W, Kim BH, Park CH, Kim CI.","Investig Clin Urol. 2017 May;58(3):164-170. doi: 10.4111/icu.2017.58.3.164. Epub 2017 Apr 13.","Ha JY","Investig Clin Urol","2017","2017/05/09","PMC5419108","","10.4111/icu.2017.58.3.164"
"15842132","Guiding prostate cancer treatment choices. Early detection means more options for more men","Sweat GT.","Postgrad Med. 2005 Apr;117(4):45-50. doi: 10.3810/pgm.2005.04.1618.","Sweat GT","Postgrad Med","2005","2005/04/22","","","10.3810/pgm.2005.04.1618"
"15547629","The watchful waiting management option for older men with prostate cancer: state of the science","Wallace M, Bailey D Jr, O'Rourke M, Galbraith M.","Oncol Nurs Forum. 2004 Nov 16;31(6):1057-66. doi: 10.1188/04.ONF.1057-1066.","Wallace M","Oncol Nurs Forum","2004","2004/11/18","","","10.1188/04.ONF.1057-1066"
"29682886","A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer","Huang EY, Chang YJ, Huang SP, Lin VC, Yu CC, Huang CY, Yin HL, Chang TY, Lu TL, Bao BY.","J Cell Mol Med. 2018 Jul;22(7):3661-3670. doi: 10.1111/jcmm.13649. Epub 2018 Apr 23.","Huang EY","J Cell Mol Med","2018","2018/04/24","PMC6010704","","10.1111/jcmm.13649"
"9383000","BRCA2 mutation in Icelandic prostate cancer patients","Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjörd JE, Jonsson E.","J Mol Med (Berl). 1997 Oct;75(10):758-61. doi: 10.1007/s001090050162.","Sigurdsson S","J Mol Med (Berl)","1997","1997/12/31","","","10.1007/s001090050162"
"25734645","The utility and limitations of contrast-enhanced ultrasound for the diagnosis and treatment of prostate cancer","Sano F, Uemura H.","Sensors (Basel). 2015 Feb 27;15(3):4947-57. doi: 10.3390/s150304947.","Sano F","Sensors (Basel)","2015","2015/03/04","PMC4435116","","10.3390/s150304947"
"29371727","Role of multi-parametric (mp) MRI in prostate cancer","Nazim SM, Ather MH, Salam B.","J Pak Med Assoc. 2018 Jan;68(1):98-104.","Nazim SM","J Pak Med Assoc","2018","2018/01/27","","",""
"21355976","Improved survival prospects for patients with castration-resistant prostate cancer","Kirby RS, Fitzpatrick JM.","BJU Int. 2011 Mar;107(5):697-700. doi: 10.1111/j.1464-410X.2010.10027.x. Epub 2011 Feb 11.","Kirby RS","BJU Int","2011","2011/03/02","","","10.1111/j.1464-410X.2010.10027.x"
"8689504","bl-2 [corrected] Expression on prostate cancer and its relationship to cell cycle and prognosis","Matsushima H, Hosaka Y, Suzuki M, Mizutani T, Ishizuka H, Kawabe K.","Int J Urol. 1996 Mar;3(2):113-7. doi: 10.1111/j.1442-2042.1996.tb00494.x.","Matsushima H","Int J Urol","1996","1996/03/01","","","10.1111/j.1442-2042.1996.tb00494.x"
"10098424","The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy","Vicini FA, Kini VR, Spencer W, Diokno A, Martinez AA.","Int J Radiat Oncol Biol Phys. 1999 Mar 1;43(4):707-13. doi: 10.1016/s0360-3016(98)00513-6.","Vicini FA","Int J Radiat Oncol Biol Phys","1999","1999/03/31","","","10.1016/s0360-3016(98)00513-6"
"20716635","A dietary tomato supplement prevents prostate cancer in TRAMP mice","Pannellini T, Iezzi M, Liberatore M, Sabatini F, Iacobelli S, Rossi C, Alberti S, Di Ilio C, Vitaglione P, Fogliano V, Piantelli M.","Cancer Prev Res (Phila). 2010 Oct;3(10):1284-91. doi: 10.1158/1940-6207.CAPR-09-0237. Epub 2010 Aug 17.","Pannellini T","Cancer Prev Res (Phila)","2010","2010/08/19","","","10.1158/1940-6207.CAPR-09-0237"
"8869957","The role of PSA in the radiotherapy of prostate cancer","Roach M 3rd.","Oncology (Williston Park). 1996 Aug;10(8):1143-53; discussion 1154-61.","Roach M 3rd","Oncology (Williston Park)","1996","1996/08/01","","",""
"29054374","Comparative Analysis of Clinical Outcomes and Procedural Costs between the Conventional Two-stage Technique and 4D Brachytherapy for Early Prostate Cancer","Langley SEM, Uribe J, Uribe-Lewis S, Money-Kyrle J, Perna C, Khaksar S, Soares R, Laing R.","Clin Oncol (R Coll Radiol). 2018 Jan;30(1):57-64. doi: 10.1016/j.clon.2017.09.006. Epub 2017 Oct 18.","Langley SEM","Clin Oncol (R Coll Radiol)","2018","2017/10/22","","","10.1016/j.clon.2017.09.006"
"19100603","Chronic periglandular inflammation on prostate needle biopsy does not increase the likelihood of cancer on subsequent biopsy","Bassett WW, Bettendorf DM, Lewis JM, Loughlin KR.","Urology. 2009 Apr;73(4):845-9. doi: 10.1016/j.urology.2008.08.508. Epub 2008 Dec 18.","Bassett WW","Urology","2009","2008/12/23","","","10.1016/j.urology.2008.08.508"
"23511665","Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer","MacVicar GR, Hussain MH.","Curr Opin Oncol. 2013 May;25(3):252-60. doi: 10.1097/CCO.0b013e32835ff161.","MacVicar GR","Curr Opin Oncol","2013","2013/03/21","","","10.1097/CCO.0b013e32835ff161"
"11851612","The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting","Arai Y, Egawa S, Kuwao S, Ogura K, Baba S.","BJU Int. 2001 Dec;88(9):909-14. doi: 10.1046/j.1464-4096.2001.01558.x.","Arai Y","BJU Int","2001","2002/02/20","","","10.1046/j.1464-4096.2001.01558.x"
"25457496","Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam","Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schröder FH, Bangma CH, Roobol MJ; ERSPC Rotterdam Study Group.","Eur Urol. 2015 Aug;68(2):179-82. doi: 10.1016/j.eururo.2014.10.008. Epub 2014 Oct 18.","Bokhorst LP","Eur Urol","2015","2014/12/03","","","10.1016/j.eururo.2014.10.008"
"27560985","Intermittent Androgen Deprivation Therapy-An Important Treatment Option for Prostate Cancer","Klotz L, Higano CS.","JAMA Oncol. 2016 Dec 1;2(12):1531-1532. doi: 10.1001/jamaoncol.2016.3138.","Klotz L","JAMA Oncol","2016","2016/08/26","","","10.1001/jamaoncol.2016.3138"
"24304274","The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities","Lugnani F, Simone G, Biava PM, Ablin RJ.","Curr Med Chem. 2014;21(9):1082-92. doi: 10.2174/0929867321666131201143752.","Lugnani F","Curr Med Chem","2014","2013/12/06","","","10.2174/0929867321666131201143752"
"22285762","Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer","Kwiatkowski M, Klotz L, Hugosson J, Recker F.","Eur Urol. 2012 Apr;61(4):851-4. doi: 10.1016/j.eururo.2012.01.023. Epub 2012 Jan 24.","Kwiatkowski M","Eur Urol","2012","2012/01/31","","","10.1016/j.eururo.2012.01.023"
"28120266","Identification of TWIST-interacting genes in prostate cancer","Lyu P, Zhang SD, Yuen HF, McCrudden CM, Wen Q, Chan KW, Kwok HF.","Sci China Life Sci. 2017 Apr;60(4):386-396. doi: 10.1007/s11427-016-0262-6. Epub 2017 Jan 22.","Lyu P","Sci China Life Sci","2017","2017/01/26","","","10.1007/s11427-016-0262-6"
"23469490","[New treatments for castration-resistant prostate cancer]","Sautois B, Gennigens C.","Rev Med Liege. 2013 Feb;68(2):94-6.","Sautois B","Rev Med Liege","2013","2013/03/09","","",""
"16786972","Do usual screening methods for prostate cancer reduce mortality?","","Manag Care Interface. 2006 May;19(5):67.","","Manag Care Interface","2006","2006/06/22","","",""
"6702037","Perioperative complications of pelvic lymphadenectomy and radical retropubic prostatectomy for Stages C and D1 prostate cancer","Patterson DE, Zincke H.","Urology. 1984 Mar;23(3):243-6.","Patterson DE","Urology","1984","1984/03/01","","",""
"24980194","A recipe for targeted therapy in prostate cancer","Masuda S, Izpisua Belmonte JC.","Nat Rev Urol. 2014 Jul;11(7):419. doi: 10.1038/nrurol.2013.110-c1. Epub 2014 Jul 1.","Masuda S","Nat Rev Urol","2014","2014/07/02","","","10.1038/nrurol.2013.110-c1"
"32134996","Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study","Beksisa J, Getinet T, Tanie S, Diribi J, Hassen HY.","PLoS One. 2020 Mar 5;15(3):e0229854. doi: 10.1371/journal.pone.0229854. eCollection 2020.","Beksisa J","PLoS One","2020","2020/03/06","PMC7058322","","10.1371/journal.pone.0229854"
"25175748","The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells","Kregel S, Szmulewitz RZ, Vander Griend DJ.","Prostate. 2014 Nov;74(15):1530-43. doi: 10.1002/pros.22870. Epub 2014 Aug 31.","Kregel S","Prostate","2014","2014/09/02","PMC4174985","NIHMS614055","10.1002/pros.22870"
"25000316","New drugs and treatment strategies in prostate cancer","Galsky MD.","Clin Adv Hematol Oncol. 2014 Jan;12(1):51-3.","Galsky MD","Clin Adv Hematol Oncol","2014","2014/07/08","","",""
"21377017","Editorial comment. Impact of prostate weight on probability of positive surgical margins in patients with low-risk prostate cancer after robotic-assisted laparoscopic radical prostatectomy","Smith JA Jr.","Urology. 2011 Mar;77(3):681. doi: 10.1016/j.urology.2010.07.513.","Smith JA Jr","Urology","2011","2011/03/08","","","10.1016/j.urology.2010.07.513"
"10906743","Screening and early detection of prostate cancer","Schröder FH, Alexander FE, Bangma CH, Hugosson J, Smith DS.","Prostate. 2000 Aug 1;44(3):255-63. doi: 10.1002/1097-0045(20000801)44:3<255::aid-pros11>3.0.co;2-i.","Schröder FH","Prostate","2000","2000/07/25","","","10.1002/1097-0045(20000801)44:3<255::aid-pros11>3.0.co;2-i"
"20452694","The potential role of G2- but not of G0-radiosensitivity for predisposition of prostate cancer","Borgmann K, Raabe A, Reuther S, Szymczak S, Schlomm T, Isbarn H, Gomolka M, Busjahn A, Bonin M, Ziegler A, Dikomey E.","Radiother Oncol. 2010 Jul;96(1):19-24. doi: 10.1016/j.radonc.2010.04.018. Epub 2010 May 7.","Borgmann K","Radiother Oncol","2010","2010/05/11","","","10.1016/j.radonc.2010.04.018"
"20815949","Vascular endothelial growth factor (VEGF) and prostate pathology","Botelho F, Pina F, Silva P, Figueiredo G, Cruz F, Lunet N.","Int Braz J Urol. 2010 Jul-Aug;36(4):430-7; discussion 438. doi: 10.1590/s1677-55382010000400006.","Botelho F","Int Braz J Urol","2010","2010/09/07","","","10.1590/s1677-55382010000400006"
"24366848","Investigation of key genes associated with prostate cancer using RNA-seq data","Wu J, Feng F, Yang D, Yu S, Liu J, Gao Z.","Int J Biol Markers. 2014 Mar 24;29(1):e86-92. doi: 10.5301/jbm.5000056.","Wu J","Int J Biol Markers","2014","2013/12/25","","","10.5301/jbm.5000056"
"28816714","Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer","De Bleser E, Tran PT, Ost P.","Curr Opin Urol. 2017 Nov;27(6):587-595. doi: 10.1097/MOU.0000000000000441.","De Bleser E","Curr Opin Urol","2017","2017/08/18","","","10.1097/MOU.0000000000000441"
"30874832","[Imaging for initial diagnosis of localized prostate cancer]","Bonekamp D, Salomon G.","Urologe A. 2019 May;58(5):494-503. doi: 10.1007/s00120-019-0901-x.","Bonekamp D","Urologe A","2019","2019/03/16","","","10.1007/s00120-019-0901-x"
"15124131","Novel therapeutic strategies for androgen-independent prostate cancer: an update","Assikis VJ, Simons JW.","Semin Oncol. 2004 Apr;31(2 Suppl 4):26-32. doi: 10.1053/j.seminoncol.2004.02.008.","Assikis VJ","Semin Oncol","2004","2004/05/05","","","10.1053/j.seminoncol.2004.02.008"
"24528523","Tea consumption and prostate cancer: an updated meta-analysis","Lin YW, Hu ZH, Wang X, Mao QQ, Qin J, Zheng XY, Xie LP.","World J Surg Oncol. 2014 Feb 14;12:38. doi: 10.1186/1477-7819-12-38.","Lin YW","World J Surg Oncol","2014","2014/02/18","PMC3925323","","10.1186/1477-7819-12-38"
"10172599","An actuarial model approach to assessing the impact of serial testing for prostate cancer using the Tandem PSA assay","Brawer M, Parson R, Costa M, Scheil B.","Clin Lab Manage Rev. 1996 Mar-Apr;10(2):157-9.","Brawer M","Clin Lab Manage Rev","1996","1996/02/07","","",""
"31326558","Identification of the perturbed metabolic pathways associating with prostate cancer cells and anticancer affects of obacunone","Xie J, Zhang AH, Qiu S, Zhang TL, Li XN, Yan GL, Sun H, Liu L, Wang XJ.","J Proteomics. 2019 Aug 30;206:103447. doi: 10.1016/j.jprot.2019.103447. Epub 2019 Jul 19.","Xie J","J Proteomics","2019","2019/07/22","","","10.1016/j.jprot.2019.103447"
"25444932","Detection and characterisation of biopsy tissue using quantitative optical coherence elastography (OCE) in men with suspected prostate cancer","Li C, Guan G, Ling Y, Hsu YT, Song S, Huang JT, Lang S, Wang RK, Huang Z, Nabi G.","Cancer Lett. 2015 Feb 1;357(1):121-128. doi: 10.1016/j.canlet.2014.11.021. Epub 2014 Nov 21.","Li C","Cancer Lett","2015","2014/12/03","","","10.1016/j.canlet.2014.11.021"
"32332299","Isolated Intravascular Prostate Carcinoma Recurrence Confirmed With 18F-Fluciclovine PET/CT and MRI","Agely A, Sharma A, Parent EE, Nawaz A, Jain MK.","Clin Nucl Med. 2020 Jun;45(6):442-443. doi: 10.1097/RLU.0000000000003011.","Agely A","Clin Nucl Med","2020","2020/04/26","","","10.1097/RLU.0000000000003011"
"9421447","Are monotherapy options reasonable for T3 prostate cancer?","Schellhammer PF, Lynch DF.","Semin Urol Oncol. 1997 Nov;15(4):207-14.","Schellhammer PF","Semin Urol Oncol","1997","1998/01/08","","",""
"15224088","Active surveillance of early prostate cancer: rationale, initial results and future developments","Parker C.","Prostate Cancer Prostatic Dis. 2004;7(3):184-7. doi: 10.1038/sj.pcan.4500720.","Parker C","Prostate Cancer Prostatic Dis","2004","2004/06/30","","","10.1038/sj.pcan.4500720"
"17432555","Diagnosis of prostate cancer","Pinthus JH, Pacik D, Ramon J.","Recent Results Cancer Res. 2007;175:83-99. doi: 10.1007/978-3-540-40901-4_6.","Pinthus JH","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_6"
"9560828","Screening, diagnosis, and management of prostate cancer: improving primary care outcomes","Goolsby MJ.","Nurse Pract. 1998 Mar;23(3):11-4,16,21-3 passim; quiz 42-3. doi: 10.1097/00006205-199803000-00001.","Goolsby MJ","Nurse Pract","1998","1998/04/30","","","10.1097/00006205-199803000-00001"
"10667047","[Surgery, radiotherapy or hormonal therapy in the treatment of prostate cancer]","Bonnet P, Coppens L, Andrianne R, Waltregny D, Keppenne V, Leduc F, Fillet M, Ghammad S, de Leval J.","Rev Med Liege. 1999 Nov;54(11):875-85.","Bonnet P","Rev Med Liege","1999","2000/02/10","","",""
"2680450","[Radiotherapy of prostate cancer]","Kellokumpu-Lehtinen P, Huovinen R.","Duodecim. 1989;105(19):1590-5.","Kellokumpu-Lehtinen P","Duodecim","1989","1989/01/01","","",""
"11965297","Eradication of a disease: how we cured symptomless prostate cancer","Tannock IF.","Lancet. 2002 Apr 13;359(9314):1341-2. doi: 10.1016/S0140-6736(02)08278-8.","Tannock IF","Lancet","2002","2002/04/20","","","10.1016/S0140-6736(02)08278-8"
"15947107","Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl- current associated with neuroendocrine differentiation of prostate cancer epithelial cells","Lemonnier L, Lazarenko R, Shuba Y, Thebault S, Roudbaraki M, Lepage G, Prevarskaya N, Skryma R.","Endocr Relat Cancer. 2005 Jun;12(2):335-49. doi: 10.1677/erc.1.00898.","Lemonnier L","Endocr Relat Cancer","2005","2005/06/11","","","10.1677/erc.1.00898"
"19947562","[Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy]","Guan YB, Zhang YF, Wen H, Zhou SQ, Dai YT.","Zhonghua Nan Ke Xue. 2009 Sep;15(9):801-5.","Guan YB","Zhonghua Nan Ke Xue","2009","2009/12/02","","",""
"9302175","Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven year follow-up","Crundwell MC, Arkell DG, Gearty J, Phillips SM.","J Urol. 1997 Oct;158(4):1568-75.","Crundwell MC","J Urol","1997","1997/09/25","","",""
"1877229","Is deleting the digital rectal examination a good idea?","Sutton MA, Gibbons RP, Correa RJ Jr.","West J Med. 1991 Jul;155(1):43-6.","Sutton MA","West J Med","1991","1991/07/11","PMC1002909","",""
"25575714","Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms","Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K.","Urol Oncol. 2015 May;33(5):245-60. doi: 10.1016/j.urolonc.2014.10.009. Epub 2015 Jan 7.","Quinn DI","Urol Oncol","2015","2015/01/11","","","10.1016/j.urolonc.2014.10.009"
"11061896","The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: implications for treatment selection","Gao X, Mohideen N, Flanigan RC, Waters WB, Wojcik EM, Leman CR.","J Urol. 2000 Dec;164(6):1982-6.","Gao X","J Urol","2000","2000/11/04","","",""
"20499060","Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy","Nguyen MC, Tu GH, Koprivnikar KE, Gonzalez-Edick M, Jooss KU, Harding TC.","Cancer Immunol Immunother. 2010 Sep;59(9):1313-23. doi: 10.1007/s00262-010-0858-5. Epub 2010 May 25.","Nguyen MC","Cancer Immunol Immunother","2010","2010/05/26","","","10.1007/s00262-010-0858-5"
"10979616","Prostate cancer treatment with ultrasound-guided transperineal brachytherapy: analysis of the treatment results of our first 150 patients","Larson G, Pappas N, Hassoun B.","J Okla State Med Assoc. 2000 Aug;93(8):391-6.","Larson G","J Okla State Med Assoc","2000","2000/09/09","","",""
"30281010","Survival and secondary interventions following treatment for locally-advanced prostate cancer","Sussman R, Carvalho FLF, Harbin A, Zheng C, Lynch JH, Stamatakis L, Hwang J, Williams SB, Hu JC, Kowalczyk KJ.","Can J Urol. 2018 Oct;25(5):9516-9524.","Sussman R","Can J Urol","2018","2018/10/04","","",""
"8717451","Prostate Cancer: Current Issues, New Approaches. Proceedings of an international congress. London, England, October 19-21, 1995","","Eur Urol. 1996;29 Suppl 2:1-135.","","Eur Urol","1996","1996/01/01","","",""
"24655933","Circumcision and prostate cancer: a population-based case-control study in Montréal, Canada","Spence AR, Rousseau MC, Karakiewicz PI, Parent MÉ.","BJU Int. 2014 Dec;114(6b):E90-E98. doi: 10.1111/bju.12741. Epub 2014 May 28.","Spence AR","BJU Int","2014","2014/03/25","PMC4309483","","10.1111/bju.12741"
"29212868","Painful testicular metastasis from prostate adenocarcinoma","Lee KA, Mayer E, Khoo V.","BMJ Case Rep. 2017 Dec 5;2017:bcr2017219963. doi: 10.1136/bcr-2017-219963.","Lee KA","BMJ Case Rep","2017","2017/12/08","PMC5728246","","10.1136/bcr-2017-219963"
"16642705","[Antiandrogen therapy of prostate carcinoma]","Altwein J, Hoesl CE.","MMW Fortschr Med. 2006 Mar 30;148(13):43-5. doi: 10.1007/BF03364617.","Altwein J","MMW Fortschr Med","2006","2006/04/29","","","10.1007/BF03364617"
"12949429","Salvage radiotherapy in patients with persisting prostate-specific antigen after radical prostatectomy for prostate cancer","Bottke D, Wiegel T, Höcht S, Müller M, Schostak M, Hinkelbein W.","Oncology. 2003;65 Suppl 1:18-23. doi: 10.1159/000072487.","Bottke D","Oncology","2003","2003/09/02","","","10.1159/000072487"
"14765017","Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies","Augustin H, Hammerer PG.","Minerva Urol Nefrol. 2003 Dec;55(4):251-61.","Augustin H","Minerva Urol Nefrol","2003","2004/02/07","","",""
"16018832","Current status of treatment for patients with metastatic prostate cancer","Higano CS.","Can J Urol. 2005 Jun;12 Suppl 2:38-41.","Higano CS","Can J Urol","2005","2005/07/16","","",""
"21837949","[Expression of ID3 protein in prostate cancer and its clinicopathological significance]","Wang K, Li XJ, Yin HL, Zhou HB, Chen FF, Wang H, Ma HH.","Zhonghua Nan Ke Xue. 2011 May;17(5):410-3.","Wang K","Zhonghua Nan Ke Xue","2011","2011/08/16","","",""
"12095940","Nutrition and prostate cancer: a review","Cohen LA.","Ann N Y Acad Sci. 2002 Jun;963:148-55. doi: 10.1111/j.1749-6632.2002.tb04106.x.","Cohen LA","Ann N Y Acad Sci","2002","2002/07/04","","","10.1111/j.1749-6632.2002.tb04106.x"
"14758139","Pattern of proliferative index (Ki-67) after anti-androgen manipulation reflects the ability of irradiation to control prostate cancer","Hintz BL, Koo C, Murphy JF.","Am J Clin Oncol. 2004 Feb;27(1):85-8. doi: 10.1097/01.coc.0000046302.23399.f3.","Hintz BL","Am J Clin Oncol","2004","2004/02/06","","","10.1097/01.coc.0000046302.23399.f3"
"12371217","Progress in the control of prostate cancer in Rhode Island, 1987-2000","Chiaverini L, Fulton JP, Darcy DM.","Med Health R I. 2002 Sep;85(9):291-3.","Chiaverini L","Med Health R I","2002","2002/10/10","","",""
"3193513","An evaluation of serial digital rectal examinations in screening for prostate cancer","Mueller EJ, Crain TW, Thompson IM, Rodriguez FR.","J Urol. 1988 Dec;140(6):1445-7. doi: 10.1016/s0022-5347(17)42069-6.","Mueller EJ","J Urol","1988","1988/12/01","","","10.1016/s0022-5347(17)42069-6"
"16966158","Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review","Downes MR, Byrne JC, Dunn MJ, Fitzpatrick JM, Watson RW, Pennington SR.","Biomarkers. 2006 Sep-Oct;11(5):406-16. doi: 10.1080/13547500600799821.","Downes MR","Biomarkers","2006","2006/09/13","","","10.1080/13547500600799821"
"9365547","Prostate volume and cancer in screening programs","Standaert B, Alwan A, Nelen V, Denis L.","Prostate. 1997 Nov 1;33(3):188-94. doi: 10.1002/(sici)1097-0045(19971101)33:3<188::aid-pros7>3.0.co;2-f.","Standaert B","Prostate","1997","1997/11/20","","","10.1002/(sici)1097-0045(19971101)33:3<188::aid-pros7>3.0.co;2-f"
"31197228","Role of the DNA damage response in prostate cancer formation, progression and treatment","Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J.","Prostate Cancer Prostatic Dis. 2020 Mar;23(1):24-37. doi: 10.1038/s41391-019-0153-2. Epub 2019 Jun 13.","Zhang W","Prostate Cancer Prostatic Dis","2020","2019/06/15","","","10.1038/s41391-019-0153-2"
"7545845","[Different determination methods make interpretation of prostate-specific antigen more difficult]","Semjonow A, Brandt B, Oberpenning F, Hertle L.","Urologe A. 1995 Jul;34(4):303-15.","Semjonow A","Urologe A","1995","1995/07/01","","",""
"23619582","The epidemiology of high-risk prostate cancer","Punnen S, Cooperberg MR.","Curr Opin Urol. 2013 Jul;23(4):331-6. doi: 10.1097/MOU.0b013e328361d48e.","Punnen S","Curr Opin Urol","2013","2013/04/27","","","10.1097/MOU.0b013e328361d48e"
"26081756","Capsaicin causes inactivation and degradation of the androgen receptor by inducing the restoration of miR-449a in prostate cancer","Zheng L, Chen J, Ma Z, Liu W, Yang F, Yang Z, Wang K, Wang X, He D, Li L.","Oncol Rep. 2015 Aug;34(2):1027-34. doi: 10.3892/or.2015.4055. Epub 2015 Jun 11.","Zheng L","Oncol Rep","2015","2015/06/18","","","10.3892/or.2015.4055"
"15269597","Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP)","Keller ET.","Anticancer Drugs. 2004 Aug;15(7):663-9. doi: 10.1097/01.cad.0000136877.89057.b9.","Keller ET","Anticancer Drugs","2004","2004/07/23","","","10.1097/01.cad.0000136877.89057.b9"
"22483701","Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen","Tai P, Tonita J, Woitas C, Zhu T, Joseph K, Skarsgard D.","Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e525-30. doi: 10.1016/j.ijrobp.2012.01.041. Epub 2012 Apr 6.","Tai P","Int J Radiat Oncol Biol Phys","2012","2012/04/10","","","10.1016/j.ijrobp.2012.01.041"
"27527734","Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death","Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA.","Prostate. 2017 Jan;77(1):41-48. doi: 10.1002/pros.23247. Epub 2016 Aug 16.","Albright FS","Prostate","2017","2016/08/17","","","10.1002/pros.23247"
"19364426","Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?","Pai HH, Eldridge B, Bishop D, Alexander A, Lesperance M, Blood P, Lim J, Ludgate C.","Can J Urol. 2009 Apr;16(2):4541-52.","Pai HH","Can J Urol","2009","2009/04/15","","",""
"15780174","International regional working groups on prostate cancer: results of consensus development","Klotz LH.","Can J Urol. 2005 Feb;12 Suppl 1:86-91.","Klotz LH","Can J Urol","2005","2005/03/23","","",""
"87401","DHT concentrations in human prostate cancer tissue","Geller J, Albert J, Loza D, Geller S, Stoeltzing W, de la Vega D.","J Clin Endocrinol Metab. 1978 Mar;46(3):440-4. doi: 10.1210/jcem-46-3-440.","Geller J","J Clin Endocrinol Metab","1978","1978/03/01","","","10.1210/jcem-46-3-440"
"26016160","[10-year results of using segmental pelvic irradiation combined with local irradiation of the prostate in patients with prostate cancer with multiple bone metastases]","Metelev VV.","Vopr Onkol. 2015;61(1):137-40.","Metelev VV","Vopr Onkol","2015","2015/05/29","","",""
"16859578","Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer","Mannuel HD, Hussain A.","Clin Genitourin Cancer. 2006 Jun;5(1):43-9. doi: 10.3816/CGC.2006.n.016.","Mannuel HD","Clin Genitourin Cancer","2006","2006/07/25","","","10.3816/CGC.2006.n.016"
"29101735","A Potential Role for Green Tea as a Radiation Sensitizer for Prostate Cancer","Schroeder AC, Xiao H, Zhu Z, Li Q, Bai Q, Wakefield MR, Mann JD, Fang Y.","Pathol Oncol Res. 2019 Jan;25(1):263-268. doi: 10.1007/s12253-017-0358-4. Epub 2017 Nov 3.","Schroeder AC","Pathol Oncol Res","2019","2017/11/05","","","10.1007/s12253-017-0358-4"
"27400876","Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study","Bratt O, Drevin L, Akre O, Garmo H, Stattin P.","J Natl Cancer Inst. 2016 Jul 10;108(10):djw110. doi: 10.1093/jnci/djw110. Print 2016 Oct.","Bratt O","J Natl Cancer Inst","2016","2016/07/13","","","10.1093/jnci/djw110"
"24715301","Biological factor may be linked to prostate cancer racial disparities","Printz C.","Cancer. 2014 Apr 15;120(8):1132-3. doi: 10.1002/cncr.28692.","Printz C","Cancer","2014","2014/04/10","","","10.1002/cncr.28692"
"16709008","[Screening for prostate cancer: arguments ""against""]","Perrin P.","Ann Urol (Paris). 2006 Apr;40(2):101-5. doi: 10.1016/j.anuro.2006.01.004.","Perrin P","Ann Urol (Paris)","2006","2006/05/20","","","10.1016/j.anuro.2006.01.004"
"16955399","Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer","Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Björk A, Olsson A, Leanderson T.","Prostate. 2006 Dec 1;66(16):1768-78. doi: 10.1002/pros.20509.","Isaacs JT","Prostate","2006","2006/09/07","","","10.1002/pros.20509"
"15988050","Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer","Brown DM, Kelly GE, Husband AJ.","Mol Biotechnol. 2005 Jul;30(3):253-70. doi: 10.1385/MB:30:3:253.","Brown DM","Mol Biotechnol","2005","2005/07/01","","","10.1385/MB:30:3:253"
"7615377","Usefulness of aspiration cytology in prostate cancer detection","Ito H, Yamaguchi K, Kotake T, Matsuzaki O, Nagao K.","Int Urol Nephrol. 1995;27(1):93-100. doi: 10.1007/BF02575226.","Ito H","Int Urol Nephrol","1995","1995/01/01","","","10.1007/BF02575226"
"19476985","Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer","Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH.","Urology. 2009 Oct;74(4):878-83. doi: 10.1016/j.urology.2009.03.004. Epub 2009 May 24.","Siemens DR","Urology","2009","2009/05/30","","","10.1016/j.urology.2009.03.004"
"17432565","Europa Uomo: the European Prostate Cancer Coalition","Hudson T, Denis LJ.","Recent Results Cancer Res. 2007;175:267-71. doi: 10.1007/978-3-540-40901-4_16.","Hudson T","Recent Results Cancer Res","2007","2007/04/17","","","10.1007/978-3-540-40901-4_16"
"20466122","Multifocal prostate cancer: biologic, prognostic, and therapeutic implications","Andreoiu M, Cheng L.","Hum Pathol. 2010 Jun;41(6):781-93. doi: 10.1016/j.humpath.2010.02.011.","Andreoiu M","Hum Pathol","2010","2010/05/15","","","10.1016/j.humpath.2010.02.011"
"24515947","Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia","Sinha I, Allen JE, Pinto JT, Sinha R.","Cancer Med. 2014 Apr;3(2):252-64. doi: 10.1002/cam4.198. Epub 2014 Feb 7.","Sinha I","Cancer Med","2014","2014/02/12","PMC3987075","","10.1002/cam4.198"
"30950457","The Role of Tumor Oxygenation Tested by Magnetic Resonance Imaging (MRI) in Prostate Cancer Grading","Geng H, Tong W, Han F, Zhu K, Cao Y, Chen X.","Med Sci Monit. 2019 Apr 5;25:2505-2510. doi: 10.12659/MSM.913110.","Geng H","Med Sci Monit","2019","2019/04/06","PMC6463617","","10.12659/MSM.913110"
"28560840","Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade","Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL.","Cancer Med. 2017 Jul;6(7):1827-1836. doi: 10.1002/cam4.1103. Epub 2017 May 31.","Jang JW","Cancer Med","2017","2017/06/01","PMC5504320","","10.1002/cam4.1103"
"27998677","Clinically localized prostate cancer in 2017: A review of comparative effectiveness","Lavery HJ, Cooperberg MR.","Urol Oncol. 2017 Feb;35(2):40-41. doi: 10.1016/j.urolonc.2016.11.013. Epub 2016 Dec 18.","Lavery HJ","Urol Oncol","2017","2016/12/22","","","10.1016/j.urolonc.2016.11.013"
"29363113","Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study","Tomic K, Ventimiglia E, Robinson D, Häggström C, Lambe M, Stattin P.","Int J Cancer. 2018 Jun 15;142(12):2478-2484. doi: 10.1002/ijc.31272. Epub 2018 Feb 2.","Tomic K","Int J Cancer","2018","2018/01/25","PMC5947133","","10.1002/ijc.31272"
"23459095","A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells","Lippolis G, Edsjö A, Stenman UH, Bjartell A.","Prostate Cancer Prostatic Dis. 2013 Jun;16(2):145-50. doi: 10.1038/pcan.2013.7. Epub 2013 Mar 5.","Lippolis G","Prostate Cancer Prostatic Dis","2013","2013/03/06","PMC3655381","","10.1038/pcan.2013.7"
"24266432","Potential implications on TCP for external beam prostate cancer treatment when considering the bystander effect in partial exposure scenarios","Balderson MJ, Kirkby C.","Int J Radiat Biol. 2014 Feb;90(2):133-41. doi: 10.3109/09553002.2014.868617.","Balderson MJ","Int J Radiat Biol","2014","2013/11/26","","","10.3109/09553002.2014.868617"
"22674346","Primary cancers before and after prostate cancer diagnosis","Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P.","Cancer. 2012 Dec 15;118(24):6207-16. doi: 10.1002/cncr.27672. Epub 2012 Jun 6.","Van Hemelrijck M","Cancer","2012","2012/06/08","","","10.1002/cncr.27672"
"20944078","Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data","Hadley J, Yabroff KR, Barrett MJ, Penson DF, Saigal CS, Potosky AL.","J Natl Cancer Inst. 2010 Dec 1;102(23):1780-93. doi: 10.1093/jnci/djq393. Epub 2010 Oct 13.","Hadley J","J Natl Cancer Inst","2010","2010/10/15","PMC2994860","","10.1093/jnci/djq393"
"10984970","Validation of a staging system for evaluating prognosis in prostate cancer","Anderson DR, Patil S, Kamina A, Penson DF, Peduzzi P, Concato J.","Conn Med. 2000 Aug;64(8):459-64.","Anderson DR","Conn Med","2000","2000/09/14","","",""
"25598677","Magnetic resonance imaging-guided prostate biopsy: present and future","Kim CK.","Korean J Radiol. 2015 Jan-Feb;16(1):90-8. doi: 10.3348/kjr.2015.16.1.90. Epub 2015 Jan 9.","Kim CK","Korean J Radiol","2015","2015/01/20","PMC4296281","","10.3348/kjr.2015.16.1.90"
"1746072","[Epidemiologic and morphogenetic aspects of prostate cancer]","Dhom G.","Urologe A. 1991 May;30(3 Suppl):3-4.","Dhom G","Urologe A","1991","1991/05/01","","",""
"17283710","[Advances in the ultrasound diagnosis of prostate cancer]","Laguna MP, Wondergem N, Wink MH, Wijkstra H, de la Rosette J.","Arch Esp Urol. 2006 Dec;59(10):965-76. doi: 10.4321/s0004-06142006001000004.","Laguna MP","Arch Esp Urol","2006","2007/02/08","","","10.4321/s0004-06142006001000004"
"24512523","Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers","Ma W, Diep K, Fritsche HA, Shore N, Albitar M.","Genet Test Mol Biomarkers. 2014 Mar;18(3):156-63. doi: 10.1089/gtmb.2013.0424. Epub 2014 Feb 10.","Ma W","Genet Test Mol Biomarkers","2014","2014/02/12","","","10.1089/gtmb.2013.0424"
"17120048","Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis","Lange EM, Robbins CM, Gillanders EM, Zheng SL, Xu J, Wang Y, White KA, Chang BL, Ho LA, Trent JM, Carpten JD, Isaacs WB, Cooney KA.","Hum Genet. 2007 Mar;121(1):49-55. doi: 10.1007/s00439-006-0274-2. Epub 2006 Nov 21.","Lange EM","Hum Genet","2007","2006/11/23","","","10.1007/s00439-006-0274-2"
"1374179","Prostatic intraepithelial neoplasia (PIN): morphological clinical significance","Mostofi FK, Sesterhenn IA, Davis CJ Jr.","Prostate Suppl. 1992;4:71-7. doi: 10.1002/pros.2990210511.","Mostofi FK","Prostate Suppl","1992","1992/01/11","","","10.1002/pros.2990210511"
"2674982","Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer","Labrie F, Dupont A, Cusan L, Manhès G, Bergeron N, Lacourcière Y, Pineault S, Bélanger A, Monfette G, Emond J.","Prog Clin Biol Res. 1989;303:161-7.","Labrie F","Prog Clin Biol Res","1989","1989/01/01","","",""
"27460354","Optimizing Active Surveillance","Carter HB.","Eur Urol. 2016 Dec;70(6):909-911. doi: 10.1016/j.eururo.2016.07.017. Epub 2016 Jul 22.","Carter HB","Eur Urol","2016","2016/07/28","","","10.1016/j.eururo.2016.07.017"
"24705774","The accuracy of magnetic resonance imaging in prostate cancer staging: a single-institution experience","Oon SF, Power SP, Kelly JS, McDermott V, Ryan P, Ryan PC.","Ir J Med Sci. 2015 Jun;184(2):313-7. doi: 10.1007/s11845-014-1109-0. Epub 2014 Apr 6.","Oon SF","Ir J Med Sci","2015","2014/04/08","","","10.1007/s11845-014-1109-0"
"16702386","Common genetic variation at PTEN and risk of sporadic breast and prostate cancer","Haiman CA, Stram DO, Cheng I, Giorgi EE, Pooler L, Penney K, Le Marchand L, Henderson BE, Freedman ML.","Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1021-5. doi: 10.1158/1055-9965.EPI-05-0896.","Haiman CA","Cancer Epidemiol Biomarkers Prev","2006","2006/05/17","","","10.1158/1055-9965.EPI-05-0896"
"25791755","Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment","Yadav SS, Li J, Lavery HJ, Yadav KK, Tewari AK.","Urol Oncol. 2015 Jun;33(6):267.e1-13. doi: 10.1016/j.urolonc.2015.02.009. Epub 2015 Mar 16.","Yadav SS","Urol Oncol","2015","2015/03/21","","","10.1016/j.urolonc.2015.02.009"
"28126217","Prostate MR Imaging: An Update","Shaish H, Taneja SS, Rosenkrantz AB.","Radiol Clin North Am. 2017 Mar;55(2):303-320. doi: 10.1016/j.rcl.2016.10.011. Epub 2016 Dec 4.","Shaish H","Radiol Clin North Am","2017","2017/01/28","","","10.1016/j.rcl.2016.10.011"
"15535434","Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment","Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW.","J Urol. 2004 Nov;172(5 Pt 2):S3-5. doi: 10.1097/01.ju.0000142276.19511.ac.","Carroll PR","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000142276.19511.ac"
"31792431","Financial toxicity associated with treatment of localized prostate cancer","Imber BS, Varghese M, Ehdaie B, Gorovets D.","Nat Rev Urol. 2020 Jan;17(1):28-40. doi: 10.1038/s41585-019-0258-3. Epub 2019 Dec 2.","Imber BS","Nat Rev Urol","2020","2019/12/04","","","10.1038/s41585-019-0258-3"
"16556016","Lycopene and prostate cancer","Ansari MS, Ansari S.","Future Oncol. 2005 Jun;1(3):425-30. doi: 10.1517/14796694.1.3.425.","Ansari MS","Future Oncol","2005","2006/03/25","","","10.1517/14796694.1.3.425"
"9099361","Meta-analyses of prostate cancer and farming","Keller-Byrne JE, Khuder SA, Schaub EA.","Am J Ind Med. 1997 May;31(5):580-6. doi: 10.1002/(sici)1097-0274(199705)31:5<580::aid-ajim13>3.0.co;2-v.","Keller-Byrne JE","Am J Ind Med","1997","1997/05/01","","","10.1002/(sici)1097-0274(199705)31:5<580::aid-ajim13>3.0.co;2-v"
"18684556","Does PCA3 help identify clinically significant prostate cancer?","Loeb S.","Eur Urol. 2008 Nov;54(5):980-1. doi: 10.1016/j.eururo.2008.07.027. Epub 2008 Jul 16.","Loeb S","Eur Urol","2008","2008/08/08","","","10.1016/j.eururo.2008.07.027"
"19486654","Psychological distress and prostate specific antigen levels in men with and without prostate cancer","Turner EL, Lane JA, Metcalfe C, Down L, Donovan JL, Hamdy F, Neal D, Vedhara K.","Brain Behav Immun. 2009 Nov;23(8):1073-8. doi: 10.1016/j.bbi.2009.01.009. Epub 2009 Jan 22.","Turner EL","Brain Behav Immun","2009","2009/06/03","","","10.1016/j.bbi.2009.01.009"
"17447492","A case of orbital metastasis from prostatic carcinoma as an initial symptom","Isshiki S, Cho S, Matsuno D, Sato N, Furuya Y.","Hinyokika Kiyo. 2007 Mar;53(3):193-5.","Isshiki S","Hinyokika Kiyo","2007","2007/04/24","","",""
"10221259","Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer","Koga H, Naito S, Koto S, Sakamoto N, Nakashima M, Yamasaki T, Noma H, Kumazawa J.","Prostate. 1999 Apr 1;39(1):1-7. doi: 10.1002/(sici)1097-0045(19990401)39:1<1::aid-pros1>3.0.co;2-x.","Koga H","Prostate","1999","1999/04/30","","","10.1002/(sici)1097-0045(19990401)39:1<1::aid-pros1>3.0.co;2-x"
"22224070","Rubin H. Flocks and colloidal gold treatments for prostate cancer","Rosevear HM, Lightfoot AJ, O'Donnell MA, Platz CE, Loening SA, Hawtrey CE.","ScientificWorldJournal. 2011;11:1560-7. doi: 10.1100/tsw.2011.145. Epub 2011 Aug 16.","Rosevear HM","ScientificWorldJournal","2011","2012/01/07","PMC3201627","","10.1100/tsw.2011.145"
"14665875","The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperineal prostate biopsy","Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansadoro A, Martini M, Pansadoro V.","J Urol. 2004 Jan;171(1):197-9. doi: 10.1097/01.ju.0000099824.73886.f3.","Emiliozzi P","J Urol","2004","2003/12/11","","","10.1097/01.ju.0000099824.73886.f3"
"25894495","Immunotherapy in prostate cancer","Sobol I, Thompson RH, Dong H, Krco C, Kwon ED.","Curr Urol Rep. 2015 Jun;16(6):34. doi: 10.1007/s11934-015-0509-7.","Sobol I","Curr Urol Rep","2015","2015/04/21","","","10.1007/s11934-015-0509-7"
"25704311","Incidental prostate cancer in Asian men: high prevalence of incidental prostatic adenocarcinoma in Chinese patients undergoing radical cystoprostatectomy for treatment of bladder cancer and selection of candidates for prostate-sparing cystectomy","Yang X, Monn MF, Liu L, Liu Y, Su J, Lyu T, Gong Y, Wang L, Davidson DD, Cheng L.","Prostate. 2015 Jun;75(8):845-54. doi: 10.1002/pros.22966. Epub 2015 Feb 19.","Yang X","Prostate","2015","2015/02/24","","","10.1002/pros.22966"
"23773557","Robotic prostatectomy for high-risk prostate cancer: translating the evidence into lessons for clinical practice","Montorsi F.","Eur Urol. 2014 May;65(5):928-30. doi: 10.1016/j.eururo.2013.05.056. Epub 2013 Jun 10.","Montorsi F","Eur Urol","2014","2013/06/19","","","10.1016/j.eururo.2013.05.056"
"16600351","Cystic recurrence of prostate cancer","Radolinski B, Diner EK, Kwart AM.","Urology. 2006 Apr;67(4):844. doi: 10.1016/j.urology.2005.10.040. Epub 2006 Apr 5.","Radolinski B","Urology","2006","2006/04/08","","","10.1016/j.urology.2005.10.040"
"7930860","Early detection and treatment of prostate cancer","Bardot SF.","J La State Med Soc. 1994 Jul;146(7):313-6.","Bardot SF","J La State Med Soc","1994","1994/07/01","","",""
"19690549","Increased expression of class III beta-tubulin in castration-resistant human prostate cancer","Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissière-Michot F, Maillé P, Kheuang L, Coppolani E, Ali A, Bibeau F, Culine S, Buttyan R, de la Taille A, Vacherot F.","Br J Cancer. 2009 Sep 15;101(6):951-6. doi: 10.1038/sj.bjc.6605245. Epub 2009 Aug 18.","Terry S","Br J Cancer","2009","2009/08/20","PMC2743364","","10.1038/sj.bjc.6605245"
"15667873","Predictors of fatigue after treatment for prostate cancer","Maliski SL, Kwan L, Orecklin JR, Saigal CS, Litwin MS.","Urology. 2005 Jan;65(1):101-8. doi: 10.1016/j.urology.2004.08.031.","Maliski SL","Urology","2005","2005/01/26","","","10.1016/j.urology.2004.08.031"
"27834470","Intraprostatic chronic inflammation is associated with a reduced risk of prostate cancer in patients elected to a first random biopsy set","Porcaro AB, Novella G, de Luyk N, Corsi P, Cacciamani G, Sebben M, Tafuri A, Processali T, Cerasuolo M, Cerruto MA, Brunelli M, Siracusano S, Artibani W.","Tumori. 2017 Sep 18;103(5):475-482. doi: 10.5301/tj.5000573. Epub 2016 Nov 9.","Porcaro AB","Tumori","2017","2016/11/12","","","10.5301/tj.5000573"
"7516457","Prostate cancer screening","Ho RC.","J Surg Oncol. 1994 Jun;56(2):69-70. doi: 10.1002/jso.2930560203.","Ho RC","J Surg Oncol","1994","1994/06/01","","","10.1002/jso.2930560203"
"16801993","Atrasentan: a rationally designed targeted therapy for cancer","Jimeno A, Carducci M.","Drugs Today (Barc). 2006 May;42(5):299-312. doi: 10.1358/dot.2006.42.5.973590.","Jimeno A","Drugs Today (Barc)","2006","2006/06/28","","","10.1358/dot.2006.42.5.973590"
"16620698","cDNA macroarray for analysis of gene expression profiles in prostate cancer","Zhong WD, He HC, Bi XC, Ou RB, Jiang SA, Liu LS.","Chin Med J (Engl). 2006 Apr 5;119(7):570-3.","Zhong WD","Chin Med J (Engl)","2006","2006/04/20","","",""
"18885138","[Hormonal treatment of prostate cancer; report of 102 cases]","HRYNTSCHAK T.","Schweiz Med Wochenschr. 1948 Sep 11;78(36):874-6.","HRYNTSCHAK T","Schweiz Med Wochenschr","1948","1948/09/11","","",""
"27301047","Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy","Lee JY, Spratt DE, Liss AL, McLaughlin PW.","Lancet Oncol. 2016 May;17(5):e198-208. doi: 10.1016/S1470-2045(16)00063-2. Epub 2016 Apr 27.","Lee JY","Lancet Oncol","2016","2016/06/15","","","10.1016/S1470-2045(16)00063-2"
"29133934","Prostate cancer: Conserved lipid synthesis drives castration resistance","Fenner A.","Nat Rev Urol. 2018 Jan;15(1):4. doi: 10.1038/nrurol.2017.198. Epub 2017 Nov 14.","Fenner A","Nat Rev Urol","2018","2017/11/15","","","10.1038/nrurol.2017.198"
"28401954","Prostate cancer: Twist and Skp2 castration resistance","Fenner A.","Nat Rev Urol. 2017 Jul;14(7):387. doi: 10.1038/nrurol.2017.56. Epub 2017 Apr 11.","Fenner A","Nat Rev Urol","2017","2017/04/13","","","10.1038/nrurol.2017.56"
"17970003","Histology of specimens taken by prostatectomy and needle biopsy","Ngugi PM, Byakika B.","East Afr Med J. 2007 Aug;84(8):363-6. doi: 10.4314/eamj.v84i8.9542.","Ngugi PM","East Afr Med J","2007","2007/11/01","","","10.4314/eamj.v84i8.9542"
"26253870","CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer","Leclerc BG, Charlebois R, Chouinard G, Allard B, Pommey S, Saad F, Stagg J.","Clin Cancer Res. 2016 Jan 1;22(1):158-66. doi: 10.1158/1078-0432.CCR-15-1181. Epub 2015 Aug 7.","Leclerc BG","Clin Cancer Res","2016","2015/08/09","","","10.1158/1078-0432.CCR-15-1181"
"19720880","Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer","Zietman A.","J Clin Oncol. 2009 Oct 20;27(30):4935-6. doi: 10.1200/JCO.2009.24.4533. Epub 2009 Aug 31.","Zietman A","J Clin Oncol","2009","2009/09/02","","","10.1200/JCO.2009.24.4533"
"15714968","[Molecular analysis for prostate cancer]","Ueda T, Suzuki H, Ichikawa T.","Nihon Rinsho. 2005 Feb;63(2):213-7.","Ueda T","Nihon Rinsho","2005","2005/02/18","","",""
"22928973","Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer","Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasarainen H, Bangma CH, Schröder FH, Roobol MJ.","BJU Int. 2012 Dec;110(11):1672-7. doi: 10.1111/j.1464-410X.2012.11434.x. Epub 2012 Aug 29.","Bul M","BJU Int","2012","2012/08/30","","","10.1111/j.1464-410X.2012.11434.x"
"28385075","Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data","Tay KJ, Polascik TJ, Elshafei A, Tsivian E, Jones JS.","J Endourol. 2017 Jun;31(6):564-571. doi: 10.1089/end.2016.0830.","Tay KJ","J Endourol","2017","2017/04/08","","","10.1089/end.2016.0830"
"25845283","Risk of prostate cancer mortality in men with a history of prior cancer","Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Orio PF, Sweeney CJ, Trinh QD, Nguyen PL.","BJU Int. 2016 Jun;117(6B):E20-8. doi: 10.1111/bju.13144. Epub 2015 May 23.","Dinh KT","BJU Int","2016","2015/04/08","","","10.1111/bju.13144"
"15667646","Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?","Gosselaar C, Roobol MJ, Schröder FH.","BJU Int. 2005 Feb;95(2):231-7. doi: 10.1111/j.1464-410X.2005.05324.x.","Gosselaar C","BJU Int","2005","2005/01/26","","","10.1111/j.1464-410X.2005.05324.x"
"22399364","Local staging of prostate cancer with MRI","Soylu FN, Eggener S, Oto A.","Diagn Interv Radiol. 2012 Jul-Aug;18(4):365-73. doi: 10.4261/1305-3825.DIR.4970-11.2. Epub 2012 Mar 8.","Soylu FN","Diagn Interv Radiol","2012","2012/03/09","","","10.4261/1305-3825.DIR.4970-11.2"
"25951372","Targeted Therapies for Prostate Cancer","Petrioli R, Francini E, Fiaschi AI, Laera L, Roviello G.","Cancer Invest. 2015;33(7):276-85. doi: 10.3109/07357907.2015.1033105. Epub 2015 May 7.","Petrioli R","Cancer Invest","2015","2015/05/08","","","10.3109/07357907.2015.1033105"
"17294287","Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer","Sullivan PW, Mulani PM, Fishman M, Sleep D.","Qual Life Res. 2007 May;16(4):571-5. doi: 10.1007/s11136-006-9156-2. Epub 2007 Feb 10.","Sullivan PW","Qual Life Res","2007","2007/02/13","","","10.1007/s11136-006-9156-2"
"11588837","Does physical activity play a role in the prevention of prostate cancer?","Lee IM, Sesso HD, Chen JJ, Paffenbarger RS Jr.","Epidemiol Rev. 2001;23(1):132-7. doi: 10.1093/oxfordjournals.epirev.a000778.","Lee IM","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000778"
"6168010","Prostate cancer. Epidemiology","Alderson MR.","Recent Results Cancer Res. 1981;78:1-19.","Alderson MR","Recent Results Cancer Res","1981","1981/01/01","","",""
"25323614","In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis","Suzman DL, Antonarakis ES.","Oncology (Williston Park). 2014 Oct;28(10):880, 882.","Suzman DL","Oncology (Williston Park)","2014","2014/10/18","","",""
"22198629","The importance of combined radiation and endocrine therapy in locally advanced prostate cancer","Gray PJ, Shipley WU.","Asian J Androl. 2012 Mar;14(2):245-6. doi: 10.1038/aja.2011.177. Epub 2011 Dec 26.","Gray PJ","Asian J Androl","2012","2011/12/27","PMC3735089","","10.1038/aja.2011.177"
"20201840","Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology?","Tollefson M, Magera J, Sebo T, Cohen J, Drauch A, Maier J, Frank I.","BJU Int. 2010 Aug;106(4):484-8. doi: 10.1111/j.1464-410X.2010.09185.x. Epub 2010 Mar 1.","Tollefson M","BJU Int","2010","2010/03/06","","","10.1111/j.1464-410X.2010.09185.x"
"8627848","Prostate cancer--our patients' questions","Theodorescu D.","J Urol. 1996 May;155(5):1661-2. doi: 10.1016/s0022-5347(01)66157-3.","Theodorescu D","J Urol","1996","1996/05/01","","","10.1016/s0022-5347(01)66157-3"
"12088206","KAI1/CD82 protein expression in primary prostate cancer and in BPH associated with cancer","Lijovic M, Somers G, Frauman AG.","Cancer Detect Prev. 2002;26(1):69-77. doi: 10.1016/s0361-090x(02)00012-0.","Lijovic M","Cancer Detect Prev","2002","2002/06/29","","","10.1016/s0361-090x(02)00012-0"
"29420986","Future Perspectives and Challenges of Prostate MR Imaging","Turkbey B, Choyke PL.","Radiol Clin North Am. 2018 Mar;56(2):327-337. doi: 10.1016/j.rcl.2017.10.013. Epub 2017 Dec 9.","Turkbey B","Radiol Clin North Am","2018","2018/02/09","PMC5808592","NIHMS926518","10.1016/j.rcl.2017.10.013"
"29758220","Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years","Goldberg H, Klaassen Z, Chandrasekar T, Wallis CJD, Toi A, Sayyid R, Bhindi B, Nesbitt M, Evans A, van der Kwast T, Sweet J, Perlis N, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta A, Fleshner N.","J Urol. 2018 Nov;200(5):1056-1061. doi: 10.1016/j.juro.2018.05.017. Epub 2018 Jul 27.","Goldberg H","J Urol","2018","2018/05/15","","","10.1016/j.juro.2018.05.017"
"8311493","[Ifosfamide in combined hormonochemotherapy on prostate cancer]","Fujita K, Matsushima H, Nakano M, Kaneko T.","Gan To Kagaku Ryoho. 1994 Feb;21(2):227-30.","Fujita K","Gan To Kagaku Ryoho","1994","1994/02/01","","",""
"10325514","PIN I-III: when should we interfere?","Newling D.","Eur Urol. 1999;35(5-6):504-7. doi: 10.1159/000019888.","Newling D","Eur Urol","1999","1999/05/15","","","10.1159/000019888"
"24771515","Concept and viability of androgen annihilation for advanced prostate cancer","Mohler JL.","Cancer. 2014 Sep 1;120(17):2628-37. doi: 10.1002/cncr.28675. Epub 2014 Apr 25.","Mohler JL","Cancer","2014","2014/04/29","PMC4140964","NIHMS602755","10.1002/cncr.28675"
"10910155","Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer","Stone NN, Stock RG, Unger P, Kao J.","J Endourol. 2000 May;14(4):375-80. doi: 10.1089/end.2000.14.375.","Stone NN","J Endourol","2000","2000/07/26","","","10.1089/end.2000.14.375"
"24180365","Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project","Muller BG, van den Bos W, Brausi M, Cornud F, Gontero P, Kirkham A, Pinto PA, Polascik TJ, Rastinehad AR, de Reijke TM, de la Rosette JJ, Ukimura O, Villers A, Walz J, Wijkstra H, Marberger M.","BJU Int. 2014 Nov;114(5):698-707. doi: 10.1111/bju.12548. Epub 2014 Aug 16.","Muller BG","BJU Int","2014","2013/11/05","","","10.1111/bju.12548"
"17569266","[Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy]","Qi SY, Wang M, Xu Y.","Zhonghua Nan Ke Xue. 2007 May;13(5):453-6.","Qi SY","Zhonghua Nan Ke Xue","2007","2007/06/16","","",""
"12856636","Treatment decision-making by men with localized prostate cancer: the influence of personal factors","Berry DL, Ellis WJ, Woods NF, Schwien C, Mullen KH, Yang C.","Urol Oncol. 2003 Mar-Apr;21(2):93-100. doi: 10.1016/s1078-1439(02)00209-0.","Berry DL","Urol Oncol","2003","2003/07/15","","","10.1016/s1078-1439(02)00209-0"
"6652446","Incidental carcinoma of the prostate: selection for deferred treatment","Beynon LL, Busuttil A, Newsam JE, Chisholm GD.","Br J Urol. 1983 Dec;55(6):733-6. doi: 10.1111/j.1464-410x.1983.tb03415.x.","Beynon LL","Br J Urol","1983","1983/12/01","","","10.1111/j.1464-410x.1983.tb03415.x"
"25903803","Current trends and new frontiers in focal therapy for localized prostate cancer","Mendez MH, Joh DY, Gupta R, Polascik TJ.","Curr Urol Rep. 2015 Jun;16(6):35. doi: 10.1007/s11934-015-0513-y.","Mendez MH","Curr Urol Rep","2015","2015/04/24","","","10.1007/s11934-015-0513-y"
"9299582","Prostate cancer; the interface between pathology and basic scientific research","Lalani EN, Stubbs A, Stamp GW.","Semin Cancer Biol. 1997 Feb;8(1):53-9. doi: 10.1006/scbi.1997.0052.","Lalani EN","Semin Cancer Biol","1997","1997/02/01","","","10.1006/scbi.1997.0052"
"25134328","The role of radical prostatectomy and lymph node dissection in the treatment of young men with high-grade node-positive prostate cancer: there may be no RCTs-but there are good reasons to include surgery","Kim SP, Smaldone MC.","Oncology (Williston Park). 2014 Jun;28(6):522, 524.","Kim SP","Oncology (Williston Park)","2014","2014/08/20","","",""
"12796685","Re: Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection","Yuen JS.","J Urol. 2003 Jul;170(1):192-3; author reply 193. doi: 10.1097/01.ju.0000069563.16034.d7.","Yuen JS","J Urol","2003","2003/06/11","","","10.1097/01.ju.0000069563.16034.d7"
"16515992","Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population","Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schröder FH.","J Urol. 2006 Apr;175(4):1332-6. doi: 10.1016/S0022-5347(05)00698-1.","Roemeling S","J Urol","2006","2006/03/07","","","10.1016/S0022-5347(05)00698-1"
"21798741","Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells","Hubbard SC, Boyce M, McVaugh CT, Peehl DM, Bertozzi CR.","Bioorg Med Chem Lett. 2011 Sep 1;21(17):4945-50. doi: 10.1016/j.bmcl.2011.05.045. Epub 2011 May 18.","Hubbard SC","Bioorg Med Chem Lett","2011","2011/07/30","PMC3341932","NIHMS372321","10.1016/j.bmcl.2011.05.045"
"28634991","Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment","Lehto US, Aromaa A, Tammela TL.","Eur J Cancer Care (Engl). 2018 Jan;27(1). doi: 10.1111/ecc.12729. Epub 2017 Jun 21.","Lehto US","Eur J Cancer Care (Engl)","2018","2017/06/22","","","10.1111/ecc.12729"
"14575819","Commentary on a multi-institutional analysis of external beam radiotherapy for T1-T2 prostate cancer: ""love the one you're with"" and ""do the right thing""","Roach M 3rd.","Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):907-9. doi: 10.1016/s0360-3016(03)01619-5.","Roach M 3rd","Int J Radiat Oncol Biol Phys","2003","2003/10/25","","","10.1016/s0360-3016(03)01619-5"
"19776642","Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer","Reese AC, Fradet V, Witte JS.","J Nutrigenet Nutrigenomics. 2009;2(3):149-58. doi: 10.1159/000235565. Epub 2009 Sep 23.","Reese AC","J Nutrigenet Nutrigenomics","2009","2009/09/25","PMC2820568","","10.1159/000235565"
"15669588","Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial","Sennfält K, Sandblom G, Carlsson P, Varenhorst E.","Scand J Urol Nephrol. 2004;38(4):291-8. doi: 10.1080/00365590410028890.","Sennfält K","Scand J Urol Nephrol","2004","2005/01/27","","","10.1080/00365590410028890"
"27185342","Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy","Chen R, Xie L, Xue W, Ye Z, Ma L, Gao X, Ren S, Wang F, Zhao L, Xu C, Sun Y; Chinese Prostate Cancer Consortium.","Urol Oncol. 2016 Sep;34(9):416.e1-7. doi: 10.1016/j.urolonc.2016.04.004. Epub 2016 May 12.","Chen R","Urol Oncol","2016","2016/05/18","","","10.1016/j.urolonc.2016.04.004"
"26153794","PSMA expression is highly homogenous in primary prostate cancer","Tsourlakis MC, Klein F, Kluth M, Quaas A, Graefen M, Haese A, Simon R, Sauter G, Schlomm T, Minner S.","Appl Immunohistochem Mol Morphol. 2015 Jul;23(6):449-55. doi: 10.1097/PAI.0000000000000110.","Tsourlakis MC","Appl Immunohistochem Mol Morphol","2015","2015/07/09","","","10.1097/PAI.0000000000000110"
"31403941","miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5","Zheng C, Guo K, Chen B, Wen Y, Xu Y.","Cancer Biomark. 2019;26(2):193-202. doi: 10.3233/CBM-190128.","Zheng C","Cancer Biomark","2019","2019/08/13","","","10.3233/CBM-190128"
"15466216","Symposium on androgen action in prostate cancer","Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P.","Cancer Res. 2004 Oct 1;64(19):7178-80. doi: 10.1158/0008-5472.CAN-04-1752.","Tindall D","Cancer Res","2004","2004/10/07","","","10.1158/0008-5472.CAN-04-1752"
"14668987","[New insights into the role of estogens and their receptors in prostate cancer]","Bonkhoff H, Motherby H, Fixemer T.","Urologe A. 2003 Dec;42(12):1594-601. doi: 10.1007/s00120-003-0438-9.","Bonkhoff H","Urologe A","2003","2003/12/12","","","10.1007/s00120-003-0438-9"
"30924454","Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer","Yano A, Kagawa M, Takeshita H, Okada Y, Morozumi M, Kawakami S.","Asian J Androl. 2019 Nov-Dec;21(6):635-636. doi: 10.4103/aja.aja_9_19.","Yano A","Asian J Androl","2019","2019/03/30","PMC6859667","","10.4103/aja.aja_9_19"
"29373089","Multiparametric MR Imaging of the Prostate after Treatment of Prostate Cancer","Patel P, Mathew MS, Trilisky I, Oto A.","Radiographics. 2018 Mar-Apr;38(2):437-449. doi: 10.1148/rg.2018170147. Epub 2018 Jan 26.","Patel P","Radiographics","2018","2018/01/27","","","10.1148/rg.2018170147"
"23259430","Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint","Birtle A.","Expert Rev Anticancer Ther. 2013 Jan;13(1):89-99. doi: 10.1586/era.12.160.","Birtle A","Expert Rev Anticancer Ther","2013","2012/12/25","","","10.1586/era.12.160"
"9074903","The antiandrogen withdrawal syndrome in relapsed prostate cancer","Scher HI, Kolvenbag GJ.","Eur Urol. 1997;31 Suppl 2:3-7; discussion 24-7. doi: 10.1159/000474540.","Scher HI","Eur Urol","1997","1997/01/01","","","10.1159/000474540"
"10408307","Influence of preoperative vesicle biopsy on the decision for radical prostatectomy","Deliveliotis CH, Varkarakis J, Trakas N, Louras G, Giannakopoulos S, Skolarikos A, Alargof E.","Int Urol Nephrol. 1999;31(1):83-7. doi: 10.1023/a:1007128008153.","Deliveliotis CH","Int Urol Nephrol","1999","1999/07/17","","","10.1023/a:1007128008153"
"25236176","Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies","Kim W, Ryan CJ.","Cancer. 2015 Feb 1;121(3):361-71. doi: 10.1002/cncr.28929. Epub 2014 Sep 18.","Kim W","Cancer","2015","2014/09/20","","","10.1002/cncr.28929"
"27337755","The role of PSA in detection and management of prostate cancer","Kirby R.","Practitioner. 2016 Apr;260(1792):17-21, 3.","Kirby R","Practitioner","2016","2016/06/25","","",""
"15903037","[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]","van der Kwast TH, Hoedemaeker RF, Schröder FH.","Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):972-6.","van der Kwast TH","Ned Tijdschr Geneeskd","2005","2005/05/21","","",""
"30685078","Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer","Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.","Eur Urol. 2019 Jul;76(1):18-23. doi: 10.1016/j.eururo.2018.12.036. Epub 2019 Jan 24.","Houlahan KE","Eur Urol","2019","2019/01/28","","","10.1016/j.eururo.2018.12.036"
"11588848","Familial prostate cancer","Stanford JL, Ostrander EA.","Epidemiol Rev. 2001;23(1):19-23. doi: 10.1093/oxfordjournals.epirev.a000789.","Stanford JL","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000789"
"11828353","Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer","Wilt TJ.","Semin Urol Oncol. 2002 Feb;20(1):10-7. doi: 10.1053/suro.2002.30393.","Wilt TJ","Semin Urol Oncol","2002","2002/02/06","","","10.1053/suro.2002.30393"
"16619528","Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells","Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW.","Anticancer Res. 2006 Mar-Apr;26(2A):1225-30.","Beklemisheva AA","Anticancer Res","2006","2006/04/20","","",""
"24713836","Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer","Albany C, Hahn NM.","Asian J Androl. 2014 May-Jun;16(3):359-63. doi: 10.4103/1008-682X.126400.","Albany C","Asian J Androl","2014","2014/04/10","PMC4023360","","10.4103/1008-682X.126400"
"8813999","Do the worst histological elements in needle biopsy specimens of prostate cancer predict prognosis?","Kubota Y, Kondo I, Harada M, Noguchi S, Hosaka M.","Lancet. 1996 Sep 21;348(9030):822-3. doi: 10.1016/S0140-6736(05)65238-5.","Kubota Y","Lancet","1996","1996/09/21","","","10.1016/S0140-6736(05)65238-5"
"15504921","Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000","McNaughton-Collins M, Walker-Corkery E, Barry MJ.","J Natl Cancer Inst Monogr. 2004;(33):78-101. doi: 10.1093/jncimonographs/lgh016.","McNaughton-Collins M","J Natl Cancer Inst Monogr","2004","2004/10/27","","","10.1093/jncimonographs/lgh016"
"25983084","An Iterative Process for Developing and Evaluating a Computer-Based Prostate Cancer Decision Aid for African American Men","Owens OL, Friedman DB, Brandt HM, Bernhardt JM, Hébert JR.","Health Promot Pract. 2015 Sep;16(5):642-55. doi: 10.1177/1524839915585737. Epub 2015 May 16.","Owens OL","Health Promot Pract","2015","2015/05/19","","","10.1177/1524839915585737"
"10893598","Histopathological prostate cancer characteristics at radical prostatectomy after population based screening","Hoedemaeker RF, Rietbergen JB, Kranse R, Schröder FH, van der Kwast TH.","J Urol. 2000 Aug;164(2):411-5.","Hoedemaeker RF","J Urol","2000","2000/07/14","","",""
"19645029","Age-specific physical activity and prostate cancer risk among white men and black men","Moore SC, Peters TM, Ahn J, Park Y, Schatzkin A, Albanes D, Hollenbeck A, Leitzmann MF.","Cancer. 2009 Nov 1;115(21):5060-70. doi: 10.1002/cncr.24538.","Moore SC","Cancer","2009","2009/08/01","PMC2767425","NIHMS123727","10.1002/cncr.24538"
"27453073","Unfoldomics of prostate cancer: on the abundance and roles of intrinsically disordered proteins in prostate cancer","Landau KS, Na I, Schenck RO, Uversky VN.","Asian J Androl. 2016 Sep-Oct;18(5):662-72. doi: 10.4103/1008-682X.184999.","Landau KS","Asian J Androl","2016","2016/07/26","PMC5000786","","10.4103/1008-682X.184999"
"22489209","Magnetic resonance image-guided biopsies with a high detection rate of prostate cancer","Engehausen DG, Engelhard K, Schwab SA, Uder M, Wach S, Wullich B, Krause FS.","ScientificWorldJournal. 2012;2012:975971. doi: 10.1100/2012/975971. Epub 2012 Mar 12.","Engehausen DG","ScientificWorldJournal","2012","2012/04/11","PMC3317570","","10.1100/2012/975971"
"12431818","Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches","van Moorselaar RJ, Voest EE.","Mol Cell Endocrinol. 2002 Nov 29;197(1-2):239-50. doi: 10.1016/s0303-7207(02)00262-9.","van Moorselaar RJ","Mol Cell Endocrinol","2002","2002/11/15","","","10.1016/s0303-7207(02)00262-9"
"18403097","Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values","Chun FK, Briganti A.","Eur Urol. 2008 Sep;54(3):702. doi: 10.1016/j.eururo.2008.03.084. Epub 2008 Apr 3.","Chun FK","Eur Urol","2008","2008/04/12","","","10.1016/j.eururo.2008.03.084"
"18221313","Melatonin as an adjuvant to therapeutic prostate cancer vaccines","Connor TP.","J Pineal Res. 2008 Sep;45(2):224. doi: 10.1111/j.1600-079X.2008.00563.x. Epub 2008 Jan 21.","Connor TP","J Pineal Res","2008","2008/01/29","","","10.1111/j.1600-079X.2008.00563.x"
"27779102","The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance","Al Fayi MS, Gou X, Forootan SS, Al-Jameel W, Bao Z, Rudland PR, Cornford PA, Hussain SA, Ke Y.","Oncotarget. 2016 Dec 13;7(50):82783-82797. doi: 10.18632/oncotarget.12635.","Al Fayi MS","Oncotarget","2016","2016/10/26","PMC5347732","","10.18632/oncotarget.12635"
"26851518","Generalized Lymphadenopathy of Prostate Adenocarcinoma Origin. A Case Series","Karatzas AD, Zachos I, Mitrakas L, Dimitropoulos K, Samarinas M, Gravas S, Oeconomou A, Tzortzis V.","Urology. 2016 May;91:e3-4. doi: 10.1016/j.urology.2016.01.026. Epub 2016 Feb 3.","Karatzas AD","Urology","2016","2016/02/07","","","10.1016/j.urology.2016.01.026"
"29799991","Reliably Quantifying Bone Metastases in Prostate Cancer-Are We Finally There?","Saad F.","JAMA Oncol. 2018 Jul 1;4(7):951-952. doi: 10.1001/jamaoncol.2018.1069.","Saad F","JAMA Oncol","2018","2018/05/26","","","10.1001/jamaoncol.2018.1069"
"28765045","Androgen-responsive circular RNA circSMARCA5 is up-regulated and promotes cell proliferation in prostate cancer","Kong Z, Wan X, Zhang Y, Zhang P, Zhang Y, Zhang X, Qi X, Wu H, Huang J, Li Y.","Biochem Biophys Res Commun. 2017 Nov 25;493(3):1217-1223. doi: 10.1016/j.bbrc.2017.07.162. Epub 2017 Jul 29.","Kong Z","Biochem Biophys Res Commun","2017","2017/08/03","","","10.1016/j.bbrc.2017.07.162"
"26135141","HOXA1 enhances the cell proliferation, invasion and metastasis of prostate cancer cells","Wang H, Liu G, Shen D, Ye H, Huang J, Jiao L, Sun Y.","Oncol Rep. 2015 Sep;34(3):1203-10. doi: 10.3892/or.2015.4085. Epub 2015 Jun 26.","Wang H","Oncol Rep","2015","2015/07/03","","","10.3892/or.2015.4085"
"7621453","An epidemiologist's viewpoint on screening","Parkes CA.","Cancer Surv. 1995;23:127-40.","Parkes CA","Cancer Surv","1995","1995/01/01","","",""
"28903742","Can you un-ring the bell? A qualitative study of how affect influences cancer screening decisions","Driedger SM, Annable G, Brouwers M, Turner D, Maier R.","BMC Cancer. 2017 Sep 13;17(1):647. doi: 10.1186/s12885-017-3596-7.","Driedger SM","BMC Cancer","2017","2017/09/15","PMC5598010","","10.1186/s12885-017-3596-7"
"15963122","The relationship between angiogenesis and cyclooxygenase-2 expression in prostate cancer","Mukherjee R, Edwards J, Underwood MA, Bartlett JM.","BJU Int. 2005 Jul;96(1):62-6. doi: 10.1111/j.1464-410X.2005.05568.x.","Mukherjee R","BJU Int","2005","2005/06/21","","","10.1111/j.1464-410X.2005.05568.x"
"22611765","Prostate cancer gene 3 urine assay cutoff in diagnosis of prostate cancer: a validation study on an Italian patient population undergoing first and repeat biopsy","Bollito E, De Luca S, Cicilano M, Passera R, Grande S, Maccagnano C, Cappia S, Milillo A, Montorsi F, Scarpa RM, Papotti M, Randone DF.","Anal Quant Cytol Histol. 2012 Apr;34(2):96-104.","Bollito E","Anal Quant Cytol Histol","2012","2012/05/23","","",""
"25259804","Molecular insights into the development of T cell-based immunotherapy for prostate cancer","Dong B, Minze LJ, Xue W, Chen W.","Expert Rev Clin Immunol. 2014 Nov;10(11):1547-57. doi: 10.1586/1744666X.2014.962515. Epub 2014 Sep 26.","Dong B","Expert Rev Clin Immunol","2014","2014/09/27","","","10.1586/1744666X.2014.962515"
"1895420","The risk of dying of prostate cancer in patients with clinically localized disease","Lerner SP, Seale-Hawkins C, Carlton CE Jr, Scardino PT.","J Urol. 1991 Oct;146(4):1040-5. doi: 10.1016/s0022-5347(17)37997-1.","Lerner SP","J Urol","1991","1991/10/11","","","10.1016/s0022-5347(17)37997-1"
"17510379","The 3rd Pacific Rim meeting on breast and prostate cancer: progress in hormonal carcinogenesis and the enduring influence of Ron Ross","Reichardt JK, Tilley WD.","Cancer Res. 2007 May 15;67(10):4550-2. doi: 10.1158/0008-5472.CAN-07-0280.","Reichardt JK","Cancer Res","2007","2007/05/19","","","10.1158/0008-5472.CAN-07-0280"
"19703300","Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment","Pinkawa M, Fischedick K, Gagel B, Piroth MD, Asadpour B, Klotz J, Borchers H, Jakse G, Eble MJ.","BMC Cancer. 2009 Aug 24;9:296. doi: 10.1186/1471-2407-9-296.","Pinkawa M","BMC Cancer","2009","2009/08/26","PMC2739535","","10.1186/1471-2407-9-296"
"9703367","Decision analysis for treatment of early stage prostate cancer","Yoshimura N, Takami N, Ogawa O, Kakehi Y, Okada Y, Fukui T, Yoshida O.","Jpn J Cancer Res. 1998 Jun;89(6):681-9. doi: 10.1111/j.1349-7006.1998.tb03271.x.","Yoshimura N","Jpn J Cancer Res","1998","1998/08/14","PMC5921872","","10.1111/j.1349-7006.1998.tb03271.x"
"31323811","Single-Nucleotide Polymorphisms Sequencing Identifies Candidate Functional Variants at Prostate Cancer Risk Loci","Zhang P, Tillmans LS, Thibodeau SN, Wang L.","Genes (Basel). 2019 Jul 18;10(7):547. doi: 10.3390/genes10070547.","Zhang P","Genes (Basel)","2019","2019/07/21","PMC6678189","","10.3390/genes10070547"
"15479293","Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2","Chatterjee S, Park ES, Soloff MS.","Int J Urol. 2004 Oct;11(10):876-84. doi: 10.1111/j.1442-2042.2004.00898.x.","Chatterjee S","Int J Urol","2004","2004/10/14","","","10.1111/j.1442-2042.2004.00898.x"
"10639188","Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia","Filella X, Alcover J, Molina R, Corral JM, Carretero P, Ballesta AM.","Prostate. 2000 Feb 15;42(3):181-5. doi: 10.1002/(sici)1097-0045(20000215)42:3<181::aid-pros3>3.0.co;2-m.","Filella X","Prostate","2000","2000/01/19","","","10.1002/(sici)1097-0045(20000215)42:3<181::aid-pros3>3.0.co;2-m"
"17119028","A meta-analysis of diabetes mellitus and the risk of prostate cancer","Kasper JS, Giovannucci E.","Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2056-62. doi: 10.1158/1055-9965.EPI-06-0410.","Kasper JS","Cancer Epidemiol Biomarkers Prev","2006","2006/11/23","","","10.1158/1055-9965.EPI-06-0410"
"16469580","Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy","Spurgeon SE, Hsieh YC, Rivadinera A, Beer TM, Mori M, Garzotto M.","J Urol. 2006 Mar;175(3 Pt 1):918-22. doi: 10.1016/S0022-5347(05)00353-8.","Spurgeon SE","J Urol","2006","2006/02/14","","","10.1016/S0022-5347(05)00353-8"
"24611795","Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories","Ohmann EL, Loeb S, Robinson D, Bill-Axelson A, Berglund A, Stattin P.","Scand J Urol. 2014 Oct;48(5):426-35. doi: 10.3109/21681805.2014.892150. Epub 2014 Mar 11.","Ohmann EL","Scand J Urol","2014","2014/03/12","","","10.3109/21681805.2014.892150"
"27986208","Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning","Moghanaki D, Turkbey B, Vapiwala N, Ehdaie B, Frank SJ, McLaughlin PW, Harisinghani M.","Semin Radiat Oncol. 2017 Jan;27(1):21-33. doi: 10.1016/j.semradonc.2016.08.008. Epub 2016 Aug 31.","Moghanaki D","Semin Radiat Oncol","2017","2016/12/18","PMC5743235","NIHMS901834","10.1016/j.semradonc.2016.08.008"
"11225000","Chemoprevention in prostate cancer","Nabhan C, Bergan R.","Cancer Treat Res. 2001;106:103-36. doi: 10.1007/978-1-4615-1657-6_5.","Nabhan C","Cancer Treat Res","2001","2001/02/28","","","10.1007/978-1-4615-1657-6_5"
"17157630","Imaging of prostate cancer","Akin O, Hricak H.","Radiol Clin North Am. 2007 Jan;45(1):207-22. doi: 10.1016/j.rcl.2006.10.008.","Akin O","Radiol Clin North Am","2007","2006/12/13","","","10.1016/j.rcl.2006.10.008"
"31868968","Automated approach for estimation of grade groups for prostate cancer based on histological image feature analysis","Hossain A, Arimura H, Kinoshita F, Ninomiya K, Watanabe S, Imada K, Koyanagi R, Oda Y.","Prostate. 2020 Feb;80(3):291-302. doi: 10.1002/pros.23943. Epub 2019 Dec 23.","Hossain A","Prostate","2020","2019/12/24","","","10.1002/pros.23943"
"15997913","Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study","Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M; National Cancer Institute of Canada Clinical Trials Group PR3/; Medical Research Council PR07 Trial Management Group.","Clin Oncol (R Coll Radiol). 2005 Jun;17(4):217-8. doi: 10.1016/j.clon.2005.02.013.","Mason M","Clin Oncol (R Coll Radiol)","2005","2005/07/07","","","10.1016/j.clon.2005.02.013"
"18485398","Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice","Dong F, Kattan MW, Steyerberg EW, Jones JS, Stephenson AJ, Schröder FH, Klein EA.","J Urol. 2008 Jul;180(1):150-4; discussion 154. doi: 10.1016/j.juro.2008.03.053. Epub 2008 May 15.","Dong F","J Urol","2008","2008/05/20","","","10.1016/j.juro.2008.03.053"
"17616657","Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response","Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, Warde P, Catton C, Menard C, Bayley A, Gospodarowicz M, Hill R.","Cancer Res. 2007 Jul 1;67(13):6022-5. doi: 10.1158/0008-5472.CAN-07-0561.","Milosevic M","Cancer Res","2007","2007/07/10","","","10.1158/0008-5472.CAN-07-0561"
"12543792","Antitumor activity of the 16-kDa prolactin fragment in prostate cancer","Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH.","Cancer Res. 2003 Jan 15;63(2):386-93.","Kim J","Cancer Res","2003","2003/01/25","","",""
"16929600","Cancer detection with TRUS-guided 10-core biopsy of the prostate. an institutional assessment at the first, repeated and surgical specimen biopsy","Campodonico F, Casarico A, Gavazzi L, Calcagno T, Capponi G, Canepa G, Bandelloni R, Maffezzini M.","Arch Ital Urol Androl. 2006 Jun;78(2):39-43.","Campodonico F","Arch Ital Urol Androl","2006","2006/08/26","","",""
"24337790","MRI-compatible positioning device for guiding a focused ultrasound system for transrectal treatment of prostate cancer","Yiallouras C, Mylonas N, Damianou C.","Int J Comput Assist Radiol Surg. 2014 Jul;9(4):745-53. doi: 10.1007/s11548-013-0964-x. Epub 2013 Dec 13.","Yiallouras C","Int J Comput Assist Radiol Surg","2014","2013/12/17","","","10.1007/s11548-013-0964-x"
"21601352","Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up","Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.","Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.","Zhu X","Eur Urol","2011","2011/05/24","","","10.1016/j.eururo.2011.05.013"
"10420032","Tissue prostate-specific antigen and androgen receptor immunoreactivity in prostate cancer biopsies before, during and after neo-adjuvant androgen deprivation followed by radiotherapy","Ogreid P, Berner A, Dahl O, Rettedal E, Fosså SD.","Eur Urol. 1999 Aug;36(2):116-22. doi: 10.1159/000067982.","Ogreid P","Eur Urol","1999","1999/07/27","","","10.1159/000067982"
"17224778","Trends in treatment costs for localized prostate cancer: the healthy screenee effect","Zeliadt SB, Etzioni R, Ramsey SD, Penson DF, Potosky AL.","Med Care. 2007 Feb;45(2):154-9. doi: 10.1097/01.mlr.0000241044.09778.3f.","Zeliadt SB","Med Care","2007","2007/01/17","","","10.1097/01.mlr.0000241044.09778.3f"
"23459624","Validation and clinical utility of prostate cancer biomarkers","Scher HI, Morris MJ, Larson S, Heller G.","Nat Rev Clin Oncol. 2013 Apr;10(4):225-34. doi: 10.1038/nrclinonc.2013.30. Epub 2013 Mar 5.","Scher HI","Nat Rev Clin Oncol","2013","2013/03/06","PMC3790270","NIHMS515843","10.1038/nrclinonc.2013.30"
"10741282","Familial prostate cancer from the family-cancer database","Hemminki K, Dong C.","Eur J Cancer. 2000 Jan;36(2):229-34. doi: 10.1016/s0959-8049(99)00263-4.","Hemminki K","Eur J Cancer","2000","2000/03/31","","","10.1016/s0959-8049(99)00263-4"
"9454284","[Adjuvant treatment after radical prostatectomy in prostatic carcinoma (pT3 or pTxN+): prognostic factors and results]","Zincke H.","Praxis (Bern 1994). 1997 Nov 12;86(46):1825-32.","Zincke H","Praxis (Bern 1994)","1997","1998/02/07","","",""
"10974062","Apoptosis: translating theory to therapy for prostate cancer","Isaacs JT.","J Natl Cancer Inst. 2000 Sep 6;92(17):1367-9. doi: 10.1093/jnci/92.17.1367.","Isaacs JT","J Natl Cancer Inst","2000","2000/09/07","","","10.1093/jnci/92.17.1367"
"15242249","Monoclonal antibodies and prostate-specific membrane antigen","Chang SS.","Curr Opin Investig Drugs. 2004 Jun;5(6):611-5.","Chang SS","Curr Opin Investig Drugs","2004","2004/07/10","","",""
"23076866","Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images?","Hwang I, Chong A, Jung SI, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K, Ryu SB.","Ann Nucl Med. 2013 Feb;27(2):140-5. doi: 10.1007/s12149-012-0663-7. Epub 2012 Oct 18.","Hwang I","Ann Nucl Med","2013","2012/10/19","","","10.1007/s12149-012-0663-7"
"25213701","Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients","Michopoulou V, Derdas SP, Symvoulakis E, Mourmouras N, Nomikos A, Delakas D, Sourvinos G, Spandidos DA.","Tumour Biol. 2014 Dec;35(12):12765-73. doi: 10.1007/s13277-014-2604-7. Epub 2014 Sep 12.","Michopoulou V","Tumour Biol","2014","2014/09/13","","","10.1007/s13277-014-2604-7"
"10379966","Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality","Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF.","J Natl Cancer Inst. 1999 Jun 16;91(12):1033-9. doi: 10.1093/jnci/91.12.1033.","Etzioni R","J Natl Cancer Inst","1999","1999/06/24","","","10.1093/jnci/91.12.1033"
"5616123","[Cancer of the prostate. Anatomy, diagnosis, therapy]","Bibus B.","Folia Clin Int (Barc). 1967 Sep;17(9):434-44.","Bibus B","Folia Clin Int (Barc)","1967","1967/09/01","","",""
"31474764","Signal transducer and activator of transcription-3 drives the high-fat diet-associated prostate cancer growth","Kwan HY, Liu B, Huang C, Fatima S, Su T, Zhao X, Ho AHM, Han Q, Hu X, Gong RH, Chen M, Wong HLX, Bian Z.","Cell Death Dis. 2019 Sep 2;10(9):637. doi: 10.1038/s41419-019-1842-4.","Kwan HY","Cell Death Dis","2019","2019/09/03","PMC6717738","","10.1038/s41419-019-1842-4"
"10411051","The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience","Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR.","J Urol. 1999 Aug;162(2):427-32.","Koppie TM","J Urol","1999","1999/07/20","","",""
"9436031","[Clinical application for gene therapy in prostate cancer]","Gotoh A, Kamidono S, Chung LW.","Hinyokika Kiyo. 1997 Nov;43(11):829-33.","Gotoh A","Hinyokika Kiyo","1997","1998/01/22","","",""
"12180237","Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization","Wolter H, Trijic D, Gottfried HW, Mattfeldt T.","Eur Urol. 2002 Mar;41(3):328-34. doi: 10.1016/s0302-2838(02)00035-0.","Wolter H","Eur Urol","2002","2002/08/16","","","10.1016/s0302-2838(02)00035-0"
"9828467","Combating prostate cancer","Garnick MB, Fair WR.","Sci Am. 1998 Dec;279(6):74-83. doi: 10.1038/scientificamerican1298-74.","Garnick MB","Sci Am","1998","1998/11/26","","","10.1038/scientificamerican1298-74"
"31451356","[Prophylactic nodal radiotherapy in prostate cancer]","Bourdais R, Achkar S, Chauffert-Yvart L, Pasquier D, Sargos P, Blanchard P, Latorzeff I.","Cancer Radiother. 2019 Oct;23(6-7):688-695. doi: 10.1016/j.canrad.2019.07.149. Epub 2019 Aug 23.","Bourdais R","Cancer Radiother","2019","2019/08/28","","","10.1016/j.canrad.2019.07.149"
"14504206","Inuit are protected against prostate cancer","Dewailly E, Mulvad G, Sloth Pedersen H, Hansen JC, Behrendt N, Hart Hansen JP.","Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):926-7.","Dewailly E","Cancer Epidemiol Biomarkers Prev","2003","2003/09/25","","",""
"16099273","Postoperative radiotherapy for prostate cancer","Höcht S, Hinkelbein W.","Lancet. 2005 Aug 13-19;366(9485):524-5. doi: 10.1016/S0140-6736(05)67075-4.","Höcht S","Lancet","2005","2005/08/16","","","10.1016/S0140-6736(05)67075-4"
"15572714","Androgen suppression plus radiation for prostate cancer","Millar J.","JAMA. 2004 Dec 1;292(21):2581-2; author reply 2582. doi: 10.1001/jama.292.21.2581-b.","Millar J","JAMA","2004","2004/12/02","","","10.1001/jama.292.21.2581-b"
"12429287","Hormonal therapy for prostate cancer: primum non nocere","Milbank AJ, Dreicer R, Klein EA.","Urology. 2002 Nov;60(5):738-41. doi: 10.1016/s0090-4295(02)01867-8.","Milbank AJ","Urology","2002","2002/11/14","","","10.1016/s0090-4295(02)01867-8"
"22344616","Math may help to guide future prostate cancer treatments","Printz C.","Cancer. 2012 Mar 1;118(5):1177. doi: 10.1002/cncr.27478.","Printz C","Cancer","2012","2012/02/21","","","10.1002/cncr.27478"
"24678551","Educating young Aussie men is key to reducing prostate cancer toll","","Aust Nurs Midwifery J. 2013 Nov;21(5):41.","","Aust Nurs Midwifery J","2013","2014/03/29","","",""
"24120779","Re: Long-term functional outcomes after treatment for localized prostate cancer","Taneja SS.","J Urol. 2013 Nov;190(5):1764-5. doi: 10.1016/j.juro.2013.07.084. Epub 2013 Aug 2.","Taneja SS","J Urol","2013","2013/10/15","","","10.1016/j.juro.2013.07.084"
"11824885","Chemotherapy for prostate cancer","Wang J, Waxman J.","Clin Oncol (R Coll Radiol). 2001;13(6):453-4. doi: 10.1053/clon.2001.9312.","Wang J","Clin Oncol (R Coll Radiol)","2001","2002/02/05","","","10.1053/clon.2001.9312"
"7490872","Re: Long-term survival and mortality in prostate cancer treated with noncurative intent","Abrahamsson A, Adami HO, Taube A, Kim K, Zelen M, Kulldorff M.","J Urol. 1996 Jan;155(1):296-8. doi: 10.1016/s0022-5347(01)66644-8.","Abrahamsson A","J Urol","1996","1996/01/01","","","10.1016/s0022-5347(01)66644-8"
"27033932","Altered expression of p53, but not Rb, is involved in canine prostatic carcinogenesis","Pagliarone S, Frattone L, Pirocchi V, Della Salda L, Palmieri C.","Res Vet Sci. 2016 Apr;105:195-9. doi: 10.1016/j.rvsc.2016.02.022. Epub 2016 Feb 23.","Pagliarone S","Res Vet Sci","2016","2016/04/02","","","10.1016/j.rvsc.2016.02.022"
"8773502","What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging","D'Amico AV.","Hematol Oncol Clin North Am. 1996 Jun;10(3):643-51. doi: 10.1016/s0889-8588(05)70358-0.","D'Amico AV","Hematol Oncol Clin North Am","1996","1996/06/01","","","10.1016/s0889-8588(05)70358-0"
"15201819","Re: no increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination","Yuen JS, Lau WK, Cheng CW.","J Urol. 2004 Jul;172(1):386-7. doi: 10.1097/01.ju.0000132365.20760.88.","Yuen JS","J Urol","2004","2004/06/18","","","10.1097/01.ju.0000132365.20760.88"
"28925011","Trends in active surveillance for very low-risk prostate cancer: do guidelines influence modern practice?","Parikh RR, Kim S, Stein MN, Haffty BG, Kim IY, Goyal S.","Cancer Med. 2017 Oct;6(10):2410-2418. doi: 10.1002/cam4.1132. Epub 2017 Sep 18.","Parikh RR","Cancer Med","2017","2017/09/20","PMC5633554","","10.1002/cam4.1132"
"18196537","Histopathological and immunohistochemical characterization of canine prostate cancer","Lai CL, van den Ham R, van Leenders G, van der Lugt J, Mol JA, Teske E.","Prostate. 2008 Apr 1;68(5):477-88. doi: 10.1002/pros.20720.","Lai CL","Prostate","2008","2008/01/16","","","10.1002/pros.20720"
"19180107","Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer'","André N, Pasquier E.","Nat Clin Pract Oncol. 2009 Feb;6(2):E1. doi: 10.1038/ncponc1317.","André N","Nat Clin Pract Oncol","2009","2009/01/31","","","10.1038/ncponc1317"
"21280905","Light penetration in the human prostate: a whole prostate clinical study at 763 nm","Moore CM, Mosse CA, Allen C, Payne H, Emberton M, Bown SG.","J Biomed Opt. 2011 Jan-Feb;16(1):015003. doi: 10.1117/1.3528638.","Moore CM","J Biomed Opt","2011","2011/02/02","","","10.1117/1.3528638"
"26286638","Topologically inferring pathway activity toward precise cancer classification via integrating genomic and metabolomic data: prostate cancer as a case","Liu W, Bai X, Liu Y, Wang W, Han J, Wang Q, Xu Y, Zhang C, Zhang S, Li X, Ren Z, Zhang J, Li C.","Sci Rep. 2015 Aug 19;5:13192. doi: 10.1038/srep13192.","Liu W","Sci Rep","2015","2015/08/20","PMC4541321","","10.1038/srep13192"
"19506821","IMRT of prostate cancer: a comparison of fluence optimization with sequential segmentation and direct step-and-shoot optimization","Treutwein M, Hipp M, Kölbl O, Bogner L.","Strahlenther Onkol. 2009 Jun;185(6):379-83. doi: 10.1007/s00066-009-1950-7. Epub 2009 Jun 9.","Treutwein M","Strahlenther Onkol","2009","2009/06/10","","","10.1007/s00066-009-1950-7"
"17763575","Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer","McKarney I.","Issues Emerg Health Technol. 2007 Sep;(101):1-4.","McKarney I","Issues Emerg Health Technol","2007","2007/09/04","","",""
"18712514","[Identification and validation of clinically relevant molecular alterations in prostate cancer]","Schlomm T, Sültmann H, Köllermann J.","Urologe A. 2008 Sep;47(9):1193-8. doi: 10.1007/s00120-008-1834-y.","Schlomm T","Urologe A","2008","2008/08/21","","","10.1007/s00120-008-1834-y"
"24383151","PSA in men in their 40s predicts risk of prostate cancer death","Rees J.","Practitioner. 2013 Sep;257(1764):5.","Rees J","Practitioner","2013","2014/01/04","","",""
"12889868","NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer","Nakada T, Noguchi Y, Satoh S, Ono T, Saika T, Kurashige T, Gnjatic S, Ritter G, Chen YT, Stockert E, Nasu Y, Tsushima T, Kumon H, Old LJ, Nakayama E.","Cancer Immun. 2003 Jul 31;3:10.","Nakada T","Cancer Immun","2003","2003/08/02","","",""
"6375857","A reexamination of the stable category for evaluating response in patients with advanced prostate cancer","Slack NH, Brady MF, Murphy GP.","Cancer. 1984 Aug 1;54(3):564-74. doi: 10.1002/1097-0142(19840801)54:3<564::aid-cncr2820540330>3.0.co;2-6.","Slack NH","Cancer","1984","1984/08/01","","","10.1002/1097-0142(19840801)54:3<564::aid-cncr2820540330>3.0.co;2-6"
"1725472","[Treatment of hormone-refractory prostate cancer with estramustine phosphate]","Morote J, López-Pacios MA, Ahmad A, Vila J, de Torres JA.","Actas Urol Esp. 1991 Sep-Oct;15(5):421-4.","Morote J","Actas Urol Esp","1991","1991/09/01","","",""
"31262898","Interleukin-24 Transduction Modulates Human Prostate Cancer Malignancy Mediated by Regulation of Anchorage Dependence","Maehana S, Matsumoto Y, Kojima F, Kitasato H.","Anticancer Res. 2019 Jul;39(7):3719-3725. doi: 10.21873/anticanres.13520.","Maehana S","Anticancer Res","2019","2019/07/03","","","10.21873/anticanres.13520"
"17593202","Assessing the attitudes to prostate cancer treatment among European male patients","Schulman C.","BJU Int. 2007 Jul;100 Suppl 1:6-11. doi: 10.1111/j.1464-410X.2007.6976.x.","Schulman C","BJU Int","2007","2007/09/28","","","10.1111/j.1464-410X.2007.6976.x"
"2474883","Palliative hemibody irradiation in hormonally refractory metastatic prostate cancer","Nseyo UO, Fontanesi J, Naftulin BN.","Urology. 1989 Aug;34(2):76-9. doi: 10.1016/0090-4295(89)90167-2.","Nseyo UO","Urology","1989","1989/08/01","","","10.1016/0090-4295(89)90167-2"
"16864169","Benefits from membership in cancer patient associations: relations to gender and involvement","Carlsson C, Bendahl PO, Nilsson K, Nilbert M.","Acta Oncol. 2006;45(5):559-63. doi: 10.1080/02841860600724419.","Carlsson C","Acta Oncol","2006","2006/07/26","","","10.1080/02841860600724419"
"29491074","A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples","Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K.","Anticancer Res. 2018 Mar;38(3):1471-1477. doi: 10.21873/anticanres.12373.","Guo J","Anticancer Res","2018","2018/03/02","","","10.21873/anticanres.12373"
"18680171","Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL","Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ, Leibovich BC.","Cancer. 2008 Oct 1;113(7):1544-51. doi: 10.1002/cncr.23767.","Inman BA","Cancer","2008","2008/08/06","PMC2789388","NIHMS160055","10.1002/cncr.23767"
"24878184","Prostate cancer relevant antigens and enzymes for targeted drug delivery","Barve A, Jin W, Cheng K.","J Control Release. 2014 Aug 10;187:118-32. doi: 10.1016/j.jconrel.2014.05.035. Epub 2014 May 27.","Barve A","J Control Release","2014","2014/06/01","PMC4079732","NIHMS600401","10.1016/j.jconrel.2014.05.035"
"18837188","[Practice guideline 'Prostate cancer: diagnosis and treatment']","Giard RW.","Ned Tijdschr Geneeskd. 2008 Sep 20;152(38):2099-100; author reply 2100.","Giard RW","Ned Tijdschr Geneeskd","2008","2008/10/08","","",""
"21761313","Laser-capture microdissection and transcriptional profiling in archival FFPE tissue in prostate cancer","Joseph A, Gnanapragasam VJ.","Methods Mol Biol. 2011;755:291-300. doi: 10.1007/978-1-61779-163-5_24.","Joseph A","Methods Mol Biol","2011","2011/07/16","","","10.1007/978-1-61779-163-5_24"
"21250491","[Determination of the progression of prostate cancer using RT-PCR method]","Zummerová A, Blasko M, Böhmer D, Filo J, Kovác P, Repiská V.","Vnitr Lek. 2010 Nov;56(11):1130-7.","Zummerová A","Vnitr Lek","2010","2011/01/22","","",""
"15046688","Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer","Johnson L.","Clin Prostate Cancer. 2002 Dec;1(3):142-4.","Johnson L","Clin Prostate Cancer","2002","2004/03/30","","",""
"31148996","Determinants of prostate specific antigen screening test uptake in an urban community in North-Central Nigeria","Bello JO, Buhari T, Mohammed TO, Olanipekun HB, Egbuniwe AM, Fasiku OK, Wasiu R.","Afr Health Sci. 2019 Mar;19(1):1665-1670. doi: 10.4314/ahs.v19i1.42.","Bello JO","Afr Health Sci","2019","2019/06/01","PMC6531987","","10.4314/ahs.v19i1.42"
"16916718","Invasion of fat justifies assignment of stage pT3a in prostatic adenocarcinoma","Sung MT, Eble JN, Cheng L.","Pathology. 2006 Aug;38(4):309-11. doi: 10.1080/00313020600820914.","Sung MT","Pathology","2006","2006/08/19","","","10.1080/00313020600820914"
"26508791","Prostate cancer-specific mortality after radical prostatectomy: value of preoperative MRI","Woo S, Cho JY, Ku JH, Kim SY, Kim SH.","Acta Radiol. 2016 Aug;57(8):1006-13. doi: 10.1177/0284185115610933. Epub 2015 Oct 26.","Woo S","Acta Radiol","2016","2015/10/29","","","10.1177/0284185115610933"
"9874300","Pubic arch detection in transrectal ultrasound guided prostate cancer therapy","Pathak SD, Grimm PD, Chalana V, Kim Y.","IEEE Trans Med Imaging. 1998 Oct;17(5):762-71. doi: 10.1109/42.736032.","Pathak SD","IEEE Trans Med Imaging","1998","1999/01/05","","","10.1109/42.736032"
"26716753","[Primary candidate rna biomarker screening by RNA-seq for prostate cancer diagnostics]","Nikitina AS, Babenko VV, Babalyan KA, Vasiliev AO, Govorov AV, Prilepskaya EA, Danilenko SA, Selezneva OV, Sharova EI.","Biomed Khim. 2015 Nov-Dec;61(6):781-4. doi: 10.18097/PBMC20156106781.","Nikitina AS","Biomed Khim","2015","2015/12/31","","","10.18097/PBMC20156106781"
"27603423","Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients","Klaff R, Varenhorst E, Berglund A, Hedlund PO, Sjöberg F, Sandblom G; SPCG-5 Study Group.","Scand J Urol. 2016 Oct;50(5):352-9. doi: 10.1080/21681805.2016.1209689. Epub 2016 Aug 9.","Klaff R","Scand J Urol","2016","2016/09/08","","","10.1080/21681805.2016.1209689"
"25896180","Prostate cancer: PSA kinetics predict survival in patients treated with abiraterone","Fenner A.","Nat Rev Urol. 2015 May;12(5):240. doi: 10.1038/nrurol.2015.87. Epub 2015 Apr 21.","Fenner A","Nat Rev Urol","2015","2015/04/22","","","10.1038/nrurol.2015.87"
"30005996","Low-risk Prostate Cancer Prior to or After Kidney Transplantation","Stöckle M, Junker K, Fornara P.","Eur Urol Focus. 2018 Mar;4(2):148-152. doi: 10.1016/j.euf.2018.07.003. Epub 2018 Jul 10.","Stöckle M","Eur Urol Focus","2018","2018/07/15","","","10.1016/j.euf.2018.07.003"
"21995634","Expressional and mutational analyses of ATG5 gene in prostate cancers","Kim MS, Song SY, Lee JY, Yoo NJ, Lee SH.","APMIS. 2011 Nov;119(11):802-7. doi: 10.1111/j.1600-0463.2011.02812.x. Epub 2011 Sep 22.","Kim MS","APMIS","2011","2011/10/15","","","10.1111/j.1600-0463.2011.02812.x"
"30325082","""It's not just about prostate cancer, it's about being a gay man"": A qualitative study of gay men's experiences of healthcare provision in the UK","Doran D, Williamson S, Margaret Wright K, Beaver K.","Eur J Cancer Care (Engl). 2018 Nov;27(6):e12923. doi: 10.1111/ecc.12923. Epub 2018 Oct 16.","Doran D","Eur J Cancer Care (Engl)","2018","2018/10/17","","","10.1111/ecc.12923"
"28317247","Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort","KandaSwamy GV, Bennett A, Narahari K, Hughes O, Rees J, Kynaston H.","BJU Int. 2017 Nov;120(5B):E59-E63. doi: 10.1111/bju.13850. Epub 2017 Apr 19.","KandaSwamy GV","BJU Int","2017","2017/03/21","","","10.1111/bju.13850"
"25997493","Docosahexaenoic acid inhibits the growth of hormone-dependent prostate cancer cells by promoting the degradation of the androgen receptor","Hu Z, Qi H, Zhang R, Zhang K, Shi Z, Chang Y, Chen L, Esmaeili M, Baniahmad A, Hong W.","Mol Med Rep. 2015 Sep;12(3):3769-3774. doi: 10.3892/mmr.2015.3813. Epub 2015 May 21.","Hu Z","Mol Med Rep","2015","2015/05/23","","","10.3892/mmr.2015.3813"
"25062311","Enhancing nurse-patient communication: a critical reflection","Farrington N, Townsend K.","Br J Nurs. 2014 Jul 24-Aug 13;23(14):771-5. doi: 10.12968/bjon.2014.23.14.771.","Farrington N","Br J Nurs","2014","2014/07/26","","","10.12968/bjon.2014.23.14.771"
"24304012","Cytogenetics of prostate cancer","Lieber MM.","Int J Urol. 1996 Jan;3(1 Suppl):S1-3. doi: 10.1111/j.1442-2042.1996.tb00074.x.","Lieber MM","Int J Urol","1996","2013/12/06","","","10.1111/j.1442-2042.1996.tb00074.x"
"22552356","Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition","Mak MP, da Costa e Silva VT, Martin RM, Lerario AM, Yu L, Hoff PM, de Castro G Jr.","Support Care Cancer. 2012 Sep;20(9):2195-7. doi: 10.1007/s00520-012-1474-z. Epub 2012 May 4.","Mak MP","Support Care Cancer","2012","2012/05/04","","","10.1007/s00520-012-1474-z"
"26081817","[Psychosocial interventions for men with prostate cancer]","Borgmann H, Schmidt S.","Urologe A. 2015 Jun;54(6):863-6. doi: 10.1007/s00120-015-3858-4.","Borgmann H","Urologe A","2015","2015/06/18","","","10.1007/s00120-015-3858-4"
"20727049","Editorial comment to Anterior perirectal fat tissue thickness closely associated with obesity strongly predicts recurrence after high-intensity focused ultrasound for prostate cancer","Hekal IA.","Int J Urol. 2010 Sep;17(9):782-3. doi: 10.1111/j.1442-2042.2010.02594.x.","Hekal IA","Int J Urol","2010","2010/08/24","","","10.1111/j.1442-2042.2010.02594.x"
"19691097","Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?","Denham JW, Steigler A, Wilcox C, Lamb DS, Joseph D, Atkinson C, Tai KH, Spry NA, Gleeson PS, D'Este C.","Cancer. 2009 Oct 1;115(19):4477-87. doi: 10.1002/cncr.24484.","Denham JW","Cancer","2009","2009/08/20","","","10.1002/cncr.24484"
"26464694","Association of serum EPCA-2 level with prostate cancer in Chinese Han population","Wang L, Ma L, Wang X, Li B, Guo S, Qiao Q.","Int J Clin Exp Pathol. 2015 Aug 1;8(8):9397-403. eCollection 2015.","Wang L","Int J Clin Exp Pathol","2015","2015/10/15","PMC4583926","",""
"18538526","Radioisotope guided sentinel lymph node dissection in patients with localized prostate cancer: results of the first 100 cases","Bastide C, Brenot-Rossi I, Garcia S, Rossi D.","Eur J Surg Oncol. 2009 Jul;35(7):751-6. doi: 10.1016/j.ejso.2008.04.007. Epub 2008 Jun 6.","Bastide C","Eur J Surg Oncol","2009","2008/06/10","","","10.1016/j.ejso.2008.04.007"
"28870416","[Combination of radiotherapy and androgen deprivation therapy for localized prostate cancer]","Hennequin C, Fumagalli I, Martin V, Quero L.","Cancer Radiother. 2017 Oct;21(6-7):462-468. doi: 10.1016/j.canrad.2017.07.045. Epub 2017 Sep 1.","Hennequin C","Cancer Radiother","2017","2017/09/06","","","10.1016/j.canrad.2017.07.045"
"27542509","Patterns of Postprostatectomy Adjuvant Radiotherapy Techniques for Nonmetastatic Prostate Cancer in a Large National Cohort","Wong AT, Schwartz D, Lee A, Safdieh J, Osborn V, Schreiber D.","Clin Genitourin Cancer. 2017 Feb;15(1):168-175. doi: 10.1016/j.clgc.2016.07.009. Epub 2016 Jul 21.","Wong AT","Clin Genitourin Cancer","2017","2016/08/21","","","10.1016/j.clgc.2016.07.009"
"31301868","Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain","Lloret-Durá MA, Panach-Navarrete J, Martínez-Jabaloyas JM, Valls-González L, Cózar-Olmo JM, Miñana-López B, Gómez-Veiga F, Rodríguez-Antolín A; Grupo Español de Cáncer de Próstata.","Actas Urol Esp. 2019 Dec;43(10):562-567. doi: 10.1016/j.acuro.2019.04.001. Epub 2019 Jul 10.","Lloret-Durá MA","Actas Urol Esp","2019","2019/07/15","","","10.1016/j.acuro.2019.04.001"
"20346033","Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology","Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, Sternberg CN.","BJU Int. 2010 Aug;106(4):462-9. doi: 10.1111/j.1464-410X.2010.09334.x. Epub 2010 Mar 25.","Droz JP","BJU Int","2010","2010/03/30","PMC3258484","","10.1111/j.1464-410X.2010.09334.x"
"3329362","The use of transrectal ultrasound in the diagnosis, guided biopsy, staging and screening of prostate cancer","Lee F, Littrup PJ, Kumasaka GH, Borlaza GS, McLeary RD.","Radiographics. 1987 Jul;7(4):627-44. doi: 10.1148/radiographics.7.4.3329362.","Lee F","Radiographics","1987","1987/07/01","","","10.1148/radiographics.7.4.3329362"
"15050948","A new approach to managing prostate cancer is essential","Reynolds TM, Mitchell HD.","Lancet Oncol. 2004 Apr;5(4):205; discussion 205-6. doi: 10.1016/S1470-2045(04)01420-2.","Reynolds TM","Lancet Oncol","2004","2004/03/31","","","10.1016/S1470-2045(04)01420-2"
"18727052","Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues","Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J.","Magn Reson Med. 2008 Sep;60(3):510-6. doi: 10.1002/mrm.21694.","Tessem MB","Magn Reson Med","2008","2008/08/30","PMC2613807","NIHMS83785","10.1002/mrm.21694"
"27010657","Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context","Etzioni R, Gulati R.","JAMA Oncol. 2016 Jul 1;2(7):955-6. doi: 10.1001/jamaoncol.2015.6310.","Etzioni R","JAMA Oncol","2016","2016/03/25","","","10.1001/jamaoncol.2015.6310"
"19039592","TGFB1 gene polymorphism Leu10Pro (c.29T>C), prostate cancer incidence and quality of life in patients treated with brachytherapy","Meyer A, Dörk T, Bogdanova N, Brinkhaus MJ, Wiese B, Hagemann J, Serth J, Bremer M, Baumann R, Karstens JH, Machtens S.","World J Urol. 2009 Jun;27(3):371-7. doi: 10.1007/s00345-008-0354-0. Epub 2008 Nov 28.","Meyer A","World J Urol","2009","2008/11/29","","","10.1007/s00345-008-0354-0"
"27647712","Associations between aerobic exercise levels and physical and mental health outcomes in men with bone metastatic prostate cancer: a cross-sectional investigation","Zopf EM, Newton RU, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, Baumann FT, Bloch W, Galvão DA.","Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12575. Epub 2016 Sep 20.","Zopf EM","Eur J Cancer Care (Engl)","2017","2016/09/21","","","10.1111/ecc.12575"
"28801885","Active Surveillance for Intermediate Risk Prostate Cancer","Klotz L.","Curr Urol Rep. 2017 Aug 11;18(10):80. doi: 10.1007/s11934-017-0726-3.","Klotz L","Curr Urol Rep","2017","2017/08/13","","","10.1007/s11934-017-0726-3"
"11295634","The Prostate Cancer Prevention Trial: Current status and lessons learned","Thompson IM Jr, Kouril M, Klein EA, Coltman CA, Ryan A, Goodman P.","Urology. 2001 Apr;57(4 Suppl 1):230-4. doi: 10.1016/s0090-4295(00)00980-8.","Thompson IM Jr","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00980-8"
"15714976","[Radical prostatectomy for localized prostate cancer]","Arai Y, Saito S, Namiki S, Ishidoya S, Satoh M.","Nihon Rinsho. 2005 Feb;63(2):261-6.","Arai Y","Nihon Rinsho","2005","2005/02/18","","",""
"29044563","The impact of socioeconomic status on stage specific prostate cancer survival and mortality before and after introduction of PSA test in Finland","Seikkula HA, Kaipia AJ, Ryynänen H, Seppä K, Pitkäniemi JM, Malila NK, Boström PJ.","Int J Cancer. 2018 Mar 1;142(5):891-898. doi: 10.1002/ijc.31109. Epub 2017 Oct 31.","Seikkula HA","Int J Cancer","2018","2017/10/19","","","10.1002/ijc.31109"
"24892256","Biomarkers in castration-resistant prostate cancer","Armstrong AJ.","Clin Adv Hematol Oncol. 2014 Feb;12(2):115-8.","Armstrong AJ","Clin Adv Hematol Oncol","2014","2014/06/04","","",""
"20028888","High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2","Kim CK, Park BK, Kim B.","AJR Am J Roentgenol. 2010 Jan;194(1):W33-7. doi: 10.2214/AJR.09.3004.","Kim CK","AJR Am J Roentgenol","2010","2009/12/24","","","10.2214/AJR.09.3004"
"16847811","Prostate cancer progression and surrounding microenvironment","Alberti C.","Int J Biol Markers. 2006 Apr-Jun;21(2):88-95. doi: 10.5301/jbm.2008.4500.","Alberti C","Int J Biol Markers","2006","2006/07/19","","","10.5301/jbm.2008.4500"
"21296394","Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades","Peltola MT, Niemelä P, Väisänen V, Viitanen T, Alanen K, Nurmi M, Pettersson K.","Urology. 2011 Apr;77(4):1009.e1-8. doi: 10.1016/j.urology.2010.11.007. Epub 2011 Feb 5.","Peltola MT","Urology","2011","2011/02/08","","","10.1016/j.urology.2010.11.007"
"10899646","Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening","Ciatto S, Zappa M, Bonardi R, Gervasi G.","Eur J Cancer. 2000 Jul;36(11):1347-50. doi: 10.1016/s0959-8049(00)00119-2.","Ciatto S","Eur J Cancer","2000","2000/07/19","","","10.1016/s0959-8049(00)00119-2"
"1887017","Invasion of the neurovascular bundle by prostate cancer: evaluation with MR imaging","Tempany CM, Rahmouni AD, Epstein JI, Walsh PC, Zerhouni EA.","Radiology. 1991 Oct;181(1):107-12. doi: 10.1148/radiology.181.1.1887017.","Tempany CM","Radiology","1991","1991/10/01","","","10.1148/radiology.181.1.1887017"
"26197791","Recent advances in prostate cancer: diagnosis, patient selection and minimally invasive treatment","Autorino R, Porpiglia F.","Minerva Urol Nefrol. 2015 Sep;67(3):197-9.","Autorino R","Minerva Urol Nefrol","2015","2015/07/23","","",""
"26752096","Reduced risk of prostate cancer in childless men as compared to fathers: a systematic review and meta-analysis","Mao Y, Xu X, Zheng X, Xie L.","Sci Rep. 2016 Jan 11;6:19210. doi: 10.1038/srep19210.","Mao Y","Sci Rep","2016","2016/01/12","PMC4707492","","10.1038/srep19210"
"24841165","Quality-of-life assessment tools for men with prostate cancer","Bergman J, Laviana A.","Nat Rev Urol. 2014 Jun;11(6):352-9. doi: 10.1038/nrurol.2014.101. Epub 2014 May 20.","Bergman J","Nat Rev Urol","2014","2014/05/21","","","10.1038/nrurol.2014.101"
"7869646","[Laparoscopic pelvic lymphadenectomy in prostate cancer]","Hattori R, Kinukawa T, Ono Y, Kato N, Sahashi M, Yamada S, Mizutani K, Fujita T, Matsuura O, Ohshima S.","Nihon Hinyokika Gakkai Zasshi. 1994 Dec;85(12):1729-33. doi: 10.5980/jpnjurol1989.85.1729.","Hattori R","Nihon Hinyokika Gakkai Zasshi","1994","1994/12/01","","","10.5980/jpnjurol1989.85.1729"
"25275059","Concordance between biopsy and radical prostatectomy specimen Gleason score in internal and external pathology facilities","Grasso AA, Cozzi G, Palumbo C, Albo G, Rocco B.","Anticancer Res. 2014 Oct;34(10):5585-8.","Grasso AA","Anticancer Res","2014","2014/10/03","","",""
"12827260","[The value of ultrasound (US) in the diagnosis of prostate cancer]","Frauscher F, Klauser A, Berger AP, Halpern EJ, Feuchtner G, Koppelstaetter F, Pallwein L, Pinggera GM, Weirich H, Horninger W, Bartsch G, zur Nedden D.","Radiologe. 2003 Jun;43(6):455-63. doi: 10.1007/s00117-003-0914-7.","Frauscher F","Radiologe","2003","2003/06/27","","","10.1007/s00117-003-0914-7"
"11446873","Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective","Vis AN, Van Der Kwast TH.","BJU Int. 2001 Jul;88(2):147-57. doi: 10.1046/j.1464-410x.2001.02295.x.","Vis AN","BJU Int","2001","2001/07/12","","","10.1046/j.1464-410x.2001.02295.x"
"24320750","Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer","Shore N, Concepcion R, Saltzstein D, Lucia MS, van Breda A, Welbourn W, Lewine N, Gustavsen G, Pothier K, Brawer MK.","Curr Med Res Opin. 2014 Apr;30(4):547-53. doi: 10.1185/03007995.2013.873398. Epub 2013 Dec 23.","Shore N","Curr Med Res Opin","2014","2013/12/11","","","10.1185/03007995.2013.873398"
"26530751","Definition and Validation of ""Favorable High-Risk Prostate Cancer"": Implications for Personalizing Treatment of Radiation-Managed Patients","Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.","Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. Epub 2015 Jul 29.","Muralidhar V","Int J Radiat Oncol Biol Phys","2015","2015/11/05","","","10.1016/j.ijrobp.2015.07.2281"
"25262852","Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations","Sartor O, Flood E, Beusterien K, Park J, Webb I, MacLean D, Wong BJ, Mark Lin H.","Clin Genitourin Cancer. 2015 Apr;13(2):101-12. doi: 10.1016/j.clgc.2014.08.001. Epub 2014 Aug 19.","Sartor O","Clin Genitourin Cancer","2015","2014/09/30","","","10.1016/j.clgc.2014.08.001"
"9749657","Trends and black/white differences in treatment for nonmetastatic prostate cancer","Klabunde CN, Potosky AL, Harlan LC, Kramer BS.","Med Care. 1998 Sep;36(9):1337-48. doi: 10.1097/00005650-199809000-00006.","Klabunde CN","Med Care","1998","1998/09/28","","","10.1097/00005650-199809000-00006"
"7543618","The utility of prostate-specific antigen for detecting prostate cancer","Peirce JC.","JAMA. 1995 Aug 23-30;274(8):608; author reply 608-9. doi: 10.1001/jama.274.8.608a.","Peirce JC","JAMA","1995","1995/08/23","","","10.1001/jama.274.8.608a"
"7543615","The utility of prostate-specific antigen for detecting prostate cancer","Marshall KG.","JAMA. 1995 Aug 23-30;274(8):607; author reply 608-9. doi: 10.1001/jama.274.8.607b.","Marshall KG","JAMA","1995","1995/08/23","","","10.1001/jama.274.8.607b"
"23346015","Potentials and limitations of real-time elastography for prostate cancer detection: a whole-mount step section analysis","Junker D, Schäfer G, Aigner F, Schullian P, Pallwein-Prettner L, Bektic J, Horninger W, Halpern EJ, Frauscher F.","ScientificWorldJournal. 2012;2012:193213. doi: 10.1100/2012/193213. Epub 2012 Dec 31.","Junker D","ScientificWorldJournal","2012","2013/01/25","PMC3549343","","10.1100/2012/193213"
"20180062","[Radiation therapy for prostate cancer in the new S3 guideline. Part 2: postoperative radiation therapy and brachytherapy]","Martin T, Wenz F, Böhmer D, Sedlmayer F, Hinkelbein W, Henkel TO, Miller K, Wiegel T.","Urologe A. 2010 Feb;49(2):216-20. doi: 10.1007/s00120-010-2242-7.","Martin T","Urologe A","2010","2010/02/25","","","10.1007/s00120-010-2242-7"
"23015678","Optimizing the management of prostate cancer in senior adults: call to action","Fitzpatrick JM.","Oncologist. 2012;17 Suppl 1(Suppl 1):1-3. doi: 10.1634/theoncologist.2012-S1-01.","Fitzpatrick JM","Oncologist","2012","2012/09/28","PMC3593778","","10.1634/theoncologist.2012-S1-01"
"26536526","Treatment improves for localized prostate cancer","Printz C.","Cancer. 2015 Nov 15;121(22):3929. doi: 10.1002/cncr.29757.","Printz C","Cancer","2015","2015/11/05","","","10.1002/cncr.29757"
"20425622","Contemporary management of high-risk localized prostate cancer","Garzotto M, Hung AY.","Curr Urol Rep. 2010 May;11(3):159-64. doi: 10.1007/s11934-010-0101-0.","Garzotto M","Curr Urol Rep","2010","2010/04/29","","","10.1007/s11934-010-0101-0"
"27034170","Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells","Chen Y, Cang S, Han L, Liu C, Yang P, Solangi Z, Lu Q, Liu D, Chiao JW.","Oncotarget. 2016 May 3;7(18):26567-79. doi: 10.18632/oncotarget.8440.","Chen Y","Oncotarget","2016","2016/04/02","PMC5041999","","10.18632/oncotarget.8440"
"29549484","Time between diagnosis and surgical treatment on pathological and clinical outcomes in prostate cancer: does it matter?","Morini MA, Muller RL, de Castro Junior PCB, de Souza RJ, Faria EF.","World J Urol. 2018 Aug;36(8):1225-1231. doi: 10.1007/s00345-018-2251-5. Epub 2018 Mar 16.","Morini MA","World J Urol","2018","2018/03/18","","","10.1007/s00345-018-2251-5"
"19258822","Body image and quality of life in men with prostate cancer","Harrington JM, Badger TA.","Cancer Nurs. 2009 Mar-Apr;32(2):E1-7. doi: 10.1097/NCC.0b013e3181982d18.","Harrington JM","Cancer Nurs","2009","2009/03/05","","","10.1097/NCC.0b013e3181982d18"
"23975220","[Biomarker docetaxel-based chemotherapy]","Pfister D, Heidenreich A, Porres D.","Urologe A. 2013 Sep;52(9):1261-4. doi: 10.1007/s00120-013-3318-y.","Pfister D","Urologe A","2013","2013/08/27","","","10.1007/s00120-013-3318-y"
"19705979","Evidence-based uncertainty: recent trial results on prostate-specific antigen testing and prostate cancer mortality","Smith DP, Banks E, Clements MS, Gardiner RA, Armstrong BK.","Med J Aust. 2009 Aug 17;191(4):199-200.","Smith DP","Med J Aust","2009","2009/08/27","","",""
"30198853","[Prostate carcinosarcoma.]","Garde García H, Hernando Arteche A, Useros Rodríguez E, López Galán C, Paños Fagundo E, García Murga JC.","Arch Esp Urol. 2018 Sep;71(7):614-617.","Garde García H","Arch Esp Urol","2018","2018/09/11","","",""
"27013005","Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide","Ting F, Van Leeuwen PJ, Stricker PD.","J Vasc Interv Radiol. 2016 Apr;27(4):568. doi: 10.1016/j.jvir.2016.01.003.","Ting F","J Vasc Interv Radiol","2016","2016/03/26","","","10.1016/j.jvir.2016.01.003"
"14501722","Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias","Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF.","J Urol. 2003 Oct;170(4 Pt 1):1189-93. doi: 10.1097/01.ju.0000085675.96097.76.","Kondylis FI","J Urol","2003","2003/09/23","","","10.1097/01.ju.0000085675.96097.76"
"20623638","Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study","Glen A, Evans CA, Gan CS, Cross SS, Hamdy FC, Gibbins J, Lippitt J, Eaton CL, Noirel J, Wright PC, Rehman I.","Prostate. 2010 Sep 1;70(12):1313-32. doi: 10.1002/pros.21167.","Glen A","Prostate","2010","2010/07/13","","","10.1002/pros.21167"
"14760390","Mucinous differentiation features associated with hormonal escape in a human prostate cancer xenograft","Legrier ME, de Pinieux G, Boyé K, Arvelo F, Judde JG, Fontaine JJ, Bara J, Poupon MF.","Br J Cancer. 2004 Feb 9;90(3):720-7. doi: 10.1038/sj.bjc.6601570.","Legrier ME","Br J Cancer","2004","2004/02/05","PMC2409592","","10.1038/sj.bjc.6601570"
"16904449","Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality","Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.","Urology. 2006 Aug;68(2):342-7. doi: 10.1016/j.urology.2006.02.030.","Efstathiou JA","Urology","2006","2006/08/15","","","10.1016/j.urology.2006.02.030"
"10511605","Re: Dietary fat, calories, and prostate cancer risk","Pretlow TG.","J Natl Cancer Inst. 1999 Oct 6;91(19):1691A-1692. doi: 10.1093/jnci/91.19.1691a.","Pretlow TG","J Natl Cancer Inst","1999","1999/10/08","","","10.1093/jnci/91.19.1691a"
"9327180","Initial therapy of advanced prostate cancer","Ismail M, Gomella LG.","Compr Ther. 1997 Oct;23(10):649-55.","Ismail M","Compr Ther","1997","1997/11/05","","",""
"11895201","Which results justify the means in prostate cancer treatment?","Albertsen PC.","Cancer J. 2002 Jan-Feb;8(1):30-2. doi: 10.1097/00130404-200201000-00006.","Albertsen PC","Cancer J","2002","2002/03/16","","","10.1097/00130404-200201000-00006"
"16619575","Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer","Miyake H, Muramaki M, Kurahashi T, Yamanaka K, Hara I, Fujisawa M.","Anticancer Res. 2006 Mar-Apr;26(2B):1583-7.","Miyake H","Anticancer Res","2006","2006/04/20","","",""
"30241972","Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study","Matta R, Wallis CJD, Goldenberg MG, Hird AE, Klaassen Z, Kulkarni G, Kodama RT, Herschorn S, Nam RK.","Eur Urol. 2019 Jan;75(1):3-7. doi: 10.1016/j.eururo.2018.08.035. Epub 2018 Sep 18.","Matta R","Eur Urol","2019","2018/09/23","","","10.1016/j.eururo.2018.08.035"
"11268308","Surgical confirmation of ProstaScint abnormalities in two patients with high risk prostate cancer","Lau HY, Kindrachuk G, Carter M, Prestage K, Webber D, Stauffer E, Haseman M.","Can J Urol. 2001 Feb;8(1):1199-202.","Lau HY","Can J Urol","2001","2001/03/27","","",""
"26779768","Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness","Storebjerg TM, Høyer S, Kirkegaard P, Bro F; LuCamp Study Group, Ørntoft TF, Borre M, Sørensen KD.","BJU Int. 2016 Oct;118(4):646-53. doi: 10.1111/bju.13416. Epub 2016 Feb 12.","Storebjerg TM","BJU Int","2016","2016/01/19","","","10.1111/bju.13416"
"28537113","Aktuelle Entwicklungen und Trends in der Urologie","Schmid HP, Betschart P, Zumstein V, Müllhaupt G, Abt D.","Praxis (Bern 1994). 2017;106(11):583-587. doi: 10.1024/1661-8157/a002692.","Schmid HP","Praxis (Bern 1994)","2017","2017/05/25","","","10.1024/1661-8157/a002692"
"12735499","The natural history of prostate cancer","Kessler B, Albertsen P.","Urol Clin North Am. 2003 May;30(2):219-26. doi: 10.1016/s0094-0143(02)00182-9.","Kessler B","Urol Clin North Am","2003","2003/05/09","","","10.1016/s0094-0143(02)00182-9"
"15988529","Global histone modification patterns predict risk of prostate cancer recurrence","Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK.","Nature. 2005 Jun 30;435(7046):1262-6. doi: 10.1038/nature03672.","Seligson DB","Nature","2005","2005/07/01","","","10.1038/nature03672"
"23154603","Predictive tools for prostate cancer staging, treatment response and outcomes","Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, Shariat SF.","Arch Esp Urol. 2012 Nov;65(9):787-807.","Green DA","Arch Esp Urol","2012","2012/11/17","","",""
"15931272","Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme","Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J; 'Casodex' Early Prostate Cancer Trialists' Group.","Prostate Cancer Prostatic Dis. 2005;8(2):194-200. doi: 10.1038/sj.pcan.4500799.","Wirth M","Prostate Cancer Prostatic Dis","2005","2005/06/03","","","10.1038/sj.pcan.4500799"
"22520266","Do we need to obtain consent for penile shortening as a complication of treatment for organ-confined prostate cancer?","Eylert MF, Bahl A, Persad R.","BJU Int. 2012 Nov;110(10):1491-500. doi: 10.1111/j.1464-410X.2012.11102.x. Epub 2012 Apr 23.","Eylert MF","BJU Int","2012","2012/04/24","","","10.1111/j.1464-410X.2012.11102.x"
"21211310","[Inhibition and significance of pigment epithelium-derived factor in the development and metastasis of prostate cancer]","Guo ZH, Huang H, DU T, Xu KW, Cao Y, Chen JQ, Dong W, Yao YS, Lin TX, Xie WL, Jiang C, Han JL, Huang J.","Zhonghua Yi Xue Za Zhi. 2010 Nov 16;90(42):2980-3.","Guo ZH","Zhonghua Yi Xue Za Zhi","2010","2011/01/08","","",""
"22537541","Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, Pinzi V, Arcangeli G.","Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1172-8. doi: 10.1016/j.ijrobp.2012.02.049. Epub 2012 Apr 24.","Arcangeli S","Int J Radiat Oncol Biol Phys","2012","2012/04/28","","","10.1016/j.ijrobp.2012.02.049"
"17296379","13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort","Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J.","J Urol. 2007 Mar;177(3):932-6. doi: 10.1016/j.juro.2006.10.051.","Albertsen PC","J Urol","2007","2007/02/14","","","10.1016/j.juro.2006.10.051"
"24321502","EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.","Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.","Heidenreich A","Eur Urol","2014","2013/12/11","","","10.1016/j.eururo.2013.11.002"
"1726788","Molecular methods for predicting the metastatic potential of prostate cancer","Schalken JA.","Cancer Surv. 1991;11:43-54.","Schalken JA","Cancer Surv","1991","1991/01/01","","",""
"30116963","Extra-target low-risk prostate cancer: implications for focal high-intensity focused ultrasound of clinically significant prostate cancer","Annoot A, Olivier J, Valtille P, Deken V, Leroy X, Puech P, Villers A.","World J Urol. 2019 Feb;37(2):261-268. doi: 10.1007/s00345-018-2442-0. Epub 2018 Aug 16.","Annoot A","World J Urol","2019","2018/08/18","","","10.1007/s00345-018-2442-0"
"18566818","[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy","Reske SN.","Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1740-1. doi: 10.1007/s00259-008-0839-5. Epub 2008 Jun 20.","Reske SN","Eur J Nucl Med Mol Imaging","2008","2008/06/21","","","10.1007/s00259-008-0839-5"
"29045185","Apparent Diffusion Coefficient Values of Prostate Cancer: Comparison of 2D and 3D ROIs","Tamada T, Huang C, Ream JM, Taffel M, Taneja SS, Rosenkrantz AB.","AJR Am J Roentgenol. 2018 Jan;210(1):113-117. doi: 10.2214/AJR.17.18495. Epub 2017 Oct 18.","Tamada T","AJR Am J Roentgenol","2018","2017/10/19","","","10.2214/AJR.17.18495"
"26481227","Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy","Boehm K, Tennstedt P, Beyer B, Schiffmann J, Beckmann A, Michl U, Beyersdorff D, Budäus L, Graefen M, Karakiewicz PI, Salomon G.","World J Urol. 2016 Jun;34(6):805-10. doi: 10.1007/s00345-015-1714-1. Epub 2015 Oct 19.","Boehm K","World J Urol","2016","2015/10/21","","","10.1007/s00345-015-1714-1"
"12121592","Prostate cancer: risk categories and role of hormones and radiotherapy","Lukka H.","Can J Urol. 2002 Jun;9 Suppl 1:26-9.","Lukka H","Can J Urol","2002","2002/07/18","","",""
"12441934","Time to achieve a prostate specific antigen nadir of 0.2 ng./ml. after simultaneous irradiation for prostate cancer","Critz FA.","J Urol. 2002 Dec;168(6):2434-8. doi: 10.1097/01.ju.0000030581.57555.04.","Critz FA","J Urol","2002","2002/11/21","","","10.1097/01.ju.0000030581.57555.04"
"31255421","Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51","Dirix PR, Mercier C, Dirix LY.","Eur Urol. 2019 Oct;76(4):e101-e102. doi: 10.1016/j.eururo.2019.06.022. Epub 2019 Jun 27.","Dirix PR","Eur Urol","2019","2019/07/01","","","10.1016/j.eururo.2019.06.022"
"19161538","C-type natriuretic peptide in prostate cancer","Nielsen SJ, Iversen P, Rehfeld JF, Jensen HL, Goetze JP.","APMIS. 2009 Jan;117(1):60-7. doi: 10.1111/j.1600-0463.2008.00016.x.","Nielsen SJ","APMIS","2009","2009/01/24","","","10.1111/j.1600-0463.2008.00016.x"
"27756608","PTTG1, A novel androgen responsive gene is required for androgen-induced prostate cancer cell growth and invasion","Zhang Z, Jin B, Jin Y, Huang S, Niu X, Mao Z, Xin D.","Exp Cell Res. 2017 Jan 1;350(1):1-8. doi: 10.1016/j.yexcr.2016.10.013. Epub 2016 Oct 15.","Zhang Z","Exp Cell Res","2017","2016/10/21","","","10.1016/j.yexcr.2016.10.013"
"7516069","Nuclear shape and prognosis following orchiectomy in stage D2 prostate cancer","Miller J, Horsfall DJ, Skinner JM, Rao DM, Leong AS, Marshall VR.","Prostate. 1994 Jun;24(6):306-12. doi: 10.1002/pros.2990240606.","Miller J","Prostate","1994","1994/06/01","","","10.1002/pros.2990240606"
"12584472","The rationale for adjuvant chemotherapy for high-risk prostate cancer","Kent EC, Hussain MH.","Curr Opin Urol. 2003 Mar;13(2):123-31. doi: 10.1097/00042307-200303000-00007.","Kent EC","Curr Opin Urol","2003","2003/02/14","","","10.1097/00042307-200303000-00007"
"31417171","Inherited risk assessment of prostate cancer: it takes three to do it right","Xu J, Labbate CV, Isaacs WB, Helfand BT.","Prostate Cancer Prostatic Dis. 2020 Mar;23(1):59-61. doi: 10.1038/s41391-019-0165-y. Epub 2019 Aug 15.","Xu J","Prostate Cancer Prostatic Dis","2020","2019/08/17","","","10.1038/s41391-019-0165-y"
"29869454","Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review","Koo KC, Dasgupta P.","Yonsei Med J. 2018 Jul;59(5):567-579. doi: 10.3349/ymj.2018.59.5.567.","Koo KC","Yonsei Med J","2018","2018/06/06","PMC5990677","","10.3349/ymj.2018.59.5.567"
"1637367","Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy","Anscher MS, Prosnitz LR.","Urology. 1992 Jan;39(1):39-43. doi: 10.1016/0090-4295(92)90038-x.","Anscher MS","Urology","1992","1992/01/01","","","10.1016/0090-4295(92)90038-x"
"1870149","Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence?","Whittemore AS, Keller JB, Betensky R.","J Natl Cancer Inst. 1991 Sep 4;83(17):1231-5. doi: 10.1093/jnci/83.17.1231.","Whittemore AS","J Natl Cancer Inst","1991","1991/09/04","","","10.1093/jnci/83.17.1231"
"23656798","Prostate cancer risk in pre-diabetic men: a matched cohort study","Onitilo AA, Berg RL, Engel JM, Stankowski RV, Glurich I, Williams GM, Doi SA.","Clin Med Res. 2013 Dec;11(4):201-9. doi: 10.3121/cmr.2013.1160. Epub 2013 May 8.","Onitilo AA","Clin Med Res","2013","2013/05/10","PMC3917991","","10.3121/cmr.2013.1160"
"23933691","Androgen receptors in early and castration resistant prostate cancer: friend or foe?","Pelekanou V, Notas G, Stathopoulos EN, Castanas E, Kampa M.","Hormones (Athens). 2013 Apr-Jun;12(2):224-35. doi: 10.14310/horm.2002.1406.","Pelekanou V","Hormones (Athens)","2013","2013/08/13","","","10.14310/horm.2002.1406"
"15183987","Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence","Miyata Y, Sakai H, Kanda S, Igawa T, Hayashi T, Kanetake H.","Urology. 2004 Jun;63(6):1184-90. doi: 10.1016/j.urology.2004.02.015.","Miyata Y","Urology","2004","2004/06/09","","","10.1016/j.urology.2004.02.015"
"19299071","Editorial comment on: tumor grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer","Yossepowitch O.","Eur Urol. 2010 Apr;57(4):639-40. doi: 10.1016/j.eururo.2009.03.009. Epub 2009 Mar 10.","Yossepowitch O","Eur Urol","2010","2009/03/21","","","10.1016/j.eururo.2009.03.009"
"7531784","Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach","Kaye KW, Olson DJ, Payne JT.","J Urol. 1995 Mar;153(3 Pt 2):1020-5.","Kaye KW","J Urol","1995","1995/03/01","","",""
"28972698","Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors","Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.","BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.","Fradet V","BJU Int","2018","2017/10/04","","","10.1111/bju.14041"
"22697234","Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study","Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R.","Diagn Pathol. 2012 Jun 14;7:68. doi: 10.1186/1746-1596-7-68.","Ishizaki F","Diagn Pathol","2012","2012/06/16","PMC3449198","","10.1186/1746-1596-7-68"
"25225697","Outcomes for depressed patients with prostate cancer","Squiers W.","Lancet Oncol. 2014 Aug;15(9):e370. doi: 10.1016/s1470-2045(14)70339-0.","Squiers W","Lancet Oncol","2014","2014/09/17","","","10.1016/s1470-2045(14)70339-0"
"20101260","Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy","Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fosså SD.","Prostate Cancer Prostatic Dis. 2010 Jun;13(2):144-50. doi: 10.1038/pcan.2009.61. Epub 2010 Jan 26.","Kyrdalen AE","Prostate Cancer Prostatic Dis","2010","2010/01/27","","","10.1038/pcan.2009.61"
"9426742","Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer","Balaji KC, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra RK, Laxmanan S.","Urology. 1997 Dec;50(6):1007-15. doi: 10.1016/s0090-4295(97)00390-7.","Balaji KC","Urology","1997","1998/01/14","","","10.1016/s0090-4295(97)00390-7"
"26088224","Re: Salvage High-Intensity Focused Ultrasound for Patients with Recurrent Prostate Cancer after Brachytherapy","Taneja SS.","J Urol. 2015 Jul;194(1):114. doi: 10.1016/j.juro.2015.04.065. Epub 2015 Apr 18.","Taneja SS","J Urol","2015","2015/06/20","","","10.1016/j.juro.2015.04.065"
"22108827","Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy","Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L.","Cancer Res. 2012 Jan 15;72(2):527-36. doi: 10.1158/0008-5472.CAN-11-3004. Epub 2011 Nov 22.","Sun Y","Cancer Res","2012","2011/11/24","","","10.1158/0008-5472.CAN-11-3004"
"30107188","Association Between Prostate Magnetic Resonance Imaging and Observation for Low-risk Prostate Cancer","Leapman MS, Wang R, Park HS, Yu JB, Weinreb JC, Gross CP, Ma X.","Urology. 2019 Feb;124:98-106. doi: 10.1016/j.urology.2018.07.041. Epub 2018 Aug 11.","Leapman MS","Urology","2019","2018/08/15","","","10.1016/j.urology.2018.07.041"
"18427569","The measurement of psychological distress in men being investigated for the presence of prostate cancer","Awsare NS, Green JS, Aldwinckle B, Hanbury DC, Boustead GB, McNicholas TA.","Prostate Cancer Prostatic Dis. 2008;11(4):384-9. doi: 10.1038/pcan.2008.21. Epub 2008 Apr 22.","Awsare NS","Prostate Cancer Prostatic Dis","2008","2008/04/23","","","10.1038/pcan.2008.21"
"26689439","Statin use and risk of disease recurrence and death after radical prostatectomy","Keskiväli T, Kujala P, Visakorpi T, Tammela TL, Murtola TJ.","Prostate. 2016 Apr;76(5):469-78. doi: 10.1002/pros.23138. Epub 2015 Dec 22.","Keskiväli T","Prostate","2016","2015/12/23","","","10.1002/pros.23138"
"27314296","Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence","Koch MO, Cho JS, Kaimakliotis HZ, Cheng L, Sangale Z, Brawer M, Welbourn W, Reid J, Stone S.","Cancer Biomark. 2016 Jun 7;17(1):83-8. doi: 10.3233/CBM-160620.","Koch MO","Cancer Biomark","2016","2016/06/18","","","10.3233/CBM-160620"
"27553466","Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer","Kratochwil C, Afshar-Oromieh A, Kopka K, Haberkorn U, Giesel FL.","Semin Nucl Med. 2016 Sep;46(5):405-18. doi: 10.1053/j.semnuclmed.2016.04.004.","Kratochwil C","Semin Nucl Med","2016","2016/08/25","","","10.1053/j.semnuclmed.2016.04.004"
"18071857","Recent advances in nonsurgical management of localized prostate cancer","Arai Y.","Int J Clin Oncol. 2007 Dec;12(6):393-4. doi: 10.1007/s10147-007-0713-7. Epub 2007 Dec 21.","Arai Y","Int J Clin Oncol","2007","2007/12/12","","","10.1007/s10147-007-0713-7"
"17872764","Should Canadians be offered systematic prostate cancer screening? Yes","Fradet Y.","Can Fam Physician. 2007 Jun;53(6):989-92, 994-7.","Fradet Y","Can Fam Physician","2007","2007/09/18","PMC1949194","",""
"10555430","Acute urinary retention: a primary manifestation of chronic lymphocytic leukemia and organ confined prostate cancer","Ather MH, Memon A.","J Pak Med Assoc. 1999 May;49(5):124-5.","Ather MH","J Pak Med Assoc","1999","1999/11/11","","",""
"31100240","Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer","Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein NH, Terstappen LWMM, Waugh D, de Bono JS.","Eur Urol Oncol. 2018 Jun;1(2):151-159. doi: 10.1016/j.euo.2018.02.009. Epub 2018 May 15.","Sumanasuriya S","Eur Urol Oncol","2018","2019/05/18","","","10.1016/j.euo.2018.02.009"
"22956807","Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines","Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.","J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7. doi: 10.6004/jnccn.2012.0114.","Mohler JL","J Natl Compr Canc Netw","2012","2012/09/08","","","10.6004/jnccn.2012.0114"
"24043527","[Prostate cancer - soy has no effect]","","Aktuelle Urol. 2013 Sep;44(5):344. doi: 10.1055/s-0033-1356863. Epub 2013 Sep 16.","","Aktuelle Urol","2013","2013/09/18","","","10.1055/s-0033-1356863"
"20495442","In the diagnosis of limited prostate cancer, is observer variability an important consideration when compared with variability of patient outcome?","Dalton L.","Am J Surg Pathol. 2010 Jul;34(7):1071-2; author reply 1072. doi: 10.1097/PAS.0b013e3181e0d2e6.","Dalton L","Am J Surg Pathol","2010","2010/05/25","","","10.1097/PAS.0b013e3181e0d2e6"
"9346465","Questioning decision analysis for treatment of clinically localized prostate cancer","Cher DJ.","J Gen Intern Med. 1997 Oct;12(10):659. doi: 10.1046/j.1525-1497.1997.07131.x.","Cher DJ","J Gen Intern Med","1997","1997/11/05","PMC1497182","","10.1046/j.1525-1497.1997.07131.x"
"26773531","Replication study of 34 common SNPs associated with prostate cancer in the Romanian population","Jinga V, Csiki IE, Manolescu A, Iordache P, Mates IN, Radavoi D, Rascu S, Badescu D, Badea P, Mates D.","J Cell Mol Med. 2016 Apr;20(4):594-600. doi: 10.1111/jcmm.12729. Epub 2016 Jan 15.","Jinga V","J Cell Mol Med","2016","2016/01/17","PMC5126261","","10.1111/jcmm.12729"
"29243168","The views of patients with metastatic prostate cancer towards physical activity: a qualitative exploration","Sheill G, Guinan E, Neill LO, Hevey D, Hussey J.","Support Care Cancer. 2018 Jun;26(6):1747-1754. doi: 10.1007/s00520-017-4008-x. Epub 2017 Dec 14.","Sheill G","Support Care Cancer","2018","2017/12/16","","","10.1007/s00520-017-4008-x"
"8483203","Radical retropubic prostatectomy and postoperative adjuvant radiation for pathological stage C (PcN0) prostate cancer from 1976 to 1989: intermediate findings","Freeman JA, Lieskovsky G, Cook DW, Petrovich Z, Chen S, Groshen S, Skinner DG.","J Urol. 1993 May;149(5):1029-34. doi: 10.1016/s0022-5347(17)36288-2.","Freeman JA","J Urol","1993","1993/05/01","","","10.1016/s0022-5347(17)36288-2"
"28282307","Health-Related Quality of Life After the Diagnosis of Locally Advanced or Advanced Prostate Cancer: A Longitudinal Study","Zajdlewicz L, Hyde MK, Lepore SJ, Gardiner RA, Chambers SK.","Cancer Nurs. 2017 Sep/Oct;40(5):412-419. doi: 10.1097/NCC.0000000000000432.","Zajdlewicz L","Cancer Nurs","2017","2017/03/11","","","10.1097/NCC.0000000000000432"
"28497893","The 4Kscore blood test accurately identifies men with aggressive prostate cancer prior to prostate biopsy with or without DRE information","Zappala SM, Dong Y, Linder V, Reeve M, Sjoberg DD, Mathur V, Roberts R, Okrongly D, Newmark J, Sant G, Steiner M.","Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12943. Epub 2017 May 12.","Zappala SM","Int J Clin Pract","2017","2017/05/13","","","10.1111/ijcp.12943"
"15150581","Prostate cancer and body size at different ages: an Italian multicentre case-control study","Dal Maso L, Zucchetto A, La Vecchia C, Montella M, Conti E, Canzonieri V, Talamini R, Tavani A, Negri E, Garbeglio A, Franceschi S.","Br J Cancer. 2004 Jun 1;90(11):2176-80. doi: 10.1038/sj.bjc.6601859.","Dal Maso L","Br J Cancer","2004","2004/05/20","PMC2409495","","10.1038/sj.bjc.6601859"
"25051936","[Prostatectomy vs. ""watchful waiting"" in early prostate cancer]","Markun S.","Praxis (Bern 1994). 2014 Jul 23;103(15):909-10. doi: 10.1024/1661-8157/a001714.","Markun S","Praxis (Bern 1994)","2014","2014/07/24","","","10.1024/1661-8157/a001714"
"25046681","Argument for prostate cancer screening in populations of African-Caribbean origin","Patrick AL, Bunker CH, Nelson JB, Dhir R, Wheeler VW, Zmuda JM, Richard JR, Belle AC, Kuller LH.","BJU Int. 2015 Oct;116(4):507-8. doi: 10.1111/bju.12869. Epub 2015 Jun 11.","Patrick AL","BJU Int","2015","2014/07/22","PMC4406859","NIHMS680759","10.1111/bju.12869"
"23040616","Editorial: Prostate cancer screening: perhaps a little patience is the answer","Jarrett TW.","Can J Urol. 2012 Oct;19(5):6409.","Jarrett TW","Can J Urol","2012","2012/10/09","","",""
"16296644","[Prostate cancer]","Agrest A.","Medicina (B Aires). 2005;65(5):458-60.","Agrest A","Medicina (B Aires)","2005","2005/11/22","","",""
"15592033","Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy","Lehrer S, Stone NN, Stock RG.","J Urol. 2005 Jan;173(1):79-81. doi: 10.1097/01.ju.0000145827.20277.e9.","Lehrer S","J Urol","2005","2004/12/14","","","10.1097/01.ju.0000145827.20277.e9"
"28869198","[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial]","Blanchard P, Foulon S, Louvel G, Habibian M, Fizazi K.","Cancer Radiother. 2017 Oct;21(6-7):491-494. doi: 10.1016/j.canrad.2017.06.007. Epub 2017 Aug 30.","Blanchard P","Cancer Radiother","2017","2017/09/05","","","10.1016/j.canrad.2017.06.007"
"19477775","The Internet as an emerging patient education tool among African American men with prostate cancer: an exploratory study","Wallington SF.","Am J Mens Health. 2008 Jun;2(2):106-21. doi: 10.1177/1557988306296156. Epub 2007 May 23.","Wallington SF","Am J Mens Health","2008","2009/05/30","","","10.1177/1557988306296156"
"11684861","Quality of life aspects of treatment options for localized and locally advanced prostate cancer","Anderson J.","Eur Urol. 2001;40 Suppl 2:24-30. doi: 10.1159/000049881.","Anderson J","Eur Urol","2001","2001/10/31","","","10.1159/000049881"
"11675914","[High dosage brachytherapy and external irradiation of localized prostate carcinoma--results at the Kiel University Clinic]","Kovács G, Galalae R, Loch T, Rzehak P, Wilhelm R, Bertermann H, Nürnberg N, Kohr P, Kimmig B.","Praxis (Bern 1994). 2001 Sep 20;90(38):1617-22.","Kovács G","Praxis (Bern 1994)","2001","2001/10/26","","",""
"15279686","Screening for prostate cancer","Wilson SS, Crawford ED.","Clin Prostate Cancer. 2004 Jun;3(1):21-5. doi: 10.3816/cgc.2004.n.008.","Wilson SS","Clin Prostate Cancer","2004","2004/07/29","","","10.3816/cgc.2004.n.008"
"20535002","Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer","Talebi TN, Manoharan M, Singal R.","Am J Ther. 2012 Jan;19(1):e59-61. doi: 10.1097/MJT.0b013e3181e1cb8c.","Talebi TN","Am J Ther","2012","2010/06/11","","","10.1097/MJT.0b013e3181e1cb8c"
"18651121","[Prostate cancer research. Biomarkers as promising options for optimized diagnosis and treatment]","Ellinger J, von Rücker A, Wernert N, Büttner R, Bastian PJ, Müller SC.","Urologe A. 2008 Sep;47(9):1190-2. doi: 10.1007/s00120-008-1833-z.","Ellinger J","Urologe A","2008","2008/07/25","","","10.1007/s00120-008-1833-z"
"18471782","Intra-prostatic androgen levels during various androgen-blockade regimens","Nishiyama T.","Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):229-41. doi: 10.1016/j.beem.2008.01.002.","Nishiyama T","Best Pract Res Clin Endocrinol Metab","2008","2008/05/13","","","10.1016/j.beem.2008.01.002"
"17958206","Diet and survival after prostate cancer diagnosis","Berkow SE, Barnard ND, Saxe GA, Ankerberg-Nobis T.","Nutr Rev. 2007 Sep;65(9):391-403. doi: 10.1111/j.1753-4887.2007.tb00317.x.","Berkow SE","Nutr Rev","2007","2007/10/26","","","10.1111/j.1753-4887.2007.tb00317.x"
"21627750","Optimizing prostate cancer detection during biopsy by standardizing the amount of tissue examined per core","Sfakianos JP, Thorner DA, Dovirak O, Weiss JP, Karanikolas NT.","BJU Int. 2011 Nov;108(10):1578-81. doi: 10.1111/j.1464-410X.2011.10239.x. Epub 2011 May 31.","Sfakianos JP","BJU Int","2011","2011/06/02","","","10.1111/j.1464-410X.2011.10239.x"
"17972182","Metachronous non-Hodgkin's lymphoma in a patient with localized prostate cancer","Kalender ME, Sevinc A, Tutar E, Buyukberber S, Camci C.","Med Oncol. 2007;24(4):466-8. doi: 10.1007/s12032-007-0024-x. Epub 2007 May 17.","Kalender ME","Med Oncol","2007","2007/11/01","","","10.1007/s12032-007-0024-x"
"23587510","Marital status and prostate cancer outcomes","Tyson MD, Andrews PE, Etzioni DA, Ferrigni RG, Humphreys MR, Swanson SK, Castle EK.","Can J Urol. 2013 Apr;20(2):6702-6.","Tyson MD","Can J Urol","2013","2013/04/17","","",""
"20553260","Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer","Caso JR, Tsivian M, Mouraviev V, Polascik TJ, Moul JW.","BJU Int. 2010 Dec;106(11):1623-7. doi: 10.1111/j.1464-410X.2010.09439.x.","Caso JR","BJU Int","2010","2010/06/18","","","10.1111/j.1464-410X.2010.09439.x"
"9719025","Alcohol use and prostate cancer in U.S. whites: no association in a confirmatory study","Lumey LH, Pittman B, Wynder EL.","Prostate. 1998 Sep 1;36(4):250-5. doi: 10.1002/(sici)1097-0045(19980901)36:4<250::aid-pros6>3.0.co;2-j.","Lumey LH","Prostate","1998","1998/08/27","","","10.1002/(sici)1097-0045(19980901)36:4<250::aid-pros6>3.0.co;2-j"
"25246816","Pain during transrectal ultrasound-guided prostate biopsy and the role of periprostatic nerve block: what radiologists should know","Nazir B.","Korean J Radiol. 2014 Sep-Oct;15(5):543-53. doi: 10.3348/kjr.2014.15.5.543. Epub 2014 Sep 12.","Nazir B","Korean J Radiol","2014","2014/09/24","PMC4170156","","10.3348/kjr.2014.15.5.543"
"18257371","[Prognosis and predictive factors of prostate cancer in the prostatic biopsy]","De Torres Ramirez I.","Actas Urol Esp. 2007 Oct;31(9):1025-44. doi: 10.1016/s0210-4806(07)73765-8.","De Torres Ramirez I","Actas Urol Esp","2007","2008/02/09","","","10.1016/s0210-4806(07)73765-8"
"11588843","Gene-environment interrelations in prostate cancer","Hayes RB.","Epidemiol Rev. 2001;23(1):163-7. doi: 10.1093/oxfordjournals.epirev.a000784.","Hayes RB","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000784"
"22249194","The emerging role of diffusion-weighted MRI in prostate cancer management","Lawrence EM, Gnanapragasam VJ, Priest AN, Sala E.","Nat Rev Urol. 2012 Jan 17;9(2):94-101. doi: 10.1038/nrurol.2011.222.","Lawrence EM","Nat Rev Urol","2012","2012/01/18","","","10.1038/nrurol.2011.222"
"23020876","Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer","Ferraldeschi R, Pezaro C, Karavasilis V, de Bono J.","Annu Rev Med. 2013;64:1-13. doi: 10.1146/annurev-med-121211-091605. Epub 2012 Sep 27.","Ferraldeschi R","Annu Rev Med","2013","2012/10/02","","","10.1146/annurev-med-121211-091605"
"7505045","The role of ultrasound in prostate cancer detection in patients with an elevated prostate specific antigen level but no prostatic nodule","Sanders RC.","Md Med J. 1993 Oct;42(10):1007-11.","Sanders RC","Md Med J","1993","1993/10/01","","",""
"15344561","[Advancements in PSA-based screening for prostate cancer]","Ito K.","Rinsho Byori. 2004 Jul;52(7):611-7.","Ito K","Rinsho Byori","2004","2004/09/04","","",""
"15316002","Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard?","DeWeese TL.","JAMA. 2004 Aug 18;292(7):864-6. doi: 10.1001/jama.292.7.864.","DeWeese TL","JAMA","2004","2004/08/19","","","10.1001/jama.292.7.864"
"22203543","Prostate cancer screening--the evidence, the recommendations, and the clinical implications","Chou R, LeFevre ML.","JAMA. 2011 Dec 28;306(24):2721-2. doi: 10.1001/jama.2011.1891.","Chou R","JAMA","2011","2011/12/29","","","10.1001/jama.2011.1891"
"4804369","[Testicular metastasis of prostate cancer]","Raymond G, Rey C.","J Urol Nephrol (Paris). 1973 Oct-Nov;79(10-11):945-7.","Raymond G","J Urol Nephrol (Paris)","1973","1973/10/01","","",""
"26975494","DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer","Liu W.","Asian J Androl. 2016 Jul-Aug;18(4):533-42. doi: 10.4103/1008-682X.177120.","Liu W","Asian J Androl","2016","2016/03/16","PMC4955176","","10.4103/1008-682X.177120"
"20551244","Use of cross species genomic profiling identifies pathways and genes differentially regulated in prostate cancer cells treated with soy protein isolates or purified genistein","Liss MA, Schlicht M, Degueme A, Hessner M, Datta MW.","Cancer Genomics Proteomics. 2010 May-Jun;7(3):111-28.","Liss MA","Cancer Genomics Proteomics","2010","2010/06/17","","",""
"24789031","Vitamin D status: ready for guiding prostate cancer diagnosis and treatment?","Grant WB.","Clin Cancer Res. 2014 May 1;20(9):2241-3. doi: 10.1158/1078-0432.CCR-14-0369.","Grant WB","Clin Cancer Res","2014","2014/05/03","","","10.1158/1078-0432.CCR-14-0369"
"12947068","Do older men benefit from curative therapy of localized prostate cancer?","Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD.","J Clin Oncol. 2003 Sep 1;21(17):3318-27. doi: 10.1200/JCO.2003.09.034.","Alibhai SM","J Clin Oncol","2003","2003/08/30","","","10.1200/JCO.2003.09.034"
"25706900","Coffee consumption and prostate cancer risk: a meta-analysis of cohort studies","Liu H, Hu GH, Wang XC, Huang TB, Xu L, Lai P, Guo ZF, Xu YF.","Nutr Cancer. 2015;67(3):392-400. doi: 10.1080/01635581.2015.1004727. Epub 2015 Feb 23.","Liu H","Nutr Cancer","2015","2015/02/24","","","10.1080/01635581.2015.1004727"
"12108954","Viral based gene therapy for prostate cancer","Lu Y.","Curr Gene Ther. 2001 Jul;1(2):183-200. doi: 10.2174/1566523013348742.","Lu Y","Curr Gene Ther","2001","2002/07/12","","","10.2174/1566523013348742"
"12690615","CYP3A4: a potential prostate cancer risk factor for high-risk groups","Zeigler-Johnson C.","Clin J Oncol Nurs. 2001 Jul-Aug;5(4):153-4.","Zeigler-Johnson C","Clin J Oncol Nurs","2001","2003/04/15","","",""
"27788496","Nuclear transcription factor Nrf2 suppresses prostate cancer cells growth and migration through upregulating ferroportin","Xue D, Zhou C, Shi Y, Lu H, Xu R, He X.","Oncotarget. 2016 Nov 29;7(48):78804-78812. doi: 10.18632/oncotarget.12860.","Xue D","Oncotarget","2016","2016/10/28","PMC5346678","","10.18632/oncotarget.12860"
"7543616","The utility of prostate-specific antigen for detecting prostate cancer","Meyerhoff J.","JAMA. 1995 Aug 23-30;274(8):607-8; author reply 608-9. doi: 10.1001/jama.274.8.607a.","Meyerhoff J","JAMA","1995","1995/08/23","","","10.1001/jama.274.8.607a"
"7543614","The utility of prostate-specific antigen for detecting prostate cancer","Brunswick D.","JAMA. 1995 Aug 23-30;274(8):607; author reply 608-9. doi: 10.1001/jama.274.8.607c.","Brunswick D","JAMA","1995","1995/08/23","","","10.1001/jama.274.8.607c"
"7529342","New information about prostate-specific antigen and the paradoxes of prostate cancer","Lange PH.","JAMA. 1995 Jan 25;273(4):336-7.","Lange PH","JAMA","1995","1995/01/25","","",""
"15066232","Complications of androgen deprivation therapy in men with prostate cancer","Chen AC, Petrylak DP.","Curr Oncol Rep. 2004 May;6(3):209-15. doi: 10.1007/s11912-004-0051-0.","Chen AC","Curr Oncol Rep","2004","2004/04/07","","","10.1007/s11912-004-0051-0"
"24745488","Re: use of statins and the risk of death in patients with prostate cancer","Taneja SS, Penson DF.","J Urol. 2014 May;191(5):1288-9. doi: 10.1016/j.juro.2014.02.2579.","Taneja SS","J Urol","2014","2014/04/22","","","10.1016/j.juro.2014.02.2579"
"14562804","Prevention of prostate cancer with finasteride","Roehrborn CG.","N Engl J Med. 2003 Oct 16;349(16):1569-72; author reply 1569-72.","Roehrborn CG","N Engl J Med","2003","2003/10/18","","",""
"11799972","Re: A structured debate: immediate versus deferred androgen suppression in prostate cancer--evidence for deferred treatment","Kirk D.","J Urol. 2002 Feb;167(2 Pt 1):652, author reply 653.","Kirk D","J Urol","2002","2002/01/22","","",""
"11588835","Smoking and prostate cancer","Hickey K, Do KA, Green A.","Epidemiol Rev. 2001;23(1):115-25. doi: 10.1093/oxfordjournals.epirev.a000776.","Hickey K","Epidemiol Rev","2001","2001/10/09","","","10.1093/oxfordjournals.epirev.a000776"
"16556045","Genes in the polyamine biosynthesis pathway may be involved in prostate cancer susceptibility","Zeegers MP, Ostrer H.","Future Oncol. 2005 Oct;1(5):683-8. doi: 10.2217/14796694.1.5.683.","Zeegers MP","Future Oncol","2005","2006/03/25","","","10.2217/14796694.1.5.683"
"20798195","Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression","Madan RA, Gulley JL, Fojo T, Dahut WL.","Oncologist. 2010;15(9):969-75. doi: 10.1634/theoncologist.2010-0129. Epub 2010 Aug 26.","Madan RA","Oncologist","2010","2010/08/28","PMC3228037","","10.1634/theoncologist.2010-0129"
"24629494","The prognostic significance of Gleason scores in metastatic prostate cancer","Rusthoven CG, Carlson JA, Waxweiler TV, Yeh N, Raben D, Flaig TW, Kavanagh BD.","Urol Oncol. 2014 Jul;32(5):707-13. doi: 10.1016/j.urolonc.2014.01.004. Epub 2014 Mar 12.","Rusthoven CG","Urol Oncol","2014","2014/03/18","","","10.1016/j.urolonc.2014.01.004"
"21896985","Expression of hypoxia inducible factor-1 alpha in matched hormone naive and castrate resistant prostate cancer specimens","Elsberger B, Lankston L, Orange C, Underwood MA, Edwards J.","Cancer Biomark. 2010-2011;8(1):1-9. doi: 10.3233/DMA-2011-0805.","Elsberger B","Cancer Biomark","2010","2011/09/08","","","10.3233/DMA-2011-0805"
"25224731","WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo","Thiele S, Göbel A, Rachner TD, Fuessel S, Froehner M, Muders MH, Baretton GB, Bernhardt R, Jakob F, Glüer CC, Bornhäuser M, Rauner M, Hofbauer LC.","J Bone Miner Res. 2015 Mar;30(3):471-80. doi: 10.1002/jbmr.2362.","Thiele S","J Bone Miner Res","2015","2014/09/17","","","10.1002/jbmr.2362"
"7523716","The use of prostate specific antigen for prostate cancer screening: a managed care perspective","Handley MR, Stuart ME.","J Urol. 1994 Nov;152(5 Pt 2):1689-92. doi: 10.1016/s0022-5347(17)32362-5.","Handley MR","J Urol","1994","1994/11/01","","","10.1016/s0022-5347(17)32362-5"
"31231006","Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice","Morgan SC.","J Med Imaging Radiat Sci. 2019 Dec;50(4S1):S26-S30. doi: 10.1016/j.jmir.2019.05.006. Epub 2019 Jun 21.","Morgan SC","J Med Imaging Radiat Sci","2019","2019/06/25","","","10.1016/j.jmir.2019.05.006"
"19418833","[EAU guidelines on prostate cancer]","Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F; European Association of Urology.","Actas Urol Esp. 2009 Feb;33(2):113-26. doi: 10.1016/s0210-4806(09)74110-5.","Heidenreich A","Actas Urol Esp","2009","2009/05/08","","","10.1016/s0210-4806(09)74110-5"
"26632144","Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis","Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, Albertsen PC, Tombal B, Payne HA, Rosario DJ.","Eur Urol. 2016 Apr;69(4):693-703. doi: 10.1016/j.eururo.2015.10.047. Epub 2015 Nov 26.","Bourke L","Eur Urol","2016","2015/12/04","","","10.1016/j.eururo.2015.10.047"
"16607648","After prostate cancer: predictors of well-being among long-term prostate cancer survivors","Blank TO, Bellizzi KM.","Cancer. 2006 May 15;106(10):2128-35. doi: 10.1002/cncr.21865.","Blank TO","Cancer","2006","2006/04/12","","","10.1002/cncr.21865"
"8946774","Prostate specific antigen in the diagnosis and staging of prostate cancer","Jung P, Wolff JM, Mattelaer P, Jakse G.","Acta Urol Belg. 1996 Sep;64(3):1-6.","Jung P","Acta Urol Belg","1996","1996/09/01","","",""
"9893221","[Trends of prostate cancer: comparison between 1986-90 and 1991-95 at Asahi General Hospital]","Tanaka M, Murakami S, Suzuki N, Oikawa T, Kinsui H, Hamano S, Shimazaki J.","Hinyokika Kiyo. 1998 Nov;44(11):775-80.","Tanaka M","Hinyokika Kiyo","1998","1999/01/20","","",""
"22498205","Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected","Rosenkrantz AB, Mendrinos S, Babb JS, Taneja SS.","J Urol. 2012 Jun;187(6):2032-8. doi: 10.1016/j.juro.2012.01.074. Epub 2012 Apr 11.","Rosenkrantz AB","J Urol","2012","2012/04/14","","","10.1016/j.juro.2012.01.074"
"17140722","Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy","Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P.","Eur Urol. 2007 Dec;52(6):1645-50. doi: 10.1016/j.eururo.2006.11.018. Epub 2006 Nov 15.","Choo R","Eur Urol","2007","2006/12/05","","","10.1016/j.eururo.2006.11.018"
"28097325","Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review","Lindenberg ML, Turkbey B, Mena E, Choyke PL.","JAMA Oncol. 2017 Oct 1;3(10):1415-1422. doi: 10.1001/jamaoncol.2016.5840.","Lindenberg ML","JAMA Oncol","2017","2017/01/19","","","10.1001/jamaoncol.2016.5840"
"30057131","How Are Gleason Scores Categorized in the Current Literature: An Analysis and Comparison of Articles Published in 2016-2017","Zhou AG, Salles DC, Samarska IV, Epstein JI.","Eur Urol. 2019 Jan;75(1):25-31. doi: 10.1016/j.eururo.2018.07.021. Epub 2018 Jul 26.","Zhou AG","Eur Urol","2019","2018/07/31","","","10.1016/j.eururo.2018.07.021"
"16832416","Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing","Pashayan N, Powles J, Brown C, Duffy SW.","Br J Cancer. 2006 Aug 7;95(3):398-400. doi: 10.1038/sj.bjc.6603247. Epub 2006 Jul 11.","Pashayan N","Br J Cancer","2006","2006/07/13","PMC2360650","","10.1038/sj.bjc.6603247"
"26053511","Effects of dihydroxy gymnemic triacetate (DGT) on expression of apoptosis associated proteins in human prostate cancer cell lines (PC3)","Pon Nivedha R, Selvaraj J, Lalitha KG, Rajalakshmi M.","J Recept Signal Transduct Res. 2015;35(6):605-12. doi: 10.3109/10799893.2015.1034368. Epub 2015 Jun 8.","Pon Nivedha R","J Recept Signal Transduct Res","2015","2015/06/09","","","10.3109/10799893.2015.1034368"
"30131606","Estrogens and prostate cancer","Dobbs RW, Malhotra NR, Greenwald DT, Wang AY, Prins GS, Abern MR.","Prostate Cancer Prostatic Dis. 2019 May;22(2):185-194. doi: 10.1038/s41391-018-0081-6. Epub 2018 Aug 21.","Dobbs RW","Prostate Cancer Prostatic Dis","2019","2018/08/23","","","10.1038/s41391-018-0081-6"
"19070812","[Role of hormonotherapy in the treatment of metastatic prostate cancer]","Lebret T, Méjean A.","Prog Urol. 2008 Nov;18 Suppl 7:S332-7. doi: 10.1016/S1166-7087(08)74563-9.","Lebret T","Prog Urol","2008","2008/12/17","","","10.1016/S1166-7087(08)74563-9"
"17997435","Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer","Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, Rittmaster RS, Too CK.","J Urol. 2008 Jan;179(1):147-51. doi: 10.1016/j.juro.2007.08.155. Epub 2007 Nov 13.","Thomas LN","J Urol","2008","2007/11/13","","","10.1016/j.juro.2007.08.155"
"17146873","When watchful waiting is right choice for prostate cancer","","Johns Hopkins Med Lett Health After 50. 2006 Oct;18(8):1-2.","","Johns Hopkins Med Lett Health After 50","2006","2006/12/07","","",""
"8905018","To screen or not to screen? The prostate cancer question","Dickman S.","Ann Oncol. 1996 Sep;7(7):648-9. doi: 10.1093/oxfordjournals.annonc.a010702.","Dickman S","Ann Oncol","1996","1996/09/01","","","10.1093/oxfordjournals.annonc.a010702"
"24713827","The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis","Luo Y, Gou X, Huang P, Mou C.","Asian J Androl. 2014 May-Jun;16(3):487-92. doi: 10.4103/1008-682X.125390.","Luo Y","Asian J Androl","2014","2014/04/10","PMC4023384","","10.4103/1008-682X.125390"
"14624904","Complexed PSA performance for prostate cancer detection in an African-American population","Martin B, Cheli CD, Lifsey D, Ward M, Pollard S, Jefferson L, Thiel RP, Rayford W.","Urology. 2003 Nov;62(5):835-9. doi: 10.1016/s0090-4295(03)00675-7.","Martin B","Urology","2003","2003/11/20","","","10.1016/s0090-4295(03)00675-7"
"20956477","Functional imaging of localized prostate cancer aggressiveness using 11C-acetate PET/CT and 1H-MR spectroscopy","Jambor I, Borra R, Kemppainen J, Lepomäki V, Parkkola R, Dean K, Alanen K, Arponen E, Nurmi M, Aronen HJ, Minn H.","J Nucl Med. 2010 Nov;51(11):1676-83. doi: 10.2967/jnumed.110.078667. Epub 2010 Oct 18.","Jambor I","J Nucl Med","2010","2010/10/20","","","10.2967/jnumed.110.078667"
"21599989","Prostate cancer metastases to the rectum: a case report","Abbas TO, Al-Naimi AR, Yakoob RA, Al-Bozom IA, Alobaidly AM.","World J Surg Oncol. 2011 May 21;9:56. doi: 10.1186/1477-7819-9-56.","Abbas TO","World J Surg Oncol","2011","2011/05/24","PMC3127764","","10.1186/1477-7819-9-56"
"25422189","Prostate cancer incidence in Turkey: an epidemiological study","Zorlu F, Zorlu R, Divrik RT, Eser S, Yorukoglu K.","Asian Pac J Cancer Prev. 2014;15(21):9125-30. doi: 10.7314/apjcp.2014.15.21.9125.","Zorlu F","Asian Pac J Cancer Prev","2014","2014/11/26","","","10.7314/apjcp.2014.15.21.9125"
"11525288","Prostate pathology: histologic and molecular perspectives","Putzi MJ, De Marzo AM.","Hematol Oncol Clin North Am. 2001 Jun;15(3):407-21. doi: 10.1016/s0889-8588(05)70223-9.","Putzi MJ","Hematol Oncol Clin North Am","2001","2001/08/30","","","10.1016/s0889-8588(05)70223-9"
"16266977","Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient","Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O.","Cancer Res. 2005 Nov 1;65(21):9611-6. doi: 10.1158/0008-5472.CAN-05-0817.","Yoshida T","Cancer Res","2005","2005/11/04","","","10.1158/0008-5472.CAN-05-0817"
"21796655","Development of a castrate resistant transplant tumor model of prostate cancer","Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R.","Prostate. 2012 May 1;72(6):587-91. doi: 10.1002/pros.21465. Epub 2011 Jul 27.","Ellis L","Prostate","2012","2011/07/29","PMC3298731","NIHMS338923","10.1002/pros.21465"
"12613352","An analysis of gene array data related to cell adhesion and prostate cancer","Jovanovic BD, Huang S, Liu Y, Naguib KN, Bergan RC.","Cancer Treat Res. 2002;113:91-111. doi: 10.1007/978-1-4757-3571-0_6.","Jovanovic BD","Cancer Treat Res","2002","2003/03/05","","","10.1007/978-1-4757-3571-0_6"
"21429659","Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf","Pitchakarn P, Suzuki S, Ogawa K, Pompimon W, Takahashi S, Asamoto M, Limtrakul P, Shirai T.","Cancer Lett. 2011 Jul 28;306(2):142-50. doi: 10.1016/j.canlet.2011.02.041. Epub 2011 Mar 22.","Pitchakarn P","Cancer Lett","2011","2011/03/25","","","10.1016/j.canlet.2011.02.041"
"22694113","Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer","Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD.","Am J Manag Care. 2012 May 1;18(5):e186-93.","Hodges JC","Am J Manag Care","2012","2012/06/15","","",""
"27617558","Enzalutamide as monotherapy for advanced prostate cancer: why not?","Dellavedova T, Boetto M, Olmedo J, Sarria JP, Nóbile R, Ponzano R, Quinteros L, Malizia Reynoso E, Minuzzi F.","Arch Esp Urol. 2016 Sep;69(7):393-7.","Dellavedova T","Arch Esp Urol","2016","2016/09/13","","",""
"7501541","Current status of neoadjuvant therapy in localized prostate cancer","Witjes WP, Oosterhof GO, Schaafsma HE, Debruyne FM.","Prostate. 1995 Dec;27(6):297-303. doi: 10.1002/pros.2990270602.","Witjes WP","Prostate","1995","1995/12/01","","","10.1002/pros.2990270602"
"19037836","Therapeutic prostate cancer vaccines: a review of the latest developments","Mohebtash M, Madan RA, Gulley JL, Arlen PM.","Curr Opin Investig Drugs. 2008 Dec;9(12):1296-301.","Mohebtash M","Curr Opin Investig Drugs","2008","2008/11/28","PMC3487159","NIHMS415896",""
"17299890","Intensity modulated radiation therapy safe, effective for prostate cancer","","Duke Med Health News. 2007 Jan;13(1):10.","","Duke Med Health News","2007","2007/02/16","","",""
"30840361","Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer","McEwan L, McBean R, Yaxley J, Wong D.","J Med Imaging Radiat Oncol. 2019 Jun;63(3):318-323. doi: 10.1111/1754-9485.12864. Epub 2019 Mar 6.","McEwan L","J Med Imaging Radiat Oncol","2019","2019/03/07","","","10.1111/1754-9485.12864"
"23271779","Active surveillance: the Canadian experience with an ""inclusive approach""","Klotz L.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):234-41. doi: 10.1093/jncimonographs/lgs042.","Klotz L","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540875","","10.1093/jncimonographs/lgs042"
"15538230","Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy","de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH.","J Urol. 2004 Dec;172(6 Pt 1):2193-6. doi: 10.1097/01.ju.0000140958.31366.9f.","de Vries SH","J Urol","2004","2004/11/13","","","10.1097/01.ju.0000140958.31366.9f"
"27573795","Evaluation of Frequency Domain Analysis of a Multiwavelength Photoacoustic Signal for Differentiating Malignant From Benign and Normal Prostates: Ex Vivo Study With Human Prostates","Sinha S, Rao NA, Chinni BK, Dogra VS.","J Ultrasound Med. 2016 Oct;35(10):2165-77. doi: 10.7863/ultra.15.09059. Epub 2016 Aug 29.","Sinha S","J Ultrasound Med","2016","2016/08/31","PMC5651985","NIHMS911213","10.7863/ultra.15.09059"
"10344223","Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)","Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH.","Prostate. 1999 Jun 1;39(4):316-22. doi: 10.1002/(sici)1097-0045(19990601)39:4<316::aid-pros14>3.0.co;2-o.","Kranse R","Prostate","1999","1999/05/27","","","10.1002/(sici)1097-0045(19990601)39:4<316::aid-pros14>3.0.co;2-o"
"3173502","Value of and indications for pelvic lymph node dissection in the staging of prostate cancer","Middleton RG.","NCI Monogr. 1988;(7):41-3.","Middleton RG","NCI Monogr","1988","1988/01/01","","",""
"31099011","Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells","Rahme K, Guo J, Holmes JD.","Methods Mol Biol. 2019;1974:291-301. doi: 10.1007/978-1-4939-9220-1_21.","Rahme K","Methods Mol Biol","2019","2019/05/18","","","10.1007/978-1-4939-9220-1_21"
"17219775","Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model","Pollard M, Suckow MA.","Comp Med. 2006 Dec;56(6):461-7.","Pollard M","Comp Med","2006","2007/01/16","","",""
"26666409","Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer","Barzi A, Klein EA, Dorff TB, Quinn DI, Sadeghi S.","Prostate Cancer Prostatic Dis. 2016 Mar;19(1):84-91. doi: 10.1038/pcan.2015.56. Epub 2015 Dec 15.","Barzi A","Prostate Cancer Prostatic Dis","2016","2015/12/16","","","10.1038/pcan.2015.56"
"16547154","Genomic and expression analysis of the 3q25-q26 amplification unit reveals TLOC1/SEC62 as a probable target gene in prostate cancer","Jung V, Kindich R, Kamradt J, Jung M, Müller M, Schulz WA, Engers R, Unteregger G, Stöckle M, Zimmermann R, Wullich B.","Mol Cancer Res. 2006 Mar;4(3):169-76. doi: 10.1158/1541-7786.MCR-05-0165.","Jung V","Mol Cancer Res","2006","2006/03/21","","","10.1158/1541-7786.MCR-05-0165"
"10502724","Decreased expression of CD44 in metastatic prostate cancer","Noordzij MA, van Steenbrugge GJ, Schröder FH, Van der Kwast TH.","Int J Cancer. 1999 Oct 22;84(5):478-83. doi: 10.1002/(sici)1097-0215(19991022)84:5<478::aid-ijc5>3.0.co;2-n.","Noordzij MA","Int J Cancer","1999","1999/09/30","","","10.1002/(sici)1097-0215(19991022)84:5<478::aid-ijc5>3.0.co;2-n"
"31570421","Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies","Mokbel K, Wazir U, Mokbel K.","Anticancer Res. 2019 Oct;39(10):5231-5259. doi: 10.21873/anticanres.13720.","Mokbel K","Anticancer Res","2019","2019/10/02","","","10.21873/anticanres.13720"
"31139907","From indecision to precision: advances in imaging in metastatic prostate cancer","Bolton D, Frydenberg M.","World J Urol. 2019 Jul;37(7):1237. doi: 10.1007/s00345-019-02820-9.","Bolton D","World J Urol","2019","2019/05/30","","","10.1007/s00345-019-02820-9"
"28753752","Comorbidity and the Receipt of Curative Therapy for Favorable-risk Prostate Cancer Prior to and Following the Publication of PIVOT","Mihalcik SA, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.","Eur Urol Focus. 2018 Jan;4(1):64-67. doi: 10.1016/j.euf.2016.02.007. Epub 2016 Mar 3.","Mihalcik SA","Eur Urol Focus","2018","2017/07/30","","","10.1016/j.euf.2016.02.007"
"16623302","Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience","Manenti G, Squillaci E, Carlani M, Mancino S, Di Roma M, Simonetti G.","Radiol Med. 2006 Feb;111(1):22-32. doi: 10.1007/s11547-006-0003-x.","Manenti G","Radiol Med","2006","2006/04/21","","","10.1007/s11547-006-0003-x"
"28605139","Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer","Sun Z, Ju Y, Han F, Sun X, Wang F.","J Clin Lab Anal. 2018 Mar;32(3):e22277. doi: 10.1002/jcla.22277. Epub 2017 Jun 12.","Sun Z","J Clin Lab Anal","2018","2017/06/13","PMC6816827","","10.1002/jcla.22277"
"26399130","[A CASE OF PROSTATE CANCER WITH UNUSUAL PATTERN OF RECURRENCE AFTER RADIOTHERAPY]","Oshinomi K, Fukagai T, Ogawa Y, Sato N, Morita J, Aso T, Igarashi A, Morita M, Naoe M, Fuji K, Ogawa Y.","Nihon Hinyokika Gakkai Zasshi. 2015 Jan;106(1):40-4. doi: 10.5980/jpnjurol.106.40.","Oshinomi K","Nihon Hinyokika Gakkai Zasshi","2015","2015/09/25","","","10.5980/jpnjurol.106.40"
"23094957","Anti-angiogenic therapies in prostate cancer","Martínez-Jabaloyas JM, March-Villalba JA, Navarro-García MM, Dasi F.","Expert Opin Biol Ther. 2013 Jan;13(1):1-5. doi: 10.1517/14712598.2013.733366. Epub 2012 Oct 24.","Martínez-Jabaloyas JM","Expert Opin Biol Ther","2013","2012/10/26","","","10.1517/14712598.2013.733366"
"10814952","After effects: tackling the morbidity of prostate cancer treatment","Moore KN.","J Wound Ostomy Continence Nurs. 2000 May;27(3):188-90. doi: 10.1016/s1071-5754(00)90057-3.","Moore KN","J Wound Ostomy Continence Nurs","2000","2000/05/18","","","10.1016/s1071-5754(00)90057-3"
"8371422","Disease-specific survival following routine prostate cancer screening by digital rectal examination","Walsh PC.","J Urol. 1993 Oct;150(4):1328-9. doi: 10.1016/s0022-5347(17)35771-3.","Walsh PC","J Urol","1993","1993/10/01","","","10.1016/s0022-5347(17)35771-3"
"3309979","Monitoring of prostate volume by ultrasound in hormonally treated prostate cancer","Brandt B, Menu G, el Khansa A, Lardennois B.","Prog Clin Biol Res. 1987;243B:13-9.","Brandt B","Prog Clin Biol Res","1987","1987/01/01","","",""
"26384467","Is there a place for cytoreduction in metastatic prostate cancer?","Reeves F, Costello AJ.","BJU Int. 2016 Jul;118(1):14-5. doi: 10.1111/bju.13323. Epub 2015 Oct 10.","Reeves F","BJU Int","2016","2015/09/20","","","10.1111/bju.13323"
"25203849","Choosing a prostate cancer drug","Baker H.","Br J Nurs. 2014 Sep 11-24;23(16):S14, S16. doi: 10.12968/bjon.2014.23.Sup16.S14.","Baker H","Br J Nurs","2014","2014/09/10","","","10.12968/bjon.2014.23.Sup16.S14"
"20660824","Do not count out external-beam radiation therapy for high-risk prostate cancer","Hamstra DA, Michalski JM, Roach M, Sandler HM.","J Clin Oncol. 2010 Oct 1;28(28):e518-9; author reply e521-e522. doi: 10.1200/JCO.2010.28.9561. Epub 2010 Jul 26.","Hamstra DA","J Clin Oncol","2010","2010/07/28","","","10.1200/JCO.2010.28.9561"
"31804971","The epigenetic and transcriptional landscape of neuroendocrine prostate cancer","Davies A, Zoubeidi A, Selth LA.","Endocr Relat Cancer. 2020 Feb;27(2):R35-R50. doi: 10.1530/ERC-19-0420.","Davies A","Endocr Relat Cancer","2020","2019/12/06","","","10.1530/ERC-19-0420"
"26101110","Prostate cancer: High-dose-rate brachytherapy as monotherapy in prostate cancer","Kelsey R.","Nat Rev Urol. 2015 Jul;12(7):359. doi: 10.1038/nrurol.2015.151. Epub 2015 Jun 23.","Kelsey R","Nat Rev Urol","2015","2015/06/24","","","10.1038/nrurol.2015.151"
"25854524","Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians","Valdivieso R, Boehm K, Meskawi M, Larcher A, Tian Z, Parent ME, Wong P, Graefen M, Montorsi F, Sun M, Saad F, Karakiewicz PI.","World J Urol. 2015 Dec;33(12):1985-91. doi: 10.1007/s00345-015-1553-0. Epub 2015 Apr 9.","Valdivieso R","World J Urol","2015","2015/04/10","","","10.1007/s00345-015-1553-0"
"31679268","MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in Prostate Cancer","Aghdam AM, Amiri A, Salarinia R, Masoudifar A, Ghasemi F, Mirzaei H.","Crit Rev Eukaryot Gene Expr. 2019;29(2):127-139. doi: 10.1615/CritRevEukaryotGeneExpr.2019025273.","Aghdam AM","Crit Rev Eukaryot Gene Expr","2019","2019/11/04","","","10.1615/CritRevEukaryotGeneExpr.2019025273"
"17672524","Application of linear discriminant analysis in prostate cancer research by synchrotron radiation-induced X-ray emission","Banaś K, Jasiński A, Banaś AM, Gajda M, Dyduch G, Pawlicki B, Kwiatek WM.","Anal Chem. 2007 Sep 1;79(17):6670-4. doi: 10.1021/ac070931u. Epub 2007 Aug 3.","Banaś K","Anal Chem","2007","2007/08/04","","","10.1021/ac070931u"
"23159454","Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience","Napoli A, Anzidei M, De Nunzio C, Cartocci G, Panebianco V, De Dominicis C, Catalano C, Petrucci F, Leonardo C.","Eur Urol. 2013 Feb;63(2):395-8. doi: 10.1016/j.eururo.2012.11.002. Epub 2012 Nov 12.","Napoli A","Eur Urol","2013","2012/11/20","","","10.1016/j.eururo.2012.11.002"
"22961777","Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort","Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM.","Cancer Prev Res (Phila). 2012 Oct;5(10):1223-8. doi: 10.1158/1940-6207.CAPR-12-0171. Epub 2012 Sep 7.","Dhillon PK","Cancer Prev Res (Phila)","2012","2012/09/11","PMC3526345","NIHMS404753","10.1158/1940-6207.CAPR-12-0171"
"11942960","Prognostic value of the Gleason score in prostate cancer","Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P.","BJU Int. 2002 Apr;89(6):538-42. doi: 10.1046/j.1464-410x.2002.02669.x.","Egevad L","BJU Int","2002","2002/04/12","","","10.1046/j.1464-410x.2002.02669.x"
"8547836","Genetic characteristics of prostate cancer","Huncharek M, Muscat J.","Cancer Epidemiol Biomarkers Prev. 1995 Sep;4(6):681-7.","Huncharek M","Cancer Epidemiol Biomarkers Prev","1995","1995/09/01","","",""
"21820580","Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial","Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.","Urology. 2011 Aug;78(2):380-5. doi: 10.1016/j.urology.2011.03.033.","Aubin SM","Urology","2011","2011/08/09","","","10.1016/j.urology.2011.03.033"
"10451026","In situ gene therapy for prostate cancer","Thompson TC.","Oncol Res. 1999;11(1):1-8.","Thompson TC","Oncol Res","1999","1999/08/18","","",""
"28666689","Optimum Tools for Predicting Clinical Outcomes in Prostate Cancer Patients Undergoing Radical Prostatectomy: A Systematic Review of Prognostic Accuracy and Validity","Campbell JM, Raymond E, O'Callaghan ME, Vincent AD, Beckmann KR, Roder D, Evans S, McNeil J, Millar J, Zalcberg J, Borg M, Moretti KL.","Clin Genitourin Cancer. 2017 Oct;15(5):e827-e834. doi: 10.1016/j.clgc.2017.06.001. Epub 2017 Jun 8.","Campbell JM","Clin Genitourin Cancer","2017","2017/07/02","","","10.1016/j.clgc.2017.06.001"
"19719458","Cytotoxic compounds in the treatment of castration-resistant prostate cancer","Lee P, Aragon-Ching JB.","Anticancer Agents Med Chem. 2009 Dec;9(10):1040-5. doi: 10.2174/187152009789734991.","Lee P","Anticancer Agents Med Chem","2009","2009/09/02","","","10.2174/187152009789734991"
"19015618","Superior vena cava syndrome caused by an intravascular thrombosis due to underlying prostate carcinoma","Takeda T, Saitoh M, Takeda S.","Intern Med. 2008;47(22):2007-9. doi: 10.2169/internalmedicine.47.1428. Epub 2008 Nov 17.","Takeda T","Intern Med","2008","2008/11/19","","","10.2169/internalmedicine.47.1428"
"30228707","Radiation Therapy for Prostate Cancer","Gay HA, Michalski JM.","Mo Med. 2018 Mar-Apr;115(2):146-150.","Gay HA","Mo Med","2018","2018/09/20","PMC6139853","",""
"19154509","Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men","van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.","BJU Int. 2009 Jun;103(11):1472-7. doi: 10.1111/j.1464-410X.2008.08281.x. Epub 2009 Jan 19.","van den Bergh RC","BJU Int","2009","2009/01/22","","","10.1111/j.1464-410X.2008.08281.x"
"23754478","Can high-spatial resolution T2-weighted endorectal MRI rule out clinically significant prostate cancer?","Roethke MC, Kniess M, Kaufmann S, Lichy MP, Schlemmer HP, Stenzl A, Schilling D.","World J Urol. 2014 Apr;32(2):379-83. doi: 10.1007/s00345-013-1106-3. Epub 2013 Jun 11.","Roethke MC","World J Urol","2014","2013/06/12","","","10.1007/s00345-013-1106-3"
"18225389","Soft tissue tumors of the prostate: a review","Wagner DG, Yao JL, di Sant'Agnese PA, Cheng L, Lopez-Beltran A, Montironi R, Huang J.","Anal Quant Cytol Histol. 2007 Dec;29(6):341-50.","Wagner DG","Anal Quant Cytol Histol","2007","2008/01/30","","",""
"24582536","Detection of prostate cancer by an electronic nose: a proof of principle study","Roine A, Veskimäe E, Tuokko A, Kumpulainen P, Koskimäki J, Keinänen TA, Häkkinen MR, Vepsäläinen J, Paavonen T, Lekkala J, Lehtimäki T, Tammela TL, Oksala NK.","J Urol. 2014 Jul;192(1):230-4. doi: 10.1016/j.juro.2014.01.113. Epub 2014 Feb 25.","Roine A","J Urol","2014","2014/03/04","","","10.1016/j.juro.2014.01.113"
"1600494","Controversies in the treatment of metastatic prostate cancer","McLeod DG, Crawford ED, Blumenstein BA, Eisenberger MA, Dorr FA.","Cancer. 1992 Jul 1;70(1 Suppl):324-8. doi: 10.1002/1097-0142(19920701)70:1+<324::aid-cncr2820701321>3.0.co;2-g.","McLeod DG","Cancer","1992","1992/07/01","","","10.1002/1097-0142(19920701)70:1+<324::aid-cncr2820701321>3.0.co;2-g"
"11095083","Evaluation of prognostic factors in prostate cancer with partial least squares analysis","Wikström P, Wikström P, Lissbrant IF, Bergh A, Damber JE, Stattin P.","Scand J Urol Nephrol. 2000 Aug;34(4):252-6. doi: 10.1080/003655900750041988.","Wikström P","Scand J Urol Nephrol","2000","2000/11/30","","","10.1080/003655900750041988"
"2626379","Morphometry of in vitro systems. An image analysis of two human prostate cancer cell lines (PC3 and DU-145)","Carruba G, Pavone C, Pavone-Macaluso M, Mesiti M, d'Aquino A, Vita G, Sica G, Castagnetta L.","Pathol Res Pract. 1989 Nov;185(5):704-8. doi: 10.1016/S0344-0338(89)80222-5.","Carruba G","Pathol Res Pract","1989","1989/11/01","","","10.1016/S0344-0338(89)80222-5"
"22826149","Declines in prostate cancer incidence after changes in screening recommendations","Howard DH.","Arch Intern Med. 2012 Sep 10;172(16):1267-8. doi: 10.1001/archinternmed.2012.2768.","Howard DH","Arch Intern Med","2012","2012/07/25","","","10.1001/archinternmed.2012.2768"
"26449176","Optimal method for measuring tumor extent in needle biopsy specimens to identify small-volume prostate cancer","Kajikawa K, Kanao K, Kobayashi I, Nishikawa G, Yoshizawa T, Kato Y, Watanabe M, Zennami K, Nakamura K, Sumitomo M.","Int J Urol. 2016 Jan;23(1):62-8. doi: 10.1111/iju.12961. Epub 2015 Oct 8.","Kajikawa K","Int J Urol","2016","2015/10/10","","","10.1111/iju.12961"
"9372882","Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series","Adolfsson J, Steineck G, Hedlund PO.","Urology. 1997 Nov;50(5):722-6. doi: 10.1016/S0090-4295(97)00320-8.","Adolfsson J","Urology","1997","1997/12/31","","","10.1016/S0090-4295(97)00320-8"
"24518783","Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer","Filson CP, Schroeck FR, Ye Z, Wei JT, Hollenbeck BK, Miller DC.","J Urol. 2014 Jul;192(1):75-80. doi: 10.1016/j.juro.2014.01.105. Epub 2014 Feb 8.","Filson CP","J Urol","2014","2014/02/13","","","10.1016/j.juro.2014.01.105"
"21656829","Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy","Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Huang CY, Pu YS, Yu CC, Huang CH.","Prostate. 2011 Aug 1;71(11):1189-97. doi: 10.1002/pros.21334. Epub 2011 Jan 12.","Huang SP","Prostate","2011","2011/06/10","","","10.1002/pros.21334"
"9072591","The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate","Ornstein DK, Rao GS, Smith DS, Andriole GL.","J Urol. 1997 Mar;157(3):880-3; discussion 883-4.","Ornstein DK","J Urol","1997","1997/03/01","","",""
"25278357","Biopsy sampling and histopathological markers for diagnosis of prostate cancer","Rodrigues Â, Freitas R, Nogueira-Silva P, Jerónimo C, Henrique R.","Expert Rev Anticancer Ther. 2014 Nov;14(11):1323-36. doi: 10.1586/14737140.2014.965688. Epub 2014 Oct 2.","Rodrigues Â","Expert Rev Anticancer Ther","2014","2014/10/04","","","10.1586/14737140.2014.965688"
"26149890","Comorbidity and the risk of venous thromboembolism in prostate cancer","Alibhai SM, O'Neill ME.","Cancer. 2015 Oct 15;121(20):3574-6. doi: 10.1002/cncr.29536. Epub 2015 Jul 6.","Alibhai SM","Cancer","2015","2015/07/08","","","10.1002/cncr.29536"
"20970419","The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population","Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, Weng Z, Li C, Wu X, Tao Z.","Exp Mol Pathol. 2011 Feb;90(1):97-100. doi: 10.1016/j.yexmp.2010.10.009. Epub 2010 Oct 20.","Shen M","Exp Mol Pathol","2011","2010/10/26","","","10.1016/j.yexmp.2010.10.009"
"8997470","Nilutamide: an antiandrogen for the treatment of prostate cancer","Dole EJ, Holdsworth MT.","Ann Pharmacother. 1997 Jan;31(1):65-75. doi: 10.1177/106002809703100112.","Dole EJ","Ann Pharmacother","1997","1997/01/01","","","10.1177/106002809703100112"
"23943809","Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer","Ragnarsson O, Johannsson G, Geterud K, Lodding P, Dahlqvist P.","BMJ Case Rep. 2013 Aug 13;2013:bcr2013010395. doi: 10.1136/bcr-2013-010395.","Ragnarsson O","BMJ Case Rep","2013","2013/08/15","PMC3761979","","10.1136/bcr-2013-010395"
"21829199","Genetic architecture of prostate cancer in the Ashkenazi Jewish population","Vijai J, Kirchhoff T, Gallagher D, Hamel N, Guha S, Darvasi A, Lencz T, Foulkes WD, Offit K, Klein RJ.","Br J Cancer. 2011 Sep 6;105(6):864-9. doi: 10.1038/bjc.2011.307. Epub 2011 Aug 9.","Vijai J","Br J Cancer","2011","2011/08/11","PMC3171013","","10.1038/bjc.2011.307"
"7924716","Is there a relationship between colorectal and prostate cancer?","Simon J, Vernava AM, Longo WE.","Dis Colon Rectum. 1994 Oct;37(10):1048. doi: 10.1007/BF02049324.","Simon J","Dis Colon Rectum","1994","1994/10/01","","","10.1007/BF02049324"
"24323132","Prostate cancer: Localized disease-are most men really suitable for focal therapy?","Challacombe B, Dixon L.","Nat Rev Urol. 2014 Jan;11(1):7-8. doi: 10.1038/nrurol.2013.297. Epub 2013 Dec 10.","Challacombe B","Nat Rev Urol","2014","2013/12/11","","","10.1038/nrurol.2013.297"
"30772358","Biological Evolution of Castration-resistant Prostate Cancer","Davies A, Conteduca V, Zoubeidi A, Beltran H.","Eur Urol Focus. 2019 Mar;5(2):147-154. doi: 10.1016/j.euf.2019.01.016. Epub 2019 Feb 14.","Davies A","Eur Urol Focus","2019","2019/02/18","","","10.1016/j.euf.2019.01.016"
"2219575","Transrectal ultrasonography for the early detection and staging of prostate cancer","Hernandez AD, Smith JA Jr.","Urol Clin North Am. 1990 Nov;17(4):745-57.","Hernandez AD","Urol Clin North Am","1990","1990/11/01","","",""
"21358335","Contemporary management of patients with T1a and T1b prostate cancer","Capitanio U.","Curr Opin Urol. 2011 May;21(3):252-6. doi: 10.1097/MOU.0b013e328344e4ad.","Capitanio U","Curr Opin Urol","2011","2011/03/02","","","10.1097/MOU.0b013e328344e4ad"
"26793871","[Molecular-targeted therapy for prostate cancer]","Miyake H, Fujisawa M.","Nihon Rinsho. 2016 Jan;74(1):2-5.","Miyake H","Nihon Rinsho","2016","2016/01/23","","",""
"26181183","Active Surveillance in Prostate Cancer: How Far Should We Go?","Saad F.","JAMA Oncol. 2015 Jun;1(3):340-1. doi: 10.1001/jamaoncol.2015.103.","Saad F","JAMA Oncol","2015","2015/07/17","","","10.1001/jamaoncol.2015.103"
"12242903","Patient comfort an important consideration for treating men with prostate cancer","","Urol Nurs. 2002 Aug;22(4):285.","","Urol Nurs","2002","2002/09/24","","",""
"9735694","Epidemiology of prostate cancer","Diokno AC.","West J Med. 1998 Aug;169(2):111-2.","Diokno AC","West J Med","1998","1998/09/15","PMC1305183","",""
"16093978","Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans","Whittemore AS, Cirillo PM, Feldman D, Cohn BA.","J Urol. 2005 Sep;174(3):872-6; discussion 876. doi: 10.1097/01.ju.0000169262.18000.8a.","Whittemore AS","J Urol","2005","2005/08/12","","","10.1097/01.ju.0000169262.18000.8a"
"23315596","Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial","Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes HL, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M.","Cancer Prev Res (Phila). 2013 Feb;6(2):91-9. doi: 10.1158/1940-6207.CAPR-12-0250. Epub 2013 Jan 11.","Neuhouser ML","Cancer Prev Res (Phila)","2013","2013/01/15","PMC3565024","NIHMS429095","10.1158/1940-6207.CAPR-12-0250"
"11121665","Real-time optimized intraoperative dosimetry for prostate brachytherapy: a pilot study","Beyer DC, Shapiro RH, Puente F.","Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1583-9. doi: 10.1016/s0360-3016(00)01363-8.","Beyer DC","Int J Radiat Oncol Biol Phys","2000","2000/12/21","","","10.1016/s0360-3016(00)01363-8"
"31672619","The role of adrenal derived androgens in castration resistant prostate cancer","Barnard M, Mostaghel EA, Auchus RJ, Storbeck KH.","J Steroid Biochem Mol Biol. 2020 Mar;197:105506. doi: 10.1016/j.jsbmb.2019.105506. Epub 2019 Oct 28.","Barnard M","J Steroid Biochem Mol Biol","2020","2019/11/02","","","10.1016/j.jsbmb.2019.105506"
"27372998","Test may diagnose prostate cancer more accurately","","Harv Mens Health Watch. 2016 Apr;20(9):8.","","Harv Mens Health Watch","2016","2016/07/05","","",""
"25908048","Loss of YAP protein in prostate cancer is associated with Gleason score increase","Hu X, Jia Y, Yu J, Chen J, Fu Q.","Tumori. 2015 Mar-Apr;101(2):189-93. doi: 10.5301/tj.5000238. Epub 2015 Apr 17.","Hu X","Tumori","2015","2015/04/25","","","10.5301/tj.5000238"
"10721945","The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer","Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, Okada K.","Jpn J Clin Oncol. 1999 Dec;29(12):623-9. doi: 10.1093/jjco/29.12.623.","Oyama N","Jpn J Clin Oncol","1999","2000/03/18","","","10.1093/jjco/29.12.623"
"16362587","Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men","Sheikh M, Al-Saeed O, Kehinde EO, Sinan T, Anim JT, Ali Y.","Int Urol Nephrol. 2005;37(4):721-6. doi: 10.1007/s11255-005-4683-2.","Sheikh M","Int Urol Nephrol","2005","2005/12/20","","","10.1007/s11255-005-4683-2"
"20460480","Susceptibility loci associated with prostate cancer progression and mortality","Gallagher DJ, Vijai J, Cronin AM, Bhatia J, Vickers AJ, Gaudet MM, Fine S, Reuter V, Scher HI, Halldén C, Dutra-Clarke A, Klein RJ, Scardino PT, Eastham JA, Lilja H, Kirchhoff T, Offit K.","Clin Cancer Res. 2010 May 15;16(10):2819-32. doi: 10.1158/1078-0432.CCR-10-0028. Epub 2010 May 11.","Gallagher DJ","Clin Cancer Res","2010","2010/05/13","PMC3732009","NIHMS268762","10.1158/1078-0432.CCR-10-0028"
"30053504","SNORA42 enhances prostate cancer cell viability, migration and EMT and is correlated with prostate cancer poor prognosis","Yi C, Wan X, Zhang Y, Fu F, Zhao C, Qin R, Wu H, Li Y, Huang Y.","Int J Biochem Cell Biol. 2018 Sep;102:138-150. doi: 10.1016/j.biocel.2018.07.009. Epub 2018 Jul 24.","Yi C","Int J Biochem Cell Biol","2018","2018/07/28","","","10.1016/j.biocel.2018.07.009"
"3618415","[A case of prostate cancer with multiple pulmonary metastases]","Katoh H, Yamamoto N, Harada Y, Chang PK, Takeuchi T, Kanematsu M, Kuriyama M, Ban Y, Matsui E.","Hinyokika Kiyo. 1987 Mar;33(3):441-6.","Katoh H","Hinyokika Kiyo","1987","1987/03/01","","",""
"24367864","Should all colorectal cancer patients over age 60 be screened for prostate cancer?","Aizer AA, D'Amico AV.","Oncology (Williston Park). 2013 Oct;27(10):1032-8.","Aizer AA","Oncology (Williston Park)","2013","2013/12/26","","",""
"14595888","[Radical prostatectomy in hemophiliac patient]","Gómez Jaramillo F, Duarte M, Raffansanabria F.","Arch Esp Urol. 2003 Sep;56(7):827-9.","Gómez Jaramillo F","Arch Esp Urol","2003","2003/11/05","","",""
"27420993","Correlation between methylation of the E-Cadherin gene and malignancy of prostate cancer","Zhang SQ, Zhang GQ, Zhang L.","Genet Mol Res. 2016 Jul 14;15(2). doi: 10.4238/gmr.15028046.","Zhang SQ","Genet Mol Res","2016","2016/07/16","","","10.4238/gmr.15028046"
"16643478","Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease","Cresswell J, Asterling S, Chaudhary M, Sheikh N, Greene D.","BJU Int. 2006 May;97(5):969-74. doi: 10.1111/j.1464-410X.2006.06073.x.","Cresswell J","BJU Int","2006","2006/04/29","","","10.1111/j.1464-410X.2006.06073.x"
"29694373","Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data","Cheung S, Hamuro Y, Mahlich J, Nakayama M, Tsubota A.","PLoS One. 2018 Apr 25;13(4):e0195789. doi: 10.1371/journal.pone.0195789. eCollection 2018.","Cheung S","PLoS One","2018","2018/04/26","PMC5919000","","10.1371/journal.pone.0195789"
"29129398","Genomic Markers in Prostate Cancer Decision Making","Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.","Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10.","Cucchiara V","Eur Urol","2018","2017/11/14","","","10.1016/j.eururo.2017.10.036"
"16651852","Detection of human chorionic gonadotrophin-beta in serum or urine of prostate cancer patients is of no clinical significance","Otite U, Baithun S, Chinegwundoh F, Nargund VH, Iles RK.","Tumour Biol. 2006;27(4):181-6. doi: 10.1159/000093021. Epub 2006 Apr 27.","Otite U","Tumour Biol","2006","2006/05/03","","","10.1159/000093021"
"18841289","Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells","Aberg M, Johnell M, Wickström M, Widunder A, Siegbahn A.","Thromb Haemost. 2008 Oct;100(4):655-62.","Aberg M","Thromb Haemost","2008","2008/10/09","","",""
"15570704","[Prostate cancer. Epidemiology. Risk factors. Pathology]","Fournier G, Valeri A, Mangin P, Cussenot O.","Ann Urol (Paris). 2004 Oct;38(5):187-206. doi: 10.1016/j.anuro.2004.07.001.","Fournier G","Ann Urol (Paris)","2004","2004/12/02","","","10.1016/j.anuro.2004.07.001"
"9286641","Long-term follow-up after open perineal cryotherapy in patients with locally confined prostate cancer","Mack D, Jungwirth A, Adam U, Kunit G, Miller K, Dietze O, Frick J.","Eur Urol. 1997;32(2):129-32.","Mack D","Eur Urol","1997","1997/01/01","","",""
"15049577","Prostate-specific antigen and screening for prostate cancer","Han M, Gann PH, Catalona WJ.","Med Clin North Am. 2004 Mar;88(2):245-65, ix. doi: 10.1016/S0025-7125(03)00188-3.","Han M","Med Clin North Am","2004","2004/03/31","","","10.1016/S0025-7125(03)00188-3"
"23485154","Salvage high-intensity focused ultrasound ablation for prostate cancer local recurrence after external-beam radiation therapy: prognostic value of prostate MRI","Rouvière O, Sbihi L, Gelet A, Chapelon JY.","Clin Radiol. 2013 Jul;68(7):661-7. doi: 10.1016/j.crad.2012.12.010. Epub 2013 Feb 26.","Rouvière O","Clin Radiol","2013","2013/03/15","","","10.1016/j.crad.2012.12.010"
"30784907","Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of prostate cancer cells by regulation of miR-23a","Xu F, Li Q, Wang Z, Cao X.","Biomed Pharmacother. 2019 Apr;112:108592. doi: 10.1016/j.biopha.2019.01.053. Epub 2019 Feb 18.","Xu F","Biomed Pharmacother","2019","2019/02/21","","","10.1016/j.biopha.2019.01.053"
"29667932","Fused-data transrectal EIT for prostate cancer imaging","Murphy EK, Wu X, Halter RJ.","Physiol Meas. 2018 May 25;39(5):054005. doi: 10.1088/1361-6579/aabf22.","Murphy EK","Physiol Meas","2018","2018/04/19","","","10.1088/1361-6579/aabf22"
"19846858","The index lesion and the origin of prostate cancer","Ahmed HU.","N Engl J Med. 2009 Oct 22;361(17):1704-6. doi: 10.1056/NEJMcibr0905562.","Ahmed HU","N Engl J Med","2009","2009/10/23","","","10.1056/NEJMcibr0905562"
"19192959","Multifunctional nanoparticles for prostate cancer therapy","Salvador-Morales C, Gao W, Ghatalia P, Murshed F, Aizu W, Langer R, Farokhzad OC.","Expert Rev Anticancer Ther. 2009 Feb;9(2):211-21. doi: 10.1586/14737140.9.2.211.","Salvador-Morales C","Expert Rev Anticancer Ther","2009","2009/02/06","","","10.1586/14737140.9.2.211"
"29789235","[Pathology findings after radical prostatectomy for prostate cancer in patients eligible for active surveillance: Contribution of multiparametric MRI to treatment decision]","Martin-Malburet A, Marcq G, Leroy X, Guiffart P, Fantoni JC, Flamand V, Villers A, Puech P, Ouzzane A.","Prog Urol. 2018 Jun;28(8-9):425-433. doi: 10.1016/j.purol.2018.03.012. Epub 2018 May 20.","Martin-Malburet A","Prog Urol","2018","2018/05/24","","","10.1016/j.purol.2018.03.012"
"30411504","Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer","Tomita N, Soga N, Ogura Y, Furusawa J, Tanaka H, Koide Y, Tachibana H, Kodira T.","Asia Pac J Clin Oncol. 2019 Feb;15(1):18-25. doi: 10.1111/ajco.13097. Epub 2018 Nov 8.","Tomita N","Asia Pac J Clin Oncol","2019","2018/11/10","","","10.1111/ajco.13097"
"26666365","Prostate cancer: Cardiac mortality associated with ADT plus radiotherapy","Bolla M, Créhange G.","Nat Rev Urol. 2016 Mar;13(3):128-9. doi: 10.1038/nrurol.2015.295. Epub 2015 Dec 15.","Bolla M","Nat Rev Urol","2016","2015/12/16","","","10.1038/nrurol.2015.295"
"24404863","Editorial comment from Dr Shiota to Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy","Shiota M.","Int J Urol. 2014 Jun;21(6):583-4. doi: 10.1111/iju.12397. Epub 2014 Jan 9.","Shiota M","Int J Urol","2014","2014/01/11","","","10.1111/iju.12397"
"21166604","WHO International Consultation on Prostate Cancer: a summary","Albertsen PC.","Acta Oncol. 2011 Jun;50 Suppl 1:155-60. doi: 10.3109/0284186X.2010.542175. Epub 2010 Dec 20.","Albertsen PC","Acta Oncol","2011","2010/12/21","","","10.3109/0284186X.2010.542175"
"10233447","Diagnosis and management of early prostate cancer. Report of a British association of urological surgeons working party","Dearnaley dP, Kirby RS, Kirk D, Malone P, Simpson RJ, Wiliams G.","BJU Int. 1999 Jan;83(1):18-33. doi: 10.1046/j.1464-410x.1999.00905.x.","Dearnaley dP","BJU Int","1999","1999/05/08","","","10.1046/j.1464-410x.1999.00905.x"
"15778638","Utilities for prostate cancer health states in men aged 60 and older","Stewart ST, Lenert L, Bhatnagar V, Kaplan RM.","Med Care. 2005 Apr;43(4):347-55. doi: 10.1097/01.mlr.0000156862.33341.45.","Stewart ST","Med Care","2005","2005/03/22","","","10.1097/01.mlr.0000156862.33341.45"
"16286247","Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression","Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM.","Cancer Cell. 2005 Nov;8(5):393-406. doi: 10.1016/j.ccr.2005.10.001.","Varambally S","Cancer Cell","2005","2005/11/16","","","10.1016/j.ccr.2005.10.001"
"10975487","Preparatory education for informed decision-making in prostate cancer early detection and treatment","Myers RE, Kunkel EJ.","Semin Urol Oncol. 2000 Aug;18(3):172-7.","Myers RE","Semin Urol Oncol","2000","2000/09/07","","",""
"19683310","Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen","Ploussard G, Dubosq F, Boublil V, Allory Y, de la Taille A, Vordos D, Hoznek A, Abbou CC, Salomon L.","J Urol. 2009 Oct;182(4):1342-9. doi: 10.1016/j.juro.2009.06.050. Epub 2009 Aug 14.","Ploussard G","J Urol","2009","2009/08/18","","","10.1016/j.juro.2009.06.050"
"12092637","Screening for prostate cancer","Gambert SR.","Int Urol Nephrol. 2001;33(2):249-57. doi: 10.1023/a:1015290429403.","Gambert SR","Int Urol Nephrol","2001","2002/07/03","","","10.1023/a:1015290429403"
"19058138","The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways","Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS.","Prostate. 2009 Mar 1;69(4):443-8. doi: 10.1002/pros.20892.","Tezval H","Prostate","2009","2008/12/06","","","10.1002/pros.20892"
"25134329","The role of radical prostatectomy and lymph node dissection in the treatment of young men with high-grade node-positive prostate cancer: less is more--the benefits of surgery do not yet outweigh potential harms","Nguyen PL.","Oncology (Williston Park). 2014 Jun;28(6):523, 525.","Nguyen PL","Oncology (Williston Park)","2014","2014/08/20","","",""
"22512845","Prostate cancer treatment unblinded","Tsivian M, Abern MR, Polascik TJ.","Lancet Oncol. 2012 Jun;13(6):567-8. doi: 10.1016/S1470-2045(12)70136-5. Epub 2012 Apr 17.","Tsivian M","Lancet Oncol","2012","2012/04/20","","","10.1016/S1470-2045(12)70136-5"
"20367407","Is focal therapy an alternative to active surveillance?","Gravas S, de Reijke T.","J Endourol. 2010 May;24(5):855-60. doi: 10.1089/end.2009.0525.","Gravas S","J Endourol","2010","2010/04/07","","","10.1089/end.2009.0525"
"29161337","Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P.","Ann Oncol. 2018 Feb 1;29(2):377-385. doi: 10.1093/annonc/mdx742.","Pettersson A","Ann Oncol","2018","2017/11/22","","","10.1093/annonc/mdx742"
"24491557","MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6)","Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, Jiang L, Zhang X, Huang X, Zhang L, Han C, Chen M.","Biochem Biophys Res Commun. 2014 Feb 28;445(1):151-6. doi: 10.1016/j.bbrc.2014.01.140. Epub 2014 Jan 31.","Liu D","Biochem Biophys Res Commun","2014","2014/02/05","","","10.1016/j.bbrc.2014.01.140"
"11502444","The effects of phytotherapeutic agents on prostate cancer: an overview of recent clinical trials of PC SPES","Pirani JF.","Urology. 2001 Aug;58(2 Suppl 1):36-8. doi: 10.1016/s0090-4295(01)01240-7.","Pirani JF","Urology","2001","2001/08/15","","","10.1016/s0090-4295(01)01240-7"
"21811932","[Testosterone substitution therapy in prostate cancer]","Kaminsky A, Sperling H.","Urologe A. 2011 Aug;50(8):977-84. doi: 10.1007/s00120-011-2610-y.","Kaminsky A","Urologe A","2011","2011/08/04","","","10.1007/s00120-011-2610-y"
"8797951","Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion","Norberg M, Holmberg L, Busch C, Häggman M, Egevad L, Magnusson A.","Eur Radiol. 1996;6(1):56-61. doi: 10.1007/BF00619953.","Norberg M","Eur Radiol","1996","1996/01/01","","","10.1007/BF00619953"
"26859936","[ASSESSMENT OF THE RISK OF INCIDENTAL PROSTATE CANCER PROGRESSION]","Marisov LV, Vinarov AZ, Alyaev YG, Gerasimov AN, Bezrukov EA.","Urologiia. 2015 Sep-Oct;(5):43-5.","Marisov LV","Urologiia","2015","2016/02/11","","",""
"16370172","[Prostate cancer: the essential from the congress of the American Urological Association (AUA) 2005]","Descazeaud A.","Ann Urol (Paris). 2005 Oct;39 Suppl 4:S89-101.","Descazeaud A","Ann Urol (Paris)","2005","2005/12/24","","",""
"28650863","Prediction models for prostate cancer outcomes: what is the state of the art in 2017?","Kearns JT, Lin DW.","Curr Opin Urol. 2017 Sep;27(5):469-474. doi: 10.1097/MOU.0000000000000423.","Kearns JT","Curr Opin Urol","2017","2017/06/27","","","10.1097/MOU.0000000000000423"
"7606192","Early life risk factors for prostate cancer: a population-based case-control study in Sweden","Andersson SO, Baron J, Wolk A, Lindgren C, Bergström R, Adami HO.","Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):187-92.","Andersson SO","Cancer Epidemiol Biomarkers Prev","1995","1995/04/01","","",""
"19727148","Radiotherapy: encouraging early data for SBRT in prostate cancer","Abdel-Wahab M, Pollack A.","Nat Rev Urol. 2009 Sep;6(9):478-9. doi: 10.1038/nrurol.2009.166.","Abdel-Wahab M","Nat Rev Urol","2009","2009/09/04","","","10.1038/nrurol.2009.166"
"18429459","Prostate cancer","Davies N.","Nurs Stand. 2008 Mar 19-25;22(28):59.","Davies N","Nurs Stand","2008","2008/04/24","","",""
"23416641","Incidence and pathological features of prostate cancer detected on transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy","Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath RW.","J Urol. 2013 Aug;190(2):509-14. doi: 10.1016/j.juro.2013.02.021. Epub 2013 Feb 14.","Bittner N","J Urol","2013","2013/02/19","","","10.1016/j.juro.2013.02.021"
"22101389","ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer","Moran BJ, DeRose P, Hsu IC, Abdel-Wahab M, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Rosenthal SA, Rossi CJ Jr, Yamada Y, Merrick GS.","Am J Clin Oncol. 2011 Dec;34(6):636-47. doi: 10.1097/COC.0b013e3182354a65.","Moran BJ","Am J Clin Oncol","2011","2011/11/22","","","10.1097/COC.0b013e3182354a65"
"19752605","Decrease in prostate cancer incidence and mortality in Germany - effects of opportunistic PSA screening or more?","Rohde V, Weidner W, Katalinic A.","Urol Int. 2009;83(2):134-40. doi: 10.1159/000230012. Epub 2009 Sep 10.","Rohde V","Urol Int","2009","2009/09/16","","","10.1159/000230012"
"17031640","Vaccination therapy in prostate cancer","Marrari A, Iero M, Pilla L, Villa S, Salvioni R, Valdagni R, Parmiani G, Rivoltini L.","Cancer Immunol Immunother. 2007 Apr;56(4):429-45. doi: 10.1007/s00262-006-0233-8. Epub 2006 Oct 10.","Marrari A","Cancer Immunol Immunother","2007","2006/10/13","","","10.1007/s00262-006-0233-8"
"18833375","[The touched masculinity: a discussion about the digital rectal exam for prostate cancer prevention]","Gomes R, do Nascimento EF, Rebello LE, de Araújo FC.","Cien Saude Colet. 2008 Nov-Dec;13(6):1975-84. doi: 10.1590/s1413-81232008000600033.","Gomes R","Cien Saude Colet","2008","2008/10/04","","","10.1590/s1413-81232008000600033"
"28006843","Identification and prediction of health-related quality of life trajectories after a prostate cancer diagnosis","Farris MS, Kopciuk KA, Courneya KS, McGregor SE, Wang Q, Friedenreich CM.","Int J Cancer. 2017 Apr 1;140(7):1517-1527. doi: 10.1002/ijc.30586. Epub 2017 Jan 6.","Farris MS","Int J Cancer","2017","2016/12/23","","","10.1002/ijc.30586"
"1382830","Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors","Villers A, McNeal JE, Freiha FS, Stamey TA.","Cancer. 1992 Nov 1;70(9):2313-8. doi: 10.1002/1097-0142(19921101)70:9<2313::aid-cncr2820700917>3.0.co;2-t.","Villers A","Cancer","1992","1992/11/01","","","10.1002/1097-0142(19921101)70:9<2313::aid-cncr2820700917>3.0.co;2-t"
"1722922","[Incidental prostate cancer: volume, location and degree of differentiation of the tumor in the radical prostatectomy specimen and value of subclassification to stage A1 and A2]","Voges GE, McNeal JE, Stamey TA.","Urologe A. 1991 Nov;30(6):401-9.","Voges GE","Urologe A","1991","1991/11/01","","",""
"25732203","'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer","Lomax AJ, Parente P, Gilfillan C, Livingston PM, Davis ID, Pezaro C.","Intern Med J. 2016 Feb;46(2):141-8. doi: 10.1111/imj.12731.","Lomax AJ","Intern Med J","2016","2015/03/04","","","10.1111/imj.12731"
"22105110","Androgen receptor co-activators in the regulation of cellular events in prostate cancer","Culig Z, Santer FR.","World J Urol. 2012 Jun;30(3):297-302. doi: 10.1007/s00345-011-0797-6. Epub 2011 Nov 22.","Culig Z","World J Urol","2012","2011/11/23","","","10.1007/s00345-011-0797-6"
"19477781","Prostate cancer screening in African American men: barriers and methods for improvement","Reynolds D.","Am J Mens Health. 2008 Jun;2(2):172-7. doi: 10.1177/1557988307312784. Epub 2008 Jan 23.","Reynolds D","Am J Mens Health","2008","2009/05/30","","","10.1177/1557988307312784"
"20702055","""I wish I'd told them"": a qualitative study examining the unmet psychosexual needs of prostate cancer patients during follow-up after treatment","O'Brien R, Rose P, Campbell C, Weller D, Neal RD, Wilkinson C, McIntosh H, Watson E; Prostate Cancer Follow-up Group.","Patient Educ Couns. 2011 Aug;84(2):200-7. doi: 10.1016/j.pec.2010.07.006. Epub 2010 Aug 10.","O'Brien R","Patient Educ Couns","2011","2010/08/13","","","10.1016/j.pec.2010.07.006"
"1844459","[A comparative evaluation between transrectal echography, venous urography, computerized axial tomography and morphology in patients with prostatic carcinoma]","Mladenov D, Tsvetkov M, Topov Ia, Kumanov Kh.","Khirurgiia (Sofiia). 1991;44(5):21-3.","Mladenov D","Khirurgiia (Sofiia)","1991","1991/01/01","","",""
"24112615","Words of wisdom. Re: African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?","Hollenbeck BK.","Eur Urol. 2013 Nov;64(5):858-9. doi: 10.1016/j.eururo.2013.08.042.","Hollenbeck BK","Eur Urol","2013","2013/10/12","","","10.1016/j.eururo.2013.08.042"
"9792984","Malacoplakia or prostate cancer? Similarities and differences","Agostinho AD, Corrêa LA, Amaro JL, Bacchi CE, Viana de Camargo JL.","Urol Int. 1998 Oct;61(1):47-9. doi: 10.1159/000030284.","Agostinho AD","Urol Int","1998","1998/10/30","","","10.1159/000030284"
"16515991","Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE","Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll PR.","J Urol. 2006 Apr;175(4):1326-31. doi: 10.1016/S0022-5347(05)00647-6.","Marr PL","J Urol","2006","2006/03/07","","","10.1016/S0022-5347(05)00647-6"
"18025848","Role of MMP-1 1G/2G promoter gene polymorphism on the development of prostate cancer in the Turkish population","Albayrak S, Cangüven O, Göktaş C, Aydemir H, Köksal V.","Urol Int. 2007;79(4):312-5. doi: 10.1159/000109715.","Albayrak S","Urol Int","2007","2007/11/21","","","10.1159/000109715"
"9060961","Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers","Andersson SO, Wolk A, Bergström R, Adami HO, Engholm G, Englund A, Nyrén O.","J Natl Cancer Inst. 1997 Mar 5;89(5):385-9. doi: 10.1093/jnci/89.5.385.","Andersson SO","J Natl Cancer Inst","1997","1997/03/05","","","10.1093/jnci/89.5.385"
"26452188","The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now","VanderWeele DJ.","Clin Adv Hematol Oncol. 2015 Sep;13(9):580-3.","VanderWeele DJ","Clin Adv Hematol Oncol","2015","2015/10/10","","",""
"18269465","Comparison of prostate and transition zone volume measured by the ellipsoid and planimetric methods with transrectal ultrasonography before seed implantation of prostate cancer","Ikeda T, Shinohara K.","Int J Urol. 2008 Feb;15(2):190-1. doi: 10.1111/j.1442-2042.2007.01939.x.","Ikeda T","Int J Urol","2008","2008/02/14","","","10.1111/j.1442-2042.2007.01939.x"
"17846906","The MTHFR 677C --> T polymorphism and risk of prostate cancer: results from the CAPS study","Johansson M, Van Guelpen B, Hultdin J, Wiklund F, Adami HO, Bälter K, Grönberg H, Stattin P.","Cancer Causes Control. 2007 Dec;18(10):1169-74. doi: 10.1007/s10552-007-9055-z. Epub 2007 Sep 6.","Johansson M","Cancer Causes Control","2007","2007/09/12","","","10.1007/s10552-007-9055-z"
"11942038","[Recommendations for treatment with permanent, interstitial brachytherapy alone in locally limited prostate cancer]","Wirth MP, Hermann T, Alken P, Kovacs G, Müller RP, Hakenberg OW, Ahlemann L, Schalkhäuser K.","Strahlenther Onkol. 2002 Feb;178(2):115-9.","Wirth MP","Strahlenther Onkol","2002","2002/04/11","","",""
"20177014","Inflammatory pathogenesis of prostate cancer and celecoxib","Mathew P.","J Clin Oncol. 2010 Apr 20;28(12):e197; author reply e198. doi: 10.1200/JCO.2009.27.1098. Epub 2010 Feb 22.","Mathew P","J Clin Oncol","2010","2010/02/24","","","10.1200/JCO.2009.27.1098"
"16741921","Mechanism of 2-chloroadenosine toxicity to PC3 cell line","Minelli A, Bellezza I, Agostini M, Bracarda S, Culig Z.","Prostate. 2006 Sep 15;66(13):1425-36. doi: 10.1002/pros.20458.","Minelli A","Prostate","2006","2006/06/03","","","10.1002/pros.20458"
"30197394","[A case of metastatic prostate cancer with gastric metastases and high serum CEA]","Aoyama Y, Wato M, Colvin M, Nakamura S, Ishikawa S, Inaba T.","Nihon Shokakibyo Gakkai Zasshi. 2018;115(9):804-810. doi: 10.11405/nisshoshi.115.804.","Aoyama Y","Nihon Shokakibyo Gakkai Zasshi","2018","2018/09/11","","","10.11405/nisshoshi.115.804"
"9478254","[Value and limitations of transrectal ultrasonography and computer tomography in preoperative staging of prostate carcinoma]","Barbieri A, Monica B, Sebastio N, Incarbone GP, Di Stefano C.","Acta Biomed Ateneo Parmense. 1997;68(1-2):23-6.","Barbieri A","Acta Biomed Ateneo Parmense","1997","1997/01/01","","",""
"10498074","Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?","O'Dell KJ, Volk RJ, Cass AR, Spann SJ.","J Fam Pract. 1999 Sep;48(9):682-8.","O'Dell KJ","J Fam Pract","1999","1999/09/25","","",""
"29988100","Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer","Miller K, Steger GG, Niepel D, Lüftner D.","Prostate Cancer Prostatic Dis. 2018 Nov;21(4):461-472. doi: 10.1038/s41391-018-0060-y. Epub 2018 Jul 9.","Miller K","Prostate Cancer Prostatic Dis","2018","2018/07/11","PMC6283859","","10.1038/s41391-018-0060-y"
"26103570","Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","Cuzick J, Stone S, Fisher G, Yang ZH, North BV, Berney DM, Beltran L, Greenberg D, Møller H, Reid JE, Gutin A, Lanchbury JS, Brawer M, Scardino P.","Br J Cancer. 2015 Jul 28;113(3):382-9. doi: 10.1038/bjc.2015.223. Epub 2015 Jun 23.","Cuzick J","Br J Cancer","2015","2015/06/24","PMC4522632","","10.1038/bjc.2015.223"
"12797718","Measuring disease specific quality of life in localized prostate cancer: the Dutch experience","Korfage IJ, Essink-Bot ML, Madalinska JB, Kirkels WJ, Litwin MS, de Koning HJ.","Qual Life Res. 2003 Jun;12(4):459-64. doi: 10.1023/a:1023402706666.","Korfage IJ","Qual Life Res","2003","2003/06/12","","","10.1023/a:1023402706666"
"19786680","A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices","Howard K, Barratt A, Mann GJ, Patel MI.","Arch Intern Med. 2009 Sep 28;169(17):1603-10. doi: 10.1001/archinternmed.2009.282.","Howard K","Arch Intern Med","2009","2009/09/30","","","10.1001/archinternmed.2009.282"
"21142862","Novel targeted agents on the horizon for castration-resistant prostate cancer","Koupparis A, Casey RG, Robinson M, Gleave ME.","Future Oncol. 2010 Dec;6(12):1883-95. doi: 10.2217/fon.10.145.","Koupparis A","Future Oncol","2010","2010/12/15","","","10.2217/fon.10.145"
"19853371","Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68","Morote J.","Eur Urol. 2010 Jan;57(1):e1; author reply e2-3. doi: 10.1016/j.eururo.2009.09.041. Epub 2009 Oct 9.","Morote J","Eur Urol","2010","2009/10/27","","","10.1016/j.eururo.2009.09.041"
"2856631","[Upper digestive hemorrhage and disseminated intravascular coagulation as the initial manifestation of prostate cancer]","Marcos Sánchez F, Llorente Domingo P, Gámez Cabero MI, Juárez Ucelay F, Durán Pérez-Navarro A.","An Med Interna. 1988 Sep;5(9):483-4.","Marcos Sánchez F","An Med Interna","1988","1988/09/01","","",""
"10096383","Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer","Kubricht WS, Kattan MW, Sartor O, Eastham JA.","Urology. 1999 Mar;53(3):553-6. doi: 10.1016/s0090-4295(98)00548-2.","Kubricht WS","Urology","1999","1999/03/30","","","10.1016/s0090-4295(98)00548-2"
"16729904","The continuing challenge of hormone-refractory prostate cancer","Sartor O.","Clin Genitourin Cancer. 2006 Mar;4(4):238-9. doi: 10.3816/CGC.2006.n.001.","Sartor O","Clin Genitourin Cancer","2006","2006/05/30","","","10.3816/CGC.2006.n.001"
"17161554","The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome","Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR.","Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):828-33. doi: 10.1016/j.ijrobp.2006.09.027. Epub 2006 Dec 8.","Vance W","Int J Radiat Oncol Biol Phys","2007","2006/12/13","","","10.1016/j.ijrobp.2006.09.027"
"24172327","Advances in prostate cancer treatment","Trewartha D, Carter K.","Nat Rev Drug Discov. 2013 Nov;12(11):823-4. doi: 10.1038/nrd4068.","Trewartha D","Nat Rev Drug Discov","2013","2013/11/01","","","10.1038/nrd4068"
"17672937","[Etiologic correlations of prostate cancer in Guangdong, China to family history of cancers, and sexual and marital factors-a case-control study]","Liang CH, Liu Q, Zhou FJ, Gao X, Chen LW.","Ai Zheng. 2007 May;26(5):484-8.","Liang CH","Ai Zheng","2007","2007/08/04","","",""
"12521073","Ultrasound imaging for external-beam prostate treatment setup and dosimetric verification","Falco T, Shenouda G, Kaufmann C, Belanger I, Procaccini C, Charrois C, Evans M.","Med Dosim. 2002 Winter;27(4):271-3. doi: 10.1016/s0958-3947(02)00144-9.","Falco T","Med Dosim","2002","2003/01/11","","","10.1016/s0958-3947(02)00144-9"
"27343801","Do Black NonHispanic Men Produce Less Prostate Specific Antigen in Benign Prostate Tissue or Cancer Compared to White NonHispanic Men with Gleason Score 6 (Grade Group 1) Prostate Cancer?","Kryvenko ON, Epstein JI, Cote RJ.","J Urol. 2016 Dec;196(6):1659-1663. doi: 10.1016/j.juro.2016.06.081. Epub 2016 Jun 23.","Kryvenko ON","J Urol","2016","2016/06/26","","","10.1016/j.juro.2016.06.081"
"31437119","Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study","Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, Briganti A, Salomon L, Ploussard G, Tilki D; EAU-YAUWP.","J Urol. 2020 Feb;203(2):338-343. doi: 10.1097/JU.0000000000000504. Epub 2019 Aug 22.","Preisser F","J Urol","2020","2019/08/23","","","10.1097/JU.0000000000000504"
"10210568","Neoadjuvant hormonal therapy in carcinoma of the prostate","Lee HH, Warde P, Jewett MA.","BJU Int. 1999 Mar;83(4):438-48. doi: 10.1046/j.1464-410x.1999.00953.x.","Lee HH","BJU Int","1999","1999/04/22","","","10.1046/j.1464-410x.1999.00953.x"
"27344742","[International trends and future perspectives on screening for prostate cancer]","Ito K.","Nihon Rinsho. 2016 May 20;74 Suppl 3:280-5.","Ito K","Nihon Rinsho","2016","2016/06/28","","",""
"29771413","Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway","Cai DW, Chen D, Sun SP, Liu ZJ, Liu F, Xian SZ, Wu PS, Kong GQ.","Eur Rev Med Pharmacol Sci. 2018 May;22(9):2572-2579. doi: 10.26355/eurrev_201805_14950.","Cai DW","Eur Rev Med Pharmacol Sci","2018","2018/05/18","","","10.26355/eurrev_201805_14950"
"8189570","Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications","Epstein JI, Carmichael MJ, Partin AW, Walsh PC.","J Urol. 1994 Jun;151(6):1587-92. doi: 10.1016/s0022-5347(17)35309-0.","Epstein JI","J Urol","1994","1994/06/01","","","10.1016/s0022-5347(17)35309-0"
"15703810","Identification of circulating prostate cancer cells: a challenge to the clinical implementation of molecular biology (review)","Schamhart DH, Maiazza R, Kurth KH.","Int J Oncol. 2005 Mar;26(3):565-77.","Schamhart DH","Int J Oncol","2005","2005/02/11","","",""
"23073701","[Focal prostate cancer therapy: capabilities, limitations and prospects]","Baumunk D, Blana A, Ganzer R, Henkel T, Köllermann J, Roosen A, Machtens S, Salomon G, Sentker L, Witzsch U, Köhrmann KU, Schostak M; Arbeitsgruppe für Fokale und Mikrotherapie.","Urologe A. 2013 Apr;52(4):549-56. doi: 10.1007/s00120-012-3002-7.","Baumunk D","Urologe A","2013","2012/10/18","","","10.1007/s00120-012-3002-7"
"23264690","Dynamic PET/CT with 11C-acetate in prostate cancer","Schiepers C, Huang SC, Dahlbom M.","J Nucl Med. 2013 Feb;54(2):326. doi: 10.2967/jnumed.112.112532. Epub 2012 Dec 21.","Schiepers C","J Nucl Med","2013","2012/12/25","","","10.2967/jnumed.112.112532"
"10022723","Re: The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer","Berteau P, Gala JL, Eschwège P, Dumas F, Loric S.","J Urol. 1999 Mar;161(3):924-6. doi: 10.1016/s0022-5347(01)61817-2.","Berteau P","J Urol","1999","1999/02/18","","","10.1016/s0022-5347(01)61817-2"
"9828585","The blackman's challenge - the prostate cancer dilemma. Foreword: the honorable Louis B. Stokes","Stokes LB.","J Natl Med Assoc. 1998 Nov;90(11 Suppl):S702-4.","Stokes LB","J Natl Med Assoc","1998","1998/11/26","PMC2652607","",""
"78579","[Cytological diagnosis of prostate cancer]","Bialik VV, Levitskiĭ EO.","Vopr Onkol. 1978;24(5):86-92.","Bialik VV","Vopr Onkol","1978","1978/01/01","","",""
"27236302","Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies","Sheikh N, Wei C, Szewczyk-Bieda M, Campbell A, Memon S, Lang S, Nabi G.","World J Urol. 2017 Feb;35(2):213-220. doi: 10.1007/s00345-016-1855-x. Epub 2016 May 28.","Sheikh N","World J Urol","2017","2016/05/30","PMC5272897","","10.1007/s00345-016-1855-x"
"26896115","Racial Disparities in Sexual Dysfunction Outcomes After Prostate Cancer Treatment: Myth or Reality?","Burnett AL.","J Racial Ethn Health Disparities. 2016 Mar;3(1):154-9. doi: 10.1007/s40615-015-0126-7. Epub 2015 May 28.","Burnett AL","J Racial Ethn Health Disparities","2016","2016/02/21","","","10.1007/s40615-015-0126-7"
"11025708","Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup","Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.","J Urol. 2000 Nov;164(5):1579-82.","Iversen P","J Urol","2000","2000/10/12","","",""
"21889355","Androgen receptor-driven chromatin looping in prostate cancer","Wu D, Zhang C, Shen Y, Nephew KP, Wang Q.","Trends Endocrinol Metab. 2011 Dec;22(12):474-80. doi: 10.1016/j.tem.2011.07.006. Epub 2011 Aug 31.","Wu D","Trends Endocrinol Metab","2011","2011/09/06","PMC3229688","NIHMS316791","10.1016/j.tem.2011.07.006"
"19766252","Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, E. Canby-Hagino and E. D. Crawford J Urol 2009; 181: 956-962","Cheng T, Heng DY, Stewart D.","J Urol. 2009 Nov;182(5):2531-2; discussion 2532-4. doi: 10.1016/j.juro.2009.07.053. Epub 2009 Sep 18.","Cheng T","J Urol","2009","2009/09/22","","","10.1016/j.juro.2009.07.053"
"28627741","Proteomics approach to identify novel metastatic bone markers from the secretome of PC-3 prostate cancer cells","Sung E, Kwon OK, Lee JM, Lee S.","Electrophoresis. 2017 Oct;38(20):2638-2645. doi: 10.1002/elps.201700052. Epub 2017 Jul 10.","Sung E","Electrophoresis","2017","2017/06/20","","","10.1002/elps.201700052"
"1719806","Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan","Sidney S, Quesenberry CP Jr, Sadler MC, Guess HA, Lydick EG, Cattolica EV.","Am J Epidemiol. 1991 Oct 15;134(8):825-9. doi: 10.1093/oxfordjournals.aje.a116157.","Sidney S","Am J Epidemiol","1991","1991/10/25","","","10.1093/oxfordjournals.aje.a116157"
"20216317","Update on chemoprevention for prostate cancer","Strope SA, Andriole GL.","Curr Opin Urol. 2010 May;20(3):194-7. doi: 10.1097/MOU.0b013e3283381966.","Strope SA","Curr Opin Urol","2010","2010/03/11","","","10.1097/MOU.0b013e3283381966"
"15283889","Microarray analysis of differential gene expression in androgen independent prostate cancer using a metastatic human prostate cancer cell line model","Balaji KC, Rao PS, Smith DJ, Louis S, Smith LM, Sherman S, Bacich D, O'Keefe D.","Urol Oncol. 2004 Jul-Aug;22(4):313-20. doi: 10.1016/S1078-1439(03)00238-2.","Balaji KC","Urol Oncol","2004","2004/07/31","","","10.1016/S1078-1439(03)00238-2"
"24433259","Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?","Wolff JM, Abrahamsson PA, Irani J, da Silva FC.","BJU Int. 2014 Oct;114(4):476-83. doi: 10.1111/bju.12626. Epub 2014 Apr 16.","Wolff JM","BJU Int","2014","2014/01/18","","","10.1111/bju.12626"
"9233872","Prostate cancer--the therapeutic challenge of locally advanced disease","Blasko JC, Lange PH.","N Engl J Med. 1997 Jul 31;337(5):340-1. doi: 10.1056/NEJM199707313370510.","Blasko JC","N Engl J Med","1997","1997/07/31","","","10.1056/NEJM199707313370510"
"23792130","Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates?","Walton Diaz A, Hoang AN, Turkbey B, Hong CW, Truong H, Sterling T, Rais-Bahrami S, Siddiqui MM, Stamatakis L, Vourganti S, Nix J, Logan J, Harris C, Weintraub M, Chua C, Merino MJ, Choyke P, Wood BJ, Pinto PA.","J Urol. 2013 Dec;190(6):2020-2025. doi: 10.1016/j.juro.2013.05.118. Epub 2013 Jun 18.","Walton Diaz A","J Urol","2013","2013/06/25","PMC6301077","NIHMS895421","10.1016/j.juro.2013.05.118"
"25164550","The impact of PSA and digital rectal examination on the risk of prostate cancer specific mortality in men with a PSA level <2.5 ng/ml","Pashtan I, Chen MH, D'Amico AV.","Cancer Epidemiol. 2014 Oct;38(5):613-8. doi: 10.1016/j.canep.2014.07.007. Epub 2014 Aug 19.","Pashtan I","Cancer Epidemiol","2014","2014/08/29","","","10.1016/j.canep.2014.07.007"
"15543092","Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer","Lieberman R.","Am J Ther. 2004 Nov-Dec;11(6):501-6. doi: 10.1097/01.mjt.0000141604.20320.0c.","Lieberman R","Am J Ther","2004","2004/11/16","","","10.1097/01.mjt.0000141604.20320.0c"
"27150032","Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients","Das T, Guleria M, Parab A, Kale C, Shah H, Sarma HD, Lele VR, Banerjee S.","Nucl Med Biol. 2016 May;43(5):296-302. doi: 10.1016/j.nucmedbio.2016.02.002. Epub 2016 Feb 15.","Das T","Nucl Med Biol","2016","2016/05/07","","","10.1016/j.nucmedbio.2016.02.002"
"22892841","How do you want your steak prepared? The impact of meat consumption and preparation on prostate cancer","Figg WD 2nd.","Cancer Biol Ther. 2012 Oct;13(12):1141-2. doi: 10.4161/cbt.21463. Epub 2012 Aug 15.","Figg WD 2nd","Cancer Biol Ther","2012","2012/08/16","PMC3469470","","10.4161/cbt.21463"
"9915437","A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer","Pisters LL, Dinney CP, Pettaway CA, Scott SM, Babaian RJ, von Eschenbach AC, Troncoso P.","J Urol. 1999 Feb;161(2):509-14.","Pisters LL","J Urol","1999","1999/01/23","","",""
"15375223","Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience","Coakley FV, Teh HS, Qayyum A, Swanson MG, Lu Y, Roach M 3rd, Pickett B, Shinohara K, Vigneron DB, Kurhanewicz J.","Radiology. 2004 Nov;233(2):441-8. doi: 10.1148/radiol.2332032086. Epub 2004 Sep 16.","Coakley FV","Radiology","2004","2004/09/18","","","10.1148/radiol.2332032086"
"11295594","Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer","Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, Malone WA, Crowell JA, Higley HR, Sigman CC.","Urology. 2001 Apr;57(4 Suppl 1):46-51. doi: 10.1016/s0090-4295(00)00940-7.","Kelloff GJ","Urology","2001","2001/04/11","","","10.1016/s0090-4295(00)00940-7"
"24682399","Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study","Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.","BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.","Carlsson S","BMJ","2014","2014/04/01","PMC3968958","","10.1136/bmj.g2296"
"23824908","Prostate cancer screening: a complicated puzzle, explanation needed","Gaster B.","J Gen Intern Med. 2013 Dec;28(12):1549-50. doi: 10.1007/s11606-013-2542-x.","Gaster B","J Gen Intern Med","2013","2013/07/05","PMC3832726","","10.1007/s11606-013-2542-x"
"16430038","[The role of prostate volume in ultrasound guided transrectal prostate biopsy: is it as important as a marker as PSA?]","Rodríguez-Patrón Rodríguez R, Mayayo Dehesa T, Burgos Revilla FJ, Alonso González M, Lennie Zucharino A, García González R.","Arch Esp Urol. 2005 Nov;58(9):903-13. doi: 10.4321/s0004-06142005000900007.","Rodríguez-Patrón Rodríguez R","Arch Esp Urol","2005","2006/01/25","","","10.4321/s0004-06142005000900007"
"19299073","Editorial comment on: tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer","Gallina A.","Eur Urol. 2010 Apr;57(4):639. doi: 10.1016/j.eururo.2009.03.008. Epub 2009 Mar 10.","Gallina A","Eur Urol","2010","2009/03/21","","","10.1016/j.eururo.2009.03.008"
"21096687","Real time MRI prostate segmentation based on wavelet multiscale products flow tracking","Flores-Tapia D, Venugopal N, Thomas G, McCurdy B, Ryner L, Pistorius S.","Annu Int Conf IEEE Eng Med Biol Soc. 2010;2010:5034-7. doi: 10.1109/IEMBS.2010.5627187.","Flores-Tapia D","Annu Int Conf IEEE Eng Med Biol Soc","2010","2010/11/25","","","10.1109/IEMBS.2010.5627187"
"24175814","Identifying differentially expressed genes and small molecule drugs for prostate cancer by a bioinformatics strategy","Li J, Xu YH, Lu Y, Ma XP, Chen P, Luo SW, Jia ZG, Liu Y, Guo Y.","Asian Pac J Cancer Prev. 2013;14(9):5281-6. doi: 10.7314/apjcp.2013.14.9.5281.","Li J","Asian Pac J Cancer Prev","2013","2013/11/02","","","10.7314/apjcp.2013.14.9.5281"
"23221788","Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in prostate cancer","Madan RA, Schwaab T, Gulley JL.","J Natl Compr Canc Netw. 2012 Dec 1;10(12):1505-12. doi: 10.6004/jnccn.2012.0156.","Madan RA","J Natl Compr Canc Netw","2012","2012/12/11","PMC6599514","NIHMS1038160","10.6004/jnccn.2012.0156"
"27749327","Immune Therapy for Prostate Cancer","Yeku O, Slovin SF.","Cancer J. 2016 Sep/Oct;22(5):334-341. doi: 10.1097/PPO.0000000000000223.","Yeku O","Cancer J","2016","2016/10/18","PMC5117426","NIHMS808881","10.1097/PPO.0000000000000223"
"11180578","The supportive care needs of men with prostate cancer (2000)","Steginga SK, Occhipinti S, Dunn J, Gardiner RA, Heathcote P, Yaxley J.","Psychooncology. 2001 Jan-Feb;10(1):66-75. doi: 10.1002/1099-1611(200101/02)10:1<66::aid-pon493>3.0.co;2-z.","Steginga SK","Psychooncology","2001","2001/02/17","","","10.1002/1099-1611(200101/02)10:1<66::aid-pon493>3.0.co;2-z"
"30194146","Identification of a Novel MicroRNA Panel Associated with Metastasis Following Radical Prostatectomy for Prostate Cancer","Nam RK, Wallis CJD, Amemiya Y, Benatar T, Seth A.","Anticancer Res. 2018 Sep;38(9):5027-5034. doi: 10.21873/anticanres.12821.","Nam RK","Anticancer Res","2018","2018/09/09","","","10.21873/anticanres.12821"
"19350286","Men with prostate cancer over the first year of illness: their experiences as biographical disruption","Cayless S, Forbat L, Illingworth N, Hubbard G, Kearney N.","Support Care Cancer. 2010 Jan;18(1):11-9. doi: 10.1007/s00520-009-0624-4. Epub 2009 Apr 7.","Cayless S","Support Care Cancer","2010","2009/04/08","","","10.1007/s00520-009-0624-4"
"21426475","Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection","Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, Villers A.","BJU Int. 2011 Oct;108(8 Pt 2):E171-8. doi: 10.1111/j.1464-410X.2011.10112.x. Epub 2011 Mar 22.","Haffner J","BJU Int","2011","2011/03/24","","","10.1111/j.1464-410X.2011.10112.x"
"21975409","In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer","Alonso O, Gambini JP, Lago G, Gaudiano J, Quagliata A, Engler H.","Clin Nucl Med. 2011 Nov;36(11):1063-4. doi: 10.1097/RLU.0b013e31822920c9.","Alonso O","Clin Nucl Med","2011","2011/10/07","","","10.1097/RLU.0b013e31822920c9"
"9516587","PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?","Kuban DA, El-Mahdi AM, Schellhammer PF.","Semin Radiat Oncol. 1998 Apr;8(2):72-80. doi: 10.1016/s1053-4296(98)80002-7.","Kuban DA","Semin Radiat Oncol","1998","1998/04/29","","","10.1016/s1053-4296(98)80002-7"
"16093992","Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment: results of the randomized trial SAKK 08/88","Walsh PC.","J Urol. 2005 Sep;174(3):929. doi: 10.1097/01.ju.0000171900.48158.20.","Walsh PC","J Urol","2005","2005/08/12","","","10.1097/01.ju.0000171900.48158.20"
"11248926","New developments in ultrasonography for the detection of prostate cancer","de la Rosette JJ, Aarnink RG.","J Endourol. 2001 Feb;15(1):93-104. doi: 10.1089/08927790150501015.","de la Rosette JJ","J Endourol","2001","2001/03/16","","","10.1089/08927790150501015"
"26489920","Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients","Leduc N, Atallah V, Creoff M, Rabia N, Taouil T, Escarmant P, Vinh-Hung V.","Brachytherapy. 2015 Nov-Dec;14(6):826-33. doi: 10.1016/j.brachy.2015.09.005. Epub 2015 Oct 17.","Leduc N","Brachytherapy","2015","2015/10/23","","","10.1016/j.brachy.2015.09.005"
"19005982","Effects of selenomethionine on the gene expression profile of cloned human prostate cancer cells representing a phenotypic continuum of cancer progression","Stewart J, Ware J, Boysen C, Gulati S, Zhou Z, Rosenfeld S, Kopelovich L, Kennedy AR.","Nutr Cancer. 2008;60(6):826-36. doi: 10.1080/01635580802090193.","Stewart J","Nutr Cancer","2008","2008/11/14","PMC3584629","NIHMS440901","10.1080/01635580802090193"
"8996578","Clinical use of posttherapy prostate-specific antigen changes in advanced prostate cancer","Kelly WK, Slovin S, Scher HI.","Semin Oncol. 1996 Dec;23(6 Suppl 14):8-14.","Kelly WK","Semin Oncol","1996","1996/12/01","","",""
"9798200","Does pelvic irradiation play a role in the management of prostate cancer?","Stock RG, Ferrari AC, Stone NN.","Oncology (Williston Park). 1998 Oct;12(10):1467-72; discussion 1472, 1475-6.","Stock RG","Oncology (Williston Park)","1998","1998/11/03","","",""
"7543617","The utility of prostate-specific antigen for detecting prostate cancer","Livingston EH.","JAMA. 1995 Aug 23-30;274(8):608; author reply 608-9. doi: 10.1001/jama.274.8.608b.","Livingston EH","JAMA","1995","1995/08/23","","","10.1001/jama.274.8.608b"
"26408707","Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer","Tolkach Y, Merseburger A, Herrmann T, Kuczyk M, Serth J, Imkamp F.","Anticancer Res. 2015 Oct;35(10):5443-51.","Tolkach Y","Anticancer Res","2015","2015/09/27","","",""
"29305198","Association Between Primary Local Treatment and Non-prostate Cancer Mortality in Men With Nonmetastatic Prostate Cancer","Wallis CJD, Satkunasivam R, Herschorn S, Law C, Seth A, Kodama RT, Kulkarni GS, Nam RK.","Urology. 2018 Apr;114:147-154. doi: 10.1016/j.urology.2017.12.013. Epub 2018 Jan 2.","Wallis CJD","Urology","2018","2018/01/07","","","10.1016/j.urology.2017.12.013"
"24487421","Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy","Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA.","Am J Clin Oncol. 2016 Apr;39(2):173-80. doi: 10.1097/COC.0000000000000037.","Vainshtein JM","Am J Clin Oncol","2016","2014/02/04","","","10.1097/COC.0000000000000037"
"20888034","Men of higher socioeconomic status have improved outcomes after radical prostatectomy for localized prostate cancer","Hellenthal NJ, Parikh-Patel A, Bauer K, Ralph W, deVere W, Koppie TM.","Urology. 2010 Dec;76(6):1409-13. doi: 10.1016/j.urology.2010.03.024.","Hellenthal NJ","Urology","2010","2010/10/05","","","10.1016/j.urology.2010.03.024"
"17154024","[Survey of factors underlying treatment choice for patients with localized prostate cancer (radical prostatectomy vs extrabeam radiotherapy)]","Teramoto S, Ota T, Itaya N, Maniwa A, Matsui T, Nishimura Y, Shofi K.","Nihon Hinyokika Gakkai Zasshi. 2006 Nov;97(7):823-9. doi: 10.5980/jpnjurol1989.97.823.","Teramoto S","Nihon Hinyokika Gakkai Zasshi","2006","2006/12/13","","","10.5980/jpnjurol1989.97.823"
"10699616","Clinical characteristics in black and white men with prostate cancer in an equal access medical center","Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ.","Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6.","Freedland SJ","Urology","2000","2000/03/04","","","10.1016/s0090-4295(99)00461-6"
"26081819","[Active surveillance of low risk prostate cancer]","Weißbach L.","Urologe A. 2015 Jun;54(6):869-70. doi: 10.1007/s00120-015-3804-5.","Weißbach L","Urologe A","2015","2015/06/18","","","10.1007/s00120-015-3804-5"
"9372904","Prostate cancer micrometastases to lymph nodes","Deguchi T, Yang M, Takahashi Y, Kawada Y, Doi T.","Urology. 1997 Nov;50(5):826-7. doi: 10.1016/s0090-4295(97)80114-8.","Deguchi T","Urology","1997","1997/12/31","","","10.1016/s0090-4295(97)80114-8"
"17333200","Optimal treatment of locally advanced prostate cancer","Wirth MP, Hakenberg OW, Froehner M.","World J Urol. 2007 Apr;25(2):169-76. doi: 10.1007/s00345-007-0158-7. Epub 2007 Feb 27.","Wirth MP","World J Urol","2007","2007/03/03","","","10.1007/s00345-007-0158-7"
"10966193","Transurethral resection of the prostate-related changes in the prostate gland: correlation of MRI and histopathology","Sheu MH, Chiang H, Wang JH, Chang YH, Chang CY.","J Comput Assist Tomogr. 2000 Jul-Aug;24(4):596-9. doi: 10.1097/00004728-200007000-00015.","Sheu MH","J Comput Assist Tomogr","2000","2000/08/31","","","10.1097/00004728-200007000-00015"
"26313229","Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy","Gee JR, Saltzstein DR, Messing E, Kim K, Kolesar J, Huang W, Havighurst TC, Harris L, Wollmer BW, Jarrard D, House M, Parnes H, Bailey HH.","Eur J Cancer Prev. 2016 Jul;25(4):312-20. doi: 10.1097/CEJ.0000000000000189.","Gee JR","Eur J Cancer Prev","2016","2015/08/28","","","10.1097/CEJ.0000000000000189"
"31343612","Gallium-68 prostate-specific membrane antigen PET-CT and the clinical management of prostate cancer","Davidson T, Amit U, Saad A, Hahiashvili M, Goshen E, Portnoy O, Berger R, Goldstein A, Sadetsky I, Weizman N, Chikman B, Dotan Z, Lawrence YR, Ben-Haim S, Symon Z, Goldstein J.","Nucl Med Commun. 2019 Sep;40(9):913-919. doi: 10.1097/MNM.0000000000001047.","Davidson T","Nucl Med Commun","2019","2019/07/26","","","10.1097/MNM.0000000000001047"
"1853855","Re: ""Vasectomy and the risk of prostate cancer""","","Am J Epidemiol. 1991 Jul 1;134(1):107-9.","","Am J Epidemiol","1991","1991/07/01","","",""
"10160261","'Clandestine' prostate cancer haunts","Chapman B.","CAP Today. 1996 Feb;10(2):1, 34-6, 38 passim.","Chapman B","CAP Today","1996","1996/01/08","","",""
"26817824","Prenatal exposure to soy and selenium reduces prostate cancer risk factors in TRAMP mice more than exposure beginning at six weeks","Nakken HL, Lephart ED, Hopkins TJ, Shaw B, Urie PM, Christensen MJ.","Prostate. 2016 May;76(6):588-96. doi: 10.1002/pros.23150. Epub 2016 Jan 28.","Nakken HL","Prostate","2016","2016/01/29","","","10.1002/pros.23150"
"11119095","Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging","Llanes L, Páez A, Ferruelo A, Luján M, Romero I, Berenguer A.","BJU Int. 2000 Dec;86(9):1023-7. doi: 10.1046/j.1464-410x.2000.00904.x.","Llanes L","BJU Int","2000","2000/12/19","","","10.1046/j.1464-410x.2000.00904.x"
"24486077","Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model","Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ.","Mayo Clin Proc. 2014 Mar;89(3):308-18. doi: 10.1016/j.mayocp.2013.12.001. Epub 2014 Jan 31.","Tollefson MK","Mayo Clin Proc","2014","2014/02/04","","","10.1016/j.mayocp.2013.12.001"
"9679894","Diagnosis and staging of prostate cancer","Flanigan RC.","J Urol. 1998 Aug;160(2):443-4. doi: 10.1016/s0022-5347(01)62920-3.","Flanigan RC","J Urol","1998","1998/07/29","","","10.1016/s0022-5347(01)62920-3"
"20959954","[Early detection of prostate cancer: is serum PSA testing alone sufficient?]","Börgermann C, Vom Dorp F, Breuer G, Kliner S, Rübben H.","Urologe A. 2010 Nov;49(11):1351-5. doi: 10.1007/s00120-010-2394-5.","Börgermann C","Urologe A","2010","2010/10/21","","","10.1007/s00120-010-2394-5"
"26506594","Prostate cancer stem cells: the role of androgen and estrogen receptors","Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Di Santi A, Cernera G, Rossi V, Abbondanza C, Moncharmont B, Sinisi AA, Castoria G, Migliaccio A.","Oncotarget. 2016 Jan 5;7(1):193-208. doi: 10.18632/oncotarget.6220.","Di Zazzo E","Oncotarget","2016","2015/10/28","PMC4807992","","10.18632/oncotarget.6220"
"17007094","Prostate cancer treatment. Permanent low-dose rate prostate brachytherapy","Langley SE.","Ann R Coll Surg Engl. 2006 Sep;88(5):442-4.","Langley SE","Ann R Coll Surg Engl","2006","2006/09/30","","",""
"14755681","Par-4 inducible apoptosis in prostate cancer cells","Gurumurthy S, Rangnekar VM.","J Cell Biochem. 2004 Feb 15;91(3):504-12. doi: 10.1002/jcb.20000.","Gurumurthy S","J Cell Biochem","2004","2004/02/03","","","10.1002/jcb.20000"
"31629424","Prostate cancer genetic testing: NCCN familial high-risk assessment: breast/ovarian","Daly MB.","Can J Urol. 2019 Oct;26(5 Suppl 2):29-30.","Daly MB","Can J Urol","2019","2019/10/21","","",""
"7972739","Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images","Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG.","Radiology. 1994 Nov;193(2):333-9. doi: 10.1148/radiology.193.2.7972739.","Outwater EK","Radiology","1994","1994/11/01","","","10.1148/radiology.193.2.7972739"
"18464297","Vimentin affects the mobility and invasiveness of prostate cancer cells","Zhao Y, Yan Q, Long X, Chen X, Wang Y.","Cell Biochem Funct. 2008 Sep-Oct;26(5):571-7. doi: 10.1002/cbf.1478.","Zhao Y","Cell Biochem Funct","2008","2008/05/09","","","10.1002/cbf.1478"
"28024263","Improved survival for patients with de novo metastatic prostate cancer in the last 20 years","Berg KD, Thomsen FB, Mikkelsen MK, Ingimarsdóttir IJ, Hansen RB, Kejs AM, Brasso K.","Eur J Cancer. 2017 Feb;72:20-27. doi: 10.1016/j.ejca.2016.11.025. Epub 2016 Dec 23.","Berg KD","Eur J Cancer","2017","2016/12/27","","","10.1016/j.ejca.2016.11.025"
"24390742","Prostate cancer: the need for biomarkers and new therapeutic targets","Felgueiras J, Silva JV, Fardilha M.","J Zhejiang Univ Sci B. 2014 Jan;15(1):16-42. doi: 10.1631/jzus.B1300106.","Felgueiras J","J Zhejiang Univ Sci B","2014","2014/01/07","PMC3891116","","10.1631/jzus.B1300106"
"16278471","High-risk localized prostate cancer: a case for early chemotherapy","Gleave M, Kelly WK.","J Clin Oncol. 2005 Nov 10;23(32):8186-91. doi: 10.1200/JCO.2005.03.3068.","Gleave M","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.03.3068"
"28107602","Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality","Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS.","BJU Int. 2017 Jun;119(6):961-967. doi: 10.1111/bju.13779. Epub 2017 Feb 11.","Pellegrini KL","BJU Int","2017","2017/01/21","PMC5444982","NIHMS845376","10.1111/bju.13779"
"10917552","Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption","Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, Ahmed T.","Br J Cancer. 2000 Aug;83(3):360-5. doi: 10.1054/bjoc.2000.1261.","Chiao JW","Br J Cancer","2000","2000/08/06","PMC2374574","","10.1054/bjoc.2000.1261"
"26112486","Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods","Moyad MA.","Asian J Androl. 2015 Nov-Dec;17(6):874-7; discussion 876. doi: 10.4103/1008-682X.156854.","Moyad MA","Asian J Androl","2015","2015/06/27","PMC4814969","","10.4103/1008-682X.156854"
"25528940","Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan","Szot W, Kostkiewicz M, Zając J, Owoc A, Bojar I.","Ann Agric Environ Med. 2014;21(4):888-92. doi: 10.5604/12321966.1129953.","Szot W","Ann Agric Environ Med","2014","2014/12/23","","","10.5604/12321966.1129953"
"11221033","[Does PSA density of the transition zone represent a useful parameter in the diagnosis of prostate carcinoma?]","Monesi G, Sala M, Baietto S, Minocci D, Kocjancic E, Marchioro G, Frea B.","Arch Ital Urol Androl. 2000 Dec;72(4):182-9.","Monesi G","Arch Ital Urol Androl","2000","2001/02/28","","",""
"10081874","Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison","Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H.","J Urol. 1999 Apr;161(4):1223-7; discussion 1227-8.","Ghavamian R","J Urol","1999","1999/03/19","","",""
"15770517","Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer","Gleave M, Miyake H.","World J Urol. 2005 Feb;23(1):38-46. doi: 10.1007/s00345-004-0474-0. Epub 2005 Jan 26.","Gleave M","World J Urol","2005","2005/03/17","","","10.1007/s00345-004-0474-0"
"19021610","Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate","Aigner F, Pallwein L, Mitterberger M, Pinggera GM, Mikuz G, Horninger W, Frauscher F.","BJU Int. 2009 Feb;103(4):458-63. doi: 10.1111/j.1464-410X.2008.08038.x. Epub 2008 Nov 18.","Aigner F","BJU Int","2009","2008/11/22","","","10.1111/j.1464-410X.2008.08038.x"
"12878247","Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results","Souchon R, Rouvière O, Gelet A, Detti V, Srinivasan S, Ophir J, Chapelon JY.","Ultrasound Med Biol. 2003 Jul;29(7):1007-15. doi: 10.1016/s0301-5629(03)00065-6.","Souchon R","Ultrasound Med Biol","2003","2003/07/25","","","10.1016/s0301-5629(03)00065-6"
"24993798","Stress and self-efficacy predict psychological adjustment at diagnosis of prostate cancer","Curtis R, Groarke A, Sullivan F.","Sci Rep. 2014 Jul 4;4:5569. doi: 10.1038/srep05569.","Curtis R","Sci Rep","2014","2014/07/05","PMC4081888","","10.1038/srep05569"
"23793845","Role of inflammasomes and their regulators in prostate cancer initiation, progression and metastasis","Veeranki S.","Cell Mol Biol Lett. 2013 Sep;18(3):355-67. doi: 10.2478/s11658-013-0095-y. Epub 2013 Jun 20.","Veeranki S","Cell Mol Biol Lett","2013","2013/06/25","PMC6275599","","10.2478/s11658-013-0095-y"
"28695241","[Metastatic prostate cancer : Update: position paper for the use of chemotherapy]","Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.","Urologe A. 2017 Dec;56(12):1597-1602. doi: 10.1007/s00120-017-0459-4.","Ohlmann CH","Urologe A","2017","2017/07/12","","","10.1007/s00120-017-0459-4"
"15992463","Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer","Beinart G, Rini BI, Weinberg V, Small EJ.","Clin Prostate Cancer. 2005 Jun;4(1):55-60. doi: 10.3816/cgc.2005.n.013.","Beinart G","Clin Prostate Cancer","2005","2005/07/05","","","10.3816/cgc.2005.n.013"
"14747927","[Optimizing the use of radiotherapy with IMRT and image guided location of advanced prostate cancer]","Lohr F, Fuss M, Tiefenbacher U, Siegsmund M, Mai S, Kunnappallil JM, Dobler B, Alken P, Wenz F.","Urologe A. 2004 Jan;43(1):43-51. doi: 10.1007/s00120-003-0481-6.","Lohr F","Urologe A","2004","2004/01/30","","","10.1007/s00120-003-0481-6"
"21832814","The value of contrast-enhanced transrectal ultrasound in predicting the nature of prostate diseases and the Gleason score of prostate cancer by a subjective blood flow grading scale","Zhao HW, Luo JH, Xu HX, Wang DH, Lai YR, Chen MN, Lv JY, Xie XY, Lu MD, Chen W.","Urol Int. 2011;87(2):165-70. doi: 10.1159/000327988. Epub 2011 Aug 11.","Zhao HW","Urol Int","2011","2011/08/12","","","10.1159/000327988"
"17640713","Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival","Daneshmand S, Quek ML, Lin E, Lee C, Cote RJ, Hawes D, Cai J, Groshen S, Lieskovsky G, Skinner DG, Lee AS, Pinski J.","Hum Pathol. 2007 Oct;38(10):1547-52. doi: 10.1016/j.humpath.2007.03.014. Epub 2007 Jul 19.","Daneshmand S","Hum Pathol","2007","2007/07/21","","","10.1016/j.humpath.2007.03.014"
"26883359","Atg7 cooperates with Pten loss to drive prostate cancer tumor growth","Santanam U, Banach-Petrosky W, Abate-Shen C, Shen MM, White E, DiPaola RS.","Genes Dev. 2016 Feb 15;30(4):399-407. doi: 10.1101/gad.274134.115.","Santanam U","Genes Dev","2016","2016/02/18","PMC4762425","","10.1101/gad.274134.115"
"18163938","Salvage options for biochemical recurrence after primary therapy for prostate cancer","Bong GW, Keane TE.","Can J Urol. 2007 Dec;14 Suppl 1:2-9.","Bong GW","Can J Urol","2007","2008/02/07","","",""
"12667424","Neoadjuvant therapy for high-risk localized prostate cancer","Yu EY, Oh WK.","Curr Oncol Rep. 2003 May;5(3):250-7. doi: 10.1007/s11912-003-0118-3.","Yu EY","Curr Oncol Rep","2003","2003/04/02","","","10.1007/s11912-003-0118-3"
"26383260","A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer","Sun Q, Arnold RS, Sun CQ, Petros JA.","Prostate. 2015 Dec;75(16):1916-25. doi: 10.1002/pros.23089. Epub 2015 Sep 18.","Sun Q","Prostate","2015","2015/09/19","","","10.1002/pros.23089"
"7516833","Prostate Cancer Awareness Week, 1992: a summary of key findings","DeAntoni E, Crawford ED, Stone NN, Blum DS, Berger ER, Eisenberger MA, Gambert SR, Staggers F.","Clin Invest Med. 1993 Dec;16(6):448-57.","DeAntoni E","Clin Invest Med","1993","1993/12/01","","",""
"22883113","[Clinical features and prognostic analysis in prostate cancer patients under 59 years of age: a report of 72 cases]","Wang X, Guo Z, Wang HT, Si TG.","Zhonghua Yi Xue Za Zhi. 2012 May 22;92(19):1300-3.","Wang X","Zhonghua Yi Xue Za Zhi","2012","2012/08/14","","",""
"23614597","Functional outcomes after treatment for prostate cancer","Mesrine S, Clavel-Chapelon F, Boutron-Ruault MC.","N Engl J Med. 2013 Apr 25;368(17):1653-4. doi: 10.1056/NEJMc1302509.","Mesrine S","N Engl J Med","2013","2013/04/26","","","10.1056/NEJMc1302509"
"23522909","Androgens and prostate cancer: we are still (almost) completely ignorant","Salonia A.","Eur Urol. 2014 Apr;65(4):690-1; discussion 691-2. doi: 10.1016/j.eururo.2013.02.041. Epub 2013 Mar 13.","Salonia A","Eur Urol","2014","2013/03/26","","","10.1016/j.eururo.2013.02.041"
"26637918","Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer","Shiota M, Takeuchi A, Sugimoto M, Kashiwagi E, Dejima T, Kiyoshima K, Inokuchi J, Tatsugami K, Yokomizo A.","Anticancer Res. 2015 Dec;35(12):6925-32.","Shiota M","Anticancer Res","2015","2015/12/06","","",""
"18337732","Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","Lilja H, Ulmert D, Vickers AJ.","Nat Rev Cancer. 2008 Apr;8(4):268-78. doi: 10.1038/nrc2351.","Lilja H","Nat Rev Cancer","2008","2008/03/14","","","10.1038/nrc2351"
"28244476","Incidence of prostate cancer at a single tertiary care center in North Karnataka","Ghagane SC, Nerli RB, Hiremath MB, Wagh AT, Magdum PV.","Indian J Cancer. 2016 Jul-Sep;53(3):429-431. doi: 10.4103/0019-509X.200671.","Ghagane SC","Indian J Cancer","2016","2017/03/01","","","10.4103/0019-509X.200671"
"10233451","Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer","Berner A, Harvei S, Skjorten FJ.","BJU Int. 1999 Jan;83(1):47-52. doi: 10.1046/j.1464-410x.1999.00896.x.","Berner A","BJU Int","1999","1999/05/08","","","10.1046/j.1464-410x.1999.00896.x"
"22203121","Improvement in urinary retention due to recurrent anastomotic prostate cancer treated with various therapies by intra-arterial infusion of cisplatin and ifosfamide","Uemura K, Nishihara K, Hayashi T, Tomiyasu K, Matsuoka K.","J Infect Chemother. 2012 Oct;18(5):753-5. doi: 10.1007/s10156-011-0352-9. Epub 2011 Dec 28.","Uemura K","J Infect Chemother","2012","2011/12/29","PMC3491188","","10.1007/s10156-011-0352-9"
"10394651","[Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml]","Herranz Amo F, Verdú Tartajo F, Díez Cordero JM, Bueno Chomón G, Leal Hernández F, Bielsa Carrillo A, García Burgos J.","Actas Urol Esp. 1999 Apr;23(4):316-22.","Herranz Amo F","Actas Urol Esp","1999","1999/07/08","","",""
"22414449","Editorial. PSA screening and low risk prostate cancer, what's going on? are we shooting the messenger?","Martínez-Salamanca JI.","Arch Esp Urol. 2012 Mar;65(2):209-14.","Martínez-Salamanca JI","Arch Esp Urol","2012","2012/03/15","","",""
"12587941","How to use PSA to screen for prostate cancer","Little B, Young M.","Int J Clin Pract. 2003 Jan-Feb;57(1):40-2.","Little B","Int J Clin Pract","2003","2003/02/18","","",""
"28389666","Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network","Yang L, Wang S, Zhou M, Chen X, Jiang W, Zuo Y, Lv Y.","Sci Rep. 2017 Apr 7;7(1):738. doi: 10.1038/s41598-017-00872-8.","Yang L","Sci Rep","2017","2017/04/09","PMC5429686","","10.1038/s41598-017-00872-8"
"20608143","Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature","Pinto F, Brescia A, Sacco E, Volpe A, Gardi M, Gulino G, Bassi P.","Arch Ital Urol Androl. 2009 Dec;81(4):212-4.","Pinto F","Arch Ital Urol Androl","2009","2010/07/09","","",""
"27286103","Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review","Castelli T, Russo GI, Reale G, Privitera S, Chisari M, Fragalà E, Favilla V, Cimino S, Morgia G.","Int Braz J Urol. 2016 May-Jun;42(3):422-30. doi: 10.1590/S1677-5538.IBJU.2015.0095.","Castelli T","Int Braz J Urol","2016","2016/06/11","PMC4920557","","10.1590/S1677-5538.IBJU.2015.0095"
"16740685","A systems approach to model metastatic progression","Taylor BS, Varambally S, Chinnaiyan AM.","Cancer Res. 2006 Jun 1;66(11):5537-9. doi: 10.1158/0008-5472.CAN-06-0415.","Taylor BS","Cancer Res","2006","2006/06/03","","","10.1158/0008-5472.CAN-06-0415"
"24988136","New recommendations in prostate cancer screening and treatment","Adams LK, Ferrington LS.","JAAPA. 2014 Aug;27(8):14-20; quiz 26. doi: 10.1097/01.JAA.0000451872.86566.bf.","Adams LK","JAAPA","2014","2014/07/03","","","10.1097/01.JAA.0000451872.86566.bf"
"23742221","Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy","Wang Y, Liu T, Rossi PJ, Watkins-Bruner D, Hsiao W, Cooper S, Yang X, Jani AB.","J Sex Med. 2013 Aug;10(8):2108-14. doi: 10.1111/jsm.12215. Epub 2013 Jun 6.","Wang Y","J Sex Med","2013","2013/06/08","PMC4345169","NIHMS563329","10.1111/jsm.12215"
"18820896","[The role of surgery in locally advanced prostate cancer]","Palisaar RJ, Noldus J.","Urologe A. 2008 Nov;47(11):1417-23. doi: 10.1007/s00120-008-1721-6.","Palisaar RJ","Urologe A","2008","2008/09/30","","","10.1007/s00120-008-1721-6"
"11474933","Helical antenna arrays for interstitial microwave thermal therapy for prostate cancer: tissue phantom testing and simulations for treatment","Shera MD, Gladman AS, Davidson SR, Trachtenberg J, Gertner MR.","Phys Med Biol. 2001 Jul;46(7):1905-18. doi: 10.1088/0031-9155/46/7/312.","Shera MD","Phys Med Biol","2001","2001/07/28","","","10.1088/0031-9155/46/7/312"
"17049718","Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study","Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, Mondaini N, Bonvini D, Tizzani A, Frea B.","Eur Urol. 2007 Apr;51(4):922-9; discussion 929-30. doi: 10.1016/j.eururo.2006.08.050. Epub 2006 Sep 11.","Gontero P","Eur Urol","2007","2006/10/20","","","10.1016/j.eururo.2006.08.050"
"14587206","Prostate cancer intervention. Involving the patient in early detection and treatment","Wilt TJ, Partin MR.","Postgrad Med. 2003 Oct;114(4):43-9; quiz 50. doi: 10.3810/pgm.2003.10.1506.","Wilt TJ","Postgrad Med","2003","2003/11/01","","","10.3810/pgm.2003.10.1506"
"20699373","Knowledge and use of finasteride for the prevention of prostate cancer","Hamilton RJ, Kahwati LC, Kinsinger LS.","Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2164-71. doi: 10.1158/1055-9965.EPI-10-0082. Epub 2010 Aug 10.","Hamilton RJ","Cancer Epidemiol Biomarkers Prev","2010","2010/08/12","","","10.1158/1055-9965.EPI-10-0082"
"11144904","Prevention of prostate cancer","Schulman CC, Zlotta AR, Denis L, Schröder FH, Sakr WA.","Scand J Urol Nephrol Suppl. 2000;(205):50-61. doi: 10.1080/003655900750169301.","Schulman CC","Scand J Urol Nephrol Suppl","2000","2001/01/06","","","10.1080/003655900750169301"
"31240466","Patterns and predictors of registration and participation at a supportive care program for prostate cancer survivors","Hedden L, Pollock P, Stirling B, Goldenberg L, Higano C.","Support Care Cancer. 2019 Nov;27(11):4363-4373. doi: 10.1007/s00520-019-04927-6. Epub 2019 Jun 25.","Hedden L","Support Care Cancer","2019","2019/06/27","","","10.1007/s00520-019-04927-6"
"16979744","Inactivation of myopodin expression associated with prostate cancer relapse","Yu YP, Tseng GC, Luo JH.","Urology. 2006 Sep;68(3):578-82. doi: 10.1016/j.urology.2006.03.027. Epub 2006 Sep 18.","Yu YP","Urology","2006","2006/09/19","","","10.1016/j.urology.2006.03.027"
"7637143","Long-term survival among men with conservatively treated localized prostate cancer","Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J.","JAMA. 1995 Aug 23-30;274(8):626-31.","Albertsen PC","JAMA","1995","1995/08/23","","",""
"9069292","Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy","Zietman AL, Shipley WU.","Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):245-6. doi: 10.1016/s0360-3016(97)00122-3.","Zietman AL","Int J Radiat Oncol Biol Phys","1997","1997/01/15","","","10.1016/s0360-3016(97)00122-3"
"21893925","A pilot study on understanding the journey of advanced prostate cancer patients","Wagholikar A, Fung M, Nelson C.","Stud Health Technol Inform. 2011;168:165-71.","Wagholikar A","Stud Health Technol Inform","2011","2011/09/07","","",""
"30027927","The Institute of Urology, Peking University prostatectomy score: a simple preoperative classification of prostate cancer for predicting surgical difficulty and risk","Ma BL, Yao L, Yu W, Wang Y, Song HF, Zhang ZN, Lu SM, Zhang Q, He ZS, Jin J, Zhou LQ.","Asian J Androl. 2018 Nov-Dec;20(6):581-586. doi: 10.4103/aja.aja_39_18.","Ma BL","Asian J Androl","2018","2018/07/21","PMC6219297","","10.4103/aja.aja_39_18"
"27825433","Advancement of MR and PET/MR in Prostate Cancer","Lindenberg L, Ahlman M, Turkbey B, Mena E, Choyke P.","Semin Nucl Med. 2016 Nov;46(6):536-543. doi: 10.1053/j.semnuclmed.2016.07.001. Epub 2016 Sep 3.","Lindenberg L","Semin Nucl Med","2016","2016/11/10","","","10.1053/j.semnuclmed.2016.07.001"
"25307545","Highlights from the field of biomarkers in prostate cancer. [corrected]","Pandha H.","Biomark Med. 2014;8(7):917-9. doi: 10.2217/bmm.14.59.","Pandha H","Biomark Med","2014","2014/10/14","","","10.2217/bmm.14.59"
"29107274","Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome","Edison E, Tariq Shah T, Ahmed HU.","Urol Clin North Am. 2017 Nov;44(4):575-585. doi: 10.1016/j.ucl.2017.07.006.","Edison E","Urol Clin North Am","2017","2017/11/07","","","10.1016/j.ucl.2017.07.006"
"17214231","[Prostate cancer in the elderly patient]","Waldert M, Djavan B.","Ann Urol (Paris). 2006 Dec;40(6):336-41. doi: 10.1016/j.anuro.2006.09.002.","Waldert M","Ann Urol (Paris)","2006","2007/01/12","","","10.1016/j.anuro.2006.09.002"
"10472353","Recent advances in early prostatic cancer","Gorgoulis VG, Tiniakos DG, Mariatos G, Manolis EN, Mitropoulos D, Kittas C.","Anticancer Res. 1999 May-Jun;19(3B):2327-48.","Gorgoulis VG","Anticancer Res","1999","1999/09/03","","",""
"25425328","The effect of dietary and exercise interventions on body weight in prostate cancer patients: a systematic review","Mohamad H, McNeill G, Haseen F, N'Dow J, Craig LC, Heys SD.","Nutr Cancer. 2015;67(1):43-60. doi: 10.1080/01635581.2015.976313. Epub 2014 Nov 25.","Mohamad H","Nutr Cancer","2015","2014/11/27","","","10.1080/01635581.2015.976313"
"29576269","The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study","Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S.","Urol Oncol. 2018 Jun;36(6):309.e15-309.e23. doi: 10.1016/j.urolonc.2018.02.016. Epub 2018 Mar 22.","Matthes KL","Urol Oncol","2018","2018/03/27","","","10.1016/j.urolonc.2018.02.016"
"9507843","The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer","Ornstein DK, Smith DS, Humphrey PA, Catalona WJ.","J Urol. 1998 Apr;159(4):1234-7.","Ornstein DK","J Urol","1998","1998/03/21","","",""
"21193912","PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy","Hofner T, Pfitzenmaier J, Alrabadi A, Pahernik S, Hadaschik B, Wagener N, Djakovic N, Haferkamp A, Hohenfellner M.","World J Urol. 2012 Feb;30(1):91-5. doi: 10.1007/s00345-010-0631-6. Epub 2010 Dec 31.","Hofner T","World J Urol","2012","2011/01/04","","","10.1007/s00345-010-0631-6"
"15831998","Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men","Song C, Kang T, Ro JY, Lee MS, Kim CS, Ahn H.","J Korean Med Sci. 2005 Apr;20(2):262-6. doi: 10.3346/jkms.2005.20.2.262.","Song C","J Korean Med Sci","2005","2005/04/16","PMC2808603","","10.3346/jkms.2005.20.2.262"
"4170154","Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients","Cook GB, Watson FR.","J Urol. 1968 Jan;99(1):87-96. doi: 10.1016/s0022-5347(17)62647-8.","Cook GB","J Urol","1968","1968/01/01","","","10.1016/s0022-5347(17)62647-8"
"30579787","Current controversies on the role of lymphadenectomy for prostate cancer","Chalouhy C, Gurram S, Ghavamian R.","Urol Oncol. 2019 Mar;37(3):219-226. doi: 10.1016/j.urolonc.2018.11.020. Epub 2018 Dec 19.","Chalouhy C","Urol Oncol","2019","2018/12/24","","","10.1016/j.urolonc.2018.11.020"
"12667420","Early chemohormonal therapy in prostate cancer: preliminary data and randomized trials","Petrylak DP.","Curr Oncol Rep. 2003 May;5(3):229-30. doi: 10.1007/s11912-003-0114-7.","Petrylak DP","Curr Oncol Rep","2003","2003/04/02","","","10.1007/s11912-003-0114-7"
"29372688","Testosterone as a prospective predictor of pathological Gleason score and pathological stage in prostate cancer","Drobková H, Jurečeková J, Grendár M, Kliment J Jr, Halašová E, Kliment J.","Gen Physiol Biophys. 2017 Dec;36(5):549-556. doi: 10.4149/gpb_2017044.","Drobková H","Gen Physiol Biophys","2017","2018/01/27","","","10.4149/gpb_2017044"
"22652112","Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate cancer mortality: results from a prospective patient database","Foo M, Lavieri M, Pickles T.","Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):385-92. doi: 10.1016/j.ijrobp.2012.04.009. Epub 2012 May 30.","Foo M","Int J Radiat Oncol Biol Phys","2013","2012/06/02","","","10.1016/j.ijrobp.2012.04.009"
"10068341","Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival","Aaltomaa S, Eskelinen M, Lipponen P.","Prostate. 1999 Feb 15;38(3):175-82. doi: 10.1002/(sici)1097-0045(19990215)38:3<175::aid-pros1>3.0.co;2-#.","Aaltomaa S","Prostate","1999","1999/03/06","","","10.1002/(sici)1097-0045(19990215)38:3<175::aid-pros1>3.0.co;2-#"
"22971685","Serum adiponectin and leptin levels are useful markers for prostate cancer screening after adjustments for age, obesity-related factors, and prostate volume","Nishimura K, Soda T, Nakazawa S, Yamanaka K, Hirai T, Kishikawa H, Ichikawa Y.","Minerva Urol Nefrol. 2012 Sep;64(3):199-208.","Nishimura K","Minerva Urol Nefrol","2012","2012/09/14","","",""
"19727146","Prostate cancer: seminal vesicle sparing: a continuing trend?","Gilbert SM.","Nat Rev Urol. 2009 Sep;6(9):475-6. doi: 10.1038/nrurol.2009.167.","Gilbert SM","Nat Rev Urol","2009","2009/09/04","","","10.1038/nrurol.2009.167"
"12581889","Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo","Abasolo I, Yang L, Haleem R, Xiao W, Pio R, Cuttitta F, Montuenga LM, Kozlowski JM, Calvo A, Wang Z.","Mol Cell Endocrinol. 2003 Jan 31;199(1-2):179-87. doi: 10.1016/s0303-7207(02)00229-0.","Abasolo I","Mol Cell Endocrinol","2003","2003/02/13","","","10.1016/s0303-7207(02)00229-0"
"25802144","Mannose-6-phosphate receptor: a target for theranostics of prostate cancer","Vaillant O, El Cheikh K, Warther D, Brevet D, Maynadier M, Bouffard E, Salgues F, Jeanjean A, Puche P, Mazerolles C, Maillard P, Mongin O, Blanchard-Desce M, Raehm L, Rébillard X, Durand JO, Gary-Bobo M, Morère A, Garcia M.","Angew Chem Int Ed Engl. 2015 May 11;54(20):5952-6. doi: 10.1002/anie.201500286. Epub 2015 Mar 20.","Vaillant O","Angew Chem Int Ed Engl","2015","2015/03/25","","","10.1002/anie.201500286"
"12956449","Case report: PET scan detects prostate cancer in a patient with Hodgkins lymphoma","Keehn CA, Seigne J, Wade M, Szabunio M, Ahmad N.","Ann Clin Lab Sci. 2003 Summer;33(3):324-5.","Keehn CA","Ann Clin Lab Sci","2003","2003/09/06","","",""
"9301699","Comparison of perspectives on prostate cancer: analyses of survey data","Crawford ED, Bennett CL, Stone NN, Knight SJ, DeAntoni E, Sharp L, Garnick MB, Porterfield HA.","Urology. 1997 Sep;50(3):366-72. doi: 10.1016/s0090-4295(97)00254-9.","Crawford ED","Urology","1997","1997/09/25","","","10.1016/s0090-4295(97)00254-9"
"27564280","Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies","Yilmaz Ö, Kurul Ö, Ates F, Soydan H, Aktas Z.","Int Braz J Urol. 2016 Jul-Aug;42(4):704-9. doi: 10.1590/S1677-5538.IBJU.2014.0598.","Yilmaz Ö","Int Braz J Urol","2016","2016/08/27","PMC5006765","","10.1590/S1677-5538.IBJU.2014.0598"
"8653039","Early detection of prostate cancer. Role of prostate-specific antigen","Prabhakaran VM.","Can Fam Physician. 1996 Apr;42:709-12.","Prabhakaran VM","Can Fam Physician","1996","1996/04/01","PMC2146418","",""
"23984644","Screening biomarkers of prostate cancer by integrating microRNA and mRNA microarrays","Feng J, Huang C, Diao X, Fan M, Wang P, Xiao Y, Zhong X, Wu R.","Genet Test Mol Biomarkers. 2013 Nov;17(11):807-13. doi: 10.1089/gtmb.2013.0226. Epub 2013 Aug 28.","Feng J","Genet Test Mol Biomarkers","2013","2013/08/30","PMC3816787","","10.1089/gtmb.2013.0226"
"30429595","Immediate treatment vs. active-surveillance in very-low-risk prostate cancer: the role of patient-, tumour-, and hospital-related factors","Jansen H, van Oort IM, van Andel G, Wijsman BP, Pos FJ, Hulshof MCCM, Hulsbergen-van de Kaa CA, van Leenders GJLH, Fütterer JJ, Somford DM, Busstra MB, van Moorselaar RJA, Kiemeney LA, Aben KKH.","Prostate Cancer Prostatic Dis. 2019 May;22(2):337-343. doi: 10.1038/s41391-018-0109-y. Epub 2018 Nov 14.","Jansen H","Prostate Cancer Prostatic Dis","2019","2018/11/16","","","10.1038/s41391-018-0109-y"
"28614085","A multiparametric approach to improve upon existing prostate cancer screening and biopsy recommendations","Helfand BT, Conran CA, Xu J, Catalona WJ.","Curr Opin Urol. 2017 Sep;27(5):475-480. doi: 10.1097/MOU.0000000000000418.","Helfand BT","Curr Opin Urol","2017","2017/06/15","PMC5972833","NIHMS970313","10.1097/MOU.0000000000000418"
"31063054","Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer","Atala A.","J Urol. 2019 Aug;202(2):214. doi: 10.1097/01.JU.0000559616.03626.0d. Epub 2019 Jul 8.","Atala A","J Urol","2019","2019/05/08","","","10.1097/01.JU.0000559616.03626.0d"
"12487058","Prostate cancer gene therapy","Steiner MS, Gingrich JR, Chauhan RD.","Surg Oncol Clin N Am. 2002 Jul;11(3):607-20. doi: 10.1016/s1055-3207(02)00026-1.","Steiner MS","Surg Oncol Clin N Am","2002","2002/12/19","","","10.1016/s1055-3207(02)00026-1"
"8187068","Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers","Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S.","Cancer Res. 1994 Jun 1;54(11):2861-4.","Gaddipati JP","Cancer Res","1994","1994/06/01","","",""
"27084245","Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study","Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.","Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.","Carlsson S","Eur Urol","2017","2016/04/17","PMC5061609","NIHMS802896","10.1016/j.eururo.2016.03.026"
"19534805","Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer","Shah MR, Kriedt CL, Lents NH, Hoyer MK, Jamaluddin N, Klein C, Baldassare J.","J Exp Clin Cancer Res. 2009 Jun 17;28(1):84. doi: 10.1186/1756-9966-28-84.","Shah MR","J Exp Clin Cancer Res","2009","2009/06/19","PMC2701928","","10.1186/1756-9966-28-84"
"16678059","Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale","Ryan CJ, Lin AM, Small EJ.","Urol Oncol. 2006 May-Jun;24(3):250-3. doi: 10.1016/j.urolonc.2005.11.021.","Ryan CJ","Urol Oncol","2006","2006/05/09","","","10.1016/j.urolonc.2005.11.021"
"17459272","The basic biochemistry and molecular events of hormone therapy","Mostaghel EA, Montgomery RB, Lin DW.","Curr Urol Rep. 2007 May;8(3):224-32. doi: 10.1007/s11934-007-0010-z.","Mostaghel EA","Curr Urol Rep","2007","2007/04/27","","","10.1007/s11934-007-0010-z"
"21257717","What do prostate cancer patients die of?","Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K.","Oncologist. 2011;16(2):175-81. doi: 10.1634/theoncologist.2010-0338. Epub 2011 Jan 21.","Riihimäki M","Oncologist","2011","2011/01/25","PMC3228081","","10.1634/theoncologist.2010-0338"
"10975496","Communicating effectively with the patient and family about treatment options for prostate cancer","Kunkel EJ, Myers RE, Lartey PL, Oyesanmi O.","Semin Urol Oncol. 2000 Aug;18(3):233-40.","Kunkel EJ","Semin Urol Oncol","2000","2000/09/07","","",""
"22822521","Skip the screen. Experts say blood tests for prostate cancer don't save lives","Park A.","Time. 2012 Jun 4;179(22):19.","Park A","Time","2012","2012/07/25","","",""
"28864839","Outcomes of treatment in men with prostate cancer at the cancer centre Bahamas","Jones GW, Kellini O, Roberts R, Girgis N, Brown C, Nottage K, McGowan T, Quee-Brown CS, Brown C.","Cancer Causes Control. 2017 Nov;28(11):1285-1293. doi: 10.1007/s10552-017-0940-9. Epub 2017 Sep 1.","Jones GW","Cancer Causes Control","2017","2017/09/03","","","10.1007/s10552-017-0940-9"
"30320610","Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy","Aoun F, Albisinni S, van Velthoven R.","Curr Opin Urol. 2019 Jan;29(1):65-69. doi: 10.1097/MOU.0000000000000560.","Aoun F","Curr Opin Urol","2019","2018/10/16","","","10.1097/MOU.0000000000000560"
"15142129","Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies","Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA.","BJU Int. 2004 May;93(8):1139-50. doi: 10.1111/j.1464-410X.2004.04795.x.","Dagnelie PC","BJU Int","2004","2004/05/15","","","10.1111/j.1464-410X.2004.04795.x"
"30224545","The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells","Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, Reed MJ, Nelson PS.","Mol Cancer Res. 2019 Jan;17(1):321-331. doi: 10.1158/1541-7786.MCR-18-0522. Epub 2018 Sep 17.","Bianchi-Frias D","Mol Cancer Res","2019","2018/09/19","","","10.1158/1541-7786.MCR-18-0522"
"28905176","The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study","Lee KS, Koo KC, Chung BH.","Int Urol Nephrol. 2017 Dec;49(12):2119-2125. doi: 10.1007/s11255-017-1696-6. Epub 2017 Sep 13.","Lee KS","Int Urol Nephrol","2017","2017/09/15","","","10.1007/s11255-017-1696-6"
"30121008","Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation","Brown NE, Paluch AM, Nashu MA, Komurov K, Waltz SE.","Neoplasia. 2018 Sep;20(9):917-929. doi: 10.1016/j.neo.2018.07.003. Epub 2018 Aug 15.","Brown NE","Neoplasia","2018","2018/08/19","PMC6098205","","10.1016/j.neo.2018.07.003"
"11170146","Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization","El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC.","Prostate. 2001 Feb 15;46(3):184-90. doi: 10.1002/1097-0045(20010215)46:3<184::aid-pros1022>3.0.co;2-8.","El Gedaily A","Prostate","2001","2001/02/15","","","10.1002/1097-0045(20010215)46:3<184::aid-pros1022>3.0.co;2-8"
"27225637","Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers","Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.","Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26.","Gleicher S","Prostate","2016","2016/05/27","PMC5470321","NIHMS794168","10.1002/pros.23204"
"16864764","No one dies from prostate cancer?","Chau D.","Arch Intern Med. 2006 Jul 24;166(14):1525; author reply 1526. doi: 10.1001/archinte.166.14.1525-c.","Chau D","Arch Intern Med","2006","2006/07/26","","","10.1001/archinte.166.14.1525-c"
"11920953","Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells","Fu Z, Dozmorov IM, Keller ET.","Prostate. 2002 Apr 1;51(1):10-20. doi: 10.1002/pros.10056.","Fu Z","Prostate","2002","2002/03/29","","","10.1002/pros.10056"
"7122334","Immunodiagnosis of prostate cancer: an evaluation of cell-mediated immunity","Bhatti RA, Guinan PD, Nagubadi SR, Khin W.","Prostate. 1982;3(4):415-9. doi: 10.1002/pros.2990030411.","Bhatti RA","Prostate","1982","1982/01/01","","","10.1002/pros.2990030411"
"3368405","Tamoxifen in advanced prostate cancer: an ECOG pilot study","Horton J, Rosenbaum C, Cummings FJ.","Prostate. 1988;12(2):173-7. doi: 10.1002/pros.2990120207.","Horton J","Prostate","1988","1988/01/01","","","10.1002/pros.2990120207"
"18268528","Recruitment strategies and comparison of prostate cancer-specific clinical data on African-American and Caucasian males with and without family history","Mandal DM, Sartor O, Halton SL, Mercante DE, Bailey-Wilson JE, Rayford W.","Prostate Cancer Prostatic Dis. 2008;11(3):274-9. doi: 10.1038/pcan.2008.5. Epub 2008 Feb 12.","Mandal DM","Prostate Cancer Prostatic Dis","2008","2008/02/13","PMC2593398","NIHMS78458","10.1038/pcan.2008.5"
"21937078","The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers","Guo CC, Wang Y, Xiao L, Troncoso P, Czerniak BA.","Hum Pathol. 2012 May;43(5):644-9. doi: 10.1016/j.humpath.2011.06.018. Epub 2011 Sep 19.","Guo CC","Hum Pathol","2012","2011/09/23","PMC3880196","NIHMS326630","10.1016/j.humpath.2011.06.018"
"17426038","Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995-2004","Robbins AS, Yin D, Parikh-Patel A.","Am J Epidemiol. 2007 Jul 1;166(1):71-8. doi: 10.1093/aje/kwm052. Epub 2007 Apr 9.","Robbins AS","Am J Epidemiol","2007","2007/04/12","","","10.1093/aje/kwm052"
"15711119","Radical prostatectomy for localized prostate cancer in a liver transplant recipient","Reiter WJ, Mock K.","Urol Int. 2005;74(1):95-6. doi: 10.1159/000082718.","Reiter WJ","Urol Int","2005","2005/02/16","","","10.1159/000082718"
"20868349","Review of chemoradiotherapy for high-risk prostate cancer","Sanfilippo N, Hardee ME, Wallach J.","Rev Recent Clin Trials. 2011 Jan;6(1):64-8. doi: 10.2174/157488711793980200.","Sanfilippo N","Rev Recent Clin Trials","2011","2010/09/28","","","10.2174/157488711793980200"
"30193584","Lipidomic profiling of extracellular vesicles derived from prostate and prostate cancer cell lines","Brzozowski JS, Jankowski H, Bond DR, McCague SB, Munro BR, Predebon MJ, Scarlett CJ, Skelding KA, Weidenhofer J.","Lipids Health Dis. 2018 Sep 8;17(1):211. doi: 10.1186/s12944-018-0854-x.","Brzozowski JS","Lipids Health Dis","2018","2018/09/09","PMC6128989","","10.1186/s12944-018-0854-x"
"29278879","Overexpression of lncRNA ANRIL promoted the proliferation and migration of prostate cancer cells via regulating let-7a/TGF-β1/ Smad signaling pathway","Zhao B, Lu YL, Yang Y, Hu LB, Bai Y, Li RQ, Zhang GY, Li J, Bi CW, Yang LB, Hu C, Lei YH, Wang QL, Liu ZM.","Cancer Biomark. 2018 Feb 14;21(3):613-620. doi: 10.3233/CBM-170683.","Zhao B","Cancer Biomark","2018","2017/12/28","PMC5859458","","10.3233/CBM-170683"
"8667899","Screening for early detection of prostate cancer","Catalona WJ.","Lancet. 1996 Jun 8;347(9015):1629. doi: 10.1016/s0140-6736(96)91116-2.","Catalona WJ","Lancet","1996","1996/06/08","","","10.1016/s0140-6736(96)91116-2"
"18436254","The heterochromatin protein 1 family is regulated in prostate development and cancer","Shapiro E, Huang H, Ruoff R, Lee P, Tanese N, Logan SK.","J Urol. 2008 Jun;179(6):2435-9. doi: 10.1016/j.juro.2008.01.091. Epub 2008 Apr 23.","Shapiro E","J Urol","2008","2008/04/26","","","10.1016/j.juro.2008.01.091"
"16006854","Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty","Andriole GL.","J Urol. 2005 Aug;174(2):413-4. doi: 10.1097/01.ju.0000171051.35187.d0.","Andriole GL","J Urol","2005","2005/07/12","","","10.1097/01.ju.0000171051.35187.d0"
"10584352","[Metastatic prostate adenocarcinoma in hernial sac. Contribution of one case]","Rodríguez Alonso A, Domínguez Freire F, Pérez García D, Ojea Calvo A, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, Nogueira March JL.","Actas Urol Esp. 1999 Sep;23(8):717-9. doi: 10.1016/s0210-4806(99)72357-0.","Rodríguez Alonso A","Actas Urol Esp","1999","1999/12/10","","","10.1016/s0210-4806(99)72357-0"
"26334083","Prostate cancer: No evidence for adjuvant chemotherapy in high-risk disease","Albers P.","Nat Rev Urol. 2015 Nov;12(11):602-3. doi: 10.1038/nrurol.2015.219. Epub 2015 Sep 1.","Albers P","Nat Rev Urol","2015","2015/09/04","","","10.1038/nrurol.2015.219"
"24684414","NICE guidelines on Prostate Cancer Active Surveillance: is UK practice leading the world?","Streeter EH, Brewster SF; BAUS Section of Oncology.","BJU Int. 2015 Jan;115(1):12-3. doi: 10.1111/bju.12752. Epub 2014 Oct 18.","Streeter EH","BJU Int","2015","2014/04/02","","","10.1111/bju.12752"
"17306442","Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells","Edwards J, Leung HY.","Eur Urol. 2007 Dec;52(6):1680-1. doi: 10.1016/j.eururo.2007.01.098.","Edwards J","Eur Urol","2007","2007/02/20","","","10.1016/j.eururo.2007.01.098"
"12426863","[Significance of endorectal nuclear magnetic resonance tomography and transrectal ultrasound diagnosis in local staging of prostatic carcinoma]","May F, Treumann T, Dettmar P, Hartung R, Breul J.","Urologe A. 2002 Sep;41(5):458-61. doi: 10.1007/s00120-001-0150-6.","May F","Urologe A","2002","2002/11/13","","","10.1007/s00120-001-0150-6"
"19353483","[Pharmacokinetic MRI of the prostate: parameters for differentiating low-grade and high-grade prostate cancer]","Franiel T, Lüdemann L, Taupitz M, Rost J, Asbach P, Beyersdorff D.","Rofo. 2009 Jun;181(6):536-42. doi: 10.1055/s-0028-1109168. Epub 2009 Apr 7.","Franiel T","Rofo","2009","2009/04/09","","","10.1055/s-0028-1109168"
"19213886","Biomarkers. Metabolite in urine may point to high-risk prostate cancer","Couzin J.","Science. 2009 Feb 13;323(5916):865. doi: 10.1126/science.323.5916.865a.","Couzin J","Science","2009","2009/02/14","","","10.1126/science.323.5916.865a"
"26293672","Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer","Kluth M, Ahrary R, Hube-Magg C, Ahmed M, Volta H, Schwemin C, Steurer S, Wittmer C, Wilczak W, Burandt E, Krech T, Adam M, Michl U, Heinzer H, Salomon G, Graefen M, Koop C, Minner S, Simon R, Sauter G, Schlomm T.","Oncotarget. 2015 Sep 29;6(29):27966-79. doi: 10.18632/oncotarget.4626.","Kluth M","Oncotarget","2015","2015/08/22","PMC4695038","","10.18632/oncotarget.4626"
"24700681","Diagnosing 'male' depression in men diagnosed with prostate cancer: the next step in effective translational psycho-oncology interventions?","Sharpley CF, Bitsika V, Christie DR.","Psychooncology. 2014 Sep;23(9):1042-8. doi: 10.1002/pon.3530. Epub 2014 Apr 3.","Sharpley CF","Psychooncology","2014","2014/04/05","","","10.1002/pon.3530"
"22257653","Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review","Arcangeli S, Scorsetti M, Alongi F.","Crit Rev Oncol Hematol. 2012 Oct;84(1):101-8. doi: 10.1016/j.critrevonc.2011.11.009. Epub 2012 Jan 17.","Arcangeli S","Crit Rev Oncol Hematol","2012","2012/01/20","","","10.1016/j.critrevonc.2011.11.009"
"19608787","A brainstem paraneoplastic syndrome associated with prostate cancer","Berger JR, Bensalem M, Dalmau J.","J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):934-5. doi: 10.1136/jnnp.2008.153015.","Berger JR","J Neurol Neurosurg Psychiatry","2009","2009/07/18","","","10.1136/jnnp.2008.153015"
"25252133","In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?","Salami SS, Ben-Levi E, Yaskiv O, Ryniker L, Turkbey B, Kavoussi LR, Villani R, Rastinehad AR.","BJU Int. 2015 Apr;115(4):562-70. doi: 10.1111/bju.12938.","Salami SS","BJU Int","2015","2014/09/25","","","10.1111/bju.12938"
"32086498","Considering the role of radical prostatectomy in 21st century prostate cancer care","Costello AJ.","Nat Rev Urol. 2020 Mar;17(3):177-188. doi: 10.1038/s41585-020-0287-y. Epub 2020 Feb 21.","Costello AJ","Nat Rev Urol","2020","2020/02/23","","","10.1038/s41585-020-0287-y"
"22942743","Exome enrichment and SOLiD sequencing of formalin fixed paraffin embedded (FFPE) prostate cancer tissue","Menon R, Deng M, Boehm D, Braun M, Fend F, Boehm D, Biskup S, Perner S.","Int J Mol Sci. 2012;13(7):8933-42. doi: 10.3390/ijms13078933. Epub 2012 Jul 17.","Menon R","Int J Mol Sci","2012","2012/09/04","PMC3430274","","10.3390/ijms13078933"
"31054217","The impact of the three degrees-of-freedom fiducial marker-based setup compared to soft tissue-based setup in hypofractionated intensity-modulated radiotherapy for prostate cancer","Tanabe S, Utsunomiya S, Abe E, Sato H, Ohta A, Sakai H, Yamada T, Kaidu M, Aoyama H.","J Appl Clin Med Phys. 2019 Jun;20(6):53-59. doi: 10.1002/acm2.12603. Epub 2019 May 4.","Tanabe S","J Appl Clin Med Phys","2019","2019/05/05","PMC6560240","","10.1002/acm2.12603"
"24950910","Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer","Stallone G, Cormio L, Netti GS, Infante B, Selvaggio O, Fino GD, Ranieri E, Bruno F, Prattichizzo C, Sanguedolce F, Tortorella S, Bufo P, Grandaliano G, Carrieri G.","Cancer Res. 2014 Aug 15;74(16):4230-8. doi: 10.1158/0008-5472.CAN-14-0369. Epub 2014 Jun 20.","Stallone G","Cancer Res","2014","2014/06/22","","","10.1158/0008-5472.CAN-14-0369"
"22886631","Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents","Khamis ZI, Iczkowski KA, Sang QX.","Med Res Rev. 2012 Sep;32(5):1026-77. doi: 10.1002/med.20232. Epub 2011 Jan 16.","Khamis ZI","Med Res Rev","2012","2012/08/14","","","10.1002/med.20232"
"18980297","Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer","D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.","Cancer. 2008 Dec 15;113(12):3290-7. doi: 10.1002/cncr.23970.","D'Amico AV","Cancer","2008","2008/11/05","","","10.1002/cncr.23970"
"7688438","Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening","Catalona WJ, Smith DS, Ratliff TL, Basler JW.","JAMA. 1993 Aug 25;270(8):948-54.","Catalona WJ","JAMA","1993","1993/08/25","","",""
"22673095","A comparative population-based study of prostate cancer incidence and mortality rates in Singapore, Sweden and Geneva, Switzerland from 1973 to 2006","Chen C, Naidoo N, Yang Q, Hartman M, Verkooijen HM, Loy EY, Bouchardy C, Chia KS, Chia SE.","BMC Cancer. 2012 Jun 6;12:222. doi: 10.1186/1471-2407-12-222.","Chen C","BMC Cancer","2012","2012/06/08","PMC3507696","","10.1186/1471-2407-12-222"
"10482482","Dietary fat and prostate cancer survival","Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L.","Cancer Causes Control. 1999 Aug;10(4):245-51. doi: 10.1023/a:1008913307947.","Meyer F","Cancer Causes Control","1999","1999/09/11","","","10.1023/a:1008913307947"
"27387852","Early salvage radiation therapy post-prostatectomy: key considerations","Morlacco A, Karnes RJ.","Future Oncol. 2016 Nov;12(22):2579-2587. doi: 10.2217/fon-2016-0208. Epub 2016 Jul 8.","Morlacco A","Future Oncol","2016","2016/07/09","","","10.2217/fon-2016-0208"
"18436466","[Optimization of MVCT imaging schedule in prostate cancer treatment using helical tomotherapy]","Beldjoudi G, Yartsev S, Battista JJ, Van Dyk J.","Cancer Radiother. 2008 Sep;12(5):316-22. doi: 10.1016/j.canrad.2008.03.002. Epub 2008 Apr 23.","Beldjoudi G","Cancer Radiother","2008","2008/04/26","","","10.1016/j.canrad.2008.03.002"
"21162790","[Relationship of body mass index with cancer detection in prostate biopsy]","Chen HX, Wang X, Zhang G, Fang ZL, Ding ZS, Liu NB.","Zhonghua Yi Xue Za Zhi. 2010 Nov 2;90(40):2820-2.","Chen HX","Zhonghua Yi Xue Za Zhi","2010","2010/12/18","","",""
"31088725","((68)Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy","De Bari B, Mazzola R, Aiello D, Aloi D, Gatta R, Corradini S, Salgarello M, Alongi F.","Cancer Radiother. 2019 Jun;23(3):194-200. doi: 10.1016/j.canrad.2018.09.003. Epub 2019 May 12.","De Bari B","Cancer Radiother","2019","2019/05/16","","","10.1016/j.canrad.2018.09.003"
"12198634","Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer","Eisenberger MA.","Semin Urol Oncol. 2002 Aug;20(3 Suppl 1):19-23. doi: 10.1053/suro.2002.35049.","Eisenberger MA","Semin Urol Oncol","2002","2002/08/29","","","10.1053/suro.2002.35049"
"18494749","Methodological considerations in cost of prostate cancer studies: a systematic review","Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulié M, Daurès JP, Grosclaude P.","Value Health. 2008 Sep-Oct;11(5):878-85. doi: 10.1111/j.1524-4733.2008.00327.x. Epub 2008 May 20.","Molinier L","Value Health","2008","2008/05/23","","","10.1111/j.1524-4733.2008.00327.x"
"16619264","Androgen receptor action in hormone-dependent and recurrent prostate cancer","Agoulnik IU, Weigel NL.","J Cell Biochem. 2006 Oct 1;99(2):362-72. doi: 10.1002/jcb.20811.","Agoulnik IU","J Cell Biochem","2006","2006/04/19","","","10.1002/jcb.20811"
"21070575","Prostate cancer immunology - an update for Urologists","Rajarubendra N, Lawrentschuk N, Bolton DM, Klotz L, Davis ID.","BJU Int. 2011 Apr;107(7):1046-51. doi: 10.1111/j.1464-410X.2010.09820.x. Epub 2010 Nov 10.","Rajarubendra N","BJU Int","2011","2010/11/13","","","10.1111/j.1464-410X.2010.09820.x"
"11992846","Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation","Martínez-Jabaloyas JM, Ruiz-Cerdá JL, Hernández M, Jiménez A, Jiménez-Cruz F.","Urology. 2002 May;59(5):715-20. doi: 10.1016/s0090-4295(02)01530-3.","Martínez-Jabaloyas JM","Urology","2002","2002/05/07","","","10.1016/s0090-4295(02)01530-3"
"1538481","Nuclear deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy","Song J, Cheng WS, Cupps RE, Earle JD, Farrow GM, Lieber MM.","J Urol. 1992 Mar;147(3 Pt 2):794-7. doi: 10.1016/s0022-5347(17)37388-3.","Song J","J Urol","1992","1992/03/01","","","10.1016/s0022-5347(17)37388-3"
"15540880","Uncovering myths and transforming realities among low-SES African-American men: implications for reducing prostate cancer disparities","Richardson JT, Webster JD, Fields NJ.","J Natl Med Assoc. 2004 Oct;96(10):1295-302.","Richardson JT","J Natl Med Assoc","2004","2004/11/16","PMC2568560","",""
"19158486","Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells","Chen M, Tanner M, Levine AC, Levina E, Ohouo P, Buttyan R.","Cell Cycle. 2009 Jan 1;8(1):149-57. doi: 10.4161/cc.8.1.7532.","Chen M","Cell Cycle","2009","2009/01/23","PMC2633936","NIHMS88554","10.4161/cc.8.1.7532"
"21150565","Toxicity associated with postoperative radiation therapy for prostate cancer","Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA.","Am J Clin Oncol. 2011 Dec;34(6):611-8. doi: 10.1097/COC.0b013e3181f946dc.","Iyengar P","Am J Clin Oncol","2011","2010/12/15","","","10.1097/COC.0b013e3181f946dc"
"23932338","Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up","Studer UE, Whelan P, Wimpissinger F, Casselman J, de Reijke TM, Knönagel H, Loidl W, Isorna S, Sundaram SK, Collette L; EORTC Genitourinary Cancer Group.","Eur Urol. 2014 Nov;66(5):829-38. doi: 10.1016/j.eururo.2013.07.024. Epub 2013 Jul 24.","Studer UE","Eur Urol","2014","2013/08/13","","","10.1016/j.eururo.2013.07.024"
"3317009","The management of clinically localized prostate cancer","","Natl Inst Health Consens Dev Conf Consens Statement. 1987 Jun 15-17;6(10):1-6.","","Natl Inst Health Consens Dev Conf Consens Statement","1987","1987/06/15","","",""
"15008719","The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer","Kumar V, Toussi H, Marr C, Hough C, Javle P.","BJU Int. 2004 Mar;93(4):507-9. doi: 10.1111/j.1464-410x.2003.04658.x.","Kumar V","BJU Int","2004","2004/03/11","","","10.1111/j.1464-410x.2003.04658.x"
"15992460","Treating the biochemical recurrence of prostate cancer after definitive primary therapy","Ward JF, Moul JW.","Clin Prostate Cancer. 2005 Jun;4(1):38-44. doi: 10.3816/cgc.2005.n.010.","Ward JF","Clin Prostate Cancer","2005","2005/07/05","","","10.3816/cgc.2005.n.010"
"21210472","Inaccuracies in assignment of clinical stage for localized prostate cancer","Reese AC, Sadetsky N, Carroll PR, Cooperberg MR.","Cancer. 2011 Jan 15;117(2):283-9. doi: 10.1002/cncr.25596. Epub 2010 Nov 22.","Reese AC","Cancer","2011","2011/01/07","","","10.1002/cncr.25596"
"21099103","The RB tumor suppressor: a gatekeeper to hormone independence in prostate cancer?","Macleod KF.","J Clin Invest. 2010 Dec;120(12):4179-82. doi: 10.1172/JCI45406. Epub 2010 Nov 22.","Macleod KF","J Clin Invest","2010","2010/11/25","PMC2993607","","10.1172/JCI45406"
"6689681","Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer","Geller J, de la Vega DJ, Albert JD, Nachtsheim DA.","J Clin Endocrinol Metab. 1984 Jan;58(1):36-40. doi: 10.1210/jcem-58-1-36.","Geller J","J Clin Endocrinol Metab","1984","1984/01/01","","","10.1210/jcem-58-1-36"
"20477543","Focal therapy in prostate cancer-report from a consensus panel","de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, Heidenreich A, Kovacs G, Mason M, Montironi R, Mouraviev V, de Reijke T, Taneja S, Thuroff S, Tombal B, Trachtenberg J, Wijkstra H, Polascik T.","J Endourol. 2010 May;24(5):775-80. doi: 10.1089/end.2009.0596.","de la Rosette J","J Endourol","2010","2010/05/19","","","10.1089/end.2009.0596"
"20861084","Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia","Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM.","Glycobiology. 2011 Feb;21(2):195-205. doi: 10.1093/glycob/cwq147. Epub 2010 Sep 22.","Saldova R","Glycobiology","2011","2010/09/24","","","10.1093/glycob/cwq147"
"30984182","The Tumor Immune Contexture of Prostate Cancer","Vitkin N, Nersesian S, Siemens DR, Koti M.","Front Immunol. 2019 Mar 28;10:603. doi: 10.3389/fimmu.2019.00603. eCollection 2019.","Vitkin N","Front Immunol","2019","2019/04/16","PMC6447686","","10.3389/fimmu.2019.00603"
"23586435","Prostate-specific antigen screening for prostate cancer: why so much controversy?","Labrie F.","Int J Urol. 2013 Nov;20(11):1148. doi: 10.1111/iju.12162. Epub 2013 Apr 15.","Labrie F","Int J Urol","2013","2013/04/17","","","10.1111/iju.12162"
"12642196","Informational needs of men with prostate cancer on hormonal manipulation therapy","Templeton H, Coates V.","Patient Educ Couns. 2003 Mar;49(3):243-56. doi: 10.1016/s0738-3991(02)00181-7.","Templeton H","Patient Educ Couns","2003","2003/03/19","","","10.1016/s0738-3991(02)00181-7"
"10910146","Role of brachytherapy in patients with stage T1c, T2a adenocarcinoma of the prostate","Chan AJ, Saltzman B.","J Endourol. 2000 May;14(4):319-24. doi: 10.1089/end.2000.14.319.","Chan AJ","J Endourol","2000","2000/07/26","","","10.1089/end.2000.14.319"
"30860943","Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial","Jayadevappa R, Chhatre S, Gallo JJ, Wittink M, Morales KH, Lee DI, Guzzo TJ, Vapiwala N, Wong YN, Newman DK, Van Arsdalen K, Malkowicz SB, Schwartz JS, Wein AJ.","J Clin Oncol. 2019 Apr 20;37(12):964-973. doi: 10.1200/JCO.18.01091. Epub 2019 Mar 12.","Jayadevappa R","J Clin Oncol","2019","2019/03/13","","","10.1200/JCO.18.01091"
"8338522","Prostate cancer: to screen or not to screen?","Schröder FH.","BMJ. 1993 Feb 13;306(6875):407-8. doi: 10.1136/bmj.306.6875.407.","Schröder FH","BMJ","1993","1993/02/13","PMC1676503","","10.1136/bmj.306.6875.407"
"1485798","[Epidemiology of prostate cancer]","Grosclaude P, Roumagnac M.","Ann Urol (Paris). 1992;26(5):294-300.","Grosclaude P","Ann Urol (Paris)","1992","1992/01/01","","",""
"11371886","Analysis of apical soft tissue margins during radical retropubic prostatectomy","Shah O, Melamed J, Lepor H.","J Urol. 2001 Jun;165(6 Pt 1):1943-8; discussion 1948-9. doi: 10.1097/00005392-200106000-00023.","Shah O","J Urol","2001","2001/05/24","","","10.1097/00005392-200106000-00023"
"29211393","The impact of metformin use on the risk of prostate cancer after prostate biopsy in patients with high grade intraepithelial neoplasia","Dell'Atti L, Galosi AB.","Int Braz J Urol. 2018 Jan-Feb;44(1):69-74. doi: 10.1590/S1677-5538.IBJU.2017.0046.","Dell'Atti L","Int Braz J Urol","2018","2017/12/07","PMC5815534","","10.1590/S1677-5538.IBJU.2017.0046"
"2731300","[Radiotherapy of carcinoma of the prostate--5 years' experience]","Strnad V, Tacev T, Malír A, Konecný M, Rasovská O.","Cesk Radiol. 1989 Mar;43(2):114-9.","Strnad V","Cesk Radiol","1989","1989/03/01","","",""
"26235660","Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer","Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL.","BJU Int. 2016 Aug;118(2):279-85. doi: 10.1111/bju.13248. Epub 2015 Aug 31.","Muralidhar V","BJU Int","2016","2015/08/04","","","10.1111/bju.13248"
"17280507","State-of-the-art radiotherapy in the management of clinically localized prostate carcinoma","Bermudez RS, Izaguirre A, Roach M 3rd.","Future Oncol. 2007 Feb;3(1):103-11. doi: 10.2217/14796694.3.1.103.","Bermudez RS","Future Oncol","2007","2007/02/07","","","10.2217/14796694.3.1.103"
"21504942","Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target","Shiota M, Yokomizo A, Naito S.","J Mol Endocrinol. 2011 Jul 12;47(1):R25-41. doi: 10.1530/JME-11-0018. Print 2011 Aug.","Shiota M","J Mol Endocrinol","2011","2011/04/21","","","10.1530/JME-11-0018"
"28939336","[Evaluation and results of ablative therapies in prostate cancer]","Renard-Penna R, Sanchez-Salas R, Barret E, Cosset JM, de Vergie S, Sapetti J, Ingels A, Gangi A, Lang H, Cathelineau X.","Prog Urol. 2017 Nov;27(15):887-908. doi: 10.1016/j.purol.2017.08.003. Epub 2017 Sep 20.","Renard-Penna R","Prog Urol","2017","2017/09/24","","","10.1016/j.purol.2017.08.003"
"8942171","Screening for prostate cancer: the role of prostate-specific antigen","Ferrer RL.","Md Med J. 1996 Nov;45(11):938-40.","Ferrer RL","Md Med J","1996","1996/11/01","","",""
"8948421","New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy","Nelson WG, Simons JW.","Urol Clin North Am. 1996 Nov;23(4):685-96. doi: 10.1016/s0094-0143(05)70346-3.","Nelson WG","Urol Clin North Am","1996","1996/11/01","","","10.1016/s0094-0143(05)70346-3"
"29107268","Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators","Loeb S, Dani H.","Urol Clin North Am. 2017 Nov;44(4):517-524. doi: 10.1016/j.ucl.2017.07.001.","Loeb S","Urol Clin North Am","2017","2017/11/07","PMC6004126","NIHMS892486","10.1016/j.ucl.2017.07.001"
"22772432","Salvage of locally recurrent prostate cancer after definitive radiotherapy","Mendenhall WM, Henderson RH, Hoppe BS, Nichols RC, Mendenhall NP.","Am J Clin Oncol. 2014 Aug;37(4):411-6. doi: 10.1097/COC.0b013e31824be3b4.","Mendenhall WM","Am J Clin Oncol","2014","2012/07/10","","","10.1097/COC.0b013e31824be3b4"
"9741419","The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer","Manyak MJ, Javitt MC.","Semin Urol Oncol. 1998 Aug;16(3):145-52.","Manyak MJ","Semin Urol Oncol","1998","1998/09/19","","",""
"23956452","Researchers link early hair loss and prostate cancer","Fillon M.","J Natl Cancer Inst. 2013 Sep 4;105(17):1258-9. doi: 10.1093/jnci/djt246. Epub 2013 Aug 16.","Fillon M","J Natl Cancer Inst","2013","2013/08/20","","","10.1093/jnci/djt246"
"24286079","Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment","Gravina GL, Festuccia C, Bonfili P, Di Staso M, Franzese P, Ruggieri V, Popov VM, Tombolini V, Masciocchi C, Carosa E, Lenzi A, Jannini EA, Di Cesare E.","Biomed Res Int. 2013;2013:460546. doi: 10.1155/2013/460546. Epub 2013 Oct 29.","Gravina GL","Biomed Res Int","2013","2013/11/29","PMC3830798","","10.1155/2013/460546"
"23608676","Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer","Kuru TH, Roethke MC, Seidenader J, Simpfendörfer T, Boxler S, Alammar K, Rieker P, Popeneciu VI, Roth W, Pahernik S, Schlemmer HP, Hohenfellner M, Hadaschik BA.","J Urol. 2013 Oct;190(4):1380-6. doi: 10.1016/j.juro.2013.04.043. Epub 2013 Apr 19.","Kuru TH","J Urol","2013","2013/04/24","","","10.1016/j.juro.2013.04.043"
"11502043","Attitudes of patients with breast and prostate cancer toward complementary therapies in Finland","Salmenperä L, Suominen T, Lauri S, Puukka P.","Cancer Nurs. 2001 Aug;24(4):328-34. doi: 10.1097/00002820-200108000-00015.","Salmenperä L","Cancer Nurs","2001","2001/08/15","","","10.1097/00002820-200108000-00015"
"19758611","Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black americans","Moses KA, Abd TT, Goodman M, Hsiao W, Hall JA, Marshall FF, Petros JA, Issa MM.","J Urol. 2009 Nov;182(5):2219-25. doi: 10.1016/j.juro.2009.07.039. Epub 2009 Sep 16.","Moses KA","J Urol","2009","2009/09/18","","","10.1016/j.juro.2009.07.039"
"23381039","Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms","Gulati R, Gore JL, Etzioni R.","Ann Intern Med. 2013 Feb 5;158(3):145-53. doi: 10.7326/0003-4819-158-3-201302050-00003.","Gulati R","Ann Intern Med","2013","2013/02/06","PMC3738063","NIHMS471819","10.7326/0003-4819-158-3-201302050-00003"
"27159369","Perioperative Blood Transfusion as a Significant Predictor of Biochemical Recurrence and Survival after Radical Prostatectomy in Patients with Prostate Cancer","Kim JK, Kim HS, Park J, Jeong CW, Ku JH, Kim HH, Kwak C.","PLoS One. 2016 May 9;11(5):e0154918. doi: 10.1371/journal.pone.0154918. eCollection 2016.","Kim JK","PLoS One","2016","2016/05/10","PMC4861293","","10.1371/journal.pone.0154918"
"18342926","Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan","Takechi H, Ito K, Yamamoto T, Miyakubo M, Ohi M, Suzuki K.","Urology. 2008 Nov;72(5):1111-5. doi: 10.1016/j.urology.2007.12.090. Epub 2008 Mar 17.","Takechi H","Urology","2008","2008/03/18","","","10.1016/j.urology.2007.12.090"
"26665764","[COMPARATIVE ANALYSIS OF POSITIVE SURGICAL MARGIN RATES IN PATIENTS UNDERGOING ROBOT- ASSISTED OR RETROPUBIC RADICAL PROSTATECTOMY FOR PROSTATE CANCER]","Veliev EL, Sokolov EA, Loran OB.","Urologiia. 2015 Jul-Aug;(4):44-7.","Veliev EL","Urologiia","2015","2015/12/16","","",""
"17639669","[The role of radiotherapy in the management of prostate cancer]","Bernier J.","Rev Med Suisse. 2007 Jun 6;3(114):1472-4.","Bernier J","Rev Med Suisse","2007","2007/07/21","","",""
"4007496","Dilemmas in managing prostate carcinoma. (Part I): Localized disease","Ahmann FR.","Geriatrics. 1985 Jul;40(7):34-9, 42.","Ahmann FR","Geriatrics","1985","1985/07/01","","",""
"31832747","[Precision of prostate magnetic resonance imaging for the detection of clinically significant prostate cancer]","Krafft U, Borkowetz A.","Urologe A. 2020 Jan;59(1):72-77. doi: 10.1007/s00120-019-01091-x.","Krafft U","Urologe A","2020","2019/12/14","","","10.1007/s00120-019-01091-x"
"18407328","Incidental prostate cancer detected by cystoprostatectomy in Korean men","Joung JY, Yang SO, Seo HK, Kim TS, Han KS, Chung J, Park WS, Jeong IG, Lee KH.","Urology. 2009 Jan;73(1):153-7. doi: 10.1016/j.urology.2008.02.040. Epub 2008 Apr 14.","Joung JY","Urology","2009","2008/04/15","","","10.1016/j.urology.2008.02.040"
"26733552","Prostate Cancer, Version 1.2016","Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA.","J Natl Compr Canc Netw. 2016 Jan;14(1):19-30. doi: 10.6004/jnccn.2016.0004.","Mohler JL","J Natl Compr Canc Netw","2016","2016/01/07","","","10.6004/jnccn.2016.0004"
"24069383","A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer","Fradet A, Sorel H, Depalle B, Serre CM, Farlay D, Turtoi A, Bellahcene A, Follet H, Castronovo V, Clézardin P, Bonnelye E.","PLoS One. 2013 Sep 19;8(9):e75092. doi: 10.1371/journal.pone.0075092. eCollection 2013.","Fradet A","PLoS One","2013","2013/09/27","PMC3777927","","10.1371/journal.pone.0075092"
"24325505","Gold standard support","Trueland J.","Nurs Stand. 2013 Dec 11-17;28(15):22-3. doi: 10.7748/ns2013.12.28.15.22.s28.","Trueland J","Nurs Stand","2013","2013/12/12","","","10.7748/ns2013.12.28.15.22.s28"
"21489075","Does prostate cancer aggressiveness change with increasing age?","Froehner M, Rosenberg MT.","Int J Clin Pract. 2011 May;65(5):521-3. doi: 10.1111/j.1742-1241.2011.02661.x.","Froehner M","Int J Clin Pract","2011","2011/04/15","","","10.1111/j.1742-1241.2011.02661.x"
"17726432","Detection of occult lymph node metastases in locally advanced node-negative prostate cancer","Dhar NB, Studer UE.","Nat Clin Pract Urol. 2007 Oct;4(10):520-1. doi: 10.1038/ncpuro0907. Epub 2007 Aug 28.","Dhar NB","Nat Clin Pract Urol","2007","2007/08/30","","","10.1038/ncpuro0907"
"12083780","Immunohistological detection of BRAF25 in human prostate tumor and cancer specimens","Wang C, McCarty IM, Balazs L, Li Y, Steiner MS.","Biochem Biophys Res Commun. 2002 Jul 5;295(1):136-41. doi: 10.1016/s0006-291x(02)00625-3.","Wang C","Biochem Biophys Res Commun","2002","2002/06/27","","","10.1016/s0006-291x(02)00625-3"
"10640455","Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer","Mark HF, Samy M, Santoro K, Mark S, Feldman D.","Exp Mol Pathol. 2000 Feb;68(1):65-9. doi: 10.1006/exmp.1999.2282.","Mark HF","Exp Mol Pathol","2000","2000/01/21","","","10.1006/exmp.1999.2282"
"9158539","Report prepared for the Health Technology Assessment panel of the NHS Executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales","Chamberlain J, Melia J, Moss S, Brown J.","Br J Urol. 1997 May;79 Suppl 3:1-32. doi: 10.1111/j.1464-410x.1997.tb16914.x.","Chamberlain J","Br J Urol","1997","1997/05/01","","","10.1111/j.1464-410x.1997.tb16914.x"
"15603294","Dose fractionation and biological optimization in carcinoma of the prostate","Perez CA.","Rays. 2004 Jul-Sep;29(3):237-52.","Perez CA","Rays","2004","2004/12/18","","",""
"17945800","Ultrasound image registration for patient setup in conformal radiotherapy of prostate cancer","Betrouni N, Pasquier D, Dewalle AS, Jounwaz R, Dubois P, Lopes R, Lartigau E.","Conf Proc IEEE Eng Med Biol Soc. 2006;2006:3795-8. doi: 10.1109/IEMBS.2006.260455.","Betrouni N","Conf Proc IEEE Eng Med Biol Soc","2006","2007/10/20","","","10.1109/IEMBS.2006.260455"
"22593016","Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status","Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L; Australian Prostate Cancer Bioresource, Collins AT, Maitland NJ, Risbridger GP.","Stem Cells. 2012 Jun;30(6):1087-96. doi: 10.1002/stem.1094.","Taylor RA","Stem Cells","2012","2012/05/18","","","10.1002/stem.1094"
"10509092","Prostate cancer screening tests now corrected","","Pa Med. 1999 Sep;102(9):10-2.","","Pa Med","1999","1999/10/06","","",""
"20435550","Organochlorines and prostate cancer in Japan: no link in men without occupational exposures","Freeman KS.","Environ Health Perspect. 2010 May;118(5):A216. doi: 10.1289/ehp.118-2866708.","Freeman KS","Environ Health Perspect","2010","2010/05/04","PMC2866708","","10.1289/ehp.118-2866708"
"15245969","Prostate cancer cells: detection and isolation from peripheral blood and bone marrow","Horan AH.","Urology. 2004 Jul;64(1):187. doi: 10.1016/j.urology.2003.03.001.","Horan AH","Urology","2004","2004/07/13","","","10.1016/j.urology.2003.03.001"
"10671684","Antiproliferative action of melatonin on human prostate cancer LNCaP cells","Moretti RM, Marelli MM, Maggi R, Dondi D, Motta M, Limonta P.","Oncol Rep. 2000 Mar-Apr;7(2):347-51.","Moretti RM","Oncol Rep","2000","2000/02/15","","",""
"20158074","[Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup (""human dock"") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer]","Oeda T, Kusumi N, Takamoto A.","Nihon Hinyokika Gakkai Zasshi. 2010 Jan;101(1):18-24. doi: 10.5980/jpnjurol.101.18.","Oeda T","Nihon Hinyokika Gakkai Zasshi","2010","2010/02/18","","","10.5980/jpnjurol.101.18"
"12012301","The dilemma of patients with a rising PSA level after definitive local therapy for prostate cancer","Lassiter LK, Eisenberger MA.","Semin Urol Oncol. 2002 May;20(2):146-54. doi: 10.1053/suro.2002.32834.","Lassiter LK","Semin Urol Oncol","2002","2002/05/16","","","10.1053/suro.2002.32834"
"18817957","CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective","Oh KS, Sandler HM.","Urology. 2008 Nov;72(5):971-3. doi: 10.1016/j.urology.2008.07.016. Epub 2008 Sep 25.","Oh KS","Urology","2008","2008/09/27","","","10.1016/j.urology.2008.07.016"
"31563295","Smoking history, intensity, and duration and risk of prostate cancer recurrence among men with prostate cancer who received definitive treatment","Khan S, Thakkar S, Drake B.","Ann Epidemiol. 2019 Oct;38:4-10. doi: 10.1016/j.annepidem.2019.08.011. Epub 2019 Sep 6.","Khan S","Ann Epidemiol","2019","2019/09/30","PMC6914316","NIHMS1543666","10.1016/j.annepidem.2019.08.011"
"29447924","New prostate cancer grade grouping system predicts survival after radical prostatectomy","Erickson A, Sandeman K, Lahdensuo K, Nordling S, Kallajoki M, Seikkula H, Bützow A, Vasarainen H, Boström PJ, Taimen P, Rannikko A, Mirtti T.","Hum Pathol. 2018 May;75:159-166. doi: 10.1016/j.humpath.2018.01.027. Epub 2018 Feb 13.","Erickson A","Hum Pathol","2018","2018/02/16","","","10.1016/j.humpath.2018.01.027"
"28211799","Increased expression of long non-coding RNA GLIDR in prostate cancer","Zhang Y, Kong Z, Zhang Y, Huang W, Wu H, Wan X, Li Y.","Cancer Biomark. 2017;19(2):145-150. doi: 10.3233/CBM-160166.","Zhang Y","Cancer Biomark","2017","2017/02/18","","","10.3233/CBM-160166"
"29948044","Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy","Dell'Oglio P, Stabile A, Dias BH, Gandaglia G, Mazzone E, Fossati N, Cucchiara V, Zaffuto E, Mirone V, Suardi N, Mottrie A, Montorsi F, Briganti A.","World J Urol. 2019 Feb;37(2):221-234. doi: 10.1007/s00345-018-2360-1. Epub 2018 Jun 9.","Dell'Oglio P","World J Urol","2019","2018/06/28","","","10.1007/s00345-018-2360-1"
"15708246","Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis","Jani AB, Kao J, Heimann R, Hellman S.","Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):687-94. doi: 10.1016/j.ijrobp.2004.09.066.","Jani AB","Int J Radiat Oncol Biol Phys","2005","2005/02/15","","","10.1016/j.ijrobp.2004.09.066"
"22682955","Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer","Killick E, Bancroft E, Kote-Jarai Z, Eeles R.","Clin Oncol (R Coll Radiol). 2012 Oct;24(8):545-55. doi: 10.1016/j.clon.2012.05.001. Epub 2012 Jun 7.","Killick E","Clin Oncol (R Coll Radiol)","2012","2012/06/12","","","10.1016/j.clon.2012.05.001"
"20224731","Sarcomatoid carcinoma of the prostate: a case report","Zizi-Sermpetzoglou A, Savvaidou V, Tepelenis N, Galariotis N, Olympitis M, Stamatiou K.","Int J Clin Exp Pathol. 2010 Feb 5;3(3):319-22.","Zizi-Sermpetzoglou A","Int J Clin Exp Pathol","2010","2010/03/13","PMC2836510","",""
"7683479","Modalities available for screening for prostate cancer","Bentvelsen FM, Schröder FH.","Eur J Cancer. 1993;29A(6):804-11. doi: 10.1016/s0959-8049(05)80413-7.","Bentvelsen FM","Eur J Cancer","1993","1993/01/01","","","10.1016/s0959-8049(05)80413-7"
"7563511","Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening","Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB.","JAMA. 1995 Oct 18;274(15):1214-20.","Catalona WJ","JAMA","1995","1995/10/18","","",""
"22641164","Cancer immunotherapy: a paradigm shift for prostate cancer treatment","Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JB.","Nat Rev Urol. 2012 May 29;9(7):376-85. doi: 10.1038/nrurol.2012.106.","Karan D","Nat Rev Urol","2012","2012/05/30","","","10.1038/nrurol.2012.106"
"1987620","Nonpalpable prostate cancer: detection with MR imaging","Carter HB, Brem RF, Tempany CM, Yang A, Epstein JI, Walsh PC, Zerhouni EA.","Radiology. 1991 Feb;178(2):523-5. doi: 10.1148/radiology.178.2.1987620.","Carter HB","Radiology","1991","1991/02/01","","","10.1148/radiology.178.2.1987620"
"25443144","Commentary on ""the burden of depression in prostate cancer."" Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA.: Psychooncology 2012;21(12):1338-45. [Epub 2011 Aug 12]. doi: 10.1002/pon.2032","Hollenbeck BK.","Urol Oncol. 2014 Oct;32(7):1089-90. doi: 10.1016/j.urolonc.2014.03.002. Epub 2014 Oct 29.","Hollenbeck BK","Urol Oncol","2014","2014/12/03","","","10.1016/j.urolonc.2014.03.002"
"29334523","Not a Straight Line-Patients' Experiences of Prostate Cancer and Their Journey Through the Healthcare System","Schildmeijer K, Frykholm O, Kneck Å, Ekstedt M.","Cancer Nurs. 2019 Jan/Feb;42(1):E36-E43. doi: 10.1097/NCC.0000000000000559.","Schildmeijer K","Cancer Nurs","2019","2018/01/16","","","10.1097/NCC.0000000000000559"
"12215973","Magnetic resonance imaging of prostate cancer","Adusumilli S, Pretorius ES.","Semin Urol Oncol. 2002 Aug;20(3):192-210. doi: 10.1053/suro.2002.35333.","Adusumilli S","Semin Urol Oncol","2002","2002/09/07","","","10.1053/suro.2002.35333"
"25578541","Electrochemical red-ox therapy of prostate cancer in nude mice","Cury FL, Bhindi B, Rocha J, Scarlata E, El Jurdi K, Ladouceur M, Beauregard S, Vijh AK, Taguchi Y, Chevalier S.","Bioelectrochemistry. 2015 Aug;104:1-9. doi: 10.1016/j.bioelechem.2014.12.004. Epub 2014 Dec 19.","Cury FL","Bioelectrochemistry","2015","2015/01/13","","","10.1016/j.bioelechem.2014.12.004"
"24490329","[Clinical guidelines for diagnosing, treatment and monitoring patients with prostate cancer--Croatian Oncology Society and Croatian Urology Society, Croatian Medical Association]","Solarić M, Grgić M, Omrcen T, Petković M, Fröbe A, Belaj N, Zorica R, Kruslin B, Dordević G, Kastelan Z, Ruzić B, Gilja I, Krolo I, Vilović K, Librenjak D, Vrdoljak E, Situm M, Padovan RS, Vojnović Z; Croatian Medical Association.","Lijec Vjesn. 2013 Nov-Dec;135(11-12):298-305.","Solarić M","Lijec Vjesn","2013","2014/02/05","","",""
"19076150","Re: Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial","Schröder FH, Roobol MJ.","BJU Int. 2009 Jan;103(2):143-4. doi: 10.1111/j.1464-410X.2008.08257.x. Epub 2008 Dec 5.","Schröder FH","BJU Int","2009","2008/12/17","","","10.1111/j.1464-410X.2008.08257.x"
"26975487","Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients","Wang Y, Dai B, Ye DW.","Asian J Androl. 2017 Mar-Apr;19(2):178-183. doi: 10.4103/1008-682X.174856.","Wang Y","Asian J Androl","2017","2016/03/16","PMC5312215","","10.4103/1008-682X.174856"
"10473115","Osteopontin: possible role in prostate cancer progression","Thalmann GN, Sikes RA, Devoll RE, Kiefer JA, Markwalder R, Klima I, Farach-Carson CM, Studer UE, Chung LW.","Clin Cancer Res. 1999 Aug;5(8):2271-7.","Thalmann GN","Clin Cancer Res","1999","1999/09/03","","",""
"10482183","The role of the androgen receptor in the development and progression of prostate cancer","Jenster G.","Semin Oncol. 1999 Aug;26(4):407-21.","Jenster G","Semin Oncol","1999","1999/09/11","","",""
"22239226","Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S.","BJU Int. 2012 Feb;109 Suppl 1:22-9. doi: 10.1111/j.1464-410X.2011.10827.x.","Grimm P","BJU Int","2012","2012/01/14","","","10.1111/j.1464-410X.2011.10827.x"
"11005444","Cryosurgery: is it an effective option for patients failing radiation?","da la Taille A, Katz AE.","Curr Opin Urol. 2000 Sep;10(5):409-13. doi: 10.1097/00042307-200009000-00008.","da la Taille A","Curr Opin Urol","2000","2000/09/27","","","10.1097/00042307-200009000-00008"
"7010754","Incidence and etiology of prostate cancer","Hutchison GB.","Urology. 1981 Mar;17(Suppl 3):4-10.","Hutchison GB","Urology","1981","1981/03/01","","",""
"16555547","Resveratrol and propolis extract: an insight into the morphological and molecular changes induced in DU145 cells","Scifo C, Milasi A, Guarnera A, Sinatra F, Renis M.","Oncol Res. 2006;15(9):409-21. doi: 10.3727/096504005776568255.","Scifo C","Oncol Res","2006","2006/03/25","","","10.3727/096504005776568255"
"11547064","SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial","Klein EA, Thompson IM, Lippman SM, Goodman PJ, Albanes D, Taylor PR, Coltman C.","J Urol. 2001 Oct;166(4):1311-5. doi: 10.1016/s0022-5347(05)65759-x.","Klein EA","J Urol","2001","2001/09/08","","","10.1016/s0022-5347(05)65759-x"
"25227898","A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","Kole TP, Nichols RC, Lei S, Wu B, Huh SN, Morris CG, Lee S, Tong M, Mendenhall NP, Dritschilo A, Collins SP.","Acta Oncol. 2015 Jun;54(6):825-31. doi: 10.3109/0284186X.2014.953260. Epub 2014 Sep 17.","Kole TP","Acta Oncol","2015","2014/09/18","","","10.3109/0284186X.2014.953260"
"25557753","The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era","Jahn JL, Giovannucci EL, Stampfer MJ.","Int J Cancer. 2015 Dec 15;137(12):2795-802. doi: 10.1002/ijc.29408. Epub 2015 Jan 8.","Jahn JL","Int J Cancer","2015","2015/01/06","PMC4485977","NIHMS651857","10.1002/ijc.29408"
"3393557","Routine screening for prostate cancer using the digital rectal examination","Chodak GW, Keller P, Schoenberg H.","Prog Clin Biol Res. 1988;269:87-98.","Chodak GW","Prog Clin Biol Res","1988","1988/01/01","","",""
"25592466","Prostate cancer: The main risk and protective factors-Epigenetic modifications","Adjakly M, Ngollo M, Dagdemir A, Judes G, Pajon A, Karsli-Ceppioglu S, Penault-Llorca F, Boiteux JP, Bignon YJ, Guy L, Bernard-Gallon D.","Ann Endocrinol (Paris). 2015 Feb;76(1):25-41. doi: 10.1016/j.ando.2014.09.001. Epub 2015 Jan 13.","Adjakly M","Ann Endocrinol (Paris)","2015","2015/01/17","","","10.1016/j.ando.2014.09.001"
"20145177","A new therapy paradigm for prostate cancer founded on clinical observations","Efstathiou E, Logothetis CJ.","Clin Cancer Res. 2010 Feb 15;16(4):1100-7. doi: 10.1158/1078-0432.CCR-09-1215. Epub 2010 Feb 9.","Efstathiou E","Clin Cancer Res","2010","2010/02/11","PMC3891669","NIHMS541678","10.1158/1078-0432.CCR-09-1215"
"20179220","Is high-grade prostate cancer easier to find in smaller prostates because there is more high-grade disease to find?--letter","Walsh P.","Clin Cancer Res. 2010 Mar 1;16(5):1690; author reply 1690. doi: 10.1158/1078-0432.CCR-09-2346. Epub 2010 Feb 23.","Walsh P","Clin Cancer Res","2010","2010/02/25","","","10.1158/1078-0432.CCR-09-2346"
"31626312","Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults","Kumar A, Nalawade V, Riviere P, Sarkar RR, Parsons JK, Murphy JD, Rose BS.","JAMA Netw Open. 2019 Oct 2;2(10):e1913612. doi: 10.1001/jamanetworkopen.2019.13612.","Kumar A","JAMA Netw Open","2019","2019/10/19","PMC6813580","","10.1001/jamanetworkopen.2019.13612"
"27502465","Survival predictors in patients with prostate adenocarcinoma with hormonal blockade","Angulo JC, Redondo C, Sánchez-Chapado M, Colás B, Ropero S, López JI.","Pathol Res Pract. 2016 Oct;212(10):899-903. doi: 10.1016/j.prp.2016.07.012. Epub 2016 Jul 27.","Angulo JC","Pathol Res Pract","2016","2016/08/10","","","10.1016/j.prp.2016.07.012"
"18782595","Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","Dillard PR, Lin MF, Khan SA.","Mol Cell Endocrinol. 2008 Nov 25;295(1-2):115-20. doi: 10.1016/j.mce.2008.08.013. Epub 2008 Aug 20.","Dillard PR","Mol Cell Endocrinol","2008","2008/09/11","PMC2802176","NIHMS79430","10.1016/j.mce.2008.08.013"
"27296649","Prostate cancer: TRIM24 acts as a transcriptional activator","Stone L.","Nat Rev Urol. 2016 Aug;13(8):437. doi: 10.1038/nrurol.2016.112. Epub 2016 Jun 14.","Stone L","Nat Rev Urol","2016","2016/06/15","","","10.1038/nrurol.2016.112"
"26091673","Progress in Prostate Cancer (at Last!)","Glodé LM.","Oncology (Williston Park). 2015 Jun;29(6):407, 414.","Glodé LM","Oncology (Williston Park)","2015","2015/06/21","","",""
"25023912","Localized prostate cancer: regional variation and national policy","Seidenwurm D, Logsdon M.","Med Care. 2014 Aug;52(8):677-9. doi: 10.1097/MLR.0000000000000192.","Seidenwurm D","Med Care","2014","2014/07/16","","","10.1097/MLR.0000000000000192"
"21035484","Targeting the cancer initiating cell: the Achilles' heel of cancer","McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, Kempf CR, Laidler P, Steelman LS.","Adv Enzyme Regul. 2011;51(1):152-62. doi: 10.1016/j.advenzreg.2010.09.002. Epub 2010 Oct 28.","McCubrey JA","Adv Enzyme Regul","2011","2010/11/02","","","10.1016/j.advenzreg.2010.09.002"
"18458914","The management of high-risk prostate cancer in 2008","Fradet Y.","World J Urol. 2008 Jun;26(3):203. doi: 10.1007/s00345-008-0261-4. Epub 2008 May 6.","Fradet Y","World J Urol","2008","2008/05/07","","","10.1007/s00345-008-0261-4"
"9583942","Prostate-cancer link sours IGF-1","Brower V.","Nat Biotechnol. 1998 Mar;16(3):223. doi: 10.1038/nbt0398-223.","Brower V","Nat Biotechnol","1998","1998/05/16","","","10.1038/nbt0398-223"
"17650746","[Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program]","Fourcade RO, Richaud P, Coloby P, Malavaud B; Groupe des investigateurs français du programme EPC.","Prog Urol. 2007 Jun;17(4 Suppl 1):891-910.","Fourcade RO","Prog Urol","2007","2007/07/27","","",""
"22141277","[Present status of clinical researches on the screening for prostate cancer biomarkers]","He Y, Qin GD, Xiao MZ.","Zhonghua Nan Ke Xue. 2011 Nov;17(11):1029-32.","He Y","Zhonghua Nan Ke Xue","2011","2011/12/07","","",""
"11998658","Prostate cancer patients show 79% cure rate with prostate brachytherapy treatment","","Urol Nurs. 2001 Jun;21(3):225.","","Urol Nurs","2001","2002/05/10","","",""
"26497920","Docetaxel for Castration-sensitive Prostate Cancer: Wrapping up Unfinished Business?","Sonpavde G, Bellmunt J.","Eur Urol. 2016 Apr;69(4):574-575. doi: 10.1016/j.eururo.2015.10.022. Epub 2015 Oct 21.","Sonpavde G","Eur Urol","2016","2015/10/27","","","10.1016/j.eururo.2015.10.022"
"21159811","Assessing the daily consistency of bladder filling using an ultrasonic Bladderscan device in men receiving radical conformal radiotherapy for prostate cancer","Hynds S, McGarry CK, Mitchell DM, Early S, Shum L, Stewart DP, Harney JA, Cardwell CR, O'Sullivan JM.","Br J Radiol. 2011 Sep;84(1005):813-8. doi: 10.1259/bjr/50048151. Epub 2010 Dec 15.","Hynds S","Br J Radiol","2011","2010/12/17","PMC3473792","","10.1259/bjr/50048151"
"20890581","PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer","Tosoian J, Loeb S.","ScientificWorldJournal. 2010 Oct 1;10:1919-31. doi: 10.1100/tsw.2010.182.","Tosoian J","ScientificWorldJournal","2010","2010/10/05","PMC5763794","","10.1100/tsw.2010.182"
"28178275","Phase of care prevalence for prostate cancer in New South Wales, Australia: A population-based modelling study","Yu XQ, Luo Q, Smith DP, Clements MS, Patel MI, O'Connell DL.","PLoS One. 2017 Feb 8;12(2):e0171013. doi: 10.1371/journal.pone.0171013. eCollection 2017.","Yu XQ","PLoS One","2017","2017/02/09","PMC5298320","","10.1371/journal.pone.0171013"
"25799728","[Benign mimics of prostatic adenocarcinoma]","Kovylina MV, Prilepskaia EA, Govorov AV, D'iakov VV, Kolontarev KB, Vasil'ev AO, Sidorenkov AV, Rasner PI, Glotov AV, Pushkar' DIu, Nikitaev VG, Pronichev AN.","Urologiia. 2014 Nov-Dec;(6):51-6.","Kovylina MV","Urologiia","2014","2015/03/25","","",""
"19261377","Is radiotherapy useful in node-positive prostate cancer patients after radical prostatectomy?","Van Poppel H.","Eur Urol. 2009 May;55(5):1012-3. doi: 10.1016/j.eururo.2009.02.015. Epub 2009 Feb 21.","Van Poppel H","Eur Urol","2009","2009/03/06","","","10.1016/j.eururo.2009.02.015"
"14607216","New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene","Schalken JA, Hessels D, Verhaegh G.","Urology. 2003 Nov;62(5 Suppl 1):34-43. doi: 10.1016/s0090-4295(03)00759-3.","Schalken JA","Urology","2003","2003/11/11","","","10.1016/s0090-4295(03)00759-3"
"10593422","A population-based survey of prostate cancer testing in New Mexico","Hoffman RM, Gilliland FD.","J Community Health. 1999 Dec;24(6):409-19. doi: 10.1023/a:1018790421714.","Hoffman RM","J Community Health","1999","1999/12/11","","","10.1023/a:1018790421714"
"7658554","Incidence of benign and malignant prostate tissue in biopsies of the bladder neck after a radical prostatectomy","Wood DP Jr, Peretsman SJ, Seay TM.","J Urol. 1995 Oct;154(4):1443-6.","Wood DP Jr","J Urol","1995","1995/10/01","","",""
"10658255","[Detection of circulating prostatic cells with RT-PCR PSA in prostatic cancer]","de la Taille A, Salomon L, Colombel M, Abbou CC, Chopin D, Groux-Muscatelli B.","Prog Urol. 1999 Dec;9(6):1084-9.","de la Taille A","Prog Urol","1999","2000/02/05","","",""
"21700508","Association of rs6983561 polymorphism at 8q24 with prostate cancer mortality in a Japanese population","Suzuki M, Liu M, Kurosaki T, Suzuki M, Arai T, Sawabe M, Kasuya Y, Kato M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Kume H, Homma Y, Kitamura T.","Clin Genitourin Cancer. 2011 Sep;9(1):46-52. doi: 10.1016/j.clgc.2011.04.004. Epub 2011 Jun 22.","Suzuki M","Clin Genitourin Cancer","2011","2011/06/25","","","10.1016/j.clgc.2011.04.004"
"18302908","Lycopene in the prevention of prostate cancer","Dahan K, Fennal M, Kumar NB.","J Soc Integr Oncol. 2008 Winter;6(1):29-36.","Dahan K","J Soc Integr Oncol","2008","2008/02/28","","",""
"10443731","Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities","Akakura K, Isaka S, Akimoto S, Ito H, Okada K, Hachiya T, Yoshida O, Arai Y, Usami M, Kotake T, Tobisu K, Ohashi Y, Sumiyoshi Y, Kakizoe T, Shimazaki J.","Urology. 1999 Aug;54(2):313-8. doi: 10.1016/s0090-4295(99)00106-5.","Akakura K","Urology","1999","1999/08/12","","","10.1016/s0090-4295(99)00106-5"
"30479377","Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies","van der Toom EE, Axelrod HD, de la Rosette JJ, de Reijke TM, Pienta KJ, Valkenburg KC.","Nat Rev Urol. 2019 Jan;16(1):7-22. doi: 10.1038/s41585-018-0119-5.","van der Toom EE","Nat Rev Urol","2019","2018/11/28","PMC6324967","NIHMS964483","10.1038/s41585-018-0119-5"
"30293836","Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients","Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ.","Brachytherapy. 2019 Jan-Feb;18(1):1-7. doi: 10.1016/j.brachy.2018.09.003. Epub 2018 Oct 4.","Routman DM","Brachytherapy","2019","2018/10/09","","","10.1016/j.brachy.2018.09.003"
"24914844","[Results of active surveillance in low and intermediate risk prostate cancer]","Llorente C, Diaz Goizueta FJ, Hernandez V, de la Morena JM, de la Peña E.","Arch Esp Urol. 2014 Jun;67(5):452-6.","Llorente C","Arch Esp Urol","2014","2014/06/11","","",""
"10803835","Prostate specific antigen: a useful screening test?","Concato J.","Cancer J. 2000 Apr;6 Suppl 2:S188-92.","Concato J","Cancer J","2000","2000/05/10","","",""
"2411962","[Clinical evaluation of prostate antigen (PA) in prostate cancer]","Kuriyama M.","Gan No Rinsho. 1985 May;31(6 Suppl):606-10.","Kuriyama M","Gan No Rinsho","1985","1985/05/01","","",""
"13130113","Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy","D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH.","J Natl Cancer Inst. 2003 Sep 17;95(18):1376-83. doi: 10.1093/jnci/djg043.","D'Amico AV","J Natl Cancer Inst","2003","2003/09/18","","","10.1093/jnci/djg043"
"27825118","Amplification of MUC1 in prostate cancer metastasis and CRPC development","Wong N, Major P, Kapoor A, Wei F, Yan J, Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ, Tang D.","Oncotarget. 2016 Dec 13;7(50):83115-83133. doi: 10.18632/oncotarget.13073.","Wong N","Oncotarget","2016","2016/11/09","PMC5347757","","10.18632/oncotarget.13073"
"18334284","Hypoxia in prostate cancer: a powerful shield against tumour destruction?","Marignol L, Coffey M, Lawler M, Hollywood D.","Cancer Treat Rev. 2008 Jun;34(4):313-27. doi: 10.1016/j.ctrv.2008.01.006. Epub 2008 Mar 10.","Marignol L","Cancer Treat Rev","2008","2008/03/13","","","10.1016/j.ctrv.2008.01.006"
"24407349","Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments","Balistreri CR, Candore G, Lio D, Carruba G.","Cancer Gene Ther. 2014 Jan;21(1):2-11. doi: 10.1038/cgt.2013.77. Epub 2014 Jan 10.","Balistreri CR","Cancer Gene Ther","2014","2014/01/11","","","10.1038/cgt.2013.77"
"9111626","Development of prostate cancer after pituitary dysfunction: a report of 8 patients","Ebling DW, Ruffer J, Whittington R, Vanarsdalen K, Broderick GA, Malkowicz SB, Wein AJ.","Urology. 1997 Apr;49(4):564-8. doi: 10.1016/s0090-4295(96)00541-9.","Ebling DW","Urology","1997","1997/04/01","","","10.1016/s0090-4295(96)00541-9"
"17678531","Can a single model explain both breast cancer and prostate cancer?","Friedman AE.","Theor Biol Med Model. 2007 Aug 1;4:28. doi: 10.1186/1742-4682-4-28.","Friedman AE","Theor Biol Med Model","2007","2007/08/07","PMC2014741","","10.1186/1742-4682-4-28"
"25847937","External Validation of the Benefit of Adjuvant Radiotherapy for Pathologic N1M0 Prostate Cancer","Rusthoven CG, Carlson JA, Kavanagh BD.","J Clin Oncol. 2015 Jun 10;33(17):1987-8. doi: 10.1200/JCO.2015.60.9404. Epub 2015 Apr 6.","Rusthoven CG","J Clin Oncol","2015","2015/04/08","","","10.1200/JCO.2015.60.9404"
"11586206","Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy","Zietman AL, Thakral H, Wilson L, Schellhammer P.","J Urol. 2001 Nov;166(5):1702-6.","Zietman AL","J Urol","2001","2001/10/05","","",""
"21943970","Screening for prostate cancer","Schröder FH.","Eur J Cancer. 2011 Sep;47 Suppl 3:S164-70. doi: 10.1016/S0959-8049(11)70160-5.","Schröder FH","Eur J Cancer","2011","2011/09/28","","","10.1016/S0959-8049(11)70160-5"
"22388666","Economic analysis of active surveillance for localized prostate cancer","Kim S 2nd, Dall'Era MA, Evans CP.","Curr Opin Urol. 2012 May;22(3):247-53. doi: 10.1097/MOU.0b013e328351dd32.","Kim S 2nd","Curr Opin Urol","2012","2012/03/06","","","10.1097/MOU.0b013e328351dd32"
"12191739","Relative advantages and disadvantages of radical perineal prostatectomy versus radical retropubic prostatectomy","Gillitzer R, Thüroff JW.","Crit Rev Oncol Hematol. 2002 Aug;43(2):167-90. doi: 10.1016/s1040-8428(02)00016-1.","Gillitzer R","Crit Rev Oncol Hematol","2002","2002/08/23","","","10.1016/s1040-8428(02)00016-1"
"23645736","Increased plasma caveolin-1 levels are associated with progression of prostate cancer among Japanese men","Sugie S, Mukai S, Tsukino H, Toda Y, Yamauchi T, Nishikata I, Kuroda Y, Morishita K, Kamoto T.","Anticancer Res. 2013 May;33(5):1893-7.","Sugie S","Anticancer Res","2013","2013/05/07","","",""
"2693330","Early detection of prostate cancer","Chodak GW.","Horm Res. 1989;32 Suppl 1:35-7. doi: 10.1159/000181306.","Chodak GW","Horm Res","1989","1989/01/01","","","10.1159/000181306"
"22453560","Androgen deprivation therapy for prostate cancer and cardiovascular death","Blankfield RP.","JAMA. 2012 Mar 28;307(12):1252; author reply 1252-3. doi: 10.1001/jama.2012.352.","Blankfield RP","JAMA","2012","2012/03/29","","","10.1001/jama.2012.352"
"19172763","Selenium for prostate cancer prevention","","Harv Health Lett. 2009 Jan;34(3):7.","","Harv Health Lett","2009","2009/01/29","","",""
"9661915","Striking a balance: Tissue harvesting for prostate cancer research","Tomaszewski JE, LiVolsi VA.","Am J Clin Pathol. 1998 Jul;110(1):1-2. doi: 10.1093/ajcp/110.1.1.","Tomaszewski JE","Am J Clin Pathol","1998","1998/07/14","","","10.1093/ajcp/110.1.1"
"17261768","Estrogens and mechanisms of prostate cancer progression","Carruba G.","Ann N Y Acad Sci. 2006 Nov;1089:201-17. doi: 10.1196/annals.1386.027.","Carruba G","Ann N Y Acad Sci","2006","2007/01/31","","","10.1196/annals.1386.027"
"22342096","Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer","Gogna NK, Baxi S, Hickey B, Baumann K, Burmeister E, Holt T.","Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):e205-11. doi: 10.1016/j.ijrobp.2011.12.028. Epub 2012 Feb 16.","Gogna NK","Int J Radiat Oncol Biol Phys","2012","2012/02/21","","","10.1016/j.ijrobp.2011.12.028"
"29141559","New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer","Chu K, Corcoran N, Norden S, Wong LM.","Anticancer Agents Med Chem. 2018;18(7):951-957. doi: 10.2174/1871520617666171114105846.","Chu K","Anticancer Agents Med Chem","2018","2017/11/17","","","10.2174/1871520617666171114105846"
"11869987","Declining deaths from prostate cancer","","Harv Mens Health Watch. 2002 Feb;6(7):7-8.","","Harv Mens Health Watch","2002","2002/03/01","","",""
"14610405","Use of expression analysis to predict outcome after radical prostatectomy","Febbo PG, Sellers WR.","J Urol. 2003 Dec;170(6 Pt 2):S11-9; discussion S19-20. doi: 10.1097/01.ju.0000095567.03807.a1.","Febbo PG","J Urol","2003","2003/11/12","","","10.1097/01.ju.0000095567.03807.a1"
"22902912","Skeletal complications of ADT: disease burden and treatment options","Planas Morin J, Morote Robles J.","Asian J Androl. 2012 Sep;14(5):670-5. doi: 10.1038/aja.2012.70. Epub 2012 Aug 20.","Planas Morin J","Asian J Androl","2012","2012/08/21","PMC3734975","","10.1038/aja.2012.70"
"26362176","Doxorubicin-loaded magnetic nanoparticle clusters for chemo-photothermal treatment of the prostate cancer cell line PC3","Zhang W, Zheng X, Shen S, Wang X.","Biochem Biophys Res Commun. 2015 Oct 16;466(2):278-82. doi: 10.1016/j.bbrc.2015.09.036. Epub 2015 Sep 9.","Zhang W","Biochem Biophys Res Commun","2015","2015/09/13","","","10.1016/j.bbrc.2015.09.036"
"12053019","Evaluation of prognostic factors in radical prostatectomy specimens with cancer","Mazzucchelli R, Santinelli A, Lopez-Beltran A, Scarpelli M, Montironi R.","Urol Int. 2002;68(4):209-15. doi: 10.1159/000058437.","Mazzucchelli R","Urol Int","2002","2002/06/08","","","10.1159/000058437"
"11253893","The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination","Leewansangtong S, Tantiwong A, Ratanarapee S, Nualyong C, Soontrapa S.","J Med Assoc Thai. 2000 Dec;83(12):1519-24.","Leewansangtong S","J Med Assoc Thai","2000","2001/03/20","","",""
"9730479","PSA of 0.5 ng/mL or less and prostate cancer radiation","Anscher MS.","Urology. 1998 Sep;52(3):531.","Anscher MS","Urology","1998","1998/09/08","","",""
"12955079","Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer","Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL.","Oncogene. 2003 Sep 4;22(38):6005-12. doi: 10.1038/sj.onc.1206797.","Henshall SM","Oncogene","2003","2003/09/05","","","10.1038/sj.onc.1206797"
"23271773","Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions","Hoffman RM.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):197-201. doi: 10.1093/jncimonographs/lgs023.","Hoffman RM","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540882","","10.1093/jncimonographs/lgs023"
"15280915","The utility of a multimedia education program for prostate cancer patients: a formative evaluation","Flynn D, van Schaik P, van Wersch A, Ahmed T, Chadwick D.","Br J Cancer. 2004 Aug 31;91(5):855-60. doi: 10.1038/sj.bjc.6602071.","Flynn D","Br J Cancer","2004","2004/07/29","PMC2409882","","10.1038/sj.bjc.6602071"
"31900916","Androgen Receptor Dependence","Chaturvedi AP, Dehm SM.","Adv Exp Med Biol. 2019;1210:333-350. doi: 10.1007/978-3-030-32656-2_15.","Chaturvedi AP","Adv Exp Med Biol","2019","2020/01/05","","","10.1007/978-3-030-32656-2_15"
"28560383","Effects of genistein supplementation on genome‑wide DNA methylation and gene expression in patients with localized prostate cancer","Bilir B, Sharma NV, Lee J, Hammarstrom B, Svindland A, Kucuk O, Moreno CS.","Int J Oncol. 2017 Jul;51(1):223-234. doi: 10.3892/ijo.2017.4017. Epub 2017 May 24.","Bilir B","Int J Oncol","2017","2017/06/01","PMC5467777","","10.3892/ijo.2017.4017"
"27760001","Geometric systematic prostate biopsy","Chang D, Chong X, Kim C, Jun C, Petrisor D, Han M, Stoianovici D.","Minim Invasive Ther Allied Technol. 2017 Apr;26(2):78-85. doi: 10.1080/13645706.2016.1249890. Epub 2016 Nov 11.","Chang D","Minim Invasive Ther Allied Technol","2017","2016/10/21","","","10.1080/13645706.2016.1249890"
"16389455","Sonic Hedgehog signaling in advanced prostate cancer","Datta S, Datta MW.","Cell Mol Life Sci. 2006 Feb;63(4):435-48. doi: 10.1007/s00018-005-5389-4.","Datta S","Cell Mol Life Sci","2006","2006/01/04","","","10.1007/s00018-005-5389-4"
"8898999","Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences","Dale W, Vijayakumar S, Lawlor EF, Merrell K.","Prostate. 1996 Nov;29(5):271-81. doi: 10.1002/(SICI)1097-0045(199611)29:5<271::AID-PROS1>3.0.CO;2-D.","Dale W","Prostate","1996","1996/11/01","","","10.1002/(SICI)1097-0045(199611)29:5<271::AID-PROS1>3.0.CO;2-D"
"24188262","Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer","McKay RR, Taplin ME, Choueiri TK.","Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20.","McKay RR","Hematol Oncol Clin North Am","2013","2013/11/06","PMC4127574","NIHMS606862","10.1016/j.hoc.2013.08.009"
"16563135","Is chronic inflammatory change in the prostate the major cause of rising serum prostate-specific antigen in patients with clinical suspicion of prostate cancer?","Chang SG, Kim CS, Jeon SH, Kim YW, Choi BY.","Int J Urol. 2006 Feb;13(2):122-6. doi: 10.1111/j.1442-2042.2006.01244.x.","Chang SG","Int J Urol","2006","2006/03/28","","","10.1111/j.1442-2042.2006.01244.x"
"16007894","External beam radiotherapy as curative treatment of prostate cancer","Pisansky TM.","Mayo Clin Proc. 2005 Jul;80(7):883-98. doi: 10.4065/80.7.883.","Pisansky TM","Mayo Clin Proc","2005","2005/07/13","","","10.4065/80.7.883"
"8507233","The lack of futility in screening for prostate cancer","Zincke H.","Minn Med. 1993 Feb;76(2):7.","Zincke H","Minn Med","1993","1993/02/01","","",""
"25085835","Vitamin D in blood and risk of prostate cancer: lessons from the Selenium and Vitamin E Cancer Prevention Trial and the Prostate Cancer Prevention Trial","Schwartz GG.","Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1447-9. doi: 10.1158/1055-9965.EPI-14-0520.","Schwartz GG","Cancer Epidemiol Biomarkers Prev","2014","2014/08/03","","","10.1158/1055-9965.EPI-14-0520"
"28349978","Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project","Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ.","Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.","Tay KJ","Prostate Cancer Prostatic Dis","2017","2017/03/29","","","10.1038/pcan.2017.8"
"15646825","The role of androgen receptors in the dynamic process of prostate cancer: their analytical determination in biopsy material","Pintér O, Pajor L, Molnár J, Márki A, Falkay G.","In Vivo. 2004 Nov-Dec;18(6):809-12.","Pintér O","In Vivo","2004","2005/01/14","","",""
"18071861","Hormonal therapy","Namiki M, Ueno S, Kitagawa Y, Konaka H, Mizokami A, Koh E, Fukagai T.","Int J Clin Oncol. 2007 Dec;12(6):427-32. doi: 10.1007/s10147-007-0704-8. Epub 2007 Dec 21.","Namiki M","Int J Clin Oncol","2007","2007/12/12","","","10.1007/s10147-007-0704-8"
"27558311","Socioeconomic disadvantage but not remoteness affects short-term survival in prostate cancer: A population-based study using competing risks","Thomas AA, Pearce A, Sharp L, Gardiner RA, Chambers S, Aitken J, Molcho M, Baade P.","Asia Pac J Clin Oncol. 2017 Apr;13(2):e31-e40. doi: 10.1111/ajco.12570. Epub 2016 Aug 25.","Thomas AA","Asia Pac J Clin Oncol","2017","2016/08/26","","","10.1111/ajco.12570"
"27244877","Exposure to pesticides and prostate cancer: systematic review of the literature","Silva JF, Mattos IE, Luz LL, Carmo CN, Aydos RD.","Rev Environ Health. 2016 Sep 1;31(3):311-27. doi: 10.1515/reveh-2016-0001.","Silva JF","Rev Environ Health","2016","2016/06/01","","","10.1515/reveh-2016-0001"
"7505230","Screening for prostate cancer","Chodak GW.","Eur Urol. 1993;24 Suppl 2:3-5. doi: 10.1159/000474379.","Chodak GW","Eur Urol","1993","1993/01/01","","","10.1159/000474379"
"17485307","Epigenetics of prostate cancer","Li LC.","Front Biosci. 2007 May 1;12:3377-97. doi: 10.2741/2320.","Li LC","Front Biosci","2007","2007/05/09","","","10.2741/2320"
"23949554","Prostate cancer metastasis to the stomach: 9 years after the initial diagnosis--case report and a literature review","Mehrzad R, Agarwal A, Faller GT, Fiore JA.","J Gastrointest Cancer. 2014 Dec;45 Suppl 1:40-3. doi: 10.1007/s12029-013-9527-1.","Mehrzad R","J Gastrointest Cancer","2014","2013/08/17","","","10.1007/s12029-013-9527-1"
"27449261","Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression: Pro","Morgentaler A.","J Urol. 2016 Oct;196(4):985-8. doi: 10.1016/j.juro.2016.07.075. Epub 2016 Jul 20.","Morgentaler A","J Urol","2016","2016/07/25","","","10.1016/j.juro.2016.07.075"
"11792945","Re: A structured debate: immediate versus deferred androgen suppression in prostate cancer--evidence for deferred treatment","Fourcade RO.","J Urol. 2002 Feb;167(2 Pt 1):651-2; author reply 653. doi: 10.1097/00005392-200202000-00052.","Fourcade RO","J Urol","2002","2002/01/17","","","10.1097/00005392-200202000-00052"
"31067846","[Granulomatous Prostatitis : Three Cases Report]","Ikeda J, Murakami S, Kawa G, Shibuya S.","Hinyokika Kiyo. 2019 Mar;65(3):69-73. doi: 10.14989/ActaUrolJap_65_3_69.","Ikeda J","Hinyokika Kiyo","2019","2019/05/10","","","10.14989/ActaUrolJap_65_3_69"
"10419049","Tumor-suppressive activity of CD66a in prostate cancer","Luo W, Tapolsky M, Earley K, Wood CG, Wilson DR, Logothetis CJ, Lin SH.","Cancer Gene Ther. 1999 Jul-Aug;6(4):313-21. doi: 10.1038/sj.cgt.7700055.","Luo W","Cancer Gene Ther","1999","1999/07/27","","","10.1038/sj.cgt.7700055"
"20718671","Dutasteride and prostate cancer","Kiemeney LA, Bosland MC.","N Engl J Med. 2010 Aug 19;363(8):793; author reply 794-5. doi: 10.1056/NEJMc1005498.","Kiemeney LA","N Engl J Med","2010","2010/08/20","","","10.1056/NEJMc1005498"
"18347174","Identification of prognostic biomarkers for prostate cancer","Kosari F, Munz JM, Savci-Heijink CD, Spiro C, Klee EW, Kube DM, Tillmans L, Slezak J, Karnes RJ, Cheville JC, Vasmatzis G.","Clin Cancer Res. 2008 Mar 15;14(6):1734-43. doi: 10.1158/1078-0432.CCR-07-1494.","Kosari F","Clin Cancer Res","2008","2008/03/19","","","10.1158/1078-0432.CCR-07-1494"
"28419541","When should active surveillance for prostate cancer stop if no progression is detected?","de Carvalho TM, Heijnsdijk EAM, de Koning HJ.","Prostate. 2017 Jun;77(9):962-969. doi: 10.1002/pros.23352. Epub 2017 Apr 17.","de Carvalho TM","Prostate","2017","2017/04/19","","","10.1002/pros.23352"
"20687228","Glycemic control and prostate cancer progression: results from the SEARCH database","Kim HS, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.","Prostate. 2010 Oct 1;70(14):1540-6. doi: 10.1002/pros.21189.","Kim HS","Prostate","2010","2010/08/06","PMC2930134","NIHMS208127","10.1002/pros.21189"
"30127462","Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study","Govers TM, Hessels D, Vlaeminck-Guillem V, Schmitz-Dräger BJ, Stief CG, Martinez-Ballesteros C, Ferro M, Borque-Fernando A, Rubio-Briones J, Sedelaar JPM, van Criekinge W, Schalken JA.","Prostate Cancer Prostatic Dis. 2019 Mar;22(1):101-109. doi: 10.1038/s41391-018-0076-3. Epub 2018 Aug 20.","Govers TM","Prostate Cancer Prostatic Dis","2019","2018/08/22","","","10.1038/s41391-018-0076-3"
"15592949","Prostate cancer screening: results of a prospective trial in Canton Aargau, Switzerland","Kwiatkowski M, Huber A, Moschopulos M, Lehmann K, Wernli M, Häfeli A, Recker F.","Swiss Med Wkly. 2004 Oct 2;134(39-40):580-5.","Kwiatkowski M","Swiss Med Wkly","2004","2004/12/14","","",""
"20587839","Detection and characteristics of primary circulating prostate cells; association with micrometastasis and implications for surgical treatment of men with prostate cancer","Murray NP, Reyes E, Badínez L, Orellana N, Dueñas R, Fuentealba C.","Arch Esp Urol. 2010 Jun;63(5):345-53.","Murray NP","Arch Esp Urol","2010","2010/07/01","","",""
"10754525","Fragile histidine triad gene expression in primary prostate cancer and in an in vitro model","Guo Z, Johansson SL, Rhim JS, Vishwanatha JK.","Prostate. 2000 May 1;43(2):101-10. doi: 10.1002/(sici)1097-0045(20000501)43:2<101::aid-pros4>3.0.co;2-a.","Guo Z","Prostate","2000","2001/02/07","","","10.1002/(sici)1097-0045(20000501)43:2<101::aid-pros4>3.0.co;2-a"
"25722318","Targeting the androgen receptor in prostate and breast cancer: several new agents in development","Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA, Traina TA.","Endocr Relat Cancer. 2015 Jun;22(3):R87-R106. doi: 10.1530/ERC-14-0543. Epub 2015 Feb 26.","Proverbs-Singh T","Endocr Relat Cancer","2015","2015/02/28","PMC4714354","NIHMS749220","10.1530/ERC-14-0543"
"15571465","The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer","Jani AB.","Expert Opin Pharmacother. 2004 Dec;5(12):2469-77. doi: 10.1517/14656566.5.12.2469.","Jani AB","Expert Opin Pharmacother","2004","2004/12/02","","","10.1517/14656566.5.12.2469"
"9202562","A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation","Bates TS, Gillatt DA, Cavanagh PM, Speakman M.","Br J Urol. 1997 Jun;79(6):927-32. doi: 10.1046/j.1464-410x.1997.00188.x.","Bates TS","Br J Urol","1997","1997/06/01","","","10.1046/j.1464-410x.1997.00188.x"
"8458708","Geographic variation in the treatment of prostate cancer in Connecticut","Polednak AP.","Int J Technol Assess Health Care. 1993 Spring;9(2):304-10. doi: 10.1017/s0266462300004517.","Polednak AP","Int J Technol Assess Health Care","1993","1993/01/01","","","10.1017/s0266462300004517"
"23185849","Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow","","Prescrire Int. 2012 Oct;21(131):242-8.","","Prescrire Int","2012","2012/11/29","","",""
"17308104","Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts","Chen D, Cui QC, Yang H, Barrea RA, Sarkar FH, Sheng S, Yan B, Reddy GP, Dou QP.","Cancer Res. 2007 Feb 15;67(4):1636-44. doi: 10.1158/0008-5472.CAN-06-3546.","Chen D","Cancer Res","2007","2007/02/20","","","10.1158/0008-5472.CAN-06-3546"
"18591961","Prostatic fluid electrolyte composition for the screening of prostate cancer: a potential solution to a major problem","Costello LC, Franklin RB.","Prostate Cancer Prostatic Dis. 2009;12(1):17-24. doi: 10.1038/pcan.2008.19. Epub 2008 Jul 1.","Costello LC","Prostate Cancer Prostatic Dis","2009","2008/07/02","PMC3734867","NIHMS495940","10.1038/pcan.2008.19"
"15668801","Rationale for the development and current status of calcitriol in androgen-independent prostate cancer","Beer TM, Myrthue A, Eilers KM.","World J Urol. 2005 Feb;23(1):28-32. doi: 10.1007/s00345-004-0476-y. Epub 2005 Jan 25.","Beer TM","World J Urol","2005","2005/01/26","","","10.1007/s00345-004-0476-y"
"7475418","Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease","Schapira MM, McAuliffe TL, Nattinger AB.","Med Care. 1995 Nov;33(11):1079-88. doi: 10.1097/00005650-199511000-00002.","Schapira MM","Med Care","1995","1995/11/01","","","10.1097/00005650-199511000-00002"
"11400919","Prostate specific antigen and screening for early prostate cancer","Davidson P.","N Z Med J. 2001 Apr 13;114(1129):150.","Davidson P","N Z Med J","2001","2001/06/13","","",""
"24910288","[Salvage cryotherapy for recurrent prostate cancer after radiotherapy failure: principles, indications, patient selection, oncological results and morbidity]","Hétet JF, Colls P, Pocholle P, Chauveau P, Barré C, Hallouin P.","Cancer Radiother. 2014 Nov;18(7):701-8. doi: 10.1016/j.canrad.2014.04.002. Epub 2014 Jun 6.","Hétet JF","Cancer Radiother","2014","2014/06/10","","","10.1016/j.canrad.2014.04.002"
"19538771","An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines","Piantino CB, Salvadori FA, Ayres PP, Kato RB, Srougi V, Leite KR, Srougi M.","Int Braz J Urol. 2009 May-Jun;35(3):354-60; discussion 361. doi: 10.1590/s1677-55382009000300012.","Piantino CB","Int Braz J Urol","2009","2009/06/23","","","10.1590/s1677-55382009000300012"
"8607237","Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen","Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M.","Urology. 1996 Feb;47(2):212-7. doi: 10.1016/S0090-4295(99)80419-1.","Labrie F","Urology","1996","1996/02/01","","","10.1016/S0090-4295(99)80419-1"
"12694463","Diagnostic value of serum prostate-specific antigen in hemodialysis patients","Sumura M, Yokogi H, Beppu M, Honda H.","Int J Urol. 2003 May;10(5):247-50. doi: 10.1046/j.1442-2042.2003.00612.x.","Sumura M","Int J Urol","2003","2003/04/16","","","10.1046/j.1442-2042.2003.00612.x"
"25026284","Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer","Mendonca J, Sharma A, Kim HS, Hammers H, Meeker A, De Marzo A, Carducci M, Kauffman M, Shacham S, Kachhap S.","Oncotarget. 2014 Aug 15;5(15):6102-12. doi: 10.18632/oncotarget.2174.","Mendonca J","Oncotarget","2014","2014/07/16","PMC4171616","","10.18632/oncotarget.2174"
"26621054","Active surveillance for prostate cancer","Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV, Touijer KA.","Int J Urol. 2016 Mar;23(3):211-8. doi: 10.1111/iju.13016. Epub 2015 Nov 30.","Romero-Otero J","Int J Urol","2016","2015/12/02","PMC4966658","NIHMS764091","10.1111/iju.13016"
"28631720","Contemporary management of men with high-risk localized prostate cancer in the United States","Weiner AB, Matulewicz RS, Schaeffer EM, Liauw SL, Feinglass JM, Eggener SE.","Prostate Cancer Prostatic Dis. 2017 Sep;20(3):283-288. doi: 10.1038/pcan.2017.5. Epub 2017 Jun 20.","Weiner AB","Prostate Cancer Prostatic Dis","2017","2017/06/21","","","10.1038/pcan.2017.5"
"10811100","Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors","McDonald S, Brive L, Agus DB, Scher HI, Ely KR.","Cancer Res. 2000 May 1;60(9):2317-22.","McDonald S","Cancer Res","2000","2000/05/16","","",""
"18641965","[Radiotherapy in prostate cancer]","Ganswindt U, Belka C.","Urologe A. 2008 Sep;47(9):1245-54; quiz 1255. doi: 10.1007/s00120-008-1846-7.","Ganswindt U","Urologe A","2008","2008/07/22","","","10.1007/s00120-008-1846-7"
"24531789","Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial","Wilt TJ.","Recent Results Cancer Res. 2014;202:149-69. doi: 10.1007/978-3-642-45195-9_18.","Wilt TJ","Recent Results Cancer Res","2014","2014/02/18","","","10.1007/978-3-642-45195-9_18"
"21942796","Independent diagnostic and post-treatment prognostic models for prostate cancer demonstrate significant correlation with disease progression end points","Graversen JA, Suh LK, Mues AC, Korets R, Donovan MJ, Khan FM, Liu Q, Landman J, Gupta M, McKiernan JM, Badani KK.","J Endourol. 2012 May;26(5):451-6. doi: 10.1089/end.2011.0192. Epub 2011 Sep 23.","Graversen JA","J Endourol","2012","2011/09/28","","","10.1089/end.2011.0192"
"22348555","In vivo versus in vitro individual radiosensitivity analysed in healthy donors and in prostate cancer patients with and without severe side effects after radiotherapy","Brzozowska K, Pinkawa M, Eble MJ, Müller WU, Wojcik A, Kriehuber R, Schmitz S.","Int J Radiat Biol. 2012 May;88(5):405-13. doi: 10.3109/09553002.2012.666002. Epub 2012 Mar 14.","Brzozowska K","Int J Radiat Biol","2012","2012/02/22","","","10.3109/09553002.2012.666002"
"18842221","[Osteonecrosis of the jaw and bisphosphonates in advanced prostate cancer]","Cuervo Pinna MA, Ramos Jiménez MA.","Med Clin (Barc). 2008 Sep 27;131(10):399. doi: 10.1016/s0025-7753(08)72294-2.","Cuervo Pinna MA","Med Clin (Barc)","2008","2008/10/10","","","10.1016/s0025-7753(08)72294-2"
"11106676","Stat bite: prostate cancer incidence and mortality in U.S. blacks and whites, 1973-1997","","J Natl Cancer Inst. 2000 Dec 6;92(23):1875. doi: 10.1093/jnci/92.23.1875.","","J Natl Cancer Inst","2000","2000/12/07","","","10.1093/jnci/92.23.1875"
"24960595","Prostate cancer: optimizing active surveillance: patient and protocol","Fenner A.","Nat Rev Urol. 2014 Jul;11(7):362. doi: 10.1038/nrurol.2014.146. Epub 2014 Jun 24.","Fenner A","Nat Rev Urol","2014","2014/06/25","","","10.1038/nrurol.2014.146"
"24535588","Prostate cancer: Genetic differences in PSA","Payton S.","Nat Rev Urol. 2014 Mar;11(3):130. doi: 10.1038/nrurol.2014.27. Epub 2014 Feb 18.","Payton S","Nat Rev Urol","2014","2014/02/19","","","10.1038/nrurol.2014.27"
"30718981","LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?","Cariello M, Ducheix S, Maqdasy S, Baron S, Moschetta A, Lobaccaro JA.","Nucl Recept Signal. 2018 Oct 16;15:1550762918801070. doi: 10.1177/1550762918801070. eCollection 2018.","Cariello M","Nucl Recept Signal","2018","2019/02/06","PMC6348739","","10.1177/1550762918801070"
"31995611","Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study","Thomsen FB, Westerberg M, Garmo H, Robinson D, Holmberg L, Ulmert HD, Stattin P.","PLoS One. 2020 Jan 29;15(1):e0228447. doi: 10.1371/journal.pone.0228447. eCollection 2020.","Thomsen FB","PLoS One","2020","2020/01/30","PMC6988964","","10.1371/journal.pone.0228447"
"20120772","Reduced expression of programmed cell death 5 protein in tissue of human prostate cancer","Du YJ, Xiong L, Lou Y, Tan WL, Zheng SB.","Chin Med Sci J. 2009 Dec;24(4):241-5. doi: 10.1016/s1001-9294(10)60009-0.","Du YJ","Chin Med Sci J","2009","2010/02/04","","","10.1016/s1001-9294(10)60009-0"
"19544540","The current state of brachytherapy nomograms for patients with clinically localized prostate cancer","Nguyen CT, Zelefsky MJ, Kattan MW.","Cancer. 2009 Jul 1;115(13 Suppl):3121-7. doi: 10.1002/cncr.24344.","Nguyen CT","Cancer","2009","2009/06/23","","","10.1002/cncr.24344"
"24774827","Words of wisdom. Re: Use of statins and the risk of death in patients with prostate cancer","van Leeuwen P.","Eur Urol. 2014 Jun;65(6):1219-20. doi: 10.1016/j.eururo.2014.02.026.","van Leeuwen P","Eur Urol","2014","2014/04/30","","","10.1016/j.eururo.2014.02.026"
"23615028","Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy","Kirby M.","BJU Int. 2013 May;111(6):854-6. doi: 10.1111/j.1464-410X.2012.11722.x.","Kirby M","BJU Int","2013","2013/04/26","","","10.1111/j.1464-410X.2012.11722.x"
"19095346","Editorial comment on: A study of diffusion-weighted magnetic resonance imaging in men with untreated localized prostate cancer on active surveillance","Sauvain JL.","Eur Urol. 2009 Dec;56(6):987-8. doi: 10.1016/j.eururo.2008.11.052. Epub 2008 Dec 6.","Sauvain JL","Eur Urol","2009","2008/12/20","","","10.1016/j.eururo.2008.11.052"
"12686844","Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk","Jacobsen SJ, Roberts RO.","J Urol. 2003 May;169(5):1798-9. doi: 10.1097/01.ju.0000057804.01025.13.","Jacobsen SJ","J Urol","2003","2003/04/11","","","10.1097/01.ju.0000057804.01025.13"
"18406046","Editorial comment on: Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam","Ciatto S.","Eur Urol. 2009 Jan;55(1):146-7. doi: 10.1016/j.eururo.2008.03.080. Epub 2008 Apr 1.","Ciatto S","Eur Urol","2009","2008/04/15","","","10.1016/j.eururo.2008.03.080"
"23578236","High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer","Smit FP, Salagierski M, Jannink S, Schalken JA.","BJU Int. 2013 May;111(5):836-42. doi: 10.1111/bju.12119.","Smit FP","BJU Int","2013","2013/04/13","","","10.1111/bju.12119"
"3071950","Relationship of androgen receptors to the growth and regression of the prostate","Rennie PS, Bruchovsky N, Goldenberg SL.","Am J Clin Oncol. 1988;11 Suppl 2:S13-7. doi: 10.1097/00000421-198801102-00004.","Rennie PS","Am J Clin Oncol","1988","1988/01/01","","","10.1097/00000421-198801102-00004"
"11796288","A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate","Roobol MJ, Kranse R, van der Cruijsen IW, Schröder FH.","Urology. 2002 Jan;59(1):91-6. doi: 10.1016/s0090-4295(01)01479-0.","Roobol MJ","Urology","2002","2002/01/18","","","10.1016/s0090-4295(01)01479-0"
"21062154","Effect of capsaicin on prostate cancer cells","Díaz-Laviada I.","Future Oncol. 2010 Oct;6(10):1545-50. doi: 10.2217/fon.10.117.","Díaz-Laviada I","Future Oncol","2010","2010/11/11","","","10.2217/fon.10.117"
"30255558","Interventions for prostate cancer survivorship: A systematic review of reviews","Crawford-Williams F, March S, Goodwin BC, Ralph N, Galvão DA, Newton RU, Chambers SK, Dunn J.","Psychooncology. 2018 Oct;27(10):2339-2348. doi: 10.1002/pon.4888.","Crawford-Williams F","Psychooncology","2018","2018/09/27","","","10.1002/pon.4888"
"16278468","Active surveillance for prostate cancer: for whom?","Klotz L.","J Clin Oncol. 2005 Nov 10;23(32):8165-9. doi: 10.1200/JCO.2005.03.3134.","Klotz L","J Clin Oncol","2005","2005/11/10","","","10.1200/JCO.2005.03.3134"
"8931964","Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer","Abbas F, Hochberg D, Civantos F, Soloway M.","Eur Urol. 1996;30(3):322-6. doi: 10.1159/000474190.","Abbas F","Eur Urol","1996","1996/01/01","","","10.1159/000474190"
"30131183","MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life","Maenhout M, Peters M, Moerland MA, Meijer RP, van den Bosch MAAJ, Frank SJ, Nguyen PL, van Vulpen M, van der Voort van Zyp JRN.","Radiother Oncol. 2018 Dec;129(3):554-560. doi: 10.1016/j.radonc.2018.07.019. Epub 2018 Aug 18.","Maenhout M","Radiother Oncol","2018","2018/08/23","","","10.1016/j.radonc.2018.07.019"
"29458069","High expression of NPRL2 is linked to poor prognosis in patients with prostate cancer","Chen Z, Luo S, Chen Y, Xie X, Du Z, Jiang L.","Hum Pathol. 2018 Jun;76:141-148. doi: 10.1016/j.humpath.2018.02.011. Epub 2018 Feb 17.","Chen Z","Hum Pathol","2018","2018/02/20","","","10.1016/j.humpath.2018.02.011"
"10636569","Treatment of advanced prostate cancer: the vaccine approach","Mulders PF.","Scand J Urol Nephrol Suppl. 1999;203:41-3. doi: 10.1080/00365599950510049.","Mulders PF","Scand J Urol Nephrol Suppl","1999","2000/01/15","","","10.1080/00365599950510049"
"26683656","Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy","Lin YL, Deng QK, Wang YH, Fu XL, Ma JG, Li WP.","Med Sci Monit. 2015 Dec 19;21:3955-690. doi: 10.12659/msm.896763.","Lin YL","Med Sci Monit","2015","2015/12/20","PMC4689382","","10.12659/msm.896763"
"19352607","[Therapy choices of German urologists and radio-oncologists if personally diagnosed with localized prostate cancer]","Gillitzer R, Hampel C, Thomas C, Schmidt F, Melchior SW, Pahernik S, Schmidberger H, Thüroff JW.","Urologe A. 2009 Apr;48(4):399-407. doi: 10.1007/s00120-008-1928-6.","Gillitzer R","Urologe A","2009","2009/04/09","","","10.1007/s00120-008-1928-6"
"26942107","Transcription Factor HBP1 Enhances Radiosensitivity by Inducing Apoptosis in Prostate Cancer Cell Lines","Chen Y, Wang Y, Yu Y, Xu L, Zhang Y, Yu S, Li G, Zhang Z.","Anal Cell Pathol (Amst). 2016;2016:7015659. doi: 10.1155/2016/7015659. Epub 2016 Jan 28.","Chen Y","Anal Cell Pathol (Amst)","2016","2016/03/05","PMC4749775","","10.1155/2016/7015659"
"9023560","Metastatic carcinoma of the prostate presenting as parotid tumour","Simpson RH, Skálová A.","Histopathology. 1997 Jan;30(1):70-4. doi: 10.1046/j.1365-2559.1997.d01-563.x.","Simpson RH","Histopathology","1997","1997/01/01","","","10.1046/j.1365-2559.1997.d01-563.x"
"7547516","Management of localized prostate cancer: an epidemiological perspective","Harwood RH.","Clin Oncol (R Coll Radiol). 1995;7(3):151-9. doi: 10.1016/s0936-6555(05)80506-0.","Harwood RH","Clin Oncol (R Coll Radiol)","1995","1995/01/01","","","10.1016/s0936-6555(05)80506-0"
"7505870","Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy","Ruckle HC, Klee GG, Oesterling JE.","Mayo Clin Proc. 1994 Jan;69(1):69-79. doi: 10.1016/s0025-6196(12)61615-2.","Ruckle HC","Mayo Clin Proc","1994","1994/01/01","","","10.1016/s0025-6196(12)61615-2"
"29489433","Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer","Ennis RD, Hu L, Ryemon SN, Lin J, Mazumdar M.","J Clin Oncol. 2018 Apr 20;36(12):1192-1198. doi: 10.1200/JCO.2017.75.9134. Epub 2018 Feb 28.","Ennis RD","J Clin Oncol","2018","2018/03/01","","","10.1200/JCO.2017.75.9134"
"12507539","PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium","Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V.","Eur Urol. 2003 Jan;43(1):12-27. doi: 10.1016/s0302-2838(02)00505-5.","Djavan B","Eur Urol","2003","2003/01/01","","","10.1016/s0302-2838(02)00505-5"
"26551297","Development of Castration Resistant Prostate Cancer can be Predicted by a DNA Hypermethylation Profile","Angulo JC, Andrés G, Ashour N, Sánchez-Chapado M, López JI, Ropero S.","J Urol. 2016 Mar;195(3):619-26. doi: 10.1016/j.juro.2015.10.172. Epub 2015 Nov 6.","Angulo JC","J Urol","2016","2015/11/10","","","10.1016/j.juro.2015.10.172"
"17760748","Significance of the craniocaudal distribution of cancer in radical prostatectomy specimens","Ishii J, Ohori M, Scardino P, Tsuboi T, Slawin K, Wheeler T.","Int J Urol. 2007 Sep;14(9):817-21. doi: 10.1111/j.1442-2042.2007.01836.x.","Ishii J","Int J Urol","2007","2007/09/01","","","10.1111/j.1442-2042.2007.01836.x"
"25134829","Autophagy as a modulator and target in prostate cancer","Farrow JM, Yang JC, Evans CP.","Nat Rev Urol. 2014 Sep;11(9):508-16. doi: 10.1038/nrurol.2014.196. Epub 2014 Aug 19.","Farrow JM","Nat Rev Urol","2014","2014/08/20","PMC4415606","NIHMS683535","10.1038/nrurol.2014.196"
"21438905","High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients","Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN.","Histopathology. 2011 Apr;58(5):781-9. doi: 10.1111/j.1365-2559.2011.03800.x. Epub 2011 Mar 25.","Fleischmann A","Histopathology","2011","2011/03/29","","","10.1111/j.1365-2559.2011.03800.x"
"23131993","Genetic ablation of the tetraspanin CD151 reduces spontaneous metastatic spread of prostate cancer in the TRAMP model","Copeland BT, Bowman MJ, Ashman LK.","Mol Cancer Res. 2013 Jan;11(1):95-105. doi: 10.1158/1541-7786.MCR-12-0468. Epub 2012 Nov 6.","Copeland BT","Mol Cancer Res","2013","2012/11/08","","","10.1158/1541-7786.MCR-12-0468"
"11127964","Prostate cancer and the androgen receptor: strategies for the development of novel therapeutics","Mendelsohn LG.","Prog Drug Res. 2000;55:213-33. doi: 10.1007/978-3-0348-8385-6_6.","Mendelsohn LG","Prog Drug Res","2000","2000/12/29","","","10.1007/978-3-0348-8385-6_6"
"15625524","Management of androgen-independent prostate cancer","Diaz M, Patterson SG.","Cancer Control. 2004 Nov-Dec;11(6):364-73. doi: 10.1177/107327480401100604.","Diaz M","Cancer Control","2004","2004/12/31","","","10.1177/107327480401100604"
"8026884","Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results","Adolfsson J.","Int J Cancer. 1994 Jul 15;58(2):211-6. doi: 10.1002/ijc.2910580212.","Adolfsson J","Int J Cancer","1994","1994/07/15","","","10.1002/ijc.2910580212"
"27015368","The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells","Labrecque MP, Takhar MK, Nason R, Santacruz S, Tam KJ, Massah S, Haegert A, Bell RH, Altamirano-Dimas M, Collins CC, Lee FJ, Prefontaine GG, Cox ME, Beischlag TV.","Oncotarget. 2016 Apr 26;7(17):24284-302. doi: 10.18632/oncotarget.8301.","Labrecque MP","Oncotarget","2016","2016/03/26","PMC5029701","","10.18632/oncotarget.8301"
"14663467","p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein","Griewe GL, Dean RC, Zhang W, Young D, Sesterhenn IA, Shanmugam N, McLeod DG, Moul JW, Srivastava S.","Prostate Cancer Prostatic Dis. 2003;6(4):281-5. doi: 10.1038/sj.pcan.4500665.","Griewe GL","Prostate Cancer Prostatic Dis","2003","2003/12/10","","","10.1038/sj.pcan.4500665"
"11355945","A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland","Mononen N, Ikonen T, Syrjäkoski K, Matikainen M, Schleutker J, Tammela TL, Koivisto PA, Kallioniemi OP.","Br J Cancer. 2001 May 18;84(10):1344-7. doi: 10.1054/bjoc.2001.1789.","Mononen N","Br J Cancer","2001","2001/05/18","PMC2363646","","10.1054/bjoc.2001.1789"
"21281898","Response to ""Urinary obstruction in prostate cancer patients from the Dutch trial (68 Gy vs. 78 Gy): relationships with local dose, acute effects, and baseline characteristics"" (Int J Radiat Oncol Biol Phys 2010;78:19-25)","Jereczek-Fossa BA, Orecchia R, Bonora M, Scardino E.","Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):956; author reply 956-7. doi: 10.1016/j.ijrobp.2010.05.040.","Jereczek-Fossa BA","Int J Radiat Oncol Biol Phys","2011","2011/02/02","","","10.1016/j.ijrobp.2010.05.040"
"11708494","DNA-based detection of prostate cancer in blood, urine, and ejaculates","Goessl C, Müller M, Heicappell R, Krause H, Miller K.","Ann N Y Acad Sci. 2001 Sep;945:51-8. doi: 10.1111/j.1749-6632.2001.tb03863.x.","Goessl C","Ann N Y Acad Sci","2001","2001/11/16","","","10.1111/j.1749-6632.2001.tb03863.x"
"29284359","Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel","Bhardwaj S, Varma S.","J Oncol Pharm Pract. 2018 Mar;24(2):153-155. doi: 10.1177/1078155217694492. Epub 2017 Feb 17.","Bhardwaj S","J Oncol Pharm Pract","2018","2017/12/30","","","10.1177/1078155217694492"
"21844952","[Expression of glycoprotein non-metastatic melanoma protein B in prostate cancer and its significance]","Xiao YB, Qiao ZG, Zhang XW, Liu ZH, Xie J, Hao YC, Yu WD, Xu T, Wang XF.","Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Aug 18;43(4):496-9.","Xiao YB","Beijing Da Xue Xue Bao Yi Xue Ban","2011","2011/08/17","","",""
"3173500","Histologic grade, clinical stage, and patient age in prostate cancer","Gleason DF.","NCI Monogr. 1988;(7):15-8.","Gleason DF","NCI Monogr","1988","1988/01/01","","",""
"23271771","The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer","Wilt TJ.","J Natl Cancer Inst Monogr. 2012 Dec;2012(45):184-90. doi: 10.1093/jncimonographs/lgs041.","Wilt TJ","J Natl Cancer Inst Monogr","2012","2012/12/29","PMC3540866","","10.1093/jncimonographs/lgs041"
"26223224","Should docetaxel be administered earlier in prostate cancer therapy?","Graff JN, Beer TM.","Expert Rev Anticancer Ther. 2015;15(9):977-9. doi: 10.1586/14737140.2015.1074042. Epub 2015 Jul 29.","Graff JN","Expert Rev Anticancer Ther","2015","2015/07/31","","","10.1586/14737140.2015.1074042"
"24686772","Prostate cancer diagnosis through electronic nose in the urine headspace setting: a pilot study","Asimakopoulos AD, Del Fabbro D, Miano R, Santonico M, Capuano R, Pennazza G, D'Amico A, Finazzi-Agrò E.","Prostate Cancer Prostatic Dis. 2014 Jun;17(2):206-11. doi: 10.1038/pcan.2014.11. Epub 2014 Apr 1.","Asimakopoulos AD","Prostate Cancer Prostatic Dis","2014","2014/04/02","","","10.1038/pcan.2014.11"
"29588305","Appendicitis before Age 20 Years Is Associated with an Increased Risk of Later Prostate Cancer","Ugge H, Udumyan R, Carlsson J, Davidsson S, Andrén O, Montgomery S, Fall K.","Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):660-664. doi: 10.1158/1055-9965.EPI-17-1204. Epub 2018 Mar 27.","Ugge H","Cancer Epidemiol Biomarkers Prev","2018","2018/03/29","","","10.1158/1055-9965.EPI-17-1204"
"22254011","Assessment of information to substantiate a health claim on the prevention of prostate cancer by lignans","Saarinen NM, Tuominen J, Pylkkänen L, Santti R.","Nutrients. 2010 Feb;2(2):99-115. doi: 10.3390/nu2020099. Epub 2010 Jan 28.","Saarinen NM","Nutrients","2010","2012/01/19","PMC3257165","","10.3390/nu2020099"
"23297498","[Onset age and pathology of prostate cancer in Uygurs and Hans in Xinjiang]","Wang F, Wang J, Huang M, Wang WG, Baihetiya A, Wang YJ.","Zhonghua Nan Ke Xue. 2012 Oct;18(10):900-3.","Wang F","Zhonghua Nan Ke Xue","2012","2013/01/10","","",""
"12907647","Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes","Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM.","Cancer Res. 2003 Aug 1;63(15):4662-70.","Shariat SF","Cancer Res","2003","2003/08/09","","",""
"24018805","Intraductal carcinoma of the prostate: the whole story","Zhou M.","Pathology. 2013 Oct;45(6):533-9. doi: 10.1097/PAT.0b013e3283653322.","Zhou M","Pathology","2013","2013/09/11","","","10.1097/PAT.0b013e3283653322"
"17651536","Attitudes of prostate cancer patients towards the diagnosis and treatment of their disease: findings from a multinational survey","Hardy C, Penn S, Morris T.","Curr Med Res Opin. 2007 Sep;23(9):2107-16. doi: 10.1185/030079907X223800.","Hardy C","Curr Med Res Opin","2007","2007/07/27","","","10.1185/030079907X223800"
"22421313","Prostate cancer stem cells","Tu SM, Lin SH.","Clin Genitourin Cancer. 2012 Jun;10(2):69-76. doi: 10.1016/j.clgc.2012.01.002. Epub 2012 Mar 14.","Tu SM","Clin Genitourin Cancer","2012","2012/03/17","PMC4141775","NIHMS615124","10.1016/j.clgc.2012.01.002"
"27080346","PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment","Cattaneo GM, Bettinardi V, Mapelli P, Picchio M.","Phys Med. 2016 Mar;32(3):452-8. doi: 10.1016/j.ejmp.2016.02.013. Epub 2016 Apr 11.","Cattaneo GM","Phys Med","2016","2016/04/16","","","10.1016/j.ejmp.2016.02.013"
"29989584","[Effect of Sodium Selenite on Gene Expression of SELF, SELW, and TGR Selenoproteins in Adenocarcinoma Cells of the Human Prostate]","Varlamova EG, Goltyaev MV, Kuznetsova JP.","Mol Biol (Mosk). 2018 May-Jun;52(3):519-526. doi: 10.7868/S0026898418030151.","Varlamova EG","Mol Biol (Mosk)","2018","2018/07/11","","","10.7868/S0026898418030151"
"17763221","Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies","Rydén L, Egevad L, Ekman P, Hellström M.","Scand J Urol Nephrol. 2007;41(4):302-7. doi: 10.1080/00365590601183634.","Rydén L","Scand J Urol Nephrol","2007","2007/09/01","","","10.1080/00365590601183634"
"17338250","[Radioisotope lymphoscintigraphy used for precise diagnosis of metastatic lymph node involvement in localized and locally advanced prostate cancer]","Rusakov IG, Alekseev BIa, Niushko KM, Frank GA, Belova EA, Bespalov PD, Vorob'ëv NV, Poliakov VA.","Vopr Onkol. 2006;52(6):686-90.","Rusakov IG","Vopr Onkol","2006","2007/03/07","","",""
"18554779","Molecular alterations in prostate cancer","Reynolds MA.","Cancer Lett. 2008 Nov 18;271(1):13-24. doi: 10.1016/j.canlet.2008.04.047. Epub 2008 Jun 12.","Reynolds MA","Cancer Lett","2008","2008/06/17","","","10.1016/j.canlet.2008.04.047"
"31567434","Optimizing prostate biopsy techniques","Omer A, Lamb AD.","Curr Opin Urol. 2019 Nov;29(6):578-586. doi: 10.1097/MOU.0000000000000678.","Omer A","Curr Opin Urol","2019","2019/10/01","","","10.1097/MOU.0000000000000678"
"7974946","Rare incidence of human papillomavirus types 16 and 18 in primary and metastatic human prostate cancer","Tu H, Jacobs SC, Mergner WJ, Kyprianou N.","Urology. 1994 Nov;44(5):726-31. doi: 10.1016/s0090-4295(94)80215-7.","Tu H","Urology","1994","1994/11/01","","","10.1016/s0090-4295(94)80215-7"
"30177389","Androgen receptor suppresses prostate cancer cell invasion via altering the miR-4496/β-catenin signals","Wang RF, Wang ZF, Cheng Q, Wang GR, Bai ZM.","Biochem Biophys Res Commun. 2018 Sep 26;504(1):82-88. doi: 10.1016/j.bbrc.2018.08.134. Epub 2018 Sep 1.","Wang RF","Biochem Biophys Res Commun","2018","2018/09/05","","","10.1016/j.bbrc.2018.08.134"
"28688020","Salvage Therapy Options for Local Prostate Cancer Recurrence After Primary Radiotherapy: a Literature Review","Golbari NM, Katz AE.","Curr Urol Rep. 2017 Aug;18(8):63. doi: 10.1007/s11934-017-0709-4.","Golbari NM","Curr Urol Rep","2017","2017/07/09","","","10.1007/s11934-017-0709-4"
"4472686","[Bone scintigram of the aged. 3. Bone scanning of 17 cases of prostate cancer: evaluation and comparison with radiographic findings]","Irikura H, Chiba K, Matsui K, Yamada H, Oishi Y.","Kaku Igaku. 1974 Apr;11(2):97-109.","Irikura H","Kaku Igaku","1974","1974/04/01","","",""
"4432963","Radiation therapy and pelvic node dissection in the management of cancer of the prostate","Hilaris BS, Whitmore WF Jr, Batata MA, Grabstald H.","Am J Roentgenol Radium Ther Nucl Med. 1974 Aug;121(4):832-8. doi: 10.2214/ajr.121.4.832.","Hilaris BS","Am J Roentgenol Radium Ther Nucl Med","1974","1974/08/01","","","10.2214/ajr.121.4.832"
"22782583","Meta-analysis of epidemiological studies demonstrates significant association of PTGS2 polymorphism rs689470 and no significant association of rs20417 with prostate cancer","Zhang HT, Xu Y, Zhang ZH, Li L.","Genet Mol Res. 2012 Jun 15;11(2):1642-50. doi: 10.4238/2012.June.15.13.","Zhang HT","Genet Mol Res","2012","2012/07/12","","","10.4238/2012.June.15.13"
"11096233","Prognostic significance of neuroendocrine differentiation in prostate cancer","Ather MH, Abbas F.","Eur Urol. 2000 Nov;38(5):535-42. doi: 10.1159/000020352.","Ather MH","Eur Urol","2000","2000/11/30","","","10.1159/000020352"
"31206668","Development of a predictive model for stromal content in prostate cancer samples to improve signature performance","Boufaied N, Takhar M, Nash C, Erho N, Bismar TA, Davicioni E, Thomson AA.","J Pathol. 2019 Dec;249(4):411-424. doi: 10.1002/path.5315. Epub 2019 Oct 16.","Boufaied N","J Pathol","2019","2019/06/18","PMC6900085","","10.1002/path.5315"
"14511065","Active surveillance: an individualized approach to early prostate cancer","Klotz L.","BJU Int. 2003 Oct;92(6):657. doi: 10.1046/j.1464-410x.2003.t01-7-04442.x.","Klotz L","BJU Int","2003","2003/09/27","","","10.1046/j.1464-410x.2003.t01-7-04442.x"
"7530163","Detection of prostate cancer","Collins JP.","CMAJ. 1995 Feb 1;152(3):328-9.","Collins JP","CMAJ","1995","1995/02/01","PMC1337524","",""
"23136314","Patient perspective on watchful waiting/active surveillance for localized prostate cancer","Xu J, Neale AV, Dailey RK, Eggly S, Schwartz KL.","J Am Board Fam Med. 2012 Nov-Dec;25(6):763-70. doi: 10.3122/jabfm.2012.06.120128.","Xu J","J Am Board Fam Med","2012","2012/11/09","PMC4212643","NIHMS635726","10.3122/jabfm.2012.06.120128"
"24647879","Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT","Verma V, Chen L, Michalski JM, Hu Y, Zhang W, Robinson K, Verma S, Eschen L, Fergus S, Mullen D, Strope S, Grubb R 3rd, Gay HA.","World J Urol. 2015 Jan;33(1):69-75. doi: 10.1007/s00345-014-1269-6. Epub 2014 Mar 20.","Verma V","World J Urol","2015","2014/03/21","","","10.1007/s00345-014-1269-6"
"6198553","[Morphological and hormonal diagnosis of prostate cancer]","Minkov N, Kumanov Kh, Tsvetkov M, Topov Ia, Maleeva A.","Khirurgiia (Sofiia). 1983;36(3):249-51.","Minkov N","Khirurgiia (Sofiia)","1983","1983/01/01","","",""
"27803045","Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk","Yin Y, Zhang Q, Zhang H, He Y, Huang J.","Clin Cancer Res. 2017 Jan 1;23(1):6-8. doi: 10.1158/1078-0432.CCR-16-2400. Epub 2016 Nov 1.","Yin Y","Clin Cancer Res","2017","2016/11/03","PMC5215130","NIHMS827159","10.1158/1078-0432.CCR-16-2400"
"9741413","The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer","Pannek J, Partin AW.","Semin Urol Oncol. 1998 Aug;16(3):100-5.","Pannek J","Semin Urol Oncol","1998","1998/09/19","","",""
"31808627","[Prostate cancer and dogs sense of smell: opportunities of noninvasive diagnostics]","Protoshhak VV, Andreev EA, Karpushhenko EG, Slepcov AV, Ovchinnikov DV, Alentev SA, Lazutkin MV, Mamaenko AV, Mamaenko TV.","Urologiia. 2019 Dec;(5):22-26.","Protoshhak VV","Urologiia","2019","2019/12/07","","",""
"26897720","Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities","Evans-Axelsson S, Timmermand OV, Bjartell A, Strand SE, Elgqvist J.","Semin Nucl Med. 2016 Mar;46(2):165-79. doi: 10.1053/j.semnuclmed.2015.10.005.","Evans-Axelsson S","Semin Nucl Med","2016","2016/02/22","","","10.1053/j.semnuclmed.2015.10.005"
"22009027","Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles","Bermudo R, Abia D, Mozos A, García-Cruz E, Alcaraz A, Ortiz AR, Thomson TM, Fernández PL.","Br J Cancer. 2011 Nov 8;105(10):1600-7. doi: 10.1038/bjc.2011.435. Epub 2011 Oct 18.","Bermudo R","Br J Cancer","2011","2011/10/20","PMC3242534","","10.1038/bjc.2011.435"
"15519769","Is prostate cancer like lung cancer?","Sandler HM.","Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1016-7. doi: 10.1016/j.ijrobp.2004.05.020.","Sandler HM","Int J Radiat Oncol Biol Phys","2004","2004/11/03","","","10.1016/j.ijrobp.2004.05.020"
"31492437","The evolving role of external beam radiotherapy in localized prostate cancer","Greco C, Vazirani AA, Pares O, Pimentel N, Louro V, Morales J, Nunes B, Vasconcelos AL, Antunes I, Kociolek J, Fuks Z.","Semin Oncol. 2019 Jun;46(3):246-253. doi: 10.1053/j.seminoncol.2019.08.001. Epub 2019 Aug 22.","Greco C","Semin Oncol","2019","2019/09/08","","","10.1053/j.seminoncol.2019.08.001"
"19806465","Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort","Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA.","Cancer Causes Control. 2010 Jan;21(1):61-8. doi: 10.1007/s10552-009-9434-8. Epub 2009 Oct 6.","Mondul AM","Cancer Causes Control","2010","2009/10/07","PMC3004752","NIHMS257643","10.1007/s10552-009-9434-8"
"28445145","Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness","Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J.","Oncotarget. 2017 Jul 18;8(29):47110-47120. doi: 10.18632/oncotarget.16943.","Schnoeller TJ","Oncotarget","2017","2017/04/27","PMC5564548","","10.18632/oncotarget.16943"
"17881151","Early prostate cancer: hedonic prices model of provider-patient interactions and decisions","Jani AB, Hellman S.","Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1158-68. doi: 10.1016/j.ijrobp.2007.07.2349. Epub 2007 Sep 19.","Jani AB","Int J Radiat Oncol Biol Phys","2008","2007/09/21","","","10.1016/j.ijrobp.2007.07.2349"
"24061634","Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men","Hughes L, Ruth K, Rebbeck TR, Giri VN.","Prostate Cancer Prostatic Dis. 2013 Dec;16(4):308-14. doi: 10.1038/pcan.2013.36. Epub 2013 Sep 24.","Hughes L","Prostate Cancer Prostatic Dis","2013","2013/09/25","PMC3865712","NIHMS529046","10.1038/pcan.2013.36"
"29146557","Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR","Gacci M, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.","Eur Urol Focus. 2017 Oct;3(4-5):321-324. doi: 10.1016/j.euf.2017.10.009. Epub 2017 Nov 13.","Gacci M","Eur Urol Focus","2017","2017/11/18","","","10.1016/j.euf.2017.10.009"
"12854876","Clinical outcome of patients with stage T1a prostate cancer","Chen WM, Yang CR, Ou YC, Cheng CL, Kao YL, Ho HC, Su CK, Chiu KY, Chen JT.","J Chin Med Assoc. 2003 Apr;66(4):236-40.","Chen WM","J Chin Med Assoc","2003","2003/07/12","","",""
"27659411","The use of (68 ) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer","Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.","BJU Int. 2016 Oct;118 Suppl 3:49-55. doi: 10.1111/bju.13616. Epub 2016 Sep 23.","Meredith G","BJU Int","2016","2016/09/24","","","10.1111/bju.13616"
"10617870","Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients","Guo Y, Sigman DB, Borkowski A, Kyprianou N.","Prostate. 2000 Feb 1;42(2):130-6. doi: 10.1002/(sici)1097-0045(20000201)42:2<130::aid-pros7>3.0.co;2-3.","Guo Y","Prostate","2000","2000/01/05","","","10.1002/(sici)1097-0045(20000201)42:2<130::aid-pros7>3.0.co;2-3"
"10037436","Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial","Walsh PC.","J Urol. 1999 Jan;161(1):350-1. doi: 10.1016/s0022-5347(01)62145-1.","Walsh PC","J Urol","1999","1999/02/26","","","10.1016/s0022-5347(01)62145-1"
"8416407","Disease-specific survival following routine prostate cancer screening by digital rectal examination","Gerber GS, Thompson IM, Thisted R, Chodak GW.","JAMA. 1993 Jan 6;269(1):61-4.","Gerber GS","JAMA","1993","1993/01/06","","",""
"12773232","Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience","Pether M, Goldenberg SL, Bhagirath K, Gleave M.","Can J Urol. 2003 Apr;10(2):1809-14.","Pether M","Can J Urol","2003","2003/05/30","","",""
"21414514","Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06","Valicenti RK, Bae K, Michalski J, Sandler H, Shipley W, Lin A, Cox J.","Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1323-9. doi: 10.1016/j.ijrobp.2010.01.009.","Valicenti RK","Int J Radiat Oncol Biol Phys","2011","2011/03/19","","","10.1016/j.ijrobp.2010.01.009"
"11564273","Rising prostate specific antigen after radical prostatectomy: a case based review","Nasr R, Goldenberg SL.","Can J Urol. 2001 Aug;8(4):1306-13.","Nasr R","Can J Urol","2001","2001/09/21","","",""
"30016891","The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection","Ploussard G, de la Taille A.","Expert Rev Anticancer Ther. 2018 Oct;18(10):1013-1020. doi: 10.1080/14737140.2018.1502086. Epub 2018 Jul 26.","Ploussard G","Expert Rev Anticancer Ther","2018","2018/07/19","","","10.1080/14737140.2018.1502086"
"20155615","Lycopene effects contributing to prostate health","Wertz K.","Nutr Cancer. 2009;61(6):775-83. doi: 10.1080/01635580903285023.","Wertz K","Nutr Cancer","2009","2010/02/16","","","10.1080/01635580903285023"
"18478158","Mass screening-based case-control study of diet and prostate cancer in Changchun, China","Li XM, Li J, Tsuji I, Nakaya N, Nishino Y, Zhao XJ.","Asian J Androl. 2008 Jul;10(4):551-60. doi: 10.1111/j.1745-7262.2008.00384.x.","Li XM","Asian J Androl","2008","2008/05/15","","","10.1111/j.1745-7262.2008.00384.x"
"19588206","The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT","Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W.","Mol Imaging Biol. 2010 Jan-Feb;12(1):98-107. doi: 10.1007/s11307-009-0239-7. Epub 2009 Jul 9.","Beheshti M","Mol Imaging Biol","2010","2009/07/10","","","10.1007/s11307-009-0239-7"
"22112489","Molecular pathology of prostate cancer","Cazares LH, Drake RR, Esquela-Kirscher A, Lance RS, Semmes OJ, Troyer DA.","Cancer Biomark. 2010;9(1-6):441-59. doi: 10.3233/CBM-2011-0181.","Cazares LH","Cancer Biomark","2010","2011/11/25","","","10.3233/CBM-2011-0181"
"15966843","What can proteomic analyses contribute to understanding the molecular biology and clinical behavior of prostate cancer?","Ware JL.","Expert Rev Proteomics. 2004 Dec;1(4):485-92. doi: 10.1586/14789450.1.4.485.","Ware JL","Expert Rev Proteomics","2004","2005/06/22","","","10.1586/14789450.1.4.485"
"18687518","Re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun, et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008;54:794-804","Bogdanovic J, Sekulic V.","Eur Urol. 2008 Oct;54(4):955-6. doi: 10.1016/j.eururo.2008.07.060. Epub 2008 Aug 3.","Bogdanovic J","Eur Urol","2008","2008/08/09","","","10.1016/j.eururo.2008.07.060"
"11204267","Diagnosis and management of incidental ureterocele during the treatment of clinically localized prostate cancer","Leventis AK, Miles BJ, Gonzales ET, Slawin KM Jr.","World J Urol. 2000 Dec;18(6):444-8. doi: 10.1007/s003459900080.","Leventis AK","World J Urol","2000","2001/02/24","","","10.1007/s003459900080"
"8944510","Influence of transurethral resection on sexual dysfunction in patients with prostate cancer","Bieri S, Miralbell R, Rohner S, Kurtz J.","Br J Urol. 1996 Oct;78(4):537-41. doi: 10.1046/j.1464-410x.1996.01478.x.","Bieri S","Br J Urol","1996","1996/10/01","","","10.1046/j.1464-410x.1996.01478.x"
"19616157","Risk factors, prevention and early detection of prostate cancer","Loeb S, Schaeffer EM.","Prim Care. 2009 Sep;36(3):603-21. doi: 10.1016/j.pop.2009.04.007.","Loeb S","Prim Care","2009","2009/07/21","","","10.1016/j.pop.2009.04.007"
"9805508","Systemic treatment for prostate cancer","Dowling AJ, Tannock IF.","Cancer Treat Rev. 1998 Aug;24(4):283-301. doi: 10.1016/s0305-7372(98)90062-7.","Dowling AJ","Cancer Treat Rev","1998","1998/11/07","","","10.1016/s0305-7372(98)90062-7"
"30160988","Reproducibility of Index Lesion Size and Mean Apparent Diffusion Coefficient Values Measured by Prostate Multiparametric MRI: Correlation With Whole-Mount Sectioning of Specimens","Diaz de Leon A, Leyendecker JR, Otero-Muinelo S, Grewal H, Xi Y, Francis F, Pedrosa I, Costa DN.","AJR Am J Roentgenol. 2018 Oct;211(4):783-788. doi: 10.2214/AJR.17.19172. Epub 2018 Aug 30.","Diaz de Leon A","AJR Am J Roentgenol","2018","2018/08/31","","","10.2214/AJR.17.19172"
"18791337","The incidence of lymph node metastases in prostate carcinoma depends not only on tumor characteristics but also on surgical performance and extent of pelvic lymphadenectomy","Klevecka V, Musch M, Roggenbuck U, Stoerkel S, Kroepfl D.","Medicina (Kaunas). 2008;44(8):601-8.","Klevecka V","Medicina (Kaunas)","2008","2008/09/16","","",""
"15386391","Identification of differentially methylated CpG islands in prostate cancer","Yamada Y, Toyota M, Hirokawa Y, Suzuki H, Takagi A, Matsuzaki T, Sugimura Y, Yatani R, Shiraishi T, Watanabe M.","Int J Cancer. 2004 Dec 10;112(5):840-5. doi: 10.1002/ijc.20335.","Yamada Y","Int J Cancer","2004","2004/09/24","","","10.1002/ijc.20335"
"25601201","The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian Prostate Cancer Registry","Weerakoon M, Papa N, Lawrentschuk N, Evans S, Millar J, Frydenberg M, Bolton D, Murphy DG.","BJU Int. 2015 Apr;115 Suppl 5:50-6. doi: 10.1111/bju.13049.","Weerakoon M","BJU Int","2015","2015/01/21","","","10.1111/bju.13049"
"18382236","Focal therapy for prostate cancer","Polascik TJ, Mouraviev V.","Curr Opin Urol. 2008 May;18(3):269-74. doi: 10.1097/MOU.0b013e3282f9b3a5.","Polascik TJ","Curr Opin Urol","2008","2008/04/03","","","10.1097/MOU.0b013e3282f9b3a5"
"22182303","Supervised regularized canonical correlation analysis: integrating histologic and proteomic measurements for predicting biochemical recurrence following prostate surgery","Golugula A, Lee G, Master SR, Feldman MD, Tomaszewski JE, Speicher DW, Madabhushi A.","BMC Bioinformatics. 2011 Dec 19;12:483. doi: 10.1186/1471-2105-12-483.","Golugula A","BMC Bioinformatics","2011","2011/12/21","PMC3267835","","10.1186/1471-2105-12-483"
"21837778","Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts","Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT.","Prostate. 2012 May 1;72(6):638-48. doi: 10.1002/pros.21467. Epub 2011 Aug 11.","Dalrymple SL","Prostate","2012","2011/08/13","PMC4086682","NIHMS455517","10.1002/pros.21467"
"2579498","Prostate cancer: experience with definitive irradiation in the aged","Green N, Bodner H, Broth E.","Urology. 1985 Mar;25(3):228-32. doi: 10.1016/0090-4295(85)90317-6.","Green N","Urology","1985","1985/03/01","","","10.1016/0090-4295(85)90317-6"
"31263949","Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis","Zhou X, Jiao D, Dou M, Chen J, Li Z, Li Y, Liu J, Han X.","J Cancer Res Clin Oncol. 2019 Aug;145(8):1939-1948. doi: 10.1007/s00432-019-02962-8. Epub 2019 Jul 1.","Zhou X","J Cancer Res Clin Oncol","2019","2019/07/03","","","10.1007/s00432-019-02962-8"
"21778786","P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype","Rogler A, Rogenhofer M, Borchardt A, Lunz JC, Knoell A, Hofstaedter F, Tannapfel A, Wieland W, Hartmann A, Stoehr R.","Pathobiology. 2011;78(4):193-200. doi: 10.1159/000326767. Epub 2011 Jul 19.","Rogler A","Pathobiology","2011","2011/07/23","","","10.1159/000326767"
"18544987","Radiotherapy in lymph node-positive prostate cancer patients - a potential cure? Single institutional experience regarding outcome and side effects","Goldner G, Pötter R.","Front Radiat Ther Oncol. 2008;41:68-76. doi: 10.1159/000139880.","Goldner G","Front Radiat Ther Oncol","2008","2008/06/12","","","10.1159/000139880"
"25547974","The role of extended pelvic lymphadenectomy with radical prostatectomy for high-risk prostate cancer","Harbin AC, Eun DD.","Urol Oncol. 2015 May;33(5):208-16. doi: 10.1016/j.urolonc.2014.11.011. Epub 2014 Dec 26.","Harbin AC","Urol Oncol","2015","2014/12/31","","","10.1016/j.urolonc.2014.11.011"
"16847528","Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan","Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T, Hara N.","Asian J Androl. 2006 Sep;8(5):555-61. doi: 10.1111/j.1745-7262.2006.00175.x.","Saito T","Asian J Androl","2006","2006/07/19","","","10.1111/j.1745-7262.2006.00175.x"
"15245825","Letter to the Editor; Re: Wirth MP, Weissbach L, Marx F-J, Heckl W, Jellinghaus W, Riedmiller H, Noack B, Hinke A, Froehner M. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 2004;45:267-70","Rocco B, Matei DV, de Cobelli O, Rocco F.","Eur Urol. 2004 Aug;46(2):272-3; author reply 273. doi: 10.1016/j.eururo.2004.03.019.","Rocco B","Eur Urol","2004","2004/07/13","","","10.1016/j.eururo.2004.03.019"
"9523663","Free/total serum prostate-specific antigen ratio: how helpful is it in detecting prostate cancer?","Masters JG, Keegan PE, Hildreth AJ, Greene DR.","Br J Urol. 1998 Mar;81(3):419-23. doi: 10.1046/j.1464-410x.1998.00566.x.","Masters JG","Br J Urol","1998","1998/04/02","","","10.1046/j.1464-410x.1998.00566.x"
"30031416","Multiparametric MRI: An Opportunity for Focal Therapy of Prostate Cancer","Calio B, Kasson M, Sugano D, Ortman M, Gaitonde K, Verma S, Sidana A.","Semin Roentgenol. 2018 Jul;53(3):227-233. doi: 10.1053/j.ro.2018.04.007. Epub 2018 Jun 6.","Calio B","Semin Roentgenol","2018","2018/07/23","","","10.1053/j.ro.2018.04.007"
"23859763","Effects of radiation on the incidence of prostate cancer among Nagasaki atomic bomb survivors","Kondo H, Soda M, Mine M, Yokota K.","Cancer Sci. 2013 Oct;104(10):1368-71. doi: 10.1111/cas.12234. Epub 2013 Aug 12.","Kondo H","Cancer Sci","2013","2013/07/18","","","10.1111/cas.12234"
"27734724","Prostate cancer imaging: a special focus issue from Future Oncology","Turkbey B, Choyke PL.","Future Oncol. 2016 Nov;12(21):2389-2391. doi: 10.2217/fon-2016-0396.","Turkbey B","Future Oncol","2016","2016/10/14","","","10.2217/fon-2016-0396"
"17644119","Bone directed therapies for prostate cancer","Bradley DA, Hussain M, Dipaola RS, Kantoff P.","J Urol. 2007 Sep;178(3 Pt 2):S42-8. doi: 10.1016/j.juro.2007.04.035. Epub 2007 Jul 20.","Bradley DA","J Urol","2007","2007/07/24","","","10.1016/j.juro.2007.04.035"
"24761887","Counts of Slackia sp. strain NATTS in intestinal flora are correlated to serum concentrations of equol both in prostate cancer cases and controls in Japanese men","Sugiyama Y, Nagata Y, Fukuta F, Takayanagi A, Masumori N, Tsukamoto T, Akasaka H, Ohnishi H, Saito S, Miura T, Moriyama K, Tsuji H, Akaza H, Mori M.","Asian Pac J Cancer Prev. 2014;15(6):2693-7. doi: 10.7314/apjcp.2014.15.6.2693.","Sugiyama Y","Asian Pac J Cancer Prev","2014","2014/04/26","","","10.7314/apjcp.2014.15.6.2693"
"18489508","Factors associated with variation in utility scores among patients with prostate cancer","Shimizu F, Fujino K, Ito YM, Fukuda T, Kawachi Y, Minowada S, Fujime M, Ohashi Y.","Value Health. 2008 Dec;11(7):1190-3. doi: 10.1111/j.1524-4733.2008.00336.x. Epub 2008 May 16.","Shimizu F","Value Health","2008","2008/05/21","","","10.1111/j.1524-4733.2008.00336.x"
"8929102","[Screening of cancer of the prostate: study in a Spanish population]","Herrero Payo JA, Montes Díaz MJ, Páez Borda A, Sánchez Sánchez E, Moreno Valle JA, Berenguer Sánchez A.","Arch Esp Urol. 1996 Jul-Aug;49(6):595-606.","Herrero Payo JA","Arch Esp Urol","1996","1996/07/01","","",""
"21305569","Muscle endurance, cancer-related fatigue, and radiotherapy in prostate cancer survivors","Alt CA, Gore EM, Montagnini ML, Ng AV.","Muscle Nerve. 2011 Mar;43(3):415-24. doi: 10.1002/mus.21913. Epub 2011 Feb 8.","Alt CA","Muscle Nerve","2011","2011/02/10","","","10.1002/mus.21913"
"12072787","Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation","Caglar M, Tuncel M.","Clin Nucl Med. 2002 Jul;27(7):532-3. doi: 10.1097/00003072-200207000-00017.","Caglar M","Clin Nucl Med","2002","2002/06/20","","","10.1097/00003072-200207000-00017"
"14709176","Identification of androgen-coregulated protein networks from the microsomes of human prostate cancer cells","Wright ME, Eng J, Sherman J, Hockenbery DM, Nelson PS, Galitski T, Aebersold R.","Genome Biol. 2003;5(1):R4. doi: 10.1186/gb-2003-5-1-r4. Epub 2003 Dec 23.","Wright ME","Genome Biol","2003","2004/01/08","PMC395736","","10.1186/gb-2003-5-1-r4"
"18821471","Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more","Dieli F, Caccamo N, Meraviglia S.","Curr Opin Investig Drugs. 2008 Oct;9(10):1089-94.","Dieli F","Curr Opin Investig Drugs","2008","2008/09/30","","",""
"31540470","Plant Bioactives and the Prevention of Prostate Cancer: Evidence from Human Studies","Livingstone TL, Beasy G, Mills RD, Plumb J, Needs PW, Mithen R, Traka MH.","Nutrients. 2019 Sep 18;11(9):2245. doi: 10.3390/nu11092245.","Livingstone TL","Nutrients","2019","2019/09/22","PMC6769996","","10.3390/nu11092245"
"24430169","Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer","Rais-Bahrami S, Turkbey B, Grant KB, Pinto PA, Choyke PL.","Curr Urol Rep. 2014 Mar;15(3):387. doi: 10.1007/s11934-013-0387-9.","Rais-Bahrami S","Curr Urol Rep","2014","2014/01/17","","","10.1007/s11934-013-0387-9"
"29767237","A novel anti‑proliferative pentapeptide (ILYMP) isolated from Cyclina sinensis protein hydrolysate induces apoptosis of DU‑145 prostate cancer cells","Yu F, Zhang Y, Ye L, Tang Y, Ding G, Zhang X, Yang Z.","Mol Med Rep. 2018 Jul;18(1):771-778. doi: 10.3892/mmr.2018.9019. Epub 2018 May 14.","Yu F","Mol Med Rep","2018","2018/05/17","PMC6059706","","10.3892/mmr.2018.9019"
"24002132","Prostate cancer treatment modalities and survival outcomes: a comparative analysis of Falmouth Hospital versus Massachusetts and nationwide hospitals","Shimer SE.","J Registry Manag. 2013 Summer;40(2):78-83.","Shimer SE","J Registry Manag","2013","2013/09/05","","",""
"24100277","Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells","Kim Y, Jeong IG, You D, Song SH, Suh N, Jang SW, Kim S, Hwang JJ, Kim CS.","Anticancer Drugs. 2014 Jan;25(1):53-62. doi: 10.1097/CAD.0000000000000013.","Kim Y","Anticancer Drugs","2014","2013/10/09","","","10.1097/CAD.0000000000000013"
"9144893","Role of proteoglycans in cell adhesion of prostate cancer cells: from review to experiment","Schamhart DH, Kurth KH.","Urol Res. 1997;25 Suppl 2:S89-96. doi: 10.1007/BF00941994.","Schamhart DH","Urol Res","1997","1997/01/01","","","10.1007/BF00941994"
"18578523","Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers","Sardana G, Jung K, Stephan C, Diamandis EP.","J Proteome Res. 2008 Aug;7(8):3329-38. doi: 10.1021/pr8003216. Epub 2008 Jun 26.","Sardana G","J Proteome Res","2008","2008/06/27","","","10.1021/pr8003216"
"15550959","[Dissemination of evidence-based information about PSA test and prostatic cancer to physicians]","Norderhaug IN, Wisløff T, Fosså S, Sandberg S, Malde K, Forland F, Førde OH.","Tidsskr Nor Laegeforen. 2004 Nov 18;124(22):2893-5.","Norderhaug IN","Tidsskr Nor Laegeforen","2004","2004/11/20","","",""
"10460402","Examining health-related quality of life in men treated for prostate cancer","Litwin MS.","World J Urol. 1999 Aug;17(4):205-10. doi: 10.1007/s003450050134.","Litwin MS","World J Urol","1999","1999/08/25","","","10.1007/s003450050134"
"24388442","Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30","Sciarra A.","Eur Urol. 2014 Apr;65(4):e57. doi: 10.1016/j.eururo.2013.12.015. Epub 2013 Dec 21.","Sciarra A","Eur Urol","2014","2014/01/07","","","10.1016/j.eururo.2013.12.015"
"25620167","Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises","Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, Montironi R.","J Biol Regul Homeost Agents. 2014 Oct-Dec;28(4):555-63.","Santoni M","J Biol Regul Homeost Agents","2014","2015/01/27","","",""
"30400784","(Cost-)effectiveness of an internet-based physical activity support program (with and without physiotherapy counselling) on physical activity levels of breast and prostate cancer survivors: design of the PABLO trial","van de Wiel HJ, Stuiver MM, May AM, van Grinsven S, Aaronson NK, Retèl VP, Oldenburg HSA, van der Poel HG, Horenblas S, van Harten WH, Groen WG.","BMC Cancer. 2018 Nov 6;18(1):1073. doi: 10.1186/s12885-018-4927-z.","van de Wiel HJ","BMC Cancer","2018","2018/11/08","PMC6220515","","10.1186/s12885-018-4927-z"
"31515155","Targeting lineage plasticity in prostate cancer","Antonarakis ES.","Lancet Oncol. 2019 Oct;20(10):1338-1340. doi: 10.1016/S1470-2045(19)30497-8. Epub 2019 Sep 9.","Antonarakis ES","Lancet Oncol","2019","2019/09/14","","","10.1016/S1470-2045(19)30497-8"
"15641481","Facing erectile dysfunction due to prostate cancer treatment: perspectives of men and their partners","Boehmer U, Babayan RK.","Cancer Invest. 2004;22(6):840-8. doi: 10.1081/cnv-200039641.","Boehmer U","Cancer Invest","2004","2005/01/12","","","10.1081/cnv-200039641"
"9076477","Application of self-expanding stents in prostate cancer with rectal involvement. Report of two cases and review of the literature","Lujan M, Llorente C, Romero I, Pinto I, Lobato RF, Zarate E, Berenguer A.","Eur Urol. 1997;31(2):251-3. doi: 10.1159/000474461.","Lujan M","Eur Urol","1997","1997/01/01","","","10.1159/000474461"
"10853035","Expression of Lewis carbohydrate antigens and chromogranin A in human prostatic cancer","Mariano A, Di Carlo A, Santonastaso C, Oliva A, D'Armiento M, Macchia V.","Int J Oncol. 2000 Jul;17(1):167-71. doi: 10.3892/ijo.17.1.167.","Mariano A","Int J Oncol","2000","2000/06/15","","","10.3892/ijo.17.1.167"
"24463248","Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era","Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E.","J Natl Cancer Inst. 2014 Feb;106(2):djt430. doi: 10.1093/jnci/djt430. Epub 2014 Jan 24.","Zu K","J Natl Cancer Inst","2014","2014/01/28","PMC3952200","","10.1093/jnci/djt430"
"30194451","A molecular portrait of epithelial-mesenchymal plasticity in prostate cancer associated with clinical outcome","Stylianou N, Lehman ML, Wang C, Fard AT, Rockstroh A, Fazli L, Jovanovic L, Ward M, Sadowski MC, Kashyap AS, Buttyan R, Gleave ME, Westbrook TF, Williams ED, Gunter JH, Nelson CC, Hollier BG.","Oncogene. 2019 Feb;38(7):913-934. doi: 10.1038/s41388-018-0488-5. Epub 2018 Sep 7.","Stylianou N","Oncogene","2019","2018/09/09","PMC6514858","","10.1038/s41388-018-0488-5"
"24012624","Choroidal metastasis secondary to prostatic adenocarcinoma: case report and review of literature","Albadainah F, Khader J, Salah S, Salem A.","Hematol Oncol Stem Cell Ther. 2015 Mar;8(1):34-7. doi: 10.1016/j.hemonc.2013.08.002. Epub 2013 Sep 5.","Albadainah F","Hematol Oncol Stem Cell Ther","2015","2013/09/10","","","10.1016/j.hemonc.2013.08.002"
"12684767","Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium","Richardsen E, Ukkonen T, Bjørnsen T, Mortensen E, Egevad L, Busch C.","Virchows Arch. 2003 Apr;442(4):329-35. doi: 10.1007/s00428-003-0786-2. Epub 2003 Apr 1.","Richardsen E","Virchows Arch","2003","2003/04/10","","","10.1007/s00428-003-0786-2"
"17968996","The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer","Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM.","Cancer. 2008 Jan 1;112(1):55-60. doi: 10.1002/cncr.23139.","Abramowitz MC","Cancer","2008","2007/10/31","","","10.1002/cncr.23139"
"24564711","The proteomics of prostate cancer exosomes","Drake RR, Kislinger T.","Expert Rev Proteomics. 2014 Apr;11(2):167-77. doi: 10.1586/14789450.2014.890894. Epub 2014 Feb 25.","Drake RR","Expert Rev Proteomics","2014","2014/02/26","","","10.1586/14789450.2014.890894"
"9817396","New indications for radical prostatectomy","Schmidt JD, Parsons CL, Doyle J.","J Urol. 1998 Dec;160(6 Pt 2):2425-7. doi: 10.1097/00005392-199812020-00011.","Schmidt JD","J Urol","1998","1998/11/17","","","10.1097/00005392-199812020-00011"
"31629445","Racial disparities in late-stage prostate cancer: a SEER analysis 2005-2015","Rodriguez S, Sparks AD, Zhou H, Amdu RL, Lin J.","Can J Urol. 2019 Oct;26(5):9946-9951.","Rodriguez S","Can J Urol","2019","2019/10/21","","",""
"23278850","Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer","Linder BJ, Boorjian SA, Umbreit EC, Carlson RE, Rangel LJ, Bergstralh EJ, Karnes RJ.","Int J Urol. 2013 Aug;20(8):798-805. doi: 10.1111/iju.12047. Epub 2012 Dec 20.","Linder BJ","Int J Urol","2013","2013/01/03","","","10.1111/iju.12047"
"14606364","Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer","Porter CR, Crawford ED.","Oncology (Williston Park). 2003 Oct;17(10):1395-9; discussion 1399, 1403-6.","Porter CR","Oncology (Williston Park)","2003","2003/11/11","","",""
"27212127","The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study","Wu YS, Zhang N, Liu SH, Xu JF, Tong SJ, Cai YH, Zhang LM, Bai PD, Hu MB, Jiang HW, Na R, Ding Q, Sun YH.","Asian J Androl. 2016 Nov-Dec;18(6):925-929. doi: 10.4103/1008-682X.181192.","Wu YS","Asian J Androl","2016","2016/05/24","PMC5109890","","10.4103/1008-682X.181192"
"15565647","Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis","Kasper S.","J Cell Biochem. 2005 Feb 1;94(2):279-97. doi: 10.1002/jcb.20339.","Kasper S","J Cell Biochem","2005","2004/11/27","","","10.1002/jcb.20339"
"9839522","Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer","Schröder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R.","J Natl Cancer Inst. 1998 Dec 2;90(23):1817-23. doi: 10.1093/jnci/90.23.1817.","Schröder FH","J Natl Cancer Inst","1998","1998/12/05","","","10.1093/jnci/90.23.1817"
"21927983","Androgen receptor footprint on the way to prostate cancer progression","Hodgson MC, Bowden WA, Agoulnik IU.","World J Urol. 2012 Jun;30(3):279-85. doi: 10.1007/s00345-011-0743-7. Epub 2011 Sep 17.","Hodgson MC","World J Urol","2012","2011/09/20","PMC3360873","","10.1007/s00345-011-0743-7"
"25075566","Analysis of the expression of interleukins, interferon β, and nuclear factor-κ B in prostate cancer and their relationship with biochemical recurrence","Eiró N, Bermudez-Fernandez S, Fernandez-Garcia B, Atienza S, Beridze N, Escaf S, Vizoso FJ.","J Immunother. 2014 Sep;37(7):366-73. doi: 10.1097/CJI.0000000000000045.","Eiró N","J Immunother","2014","2014/07/31","","","10.1097/CJI.0000000000000045"
"21144054","Differential expression of anterior gradient gene AGR2 in prostate cancer","Maresh EL, Mah V, Alavi M, Horvath S, Bagryanova L, Liebeskind ES, Knutzen LA, Zhou Y, Chia D, Liu AY, Goodglick L.","BMC Cancer. 2010 Dec 13;10:680. doi: 10.1186/1471-2407-10-680.","Maresh EL","BMC Cancer","2010","2010/12/15","PMC3009682","","10.1186/1471-2407-10-680"
"30489032","Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer","Cheung FY.","Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:13-15. doi: 10.1111/ajco.13061.","Cheung FY","Asia Pac J Clin Oncol","2018","2018/11/30","","","10.1111/ajco.13061"
"22240788","Changes in circulating microRNA levels associated with prostate cancer","Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC.","Br J Cancer. 2012 Feb 14;106(4):768-74. doi: 10.1038/bjc.2011.595. Epub 2012 Jan 12.","Bryant RJ","Br J Cancer","2012","2012/01/14","PMC3322952","","10.1038/bjc.2011.595"
"21554043","Joint genitourinary cancer symposium between Egyptian and American centers","Zaghloul MS.","Expert Rev Anticancer Ther. 2011 May;11(5):697-9. doi: 10.1586/era.11.29.","Zaghloul MS","Expert Rev Anticancer Ther","2011","2011/05/11","","","10.1586/era.11.29"
"9096649","Family history of prostate cancer: a multi-center case-control study in Canada","Ghadirian P, Howe GR, Hislop TG, Maisonneuve P.","Int J Cancer. 1997 Mar 17;70(6):679-81. doi: 10.1002/(sici)1097-0215(19970317)70:6<679::aid-ijc9>3.0.co;2-s.","Ghadirian P","Int J Cancer","1997","1997/03/17","","","10.1002/(sici)1097-0215(19970317)70:6<679::aid-ijc9>3.0.co;2-s"
"20718248","Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversy","Raldow A, Hamstra DA, Kim S, Yu JB.","Oncology (Williston Park). 2010 Jul;24(8):692-700, 702.","Raldow A","Oncology (Williston Park)","2010","2010/08/20","","",""
"30642743","Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells","Dai X, Liu L, Liang Z, Guo K, Xu S, Wang H.","Pathol Res Pract. 2019 Apr;215(4):712-721. doi: 10.1016/j.prp.2019.01.011. Epub 2019 Jan 7.","Dai X","Pathol Res Pract","2019","2019/01/16","","","10.1016/j.prp.2019.01.011"
"23492883","Sentinel lymph node biopsy for prostate cancer: a hybrid approach","van den Berg NS, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW.","J Nucl Med. 2013 Apr;54(4):493-6. doi: 10.2967/jnumed.112.113746. Epub 2013 Mar 14.","van den Berg NS","J Nucl Med","2013","2013/03/16","","","10.2967/jnumed.112.113746"
"27449259","A Whole Blood Assay for AR-V7 and AR(v567es) in Patients with Prostate Cancer","Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, Dong Y, Sartor O, Zhang H.","J Urol. 2016 Dec;196(6):1758-1763. doi: 10.1016/j.juro.2016.06.095. Epub 2016 Jul 20.","Liu X","J Urol","2016","2016/07/25","PMC5161406","NIHMS824907","10.1016/j.juro.2016.06.095"
"24637418","Prostate cancer: eNose--man's new best friend?","Phillips R.","Nat Rev Urol. 2014 Apr;11(4):187. doi: 10.1038/nrurol.2014.69. Epub 2014 Mar 18.","Phillips R","Nat Rev Urol","2014","2014/03/19","","","10.1038/nrurol.2014.69"
"11913649","Prostate cancer","Anderson DW.","Ethn Dis. 2002 Winter;12(1):S2-63-5.","Anderson DW","Ethn Dis","2002","2002/03/27","","",""
"8893633","The changing role of transrectal ultrasound in the diagnosis of prostate cancer","Clements R.","Clin Radiol. 1996 Oct;51(10):671-6. doi: 10.1016/s0009-9260(96)80236-4.","Clements R","Clin Radiol","1996","1996/10/01","","","10.1016/s0009-9260(96)80236-4"
"4594097","Proceedings: The natural history of prostatic cancer","Whitmore WF Jr.","Cancer. 1973 Nov;32(5):1104-12. doi: 10.1002/1097-0142(197311)32:5<1104::aid-cncr2820320515>3.0.co;2-t.","Whitmore WF Jr","Cancer","1973","1973/11/01","","","10.1002/1097-0142(197311)32:5<1104::aid-cncr2820320515>3.0.co;2-t"
"9126229","Prostate-specific antigen as a screening test. The Austrian experience","Reissigl A, Bartsch G.","Urol Clin North Am. 1997 May;24(2):315-21. doi: 10.1016/s0094-0143(05)70378-5.","Reissigl A","Urol Clin North Am","1997","1997/05/01","","","10.1016/s0094-0143(05)70378-5"
"11371940","Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy","Szostak MJ, Kaur P, Amin P, Jacobs SC, Kyprianou N.","J Urol. 2001 Jun;165(6 Pt 1):2126-30. doi: 10.1097/00005392-200106000-00082.","Szostak MJ","J Urol","2001","2001/05/24","","","10.1097/00005392-200106000-00082"
"24914845","[Opportunities and risks of 5α reductase inhibitors in the medical management of Active surveillance for localized prostate cancer]","Linares Espinos E, Carballido Rodriguez J.","Arch Esp Urol. 2014 Jun;67(5):457-61.","Linares Espinos E","Arch Esp Urol","2014","2014/06/11","","",""
"9801090","Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer","Hanlon AL, Hanks GE.","Urology. 1998 Nov;52(5):735-8. doi: 10.1016/s0090-4295(98)00398-7.","Hanlon AL","Urology","1998","1998/11/04","","","10.1016/s0090-4295(98)00398-7"
"20001796","Critical review of prostate cancer predictive tools","Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT.","Future Oncol. 2009 Dec;5(10):1555-84. doi: 10.2217/fon.09.121.","Shariat SF","Future Oncol","2009","2009/12/17","PMC2933457","NIHMS215983","10.2217/fon.09.121"
"18289585","Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer","Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A.","J Urol. 2008 Apr;179(4):1368-73; discussion 1373. doi: 10.1016/j.juro.2007.11.063. Epub 2008 Mar 4.","Zelefsky MJ","J Urol","2008","2008/02/22","PMC2646887","NIHMS53642","10.1016/j.juro.2007.11.063"
"23059047","A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study","Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK.","Lancet Oncol. 2012 Nov;13(11):1105-13. doi: 10.1016/S1470-2045(12)70263-2. Epub 2012 Oct 9.","Ross RW","Lancet Oncol","2012","2012/10/13","","","10.1016/S1470-2045(12)70263-2"
"26077429","DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate","Keil KP, Vezina CM.","Epigenomics. 2015;7(3):413-25. doi: 10.2217/epi.15.8.","Keil KP","Epigenomics","2015","2015/06/17","PMC4500939","NIHMS706076","10.2217/epi.15.8"
"24759588","New developments in the treatment of castration resistant prostate cancer","Wadia R, Petrylak DP.","Asian J Androl. 2014 Jul-Aug;16(4):555-60. doi: 10.4103/1008-682X.127824.","Wadia R","Asian J Androl","2014","2014/04/25","PMC4104080","","10.4103/1008-682X.127824"
"26833820","European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study","Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G, Power R, O'Brien F, O'Malley KJ, Galvin DJ, Brendan Murphy T, William Watson R.","BJU Int. 2016 Nov;118(5):706-713. doi: 10.1111/bju.13437. Epub 2016 Feb 29.","Foley RW","BJU Int","2016","2016/02/03","","","10.1111/bju.13437"
"12639196","An argument against routine prostate cancer screening","Hoffman RM.","Arch Intern Med. 2003 Mar 24;163(6):663-5; discussion 665-6. doi: 10.1001/archinte.163.6.663.","Hoffman RM","Arch Intern Med","2003","2003/03/18","","","10.1001/archinte.163.6.663"
"22777287","Isolated, disseminated and circulating tumour cells in prostate cancer","Schilling D, Todenhöfer T, Hennenlotter J, Schwentner C, Fehm T, Stenzl A.","Nat Rev Urol. 2012 Aug;9(8):448-63. doi: 10.1038/nrurol.2012.136. Epub 2012 Jul 10.","Schilling D","Nat Rev Urol","2012","2012/07/11","","","10.1038/nrurol.2012.136"
"19401683","Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer","Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A.","Br J Cancer. 2009 May 19;100(10):1603-7. doi: 10.1038/sj.bjc.6605058. Epub 2009 Apr 28.","Nilsson J","Br J Cancer","2009","2009/04/30","PMC2696767","","10.1038/sj.bjc.6605058"
"31469635","A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies","Alsinnawi M, Cullen J, Hurwitz LM, Levie KE, Burns JF, Rosner IL, Brand TC, Stroup S, Sterbis JR, Rice K, Conti G, Porter CR.","Can J Urol. 2019 Aug;26(4):9809-9820.","Alsinnawi M","Can J Urol","2019","2019/08/31","","",""
"28391715","Curcumin sensitizes prostate cancer cells to radiation partly via epigenetic activation of miR-143 and miR-143 mediated autophagy inhibition","Liu J, Li M, Wang Y, Luo J.","J Drug Target. 2017 Aug;25(7):645-652. doi: 10.1080/1061186X.2017.1315686. Epub 2017 Apr 20.","Liu J","J Drug Target","2017","2017/04/11","","","10.1080/1061186X.2017.1315686"
"26381851","Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer","De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M.","Future Oncol. 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18.","De Cobelli O","Future Oncol","2015","2015/09/19","PMC5549758","","10.2217/fon.15.249"
"17085120","Comparison of methods for calculating prostate specific antigen velocity","Yu X, Han M, Loeb S, Gashti SN, Yeh JT, Roehl KA, Catalona WJ.","J Urol. 2006 Dec;176(6 Pt 1):2427-31; discussion 2431. doi: 10.1016/j.juro.2006.08.006.","Yu X","J Urol","2006","2006/11/07","","","10.1016/j.juro.2006.08.006"
"28440322","Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?","Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, Moul JW, Polascik TJ.","Prostate Cancer Prostatic Dis. 2017 Sep;20(3):323-327. doi: 10.1038/pcan.2017.20. Epub 2017 Apr 25.","Tay KJ","Prostate Cancer Prostatic Dis","2017","2017/04/26","","","10.1038/pcan.2017.20"
"21071914","Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up","McArdle PA, Qayyum T, McMillan DC.","Urol Int. 2010;85(4):482. doi: 10.1159/000320242. Epub 2010 Nov 13.","McArdle PA","Urol Int","2010","2010/11/13","","","10.1159/000320242"
"9454281","[Prognostic parameters of locally confined prostate carcinoma]","Keuler FU, Almer FM, Altwein JE.","Praxis (Bern 1994). 1997 Nov 12;86(46):1811-4.","Keuler FU","Praxis (Bern 1994)","1997","1998/02/07","","",""
"21537882","Interstitial pneumonitis induced by bicalutamide given for prostate cancer","Masago T, Watanabe T, Nemoto R, Motoda K.","Int J Clin Oncol. 2011 Dec;16(6):763-5. doi: 10.1007/s10147-011-0239-x. Epub 2011 May 3.","Masago T","Int J Clin Oncol","2011","2011/05/04","","","10.1007/s10147-011-0239-x"
"22440684","Re: novel therapies for metastatic castrate-resistant prostate cancer","Sartor O, Parker C.","J Natl Cancer Inst. 2012 May 2;104(9):717; author reply 717. doi: 10.1093/jnci/djs162. Epub 2012 Mar 22.","Sartor O","J Natl Cancer Inst","2012","2012/03/24","","","10.1093/jnci/djs162"
"12415186","Alterations of cell cycle-regulatory genes in prostate cancer","Fernández PL, Hernández L, Farré X, Campo E, Cardesa A.","Pathobiology. 2002;70(1):1-10. doi: 10.1159/000065998.","Fernández PL","Pathobiology","2002","2002/11/05","","","10.1159/000065998"
"7704075","Prostate cancer in Florida: knowledge, attitudes, practices, and beliefs","McCoy CB, Anwyl RS, Metsch LR, Inciardi JA, Smith SA, Correa R.","Cancer Pract. 1995 Mar-Apr;3(2):88-93.","McCoy CB","Cancer Pract","1995","1995/03/01","","",""
"11008904","Serum selenium and subsequent risk of prostate cancer","Nomura AM, Lee J, Stemmermann GN, Combs GF Jr.","Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):883-7.","Nomura AM","Cancer Epidemiol Biomarkers Prev","2000","2000/09/29","","",""
"11549558","Energy restriction in childhood and adolescence and risk of prostate cancer: results from the Netherlands Cohort Study","Dirx MJ, van den Brandt PA, Goldbohm RA, Lumey LH.","Am J Epidemiol. 2001 Sep 15;154(6):530-7. doi: 10.1093/aje/154.6.530.","Dirx MJ","Am J Epidemiol","2001","2001/09/11","","","10.1093/aje/154.6.530"
"18037873","Active surveillance for favorable-risk prostate cancer: who, how and why?","Klotz L.","Nat Clin Pract Oncol. 2007 Dec;4(12):692-8. doi: 10.1038/ncponc0966.","Klotz L","Nat Clin Pract Oncol","2007","2007/11/27","","","10.1038/ncponc0966"
"26495071","Comparison of biochemical recurrence in prostate cancer patients treated with radical prostatectomy or radiotherapy","Kim DS, Jeon SH, Chang SG, Lee SH.","Korean J Urol. 2015 Oct;56(10):703-9. doi: 10.4111/kju.2015.56.10.703. Epub 2015 Oct 2.","Kim DS","Korean J Urol","2015","2015/10/24","PMC4610897","","10.4111/kju.2015.56.10.703"
"9783961","1997 American Urological Association Gallup survey: Changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997","Gee WF, Holtgrewe HL, Blute ML, Miles BJ, Naslund MJ, Nellans RE, O'Leary MP, Thomas R, Painter MR, Meyer JJ, Rohner TJ, Cooper TP, Blizzard R, Fenninger RB, Emmons L.","J Urol. 1998 Nov;160(5):1804-7. doi: 10.1016/s0022-5347(01)62418-2.","Gee WF","J Urol","1998","1998/10/23","","","10.1016/s0022-5347(01)62418-2"
"31266699","[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review]","Kleinclauss F, Frontczak A, Balssa L, Lebdai S, Azzouzi R.","Prog Urol. 2019 Jul-Aug;29(8-9):393-401. doi: 10.1016/j.purol.2019.05.004. Epub 2019 Jun 29.","Kleinclauss F","Prog Urol","2019","2019/07/04","","","10.1016/j.purol.2019.05.004"
"26903562","Investigating the Distribution of Chemical Forms of Sulfur in Prostate Cancer Tissue Using X-ray Absorption Spectroscopy","Czapla-Masztafiak J, Okoń K, Gałka M, Huthwelker T, Kwiatek WM.","Appl Spectrosc. 2016 Feb;70(2):264-71. doi: 10.1177/0003702815620128. Epub 2015 Dec 23.","Czapla-Masztafiak J","Appl Spectrosc","2016","2016/02/24","","","10.1177/0003702815620128"
"27567745","MRI evaluation following partial HIFU therapy for localized prostate cancer: A single-center study","Hoquetis L, Malavaud B, Game X, Beauval JB, Portalez D, Soulie M, Rischmann P.","Prog Urol. 2016 Sep;26(9):517-23. doi: 10.1016/j.purol.2016.07.006. Epub 2016 Aug 24.","Hoquetis L","Prog Urol","2016","2016/08/29","","","10.1016/j.purol.2016.07.006"
"15704001","Magmas expression in neoplastic human prostate","Jubinsky PT, Short MK, Mutema G, Morris RE, Ciraolo GM, Li M.","J Mol Histol. 2005 Feb;36(1-2):69-75. doi: 10.1007/s10735-004-3840-8.","Jubinsky PT","J Mol Histol","2005","2005/02/11","","","10.1007/s10735-004-3840-8"
"30269774","[Pathological assessment of prostate cancer. New problems]","García-González R, Montans Araujo J, García-Navas R.","Rev Esp Patol. 2018 Oct-Dec;51(4):232-238. doi: 10.1016/j.patol.2018.03.006.","García-González R","Rev Esp Patol","2018","2018/10/02","","","10.1016/j.patol.2018.03.006"
"10530605","Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group","Villeneuve PJ, Johnson KC, Kreiger N, Mao Y.","Cancer Causes Control. 1999 Oct;10(5):355-67. doi: 10.1023/a:1008958103865.","Villeneuve PJ","Cancer Causes Control","1999","1999/10/26","","","10.1023/a:1008958103865"
"28391284","Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score","Slaoui H, Neuzillet Y, Ghoneim T, Rouanne M, Abdou A, Lugagne-Delpon PM, Scherrer A, Radulescu C, Delancourt C, Molinié V, Lebret T.","Urol Int. 2017;99(2):156-161. doi: 10.1159/000468947. Epub 2017 Apr 8.","Slaoui H","Urol Int","2017","2017/04/10","","","10.1159/000468947"
"25650518","[Prostate cancer presenting with diffuse infiltration of metastases to the pancreas]","Hult M, Sandstrøm H, Wittendorff HE.","Ugeskr Laeger. 2015 Jan 26;177(5):V09140491.","Hult M","Ugeskr Laeger","2015","2015/02/05","","",""
"10737483","The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis","Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA.","J Urol. 2000 Apr;163(4):1138-43.","Albertsen PC","J Urol","2000","2000/03/29","","",""
"14663470","Androgen receptor antigen density and S-phase fraction in prostate cancer: a pilot study","Abdel-Wahab M, Krishan A, Milikowski C, Wahab AA, Walker G, Markoe A.","Prostate Cancer Prostatic Dis. 2003;6(4):294-300. doi: 10.1038/sj.pcan.4500672.","Abdel-Wahab M","Prostate Cancer Prostatic Dis","2003","2003/12/10","","","10.1038/sj.pcan.4500672"
"22416385","[Cryosurgical treatment for prostate cancer: current state]","Prokhorov DG, Skol'nik MI, Karelin MI.","Vopr Onkol. 2011;57(6):707-16.","Prokhorov DG","Vopr Onkol","2011","2012/03/16","","",""
"17619079","Editorial comment on: Erectile function in prostate cancer-free patients who underwent prostate saturation biopsy","Truss MC.","Eur Urol. 2008 Mar;53(3):545. doi: 10.1016/j.eururo.2007.06.041. Epub 2007 Dec 27.","Truss MC","Eur Urol","2008","2007/07/10","","","10.1016/j.eururo.2007.06.041"
"21935751","Comorbidities, treatment and ensuing survival in men with prostate cancer","Chamie K, Daskivich TJ, Kwan L, Labo J, Dash A, Greenfield S, Litwin MS.","J Gen Intern Med. 2012 May;27(5):492-9. doi: 10.1007/s11606-011-1869-4. Epub 2011 Sep 21.","Chamie K","J Gen Intern Med","2012","2011/09/22","PMC3326114","","10.1007/s11606-011-1869-4"
"25141965","Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: validation of recently released criteria","Gandaglia G, Karakiewicz PI, Briganti A, Trudeau V, Trinh QD, Kim SP, Montorsi F, Nguyen PL, Abdollah F, Sun M.","Int J Urol. 2015 Jan;22(1):89-95. doi: 10.1111/iju.12605. Epub 2014 Aug 21.","Gandaglia G","Int J Urol","2015","2014/08/22","","","10.1111/iju.12605"
"25552064","[Epidemiology of prostate cancer (cohort study)]","Merabishvili VM, Petrova NG, Atroshchenko AV, Kharitonov MV.","Vopr Onkol. 2014;60(4):457-63.","Merabishvili VM","Vopr Onkol","2014","2015/01/02","","",""
"16844894","Assessing anxiety in men with prostate cancer: further data on the reliability and validity of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC)","Roth A, Nelson CJ, Rosenfeld B, Warshowski A, O'Shea N, Scher H, Holland JC, Slovin S, Curley-Smart T, Reynolds T, Breitbart W.","Psychosomatics. 2006 Jul-Aug;47(4):340-7. doi: 10.1176/appi.psy.47.4.340.","Roth A","Psychosomatics","2006","2006/07/18","","","10.1176/appi.psy.47.4.340"
"17162013","Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?","Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, Catalona WJ.","J Urol. 2007 Jan;177(1):102-6; discussion 106. doi: 10.1016/j.juro.2006.08.097.","Loeb S","J Urol","2007","2006/12/13","","","10.1016/j.juro.2006.08.097"
"24589464","Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer","Zhang J.","Asian J Androl. 2014 May-Jun;16(3):401-6. doi: 10.4103/1008-682X.123684.","Zhang J","Asian J Androl","2014","2014/03/05","PMC4023365","","10.4103/1008-682X.123684"
"12566809","Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy","Hakenberg OW, Wirth MP, Hermann T, Alken P, Kovacs G, Müller RP, Ahlemann L, Schalkhäuser K.","Urol Int. 2003;70(1):15-20. doi: 10.1159/000067699.","Hakenberg OW","Urol Int","2003","2003/02/05","","","10.1159/000067699"
"4007495","Prostate cancer: toward more rational therapy","Vaughan WP.","Geriatrics. 1985 Jul;40(7):16.","Vaughan WP","Geriatrics","1985","1985/07/01","","",""
"22585653","Priapism secondary to involvement of corpora cavernosa by locally advanced prostate cancer","Sallami S, Ben Rhouma S, Horchani A.","Tunis Med. 2012 May;90(5):411-2.","Sallami S","Tunis Med","2012","2012/05/16","","",""
"18939452","[Cae of double cancer involving of the bladder and prostate which was treated by radical cystectomy 8 years after radical prostatectomy]","Tamura Y, Ohki K, Sasaki Y, Ohtake N, Ohnuki T, Kurokawa K.","Nihon Hinyokika Gakkai Zasshi. 2008 Sep;99(6):694-7. doi: 10.5980/jpnjurol1989.99.694.","Tamura Y","Nihon Hinyokika Gakkai Zasshi","2008","2008/10/23","","","10.5980/jpnjurol1989.99.694"
"16465189","Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men","Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S.","Br J Cancer. 2006 Mar 13;94(5):740-2. doi: 10.1038/sj.bjc.6602983.","Kurahashi N","Br J Cancer","2006","2006/02/09","PMC2361195","","10.1038/sj.bjc.6602983"
"24518526","BRCA mutations in prostate cancer patients","Olmos D, Castro E.","Clin Adv Hematol Oncol. 2013;11(9):598-9.","Olmos D","Clin Adv Hematol Oncol","2013","2014/02/13","","",""
"8049642","Correspondence re: E. H. Corder et al., Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol., Biomarkers & Prev., 2: 467-472, 1993","Schwartz GG.","Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):183-4.","Schwartz GG","Cancer Epidemiol Biomarkers Prev","1994","1994/03/01","","",""
"12909213","Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy","Fosså SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, Olsen DR.","Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):33-41. doi: 10.1016/s0360-3016(03)00428-0.","Fosså SD","Int J Radiat Oncol Biol Phys","2003","2003/08/12","","","10.1016/s0360-3016(03)00428-0"
"11061900","Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited","Vaidya A, Soloway MS.","J Urol. 2000 Dec;164(6):1998-2001.","Vaidya A","J Urol","2000","2000/11/04","","",""
"29893267","Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer","Spratt DE.","Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):513-515. doi: 10.1016/j.ijrobp.2018.03.008.","Spratt DE","Int J Radiat Oncol Biol Phys","2018","2018/06/13","","","10.1016/j.ijrobp.2018.03.008"
"24694634","Complications of prostate cancer treatment","Linton KD, Woo HH; Twitter International Urology Journal Club.","Lancet Oncol. 2014 Apr;15(4):e150-1. doi: 10.1016/S1470-2045(14)70092-0.","Linton KD","Lancet Oncol","2014","2014/04/04","","","10.1016/S1470-2045(14)70092-0"
"19185908","Combined androgen blockade revisited: emerging options for the treatment of castration-resistant prostate cancer","Simmons MN, Klein EA.","Urology. 2009 Apr;73(4):697-705. doi: 10.1016/j.urology.2008.09.040. Epub 2009 Jan 30.","Simmons MN","Urology","2009","2009/02/03","","","10.1016/j.urology.2008.09.040"
"7664288","Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression","Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB.","Cancer Res. 1995 Sep 15;55(18):4114-9.","Takahashi S","Cancer Res","1995","1995/09/15","","",""
"10404100","Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam)","Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schröder FH.","Int J Cancer. 1999 Aug 20;84(4):437-41. doi: 10.1002/(sici)1097-0215(19990820)84:4<437::aid-ijc19>3.0.co;2-s.","Beemsterboer PM","Int J Cancer","1999","1999/07/15","","","10.1002/(sici)1097-0215(19990820)84:4<437::aid-ijc19>3.0.co;2-s"
"31045265","The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease","Kurul NO, Ates F, Yilmaz I, Narli G, Yesildal C, Senkul T.","Prostate. 2019 Jul;79(10):1125-1132. doi: 10.1002/pros.23825. Epub 2019 May 2.","Kurul NO","Prostate","2019","2019/05/03","","","10.1002/pros.23825"
"16848364","[The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer]","Tanaka T, Kawashima H, Kuratsukuri K, Sugimura K, Nakatani T.","Hinyokika Kiyo. 2006 Jun;52(6):491-4.","Tanaka T","Hinyokika Kiyo","2006","2006/07/20","","",""
"29182605","Prostate cancer: Glycolysis and AR expression as biomarkers","Kelsey R.","Nat Rev Urol. 2018 Jan;15(1):2. doi: 10.1038/nrurol.2017.205. Epub 2017 Nov 28.","Kelsey R","Nat Rev Urol","2018","2017/11/29","","","10.1038/nrurol.2017.205"
"17698092","The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score","Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K.","J Urol. 2007 Oct;178(4 Pt 1):1282-8; discussion 1288-9. doi: 10.1016/j.juro.2007.05.138. Epub 2007 Aug 14.","Nishiyama T","J Urol","2007","2007/08/19","","","10.1016/j.juro.2007.05.138"
"12018806","Neurologic complications of prostate cancer","Benjamin R.","Am Fam Physician. 2002 May 1;65(9):1834-40.","Benjamin R","Am Fam Physician","2002","2002/05/23","","",""
"17126525","An improved in vitro model to characterize invasive growing cancer cells simultaneously by function and genetic aberrations","Jung V, Wullich B, Kamradt J, Stöckle M, Unteregger G.","Toxicol In Vitro. 2007 Mar;21(2):183-90. doi: 10.1016/j.tiv.2006.09.021. Epub 2006 Oct 4.","Jung V","Toxicol In Vitro","2007","2006/11/28","","","10.1016/j.tiv.2006.09.021"
"16678061","Current status of anti-angiogenesis therapy for prostate cancer","Jiménez JA, Kao C, Raikwar S, Gardner TA.","Urol Oncol. 2006 May-Jun;24(3):260-8. doi: 10.1016/j.urolonc.2005.11.022.","Jiménez JA","Urol Oncol","2006","2006/05/09","","","10.1016/j.urolonc.2005.11.022"
"16018293","Prostate-specific antigen: how to advise patients as the screening debate continues","Albertsen PC.","Cleve Clin J Med. 2005 Jun;72(6):521-7. doi: 10.3949/ccjm.72.6.521.","Albertsen PC","Cleve Clin J Med","2005","2005/07/16","","","10.3949/ccjm.72.6.521"
"9305688","Determinants of prostate-specific antigen test use in prostate cancer screening by primary care physicians","Austin OJ, Valente S, Hasse LA, Kues JR.","Arch Fam Med. 1997 Sep-Oct;6(5):453-8. doi: 10.1001/archfami.6.5.453.","Austin OJ","Arch Fam Med","1997","1997/09/26","","","10.1001/archfami.6.5.453"
"17949319","Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of the prostate: is it necessary?","Manikandan R, Qazi HA, Philip J, Mistry R, Lamb GH, Woolfenden KA, Cornford PA, Parsons KF.","J Endourol. 2007 Oct;21(10):1171-4. doi: 10.1089/end.2007.9912.","Manikandan R","J Endourol","2007","2007/10/24","","","10.1089/end.2007.9912"
"20647476","Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer","Yamaoka M, Hara T, Kusaka M.","Clin Cancer Res. 2010 Sep 1;16(17):4319-24. doi: 10.1158/1078-0432.CCR-10-0255. Epub 2010 Jul 20.","Yamaoka M","Clin Cancer Res","2010","2010/07/22","","","10.1158/1078-0432.CCR-10-0255"
"30512875","[Localized prostate cancer: if not aggressive, tracking does not mean treating]","Desgrandchamps F, Masson-Lecomte A.","Rev Prat. 2017 Apr;67(4):361-363.","Desgrandchamps F","Rev Prat","2017","2018/12/05","","",""
"1289676","Prostate cancer tumor location as predicted by digital rectal examination transferred to ultrasound and ultrasound-guided prostate needle biopsy","Brawer MK, Ploch NR, Bigler SA.","J Cell Biochem Suppl. 1992;16H:74-7. doi: 10.1002/jcb.240501217.","Brawer MK","J Cell Biochem Suppl","1992","1992/01/01","","","10.1002/jcb.240501217"
"16336331","Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer","Ku JH.","BJU Int. 2006 Jan;97(1):69-72. doi: 10.1111/j.1464-410X.2005.05866.x.","Ku JH","BJU Int","2006","2005/12/13","","","10.1111/j.1464-410X.2005.05866.x"
